PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	RP	EM	RI	OI	FU	FX	CR	NR	TC	Z9	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	D2	PG	WC	SC	GA	UT	PM
J	Duolikun, D; Enokido, T; Aikebaier, A; Takizawa, M				Duolikun, Dilawaer; Enokido, Tomoya; Aikebaier, Ailixier; Takizawa, Makoto			Energy-efficient dynamic clusters of servers	JOURNAL OF SUPERCOMPUTING			English	Article						Power consumption mode; Dynamic cluster; Energy-aware cluster; Storage- and computation-based power consumption (SCBPC) model; Storage- and computation-based processing (SCB) model	TO-PEER SYSTEMS; POWER-CONSUMPTION	Electric power consumed by servers has to be reduced in order to realize green societies. We consider computation (CP) and storage (ST) types of application processes performed on servers in this paper, where CPU and storage drives are mainly used, respectively. In the storage- and computation-based power consumption model proposed by the authors, the power consumption rate of a server depends on what types of processes are performed but is independent of how may processes are performed on the server. In the storage- and computation-based processing model, the execution time of an ST process depends on the number of concurrent CP and ST processes but the execution time of a CP process depends on only CP processes and is independent of ST processes. In our previous studies, the energy-aware algorithm is discussed to select a server in a cluster of servers for each request so that the total power consumption of the servers can be reduced. However, a server consumes electric power even if the server is idle, i.e. no process is performed. In this paper, we discuss a dynamic energy-aware (DEA) cluster which includes only active servers where at least one process is performed. A server for each request is selected in a dynamic cluster so that the total power consumption of servers in the cluster can be reduced. We evaluate the DEA algorithm in terms of the total power consumption and average execution time and show the total power consumption can be reduced.	[Duolikun, Dilawaer; Takizawa, Makoto] Hosei Univ, Tokyo 1848584, Japan; [Enokido, Tomoya] Rissho Univ, Shinagawa, Tokyo 1418602, Japan; [Aikebaier, Ailixier] Natl Inst Informat & Commun Technol, Koganei, Tokyo 1848795, Japan	Takizawa, M (reprint author), Hosei Univ, 3-7-2 Kajino Cho, Tokyo 1848584, Japan.	dilewerdolkun@gmail.com; eno@ris.ac.jp; alisher@nict.go.jp; makoto.takizawa@computer.org					Enokido T, 2010, IEEE SYST J, V4, P221, DOI 10.1109/JSYST.2010.2047296; Bianchini R, 2004, COMPUTER, V37, P68, DOI 10.1109/MC.2004.217; Enokido T, 2011, IEEE T IND ELECTRON, V58, P2097, DOI 10.1109/TIE.2010.2060453; Waluyo AB, 2011, IEEE T IND ELECTRON, V58, P2173, DOI 10.1109/TIE.2009.2035457; Dong H, 2010, P COMPL INT SOFTW IN, P153; Enokido T, 2012, INT CON ADV INFO NET, P912, DOI 10.1109/AINA.2012.90; Enokido Tomoya, 2010, Proceedings of the 24th IEEE International Conference on Advanced Information Networking and Applications (AINA 2010), DOI 10.1109/AINA.2010.109; Enokido Tomoya, 2010, Proceedings of the 13th International Conference on Network-Based Information Systems (NBiS 2010), DOI 10.1109/NBiS.2010.80; Ghobadi A, 2009, 11TH INTERNATIONAL CONFERENCE ON ADVANCED COMMUNICATION TECHNOLOGY, VOLS I-III, PROCEEDINGS,, P315; Inoue T., 2012, P IEEE 26 INT C ADV, P217; Inoue T, 2012, P 7 INT C BROADB WIR; Inoue T., 2011, Proceedings of the 2011 14th International Conference on Network-Based Information Systems (NBiS 2011), DOI 10.1109/NBiS.2011.64; Inoue T., 2011, Proceedings of the 2011 International Conference on Complex, Intelligent and Software Intensive Systems (CISIS 2011), DOI 10.1109/CISIS.2011.101; Inoue T, 2012, P 6 INT C COMPL INT	14	0	0	SPRINGER	DORDRECHT	VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS	0920-8542	1573-0484		J SUPERCOMPUT	J. Supercomput.	MAY	2015	71	5					1642	1656		10.1007/s11227-014-1261-3		15	Computer Science, Hardware & Architecture; Computer Science, Theory & Methods; Engineering, Electrical & Electronic	Computer Science; Engineering	CH1MV	WOS:000353786700004		
J	Pop, F; Dobre, C; Cristea, V; Bessis, N; Xhafa, F; Barolli, L				Pop, Florin; Dobre, Ciprian; Cristea, Valentin; Bessis, Nik; Xhafa, Fatos; Barolli, Leonard			Deadline scheduling for aperiodic tasks in inter-Cloud environments: a new approach to resource management	JOURNAL OF SUPERCOMPUTING			English	Article						Deadline scheduling; Aperiodic tasks; Resource allocation and Cloud environments; Big data	ALGORITHM; GRIDS	In the big data era, the speed of analytical processing is influenced by the storage and retrieval capabilities to handle large amounts of data. While the distributed crunching applications themselves can yield useful information, the analysts face difficult challenges: they need to predict how much data to process and where, such that to get an optimum data crunching cost, while also respect deadlines and service level agreements within a limited budget. In today's data centers, data processing on demand and data transfers requests coming from distributed applications are usually expressed as aperiodic tasks. In this paper, we challenge the problem of tasks scheduling with deadline constraints of aperiodic tasks within inter-Cloud environments. In massively multithreaded computing systems that deal with data-intensive applications, Hadoop and BaTs tasks arrive periodically, which challenges traditional scheduling approaches previously proposed for supercomputing. Here, we consider the deadline as the main constraint, and propose a method to estimate the number of resources needed to schedule a set of aperiodic tasks, considering both execution and data transfers costs. Starting from classical scheduling techniques, and considering asynchronous tasks handling, we analyze the possibility of decoupling task arriving from task creation, scheduling and execution, sets of actions that can be put into a peer-to-peer relation over a network or over a client-server architecture in the Cloud. Based on a mathematical model, and using different simulation scenarios, we prove the following statements: (1) multiple source of independent aperiodic tasks can be considered similar to a single one; (2) with respect to the global deadline, the tasks migration between different regional centers is the appropriate solution when the number of estimated resources exceed a data center capacity; and (3) in a heterogeneous data center, we need a higher number of resources for the same request in order to respect the deadline constraints. We believe such results will benefit researchers and practitioners alike, who are interested in optimizing the resource management in data centers according to novel challenges coming from next-generation big data applications.	[Pop, Florin; Dobre, Ciprian; Cristea, Valentin] Univ Politehn Bucuresti, Fac Automat Control & Comp, Dept Comp Sci, Bucharest, Romania; [Bessis, Nik] Univ Derby, Sch Comp & Maths, Derby DE22 1GB, England; [Xhafa, Fatos] Tech Univ Catalonia Barcelona, Dept Language & Informat Syst, Barcelona, Spain; [Barolli, Leonard] Fukuoka Inst Technol FIT, Fac Informat Engn, Dept Informat & Commun Engn, Fukuoka, Japan	Dobre, C (reprint author), Univ Politehn Bucuresti, Fac Automat Control & Comp, Dept Comp Sci, Bucharest, Romania.	florin.pop@cs.pub.ro; ciprian.dobre@cs.pub.ro; valentin.cristea@cs.pub.ro; N.Bessis@derby.ac.uk; fatos@lsi.upc.edu; barolli@fit.ac.jp		Bessis, Nik/0000-0002-6013-3935	project: "SideSTEP-Scheduling Methods for Dynamic Distributed Systems: a self-* approach" [PN-II-CT-RO-FR-2012-1-0084]; Cyber-Water: grant of the Romanian National Authority for Scientific Research, CNDI-UEFISCDI [47/2012]; MobiWay: Mobility Beyond Individualism: an Integrated Platform for Intelligent Transportation Systems of Tomorrow [PN-II-PT-PCCA-2013-4-0321]; clueFarm: Information system based on cloud services accessible through mobile devices, to increase product quality and business development farms [PN-II-PT-PCCA-2013-4-0870]	The research presented in this paper is supported by projects: "SideSTEP-Scheduling Methods for Dynamic Distributed Systems: a self-* approach", ID: PN-II-CT-RO-FR-2012-1-0084; Cyber-Water: grant of the Romanian National Authority for Scientific Research, CNDI-UEFISCDI, project number 47/2012; MobiWay: Mobility Beyond Individualism: an Integrated Platform for Intelligent Transportation Systems of Tomorrow-PN-II-PT-PCCA-2013-4-0321; clueFarm: Information system based on cloud services accessible through mobile devices, to increase product quality and business development farms-PN-II-PT-PCCA-2013-4-0870.	Wang LZ, 2013, FUTURE GENER COMP SY, V29, P1661, DOI 10.1016/j.future.2013.02.010; STROSNIDER JK, 1995, IEEE T COMPUT, V44, P73, DOI 10.1109/12.368008; Liu K, 2010, INT J HIGH PERFORM C, V24, P445, DOI 10.1177/1094342010369114; Kolodziej J, 2011, FUTURE GENER COMP SY, V27, P1035, DOI 10.1016/j.future.2011.04.011; Moschakis IA, 2012, J SUPERCOMPUT, V59, P975, DOI 10.1007/s11227-010-0481-4; Huang Y, 2013, FUTURE GENER COMP SY, V29, P402, DOI 10.1016/j.future.2011.05.006; Ba W, 2012, J SUPERCOMPUT, V59, P227, DOI 10.1007/s11227-010-0433-z; Buttazzo GC, 2011, HARD REAL-TIME COMPUTING SYSTEMS: PREDICTABLE SCHEDULING ALGORITHMS AND APPLICATIONS, THIRD EDITION, P1, DOI 10.1007/978-1-14614-0676-1; Conway R. W., 2003, THEORY OF SCHEDULING; Cox D. R., 1961, QUEUES; Davis R., 1995, Proceedings. 16th IEEE Real-Time Systems Symposium (Cat. No.95CB35882), DOI 10.1109/REAL.1995.495200; Dobre C, 2008, P 37 INT C PAR PROC, P181; Gotoh Y, 2012, INT CON ADV INFO NET, P787, DOI 10.1109/AINA.2012.126; Jia Yu, 2006, Scientific Programming, V14; Kalim Q, 2012, J SUPERCOMPUT, V59, P1348; Kamal Kc, 2010, P 2010 IEEE 2 INT C, P388; Kato S, 2009, EUROMICRO, P249, DOI 10.1109/ECRTS.2009.22; Kebarighotbi A, 2011, DISCRETE EVENT DYN S, V21, P547, DOI 10.1007/s10626-011-0105-z; Brucker P, 2012, GOR-PUBL, P1, DOI 10.1007/978-3-642-23929-8; Lehoczky JP, 1995, ADV REAL TIME SYSTEM, P175; Leung J, 2004, HDB SCHEDULING ALGOR; Liu Jane W. S., 2000, REAL TIME SYSTEMS; McKnight C, 2012, P 2012 7 INT C P2P P, P218; Ming M, 2011, P 2011 INT C HIGH PE, P49; Mocanu M, 2012, EM INT DAT WEB TECHN, P287; Oprescu AM, 2012, 2012 IEEE/ACM FIFTH INTERNATIONAL CONFERENCE ON UTILITY AND CLOUD COMPUTING (UCC 2012), P204, DOI 10.1109/UCC.2012.23; Pop F, 2013, INT CON ADV INFO NET, P764, DOI 10.1109/AINA.2013.103; Serbanescu C, 1998, B MATH SOC SCI MATH, V41, P311; Serbanescu C., 1998, B MATH SOC SCI MATH, V41, P219; Sprunt B, 1990, THESIS CARNEGIE MELL	30	0	0	SPRINGER	DORDRECHT	VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS	0920-8542	1573-0484		J SUPERCOMPUT	J. Supercomput.	MAY	2015	71	5					1754	1765		10.1007/s11227-014-1285-8		12	Computer Science, Hardware & Architecture; Computer Science, Theory & Methods; Engineering, Electrical & Electronic	Computer Science; Engineering	CH1MV	WOS:000353786700010		
J	Nakata, S; Sakamoto, Y				Nakata, Susumu; Sakamoto, Yasuaki			Particle-based parallel fluid simulation in three-dimensional scene with implicit surfaces	JOURNAL OF SUPERCOMPUTING			English	Article						Fluid simulation; Smoothed particle hydrodynamics; Implicit surface; Graphics processing units		We propose an algorithm for fluid simulation in three-dimensional scenes with obstacles represented as implicit surfaces. The fluid simulation is performed based on the smoothed particle hydrodynamics method and the behavior of fluid particles in the vicinity of obstacles is defined by introducing a new model of particle motion specific to implicitly representation. For effective parallelization on the graphics processing units, we apply the grid of polynomial method to express the implicitly defined obstacles. The proposed method takes advantage of the properties of implicit representation such as smoothness, shape modelling and the expression of deforming objects.	[Nakata, Susumu; Sakamoto, Yasuaki] Ritsumeikan Univ, Coll Informat Sci & Engn, Kyoto, Japan	Nakata, S (reprint author), Ritsumeikan Univ, Coll Informat Sci & Engn, Kyoto, Japan.	snakata@is.ritsumei.ac.jp			JSPS KAKENHI [00351320, 60251980]	This study was supported by JSPS KAKENHI Grant Numbers 00351320 and 60251980	Reiner T, 2011, COMPUT GRAPH-UK, V35, P596, DOI 10.1016/j.cag.2011.03.010; Becker M, 2007, SYMPOSIUM ON COMPUTER ANIMATION 2007: ACM SIGGRAPH/ EUROGRAPHICS SYMPOSIUM PROCEEDINGS, P209; MONAGHAN JJ, 1992, ANNU REV ASTRON ASTR, V30, P543, DOI 10.1146/annurev.aa.30.090192.002551; Schmidt R, 2006, ACM T GRAPHIC, V25, P605, DOI 10.1145/1141911.1141930; Koshizuka S, 1996, NUCL SCI ENG, V123, P421; Berger M, 2013, ACM T GRAPHIC, V32, DOI 10.1145/2451236.2451246; Goswami P, 2010, ACM SIGGRAPH EUR S C, P55; Harada T., 2007, COMPUTER GRAPHICS GE, V9, P2; Kazhdan M, 2005, EUR S GEOM PROC, P73; Kazhdan M, 2013, ACM T GRAPHIC, V32, DOI 10.1145/2487228.2487237; Liu G.R., 2003, SMOOTHED PARTICLE HY; Macklin M, 2013, ACM T GRAPHIC, V32, DOI 10.1145/2461912.2461984; Manson J, 2008, COMPUT GRAPH FORUM, V27, P1411, DOI 10.1111/j.1467-8659.2008.01281.x; Muller M., 2003, SCA 03, P154; Nakata S, 2012, J VISUAL-JAPAN, V15, P179, DOI 10.1007/s12650-011-0119-5; Solenthaler B, 2009, ACM T GRAPHIC, V28, DOI 10.1145/1531326.1531346; Sussmuth J, 2010, COMPUT GRAPH FORUM, V29, P1854, DOI 10.1111/j.1467-8659.2010.01653.x; TAUBIN G, 1994, ACM T GRAPHIC, V13, P3, DOI 10.1145/174462.174531	18	0	0	SPRINGER	DORDRECHT	VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS	0920-8542	1573-0484		J SUPERCOMPUT	J. Supercomput.	MAY	2015	71	5					1766	1775		10.1007/s11227-014-1323-6		10	Computer Science, Hardware & Architecture; Computer Science, Theory & Methods; Engineering, Electrical & Electronic	Computer Science; Engineering	CH1MV	WOS:000353786700011		
J	Sakabe, J; Uchida, H; Shimoyama, Y				Sakabe, Junichi; Uchida, Hirohisa; Shimoyama, Yusuke			Mixed solid phase model using equation of state based on hole-theory for solubility prediction of pharmaceutical compound in supercritical CO2	JOURNAL OF SUPERCRITICAL FLUIDS			English	Article						Supercritical carbon dioxide; Pharmaceutical compound solubility; Mixed solid phase model; Prediction; Hole-theory	CARBON-DIOXIDE; RAPID EXPANSION; ANTIINFLAMMATORY DRUGS; MICRONIZATION; PARTICLES; NAPROXEN; DENSITY; ACID; RESS; 9,10-ANTHRAQUINONE	A mixed solid phase model using an equation of state based on hole-theory is developed for solubility calculation in supercritical CO2 considering the dissolution of CO2 into solid phase at high-pressure condition. Parameters in the equation of state were obtained from the molecular information calculated by a quantum calculation based on conductor-like screening model (COSMO). Twenty-three species of pharmaceutical compounds are mentioned as the target for the correlation or prediction of solubility in supercritical CO2. The predicted results of the solubility in supercritical CO2 by the mixed solid phase model are compared with those by the conventional pure solid phase model. It is found that the results for the pharmaceutical compounds with S,N, F, Cl and I atoms using the mixed solid phase model give the calculation performance better than those of the pure solid phase model. The mixed solid phase model was also applied for calculation of the CO2 solubility in solid phase. (C) 2015 Elsevier B.V. All rights reserved.	[Sakabe, Junichi; Shimoyama, Yusuke] Tokyo Inst Technol, Dept Chem Engn, Meguto Ku, Tokyo 1528550, Japan; [Uchida, Hirohisa] Shinshu Univ, Dept Chem & Mat Engn, Nagano 3808553, Japan	Shimoyama, Y (reprint author), Tokyo Inst Technol, Dept Chem Engn, Meguto Ku, S1-33,2-12-1 Ookayama, Tokyo 1528550, Japan.	yshimo@chemeng.titech.ac.jp					Jun SW, 2007, EUR J PHARM BIOPHARM, V66, P413, DOI 10.1016/j.ejpb.2006.11.013; Cortesi A, 1999, J SUPERCRIT FLUID, V14, P139, DOI 10.1016/S0896-8446(98)00119-3; Turk M, 2010, J SUPERCRIT FLUID, V55, P778, DOI 10.1016/j.supflu.2010.09.023; Yildiz N, 2007, J SUPERCRIT FLUID, V41, P440, DOI 10.1016/j.supflu.2006.12.012; Stassi A, 2000, J CHEM ENG DATA, V45, P161, DOI 10.1021/je990114u; Tandya A, 2006, J SUPERCRIT FLUID, V37, P272, DOI 10.1016/j.supflu.2005.10.004; Lin ST, 2002, IND ENG CHEM RES, V41, P899, DOI 10.1021/ie001047w; Saldana MDA, 1999, J AGR FOOD CHEM, V47, P3804, DOI 10.1021/jf981369z; Yamini Y, 2001, J CHEM ENG DATA, V46, P451, DOI 10.1021/je000286n; [Anonymous], 2013, TURBOMOLE 6 5; Duarte ARC, 2004, J CHEM ENG DATA, V49, P449, DOI 10.1021/je034099b; Uchida H, 2009, J SUPERCRIT FLUID, V51, P136, DOI 10.1016/j.supflu.2009.08.007; de Sousa ARS, 2007, J SUPERCRIT FLUID, V43, P120, DOI 10.1016/j.supflu.2007.03.015; Su CS, 2007, FLUID PHASE EQUILIBR, V254, P167, DOI 10.1016/j.fluid.2007.03.004; Wang LH, 2014, J SUPERCRIT FLUID, V85, P81, DOI [10.1016/j.tws.2014.08.002, 10.1016/j.supflu.2013.10.019]; Coimbra P, 2006, FLUID PHASE EQUILIBR, V239, P188, DOI 10.1016/j.fluid.2005.11.028; Macnaughton SJ, 1996, J CHEM ENG DATA, V41, P1083, DOI 10.1021/je960103q; LI S, 1991, FLUID PHASE EQUILIBR, V68, P263, DOI 10.1016/0378-3812(91)85023-N; Turk M, 2008, J SUPERCRIT FLUID, V45, P346, DOI 10.1016/j.supflu.2008.01.019; Rodrigues M, 2004, J SUPERCRIT FLUID, V29, P175, DOI 10.1016/S0896-8446(03)00034-2; FLORY PJ, 1964, J AM CHEM SOC, V86, P3507, DOI 10.1021/ja01071a023; Sanli D, 2012, J MATER SCI, V47, P2995, DOI 10.1007/s10853-011-6054-y; Garmroodi A, 2004, J CHEM ENG DATA, V49, P709, DOI 10.1021/je020218w; TING SST, 1993, IND ENG CHEM RES, V32, P1471, DOI 10.1021/ie00019a022; Hojjati M, 2007, J SUPERCRIT FLUID, V41, P187, DOI 10.1016/j.supflu.2006.10.006; Huang Z, 2005, POWDER TECHNOL, V160, P127, DOI 10.1016/j.powtec.2005.08.024; Charoenchaitrakool M, 2000, IND ENG CHEM RES, V39, P4794, DOI 10.1021/ie000151a; Cheng JS, 2003, MOL SIMULAT, V29, P749, DOI 10.1080/0892702031000121806; Coutsikos P, 1997, J CHEM ENG DATA, V42, P463, DOI 10.1021/je960309r; Demessie E.S., 2003, J CHEM ENG DATA, V48, P541; Hezave AZ, 2010, J AEROSOL SCI, V41, P821, DOI 10.1016/j.jaerosci.2010.01.006; Housaindokht MR, 2008, J SUPERCRIT FLUID, V43, P390, DOI 10.1016/j.supflu.2007.07.013; Hsieh C.M., 2011, ASIA PACIFIC J CHEM; Huang Z, 2004, J CHEM ENG DATA, V49, P1323, DOI 10.1021/je0499465; ISHIZUKA I, 1980, J CHEM ENG JPN, V13, P90, DOI 10.1252/jcej.13.90; KLAMT A, 1993, J CHEM SOC PERK T 2, P799, DOI 10.1039/p29930000799; KLAMT A, 1995, J PHYS CHEM-US, V99, P2224, DOI 10.1021/j100007a062; Poling B.E., 2001, PROPERTIES GASES LIQ; Sakabe J, 2014, CHEM ENG RES DES, V92, P2970, DOI 10.1016/j.cherd.2014.08.003; SCHMITT WJ, 1986, J CHEM ENG DATA, V31, P204, DOI 10.1021/je00044a021; Shamsipur M, 2008, J SUPERCRIT FLUID, V47, P154, DOI 10.1016/j.supflu.2008.07.002; Shimoyama Y, 2013, FLUID PHASE EQUILIBR, V357, P30, DOI 10.1016/j.fluid.2013.05.024; Shimoyama Y, 2008, J SUPERCRIT FLUID, V44, P266, DOI 10.1016/j.supflu.2007.09.028; Skerget M, 2002, FLUID PHASE EQUILIBR, V203, P111, DOI 10.1016/S0378-3812(02)00177-2; Solorzano G.I.B., 2004, FLUID PHASE EQUILIBR, V220, P57; Sovova H, 2001, J CHEM ENG DATA, V46, P1255, DOI 10.1021/je0101146; Su CS, 2008, J SUPERCRIT FLUID, V43, P438, DOI 10.1016/j.supflu.2007.08.006; Takebayashi Y, 2014, J SUPERCRIT FLUID, V86, P91, DOI 10.1016/j.supflu.2013.12.007; Uchida H, 2010, J CHEM ENG DATA, V55, P925, DOI 10.1021/je9005272; Yamini Y, 2003, J PHARMACEUT BIOMED, V32, P181, DOI 10.1016/S0731-7085(03)00016-5	50	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0896-8446	1872-8162		J SUPERCRIT FLUID	J. Supercrit. Fluids	MAY	2015	100						26	33		10.1016/j.supflu.2015.02.002		8	Chemistry, Physical; Engineering, Chemical	Chemistry; Engineering	CH0RI	WOS:000353729700004		
J	Iwai, Y; Sameshima, S; Yonezawa, S; Katayama, S				Iwai, Yoshio; Sameshima, Sho; Yonezawa, Setsuko; Katayama, Shigeo			Fabrication of conductive cotton by electroless plating method with supercritical carbon dioxide	JOURNAL OF SUPERCRITICAL FLUIDS			English	Article						Electroless copper plate; Supercritical carbon dioxide; Cotton	NANOPARTICLES; SOLUBILITY; SUPPORT; ETHANOL; FIBERS; WATER	Palladium(II) hexafluoroacetylacetonate was impregnated into cotton cloth at 80 degrees C and 20 MPa for 2 h by supercritical CO2. Then, the cotton cloth was immersed in NaBH4 aqueous solution at 50 degrees C for 2 h for reduction. Many Pd particles were observed not only on the surface of the cotton, but also inside of the cotton by TEM analysis. The cotton cloth was immersed in an electroless copper plating liquid with applying ultrasonic at 40 degrees C for 15 min. The plated layer on the surface of cotton was uniform in thickness and adhered strongly to the cotton cloth. The conductivities of copper plated cloth were high. (C) 2015 Elsevier B.V. All rights reserved.	[Iwai, Yoshio; Sameshima, Sho; Yonezawa, Setsuko] Kyushu Univ, Fac Engn, Dept Chem Engn, Nishi Ku, Fukuoka 8190395, Japan; [Katayama, Shigeo] Marusan Ind Co Ltd, Uchiko, Ehime 7950301, Japan	Iwai, Y (reprint author), Kyushu Univ, Fac Engn, Dept Chem Engn, Nishi Ku, 744 Motooka, Fukuoka 8190395, Japan.	iwai@chem-eng.kyushu-u.ac.jp					Katayama S, 2012, J SUPERCRIT FLUID, V61, P199, DOI 10.1016/j.supflu.2011.10.008; Aschenbrenner O, 2007, J SUPERCRIT FLUID, V41, P179, DOI 10.1016/j.supflu.2006.10.011; Sanz-Moral LM, 2014, J SUPERCRIT FLUID, V92, P24, DOI 10.1016/j.supflu.2014.05.004; Zhao X, 2006, SURF COAT TECH, V201, P628, DOI 10.1016/j.surfcoat.2005.12.021; Aslanidou D, 2013, J SUPERCRIT FLUID, V76, P83, DOI 10.1016/j.supflu.2013.02.005; Binran Sen-i, 1994, SOC FIBER SCI TECHNO; Foster N. R., 1995, ACS S SER, V608; Hayashi T., 1994, ELECTROLESS METAL PL, V131; Katayama S, 2013, KAGAKU KOGAKU RONBUN, V39, P138, DOI 10.1252/kakoronbunshu.39.138; Knittel D., 1997, CHEM FIBERS INT, V47, P46; LUFT JH, 1961, J BIOPHYS BIOCHEM CY, V9, P409, DOI 10.1083/jcb.9.2.409; Obata H., 2004, REPORTS FUKUOKA IND, V14, P107; SAUS W, 1993, TEXT RES J, V63, P135, DOI 10.1177/004051759306300302; Tenorio MJ, 2012, J SUPERCRIT FLUID, V70, P106, DOI 10.1016/j.supflu.2012.06.014; THIBAULT J, 1987, BIOTECHNOL BIOENG, V30, P74, DOI 10.1002/bit.260300111; YONEI Y, 1995, J SUPERCRIT FLUID, V8, P156, DOI 10.1016/0896-8446(95)90028-4	16	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0896-8446	1872-8162		J SUPERCRIT FLUID	J. Supercrit. Fluids	MAY	2015	100						46	51		10.1016/j.supflu.2015.02.027		6	Chemistry, Physical; Engineering, Chemical	Chemistry; Engineering	CH0RI	WOS:000353729700006		
J	Haruki, M; Hasegawa, Y; Kihara, S; Takishima, S				Haruki, Masashi; Hasegawa, Yumi; Kihara, Shin-ichi; Takishima, Shigeki			Deposition of ODA-PMDA types of polyimide thin film inside a microscopic-scale space using supercritical carbon dioxide	JOURNAL OF SUPERCRITICAL FLUIDS			English	Article						Polyimide; Supercritical carbon dioxide; Deposition; Thin film; Microfabrication	VAPOR-DEPOSITION; KEY TECHNOLOGIES; POLYMERIZATION; MONOMERS; PRESSURE	Aromatic polyimide (API) thin films were deposited onto silicon wafers with microscopic-scale trenches (width: 5 mu m, depth: 30 mu m) using supercritical carbon dioxide at deposition temperatures that ranged from 150 to 230 degrees C and at a constant deposition time of 90 min. Moreover, the relationship between deposition time and film thickness was also investigated for durations that ranged from 30 to 180 min at a deposition temperature of 200 degrees C. We used 4,4 '-diaminodiphenyl ether and pyromellitic dianhydride of Kapton-type polyimide API monomers. Although the morphologies of the API films deposited on the outside surfaces of the trenches depended on the distance from the supply outlets of the monomers, the API thin films were deposited onto the surfaces of the walls of the trenches with an approximately equal thickness from the outer surface position to the bottom position regardless of the distance from the supply outlets. However, the film thickness on the walls of the trenches depended on the distance from the supply outlets, because the trenches near the supply outlets were likely to be blocked by the masses of APIs during deposition. The film deposited at 230 degrees C was much smoother than that deposited at either 150 or 200 degrees C, which could have been caused by the differences in imidization rates and the amounts of PAA entering into the trenches based on the differences in the deposition temperatures although the film thickness showed no significant temperature dependency in the experimental conditions. The film thickness increased with increases in deposition time on the walls of the trenches in positions where no masses of APIs were found on the outer surface. (C) 2015 Elsevier B.V. All rights reserved.	[Haruki, Masashi; Hasegawa, Yumi; Kihara, Shin-ichi; Takishima, Shigeki] Hiroshima Univ, Grad Sch Engn, Dept Chem Engn, Higashihiroshima 7398527, Japan	Haruki, M (reprint author), Hiroshima Univ, Grad Sch Engn, Dept Chem Engn, 1-4-1 Kagamiyama, Higashihiroshima 7398527, Japan.	mharuki@hiroshima-u.ac.jp	Haruki, Masashi/C-9060-2011; Takishima, Shigeki/D-7198-2011		Ministry of Education, Culture, Science and Technology of Japan [23760722]	This study was financially supported by Grants-in-Aid for Young Scientists (B) (23760722) from the Ministry of Education, Culture, Science and Technology of Japan. Moreover, the authors gratefully acknowledge the Research Institute for Nanodevice and Bio Systems of Hiroshima University, and the Nanotechnology Platform of the Ministry of Education, Culture, Science and Technology of Japan for the preparation of the silicon wafers with microscopic patterned trenches. We also thank Dr. Maeda, the Natural Science Center for Basic Research and Development (N-BARD), Hiroshima University for a lot of useful advice about the film characterization using the SEM with EDX.	SROOG CE, 1991, PROG POLYM SCI, V16, P561, DOI 10.1016/0079-6700(91)90010-I; Liaw DJ, 2012, PROG POLYM SCI, V37, P907, DOI 10.1016/j.progpolymsci.2012.02.005; Blackburn JM, 2001, SCIENCE, V294, P141, DOI 10.1126/science.1064148; Tu KN, 2013, MICROELECTRON RELIAB, V53, P2, DOI 10.1016/j.microrel.2012.07.029; SALEM JR, 1986, J VAC SCI TECHNOL A, V4, P369, DOI 10.1116/1.573930; O'Neil A, 2007, CHEM MATER, V19, P5460, DOI 10.1021/cm070288s; Romang AH, 2010, CHEM REV, V110, P459, DOI 10.1021/cr900255w; Kurosawa T, 2013, POLYM CHEM-UK, V4, P16, DOI 10.1039/c2py20632c; Gougousi T, 2005, CHEM MATER, V17, P5093, DOI 10.1021/cm0510965; Dutt R, 1999, JPN J APPL PHYS 2, V38, pL687, DOI 10.1143/JJAP.38.L687; Haruki M, 2014, J SUPERCRIT FLUID, V94, P147, DOI 10.1016/j.supflu.2014.07.010; Haruki M, 2012, J CHEM THERMODYN, V54, P261, DOI 10.1016/j.jct.2012.04.013; Haruki M, 2014, J APPL POLYM SCI, V131, DOI 10.1002/app.39878; Haruki M, 2011, IND ENG CHEM RES, V50, P11942, DOI 10.1021/ie2013289; Horvath B, 2014, JPN J APPL PHYS, V53, DOI 10.7567/JJAP.53.06JH01; Iijima M., 1985, J VAC SOC JPN, V28, P437; Ko CT, 2013, MICROELECTRON RELIAB, V53, P7, DOI 10.1016/j.microrel.2012.08.011; Lai MF, 2011, MICROELECTRON ENG, V88, P3282, DOI 10.1016/j.mee.2011.05.036; Lee BJ, 2002, SURF COAT TECH, V150, P182, DOI 10.1016/S0257-8972(01)01535-3; Ma S., 2013, ADV POLYM TECHNOLOGY, V32; Naganuma T, 2011, CARBON, V49, P3881, DOI 10.1016/j.carbon.2011.05.026; Naganuma T, 2009, COMPOS SCI TECHNOL, V69, P1319, DOI 10.1016/j.compscitech.2009.03.002; Naito K, 2013, J MATER SCI, V48, P6056, DOI 10.1007/s10853-013-7402-x; Papastrat AG, 2011, CHEM VAPOR DEPOS, V17, P141, DOI 10.1002/cvde.201006893; Said-Galiyev EE, 2003, J SUPERCRIT FLUID, V26, P147, DOI 10.1016/S0896-8446(02)00210-3; TAKAHASHI Y, 1993, JPN J APPL PHYS 2, V32, pL875, DOI 10.1143/JJAP.32.L875; TAKAHASHI Y, 1987, J VAC SCI TECHNOL A, V5, P2253, DOI 10.1116/1.574429	27	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0896-8446	1872-8162		J SUPERCRIT FLUID	J. Supercrit. Fluids	MAY	2015	100						52	57		10.1016/j.supflu.2015.02.016		6	Chemistry, Physical; Engineering, Chemical	Chemistry; Engineering	CH0RI	WOS:000353729700007		
J	Seo, Y; Ishizu, T; Kawamura, R; Yamamoto, M; Kuroki, K; Igarashi, M; Sekiguchi, Y; Nogami, A; Aonuma, K				Seo, Yoshihiro; Ishizu, Tomoko; Kawamura, Ryo; Yamamoto, Masayoshi; Kuroki, Kenji; Igarashi, Miyako; Sekiguchi, Yukio; Nogami, Akihiko; Aonuma, Kazutaka			Three-Dimensional Propagation Imaging of Left Ventricular Activation by Speckle-Tracking Echocardiography to Predict Responses to Cardiac Resynchronization Therapy	JOURNAL OF THE AMERICAN SOCIETY OF ECHOCARDIOGRAPHY			English	Article						Three-dimensional echocardiography; Speckle-tracking echocardiography; Dyssynchrony; Heart failure; Cardiac resynchronization therapy	BUNDLE-BRANCH-BLOCK; ENDOCARDIAL ACTIVATION; CLINICAL-OUTCOMES; DEFORMATION; SCAR; CRT	Background: On the basis of the electromechanical coupling theory, an activation imaging system has been developed with three-dimensional speckle-tracking echocardiography. The aim of this study was to determine the association between left ventricular (LV) propagation patterns by activation imaging and response to cardiac resynchronization therapy (CRT). Methods: This was a retrospective, single-center study. Eighty-one patients undergoing CRT, of whom 50 (61.7%) had left bundle branch block (LBBB), were enrolled. Activation imaging studies were performed with a three-dimensional speckle-tracking echocardiographic system, which allowed visualization of LV activation propagation and measurement of the time from the QRS complex to activation onset. A CRT volume responder was defined as a patient with >= 15% reduction of LV end-systolic volume at 6 months after CRT. Clinical outcomes were assessed with the composite end point of death due to cardiac causes or unplanned hospitalization for cardiac diseases. Results: In patients with LBBB, the main activation pattern (74%) was a U-shaped propagation pattern, which was characterized as propagation from the midseptum to the lateral or posterior wall through the apex. In patients without LBBB, various non-U-shaped propagation patterns were observed in the majority of patients (97%). Among the 41 CRT responders, almost all (87.8%) had the U-shaped propagation pattern. During follow-up (median, 20 months), 29 patients (35.8%) reached the clinical end points. In a multivariate Cox proportional hazards model, a U-shaped propagation pattern was associated with the end points independently of LBBB or LV end-diastolic volume. Conclusions: The U-shaped propagation pattern on three-dimensional speckle-tracking echocardiography was significantly associated with a favorable CRT response. Activation pattern analysis may provide additional information to predict response to CRT.	[Seo, Yoshihiro; Ishizu, Tomoko; Yamamoto, Masayoshi; Kuroki, Kenji; Igarashi, Miyako; Sekiguchi, Yukio; Nogami, Akihiko; Aonuma, Kazutaka] Univ Tsukuba, Fac Med, Cardiovasc Div, Tsukuba, Ibaraki 3058575, Japan; [Kawamura, Ryo] Univ Tsukuba, Cardiovasc Div, Grad Sch Comprehens Human Sci, Tsukuba, Ibaraki 3058575, Japan	Seo, Y (reprint author), Univ Tsukuba, Fac Med, Cardiovasc Div, 1-1-1 Tennodai, Tsukuba, Ibaraki 3058575, Japan.	yo-seo@md.tsukuba.ac.jp					VASSALLO JA, 1984, CIRCULATION, V69, P914; Seo Y, 2011, JACC-CARDIOVASC IMAG, V4, P358, DOI 10.1016/j.jcmg.2010.12.007; Chung ES, 2008, CIRCULATION, V117, P2608, DOI 10.1161/CIRCULATIONAHA.107.743120; Marechaux S, 2014, J AM SOC ECHOCARDIOG, V27, P501, DOI 10.1016/j.echo.2014.01.004; Tanaka H, 2010, EUR HEART J, V31, P1690, DOI 10.1093/eurheartj/ehq213; Sohal M, 2013, JACC-CARDIOVASC IMAG, V6, P864, DOI 10.1016/j.jcmg.2012.11.019; Strauss DG, 2011, AM J CARDIOL, V107, P927, DOI 10.1016/j.amjcard.2010.11.010; Auricchio A, 2004, CIRCULATION, V109, P1133, DOI 10.1161/01.CIR.0000118502.91105.F6; Bilchick KC, 2014, J AM COLL CARDIOL, V63, P1657, DOI 10.1016/j.jacc.2014.02.533; Chan YH, 2013, J AM SOC ECHOCARDIOG, V26, P307, DOI 10.1016/j.echo.2012.11.012; Epstein AE, 2013, J AM COLL CARDIOL, V61, pE6, DOI 10.1016/j.jacc.2012.11.007; Fung JWH, 2007, HEART, V93, P432, DOI 10.1136/hrt.2007.115295; Sade LE, 2014, J AM SOC ECHOCARDIOG, V27, P648, DOI 10.1016/j.echo.2014.01.025; Seo Y, 2013, CIRC J, V77, P2481, DOI 10.1253/circj.CJ-13-0380; Seo Y, 2011, CIRC J, V75, P1156, DOI 10.1253/circj.CJ-10-0861; Strik M, 2012, J CARDIOVASC TRANSL, V5, P117, DOI 10.1007/s12265-012-9351-1	16	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0894-7317			J AM SOC ECHOCARDIOG	J. Am. Soc. Echocardiogr.	MAY	2015	28	5					606	614		10.1016/j.echo.2015.02.003		9	Cardiac & Cardiovascular Systems	Cardiovascular System & Cardiology	CH2ZJ	WOS:000353894400014		
J	Shibuya, R; Sato, K; Tomikawa, Y; Tsutsumi, M; Sato, T				Shibuya, Ryosuke; Sato, Kaoru; Tomikawa, Yoshihiro; Tsutsumi, Masaki; Sato, Toru			A Study of Multiple Tropopause Structures Caused by Inertia-Gravity Waves in the Antarctic	JOURNAL OF THE ATMOSPHERIC SCIENCES			English	Article							GENERAL-CIRCULATION MODEL; LOWER STRATOSPHERE; SOUTHERN-HEMISPHERE; MOMENTUM FLUXES; CLIMATE MODELS; PART I; BREAKING; PARAMETERIZATION; COORDINATE; TRANSPORT	Multiple tropopauses (MTs) defined by theWorldMeteorologicalOrganization are frequently detected from autumn to spring at Syowa Station (69.0 degrees S, 39.6 degrees E). The dynamical mechanism of MT events was examined by observations of the first mesosphere-stratosphere-troposphere (MST) radar in the Antarctic, the Program of the Antarctic Syowa MST/Incoherent Scatter (IS) Radar (PANSY), and of radiosondes on 8-11 April 2013. The MT structure above the first tropopause is composed of strong temperature fluctuations. By a detailed analysis of observed three-dimensional wind and temperature fluctuation components, it is shown that the phase and amplitude relations between these components are consistent with the theoretical characteristics of linear inertia-gravity waves (IGWs). Numerical simulations were performed by using a nonhydrostatic model. The simulated MT structures and IGW parameters agree well with the observation. In the analysis using the numerical simulation data, it is seen that IGWs were generated around 65 degrees S, 15 degrees E and around 70 degrees S, 15 degrees E, propagated eastward, and reached the region above Syowa Station when the MT event was observed. These IGWs were likely radiated spontaneously from the upper-tropospheric flow around 65 degrees S, 15 degrees E and were forced by strong southerly surface winds over steep topography (70 degrees S, 15 degrees E). The MT occurrence is attributable to strong IGWs and the low mean static stability in the polar winter lower stratosphere. It is also shown that nonorographic gravity waves associated with the tropopause folding event contribute to 40% of the momentum fluxes, as shown by a gravity wave-resolving general circulation model in the lower stratosphere around 65 degrees S. This result indicates that they are one of the key components for solving the cold-bias problem found in most climate models.	[Shibuya, Ryosuke; Sato, Kaoru] Univ Tokyo, Dept Earth & Planetary Sci, Tokyo 1130033, Japan; [Tomikawa, Yoshihiro; Tsutsumi, Masaki] Natl Inst Polar Res, Tokyo, Japan; [Tomikawa, Yoshihiro; Tsutsumi, Masaki] Grad Univ Adv Studies SOKENDAI, Tokyo, Japan; [Sato, Toru] Kyoto Univ, Dept Commun & Comp Engn, Kyoto, Japan	Shibuya, R (reprint author), Univ Tokyo, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1130033, Japan.	shibuya@eps.s.u-tokyo.ac.jp	Tomikawa, Yoshihiro/D-5304-2012; Satoh, Kaoru/P-2047-2015	Tomikawa, Yoshihiro/0000-0002-5652-3017; 	program for Leading Graduate Schools, MEXT, Japan; Japan Society for the Promotion of Science (JSPS) [25247075, 26-9257]	The authors thank associate professors H. Miura and M. Koike for their many useful comments and discussions. Numerical simulations were run on the supercomputer in NIPR. All figures in this paper are pictured by using Dennou Club Library (DCL). This work was supported by the program for Leading Graduate Schools, MEXT, Japan. This study was also supported by Grant-in-Aid Scientific Research (A) 25247075 and by Grant-in-Aid for Research Fellow (26-9257) provided by the Japan Society for the Promotion of Science (JSPS).	Anel JA, 2008, J GEOPHYS RES-ATMOS, V113, DOI 10.1029/2007JD009697; Tomita H, 2005, GEOPHYS RES LETT, V32, DOI 10.1029/2005GL022459; Olsen MA, 2010, J GEOPHYS RES-ATMOS, V115, DOI 10.1029/2009JD013004; Birner T, 2010, J ATMOS SCI, V67, P2582, DOI 10.1175/2010JAS3287.1; Nakanishi M, 2004, BOUND-LAY METEOROL, V112, P1, DOI 10.1023/B:BOUN.0000020164.04146.98; Dee DP, 2011, Q J ROY METEOR SOC, V137, P553, DOI 10.1002/qj.828; Scinocca JF, 2003, J ATMOS SCI, V60, P667, DOI 10.1175/1520-0469(2003)060<0667:AASNGW>2.0.CO;2; Yoshiki M, 2000, J GEOPHYS RES-ATMOS, V105, P17995, DOI 10.1029/2000JD900204; Miura H, 2007, SCIENCE, V318, P1763, DOI 10.1126/science.1148443; Zhang FQ, 2004, J ATMOS SCI, V61, P440, DOI 10.1175/1520-0469(2004)061<0440:GOMGWI>2.0.CO;2; Olsen MA, 2008, GEOPHYS RES LETT, V35, DOI 10.1029/2008GL035514; Koch SE, 2005, J ATMOS SCI, V62, P3885, DOI 10.1175/JAS3574.1; [Anonymous], 2008, WPA WRITING PROGRAM, V31.3, P3, DOI DOI 10.1175/2008JAS2539.1; Watanabe S, 2008, J GEOPHYS RES-ATMOS, V113, DOI 10.1029/2008JD010026; Stolarski RS, 2006, GEOPHYS RES LETT, V33, DOI 10.1029/2006GL026820; McLandress C, 2012, J ATMOS SCI, V69, P802, DOI 10.1175/JAS-D-11-0159.1; Klemp JB, 2011, MON WEATHER REV, V139, P2163, DOI 10.1175/MWR-D-10-05046.1; Satoh M, 2008, J COMPUT PHYS, V227, P3486, DOI 10.1016/j.jcp.2007.02.006; Hertzog A, 2008, J ATMOS SCI, V65, P3056, DOI 10.1175/2008JAS2710.1; Plougonven R, 2007, J ATMOS SCI, V64, P2502, DOI 10.1175/JAS3953.1; Schmidt T, 2006, GEOPHYS RES LETT, V33, DOI 10.1029/2005GL024600; Alexander MJ, 2009, GEOPHYS RES LETT, V36, DOI 10.1029/2009GL038587; Sato K, 2009, GEOPHYS RES LETT, V36, DOI 10.1029/2009GL039908; Geller MA, 2013, J CLIMATE, V26, P6383, DOI 10.1175/JCLI-D-12-00545.1; Plougonven R, 2005, GEOPHYS RES LETT, V32, DOI 10.1029/2005GL023730; Plougonven R, 2013, Q J ROY METEOR SOC, V139, P101, DOI 10.1002/qj.1965; Berthet G, 2007, J GEOPHYS RES-ATMOS, V112, DOI 10.1029/2006JD008295; [Anonymous], 2014, TOTENTANZ ERSTE WELT, V64, DOI DOI 10.1016/J.JASTP.2013.08.022; Richter JH, 2010, J ATMOS SCI, V67, P136, DOI 10.1175/2009JAS3112.1; Schar C, 2002, MON WEATHER REV, V130, P2459, DOI 10.1175/1520-0493(2002)130<2459:ANTFVC>2.0.CO;2; Sato K, 2012, J ATMOS SCI, V69, P1378, DOI 10.1175/JAS-D-11-0101.1; Vogel B, 2011, J GEOPHYS RES-ATMOS, V116, DOI 10.1029/2010JD014876; Randel WJ, 2007, J GEOPHYS RES-ATMOS, V112, DOI 10.1029/2006JD007904; VINCENT RA, 1983, J ATMOS SCI, V40, P1321, DOI 10.1175/1520-0469(1983)040<1321:HDMOMG>2.0.CO;2; Pan LL, 2009, J GEOPHYS RES-ATMOS, V114, DOI 10.1029/2008JD011374; TRENBERTH KE, 1991, J ATMOS SCI, V48, P2159, DOI 10.1175/1520-0469(1991)048<2159:STITSH>2.0.CO;2; GALCHEN T, 1975, J COMPUT PHYS, V17, P209, DOI 10.1016/0021-9991(75)90037-6; Tomikawa Y, 2009, SOLA, V5, P141, DOI 10.2151/sola.2009-036; Gettelman A, 2011, REV GEOPHYS, V49, DOI 10.1029/2011RG000355; Pavelin E, 2001, J GEOPHYS RES-ATMOS, V106, P5173, DOI 10.1029/2000JD900480; Beres JH, 2004, J ATMOS SCI, V61, P324, DOI 10.1175/1520-0469(2004)061<0324:AMOSTG>2.0.CO;2; Buhler O, 2005, J FLUID MECH, V534, P67, DOI 10.1017/S0022112005004374; DANIELSEN EF, 1991, J GEOPHYS RES-ATMOS, V96, P17433, DOI 10.1029/91JD01362; ECKERMANN SD, 1989, J GEOPHYS RES-ATMOS, V94, P6333, DOI 10.1029/JD094iD05p06333; Eyring V., 2010, 5 SPARC; Geller MA, 2011, J CLIMATE, V24, P3989, DOI 10.1175/2011JCLI4013.1; Guest FM, 2000, J ATMOS SCI, V57, P737, DOI 10.1175/1520-0469(2000)057<0737:IGWOIT>2.0.CO;2; Haynes P, 2000, J GEOPHYS RES-ATMOS, V105, P22795, DOI 10.1029/2000JD900092; Hertzog A, 2001, ANN GEOPHYS, V19, P1141; Hoskins B. J., 1985, J ROY METEOR SOC, V111, P877, DOI [10.1002/qj.49711147002, DOI 10.1002/QJ.49711147002]; KEYSER D, 1986, MON WEATHER REV, V114, P452, DOI 10.1175/1520-0493(1986)114<0452:AROTSA>2.0.CO;2; Lamarque JF, 1996, J GEOPHYS RES-ATMOS, V101, P22969, DOI 10.1029/96JD02442; O'Sullivan D., 1995, J ATMOS SCI, V52, DOI DOI 10.1175/1520-0469(1995)052; PEDLOSKY J., 1987, GEOPHYS FLUID DYNAMI; Peevey TR, 2014, J GEOPHYS RES-ATMOS, V119, DOI 10.1002/2014JD021808; Rao TN, 2008, J GEOPHYS RES-ATMOS, V113, DOI 10.1029/2007JD009638; Sato K, 2014, J ATMOS SOL-TERR PHY, V118, P2, DOI 10.1016/j.jastp.2013.08.022; SATO K, 1994, J GEOPHYS RES-ATMOS, V99, P20623, DOI 10.1029/94JD01818; Sato K, 1997, GEOPHYS RES LETT, V24, P1739, DOI 10.1029/97GL01759; Shibata T, 2003, J GEOPHYS RES-ATMOS, V108, DOI 10.1029/2002JD002713; Vaughan G, 2007, Q J ROY METEOR SOC, V133, P179, DOI 10.1002/qj.142; Wilcox LJ, 2012, Q J ROY METEOR SOC, V138, P561, DOI 10.1002/qj.951; WMO, 1957, WMO B, V6, P134; Zhang FQ, 2001, Q J ROY METEOR SOC, V127, P2209; Zulicke C, 2006, J ATMOS SCI, V63, P3253, DOI 10.1175/JAS3805.1; Zulicke C, 2008, MON WEATHER REV, V136, P98, DOI 10.1175/2007MWR2060.1	66	0	0	AMER METEOROLOGICAL SOC	BOSTON	45 BEACON ST, BOSTON, MA 02108-3693 USA	0022-4928	1520-0469		J ATMOS SCI	J. Atmos. Sci.	MAY	2015	72	5					2109	2130		10.1175/JAS-D-14-0228.1		22	Meteorology & Atmospheric Sciences	Meteorology & Atmospheric Sciences	CH2FC	WOS:000353840100024		
J	Nishikawa, J; Ohtsuka, S; Mulyadi; Mujiono, N; Lindsay, DJ; Miyamoto, H; Nishida, S				Nishikawa, Jun; Ohtsuka, Susumu; Mulyadi; Mujiono, Nova; Lindsay, Dhugal J.; Miyamoto, Hiroomi; Nishida, Shuhei			A new species of the commercially harvested jellyfish Crambionella (Scyphozoa) from central Java, Indonesia with remarks on the fisheries	JOURNAL OF THE MARINE BIOLOGICAL ASSOCIATION OF THE UNITED KINGDOM			English	Article						jellyfish; new species; fisheries; Indonesia; Crambionella; taxonomy; Scyphozoa; Rhizostomeae	ST-LUCIA ESTUARY; SOUTHEAST-ASIA; RHIZOSTOMEAE; AFRICA	We describe a new species of Crambionella, C. helmbiru, from central Java, Indonesia. The combination of the mean number of lappets per octant (14), presence of foliaceous appendages amongst frills on oral-arms, absence of tubercles on the velar lappets, proportion of terminal club length to oral-arm length (0.28), and the body colour distinguish this species from three previously described congeners. In addition, the analysis of partial sequences of the cytochrome c oxidase subunit I gene indicate substantial genetic differences from both Crambionella orsini and Crambionella stuhlmanni, supporting the validity of this new species. A combination of morphological and genetic approaches determined that the remarkable differences in exumbrellar colours observed in specimens are simply intra-specific variation. Surprisingly, this species has been commercially harvested for more than 20 years and is well-known to the local people in the region, yet it had remained unknown to science until this point. The commercial fisheries targeting this formerly unknown species are also described in detail.	[Nishikawa, Jun; Miyamoto, Hiroomi; Nishida, Shuhei] Tokai Univ, Sch Marine Sci & Technol, Shimizu, Shizuoka 4248610, Japan; [Ohtsuka, Susumu] Hiroshima Univ, Grad Sch Biosphere Sci, Takehara Marine Sci Stn, Hiroshima 7250024, Japan; [Mulyadi; Mujiono, Nova] Indonesian Inst Sci, Biol Res Ctr, Div Zool, Cibinong 16911, Indonesia; [Lindsay, Dhugal J.] Japan Agcy Marine Earth Sci & Technol, Yokosuka, Kanagawa 2370061, Japan	Nishikawa, J (reprint author), Tokai Univ, Sch Marine Sci & Technol, 3-20-1 Orido, Shimizu, Shizuoka 4248610, Japan.	jun_nishikawa@tokai-u.jp			Japanese Society for the Promotion of Science (JSPS) KAKENHI [23405031, 26304030, 20380110, 25304031, 24248032]; bilateral joint project between Japan and Indonesia (LIPI); JSPS for the Asian CORE Programme (Coastal Marine Science in Southeast Asia: COMSEA)	This work was supported by grants from the Japanese Society for the Promotion of Science (JSPS) KAKENHI (J.N., grant numbers 23405031, 26304030), (S.O., grant numbers 20380110, 25304031), (D.L., grant number 24248032), a bilateral joint project between Japan and Indonesia (LIPI), and the JSPS for the Asian CORE Programme (Coastal Marine Science in Southeast Asia: COMSEA).	Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Billett DSM, 2006, LIMNOL OCEANOGR, V51, P2077; Perissinotto R, 2013, AFR INVERTEBR, V54, P161; Tamura K, 2007, MOL BIOL EVOL, V24, P1596, DOI 10.1093/molbev/msm092; Daryanabard R, 2008, J MAR BIOL ASSOC UK, V88, P477, DOI 10.1017/S0025315408000945; Folmer O., 1994, Molecular Marine Biology and Biotechnology, V3, P294; Hsieh YHP, 2001, HYDROBIOLOGIA, V451, P11, DOI 10.1023/A:1011875720415; Omori M, 2001, HYDROBIOLOGIA, V451, P19, DOI 10.1023/A:1011879821323; Ohtsuka Susumu, 2009, Plankton & Benthos Research, V4, P1; Kingsford MJ, 2000, OCEANOGR MAR BIOL, V38, P85; Nishikawa Jun, 2008, Plankton & Benthos Research, V3, P227; Dawson MN, 1998, MOL MAR BIOL BIOTECH, V7, P145; Dawson MN, 2005, J BIOGEOGR, V32, P515, DOI 10.1111/j.1365-2699.2004.01193.x; Dawson MN, 2001, BIOL BULL, V200, P92, DOI 10.2307/1543089; Chun C., 1896, BEITRAGE KENNTNISS O, V13, P1; Cuvier G., 1799, J PHYS CHIM HIST, V49, P436; HERRING PJ, 1965, NATURE, V205, P103, DOI 10.1038/205103a0; Hon H.-C., 1978, HAI TSUE; Kitamura Minoru, 2010, Plankton & Benthos Research, V5, P106; Kramp P.L., 1961, J MAR BIOL ASSOC UK, V40, P1, DOI DOI 10.1017/S0025315400007347; KRAMP P. L., 1956, VIDENSK MEDDEL DANSK NATURHIST FOR KOBENHAVN, V118, P235; Manuputty A.E.W., 1988, OSEANA, V8, P49; Menon M. G. K., 1930, Bulletin of the Madras Government Museum, V3, P1; Menon M. G. K., 1936, Bulletin of the Madras Government Museum New Series Natural History Sect, V1 2 3, P1; Nair K. K., 1954, Bulletin of the Central Research Institute University of Travancore, V2C, P47; Neethling S, 2011, J MAR BIOL ASSOC UK, V91, P357, DOI 10.1017/S0025315410001566; Nishida S., 2011, COASTAL MARINE SCI S, P59; Nishikawa J., 2009, KAIYO MONTHLY, V41, P401; Ohtsuka S, 2010, B HIROSHIMA U MUSEUM, V2, P9; Omori M., 2011, Midoriishi, V22, P1; Quinn G., 2002, HYPOTHESIS TESTING E, P32; Ranson G., 1945, B MUS NATL HIST NAT, V16, P312; Rao H. S., 1931, Records of the Indian Museum, V33, P25; Stiasny G., 1937, Scientific Reports John Murray Expedition 1933-34 London, V4, P203; Stiasny G., 1921, CAPITA ZOOLOGICA DEE, V1, P179; Vanhoffen E., 1888, BIBLIOTHECA ZOOLOGIC, V1, P52	36	0	0	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	0025-3154	1469-7769		J MAR BIOL ASSOC UK	J. Mar. Biol. Assoc. U.K.	MAY	2015	95	3					471	481		10.1017/S002531541400157X		11	Marine & Freshwater Biology	Marine & Freshwater Biology	CG8WE	WOS:000353595500005		
J	Murakoshi, H; Akahoshi, T; Koyanagi, M; Chikata, T; Naruto, T; Maruyama, R; Tamura, Y; Ishizuka, N; Gatanaga, H; Oka, S; Takiguchi, M				Murakoshi, Hayato; Akahoshi, Tomohiro; Koyanagi, Madoka; Chikata, Takayuki; Naruto, Takuya; Maruyama, Rie; Tamura, Yoshiko; Ishizuka, Naoki; Gatanaga, Hiroyuki; Oka, Shinichi; Takiguchi, Masafumi			Clinical Control of HIV-1 by Cytotoxic T Cells Specific for Multiple Conserved Epitopes	JOURNAL OF VIROLOGY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; VIRAL LOAD; JAPANESE POPULATION; LYMPHOCYTE RESPONSE; EFFICACY TRIAL; ESCAPE; TYPE-1; INFECTION; REGIONS; VACCINE	Identification and characterization of CD8(+) T cells effectively controlling HIV-1 variants are necessary for the development of AIDS vaccines and for studies of AIDS pathogenesis, although such CD8(+) T cells have been only partially identified. In this study, we sought to identify CD8(+) T cells controlling HIV-1 variants in 401 Japanese individuals chronically infected with HIV-1 subtype B, in which protective alleles HLA-B*57 and HLA-B*27 are very rare, by using comprehensive and exhaustive methods. We identified 13 epitope-specific CD8(+) T cells controlling HIV-1 in Japanese individuals, though 9 of these epitopes were not previously reported. The breadths of the T cell responses to the 13 epitopes were inversely associated with plasma viral load (P = 2.2 x 10(-11)) and positively associated with CD4 count (P = 1.2 x 10(-11)), indicating strong synergistic effects of these T cells on HIV-1 control in vivo. Nine of these epitopes were conserved among HIV-1 subtype B-infected individuals, whereas three out of four nonconserved epitopes were cross-recognized by the specific T cells. These findings indicate that these 12 epitopes are strong candidates for antigens for an AIDS vaccine. The present study highlighted a strategy to identify CD8(+) T cells controlling HIV-1 and demonstrated effective control of HIV-1 by those specific for 12 conserved or cross-reactive epitopes. IMPORTANCE HLA-B*27-restricted and HLA-B*57-restricted cytotoxic T lymphocytes (CTLs) play a key role in controlling HIV-1 in Caucasians and Africans, whereas it is unclear which CTLs control HIV-1 in Asian countries, where HLA-B*57 and HLA-B*27 are very rare. A recent study showed that HLA-B*67:01 and HLA-B*52:01-C*12:02 haplotypes were protective alleles in Japanese individuals, but it is unknown whether CTLs restricted by these alleles control HIV-1. In this study, we identified 13 CTLs controlling HIV-1 in Japan by using comprehensive and exhaustive methods. They included 5 HLA-B*52:01-restricted and 3 HLA-B*67:01-restricted CTLs, suggesting that these CTLs play a predominant role in HIV-1 control. The 13 CTLs showed synergistic effects on HIV-1 control. Twelve out of these 13 epitopes were recognized as conserved or cross-recognized ones. These findings strongly suggest that these 12 epitopes are candidates for antigens for AIDS vaccines.	[Murakoshi, Hayato; Akahoshi, Tomohiro; Koyanagi, Madoka; Chikata, Takayuki; Naruto, Takuya; Maruyama, Rie; Tamura, Yoshiko; Gatanaga, Hiroyuki; Oka, Shinichi; Takiguchi, Masafumi] Kumamoto Univ, Ctr AIDS Res, Chuo Ku, Kumamoto, Japan; [Takiguchi, Masafumi] Kumamoto Univ, Int Res Ctr Med Sci, Chuo Ku, Kumamoto, Japan; [Ishizuka, Naoki] Canc Inst Hosp, Clin Trial Dept, Koto Ku, Tokyo, Japan; [Gatanaga, Hiroyuki; Oka, Shinichi] Natl Ctr Global Hlth & Med, AIDS Clin Ctr, Shinjuku Ku, Tokyo, Japan	Takiguchi, M (reprint author), Kumamoto Univ, Ctr AIDS Res, Chuo Ku, Kumamoto, Japan.	masafumi@kumamoto-u.ac.jp	Takiguchi, Masafumi/E-7468-2013		Global COE program Global Education and Research Center Aiming at the Control of AIDS; Ministry of Health, Labor, and Welfare [H24-AIDS-007]; Ministry of Education, Science, Sports and Culture, Japan [26293240, 25870550]	This research was supported by the Global COE program Global Education and Research Center Aiming at the Control of AIDS, launched as a project commissioned by the Ministry of Education, Science, Sports, and Culture, Japan, by a grant-in-aid for AIDS Research (H24-AIDS-007) from the Ministry of Health, Labor, and Welfare, and by a grant-in-aid (26293240, 25870550) for scientific research from the Ministry of Education, Science, Sports and Culture, Japan.	Hammer SM, 2013, NEW ENGL J MED, V369, P2083, DOI 10.1056/NEJMoa1310566; Iglesias MC, 2011, BLOOD, V118, P2138, DOI 10.1182/blood-2011-01-328781; Streeck H, 2014, J VIROL, V88, P12793, DOI 10.1128/JVI.02016-14; Day CL, 2006, NATURE, V443, P350, DOI 10.1038/nature05115; Naruto T, 2012, J VIROL, V86, P10870, DOI 10.1128/JVI.00689-12; Kiepiela P, 2007, NAT MED, V13, P46, DOI 10.1038/nm1520; Jia MM, 2012, CELL RES, V22, P903, DOI 10.1038/cr.2012.19; Migueles SA, 2002, NAT IMMUNOL, V3, P1061, DOI 10.1038/ni845; Rerks-Ngarm S, 2009, NEW ENGL J MED, V361, P2209, DOI 10.1056/NEJMoa0908492; Yang HB, 2012, J INFECT DIS, V206, P552, DOI 10.1093/infdis/jis379; Goulder PJR, 1997, NAT MED, V3, P212, DOI 10.1038/nm0297-212; Brockman MA, 2007, J VIROL, V81, P12608, DOI 10.1128/JVI.01369-07; Almeida JR, 2007, J EXP MED, V204, P2473, DOI 10.1084/jem.20070784; Crawford H, 2009, J EXP MED, V206, P909, DOI 10.1084/jem.20081984; Addo MM, 2003, J VIROL, V77, P2081, DOI 10.1128/JVI.77.3.2081-2092.2003; Yagita Y, 2013, J VIROL, V87, P2253, DOI 10.1128/JVI.02572-12; Betts MR, 2006, BLOOD, V107, P4781, DOI 10.1182/blood-2005-12-4818; Zuniga R, 2006, J VIROL, V80, P3122, DOI 10.1128/JVI.80.6.3122-3125.2006; Edwards BH, 2002, J VIROL, V76, P2298, DOI 10.1128/JVI.76.5.2298-2305.2002; Leslie AJ, 2004, NAT MED, V10, P282, DOI 10.1038/nm992; Chikata T, 2014, J VIROL, V88, P4764, DOI 10.1128/JVI.00147-14; Almeida JR, 2009, BLOOD, V113, P6351, DOI 10.1182/blood-2009-02-206557; Frahm N, 2004, J VIROL, V78, P2187, DOI 10.1128/JVI.78.5.2187-2200.2004; Geldmacher C, 2007, J VIROL, V81, P2440, DOI 10.1128/JVI.01847-06; Haynes BF, 2012, NEW ENGL J MED, V366, P1275, DOI 10.1056/NEJMoa1113425; Saez-Cirion A, 2007, P NATL ACAD SCI USA, V104, P6776, DOI 10.1073/pnas.0611244104; Storey JD, 2003, P NATL ACAD SCI USA, V100, P9440, DOI 10.1073/pnas.1530509100; Masemola A, 2004, J VIROL, V78, P3233, DOI 10.1128/JVI.78.7.3233-3243.2004; FALK K, 1995, IMMUNOGENETICS, V41, P165, DOI 10.1007/BF00182333; Knudsen ML, 2012, J VIROL, V86, P4082, DOI 10.1128/JVI.06535-11; Borghan MA, 2005, TISSUE ANTIGENS, V66, P305, DOI 10.1111/j.1399-0039.2005.00489.x; Borthwick N, 2014, MOL THER, V22, P464, DOI 10.1038/mt.2013.248; Fujiwara M, 2008, J VIROL, V82, P138, DOI 10.1128/JVI.01452-07; Honda K, 2011, EUR J IMMUNOL, V41, P97, DOI 10.1002/eji.201040841; Koizumi H, 2010, J VIROL, V84, P5508, DOI 10.1128/JVI.02483-09; Ladell K, 2013, IMMUNITY, V38, P425, DOI 10.1016/j.immuni.2012.11.021; Letourneau S, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000984; Mothe B, 2011, J TRANSL MED, V9, DOI 10.1186/1479-5876-9-208; Novitsky V, 2003, J VIROL, V77, P882, DOI 10.1128/JVI.77.2.882-890.2003; Pereyra F, 2014, J VIROL, V88, P12937, DOI 10.1128/JVI.01004-14; Rolland M, 2007, PLOS PATHOG, V3, P1551, DOI 10.1371/journal.ppat.0030157; Rosario M, 2010, EUR J IMMUNOL, V40, P1973, DOI 10.1002/eji.201040344; Rosario M, 2012, AIDS, V26, P275, DOI 10.1097/QAD.0b013e32834ed9b2; Rowland-Jones SL, 1998, J CLIN INVEST, V102, P1758, DOI 10.1172/JCI4314; Watanabe K, 2013, MICROBES INFECT, V15, P874, DOI 10.1016/j.micinf.2013.08.002; Watanabe T, 2011, MICROBES INFECT, V13, P160, DOI 10.1016/j.micinf.2010.10.006	46	1	1	AMER SOC MICROBIOLOGY	WASHINGTON	1752 N ST NW, WASHINGTON, DC 20036-2904 USA	0022-538X	1098-5514		J VIROL	J. Virol.	MAY	2015	89	10					5330	5339		10.1128/JVI.00020-15		10	Virology	Virology	CG5KB	WOS:000353329300014		
J	Shinozaki-Ushiku, A; Kunita, A; Isogai, M; Hibiya, T; Ushiku, T; Takada, K; Fukayama, M				Shinozaki-Ushiku, Aya; Kunita, Akiko; Isogai, Maya; Hibiya, Takashi; Ushiku, Tetsuo; Takada, Kenzo; Fukayama, Masashi			Profiling of Virus-Encoded MicroRNAs in Epstein-Barr Virus-Associated Gastric Carcinoma and Their Roles in Gastric Carcinogenesis	JOURNAL OF VIROLOGY			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; LARGE GENE LISTS; B-CELL LYMPHOMA; NASOPHARYNGEAL CARCINOMA; MIR-200 FAMILY; REPRESSORS ZEB1; EBV; EXPRESSION; INFECTION; IDENTIFICATION	Epstein-Barr virus (EBV) is one of the major oncogenic viruses and is found in nearly 10% of gastric carcinomas. EBV is known to encode its own microRNAs (miRNAs); however, their roles have not been fully investigated. The present report is the largest series to comprehensively profile the expression of 44 known EBV miRNAs in tissue samples from patients with EBV-associated gastric carcinoma. Several miRNAs were highly expressed in EBV-associated gastric carcinoma, and in silico analysis revealed that the target genes of these EBV miRNAs had functions associated with cancer-related pathways, especially the regulation of apoptosis. Apoptosis was reduced in EBV-associated gastric carcinoma tissue samples, and gastric carcinoma cell lines infected with EBV exhibited downregulation of the proapoptotic protein Bid (the BH3-interacting domain death agonist), a member of the Bcl-2 family. The luciferase activity of the reporter vector containing the 3 ' untranslated region of BID was inhibited by an ebv-miR-BART4-5p mimic in gastric cancer cell lines. Transfection of an ebvmiR-BART4-5p mimic reduced Bid expression in EBV-negative cell lines, leading to reduced apoptosis under serum deprivation. The inhibition of ebv-miR-BART4-5p expression was associated with partial recovery of Bid levels in EBV-positive cell lines. The results demonstrated the antiapoptotic role of EBV miRNA via regulation of Bid expression in EBV-associated gastric carcinoma. These findings provide novel insights in the roles of EBV miRNAs in gastric carcinogenesis, which would be a potential therapeutic target. IMPORTANCE This report is the largest series to comprehensively profile the expression of 44 known EBV miRNAs in clinical samples from EBV-associated gastric carcinoma patients. Of the EBV miRNAs, ebv-miR-BART4-5p plays an important role in gastric carcinogenesis via regulation of apoptosis.	[Shinozaki-Ushiku, Aya; Kunita, Akiko; Isogai, Maya; Ushiku, Tetsuo; Fukayama, Masashi] Univ Tokyo, Grad Sch Med, Dept Pathol, Tokyo, Japan; [Hibiya, Takashi] Yokohama City Univ Med, Dept Pathol, Yokohama, Kanagawa, Japan; [Takada, Kenzo] Hokkaido Univ, Sapporo, Hokkaido, Japan	Fukayama, M (reprint author), Univ Tokyo, Grad Sch Med, Dept Pathol, Tokyo, Japan.	mfukayama-tky@umin.org			Japan Society for the Promotion of Science (JSPS) [25860262]; Ministry of Education, Culture, Sports, Science, and Technology (MEXT) [25114702]	This work was supported by a Grant-in-Aid for Young Scientists (B) from the Japan Society for the Promotion of Science (JSPS) (grant number 25860262) to A.S-U. and a Grant-in-Aid for Scientific Research on Innovative Areas from the Ministry of Education, Culture, Sports, Science, and Technology (MEXT) (grant number 25114702) to M.F.	Gourzones C, 2013, VIROL J, V10, DOI 10.1186/1743-422X-10-119; Kutok JL, 2006, ANNU REV PATHOL-MECH, V1, P375, DOI 10.1146/annurev.pathol.1.110304.100209; Lung RWM, 2013, INT J MOL SCI, V14, P17378, DOI 10.3390/ijms140917378; Wong AMG, 2012, CANCER-AM CANCER SOC, V118, P698, DOI 10.1002/cncr.26309; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Xia T, 2008, CANCER RES, V68, P1436, DOI 10.1158/0008-5472.CAN-07-5126; Cosmopoulos K, 2009, J VIROL, V83, P2357, DOI 10.1128/JVI.02104-08; Pfeffer S, 2004, SCIENCE, V304, P734, DOI 10.1126/science.1096781; Gregory PA, 2008, NAT CELL BIOL, V10, P593, DOI 10.1038/ncb1722; Zhu JY, 2009, J VIROL, V83, P3333, DOI 10.1128/JVI.01689-08; Hino R, 2008, CANCER RES, V68, P1427, DOI 10.1158/0008-5472.CAN-07-3027; Choi H, 2013, J VIROL, V87, P8135, DOI 10.1128/JVI.03159-12; Korpal M, 2008, J BIOL CHEM, V283, P14910, DOI 10.1074/jbc.C800074200; Bracken CP, 2008, CANCER RES, V68, P7846, DOI 10.1158/0008-5472.CAN-08-1942; Riley KJ, 2012, EMBO J, V31, P2207, DOI 10.1038/emboj.2012.63; FUKAYAMA M, 1994, LAB INVEST, V71, P73; Vereide DT, 2014, ONCOGENE, V33, P1258, DOI 10.1038/onc.2013.71; Iwasaki Y, 1998, J VIROL, V72, P8321; Choy EYW, 2008, J EXP MED, V205, P2551, DOI 10.1084/jem.20072581; FUKAYAMA M, 1993, AM J PATHOL, V143, P1044; Young LS, 2003, ONCOGENE, V22, P5108, DOI 10.1038/sj.onc.1206556; Imai S, 1998, J VIROL, V72, P4371; Young LS, 2004, NAT REV CANCER, V4, P757, DOI 10.1038/nrc1452; Shinozaki A, 2010, CANCER RES, V70, P4719, DOI 10.1158/0008-5472.CAN-09-4620; Barth S, 2011, BBA-GENE REGUL MECH, V1809, P631, DOI 10.1016/j.bbagrm.2011.05.010; Marquitz AR, 2012, P NATL ACAD SCI USA, V109, P9593, DOI 10.1073/pnas.1202910109; Marquitz AR, 2011, VIROLOGY, V412, P392, DOI 10.1016/j.virol.2011.01.028; Imig J, 2011, NUCLEIC ACIDS RES, V39, P1880, DOI 10.1093/nar/gkq1043; Kim DN, 2007, J VIROL, V81, P1033, DOI 10.1128/JVI.02271-06; Park SM, 2008, GENE DEV, V22, P894, DOI 10.1101/gad.1640608; Chan JYW, 2012, ANTICANCER RES, V32, P3201; Chen SJ, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012745; Fukayama M, 2008, CANCER SCI, V99, P1726, DOI 10.1111/j.1349-7006.2008.00888.x; Gourzones C, 2010, VIROL J, V7, DOI 10.1186/1743-422X-7-271; Kozomara A, 2014, NUCLEIC ACIDS RES, V42, pD68, DOI 10.1093/nar/gkt1181; Huang DW, 2009, NUCLEIC ACIDS RES, V37, P1, DOI 10.1093/nar/gkn923; Kim DN, 2013, J GEN VIROL, V94, P497, DOI 10.1099/vir.0.045237-0; Motsch N, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042193; Nourse JP, 2012, J VIROL METHODS, V184, P46, DOI 10.1016/j.jviromet.2012.05.005; Qiu J, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002193	40	4	4	AMER SOC MICROBIOLOGY	WASHINGTON	1752 N ST NW, WASHINGTON, DC 20036-2904 USA	0022-538X	1098-5514		J VIROL	J. Virol.	MAY	2015	89	10					5581	5591		10.1128/JVI.03639-14		11	Virology	Virology	CG5KB	WOS:000353329300035		
J	Kato, S; Saito, M; Funasaki, H; Marumo, K				Kato, Soki; Saito, Mitsuru; Funasaki, Hiroki; Marumo, Keishi			Distinctive collagen maturation process in fibroblasts derived from rabbit anterior cruciate ligament, medial collateral ligament, and patellar tendon in vitro	KNEE SURGERY SPORTS TRAUMATOLOGY ARTHROSCOPY			English	Article						Cell culture; Collagen; Cross-linking; Fibroblast; Ligament; Tendon	MESENCHYMAL STEM-CELLS; INTRINSIC-PROPERTIES; AUTOGENOUS PATELLAR; MCL CELLS; ACL; RECONSTRUCTION; MIGRATION; SCAFFOLD; DIFFERENTIATION; OSTEOBLASTS	Differences in the tissue-specific collagen maturation process between tendon and ligament are still unknown. Collagen cross-link formation is crucial for the collagen maturation process. The aim of this study is to examine collagen maturation processes of anterior cruciate ligament (ACL), medial collateral ligament (MCL), and patellar tendon (PT) in vitro, in order to determine the optimal cell source for tissue engineering of ligament. Cells derived from the ACL, MCL, and PT of New Zealand white rabbits were isolated. Each cell type was cultured for up to 4 weeks after reaching confluence. Cell-matrix layers were evaluated and compared for their morphology, collagen cross-links, and gene expression levels of lysine hydroxylase 1 and 2, lysyl oxidase (LOX), tenomodulin, collagen1A1 (Col1A1), and collagen3A1 (Col3A1). Transmission electron microscopy photomicrographs verified that collagen fibrils were secreted from all three types of fibroblasts. A higher ratio of dihydroxylysinonorleucine/hydroxylysinonorleucine was evident in the ligament compared to the tendon, which was consistent with lysine hydroxylase 2/lysine hydroxylase 1 gene expression. The gene expression of LOX, which regulates the total amount of enzymatic cross-linking, and the gene expression levels of Col1A1 and Col3A1 were higher in the ACL matrix than in the MCL and PT matrices. ACL, MCL, and PT cells have distinct collagen maturation processes at the cellular level. In addition, the collagen maturation of ACL cells is not necessarily inferior to that of MCL and PT cells in that all three cell types have a good ability to synthesize collagen and induce collagen maturation. This bioactivity of ACL cells in terms of ligament-specific mature collagen induction can be applied to tissue-engineered ACL reconstruction or remnant preserving procedure with ACL reconstruction.	[Kato, Soki; Saito, Mitsuru; Funasaki, Hiroki; Marumo, Keishi] Jikei Univ, Dept Orthopaed Surg, Sch Med, Minato Ku, Tokyo 1058461, Japan	Kato, S (reprint author), Jikei Univ, Dept Orthopaed Surg, Sch Med, Minato Ku, 3-25-8 Nishi Shinbashi, Tokyo 1058461, Japan.	soki@jikei.ac.jp					AMIEL D, 1995, MED SCI SPORT EXER, V27, P844; AMIEL D, 1984, Journal of Orthopaedic Research, V1, P257; AMIEL D, 1986, J ORTHOPAED RES, V4, P162, DOI 10.1002/jor.1100040204; Fan HB, 2008, BIOMATERIALS, V29, P3324, DOI 10.1016/j.biomaterials.2008.04.012; Fan HB, 2006, J BIOMED MATER RES A, V77A, P785, DOI 10.1002/jbm.a.30647; Van Eijk F, 2004, TISSUE ENG, V10, P893, DOI 10.1089/1076327041348428; Song GY, 2013, ARTHROSCOPY, V29, P1253, DOI 10.1016/j.arthro.2013.03.078; AMIEL D, 1991, J GERONTOL, V46, pB159; Marumo K, 2005, AM J SPORT MED, V33, P1166, DOI 10.1177/0363546504271973; Guidoin MF, 2000, BIOMATERIALS, V21, P2461, DOI 10.1016/S0142-9612(00)00114-9; Saito M, 2004, BONE, V35, P644, DOI 10.1016/j.bone.2004.04.024; Saito M, 2003, J BONE MINER RES, V18, P1695, DOI 10.1359/jbmr.2003.18.9.1695; Saito M, 1997, ANAL BIOCHEM, V253, P26, DOI 10.1006/abio.1997.2350; Fan HB, 2006, BIOMATERIALS, V27, P4573, DOI 10.1016/j.biomaterials.2006.04.013; Lu HH, 2005, BIOMATERIALS, V26, P4805, DOI 10.1016/j.biomaterials.2004.11.050; Saito M, 2010, OSTEOPOROSIS INT, V21, P195, DOI 10.1007/s00198-009-1066-z; Ge ZG, 2005, CELL TRANSPLANT, V14, P573, DOI 10.3727/000000005783982819; Laurencin CT, 1999, ANNU REV BIOMED ENG, V1, P19, DOI 10.1146/annurev.bioeng.1.1.19; LABARCA C, 1980, ANAL BIOCHEM, V102, P344, DOI 10.1016/0003-2697(80)90165-7; BOLTON CW, 1985, CLIN ORTHOP RELAT R, P202; Chen Honghui, 2002, Chin J Traumatol, V5, P92; Chun J, 2003, CONNECT TISSUE RES, V44, P81, DOI 10.1080/03008200390200210; Cooper JA, 2006, BIOMATERIALS, V27, P2747, DOI 10.1016/j.biomaterials.2005.12.013; Date H, 2010, J ORTHOP RES, V28, P225, DOI 10.1002/jor.20981; FRANK C, 1995, J ORTHOP RES, V13, P157, DOI 10.1002/jor.1100130203; Fujii K., 1994, SPORTS TRAUMATOL ART, V2, P229; GEIGER MH, 1994, CONNECT TISSUE RES, V30, P215, DOI 10.3109/03008209409061973; Haddad-Weber M, 2010, CYTOTHERAPY, V12, P505, DOI 10.3109/14653241003709652; Hadjicostas PT, 2008, KNEE SURG SPORT TR A, V16, P1099, DOI 10.1007/s00167-008-0603-1; Hankenson KD, 1999, CONNECT TISSUE RES, V40, P13, DOI 10.3109/03008209909005274; Harner C D, 2001, Instr Course Lect, V50, P463; Hiraki Yuji, 2005, Connect Tissue Res, V46, P3, DOI 10.1080/03008200590935547; Kobayashi K, 2000, TISSUE ENG, V6, P29, DOI 10.1089/107632700320865; MCPHERSON GK, 1985, CLIN ORTHOP RELAT R, P186; NAGINENI CN, 1992, J ORTHOPAED RES, V10, P465, DOI 10.1002/jor.1100100402; Oshima Y, 2004, J CELL SCI, V117, P2731, DOI 10.1242/jcs.01112; RICHMOND JC, 1992, AM J SPORT MED, V20, P24, DOI 10.1177/036354659202000107; ROSS SM, 1990, IN VITRO CELL DEV B, V26, P579; Rumian AP, 2007, J ORTHOP RES, V25, P458, DOI 10.1002/jor.20218; Willems MET, 2001, EUR J APPL PHYSIOL, V85, P405, DOI 10.1007/s004210100480; Yoshida M, 1999, J Orthop Sci, V4, P293, DOI 10.1007/s007760050106	41	1	1	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0942-2056	1433-7347		KNEE SURG SPORT TR A	Knee Surg. Sports Traumatol. Arthrosc.	MAY	2015	23	5					1384	1392		10.1007/s00167-013-2773-8		9	Orthopedics; Sport Sciences; Surgery	Orthopedics; Sport Sciences; Surgery	CH2BP	WOS:000353829500017		
J	Matsuo, T; Kita, K; Mae, T; Yonetani, Y; Miyamoto, S; Yoshikawa, H; Nakata, K				Matsuo, Tomohiko; Kita, Keisuke; Mae, Tatsuo; Yonetani, Yasukazu; Miyamoto, Satoshi; Yoshikawa, Hideki; Nakata, Ken			Bone substitutes and implantation depths for subchondral bone repair in osteochondral defects of porcine knee joints	KNEE SURGERY SPORTS TRAUMATOLOGY ARTHROSCOPY			English	Article						Subchondral bone osteochondral defect; Bone substitute; Hydroxyapatite; Beta-tricalcium phosphate	GRAFT SUBSTITUTES; ARTICULAR-CARTILAGE; IN-VIVO; ALLOGRAFTS; MANAGEMENT; CELLS; TUMOR; MODEL	The purpose of this study was to identify the optimal material and implantation method for subchondral bone repair. Four osteochondral defects in a femoral groove were created in both knees of 12 pigs, and the total number of defects was 96. Eight defects were left empty (empty group). Beta-tricalcium phosphate (beta-TCP) bone substitutes with 75 and 67 % porosity were implanted in 30 and 29 defects, respectively (beta-TCP75 and beta-TCP67 groups). Hydroxyapatite (HA) bone substitutes with 75 % porosity were filled in 29 defects (HA group). Bone substitutes were implanted at 0, 2, or 4 mm below the subchondral bone plate (SBP). The reparative tissue was assessed using microfocus computed tomography and histology 3 months after implantation. Regardless of the kind of bone substitutes, the defects were filled almost completely after implanting them at the level of the SBP, while the defects remained after implanting them at 2 or 4 mm below the SBP. Reparative tissue of the beta-TCP75 group was similar to the normal cancellous bone, while that of the beta-TCP67 or HA group was not. Subchondral bone defects were filled almost completely only when bone substitutes were implanted at the level of the SBP. The reparative tissue after implanting the beta-TCP bone substitutes with 75 % porosity was the most similar to the normal cancellous bone. Therefore, implanting the beta-TCP bone substitutes with 75 % porosity at the level of the SBP could be recommended as a treatment method for subchondral bone repair in osteochondral defects. I.	[Matsuo, Tomohiko; Mae, Tatsuo; Yonetani, Yasukazu; Miyamoto, Satoshi; Yoshikawa, Hideki] Osaka Univ, Dept Orthopaed Surg, Grad Sch Med, Suita, Osaka 5650871, Japan; [Kita, Keisuke] Osaka Rosai Hosp, Dept Sports Orthopaed, Kita Ku, Sakai, Osaka 5838555, Japan; [Nakata, Ken] Osaka Univ, Grad Sch Med, Dept Hlth & Sports Sci, Med Sports & Performing Arts, Toyonaka, Osaka 5600043, Japan	Nakata, K (reprint author), Osaka Univ, Grad Sch Med, Dept Hlth & Sports Sci, Med Sports & Performing Arts, 1-17 Machikaneyama Cho, Toyonaka, Osaka 5600043, Japan.	ken-nakata@umin.ac.jp					Arkill KP, 2008, OSTEOARTHR CARTILAGE, V16, P708, DOI 10.1016/j.joca.2007.10.001; Kurien T, 2013, BONE JOINT J, V95B, P583, DOI 10.1302/0301-620X.95B5.30286; Madry H, 2010, KNEE SURG SPORT TR A, V18, P419, DOI 10.1007/s00167-010-1054-z; Shimomura K, 2010, BIOMATERIALS, V31, P8004, DOI 10.1016/j.biomaterials.2010.07.017; Finkemeier CG, 2002, J BONE JOINT SURG AM, V84A, P454; Gomoll AH, 2010, KNEE SURG SPORT TR A, V18, P434, DOI 10.1007/s00167-010-1072-x; Koga H, 2009, KNEE SURG SPORT TR A, V17, P1289, DOI 10.1007/s00167-009-0782-4; Delloye C, 2007, J BONE JOINT SURG BR, V89B, P574, DOI 10.1302/0301-620X.89B5.19039; Wang W, 2010, BIOMATERIALS, V31, P8964, DOI 10.1016/j.biomaterials.2010.08.018; Ando W, 2012, EUR CELLS MATER, V24, P292; Tamai N, 2010, J ORTHOP SCI, V15, P560, DOI 10.1007/s00776-010-1479-8; Reddy S, 2007, AM J SPORT MED, V35, P80, DOI 10.1177/0363546506290986; Yoshikawa H, 2009, J R SOC INTERFACE, V6, pS341, DOI 10.1098/rsif.2008.0425.focus; Matsumine A, 2004, J BONE JOINT SURG BR, V86B, P719, DOI 10.1302/0301-620X.86B5.14242; Lopiz-Morales Y, 2010, EUR CELLS MATER, V20, P367; Tamai N, 2002, J BIOMED MATER RES, V59, P110, DOI 10.1002/jbm.1222; Sakamoto M, 2007, J BIOMED MATER RES A, V82A, P238, DOI 10.1002/jbm.a.31013; Maehara H, 2010, J ORTHOP RES, V28, P677, DOI 10.1002/jor.21032; Benthien JP, 2011, KNEE SURG SPORT TR A, V19, P1316, DOI 10.1007/s00167-010-1356-1; Feng YF, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049955; Goff T, 2013, INJURY, V44, pS86, DOI 10.1016/S0020-1383(13)70019-6; GOLDBERG VM, 1987, CLIN ORTHOP RELAT R, P7; Goto Akira, 2011, Hand Surg, V16, P29, DOI 10.1142/S0218810411005023; Koepp HE, 2004, J BIOMED MATER RES B, V70B, P209, DOI 10.1002/jbm.b.30034; Lafantaisie-Favreau CH, 2013, BMC MUSCULOSKEL DIS, V14, DOI 10.1186/1471-2474-14-27; LaPrade Robert F, 2004, Arthroscopy, V20, pe69, DOI 10.1016/S0749-8063(04)00607-3; Mauffrey C, 2011, INJURY, V42, pS35, DOI 10.1016/j.injury.2011.06.012; Ng AMH, 2008, J BIOMED MATER RES A, V85A, P301, DOI 10.1002/jbm.a.31324; Nosewicz TL, 2012, KNEE SURG SPORT TR A, V20, P1919, DOI 10.1007/s00167-011-1831-3; Oka K, 2010, INT J MED ROBOT COMP, V6, P186, DOI 10.1002/rcs.305; Onodera J, 2014, KNEE SURG SPORT TR A, V22, P2763, DOI 10.1007/s00167-013-2681-y; TOMFORD WW, 1995, J BONE JOINT SURG AM, V77A, P1742; Valderrabano V, 2009, AM J SPORT MED, V37, P105, DOI [DOI 10.1177/0363546509351481, 10.1177/0363546509351481]; Van Hoff Corey, 2012, Am J Orthop (Belle Mead NJ), V41, P20; Yamasaki N, 2009, J BIOMED MATER RES B, V91B, P788, DOI 10.1002/jbm.b.31457	35	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0942-2056	1433-7347		KNEE SURG SPORT TR A	Knee Surg. Sports Traumatol. Arthrosc.	MAY	2015	23	5					1401	1409		10.1007/s00167-014-2853-4		9	Orthopedics; Sport Sciences; Surgery	Orthopedics; Sport Sciences; Surgery	CH2BP	WOS:000353829500019		
J	Hagiwara, Y; Kanazawa, K; Ando, A; Nimura, A; Watanabe, T; Majima, K; Akita, K; Itoi, E				Hagiwara, Yoshihiro; Kanazawa, Kenji; Ando, Akira; Nimura, Akimoto; Watanabe, Takashi; Majima, Kazuhiro; Akita, Keiichi; Itoi, Eiji			Blood flow changes of the anterior humeral circumflex artery decrease with the scapula in internal rotation	KNEE SURGERY SPORTS TRAUMATOLOGY ARTHROSCOPY			English	Article						Humeral circumflex artery; Shoulder; MRI; Blood flow; Scapular position; Posture	SHOULDER STIFFNESS; FROZEN SHOULDER; MUSCLE-ACTIVITY; PASSIVE MOTION; SKIN; KINEMATICS; IMMOBILIZATION; TEMPERATURE; VASCULARITY; SYMPTOMS	Poor posture is strongly related to scapular kinematics and shoulder diseases. The purpose of this study was to clarify the blood flow changes of the anterior and posterior humeral circumflex arteries in reference to the scapular position and to clarify anatomical features related to the changes in blood flow. Cadaveric shoulders were dissected to elucidate the anatomical difference between the two arteries. The blood flow of these arteries in healthy volunteers (22-48 years, 113 shoulders) was evaluated by MRI with changing the position of the scapula (internal and external rotation). The anterior humeral circumflex artery was attached to the subscapularis tendon and located beneath the subdeltoid bursa. The posterior humeral circumflex artery was located between the deltoid muscle and the bursa, which allowed free movement during scapular motion. There were no direct extraosseous anastomoses between the two arteries. Compared with the posterior humeral circumflex artery, the anterior humeral circumflex artery decreased blood flow with the scapula in internal rotation. No direct extraosseous anastomoses between the two arteries were observed. Internal rotation of the scapula decreased blood flow of the anterior humeral circumflex artery, which might be related to various pathologies of the shoulder. Diagnostic studies, Level III.	[Hagiwara, Yoshihiro; Kanazawa, Kenji; Ando, Akira; Itoi, Eiji] Tohoku Univ, Sch Med, Dept Orthopaed Surg, Aoba Ku, Sendai, Miyagi 9808574, Japan; [Nimura, Akimoto; Akita, Keiichi] Tokyo Med & Dent Univ, Grad Sch, Unit Clin Anat, Bunkyo Ku, Tokyo 1138519, Japan; [Watanabe, Takashi] Tohoku Univ, Div Epidemiol, Dept Publ Hlth & Forens Med, Grad Sch Med,Aoba Ku, Sendai, Miyagi 9808574, Japan; [Majima, Kazuhiro] Takeda Gen Hosp, Dept Radiol, Aizu Wakamatsu, Fukushima 9658585, Japan	Hagiwara, Y (reprint author), Tohoku Univ, Sch Med, Dept Orthopaed Surg, Aoba Ku, 1-1 Seiryo Machi, Sendai, Miyagi 9808574, Japan.	hagi@med.tohoku.ac.jp					Andary JL, 2002, J BONE JOINT SURG AM, V84A, P2258; Ando A, 2013, INT ORTHOP, V37, P859, DOI 10.1007/s00264-013-1859-8; Ludewig PM, 2000, PHYS THER, V80, P276; Urwin M, 1998, ANN RHEUM DIS, V57, P649, DOI 10.1136/ard.57.11.649; Borstad JD, 2005, J ORTHOP SPORT PHYS, V35, P227; Hand C, 2008, J SHOULDER ELB SURG, V17, P231, DOI 10.1016/j.jse.2007.05.009; Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187; Ludewig PM, 1996, J ORTHOP SPORT PHYS, V24, P57; Kim YS, 2012, AM J SPORT MED, V40, P815, DOI 10.1177/0363546511434287; Hettrich CM, 2010, J BONE JOINT SURG AM, V92A, P943, DOI 10.2106/JBJS.H.01144; Omoigui S, 2007, MED HYPOTHESES, V69, P1169, DOI 10.1016/j.mehy.2007.06.033; Duparc F, 2001, SURG RADIOL ANAT, V23, P185, DOI 10.1007/s00276-001-0185-9; LANE LB, 1977, J BONE JOINT SURG BR, V59, P272; Finley MA, 2003, ARCH PHYS MED REHAB, V84, P563, DOI 10.1053/apmr.2003.50087; Hagiwara Y, 2012, OSTEOARTHR CARTILAGE, V20, P241, DOI 10.1016/j.joca.2011.12.008; Arndt J, 2012, ORTHOP TRAUMATOL-SUR, V98, pS131, DOI 10.1016/j.otsr.2012.05.003; Codman EA, 1934, SHOULDER RUPTURE SUP, P123; Duplay ES, 1896, REV FRAT TRAY MED, V53, P226; Gerber C, 2001, CLIN ORTHOP RELAT R, P119; Griegel-Morris P, 1992, Phys Ther, V72, P425; Grimsby O, 1997, PHYS THERAPY SHOULDE, P95; Gumina Stefano, 2008, Chir Organi Mov, V91, P93, DOI 10.1007/s12306-007-0016-1; Holloway GB, 2001, J BONE JOINT SURG AM, V83A, P1682; JERACITANO D, 1992, BRIT J RHEUMATOL, V31, P539; Lewis C, 2008, J MANIP PHYSIOL THER, V31, P715, DOI 10.1016/j.jmpt.2008.10.003; Miyakoshi N, 1998, J SHOULDER ELB SURG, V7, P625; RUSSEK AS, 1952, JAMA-J AM MED ASSOC, V150, P25; SARRAFIAN SK, 1983, CLIN ORTHOP RELAT R, P11; Solem-Bertoft E, 1999, CRIT REV PHYS REHABI, V11, P229; TSUCHIDA Y, 1979, PLAST RECONSTR SURG, V64, P505, DOI 10.1097/00006534-197910000-00010; Yabe Y, 2013, CONNECT TISSUE RES, V54, P210, DOI 10.3109/03008207.2013.786056	31	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0942-2056	1433-7347		KNEE SURG SPORT TR A	Knee Surg. Sports Traumatol. Arthrosc.	MAY	2015	23	5					1467	1472		10.1007/s00167-013-2823-2		6	Orthopedics; Sport Sciences; Surgery	Orthopedics; Sport Sciences; Surgery	CH2BP	WOS:000353829500029		
J	Tasaki, A; Nimura, A; Nozaki, T; Yamakawa, A; Niitsu, M; Morita, W; Hoshikawa, Y; Akita, K				Tasaki, Atsushi; Nimura, Akimoto; Nozaki, Taiki; Yamakawa, Akira; Niitsu, Mamoru; Morita, Wataru; Hoshikawa, Yoshimitsu; Akita, Keiichi			Quantitative and qualitative analyses of subacromial impingement by kinematic open MRI	KNEE SURGERY SPORTS TRAUMATOLOGY ARTHROSCOPY			English	Article						Subacromial impingement; Rotator cuff; Acromioclavicular joint; Three dimensional MRI	SHOULDER IMPINGEMENT; SIGN POSITIONS; CUFF REPAIR; ACROMIOPLASTY	Quantitative and qualitative kinematic analyses of subacromial impingement by 1.2T open MRI were performed to determine the location of impingement and the involvement of the acromioclavicular joint. In 20 healthy shoulders, 10 sequential images in the scapular plane were taken in a 10-s pause at equal intervals from 30A degrees to maximum abduction in neutral and internal rotation. The distances between the rotator cuff (RC) and the acromion and the acromioclavicular joint were measured. To comprehend the positional relationships, cadaveric specimens were also observed. Although asymptomatic, the RC came into contact with the acromion and the acromioclavicular joint in six and five cases, respectively. The superior RC acted as a depressor for the humeral head against the acromion as the shoulder elevated. The mean elevation angle and distance at the closest position between the RC and the acromion in neutral rotation were 93.5A degrees and 1.6 mm, respectively, while those between the RC and the acromioclavicular joint were 86.7A degrees and 2.0 mm. When comparing this distance and angle, there was no significant difference between the RC to the acromion and to the acromioclavicular joint. The minimum distance between the RC and the acromion was significantly shorter than that between the greater tuberosity and the acromion. The location of RC closest to the acromion and the acromioclavicular joint differed significantly. Although asymptomatic, contact was found between the RC and the acromion and the acromioclavicular joint. The important role of the RC to prevent impingement was observed, and hence, dysfunction of the RC could lead to impingement that could result in a RC lesion. The RC lesions may differ when they are caused by impingement from either the acromion or the acromioclavicular joint.	[Tasaki, Atsushi; Nimura, Akimoto; Akita, Keiichi] Tokyo Med & Dent Univ, Grad Sch, Unit Clin Anat, Bunkyo Ku, Tokyo 1138519, Japan; [Tasaki, Atsushi; Yamakawa, Akira; Morita, Wataru; Hoshikawa, Yoshimitsu] St Lukes Int Hosp, Dept Orthopaed Surg, Tokyo, Japan; [Nozaki, Taiki] St Lukes Int Hosp, Dept Radiol, Tokyo, Japan; [Niitsu, Mamoru] Saitama Med Coll, Dept Radiol, Moroyama, Saitama, Japan	Akita, K (reprint author), Tokyo Med & Dent Univ, Grad Sch, Unit Clin Anat, Bunkyo Ku, 1-5-45 Yushima, Tokyo 1138519, Japan.	akita.fana@tmd.ac.jp			Ministry of Education, Culture, Sports [20590168]; Nokyo Kyosai Research Institute (Agricultural Cooperative Insurance Research Institute)	This study was partly supported by a Grant-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports (C) (No. 20590168) and also by a grant from Nokyo Kyosai Research Institute (Agricultural Cooperative Insurance Research Institute). We thank Eiji Okamoto, R.T. and Youichi Ito, for valuable assistance in this study.	Schneeberger AG, 1998, J SHOULDER ELB SURG, V7, P375, DOI 10.1016/S1058-2746(98)90026-X; McCallister WV, 2005, J BONE JOINT SURG AM, V87A, P1278, DOI 10.2106/JBJS.D.02432; Nyffeler RW, 2006, J BONE JOINT SURG AM, V88A, P800, DOI 10.2106/JBJS.D.03042; Hashimoto T, 2003, CLIN ORTHOP RELAT R, P111, DOI 10.1097/01/blo.0000092974.12414.22; THIEL W, 1992, ANN ANAT, V174, P197; Yamamoto N, 2010, J SHOULDER ELB SURG, V19, P681, DOI 10.1016/j.jse.2009.12.006; Mochizuki T, 2008, J BONE JOINT SURG AM, V90A, P962, DOI 10.2106/JBJS.G.00427; NEER CS, 1972, J BONE JOINT SURG AM, VA 54, P41; Chen AL, 2003, CLIN SPORT MED, V22, P343, DOI 10.1016/S0278-5919(03)00015-2; Goldberg BA, 2001, CLIN ORTHOP RELAT R, P142; Han KJ, 2012, KNEE SURG SPORT TR A, V20, P1954, DOI 10.1007/s00167-011-1805-5; KESSEL L, 1977, J BONE JOINT SURG BR, V59, P166; Ketola S, 2013, BONE JOINT RES, V2, P132, DOI 10.1302/2046-3758.27.2000163; Michener LA, 2015, KNEE SURG SPORT TR A, V23, P363, DOI 10.1007/s00167-013-2542-8; Pappas GP, 2006, J SHOULDER ELB SURG, V15, P40, DOI 10.1016/j.jse.2005.04.007; Roberts CS, 2002, J SHOULDER ELB SURG, V11, P595, DOI 10.1067/mse.2002.127095; WILEY AM, 1991, CLIN ORTHOPAEDICS, V263, P135; WUELKER N, 1994, CLIN ORTHOP RELAT R, P242; Yamamoto N, 2009, J SHOULDER ELB SURG, V18, P942, DOI 10.1016/j.jse.2009.02.012	19	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0942-2056	1433-7347		KNEE SURG SPORT TR A	Knee Surg. Sports Traumatol. Arthrosc.	MAY	2015	23	5					1489	1497		10.1007/s00167-014-2876-x		9	Orthopedics; Sport Sciences; Surgery	Orthopedics; Sport Sciences; Surgery	CH2BP	WOS:000353829500032		
J	Hagiwara, Y; Sugaya, H; Takahashi, N; Kawai, N; Ando, A; Hamada, J; Itoi, E				Hagiwara, Yoshihiro; Sugaya, Hiroyuki; Takahashi, Norimasa; Kawai, Nobuaki; Ando, Akira; Hamada, Junichiro; Itoi, Eiji			Effects of intra-articular steroid injection before pan-capsular release in patients with refractory frozen shoulder	KNEE SURGERY SPORTS TRAUMATOLOGY ARTHROSCOPY			English	Article						Intra-articular steroid injection; Frozen shoulder; Adhesive capsulitis; Pan-capsular release	IDIOPATHIC ADHESIVE CAPSULITIS; RANDOMIZED CONTROLLED-TRIAL; LOCAL CORTICOSTEROID INJECTION; NONOPERATIVE TREATMENT; DIABETES-MELLITUS; PHYSICAL-THERAPY; MANAGEMENT; PHYSIOTHERAPY; PAIN; PREDNISOLONE	The purpose of the study was to retrospectively determine the effects of intra-articular steroid injection on the clinical outcome of patients who underwent arthroscopic pan-capsular release for refractory frozen shoulder. Between 2000 and 2010, 34 patients (20 males, 14 females) who underwent an arthroscopic pan-capsular release for frozen shoulder were included. Intra-articular steroid injections were administered from April 2006, and just before surgery and at the final follow-up, ranges of motion (ROM) and scores of the Shoulder Rating Scale of the University of California, Los Angeles (UCLA) scoring system were evaluated. Intra-articular steroid injection significantly improved the UCLA scores of pain just before surgery and at the final follow-up (1.7 +/- A 0.5 vs. 6 +/- A 2, p < 0.0001). We subdivided the patients into those with and without diabetes mellitus. Steroid injection had a significant effect on the ROM in forward flexion (166.6 +/- A 8.6 vs. 140 +/- A 36.1, p = 0.026) and the scores of pain (10 vs. 9.3 +/- A 1.2, p = 0.046) at the final follow-up in the group without diabetes mellitus compared with those with it. Intra-articular steroid injection improves pain just before an arthroscopic pan-capsular release and at the final follow-up in all the patients with refractory frozen shoulder. However, it improves the ROM in forward flexion and the UCLA scores of pain at the final follow-up only in those without diabetes mellitus. Therapeutic studies, Level IV.	[Hagiwara, Yoshihiro; Ando, Akira; Itoi, Eiji] Tohoku Univ, Dept Orthopaed Surg, Sch Med, Aoba Ku, Sendai, Miyagi 9808574, Japan; [Sugaya, Hiroyuki; Takahashi, Norimasa; Kawai, Nobuaki] Funabashi Orthopaed Sports Med Ctr, Funabashi, Chiba, Japan; [Hamada, Junichiro] Kuwano Kyoritsu Hosp, Dept Orthopaed Surg, Koriyama, Fukushima, Japan	Hagiwara, Y (reprint author), Tohoku Univ, Dept Orthopaed Surg, Sch Med, Aoba Ku, 1-1 Seiryo Machi, Sendai, Miyagi 9808574, Japan.	hagi@med.tohoku.ac.jp; Hsugaya@nifty.com; n-h-taka@qc4.so-net.ne.jp; michael_ortho@yahoo.co.jp; andoakir@yahoo.co.jp; i-hamada@koriyama-h-coop.or.jp; itoi-eiji@med.tohoku.ac.jp					Ando A, 2013, INT ORTHOP, V37, P859, DOI 10.1007/s00264-013-1859-8; Griggs SM, 2000, J BONE JOINT SURG AM, V82A, P1398; Arslan S, 2001, RHEUMATOL INT, V21, P20; Mifflin KA, 2014, CAN J ANESTH, V61, P112, DOI 10.1007/s12630-013-0087-4; Miller MD, 1996, ORTHOPEDICS, V19, P849; Ryans I, 2005, RHEUMATOLOGY, V44, P529, DOI 10.1093/rheumatology/keh535; Buchbinder R, 2004, ANN RHEUM DIS, V63, P1460, DOI 10.1136/ard.2003.018218; Carette S, 2003, ARTHRITIS RHEUM, V48, P829, DOI 10.1002/art.10954; Vermeulen HM, 2006, PHYS THER, V86, P355; REEVES B, 1975, SCAND J RHEUMATOL, V4, P193; Harryman DT, 1997, ARTHROSCOPY, V13, P133, DOI 10.1016/S0749-8063(97)90146-8; Diercks RL, 2004, J SHOULDER ELB SURG, V13, P499, DOI 10.1016/j.jse.2004.03.002; Levine WN, 2007, J SHOULDER ELB SURG, V16, P569, DOI 10.1016/j.jse.2006.12.007; SHAFFER B, 1992, J BONE JOINT SURG AM, V74A, P738; Sheridan MA, 2006, ORTHOP CLIN N AM, V37, P531, DOI 10.1016/j.ocl.2006.09.009; Hannafin JA, 2000, CLIN ORTHOP RELAT R, P95; [Anonymous], 1984, CLIN ORTHOPAEDICS; Rao SR, 2006, FOOT ANKLE INT, V27, P617; Lorbach O, 2010, J SHOULDER ELB SURG, V19, P172, DOI 10.1016/j.jse.2009.06.013; BINDER A, 1986, BRIT J RHEUMATOL, V25, P288; Bot SDM, 2005, SPINE, V30, pE459, DOI 10.1097/01.brs.0000174279.44855.02; Codman EA., 1934, SHOULDER, P216; Cuomo F, 2005, IDIOPATHIC DIABETIC, P205; Hay EM, 2003, ANN RHEUM DIS, V62, P394, DOI 10.1136/ard.62.5.394; Jenkins EF, 2012, J SHOULDER ELB SURG, V21, P1492, DOI 10.1016/j.jse.2011.11.006; Jerosch J, 2013, KNEE SURG SPORT TR A, V21, P1195, DOI 10.1007/s00167-012-2124-1; Khan A A, 2005, Mymensingh Med J, V14, P67; Lafosse L, 2012, ARTHROSCOPY, V28, P916, DOI 10.1016/j.arthro.2011.12.014; Laslett LL, 2008, RHEUMATOLOGY, V47, P1583, DOI 10.1093/rheumatology/ken333; Le Lievre HMJ, 2012, J BONE JOINT SURG AM, V94A, P1208, DOI 10.2106/JBJS.J.00952; Lundberg B J, 1969, Acta Orthop Scand Suppl, V119, P1; REEVES B, 1966, P ROY SOC MED, V59, P827; Vastamaki H, 2012, CLIN ORTHOP RELAT R, V470, P1133, DOI 10.1007/s11999-011-2176-4; Yian EH, 2012, J BONE JOINT SURG AM, V94A, P919, DOI 10.2106/JBJS.J.01930	34	0	1	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0942-2056	1433-7347		KNEE SURG SPORT TR A	Knee Surg. Sports Traumatol. Arthrosc.	MAY	2015	23	5					1536	1541		10.1007/s00167-014-2936-2		6	Orthopedics; Sport Sciences; Surgery	Orthopedics; Sport Sciences; Surgery	CH2BP	WOS:000353829500038		
J	Ishida, Y; Chosa, E; Taniguchi, N				Ishida, Yasuyuki; Chosa, Etsuo; Taniguchi, Noboru			Pseudoaneurysm as a complication of shoulder arthroscopy	KNEE SURGERY SPORTS TRAUMATOLOGY ARTHROSCOPY			English	Article						Pseudoaneurysm; Shoulder arthroscopy; Complication; Arthroscopic rotator cuff repair; Iatrogenic	ANTERIOR TIBIAL ARTERY; ANKLE ARTHROSCOPY	A case of pseudoaneurysm that is a rare complication of shoulder arthroscopy is reported. A 73-year-old man with rotator cuff tear underwent arthroscopic rotator cuff repair. On post-operative day 3, a pulsating mass (diameter 5 mm) was detected near the anterior portal. Then, the mass gradually enlarged, which was diagnosed as pseudoaneurysm. After the consultation with vascular surgeons, the mass was surgically excised following ligation of feeding artery 6 weeks after the arthroscopic surgery. Thus far, no recurrence has been observed. Level of evidence V.	[Ishida, Yasuyuki; Chosa, Etsuo; Taniguchi, Noboru] Miyazaki Univ, Dept Orthopaed Surg, Fac Med, Miyazaki, Miyazaki 8891692, Japan	Ishida, Y (reprint author), Miyazaki Univ, Dept Orthopaed Surg, Fac Med, 5200 Kihara,Kiyotake Cho, Miyazaki, Miyazaki 8891692, Japan.	yasu-isi@med.miyazaki-u.ac.jp					Wilson JS, 2003, ANN VASC SURG, V17, P641, DOI 10.1007/s10016-003-0074-2; ARTZ T, 1972, J BONE JOINT SURG AM, V54, P1293; Audenaert Emmanuel, 2003, Acta Orthop Belg, V69, P382; BECK DE, 1986, J TRAUMA, V26, P87, DOI 10.1097/00005373-198601000-00017; Bruno M, 2011, ARTHROSCOPY, V27, P1150, DOI 10.1016/j.arthro.2011.02.012; Cameron S E, 1996, J Shoulder Elbow Surg, V5, P404, DOI 10.1016/S1058-2746(96)80073-5; Choo HJ, 2013, J SHOULDER ELB SURG, V22, pE15, DOI 10.1016/j.jse.2013.07.056; Delee JC, 1985, ARTHROSCOPY, V1, P214, DOI 10.1016/S0749-8063(85)80086-4; Gullo J, 2013, ANN EMERG MED, V61, P204, DOI 10.1016/j.annemergmed.2012.05.037; Jang EC, 2008, J BONE JOINT SURG AM, V90A, P2235, DOI [10.2106/JBJS.G.01409, 10.2106/JRJS.G.01409]; Panagiotopoulos Elias, 2009, J Med Case Rep, V3, P6627, DOI 10.4076/1752-1947-3-6627; Ramavath Ashok L, 2009, Cases J, V2, P162, DOI 10.1186/1757-1626-2-162; Salgado CJ, 1998, CARDIOVASC SURG, V6, P604, DOI 10.1016/S0967-2109(98)00087-8	13	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0942-2056	1433-7347		KNEE SURG SPORT TR A	Knee Surg. Sports Traumatol. Arthrosc.	MAY	2015	23	5					1549	1551		10.1007/s00167-014-2956-y		3	Orthopedics; Sport Sciences; Surgery	Orthopedics; Sport Sciences; Surgery	CH2BP	WOS:000353829500040		
J	Kawaguchi, K; Tanaka, S; Yoshitomi, H; Nagai, I; Sato, W; Karita, T; Kondo, T				Kawaguchi, Kohei; Tanaka, Sayo; Yoshitomi, Hiroki; Nagai, Ichiro; Sato, Wakyo; Karita, Tasturo; Kondo, Taiji			Double figure-of-eight reconstruction technique for chronic anterior sternoclavicular joint dislocation	KNEE SURGERY SPORTS TRAUMATOLOGY ARTHROSCOPY			English	Article						Sternoclavicular joint; Reconstruction; Dislocation; Autologous transplantation; Gracilis tendon	INSTABILITY; SUBLUXATION; TENDON	Sternoclavicular joint dislocations account for < 5 % of all dislocations of the shoulder girdle. Whereas most cases of anterior dislocation do not experience symptoms, some patients with anterior instability remain symptomatic and require reconstructive surgery to stabilize the sternoclavicular joint. We present the case of a 57-year-old male diagnosed with sternoclavicular joint anterior dislocation and unusual swallowing difficulty while bending the neck forward. The patient was treated using a new and effective surgical technique of sternoclavicular joint reconstruction named "double figure-of-eight" using the ipsilateral gracilis tendon. Surgical outcome was successful, based on the Rockwood SC joint rating scale, and the patient maintained excellent stability even after 2 years. This new surgical technique offers superior stability, without harvest site morbidity, to patients with rare, severe, and chronic sternoclavicular joint dislocation. Level of evidence IV.	[Kawaguchi, Kohei; Tanaka, Sayo; Yoshitomi, Hiroki; Nagai, Ichiro; Sato, Wakyo; Karita, Tasturo; Kondo, Taiji] Tokyo Metropolitan Tama Med Ctr, Dept Orthopaed Surg, Fuchu, Tokyo, Japan	Kawaguchi, K (reprint author), Tokyo Metropolitan Tama Med Ctr, Dept Orthopaed Surg, 2-8-29 Musashidai, Fuchu, Tokyo, Japan.	kkohei0602@yahoo.co.jp					Abiddin Z, 2006, J SHOULDER ELB SURG, V15, P315, DOI 10.1016/j.jse.2005.07.005; Rockwood CA, 1997, J BONE JOINT SURG AM, V79A, P387; Bak K, 2014, J SHOULDER ELB SURG, V23, P245, DOI 10.1016/j.jse.2013.05.010; Robinson CM, 2008, J BONE JOINT SURG BR, V90B, P685, DOI 10.1302/0301-620X.90B6.20391; Armstrong AL, 2008, J BONE JOINT SURG BR, V90B, P610, DOI 10.1302/0301-620X.90B5.20293; Bae DS, 2006, J PEDIATR ORTHOPED, V26, P71, DOI 10.1097/01.bpo.0000187998.91837.b2; BURROWS HJ, 1951, J BONE JOINT SURG BR, V33, P240; Castropil W, 2008, KNEE SURG SPORT TR A, V16, P865, DOI 10.1007/s00167-008-0527-9; de Jong K P, 1990, J Orthop Trauma, V4, P420, DOI 10.1097/00005131-199004000-00010; ESKOLA A, 1989, J BONE JOINT SURG BR, V71, P63; Friedrich L, 2012, KNEE SURG SPORT TR A, V20, P1974, DOI 10.1007/s00167-011-1852-y; ROCKWOOD CA, 1989, J BONE JOINT SURG AM, V71A, P1280; Singer G, 2013, J SHOULDER ELB SURG, V22, P64, DOI 10.1016/j.jse.2012.02.009; Spencer EE, 2002, J SHOULDER ELB SURG, V11, P43, DOI 10.1067/mse.2002.119394; Spencer EE, 2004, J BONE JOINT SURG AM, V86A, P98; Thut David, 2011, Bull NYU Hosp Jt Dis, V69, P128; Wettstein M, 2004, KNEE SURG SPORT TR A, V12, P453, DOI 10.1007/s00167-004-0504-x; Wirth MA, 1996, J AM ACAD ORTHOP SUR, V4, P268; Wirth MA, 2009, SHOULDER, P527	19	0	1	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0942-2056	1433-7347		KNEE SURG SPORT TR A	Knee Surg. Sports Traumatol. Arthrosc.	MAY	2015	23	5					1559	1562		10.1007/s00167-014-2979-4		4	Orthopedics; Sport Sciences; Surgery	Orthopedics; Sport Sciences; Surgery	CH2BP	WOS:000353829500042		
J	Cobo, MJ; Martinez, MA; Gutierrez-Salcedo, M; Fujita, H; Herrera-Viedma, E				Cobo, M. J.; Martinez, M. A.; Gutierrez-Salcedo, M.; Fujita, H.; Herrera-Viedma, E.			25 years at Knowledge-Based Systems: A bibliometric analysis	KNOWLEDGE-BASED SYSTEMS			English	Article						Bibliometrics; Science mapping; Citations; Co-word analysis; h-index	CO-WORD ANALYSIS; ARTIFICIAL NEURAL-NETWORKS; ATTRIBUTE DECISION-MAKING; SCIENCE MAPPING ANALYSIS; RESEARCH PERFORMANCE; FEATURE-SELECTION; INFORMATION; PREDICTION; OPERATORS; EVOLUTION	In commemoration of the Anniversary 25th of KnoSys we present a bibliometric analysis of the scientific content of the journal during the period 1991-2014. This analysis shows the conceptual evolution of the journal and some of its performance bibliometric indicators based on citations, as the evolution of its impact factor, its h-index, and its most cited authors/documents. (C) 2015 Elsevier B.V. All rights reserved.	[Cobo, M. J.] Univ Cadiz, Dept Comp Sci, Cadiz, Spain; [Martinez, M. A.] UNIR Res, Dept Social Work, La Rioja, Spain; [Gutierrez-Salcedo, M.] Univ Jaen, Dept Management & Mkt, Jaen, Spain; [Fujita, H.] Iwate Prefectural Univ, Intelligent Software Syst Lab, Takizawa, Iwate, Japan; [Herrera-Viedma, E.] Univ Granada, Dept Comp Sci & Artificial Intelligence, E-18071 Granada, Spain	Cobo, MJ (reprint author), Univ Cadiz, Dept Comp Sci, Cadiz, Spain.	manueljesus.cobo@uca.es; mundodesilencio@hotmail.com; msalcedo@ujaen.es; HFujita-799@acm.org; viedma@decsai.ugr.es	Cobo, Manuel Jesus/C-5581-2011	Cobo, Manuel Jesus/0000-0001-6575-803X	Excellence Andalusian Projects [TIC-5299, TIC-5991]; National Project [TIN2010-17876, TIN2013-40658-P]	This work has been supported by the Excellence Andalusian Projects TIC-5299 and TIC-5991, and National Project TIN2010-17876 and TIN2013-40658-P.	Aha DW, 1998, KNOWL-BASED SYST, V11, P261, DOI 10.1016/S0950-7051(98)00066-5; Misevicius A, 2004, KNOWL-BASED SYST, V17, P65, DOI 10.1016/j.knosys.2004.03.001; Tang L, 2011, SCIENTOMETRICS, V88, P1, DOI 10.1007/s11192-011-0376-z; CALLON M, 1991, SCIENTOMETRICS, V22, P155, DOI 10.1007/BF02019280; Timmis J, 2001, KNOWL-BASED SYST, V14, P121, DOI 10.1016/S0950-7051(01)00088-0; Gero JS, 1996, KNOWL-BASED SYST, V9, P435, DOI 10.1016/S0950-7051(96)01054-4; He Q, 1999, LIBR TRENDS, V48, P133; Yang BA, 2001, KNOWL-BASED SYST, V14, P303, DOI 10.1016/S0950-7051(01)00110-1; Hadavandi E, 2010, KNOWL-BASED SYST, V23, P800, DOI 10.1016/j.knosys.2010.05.004; DAHLBACK N, 1993, KNOWL-BASED SYST, V6, P258, DOI 10.1016/0950-7051(93)90017-N; Hirsch JE, 2005, P NATL ACAD SCI USA, V102, P16569, DOI 10.1073/pnas.0507655102; Xu ZS, 2011, KNOWL-BASED SYST, V24, P749, DOI 10.1016/j.knosys.2011.01.011; Alonso S, 2009, J INFORMETR, V3, P273, DOI 10.1016/j.joi.2009.04.001; Li TR, 2007, KNOWL-BASED SYST, V20, P485, DOI 10.1016/j.knosys.2007.01.002; Bobadilla J, 2009, KNOWL-BASED SYST, V22, P261, DOI 10.1016/j.knosys.2009.01.008; Small H, 1999, J AM SOC INFORM SCI, V50, P799, DOI 10.1002/(SICI)1097-4571(1999)50:9<799::AID-ASI9>3.3.CO;2-7; Delany SJ, 2005, KNOWL-BASED SYST, V18, P187, DOI 10.1016/j.knosys.2004.10.002; Coulter N, 1998, J AM SOC INFORM SCI, V49, P1206, DOI 10.1002/(SICI)1097-4571(1998)49:13<1206::AID-ASI7>3.3.CO;2-6; Braun T, 2006, SCIENTOMETRICS, V69, P169, DOI 10.1007/s11192-006-0147-4; Xu ZS, 2007, KNOWL-BASED SYST, V20, P719, DOI 10.1016/j.knosys.2006.10.002; Borner K, 2003, ANNU REV INFORM SCI, V37, P179, DOI 10.1002/aris.1440370106; Chapman CB, 1999, KNOWL-BASED SYST, V12, P257, DOI 10.1016/S0950-7051(99)00013-1; Wei GW, 2010, KNOWL-BASED SYST, V23, P243, DOI 10.1016/j.knosys.2010.01.003; Tsai CF, 2009, KNOWL-BASED SYST, V22, P120, DOI 10.1016/j.knosys.2008.08.002; Yue ZL, 2011, KNOWL-BASED SYST, V24, P146, DOI 10.1016/j.knosys.2010.07.014; Norman TJ, 2004, KNOWL-BASED SYST, V17, P103, DOI 10.1016/j.knosys.2004.03.005; Li H, 2008, KNOWL-BASED SYST, V21, P868, DOI 10.1016/j.knosys.2008.03.047; Wang J, 2013, SCIENTOMETRICS, V94, P851, DOI 10.1007/s11192-012-0775-9; Zeng SZ, 2011, KNOWL-BASED SYST, V24, P1224, DOI 10.1016/j.knosys.2011.05.013; Fenton N, 2006, KNOWL-BASED SYST, V19, P430, DOI 10.1016/j.knosys.2006.03.002; Cobo MJ, 2011, J INFORMETR, V5, P146, DOI 10.1016/j.joi.2010.10.002; Hu QH, 2008, KNOWL-BASED SYST, V21, P294, DOI 10.1016/j.knoys.2007.07.001; Zou Y, 2008, KNOWL-BASED SYST, V21, P941, DOI 10.1016/j.knosys.2008.04.004; Noyons ECM, 1999, J AM SOC INFORM SCI, V50, P115, DOI 10.1002/(SICI)1097-4571(1999)50:2<115::AID-ASI3>3.0.CO;2-J; CALLON M, 1983, SOC SCI INFORM, V22, P191, DOI 10.1177/053901883022002003; MOED HF, 1995, SCIENTOMETRICS, V33, P381, DOI 10.1007/BF02017338; Wei GW, 2012, KNOWL-BASED SYST, V31, P176, DOI 10.1016/j.knosys.2012.03.011; Choy KL, 2005, KNOWL-BASED SYST, V18, P1, DOI 10.1016/j.knosys.2004.05.003; Cobo MJ, 2012, J AM SOC INF SCI TEC, V63, P1609, DOI 10.1002/asi.22688; Li YF, 2004, KNOWL-BASED SYST, V17, P207, DOI 10.1016/j.knosys.2004.05.002; Porcel C, 2010, KNOWL-BASED SYST, V23, P32, DOI 10.1016/j.knosys.2009.07.007; Xu ZS, 2011, KNOWL-BASED SYST, V24, P197, DOI 10.1016/j.knosys.2010.04.010; Ma J, 2010, KNOWL-BASED SYST, V23, P23, DOI 10.1016/j.knosys.2009.07.006; Chung PWH, 2003, KNOWL-BASED SYST, V16, P149, DOI 10.1016/S0950-7051(02)00080-1; Li Y, 2000, KNOWL-BASED SYST, V13, P285, DOI 10.1016/S0950-7051(00)00088-5; Cabrerizo FJ, 2010, KNOWL-BASED SYST, V23, P169, DOI 10.1016/j.knosys.2009.11.019; Shen W, 2011, KNOWL-BASED SYST, V24, P378, DOI 10.1016/j.knosys.2010.11.001; Cobo MJ, 2011, J AM SOC INF SCI TEC, V62, P1382, DOI 10.1002/asi.21525; Cobo MJ, 2012, IEEE T INTELL TRANSP, V13, P413, DOI 10.1109/TITS.2011.2167968; Andrews R, 1995, KNOWL-BASED SYST, V8, P373, DOI 10.1016/0950-7051(96)81920-4; Budzik J, 2001, KNOWL-BASED SYST, V14, P37, DOI 10.1016/S0950-7051(00)00105-2; Cartes-Velasquez R, 2014, SCIENTOMETRICS, V98, P2223, DOI 10.1007/s11192-013-1173-7; Cobo MJ, 2014, IEEE T INTELL TRANSP, V15, P901, DOI 10.1109/TITS.2013.2284756; Freitas AA, 1999, KNOWL-BASED SYST, V12, P309, DOI 10.1016/S0950-7051(99)00019-2; Gao-Yong L., 2012, SCIENTOMETRICS, V91, P203, DOI DOI 10.1007/S11192-011-0586-4; GARFIELD E, 1977, CURR CONTENTS, P5; Garfield E., 1972, SCIENCE, V178, P417; Guan J, 2008, SCIENTOMETRICS, V75, P357, DOI 10.1007/s11192-007-1871-0; Haque BU, 2000, KNOWL-BASED SYST, V13, P101, DOI 10.1016/S0950-7051(00)00051-4; Huang M.-H., 2014, SCIENTOMETRICS, V98; Jung JJ, 2008, KNOWL-BASED SYST, V21, P573, DOI 10.1016/j.knosys.2008.03.015; Lin FY, 2001, KNOWL-BASED SYST, V14, P189, DOI 10.1016/S0950-7051(01)00096-X; Lopez-Herrera AG, 2012, INT J INF TECH DECIS, V11, P247, DOI 10.1142/S0219622012400020; Martinez MA, 2014, SCIENTOMETRICS, V98, P1971, DOI 10.1007/s11192-013-1155-9; Martinez M.A., 2014, SCIENTOMETR IN PRESS; Martinez-Sanchez M.A., 2014, RES SOC WOR IN PRESS; Murgado-Armenteros EM, 2015, SCIENTOMETRICS, V102, P519, DOI 10.1007/s11192-014-1443-z; Ponce FA, 2011, MOVEMENT DISORD, V26, P380, DOI 10.1002/mds.23445; Rodriguez-Ledesma A., 2014, J ANIM BREE IN PRESS; Schubert A, 2007, SCIENTOMETRICS, V70, P201, DOI 10.1007/s11192-007-0112-x; Sternitzke C, 2009, SCIENTOMETRICS, V78, P113, DOI 10.1007/s11192-007-1961-z; van Raan A., 2005, HDB QUANTITATIVE SCI, P19; Watson I, 1999, KNOWL-BASED SYST, V12, P303, DOI 10.1016/S0950-7051(99)00020-9; Wheeler R, 2000, KNOWL-BASED SYST, V13, P93, DOI 10.1016/S0950-7051(00)00050-2	74	2	2	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0950-7051	1872-7409		KNOWL-BASED SYST	Knowledge-Based Syst.	MAY	2015	80				SI		3	13		10.1016/j.knosys.2014.12.035		11	Computer Science, Artificial Intelligence	Computer Science	CH2KD	WOS:000353853200002		
J	Salehi, S; Selamat, A; Fujita, H				Salehi, Saber; Selamat, Ali; Fujita, Hamido			Systematic mapping study on granular computing	KNOWLEDGE-BASED SYSTEMS			English	Article						Granular computing; Granular classifier; Clustering algorithm; Systematic mapping; DBSCAN; k-means; c-means	GROUP DECISION-MAKING; ROUGH SETS; INFORMATION GRANULATION; CLUSTERING-ALGORITHM; APPROXIMATION SPACE; PATTERN-RECOGNITION; SHADOWED SETS; FUZZY-LOGIC; TIME-SERIES; CLASSIFICATION	Granular computing has attracted many researchers as a new and rapidly growing paradigm of information processing. In this paper, we apply systematic mapping study to classify the granular computing researches to discover relative derivations to specify its research strength and quality. Our search scope is limited to the Science Direct and IEEE Transactions papers published between January 2012 and August 2014. We defined four perspectives of classification schemes to map the selected studies that are focus area, contribution type, research type and framework. Results of mapping the selected studies show that almost half of the research focused area belongs to category of data analysis. In addition, most of the selected papers belong to proposing the solutions in research type scheme. Distribution of papers between tool, method and enhancement categories of contribution type are almost equal. Moreover, 39% of the relevant papers belong to the rough set framework. The results show that there is little attention paid to cluster analysis in existing frameworks to discover granules for classification. We applied five clustering algorithms on three datasets from UCI repository to compare the form of information granules, and then classify the patterns and define them to a specific class based on their geometry and belongings. The clustering algorithms are DBSCAN, c-means, k-means, GAk-means and Fuzzy-GrC and the comparison of information granules are based on the coverage, misclassification and accuracy. The survey of experimental results mostly shows Fuzzy-GrC and GAk-means algorithm superior to other clustering algorithms; while, c-means clustering algorithm shows inferior to other clustering algorithms. (C) 2015 Elsevier B.V. All rights reserved.	[Salehi, Saber; Selamat, Ali] Univ Teknol Malaysia, UTM IRDA Digital Media Ctr Excellence, Skudai 81310, Johor, Malaysia; [Salehi, Saber; Selamat, Ali] Univ Teknol Malaysia, Fac Comp, Skudai 81310, Johor, Malaysia; [Fujita, Hamido] Iwate Prefectural Univ, Takizawa, Iwate 0200193, Japan	Selamat, A (reprint author), Univ Teknol Malaysia, UTM IRDA Digital Media Ctr Excellence, Skudai 81310, Johor, Malaysia.	aselamat@utm.my			Universiti Teknologi Malaysia (UTM); Ministry of Education Malaysia [00M19, 01G72]	The Universiti Teknologi Malaysia (UTM) and Ministry of Education Malaysia under research university Grants 00M19 and 01G72 are hereby acknowledged for some of the facilities that were utilized during the course of this research work.	Zhang Z, 2012, KNOWL-BASED SYST, V26, P111, DOI 10.1016/j.knosys.2011.07.009; Zhang XY, 2014, INFORM SCIENCES, V268, P147, DOI 10.1016/j.ins.2013.09.020; Sanchez D, 2014, ENG APPL ARTIF INTEL, V27, P41, DOI 10.1016/j.engappai.2013.09.014; Lingras P, 2014, INFORM SCIENCES, V257, P14, DOI 10.1016/j.ins.2013.09.018; Yao YY, 2005, 2005 IEEE INTERNATIONAL CONFERENCE ON GRANULAR COMPUTING, VOLS 1 AND 2, P85; Bhatt HS, 2013, IEEE T INF FOREN SEC, V8, P89, DOI 10.1109/TIFS.2012.2223684; San Roque AM, 2007, NEURAL PROCESS LETT, V25, P157, DOI 10.1007/s11063-007-9035-z; Skowron A, 2012, INFORM SCIENCES, V184, P20, DOI 10.1016/j.ins.2011.08.001; Albanese A, 2014, IEEE T KNOWL DATA EN, V26, P194, DOI 10.1109/TKDE.2012.234; Yao JT, 2005, 2005 IEEE INTERNATIONAL CONFERENCE ON GRANULAR COMPUTING, VOLS 1 AND 2, P326; Wei W, 2012, INFORM SCIENCES, V190, P1, DOI 10.1016/j.ins.2011.12.006; Velmurugan T, 2014, APPL SOFT COMPUT, V19, P134, DOI 10.1016/j.asoc.2014.02.011; Tang XQ, 2013, IEEE T FUZZY SYST, V21, P814, DOI 10.1109/TFUZZ.2012.2230176; Yang T, 2013, INFORM SCIENCES, V228, P175, DOI 10.1016/j.ins.2012.11.005; Huang B, 2013, EUR J OPER RES, V231, P162, DOI 10.1016/j.ejor.2013.05.006; Pal SK, 2013, APPL SOFT COMPUT, V13, P3944, DOI 10.1016/j.asoc.2013.06.026; Liang JY, 2012, INT J APPROX REASON, V53, P912, DOI 10.1016/j.ijar.2012.02.004; Zadeh LA, 1997, FUZZY SET SYST, V90, P111, DOI 10.1016/S0165-0114(97)00077-8; Maulik U, 2000, PATTERN RECOGN, V33, P1455, DOI 10.1016/S0031-3203(99)00137-5; Cabrerizo FJ, 2013, EUR J OPER RES, V230, P624, DOI 10.1016/j.ejor.2013.04.046; Sanchez MA, 2014, INFORM SCIENCES, V279, P498, DOI 10.1016/j.ins.2014.04.005; Wang LZ, 2014, EXPERT SYST APPL, V41, P3134, DOI 10.1016/j.eswa.2013.10.046; Chen HM, 2012, KNOWL-BASED SYST, V31, P140, DOI 10.1016/j.knosys.2012.03.001; Yao YY, 2012, INFORM SCIENCES, V213, P1, DOI 10.1016/j.ins.2012.05.021; Pedrycz W, 2014, KNOWL-BASED SYST, V58, P3, DOI 10.1016/j.knosys.2013.07.022; Yao JT, 2013, IEEE T CYBERNETICS, V43, P1977, DOI 10.1109/TSMCC.2012.2236648; Li M, 2014, KNOWL-BASED SYST, V65, P60, DOI 10.1016/j.knosys.2014.04.008; Lin GP, 2012, INT J APPROX REASON, V53, P1080, DOI 10.1016/j.ijar.2012.05.004; Pal SK, 2012, PATTERN RECOGN, V45, P2690, DOI 10.1016/j.patcog.2011.12.027; Escobar JW, 2013, COMPUT OPER RES, V40, P70, DOI 10.1016/j.cor.2012.05.008; Yao JT, 2007, GRC: 2007 IEEE INTERNATIONAL CONFERENCE ON GRANULAR COMPUTING, PROCEEDINGS, P734, DOI 10.1109/GrC.2007.11; Lin YJ, 2014, KNOWL-BASED SYST, V67, P162, DOI 10.1016/j.knosys.2014.05.019; Sanchez-Valdes D, 2013, APPL SOFT COMPUT, V13, P4738, DOI 10.1016/j.asoc.2013.08.003; Pedrycz W, 2008, PATTERN RECOGN, V41, P3720, DOI 10.1016/j.patcog.2008.06.004; Solis AR, 2013, APPL SOFT COMPUT, V13, P4010, DOI 10.1016/j.asoc.2012.09.002; Pedrycz W, 2002, INT J INTELL SYST, V17, P173, DOI 10.1002/int.10015; Liu CH, 2014, INT J APPROX REASON, V55, P1404, DOI 10.1016/j.ijar.2014.01.002; Zhu W, 2012, INFORM SCIENCES, V201, P80, DOI 10.1016/j.ins.2012.01.026; Bache K., 2013, UCI MACHINE LEARNING, V19; Budgen D., 2008, EVIDENCE BASED SOFTW, V8, P195; Chiu DKY, 2013, IEEE T KNOWL DATA EN, V25, P2314, DOI 10.1109/TKDE.2012.151; Cimino MGCA, 2014, INFORM SCIENCES, V257, P313, DOI 10.1016/j.ins.2012.12.049; Davtalab R., 2014, MULTILEVEL FUZZY MIN; Ester M, 1996, KDD, V96, P226; Grzegorzewski P, 2013, INFORM SCIENCES, V225, P35, DOI 10.1016/j.ins.2012.10.028; Honko P, 2012, INFORM SCIENCES, V189, P208, DOI 10.1016/j.ins.2011.12.004; Honko P., 2012, ADV COMPUTATIONAL IN, P290; Hu B.Q, 2014, INF SCI; Hu H, 2014, EXPERT SYST APPL, V41, P2729, DOI 10.1016/j.eswa.2013.11.006; Kaburlasos VG, 2014, INFORM FUSION, V16, P68, DOI 10.1016/j.inffus.2011.04.003; Kaburlasos V.G., 2013, FUZZY INFERENCE SYST; Keele S, 2007, EBSE200701; KUNDU MK, 1986, PATTERN RECOGN LETT, V4, P433, DOI 10.1016/0167-8655(86)90041-3; Li HY, 2013, AASRI PROC, V4, P329, DOI 10.1016/j.aasri.2013.10.048; LIM YW, 1990, PATTERN RECOGN, V23, P935; Lin T.Y., 1999, COMPUTING WORDS INFO, V1, P183; Lu W, 2014, EXPERT SYST APPL, V41, P3799, DOI 10.1016/j.eswa.2013.12.005; Mingli Song, 2013, IEEE Transactions on Neural Networks and Learning Systems, V24, DOI 10.1109/TNNLS.2013.2237787; Nandedkar A.V., 2013, ELECT ENG INTELLIGEN, P135; Pedrycz W, 2012, APPL SOFT COMPUT, V12, P1985, DOI 10.1016/j.asoc.2012.02.004; Petersen K., 2008, 12 INT C EV ASS SOFT, P1; Qian YH, 2014, INT J APPROX REASON, V55, P225, DOI 10.1016/j.ijar.2013.03.004; Roh S.-B., 2014, EXPERT SYST APPL, P66; Rosenfeld A., 1978, ITERATIVE HISTOGRAM, P300; Salehi S., 2011, 2011 IEEE 2 INT C SO, P594; Salehi S., 2015, KNOWLEDGE BASED SYST; Seifi F., 2007, ICCSA, P337; Skowron A, 2009, LECT NOTES COMPUT SC, V5909, P92; Wang LD, 2012, INT J APPROX REASON, V53, P200, DOI 10.1016/j.ijar.2011.10.001; Wang LJ, 2012, INFORM SCIENCES, V207, P66, DOI 10.1016/j.ins.2012.03.023; Wieringa R, 2006, REQUIR ENG, V11, P102, DOI 10.1007/s00766-005-0021-6; Yang X., 2012, INCOMPLETE INFORM SY, P101; Yao J., 2010, INF SCI REF; Yao Y., 2013, SIST, V13, P307; Yao YY, 2007, LECT NOTES ARTIF INT, V4585, P101, DOI 10.1007/978-3-540-73451-2_12; Yao YY, 2009, PROCEEDINGS OF THE 8TH IEEE INTERNATIONAL CONFERENCE ON COGNITIVE INFORMATICS, P307; Ye MQ, 2013, KNOWL-BASED SYST, V43, P82, DOI 10.1016/j.knosys.2013.01.007; Zadeh LA, 1996, IEEE T FUZZY SYST, V4, P103, DOI 10.1109/91.493904	78	7	7	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0950-7051	1872-7409		KNOWL-BASED SYST	Knowledge-Based Syst.	MAY	2015	80				SI		78	97		10.1016/j.knosys.2015.02.018		20	Computer Science, Artificial Intelligence	Computer Science	CH2KD	WOS:000353853200009		
J	Bernabe-Moreno, J; Tejeda-Lorente, A; Porcel, C; Fujita, H; Herrera-Viedma, E				Bernabe-Moreno, J.; Tejeda-Lorente, A.; Porcel, C.; Fujita, H.; Herrera-Viedma, E.			CARESOME: A system to enrich marketing customers acquisition and retention campaigns using social media information	KNOWLEDGE-BASED SYSTEMS			English	Article						Intrinsic impact; Extrinsic impact; Social CRM; Customers retention; Customers acquisition; Localized social media; Ubiquitous insights	WORD-OF-MOUTH; EARLY-WARNING SYSTEM; RELATIONSHIP MANAGEMENT; FINANCIAL CRISES; IMPACT; CHALLENGES; NETWORKS; STRENGTH; ELEMENT; USERS	The enabling of geo-localization for Social Media content opens the door to a new set of applications based on the voice of the customer. For any company it is critical to understand both their own and their competitors' strengths and weaknesses in all locations where they offer a service. With this motivation we created a Customers Acquisition and REtention system based on SOcial MEdia (CARESOME). Our system extracts and separates all social media interactions in a given location by market player and communication purpose and quantifies the impact of each single interaction over a given time period. To model the impact of the social media interactions, CARESOME relies on a set of metrics based on both intrinsic and extrinsic components including Entity Engagement Index, Differential Perception Factor, Tie-Strength and Number of Exposed users. In addition to the definition of our impact quantification metrics, we provide a thorough discussion about the design decisions taken to build our system. To illustrate the behavior of our system, we show-case a real world scenario from the airline industry based on two major airports in Great Britain. (C) 2015 Elsevier B.V. All rights reserved.	[Bernabe-Moreno, J.; Tejeda-Lorente, A.; Herrera-Viedma, E.] Univ Granada, Dept Comp Sci & AI, E-18071 Granada, Spain; [Porcel, C.] Univ Jaen, Dept Comp Sci, E-23071 Jaen, Spain; [Fujita, H.] IPU, Takizawa, Iwate, Japan	Bernabe-Moreno, J (reprint author), Univ Granada, Dept Comp Sci & AI, E-18071 Granada, Spain.	juan.bernabe-moreno@webentity.de; cporcel@ujaen.es; viedma@decsai.ugr.es		Porcel Gallego, Carlos Gustavo/0000-0002-0219-2937	 [TIN2010-17876];  [TIC5299];  [TIC-5991];  [TIN2013-40658-P]	This paper has been developed with the financing of Projects TIN2010-17876, TIC5299, TIC-5991 and TIN2013-40658-P.	Adam NR, 2012, IEEE INTELL SYST, V27, P90, DOI 10.1109/MIS.2012.113; Thomson MC, 2006, NATURE, V439, P576, DOI 10.1038/nature04503; Wang XR, 2007, IEEE DATA MINING, P697, DOI 10.1109/ICDM.2007.86; Jansen BJ, 2009, J AM SOC INF SCI TEC, V60, P2169, DOI 10.1002/asi.21149; MARSDEN PV, 1984, SOC FORCES, V63, P482, DOI 10.2307/2579058; Corley CD, 2010, INT J ENV RES PUB HE, V7, P596, DOI 10.3390/ijerph7020596; Villanueva J, 2008, J MARKETING RES, V45, P48, DOI 10.1509/jmkr.45.1.48; Grabowicz PA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029358; Gao H, 2011, IEEE INTELL SYST, V26, P10; Li T, 2013, INT J ELECTRON COMM, V18, P97, DOI 10.2753/JEC1086-4415180204; Mares J, 2013, KNOWL-BASED SYST, V49, P134, DOI 10.1016/j.knosys.2013.05.002; Basher R, 2006, PHILOS T R SOC A, V364, P2167, DOI 10.1098/rsta.2006.1819; Mangold WG, 2009, BUS HORIZONS, V52, P357, DOI 10.1016/j.bushor.2009.03.002; Liu Y, 2006, J MARKETING, V70, P74, DOI 10.1509/jmkg.70.3.74; Rapp A, 2013, J ACAD MARKET SCI, V41, P547, DOI 10.1007/s11747-013-0326-9; Tejeda-Lorente A, 2014, INFORM SCIENCES, V261, P52, DOI 10.1016/j.ins.2013.10.036; Rishika R, 2013, INFORM SYST RES, V24, P108, DOI 10.1287/isre.1120.0460; Kiss T, 2006, COMPUT LINGUIST, V32, P485, DOI 10.1162/coli.2006.32.4.485; Ye SZ, 2010, LECT NOTES COMPUT SC, V6430, P216; Yates D, 2011, INT J INFORM MANAGE, V31, P6, DOI 10.1016/j.ijinfomgt.2010.10.001; Bussiere M, 2006, J INT MONEY FINANC, V25, P953, DOI 10.1016/j.jimonfin.2006.07.007; Sen A, 2011, DECIS SUPPORT SYST, V51, P609, DOI 10.1016/j.dss.2010.12.014; Kaplan AM, 2010, BUS HORIZONS, V53, P59, DOI 10.1016/j.bushor.2009.09.003; Hennig-Thurau T, 2010, J SERV RES-US, V13, P311, DOI 10.1177/1094670510375460; Chen YB, 2008, MANAGE SCI, V54, P477, DOI 10.1287/mnsc.1070.0810; Shin H, 2012, INFORM SCIENCES, V196, P28, DOI 10.1016/j.ins.2012.01.040; Scheffer M, 2009, NATURE, V461, P53, DOI 10.1038/nature08227; Gilbert E, 2009, CHI2009: PROCEEDINGS OF THE 27TH ANNUAL CHI CONFERENCE ON HUMAN FACTORS IN COMPUTING SYSTEMS, VOLS 1-4, P211; Dellarocas C, 2003, MANAGE SCI, V49, P1407, DOI 10.1287/mnsc.49.10.1407.17308; Kim YA, 2013, KNOWL-BASED SYST, V37, P438, DOI 10.1016/j.knosys.2012.09.002; Bruce NI, 2012, J MARKETING RES, V49, P469; Serrano-Guerrero J, 2011, INFORM SCIENCES, V181, P1503, DOI 10.1016/j.ins.2011.01.012; Porcel C, 2012, INFORM SCIENCES, V184, P1, DOI 10.1016/j.ins.2011.08.026; Chevalier JA, 2006, J MARKETING RES, V43, P345, DOI 10.1509/jmkr.43.3.345; Chen CLP, 2014, INFORM SCIENCES, V275, P314, DOI 10.1016/j.ins.2014.01.015; Bolton RN, 1998, MARKET SCI, V17, P45, DOI 10.1287/mksc.17.1.45; Candelon B, 2012, IMF ECON REV, V60, P75, DOI 10.1057/imfer.2012.4; Bothos E, 2010, IEEE INTELL SYST, V25, P50, DOI 10.1109/MIS.2010.152; Cha M., 2010, ICWSM, V10, P10, DOI DOI 10.1093/JSCR/2010.10.10; Chan J.M., 2014, J RES MARKET, V2, P157; Colbaugh R., 2012, SECURITY INFORM, V1, P1; Culnan M.J., 2010, MIS Q EXEC, V9, P112; Culotta A., 2010, P 1 WORKSH SOC MED A, P115; Gencosman BC, 2014, INFORM PROCESS MANAG, V50, P821, DOI 10.1016/j.ipm.2014.06.005; Granovetter M, 1973, AM J SOCIOL, V78, P1; Haythornthwaite C., 2001, P ANN HAW INT C SYST, P11; Hennig-Thurau T., 2012, EXPLORING TWITTER EF, P1; Java A., 2007, P 9 WEBKDD 1 SNA KDD, P56, DOI DOI 10.1145/1348549.1348556; Jiang CQ, 2014, SCI CHINA INFORM SCI, V57, DOI 10.1007/s11432-013-4860-3; Kempe D., 2003, P 9 ACM SIGKDD INT C, P137, DOI DOI 10.1145/956750.956769; Krieger M., 2010, TWEETMOTIF EXPLORATO; Kwak H., 2010, P 19 INT C WORLD WID, V112, P591, DOI DOI 10.1145/1772690.1772751; Likert R., 1932, ARCH PSYCHOL, V140, P1, DOI DOI 10.1111/J.1540-5834.2010.00585; Meadows M., 2012, J STRATEGIC MARKETIN, V20, P323; Middleton S., 2014, IEEE INTELL SYST, V99, P1; Naveed N, 2011, P 3 INT WEB SCI C, P8; Page L., 1998, P 7 INT WORLD WID WE, P161; Pan RK, 2012, EPL-EUROPHYS LETT, V97, DOI 10.1209/0295-5075/97/18007; Park J, 2012, ICWSM; Romero D. M., 2011, P 20 INT C WORLD WID, P695, DOI [DOI 10.1145/1963405.1963503, 10.1145/1963405.1963503]; Sakaki T., 2010, P 19 INT C WORLD WID, P851, DOI [DOI 10.1145/1772690.1772777, 10.1145/1772690.177277712]; Smailovic J., 2014, INFORM SCI; Stein AD, 2013, IND MARKET MANAG, V42, P855, DOI 10.1016/j.indmarman.2013.06.004; Yang CC, 2012, IEEE INTELL SYST, V27, P44, DOI 10.1109/MIS.2010.113; Yang QX, 2003, PATTERN ANAL APPL, V6, P122, DOI 10.1007/s10044-002-0180-8; Yin J, 2012, IEEE INTELL SYST, V27, P52; Zhang X., 2011, PROCEDIA SOCIAL BEHA, V26, P55, DOI DOI 10.1016/J.SBSPR0.2011.10.562	67	1	1	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0950-7051	1872-7409		KNOWL-BASED SYST	Knowledge-Based Syst.	MAY	2015	80				SI		163	179		10.1016/j.knosys.2014.12.033		17	Computer Science, Artificial Intelligence	Computer Science	CH2KD	WOS:000353853200016		
J	Tezuka, Y; Herai, N; Inomata, Y; Kagami, K; Yamauchi, J; Nishigori, H; Sanbe, A				Tezuka, Yu; Herai, Natsumi; Inomata, Yui; Kagami, Keisuke; Yamauchi, Junji; Nishigori, Hideo; Sanbe, Atsushi			Upregulation of inorganic pyrophosphatase 1 as a JNK phosphatase in hypothyroid embryonic chick cerebellum	LIFE SCIENCES			English	Article						Protein pyrophosphatase; JNK; Neuronal development	THYROID-HORMONE RECEPTORS; BRAIN-DEVELOPMENT; PRENATAL EXPOSURE; LAST WEEK; CARDIOMYOPATHY; EMBRYOGENESIS; INHIBITION; EXPRESSION; BEHAVIOR; NEURONS	Aim: Thyroid hormones play important roles in vertebrate neuronal development and differentiation. In our previous study, we showed that fetal thyroid dysfunction led to impaired social behaviors of hatchlings on post-hatch day 3, as well as to impaired learning and memory determined by the imprinting preference. However, little is known about the mechanisms underlying the direct adverse effects of fetal thyroid dysfunction on neuronal development. Materials and methods: We used a chick embryo as a fetal model to investigate the effects of prenatal exposure to antithyroid drugs on neuronal development in the chick cerebellum. Methimazole (MMI) at a dose of 20 mu mol/egg was administered to eggs on day 14, while the control was given only a vehicle. In order to address the underlying mechanisms of the impaired behavior, proteomic approaches were employed in the chick cerebellum two days after MMI treatment. Key findings: In this experiment, we found that inorganic pyrophosphatase 1 (PPA1) was upregulated in the chick cerebellum treated with MMI, and we confirmed this upregulation of PPA1 by Western blot analysis as well as by RT-PCR analysis. Concomitant with the upregulation of PPA1, a marked reduction in JNK activity, as well as of phospho-JNK level, was detected in the MMI-treated chick cerebellum. Significance: Since PPA1 can dephosphorylate JNK, these results suggest that the upregulation of PPA1 during neuronal development in the hypothyroid chick cerebellum may lead to impaired social behaviors as well as to impaired learning and memory via JNK dephosphorylation and inactivation in the chick cerebellum. (C) 2015 Elsevier Inc. All rights reserved.	[Tezuka, Yu; Herai, Natsumi; Inomata, Yui; Kagami, Keisuke; Nishigori, Hideo; Sanbe, Atsushi] Iwate Med Univ, Sch Pharm, Dept Pharmacotherapeut, Yahaba, Iwate 0283694, Japan; [Yamauchi, Junji] Natl Res Inst Child Hlth & Dev, Dept Pharmacol, Tokyo 1578535, Japan	Sanbe, A (reprint author), Iwate Med Univ, Sch Pharm, Dept Pharmacotherapeut, 2-1-1 Nishitokuda, Yahaba, Iwate 0283694, Japan.	asanbe@iwate-med.ac.jp			Ministry of Education, Culture, Sports, Science and Technology of Japan; SENSHIN Medical Research Foundation; Keiryoukai Research Foundation [121]	We appreciate the technical support provided for the 2-DE analysis by Mr. Koga (Anatech Corp.) and for the mass spectrometric analysis by Mr. Minohata (Shimadzu Corp.). This work was supported in part by research grants from the Scientific Fund of the Ministry of Education, Culture, Sports, Science and Technology of Japan, SENSHIN Medical Research Foundation and Keiryoukai Research Foundation No. 121.	Anderson GW, 2008, CEREBELLUM, V7, P60, DOI 10.1007/s12311-008-0021-4; Taylor DM, 2013, J NEUROSCI, V33, P2313, DOI 10.1523/JNEUROSCI.4965-11.2013; Ahmed OM, 2008, INT J DEV NEUROSCI, V26, P147, DOI 10.1016/j.ijdevneu.2007.09.011; Smith JW, 2002, NEUROSCI BIOBEHAV R, V26, P45, DOI 10.1016/S0149-7634(01)00037-9; Nishigori H, 2013, PSYCHOPHARMACOLOGY, V227, P393, DOI 10.1007/s00213-013-2979-y; Wallis K, 2008, J NEUROSCI, V28, P1904, DOI 10.1523/JNEUROSCI.5163-07.2008; Bjorkblom B, 2005, J NEUROSCI, V25, P6350, DOI 10.1523/JNEUROSCI.1517-05.2005; Bernal J, 2007, NAT CLIN PRACT ENDOC, V3, P249, DOI 10.1038/ncpendmet0424; FORREST D, 1991, EMBO J, V10, P269; CHEN J, 1990, J BACTERIOL, V172, P5686; Ferjani A, 2011, PLANT CELL, V23, P2895, DOI 10.1105/tpc.111.085415; Kins S, 2003, AM J PATHOL, V163, P833, DOI 10.1016/S0002-9440(10)63444-X; Darras VM, 2009, GEN COMP ENDOCR, V163, P58, DOI 10.1016/j.ygcen.2008.11.014; Muchow M, 2005, J ENDOCRINOL, V184, P407, DOI 10.1677/joe.1.05944; Venero C, 2005, GENE DEV, V19, P2152, DOI 10.1101/gad.346105; Grommen SVH, 2008, J ENDOCRINOL, V196, P519, DOI 10.1677/JOE-07-0443; Curbo S, 2006, GENOMICS, V87, P410, DOI 10.1016/j.ygeno.2005.09.017; Dallaire R, 2009, ENVIRON HEALTH PERSP, V117, P1014, DOI 10.1289/ehp.0800219; GOULD E, 1989, J NEUROSCI, V9, P3347; Haba G, 2011, J OBSTET GYNAECOL RE, V37, P1549, DOI 10.1111/j.1447-0756.2011.01573.x; Haba G, 2014, PSYCHOPHARMACOLOGY, V231, P221, DOI 10.1007/s00213-013-3229-z; Kagami K, 2010, PHYSIOL BEHAV, V101, P297, DOI 10.1016/j.physbeh.2010.05.015; Leijs MM, 2012, ENVIRON HEALTH-GLOB, V11, DOI 10.1186/1476-069X-11-S1-S10; RUIZMARCOS A, 1982, BRAIN RES, V239, P559, DOI 10.1016/0006-8993(82)90530-3; RUIZMARCOS A, 1980, BRAIN RES, V185, P91, DOI 10.1016/0006-8993(80)90674-5; Sanbe A, 2013, J BIOL CHEM, V288, P8910, DOI 10.1074/jbc.M112.368324; Sanbe A, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005351; Sanbe A, 2009, N-S ARCH PHARMACOL, V380, P569, DOI 10.1007/s00210-009-0455-3; Sanbe A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018922; Santisteban P, 2005, REV ENDOCR METAB DIS, V6, P217, DOI 10.1007/s11154-005-3053-9; Weston CR, 2007, CURR OPIN CELL BIOL, V19, P142, DOI 10.1016/j.ceb.2007.02.001; Wilhelm M, 2008, MUTAT RES-REV MUTAT, V659, P83, DOI 10.1016/j.mrrev.2007.11.002; Yamasaki T., 2012, J SIGNAL TRANSDUCT, V2012, DOI DOI 10.1155/2012/459265; Yang Z., 1992, J BIOL CHEM, V267, P24641	34	0	0	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0024-3205	1879-0631		LIFE SCI	Life Sci.	MAY 1	2015	128						94	100		10.1016/j.lfs.2015.02.019		7	Medicine, Research & Experimental; Pharmacology & Pharmacy	Research & Experimental Medicine; Pharmacology & Pharmacy	CH3JW	WOS:000353928000012		
J	Kamo, N; Kaido, T; Hammad, A; Ogawa, K; Fujimoto, Y; Uemura, T; Mori, A; Hatano, E; Okajima, H; Uemoto, S				Kamo, Naoko; Kaido, Toshimi; Hammad, Ahmed; Ogawa, Kohei; Fujimoto, Yasuhiro; Uemura, Tadahiro; Mori, Akira; Hatano, Etsuro; Okajima, Hideaki; Uemoto, Shinji			Impact of Elderly Donors for Liver Transplantation: A Single-Center Experience	LIVER TRANSPLANTATION			English	Article							HEPATITIS-C; HEPATOCELLULAR-CARCINOMA; RISK-FACTORS; AGE; EVOLUTION; OUTCOMES; GRAFT; OLDER	Elderly donor grafts for liver transplantation (LT) are recognized to be marginal grafts. The present study investigated the impact of using elderly donors for LT. Between June 1990 and August 2012, 1631 patients received LT at Kyoto University Hospital. Out of 1631 patients, 1597 patients received living donor liver transplantation (LDLT), whereas the other 34 patients underwent deceased donor liver transplantation (DDLT). Seventy-five grafts that were used came from individuals who were 60 years old. We retrospectively analyzed the recipients' survival rates according to donor age. The overall survival rates of the recipients of all LDLT (P<0.001), adult-to-adult LDLT (P=0.007), all DDLT (P=0.026), and adult-to-adult DDLT (P=0.011) were significantly lower for the elderly donor group versus the younger group and especially for those who were hepatitis C-positive. A multivariate analysis revealed that donor age, ABO incompatibility, and preoperative intensive care unit stay were independent risk factors for poor patient survival in adult-to-adult LDLT. However, no significant differences existed between the 2 groups among those who received adult-to-adult LDLT in and after April 2006. No significant association was found between donor age and incidence of acute cellular rejection. In conclusion, donor age was closely related to the survival rate for LDLT and DDLT, although the impact of donor age was not shown in the recent cases. Liver Transpl 21:591-598, 2015. (c) 2015 AASLD.	[Kamo, Naoko; Kaido, Toshimi; Hammad, Ahmed; Ogawa, Kohei; Fujimoto, Yasuhiro; Uemura, Tadahiro; Mori, Akira; Hatano, Etsuro; Okajima, Hideaki; Uemoto, Shinji] Kyoto Univ, Grad Sch Med, Dept Surg, Div Hepatobiliary Pancreat & Transplant Surg, Kyoto 6068507, Japan; [Hammad, Ahmed] Mansoura Univ, Dept Surg, Mansoura, Egypt	Kaido, T (reprint author), Kyoto Univ, Grad Sch Med, Div Hepatobiliary Pancreat & Transplant Surg,Dept, Sakyo Ku, 54 Kawahara Cho, Kyoto 6068507, Japan.	kaido@kuhp.kyoto-u.ac.jp					Franco CC, 2013, TRANSPL P, V45, P3647, DOI 10.1016/j.transproceed.2013.10.024; Kuramitsu K, 2007, TRANSPLANTATION, V84, P166, DOI 10.1097/01.tp.0000269103.87633.06; Selzner M, 2009, LIVER TRANSPLANT, V15, P1288, DOI [10.1002/lt.21828, 10.1002/It.21828]; Attia M, 2008, TRANSPL INT, V21, P713, DOI 10.1111/j.1432-2277.2008.00696.x; Yoshizumi T, 2012, TRANSPLANTATION, V93, P93, DOI 10.1097/TP.0b013e318238dacd; Akamatsu N, 2007, TRANSPL P, V39, P3189, DOI 10.1016/j.transproceed.2007.03.116; Kaido T, 2010, J GASTROEN HEPATOL, V25, P1598, DOI 10.1111/j.1440-1746.2010.06418.x; Forman LM, 2002, GASTROENTEROLOGY, V122, P889, DOI 10.1053/gast.2002.32418; Morioka D, 2007, ANN SURG, V245, P315, DOI 10.1097/01.sla.0000236600.24667.a4; Ueda Y, 2010, TRANSPLANTATION, V90, P661, DOI 10.1097/TP.0b013e3181d2bfca; Iwamoto T, 2008, TRANSPLANTATION, V85, P1240, DOI 10.1097/TP.0b013e31816c7e90; Lopez-Navidad A, 2003, CLIN TRANSPLANT, V17, P308, DOI 10.1034/j.1399-0012.2003.00119.x; Ito T, 2003, TRANSPLANTATION, V76, P158, DOI 10.1097/01.TP.0000072372.42396.47; Busuttil RW, 2003, LIVER TRANSPLANT, V9, P651, DOI 10.1053/jlts.2003.50105; De Villa V, 2007, ONCOLOGIST, V12, P1321, DOI 10.1634/theoncologist.12-11-1321; Inomata Y, 1996, TRANSPLANTATION, V61, P247, DOI 10.1097/00007890-199601270-00015; Kashyap R, 2009, J GASTROINTEST SURG, V13, P1480, DOI 10.1007/s11605-009-0898-3; Moon DB, 2009, GUT LIVER, V3, P145, DOI 10.5009/gnl.2009.3.3.145; Pol Stanislas, 2014, Rev Prat, V64, P605; Rayhill SC, 2007, TRANSPLANTATION, V84, P331, DOI 10.1097/01.tp.0000270313.31328.63; STARZL TE, 1982, HEPATOLOGY, V2, P614; Takada Y, 2006, LIVER TRANSPLANT, V12, P912, DOI 10.1002/lt.20642; Ueda Y, 2012, J VIRAL HEPATITIS, V19, P32, DOI 10.1111/j.1365-2893.2010.01398.x; Yoshida R, 2008, WORLD J SURG, V32, P2419, DOI 10.1007/s00268-008-9715-5	24	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1527-6465	1527-6473		LIVER TRANSPLANT	Liver Transplant.	MAY	2015	21	5					591	598		10.1002/lt.24086		8	Gastroenterology & Hepatology; Surgery; Transplantation	Gastroenterology & Hepatology; Surgery; Transplantation	CH3KB	WOS:000353928500005		
J	Katsuya, Y; Fujita, Y; Horinouchi, H; Ohe, Y; Watanabe, SI; Tsuta, K				Katsuya, Yuki; Fujita, Yu; Horinouchi, Hidehito; Ohe, Yuichiro; Watanabe, Shun-ichi; Tsuta, Koji			Immunohistochemical status of PD-L1 in thymoma and thymic carcinoma	LUNG CANCER			English	Article						Thymoma; Thymic carcinoma; PD-1; PD-L1; Immunohistochemistry; Clone E1L3N	CELL LUNG-CANCER; PROGRAMMED DEATH-1 LIGAND-1; CLINICAL-SIGNIFICANCE; PROGNOSTIC-FACTORS; 1 EXPRESSION; B7-H1 EXPRESSION; TUMOR B7-H1; SURVIVAL; ASSOCIATION; RECURRENCE	Purpose: The immune checkpoint ligand programmed cell death 1 ligand 1 (PD-L1) is expressed in various tumors and is associated with the response to anti programmed cell death 1 (PD-1)/PD-L1 drugs. We evaluated PD-L1 expression in thymomas and thymic carcinomas to determine whether PD-L1 represents a therapeutic target in unresectable thymomas or thymic carcinomas that could be amenable to antibody-based immunotherapy. Method: A tissue microarray (TMA) comprised of 101 thymomas and 38 thymic carcinomas samples was evaluated. After validation of the rabbit monoclonal PD-L1 antibody (clone E1L3N), the TMA was stained and the tumor PD-L1 expression score was calculated using a semiquantitive method (by multiplying the intensity [0-3] by the staining area [0-100%]). Results: Seventy percent of thymic carcinoma (type C) and 23% of thymoma (types A, AB, and B) samples stained positive for PD-L1 (P<.001). A WHO classification (type C vs types A, AB, and B) was significantly associated with positive PD-L1 expression (P=0.006), though multivariate analysis did not show PD-L1 positive was a significant negative factor of overall survival (hazard ratio = 0.99, 95% confidence interval=0.35-2.73; P=0.987). Conclusions: To the best of our knowledge, this is the largest-scale study to evaluate PD-L1 expression in thymomas and thymic carcinomas. The data suggest that the anti PD-1/PD-L1 drug could be of potential use in immunotherapy for unresectable or relapsed thymomas and thymic carcinomas. (C) 2015 Elsevier Ireland Ltd. All rights reserved.	[Katsuya, Yuki; Tsuta, Koji] Natl Canc Ctr, Div Pathol & Clin Lab, Tokyo 1040045, Japan; [Katsuya, Yuki; Horinouchi, Hidehito; Ohe, Yuichiro] Natl Canc Ctr, Dept Thorac Oncol, Tokyo 1040045, Japan; [Fujita, Yu] Natl Canc Ctr, Div Mol & Cellular Med, Tokyo, Japan; [Watanabe, Shun-ichi] Natl Canc Ctr, Div Thorac Surg, Tokyo 1040045, Japan	Tsuta, K (reprint author), Natl Canc Ctr, Div Pathol & Clin Lab, Chuo Ku, 1-1 Tsukiji 5 Chome, Tokyo 1040045, Japan.	ktsuta@ncc.go.jp		Fujita, Yu/0000-0002-8916-7303	National Cancer Center Research and Development Fund [24-A-1, 26-A-13];  [25460446]	This work was supported in part by the National Cancer Center Research and Development Fund (24-A-1) and (26-A-13), and Grant-in-Aid for Scientific Research (C) Grant Number 25460446.	MCCARTY KS, 1985, ARCH PATHOL LAB MED, V109, P716; Lipson EJ, 2013, CANCER IMMUNOL RES, V1, P54, DOI 10.1158/2326-6066.CIR-13-0034; Konishi J, 2004, CLIN CANCER RES, V10, P5094, DOI 10.1158/1078-0432.CCR-04-0428; Mimae T, 2011, CANCER-AM CANCER SOC, V117, P4396, DOI 10.1002/cncr.26061; Strobel P, 2004, J CLIN ONCOL, V22, P1501, DOI 10.1200/JCO.2004.10.113; Dong HD, 2002, NAT MED, V8, P793, DOI 10.1038/nm730; Thompson RH, 2006, CANCER RES, V66, P3381, DOI 10.1158/0008-5472.CAN-05-4303; Chen YB, 2012, TUMORI, V98, P751, DOI 10.1700/1217.13499; Gao Q, 2009, CLIN CANCER RES, V15, P971, DOI 10.1158/1078-0432.CCR-08-1608; Brown JA, 2003, J IMMUNOL, V170, P1257; Droeser RA, 2013, EUR J CANCER, V49, P2233, DOI 10.1016/j.ejca.2013.02.015; Engels EA, 2003, INT J CANCER, V105, P546, DOI 10.1002/ijc.11099; Nomi T, 2007, CLIN CANCER RES, V13, P2151, DOI 10.1158/1078-0432.CCR-06-2746; Okazaki T, 2013, NAT IMMUNOL, V14, P1212, DOI 10.1038/ni.2762; Velcheti V, 2014, LAB INVEST, V94, P107, DOI 10.1038/labinvest.2013.130; Wu CP, 2006, ACTA HISTOCHEM, V108, P19, DOI 10.1016/j.acthis.2006.01.003; Zandberg DP, 2014, ORAL ONCOL, V50, P627, DOI 10.1016/j.oraloncology.2014.04.003; Hamanishi J, 2007, P NATL ACAD SCI USA, V104, P3360, DOI 10.1073/pnas.0611533104; Boland JM, 2013, CLIN LUNG CANCER, V14, P157, DOI 10.1016/j.cllc.2012.05.006; Hino R, 2010, CANCER-AM CANCER SOC, V116, P1757, DOI 10.1002/cncr.24899; Topalian SL, 2012, NEW ENGL J MED, V366, P2443, DOI 10.1056/NEJMoa1200690; Schalper KA, 2014, CLIN CANCER RES, V20, P2773, DOI 10.1158/1078-0432.CCR-13-2702; Ohigashi Y, 2005, CLIN CANCER RES, V11, P2947, DOI 10.1158/1078-0432.CCR-04-1469; Lamarca A, 2013, CANCER TREAT REV, V39, P413, DOI 10.1016/j.ctrv.2012.11.005; Yang CY, 2014, EUR J CANCER, V50, P1361, DOI 10.1016/j.ejca.2014.01.018; Antonia SJ, 2013, J THORAC ONCOL S2, V8; Azuma K, 2014, ANN ONCOL, V25, P1935, DOI 10.1093/annonc/mdu242; Gandhi L, 2014, AACR ANN M; Ishii H, 2015, J THORAC ONCOL, V10, P426, DOI 10.1097/JTO.0000000000000414; Kefford R, 2014, J CLIN ONCOL, V32; McLaughlin J, 2014, J CLIN ONCOL, V32; Padda SK, 2015, J THORAC ONCOL, V10, P500, DOI 10.1097/JTO.0000000000000429; Ruffini E, 2014, EUR J CARDIO-THORAC, V46, P361, DOI 10.1093/ejcts/ezt649; Safieddine N, 2014, J THORAC ONCOL, V9, P1018, DOI 10.1097/JTO.0000000000000215; Schultheis AM, 2015, EUR J CANCER, V51, P421, DOI 10.1016/j.ejca.2014.12.006; Taube JM, 2014, CLIN CANCER RES, V20, P5064, DOI 10.1158/1078-0432.CCR-13-3271; Thompson RH, 2007, CLIN CANCER RES, V13, p709S, DOI 10.1158/1078-0432.CCR-06-1868	37	0	0	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0169-5002	1872-8332		LUNG CANCER	Lung Cancer	MAY	2015	88	2					154	159		10.1016/j.lungcan.2015.03.003		6	Oncology; Respiratory System	Oncology; Respiratory System	CH1BE	WOS:000353755300006		
J	Shimada, Y; Saji, H; Otani, K; Maehara, S; Maeda, J; Yoshida, K; Kato, Y; Hagiwara, M; Kakihana, M; Kajiwara, N; Ohira, T; Akata, S; Ikeda, N				Shimada, Yoshihisa; Saji, Hisashi; Otani, Keishi; Maehara, Sachio; Maeda, Junichi; Yoshida, Koichi; Kato, Yasufumi; Hagiwara, Masaru; Kakihana, Masatoshi; Kajiwara, Naohiro; Ohira, Tatsuo; Akata, Soichi; Ikeda, Norihiko			Survival of a surgical series of lung cancer patients with synchronous multiple ground-glass opacities, and the management of their residual lesions	LUNG CANCER			English	Article						Non-small cell lung cancer; Multiple lung cancer; Ground-glass opacity; Surgical resection	ONCOLOGY GROUP 0201; THIN-SECTION CT; COMPUTED-TOMOGRAPHY; BRONCHIOLOALVEOLAR CARCINOMA; FOLLOW-UP; ADENOCARCINOMA; NODULES; ORIGIN; LESS; RESECTION	Objectives: We reviewed the medical record of a series of patients with synchronous multiple lung cancers (SMLC), in an attempt to identify the optimal treatment strategy for multiple ground-glass opacities (GGOs). Materials and methods: From 2004 to 2010, 1223 patients underwent complete resection of non-small cell lung cancer. Among these, there were 67 patients (5.5%) with SMLC with at least 1 of the nodules showing GGO appearance. SMLC was divided into the main cancer (MC) which was a main target based on its tumor size or radiological invasiveness and sub-nodules. According to consolidation/tumor ratio (CTR) on thin-section computed tomography, 67 cases were classified into GG-group (MC showing GGO-dominant lesion; CTR <= 0.5) and GS-group (MC showing solid-dominant lesion; CTR>0.5). Results: There were 24 patients in the GG-group (36%) and 43 patients in the GS-group (64%). Surgical resections included 11 sublobar resections (SLs), 32 lobectomies, 19 lobectomy + SLs, and 4 bilobectomies. There were 39 patients with a total of 118 unresected GGOs after the initial surgery. Among them, the frequency of growth was 8% on a per-nodule basis with the median tumor doubling time of 1373 days, and new GGOs emerged in 15 patients (23%). Multivariate analysis demonstrated that larger size of MC and the GS-group was associated with poor prognosis, whereas growth of the residual GGOs, the development of new GG0s, or whether or not all GGOs were treated did not affect survival. The 5-year OS proportions were 95.8% for the GG-group and 68.0% for the GS-group (p = 0.009), and 92.4% for a MC of <= 25 mm and 53.6% for a MC of >25 mm (p = 0.008). Conclusion: Survival of patients with multifocal GGOs is strongly affected by radiological findings of the MC. Strict surgical control for MC could be most important 2015 Elsevier Ireland Ltd. All rights reserved.	[Shimada, Yoshihisa; Otani, Keishi; Maehara, Sachio; Maeda, Junichi; Yoshida, Koichi; Kato, Yasufumi; Hagiwara, Masaru; Kakihana, Masatoshi; Kajiwara, Naohiro; Ohira, Tatsuo; Ikeda, Norihiko] Tokyo Med Univ Hosp, Dept Surg 1, Tokyo, Japan; [Akata, Soichi] Tokyo Med Univ Hosp, Dept Radiol, Tokyo, Japan; [Saji, Hisashi] St Marianna Univ, Sch Med, Dept Chest Surg, Yokohama, Kanagawa, Japan	Shimada, Y (reprint author), Tokyo Med Univ, Dept Surg 1, Shinjuku Ku, 6-7-1 Nishishinjuku, Tokyo 1600023, Japan.	zenkyu@za3.so-net.ne.jp			Japan Society for the Promotion of Science [26861130]; Ministry of Education, Culture, Sports, Science and Technology, Japan	This study was supported by Grants-in-Aid for Scientific Research from the Japan Society for the Promotion of Science (26861130), and the Ministry of Education, Culture, Sports, Science and Technology, Japan.	Cho S, 2013, ANN THORAC SURG, V96, P1190, DOI 10.1016/j.athoracsur.2013.05.062; Matsuguma H, 2013, CHEST, V143, P436, DOI 10.1378/chest.11-3306; Suzuki K, 2011, J THORAC ONCOL, V6, P751, DOI 10.1097/JTO.0b013e31821038ab; Kim HK, 2010, J THORAC ONCOL, V5, P206, DOI 10.1097/JTO.0b013e3181c422be; Mun M, 2007, J THORAC CARDIOV SUR, V134, P877, DOI 10.1016/j.jtcvs.2007.06.010; Gu B, 2013, ANN THORAC SURG, V96, P411, DOI 10.1016/j.athoracsur.2013.04.048; Hayat MJ, 2007, ONCOLOGIST, V12, P20, DOI 10.1634/theoncologist.12-1-20; Chang B, 2013, CHEST, V143, P172, DOI 10.1378/chest.11-2501; Habuchi T, 2005, INT J UROL, V12, P709, DOI 10.1111/j.1442-2042.2005.01155.x; Ikeda N, 2004, ANN THORAC SURG, V78, P1011, DOI 10.1016/j.athorascur.2004.03.048; Chung JH, 2009, J THORAC ONCOL, V4, P1490, DOI 10.1097/JTO.0b013e3181bc9731; Nakata M, 2004, ANN THORAC SURG, V78, P1194, DOI 10.1016/j.athoracsur.2004.03.102; Henschke CI, 1999, LANCET, V354, P99, DOI 10.1016/S0140-6736(99)06093-6; Finley DJ, 2010, J THORAC ONCOL, V5, P197, DOI 10.1097/JTO.0b013e3181c814c5; Sone S, 1998, LANCET, V351, P1242, DOI 10.1016/S0140-6736(97)08229-9; Asamura H, 2013, J THORAC CARDIOV SUR, V146, P24, DOI 10.1016/j.jtcvs.2012.12.047; Girard N, 2009, CLIN CANCER RES, V15, P5184, DOI 10.1158/1078-0432.CCR-09-0594; Shimada Y, 2012, CHEST, V141, P1003, DOI 10.1378/chest.11-0017; Hashizume T, 2008, CHEST, V133, P441, DOI 10.1378/chest.07-1533; Park CM, 2007, RADIOGRAPHICS, V27, P391, DOI 10.1148/rg.272065061; BARSKY SH, 1994, MODERN PATHOL, V7, P633; Leslie Sobin MGCW, 2009, TNM CLASSIFICATION M; Matsuguma H, 2013, ANN THORAC SURG, V95, P1878, DOI 10.1016/j.athoracsur.2013.02.022; Okada M, 2003, ANN THORAC SURG, V76, P1828, DOI 10.1016/S0003-4975(03)01077-4; Shen KR, 2007, CHEST, V132, p290S, DOI 10.1378/chest.07-1382; Tamura M, 2014, J THORAC ONCOL, V9, P469, DOI 10.1097/JTO.0000000000000117; Tsutsui S, 2010, AM J ROENTGENOL, V195, pW131, DOI 10.2214/AJR.09.3828	27	0	1	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0169-5002	1872-8332		LUNG CANCER	Lung Cancer	MAY	2015	88	2					174	180		10.1016/j.lungcan.2015.02.016		7	Oncology; Respiratory System	Oncology; Respiratory System	CH1BE	WOS:000353755300009		
J	Fukuhara, T; Maemondo, M; Inoue, A; Kobayashi, K; Sugawara, S; Oizumi, S; Isobe, H; Gemma, A; Harada, M; Yoshizawa, H; Kinoshita, I; Fujita, Y; Saijo, Y; Hagiwara, K; Morita, S; Nukiwa, T				Fukuhara, Tatsuro; Maemondo, Makoto; Inoue, Akira; Kobayashi, Kunihiko; Sugawara, Shunichi; Oizumi, Satoshi; Isobe, Hiroshi; Gemma, Akihiko; Harada, Masao; Yoshizawa, Hirohisa; Kinoshita, Ichiro; Fujita, Yuka; Saijo, Yasuo; Hagiwara, Koichi; Morita, Satoshi; Nukiwa, Toshihiro			Factors associated with a poor response to gefitinib in the NEJ002 study: Smoking and the L858R mutation	LUNG CANCER			English	Article						EGFR; Gefitinib; NEJ002; Smoking; Carboplatin-paclitaxel; L858R mutation	CELL LUNG-CANCER; TYROSINE KINASE INHIBITORS; EGFR MUTATIONS; RESISTANCE; ADENOCARCINOMA; ACTIVATION	Introduction: Epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) treatment is the standard therapy for non-small cell lung cancer (NSCLC) harbouring EGFR-activating mutations. The NEJ002 phase 3 clinical trial demonstrated the efficacy of EGFR-TKI; gefitinib was significantly superior in both progression-free survival (PFS) and objective response rate (ORR) than carboplatin plus paclitaxel. However, several cases showed no response. In this study, we performed further analysis of the characteristics of these non-responders. Methods: Available data from NEJ002 on maximum changes in tumour size were obtained from 103 cases (90.4%) and 110 cases (96.5%) in the carboplatin paclitaxel and gefitinib groups, respectively. Waterfall plots of maximum tumour size changes were created for non-responders. Results: Five (4.9%) and 9 (8.2%) cases in the carboplatin paclitaxel and gefitinib groups were non-responders, respectively. The mean pack years of the non-responders in the carboplatin paclitaxel and gefitinib groups were 0.33 and 31.7, respectively. The ORR of total smokers (61.5%) and heavy smokers (over 40 pack years, 52.6%) in the gefitinib group were significantly lower compared to people who have never smoked (80.0%) (P = 0.044 and P=0.020, respectively). Smoker cases also showed a tendency towards lower PFS and overall survival (05). In addition, the EGFR common mutation types did not affect PFS and OS in gefitinib-treated cases in NEJ002. However, in this study, the ORR and waterfall plots showed that gefitinib-treated non-responders who had a deletion in exon 19 in the EGFR gene exhibited a tendency towards a higher response compared to those with a L858R mutation. Conclusions: NSCLC patients with a smoking history or the EGFR L858R mutation may demonstrate a poorer response to gefitinib treatment. 0 2015 The Authors. Published by Elsevier Ireland Ltd.	[Fukuhara, Tatsuro; Maemondo, Makoto] Miyagi Canc Ctr, Dept Resp Med, Natori, Miyagi 9811293, Japan; [Inoue, Akira] Tohoku Univ, Dept Resp Med, Aoba Ku, Sendai, Miyagi 9808574, Japan; [Kobayashi, Kunihiko] Saitama Med Univ, Int Med Ctr, Dept Resp Med, Saitama 3501298, Japan; [Sugawara, Shunichi] Sendai Kousei Hosp, Dept Pulm Med, Aoba Ku, Sendai, Miyagi 9800873, Japan; [Oizumi, Satoshi] Hokkaido Univ, Sch Med, Dept Med 1, Kita Ku, Sapporo, Hokkaido 0608638, Japan; [Isobe, Hiroshi] KKR Sapporo Med Ctr, Dept Med Oncol, Toyohira Ku, Sapporo, Hokkaido 0620931, Japan; [Gemma, Akihiko] Nipppon Med Sch, Div Pulm Med Infect Dis & Oncol, Dept Internal Med, Tokyo 1138602, Japan; [Harada, Masao] Natl Hosp Org, Hokkaido Canc Ctr, Dept Resp Med, Shiroishi Ku, Sapporo, Hokkaido 0030804, Japan; [Yoshizawa, Hirohisa] Niigata Univ Med & Dent Hosp, Biosci Med Res Ctr, Nishi Ku, Niigata 9502181, Japan; [Kinoshita, Ichiro] Hokkaido Univ, Grad Sch Med, Dept Med Oncol, Kita Ku, Sapporo, Hokkaido 0608638, Japan; [Fujita, Yuka] Natl Hosp Org, Asahikawa Med Ctr, Dept Resp Med, Asahikawa, Hokkaido 0700901, Japan; [Saijo, Yasuo] Niigata Univ Med & Dent Hosp, Dept Med Oncol, Niigata 9502181, Japan; [Hagiwara, Koichi] Saitama Med Univ, Dept Resp Med, Saitama 3500495, Japan; [Morita, Satoshi] Kyoto Univ Hosp, Inst Adv Clin & Translat Sci, Dept Data Sci, Sakyo Ku, Kyoto 6068507, Japan; [Nukiwa, Toshihiro] Japan AntiTB Assoc, Chiyoda Ku, Tokyo 1010061, Japan	Fukuhara, T (reprint author), Miyagi Canc Ctr, Dept Resp Med, 47-1 Nodayama, Natori, Miyagi 9811293, Japan.	fukuhara-tatsuro@miyagi-pho.jp			Tokyo Cooperative Oncology Group, non-profit organization, Japan	We thank Hiromi Odagiri for her expert assistance with data collection and management. This study was supported by the Tokyo Cooperative Oncology Group, non-profit organization, Japan.	Helfrich BA, 2006, CLIN CANCER RES, V12, P7117, DOI 10.1158/1078-0432.CCR-06-0760; Inoue A, 2013, ANN ONCOL, V24, P54, DOI 10.1093/annonc/mds214; Tanaka K, 2013, J THORAC ONCOL, V8, P892, DOI 10.1097/JTO.0b013e31828c3929; Shan YB, 2012, CELL, V149, P860, DOI 10.1016/j.cell.2012.02.063; Rosell R, 2009, NEW ENGL J MED, V361, P958, DOI 10.1056/NEJMoa0904554; Chen Z, 2014, NAT REV CANCER, V14, P535, DOI 10.1038/nrc3775; De Flora S, 2003, MUTAT RES-FUND MOL M, V523, P237, DOI 10.1016/S0027-5107(02)00340-8; Maemondo M, 2010, NEW ENGL J MED, V362, P2380, DOI 10.1056/NEJMoa0909530; Filosto S, 2012, MOL CANCER THER, V11, P795, DOI 10.1158/1535-7163.MCT-11-0698; Filosto S, 2013, MOL CANCER THER, V12, P1579, DOI 10.1158/1535-7163.MCT-12-1029; Kim MH, 2014, LUNG CANCER, V84, P196, DOI 10.1016/j.lungcan.2014.01.022; Wang S, 2013, J THORAC ONCOL, V8, P719, DOI 10.1097/JTO.0b013e31828b51d4; Mitsudomi T, 2010, LANCET ONCOL, V11, P121, DOI 10.1016/S1470-2045(09)70364-X; Imielinski M, 2012, CELL, V150, P1107, DOI 10.1016/j.cell.2012.08.029; Guo A, 2008, P NATL ACAD SCI USA, V105, P692, DOI 10.1073/pnas.0707270105; Govindan R, 2012, CELL, V150, P1121, DOI 10.1016/j.cell.2012.08.024; Lee JK, 2013, ANN ONCOL, V24, P2080, DOI 10.1093/annonc/mdt127; Paez JG, 2004, SCIENCE, V304, P1497, DOI 10.1126/science.1099314; Lynch TJ, 2004, NEW ENGL J MED, V350, P2129, DOI 10.1056/NEJMoa040938; Viswanath K, 2010, CANCER RES, V70, P3419, DOI 10.1158/0008-5472.CAN-10-1087; Watanabe S, 2014, J THORAC ONCOL, V9, P189, DOI 10.1097/JTO.0000000000000048; Yang JCH SL, 2014, J CLIN ONCOL, V32, P32	22	3	3	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0169-5002	1872-8332		LUNG CANCER	Lung Cancer	MAY	2015	88	2					181	186		10.1016/j.lungcan.2015.02.004		6	Oncology; Respiratory System	Oncology; Respiratory System	CH1BE	WOS:000353755300010		
J	Yamada, I; Miyasaka, N; Hikishima, K; Tokairin, Y; Kawano, T; Ito, E; Kobayashi, D; Eishi, Y; Okano, H				Yamada, Ichiro; Miyasaka, Naoyuki; Hikishima, Keigo; Tokairin, Yutaka; Kawano, Tatsuyuki; Ito, Eisaku; Kobayashi, Daisuke; Eishi, Yoshinobu; Okano, Hideyuki			Ultra-high-resolution MR imaging of esophageal carcinoma at ultra-high field strength (7.0 T) ex vivo: correlation with histopathologic findings	MAGNETIC RESONANCE IMAGING			English	Article						Esophagus; Esophageal carcinoma; Ultra-high spatial resolution; Ultra-high field strength; MR imaging	IN-VITRO; ENDOSCOPIC ULTRASONOGRAPHY; SURFACE-COIL; CANCER; TRACTOGRAPHY; CT	Purpose: To determine the usefulness of ultra-high-resolution magnetic resonance (MR) imaging at an ultra-high field strength (7.0 T), using a voxel volume of 9.5-14 nL, as means of evaluating the depth of mural invasion by esophageal carcinomas. Materials and Methods: Twenty esophageal specimens containing 20 carcinomas were studied using a 7.0-T MR imaging system with a four-channel surface coil. Ultra-high-resolution MR images were obtained with a field of view of 50-60 mm x 25-30 mm, a matrix of 512 x 256, and a section thickness of 1.0 mm, resulting in a voxel volume of 0.0095-0.014 mm(3) (9.5-14 nL). Differences between tumor tissue and the esophageal wall layers and between tumor tissue and fibrosis were evaluated using visual signal intensity scoring measurements. MR images were then compared with histopathologic findings as the reference standard. Results: Ultra-high-resolution T2-weighted MR images at 7.0 T clearly depicted the normal esophageal wall in all 20 specimens (100%) as consisting of eight layers, which clearly corresponded to the tissue layers of the esophageal wall. Ultra-high-resolution T2-weighted MR images made it possible to differentiate between the tumor tissue and fibrosis clearly (P < 0.01). In all 20 esophageal carcinomas (100%), ultra-high-resolution T2-weighted MR images made it possible to determine the depth of tumor invasion in the esophageal wall as observed in the histopathologic sections. Regional lymph node involvement was also clearly depicted in four specimens. Conclusion: Ultra-high-resolution 7.0-T MR imaging, using a voxel volume of 9.5-14 nL, provides clear delineation of the esophageal wall layers, clear differentiation of tumor tissue from fibrosis, and excellent diagnostic accuracy for evaluating mural invasion by esophageal carcinomas. (C) 2015 Elsevier Inc. All rights reserved.	[Yamada, Ichiro] Tokyo Med & Dent Univ, Grad Sch, Dept Diagnost Radiol & Oncol, Tokyo 1138519, Japan; [Miyasaka, Naoyuki] Tokyo Med & Dent Univ, Dept Pediat Perinatal & Maternal Med, Tokyo 1138519, Japan; [Hikishima, Keigo; Okano, Hideyuki] Keio Univ, Sch Med, Dept Physiol, Tokyo 160, Japan; [Hikishima, Keigo] Cent Inst Expt Anim, Kawasaki, Kanagawa, Japan; [Tokairin, Yutaka; Kawano, Tatsuyuki] Tokyo Med & Dent Univ, Dept Esophagogastr Surg, Tokyo 1138519, Japan; [Ito, Eisaku; Kobayashi, Daisuke; Eishi, Yoshinobu] Tokyo Med & Dent Univ, Dept Pathol, Tokyo 1138519, Japan	Yamada, I (reprint author), Tokyo Med & Dent Univ, Grad Sch, Dept Diagnost Radiol & Oncol, Bunkyo Ku, 1-5-45 Yushima, Tokyo 1138519, Japan.	yamada.crad@tmd.ac.jp	Okano, Hideyuki/J-5973-2013		MEXT, Japan [23591753]	For all the authors listed, no conflicts are declared. Dr. Yamada has received the Grant-in-Aid for Scientific Research (C) of MEXT, Japan (23591753).	Misra S, 2012, SURG ENDOSC, V26, P518, DOI 10.1007/s00464-011-1911-y; Dave UR, 2004, RADIOLOGY, V230, P281, DOI 10.1148/radiol.2301021047; Rice TW, 2010, CANCER-AM CANCER SOC, V116, P3763, DOI 10.1002/cncr.25146; van der Kolk AG, 2013, EUR J RADIOL, V82, P708, DOI 10.1016/j.ejrad.2011.07.007; Yamada I, 2006, J MAGN RESON IMAGING, V24, P1326, DOI 10.1002/jmri.20741; Riddell AM, 2006, BRIT J RADIOL, V79, P873, DOI 10.1259/bjr/36989440; Lightdale CJ, 2005, J CLIN ONCOL, V23, P4483, DOI 10.1200/JCO.2005.20.644; AUH YH, 1994, RADIOLOGY, V191, P129; Bucher O, 1980, CYTOLOGIE HISTOLOGIE, V10th; Cho Jin Woong, 2013, Clin Endosc, V46, P239, DOI 10.5946/ce.2013.46.3.239; Edge S, 2010, AJCC CANC STAGING MA, P103; Feldman DR, 1997, RADIOLOGY, V202, P868; IMAI Y, 1990, RADIOLOGY, V177, P695; Murata Y, 2003, ENDOSCOPY, V35, P429, DOI 10.1055/s-2003-38774; Onbas O, 2006, EUR J RADIOL, V57, P90, DOI 10.1016/j.ejrad.2005.07.012; Panebianco V, 2006, EUR RADIOL, V16, P414, DOI 10.1007/s00330-005-2851-5; Preston SR, 2003, BRIT J SURG, V90, P1220, DOI 10.1002/bjs.4268; Riddell AM, 2007, AM J ROENTGENOL, V188, pW37, DOI 10.2214/AJR.05.1795; Riddell AM, 2006, AM J ROENTGENOL, V187, P1280, DOI 10.2214/AJR.05.0559; Riddell AM, 2007, EUR RADIOL, V17, P391, DOI 10.1007/s00330-006-0363-6; Satoh T, 1993, REGIONAL ANATOMY GAS; Schlick T, 1999, SURG ENDOSC-ULTRAS, V13, P894, DOI 10.1007/s004649901128; Stollfuss JC, 2006, RADIOLOGY, V241, P132, DOI 10.1148/radiol.2411050942; Wakelin SJ, 2002, EUR J RADIOL, V41, P161, DOI 10.1016/S0720-048X(01)00418-1; Yamada I, 2014, J MAGN RESON IMAGING, V40, P567, DOI 10.1002/jmri.24411; Yamada I, 2001, J MAGN RESON IMAGING, V13, P225, DOI 10.1002/1522-2586(200102)13:2<225::AID-JMRI1033>3.0.CO;2-Z; Yamada I, 2014, RADIOLOGY, V272, P164, DOI 10.1148/radiol.14132170; Yamada I, 1997, RADIOLOGY, V204, P521; Zeineh MM, 2014, INVEST RADIOL, V49, P278, DOI 10.1097/RLI.0000000000000015	29	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0730-725X	1873-5894		MAGN RESON IMAGING	Magn. Reson. Imaging	MAY	2015	33	4					413	419		10.1016/j.mri.2014.11.005		7	Radiology, Nuclear Medicine & Medical Imaging	Radiology, Nuclear Medicine & Medical Imaging	CG9VW	WOS:000353669200007		
J	Kioka, A; Ashi, J; Sakaguchi, A; Sato, T; Muraoka, S; Yamaguchi, A; Hamamoto, H; Wang, KL; Tokuyama, H				Kioka, Arata; Ashi, Juichiro; Sakaguchi, Arito; Sato, Tokiyuki; Muraoka, Satoru; Yamaguchi, Asuka; Hamamoto, Hideki; Wang, Kelin; Tokuyama, Hidekazu			Possible mechanism of mud volcanism at the prism-backstop contact in the western Mediterranean Ridge Accretionary Complex	MARINE GEOLOGY			English	Article						Mud volcano; Mediterranean Ridge; Vitrinite reflectance; Thermal structure; Overpressure	SUBDUCTION ZONE; THRUST BELTS; SANDBOX EXPERIMENTS; SETTLING VELOCITY; ACTIVE TECTONICS; STRUCTURAL STYLE; SOUTHWEST JAPAN; ORGANIC-MATTER; SEISMIC DATA; FLUID-FLOW	The Eastern Mediterranean seafloor has numerous mud volcanoes, most of which form a well-defined belt within the Mediterranean Ridge (MedRidge) accretionary complex. However, mud volcano fields in the western MedRidge are less well known as those in the central and eastern MedRidge. This study investigates material cycling and fluid migration within the western MedRidge. We propose a possible ascent style of the ejecta forming the Medee-Hakuho Mud Volcano (MHMV) in the western MedRidge by applying the vitrinite reflectance technique to ejecta samples. First, we model the 2-D thermal structure in the western MedRidge, taking into account frictional heating on the plate interface, to help estimate the source depth of the MHMV ejecta. The result suggests an effective coefficient of friction of around 0.01, and a temperature of about 160 +/- 15 degrees C along the plate interface at a distance of similar to 180 km from the deformation front, the location of the seaward toe of the Aegean backstop. Second, we evaluate the source depth of the MHMV ejecta using vitrinite reflectance in conjunction with the modeled thermal structure. The results suggest that the ejecta matrix showing vitrinite reflectance values of similar to 0.6% was subjected to a temperature of around 85 degrees C, corresponding to a depth of approximately 5 km below the seafloor (kmbsf), whereas older clasts of Aptian or earlier age, with vitrinite reflectance values of similar to 0.6-1.0%, are derived from much deeper depths. Most of the clasts are considered to have been lifted to the depth of 5 kmbsf as a result of underplating at the toe of a rigid backstop that had developed below MHMV after underthrusting related to plate subduction. At that depth, fluid pressures that are dramatically increased because of underplating promote the ascent of fluid-rich sediments and entrain clasts along an existing fault in the accretionary wedge. (C) 2015 Elsevier B.V. All rights reserved.	[Kioka, Arata; Ashi, Juichiro; Muraoka, Satoru; Yamaguchi, Asuka] Univ Tokyo, Atmosphere & Ocean Res Inst, Kashiwa, Chiba 2778564, Japan; [Sakaguchi, Arito] Yamaguchi Univ, Dept Geosphere Sci, Yamaguchi, Yamaguchi 7538512, Japan; [Sato, Tokiyuki] Akita Univ, Fac Int Resource Sci, Akita, Akita 0108502, Japan; [Hamamoto, Hideki] Ctr Environm Sci Saitama, Kozo, Saitama 3470115, Japan; [Wang, Kelin] Geol Survey Canada, Pacific Geosci Ctr, Sidney, BC V8L 4B2, Canada; [Tokuyama, Hidekazu] Kochi Univ, Ctr Adv Marine Core Res, Nankoku, Kochi 7838502, Japan	Kioka, A (reprint author), Univ Tokyo, Atmosphere & Ocean Res Inst, Kashiwa, Chiba 2778564, Japan.	kioka@aori.u-tokyo.ac.jp		Kioka, Arata/0000-0002-0922-1112	MEXT of Japan [21107003]	The authors highly appreciate the effort of shipboard scientists and staffs of PENELOPE Cruise (KH-06-4 Leg 6) to acquire the data used in this work. We thank Dr. A. Omura for her kind supports on measurement of density and other pretreatments of samples as well as her helpful comments, and we thank Profs. G. Kimura, Y. Ikeda, and M. Yamano, Drs. H. Otsuka and A Misawa, Mrs. T. Ojima, M. Fujii and K. Yagasaki for discussions. The manuscript benefited from reviews by two anonymous reviewers and Editor G.J. De Lange. Dr. F. Harmegnies provided the geothermal data obtained during the MEDRIFF project. Some figures were drafted using Generic Mapping Tools (GMT) software developed by Wessel and Smith (1998). This study was supported by Grant-in-Aid for Scientific Research on Innovative Areas (No. 21107003) from MEXT of Japan. This is Geological Survey of Canada contribution 20140139.	ANDERSON DL, 1981, GEOLOGY, V9, P7, DOI 10.1130/0091-7613(1981)9<7:RODD>2.0.CO;2; Chaumillon E, 1997, MAR GEOL, V138, P237, DOI 10.1016/S0025-3227(97)00002-9; Saffer DM, 2011, ANNU REV EARTH PL SC, V39, P157, DOI 10.1146/annurev-earth-040610-133408; Huguen C, 2004, MAR GEOL, V209, P245, DOI 10.1016/j.margeo.2004.05.002; McClusky S, 2000, J GEOPHYS RES-SOL EA, V105, P5695, DOI 10.1029/1999JB900351; Camerlenghi A, 2009, SEDIMENTOLOGY, V56, P319, DOI 10.1111/j.1365-3091.2008.01016.x; Sakaguchi A, 2011, GEOLOGY, V39, P395, DOI 10.1130/G31642.1; Akoumianaki I, 2012, MICROBES ENVIRON, V27, P504, DOI 10.1264/jsme2.ME12045; Le Pichon X, 2002, MAR GEOL, V186, P111, DOI 10.1016/S0025-3227(02)00175-5; DAVIS D, 1983, J GEOPHYS RES, V88, P1153, DOI 10.1029/JB088iB02p01153; Kopp C, 2000, TECTONOPHYSICS, V329, P171, DOI 10.1016/S0040-1951(00)00195-5; Muller RD, 2008, GEOCHEM GEOPHY GEOSY, V9, DOI 10.1029/2007GC001743; Gutscher MA, 1996, GEOLOGY, V24, P135, DOI 10.1130/0091-7613(1996)024<0135:CBOTWI>2.3.CO;2; Rabaute A, 2007, MAR GEOPHYS RES, V28, P271, DOI 10.1007/s11001-007-9031-8; Ohmori K, 1997, GEOLOGY, V25, P327, DOI 10.1130/0091-7613(1997)025<0327:PSOTSA>2.3.CO;2; SHIMIZU I, 1995, TECTONOPHYSICS, V245, P121, DOI 10.1016/0040-1951(94)00230-7; TURCOTTE DL, 1978, TECTONOPHYSICS, V47, P193, DOI 10.1016/0040-1951(78)90030-6; Speranza F, 2012, J GEOPHYS RES-SOL EA, V117, DOI 10.1029/2012JB009475; Limonov AF, 1996, MAR GEOL, V132, P7, DOI 10.1016/0025-3227(96)00150-8; Rudolph ML, 2010, J GEOPHYS RES-SOL EA, V115, DOI 10.1029/2010JB007737; Manga M, 2009, MAR PETROL GEOL, V26, P1785, DOI 10.1016/j.marpetgeo.2009.01.019; Lykousis V, 2009, MAR PETROL GEOL, V26, P854, DOI 10.1016/j.marpetgeo.2008.05.002; BARKER CE, 1990, GEOLOGY, V18, P1003, DOI 10.1130/0091-7613(1990)018<1003:FITFDM>2.3.CO;2; DIETRICH WE, 1982, WATER RESOUR RES, V18, P1615, DOI 10.1029/WR018i006p01615; Ashi J, 2002, MAR GEOL, V187, P177, DOI 10.1016/S0025-3227(02)00265-7; Shaw B, 2008, NAT GEOSCI, V1, P268, DOI 10.1038/ngeo151; STEIN CA, 1992, NATURE, V359, P123, DOI 10.1038/359123a0; Kreemer C, 2004, GEOPHYS J INT, V157, P1377, DOI [10.1111/j.1365-246X.2004.02270.x, 10.1111/j.1365-246X.2004-02270.x]; Mellors R, 2007, J GEOPHYS RES-SOL EA, V112, DOI 10.1029/2006JB004489; BYERLEE J, 1978, PURE APPL GEOPHYS, V116, P615, DOI 10.1007/BF00876528; Clift P, 2004, REV GEOPHYS, V42, DOI 10.1029/2003RG000127; Saffer DM, 2006, J GEOPHYS RES-SOL EA, V111, DOI 10.1029/2005JB003990; HYNDMAN RD, 1995, J GEOPHYS RES-SOL EA, V100, P15373, DOI 10.1029/95JB00153; MCKENZIE D, 1972, GEOPHYS J ROY ASTR S, V30, P109, DOI 10.1111/j.1365-246X.1972.tb02351.x; DAVIS DM, 1985, TECTONOPHYSICS, V119, P67, DOI 10.1016/0040-1951(85)90033-2; Kopf AJ, 2002, REV GEOPHYS, V40, DOI 10.1029/2000RG000093; Schulz HM, 1997, EARTH PLANET SC LETT, V147, P141, DOI 10.1016/S0012-821X(97)00013-7; NGUYEN QD, 1992, ANNU REV FLUID MECH, V24, P47; Manga M, 2012, NAT HAZARD EARTH SYS, V12, P3377, DOI 10.5194/nhess-12-3377-2012; Kopf A, 2000, GEOL SOC SPEC PUBL, V174, P169, DOI 10.1144/GSL.SP.1999.174.01.10; Jimenez JA, 2003, J WATERW PORT C-ASCE, V129, P70, DOI 10.1061/(ASCE)0733-950X(2003)129:2(70); Robertson A, 1996, GEOLOGY, V24, P239, DOI 10.1130/0091-7613(1996)024<0239:MVOTMR>2.3.CO;2; LEPICHON X, 1982, TECTONOPHYSICS, V86, P243, DOI 10.1016/0040-1951(82)90069-5; O'Hara K, 2004, GEOPHYS RES LETT, V31, DOI 10.1029/2003GL018890; Ashi J, 2012, ADV NAT TECH HAZ RES, V31, P561, DOI 10.1007/978-94-007-2162-3_50; Ashi J, 2014, EARTH PLANETS SPACE, V66, DOI 10.1186/1880-5981-66-51; Barker C., 1996, THERMAL MODELING PET; Barker C. E., 1986, LECTURE NOTES EARTH, V5, P79; Beardsmore G. R, 2001, CRUSTAL HEAT FLOW GU; BEKINS B, 1994, J GEOPHYS RES-SOL EA, V99, P18147, DOI 10.1029/94JB01187; BETHKE CM, 1986, J GEOPHYS RES-SOLID, V91, P6535, DOI 10.1029/JB091iB06p06535; BUSTIN RM, 1983, TECTONOPHYSICS, V95, P309, DOI 10.1016/0040-1951(83)90075-6; CAMERLENGHI A, 1990, GEO-MAR LETT, V10, P23, DOI 10.1007/BF02431018; CAMERLENGHI A, 1995, MAR GEOPHYS RES, V17, P115, DOI 10.1007/BF01203423; Chamotrooke N, 2005, GEOLOGY, V33, P861, DOI 10.1130/G21469.1; Chamot-Rooke N., 2005, AM ASS PET GEOL SPEC, V64, P177; Chaumillon E, 1996, TECTONOPHYSICS, V263, P163, DOI 10.1016/S0040-1951(96)00035-2; Clauser C, 1995, ROCK PHYS PHASE RELA, V3, P105, DOI DOI 10.1029/RF003P0105; Corey A.T., 1949, THESIS COLL FORT COL; CORSELLI C, 1987, MAR GEOL, V75, P185, DOI 10.1016/0025-3227(87)90103-4; Della Vedova B, 2003, J GEOPHYS RES-OCEANS, V108, DOI 10.1029/2002JC001402; DEVOOGD B, 1992, GEOPHYS J INT, V109, P536; Drury M.J., 1986, 865 EARTH PHYS BRANC; Emeis K.-C., 1996, P OCEAN DRILLING PRO, V160, P972; EMERMAN SH, 1983, EARTH PLANET SC LETT, V63, P379, DOI 10.1016/0012-821X(83)90111-5; EMERY K. O., 1966, DEEP SEA RES, V13, P173, DOI 10.1016/0011-7471(66)91098-9; Erickson AJ, 1970, THESIS MIT CAMBRIDGE; Fruehn J, 2002, MAR GEOL, V186, P43, DOI 10.1016/S0025-3227(02)00172-X; Fusi N, 1996, MAR GEOL, V132, P21, DOI 10.1016/0025-3227(95)00151-4; Gutscher MA, 1998, J STRUCT GEOL, V20, P407, DOI 10.1016/S0191-8141(97)00096-5; HEASLER HP, 1985, AAPG BULL, V69, P1386; Hieke W, 1996, MAR GEOL, V132, P63, DOI 10.1016/0025-3227(95)00154-9; Izumitani N., 2009, JAP GEOSC UN M 2009; KASTENS KA, 1991, TECTONOPHYSICS, V199, P25, DOI 10.1016/0040-1951(91)90117-B; Kitamura M, 2012, GEOPHYS RES LETT, V39, DOI 10.1029/2012GL052316; Kopf A, 2003, J GEOPHYS RES-SOL EA, V108, DOI 10.1029/2001JB000473; Kopf A, 2001, EARTH PLANET SC LETT, V189, P295, DOI 10.1016/S0012-821X(01)00278-3; Kopf A, 2000, MAR GEOL, V166, P65, DOI 10.1016/S0025-3227(00)00009-8; Kukowski N, 2002, MAR GEOL, V186, P29, DOI 10.1016/S0025-3227(02)00171-8; LALLEMANT S, 1994, TECTONOPHYSICS, V234, P33, DOI 10.1016/0040-1951(94)90203-8; LEPICHON X, 1995, J GEOPHYS RES-SOL EA, V100, P12675, DOI 10.1029/95JB00317; MCKENZIE D, 1978, GEOPHYS J ROY ASTR S, V55, P217, DOI 10.1111/j.1365-246X.1978.tb04759.x; Miyake Y., 1975, NATURAL RAD ENV, VII, P535; MOORE JC, 1992, REV GEOPHYS, V30, P113, DOI 10.1029/92RG00201; Muraoka S., 2011, 2011 FALL M; O'Hara K, 2006, TECTONOPHYSICS, V424, P109, DOI 10.1016/j.tecto.2006.07.007; Papadopoulos GA, 2007, NAT HAZARD EARTH SYS, V7, P57; Pasquale V, 2001, TECTONOPHYSICS, V331, P269, DOI 10.1016/S0040-1951(00)00294-8; Pearce FD, 2012, J GEOPHYS RES-SOL EA, V117, DOI 10.1029/2011JB009023; Platt JP, 2000, TECTONICS, V19, P529, DOI 10.1029/1999TC001121; Polonia A, 2002, MAR GEOL, V186, P127, DOI 10.1016/S0025-3227(02)00176-7; Rabaute A., 2003, GEOPH RES ABSTR, V5, P12007; Reilinger R, 2006, J GEOPHYS RES-SOL EA, V111, DOI 10.1029/2005JB004051; Reston TJ, 2002, MAR GEOL, V186, P59, DOI 10.1016/S0025-3227(02)00173-1; Reston TJ, 2002, MAR GEOL, V186, P83, DOI 10.1016/S0025-3227(02)00174-3; Roy R.F., 1981, PHYSICAL PROPERTIES, P409; RYAN WBF, 1982, TECTONOPHYSICS, V86, P213, DOI 10.1016/0040-1951(82)90068-3; Sakaguchi A, 2007, TECTONOPHYSICS, V443, P220, DOI 10.1016/j.tecto.2007.01.017; Sakaguchi A., 2012, J GEOL SOC JPN, V118, P240, DOI DOI 10.5575/geosoc.2012.0002; SIBSON RH, 1985, J STRUCT GEOL, V7, P751, DOI 10.1016/0191-8141(85)90150-6; Silva IP, 1996, MAR GEOL, V132, P175, DOI 10.1016/0025-3227(95)00160-3; SWEENEY JJ, 1990, AAPG BULL, V74, P1559; Taira A., 1991, P OCEAN DRILLING PRO, V131; Tokuyama H., 2007, 114 ANN M GEOL SOC J; TRUFFERT C, 1993, GEOPHYS J INT, V114, P360, DOI 10.1111/j.1365-246X.1993.tb03924.x; VANDENBEUKEL J, 1988, TECTONOPHYSICS, V154, P177, DOI 10.1016/0040-1951(88)90101-1; WANG K, 1992, GEOPHYS J INT, V110, P70, DOI 10.1111/j.1365-246X.1992.tb00714.x; WANG KL, 1995, TECTONOPHYSICS, V248, P53, DOI 10.1016/0040-1951(95)00028-L; WESSEL P, 1998, EOS T AGU, V0079; Westbrook GK, 2002, MAR GEOL, V186, P1, DOI 10.1016/S0025-3227(02)00169-X; Wheildon J., 1974, INITIAL REPORTS DEEP, V23, P909; Woodside JM, 1996, MAR GEOL, V132, P55, DOI 10.1016/0025-3227(95)00153-0; Yakimov MM, 2013, SCI REP-UK, V3, DOI 10.1038/srep03554; Yamaguchi TI, 2001, PHYS EARTH PLANET IN, V126, P269, DOI 10.1016/S0031-9201(01)00260-6; YAMANO M, 1982, GEOLOGY, V10, P339, DOI 10.1130/0091-7613(1982)10<339:EOHFDF>2.0.CO;2	115	1	1	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0025-3227	1872-6151		MAR GEOL	Mar. Geol.	MAY 1	2015	363						52	64		10.1016/j.margeo.2015.01.014		13	Geosciences, Multidisciplinary; Oceanography	Geology; Oceanography	CH0TN	WOS:000353735400004		
J	Wang, H; Cao, XL; Takagiwa, Y; Snyder, GJ				Wang, Heng; Cao, Xianlong; Takagiwa, Yoshiki; Snyder, G. Jeffrey			Higher mobility in bulk semiconductors by separating the dopants from the charge-conducting band - a case study of thermoelectric PbSe	MATERIALS HORIZONS			English	Article							DOPED GALLIUM ARSENIDE; LEAD SELENIDE; ELECTRON-MOBILITY; TRANSPARENT ELECTRODES; SOLID-SOLUTIONS; PERFORMANCE; SCATTERING; SILICON; ENHANCEMENT; IMPURITIES	In the rigid band approximation dopants in semiconductors only change the Fermi level and carrier concentration such that different dopants are thought equivalent when fully ionized. In this work we examine the small but significant difference in mobility due to the type of dopant in heavily doped PbSe by studying n-type samples doped with Br, In and Bi. We propose that cation and anion dopants lead to a difference in mobility at high concentrations. This can be understood considering the predominance of cation states to the conduction band and anion states to the valence band. For higher mobility and better performance for most applications of heavily doped semiconductors, dopants should be on the site that is of less influence on the charge-conducting band. This concept can be viewed as an analog of modulation doping on the atomic level. Its physical origin is the random potential due to disorder that perturbs carriers, which is also the origin of Anderson localization at low temperature, a well-studied topic in theoretical physics. In thermoelectric PbSe, the selection of dopant can lead to 10% difference in mobility and in zT.	[Wang, Heng; Snyder, G. Jeffrey] CALTECH, Mat Sci, Pasadena, CA 91125 USA; [Cao, Xianlong] Chongqing Univ Sci & Technol, Dept Met & Mat Engn, Chongqing 401331, Peoples R China; [Takagiwa, Yoshiki] Univ Tokyo, Dept Adv Mat Sci, Kashiwa, Chiba 2778561, Japan; [Snyder, G. Jeffrey] ITMO Univ, St Petersburg, Russia; [Wang, Heng; Snyder, G. Jeffrey] Northwestern Univ, Mat Sci & Engn, Evanston, IL 60208 USA	Wang, H (reprint author), CALTECH, Mat Sci, Pasadena, CA 91125 USA.	hengwang@caltech.edu; jsnyder@caltech.edu	Snyder, G/I-2263-2015; Snyder, Jeff/E-4453-2011	Snyder, Jeff/0000-0003-1414-8682	Solid-State Solar-Thermal Energy Conversion Center (S3TEC), an Energy Frontier Research Center - U.S. Department of Energy, Office of Science, Basic Energy Sciences [DE-SC0001299]; Scientific and Technological Research Program of Chongqing Municipal Education Commission [KJ1401314, KJ1401310]; Cooperative Project of Academician Workstation of Chongqing U. Sci. Tech. [CKYS2014Z03]; Research Foundation of Chongqing U. Sci. Tech. [CK2014Z22]; JSPS KAKENHI [26709051]	This work was supported as part of the Solid-State Solar-Thermal Energy Conversion Center (S3TEC), an Energy Frontier Research Center funded by the U.S. Department of Energy, Office of Science, Basic Energy Sciences under Award # DE-SC0001299. X. C. acknowledges support from Scientific and Technological Research Program of Chongqing Municipal Education Commission (KJ1401314 & KJ1401310); Cooperative Project of Academician Workstation of Chongqing U. Sci. & Tech. (CKYS2014Z03); Research Foundation of Chongqing U. Sci. & Tech. (CK2014Z22). Y. I. acknowledges support from JSPS KAKENHI Grant No. 26709051. The authors would like to thank Prof. Gang Chen and Prof. David Singh for insightful comments.	Alekseeva GT, 1998, SEMICONDUCTORS+, V32, P716, DOI 10.1134/1.1187491; Androulakis J, 2011, PHYS REV B, V84, DOI 10.1103/PhysRevB.84.155207; Androulakis J, 2011, PHYS REV B, V83, DOI 10.1103/PhysRevB.83.195209; Zhang Q, 2012, J AM CHEM SOC, V134, P17731, DOI 10.1021/ja307910u; HARRISON JW, 1976, PHYS REV B, V13, P5347, DOI 10.1103/PhysRevB.13.5347; Zunger A, 2003, APPL PHYS LETT, V83, P57, DOI 10.1063/1.1584074; Bell LE, 2008, SCIENCE, V321, P1457, DOI 10.1126/science.1158899; CHATTOPADHYAY D, 1981, REV MOD PHYS, V53, P745, DOI 10.1103/RevModPhys.53.745; Wang H, 2012, P NATL ACAD SCI USA, V109, P9705, DOI 10.1073/pnas.1111419109; Wang H, 2014, ENERG ENVIRON SCI, V7, P804, DOI 10.1039/c3ee43438a; RALPH HI, 1975, PHYS REV B, V11, P2948, DOI 10.1103/PhysRevB.11.2948; Heremans JP, 2012, ENERG ENVIRON SCI, V5, P5510, DOI 10.1039/c1ee02612g; Heremans JP, 2008, SCIENCE, V321, P554, DOI 10.1126/science.1159725; Zebarjadi M, 2011, NANO LETT, V11, P2225, DOI 10.1021/nl201206d; Gaska R, 1999, APPL PHYS LETT, V74, P287, DOI 10.1063/1.123001; Jaworski CM, 2009, PHYS REV B, V80, DOI 10.1103/PhysRevB.80.125208; Ellmer K, 2012, NAT PHOTONICS, V6, P808, DOI [10.1038/nphoton.2012.282, 10.1038/NPHOTON.2012.282]; Wang H, 2013, ADV ENERGY MATER, V3, P488, DOI 10.1002/aenm.201200683; Iwanaga S, 2011, REV SCI INSTRUM, V82, DOI 10.1063/1.3601358; Androulakis J, 2011, J AM CHEM SOC, V133, P10920, DOI 10.1021/ja203022c; Han YM, 2014, J ALLOY COMPD, V600, P91, DOI 10.1016/j.jallcom.2014.02.077; PFEIFFER L, 1989, APPL PHYS LETT, V55, P1888, DOI 10.1063/1.102162; Pei YZ, 2012, ENERG ENVIRON SCI, V5, P7963, DOI 10.1039/c2ee21536e; Jaworski CM, 2012, PHYS REV B, V85, DOI 10.1103/PhysRevB.85.033204; Zhao LD, 2013, J AM CHEM SOC, V135, P7364, DOI 10.1021/ja403134b; Wang H, 2014, J MATER CHEM A, V2, P3169, DOI 10.1039/c3ta14929c; LaLonde AD, 2011, ENERG ENVIRON SCI, V4, P2090, DOI 10.1039/c1ee01314a; Jovovic V, 2007, J APPL PHYS, V102, DOI 10.1063/1.2771048; Wang H, 2013, ADV FUNCT MATER, V23, P1586, DOI 10.1002/adfm.201201576; Borup KA, 2012, REV SCI INSTRUM, V83, DOI 10.1063/1.4770124; KRAMER B, 1993, REP PROG PHYS, V56, P1469, DOI 10.1088/0034-4885/56/12/001; Yu B, 2012, NANO LETT, V12, P2077, DOI 10.1021/nl3003045; Lagendijk A, 2009, PHYS TODAY, V62, P24, DOI 10.1063/1.3206091; Jancu JM, 1998, PHYS REV B, V57, P6493, DOI 10.1103/PhysRevB.57.6493; Wang H, 2011, ADV MATER, V23, P1366, DOI 10.1002/adma.201004200; Zhang QY, 2012, ENERG ENVIRON SCI, V5, P5246, DOI 10.1039/c1ee02465e; Snyder GJ, 2008, NAT MATER, V7, P105, DOI 10.1038/nmat2090; Askerov B. M., 1991, ELECT TRANSPORT PHEN; BACSKAY GB, 1968, J PHYS CHEM SOLIDS, V29, P1213, DOI 10.1016/0022-3697(68)90213-8; BYLANDER EG, 1966, SOLID STATE COMMUN, V4, P51, DOI 10.1016/0038-1098(66)90104-9; CHERNIK IA, 1980, SOV PHYS SEMICOND+, V14, P44; CHERNIK IA, 1969, SOV PHYS SEMICOND+, V2, P825; DAGA OP, 1971, J PHYS PART C SOLID, V4, P190, DOI 10.1088/0022-3719/4/2/008; dos Anjos AMP, 2004, BRAZ J PHYS, V34, P653; EFIMOVA BA, 1960, SOV PHYS-SOL STATE, V1, P1217; EMELYANENKO OV, 1960, SOV PHYS-SOL STATE, V2, P176; Evola EG, 2014, J APPL PHYS, V115, DOI 10.1063/1.4862812; HILL DE, 1964, PHYS REV A-GEN PHYS, V133, pA866, DOI 10.1103/PhysRev.133.A866; ALEXANDE.MN, 1968, REV MOD PHYS, V40, P815, DOI 10.1103/RevModPhys.40.815; Kaiblinger-Grujin G, 1998, J APPL PHYS, V83, P3096, DOI 10.1063/1.367067; KAIDANOV VI, 1992, SOV PHYS SEMICOND+, V26, P113; KLAUSMEIERBROWN ME, 1990, APPL PHYS LETT, V56, P160, DOI 10.1063/1.103037; LaLonde AD, 2011, REV SCI INSTRUM, V82, DOI 10.1063/1.3534080; Lee Y, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4640; KOHN W, 1955, PHYS REV, V98, P915, DOI 10.1103/PhysRev.98.915; MAKOWSKI L, 1973, J PHYS CHEM SOLIDS, V34, P487, DOI 10.1016/0022-3697(73)90042-5; MASETTI G, 1983, IEEE T ELECTRON DEV, V30, P764, DOI 10.1109/T-ED.1983.21207; Minami T, 2005, SEMICOND SCI TECH, V20, pS35, DOI 10.1088/0268-1242/20/4/004; Nemov SA, 1998, SEMICONDUCTORS+, V32, P689, DOI 10.1134/1.1187484; Parker D, 2010, PHYS REV B, V82, DOI 10.1103/PhysRevB.82.035204; PROKOFEVA LV, 1987, SOV PHYS SEMICOND+, V21, P1078; Ravich Y. I., 2003, LEAD CHALCOGENIDES P, V18; Rogacheva E. I., 2006, ICT06 25 INT C THERM; ROSZTOCZ.FE, 1970, J APPL PHYS, V41, P264, DOI 10.1063/1.1658332; Skipetrov EP, 2014, J APPL PHYS, V115, DOI 10.1063/1.4870230; SUN SZ, 1991, J CRYST GROWTH, V113, P103, DOI 10.1016/0022-0248(91)90014-V; Takagiwa Y, 2013, APL MATER, V1, DOI 10.1063/1.4809545; VILMS J, 1972, SOLID STATE ELECTRON, V15, P443, DOI 10.1016/0038-1101(72)90115-3; VONBARTH U, 1972, J PHYS PART C SOLID, V5, P1629, DOI 10.1088/0022-3719/5/13/012; YIN LC, 2008, P ICT 07, V48, P71	70	2	2	ROYAL SOC CHEMISTRY	CAMBRIDGE	THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS, ENGLAND	2051-6347	2051-6355		MATER HORIZ	Mater. Horizons	MAY	2015	2	3					323	329		10.1039/c5mh00021a		7	Chemistry, Multidisciplinary; Materials Science, Multidisciplinary	Chemistry; Materials Science	CG8TS	WOS:000353586300007		
J	Herzog, J; Qureshi, AA; Shikama, A				Herzog, Juergen; Qureshi, Ayesha Asloob; Shikama, Akihiro			Grobner bases of balanced polyominoes	MATHEMATISCHE NACHRICHTEN			English	Article						Polyominoes; Grobner bases; lattice ideals	IDEALS	We introduce balanced polyominoes and show that their ideal of inner minors is a prime ideal and has a squarefree Grobner basis with respect to any monomial order, and we show that any row or column convex and any tree-like polyomino is simple and balanced. (c) 2015 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim	[Herzog, Juergen] Univ Duisburg Essen, Fachbereich Math, D-45117 Essen, Germany; [Qureshi, Ayesha Asloob] Abdus Salam Int Ctr Theoret Phys, Trieste, Italy; [Shikama, Akihiro] Osaka Univ, Grad Sch Informat Sci & Technol, Dept Pure & Appl Math, Toyonaka, Osaka 5600043, Japan	Qureshi, AA (reprint author), Abdus Salam Int Ctr Theoret Phys, Trieste, Italy.	juergen.herzog@uni-essen.de; aqureshi@ictp.it; a-shikama@cr.math.sci.osaka-u.ac.jp			Abdus Salam International Centre for Theoretical Physics (ICTP), Trieste, Italy	This paper was partially written during the visit of the second and third author at Universitat Duisburg-Essen, Campus Essen. The second author wants to thank the Abdus Salam International Centre for Theoretical Physics (ICTP), Trieste, Italy for supporting her. The third author wants to thank Professor Hibi who made his visit to Essen possible.	Eisenbud D, 1996, DUKE MATH J, V84, P1, DOI 10.1215/S0012-7094-96-08401-X; Bruns W., 1993, COHEN MACAULAY RINGS; Bruns W., 1988, LECT NOTES MATH, V327; CONCA A, 1995, J PURE APPL ALGEBRA, V98, P119, DOI 10.1016/0022-4049(94)00039-L; Ene V., ARXIV14034349MATHAC; Ene V., 2011, GRADUATE STUDIES MAT, V130; Ene V., 2013, ELECTRON J COMB, V20, P20; HERZOG J, 1992, ADV MATH, V96, P1, DOI 10.1016/0001-8708(92)90050-U; Herzog J, 2011, GRAD TEXTS MATH, V260, P3, DOI 10.1007/978-0-85729-106-6; Miller E., 2005, GRADUATE TEXTS MATH, V260; Qureshi AA, 2012, J ALGEBRA, V357, P279, DOI 10.1016/j.jalgebra.2012.01.032; Shapiro J., 2000, J SYMB COMPUTAT, V29, P625; Sturmfels B., 1995, GROBNER BASES CONVEX; Villarreal R.H, 2001, MONOGRAPHS TXB PURE, V238	14	0	0	WILEY-V C H VERLAG GMBH	WEINHEIM	BOSCHSTRASSE 12, D-69469 WEINHEIM, GERMANY	0025-584X	1522-2616		MATH NACHR	Math. Nachr.	MAY	2015	288	7					775	783		10.1002/mana.201400153		9	Mathematics	Mathematics	CG8IY	WOS:000353552100005		
J	Newton, KM; Reed, SD; Uchiyama, S; Qu, CH; Ueno, T; Iwashita, S; Gunderson, G; Fuller, S; Lampe, JW				Newton, Katherine M.; Reed, Susan D.; Uchiyama, Shigeto; Qu, Conghui; Ueno, Tomomi; Iwashita, Soh; Gunderson, Gabrielle; Fuller, Sharon; Lampe, Johanna W.			A cross-sectional study of equol producer status and self-reported vasomotor symptoms	MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY			English	Article						Equol; Vasomotor symptoms; Menopause; Daidzein	DAIDZEIN-METABOLIZING PHENOTYPES; HOT FLASH FREQUENCY; MENOPAUSAL SYMPTOMS; SOY ISOFLAVONES; S-EQUOL; POSTMENOPAUSAL WOMEN; DIVERSE POPULATION; JAPANESE WOMEN; HABITUAL DIET; FLUSHES	Objective: This study aims to evaluate the associations of vasomotor symptom (VMS) frequency, bother, and severity with equol producer status and dietary daidzein intake. Methods: This is an observational study. This study included women aged 45 to 55 years, in postmenopause or in the menopausal transition, who had soy food intake of three or more servings per week. Exclusion criteria included severe concurrent disease, pregnancy or planned pregnancy, and current use of oral or transdermal hormones or selective estrogen receptor modulators. After screening, 375 participants completed a 3-day VMS diary and a 24-hour urine collection. Women with a urine daidzein or genistein concentration of 100 ng/mL or higher were included. We evaluated the association of VMS-dichotomized as lower than or equal to versus higher than the mean number of VMS per day (<2.33, >= 2.33)-with quartiles of daidzein intake. Results: Overall, 129 (35%) of 365 women were equol producers. The mean (SD) urinary equol excretion was 0.67 (1.57) mg/day (50th percentile, 0 mg/d; 95th percentile, 4.12 mg/d). Among equol producers, the mean (SD) urinary equol excretion was 1.91 (2.15) mg/day (50th percentile, 1.09 mg/d; 95th percentile, 6.27 mg/d). Among equol producers, compared with those in the lowest quartile of dietary daidzein intake (mean, 4.9 mg/d), those in the highest quartile (mean, 28.5 mg/d) were 76% less likely to have VMS higher than the mean number of VMS (odds ratio, 0.24; 95% CI, 0.07-0.83; trend test across all daidzein levels, P = 0.06). Among equol nonproducers, there were no associations between daidzein intake and VMS frequency. There were no differences in VMS bother or severity among equol producers or nonproducers by dietary daidzein level. Conclusions: Among equol producers, higher equol availability attributable to higher soy consumption contributes to decreased VMS.	[Newton, Katherine M.; Reed, Susan D.; Gunderson, Gabrielle; Fuller, Sharon] Grp Hlth Res Inst, Seattle, WA 98191 USA; [Newton, Katherine M.; Reed, Susan D.] Univ Washington, Sch Publ Hlth & Community Med, Dept Epidemiol, Seattle, WA 98195 USA; [Reed, Susan D.; Qu, Conghui] Univ Washington, Sch Med, Dept Obstet & Gynecol, Seattle, WA 98195 USA; [Reed, Susan D.; Lampe, Johanna W.] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA; [Uchiyama, Shigeto; Ueno, Tomomi; Iwashita, Soh] Otsuka Pharmaceut Co Ltd, Tokyo, Japan; [Iwashita, Soh] Pharmavite LLC, Mission Hills, CA USA	Newton, KM (reprint author), Grp Hlth Res Inst, 1730 Minor Ave,Ste 1600, Seattle, WA 98191 USA.	newton.k@ghc.org			Otsuka Pharmaceutical Co Ltd.	This study was supported by a research grant from Otsuka Pharmaceutical Co Ltd.	Setchell KDR, 2002, J NUTR, V132, P3577; Jenks BH, 2012, J WOMENS HEALTH, V21, P674, DOI 10.1089/jwh.2011.3153; Freeman EW, 2007, CLIMACTERIC, V10, P197, DOI 10.1080/13697130601181486; Rowland IR, 2000, NUTR CANCER, V36, P27, DOI 10.1207/S15327914NC3601_5; Messina M, 2006, NUTR CANCER, V55, P1, DOI 10.1207/s15327914nc5501_1; Atkinson C, 2008, AM J CLIN NUTR, V87, P679; Lampe JW, 1998, P SOC EXP BIOL MED, V217, P335; Jackson RL, 2011, NUTR REV, V69, P432, DOI 10.1111/j.1753-4887.2011.00400.x; Taku K, 2012, MENOPAUSE, V19, P776, DOI 10.1097/gme.0b013e3182410159; Carpenter JS, 2001, J PAIN SYMPTOM MANAG, V22, P979, DOI 10.1016/S0885-3924(01)00353-0; Reed SD, 2014, MENOPAUSE, V21, P153, DOI 10.1097/GME.0b013e3182952228; Jou HJ, 2008, INT J GYNECOL OBSTET, V102, P44, DOI 10.1016/j.ijgo.2008.01.028; Sloan JA, 2001, J CLIN ONCOL, V19, P4280; Aso T, 2012, J WOMENS HEALTH, V21, P92, DOI 10.1089/jwh.2011.2753; Reed SD, 2013, MATURITAS, V75, P152, DOI 10.1016/j.maturitas.2013.03.003; Jacobs A, 2009, MOL NUTR FOOD RES, V53, P1084, DOI 10.1002/mnfr.200800552; Setchell KDR, 2006, J NUTR, V136, P2188; Song KB, 2006, J NUTR, V136, P1347; Carpenter JS, 2012, MENOPAUSE, V19, P664, DOI 10.1097/gme.0b013e31823dbbe3; Frankenfeld CL, 2004, J STEROID BIOCHEM, V88, P399, DOI 10.1016/j.jsbmb.2004.01.006; Frankenfeld CL, 2003, AM J CLIN NUTR, V77, P674; Howes LG, 2006, MATURITAS, V55, P203, DOI 10.1016/j.maturitas.2006.03.008; Japanese Food Safety Commission, 2006, FUND VIEW SAF ASS; Lethaby AE, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001395.pub3; Nagata C, 2001, AM J EPIDEMIOL, V153, P790, DOI 10.1093/aje/153.8.790; North American Menopause Society, 2011, MENOPAUSE, V18, P732, DOI DOI 10.1097/GME.0B013E31821FC8E0; R Development Core Team, LANG ENV STAT COMP; Reinli K, 1996, NUTR CANCER, V26, P123; Setchell K, 1988, MAMMALIAN LIGNANS PH	29	3	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1072-3714	1530-0374		MENOPAUSE	Menopause-J. N. Am. Menopause Soc.	MAY	2015	22	5					489	495		10.1097/gme.0000000000000363		7	Obstetrics & Gynecology	Obstetrics & Gynecology	CG9ZB	WOS:000353677500004		
J	Huang, CY; Matsuda, Y; Gregory, JW; Nagai, H; Asai, K				Huang, Chih-Yung; Matsuda, Yu; Gregory, James W.; Nagai, Hiroki; Asai, Keisuke			The applications of pressure-sensitive paint in microfluidic systems	MICROFLUIDICS AND NANOFLUIDICS			English	Article						Pressure-sensitive paint; Microfluidics; Experimental measurement; Pressure; Internal flow field	MICRO GAS-FLOWS; MOLECULAR FILM; OXYGEN DISTRIBUTION; MICROCHANNEL FLOW; DISSOLVED-OXYGEN; PIV MEASUREMENTS; VISUALIZATION; COMPRESSIBILITY; RAREFACTION; OSCILLATOR	Pressure-sensitive paint is an experimental technique that has been developed for decades and recently applied for microscale measurements to retrieve surface pressure data. Promising results have been reported at various flow regions including transition flow, supersonic flow, and unsteady flow regimes. The experimental results acquired by pressure-sensitive paint have been compared with computational simulation and theoretical analysis, and good agreements have been established. This technique provides not only qualitative information but also quantitative data for the flow field inside microfluidic systems. This paper summarizes the methodology and applications of pressure-sensitive paint in microscale measurements as well as their usage for oxygen detection in several areas. Critical comments and future aspects of the technique have also been provided.	[Huang, Chih-Yung] Natl Tsing Hua Univ, Dept Power Mech Engn, Hsinchu 30013, Taiwan; [Matsuda, Yu] Nagoya Univ, Dept Micronano Syst Engn, Nagoya, Aichi 4648601, Japan; [Gregory, James W.] Ohio State Univ, Dept Mech & Aerosp Engn, Columbus, OH 43235 USA; [Nagai, Hiroki; Asai, Keisuke] Tohoku Univ, Dept Aerosp Engn, Sendai, Miyagi 980, Japan	Huang, CY (reprint author), Natl Tsing Hua Univ, Dept Power Mech Engn, Hsinchu 30013, Taiwan.	cyhuang@pme.nthu.edu.tw	Huang, Chih-Yung/D-9059-2012; Gregory, James/A-2343-2015	Gregory, James/0000-0002-8589-8758			Agrawal A, 2011, INT J MICRONANOSCALE, V2, P1; Alexeenko AA, 2000, 36 AIAA ASME SAE ASE; Meinhart CD, 1999, EXP FLUIDS, V27, P414, DOI 10.1007/s003480050366; Matsuda Y, 2011, MICROFLUID NANOFLUID, V10, P165, DOI 10.1007/s10404-010-0664-6; Roy S, 2003, J APPL PHYS, V93, P4870, DOI 10.1063/1.1559936; Beskok A, 2001, NUMER HEAT TR B-FUND, V40, P451, DOI 10.1080/104077901753306593; Morini GL, 2011, EXP THERM FLUID SCI, V35, P849, DOI 10.1016/j.expthermflusci.2011.02.005; Tang GH, 2007, INT J HEAT MASS TRAN, V50, P2282, DOI 10.1016/j.ijheatmasstransfer.2006.10.034; Borisov SM, 2009, MICROCHIM ACTA, V164, P7, DOI 10.1007/s00604-008-0047-9; Beskok A, 1996, J FLUID ENG-T ASME, V118, P448, DOI 10.1115/1.2817779; King C, 2007, MICROFLUID NANOFLUID, V3, P463, DOI 10.1007/s10404-006-0139-y; Jie D, 2000, J MICROMECH MICROENG, V10, P372, DOI 10.1088/0960-1317/10/3/311; Chamarthy P, 2010, INT J HEAT MASS TRAN, V53, P3275, DOI 10.1016/j.ijheatmasstransfer.2010.02.052; Matsuda Y, 2011, MICROFLUID NANOFLUID, V11, P507, DOI 10.1007/s10404-011-0825-2; Gregory JW, 2014, ANNU REV FLUID MECH, V46, P303, DOI 10.1146/annurev-fluid-010313-141304; Inukai J, 2008, ANGEW CHEM INT EDIT, V47, P2792, DOI 10.1002/anie.200705516; Ho CM, 1996, J FLUID ENG-T ASME, V118, P437, DOI 10.1115/1.2817778; Ho CM, 1998, ANNU REV FLUID MECH, V30, P579, DOI 10.1146/annurev.fluid.30.1.579; Sakaue H, 2009, SENSORS-BASEL, V9, P4151, DOI 10.3390/s90604151; Buoni M, 2001, 35 AIAA THERM C AN C; Chiang K-C, 2013, 10 INT C FLOW DYN SE; Crafton J, 1999, AIAA 37 AER SCI M EX; Crafton J, 2005, 43 AIAA AER SCI M EX; Goss L, 2005, 43 AIAA AER SCI M EX; Gregory JW, 2007, AIAA J, V45, P568, DOI 10.2514/1.26127; Gregory JW, 2005, J VISUAL-JAPAN, V8, P169; Guo XH, 2008, J MICROMECH MICROENG, V18, DOI 10.1088/0960-1317/18/2/025034; Hamner MP, 2008, MEAS SCI TECHNOL, V19, DOI 10.1088/0957-0233/19/9/095201; Hong CP, 2012, INT J HEAT MASS TRAN, V55, P4397, DOI 10.1016/j.ijheatmasstransfer.2012.04.008; Huang C, 2006, THESIS PURDUE U; Huang C, 2008, 22 INT C THEOR APPL; Huang C, 2006, ASME INT MECH ENG C; Huang C, 2007, J VISUAL-JAPAN, V10, P281; Huang C, 2007, J MICROELECTROMECH S, V16, P777, DOI 10.1109/JMEMS.2007.892914; Huang C, 2002, 40 AER SCI M EXH; Huang CY, 2012, J MICROMECH MICROENG, V22, DOI 10.1088/0960-1317/22/6/065021; Huang CY, 2012, J MICROELECTROMECH S, V21, P1090, DOI 10.1109/JMEMS.2012.2203106; Inagaki S, 2007, P 2007 ASME JSME THE; Ivanov MS, 1999, 37 AER SCI M EXH REN; Jang J, 2004, MICROFLUID NANOFLUID, V1, P41, DOI 10.1007/s10404-004-0005-8; Karniadakis G. E., 2002, MICROFLOWS FUNDAMENT; Liu T., 2004, PRESSURE TEMPERATURE; Maruyama H, 2012, 16 INT C MIN SYST CH; Matsuda Y, 2007, EXP FLUIDS, V42, P543, DOI 10.1007/s00348-007-0259-5; Matsuda Y, 2009, AIP CONF PROC, V1084, P527; Matsuda Y, 2012, T JPN SOC MECH ENG-B, V78, P1260; Matsuda Y, 2009, EXP FLUIDS, V47, P1025, DOI 10.1007/s00348-009-0694-6; Matsuda Y, 2011, SENSOR ACTUAT B-CHEM, V160, P1464, DOI 10.1016/j.snb.2011.07.031; Meinhart CD, 1999, 30 AIAA FLUID DYN C; Mitsuo K, 2006, MEAS SCI TECHNOL, V17, P1282, DOI 10.1088/0957-0233/17/6/S07; Mori H, 2005, PHYS FLUIDS, V17, DOI 10.1063/1.1921927; Mosharov VE, 1997, LUMINESCENT PRESSURE; Nagai H, 2008, AIAA J, V46, P215, DOI 10.2514/1.28371; Nguyen N-T, 2002, MICROELECTROMECHANIC; Osafune T, 2004, 42 AIAA AER SCI M EX; Peng D., 2010, 27 AIAA AER MEAS TEC, P2010; Pong K, 1994, ASME WINT ANN M; Sakamura Y, 2014, 16 INT S FLOW VIS OK; Song WZ, 2011, BIOMICROFLUIDICS, V5, DOI 10.1063/1.3664693; Yamaguchi H, 2009, SENSOR ACTUAT B-CHEM, V142, P224, DOI 10.1016/j.snb.2009.07.022; Zare-Behtash H, 2009, EXP THERM FLUID SCI, V33, P852, DOI 10.1016/j.expthermflusci.2009.03.002; Zohar Y, 2002, J FLUID MECH, V472, P125, DOI 10.1017/S0022112002002203	62	0	0	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	1613-4982	1613-4990		MICROFLUID NANOFLUID	Microfluid. Nanofluid.	MAY	2015	18	5-6					739	753		10.1007/s10404-014-1510-z		15	Nanoscience & Nanotechnology; Instruments & Instrumentation; Physics, Fluids & Plasmas	Science & Technology - Other Topics; Instruments & Instrumentation; Physics	CH1YP	WOS:000353819900002		
J	Li, XB; Li, FC; Kinoshita, H; Oishi, M; Oshima, M				Li, Xiao-Bin; Li, Feng-Chen; Kinoshita, Haruyuki; Oishi, Masamichi; Oshima, Marie			Dynamics of viscoelastic fluid droplet under very low interfacial tension in a serpentine T-junction microchannel	MICROFLUIDICS AND NANOFLUIDICS			English	Article						Droplet; Multiphase flow; Viscoelasticity; Surfactant; Low interfacial tension; Tail fragmentation	VELOCITY FLUCTUATIONS; ADSORPTION-KINETICS; STRING FORMATION; SEGMENTED FLOW; MICROFLUIDICS; MOTION; SURFACTANTS; TRANSITION; MECHANISM; CAPILLARY	Droplets of viscoelastic fluid were generated in silicone oil using a microfluidic T-junction device, and their intrinsic dynamics were studied. The viscoelastic fluid used was a dilute aqueous solution of cetyltrimethylammonium chloride (CTAC) with sodium salicylate (NaSal) at the same mass concentration as CTAC. The surfactant greatly lowered the interfacial tension between the silicone oil and surfactant-laden droplet and also introduced elasticity to the aqueous solution. The generated droplets experienced extension-shearing mixed kinematics as they moved along the confined microchannel, showing distinct morphological evolvement compared with those of Newtonian fluids and polymeric solutions under normal magnitudes of interfacial tension. With surfactant additives in the dispersed phase, the droplet tail streaming was composed of tiny satellites at the rear (upstream) of the droplet. The emergence of tails depended on the physical properties, such as the flow rate ratio, of the two fluids. This phenomenon indicates a new regime for the deformation of soluble-surfactant-laden droplets governed sequentially by three different processes of dynamic shearing, elongation and interfacial instability.	[Li, Xiao-Bin; Li, Feng-Chen] Harbin Inst Technol, Sch Energy Sci & Engn, Harbin 150001, Peoples R China; [Li, Xiao-Bin] Harbin Inst Technol, Sch Mechatron Engn, Harbin 150001, Peoples R China; [Li, Xiao-Bin; Kinoshita, Haruyuki; Oishi, Masamichi; Oshima, Marie] Univ Tokyo, Inst Ind Sci, Tokyo 1538505, Japan	Li, FC (reprint author), Harbin Inst Technol, Sch Energy Sci & Engn, Harbin 150001, Peoples R China.	lifch@hit.edu.cn			National Natural Science Foundation of China [51276046]; Foundation for Innovative Research Groups of the National Natural Science Foundation of China [51121004]; Specialized Research Fund for the Doctoral Program of Higher Education of China [20112302110020]; China Postdoctoral Science Foundation [2013M541374]; Heilongjiang Postdoctoral Fund of China [LBH-Z12110]	This work is sponsored by the National Natural Science Foundation of China (51276046), Foundation for Innovative Research Groups of the National Natural Science Foundation of China (51121004), Specialized Research Fund for the Doctoral Program of Higher Education of China (20112302110020), China Postdoctoral Science Foundation (2013M541374) and Heilongjiang Postdoctoral Fund (LBH-Z12110) of China. We are very grateful to the anonymous reviewers and the editor for their valuable comments and encouragement.	Anna SL, 2006, PHYS FLUIDS, V18, DOI 10.1063/1.2397023; Qiu DM, 2010, MICROFLUID NANOFLUID, V8, P531, DOI 10.1007/s10404-009-0487-5; Li XB, 2012, CHEM ENG SCI, V69, P340, DOI 10.1016/j.ces.2011.10.048; Garstecki P, 2006, LAB CHIP, V6, P437, DOI 10.1039/b510841a; Gunther A, 2005, LANGMUIR, V21, P1547, DOI 10.1021/la0482406; Afkhami S, 2011, PHYS FLUIDS, V23, DOI 10.1063/1.3549266; Ahn K, 2006, APPL PHYS LETT, V88, DOI 10.1063/1.2218058; Husny J, 2006, J NON-NEWTON FLUID, V137, P121, DOI 10.1016/j.jnnfm.2006.03.007; van Steijn V, 2010, LAB CHIP, V10, P2513, DOI 10.1039/c002625e; Whitesides GM, 2001, ANNU REV BIOMED ENG, V3, P335, DOI 10.1146/annurev.bioeng.3.1.335; Beer NR, 2009, LAB CHIP, V9, P838, DOI 10.1039/b818479h; Squires TM, 2005, REV MOD PHYS, V77, P977, DOI 10.1103/RevModPhys.77.977; DEBRUIJN RA, 1993, CHEM ENG SCI, V48, P277, DOI 10.1016/0009-2509(93)80015-I; Mulligan MK, 2011, LANGMUIR, V27, P9760, DOI 10.1021/la201523r; Christopher GF, 2008, PHYS REV E, V78, DOI 10.1103/PhysRevE.78.036317; Wagner C, 2005, PHYS REV LETT, V95, DOI 10.1103/PhysRevLett.95.164504; Baroud CN, 2010, LAB CHIP, V10, P2032, DOI 10.1039/c001191f; Baret JC, 2012, LAB CHIP, V12, P422, DOI 10.1039/c1lc20582j; Bringer MR, 2004, PHILOS T ROY SOC A, V362, P1087, DOI 10.1098/rsta.2003.1364; Dendukuri D, 2005, LANGMUIR, V21, P2113, DOI 10.1021/la047368k; LIN Z, 1994, J PHYS CHEM-US, V98, P5984, DOI 10.1021/j100074a027; Jin BJ, 2010, J MICROMECH MICROENG, V20, DOI 10.1088/0960-1317/20/3/035003; Teh SY, 2008, LAB CHIP, V8, P198, DOI 10.1039/b715524g; Wang K, 2009, LANGMUIR, V25, P2153, DOI 10.1021/la803049s; Vonnegut B, 1942, REV SCI INSTRUM, V13, P6, DOI 10.1063/1.1769937; De Menech M, 2008, J FLUID MECH, V595, P141, DOI 10.1017/S002211200700910X; Carrier O, 2015, MICROSYST TECHNOL, V21, P499, DOI 10.1007/s00542-013-1905-x; Tan YC, 2004, LAB CHIP, V4, P292, DOI 10.1039/b403280m; Paria S, 2004, ADV COLLOID INTERFAC, V110, P75, DOI 10.1016/j.cis.2004.03.001; Clasen C, 2006, J FLUID MECH, V556, P283, DOI 10.1017/S0022112006009633; Bhat PP, 2009, J NON-NEWTON FLUID, V159, P64, DOI 10.1016/j.jnnfm.2009.01.004; Glawdel T, 2012, PHYS REV E, V85, DOI 10.1103/PhysRevE.85.016322; Link DR, 2004, PHYS REV LETT, V92, DOI 10.1103/PhysRevLett.92.054503; Thorsen T, 2001, PHYS REV LETT, V86, P4163, DOI 10.1103/PhysRevLett.86.4163; Christopher GF, 2007, J PHYS D APPL PHYS, V40, pR319, DOI 10.1088/0022-3727/40/19/R01; Fischer P, 2007, CURR OPIN COLLOID IN, V12, P196, DOI 10.1016/j.cocis.2007.07.014; Hashimoto M, 2008, SOFT MATTER, V4, P1403, DOI 10.1039/b715867j; Glawdel T, 2012, PHYS REV E, V85, DOI 10.1103/PhysRevE.85.016323; Atkin R, 2001, LANGMUIR, V17, P6155, DOI 10.1021/la001396v; van Steijn V, 2008, CHEM ENG J, V135, pS159, DOI 10.1016/j.cej.2007.07.037; Migler KB, 2001, PHYS REV LETT, V86, P1023, DOI 10.1103/PhysRevLett.86.1023; Mulligan MK, 2011, PHYS FLUIDS, V23, DOI 10.1063/1.3548856; Wehking JD, 2014, MICROFLUID NANOFLUID, V16, P441, DOI 10.1007/s10404-013-1239-0; Arratia P E, 2007, Chaos, V17, P041102, DOI 10.1063/1.2786006; Atkin R, 2003, J COLLOID INTERF SCI, V266, P236, DOI 10.1016/S0021-9797(03)00631-3; Carrier O, 2014, PHYS REV E, V89, DOI 10.1103/PhysRevE.89.013003; Glawdel T, 2012, PHYS REV E, V86, DOI 10.1103/PhysRevE.86.026308; Gupta A, 2010, MICROFLUID NANOFLUID, V8, P799, DOI 10.1007/s10404-009-0513-7; Gupta A, 2010, PHYS FLUIDS, V22, DOI 10.1063/1.3523483; Hong JW, 2001, BIOTECHNOL PROGR, V17, P958, DOI 10.1021/bp010075m; Humphry KJ, 2009, PHYS REV E, V79, DOI 10.1103/PhysRevE.79.056310; Lac E, 2009, J FLUID MECH, V640, P27, DOI 10.1017/S0022112009991212; Lindner A, 2009, CR PHYS, V10, P712, DOI 10.1016/j.crhy.2009.10.017; Myska J, 2001, J NON-NEWTON FLUID, V97, P251, DOI 10.1016/S0377-0257(01)00097-0; Oishi M, 2011, MEAS SCI TECHNOL, V22, DOI 10.1088/0957-0233/22/10/105401; Sostarecz MC, 2004, PHYS FLUIDS, V16, pL67, DOI 10.1063/1.1779672; van Steijn V, 2007, CHEM ENG SCI, V62, P7505, DOI 10.1016/j.ces.2007.08.068; Wei JJ, 2006, J HEAT TRANS-T ASME, V128, P977, DOI 10.1115/1.2345422; Wei JJ, 2006, J FLUID ENG-T ASME, V128, P69, DOI 10.1115/1.2136928; Xu N, 2014, ADV MECH ENG, V179394, P1	60	1	1	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	1613-4982	1613-4990		MICROFLUID NANOFLUID	Microfluid. Nanofluid.	MAY	2015	18	5-6					1007	1021		10.1007/s10404-014-1490-z		15	Nanoscience & Nanotechnology; Instruments & Instrumentation; Physics, Fluids & Plasmas	Science & Technology - Other Topics; Instruments & Instrumentation; Physics	CH1YP	WOS:000353819900023		
J	Sun, T; Hu, CZ; Nakajima, M; Takeuchi, M; Seki, M; Yue, T; Shi, Q; Fukuda, T; Huang, Q				Sun, Tao; Hu, Chengzhi; Nakajima, Masahiro; Takeuchi, Masaru; Seki, Minoru; Yue, Tao; Shi, Qing; Fukuda, Toshio; Huang, Qiang			On-chip fabrication and magnetic force estimation of peapod-like hybrid microfibers using a microfluidic device	MICROFLUIDICS AND NANOFLUIDICS			English	Article						Microfluidic flow-focusing device; Gelation microchannel; Magnetic microfibers; Microfiber generation model; Magnetic force estimation	ALGINATE FIBERS; MANIPULATION; GENERATION; HYDROGELS	Combining microfluidic methods for generating microdroplets and spinning microfibers, a novel type of alginate hybrid microfiber encapsulating different microdroplets is fabricated for various applications such as cell culture, tissue engineering and drug release. Traditional fabrication methods mainly depend on the microfluidic structure, so an effective method that uses microfluidic solution flow rates to control the generation of hybrid microfibers has not yet been developed. In this paper, we fabricate a microfluidic flow-focusing device with a long gelation microchannel to encapsulate magnetic oil microdroplets (MOMs) into alginate microfibers. We establish a hybrid microfiber generation model for this fabrication method based on limited flow rate to control microfiber width, MOM diameter and the distance between consecutive MOMs. We also calculate the magnetic force acting on a single MOM by measuring the distance and the MOM is deflected by disk magnets with respect to time in the long gelation microchannel. The magnetic forces acting on the microfibers can be further calculated by counting the number of encapsulated MOMs. The developed method has great potential for quantitative fabrication of diverse hybrid microfibers encapsulating a variety of magnetic hydrophobic microdroplets with estimated magnetic forces. Such magnetic hybrid microfibers are attractive for use in higher order alginate microfiber assemblies and dual drug delivery systems.	[Sun, Tao; Shi, Qing; Fukuda, Toshio; Huang, Qiang] Beijing Inst Technol, Intelligent Robot Inst, Sch Mechatron Engn, Beijing 100081, Peoples R China; [Hu, Chengzhi; Nakajima, Masahiro; Takeuchi, Masaru; Yue, Tao] Nagoya Univ, Dept Micronano Syst Engn, Chikusa Ku, Nagoya, Aichi 4648603, Japan; [Seki, Minoru] Chiba Univ, Dept Appl Chem & Bioengn, Inage Ku, Chiba 2638522, Japan	Shi, Q (reprint author), Beijing Inst Technol, Intelligent Robot Inst, Sch Mechatron Engn, 5 South Zhongguancun St, Beijing 100081, Peoples R China.	shiqing@bit.edu.cn	Yue, Tao/N-7344-2014	Yue, Tao/0000-0001-8321-1898	National Natural Science Foundation of China [61375108, 61433010]; 111 Project [B08043]	We thank Hasegawa lab at Nagoya University for the help during the design of microfluidic device. This work is supported by the National Natural Science Foundation of China under Grant Nos: 61375108, 61433010 and "111 Project" under Grant No: B08043.	Kang E, 2011, NAT MATER, V10, P877, DOI [10.1038/nmat3108, 10.1038/NMAT3108]; Yang CH, 2009, LAB CHIP, V9, P961, DOI 10.1039/b814952f; Miller E, 2010, LAB CHIP, V10, P1293, DOI 10.1039/b925497h; Xu F, 2011, ADV MATER, V23, P4254, DOI 10.1002/adma.201101962; Yu Y, 2014, ADV MATER, V26, P2494, DOI 10.1002/adma.201304974; Zhang K, 2009, LAB CHIP, V9, P2992, DOI 10.1039/b906229g; Liu J, 2012, APPL SURF SCI, V258, P7530, DOI 10.1016/j.apsusc.2012.04.077; THOMAS A, 1995, J CHEM TECHNOL BIOT, V64, P73, DOI 10.1002/jctb.280640112; Vladisavljevic GT, 2012, MICROFLUID NANOFLUID, V13, P151, DOI 10.1007/s10404-012-0948-0; Agarwal P, 2013, LAB CHIP, V13, P4525, DOI 10.1039/c3lc50678a; Hu CZ, 2014, MICROFLUID NANOFLUID, V17, P457, DOI 10.1007/s10404-013-1325-3; Kang E, 2012, ADV MATER, V24, P4271, DOI 10.1002/adma.201201232; Sun RP, 2011, LAB CHIP, V11, P2924, DOI 10.1039/c1lc20348g; Li YH, 2013, ADV FUNCT MATER, V23, P660, DOI 10.1002/adfm.201201708; Thorsen T, 2001, PHYS REV LETT, V86, P4163, DOI 10.1103/PhysRevLett.86.4163; Shin S, 2007, LANGMUIR, V23, P9104, DOI 10.1021/la700818q; Yang K, 2010, APPL SURF SCI, V256, P3093, DOI 10.1016/j.apsusc.2009.11.079; Yamada M, 2012, SOFT MATTER, V8, P3122, DOI 10.1039/c2sm07263g; Atencia J, 2005, NATURE, V437, P648, DOI 10.1038/nature04163; Ghorbanian S, 2014, BIOMED MICRODEVICES, V16, P387, DOI 10.1007/s10544-014-9842-8; Hanus J, 2013, LANGMUIR, V29, P4381, DOI 10.1021/la4000318; Christopher G., 2007, J PHYS D, V40, pR319; Jose MB, 2012, MICROFLUID NANOFLUID, V12, P687, DOI [10.1007/s10404-011-0909-z, DOI 10.1007/S10404-011-0909-Z]; Lee CB, 2006, J MICROMECH MICROENG, V16, P1024; Lin YS, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033184; Liu HH, 2011, PHYS FLUIDS, V23, P987; Suh SK, 2012, MICROFLUID NANOFLUID, V13, P665, DOI 10.1007/s10404-012-0977-8	27	2	2	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	1613-4982	1613-4990		MICROFLUID NANOFLUID	Microfluid. Nanofluid.	MAY	2015	18	5-6					1177	1187		10.1007/s10404-014-1511-y		11	Nanoscience & Nanotechnology; Instruments & Instrumentation; Physics, Fluids & Plasmas	Science & Technology - Other Topics; Instruments & Instrumentation; Physics	CH1YP	WOS:000353819900039		
J	Blois, G; Barros, JM; Christensen, KT				Blois, Gianluca; Barros, Julio M.; Christensen, Kenneth T.			A microscopic particle image velocimetry method for studying the dynamics of immiscible liquid-liquid interactions in a porous micromodel	MICROFLUIDICS AND NANOFLUIDICS			English	Article						Multiphase flow; Trapping; Flow measurements; Micro-PIV	CAPILLARY-PRESSURE; FLUID DISPLACEMENT; FLOW; SIMULATIONS; TRANSITION; TURBULENCE; MEDIA; SEQUESTRATION; HYSTERESIS; NETWORK	The development of an experimental protocol to investigate the flow field produced by the interaction of two immiscible liquids flowing through a porous network is reported. The experimental protocol allows simultaneous quantification of the velocity distribution in a multi-liquid system based on the microscopic particle image velocimetry technique. The experimental challenges associated with this unique application are discussed, including two-liquid imaging and interface tracking, and solutions that couple refractive index matching and fluorescent signal separation are described. The technique was applied to both single- and two-liquid flows in a two-dimensional pore network comprising a staggered array of circular pillars wherein the flow was driven by a steady pressure gradient. Both drainage and imbibition were considered herein with a focus on fluid-fluid front migration and effects owing to the passage of the interface. The velocity distribution obtained for these two-liquid-phase flow scenarios revealed several peculiarities when compared to the reference case of single-liquid-phase flow. In particular, the instabilities associated with the interfacial processes propagate downstream and perturb the flow field, resulting in dramatic differences from the regular and periodic flow paths typical of steady-state, single-phase flow. Additionally, the passage of the interface does not restore previous flow patterns, but instead yields complex preferential flow paths that mutually interact with residual trapped pockets of fluid. Such dynamical events must be quantified in order to properly model the pore-scale physics central to fully understanding the wealth of practical applications represented by this model flow system.	[Blois, Gianluca] Univ Illinois, Dept Geol, Urbana, IL 61801 USA; [Barros, Julio M.] US Naval Acad, Dept Mech Engn, Annapolis, MD 21402 USA; [Barros, Julio M.; Christensen, Kenneth T.] Univ Illinois, Dept Mech Sci, Urbana, IL 61801 USA; [Barros, Julio M.; Christensen, Kenneth T.] Univ Illinois, Dept Engn, Urbana, IL 61801 USA; [Christensen, Kenneth T.] Kyushu Univ, Int Inst Carbon Neutral Energy Res WPI I2CNER, Nishi Ku, Fukuoka 8190395, Japan	Blois, G (reprint author), Univ Notre Dame, Aerosp & Mech Engn, Civil & Environm Engn & Earth Sci, Notre Dame, IN 46556 USA.	blois@illinois.edu; barros@usna.edu; christensen.33@nd.edu	Christensen, Kenneth/B-1123-2009		International Institute for Carbon Neutral Energy Research (WPI-I2CNER) - World Premier International Research Center Initiative (WPI), MEXT, Japan; Roscoe Jackson Postdoctoral Fellowship at the University of Illinois	The authors gratefully acknowledge the support of the International Institute for Carbon Neutral Energy Research (WPI-I2CNER), sponsored by the World Premier International Research Center Initiative (WPI), MEXT, Japan. The first author (G.B.) was supported by the Roscoe Jackson Postdoctoral Fellowship at the University of Illinois.	Adrian RJ, 2011, PARTICLE IMAGE VELOC, V30; Moebius F, 2012, J COLLOID INTERF SCI, V377, P406, DOI 10.1016/j.jcis.2012.03.070; Armstrong RT, 2012, ADV WATER RESOUR, V46, P55, DOI 10.1016/j.advwatres.2012.05.009; Ferrari A, 2013, ADV WATER RESOUR, V57, P19, DOI 10.1016/j.advwatres.2013.03.005; Natrajan VK, 2009, MEAS SCI TECHNOL, V20, DOI 10.1088/0957-0233/20/1/015401; DiCarlo DA, 2003, GEOPHYS RES LETT, V30, DOI 10.1029/2003GL017811; Worner M, 2012, MICROFLUID NANOFLUID, V12, P841, DOI 10.1007/s10404-012-0940-8; Berg S, 2013, P NATL ACAD SCI USA, V110, P3755, DOI 10.1073/pnas.1221373110; LENORMAND R, 1988, J FLUID MECH, V189, P165, DOI 10.1017/S0022112088000953; Qin D, 2010, NAT PROTOC, V5, P491, DOI 10.1038/nprot.2009.234; Haines WB, 1930, J AGR SCI, V20, P97; Krummel AT, 2013, AICHE J, V59, P1022, DOI 10.1002/aic.14005; JOLLS KR, 1966, CHEM ENG SCI, V21, P1185, DOI 10.1016/0009-2509(66)85038-8; Liu HH, 2013, TRANSPORT POROUS MED, V99, P555, DOI 10.1007/s11242-013-0200-8; Zhang CY, 2011, ENERG FUEL, V25, P3493, DOI 10.1021/ef101732k; Hlushkou D, 2006, J CHROMATOGR A, V1126, P70, DOI 10.1016/j.chroma.2006.06.011; Acharya RC, 2007, WATER RESOUR RES, V43, DOI 10.1029/2007WR005969; LENORMAND R, 1983, J FLUID MECH, V135, P337, DOI 10.1017/S0022112083003110; MacMinn CW, 2010, J FLUID MECH, V662, P329, DOI 10.1017/S0022112010003319; DiCarlo DA, 2013, WATER RESOUR RES, V49, P4531, DOI 10.1002/wrcr.20359; Huppert HE, 2014, ANNU REV FLUID MECH, V46, P255, DOI 10.1146/annurev-fluid-011212-140627; Armstrong RT, 2013, PHYS REV E, V88, DOI 10.1103/PhysRevE.88.043010; Corapcioglu MY, 2009, TRANSPORT POROUS MED, V79, P419, DOI 10.1007/s11242-008-9331-8; CRAWFORD FW, 1966, J GEOPHYS RES, V71, P2911; Datta SS, 2013, PHYS FLUIDS, V26; Dijkhuizen W, 2010, CHEM ENG SCI, V65, P1427, DOI 10.1016/j.ces.2009.10.022; Heyes DM, 2004, PHILOS T ROY SOC A, V362, P1853, DOI 10.1098/rsta.2004.1420; JERAULD GR, 1990, TRANSPORT POROUS MED, V5, P103, DOI 10.1007/BF00144600; Kazemifar F, 2014, EXP THERM FLUID SCI, V53, P161, DOI 10.1016/j.expthermflusci.2013.11.026; Kim BJ, 2004, MEAS SCI TECHNOL, V15, P1097, DOI 10.1088/0957-0233/15/6/008; Krishnamurthy S, 2007, PHYS FLUIDS, V19, DOI 10.1063/1.2722424; Moebius F, 2012, WATER RESOUR RES, V48, DOI 10.1029/2012WR012525; Mohanty K.K., 1987, SPE RESERVOIR ENG, V2, P113; Natrajan VK, 2007, EXP FLUIDS, V43, P1, DOI 10.1007/s00348-007-0301-7; Natrajan VK, 2007, MICROFLUID NANOFLUID, V3, P89, DOI 10.1007/s10404-006-0105-8; Niessner J, 2011, TRANSPORT POROUS MED, V88, P133, DOI 10.1007/s11242-011-9730-0; Oishi M, 2011, MEAS SCI TECHNOL, V22, DOI 10.1088/0957-0233/22/10/105401; Rohaly J, 2000, EXP FLUIDS, V29, pS23, DOI 10.1007/s003480070004; Suga K, 2013, FLUID DYN RES, V45, DOI 10.1088/0169-5983/45/3/034501; Tamayol A, 2012, INT J HEAT MASS TRAN, V55, P3900, DOI 10.1016/j.ijheatmasstransfer.2012.03.008; Meakin P, 2009, REV GEOPHYS, V47, DOI 10.1029/2008RG000263; Yuan H.H., 1989, SPE FORMATION EVAL, V4, P17	42	0	0	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	1613-4982	1613-4990		MICROFLUID NANOFLUID	Microfluid. Nanofluid.	MAY	2015	18	5-6					1391	1406		10.1007/s10404-014-1537-1		16	Nanoscience & Nanotechnology; Instruments & Instrumentation; Physics, Fluids & Plasmas	Science & Technology - Other Topics; Instruments & Instrumentation; Physics	CH1YP	WOS:000353819900059		
J	Amin, MB; Smith, SC; Reuter, VE; Epstein, JI; Grignon, DJ; Hansel, DE; Lin, O; McKenney, JK; Montironi, R; Paner, GP; Al-Ahmadie, HA; Algaba, F; Ali, S; Alvarado-Cabrero, I; Bubendorf, L; Cheng, L; Cheville, JC; Kristiansen, G; Cote, RJ; Delahunt, B; Eble, JN; Genega, EM; Gulmann, C; Hartmann, A; Langner, C; Lopez-Beltran, A; Magi-Galluzzi, C; Merce, J; Netto, GJ; Oliva, E; Rao, P; Ro, JY; Srigley, JR; Tickoo, SK; Tsuzuki, T; Umar, SA; Van der Kwast, T; Young, RH; Soloway, MS				Amin, Mahul B.; Smith, Steven C.; Reuter, Victor E.; Epstein, Jonathan I.; Grignon, David J.; Hansel, Donna E.; Lin, Oscar; McKenney, Jesse K.; Montironi, Rodolfo; Paner, Gladell P.; Al-Ahmadie, Hikmat A.; Algaba, Ferran; Ali, Syed; Alvarado-Cabrero, Isabel; Bubendorf, Lukas; Cheng, Liang; Cheville, John C.; Kristiansen, Glen; Cote, Richard J.; Delahunt, Brett; Eble, John N.; Genega, Elizabeth M.; Gulmann, Christian; Hartmann, Arndt; Langner, Cord; Lopez-Beltran, Antonio; Magi-Galluzzi, Cristina; Merce, Jorda; Netto, George J.; Oliva, Esther; Rao, Priya; Ro, Jae Y.; Srigley, John R.; Tickoo, Satish K.; Tsuzuki, Toyonori; Umar, Saleem A.; Van der Kwast, Theo; Young, Robert H.; Soloway, Mark S.			Update for the practicing pathologist: The International Consultation On Urologic Disease-European association of urology consultation on bladder cancer	MODERN PATHOLOGY			English	Review							MICROPAPILLARY UROTHELIAL CARCINOMA; TRANSITIONAL-CELL-CARCINOMA; HEALTH-ORGANIZATION/INTERNATIONAL-SOCIETY; DIVERGENT HISTOLOGIC DIFFERENTIATION; INVERTED GROWTH-PATTERN; IN-SITU HYBRIDIZATION; VON BRUNN NESTS; URINARY-BLADDER; TRANSURETHRAL RESECTION; CLINICOPATHOLOGICAL ANALYSIS	The International Consultations on Urological Diseases are international consensus meetings, supported by the World Health Organization and the Union Internationale Contre le Cancer, which have occurred since 1981. Each consultation has the goal of convening experts to review data and provide evidence-based recommendations to improve practice. In 2012, the selected subject was bladder cancer, a disease which remains a major public health problem with little improvement in many years. The proceedings of the 2nd International Consultation on Bladder Cancer, which included a 'Pathology of Bladder Cancer Work Group,' have recently been published; herein, we provide a summary of developments and consensus relevant to the practicing pathologist. Although the published proceedings have tackled a comprehensive set of issues regarding the pathology of bladder cancer, this update summarizes the recommendations regarding selected issues for the practicing pathologist. These include guidelines for classification and grading of urothelial neoplasia, with particular emphasis on the approach to inverted lesions, the handling of incipient papillary lesions frequently seen during surveillance of bladder cancer patients, descriptions of newer variants, and terminology for urine cytology reporting.	[Amin, Mahul B.; Smith, Steven C.] Cedars Sinai Med Ctr, Dept Pathol & Lab Med, Los Angeles, CA 90048 USA; [Reuter, Victor E.; Lin, Oscar; Al-Ahmadie, Hikmat A.; Tickoo, Satish K.] Mem Sloan Kettering Canc Ctr, Dept Pathol, New York, NY 10021 USA; [Epstein, Jonathan I.; Ali, Syed; Netto, George J.] Johns Hopkins Univ Hosp, Dept Pathol, Baltimore, MD 21287 USA; [Grignon, David J.; Cheng, Liang; Eble, John N.] Indiana Univ, Sch Med, Dept Pathol, Indianapolis, IN 46204 USA; [Hansel, Donna E.] Univ Calif San Diego, Dept Pathol, San Diego, CA 92103 USA; [McKenney, Jesse K.; Magi-Galluzzi, Cristina] Cleveland Clin Fdn, Dept Pathol, Cleveland, OH 44195 USA; [Montironi, Rodolfo] United Hosp, Polytech Univ Med, Sect Pathol Anat, Ancona, Italy; [Paner, Gladell P.] Univ Chicago, Dept Pathol, Chicago, IL 60637 USA; [Algaba, Ferran] Univ Autonoma Barcelona, Fundacio Puigvert, Pathol Sect, E-08193 Barcelona, Spain; [Alvarado-Cabrero, Isabel] Mexican Oncol Hosp, Dept Pathol, Mexico City, DF, Mexico; [Bubendorf, Lukas] Univ Basel Hosp, Inst Pathol, CH-4031 Basel, Switzerland; [Cheville, John C.] Mayo Clin, Div Anat Pathol, Rochester, MN USA; [Kristiansen, Glen] Univ Hosp Bonn, Inst Pathol, Bonn, Germany; [Cote, Richard J.; Merce, Jorda; Umar, Saleem A.; Soloway, Mark S.] Univ Miami, Miller Sch Med, Dept Pathol, Miami, FL 33136 USA; [Delahunt, Brett] Univ Otago, Wellington Sch Med & Hlth Sci, Dept Pathol, Wellington, New Zealand; [Genega, Elizabeth M.] Tufts Med Ctr, Dept Pathol & Lab Med, Boston, MA USA; [Gulmann, Christian] Beaumont Hosp, Dept Pathol, Dublin 9, Ireland; [Hartmann, Arndt] Univ Erlangen Nurnberg, Inst Pathol, D-91054 Erlangen, Germany; [Langner, Cord] Med Univ Graz, Inst Pathol, Graz, Austria; [Lopez-Beltran, Antonio] Univ Cordoba, Fac Med, Anat Pathol Unit, Sch Med, E-14071 Cordoba, Spain; [Oliva, Esther; Young, Robert H.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Pathol,James Homer Wright Pathol Labs, Boston, MA 02115 USA; [Rao, Priya] Univ Texas MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA; [Ro, Jae Y.] Cornell Univ, Weill Cornell Med Coll, Methodist Hosp Phys Org, Dept Pathol & Genom Med, Houston, TX USA; [Srigley, John R.] McMaster Univ, Dept Pathol & Mol Med, Hamilton, ON, Canada; [Tsuzuki, Toyonori] Japanese Red Cross Nagoya Daini Hosp, Dept Pathol, Nagoya, Aichi, Japan; [Van der Kwast, Theo] Univ Miami, Miller Sch Med, Dept Urol, Miami, FL 33136 USA	Amin, MB (reprint author), Cedars Sinai Med Ctr, Dept Pathol & Lab Med, 8700 Beverly Blvd,S Tower,Rm 8707, Los Angeles, CA 90048 USA.	aminm@cshs.org					Akki AS, 2014, MODERN PATHOL, V27, p212A; Amin MB, 1997, ADV ANAT PATHOL, V4, P244, DOI 10.1097/00125480-199707000-00005; Amin MB, 2002, ADV ANAT PATHOL, V9, P222, DOI 10.1097/00125480-200207000-00002; Amin MB, 2013, PROTOCOL EXAMINATION; Otto W, 2011, BJU INT, V107, P404, DOI 10.1111/j.1464-410X.2010.09515.x; Cao DF, 2010, UROLOGY, V76, P593, DOI 10.1016/j.urology.2010.01.032; JORDAN AM, 1987, CANCER, V60, P2766, DOI 10.1002/1097-0142(19871201)60:11<2766::AID-CNCR2820601129>3.0.CO;2-0; Hodges KB, 2011, BJU INT, V107, P532, DOI 10.1111/j.1464-410X.2010.09853.x; May M, 2010, EUR UROL, V57, P850, DOI 10.1016/j.eururo.2009.03.052; Shah RB, 2013, UROL ONCOL-SEMIN ORI, V31, P1650, DOI 10.1016/j.urolonc.2012.04.009; Sternberg CN, 2013, EUR UROL, V63, P58, DOI 10.1016/j.eururo.2012.08.010; Gakis G, 2013, EUR UROL, V63, P45, DOI 10.1016/j.eururo.2012.08.009; Billis A, 2001, SCAND J UROL NEPHROL, V35, P275; Amin MB, 1997, AM J SURG PATHOL, V21, P1057, DOI 10.1097/00000478-199709000-00010; Terada T, 2013, INT J CLIN EXP PATHO, V6, P766; TALBERT ML, 1989, AM J SURG PATHOL, V13, P374, DOI 10.1097/00000478-198905000-00004; Ching CB, 2011, MODERN PATHOL, V24, P1111, DOI 10.1038/modpathol.2011.69; Kamat AM, 2006, J UROLOGY, V175, P881, DOI 10.1016/S0022-5347(05)00423-4; Iyer G, 2013, J CLIN ONCOL, V31, P3133, DOI 10.1200/JCO.2012.46.5740; Ghoneim IA, 2011, UROLOGY, V77, P867, DOI 10.1016/j.urology.2010.11.043; Montironi R, 2005, INT J SURG PATHOL, V13, P143, DOI 10.1177/106689690501300203; AMIN MB, 1994, AM J SURG PATHOL, V18, P1224, DOI 10.1097/00000478-199412000-00005; Miyamoto H, 2010, ARCH PATHOL LAB MED, V134, P1160, DOI 10.1043/2009-0403-OA.1; Hansel DE, 2013, EUR UROL, V63, P321, DOI 10.1016/j.eururo.2012.10.008; Schneider SA, 2014, MODERN PATHOL, V27, P758, DOI 10.1038/modpathol.2013.201; Amin MB, 2013, EUR UROL, V63, P16, DOI 10.1016/j.eururo.2012.09.063; MALMSTROM PU, 1987, SCAND J UROL NEPHROL, V21, P185; PARHAM DM, 1994, AM J SURG PATHOL, V18, P1010, DOI 10.1097/00000478-199410000-00005; Toll AD, 2012, AM J SURG PATHOL, V36, P1081, DOI 10.1097/PAS.0b013e318253d6e0; Hoot AC, 2004, AM J SURG PATHOL, V28, P1485, DOI 10.1097/01.pas.0000141390.14548.34; Brimo F, 2009, AM J CLIN PATHOL, V132, P785, DOI 10.1309/AJCPPRZLG9KT9AXL; Samaratunga H, 2004, HISTOPATHOLOGY, V45, P55, DOI 10.1111/j.1365-2559.2004.01895.x; Paner GP, 2014, HUM PATHOL, V45, P1473, DOI 10.1016/j.humpath.2014.02.024; Amin MB, 2014, AM J SURG PATHOL, V38, pE20, DOI 10.1097/PAS.0000000000000240; Palou J, 2013, EUR UROL, V63, P81, DOI 10.1016/j.eururo.2012.08.011; Solomon D, 2002, JAMA-J AM MED ASSOC, V287, P2114, DOI 10.1001/jama.287.16.2114; Epstein JI, 1998, AM J SURG PATHOL, V22, P1435, DOI 10.1097/00000478-199812000-00001; Epstein JI, 2003, CRIT REV ONCOL HEMAT, V47, P83, DOI 10.1016/S1040-8428(03)00073-8; Sung MT, 2006, CANCER, V107, P2622, DOI 10.1002/cncr.22311; Ross JS, 2014, CLIN CANCER RES, V20, P68, DOI 10.1158/1078-0432.CCR-13-1992; Parwani AV, 2006, HUM PATHOL, V37, P168, DOI 10.1016/j.humpath.2005.10.002; Cox R, 2011, AM J SURG PATHOL, V35, P1337, DOI 10.1097/PAS.0b013e318222a653; Kamat AM, 2007, CANCER, V110, P62, DOI 10.1002/cncr.22756; Jones TD, 2007, AM J SURG PATHOL, V31, P1861, DOI 10.1097/PAS.0b013e318060cb9d; Amin MB, 2009, MODERN PATHOL, V22, pS96, DOI 10.1038/modpathol.2009.26; Wasco MJ, 2010, HUM PATHOL, V41, P163, DOI 10.1016/j.humpath.2009.07.015; Wasco MJ, 2007, UROLOGY, V70, P69, DOI 10.1016/j.urology.2007.03.033; Beltran AL, 2014, HISTOPATHOLOGY, V64, P872, DOI 10.1111/his.12345; Bircan S, 2004, UROL INT, V73, P201, DOI 10.1159/000080828; Burger M, 2013, EUR UROL, V63, P36, DOI 10.1016/j.eururo.2012.08.061; Cheng L, 2000, CANCER, V88, P1663, DOI 10.1002/(SICI)1097-0142(20000401)88:7<1663::AID-CNCR21>3.0.CO;2-8; Chow NH, 2000, INT J CANCER, V89, P514, DOI 10.1002/1097-0215(20001120)89:6<514::AID-IJC8>3.3.CO;2-8; Comperat E, 2010, PATHOLOGY, V42, P650, DOI 10.3109/00313025.2010.522173; Cox RM, 2009, AM J SURG PATHOL, V33, P1213, DOI 10.1097/PAS.0b013e3181a8ffbe; Eble JN, 2004, PATHOLOGY GENETICS T, P89; Edge SB, 2010, AJCC CANC STAGING MA, p[xiv, 648]; Gaya JM, 2010, CAN J UROL, V17, P5370; Huang Q, 2004, HUM PATHOL, V35, P769, DOI 10.1016/j.humpath.2004.01.012; Kirkali Z, 2005, BLADDER TUMORS, P13; Koss LG, 1975, TUMORS URINARY BLADD, P1; KUMAR S, 1992, AM J SURG PATHOL, V16, P515, DOI 10.1097/00000478-199205000-00011; McQuitty E, 2012, ARCH PATHOL LAB MED, V136, P635, DOI 10.5858/arpa.2011-0463-OA; Montironi R, 2011, EUR UROL, V59, P225, DOI 10.1016/j.eururo.2010.11.018; Mostofi FK, 1999, HISTOLOGICAL TYPING, P3; Mostofi FK, 1973, HIST TYPING URINARY; Murphy WM, 2004, TUMORS KIDNEY BLADDE, P394; Murphy WM, 1994, TUMORS OF THE KIDNEY, P326; Nigwekar P, 2008, ADV ANAT PATHOL, V15, P218, DOI 10.1097/PAP.0b013e31817d79b9; Readal N, 2010, PATHOLOGY, V42, P360, DOI 10.3109/00313021003767322; Renshaw AA, 2000, CANCER CYTOPATHOL, V90, P222, DOI 10.1002/1097-0142(20000825)90:4<222::AID-CNCR4>3.0.CO;2-A; Sangoi AR, 2010, AM J SURG PATHOL, V34, P1367, DOI 10.1097/PAS.0b013e3181ec86b3; Smith SC, 2014, HISTOPATHOLOGY, V65, P132, DOI 10.1111/his.12360; Soloway M, 2012, BLADDER CANC; Spaliviero M, 2014, J UROLOGY, V192, P702, DOI 10.1016/j.juro.2014.02.2565; Swierczynski SL, 2002, HUM PATHOL, V33, P512, DOI 10.1053/hua.2002.124031; Szymanski KM, 2013, UROLOGY, V82, P1158, DOI 10.1016/j.urology.2013.04.050; Tavora F, 2009, HUM PATHOL, V40, P1391, DOI 10.1016/j.humpath.2009.04.002; Taylor DC, 1996, AM J SURG PATHOL, V20, P1481, DOI 10.1097/00000478-199612000-00007; Volmar KE, 2003, AM J SURG PATHOL, V27, P1243, DOI 10.1097/00000478-200309000-00008; Wang C, 2012, MODERN PATHOL, V25, p226A; Young RH, 1996, AM J SURG PATHOL, V20, P1448, DOI 10.1097/00000478-199612000-00003; Zhao L, 2013, AM J SURG PATHOL, V37, P1876, DOI 10.1097/PAS.0b013e31829e2525	82	1	1	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0893-3952	1530-0285		MODERN PATHOL	Mod. Pathol.	MAY	2015	28	5					612	630		10.1038/modpathol.2014.158		19	Pathology	Pathology	CH1IE	WOS:000353774200002		
J	Reid, MD; Bagci, P; Ohike, N; Saka, B; Seven, IE; Dursun, N; Balci, S; Gucer, H; Jang, KT; Tajiri, T; Basturk, O; Kong, SY; Goodman, M; Akkas, G; Adsay, V				Reid, Michelle D.; Bagci, Pelin; Ohike, Nobuyuki; Saka, Burcu; Seven, Ipek Erbarut; Dursun, Nevra; Balci, Serdar; Gucer, Hasan; Jang, Kee-Taek; Tajiri, Takuma; Basturk, Olca; Kong, So Yeon; Goodman, Michael; Akkas, Gizem; Adsay, Volkan			Calculation of the Ki67 index in pancreatic neuroendocrine tumors: a comparative analysis of four counting methodologies	MODERN PATHOLOGY			English	Article							PROLIFERATIVE INDEX; ENDOCRINE TUMORS; LABELING INDEX; DIAGNOSIS; HETEROGENEITY; GUIDELINES; MANAGEMENT; SYSTEM; TRACT	Ki67 index is now an essential part of classification of pancreatic neuroendocrine tumors. However, its adaptation into daily practice has been fraught with challenges related to counting methodology. In this study, three reviewers used four counting methodologies to calculate Ki67 index in 68 well-differentiated pancreatic neuroendocrine tumors: (1) 'eye-ball' estimation, which has been advocated as reliable and is widely used; (2) automated counting by image analyzer; (3) manual eye-counting (eye under a microscope without a grid); and (4) manual count of camera-captured/printed image. Pearson's correlation (R) was used to measure pair-wise correlation among three reviewers using all four methodologies. Average level of agreement was calculated using mean of R values. The results showed that: (1) 'eye-balling' was least expensive and fastest (average time <1 min) but had poor reliability and reproducibility. (2) Automated count was the most expensive and least practical with major impact on turnaround time (limited by machine and personnel accessibility), and, more importantly, had inaccuracies in overcounting unwanted material. (3) Manual eye count had no additional cost, averaged 6 min, but proved impractical and poorly reproducible. (4) Camera-captured/printed image was most reliable, had highest reproducibility, but took longer than 'eye-balling'. In conclusion, based on its comparatively low cost/benefit ratio and reproducibility, camera-captured/printed image appears to be the most practical for calculating Ki67 index. Although automated counting is generally advertised as the gold standard for index calculation, in this study it was not as accurate or cost-effective as camera-captured/printed image and was highly operator-dependent. 'Eye-balling' produces highly inaccurate and unreliable results, and is not recommended for routine use.	[Reid, Michelle D.; Akkas, Gizem; Adsay, Volkan] Emory Univ, Sch Med, Dept Pathol, Atlanta, GA 30322 USA; [Bagci, Pelin; Seven, Ipek Erbarut] Marmara Univ, Dept Pathol, Istanbul, Turkey; [Ohike, Nobuyuki] Showa Univ, Sch Med, Dept Pathol, Tokyo 142, Japan; [Saka, Burcu] Medipol Univ, Dept Pathol, Istanbul, Turkey; [Dursun, Nevra] Istanbul Educ & Training Hosp, Dept Pathol, Istanbul, Turkey; [Balci, Serdar] Yildirim Beyazit Univ, Dept Pathol, Ankara, Turkey; [Gucer, Hasan] RTE Univ, Dept Pathol, Rize, Turkey; [Jang, Kee-Taek] Samsung Med Ctr, Dept Pathol, Seoul, South Korea; [Tajiri, Takuma] Tokai Univ, Hachiouji Hosp, Dept Pathol, Tokyo 151, Japan; [Basturk, Olca] Mem Sloan Kettering Canc Ctr, Dept Pathol, New York, NY 10021 USA; [Kong, So Yeon; Goodman, Michael] Emory Univ, Dept Epidemiol, Dept Pathol, Atlanta, GA 30322 USA	Adsay, V (reprint author), Emory Univ, Emory Univ Hosp, Sch Med, Dept Pathol, 1364 Clifton Rd NE,Room H-180B, Atlanta, GA 30322 USA.	nadsay@emory.edu	BALCI, Serdar/B-6401-2011	BALCI, Serdar/0000-0002-7852-3851	Turkiye Bilimsel ve Teknik Arastirma Kurumu (State Department of Scientific and Technical Investigation) of the Republic of Turkey	A preliminary analysis involving part of this cohort was reported at the 101st annual meeting (in 2012) of the United States and Canadian Academy of Pathology in Vancouver, Canada. Dr Nevra Dursun is the recipient of a scholarship from Turkiye Bilimsel ve Teknik Arastirma Kurumu (State Department of Scientific and Technical Investigation) of the Republic of Turkey. The other authors declare no conflict of interest.	Anthony LB, 2010, PANCREAS, V39, P767, DOI 10.1097/MPA.0b013e3181ec1261; Reid MD, 2014, ENDOCR PATHOL, V25, P65, DOI 10.1007/s12022-013-9295-2; Kulke MH, 2010, PANCREAS, V39, P735, DOI 10.1097/MPA.0b013e3181ebb168; Boudreaux JP, 2010, PANCREAS, V39, P753, DOI 10.1097/MPA.0b013e3181ebb2a5; Couvelard A, 2009, MODERN PATHOL, V22, P273, DOI 10.1038/modpathol.2008.177; Yang ZH, 2011, AM J SURG PATHOL, V35, P853, DOI 10.1097/PAS.0b013e31821a0696; Yao JC, 2008, J CLIN ONCOL, V26, P4311, DOI 10.1200/JCO.2008.16.7858; Klimstra DS, 2010, AM J SURG PATHOL, V34, P300, DOI 10.1097/PAS.0b013e3181ce1447; Tang LH, 2012, AM J SURG PATHOL, V36, P1761, DOI 10.1097/PAS.0b013e318263207c; Verbeke CS, 2010, HISTOPATHOLOGY, V56, P669, DOI 10.1111/j.1365-2559.2010.03490.x; Adsay V, 2012, AM J SURG PATHOL, V36, P1743, DOI 10.1097/PAS.0b013e318272ff77; Rindi G, 2006, VIRCHOWS ARCH, V449, P395, DOI 10.1007/s00428-006-0250-1; Goodell PP, 2012, AM J CLIN PATHOL, V137, P576, DOI 10.1309/AJCP92UCXPJMMSDU; Fung AD, 2013, ACTA CYTOL, V57, P501, DOI 10.1159/000351475; Klimstra DS, 2013, SEMIN ONCOL, V40, P23, DOI 10.1053/j.seminoncol.2012.11.001; Basturk O, 2013, MODERN PATHOL, V26, p423A; Dhall D, 2009, MOD PATHOL, V22, p116A; Edge SB, 2010, AJCC CANC STAGING MA, P241; Heitz P, 2004, WHO CLASSIFICATION T, P177; Kloppel G, 2000, WHO INT HISTOLOGICAL, V2nd, P56; McCall CM, 2013, AM J SURG PATHOL, V37, P1671, DOI 10.1097/PAS.0000000000000089; NANETS, ADV ISL CELL PANCR N; Ong CW, 2010, HISTOPATHOLOGY, V56, P523, DOI 10.1111/j.1365-2559.2010.03496.x; Rindi G, 2010, WHO CLASSIFICATION T, V3, P13; Tang LH, 2012, CANC PROTOCOLOS	25	5	5	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0893-3952	1530-0285		MODERN PATHOL	Mod. Pathol.	MAY	2015	28	5					686	694		10.1038/modpathol.2014.156		9	Pathology	Pathology	CH1IE	WOS:000353774200008		
J	Kobayashi, I; Mori, M; Yamaguchi, K; Ito, S; Iwata, N; Masunaga, K; Shimojo, N; Ariga, T; Okada, K; Takei, S				Kobayashi, Ichiro; Mori, Masaaki; Yamaguchi, Ken-ichi; Ito, Shuichi; Iwata, Naomi; Masunaga, Kenji; Shimojo, Naoki; Ariga, Tadashi; Okada, Kenji; Takei, Shuji			Pediatric Rheumatology Association of Japan recommendation for vaccination in pediatric rheumatic diseases	MODERN RHEUMATOLOGY			English	Review						Immunosuppression; Pediatric; Rheumatic disease; Vaccine	SYSTEMIC-LUPUS-ERYTHEMATOSUS; JUVENILE IDIOPATHIC ARTHRITIS; INFLAMMATORY-BOWEL-DISEASE; IMMUNIZATION PRACTICES ACIP; HEPATITIS-B VACCINATION; PNEUMOCOCCAL POLYSACCHARIDE VACCINE; SQUAMOUS INTRAEPITHELIAL LESIONS; HUMAN-PAPILLOMAVIRUS VACCINE; INFLUENZA VACCINATION; ANTIBODY-RESPONSES	Pediatric Rheumatology Association of Japan has developed evidence-based guideline of vaccination in pediatric rheumatic diseases (PRDs) as a part of Guideline of Vaccination for Pediatric Immunocompromised Hosts. Available articles on vaccination in both adult rheumatic diseases and PRDs were analyzed. Non-live vaccines are generally safe and effective in patients with PRDs on corticosteroid, immunosuppressant, and/or biologics, although efficacy may be attenuated under high dose of the drugs. On the other hand, efficacy and safety of live-attenuated vaccine for the patients on such medication have not been established. Thus, live-attenuated vaccines should be withheld and, if indicated, may be considered as a clinical trial under the approval by Institutional Review Board. All patients with PRDs anticipating treatment with immunosuppressants or biologics should be screened for infection of hepatitis B and C and tuberculosis before the commencement of medication. Varicella vaccine should be considered in sensitive patients ideally 3 weeks or longer before the commencement of immunosuppressants, corticosteroids, or biologics. Bacille Calmette-Guerin should be withheld at least for 6 months after birth, if their mothers have received anti-tumor necrosis factor-alpha antibodies during the second or third trimester of pregnancy	[Kobayashi, Ichiro; Ariga, Tadashi] Hokkaido Univ, Grad Sch Med, Dept Pediat, Sapporo, Hokkaido 0608638, Japan; [Mori, Masaaki] Yokohama City Univ, Dept Pediat, Yokohama, Kanagawa 232, Japan; [Yamaguchi, Ken-ichi] St Lukas Int Hosp, Dept Rheumatol, Tokyo, Japan; [Ito, Shuichi] Natl Ctr Child Hlth & Dev, Dept Nephrol & Rheumat Dis, Tokyo, Japan; [Iwata, Naomi] Aichi Childrens Hlth & Med Ctr, Dept Infect & Immunol, Obu, Japan; [Masunaga, Kenji] Kurume Univ, Sch Med, Dept Infect Control & Prevent, Kurume, Fukuoka 830, Japan; [Shimojo, Naoki] Chiba Univ, Grad Sch Med, Dept Pediat, Chiba, Japan; [Okada, Kenji] Fukuoka Dent Coll, Div Oral & Med Management, Dept Med, Sect Pediat, Fukuoka, Japan; [Takei, Shuji] Kagoshima Univ, Grad Sch Hlth Sci, Dept Pediat, Kagoshima 890, Japan	Kobayashi, I (reprint author), Hokkaido Univ, Grad Sch Med, Dept Pediat, Kita Ku, North 15 West 7, Sapporo, Hokkaido 0608638, Japan.	ichikobaya@med.hokudai.ac.jp			Kitasato Daiichi Sankyo Vaccine Co., Ltd; Abbvie GK; MSD Japan; Astellas Pharma Inc; Sanofi-Pasteur Japan; Mitsubishi-Tanabe Pharma; Pfizer Japan; Glaxo-Smith-Klein Japan; Kaketsuken; Research Foundation for Microbial Diseases of Osaka University; Takeda Pharmaceutical Co Ltd; Japan BCG Laboratory	M. Mori has received lecture fees from Kitasato Daiichi Sankyo Vaccine Co., Ltd, Abbvie GK, MSD Japan, Astellas Pharma Inc, Sanofi-Pasteur Japan, Mitsubishi-Tanabe Pharma, Pfizer Japan, and Glaxo-Smith-Klein Japan.; K. Okada has received lecture fees from Kaketsuken, MSD Japan, The Research Foundation for Microbial Diseases of Osaka University, Kitasato Daiichi Sankyo Vaccine Co., Ltd, Takeda Pharmaceutical Co Ltd, Sanofi-Pasteur Japan, Pfizer Japan, Glaxo-Smith-Klein Japan, and Japan BCG Laboratory.	Abe T, 1971, Acta Rheumatol Scand, V17, P35; Abu-Shakra M, 2000, J RHEUMATOL, V27, P1681; van Assen S, 2011, ANN RHEUM DIS, V70, P414, DOI 10.1136/ard.2010.137216; Aikawa NE, 2011, PEDIAT RHEUMATOLO S1, V9, P133; Mok CC, 2013, ANN RHEUM DIS, V72, P659, DOI 10.1136/annrheumdis-2012-201393; Askling J, 2005, ARTHRITIS RHEUM, V52, P1986, DOI 10.1002/art.21137; Erguven M, 2011, J CHIN MED ASSOC, V74, P205, DOI 10.1016/j.jcma.2011.03.004; Lovell DJ, 2008, ARTHRITIS RHEUM, V58, P1496, DOI 10.1002/art.23427; Fomin I, 2006, ANN RHEUM DIS, V65, P191, DOI 10.1136/ard.2005.036434; Dell'Era L, 2012, VACCINE, V30, P936, DOI 10.1016/j.vaccine.2011.11.083; Tam LS, 2004, ARTHRITIS RHEUM, V50, P3619, DOI 10.1002/art.20616; Elkayam O, 2004, SEMIN ARTHRITIS RHEU, V33, P283, DOI 10.1053/S0049-0172(03)00212-9; Grimaldi-Bensouda L, 2014, J INTERN MED, V275, P398, DOI 10.1111/joim.12155; Perez-Alvarez R, 2011, MEDICINE, V90, P359, DOI 10.1097/MD.0b013e3182380a76; Elkayam O, 2002, ANN RHEUM DIS, V61, P623, DOI 10.1136/ard.61.7.623; Setti M, 2009, VACCINE, V27, P3367, DOI 10.1016/j.vaccine.2009.01.078; Mamula P, 2007, CLIN GASTROENTEROL H, V5, P851, DOI 10.1016/j.cgh.2007.02.035; Lossius A, 2012, VIRUSES-BASEL, V4, P3701, DOI 10.3390/v4123701; Doran MF, 2002, ARTHRITIS RHEUM, V46, P2287, DOI 10.1002/art.10524; Millet A, 2009, EUR J INTERN MED, V20, P236, DOI 10.1016/j.ejim.2008.07.017; Kroger Andrew T., 2006, Morbidity and Mortality Weekly Report, V55, P1; Arad U, 2011, VACCINE, V29, P1643, DOI 10.1016/j.vaccine.2010.12.072; Tam LS, 2010, CLIN EXP RHEUMATOL, V28, P679; Kim HA, 1998, CLIN EXP RHEUMATOL, V16, P9; Gomez-Reino JJ, 2003, ARTHRITIS RHEUM, V48, P2122, DOI 10.1002/art.11137; Stojanovich L, 2006, CLIN DEV IMMUNOL, V13, P373, DOI 10.1080/17402520600800820; Strangfeld A, 2009, JAMA-J AM MED ASSOC, V301, P737, DOI 10.1001/jama.2009.146; van Assen S, 2010, ARTHRITIS RHEUM-US, V62, P75, DOI 10.1002/art.25033; Vasiliauskas EA, 2006, CLIN GASTROENTEROL H, V4, P1255, DOI 10.1016/j.cgh.2006.07.018; Vassilopoulos D, 2012, NAT REV RHEUMATOL, V8, P348, DOI 10.1038/nrrheum.2012.63; TINGLE AJ, 1986, ANN RHEUM DIS, V45, P110, DOI 10.1136/ard.45.2.110; Gatto M, 2013, CLIN RHEUMATOL, V32, P1301, DOI 10.1007/s10067-013-2266-7; Gilliam BE, 2007, JCR-J CLIN RHEUMATOL, V13, P256, DOI 10.1097/RHU.0b013e318156b9e3; Kaine JL, 2007, J RHEUMATOL, V34, P272; Ray P, 1997, JAMA-J AM MED ASSOC, V278, P551, DOI 10.1001/jama.278.7.551; Miyamoto M, 2011, LUPUS, V20, P736, DOI 10.1177/0961203310397409; Brassard P, 2006, CLIN INFECT DIS, V43, P717, DOI 10.1086/506935; Kinder AJ, 2005, RHEUMATOLOGY, V44, P61, DOI 10.1093/rheumatology/keh512; Tam LS, 2002, SCAND J RHEUMATOL, V31, P296; PELTOLA H, 1986, LANCET, V1, P939; Marin Mona, 2007, Morbidity and Mortality Weekly Report, V56, P1; Ruperto N, 2010, ARTHRITIS RHEUM-US, V62, P1792, DOI 10.1002/art.27431; Farmaki E, 2010, VACCINE, V28, P5109, DOI 10.1016/j.vaccine.2010.03.080; Gelinck LBS, 2008, VACCINE, V26, P3528, DOI 10.1016/j.vaccine.2008.04.028; ABUSHAKRA M, 1995, J RHEUMATOL, V22, P1259; Heijstek MW, 2013, JAMA-J AM MED ASSOC, V309, P2449, DOI 10.1001/jama.2013.6768; Nath R, 2007, ARTHRIT RHEUM-ARTHR, V57, P619, DOI 10.1002/art.22667; Slade BA, 2009, JAMA-J AM MED ASSOC, V302, P750, DOI 10.1001/jama.2009.1201; Kuruma KAM, 2007, LUPUS, V16, P350, DOI 10.1177/0961203307078225; RODRIGUES LC, 1993, INT J EPIDEMIOL, V22, P1154, DOI 10.1093/ije/22.6.1154; Sayarlioglu M, 2004, LUPUS, V13, P274, DOI 10.1191/0961203303lu529xx; Goldblatt F, 2009, LUPUS, V18, P682, DOI 10.1177/0961203308101019; Mahadevan U, 2013, CLIN GASTROENTEROL H, V11, P286, DOI 10.1016/j.cgh.2012.11.011; Visvanathan S, 2007, J RHEUMATOL, V34, P952; Colmegna I, 2009, RHEUM DIS CLIN N AM, V35, P95, DOI 10.1016/j.rdc.2009.03.004; Gelinck LBS, 2008, ANN RHEUM DIS, V67, P713, DOI 10.1136/ard.2007.077552; Pileggi GS, 2010, ARTHRIT CARE RES, V62, P1034, DOI 10.1002/acr.20183; Heijstek MW, 2014, ANN RHEUM DIS, V73, P1500, DOI 10.1136/annrheumdis-2013-203429; Mahadevan Uma, 2011, Am J Gastroenterol, V106, P214, DOI 10.1038/ajg.2010.464; Cheent K, 2010, J CROHNS COLITIS, V4, P603, DOI 10.1016/j.crohns.2010.05.001; Kapetanovic MC, 2006, RHEUMATOLOGY, V45, P106, DOI 10.1093/rheumatology/kei193; Heijstek MW, 2011, ANN RHEUM DIS, V70, P1704, DOI 10.1136/ard.2011.150193; Lu Y, 2009, AM J GASTROENTEROL, V104, P444, DOI 10.1038/ajg.2008.120; Elkayam O, 2011, ARTHRIT CARE RES, V63, P1062, DOI 10.1002/acr.20465; Cervera R, 2003, MEDICINE, V82, P299, DOI 10.1097/01.md.0000091181.93.122.55; Bijl M, 2012, AUTOIMMUN REV, V11, P572, DOI 10.1016/j.autrev.2011.10.015; Seong SS, 2007, J RHEUMATOL, V34, P706; Aytac MB, 2011, CLIN EXP RHEUMATOL, V29, P882; Brassard P, 2009, ARTHRIT RHEUM-ARTHR, V61, P300, DOI 10.1002/art.24476; Melmed GY, 2010, AM J GASTROENTEROL, V105, P148, DOI 10.1038/ajg.2009.523; Abu-Shakra M, 2002, J RHEUMATOL, V29, P2555; Antony D, 2005, INDIAN PEDIATR, V42, P83; Atzeni F, 2008, CLIN EXP RHEUMATOL, V26, pS67; Battafarano DF, 1998, ARTHRITIS RHEUM, V41, P1828, DOI 10.1002/1529-0131(199810)41:10<1828::AID-ART15>3.0.CO;2-T; BAUM J, 1971, ARTHRITIS RHEUM, V14, P135, DOI 10.1002/art.1780140119; BENJAMIN CM, 1992, BRIT MED J, V304, P1075; Beran J., 2005, Central European Journal of Public Health, V13, P20; Bingham CO, 2010, ARTHRITIS RHEUM-US, V62, P64, DOI 10.1002/art.25034; Borte S, 2009, RHEUMATOLOGY, V48, P144, DOI 10.1093/rheumatology/ken436; BRODMAN R, 1978, ANN INTERN MED, V88, P735; Kroger Andrew T., 2011, Morbidity and Mortality Weekly Report, V60, P3; CHALMERS A, 1994, J RHEUMATOL, V21, P1203; CROFT SM, 1984, J RHEUMATOL, V11, P141; Del Porto F, 2006, VACCINE, V24, P3217, DOI 10.1016/j.vaccine.2006.01.028; DENMAN EJ, 1970, ANN RHEUM DIS, V29, P220, DOI 10.1136/ard.29.3.220; Elkayam O, 2010, SEMIN ARTHRITIS RHEU, V39, P442, DOI 10.1016/j.semarthrit.2008.12.002; Erkek E, 2005, J GASTROEN HEPATOL, V20, P1508, DOI 10.1111/j.1440-1746.2005.03903.x; Fujikawa S, 1997, ACTA PAEDIATR JAPON, V39, P242; Geier DA, 2005, AUTOIMMUNITY, V38, P295, DOI 10.1080/08916930500144484; Heijstek MW, 2007, ANN RHEUM DIS, V66, P1384, DOI 10.1136/ard.2006.063586; HERRON A, 1979, JAMA-J AM MED ASSOC, V242, P53, DOI 10.1001/jama.242.1.53; Holvast A, 2006, ANN RHEUM DIS, V65, P913, DOI 10.1136/ard.2005.043943; Holvast A, 2009, ARTHRITIS RHEUM, V60, P2438, DOI 10.1002/art.24679; HOYERAAL HM, 1974, ANN RHEUM DIS, V33, P248, DOI 10.1136/ard.33.3.248; JARRETT MP, 1980, ARTHRITIS RHEUM, V23, P1287, DOI 10.1002/art.1780231110; Kanakoudi-Tsakalidou F, 2001, CLIN EXP RHEUMATOL, V19, P589; Kapetanovic MC, 2011, ARTHRITIS RHEUM, V63, P3727; Kasapcopur O, 2004, ANN RHEUM DIS, V63, P1128, DOI 10.1136/ard.2003.013201; Kashef Sara, 2008, Iran J Immunol, V5, P181, DOI IJIv5i3A7; Kiray E, 2009, J RHEUMATOL, V36, P2029, DOI 10.3899/jrheum.090173; Korematsu S, 2009, VACCINE, V27, P5041, DOI 10.1016/j.vaccine.2009.06.052; Kubota Tetsuo, 2007, Mod Rheumatol, V17, P531, DOI 10.1007/s10165-007-0632-5; LIPNICK RN, 1985, J RHEUMATOL, V12, P1118; Litinsky I, 2012, CLIN EXP RHEUMATOL, V30, pS7; LOUIE JS, 1978, ANN INTERN MED, V88, P790; Maillefert JF, 1999, RHEUMATOLOGY, V38, P978, DOI 10.1093/rheumatology/38.10.978; MALLESON PN, 1993, J RHEUMATOL, V20, P1769; Mease PJ, 2004, J RHEUMATOL, V31, P1356; Mercado U, 2004, REV INVEST CLIN, V56, P16; Mercado U, 2006, J RHEUMATOL, V33, P1469; O 'dell Jr, 1996, J CLINRHEUMATOL, V2, P59; Ogimi C, 2011, PEDIATR INFECT DIS J, V30, P208, DOI 10.1097/INF.0b013e3181f7ce44; Oren S, 2008, ANN RHEUM DIS, V67, P937, DOI 10.1136/ard.2007.077461; PONS VG, 1979, J MED VIROL, V4, P15, DOI 10.1002/jmv.1890040103; PREBLUD SR, 1985, JAMA-J AM MED ASSOC, V254, P253, DOI 10.1001/jama.254.2.253; Rahier JF, 2010, RHEUMATOLOGY, V49, P1815, DOI 10.1093/rheumatology/keq183; Rehnberg M, 2010, ARTHRITIS RES THER, V12, DOI 10.1186/ar3047; RISTOW SC, 1978, ANN INTERN MED, V88, P786; Shimizu M, 2012, CLIN VACCINE IMMUNOL, V19, P1700, DOI 10.1128/CVI.00309-12; Shinoki T, 2012, MOD RHEUMATOL, DOI [10.1007/s10165-012-0595-z(LoE;III), DOI 10.1007/S10165-012-0595-Z(LOE;III)]; Soldevilla HF, 2012, LUPUS, V21, P158, DOI 10.1177/0961203311429556; Sturkenboom Miriam C., 2000, Pharmacoepidemiology and Drug Safety, V9, pS71; Takamatsu I, 1995, Kekkaku, V70, P561; Tay L, 2007, ARTHRITIS RES THER, V9, DOI 10.1186/ar2174; Tingle AJ, 1997, LANCET, V349, P1277, DOI 10.1016/S0140-6736(96)12031-6; Tomilijenovic L, 2012, PHARMACEUTREG AFFAIR, pS12, DOI 10 . 4172/ 2167 - 7689 . S12 - 001; Vonkeman H, 2004, J RHEUMATOL, V31, P2517; Wallace DJ, 2007, DUBOIS LUPUS ERYTHEM; Weinstein M, 2006, CAN MED ASSOC J, V174, P459, DOI 10.1503/cmaj.051211; Wiesik-Szewczyk E, 2010, CLIN RHEUMATOL, V29, P605, DOI 10.1007/s10067-010-1373-y; WILLIAMS GW, 1978, ANN INTERN MED, V88, P729; Zycinska K, 2007, J PHYSIOL PHARMACOL, V58, P819	132	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1439-7595	1439-7609		MOD RHEUMATOL	Mod. Rheumatol.	MAY	2015	25	3					335	343		10.3109/14397595.2014.969916		9	Rheumatology	Rheumatology	CH1HS	WOS:000353772900001		
J	Hirata, S; Li, WY; Defranoux, N; Cavet, G; Bolce, R; Yamaoka, K; Saito, K; Tanaka, Y				Hirata, Shintaro; Li, Wanying; Defranoux, Nadine; Cavet, Guy; Bolce, Rebecca; Yamaoka, Kunihiro; Saito, Kazuyoshi; Tanaka, Yoshiya			A multi-biomarker disease activity score tracks clinical response consistently in patients with rheumatoid arthritis treated with different anti-tumor necrosis factor therapies: A retrospective observational study	MODERN RHEUMATOLOGY			English	Article						Biomarkers; Disease activity; Rheumatoid arthritis; TNF inhibitor	MODIFYING ANTIRHEUMATIC DRUGS; ACTIVITY INDEX; TIGHT CONTROL; TASK-FORCE; RECOMMENDATIONS; VALIDATION; VARIABILITY; EFFICACY; COUNTS	Objectives. To assess the ability of a multi-biomarker disease activity (MBDA) score to track clinical response in patients with rheumatoid arthritis (RA) treated with different TNF inhibitors. Methods. The study included 147 patients who had received adalimumab, etanercept, or infliximab for a year or more, during routine clinical care at the University Hospital of Occupational and Environmental Health, Japan. MBDA scores and clinical measures of disease activity were evaluated at baseline and, after 24 weeks (N = 84) and 52 weeks of treatment. Relationships between the changes (Delta) in MBDA score and changes in clinical measures or EULAR response categories were evaluated. Results. The median disease activity was 5.7 by DAS28-ESR and 64 by MBDA score at baseline, and decreased significantly with treatment. Delta MBDA scores over 1 year correlated with Delta DAS28-ESR (r = 0.48) and Delta DAS28-CRP (r = 0.46). Linear relationships between Delta MBDA scores and Delta DAS28-ESR or Delta DAS28-CRP were not significantly different between TNF inhibitors. The MBDA scores declined significantly more in good responders (median change: -29) than moderate (-21), and more in moderate than in non-responders (+ 2), by the EULAR criteria. Conclusions. MBDA scores tracked disease activity and treatment response in patients with RA treated with three TNF inhibitors. The relationships between Delta MBDA scores and Delta DAS28-ESR or Delta DAS28-CRP were consistent across the three TNF inhibitor groups.	[Hirata, Shintaro; Yamaoka, Kunihiro; Saito, Kazuyoshi; Tanaka, Yoshiya] Univ Occupat & Environm Hlth Japan, Dept Internal Med 1, Sch Med, Kitakyushu, Fukuoka 8078555, Japan; [Li, Wanying; Defranoux, Nadine; Cavet, Guy; Bolce, Rebecca] Crescendo Biosci Inc, San Francisco, CA USA	Tanaka, Y (reprint author), Univ Occupat & Environm Hlth Japan, Dept Internal Med 1, Sch Med, 1-1 Iseigaoka, Kitakyushu, Fukuoka 8078555, Japan.	tanaka@med.uoeh-u.ac.jp			Ministry of Health, Labor and Welfare of Japan; University of Occupational and Environmental Health, Japan; Ministry of Education, Culture, Sports, Science and Technology of Japan	This work was supported in part by Crescendo Bioscience, who supported shipment and testing of the serum samples. No other funding by Crescendo Bioscience was received for this study. The study was also supported in part by a Research Grant-In-Aid for Scientific Research by the Ministry of Health, Labor and Welfare of Japan, the Ministry of Education, Culture, Sports, Science and Technology of Japan, and the University of Occupational and Environmental Health, Japan.	Aletaha D, 2005, CLIN EXP RHEUMATOL, V23, pS100; Aletaha D, 2005, ARTHRITIS RES THER, V7, pR796, DOI 10.1186/ar1740; Combe B, 2007, ANN RHEUM DIS, V66, P34, DOI 10.1136/ard.2005.044354; Smolen JS, 2003, RHEUMATOLOGY, V42, P244, DOI 10.1093/rheumatology/keg072; Eastman PS, 2012, J PHARMACEUT BIOMED, V70, P415, DOI 10.1016/j.jpba.2012.06.003; Hirata S, 2013, RHEUMATOLOGY, V52, P1202, DOI 10.1093/rheumatology/kes362; PREVOO MLL, 1995, ARTHRITIS RHEUM, V38, P44, DOI 10.1002/art.1780380107; Bakker MF, 2007, ANN RHEUM DIS, V66, P56, DOI 10.1136/ard.2007.078360; Smolen JS, 2010, ANN RHEUM DIS, V69, P631, DOI 10.1136/ard.2009.123919; Curtis JR, 2012, ARTHRIT CARE RES, V64, P1794, DOI 10.1002/acr.21767; VANDERHEIJDE DMFM, 1993, J RHEUMATOL, V20, P579; Singh JA, 2012, ARTHRIT CARE RES, V64, P625, DOI 10.1002/acr.21641; Bakker MF, 2012, ANN RHEUM DIS, V71, P1692, DOI 10.1136/annrheumdis-2011-200963; Inoue E, 2007, ANN RHEUM DIS, V66, P407, DOI 10.1136/ard.2006.054205; Pincus T, 2008, J RHEUMATOL, V35, P2136, DOI 10.3899/jrheum.080182; Burmester GR, 2013, ANN RHEUM DIS, V72, P1445, DOI 10.1136/annrheumdis-2012-202450; Centola M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060635; Fransen J, 2009, RHEUM DIS CLIN N AM, V35, P745, DOI 10.1016/j.rdc.2009.10.001; Grunke M, 2010, J RHEUMATOL, V37, P860, DOI 10.3899/jrheum.090195; Hambardzumyan K, 2014, ANN RHEUM DIS, DOI [10.1136/annrheumdis-2013-204986, DOI 10.1136/ANNRHEUMDIS-2013-204986]; Japan College of Rheumatology, 2012, TNF INH US GUID RHEU; KLINKHOFF AV, 1988, J RHEUMATOL, V15, P492; Mease PJ, 2011, CLIN EXP RHEUMATOL, V29, P567; Saag KG, 2008, ARTHRIT RHEUM-ARTHR, V59, P762, DOI 10.1002/art.23721; van der Helm-van Mil AHM, 2013, RHEUMATOLOGY, V52, P839, DOI 10.1093/rheumatology/kes378	25	1	1	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1439-7595	1439-7609		MOD RHEUMATOL	Mod. Rheumatol.	MAY	2015	25	3					344	349		10.3109/14397595.2014.958893		6	Rheumatology	Rheumatology	CH1HS	WOS:000353772900002		
J	Sato, E; Tanaka, E; Ochiai, M; Shimizu, Y; Kobayashi, A; Shidara, K; Hoshi, D; Sugimoto, N; Inoue, E; Seto, Y; Nakajima, A; Taniguchi, A; Momohara, S; Yamanaka, H				Sato, Eri; Tanaka, Eiichi; Ochiai, Moeko; Shimizu, Yoko; Kobayashi, Akiko; Shidara, Kumi; Hoshi, Daisuke; Sugimoto, Naoki; Inoue, Eisuke; Seto, Yohei; Nakajima, Ayako; Taniguchi, Atsuo; Momohara, Shigeki; Yamanaka, Hisashi			Chronological changes in baseline disease activity of patients with rheumatoid arthritis who received biologic DMARDs between 2003 and 2012	MODERN RHEUMATOLOGY			English	Article						Biologic DMARD; Disease activity score 28; Methotrexate; Rheumatoid arthritis	MODIFYING ANTIRHEUMATIC DRUGS; POSTMARKETING SURVEILLANCE; JAPANESE PATIENTS; AMERICAN-COLLEGE; ETANERCEPT; INFLIXIMAB; SAFETY; RECOMMENDATIONS; TOCILIZUMAB; ADALIMUMAB	Background/Purpose. The use of biologic disease-modifying anti-rheumatic drugs (DMARDs) for rheumatoid arthritis (RA) has been increasing since 2003. In this study, we evaluated changes in the characteristics of patients receiving biologic DMARDs daily, in Japan. Methods. The characteristics of all RA patients who received any biologic DMARD at the Institute of Rheumatology, Tokyo Women's Medical University, within 1 year after its approval in Japan, were retrospectively evaluated. The periods of patient enrollment for each biologic agent were: infliximab (IFX), 2003-2004; etanercept (ETN), 2005-2006; tocilizumab (TCZ), 2008-2009; adalimumab (ADA), 2008-2009; abatacept (ABT), 2010-2011; and golimumab (GLM), 2011-2012. We retrospectively collected individual patient characteristics, concomitant medication usage, and disease activity assessed by disease activity score 28 (DAS28) at the time of administration, from the medical records. The retention rate for each agent at 6 months after treatment initiation was also assessed. Results. The numbers of patients who received each biologic DMARD at our institute within 1 year after its approval were: IFX, 49; ETN, 50; TCZ, 62; ADA, 52; ABT, 40; and GLM, 77. From 2003 to 2012, the proportion of patients with prior use of any biologic DMARD increased, as did concomitant use and dose of methotrexate (MTX); however, corticosteroid use and doses decreased. DAS28, at the time of treatment initiation, gradually decreased. At the time of IFX administration, 75% and 25% of patients had high and moderate disease activity respectively, compared to 25% and 58% respectively, of patients who received GLM. No significant difference was observed in the retention rate of biologic DMARDs at 6 months (range, 75.0% to 89.6%). Conclusion. Baseline disease activity of RA patients who received biologic DMARDs between 2003 and 2012 has changed from high to moderate in daily practice in Japan.	[Sato, Eri; Tanaka, Eiichi; Ochiai, Moeko; Shimizu, Yoko; Kobayashi, Akiko; Shidara, Kumi; Hoshi, Daisuke; Sugimoto, Naoki; Inoue, Eisuke; Seto, Yohei; Nakajima, Ayako; Taniguchi, Atsuo; Momohara, Shigeki; Yamanaka, Hisashi] Tokyo Womens Med Univ, Inst Rheumatol, Shinjuku Ku, Tokyo 162054, Japan	Sato, E (reprint author), Tokyo Womens Med Univ, Inst Rheumatol, Shinjuku Ku, 10-22 Kawada Cho, Tokyo 162054, Japan.	satoueri@ior.twmu.ac.jp			AbbVie; Asahikasei Pharma; Astellas; Bristol-Myers-Squibb; Chugai; Daiichi-Sankyo; Eisai; GlaxoSmithKline; Janssen; Mitsubishi-Tanabe; MSD; Nippon Kayaku; Pfizer; Santen; Taisho-Toyama; Takeda; Teijin Pharma	Hisashi Yamanaka has received honorarium for lecture or consultancy from Teijin Pharma, Chugai, Astellas, Bristol-Meyers, AbbVie, Daiichi-Sankyo, Nihon-Kayaku, Mitsubishi-Tanabe, Pfizer, Takeda, UCB and received a research grant from AbbVie, Asahikasei Pharma, Astellas, Bristol-Myers-Squibb, Chugai, Daiichi-Sankyo, Eisai, GlaxoSmithKline, Janssen, Mitsubishi-Tanabe, MSD, Nippon Kayaku, Pfizer, Santen, Taisho-Toyama, Takeda, Teijin Pharma.	Smolen JS, 2010, ANN RHEUM DIS, V69, P964, DOI 10.1136/ard.2009.126532; Takeuchi T, 2008, ANN RHEUM DIS, V67, P189, DOI 10.1136/ard.2007.072967; Tanaka M, 2012, MOD RHEUMATOL, V22, P849, DOI 10.1007/s10165-012-0615-z; Gomez-Reino JJ, 2012, ANN RHEUM DIS, V71, P382, DOI 10.1136/annrheumdis-2011-200302; PREVOO MLL, 1995, ARTHRITIS RHEUM, V38, P44, DOI 10.1002/art.1780380107; Malottki K, 2011, HEALTH TECHNOL ASSES, V15, P1, DOI 10.3310/hta15140; Matsuda Y, 2003, ARTHRIT RHEUM-ARTHR, V49, P784, DOI 10.1002/art.11465; Aletaha D, 2010, ANN RHEUM DIS, V69, P1580, DOI 10.1136/ard.2010.138461; Smolen JS, 2010, ANN RHEUM DIS, V69, P631, DOI 10.1136/ard.2009.123919; Kameda H, 2013, ANN RHEUM DIS, V72, P310, DOI 10.1136/annrheumdis-2012-201804; Soliman MM, 2012, ARTHRIT CARE RES, V64, P1108, DOI 10.1002/acr.21663; Yamanaka H, 2013, MOD RHEUMATOL, V23, P1, DOI 10.1007/s10165-012-0702-1; Koike T, 2012, MOD RHEUMATOL, V22, P498, DOI 10.1007/s10165-011-0541-5; Singh JA, 2012, ARTHRIT CARE RES, V64, P625, DOI 10.1002/acr.21641; Hyrich KL, 2006, RHEUMATOLOGY, V45, P1558, DOI 10.1093/rheumatology/kel149; Klareskog L, 2004, LANCET, V363, P675, DOI 10.1016/S0140-6736(04)15640-7; Simard JF, 2011, RHEUMATOLOGY, V50, P204, DOI 10.1093/rheumatology/keq326; Zhang J, 2011, ARTHRIT CARE RES, V63, P1672, DOI 10.1002/acr.20643; Kameda H, 2011, J RHEUMATOL, V38, P1585, DOI 10.3899/jrheum.110014; Hetland ML, 2008, ANN RHEUM DIS, V67, P1023, DOI 10.1136/ard.2007.087262; Koike T, 2011, MOD RHEUMATOL, V21, P343, DOI 10.1007/s10165-010-0406-3; Koike T, 2009, J RHEUMATOL, V36, P898, DOI 10.3899/jrheum.080791; Isaacs JD, 2011, ANN RHEUM DIS, V70, P4, DOI 10.1136/ard.2010.135376; ARNETT FC, 1988, ARTHRITIS RHEUM, V31, P315, DOI 10.1002/art.1780310302; Chiu Y, 2012, CLIN RHEUMATOL, V31, P1005, DOI 10.1007/s10067-011-1936-6; Harigai M, 2007, NEW ENGL J MED, V357, P1874, DOI 10.1056/NEJMc070728; Iikuni N, 2008, RHEUMATOLOGY, V47, P519, DOI 10.1093/rheumatology/ken047; Kawashiri S, 2011, MOD RHEUMATOL, V21, P365, DOI 10.1007/s10165-010-0402-7; Koike R, 2009, MOD RHEUMATOL, V19, P351, DOI 10.1007/s10165-009-0197-6; Koike T, 2012, RHEUMATOL INT, V32, P1617, DOI 10.1007/s00296-011-1807-0; Koike T, 2012, RHEUMATOL INT, V32, P1511, DOI 10.1007/s00296-010-1784-8; Koike T, 2011, ANN RHEUM DIS, V70, P2148, DOI 10.1136/ard.2011.151092; Komano Y, 2009, ARTHRIT RHEUM-ARTHR, V61, P305, DOI 10.1002/art.24283; Miyasaka N, 2006, MOD RHEUMATOL, V16, P63; Pomirleanu C, 2013, CLIN RHEUMATOL, V32, P665, DOI 10.1007/s10067-012-2146-6; Seto Y, 2011, MOD RHEUMATOL, V21, P579, DOI 10.1007/s10165-011-0445-4; Singh JA, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008794.pub2; Takeuchi, 2014, JAPANESE GUIDELINES; Takeuchi T, 2012, MOD RHEUMATOL, V22, P327, DOI 10.1007/s10165-011-0516-6; Tanaka E, 2012, MOD RHEUMATOL; Tanaka E, 2012, RHEUMATOL INT, V32, P749, DOI 10.1007/s00296-010-1638-4; Tanaka Y, 2008, MOD RHEUMATOL, V18, P146, DOI 10.1007/s10165-008-0026-3; Watanabe K, 2012, MOD RHEUMATOL; Yamanaka H, 2007, MOD RHEUMATOL, V17, P28, DOI 10.1007/s10165-006-0532-0; Yamanaka Hisashi, 2007, Mod Rheumatol, V17, P283, DOI 10.1007/s10165-007-0587-6; Yamanaka Hisashi, 2007, Mod Rheumatol, V17, P98, DOI 10.1007/s10165-006-0546-7	46	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1439-7595	1439-7609		MOD RHEUMATOL	Mod. Rheumatol.	MAY	2015	25	3					350	357		10.3109/14397595.2014.958274		8	Rheumatology	Rheumatology	CH1HS	WOS:000353772900003		
J	Yano, K; Ikari, K; Ochi, K; Ishida, O; Sakuma, Y; Yoshida, S; Koyama, T; Koenuma, N; Momohara, S				Yano, Koichiro; Ikari, Katsunori; Ochi, Kensuke; Ishida, Osamu; Sakuma, Yu; Yoshida, Shinji; Koyama, Takuma; Koenuma, Naoko; Momohara, Shigeki			Validity and responsiveness of a self-administered foot evaluation questionnaire in rheumatoid arthritis	MODERN RHEUMATOLOGY			English	Article						Rheumatoid arthritis; Responsiveness; SAFE-Q; Validity	HEALTH-ASSESSMENT QUESTIONNAIRE; CLINICAL RATING SYSTEMS; OUTCOME MEASUREMENT; RELIABILITY; VALIDATION; INSTRUMENTS; DISABILITY; SCALES; INDEX; PAIN	Objectives. A self-administered foot evaluation questionnaire (SAFE-Q) was developed by the Japanese Society for Surgery of the Foot (JSSF). The aim of this study is to evaluate the validity and responsiveness of the SAFE-Q in patients with rheumatoid arthritis (RA). Methods. In total, 180 patients with RA answered the SAFE-Q. Of 180 patients, 34 answered the SAFE-Q twice, preoperatively and postoperatively, to assess responsiveness. Construct validity was tested by comparing the 5 SAFE-Q subscales and the JSSF standard rating system for the RA foot and ankle scale (JSSF-RA), a Japanese version of the Health Assessment Questionnaire (JHAQ), disease activity score in 28 joints (DAS28), simplified disease activity index (SDAI), and clinical disease activity index (CDAI). Responsiveness was examined by calculating the standardized response mean (SRM) and effect size (ES) 3 months after surgery. Results. There were moderate correlations between the SAFE-Q and the JSSF-RA and JHAQ. Conversely, a low correlation was observed between the SAFE-Q and DAS28, SDAI, and CDAI. The responsiveness was high, with an SRM of 0.9 and ES of 0.7 for pain subscales. Conclusion. SAFE-Q is a useful tool for assessing the foot and ankle in RA patients.	[Yano, Koichiro; Ikari, Katsunori; Ochi, Kensuke; Ishida, Osamu; Sakuma, Yu; Yoshida, Shinji; Koyama, Takuma; Koenuma, Naoko; Momohara, Shigeki] Tokyo Womens Med Univ, Inst Rheumatol, Dept Orthoped Surg, Shinjuku Ku, Tokyo 1620054, Japan	Ikari, K (reprint author), Tokyo Womens Med Univ, Inst Rheumatol, Shinjuku Ku, 10-22 Kawada, Tokyo 1620054, Japan.	kikari@twmu.ac.jp					Aletaha D, 2005, ARTHRITIS RES THER, V7, pR796, DOI 10.1186/ar1740; AMUSO SJ, 1971, CLIN ORTHOP RELAT R, P94; Smolen JS, 2003, RHEUMATOLOGY, V42, P244, DOI 10.1093/rheumatology/keg072; PREVOO MLL, 1995, ARTHRITIS RHEUM, V38, P44, DOI 10.1002/art.1780380107; Niki H, 2013, J ORTHOP SCI, V18, P298, DOI 10.1007/s00776-012-0337-2; Niki H, 2005, J ORTHOP SCI, V10, P466, DOI 10.1007/s00776-005-0937-1; Matsuda Y, 2003, ARTHRIT RHEUM-ARTHR, V49, P784, DOI 10.1002/art.11465; Martin RRL, 2005, FOOT ANKLE INT, V26, P968; Johanson NA, 2004, J BONE JOINT SURG AM, V86A, P902; KAZIS LE, 1989, MED CARE, V27, pS178, DOI 10.1097/00005650-198903001-00015; Niki H, 2005, J ORTHOP SCI, V10, P457, DOI 10.1007/s00776-005-0936-2; SooHoo NF, 2003, FOOT ANKLE INT, V24, P50; KITAOKA HB, 1994, FOOT ANKLE INT, V15, P349; LIANG MH, 1990, MED CARE, V28, P632, DOI 10.1097/00005650-199007000-00008; BUDIMANMAK E, 1991, J CLIN EPIDEMIOL, V44, P561, DOI 10.1016/0895-4356(91)90220-4; FRIES JF, 1982, J RHEUMATOL, V9, P789; Niki H, 2013, NIHONSEIKEIGEKAGAKKA, V87, P451	17	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1439-7595	1439-7609		MOD RHEUMATOL	Mod. Rheumatol.	MAY	2015	25	3					358	361		10.3109/14397595.2014.959243		4	Rheumatology	Rheumatology	CH1HS	WOS:000353772900004		
J	Tada, M; Koike, T; Okano, T; Sugioka, Y; Wakitani, S; Mamoto, K; Inui, K; Nakamura, H				Tada, Masahiro; Koike, Tatsuya; Okano, Tadashi; Sugioka, Yuko; Wakitani, Shigeyuki; Mamoto, Kenji; Inui, Kentaro; Nakamura, Hiroaki			Preference of surgical procedure for the forefoot deformity in the rheumatoid arthritis patients-A prospective, randomized, internal controlled study	MODERN RHEUMATOLOGY			English	Article						Arthrodesis; Clinical results; Forefoot deformity; Resection; Rheumatoid arthritis	1ST METATARSOPHALANGEAL JOINT; TERM-FOLLOW-UP; RESECTION ARTHROPLASTY; HALLUX VALGUS; ARTHRODESIS; RECONSTRUCTION; DISEASE; OPERATIONS; SURGERY; FOOT	Objectives. The deformed rheumatoid forefoot may be treated with resection of lesser metatarsal heads combined with arthrodesis or resection of the first metatarsophalangeal joint. Recurrent hallux valgus deformity has been reported by resection. We performed a prospective, randomized, internal-controlled study to compare results between arthrodesis and resection. Methods. We resected the lesser metatarsal heads bilaterally and performed arthrodesis of the first metatarsophalangeal joint on one side and resection on the opposite side. We investigated 26 patients (52 feet) who were followed at least one year. Patients were assessed for clinical score, hallux valgus angle (HVA), angle between first and second metatarsals, and angle between first and fifth metatarsals preoperatively, postoperatively and at final follow-up. We evaluated callosities, claw toes, recurrences, and procedure preferences. Results. The mean follow-up period was 4.1 years. No significant differences between arthrodesis and resection were seen, with the exception of HVA. That was significantly less on arthrodesis side (11.5 degrees) than on resection side (17.0 degrees, p<0.05). Seven callosities on resection side and four on arthrodesis side were observed. On resection side, hallux valgus deformity often recurred (15.3%). Patients expressed a signifi cant preference for arthrodesis over resection (p = 0.008). Conclusions. Arthrodesis provides better results for maintaining HVA.	[Tada, Masahiro; Okano, Tadashi; Wakitani, Shigeyuki; Mamoto, Kenji; Nakamura, Hiroaki] Osaka City Univ, Sch Med, Dept Orthopaed Surg, Osaka 5458585, Japan; [Koike, Tatsuya; Sugioka, Yuko] Osaka City Univ, Sch Med, Ctr Senile Degenerat Disorders, Osaka 5458585, Japan; [Inui, Kentaro] Osaka City Univ, Sch Med, Dept Rheumatosurg, Osaka 5458585, Japan; [Koike, Tatsuya] Shirahama Fdn Hlth & Welf, Search Inst Bone & Arthrit Dis, Wakayama, Japan	Koike, T (reprint author), Osaka City Univ, Sch Med, Ctr Senile Degenerat Disorders, Abeno Ku, 1-4-3 Asahimachi, Osaka 5458585, Japan.	tatsuya@med.osaka-cu.ac.jp			Takeda Pharmaceutical; Mitsubishi Tanabe Pharma Corporation; Chugai Pharmaceutical; Eisai; Abbott Japan; Teijin Pharma; Banyu Pharmaceutical; Ono Pharmaceutical; Astellas Pharma; Janssen Pharmaceutica; Glaxo-SmithKline; Pfizer; Daiichi Sankyo	Dr. Koike has received research grants and/or speaking fees from Takeda Pharmaceutical, Mitsubishi Tanabe Pharma Corporation, Chugai Pharmaceutical, Eisai, Abbott Japan, Teijin Pharma, Banyu Pharmaceutical and Ono Pharmaceutical.; Dr. Nakamura has received research grants and/or speaking fees from Chugai Pharmaceutical, Astellas Pharma, Janssen Pharmaceutica, Glaxo-SmithKline, Pfizer, Daiichi Sankyo and Ono Pharmaceutical. All other authors have declared no conflicts of interest.	PREVOO MLL, 1995, ARTHRITIS RHEUM, V38, P44, DOI 10.1002/art.1780380107; Grondal L, 2006, J BONE JOINT SURG BR, V88B, P914, DOI 10.1302/0301-620X.88B7.17472; Yano K, 2013, MOD RHEUMATOL, V23, P953, DOI 10.1007/s10165-012-0776-9; RAHMAN H, 1993, J BONE JOINT SURG BR, V75, P637; KITAOKA HB, 1994, FOOT ANKLE INT, V15, P349; Coughlin MJ, 2000, J BONE JOINT SURG AM, V82A, P322; MANN RA, 1984, J BONE JOINT SURG AM, V66A, P687; Arnett FC, 1987, ARTHRITIS RHEUM, V31, P315; Barton N J, 1973, J Bone Joint Surg Br, V55, P126; CLAYTON ML, 1963, J BONE JOINT SURG AM, V45, P1517; CRACCHIOLO A, 1992, J BONE JOINT SURG AM, V74A, P552; Dereymaeker G, 1997, FOOT ANKLE INT, V18, P270; FLEMING A, 1976, ANN RHEUM DIS, V35, P361, DOI 10.1136/ard.35.4.361; FLEMING A, 1976, I ONSET ANN RHEUM DI, V35, P357; Hamalainen M, 1997, CLIN ORTHOP RELAT R, P34; HENRY APJ, 1975, J BONE JOINT SURG BR, V57, P478; Kates A, 1967, J Bone Joint Surg Br, V49, P552; KIRKUP JR, 1977, ACTA ORTHOP SCAND, V48, P527; LeLievre J., 1961, PATHOLOGY FOOT; MARMOR L, 1975, CLIN ORTHOP RELAT R, P223; MCGARVEY SR, 1988, FOOT ANKLE, V9, P75; MICHELSON J, 1994, FOOT ANKLE INT, V15, P608; Mulcahy D, 2003, J RHEUMATOL, V30, P1440; Patsalis T, 1996, ORTHOPEDICS, V19, P439; Shi K, 2000, J RHEUMATOL, V27, P84; Shi Kenrin, 2007, Mod Rheumatol, V17, P110, DOI 10.1007/s10165-006-0551-x; STOCKLEY I, 1989, CLIN ORTHOP RELAT R, P213; Torikai E, 2008, MOD RHEUMATOL, V18, P486, DOI 10.1007/s10165-008-0086-4; VAINIO K, 1956, Ann Chir Gynaecol Fenn Suppl, V45, P1; Vandeputte G, 1999, FOOT ANKLE INT, V20, P438; YU GV, 1994, J AM PODIAT MED ASSN, V84, P266	31	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1439-7595	1439-7609		MOD RHEUMATOL	Mod. Rheumatol.	MAY	2015	25	3					362	366		10.3109/14397595.2014.956984		5	Rheumatology	Rheumatology	CH1HS	WOS:000353772900005		
J	Ishie, S; Ito, H; Azukizawa, M; Furu, M; Ishikawa, M; Ogino, H; Hamamoto, Y; Matsuda, S				Ishie, Shinichiro; Ito, Hiromu; Azukizawa, Masayuki; Furu, Moritoshi; Ishikawa, Masahiro; Ogino, Hiroko; Hamamoto, Yosuke; Matsuda, Shuichi			Delayed wound healing after forefoot surgery in patients with rheumatoid arthritis	MODERN RHEUMATOLOGY			English	Article						Delayed wound healing; Forefoot surgery; Operative complication; Rheumatoid arthritis	FOOT; COMPLICATIONS; CLASSIFICATION; CRITERIA; ANKLE	Objective. To elucidate the systemic and local risk factors and the effect of surgical procedures for delayed wound healing after forefoot surgery in patients with rheumatoid arthritis (RA). Methods. Fifty forefoot surgeries were performed in 39 patients using resection arthroplasty or a joint-preserving procedure (25 feet for each procedure). The associations between the occurrence of delayed wound healing and clinical variables, radiological assessment, or surgical procedures were analyzed. Results. Delayed wound healing was recorded in nine feet of eight patients. The duration of RA was significantly longer in the delayed healing group than that in the healed group. Age, sex, smoking history, concomitant diabetes, and RA medication did not differ between the groups. Radiological evaluation showed significant differences between groups in metatarsophalangeal dorsal flexion angle. The shortened length of the fourth and the fifth metatarsal bones affected the occurrence of the complication. The joint-preserving procedure had significantly less delayed wound healing compared with resection arthroplasty. Conclusions. Preoperative dorsoplantar deformity and perioperative tissue damage can cause delayed wound healing after forefoot surgery in RA patients.	[Ishie, Shinichiro; Ito, Hiromu; Azukizawa, Masayuki; Furu, Moritoshi; Ishikawa, Masahiro; Ogino, Hiroko; Hamamoto, Yosuke; Matsuda, Shuichi] Kyoto Univ, Grad Sch Med, Dept Orthopaed Surg, Sakyo Ku, Kyoto 6068507, Japan; [Furu, Moritoshi; Ishikawa, Masahiro] Kyoto Univ, Grad Sch Med, Dept Control Rheumat Dis, Kyoto 6068507, Japan	Ito, H (reprint author), Kyoto Univ, Grad Sch Med, Dept Orthopaed Surg, Sakyo Ku, 54 Kawahara Cho, Kyoto 6068507, Japan.	hiromu@kuhp.kyoto-u.ac.jp			Mitsubishi Tanabe Pharma Co.; Bristol-Myers K.K.; Chugai Pharmaceutical Co., Ltd.; Eisai Co., Ltd.; Takeda Pharmaceutical Co., Ltd.; Pfizer Japan Inc.; Astellas Pharma Inc.; Daiichi Sankyo Co., Ltd.; Kyocera Medical Co., Ltd.; Ishihara Sangyo Kaisha. Ltd.; Asahi Kasei Parma Co. Ltd.; Taisho Toyama Pharmaceutical Co. Ltd.; Hisamitsu Pharmaceutical Co. Inc.; Kaken Pharmaceutical Co. Ltd.; MSD K.K.; Teijin Pharma Ltd.; Smith & Nephew Orthopaedics KK; Eli Lilly Japan K.K.; Zimmer Inc.	M.F. and M.I. are affiliated with a department that is supported financially by four pharmaceutical companies (Mitsubishi Tanabe Pharma Co., Bristol-Myers K.K., Chugai Pharmaceutical Co., Ltd., Eisai Co., Ltd.). H.I. has received grant and research support from Takeda Pharmaceutical Co., Ltd., Mitsubishi Tanabe Pharma Co., Chugai Pharmaceutical Co., Ltd., Pfizer Japan Inc., Astellas Pharma Inc., and Daiichi Sankyo Co., Ltd. M.F. has received grant and research support from Mitsubishi Tanabe Pharma Co., Astellas Pharma Inc., and Pfizer Japan Inc. S. M. has received grant and research support from Kyocera Medical Co., Ltd., Ishihara Sangyo Kaisha. Ltd., Asahi Kasei Parma Co. Ltd., Taisho Toyama Pharmaceutical Co. Ltd., Hisamitsu Pharmaceutical Co. Inc., Kaken Pharmaceutical Co. Ltd., Astellas Pharma Inc., MSD K.K., Eisai Co., Ltd., Pfizer Japan Inc., Teijin Pharma Ltd., Smith & Nephew Orthopaedics KK, Eli Lilly Japan K.K., Daiichi Sankyo Co., Ltd., and Zimmer Inc.; The sponsors were not involved in the study design; in the collection, analysis, interpretation of data; in the writing of this manuscript; or in the decision to submit the article for publication. The authors, their immediate families, and any research foundations with which they are affiliated have not received any financial payments or other benefits from any commercial entity related to the subject of this article.	Aletaha D, 2010, ARTHRITIS RHEUM-US, V62, P2569, DOI 10.1002/art.27584; Guo S, 2010, J DENT RES, V89, P219, DOI 10.1177/0022034509359125; Niki H, 2010, J BONE JOINT SURG BR, V92B, P380, DOI 10.1302/0301-620X.92B3.23186; Trieb K, 2005, J BONE JOINT SURG BR, V87B, P1171, DOI 10.1302/0301-620X.87B9.16288; Bibbo C, 2004, FOOT ANKLE INT, V25, P331; Coughlin MJ, 2000, J BONE JOINT SURG AM, V82A, P322; LARSEN A, 1977, ACTA RADIOL DIAGN, V18, P481; ARNETT FC, 1988, ARTHRITIS RHEUM, V31, P315, DOI 10.1002/art.1780310302; Bibbo C, 2003, FOOT ANKLE INT, V24, P40; Bibbo Christopher, 2010, Clin Podiatr Med Surg, V27, P485, DOI 10.1016/j.cpm.2010.06.001; Hanyu T, 2001, J Orthop Sci, V6, P141, DOI 10.1007/s007760100062; Hulse Narayan, 2006, J Foot Ankle Surg, V45, P107, DOI 10.1053/j.jfas.2005.12.005; Nagashima M, 2007, CLIN RHEUMATOL, V26, P748, DOI 10.1007/s10067-006-0514-9; Nassar J, 2001, CLIN ORTHOP RELAT R, P140; Reeves Christopher L, 2010, Clin Podiatr Med Surg, V27, P313, DOI 10.1016/j.cpm.2009.12.002; Reize P, 2006, FOOT ANKLE INT, V27, P586; Rojas-Villarraga A, 2009, BMC MUSCULOSKEL DIS, V10, DOI 10.1186/1471-2474-10-67; Thomas S, 2005, J BONE JOINT SURG AM, V87A, P748, DOI 10.2106/JBJS.C.01696	18	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1439-7595	1439-7609		MOD RHEUMATOL	Mod. Rheumatol.	MAY	2015	25	3					367	372		10.3109/14397595.2014.966975		6	Rheumatology	Rheumatology	CH1HS	WOS:000353772900006		
J	Ishida, O; Furuya, T; Inoue, E; Ochi, K; Ikari, K; Taniguchi, A; Yamanaka, H; Momohara, S				Ishida, Osamu; Furuya, Takefumi; Inoue, Eisuke; Ochi, Kensuke; Ikari, Katsunori; Taniguchi, Atsuo; Yamanaka, Hisashi; Momohara, Shigeki			Risk factors for established vertebral fractures in Japanese patients with rheumatoid arthritis: Results from a large prospective observational cohort study	MODERN RHEUMATOLOGY			English	Article						Japanese; Prednisolone; Rheumatoid arthritis; Risk factors; Vertebral fracture	BONE-MINERAL DENSITY; POSTMENOPAUSAL WOMEN; INCIDENT FRACTURES; FEMALE-PATIENTS; OSTEOPOROSIS; DEFORMITIES; PREVALENCE; VALIDATION; TRIAL	Objective. The aim of this study was to evaluate the associations between potential risk factors and the occurrence of established vertebral fractures in Japanese patients with rheumatoid arthritis (RA). Methods. A total of 10,469 patients with RA were enrolled in a prospective, observational study from 2000 to 2011. Self-reported vertebral fractures were verified using patient's medical records and radiographs. Cox proportional hazards models were used to analyze independent contributions of various risk factors for established vertebral fracture occurrence. Results. During a mean follow-up of 5.8 years, established vertebral fractures in 170 patients were verified with medical records and radiographs. Multivariate Cox regression analyses estimated that the hazards ratios of sustaining vertebral fractures increased by 1.84 for female gender, 1.72 for every 10 years of increased age, 1.26 for Disease Activity Score in 28 joints (DAS28), 1.44 for Japanese Health Assessment Questionnaire-Disability Index (J-HAQ-DI), 2.21 for history of any previous fractures, and 1.09 for daily prednisolone dose (mg/day). Conclusion. We confirmed the associations between vertebral fractures and advanced age, J-HAQ-DI, and high daily prednisolone dose; and found significant correlations between vertebral fractures and female gender, DAS28, and history of any previous fracture in Japanese RA patients.	[Ishida, Osamu; Furuya, Takefumi; Inoue, Eisuke; Ochi, Kensuke; Ikari, Katsunori; Taniguchi, Atsuo; Yamanaka, Hisashi; Momohara, Shigeki] Tokyo Womens Med Univ, Inst Rheumatol, Shinjuku Ku, Tokyo 1620054, Japan	Furuya, T (reprint author), Tokyo Womens Med Univ, Inst Rheumatol, Shinjuku Ku, 10-22 Kawada Cho, Tokyo 1620054, Japan.	furuyat@twmu.ac.jp			Japan Osteoporosis Foundation and Society	We thank all the members of the Institute of Rheumatology, Tokyo Women's Medical University for the successful management of the IORRA cohort. This work was supported in part by grants-in-aid for scientific research from the Japan Osteoporosis Foundation and Society to TF.	Chen Z, 2004, MENOPAUSE, V11, P264, DOI 10.1097/01.GME.0000094210.15096.FD; PREVOO MLL, 1995, ARTHRITIS RHEUM, V38, P44, DOI 10.1002/art.1780380107; Dore RK, 2010, ANN RHEUM DIS, V69, P872, DOI 10.1136/ard.2009.112920; Matsuda Y, 2003, ARTHRIT RHEUM-ARTHR, V49, P784, DOI 10.1002/art.11465; Karras D, 2012, J RHEUMATOL, V39, P600, DOI 10.3899/jrheum.110947; Yamanaka H, 2013, MOD RHEUMATOL, V23, P1, DOI 10.1007/s10165-012-0702-1; Sinigaglia L, 2000, J RHEUMATOL, V27, P2582; Angeli A, 2006, BONE, V39, P253, DOI 10.1016/j.bone.2006.02.005; Furuya T, 2011, CLIN RHEUMATOL, V30, P1105, DOI 10.1007/s10067-011-1748-8; Vis M, 2011, OSTEOPOROSIS INT, V22, P2413, DOI 10.1007/s00198-010-1517-6; van Staa TP, 2006, ARTHRITIS RHEUM, V54, P3104, DOI 10.1002/art.22117; Yoshimura N, 2011, MOD RHEUMATOL, V21, P608, DOI 10.1007/s10165-011-0455-2; Arai K, 2006, J BONE MINER METAB, V24, P118, DOI 10.1007/s00774-005-0657-9; Dirven L, 2012, BMC MUSCULOSKEL DIS, V13, DOI 10.1186/1471-2474-13-125; Furuya T, 2007, J RHEUMATOL, V34, P303; Furuya T, 2013, OSTEOPOROSIS INT, V24, P1257, DOI 10.1007/s00198-012-2080-0; Furuya T, 2009, MOD RHEUMATOL, V19, P140, DOI 10.1007/s10165-008-0138-9; Furuya T, 2008, J BONE MINER METAB, V26, P499, DOI 10.1007/s00774-007-0836-y; Hagino H, 2013, J BONE MINER METAB, V31, P544, DOI 10.1007/s00774-013-0439-8; Iwamoto J, 2012, DRUG AGING, V29, P191, DOI 10.2165/11597480-000000000-00000; Lems WF, 2006, OSTEOPOROSIS INT, V17, P716, DOI 10.1007/s00198-005-0037-2; Nampei A, 2008, MOD RHEUMATOL, V18, P170, DOI 10.1007/s10165-008-0032-5; Ochi K, 2015, OSTEOPOROSIS INT, V26, P961, DOI 10.1007/s00198-014-2911-2; Ochi K, 2014, CLIN RHEUMATOL, V33, P477, DOI 10.1007/s10067-013-2415-z; Ochi Kensuke, 2013, Arch Osteoporos, V8, P130, DOI 10.1007/s11657-013-0130-7; Omata Y, 2014, J BONE MINER METAB, V32, P725, DOI 10.1007/s00774-013-0552-8; Orstavik RE, 2003, ARTHRIT RHEUM-ARTHR, V49, P355, DOI 10.1002/art.11118; Orstavik RE, 2004, ARCH INTERN MED, V164, P420, DOI 10.1001/archinte.164.4.420; Urano W, 2009, J BONE MINER METAB, V27, P574, DOI 10.1007/s00774-009-0073-7	29	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1439-7595	1439-7609		MOD RHEUMATOL	Mod. Rheumatol.	MAY	2015	25	3					373	378		10.3109/14397595.2015.1004276		6	Rheumatology	Rheumatology	CH1HS	WOS:000353772900007		
J	Yoshimi, R; Ihata, A; Kunishita, Y; Kishimoto, D; Kamiyama, R; Minegishi, K; Hama, M; Kirino, Y; Asami, Y; Ohno, S; Ueda, A; Takeno, M; Ishigatsubo, Y				Yoshimi, Ryusuke; Ihata, Atsushi; Kunishita, Yosuke; Kishimoto, Daiga; Kamiyama, Reikou; Minegishi, Kaoru; Hama, Maasa; Kirino, Yohei; Asami, Yukiko; Ohno, Shigeru; Ueda, Atsuhisa; Takeno, Mitsuhiro; Ishigatsubo, Yoshiaki			A novel 8-joint ultrasound score is useful in daily practice for rheumatoid arthritis	MODERN RHEUMATOLOGY			English	Article						Power Doppler; Rheumatoid arthritis; Ultrasound	POWER DOPPLER ULTRASONOGRAPHY; C-REACTIVE PROTEIN; CLINICAL REMISSION; MUSCULOSKELETAL ULTRASOUND; JOINT INFLAMMATION; DISEASE-ACTIVITY; CLASSIFICATION CRITERIA; SYNOVITIS; RECOMMENDATIONS; SEDIMENTATION	Objectives. To investigate the optimal number and combination of joints to be assessed by power Doppler ultrasonography (PDUS) in daily practice for rheumatoid arthritis (RA). Methods. PDUS were performed in 24 joints, including all proximal interphalangeal, metacarpophalangeal (MCP), and bilateral wrist and knee joints in 234 patients with RA. PD signals were scored semiquantitatively from 0 to 3 in each joint, and total PD score-24 was calculated by summing them up as comprehensive assessment. Results. Positive PD signals were more frequently found in bilateral wrist, knee, and the second and third MCP joints than the other joints. The individual PD scores of these 8 joints also showed higher correlation coefficients with total PD score-24 (r(s) >= 0.4). Among the sum PD scores of various selected joint combinations, the score of the combination of 8 joints (total PD score-8), including bilateral second and third MCP, wrist, and knee joints, showed the highest sensitivity and negative predictive value (98.1% and 96.2%, respectively). Total PD score-8 showed high correlation with the total PD score-24 (r(s) = 0.97, p < 0.01). Conclusions. Total PD score-8 is simple and efficient enough for monitoring disease activity and judging imaging remission of RA in daily practice.	[Yoshimi, Ryusuke; Ihata, Atsushi; Kunishita, Yosuke; Kishimoto, Daiga; Kamiyama, Reikou; Minegishi, Kaoru; Hama, Maasa; Kirino, Yohei; Asami, Yukiko; Ueda, Atsuhisa; Takeno, Mitsuhiro; Ishigatsubo, Yoshiaki] Yokohama City Univ, Grad Sch Med, Dept Internal Med & Clin Immunol, Yokohama, Kanagawa 2360004, Japan; [Ihata, Atsushi] Yokohama Minami Kyosai Hosp, Dept Rheumatol, Yokohama, Kanagawa, Japan; [Ohno, Shigeru] Yokohama City Univ, Ctr Rheumat Dis, Med Ctr, Yokohama, Kanagawa 2360004, Japan	Ishigatsubo, Y (reprint author), Yokohama City Univ, Grad Sch Med, Dept Internal Med & Clin Immunol, Kanazawa Ku, 3-9 Fukuura, Yokohama, Kanagawa 2360004, Japan.	ishigats@med.yokohama-cu.ac.jp			Japan Rheumatism Foundation	We thank all the colleagues in our laboratories for kind cooperation in this project. We also thank Mr. Tom Kiper for his review of the manuscript. This work was supported by the Japan Rheumatism Foundation (R. Y.).	Kawashiri S, 2013, MOD RHEUMATOL, V23, P36, DOI 10.1007/s10165-012-0628-7; Kane D, 2003, J RHEUMATOL, V30, P966; Takase K, 2012, CLIN EXP RHEUMATOL, V30, P85; Mandl P, 2011, J RHEUMATOL, V38, P2055, DOI 10.3899/jrheum.110424; Aletaha D, 2010, ANN RHEUM DIS, V69, P1580, DOI 10.1136/ard.2010.138461; Smolen JS, 2010, ANN RHEUM DIS, V69, P631, DOI 10.1136/ard.2009.123919; Mulherin D, 1996, BRIT J RHEUMATOL, V35, P1263; Naredo E, 2005, ANN RHEUM DIS, V64, P375, DOI 10.1136/ard.2004.023929; Perricone C, 2012, RHEUMATOLOGY, V51, P866, DOI 10.1093/rheumatology/ker405; Naredo E, 2013, ARTHRIT CARE RES, V65, P512, DOI 10.1002/acr.21869; Scire CA, 2009, RHEUMATOLOGY, V48, P1092, DOI 10.1093/rheumatology/kep171; Backhaus M, 2001, ANN RHEUM DIS, V60, P641, DOI 10.1136/ard.60.7.641; Molenaar ETH, 2004, ARTHRITIS RHEUM, V50, P36, DOI 10.1002/art.11481; Ikeda K, 2014, ARTHRITIS RHEUMATOL, V66, P523, DOI 10.1002/art.38280; Iagnocco A, 2008, J RHEUMATOL, V35, P35; Yoshimi R, 2014, MOD RHEUMATOL, V24, P590, DOI 10.3109/14397595.2013.857800; Cheung PP, 2010, ARTHRIT CARE RES, V62, P323, DOI 10.1002/acr.20102; Hama M, 2012, RHEUMATOL INT, V32, P1327, DOI 10.1007/s00296-011-1802-5; Brown AK, 2006, ARTHRITIS RHEUM, V54, P3761, DOI 10.1002/art.22190; Kawashiri SY, 2011, RHEUMATOLOGY, V50, P962, DOI 10.1093/rheumatology/keq415; Wakefield RJ, 2007, J RHEUMATOL, V34, P848; Naredo E, 2008, ARTHRIT RHEUM-ARTHR, V59, P515, DOI 10.1002/art.23529; Torp-Pedersen ST, 2008, ANN RHEUM DIS, V67, P143, DOI 10.1136/ard.2007.078451; Matsui T, 2007, ANN RHEUM DIS, V66, P1221, DOI 10.1136/ard.2006.063834; Horikoshi M, 2010, MOD RHEUMATOL, V20, P556, DOI 10.1007/s10165-010-0318-2; Wakefield RJ, 2005, J RHEUMATOL, V32, P2485; Iagnocco A, 2008, CLIN RHEUMATOL, V27, P491, DOI 10.1007/s10067-007-0738-3; Backhaus M, 2009, ARTHRIT RHEUM-ARTHR, V61, P1194, DOI 10.1002/art.24646; ARNETT FC, 1988, ARTHRITIS RHEUM, V31, P315, DOI 10.1002/art.1780310302; Filippucci E, 2007, CLIN EXP RHEUMATOL, V25, P5; Fukae J, 2009, MOD RHEUMATOL, V19, P502, DOI 10.1007/s10165-009-0190-0; KUSHNER I, 1991, ARTHRITIS RHEUM, V34, P1065, DOI 10.1002/art.1780340819; Matsui T, 2011, MOD RHEUMATOL, V21, P134, DOI 10.1007/s10165-010-0367-6; Nakagomi D, 2013, ARTHRITIS RHEUM, V65, P890; Naredo E, 2008, ANN RHEUM DIS, V67, P1017, DOI 10.1136/ard.2007.082560; Prevoo ML, 1995, ARTHRITIS RHEUM, V38, p:; Rees JD, 2007, RHEUMATOLOGY, V46, P454, DOI 10.1093/rheumatology/kel256; Soshimi R, 2013, MOD RHEUMATOL, V23, P456; TALSTAD I, 1983, SCAND J HAEMATOL, V31, P478	39	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1439-7595	1439-7609		MOD RHEUMATOL	Mod. Rheumatol.	MAY	2015	25	3					379	385		10.3109/14397595.2014.974305		7	Rheumatology	Rheumatology	CH1HS	WOS:000353772900008		
J	Hiraga, M; Ikeda, K; Shigeta, K; Sato, A; Yoshitama, T; Hara, R; Tanaka, Y				Hiraga, Masao; Ikeda, Kei; Shigeta, Koichiro; Sato, Akito; Yoshitama, Tamami; Hara, Ryota; Tanaka, Yasuhito			Sonographic measurements of low-echoic synovial area in the dorsal aspect of metatarsophalangeal joints in healthy subjects	MODERN RHEUMATOLOGY			English	Article						Metatarsophalangeal joint; Measurement; Rheumatoid arthritis; Synovitis; Ultrasound	EARLY RHEUMATOID-ARTHRITIS; POWER DOPPLER ULTRASONOGRAPHY; EARLY INFLAMMATORY ARTHRITIS; DISEASE-ACTIVITY; CLASSIFICATION CRITERIA; AMERICAN-COLLEGE; RHEUMATOLOGY/EUROPEAN LEAGUE; MUSCULOSKELETAL ULTRASONOGRAPHY; INTEROBSERVER AGREEMENT; CLINICAL EXAMINATION	Introduction. Assessment of synovitis in the metatarsophalangeal (MTP) joints with ultrasound has been shown to improve the accuracy of assessment of rheumatoid arthritis (RA). However, the presence of intraarticular low-echoic synovial area (LESA) in the MTP joints in healthy subjects complicates the sonographic assessment of these joints. Method. Healthy subjects with no arthritic symptoms in their MTP joints were recruited. All subjects completed a questionnaire and underwent physical examination and sonographic assessment. LESAs in the dorsal aspect of all MTP joints were measured in the longitudinal view. Results. One thousand non-arthritic MTP joints in 100 healthy subjects (female 73, mean age 41.0 years old) were evaluated. Measurable LESAs were identified in all joints assessed. Mean length of LESA in each of the 1st-5th MTP joints was 17.8, 13.9, 11.9, 10.6, and 9.2 mm, respectively, whereas mean thickness was 2.4, 2.4, 1.8, 1.2, and 0.8 mm, respectively. Multivariate linear regression models identified the difference between 1st and 5th MTP joints as the most independently influential factor on the measurement of LESA. Conclusions. Our data provide the normal reference values for the measurements of LESA in Japanese, which should be taken into consideration when the synovitis in MTP joints is evaluated with ultrasound.	[Hiraga, Masao; Shigeta, Koichiro] Kirishima Med Ctr, Kagoshima, Japan; [Ikeda, Kei] Chiba Univ Hosp, Dept Allergy & Clin Immunol, Chiba, Chiba 2608677, Japan; [Sato, Akito] Sato Clin, Kagoshima, Japan; [Yoshitama, Tamami] Yoshitama Rheumatoid Arthrit & Internal Med Clin, Kagoshima, Japan; [Hara, Ryota; Tanaka, Yasuhito] Nara Med Univ, Dept Orthopaed Surg, Ctr Rheumat Dis, Kashihara, Nara 634, Japan	Ikeda, K (reprint author), Chiba Univ Hosp, Dept Allergy & Clin Immunol, Chuo Ku, 1-8-1 Inohana, Chiba, Chiba 2608677, Japan.	K.Ikeda@faculty.chiba-u.jp					Kremer JM, 2006, ANN INTERN MED, V144, P865; Brown AK, 2008, ARTHRITIS RHEUM-US, V58, P2958, DOI 10.1002/art.23945; Aletaha D, 2010, ARTHRITIS RHEUM-US, V62, P2569, DOI 10.1002/art.27584; Schmidt WA, 2004, ANN RHEUM DIS, V63, P988, DOI 10.1136/ard.2003.015081; Kawashiri S, 2013, MOD RHEUMATOL, V23, P36, DOI 10.1007/s10165-012-0628-7; Filer A, 2011, ANN RHEUM DIS, V70, P500, DOI 10.1136/ard.2010.131573; PREVOO MLL, 1995, ARTHRITIS RHEUM, V38, P44, DOI 10.1002/art.1780380107; Naredo E, 2008, ARTHRITIS RHEUM, V58, P2248, DOI 10.1002/art.23682; Wittoek R, 2011, ANN RHEUM DIS, V70, P278, DOI 10.1136/ard.2010.134932; Aletaha D, 2010, ANN RHEUM DIS, V69, P1580, DOI 10.1136/ard.2010.138461; Hayashi D, 2011, SEMIN ARTHRITIS RHEU, V41, P116, DOI 10.1016/j.semarthrit.2010.12.003; FELSON DT, 1993, ARTHRITIS RHEUM, V36, P729, DOI 10.1002/art.1780360601; Naredo E, 2005, ANN RHEUM DIS, V64, P375, DOI 10.1136/ard.2004.023929; Ikeda K, 2013, J RHEUMATOL, V40, P1967, DOI 10.3899/jrheum.130556; Freeston JE, 2010, ANN RHEUM DIS, V69, P417, DOI 10.1136/ard.2008.106658; Wakefield RJ, 2012, ANN RHEUM DIS, V71, P799, DOI 10.1136/annrheumdis-2011-201048; Nakagomi D, 2013, ARTHRITIS RHEUM-US, V65, P890, DOI 10.1002/art.37848; Szkudlarek M, 2003, ARTHRITIS RHEUM, V48, P955, DOI 10.1002/art.10877; Dougados M, 2013, ANN RHEUM DIS, V72, P665, DOI 10.1136/annrheumdis-2012-201469; VANDERHEIJDE DMFM, 1990, ANN RHEUM DIS, V49, P916, DOI 10.1136/ard.49.11.916; Kortekaas MC, 2013, ANN RHEUM DIS, V72, P930, DOI 10.1136/annrheumdis-2012-201458; Wakefield RJ, 2004, ANN RHEUM DIS, V63, P382, DOI 10.1136/ard.2003.007062; Marhadour T, 2010, J RHEUMATOL, V37, P932, DOI 10.3899/jrheum.090879; Dougados M, 2010, ANN RHEUM DIS, V69, P828, DOI 10.1136/ard.2009.115493; Wakefield RJ, 2005, J RHEUMATOL, V32, P2485; Backhaus M, 2009, ARTHRIT RHEUM-ARTHR, V61, P1194, DOI 10.1002/art.24646; Yoshimi R, 2013, MOD RHEUMATOL, V23, P456, DOI 10.1007/s10165-012-0690-1; VANDERHEIJDE DMFM, 1992, ARTHRITIS RHEUM, V35, P26; Krasnokutsky S, 2011, ARTHRITIS RHEUM-US, V63, P2983, DOI 10.1002/art.30471; Bakker MF, 2012, ANN RHEUM DIS, V71, P830, DOI 10.1136/annrheumdis-2011-146670; BUDIMANMAK E, 1991, J CLIN EPIDEMIOL, V44, P561, DOI 10.1016/0895-4356(91)90220-4; FUCHS HA, 1994, ARTHRITIS RHEUM, V37, P470, DOI 10.1002/art.1780370406; Fukae J, 2009, MOD RHEUMATOL, V19, P502, DOI 10.1007/s10165-009-0190-0; Hulsmans HMJ, 2000, ARTHRITIS RHEUM, V43, P1927, DOI 10.1002/1529-0131(200009)43:9<1927::AID-ANR3>3.0.CO;2-B; Iagnocco A, 2011, CLIN EXP RHEUMATOL, V29, P757; Iwamoto T, 2014, ARTHRIT CARE RES, V66, P1576, DOI 10.1002/acr.22303; Kapral T, 2007, ARTHRITIS RES THER, V9, DOI 10.1186/ar2270; Keen HI, 2011, ANN RHEUM DIS, V70, P2140, DOI 10.1136/annrheumdis-2011-200349; Landewe R, 2006, ANN RHEUM DIS, V65, P637, DOI 10.1136/ard.2005.039859; Landewe RBM, 2011, J RHEUMATOL, V38, P2018, DOI 10.3899/jrheum.110417; Le Boedec M, 2013, J RHEUMATOL, V40, P244, DOI 10.3899/jrheum.120843; Ogishima H, 2013, MOD RHEUMATOL; Salaffi F, 2008, RHEUMATOLOGY, V47, P54, DOI 10.1093/rheumatology/kem286; Sheane BJ, 2009, ARTHRIT RHEUM-ARTHR, V61, P1004, DOI 10.1002/art.24564; SMOLEN JS, 1995, ARTHRITIS RHEUM, V38, P38, DOI 10.1002/art.1780380106; van der Leeden M, 2007, CLIN EXP RHEUMATOL, V25, P275; van Tuyl LHD, 2012, ANN RHEUM DIS, V71, P33, DOI 10.1136/ard.2011.153742	47	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1439-7595	1439-7609		MOD RHEUMATOL	Mod. Rheumatol.	MAY	2015	25	3					386	392		10.3109/14397595.2014.970740		7	Rheumatology	Rheumatology	CH1HS	WOS:000353772900009		
J	Asanuma, YF; Mimura, T; Tsuboi, H; Noma, H; Miyoshi, F; Yamamoto, K; Sumida, T				Asanuma, Yu Funakubo; Mimura, Toshihide; Tsuboi, Hiroto; Noma, Hisashi; Miyoshi, Fumihiko; Yamamoto, Kazuhiko; Sumida, Takayuki			Nationwide epidemiological survey of 169 patients with adult Still's disease in Japan	MODERN RHEUMATOLOGY			English	Article						Adult Still's disease; Ferritin; Methotrexate; Multicenter study; Tocilizumab	HEMOPHAGOCYTIC SYNDROME; TOCILIZUMAB; MARKER; MANIFESTATIONS; FERRITIN	Objectives. A nationwide survey was conducted to assess the number of patients, clinical aspects, treatment, and prognosis of adult Still's disease (ASD) in Japan. Methods. A primary questionnaire was sent to randomly selected medical institutions in order to estimate the number of patients. We sent a secondary questionnaire to the same institutions to characterize the clinical manifestations and treatment of ASD. Results. The estimated prevalence of ASD was 3.9 per 100,000. Analysis of 169 patients showed a mean age at onset of 46 years. The main clinical symptoms were fever, arthritis, and typical rash in agreement with previous surveys. Oral glucocorticoids were used to treat 96% of the patients, while methotrexate was used in 41% and biological agents were used in 16%. Lymphadenopathy and macrophage activation syndrome were significantly associated with increased risk of relapse (P < 0.05, each). Patients who achieved remission after tocilizumab therapy had significantly longer disease duration (6.2 years) than patients who did not (1.9 years) (p < 0.05). Conclusions. The 2010-2011 nationwide survey of ASD identified important changes in treatment and improvement of prognosis compared with previous surveys.	[Asanuma, Yu Funakubo; Mimura, Toshihide; Miyoshi, Fumihiko] Saitama Med Univ, Dept Rheumatol & Appl Immunol, Fac Med, Moroyama, Saitama 3500495, Japan; [Tsuboi, Hiroto; Sumida, Takayuki] Univ Tsukuba, Dept Internal Med, Fac Med, Ibaraki, Japan; [Noma, Hisashi] Inst Stat Math, Dept Data Sci, Tokyo, Japan; [Yamamoto, Kazuhiko] Univ Tokyo, Grad Sch Med, Dept Allergy & Rheumatol, Tokyo, Japan; [Mimura, Toshihide; Tsuboi, Hiroto; Yamamoto, Kazuhiko; Sumida, Takayuki] Minist Hlth Labor & Welf, Res Team Autoimmune Dis, Res Program Intractable Dis, Tokyo, Japan	Asanuma, YF (reprint author), Saitama Med Univ, Dept Rheumatol & Appl Immunol, Fac Med, 38 Morohongo, Moroyama, Saitama 3500495, Japan.	yu2asa@aol.com			Ministry of Education, Culture, Sports, Science and Technology of Japan; Ministry of Health, Labour and Welfare of Japan	This study was supported by research grants from the Ministry of Education, Culture, Sports, Science and Technology of Japan, and Health and Labour Sciences Research Grants for research on intractable diseases (The Research Team for Autoimmune Diseases) from the Ministry of Health, Labour and Welfare of Japan.	Akritidis N, 1996, J RHEUMATOL, V23, P201; Arlet JB, 2006, ANN RHEUM DIS, V65, P1596, DOI 10.1136/ard.2005.046904; YAMAGUCHI M, 1992, J RHEUMATOL, V19, P424; White IR, 2011, STAT MED, V30, P377, DOI 10.1002/sim.4067; POUCHOT J, 1991, MEDICINE, V70, P118; OHTA A, 1990, J RHEUMATOL, V17, P1058; SCHWARZEYWILL M, 1992, ANN RHEUM DIS, V51, P683, DOI 10.1136/ard.51.5.683; Kawaguchi Y, 2001, ARTHRITIS RHEUM, V44, P1716, DOI 10.1002/1529-0131(200107)44:7<1716::AID-ART298>3.0.CO;2-I; Puechal X, 2011, ARTHRIT CARE RES, V63, P155, DOI 10.1002/acr.20319; Gerfaud-Valentin M, 2014, MEDICINE, V93, P91, DOI 10.1097/MD.0000000000000021; Suematsu R, 2012, MOD RHEUMATOL, V22, P712, DOI 10.1007/s10165-011-0569-6; Mitamura M, 2009, MOD RHEUMATOL, V19, P57, DOI 10.1007/s10165-008-0126-0; de Boysson H, 2013, CLIN RHEUMATOL, V32, P141, DOI 10.1007/s10067-012-2105-2; Sawhney S, 2001, ARCH DIS CHILD, V85, P421, DOI 10.1136/adc.85.5.421; Yokota S, 2014, J RHEUMATOL, V41, P759, DOI 10.3899/jrheum.130690; COFFERNILS M, 1992, J RHEUMATOL, V19, P1425; BYWATERS EG, 1971, ANN RHEUM DIS, V30, P121, DOI 10.1136/ard.30.2.121; MAGADURJOLY G, 1995, ANN RHEUM DIS, V54, P587, DOI 10.1136/ard.54.7.587; Bannai E, 2014, MOD RHEUMATOL; Elcon KB, 1982, ARTHRITIS RHEUM, V25, P647; Ortiz-Sanjuan F, 2014, ARTHRITIS RHEUMATOL, V66, P1659, DOI 10.1002/art.38398; Scheinberg MA, 1996, CLIN EXP RHEUMATOL, V14, P653; Wakai K, 1997, J Epidemiol, V7, P221	23	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1439-7595	1439-7609		MOD RHEUMATOL	Mod. Rheumatol.	MAY	2015	25	3					393	400		10.3109/14397595.2014.974881		8	Rheumatology	Rheumatology	CH1HS	WOS:000353772900010		
J	Nishina, N; Kaneko, Y; Kameda, H; Takeuchi, T				Nishina, Naoshi; Kaneko, Yuko; Kameda, Hideto; Takeuchi, Tsutomu			The effect of tocilizumab on preventing relapses in adult-onset Still's disease: A retrospective, single-center study	MODERN RHEUMATOLOGY			English	Article						Adult-onset Still's disease; Glucocorticoids; Relapse; Tocilizumab	JUVENILE IDIOPATHIC ARTHRITIS; EFFICACY; TRIAL	Objectives. To investigate the clinical effectiveness of tocilizumab (TCZ), a monoclonal antibody against the interleukin-6 receptor, in preventing relapse in patients with adult-onset Still's disease (AOSD). Methods. This retrospective study included clinical data from 40 patients who underwent regular follow-up at our institution in June 2013. Among these patients, 10 received TCZ. The relapse-free rate was analyzed by the Kaplan-Meier method. Results. The age at disease onset (median, interquartile range [IQR]) was 39 (29-52) years. The duration of disease in June 2013 (median, IQR) was 86 (41-193) months. A total of 87 relapses were documented in 27 patients. Ten patients with refractory or relapsing disease received 8 mg/kg of TCZ every 2-4 weeks. After 6 months of TCZ treatment, the median levels of C-reactive protein significantly decreased from 6.3 to 0.01 mg/dl (p<0.01). Among these 10 patients, 11 relapses were observed before TCZ treatment, and none were observed after the treatment. The relapse-free rate of the 10 patients after starting TCZ was significantly higher than that of all 40 patients after the initial treatments (100% and 67% at 12 months, respectively; p = 0.03). Conclusions. TCZ effectively prevented relapses of AOSD, and it resolved the disease activity.	[Nishina, Naoshi; Kaneko, Yuko; Kameda, Hideto; Takeuchi, Tsutomu] Keio Univ, Sch Med, Div Rheumatol, Dept Internal Med, Tokyo 1608582, Japan; [Kameda, Hideto] Toho Univ, Ohashi Med Ctr, Div Rheumatol, Dept Internal Med, Tokyo, Japan	Nishina, N (reprint author), Keio Univ, Sch Med, Div Rheumatol, Dept Internal Med,Shinjuku Ku, 35 Shinanomachi, Tokyo 1608582, Japan.	nnishina@a7.keio.jp	Takeuchi, Tsutomu/L-2327-2013	Takeuchi, Tsutomu/0000-0003-1111-8218	Chugai Pharmaceutical Co., Ltd.	NN declare no conflict of interest. YK and HK received grant/research support from Chugai Pharmaceutical Co., Ltd. TT received grant/research support and consulting fees from Chugai Pharmaceutical Co., Ltd.	YAMAGUCHI M, 1992, J RHEUMATOL, V19, P424; POUCHOT J, 1991, MEDICINE, V70, P118; Elkayam O, 2014, J RHEUMATOL, V41, P244, DOI 10.3899/jrheum.130881; Puechal X, 2011, ARTHRIT CARE RES, V63, P155, DOI 10.1002/acr.20319; Cipriani P, 2014, CLIN RHEUMATOL, V33, P49, DOI 10.1007/s10067-013-2381-5; Suematsu R, 2012, MOD RHEUMATOL, V22, P712, DOI 10.1007/s10165-011-0569-6; Yokota S, 2008, LANCET, V371, P998, DOI 10.1016/S0140-6736(08)60454-7; Fautrel B, 2008, BEST PRACT RES CL RH, V22, P773, DOI 10.1016/j.berh.2008.08.006; Bannai E, 2014, MOD RHEUMATOL; De Benedetti F, 2012, NEW ENGL J MED, V367, P2385, DOI 10.1056/NEJMoa1112802; Ortiz-Sanjuan F, 2014, ARTHRITIS RHEUMATOL, V66, P1659, DOI 10.1002/art.38398; Wakai K, 1997, J Epidemiol, V7, P221	12	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1439-7595	1439-7609		MOD RHEUMATOL	Mod. Rheumatol.	MAY	2015	25	3					401	404		10.3109/14397595.2014.973659		4	Rheumatology	Rheumatology	CH1HS	WOS:000353772900011		
J	Aoki, S; Mochimaru, A; Yamamoto, Y; Kurasawa, K; Takahashi, T; Hirahara, F				Aoki, Shigeru; Mochimaru, Aya; Yamamoto, Yuriko; Kurasawa, Kentaro; Takahashi, Tsuneo; Hirahara, Fumiki			Pregnancy outcomes of women with coexisting systemic lupus erythematosus flare and preeclampsia	MODERN RHEUMATOLOGY			English	Article						Coexistence; Preeclampsia; Pregnancy; SLE flare	NEPHRITIS; SLE; CLASSIFICATION	Objectives. Systemic lupus erythematosus (SLE) flare and preeclampsia are difficult to differentiate from each other and occasionally coexist; This study aimed to analyze cases requiring termination of pregnancy due to SLE flare or preeclampsia and to elucidate the association between these two conditions; Methods. Out of 71 pregnancies in 60 women managed for SLE-complicated pregnancies who delivered at or after 22 weeks' gestation at a tertiary center, 7 pregnancies were terminated due to uncontrollable severe SLE flare or severe preeclampsia We retrospectively analyzed the clinical courses and laboratory findings of these 7 cases to determine whether their pathological conditions were attributable to SLE flare alone, preeclampsia alone, or the coexistence of these two conditions. Results. One of the 7 cases had preeclampsia alone, two had SLE alone, and four had both conditions. The coexistence of preeclampsia and SLE was thus the most common condition. In cases with both conditions, SLE flare had preceded preeclampsia, thereby making treatment after delivery difficult. Conclusion. Severe SLE flare often preceded severe preeclampsia and worsened after delivery. When differentiating severe SLE flare from severe preeclampsia is difficult during pregnancy, women should be regarded as having SLE flare rather than preeclampsia and aggressively treated.	[Aoki, Shigeru; Mochimaru, Aya; Yamamoto, Yuriko; Kurasawa, Kentaro; Takahashi, Tsuneo] Yokohama City Univ, Med Ctr, Perinatal Ctr Matern & Neonate, Yokohama, Kanagawa 2320024, Japan; [Hirahara, Fumiki] Yokohama City Univ Med, Dept Obstet & Gynecol, Yokohama, Kanagawa, Japan	Aoki, S (reprint author), Yokohama City Univ, Med Ctr, Perinatal Ctr Matern & Neonate, Minami Ku, 4-57 Urafunecyou, Yokohama, Kanagawa 2320024, Japan.			Aoki, Shigeru/0000-0001-5307-575X			Moroni G, 2003, J NEPHROL, V16, P161; LOCKSHIN MD, 1984, AM J MED, V77, P893, DOI 10.1016/0002-9343(84)90538-2; Moroni G, 2002, AM J KIDNEY DIS, V40, P713, DOI 10.1053/ajkd.2002.35678; UROWITZ MB, 1993, ARTHRITIS RHEUM, V36, P1392, DOI 10.1002/art.1780361011; Hochberg MC, 1997, ARTHRITIS RHEUM, V40, P1725, DOI 10.1002/art.1780400928; Petri M, 1999, LUPUS, V8, P685, DOI 10.1191/096120399680411281; RuizIrastorza G, 1996, BRIT J RHEUMATOL, V35, P133; Huong DLT, 2001, ANN RHEUM DIS, V60, P599, DOI 10.1136/ard.60.6.599; Liu JT, 2012, J MATERN-FETAL NEO M, V25, P261, DOI 10.3109/14767058.2011.572310; Baer AN, 2011, OBSTET GYNECOL SURV, V66, P639, DOI 10.1097/OGX.0b013e318239e1ee; PETRI M, 1991, ARTHRITIS RHEUM, V34, P1538; Kwok LW, 2011, LUPUS, V20, P829, DOI 10.1177/0961203310397967; Al Arfaj AS, 2010, LUPUS, V19, P1665, DOI 10.1177/0961203310378669; Chakravarty EF, 2006, ARTHRITIS RHEUM, V54, P899, DOI 10.1002/art.21663; Chakravarty EF, 2005, AM J OBSTET GYNECOL, V192, P1897, DOI 10.1016/j.ajog.2005.02.063; Aoki S, 2014, PREGNANCY HYPERTENS, V4, P81, DOI 10.1016/j.preghy.2013.11.006; Clowse MEB, 2008, AM J OBSTET GYNECOL, V199, DOI 10.1016/j.ajog.2008.03.012; Fatemi Alimohammad, 2013, Int J Prev Med, V4, P1004; Johns KR, 1998, AUST NZ J MED, V28, P18, DOI 10.1111/j.1445-5994.1998.tb04453.x; Molad Y., 2005, Lupus, V14, P145, DOI 10.1191/0961203305lu2072oa; Repke JT, 1998, J REPROD MED, V43, P350; Ruiz-Irastorza G, 2004, LUPUS, V13, P679, DOI 10.1191/0961203304lu1099oa; Yang Ming-Jie, 2006, J Chin Med Assoc, V69, P130	23	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1439-7595	1439-7609		MOD RHEUMATOL	Mod. Rheumatol.	MAY	2015	25	3					410	414		10.3109/14397595.2014.979522		5	Rheumatology	Rheumatology	CH1HS	WOS:000353772900013		
J	Yokosawa, M; Tsuboi, H; Nasu, K; Hagiya, C; Hagiwara, S; Hirota, T; Ebe, H; Takahashi, H; Asashima, H; Kondo, Y; Ogishima, H; Suzuki, T; Minami, M; Bukawa, H; Matsumoto, I; Sumida, T				Yokosawa, Masahiro; Tsuboi, Hiroto; Nasu, Katsuhiro; Hagiya, Chihiro; Hagiwara, Shinya; Hirota, Tomoya; Ebe, Hiroshi; Takahashi, Hiroyuki; Asashima, Hiromitsu; Kondo, Yuya; Ogishima, Hiroshi; Suzuki, Takeshi; Minami, Manabu; Bukawa, Hiroki; Matsumoto, Isao; Sumida, Takayuki			Usefulness of MR imaging of the parotid glands in patients with secondary Sjogren's syndrome associated with rheumatoid arthritis	MODERN RHEUMATOLOGY			English	Article						MR imaging; Parotid glands; Sjogren's syndrome; Rheumatoid arthritis	CLASSIFICATION CRITERIA; AMERICAN-COLLEGE; SALIVARY-GLANDS; SIALOGRAPHY	Objective. To assess the correlation between MR imaging (MRI) of parotid glands with X-ray sialography, histopathology of the labial salivary glands, and salivary secretion, in patients with secondary Sjogren's syndrome (SS) associated with rheumatoid arthritis (RA). Methods. Non-contrast MRI of the parotid glands was performed in 13 secondary SS patients associated with RA who satisfied the revised Japanese diagnostic criteria for SS (1999), and the ACR/EULAR classification criteria for RA (2010). The MRI findings were classified according to the degree of high-intensity signal on T1-weighted images (T1WI) and short inversion time inversion recovery (STIR) images into five grades (0-4), using the modified Nagasaki University grading method. The results of MRI grading were compared with the Rubin and Holt staging of X-ray sialography (0-4), the Greenspan grading of labial salivary gland histopathology (0-4), and salivary secretion by the gum test (ml/10 min). Results. All 13 patients were females, with a mean age of 50.2 +/- 11.3 years. According to the MRI grading, 3 patients were Grade 1, 5 were Grade 2, 5 were Grade 3, and none was Grade 0 or Grade 4. The mean stage by X-ray sialography was 1.7 +/- 1.0, the mean grade by histopathology was 2.4 +/- 1.2, and the mean volume of salivary secretion was 9.7 +/- 3.9 ml. The MRI grading correlated significantly with the Rubin and Holt staging and Greenspan grading (P<0.01 each, Spearman's rank correlation), and significantly and inversely with the results of the gum test (P<0.05). Conclusion. The results suggest that MRI of the parotid glands is a useful noninvasive tool for evaluating destruction and inflammation in the salivary glands.	[Yokosawa, Masahiro; Tsuboi, Hiroto; Hagiya, Chihiro; Hagiwara, Shinya; Hirota, Tomoya; Ebe, Hiroshi; Takahashi, Hiroyuki; Asashima, Hiromitsu; Kondo, Yuya; Ogishima, Hiroshi; Suzuki, Takeshi; Matsumoto, Isao; Sumida, Takayuki] Univ Tsukuba, Dept Internal Med, Fac Med, Tsukuba, Ibaraki 3058575, Japan; [Nasu, Katsuhiro; Minami, Manabu] Univ Tsukuba, Dept Radiol, Fac Med, Tsukuba, Ibaraki 3058575, Japan; [Bukawa, Hiroki] Univ Tsukuba, Dept Oral & Maxillofacial Surg, Fac Med, Tsukuba, Ibaraki 3058575, Japan	Sumida, T (reprint author), Univ Tsukuba, Dept Internal Med, Fac Med, 1-1-1 Tennodai, Tsukuba, Ibaraki 3058575, Japan.	tsumida@md.tsukuba.ac.jp			Ministry of Health, Labour and Welfare of Japan; Ministry of Education, Culture, Sports, Science and Technology; Japan Society for the Promotion of Science	We thank Dr. F. G. Issa for the critical reading of the manuscript. This work was supported in part by the Health and Labour Sciences Research Grants for research on intractable diseases from the Ministry of Health, Labour and Welfare of Japan, and Grants-in-Aid for Scientific Research (Grant-in-Aid for Young Scientists (B)) from the Ministry of Education, Culture, Sports, Science and Technology and Japan Society for the Promotion of Science.	Aletaha D, 2010, ARTHRITIS RHEUM-US, V62, P2569, DOI 10.1002/art.27584; Ramos-Casals M, 2007, RHEUMATOLOGY, V46, P1389, DOI 10.1093/rheumatology/kem078; Seror R, 2010, ANN RHEUM DIS, V69, P1103, DOI 10.1136/ard.2009.110619; Seror R, 2011, ANN RHEUM DIS, V70, P968, DOI 10.1136/ard.2010.143743; Vitali C, 2002, ANN RHEUM DIS, V61, P554, DOI 10.1136/ard.61.6.554; RUBIN P, 1957, AMER J ROENTGENOL RA, V77, P575; Shiboski SC, 2012, ARTHRIT CARE RES, V64, P475, DOI 10.1002/acr.21591; Fujibayashi T, 2004, MOD RHEUMATOL, V14, P425; GREENSPA.JS, 1974, ORAL SURG ORAL MED O, V37, P217, DOI 10.1016/0030-4220(74)90417-4; Izumi M, 1996, AM J ROENTGENOL, V166, P1483; Izumi M, 1997, AM J NEURORADIOL, V18, P951; Meijer JM, 2007, CLIN REV ALLERG IMMU, V32, P292, DOI 10.1007/s12016-007-8005-6; Miedany EI YM, 2004, JOINT BONE SPINE, V71, P29; Morimoto Y, 2006, ORAL DIS, V12, P408, DOI 10.1111/j.1601-0825.2005.01215.x; Roberts C, 2008, RADIOLOGY, V246, P845, DOI 10.1148/radiol.2463070298; SPATH M, 1991, J RHEUMATOL, V18, P1372; TAKASHIMA S, 1991, J COMPUT ASSIST TOMO, V15, P393, DOI 10.1097/00004728-199105000-00009; Tonami H, 2001, J COMPUT ASSIST TOMO, V25, P262, DOI 10.1097/00004728-200103000-00020; Tonami H, 1998, AM J NEURORADIOL, V19, P1199; Tsuboi H, 2013, MOD RHEUMATOL; VALESINI G, 1994, SCAND J RHEUMATOL, V23, P103; Vissink A, 2010, JAMA-J AM MED ASSOC, V304, P2015, DOI 10.1001/jama.2010.1582; Youinou P, 2011, ARTHRITIS RES THER, V13, DOI 10.1186/ar3348	23	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1439-7595	1439-7609		MOD RHEUMATOL	Mod. Rheumatol.	MAY	2015	25	3					415	420		10.3109/14397595.2014.958892		6	Rheumatology	Rheumatology	CH1HS	WOS:000353772900014		
J	Maki, M; Ikoma, K; Imai, K; Kido, M; Hara, Y; Arai, Y; Fujiwara, H; Kubo, T				Maki, Masahiro; Ikoma, Kazuya; Imai, Kan; Kido, Masamitsu; Hara, Yusuke; Arai, Yuji; Fujiwara, Hiroyoshi; Kubo, Toshikazu			Correlation between the outcome of extracorporeal shockwave therapy and pretreatment MRI findings for chronic plantar fasciitis	MODERN RHEUMATOLOGY			English	Article						Chronic plantar fasciitis; Extracorporeal shockwave therapy; Magnetic resonance imaging; Multiple logistic regression analysis; Visual Analog Scale	STANDARD RATING SYSTEM; WAVE THERAPY; HEEL PAIN; RISK-FACTORS; FOLLOW-UP; RELIABILITY; FOOT; SPUR; ESWT	Background. The purpose of this study was to investigate the relationship between magnetic resonance imaging (MRI) findings before extracorporeal shockwave therapy (ESWT) and the treatment outcome of ESWT. Methods. This study examined 50 feet with chronic plantar fasciitis. The scores before ESWT and after a six-month follow-up were investigated using the Japanese Society for Surgery of the Foot (JSSF) Ankle-Hindfoot Scale and the Visual Analog Scale (VAS). MRI before ESWT was used for image evaluation. MRI revealed thickening of the plantar fascia (PF), and an investigation was conducted regarding the findings of a high-signal-intensity area (HSIA) inside the PF, edema near the PF, and bone marrow edema (BME) of the calcaneus. Results. The average JSSF score and VAS score improved significantly at follow-up. In total, 44 feet were noted in the improved group. MRI revealed that the average amounts of PF thickening did not significantly differ between the improved group and the non-improved group. HSIA, edema near the PF, and BME were observed in 36, 41, and 11 feet in the improved group, respectively; and 2, 4, and 2 feet in the non-improved group, respectively. Conclusions. An HSIA in the PF predicted symptom improvement more easily than other MRI findings.	[Maki, Masahiro; Ikoma, Kazuya; Imai, Kan; Kido, Masamitsu; Hara, Yusuke; Arai, Yuji; Fujiwara, Hiroyoshi; Kubo, Toshikazu] Kyoto Prefectural Univ Med, Grad Sch Med Sci, Dept Orthopaed, Kamigyo Ku, Kyoto, Japan	Ikoma, K (reprint author), Kyoto Prefectural Univ Med, Grad Sch Med Sci, Dept Orthopaed, Kamigyo Ku, 465 Kajii Cho, Kyoto, Japan.	kazuya@koto.kpu-m.ac.jp					Riddle D, 2003, J BONE JOINT SURG AM, V85A, P872; DiGiovanni BF, 2003, J BONE JOINT SURG AM, V85A, P1270; Rompe JD, 2009, SPORTS MED ARTHROSC, V17, P100, DOI 10.1097/JSA.0b013e3181a3d60e; Niki H, 2005, J ORTHOP SCI, V10, P466, DOI 10.1007/s00776-005-0937-1; Lemont H, 2003, J AM PODIAT MED ASSN, V93, P234; Hammer DS, 2003, FOOT ANKLE INT, V24, P823; Farrar JT, 2001, PAIN, V94, P149, DOI 10.1016/S0304-3959(01)00349-9; Goff JD, 2011, AM FAM PHYSICIAN, V84, P676; WOLGIN M, 1994, FOOT ANKLE INT, V15, P97; Theodore GH, 2004, FOOT ANKLE INT, V25, P290; BERKOWITZ JF, 1991, RADIOLOGY, V179, P665; Niki H, 2005, J ORTHOP SCI, V10, P457, DOI 10.1007/s00776-005-0936-2; Bader L, 2012, FOOT ANKLE INT, V33, P37, DOI 10.3113/FAI.2012.0037; [Anonymous], 2001, CLIN ORTHOPAEDICS, DOI 10.1097/00003086-200106000-00007; Grasel RP, 1999, AM J ROENTGENOL, V173, P699; TURK DC, 1993, PAIN, V53, P3, DOI 10.1016/0304-3959(93)90049-U; Chimutengwende-Gordon M, 2010, FOOT ANKLE INT, V31, P865, DOI 10.3113/FAI.2010.0865; Chuckpaiwong B, 2009, J FOOT ANKLE SURG, V48, P148, DOI 10.1053/j.jfas.2008.11.001; Covey CJ, 2013, J FAM PRACTICE, V62, P466; DAVIS PF, 1994, FOOT ANKLE INT, V15, P531; Gill LH, 1997, J AM ACAD ORTHOP SUR, V5, P109; Guner S, 2013, ORTHOPEDICS, V36, pE1322, DOI 10.3928/01477447-20130920-27; HUSKISSO.EC, 1974, LANCET, V2, P1127; Kumai T, 2002, J RHEUMATOL, V29, P1957; Maier M, 2000, J RHEUMATOL, V27, P2455; Metzner G, 2010, FOOT ANKLE INT, V31, P790, DOI 10.3113/FAI.2010.0790; PRICHASUK S, 1994, CLIN ORTHOP RELAT R, P192; Rano J A, 2001, J Foot Ankle Surg, V40, P351; Rompe JD, 1998, J BONE JOINT SURG BR, V80B, P546, DOI 10.1302/0301-620X.80B3.8434; Scher DL, 2009, J BONE JOINT SURG AM, V91A, P2867, DOI 10.2106/JBJS.I.00257; Steinborn M, 1999, ROFO-FORTSCHR RONTG, V170, P41; Weil Lowell Scott Jr, 2002, J Foot Ankle Surg, V41, P166; Werner RA, 2010, PM&R, V2, P110, DOI 10.1016/j.pmrj.2009.11.012; Zhu F, 2005, RADIOLOGY, V234, P206, DOI 10.1148/radiol.2341031653	34	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1439-7595	1439-7609		MOD RHEUMATOL	Mod. Rheumatol.	MAY	2015	25	3					427	430		10.3109/14397595.2014.978526		4	Rheumatology	Rheumatology	CH1HS	WOS:000353772900016		
J	Mori, Y; Kuwahara, Y; Chiba, S; Itoi, E				Mori, Yu; Kuwahara, Yoshiyuki; Chiba, Shinpei; Itoi, Eiji			Efficacy of methotrexate and tumor necrosis factor inhibitors in Japanese patients with active psoriatic arthritis	MODERN RHEUMATOLOGY			English	Article						Methotrexate; Psoriatic arthritis; Psoriasis; Tumor necrosis factor inhibitors	PLACEBO-CONTROLLED TRIAL; QUALITY-OF-LIFE; LONG-TERM TREATMENT; DOUBLE-BLIND; ADALIMUMAB EFFECTIVENESS; IMPACT-2 TRIAL; INFLIXIMAB; THERAPY; MANIFESTATIONS; CRITERIA	Objective. The aim of this study was to assess the efficacy of oral methotrexate and tumor necrosis factor inhibitors in Japanese patients with active psoriatic arthritis. Methods. We retrospectively investigated 51 patients who fulfilled the ClASsification criteria for Psoriatic ARthritis (CASPAR) criteria for the efficacy of tumor necrosis factor inhibitors and methotrexate. We assessed the visual analog scale score, psoriasis area and severity index score, C-reactive protein-based disease activity score in 28 joints (DAS28), swollen joint count (0-66), tender joint count (0-68), health assessment questionnaire score, C-reactive protein level, erythrocyte sedimentation rate, and matrix metalloproteinase 3, at both baseline and week 24. Results. Of the 51 patients, 34 were male and 17 were female, with a mean age of 50.3 +/- 13.2 years. The duration of psoriasis to onset of arthritis was 10.2 +/- 9.1 years. At week 24, in the group treated with the tumor necrosis factor inhibitor plus methotrexate, the tender joint count declined from 6.05 +/- 5.84 to 0.43 +/- 1.03, the swollen joint count declined from 6.42 +/- 4.36 to 0.00 +/- 0.00, and the DAS28 declined from 4.35 +/- 0.82 to 2.04 +/- 0.68. In the group treated with methotrexate alone, the tender joint count declined from 3.70 +/- 1.76 to 0.60 +/- 0.86, the swollen joint count declined from 5.26 +/- 4.00 to 0.27 +/- 0.70, and the DAS28 declined from 3.91 +/- 0.82 to 1.94 +/- 0.53. There were no significant differences in the mean reduction in clinical measurements between the two groups. Conclusion. Our study demonstrated that methotrexate and tumor necrosis factor inhibitors are effective for the treatment of active psoriatic arthritis in Japanese patients.	[Mori, Yu; Kuwahara, Yoshiyuki; Chiba, Shinpei; Itoi, Eiji] Tohoku Univ, Dept Orthopaed Surg, Grad Sch Med, Sendai, Miyagi 9808574, Japan	Mori, Y (reprint author), Tohoku Univ, Dept Orthopaed Surg, Grad Sch Med, Aoba Ku, Seiryo Machi, Sendai, Miyagi 9808574, Japan.	yu-mori@med.tohoku.ac.jp					Mease PJ, 2009, ANN RHEUM DIS, V68, P702, DOI 10.1136/ard.2008.092767; Mease PJ, 2004, ARTHRITIS RHEUM, V50, P2264, DOI 10.1002/art.20335; Kavanaugh A, 2007, ANN RHEUM DIS, V66, P498, DOI 10.1136/ard.2006.058339; Sokoll KB, 2001, J RHEUMATOL, V28, P1842; Wong K, 1997, ARTHRITIS RHEUM-US, V40, P1868, DOI 10.1002/art.1780401021; Shbeeb M, 2000, J RHEUMATOL, V27, P1247; DOUGADOS M, 1991, ARTHRITIS RHEUM, V34, P1218, DOI 10.1002/art.1780341003; Antoni C, 2005, ANN RHEUM DIS, V64, P1150, DOI 10.1136/ard.2004.032268; Gladman DD, 1998, ARTHRITIS RHEUM-US, V41, P1103, DOI 10.1002/1529-0131(199806)41:6<1103::AID-ART18>3.0.CO;2-N; VANDERLINDEN S, 1984, ARTHRITIS RHEUM, V27, P361; Gladman DD, 2007, ARTHRITIS RHEUM, V56, P476, DOI 10.1002/art.22379; Kavanaugh A, 2009, ARTHRITIS RHEUM, V60, P976, DOI 10.1002/art.24403; Kingsley GH, 2012, RHEUMATOLOGY, V51, P1368, DOI 10.1093/rheumatology/kes001; Alenius GM, 2002, J RHEUMATOL, V29, P2577; Mease PJ, 2005, ARTHRITIS RHEUM, V52, P3279, DOI 10.1002/art.21306; Taylor W, 2006, ARTHRITIS RHEUM, V54, P2665, DOI 10.1002/art.21972; Mease PJ, 2006, J RHEUMATOL, V33, P712; Antoni CE, 2005, ARTHRITIS RHEUM, V52, P1227, DOI 10.1002/art.20967; Ritchlin CT, 2009, ANN RHEUM DIS, V68, P1387, DOI 10.1136/ard.2008.094946; Kyle S, 2005, RHEUMATOLOGY, V44, P390, DOI 10.1093/rheumatology/keh514; Fagerli KM, 2014, ANN RHEUM DIS, V73, P132, DOI 10.1136/annrheumdis-2012-202347; WILLKENS RF, 1984, ARTHRITIS RHEUM, V27, P376, DOI 10.1002/art.1780270403; Koo J, 1996, DERMATOL CLIN, V14, P485, DOI 10.1016/S0733-8635(05)70376-4; Kavanaugh A, 2006, ANN RHEUM DIS, V65, P1038, DOI 10.1136/ard.2005.045658; Zachariae H, 2003, AM J CLIN DERMATOL, V4, P441, DOI 10.2165/00128071-200304070-00001; Torii H, 2010, J DERMATOL SCI, V59, P40, DOI 10.1016/j.jdermsci.2010.04.014; BLACK RL, 1964, JAMA-J AM MED ASSOC, V189, P743; Dernis E, 2009, JOINT BONE SPINE, V76, P524, DOI 10.1016/j.jbspin.2009.03.002; Gladman DD, 2009, J RHEUMATOL, V36, P4, DOI 10.3899/jrheum.090209; Gottlieb A, 2008, J AM ACAD DERMATOL, V58, P851, DOI 10.1016/j.jaad.2008.02.040; LEONARD DG, 1978, MAYO CLIN PROC, V53, P511; Leung YY, 2013, J RHEUMATOL, V40, P859, DOI 10.3899/jrheum.120782; Maejima H, 2010, J DERMATOL, V37, P647, DOI 10.1111/j.1346-8138.2010.00919.x; Menter A, 2009, J AM ACAD DERMATOL, V61, P451, DOI 10.1016/j.jaad.2009.03.027; Ohtsuki M, 2011, JPN J DERMATOL, V121, P1561; Torii H, 2011, J DERMATOL, V38, P310, DOI 10.1111/j.1346-8138.2010.00971.x; Tsuji S, 2013, MOD RHEUMATOL, V23, P529, DOI 10.1007/s10165-012-0700-3	37	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1439-7595	1439-7609		MOD RHEUMATOL	Mod. Rheumatol.	MAY	2015	25	3					431	434		10.3109/14397595.2014.958891		4	Rheumatology	Rheumatology	CH1HS	WOS:000353772900017		
J	Kamo, K; Shuto, T; Haraguchi, A				Kamo, Kenta; Shuto, Toshihide; Haraguchi, Akihisa			Prevalence of spondyloarthritis symptom in inflammatory bowel disease patients: A questionnaire survey	MODERN RHEUMATOLOGY			English	Article						Crohns' disease; Spondyloarthritis; Ulcerative colitis	SOCIETY CLASSIFICATION CRITERIA; MANIFESTATIONS; VALIDATION; FEATURES; COHORT	Objectives. We clarified the prevalence of spondyloarthritis (SpA) symptom in inflammatory bowel disease (IBD). Methods. We performed the questionnaire survey of SpA symptom in IBD patients on their office visit. Results. One hundred and thirty seven patients were evaluated. The SpA features group included 46 (33.6%) patients (32 Men). Among them there were 22 Crohn's disease (CD) patients and 24 ulcerative colitis (UC) patients. The patients had a mean age of 48.3 years with a mean disease duration of 12.3 years. Non-SpA group (66.4%) included 91 patients (49 Men). Among them there were 27 CD patients and 64 UC patients. The patients had a mean age of 43.3 years with a mean disease duration of 9.2 years. In univariate analysis, the SpA group (33.6%) had longer disease duration than non-SpA group (p<0.05). However, age at onset and sex were not significantly different among the groups. Multivariate analysis showed that disease duration was independently associated with SpA symptom (OR, 1.05; 95% CI, 1-1.09; p=0.036). Conclusions. The prevalence of SpA symptom was relatively higher than what we had expected. Physicians should consider SpA when they observe IBD patients with arthralgia, and refer them to an appropriate department if needed.	[Kamo, Kenta; Haraguchi, Akihisa] Yamaguchi Red Cross Hosp, Dept Orthopaed Surg, Yamaguchi 7538519, Japan; [Shuto, Toshihide] Chiyoda Hosp, Dept Rheumatol & Orthopaed Surg, Miyazaki, Japan	Kamo, K (reprint author), Yamaguchi Red Cross Hosp, Dept Orthopaed Surg, 53-1 Yahatababa Yamaguchi, Yamaguchi 7538519, Japan.	kamoknts@gaea.ocn.ne.jp					Alnaqbi KA, 2013, J RHEUMATOL, V40, P1726, DOI 10.3899/jrheum.130048; Rudwaleit M, 2009, ANN RHEUM DIS, V68, P777, DOI 10.1136/ard.2009.108233; Atzeni F, 2014, AUTOIMMUN REV, V13, P20, DOI 10.1016/j.autrev.2013.06.006; GRAVALLESE EM, 1988, AM J GASTROENTEROL, V83, P703; Veloso FT, 1996, J CLIN GASTROENTEROL, V23, P29, DOI 10.1097/00004836-199607000-00009; Rudwaleit M, 2004, ANN RHEUM DIS, V63, P535, DOI 10.1136/ard.2003.011247; van den Berg R, 2013, ANN RHEUM DIS, V72, P1646, DOI 10.1136/annrheumdis-2012-201884; DOUGADOS M, 1991, ARTHRITIS RHEUM, V34, P1218, DOI 10.1002/art.1780341003; Shivashankar R, 2013, J RHEUMATOL, V40, P1153, DOI 10.3899/jrheum.121029; Varkas G, 2013, Z RHEUMATOL, V72, P524, DOI 10.1007/s00393-012-1114-5; Stolwijk C, 2013, CAN J GASTROENTEROL, V27, P199; VANDERLINDEN S, 1984, ARTHRITIS RHEUM, V27, P361; Salvarani C, 2009, WORLD J GASTROENTERO, V15, P2449, DOI 10.3748/wjg.15.2449; Rudwaleit M, 2011, ANN RHEUM DIS, V70, P25, DOI 10.1136/ard.2010.133645; Aydin SZ, 2012, ANN RHEUM DIS, V71, P56, DOI 10.1136/ard.2011.153064; Brakenhoff LKPM, 2010, J CROHNS COLITIS, V4, P257, DOI 10.1016/j.crohns.2009.11.005; Levine Jonathan S, 2011, Gastroenterol Hepatol (N Y), V7, P235; van der Horst-Bruinsma Irene E, 2012, Ther Adv Musculoskelet Dis, V4, P413, DOI 10.1177/1759720X12458372; Sakurai T, 2013, STOMACH INTESTINE, V48, P591; Shivashankar R, 2012, J RHEUMATOL, V39, P2148, DOI 10.3899/jrheum.120321	20	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1439-7595	1439-7609		MOD RHEUMATOL	Mod. Rheumatol.	MAY	2015	25	3					435	437		10.3109/14397595.2014.964925		3	Rheumatology	Rheumatology	CH1HS	WOS:000353772900018		
J	Yoshimura, N; Muraki, S; Oka, H; Tanaka, S; Kawaguchi, H; Nakamura, K; Akune, T				Yoshimura, Noriko; Muraki, Shigeyuki; Oka, Hiroyuki; Tanaka, Sakae; Kawaguchi, Hiroshi; Nakamura, Kozo; Akune, Toru			Mutual associations among musculoskeletal diseases and metabolic syndrome components: A 3-year follow-up of the ROAD study	MODERN RHEUMATOLOGY			English	Article						Incidence; Knee osteoarthritis; Lumbar spondylosis; Metabolic risk factor; Osteoporosis	RADIOGRAPHIC KNEE OSTEOARTHRITIS; BODY-MASS INDEX; POPULATION-BASED COHORT; RISK-FACTORS; LUMBAR SPONDYLOSIS; JAPANESE MEN; OSTEOPOROSIS; WOMEN; PROGRESSION; FRACTURES	Objective. This study aimed to assess the mutual associations between musculoskeletal diseases (knee osteoarthritis [KOA], lumbar spondylosis [LS], osteoporosis [OP]) and metabolic syndrome components (obesity [OB], hypertension [HT], dyslipidemia [DL], impaired glucose tolerance [IGT]). Methods. Of the 1,690 participants (596 men, 1,094 women) at baseline, 1,384 individuals (81.9%; 466 men, 918 women) had complete data at the first follow-up in 2008. Logistic regression analysis included the occurrence or nonoccurrence of the musculoskeletal diseases or metabolic components as the outcome variable and the remaining musculoskeletal diseases and metabolic components at baseline as explanatory variables, adjusted for age, sex, residential region, smoking, and alcohol consumption. Results. The risk of KOA occurring increased significantly with HT (odds ratio [OR], 2.57; 95% confidence interval [CI], 1.22-5.42; p = 0.013) and IGT (OR, 1.99; 95% CI, 1.07-3.70; p = 0.029). The risk of OP occurring at the lumbar spine increased with OP at the femoral neck (OR, 4.21; 95% CI 1.46-12.1; p = 0.008), and vice versa (OR, 2.19; 95% CI, 1.01-479; p = 0.047). KOA increased the risk of HT (Kellgren-Lawrence [KL] grade=0, 1 vs. KL = 2: OR, 1.84; 95% CI, 1.09-3.12; p = 0.024) and DL (KL = 0, 1 vs. KL >= 3: OR, 1.66; 95% CI, 1.05-2.61; p = 0.029) occurring. Reciprocal relationships existed between the presence of metabolic components and the occurrence of the other metabolic components. Conclusion. Mutual relationships existed between the occurrence and presence of musculoskeletal diseases, particularly KOA, and metabolic syndrome components.	[Yoshimura, Noriko; Oka, Hiroyuki] Univ Tokyo, 22nd Century Med & Res Ctr, Dept Joint Dis Res, Tokyo 1138655, Japan; [Muraki, Shigeyuki; Akune, Toru] Univ Tokyo, 22nd Century Med & Res Ctr, Dept Clin Motor Syst Med, Tokyo 1138655, Japan; [Tanaka, Sakae] Univ Tokyo, Dept Orthopaed Surg Sensory & Motor Syst Med, Grad Sch Med, Tokyo 1138655, Japan; [Kawaguchi, Hiroshi] JCHO Tokyo Shinjuku Med Ctr, Shinjyuku Ku, Tokyo, Japan; [Nakamura, Kozo] Natl Rehabil Ctr Persons Disabil, Saitama, Japan	Yoshimura, N (reprint author), Univ Tokyo, 22nd Century Med & Res Ctr, Dept Joint Dis Res, Grad Sch Med,Bunkyo Ku, Hongo 7-3-1, Tokyo 1138655, Japan.	yoshimuran-ort@h.u-tokyo.ac.jp			Ministry of Health, Labour and Welfare [H17-Men-eki-009, H20-Choujyu-009, H23-Choujyu-002, H-25-Choujyu-007, H25-Nanchitou(Men)-005]; Ministry of Education, Culture, Sports, Science and Technology in Japan [B23390172, B20390182, 24659317, B23390357, C20591737, B23390356, C20591774, 23659580, 24659666, 21659349, A18689031]; NSF [08033011-00262]; Japan Osteoporosis Society; Japanese Orthopaedic Association (JOA) [2006-1, 2010-2]	This work was supported by a Grant-in-Aid for H17-Men-eki-009 (Director, Kozo Nakamura), H20-Choujyu-009 (Director, Noriko Yoshimura), H23-Choujyu-002 (Director, Toru Akune), H-25-Choujyu-007 (Director, Noriko Yoshimura), and H25-Nanchitou(Men)-005 (Director, Sakae Tanaka) of the Ministry of Health, Labour and Welfare; and Scientific Research B23390172, B20390182, and Challenging Exploratory Research 24659317 to Noriko Yoshimura; B23390357 and C20591737 to Toru Akune; B23390356, C20591774, and Challenging Exploratory Research 23659580 to Shigeyuki Muraki; Challenging Exploratory Research 24659666 and 21659349 and Young Scientists A18689031 to Hiroyuki Oka; and Collaborating Research with NSF 08033011-00262 (Director, Noriko Yoshimura) from the Ministry of Education, Culture, Sports, Science and Technology in Japan. This study also was supported by grants from the Japan Osteoporosis Society (Noriko Yoshimura, Shigeyuki Muraki, Hiroyuki Oka, and Toru Akune), and research aid from the Japanese Orthopaedic Association (JOA-Subsidized Science Project Research 2006-1 & 2010-2; Director, Hiroshi Kawaguchi).	Yoshimura N, 2009, J BONE MINER METAB, V27, P620, DOI 10.1007/s00774-009-0080-8; Zhuo Q, 2012, NAT REV RHEUMATOL, V8, P729, DOI 10.1038/nrrheum.2012.135; Cooper C, 2000, ARTHRITIS RHEUM, V43, P995, DOI 10.1002/1529-0131(200005)43:5<995::AID-ANR6>3.0.CO;2-1; Ghosh M, 2014, ENDOCRINE, V46, P397, DOI 10.1007/s12020-014-0167-4; Hart DJ, 1999, ARTHRITIS RHEUM, V42, P17, DOI 10.1002/1529-0131(199901)42:1<17::AID-ANR2>3.0.CO;2-E; Reijman M, 2007, ANN RHEUM DIS, V66, P158, DOI 10.1136/ard.2006.053538; Ahmed LA, 2006, OSTEOPOROSIS INT, V17, P426, DOI 10.1007/s00198-005-0003-z; Grundy SM, 2004, CIRCULATION, V109, P433, DOI 10.1161/01.CIR.0000111245.75752.C6; Yoshimura N, 2011, J RHEUMATOL, V38, P921, DOI 10.3899/jrheum.100569; Orwoll E, 2005, CONTEMP CLIN TRIALS, V26, P569, DOI 10.1016/j.cct.2005.05.006; Johansson H, 2014, J BONE MINER RES, V29, P223, DOI 10.1002/jbmr.2017; Janghorbani M, 2007, AM J EPIDEMIOL, V166, P495, DOI 10.1093/aje/kwm106; Yoshimura N, 2010, INT J EPIDEMIOL, V39, P988, DOI 10.1093/ije/dyp276; Muraki S, 2012, OSTEOARTHR CARTILAGE, V20, P712, DOI 10.1016/j.joca.2012.03.009; Yoshimura N, 2012, OSTEOARTHR CARTILAGE, V20, P1217, DOI 10.1016/j.joca.2012.06.006; Buizert PJ, 2009, J BONE MINER RES, V24, P1103, DOI [10.1359/jbmr.081262, 10.1359/JBMR.081262]; Lohmander LS, 2009, ANN RHEUM DIS, V68, P490, DOI 10.1136/ard.2008.089748; Orimo H, 2001, J BONE MINER METAB, V19, P331, DOI 10.1007/s007740170001; Barba C, 2004, LANCET, V363, P157; Dahlöf Björn, 2010, Am J Cardiol, V105, p3A, DOI 10.1016/j.amjcard.2009.10.007; Day Caroline, 2007, Diab Vasc Dis Res, V4, P32, DOI 10.3132/dvdr.2007.003; Engstrom G, 2009, OSTEOARTHR CARTILAGE, V17, P168, DOI 10.1016/j.joca.2008.07.003; Kellgren JH, 1963, EPIDEMIOLOGY CHRONIC; Ministry of Health Labour and Welfare, MAN NAT HLTH NUTR SU; Ministry of Health Labour and Welfare, 2010, OUTL RES NAT LIV SUR; Muraki S, 2009, ARTHRIT RHEUM-ARTHR, V61, P779, DOI 10.1002/art.24514; Muraki S, 2012, ARTHRITIS RHEUM-US, V64, P1447, DOI 10.1002/art.33508; Seino Y, 2010, DIABETOL INT, V1, P2, DOI 10.1007/s13340-010-0006-7; Shibata Kiyoshi, 2010, Environmental Health and Preventive Medicine, V15, P229, DOI 10.1007/s12199-009-0132-7; The Examination Committee for Criteria of Metabolic Syndrome in Japan, 2005, J JPN SOC INTERN MED, V94; Matsuzawa Y, 2002, CIRC J, V66, P987; WHO, 1994, WHO TECHN REP SER; Yoshimura N, 2009, OSTEOPOROSIS INT, V20, P999, DOI 10.1007/s00198-008-0771-3	33	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1439-7595	1439-7609		MOD RHEUMATOL	Mod. Rheumatol.	MAY	2015	25	3					438	448		10.3109/14397595.2014.972607		11	Rheumatology	Rheumatology	CH1HS	WOS:000353772900019		
J	Nakashima, Y; Nakamura, H; Horai, Y; Hayashi, T; Takagi, Y; Nakamura, T; Kawakami, A				Nakashima, Yoshikazu; Nakamura, Hideki; Horai, Yoshiro; Hayashi, Tomayoshi; Takagi, Yukinori; Nakamura, Takashi; Kawakami, Atsushi			Comorbid case of IgG4-related disease and primary Sjogren's syndrome	MODERN RHEUMATOLOGY			English	Article						Apoptosis; IgG4-related disease; Sjogren's syndrome; TUNEL	ENLARGED EXOCRINE GLANDS; MESSENGER-RNA; FAS-LIGAND; EXPRESSION; CRITERIA	A 63-year-old man with enlargement of the bilateral submandibular glands visited with elevated serum IgG4. A biopsy specimen showed plasma cell infiltration with more than 50% IgG4/IgG staining, suggesting the existence of IgG4-related disease (IgG4-RD). Positive anti-SS-A/Ro antibody and the labial salivary gland's biopsy suggested existence of primary Sjogren's syndrome (pSS). Administration of glucocorticoid improved the serum IgG4 level while reducing the submandibular gland lesions. Positive TUNEL staining suggested the coexistence of IgG4-RD and pSS.	[Nakashima, Yoshikazu; Nakamura, Hideki; Horai, Yoshiro; Kawakami, Atsushi] Nagasaki Univ, Grad Sch Biomed Sci, Dept Immunol & Rheumatol, Unit Translat Med, Nagasaki, Nagasaki 8528501, Japan; [Hayashi, Tomayoshi] Nagasaki Univ Hosp, Dept Pathol, Nagasaki, Japan; [Takagi, Yukinori; Nakamura, Takashi] Nagasaki Univ, Dept Radiol & Canc Biol, Sch Dent, Nagasaki, Nagasaki 8528501, Japan	Nakamura, H (reprint author), Nagasaki Univ, Grad Sch Biomed Sci, Dept Immunol & Rheumatol, Unit Translat Med, 1-7-1 Sakamoto, Nagasaki, Nagasaki 8528501, Japan.	nhideki@nagasaki-u.ac.jp					Ohlsson M, 2002, SCAND J IMMUNOL, V56, P456, DOI 10.1046/j.1365-3083.2002.01072_79.x; Masaki Y, 2009, ANN RHEUM DIS, V68, P1310, DOI 10.1136/ard.2008.089169; Tsubota K, 2000, INVEST OPHTH VIS SCI, V41, P1666; Umehara H, 2012, MOD RHEUMATOL, V22, P21, DOI 10.1007/s10165-011-0571-z; Umehara H, 2012, MOD RHEUMATOL, V22, P1, DOI 10.1007/s10165-011-0508-6; Nakamura H, 2006, TRANSL RES, V148, P281, DOI 10.1016/j.trsl.2006.07.003; Shiboski SC, 2012, ARTHRIT CARE RES, V64, P475, DOI 10.1002/acr.21591; Takagi Y, 2010, ANN RHEUM DIS, V69, P1321, DOI 10.1136/ard.2009.123836; Baer AN, 2013, OR SURG OR MED OR PA, V115, pE34, DOI 10.1016/j.oooo.2012.07.485; Barcellos KSA, 2007, J RHEUMATOL, V34, P1283; Shimizu M, 2009, ORAL SURG ORAL MED O, V108, P105, DOI 10.1016/j.tripleo.2009.02.032; Trimarchi Carmela, 2004, Methods Mol Biol, V285, P113; Tsubota K, 2002, CLIN EXP IMMUNOL, V129, P177, DOI 10.1046/j.1365-2249.2002.01882.x; Tsuzaka K, 2007, AUTOIMMUNITY, V40, P497, DOI 10.1080/08916930701580320	14	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1439-7595	1439-7609		MOD RHEUMATOL	Mod. Rheumatol.	MAY	2015	25	3					462	467		10.3109/14397595.2013.843750		6	Rheumatology	Rheumatology	CH1HS	WOS:000353772900022		
J	Tani, T; Ishihara, C; Kaneko, T; Tsuruoka, S; Iino, Y				Tani, Takashi; Ishihara, Chikara; Kaneko, Tomohiro; Tsuruoka, Syuichi; Iino, Yasuhiko			Multiple cerebral lesions as the unique complication of idiopathic retroperitoneal fibrosis	MODERN RHEUMATOLOGY			English	Article						Autoimmune diseases; Cerebral vasculitis; Idiopathic retroperitoneal fibrosis	CHRONIC PERIAORTITIS; VASCULITIS; DISEASE; SYSTEM	We present a case of idiopathic retroperitoneal fibrosis (IRF) complicated by severe renal failure and multiple intracranial lesions, which are probable results of cerebral vasculitis. IRF is an idiopathic hyperplasia of the retroperitoneal tissue that often entraps the ureters and causes post-renal failure. While the etiology of IRF is unclear, researchers consider IRF a systemic autoimmune disease complicated by immune-mediated vasculitides. The chief complaints of the patient were cognitive disorders, and brain MRI findings revealed multiple intracranial lesions with accompanying central degeneration. Given that vasogenic cerebral edemas derive from uremia, we speculated that the lesions in our case were related to more destructive changes such as aortic and periaortic inflammation. Details on this case manifesting rare cerebrovascular complications may help elucidate the pathogenesis of IRF.	[Tani, Takashi; Ishihara, Chikara; Kaneko, Tomohiro; Tsuruoka, Syuichi; Iino, Yasuhiko] Nippon Med Sch, Dept Nephrol, Tokyo 1138603, Japan	Tani, T (reprint author), Nippon Med Sch, Dept Nephrol, Bunkyo Ku, 1-1-5 Sendagi, Tokyo 1138603, Japan.	tani@nms.ac.jp					Vaglio A, 2005, CURR OPIN RHEUMATOL, V17, P34, DOI 10.1097/01.bor.0000145517.83972.40; Jennette JC, 2013, ARTHRITIS RHEUM-US, V65, P1, DOI 10.1002/art.37715; Moroni G, 2005, KIDNEY INT, V68, P562, DOI 10.1111/j.1523-1755.2005.00434.x; PARUMS DV, 1986, ATHEROSCLEROSIS, V61, P117, DOI 10.1016/0021-9150(86)90070-5; Ghinoi A, 2010, CLIN EXP RHEUMATOL, V28, P759; Lamy C, 2004, J NEUROIMAGING, V14, P89, DOI 10.1177/1051228403258161; Vaglio A, 2011, CURR OPIN RHEUMATOL, V23, P1, DOI 10.1097/BOR.0b013e328341137d; Klein J, 2000, NEW ENGL J MED, V343, P782; COHLE SD, 1988, ARCH PATHOL LAB MED, V112, P1121; Doi M, SHINDAN BYO IN PRESS; Gilkeson GS, 1996, RHEUM DIS CLIN N AM, V22, P23, DOI 10.1016/S0889-857X(05)70260-X; KOEP L, 1977, SURGERY, V81, P250; Kottra JJ, 1996, RADIOL CLIN N AM, V34, P1259; Martorana D, 2006, ARTHRIT RHEUM-ARTHR, V55, P126, DOI 10.1002/art21698; MITCHINS.MJ, 1970, J CLIN PATHOL, V23, P681, DOI 10.1136/jcp.23.8.681	15	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1439-7595	1439-7609		MOD RHEUMATOL	Mod. Rheumatol.	MAY	2015	25	3					468	471		10.3109/14397595.2013.843754		4	Rheumatology	Rheumatology	CH1HS	WOS:000353772900023		
J	Umemura, M; Miwa, Y; Yanai, R; Isojima, S; Tokunaga, T; Tsukamoto, H; Takahashi, R; Yajima, N; Kasama, T; Takahashi, N; Sueki, H; Yamaguchi, S; Arai, K; Takeuchi, Y; Ohike, N; Norose, T; Yamochi-Onizuka, T; Takimoto, M				Umemura, Masayu; Miwa, Yusuke; Yanai, Ryo; Isojima, Sakiko; Tokunaga, Takahiro; Tsukamoto, Hiroyuki; Takahashi, Ryo; Yajima, Nobuyuki; Kasama, Tsuyoshi; Takahashi, Nanako; Sueki, Hirohiko; Yamaguchi, Sayaka; Arai, Katsuhito; Takeuchi, Yoshiaki; Ohike, Nobuyuki; Norose, Tomoko; Yamochi-Onizuka, Toshiko; Takimoto, Masafumi			A case of Degos disease: demonstration of C5b-9-mediated vascular injury	MODERN RHEUMATOLOGY			English	Article						Degos disease; C5b-9 deposition	MALIGNANT ATROPHIC PAPULOSIS; LUPUS-ERYTHEMATOSUS	A 68-year-old Japanese male presented with atrophic erythematous white lesions with peripheral dark reddish rims on his back. Multiple ulcers were detected from his stomach to his large intestine using endoscopy. Although the patient was given high doses of a steroid, aspirin, dipyridamole, and intravenous immunoglobulin therapy, he died of gastro intestinal hemorrhage, perforation and septic shock. An autopsy examination revealed pauci-inflammatory thrombotic microangiopathy with endothelial cell injury, fibrous occlusive arteriopathy, and vascular C5b-9 deposition in the wall of the gastro intestinal tract from the esophagus to the large intestine as well as in the dermis of the skin.	[Umemura, Masayu; Miwa, Yusuke; Yanai, Ryo; Isojima, Sakiko; Tokunaga, Takahiro; Tsukamoto, Hiroyuki; Takahashi, Ryo; Yajima, Nobuyuki; Kasama, Tsuyoshi] Showa Univ, Sch Med, Div Rheumatol, Dept Med, Tokyo 142, Japan; [Takahashi, Nanako; Sueki, Hirohiko] Showa Univ, Sch Med, Dept Dermatol, Tokyo 142, Japan; [Yamaguchi, Sayaka; Arai, Katsuhito; Takeuchi, Yoshiaki] Showa Univ, Sch Med, Dept Med, Div Gastroenterol, Tokyo 142, Japan; [Ohike, Nobuyuki; Norose, Tomoko; Yamochi-Onizuka, Toshiko; Takimoto, Masafumi] Showa Univ, Sch Med, Dept Pathol, Tokyo 142, Japan	Miwa, Y (reprint author), Showa Univ, Sch Med, Div Rheumatol, Dept Med,Shinagawa Ku, 1-5-8 Hatanodai, Tokyo 142, Japan.	y.miwa@mbf.ocn.ne.jp					Beljaards R C, 1988, Ned Tijdschr Geneeskd, V132, P269; DOUTRE MS, 1987, DERMATOLOGICA, V175, P45; DURIE BGM, 1969, ARCH DERMATOL, V100, P575, DOI 10.1001/archderm.100.5.575; Ernandez- Flores A, 2008, BRATISL LEK LISTY, V109, P414; Ernandez- Flores A, 2008, BRATISL LEK LISTY, V109, P533; Heymann WR, 2009, J AM ACAD DERMATOL, V61, P505, DOI 10.1016/j.jaad.2009.03.028; High WA, 2004, J AM ACAD DERMATOL, V50, P895, DOI 10.1016/j.jaad.2003.11.063; Kinoshita T, 1991, IMMUNOL TODAY, V12, P202; KOLB WP, 1975, P NATL ACAD SCI USA, V72, P1687, DOI 10.1073/pnas.72.5.1687; Megro CM, 2011, AM J CLIN PATHOL, V135, P599; NORRIS DA, 1985, J IMMUNOL, V135, P1073; NORRIS DA, 1985, J INVEST DERMATOL, V85, pS165; NORRIS DA, 1993, J INVEST DERMATOL, V100, pS58, DOI 10.1038/jid.1993.25; Notash AY, 2008, SAUDI MED J, V29, P133; SNOW JL, 1995, SEMIN DERMATOL, V14, P99; Tsao H, 1997, J AM ACAD DERMATOL, V36, P317, DOI 10.1016/S0190-9622(97)80407-0	16	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1439-7595	1439-7609		MOD RHEUMATOL	Mod. Rheumatol.	MAY	2015	25	3					480	483		10.3109/14397595.2013.874761		4	Rheumatology	Rheumatology	CH1HS	WOS:000353772900026		
J	Yamamoto, M; Shimizu, Y; Takahashi, H; Yajima, H; Yokoyama, Y; Ishigami, K; Tabeya, T; Suzuki, C; Matsui, M; Naishiro, Y; Imai, K; Shinomura, Y				Yamamoto, Motohisa; Shimizu, Yui; Takahashi, Hiroki; Yajima, Hidetaka; Yokoyama, Yoshihiro; Ishigami, Keisuke; Tabeya, Tetsuya; Suzuki, Chisako; Matsui, Mikiko; Naishiro, Yasuyoshi; Imai, Kohzon; Shinomura, Yasuhisa			CCAAT/enhancer binding protein alpha (C/EBP alpha)(+) M2 macrophages contribute to fibrosis in IgG4-related disease?	MODERN RHEUMATOLOGY			English	Article						CCAAT/enhancer binding protein alpha; Fibrosis; IgG4-related disease; Macrophage	METALLOPROTEINASES	IgG4-related disease (IgG4-RD) is a new disease entity characterized by type 2 helper T (Th2)-dominant inflammation and progressive fibrosis. We found the infiltration of strange cell populations in the fibrotic lesions of submandibular gland specimens obtained from 15 patients with IgG4-RD. These cells expressed CCAAT/enhancer binding protein a (C/EBP alpha). Many of the cell populations were identified with M2 macrophages. The degrees of infiltration of C/EBP alpha(+)M2 macrophages and the ratio of fibrotic lesions in the specimens were correlated (r(2) = 0.83, p < 0.01). We also analyzed the expression of C/EBP alpha in other chronic inflammatory disorders: synovium in rheumatoid arthritis (RA), liver tissue in chronic viral hepatitis, and mucosa in ulcerative colitis. The specimens from RA and chronic viral hepatitis showed infiltration of C/EBP alpha(+) cells, but there were few C/EBP alpha-positive cells in ulcerative colitis. Fibrosis is not a major issue in ulcerative colitis. In conclusion, we found the remarkable infiltration of C/EBP alpha(+)M2 macrophages in cases of chronic inflammation with fibrosis, including IgG4-RD. This primitive study also disclosed that most of C/EBP alpha(+)M2 macrophages localized in fibrotic lesions, and the degree of the infiltration and the ratio of fibrotic area were correlated.	[Yamamoto, Motohisa; Shimizu, Yui; Takahashi, Hiroki; Yajima, Hidetaka; Yokoyama, Yoshihiro; Ishigami, Keisuke; Tabeya, Tetsuya; Suzuki, Chisako; Matsui, Mikiko; Naishiro, Yasuyoshi; Shinomura, Yasuhisa] Sapporo Med Univ, Sch Med, Dept Gastroenterol Rheumatol & Clin Immunol, Sapporo, Hokkaido 0608543, Japan; [Imai, Kohzon] Univ Tokyo, Inst Med Sci, Ctr Antibody & Vaccine Therapy, Tokyo, Japan	Yamamoto, M (reprint author), Sapporo Med Univ, Sch Med, Dept Gastroenterol Rheumatol & Clin Immunol, Chuo Ku, South 1,West 16, Sapporo, Hokkaido 0608543, Japan.	mocha@cocoa.plala.or.jp			Ministry of Health Labour and Welfare, Japan	This work was supported by the Research on Measures for Intractable Diseases Project matching fund subsidy from Ministry of Health Labour and Welfare, Japan.	Burrage PS, 2006, FRONT BIOSCI, V11, P529, DOI 10.2741/1817; Khosroshahi A, 2012, MEDICINE, V91, P57, DOI 10.1097/MD.0b013e3182431ef6; Xie HF, 2004, CELL, V117, P663, DOI 10.1016/S0092-8674(04)00419-2; Bussmann LH, 2009, CELL STEM CELL, V5, P554, DOI 10.1016/j.stem.2009.10.004; Yamamoto M, 2014, NAT REV RHEUMATOL, V10, P148, DOI 10.1038/nrrheum.2013.183; Wynn TA, 2013, NATURE, V496, P445, DOI 10.1038/nature12034; Khokha R, 2013, NAT REV IMMUNOL, V13, P649, DOI 10.1038/nri3499; Heinrichs D, 2011, P NATL ACAD SCI USA, V108, P17444, DOI 10.1073/pnas.1107023108; Friedman AD, 2003, BLOOD CELL MOL DIS, V31, P338, DOI 10.1016/S1079-9796(03)00135-9	9	1	1	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1439-7595	1439-7609		MOD RHEUMATOL	Mod. Rheumatol.	MAY	2015	25	3					484	486		10.3109/14397595.2014.950826		3	Rheumatology	Rheumatology	CH1HS	WOS:000353772900027		
J	Minota, S				Minota, Seiji			Comments on the paper showing an exceptionally favorable response to tofacitinib among Japanese rheumatoid patients and an issue surrounding clinical trial led by pharmaceutical company	MODERN RHEUMATOLOGY			English	Letter						DMARD; Odds ratio; Tofacitinib; Clinical trial	INADEQUATE RESPONSE; METHOTREXATE; ARTHRITIS; COMBINATION; CP-690,550; PLACEBO		Jichi Med Univ, Div Rheumatol & Clin Immunol, Shimotsuke, Tochigi 3290498, Japan	Minota, S (reprint author), Jichi Med Univ, Div Rheumatol & Clin Immunol, 3311-1 Yakushiji, Shimotsuke, Tochigi 3290498, Japan.	sminota@jichi.ac.jp					Kremer JM, 2012, ARTHRITIS RHEUM-US, V64, P970, DOI 10.1002/art.33419; Abe T, 2006, J RHEUMATOL, V33, P37; Tanaka Y, 2012, ANN RHEUM DIS, V71, P817, DOI 10.1136/ard.2011.200317; Tanaka Y, 2011, ARTHRIT CARE RES, V63, P1150, DOI 10.1002/acr.20494; Yamamoto K, 2013, MOD RHEUMATOL, V21, P458	5	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1439-7595	1439-7609		MOD RHEUMATOL	Mod. Rheumatol.	MAY	2015	25	3					493	494		10.3109/14397595.2014.917600		2	Rheumatology	Rheumatology	CH1HS	WOS:000353772900030		
J	Inaoki, M; Nishijima, C; Miyake, M; Asaka, T; Hasegawa, Y; Anzawa, K; Mochizuki, T				Inaoki, Makoto; Nishijima, Chihiro; Miyake, Miho; Asaka, Toshiyuki; Hasegawa, Youichi; Anzawa, Kazushi; Mochizuki, Takashi			Case of dermatophyte abscess caused by Trichophyton rubrum: a case report and review of the literature	MYCOSES			English	Article						Abscess; dermis; dermatophytosis; Trichophyton rubrum; terbinafine	DEEP DERMATOPHYTOSIS; PATIENT	A 54-year-old Japanese man without apparent immunosuppression presented with nodules with purulent drainage on the right lower leg. He had ringworm of the right leg and tinea unguium. A biopsy specimen of the nodule showed intradermal abscesses with fungal elements, and Trichophyton rubrum was cultured from both the pus and the biopsy specimen. Treatment with oral terbinafine resolved the nodules. Dermatophyte abscess is a rare, deep and invasive dermatophytosis, which is often associated with immunocompromised conditions. We provide a review of the literature including Japanese cases.	[Inaoki, Makoto; Nishijima, Chihiro; Miyake, Miho] Natl Hosp Org, Dept Dermatol, Kanazawa Med Ctr, Kanazawa, Ishikawa 9208650, Japan; [Asaka, Toshiyuki] Natl Hosp Org, Dept Lab Med, Kanazawa Med Ctr, Kanazawa, Ishikawa 9208650, Japan; [Hasegawa, Youichi] Hasegawa Skin Clin, Kanazawa, Ishikawa, Japan; [Anzawa, Kazushi; Mochizuki, Takashi] Kanazawa Med Univ, Dept Dermatol, Uchinada, Ishikawa 92002, Japan	Inaoki, M (reprint author), Natl Hosp Org, Dept Dermatol, Kanazawa Med Ctr, 1-1 Shimoishibiki Machi, Kanazawa, Ishikawa 9208650, Japan.	inaoki-m@kinbyou.hosp.go.jp					Lanternier F, 2013, NEW ENGL J MED, V369, P1704, DOI 10.1056/NEJMoa1208487; Matsuzaki Y, 2013, ACTA DERM-VENEREOL, V93, P358, DOI 10.2340/00015555-1452; Smith KJ, 2001, BRIT J DERMATOL, V145, P344, DOI 10.1046/j.1365-2133.2001.04331.x; Azib S, 2013, JAMA DERMATOL, V149, P475, DOI [10.1001/jamadermatol.2013.2129a, 10.1001/jamadermatol.2013.2129b]; Chastain MA, 2001, CUTIS, V67, P457; Colwell AS, 2004, PLAST RECONSTR SURG, V113, P1072, DOI 10.1097/01.PRS.0000107650.25327.71; FAERGEMANN J, 1989, ACTA DERM-VENEREOL, V69, P244; Franco RC, 2001, INT J DERMATOL, V40, P363, DOI 10.1046/j.1365-4362.2001.01096.x; Fukushiro R, 1999, COLOR ATLAS DERMATOP, P89; Iijima S, 2008, RINSHO DERMA, V50, P957; Kobayashi M, 2006, J AM ACAD DERMATOL, V54, pS11, DOI 10.1016/j.jaad.2005.03.058; Marconi VC, 2010, MED MYCOL, V48, P518, DOI 10.3109/13693780903213512; Patel GK, 2000, CLIN EXP DERMATOL, V25, P608, DOI 10.1046/j.1365-2230.2000.00718.x; SMITH EB, 1982, INT J DERMATOL, V21, P338, DOI 10.1111/j.1365-4362.1982.tb03141.x; THORNE E, 1971, DERMATOLOGICA, V142, P167; WILSON JW, 1954, AMA ARCH DERM SYPH, V69, P258; Yonebayashi K, 1998, SKIN RES, V40, P394	17	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0933-7407	1439-0507		MYCOSES	Mycoses	MAY	2015	58	5					318	323		10.1111/myc.12317		6	Dermatology; Mycology	Dermatology; Mycology	CG9OW	WOS:000353647000011		
J	Walowski, KJ; Wallace, PJ; Hauri, EH; Wada, I; Clynne, MA				Walowski, K. J.; Wallace, P. J.; Hauri, E. H.; Wada, I.; Clynne, M. A.			Slab melting beneath the Cascade Arc driven by dehydration of altered oceanic peridotite	NATURE GEOSCIENCE			English	Article							HYDROGEN ISOTOPES; SUBDUCTION ZONE; SILICATE-GLASSES; MANTLE WEDGE; OXYGEN FUGACITY; RIDGE BASALTS; INCLUSIONS; WATER; CONSTRAINTS; CALIFORNIA	Water is returned to Earth's interior at subduction zones. However, the processes and pathways by which water leaves the subducting plate and causes melting beneath volcanic arcs are complex; the source of the water-subducting sediment, altered oceanic crust, or hydrated mantle in the downgoing plate-is debated; and the role of slab temperature is unclear. Here we analyse the hydrogen-isotope and trace-element signature of melt inclusions in ash samples from the Cascade Arc, where young, hot lithosphere subducts. Comparing these data with published analyses, we find that fluids in the Cascade magmas are sourced from deeper parts of the subducting slab-hydrated mantle peridotite in the slab interior-compared with fluids in magmas from the Marianas Arc, where older, colder lithosphere subducts. We use geodynamic modelling to show that, in the hotter subduction zone, the upper crust of the subducting slab rapidly dehydrates at shallow depths. With continued subduction, fluids released from the deeper plate interior migrate into the dehydrated parts, causing those to melt. These melts in turn migrate into the overlying mantle wedge, where they trigger further melting. Our results provide a physical model to explain melting of the subducted plate and mass transfer from the slab to the mantle beneath arcs where relatively young oceanic lithosphere is subducted.	[Walowski, K. J.; Wallace, P. J.] 1272 Univ Oregon, Dept Geol Sci, Eugene, OR 97403 USA; [Hauri, E. H.] Carnegie Inst Sci, Dept Terr Magnetism, Broad Branch Rd, Washington, DC 20015 USA; [Wada, I.] Tohoku Univ, IRIDeS, Sendai, Miyagi 9808578, Japan; [Clynne, M. A.] US Geol Survey, Volcano Sci Ctr, Menlo Pk, CA 94025 USA	Walowski, KJ (reprint author), 1272 Univ Oregon, Dept Geol Sci, Eugene, OR 97403 USA.	walowski@uoregon.edu			National Science Foundation [EAR-1119224, EAR-1019848]; Carnegie Institution of Washington	We thank A. Kent (Oregon State University) for assistance with the LA-ICP-MS measurements, J. Wang for support in the Carnegie SIMS lab, and T. Plank and J. Lowenstern for helpful discussions. Financial support was provided by the National Science Foundation (grants EAR-1119224 and EAR-1019848) and the Carnegie Institution of Washington.	Abers GA, 2009, GEOLOGY, V37, P1119, DOI 10.1130/G30143A.1; Borg LE, 1997, CAN MINERAL, V35, P425; Gaetani GA, 2012, GEOLOGY, V40, P915, DOI 10.1130/G32992.1; Le Voyer M, 2010, J PETROL, V51, P1571, DOI 10.1093/petrology/egq030; Klimm K, 2008, J PETROL, V49, P523, DOI 10.1093/petrology/egn001; Skora S, 2010, J PETROL, V51, P2211, DOI 10.1093/petrology/egq054; Shaw AM, 2012, NAT GEOSCI, V5, P224, DOI [10.1038/ngeo1406, 10.1038/NGEO1406]; MCDONOUGH WF, 1995, CHEM GEOL, V120, P223, DOI 10.1016/0009-2541(94)00140-4; GIGGENBACH WF, 1992, EARTH PLANET SC LETT, V113, P495, DOI 10.1016/0012-821X(92)90127-H; Hauri E, 2002, CHEM GEOL, V183, P115, DOI 10.1016/S0009-2541(01)00374-6; Wada I, 2012, EARTH PLANET SC LETT, V353, P60, DOI 10.1016/j.epsl.2012.07.025; Rondenay S, 2008, GEOLOGY, V36, P275, DOI 10.1130/G24112A.1; Plank T, 2013, EARTH PLANET SC LETT, V364, P168, DOI 10.1016/j.epsl.2012.11.044; Workman RK, 2005, EARTH PLANET SC LETT, V231, P53, DOI 10.1016/j.epsl.2004.12.005; Loewen MW, 2012, J ANAL ATOM SPECTROM, V27, P1502, DOI 10.1039/c2ja30075c; Till CB, 2012, CONTRIB MINERAL PETR, V163, P669, DOI 10.1007/s00410-011-0692-6; Bucholz CE, 2013, EARTH PLANET SC LETT, V374, P145, DOI 10.1016/j.epsl.2013.05.033; DEFANT MJ, 1990, NATURE, V347, P662, DOI 10.1038/347662a0; Wannamaker PE, 2014, GEOCHEM GEOPHY GEOSY, V15, P4230, DOI 10.1002/2014GC005509; POREDA R, 1986, EARTH PLANET SC LETT, V78, P1, DOI 10.1016/0012-821X(86)90168-8; Alt JC, 2012, EARTH PLANET SC LETT, V327, P50, DOI 10.1016/j.epsl.2012.01.029; Spandler C, 2013, LITHOS, V170, P208, DOI 10.1016/j.lithos.2013.02.016; Leeman WP, 2004, CHEM GEOL, V212, P101, DOI 10.1016/j.chemgeo.2004.08.010; Schmidt MW, 1998, EARTH PLANET SC LETT, V163, P361, DOI 10.1016/S0012-821X(98)00142-3; Hermann J, 2008, J PETROL, V49, P717, DOI 10.1093/petrology/egm073; Shaw AM, 2008, EARTH PLANET SC LETT, V275, P138, DOI 10.1016/j.epsl.2008.08.015; Jego S, 2013, GEOCHIM COSMOCHIM AC, V110, P106, DOI 10.1016/j.gca.2013.02.011; Grove TL, 2002, CONTRIB MINERAL PETR, V142, P375; Plank T, 2005, J PETROL, V46, P921, DOI 10.1093/petrology/egi005; Donnelly KE, 2004, EARTH PLANET SC LETT, V226, P347, DOI 10.1016/j.epsl.2004.07.019; Borg LE, 2002, J PETROL, V43, P705, DOI 10.1093/petrology/43.4.705; Connolly JAD, 2009, GEOCHEM GEOPHY GEOSY, V10, DOI 10.1029/2009GC002540; Cooper L. B., 2012, GEOCHEM GEOPHY GEOSY, V13, P1; Cozzens BD, 2012, GEOLOGY, V40, P899, DOI 10.1130/G33019.1; Davis A. S., 2008, GEOCHEM GEOPHY GEOSY, V9, P1; Hauri EH, 2006, CHEM GEOL, V235, P352, DOI 10.1016/j.chemgeo.2006.08.010; Jicha BR, 2009, CONTRIB MINERAL PETR, V157, P189, DOI 10.1007/s00410-008-0329-6; Kirby S. H., 2002, USGS OPEN FILE REP, V328, P79; Liu KJ, 2012, EARTH PLANET SC LETT, V323, P60, DOI 10.1016/j.epsl.2012.01.020; McCrory P. A., 2012, J GEOPHYS RES, V117, P1; Mullen EK, 2015, EARTH PLANET SC LETT, V414, P100, DOI 10.1016/j.epsl.2015.01.010; NEWMAN S, 1988, J VOLCANOL GEOTH RES, V35, P75, DOI 10.1016/0377-0273(88)90007-8; Ruscitto DM, 2010, EARTH PLANET SC LETT, V298, P153, DOI 10.1016/j.epsl.2010.07.037; Ruscitto DM, 2011, CONTRIB MINERAL PETR, V162, P109, DOI 10.1007/s00410-010-0587-y; Taran YA, 1997, GEOCHEM J, V31, P203; van Keken PE, 2011, J GEOPHYS RES-SOL EA, V116, DOI 10.1029/2010JB007922; Wada I., 2009, GEOCHEM GEOPHY GEOSY, V10, P1; Wilson CR, 2014, EARTH PLANET SC LETT, V401, P261, DOI 10.1016/j.epsl.2014.05.052; Wilson D. S, 2002, USGS OPEN FILE REP, V328, P9	49	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1752-0894	1752-0908		NAT GEOSCI	Nat. Geosci.	MAY	2015	8	5					404	+		10.1038/NGEO2417		6	Geosciences, Multidisciplinary	Geology	CG9MO	WOS:000353640100020		
J	Furutachi, S; Miya, H; Watanabe, T; Kawai, H; Yamasaki, N; Harada, Y; Imayoshi, I; Nelson, M; Nakayama, KI; Hirabayashi, Y; Gotoh, Y				Furutachi, Shohei; Miya, Hiroaki; Watanabe, Tomoyuki; Kawai, Hiroki; Yamasaki, Norihiko; Harada, Yujin; Imayoshi, Itaru; Nelson, Mark; Nakayama, Keiichi I.; Hirabayashi, Yusuke; Gotoh, Yukiko			Slowly dividing neural progenitors are an embryonic origin of adult neural stem cells	NATURE NEUROSCIENCE			English	Article							SUBVENTRICULAR ZONE; MAMMALIAN BRAIN; NEURONAL DIFFERENTIATION; OLFACTORY-BULB; SELF-RENEWAL; RADIAL GLIA; NEUROGENESIS; QUIESCENCE; CYCLE; MAINTENANCE	The mechanism by which adult neural stem cells (NSCs) are established during development is unclear. In this study, analysis of cell cycle progression by examining retention of a histone 2B (H2B)-GFP fusion protein revealed that, in a subset of mouse embryonic neural progenitor cells (NPCs), the cell cycle slows between embryonic day (E) 13.5 and E15.5 while other embryonic NPCs continue to divide rapidly. By allowing H2B-GFP expressed at E9.5 to become diluted in dividing cells until the young adult stage, we determined that a majority of NSCs in the young adult subependymal zone (SEZ) originated from these slowly dividing embryonic NPCs. The cyclin-dependent kinase inhibitor p57 is highly expressed in this embryonic subpopulation, and the deletion of p57 impairs the emergence of adult NSCs. Our results suggest that a substantial fraction of adult SEZ NSCs is derived from a slowly dividing subpopulation of embryonic NPCs and identify p57 as a key factor in generating this embryonic origin of adult SEZ NSCs.	[Furutachi, Shohei; Miya, Hiroaki; Watanabe, Tomoyuki; Kawai, Hiroki; Yamasaki, Norihiko; Harada, Yujin; Hirabayashi, Yusuke; Gotoh, Yukiko] Univ Tokyo, Grad Sch Pharmaceut Sci, Tokyo, Japan; [Imayoshi, Itaru] Kyoto Univ, Inst Virus Res, Hakubi Ctr, Kyoto 606, Japan; [Nelson, Mark] Echelon Biosci, Salt Lake City, UT USA; [Nakayama, Keiichi I.] Kyushu Univ, Med Inst Bioregulat, Dept Mol & Cellular Biol, Fukuoka 812, Japan	Gotoh, Y (reprint author), Univ Tokyo, Grad Sch Pharmaceut Sci, Tokyo, Japan.	ygotoh@mol.f.u-tokyo.ac.jp			Core Research for Evolutional Science and Technology (CREST) of the Japan Science and Technology Agency	We thank K. Tyssowski for editing the manuscript, F. Calegari (Center for Regenerative Therapies Dresden (CRTD)) for reagents, H. Sugizaki, C. Koga and J. Takeuchi for FACS analysis, A Shitamukai, F. Matsuzaki and Y. Sasai for comments and members of the Gotoh laboratory for discussion. This work was supported by Core Research for Evolutional Science and Technology (CREST) of the Japan Science and Technology Agency.	Merkle FT, 2007, SCIENCE, V317, P381, DOI 10.1126/science.1144914; Lledo PM, 2008, TRENDS NEUROSCI, V31, P392, DOI 10.1016/j.tins.2008.05.006; Cheung TH, 2013, NAT REV MOL CELL BIO, V14, P329, DOI 10.1038/nrm3591; Doetsch F, 2003, NAT NEUROSCI, V6, P1127, DOI 10.1038/nn1144; Chakkalakal JV, 2012, NATURE, V490, P355, DOI 10.1038/nature11438; Furutachi S, 2013, EMBO J, V32, P970, DOI 10.1038/emboj.2013.50; TAKAHASHI T, 1995, J NEUROSCI, V15, P6046; Graham V, 2003, NEURON, V39, P749, DOI 10.1016/S0896-6273(03)00497-5; Groszer M, 2006, P NATL ACAD SCI USA, V103, P111, DOI 10.1073/pnas.0509939103; Calegari F, 2005, J NEUROSCI, V25, P6533, DOI 10.1523/JNEUROSCI.0778-05.2005; Gotz M, 2005, NAT REV MOL CELL BIO, V6, P777, DOI 10.1038/nrm1739; Imayoshi I, 2010, J NEUROSCI, V30, P3489, DOI 10.1523/JNEUROSCI.4987-09.2010; Tumbar T, 2004, SCIENCE, V303, P359, DOI 10.1126/science.1092436; Imayoshi I, 2008, NAT NEUROSCI, V11, P1153, DOI 10.1038/nn.2185; Doetsch F, 1999, CELL, V97, P703, DOI 10.1016/S0092-8674(00)80783-7; Doetsch F, 1999, P NATL ACAD SCI USA, V96, P11619, DOI 10.1073/pnas.96.20.11619; Nonaka-Kinoshita M, 2013, EMBO J, V32, P1817, DOI 10.1038/emboj.2013.96; Corti S, 2007, EXP NEUROL, V205, P547, DOI 10.1016/j.expneurol.2007.03.021; Merkle FT, 2004, P NATL ACAD SCI USA, V101, P17528, DOI 10.1073/pnas.0407893101; Kippin TE, 2005, GENE DEV, V19, P756, DOI 10.1101/gad.1272305; Kueh HY, 2013, SCIENCE, V341, P670, DOI 10.1126/science.1240831; Anthony TE, 2004, NEURON, V41, P881, DOI 10.1016/S0896-6273(04)00140-0; Konno D, 2008, NAT CELL BIOL, V10, P93, DOI 10.1038/ncb1673; Pateras IS, 2009, MOL CANCER RES, V7, P1902, DOI 10.1158/1541-7786.MCR-09-0317; Tran V, 2012, SCIENCE, V338, P679, DOI 10.1126/science.1226028; Bowman AN, 2013, P NATL ACAD SCI USA, V110, P7324, DOI 10.1073/pnas.1305411110; Noctor SC, 2008, J COMP NEUROL, V508, P28, DOI 10.1002/cne.21669; Mignone JL, 2004, J COMP NEUROL, V469, P311, DOI 10.1002/cne.10964; Spassky N, 2005, J NEUROSCI, V25, P10, DOI 10.1523/JNEUROSCI.1108-04.2005; Ming GL, 2011, NEURON, V70, P687, DOI 10.1016/j.neuron.2011.05.001; Mirzadeh Z, 2008, CELL STEM CELL, V3, P265, DOI 10.1016/j.stem.2008.07.004; Porlan E, 2013, NAT NEUROSCI, V16, P1567, DOI 10.1038/nn.3545; Kriegstein A, 2009, ANNU REV NEUROSCI, V32, P149, DOI 10.1146/annurev.neuro.051508.135600; Matsumoto A, 2011, CELL STEM CELL, V9, P262, DOI 10.1016/j.stem.2011.06.014; Young KM, 2007, J NEUROSCI, V27, P8286, DOI 10.1523/JNEUROSCI.0476-07.2007; Renault VM, 2009, CELL STEM CELL, V5, P527, DOI 10.1016/j.stem.2009.09.014; Mira H, 2010, CELL STEM CELL, V7, P78, DOI 10.1016/j.stem.2010.04.016; Joseph B, 2003, P NATL ACAD SCI USA, V100, P15619, DOI 10.1073/pnas.2635658100; Hirabayashi Y, 2004, DEVELOPMENT, V131, P2791, DOI 10.1242/dev.01165; Lopez-Juarez A, 2013, GENE DEV, V27, P1272, DOI 10.1101/gad.217539.113; Wilson A, 2008, CELL, V135, P1118, DOI 10.1016/j.cell.2008.10.048; Ernst A, 2014, CELL, V156, P1072, DOI 10.1016/j.cell.2014.01.044; Isaka F, 1999, EUR J NEUROSCI, V11, P2582, DOI 10.1046/j.1460-9568.1999.00699.x; Joseph B, 2009, CELL DEATH DIFFER, V16, P1256, DOI 10.1038/cdd.2009.72; Kageyama R, 2012, BEHAV BRAIN RES, V227, P459, DOI 10.1016/j.bbr.2011.04.038; Kawaguchi D, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2895; Matsumoto A, 2011, MOL CELL BIOL, V31, P4176, DOI 10.1128/MCB.05370-11	47	4	4	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1097-6256	1546-1726		NAT NEUROSCI	Nat. Neurosci.	MAY	2015	18	5					657	+		10.1038/nn.3989		11	Neurosciences	Neurosciences & Neurology	CG9LN	WOS:000353636900012		
J	Tsuboi, D; Kuroda, K; Tanaka, M; Namba, T; Iizuka, Y; Taya, S; Shinoda, T; Hikita, T; Muraoka, S; Iizuka, M; Nimura, A; Mizoguchi, A; Shiina, N; Sokabe, M; Okano, H; Mikoshiba, K; Kaibuchi, K				Tsuboi, Daisuke; Kuroda, Keisuke; Tanaka, Motoki; Namba, Takashi; Iizuka, Yukihiko; Taya, Shinichiro; Shinoda, Tomoyasu; Hikita, Takao; Muraoka, Shinsuke; Iizuka, Michiro; Nimura, Ai; Mizoguchi, Akira; Shiina, Nobuyuki; Sokabe, Masahiro; Okano, Hideyuki; Mikoshiba, Katsuhiko; Kaibuchi, Kozo			Disrupted-in-schizophrenia 1 regulates transport of ITPR1 mRNA for synaptic plasticity	NATURE NEUROSCIENCE			English	Article							MENTAL-RETARDATION PROTEIN; UTERO GENE-TRANSFER; MOLECULAR MOTORS; DISC1 KNOCKDOWN; LIVING NEURONS; BRAIN-FUNCTION; ADULT BRAIN; TRANSLOCATION; GRANULES; LOCALIZATION	Disrupted-in-schizophrenia 1 (DISC1) is a susceptibility gene for major psychiatric disorders, including schizophrenia. DISC1 has been implicated in neurodevelopment in relation to scaffolding signal complexes. Here we used proteomic analysis to screen for DISC1 interactors and identified several RNA-binding proteins, such as hematopoietic zinc finger (HZF), that act as components of RNA-transporting granules. HZF participates in the mRNA localization of inositol-1,4,5-trisphosphate receptor type 1 (ITPR1), which plays a key role in synaptic plasticity. DISC1 colocalizes with HZF and ITPR1 mRNA in hippocampal dendrites and directly associates with neuronal mRNAs, including ITPR1 mRNA. The binding potential of DISC1 for ITPR1 mRNA is facilitated by HZF. Studies of Disc1-knockout mice have revealed that DISC1 regulates the dendritic transport of Itpr1 mRNA by directly interacting with its mRNA. The DISC1-mediated mRNA regulation is involved in synaptic plasticity. We show that DISC1 binds ITPR1 mRNA with HZF, thereby regulating its dendritic transport for synaptic plasticity.	[Tsuboi, Daisuke; Kuroda, Keisuke; Namba, Takashi; Iizuka, Yukihiko; Taya, Shinichiro; Shinoda, Tomoyasu; Hikita, Takao; Muraoka, Shinsuke; Nimura, Ai; Kaibuchi, Kozo] Nagoya Univ, Grad Sch Med, Dept Cell Pharmacol, Nagoya, Aichi 4648601, Japan; [Tsuboi, Daisuke; Kuroda, Keisuke; Namba, Takashi; Iizuka, Yukihiko; Taya, Shinichiro; Iizuka, Michiro; Kaibuchi, Kozo] CREST, JST, Tokyo, Japan; [Tanaka, Motoki; Sokabe, Masahiro] Nagoya Univ, Grad Sch Med, Dept Physiol, Nagoya, Aichi 4648601, Japan; [Taya, Shinichiro] Natl Inst Neurosci, Dept Biochem & Cellular Biol, Kodaira, Tokyo 187, Japan; [Shinoda, Tomoyasu] Nagoya Univ, Grad Sch Med, Dept Anat & Cell Biol, Nagoya, Aichi 4648601, Japan; [Hikita, Takao] Nagoya Univ, Grad Sch Med Sci, Dept Dev & Regenerat Biol, Nagoya, Aichi 4648601, Japan; [Iizuka, Michiro; Mizoguchi, Akira] Mie Univ, Grad Sch Med, Dept Neural Regenerat & Cell Commun, Tsu, Mie 514, Japan; [Shiina, Nobuyuki] Okazaki Natl Res Inst, Dept Neuronal Cell Biol, Okazaki, Aichi, Japan; [Shiina, Nobuyuki] Natl Inst Nat Sci, Natl Inst Basic Biol, Okazaki, Aichi 4448585, Japan; [Okano, Hideyuki] Keio Univ, Sch Med, Dept Physiol, Shinjuku Ku, Tokyo 160, Japan; [Mikoshiba, Katsuhiko] RIKEN, Brain Sci Inst, Wako, Saitama, Japan	Kaibuchi, K (reprint author), Nagoya Univ, Grad Sch Med, Dept Cell Pharmacol, Nagoya, Aichi 4648601, Japan.	kaibuchi@med.nagoya-u.ac.jp	Okano, Hideyuki/J-5973-2013; 	Muraoka, Shinsuke/0000-0003-4225-110X	Ministry of Education, Culture, Sports, Science and Technology of Japan (MEXT) [26-J-JG38, 20227006]; Japan Society for the Promotion of Science, Japan Science and Technology Agency, CREST [26-J-Jc08]	We gratefully acknowledge T. Takumi (Hiroshima University, Higashihiroshima, Japan) for providing rat Staufen cDNA, S. Okabe (University of Tokyo, Tokyo, Japan) for providing the pAct expression vector, H. Song (Johns Hopkins University school of Medicine, Baltimore, Maryland) for providing the Disc1 shRNA vector and K. Kosik (University of California, Santa Barbara, Santa Barbara, California) for providing the RSV-MS2-CAMK2A 3' UTR construct. We thank T. Fujiwara (Kobe University) and A. Sawa (Johns Hopkins University) for helpful discussions. We also thank Y. Funahashi, Y. Fujino, H. Yano and T. Watanabe for providing materials; K. Kobayash and S. Suzuki for technical assistance; and T. Ishii for secretarial assistance. This work was supported in part by a Grant-in-Aid for the Strategic Research Program for Brain Science (SRPBS; Theme G) (26-J-JG38), a Grant-in-Aid for Scientific Research (S) (20227006), an Academic Frontier Project from the Ministry of Education, Culture, Sports, Science and Technology of Japan (MEXT) and a Grant-in-Aid for Creative Scientific Research from the Japan Society for the Promotion of Science, Japan Science and Technology Agency, CREST (26-J-Jc08).	Zhou MO, 2013, NEURON, V77, P647, DOI 10.1016/j.neuron.2012.12.033; Dictenberg JB, 2008, DEV CELL, V14, P926, DOI 10.1016/j.devcel.2008.04.003; Kamiya A, 2005, NAT CELL BIOL, V7, P1167, DOI 10.1038/ncb1328; Hayashi-Takagi A, 2010, NAT NEUROSCI, V13, P327, DOI 10.1038/nn.2487; Moosmang S, 2005, J NEUROSCI, V25, P9883, DOI 10.1523/JNEUROSCI.1531-05.2005; Brandon NJ, 2009, J NEUROSCI, V29, P12768, DOI 10.1523/JNEUROSCI.3355-09.2009; Bramham CR, 2007, NAT REV NEUROSCI, V8, P776, DOI 10.1038/nrn2150; Kiebler MA, 2006, NEURON, V51, P685, DOI 10.1016/j.neuron.2006.08.021; Hirokawa N, 2005, NAT REV NEUROSCI, V6, P201, DOI 10.1038/nrn1624; Miller S, 2002, NEURON, V36, P507, DOI 10.1016/S0896-6273(02)00978-9; Chubb JE, 2008, MOL PSYCHIATR, V13, P36, DOI 10.1038/sj.mp.4002106; Niwa M, 2010, NEURON, V65, P480, DOI 10.1016/j.neuron.2010.01.019; Brandon NJ, 2011, NAT REV NEUROSCI, V12, P707, DOI 10.1038/nrn3120; Blackwood DHR, 2001, AM J HUM GENET, V69, P428, DOI 10.1086/321969; Baek ST, 2014, NEURON, V82, P1255, DOI 10.1016/j.neuron.2014.04.036; McBride JL, 2008, P NATL ACAD SCI USA, V105, P5868, DOI [10.1073/pnas.0801775105, 10.1073/pnas.080177S105]; Strumbos JG, 2010, J NEUROSCI, V30, P10263, DOI 10.1523/JNEUROSCI.1125-10.2010; Huang YY, 2005, P NATL ACAD SCI USA, V102, P9365, DOI 10.1073/pnas.0503777102; Eberhart DE, 1996, HUM MOL GENET, V5, P1083, DOI 10.1093/hmg/5.8.1083; Koike H, 2006, P NATL ACAD SCI USA, V103, P3693, DOI 10.1073/pnas.0511189103; Millar JK, 2000, HUM MOL GENET, V9, P1415, DOI 10.1093/hmg/9.9.1415; Arimura N, 2009, DEV CELL, V16, P675, DOI 10.1016/j.devcel.2009.03.005; Funahashi Y, 2013, J NEUROSCI, V33, P13270, DOI 10.1523/JNEUROSCI.4210-12.2013; Rudy B, 2001, TRENDS NEUROSCI, V24, P517, DOI 10.1016/S0166-2236(00)01892-0; Mao YW, 2009, CELL, V136, P1017, DOI 10.1016/j.cell.2008.12.044; Yeap BB, 2002, J BIOL CHEM, V277, P27183, DOI 10.1074/jbc.M202883200; Kang EC, 2011, NEURON, V72, P559, DOI 10.1016/j.neuron.2011.09.032; Shinoda T, 2007, J NEUROSCI, V27, P4, DOI 10.1523/JNEUROSCI.3825-06.2007; Jones SW, 2005, BRIT J PHARMACOL, V145, P1093, DOI 10.1038/sj.bjp.0706279; Duan X, 2007, CELL, V130, P1146, DOI 10.1016/j.cell.2007.07.010; Nguyen PV, 1996, J NEUROSCI, V16, P3189; Bannai H, 2004, J BIOL CHEM, V279, P53427, DOI 10.1074/jbc.M409732200; Watanabe N, 2002, SCIENCE, V295, P1083, DOI 10.1126/science.1067470; Bertrand E, 1998, MOL CELL, V2, P437, DOI 10.1016/S1097-2765(00)80143-4; Kim JY, 2009, NEURON, V63, P761, DOI 10.1016/j.neuron.2009.08.008; Anderson P, 2006, J CELL BIOL, V172, P803, DOI 10.1083/jcb.200512082; Nakata K, 2009, P NATL ACAD SCI USA, V106, P15873, DOI 10.1073/pnas.0903413106; Hirokawa N, 2010, NEURON, V68, P610, DOI 10.1016/j.neuron.2010.09.039; Presley JF, 1997, NATURE, V389, P81; Nakata T, 2003, J CELL BIOL, V162, P1045, DOI 10.1083/jcb.200302175; Bayer TS, 2005, RNA, V11, P1848, DOI 10.1261/rna.2167605; Bardo S, 2006, TRENDS PHARMACOL SCI, V27, P78, DOI 10.1016/j.tips.2005.12.008; Kuroda K, 2011, HUM MOL GENET, V20, P4666, DOI 10.1093/hmg/ddr400; Taya S, 2007, J NEUROSCI, V27, P15, DOI 10.1523/JNEUROSCI.3826-06.2006; Kvajo M, 2012, NEUROSCIENCE, V211, P136, DOI 10.1016/j.neuroscience.2011.07.051; Kanai Y, 2004, NEURON, V43, P513, DOI 10.1016/j.neuron.2004.07.022; King SJ, 2000, NAT CELL BIOL, V2, P20; Clapcote SJ, 2006, GENETICS, V173, P2407, DOI 10.1534/genetics.106.060749; Iijima T, 2005, P NATL ACAD SCI USA, V102, P17190, DOI 10.1073/pnas.0504684102; Iijima T, 2007, NEUROSCI RES, V58, P183, DOI 10.1016/j.neures.2007.02.013; Ishizuka K, 2007, MOL PSYCHIATR, V12, P897, DOI 10.1038/sj.mp.4002024; Knowles RB, 1996, J NEUROSCI, V16, P7812; Kohrmann M, 1999, MOL BIOL CELL, V10, P2945; Kubo K, 2010, BIOCHEM BIOPH RES CO, V400, P631, DOI 10.1016/j.bbrc.2010.08.117; Li Y, 2004, J BIOCHEM BIOPH METH, V60, P85, DOI 10.1016/j.jbbm.2004.03.008; Maher BJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034053; Rook MS, 2000, J NEUROSCI, V20, P6385; Sugimoto M, 2006, MOL CELL BIOL, V26, P502, DOI 10.1128/MCB.26.2.502-512.2006	58	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1097-6256	1546-1726		NAT NEUROSCI	Nat. Neurosci.	MAY	2015	18	5					698	+		10.1038/nn.3984		12	Neurosciences	Neurosciences & Neurology	CG9LN	WOS:000353636900017		
J	Wan, XH; Cheng, K; Tanaka, KJ				Wan, Xiaohong; Cheng, Kang; Tanaka, Keiji			Neural encoding of opposing strategy values in anterior and posterior cingulate cortex	NATURE NEUROSCIENCE			English	Article							DECISION-MAKING; PREFRONTAL CORTEX; INTERTEMPORAL CHOICE; HUMAN BRAIN; MECHANISMS; OPTIMISM; MACAQUE; HUMANS; THREAT; RISK	Humans, and animals, often encounter ambiguous situations that require a decision on whether to take an offense or a defense strategy. Behavioral studies suggest that a strategy decision is frequently made before concrete options are evaluated. It remains enigmatic, however, how a strategy is determined without exploration of options. Here we investigated neural correlates of quick offense-versus-defense strategy decision in a board game, shogi. We found that the rostral anterior cingulate cortex and the posterior cingulate cortex complementally encoded the defense and attack strategy values, respectively. The dorsolateral prefrontal cortex compared the two strategy values. Several brain regions were activated during decision of concrete moves under an instructed strategy, whereas none of them showed correlation with defense or attack strategy values in their activities during strategy decision. These findings suggest that values of alternative strategies represented in different parts of the cingulate cortex have essential roles in intuitive strategy decision-making.	[Wan, Xiaohong; Cheng, Kang; Tanaka, Keiji] RIKEN, Brain Sci Inst, Cognit Brain Mapping Lab, Wako, Saitama, Japan; [Wan, Xiaohong] Beijing Normal Univ, State Key Lab Cognit Neurosci & Learning, Beijing 100875, Peoples R China; [Wan, Xiaohong] Beijing Normal Univ, IDG McGovern Inst Brain Res, Beijing 100875, Peoples R China; [Cheng, Kang] RIKEN, Brain Sci Inst, Support Unit Funct Magnet Resonance Imaging, Wako, Saitama, Japan	Tanaka, KJ (reprint author), RIKEN, Brain Sci Inst, Cognit Brain Mapping Lab, Wako, Saitama, Japan.	keiji@riken.jp			Fujitsu Laboratories; 111 Project in China [B07008]	We thank N. Nakatani, T. Asamizuya, K. Ueno and C. Suzuki for technical help, T. Ito and Y. Tsuruoka for invaluable discussions of the computational shogi program, Japan Shogi Association for advice on the task, and K. Matsumoto and H. Nakahara for valuable comments on an earlier version of the manuscript. This work was partially supported by the Fujitsu Laboratories and the 111 Project (B07008) in China.	Kellman P, 2001, MAGNET RESON MED, V45, P846, DOI 10.1002/mrm.1113; Kim S, 2011, BIOL PSYCHIAT, V69, P1140, DOI 10.1016/j.biopsych.2010.07.005; Wan XH, 2012, J NEUROSCI, V32, P17492, DOI 10.1523/JNEUROSCI.2312-12.2012; MACMILLAN NA, 1990, PSYCHOL BULL, V107, P401, DOI 10.1037/0033-2909.107.3.401; FLETCHER PC, 1995, COGNITION, V57, P109, DOI 10.1016/0010-0277(95)00692-R; Kolling N, 2012, SCIENCE, V336, P95, DOI 10.1126/science.1216930; Kable JW, 2007, NAT NEUROSCI, V10, P1625, DOI 10.1038/nn2007; Kim S, 2008, NEURON, V59, P161, DOI 10.1016/j.neuron.2008.05.010; Philiastides MG, 2010, P NATL ACAD SCI USA, V107, P9430, DOI 10.1073/pnas.1001732107; Rangel A, 2008, NAT REV NEUROSCI, V9, P545, DOI 10.1038/nrn2357; Hunt LT, 2012, NAT NEUROSCI, V15, P470, DOI 10.1038/nn.3017; Bush G, 2000, TRENDS COGN SCI, V4, P215, DOI 10.1016/S1364-6613(00)01483-2; Shenhav A, 2010, NEURON, V67, P667, DOI 10.1016/j.neuron.2010.07.020; Wagner AD, 2005, TRENDS COGN SCI, V9, P445, DOI 10.1016/j.tics.2005.07.001; Tom SM, 2007, SCIENCE, V315, P515, DOI 10.1126/science.1134239; MINTZBERG H, 1976, ADMIN SCI QUART, V21, P246, DOI 10.2307/2392045; DUTTON JE, 1987, ACAD MANAGE REV, V12, P76, DOI 10.2307/257995; McCoy AN, 2005, NAT NEUROSCI, V8, P1220, DOI 10.1038/nn1523; TVERSKY A, 1974, SCIENCE, V185, P1124, DOI 10.1126/science.185.4157.1124; Pearson JM, 2011, TRENDS COGN SCI, V15, P143, DOI 10.1016/j.tics.2011.02.002; Mobbs D, 2007, SCIENCE, V317, P1079, DOI 10.1126/science.1144298; FitzGerald THB, 2009, J NEUROSCI, V29, P8388, DOI 10.1523/JNEUROSCI.0717-09.2009; Levy DJ, 2012, CURR OPIN NEUROBIOL, V22, P1027, DOI 10.1016/j.conb.2012.06.001; Kim JN, 1999, NAT NEUROSCI, V2, P176; Mobbs D, 2009, J NEUROSCI, V29, P12236, DOI 10.1523/JNEUROSCI.2378-09.2009; Amemori KI, 2012, NAT NEUROSCI, V15, P776, DOI 10.1038/nn.3088; Heekeren HR, 2004, NATURE, V431, P859, DOI 10.1038/nature02966; VOGT BA, 1987, J COMP NEUROL, V262, P271, DOI 10.1002/cne.902620208; Strait CE, 2014, NEURON, V82, P1357, DOI 10.1016/j.neuron.2014.04.032; Boorman ED, 2009, NEURON, V62, P733, DOI 10.1016/j.neuron.2009.05.014; Schiller D, 2009, NAT NEUROSCI, V12, P508, DOI 10.1038/nn.2278; Rushworth MFS, 2011, NEURON, V70, P1054, DOI 10.1016/j.neuron.2011.05.014; Sharot T, 2007, NATURE, V450, P102, DOI 10.1038/nature06280; McNaughton N, 2004, NEUROSCI BIOBEHAV R, V28, P285, DOI 10.1016/j.neubiorev.2004.03.005; BLANCHARD DC, 1988, ANNU REV PSYCHOL, V39, P43, DOI 10.1146/annurev.psych.39.1.43; de Groot A. D., 1965, THOUGHT CHOICE CHESS; DEAKIN J F W, 1991, Journal of Psychopharmacology, V5, P305, DOI 10.1177/026988119100500414; Heilbronner SR, 2011, FRONT NEUROSCI-SWITZ, V5, DOI 10.3389/fnins.2011.00055; Jekins G. M., 1968, SPECTRAL ANAL ITS AP; Kahneman D., 1979, MANAGE SCI, V12, P313; Mintzberg H., 1989, MINTZBERG MANAGEMENT; Simon H. A., 1997, ADM BEHAV STUDY DECI; Sutton R., 1998, REINFORCEMENT LEARNI; Talairach J., 1988, COPLANAR STEREOTAXIC; Tesauro G, 2001, ADV COMP THE PRACT, V8, P117; von Neumann J, 1928, MATH ANN, V100, P295; von Neumann J., 1953, THEORY GAMES EC BEHA; Wan XH, 2011, SCIENCE, V331, P341, DOI 10.1126/science.1194732; WEINSTEIN ND, 1980, J PERS SOC PSYCHOL, V39, P806, DOI 10.1037//0022-3514.39.5.806	49	2	2	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1097-6256	1546-1726		NAT NEUROSCI	Nat. Neurosci.	MAY	2015	18	5					752	+		10.1038/nn.3999		11	Neurosciences	Neurosciences & Neurology	CG9LN	WOS:000353636900023		
J	Suzuki, T; Ueda, H; Okada, S; Sakurai, M				Suzuki, Tsutomu; Ueda, Hiroki; Okada, Shunpei; Sakurai, Masayuki			Transcriptome-wide identification of adenosine-to-inosine editing using the ICE-seq method	NATURE PROTOCOLS			English	Article							DNA-SEQUENCE DIFFERENCES; WIDESPREAD RNA; MESSENGER-RNA; GENETIC-VARIATION; SPLICE JUNCTIONS; GLUR-B; ADAR1; SITES; DEAMINASE; MUTATION	Inosine (I), a modified base found in the double-stranded regions of RNA in metazoans, has various roles in biological processes by modulating gene expression. Inosine is generated from adenosine (A) catalyzed by ADAR (adenosine deaminase acting on RNA) enzymes in a process called A-to-I RNA editing. As inosine is converted to guanosine (G) by reverse transcription, the editing sites can be identified by simply comparing cDNA sequences with the corresponding genomic sequence. One approach to screening I sites is by deep sequencing based on A-to-G conversion from genomic sequence to cDNA; however, this approach produces a high rate of false positives because it cannot efficiently eliminate G signals arising from inevitable mapping errors. To address this issue, we developed a biochemical method to identify inosines called inosine chemical erasing (ICE), which is based on cyanoethylation combined with reverse transcription. ICE was subsequently combined with deep sequencing (ICE-seq) for the reliable identification of transcriptome-wide A-to-I editing sites. Here we describe a protocol for the practical application of ICE-seq, which can be completed within 22 d, and which allows the accurate identification of transcriptome-wide A-to-I RNA editing sites.	[Suzuki, Tsutomu; Ueda, Hiroki; Okada, Shunpei; Sakurai, Masayuki] Univ Tokyo, Grad Sch Engn, Dept Chem & Biotechnol, Tokyo, Japan	Suzuki, T (reprint author), Univ Tokyo, Grad Sch Engn, Dept Chem & Biotechnol, Tokyo, Japan.	ts@chembio.t.u-tokyo.ac.jp	Suzuki, Tsutomu/J-1776-2015	Suzuki, Tsutomu/0000-0002-9731-1731	Ministry of Education, Science, Sports and Culture of Japan; New Energy and Industrial Technology Development Organization	We thank members of the Suzuki laboratory for their experimental assistance and fruitful discussions of this study. Special thanks are due to A. Fujiyama and A. Toyoda (National Institute of Genomics, Japan) for deep sequencing. This work was supported by Grants-in-Aid for Scientific Research on Priority Areas from the Ministry of Education, Science, Sports and Culture of Japan and by a grant from the New Energy and Industrial Technology Development Organization (to T.S.).	Altshuler DM, 2012, NATURE, V491, P56, DOI 10.1038/nature11632; Levanon EY, 2004, NAT BIOTECHNOL, V22, P1001, DOI 10.1038/nbt996; Rice GI, 2012, NAT GENET, V44, P1243, DOI 10.1038/ng.2414; Trapnell C, 2009, BIOINFORMATICS, V25, P1105, DOI 10.1093/bioinformatics/btp120; Sakurai M, 2010, NAT CHEM BIOL, V6, P733, DOI [10.1038/nchembio.434, 10.1038/.NCHEMBIO.434]; Kawahara Y, 2007, SCIENCE, V315, P1137, DOI 10.1126/science.1138050; Burns CM, 1997, NATURE, V387, P303, DOI 10.1038/387303a0; Ota H, 2013, CELL, V153, P575, DOI 10.1016/j.cell.2013.03.024; Kent WJ, 2002, GENOME RES, V12, P656, DOI [10.1101/gr.229202, 10.1101/gr.229202. Article published online before March 2002]; BRESLAUER KJ, 1986, P NATL ACAD SCI USA, V83, P3746, DOI 10.1073/pnas.83.11.3746; Li H, 2009, BIOINFORMATICS, V25, P1754, DOI 10.1093/bioinformatics/btp324; Paz N, 2007, GENOME RES, V17, P1586, DOI 10.1101/gr.6493107; Li H, 2009, BIOINFORMATICS, V25, P2078, DOI 10.1093/bioinformatics/btp352; HIGUCHI M, 1993, CELL, V75, P1361, DOI 10.1016/0092-8674(93)90622-W; Chen LL, 2008, EMBO J, V27, P1694, DOI 10.1038/emboj.2008.94; Li MY, 2011, SCIENCE, V333, P53, DOI 10.1126/science.1207018; Cattenoz PB, 2013, RNA, V19, P257, DOI 10.1261/rna.036202.112; Peng ZY, 2012, NAT BIOTECHNOL, V30, P253, DOI 10.1038/nbt.2122; Hundley HA, 2008, RNA, V14, P2050, DOI 10.1261/rna.1165008; Wang QD, 2004, J BIOL CHEM, V279, P4952, DOI 10.1074/jbc.M310162200; SMITH TF, 1981, J MOL BIOL, V147, P195, DOI 10.1016/0022-2836(81)90087-5; Piskol R, 2013, NAT BIOTECHNOL, V31, P19, DOI 10.1038/nbt.2472; Cibulskis K, 2013, NAT BIOTECHNOL, V31, P213, DOI 10.1038/nbt.2514; Wang Q, 2000, SCIENCE, V290, P1765, DOI 10.1126/science.290.5497.1765; Ohlson J, 2007, RNA, V13, P698, DOI 10.1261/rna.349107; KIM U, 1994, P NATL ACAD SCI USA, V91, P11457, DOI 10.1073/pnas.91.24.11457; Hoopengardner B, 2003, SCIENCE, V301, P832, DOI 10.1126/science.1086763; Garber M, 2011, NAT METHODS, V8, P469, DOI [10.1038/nmeth.1613, 10.1038/NMETH.1613]; Higuchi M, 2000, NATURE, V406, P78; Kawahara Y, 2004, NATURE, V427, P801, DOI 10.1038/427801a; Sakurai M, 2011, METHODS MOL BIOL, V718, P89, DOI 10.1007/978-1-61779-018-8_5; Paz-Yaacov N, 2010, P NATL ACAD SCI USA, V107, P12174, DOI 10.1073/pnas.1006183107; KIM U, 1994, J BIOL CHEM, V269, P13480; Melcher T, 1996, NATURE, V379, P460, DOI 10.1038/379460a0; Martin JA, 2011, NAT REV GENET, V12, P671, DOI 10.1038/nrg3068; Koboldt DC, 2012, GENOME RES, V22, P568, DOI 10.1101/gr.129684.111; Nishikura K, 2010, ANNU REV BIOCHEM, V79, P321, DOI 10.1146/annurev-biochem-060208-105251; Wu TD, 2005, BIOINFORMATICS, V21, P1859, DOI 10.1093/bioinformatics/bti310; Sakurai M, 2014, GENOME RES, V24, P522, DOI 10.1101/gr.162537.113; Tojo K, 2006, MOVEMENT DISORD, V21, P1510, DOI 10.1002/mds.21011; Rueter SM, 1999, NATURE, V399, P75; Bahn JH, 2012, GENOME RES, V22, P142, DOI 10.1101/gr.124107.111; Borchert GM, 2009, HUM MOL GENET, V18, P4801, DOI 10.1093/hmg/ddp443; Tonkin LA, 2002, EMBO J, V21, P6025, DOI 10.1093/emboj/cdf607; Jepson JEC, 2008, BBA-GENE REGUL MECH, V1779, P459, DOI 10.1016/j.bbagrm.2007.11.009; Li JB, 2009, SCIENCE, V324, P1210, DOI 10.1126/science.1170995; Maas S, 2001, P NATL ACAD SCI USA, V98, P14687, DOI 10.1073/pnas.251531398; Sherry ST, 2001, NUCLEIC ACIDS RES, V29, P308, DOI 10.1093/nar/29.1.308; Agranat L, 2008, P NATL ACAD SCI USA, V105, P5028, DOI 10.1073/pnas.0710576105; Barak M, 2009, NUCLEIC ACIDS RES, V37, P6905, DOI 10.1093/nar/gkp729; Bass BL, 2006, COLD SPRING HARB SYM, V71, P285, DOI 10.1101/sqb.2006.71.037; Bjork Glenn R., 1995, P165; Grosjean H, 2005, TOP CURR GENET, V12, P1, DOI 10.1007/b106848; HOUGH RF, 1994, J BIOL CHEM, V269, P9933; Huang Songbo, 2011, Frontiers in Genetics, V2, P46, DOI 10.3389/fgene.2011.00046; Kawahara Y, 2012, NAT PROTOC, V7, P1426, DOI 10.1038/nprot.2012.073; Kawahara Y, 2007, EMBO REP, V8, P763, DOI 10.1038/sj.embor.7401011; Kleinman CL, 2012, SCIENCE, V335, DOI 10.1126/science.1209658; Lin W, 2012, SCIENCE, V335, DOI 10.1126/science.1210624; Metzker ML, 2010, NAT REV GENET, V11, P31, DOI 10.1038/nrg2626; Morse DP, 1997, BIOCHEMISTRY-US, V36, P8429, DOI 10.1021/bi9709607; Pickrell JK, 2012, SCIENCE, V335, DOI 10.1126/science.1210484; Sambrook J., 2012, MOL CLONING LAB MANU; Sims D, 2014, NAT REV GENET, V15, P121, DOI 10.1038/nrg3642; Suzuki T, 2005, TOPICS CURRENT GENET, V12, P24; Wang K, 2010, NUCLEIC ACIDS RES, V38, DOI 10.1093/nar/gkq603; Wang Qiong, 2013, RNA, V19, P1525, DOI 10.1261/rna.041533.113	67	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1754-2189	1750-2799		NAT PROTOC	Nat. Protoc.	MAY	2015	10	5					715	732		10.1038/nprot.2015.037		18	Biochemical Research Methods	Biochemistry & Molecular Biology	CH1KJ	WOS:000353780000005		
J	Moro, K; Ealey, KN; Kabata, H; Koyasu, S				Moro, Kazuyo; Ealey, Kafi N.; Kabata, Hiroki; Koyasu, Shigeo			Isolation and analysis of group 2 innate lymphoid cells in mice	NATURE PROTOCOLS			English	Article							NATURAL HELPER-CELLS; IMMUNE-RESPONSES; AIRWAY INFLAMMATION; LUNG INFLAMMATION; ADAPTIVE IMMUNITY; TYPE-2 IMMUNITY; MAINTENANCE; REGULATORS; CYTOKINES; GATA3	Recent studies have identified distinct subsets of innate lymphocytes, collectively called innate lymphoid cells (ILCs), which lack antigen receptor expression but produce various effector cytokines. Group 2 ILCs (ILC2s) respond to epithelial cell-derived cytokines such as interleukin (IL)-25, IL-33 and thymic stromal lymphopoietin (TSLP), produce large amounts of type 2 cytokines, and have a key role in anti-helminth innate immunity and in the pathophysiology of allergic inflammation. The reported phenotypic characteristics of mouse ILC2s vary, depending on the tissue source and preparation method. This protocol describes improved methods for tissue-specific isolation and analysis of mouse ILC2s of high purity and yield from fat tissue, lung, bronchoalveolar lavage fluid (BALF) and small intestine. These improved methods are the result of our thorough investigation of enzymes used for tissue digestion, methods for the elimination of undesired cells, and a combination of antibodies for the detection and isolation of ILC2s. In addition, this new protocol now enables the isolation of ILC2s of high yield, even from inflamed tissues. Depending on the tissue being analyzed, it takes similar to 2-4 h for isolation and flow cytometric analysis of ILC2s from the various tissues of a single mouse and similar to 4-8 h to sort purified ILC2s from pooled tissues of multiple mice.	[Moro, Kazuyo; Ealey, Kafi N.; Kabata, Hiroki; Koyasu, Shigeo] RIKEN, Ctr Integrat Med Sci IMS, Lab Immune Cell Syst, Yokohama, Kanagawa, Japan; [Moro, Kazuyo] Japan Sci & Technol Agcy, Precursory Res Embryon Sci & Technol PRESTO, Tokyo, Japan; [Moro, Kazuyo] Yokohama City Univ, Grad Sch Med Life Sci, Dept Med Life Sci, Div Immunobiol, Yokohama, Kanagawa 232, Japan; [Kabata, Hiroki] Keio Univ, Sch Med, Dept Med, Div Pulm Med, Tokyo 160, Japan; [Koyasu, Shigeo] Keio Univ, Sch Med, Dept Microbiol & Immunol, Tokyo, Japan	Moro, K (reprint author), RIKEN, Ctr Integrat Med Sci IMS, Lab Immune Cell Syst, Yokohama, Kanagawa, Japan.	kazuyo.moro@riken.jp	Koyasu, Shigeo/J-5583-2015	Koyasu, Shigeo/0000-0001-9585-3038	Japan Science and Technology Agency; Japan Society for the Promotion of Science [26293110, 24659373, 22229004, 25670235]; Ministry of Education, Culture, Sports, Science and Technology, Japan [23118526, 15H01166]; Nakajima Foundation; Mochida Memorial Foundation for Medical and Pharmaceutical Research	We thank M. Mochitzuki and N. Takeno for technical assistance. We also thank S. Wada, C. Yamamoto and T. Shitamichi for taking care of mice. Thanks are also due to J. Furusawa, T. Sasaki and S. Koga for helpful advice and discussions. This work was supported by PRESTO to K.M. from the Japan Science and Technology Agency; a Grant-in Aid for Scientific Research (B) (26293110) and a Grant-in-Aid for Challenging Exploratory Research (24659373) to K.M.; a Grant-in-Aid for Scientific Research (S) (22229004) and a Grant-in-Aid for Challenging Exploratory Research (25670235) to S.K. from the Japan Society for the Promotion of Science; a Grant-in-Aid for Scientific Research on Innovative Areas (23118526 and 15H01166) to K.M. from the Ministry of Education, Culture, Sports, Science and Technology, Japan; and grants from The Nakajima Foundation and Mochida Memorial Foundation for Medical and Pharmaceutical Research to K.M.	Halim TYF, 2012, IMMUNITY, V36, P451, DOI 10.1016/j.immuni.2011.12.020; Spits H, 2012, ANNU REV IMMUNOL, V30, P647, DOI 10.1146/annurev-immunol-020711-075053; Halim TYF, 2014, IMMUNITY, V40, P425, DOI 10.1016/j.immuni.2014.01.011; Koyasu S, 2010, ADV IMMUNOL, V108, P21, DOI [10.1016/B978-0-12-380995-7.00002-1, 10.1016/S0065-2776(10)08002_8]; Kim BS, 2013, CURR OPIN IMMUNOL, V25, P738, DOI 10.1016/j.coi.2013.07.013; Hoyler T, 2012, IMMUNITY, V37, P634, DOI 10.1016/j.immuni.2012.06.020; Licona-Limon P, 2013, NAT IMMUNOL, V14, P536, DOI 10.1038/ni.2617; Koyasu S, 2011, IMMUNOLOGY, V132, P475, DOI 10.1111/j.1365-2567.2011.03413.x; Price AE, 2010, P NATL ACAD SCI USA, V107, P11489, DOI 10.1073/pnas.1003988107; Spits H, 2013, NAT REV IMMUNOL, V13, P145, DOI 10.1038/nri3365; Motomura Y, 2014, IMMUNITY, V40, P758, DOI 10.1016/j.immuni.2014.04.013; Spits H, 2011, NAT IMMUNOL, V12, P21, DOI 10.1038/ni.1962; Paul WE, 2010, NAT REV IMMUNOL, V10, P225, DOI 10.1038/nri2735; Vasanthakumar A, 2015, NAT IMMUNOL, V16, P276, DOI 10.1038/ni.3085; Holgate ST, 2012, NAT MED, V18, P673, DOI 10.1038/nm.2731; Sanos SL, 2010, METHODS MOL BIOL, V612, P505, DOI 10.1007/978-1-60761-362-6_32; Chang YJ, 2011, NAT IMMUNOL, V12, P631, DOI 10.1038/ni.2045; Neill DR, 2010, NATURE, V464, P1367, DOI 10.1038/nature08900; Furusawa J, 2013, J IMMUNOL, V191, P1818, DOI 10.4049/jimmunol.1300379; Caesar R, 2008, J LIPID RES, V49, P1588, DOI 10.1194/jlr.D800013-JLR200; Eberl G, 2010, NATURE, V464, P1285, DOI 10.1038/4641285a; Halim T.Y., 2014, CURR PROTOC IMMUNOL, V106; Huang YF, 2015, NAT IMMUNOL, V16, P161, DOI 10.1038/ni.3078; Kabata H, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3675; Kim HY, 2012, J ALLERGY CLIN IMMUN, V129, P216, DOI 10.1016/j.jaci.2011.10.036; Koyasu S, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00101; Moro K, 2010, NATURE, V463, P540, DOI 10.1038/nature08636	27	1	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1754-2189	1750-2799		NAT PROTOC	Nat. Protoc.	MAY	2015	10	5					792	806		10.1038/nprot.2015.047		15	Biochemical Research Methods	Biochemistry & Molecular Biology	CH1KJ	WOS:000353780000010		
J	Abe, M; Kalantar-Zadeh, K				Abe, Masanori; Kalantar-Zadeh, Kamyar			Haemodialysis-induced hypoglycaemia and glycaemic disarrays	NATURE REVIEWS NEPHROLOGY			English	Review							CHRONIC KIDNEY-DISEASE; STAGE RENAL-DISEASE; TYPE-2 DIABETIC-PATIENTS; HEMOGLOBIN A(1C) LEVELS; ATHEROSCLEROSIS MIA SYNDROME; INTENSIVE INSULIN THERAPY; GLYCATED ALBUMIN; DIALYSIS PATIENTS; MAINTENANCE HEMODIALYSIS; PLASMA-GLUCOSE	In patients with diabetes receiving chronic haemodialysis, both very high and low glucose levels are associated with poor outcomes, including mortality. Conditions that are associated with an increased risk of hypoglycaemia in these patients include decreased gluconeogenesis in the remnant kidneys, deranged metabolic pathways, inadequate nutrition, decreased insulin clearance, glucose loss to the dialysate and diffusion of glucose into erythrocytes during haemodialysis. Haemodialysis-induced hypoglycaemia is common during treatments with glucose-free dialysate, which engenders a catabolic status similar to fasting; this state can also occur with 5.55 mmol/l glucose-containing dialysate. Haemodialysis-induced hypoglycaemia occurs more frequently in patients with diabetes than in those without. Insulin therapy and oral hypoglycaemic agents should, therefore, be used with caution in patients on dialysis. Several hours after completion of haemodialysis treatment a paradoxical rebound hyperglycaemia may occur via a similar mechanism as the Somogyi effect, together with insulin resistance. Appropriate glycaemic control tailored for patients on haemodialysis is needed to avoid haemodialysis-induced hypoglycaemia and other glycaemic disarrays. In this Review we summarize the pathophysiology and current management of glycaemic disarrays in patients on haemodialysis.	[Abe, Masanori] Nihon Univ, Sch Med, Dept Internal Med, Div Nephrol Hypertens & Endocrinol,Itabashi Ku, Tokyo 1738610, Japan; [Kalantar-Zadeh, Kamyar] Univ Calif Irvine, Div Nephrol & Hypertens, Dept Med, Orange, CA 92868 USA	Abe, M (reprint author), Nihon Univ, Sch Med, Dept Internal Med, Div Nephrol Hypertens & Endocrinol,Itabashi Ku, 30-1 Oyaguchi Kami Chou, Tokyo 1738610, Japan.	abe.masanori@nihon-u.ac.jp			NIH/NIDDK [K24-DK091419, R01-DK078106]; AVEO	K.K.Z.'s work is supported by research grants from the NIH/NIDDK (K24-DK091419 and R01-DK078106) and philanthropic grants from Harold Simmons, Louis Chang, and AVEO. The authors appreciate invaluable advice on this manuscript given by K. Kaizu (Abe Clinic and Nihon University School of Medicine, Japan).	Abe M, 2011, CLIN NEPHROL, V75, P49, DOI 10.2379/CNP75049; Abe Masanori, 2008, Diabetes Res Clin Pract, V82, pe17, DOI 10.1016/j.diabres.2008.07.020; Abe M, 2008, CLIN NEPHROL, V69, P354; Abe M, 2011, CLIN NEPHROL, V76, P401, DOI 10.5414/CN106622; Abe M, 2011, INT J ARTIF ORGANS, V34, P16, DOI 10.5301/IJAO.2011.6314; Abe M, 2009, CLIN NEPHROL, V71, P514; Abe M, 2007, THER APHER DIAL, V11, P280, DOI 10.1111/j.1744-9987.2007.00491.x; Akmal M, 2001, AM J KIDNEY DIS, V38, pS195, DOI 10.1053/ajkd.2001.27443; AMIEL SA, 1988, DIABETES, V37, P901, DOI 10.2337/diabetes.37.7.901; Dong J, 2011, J RENAL NUTR, V21, P149, DOI 10.1053/j.jrn.2010.03.004; Ramirez SPB, 2012, DIABETES CARE, V35, P2527, DOI 10.2337/dc12-0573; Peacock TP, 2008, KIDNEY INT, V73, P1062, DOI 10.1038/ki.2008.25; Shinohara K, 2002, J AM SOC NEPHROL, V13, P1894, DOI 10.1097/01.ASN.0000019900.87535.43; Kalantar-Zadeh K, 2013, NEW ENGL J MED, V369, P374, DOI 10.1056/NEJMcpc1208154; GOLDBERG AP, 1980, KIDNEY INT, V18, P754, DOI 10.1038/ki.1980.194; Kim JC, 2013, J AM SOC NEPHROL, V24, P337, DOI 10.1681/ASN.2012010047; Siew ED, 2010, SEMIN DIALYSIS, V23, P378, DOI 10.1111/j.1525-139X.2010.00763.x; Mak RHK, 2000, SEMIN DIALYSIS, V13, P4, DOI 10.1046/j.1525-139x.2000.00007.x; Kovesdy CP, 2010, SEMIN DIALYSIS, V23, P148, DOI 10.1111/j.1525-139X.2010.00701.x; Duranton F, 2012, J AM SOC NEPHROL, V23, P1258, DOI 10.1681/ASN.2011121175; Zimmermann J, 1999, KIDNEY INT, V55, P648, DOI 10.1046/j.1523-1755.1999.00273.x; Abe M, 2011, ARTIF ORGANS, V35, P398, DOI 10.1111/j.1525-1594.2010.01112.x; Zoccali C, 2002, J AM SOC NEPHROL, V13, P134; OHKUBO Y, 1995, DIABETES RES CLIN PR, V28, P103, DOI 10.1016/0168-8227(95)01064-K; Hung AM, 2011, J AM SOC NEPHROL, V22, P437, DOI 10.1681/ASN.2010070760; MARAN A, 1995, DIABETOLOGIA, V38, P1412, DOI 10.1007/BF00400601; Raimann JG, 2012, NEPHROL DIAL TRANSPL, V27, P1559, DOI 10.1093/ndt/gfr520; Kalantar-Zadeh K, 2004, AM J CLIN NUTR, V80, P299; Abe M, 2008, NAT CLIN PRACT NEPHR, V4, P482, DOI 10.1038/ncpneph0881; Evenepoel P, 2009, KIDNEY INT, V76, pS12, DOI 10.1038/ki.2009.402; Oomichi T, 2006, DIABETES CARE, V29, P1496, DOI 10.2337/dc05-1887; Drechsler C, 2009, CIRCULATION, V120, P2421, DOI 10.1161/CIRCULATIONAHA.109.857268; Flynn C, 2013, NAT REV NEPHROL, V9, P147, DOI 10.1038/nrneph.2013.12; Charpentier G, 2000, DIABETES METAB, V26, P73; Ricks J, 2012, DIABETES, V61, P708, DOI 10.2337/db11-1015; Kalantar-Zadeh K, 2003, AM J KIDNEY DIS, V42, P864, DOI 10.1053/S0272-6386(03)01005-9; Abe M, 2007, THER APHER DIAL, V11, P288, DOI 10.1111/j.1744-9987.2007.00492.x; Slinin Y, 2012, AM J KIDNEY DIS, V60, P747, DOI 10.1053/j.ajkd.2012.07.017; Rhee CM, 2014, SEMIN DIALYSIS, V27, P135, DOI 10.1111/sdi.12198; Nakai S, 2013, THER APHER DIAL, V17, P567, DOI 10.1111/1744-9987.12147; Mather A, 2011, KIDNEY INT, V79, pS1, DOI 10.1038/ki.2010.509; Abe M, 2007, CLIN NEPHROL, V68, P287; Hayashino Y, 2007, DIABETOLOGIA, V50, P1170, DOI 10.1007/s00125-007-0650-z; Williams ME, 2010, CLIN J AM SOC NEPHRO, V5, P1595, DOI 10.2215/CJN.09301209; Okada T, 2007, INTERNAL MED, V46, P807, DOI 10.2169/internalmedicine.46.6355; Haviv YS, 2000, RENAL FAILURE, V22, P219, DOI 10.1081/JDI-100100866; Kalantar-Zadeh K, 2007, DIABETES CARE, V30, P1049, DOI 10.2337/dc06-2127; Vanholder R, 2008, PEDIATR NEPHROL, V23, P1211, DOI 10.1007/s00467-008-0762-9; Ito M, 2011, ENDOCR J, V58, P979; Stumvoll M, 1998, AM J PHYSIOL-ENDOC M, V274, pE817; Duong U, 2011, CLIN J AM SOC NEPHRO, V6, P1041, DOI 10.2215/CJN.08921010; MCCALL AL, 1986, AM J PHYSIOL, V251, pE442; Stubbs JR, 2010, J AM SOC NEPHROL, V21, P353, DOI 10.1681/ASN.2009040451; Holstein A, 2003, EUR J CLIN PHARMACOL, V59, P91, DOI 10.1007/s00228-003-0592-4; Abe M, 2011, CURR DRUG METAB, V12, P57, DOI 10.2174/138920011794520053; Inaba M, 2007, J AM SOC NEPHROL, V18, P896, DOI 10.1681/ASN.2006070772; Fukuoka K, 2008, NEPHROLOGY, V13, P278, DOI 10.1111/j.1440-1797.2007.00864.x; Nakao T, 1998, INTERNAL MED, V37, P826, DOI 10.2169/internalmedicine.37.826; Mehrotra R, 2011, CLIN J AM SOC NEPHRO, V6, P1520, DOI 10.2215/CJN.04210511; AREM R, 1989, ENDOCRIN METAB CLIN, V18, P103; Stenvinkel P, 2000, NEPHROL DIAL TRANSPL, V15, P953, DOI 10.1093/ndt/15.7.953; Stenvinkel P, 2005, KIDNEY INT, V67, P1216, DOI 10.1111/j.1523-1755.2005.00200.x; Ikizler TA, 2013, KIDNEY INT, V84, P1096, DOI 10.1038/ki.2013.147; Morioka T, 2001, DIABETES CARE, V24, P909, DOI 10.2337/diacare.24.5.909; Monnier L, 2011, DIABETES TECHNOL THE, V13, P813, DOI 10.1089/dia.2011.0049; Perkins RM, 2009, AM J KIDNEY DIS, V53, P606, DOI 10.1053/j.ajkd.2008.11.026; DEFRONZO RA, 1981, J CLIN INVEST, V67, P563, DOI 10.1172/JCI110067; Gerich JE, 2001, DIABETES CARE, V24, P382, DOI 10.2337/diacare.24.2.382; Meyer C, 2004, AM J PHYSIOL-ENDOC M, V287, pE1049, DOI 10.1152/ajpendo.00041.2004; AVRAM MM, 1976, T AM SOC ART INT ORG, V22, P412; Bober J, 2003, NEPHRON CLIN PRACT, V95, pC31, DOI 10.1159/000073016; Bober J, 2005, BLOOD PURIFICAT, V23, P219, DOI 10.1159/000084906; Boden G, 2004, J INVEST MED, V52, P375, DOI 10.2310/6650.2004.00608; BORAH MF, 1978, KIDNEY INT, V14, P491, DOI 10.1038/ki.1978.154; Burmeister JE, 2007, NEPHROL DIAL TRANSPL, V22, P1184, DOI 10.1093/ndt/gfl710; Collins Allan J, 2010, Am J Kidney Dis, V55, pS1, DOI 10.1053/j.ajkd.2009.10.009; DEFEO P, 1988, J CLIN INVEST, V82, P436, DOI 10.1172/JCI113616; Don BR, 2010, CLIN NEPHROL, V73, P431; DZURIK R, 1993, NEPHRON, V65, P108; Eidmak I., 1995, DIABETOLOGIA, V38, P565; Filho R. P., 2002, NEPHROL DIAL TRANSPL, V17, P28; Fouque D, 2008, KIDNEY INT, V73, P391, DOI 10.1038/sj.ki.5002585; Fujii Y, 2013, EXPERT OPIN PHARMACO, V14, P259, DOI 10.1517/14656566.2013.761690; GANDA OP, 1976, J CLIN INVEST, V57, P1403, DOI 10.1172/JCI108409; Gerich JE, 2000, DIABETES OBES METAB, V2, P345, DOI 10.1046/j.1463-1326.2000.00085.x; Grey AB, 2008, ANN INTERN MED, V148, P563; Guarnieri G, 2011, J RENAL NUTR, V21, P2, DOI 10.1053/j.jrn.2010.10.008; Guebre-Egziabher F, 2009, J CLIN ENDOCR METAB, V94, P2299, DOI 10.1210/jc.2008-2262; GUTIERREZ A, 1994, KIDNEY INT, V46, P814, DOI 10.1038/ki.1994.337; Haneda M, 2009, NEPHROL DIAL TRANSPL, V24, P338, DOI 10.1093/ndt/gfn616; HELLER SR, 1991, AM J PHYSIOL, V261, pE41; HELLER SR, 1991, CLIN SCI, V81, P1; HELLER SR, 1991, DIABETES, V40, P223, DOI 10.2337/diabetes.40.2.223; HENRICH WL, 1982, AM J KIDNEY DIS, V2, P349; Hill CJ, 2014, AM J KIDNEY DIS, V63, P84, DOI 10.1053/j.ajkd.2013.06.020; IKIZLER TA, 2013, J AM SOC NEPHROL, V8, P2174; Inaba M, 2012, CLIN NEPHROL, V78, P273, DOI 10.5414/CN106940; Isshiki K, 2014, THER APHER DIAL, V18, P434, DOI 10.1111/1744-9987.12123; Jackson MA, 1999, CLIN NEPHROL, V51, P242; Jackson MA, 2000, CLIN NEPHROL, V54, P30; Johansen KL, 1999, JAMA-J AM MED ASSOC, V281, P1275, DOI 10.1001/jama.281.14.1275; Kalantar-Zadeh K, 2009, J RENAL NUTR, V19, P33, DOI 10.1053/j.jrn.2008.11.012; Kidney Disease Improving Global Outcomes (KDIGO) CKD Work Group, 2012, KIDNEY INT S, V3, P1; Kidney Disease Outcomes Quality Initiative (KDOQI), 2007, AM J KIDNEY DIS, V49, pS62; Kim Y, 2013, INT UROL NEPHROL, V45, P1079, DOI 10.1007/s11255-012-0208-y; Kopple JD, 2011, NEPHROL DIAL TRANSPL, V26, P4095, DOI 10.1093/ndt/gfr363; Kume S, 2012, J DIABETES INVEST, V3, P298, DOI 10.1111/j.2040-1124.2011.00169.x; Loipl J, 2005, RENAL FAILURE, V27, P305, DOI 10.1081/JDI-200056608; Macdonald Jamie H, 2007, Nephron Clin Pract, V106, pc125, DOI 10.1159/000103000; Mak R. H., 1996, AM J PHYSIOL, V270, pF839; Mak R. H. K., 1994, DIABETES REV, V2, P19; MCCALEB ML, 1985, J CLIN INVEST, V75, P391, DOI 10.1172/JCI111712; Meyer C, 2002, AM J PHYSIOL-ENDOC M, V282, pE428; Molnar MZ, 2011, DIABETES CARE, V34, P2536, DOI 10.2337/dc11-0906; Munoz Mendoza J., 2012, CLIN J AM SOC NEPHRO, V7, P1155; National Kidney Foundation, 2012, AM J KIDNEY DIS, V60, P850, DOI DOI 10.1053/J.AJKD.2012.07.005; Park J, 2012, CURR DIABETES REP, V12, P432, DOI 10.1007/s11892-012-0286-3; Parsaw F, 1983, REPLACEMENT RENAL FU, P148; PEITZMAN SJ, 1977, NEPHRON, V19, P131, DOI 10.1159/000180877; Pupim LB, 2004, AM J PHYSIOL-ENDOC M, V286, pE589, DOI 10.1152/ajpendo.00384.2003; Reilly JB, 2010, SEMIN DIALYSIS, V23, P163, DOI 10.1111/j.1525-139X.2010.00703.x; Sam Ramin, 2006, Hemodial Int, V10, P15, DOI 10.1111/j.1542-4758.2006.01170.x; Sande FM, 2006, BLOOD PURIFICAT, V24, P335; Sangill M, 2006, AM J KIDNEY DIS, V47, P636, DOI 10.1053/j.ajkd.2006.01.007; Schernthaner G, 2010, NEPHROL DIAL TRANSPL, V25, P2044, DOI 10.1093/ndt/gfq199; Sharma R, 2008, HEMODIAL INT, V12, P221, DOI 10.1111/j.1542-4758.2008.00256.x; Shoji T, 2000, ATHEROSCLEROSIS, V153, P257, DOI 10.1016/S0021-9150(00)00529-3; Simic-Ogrizovic S, 2001, INT J ARTIF ORGANS, V24, P863; Skutches CL, 1997, AM J CLIN NUTR, V65, P128; Snyder RW, 2004, SEMIN DIALYSIS, V17, P365, DOI 10.1111/j.0894-0959.2004.17346.x; Takahashi A, 2004, CLIN NEPHROL, V62, P362; Diabet Contr Complicat Trial Res Grp, 1998, ARCH OPHTHALMOL-CHIC, V116, P874; The Diabetes Control and Complications Trial Research Group, 1993, NEW ENGL J MED, V329, P977, DOI [10.1056/NEJM199309303291401, DOI 10.1056/NEJM199309303291401]; Tuttle KR, 2014, AM J KIDNEY DIS, V64, P510, DOI 10.1053/j.ajkd.2014.08.001; United States Renal Data System, 2014, 2014 ANN DAT REP EP; WARD RA, 1987, KIDNEY INT, V32, P129, DOI 10.1038/ki.1987.182; WARD RA, 1979, AM J CLIN NUTR, V32, P2443; WATHEN RL, 1978, AM J CLIN NUTR, V31, P1870; Williams ME, 2006, KIDNEY INT, V70, P1503, DOI 10.1038/sj.ki.5001789; Yale J. F., 2005, J AM SOC NEPHROL, V16, P7	140	1	1	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1759-5061	1759-507X		NAT REV NEPHROL	Nat. Rev. Nephrol.	MAY	2015	11	5					302	313		10.1038/nrneph.2015.38		12	Urology & Nephrology	Urology & Nephrology	CG8TN	WOS:000353585600008		
J	Tsai, MS; Lee, ML; Chang, CY; Fan, HH; Yu, IS; Chen, YT; You, JY; Chen, CY; Chang, FC; Hsiao, JH; Khorkova, O; Liou, HH; Yanagawa, Y; Lee, LJ; Lin, SW				Tsai, Ming-Shian; Lee, Meng-Larn; Chang, Chun-Yun; Fan, Hsiang-Hsuan; Yu, I-Shing; Chen, You-Tzung; You, Jhih-Yi; Chen, Chun-Yu; Chang, Fang-Chia; Hsiao, Jane H.; Khorkova, Olga; Liou, Horng-Huei; Yanagawa, Yuchio; Lee, Li-Jen; Lin, Shu-Wha			Functional and structural deficits of the dentate gyrus network coincide with emerging spontaneous seizures in an Scn1a mutant Dravet Syndrome model during development	NEUROBIOLOGY OF DISEASE			English	Article						SCN1A; Dravet syndrome; Epilepsy; Mouse model	GABAERGIC SYNAPTIC-TRANSMISSION; HYPERTHERMIA-INDUCED SEIZURES; EXPERIMENTAL FEBRILE SEIZURES; SEVERE MYOCLONIC EPILEPSY; MOUSE MODEL; PYRAMIDAL NEURONS; RAT HIPPOCAMPUS; INHIBITORY INTERNEURONS; ELECTRICAL-STIMULATION; CORTICAL INTERNEURONS	Dravet syndrome (DS) is characterized by severe infant-onset myoclonic epilepsy along with delayed psychomotor development and heightened premature mortality. A primary monogenic cause is mutation of the SCN1A gene, which encodes the voltage-gated sodium channel subunit Na(v)1:1. The nature and timing of changes caused by SCN1A mutation in the hippocampal dentate gyrus (DG) network, a core area for gating major excitatory input to hippocampus and a classic epileptogenic zone, are not well known. In particularly, it is still not clear whether the developmental deficit of this epileptogenic neural network temporally matches with the progress of seizure development. Here, we investigated the emerging functional and structural deficits of the DG network in a novel mouse model (scn1a(E1099X/+)) that mimics the genetic deficit of human DS. Scn1a(E1099X/+) (Het) mice, similarly to human DS patients, exhibited early spontaneous seizures and were more susceptible to hyperthermia-induced seizures starting at postnatal week (PW) 3, with seizures peaking at PW4. During the same period, the Het DG exhibited a greater reduction of Na(v)1.1-expressing GABAergic neurons compared to other hippocampal areas. Het DG GABAergic neurons showed altered action potential kinetics, reduced excitability, and generated fewer spontaneous inhibitory inputs into DG granule cells. The effect of reduced inhibitory input to DC granule cells was exacerbated by heightened spontaneous excitatory transmission and elevated excitatory release probability in these cells. In addition to electrophysiological deficit, we observed emerging morphological abnormalities of DG granule cells. Het granule cells exhibited progressively reduced dendritic arborization and excessive spines, which coincided with imbalanced network activity and the developmental onset of spontaneous seizures. Taken together, our results establish the existence of significant structural and functional developmental deficits of the DG network and the temporal correlation between emergence of these deficits and the onset of seizures in Net animals. Most importantly, our results uncover the developmental deficits of neural connectivity in Net mice. Such structural abnormalities likely further exacerbate network instability and compromise higher-order cognitive processing later in development, and thus highlight the multifaceted impacts of Scn1a deficiency on neural development. (C) 2015 Elsevier Inc. All rights reserved.	[Tsai, Ming-Shian; You, Jhih-Yi; Chen, Chun-Yu; Lin, Shu-Wha] Natl Taiwan Univ, Natl Taiwan Univ Hosp, Coll Med, Dept Clin Lab Sci & Med Biotechnol, Taipei 100, Taiwan; [Lee, Meng-Larn; Chang, Fang-Chia] Natl Taiwan Univ, Dept Vet Med, Taipei 100, Taiwan; [Chang, Chun-Yun] NIDA, Intramural Res Program, Baltimore, MD 21224 USA; [Fan, Hsiang-Hsuan; Chen, You-Tzung] Natl Taiwan Univ, Natl Taiwan Univ Hosp, Coll Med, Grad Inst Med Genom & Prote, Taipei 100, Taiwan; [Yu, I-Shing] Natl Taiwan Univ, Natl Taiwan Univ Hosp, Coll Med, Lab Anim Ctr, Taipei 100, Taiwan; [Hsiao, Jane H.; Khorkova, Olga] OPKO Hlth Inc, Miami, FL 33137 USA; [Liou, Horng-Huei] Natl Taiwan Univ, Natl Taiwan Univ Hosp, Coll Med, Dept Neurol, Taipei 100, Taiwan; [Yanagawa, Yuchio] Gunma Univ, Grad Sch Med, Dept Genet & Behav Neurosci, Maebashi, Gumma 3718511, Japan; [Yanagawa, Yuchio] JST, CREST, Maebashi, Gumma 3718511, Japan; [Lee, Li-Jen] Natl Taiwan Univ, Natl Taiwan Univ Hosp, Coll Med, Grad Inst Anat & Cell Biol, Taipei 100, Taiwan; [Lee, Li-Jen] Natl Taiwan Univ, Natl Taiwan Univ Hosp, Coll Med, Grad Inst Brain & Mind Sci, Taipei 100, Taiwan; [Lin, Shu-Wha] Natl Taiwan Univ, Natl Taiwan Univ Hosp, Coll Med, Dept Lab Med, Taipei 100, Taiwan; [Lin, Shu-Wha] Natl Taiwan Univ, Ctr Genom Med, Taipei 100, Taiwan	Lee, LJ (reprint author), Natl Taiwan Univ, Coll Med, Grad Inst Anat & Cell Biol, 1 Sect 1,Ren Ai Rd, Taipei 100, Taiwan.	ljlee@ntu.edu.tw; mtshuwha@ntu.edu.tw		LEE, LI-JEN/0000-0001-9108-3654	National Taiwan University [103R7152]; Ministry of Science and Technology [MOST 103-2321-B-002-018]; Ministry of Health and Welfare in Taiwan [MOHW103-TDU-PB-211-133008]; MEXT of Japan; Takeda Science Foundation	Funding for this study was provided by National Taiwan University (103R7152), the Ministry of Science and Technology (MOST 103-2321-B-002-018), and the Ministry of Health and Welfare in Taiwan (MOHW103-TDU-PB-211-133008) for SW Lin, and the MEXT of Japan and Takeda Science Foundation for Y Yanagawa.	RACINE RJ, 1972, ELECTROEN CLIN NEURO, V32, P281, DOI 10.1016/0013-4694(72)90177-0; SHOLL DA, 1953, J ANAT, V87, P387; Jonas P, 2004, TRENDS NEUROSCI, V27, P30, DOI 10.1016/j.tins.2003.10.010; Brauchi S, 2006, J NEUROSCI, V26, P4835, DOI 10.1523/JNEUROSCI.5080-05.2006; Mistry AM, 2014, NEUROBIOL DIS, V65, P1, DOI 10.1016/j.nbd.2014.01.006; Wong ROL, 2002, NAT REV NEUROSCI, V3, P803, DOI 10.1038/nrn941; Garrido JJ, 2003, SCIENCE, V300, P2091, DOI 10.1126/science.1085167; Miller AR, 2014, GENES BRAIN BEHAV, V13, P163, DOI 10.1111/gbb.12099; Duflocq A, 2008, MOL CELL NEUROSCI, V39, P180, DOI 10.1016/j.mcn.2008.06.008; Tamamaki N, 2003, J COMP NEUROL, V467, P60, DOI 10.1002/cne.10905; Chen CY, 2012, HUM MOL GENET, V21, P4270, DOI 10.1093/hmg/dds261; Huang HP, 2011, GENE EXPR PATTERNS, V11, P316, DOI 10.1016/j.gep.2011.03.001; Schuchmann S, 2006, NAT MED, V12, P817, DOI 10.1038/nm1422; Cheah CS, 2012, P NATL ACAD SCI USA, V109, P14646, DOI 10.1073/pnas.1211591109; Yu FH, 2006, NAT NEUROSCI, V9, P1142, DOI 10.1038/nn1754; Lothman E W, 1992, Epilepsy Res Suppl, V7, P301; Harkin LA, 2007, BRAIN, V130, P843, DOI 10.1093/brain/awm002; Waxman SG, 2007, NAT NEUROSCI, V10, P405, DOI 10.1038/nn1857; DELANEROLLE NC, 1989, BRAIN RES, V495, P387, DOI 10.1016/0006-8993(89)90234-5; Lorincz A, 2008, J NEUROSCI, V28, P14329, DOI 10.1523/JNEUROSCI.4833-08.2008; Deller T, 1996, J NEUROSCI, V16, P3322; Bian F, 2006, BRAIN RES, V1075, P68, DOI 10.1016/j.brainres.2005.12.084; MILLER M, 1981, J NEUROCYTOL, V10, P859, DOI 10.1007/BF01262658; Kalume F, 2013, J CLIN INVEST, V123, P1798, DOI 10.1172/JCI66220; Sakauchi M, 2011, EPILEPSIA, V52, P50, DOI 10.1111/j.1528-1167.2011.03002.x; Depienne C, 2009, J MED GENET, V46, P183, DOI 10.1136/jmg.2008.062323; Han S, 2012, NATURE, V489, P385, DOI 10.1038/nature11356; Ohmori I, 2013, EPILEPSY RES, V105, P220, DOI 10.1016/j.eplepsyres.2013.01.003; Qu LT, 2007, NEUROBIOL DIS, V27, P320, DOI 10.1016/j.nbd.2007.06.003; Liu PT, 2003, GENOME RES, V13, P476, DOI 10.1101/gr.749203; Amaral DG, 2007, PROG BRAIN RES, V163, P3, DOI 10.1016/S0079-6123(07)63001-5; Ito S, 2013, NEUROBIOL DIS, V49, P29, DOI 10.1016/j.nbd.2012.08.003; ZUCKER RS, 1989, ANNU REV NEUROSCI, V12, P13, DOI 10.1146/annurev.neuro.12.1.13; Dickerson LW, 2002, BRAIN RES, V958, P227, DOI 10.1016/S0006-8993(02)03519-9; Ogiwara I, 2007, J NEUROSCI, V27, P5903, DOI 10.1523/JNEUROSCI.5270-06.2007; Butt SJB, 2005, NEURON, V48, P591, DOI 10.1016/j.neuron.2005.09.034; Bean BP, 2009, NAT NEUROSCI, V12, P530, DOI 10.1038/nn0509-530; Burgess DL, 2000, EPILEPSIA, V41, P1074, DOI 10.1111/j.1528-1157.2000.tb00305.x; Cao DZ, 2012, EPILEPSIA, V53, P1140, DOI 10.1111/j.1528-1167.2012.03497.x; CARPENTE.DO, 1968, J GEN PHYSIOL, V52, P1, DOI 10.1085/jgp.52.1.1; Dutton S.B., 2012, NEUROBIOL DIS C, V49C, P211, DOI DOI 10.1016/J.NBD.2012.08.012; Gazina EV, 2010, NEUROSCIENCE, V166, P195, DOI 10.1016/j.neuroscience.2009.12.011; Gloyn AL, 2006, EUR J HUM GENET, V14, P824, DOI 10.1038/sj.ejhg.5201629; GomezDiCesare CM, 1997, J COMP NEUROL, V384, P165, DOI 10.1002/(SICI)1096-9861(19970728)384:2<165::AID-CNE1>3.0.CO;2-#; GORMAN ALF, 1970, J PHYSIOL-LONDON, V210, P919; Gu F, 2014, EPILEPSIA, V55, P245, DOI 10.1111/epi.12487; Hernandez CC, 2011, J PHYSIOL-LONDON, V589, P5857, DOI 10.1113/jphysiol.2011.218883; Jou SB, 2013, SEIZURE-EUR J EPILEP, V22, P221, DOI 10.1016/j.seizure.2012.12.015; Leterrier C, 2011, SEMIN CELL DEV BIOL, V22, P171, DOI 10.1016/j.semcdb.2010.09.014; Liautard C, 2013, EPILEPSIA, V54, P1251, DOI 10.1111/epi.12213; LOVICK TA, 1988, BRAIN RES, V454, P123, DOI 10.1016/0006-8993(88)90810-4; Macdonald R.L, 2012, SOURCE JASPERS BASIC, V4th; Mancardi MM, 2006, EPILEPSIA, V47, P1629, DOI 10.1111/j.1528-1167.2006.00641.x; Martina M, 1998, J NEUROSCI, V18, P8111; Ohno Y, 2011, NEUROBIOL DIS, V41, P261, DOI 10.1016/j.nbd.2010.09.013; Qiao X, 2013, EPILEPSY RES, V106, P17, DOI 10.1016/j.eplepsyres.2013.06.006; Qu LT, 2008, J NEUROCHEM, V106, P2158, DOI 10.1111/j.1471-4159.2008.05576.x; Ribak C E, 1992, Epilepsy Res Suppl, V7, P29; Riva D, 2009, AM J MED GENET A, V149A, P2339, DOI 10.1002/ajmg.a.33029; Schmidt-Hieber C, 2007, J NEUROSCI, V27, P8430, DOI 10.1523/JNEUROSCI.1787-07.2007; Tai C, 2014, P NATL ACAD SCI USA, V111, pE3139, DOI 10.1073/pnas.1411131111; Tessier Charles R, 2009, Front Mol Neurosci, V2, P8, DOI 10.3389/neuro.02.008.2009; WANG W. D., 2011, J INEQUAL APPL, V6, P1, DOI DOI 10.1659/MRD-J0URNAL-D-10-00059.1); Wu J, 2000, J NEUROPHYSIOL, V84, P1355; Yamada K, 2001, SCIENCE, V292, P1543, DOI 10.1126/science.1059829; Liu YC, 2014, J NEUROSCI, V34, P1344, DOI 10.1523/JNEUROSCI.2566-13.2014	66	0	0	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0969-9961	1095-953X		NEUROBIOL DIS	Neurobiol. Dis.	MAY	2015	77						35	48		10.1016/j.nbd.2015.02.010		14	Neurosciences	Neurosciences & Neurology	CG9CO	WOS:000353612200004		
J	Yagi, Y; Yokote, H; Watanabe, Y; Amino, T; Kamata, T; Kusunoki, S				Yagi, Yohsuke; Yokote, Hiroaki; Watanabe, Yukiko; Amino, Takeshi; Kamata, Tomoyuki; Kusunoki, Susumu			Taste impairment in Miller Fisher syndrome	NEUROLOGICAL SCIENCES			English	Letter							BRAIN-STEM ENCEPHALITIS		[Yagi, Yohsuke; Yokote, Hiroaki; Watanabe, Yukiko; Amino, Takeshi; Kamata, Tomoyuki] Musashino Red Cross Hosp, Dept Neurol, Musashino, Tokyo 1808610, Japan; [Kusunoki, Susumu] Kinki Univ, Fac Med, Dept Neurol, Osaka, Japan	Yagi, Y (reprint author), Musashino Red Cross Hosp, Dept Neurol, Kyonancho 1-26-1, Musashino, Tokyo 1808610, Japan.	yyagi-tmd@umin.ac.jp					Shahrizaila N, 2013, J NEUROL NEUROSUR PS, V84, P576, DOI 10.1136/jnnp-2012-302824; Odaka M, 2002, NEUROLOGY, V58, P1437; Ohe Y, 2012, INTERNAL MED, V51, P2977, DOI 10.2169/internalmedicine.51.7769; FISHER M, 1956, NEW ENGL J MED, V255, P57, DOI 10.1056/NEJM195607122550201; Koga M, 2012, J NEUROL NEUROSUR PS, V83, P1210, DOI 10.1136/jnnp-2012-303060; Uchibori Ayumi, 2006, Rinsho Shinkeigaku, V46, P281; WINER JB, 1988, J NEUROL NEUROSUR PS, V51, P605, DOI 10.1136/jnnp.51.5.605; Yuki N, 2014, MUSCLE NERVE, V49, P629, DOI 10.1002/mus.24192	8	0	0	SPRINGER-VERLAG ITALIA SRL	MILAN	VIA DECEMBRIO, 28, MILAN, 20137, ITALY	1590-1874	1590-3478		NEUROL SCI	Neurol. Sci.	MAY	2015	36	5					809	810		10.1007/s10072-014-1916-0		2	Clinical Neurology; Neurosciences	Neurosciences & Neurology	CH1SB	WOS:000353800600025		
J	Abe, T; Fujimoto, Y; Kobayashi, T; Miura, T; Nishiwaki, K; Sakamoto, M; Tatsuta, Y				Abe, Tomo-hiro; Fujimoto, Yukihiro; Kobayashi, Tatsuo; Miura, Takashi; Nishiwaki, Kenji; Sakamoto, Makoto; Tatsuta, Yoshiyuki			Classification of three-generation models on magnetized orbifolds	NUCLEAR PHYSICS B			English	Article							DISCRETE FLAVOR SYMMETRIES; BRANE MODELS; EXTRA DIMENSIONS; WILSON LINES; BREAKING; FLUXES; ORIGIN; MASSES; BOSON; LHC	We classify the combinations of parameters which lead three generations of quarks and leptons in the framework of magnetized twisted orbifolds on T-2/Z(2), T-2/Z(3), T-2/Z(4) and T-2/Z(6) with allowing nonzero discretized Wilson line phases and Scherk-Schwarz phases. We also analyze two actual examples with nonzero phases leading to one-pair Higgs and five-pair Higgses and discuss the difference from the results without nonzero phases studied previously. (Note: this article is registered under preprint number: arXiv:1501.02787 [hep-ph].) (C) 2015 The Authors. Published by Elsevier B.V.	[Abe, Tomo-hiro] Kyoto Univ, Dept Phys, Kyoto 6068502, Japan; [Fujimoto, Yukihiro] Osaka Univ, Dept Phys, Toyonaka, Osaka 5600043, Japan; [Kobayashi, Tatsuo] Hokkaido Univ, Dept Phys, Sapporo, Hokkaido 0600810, Japan; [Miura, Takashi; Sakamoto, Makoto] Kobe Univ, Dept Phys, Kobe, Hyogo 6578501, Japan; [Nishiwaki, Kenji] Korea Inst Adv Study, Sch Phys, Seoul 130722, South Korea; [Tatsuta, Yoshiyuki] Waseda Univ, Dept Phys, Tokyo 1698555, Japan	Nishiwaki, K (reprint author), Korea Inst Adv Study, Sch Phys, Seoul 130722, South Korea.	t-abe@scphys.kyoto-u.ac.jp; fujimoto@het.phys.sci.osaka-u.ac.jp; kobayashi@particle.sci.holcudai.ac.jp; takashi.miura@people.kobe-u.ac.jp; nishiken@kias.re.kr; dragon@kob6-u.ac.jp; y_tatsuta@akane.waseda.jp			Ministry of Education, Culture, Sports, Science, and Technology [25.3825, 25400252, 20540274]	Y.T. would like to thank Hiroyuki Abe for useful comments. This work was supported in part by scientific grants from the Ministry of Education, Culture, Sports, Science, and Technology under Grants No. 25.3825 (Y.F.), No. 25400252 (T.K.) and No. 20540274 (M.S.).	Abe H, 2009, NUCL PHYS B, V814, P265, DOI 10.1016/j.nuclphysb.2009.02.002; Abe H, 2009, PHYS REV D, V80, DOI 10.1103/PhysRevD.80.126006; Abe H., ARXIV13071831; Abe H, 2010, PHYS REV D, V81, DOI 10.1103/PhysRevD.81.126003; Abe H, 2009, NUCL PHYS B, V820, P317, DOI [10.1016/j.nuclphysb.2009.05.024, 10.1010/j.nuclphysb.2009.05.024]; Abe H., 2014, J HIGH ENERGY PHYS, V1406; Abe H, 2009, J HIGH ENERGY PHYS, DOI 10.1088/1126-6708/2009/06/080; Abe H., 2008, JHEP, V0809; Abe TH, 2014, J HIGH ENERGY PHYS, DOI 10.1007/JHEP01(2014)065; Abe T.-h., ARXIV14095421; Abe T.-h., ARXIV150102787; Abel SA, 2003, NUCL PHYS B, V663, P197, DOI 10.1016/S0550-3213(03)00370-5; Abe H, 2014, PHYS REV D, V90, DOI 10.1103/PhysRevD.90.105006; Blumenhagen R, 2005, ANNU REV NUCL PART S, V55, P71, DOI 10.1146/annurev.nucl.55.090704.151541; Angelantonj C, 2000, PHYS LETT B, V489, P223, DOI 10.1016/S0370-2693(00)00907-2; FROGGATT CD, 1979, NUCL PHYS B, V147, P277, DOI 10.1016/0550-3213(79)90316-X; Kobayashi T, 2007, NUCL PHYS B, V768, P135, DOI 10.1016/j.nuclphysb.2007.01.018; Hashimoto A, 1997, NUCL PHYS B, V503, P193, DOI 10.1016/S0550-3213(97)00399-4; Angelantonj C, 2009, NUCL PHYS B, V818, P52, DOI 10.1016/j.nuclphysb.2009.03.018; Blumenhagen R, 2007, PHYS REP, V445, P1, DOI 10.1016/j.physrep.2007.04.003; Abe H, 2012, NUCL PHYS B, V863, P1, DOI 10.1016/j.nuclphysb.2012.05.012; Fujimoto Y, 2013, PHYS REV D, V87, DOI 10.1103/PhysRevD.87.086001; Abe H, 2013, NUCL PHYS B, V870, P30, DOI 10.1016/j.nuclphysb.2013.01.014; IBANEZ LE, 1987, PHYS LETT B, V187, P25, DOI 10.1016/0370-2693(87)90066-9; SCHERK J, 1979, NUCL PHYS B, V153, P61, DOI 10.1016/0550-3213(79)90462-0; SCHERK J, 1979, PHYS LETT B, V82, P60, DOI 10.1016/0370-2693(79)90425-8; Olive KA, 2014, CHINESE PHYS C, V38, DOI 10.1088/1674-1137/38/9/090001; Angelantonj C, 2005, NUCL PHYS B, V725, P115, DOI 10.1016/j.nuclphysb.2005.07.025; Antoniadis I, 2005, NUCL PHYS B, V716, P3, DOI 10.1016/j.nuclphysb.2005.03.026; Antoniadis I, 2009, NUCL PHYS B, V823, P116, DOI 10.1016/j.nuclphysb.2009.08.002; Bachas C., ARXIVHEPTH9503030; Berasaluce-Gonzalez M., 2012, J HIGH ENERGY PHYS, V1209, P059, DOI DOI 10.1007/JHEP09(2012)059; Beye F, 2014, PHYS LETT B, V736, P433, DOI 10.1016/j.physletb.2014.07.058; Blumenhagen R, 2000, J HIGH ENERGY PHYS; Blumenhagen R, 2005, J HIGH ENERGY PHYS; Blumenhagen R, 2001, J HIGH ENERGY PHYS; CHOI K, 2006, LECT NOTES PHYS, V696, P1; Choi KS, 2010, EUR PHYS J C, V67, P273, DOI 10.1140/epjc/s10052-010-1275-9; Cremades D, 2004, J HIGH ENERGY PHYS, DOI 10.1088/1126-6708/2004/05/079; Cremades D., 2003, JHEP, V0307; Cvetic M, 2003, PHYS REV D, V68, DOI 10.1103/PhysRevD.68.046001; De Angelis L, 2012, J HIGH ENERGY PHYS, DOI 10.1007/JHEP10(2012)052; Di Vecchia P, 2011, J PHYS A-MATH THEOR, V44, DOI 10.1088/1751-8113/44/24/245401; Forste S., 2011, J HIGH ENERGY PHYS, V1101; Fujimoto Y., 2014, J HIGH ENERGY PHYS, V1410, P191; Fujimoto Y, 2013, PHYS REV D, V88, DOI 10.1103/PhysRevD.88.115007; Fujimoto Y., 2013, PROG THEOR EXP PHYS, V2013; Goto Y, 2013, PHYS REV D, V88, DOI 10.1103/PhysRevD.88.055016; Goto Y, 2014, INT J MOD PHYS A, V29, DOI 10.1142/S0217751X14501504; Hamada Y., ARXIV14022052; Hamada Y, 2012, PROG THEOR PHYS, V128, P903; Honecker G, 2013, J HIGH ENERGY PHYS, DOI 10.1007/JHEP10(2013)146; KATSUKI Y, 1990, NUCL PHYS B, V341, P611, DOI 10.1016/0550-3213(90)90542-L; Kawamura Y, 2008, PROG THEOR PHYS, V120, P815, DOI 10.1143/PTP.120.815; Kawamura Y, 2007, PHYS REV D, V76, DOI [10.1103/PhysRevD.76.035001, 10.1103/PhysRevE.76.035001]; Kawamura Y, 2010, PHYS REV D, V81, DOI 10.1103/PhysRevD.81.075011; Kawamura Y., 2010, PROG THEOR PHYS, V122, P847; Ko P, 2007, PHYS REV D, V76, DOI 10.1106/PhysRevE.76.035005; KOBAYASHI T, 1994, INT J MOD PHYS A, V9, P87, DOI 10.1142/S0217751X94000054; Kobayashi T, 2010, J HIGH ENERGY PHYS, DOI 10.1007/JHEP05(2010)050; Kobayashi T, 2005, NUCL PHYS B, V704, P3, DOI 10.1016/j.nuclphysb.2004.10.035; KOBAYASHI T, 1991, PHYS LETT B, V257, P56, DOI 10.1016/0370-2693(91)90858-N; Marchesano F, 2013, J HIGH ENERGY PHYS, DOI 10.1007/JHEP09(2013)028; Sakamoto M, 2003, J MATH PHYS, V44, P5042, DOI 10.1063/1.1616203; Aad G, 2012, PHYS LETT B, V716, P1, DOI 10.1016/j.physletb.2012.08.020; Chatrchyan S, 2012, PHYS LETT B, V716, P30, DOI 10.1016/j.physletb.2012.08.021; Honecker G, 2012, J HIGH ENERGY PHYS, DOI 10.1007/JHEP04(2012)085; Vaudrevange P. K., 2013, J HIGH ENERGY PHYS, V1303, P142	68	2	2	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0550-3213	1873-1562		NUCL PHYS B	Nucl. Phys. B	MAY	2015	894						374	406		10.1016/j.nuclphysb.2015.03.004		33	Physics, Particles & Fields	Physics	CH2KE	WOS:000353853300018		
J	Grzadkowski, B; Hioki, Z				Grzadkowski, Bohdan; Hioki, Zenro			Optimal-observable analysis of the angular and energy distributions for top-quark decay products at polarized linear colliders (vol 585, pg 3, 2000)	NUCLEAR PHYSICS B			English	Correction									[Grzadkowski, Bohdan] Univ Warsaw, Inst Theoret Phys, PL-00681 Warsaw, Poland; [Hioki, Zenro] Univ Tokushima, Inst Theoret Phys, Tokushima 7708502, Japan	Hioki, Z (reprint author), Univ Tokushima, Inst Theoret Phys, Tokushima 7708502, Japan.	bohdan.grzadkowski@fuw.edu.pl; hioki@tokushima-u.ac.jp					Grzadkowski B, 2000, NUCL PHYS B, V585, P3, DOI 10.1016/S0550-3213(00)00385-0	1	1	1	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0550-3213	1873-1562		NUCL PHYS B	Nucl. Phys. B	MAY	2015	894						585	587		10.1016/j.nuclphysb.2015.03.020		3	Physics, Particles & Fields	Physics	CH2KE	WOS:000353853300027		
J	Girardi, I; Petcov, ST; Titov, AV				Girardi, I.; Petcov, S. T.; Titov, A. V.			Determining the Dirac CP violation phase in the neutrino mixing matrix from sum rules	NUCLEAR PHYSICS B			English	Article							DISCRETE FLAVOR SYMMETRIES; DOUBLE-BETA-DECAY; OSCILLATIONS; MASSES; RENORMALIZATION; PARAMETRIZATION; AMPLIFICATION; DELTA(6N(2)); PARAMETERS; EQUATIONS	Using the fact that the neutrino mixing matrix U = (UeU nu)-U-dagger, where U-e and U-v, result from the diagonalisation of the charged lepton and neutrino mass matrices, we analyse the sum rules which the Dirac phase delta present in U satisfies when U-nu has a form dictated by, or associated with, discrete symmetries and U-e has a "minimal" form (in terms of angles and phases it contains) that can provide the requisite corrections to U-nu, so that reactor, atmospheric and solar neutrino mixing angles theta(13), theta(23) and theta(12) have values compatible with the current data. The following symmetry forms are considered: i) tri-bimaximal (IBM), ii) bimaximal (BM) (or corresponding to the conservation of the lepton charge L' = L-e - L-mu - L-tau (LC)), iii) golden ratio type A (GRA), iv) golden ratio type B (GRB), and v) hexagonal (HG). We investigate the predictions for delta in the cases of TBM, BM (LC), GRA, GRB and HG forms using the exact and the leading order sum rules for cos delta proposed in the literature, taking into account also the uncertainties in the measured values of sin(2) theta(12), sin(2) theta(23) and sin(2) theta(13). This allows us, in particular, to assess the accuracy of the predictions for cos delta based on the leading order sum rules and its dependence on the values of the indicated neutrino mixing parameters when the latter are varied in their respective 3 sigma experimentally allowed ranges. (C) 2015 The Authors. Published by Elsevier B.V.	[Girardi, I.; Petcov, S. T.; Titov, A. V.] SISSA INFN, I-34136 Trieste, Italy; [Petcov, S. T.] Univ Tokyo, Kavli IPMU WPI, Kashiwa, Chiba 2778583, Japan; [Petcov, S. T.] Bulgarian Acad Sci, Inst Nucl Res & Nucl Energy, BU-1784 Sofia, Bulgaria	Girardi, I (reprint author), SISSA INFN, Via Bonomea 265, I-34136 Trieste, Italy.	igirardi@sissa.it		Titov, Arsenii/0000-0003-1311-6072	European Union FP7 ITN INVISIBLES (Marie Curie Actions) [PITN-GA-2011-289442-INVISIBLES]; INFN program on Theoretical Astroparticle Physics (TASP); the program PRIN - Italian Ministry of Education, University and Research (MIUR) [2012CPPYP7]; World Premier International Research Center Initiative (WPI Initiative, MEXT), Japan	This work was supported in part by the European Union FP7 ITN INVISIBLES (Marie Curie Actions, PITN-GA-2011-289442-INVISIBLES), by the INFN program on Theoretical Astroparticle Physics (TASP), by the research grant 2012CPPYP7 (Theoretical Astroparticle Physics) under the program PRIN 2012 funded by the Italian Ministry of Education, University and Research (MIUR) and by the World Premier International Research Center Initiative (WPI Initiative, MEXT), Japan (STP).	Adams C., ARXIV13077335HEPEX; Adulpravitchai A, 2009, NEW J PHYS, V11, DOI 10.1088/1367-2630/11/6/063026; Agarwalla S. K., 2014, J HIGH ENERGY PHYS, V1405; Altarelli G., 2012, J HIGH ENERGY PHYS, V1208; Antusch S, 2003, NUCL PHYS B, V674, P401, DOI 10.1016/j.nuclphysb.2003.09.050; Hagedorn C, 2015, NUCL PHYS B, V891, P499, DOI 10.1016/j.nuclphysb.2014.12.013; Chen MC, 2009, PHYS LETT B, V681, P444, DOI 10.1016/j.physletb.2009.10.059; Baltz AJ, 1998, PHYS REV LETT, V81, P5730, DOI 10.1103/PhysRevLett.81.5730; LANGACKER P, 1987, NUCL PHYS B, V282, P589, DOI 10.1016/0550-3213(87)90699-7; Kajiyama Y, 2007, PHYS REV D, V76, DOI 10.1103/PhysRevD.76.117301; Antusch S, 2005, PHYS LETT B, V631, P42, DOI 10.1016/j/physletb.2005.09.075; Masina I, 2006, PHYS LETT B, V633, P134, DOI 10.1016/j.physletb.2005.10.097; Xing ZZ, 2002, PHYS LETT B, V533, P85, DOI 10.1016/S0370-2693(02)01649-0; BABU KS, 1993, PHYS LETT B, V319, P191, DOI 10.1016/0370-2693(93)90801-N; Luhn C, 2013, NUCL PHYS B, V875, P80, DOI 10.1016/j.nuclphysb.2013.07.003; Altarelli G, 2004, NUCL PHYS B, V689, P157, DOI [10.1016/j.nuclphysb.2004.04.012, 10.1016/j.nuclphysb.2004.02.012]; CHANKOWSKI PH, 1993, PHYS LETT B, V316, P312, DOI 10.1016/0370-2693(93)90330-K; Barger V, 1998, PHYS LETT B, V437, P107, DOI 10.1016/S0370-2693(98)00880-6; CABIBBO N, 1978, PHYS LETT B, V72, P333, DOI 10.1016/0370-2693(78)90132-6; Pascoli S, 2007, NUCL PHYS B, V774, P1, DOI 10.1016/j.nuclphysb.2007.02.019; King SF, 2014, NEW J PHYS, V16, DOI 10.1088/1367-2630/16/4/045018; Petcov ST, 2006, NUCL PHYS B, V738, P219, DOI 10.1016/j.nuciphysb.2005.12.028; WOLFENSTEIN L, 1978, PHYS REV D, V18, P958, DOI 10.1103/PhysRevD.18.958; Petcov ST, 2015, NUCL PHYS B, V892, P400, DOI 10.1016/j.nuclphysb.2015.01.011; Altarelli G, 2013, FORTSCHR PHYS, V61, P507, DOI 10.1002/prop.201200117; Harrison PF, 2002, PHYS LETT B, V530, P167, DOI 10.1016/S0370-2693(02)01336-9; Casas JA, 2000, NUCL PHYS B, V573, P652, DOI 10.1016/S0550-3213(99)00781-6; [Anonymous], 2001, PHYS REV D; Harrison PF, 2002, PHYS LETT B, V535, P163, DOI 10.1016/S0370-2693(02)01753-7; Albright CH, 2010, EUR PHYS J C, V70, P1099, DOI 10.1140/epjc/s10052-010-1492-2; BILENKY SM, 1980, PHYS LETT B, V94, P495, DOI 10.1016/0370-2693(80)90927-2; Coloma P, 2014, PHYS REV D, V90, DOI 10.1103/PhysRevD.90.093003; Gehrlein J, 2015, NUCL PHYS B, V890, P539, DOI 10.1016/j.nuclphysb.2014.11.023; BILENKY SM, 1987, REV MOD PHYS, V59, P671, DOI 10.1103/RevModPhys.59.671; Albright CH, 2006, PHYS REV D, V74, DOI 10.1103/PhysRevD.74.113006; Giunti C, 2002, PHYS REV D, V66, DOI 10.1103/PhysRevD.66.053013; King SF, 2013, PHYS LETT B, V726, P312, DOI 10.1016/j.physletb.2013.08.052; KRASTEV PI, 1988, PHYS LETT B, V205, P84, DOI 10.1016/0370-2693(88)90404-2; He XG, 2003, PHYS LETT B, V560, P87, DOI 10.1016/S0370-2693(03)00390-3; Antusch S, 2013, NUCL PHYS B, V866, P255, DOI 10.1016/j.nuclphysb.2012.09.002; King SF, 2013, REP PROG PHYS, V76, DOI 10.1088/0034-4885/76/5/056201; Meroni A, 2012, PHYS REV D, V86, DOI 10.1103/PhysRevD.86.113003; Romanino A, 2004, PHYS REV D, V70, DOI 10.1103/PhysRevD.70.013003; Antusch S, 2011, PHYS REV D, V84, DOI 10.1103/PhysRevD.84.117301; Bazzocchi F, 2013, FORTSCHR PHYS, V61, P571, DOI 10.1002/prop.201200123; Capozzi F, 2014, PHYS REV D, V89, DOI 10.1103/PhysRevD.89.093018; Chao W, 2013, J HIGH ENERGY PHYS, V1302; Chen M.-C., 2013, J HIGH ENERGY PHYS, V1310, P112; de Gouvea A., ARXIV13104340HEPEX; Everett LL, 2009, PHYS REV D, V79, DOI 10.1103/PhysRevD.79.085005; Frampton PH, 2004, NUCL PHYS B, V687, P31, DOI 10.1016/j.nuclphysb.2004.03.014; Garg S.K., 2013, J HIGH ENERGY PHYS, V1310, P128; Girardi I., 2014, J HIGH ENERGY PHYS, V1402, P050; Gonzalez-Garcia M. C., 2014, J HIGH ENERGY PHYS, V1411, P052; Hall L.J., 2013, J HIGH ENERGY PHYS, V1311; Hochmuth KA, 2007, PHYS LETT B, V654, P177, DOI 10.1016/j.physletb.2007.08.072; Kim J.E., 2011, J HIGH ENERGY PHYS, V1102; King S. F., 2005, JHEP, V0508, P105; Liu Z, 2014, PHYS LETT B, V733, P226, DOI 10.1016/j.physletb.2014.04.049; Marzocca D, 2011, J HIGH ENERGY PHYS, DOI 10.1007/JHEP11(2011)009; Marzocca D., 2013, J HIGH ENERGY PHYS, V1305, P073; Nakamura K., 2014, CHINESE PHYS C, V38; Pascoli S, 2007, PHYS REV D, V75, DOI [10.1103/PhysRevD.75.083511, 10.1103/PhysRevA.75.083511]; PETCOV ST, 1982, PHYS LETT B, V110, P245, DOI 10.1016/0370-2693(82)91246-1; Rodejohann W, 2011, INT J MOD PHYS E, V20, P1833, DOI 10.1142/S0218301311020186; Rodejohann W, 2009, PHYS LETT B, V671, P267, DOI 10.1016/j.physletb.2008.12.010; Shimizu Y., ARXIV14051521HEPPH; Vissani F., ARXIVHEPPH9708483; Wang Y., 2013, POS NEUTEL, V2013	69	8	8	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0550-3213	1873-1562		NUCL PHYS B	Nucl. Phys. B	MAY	2015	894						733	768		10.1016/j.nuclphysb.2015.03.026		36	Physics, Particles & Fields	Physics	CH2KE	WOS:000353853300033		
J	Matsumoto, T; Imai, Y; Kosaka, Y; Shintani, T; Tomii, K				Matsumoto, Takeshi; Imai, Yukihiro; Kosaka, Yasuhiro; Shintani, Takashi; Tomii, Keisuke			Mixed large cell neuroendocrine carcinoma and mucosa-associated lymphoid tissue lymphoma of the lung: A case report	ONCOLOGY LETTERS			English	Article						large cell neuroendocrine carcinoma; mucosa-associated lymphoid tissue lymphoma; mix; chemoradiotherapy	PRIMARY PULMONARY LYMPHOMA; MALIGNANT-LYMPHOMA; MALT LYMPHOMA; ADENOCARCINOMA	In the present study, a 79-year-old male was referred to Kobe City Medical Center General Hospital due to an abnormal shadow that was revealed on a chest X-ray. The patient possessed a five-year history of consolidation in the right lower lobe, which was diagnosed as chronic aspiration pneumonia and followed up. However, the abnormal shadow adjacent to the pleura gradually increased in size and a novel mass appeared in the right lower lobe that rapidly increased in size. A repeat biopsy revealed a combination of large cell neuroendocrine carcinoma with a clinical tumor-node-metastasis (CTNM) stage of cT2bN2M0 (stage 3A) and mucosa-associated lymphoid tissue lymphoma at Ann Arbor stage 1E. Chemoradiotherapy markedly affected. the lesion and the size of the mass was significantly reduced subsequent to four cycles of chemotherapy, which was considered to be a near complete response. The present study reports an extremely rare combination of tumors. The disease course was followed over a period of six years, which included the onset of disease, and the present case may therefore be valuable in clarifying the mechanism of lung cancer development.	[Matsumoto, Takeshi; Tomii, Keisuke] Kobe City Med Ctr Gen Hosp, Dept Resp Med, Kobe, Hyogo 6500047, Japan; [Imai, Yukihiro] Kobe City Med Ctr Gen Hosp, Dept Pathol, Kobe, Hyogo 6500047, Japan; [Kosaka, Yasuhiro; Shintani, Takashi] Kobe City Med Ctr Gen Hosp, Dept Radiat Therapy, Kobe, Hyogo 6500047, Japan	Matsumoto, T (reprint author), Kobe City Med Ctr Gen Hosp, Dept Resp Med, 2-1-1 Minatojima Minamimachi, Kobe, Hyogo 6500047, Japan.	fu_rinkazan0202@yahoo.co.jp					Adrish Muhammad, 2014, J Bronchology Interv Pulmonol, V21, P96, DOI 10.1097/LBR.0000000000000038; Cadranel J, 2002, EUR RESPIR J, V20, P750, DOI 10.1183/09031936.02.00404102; Iyoda A, 2007, ANN THORAC SURG, V84, P702, DOI 10.1016/j.athoracsur.2007.03.093; ISAACSON P, 1983, CANCER, V52, P1410, DOI 10.1002/1097-0142(19831015)52:8<1410::AID-CNCR2820520813>3.0.CO;2-3; ADDIS BJ, 1988, HISTOPATHOLOGY, V13, P1, DOI 10.1111/j.1365-2559.1988.tb02000.x; Troch M, 2007, ANTICANCER RES, V27, P3633; Thieblemont C, 2000, BLOOD, V95, P802; Oh SY, 2010, ANN HEMATOL, V89, P563, DOI 10.1007/s00277-009-0875-7; Iyoda A, 2006, J THORAC CARDIOV SUR, V132, P312, DOI 10.1016/j.jtcvs.2006.02.046; Thieblemont C, 1997, J CLIN ONCOL, V15, P1624; Tihan T, 1996, CANCER, V77, P2325, DOI 10.1002/(SICI)1097-0142(19960601)77:11<2325::AID-CNCR22>3.0.CO;2-Y; Chanel S, 2001, HUM PATHOL, V32, P129, DOI 10.1053/hupa.2001.20893; Chilosi M, 2005, SEM RESP CRIT CARE M, V26, P490, DOI 10.1055/s-2005-922032; Du Ming-Qing, 2007, J Clin Exp Hematop, V47, P31, DOI 10.3960/jslrt.47.31; Fujiwara Y, 2007, JPN J CLIN ONCOL, V37, P482, DOI 10.1093/jjco/hym053; Ichihara E, 2008, J THORAC ONCOL, V3, P1362, DOI 10.1097/JTO.0b013e31818b1b07; Itoh Tomoyoshi, 2009, Nihon Kokyuki Gakkai Zasshi, V47, P410; Iyoda A, 2001, CANCER, V91, P1992, DOI 10.1002/1097-0142(20010601)91:11<1992::AID-CNCR1224>3.0.CO;2-5; Jung Chi Young, 2012, Tuberc Respir Dis (Seoul), V73, P61, DOI 10.4046/trd.2012.73.1.61; Stagnaro E, 2004, CANCER EPIDEM BIOMAR, V13, P431; Suzuki T, 2000, Jpn J Thorac Cardiovasc Surg, V48, P817; TRAVIS WD, 1991, AM J SURG PATHOL, V15, P529, DOI 10.1097/00000478-199106000-00003	22	0	0	SPANDIDOS PUBL LTD	ATHENS	POB 18179, ATHENS, 116 10, GREECE	1792-1074	1792-1082		ONCOL LETT	Oncol. Lett.	MAY	2015	9	5					2068	2072		10.3892/ol.2015.2994		5	Oncology	Oncology	CH2IW	WOS:000353849900016		
J	Hakozaki, M; Yamada, H; Tajino, T; Konno, S				Hakozaki, Michiyuki; Yamada, Hitoshi; Tajino, Takahiro; Konno, Shinichi			Functional reconstruction of the knee extension mechanism following wide resection for a prepatellar soft-tissue sarcoma: A case report	ONCOLOGY LETTERS			English	Article						biological reconstruction; pedicle frozen autograft; juxta-articular malignant tumor; knee extension mechanism; functional reconstruction	FROZEN AUTOGRAFT; TUMORS; BONE	Functional reconstruction following a wide resection for a malignant musculoskeletal tumor is often challenging, particularly for juxta-articular tumors. The current study describes a novel surgical procedure for the functional reconstruction of the knee extensor mechanism with a pedicle frozen auto-bone and -tendon graft, in a case of prepatellar clear cell sarcoma. The active range of motion of the knee was from 0-135, and the extension muscular strength of the knee was evaluated as 5/5 by a manual muscle test at 14 months post-surgery (International Society of Limb Salvage score, 73%); this was improved compared with a similar procedure previously described by Muramatsu et al. This procedure must be considered following the wide resection of juxta-articular malignant musculoskeletal tumors.	[Hakozaki, Michiyuki; Yamada, Hitoshi; Tajino, Takahiro; Konno, Shinichi] Fukushima Med Univ, Dept Orthopaed Surg, Sch Med, Fukushima 9601295, Japan	Hakozaki, M (reprint author), Fukushima Med Univ, Dept Orthopaed Surg, Sch Med, 1 Hikarigaoka, Fukushima 9601295, Japan.	paco@fmu.ac.jp					Tanzawa Y, 2009, J ORTHOP SCI, V14, P761, DOI 10.1007/s00776-009-1392-1; ENNEKING WF, 1993, CLIN ORTHOP RELAT R, P241; Cho Y, 2009, ORTHOPEDICS, DOI [10.3928/01477447-20090818-27, DOI 10.3928/01477447-20090818-27]; Ek EW, 2011, ARCH ORTHOP TRAUM SU, V131, P487, DOI 10.1007/s00402-010-1158-4; Jentzsch T, 2013, CLIN ORTHOP RELAT R, V471, P2333, DOI 10.1007/s11999-013-2851-8; Machens HG, 2005, J RECONSTR MICROSURG, V21, P235, DOI 10.1055/s-2005-871749; Muramatsu Keiichi, 2010, Orthopedics, V33, P773, DOI 10.3928/01477447-20100826-32; Nakashima H, 2012, UPSALA J MED SCI, V117, P460, DOI 10.3109/03009734.2012.689379; National Cancer Institute, CTCAE V4 03; Shimozaki S, 2014, J ORTHOP SCI, V19, P156, DOI 10.1007/s00776-013-0487-x	10	0	0	SPANDIDOS PUBL LTD	ATHENS	POB 18179, ATHENS, 116 10, GREECE	1792-1074	1792-1082		ONCOL LETT	Oncol. Lett.	MAY	2015	9	5					2095	2098		10.3892/ol.2015.2991		4	Oncology	Oncology	CH2IW	WOS:000353849900021		
J	Ikeda, S; Naruse, K; Nagata, C; Kuramochi, M; Onuki, T; Inagaki, M; Suzuki, K				Ikeda, Satoshi; Naruse, Keishi; Nagata, Chigusa; Kuramochi, Masami; Onuki, Takuya; Inagaki, Masaharu; Suzuki, Keiko			Immunostaining for thyroid transcription factor 1, Napsin A, p40, and cytokeratin 5 aids in differential diagnosis of non-small cell lung carcinoma	ONCOLOGY LETTERS			English	Article						immunocytochemistry; lung cytopathology; scoring	FACTOR-I; PULMONARY; P63; ADENOCARCINOMA; EXPRESSION; CANCER; BREAST; DELTA-NP63; SPECIMENS; CYTOLOGY	The present study aimed to examine the effectiveness of immunostaining of cytological specimens in discerning squamous from non-squamous cell carcinoma. Various combinations of six antibodies were examined in order to determine the optimal combination for use in differential diagnosis. Immunostaining was performed using tumor imprint smears obtained from 70 lung carcinoma cases. The results were scored based on positive area and intensity. For objective evaluation, scores for thyroid transcription factor 1 (TTF-1), napsin A, and CK CAM5.2 were expressed with positive values, while those for p40, cytokeratin (CK) 5/6 and CK5 were expressed with negative values. Histograms were produced to evaluate which combination was the most effective in differentiating squamous cell carcinoma from adenocarcinoma. The sensitivity for these molecules in adenocarcinoma was 88% for TTF-1, 85% for napsin A, and 100% for CAM5.2. In squamous cell carcinomas, sensitivity was determined to be 90% for p40, 86% for CK5, and 76% for CK5/6. The specificity for these molecules was calculated as 100%, 95%, 43%, 98%, 100% and 95%, respectively. Each combination was evaluated for scoring and the values were averaged. The most effective combination for mode and mean was TTF-1, napsin A, p40, and CK5, for which all adenocarcinomas had a score >1, and all squamous cell carcinomas scored <-2. Immunostaining scoring may therefore be useful for the differential diagnosis of these carcinomas when a limited number of tumor cells are present.	[Ikeda, Satoshi; Nagata, Chigusa; Suzuki, Keiko] Tsuchiura Kyodo Gen Hosp, Dept Pathol, Tsuchiura, Ibaraki 3000053, Japan; [Naruse, Keishi] Natl Hosp Org Natl Kochi Hosp, Dept Pathol, Kochi 7808077, Japan; [Kuramochi, Masami; Onuki, Takuya; Inagaki, Masaharu] Tsuchiura Kyodo Gen Hosp, Dept Resp Surg, Tsuchiura, Ibaraki 3000053, Japan	Ikeda, S (reprint author), Tsuchiura Kyodo Gen Hosp, Dept Pathol, 11-7 Manabe Shinmachi, Tsuchiura, Ibaraki 3000053, Japan.	isohama2587@proof.ocn.ne.jp					Walker RA, 2012, J CLIN PATHOL, V65, P771, DOI 10.1136/jclinpath-2012-200733; Yatabe Y, 2002, AM J SURG PATHOL, V26, P767, DOI 10.1097/00000478-200206000-00010; Ciuleanu T, 2009, LANCET, V374, P1432, DOI 10.1016/S0140-6736(09)61497-5; Nonaka D, 2012, AM J SURG PATHOL, V36, P895, DOI 10.1097/PAS.0b013e3182498f2b; Whithaus K, 2012, ARCH PATHOL LAB MED, V136, P155, DOI 10.5858/arpa.2011-0232-OA; Sandler A, 2006, NEW ENGL J MED, V355, P2542, DOI 10.1056/NEJMoa061884; Turner BM, 2012, ARCH PATHOL LAB MED, V136, P163, DOI 10.5858/arpa.2011-0320-OA; Aikawa E, 2011, CANCER CYTOPATHOL, V119, P335, DOI 10.1002/cncy.20162; Bhargava R, 2008, AM J CLIN PATHOL, V130, P724, DOI 10.1309/AJCP3KFF1LTYWQIY; Bishop JA, 2012, MODERN PATHOL, V25, P405, DOI 10.1038/modpathol.2011.173; Hirano T, 2000, JPN J CANCER RES, V91, P1015; Ikeda S, 2003, J JPN CLIN CYTOL, V42, P5; Kakizaki Y, 2007, J JPN CLIN CYTOL, V46, P120; Kim DH, 2010, ACTA CYTOL, V54, P55, DOI 10.1159/000324967; Li Yan, 2013, Clin Proteomics, V10, P15, DOI 10.1186/1559-0275-10-15; Ng WK, 2002, CANCER CYTOPATHOL, V96, P43, DOI 10.1002/cncr.10310; Pennacchia I, 2015, BREAST          0219; Sethi S, 2012, CYTOJOURNAL, V9, DOI 10.4103/1742-6413.94570; Shibuki Y, 2006, J JPN CLIN CYTOL, V45, P6; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; Uke M, 2010, CYTOPATHOLOGY, V21, P56, DOI 10.1111/j.1365-2303.2009.00678.x; Yanagita Emmy, 2011, Appl Immunohistochem Mol Morphol, V19, P509, DOI 10.1097/PAI.0b013e318212f027	22	0	0	SPANDIDOS PUBL LTD	ATHENS	POB 18179, ATHENS, 116 10, GREECE	1792-1074	1792-1082		ONCOL LETT	Oncol. Lett.	MAY	2015	9	5					2099	2104		10.3892/ol.2015.3045		6	Oncology	Oncology	CH2IW	WOS:000353849900022		
J	Takakuwa, O; Oguri, T; Maeno, K; Murase, H; Asano, T; Ichikawa, H; Kawaguchi, Y; Uemura, T; Ohkubo, H; Takemura, M; Niimi, A				Takakuwa, Osamu; Oguri, Tetsuya; Maeno, Ken; Murase, Hiroki; Asano, Takamitsu; Ichikawa, Hiroya; Kawaguchi, Yuko; Uemura, Takehiro; Ohkubo, Hirotsugu; Takemura, Masaya; Niimi, Akio			Long-term use of a once-a-day fentanyl citrate transdermal patch in lung cancer patients	ONCOLOGY LETTERS			English	Article						fentanyl citrate; lung cancer; palliative treatment; transdermal patch; terminal care; transdermal fentanyl	QUALITY-OF-LIFE; ORAL MORPHINE; PAIN; RECOMMENDATIONS; DYSPNEA; OPIOIDS; EAPC	Transdermal fentanyl is widely administered as an analgesic therapy for cancer patients. Recently, a novel fentanyl citrate transdermal patch was developed in Japan, which is the first such patch that requires changing only once a day. The patch releases more stable serum fentanyl concentrations and results in less frequent adverse skin symptoms compared with the conventional 72-h transdermal fentanyl patch. A previous study has reported the short-term analgesic effects and safety of this transdermal patch. However, the long-term efficacy has yet to be determined. Therefore, the present study retrospectively investigated the adverse effects and outcomes of treatment with this product in 46 lung cancer patients. In total, 35 (76%) patients were able to continue the treatment until the end of the observation period, including 32 (69%) who succumbed to the disease and three (7%) who were transferred from Nagoya City University Hospital to a hospice. Of the 11(24%) discontinued cases, six were changed to a course of injectable opioids for the palliation of terminal symptoms, including dyspnea. Adverse effects were observed in 11(24%) cases, but discontinuation due to adverse effects occurred in only four cases. Therefore, the present study indicates that palliative treatment with the once-a-day fentanyl citrate transdermal patch is well-tolerated by lung cancer patients.	[Takakuwa, Osamu; Oguri, Tetsuya; Maeno, Ken; Murase, Hiroki; Asano, Takamitsu; Ichikawa, Hiroya; Kawaguchi, Yuko; Uemura, Takehiro; Ohkubo, Hirotsugu; Takemura, Masaya; Niimi, Akio] Nagoya City Univ, Dept Resp Med Allergy & Clin Immunol, Grad Sch Med Sci, Nagoya, Aichi 4678601, Japan	Oguri, T (reprint author), Nagoya City Univ, Dept Resp Med Allergy & Clin Immunol, Grad Sch Med Sci, Mizuho Ku, 1 Kawasumi,Mizuho Cho, Nagoya, Aichi 4678601, Japan.	t-oguri@med.nagoya-cu.ac.jp					Vigano A, 2004, CANCER, V101, P1090, DOI 10.1002/cncr.20472; Hanks GW, 2001, BRIT J CANCER, V84, P587, DOI 10.1054/bjoc.2001.1680; Shimizu Y, 2003, CLIN CANCER RES, V9, P774; CLEELAND CS, 1994, NEW ENGL J MED, V330, P592, DOI 10.1056/NEJM199403033300902; Caraceni A, 2012, LANCET ONCOL, V13, pE58, DOI 10.1016/S1470-2045(12)70040-2; Payne R, 1998, J CLIN ONCOL, V16, P1588; BRUERA E, 1993, ANN INTERN MED, V119, P906; Claessens MT, 2000, J AM GERIATR SOC, V48, pS146; Mazzocato C, 1999, ANN ONCOL, V10, P1511, DOI 10.1023/A:1008337624200; Mercadante S, 2008, EUR J PAIN, V12, P1040, DOI 10.1016/j.ejpain.2008.01.013; Miyazaki Toyo, 2010, Gan To Kagaku Ryoho, V37, P1747; National Collaborating Centre for Cancer (UK), 2012, OP PALL CAR SAF EFF; Pinna MA, 2013, AM J HOSP PALLIAT CA; Takakuwa O, 2013, AM J HOSP PALLIAT ME, V30, P726, DOI 10.1177/1049909112470020; van den Beuken-van Everdingen M H J, 2007, Ann Oncol, V18, P1437, DOI 10.1093/annonc/mdm056; World Health Organization (WHO), 1996, CHAG DIS PROGR EL TR, V2nd, P12	16	0	0	SPANDIDOS PUBL LTD	ATHENS	POB 18179, ATHENS, 116 10, GREECE	1792-1074	1792-1082		ONCOL LETT	Oncol. Lett.	MAY	2015	9	5					2105	2108		10.3892/ol.2015.3022		4	Oncology	Oncology	CH2IW	WOS:000353849900023		
J	Hayashi, S; Abe, Y; Tomita, S; Nakanishi, Y; Miwa, S; Nakajima, T; Nomoto, K; Tsuneyama, K; Fujimori, T; Imura, J				Hayashi, Shinichi; Abe, Yoshiro; Tomita, Shigeki; Nakanishi, Yuko; Miwa, Shigeharu; Nakajima, Takahiko; Nomoto, Kazuhiro; Tsuneyama, Koichi; Fujimori, Takahiro; Imura, Johji			Primary non-gestational pure choriocarcinoma arising in the ovary: A case report and literature review	ONCOLOGY LETTERS			English	Article						choriocarcinoma; non-gestational; ovary; beta 2-microglobulin; pathology	BETA-2-MICROGLOBULIN	Pure non-gestational choriocarcinoma is a primary germ cell neoplasm that has been defined as a tumor without other germ cell elements. The current study presents an extremely rare case of non-gestational pure choriocarcinoma in a postmenarcheal young female and describes details of the tumor, including the clinicopathological findings. The patient was a 10-year-old female who underwent salpingo-oophorectomy. Histologically, the extensive hemorrhagic tumor was composed of choriocarcinoma without additional germ cell tumor components. The tumor cells were immunohistochemically positive for epithelial markers, including cytokeratins and epithelial membrane antigens, and there was a positive cytoplasmic reaction for beta-human chorionic gonadotropin in the syncytiotrophoblasts. Furthermore, numerous tumor cells were immunohistochemically positive for the beta 2-microglobulin antibody. The patient received adjuvant cisplatin, etoposide and bleomycin chemotherapy, and is currently disease-free without evidence of recurrence or metastasis subsequent to 62 months of follow-up.	[Hayashi, Shinichi; Nakanishi, Yuko; Miwa, Shigeharu; Nakajima, Takahiko; Nomoto, Kazuhiro; Tsuneyama, Koichi; Imura, Johji] Toyama Univ, Dept Diagnost Pathol, Grad Sch Med & Pharmaceut Sci, Toyama, Toyama 9300194, Japan; [Abe, Yoshiro] Dokkyo Univ, Dept Neurosurg, Sch Med, Mibu, Tochigi 3210293, Japan; [Tomita, Shigeki; Fujimori, Takahiro] Dokkyo Univ, Dept Surg & Mol Pathol, Sch Med, Mibu, Tochigi 3210293, Japan	Imura, J (reprint author), Toyama Univ, Dept Diagnost Pathol, Grad Sch Med & Pharmaceut Sci, 2,630 Sugitani, Toyama, Toyama 9300194, Japan.	imura@med.u-toyama.ac.jp					Goswami D, 2001, GYNECOL ONCOL, V80, P262, DOI 10.1006/gyno.2000.6043; Inaba H, 2000, PEDIATR INT, V42, P383, DOI 10.1046/j.1442-200x.2000.01236.x; Jacobs A J, 1982, Obstet Gynecol Surv, V37, P603, DOI 10.1097/00006254-198210000-00001; KATO M, 1991, PLACENTA, V12, P217, DOI 10.1016/0143-4004(91)90003-X; NORMAN RJ, 1983, S AFR MED J, V64, P90; Russell P, 1997, SURG PATHOLOGY OVARI, P263; Scully RE, 1998, TUMORS OVARY MALDEVE, P258; TANAKA K, 1981, CANCER RES, V41, P3639	8	0	0	SPANDIDOS PUBL LTD	ATHENS	POB 18179, ATHENS, 116 10, GREECE	1792-1074	1792-1082		ONCOL LETT	Oncol. Lett.	MAY	2015	9	5					2109	2111		10.3892/ol.2015.2985		3	Oncology	Oncology	CH2IW	WOS:000353849900024		
J	Shibata, K; Fukamachi, K; Tsuji, A; Saga, T; Futakuchi, M; Nagino, M; Tsuda, H; Suzui, M				Shibata, Koji; Fukamachi, Katsumi; Tsuji, Atsushi; Saga, Tsuneo; Futakuchi, Mitsuru; Nagino, Masato; Tsuda, Hiroyuki; Suzui, Masumi			In vivo F-18-fluorodeoxyglucose-positron emission tomography/computed tomography imaging of pancreatic tumors in a transgenic rat model carrying the human KRAS(G12V) oncogene	ONCOLOGY LETTERS			English	Article						carcinogenesis; positron emission tomography/computed tomography; F-18-fluorodeoxyglucose; laparotomy; pancreatic tumor; rat model	DUCTAL ADENOCARCINOMAS; CANCER; RECURRENCE; ACTIVATION; DIAGNOSIS; UTILITY; PET; CT	A novel KRAS-mediated transgenic rat model has previously been demonstrated, in which animals develop multiple pancreatic ductal adenocarcinoma (PDAC) that is histologically similar to human PDAC within two weeks. Positron emission tomography (PET)/computed tomography (CT) is commonly used for the diagnosis and staging of PDAC in humans, and can be adopted for optimal use in animal experiments. The aim of the present study was to evaluate the carcinogenic process in a rat pancreatic carcinoma model using small-animal multimodality imaging systems. The utility of fluorodeoxyglucose (FDG)-PET/CT in detecting the location and size of PDAC during tumor development in the present transgenic rat model was assessed. A small animal multimodality PET/CT system and contrast-enhanced CT (CECT) system were used for the imaging analysis of KRAS(G12V) male transgenic rats (n=6), which developed pancreatic tumors following the administration of an injection of Cre recombinase (Cre)-carrying adenovirus. Laparotomies performed at six weeks post-treatment revealed that all three (100%) Cre-expressing rats developed pancreatic tumors that were <2 mm in diameter; none of which were detected by F-18-FDG PET/CT or CECT. At eight weeks post-treatment, the pancreatic tumors were heterogeneously visualized by F-18-FDG-PET/CT and CECT in two of the three rats. Furthermore, the autopsies confirmed that all three rats had developed pancreatic tumors. These novel findings provide evidence that the FDG-PET/CT imaging system is a valuable tool for the evaluation of the carcinogenic process, and one which may aid in treatment and preventive methods for pancreatic tumors in mammalian models. A limitation associated with the early detection of PDACs warrants further investigation.	[Shibata, Koji; Fukamachi, Katsumi; Futakuchi, Mitsuru; Suzui, Masumi] Nagoya City Univ, Dept Mol Toxicol, Grad Sch Med Sci, Nagoya, Aichi 4678601, Japan; [Shibata, Koji; Fukamachi, Katsumi; Futakuchi, Mitsuru; Suzui, Masumi] Sch Med, Nagoya, Aichi 4678601, Japan; [Shibata, Koji; Nagino, Masato] Nagoya City Univ, Grad Sch Med, Dept Surg, Div Surg Oncol, Nagoya, Aichi 4668550, Japan; [Tsuji, Atsushi; Saga, Tsuneo] Natl Inst Radiol Sci, Mol Imaging Ctr, Diagnost Imaging Program, Chiba, Chiba 2638555, Japan; [Tsuda, Hiroyuki] Nagoya Univ, Lab Nanotoxicol Project, Nagoya, Aichi 4678603, Japan	Suzui, M (reprint author), Nagoya City Univ, Dept Mol Toxicol, Grad Sch Med Sci, Mizuho Ku, 1 Kawasumi,Mizuho Cho, Nagoya, Aichi 4678601, Japan.	suzui@med.nagoya-cu.ac.jp					CUBILLA AL, 1985, CA-CANCER J CLIN, V35, P2, DOI 10.3322/canjclin.35.1.2; Ferlay J, 2010, INT J CANCER, V127, P2893, DOI 10.1002/ijc.25516; Tomimaru Y, 2010, ONCOL REP, V24, P613, DOI 10.3892/or_00000899; MOROHOSHI T, 1983, HISTOPATHOLOGY, V7, P645, DOI 10.1111/j.1365-2559.1983.tb02277.x; Asagi A, 2013, PANCREAS, V42, P11, DOI 10.1097/MPA.0b013e3182550d77; Yabushita S, 2012, PANCREAS, V41, P1013, DOI 10.1097/MPA.0b013e31824ac3a5; KANEGAE Y, 1995, NUCLEIC ACIDS RES, V23, P3816, DOI 10.1093/nar/23.19.3816; Studwell AJ, 2011, MOL THER, V19, P1933, DOI 10.1038/mt.2011.194; Wolfgang CL, 2013, CA-CANCER J CLIN, V63, P318, DOI 10.3322/caac.21190; Siegel R, 2013, CA-CANCER J CLIN, V63, P11, DOI 10.3322/caac.21166; Fendrich V, 2011, NEOPLASIA, V13, P180, DOI 10.1593/neo.10956; Bosetti C, 2012, MOL CARCINOGEN, V51, P3, DOI 10.1002/mc.20785; Fukamachi K, 2009, BIOCHEM BIOPH RES CO, V390, P636, DOI 10.1016/j.bbrc.2009.10.019; Kayed Hany, 2012, Transl Oncol, V5, P335; Kitahashi T, 2010, CANCER SCI, V101, P1761, DOI 10.1111/j.1349-7006.2010.01588.x; Lan BY, 2012, AM J SURG, V204, P232, DOI 10.1016/j.amjsurg.2011.07.025; Matsuda A, 2013, JPN J CLIN ONCOL, V43, P328, DOI 10.1093/jjco/hys233; Russell WMS, 1992, PRINCIPLES HUMANE EX; Sakai T, 2011, ANN THORAC CARDIOVAS, V17, P539, DOI 10.5761/atcs.oa.11.01660; Ueda S, 2006, CARCINOGENESIS, V27, P2497, DOI 10.1093/carcin/bgl090; van Kouwen MCA, 2005, NUCL MED BIOL, V32, P445, DOI 10.1016/j.nucmedbio.2005.03.002; Yabushita S, 2013, PANCREAS, V42, P1034, DOI 10.1097/MPA.0b013e3182883624; Yabushita S, 2013, CARCINOGENESIS, V34, P1251, DOI 10.1093/carcin/bgt053	23	0	0	SPANDIDOS PUBL LTD	ATHENS	POB 18179, ATHENS, 116 10, GREECE	1792-1074	1792-1082		ONCOL LETT	Oncol. Lett.	MAY	2015	9	5					2112	2118		10.3892/ol.2015.3053		7	Oncology	Oncology	CH2IW	WOS:000353849900025		
J	Takai, M; Yamauchi, T; Matsuda, Y; Tai, K; Ikegaya, S; Kishi, S; Urasaki, Y; Yoshida, A; Iwasaki, H; Ueda, T				Takai, Mihoko; Yamauchi, Takahiro; Matsuda, Yasufumi; Tai, Katsunori; Ikegaya, Satoshi; Kishi, Shinji; Urasaki, Yoshimasa; Yoshida, Akira; Iwasaki, Hiromichi; Ueda, Takanori			Reduced administration of rasburicase for tumor lysis syndrome: A single-institution experience	ONCOLOGY LETTERS			English	Article						tumor lysis syndrome; rasburicase; hematological malignancy; hyperuricemia	RECOMBINANT URATE OXIDASE; DOSE RASBURICASE; URIC-ACID; HYPERURICEMIA; MANAGEMENT; EFFICACY; SAFETY; ADULTS; RISK; PROPHYLAXIS	In the present study, the dosage and duration of rasburicase administration were retrospectively evaluated for the ability to control the serum uric acid (S-UA) level in 13 patients diagnosed with hematological malignancies and tumor lysis syndrome (TLS), or those at risk of developing TLS, at the University of Fukui Hospital. At the time of diagnosis, seven patients already exhibited laboratory TLS, and three demonstrated clinical TLS. All patients received rasburicase in addition to chemotherapy agents. The median dose was 0.19 mg/kg (range, 0.13-0.25 mg/kg), and the median duration was four days (range, 1-7 days). Six patients sequentially received a xanthine oxidase inhibitor, allopurinol or febuxostat. The primary estimate was the normalization of the S-UA level at the end of rasburicase treatment and on treatment day seven. The average S-UA level prior to treatment was 10.4 +/- 4.5 mg/dl (mean standard deviation), and 11 out of 13 patients demonstrated a S-UA level >7 mg/dl. The S-UA level at the end of rasburicase administration was 0.5 +/- 1.5 mg/dl and the S-UA level at day seven was 1.4 +/- 1.5 mg/dl. All the patients achieved normalization of the S-UA level. On day seven subsequent to the initiation of treatment, the patients receiving rasburicase for a maximum of three days exhibited an S-UA level of 1.9 +/- 1.8 mg/dl, while the patients receiving rasburicase for longer than three days demonstrated an S-UA level of 1.0 +/- 1.3 mg/dl (P=0.20; Mann-Whitney test). The administration of 0.13 mg/kg and 0.22 mg/kg resulted in comparable UA level reductions. The administration of allopurinol or febuxostat following rasburicase administration suppressed the re-increase in S-UA level. Therefore, it was concluded that reduced administration of rasburicase successfully controlled the S-UA level in TLS.	[Takai, Mihoko; Yamauchi, Takahiro; Matsuda, Yasufumi; Tai, Katsunori; Kishi, Shinji; Urasaki, Yoshimasa; Yoshida, Akira; Ueda, Takanori] Univ Fukui, Dept Hematol & Oncol, Fac Med Sci, Fukui 9101193, Japan; [Ikegaya, Satoshi; Iwasaki, Hiromichi] Univ Fukui, Div Infect Control, Fac Med Sci, Fukui 9101193, Japan	Yamauchi, T (reprint author), Univ Fukui, Dept Hematol & Oncol, Fac Med Sci, 23-3 Shimoaizuki, Fukui 9101193, Japan.	tyamauch@u-fukui.ac.jp					Ishizawa K, 2009, CANCER SCI, V100, P357, DOI 10.1111/j.1349-7006.2008.01047.x; Cortes J, 2010, J CLIN ONCOL, V28, P4207, DOI 10.1200/JCO.2009.26.8896; Howard SC, 2011, NEW ENGL J MED, V364, P1844, DOI 10.1056/NEJMra0904569; Cairo MS, 2010, BRIT J HAEMATOL, V149, P578, DOI 10.1111/j.1365-2141.2010.08143.x; Trifilio S, 2006, BONE MARROW TRANSPL, V37, P997, DOI 10.1038/sj.bmt.1705379; Vadhan-Raj S, 2012, ANN ONCOL, V23, P1640, DOI 10.1093/annonc/mdr490; Coiffier B, 2008, J CLIN ONCOL, V26, P2767, DOI 10.1200/JCO.2007.15.0177; Cairo MS, 2004, BRIT J HAEMATOL, V127, P3, DOI 10.1111/j.1365-2141.2004.05094.x; Cammalleri Lisa, 2007, Int J Med Sci, V4, P83; Cheuk DK, 2010, COCHRANE DB SYST REV, V16; Firwana BM, 2012, POSTGRAD MED, V124, P92, DOI 10.3810/pgm.2012.03.2540; Jeha S, 2005, LEUKEMIA, V19, P34, DOI 10.1038/sj.leu.2403566; McBride A, 2013, PHARMACOTHERAPY, V33, P295, DOI 10.1002/phar.1198; McDonnell AM, 2006, PHARMACOTHERAPY, V26, P806, DOI 10.1592/phco.26.6.806; Pui CH, 2001, J CLIN ONCOL, V19, P697; The guideline revising committee of Japanese Society of Gout and Nucleic Acid Metabolism, 2010, GOUT NUCL ACID METAB, V34, P107; Wilson FP, 2012, CLIN J AM SOC NEPHRO, V7, P1730, DOI 10.2215/CJN.03150312; Yamauchi T, 2013, ANTICANCER RES, V33, P3947; YELDANDI AV, 1991, GENE, V109, P281, DOI 10.1016/0378-1119(91)90622-I	19	0	0	SPANDIDOS PUBL LTD	ATHENS	POB 18179, ATHENS, 116 10, GREECE	1792-1074	1792-1082		ONCOL LETT	Oncol. Lett.	MAY	2015	9	5					2119	2125		10.3892/ol.2015.3009		7	Oncology	Oncology	CH2IW	WOS:000353849900026		
J	Sakamoto, Y; Takei, Y; Fujiwara, H; Machida, S; Taneichi, A; Suzuki, M				Sakamoto, Yuki; Takei, Yuji; Fujiwara, Hiroyuki; Machida, Shizuo; Taneichi, Akiyo; Suzuki, Mitsuaki			Gestational choriocarcinoma with uterine serosal metastasis mimicking ruptured ectopic pregnancy: A case report	ONCOLOGY LETTERS			English	Article						gestational choriocarcinoma; uterine serosal metastasis; ectopic pregnancy		Primary gestational choriocarcinoma is commonly present in the uterus in cases of atypical genital bleeding. Symptoms similar to those of an ectopic pregnancy develop when an extra-uterine lesion is present in the abdominal cavity, and lesions have been detected in the ovaries and fallopian tubes in a number of cases. In the present study, we describe a patient with choriocarcinoma that metastasized to the uterine serosa and caused symptoms similar to those of an ectopic pregnancy. The patient was a 30-year-old female who presented to our hospital with atypical genital bleeding and a positive pregnancy test 3 months after missed abortion at 10 weeks of gestation. Transvaginal ultrasonography revealed the absence of a gestational sac in or outside the uterus, and intra-abdominal bleeding was noted. An ectopic pregnancy was suspected based on these findings, and emergency laparotomy was performed. A hemorrhagic mass was present on the uterine serosa, and was subsequently resected. Trophoblastic disease was suspected following histopathological examination, for which intra-uterine curettage was performed and choriocarcinoma was diagnosed. Lung metastasis was detected on computed tomography, and a high serum human chorionic gonadotropin (hCG) level persisted following surgery. The lesion disappeared following five cycles of methotrexate+etoposide+actinomycin D therapy, which was performed as postoperative chemotherapy, and the patient's serum hCG level decreased to below the detection limit. In this case of choriocarcinoma, the primary lesion was present in the uterus and had metastasized to the uterine serosa, which is a very rare metastatic site. This uterine serosal metastatic lesion bled and caused symptoms similar to those of an ectopic pregnancy. Certain patients who undergo surgery for a suspected peritoneal pregnancy may have gestational choriocarcinoma, similar to this case.	[Sakamoto, Yuki; Takei, Yuji; Fujiwara, Hiroyuki; Machida, Shizuo; Taneichi, Akiyo; Suzuki, Mitsuaki] Jichi Med Univ, Dept Obstet & Gynecol, Shimotsuke, Tochigi 3290498, Japan	Takei, Y (reprint author), Jichi Med Univ, Dept Obstet & Gynecol, 3311-1 Yakushiji, Shimotsuke, Tochigi 3290498, Japan.	ytakei@jichi.ac.jp					Berkowitz RS, 1996, NEW ENGL J MED, V335, P1740, DOI 10.1056/NEJM199612053352306; Ashraf-Ganjooei T, 2008, ARCH GYNECOL OBSTET, V277, P465, DOI 10.1007/s00404-007-0469-3; Chen MJ, 2004, BJOG-INT J OBSTET GY, V111, P188, DOI 10.1046/j.1471-0528.2003.00048.x; KUCUKOZKAN T, 1992, ACTA OBSTET GYN SCAN, V71, P636; Maesta I, 2010, J REPROD MED, V55, P311; Mittal S, 2012, J OBSTET GYNAECOL, V32, P499, DOI 10.3109/01443615.2012.675369; Sakumoto K, 2005, GYNECOL ONCOL, V97, P243, DOI 10.1016/j.ygyno.2004.09.036; Wan X, 2006, INT J GYNECOL CANCER, V16, P1476, DOI 10.1111/j.1525-1438.2006.00610.x	8	0	0	SPANDIDOS PUBL LTD	ATHENS	POB 18179, ATHENS, 116 10, GREECE	1792-1074	1792-1082		ONCOL LETT	Oncol. Lett.	MAY	2015	9	5					2185	2188		10.3892/ol.2015.2999		4	Oncology	Oncology	CH2IW	WOS:000353849900039		
J	Subarnas, A; Diantini, A; Abdulah, R; Zuhrotun, A; Hadisaputri, YE; Puspitasari, IM; Yamazaki, C; Kuwano, H; Koyama, H				Subarnas, Anas; Diantini, Ajeng; Abdulah, Rizky; Zuhrotun, Ade; Hadisaputri, Yuni E.; Puspitasari, Irma M.; Yamazaki, Chiho; Kuwano, Hiroyuki; Koyama, Hiroshi			Apoptosis induced in MCF-7 human breast cancer cells by 2 ',4 '-dihydroxy-6-methoxy-3,5-dimethylchalcone isolated from Eugenia aquea Burm f. leaves	ONCOLOGY LETTERS			English	Article						Eugenia aquea; primates; cancer; apoptosis	ANTITUMOR-ACTIVITY; ANTICANCER AGENTS; STRATEGIES; DISCOVERY	During a previous study that aimed to identify anticancer agents within primate-consumed plants, the present group identified that Eugenia aquea (E. aquea) possessed potential as a source of anticancer agents. The ethanol extract of E. aquea leaves exhibited strong inhibitory activity against the proliferation of the human breast adenocarcinoma MCF-7 cell line. The inhibition of proliferation was determined using an MTT assay. The present study was performed to isolate the active compound within the E. aquea leaves that generated the aforementioned activity, and resulted in the isolation of 2',4'-dihydroxy-6-methoxy-3,5-dimethylchalcone, which was identified through the analysis of spectroscopic data. This compound was examined for its inhibitory activity against the MCF-7 cell line using a MTT assay, and the ability of 2',4'-dihydroxy-6-methoxy-3,5-dimethylchalcone to induce apoptosis through the activation of the poly(adenosine diphosphate-ribose) polymerase (PARP) protein was also investigated. The results of the present study revealed that the isolated compound inhibited cell proliferation in a dose-dependent manner, possessed an IC50 of 74.5 mu g/ml (250 mu M) and promoted apoptosis via the activation of PARP. It was concluded that these results indicated a requirement for additional investigations into 2',4'-dihydroxy-6-methoxy-3,5-dimethylchalcone in order to provide a basis for the use of this compound in the management of cancer.	[Subarnas, Anas; Diantini, Ajeng; Abdulah, Rizky; Puspitasari, Irma M.] Padjadjaran State Univ, Dept Pharmacol & Clin Pharm, Fac Pharm, Jatinangor 45363, West Java, Indonesia; [Abdulah, Rizky; Puspitasari, Irma M.; Yamazaki, Chiho; Koyama, Hiroshi] Gunma Univ, Grad Sch Med, Dept Publ Hlth, Maebashi, Gunma 371, Japan; [Zuhrotun, Ade] Padjadjaran State Univ, Dept Biol Pharm, Fac Pharm, Jatinangor 45363, West Java, Indonesia; [Hadisaputri, Yuni E.; Kuwano, Hiroyuki] Gunma Univ, Grad Sch Med, Dept Gen Surg Sci, Maebashi, Gunma, Japan	Subarnas, A (reprint author), Padjadjaran State Univ, Dept Pharmacol & Clin Pharm, Fac Pharm, Jalan Raya Bandung Sumedang Km 21, Jatinangor 45363, West Java, Indonesia.	aasubarnas@yahoo.co.id			Directorate General of Higher Education of The Ministry of Education and Culture of Indonesia [430/SP2H/PP/DP2M/VII/2010]	This study was supported by The Directorate General of Higher Education of The Ministry of Education and Culture of Indonesia (Grand-in-Aid for The International Research Collaborations and Publications, grant no. 430/SP2H/PP/DP2M/VII/2010).	Abdulah R, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-414; Amor EC, 2004, Z NATURFORSCH C, V59, P86; Kinghorn AD, 1999, PURE APPL CHEM, V71, P1611, DOI 10.1351/pac199971091611; Ye CL, 2005, CANCER CHEMOTH PHARM, V56, P70, DOI 10.1007/s00280-004-0975-y; Ferlay J, 2010, INT J CANCER, V127, P2893, DOI 10.1002/ijc.25516; Kinghorn AD, 2003, PHARM BIOL, V41, P53, DOI 10.1080/1388020039051744; Diantini A, 2012, ONCOL LETT, V3, P1069, DOI 10.3892/ol.2012.596; Yu WG, 2011, J AGR FOOD CHEM, V59, P12821, DOI 10.1021/jf2042032; Kinghorn A Douglas, 2002, Expert Opin Pharmacother, V3, P77, DOI 10.1517/14656566.3.2.77; Koshimizu K, 1998, P TOK INT FOR CONS S, P203; Marby TJ, 1970, SYSTEMATIC IDENTIFIC, P253; Sakarkar D. M., 2011, International Journal of PharmTech Research, V3, P298; Subarnas A., 2012, E3 J MED RES, V1, P38; Ye CL, 2004, PHARMACOL RES, V50, P505, DOI 10.1016/j.phrs.2004.05.004	14	0	0	SPANDIDOS PUBL LTD	ATHENS	POB 18179, ATHENS, 116 10, GREECE	1792-1074	1792-1082		ONCOL LETT	Oncol. Lett.	MAY	2015	9	5					2303	2306		10.3892/ol.2015.2981		4	Oncology	Oncology	CH2IW	WOS:000353849900063		
J	Kimura, M; Nakashima, K; Usami, E; Iwai, M; Nakao, T; Yoshimura, T; Mori, H; Teramachi, H				Kimura, Michio; Nakashima, Keiji; Usami, Eiseki; Iwai, Mina; Nakao, Toshiya; Yoshimura, Tomoaki; Mori, Hiromi; Teramachi, Hitomi			Adherence and awareness of the therapeutic intent of oral anticancer agents in an outpatient setting	ONCOLOGY LETTERS			English	Article						adherence; patient awarencess; oral anticancer agent; adjuvant; progressive	CHRONIC MYELOID-LEUKEMIA; RENAL-CELL CARCINOMA; PATIENT ADHERENCE; CANCER; EFFICACY; SAFETY; TRIAL	The aim of the present study was to clarify the adherence and awareness of oral anticancer agents by type and therapeutic purpose in outpatients prescribed with tegafur/gimeracil/oteracil potassium (S-1) or capecitabine. Outpatients undergoing treatment with the S-1 or capecitabine oral anticancer agents at Ogaki Municipal Hospital (Ogaki, Japan) in June 2013 completed a questionnaire survey and the survey findings were evaluated. No significant differences in medication adherence were identified between the patients administered S-1 and the patients administered capecitabine (P=0.4586). In addition, no significant differences were identified in therapeutic purpose between adjuvant therapy, and advanced and recurrent therapies. However, for S-1 and capecitabine, medication adherence was significantly higher in those undergoing combination therapy compared with those undergoing monotherapy (P=0.0046). In addition, for patients taking S-1, the median age for good adherence was significantly lower than that for insufficient adherence (66.1 +/- 10.5 vs. 72.1 +/- 7.9 years, respectively; P=0.0035). Furthermore, a significant negative correlation was identified between the awareness score of research regarding the medication and age (n=109; P=0.0045). In conclusion, for patients treated with S-1 or capecitabine, the type and therapeutic purpose of oral anticancer agents did not affect medication adherence. Elderly patients expressed a low interest in medications and typically exhibited insufficient medication adherence. Therefore, patient guidance by pharmacists is important, as it may result in improved medication adherence and an improved understanding of the treatment side-effects in patients self-administering prescribed drugs.	[Kimura, Michio; Nakashima, Keiji; Usami, Eiseki; Iwai, Mina; Nakao, Toshiya; Yoshimura, Tomoaki; Mori, Hiromi] Ogaki Municipal Hosp, Dept Pharm, Ogaki, Gifu 5038502, Japan; [Teramachi, Hitomi] Gifu Pharmaceut Univ, Lab Clin Pharm, Ogaki, Gifu 5011196, Japan	Kimura, M (reprint author), Ogaki Municipal Hosp, Dept Pharm, 4-86 Minaminokawa Cho, Ogaki, Gifu 5038502, Japan.	kimkim0305nao@yahoo.co.jp					Marin D, 2010, J CLIN ONCOL, V28, P2381, DOI 10.1200/JCO.2009.26.3087; Noens L, 2009, BLOOD, V113, P5401, DOI 10.1182/blood-2008-12-196543; Nilsson JLG, 2006, EUR J CANCER CARE, V15, P235, DOI 10.1111/j.1365-2354.2006.00645.x; Macintosh PW, 2007, EUR J CANCER CARE, V16, P380, DOI 10.1111/j.1365-2354.2006.00758.x; Gore ME, 2009, LANCET ONCOL, V10, P757, DOI 10.1016/S1470-2045(09)70162-7; Ruddy K, 2009, CA-CANCER J CLIN, V59, P56, DOI 10.3322/caac.20004; Partridge AH, 2010, J CLIN ONCOL, V28, P2418, DOI 10.1200/JCO.2009.26.4671; Escudier B, 2009, J CLIN ONCOL, V27, P3312, DOI 10.1200/JCO.2008.19.5511; Hasegawa K, 2008, JPN J PHARM HLTH CAR, V34, P800; Kimura M, 2014, ONCOL LETT, V8, P2318, DOI 10.3892/ol.2014.2480; Reginster Jean-Yves, 2006, Bone, V38, pS18; Russmann Stefan, 2010, Ther Umsch, V67, P303, DOI 10.1024/0040-5930/a000054; Sakuramoto S, 2007, NEW ENGL J MED, V357, P1810, DOI 10.1056/NEJMoa072252; Tsang J, 2006, J CLIN ONCOL, V24, P6119; Tsuboi K, 2012, JPN J PHARM HLTH CAR, V38, P522; Winkeljohn D, 2010, CLIN J ONCOL NURS, V14, P461, DOI 10.1188/10.CJON.461-466; Wu EQ, 2010, CURR MED RES OPIN, V26, P2861, DOI 10.1185/03007995.2010.533648	17	0	0	SPANDIDOS PUBL LTD	ATHENS	POB 18179, ATHENS, 116 10, GREECE	1792-1074	1792-1082		ONCOL LETT	Oncol. Lett.	MAY	2015	9	5					2341	2346		10.3892/ol.2015.3027		6	Oncology	Oncology	CH2IW	WOS:000353849900070		
J	Nishikawa, S; Konno, M; Hamabe, A; Hasegawa, S; Kano, Y; Fukusumi, T; Satoh, T; Takiguchi, S; Mori, M; Doki, Y; Ishii, H				Nishikawa, Shimpei; Konno, Masamitsu; Hamabe, Atsushi; Hasegawa, Shinichiro; Kano, Yoshihiro; Fukusumi, Takahito; Satoh, Taroh; Takiguchi, Shuji; Mori, Masaki; Doki, Yuichiro; Ishii, Hideshi			Surgically resected human tumors reveal the biological significance of the gastric cancer stem cell markers CD44 and CD26	ONCOLOGY LETTERS			English	Article						gastric cancer; cancer stem cell; tumor-initiating cell; chemotherapy; CD44; CD26	ACUTE MYELOID-LEUKEMIA; INITIATING CELLS; IDENTIFICATION; CHEMOTHERAPY	Cancer tissue is maintained by relatively small populations of cancer stem cells (CSCs), which are involved in chemotherapy resistance, recurrence and metastasis. As tumor tissues are comprised of various cells, studies of human clinical samples are important for the characterization of CSCs. In the present study, an expression profiling study was performed in which an anti-cell surface marker antibody-based array platform, a flow cytometry-based cell separation technique and a tumorigenicity analysis in immunodeficient animals were utilized. These approaches revealed that the markers cluster of differentiation (CD)44 and CD26 facilitated the fractionation of surgically resected human gastric cancer (GC) cells into the following subset populations with distinct tumorigenic potentials: Highly tumorigenic CD26(+)CD44(+) cells (6/6 mice formed tumors), moderately tumorigenic CD26(+)CD44(-) cells (5/6 mice formed tumors), and weakly or non-tumorigenic CD26(-)CD44(-) cells (2/6 mice formed tumors). Furthermore, exposure to 5-fluorouracil significantly increased the proportion of CD26(+) cells in vitro. The present study demonstrated that the combined expression of CD26 and CD44 presents a potential marker of human GC stem cells.	[Nishikawa, Shimpei; Konno, Masamitsu; Hamabe, Atsushi; Hasegawa, Shinichiro; Kano, Yoshihiro; Satoh, Taroh; Ishii, Hideshi] Osaka Univ, Grad Sch Med, Dept Frontier Sci Canc & Chemotherapy, Suita, Osaka 5650871, Japan; [Nishikawa, Shimpei; Hamabe, Atsushi; Hasegawa, Shinichiro; Kano, Yoshihiro; Takiguchi, Shuji; Mori, Masaki; Doki, Yuichiro] Osaka Univ, Grad Sch Med, Dept Gastroenterol Surg, Suita, Osaka 5650871, Japan; [Fukusumi, Takahito] Osaka Univ, Grad Sch Med, Dept Otorhinolaryngol Head & Neck Surg, Suita, Osaka 5650871, Japan	Mori, M (reprint author), Osaka Univ, Grad Sch Med, Dept Gastrointestinal Surg, 2-2 E2 Yamadaoka, Suita, Osaka 5650871, Japan.	mmori@gesurg.med.osaka-u.ac.jp; hishii@gesurg.med.osaka-u.ac.jp			Ministry of Education, Culture, Sports, Science and Technology in Japan [26670604, 23390199, 21229015]; Ministry of Health, Labor, and Welfare in Japan [H26-018]; Kobayashi Cancer Research Foundation [H24]; Princess Takamatsu Cancer Research Fund, Japan [H22]; SENSHIN Medical Research Foundation [H25]; Chugai Pharmaceutical Co., Ltd. (Tokyo, Japan); Yakult Honsha Co., Ltd. (Tokyo, Japan); Takeda Pharmaceutical Co., Ltd (Osaka, Japan)	The authors would like to thank Miyuki Ozaki and Yuko Noguchi for their technical support. The current study was partly supported by a Core Research Grant-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology in Japan (to M.K., H.I. and M.M.; grant nos.; 26670604, 23390199 and 21229015); a Grant-in-Aid from the Third Term Comprehensive 10-year Strategy for Cancer Control of the Ministry of Health, Labor, and Welfare in Japan (to H.I. and M.M.; grant no. H26-018); a grant from the Kobayashi Cancer Research Foundation (to H.I.; grant no. H24); a grant from the Princess Takamatsu Cancer Research Fund, Japan (to H.I.; grant no. H22); and a grant from the SENSHIN Medical Research Foundation (to H.I.; grant no. H25).; The authors received partial support from Chugai Pharmaceutical Co., Ltd. (Tokyo, Japan), Yakult Honsha Co., Ltd. (Tokyo, Japan), and Takeda Pharmaceutical Co., Ltd (Osaka, Japan).	Singh SK, 2004, NATURE, V432, P396, DOI 10.1038/nature03128; O'Brien CA, 2010, CLIN CANCER RES, V16, P3113, DOI 10.1158/1078-0432.CCR-09-2824; Katsuno Y, 2012, J PATHOL, V228, P391, DOI 10.1002/path.4020; Ferlay J, 2010, INT J CANCER, V127, P2893, DOI 10.1002/ijc.25516; Ponti D, 2005, CANCER RES, V65, P5506, DOI 10.1158/0008-5472.CAN-05-0626; Takaishi S, 2009, STEM CELLS, V27, P1006, DOI 10.1002/stem.30; Medema JP, 2013, NAT CELL BIOL, V15, P338, DOI 10.1038/ncb2717; Kreso A, 2013, SCIENCE, V339, P543, DOI 10.1126/science.1227670; Zhang CJ, 2011, J CANCER RES CLIN, V137, P1679, DOI 10.1007/s00432-011-1038-5; Li CW, 2007, CANCER RES, V67, P1030, DOI 10.1158/0008-5472.CAN-06-2030; Han ME, 2011, CELL MOL LIFE SCI, V68, P3589, DOI 10.1007/s00018-011-0672-z; Bonnet D, 1997, NAT MED, V3, P730, DOI 10.1038/nm0797-730; LAPIDOT T, 1994, NATURE, V367, P645, DOI 10.1038/367645a0; Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Ricci-Vitiani L, 2007, NATURE, V445, P111, DOI 10.1038/nature05384; Haraguchi N, 2010, J CLIN INVEST, V120, P3326, DOI 10.1172/JCI42550; Jiang J, 2012, ONCOGENE, V31, P671, DOI 10.1038/onc.2011.282; da Cunha JPC, 2009, P NATL ACAD SCI USA, V106, P16752, DOI 10.1073/pnas.0907939106; Dieter SM, 2011, CELL STEM CELL, V9, P357, DOI 10.1016/j.stem.2011.08.010; Fukuda K, 2009, INT J ONCOL, V34, P1201, DOI 10.3892/ijo_00000248; O'Brien CA, 2007, NATURE, V445, P106, DOI 10.1038/nature05372; Zola H, 2006, MOL MED, V12, P312, DOI 10.2119/2006-00081.Zola; Bang YJ, 2010, LANCET, V376, P687, DOI 10.1016/S0140-6736(10)61121-X; Clarke Michael F, 2006, Cancer Res, V66, P9339, DOI 10.1158/0008-5472.CAN-06-3126; Nishikawa S, 2013, INT J ONCOL, V42, P1437, DOI 10.3892/ijo.2013.1837; Rocco A, 2012, J CELL PHYSIOL, V227, P2686, DOI 10.1002/jcp.23013	26	0	0	SPANDIDOS PUBL LTD	ATHENS	POB 18179, ATHENS, 116 10, GREECE	1792-1074	1792-1082		ONCOL LETT	Oncol. Lett.	MAY	2015	9	5					2361	2367		10.3892/ol.2015.3063		7	Oncology	Oncology	CH2IW	WOS:000353849900073		
J	Kojima, F; Ishida, M; Tsujimoto, Y; Hosomi, M; Toshiaki, K; Okabe, H				Kojima, Fumiyoshi; Ishida, Mitsuaki; Tsujimoto, Yuichi; Hosomi, Masahiro; Toshiaki, Kinouchi; Okabe, Hidetoshi			First adult case of sporadic localized glomerulocystic kidney mimicking a tumor	ONCOLOGY LETTERS			English	Article						glomerular cyst; glomerulocystic kidney; adult; localized	DISEASE	Glomerulocystic kidneys (GCKs) are mainly observed in infants and young children, and are characterized by the cystic dilatation of Bowman's space to form glomerular cysts (GCs). GCKs are associated with various conditions. Additionally, the cystogenesis of GCKs remains controversial. The present study describes a rare adult case of a sporadic localized GCK that radiologically mimicked a multilocular cystic tumor, and analyses the features of GC. A 42-year-old male with hematuria underwent a right partial nephrectomy for a cystic mass. The majority of the cyst was distributed in the cortex and contained a single collapsed glomerulus. Using serial sections, narrow and serpiginous proximal tubules that continued to the GCs were detected. These findings suggested that obliteration at the glomerulotubular junction was not the primary cause of GC in this case. To the best of our knowledge, this is the first adult case of a sporadic localized GCK mimicking a tumor. Unnecessary surgical procedures may be avoided by careful evaluation of computed tomography scans and magnetic resonance imaging, although localized GCKs are quite rare.	[Kojima, Fumiyoshi] Saiseikai Senri Hosp, Dept Diagnost Pathol, Suita, Osaka 5650862, Japan; [Ishida, Mitsuaki; Okabe, Hidetoshi] Shiga Univ Med Sci, Dept Clin Lab Med, Otsu, Shiga 5202192, Japan; [Ishida, Mitsuaki; Okabe, Hidetoshi] Shiga Univ Med Sci, Div Diagnost Pathol, Otsu, Shiga 5202192, Japan; [Tsujimoto, Yuichi; Hosomi, Masahiro; Toshiaki, Kinouchi] Saiseikai Semi Hosp, Dept Urol, Suita, Osaka 5650862, Japan	Kojima, F (reprint author), Saiseikai Senri Hosp, Dept Diagnost Pathol, 1-1-6 Tsukumodai, Suita, Osaka 5650862, Japan.	fumiyosh@belle.shiga-med.ac.jp					Bosniak MA, 2012, RADIOLOGY, V262, P781, DOI 10.1148/radiol.11111595; Lennerz JK, 2010, ARCH PATHOL LAB MED, V134, P583, DOI 10.1043/1543-2165-134.4.583; Obata Y, 2011, CLIN NEPHROL, V75, P158, DOI 10.2379/CNP75158; Hotta O, 1999, CLIN NEPHROL, V51, P177; Kanouzawa K, 1994, Nihon Jinzo Gakkai Shi, V36, P762; Liu JS, 2000, AM J KIDNEY DIS, V35, P216, DOI 10.1016/S0272-6386(00)70329-5	6	0	0	SPANDIDOS PUBL LTD	ATHENS	POB 18179, ATHENS, 116 10, GREECE	1792-1074	1792-1082		ONCOL LETT	Oncol. Lett.	MAY	2015	9	5					2368	2370		10.3892/ol.2015.3060		3	Oncology	Oncology	CH2IW	WOS:000353849900074		
J	Minami, S; Ohnishi, T; Sano, T; Sugiura, K; Nakayama, E				Minami, Seiji; Ohnishi, Takashi; Sano, Tomoaki; Sugiura, Kazutaka; Nakayama, Eiji			Comparison between cone-beam CT and multidetector-row CT by ROC analysis regarding diagnostic accuracy for artificial alveolar bone defects in the mandibular molar region	ORAL RADIOLOGY			English	Article						ROC analysis; Diagnostic accuracy; Bone defect; Cone-beam CT; Multidetector-row CT	FLAT-PANEL DETECTOR; COMPUTED-TOMOGRAPHY; MDCT	The purpose of this study was to clarify the difference in diagnostic accuracy for alveolar bone defects of the mandibular molar region between cone-beam computed tomography (CBCT) and multidetector-row CT (MDCT) by receiver-operating characteristic (ROC) analysis. Artificial alveolar bone defects in a dry human mandible were scanned with a CBCT system (CB MercuRay; Hitachi Medical Corporation) and an MDCT scanner (Aquilion 16-slice; Toshiba Medical Systems Corporation). The field of view (FOV) for the CT images was 5, 10, and 15 cm. Five radiologists observed the obtained DICOM CT images using OsiriX version 3.8.1 (OsiriX Foundation) on an iMac computer (Apple Computer Inc.), and rated the confidence levels for detecting the bone defects using a continuously distributed test. The areas under the ROC curves (Az values) were then calculated with ROCKIT 1.1B (Charles E Metz, The University of Chicago). The significance of differences in the Az values between CBCT and MDCT was tested by the Steel-Dwass method with a significance level of 5 %. The overall differences in the Az values between CBCT and MDCT were not significant. However, in the images with 15-cm FOV, the Az value for CBCT was significantly lower than that for MDCT. The diagnostic accuracy for alveolar bone defects was comprehensively equal between CBCT and MDCT. In CBCT, a large FOV can be avoided to reduce the radiation exposure dose, because enlargement of the FOV does not improve the diagnostic accuracy.	[Minami, Seiji; Ohnishi, Takashi; Sano, Tomoaki; Sugiura, Kazutaka; Nakayama, Eiji] Hlth Sci Univ Hokkaido, Sch Dent, Dept Human Biol & Pathophysiol, Div Oral & Maxillofacial Radiol, Ishikari, Hokkaido 0610293, Japan	Nakayama, E (reprint author), Hlth Sci Univ Hokkaido, Sch Dent, Dept Human Biol & Pathophysiol, Div Oral & Maxillofacial Radiol, 1757 Kanazawa, Ishikari, Hokkaido 0610293, Japan.	enaka@hoku-iryo-u.ac.jp					Rosset A, 2004, J DIGIT IMAGING, V17, P205, DOI 10.1007/s10278-004-1014-6; Baba R, 2004, DENTOMAXILLOFAC RAD, V33, P285, DOI 10.1259/dmfr/87440549; Bonel HM, 2005, AM J ROENTGENOL, V185, P647; METZ CE, 1986, INVEST RADIOL, V21, P720; Liang X, 2010, EUR J RADIOL, V75, P270, DOI 10.1016/j.ejrad.2009.04.016; ROCKETTE HE, 1992, INVEST RADIOL, V27, P169, DOI 10.1097/00004424-199202000-00016; Liang X, 2010, EUR J RADIOL, V75, P265, DOI 10.1016/j.ejrad.2009.03.042; Arai Y, 1999, DENTOMAXILLOFAC RAD, V28, P245, DOI 10.1038/sj.dmfr.4600448; Baba R, 2002, COMPUT MED IMAG GRAP, V26, P153, DOI 10.1016/S0895-6111(02)00008-3; McCollough CH, 2009, RADIOL CLIN N AM, V47, P27, DOI 10.1016/j.rcl.2008.10.006; Scarfe WC, 2006, J CAN DENT ASSOC, V72, P75; Fahrig R, 1997, MED PHYS, V24, P1097, DOI 10.1118/1.598013; Gulsahi A, 2014, ORAL RADIOL, V30, P111, DOI 10.1007/s11282-013-0130-8; Honda K, 2004, DENTOMAXILLOFAC RAD, V33, P391, DOI 10.1259/dmfr/54316470; Hsieh J, 2008, COMPUT TOMOGR, V3rd, P188; Imhof H, 2003, EUR J RADIOL, V45, pS23, DOI 10.1016/S0720-048X(02)00002-0; Kalra MK, 2004, J COMPUT ASSIST TOMO, V28, pS2, DOI 10.1097/01.rct.0000120857.80935.bd; Scarfe WC, 2013, ORAL RADIOLOGY PRINC, V3rd, P185; Seeram E, 2009, COMPUTED TOMOGRAPHY; Seweram E, 2008, COMPUT TOMOGR, V3rd, P226; Wojciechowski W, 2009, POL J RADIOL, V74, P69	21	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0911-6028	1613-9674		ORAL RADIOL	Oral Radiol.	MAY	2015	31	2					97	104		10.1007/s11282-014-0189-x		8	Dentistry, Oral Surgery & Medicine	Dentistry, Oral Surgery & Medicine	CH2AC	WOS:000353824100004		
J	Araki, M; Ishii, T; Matsumoto, N; Matsumoto, K; Honda, K; Nishimura, S; Tanaka, T				Araki, Masao; Ishii, Teruhiko; Matsumoto, Naoyuki; Matsumoto, Kunihito; Honda, Kazuya; Nishimura, Satoshi; Tanaka, Takayoshi			Extremely aggressive behavior of central giant cell granuloma after biopsy:a case report	ORAL RADIOLOGY			English	Article						Central giant cell granuloma; Computed tomography; Magnetic resonance imaging; Mandible	REPARATIVE GRANULOMA; RADIOLOGIC FEATURES; JAWS; LESIONS; TUMOR	Although central giant cell granulomas (CGCGs) appear to be benign, their radiographic findings are active. These tumors become severely invasive with the stimulus of surgery, resembling malignant tumors. Achieving the correct diagnosis is reportedly difficult because CGCGs are very similar to odontogenic jaw tumors. We herein describe an intriguing case of a 21-year-old male patient who was referred to our outpatient clinic with persistent swelling of the left buccal region. After making a provisional diagnosis of ameloblastoma from panoramic and computed tomography images, a biopsy was performed. Nine days after this operation, the intraoral lesion started to enlarge, causing facial disfigurement. Soon afterward, this lesion was examined by computed tomography, magnetic resonance imaging, and by both bone and tumor scintigraphy. Segmental resection of the mandible was conducted in the hospital, and the histopathological appearance was consistent with CGCG. Although CGCG tends to be indolent, the present case suggests that the stimulus of surgery can trigger clinically invasive behavior more characteristic of malignancy. CGCG exhibits variable features, but with the stimulus of surgery, its clinical behavior becomes extremely invasive, resembling a malignant tumor. The CGCG in the present case showed unusual development and intriguing radiographic and histopathological findings. It is important to be aware of the findings that can help to achieve a correct diagnosis.	[Araki, Masao; Matsumoto, Kunihito; Honda, Kazuya] Nihon Univ, Sch Dent, Dent Res Ctr, Dept Oral & Maxillofacial Radiol,Chiyoda Ku, Tokyo 1018310, Japan; [Araki, Masao; Matsumoto, Kunihito; Honda, Kazuya] Nihon Univ, Sch Dent, Dent Res Ctr, Div Adv Dent Treatment, Tokyo 1018310, Japan; [Ishii, Teruhiko; Nishimura, Satoshi; Tanaka, Takayoshi] Nihon Univ, Sch Dent, Dent Res Ctr, Dept Oral & Maxillofacial Surg, Tokyo 1018310, Japan; [Ishii, Teruhiko; Matsumoto, Naoyuki; Nishimura, Satoshi; Tanaka, Takayoshi] Nihon Univ, Sch Dent, Dent Res Ctr, Div Immunol & Pathobiol, Tokyo 1018310, Japan; [Matsumoto, Naoyuki] Nihon Univ, Sch Dent, Dent Res Ctr, Dept Pathol, Tokyo 1018310, Japan	Araki, M (reprint author), Nihon Univ, Sch Dent, Dent Res Ctr, Dept Oral & Maxillofacial Radiol,Chiyoda Ku, 1-8-13 Kanda Surugadai, Tokyo 1018310, Japan.	araki.masao@nihon-u.ac.jp			Sato Fund; Nihon University School of Dentistry	This study was supported by grants from the Sato Fund and the Nihon University School of Dentistry for 2012.	Abu-El-Naaj I, 2002, J ORAL MAXIL SURG, V60, P939, DOI 10.1053/jams.2002.33867; WHITAKER SB, 1993, ORAL SURG ORAL MED O, V75, P199, DOI 10.1016/0030-4220(93)90094-K; OMalley M, 1997, J ORAL PATHOL MED, V26, P159; CHUONG R, 1986, J ORAL MAXIL SURG, V44, P708; ECKARDT A, 1989, INT J ORAL MAX SURG, V18, P3, DOI 10.1016/S0901-5027(89)80004-9; Kaffe I, 1996, ORAL SURG ORAL MED O, V81, P720, DOI 10.1016/S1079-2104(96)80079-5; Murphey MD, 2001, RADIOGRAPHICS, V21, P1283; JAFFE HL, 1953, ORAL SURG ORAL MED O, V6, P159, DOI 10.1016/0030-4220(53)90151-0; FICARRA G, 1987, ORAL SURG ORAL MED O, V64, P44, DOI 10.1016/0030-4220(87)90115-0; AUCLAIR PL, 1988, ORAL SURG ORAL MED O, V66, P197, DOI 10.1016/0030-4220(88)90094-1; EISENBUD L, 1988, J ORAL MAXIL SURG, V46, P376, DOI 10.1016/0278-2391(88)90221-2; AUSTIN L T Jr, 1959, Oral Surg Oral Med Oral Pathol, V12, P1285, DOI 10.1016/0030-4220(59)90215-4; Barnes L, 2005, WHO CLASSIFICATION T, P324; COHEN D, 1993, PEDIATR RADIOL, V23, P319, DOI 10.1007/BF02010927; COHEN MA, 1988, ORAL SURG ORAL MED O, V65, P255, DOI 10.1016/0030-4220(88)90176-4; De Corso E, 2006, Acta Otorhinolaryngol Ital, V26, P168; Goaz PW, 1994, ORAL RADIOLOGY PRINC, P514; Kramer IRH, 1991, HISTOLOGICAL TYPING, P31; Mintz GA, 1981, ORAL SURG ORAL MED O, V14, P164; Okade Durga Rajaram, 2012, J Contemp Dent Pract, V13, P930; Orhan E, 2010, INT J PEDIATR OTORHI, V74, P547, DOI [10.1016/j.ijporl.2010.02.006, 10.1016/j.ijpor1.2010.02.006]; Sciubba JJ, 2001, ATLAS TUMOR PATHOL, p[161, 170]; Shklar G, 1961, ORAL SURG ORAL MED O, V14, P809, DOI 10.1016/S0030-4220(61)80012-1; Unal M, 2006, INT J PEDIATR OTORHI, V70, P745, DOI 10.1016/j.ijporl.2005.09.014; Valentine James C, 2011, Head Neck Pathol, V5, P385, DOI 10.1007/s12105-011-0297-4; WALDRON CA, 1966, AM J CLIN PATHOL, V45, P437; Wood NK, 1991, DIFFERENTIAL DIAGNOS, V4th, P393	27	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0911-6028	1613-9674		ORAL RADIOL	Oral Radiol.	MAY	2015	31	2					115	122		10.1007/s11282-014-0177-1		8	Dentistry, Oral Surgery & Medicine	Dentistry, Oral Surgery & Medicine	CH2AC	WOS:000353824100007		
J	Gamoh, S; Nakashima, Y; Yamamoto, E; Yamada, K; Akiyama, H; Morita, S; Shimizutani, K				Gamoh, Shoko; Nakashima, Yukako; Yamamoto, Emi; Yamada, Koji; Akiyama, Hironori; Morita, Shosuke; Shimizutani, Kimishige			Establishing differential diagnoses of simple bone cysts: a case series and literature review	ORAL RADIOLOGY			English	Article						Simple bone cyst; Dental radiograph; Computed tomography (CT); Magnetic resonance imaging (MRI)	JAWS; PRESENTATIONS	Simple bone cysts (SBCs) are connective tissue-lined cavities within bone. They may be empty or may contain fluid. However, because they have no epithelial lining, they are not true cysts. The etiology of SBCs is unknown, although they may be a localized aberration that occurs during normal bone remodeling or metabolism. They are usually asymptomatic and appear on routine radiographs. Because of their lack of unique clinical and radiographic features, it is important to establish differential diagnoses between SBCs and other lesions of the jaws, especially radiolucent lesions. There is no reported evidence of a traumatic cause. SBCs may be misinterpreted when associated with atypical clinical and radiographic characteristics, in turn causing diagnostic and endodontic problems. We herein present three cases of SBCs that were once misdiagnosed as radicular cysts. The difficulty of diagnosis, treatment, controversies regarding terminology, and process of reaching a correct diagnosis are also discussed.	[Gamoh, Shoko; Nakashima, Yukako; Akiyama, Hironori; Shimizutani, Kimishige] Osaka Dent Univ, Dept Oral Radiol, Chuo Ku, Osaka 5400008, Japan; [Yamamoto, Emi; Yamada, Koji; Morita, Shosuke] Osaka Dent Univ, Dept Oral & Maxillofacial Surg 1, Osaka 5400008, Japan	Gamoh, S (reprint author), Osaka Dent Univ, Dept Oral Radiol, Chuo Ku, 1-5-17 Otemae, Osaka 5400008, Japan.	gamo-s@cc.osaka-dent.ac.jp					Pitak-Arnnop P, 2010, J CRANIO MAXILL SURG, V38, P358, DOI 10.1016/j.jcms.2009.10.006; Manor E, 2012, INT J MED SCI, V9, P20; Cortell-Ballester I, 2009, MED ORAL PATOL ORAL, V14, pE239; Noronha VRAD, 2012, J CRANIO MAXILL SURG, V40, pE328, DOI 10.1016/j.jcms.2012.02.001; de Carvalho ALH, 2010, INT J PEDIATR OTORHI, V74, P1449, DOI 10.1016/j.ijporl.2010.09.014; FORSSELL K, 1988, INT J ORAL MAX SURG, V17, P21, DOI 10.1016/S0901-5027(88)80223-6; Harnet JC, 2008, J ORAL MAXIL SURG, V66, P2345, DOI 10.1016/j.joms.2007.08.035; Martins PRS, 2012, BRAZ J OTORHINOLAR, V78, P16, DOI 10.1590/S1808-86942012000200004; RUSHTON M A, 1946, Br Dent J, V81, P37; Sabino-Bezerra JR, 2013, J CRANIO MAXILL SURG, V41, P391, DOI 10.1016/j.jcms.2012.11.002; Stuart WC, 2009, ORAL RADIOLOGY PRINC; Suei Y, 2007, J ORAL MAXIL SURG, V65, P918, DOI 10.1016/j.joms.2006.06.297; Suei Y, 2007, DENTOMAXILLOFAC RAD, V36, P125, DOI 10.1259/dmfr/29967141; Suomalainen A, 2009, DENTOMAXILLOFAC RAD, V38, P174, DOI 10.1259/dmfr/21814355; Tong ACK, 2003, J ORAL MAXIL SURG, V61, P1487, DOI 10.1016/j.joms.2003.05.003	15	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0911-6028	1613-9674		ORAL RADIOL	Oral Radiol.	MAY	2015	31	2					123	128		10.1007/s11282-014-0178-0		6	Dentistry, Oral Surgery & Medicine	Dentistry, Oral Surgery & Medicine	CH2AC	WOS:000353824100008		
J	Suka, M; Odajima, T; Okamoto, M; Sumitani, M; Igarashi, A; Ishikawa, H; Kusama, M; Yamamoto, M; Nakayama, T; Sugimori, H				Suka, Machi; Odajima, Takeshi; Okamoto, Masako; Sumitani, Masahiko; Igarashi, Ataru; Ishikawa, Hirono; Kusama, Makiko; Yamamoto, Michiko; Nakayama, Takeo; Sugimori, Hiroki			Relationship between health literacy, health information access, health behavior, and health status in Japanese people	PATIENT EDUCATION AND COUNSELING			English	Article						Health literacy; Health behavior; Health status; Japan; Path analysis	PUBLIC-HEALTH; POPULATION; ADULTS; COMMUNICATION; EDUCATION; NUMERACY; INTERNET; SCALE; CARE	Objective: To examine the relationship between health literacy (HL), health information access, health behavior, and health status in Japanese people. Methods: A questionnaire survey was conducted at six healthcare facilities in Japan. Eligible respondents aged 20-64 years (n = 1218) were included. Path analysis with structural equation modeling was performed to test the hypothesis model linking HL to health information access, health behavior, and health status. Results: The acceptable fitting model indicated that the pathways linking HL to health status consisted of two indirect,paths; one intermediated by health information access and another intermediated by health behavior. Those with higher HL as measured by the 14-item Health Literacy Scale (HLS-14) were significantly more likely to get sufficient health information from multiple sources, less likely to have risky habits of smoking, regular drinking, and lack of exercise, and in turn, more likely to report good self-rated health. Conclusion: HL was significantly associated with health information access and health behavior in Japanese people. HL may play a key role in health promotion, even in highly educated countries like Japan. Practice implications: In order to enhance the effects of health promotion interventions, health professionals should aim at raising HL levels of their target population groups. (C) 2015 Elsevier Ireland Ltd. All rights reserved.	[Suka, Machi] Jikei Univ, Sch Med, Dept Publ Hlth & Environm Med, Tokyo 1058461, Japan; [Odajima, Takeshi] Japanese Red Cross Kanto Koshinetsu Block Blood C, Tokyo, Japan; [Okamoto, Masako] Univ Tokyo, Grad Sch Agr & Life Sci, Dept Appl Biol Chem, Tokyo, Japan; [Sumitani, Masahiko] Tokyo Univ Hosp, Dept Pain & Palliat Med, Tokyo 113, Japan; [Igarashi, Ataru] Univ Tokyo, Grad Sch Pharmaceut Sci, Dept Drug Policy & Management, Tokyo, Japan; [Ishikawa, Hirono] Univ Tokyo, Sch Publ Hlth, Dept Hlth Commun, Tokyo, Japan; [Kusama, Makiko] Univ Tokyo, Grad Sch Pharmaceut Sci, Lab Pharmaceut Regulatory Sci, Tokyo, Japan; [Yamamoto, Michiko] Showa Pharmaceut Univ, Educ Ctr Clin Pharm Practice, Tokyo, Japan; [Nakayama, Takeo] Kyoto Univ, Sch Publ Hlth, Dept Hlth Informat, Kyoto, Japan; [Sugimori, Hiroki] Daito Bunka Univ, Grad Sch Sports & Hlth Sci, Dept Prevent Med, Saitama, Japan	Suka, M (reprint author), Jikei Univ, Sch Med, Dept Publ Hlth & Environm Med, Minato Ku, 3-25-8 Nishi Shimbashi, Tokyo 1058461, Japan.	suka@jikei.ac.jp			Health Labour Sciences Research Grant from the Ministry of Health, Labour, and Welfare; JSPS KAKENHI from the Japan Society for the Promotion of Science [23590814]	We would like to thank Noriyuki Yamane (Japan Association of Health Service), Minoru Ishiyama (Tokyo Health Service Association), Fumiki Shimbo (Kanagawa Health Service Association), Yasuhiro Tsuda (Tochigi Public Health Service Association), Hiromi Chino (Gunma Health foundation), Masako Nakamura (Shizuokaken Yobou Igaku Kyokai), Takashi Yamagami (Hokuriku Yobou Igaku Kyoukai) and all the staff of the six healthcare facilities for their contributions to the questionnaire survey. This work was supported by the Health Labour Sciences Research Grant from the Ministry of Health, Labour, and Welfare and the JSPS KAKENHI 23590814 from the Japan Society for the Promotion of Science.	von Wagner C, 2007, J EPIDEMIOL COMMUN H, V61, P1086, DOI 10.1136/jech.2006.053967; Suka M, 2013, ENVIRON HEALTH PREV, V18, P407, DOI 10.1007/s12199-013-0340-z; McDonald RP, 2002, PSYCHOL METHODS, V7, P64, DOI 10.1037//1082-989X.7.1.64; Tokuda Y, 2009, PATIENT EDUC COUNS, V75, P411, DOI 10.1016/j.pec.2009.03.031; Berkman ND, 2011, ANN INTERN MED, V155, P97, DOI [10.7326/0003-4819-155-2-201107190-00005, 10.1059/0003-4819-155-2-201107190-00005]; Nutbeam D, 2000, HEALTH PROMOT INT, V15, P259, DOI 10.1093/heapro/15.3.259; Chinn D, 2011, SOC SCI MED, V73, P60, DOI 10.1016/j.socscimed.2011.04.004; Yamada Chizumi, 2012, Environmental Health and Preventive Medicine, V17, P457, DOI 10.1007/s12199-012-0274-x; Sentell T, 2011, J HEALTH COMMUN, V16, P279, DOI 10.1080/10810730.2011.604390; Lipkus IM, 2001, MED DECIS MAKING, V21, P37; Sentell T, 2012, J HEALTH COMMUN, V17, P82, DOI 10.1080/10810730.2012.712621; Ishikawa H, 2008, DIABETES CARE, V31, P874, DOI 10.2337/dc07-1932; Osborn CY, 2011, AM J HEALTH BEHAV, V35, P118; Koch-Weser S, 2010, J HEALTH COMMUN, V15, P279, DOI 10.1080/10810730.2010.522700; Nutbeam D, 2008, SOC SCI MED, V67, P2072, DOI 10.1016/j.socscimed.2008.09.050; Barry DW, 2005, ANN FAM MED, V3, P514; Ishikawa H, 2008, HEALTH PROMOT INT, V23, P269, DOI 10.1093/heapro/dan017; Ishikawa Y, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040664; Kline R. B., 2011, PRINCIPLES PRACTICE; Kogure T, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094582; Lee SYD, 2010, BMC PUBLIC HEALTH, V10, DOI 10.1186/1471-2458-10-614; MCHORNEY CA, 1995, QUAL LIFE RES, V4, P293, DOI 10.1007/BF01593882; Ministry of Public Management Home Affairs Posts and Telecommunications, 2013, COMM US TREND SURV; OECD, 2014, ED GLANC; Okamoto M, 2012, BMC MED INFORM DECIS, V12, DOI 10.1186/1472-6947-12-104; Organisation for Economic Co-operation and Development (OECD), 2013, OECD SKILLS OUTL; Sakai Y, 2012, J MED LIBR ASSOC, V100, P205, DOI 10.3163/1536-5050.100.3.011; Sorensen K, 2012, BMC PUBLIC HEALTH, V12, DOI 10.1186/1471-2458-12-80; Taggart J, 2012, BMC FAM PRACT, V13, DOI 10.1186/1471-2296-13-49; Takahashi Y, 2011, J MED INTERNET RES, V13, DOI 10.2196/jmir.1796; van der Heide I, 2013, J HEALTH COMMUN, V18, P172, DOI 10.1080/10810730.2013.825668; World Health Organization. Health Promotion Glossary, 1998, WHOHPRHEP981; Wu SQ, 2013, BMC PUBLIC HEALTH, V13, DOI 10.1186/1471-2458-13-320	33	3	3	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0738-3991			PATIENT EDUC COUNS	Patient Educ. Couns.	MAY	2015	98	5					660	668		10.1016/j.pec.2015.02.013		9	Public, Environmental & Occupational Health; Social Sciences, Interdisciplinary	Public, Environmental & Occupational Health; Social Sciences - Other Topics	CG8ZZ	WOS:000353605500017		
J	Nishiyama, M; Nagase, H; Tanaka, T; Fujita, K; Maruyama, A; Toyoshima, D; Nakagawa, T; Taniguchi-Ikeda, M; Morioka, I; Morisada, N; Takada, S; Iijima, K				Nishiyama, Masahiro; Nagase, Hiroalci; Tanaka, Tsukasa; Fujita, Kyoko; Maruyama, Azusa; Toyoshima, Daisaku; Nakagawa, Taku; Taniguchi-Ikeda, Mariko; Morioka, Ichiro; Morisada, Naoya; Takada, Satoshi; Iijima, Kazumoto			Demographics and Outcomes of Patients With Pediatric Febrile Convulsive Status Epilepticus	PEDIATRIC NEUROLOGY			English	Article						status epilepticus; febrile seizure; fever; consciousness; outcome; children; hyperthermia	CRITICALLY-ILL CHILDREN; ACUTE ENCEPHALOPATHY; SEIZURES; CHILDHOOD; MORTALITY; RISK	BACKGROUND: Convulsive status epilepticus with fever is common and may be related to neurological sequela in children. However, there are limited data on the demographics and risk factors of this phenomenon. Thus, we aimed to describe the demographics and risk factors of neurological sequela among children with convulsive status epilepticus with fever. METHODS: We reviewed convulsive status epilepticus with fever cases in the pediatric intensive care unit at Kobe Children's Hospital between 2002 and 2013. We included patients with intrinsic neurological disease, and excluded those with obvious central nervous system infection. Cases of neurological worsening were categorized as poor outcome using the pediatric cerebral performance category scale. Possible risk factors for poor outcome included age, sex, neurological medical history, seizure duration, body temperature, and level of consciousness. RESULTS: A total of 253 patients (128 males), aged 1 month to 15 years (mean 45 +/- 40 months), were enrolled. Three patients (1.2%) died during hospitalization, and 32 (12.6%) patients had a poor outcome. A univariate analysis identified male sex, absence of epilepsy history, body temperature above 40 degrees C on admission, seizure duration longer than 120 minutes, impaired consciousness at 12 hours after onset, and presence of nonconvulsive seizure as potential predictors of poor outcome. A multivariate analysis, revealed that an absence of epilepsy history (odds ratio = 11.18), body temperature above 40 degrees C on admission (odds ratio = 3.39), or impaired consciousness at 12 hours after onset (odds ratio = 41.85) was associated with poor outcome. CONCLUSIONS: Our study indicated that absence of epilepsy history, high temperature, and/or prolonged impaired consciousness were associated with brain injury.	[Nishiyama, Masahiro; Toyoshima, Daisaku; Nakagawa, Taku; Taniguchi-Ikeda, Mariko; Morioka, Ichiro; Morisada, Naoya; Takada, Satoshi; Iijima, Kazumoto] Kobe Univ, Grad Sch Med, Dept Pediat, Kobe, Hyogo 6500017, Japan; [Nishiyama, Masahiro; Nagase, Hiroalci; Tanaka, Tsukasa; Fujita, Kyoko; Maruyama, Azusa] Hyogo Prefectural Kobe Childrens Hosp, Dept Neurol, Kobe, Hyogo, Japan	Nishiyama, M (reprint author), Kobe Univ, Grad Sch Med, Dept Pediat, Chuo Ku, 7-5-2 Kusunoki Cho, Kobe, Hyogo 6500017, Japan.	nishiyan0203@yahoo.co.jp			Hyogo prefectural medical association	This study was supported by the Hyogo prefectural medical association.	Raspall-Chaure M, 2007, EPILEPSIA, V48, P1652, DOI 10.1111/j.1528-1167.2007.01175.x; [Anonymous], 1993, EPILEPSIA, V34, P592, DOI 10.1111/j.1528-1157.1993.tb00433.x; DeLorenzo RJ, 1996, NEUROLOGY, V46, P1029; FISER DH, 1992, J PEDIATR-US, V121, P68, DOI 10.1016/S0022-3476(05)82544-2; Nabbout R, 2011, LANCET NEUROL, V10, P99, DOI 10.1016/S1474-4422(10)70214-3; Raspall-Chaure M, 2006, LANCET NEUROL, V5, P769, DOI 10.1016/S1474-4422(06)70546-4; MAYTAL J, 1989, PEDIATRICS, V83, P323; Wagenman KL, 2014, NEUROLOGY, V82, P396, DOI 10.1212/WNL.0000000000000082; Lin KL, 2009, PEDIATR NEUROL, V41, P413, DOI 10.1016/j.pediatrneurol.2009.06.004; Auvin S, 2012, EUR J PAEDIATR NEURO, V16, P413, DOI 10.1016/j.ejpn.2012.01.007; Nishiyama I, 2011, EPILEPSY RES, V96, P89, DOI 10.1016/j.eplepsyres.2011.05.004; Polderman KH, 2008, LANCET, V371, P1955, DOI 10.1016/S0140-6736(08)60837-5; Shinnar S, 2012, NEUROLOGY, V79, P871, DOI 10.1212/WNL.0b013e318266fcc5; Abend NS, 2013, LANCET NEUROL, V12, P1170, DOI 10.1016/S1474-4422(13)70246-1; Kramer U, 2011, EPILEPSIA, V52, P1956, DOI 10.1111/j.1528-1167.2011.03250.x; Claassen J, 2002, NEUROLOGY, V58, P139; Fountain NB, 2000, EPILEPSIA, V41, pS23, DOI 10.1111/j.1528-1157.2000.tb01521.x; Chin RFM, 2006, LANCET, V368, P222, DOI 10.1016/S0140-6736(06)69043-0; Chong DJ, 2005, J CLIN NEUROPHYSIOL, V22, P79, DOI 10.1097/01.WNP.0000158699.78529.AF; Appleton R, 2000, ARCH DIS CHILD, V83, P415; Mizuguchi M, 2007, ACTA NEUROL SCAND, V115, P45, DOI 10.1111/j.1600-0404.2007.00809.x; Campos F, 2012, NEUROCHEM INT, V60, P495, DOI 10.1016/j.neuint.2012.02.003; Campos F, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044191; Chin RFM, 2009, EPILEPSIA, V50, P1022, DOI 10.1111/j.1528-1167.2008.01796.x; Dennis M, 2013, NEUROSCI BIOBEHAV R, V37, P2760, DOI 10.1016/j.neubiorev.2013.09.010; Hirsch Lawrence J, 2013, Continuum (Minneap Minn), V19, P767, DOI 10.1212/01.CON.0000431395.16229.5a; Maegaki Y, 2005, NEUROPEDIATRICS, V36, P86; Maegaki Y, 2014, BRAIN DEV; Nagase H, 2013, PEDIATR INT, V55, P310, DOI 10.1111/ped.12046; Scott RC, 2006, EPILEPSIA, V47, P1493, DOI 10.1111/j.1528-1167.2006.00621.x	30	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0887-8994	1873-5150		PEDIATR NEUROL	Pediatr. Neurol.	MAY	2015	52	5					499	503		10.1016/j.pediatrneurol.2015.02.001		5	Clinical Neurology; Pediatrics	Neurosciences & Neurology; Pediatrics	CG9BL	WOS:000353609300004		
J	Yoshinaga, H; Sakoda, S; Shibata, T; Aldyama, T; Oka, M; Yuan, JH; Takashima, H; Takahashi, MP; Kitamura, T; Murakami, N; Kobayashi, K				Yoshinaga, Harumi; Sakoda, Shunichi; Shibata, Takashi; Aldyama, Tomoyuld; Oka, Makio; Yuan, Jun-Hui; Takashima, Hiroshi; Takahashi, Masanori P.; Kitamura, Tetsuro; Murakami, Nagako; Kobayashi, Katsuhiro			Phenotypic Variability in Childhood of Skeletal Muscle Sodium Channelopathies	PEDIATRIC NEUROLOGY			English	Article						sodium channelopathy; SCN4A; mutation; myotonia; periodic paralysis; electromyography; genetic testing	PARALYSIS PERIODICA PARAMYOTONICA; NONDYSTROPHIC MYOTONIAS; CHANNEL GENE; MUTATION; DISORDERS	BACKGROUND: Mutations of the SCN4A gene cause several skeletal muscle channelopathies and overlapping forms of these disorders. However, the variability of the clinical presentation in childhood is confusing and not fully understood among pediatric neurologists. PATIENTS: We found three different mutations (p.V445M, p.I693L, and a novel mutation, p.V1149L) in SCN4A but not in the CLCN1 gene. The patient with p.V445M showed the clinical phenotype of sodium channel myotonia, but her clear symptoms did not appear until 11 years of age. Her younger sister and mother, who have the same mutation, displayed marked intrafamilial phenotypic heterogeneity from mild to severe painful myotonia with persistent weakness. The patient with p.I693L exhibited various symptoms that evolved with age, including apneic episodes, tonic muscular contractions during sleep, fluctuating severe episodic myotonia, and finally episodic paralyses. The patient with the novel p.V1149L mutation exhibited episodic paralyses starting at 3 years of age, and myotonic discharges were detected at 11 years of age for the first time. CONCLUSION: The present cohort reveals the complexity, variability, and overlapping nature of the clinical features of skeletal muscle sodium channelopathies. These are basically treatable disorders, so it is essential to consider genetic testing before the full development of a patient's condition.	[Yoshinaga, Harumi; Shibata, Takashi; Aldyama, Tomoyuld; Oka, Makio; Kobayashi, Katsuhiro] Okayama Univ, Univ Grad Sch Med Dent & Pharmaceut Sci, Dept Child Neurol, Okayama 7008558, Japan; [Sakoda, Shunichi; Yuan, Jun-Hui; Takahashi, Masanori P.] Kagoshima Univ, Grad Sch Med & Dent Sci, Dept Neurol & Geriatr, Kagoshima 890, Japan; [Takahashi, Masanori P.] Osaka Univ, Grad Sch Med, Dept Neurol, Osaka, Japan; [Kitamura, Tetsuro; Murakami, Nagako] Nipponkokan Fukuyama Hosp, Dept Pediat, Hiroshima, Japan	Yoshinaga, H (reprint author), Okayama Univ, Univ Grad Sch Med Dent & Pharmaceut Sci, Dept Child Neurol, Shikatacho 2-5-1, Okayama 7008558, Japan.	magenta@md.okayama-u.ac.jp			Intramural Research Grant on the Nervous and Mental Disorders of NCNP [26-08]; Research Grant for Intractable Disease [H26-079]; Research Committee for Applying Health and Technology of the Ministry of Health, Welfare and Labor of Japan	This study was supported in part by an Intramural Research Grant on the Nervous and Mental Disorders of NCNP (26-08) and a Research Grant for Intractable Disease (H26-079) and the Research Committee for Applying Health and Technology of the Ministry of Health, Welfare and Labor of Japan.	Fournier E, 2006, ANN NEUROL, V60, P356, DOI 10.1002/ana.20905; Matthews E, 2011, ARCH NEUROL-CHICAGO, V68, P127, DOI 10.1001/archneurol.2010.347; Matthews E, 2010, BRAIN, V133, P9, DOI 10.1093/brain/awp294; Lee SC, 2009, J CLIN NEUROL, V5, P186, DOI 10.3988/jcn.2009.5.4.186; Fournier E, 2004, ANN NEUROL, V56, P650, DOI 10.1002/ana.20241; Plassart E, 1996, J NEUROL SCI, V142, P126, DOI 10.1016/0022-510X(96)00173-6; Rosenfeld J, 1997, ANN NEUROL, V42, P811, DOI 10.1002/ana.410420520; Lion-Francois L, 2010, NEUROLOGY, V75, P641, DOI 10.1212/WNL.0b013e3181ed9e96; Heatwole CR, 2007, NEUROTHERAPEUTICS, V4, P238, DOI 10.1016/j.nurt.2007.01.012; Hsu WC, 2006, J FORMOS MED ASSOC, V105, P503; Kim J, 2001, J NEUROL NEUROSUR PS, V70, P618, DOI 10.1136/jnnp.70.5.618; Lehmann-Horn F, 2004, MYOLOGY, P1257; Mankodi A, 2008, NEUROL INDIA, V56, P298; Matthews E, 2008, NEUROLOGY, V71, P1740, DOI 10.1212/01.wnl.0000335269.21550.0e; Saleem Rashid, 2013, J Pediatr Neurosci, V8, P138, DOI 10.4103/1817-1745.117848; Simkin D, 2011, FRONT PHARMACOL, V2, DOI 10.3389/fphar.2011.00063; Song YW, 2012, MUSCLE NERVE, V46, P914, DOI 10.1002/mus.23441; Yoshinaga H, 2012, J NEUROL SCI, V315, P15, DOI 10.1016/j.jns.2011.12.015	18	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0887-8994	1873-5150		PEDIATR NEUROL	Pediatr. Neurol.	MAY	2015	52	5					504	508		10.1016/j.pediatrneurol.2015.01.014		5	Clinical Neurology; Pediatrics	Neurosciences & Neurology; Pediatrics	CG9BL	WOS:000353609300005		
J	Moriyama, K; Watanabe, M; Yamada, Y; Shiihara, T				Moriyama, Kengo; Watanabe, Mio; Yamada, Yoshiyuki; Shiihara, Takashi			Protein-Losing Enteropathy as a Rare Complication of the Ketogenic Diet	PEDIATRIC NEUROLOGY			English	Article						ketogenic diet; protein-losing enteropathy; scintigraphy; 99mTc-diethylene triamine pentaacetic acid human serum albumin	STATUS EPILEPTICUS; SCINTIGRAPHY; DIAGNOSIS; EFFICACY; CHILDREN; AERRPS; FIRES	INTRODUCTION: The ketogenic diet is a valuable therapy for patients with intractable epilepsy, but it can result in a variety of complications that sometimes limits its usefulness. Hypoproteinemia is one of the common adverse effects of this diet, although the underling mechanism is largely unknown except for the diet's reduced protein intake. Only one case of protein-losing enteropathy during the ketogenic diet has been reported. PATIENT DESCRIPTION: A previously healthy 9-year-old girl experienced fever for 5 days then suddenly developed convulsive seizures that subsequently evolved to severe refractory status epilepticus. After multiple antiepileptic drugs failed to improve the patient's condition, we introduced the ketogenic diet. Although her seizures diminished, her course was complicated by hypoproteinemia. An abdominal dynamic scintigraphy and colonoscopy findings indicated protein-losing enteropathy with nonspecific mucosal inflammation. Her nutritional status deteriorated; thus, we discontinued the ketogenic diet. Her nutritional status gradually improved, whereas her seizures increased. DISCUSSION: Hypoproteinemia during the ketogenic diet is common, but the underlying etiologies are not well understood. Abdominal dynamic scintigraphy could be valuable for clarifying the etiology of hypoproteinemia during the ketogenic diet.	[Moriyama, Kengo; Watanabe, Mio; Shiihara, Takashi] Gunma Childrens Med Ctr, Dept Neurol, Shibukawa, Gunma 3778577, Japan; [Yamada, Yoshiyuki] Gunma Childrens Med Ctr, Dept Allergy & Immunol, Gunma, Japan	Moriyama, K (reprint author), Gunma Childrens Med Ctr, Dept Neurol, 779 Shimohakoda, Shibukawa, Gunma 3778577, Japan.	medical-kengo@umin.ac.jp					Kang HC, 2004, EPILEPSIA, V45, P1116, DOI 10.1111/j.0013-9580.2004.10004.x; Nabbout R, 2010, EPILEPSIA, V51, P2033, DOI 10.1111/j.1528-1167.2010.02703.x; Chiu NT, 2001, RADIOLOGY, V219, P86; Braamskamp MJAM, 2010, EUR J PEDIATR, V169, P1179, DOI 10.1007/s00431-010-1235-2; Ismail FY, 2011, EPILEPSIA, V52, pE185, DOI 10.1111/j.1528-1167.2011.03293.x; Suo CQ, 2013, SEIZURE-EUR J EPILEP, V22, P174, DOI 10.1016/j.seizure.2012.11.014; Hartman AL, 2007, PEDIATR NEUROL, V36, P281, DOI 10.1016/j.pediatrneurol.2007.02.008; Sakuma H, 2010, ACTA NEUROL SCAND, V121, P251, DOI 10.1111/j.1600-0404.2009.01198.x; DiMario FJ, 2002, PEDIATR NEUROL, V26, P288, DOI 10.1016/S0887-8994(01)00405-2; O'Connor SE, 2014, PEDIATR NEUROL, V50, P101, DOI 10.1016/j.pediatrneurol.2013.07.020; Sakuma H, 2014, J NEUROL NEUROSURG P; Suzuki C, 1997, J GASTROENTEROL, V32, P78, DOI 10.1007/BF01213300	12	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0887-8994	1873-5150		PEDIATR NEUROL	Pediatr. Neurol.	MAY	2015	52	5					526	528		10.1016/j.pediatrneurol.2015.01.009		3	Clinical Neurology; Pediatrics	Neurosciences & Neurology; Pediatrics	CG9BL	WOS:000353609300009		
J	Gao, X				Gao, Xian			Covariant expansion of the gravitational Stuckelberg trick	PHYSICAL REVIEW D			English	Article							FIELD-THEORY; GRAVITY; MODEL	A new approach to expanding the Stuckelbergized fiducial metric in a covariant manner is developed. The idea is to consider the curved 4-dimensional space as a codimension-one hypersurface embedded in a 5-dimensional Minkowski bulk, in which the 5-dimensional Goldstone modes can be defined as usual. After solving one constraint among the five 5-dimensional Goldstone modes and projecting to the 4-dimensional hypersurface, we are able to express the Stuckelbergized fiducial metric in terms of the 4-dimensional Goldstone modes as well as 4- dimensional curvature quantities. We also compared the results with expressions gotten using the Riemann normal coordinates in Gao et al. [Phys. Rev. D 90, 124073 (2014)] and find that, after a simple field redefinition, results gotten in two approaches exactly coincide.	Tokyo Inst Technol, Dept Phys, Tokyo 1528551, Japan	Gao, X (reprint author), Tokyo Inst Technol, Dept Phys, 2-12-1 Ookayama, Tokyo 1528551, Japan.	gao@th.phys.titech.ac.jp	Gao, Xian/G-9707-2015	Gao, Xian/0000-0002-5216-2453	JSPS [25287054]	I would like to thank Masahide Yamaguchi for discussions and comments. I was supported by JSPS Grant-in-Aid for Scientific Research No. 25287054.	Alberte L, 2012, INT J MOD PHYS D, V21, DOI 10.1142/S0218271812500587; SIEGEL W, 1994, PHYS REV D, V49, P4144, DOI 10.1103/PhysRevD.49.4144; Cheung C, 2008, J HIGH ENERGY PHYS; Hinterbichler K, 2010, PHYS REV D, V82, DOI 10.1103/PhysRevD.82.124018; [Anonymous], 2014, RELATIVITY, V17, P7; Clifton T, 2012, PHYS REP, V513, P1, DOI 10.1016/j.physrep.2012.01.001; Mirbabayi M, 2012, PHYS REV D, V86, DOI 10.1103/PhysRevD.86.084006; ALVAREZGAUME L, 1981, ANN PHYS-NEW YORK, V134, P85, DOI 10.1016/0003-4916(81)90006-3; Joyce A, 2015, PHYS REP, V568, P1, DOI 10.1016/j.physrep.2014.12.002; Arkani-Hamed N, 2003, ANN PHYS-NEW YORK, V305, P96, DOI 10.1016/S0003-4916(03)00068-X; BOULWARE DG, 1972, PHYS REV D, V6, P3368, DOI 10.1103/PhysRevD.6.3368; Deffayet C, 2005, PHYS REV D, V72, DOI 10.1103/PhysRevD.72.044003; de Rham C, 2011, PHYS REV LETT, V106, DOI 10.1103/PhysRevLett.106.231101; Hinterbichler K, 2012, REV MOD PHYS, V84, P671, DOI 10.1103/RevModPhys.84.671; Burrage C, 2011, J COSMOL ASTROPART P, DOI 10.1088/1475-7516/2011/05/025; Comelli D, 2013, J HIGH ENERGY PHYS, DOI 10.1007/JHEP07(2013)161; Creminelli P, 2006, J HIGH ENERGY PHYS, DOI 10.1088/1126-6708/2006/12/080; Creminelli P, 2005, J HIGH ENERGY PHYS, DOI 10.1088/1126-6708/2005/09/003; de Rham C, 2011, J HIGH ENERGY PHYS, DOI 10.1007/JHEP11(2011)093; de Rham Claudia, 2012, Physics Letters B, V711, DOI 10.1016/j.physletb.2012.03.081; Fasiello M, 2013, J COSMOL ASTROPART P, DOI 10.1088/1475-7516/2013/12/002; Gao X, 2014, PHYS REV D, V90, DOI 10.1103/PhysRevD.90.124073; Gao X., UNPUB; Gao X, 2014, PHYS REV D, V90, DOI 10.1103/PhysRevD.90.104033; Gao X, 2014, PHYS REV D, V90, DOI 10.1103/PhysRevD.90.081501; Gleyzes J., ARXIV14046495; Gleyzes J, 2015, J COSMOL ASTROPART P, DOI 10.1088/1475-7516/2015/02/018; Goon GL, 2011, PHYS REV LETT, V106, DOI 10.1103/PhysRevLett.106.231102; Goon G, 2011, J COSMOL ASTROPART P, DOI 10.1088/1475-7516/2011/07/017; GREEN MB, 1991, NUCL PHYS B, V367, P462, DOI 10.1016/0550-3213(91)90022-P; Hassan SF, 2011, J HIGH ENERGY PHYS, DOI 10.1007/JHEP07(2011)009; Khoury J., ARXIV13122006; Kugo T., 2014, PROG THEOR EXP PHYS, V2014; Lin C., ARXIV150107160; Lin CS, 2014, J COSMOL ASTROPART P, DOI 10.1088/1475-7516/2014/10/071; de Rham C, 2013, J COSMOL ASTROPART P, DOI 10.1088/1475-7516/2013/01/035; de Rham C, 2010, J COSMOL ASTROPART P, DOI 10.1088/1475-7516/2010/05/015; Zumalacarregui M, 2014, PHYS REV D, V89, DOI 10.1103/PhysRevD.89.064046	38	1	1	AMER PHYSICAL SOC	COLLEGE PK	ONE PHYSICS ELLIPSE, COLLEGE PK, MD 20740-3844 USA	1550-7998	1550-2368		PHYS REV D	Phys. Rev. D	MAY 1	2015	91	9							094001	10.1103/PhysRevD.91.094001		7	Astronomy & Astrophysics; Physics, Particles & Fields	Astronomy & Astrophysics; Physics	CH1EN	WOS:000353764000001		
J	Yamamoto, Y; Ueyama, T; Ito, T; Tsuruo, Y				Yamamoto, Yuta; Ueyama, Takashi; Ito, Takao; Tsuruo, Yoshihiro			Downregulation of growth hormone 1 gene in the cerebellum and prefrontal cortex of rats with depressive-like behavior	PHYSIOLOGICAL GENOMICS			English	Article						depression; growth hormone 1; forced swimming test; brain; microarray analysis; Ingenuity Pathway Analysis	INDIVIDUAL-DIFFERENCES; ANIMAL-MODELS; EXPRESSION; HIPPOCAMPUS; STRESS; MECHANISMS; AMYGDALA; ANXIETY; BRAIN; MICE	Depressive-like behaviors in animals are usually assessed by standardized behavioral tests such as the forced swimming test (FST). However, individual variation in test performance may obscure group differences and thereby hinder the discovery of genes responsible for depression. Few reports have shown the influence of individual variability in identifying the genes associated with depressive-like behaviors. In this study, we conducted microarray analysis to identify genes differentially expressed in the prefrontal cortex (PFC) and cerebellum of rats stratified by FST immobility ratio (% immobility in 5 min) into a control group [immobility ratio: --1 to + 1 standard deviation (SD) from the mean] and a depressive group (immobility ratio: -1 to + 2 SDs above the mean). Genes differentially expressed in both the cerebellum and PFC of the depressive group were Alas2, Gh1, Hba-a2, Hbb, Hbb-b1, Hbe2, LOC689064, Mrps10, Mybpc, Olf6415, and Pfkb1. Ingenuity Pathway Analysis identified Gh1 as a hub gene in the networks of differentially expressed genes in both brain regions. This study indicates that the depressive-like behavior may be related to the decrease of Gh1 expression in the cerebellum and PFC.	[Yamamoto, Yuta; Ueyama, Takashi; Ito, Takao; Tsuruo, Yoshihiro] Wakayama Med Univ, Sch Med, Dept Anat & Cell Biol, Wakayama 6418509, Japan	Yamamoto, Y (reprint author), Wakayama Med Univ, Sch Med, Dept Anat & Cell Biol, 811-1 Kimiidera, Wakayama 6418509, Japan.	yuta-y@wakayama-med.ac.jp			JSPS KAKENHI [24790662]; Wakayama Medical University	This work was supported by JSPS KAKENHI Grant 24790662 and a Wakayama Medical University Special Grant-in-Aid for Research Projects.	Herman JP, 2005, PROG NEURO-PSYCHOPH, V29, P1201, DOI 10.1016/j.pnpbp.2005.08.006; Koolhaas JM, 2010, FRONT NEUROENDOCRIN, V31, P307, DOI 10.1016/j.yfrne.2010.04.001; Murray EA, 2011, BIOL PSYCHIAT, V69, pE43, DOI 10.1016/j.biopsych.2010.09.041; Baldacara L, 2008, REV BRAS PSIQUIATR, V30, P281, DOI 10.1590/S1516-44462008000300016; JARQUE CM, 1987, INT STAT REV, V55, P163, DOI 10.2307/1403192; Everts RE, 2008, PHYSIOL GENOMICS, V33, P65, DOI 10.1152/physiolgenomics.00223.2007; Wang F, 2011, SCIENCE, V334, P693, DOI 10.1126/science.1209951; Alba-Betancourt C, 2011, GEN COMP ENDOCR, V170, P528, DOI 10.1016/j.ygcen.2010.11.009; Nyberg F, 2000, FRONT NEUROENDOCRIN, V21, P330, DOI 10.1006/frne.2000.0200; Frenois F, 2007, PSYCHONEUROENDOCRINO, V32, P516, DOI 10.1016/j.psyneuen.2007.03.005; Nestler EJ, 2002, NEURON, V34, P13, DOI 10.1016/S0896-6273(02)00653-0; Eisch AJ, 2012, SCIENCE, V338, P72, DOI 10.1126/science.1222941; Silva R, 2008, NEUROSCIENCE, V152, P656, DOI 10.1016/j.neuroscience.2007.12.026; Anand A, 2005, BIOL PSYCHIAT, V57, P1079, DOI 10.1016/j.biopsych.2005.02.021; Yamamoto Y, 2009, PHYSIOL GENOMICS, V39, P227, DOI 10.1152/physiolgenomics.00082.2009; Walf AA, 2006, NEUROPSYCHOPHARMACOL, V31, P1097, DOI 10.1038/sj.npp; Tempere S, 2011, CHEMOSENS PERCEPT, V4, P99, DOI 10.1007/s12078-011-9090-8; Malatynska E, 2005, NEUROSCI BIOBEHAV R, V29, P715, DOI 10.1016/j.neubiorev.2005.03.014; Prica C, 2008, BEHAV BRAIN RES, V191, P49, DOI 10.1016/j.bbr.2008.03.007; Angelucci F, 2005, MOL PSYCHIATR, V10, P345, DOI 10.1038/sj.mp.4001637; Chikahisa S, 2007, BEHAV BRAIN RES, V179, P50, DOI 10.1016/j.bbr.2007.01.010; Donahue CP, 2006, P NATL ACAD SCI USA, V103, P6031, DOI 10.1073/pnas.0507776103; Grundberg E, 2008, PHYSIOL GENOMICS, V33, P301, DOI 10.1152/physiolgenomics.00028.2008; Hallberg M, 2012, OPEN ENDOCRINOL J, V6, P27; HOJVAT S, 1982, BRAIN RES, V239, P543, DOI 10.1016/0006-8993(82)90529-7; Leuner B, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089912; MASSEY FJ, 1951, J AM STAT ASSOC, V46, P68, DOI 10.2307/2280095; Pawlak CR, 2008, NEUROSCI BIOBEHAV R, V32, P1544, DOI 10.1016/j.neubiorev.2008.06.007; Paxinos G., 1996, MOUSE BRAIN STEREOTA; Peng HJ, 2013, BMC PSYCHIATRY, V13, DOI 10.1186/1471-244X-13-72; Sequeira-Cordero A, 2013, BEHAV BRAIN RES, V252, P77, DOI 10.1016/j.bbr.2013.05.046; Strick PL, 2009, ANNU REV NEUROSCI, V32, P413, DOI 10.1146/annurev.neuro.31.060407.125606; Yamamoto Y, 2010, J NEUROIMMUNOL, V229, P129, DOI 10.1016/j.jneuroim.2010.07.024	33	1	1	AMER PHYSIOLOGICAL SOC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	1094-8341	1531-2267		PHYSIOL GENOMICS	Physiol. Genomics	MAY 1	2015	47	5					170	176		10.1152/physiolgenomics.00119.2014		7	Cell Biology; Genetics & Heredity; Physiology	Cell Biology; Genetics & Heredity; Physiology	CH3JI	WOS:000353926600004		
J	Ito, Y; Matsuoka, K; Uesato, T; Sago, H; Okamoto, A; Nakazawa, A; Hata, K				Ito, Y.; Matsuoka, K.; Uesato, T.; Sago, H.; Okamoto, A.; Nakazawa, A.; Hata, K.			Increased expression of perforin, granzyme B, and C5b-9 in villitis of unknown etiology	PLACENTA			English	Article						Fetal growth restriction; Placental inflammation; T lymphocytes; Apoptosis; Placental villi	CYTOTOXIC T-LYMPHOCYTES; TARGET-CELLS; DECIDUAL MACROPHAGES; APOPTOSIS; COMPLEMENT; INFANTS; ACTIVATION; PHENOTYPE; PLACENTA; PATHWAY	Introduction: Villitis of unknown etiology (VUE) is associated with fetal growth restriction. However, the underlying mechanisms of villous injury in placentas with VUE are still largely unknown. We aimed to verify whether apoptosis-related factors are increased in VUE placentas. Furthermore, we determined apoptosis of villous cells. Methods: Six placentas with VUE and 3 control placentas were stained using immunohistochemistry with antibodies for CD3, CD4, CD8, CD68, CD163, perforin, granzyme B, granzyme K, and C5b-9. TUNEL assay analysis was also performed with these placentas. The percentage of cells that stained positive, CD163/CD68 ratio, percentage of C5b-9 positive area, and apoptosis index were quantified and compared between the inflammatory lesions of the VUE placentas, non-VUE inflammatory lesions of the VUE placentas, and control placentas. Results: The percentages of CD3, CD4, CD8 CD68, CD163, perforin, and granzyme B positive cells were significantly higher in the inflammatory lesions of the VUE placentas (p < 0.05). The intravillous CD163/CD68 ratio was higher in the inflammatory lesions compared with the non-inflammatory lesion of the VUE placentas (p < 0.05). The percentage of granzyme K-positive cells was not significantly different between the groups. C5b-9 deposition was higher in the inflammatory lesions of the VUE placentas (p < 0.05). TUNEL-positive cells were significantly higher in the inflammatory lesions of the VUE placentas (p < 0.05). Discussion: To the best of our knowledge, this is the first report to assess villous injury, especially from a viewpoint of villous apoptosis in VUE placentas. An activated perforin/granzyme pathway and C5b-9 are suggested as possible mechanisms of apoptosis. (C) 2015 Elsevier Ltd. All rights reserved.	[Ito, Y.; Okamoto, A.] Jikei Univ, Sch Med, Dept Obstet & Gynecol, Minato Ku, Tokyo 1058461, Japan; [Ito, Y.; Matsuoka, K.; Uesato, T.; Nakazawa, A.] Natl Ctr Child Hlth & Dev, Dept Pathol, Setagaya Ku, Tokyo 1578535, Japan; [Ito, Y.; Hata, K.] Natl Res Inst Child Hlth & Dev, Dept Maternal Fetal Biol, Setagaya Ku, Tokyo 1578535, Japan; [Uesato, T.] St Marianna Univ, Sch Med, Dept Obstet & Gynecol, Miyamae Ku, Kawasaki, Kanagawa 2168511, Japan; [Sago, H.] Natl Ctr Child Hlth & Dev, Dept Maternal Fetal & Neonatal Med, Setagaya Ku, Tokyo 1578535, Japan	Matsuoka, K (reprint author), Natl Ctr Child Hlth & Dev, Dept Pathol, Setagaya Ku, 2-10-1 Okura, Tokyo 1578535, Japan.	matsuoka-k@ncchd.go.jp			Ministry of Health, Labor and Welfare [H26-082]; Ministry of Education, Culture, Sports, Science and Technology [26670734]; National Center for Child Health and Development [26-13]	Grant for Research on Intractable Diseases from the Ministry of Health, Labor and Welfare (H26-082).; Grant-in-Aid for Scientific Research on Innovative Areas from the Ministry of Education, Culture, Sports, Science and Technology (26670734).; Grant of National Center for Child Health and Development (26-13).	AL K, 2013, PLACENTA, V34, P432; Thiery J, 2011, NAT IMMUNOL, V12, P770, DOI 10.1038/ni.2050; SALAFIA CM, 1995, AM J OBSTET GYNECOL, V173, P1049, DOI 10.1016/0002-9378(95)91325-4; Trapani JA, 2002, NAT REV IMMUNOL, V2, P735, DOI 10.1038/nri911; Redline RW, 2007, HUM PATHOL, V38, P1439, DOI 10.1016/j.humpath.2007.05.025; Katzman PJ, 2011, PEDIATR DEVEL PATHOL, V14, P284, DOI 10.2350/10-09-0910-OA.1; Zhao T, 2007, CELL DEATH DIFFER, V14, P489, DOI 10.1038/sj.cdd.4402040; LABARRERE C, 1982, PLACENTA, V3, P309, DOI 10.1016/S0143-4004(82)80007-6; Bohana-Kashtan O, 2004, MOL IMMUNOL, V41, P583, DOI 10.1016/j.molimm.2004.04.007; Rudzinski E, 2013, PEDIATR DEVEL PATHOL, V16, P7, DOI 10.2350/12-05-1195-OA.1; Myerson D, 2006, PEDIATR DEVEL PATHOL, V9, P257, DOI 10.2350/08-05-0103.1; Boog G, 2008, EUR J OBSTET GYN R B, V136, P9, DOI 10.1016/j.ejogrb.2007.06.018; Kim JS, 2008, HISTOPATHOLOGY, V52, P457, DOI 10.1111/j.1365-2559.2008.02964.x; Chowdhury D, 2008, ANNU REV IMMUNOL, V26, P389, DOI 10.1146/annurev.immunol.26.021607.090404; Schonkeren D, 2011, AM J PATHOL, V178, P709, DOI 10.1016/j.ajpath.2010.10.011; Adutler-Lieber S, 2013, J CARDIOVASC PHARM T, V18, P78, DOI 10.1177/1074248412453875; Murray PJ, 2011, NAT REV IMMUNOL, V11, P723, DOI 10.1038/nri3073; Vakeva AP, 1998, CIRCULATION, V97, P2259; Gupta N, 2007, J IMMUNOL, V179, P1855; Lee H, 2005, PLACENTA, V26, P226, DOI 10.1016/j.placenta.2004.05.012; HEUSEL JW, 1994, CELL, V76, P977, DOI 10.1016/0092-8674(94)90376-X; ALTHABE O, 1985, PLACENTA, V6, P369, DOI 10.1016/S0143-4004(85)80047-3; Benirschke K, 2006, PATHOLOGY HUMAN PLAC, Vxx, P1050; Gustafsson C, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002078; Kapur P, 2004, PEDIATR DEVEL PATHOL, V7, P453, DOI 10.1007/s10024-004-2124-3; LABARRERE C, 1987, PLACENTA, V8, P167, DOI 10.1016/0143-4004(87)90019-1; Lokki AI, 2014, FRONT IMMUNOL, V5, P1, DOI 10.3389/fimmu.2014.00312; Porakishvili N, 2004, HAEMATOLOGICA, V89, P435; Prewitt CMF, 1997, EXP NEUROL, V148, P433, DOI 10.1006/exnr.1997.6694; Rampersad R, 2008, PLACENTA, V29, P855, DOI 10.1016/j.placenta.2008.07.008; REDLINE RW, 1993, AM J PATHOL, V143, P473; REDLINE RW, 1985, HUM PATHOL, V16, P727, DOI 10.1016/S0046-8177(85)80159-3; Sato T, 1999, J AM SOC NEPHROL, V10, P1242; Shiraishi H, 1996, J Clin Lab Immunol, V48, P93; Susskind B, 1996, HUM IMMUNOL, V45, P64, DOI 10.1016/0198-8859(95)00151-4; Tamblyn JA, 2013, PLACENTA, V34, P846, DOI 10.1016/j.placenta.2013.07.002; Zhang T, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0083281	37	1	1	W B SAUNDERS CO LTD	LONDON	32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND	0143-4004	1532-3102		PLACENTA	Placenta	MAY	2015	36	5					531	537		10.1016/j.placenta.2015.02.004		7	Developmental Biology; Obstetrics & Gynecology; Reproductive Biology	Developmental Biology; Obstetrics & Gynecology; Reproductive Biology	CG9CL	WOS:000353611900002		
J	Shoji, D; Kurita, K				Shoji, D.; Kurita, K.			Delamination in super-Earths extrapolated from the Earth model	PLANETARY AND SPACE SCIENCE			English	Article						Delamination; Super-Earth; Interior dynamics	PLATE-TECTONICS; CONTINENTAL DELAMINATION; TERRESTRIAL PLANETS; MANTLE RHEOLOGY; EVOLUTION; LITHOSPHERE; EXTENSION; DYNAMICS; ROOT	It is suggested that the delamination process, in which the mantle lithosphere is peeled into the asthenosphere, contributes to the topographies and magmatism of the Earth. We investigated the vigorousness of the delamination in super-Earths by applying the Earth model to planets of heavy mass. Delamination is induced in planets of mass 5M(circle plus) by the negative buoyancy of the mantle lithosphere. However, assuming pressure dependent rheology, the thermal Rayleigh number decreases due to the high pressure in super-Earths and thus the magnitude of convection in the Moho decreases. Because reduced convection in the Moho weakens the peeling of the mantle lithosphere, the delaminated area is narrower. The magnitude of the heat flux caused by the delamination process is also reduced in planets large in size compared with Earth. Although further work is needed, our model indicates that delamination can transfer more heat than the conduction of the lithosphere if the planet's mass is less than 5M(circle plus).(C) 2015 Elsevier Ltd. All rights reserved.	[Shoji, D.; Kurita, K.] Univ Tokyo, Earthquake Res Inst, Bunkyo Ku, Tokyo, Japan	Shoji, D (reprint author), Univ Tokyo, Earthquake Res Inst, Bunkyo Ku, 1-1-1 Yayoi, Tokyo, Japan.	daigo@eri.u-tokyo.ac.jp			JSPS Research Fellowship	This work is supported by the JSPS Research Fellowship. For the calculations, we have used the computer systems of the Earthquake and Volcano Information Center of the Earthquake Research Institute, University of Tokyo.	Noack L, 2014, PLANET SPACE SCI, V98, P41, DOI 10.1016/j.pss.2013.06.020; BIRD P, 1979, J GEOPHYS RES, V84, P7561; Tackley PJ, 2013, ICARUS, V225, P50, DOI 10.1016/j.icarus.2013.03.013; Valencia D, 2006, ICARUS, V181, P545, DOI 10.1016/j.icarus.2005.11.021; Schott B, 1998, TECTONOPHYSICS, V296, P225, DOI 10.1016/S0040-1951(98)00154-1; Schott B, 2000, PHYS EARTH PLANET IN, V118, P273, DOI 10.1016/S0031-9201(99)00159-4; Morency C, 2004, J GEOPHYS RES-SOL EA, V109, DOI 10.1029/2003JB002414; Karato SI, 2011, ICARUS, V212, P14, DOI 10.1016/j.icarus.2010.12.005; van Heck HJ, 2011, EARTH PLANET SC LETT, V310, P252, DOI 10.1016/j.epsl.2011.07.029; Le Pourhiet L, 2006, EARTH PLANET SC LETT, V251, P104, DOI 10.1016/j.epsl.2006.08.028; SEGATZ M, 1988, ICARUS, V75, P187, DOI 10.1016/0019-1035(88)90001-2; Gvirtzman Z, 2001, EARTH PLANET SC LETT, V187, P117, DOI 10.1016/S0012-821X(01)00272-2; O'Rourke JG, 2012, ICARUS, V221, P1043, DOI 10.1016/j.icarus.2012.10.015; Kasting JF, 2003, ANNU REV ASTRON ASTR, V41, P429, DOI 10.1146/annurev.astro.41.071601.170049; Grott M, 2008, ICARUS, V193, P503, DOI 10.1016/j.icarus.2007.08.015; Foley BJ, 2012, EARTH PLANET SC LETT, V331, P281, DOI 10.1016/j.epsl.2012.03.028; BIRD P, 1978, J GEOPHYS RES, V83, P4975, DOI 10.1029/JB083iB10p04975; Elkins-Tanton LT, 2005, GEOL SOC AM SPEC PAP, V388, DOI 10.1130/2005.2388(27); Gogus OH, 2008, GEOLOGY, V36, P723, DOI 10.1130/G24982A.1; Karato S, 2014, TECTONOPHYSICS, V631, P4, DOI 10.1016/j.tecto.2014.05.025; Kite ES, 2009, ASTROPHYS J, V700, P1732, DOI 10.1088/0004-637X/700/2/1732; Korenaga J, 2010, ASTROPHYS J LETT, V725, pL43, DOI 10.1088/2041-8205/725/1/L43; Moore WB, 2003, J GEOPHYS RES-PLANET, V108, DOI 10.1029/2002JE001943; O'Neill C, 2007, GEOPHYS RES LETT, V34, DOI 10.1029/2007GL030598; Gogus OH, 2008, J GEOPHYS RES-SOL EA, V113, DOI 10.1029/2007JB005123; Gray R, 2012, J GEOPHYS RES-SOL EA, V117, DOI 10.1029/2011JB008692; Stamenkovic V, 2014, ICARUS, V234, P174, DOI 10.1016/j.icarus.2014.01.042; Stamenkovic V., 2011, ICARUS, V216, P569; Stein C, 2013, EARTH PLANET SC LETT, V361, P448, DOI 10.1016/j.epsl.2012.11.011; Valencia D., 2007, ASTROPHYS J, V670, P45; Valera JL, 2011, TECTONOPHYSICS, V502, P257, DOI 10.1016/j.tecto.2010.04.002; Wagner FW, 2012, ASTRON ASTROPHYS, V541, DOI 10.1051/0004-6361/201118441; Wagner FW, 2011, ICARUS, V214, P366, DOI 10.1016/j.icarus.2011.05.027	33	0	0	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0032-0633			PLANET SPACE SCI	Planet Space Sci.	MAY	2015	109						38	45		10.1016/j.pss.2015.01.016		8	Astronomy & Astrophysics	Astronomy & Astrophysics	CH0YY	WOS:000353749500004		
J	Wei, LX; Lv, BS; Wang, MM; Ma, HY; Yang, HY; Liu, XL; Jiang, CJ; Liang, ZW				Wei, Li-Xing; Lv, Bing-Sheng; Wang, Ming-Ming; Ma, Hong-Yuan; Yang, Hao-Yu; Liu, Xiao-Long; Jiang, Chang-Jie; Liang, Zheng-Wei			Priming effect of abscisic acid on alkaline stress tolerance in rice (Oryza sativa L.) seedlings	PLANT PHYSIOLOGY AND BIOCHEMISTRY			English	Article						Abscisic acid (ABA); Alkaline stress; Priming; Stress tolerance; Rice (Oryza sativa)	SALINE-SODIC SOIL; PHYSIOLOGICAL-RESPONSES; ANTIOXIDANT SYSTEM; IONIC BALANCE; SALT STRESS; GROWTH; ABA; GERMINATION; CHLORIDE; YIELD	Saline alkaline stress is characterized by high salinity and high alkalinity (high pH); alkaline stress has been shown to be the primary factor inhibiting rice seedling growth. In this study, we investigated the potential priming effect of abscisic acid (ABA) on tolerance of rice seedlings to alkaline stress simulated by Na2CO3. Seedlings were pretreated with ABA at concentrations of 0 (control), 10, and 50 mu M by root-drench for 24 h and then transferred to a Na2CO3 solution that did not contain ABA. Compared to control treatment, pretreatment with ABA substantially improved the survival rate of rice seedlings and increased biomass accumulation after 7 days under the alkaline condition. ABA application at 10 mu M also alleviated the inhibitory effects of alkaline stress on the total root length and root surface area. Physiologically, ABA increased relative water content (RWC) and decreased cell membrane injury degree (MI) and Na+/K+ ratios. In contrast, fluridone (an ABA biosynthesis inhibitor) decreased the RWC and increased MI in shoots under the alkaline conditions. These data suggest that ABA has a potent priming effect on the adaptive response to alkaline stress in rice and may be useful for improving rice growth in saline alkaline paddy fields. (C) 2015 Elsevier Masson SAS. All rights reserved.	[Wei, Li-Xing; Lv, Bing-Sheng; Wang, Ming-Ming; Ma, Hong-Yuan; Yang, Hao-Yu; Liu, Xiao-Long; Liang, Zheng-Wei] Chinese Acad Sci, Northeast Inst Geog & Agroecol, Changchun 130102, Jilin, Peoples R China; [Wei, Li-Xing; Lv, Bing-Sheng] Univ Chinese Acad Sci, Beijing 100049, Peoples R China; [Wang, Ming-Ming; Ma, Hong-Yuan; Yang, Hao-Yu; Liu, Xiao-Long; Liang, Zheng-Wei] Daan Sod Land Expt Stn, Daan 131317, Jilin, Peoples R China; [Liang, Zheng-Wei] Chinese Acad Sci, Key Lab Soybean Mol Design Breeding, Harbin 150081, Heilongjiang, Peoples R China; [Jiang, Chang-Jie] Natl Inst Agrobiol Sci, Tsukuba, Ibaraki 3058602, Japan	Jiang, CJ (reprint author), Natl Inst Agrobiol Sci, Kannondai 2-1-2, Tsukuba, Ibaraki 3058602, Japan.	cjjiang@affrc.go.jp; liangzw@neigae.ac.cn			National science & Technology pillar Program of China [2012BAD20B03-05]; Chinese Academy of Sciences Action-plan for West Development [KZCX2-XB3-16]; Key Research Program of the Chinese Academy of Sciences [KZZD-EW-TZ-07-08]	This study was supported by the National science & Technology pillar Program of China (No. 2012BAD20B03-05), the Chinese Academy of Sciences Action-plan for West Development (KZCX2-XB3-16), the Key Research Program of the Chinese Academy of Sciences (KZZD-EW-TZ-07-08).	BOHRA JS, 1995, J AGRON CROP SCI, V174, P79, DOI 10.1111/j.1439-037X.1995.tb00197.x; Ren ZH, 2005, NAT GENET, V37, P1141, DOI 10.1038/ng1643; Uddin MK, 2011, AUST J CROP SCI, V5, P620; Yang CW, 2008, PLANT GROWTH REGUL, V56, P179, DOI 10.1007/s10725-008-9299-y; Munns R, 2008, ANNU REV PLANT BIOL, V59, P651, DOI 10.1146/annurev.arplant.59.032607.092911; Zhang JT, 2009, SOIL SCI PLANT NUTR, V55, P685, DOI 10.1111/j.1747-0765.2009.00411.x; Beckers GJ, 2007, CURR OPIN PLANT BIOL, V10, P425, DOI 10.1016/j.pbi.2007.06.002; Wang MM, 2010, J FOOD AGRIC ENVIRON, V8, P628; Sripinyowanich S, 2013, ENVIRON EXP BOT, V86, P94, DOI 10.1016/j.envexpbot.2010.01.009; Goellner K, 2008, EUR J PLANT PATHOL, V121, P233, DOI 10.1007/s10658-007-9251-4; Khadri M, 2007, ENVIRON EXP BOT, V60, P211, DOI 10.1016/j.envexpbot.2006.10.008; Wang H, 2011, PLANT SOIL ENVIRON, V57, P286; Khan MSA, 1997, J AGRON CROP SCI, V179, P163, DOI 10.1111/j.1439-037X.1997.tb00512.x; Lu SY, 2009, PLANT PHYSIOL BIOCH, V47, P132, DOI 10.1016/j.plaphy.2008.10.006; Yin CY, 2004, PLANT SCI, V167, P1091, DOI 10.1016/j.plantsci.2004.06.005; Jisha KC, 2013, ACTA PHYSIOL PLANT, V35, P1381, DOI 10.1007/s11738-012-1186-5; Amjad M, 2014, SCI HORTIC-AMSTERDAM, V172, P109, DOI 10.1016/j.scienta.2014.03.024; Yu JB, 2010, CLEAN-SOIL AIR WATER, V38, P1010, DOI 10.1002/clen.201000276; Zhang JH, 2006, FIELD CROP RES, V97, P111, DOI 10.1016/j.fcr.2005.08.018; CHEN HH, 1983, PLANT PHYSIOL, V71, P362, DOI 10.1104/pp.71.2.362; Zhang JL, 2010, PLANT SOIL, V326, P45, DOI 10.1007/s11104-009-0076-0; van Asten PJA, 2004, GEODERMA, V119, P233, DOI 10.1016/j.geoderma.2003.08.002; Aranega Bou P., 2014, FRONT PLANT SCI, V5, P488; Cheng HaiTao, 2008, Acta Agronomica Sinica, V34, P1719; Gao YP, 2002, J PLANT PHYSIOL, V159, P951, DOI 10.1078/0176-1617-00782; Gurmani AR, 2011, AUST J CROP SCI, V5, P1278; Gurmani A. R., 2013, Australian Journal of Crop Science, V7, P1219; INAN G, 2004, PLANT PHYSIOL, V135, P1717; Islam MS, 2011, AUST J CROP SCI, V5, P1269; Khan N. A., 2012, PHYTOHORMONES ABIOTI, DOI [10.1007/978-3-642-25829-9, DOI 10.1007/978-3-642-25829-9]; Li X., 2008, CHIN AGR SCI B, V8, P252; LI X, 2002, RES AGR MOD, V5, P361; [梁正伟 Liang Zhengwei], 2004, [生态环境, Ecology and Environment], V13, P43; Liu MA, 2010, J FOOD AGRIC ENVIRON, V8, P412; Lv BS, 2013, AGRON J, V105, P1119, DOI 10.2134/agronj2013.0017; Ma H.Y., 2007, B BOR, V24, P181; Martinez-Beltran J., 2005, P INT SAL FOR RIV CA, P311; [祁栋灵 QI Dongling], 2007, [植物遗传资源学报, Journal of Plant Genetic Resources], V8, P486; ROBERTSON AJ, 1994, AM SOC PLANT BIOL, V105, P181; Rodriguez-Navarro A, 2006, J EXP BOT, V57, P1149, DOI 10.1093/jxb/erj068; Ruan S.L., 2001, CHINESE J RICE SCI, V16, P281; Shan W.Z., 2006, RECLAIMING RICE CULT, V1, P44; Sun T., 2004, J JILIN AGR U, V6, P597; TANTAU H, 1991, PHYSIOL PLANTARUM, V82, P243; Tuteja Narendra, 2007, Plant Signal Behav, V2, P135, DOI 10.4161/psb.2.3.4156; [王春裕 Wang Chunyu], 2004, [土壤通报, Journal of Soil Science], V35, P643; Wang GJ, 2013, J AGRON CROP SCI, V199, P200, DOI 10.1111/jac.12004; Wang Y., 2006, J JILIN AGR U, V6, P652; [张晓光 Zhang Xiaoguang], 2013, [土壤, Soils], V45, P332	49	0	0	ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER	PARIS	23 RUE LINOIS, 75724 PARIS, FRANCE	0981-9428			PLANT PHYSIOL BIOCH	Plant Physiol. Biochem.	MAY	2015	90						50	57		10.1016/j.plaphy.2015.03.002		8	Plant Sciences	Plant Sciences	CH2GZ	WOS:000353845000006		
J	Nakagawa, T; Goto, M				Nakagawa, Takaharu; Goto, Motonobu			Recycling thermosetting polyester resin into functional polymer using subcritical water	POLYMER DEGRADATION AND STABILITY			English	Article						Subcritical water; Thermosetting polyester resin; Recycling; Hydrolysis; Styrene-fumaric acid copolymer; Glycol	FIBER-REINFORCED PLASTICS; GLASS-FIBERS; COMPOSITES; WASTE; RECOVERY; DEPOLYMERIZATION; DECOMPOSITION; MONOMERS	Subcritical water and soluble alkali were applied to hydrolyze thermosetting polyester resins of fiber reinforced plastic (FRP) to recover a styrene-fumaric acid copolymer (SFC) in high yield. SFC is a functional polymer and has the same molecular structure as that of styrene-maleic acid copolymer, which is applied as high value-added additive. Potassium hydroxide (KOH) contributed to accelerate hydrolysis and to provide water solubility to the SFC. The optimized reaction conditions based on the SFC yield were at either a temperature of 230 degrees C, reaction time of 2 h, and with a KOH concentration of 0.38 mol/L, or 230 degrees C, 1 h, and 0.72 mol/L for sodium hydroxide (NaOH). It was verified that this method had the potential to recycle thermosetting polyester resin of FRPs to produce SFC. (C) 2015 Elsevier Ltd. All rights reserved.	[Nakagawa, Takaharu] Panasonic Corp, Eco Solut Co, Osaka 5718686, Japan; [Nakagawa, Takaharu; Goto, Motonobu] Nagoya Univ, Dept Chem Engn, Chikusa Ku, Nagoya, Aichi 4648603, Japan	Nakagawa, T (reprint author), Panasonic Corp, Eco Solut Co, Osaka 5718686, Japan.	nakagawa.takaharu@jp.panasonic.com			Ministry of Economy, Trade and Industry; International Center for Environmental Technology Transfer (ICETT); New Energy and Industrial Technology Development Organization (NEDO)	The research on the investigation on the proposed subcritical hydrolysis was supported by the Ministry of Economy, Trade and Industry, as a part of joint research project with the International Center for Environmental Technology Transfer (ICETT). The research on the evaluation of subcritical hydrolysis applied to various FRPs was supported by the New Energy and Industrial Technology Development Organization (NEDO). We also received cooperation from Showa Denko K.K. (formerly Showa High Polymer Co., Ltd.) to obtain FRP samples. We would like to express our sincere appreciation to these entities.	Oliveux G, 2012, COMPOS PART A-APPL S, V43, P1809, DOI 10.1016/j.compositesa.2012.06.008; Suyama K, 2010, POLYM DEGRAD STABIL, V95, P1588, DOI 10.1016/j.polymdegradstab.2010.05.034; Suyama K, 2007, POLYM DEGRAD STABIL, V92, P317, DOI 10.1016/j.polymdegradstab.2006.10.008; Vallee M, 2004, IND ENG CHEM RES, V43, P6317, DOI 10.1021/ie049871y; Shima H, 2011, MATER TRANS, V52, P1327, DOI 10.2320/matertrans.M2011044; Adschiri T, 1997, KAGAKU KOGAKU RONBUN, V23, P505; Shi J, 2012, COMPOS SCI TECHNOL, V72, P1298, DOI 10.1016/j.compscitech.2012.05.003; Pickering SJ, 2000, COMPOS SCI TECHNOL, V60, P509, DOI 10.1016/S0266-3538(99)00154-2; Asokan P, 2009, J CLEAN PROD, V17, P821, DOI 10.1016/j.jclepro.2008.12.004; Grause G, 2013, J MATER CYCLES WASTE, V15, P122, DOI 10.1007/s10163-012-0101-x; Iwaya T, 2008, J MATER SCI, V43, P2452, DOI 10.1007/s10853-007-2017-8; Kamimura A, 2009, J MATER CYCLES WASTE, V11, P133, DOI 10.1007/s10163-008-0225-1; Kamimura A, 2006, CHEM LETT, V35, P586, DOI 10.1246/cl.2006.586; Kamimura A, 2009, J MATER CYCLES WASTE, V11, P38, DOI 10.1007/s10163-008-0217-1; Kamimura A, ISSF ARC FRANC; Kao CC, 2011, 18 INT C COMP MAT; Kubota S, 1999, 1 INT S FEEDST REC P, P247; Kubota S, 2003, NIPPON SETCHAKU GAKK, V24-1, P22; Nakagawa T, 2003, P 11 US JAP SEM DIEL, P85; Nakamura T, 2006, AIP CONF PROC, V865, P28, DOI 10.1063/1.2398824; Nakagawa T, 2006, P OCEANS2006 MTS IEE, P1; Nakagawa T, 2008, JEC COMPOSITES M MAR, P40; Nakai S, 2011, 6 INT S FEEDST REC P, P165; Oliveux G, 2013, POLYM DEGRAD STABIL, V98, P785, DOI 10.1016/j.polymdegradstab.2012.12.010; Perrin D, 2006, J MATER SCI, V41, P3593, DOI 10.1007/s10853-005-5563-y; Ribeiro MCS, 2011, ICCE19, P961; Sugeta T, 2001, KOBUNSHI RONBUNSHU, V58, P557; TESTER JW, 1993, ACS SYM SER, V518, P35; Torres A, 2009, ADV POLYM TECH, V28, P141, DOI 10.1002/adv.20150; Yamada K, 2010, J MATER CYCLES WASTE, V12, P271, DOI 10.1007/s10163-010-0296-7; Yoon KH, 1997, POLYMER, V38, P2281, DOI 10.1016/S0032-3861(96)00951-2	31	0	0	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0141-3910	1873-2321		POLYM DEGRAD STABIL	Polym. Degrad. Stabil.	MAY	2015	115						16	23		10.1016/j.polymdegradstab.2015.02.005		8	Polymer Science	Polymer Science	CG9CB	WOS:000353610900002		
J	Satoh, C; Ishii, H; Hasumi, M; Yamada, E; Millington, KR; Nakata, M				Satoh, Chikahiro; Ishii, Hiroshi; Hasumi, Masatake; Yamada, Emi; Millington, Keith R.; Nakata, Munetaka			Chemiluminescence spectral analysis of styrene-butadiene and acrylonitrile-butadiene rubbers using a multichannel Fourier-transform chemiluminescence spectrometer	POLYMER TESTING			English	Article						Chemiluminescence spectra; Styrene-butadiene rubbers; Acrylonitrile-butadiene rubbers; Multichannel Fourier-transform spectrometer	GAMMA-IRRADIATED POLYTETRAFLUOROETHYLENE; LUMINESCENCE SPECTROSCOPY; THERMAL CHEMILUMINESCENCE; MECHANISM; EMISSION; ELASTOMERS; OXIDATION	The chemiluminescence spectra of styrene-butadiene and acrylonitrile-butadiene rubbers isothermally heated in the range between room temperature and 200 degrees C were measured with a multichannel Fourier-transform chemiluminescence spectrometer. The observed spectra were analyzed by a least-squares fit using a Gaussian function to determine the peak intensity and the peak wavelength of emission bands. It was found that the peak wavelength of acrylonitrile-butadiene rubbers was slightly longer than that of styrene-butadiene rubbers due to the influence of the nitrile groups. The peak intensity of chemiluminescence from styrene-butadiene rubbers decreased with the styrene content, while that from hydrogenated acrylonitrile-butadiene rubbers increased with the iodine value. From these experimental results, it is concluded that the content of double bonds in the butadiene units in rubbers is measurable by chemiluminescence spectral analysis. (C) 2015 Elsevier Ltd. All rights reserved.	[Satoh, Chikahiro; Ishii, Hiroshi; Hasumi, Masatake] Japan Appl Technol Inc, Kunitachi, Tokyo 1860011, Japan; [Yamada, Emi; Nakata, Munetaka] Tokyo Univ Agr & Technol, Grad Sch BASE Bioapplicat & Syst Engn, Koganei, Tokyo 1848588, Japan; [Millington, Keith R.] Geelong Technol Precinct, CSIRO Mfg, Waurn Ponds, Vic 3216, Australia	Nakata, M (reprint author), Tokyo Univ Agr & Technol, Grad Sch BASE Bioapplicat & Syst Engn, Koganei, Tokyo 1848588, Japan.	necom816@cc.tuat.ac.jp	Millington, Keith/B-9933-2008	Millington, Keith/0000-0003-4071-1213	JSPS [24550012]	This work was supported by a JSPS Grant-in-Aid for Scientific Research (C), Grant number 24550012.	RUSSELL GA, 1957, J AM CHEM SOC, V79, P3871, DOI 10.1021/ja01571a068; KHAN AU, 1970, J AM CHEM SOC, V92, P3293, DOI 10.1021/ja00714a010; BEAVAN SW, 1974, EUR POLYM J, V10, P925, DOI 10.1016/0014-3057(74)90030-5; Hironiwa T, 2012, POLYM J, V44, P1015, DOI 10.1038/pj.2012.56; Noguchi T, 2014, CHEM PHYS LETT, V614, P181, DOI 10.1016/j.cplett.2014.09.031; Osawa Z, 1997, POLYM DEGRAD STABIL, V57, P69, DOI 10.1016/S0141-3910(97)86335-5; Santoso M., 2007, RUBBER CHEM TECHNOL, V80, P762, DOI 10.5254/1.3539415; Tsukino K, 2008, CHEM PHYS LETT, V457, P444, DOI 10.1016/j.cplett.2008.04.044; Yamada E, 2014, CHEM PHYS LETT, V616, P104, DOI 10.1016/j.cplett.2014.10.026; Yano A, 2013, POLYM DEGRAD STABIL, V98, P2680, DOI 10.1016/j.polymdegradstab.2013.09.031; Yano A, 2014, CHEM PHYS LETT, V591, P259, DOI 10.1016/j.cplett.2013.11.053	11	0	0	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0142-9418	1873-2348		POLYM TEST	Polym. Test	MAY	2015	43						44	48		10.1016/j.polymertesting.2015.02.009		5	Materials Science, Characterization & Testing; Polymer Science	Materials Science; Polymer Science	CH2KP	WOS:000353854400007		
J	Hiroi, Z				Hiroi, Zenji			Structural instability of the rutile compounds and its relevance to the metal-insulator transition of VO2	PROGRESS IN SOLID STATE CHEMISTRY			English	Review						VO2; Rutile compound; Spinodal decomposition; Metal-insulator transition; Metal-metal bonding; Molecular orbital crystal	POWDER NEUTRON-DIFFRACTION; PHASE-TRANSITION; CRYSTAL-STRUCTURE; V1-XNBXO2 SYSTEM; VANADIUM DIOXIDE; SINGLE-CRYSTALS; NIOBIUM DIOXIDE; X-RAY; ELECTRICAL-CONDUCTIVITY; ELECTRONIC-STRUCTURE	The metal insulator transition (MIT) of VO2 is discussed with particular emphasis on the structural instability of the rutile compounds toward dimerization. Ti substitution experiments reveal that the MIT is robust up to 20% Ti substitutions and occurs even in extremely thin V-rich lamellas in spinodally decomposed TiO2-VO2 composites, indicating that the MIT is insensitive to hole doping and essentially takes on a local character. These observations suggest that either electron correlation in the Mott-Hubbard sense or Peierls (Fermi-surface) instability plays a minor role on the MIT. Through a broad perspective of crystal chemistry on the rutile-related compounds, it is noted that VO2 and another MIT compound NbO2 in the family eventually lie just near the borderline between the two structural groups with the regular rutile structure and the distorted structures characterized by the formation of dimers with direct metal metal bonding. It is also shown that the two compounds of the rutile form do not follow the general trends in structure observed for the other rutile compounds, giving clear evidence of an inherent structural instability present in the two compounds. The MITs of VO2 and NbO2 are natural consequences of structural transitions between the two groups, as all the d electrons are trapped in the bonding molecular orbitals of dimers at low temperatures. Such dimer crystals are ubiquitously found in early transition metal compounds having chain-like structures, such as MoBr3, NbCl4, Ti4O7, and V4O7, the latter two of which also exhibit MITs probably of the same origin. In a broader sense, the dimer crystal is a kind of "molecular orbital crystals" in which virtual molecules made of transition metal atoms with partially-filled t(2g) shells, such as dimers, trimers or larger ones, are generated by metal metal bonding and are embedded into edge- or face-sharing octahedron networks of various kinds. The molecular orbital crystallization opens a natural route to stabilization of unpaired t2g electrons in crystals. (C) 2015 Elsevier Ltd. All rights reserved.	Univ Tokyo, Inst Solid State Phys, Kashiwa, Chiba 2778581, Japan	Hiroi, Z (reprint author), Univ Tokyo, Inst Solid State Phys, Kashiwa, Chiba 2778581, Japan.	hiroi@issp.u-tokyo.ac.jp					AMADOR J, 1981, J APPL CRYSTALLOGR, V14, P348, DOI 10.1107/S0021889881009515; RICE TM, 1994, PHYS REV LETT, V73, P3042, DOI 10.1103/PhysRevLett.73.3042; ROGERS DB, 1969, INORG CHEM, V8, P841, DOI 10.1021/ic50074a029; PAQUET D, 1980, PHYS REV B, V22, P5284, DOI 10.1103/PhysRevB.22.5284; Jackeli G, 2008, PHYS REV LETT, V100, DOI 10.1103/PhysRevLett.100.147203; Shibuya K, 2010, PHYS REV B, V82, DOI 10.1103/PhysRevB.82.205118; COTTON FA, 1966, Q REV CHEM SOC, V20, P389, DOI 10.1039/qr9662000389; SHIN S, 1990, PHYS REV B, V41, P4993, DOI 10.1103/PhysRevB.41.4993; LAKKIS S, 1976, PHYS REV B, V14, P1429, DOI 10.1103/PhysRevB.14.1429; McWhan DB, 1970, PHYS REV B-SOLID ST, V2, P3734, DOI 10.1103/PhysRevB.2.3734; Senn MS, 2012, NATURE, V481, P173, DOI 10.1038/nature10704; Lazarovits B, 2010, PHYS REV B, V81, DOI 10.1103/PhysRevB.81.115117; MAREZIO M, 1973, J SOLID STATE CHEM, V6, P213, DOI 10.1016/0022-4596(73)90184-9; Shibuya K, 2010, APPL PHYS LETT, V96, DOI 10.1063/1.3291053; Pinsard-Gaudart L, 2007, PHYS REV B, V76, DOI 10.1103/PhysRevB.76.045119; Baum P, 2007, SCIENCE, V318, P788, DOI 10.1126/science.1147724; HORLIN T, 1972, MATER RES BULL, V7, P1515, DOI 10.1016/0025-5408(72)90189-4; GOODENOUGH JB, 1960, PHYS REV, V117, P1442, DOI 10.1103/PhysRev.117.1442; ZYLBERSZTEJN A, 1975, PHYS REV B, V11, P4383, DOI 10.1103/PhysRevB.11.4383; Dernier PD, 1970, PHYS REV B-SOLID ST, V2, P3771, DOI 10.1103/PhysRevB.2.3771; Cavalleri A, 2004, PHYS REV B, V70, DOI 10.1103/PhysRevB.70.161102; Horibe Y, 2006, PHYS REV LETT, V96, DOI 10.1103/PhysRevLett.96.086406; MAGNELI A, 1955, ACTA CHEM SCAND, V9, P1378, DOI 10.3891/acta.chem.scand.09-1378; NAKUA A, 1991, J SOLID STATE CHEM, V91, P105, DOI 10.1016/0022-4596(91)90062-M; HORLIN T, 1976, ACTA CHEM SCAND A, V30, P619, DOI 10.3891/acta.chem.scand.30a-0619; Khomskii DI, 2005, PHYS REV LETT, V94, DOI 10.1103/PhysRevLett.94.156402; ADLER D, 1968, REV MOD PHYS, V40, P714, DOI 10.1103/RevModPhys.40.714; Lee SH, 2004, PHYS REV LETT, V93, DOI [10.1103/PhysRevLett.93.156407, 10.1103/PhysRevLett.93.164102]; Muraoka Y, 2002, APPL PHYS LETT, V80, P583, DOI 10.1063/1.1446215; Park JH, 2013, NATURE, V500, P431, DOI 10.1038/nature12425; MCWHAN DB, 1974, PHYS REV B, V10, P490, DOI 10.1103/PhysRevB.10.490; POUGET JP, 1975, PHYS REV LETT, V35, P873, DOI 10.1103/PhysRevLett.35.873; MATTHEISS LF, 1976, PHYS REV B, V13, P2433, DOI 10.1103/PhysRevB.13.2433; BOLZAN AA, 1995, AUST J CHEM, V48, P1473, DOI 10.1071/CH9951473; BAUR WH, 1956, ACTA CRYSTALLOGR, V9, P515, DOI 10.1107/S0365110X56001388; MAREZIO M, 1972, PHYS REV B-SOLID ST, V5, P2541, DOI 10.1103/PhysRevB.5.2541; BANDO Y, 1969, JPN J APPL PHYS, V8, P633, DOI 10.1143/JJAP.8.633; BOLZAN AA, 1994, J SOLID STATE CHEM, V113, P9, DOI 10.1006/jssc.1994.1334; ANDERSSON S, 1957, ACTA CHEM SCAND, V11, P1641, DOI 10.3891/acta.chem.scand.11-1641; Miura Y, 2007, J PHYS SOC JPN, V76, DOI 10.1143/JPSJ.76.033705; Haverkort MW, 2005, PHYS REV LETT, V95, DOI 10.1103/PhysRevLett.95.196404; SLATER JC, 1951, PHYS REV, V82, P538, DOI 10.1103/PhysRev.82.538; Mazin II, 2012, PHYS REV LETT, V109, DOI 10.1103/PhysRevLett.109.197201; MAREZIO M, 1973, J SOLID STATE CHEM, V6, P419, DOI 10.1016/0022-4596(73)90233-8; Rodriguez EE, 2007, J AM CHEM SOC, V129, P10244, DOI 10.1021/ja0727363; JANNINCK RF, 1966, J PHYS CHEM SOLIDS, V27, P1183, DOI 10.1016/0022-3697(66)90094-1; Nakano M, 2012, NATURE, V487, P459, DOI 10.1038/nature11296; Isobe M, 2006, J PHYS SOC JPN, V75, DOI 10.1143/JPSJ.75.073801; SHANNON RD, 1968, SOLID STATE COMMUN, V6, P139, DOI 10.1016/0038-1098(68)90019-7; Eyert V, 2002, ANN PHYS-BERLIN, V11, P650, DOI 10.1002/1521-3889(200210)11:9<650::AID-ANDP650>3.0.CO;2-K; Lee SH, 2000, PHYS REV LETT, V84, P3718, DOI 10.1103/PhysRevLett.84.3718; BIANCONI A, 1982, PHYS REV B, V26, P2741, DOI 10.1103/PhysRevB.26.2741; Irizawa A, 2011, PHYS REV B, V84, DOI 10.1103/PhysRevB.84.235116; KACHI S, 1973, J SOLID STATE CHEM, V6, P258, DOI 10.1016/0022-4596(73)90189-8; MORIN FJ, 1959, PHYS REV LETT, V3, P34, DOI 10.1103/PhysRevLett.3.34; Holman KL, 2009, PHYS REV B, V79, DOI 10.1103/PhysRevB.79.245114; Radaelli PG, 2002, NATURE, V416, P155, DOI 10.1038/416155a; Eyert V, 2002, EUROPHYS LETT, V58, P851, DOI 10.1209/epl/i2002-00452-6; WENTZCOVITCH RM, 1994, PHYS REV LETT, V72, P3389, DOI 10.1103/PhysRevLett.72.3389; ANDERSSON G, 1954, ACTA CHEM SCAND, V8, P1599, DOI 10.3891/acta.chem.scand.08-1599; Isobe M, 2002, J PHYS SOC JPN, V71, P1423, DOI 10.1143/JPSJ.71.1423; TSUCHIDA Y, 1990, NATURE, V347, P267, DOI 10.1038/347267a0; Cao J, 2009, NAT NANOTECHNOL, V4, P732, DOI [10.1038/nnano.2009.266, 10.1038/NNANO.2009.266]; POUGET JP, 1974, PHYS REV B, V10, P1801, DOI 10.1103/PhysRevB.10.1801; Imada M, 1998, REV MOD PHYS, V70, P1039, DOI 10.1103/RevModPhys.70.1039; Hiroi Z, 2013, CHEM MATER, V25, P2202, DOI 10.1021/cm400236p; MOTT NF, 1968, REV MOD PHYS, V40, P677, DOI 10.1103/RevModPhys.40.677; Bongers PF, 1965, SOLID STATE COMMUN, V3, P275, DOI 10.1016/0038-1098(65)90032-3; ADLER D, 1967, PHYS REV, V155, P826, DOI 10.1103/PhysRev.155.826; TAKANASHI K, 1983, J PHYS SOC JPN, V52, P3953, DOI 10.1143/JPSJ.52.3953; ASTROV DN, 1972, KRISTALLOGRAFIYA+, V17, P1152; Attfield JP, 2015, APL MATER, V3, DOI 10.1063/1.4913736; BALBERG I, 1974, THIN SOLID FILMS, V24, P307, DOI 10.1016/0040-6090(74)90175-8; BARTHOLO.RF, 1969, PHYS REV, V187, P828, DOI 10.1103/PhysRev.187.828; BAUR WH, 1976, ACTA CRYSTALLOGR B, V32, P2200, DOI 10.1107/S0567740876007371; BAUR WH, 1971, ACTA CRYSTALL B-STRU, VB 27, P2133, DOI 10.1107/S0567740871005466; Biermann S, 2005, PHYS REV LETT, V94, DOI 10.1103/PhysRevLett.94.026404; Bolzan AA, 1997, ACTA CRYSTALLOGR B, V53, P373, DOI 10.1107/S0108768197001468; BOMAN CE, 1970, ACTA CHEM SCAND, V24, P123, DOI 10.3891/acta.chem.scand.24-0123; Bramnik KG, 2003, Z KRISTALLOGR, V218, P455, DOI 10.1524/zkri.218.7.455.20715; BREWS JR, 1970, PHYS REV B, V1, P2557, DOI 10.1103/PhysRevB.1.2557; Bridges CA, 2004, J SOLID STATE CHEM, V177, P1098, DOI 10.1016/j.jssc.2003.10.025; BURDETT JK, 1985, INORG CHEM, V24, P2244, DOI 10.1021/ic00208a025; Cavalleri A, 2001, PHYS REV LETT, V87, DOI 10.1103/PhysRevLett.87.237401; Chakraverty B. K., 1976, Journal of Magnetism and Magnetic Materials, V3, DOI 10.1016/0304-8853(76)90029-9; CHEETHAM AK, 1976, ACTA CRYSTALLOGR B, V32, P1579, DOI 10.1107/S0567740876005876; COTTON FA, 1977, INORG CHEM, V16, P1865, DOI 10.1021/ic50174a008; DANTONIO P, 1980, ACTA CRYSTALLOGR B, V36, P2394, DOI 10.1107/S0567740880008813; DRILLON M, 1974, MATER RES BULL, V9, P1199, DOI 10.1016/0025-5408(74)90038-5; GERVAIS F, 1985, PHYS REV B, V31, P4809, DOI 10.1103/PhysRevB.31.4809; Goodenough J. B., 1963, MAGNETISM CHEM BOND; Goodenough J.B., 1971, PROGR SOLID STATE CH, V5, P145, DOI 10.1016/0079-6786(71)90018-5; GOODENOU.JB, 1973, PHYS REV B, V8, P1323, DOI 10.1103/PhysRevB.8.1323; Goodenough JB, 1961, B SOC CHIM FR, V4, P1200; GOODENOU.JB, 1971, J SOLID STATE CHEM, V3, P490, DOI 10.1016/0022-4596(71)90091-0; GOODENOUGH JB, 1991, PHYS REV B, V43, P10170, DOI 10.1103/PhysRevB.43.10170; GUPTA M, 1977, PHYS REV B, V16, P3338, DOI 10.1103/PhysRevB.16.3338; Gurvitch M., 2009, J APPL PHYS, V106; Hayamizu H, UNPUB; Herrero Fernandez M. P., 1984, Journal of the Less-Common Metals, V99; HIBBLE SJ, 1995, INORG CHEM, V34, P500, DOI 10.1021/ic00106a011; Hikihara T, 2004, PHYS REV B, V70, DOI 10.1103/PhysRevB.70.214404; HODEAU JL, 1978, J PHYS C SOLID STATE, V11, P4117, DOI 10.1088/0022-3719/11/20/009; Horlin T, 1976, J PHYS C SOLID STATE, V4, P69; Howard CJ, 2005, PHYS REV B, V72, DOI 10.1103/PhysRevB.72.214114; Isasi J, 1996, J ALLOY COMPD, V232, P36, DOI 10.1016/0925-8388(95)01968-5; Ismunandar BJ, 1998, MATER SCI FORUM, V278, P714; Isobe M, 2002, J PHYS SOC JPN, V71, P1848, DOI 10.1143/JPSJ.71.1848; JASPERTONNIES B, 1983, Z ANORG ALLG CHEM, V504, P113, DOI 10.1002/zaac.19835040914; JEROMINEK H, 1993, OPT ENG, V32, P2092, DOI 10.1117/12.143951; Kajita T, 2010, PHYS REV B, V81, DOI 10.1103/PhysRevB.81.060405; KAWAKUBO T, 1965, J PHYS SOC JPN, V20, P516, DOI 10.1143/JPSJ.20.516; Khalifah P, 2001, PHYS REV B, V64, DOI 10.1103/PhysRevB.64.085111; Khitrova V.I., 1967, Kristallografiya, V12; Kitamura M, 1998, MATER CHEM PHYS, V56, P1, DOI 10.1016/S0254-0584(98)00116-3; Konstantinovic MJ, 2004, PHYS REV B, V69, DOI 10.1103/PhysRevB.69.020409; KOSUGE K, 1967, J PHYS SOC JPN, V22, P551, DOI 10.1143/JPSJ.22.551; KUKLI K, 1995, THIN SOLID FILMS, V260, P135, DOI 10.1016/0040-6090(94)06388-5; LEDERER P, 1972, J PHYS CHEM SOLIDS, V33, P1969; MAREZIO M, 1972, PHYS REV LETT, V28, P1390, DOI 10.1103/PhysRevLett.28.1390; MAREZIO M, 1974, J SOLID STATE CHEM, V11, P301, DOI 10.1016/S0022-4596(74)80035-6; MARINDER BO, 1958, ACTA CHEM SCAND, V12, P1345, DOI 10.3891/acta.chem.scand.12-1345; MARINDER BO, 1957, ACTA CHEM SCAND, V11, P1635, DOI 10.3891/acta.chem.scand.11-1635; MCCARROLL WH, 1977, INORG CHEM, V16, P3351, DOI 10.1021/ic50178a075; Merlino S, 2004, CHEM MATER, V16, P3895, DOI 10.1021/cm049235q; Mott N.F., 1990, METAL INSULATOR TRAN; Muller U., 2007, INORGANIC STRUCTURAL; NEURGAONKAR RR, 1977, INORG CHEM, V16, P3349, DOI 10.1021/ic50178a073; Okamoto Y, 2008, PHYS REV LETT, V101, DOI 10.1103/PhysRevLett.101.086404; PARK M, 1975, J AM CERAM SOC, V58, P43, DOI 10.1111/j.1151-2916.1975.tb18980.x; Petersen A, 1992, ANORG Z ALLG CHEM, V609, P51; POUGET JP, 1972, J PHYS CHEM SOLIDS, V33, P1961; POURROY G, 1983, PHYSICA B & C, V123, P21, DOI 10.1016/0378-4363(83)90006-2; RUDORFF W, 1958, ANORG Z ALLG CHEM, V297, P1; Sakai E, 2011, PHYS REV B, V84, DOI 10.1103/PhysRevB.84.195132; SAKATA K, 1969, J PHYS SOC JPN, V26, P582, DOI 10.1143/JPSJ.26.582; SAKATA K, 1967, JPN J APPL PHYS, V6, P112, DOI 10.1143/JJAP.6.112; SAKATA T, 1967, PHYS STATUS SOLIDI, V20, pK155, DOI 10.1002/pssb.19670200263; SCHONBERG N, 1954, ACTA CHEM SCAND, V8, P240, DOI 10.3891/acta.chem.scand.08-0240; Senn MS, 2012, PHYS REV B, V85, DOI 10.1103/PhysRevB.85.125119; Shannon BRD, 1969, ACTA CRYSTALLOGR B, V825, P925; SHAPIRO SM, 1974, SOLID STATE COMMUN, V15, P377, DOI 10.1016/0038-1098(74)90780-7; Sleight AW, 2009, PROG SOLID STATE CH, V37, P251, DOI 10.1016/j.progsolidstchem.2010.08.001; SLEIGHT TP, 1968, MATER RES BULL, V3, P437, DOI 10.1016/0025-5408(68)90035-4; SOMMERS C, 1975, J PHYS LETT-PARIS, V36, pL157; SRIVASTA.R, 1971, PHYS REV LETT, V27, P727, DOI 10.1103/PhysRevLett.27.727; SUGIYAMA K, 1991, Z KRISTALLOGR, V194, P305, DOI 10.1524/zkri.1991.194.3-4.305; Toriyama T, 2013, PHYS REV B, V88, DOI 10.1103/PhysRevB.88.235116; Tsuda N, 1991, ELECT CONDUCTION OXI, P120; Tsunetsugu H, 2003, PHYS REV B, V68, DOI 10.1103/PhysRevB.68.060405; Vernon LW, 1951, TEX J SCI, V1, P81; VILLENEU.G, 1972, J PHYS CHEM SOLIDS, V33, P1953; VILLENEU.G, 1971, MATER RES BULL, V6, P119, DOI 10.1016/0025-5408(71)90096-1; Wells A. F., 1984, STRUCTURAL INORGANIC; Wyckoff R. W. G., 1965, CRYSTAL STRUCTURES	155	1	1	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0079-6786			PROG SOLID STATE CH	Prog. Solid State Chem.	MAY	2015	43	1-2					47	69		10.1016/j.progsolidstchem.2015.02.001		23	Chemistry, Inorganic & Nuclear	Chemistry	CH0VR	WOS:000353741000003		
J	Hamazaki, K; Kawaguchi, Y; Nakano, M; Yasuda, T; Seki, S; Hori, T; Hamazaki, T; Kimura, T				Hamazaki, Kei; Kawaguchi, Yoshiharu; Nakano, Masato; Yasuda, Taketoshi; Seki, Shoji; Hori, Takeshi; Hamazaki, Tomohito; Kimura, Tomoatsu			Mead acid (20:3n-9) and n-3 polyunsaturated fatty acids are not associated with risk of posterior longitudinal ligament ossification: Results of a case-control study	PROSTAGLANDINS LEUKOTRIENES AND ESSENTIAL FATTY ACIDS			English	Article						Ossification of the posterior longitudinal ligament; Case-control study; Mead acid; N-3 polyunsaturated fatty acids	5,8,11-EICOSATRIENOIC ACID; HETEROTOPIC OSSIFICATION; CARTILAGE; MEMBRANE; SPINE	Ossification of the posterior longitudinal ligament (OPLL) involves the replacement of ligamentous tissue with ectopic bone. Although genetics and heritability appear to be involved in the development of OPLL, its pathogenesis remains to be elucidated. Given previous findings that 5,8,11-eicosatrienoic acid [20:3n-9, Mead acid (MA)] has depressive effects on osteoblastic activity and anti-angiogenic effects, and that n-3 polyunsaturated fatty acids (PUFAs) have a preventive effect on heterotopic ossification, we hypothesized that both fatty acids would be involved in OPLL development. To examine the biological significance of these and other fatty acids in OPLL, we conducted this case-control study involving 106 patients with cervical OPLL and 109 age matched controls. Fatty acid composition was determined from plasma samples by gas chromatography. Associations between fatty acid levels and incident OPLL were evaluated by logistic regression. Contrary to our expectations, we found no significant differences between patients and controls in the levels of MA or n-3 PUFAs (e.g., eicosapentaenoic acid and docosahexaenoic acid). Logistic regression analysis did not reveal any associations with OPLL risk for MA or n-3 PUFAs. In conclusion, no potential role was found for MA or n-3 PUFAs in ectopic bone formation in the spinal canal. (C) 2015 Elsevier Ltd. All rights reserved.	[Hamazaki, Kei; Yasuda, Taketoshi] Toyama Univ, Fac Med, Dept Publ Hlth, Toyama, Toyama 9300194, Japan; [Kawaguchi, Yoshiharu; Nakano, Masato; Seki, Shoji; Hori, Takeshi; Kimura, Tomoatsu] Toyama Univ, Fac Med, Dept Orthopaed Surg, Toyama, Toyama 9300194, Japan; [Hamazaki, Tomohito] Toyama Jounan Daini Hosp, Toyama, Japan	Hamazaki, K (reprint author), Toyama Univ, Fac Med, Dept Publ Hlth, 2630 Sugitani, Toyama, Toyama 9300194, Japan.	keihama@med.u-toyama.ac.jp			Japanese Ministry of Education, Culture, Sports, Science and Technology [22591628]; Investigation Committee on the Ossification of the Spinal Ligaments of the Japanese Ministry of Health, Labour and Welfare	This work was partially supported by Grants-in-Aid for Scientific Research (#22591628, 2010-2012) from Japanese Ministry of Education, Culture, Sports, Science and Technology. Funds from the Investigation Committee on the Ossification of the Spinal Ligaments of the Japanese Ministry of Health, Labour and Welfare were also received, in part, to support this work. No relevant financial activities outside the submitted work. The funding source had no role in the study design; the collection, analysis, and interpretation of data; writing the report; or the decision to submit the paper for publication.	ADKISSON HD, 1991, FASEB J, V5, P344; Pan DA, 1995, J CLIN INVEST, V96, P2802, DOI 10.1172/JCI118350; [Anonymous], 1960, NIHON GEKA HOKAN, V29, P1003; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; CHYUN YS, 1984, PROSTAGLANDINS, V27, P97, DOI 10.1016/0090-6980(84)90223-5; Dilling CF, 2010, J BONE MINER RES, V25, P1147, DOI 10.1359/jbmr.091031; EPSTEIN NE, 1994, SPINE, V19, P664, DOI 10.1097/00007632-199403001-00005; Epstein NE, 1999, J SPINAL DISORD, V12, P250; Hamazaki T, 2009, LIPIDS, V44, P97, DOI 10.1007/s11745-008-3252-8; Hamazaki T, 2012, PROSTAG LEUKOTR ESS, V86, P221, DOI 10.1016/j.plefa.2012.04.004; ISHIDA Y, 1993, BONE, V14, P85, DOI 10.1016/8756-3282(93)90232-Y; Itomura M, 2008, IN VIVO, V22, P131; MEAD JF, 1956, J BIOL CHEM, V219, P705; ONJI Y, 1967, J BONE JOINT SURG AM, VA 49, P1314; Perona JS, 2013, J MEMBRANE BIOL, V246, P939, DOI 10.1007/s00232-013-9596-x; SAKOU T, 1991, SPINE, V16, P1249, DOI 10.1097/00007632-199111000-00001; Stetler WR, 2011, NEUROSURG FOCUS, V30, DOI 10.3171/2010.12.FOCUS10275; Wang L, 2013, MED HYPOTHESES, V80, P57, DOI 10.1016/j.mehy.2012.10.012	18	0	0	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0952-3278	1532-2823		PROSTAG LEUKOTR ESS	Prostaglandins Leukot. Essent. Fatty Acids	MAY	2015	96						31	36		10.1016/j.plefa.2015.01.003		6	Biochemistry & Molecular Biology; Cell Biology; Endocrinology & Metabolism	Biochemistry & Molecular Biology; Cell Biology; Endocrinology & Metabolism	CH0RV	WOS:000353731000005		
J	Tho, NV; Ryujin, Y; Ogawa, E; Trang, LTH; Kanda, R; Goto, K; Yamaguchi, M; Nagao, T; Lan, LTT; Nakano, Y				Nguyen Van Tho; Ryujin, Yasushi; Ogawa, Emiko; Le Thi Huyen Trang; Kanda, Rie; Goto, Kenichi; Yamaguchi, Masafumi; Nagao, Taishi; Le Thi Tuyet Lan; Nakano, Yasutaka			Relative contributions of emphysema and airway remodelling to airflow limitation in COPD: Consistent results from two cohorts	RESPIROLOGY			English	Article						airway remodelling; chronic obstructive pulmonary disease; computed tomography; emphysema; quantitative imaging	OBSTRUCTIVE PULMONARY-DISEASE; QUANTITATIVE COMPUTED-TOMOGRAPHY; CT-QUANTIFIED EMPHYSEMA; WALL THICKNESS; LUNG-FUNCTION; MICROSCOPIC MORPHOMETRY; REFERENCE VALUES; DENSITY; DIMENSIONS; SMOKERS	Background and objectiveThe relative contributions of emphysema and airway remodelling to airflow limitation remain unclear in chronic obstructive pulmonary disease (COPD). We aimed to evaluate the relative contributions of emphysema and airway wall thickness measured by quantitative computed tomography (CT) to the prediction of airflow limitation in two separate COPD cohorts. MethodsPulmonary function tests and whole-lung CT were performed in 250 male smokers with COPD, including 167 from University Medical Center at Ho Chi Minh City, Vietnam, and 83 from Shiga University of Medical Science Hospital, Japan. The same CT analysis software was used to measure the percentage of low attenuation volume (%LAV) at the threshold of -950 Hounsfield units and the square root of wall area of a hypothetical airway with an internal perimeter of 10mm (Pi10). The standardized coefficients in multiple linear regressions were used to evaluate the relative contributions of %LAV and Pi10 to predictions of FEV1/FVC and FEV1% predicted. ResultsBoth %LAV and Pi10 independently predicted either forced expiratory volume in 1s/forced vital capacity (FEV1/FVC) or FEV1% predicted (P0.001 for all standardized coefficients). However, the absolute values of the standardized coefficients were 2-3 times higher for %LAV than for Pi10 in all prediction models. The results were consistent in the two COPD cohorts. Conclusions%LAV predicts both FEV1/FVC and FEV1 better than Pi10 in patients with COPD. Thus, emphysema may make a greater contribution to airflow limitation than airway remodelling in COPD.	[Nguyen Van Tho; Ryujin, Yasushi; Ogawa, Emiko; Kanda, Rie; Goto, Kenichi; Yamaguchi, Masafumi; Nagao, Taishi; Nakano, Yasutaka] Shiga Univ Med Sci, Dept Med, Div Resp Med, Otsu, Shiga 5202192, Japan; [Ogawa, Emiko] Shiga Univ Med Sci, Hlth Adm Ctr, Otsu, Shiga 5202192, Japan; [Nguyen Van Tho; Le Thi Huyen Trang; Le Thi Tuyet Lan] Univ Med Ctr, Resp Care Ctr, Ho Chi Minh City, Vietnam	Nakano, Y (reprint author), Shiga Univ Med Sci, Dept Med, Div Resp Med, Seta Tsukinowa Cho, Otsu, Shiga 5202192, Japan.	nakano@belle.shiga-med.ac.jp		Tho, Nguyen Van/0000-0003-4004-9872	JSPS KAKENHI [18590847]	The study was partially funded by JSPS KAKENHI Grant No. 18590847. The authors would like to thank the staff of the Respiratory Care Center, University Medical Center at Ho Chi Minh City, Vietnam, for recruiting the patients. The authors also want to thank Prof. Peter D. Pare, MD, James Hogg Research Center, University of British Columbia, Vancouver, Canada, for helpful comments on the manuscript.	Coxson HO, 2009, AM J RESP CRIT CARE, V180, P588, DOI 10.1164/rccm.200901-0159PP; Coxson HO, 2005, ACAD RADIOL, V12, P1457, DOI 10.1016/j.acra.2005.08.013; Hankinson JL, 2010, CHEST, V137, P138, DOI 10.1378/chest.09-0919; Kim WJ, 2009, CHEST, V136, P396, DOI 10.1378/chest.08-2858; Hoesein FAAM, 2011, THORAX, V66, P782, DOI 10.1136/thx.2010.145995; Johannessen A, 2013, AM J RESP CRIT CARE, V187, P602, DOI 10.1164/rccm.201209-1722OC; Barnes PJ, 2003, EUR RESPIR J, V22, P672, DOI 10.1183/09031936.03.00040703; Nakano Y, 2000, AM J RESP CRIT CARE, V162, P1102; Hogg JC, 2004, LANCET, V364, P709, DOI 10.1016/S0140-6736(04)16900-6; Grydeland TB, 2009, EUR RESPIR J, V34, P858, DOI 10.1183/09031936.00167908; Madani A, 2006, RADIOLOGY, V238, P1036, DOI 10.1148/radiol.2382042196; HOGG JC, 1968, NEW ENGL J MED, V278, P1355, DOI 10.1056/NEJM196806202782501; Hankinson JL, 1999, AM J RESP CRIT CARE, V159, P179; Nakano Y, 2005, AM J RESP CRIT CARE, V171, P142, DOI 10.1164/rccm.200407-874OC; MULLER NL, 1988, CHEST, V94, P782, DOI 10.1378/chest.94.4.782; Tschirren J, 2005, IEEE T MED IMAGING, V24, P1529, DOI 10.1109/TMI.2005.857654; McDonough JE, 2011, NEW ENGL J MED, V365, P1567, DOI 10.1056/NEJMoa1106955; Patel BD, 2008, AM J RESP CRIT CARE, V178, P500, DOI 10.1164/rccm.200801-059OC; Gevenois PA, 1996, AM J RESP CRIT CARE, V154, P187; Hu SY, 2001, IEEE T MED IMAGING, V20, P490, DOI 10.1109/42.929615; GEVENOIS PA, 1995, AM J RESP CRIT CARE, V152, P653; Tschirren J, 2005, IEEE T MED IMAGING, V24, P1540, DOI 10.1109/TMI.2005.857653; Nishimura M, 2012, AM J RESP CRIT CARE, V185, P44, DOI 10.1164/rccm.201106-0992OC; Miller MR, 2005, EUR RESPIR J, V26, P319, DOI 10.1183/09031936.05.00034805; MacIntyre N, 2005, EUR RESPIR J, V26, P720, DOI 10.1183/09031936.05.00034905; Burney P, 2014, LANCET RESP MED, V2, P174, DOI 10.1016/S2213-2600(14)70040-2; Camiciottoli G, 2006, CHEST, V129, P558, DOI 10.1378/chest.129.3.558; Cerveri I, 2004, CHEST, V125, P1714, DOI 10.1378/chest.125.5.1714; Coxson Harvey O, 2008, Proc Am Thorac Soc, V5, P940, DOI 10.1513/pats.200806-057QC; Global Initiative for Chronic Obstructive Lung Disease (GOLD), 2014, GLOB STRAT DIAGN MAN; Haruna A, 2010, CHEST, V138, P635, DOI 10.1378/chest.09-2836; Hogg JC, 2004, NEW ENGL J MED, V350, P2645, DOI 10.1056/NEJMoa032158; Japanese Respiratory Society, 2001, J JAPANESE RESP SOC, V39; Kim EY, 2015, EUR RADIOL, V25, P541, DOI 10.1007/s00330-014-3418-0; Martinez CH, 2012, THORAX, V67, P399, DOI 10.1136/thoraxjnl-2011-201185; Hoesein FAAM, 2014, COPD, V11, P503, DOI 10.3109/15412555.2014.933952; Newell J D Jr, 2004, Eur Respir J, V23, P769, DOI 10.1183/09031936.04.00026504; Peat J, 2005, MED STAT GUIDE DATA, P156; Smith BM, 2014, THORAX, V69, P987, DOI 10.1136/thoraxjnl-2014-205160; Tabachnick BG, 2006, USING MULTIVARIATE S, P117; Tho NV, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0098335; Tho NV, 2013, RESPIROLOGY, V18, pOS119; Van Tho Nguyen, 2012, Respir Investig, V50, P78, DOI 10.1016/j.resinv.2012.08.002	43	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1323-7799	1440-1843		RESPIROLOGY	Respirology	MAY	2015	20	4					594	601		10.1111/resp.12505		8	Respiratory System	Respiratory System	CH2XW	WOS:000353889700012		
J	Ijiri, N; Kanazawa, H; Asai, K; Watanabe, T; Hirata, K				Ijiri, Naoki; Kanazawa, Hiroshi; Asai, Kazuhisa; Watanabe, Tetsuya; Hirata, Kazuto			Irisin, a newly discovered myokine, is a novel biomarker associated with physical activity in patients with chronic obstructive pulmonary disease	RESPIROLOGY			English	Article						6-min walk distance; exercise; fibronectin type III domain-containing protein 5; irisin; physical activity	POPULATION-BASED COHORT; ALL-CAUSE MORTALITY; DAILY-LIFE; BROWN-FAT; COPD; EXERCISE; RISK; PLASMA; SERUM; WHITE	Background and objectiveIrisin is a recently identified hormone secreted by skeletal myocytes, which has been proposed to mediate the beneficial effects of exercise. Physical activity has been emphasized as one of the principal targets of the treatment for chronic obstructive pulmonary disease (COPD). This study was designed to evaluate the possibility of using serum irisin level as a novel biomarker associated with physical activity in patients with COPD. MethodsWe measured the serum irisin level in 72 COPD patients and 27 control subjects, and investigated its correlation to pulmonary function parameters, exercise capacity and physical activity level. In addition, we analysed the effects of acute and chronic exercise on serum irisin level. ResultsFat-free mass index was not significantly different between the two study groups. However, lower serum irisin level was observed in COPD patients than in the control subjects (COPD patients: median (interquartile range) 31.6 (22.7-40.4) ng/mL; control subjects: 50.7 (39.3-65.8) ng/mL; P<0.001). The serum irisin level did not significantly correlate with any pulmonary function parameters and 6-min walk distance. However, serum irisin level was associated with the physical activity level in all subjects. In COPD patients, acute exercise did not affect serum irisin level, but an 8-week exercise training was linked to the significant increase in its level. ConclusionsCirculating irisin could be used to evaluate physical activity in COPD patients and increased after an 8-week exercise training. Serum irisin level may prove to be a valuable biomarker in clinical follow up of COPD. Serum levels of irisin increased in COPD patients following an 8-week training programme. Serum irisin level could be used as a novel biomarker associated with physical activity in patients with COPD and may prove to be a valuable tool in clinical follow up of COPD.	[Ijiri, Naoki; Kanazawa, Hiroshi; Asai, Kazuhisa; Watanabe, Tetsuya; Hirata, Kazuto] Osaka City Univ, Grad Sch Med, Dept Resp Med, Osaka 5458585, Japan	Kanazawa, H (reprint author), Osaka City Univ, Grad Sch Med, Dept Resp Med, Abeno Ku, 1-4-3 Asahi Machi, Osaka 5458585, Japan.	kanazawa-h@med.osaka-cu.ac.jp					American Thoracic Society, 1995, AM J RESP CRIT CARE, V152, P1107; Pitta F, 2005, AM J RESP CRIT CARE, V171, P972, DOI 10.1164/rccm.200407-855OC; Kelly DP, 2012, SCIENCE, V336, P42, DOI 10.1126/science.1221688; Shrikrishna D, 2012, EUR RESPIR J, V40, P1115, DOI 10.1183/09031936.00170111; Garcia-Aymerich J, 2007, AM J RESP CRIT CARE, V175, P458, DOI 10.1164/rccm.200607-896OC; Emanuele E, 2014, AM J MED, V127, P888, DOI 10.1016/j.amjmed.2014.04.025; Otsuka T, 1997, CLIN PHYSIOL, V17, P287, DOI 10.1111/j.1365-2281.1997.tb00008.x; Pitta F, 2006, EUR RESPIR J, V27, P1040, DOI 10.1183/09031936.06.00064105; Polyzos SA, 2013, METABOLISM, V62, P1037, DOI 10.1016/j.metabol.2013.04.008; Garcia-Aymerich J, 2003, THORAX, V58, P100, DOI 10.1136/thorax.58.2.100; Seymour JM, 2010, EUR RESPIR J, V36, P81, DOI 10.1183/09031936.00104909; Watz H, 2009, EUR RESPIR J, V33, P262, DOI 10.1183/09031936.00024608; Leenders NYJM, 2001, MED SCI SPORT EXER, V33, P1233; Huh JY, 2012, METABOLISM, V61, P1725, DOI 10.1016/j.metabol.2012.09.002; Waschki B, 2011, CHEST, V140, P331, DOI 10.1378/chest.10-2521; Zhang HJ, 2013, J HEPATOL, V59, P557, DOI 10.1016/j.jhep.2013.04.030; Garcia-Aymerich J, 2006, THORAX, V61, P772, DOI 10.1136/thx.2006.060145; Barnes PJ, 2009, EUR RESPIR J, V33, P1165, DOI 10.1183/09031936.00128008; Schnohr P, 2003, AM J EPIDEMIOL, V158, P639, DOI 10.1093/aje/kwg207; Nimmo MA, 2013, DIABETES OBES METAB, V15, P51, DOI 10.1111/dom.12156; Bostrom P, 2012, NATURE, V481, P463, DOI 10.1038/nature10777; Vestbo J, 2013, AM J RESP CRIT CARE, V187, P347, DOI 10.1164/rccm.201204-0596PP; Moraes C, 2013, HORM METAB RES, V45, P900, DOI 10.1055/s-0033-1354402; Ward DS, 2005, MED SCI SPORT EXER, V37, pS582, DOI 10.1249/01.mss.0000185292.71933.91; Castillo-Quan JI, 2012, DIS MODEL MECH, V5, P293, DOI 10.1242/dmm.009894; Greulich T, 2014, BMC PULM MED, V14, DOI 10.1186/1471-2466-14-60; Kawagoshi A, 2013, INT J CHRONIC OBSTR, V8, P397, DOI 10.2147/COPD.S49491; Moreno-Navarrete MJ, 2013, J CLIN ENDOCR METAB, V98, pE769; Nguyen Huong Q, 2006, Int J Chron Obstruct Pulmon Dis, V1, P455, DOI 10.2147/copd.2006.1.4.455; Ries AL, 2007, CHEST, V131, P4, DOI DOI 10.1378/CHEST.06-2418; Robert O, 2002, AM J RESP CRIT CARE, V166, P111; Swick AG, 2013, METABOLISM, V62, P70; Timmons JA, 2012, NATURE, V488, pE9, DOI 10.1038/nature11364; Vaes AW, 2014, EUR RESPIR J, V44, P1199, DOI 10.1183/09031936.00023214; Wen MS, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064025	35	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1323-7799	1440-1843		RESPIROLOGY	Respirology	MAY	2015	20	4					612	617		10.1111/resp.12513		6	Respiratory System	Respiratory System	CH2XW	WOS:000353889700014		
J	Nakayama, M; Bando, M; Araki, K; Sekine, T; Kurosaki, F; Sawata, T; Nakazawa, S; Mato, N; Yamasawa, H; Sugiyama, Y				Nakayama, Masayuki; Bando, Masashi; Araki, Koji; Sekine, Toshie; Kurosaki, Fumio; Sawata, Tetsuro; Nakazawa, Shoko; Mato, Naoko; Yamasawa, Hideaki; Sugiyama, Yukihiko			Physical activity in patients with idiopathic pulmonary fibrosis	RESPIROLOGY			English	Article						accelerometer; idiopathic pulmonary fibrosis; Krebs von den Lungen-6; physical activity; 6-min walk test	PROGNOSTIC VALUE; DAILY-LIFE; COPD; STANDARDIZATION; GUIDELINES; STATEMENT; DIAGNOSIS; LUNG; KL-6	Background and objectivePhysical activity is an important parameter in patients with chronic obstructive pulmonary disease, but has not been studied in detail in patients with interstitial lung disease. This study aimed to evaluate physical activity in patients with idiopathic pulmonary fibrosis (IPF). MethodsPhysical activity was monitored in 31 stable IPF patients using an accelerometer for 1 month. The following factors reflecting physical activity were measured: the number of steps, walking distance, the time spent at magnitude of movement (MM) 1-6, physical activity-related energy expenditure (PAEE) and total energy expenditure. We also measured the following clinical parameters: the modified Medical Research Council (MRC) scale, Krebs von den Lungen-6 (KL-6), pulmonary function parameters, 6-min walk test (6MWT) results and high-resolution computed tomography (HRCT) findings of the chest. We determined the relationship between these parameters and physical activity. ResultsWe recorded 24 days of physical activity data. The time spent at MM<1 was more than 10h per day, whereas that at MM>1 was approximately 1h per day. The modified MRC scale, serum KL-6 levels, 6MWT distance, and the extent of honeycomb and reticular abnormality on HRCT were associated with several facets of physical activity. In particular, lower KL-6 levels were correlated with higher physical activity based on the number of steps, walking distance, the time spent at MM 1-4 and PAEE. ConclusionsThe modified MRC scale, 6MWT distance, extent of fibrosis on HRCT and serum KL-6 levels are strongly associated with physical activity. We evaluated physical activity in patients with IPF. The modified MRC scale, 6MWT distance, extent of honeycomb and reticular abnormality on HRCT scans of the chest, and serum KL-6 levels were strongly correlated with physical activity. Physical activity may be an important indicator in multifaceted evaluation of patients with IPF.	[Nakayama, Masayuki; Bando, Masashi; Kurosaki, Fumio; Sawata, Tetsuro; Nakazawa, Shoko; Mato, Naoko; Yamasawa, Hideaki; Sugiyama, Yukihiko] Jichi Med Univ, Dept Med, Div Pulm Med, Shimotsuke, Tochigi 3290498, Japan; [Araki, Koji; Sekine, Toshie] Jichi Med Univ, Dept Rehabil, Shimotsuke, Tochigi 3290498, Japan	Nakayama, M (reprint author), Jichi Med Univ, Dept Med, Div Pulm Med, 3311-1 Yakushiji, Shimotsuke, Tochigi 3290498, Japan.	mnakayama723@jichi.ac.jp					Crapo RO, 2002, AM J RESP CRIT CARE, V166, P111, DOI 10.1164/rccm.166/1/111; Kumahara H, 2004, BRIT J NUTR, V91, P235, DOI 10.1079/BJN20031033; Rabinovich RA, 2013, EUR RESPIR J, V42, P1205, DOI 10.1183/09031936.00134312; Caminati A, 2009, RESP MED, V103, P117, DOI 10.1016/j.rmed.2008.07.022; Watz H, 2009, EUR RESPIR J, V33, P262, DOI 10.1183/09031936.00024608; Sewell L, 2010, J CARDIOPULM REHABIL, V30, P329, DOI 10.1097/HCR.0b013e3181e175f2; Waschki B, 2011, CHEST, V140, P331, DOI 10.1378/chest.10-2521; Wanger J, 2005, EUR RESPIR J, V26, P511, DOI 10.1183/09031936.05.00035005; Wallaert B, 2013, CHEST, V144, P1652, DOI 10.1378/chest.13-0806; Lynch DA, 2005, AM J RESP CRIT CARE, V172, P488, DOI 10.1164/rccm.200412-1756OC; Garcia-Rio F, 2012, CHEST, V142, P338, DOI 10.1378/chest.11-2014; Yokoyama A, 2006, RESPIROLOGY, V11, P164, DOI 10.1111/j.1440-1843.2006.00834.x; Miller MR, 2005, EUR RESPIR J, V26, P319, DOI 10.1183/09031936.05.00034805; KOHNO N, 1989, CHEST, V96, P68, DOI 10.1378/chest.96.1.68; MacIntyre N, 2005, EUR RESPIR J, V26, P720, DOI 10.1183/09031936.05.00034905; Raghu G, 2011, AM J RESP CRIT CARE, V183, P788, DOI 10.1164/rccm.2009-040GL; Van Remoortel H, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039198; Sugino A, 2012, RESPIRATION, V83, P300, DOI 10.1159/000330046; Van Remoortel H, 2014, AM J RESP CRIT CARE, V189, P30, DOI 10.1164/rccm.201307-1240OC; Yokoyama A, 1998, Respirology, V3, P199, DOI 10.1111/j.1440-1843.1998.tb00121.x	20	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1323-7799	1440-1843		RESPIROLOGY	Respirology	MAY	2015	20	4					640	646		10.1111/resp.12500		7	Respiratory System	Respiratory System	CH2XW	WOS:000353889700018		
J	Shiroishi, R; Kitagawa, C; Miyamoto, N; Kakuno, N; Koyanagi, H; Rikitomi, N; Senjyu, H				Shiroishi, Ryota; Kitagawa, Chika; Miyamoto, Naomi; Kakuno, Nao; Koyanagi, Harumi; Rikitomi, Naoto; Senjyu, Hideaki			Heart rate recovery after the 6-min walk test is related to 6-min walk distance and percutaneous oxygen saturation recovery in patients with COPD	RESPIROLOGY			English	Article						6-min walk test; chronic obstructive pulmonary disease; dyspnoea; heart rate recovery; percutaneous oxygen saturation recovery	OBSTRUCTIVE PULMONARY-DISEASE; EXERCISE; MORTALITY	Heart rate recovery (HRR) after maximal load exercise affects mortality in chronic obstructive pulmonary disease (COPD). However, the associations of clinical characteristics with HRR after the 6-min walk test (6MWT), which is defined as a submaximal load test, remain unclear. We showed that HRR in patients with COPD after 6MWT was related to 6-min walk distance and percutaneous oxygen saturation recovery. HRR after the 6MWT may be useful to assess exercise capacity in COPD.	[Shiroishi, Ryota; Kitagawa, Chika; Kakuno, Nao; Koyanagi, Harumi] Nagasaki Pulm Rehabil Clin, Dept Rehabil Med, Nagasaki, Japan; [Miyamoto, Naomi] Kio Univ, Div Hlth Sci, Nara, Japan; [Rikitomi, Naoto] Nagasaki Pulm Rehabil Clin, Dept Internal Med, Nagasaki, Japan; [Senjyu, Hideaki] Nagasaki Univ, Grad Sch Biomed Sci, Dept Cardiopulm Rehabil Sci, Nagasaki 852, Japan	Shiroishi, R (reprint author), Nagasaki Pulm Rehabil Clin, Dept Rehabil, 1694 Kaizu, Isahaya 8540063, Japan.	ryoryo1765@gmail.com					Gupta M, 2013, CHRON RESP DIS, V10, P117, DOI 10.1177/1479972313493097; Lacasse M, 2005, RESP MED, V99, P877, DOI 10.1016/j.rmed.2004.11.012; IMAI K, 1994, J AM COLL CARDIOL, V24, P1529; STEWART AG, 1994, EUR RESPIR J, V7, P1090; Cole CR, 1999, NEW ENGL J MED, V341, P1351, DOI 10.1056/NEJM199910283411804; Seshadri N, 2004, CHEST, V125, P1286, DOI 10.1378/chest.125.4.1286	6	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1323-7799	1440-1843		RESPIROLOGY	Respirology	MAY	2015	20	4					671	673		10.1111/resp.12510		3	Respiratory System	Respiratory System	CH2XW	WOS:000353889700023		
J	Takahashi, K; Porcel, JM; Lee, P; Leung, CC				Takahashi, Kazuhisa; Porcel, Jose M.; Lee, Pyng; Leung, Chi Chiu			Year in review 2014: Lung cancer, pleural diseases, respiratory infections and tuberculosis, bronchoscopic intervention and imaging	RESPIROLOGY			English	Review						intervention pulmonology; lung cancer; pleural disease; respiratory infection; tuberculosis	COMMUNITY-ACQUIRED PNEUMONIA; AUREUS BIO-PRODUCTS; TRANSBRONCHIAL CRYOBIOPSY; STREPTOCOCCUS-PNEUMONIAE; HISTOLOGICAL TYPE; TRACT INFECTIONS; METAANALYSIS; DIAGNOSIS; EFFUSION; PERFORMANCE		[Takahashi, Kazuhisa] Juntendo Univ, Grad Sch Med, Dept Resp Med, Tokyo, Japan; [Porcel, Jose M.] Arnau de Vilanova Univ Hosp, Biomed Res Inst Lleida, Dept Internal Med, Pleural Med Unit, Lleida, Spain; [Lee, Pyng] Natl Univ Singapore Hosp, Dept Med, Singapore 117548, Singapore; [Leung, Chi Chiu] Dept Hlth, TB & Chest Serv, Hong Kong, Hong Kong, Peoples R China	Leung, CC (reprint author), Wanchai Chest Clin, 99 Kennedy Rd, Wanchai, Hong Kong, Peoples R China.	cc_leung@dh.gov.hk					Alcada J, 2014, RESPIROLOGY, V19, P339, DOI 10.1111/resp.12241; Babiak A, 2009, RESPIRATION, V78, P203, DOI 10.1159/000203987; Thomas R, 2014, RESPIROLOGY, V19, P809, DOI 10.1111/resp.12328; Memoli JSW, 2012, CHEST, V142, P385, DOI 10.1378/chest.11-1764; Poletti V, 2014, RESPIROLOGY, V19, P645, DOI 10.1111/resp.12309; Nie WC, 2014, CLIN RESPIR J, V8, P281, DOI 10.1111/crj.12068; Shorr AF, 2012, CLIN INFECT DIS, V54, P193, DOI 10.1093/cid/cir813; Pajares V, 2010, ARCH BRONCONEUMOL, V46, P111, DOI 10.1016/j.arbres.2009.09.012; Zalacain R, 2014, RESPIROLOGY, V19, P936, DOI 10.1111/resp.12341; See KC, 2014, RESPIROLOGY, V19, P396, DOI 10.1111/resp.12244; Fruchter O, 2013, RESPIROLOGY, V18, P669, DOI 10.1111/resp.12037; Rahman NM, 2011, NEW ENGL J MED, V365, P518, DOI 10.1056/NEJMoa1012740; Aldington S, 2007, THORAX, V62, P1058, DOI 10.1136/thx.2006.077081; Yarmus L, 2013, CHEST, V143, P621, DOI 10.1378/chest.12-2290; Yang B, 2014, RESPIROLOGY, V19, P834, DOI 10.1111/resp.12335; Huang ZK, 2014, RESPIROLOGY, V19, P132, DOI 10.1111/resp.12192; Gompelmann D, 2014, RESPIROLOGY, V19, P524, DOI 10.1111/resp.12253; Crisafulli E, 2013, CHEST, V143, P1009, DOI 10.1378/chest.12-1684; Fruchter O, 2013, LUNG, V191, P619, DOI 10.1007/s00408-013-9507-z; Maskell NA, 2005, NEW ENGL J MED, V352, P865, DOI 10.1056/NEJMoa042473; Schuhmann M, 2014, EUR RESPIR J, V43, P233, DOI 10.1183/09031936.00011313; Sinclair A, 2013, J CLIN MICROBIOL, V51, P2303, DOI 10.1128/JCM.00137-13; Araz O, 2014, RESPIROLOGY, V19, P1034, DOI 10.1111/resp.12345; Ault MJ, 2015, THORAX, V70, P127, DOI 10.1136/thoraxjnl-2014-206114; Breen DP, 2014, RESPIROLOGY, V19, P970, DOI 10.1111/resp.12339; Brenn DP, 2014, RESPIROLOGY, V19, P970; Cameron R, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002312.pub3; Casoni GL, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0086716; Cha N, 2014, RESPIROLOGY, V19, P544, DOI 10.1111/resp.12272; Colicc GL, 2000, CHEST, V118, P1158, DOI 10.1378/chest.118.4.1158; Czarnecka-Kujawa K, 2014, RESPIROLOGY, V19, P1117, DOI 10.1111/resp.12377; Davies CWH, 2003, THORAX S2, V58, pii18; Eom JS, 2014, RESPIROLOGY, V19, P914, DOI 10.1111/resp.12336; Everatt R, 2011, MED LITH, V47, P222; Ferrer M, 2014, RESPIROLOGY, V19, P929, DOI 10.1111/resp.12324; Fielding DI, 2014, RESPIROLOGY, V19, P472, DOI 10.1111/resp.12279; Gates P, 2014, RESPIROLOGY, V19, P655, DOI 10.1111/resp.12298; Gidaris D, 2014, RESPIROLOGY, V19, P1158, DOI 10.1111/resp.12371; Gilbert C, 2014, RESPIROLOGY, V19, P636, DOI 10.1111/resp.12301; Gould MK, 2007, CHEST, V132, p108S, DOI 10.1378/chest.07-1353; Ho HT, 2014, RESPIROLOGY, V19, P109, DOI 10.1111/resp.12191; Jeyabalan A, 2014, RESPIROLOGY, V19, P735, DOI 10.1111/resp.12293; Kang JY, 2015, RESPIROLOGY, V20, P138, DOI 10.1111/resp.12413; Kong JY, 2014, RESPIROLOGY, V19, P1222, DOI 10.1111/resp.12373; Kropski JA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078674; Lam DCL, 2014, RESPIROLOGY, V19, P945, DOI 10.1111/resp.12374; Lansley SM, 2014, RESPIROLOGY, V19, P1025, DOI 10.1111/resp.12351; Lee JK, 2014, RESPIROLOGY, V19, P1066, DOI 10.1111/resp.12344; Light RW., 2013, PLEURAL DIS, V6th; Ma HM, 2014, RESPIROLOGY, V19, P549, DOI 10.1111/resp.12267; Mackintosh JA, 2014, RESPIROLOGY, V19, P755, DOI 10.1111/resp.12311; Maldonado F, 2014, RESPIROLOGY, V19, P471, DOI 10.1111/resp.12289; Mazzone P, 2015, CHEST, V147, P295, DOI 10.1378/chest.14-2500; Miyashita N, 2014, RESPIROLOGY, V19, P144, DOI 10.1111/resp.12218; Moodley Y, 2014, RESPIROLOGY, V19, P5, DOI 10.1111/resp.12222; Nagaoka K, 2014, RESPIROLOGY, V19, P556, DOI 10.1111/resp.12288; Aberle DR, 2011, NEW ENGL J MED, V365, P395, DOI 10.1056/NEJMoa1102873; Psallidas I, 2014, RESPIROLOGY, V19, P948, DOI 10.1111/resp.12354; Qvale TH, 2014, RESPIROLOGY, V19, P730, DOI 10.1111/resp.12292; Roman MA, 2014, RESPIROLOGY, V19, P105, DOI 10.1111/resp.12162; Saettele TM, 2014, RESPIROLOGY, V19, P800, DOI 10.1111/resp.12310; Sanz F, 2014, RESPIROLOGY, V19, P1073, DOI 10.1111/resp.12346; Schuetz Philipp, 2013, Evid Based Child Health, V8, P1297, DOI 10.1002/ebch.1927; Sellares J, 2013, AM J RESP CRIT CARE, V187, P1241, DOI 10.1164/rccm.201209-1732OC; Shin KE, 2014, RESPIROLOGY, V19, P921, DOI 10.1111/resp.12337; Snell GI, 2014, RESPIROLOGY, V19, P465, DOI 10.1111/resp.12282; Sorokina A, 2014, RESPIROLOGY, V19, P921; Tashkin DP, 2014, RESPIROLOGY, V19, P619, DOI 10.1111/resp.12308; Tokman S, 2014, RESPIROLOGY, V19, P382, DOI 10.1111/resp.12237; Ulasli SS, 2014, RESPIROLOGY, V19, P288, DOI 10.1111/resp.12232; Valdes L, 2014, RESPIROLOGY, V19, P985, DOI 10.1111/resp.12357; vansMens SP, 2015, EUR J CLIN MICROBIOL, V34, P115; WAITE RJ, 1990, RADIOLOGY, V175, P145; Wang K, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009175.pub2; Wu ZG, 2014, RESPIROLOGY, V19, P218, DOI 10.1111/resp.12205; YANG PC, 1992, AM J ROENTGENOL, V159, P29; Ye W, 2014, RESPIROLOGY, V19, P501, DOI 10.1111/resp.12270; Zielinska-Krawczyk M, 2015, RESPIROLOGY, V20, P166, DOI 10.1111/resp.12426; Zoumot Z, 2014, RESPIROLOGY, V19, P714, DOI 10.1111/resp.12287	79	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1323-7799	1440-1843		RESPIROLOGY	Respirology	MAY	2015	20	4					674	683		10.1111/resp.12502		10	Respiratory System	Respiratory System	CH2XW	WOS:000353889700024		
J	Hirota, K; Itoh, Y; Rii, T; Inoue, M; Hirakata, A				Hirota, Kazunari; Itoh, Yuji; Rii, Tosho; Inoue, Makoto; Hirakata, Akito			CORRELATION BETWEEN FOVEAL INTERDIGITATION ZONE BAND DEFECT AND VISUAL ACUITY AFTER SURGERY FOR MACULAR PSEUDOHOLE	RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES			English	Article						ellipsoid zone; epiretinal membrane; interdigitation zone; macular pseudohole; pars plana vitrectomy; spectral domain optical coherence tomography	OPTICAL COHERENCE TOMOGRAPHY; EPIRETINAL MEMBRANE SURGERY; OUTER SEGMENT TIPS; RETINAL THICKNESS MEASUREMENTS; HOLE SURGERY; RECOVERY; LINE; REPRODUCIBILITY; MICROSTRUCTURE; ABNORMALITY	Purpose: To determine the correlation between the integrity of the foveal microstructures and the best-corrected visual acuity (BCVA) after pars plana vitrectomy for a macular pseudohole. Methods: Thirty-one eyes of 31 patients with a macular pseudohole underwent vitrectomy with internal limiting membrane removal. The foveal area was examined by spectral domain optical coherence tomography preoperatively and postoperatively. The correlations between the BCVA and the lengths of the photoreceptor interdigitation zone (IZ), the ellipsoid zone, and the external limiting membrane band defects, and central foveal thickness were determined. Results: The BCVA improved significantly and the length of the IZ band defect decreased significantly after the surgery. Simple linear regression analyses showed that the BCVA was significantly correlated with the length of the IZ band defect preoperatively and also at 1 to 12 months postoperatively (P < 0.001 for all). The BCVA was not significantly correlated with the length of the ellipsoid zone, external limiting membrane band defect, and the central foveal thickness. Conclusion: The significant correlation between the length of the foveal IZ band defect and the BCVA preoperatively and postoperatively indicates that the foveal IZ band is related to the visual recovery in patients with macular pseudohole.	[Hirota, Kazunari; Itoh, Yuji; Rii, Tosho; Inoue, Makoto; Hirakata, Akito] Kyorin Univ, Sch Med, Kyorin Eye Ctr, Mitaka, Tokyo 1818611, Japan; [Rii, Tosho] Shin Kong Wu Ho Su Mem Hosp, Dept Ophthalmol, Taipei, Taiwan	Inoue, M (reprint author), Kyorin Univ, Sch Med, Kyorin Eye Ctr, 6-20-2 Shinkawa, Mitaka, Tokyo 1818611, Japan.	inoue@eye-center.org					Itoh Y, 2012, AM J OPHTHALMOL, V153, P111, DOI 10.1016/j.ajo.2011.05.039; Mitamura Y, 2009, BRIT J OPHTHALMOL, V93, P171, DOI 10.1136/bjo.2008.146381; Itoh Y, 2013, INVEST OPHTH VIS SCI, V54, P7302, DOI 10.1167/iovs.13-12702; Spaide RF, 2011, RETINA-J RET VIT DIS, V31, P1609, DOI 10.1097/IAE.0b013e3182247535; Giani A, 2010, AM J OPHTHALMOL, V150, P815, DOI 10.1016/j.ajo.2010.06.025; Lai WW, 2010, BRIT J OPHTHALMOL, V94, P311, DOI 10.1136/bjo.2009.163584; Ooto S, 2011, OPHTHALMOLOGY, V118, P873, DOI 10.1016/j.ophtha.2010.08.032; Kiernan DF, 2010, AM J OPHTHALMOL, V149, P18, DOI 10.1016/j.ajo.2009.08.037; Wakabayashi T, 2010, OPHTHALMOLOGY, V117, P1815, DOI 10.1016/j.ophtha.2010.01.017; Massin P, 2000, AM J OPHTHALMOL, V130, P732, DOI 10.1016/S0002-9394(00)00574-2; Varano M, 2002, RETINA-J RET VIT DIS, V22, P435, DOI 10.1097/00006982-200208000-00007; Oishi A, 2010, AM J OPHTHALMOL, V150, P27, DOI 10.1016/j.ajo.2010.02.012; Shimozono M, 2012, AM J OPHTHALMOL, V153, P698, DOI 10.1016/j.ajo.2011.09.011; Park SJ, 2010, INVEST OPHTH VIS SCI, V51, P3673, DOI 10.1167/iovs.09-4169; Suh MH, 2009, AM J OPHTHALMOL, V147, P473, DOI 10.1016/j.ajo.2008.09.020; Tsunoda K, 2011, ARCH OPHTHALMOL-CHIC, V129, P1099, DOI 10.1001/archophthalmol.2011.217; ALLEN AW, 1976, AM J OPHTHALMOL, V82, P684; Watanabe K, 2013, JAMA OPHTHALMOL, V131, P172, DOI 10.1001/jamaophthalmol.2013.686; Staurenghi G, 2014, OPHTHALMOLOGY, V121, P1572, DOI 10.1016/j.ophtha.2014.02.023; Ooka E, 2011, AM J OPHTHALMOL, V152, P283, DOI 10.1016/j.ajo.2011.02.001; Wakabayashi T, 2009, OPHTHALMOLOGY, V116, P519, DOI 10.1016/j.ophtha.2008.10.001; Yamashita T, 2012, INVEST OPHTH VIS SCI, V53, P1102, DOI 10.1167/iovs.11-8836; Inoue M, 2010, AM J OPHTHALMOL, V150, P834, DOI 10.1016/j.ajo.2010.06.006; Massin P, 1999, OPHTHALMOLOGY, V106, P580, DOI 10.1016/S0161-6420(99)90119-7; GASS JDM, 1995, AM J OPHTHALMOL, V119, P752; Srinivasan VJ, 2008, INVEST OPHTH VIS SCI, V49, P1571, DOI 10.1167/iovs.07-0838; Heussen FM, 2012, BRIT J OPHTHALMOL, V96, P380, DOI 10.1136/bjo.2010.201111; Cheung CMG, 2010, ARCH OPHTHALMOL-CHIC, V128, P644, DOI 10.1001/archophthalmol.2010.48; Emery JM, 1979, PHACOEMULSIFICATION, P45; Greven CM, 1998, AM J OPHTHALMOL, V125, P360, DOI 10.1016/S0002-9394(99)80147-0; Guidry C, 2005, PROG RETIN EYE RES, V24, P75, DOI 10.1016/j.preteyeres.2004.07.001; Ho AC, 1998, SURV OPHTHALMOL, V42, P393; Itoh Y, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.01.023; McDonald HR, 2005, RETINA, V4th, P2509; Mitamura Y, 2013, J OPHTHALMOL, DOI 10.1155/2013/518170; Ooto S, 2010, OPHTHALMOLOGY, V117, P1800, DOI 10.1016/j.ophtha.2010.01.042; Puche N, 2010, BRIT J OPHTHALMOL, V94, P1190, DOI 10.1136/bjo.2009.175075; Wolf S, 2010, OPHTHALMOLOGICA, V224, P333, DOI 10.1159/000313814	38	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0275-004X	1539-2864		RETINA-J RET VIT DIS	Retin.-J. Retin. Vitr. Dis.	MAY	2015	35	5					908	914				7	Ophthalmology	Ophthalmology	CG6KI	WOS:000353408900011		
J	Terasaki, H; Sakamoto, T; Shirasawa, M; Yoshihara, N; Otsuka, H; Sonoda, S; Hisatomi, T; Ishibashi, T				Terasaki, Hiroto; Sakamoto, Taiji; Shirasawa, Makoto; Yoshihara, Naoya; Otsuka, Hiroki; Sonoda, Shozo; Hisatomi, Toshio; Ishibashi, Tatsuro			PENETRATION OF BEVACIZUMAB AND RANIBIZUMAB THROUGH RETINAL PIGMENT EPITHELIAL LAYER IN VITRO	RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES			English	Article						polarized RPE cells; bevacizumab; ranibizumab; endocytosis; VEGF	SINGLE INTRAVITREAL INJECTION; MACULAR DEGENERATION; INTRAOCULAR PHARMACOKINETICS; GROWTH-FACTOR; VEGF; PERMEABILITY; PEGAPTANIB; MEMBRANE; PROTEIN; HUMANS	Purpose: To determine the permeability of bevacizumab and ranibizumab through highly-polarized retinal pigment epithelial (RPE) cells in vitro. Methods: Highly-polarized RPE cells were cultured in the upper chamber of a Transwell culture system. Bevacizumab or ranibizumab was added to the upper chamber. After 3 hours, the concentrations of bevacizumab or ranibizumab were determined in the upper and lower chambers. The cytotoxicities of the two anti-vascular endothelial growth factor agents were determined histologically. The effects of inhibiting endocytosis by pharmacologic inhibitors were also evaluated. Results: The concentration of ranibizumab was higher than that of bevacizumab in the lower chamber (P < 0.05). Vascular endothelial growth factor was found mainly in the lower chamber under normal conditions. However, the concentration of vascular endothelial growth factor in the lower chamber was significantly less when ranibizumab was added to the upper chamber than when bevacizumab was added. Histology showed no obvious changes in bevacizumab-exposed or ranibizumab-exposed RPE cells. Pretreatment with protein kinase C inhibitor staurosporine had significant negative effects on the permeability of bevacizumab and ranibizumab (P < 0.05). Conclusion: Ranibizumab is more permeable than bevacizumab through the highly-polarized RPE layer at clinically equivalent concentrations, and their permeability was partially protein kinase C-dependent. Ranibizumab might be more therapeutically effective than bevacizumab on choroidal neovascularization beneath the RPE layer.	[Terasaki, Hiroto; Sakamoto, Taiji; Shirasawa, Makoto; Yoshihara, Naoya; Otsuka, Hiroki; Sonoda, Shozo] Kagoshima Univ, Grad Sch Med & Dent Sci, Dept Ophthalmol, Kagoshima 8908520, Japan; [Hisatomi, Toshio; Ishibashi, Tatsuro] Kyushu Univ, Dept Ophthalmol, Fukuoka 812, Japan	Sakamoto, T (reprint author), Kagoshima Univ, Grad Sch Med & Dent Sci, Dept Ophthalmol, Kagoshima 8908520, Japan.	tsakamot@m3.kufm.kagoshima-u.ac.jp			Novartis Pharma K.K.; Research Committee on Chorioretinal Degeneration and Optic Atrophy, Ministry of Health, Labor, and Welfare, Tokyo, Japan; Ministry of Education, Science, and Culture of the Japanese Government, Tokyo, Japan	Supported in part by Novartis Pharma K.K. and conducted as a collaborative research, a grant from the Research Committee on Chorioretinal Degeneration and Optic Atrophy, Ministry of Health, Labor, and Welfare, Tokyo, Japan; and by a Grant-in-Aid for Scientific Research from the Ministry of Education, Science, and Culture of the Japanese Government, Tokyo, Japan.	AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203; Klettner AK, 2009, GRAEF ARCH CLIN EXP, V247, P1601, DOI 10.1007/s00417-009-1136-0; Mordenti J, 1999, TOXICOL PATHOL, V27, P536, DOI 10.1177/019262339902700507; Carneiro AM, 2011, OPHTHALMOLOGICA, V225, P211, DOI 10.1159/000323943; Krishnan R, 2009, CLIN EXP OPHTHALMOL, V37, P384, DOI 10.1111/j.1442-9071.2009.02043.x; Quan A, 2013, FEBS J, V280, P5198, DOI 10.1111/febs.12343; Krohne TU, 2012, AM J OPHTHALMOL, V154, P682, DOI 10.1016/j.ajo.2012.03.047; Shirasawa M, 2013, EXP EYE RES, V110, P59, DOI 10.1016/j.exer.2013.02.012; Thaler S, 2010, ACTA OPHTHALMOL, V88, pE170, DOI 10.1111/j.1755-3768.2010.01927.x; Klettner A, 2008, INVEST OPHTH VIS SCI, V49, P4523, DOI 10.1167/iovs.08-2055; STEINMAN RM, 1983, J CELL BIOL, V96, P1, DOI 10.1083/jcb.96.1.1; Krohne TU, 2008, AM J OPHTHALMOL, V146, P508, DOI 10.1016/j.ajo.2008.05.036; Cho HJ, 2012, EYE, V26, P426, DOI 10.1038/eye.2011.324; Peters S, 2007, AM J OPHTHALMOL, V143, P995, DOI 10.1016/j.ajo.2007.03.007; Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)000304; Sonoda S, 2009, NAT PROTOC, V4, P662, DOI 10.1038/nprot.2009.33; Evans J, 1996, BRIT J OPHTHALMOL, V80, P9, DOI 10.1136/bjo.80.1.9; Heiduschka P, 2007, INVEST OPHTH VIS SCI, V48, P2814, DOI 10.1167/iovs.06-1171; Ivanov AI, 2008, PREFACE METHODS MOL, V440, pv; Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673; Miura Y, 2010, INVEST OPHTH VIS SCI, V51, P4848, DOI 10.1167/iovs.09-4699; Peng SM, 2010, INVEST OPHTH VIS SCI, V51, P3216, DOI 10.1167/iovs.09-4162; Rezai KA, 1997, GRAEF ARCH CLIN EXP, V235, P48, DOI 10.1007/BF01007837; SHEU SJ, 1994, GRAEF ARCH CLIN EXP, V232, P695, DOI 10.1007/BF00171387; Terasaki H, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069994	25	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0275-004X	1539-2864		RETINA-J RET VIT DIS	Retin.-J. Retin. Vitr. Dis.	MAY	2015	35	5					1007	1015				9	Ophthalmology	Ophthalmology	CG6KI	WOS:000353408900023		
J	Shimizu, M				Shimizu, Masayuki			Analytical inverse kinematics for 5-DOF humanoid manipulator under arbitrarily specified unconstrained orientation of end-effector	ROBOTICA			English	Article						Inverse kinematics; 5-DOF manipulator; Unconstrained orientation; Singular configuration; Humanoid robots	ROBOT MANIPULATORS; GENERAL 6R; 5R; ARM	This paper proposes an analytical method of solving the inverse kinematic problem for a humanoid manipulator with five degrees-of-freedom (DOF) under the condition that the target orientation of the manipulator's end-effector is not constrained around an axis fixed with respect to the environment. Since the number of the joints is less than six, the inverse kinematic problem cannot be solved for arbitrarily specified position and orientation of the end-effector. To cope with the problem, a generalized unconstrained orientation is introduced in this paper. In addition, this paper conducts the singularity analysis to identify all singular conditions.	Shizuoka Univ, Dept Mech Engn, Hamamatsu, Shizuoka, Japan	Shimizu, M (reprint author), Shizuoka Univ, Dept Mech Engn, Hamamatsu, Shizuoka, Japan.	tmsimiz@ipc.shizuoka.ac.jp					ANGELES J, 1986, INT J ROBOT RES, V4, P59, DOI 10.1177/027836498600400405; Xin SZ, 2007, J MECH DESIGN, V129, P793, DOI 10.1115/1.2735636; RAGHAVAN M, 1993, J MECH DESIGN, V115, P502, DOI 10.1115/1.2919218; MANOCHA D, 1994, IEEE T ROBOTIC AUTOM, V10, P648, DOI 10.1109/70.326569; Shimizu M, 2008, IEEE T ROBOT, V24, P1131, DOI 10.1109/TRO.2008.2003266; Bedrossian N. S., 1990, Proceedings 1990 IEEE International Conference on Robotics and Automation (Cat. No.90CH2876-1), DOI 10.1109/ROBOT.1990.126089; Chen IM, 2001, IEEE INT CONF ROBOT, P2395, DOI 10.1109/ROBOT.2001.932980; Gan JQ, 2005, ROBOTICA, V23, P123, DOI 10.1017/S0263574704000529; Goel P. K., 1988, P IEEE INT C ROB AUT, V3, P1688; Jazar R. N., 2010, THEORY APPL ROBOTICS; KOHLI D, 1993, J MECH DESIGN, V115, P922, DOI 10.1115/1.2919288; Lee HY, 1996, J MECH DESIGN, V118, P396, DOI 10.1115/1.2826899; MANSEUR R, 1992, MECH MACH THEORY, V27, P587, DOI 10.1016/0094-114X(92)90047-L; MANSEUR R, 1992, MECH MACH THEORY, V27, P575, DOI 10.1016/0094-114X(92)90046-K; McCarthy J. M., 1990, INTRO THEORETICAL KI; Ramirez-Torres J. G., 2010, P 2010 EL ROB AUT ME, P372; Sato F, 2011, IEEE INT C INT ROBOT, P3179, DOI 10.1109/IROS.2011.6048182; SUGIMOTO K, 1983, J MECH TRANSM-T ASME, V105, P23; The Mathematical Society of Japan, 1993, ENCY DICT MATH, V2nd; Tsai L.-W., 1985, Transactions of the ASME. Journal of Mechanisms, Transmissions, and Automation in Design, V107; WAMPLER C, 1991, MECH MACH THEORY, V26, P91, DOI 10.1016/0094-114X(91)90024-X; Wang H., 2007, P 2007 IEEE INT C NE, P507; Wang HB, 1998, MECH MACH THEORY, V33, P895, DOI 10.1016/S0094-114X(97)00067-0; Xu D, 2005, INT J AUTOMATION COM, V2, P114, DOI 10.1007/s11633-005-0114-1; ZHOU YB, 1995, MECH MACH THEORY, V30, P421, DOI 10.1016/0094-114X(94)00030-O; Zhou YB, 1998, MECH MACH THEORY, V33, P175, DOI 10.1016/S0094-114X(97)00018-9	26	0	0	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	0263-5747	1469-8668		ROBOTICA	Robotica	MAY	2015	33	4					747	767		10.1017/S0263574714000538		21	Robotics	Robotics	CG9SO	WOS:000353660600003		
J	Inokuma, S; Miura, Y; Kobuna, M; Okada, R; Horikoshi, M; Kobayashi, S				Inokuma, Shiqeko; Miura, Yoko; Kobuna, Mika; Okada, Rika; Horikoshi, Masanobu; Kobayashi, Shoko			Comparison of Scialoscintigraphic Uptake Among Bilateral Parotid and Submandibular Glands in Patients of Confirmed and Non-Confirmed Sjogren Syndrome (SjS)	SCANDINAVIAN JOURNAL OF IMMUNOLOGY			English	Meeting Abstract	13th International Symposium on Sjogren's Syndrome	MAY 19-22, 2015	Bergen, NORWAY						[Inokuma, Shiqeko; Miura, Yoko; Kobuna, Mika; Okada, Rika; Horikoshi, Masanobu; Kobayashi, Shoko] Japanese Red Cross Med Ctr, Dept Allergy & Rheumat Dis, Tokyo, Japan								0	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0300-9475	1365-3083		SCAND J IMMUNOL	Scand. J. Immunol.	MAY	2015	81	5				S2.6	339	340				2	Immunology	Immunology	CG6HV	WOS:000353401300028		
J	Tomiita, M; Inoue, Y; Arima, T; Nakano, N; Yamamoto, K; Yamaide, F; Kudo, K; Yamaide, A; Hoshioka, A; Shimojo, N				Tomiita, M.; Inoue, Y.; Arima, T.; Nakano, N.; Yamamoto, K.; Yamaide, F.; Kudo, K.; Yamaide, A.; Hoshioka, A.; Shimojo, N.			Long time Follow-up of Pediatric Sjogren's Syndrome: The Rate of Patients who Developed Other Rheumatic diseases is not High	SCANDINAVIAN JOURNAL OF IMMUNOLOGY			English	Meeting Abstract	13th International Symposium on Sjogren's Syndrome	MAY 19-22, 2015	Bergen, NORWAY						[Tomiita, M.; Yamaide, A.; Hoshioka, A.] Chiba Childrens Hosp, Dept Allergy & Rheumotol, Chiba, Japan; [Tomiita, M.; Inoue, Y.; Arima, T.; Nakano, N.; Yamamoto, K.; Yamaide, F.; Kudo, K.; Shimojo, N.] Chiba Univ, Dept Pediat, Chiba, Japan								0	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0300-9475	1365-3083		SCAND J IMMUNOL	Scand. J. Immunol.	MAY	2015	81	5				S2.11	342	342				1	Immunology	Immunology	CG6HV	WOS:000353401300033		
J	Nishiyama, S; Aita, T; Yoshinaga, Y; Miyawaki, S				Nishiyama, S.; Aita, T.; Yoshinaga, Y.; Miyawaki, S.			Effect of Age at Onset on Disease Activity and Clinical Features in Patients with Primary Sjogren's Syndrome	SCANDINAVIAN JOURNAL OF IMMUNOLOGY			English	Meeting Abstract	13th International Symposium on Sjogren's Syndrome	MAY 19-22, 2015	Bergen, NORWAY						[Nishiyama, S.; Aita, T.; Yoshinaga, Y.; Miyawaki, S.] Kurashiki Med Ctr, Ctr Rheumat Dis, Kurashiki, Okayama, Japan								0	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0300-9475	1365-3083		SCAND J IMMUNOL	Scand. J. Immunol.	MAY	2015	81	5				S5.16	368	368				1	Immunology	Immunology	CG6HV	WOS:000353401300083		
J	Ishioka, E; Yoshimoto, K; Nishikawa, A; Suzuki, K; Yamaoka, K; Takeuchi, T				Ishioka, E.; Yoshimoto, K.; Nishikawa, A.; Suzuki, K.; Yamaoka, K.; Takeuchi, T.			Increased CD38(high)IgD(+) B Cells Contribute to Pathogenesis and Activity of Primary Sjogren's Syndrome	SCANDINAVIAN JOURNAL OF IMMUNOLOGY			English	Meeting Abstract	13th International Symposium on Sjogren's Syndrome	MAY 19-22, 2015	Bergen, NORWAY						[Ishioka, E.; Yoshimoto, K.; Nishikawa, A.; Suzuki, K.; Yamaoka, K.; Takeuchi, T.] Keio Univ, Sch Med, Dept Internal Med, Div Rheumatol,Shinjuku Ku, Tokyo 1608582, Japan			Takeuchi, Tsutomu/L-2327-2013	Takeuchi, Tsutomu/0000-0003-1111-8218				0	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0300-9475	1365-3083		SCAND J IMMUNOL	Scand. J. Immunol.	MAY	2015	81	5				S7.4	379	379				1	Immunology	Immunology	CG6HV	WOS:000353401300103		
J	Yoshimoto, K; Ishioka, E; Nishikawa, A; Suzuki, K; Takeuchi, T				Yoshimoto, Keiko; Ishioka, Eriko; Nishikawa, Ayumi; Suzuki, Katsuya; Takeuchi, Tsutomu			BAFF-Stimulated Monocytes Accelerates IgG Production by B Cells in Patients with Primary Sjogren's Syndrome	SCANDINAVIAN JOURNAL OF IMMUNOLOGY			English	Meeting Abstract	13th International Symposium on Sjogren's Syndrome	MAY 19-22, 2015	Bergen, NORWAY						[Yoshimoto, Keiko; Ishioka, Eriko; Nishikawa, Ayumi; Suzuki, Katsuya; Takeuchi, Tsutomu] Keio Univ, Sch Med, Dept Internal Med, Div Rheumatol, Tokyo, Japan			Takeuchi, Tsutomu/L-2327-2013	Takeuchi, Tsutomu/0000-0003-1111-8218				0	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0300-9475	1365-3083		SCAND J IMMUNOL	Scand. J. Immunol.	MAY	2015	81	5				S7.8	381	382				2	Immunology	Immunology	CG6HV	WOS:000353401300107		
J	Furukawa, S; Moriyama, M; Tanaka, A; Maehara, T; Iizuka, M; Tsuboi, H; Hayashida, JN; Ohta, M; Yamauchi, M; Ishiguro, N; Nakashima, H; Sumida, T; Nakamura, S				Furukawa, Sachiko; Moriyama, Masafumi; Tanaka, Akihiko; Maehara, Takashi; Iizuka, Mana; Tsuboi, Hiroshi; Hayashida, Jun-Nosuke; Ohta, Miho; Yamauchi, Masaki; Ishiguro, Noriko; Nakashima, Hitoshi; Sumida, Takayuki; Nakamura, Seiji			IL-33 Secreted by M2 Macrophage Promotes the Pathogenesis of IgG4-Related Disease	SCANDINAVIAN JOURNAL OF IMMUNOLOGY			English	Meeting Abstract	13th International Symposium on Sjogren's Syndrome	MAY 19-22, 2015	Bergen, NORWAY						[Furukawa, Sachiko; Moriyama, Masafumi; Tanaka, Akihiko; Maehara, Takashi; Hayashida, Jun-Nosuke; Ohta, Miho; Yamauchi, Masaki; Ishiguro, Noriko; Nakamura, Seiji] Kyushu Univ, Fac Dent Sci, Div Maxillofacial Diagnost & Surg Sci, Sect Oral & Maxillofacial Oncol, Fukuoka 812, Japan; [Nakashima, Hitoshi] Fukuoka Univ, Fac Med, Dept Internal Med, Div Nephrol & Rheumatol, Fukuoka 81401, Japan; [Iizuka, Mana; Tsuboi, Hiroshi; Sumida, Takayuki] Univ Tsukuba, Fac Med, Dept Internal Med, Tsukuba, Ibaraki 305, Japan								0	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0300-9475	1365-3083		SCAND J IMMUNOL	Scand. J. Immunol.	MAY	2015	81	5				S7.17	386	386				1	Immunology	Immunology	CG6HV	WOS:000353401300116		
J	Yajima, H; Yamamoto, M; Shimizu, Y; Suzuki, C; Naishiro, Y; Takahashi, SH; Shinomura, Y				Yajima, H.; Yamamoto, M.; Shimizu, Y.; Suzuki, C.; Naishiro, Y.; Takahashi, S. H.; Shinomura, Y.			Possible Involvement of Toll-like Receptor 7-Interferon alpha Axis Modified with Interleukin-21 and Thymic Stromal Lymphopoietin in IgG4-Related Disease	SCANDINAVIAN JOURNAL OF IMMUNOLOGY			English	Meeting Abstract	13th International Symposium on Sjogren's Syndrome	MAY 19-22, 2015	Bergen, NORWAY						[Yajima, H.; Yamamoto, M.; Shimizu, Y.; Suzuki, C.; Naishiro, Y.; Takahashi, S. H.; Shinomura, Y.] Sapporo Med Univ, Sch Med, Dept Gastroenterol Rheumatol & Clin Immunol, Sapporo, Hokkaido, Japan								0	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0300-9475	1365-3083		SCAND J IMMUNOL	Scand. J. Immunol.	MAY	2015	81	5				S8.6	392	392				1	Immunology	Immunology	CG6HV	WOS:000353401300129		
J	Yamamoto, M; Yajima, H; Shimizu, Y; Suzuki, C; Naishiro, Y; Okazaki, S; Nagoya, S; Takahashi, H; Shinomura, Y				Yamamoto, M.; Yajima, H.; Shimizu, Y.; Suzuki, C.; Naishiro, Y.; Okazaki, S.; Nagoya, S.; Takahashi, H.; Shinomura, Y.			Occurrence of Glucocorticoid-Induced Avascular Necrosis of the Femoral Heads in IgG4-Related Disease and the Roles of Interferon alpha to the Pathogenesis	SCANDINAVIAN JOURNAL OF IMMUNOLOGY			English	Meeting Abstract	13th International Symposium on Sjogren's Syndrome	MAY 19-22, 2015	Bergen, NORWAY						[Yamamoto, M.; Yajima, H.; Shimizu, Y.; Suzuki, C.; Naishiro, Y.; Takahashi, H.; Shinomura, Y.] Sapporo Med Univ, Sch Med, Dept Gastroenterol Rheumatol & Clin Immunol, Sapporo, Hokkaido, Japan; [Okazaki, S.; Nagoya, S.] Sapporo Med Univ, Sch Med, Dept Musculoskeletal Biomech & Surg Dev, Sapporo, Hokkaido, Japan								0	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0300-9475	1365-3083		SCAND J IMMUNOL	Scand. J. Immunol.	MAY	2015	81	5				S8.7	392	393				2	Immunology	Immunology	CG6HV	WOS:000353401300130		
J	Itoh, Y; Shigemori, T; Ozaki, Y; Takeshita, H; Narazaki, H; Igarashi, T				Itoh, Y.; Shigemori, T.; Ozaki, Y.; Takeshita, H.; Narazaki, H.; Igarashi, T.			Development of Dryness in Children with Positive Anti-Ro with or Without Treatment by Immunosuppressants	SCANDINAVIAN JOURNAL OF IMMUNOLOGY			English	Meeting Abstract	13th International Symposium on Sjogren's Syndrome	MAY 19-22, 2015	Bergen, NORWAY						[Itoh, Y.; Shigemori, T.; Ozaki, Y.; Takeshita, H.; Narazaki, H.; Igarashi, T.] Nippon Med Sch, Dept Pediat, Tokyo 113, Japan								0	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0300-9475	1365-3083		SCAND J IMMUNOL	Scand. J. Immunol.	MAY	2015	81	5				S9.13	399	400				2	Immunology	Immunology	CG6HV	WOS:000353401300144		
J	Suzuki, Y; Fujii, H; Yamada, K; Kawano, M				Suzuki, Yasunori; Fujii, Hiroshi; Yamada, Kazunori; Kawano, Mitsuhiro			Anti-CCP Antibody-Positive Articular Symptom in Sjogren's Syndrome: Case Series of Nine Cases	SCANDINAVIAN JOURNAL OF IMMUNOLOGY			English	Meeting Abstract	13th International Symposium on Sjogren's Syndrome	MAY 19-22, 2015	Bergen, NORWAY						[Suzuki, Yasunori; Fujii, Hiroshi; Yamada, Kazunori; Kawano, Mitsuhiro] Kanazawa Univ, Grad Sch Med, Dept Internal Med, Div Rheumatol, Kanazawa, Ishikawa, Japan								0	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0300-9475	1365-3083		SCAND J IMMUNOL	Scand. J. Immunol.	MAY	2015	81	5				S9.11	399	399				1	Immunology	Immunology	CG6HV	WOS:000353401300142		
J	Tomiita, M; Malyavantham, K; Kobayashi, I; Nonaka, Y; Hoshioka, A; Ambrus, JL; Suresh, L				Tomiita, M.; Malyavantham, K.; Kobayashi, I.; Nonaka, Y.; Hoshioka, A.; Ambrus, J. L., Jr.; Suresh, L.			Novel Autoantibodies in Pediatric Sjogren's Patients	SCANDINAVIAN JOURNAL OF IMMUNOLOGY			English	Meeting Abstract	13th International Symposium on Sjogren's Syndrome	MAY 19-22, 2015	Bergen, NORWAY						[Tomiita, M.; Hoshioka, A.] Chiba Childrens Hosp, Dept Allergy & Rheumatol, Chiba, Japan; [Malyavantham, K.; Suresh, L.] Immco Diagnost, Buffalo, NY USA; [Kobayashi, I.] Hokkaido Univ Sapporo, Dept Pediat, Sapporo, Hokkaido, Japan; [Nonaka, Y.] Kagoshima Univ Kagoshima, Dept Pediat, Kagoshima, Japan; [Ambrus, J. L., Jr.] SUNY Buffalo, Sch Med, Dept Med, Buffalo, NY 14260 USA								0	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0300-9475	1365-3083		SCAND J IMMUNOL	Scand. J. Immunol.	MAY	2015	81	5				S9.12	399	399				1	Immunology	Immunology	CG6HV	WOS:000353401300143		
J	Ohta, M; Moriyama, M; Tanaka, A; Maehara, T; Furukawa, S; Tsuboi, H; Iizuka, M; Kawano, S; Hayashida, JN; Imabayashi, Y; Yamauchi, M; Ishiguro, N; Sumida, T; Nakamura, S				Ohta, M.; Moriyama, M.; Tanaka, A.; Maehara, T.; Furukawa, S.; Tsuboi, H.; Iizuka, M.; Kawano, S.; Hayashida, J. -N.; Imabayashi, Y.; Yamauchi, M.; Ishiguro, N.; Sumida, T.; Nakamura, S.			DNA Microarray Analysis of Submandibular Glands in IgG4-Related Dacryoadenitis and Sialoadenitis	SCANDINAVIAN JOURNAL OF IMMUNOLOGY			English	Meeting Abstract	13th International Symposium on Sjogren's Syndrome	MAY 19-22, 2015	Bergen, NORWAY						[Ohta, M.; Moriyama, M.; Tanaka, A.; Maehara, T.; Furukawa, S.; Kawano, S.; Hayashida, J. -N.; Imabayashi, Y.; Yamauchi, M.; Ishiguro, N.; Nakamura, S.] Kyushu Univ, Fac Dent Sci, Div Maxillofacial Diagnost & Surg Sci, Sect Oral & Maxillofacial Oncol, Fukuoka 812, Japan; [Tsuboi, H.; Iizuka, M.; Sumida, T.] Univ Tsukuba, Fac Med, Dept Internal Med, Ibaraki, Japan								0	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0300-9475	1365-3083		SCAND J IMMUNOL	Scand. J. Immunol.	MAY	2015	81	5				S11.17	419	419				1	Immunology	Immunology	CG6HV	WOS:000353401300181		
J	Takahashi, H; Tsuboi, H; Nakai, Y; Iizuka, M; Asashima, H; Hirota, T; Kondo, Y; Moriyama, M; Furukawa, S; Matsumoto, I; Nakamura, S; Yoshihara, T; Abe, K; Sumida, T				Takahashi, Hiroyuki; Tsuboi, Hiroto; Nakai, Yuji; Iizuka, Mana; Asashima, Hiromitsu; Hirota, Tomoya; Kondo, Yuya; Moriyama, Masafumi; Furukawa, Sachiko; Matsumoto, Isao; Nakamura, Seiji; Yoshihara, Toshio; Abe, Keiko; Sumida, Takayuki			DNA Microarray Analysis of Labial Salivary Glands in Patients with Sjogren's Syndrome: Comparison with IgG4-Related Disease	SCANDINAVIAN JOURNAL OF IMMUNOLOGY			English	Meeting Abstract	13th International Symposium on Sjogren's Syndrome	MAY 19-22, 2015	Bergen, NORWAY						[Takahashi, Hiroyuki; Tsuboi, Hiroto; Iizuka, Mana; Asashima, Hiromitsu; Hirota, Tomoya; Kondo, Yuya; Matsumoto, Isao; Sumida, Takayuki] Univ Tsukuba, Fac Med, Dept Internal Med, Tsukuba, Ibaraki, Japan; [Nakai, Yuji; Abe, Keiko] Univ Tokyo, Grad Sch Agr & Life Sci, Funct Food Sci & Nutrigen, Tokyo, Japan; [Moriyama, Masafumi; Furukawa, Sachiko; Nakamura, Seiji] Kyushu Univ, Fac Dent Sci, Div Maxillofacial Diagnost & Surg Sci, Sect Oral & Maxillofacial Oncol, Fukuoka 812, Japan; [Yoshihara, Toshio] Tokyo Womens Med Univ, Dept Otolaryngol, Tokyo, Japan			NAKAI, Yuji/G-3433-2014					0	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0300-9475	1365-3083		SCAND J IMMUNOL	Scand. J. Immunol.	MAY	2015	81	5				S11.18	420	420				1	Immunology	Immunology	CG6HV	WOS:000353401300182		
J	Asashima, H; Tsuboi, H; Takahashi, H; Hirota, T; Iizuka, M; Kondo, Y; Matsumoto, I; Sumida, T				Asashima, H.; Tsuboi, H.; Takahashi, H.; Hirota, T.; Iizuka, M.; Kondo, Y.; Matsumoto, I.; Sumida, T.			The anergy induction of M3R reactive CD4(+) T cells suppresses experimental sialadenitis like Sjogren's syndrome in vivo	SCANDINAVIAN JOURNAL OF IMMUNOLOGY			English	Meeting Abstract	13th International Symposium on Sjogren's Syndrome	MAY 19-22, 2015	Bergen, NORWAY						[Asashima, H.; Tsuboi, H.; Takahashi, H.; Hirota, T.; Iizuka, M.; Kondo, Y.; Matsumoto, I.; Sumida, T.] Univ Tsukuba, Fac Med, Dept Internal Med, Ibaraki, Japan								0	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0300-9475	1365-3083		SCAND J IMMUNOL	Scand. J. Immunol.	MAY	2015	81	5				S12.4	422	423				2	Immunology	Immunology	CG6HV	WOS:000353401300186		
J	Iizuka, M; Tsuboi, H; Asashima, H; Hirota, T; Takahashi, H; Kondo, Y; Takahashi, S; Matsumoto, I; Sumida, T				Iizuka, M.; Tsuboi, H.; Asashima, H.; Hirota, T.; Takahashi, H.; Kondo, Y.; Takahashi, S.; Matsumoto, I.; Sumida, T.			A Pathological Role of ROR gamma t in the Development of Sialadenitis like Sjogren's Syndrome	SCANDINAVIAN JOURNAL OF IMMUNOLOGY			English	Meeting Abstract	13th International Symposium on Sjogren's Syndrome	MAY 19-22, 2015	Bergen, NORWAY						[Iizuka, M.; Tsuboi, H.; Asashima, H.; Hirota, T.; Takahashi, H.; Kondo, Y.; Matsumoto, I.; Sumida, T.] Univ Tsukuba, Fac Med, Dept Internal Med, Tsukuba, Ibaraki, Japan; [Takahashi, S.] Univ Tsukuba, Fac Med, Dept Anat & Embryol, Tsukuba, Ibaraki, Japan								0	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0300-9475	1365-3083		SCAND J IMMUNOL	Scand. J. Immunol.	MAY	2015	81	5				S12.9	425	425				1	Immunology	Immunology	CG6HV	WOS:000353401300191		
J	Tsuboi, H; Matsumoto, I; Hagiwara, S; Hirota, T; Takahashi, H; Ebe, H; Yokosawa, M; Asashima, H; Umeda, N; Kondo, Y; Ogishima, H; Suzuki, T; Hirata, S; Saito, K; Tanaka, Y; Horai, Y; Nakamura, H; Kawakami, A; Sumida, T				Tsuboi, H.; Matsumoto, I.; Hagiwara, S.; Hirota, T.; Takahashi, H.; Ebe, H.; Yokosawa, M.; Asashima, H.; Umeda, N.; Kondo, Y.; Ogishima, H.; Suzuki, T.; Hirata, S.; Saito, K.; Tanaka, Y.; Horai, Y.; Nakamura, H.; Kawakami, A.; Sumida, T.			New Therapeutic Strategy for Sjogren's Syndrome Associated with Rheumatoid Arthritis Targeted on T cells	SCANDINAVIAN JOURNAL OF IMMUNOLOGY			English	Meeting Abstract	13th International Symposium on Sjogren's Syndrome	MAY 19-22, 2015	Bergen, NORWAY						[Tsuboi, H.; Matsumoto, I.; Hagiwara, S.; Hirota, T.; Takahashi, H.; Ebe, H.; Yokosawa, M.; Asashima, H.; Umeda, N.; Kondo, Y.; Ogishima, H.; Suzuki, T.; Sumida, T.] Univ Tsukuba, Fac Med, Dept Internal Med, Tsukuba, Ibaraki, Japan; [Hirata, S.; Saito, K.; Tanaka, Y.] Univ Occupat & Environm Hlth, Sch Med, Dept Internal Med 1, Kitakyushu, Fukuoka 807, Japan; [Horai, Y.; Nakamura, H.; Kawakami, A.] Nagasaki Univ, Grad Sch Biomed Sci, Dept Immunol & Rheumatol, Unit Translat Med, Nagasaki 852, Japan								0	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0300-9475	1365-3083		SCAND J IMMUNOL	Scand. J. Immunol.	MAY	2015	81	5				S14.13	438	439				2	Immunology	Immunology	CG6HV	WOS:000353401300216		
J	Masaki, Y				Masaki, Y.		All Japan IgG4 RD Res Grp	A Multicenter Phase II Prospective Clinical Trial of Glucocorticoid Treatment for Patients with Untreated IgG4-Related Disease	SCANDINAVIAN JOURNAL OF IMMUNOLOGY			English	Meeting Abstract	13th International Symposium on Sjogren's Syndrome	MAY 19-22, 2015	Bergen, NORWAY						[Masaki, Y.; All Japan IgG4 RD Res Grp] Kanazawa Med Univ, Hematol & Immunol, Uchinada, Ishikawa, Japan								0	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0300-9475	1365-3083		SCAND J IMMUNOL	Scand. J. Immunol.	MAY	2015	81	5				S14.15	439	440				2	Immunology	Immunology	CG6HV	WOS:000353401300218		
J	Tsuboi, T; Suzuki, T; Bies, RR; Remington, G; Pollock, BG; Mimura, M; Uchida, H				Tsuboi, Takashi; Suzuki, Takefumi; Bies, Robert R.; Remington, Gary; Pollock, Bruce G.; Mimura, Masaru; Uchida, Hiroyuki			Challenging the need for sustained blockade of dopamine D-2 receptor estimated from antipsychotic plasma levels in the maintenance treatment of schizophrenia: A single-blind, randomized, controlled study	SCHIZOPHRENIA RESEARCH			English	Article						Antipsychotics; Dopamine D-2 receptor; Maintenance treatment; Schizophrenia	CATIE-DATA; POOLED ANALYSIS; OLDER PATIENTS; RATING-SCALE; OCCUPANCY; RISPERIDONE; DRUGS; PET; SENSITIVITY; MECHANISMS	Objective: Blockade of dopamine D-2 receptors with antipsychotics above 65% is associated with optimal chance of clinical response although recent data suggest a lower threshold for the maintenance treatment of schizophrenia. The objective of this study was to prospectively examine whether such continuous high blockade would be necessary for maintenance treatment. Method: In this single-blind, 52-week, randomized controlled trial, clinically stable patients with schizophrenia receiving risperidone or olanzapine were randomly assigned to the continuous D-2 blockade (i.e. an estimated trough D-2 blockade of N65%) or non-continuous blockade group (i.e. an estimated peak level of N65% with an estimated trough level of >65%). Oral doses corresponding to the assigned blockade levels were estimated from random plasma drug concentrations, using the models we developed; antipsychotic doses were then adjusted accordingly. Psychopathology and side effects were assessed at baseline and one year with the Positive and Negative Syndrome Scale (PANSS), Simpson-Angus Scale (SAS), and Abnormal Involuntary Movement Scale (AIMS). Results: Sixty-eight subjects (34 in each group) were enrolled. Twenty-six (76.5%) and thirty-one (91.2%) subjects completed the study in the continuous and non-continuous blockade groups, respectively, without any significant group difference. No significant differences were found on any of the assessment scales between the two groups. The degree of dosage change was small in both groups. Conclusion: These results offer support that the threshold for D-2 receptor lockade in the maintenance treatment can be lower than 65%. However, these preliminary findings have to be confirmed through double-blind, larger scale trials with longer follow-up periods. (C) 2015 Elsevier B.V. All rights reserved.	[Tsuboi, Takashi; Suzuki, Takefumi; Mimura, Masaru; Uchida, Hiroyuki] Keio Univ, Sch Med, Dept Neuropsychiat, Tokyo 1608582, Japan; [Suzuki, Takefumi] Inokashira Hosp, Dept Psychiat, Tokyo, Japan; [Bies, Robert R.] Indiana Univ Sch Med, Div Clin Pharmacol, Indianapolis, IN 46202 USA; [Bies, Robert R.] Indiana Clin & Translat Sci Inst, Indianapolis, IN USA; [Bies, Robert R.; Pollock, Bruce G.; Uchida, Hiroyuki] Ctr Addict & Mental Hlth, Geriatr Psychiat Div, Toronto, ON, Canada; [Remington, Gary; Pollock, Bruce G.] Univ Toronto, Dept Psychiat, Toronto, ON, Canada; [Pollock, Bruce G.] Ctr Addict & Mental Hlth, Schizophrenia Div, Toronto, ON, Canada	Uchida, H (reprint author), Keio Univ, Sch Med, Dept Neuropsychiat, Shinjuku Ku, 35 Shinanomachi, Tokyo 1608582, Japan.	hiroyuki.uchida.hu@gmail.com	Uchida, Hiroyuki/I-4867-2015	Uchida, Hiroyuki/0000-0002-0628-7036	Takeda Science Foundation; Kanae Science Foundation; Keio Academic Development Funds; Research Group for Schizophrenia	This study was partially funded by Takeda Science Foundation, Kanae Science Foundation, Keio Academic Development Funds, and Research Group for Schizophrenia.	Kapur S, 2000, AM J PSYCHIAT, V157, P514, DOI 10.1176/appi.ajp.157.4.514; Uchida H, 2011, J CLIN PSYCHOPHARM, V31, P497, DOI 10.1097/JCP.0b013e3182214aad; Uchida H, 2009, CLIN PHARMACOL THER, V86, P360, DOI 10.1038/clpt.2009.133; KAY SR, 1987, SCHIZOPHRENIA BULL, V13, P261; DAVIS JM, 1975, AM J PSYCHIAT, V132, P1237; Naber D, 1995, INT CLIN PSYCHOPHARM, V10, P133, DOI 10.1097/00004850-199509000-00017; ADDINGTON D, 1990, SCHIZOPHR RES, V3, P247, DOI 10.1016/0920-9964(90)90005-R; ENDICOTT J, 1976, ARCH GEN PSYCHIAT, V33, P766; JESTE DV, 1995, ARCH GEN PSYCHIAT, V52, P756; SHEINER LB, 1977, J PHARMACOKINET BIOP, V5, P445, DOI 10.1007/BF01061728; Remington G, 2011, J CLIN PSYCHIAT, V72, P1042, DOI 10.4088/JCP.09m05866yel; Uchida H, 2011, J CLIN PSYCHOPHARM, V31, P318, DOI 10.1097/JCP.0b013e318218d339; FARDE L, 1992, ARCH GEN PSYCHIAT, V49, P538; Tsuboi T, 2013, PROG NEURO-PSYCHOPH, V45, P178, DOI 10.1016/j.pnpbp.2013.05.010; Feng Y, 2008, BRIT J CLIN PHARMACO, V66, P629, DOI 10.1111/j.1365-2125.2008.03276.x; Sakurai H, 2013, SCHIZOPHRENIA BULL, V39, P564, DOI 10.1093/schbul/sbr189; Bigos KL, 2008, J CLIN PHARMACOL, V48, P157, DOI 10.1177/0091270007310385; Uchida H, 2012, THER DRUG MONIT, V34, P182, DOI 10.1097/FTD.0b013e3182489a6f; Ikai S, 2012, J CLIN PSYCHIAT, V73, P1147, DOI 10.4088/JCP.12m07638; BARNES TRE, 1989, BRIT J PSYCHIAT, V154, P672, DOI 10.1192/bjp.154.5.672; Guy W., 1976, ECDEU ASSESSMENT MAN; Haro JM, 2003, ACTA PSYCHIAT SCAND, V107, P16, DOI 10.1034/j.1600-0447.107.s416.5.x; Lemmens P, 1999, ACTA PSYCHIAT SCAND, V99, P160, DOI 10.1111/j.1600-0447.1999.tb00972.x; Leucht S, 2012, COCHRANE DB SYST REV, V5; Mizuno Y, 2012, PROG NEURO-PSYCHOPH, V37, P182, DOI 10.1016/j.pnpbp.2011.12.013; Moriguchi S, 2013, J CLIN PSYCHOPHARM, V33, P682, DOI 10.1097/JCP.0b013e3182979a0a; NYBERG S, 1995, AM J PSYCHIAT, V152, P173; Rasmussen HB, 2006, AM J PSYCHIAT, V163, P507, DOI 10.1176/appi.ajp.163.3.507; Ray WA, 2009, NEW ENGL J MED, V360, P225, DOI 10.1056/NEJMoa0806994; Simpson G M, 1970, Acta Psychiatr Scand Suppl, V212, P11; Takeuchi H, 2013, SCHIZOPHR RES, V150, P373, DOI 10.1016/j.schres.2013.08.033; Tsuboi T., 2013, 23 ANN M JAP SOC CLI; Uchida H, 2009, AM J GERIAT PSYCHIAT, V17, P255, DOI 10.1097/JGP.0b013e318198776d; Uchida H, 2009, J CLIN PSYCHIAT, V70, P397; Uchida H, 2008, J CLIN PSYCHIAT, V69, P1281; Uchida H., 2013, 3 C AS COLL NEUR BEI; Uchida H, 2011, SCHIZOPHRENIA BULL, V37, P788, DOI 10.1093/schbul/sbp149; Uchida H, 2014, J CLIN PSYCHOPHARM, V34, P728, DOI 10.1097/JCP.0000000000000065	38	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0920-9964	1573-2509		SCHIZOPHR RES	Schizophr. Res.	MAY	2015	164	1-3					149	154		10.1016/j.schres.2015.03.025		6	Psychiatry	Psychiatry	CG5MX	WOS:000353337100022		
J	Nakajima, S; Takeuchi, H; Plitman, E; Fervaha, G; Gerretsen, P; Caravaggio, F; Chung, JK; Iwata, Y; Remington, G; Graff-Guerrero, A				Nakajima, Shinichiro; Takeuchi, Hiroyoshi; Plitman, Eric; Fervaha, Gagan; Gerretsen, Philip; Caravaggio, Fernando; Chung, Jun Ku; Iwata, Yusuke; Remington, Gary; Graff-Guerrero, Ariel			Neuroimaging findings in treatment-resistant schizophrenia: A systematic review Lack of neuroimaging correlates of treatment-resistant schizophrenia	SCHIZOPHRENIA RESEARCH			English	Review						Schizophrenia; Treatment-resistance; Clozapine; Neuroimaging; Glutamate	AUDITORY VERBAL HALLUCINATIONS; MEDIAL PREFRONTAL CORTEX; LIKELIHOOD ESTIMATION METAANALYSIS; DOPAMINE-D-2 RECEPTOR OCCUPANCY; INDUCED COGNITIVE DEFICITS; TREATMENT RESPONSE; DOUBLE-BLIND; 1ST-EPISODE SCHIZOPHRENIA; ATYPICAL ANTIPSYCHOTICS; D-2 RECEPTORS	Background: Recent developments in neuroimaging have advanced the understanding of biological mechanisms underlying schizophrenia. However, neuroimaging correlates of treatment-resistant schizophrenia (TRS) and superior effects of clozapine on TRS remain unclear. Methods: Systematic search was performed to identify neuroimaging characteristics unique to TRS and ultra-resistant schizophrenia (i.e. clozapine-resistant [URS]), and clozapine's efficacy in TRS using Embase, Medline, and PsychInfo. Search terms included (schizophreni*) and (resistan* OR refractory OR clozapine) and (ASL OR CT OR DTI OR FMRI OR MRI OR MRS OR NIRS OR PET OR SPECT). Results: 25 neuroimaging studies have investigated TRS and effects of clozapine. Only 5 studies have compared TRS and non-TRS, collectively providing no replicated neuroimaging finding specific to TRS. Studies comparing TRS and healthy controls suggest that hypometabolism in the prefrontal cortex, hypermetabolism in the basal ganglia, and structural anomalies in the corpus callosum contribute to TRS. Clozapine may increase prefrontal hypoactivation in TRS although this was not related to clinical improvement; in contrast, evidence has suggested a link between clozapine efficacy and decreased metabolism in the basal ganglia and thalamus. Conclusion: Existing literature does not elucidate neuroimaging correlates specific to TRS or URS, which, if present, might also shed light on clozapine's efficacy in TRS. This said, leads from other lines of investigation, including the glutamatergic system can prove useful in guiding future neuroimaging studies focused on, in particular, the frontocortical-basal ganglia-thalamic circuits. Critical to the success of this work will be precise subtyping of study subjects based on treatment response/nonresponse and the use of multimodal neuroimaging. (C) 2015 Elsevier B.V. All rights reserved.	[Nakajima, Shinichiro; Plitman, Eric; Gerretsen, Philip; Caravaggio, Fernando; Chung, Jun Ku; Iwata, Yusuke; Graff-Guerrero, Ariel] Ctr Addict & Mental Hlth, Multimodal Imaging Grp, Res Imaging Ctr, Toronto, ON M5T 1R8, Canada; [Nakajima, Shinichiro; Gerretsen, Philip; Graff-Guerrero, Ariel] Ctr Addict & Mental Hlth, Geriatr Mental Hlth Div, Toronto, ON M5T 1R8, Canada; [Nakajima, Shinichiro; Takeuchi, Hiroyoshi; Gerretsen, Philip; Iwata, Yusuke; Remington, Gary; Graff-Guerrero, Ariel] Univ Toronto, Dept Psychiat, Toronto, ON, Canada; [Nakajima, Shinichiro; Takeuchi, Hiroyoshi; Iwata, Yusuke] Keio Univ, Sch Med, Dept Neuropsychiat, Tokyo, Japan; [Takeuchi, Hiroyoshi; Fervaha, Gagan; Remington, Gary] Ctr Addict & Mental Hlth, Schizophrenia Div, Complex Mental Illness Program, Toronto, ON M5T 1R8, Canada; [Plitman, Eric; Fervaha, Gagan; Gerretsen, Philip; Caravaggio, Fernando; Chung, Jun Ku] Univ Toronto, Inst Med Sci, Toronto, ON, Canada; [Remington, Gary; Graff-Guerrero, Ariel] Ctr Addict & Mental Hlth, Campbell Res Inst, Toronto, ON M5T 1R8, Canada	Graff-Guerrero, A (reprint author), Ctr Addict & Mental Hlth, Multimodal Imaging Grp, Res Imaging Ctr, 250 Coll St, Toronto, ON M5T 1R8, Canada.	shinichiro_nakajima@hotmail.com; hirotak@dk9.so-net.ne.jp; plitmaneric@gmail.com; gagan.fervaha@camh.ca; philgerretsen@yahoo.com; fernando.caravaggio@gmail.com; junku.chung@mail.utoronto.ca; yusuke.iwata2010@gmail.com; gary.remington@camh.ca; ariel_graff@yahoo.com.mx		Gerretsen, Philip/0000-0003-4053-6814	NARSAD Independent Investigator Grant from the Brain and Behavioural Research Foundation; Ontario Early Researcher Award; CIHR fellowship award	The work for this review was supported by NARSAD Independent Investigator Grant from the Brain and Behavioural Research Foundation (AG), Ontario Early Researcher Award (AG), and CIHR fellowship award (SN).	Abbott C, 2006, CURR OPIN PSYCHIATR, V19, P135, DOI 10.1097/01.yco.0000214337.29378.cd; Abekawa T, 2006, N-S ARCH PHARMACOL, V374, P177, DOI 10.1007/s00210-006-0115-9; Abekawa T, 2007, N-S ARCH PHARMACOL, V375, P261, DOI 10.1007/s00210-007-0154-x; KANE J, 1988, ARCH GEN PSYCHIAT, V45, P789; Arnone D, 2009, BRIT J PSYCHIAT, V195, P194, DOI 10.1192/bjp.bp.108.059717; Kapur S, 2003, AM J PSYCHIAT, V160, P13, DOI 10.1176/appi.ajp.160.1.13; Hietala J, 1999, SCHIZOPHR RES, V35, P41, DOI 10.1016/S0920-9964(98)00113-3; Kapur S, 2000, AM J PSYCHIAT, V157, P514, DOI 10.1176/appi.ajp.157.4.514; Abi-Dargham A, 1998, AM J PSYCHIAT, V155, P761; Hashimoto K, 2005, EUR J PHARMACOL, V519, P114, DOI 10.1016/j.ejphar.2005.07.002; Idris NF, 2005, PSYCHOPHARMACOLOGY, V179, P336, DOI 10.1007/s00213-004-2058-5; Kapur S, 2001, AM J PSYCHIAT, V158, P360, DOI 10.1176/appi.ajp.158.3.360; Amitai N, 2007, PSYCHOPHARMACOLOGY, V193, P521, DOI 10.1007/s00213-007-0808-x; Malhotra AK, 1997, NEUROPSYCHOPHARMACOL, V17, P141; Breier A, 1998, SYNAPSE, V29, P142, DOI 10.1002/(SICI)1098-2396(199806)29:2<142::AID-SYN5>3.0.CO;2-7; Lindenmayer JP, 2000, PSYCHIAT QUART, V71, P373, DOI 10.1023/A:1004640408501; Laruelle M, 1996, P NATL ACAD SCI USA, V93, P9235, DOI 10.1073/pnas.93.17.9235; Farooq S, 2013, SCHIZOPHRENIA BULL, V39, P1169, DOI 10.1093/schbul/sbt137; Malhotra AK, 1996, NEUROPSYCHOPHARMACOL, V14, P301, DOI 10.1016/0893-133X(95)00137-3; Grayson B, 2007, BEHAV BRAIN RES, V184, P31, DOI 10.1016/j.bbr.2007.06.012; Tauscher J, 2004, AM J PSYCHIAT, V161, P1620, DOI 10.1176/appi.ajp.161.9.1620; Chakos M, 2001, AM J PSYCHIAT, V158, P518, DOI 10.1176/appi.ajp.158.4.518; Howes OD, 2009, CURR PHARM DESIGN, V15, P2550; Wolf ND, 2012, SCHIZOPHR RES, V134, P285, DOI 10.1016/j.schres.2011.11.018; Didriksen M, 2007, PSYCHOPHARMACOLOGY, V193, P225, DOI 10.1007/s00213-007-0774-3; Krystal JH, 2008, BIOL PSYCHIAT, V64, P358, DOI 10.1016/j.biopsych.2008.06.011; Kegeles LS, 2000, BIOL PSYCHIAT, V48, P627, DOI 10.1016/S0006-3223(00)00976-8; Arango C, 2003, AM J PSYCHIAT, V160, P1421, DOI 10.1176/appi.ajp.160.8.1421; Nord M, 2011, CNS NEUROSCI THER, V17, P97, DOI 10.1111/j.1755-5949.2010.00222.x; Brugger S, 2011, BIOL PSYCHIAT, V69, P495, DOI 10.1016/j.biopsych.2010.10.004; Steen RG, 2006, BRIT J PSYCHIAT, V188, P510, DOI 10.1192/bjp.188.6.510; Leung M, 2011, SCHIZOPHRENIA BULL, V37, P199, DOI 10.1093/schbul/sbp099; Howes OD, 2009, SCHIZOPHRENIA BULL, V35, P549, DOI 10.1093/schbul/sbp006; Ebdrup BH, 2013, CURR MED CHEM, V20, P438; Lieberman JA, 2008, PHARMACOL REV, V60, P358, DOI 10.1124/pr.107.00107; Uchida H, 2011, J CLIN PSYCHOPHARM, V31, P318, DOI 10.1097/JCP.0b013e318218d339; Demjaha A, 2012, AM J PSYCHIAT, V169, P1203, DOI 10.1176/app.ajp.2012.12010144; CARLSSON M, 1990, TRENDS NEUROSCI, V13, P272, DOI 10.1016/0166-2236(90)90108-M; Abdul-Monim Z, 2006, BEHAV BRAIN RES, V169, P263, DOI 10.1016/j.bbr.2006.01.019; Conley RR, 2001, BIOL PSYCHIAT, V50, P898, DOI 10.1016/S0006-3223(01)01271-9; Grace AA, 2000, BRAIN RES REV, V31, P330, DOI 10.1016/S0165-0173(99)00049-1; LIEBERMAN JA, 1994, AM J PSYCHIAT, V151, P1744; MELTZER HY, 1990, HOSP COMMUNITY PSYCH, V41, P892; Di Costanzo A, 2003, EUR J RADIOL, V48, P146, DOI 10.1016/j.ejrad.2003.08.009; Suzuki T, 2012, PSYCHIAT RES, V197, P1, DOI 10.1016/j.psychres.2012.02.013; Seeman P, 2000, P NATL ACAD SCI USA, V97, P7673, DOI 10.1073/pnas.97.14.7673; Agid O, 2011, J CLIN PSYCHIAT, V72, P1439, DOI 10.4088/JCP.09m05785yel; Ellison-Wright I, 2008, AM J PSYCHIAT, V165, P1015, DOI 10.1176/appi.ajp.2008.07101562; Holleran L, 2014, NEUROPSYCHOPHARMACOL, V39, P944, DOI 10.1038/npp.2013.294; Jardri R, 2009, NEUROPSYCHOLOGIA, V47, P132, DOI 10.1016/j.neuropsychologia.2008.08.006; Amitai N, 2012, NEUROPHARMACOLOGY, V62, P1422, DOI 10.1016/j.neuropharm.2011.01.008; Lopez-Gil X, 2007, NEUROPSYCHOPHARMACOL, V32, P2087, DOI 10.1038/sj.npp.1301356; Kubera KM, 2014, PROG NEURO-PSYCHOPH, V50, P102, DOI 10.1016/j.pnpbp.2013.11.015; Buchsbaum MS, 2009, SCHIZOPHR RES, V114, P161, DOI 10.1016/j.schres.2009.07.015; Wolf ND, 2011, J PSYCHIATR NEUROSCI, V36, P366, DOI 10.1503/jpn.110008; KRYSTAL JH, 1994, ARCH GEN PSYCHIAT, V51, P199; Zugman A, 2013, SCHIZOPHR RES, V148, P81, DOI 10.1016/j.schres.2013.05.002; Mamo D, 2007, AM J PSYCHIAT, V164, P1411, DOI 10.1176/appi.apj.2007.0601479; Liao ZL, 2012, CHINESE MED J-PEKING, V125, P1349, DOI 10.3760/cma.j.issn.0366-6999.2012.07.029; Samaha AN, 2008, BIOL PSYCHIAT, V64, P145, DOI 10.1016/j.biopsych.2008.01.010; NORDSTROM AL, 1995, AM J PSYCHIAT, V152, P1444; Selvaraj S, 2014, NEUROSCI BIOBEHAV R, V45, P233, DOI 10.1016/j.neubiorev.2014.06.005; Yao L, 2013, PROG NEURO-PSYCHOPH, V45, P100, DOI 10.1016/j.pnpbp.2013.04.019; Di Costanzo A, 2007, EUR RADIOL, V17, P1651, DOI 10.1007/s00330-006-0546-1; Abi-Dargham A, 2000, P NATL ACAD SCI USA, V97, P8104, DOI 10.1073/pnas.97.14.8104; Sharp FR, 2001, TRENDS NEUROSCI, V24, P330, DOI 10.1016/S0166-2236(00)01817-8; Kulagina NV, 2001, NEUROSCIENCE, V102, P121, DOI 10.1016/S0306-4522(00)00480-2; Howes OD, 2012, ARCH GEN PSYCHIAT, V69, P776, DOI 10.1001/archgenpsychiatry.2012.169; David HN, 2005, BRAIN RES REV, V50, P336, DOI 10.1016/j.brainreserv.2005.09.002; Cachia A, 2008, NEUROIMAGE, V39, P927, DOI 10.1016/j.neuroimage.2007.08.049; Roberts RC, 2009, SYNAPSE, V63, P520, DOI 10.1002/syn.20623; Buchanan RW, 1998, AM J PSYCHIAT, V155, P751; Cadenhead KS, 2011, PSYCHIAT RES, V188, P208, DOI 10.1016/j.psychres.2011.04.011; Cepeda C, 1998, DEV NEUROSCI-BASEL, V20, P1, DOI 10.1159/000017294; Chung C, 2005, PSYCHOPHARMACOLOGY, V179, P317, DOI 10.1007/s00213-005-2174-x; Cipriani A., 2009, COCHRANE DB SYST REV, V3; Conley RR, 2004, J PSYCHOPHARMACOL, V18, P429, DOI 10.1177/0269881104044586; COPPENS HJ, 1991, BIOL PSYCHIAT, V29, P629, DOI 10.1016/0006-3223(91)90132-6; Demjaha A, 2014, BIOL PSYCHIAT, V75, pE11, DOI 10.1016/j.biopsych.2013.06.011; Fitzgerald PB, 2007, PSYCHIAT RES-NEUROIM, V155, P83, DOI 10.1016/j.psychresns.2006.12.011; FRIEDMAN L, 1991, BIOL PSYCHIAT, V29, P865, DOI 10.1016/0006-3223(91)90053-O; Fusar-Poli P, 2013, SCHIZOPHRENIA BULL, V39, P33, DOI 10.1093/schbul/sbr180; Giesel FL, 2012, EUR J RADIOL, V81, P1273, DOI 10.1016/j.ejrad.2011.03.002; Howes OD, 2007, BRIT J PSYCHIAT, V191, pS13, DOI 10.1192/bjp.191.51.s13; JAVITT DC, 1991, AM J PSYCHIAT, V148, P1301; Klirova M, 2013, EUR ARCH PSY CLIN N, V263, P475, DOI 10.1007/s00406-012-0368-x; Konicki PE, 2001, SCHIZOPHR RES, V48, P173, DOI 10.1016/S0920-9964(00)00130-4; Kuroki T, 2008, PROG BRAIN RES, V172, P199, DOI 10.1016/S0079-6123(08)00910-2; Langguth B, 2006, SCHIZOPHR RES, V84, P185, DOI 10.1016/j.schres.2006.02.019; Levine M S, 1998, Adv Pharmacol, V42, P724; Marsman A, 2013, SCHIZOPHR B, V1, P120; Moher D, 2009, BMJ-BRIT MED J, V21, P339, DOI DOI 10.1136/BMJ.B2535; Molina R. V., 1997, SCHIZOPHR RES, V25, P11; Molina Rodriguez V., 2003, PSYCHIAT RES, V124, P153; Molina Rodriguez V., 2007, PHARMACOPSYCHIATRY, V40, P157; Molina Rodriguez V., 2008, PROG NEUROPSYCHOPHAR, V32, P948; Molina Rodriguez V., 2005, PSYCHOPHARMACOLOGY B, V178, P17; OLNEY JW, 1995, ARCH GEN PSYCHIAT, V52, P998; Remington G, 2012, J CLIN PSYCHOPHARM, V32, P95, DOI 10.1097/JCP.0b013e31823f913e; Rodriguez VM, 1997, PSYCHIAT RES-NEUROIM, V76, P51, DOI 10.1016/S0925-4927(97)00057-7; Rodriguez VM, 1996, AM J PSYCHIAT, V153, P1343; SATO M, 1992, SCHIZOPHRENIA BULL, V18, P115; Schreiber S, 2002, PSYCHIAT RES-NEUROIM, V116, P113, DOI 10.1016/S0925-4927(02)00065-3; Sommer IE, 2012, SCHIZOPHRENIA BULL, V38, P1003, DOI 10.1093/schbul/sbr004; Sun J, 2009, ACTA PSYCHIAT SCAND, V120, P265, DOI 10.1111/j.1600-0447.2009.01389.x; Suzuki T, 2011, PSYCHOPHARMACOL BULL, V44, P32; Tauscher J, 1999, PSYCHOPHARMACOLOGY, V141, P175, DOI 10.1007/s002130050822; Vercammen A, 2010, J PSYCHIATR RES, V44, P725, DOI 10.1016/j.jpsychires.2009.12.011; West AR, 2003, ANN NY ACAD SCI, V1003, P53, DOI 10.1196/annals.1300.004; Yamamoto H, 1999, INT J NEUROPSYCHOP, V2, P155, DOI 10.1017/S1461145799001480; Yilmaz Z, 2012, SCHIZOPHR RES, V140, P214, DOI 10.1016/j.schres.2012.06.027; Yoshimura R, 2003, INT CLIN PSYCHOPHARM, V18, P107, DOI 10.1097/01.yic.0000056180.28244.da	112	3	3	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0920-9964	1573-2509		SCHIZOPHR RES	Schizophr. Res.	MAY	2015	164	1-3					164	175		10.1016/j.schres.2015.01.043		12	Psychiatry	Psychiatry	CG5MX	WOS:000353337100024		
J	Son, S; Kubota, M; Miyata, J; Fukuyama, H; Aso, T; Urayama, SI; Murai, T; Takahashi, H				Son, Shuraku; Kubota, Manabu; Miyata, Jun; Fukuyama, Hidenao; Aso, Toshihiko; Urayama, Shin-Ichi; Murai, Toshiya; Takahashi, Hidehiko			Creativity and positive symptoms in schizophrenia revisited: Structural connectivity analysis with diffusion tensor imaging	SCHIZOPHRENIA RESEARCH			English	Article						Automatic spreading activation; Phonological fluency; Delusions; Interhemispheric dysconnectivity; Executive dysfunction; Corpus callosum	WHITE-MATTER INTEGRITY; VERBAL FLUENCY; DIVERGENT THINKING; JAPANESE VERSION; THOUGHT-DISORDER; CORPUS-CALLOSUM; PSYCHOPATHOLOGY; COGNITION; VALIDATION; ACTIVATION	Both creativity and schizotypy are suggested to be manifestations of the hyperactivation of unusual or remote concepts/words. However, the results of studies on creativity in schizophrenia are diverse, possibly due to the multifaceted aspects of creativity and difficulties of differentiating adaptive creativity from pathological schizotypy/positive symptoms. To date, there have been no detailed studies comprehensively investigating creativity, positive symptoms including delusions, and their neural bases in schizophrenia. In this study, we investigated 43 schizophrenia and 36 healthy participants using diffusion tensor imaging. We used idea, design, and verbal (semantic and phonological) fluency tests as creativity scores and Peters Delusions Inventory as delusion scores. Subsequently, we investigated group differences in every psychological score, correlations between fluency and delusions, and relationships between these scores and whitematter integrity using tract-based spatial statistics (TBSS). In schizophrenia, idea and verbal fluency were significantly lower in general, and delusion score was higher than in healthy controls, whereas there were no group differences in design fluency. We also found positive correlation between phonological fluency and delusions in schizophrenia. By correlation analyses using TBSS, we found that the anterior part of corpus callosum was the substantially overlapped area, negatively correlated with both phonological fluency and delusion severity. Our results suggest that the anterior interhemispheric dysconnectivity might be associated with executive dysfunction, and disinhibited automatic spreading activation in the semantic network was manifested as uncontrollable phonological fluency or delusions. This dysconnectivity could be one possible neural basis that differentiates pathological positive symptoms from adaptive creativity. (C) 2015 Elsevier B.V. All rights reserved.	[Son, Shuraku; Kubota, Manabu; Miyata, Jun; Murai, Toshiya; Takahashi, Hidehiko] Kyoto Univ, Grad Sch Med, Dept Psychiat, Sakyo Ku, Kyoto 6068507, Japan; [Fukuyama, Hidenao; Aso, Toshihiko; Urayama, Shin-Ichi] Kyoto Univ, Grad Sch Med, Human Brain Res Ctr, Sakyo Ku, Kyoto 6068507, Japan	Takahashi, H (reprint author), Kyoto Univ, Grad Sch Med, Dept Psychiat, Sakyo Ku, 54 Shogoin Kawaharacho, Kyoto 6068507, Japan.	hidehiko@kuhp.kyoto-u.ac.jp			Japan Society for the Promotion of Science [23680045, 23791329]; Ministry of Education, Culture, Sports, Science and Technology of Japan (MEXT) [24243061, 23390290, 22220003, 23118004, 23120009]	This work was supported by grants-in-aid for scientific research A (24243061), B (23390290), S (22220003), and on innovative areas (23118004, 23120009), from the Ministry of Education, Culture, Sports, Science and Technology of Japan (MEXT), and Grants-in-Aid for Young Scientists A (23680045), B (23791329) from the Japan Society for the Promotion of Science. A part of this study is the result of Development of BMI Technologies for Clinical Application carried out under the Strategic Research Program for Brain Sciences by MEXT.	Fujino J, 2014, PROG NEURO-PSYCHOPH, V48, P117, DOI 10.1016/j.pnpbp.2013.09.018; Matsuoka K, 2006, PSYCHIAT CLIN NEUROS, V60, P332, DOI 10.1111/j.1440-1819.2006.01510.x; Genovese CR, 2002, NEUROIMAGE, V15, P870, DOI 10.1006/nimg.2001.1037; Edwards TJ, 2014, BRAIN, V137, P1579, DOI 10.1093/brain/awt358; KAY SR, 1987, SCHIZOPHRENIA BULL, V13, P261; Smith SM, 2009, NEUROIMAGE, V44, P83, DOI 10.1016/j.neuroimage.2008.03.061; Friston KJ, 1998, SCHIZOPHR RES, V30, P115, DOI 10.1016/S0920-9964(97)00140-0; Shobe ER, 2009, BRAIN COGNITION, V71, P204, DOI 10.1016/j.bandc.2009.08.017; Runco MA, 2004, ANNU REV PSYCHOL, V55, P657, DOI 10.1146/annurev.psych.55.090902.141502; Bhattacharya J, 2005, HUM BRAIN MAPP, V26, P1, DOI 10.1002/hbm.20104; Peters E, 2004, SCHIZOPHRENIA BULL, V30, P1005; OLDFIELD RC, 1971, NEUROPSYCHOLOGIA, V9, P97, DOI 10.1016/0028-3932(71)90067-4; O'Leary DS, 2000, J NEUROPSYCH CLIN N, V12, P4; FRITH CD, 1991, NEUROPSYCHOLOGIA, V29, P1137, DOI 10.1016/0028-3932(91)90029-8; Mohr C, 2001, J PSYCHOLINGUIST RES, V30, P475, DOI 10.1023/A:1010461429079; Mamah D, 2010, PSYCHIAT RES-NEUROIM, V183, P144, DOI 10.1016/j.pscychresns.2010.04.013; Nemoto T, 2005, BEHAV NEUROL, V16, P217; Keefe RSE, 2004, SCHIZOPHR RES, V68, P283, DOI 10.1016/j.schres.2003.09.011; Lehman AF, 2004, AM J PSYCHIAT, V161, P1; Nelson B, 2010, SCHIZOPHRENIA BULL, V36, P388, DOI 10.1093/schbul/sbn098; ALLEN HA, 1993, BRIT J PSYCHIAT, V163, P769, DOI 10.1192/bjp.163.6.769; Paul LK, 2007, NAT REV NEUROSCI, V8, P287, DOI 10.1038/nrn2107; Kyaga S, 2011, BRIT J PSYCHIAT, V199, P373, DOI 10.1192/bjp.bp.110.085316; Nemoto T, 2007, PROG NEURO-PSYCHOPH, V31, P517, DOI 10.1016/j.pnpbp.2006.12.001; Kreher DA, 2008, SCHIZOPHRENIA BULL, V34, P473, DOI 10.1093/schbul/sbm108; Kaneda Y, 2007, PSYCHIAT CLIN NEUROS, V61, P602, DOI 10.1111/j.1440-1819.2007.01725.x; Dollinger SJ, 2004, CREATIVITY RES J, V16, P35, DOI 10.1207/s15326934crj1601_4; Bhattacharya J, 2002, COGNITIVE BRAIN RES, V13, P179, DOI 10.1016/S0926-6410(01)00110-0; Badzakova-Trajkov G, 2011, NEUROPSYCHOLOGIA, V49, P2896, DOI 10.1016/j.neuropsychologia.2011.06.016; Benson T.L., 2013, FRONT HUM NEUROSCI, V7; Berlucchi G, 2012, CORTEX, V48, P36, DOI 10.1016/j.cortex.2011.04.008; Cardillo ER, 2004, J COGNITIVE NEUROSCI, V16, P1552, DOI 10.1162/0898929042568523; Debruille JB, 2007, SCHIZOPHR RES, V89, P261, DOI 10.1016/j.schres.2006.07.014; Fisher JE, 2004, J RES PERS, V38, P24, DOI 10.1016/j.jrp.2003.09.014; Fisher JE, 2013, PERS INDIV DIFFER, V54, P70, DOI 10.1016/j.paid.2012.08.003; Guilford J. P., 1959, PERSONALITY; Hirose K., 2014, J PSYCHIAT RES; Inada T, 2008, JPN J CLIN PSYCHOPHA, V11, P887; Jaracz J, 2012, J NERV MENT DIS, V200, P588, DOI 10.1097/NMD.0b013e31825bfc49; Jung RE, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009818; Kerns JG, 1999, PSYCHIAT RES, V87, P29, DOI 10.1016/S0165-1781(99)00052-9; Leonhard D, 1998, NEUROPSY NEUROPSY BE, V11, P177; Lindamer LA, 1997, ARCH CLIN NEUROPSYCH, V12, P358; Matsuoka K., 2007, JAPANESE ADULT READI; Mumford MD, 2003, CREATIVITY RES J, V15, P107, DOI 10.1207/S15326934CRJ152&3_01; Sass LA, 2000, CREATIVITY RES J, V13, P55; Spitzer M, 1997, SCHIZOPHRENIA BULL, V23, P29; Sumiyoshi C, 2005, SCHIZOPHR RES, V74, P91, DOI 10.1016/j.schres.2004.05.011; Tsakanikos E, 2005, PERS INDIV DIFFER, V39, P705, DOI 10.1016/j.paid.2005.02.019; Waseda Creativity Society, 1984, HDB TCT CREAT TESTS	50	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0920-9964	1573-2509		SCHIZOPHR RES	Schizophr. Res.	MAY	2015	164	1-3					221	226		10.1016/j.schres.2015.03.009		6	Psychiatry	Psychiatry	CG5MX	WOS:000353337100033		
J	Nakajima, S; Caravaggio, F; Mamo, DC; Mulsant, BH; Chung, JK; Plitman, E; Iwata, Y; Gerretsen, P; Uchida, H; Suzuki, T; Mar, W; Wilson, AA; Houle, S; Graff-Guerrero, A				Nakajima, Shinichiro; Caravaggio, Fernando; Mamo, David C.; Mulsant, Benoit H.; Chung, Jun Ku; Plitman, Eric; Iwata, Yusuke; Gerretsen, Philip; Uchida, Hiroyuki; Suzuki, Takefumi; Mar, Wanna; Wilson, Alan A.; Houle, Sylvain; Graff-Guerrero, Ariel			Dopamine D-2/3 receptor availability in the striatum of antipsychotic-free older patients with schizophrenia-A [C-11]-raclopride PET study	SCHIZOPHRENIA RESEARCH			English	Article						Schizophrenia; Aging; Dopamine; PET; D-2/3 receptor	POSITRON-EMISSION-TOMOGRAPHY; LIVING HUMAN BRAIN; RATING-SCALE; BINDING; QUANTIFICATION; NEURORECEPTORS; ILLNESS; HUMANS; ADULTS; MODEL	Background: No study has examined dopamine D-2/3 receptor (D2/3R) availability in antipsychotic-free older patients with schizophrenia. Methods: We included patients with schizophrenia 50 years or older who were antipsychotic-free for at least 3 months. We compared non-displaceable binding potential (BPND) of [C-11]-raclopride in the caudate, putamen, ventral striatum, and globus pallidus between patients and age-and sex-matched healthy controls. Results: Ten patients participated (antipsychotic-naive = 4). No differences in BPND were found between patients and controls in any ROIs (F(1, 72) = .42, p = .52). Conclusion: The preliminary results suggest no differences in D2/3R availability between antipsychotic-free older patients with schizophrenia and controls. (C) 2015 Elsevier B.V. All rights reserved.	[Nakajima, Shinichiro; Caravaggio, Fernando; Chung, Jun Ku; Plitman, Eric; Iwata, Yusuke; Gerretsen, Philip; Mar, Wanna; Wilson, Alan A.; Houle, Sylvain; Graff-Guerrero, Ariel] Ctr Addict & Mental Hlth, Res Imaging Ctr, Toronto, ON M5T 1R8, Canada; [Nakajima, Shinichiro; Mulsant, Benoit H.; Gerretsen, Philip; Uchida, Hiroyuki; Graff-Guerrero, Ariel] Ctr Addict & Mental Hlth, Geriatr Mental Hlth Div, Toronto, ON M5T 1R8, Canada; [Nakajima, Shinichiro; Mulsant, Benoit H.; Iwata, Yusuke; Gerretsen, Philip; Graff-Guerrero, Ariel] Univ Toronto, Dept Psychiat, Toronto, ON, Canada; [Nakajima, Shinichiro; Iwata, Yusuke; Uchida, Hiroyuki; Suzuki, Takefumi] Keio Univ, Sch Med, Dept Neuropsychiat, Tokyo, Japan; [Caravaggio, Fernando; Chung, Jun Ku; Plitman, Eric; Gerretsen, Philip] Univ Toronto, Inst Med Sci, Toronto, ON, Canada; [Mamo, David C.] Univ Malta, Dept Psychiat, Fac Med, Msida, Malta; [Mamo, David C.] Univ Malta, Dept Psychiat, Fac Hlth Sci, Msida, Malta; [Mulsant, Benoit H.; Wilson, Alan A.; Houle, Sylvain; Graff-Guerrero, Ariel] Ctr Addict & Mental Hlth, Campbell Res Inst, Toronto, ON M5T 1R8, Canada	Graff-Guerrero, A (reprint author), Ctr Addict & Mental Hlth, Multimodal Imaging Grp, Res Imaging Ctr, 250 Coll St, Toronto, ON M5T 1R8, Canada.	shinichiro.l.nakajima@gmail.com; fernando.caravaggio@gmail.com; mamodc@gmail.com; benoit.mulsant@camh.ca; junku.chung@mail.utoronto.ca; plitmaneric@gmail.com; yusuke.iwata2010@gmail.com; philgerretsen@yahoo.com; hiroyuki.uchida.hu@gmail.com; takefumi@oak.dti.ne.jp; wanna.mar@camh.ca; alan.wilson@camh.ca; sylvain.houle@camh.ca; ariel_graff@yahoo.com.mx	Uchida, Hiroyuki/I-4867-2015; 	Uchida, Hiroyuki/0000-0002-0628-7036; Gerretsen, Philip/0000-0003-4053-6814	Canadian Institutes of Health Research [MOP-97946, MOP-114989]; US National Institutes of Health [RO1MH084886]	This study was supported by the Canadian Institutes of Health Research (MOP-97946 and MOP-114989; Drs. Graff-Guerrero and Mamo) and the US National Institutes of Health (RO1MH084886) (Drs. Graff-Guerrero and Mamo).	American Psychiatric Association, 1994, DIAGN STAT MAN MENT; Nader MA, 2005, AM J PSYCHIAT, V162, P1473, DOI 10.1176/appi.ajp.162.8.1473; Tziortzi AC, 2011, NEUROIMAGE, V54, P264, DOI 10.1016/j.neuroimage.2010.06.044; KAY SR, 1987, SCHIZOPHRENIA BULL, V13, P261; Sheehan DV, 1998, J CLIN PSYCHIAT, V59, P22, DOI 10.4088/JCP.09m05305whi; Caligiuri MP, 1999, J CLIN PSYCHOPHARM, V19, P322, DOI 10.1097/00004714-199908000-00007; Graff-Guerrero A, 2008, HUM BRAIN MAPP, V29, P400, DOI 10.1002/hbm.20392; Jeste DV, 2011, SCHIZOPHRENIA BULL, V37, P451, DOI 10.1093/schbul/sbr026; Backman L, 2006, NEUROSCI BIOBEHAV R, V30, P791, DOI 10.1016/j.neubiorev.2006.06.005; MILLER MD, 1992, PSYCHIAT RES, V41, P237, DOI 10.1016/0165-1781(92)90005-N; Gunn RN, 1997, NEUROIMAGE, V6, P279, DOI 10.1006/nimg.1997.0303; Wong DF, 1997, J CEREBR BLOOD F MET, V17, P331; Wong DF, 1997, J CEREBR BLOOD F MET, V17, P316; Graff-Guerrero A, 2010, INT J NEUROPSYCHOPH, V13, P273, DOI 10.1017/S1461145709990642; Lammertsma AA, 1996, NEUROIMAGE, V4, P153, DOI 10.1006/nimg.1996.0066; Wilson AA, 2000, NUCL MED BIOL, V27, P529, DOI 10.1016/S0969-8051(00)00132-3; Mawlawi O, 2001, J CEREBR BLOOD F MET, V21, P1034; Studholme C, 1997, MED PHYS, V24, P25, DOI 10.1118/1.598130; Howes OD, 2012, ARCH GEN PSYCHIAT, V69, P776, DOI 10.1001/archgenpsychiatry.2012.169; BARNES TRE, 1989, BRIT J PSYCHIAT, V154, P672, DOI 10.1192/bjp.154.5.672; Graff-Guerrero A., 2014, AM COLL NEUR ANN M P; Jeste DV, 2013, SCHIZOPHRENIA BULL, V39, P966, DOI 10.1093/schbul/sbt043; Lingjaerde O, 1987, Acta Psychiatr Scand Suppl, V334, P1; Nakajima S., LACK AGE DEPENDENT D; NORDSTROM AL, 1992, HUM PSYCHOPHARM CLIN, V7, P157, DOI 10.1002/hup.470070302; Overall JE, 1962, PSYCHOL REP, V10, P790; Simpson G M, 1970, Acta Psychiatr Scand Suppl, V212, P11; Talvik M, 2006, PSYCHIAT RES-NEUROIM, V148, P165, DOI 10.1016/j.pscychresns.2006.05.009; Uchida H, 2009, J CLIN PSYCHIAT, V70, P397	29	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0920-9964	1573-2509		SCHIZOPHR RES	Schizophr. Res.	MAY	2015	164	1-3					263	267		10.1016/j.schres.2015.02.020		5	Psychiatry	Psychiatry	CG5MX	WOS:000353337100039		
J	Tanaka, A; Sakaguchi, S				Tanaka, Atsushi; Sakaguchi, Shimon			Early life Aire	SCIENCE			English	Editorial Material							REGULATORY T-CELLS; THYMIC EPITHELIAL-CELLS; SELF-TOLERANCE		[Tanaka, Atsushi; Sakaguchi, Shimon] Osaka Univ, Immunol Frontier Res Ctr, Dept Expt Immunol, Osaka 5650871, Japan	Tanaka, A (reprint author), Osaka Univ, Immunol Frontier Res Ctr, Dept Expt Immunol, Osaka 5650871, Japan.	shimon@ifrec.osaka-u.ac.jp	Sakaguchi, Shimon/C-9535-2009				Aschenbrenner K, 2007, NAT IMMUNOL, V8, P351, DOI 10.1038/ni1444; Yang SY, 2015, SCIENCE, V348, P589, DOI 10.1126/science.aaa7017; Hinterberger M, 2010, NAT IMMUNOL, V11, P512, DOI 10.1038/ni.1874; Asano M, 1996, J EXP MED, V184, P387, DOI 10.1084/jem.184.2.387; Husebye ES, 2010, IMMUNITY, V32, P479, DOI 10.1016/j.immuni.2010.03.016; Darrasse-Jeze G, 2005, BLOOD, V105, P4715, DOI 10.1182/blood-2004-10-4051; Kyewski B, 2006, ANNU REV IMMUNOL, V24, P571, DOI 10.1146/annurev.immunol.23.021704.115601; Malchow S, 2013, SCIENCE, V339, P1219, DOI 10.1126/science.1233913; Guerau-De-Arellano M, 2009, J EXP MED, V206, P1245, DOI 10.1084/jem.20090300; Perry JSA, 2014, IMMUNITY, V41, P414, DOI 10.1016/j.immuni.2014.08.007; Romagnoli P, 2012, J IMMUNOL, V189, P3831, DOI 10.4049/jimmunol.1201564; Sakaguchi S, 2004, ANNU REV IMMUNOL, V22, P531, DOI 10.1146/annurev.immunol.21.120601.141122	12	1	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 1	2015	348	6234					506	507		10.1126/science.aab2998		2	Multidisciplinary Sciences	Science & Technology - Other Topics	CH1JR	WOS:000353778100024		
J	Miao, JW; Ishikawa, T; Robinson, IK; Murnane, MM				Miao, Jianwei; Ishikawa, Tetsuya; Robinson, Ian K.; Murnane, Margaret M.			Beyond crystallography: Diffractive imaging using coherent x-ray light sources	SCIENCE			English	Review							FREE-ELECTRON LASER; 3-DIMENSIONAL STRUCTURE DETERMINATION; MICROSCOPY; RESOLUTION; NANOSCALE; PROTEIN; NANOCRYSTALS; REFLECTION; DYNAMICS; OBJECTS	X-ray crystallography has been central to the development of many fields of science over the past century. It has now matured to a point that as long as good-quality crystals are available, their atomic structure can be routinely determined in three dimensions. However, many samples in physics, chemistry, materials science, nanoscience, geology, and biology are noncrystalline, and thus their three-dimensional structures are not accessible by traditional x-ray crystallography. Overcoming this hurdle has required the development of new coherent imaging methods to harness new coherent x-ray light sources. Here we review the revolutionary advances that are transforming x-ray sources and imaging in the 21st century.	[Miao, Jianwei] Univ Calif Los Angeles, Dept Phys & Astron, Los Angeles, CA 90095 USA; [Miao, Jianwei] Univ Calif Los Angeles, Calif NanoSyst Inst, Los Angeles, CA 90095 USA; [Ishikawa, Tetsuya] RIKEN SPring 8 Ctr, Sayo, Hyogo 6795148, Japan; [Robinson, Ian K.] UCL, London Ctr Nanotechnol, London WC1H 0AH, England; [Robinson, Ian K.] Res Complex Harwell, Oxford OX11 0DE, England; [Murnane, Margaret M.] Univ Colorado, JILA, Boulder, CO 80309 USA; [Murnane, Margaret M.] NIST, Boulder, CO 80309 USA	Miao, JW (reprint author), Univ Calif Los Angeles, Dept Phys & Astron, Los Angeles, CA 90095 USA.	miao@physics.ucla.edu	Ishikawa, Tetsuya/I-4775-2012	Ishikawa, Tetsuya/0000-0002-6906-9909	Defense Advanced Research Projects Agency PULSE program through a grant from AMRDEC; NSF [DMR-1437263]; NSF; DOE; SRC; ERC "Advanced" grant	We thank C. Pellegrini and J. M. Rodenburg for stimulating discussions and H. Jiang, J. Zhou, Y. Yang, and D. Adams for help with the figures and references. J. M. and M. M. M. acknowledge support from the Defense Advanced Research Projects Agency PULSE program through a grant from AMRDEC. J. M. thanks support from NSF (grant DMR-1437263). M. M. M. thanks support from NSF, DOE, and SRC. I.K.R. acknowledges support from an ERC "Advanced" grant. The University of Colorado and the University of Michigan have patents coauthored by M. M. M. in the area of high harmonic sources: U.S. Patent 8,462,824 (2013) and U.S. Patent 6151155 (2000).	Szameit A, 2012, NAT MATER, V11, P455, DOI [10.1038/nmat3289, 10.1038/NMAT3289]; Chapman HN, 2006, NAT PHYS, V2, P839, DOI 10.1038/nphys461; Song CY, 2008, PHYS REV LETT, V100, DOI 10.1103/PhysRevLett.100.025504; Barty A, 2008, NAT PHOTONICS, V2, P415, DOI 10.1038/nphoton.2008.128; Miao JW, 1999, NATURE, V400, P342, DOI 10.1038/22498; Fung R, 2009, NAT PHYS, V5, P64, DOI [10.1038/nphys1129, 10.1038/NPHYS1129]; Roy S, 2011, NAT PHOTONICS, V5, P243, DOI [10.1038/nphoton.2011.11, 10.1038/NPHOTON.2011.11]; Miao JW, 2003, P NATL ACAD SCI USA, V100, P110, DOI 10.1073/pnas.232691299; Liu W, 2013, SCIENCE, V342, P1521, DOI 10.1126/science.1244142; Dierolf M, 2010, NATURE, V467, P436, DOI 10.1038/nature09419; Williams GJ, 2006, PHYS REV LETT, V97, DOI 10.1103/PhysRevLett.97.025506; Nishino Y, 2009, PHYS REV LETT, V102, DOI 10.1103/PhysRevLett.102.018101; Clark JN, 2013, SCIENCE, V341, P56, DOI 10.1126/science.1236034; Tenboer J, 2014, SCIENCE, V346, P1242, DOI 10.1126/science.1259357; Miao J, 1998, J OPT SOC AM A, V15, P1662, DOI 10.1364/JOSAA.15.001662; Seaberg MD, 2011, OPT EXPRESS, V19, P22470, DOI 10.1364/OE.19.022470; Seaberg MD, 2014, OPTICA, V1, P39, DOI 10.1364/OPTICA.1.000039; Chapman HN, 2011, NATURE, V470, P73, DOI 10.1038/nature09750; Kern J, 2013, SCIENCE, V340, P491, DOI 10.1126/science.1234273; Neutze R, 2000, NATURE, V406, P752, DOI 10.1038/35021099; Pfeifer MA, 2006, NATURE, V442, P63, DOI 10.1038/nature04867; Shapiro DA, 2014, NAT PHOTONICS, V8, P765, DOI [10.1038/nphoton.2014.207, 10.1038/NPHOTON.2014.207]; Ishikawa T, 2012, NAT PHOTONICS, V6, P540, DOI 10.1038/nphoton.2012.141; Jiang HD, 2010, P NATL ACAD SCI USA, V107, P11234, DOI 10.1073/pnas.1000156107; Chapman HN, 2006, J OPT SOC AM A, V23, P1179, DOI 10.1364/JOSAA.23.001179; Tripathi A, 2011, P NATL ACAD SCI USA, V108, P13393, DOI 10.1073/pnas.1104304108; Nelson J, 2010, P NATL ACAD SCI USA, V107, P7235, DOI 10.1073/pnas.0910874107; Seibert MM, 2011, NATURE, V470, P78, DOI 10.1038/nature09748; Shapiro D, 2005, P NATL ACAD SCI USA, V102, P15343, DOI 10.1073/pnas.0503305102; Sun T, 2012, NAT PHOTONICS, V6, P586, DOI 10.1038/NPHOTON.2012.178; Emma P, 2010, NAT PHOTONICS, V4, P641, DOI [10.1038/nphoton.2010.176, 10.1038/NPHOTON.2010.176]; Miao JW, 2001, P NATL ACAD SCI USA, V98, P6641, DOI 10.1073/pnas.111083998; Song CY, 2008, PHYS REV LETT, V101, DOI 10.1103/PhysRevLett.101.158101; Siemens ME, 2010, NAT MATER, V9, P26, DOI [10.1038/nmat2568, 10.1038/NMAT2568]; Hoogeboom-Pot KM, 2015, P NATL ACAD SCI USA, V112, P4846, DOI 10.1073/pnas.1503449112; Robinson IK, 1999, PHYS REV B, V60, P9965, DOI 10.1103/PhysRevB.60.9965; Loh NTD, 2009, PHYS REV E, V80, DOI 10.1103/PhysRevE.80.026705; Sakdinawat A, 2010, NAT PHOTONICS, V4, P840, DOI 10.1038/nphoton.2010.267; Turgut E, 2013, PHYS REV LETT, V110, DOI 10.1103/PhysRevLett.110.197201; Thibault P, 2008, SCIENCE, V321, P379, DOI 10.1126/science.1158573; Raines KS, 2010, NATURE, V463, P214, DOI 10.1038/nature08705; Popmintchev T, 2012, SCIENCE, V336, P1287, DOI 10.1126/science.1218497; FIENUP JR, 1978, OPT LETT, V3, P27, DOI 10.1364/OL.3.000027; Miao JW, 2002, PHYS REV LETT, V89, DOI 10.1103/PhysRevLett.89.088303; Maiden AM, 2009, ULTRAMICROSCOPY, V109, P1256, DOI 10.1016/j.ultramic.2009.05.012; Ekeberg T, 2015, PHYS REV LETT, V114, DOI 10.1103/PhysRevLett.114.098102; Gallagher-Jones M, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4798; Hantke MF, 2014, NAT PHOTONICS, V8, P943, DOI 10.1038/NPHOTON.2014.270; Hernandez-Garcia C, 2013, PHYS REV LETT, V111, DOI 10.1103/PhysRevLett.111.033002; Huang XJ, 2009, OPT EXPRESS, V17, P13541, DOI 10.1364/OE.17.013541; Jiang HD, 2013, PHYS REV LETT, V110, DOI 10.1103/PhysRevLett.110.205501; Jiang HD, 2008, PHYS REV LETT, V100, DOI 10.1103/PhysRevLett.100.038103; Kfir O, 2015, NAT PHOTONICS, V9, P99, DOI 10.1038/NPHOTON.2014.293; Kimura T, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4052; Newton MC, 2010, NAT MATER, V9, P120, DOI [10.1038/nmat2607, 10.1038/NMAT2607]; Nicolas JD, 2014, J APPL CRYSTALLOGR, V47, P1596, DOI 10.1107/S1600576714016896; Robinson IK, 2001, PHYS REV LETT, V87, DOI 10.1103/PhysRevLett.87.195505; Rodenburg JM, 2007, PHYS REV LETT, V98, DOI 10.1103/PhysRevLett.98.034801; Rudolf D, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms2029; Takahashi Y, 2010, PHYS REV B, V82, DOI 10.1103/PhysRevB.82.214102; Xu R, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5061	61	26	26	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 1	2015	348	6234					530	535		10.1126/science.aaa1394		6	Multidisciplinary Sciences	Science & Technology - Other Topics	CH1JR	WOS:000353778100031		
J	Chen, S; Itoh, Y; Masuda, T; Shimizu, S; Zhao, J; Ma, J; Nakamura, S; Okuro, K; Noguchi, H; Uosaki, K; Aida, T				Chen, Shuo; Itoh, Yoshimitsu; Masuda, Takuya; Shimizu, Seishi; Zhao, Jun; Ma, Jing; Nakamura, Shugo; Okuro, Kou; Noguchi, Hidenori; Uosaki, Kohei; Aida, Takuzo			Subnanoscale hydrophobic modulation of salt bridges in aqueous media	SCIENCE			English	Article							SELF-ASSEMBLED MONOLAYERS; AIR/WATER INTERFACE; WATER; SURFACE; FLUORESCENCE; VOLTAGE; ENERGY; FORCE; PH	Polar interactions such as electrostatic forces and hydrogen bonds play an essential role in biological molecular recognition. On a protein surface, polar interactions occur mostly in a hydrophobic environment because nonpolar amino acid residues cover similar to 75% of the protein surface. We report that ionic interactions on a hydrophobic surface are modulated by their subnanoscale distance to the surface. We developed a series of ionic head groups-appended self-assembled monolayers with C2, C6, C8, and C12 space-filling alkyl chains, which capture a dendritic guest via the formation of multiple salt bridges. The guest release upon protonolysis is progressively suppressed when its distance from the background hydrophobe changes from 1.2 (C2) to 0.2 (C12) nanometers, with an increase in salt bridge strength of similar to 3.9 kilocalories per mole.	[Chen, Shuo; Itoh, Yoshimitsu; Okuro, Kou; Aida, Takuzo] Univ Tokyo, Sch Engn, Dept Chem & Biotechnol, Bunkyo Ku, Tokyo 1138656, Japan; [Masuda, Takuya; Noguchi, Hidenori; Uosaki, Kohei] Natl Inst Mat Sci, Global Res Ctr Environm & Energy Based Nanomat Sc, Tsukuba, Ibaraki 3050044, Japan; [Shimizu, Seishi] Univ York, Dept Chem, York Struct Biol Lab, York YO10 5DD, N Yorkshire, England; [Zhao, Jun; Ma, Jing] Nanjing Univ, Sch Chem & Chem Engn, Collaborat Innovat Ctr Chem Life Sci, Nanjing 210093, Jiangsu, Peoples R China; [Nakamura, Shugo] Univ Tokyo, Grad Sch Agr & Life Sci, Dept Biotechnol, Bunkyo Ku, Tokyo 1138657, Japan; [Noguchi, Hidenori; Uosaki, Kohei] Natl Inst Mat Sci, Int Ctr Mat Nanoarchitecton WPI MANA, Tsukuba, Ibaraki 3050044, Japan; [Noguchi, Hidenori; Uosaki, Kohei] Hokkaido Univ, Grad Sch Chem Sci & Engn, Sapporo, Hokkaido 0600810, Japan; [Aida, Takuzo] RIKEN, Ctr Emergent Matter Sci, Wako, Saitama 3510198, Japan	Itoh, Y (reprint author), Univ Tokyo, Sch Engn, Dept Chem & Biotechnol, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1138656, Japan.	itoh@macro.t.u-tokyo.ac.jp; aida@macro.t.u-tokyo.ac.jp	Uosaki, Kohei/A-8217-2008; Itoh, Yoshimitsu/G-8162-2012	Itoh, Yoshimitsu/0000-0002-8356-7605	Japan Society for the Promotion of Science (JSPS) through its Funding Program for World-Leading Innovative R&D on Science and Technology (FIRST Program); Ministry of Education, Culture, Sports, Science and Technology (MEXT), Japan; Platform for Drug Discovery, Informatics, and Structural Life Science from MEXT, Japan; National Natural Science Foundation of China [21273102]	We thank N. Matubayashi from Division of Chemical Engineering, Graduate School of Engineering Science, Osaka University for valuable discussion. We also thank E. Silver for generous discussion. This work was supported by the Japan Society for the Promotion of Science (JSPS) through its Funding Program for World-Leading Innovative R&D on Science and Technology (FIRST Program). Y. I. acknowledges the Ministry of Education, Culture, Sports, Science and Technology (MEXT), Japan, Grant-in-Aid for Young Scientists B. S.N. is partly supported by the Platform for Drug Discovery, Informatics, and Structural Life Science from MEXT, Japan. K.U. and H.N. thank the World Premier International Research Center (WPI) Initiative on Materials Nanoarchitectonics from MEXT, Japan. J.M. is supported by the National Natural Science Foundation of China (no. 21273102).	Schaefer M, 1996, J PHYS CHEM-US, V100, P1578, DOI 10.1021/jp9521621; Williams DH, 2004, ANGEW CHEM INT EDIT, V43, P6596, DOI 10.1002/anie.200300644; Chandler D, 2005, NATURE, V437, P640, DOI 10.1038/nature04162; Yeung CL, 2010, ADV FUNCT MATER, V20, P2657, DOI 10.1002/adfm.201000411; Snyder PW, 2014, EUR PHYS J-SPEC TOP, V223, P853, DOI 10.1140/epjst/e2013-01818-y; DIETRICH B, 1979, HELV CHIM ACTA, V62, P2763, DOI 10.1002/hlca.19790620827; ALIVISATOS AP, 1987, J CHEM PHYS, V86, P6540, DOI 10.1063/1.452396; Jungwirth P, 2006, CHEM REV, V106, P1259, DOI 10.1021/cr0403741; MARTIN MM, 1975, J LUMIN, V10, P381, DOI 10.1016/0022-2313(75)90003-4; Dill KA, 2012, SCIENCE, V338, P1042, DOI 10.1126/science.1219021; Venkateshwaran V, 2014, P NATL ACAD SCI USA, V111, P8729, DOI 10.1073/pnas.1403294111; Lahann J, 2003, SCIENCE, V299, P371, DOI 10.1126/science.1078933; Wang Q, 2010, NATURE, V463, P339, DOI 10.1038/nature08693; Shen YR, 2006, CHEM REV, V106, P1140, DOI 10.1021/cr040377d; Ng CCA, 2012, ANGEW CHEM INT EDIT, V51, P7706, DOI 10.1002/anie.201202118; Luo MX, 2012, J PHYS CHEM C, V116, P13964, DOI 10.1021/jp3020996; Onclin S, 2005, ANGEW CHEM INT EDIT, V44, P6282, DOI 10.1002/anie.200500633; Rant U, 2007, P NATL ACAD SCI USA, V104, P17364, DOI 10.1073/pnas.0703974104; Ball P, 2008, CHEM REV, V108, P74, DOI 10.1021/cr068037a; Valtiner M, 2012, J AM CHEM SOC, V134, P1746, DOI 10.1021/ja209653n; McArthur EA, 2004, J AM CHEM SOC, V126, P2260, DOI 10.1021/ja038062n; Nihonyanagi S, 2011, J AM CHEM SOC, V133, P16875, DOI 10.1021/ja2053754; Burgess I, 2006, LANGMUIR, V22, P4420, DOI 10.1021/la052767g; Bard AJ, 2001, ELECTROCHEMICAL METH; Ben-Naim A., 1992, STAT THERMODYNAMICS; Chorny I, 2005, J PHYS CHEM B, V109, P24056, DOI 10.1021/jp055043m; DIEHL H, 1985, TALANTA, V32, P159, DOI 10.1016/0039-9140(85)80049-7; Han Y, 2011, LANGMUIR, V27, P11951, DOI 10.1021/la2020995; Ma CD, 2015, NATURE, V517, P347, DOI 10.1038/nature14018; Morrow R, 2012, P ROY SOC A-MATH PHY, V468, P18, DOI 10.1098/rspa.2011.0323; Presiado I, 2011, J PHYS CHEM C, V115, P10245, DOI 10.1021/jp2008094; SCHELLMAN JA, 1953, J PHYS CHEM-US, V57, P472, DOI 10.1021/j150505a020; Teschke O, 2003, APPL PHYS LETT, V82, P1126, DOI 10.1063/1.1542945	33	1	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 1	2015	348	6234					555	559		10.1126/science.aaa7532		5	Multidisciplinary Sciences	Science & Technology - Other Topics	CH1JR	WOS:000353778100037		
J	Taylor, DW; Zhu, YF; Staals, RHJ; Kornfeld, JE; Shinkai, A; van der Oost, J; Nogales, E; Doudna, JA				Taylor, David W.; Zhu, Yifan; Staals, Raymond H. J.; Kornfeld, Jack E.; Shinkai, Akeo; van der Oost, John; Nogales, Eva; Doudna, Jennifer A.			Structures of the CRISPR-Cmr complex reveal mode of RNA target positioning	SCIENCE			English	Article							GUIDED SURVEILLANCE COMPLEX; CRYSTAL-STRUCTURE; DNA RECOGNITION; CLEAVAGE; ENDONUCLEASE; PROKARYOTES; SYSTEM; CAS9	Adaptive immunity in bacteria involves RNA-guided surveillance complexes that use CRISPR (clustered regularly interspaced short palindromic repeats)-associated (Cas) proteins together with CRISPR RNAs (crRNAs) to target invasive nucleic acids for degradation. Whereas type I and type II CRISPR-Cas surveillance complexes target double-stranded DNA, type III complexes target single-stranded RNA. Near-atomic resolution cryo-electron microscopy reconstructions of native type III Cmr (CRISPR RAMP module) complexes in the absence and presence of target RNA reveal a helical protein arrangement that positions the crRNA for substrate binding. Thumblike b hairpins intercalate between segments of duplexed crRNA: target RNA to facilitate cleavage of the target at 6-nucleotide intervals. The Cmr complex is architecturally similar to the type I CRISPR-Cascade complex, suggesting divergent evolution of these immune systems from a common ancestor.	[Taylor, David W.; Kornfeld, Jack E.; Nogales, Eva; Doudna, Jennifer A.] Univ Calif Berkeley, Howard Hughes Med Inst, Berkeley, CA 94720 USA; [Taylor, David W.; Nogales, Eva; Doudna, Jennifer A.] Univ Calif Berkeley, Calif Inst Quantitat Biosci, Berkeley, CA 94720 USA; [Zhu, Yifan; Staals, Raymond H. J.; van der Oost, John] Wageningen Univ, Lab Microbiol, Dept Agrotechnol & Food Sci, NL-6703 HB Wageningen, Netherlands; [Shinkai, Akeo] RIKEN SPring 8 Ctr, Mikazuki, Hyogo 6795148, Japan; [Shinkai, Akeo] RIKEN Struct Biol, Yokohama, Kanagawa 2300045, Japan; [Nogales, Eva; Doudna, Jennifer A.] Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA; [Nogales, Eva] Univ Calif Berkeley, Lawrence Berkeley Natl Lab, Life Sci Div, Berkeley, CA 94720 USA; [Doudna, Jennifer A.] Univ Calif Berkeley, Dept Chem, Berkeley, CA 94720 USA; [Doudna, Jennifer A.] Univ Calif Berkeley, Lawrence Berkeley Natl Lab, Phys Biosci Div, Berkeley, CA 94720 USA	Doudna, JA (reprint author), Univ Calif Berkeley, Howard Hughes Med Inst, Berkeley, CA 94720 USA.	enogales@lbl.gov; doudna@berkeley.edu	Shinkai, Akeo/E-8354-2013; 	Shinkai, Akeo/0000-0002-9867-0832; Taylor, David/0000-0002-6198-1194	Damon Runyon Cancer Research Foundation [DRG-2218-15]; University of Otago's Division of Health Sciences Career Development postdoctoral fellowship; Netherlands Organisation for Scientific Research (NWO) [024.002.002, 854.10.003]; Japan Society for the Promotion of Science [25440013]	The structures of intact apo-Cmr, smaller apo-Cmr, and target-bound Cmr have been deposited into the EMDataBank with accession codes EMD-2898, EMD-2899, and EMD-2900, respectively. We thank R. Louder, S. Howes, E. Kellogg, R. Zhang, P. Grob, Y. He, T. Houweling, Z. Yu, and M. J. de la Cruz for expert electron microscopy assistance. D.W.T is a Damon Runyon Fellow supported by the Damon Runyon Cancer Research Foundation (DRG-2218-15). R.H.J.S. was supported by the University of Otago's Division of Health Sciences Career Development postdoctoral fellowship. Y. Z. and J.v.d.O. received financial support from the Netherlands Organisation for Scientific Research (NWO), via a Gravitation grant to the Soehngen Institute for Anaerobic Microbiology (024.002.002) and an ALW-TOP project (854.10.003), respectively. This work was supported in part by Japan Society for the Promotion of Science KAKENHI grant 25440013 (to A. S.). J. A. D and E.N. are Howard Hughes Medical Institute Investigators. The T. thermophilus Cmr complex and T. thermophilus strain-producing Cmr6-His protein are available from A. S. under a material transfer agreement with RIKEN.	Jinek M, 2012, SCIENCE, V337, P816, DOI 10.1126/science.1225829; Goldberg GW, 2014, NATURE, V514, P633, DOI 10.1038/nature13637; Jackson RN, 2014, SCIENCE, V345, P1473, DOI 10.1126/science.1256328; Hochstrasser ML, 2014, P NATL ACAD SCI USA, V111, P6618, DOI 10.1073/pnas.1405079111; Brouns SJJ, 2008, SCIENCE, V321, P960, DOI 10.1126/science.1159689; Jore MM, 2011, NAT STRUCT MOL BIOL, V18, P529, DOI 10.1038/nsmb.2019; DiMaio F, 2009, J MOL BIOL, V392, P181, DOI 10.1016/j.jmb.2009.07.008; Barrangou R, 2007, SCIENCE, V315, P1709, DOI 10.1126/science.1138140; Mulepati S, 2014, SCIENCE, V345, P1479, DOI 10.1126/science.1256996; Suloway C, 2005, J STRUCT BIOL, V151, P41, DOI 10.1016/j.jsb.2005.03.010; Staals RHJ, 2013, MOL CELL, V52, P135, DOI 10.1016/j.molcel.2013.09.013; Lander GC, 2009, J STRUCT BIOL, V166, P95, DOI 10.1016/j.jsb.2009.01.002; Wiedenheft B, 2011, NATURE, V477, P486, DOI 10.1038/nature10402; Anders C, 2014, NATURE, V513, P569, DOI 10.1038/nature13579; Wiedenheft B, 2012, NATURE, V482, P331, DOI 10.1038/nature10886; Hale CR, 2009, CELL, V139, P945, DOI 10.1016/j.cell.2009.07.040; Scheres SHW, 2012, J STRUCT BIOL, V180, P519, DOI 10.1016/j.jsb.2012.09.006; Chen ZC, 2008, NATURE, V453, P489, DOI 10.1038/nature06971; Benda C, 2014, MOL CELL, V56, P43, DOI 10.1016/j.molcel.2014.09.002; Hale CR, 2014, GENE DEV, V28, P2432, DOI 10.1101/gad.250712.114; Nishimasu H, 2014, CELL, V156, P935, DOI 10.1016/j.cell.2014.02.001; Ryan OW, 2014, ELIFE, V3, DOI DOI 10.7554/ELIFE.03703	22	4	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 1	2015	348	6234					581	585		10.1126/science.aaa4535		5	Multidisciplinary Sciences	Science & Technology - Other Topics	CH1JR	WOS:000353778100044		
J	Fischer, S; Hu, ZJ; Pacheco, H				Fischer, Sebastian; Hu ZhenJiang; Pacheco, Hugo			The essence of bidirectional programming	SCIENCE CHINA-INFORMATION SCIENCES			English	Article						bidirectional transformation; software adaption and coevolution; bidirectional programming	RELATIONAL VIEWS; UPDATE SEMANTICS; TRANSFORMATIONS; LENSES	Bidirectional transformations (BXs), programs with a forward transformation and a backward transformation that maintain consistency between input and output, are routinely written in ways that do not let programmers specify their behavior completely. Several bidirectional programming languages exist to aid programmers in writing BXs with increased maintainability but decreased expressiveness. Such languages allow programmers to write BXs as one program for both directions, which is easier to maintain than separate programs for each direction. However, the maintainability provided by existing bidirectional languages comes at the cost of expressiveness because the ambiguity of synchronization is solved by default strategies which are hidden from programmers. The programmers' inability to influence synchronization strategies has led to the proposal of a vast number of approaches that consider tailor-made synchronization strategies for particular applications. In this paper, we argue that such ambiguity is essential for BX and advocate that the synchronization strategy should not be hidden from programmers but considered from the start. We propose a novel approach to specifying so-called well-behaved bidirectional programs by their backward transformations, capable of expressing all aspects of a BX while retaining maintainability. Soundness of our approach results from a systematic analysis, based on existing mathematical concepts, of the instrumental laws of well-behaved BXs. We show that well-behaved BXs are uniquely determined by their backward transformations and corresponding forward transformations can be obtained for free.	[Fischer, Sebastian] Univ Kiel, Dept Comp Sci, D-24098 Kiel, Germany; [Hu ZhenJiang] Natl Inst Informat, Informat Syst Architecture Res Div, Tokyo 1018430, Japan; [Pacheco, Hugo] Cornell Univ, Dept Comp Sci, Ithaca, NY 14853 USA; [Hu ZhenJiang] Grad Univ Adv Studies SOKENDAI, Dept Informat, Hayama, Kanagawa 2400193, Japan; [Hu ZhenJiang] Peking Univ, Sch Elect Engn & Comp Sci, Beijing 100871, Peoples R China	Hu, ZJ (reprint author), Natl Inst Informat, Informat Syst Architecture Res Div, Tokyo 1018430, Japan.	hu@nii.ac.jp		Pacheco, Hugo/0000-0003-0720-7744	National Basic Research Program of China (973 Program) in China [2015CB352201]; JSPS in China [25240009]	This work was supported by National Basic Research Program of China (973 Program) (Grant No. 2015CB352201) and JSPS Grant-in-Aid for Scientific Research (A) (Grant No. 25240009) in Japan.	BANCILHON F, 1981, ACM T DATABASE SYST, V6, P557, DOI 10.1145/319628.319634; Czarnecki K, 2009, LECT NOTES COMPUT SC, V5563, P260, DOI 10.1007/978-3-642-02408-5_19; Barbosa DMJ, 2010, ACM SIGPLAN NOTICES, V45, P193, DOI 10.1145/1932681.1863572; Bohannon A., 2006, P 25 ACM SIGMOD SIGA, P338, DOI 10.1145/1142351.1142399; Bohannon A, 2008, ACM SIGPLAN NOTICES, V43, P407; Buneman P, 2008, ACM T DATABASE SYST, V33, DOI 10.1145/1412331.1412340; DAYAL U, 1982, ACM T DATABASE SYST, V7, P381, DOI 10.1145/319732.319740; Fischer S, 2012, 201208 GRACE NAT I I; Foster J N, 2009, THESIS U PENNSYLVANI; Foster JN, 2007, ACM T PROGR LANG SYS, V29, DOI 10.1145/1232420.1232424; GOTTLOB G, 1988, ACM T DATABASE SYST, V13, P486, DOI 10.1145/49346.50068; Hanus M, 2012, TECHNICAL REPORT; Hidaka S, 2010, ACM SIGPLAN NOTICES, V45, P205, DOI 10.1145/1932681.1863573; Hofmann M, 2011, ACM SIGPLAN NOTICES, V46, P371, DOI 10.1145/1925844.1926428; Hofmann M, 2012, ACM SIGPLAN NOTICES, V47, P495, DOI 10.1145/2103621.2103715; Hu Z., 2008, HIGHER ORDER SYMBOLI, V21, P89, DOI 10.1007/s10990-008-9025-5; Hu ZJ, 2014, LECT NOTES COMPUT SC, V8442, P1; Hu ZJ, 2011, SIGMOD REC, V40, P35, DOI 10.1145/2007206.2007217; Keller A. M., 1986, Proceedings of Very Large Data Bases. Twelfth International Conference on Very Large Data Bases; Lammel R., 2004, P INT WORKSH SOFTW E, P31; LARSON JA, 1991, INFORM SYST, V16, P145, DOI 10.1016/0306-4379(91)90012-X; MATSUDA K, 2007, P 12 ACM SIGPLAN INT, V42, P47; Pacheco H, 2014, P 16 INT S PRINC PRA; Pacheco H, 2012, ELECT COMMUN EASST, V49, P2; Pacheco H, 2010, LECT NOTES COMPUT SC, V6120, P331, DOI 10.1007/978-3-642-13321-3_19; Pacheco H., 2014, PEPM 2014 ACM, P39; Pacheco H, 2012, THESIS U MINHO; Xiong Y., 2007, P 22 IEEE ACM INT C, P164, DOI 10.1145/1321631.1321657	28	0	0	SCIENCE PRESS	BEIJING	16 DONGHUANGCHENGGEN NORTH ST, BEIJING 100717, PEOPLES R CHINA	1674-733X	1869-1919		SCI CHINA INFORM SCI	Sci. China-Inf. Sci.	MAY	2015	58	5							052106	10.1007/s11432-015-5316-8		21	Computer Science, Information Systems	Computer Science	CH1XY	WOS:000353818200015		
J	Goldstein, CL; Varga, PP; Gokaslan, ZL; Boriani, S; Luzzati, A; Rhines, L; Fisher, CG; Chou, D; Williams, RP; Dekutoski, MB; Quraishi, NA; Bettegowda, C; Kawahara, N; Fehlings, MG				Goldstein, Christina L.; Varga, Peter Pal; Gokaslan, Ziya L.; Boriani, Stefano; Luzzati, Alessandro; Rhines, Laurence; Fisher, Charles G.; Chou, Dean; Williams, Richard P.; Dekutoski, Mark B.; Quraishi, Nasir A.; Bettegowda, Chetan; Kawahara, Norio; Fehlings, Michael G.			Spinal Hemangiomas: Results of Surgical Management for Local Recurrence and Mortality in a Multicenter Study	SPINE			English	Article						spinal hemangioma; spinal tumor; multicenter cohort; surgical treatment; benign tumor; recurrence; mortality rates; symptomatic spinal hemangiomas; multicenter database	SYMPTOMATIC VERTEBRAL HEMANGIOMAS; PERCUTANEOUS VERTEBROPLASTY; PREOPERATIVE EMBOLIZATION; CORD COMPRESSION; INTRALESIONAL INJECTION; CEMENT VERTEBROPLASTY; NEUROLOGIC SYMPTOMS; RADIATION-THERAPY; NATURAL-HISTORY; FOLLOW-UP	Study Design. Multicenter, ambispective observational study. Objective. To quantify local recurrence and mortality rates after surgical treatment of symptomatic spinal hemangiomas and identify prognostic variables for local disease control. Summary of Background Data. Spinal hemangiomas are the most common primary tumors of the spine and are generally benign and usually asymptomatic. Because of the rarity of symptomatic spinal hemangiomas, optimal surgical treatment remains unclear. Methods. AOSpine Knowledge Forum Tumor Investigators created a multicenter database of primary spinal tumors including demographics, presentation, diagnosis, treatment, survival, and recurrence data. Tumors were classifi ed according to Enneking and Weinstein-Boriani-Biagini. Descriptive statistics were summarized and time to mortality and recurrence was determined. Results. Between 1996 and 2012, 68 patients (mean age = 51 yr, SD = 16) underwent surgical treatment of a spinal hemangioma. Epidural disease was present in 55% of patients (n = 33). Pain and neurological compromise were presenting symptoms in 82% (n = 54) and 37% (n = 24) of patients, respectively. Preoperative embolization was performed in 35% of patients (n = 23), 10% (n = 7) had adjuvant radiotherapy, and 81% (n = 55) underwent posterior-alone surgery. The local recurrence rate was 3% (n = 2). Mortality secondary to spinal hemangioma was not observed (mean follow-up = 3.9 yr, SD = 3.8). Conclusion. This is the largest multicenter surgical cohort of spinal hemangiomas. Symptomatic spinal hemangiomas are a benign tumor despite frequently presenting with epidural disease and neurological compromise. Thus, formal en bloc resection is not required, and excellent rates of local control and long-term survival can result from aggressive intralesional resection during index surgery.	[Goldstein, Christina L.; Fehlings, Michael G.] Univ Toronto, Dept Surg, Div Neurosurg, Toronto, ON, Canada; [Goldstein, Christina L.; Fehlings, Michael G.] Toronto Western Hosp, Toronto, ON M5T 2S8, Canada; [Varga, Peter Pal] Natl Ctr Spinal Disorders, Budapest, Hungary; [Varga, Peter Pal] Buda Hlth Ctr, Budapest, Hungary; [Gokaslan, Ziya L.; Bettegowda, Chetan] Johns Hopkins Univ, Sch Med, Dept Neurosurg, Baltimore, MD 21205 USA; [Boriani, Stefano] Rizzoli Inst, Dept Degenerat & Oncol Spine Surg, Bologna, Italy; [Luzzati, Alessandro] Ist Ortoped Galeazzi, Oncol Ortoped & Ricostrutt Rachide, Milan, Italy; [Rhines, Laurence] Univ Texas MD Anderson Canc Ctr, Dept Neurosurg, Houston, TX 77030 USA; [Fisher, Charles G.] Univ British Columbia, Dept Paediat, Div Spine, Vancouver, BC, Canada; [Fisher, Charles G.] Vancouver Coastal Hlth, Vancouver, BC, Canada; [Chou, Dean] Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA USA; [Williams, Richard P.] Princess Alexandra Hosp, Dept Orthopaed, Brisbane, Qld 4102, Australia; [Dekutoski, Mark B.] CORE Inst, Orthopaed Surg, Sun City West, AZ USA; [Quraishi, Nasir A.] Nottingham Univ Hosp NHS Trust, Queens Med Ctr, Ctr Spine Studies & Surg, Nottingham, England; [Kawahara, Norio] Kanazawa Med Univ, Dept Orthopaed Surg, Uchinada, Ishikawa, Japan	Fehlings, MG (reprint author), Toronto Western Hosp, West Wing,4th Floor Room 4WW449,399 Bathurst St, Toronto, ON M5T 2S8, Canada.	michael.fehlings@uhn.ca			AOSpine International Knowledge Forum Tumor (AOSKFT)	AOSpine International Knowledge Forum Tumor (AOSKFT) funds were received to support this work.	Aich RK, 2010, J CANCER RES THER, V6, P199, DOI 10.4103/0973-1482.65248; NGUYEN JP, 1987, SURG NEUROL, V27, P391, DOI 10.1016/0090-3019(87)90020-6; Acosta FL, 2006, NEUROSURGERY, V58, P287, DOI 10.1227/01.NEU.0000194846.55984.C8; FOX MW, 1993, J NEUROSURG, V78, P36, DOI 10.3171/jns.1993.78.1.0036; Fisher CG, 2010, SPINE, V35, pE1221, DOI 10.1097/BRS.0b013e3181e16ae2; Castel E, 1999, EUR SPINE J, V8, P244, DOI 10.1007/s005860050167; Boschi V, 2011, SCAND J SURG, V100, P120; Boriani S, 1997, SPINE, V22, P1036, DOI 10.1097/00007632-199705010-00020; Doppman JL, 2000, RADIOLOGY, V214, P341; Acosta FL, 2008, NEUROSURG CLIN N AM, V19, P17, DOI 10.1016/j.nec.2007.09.010; Goyal M, 1999, AM J NEURORADIOL, V20, P1091; Niemeyer T, 1999, SPINE, V24, P1845, DOI 10.1097/00007632-199909010-00015; Barr JD, 2000, SPINE, V25, P923, DOI 10.1097/00007632-200004150-00005; Deramond H, 1998, RADIOL CLIN N AM, V36, P533, DOI 10.1016/S0033-8389(05)70042-7; Blecher R, 2011, J SPINAL DISORD TECH, V24, P196, DOI 10.1097/BSD.0b013e3181e489df; Pastushyn AI, 1998, SURG NEUROL, V50, P535, DOI 10.1016/S0090-3019(98)00007-X; Jiang L, 2014, SPINE J, V14, P944, DOI 10.1016/j.spinee.2013.07.450; HEALY M, 1983, NEUROSURGERY, V13, P689; Cotten A, 1996, AM J NEURORADIOL, V17, P137; BAKER ND, 1986, SKELETAL RADIOL, V15, P458; Bandiera S, 2002, Chir Organi Mov, V87, P1; Barzin M, 2009, Pak J Biol Sci, V12, P542, DOI 10.3923/pjbs.2009.542.544; Bas T, 2001, SPINE, V26, P1577, DOI 10.1097/00007632-200107150-00015; BLANKSTEIN A, 1988, PARAPLEGIA, V26, P186; Bremnes RM, 1996, NEUROSURGERY, V39, P1054, DOI 10.1097/00006123-199611000-00039; Cohen JE, 2004, NEUROL RES, V26, P41, DOI 10.1179/016164104225013572; Dagi TF, 1990, TUMORS SPINE DIAGNOS, P181; ENNEKING WF, 1986, CLIN ORTHOP RELAT R, P9; ESPARZA J, 1978, SURG NEUROL, V10, P171; FARIA SL, 1985, INT J RADIAT ONCOL, V11, P387; FEUERMAN T, 1986, J NEUROSURG, V65, P404, DOI 10.3171/jns.1986.65.3.0404; Gabal AM, 2002, CARDIOVASC INTER RAD, V25, P494, DOI 10.1007/s00270-002-1944-7; GALIBERT P, 1987, NEUROCHIRURGIE, V33, P166; GLANZMANN C, 1977, STRAHLENTHER ONKOL, V153, P522; GRAHAM JJ, 1984, SPINE, V9, P97, DOI 10.1097/00007632-198401000-00022; Guo CA, 2011, EUR SPINE J, V20, P655, DOI 10.1007/s00586-010-1618-0; Hao J, 2012, PAIN PHYSICIAN, V15, P43; HEKSTER REM, 1987, NEURORADIOLOGY, V29, P101; Hemmy D, 1996, NEUROSURGERY, V1st, P1827; HEMMY DC, 1977, J NEUROSURG, V47, P282, DOI 10.3171/jns.1977.47.2.0282; Heyd R, 2010, STRAHLENTHER ONKOL, V186, P430, DOI 10.1007/s00066-010-2140-3; Jankowski R, 2011, NEUROL NEUROCHIR POL, V45, P577; Jayakumar PN, 1997, SPINAL CORD, V35, P624, DOI 10.1038/sj.sc.3100438; Kato S, 2010, J ORTHOP SCI, V15, P350, DOI 10.1007/s00776-010-1483-z; KRUEGER EG, 1961, J NEUROSURG, V18, P331, DOI 10.3171/jns.1961.18.3.0331; Larsen Dorthe, 2004, Nurs Stand, V19, P33; MACERLEAN DP, 1978, BRIT J RADIOL, V51, P414; MCALLISTER VL, 1975, BRAIN, V98, P71, DOI 10.1093/brain/98.1.71; Miszczyk Leszek, 2012, Int J Radiat Oncol Biol Phys, V82, pe173, DOI 10.1016/j.ijrobp.2011.04.028; MOHAN V, 1980, CLIN RADIOL, V31, P575, DOI 10.1016/S0009-9260(80)80055-9; Munk PL, 1999, AM J NEURORADIOL, V20, P959; Murugan L, 2002, Neurol India, V50, P300; Nassar SI, 1998, CLIN IMAG, V22, P65; Nguyen JP, 1989, NEUROCHIRURGIE, V35, P305; NGUYEN JP, 1989, NEUROCHIRURGIE, V35, P299; Ogura T, 2002, POSTGRAD MED J, V78, P559, DOI 10.1136/pmj.78.923.559; Park HJ, 2011, AM J ROENTGENOL, V196, P1151, DOI 10.2214/AJR.10.5457; Peh WCG, 2003, BRIT J RADIOL, V76, P69, DOI 10.1259/bjr/10254271; Acosta FL, 2011, J SPINAL DISORD TECH, V24, P268, DOI 10.1097/BSD.0b013e3181efe0a4; Schwartz TH, 2000, NEUROSURGERY, V46, P218; Smith T P, 1993, J Vasc Interv Radiol, V4, P681, DOI 10.1016/S1051-0443(93)71948-X; Song Ruo-xian, 2012, Zhonghua Wai Ke Za Zhi, V50, P342; Urrutia J, 2011, J CLIN NEUROSCI, V18, P209, DOI 10.1016/j.jocn.2010.05.022; Varghese R, 1998, J Indian Med Assoc, V96, P63; YANG ZY, 1985, ACTA RADIOL ONCOL, V24, P129	65	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0362-2436	1528-1159		SPINE	SPINE	MAY 1	2015	40	9					656	664		10.1097/BRS.0000000000000840		9	Clinical Neurology; Orthopedics	Neurosciences & Neurology; Orthopedics	CH2CX	WOS:000353833700018		
J	Miyashita, T; Ataka, H; Kato, K; Tanno, T				Miyashita, Tomohiro; Ataka, Hiromi; Kato, Kei; Tanno, Takaaki			Good Clinical Outcomes and Fusion Rate of Facet Fusion With a Percutaneous Pedicle Screw System for Degenerative Lumbar Spondylolisthesis Minimally Invasive Evolution of Posterolateral Fusion	SPINE			English	Article						facet fusion; degenerative lumbar spondylolisthesis; minimally invasive surgery; percutaneous pedicle screw; posterolateral fusion; clinical results	FOLLOW-UP; SPINAL STENOSIS; BACK-PAIN; INSTRUMENTATION; ARTHRODESIS; LAMINECTOMY	Study Design. A retrospective clinical and radiographical study. Objective. To assess the clinical outcomes and fusion rate of facet fusion (FF) for degenerative lumbar spondylolisthesis (DLS). Summary of Background Data. On the basis of the long-term clinical and radiological follow-up studies of posterolateral fusion (PLF)-that is, intertransverse process fusion with pedicle screw instrumentation-for DLS, we recognized that FF alone would be sufficient for spinal fusion. Methods. Eighty-eight patients who underwent FF for single-level DLS were retrospectively reviewed after at least 1 year of follow-up. The control group comprised 21 patients who underwent conventional PLF. The operative technique involved a 5-cm midline skin incision, bilateral laminar fenestration, and FF with autologous bone harvested from the spinous process. Percutaneous pedicle screws were then inserted through the fascia. The fusion rate of FF was evaluated using computed tomography, and the change in the range of motion at the fused level was assessed on flexion-extension lateral radiographs. The Japanese Orthopaedic Association Back Pain Evaluation Questionnaire was used to assess the therapeutic effectiveness of FF. The results of the Roland-Morris Disability Questionnaire and the visual analogue scales of low back pain, buttock and lower limb pain, and buttock and lower limb numbness were evaluated. Results. The fusion rate was 88.6% (78/88 cases). Among 10 patients with inadequate fusion, the average range of motion significantly decreased from 14.4 degrees preoperatively to 4.3 degrees postoperatively. The Japanese Orthopaedic Association Back Pain Evaluation Questionnaire category scores demonstrated therapeutic effectiveness in 93.0% of the patients for walking ability and in 73.0% of the patients for low back pain. The average preoperative scores of the Roland-Morris Disability Questionnaire and the visual analogue scales of low back pain, buttock and lower limb pain, and buttock and lower limb numbness were significantly reduced postoperatively in the FF group. Conclusion. FF achieved good clinical outcomes that were superior to those of conventional PLF with a comparable fusion rate. It is useful for managing DLS and is a minimally invasive evolution of PLF.	[Miyashita, Tomohiro; Kato, Kei] Matsudo City Hosp, Spine Ctr, Matsudo, Chiba 2718511, Japan; [Ataka, Hiromi; Tanno, Takaaki] Matsudo Orthopaed Hosp, Spine Ctr, Matsudo, Chiba, Japan	Miyashita, T (reprint author), Matsudo City Hosp, Spine Ctr, 4005 Kamihongo, Matsudo, Chiba 2718511, Japan.	tommiya3@yahoo.co.jp					Kho VKS, 2008, INT ORTHOP, V32, P115, DOI 10.1007/s00264-006-0274-9; Fernandez-Fairen M, 2007, SPINE, V32, P395, DOI 10.1097/01.brs.0000255023.56466.44; Fritzell P, 2002, SPINE, V27, P1131, DOI 10.1097/00007632-200206010-00002; Etebar S, 1999, J NEUROSURG, V90, P163, DOI 10.3171/spi.1999.90.2.0163; KANT AP, 1995, SPINE, V20, P2313, DOI 10.1097/00007632-199511000-00009; HERKOWITZ HN, 1991, J BONE JOINT SURG AM, V73A, P802; Fukui M, 2009, J ORTHOP SCI, V14, P348, DOI 10.1007/s00776-009-1337-8; Santoni BG, 2009, SPINE J, V9, P366, DOI 10.1016/j.spinee.2008.07.008; Kotani Y, 2012, EUR SPINE J, V21, P1171, DOI 10.1007/s00586-011-2114-x; Ohtori S, 2011, EUR SPINE J, V20, P635, DOI 10.1007/s00586-010-1656-7; Kimura I, 2001, J SPINAL DISORD, V14, P301, DOI 10.1097/00002517-200108000-00004; Ekman P, 2007, SPINE, V32, P2178; Andersen T, 2008, EUR SPINE J, V17, P272, DOI 10.1007/s00586-007-0494-8; Christensen FB, 2001, J BONE JOINT SURG AM, V26, P538; Fischgrund JS, 1997, SPINE, V22, P2807, DOI 10.1097/00007632-199712150-00003; Kanayama M, 2007, SPINE, V32, P1992, DOI 10.1097/BRS.0b013e318133faae; Kim KT, 2006, SPINE, V31, P1351; Mochida J, 1999, CLIN ORTHOP RELAT R, P126; Park YK, 2002, NEUROSURGERY, V51, P88, DOI 10.1227/01.NEU.0000017311.50919.2D; Park YK, 1999, ACTA NEUROCHIR, V141, P915, DOI 10.1007/s007010050397; Tanno T, 2008, NIHON SEKITSUISEKIZU, V19, P617; Turunen V, 2012, EUR SPINE J, V21, P2140, DOI 10.1007/s00586-012-2320-1; ZDEBLICK TA, 1993, SPINE, V18, P983, DOI 10.1097/00007632-199306150-00006	23	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0362-2436	1528-1159		SPINE	SPINE	MAY 1	2015	40	9					E552	E557		10.1097/BRS.0000000000000842		6	Clinical Neurology; Orthopedics	Neurosciences & Neurology; Orthopedics	CH2CX	WOS:000353833700006		
J	Takeuchi, M; Wakao, N; Kamiya, M; Hirasawa, A; Osuka, K; Joko, M; Kawanami, K; Takayasu, M				Takeuchi, Mikinobu; Wakao, Norimitsu; Kamiya, Mitsuhiro; Hirasawa, Atsuhiko; Osuka, Koji; Joko, Masahiro; Kawanami, Katsuhisa; Takayasu, Masakazu			Lumbar extraforaminal entrapment: performance characteristics of detecting the foraminal spinal angle using oblique coronal MRI. A multicenter study	SPINE JOURNAL			English	Article						Lumbar extraforaminal entrapment; Foraminal spinal nerve angle; Lumbar foramina stenosis; Far-out syndrome; Oblique coronal magnetic resonance imaging; L5 nerve root	NERVE ROOT ENTRAPMENT; LUMBOSACRAL RADICULOGRAPHY; DIAGNOSTIC-VALUE; DISC HERNIATION; STENOSIS; LIGAMENTS; TUNNEL	BACKGROUND CONTEXT: Previous conventional magnetic resonance imaging reports on extraforaminal entrapment (e-FE) on L5-S1 have been problematic because of their complexity or lack of sensitivity and specificity. In this study, we propose a simple diagnostic method for e-FE. PURPOSE: The purpose of this study was to determine the sensitivity and specificity of using the difference in the foraminal spinal nerve (FSN) angle of the L5 nerve, as determined by oblique coronal T2-weighted imaging (OC-T2WI), for diagnosing L5-S1 unilateral e-FE. STUDY DESIGN: The study design involves diagnostic accuracy with retrospective case-control study. PATIENT SAMPLE: Seventy consecutive patients with unilateral L5 radiculopathy who underwent unilateral L5-S1 extraspinal canal decompression for e-FE or 4/5 intraspinal canal decompression for lumbar spinal canal stenosis between 2009 and 2013 were included. OUTCOME MEASURES: The Japanese Orthopedic Association score, Visual Analog Scale score for leg pain, and OC-T2WI for the FSN angle of the L5 nerve were examined. METHODS: The 70 patients were divided into two groups: Group A (n=21) with unilateral L5-S1 e-FE and Group B (n-49) with intraspinal canal L4-L5. Group C (n-44) comprised the control group, which included only patients with back pain without leg radiculopathy. All patients underwent OC-T2WI, and the differences in the FSN angle of the fifth lumbar spinal nerve between the symptomatic and asymptomatic sides (Delta FSN angle) were examined and compared among the groups. RESULTS: There were no significant differences in the patient characteristics among the three groups. The DFSN angle was 17 degrees in Group A, 4.8 degrees in Group B, and 6.4 degrees in Group C, and the laterality was significantly larger in Group A than in the other two groups. A receiver-operating characteristic curve showed areas under the curve between groups A and B and between groups A and C of 0.93 and 0.97, respectively. In addition, the cutoff value of the Delta FSN angle (10 degrees) indicated diagnostic accuracies of 94% and 91% (sensitivity and specificity) and of 93% and 95%, respectively. CONCLUSIONS: Determining differences in the FSN angle between the symptomatic and asymptomatic sides of greater than 10 degrees via OC-T2WI represented a simple, readily available, and complementary diagnostic method for lumbar e-FE. (C) 2015 Elsevier Inc. All rights reserved.	[Takeuchi, Mikinobu; Wakao, Norimitsu; Kamiya, Mitsuhiro; Hirasawa, Atsuhiko; Kawanami, Katsuhisa] Aichi Med Univ Hosp, Dept Spine Ctr, Nagakute, Aichi 4801195, Japan; [Osuka, Koji; Joko, Masahiro; Takayasu, Masakazu] Aichi Med Univ Hosp, Dept Neurol Surg, Nagakute, Aichi 4801195, Japan	Takeuchi, M (reprint author), Aichi Med Univ Hosp, Dept Spine Ctr, Nagakute, Aichi 4801195, Japan.	take7106@aichi-med-u.ac.jp					Ando M, 2013, EUR SPINE J, V22, P833, DOI 10.1007/s00586-012-2592-5; KUNOGI J, 1991, SPINE, V16, P1312, DOI 10.1097/00007632-199111000-00012; Taguchi T, 2002, J NEURORADIOLOGY, V29, P122; Eguchi Y, 2011, AM J NEURORADIOL, V32, P1824, DOI 10.3174/ajnr.A2681; WILTSE LL, 1988, SPINE, V13, P696; Aota Y, 2007, SPINE, V32, P896, DOI 10.1097/01.brs.0000259809.75760.d5; LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310; Chang HS, 2011, J SPINAL DISORD TECH, V24, P302, DOI 10.1097/BSD.0b013e3181f7cc9f; Nakao S, 2010, J SPINAL DISORD TECH, V23, pE47, DOI 10.1097/BSD.0b013e3181cdd262; TRANSFELDT EE, 1993, J SPINAL DISORD, V6, P507; Akobeng AK, 2007, ACTA PAEDIATR, V96, P644, DOI 10.1111/j.1651-2227.2006.00178.x; Maher CO, 1999, J NEUROSURG, V90, P52, DOI 10.3171/spi.1999.90.1.0052; Park YK, 2003, J NEUROSURG, V98, P264, DOI 10.3171/spi.2003.98.3.0264; Fischer JE, 2003, INTENS CARE MED, V29, P1043, DOI 10.1007/s00134-003-1761-8; Byun WM, 2012, KOREAN J RADIOL, V13, P403, DOI 10.3348/kjr.2012.13.4.403; Hashimoto M, 1996, ACTA RADIOL, V37, P610; Matsumoto M, 2006, J NEUROSURG-SPINE, V4, P342, DOI 10.3171/spi.2006.4.4.342; WILTSE LL, 1984, SPINE, V9, P31, DOI 10.1097/00007632-198401000-00008; Byun WM, 2012, SPINE, V37, P840, DOI 10.1097/BRS.0b013e3182374465; Heo DH, 2009, SPINE, V34, P2419, DOI 10.1097/BRS.0b013e3181b96187; HUSKISSO.EC, 1974, LANCET, V2, P1127; Izumida S, 1986, J JPN ORTHOP ASSOC, V60, P391; Matsumoto M, 2002, SPINE, V27, pE169, DOI 10.1097/00007632-200203150-00020; NATHAN H, 1982, INT ORTHOP, V6, P197, DOI 10.1007/BF00267730; OLSEWSKI JM, 1991, SPINE, V16, P336, DOI 10.1097/00007632-199103000-00014; Pointillart V, 1997, Eur Spine J, V6, P102, DOI 10.1007/BF01358741; RAUSCHNING W, 1987, SPINE, V12, P1008, DOI 10.1097/00007632-198712000-00012	27	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1529-9430	1878-1632		SPINE J	Spine Journal	MAY 1	2015	15	5					895	900		10.1016/j.spinee.2015.02.011		6	Clinical Neurology; Orthopedics	Neurosciences & Neurology; Orthopedics	CG9HQ	WOS:000353626100017		
J	Ueno, M; Saito, W; Yamagata, M; Imura, T; Inoue, G; Nakazawa, T; Takahira, N; Uchida, K; Fukahori, N; Shimomura, K; Takaso, M				Ueno, Masaki; Saito, Wataru; Yamagata, Megumu; Imura, Takayuki; Inoue, Gen; Nakazawa, Toshiyuki; Takahira, Naonobu; Uchida, Kentaro; Fukahori, Nobuko; Shimomura, Kiyomi; Takaso, Masashi			Triclosan-coated sutures reduce wound infections after spinal surgery: a retrospective, nonrandomized, clinical study	SPINE JOURNAL			English	Article						Surgical site infection; Spinal surgery; Triclosan; Antimicrobial suture; Wound closure	SURGICAL SITE INFECTION; POLYGLACTIN 910; EFFICACY; VICRYL; IMPACT; TRIAL	BACKGROUND CONTEXT: Surgical site infection (SSI) is a serious postoperative complication. The incidence of SSIs is lower in clean orthopedic surgery than in other fields, but it is higher after spinal surgery, reaching 4.15% in high-risk patients. Several studies reported that triclosancoated polyglactin 910 sutures (Vicryl Plus; Ethicon, Inc., Somerville, NJ, USA) significantly reduced the infection rate in the general surgical, neurosurgical, and thoracic surgical fields. However, there have been no studies on the effects of such coated sutures on the incidence of SSIs in orthopedics. PURPOSE: To compare the incidence of wound infections after spinal surgery using triclosancoated suture materials with that of noncoated ones. STUDY DESIGN/SETTING: A retrospective, nonrandomized, and clinical study. PATIENT SAMPLE: From May 2010 to April 2012, 405 patients underwent a spinal surgical procedure in the Department of Orthopedic Surgery of two university hospitals. OUTCOME MEASURES: The primary outcome was the number of wound infections and dehiscences. METHODS: Two hundred five patients had a conventional wound closure with polyglactin 910 suture (Vicryl) between May 2010 and April 2011 (Time Period 1 [TP1]), and 200 patients underwent wound closure with triclosan-coated polyglactin 910 suture (Vicryl Plus) between May 2011 and April 2012 (TP2). Statistical comparisons of wound infections, dehiscence, and risk factors for poor wound healing or infection were performed. None of the authors has any conflict of interest associated with this study. RESULTS: There were two cases of wound dehiscence in TP1 and one in TP2 (p=.509). Using noncoated sutures in TP1, eight patients (3.90%) had wound infections, whereas one patient (0.50%) had wound infections in TP2 (using triclosan-coated sutures); the difference was significant (p=.020). CONCLUSIONS: The use of triclosan-coated polyglactin 910 sutures instead of polyglactin 910 sutures may reduce the number of wound infections after spinal surgery. (C) 2015 Elsevier Inc. All rights reserved.	[Ueno, Masaki; Saito, Wataru; Imura, Takayuki; Inoue, Gen; Nakazawa, Toshiyuki; Uchida, Kentaro; Takaso, Masashi] Kitasato Univ, Sch Med, Dept Orthopaed Surg, Sagamihara, Kanagawa 2520373, Japan; [Takahira, Naonobu] Kitasato Univ, Sch Allied Hlth Sci, Dept Rehabil, Sagamihara, Kanagawa 2520373, Japan; [Yamagata, Megumu; Fukahori, Nobuko] Kitasato Univ, East Hosp, Dept Nursing, Sagamihara, Kanagawa 2520380, Japan	Ueno, M (reprint author), Kitasato Univ, Sch Med, Dept Orthopaed Surg, 1-15-1 Kitasato, Sagamihara, Kanagawa 2520373, Japan.	masaki.ueno00@gmail.com					Murdoch DR, 2001, CLIN INFECT DIS, V32, P647, DOI 10.1086/318704; Galal I, 2011, AM J SURG, V202, P133, DOI 10.1016/j.amjsurg.2010.06.011; Rozzelle CJ, 2008, J NEUROS-PEDIATR, V2, P111, DOI 10.3171/PED/2008/2/8/111; Justinger C, 2009, SURGERY, V145, P330, DOI 10.1016/j.surg.2008.11.007; Venema S, 2011, J ORAL MAXIL SURG, V69, P980, DOI 10.1016/j.joms.2010.02.030; Fleck T, 2007, ANN THORAC SURG, V84, P232, DOI 10.1016/j.athoracsur.2007.03.045; Kirkland KB, 1999, INFECT CONT HOSP EP, V20, P725, DOI 10.1086/501572; Mingmalairak Chatchai, 2009, Journal of the Medical Association of Thailand, V92, P770; Edmiston CE, 2006, J AM COLL SURGEONS, V203, P481, DOI 10.1016/j.jamcollsurg.2006.06.026; Edwards JR, 2009, AM J INFECT CONTROL, V37, P783, DOI 10.1016/j.ajic.2009.10.001; Giulieri SG, 2004, INFECTION, V32, P222, DOI 10.1007/s15010-004-4020-1; Barbolt Thomas A, 2002, Surg Infect (Larchmt), V3 Suppl 1, pS45, DOI 10.1089/sur.2002.3.s1-45; Chen SY, 2011, EJSO-EUR J SURG ONC, V37, P300, DOI 10.1016/j.ejso.2011.01.015; Deliaert AE, 2009, J PLAST RECONSTR AES, V62, P771, DOI 10.1016/j.bjps.2007.10.075; Gomez-Alonso A, 2007, J INFECTION, V54, P82, DOI 10.1016/j.jinf.2006.01.008; Justinger C, 2011, LANGENBECK ARCH SURG, V396, P845, DOI 10.1007/s00423-011-0786-7; Marco Fernando, 2007, Surg Infect (Larchmt), V8, P359, DOI 10.1089/sur.2006.013; Marculescu C E, 2005, Clin Orthop Relat Res, V439, P38, DOI 10.1097/01.blo.0000183091.83509.d8; Rothenburger Stephen, 2002, Surg Infect (Larchmt), V3 Suppl 1, pS79, DOI 10.1089/sur.2002.3.s1-79	19	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1529-9430	1878-1632		SPINE J	Spine Journal	MAY 1	2015	15	5					933	938		10.1016/j.spinee.2013.06.046		6	Clinical Neurology; Orthopedics	Neurosciences & Neurology; Orthopedics	CG9HQ	WOS:000353626100022		
J	Kuroki, K; Sudo, H; Iwasaki, N				Kuroki, Kei; Sudo, Hideki; Iwasaki, Norimasa			Right-convex thoracolumbar scoliosis	SPINE JOURNAL			English	Editorial Material							SYRINGOMYELIA		[Kuroki, Kei; Sudo, Hideki; Iwasaki, Norimasa] Hokkaido Univ Hosp, Dept Orthopaed Surg, Kita Ku, Sapporo, Hokkaido 0608638, Japan	Kuroki, K (reprint author), Hokkaido Univ Hosp, Dept Orthopaed Surg, Kita Ku, N-15,W-7, Sapporo, Hokkaido 0608638, Japan.						Yeom JS, 2007, EUR SPINE J, V16, P1629, DOI 10.1007/s00586-007-0472-1; ARAI S, 1993, SPINE, V18, P1591, DOI 10.1097/00007632-199309000-00004; FARLEY FA, 1995, J PEDIATR ORTHOPED, V15, P187; Zhang ZX, 2014, EUR SPINE J	4	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1529-9430	1878-1632		SPINE J	Spine Journal	MAY 1	2015	15	5					1154	1155		10.1016/j.spinee.2015.02.014		2	Clinical Neurology; Orthopedics	Neurosciences & Neurology; Orthopedics	CG9HQ	WOS:000353626100051		
J	Dong, JY; Iso, H; Kitamura, A; Tamakoshi, A				Dong, Jia-Yi; Iso, Hiroyasu; Kitamura, Akihiko; Tamakoshi, Akiko		Japan Collaborative Cohort Study	Multivitamin Use and Risk of Stroke Mortality The Japan Collaborative Cohort Study	STROKE			English	Article						cohort studies; mortality; stroke	CARDIOVASCULAR-DISEASE; CANCER INCIDENCE; VITAMIN-E; METAANALYSIS; SUPPLEMENTS; HEALTH; JACC; MEN; PREVENTION; PHYSICIANS	Background and Purpose-An effect of multivitamin supplement on stroke risk is uncertain. We aimed to examine the association between multivitamin use and risk of death from stroke and its subtypes. Methods-A total of 72 180 Japanese men and women free from cardiovascular diseases and cancers at baseline in 1988 to 1990 were followed up until December 31, 2009. Lifestyles including multivitamin use were collected using self-administered questionnaires. Cox proportional hazards regression models were used to estimate hazard ratios (HRs) of total stroke and its subtypes in relation to multivitamin use. Results-During a median follow-up of 19.1 years, we identified 2087 deaths from stroke, including 1148 ischemic strokes and 877 hemorrhagic strokes. After adjustment for potential confounders, multivitamin use was associated with lower but borderline significant risk of death from total stroke (HR, 0.87; 95% confidence interval, 0.76-1.01), primarily ischemic stroke (HR, 0.80; 95% confidence interval, 0.63-1.01), but not hemorrhagic stroke (HR, 0.96; 95% confidence interval, 0.78-1.18). In a subgroup analysis, there was a significant association between multivitamin use and lower risk of mortality from total stroke among people with fruit and vegetable intake <3 times/d (HR, 0.80; 95% confidence interval, 0.65-0.98). That association seemed to be more evident among regular users than casual users. Similar results were found for ischemic stroke. Conclusions-Multivitamin use, particularly frequent use, was associated with reduced risk of total and ischemic stroke mortality among Japanese people with lower intake of fruits and vegetables.	[Dong, Jia-Yi; Iso, Hiroyasu; Kitamura, Akihiko] Osaka Univ, Dept Social Med, Publ Hlth, Grad Sch Med, Suita, Osaka 5650871, Japan; [Tamakoshi, Akiko] Hokkaido Univ, Grad Sch Med, Dept Publ Hlth, Sapporo, Hokkaido, Japan	Iso, H (reprint author), Osaka Univ, Dept Social Med, Grad Sch Med, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.	iso@pbhel.med.osaka-u.ac.jp			Ministry of Education, Science, Sports and Culture of Japan (Monbusho); Japanese Ministry of Education, Culture, Sports, Science and Technology (Monbu-Kagaku-sho) [61010076, 62010074, 63010074, 1010068, 2151065, 3151064, 4151063, 5151069, 6279102, 11181101, 17015022, 18014011, 20014026, 20390156]; Ministry of Health, Labour and Welfare, Health and Labor Sciences research grant, Japan (Research on Health Services) [H17-Kenkou-007]; Ministry of Health, Labour and Welfare, Health and Labor Sciences research grants, Japan (Comprehensive Research on Cardiovascular Disease and Life-Related Disease) [H18-Junkankitou [Seishuu]-Ippan-012, H19-Junkankitou [Seishuu]-Ippan-012, H20-Junkankitou [Seishuu]-Ippan-013, H23-Junkankitou [Seishuu]-Ippan-005]; Intramural Research Fund for Cardiovascular Diseases of National Cerebral and Cardiovascular Center [22-4-5]; Comprehensive Research on Cardiovascular and LifeStyle Related Diseases [H26-Junkankitou [Seisaku]-Ippan-001]	This work was supported by Grants-in-Aid for Scientific Research from the Ministry of Education, Science, Sports and Culture of Japan (Monbusho), Grants-in-Aid for Scientific Research on Priority Areas of Cancer, Grants-in-Aid for Scientific Research on Priority Areas of Cancer Epidemiology from the Japanese Ministry of Education, Culture, Sports, Science and Technology (Monbu-Kagaku-sho; Nos. 61010076, 62010074, 63010074, 1010068, 2151065, 3151064, 4151063, 5151069, 6279102, 11181101, 17015022, 18014011, 20014026, and 20390156), Grant-in-Aid from the Ministry of Health, Labour and Welfare, Health and Labor Sciences research grants, Japan (Research on Health Services: H17-Kenkou-007; Comprehensive Research on Cardiovascular Disease and Life-Related Disease: H18-Junkankitou [Seishuu]-Ippan-012; Comprehensive Research on Cardiovascular Disease and Life-Related Disease: H19-Junkankitou [Seishuu]-Ippan-012; Comprehensive Research on Cardiovascular and LifeStyle Related Diseases: H20-Junkankitou [Seishuu]-Ippan-013; Comprehensive Research on Cardiovascular and LifeStyle Related Diseases: H23-Junkankitou [Seishuu]-Ippan-005), and an Intramural Research Fund (22-4-5) for Cardiovascular Diseases of National Cerebral and Cardiovascular Center; and Comprehensive Research on Cardiovascular and LifeStyle Related Diseases: H26-Junkankitou [Seisaku]-Ippan-001.	Aburto NJ, 2013, BMJ-BRIT MED J, V346, DOI 10.1136/bmj.f1378; Moyer VA, 2014, ANN INTERN MED, V160, P558, DOI 10.7326/M14-0198; Muntwyler J, 2002, ARCH INTERN MED, V162, P1472, DOI 10.1001/archinte.162.13.1472; Bazzano LA, 2002, STROKE, V33, P1183, DOI 10.1161/01.STR.0000014607.90464.88; Sesso HD, 2012, JAMA-J AM MED ASSOC, V308, P1751, DOI 10.1001/jama.2012.14805; Larsson SC, 2012, AM J CLIN NUTR, V95, P362, DOI 10.3945/ajcn.111.022376; Date C, 2005, J EPIDEMIOL, V15, pS9, DOI 10.2188/jea.15.S9; He FJ, 2006, LANCET, V367, P320, DOI 10.1016/S0140-6736(06)68069-0; Larsson SC, 2011, STROKE, V42, P2746, DOI 10.1161/STROKEAHA.111.622142; Cui RZ, 2010, STROKE, V41, P1285, DOI 10.1161/STROKEAHA.110.578906; Neuhouser ML, 2009, ARCH INTERN MED, V169, P294, DOI 10.1001/archinternmed.2008.540; Park SY, 2011, AM J EPIDEMIOL, V173, P906, DOI 10.1093/aje/kwq447; Mursu J, 2011, ARCH INTERN MED, V171, P1625, DOI 10.1001/archinternmed.2011.445; He K, 2004, STROKE, V35, P169, DOI 10.1161/01.STR.0000106762.55994.86; Kubota Y, 2011, STROKE, V42, P1665, DOI 10.1161/STROKEAHA.110.601526; LI JY, 1993, J NATL CANCER I, V85, P1492, DOI 10.1093/jnci/85.18.1492; Li KR, 2012, EUR J NUTR, V51, P407, DOI 10.1007/s00394-011-0224-1; Ohno Y, 2001, J Epidemiol, V11, P144; Pocobelli G, 2009, AM J EPIDEMIOL, V170, P472, DOI 10.1093/aje/kwp167; Schurks M, 2010, BRIT MED J, V341, DOI 10.1136/bmj.c5702; Tamakoshi A, 2005, J EPIDEMIOL, V15, pS4, DOI 10.2188/jea.15.S4; Voko Z, 2003, NEUROLOGY, V61, P1273; Watkins ML, 2000, AM J EPIDEMIOL, V152, P149, DOI 10.1093/aje/152.2.149	23	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0039-2499	1524-4628		STROKE	Stroke	MAY	2015	46	5					1167	1172		10.1161/STROKEAHA.114.008270		6	Clinical Neurology; Peripheral Vascular Disease	Neurosciences & Neurology; Cardiovascular System & Cardiology	CG8LR	WOS:000353559800020		
J	Llombart, V; Antolin-Fontes, A; Bustamante, A; Giralt, D; Rost, NS; Furie, K; Shibazaki, K; Biteker, M; Castillo, J; Rodriguez-Yanez, M; Fonseca, AC; Watanabe, T; Purroy, F; Wu, ZX; Etgen, T; Hosomi, N; Kerman, SRJ; Sharma, JC; Knauer, C; Santamarina, E; Giannakoulas, G; Garcia-Berrocoso, T; Montaner, J				Llombart, Victor; Antolin-Fontes, Albert; Bustamante, Alejandro; Giralt, Dolors; Rost, Natalia S.; Furie, Karen; Shibazaki, Kensaku; Biteker, Murat; Castillo, Jose; Rodriguez-Yanez, Manuel; Fonseca, Ana Catarina; Watanabe, Tetsu; Purroy, Francisco; Wu Zhixin; Etgen, Thorleif; Hosomi, Naohisa; Kerman, Scott Reza Jafarian; Sharma, Jagdish C.; Knauer, Carolin; Santamarina, Estevo; Giannakoulas, George; Garcia-Berrocoso, Teresa; Montaner, Joan			B-Type Natriuretic Peptides Help in Cardioembolic Stroke Diagnosis Pooled Data Meta-Analysis	STROKE			English	Article						biomarker; etiology	ACUTE ISCHEMIC-STROKE; ATRIAL-FIBRILLATION; CRYPTOGENIC STROKE; UNDETERMINED SOURCE; EMBOLIC STROKES; ATTACK PATIENTS; INCREASED RISK; LEVELS PREDICT; HEART-DISEASE; MORTALITY	Background and Purpose-Determining the underlying cause of stroke is important to optimize secondary prevention treatment. Increased blood levels of natriuretic peptides (B-type natriuretic peptide/N-terminal pro-BNP [BNP/NT-proBNP]) have been repeatedly associated with cardioembolic stroke. Here, we evaluate their clinical value as pathogenic biomarkers for stroke through a literature systematic review and individual participants' data meta-analysis. Methods-We searched publications in PubMed database until November 2013 that compared BNP and NT-proBNP circulating levels among stroke causes. Standardized individual participants' data were collected to estimate predictive values of BNP/NT-proBNP for cardioembolic stroke. Dichotomized BNP/NT-proBNP levels were included in logistic regression models together with clinical variables to assess the sensitivity and specificity to identify cardioembolic strokes and the additional value of biomarkers using area under the curve and integrated discrimination improvement index. Results-From 23 selected articles, we collected information of 2834 patients with a defined cause. BNP/NT-proBNP levels were significantly elevated in cardioembolic stroke until 72 hours from symptoms onset. Predictive models showed a sensitivity >90% and specificity >80% when BNP/NT-proBNP were added considering the lowest and the highest quartile, respectively. Both peptides also increased significantly the area under the curve and integrated discrimination improvement index compared with clinical models. Sensitivity, specificity, and precision of the models were validated in 197 patients with initially undetermined stroke with final pathogenic diagnosis after ancillary follow-up. Conclusions-Natriuretic peptides are strongly increased in cardioembolic strokes. Future multicentre prospective studies comparing BNP and NT-proBNP might aid in finding the optimal biomarker, the best time point, and the optimal cutoff points for cardioembolic stroke identification.	[Llombart, Victor; Antolin-Fontes, Albert; Bustamante, Alejandro; Giralt, Dolors; Garcia-Berrocoso, Teresa; Montaner, Joan] Univ Autonoma Barcelona, Inst Recerca Vall Hebron, Dept Neurol, Neurovasc Unit,Neurovasc Res Lab, E-08193 Barcelona, Spain; [Rost, Natalia S.] Massachusetts Gen Hosp, J Philip Kistler Stroke Res Ctr, Acute Stroke Serv, Boston, MA 02114 USA; [Furie, Karen] Brown Univ, Rhode Isl Hosp, Alpert Med Sch, Dept Neurol, Providence, RI 02903 USA; [Shibazaki, Kensaku] Kawasaki Med Univ, Dept Stroke Med, Kurashiki, Okayama, Japan; [Biteker, Murat] Haydarpasa Numune Educ & Res Hosp, Dept Cardiol, Istanbul, Turkey; [Castillo, Jose; Rodriguez-Yanez, Manuel] Clin Univ, Hosp Univ Santiago Compostela, Hlth Res Inst Santiago Compostela IDIS, Dept Neurol, Santiago De Compostela, Spain; [Fonseca, Ana Catarina] Univ Lisbon, Hosp Santa Maria, Dept Neurosci Neurol, P-1699 Lisbon, Portugal; [Watanabe, Tetsu] Yamagata Univ, Sch Med, Dept Cardiol Pulmonol & Nephrol, Yamagata 990, Japan; [Purroy, Francisco] Hosp Arnau Vilanova, Dept Neurol, Stroke Unit, Grp Neurociencies Clin IRBLleida, Lleida, Spain; [Wu Zhixin] Foshan Hosp Tradit Chinese Med, Dept Emergency Med, Foshan, Guangdong, Peoples R China; [Etgen, Thorleif] Kliniken Sudostbayern Klinikum Traunstein, Dept Neurol, Traunstein, Germany; [Etgen, Thorleif] Tech Univ Munich, Dept Psychiat & Psychotherapy, D-80290 Munich, Germany; [Hosomi, Naohisa] Hiroshima Univ, Grad Sch Biomed & Hlth Sci, Dept Clin Neurosci & Therapeut, Hiroshima, Japan; [Kerman, Scott Reza Jafarian] Univ Tehran Med Sci, Tehran, Iran; [Kerman, Scott Reza Jafarian] Hlth Serv, Tehran, Iran; [Sharma, Jagdish C.] Univ Nottingham, Lincoln Cty Hosp, Stroke & Parkinsons Dis Serv, Nottingham NG7 2RD, England; [Knauer, Carolin] Univ Ulm, Dept Neurol, D-89069 Ulm, Germany; [Santamarina, Estevo] Hosp Valle De Hebron, Dept Neurol, Stroke Unit, Barcelona, Spain; [Giannakoulas, George] AHEPA Univ Hosp, Dept Cardiol, Thessaloniki, Greece	Montaner, J (reprint author), Vall Hebron Univ Hosp, VHIR, Neurovasc Res Lab, Pg Vall Hebron 119-129, Barcelona 08035, Spain.	31862jmv@comb.es	Montaner, Joan/D-3063-2015; Jafarian Kerman, Scott/H-6329-2015	Jafarian Kerman, Scott/0000-0003-0256-5251	Fondo de Investigaciones Sanitarias [PI11/00176]; Vall Hebron Institute of Research; Instituto de Salud Carlos III [CM/00265]; Smoking Research Foundation	Neurovascular Research Laboratory takes part into the Spanish stroke research network INVICTUS (RD12/0014/0005) and is partially funded by grants from the Fondo de Investigaciones Sanitarias PI11/00176). V. Llombart is supported by a predoctoral fellowship from Vall Hebron Institute of Research. Dr Bustamante is supported by a Rio Hortega contract CM/00265 from the Instituto de Salud Carlos III. Dr Hosomi is supported by the Smoking Research Foundation.	Amarenco P, 2009, CEREBROVASC DIS, V27, P97, DOI 10.1159/000200446; Sanna T, 2014, NEW ENGL J MED, V370, P2478, DOI 10.1056/NEJMoa1313600; Gray LJ, 2009, J STROKE CEREBROVASC, V18, P466, DOI 10.1016/j.jstrokecerebrovasdis.2009.02.003; Giannakoulas G, 2005, ANGIOLOGY, V56, P723, DOI 10.1177/000331970505600610; Hijazi Z, 2012, CIRCULATION, V125, P1605, DOI 10.1161/CIRCULATIONAHA.111.038729; Guercini F, 2008, J THROMB HAEMOST, V6, P549, DOI 10.1111/j.1538-7836.2008.02903.x; Rost NS, 2012, STROKE, V43, P441, DOI 10.1161/STROKEAHA.111.629212; ADAMS HP, 1993, STROKE, V24, P35, DOI 10.1161/01.STR.24.1.35; Furie KL, 2011, STROKE, V42, P227, DOI 10.1161/STR.0b013e3181f7d043; de Lemos JA, 2003, LANCET, V362, P316, DOI 10.1016/S0140-6736(03)13976-1; Ferro JM, 2003, LANCET NEUROL, V2, P177, DOI 10.1016/S1474-4422(03)00324-7; Kolominsky-Rabas PL, 2001, STROKE, V32, P2735, DOI 10.1161/hs1201.100209; Shibazaki K, 2009, INTERNAL MED, V48, P1601, DOI 10.2169/internalmedicine.48.2166; Etgen T, 2005, STROKE, V36, P270, DOI 10.1161/01.STR.0000151364.19066.a1; Shibazaki K, 2011, EUR J NEUROL, V18, P165, DOI 10.1111/j.1468-1331.2010.03101.x; Sorensen AG, 2011, NEUROIMAG CLIN N AM, V21, P303, DOI 10.1016/j.nic.2011.01.013; Tamura H, 2012, J CARDIOL, V60, P126, DOI 10.1016/j.jjcc.2012.02.010; Fonseca AC, 2013, ACTA NEUROL SCAND, V128, P235, DOI 10.1111/ane.12112; Purroy F, 2014, EUR J NEUROL, V21, P679, DOI 10.1111/ene.12222; Gladstone DJ, 2014, NEW ENGL J MED, V370, P2467, DOI 10.1056/NEJMoa1311376; Fonseca AC, 2014, INT J STROKE, V9, P419, DOI 10.1111/ijs.12126; Montaner J, 2008, STROKE, V39, P2280, DOI 10.1161/STROKEAHA.107.505354; Shibazaki K, 2009, INTERNAL MED, V48, P259, DOI 10.2169/internalmedicine.48.1475; Daniels LB, 2007, J AM COLL CARDIOL, V50, P2357, DOI 10.1016/j.jacc.2007.09.021; Petty GW, 2000, STROKE, V31, P1062; Arboix Adrià, 2011, Expert Rev Cardiovasc Ther, V9, P367, DOI 10.1586/erc.10.192; Biteker M, 2013, INT J STROKE; Bustamante A, 2014, J NEUROIMMUNOL, V274, P215, DOI 10.1016/j.jneuroim.2014.07.015; Efron B, 1993, MONOGRAPHS STAT APPL, P1; European Stroke Organization (ESO), 2008, CEREBROVASC, V25, P457; Fonseca AC, 2011, INT J STROKE, V6, P398, DOI 10.1111/j.1747-4949.2011.00606.x; Garcia-Berrocoso T, 2013, NEUROLOGY, V81, P1976, DOI 10.1212/01.wnl.0000436937.32410.32; Go AS, 2014, CIRCULATION, V129, pE28, DOI 10.1161/01.cir.0000441139.02102.80; Hajsadeghi S, 2013, J STROKE CEREBROVASC, V22, P554, DOI 10.1016/j.jstrokecerebrovasdis.2013.01.012; Hart RG, 2014, LANCET NEUROL, V13, P429, DOI 10.1016/S1474-4422(13)70310-7; Hoogeveen RC, 2005, EXPERT REV MOL DIAGN, V5, P9, DOI 10.1586/14737159.5.1.9; Kim SJ, 2013, STROKE, V15, P27, DOI [10.5853/jos.2013.15.1.27, DOI 10.5853/JOS.2013.15.1.27]; Knauer C, 2012, BMC NEUROL, V12, DOI 10.1186/1471-2377-12-14; Llombart V, 2013, PROSPERO; Nam HS, 2012, STROKE, V43, P2948, DOI 10.1161/STROKEAHA.112.661074; Naya T, 2008, CEREBROVASC DIS, V26, P434, DOI 10.1159/000155640; Ntaios G, 2015, STROKE, V46, P176, DOI 10.1161/STROKEAHA.114.007240; R Development Core Team, 2012, R LANG ENV STAT COMP; Riley RD, 2010, BRIT MED J, V340, DOI 10.1136/bmj.c221; Rodriguez-Yanez M, 2013, NEUROLOGY, V81, P444, DOI 10.1212/WNL.0b013e31829d8773; Rodriguez-Yanez M, 2009, DIS MARKERS, V26, P189, DOI 10.3233/DMA-2009-0630; Sakai K, 2013, EUR NEUROL, V69, P246, DOI 10.1159/000342887; Santamarina E, 2012, J NEUROL, V259, P2538, DOI 10.1007/s00415-012-6532-4; Sharma Jagdish C, 2006, J Stroke Cerebrovasc Dis, V15, P121, DOI 10.1016/j.jstrokecerebrovasdis.2006.03.003; Hart RG, 2007, NEUROLOGY, V69, P546; Yang HL, 2014, J STROKE CEREBROVASC, V23, P1882, DOI 10.1016/j.jstrokecerebrovasdis.2014.02.014; Yukiiri K, 2008, BMC NEUROL, V8, DOI 10.1186/1471-2377-8-45; Zhixin Wu, 2013, Clin Neurol Neurosurg, V115, P1671, DOI 10.1016/j.clineuro.2013.02.021	53	1	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0039-2499	1524-4628		STROKE	Stroke	MAY	2015	46	5					1187	1195		10.1161/STROKEAHA.114.008311		9	Clinical Neurology; Peripheral Vascular Disease	Neurosciences & Neurology; Cardiovascular System & Cardiology	CG8LR	WOS:000353559800023		
J	Saura, H; Ogasawara, K; Beppu, T; Yoshida, K; Kobayashi, M; Yoshida, K; Terasaki, K; Takai, Y; Ogawa, A				Saura, Hiroaki; Ogasawara, Kuniaki; Beppu, Takaaki; Yoshida, Koji; Kobayashi, Masakazu; Yoshida, Kenji; Terasaki, Kazunori; Takai, Yoshihiro; Ogawa, Akira			Hypoxic Viable Tissue in Human Chronic Cerebral Ischemia Because of Unilateral Major Cerebral Artery Steno-Occlusive Disease	STROKE			English	Article						cerebrovascular disease; positron-emission tomography	POSITRON-EMISSION-TOMOGRAPHY; F-18-LABELED 2-NITROIMIDAZOLE ANALOG; BLOOD-FLOW; OXYGEN-METABOLISM; CEREBROVASCULAR-DISEASE; CAROTID-ENDARTERECTOMY; COGNITIVE IMPROVEMENT; IMAGING HYPOXIA; CELL FRACTION; STROKE	Background and Purpose-Positron emission tomography (PET) with radiolabeled 2-nitroimidazoles directly detects hypoxic but viable tissue present in an acute ischemic area in the human brain. This study using PET with 1-(2-F-18-fluoro-1-[ [hydroxymethyl] ethoxy) methyl-2-nitroimidazole (F-18-FRP170) aimed to determine whether tissue with an abnormally elevated uptake of F-18-FRP170 exists in human chronic cerebral ischemia because of unilateral atherosclerotic major cerebral artery steno-occlusive disease. Methods-F-18-FRP170 PET was performed, and cerebral blood flow and metabolism were assessed using O-15-gas PET in 20 healthy subjects and 52 patients. A region of interest (ROI) was automatically placed in 3 segments of the middle cerebral artery territory in both cerebral hemispheres with a 3-dimensional stereotaxic ROI template using SPM2, and each PET value was determined in each ROI. The ratio of values in the affected versus contralateral hemispheres was calculated for the F-18-FRP170 PET image. Results-A significant correlation was observed between oxygen extraction fraction and F-18-FRP170 ratios (rho= 0.509; P<0.0001) in a total of 156 ROIs in 52 patients. The specificity and positive-predictive value for a combination of an elevated oxygen extraction fraction and a moderately reduced cerebral oxygen metabolism for detection of an abnormally elevated F-18-FRP170 ratio (19 ROIs: 12%) were significantly greater than those for the individual categories (elevated oxygen extraction fraction, moderately reduced cerebral oxygen metabolism, or reduced cerebral blood flow). Conclusions-Tissues with abnormally elevated uptake of 18F-FRP170 exist in human chronic cerebral ischemia characterized by a combination of misery perfusion and moderately reduced oxygen metabolism because of unilateral atherosclerotic major cerebral artery steno-occlusive disease.	[Saura, Hiroaki; Ogasawara, Kuniaki; Beppu, Takaaki; Yoshida, Koji; Kobayashi, Masakazu; Yoshida, Kenji; Ogawa, Akira] Iwate Med Univ, Sch Med, Dept Neurosurg, Morioka, Iwate 0208505, Japan; [Terasaki, Kazunori] Iwate Med Univ, Sch Med, Cyclotron Res Ctr, Morioka, Iwate 0208505, Japan; [Takai, Yoshihiro] Hirosaki Univ, Grad Sch Med, Dept Radiol & Radiat Oncol, Hirosaki, Aomori, Japan	Saura, H (reprint author), Iwate Med Univ, Sch Med, Dept Neurosurg, 19-1 Uchimaru, Morioka, Iwate 0208505, Japan.	hirosau33@gmail.com			Ministry of Education, Culture, Sports, Science and Technology of Japan [S1491001]; Japan Society for the Promotion of Science [2612345]	This work was partly supported by Grant-in-Aid for Strategic Medical Science Research (S1491001, 2014-2018) from the Ministry of Education, Culture, Sports, Science and Technology of Japan; Grant-in- Aid for Scientific Research (2612345) from Japan Society for the Promotion of Science.	Alawneh JA, 2014, EUR J NUCL MED MOL I, V41, P736, DOI 10.1007/s00259-013-2581-x; Spence AM, 2008, CLIN CANCER RES, V14, P2623, DOI 10.1158/1078-0432.CCR-07-4995; POWERS WJ, 1985, STROKE, V16, P361; Markus R, 2004, BRAIN, V127, P1427, DOI 10.1093/brain/awh162; Takeuchi R, 2004, EUR J NUCL MED MOL I, V31, P578, DOI 10.1007/s00259-003-1406-8; Chida K, 2010, CEREBROVASC DIS, V29, P343, DOI 10.1159/000278930; Ibaraki M, 2008, J NUCL MED, V49, P50, DOI 10.2967/jnumed.107.044008; GIBBS JM, 1984, LANCET, V1, P310; Furlan M, 1996, ANN NEUROL, V40, P216, DOI 10.1002/ana.410400213; ASTRUP J, 1981, STROKE, V12, P723; FRACKOWIAK RSJ, 1980, J COMPUT ASSIST TOMO, V4, P727, DOI 10.1097/00004728-198012000-00001; NUNN A, 1995, EUR J NUCL MED, V22, P265, DOI 10.1007/BF01081524; Saito H, 2013, AM J NEURORADIOL, V34, P976, DOI 10.3174/ajnr.A3344; Tochon-Danguy HJ, 2002, NUCL MED BIOL, V29, P191, DOI 10.1016/S0969-8051(01)00298-0; Derdeyn CP, 2001, RADIOLOGY, V220, P195; Yoshida K, 2012, NEUROL MED-CHIR, V52, P154; Momjian-Mayor I, 2005, STROKE, V36, P567, DOI 10.1161/01.STR.0000155727.82242.e1; POWERS WJ, 1991, ANN NEUROL, V29, P231, DOI 10.1002/ana.410290302; Spratt NJ, 2006, STROKE, V37, P1862, DOI 10.1161/01.STR.000022690B.9329S.9d; Shibahara I, 2010, J NEUROSURG, V113, P358, DOI 10.3171/2009.10.JNS09510; BARON JC, 1981, STROKE, V12, P454; HOSSMANN KA, 1994, ANN NEUROL, V36, P557, DOI 10.1002/ana.410360404; Lee ST, 2007, SEMIN NUCL MED, V37, P451, DOI 10.1053/j.semnuclmed.2007.07.00.1; BARON JC, 1991, CEREBROVASC DIS, V1, P22, DOI 10.1159/000108877; Beppu T, 2014, MOL IMAGING BIOL, V16, P127, DOI 10.1007/s11307-013-0670-7; CHAPMAN JD, 1981, BRIT J CANCER, V43, P546, DOI 10.1038/bjc.1981.79; Cher LM, 2006, J NUCL MED, V47, P410; HEISS WD, 1994, EUR J NUCL MED, V21, P455; HEISS WD, 1992, J CEREBR BLOOD F MET, V12, P193; Ishikawa Y, 2005, APPL RADIAT ISOTOPES, V62, P705, DOI 10.1016/j.apradiso.2004.09.008; Isozaki M, 2011, EUR J NUCL MED MOL I, V38, P1075, DOI 10.1007/s00259-011-1734-z; Kaneta T, 2002, J NUCL MED, V43, P109; Kaneta T, 2007, ANN NUCL MED, V21, P101; Kuroda S, 2006, STROKE, V37, P393, DOI 10.1161/01.STR.0000198878.66000.4e; LAMMERTSMA AA, 1983, J CEREBR BLOOD F MET, V3, P416; Markus R, 2003, STROKE, V34, P2646, DOI 10.1161/01.STR.0000094422.74023.FF; MARTIN GV, 1992, J NUCL MED, V33, P2202; Nishimiya M, 2008, ANN NUCL MED, V22, P921, DOI 10.1007/s12149-008-0211-7; Read SJ, 2000, ANN NEUROL, V48, P228, DOI 10.1002/1531-8249(200008)48:2<228::AID-ANA13>3.0.CO;2-B; Read SJ, 1998, NEUROLOGY, V51, P1617; Wada H, 2000, J LABELLED COMPD RAD, V43, P785, DOI 10.1002/1099-1344(200007)43:8<785::AID-JLCR363>3.3.CO;2-X; Yamashita T, 2012, CLIN NUCL MED, V37, P128, DOI 10.1097/RLU.0b013e31823e9a9a; Yamauchi H, 2011, J CEREBR BLOOD F MET, V31, P953, DOI 10.1038/jcbfm.2010.176	43	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0039-2499	1524-4628		STROKE	Stroke	MAY	2015	46	5					1250	1256		10.1161/STROKEAHA.114.008238		7	Clinical Neurology; Peripheral Vascular Disease	Neurosciences & Neurology; Cardiovascular System & Cardiology	CG8LR	WOS:000353559800033		
J	Shibata, J; Ishihara, S; Tada, N; Kawai, K; Tsuno, NH; Yamaguchi, H; Sunami, E; Kitayama, J; Watanabe, T				Shibata, J.; Ishihara, S.; Tada, N.; Kawai, K.; Tsuno, N. H.; Yamaguchi, H.; Sunami, E.; Kitayama, J.; Watanabe, T.			Surgical stress response after colorectal resection: a comparison of robotic, laparoscopic, and open surgery	TECHNIQUES IN COLOPROCTOLOGY			English	Article						Robotic surgery; Laparoscopic surgery; Colorectal resection; HLA-DR; Lymphocyte subsets	POSTOPERATIVE NEUTROPHIL LEUKOCYTOSIS; RECTAL-CANCER; HLA-DR; RANDOMIZED-TRIAL; CLASICC TRIAL; OUTCOMES; COMPLICATIONS; COLECTOMY; CHEMORADIOTHERAPY; GASTRECTOMY	The perioperative immune status of colorectal robotic surgery (RS), laparoscopic surgery (LS), and open surgery (OS) patients has not been compared. Our aim was to evaluate perioperative stress and immune response after RS, LS and OS. This prospective study included 46 colorectal surgery patients from the Department of Surgical Oncology of the University of Tokyo Hospital. Peripheral venous blood samples were obtained preoperatively and on postoperative days 1, 3, and 6. We evaluated expression of HLA-DR (marker of immune competence), C-reactive protein (CRP) levels, and lymphocyte subset counts (natural killers, cytotoxic T cells and helper T cells). Fifteen, 23, and 8 patients underwent RS, LS and OS, respectively. HLA-DR expression was the lowest on day 1 and gradually increased on days 3 and 6 in all the groups. There was no significant difference in postoperative HLA-DR expression between the RS and LS group. However, on day 3, HLA-DR expression in the RS group was significantly higher than in the OS group (p = 0.04). On day 1, CRP levels in the LS group were significantly lower than in the RS group (p = 0.038). There were no significant perioperative changes in the lymphocyte subset cell count between the three groups. Perioperative surgical stress, as evaluated by immunological parameters, was comparable between robotic and laparoscopic surgery and higher with open surgery. Robotic surgery may be an alternative to laparoscopic surgery, as a minimally invasive surgery option for colorectal cancer.	[Shibata, J.; Ishihara, S.; Tada, N.; Kawai, K.; Yamaguchi, H.; Sunami, E.; Kitayama, J.; Watanabe, T.] Univ Tokyo, Dept Surg Oncol, Fac Med, Bunkyo Ku, Tokyo 1130033, Japan; [Tsuno, N. H.] Univ Tokyo, Dept Transfus Med, Fac Med, Tokyo 1130033, Japan	Shibata, J (reprint author), Univ Tokyo, Dept Surg Oncol, Fac Med, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1130033, Japan.	shibata200101545@yahoo.co.jp					Veenhof AAFA, 2012, ANN SURG, V255, P216, DOI 10.1097/SLA.0b013e31824336e2; Kawasaki T, 2001, ANESTH ANALG, V92, P1322; Kawai K, 2003, J ALLERGY CLIN IMMUN, V112, P951, DOI [10.1067/mai.2003.1756, 10.1016/S0091-6749(03)02007-4]; Hyun MH, 2013, ANN SURG ONCOL, V20, P1258, DOI 10.1245/s10434-012-2679-6; Pigazzi A, 2006, SURG ENDOSC, V20, P1521, DOI 10.1007/s00464-005-0855-5; Park JY, 2012, BRIT J SURG, V99, P1554, DOI 10.1002/bjs.8887; Halabi WJ, 2013, WORLD J SURG, V37, P2782, DOI 10.1007/s00268-013-2024-7; van der Pas MHGM, 2013, LANCET ONCOL, V14, P210, DOI 10.1016/S1470-2045(13)70016-0; Fleshman J, 2007, ANN SURG, V246, P655, DOI 10.1097/SLA.0b013e318155a762; Tyler JA, 2013, DIS COLON RECTUM, V56, P458, DOI 10.1097/DCR.0b013e31827085ec; Kim CW, 2014, J GASTROINTEST SURG, V18, P816, DOI 10.1007/s11605-014-2469-5; Jayne DG, 2010, BRIT J SURG, V97, P1638, DOI 10.1002/bjs.7160; Jayne DG, 2007, J CLIN ONCOL, V25, P3061, DOI 10.1200/JCO.2006.09.7758; Salman M, 2013, AM SURGEON, V79, P553; Scarpinata R, 2013, DIS COLON RECTUM, V56, P253, DOI 10.1097/DCR.0b013e3182694595; Saklani AP, 2013, INT J COLORECTAL DIS, V28, P1689, DOI 10.1007/s00384-013-1756-z; Tsimogiannis KE, 2012, SURG ENDOSC, V26, P330, DOI 10.1007/s00464-011-1871-2; Han SA, 2010, INT J COLORECTAL DIS, V25, P631, DOI 10.1007/s00384-010-0882-0; Braga M, 2002, DIS COLON RECTUM, V45, P1070, DOI 10.1097/01.DCR.0000017602.54619.E3; Baumgartner JM, 2009, J AM COLL SURGEONS, V208, P110, DOI 10.1016/j.jamcollsurg.2008.08.012; Biondi A, 2013, BMC SURG, V13, DOI 10.1186/1471-2482-13-S2-S12; Fleshman J, 2007, ANN SURG, V246, P662, DOI DOI 10.1097/SLA.0B013E318155A762; Flohe S, 2004, INTENS CARE MED, V30, P96, DOI 10.1007/s00134-003-2041-3; Group CS, 2004, NEW ENGL J MED, V350, P2050; Hartley A, 2003, EUR J SURG ONCOL, V29, P155, DOI 10.1053/ejso.2002.1364; Karanika Styliani, 2013, Gastroenterol Rep (Oxf), V1, P85, DOI 10.1093/gastro/got014; Keller DS, 2013, SURG ENDOSC, V28, P212; Kerr SF, 2010, COLORECTAL DIS, V12, P549, DOI 10.1111/j.1463-1318.2009.01858.x; KONO K, 1995, J SURG RES, V58, P275, DOI 10.1006/jsre.1995.1043; Mokart D, 2011, MINERVA ANESTESIOL, V77, P522; Park EJ, 2015, ANN SURG, V261, P129, DOI 10.1097/SLA.0000000000000613; Peterson CY, 2014, J GASTROINTEST SURG, V18, P398, DOI 10.1007/s11605-013-2313-3; Veenhof AAFA, 2011, INT J COLORECTAL DIS, V26, P53, DOI 10.1007/s00384-010-1056-9; Veldkamp R, 2004, SURG ENDOSC, V18, P1163, DOI 10.1007/s00464-003-8253-3; Wichmann MW, 2003, DIS COLON RECTUM, V46, P875, DOI 10.1097/01.DCR.0000070527.70297.09	35	2	2	SPRINGER-VERLAG ITALIA SRL	MILAN	VIA DECEMBRIO, 28, MILAN, 20137, ITALY	1123-6337	1128-045X		TECH COLOPROCTOL	Tech. Coloproctology	MAY	2015	19	5					275	280		10.1007/s10151-014-1263-4		6	Gastroenterology & Hepatology; Surgery	Gastroenterology & Hepatology; Surgery	CH1OL	WOS:000353791000002		
J	Imamura, T; Ogawa, T; Minagawa, T; Yokoyama, H; Nakazawa, M; Nishizawa, O; Ishizuka, O				Imamura, Tetsuya; Ogawa, Teruyuki; Minagawa, Tomonori; Yokoyama, Hitoshi; Nakazawa, Masaki; Nishizawa, Osamu; Ishizuka, Osamu			Engineered Bone Marrow-Derived Cell Sheets Restore Structure and Function of Radiation-Injured Rat Urinary Bladders	TISSUE ENGINEERING PART A			English	Article							RESPONSIVE CULTURE SURFACES; DEMUCOSALIZED GASTRIC FLAPS; TRANSPLANTATION IMPROVES; MYOCARDIAL-INFARCTION; CARDIOMYOCYTE SHEETS; MYOBLAST SHEETS; HEART FUNCTION; REPAIR; TEMPERATURE; TISSUES	Previously, we reported that implantation of isolated single bone marrow-derived cells into radiation-injured urinary bladders could restore structure and function. However, injections of isolated single cells had some limitations. Thus, in this study, we produced bone marrow-derived cell sheets in temperature-responsive culture dishes that release the monolayer sheets intact. We then determined whether the produced cell sheets could restore function to irradiated urinary bladders. Twenty female 10-week-old Sprague-Dawley (SD) rats were irradiated with 2 gray once a week for 5 weeks. Bone marrow cells harvested from two male 17-week-old green fluorescence protein-transfected SD rats were placed in primary culture for 7 days. Bone marrow cell-derived outgrowths were harvested by enzymatic digestion and transferred into the atelocollagen-coated temperature-responsive culture dishes for 2 days. To harvest the secondarily cultured cells as monolayer sheets, a support membrane was put in each culture dish, and then the temperature was reduced to 20 degrees C. Each released cell sheet was then patched onto the irradiated anterior bladder wall (n=10). As controls, cell-free sheets were similarly patched (n=10). After 4 weeks, transplanted cells were detected on the bladder walls. The cell sheet-transplanted bladders had smooth muscle layers and acetylcholinesterase-positive nerve fibers in proportions that were significantly larger than those of the control bladders. In addition, the cell sheet-transplanted bladders had reduced prolyl 4-hydroxylase beta (P4HB)-positive regions of collagen synthesis and apoptosis within the smooth muscle layers. In cystometric investigations, threshold pressures, voiding interval, micturition volume, and bladder capacity in the cell sheet-transplantation group were significantly higher than those in the control group. Residual volume of the cell sheet-transplantation group was significantly lower compared with the control. There were 24 growth factor mRNAs in the cell sheet-transplanted urinary bladders that were expressed greater than or equal to two-fold over the controls. In conclusion, cell sheet engineering has great potential to restore damaged urinary bladders.	[Imamura, Tetsuya; Nishizawa, Osamu; Ishizuka, Osamu] Shinshu Univ, Sch Med, Dept Lower Urinary Tract Med, Matsumoto, Nagano 3908621, Japan; [Ogawa, Teruyuki; Minagawa, Tomonori; Yokoyama, Hitoshi; Nakazawa, Masaki; Nishizawa, Osamu; Ishizuka, Osamu] Shinshu Univ, Sch Med, Dept Urol, Matsumoto, Nagano 3908621, Japan	Imamura, T (reprint author), Shinshu Univ, Sch Med, Dept Lower Urinary Tract Med, 3-1-1 Asahi, Matsumoto, Nagano 3908621, Japan.	imatetu@shinshu-u.ac.jp			Japanese Ministry of Education, Culture, Sport, Science and Technology [24592427]	This study was supported by a Grant-in-Aid for Scientific Research from the Japanese Ministry of Education, Culture, Sport, Science and Technology (no. 24592427).	Imamura T, 2008, CELL TRANSPLANT, V17, P267; Kushida A, 1999, J BIOMED MATER RES, V45, P355, DOI 10.1002/(SICI)1097-4636(19990615)45:4<355::AID-JBM10>3.0.CO;2-7; Kawamura M, 2013, CIRCULATION, V128, pS87, DOI 10.1161/CIRCULATIONAHA.112.000366; Kawamura M, 2012, CIRCULATION, V126, pS29, DOI 10.1161/CIRCULATIONAHA.111.084343; Hoashi T, 2009, J THORAC CARDIOV SUR, V138, P460, DOI 10.1016/j.jtcvs.2009.02.018; Yang J, 2006, J CONTROL RELEASE, V116, P193, DOI 10.1016/j.jconrel.2006.06.022; Yamato M, 2002, BIOMATERIALS, V23, P561, DOI 10.1016/S0142-9612(01)00138-7; Yamato M, 2000, BIOMATERIALS, V21, P981, DOI 10.1016/S0142-9612(99)00239-2; Nishida K, 2004, NEW ENGL J MED, V351, P1187, DOI 10.1056/NEJMoa040455; Sekine H, 2006, J HEART LUNG TRANSPL, V25, P324, DOI 10.1016/j.healun.2005.09.017; Shiroyanagi Y, 2003, TISSUE ENG, V9, P1005, DOI 10.1089/107632703322495646; Sawa Y, 2012, SURG TODAY, V42, P181, DOI 10.1007/s00595-011-0106-4; Masumoto H, 2012, STEM CELLS, V30, P1196, DOI 10.1002/stem.1089; Sekiya N, 2009, J THORAC CARDIOV SUR, V138, P985, DOI 10.1016/j.jtcvs.2009.02.004; Yano F, 2013, BIOMATERIALS, V34, P5581, DOI 10.1016/j.biomaterials.2013.04.008; Memon IA, 2005, J THORAC CARDIOV SUR, V130, P1333, DOI 10.1016/j.jtcvs.2005.07.023; Kwon OH, 2003, BIOMATERIALS, V24, P1223; Sekine H, 2011, TISSUE ENG PT A, V17, P2973, DOI 10.1089/ten.tea.2010.0659; Matsuura K, 2009, J CLIN INVEST, V119, P2204, DOI 10.1172/JCI37456; Ohki T, 2012, GASTROENTEROLOGY, V143, P582, DOI 10.1053/j.gastro.2012.04.050; Kwon OH, 2000, J BIOMED MATER RES, V50, P82, DOI 10.1002/(SICI)1097-4636(200004)50:1<82::AID-JBM12>3.0.CO;2-7; Sekine H, 2008, CIRCULATION, V118, pS145, DOI 10.1161/CIRCULATIONAHA.107.757286; Miyahara Y, 2006, NAT MED, V12, P459, DOI 10.1038/nm1391; Shimizu T, 2006, FASEB J, V20, P708, DOI 10.1096/fj.05-4715fje; Imamura T, 2012, TISSUE ENG PT A, V18, P1698, DOI [10.1089/ten.TEA.2012.0061, 10.1089/ten.tea.2012.0061]; Imanishi Y, 2011, CIRCULATION, V124, pS10, DOI 10.1161/CIRCULATIONAHA.110.009993; Ito S, 2012, BIOMATERIALS, V33, P5278, DOI 10.1016/j.biomaterials.2012.03.073; Iwata T, 2015, J TISSUE ENG REGEN M, V9, P343, DOI 10.1002/term.1785; Kadota S, 2013, EUR HEART J, V34, P1147, DOI 10.1093/eurheartj/ehs418; Matsuura K, 2013, J CONTROL RELEASE, V169, P336, DOI 10.1016/j.jconrel.2013.03.003; Shiroyanagi Y, 2004, BJU INT, V93, P1069, DOI 10.1111/j.1464-410X.2004.04783.x; TAKEZAWA T, 1990, BIO-TECHNOL, V8, P854, DOI 10.1038/nbt0990-854; Watanabe E, 2011, TRANSPLANTATION, V91, P700, DOI 10.1097/TP.0b013e31820e0170	33	0	0	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	1937-3341	1937-335X		TISSUE ENG PT A	Tissue Eng. Part A	MAY 1	2015	21	9-10					1600	1610		10.1089/ten.tea.2014.0592		11	Cell & Tissue Engineering; Biotechnology & Applied Microbiology; Cell Biology	Cell Biology; Biotechnology & Applied Microbiology	CH3TD	WOS:000353952300012		
J	Okita, N; Honda, Y; Kishimoto, N; Liao, W; Azumi, E; Hashimoto, Y; Matsumoto, N				Okita, Naoya; Honda, Yoshitomo; Kishimoto, Naotaka; Liao, Wen; Azumi, Eiko; Hashimoto, Yoshiya; Matsumoto, Naoyuki			Supplementation of Strontium to a Chondrogenic Medium Promotes Chondrogenic Differentiation of Human Dedifferentiated Fat Cells	TISSUE ENGINEERING PART A			English	Article							MESENCHYMAL STEM-CELLS; CALCIUM-SENSING RECEPTOR; IN-VITRO; OSTEOBLASTIC DIFFERENTIATION; EPIGENETIC REGULATION; BONE; RANELATE; EXPRESSION; PATHWAY; TISSUE	Dedifferentiated fat cells (DFAT cells) isolated from adipose tissue have been demonstrated to differentiate into chondrogenic cells in vitro. Nevertheless, an efficient method to facilitate its chondrogenic differentiation is still unexplored, hampering the extensive application of these cells in cartilage regeneration therapies. Here we provide the evidence that supplementation of strontium ions (Sr) in a chondrogenic medium (CM) significantly promotes early chondrogenic differentiation of DFAT cells. Human DFAT cells and the mesenchymal stem cell line (RCB2153) were subjected to the CM supplemented with/without Sr. After 14 days, alcian blue staining intensity significantly increased in DFAT cells, but not in RCB2153, subjected to CM with Sr. mRNA expression analysis revealed that the CM with 1.5 mM Sr increased the expression of chondrogenic marker, collagen type 2 alpha 1, whereas there was no significant change in osteogenic markers, collagen type 1 alpha 1, runt-related transcription factor 2, and osteocalcin, and hypertrophic chondrogenic marker, collagen type 10 alpha 1. Inhibitors for extracellular signal-regulated kinase 1/2 (ERK1/2), Akt, and calcium-sensing receptor (CaSR) pathways significantly diminished the alcian blue staining intensity, providing the first evidence that these signal pathways are associated with chondrogenic differentiation of DFAT cells. CaSR and ERK1/2 pathways independently induced Sr-mediated early chondrogenic differentiation. These results suggest that Sr supplementation into the CM may provide a powerful platform for preparing chondrogenically differentiated DFAT cells for cartilage regeneration.	Osaka Dent Univ, Hirakata, Osaka 5731121, Japan; Amagasaki Chuo Hosp, Amagasaki, Hyogo, Japan; [Okita, Naoya; Liao, Wen; Azumi, Eiko; Matsumoto, Naoyuki] Osaka Dent Univ, Dept Orthodont, Hirakata, Osaka 5731121, Japan; [Honda, Yoshitomo] Osaka Dent Univ, Inst Dent Res, Hirakata, Osaka 5731121, Japan; [Kishimoto, Naotaka] Osaka Dent Univ, Dept Anesthesiol, Hirakata, Osaka 5731121, Japan; [Hashimoto, Yoshiya] Osaka Dent Univ, Dept Biomat, Hirakata, Osaka 5731121, Japan	Honda, Y (reprint author), Osaka Dent Univ, Inst Dent Res, 8-1 Kuzuha Hanazonocho, Hirakata, Osaka 5731121, Japan.	honda-y@cc.osaka-dent.ac.jp			Japan Science and Technology Agency [25861904]	This study was supported, in part, by a Grant-in-aid (25861904) from the Japan Science and Technology Agency. We thank H. Kawaki (Department of Oral Biochemistry, Asahi University School of Dentistry) for technical advice for western blotting, F. Sakamoto (Department of Orthodontics, Osaka Dental University) and A. Nishio (Second Department of Oral and Maxillofacial Surgery, Osaka Dental University) for technical support.	Justesen J, 2004, TISSUE ENG, V10, P381, DOI 10.1089/107632704323061744; Peng SL, 2009, CELL PHYSIOL BIOCHEM, V23, P165, DOI 10.1159/000204105; Brown EM, 2001, PHYSIOL REV, V81, P239; Pelttari K, 2008, INJURY, V39, pS58, DOI 10.1016/j.injury.2008.01.038; Bonnelye E, 2008, BONE, V42, P129, DOI 10.1016/j.bone.2007.08.043; Shen BJ, 2009, TISSUE ENG PT A, V15, P1311, DOI 10.1089/ten.tea.2008.0132; Arzate-Mejia RG, 2011, IUBMB LIFE, V63, P881, DOI 10.1002/iub.557; Kypriotou M, 2003, DNA CELL BIOL, V22, P119, DOI 10.1089/104454903321515922; Leijten JCH, 2013, TISSUE ENG PART B-RE, V19, P31, DOI [10.1089/ten.TEB.2012.0273, 10.1089/ten.teb.2012.0273]; Akiyama H, 2002, GENE DEV, V16, P2813, DOI 10.1101/gad.1017802; Tsuda M, 2003, J BIOL CHEM, V278, P27224, DOI 10.1074/jbc.M303471200; Jumabay M, 2009, J MOL CELL CARDIOL, V47, P565, DOI 10.1016/j.yjmcc.2009.08.004; Eslaminejad MB, 2013, CELL J, V15, P1; Kikuta S, 2013, TISSUE ENG PT A, V19, P1792, DOI [10.1089/ten.TEA.2012.0380, 10.1089/ten.tea.2012.0380]; Henrotin Y, 2001, J BONE MINER RES, V16, P299, DOI 10.1359/jbmr.2001.16.2.299; Magno AL, 2011, ENDOCR REV, V32, P3, DOI 10.1210/er.2009-0043; Fromigue O, 2009, J CELL MOL MED, V13, P2189, DOI 10.1111/j.1582-4934.2009.00673.x; Guo X, 2009, CELL RES, V19, P71, DOI 10.1038/cr.2008.302; Kishimoto N, 2013, CYTOTECHNOLOGY, V65, P15, DOI 10.1007/s10616-012-9456-z; SUGIHARA H, 1986, DIFFERENTIATION, V31, P42, DOI 10.1111/j.1432-0436.1986.tb00381.x; Matsumoto T, 2008, J CELL PHYSIOL, V215, P210, DOI 10.1002/jcp.21304; Caverzasio J, 2008, BONE, V42, P1131, DOI 10.1016/j.bone.2008.02.010; Matsuda N, 2007, ADV MATER, V19, P3089, DOI 10.1002/adma.200701978; Shimomura K, 2014, TISSUE ENG PT A, V20, P2291, DOI 10.1089/ten.tea.2013.0414; Carney Ellen F, 2012, Nat Rev Rheumatol, V8, P563, DOI 10.1038/nrrheum.2012.155; Egusa H, 2012, J PROSTHODONT RES, V56, P151, DOI 10.1016/j.jpor.2012.06.001; Handlogten ME, 2001, J BIOL CHEM, V276, P13941; Holstein DM, 2004, J BIOL CHEM, V279, P10060, DOI 10.1074/jbc.M312039200; Honda Y, 2013, SCI REP-UK, V3, DOI 10.1038/srep03420; Hoshi K., 2013, ORAL SCI INT, V10, P15; Kazama T, 2008, BIOCHEM BIOPH RES CO, V377, P780, DOI 10.1016/j.bbrc.2008.10.046; Kishimoto N, 2008, J ORAL TISSUE ENG, V6, P127; Kishimoto N, 2014, CLIN ORAL INVEST, V18, P1893, DOI 10.1007/s00784-013-1166-1; Kishimoto N, 2011, J ORAL TISSUE ENG, V8, P151; Lee CSD, 2012, STEM CELL RES THER, V3, DOI 10.1186/scrt126; Lee EH, 2006, J BONE JOINT SURG BR, V88B, P841, DOI 10.1302/0301-620X.88B7.17305; Lee JH, 2004, IEEE ROBOT AUTOM MAG, V11, P41; Marie PJ, 2007, BONE, V40, pS5, DOI 10.1016/j.bone.2007.02.003; Nakamura T, 2013, BIOCHEM BIOPH RES CO, V440, P289, DOI 10.1016/j.bbrc.2013.09.073; Oki Y, 2008, CELL STRUCT FUNCT, V33, P211; Sakamoto F, 2015, CYTOTECHNOLOGY, V67, P75, DOI 10.1007/s10616-013-9659-y; Sakuma T, 2009, J UROLOGY, V182, P355, DOI 10.1016/j.juro.2009.02.103; Shen JF, 2011, INT J ORAL SCI, V3, P117, DOI 10.4248/IJOS11044; Shirakata Y, 2014, J MATER SCI-MATER M, V25, P899, DOI 10.1007/s10856-013-5124-x; Tang QO, 2009, EXPERT OPIN BIOL TH, V9, P689, DOI [10.1517/14712590902936823 , 10.1517/14712590902936823]; Wang JG, 2013, BIOL TRACE ELEM RES, V153, P212, DOI 10.1007/s12011-013-9640-9; Yagi K, 2004, BIOCHEM BIOPH RES CO, V321, P967, DOI 10.1016/j.bbrc.2004.07.055; Zuk P., 2013, ISRN STEM CELLS, DOI DOI 10.1155/2013/713959	48	0	0	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	1937-3341	1937-335X		TISSUE ENG PT A	Tissue Eng. Part A	MAY 1	2015	21	9-10					1695	1704		10.1089/ten.tea.2014.0282		10	Cell & Tissue Engineering; Biotechnology & Applied Microbiology; Cell Biology	Cell Biology; Biotechnology & Applied Microbiology	CH3TD	WOS:000353952300021		
J	Karasaki, K; Doughty, C; Onishi, CT; Goto, J				Karasaki, Kenzi; Doughty, Christine; Onishi, Celia T.; Goto, Junichi			Development of Geohydrologic Model of the Wildcat Fault Zone	TRANSPORT IN POROUS MEDIA			English	Article						Fault zone; Anisotropy; Fractured rock; Characterization; Cross-hole test; Geophysical survey; Borehole logging; Pressure profile; Temperature profile; Long-term monitoring; Recharge Rate; Model uncertainty; Scale-up		We have conducted field investigations of the Wildcat fault in Strawberry Canyon in the East Bay Hills of Berkeley, California, including a literature survey, aerial-photographic-based geomorphological study, geologic mapping, geophysical surveys, trenching, and borehole drilling and hydraulic testing. A geologic model was constructed, which became the basis of the hydrologic model. We outline the effort of constructing the geohydrologic model of the Strawberry Canyon area. We also created an East Canyon sub-model, which is a part of the Strawberry Canyon area. These models were constructed using Petrasim commercial software, which is a pre- and post- processor for TOUGH2, a non-isothermal multiphase flow and transport simulator. One of our goals is to understand the role of the Wildcat fault in controlling the natural-state groundwater flow. Another goal is that with limited data in numbers and areal extent, we evaluate the viability of modeling a relatively complex geologic area in hopes of to building a model that is valid for a scale larger than the observation. We performed both manual and automated inversion analyses and produced reasonable matches between the observed head data and model predictions. By varying the structure of the Wildcat fault, the base-case representation, which includes a high permeability damage zone and a low permeability fault core, best matches the observed head data. Using the sub-model, we conducted two-phase non-isothermal simulations utilizing the pressure and temperature data from the boreholes. We also used the information obtained from pump tests including permeability anisotropy of the fault plane. After parameter searches, we were able to match the head and temperature profiles along boreholes relatively well. We then used the best matching models to predict the observed rate of head decline during a dry period and found that anisotropic fault zone with 5 % porosity predicts the rate of decline reasonably well. There is a potential that the rate of decline may be useful to estimate the parameters downstream where there are no boreholes for observation/testing.	[Karasaki, Kenzi; Doughty, Christine] Univ Calif Berkeley, Lawrence Berkeley Natl Lab, Berkeley, CA 94720 USA; [Onishi, Celia T.] US Geol Survey, Menlo Pk, CA 94025 USA; [Goto, Junichi] Nucl Waste Management Org Japan, Tokyo, Japan	Karasaki, K (reprint author), Univ Calif Berkeley, Lawrence Berkeley Natl Lab, Berkeley, CA 94720 USA.	kkarasaki@lbl.gov; CADoughty@lbl.gov; ctonishi@usgs.gov; jgoto@numo.or.jp	Doughty, Christine/G-2389-2015		Nuclear Waste Management Organization of Japan;  [DE-AC02-05CH11231]	This work was supported by Nuclear Waste Management Organization of Japan and performed under Contract No. DE-AC02-05CH11231. The authors would like to thank Dr. David Buesch of USGS, Menlo Park for his extensive review and extremely helpful suggestions.	[Anonymous], 2008, GEOM PREL GEOL SECT; Caine JS, 1996, GEOLOGY, V24, P1025, DOI 10.1130/0091-7613(1996)024<1025:FZAAPS>2.3.CO;2; Bishop C.C., 1973, CALIF DIV MINES GEOL, V19, P44; Curtis G.H., 1989, GEOLOGY SAN FRANCISC, V105, P33; Doughty C, 2008, WATER RESOUR RES, V44, DOI 10.1029/2007WR006441; Finsterle S., 1999, LBNL40040; Freeze R. A., 1979, GROUNDWATER; Goldman M.R., 2013, 2013 FALL M AGU SAN; GRAHAM SA, 1984, AAPG BULL, V68, P233; Graymer R.W., 2000, USGS MISCELLANEOUS F; Harding Lawson Associates (HLA), 1974, 23800001 HLA LAWR BE; Jones D.L., 1991, SPECIAL PUBLICATION, V109, P63; Karasaki K., 2012, 2012 FALL M AGU SAN; Karasaki K., 2012, LBNL5862E; Karasaki K., 2009, 1635E2009 LBNL; Karasaki K., 2008, LBNL1635E, P157; Karasaki K, 2011, J HYDROL, V403, P49, DOI 10.1016/j.jhydrol.2011.03.039; Kiho K., 2012, CRIEPI TECHNICAL REP; LBNL and Parsons, 2000, RCRA FAC INV REP LAW; Onishi C.T., 2009, EOS T AGU, V90; Pruess K., 1999, LBNL43134; Simpson RW, 2000, SCIENCE, V289, P1147, DOI 10.1126/science.289.5482.1147; William Lettis and Asscoicates Inc. (WLA), 2008, SURF FAULT RUPT HAZ	23	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0169-3913	1573-1634		TRANSPORT POROUS MED	Transp. Porous Media	MAY	2015	108	1			SI		3	22		10.1007/s11242-014-0348-x		20	Engineering, Chemical	Engineering	CH2VP	WOS:000353883200002		
J	Mukhopadhyay, S; Doughty, C; Bacon, D; Li, J; Wei, LL; Yamamoto, H; Gasda, S; Hosseini, SA; Nicot, JP; Birkholzer, JT				Mukhopadhyay, Sumit; Doughty, Christine; Bacon, Diana; Li, Jun; Wei, Lingli; Yamamoto, Hajime; Gasda, Sarah; Hosseini, Seyyed A.; Nicot, Jean-Philippe; Birkholzer, Jens T.			The Sim-SEQ Project: Comparison of Selected Flow Models for the S-3 Site	TRANSPORT IN POROUS MEDIA			English	Article						Carbon sequestration; Geologic carbon storage; Model comparison; Sim-SEQ; Model uncertainty	CARBON-DIOXIDE; CO2 STORAGE; INJECTION; SIMULATION; CRANFIELD; RESERVOIR; SEQUESTRATION; MISSISSIPPI; UNCERTAINTY; PRESSURES	Sim-SEQ is an international initiative on model comparison for geologic carbon sequestration, with an objective to understand and, if possible, quantify model uncertainties. Model comparison efforts in Sim-SEQ are at present focusing on one specific field test site, hereafter referred to as the Sim-SEQ Study site (or S-3 site). Within Sim-SEQ, different modeling teams are developing conceptual models of injection at the S-3 site. In this paper, we select five flow models of the S-3 site and provide a qualitative comparison of their attributes and predictions. These models are based on five different simulators or modeling approaches: TOUGH2/EOS7C, STOMP-CO2e, MoReS, TOUGH2-MP/ECO2N, and VESA. In addition to model-to-model comparison, we perform a limited model-to-data comparison, and illustrate how model choices impact model predictions. We conclude the paper by making recommendations for model refinement that are likely to result in less uncertainty in model predictions.	[Mukhopadhyay, Sumit; Doughty, Christine; Birkholzer, Jens T.] Univ Calif Berkeley, Lawrence Berkeley Natl Lab, Div Earth Sci, Berkeley, CA 94720 USA; [Bacon, Diana] Pacific NW Natl Lab, Richland, WA 99352 USA; [Li, Jun] Chinese Acad Sci, Inst Rock & Soil Mech, State Key Lab Geomech & Geotech Engn, Wuhan 430071, Peoples R China; [Wei, Lingli] Shell China Innovat & R&D Ctr, Beijing 100004, Peoples R China; [Yamamoto, Hajime] Taisei Corp, Totsuka Ku, Yokohama, Kanagawa 2450051, Japan; [Gasda, Sarah] Uni Res, Ctr Integrated Petr Res, N-5020 Bergen, Norway; [Hosseini, Seyyed A.; Nicot, Jean-Philippe] Univ Texas Austin, Bur Econ Geol, Austin, TX 78713 USA	Mukhopadhyay, S (reprint author), Univ Calif Berkeley, Lawrence Berkeley Natl Lab, Div Earth Sci, 1 Cyclotron Rd, Berkeley, CA 94720 USA.	smukhopadhyay@lbl.gov	Birkholzer, Jens/C-6783-2011; Doughty, Christine/G-2389-2015; Hosseini, Seyyed Abolfazl/C-5289-2011; 	Bacon, Diana/0000-0001-9122-5333	U.S. Department of Energy [DE-AC02-05CH11231]; Department of Energy; MatMoRA project - CLIMIT program of the Research Council of Norway [215641]; Statoil	The authors thank Curt Oldenburg (LBNL) and Dan Hawkes (LBNL) for their constructive reviews of the draft manuscript. LBNL's (Berkeley Lab.) efforts in coordinating Sim-SEQ are supported through funds provided by the U.S. Department of Energy and managed by the National Energy Technology Laboratory. Funds were provided to Berkeley Lab. through the U.S. Department of Energy Contract No. DE-AC02-05CH11231. BEG's efforts, headed by Susan Hovorka, were partly supported by funds provided by the Department of Energy and managed by the National Energy Technology Laboratory through the Southeast Regional Carbon Sequestration Partnership (SECARB) (managed by the Southern State Energy Board). URN's modeling effort is supported by the MatMoRA project under Contract No. 215641, funded by the CLIMIT program of the Research Council of Norway and Statoil. The publisher, by accepting the article for publication, acknowledges that the United States Government retains a non-exclusive, paid-up, irrevocable, world-wide license to publish or reproduce the published form of this manuscript, or allow others to do so, for United States Government purposes. The views expressed in this article are those of the authors and do not necessarily reflect the views or policies of the United States Department of Energy or the Berkeley Lab.	Hovorka SD, 2013, INT J GREENH GAS CON, V18, P345, DOI 10.1016/j.ijggc.2013.03.021; Spycher N, 2010, TRANSPORT POROUS MED, V82, P173, DOI 10.1007/s11242-009-9425-y; Nordbotten JM, 2012, INT J GREENH GAS CON, V9, P234, DOI 10.1016/j.ijggc.2012.03.007; Hosseini SA, 2013, INT J GREENH GAS CON, V18, P449, DOI 10.1016/j.ijggc.2012.11.009; Carle SF, 1996, MATH GEOL, V28, P453, DOI 10.1007/BF02083656; Gasda SE, 2009, COMPUTAT GEOSCI, V13, P469, DOI 10.1007/s10596-009-9138-x; Lu JM, 2012, CHEM GEOL, V291, P269, DOI 10.1016/j.chemgeo.2011.10.020; PEACEMAN DW, 1983, SOC PETROL ENG J, V23, P531; Pruess K, 2007, ENERG CONVERS MANAGE, V48, P1761, DOI 10.1016/j.enconman.2007.01.016; Lu J, 2013, INT J GREENH GAS CON, V18, P361, DOI 10.1016/j.ijggc.2012.10.007; Wei LL, 2012, SPE J, V17, P469; Yamamoto H, 2011, INT J GREENH GAS CON, V5, P975, DOI 10.1016/j.ijggc.2011.02.007; Span R, 1996, J PHYS CHEM REF DATA, V25, P1509; Mukhopadhyay S, 2012, ENVIRON EARTH SCI, V67, P601, DOI 10.1007/s12665-012-1668-1; Pruess K, 2004, ENERGY, V29, P1431, DOI 10.1016/j.energy.2004.03.077; Chiquet P, 2007, GEOFLUIDS, V7, P112, DOI 10.1111/j.1468-8123.2007.00168.x; Class H, 2009, COMPUTAT GEOSCI, V13, P409, DOI 10.1007/s10596-009-9146-x; Rutqvist J, 2008, NUCL TECHNOL, V163, P101; Giorgis T, 2007, ENERG CONVERS MANAGE, V48, P1816, DOI 10.1016/j.enconman.2007.01.012; Hovorka SD, 2011, ENRGY PROCED, V4, P3478, DOI 10.1016/j.egypro.2011.02.274; Bikkina S., 2011, INT J GREENH GAS CON, V5, P1259; Devooght J, 1998, RELIAB ENG SYST SAFE, V59, P171, DOI 10.1016/S0951-8320(97)00137-3; Lu JM, 2012, J GEOPHYS RES-SOL EA, V117, DOI 10.1029/2011JB008939; MOGB: Cranfield Field Cranfield Unit, 1966, BAS TUSC RES, P42; Mukhopadhyay S, 2013, ENRGY PROCED, V37, P3867, DOI 10.1016/j.egypro.2013.06.284; Oldenburg C.M., 2004, LBNL56589; Pruess K, 2009, WATER RESOUR RES, V45, DOI 10.1029/2008WR007101; Pruess K., 1999, LBNL43134; Spycher N, 2003, GEOCHIM COSMOCHIM AC, V67, P3015, DOI 10.1016/S0016-7037(03)00273-4; Tsang CF, 2009, ENVIRON GEOL, V57, P1217, DOI 10.1007/s00254-008-1626-0; White M. D., 2012, PNNL21268; Zhang K., 2008, LBNL315E	32	2	2	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0169-3913	1573-1634		TRANSPORT POROUS MED	Transp. Porous Media	MAY	2015	108	1			SI		207	231		10.1007/s11242-014-0361-0		25	Engineering, Chemical	Engineering	CH2VP	WOS:000353883200012		
J	Kiyomitsu, T				Kiyomitsu, Tomomi			Mechanisms of daughter cell-size control during cell division	TRENDS IN CELL BIOLOGY			English	Review						spindle positioning; daughter cell size; dynein; myosin; Ran-GTP	REGULATES SPINDLE ORIENTATION; MITOTIC SPINDLE; CORTICAL DYNEIN; DROSOPHILA NEUROBLAST; CLEAVAGE FURROW; CAENORHABDITIS-ELEGANS; ASYMMETRIC DIVISION; MICROTUBULE ASTERS; PULLING FORCES; ADHERENT CELLS	Daughter cell size is tightly regulated during cell division. In animal cells, the position of the anaphase spindle specifies the cell cleavage site to dictate the relative size of the daughter cells. Although spindle orientation is regulated by dynein-dependent cortical pulling forces exerted on astral microtubules in many cell types, it was unclear how these forces are precisely regulated to center or displace the spindle. Recently, intrinsic signals derived from chromosomes or spindle poles have been demonstrated to regulate dynein-dependent pulling forces in symmetrically dividing cells. Unexpectedly, myosin-dependent contractile forces have also been shown to control spindle position by altering the cellular boundaries during anaphase. In this review, I discuss how dynein- and myosin-dependent forces are coordinately regulated to control daughter cell size.	[Kiyomitsu, Tomomi] Nagoya Univ, Grad Sch Sci, Div Biol Sci, Chikusa Ku, Nagoya, Aichi 4648602, Japan; [Kiyomitsu, Tomomi] Japan Sci & Technol Agcy, Precursory Res Embryon Sci & Technol PRESTO Progr, Kawaguchi, Saitama 3320012, Japan	Kiyomitsu, T (reprint author), Nagoya Univ, Grad Sch Sci, Div Biol Sci, Chikusa Ku, Nagoya, Aichi 4648602, Japan.	kiyomitsu@bio.nagoya-u.ac.jp			Japan Science and Technology Agency; PRESTO program; JSPS KAKENIE [26840063]; Novartis Foundation (Japan) for the Promotion of Science; Career Development Award of the Human Frontier Science Program	The author thanks lain Cheeseman, Akatsuki Kimura, Gohta Goshima, Sadanori Watanabe, and Shigeki Yoshiura for critical comments and suggestions. He also thanks Danielle Loughlin and reviewers for helpful comments. The author's research is supported by the Japan Science and Technology Agency, the PRESTO program, and JSPS KAKENIE (grant number 26840063). He is a recipient of a research grant from the Novartis Foundation (Japan) for the Promotion of Science and a Career Development Award of the Human Frontier Science Program.	Kiyomitsu T, 2013, CELL, V154, P391, DOI 10.1016/j.cell.2013.06.010; Holubcova Z, 2013, NAT CELL BIOL, V15, P937, DOI 10.1038/ncb2802; Rivers DM, 2008, J CELL BIOL, V180, P877, DOI 10.1083/jcb.200710018; Kardon JR, 2009, NAT REV MOL CELL BIO, V10, P854, DOI 10.1038/nrm2804; Welburn JPI, 2010, MOL CELL, V38, P383, DOI 10.1016/j.molcel.2010.02.034; Lancaster OM, 2013, DEV CELL, V25, P270, DOI 10.1016/j.devcel.2013.03.014; McKenney RJ, 2010, CELL, V141, P304, DOI 10.1016/j.cell.2010.02.035; Schmidt JC, 2012, DEV CELL, V23, P968, DOI 10.1016/j.devcel.2012.09.012; Ou GS, 2010, SCIENCE, V330, P677, DOI 10.1126/science.1196112; Fink J, 2011, NAT CELL BIOL, V13, P771, DOI 10.1038/ncb2269; Sung YJ, 2013, P NATL ACAD SCI USA, V110, P16687, DOI 10.1073/pnas.1315290110; Morin X, 2011, DEV CELL, V21, P102, DOI 10.1016/j.devcel.2011.06.012; Petronczki M, 2008, DEV CELL, V14, P646, DOI 10.1016/j.devcel.2008.04.014; Albertson R, 2003, NAT CELL BIOL, V5, P166, DOI 10.1038/ncb922; Kotak S, 2013, EMBO J, V32, P2517, DOI 10.1038/emboj.2013.172; Izumi Y, 2006, NAT CELL BIOL, V8, P586, DOI 10.1038/ncb1409; Dogterom M, 2005, CURR OPIN CELL BIOL, V17, P67, DOI 10.1016/j.ceb.2004.12.011; Howard M, 2012, TRENDS CELL BIOL, V22, P311, DOI 10.1016/j.tcb.2012.03.002; Nachury MV, 2001, CELL, V104, P95, DOI 10.1016/S0092-8674(01)00194-5; Kimura K, 2011, P NATL ACAD SCI USA, V108, P137, DOI 10.1073/pnas.1013275108; Basto R, 2006, CELL, V125, P1375, DOI 10.1016/j.cell.2006.05.025; Laan L, 2012, CELL, V148, P502, DOI 10.1016/j.cell.2012.01.007; HORVITZ HR, 1992, CELL, V68, P237, DOI 10.1016/0092-8674(92)90468-R; Wiese C, 2001, SCIENCE, V291, P653, DOI 10.1126/science.1057661; Martin SG, 2009, NATURE, V459, P852, DOI 10.1038/nature08054; Salbreux G, 2012, TRENDS CELL BIOL, V22, P536, DOI 10.1016/j.tcb.2012.07.001; Kiyomitsu T, 2012, NAT CELL BIOL, V14, P311, DOI 10.1038/ncb2440; Bowman SK, 2006, DEV CELL, V10, P731, DOI 10.1016/j.devcel.2006.05.005; Knoblich JA, 2008, CELL, V132, P583, DOI 10.1016/j.cell.2008.02.007; Cadart C, 2014, DEV CELL, V29, P159, DOI 10.1016/j.devcel.2014.04.009; Gonczy P, 2008, NAT REV MOL CELL BIO, V9, P355, DOI 10.1038/nrm2388; Tzur A, 2009, SCIENCE, V325, P167, DOI 10.1126/science.1174294; Roberts AJ, 2013, NAT REV MOL CELL BIO, V14, P713, DOI 10.1038/nrm3667; Kalab P, 2008, J CELL SCI, V121, P1577, DOI 10.1242/jcs.005959; Baines AJ, 2014, BBA-BIOMEMBRANES, V1838, P605, DOI 10.1016/j.bbamem.2013.05.030; Padte NN, 2006, CURR BIOL, V16, P2480, DOI 10.1016/j.cub.2006.11.024; Collins ES, 2012, MOL BIOL CELL, V23, P3380, DOI 10.1091/mbc.E12-02-0109; Huang J, 2012, CELL, V150, P975, DOI 10.1016/j.cell.2012.07.022; Nguyen-Ngoc T, 2007, NAT CELL BIOL, V9, P1294, DOI 10.1038/ncb1649; Poulson ND, 2010, J CELL BIOL, V191, P915, DOI 10.1083/jcb.201008001; Minc N, 2011, CELL, V144, P414, DOI 10.1016/j.cell.2011.01.016; Williams SE, 2013, CURR OPIN CELL BIOL, V25, P749, DOI 10.1016/j.ceb.2013.08.003; Schlager MA, 2014, EMBO J, V33, P1855, DOI 10.15252/embj.201488792; Kotak S, 2012, J CELL BIOL, V199, P97, DOI 10.1083/jcb.201203166; Chaigne A, 2013, NAT CELL BIOL, V15, P958, DOI 10.1038/ncb2799; Habib SJ, 2013, SCIENCE, V339, P1445, DOI 10.1126/science.1231077; Siller KH, 2009, NAT CELL BIOL, V11, P365, DOI 10.1038/ncb0409-365; Segalen M, 2010, DEV CELL, V19, P740, DOI 10.1016/j.devcel.2010.10.004; Budirahardja Y, 2008, DEVELOPMENT, V135, P1303, DOI 10.1242/dev.019075; Green RA, 2012, ANNU REV CELL DEV BI, V28, P29, DOI 10.1146/annurev-cellbio-101011-155718; Li R, 2013, NAT REV MOL CELL BIO, V14, P141, DOI 10.1038/nrm3531; Matsumura S, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms1634; Moseley JB, 2009, NATURE, V459, P857, DOI 10.1038/nature08074; McKenney RJ, 2014, SCIENCE, V345, P337, DOI 10.1126/science.1254198; Wuhr M, 2010, CURR BIOL, V20, P2040, DOI 10.1016/j.cub.2010.10.024; McNally FJ, 2013, J CELL BIOL, V200, P131, DOI 10.1083/jcb.201210007; Trokter M, 2012, P NATL ACAD SCI USA, V109, P20895, DOI 10.1073/pnas.1210573110; Hara Y, 2009, CURR BIOL, V19, P1549, DOI 10.1016/j.cub.2009.07.050; Cabernard C, 2010, NATURE, V467, P91, DOI 10.1038/nature09334; Siller KH, 2006, NAT CELL BIOL, V8, P594, DOI 10.1038/ncb1412; Dalton CM, 2013, J CELL SCI, V126, P2955, DOI 10.1242/jcs.128744; Rasmussen CG, 2011, ANNU REV PLANT BIOL, V62, P387, DOI 10.1146/annurev-arplant-042110-103802; Inaba M, 2012, CELL STEM CELL, V11, P461, DOI 10.1016/j.stem.2012.09.003; Tang XY, 2012, J CELL BIOL, V196, P743, DOI 10.1083/jcb.201112017; Liu D, 2009, SCIENCE, V323, P1350, DOI 10.1126/science.1167000; Grill SW, 2005, DEV CELL, V8, P461, DOI 10.1016/j.devcel.2005.03.014; Sedzinski J, 2011, NATURE, V476, P462, DOI 10.1038/nature10286; Deng MQ, 2007, DEV CELL, V12, P301, DOI 10.1016/j.devcel.2006.11.008; Shitamukai A, 2012, DEV GROWTH DIFFER, V54, P277, DOI 10.1111/j.1440-169X.2012.01345.x; Mitchison T, 2012, CYTOSKELETON, V69, P738, DOI 10.1002/cm.21050; Minc N, 2012, TRENDS CELL BIOL, V22, P193, DOI 10.1016/j.tcb.2012.01.003; Archambault V, 2009, NAT REV MOL CELL BIO, V10, P265, DOI 10.1038/nrm2653; Burgess DR, 2005, TRENDS CELL BIOL, V15, P156, DOI 10.1016/j.tcb.2005.01.006; Cai Y, 2003, CELL, V112, P51, DOI 10.1016/S0092-8674(02)01170-4; Cheeseman IM, 2014, CSH PERSPECT BIOL, V6, DOI 10.1101/cshperspect.a015826; Chew TG, 2012, CYTOSKELETON, V69, P1040, DOI 10.1002/cm.21062; COMPTON DA, 1995, J CELL SCI, V108, P621; Connell M, 2011, MOL BIOL CELL, V22, P4220, DOI 10.1091/mbc.E11-02-0173; Couwenbergs C, 2007, J CELL BIOL, V179, P15, DOI 10.1083/jcb.200707085; D'Avino PP, 2009, J CELL SCI, V122, P1071, DOI 10.1242/jcs.034785; Fuse N, 2003, CURR BIOL, V13, P947, DOI 10.1016/S0960-9822(03)00334-8; Goshima G, 2010, ANNU REV CELL DEV BI, V26, P21, DOI 10.1146/annurev-cellbio-100109-104006; Hara Y, 2011, RESULTS PROBL CELL D, V53, P93, DOI 10.1007/978-3-642-19065-0_5; Hasegawa Kohei, 2014, Allergy Asthma Proc, V35, P42, DOI 10.2500/aap.2014.35.3747; Kiekebusch D, 2014, TRENDS MICROBIOL, V22, P65, DOI 10.1016/j.tim.2013.11.005; Kimura A, 2005, DEV CELL, V8, P765, DOI 10.1016/j.devcel.2005.03.007; Kotak S., 2014, EMBO J, V18, P1815; Kunda P, 2012, CURR BIOL, V22, P231, DOI 10.1016/j.cub.2011.12.016; London N, 2014, NAT REV MOL CELL BIO, V15, P735, DOI 10.1038/nrm3888; Izumi Y, 2004, J CELL BIOL, V164, P729, DOI 10.1083/jcb.200309162; Mattagajasingh SN, 1999, J CELL BIOL, V145, P29, DOI 10.1083/jcb.145.1.29; RAPPAPORT R, 1985, J EXP ZOOL, V234, P167, DOI 10.1002/jez.1402340120; Rappaport R, 1996, CYTOKINESIS ANIMAL C; Roubinet C, 2011, J CELL BIOL, V195, P99, DOI 10.1083/jcb.201106048; Seldin L, 2013, MOL BIOL CELL, V24, P3651, DOI 10.1091/mbc.E13-05-0277; Silverman-Gavrila RV, 2008, MOL BIOL CELL, V19, P3735, DOI 10.1091/mbc.E08-01-0049; Xiao ZN, 2012, BIOCHEM BIOPH RES CO, V420, P888, DOI 10.1016/j.bbrc.2012.03.095; Yi KX, 2013, J CELL BIOL, V200, P567, DOI 10.1083/jcb.201211068; Zheng Z, 2014, MOL BIOL CELL, V25, P606, DOI 10.1091/mbc.E13-08-0474	99	0	0	ELSEVIER SCIENCE LONDON	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0962-8924			TRENDS CELL BIOL	Trends Cell Biol.	MAY	2015	25	5					286	295		10.1016/j.tcb.2014.12.003		10	Cell Biology	Cell Biology	CH2OE	WOS:000353863700004		
J	Kimura, M; Zodda, AR; Mahmood, J; Das, SK; Nguyen, GB; Jackson, IL; Vujaskovic, Z				Kimura, Masaki; Zodda, Andrew R.; Mahmood, Javed; Das, Shiva K.; Nguyen, Giao B.; Jackson, Isabel L.; Vujaskovic, Zeljko			Pilot Study Evaluating a Rat Model of Radiation-induced Erectile Dysfunction Using an Image-guided Microirradiator	UROLOGY			English	Article							PROSTATE-CANCER; SEXUAL FUNCTION; RADIOTHERAPY; QUALITY	OBJECTIVE To establish a feasible rat model of radiation-induced erectile dysfunction after targeted prostate irradiation using an image-guided irradiation unit specially designed for small-animal radiation research. METHODS The X-RAD 225Cx research platform was used in the present study. We first performed quality assurance testing using a rat cadaver. After confirming dosimetry, 24 age-matched, young, adult, male rats were assigned to sham radiation or radiation to the prostate with doses of 15, 20, or 25 Gy. To confirm appropriate prostate irradiation, physiological erectile function was evaluated using intracavernous pressure (ICP) measurements with cavernous nerve electrical stimulation at 9 weeks after radiotherapy. Each animal was weighed at the time of ICP measurement. In addition, we investigated the cyclic guanosine monophosphate level in the penile cavernosa using a commercial enzyme-linked immunosorbent assay kit. RESULTS Quality assurance results confirmed the accuracy of the irradiation technique. Dose-dependent decreases in ICP in irradiated rats were observed without major toxicity. No difference in body weight was noted among the experimental groups. Cyclic guanosine monophosphate levels were significantly decreased in the group that received 25 Gy compared with the age-matched sham-irradiated group. CONCLUSION High-precision imaging and targeting capabilities provided by the micro-IGRT platform enable us to develop a reproducible animal model of radiation-induced erectile dysfunction in prostate cancer research. (C) 2015 Elsevier Inc.	Teikyo Univ, Dept Urol, Kaga, Itabashi, Japan; Univ Maryland, Dept Radiat Oncol, Div Translat Radiat Sci, Baltimore, MD 21201 USA; Duke Univ, Dept Radiat Oncol, Durham, NC USA; Duke Univ, Dept Radiol, Div Radiat Safety, Durham, NC 27710 USA	Vujaskovic, Z (reprint author), Univ Maryland, Dept Radiat Oncol, Div Translat Radiat Sci, Med Sci Teaching Facil 700A, 685 W Baltimore St, Baltimore, MD 21201 USA.	zvujaskovic@som.umaryland.edu					Kimura M, 2011, INT J IMPOT RES, V23, P49, DOI 10.1038/ijir.2011.3; Kimura M, 2012, J SEX MED, V9, P1535, DOI 10.1111/j.1743-6109.2012.02716.x; van der Wielen GJ, 2007, INT J RADIAT ONCOL, V68, P479, DOI 10.1016/j.ijrobp.2006.12.015; Pienta KJ, 2008, PROSTATE, V68, P629, DOI 10.1002/pros.20726; Wong J, 2008, INT J RADIAT ONCOL, V71, P1591, DOI 10.1016/j.ijrobp.2008.04.025; Clarkson R, 2011, MED PHYS, V38, P845, DOI 10.1118/1.3533947; Potosky AL, 2004, J NATL CANCER I, V96, P1358, DOI 10.1093/jnci/djh259; CARRIER S, 1995, RADIOLOGY, V195, P95; DiBiase SJ, 2000, INT J RADIAT ONCOL, V46, P1301, DOI 10.1016/S0360-3016(99)00551-9; Karakiewicz PI, 2000, PROSTATE CANCER P D, V3, pS21, DOI 10.1038/sj.pcan.4500446; Kimura M, 2011, J SEX MED, V8, P2215, DOI 10.1111/j.1743-6109.2011.02351.x; Koontz BF, 2011, J SEX MED, V8, P411, DOI 10.1111/j.1743-6109.2010.02125.x; Litwin MS, 1999, UROLOGY, V54, P503, DOI 10.1016/S0090-4295(99)00172-7; Merlin SL, 2001, INT J IMPOT RES, V13, P104, DOI 10.1038/sj.ijir.3900652; Qiu XF, 2012, J SEX MED, V9, P1834, DOI 10.1111/j.1743-6109.2012.02753.x; Roach M, 2010, INT J RADIAT ONCOL, V76, pS130, DOI 10.1016/j.ijrobp.2009.04.094; van der Wielen GJ, 2009, J SEX MED, V6, P1908, DOI 10.1111/j.1743-6109.2009.01272.x	17	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0090-4295	1527-9995		UROLOGY	Urology	MAY	2015	85	5							1214.e1	10.1016/j.urology.2014.12.020		6	Urology & Nephrology	Urology & Nephrology	CG8XI	WOS:000353598600067		
J	Nishikawa, M; Miyake, H; Fujisawa, M				Nishikawa, Masatomo; Miyake, Hideaki; Fujisawa, Masato			Enhanced Sensitivity to Sunitinib by Inhibition of Akt1 Expression in Human Castration-resistant Prostate Cancer PC3 Cells Both In Vitro and In Vivo	UROLOGY			English	Article							MULTIDRUG-RESISTANCE; PTEN EXPRESSION; GROWTH-FACTOR; MIGRATION; MODULATION; ACTIVATION; PATHWAYS; BREAST; DRUGS; LUNG	OBJECTIVE To investigate whether antitumor activity of sunitinib is enhanced by silencing Akt1 in a human castration-resistant prostate cancer PC3 model. MATERIALS AND METHODS We initially established PC3 in which the expression vector containing a short hairpin ribonucleic acid targeting Akt1 was introduced (PC3/sh-Akt1). Changes in various phenotypes of PC3/sh-Akt1 after treatment with sunitinib were compared with those of PC3 transfected with control vector alone (PC3/C) both in vitro and in vivo. RESULTS When cultured in the standard medium, in vitro growth of PC3/sh-Akt1 was almost similar to that of PC3/C. However, compared with PC3/C, PC3/sh-Akt1 showed a significantly higher sensitivity to sunitinib, accompanying impaired phosphorylation of p44/42 mitogen-activated protein kinase, downregulation of Bcl-2, and upregulation of Bax. In addition, treatment with sunitinib significantly suppressed the migration ability of PC3/sh-Akt1 compared with that of PC3/C. In vivo, administration of sunitinib induced the significantly marked growth inhibition of PC3/sh-Akt1 compared with that of PC3/C, and apoptotic index in PC3/sh-Akt1 tumor in mice treated with sunitinib was significantly greater than that in PC3/C tumor. CONCLUSION Combined treatment with Akt1 inhibitor and sunitinib could be a promising therapeutic approach for men with castration-resistant prostate cancer. (C) 2015 Elsevier Inc.	[Nishikawa, Masatomo; Miyake, Hideaki; Fujisawa, Masato] Kobe Univ, Grad Sch Med, Div Urol, Kobe, Hyogo 6500017, Japan	Miyake, H (reprint author), Kobe Univ, Grad Sch Med, Div Urol, Chuo Ku, 7-5-1 Kusunoki Cho, Kobe, Hyogo 6500017, Japan.	hideakimiyake@hotmail.com					Zinda MJ, 2001, CLIN CANCER RES, V7, P2475; Makhov PB, 2012, MOL CANCER THER, V11, P1510, DOI 10.1158/1535-7163.MCT-11-0907; Gan HK, 2009, EXPERT OPIN INV DRUG, V18, P821, DOI 10.1517/13543780902980171; Guo DD, 2012, BIOMATERIALS, V33, P2272, DOI 10.1016/j.biomaterials.2011.12.011; Bedolla R, 2007, CLIN CANCER RES, V13, P3860, DOI 10.1158/1078-0432.CCR-07-0091; Boldt S, 2002, CARCINOGENESIS, V23, P1831, DOI 10.1093/carcin/23.11.1831; Mendel DB, 2003, CLIN CANCER RES, V9, P327; Sonpavde G, 2010, ANN ONCOL, V21, P319, DOI 10.1093/annonc/mdp323; Gotink KJ, 2010, ANGIOGENESIS, V13, P1, DOI 10.1007/s10456-009-9160-6; Andrae N, 2012, EUR J CANCER, V48, P1831, DOI 10.1016/j.ejca.2012.01.032; Chin YR, 2009, CELL SIGNAL, V21, P470, DOI 10.1016/j.cellsig.2008.11.015; Yang LF, 2009, CANCER BIOL THER, V8, P366, DOI 10.4161/cbt.8.4.7433; Abouantoun TJ, 2011, J NEURO-ONCOL, V101, P215, DOI 10.1007/s11060-010-0259-9; Goc A, 2012, BRIT J CANCER, V107, P713, DOI 10.1038/bjc.2012.295; Chen KG, 2012, CLIN CANCER RES, V18, P1863, DOI 10.1158/1078-0432.CCR-11-1590; Han Z, 2006, J EXP CLIN CANC RES, V25, P601; Sasaki T, 2010, BIOCHEM BIOPH RES CO, V399, P79, DOI 10.1016/j.bbrc.2010.07.045; Cersosimo RJ, 2012, ANN PHARMACOTHER, V46, P1518, DOI 10.1345/aph.1R169; Cheung M, 2013, CURR CANCER DRUG TAR, V13, P2340; Dror Michaelson M, 2009, Ann Oncol, V20, P913, DOI 10.1093/annonc/mdp111; Kim EK, 2008, CELL SIGNAL, V20, P2030, DOI 10.1016/j.cellsig.2008.07.012; Kumano M, 2008, BRIT J CANCER, V98, P356, DOI 10.1038/sj.bjc.6604169; Lee MW, 2008, INT J CANCER, V122, P2380, DOI 10.1002/ijc.23371; Li RL, 2009, CLIN CANCER RES, V15, P3568, DOI 10.1158/1078-0432.CCR-08-0826; Pore N, 2006, MOL CANCER RES, V4, P471, DOI 10.1158/1541-7786.MCR-05-0234; Sakai I, 2012, BJU INT, V112, pE211; Terakawa T, 2009, BRIT J CANCER, V101, P1731, DOI 10.1038/sj.bjc.6605358; Wang J, 2003, CANCER CELL, V4, P209; Yanagihara M, 2005, CANCER SCI, V96, P620, DOI 10.1111/j.1349-7006.2005.00088.x; Yoon H, 2009, J CELL BIOCHEM, V108, P832, DOI 10.1002/jcb.22311	30	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0090-4295	1527-9995		UROLOGY	Urology	MAY	2015	85	5							1215.e1	10.1016/j.urology.2015.02.016		7	Urology & Nephrology	Urology & Nephrology	CG8XI	WOS:000353598600070		
J	Maeda, T; Kikuchi, E; Hasegawa, M; Ishioka, K; Hagiwara, M; Miyazaki, Y; Shinojima, T; Miyajima, A; Oya, M				Maeda, Takahiro; Kikuchi, Eiji; Hasegawa, Masanori; Ishioka, Katsura; Hagiwara, Masayuki; Miyazaki, Yasumasa; Shinojima, Toshiaki; Miyajima, Akira; Oya, Mototsugu			Solifenacin or Mirabegron Could Improve Persistent Overactive Bladder Symptoms After Dutasteride Treatment in Patients With Benign Prostatic Hyperplasia	UROLOGY			English	Article							URINARY-TRACT SYMPTOMS; SAFETY; MEN; COMBINATION; EFFICACY; THERAPY; BPH	OBJECTIVE To evaluate the clinical response and adverse events (AEs) of solifenacin (SOL) or mirabegron (MIR) in benign prostatic hyperplasia patients with persistent overactive bladder (OAB) symptoms after dutasteride (DUT) treatment. METHODS Fifty cases with residual OAB symptom score (OABSS) >= 5 and OABSS Q3 >= 2 after at least 6 months treatment of DUT were included in this study. Patients were administered 5 mg/d of SOL (N = 25) or 50 mg/d of MIR (N = 25), and International Prostate Symptom Score (IPSS) and OABSS were prospectively collected at 4 and 12 weeks. The safety was evaluated by changes in postvoided residual urine volume and the incidence of AEs. RESULTS After DUT administration, the mean prostate volume, IPSS, and OABSS were 39.0 mL, 17.6, and 8.1, respectively. SOL 5 mg significantly reduced the IPSS, OABSS, and OABSS Q3 at 4 and at 12 weeks (-3.1, -2.7, -1.3; P<.05); however, 4 patients could not continue the SOL treatment owing to AEs. All patients could continue the 12 weeks of MIR treatment, and MIR 50 mg reduced IPSS and OABSS at 4 weeks and reduced IPSS, OABSS, and the OABSS Q3 (-3.0, -2.5, -0.9; P<.05) at 12 weeks. Postvoided residual urine volume increased by >= 100 mL after treatment in 2 cases in the SOL group but not in any patient in the MIR group. CONCLUSION Additional SOL or MIR might result in amelioration of the persistent OAB symptom after DUT treatment in patients with an enlarged prostate. (C) 2015 Elsevier Inc.	Keio Univ, Sch Med, Dept Urol, Tokyo 1608582, Japan; Tokyo Saiseikai Cent Hosp, Dept Urol, Tokyo, Japan	Kikuchi, E (reprint author), Keio Univ, Sch Med, Dept Urol, Shinjuku Ku, 35 Shinanomachi, Tokyo 1608582, Japan.	eiji-k@kb3.so-net.ne.jp			Ministry of Education, Culture, Sports, Science, and Technology, Japan [25861453]	This work was supported in part by Grant-in-Aid for Young Scientists (B) (#25861453) from the Ministry of Education, Culture, Sports, Science, and Technology, Japan.	Akino H, 2014, INT J UROL, V21, P389, DOI 10.1111/iju.12298; Peters TJ, 1997, J UROLOGY, V157, P885, DOI 10.1016/S0022-5347(01)65075-4; Yamaguchi O, 2013, INT J UROL, V20, P28, DOI 10.1111/iju.12008; Otsuki H, 2013, INT UROL NEPHROL, V45, P53, DOI 10.1007/s11255-012-0343-5; Oelke M, 2013, EUR UROL, V64, P118, DOI 10.1016/j.eururo.2013.03.004; McConnell JD, 2003, NEW ENGL J MED, V349, P2387, DOI 10.1056/NEJMoa030656; Chapple CR, 2006, EUR UROL, V49, P651, DOI 10.1016/j.eururo.2006.02.018; Kaplan SA, 2009, J UROLOGY, V182, P2825, DOI 10.1016/j.juro.2009.08.023; Kaplan SA, 2013, J UROLOGY, V189, pS129, DOI 10.1016/j.juro.2012.11.030; Montorsi F, 2011, BJU INT, V107, P1426, DOI 10.1111/j.1464-410X.2011.10129.x; Nitti VW, 2013, J UROLOGY, V189, P1388, DOI 10.1016/j.juro.2012.10.017; Roehrborn CG, 2010, EUR UROL, V57, P123, DOI 10.1016/j.eururo.2009.09.035; Chapple CR, 2013, EUR UROL, V63, P296, DOI 10.1016/j.eururo.2012.10.048; Chung DE, 2010, UROLOGY, V75, P1144, DOI 10.1016/j.urology.2009.12.010; Masumori N, 2011, ADV UROL, V2011; Takeda M, 2013, UROLOGY, V82, P887, DOI 10.1016/j.urology.2013.05.008	16	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0090-4295	1527-9995		UROLOGY	Urology	MAY	2015	85	5					1151	1155		10.1016/j.urology.2015.01.028		5	Urology & Nephrology	Urology & Nephrology	CG8XI	WOS:000353598600051		
J	Tanaka, H; Tsuruga, K; Imaizumi, T				Tanaka, Hiroshi; Tsuruga, Kazushi; Imaizumi, Taddatsu			Mizoribine in the treatment of pediatric-onset glomerular disease	WORLD JOURNAL OF PEDIATRICS			English	Article						macrophage infiltration; mesangial cells; mizoribine; monocyte chemoattractant protein-1; podocytes	INTERMITTENT PULSE THERAPY; SEVERE LUPUS NEPHRITIS; HUMAN MESANGIAL CELLS; FOCAL SEGMENTAL GLOMERULOSCLEROSIS; MONOCYTE CHEMOATTRACTANT PROTEIN-1; RELAPSING NEPHROTIC SYNDROME; IGA NEPHROPATHY; YOUNG-PATIENTS; IMMUNOSUPPRESSANT MIZORIBINE; PUROMYCIN AMINONUCLEOSIDE	Mizoribine (MZR) is a selective inhibitor of inosine monophosphate dehydrogenase, a key enzyme in the pathway responsible for de novo synthesis of guanine nucleotides. As an immunosuppressant, MZR has been used successfully without any serious adverse effects in the treatment of renal diseases in children as well as adults. Besides its immunosuppressive effect, MZR has been reported to ameliorate tubulointerstitial fibrosis in rats via suppression of macrophage infiltration. In this review, we summarize reported possible benefits of MZR in the treatment of pediatriconset glomerular disease. We recently observed that MZR itself selectively attenuates the expression of monocyte chemoattractant protein-1 at both the mRNA and protein levels in human mesangial cells. Since MZR binds specifically to 14-3-3 proteins and heat shock protein 60, both of which are reportedly expressed in inflamed glomeruli, MZR may bind directly to inflamed glomerular cells, thereby possibly preventing progressive damage from glomerulonephritis through a suppressive effect on activated macrophages and intrinsic renal cells. Moreover, it has recently been reported that MZR directly prevents podocyte injury through correction of the intracellular energy balance and nephrin biogenesis in cultured podocyte and rat models, suggesting a direct anti-proteinuric effect of MZR. These beneficial mechanisms of action of MZR as well as its immunosuppressive effect would warrant its use in the treatment of pediatric-onset glomerular disease. Although further studies remain to be done, we believe that MZR may be an attractive treatment of choice for children with glomerular diseases from a histologic as well as clinical standpoint.	[Tanaka, Hiroshi] Hirosaki Univ, Dept Sch Hlth Sci, Fac Educ, Hirosaki, Aomori 0368560, Japan; [Tanaka, Hiroshi; Tsuruga, Kazushi] Hirosaki Univ Hosp, Dept Pediat, Hirosaki, Aomori 0368563, Japan; [Imaizumi, Taddatsu] Hirosaki Univ, Grad Sch Med, Dept Vacular Biol, Hirosaki, Aomori 0368562, Japan	Tanaka, H (reprint author), Hirosaki Univ, Dept Sch Hlth Sci, Fac Educ, 1 Bunkyo Cho, Hirosaki, Aomori 0368560, Japan.	hirotana@cc.hirosaki-u.ac.jp			Ministry of Education, Culture, Sports, Science and Technology of Japan	Part of this work was supported by grants-in-aid for Science from the Ministry of Education, Culture, Sports, Science and Technology of Japan (TH and IT).	Aizawa-Yashiro T, 2011, PEDIATR NEPHROL, V26, P1255, DOI 10.1007/s00467-011-1876-z; Aizawa-Yashiro T, 2013, PEDIATR RES, V73, P180, DOI 10.1038/pr.2012.165; Imaizumi T, 2012, TOHOKU J EXP MED, V228, P17, DOI 10.1620/tjem.228.17; Sonda K, 1996, TRANSPLANT P, V28, P3643; Imaizumi T, 2010, NEPHROL DIAL TRANSPL, V25, P3534, DOI 10.1093/ndt/gfq270; Takahashi S, 2000, BIOCHEM BIOPH RES CO, V274, P87, DOI 10.1006/bbrc.2000.3104; Itoh H, 1999, J BIOL CHEM, V274, P35147, DOI 10.1074/jbc.274.49.35147; Tanaka H, 2013, CLIN DEV IMMUNOL, DOI 10.1155/2013/984708; Anders HJ, 2009, TRENDS MOL MED, V15, P553, DOI 10.1016/j.molmed.2009.10.004; Kikuchi Y, 2005, NEPHROL DIAL TRANSPL, V20, P1573, DOI 10.1093/ndt/gfh888; Kawasaki Y, 2009, CLIN DEV IMMUNOL, DOI 10.1155/2009/681482; Ikezumi Y, 2010, AM J NEPHROL, V31, P273, DOI 10.1159/000279163; Takeuchi S, 2010, NEPHRON EXP NEPHROL, V116, pE3, DOI 10.1159/000314668; Kawasaki Y, 2004, AM J NEPHROL, V24, P576, DOI 10.1159/000082202; Aizawa T, 2014, NEPHROLOGY, V19, P47, DOI 10.1111/nep.12171; Doi T, 2008, CLIN NEPHROL, V69, P433; Fujita T, 2010, CLIN NEPHROL, V74, P81; Fuke T, 2012, PEDIATR INT, V54, P885, DOI 10.1111/j.1442-200X.2012.03733.x; Hara S, 2009, PEDIATR RES, V66, P524, DOI 10.1203/PDR.0b013e3181b9b48a; Hirose C, 2014, PEDIATR INT, V56, P129, DOI 10.1111/ped.12261; Honda M, 2002, PEDIATR INT, V44, P210, DOI 10.1046/j.1328-8067.2001.01533.x; Ikezumi Y, 2008, PEDIATR NEPHROL, V23, P645, DOI 10.1007/s00467-007-0664-2; Kawasaki Y, 2007, J NEPHROL, V20, P52; Kuroda Takeshi, 2007, Mod Rheumatol, V17, P206, DOI 10.1007/s10165-007-0567-x; Nakajo A, 2007, J AM SOC NEPHROL, V18, P2554, DOI 10.1681/ASN.2006070732; Ohtomo Y, 2005, PEDIATR NEPHROL, V20, P1744, DOI 10.1007/s00467-005-2025-3; Sato N, 2001, NEPHRON, V89, P177, DOI 10.1159/000046065; Shibasaki T, 1996, AM J NEPHROL, V16, P167, DOI 10.1159/000168992; Shimizu H, 2003, MICROSURG, V23, P454, DOI 10.1002/micr.10171; Stypinski D, 2007, BRIT J CLIN PHARMACO, V63, P459, DOI 10.1111/j.1365-2125.2006.02779.x; Takahashi S, 2009, NEPHRON EXP NEPHROL, V112, pE59, DOI 10.1159/000213896; Tanaka H, 2003, CLIN NEPHROL, V60, P390; Tanaka H, 2007, NEPHROLOGY, V12, P376, DOI 10.1111/j.1440-1797.2007.00793.x; Tanaka H, 2004, CLIN NEPHROL, V62, P412; Tanaka H, 2008, NEPHRON CLIN PRACT, V110, pC73, DOI 10.1159/000151721; Tanaka H, 2007, CLIN NEPHROL, V68, P198; Tanaka H, 2006, PEDIATR NEPHROL, V21, P962, DOI 10.1007/s00467-006-0120-8; Tanaka H, 2010, CLIN RHEUMATOL, V29, P1049, DOI 10.1007/s10067-010-1484-5; Uemura O, 2007, JPN PEDIAT NEPHROL, V20, P9; Yamabe H, 2012, BIOL PHARM BULL, V35, P705; Yokota S, 2002, PEDIATR INT, V44, P196, DOI 10.1046/j.1328-8067.2002.01536.x; Yoshikawa N, 2008, PEDIATR NEPHROL, V23, P757, DOI 10.1007/s00467-007-0731-8; Yoshioka K, 2000, KIDNEY INT, V58, P317, DOI 10.1046/j.1523-1755.2000.00168.x; Yumura W, 2005, CLIN NEPHROL, V64, P28	44	0	0	ZHEJIANG UNIV SCH MEDICINE	HANGZHOU	CHILDRENS HOSPITAL, 57 ZHUGAN XIANG, HANGZHOU, 310003, PEOPLES R CHINA	1708-8569	1867-0687		WORLD J PEDIATR	World Journal of Pediatrics	MAY	2015	11	2					108	112		10.1007/s12519-015-0013-7		5	Pediatrics	Pediatrics	CH1YB	WOS:000353818500002		
J	Maruo, Y; Suzaki, M; Matsui, K; Mimura, Y; Mori, A; Shintaku, H; Takeuchi, Y				Maruo, Yoshihiro; Suzaki, Masafumi; Matsui, Katsuyuki; Mimura, Yu; Mori, Asami; Shintaku, Haruo; Takeuchi, Yoshihiro			A novel large deletion (exons 12, 13) and a missense mutation (p.G46R) in the PAH in a Japanese patient with phenylketonuria	WORLD JOURNAL OF PEDIATRICS			English	Article						large deletion; multiplex ligation-dependent probe amplification; phenylalanine hydroxylase; phenylketonuria	GENE	Phenylketonuria (PKU) is caused by a defect in phenylalanine hydroxylase (PAH). More than 500 mutations have been reported for the gene encoding PAH. However, approximately 1%-5% of these include large deletions and large duplications that cannot be detected by conventional methods. In this report we tried to fully characterize a PAH-deficient patient. The patient was a 2-year-old Japanese boy who was diagnosed with classical PKU at the time of neonatal screening, which was confirmed by the tetrahydrobiopterin-loading test. PCR-related direct sequencing and multiplex ligation-dependent probe amplification (MLPA) were used to analyze of the PAH of the patient. Using PCR-related direct sequencing method, we could detect only a heterozygous novel missense mutation: p.136G > C (p.G46R). A second mutation was detected by MLPA. The patient was heterozygous for a novel large deletion of exons 12 and 13: c.1200-?_1359+?del (EX12_13del). For genetic counseling, an accurate genetic diagnosis is often necessary. Through a combination of MLPA and conventional methods, the success rate of PAH mutation identification can be close to 100%.	[Maruo, Yoshihiro; Matsui, Katsuyuki; Mimura, Yu; Mori, Asami; Takeuchi, Yoshihiro] Shiga Univ Med Sci, Dept Pediat, Otsu, Shiga 5202192, Japan; [Suzaki, Masafumi] Shiga Univ Med Sci, Cent Res Lab, Otsu, Shiga 5202192, Japan; [Shintaku, Haruo] Osaka City Univ, Grad Sch Med, Dept Pediat, Osaka 558, Japan	Maruo, Y (reprint author), Shiga Univ Med Sci, Dept Pediat, Otsu, Shiga 5202192, Japan.	maruo@belle.shiga-med.ac.jp					Schouten JP, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/gnf056; Zschocke J, 2003, HUM MUTAT, V21, P345, DOI 10.1002/humu.10192; Okano Y, 2011, J HUM GENET, V56, P306, DOI 10.1038/jhg.2011.10; Bik-Multanowski M, 2008, MOL GENET METAB, V94, P267, DOI 10.1016/j.ymgme.2008.02.007; Birk Moller L, 2007, HUM MUTAT, V28, P207; Desviat LR, 2006, CLIN CHIM ACTA, V373, P164, DOI 10.1016/j.cca.2006.05.003; Leandro J, 2011, MOL GENET METAB, V104, pS40, DOI 10.1016/j.ymgme.2011.07.024; Lee YW, 2008, EXP MOL MED, V40, P533, DOI 10.3858/emm.2008.40.5.533; Scriver CR, 2001, METABOLIC MOL BASES, V2, P1667; TREFZ FK, 1990, HUM GENET, V85, P121	10	0	0	ZHEJIANG UNIV SCH MEDICINE	HANGZHOU	CHILDRENS HOSPITAL, 57 ZHUGAN XIANG, HANGZHOU, 310003, PEOPLES R CHINA	1708-8569	1867-0687		WORLD J PEDIATR	World Journal of Pediatrics	MAY	2015	11	2					181	184		10.1007/s12519-015-0020-8		4	Pediatrics	Pediatrics	CH1YB	WOS:000353818500013		
J	Yagi, R; Tsuji, K				Yagi, Ryota; Tsuji, Kouichi			Confocal micro-XRF analysis of light elements with Rh X-ray tube and its application for painted steel sheet	X-RAY SPECTROMETRY			English	Article						confocal micro-XRF; polycapillary optics; X-ray filter; detection of Cl	FLUORESCENCE; SURFACE; OPTICS	A confocal micro-X-ray fluorescence (XRF) instrument with a vacuum chamber was applied for analysis of light elements for painted steel sheet. Because this instrument is equipped with a Rh-anode X-ray tube, light elements are excited more effectively by the Rh-L lines. However, it was difficult to analyze Cl, because the energies of the Cl-K lines are close to those of the Rh-L lines. Thus, we applied an Al thin film as a primary X-ray filter to eliminate the Rh-L lines and confirmed the feasibility of Cl analysis using a Rh X-ray tube. Rh-L scattered X-rays were observed by using an acrylic plate as a sample. The Rh-L scattered X-rays were completely absorbed by a 24 mu m thick Al filter. A calibration curve of Cl was prepared by using certified reference materials with different Cl concentrations. The limit of detection for Cl was 11.9ppm as estimated from the calibration curve. Confocal micro-XRF with a Rh X-ray tube enables the analysis of low Z elements including Cl by applying an Al filter. This technique was applied for a practical painted steel sheet sample. The elemental image of Cl was successfully observed after corrosion in NaCl solution as well as other light elemental maps. Copyright (c) 2015 John Wiley & Sons, Ltd.	[Yagi, Ryota; Tsuji, Kouichi] Osaka City Univ, Grad Sch Engn, Sumiyoshi Ku, Osaka 5588585, Japan	Yagi, R (reprint author), Osaka City Univ, Sumiyoshi Ku, 3-3-138 Sugimoto, Osaka 5588585, Japan.	ryota.yagi.8@gmail.com			Japan Society for the Promotion of Science (JSPS)	This work was financially supported by a Japan Society for the Promotion of Science (JSPS) Grant-in-Aid for Science Research (B). The authors appreciate Prof. Christina Streli for her useful suggestions regarding Al filters and also Mr. Koji Akioka at Nippon Steel & Sumitomo Metal Corporation for useful discussion on the corrosion process of the painted steel sheet.	Nakano K, 2011, ANAL CHEM, V83, P3477, DOI 10.1021/ac1033177; Kanngiesser B, 2003, NUCL INSTRUM METH B, V211, P259, DOI 10.1016/S0168-583X(03)01321-1; Nakazawa T, 2013, X-RAY SPECTROM, V42, P123, DOI 10.1002/xrs.2442; Nakazawa T, 2013, X-RAY SPECTROM, V42, P374, DOI 10.1002/xrs.2458; Ding X, 2000, P SOC PHOTO-OPT INS, V4144, P174, DOI 10.1117/12.405891; KUMAKHOV MA, 1990, PHYS REP, V191, P289, DOI 10.1016/0370-1573(90)90135-O; Smolek S, 2014, X-RAY SPECTROM, V43, P93, DOI 10.1002/xrs.2521; Gao N., 2004, XRAY SPECTROMETRY RE, P89; GIBSON WM, 1993, P SOC PHOTO-OPT INS, V1736, P172, DOI 10.1117/12.140473; Janssens K.H.A., 2000, MICROSCOPIC XRAY FLU; Kanngiesser B, 2005, SPECTROCHIM ACTA B, V60, P41, DOI 10.1016/j.sad.2004.10.012; Smolek S, 2012, REV SCI INSTRUM, V83, DOI 10.1063/1.4744934; Tsuji K, 2014, TETSU TO HAGANE, V100, P897, DOI 10.2355/tetsutohagane.100.897	13	1	1	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0049-8246	1097-4539		X-RAY SPECTROM	X-Ray Spectrom.	MAY-JUN	2015	44	3			SI		186	189		10.1002/xrs.2599		4	Spectroscopy	Spectroscopy	CG9OD	WOS:000353644500017		
J	Saito, Y; Tohkin, M				Saito, Yoshiro; Tohkin, Masahiro			Regulatory Science on Biomarker Usage for Development and Proper Use of Drugs-Foreward	YAKUGAKU ZASSHI-JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN			Japanese	Editorial Material									[Saito, Yoshiro] Natl Inst Hlth Sci, Div Med Safety Sci, Setagaya Ku, Tokyo 1588501, Japan; [Tohkin, Masahiro] Nagoya City Univ, Grad Sch Pharmaceut Sci, Dept Regulatory Sci, Mizuho Ku, Nagoya, Aichi 4678603, Japan	Saito, Y (reprint author), Natl Inst Hlth Sci, Div Med Safety Sci, Setagaya Ku, 1-18-1 Kamiyoga, Tokyo 1588501, Japan.	yoshiro@nihs.go.jp						0	0	0	PHARMACEUTICAL SOC JAPAN	TOKYO	2-12-15 SHIBUYA, SHIBUYA-KU, TOKYO, 150-0002, JAPAN	0031-6903			YAKUGAKU ZASSHI	Yakugaku Zasshi-J. Pharm. Soc. Jpn.	MAY	2015	135	5					647	648				2	Pharmacology & Pharmacy	Pharmacology & Pharmacy	CH2LB	WOS:000353855600001		
J	Tohkin, M; Saito, Y				Tohkin, Masahiro; Saito, Yoshiro			Regulatory Science for the Proper Evaluation of Biomarkers (Overview)	YAKUGAKU ZASSHI-JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN			Japanese	Review						clinical study design; efficacy and safety; biomarker; new drug development	WARFARIN	New drug development (NDD) for intractable diseases such as cancer and Alzheimer's disease has been challenging in recent years because it is difficult to evaluate the therapeutic efficacy of new drugs and the response of individual patients. Thus biomarkers might be a useful tool to facilitate NDD because they can be used to evaluate accurately drug responses. Biomarkers include proteins, metabolites, and genetic targets; imaging data and can also be used in pre-clinical studies, clinical trials, and post-marketing surveillance. In pre-clinical studies, biomarkers are used as an index of the pharmacological and toxicological effects of a new drug, which may help to predict the clinical response. In clinical studies, biomarkers are widely used as an index of clinical efficacy and safety for dose-adjustment and for patient selection. In post-clinical studies, biomarkers may facilitate the evaluation of drug responses, as well as aid improvements in drug efficacy. Several points should be considered for biomarker-guided NDD. First, the clinical study design is very important and must be suitable to permit the use of the relevant biomarkers. The analytical methods should be carefully evaluated, and evidence should be provided regarding the physiological significance and relevance of the biomarker with regard to its intended use. Regulatory sciences are required to resolve these issues and bridge the gap between basic science and clinical studies that involve biomarkers.	[Tohkin, Masahiro] Nagoya City Univ, Grad Sch Pharmaceut Sci, Dept Regulatory Sci, Mizuho Ku, Nagoya, Aichi 4678603, Japan; [Saito, Yoshiro] Natl Inst Hlth Sci, Div Med Safety Sci, Setagaya Ku, Tokyo 1588501, Japan	Tohkin, M (reprint author), Nagoya City Univ, Grad Sch Pharmaceut Sci, Dept Regulatory Sci, Mizuho Ku, 3-1 Tanabe Dori, Nagoya, Aichi 4678603, Japan.	tohkin@phar.nagoya-cu.ac.jp					Scannell JW, 2012, NAT REV DRUG DISCOV, V11, P191, DOI 10.1038/nrd3681; Kaniwa N, 2013, PHARMACOGENOMICS, V14, P1821, DOI 10.2217/pgs.13.180; Morimoto T, 2011, J GEN INTERN MED, V26, P148, DOI 10.1007/s11606-010-1518-3; Rieder MJ, 2005, NEW ENGL J MED, V352, P2285, DOI 10.1056/NEJMoa044503; Lazarou J, 1998, JAMA-J AM MED ASSOC, V279, P1200, DOI 10.1001/jama.279.15.1200; Vaidya VS, 2006, AM J PHYSIOL-RENAL, V290, pF517, DOI 10.1152/ajprenal.00291.2005; [Anonymous], 2007, ICH HARM TRIP GUID D; Janne PA, 2006, CLIN CANCER RES, V12, p4416S, DOI 10.1158/1078-0432.CCR-06-0555; Rettie AE, 2006, MOL INTERV, V6, P223, DOI 10.1124/mi.6.4.8; Takeuchi F, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000433	10	0	0	PHARMACEUTICAL SOC JAPAN	TOKYO	2-12-15 SHIBUYA, SHIBUYA-KU, TOKYO, 150-0002, JAPAN	0031-6903			YAKUGAKU ZASSHI	Yakugaku Zasshi-J. Pharm. Soc. Jpn.	MAY	2015	135	5					649	653				5	Pharmacology & Pharmacy	Pharmacology & Pharmacy	CH2LB	WOS:000353855600002		
J	Kobayashi, A; Kondo, K; Sugai, S				Kobayashi, Akio; Kondo, Kazuma; Sugai, Shoichiro			Investigation of Predisposition Biomarkers to Identify Risk Factors for Drug-induced Liver Injury in Humans: Analyses of Endogenous Metabolites in an Animal Model Mimicking Human Responders to APAP-induced Hepatotoxicity	YAKUGAKU ZASSHI-JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN			Japanese	Review						acetaminophen; hepatotoxicity; glutathione; glutathione-related metabolome; restricted feeding	TRANSAMINASE LEVELS; ACETAMINOPHEN; RATS; TOXICITY; METABONOMICS; PARACETAMOL; MECHANISM; SAFETY	Drug-induced liver injury is a main reason of regulatory action pertaining to drugs, including restrictions to clinical indications and withdrawal from the marketplace. Acetaminophen (APAP) is a commonly used and effective analgesic/antipyretic agent and relatively safe drug even in long-term treatment. However, it is known that APAP at therapeutic doses may cause hepatotoxicity in some individuals. Hence great efforts have been made to identify risk factors for APAP-induced chronic hepatotoxicity. We investigated the contribution of undernourishment to susceptibility to APAP-induced chronic hepatotoxicity using an animal model. We employed daytime restricted fed (RF) rats as a modified-nutritional state model for human APAP-induced hepatotoxicity. RF and ad libitum fed (ALF) rats were given APAP at 0, 300, and 500 mg/kg for 3 months. Plasma and urinary glutathione-related metabolomes and liver function parameters were measured during the dosing period. Endogenous metabolites forming at different levels between the RF and ALF rats could be potential predisposition biomarkers for APAP-induced hepatotoxicity. In addition, RF rats were considered a useful model to estimate the contribution of nutritional state of patients to APAP-induced chronic hepatotoxicity. In this article we report our current research focusing on nutritional state as risk factor for APAP-induced chronic hepatotoxicity and our findings of hepatotoxicity biomarkers.	[Kobayashi, Akio; Kondo, Kazuma; Sugai, Shoichiro] JAPAN TOBACCO INC, Cent Pharmaceut Res Inst, Toxicol Res Lab, Hadano, Kanagawa 2570024, Japan	Kobayashi, A (reprint author), JAPAN TOBACCO INC, Cent Pharmaceut Res Inst, Toxicol Res Lab, 23 Naganuki, Hadano, Kanagawa 2570024, Japan.	akio.kobayashi@jt.com					Amar PJ, 2007, EXPERT OPIN DRUG SAF, V6, P341, DOI 10.1517/1470338.6.4.341; Andersson U, 2009, BIOMARKERS, V14, P572, DOI 10.3109/13547500903261354; Stevens JL, 2009, DRUG DISCOV TODAY, V14, P162, DOI 10.1016/j.drudis.2008.11.009; VERMEULEN NPE, 1992, DRUG METAB REV, V24, P367, DOI 10.3109/03602539208996298; DAVIDSON DG, 1966, BRIT MED J, V2, P497; Yang X, 2012, TOXICOL SCI, V125, P335, DOI 10.1093/toxsci/kfr321; BLACK M, 1984, ANNU REV MED, V35, P577, DOI 10.1146/annurev.med.35.1.577; Schomaker S, 2013, TOXICOL SCI, V132, P276, DOI 10.1093/toxsci/kft009; Shimizu S, 2009, ARCH TOXICOL, V83, P701, DOI 10.1007/s00204-009-0436-9; Winnike JH, 2010, CLIN PHARMACOL THER, V88, P45, DOI 10.1038/clpt.2009.240; Lee WM, 2004, HEPATOLOGY, V40, P6, DOI 10.1002/hep.20293; O'Connell TM, 2010, CLIN PHARMACOL THER, V88, P394, DOI 10.1038/clpt.2010.151; Feldstein AE, 2009, HEPATOLOGY, V50, P1072, DOI 10.1002/hep.23050; Lee SST, 1996, J BIOL CHEM, V271, P12063; Olson H, 2000, REGUL TOXICOL PHARM, V32, P56, DOI 10.1006/rtph.2000.1399; Car B., 2006, AM DRUG DISCOVERY, V1, P53; Kasahara H, 2010, J TOXICOL SCI, V35, P779; Kobayashi A, 2011, J TOXICOL SCI, V36, P325; Kondo K, 2012, J TOXICOL SCI, V37, P911; LAUTERBURG BH, 1983, J CLIN INVEST, V71, P980, DOI 10.1172/JCI110853; Nishiya T, 2008, TOXICOL APPL PHARM, V232, P280, DOI 10.1016/j.taap.2008.06.024; Schiodt FV, 1997, NEW ENGL J MED, V337, P1112, DOI 10.1056/NEJM199710163371602; SCHMIDT ES, 1988, CLIN CHIM ACTA, V173, P43, DOI 10.1016/0009-8981(88)90356-7; Schnackenberg LK, 2009, TOXICOL APPL PHARM, V235, P25, DOI 10.1016/j.taap.2008.11.015; Sun Jinchun, 2009, Drug Metab Lett, V3, P130; TIMBRELL JA, 1995, COMP HAEMATOL INT, V5, P112, DOI 10.1007/BF00638929; Yamamoto Toshinori, 2006, Journal of Toxicological Sciences, V31, P49, DOI 10.2131/jts.31.49	27	0	0	PHARMACEUTICAL SOC JAPAN	TOKYO	2-12-15 SHIBUYA, SHIBUYA-KU, TOKYO, 150-0002, JAPAN	0031-6903			YAKUGAKU ZASSHI	Yakugaku Zasshi-J. Pharm. Soc. Jpn.	MAY	2015	135	5					655	662				8	Pharmacology & Pharmacy	Pharmacology & Pharmacy	CH2LB	WOS:000353855600003		
J	Iida, S; Ishida, T; Ueda, R				Iida, Shinsuke; Ishida, Takashi; Ueda, Ryuzo			Development of Mogamulizumab and Establishment of an Optimal Therapy Based on Genomic Biomarkers: From the Academic Viewpoint	YAKUGAKU ZASSHI-JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN			Japanese	Review						CC chemokine receptor 4; mogamulizumab; adult T-cell leukemia/lymphoma; immune-related adverse event (irAE); genomic biomarker	T-CELL LEUKEMIA/LYMPHOMA; ANTI-CCR4 MONOCLONAL-ANTIBODY; MULTICENTER PHASE-II; LEUKEMIA-LYMPHOMA; MOUSE MODEL; KW-0761; CANCER; EXPRESSION; SAFETY	Mogamulizumab (Moga; KW-0761) is a defucosylated humanized anti-CC chemokine receptor 4 (CCR4) antibody engineered to exert potent antibody-dependent cellular cytotoxicity (ADCC). A collaborative investigation with industry in preclinical studies has demonstrated in vitro and in vivo efficacy via ADCC for adult T-cell leukemia/lymphoma (ATLL) and CCR4-positive peripheral T-cell lymphoma (PTCL). In a phase I study, once-weekly administration of mogamulizumab (0.01-1.0 mg/kg) for 4 weeks was well tolerated. In a phase II study of once-weekly mogamulizumab (1.0 mg/kg) for 8 weeks in relapsed/refractory ATLL patients, an overall response rate of 50% including 30% complete response rate with a median progression-free survival of 5.2 months was observed. The drug was subsequently approved by Pharmaceuticals and Medical Devices Agency (PMDA) in March 2012. Because CCR4 is abundantly expressed on the surface of effector regulatory T cells, a phase I study is being conducted to enhance antitumor immune response in patients with solid tumors. However, approximately 60% of patients receiving mogamulizumab experience skin eruption with 19% showing grade >= 3 rash. Postmarketing surveillance of mogamulizumab revealed a 3-4% incidence rate of skin-related serious adverse events (SAEs) such as Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN). Therefore we initiated a search for predictive genomic biomarkers in the blood of patients with ATLL or solid tumors prior to treatment with mogamulizumab for not only efficacy but also immune-related SAEs. We believe the results of this study may lead to safer and more efficient use of this agent in the near future.	[Iida, Shinsuke; Ishida, Takashi] Nagoya City Univ, Grad Sch Med Sci, Dept Hematol & Oncol, Mizuho Ku, Nagoya, Aichi 4678601, Japan; [Ueda, Ryuzo] Aichi Med Univ, Sch Med, Dept Tumor Immunol, Nagakute, Aichi 4801195, Japan	Iida, S (reprint author), Nagoya City Univ, Grad Sch Med Sci, Dept Hematol & Oncol, Mizuho Ku, 1 Kawasumi,Mizuho Cho, Nagoya, Aichi 4678601, Japan.	iida@med.nagoya-cu.ac.jp					Ishida T, 2003, CLIN CANCER RES, V9, P3625; Ogura M, 2014, J CLIN ONCOL, V32, P1157, DOI 10.1200/JCO.2013.52.0924; Hodi FS, 2010, NEW ENGL J MED, V363, P711, DOI 10.1056/NEJMoa1003466; Tsukasaki K, 2007, J CLIN ONCOL, V25, P5458, DOI 10.1200/JCO.2007.11.9958; Sugiyama D, 2013, P NATL ACAD SCI USA, V110, P17945, DOI 10.1073/pnas.1316796110; Ishida T, 2012, J CLIN ONCOL, V30, P837, DOI 10.1200/JCO.2011.37.3472; Ishida T, 2004, CLIN CANCER RES, V10, P5494, DOI 10.1158/1078-0432.CCR-04-0371; McLeod HL, 2013, SCIENCE, V339, P1563, DOI 10.1126/science.1234139; Yano H, 2007, INT J CANCER, V120, P2052, DOI 10.1002/ijc.22536; Niwa R, 2004, CANCER RES, V64, P2127, DOI 10.1158/0008-5472.CAN-03-2068; Tohkin M, 2013, PHARMACOGENOMICS J, V13, P60, DOI 10.1038/tpj.2011.41; Ishida T, 2004, CLIN CANCER RES, V10, P7529, DOI 10.1158/1078-0432.CCR-04-0983; Masaki A, 2013, J IMMUNOL, V191, P135, DOI 10.4049/jimmunol.1202692; Ito A, 2009, J IMMUNOL, V183, P4782, DOI 10.4049/jimmunol.0900699; Brahmer JR, 2012, NEW ENGL J MED, V366, P2455, DOI 10.1056/NEJMoa1200694; Ito A, 2009, CANCER IMMUNOL IMMUN, V58, P1195, DOI 10.1007/s00262-008-0632-0; Topalian SL, 2012, NEW ENGL J MED, V366, P2443, DOI 10.1056/NEJMoa1200690; Curiel TJ, 2004, NAT MED, V10, P942, DOI 10.1038/nm1093; Yamamoto K, 2010, J CLIN ONCOL, V28, P1591, DOI 10.1200/JCO.2009.25.3575; Ishida T, 2013, CANCER SCI, V104, P647, DOI 10.1111/cas.12116; Chessman D, 2008, IMMUNITY, V28, P822, DOI 10.1016/j.immuni.2008.04.020; Kyowa Hakko Kirin Co. Ltd., 2014, POT INJ 20 MG GEN PR, P37; Yano H, 2008, BRIT J HAEMATOL, V140, P586, DOI 10.1111/j.1365-2141.2007.06947.x	23	0	0	PHARMACEUTICAL SOC JAPAN	TOKYO	2-12-15 SHIBUYA, SHIBUYA-KU, TOKYO, 150-0002, JAPAN	0031-6903			YAKUGAKU ZASSHI	Yakugaku Zasshi-J. Pharm. Soc. Jpn.	MAY	2015	135	5					663	669				7	Pharmacology & Pharmacy	Pharmacology & Pharmacy	CH2LB	WOS:000353855600004		
J	Kaniwa, N				Kaniwa, Nahoko			Utilization of Genomic Biomarkers for Post-marketing Safety of Drugs	YAKUGAKU ZASSHI-JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN			Japanese	Review						genomic biomarker; anti-cancer drug; cutaneous adverse reaction; Stevens-Johnson syndrome; toxic epidermal necrolysis; human leukocyte antigen (HLA) type	STEVENS-JOHNSON-SYNDROME; CUTANEOUS ADVERSE-REACTIONS; TOXIC EPIDERMAL NECROLYSIS; HLA-B-ASTERISK-1502 ALLELE; THAI POPULATION; HAN CHINESE; RISK-FACTOR; HLA-B; CARBAMAZEPINE; ASSOCIATION	To prevent adverse drug reactions in the post-marketing phase, therapeutic drug monitoring and various laboratory tests have been used for decades. Recently, data on associations between drug adverse reactions and biomarkers based on "omics" technologies/studies have been increasing. Using genomic biomarkers, patients at high risk for developing side effects can be distinguished before initiating medical treatment, allowing the choice of an appropriate drug/initial dosage regimen. Biomarkers based on proteomics or metabolomics can detect the onset of adverse reactions at an earlier stage than can be accomplished with classical laboratory tests. However, the clinical use of drug safety-related biomarkers is still limited compared with biomarkers that predict drug efficacy of, for example, molecular-targeted drugs. In this symposium, genomic biomarkers associated with the safety of anticancer drugs and idiosyncratic adverse reactions are introduced and compared between Japan and other countries. Prospective studies evaluating the application of screening tests to prevent adverse drug reactions are also shown, and steps necessary to accelerate the use of drug safety-related biomarkers are discussed.	Natl Inst Hlth Sci, Div Med Safety Sci, Setagaya Ku, Tokyo 1588501, Japan	Kaniwa, N (reprint author), Natl Inst Hlth Sci, Div Med Safety Sci, Setagaya Ku, Kamiyoga 1-18-1, Tokyo 1588501, Japan.	nkaniwa@nihs.go.jp					Kaniwa N, 2013, PHARMACOGENOMICS, V14, P1821, DOI 10.2217/pgs.13.180; Mallal S, 2008, NEW ENGL J MED, V358, P568, DOI 10.1056/NEJMoa0706135; Chung WH, 2004, NATURE, V428, P486, DOI 10.1038/428486a; McCormack M, 2011, NEW ENGL J MED, V364, P1134, DOI 10.1056/NEJMoa1013297; Locharernkul C, 2008, EPILEPSIA, V49, P2087, DOI 10.1111/j.1528-1167.2008.01719.x; Lonjou C, 2008, PHARMACOGENET GENOM, V18, P99, DOI 10.1097/FPC.0b013e3282f3ef9c; Kang HR, 2011, PHARMACOGENET GENOM, V21, P303, DOI 10.1097/FPC.0b013e32834282b8; Minami H, 2007, PHARMACOGENET GENOM, V17, P497, DOI 10.1097/FPC.0b013e328014341f; Tassaneeyakul W, 2009, PHARMACOGENET GENOM, V19, P704, DOI 10.1097/FPC.0b013e328330a3b8; Mehta TY, 2009, INDIAN J DERMATOL VE, V75, P579, DOI 10.4103/0378-6323.57718; Kaniwa N, 2010, EPILEPSIA, V51, P2461, DOI 10.1111/j.1528-1167.2010.02766.x; Hung SL, 2005, P NATL ACAD SCI USA, V102, P4134, DOI 10.1073/pnas.0409500102; Kim SH, 2011, EPILEPSY RES, V97, P190, DOI 10.1016/j.eplepsyres.2011.08.010; Cao ZH, 2012, PHARMACOGENOMICS, V13, P1193, DOI [10.2217/pgs.12.89, 10.2217/PGS.12.89]; Saag M, 2008, CLIN INFECT DIS, V46, P1111, DOI 10.1086/529382; Wei CY, 2012, J ALLERGY CLIN IMMUN, V129, P1562, DOI 10.1016/j.jaci.2011.12.990; Lonjou C, 2006, PHARMACOGENOMICS J, V6, P265, DOI 10.1038/sj.tpj.6500356; Tohkin M, 2013, PHARMACOGENOMICS J, V13, P60, DOI 10.1038/tpj.2011.41; Chen P, 2011, NEW ENGL J MED, V364, P1126, DOI 10.1056/NEJMoa1009717; Man CBL, 2007, EPILEPSIA, V48, P1015, DOI 10.1111/j.1528-1167.2007.01022.x; Ozeki T, 2011, HUM MOL GENET, V20, P1034, DOI 10.1093/hmg/ddq537; Zhang Y, 2011, EUR J CLIN PHARMACOL, V67, P885, DOI 10.1007/s00228-011-1009-4; Hung SL, 2006, PHARMACOGENET GENOM, V16, P297, DOI 10.1097/01.fpc.0000199500.46842.4a; Tassaneeyakul W, 2010, EPILEPSIA, V51, P926, DOI [10.1111/j.1528-1167.2010.02533.x, 10.1111/j.1528-1167.2009.02533.x]; Kaniwa N, 2011, YAKUGAKU ZASSHI, V131, P255, DOI 10.1248/yakushi.131.255; Kaniwa Nahoko, 2013, Ther Adv Drug Saf, V4, P246, DOI 10.1177/2042098613499791; Kim S. H., 2011, PHARMACOGENOMICS, V11, P879; U. S. Food and Drug Administration, TABL PHARM BIOM DRUG; Ueno H, 2009, BRIT J CANCER, V100, P870, DOI 10.1038/sj.bjc.6604971; Wang Q, 2011, SEIZURE-EUR J EPILEP, V20, P446, DOI 10.1016/j.seizure.2011.02.003	30	0	0	PHARMACEUTICAL SOC JAPAN	TOKYO	2-12-15 SHIBUYA, SHIBUYA-KU, TOKYO, 150-0002, JAPAN	0031-6903			YAKUGAKU ZASSHI	Yakugaku Zasshi-J. Pharm. Soc. Jpn.	MAY	2015	135	5					671	679				9	Pharmacology & Pharmacy	Pharmacology & Pharmacy	CH2LB	WOS:000353855600005		
J	Ishiguro, A				Ishiguro, Akihiro			Current PMDA Activities for Use of Biomarkers in Drug Evaluation	YAKUGAKU ZASSHI-JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN			Japanese	Review						biomarker; drug development; international harmonization; pharmacogenomics	REGULATORY PERSPECTIVE; CLINICAL-TRIALS; PHARMACOGENETICS; CHALLENGES	Biomarkers (BM) are gradually being recognized as useful tools to evaluate drugs from development through post-approval periods. In the past decade, practical use of BM has advanced particularly in the field of anti-cancer drug development. Regardless of the use of BM, approximately 10% of key clinical trials for new drug applications of anti-cancer drugs were conducted as multiregional clinical trials. In the era of globalization of drug development, common understanding regarding the usefulness and limitations of BM availabilities in drug evaluation will contribute to provide better evidence in multiple clinical trials. However, only two guidelines regarding BM, i.e., terminologies of pharmacogenomics (E15 guideline) and document format in BM qualification submission to regulatory agencies (E16 guideline), have been harmonized in the International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) so far. It is important to strengthen international harmonization and collaboration among academia, industry, and regulatory agencies, followed by the establishment of an international guideline on the application of BM in drug evaluation. This article outlines the regulatory perspective on remaining challenges and current Pharmaceuticals and Medical Devices Agency (PMDA) activities for use of BM in drug evaluation.	PMDA, Off New Drug 5, Chiyoda Ku, Tokyo 1000013, Japan	Ishiguro, A (reprint author), PMDA, Off New Drug 5, Chiyoda Ku, Shin Kasumigaseki Bldg,3-3-2 Kasumigaseki, Tokyo 1000013, Japan.	ishiguro-akihiro@pmda.go.jp					Warner AW, 2011, CLIN PHARMACOL THER, V89, P529, DOI 10.1038/clpt.2010.305; Otsubo Y, 2013, PHARMACOGENOMICS, V14, P195, DOI [10.2217/pgs.12.194, 10.2217/PGS.12.194]; Maliepaard M, 2013, NAT REV DRUG DISCOV, V12, P103, DOI 10.1038/nrd3931; [Anonymous], GUID IND CLIN PHARM; Ishiguro A, 2013, J HUM GENET, V58, P313, DOI 10.1038/jhg.2013.36; European Medicines Agency, GUID US PHARM METH P; European Medicines Agency, GUID INV DRUG INT; European Medicines Agency, REFL PAP PHARM SAMPL; Krejsa C, 2006, NAT REV DRUG DISCOV, V5, P507, DOI 10.1038/nrd2039; Ministry of Health Labour and Welfare, GUID CLIN PHRAM STUD; Ministry of Health Labour and Welfare, GUID METH DRUG INT S; Ministry of Health Labour and Welfare, GEN PRINC CLIN TRIAL; Sakamoto Y., 2014, HDB PHARMACOGENOMICS, P951; U.S. Food and Drug Administration, DRAFT GUID IND DRUG	14	0	0	PHARMACEUTICAL SOC JAPAN	TOKYO	2-12-15 SHIBUYA, SHIBUYA-KU, TOKYO, 150-0002, JAPAN	0031-6903			YAKUGAKU ZASSHI	Yakugaku Zasshi-J. Pharm. Soc. Jpn.	MAY	2015	135	5					681	684				4	Pharmacology & Pharmacy	Pharmacology & Pharmacy	CH2LB	WOS:000353855600006		
J	Tokuyama, S; Kawakami, J				Tokuyama, Shogo; Kawakami, Junichi			Frontiers in Research of Drug Transporters Aimed at Appropriate Pain Relief by Narcotic Analgesics-Foreword	YAKUGAKU ZASSHI-JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN			Japanese	Editorial Material									[Tokuyama, Shogo] Kobe Gakuin Univ, Sch Pharmaceutucal Sci, Dept Clin Pharm, Chuo Ku, Kobe, Hyogo 6508586, Japan; [Kawakami, Junichi] Hamamatsu Univ Sch Med, Dept Hosp Pharm, Higashi Ku, Hamamatsu, Shizuoka 4313192, Japan	Tokuyama, S (reprint author), Kobe Gakuin Univ, Sch Pharmaceutucal Sci, Dept Clin Pharm, Chuo Ku, 1-1-3 Minatojima, Kobe, Hyogo 6508586, Japan.	stoku@pharm.kobegakuin.ac.jp						0	0	0	PHARMACEUTICAL SOC JAPAN	TOKYO	2-12-15 SHIBUYA, SHIBUYA-KU, TOKYO, 150-0002, JAPAN	0031-6903			YAKUGAKU ZASSHI	Yakugaku Zasshi-J. Pharm. Soc. Jpn.	MAY	2015	135	5					685	685				1	Pharmacology & Pharmacy	Pharmacology & Pharmacy	CH2LB	WOS:000353855600007		
J	Kobori, T; Harada, S; Nakamoto, K; Tokuyama, S				Kobori, Takuro; Harada, Shinichi; Nakamoto, Kazuo; Tokuyama, Shogo			Role of Scaffold Proteins in Functional Alteration of Small Intestinal P-glycoprotein by Anti-cancer Drugs	YAKUGAKU ZASSHI-JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN			Japanese	Review						P-glycoprotein; opioid analgesics; anti-cancer drug; ezrin/radixin/moesin; RhoA	CANCER RESISTANCE PROTEIN; ORAL MORPHINE ANALGESIA; SPRAGUE-DAWLEY RATS; BLOOD-BRAIN-BARRIER; IN-VIVO; ETOPOSIDE TREATMENT; EZRIN/RADIXIN/MOESIN PROTEINS; 1ST-PASS METABOLISM; EPITHELIAL-CELLS; CYCLOSPORINE-A	Since there is accumulating evidence to indicate that introduction of early palliative care for cancer patients may improved their quality of life or survival rates, the number of patients receiving pain relief by narcotic analgesics in conjunction with chemotherapy is predicted to increase. Therefore to provide effective combination treatments it is important to evaluate basic evidence regarding drug-drug interactions between anti-cancer drugs and narcotics. We have focused on P-glycoprotein (P-gp), a drug efflux transporter, in small intestine where the absorption process of drugs administered via oral route is greatly limited. Then, we revealed that repeated oral treatment with etoposide (ETP) increases P-gp levels in the small intestinal membrane via RhoA/ROCK activation, leading to decrease in analgesia of morphine, a P-gp substrate drug, with alteration of its disposition after oral administration. Furthermore, we found that activation of ezrin/radixin/moesin (ERM), scaffold proteins that regulate plasma membrane localization or function of certain plasma membrane proteins such as P-gp, are involved in this mechanism. Of particular interest is that among ERM proteins, radixin may contribute, at least in part, to increased expression of P-gp in the small intestine under repeated oral treatment with ETP.	[Kobori, Takuro; Harada, Shinichi; Nakamoto, Kazuo; Tokuyama, Shogo] Kobe Gakuin Univ, Sch Pharmaceut Sci, Dept Clin Pharm, Chuo Ku, Kobe, Hyogo 6508586, Japan	Tokuyama, S (reprint author), Kobe Gakuin Univ, Sch Pharmaceut Sci, Dept Clin Pharm, Chuo Ku, 1-1-3 Minatojima, Kobe, Hyogo 6508586, Japan.	stoku@pharm.kobegakuin.ac.jp					Kharasch ED, 2003, CLIN PHARMACOL THER, V74, P543, DOI 10.1016/j.clpt.2003.08.011; Luciani F, 2002, BLOOD, V99, P641, DOI 10.1182/blood.V99.2.641; Allen JD, 2003, CANCER RES, V63, P1339; Temel JS, 2010, NEW ENGL J MED, V363, P733, DOI 10.1056/NEJMoa1000678; UEDA K, 1987, J BIOL CHEM, V262, P505; Yonemura S, 2002, J CELL SCI, V115, P2569; Lin JH, 2003, ADV DRUG DELIVER REV, V55, P53, DOI 10.1016/S0169-409X(02)00171-0; Lagas JS, 2010, MOL CANCER THER, V9, P319, DOI 10.1158/1535-7163.MCT-09-0663; Yang Q, 2007, EXP CELL RES, V313, P3517, DOI 10.1016/j.yexcr.2007.07.033; Hassan HE, 2007, J PHARM SCI-US, V96, P2494, DOI 10.1002/jps.20893; Westphal K, 2000, CLIN PHARMACOL THER, V68, P345, DOI 10.1067/mcp.2000.109797; Callaghan R, 2008, J CLIN PHARMACOL, V48, P365, DOI 10.1177/0091270007311568; Dagenais C, 2004, BIOCHEM PHARMACOL, V67, P269, DOI 10.1016/j.bcp.2003.08.027; Zong J, 2000, PHARMACEUT RES, V17, P749, DOI 10.1023/A:1007546719287; Tsukita S, 1999, J BIOL CHEM, V274, P34507, DOI 10.1074/jbc.274.49.34507; Wang W, 2006, GASTROENTEROLOGY, V131, P878, DOI 10.1053/j.gastro2006.06.013; Henthorn TK, 1999, J PHARMACOL EXP THER, V289, P1084; Demeule M, 1999, FEBS LETT, V442, P208, DOI 10.1016/S0014-5793(98)01663-9; Xie RJ, 1999, BRIT J PHARMACOL, V128, P563, DOI 10.1038/sj.bjp.0702804; Saotome I, 2004, DEV CELL, V6, P855, DOI 10.1016/j.devcel.2004.05.007; Ruddy K, 2009, CA-CANCER J CLIN, V59, P56, DOI 10.3322/caac.20004; Bandieri E, 2012, ANN ONCOL, V23, P2016, DOI 10.1093/annonc/mds103; Okura T, 2009, J PHARM PHARMACOL, V61, P593, DOI [10.1211/jpp/61.05.0007, 10.1211/jpp.61.05.0007]; Marchetti S, 2007, ONCOLOGIST, V12, P927, DOI 10.1634/theoncologist.12-8-927; Dohse M, 2010, DRUG METAB DISPOS, V38, P1371, DOI 10.1124/dmd.109.031302; Greiner B, 1999, J CLIN INVEST, V104, P147, DOI 10.1172/JCI6663; Kojima H, 2008, J GASTROEN HEPATOL, V23, pE120, DOI 10.1111/j.1440-1746.2007.05109.x; Bardelmeijer HA, 2002, CANCER RES, V62, P6158; Zhong Y, 2010, J CEREBR BLOOD F MET, V30, P522, DOI 10.1038/jcbfm.2009.214; Lown KS, 1997, CLIN PHARMACOL THER, V62, P248, DOI 10.1016/S0009-9236(97)90027-8; Thompson SJ, 2000, ANESTHESIOLOGY, V92, P1392, DOI 10.1097/00000542-200005000-00030; Zhang L, 2006, MOL PHARMACEUT, V3, P62, DOI 10.1021/mp050095h; Kikuchi S, 2002, NAT GENET, V31, P320, DOI 10.1038/ng905; Stuurman FE, 2013, CLIN PHARMACOKINET, V52, P399, DOI 10.1007/s40262-013-0040-2; Marchetti S, 2008, MOL CANCER THER, V7, P2280, DOI 10.1158/1535-7163.MCT-07-2250; Kojima H, 2003, J HEPATOL, V39, P693, DOI 10.1016/S0168-8278(03)00410-0; Nakano T, 2009, DRUG METAB DISPOS, V37, P1521, DOI 10.1124/dmd.108.024836; Bretscher A, 2002, NAT REV MOL CELL BIO, V3, P586, DOI 10.1038/nrm882; Letrent SP, 1998, PHARMACEUT RES, V15, P599, DOI 10.1023/A:1011938112599; Balayssac D, 2005, J PERIPHER NERV SYST, V10, P301, DOI 10.1111/j.1085-9489.2005.10308.x; Bulhak A, 2007, AM J PHYSIOL-HEART C, V292, P3158; Doublier S, 2008, MOL CANCER RES, V6, P1607, DOI 10.1158/1541-7786.MCR-08-0251; Elkiweri IA, 2009, ANESTH ANALG, V108, P149, DOI 10.1213/ane.0b013e31818e0bd1; Patta A, 2011, ANTICANCER RES, V31, P975; FOLEY KM, 1985, NEW ENGL J MED, V313, P84, DOI 10.1056/NEJM198507113130205; Fricker G, 2002, PHARMACOL TOXICOL, V90, P5, DOI 10.1034/j.1600-0773.2002.900103.x; Fujita-Hamabe W, 2012, J PHARM PHARMACOL, V64, P496, DOI 10.1111/j.2042-7158.2011.01426.x; Glare P, 2011, J PEDIAT HEMATOL ONC, V33, pS6, DOI 10.1097/MPH.0b013e3182121a2b; Hirao M, 1996, J CELL BIOL, V135, P37, DOI 10.1083/jcb.135.1.37; Ikemura K, 2009, J PHARMACOL EXP THER, V328, P249, DOI 10.1124/jpet.108.145581; Jette L, 1996, AM J PHYSIOL-RENAL, V270, pF756; Kano T, 2011, J PHARM SCI-US, V100, P5308, DOI 10.1002/jps.22718; Kharasch ED, 2004, J CLIN PHARMACOL, V44, P224, DOI 10.1177/0091270003262075; Kobori T, 2013, J PHARM SCI-US, V102, P1670, DOI 10.1002/jps.23503; Kobori T, 2012, EUR J PHARM SCI, V47, P934, DOI 10.1016/j.ejps.2012.08.019; Kobori T, 2014, BIOL PHARM BULL, V37, P1124; Kobori T, 2013, BIOL PHARM BULL, V36, P1822; Liukas A, 2011, J CLIN PSYCHOPHARM, V31, P302, DOI 10.1097/JCP.0b013e3182189892; Masuda S, 2000, CLIN PHARMACOL THER, V68, P98, DOI 10.1067/mcp.2000.107912; Ministry of Health Labour and Welfare, BAS PLAN PROM CANC C; Mizuno Naomi, 2002, Drug Metab Pharmacokinet, V17, P93, DOI 10.2133/dmpk.17.93; Mizuno Naomi, 2005, Nihon Yakurigaku Zasshi, V125, P200; Namukwaya E., 2011, PAIN RES TREAT, V2011; Ogihara T, 2006, DRUG METAB PHARMACOK, V21, P238, DOI 10.2133/dmpk.21.238; Okura T, 2009, BIOL PHARM BULL, V32, P1571; Okura T, 2008, BIOL PHARM BULL, V31, P2338, DOI 10.1248/bpb.31.2338; Skarke C, 2003, CLIN PHARMACOL THER, V74, P303, DOI 10.1067/S0009-9236(03)00220-0; Sparreboom A, 1997, P NATL ACAD SCI USA, V94, P2031, DOI 10.1073/pnas.94.5.2031; Statistics and Information Department Ministry of Health Labour and Welfare, 2013, VIT STAT JAP; Tokuyama S, 2007, J PHARM PHARMACOL, V59, P1109, DOI 10.1211/ipp.59.8.0008; van den Beuken-van Everdingen M H J, 2007, Ann Oncol, V18, P1437, DOI 10.1093/annonc/mdm056; Yano K, 2013, J PHARM SCI-US, V102, P2875, DOI 10.1002/jps.23637	72	0	0	PHARMACEUTICAL SOC JAPAN	TOKYO	2-12-15 SHIBUYA, SHIBUYA-KU, TOKYO, 150-0002, JAPAN	0031-6903			YAKUGAKU ZASSHI	Yakugaku Zasshi-J. Pharm. Soc. Jpn.	MAY	2015	135	5					687	695				9	Pharmacology & Pharmacy	Pharmacology & Pharmacy	CH2LB	WOS:000353855600008		
J	Okura, T; Higuchi, K; Deguchi, Y				Okura, Takashi; Higuchi, Kei; Deguchi, Yoshiharu			The Blood-Brain Barrier Transport Mechanism Controlling Analgesic Effects of Opioid Drugs in CNS	YAKUGAKU ZASSHI-JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN			Japanese	Review						blood-brain barrier; transporter; oxycodone	ENDOTHELIAL-CELL LINE; ORGANIC CATION TRANSPORTER; IN-VIVO; MORPHINE; OXYCODONE; HCMEC/D3; MODEL; RATS; MORPHINE-6-BETA-GLUCURONIDE; INVOLVEMENT	The transport of opioid analgesics across the blood-brain barrier (BBB) is an important determinant of their therapeutic effects. The human brain is protected by the BBB, which consists of brain capillary endothelial cells linked with tight junctions. It is well established that the polarized expression of numerous transporters and receptors at the brain capillary endothelial cells controls the blood-brain exchange of nutrients, waste products deriving from neurotransmitter substances, and drugs. Morphine is a substrate of P-glycoprotein and the P-glycoprotein-mediated efflux transport at the BBB maintains a lower unbound concentration of morphine in the brain compared with plasma. On the other hand, oxycodone has 3 times higher unbound concentration in the brain than plasma, suggesting an active transport mechanism of oxycodone across the BBB into the brain. In vitro transport study using BBB model cells showed that oxycodone is efficiently transported by a proton-coupled organic cation antiporter. Human BBB model cells also retain the proton-coupled organic cation antiporter. Although adjuvant analgesics include many cationic drugs that interact with oxycodone transport across the BBB at relatively high concentrations, these drugs would enhance the antinociceptive effects of oxycodone with little effect on oxycodone pharmacokinetics, including brain distribution at therapeutically or pharmacologically relevant concentrations. These findings support the idea that proton-coupled organic cation antiporter-mediated transport of oxycodone at the BBB plays a role in determining the therapeutic efficacy of this opioid analgesic drug.	[Okura, Takashi; Higuchi, Kei; Deguchi, Yoshiharu] Teikyo Univ, Fac Pharma Sci, Lab Drug Disposit & Pharmacokinet, Itabashi Ku, Tokyo 1738605, Japan	Deguchi, Y (reprint author), Teikyo Univ, Fac Pharma Sci, Lab Drug Disposit & Pharmacokinet, Itabashi Ku, 2-11-1 Kaga, Tokyo 1738605, Japan.	deguchi@pharm.teikyo-u.ac.jp					Andre P, 2009, J CEREBR BLOOD F MET, V29, P1293, DOI 10.1038/jcbfm.2009.54; Okura T, 2007, LIFE SCI, V80, P1564, DOI 10.1016/j.lfs.2007.01.035; Ball K, 2012, J PHARM SCI-US, V101, P4277, DOI 10.1002/jps.23266; Peckham EM, 2006, J PHARMACOL EXP THER, V316, P1195, DOI 10.1124/jpet.105.094276; YAMAZAKI M, 1994, PHARMACEUT RES, V11, P975, DOI 10.1023/A:1018923017954; Ohtsuki S, 2013, MOL PHARMACEUT, V10, P289, DOI 10.1021/mp3004308; Sadiq MW, 2011, J PHARM SCI-US, V100, P3912, DOI 10.1002/jps.22567; Okura T, 2008, DRUG METAB DISPOS, V36, P2005, DOI 10.1124/dmd.108.022087; Weksler BB, 2005, FASEB J, V19, P1872; Bostrom E, 2006, DRUG METAB DISPOS, V34, P1624, DOI 10.1124/dmd.106.009746; Bostrom E, 2008, ANESTHESIOLOGY, V108, P495, DOI 10.1097/ALN.0b013e318164cf9e; Deguchi Y, 2003, J NEUROCHEM, V84, P1154, DOI 10.1046/j.0022-3042.2003.01582.x; Kubo Y, 2013, J PHARM SCI-US, V102, P3332, DOI 10.1002/jps.23535; Nakazawa Y, 2010, J PHARM SCI-US, V99, P467, DOI 10.1002/jps.21807; Ohtsuki S., 2007, PHARM RES, V24, P1715; Okura T, 2007, LIFE SCI, V80, P1319, DOI 10.1016/j.lfs.2006.12.018; Okura T, 2014, BIOL PHARM BULL, V37, P286; Okura T, 2014, DRUG METAB PHARMACOK, V29, P69, DOI 10.2133/dmpk.DMPK-13-RG-058; Okura T, 2003, BRIT J PHARMACOL, V140, P211, DOI 10.1038/sj.bjp.0705418; Shimomura Keita, 2013, Fluids Barriers CNS, V10, P8, DOI 10.1186/2045-8118-10-8; Tunblad K, 2003, PHARMACEUT RES, V20, P618, DOI 10.1023/A:1023250900462; Weksler Babette, 2013, Fluids Barriers CNS, V10, P16, DOI 10.1186/2045-8118-10-16	22	0	0	PHARMACEUTICAL SOC JAPAN	TOKYO	2-12-15 SHIBUYA, SHIBUYA-KU, TOKYO, 150-0002, JAPAN	0031-6903			YAKUGAKU ZASSHI	Yakugaku Zasshi-J. Pharm. Soc. Jpn.	MAY	2015	135	5					697	702				6	Pharmacology & Pharmacy	Pharmacology & Pharmacy	CH2LB	WOS:000353855600009		
J	Ochiai, W; Sugiyama, K				Ochiai, Wataru; Sugiyama, Kiyoshi			Altered Expression of Transporter and Analgesic of Morphine in Neuropathic Pain Mice	YAKUGAKU ZASSHI-JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN			Japanese	Review						morphine; neuropathic pain; P-glycoprotein; uridine diphosphate glucuronosyltransferase	BLOOD-BRAIN-BARRIER; P-GLYCOPROTEIN; METABOLITE MORPHINE-6-GLUCURONIDE; RAT; GLUCURONIDATION; PERMEABILITY; MODULATION; TOLERANCE; CYP3A4; LIVER	It is known that morphine is less effective for patients with neuropathic pain, accounting for approximately 70% of cancer patients with severe pain. One of the causes of the decline is reported as a decreased function of the p-opioid receptor, which binds to the active metabolites of morphine in the mesencephalic ventral tegmental area. However, the details of this mechanism are not understood. We hypothesized that a decrease in the concentration of morphine in the brain reduces its analgesic effect on neuropathic pain, and found that the analgesic effect of morphine was correlated with its concentration in the brain. We examined the reason for the decreased concentration of morphine in the brain in case of neuropathic pain. We discovered increased P-glycoprotein (P-gp) expression in the small intestine, increased expression and activity of UGT2B in the liver, and increased P-gp expression in the brain under conditions of neuropathic pain. In this symposium, we argue that low brain morphine concentration is considered one of the causes of lower sensitivity to morphine in neuropathic pain patients.	[Ochiai, Wataru; Sugiyama, Kiyoshi] Hoshi Univ, Sch Pharm & Pharmaceut Sci, Dept Clin Pharmacokinet, Shinagawa Ku, Tokyo 1428501, Japan	Ochiai, W (reprint author), Hoshi Univ, Sch Pharm & Pharmaceut Sci, Dept Clin Pharmacokinet, Shinagawa Ku, 2-4-41 Ebara, Tokyo 1428501, Japan.	w-ochiai@hoshi.ac.jp					Kharasch ED, 2003, CLIN PHARMACOL THER, V74, P543, DOI 10.1016/j.clpt.2003.08.011; CHAPLAN SR, 1994, J NEUROSCI METH, V53, P55, DOI 10.1016/0165-0270(94)90144-9; Bickel U, 1996, J PHARMACOL EXP THER, V278, P107; Lotsch J, 1998, CLIN NEUROPHARMACOL, V21, P351; SELTZER Z, 1990, PAIN, V43, P205, DOI 10.1016/0304-3959(90)91074-S; PAUL D, 1989, J PHARMACOL EXP THER, V251, P477; PORTENOY RK, 1992, CLIN PHARMACOL THER, V51, P422; OSBORNE R, 1990, CLIN PHARMACOL THER, V47, P12; Lotsch J, 2001, CLIN PHARMACOKINET, V40, P485; Hamabe W, 2007, J PHARMACOL SCI, V105, P353, DOI 10.1254/jphs.FP0071287; Narita M, 2008, NEUROPSYCHOPHARMACOL, V33, P1097, DOI 10.1038/sj.npp.1301471; Wang Y, 2012, NAT MED, V18, P385, DOI 10.1038/nm.2633; Wu DF, 1997, DRUG METAB DISPOS, V25, P768; Yousif S, 2008, J NEUROCHEM, V107, P647, DOI 10.1111/j.1471-4159.2008.05647.x; Coffman BL, 1997, DRUG METAB DISPOS, V25, P1; Dobashi T, 2010, J CELL MOL MED, V14, P2816, DOI 10.1111/j.1582-4934.2009.00932.x; Dobashi T, 2010, NEUROSCI LETT, V485, P125, DOI 10.1016/j.neulet.2010.08.084; Hasegawa Y, 2010, J PHARM PHARMACOL, V62, P310, DOI [10.1211/jpp.62.03.0004, 10.1211/jpp/62.03.0004]; Kamei J, 2005, J PHARMACOL SCI, V97, P266, DOI 10.1254/jphs.FP0040832; KUO CK, 1991, J PHARMACOBIO-DYNAM, V14, P187; LAIZURE SC, 1994, AM J HOSP PHARM, V51, P2042; Moran TD, 2002, J PHARMACOL EXP THER, V302, P568, DOI 10.1124/jpet.102.035626; MURPHY LG, 1991, PAIN, V46, P347, DOI 10.1016/0304-3959(91)90120-M; Ohno S, 2008, DRUG METAB DISPOS, V36, P688, DOI 10.1124/dmd.107.019281; OSBORNE R, 1988, LANCET, V1, P828; Takeda S, 2005, MOL PHARMACOL, V67, P665, DOI 10.1124/mol.104.007641; Takeda S, 2005, BIOL PHARM BULL, V28, P2026, DOI 10.1248/bpb.28.2026; Tunblad K, 2003, PHARMACEUT RES, V20, P618, DOI 10.1023/A:1023250900462; YUE QY, 1990, PHARMACOL TOXICOL, V66, P221	29	0	0	PHARMACEUTICAL SOC JAPAN	TOKYO	2-12-15 SHIBUYA, SHIBUYA-KU, TOKYO, 150-0002, JAPAN	0031-6903			YAKUGAKU ZASSHI	Yakugaku Zasshi-J. Pharm. Soc. Jpn.	MAY	2015	135	5					703	708				6	Pharmacology & Pharmacy	Pharmacology & Pharmacy	CH2LB	WOS:000353855600010		
J	Naito, T; Kawakami, J				Naito, Takafumi; Kawakami, Junichi			Interindividual Variation of Pharmacokinetic Disposition of and Clinical Responses to Opioid Analgesics in Cancer Pain Patients	YAKUGAKU ZASSHI-JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN			Japanese	Review						cancer pain; individualized therapy; opioid; analgesics; pharmacokinetics	GENETIC POLYMORPHISMS; DRUG-INTERACTIONS; OXYCODONE; FENTANYL; CYP2D6; MORPHINE; ABCB1; REQUIREMENTS; METABOLISM; EFFICACY	Use of prescription opioids for cancer pain according to the World Health Organization analgesic ladder has been accepted in Japan. Although oxycodone and fentanyl are commonly used as first-line analgesics, a few clinical reports have been published on interindividual variations in their pharmacokinetics and clinical responses in cancer patients. (1) Some factors relating to CYP2D6, CYP3A, ATP-binding cassette sub-family B member 1 (ABCB1), and opioid receptor mu 1 (OPRM1) involve oxycodone pharmacokinetics and sensitivity in humans. The relations between their genetic variations and clinical responses to oxycodone are being revealed in limited groups. In our study, the impact of genetic variants and pharmacokinetics on clinical responses to oxycodone were evaluated in Japanese populations. (2) Opioid switching improves the opioid tolerance related to the balance between analgesia and adverse effects. Some patients have difficulty in obtaining better opioid tolerance in recommended conversion ratios. The activities of CYP3A, ABCB1, and OPRM1 contribute to the interindividual variations in clinical responses to fentanyl in cancer patients. However, the variations in opioid switching remain to be clarified in clinical settings. In our study, genetic factors related to interindividual variations in clinical responses in opioid switching to fentanyl were revealed in Japanese populations. In this symposium review, the possibility of approaches to personalized palliative care using opioids based on genetic variants of CYP2D6, CYP3A5, ABCB1, and OPRM1 is discussed.	[Naito, Takafumi; Kawakami, Junichi] Hamamatsu Univ Sch Med, Dept Hosp Pharm, Higashi Ku, Hamamatsu, Shizuoka 4313192, Japan	Naito, T (reprint author), Hamamatsu Univ Sch Med, Dept Hosp Pharm, Higashi Ku, 1-20-1 Handayama, Hamamatsu, Shizuoka 4313192, Japan.	naitou@hama-med.ac.jp					Zwisler ST, 2010, ACTA ANAESTH SCAND, V54, P232, DOI 10.1111/j.1399-6576.2009.02104.x; Takashina Y, 2012, DRUG METAB PHARMACOK, V27, P414, DOI 10.2133/dmpk.DMPK-11-RG-134; Naito T, 2011, J CLIN PHARMACOL, V51, P1529, DOI 10.1177/0091270010388033; Morita T, 2005, J PAIN SYMPTOM MANAG, V30, P96, DOI 10.1016/j.jpainsymman.2004.12.010; Mercadante S, 2006, CANCER TREAT REV, V32, P304, DOI 10.1016/j.ctrv.2006.03.001; Klepstad P, 2004, ACTA ANAESTH SCAND, V48, P1232, DOI 10.1111/j.1399-6576.2004.00517.x; Zwisler ST, 2010, FUND CLIN PHARMACOL, V24, P517, DOI 10.1111/j.1472-8206.2009.00781.x; Hassan HE, 2007, J PHARM SCI-US, V96, P2494, DOI 10.1002/jps.20893; Zhang W, 2011, EUR J ANAESTH, V28, P245, DOI 10.1097/EJA.0b013e3283438b39; Henthorn TK, 1999, J PHARMACOL EXP THER, V289, P1084; Labroo RB, 1997, DRUG METAB DISPOS, V25, P1072; Mercadante S, 1999, J PAIN SYMPTOM MANAG, V18, P347, DOI 10.1016/S0885-3924(99)00099-8; Oertel BG, 2008, CLIN PHARMACOL THER, V83, P577, DOI 10.1038/sj.clpt.6100441; Andreassen TN, 2012, EUR J CLIN PHARMACOL, V68, P55, DOI 10.1007/s00228-011-1093-5; Holtman JR, 2006, PHARMACOL BIOCHEM BE, V83, P100, DOI 10.1016/j.pbb.2005.12.013; Lalovic B, 2004, DRUG METAB DISPOS, V32, P447, DOI 10.1124/dmd.32.4.447; McNamara P, 2002, PALLIATIVE MED, V16, P425, DOI 10.1191/0269216302pm536oa; Otsuka Kuniko, 2007, J Pain Palliat Care Pharmacother, V21, P37, DOI 10.1300/J354v21n03_06; Park HJ, 2007, CLIN PHARMACOL THER, V81, P539, DOI 10.1038/sj.clpt.6100046; Samer CF, 2010, BRIT J PHARMACOL, V160, P919, DOI 10.1111/j.1476-5381.2010.00709.x; Takeda F., 2001, JPN J CLIN MED, V59, P1663; Yamaguchi T, 2013, JPN J CLIN ONCOL, V43, P896, DOI 10.1093/jjco/hyt099	22	0	0	PHARMACEUTICAL SOC JAPAN	TOKYO	2-12-15 SHIBUYA, SHIBUYA-KU, TOKYO, 150-0002, JAPAN	0031-6903			YAKUGAKU ZASSHI	Yakugaku Zasshi-J. Pharm. Soc. Jpn.	MAY	2015	135	5					709	715				7	Pharmacology & Pharmacy	Pharmacology & Pharmacy	CH2LB	WOS:000353855600011		
J	Anzai, K; Hyodo, F				Anzai, Kazunori; Hyodo, Fuminori			Imaging in Vivo Redox Metabolism-Foreword	YAKUGAKU ZASSHI-JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN			Japanese	Editorial Material									[Anzai, Kazunori] Nihon Pharmaceut Univ, Div Phys & Analyt Chem, Ina, Saitama 3620806, Japan; [Hyodo, Fuminori] Kyushu Univ, Innovat Ctr Med Redox Nav, Higashi Ku, Fukuoka 8128582, Japan	Anzai, K (reprint author), Nihon Pharmaceut Univ, Div Phys & Analyt Chem, 10281 Komuro, Ina, Saitama 3620806, Japan.	anzai@nichiyaku.ac.jp						0	0	0	PHARMACEUTICAL SOC JAPAN	TOKYO	2-12-15 SHIBUYA, SHIBUYA-KU, TOKYO, 150-0002, JAPAN	0031-6903			YAKUGAKU ZASSHI	Yakugaku Zasshi-J. Pharm. Soc. Jpn.	MAY	2015	135	5					717	718				2	Pharmacology & Pharmacy	Pharmacology & Pharmacy	CH2LB	WOS:000353855600012		
J	Matsumoto, K				Matsumoto, Ken-ichiro			Radiation Therapy and Redox Imaging	YAKUGAKU ZASSHI-JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN			Japanese	Review						redox imaging; radiation theranostics; magnetic resonance; nitroxyl radical; redox sensitive contrast agent	SENSITIVE CONTRAST AGENTS; IN-VIVO; BRAIN; MRI	Radiation therapy kills cancer cells in part by flood of free radicals. Radiation ionizes and/or excites water molecules to create highly reactive species, i.e. free radicals and/or reactive oxygen species. Free radical chain reactions oxidize biologically important molecules and thereby disrupt their function. Tissue oxygen and/or redox status, which can influence the course of the free radical chain reaction, can affect the efficacy of radiation therapy. Prior observation of tissue oxygen and/or redox status is helpful for planning a safe and efficient course of radiation therapy. Magnetic resonance-based redox imaging techniques, which can estimate tissue redox status non-invasively, have been developed not only for diagnostic information but also for estimating the efficacy of treatment. Redox imaging is now spotlighted to achieve radiation theranostics.	Natl Inst Radiol Sci, Res Ctr Charged Particle Therapy, Adv Particle Radiat Biol Res Program, Radioredox Response Res Team,Inage Ku, Chiba 2638555, Japan	Matsumoto, K (reprint author), Natl Inst Radiol Sci, Res Ctr Charged Particle Therapy, Adv Particle Radiat Biol Res Program, Radioredox Response Res Team,Inage Ku, 4-9-1 Anagawa, Chiba 2638555, Japan.	matsumok@nirs.go.jp					Matsumoto K, 2006, CLIN CANCER RES, V12, P2455, DOI 10.1158/1078-0432.CCR-05-2747; Hyodo F, 2006, CANCER RES, V66, P9921, DOI 10.1158/0008-5472.CAN-06-0879; Hyodo F, 2008, J CEREBR BLOOD F MET, V28, P1165, DOI 10.1038/jcbfm.2008.5; Hyodo F, 2012, INT J ONCOL, V41, P2103, DOI 10.3892/ijo.2012.1638; Matsumoto K, 2011, METHODS MOL BIOL, V711, P397, DOI 10.1007/978-1-61737-992-5_20; Matsumoto K, 2009, BIOL PHARM BULL, V32, P711; Matsumoto KI, 2007, ANTIOXID REDOX SIGN, V9, P1125, DOI 10.1089/ars.2007.1638; Ozawa T., 2012, HOSHASEN KAGAKU SEIT; Subramanian S, 2004, NMR BIOMED, V17, P263, DOI 10.1002/nbm.897; Zhelev Z, 2009, CHEM COMMUN, P53, DOI 10.1039/b816878d; Zhelev Z, 2009, GEN PHYSIOL BIOPHYS, V28, P356, DOI 10.4149/gpb_2009_04_356; Zhelev Z, 2009, MOL PHARMACEUT, V6, P504, DOI 10.1021/mp800175k	12	0	0	PHARMACEUTICAL SOC JAPAN	TOKYO	2-12-15 SHIBUYA, SHIBUYA-KU, TOKYO, 150-0002, JAPAN	0031-6903			YAKUGAKU ZASSHI	Yakugaku Zasshi-J. Pharm. Soc. Jpn.	MAY	2015	135	5					719	724				6	Pharmacology & Pharmacy	Pharmacology & Pharmacy	CH2LB	WOS:000353855600013		
J	Hyodo, F; Ito, S; Utsumi, H				Hyodo, Fuminori; Ito, Shinji; Utsumi, Hideo			Redox Molecular Imaging Using ReMI	YAKUGAKU ZASSHI-JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN			Japanese	Review						redox imaging; dynamic nuclear polarization; nitroxyl radical; magnetic resonance imaging	OVERHAUSER-ENHANCED MRI; ELECTRON-PARAMAGNETIC-RESONANCE; NUCLEAR MAGNETIC-RESONANCE; SENSITIVE CONTRAST AGENTS; NITROXIDE COMPOUNDS; RADICAL CLEARANCE; MOUSE; MICE; EPR	Tissue redox status is one of the most important parameters to maintain homeostasis in the living body. Numerous redox reactions are involved in metabolic processes, such as energy production in the mitochondrial electron transfer system. A variety of intracellular molecules such as reactive oxygen species, glutathione, thioredoxins, NADPH, flavins, and ascorbic acid may contribute to the overall redox status in tissues. Breakdown of redox balance may lead to oxidative stress and can induce many pathological conditions such as cancer, neurological disorders, and aging. Therefore imaging of tissue redox status and monitoring antioxidant levels in living organisms can be useful in the diagnosis of disease states and assessment of treatment response. In vivo redox molecular imaging technology such as electron spin resonance imaging (ESRI), magnetic resonance imaging (MRI), and dynamic nuclear polarization (DNP)-MRI (redox molecular imaging; ReMI) is emerging as a viable redox status imaging modality. This review focuses on the application of magnetic resonance technologies using MRI or DNP-MRI and redox-sensitive contrast agents.	[Hyodo, Fuminori; Ito, Shinji; Utsumi, Hideo] Kyushu Univ, Innovat Ctr Med Redox Nav, Higashi Ku, Fukuoka 8128582, Japan	Hyodo, F (reprint author), Kyushu Univ, Innovat Ctr Med Redox Nav, Higashi Ku, 3-1-1 Maidashi, Fukuoka 8128582, Japan.	hyodof@redoxnavi.med.kyushu-u.ac.jp					Alecci M, 1998, PHYS MED BIOL, V43, P1899, DOI 10.1088/0031-9155/43/7/011; Matsumoto K, 2006, CLIN CANCER RES, V12, P2455, DOI 10.1158/1078-0432.CCR-05-2747; TAKESHITA K, 1991, BIOCHEM BIOPH RES CO, V177, P874, DOI 10.1016/0006-291X(91)91871-9; Soule BP, 2007, ANTIOXID REDOX SIGN, V9, P1731, DOI 10.1089/ars.2007.1722; Krishna MC, 2002, P NATL ACAD SCI USA, V99, P2216, DOI 10.1073/pnas.042671399; Biller JR, 2014, J MAGN RESON, V242, P162, DOI 10.1016/j.jmr.2014.02.015; Hyodo F, 2008, J PHARM PHARMACOL, V60, P1049, DOI 10.1211/jpp.60.8.0011; Murphy MP, 2009, BIOCHEM J, V417, P1, DOI 10.1042/BJ20081386; Soule BP, 2007, FREE RADICAL BIO MED, V42, P1632, DOI 10.1016/j.freeradbiomed.2007.02.030; LURIE DJ, 1988, J MAGN RESON, V76, P366, DOI 10.1016/0022-2364(88)90123-0; Utsumi H, 2006, P NATL ACAD SCI USA, V103, P1463, DOI 10.1073/pnas.0510670103; BRASCH RC, 1983, AM J ROENTGENOL, V141, P1019; BRASCH RC, 1983, RADIOLOGY, V147, P773; Fujii HG, 2013, MAGN RESON IMAGING, V31, P130, DOI 10.1016/j.mri.2012.06.021; Hyodo F, 2006, CANCER RES, V66, P9921, DOI 10.1158/0008-5472.CAN-06-0879; Hyodo F, 2008, J MAGN RESON, V190, P105, DOI 10.1016/j.jmr.2007.10.013; Kosem N, 2012, FREE RADICAL BIO MED, V53, P328, DOI 10.1016/j.freeradbiomed.2012.04.026; Li HH, 2002, MAGNET RESON MED, V48, P530, DOI 10.1002/mrm.10222; Matsumoto S, 2009, P NATL ACAD SCI USA, V106, P17898, DOI 10.1073/pnas.0908447106; OVERHAUSER AW, 1953, PHYS REV, V92, P411, DOI 10.1103/PhysRev.92.411; Yamato M, 2009, J CEREBR BLOOD F MET, V29, P1655, DOI 10.1038/jcbfm.2009.84; Yokoyama H, 1999, FREE RADICAL BIO MED, V27, P442, DOI 10.1016/S0891-5849(99)00093-3	22	0	0	PHARMACEUTICAL SOC JAPAN	TOKYO	2-12-15 SHIBUYA, SHIBUYA-KU, TOKYO, 150-0002, JAPAN	0031-6903			YAKUGAKU ZASSHI	Yakugaku Zasshi-J. Pharm. Soc. Jpn.	MAY	2015	135	5					725	731				7	Pharmacology & Pharmacy	Pharmacology & Pharmacy	CH2LB	WOS:000353855600014		
J	Naganuma, T; Nakao, M; Ichikawa, K; Utsumi, H				Naganuma, Tatsuya; Nakao, Motonao; Ichikawa, Kazuhiro; Utsumi, Hideo			Development of a New Redox Molecular Imaging Method	YAKUGAKU ZASSHI-JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN			Japanese	Review						overhauser effect; redox; magnetic resonance imaging	DESIGN	For indirect tissue observation, electron-spin, Overhauser-enhanced, dynamic nuclear polarization magnetic resonance imaging (DNP-MRI) is a useful technique. However, its sensitivity and resolution are low compared with the clinical MRI apparatus. By switching to electron spin resonance (ESR) excitation, the magnetic field of the NMR detection, field cycle technique, which aims to improve resolution, was proposed. However, the effect of eddy currents or current value was altered unsatisfactorily. A team at Kyushu University proposed a new DNP-MRI technique capable of improving NMR detection field by preparing in advance a magnetic field, which was connected by the sample transport system. By developing a mobile MRI method that can be used while moving, and fastening the sample in a disk that rotates at a constant speed, they have developed a circular transport DNP-MRI method that greatly reduces the load on the sample. The circular transport DNP-MRI system comprises a circular sample transport system, detection of an MRI magnetic field of 1.5 T, and ESR excitation magnetic field of 20 mT. The developed DNP-MRI had a clear glass tube phantom and resolution of 0.15 mm, and was successful in imaging multiple radical resonant points. It has been commercialized by Japan Redox Limited. In the process of equipment commercialization, a new digital spectrometer has been developed, which expanded the MRI apparatus.	[Naganuma, Tatsuya; Nakao, Motonao] Japan REDOX Ltd, Hakata Ku, Fukuoka 8120044, Japan; [Ichikawa, Kazuhiro; Utsumi, Hideo] Kyushu Univ, Innovat Ctr Med Redox Nav, Higashi Ku, Fukuoka 8128582, Japan	Naganuma, T (reprint author), Japan REDOX Ltd, Hakata Ku, 4-29-49-805 Chiyo, Fukuoka 8120044, Japan.	tnaganuma@jrx.co.jp					Lurie DJ, 2005, MAGN RESON IMAGING, V23, P175, DOI 10.1016/j.mri.2004.11.051; ALDERMAN DW, 1979, J MAGN RESON, V36, P447, DOI 10.1016/0022-2364(79)90123-9; Golman K, 2002, ACAD RADIOL, V9, pS507, DOI 10.1016/S1076-6332(03)80278-7; Lurie DJ, 1998, PHYS MED BIOL, V43, P1877, DOI 10.1088/0031-9155/43/7/008; OVERHAUSER AW, 1953, PHYS REV, V92, P411, DOI 10.1103/PhysRev.92.411	5	0	0	PHARMACEUTICAL SOC JAPAN	TOKYO	2-12-15 SHIBUYA, SHIBUYA-KU, TOKYO, 150-0002, JAPAN	0031-6903			YAKUGAKU ZASSHI	Yakugaku Zasshi-J. Pharm. Soc. Jpn.	MAY	2015	135	5					733	738				6	Pharmacology & Pharmacy	Pharmacology & Pharmacy	CH2LB	WOS:000353855600015		
J	Kato, TA; Hyodo, F; Yamato, M; Utsumi, H; Kanba, S				Kato, Takahiro A.; Hyodo, Fuminori; Yamato, Mayumi; Utsumi, Hideo; Kanba, Shigenobu			Redox and Microglia in the Pathophysiology of Schizophrenia	YAKUGAKU ZASSHI-JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN			Japanese	Review						schizophrenia; microglia; free radical; inflammatory cytokine; antipsychotics; minocycline	EARLY-PHASE SCHIZOPHRENIA; OXIDATIVE STRESS; DOUBLE-BLIND; INTERFERON-GAMMA; NEGATIVE SYMPTOMS; IN-VITRO; CONTROLLED-TRIAL; MINOCYCLINE; ACTIVATION; MODEL	Altered antioxidant status has been implicated in schizophrenia. Microglia are major sources of free radicals such as superoxide in the brain, and play crucial roles in various brain diseases. Recent postmortem and imaging studies have indicated microglial activation in the brain of schizophrenia patients. Animal models that express some phenotypes of schizophrenia have revealed the underlying microglial pathology. In addition, minocycline, an antibiotic and the best known inhibitor of microglial activation, has therapeutic efficacy in schizophrenia. We have recently revealed that various antipsychotics directly affect microglia via proinfiammatory reactions such as oxidative stress, by in vitro studies using rodent microglial cells. Based on these findings, we have suggested that microglia are crucial players in the brain in schizophrenia, and modulating microglia may be a novel therapeutic target. In this review paper, we introduce our hypothesis based on the above evidence. The technique of in vivo molecular redox imaging is expected to be a powerful tool to clarify this hypothesis.	[Kato, Takahiro A.; Hyodo, Fuminori; Yamato, Mayumi; Utsumi, Hideo] Kyushu Univ, Innovat Ctr Med Redox Nav, Higashi Ku, Fukuoka 8128582, Japan; [Kato, Takahiro A.; Kanba, Shigenobu] Kyushu Univ, Grad Sch Med Sci, Dept Neuropsychiat, Higashi Ku, Fukuoka 8128582, Japan	Kato, TA (reprint author), Kyushu Univ, Innovat Ctr Med Redox Nav, Higashi Ku, 3-1-1 Maidashi, Fukuoka 8128582, Japan.	takahiro@npsych.med.kyushu-u.ac.jp					Nawa H, 2000, MOL PSYCHIATR, V5, P594, DOI 10.1038/sj.mp.4000730; Asevedo E, 2013, J PSYCHIATR RES, V47, P1376, DOI 10.1016/j.jpsychires.2013.05.032; Schiavone S, 2009, BIOL PSYCHIAT, V66, P384, DOI 10.1016/j.biopsych.2009.04.033; Hinwood M, 2012, CEREB CORTEX, V22, P1442, DOI 10.1093/cercor/bhr229; Kato T, 2008, J NEUROCHEM, V106, P815, DOI 10.1111/j.1471-4159.2008.05435.x; Khodaie-Ardakani MR, 2014, PSYCHIAT RES, V215, P540, DOI 10.1016/j.psychres.2013.12.051; Paolicelli RC, 2011, SCIENCE, V333, P1456, DOI 10.1126/science.1202529; Ng F, 2008, INT J NEUROPSYCHOPH, V11, P851, DOI 10.1017/S1461145707008401; Juckel G, 2011, SCHIZOPHR RES, V131, P96, DOI 10.1016/j.schres.2011.06.018; Kato TA, 2013, CURR MED CHEM, V20, P331; Levkovitz Y, 2010, J CLIN PSYCHIAT, V71, P138, DOI 10.4088/JCP.08m04666yel; Liu F, 2014, SCHIZOPHR RES, V153, P169, DOI 10.1016/j.schres.2014.01.011; Steiner J, 2008, J PSYCHIATR RES, V42, P151, DOI 10.1016/j.jpsychires.2006.10.013; Flatow J, 2013, BIOL PSYCHIAT, V74, P400, DOI 10.1016/j.biopsych.2013.03.018; MacDowell KS, 2013, INT J NEUROPSYCHOPH, V16, P121, DOI 10.1017/S1461145711001775; Miyaoka T, 2008, CLIN NEUROPHARMACOL, V31, P287, DOI [10.1097/WNF.0b013e3181593d45, 10.1097/wnf.0b013e3181593d45]; van Berckel BN, 2008, BIOL PSYCHIAT, V64, P820, DOI 10.1016/j.biopsych.2008.04.025; Berk M, 2008, BIOL PSYCHIAT, V64, P361, DOI [10.1016/j.biopsych.2008.03.004, 10.1016/j.biopsych.2008.03-004]; Wake H, 2009, J NEUROSCI, V29, P3974, DOI 10.1523/JNEUROSCI.4363-08.2009; Bian Q, 2008, PROG NEURO-PSYCHOPH, V32, P42, DOI 10.1016/j.pnpbp.2007.06.031; Chaudhry IB, 2012, J PSYCHOPHARMACOL, V26, P1185, DOI 10.1177/0269881112444941; Zhang XY, 2009, SCHIZOPHR RES, V113, P151, DOI 10.1016/j.schres.2009.05.016; Shiba T, 2011, NEUROIMAGE, V57, P866, DOI 10.1016/j.neuroimage.2011.05.041; Kato TA, 2011, SCHIZOPHR RES, V129, P172, DOI 10.1016/j.schres.2011.03.019; Takano A, 2010, INT J NEUROPSYCHOPH, V13, P943, DOI 10.1017/S1461145710000313; Chew LJ, 2013, DEV NEUROSCI-BASEL, V35, P102, DOI 10.1159/000346157; Lieberman JA, 1999, BIOL PSYCHIAT, V46, P729, DOI 10.1016/S0006-3223(99)00147-X; Kato T, 2007, SCHIZOPHR RES, V92, P108, DOI 10.1016/j.schres.2007.01.019; Bilbo SD, 2009, FRONT BEHAV NEUROSCI, V3, DOI 10.3389/neuro.08.014.2009; Bulbul F, 2014, ACTA NEUROPSYCHIATR, V26, P120, DOI 10.1017/neu.2013.44; Fournier M, 2014, SCHIZOPHRENIA BULL, V40, P973, DOI 10.1093/schbul/sbu053; Kato Takahiro A, 2013, Front Hum Neurosci, V7, P13, DOI 10.3389/fnhum.2013.00013; Kato Takahiro A, 2013, Front Psychiatry, V4, P139, DOI 10.3389/fpsyt.2013.00139; Massuda R, 2013, SCHIZOPHR RES, V147, P398, DOI 10.1016/j.schres.2013.04.025; Seki Y, 2013, SCHIZOPHR RES, V151, P20, DOI 10.1016/j.schres.2013.09.011; Singh V, 2010, INT J NEUROPSYCHOPH, V13, P257, DOI 10.1017/S1461145709990654	36	0	0	PHARMACEUTICAL SOC JAPAN	TOKYO	2-12-15 SHIBUYA, SHIBUYA-KU, TOKYO, 150-0002, JAPAN	0031-6903			YAKUGAKU ZASSHI	Yakugaku Zasshi-J. Pharm. Soc. Jpn.	MAY	2015	135	5					739	743				5	Pharmacology & Pharmacy	Pharmacology & Pharmacy	CH2LB	WOS:000353855600016		
J	Irikuchi, J; Imai, T; Yoshida, Y; Orii, T				Irikuchi, Jinshi; Imai, Toru; Yoshida, Yoshikazu; Orii, Takao			Influence of Systemic Inflammatory Response Syndrome on the Pharmacokinetics of Vancomycin	YAKUGAKU ZASSHI-JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN			Japanese	Article						vancomycin; systemic inflammatory response syndrome; therapeutic drug monitoring; pharmacokinetic parameter	SEPTIC SHOCK; SEVERE SEPSIS; BURN PATIENTS; GUIDELINES; INFECTIONS; BLOOD	Therapeutic drug monitoring (TDM) of vancomycin (VCM) is recommended to minimize its nephrotoxicity and maximize efficacy. Recently, the concept of systemic inflammatory response syndrome (SIRS) has been introduced to describe a clinical state resulting from the actions of complex intrinsic mediators in an acute-phase systemic response. However, there are few reports on the pharmacokinetics of VCM in patients with SIRS. This study investigated the effect of SIRS on the pharmacokinetics of VCM by analyzing the predictability of TDM and pharmacokinetic parameters in 31 non-SIRS patients and 52 SIRS patients, with stratification by SIRS score. The mean prediction error (ME) and mean absolute prediction error in SIRS score 2 and 3 patients differed from those in non-SIRS patients. The ME in the score 4 group showed a negative value. In the comparison of pharmacokinetic parameters by SIRS score, a significantly lower CLvcm value was observed at score 4 compared with scores 2 and 3, a higher Yd value was observed at score 4 compared with non-SIRS and at score 3, and a longer T-1/2 was observed at score 2. In the comparison of patient characteristics by SIRS score, albumin, aspartate aminotransferase, and alanine aminotransferase levels showed differences among the scores. However, no correlation was observed between VCM pharmacokinetics and these three laboratory parameters. These findings suggest that the pharmacokinetics of VCM may be affected by the pathology of SIRS rather than by patient characteristics.	[Irikuchi, Jinshi; Orii, Takao] NTT Med Ctr Tokyo, Dept Pharm, Shinagawa Ku, Tokyo 1418625, Japan; [Imai, Toru; Yoshida, Yoshikazu] Nihon Univ, Itabashi Hosp, Dept Pharm, Itabashi Ku, Tokyo 1738610, Japan	Irikuchi, J (reprint author), NTT Med Ctr Tokyo, Dept Pharm, Shinagawa Ku, 5-9-22 Higashi Gotanda, Tokyo 1418625, Japan.	jinshi.irikuchi@east.ntt.co.jp					Angus DC, 2013, NEW ENGL J MED, V369, P840, DOI 10.1056/NEJMra1208623; Xu J, 2009, NAT MED, V15, P1318, DOI 10.1038/nm.2053; Strassburg CP, 2003, BEST PRACT RES CL GA, V17, P369, DOI 10.1053/ybega.2003.383; GARRELTS JC, 1988, CLIN PHARMACOL THER, V44, P9; Brinkmann V, 2004, SCIENCE, V303, P1532, DOI 10.1126/science.1092385; COCKCROFT DW, 1976, NEPHRON, V16, P31, DOI 10.1159/000180580; Rybak MJ, 2009, CLIN INFECT DIS, V49, P325, DOI 10.1086/600877; RYBAK MJ, 1990, ANTIMICROB AGENTS CH, V34, P792; Shimamoto Y, 2013, INTENS CARE MED, V39, P1247, DOI 10.1007/s00134-013-2909-9; RODVOLD KA, 1988, ANTIMICROB AGENTS CH, V32, P848; Clark SR, 2007, NAT MED, V13, P463, DOI 10.1038/nm1565; Wisplinghoff H, 2004, CLIN INFECT DIS, V39, P309, DOI 10.1086/421946; Kumar A, 2009, CHEST, V136, P1237, DOI 10.1378/chest.09-0087; BONE RC, 1992, CHEST, V101, P1644, DOI 10.1378/chest.101.6.1644; Dellinger RP, 2013, INTENS CARE MED, V39, P165, DOI 10.1007/s00134-012-2769-8; Grace E, 2012, J ANTIMICROB CHEMOTH, V67, P1305, DOI 10.1093/jac/dks066; Mutunga M, 2001, AM J RESP CRIT CARE, V163, P195; Aoyama S., 2013, JPN J TDM, V30, P1; BROWN N, 1983, ANTIMICROB AGENTS CH, V23, P603; Committee for Guideline for treatment of MRSA infection, 2013, GUID TREATM MRSA INF; Giulano C, 2010, EXPERT REV ANTI-INFE, V8, P95, DOI [10.1586/eri.09.123, 10.1586/ERI.09.123]; Kimura T., 2007, ZUKAI YOKUWAKARU TDM, V2nd; McKenzie C, 2011, J ANTIMICROB CHEM S2, V66, pii25; Ministry of Health Labour and Welfare, JAP NOS INF SURV; Paepe P., 2002, CLIN PHARMACOKINET, V41, P1135; PARRILLO JE, 1993, NEW ENGL J MED, V328, P1471; SHEINER LB, 1981, J PHARMACOKINET BIOP, V9, P503, DOI 10.1007/BF01060893; Spesis Registry Committee of the Japanese Society of Intensive Care Medicine, 2013, J JPN SOC INTENSIVE, V20, P124; Szabo Gyongyi, 2002, Clin Liver Dis, V6, P1045, DOI 10.1016/S1089-3261(02)00058-2; Takane H., 2012, JPN J PHARM HLTH CAR, V38, P785; Winter M. E., 1994, BASIC CLIN PHARMACOK, V3rd, P294; Ye ZK, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0077169	32	0	0	PHARMACEUTICAL SOC JAPAN	TOKYO	2-12-15 SHIBUYA, SHIBUYA-KU, TOKYO, 150-0002, JAPAN	0031-6903			YAKUGAKU ZASSHI	Yakugaku Zasshi-J. Pharm. Soc. Jpn.	MAY	2015	135	5					745	751				7	Pharmacology & Pharmacy	Pharmacology & Pharmacy	CH2LB	WOS:000353855600017		
J	Yasuhara, T; Sone, T; Konishi, M; Kushihata, T; Nishikawa, T; Yamamoto, Y; Kurio, W; Kohno, T				Yasuhara, Tomohisa; Sone, Tomomichi; Konishi, Motomi; Kushihata, Taro; Nishikawa, Tomoe; Yamamoto, Yumi; Kurio, Wasako; Kohno, Takeyuki			Studies Using Text Mining on the Differences in Learning Effects between the KJ and World Cafe Method as Learning Strategies	YAKUGAKU ZASSHI-JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN			Japanese	Article						World Cafe; KJ method; active learning; text mining		The KJ method (named for developer Jiro Kawakita; also known as affinity diagramming) is widely used in participatory learning as a means to collect and organize information. In addition, the World Cafe (WC) has recently become popular. However, differences in the information obtained using each method have not been studied comprehensively. To determine the appropriate information selection criteria, we analyzed differences in the information generated by the WC and KJ methods. Two groups engaged in sessions to collect and organize information using either the WC or KJ method and small group discussions were held to create "proposals to improve first-year education". Both groups answered two pre- and post- session questionnaires that asked for free descriptions. Key words were extracted from the results of the two questionnaires and categorized using text mining. In the responses to questionnaire 1, which was directly related to the session theme, a significant increase in the number of key words was observed in the WC group (p=0.0050, Fisher's exact test). However, there was no significant increase in the number of key words in the responses to questionnaire 2, which was not directly related to the session theme (p=0.8347, Fisher's exact test). In the KJ method, participants extracted the most notable issues and progressed to a detailed discussion, whereas in the WC method, various information and problems were spread among the participants. The choice between the WC and KJ method should be made to reflect the educational objective and desired direction of discussion.	[Yasuhara, Tomohisa; Sone, Tomomichi; Konishi, Motomi; Kushihata, Taro; Nishikawa, Tomoe; Yamamoto, Yumi; Kurio, Wasako; Kohno, Takeyuki] Setsunan Univ, Fac Pharmaceut Sci, Hirakata, Osaka 5730101, Japan	Yasuhara, T (reprint author), Setsunan Univ, Fac Pharmaceut Sci, 45-1 Nagaotoge Cho, Hirakata, Osaka 5730101, Japan.	yasuhara@pharm.setsunan.ac.jp					Brown J., 2007, WORLD CAFE SHAPING O; Katori K., 2009, WORLD CAFE O YAROU; Kawakita J, 1967, HASSOUHOU SOUZOUSEIK; Kawakita J, 1970, ZOKUHASSOUHOU KJ HOU; Ministry of Education Culture Sports Science and Technology Central Council for Education, 2014, YOS JID SHOUG MAN SH; Ministry of Education Culture Sports Science and Technology Central Council for Education, 2014, AR MIR KIZ DIAG SHIT; Yasuhara T, 2012, YAKUGAKU ZASSHI, V132, P1179	7	0	0	PHARMACEUTICAL SOC JAPAN	TOKYO	2-12-15 SHIBUYA, SHIBUYA-KU, TOKYO, 150-0002, JAPAN	0031-6903			YAKUGAKU ZASSHI	Yakugaku Zasshi-J. Pharm. Soc. Jpn.	MAY	2015	135	5					753	759				7	Pharmacology & Pharmacy	Pharmacology & Pharmacy	CH2LB	WOS:000353855600018		
J	Matsuoka, S; Yamashiro, T; Matsushita, S; Kotoku, A; Fujikawa, A; Yagihashi, K; Nakajima, Y				Matsuoka, Shin; Yamashiro, Tsuneo; Matsushita, Shoichiro; Kotoku, Akiyuki; Fujikawa, Atsuko; Yagihashi, Kunihiro; Nakajima, Yasuo			Quantitative CT Evaluation in Patients with Combined Pulmonary Fibrosis and Emphysema: Correlation with Pulmonary Function	ACADEMIC RADIOLOGY			English	Article						Combined pulmonary fibrosis and emphysema; computed tomography; densitometry; CT quantification	PHYSIOLOGICAL TESTS; VISUAL SCORES; DENSITY; INDEXES	Rationale and Objectives: The purpose of this study was to evaluate the correlations between objective quantitative computed tomography (Cl) measurements of the extent of emphysematous and fibrotic lesions and the results of pulmonary function tests (PFTs) in patients with combined pulmonary fibrosis and emphysema (CPFE). Materials and Methods: This study involved 43 CPFE patients who underwent CT and PFTs. The extent of emphysematous lesions was obtained by calculating the percentage of low attenuation area (%LAA) values lower than -950 Hounsfield units (HU). Fibrotic lesions were defined as high attenuation area (HAA) using thresholds with pixels between 0 and -700 HU, and the extent of fibrosis was obtained by calculating the percentage of HAA (%HAA). The correlations of %LAA and %HAA with PFTs were evaluated by the Spearman rank correlation coefficients and multiple linear regression analysis. Results: A significant negative correlation was found between %HAA and diffusing capacity of the lung for carbon monoxide (DLco) % predicted (p = -0.747; P < .001), whereas no significant correlation was found between %LAA and DLco %predicted. On multiple linear regression analysis, although the %HAA and %LAA were independent contributors to DLco %predicted, the predictive power of %HAA was superior to that of %LAA. Conclusions: In CPFE, the extent of fibrosis has a more significant impact on DLco than emphysema.	[Matsuoka, Shin; Yamashiro, Tsuneo; Matsushita, Shoichiro; Kotoku, Akiyuki; Fujikawa, Atsuko; Yagihashi, Kunihiro; Nakajima, Yasuo] St Marianna Univ, Sch Med, Dept Radiol, Miyamae Ku, Kawasaki, Kanagawa 2168511, Japan; [Yamashiro, Tsuneo] Univ Ryukyus, Dept Radiol, Grad Sch Med Sci, Nishihara, Ryukyu, Japan	Matsuoka, S (reprint author), St Marianna Univ, Sch Med, Dept Radiol, Miyamae Ku, 2-16-1 Sugao, Kawasaki, Kanagawa 2168511, Japan.	shin4114@mac.com					Cottin V, 2005, EUR RESPIR J, V26, P586, DOI 10.1183/09031936.05.00021005; KINSELLA M, 1990, CHEST, V97, P315, DOI 10.1378/chest.97.2.315; Best AC, 2008, RADIOLOGY, V246, P935, DOI 10.1148/radiol.2463062200; Shin KE, 2011, J COMPUT ASSIST TOMO, V35, P266, DOI 10.1097/RCT.0b013e31820ccf18; Gevenois PA, 1996, AM J RESP CRIT CARE, V154, P187; Ando K, 2013, LUNG, V191, P585, DOI 10.1007/s00408-013-9513-1; Kitaguchi Y, 2010, RESPIROLOGY, V15, P265, DOI 10.1111/j.1440-1843.2009.01676.x; Grubstein A, 2005, RESP MED, V99, P948, DOI 10.1016/j.rmed.2004.12.010; Jankowich MD, 2008, RESPIRATION, V75, P411, DOI 10.1159/000107048; Mejfa M, 2009, CHEST, V136, P10; Mura M, 2006, RESPIR CARE, V51, P257; Raghu G, 2011, AM J RESP CRIT CARE, V183, P788, DOI 10.1164/rccm.2009-040GL; SCHWARTZ DA, 1991, AM REV RESPIR DIS, V144, P504; STRICKLAND NH, 1993, AM J ROENTGENOL, V161, P719	14	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1076-6332	1878-4046		ACAD RADIOL	Acad. Radiol.	MAY	2015	22	5					626	631		10.1016/j.acra.2015.01.008		6	Radiology, Nuclear Medicine & Medical Imaging	Radiology, Nuclear Medicine & Medical Imaging	CG2AZ	WOS:000353078600011		
J	Suzudo, T; Nagai, Y; Schwen, D; Caro, A				Suzudo, Tomoaki; Nagai, Yasuyoshi; Schwen, Daniel; Caro, Alfredo			Hardening in thermally-aged Fe-Cr binary alloys: Statistical parameters of atomistic configuration	ACTA MATERIALIA			English	Article						Spinodal decomposition; Iron-chromium alloy; Thermal aging; Hardening; Molecular dynamics	DUPLEX STAINLESS-STEEL; IRON-CHROMIUM ALLOYS; SPINODAL DECOMPOSITION; COMPUTER-MODELS; NEUTRON-IRRADIATION; LEVEL; EMBRITTLEMENT; SYSTEM	By exploiting Monte Carlo methodology and molecular dynamics, we computationally simulate the spinodal decomposition of iron chromium binary alloys and analyze the relationship between the increase of yield strength induced by the phase separation phenomenon, and statistical parameters of the atomistic configuration. We successfully model the experimentally-discovered proportional relationship between the hardness and the variation parameter (or V), and also found that the adequacy of the parameter V as an empirical indicator of hardening is limited, because it does not properly capture short-range atomistic configurations that influence the hardening. We suggest that the short-range-order parameter has more potential to become universal descriptor of the phenomenon. (C) 2015 Acta Materialia Inc. Published by Elsevier Ltd. All rights reserved.	[Suzudo, Tomoaki] Japan Atom Energy Agcy, Ctr Computat Sci & e Syst, Tokai, Ibaraki 3191195, Japan; [Nagai, Yasuyoshi] Tohoku Univ, Inst Mat Res, Oarai Ctr, Oarai, Ibaraki 3111313, Japan; [Schwen, Daniel; Caro, Alfredo] Los Alamos Natl Lab, Div Mat Sci & Technol, Los Alamos, NM 87545 USA	Suzudo, T (reprint author), Japan Atom Energy Agcy, Ctr Computat Sci & e Syst, 2-4 Shirane Shirakata, Tokai, Ibaraki 3191195, Japan.	suzudo.tomoaki@jaea.go.jp	Nagai, Yasuyoshi/A-8995-2011		Center for Materials under Irradiation and Mechanical Extremes, a DOE-OBES Energy Frontier Research Center	The first author (T. Suzudo) thanks to T. Tsuru of Japan Atomic Energy Agency for helpful discussion on molecular dynamics simulations. This work include the result of "Research and development on degradation prediction of structural materials in nuclear reactors based on microstructural damage mechanisms" entrusted to Tohoku university by Education, Culture, Sports, Science and Technology of Japan (MEXT). A. Caro acknowledges support from the Center for Materials under Irradiation and Mechanical Extremes, a DOE-OBES Energy Frontier Research Center.	Sadigh B, 2012, PHYS REV B, V85, DOI 10.1103/PhysRevB.85.184203; Takeuchi T, 2013, J NUCL MATER, V443, P266, DOI 10.1016/j.jnucmat.2013.07.035; MILLER MK, 1995, ACTA METALL MATER, V43, P3385, DOI 10.1016/0956-7151(95)00040-3; Caro A, 2005, PHYS REV LETT, V95, DOI 10.1103/PhysRevLett.95.075702; Klueh RL, 2007, J NUCL MATER, V371, P37, DOI 10.1016/j.jnucmat.2007.05.005; Li SL, 2013, MAT SCI ENG A-STRUCT, V564, P85, DOI 10.1016/j.msea.2012.11.046; COWLEY JM, 1950, PHYS REV, V77, P669, DOI 10.1103/PhysRev.77.669; Osetsky YN, 2003, PHILOS MAG, V83, P3623, DOI 10.1080/14786430310001603364; Erhart P, 2008, PHYS REV B, V77, DOI 10.1103/PhysRevB.77.134206; Terentyev DA, 2008, ACTA MATER, V56, P3229, DOI 10.1016/j.actamat.2008.03.004; Fujii K, 2013, J NUCL MATER, V440, P612, DOI 10.1016/j.jnucmat.2013.04.072; Pareige C, 2011, J NUCL MATER, V411, P90, DOI 10.1016/j.jnucmat.2011.01.036; Bonny G, 2009, J NUCL MATER, V385, P278, DOI 10.1016/j.jnucmat.2008.12.002; Gilbert MR, 2011, PHYS REV B, V84, DOI 10.1103/PhysRevB.84.174103; KATO M, 1980, ACTA METALL MATER, V28, P285, DOI 10.1016/0001-6160(80)90163-7; CORTIE MB, 1995, MAT SCI ENG A-STRUCT, V199, P153, DOI 10.1016/0921-5093(94)09731-3; PLIMPTON S, 1995, J COMPUT PHYS, V117, P1, DOI 10.1006/jcph.1995.1039; Lo KH, 2009, MAT SCI ENG R, V65, P39, DOI 10.1016/j.mser.2009.03.001; Miller MK, 1996, J NUCL MATER, V230, P219, DOI 10.1016/0022-3115(96)80017-1; BLAVETTE D, 1988, J PHYS-PARIS, V49, P433, DOI 10.1051/jphyscol:1988674; Bonny G, 2009, J NUCL MATER, V385, P268, DOI 10.1016/j.jnucmat.2008.12.001; CAHN JW, 1963, ACTA METALL MATER, V11, P1275; HYDE JM, 1995, ACTA METALL MATER, V43, P3403, DOI 10.1016/0956-7151(95)00041-S; HYDE JM, 1995, ACTA METALL MATER, V43, P3415, DOI 10.1016/0956-7151(95)00042-T; LAGNEBOR.R, 1967, ACTA METALL MATER, V15, P1737, DOI 10.1016/0001-6160(67)90065-X; Olsson P, 2005, PHYS REV B, V72, DOI 10.1103/PhysRevB.72.214119; RUSSELL KC, 1972, ACTA METALL MATER, V20, P969, DOI 10.1016/0001-6160(72)90091-0; Soriano-Vargas O, 2010, MAT SCI ENG A-STRUCT, V527, P2910, DOI 10.1016/j.msea.2010.01.020; Stukowski A, 2009, MODEL SIMUL MATER SC, V17, DOI 10.1088/0965-0393/17/7/075005; WAGNER R, 1981, CZECH J PHYS, V31, P198, DOI 10.1007/BF01959443; WILLIAMS RO, 1957, ACTA METALL MATER, V5, P385, DOI 10.1016/0001-6160(57)90007-X	31	1	1	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	1359-6454	1873-2453		ACTA MATER	Acta Mater.	MAY 1	2015	89						116	122		10.1016/j.actamat.2015.02.013		7	Materials Science, Multidisciplinary; Metallurgy & Metallurgical Engineering	Materials Science; Metallurgy & Metallurgical Engineering	CG4IP	WOS:000353249100012		
J	Kunimune, T; Kuramoto, M; Ogawa, S; Sugahara, T; Nagao, S; Suganuma, K				Kunimune, Teppei; Kuramoto, Masafumi; Ogawa, Satoru; Sugahara, Tohru; Nagao, Shijo; Suganuma, Katsuaki			Ultra thermal stability of LED die-attach achieved by pressureless Ag stress-migration bonding at low temperature	ACTA MATERIALIA			English	Article						Stress migration bonding; Silver thin films; Die attach; Light emitting diode	THIN SILVER FILMS; HILLOCK FORMATION; DIFFUSION; GROWTH; INTERCONNECTIONS; MODEL; CU	Using recently-developed Ag stress-migration bonding (SMB), a light-emitting diode (LED) die can be bonded on a glass substrate above 200 degrees C in air without pressure, where both the die and substrate surfaces are coated with a few-microns-thick Ag layer. We investigate this emerging die-attach method and reveal the detailed bonding processes. The thermal residual stress in the Ag coating layer causes hillock formation on both the surfaces, and the extruded Ag grains grow to fill the gap between the contacted surfaces. A sound contact over the large bonded area can be achieved without applying any pressure. However, the LED dies exposed to a high working temperature may increase the risk of void formation in the bonding interface structure, leading to a crack or interface failure due to the bond strength degradation. In this study, we insert a barrier layer of a high melting-point metal like Pt or Ru under the Ag bond layer to prevent void diffusion from the Ag layer. The high bond strength achieved by Ag SMB is then unaffected by the heat exposure tests even at 440 degrees C for 2 h, assuring sufficiently long lifetime for the LED die-attach. Our pressureless Ag SMB method thus achieves excellent thermal stability, in addition to the ideal reflectivity and electric/heat conductivities of Ag, perfectly suitable for LED applications, as well as various other power devices of high-temperature wide-bandgap power semiconductors like GaN and SiC. (C) 2015 Acta Materialia Inc. Published by Elsevier Ltd. All rights reserved.	[Kunimune, Teppei; Sugahara, Tohru; Nagao, Shijo; Suganuma, Katsuaki] Osaka Univ, Inst Sci & Ind Res, Ibaraki, Japan; [Kunimune, Teppei; Kuramoto, Masafumi; Ogawa, Satoru] Nichia Corp, Mat & Proc Engn Div, Anan, Japan	Nagao, S (reprint author), Osaka Univ, Inst Sci & Ind Res, Mihogaoka 8-1, Ibaraki, Japan.	shijo.nagao@sanken.osaka-u.ac.jp	Nagao, Shijo/E-4870-2012	Nagao, Shijo/0000-0002-2764-3458	JSPS [24226017]	T. Sugahara, S. Nagao, and K. Suganuma are grateful to the support from JSPS Grant-in-Aid for Scientific Research: Grant No. 24226017.	Manikam VR, 2011, IEEE T COMP PACK MAN, V1, P457, DOI 10.1109/TCPMT.2010.2100432; Kisiel R, 2009, MICROELECTRON RELIAB, V49, P627, DOI 10.1016/j.microrel.2009.03.009; Zeng KJ, 2005, J APPL PHYS, V97, DOI 10.1063/1.1839637; PRESLAND AE, 1972, SURF SCI, V29, P424, DOI 10.1016/0039-6028(72)90229-4; Onishi T, 1999, THIN SOLID FILMS, V340, P306, DOI 10.1016/S0040-6090(98)01466-7; DERBY B, 1984, MET SCI, V18, P427; Aoyagi M, 1999, JPN J APPL PHYS 1, V38, P1909, DOI 10.1143/JJAP.38.1909; Curry J., 1984, REL PHYS S 22 ANN, P6; Dini J.W., 1984, WELD J, V63, P26; GOPAL R, 1957, Z ANORG ALLG CHEM, V293, P53, DOI 10.1002/zaac.19572930106; Greiser J, 1999, SCRIPTA MATER, V41, P709, DOI 10.1016/S1359-6462(99)00205-5; Hiraoka K., 1993, IEICE T, P644; KATO M, 1990, J APPL PHYS, V68, P334, DOI 10.1063/1.347198; Kunimune T, 2013, IEEE T COMP PACK MAN, V3, P363, DOI 10.1109/TCPMT.2012.2231901; Kuramoto M, 2012, IEEE T COMP PACK MAN, V2, P548, DOI 10.1109/TCPMT.2011.2180385; LAHIRI SK, 1970, J APPL PHYS, V41, P3172, DOI 10.1063/1.1659383; MCPHERSON JW, 1987, J VAC SCI TECHNOL B, V5, P1321, DOI 10.1116/1.583609; Oh C, 2014, APPL PHYS LETT, V104, DOI 10.1063/1.4872320; Onishi T, 2002, MATER TRANS, V43, P1605, DOI 10.2320/matertrans.43.1605; Presland A.E.B., 1973, PROG SURF SCI, V3, P63; SHARMA SK, 1980, THIN SOLID FILMS, V65, P339, DOI 10.1016/0040-6090(80)90244-8; Shioi N., 2011, P 21 MES 2011, P237; Tsuchikawa H, 2006, JPN J APPL PHYS 1, V45, P714, DOI 10.1143/JJAP.45.714; Yamashita M, 2006, MICROELECTRON RELIAB, V46, P850, DOI 10.1016/j.microrel.2005.05.020; Yanagitani T., 2007, P S ULTRASONIC ELECT, V28, P155	25	0	0	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	1359-6454	1873-2453		ACTA MATER	Acta Mater.	MAY 1	2015	89						133	140		10.1016/j.actamat.2015.02.011		8	Materials Science, Multidisciplinary; Metallurgy & Metallurgical Engineering	Materials Science; Metallurgy & Metallurgical Engineering	CG4IP	WOS:000353249100014		
J	Kido, J; Yoshida, F; Sakaguchi, K; Ueno, Y; Yanai, M				Kido, Jun; Yoshida, Fuminori; Sakaguchi, Katsuya; Ueno, Yasushi; Yanai, Masaaki			Ultrasonography and C-reactive protein can predict the outcomes of voiding cystography after the first urinary tract infection	ACTA PAEDIATRICA			English	Article						C-reactive protein; Ultrasonography; Urinary tract infection; Vesicoureteric reflux; Voiding cystography	VESICOURETERAL REFLUX; YOUNG-CHILDREN; FEBRILE UTI; ULTRASOUND; DIAGNOSIS; INFANTS; SYSTEM	AimThis study evaluated whether sex, clinical variables, laboratory variables or ultrasonography predicted the presence of vesicoureteric reflux during the first episode of urinary tract infection in paediatric patients. We also aimed to define the criteria that indicated the need for voiding cystography testing. MethodsWe used voiding cystography to investigate 200 patients who experienced their first urinary tract infection at our institution between 2004 and 2013 and retrospectively analysed the data by reviewing their medical records. ResultsSex (p=0.001), peak blood C-reactive protein levels (p<0.001), the duration of fever after antibiotic administration (p=0.007) and the ultrasonography findings grade (p<0.001) were significantly different between patients with and without vesicoureteric reflux. Grade IV-V ultrasonography findings and C-reactive protein levels of 80mg/L predicted vesicoureteric reflux with a sensitivity, specificity and odds ratio of 47.8%, 87.8% and 6.59 (95% confidence interval=3.26-13.33), respectively (p<0.001). ConclusionVoiding cystography should be performed for patients with C-reactive protein levels of 80mg/L and grade IV-V ultrasonography findings, but is not necessary in patients with C-reactive protein levels of <80mg/L and grade I-III ultrasonography findings.	[Kido, Jun; Yoshida, Fuminori; Ueno, Yasushi; Yanai, Masaaki] Kumamoto Reg Med Ctr, Dept Pediat, Kumamoto, Kumamoto, Japan; [Kido, Jun] Kumamoto Univ, Grad Sch Med Sci, Dept Pediat, Kumamoto, Kumamoto, Japan; [Yoshida, Fuminori] Miyazaki Prefectural Nobeoka Hosp, Dept Pediat, Nobeoka City, Miyazaki, Japan; [Sakaguchi, Katsuya] Kumamoto Reg Med Ctr, Div Clin Lab, Kumamoto, Kumamoto, Japan; [Yanai, Masaaki] Kumamoto Prefectural Vaccinat Ctr, Kumamoto, Kumamoto, Japan	Yanai, M (reprint author), Kumamoto Reg Med Ctr, Dept Pediat, Chuo Ku, 5-16-10 Honjo, Kumamoto, Kumamoto 8600811, Japan.	bnnhh863@gmail.com			Ministry of Education, Culture, Sports, Science, and Technology	This study was supported in part by a Grant-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science, and Technology.	Adibi Atoosa, 2013, Saudi J Kidney Dis Transpl, V24, P297; Montini G, 2009, PEDIATRICS, V123, pE239, DOI 10.1542/peds.2008-1003; Massanyi EZ, 2013, UROLOGY, V82, P905, DOI 10.1016/j.urology.2013.04.026; Jahnukainen T, 2006, EUR J PEDIATR, V165, P556, DOI 10.1007/s00431-006-0113-4; Hoberman A, 2003, NEW ENGL J MED, V348, P195, DOI 10.1056/NEJMoa021698; LEBOWITZ RL, 1985, PEDIATR RADIOL, V15, P105, DOI 10.1007/BF02388714; Zamir G, 2004, ARCH DIS CHILD, V89, P466, DOI 10.1136/adc.2003.019182; Preda I, 2007, J PEDIATR-US, V151, P581, DOI 10.1016/j.jpeds.2007.05.008; Carpenter MA, 2013, PEDIATRICS, V132, pE34, DOI 10.1542/peds.2012-2301; FERNBACH SK, 1993, PEDIATR RADIOL, V23, P478, DOI 10.1007/BF02012459; Darge K, 2004, WORLD J UROL, V22, P88, DOI 10.1007/s00345-004-0404-1; Giorgi LJ, 2005, J UROLOGY, V173, P568, DOI 10.1097/01.ju.0000149826.70405.c5; HAYCOCK GB, 1991, PEDIATR NEPHROL, V5, P401; Hellerstein S, 2006, CURR OPIN PEDIATR, V18, P134, DOI 10.1097/01.mop.0000193271.09001.a3; Jodal U, 2006, PEDIATR NEPHROL, V21, P785, DOI 10.1007/s00467-006-0063-0; Klar A, 1996, J PEDIATR-US, V128, P850, DOI 10.1016/S0022-3476(96)70340-2; Soylu A, 2007, PEDIATR NEPHROL, V22, P844, DOI 10.1007/s00467-006-0418-6; SPENCER JR, 1986, UROL CLIN N AM, V13, P661; Roberts KB, 2011, PEDIATRICS, V128, P595, DOI 10.1542/peds.2011-1330; Wang HH, 2014, J UROLOGY, V6; Williams G, 2011, COCHRANE DB SYST REV, V16; Zhang X, 2014, PEDIATRICS, V133, pE30, DOI 10.1542/peds.2012-2650	22	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0803-5253	1651-2227		ACTA PAEDIATR	Acta Paediatr.	MAY	2015	104	5					e216	e221		10.1111/apa.12941		6	Pediatrics	Pediatrics	CG9NT	WOS:000353643400007		
J	Takayanagi, T; Matsuo, K; Egashira, T; Mizukami, T				Takayanagi, Toshimitsu; Matsuo, Koji; Egashira, Tomoko; Mizukami, Tomoko			Neonatal hydrocortisone therapy does not have a serious suppressive effect on the later function of the hypothalamus-pituitary-adrenal axis	ACTA PAEDIATRICA			English	Article						Cortisol; Extremely low birthweight infants; Hydrocortisone therapy; Hypothalmus-pituitary-adrenal axis; Neonatal intensive care unit	CORTICOTROPIN-RELEASING HORMONE; LOW-BIRTH-WEIGHT; CHRONIC LUNG-DISEASE; PRETERM INFANTS; CHILDREN	AimThis study investigated whether providing extremely low birthweight (ELBW) infants with a large amount of hydrocortisone had a serious suppressive effect on the later function of the hypothalamus-pituitary-adrenal (HPA) axis. MethodsWe evaluated the function of the HPA axis in 58 ELBW infants receiving 9.07.2mg/kg of intravenous and 68.134.1mg/kg of oral hydrocortisone using a human corticotropin-releasing hormone stimulation test. The mean age at investigation was 12.0 +/- 5.2months. The response was judged to be normal when the maximum to minimum ratio of the plasma adrenocorticotropic hormone (ACTH) concentration was >2, the peak value of the serum cortisol concentration was >552nmol/L, or the increment was >193nmol/L than baseline concentration. ResultsOf the 58 infants studied, 51 (88%) displayed a normal response to both the ACTH and cortisol secretion and seven infants (12%) who were judged to be poor responders exhibited a peak cortisol value of >386nmol/L without any episode of adrenal insufficiency. ConclusionProviding ELBW infants with a daily low dose of long-term hydrocortisone therapy should not lead to a serious suppressive effect on the later function of the HPA axis, regardless of the administration method.	[Takayanagi, Toshimitsu; Matsuo, Koji; Egashira, Tomoko; Mizukami, Tomoko] Saga Natl Hosp, Natl Hosp Org, Dept Pediat, Saga 8498577, Japan	Takayanagi, T (reprint author), Saga Natl Hosp, Natl Hosp Org, Dept Pediat, 1-20-1 Hinode, Saga 8498577, Japan.	toshi-t@po.bunbun.ne.jp					Blackmon LR, 2002, PEDIATRICS, V109, P330; Karlsson R, 2000, J CLIN ENDOCR METAB, V85, P4592, DOI 10.1210/jc.85.12.4592; Palisano RJ, 2008, DEV MED CHILD NEUROL, V50, P744, DOI 10.1111/j.1469-8749.2008.03089.x; Masumoto K, 2008, PEDIATR RES, V63, P686, DOI 10.1203/PDR.0b013e31816c8fcc; Lodygensky GA, 2005, PEDIATRICS, V116, P1, DOI 10.1542/peds.2004-1275; Rademaker KJ, 2007, J PEDIATR-US, V150, P351, DOI 10.1016/j.jpeds.2006.10.051; Ng PC, 2002, J CLIN ENDOCR METAB, V87, P4621, DOI 10.1210/jc.2001-011620; Doyle LW, 2010, NEONATOLOGY, V98, P111, DOI 10.1159/000279992; DAHL RE, 1992, PEDIATR RES, V32, P64, DOI 10.1203/00006450-199207000-00012; Dehrendorf H, 1991, J CLIN PHARMACOL, V31, P473; Fluck CE, 2011, DIAGNOSTICS OF ENDOCRINE FUNCTION IN CHILDREN AND ADOLESCENTS, 4TH EDITION, P350; Heide-Jalving M, 2003, ACTA PAEDIATR, V92, P827, DOI 10.1080/08035250310002425; Kusuda S, 2006, PEDIATRICS, V118, pE1130, DOI 10.1542/peds.2005-2724; Melmed S, 2011, WILLIAM TXB ENDOCRIN, P211; Nakanishi N, 2010, J PERINATOL, V30, P751; Ng PC, 1997, J CLIN ENDOCR METAB, V82, P797, DOI 10.1210/jc.82.3.797; Rademaker KJ, 2009, SEMIN FETAL NEONAT M, V14, P171, DOI 10.1016/j.siny.2008.11.004; Rademaker KJ, 2008, ARCH DIS CHILD-FETAL, V93, P58; Stewart PM, 2011, WILLIAM TXB ENDOCRIN, V12th, P515; WAND GS, 1985, CLIN ENDOCRINOL META, V14, P33	20	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0803-5253	1651-2227		ACTA PAEDIATR	Acta Paediatr.	MAY	2015	104	5					e195	e199		10.1111/apa.12926		5	Pediatrics	Pediatrics	CG9NT	WOS:000353643400003		
J	Yoshimatsu, R; Yamagami, T; Miura, H; Hashiba, M				Yoshimatsu, Rika; Yamagami, Takuji; Miura, Hiroshi; Hashiba, Mitsuoki			Factors related to thrombosis of gastric varix during balloon-occluded retrograde transvenous obliteration	ACTA RADIOLOGICA			English	Article						Balloon-occluded retrograde transvenous obliteration; gastric varices	GASTRORENAL SHUNT; COMPLICATIONS; EXPERIENCE; VEINS	Background: Balloon-occluded retrograde transvenous obliteration (B-RTO) has become known as an effective treatment for gastric varices with a gastrorenal shunt. However, the appropriate duration to maintain inflation of the catheter balloon for sufficient thrombosis has been unknown. Purpose: To evaluate retrospectively the factors related to the development of thrombus in gastric varices by evaluating the necessity of the addition of a sclerosing agent on the second day in overnight B-RTO. Material and Methods: Sixty-five patients who underwent B-RTO for gastric varices with a gastrorenal shunt were studied. The B-RTO catheter was retained overnight in all patients. Incidence of and factors influencing the necessity of additional injections of a sclerosing agent on the second day were investigated. Results: In all 65 patients (100%), B-RTO was technically successful and in 61 patients (93.8%) complete thrombosis of the gastric varices was achieved. In 46 of the 65 patients (70.8%), the sclerosing agent was added on the second day. Higher Child-Pugh score, in particular, lower serum albumin level, and higher prothrombin time-international normalized ratio (PT-INR) were significantly associated with the need for the addition of the sclerosing agent on the second day. Optimal cut-off values for the serum albumin level and PT-INR were 3.6 g/dL and 1.13, respectively. Conclusion: Liver function might influence the development of thrombosis of gastric varices in B-RTO. Serum albumin and PT-INR levels would provide information for deciding on the duration of retention of the B-RTO catheter to obtain sufficient therapeutic effectiveness.	[Yoshimatsu, Rika; Yamagami, Takuji] Hiroshima Univ, Inst & Grad Sch Biomed Sci, Dept Diagnost Radiol, Hiroshima 7348551, Japan; [Yoshimatsu, Rika; Yamagami, Takuji; Miura, Hiroshi] Kyoto Prefectural Univ Med, Grad Sch Med Sci, Dept Radiol, Kyoto, Japan; [Hashiba, Mitsuoki] Fukuchiyama City Hosp, Dept Radiol, Kyoto, Japan	Yoshimatsu, R (reprint author), Hiroshima Univ, Inst & Grad Sch Biomed Sci, Dept Diagnost Radiol, Minami Ku, 1-2-3 Kasumi, Hiroshima 7348551, Japan.	rika442@hiroshima-u.ac.jp					Akahoshi T, 2008, J GASTROEN HEPATOL, V23, P1702, DOI 10.1111/j.1440-1746.2008.05549.x; Kiyosue H, 2003, RADIOGRAPHICS, V23, P921, DOI 10.1148/rg.234025135; Kanagawa H, 1996, J GASTROEN HEPATOL, V11, P51, DOI 10.1111/j.1440-1746.1996.tb00010.x; Ninoi T, 2005, AM J ROENTGENOL, V184, P1340; Yamagami T, 2007, AUSTRALAS RADIOL, V51, P334, DOI 10.1111/j.1440-1673.2007.01746.x; Cho SK, 2007, AM J ROENTGENOL, V189, pW365, DOI 10.2214/AJR.07.2266; Koito K, 1996, AM J ROENTGENOL, V167, P1317; Shimoda R, 2005, ABDOM IMAGING, V30, P306, DOI 10.1007/s00261-004-0270-8; Fukuda T, 2001, J VASC INTERV RADIOL, V12, P327, DOI 10.1016/S1051-0443(07)61912-5; Hirota S, 1999, RADIOLOGY, V211, P349; Chikamori F, 2001, SURGERY, V129, P414, DOI 10.1067/msy.2001.112000; Cho SK, 2008, J VASC INTERV RADIOL, V19, P529, DOI 10.1016/j.jvir.2007.10.012; Katoh Kenichi, 2010, BMC Med Imaging, V10, P2, DOI 10.1186/1471-2342-10-2; Kiamoto M, 2002, AM J ROENTGENOL, V178, P1167; Sugimori K, 2005, J VASC INTERV RADIOL, V16, P113, DOI 10.1097/01.RVI.0000143765.38128.23; Yoshimatsu R, 2012, KOREAN J RADIOL, V13, P324, DOI 10.3348/kjr.2012.13.3.324	16	0	0	SAGE PUBLICATIONS LTD	LONDON	1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND	0284-1851	1600-0455		ACTA RADIOL	Acta Radiol.	MAY	2015	56	5					592	597		10.1177/0284185114532080		6	Radiology, Nuclear Medicine & Medical Imaging	Radiology, Nuclear Medicine & Medical Imaging	CF8AW	WOS:000352778600012		
J	Iwakura, N; Fujiwara, Y; Arakawa, T				Iwakura, N.; Fujiwara, Y.; Arakawa, T.			Editorial: is eosinophilic oesophagitis different to proton pump inhibitor-responsive oesophageal eosinophilia? Authors' reply	ALIMENTARY PHARMACOLOGY & THERAPEUTICS			English	Editorial Material									[Iwakura, N.; Fujiwara, Y.; Arakawa, T.] Osaka City Univ, Dept Gastroenterol, Grad Sch Med, Osaka 558, Japan	Iwakura, N (reprint author), Osaka City Univ, Dept Gastroenterol, Grad Sch Med, Osaka 558, Japan.	yasu@med.osaka-cu.ac.jp					Spechler SJ, 2007, AM J GASTROENTEROL, V102, P1301, DOI 10.1111/j.1572-0241.2007.01179.x; Molina-Infante J, 2015, ALIMENT PHARM THER, V41, P1023, DOI 10.1111/apt.13165; Noti M, 2013, NAT MED, V19, P1005, DOI 10.1038/nm.3281; Cheng E, 2013, GUT, V62, P824, DOI 10.1136/gutjnl-2012-302250; Iwakura N, 2015, ALIMENT PHARM THER, V41, P776, DOI 10.1111/apt.13141; vansRhijn BD, 2014, CLIN GASTROENTEROL H, V12, P1815; Zhang X, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050037	7	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0269-2813	1365-2036		ALIMENT PHARM THER	Aliment. Pharmacol. Ther.	MAY	2015	41	10					1024	1025		10.1111/apt.13180		2	Gastroenterology & Hepatology; Pharmacology & Pharmacy	Gastroenterology & Hepatology; Pharmacology & Pharmacy	CG1RG	WOS:000353050600012		
J	Fujimoto, M; Basko-Plluska, JL; Petronic-Rosic, V; Shea, CR				Fujimoto, Masakazu; Basko-Plluska, Juliana L.; Petronic-Rosic, Vesna; Shea, Christopher R.			Early Morphea Simulating Patch-Stage Mycosis Fungoides	AMERICAN JOURNAL OF DERMATOPATHOLOGY			English	Editorial Material						morphea; localized scleroderma; mycosis fungoides	LICHEN-SCLEROSUS; GRANULOMA-ANNULARE; PATHOGENESIS; FEATURES	Morphea is a rare fibrosing condition of the skin and underlying tissues characterized histopathologically by thickened collagen bundles throughout the dermis, loss of adnexal structures, and "fat trapping." In the early stages of morphea, the absence of the fully developed characteristic findings may cause diagnostic confusion for the practicing pathologist. The authors report an unusual case of early morphea misdiagnosed as patch-stage poikilodermatous mycosis fungoides (MF) based on the initial clinical, histopathologic, and molecular findings. However, as time elapsed, well-developed lesions revealed clinical and histopathologic features diagnostic of morphea. The authors report this case to illustrate that lesions of early morphea may simulate MF. Given the similarities in clinicopathologic presentation, dermatologists and dermatopathologists should be cautious not to inadvertently misinterpret early morphea as MF.	[Fujimoto, Masakazu; Basko-Plluska, Juliana L.; Petronic-Rosic, Vesna; Shea, Christopher R.] Univ Chicago Med, Dermatol Sect, Dept Med, Chicago, IL 60637 USA; [Fujimoto, Masakazu] Kyoto Univ Hosp, Dept Diagnost Pathol, Kyoto 606, Japan	Shea, CR (reprint author), Univ Chicago Med, Dermatol Sect, Dept Med, 5841 South Maryland Ave,MC 5067, Chicago, IL 60637 USA.	cshea@medicine.bsd.uchicago.edu					Abbott RA, 2011, J AM ACAD DERMATOL, V65, P313, DOI 10.1016/j.jaad.2010.05.041; Fett N, 2011, J AM ACAD DERMATOL, V64, P217, DOI 10.1016/j.jaad.2010.05.045; Langerak AW, 2012, LEUKEMIA, V26, P2159, DOI 10.1038/leu.2012.246; Lukowsky A, 2000, J INVEST DERMATOL, V115, P254, DOI 10.1046/j.1523-1747.2000.00040.x; Pimpinelli N, 2005, J AM ACAD DERMATOL, V53, P1053, DOI 10.1016/j.jaad.2005.08.057; Carlson JA, 2000, AM J DERMATOPATH, V22, P7, DOI 10.1097/00000372-200002000-00002; Citarella L, 2003, AM J DERMATOPATH, V25, P463, DOI 10.1097/00000372-200312000-00002; Ghatalia P, 2013, J CUTAN PATHOL, V40, P477, DOI 10.1111/cup.12102; Koochek A, 2012, AM J DERMATOPATH, V34, P198, DOI 10.1097/DAD.0b013e318230ee1c; Su LD, 2002, J CUTAN PATHOL, V29, P135, DOI 10.1034/j.1600-0560.2002.290302.x; WEI N, 1985, ARCH INTERN MED, V145, P139, DOI 10.1001/archinte.145.1.139; Yasuda M, 2008, J DERMATOL, V35, P21, DOI 10.1111/j.1346-8138.2007.00405.x	12	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0193-1091	1533-0311		AM J DERMATOPATH	Am. J. Dermatopathol.	MAY	2015	37	5					409	412		10.1097/DAD.0000000000000271		4	Dermatology	Dermatology	CG5PX	WOS:000353346500014		
J	Morita, A; Natsuhara, K; Tomitsuka, E; Odani, S; Baba, J; Tadokoro, K; Igai, K; Greenhill, AR; Horwood, PF; Soli, KW; Phuanukoonnon, S; Siba, PM; Umezaki, M				Morita, Ayako; Natsuhara, Kazumi; Tomitsuka, Eriko; Odani, Shingo; Baba, Jun; Tadokoro, Kiyoshi; Igai, Katsura; Greenhill, Andrew R.; Horwood, Paul F.; Soli, Kevin W.; Phuanukoonnon, Suparat; Siba, Peter M.; Umezaki, Masahiro			Development, Validation, and Use of a Semi-Quantitative Food Frequency Questionnaire for Assessing Protein Intake in Papua New Guinean Highlanders	AMERICAN JOURNAL OF HUMAN BIOLOGY			English	Article							NITROGEN-BALANCE; DIETARY CHANGE; WESTERN MALI; VALIDITY; HAIR; REPRODUCIBILITY; POPULATION; ADULTS; NUTRITION; ANIMALS	ObjectivesThe aim of this article was to develop a semi-quantitative food frequency questionnaire (FFQ) and evaluate its validity to estimate habitual protein intake, and investigate current dietary protein intakes of Papua New Guinea (PNG) Highlanders. MethodsA 32-item FFQ was developed and tested among 135 healthy male and female volunteers. The FFQ-estimated daily total and animal protein intakes were compared with biomarkers and 3-day Weighed Food Records (WFR) by correlation analyses, Bland-Altman plot analyses and joint classification analyses. ResultsThe FFQ-estimated total protein intake significantly correlated with urinary nitrogen in the first morning void after adjusting urinary creatinine concentration (r=0.28, P<0.01) and the FFQ-estimated animal protein intake significantly correlated with the hair N-15 (Spearman's r=0.34, P<0.001). The limits of agreement were 2.39 Z-score residuals for total protein intake and +/- 2.19 Z-score for animal protein intake, and intra-individual differences increased as protein intake increased. The classification into the same and adjacent quartiles was 66.0% for total protein intake and 73.6% for animal protein intake. Median daily total and animal protein intake estimates from the FFQ and the 3-day WFR showed a good agreement with differences of 0.2 and 4.9 g, respectively. None of the studied communities in the PNG Highlands met the biologically required protein intake; although the community closer to an urban center showed higher protein intake than the more remote communities. ConclusionsThe newly developed 32-item FFQ for PNG Highlanders is applicable for evaluation of protein intake at the individual level. Am. J. Hum. Biol. 27:349-357, 2015. (c) 2014 Wiley Periodicals, Inc.	[Morita, Ayako; Tomitsuka, Eriko; Tadokoro, Kiyoshi; Igai, Katsura; Umezaki, Masahiro] Univ Tokyo, Dept Human Ecol, Tokyo 1130033, Japan; [Morita, Ayako] Tokyo Med & Dent Univ, Dept Hlth Promot, Tokyo 1130034, Japan; [Natsuhara, Kazumi] Japanese Red Cross Akita Coll Nursing, Fac Nursing, Akita 0101493, Japan; [Tomitsuka, Eriko] Niigata Univ Pharm & Appl Life Sci, Niigata 9568603, Japan; [Odani, Shingo] Chiba Univ, Fac Letter, Chiba 2638522, Japan; [Baba, Jun] Tokyo Metropolitan Univ, Tokyo 1920397, Japan; [Tadokoro, Kiyoshi] Akita Univ, Fac Int Resource Sci, Akita 0108502, Japan; [Igai, Katsura] Nagasaki Univ, Dept Int Hlth, Nagasaki 8528523, Japan; [Greenhill, Andrew R.; Horwood, Paul F.; Soli, Kevin W.; Phuanukoonnon, Suparat; Siba, Peter M.] Papua New Guinea Inst Med Res, Goroka, Papua N Guinea; [Greenhill, Andrew R.] Federat Univ, Sch Appl & Biomed Sci, Churchill, Vic 3841, Australia; [Phuanukoonnon, Suparat] Walter & Eliza Hall Inst Med Res, Infect & Immun Div, Melbourne, Vic 3052, Australia	Morita, A (reprint author), Univ Tokyo, Dept Human Ecol, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1130033, Japan.	morita@humeco.m.u-tokyo.ac.jp			Cabinet Office, Government of Japan [LS024]	Contract grant sponsor: Cabinet Office, Government of Japan (Funding Program for Next Generation World-Leading Researchers); Contract grant number: LS024.	Marks GC, 2006, J NUTR, V136, P459; Fuller BT, 2005, RAPID COMMUN MASS SP, V19, P2497, DOI 10.1002/rcm.2090; Yoshinaga J, 1996, AM J PHYS ANTHROPOL, V100, P23; Xu LZ, 2004, PUBLIC HEALTH NUTR, V7, P91, DOI 10.1079/PHN2003510; YOSHINAGA J, 1991, ECOL FOOD NUTR, V26, P17; Reitsema LJ, 2013, AM J HUM BIOL, V25, P445, DOI 10.1002/ajhb.22398; Petzke KJ, 2005, RAPID COMMUN MASS SP, V19, P1392, DOI 10.1002/rcm.1925; O'Connell TC, 1999, AM J PHYS ANTHROPOL, V108, P409, DOI 10.1002/(SICI)1096-8644(199904)108:4<409::AID-AJPA3>3.0.CO;2-E; Chen Y, 2004, BRIT J NUTR, V92, P851, DOI 10.1079/BJN20041277; BINGHAM SA, 1985, AM J CLIN NUTR, V42, P1276; Slater B, 2003, EUR J CLIN NUTR, V57, P629, DOI 10.1038/sj.ejcn.1601588; Iqbal R, 2009, PUBLIC HEALTH NUTR, V12, P12, DOI 10.1017/S1368980008001845; Barr DB, 2005, ENVIRON HEALTH PERSP, V113, P192, DOI 10.1289/ehp.7337; Hong TK, 2010, PUBLIC HEALTH NUTR, V13, P368, DOI [10.1017/S136898000999125X, 10.1109/ICEMI.2009.5274817]; Rush EC, 2009, BRIT J NUTR, V102, P632, DOI 10.1017/S0007114508207221; Loussouarn G, 2001, BRIT J DERMATOL, V145, P294, DOI 10.1046/j.1365-2133.2001.04350.x; Nurul-Fadhilah A, 2012, ASIA PAC J CLIN NUTR, V21, P97; Petzke KJ, 2010, CURR OPIN CLIN NUTR, V13, P532, DOI 10.1097/MCO.0b013e32833c3c84; Bowen L, 2012, ASIA PAC J CLIN NUTR, V21, P355; BAILEY K. V., 1963, TROP GEOGR MED, V15, P377; Bautista LE, 2005, PUBLIC HEALTH NUTR, V8, P181, DOI 10.1079/PHN2004672; BERGERSE.FJ, 1970, J GEN MICROBIOL, V60, P61; Bingham SA, 2003, J NUTR, V133, P921; BLAND JM, 1986, LANCET, V1, P307; Bol R, 2002, RAPID COMMUN MASS SP, V16, P2195, DOI 10.1002/rcm.706; Bourke RM, 2010, FOOD AGR PAPUA NEW G, P464; Dignan C., 2004, PACIFIC ISLANDS FOOD; Ferro-Luzzi A, 2002, KEYNOTE PAPER INDIVI; Food Standards Australia New Zealand, 2008, AUSTR FOOD SUPPL NUT; Fornes NS, 2003, PUBLIC HEALTH NUTR, V6, P821, DOI 10.1079/PHN2003505; FUJITA Y, 1986, J NUTR, V116, P536; Gibson J., 1998, RESULTS HOUSEHOLD SU; HARVEY PW, 1983, ECOL FOOD NUTR, V13, P27; Hipsley EH, 1950, REPORT NEW GUINEA NU; Japanese Ministry of Education Culture Sports Science and Technology, 2005, STAND TABL FOOD COMP; KOISHI H, 1990, EUR J CLIN NUTR, V44, P853; Kuzma J W, 1990, Epidemiology, V1, P386, DOI 10.1097/00001648-199009000-00009; LUYKEN R, 1964, AM J CLIN NUTR, V14, P13; Maclntyre UE, 2001, PUBLIC HEALTH NUTR, V4, P63; Mojtahedi M, 2002, AM J CLIN NUTR, V75, P1078; Muntwiler M., 2001, Food security for Papua New Guinea. Proceedings of the Papua New Guinea Food and Nutrition 2000 Conference, PNG University of Technology, Lae, Papua New Guinea, 26-30 June 2000, P432; Natsuhara K, 2002, THESIS U TOKYO TOKYO; Natsuhara K, 1999, MAN CULTURE OCEANIA, V15, P95; NORGAN NG, 1974, PHILOS T ROY SOC B, V268, P309, DOI 10.1098/rstb.1974.0033; OOMEN HAP, 1972, NUTR METAB, V14, P65; Parr CL, 2002, PUBLIC HEALTH NUTR, V5, P769, DOI 10.1079/PHN2002357; Rodriguez MM, 2002, PUBLIC HEALTH NUTR, V5, P691, DOI 10.1079/PHN2002333; Sinnett PF, 1968, PAPUA NEW GUINEA MED, V11, P56; SINNETT P, 1972, Human Biology in Oceania, V1, P299; Tang AM, 2013, USE CUTOFFS MIDUPPER, P34; Torheim LE, 2001, PUBLIC HEALTH NUTR, V4, P1267, DOI 10.1079/PHN2001181; ULIJASZEK SJ, 1987, ECOL FOOD NUTR, V20, P143; Umezaki M, 2002, MT RES DEV, V22, P256, DOI 10.1659/0276-4741(2002)022[0256:CMPOTH]2.0.CO;2; Umezaki M, 2001, ECOL FOOD NUTR, V40, P471; Umezaki M, 1999, ECOL FOOD NUTR, V37, P409; Upreti D, 2012, P NUTR SOC, V71, pE5, DOI 10.1017/S002966511200033X; Weiner J, 1981, PRACTICAL HUMAN BIOL, P439; WHO/FAO/UNU, 2007, WHO TECH REP SER, V935, P1; Willett WC., 1986, NUTR EPIDEMIOLOGY; WILLETT WC, 1985, AM J EPIDEMIOL, V122, P51; Yamauchi T, 2001, FOOD SECURITY PAPUA, P432	61	1	1	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1042-0533	1520-6300		AM J HUM BIOL	Am. J. Hum. Biol.	MAY-JUN	2015	27	3					349	357		10.1002/ajhb.22647		9	Anthropology; Biology	Anthropology; Life Sciences & Biomedicine - Other Topics	CG4ZZ	WOS:000353299400009		
J	Ko, JM; Bae, JS; Choi, JS; Miura, K; Lee, HR; Kim, OH; Kim, NKD; Oh, SK; Ozono, K; Lee, CK; Choi, IH; Park, WY; Cho, TJ				Ko, Jung Min; Bae, Jun-Seok; Choi, Jin Sun; Miura, Kohji; Lee, Hye Ran; Kim, Ok-Hwa; Kim, Nayoung K. D.; Oh, Sun Kyung; Ozono, Keiichi; Lee, Choon-Ki; Choi, In Ho; Park, Woong-Yang; Cho, Tae-Joon			Skeletal Overgrowth Syndrome Caused by Overexpression of C-Type Natriuretic Peptide in a Girl with Balanced Chromosomal Translocation, t(1;2) (q41;q37.1)	AMERICAN JOURNAL OF MEDICAL GENETICS PART A			English	Article						chromosome translocation; C-type natriuretic peptide; Loeys-Dietz syndrome; NPPC; TGFB2	ENDOCHONDRAL OSSIFICATION; MUTATIONS; RECEPTOR; GROWTH; GENE; ROLES; MICE	Chromosomal translocation of 2q37.1 just distal to the NPPC gene coding for C-type natriuretic peptide (CNP) and subsequent overproduction of CNP have been reported to cause a skeletal overgrowth syndrome. Loeys-Dietz syndrome (LDS) is one of marfanoid overgrowth syndromes, of which subtype IV is caused by haploinsufficiency of transforming growth factor beta 2 (TGFB2). We report on a girl with clinical phenotypes of overgrowth syndrome, including long and slim body habitus, macrodactyly of the big toe, scoliosis, ankle valgus deformity, coxa valga, slipped capital femoral epiphysis, and aortic root dilatation. Karyotyping revealed a balanced chromosomal translocation between 1q41 and 2q37.1, and the breakpoints could be mapped by targeted resequencing analysis. On chromosome 2q37.1, the translocation took place 200,365 bp downstream of NPPC, and serum level of the amino terminal of CNP was elevated. The contralateral site of translocation on chromosome 1q41 disrupted TGFB2 gene, presumed to cause its haploinsufficiency. This case supports the concept that NPPC is overexpressed because of the loss of a specific negative regulatory control in the normal chromosomal location, and demonstrates the effectiveness of targeted resequencing in the mapping of breakpoints. (c) 2015 Wiley Periodicals, Inc.	[Ko, Jung Min] Seoul Natl Univ, Coll Med, Dept Pediat, Seoul, South Korea; [Bae, Jun-Seok; Kim, Nayoung K. D.; Park, Woong-Yang] Samsung Genome Inst, Samsung Med Ctr, Seoul 135710, South Korea; [Bae, Jun-Seok; Park, Woong-Yang] Sungkyunkwan Univ, Samsung Adv Inst Hlth Sci & Technol, Dept Hlth Sci & Technol, Seoul, South Korea; [Choi, Jin Sun; Oh, Sun Kyung] Seoul Natl Univ, Coll Med, Inst Reprod Med, Seoul, South Korea; [Choi, Jin Sun; Oh, Sun Kyung] Seoul Natl Univ, Coll Med, Populat Med Res Ctr, Seoul, South Korea; [Miura, Kohji; Ozono, Keiichi] Osaka Univ, Dept Pediat, Grad Sch Med, Osaka, Japan; [Lee, Hye Ran; Lee, Choon-Ki; Choi, In Ho; Cho, Tae-Joon] Seoul Natl Univ, Coll Med, Dept Orthopaed Surg, Seoul, South Korea; [Kim, Ok-Hwa] Woorisoa Childrens Hosp, Radiol, Seoul, South Korea	Cho, TJ (reprint author), Seoul Natl Univ, Div Pediat Orthopaed, 101 Daehangno, Seoul, South Korea.	woongyang@gmail.com; tjcho@snu.ac.kr			Ministry of Science, ICT, and Future Planning [2013R1A2A2A01067398]	Grant sponsor: Ministry of Science, ICT, and Future Planning; Grant number: 2013R1A2A2A01067398.	Miura K, 2014, AM J MED GENET A, V164, P156, DOI 10.1002/ajmg.a.36218; Schluth-Bolard C, 2013, J MED GENET, V50, P144, DOI 10.1136/jmedgenet-2012-101351; Bocciardi R, 2007, HUM MUTAT, V28, P724, DOI 10.1002/humu.20511; Boileau C, 2012, NAT GENET, V44, P916, DOI 10.1038/ng.2348; Chusho H, 2001, P NATL ACAD SCI USA, V98, P4016, DOI 10.1073/pnas.071389098; Bartels CF, 2004, AM J HUM GENET, V75, P27, DOI 10.1086/422013; Lindsay ME, 2012, NAT GENET, V44, P922, DOI 10.1038/ng.2349; Moncla A, 2007, HUM MUTAT, V28, P1183, DOI 10.1002/humu.20611; Tamura N, 2004, P NATL ACAD SCI USA, V101, P17300, DOI 10.1073/pnas.0407894101; Fontana P, 2014, GENE, V538, P69, DOI 10.1016/j.gene.2014.01.017; Kake T, 2009, AM J PHYSIOL-ENDOC M, V297, pE1339, DOI 10.1152/ajpendo.00272.2009; Miura K, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042180; Olney RC, 2006, GROWTH HORM IGF RES, V16, pS6, DOI 10.1016/j.ghir.2006.03.016; Robin M, 2013, PHASE 2 STUDY BMN 11; Tassano E, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066048; Yasoda A, 1998, J BIOL CHEM, V273, P11695, DOI 10.1074/jbc.273.19.11695	16	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1552-4825	1552-4833		AM J MED GENET A	Am. J. Med. Genet. A	MAY	2015	167	5					1033	1038		10.1002/ajmg.a.36884		6	Genetics & Heredity	Genetics & Heredity	CG3HY	WOS:000353171900010		
J	Jia, ZL; Leslie, EJ; Cooper, ME; Butali, A; Standley, J; Rigdon, J; Suzuki, S; Gongorjav, A; Shonkhuuz, TE; Natsume, N; Shi, B; Marazita, ML; Murray, JC				Jia, Zhonglin; Leslie, Elizabeth J.; Cooper, Margaret E.; Butali, Azeez; Standley, Jennifer; Rigdon, Jennifer; Suzuki, Satoshi; Gongorjav, Ayana; Shonkhuuz, T. Enkhtur; Natsume, Nagato; Shi, Bing; Marazita, Mary L.; Murray, Jeffrey C.			Replication of 13q31.1 Association in Nonsyndromic Cleft Lip with Cleft Palate in Europeans	AMERICAN JOURNAL OF MEDICAL GENETICS PART A			English	Article						GWA study; nonsyndromic orofacial clefting; replication; SPRY2	GENOME-WIDE ASSOCIATION; ENHANCER; GROWTH; RISK; VARIANTS; LOCUS; 8Q24	Genome wide association (GWA) studies have successfully identified at least a dozen loci associated with orofacial clefts. However, these signals may be unique to specific populations and require replication to validate and extend findings as a prelude to etiologic SNP discovery. We attempted to replicate the findings of a recent meta-analysis of orofacial cleft GWA studies using four different ancestral populations. We studied 946 pedigrees (3,436 persons) of European (US white and Danish) and Asian (Japanese and Mongolian) origin. We genotyped six SNPs that represented the most significant P-value associations identified in published studies: rs742071 (1p36), rs7590268 (2p21), rs7632427 (3p11.1), rs12543318 (8q21.3), rs8001641 (13q31.1), and rs7179658 (15q22.2). We directly sequenced three non-coding conserved regions 200kb downstream of SPRY2 in 713 cases, 438 controls, and 485 trios from the US, Mongolia, and the Philippines. We found rs8001641 to be significantly associated with nonsyndromic cleft lip with cleft palate (NSCLP) in Europeans (P-value=4x10(-5), ORtransmission=1.86 with 95% confidence interval: 1.38-2.52). We also found several novel sequence variants in the conserved regions in Asian and European samples, which may help to localize common variants contributing directly to the risk for NSCLP. This study confirms the prior association between rs8001641 and NSCLP in European populations. (c) 2015 Wiley Periodicals, Inc.	[Jia, Zhonglin; Suzuki, Satoshi; Shi, Bing] Sichuan Univ, West China Hosp Stomatol, State Key Lab Oral Dis, Chengdu, Sichaun, Peoples R China; [Jia, Zhonglin; Standley, Jennifer; Rigdon, Jennifer; Suzuki, Satoshi; Murray, Jeffrey C.] Univ Iowa, Dept Pediat, Iowa City, IA 52242 USA; [Jia, Zhonglin; Shi, Bing] Sichuan Univ, Dept Cleft Lip & Palate Surg, West China Hosp Stomatol, Chengdu 610064, Sichuan, Peoples R China; [Leslie, Elizabeth J.; Cooper, Margaret E.; Marazita, Mary L.] Univ Pittsburgh, Sch Dent Med, Ctr Craniofacial & Dent Genet, Dept Oral Biol, Pittsburgh, PA USA; [Butali, Azeez] Univ Iowa, Coll Dent, Dept Oral Pathol Radiol & Med, Iowa City, IA 52242 USA; [Suzuki, Satoshi; Natsume, Nagato] Aichi Gakuin Univ, Sch Dent, Div Res & Treatment Oral & Maxillofacial Congenit, Nagoya, Aichi 464, Japan; [Gongorjav, Ayana; Shonkhuuz, T. Enkhtur] Natl Ctr Maternal & Child Hlth, Ulaanbaatar, Mongol Peo Rep	Leslie, EJ (reprint author), Univ Pittsburgh, Sch Dent Med, Dept Oral Biol, Ctr Craniofacial & Dent Genet, 100 Technol Dr,Suite 500, Pittsburgh, PA 15219 USA.	ejl40@pitt.edu			NIDCR (NIH) [R37-DE08559, U01-DE20057, K99/R00-DE022378]; JSPS KAKENHI [26861757];  [242 49092]	Grant sponsor: NIDCR (NIH); Grant numbers: R37-DE08559, U01-DE20057, K99/R00-DE022378; Grant sponsor: Grant-in-Aid; Grant number: 242 49092; Grant sponsor: JSPS KAKENHI grant-in-Aid; Grant number: 26861757.	Amendt BA, 1998, J BIOL CHEM, V273, P20066, DOI 10.1074/jbc.273.32.20066; Visel A, 2009, NATURE, V461, P199, DOI 10.1038/nature08451; Pennacchio LA, 2006, NATURE, V444, P499, DOI 10.1038/nature05295; Birnbaum S, 2009, NAT GENET, V41, P473, DOI 10.1038/ng.333; Beaty TH, 2011, GENET EPIDEMIOL, V35, P469, DOI 10.1002/gepi.20595; Pearson TA, 2008, JAMA-J AM MED ASSOC, V299, P1335, DOI 10.1001/jama.299.11.1335; Goodnough LH, 2007, DEV DYNAM, V236, P1918, DOI 10.1002/dvdy.21195; Mangold E, 2010, NAT GENET, V42, P24, DOI 10.1038/ng.506; Matsumura K, 2011, BIOCHEM BIOPH RES CO, V404, P1076, DOI 10.1016/j.bbrc.2010.12.116; Visel A, 2007, NUCLEIC ACIDS RES, V35, pD88, DOI 10.1093/nar/gkl822; Purcell S, 2007, AM J HUM GENET, V81, P559, DOI 10.1086/519795; Horvath S, 2004, GENET EPIDEMIOL, V26, P61, DOI 10.1002/gepi.10295; Beaty TH, 2010, NAT GENET, V42, P525, DOI 10.1038/ng.580; Rahimov F, 2008, NAT GENET, V40, P1341, DOI 10.1038/ng.242; Ludwig KU, 2012, NAT GENET, V44, P968, DOI 10.1038/ng.2360; Dixon MJ, 2011, NAT REV GENET, V12, P167, DOI 10.1038/nrg2933; Manolio TA, 2010, NEW ENGL J MED, V363, P166, DOI 10.1056/NEJMra0905980; Grant SFA, 2009, J PEDIATR-US, V155, P909, DOI 10.1016/j.jpeds.2009.06.020; Iwata J, 2012, J BIOL CHEM, V287, P2353, DOI 10.1074/jbc.M111.280974; Leslie EJ, 2013, CLIN GENET, V84, P496, DOI 10.1111/cge.12018; Marazita ML, 2012, ANNU REV GENOM HUM G, V13, P263, DOI 10.1146/annurev-genom-090711-163729; Nawshad A, 2004, ARCH ORAL BIOL, V49, P675, DOI 10.1016/j.archoralbio.2004.05.007; Schwender H, 2012, BIOMETRICS, V68, P766, DOI 10.1111/j.1541-0420.2011.01713.x; Smith Tara M, 2012, Front Physiol, V3, P488, DOI 10.3389/fphys.2012.00488; Welsh IC, 2007, MECH DEVELOP, V124, P746, DOI 10.1016/j.mod.2007.06.007; Yip De G, 2013, PLOS ONE, V8	26	1	1	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1552-4825	1552-4833		AM J MED GENET A	Am. J. Med. Genet. A	MAY	2015	167	5					1054	1060		10.1002/ajmg.a.36912		7	Genetics & Heredity	Genetics & Heredity	CG3HY	WOS:000353171900013		
J	Okubo, M; Fujita, A; Saito, Y; Komaki, H; Ishiyama, A; Takeshita, E; Kojima, E; Koichihara, R; Saito, T; Nakagawa, E; Sugai, K; Yamazaki, H; Kusaka, K; Tanaka, H; Miyake, N; Matsumoto, N; Sasaki, M				Okubo, Mariko; Fujita, Atsushi; Saito, Yoshiaki; Komaki, Hirofumi; Ishiyama, Akihiko; Takeshita, Eri; Kojima, Emiko; Koichihara, Reiko; Saito, Takashi; Nakagawa, Eiji; Sugai, Kenji; Yamazaki, Hiroko; Kusaka, Kei; Tanaka, Hiroshi; Miyake, Noriko; Matsumoto, Naomichi; Sasaki, Masayuki			A Family of Distal Arthrogryposis Type 5 Due to a Novel PIEZO2 Mutation	AMERICAN JOURNAL OF MEDICAL GENETICS PART A			English	Article						distal arthrogryposis type 5; restrictive lung disease; myopathy; optic nerve; synostosis; PIEZO2; mechanosensitive ion channel	CHANNELS; ECEL1; IIB	Distal arthrogryposis (DA) encompasses a heterogeneous group of hereditary disorders with multiple congenital contractures predominant in the distal extremities. A total of 10 subtypes are proposed based on the pattern of contractures and association with extraarticular symptoms. DA5 is defined as a subtype with ptosis/oculomotor limitation. However, affected individuals have a variety of non-ocular features as well. We report on a two-generation family, including four affected individuals who all had congenital contractures of the distal joints, ptosis, restricted ocular movements, distinct facial appearance with deep-set eyes, and shortening of the 1st and 5th toes. The proband and her affected mother had restrictive lung disease, a recently recognized syndromic component of DA5, while younger patients did not. The proband had metacarpal and metatarsal synostosis, and the mother showed excavation of the optic disk. Whole-exome sequencing revealed a novel heterozygous mutation c.4456G>C (p.A1486P) of PIEZO2. PIEZO2 encodes a mechanosensitive ion channel, malfunction of which provides pleiotropic effects on joints, ocular muscles, lung function, and bone development. (c) 2015 Wiley Periodicals, Inc.	[Okubo, Mariko; Saito, Yoshiaki; Komaki, Hirofumi; Ishiyama, Akihiko; Takeshita, Eri; Kojima, Emiko; Koichihara, Reiko; Saito, Takashi; Nakagawa, Eiji; Sugai, Kenji; Sasaki, Masayuki] Natl Ctr Neurol & Psychiat, Dept Child Neurol, Kodaira, Tokyo 1878551, Japan; [Fujita, Atsushi; Miyake, Noriko; Matsumoto, Naomichi] Yokohama City Univ, Dept Human Genet, Grad Sch Med, Yokohama, Kanagawa, Japan; [Yamazaki, Hiroko] Natl Ctr Neurol & Psychiat, Dept Ophthalmol, Kodaira, Tokyo 1878551, Japan; [Kusaka, Kei] Tokyo Natl Hosp, Ctr Pulm Dis, Natl Hosp Org, Tokyo, Japan; [Tanaka, Hiroshi] Natl Rehabil Ctr Children Disabil, Dept Orthoped, Tokyo, Japan	Okubo, M (reprint author), Natl Ctr Neurol & Psychiat, Dept Child Neurol, 4-1-1 Ogawahigashi Cho, Kodaira, Tokyo 1878551, Japan.	ohkubom@ncnp.go.jp					Bamshad M, 2009, J BONE JOINT SURG AM, V91A, P40, DOI 10.2106/JBJS.I.00281; McMillin MJ, 2014, AM J HUM GENET, V94, P734, DOI 10.1016/j.ajhg.2014.03.015; Sung SS, 2003, AM J HUM GENET, V72, P681, DOI 10.1086/368294; Bamshad M, 1996, AM J MED GENET, V65, P277, DOI 10.1002/(SICI)1096-8628(19961111)65:4<277::AID-AJMG6>3.0.CO;2-M; Xiao R, 2010, CURR BIOL, V20, pR936, DOI 10.1016/j.cub.2010.09.053; Dieterich K, 2013, HUM MOL GENET, V22, P1483, DOI 10.1093/hmg/dds514; McMillin MJ, 2013, AM J HUM GENET, V92, P150, DOI 10.1016/j.ajhg.2012.11.014; Coste B, 2010, SCIENCE, V330, P55, DOI 10.1126/science.1193270; Toydemir RM, 2006, NAT GENET, V38, P561, DOI 10.1038/ng1775; Gurnett CA, 2010, HUM MOL GENET, V19, P1165, DOI 10.1093/hmg/ddp587; Beals RK, 2004, AM J MED GENET A, V131A, P67, DOI 10.1002/ajmg.a.30289; Castori M, 2009, AM J MED GENET A, V149A, P482, DOI 10.1002/ajmg.a.32668; Coste B, 2013, P NATL ACAD SCI USA, V110, P4667, DOI 10.1073/pnas.1221400110; Davydov EV, 2010, PLOS COMPUT BIOL, V6, DOI 10.1371/journal.pcbi.1001025; HALL JG, 1982, AM J MED GENET, V11, P185, DOI 10.1002/ajmg.1320110208; KAWIRA EL, 1985, AM J MED GENET, V20, P425, DOI 10.1002/ajmg.1320200302; KRIEGER I, 1972, AM J DIS CHILD, V123, P141; McMillin MJ, 2011, ANN M AM SOC HUM GEN; Pallotta R, 2000, AM J MED GENET, V95, P477, DOI 10.1002/1096-8628(20001218)95:5<477::AID-AJMG13>3.0.CO;2-M; Sach Jr GH, 1978, CLIN GENET, V14, P317; Sahni J, 2004, AM J MED GENET A, V127A, P35, DOI 10.1002/ajmg.a.10634; Scharander-Stumpel CT, 1993, J MED GENET, V30, P78; Tajsharghi H, 2007, NEUROLOGY, V68, P772, DOI 10.1212/01.wnl.0000256339.40667.fb; Williams MS, 2007, AM J MED GENET A, V143A, P752, DOI 10.1002/ajmg.a.31648; Zeiter J H, 1989, J Pediatr Ophthalmol Strabismus, V26, P204	25	1	1	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1552-4825	1552-4833		AM J MED GENET A	Am. J. Med. Genet. A	MAY	2015	167	5					1100	1106		10.1002/ajmg.a.36881		7	Genetics & Heredity	Genetics & Heredity	CG3HY	WOS:000353171900018		
J	Nakamura, Y; Takagi, M; Yoshihashi, H; Miura, M; Narumi, S; Hasegawa, T; Miyake, Y; Hasegawa, Y				Nakamura, Yoshie; Takagi, Masaki; Yoshihashi, Hiroshi; Miura, Masaru; Narumi, Satoshi; Hasegawa, Tomonobu; Miyake, Yoshishige; Hasegawa, Yukihiro			A Case with Neonatal Hyperinsulinemic Hypoglycemia: It is a Characteristic Complication of Sotos Syndrome	AMERICAN JOURNAL OF MEDICAL GENETICS PART A			English	Article						sotos syndrome; hyperinsulinemic hypoglycemia	CONGENITAL HYPERINSULINISM	Sotos syndrome (SoS, OMIM #117550) is an overgrowth syndrome. Deletions or intragenic mutations of the NSD1 , which is located at chromosome 5q35, are responsible for more than 75% of SoS. Conventionally, neonatal hypoglycemia was reported briefly as one of the infrequent symptoms of SoS. However, Matsuo et al. published a report describing five patients with SoS who presented with transient hyperinsulinemic hypoglycemia (HIH) in the neonatal period. We report on an additional patient of SoS, who presented transient HIH in the neonatal period. All of this patient and previous patients have microdeletions at the 5q35 chromosome. Therefore, we examined the following three in considering the possibility that other factor than NSD1 caused HIH. 1) This patient had no mutation of four currently known HIH related genes, ABCC8, KCNJ11, GLUD1, and GCK. 2) He had no further deletion than commonly observed region encompassing NSD1 by comparative genomic hybridization to DNA microarrays. 3) He had no mutation in the 5q35 region in the non-deleted chromosome using exsome sequence analysis. In conclusion, our patient supported that HIH could be one of the characteristic symptoms of SoS in the neonatal period, and could be useful for early diagnosis. (c) 2015 Wiley Periodicals, Inc.	[Nakamura, Yoshie; Hasegawa, Yukihiro] Tokyo Metropolitan Childrens Med Ctr, Div Genet Res, Fuchu, Tokyo 1838561, Japan; [Takagi, Masaki; Hasegawa, Yukihiro] Tokyo Metropolitan Childrens Med Ctr, Div Endocrinol & Metab, Fuchu, Tokyo 1838561, Japan; [Yoshihashi, Hiroshi] Tokyo Metropolitan Childrens Med Ctr, Div Med Genet, Fuchu, Tokyo 1838561, Japan; [Miura, Masaru] Tokyo Metropolitan Childrens Med Ctr, Div Cardiol, Fuchu, Tokyo 1838561, Japan; [Narumi, Satoshi; Hasegawa, Tomonobu] Keio Univ, Sch Med, Dept Pediat, Tokyo, Japan; [Miyake, Yoshishige] Ichinomiya Municipal Hosp, Div Pediat, Ichinomiya, Aichi, Japan	Hasegawa, Y (reprint author), Tokyo Metropolitan Childrens Med Ctr, Div Genet Res, 2-8-29 Musashidai, Fuchu, Tokyo 1838561, Japan.	yukihiro_hasegawa@tmhp.jp			Ministry of Health, Labour and Welfare of Japan; Tokyo Metropolitan Foundation [Jitsuyoka (Nanbyo)-Ippan-014(23300102)]	Grant sponsor: Ministry of Health, Labour and Welfare of Japan; Tokyo Metropolitan Foundation; Grant number: Jitsuyoka (Nanbyo)-Ippan-014(23300102).	Kurotaki N, 2003, HUM MUTAT, V22, P378, DOI 10.1002/humu.10270; Tatton-Brown K, 2005, AM J HUM GENET, V77, P193, DOI 10.1086/432082; Henquin JC, 2013, DIABETES, V62, P1689, DOI 10.2337/db12-1414; Kurotaki N, 2002, NAT GENET, V30, P365, DOI 10.1038/ng863; Arnoux JB, 2010, EARLY HUM DEV, V86, P287, DOI 10.1016/j.earlhumdev.2010.05.003; Barres R, 2006, MOL ENDOCRINOL, V20, P2864, DOI 10.1210/me.2005-0455; Baujat G, 2007, ORPHANET J RARE DIS, V2, DOI 10.1186/1750-1172-2-36; Matsuo T, 2013, AM J MED GENET A, V161A, P34, DOI 10.1002/ajmg.a.35657	8	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1552-4825	1552-4833		AM J MED GENET A	Am. J. Med. Genet. A	MAY	2015	167	5					1171	1174		10.1002/ajmg.a.36996		4	Genetics & Heredity	Genetics & Heredity	CG3HY	WOS:000353171900031		
J	Shikino, K; Noda, K; Ohira, Y; Ikusaka, M				Shikino, Kiyoshi; Noda, Kazutaka; Ohira, Yoshiyuki; Ikusaka, Masatomi			Abnormal Paroxysmal Nocturnal Behavior Due to Insulinoma	AMERICAN JOURNAL OF MEDICINE			English	Editorial Material									[Shikino, Kiyoshi; Noda, Kazutaka; Ohira, Yoshiyuki; Ikusaka, Masatomi] Chiba Univ Hosp, Dept Gen Med, Chiba, Chiba, Japan	Shikino, K (reprint author), Chiba Univ Hosp, Dept Gen Med, Chuo Ku, 1-8-1 Inohana, Chiba, Chiba, Japan.	kshikino@gmail.com					SERVICE FJ, 1976, MAYO CLIN PROC, V51, P417; MITRAKOU A, 1993, NEW ENGL J MED, V329, P834, DOI 10.1056/NEJM199309163291203; Munir A, 2008, CLIN ENDOCRINOL, V68, P912, DOI 10.1111/j.1365-2265.2007.03161.x; Suzuki Keisuke, 2007, Intern Med, V46, P405, DOI 10.2169/internalmedicine.46.6071	4	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0002-9343	1555-7162		AM J MED	Am. J. Med.	MAY	2015	128	5					E7	E8		10.1016/j.amjmed.2014.11.037		2	Medicine, General & Internal	General & Internal Medicine	CG7XK	WOS:000353520500004		
J	Oishi, A; Tsujikawa, A; Yamashiro, K; Ooto, S; Tamura, H; Nakanishi, H; Ueda-Arakawa, N; Miyake, M; Akagi-Kurashige, Y; Hata, M; Yoshikawa, M; Kuroda, Y; Takahashi, A; Yoshimura, N				Oishi, Akio; Tsujikawa, Akitaka; Yamashiro, Kenji; Ooto, Sotaro; Tamura, Hiroshi; Nakanishi, Hideo; Ueda-Arakawa, Naoko; Miyake, Masahiro; Akagi-Kurashige, Yumiko; Hata, Masayuki; Yoshikawa, Munemitsu; Kuroda, Yoshimasa; Takahashi, Ayako; Yoshimura, Nagahisa			One-Year Result of Aflibercept Treatment on Age-Related Macular Degeneration and Predictive Factors for Visual Outcome	AMERICAN JOURNAL OF OPHTHALMOLOGY			English	Article							POLYPOIDAL CHOROIDAL VASCULOPATHY; INTRAVITREAL RANIBIZUMAB INJECTIONS; OPTICAL COHERENCE TOMOGRAPHY; PHOTODYNAMIC THERAPY; VERTEPORFIN; THICKNESS; ACUITY; LAPTOP	PURPOSE: To investigate the efficacy of periodic injection of aflibercept in each subtype of age-related macular degeneration (AMD) and to explore the predictive factors for visual outcome in clinical settings. DESIGN: Prospective nonrandomized interventional case series. METHODS: Patients with AMD were recruited and were administered aflibercept injections once a month for 3 months followed by once every 2 months for 8 months. The logarithm of the minimal angle of resolution (logMAR) at 12 months and improvement of vision from baseline were compared among polypoidal choroidal vasculopathy (PCV), retinal angiomatous proliferation (RAP), and typical AMD. Regression rate of polypoidal lesions was assessed. We also performed regression analysis with logMAR at 12. months as the dependent variable. RESULTS: The study sample consisted of 98 patients: 46 had typical AMD, 42 had PCV, and 10 had RAP. Mean logMAR improved from 0.36 to 0.21 in 12 months. While there was no difference in visual improvement between typical AMD and PCV, final logMAR was better in PCV (0.32 +/- 0.09 vs 0.08 +/- 0.04, P = .016). Thirty-nine PCV patients underwent follow-up angiography, and regression of polyps was observed in 27 cases (69.2%). Multiple regression analysis showed that the presence of external limiting membrane (ELM), smaller greatest linear dimension, and the presence of polypoidal lesion were associated with better visual outcome (R-2 = 0.53, P = 2.73 x 10(-14)) CONCLUSIONS: Periodic injection of aflibercept is effective for PCV as well as for typical AMD. The statuses of ELM, greatest linear dimension, and polypoidal lesion are predictive for visual outcome. (C) 2015 by Elsevier Inc. All rights reserved.	[Oishi, Akio; Tsujikawa, Akitaka; Yamashiro, Kenji; Ooto, Sotaro; Tamura, Hiroshi; Nakanishi, Hideo; Ueda-Arakawa, Naoko; Miyake, Masahiro; Akagi-Kurashige, Yumiko; Hata, Masayuki; Yoshikawa, Munemitsu; Kuroda, Yoshimasa; Takahashi, Ayako; Yoshimura, Nagahisa] Kyoto Univ, Grad Sch Med, Dept Ophthalmol & Visual Sci, Kyoto 6068507, Japan	Oishi, A (reprint author), Kyoto Univ, Grad Sch Med, Dept Ophthalmol & Visual Sci, Sakyo Ku, 54 Kawahara, Kyoto 6068507, Japan.	aquio@kuhp.kyoto-u.ac.jp			Japan Society for the Promotion of Science, Tokyo, Japan [24791847]; Ministry of Education, Culture, Sports, Science, and Technology (MEXT), Tokyo, Japan	This research was supported in part by a grant-in-aid for scientific research (No. 24791847) from the Japan Society for the Promotion of Science, Tokyo, Japan and the Innovative Techno-Hub for Integrated Medical Bio-Imaging of the Project for Developing Innovation Systems, from the Ministry of Education, Culture, Sports, Science, and Technology (MEXT), Tokyo, Japan.	Akagi-Kurashige Y, 2012, GRAEF ARCH CLIN EXP, V250, P1129, DOI 10.1007/s00417-012-1928-5; Hirami Y, 2007, RETINA-J RET VIT DIS, V27, P335, DOI 10.1097/01.iae.0000233647.78726.46; Gupta B, 2010, BRIT J OPHTHALMOL, V94, P672, DOI 10.1136/bjo.2009.166975; Koizumi H, 2011, GRAEF ARCH CLIN EXP, V249, P1123, DOI 10.1007/s00417-011-1620-1; Oishi A, 2013, AM J OPHTHALMOL, V156, P644, DOI 10.1016/j.ajo.2013.05.024; Spaide RF, 2008, AM J OPHTHALMOL, V146, P496, DOI 10.1016/j.ajo.2008.05.032; Koh AHC, 2013, RETINA-J RET VIT DIS, V33, P686, DOI 10.1097/IAE.0b013e3182852446; Stangos AN, 2010, AM J OPHTHALMOL, V150, P666, DOI 10.1016/j.ajo.2010.05.035; Oishi A, 2010, AM J OPHTHALMOL, V150, P27, DOI 10.1016/j.ajo.2010.02.012; Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7; Oishi A, 2014, OPHTHALMOLOGY, V121, P1151, DOI 10.1016/j.ophtha.2013.12.037; Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006; Nowak-Sliwinska P, 2013, PROG RETIN EYE RES, V37, P182, DOI 10.1016/j.preteyeres.2013.09.003; Oishi A, 2011, EUR J OPHTHALMOL, V21, P777, DOI 10.5301/EJO.2011.7430; Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481; Cho M, 2009, AM J OPHTHALMOL, V148, P70, DOI 10.1016/j.ajo.2009.02.012; Yamashiro K, 2012, AM J OPHTHALMOL, V154, P125, DOI 10.1016/j.ajo.2012.01.010; Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655; Mathew R, 2013, AM J OPHTHALMOL, V155, P720, DOI 10.1016/j.ajo.2012.11.003; Kang HM, 2014, AM J OPHTHALMOL, V157, P1013, DOI 10.1016/j.ajo.2014.01.019; Hikichi T, 2013, BRIT J OPHTHALMOL, V97, P617, DOI 10.1136/bjophthalmol-2012-302652; Haller JA, 2013, OPHTHALMOLOGY, V120, pS3, DOI 10.1016/j.ophtha.2013.01.057; Kang HM, 2013, AM J OPHTHALMOL, V156, P652, DOI 10.1016/j.ajo.2013.05.038; Kuo HK, 2011, GRAEF ARCH CLIN EXP, V249, P601, DOI 10.1007/s00417-010-1461-3; Ojima Y, 2006, AM J OPHTHALMOL, V141, P958, DOI 10.1016/j.ajo.2005.12.002; Schmidt-Erfurth U, 2013, OPHTHALMOLOGY, V121, P193; Scott AW, 2010, EYE, V24, P491, DOI 10.1038/eye.2009.311; Stewart MW, 2012, NAT REV DRUG DISCOV, V11, P269, DOI 10.1038/nrd3700	28	2	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0002-9394	1879-1891		AM J OPHTHALMOL	Am. J. Ophthalmol.	MAY	2015	159	5					853	860		10.1016/j.ajo.2015.01.018		8	Ophthalmology	Ophthalmology	CG5VW	WOS:000353365000005		
J	Ohno-Matsui, K; Kawasaki, R; Jonas, JB; Cheung, CMG; Saw, SM; Verhoeven, VJM; Klaver, CCW; Moriyama, M; Shinohara, K; Kawasaki, Y; Yamazaki, M; Meuer, S; Ishibashi, T; Yasuda, M; Yamashita, H; Sugano, A; Wang, JJ; Mitchell, P; Wong, TY				Ohno-Matsui, Kyoko; Kawasaki, Ryo; Jonas, Jost B.; Cheung, Chui Ming Gemmy; Saw, Seang-Mei; Verhoeven, Virginie J. M.; Klaver, Caroline C. W.; Moriyama, Muka; Shinohara, Kosei; Kawasaki, Yumiko; Yamazaki, Mai; Meuer, Stacy; Ishibashi, Tatsuro; Yasuda, Miho; Yamashita, Hidetoshi; Sugano, Akira; Wang, Jie Jin; Mitchell, Paul; Wong, Tien Yin		META-Anal Pathologic Myopia META	International Photographic Classification and Grading System for Myopic Maculopathy	AMERICAN JOURNAL OF OPHTHALMOLOGY			English	Article							CHOROIDAL NEOVASCULARIZATION SECONDARY; PATHOLOGICAL MYOPIA; VISUAL IMPAIRMENT; LOW-VISION; ADULT-POPULATION; OLDER POPULATION; PREVALENCE; BLINDNESS; EYE; RETINOPATHY	PURPOSE: To develop a classification and grading system for myopic maculopathy. DESIGN: Development and evaluation of a classification system for myopic maculopathy based on observational case series. METHODS: A comprehensive set of myopic macular lesions was defined via literature review and through consensus meetings among retinal specialists and clinician scientists. A classification of myopic maculopathy was formulated based on fundus photographs and a modified Delphi process and consensus. Inter- and intraobserver reproducibility, assessed as agreement (%) and weighted kappa values, were evaluated. One hundred retinal photographs with myopia and myopic macular lesions were selected from case series at the High Myopia Clinic of the Tokyo Medical and Dental University, Tokyo, Japan. RESULTS: We defined 5 categories of myopic maculopathy including "no myopic retinal degenerative lesion" (Category 0), "tessellated fundus" (Category 1), "diffuse chorioretinal atrophy" (Category 2), "patchy chorioretinal atrophy" (Category 3), and "macular atrophy" (Category 4). Three additional features to supplement these categories were defined as "plus" lesions, namely, lacquer cracks, myopic choroidal neovascularization, and Fuchs spot. Posterior staphyloma was considered as a further, important sign of myopic retinopathy. The intraobserver agreement was >= 85% and the corresponding weighted kappa statistic was >= 0.6 between observations. After a brief training session, interobserver kappa statistics reached the predefined satisfactory level (>= 0.4), considered as above moderate agreement. CONCLUSIONS: We propose a classification system for myopic maculopathy that was found to be reproducible. Applying a uniform classification in different studies will facilitate communication and comparison of findings from clinical trials and epidemiologic studies. (C) 2015 by Elsevier Inc. All rights reserved.	[Ohno-Matsui, Kyoko; Moriyama, Muka; Shinohara, Kosei] Tokyo Med & Dent Univ, Tokyo 1138510, Japan; [Kawasaki, Ryo; Kawasaki, Yumiko] Yamagata Univ, Dept Publ Hlth, Yamagata 990, Japan; [Jonas, Jost B.] Heidelberg Univ, Dept Ophthalmol, Med Fac Mannheim, Heidelberg, Germany; [Cheung, Chui Ming Gemmy; Saw, Seang-Mei; Wong, Tien Yin] Natl Univ Singapore, Singapore Eye Res Inst, Singapore 117548, Singapore; [Verhoeven, Virginie J. M.; Klaver, Caroline C. W.] Erasmus MC, Dept Ophthalmol, Rotterdam, Netherlands; [Yamazaki, Mai] Tohoku Cent Hosp, Yamagata, Japan; [Meuer, Stacy] Univ Wisconsin, Dept Ophthalmol & Visual Sci, Sch Med & Publ Hlth, Madison, WI USA; [Ishibashi, Tatsuro; Yasuda, Miho] Kyushu Univ, Dept Ophthalmol, Fukuoka 812, Japan; [Yamashita, Hidetoshi; Sugano, Akira] Yamagata Univ, Dept Ophthalmol, Yamagata 990, Japan; [Wang, Jie Jin; Mitchell, Paul] Univ Sydney, Dept Ophthalmol, Ctr Vis Res, Sydney, NSW 2006, Australia; [Wang, Jie Jin; Mitchell, Paul] Univ Sydney, Westmead Millennium Inst, Sydney, NSW 2006, Australia	Ohno-Matsui, K (reprint author), Tokyo Med & Dent Univ, Dept Ophthalmol & Visual Sci, Bunkyo Ku, 1-5-45 Yushima, Tokyo 1138510, Japan.	k.ohno.oph@med.tmd.ac.jp	Wang, Jie Jin/P-1499-2014; Mitchell, Paul/P-1498-2014; Polasek, Ozren/B-6002-2011	Wang, Jie Jin/0000-0001-9491-4898; Polasek, Ozren/0000-0002-5765-1862	Japanese Society for Promotion of Science in Tokyo, Japan [22390322, 25670729]; Novartis Pharma (Basel, Switzerland)	Tien Y. Wong is a consultant for Novartis Pharma (Basel, Switzerland) and Bayer (Leyerkusen, Germany); Kyoko Ohno-Matsui is a consultant for Bayer (Leverkusen, Germany); Ryo Kawasaki is a consultant for Office Future Inc (Tokyo, Japan); Jost B. Jonas is a consultant for Allergan Inc (Irvine, California), Merck Sharp & Dohme Co, Inc (Munchen, Germany), Alimera Co (Alpharetta, Georgia), Boehringer Ingelheim Co (Ingelheim, Germany), and Sanofi Co (Frankfurt, Germany) and is a patent holder with CellMed AG (Alzenau, Germany); Ryo Kawasaki had support for travel for the meeting of the present study from Novartis Pharma (Basel, Switzerland). Kyoko Ohno-Matsui has obtained research funding from the Japanese Society for Promotion of Science in Tokyo, Japan (22390322 and 25670729). Kyoko Ohno-Matsui and Ryo Kawasaki have obtained research funding from Novartis Pharma (Basel, Switzerland). The funding source had no influence on the interpretation or publication of the study.	Tufail A, 2013, OPHTHALMOLOGY, V120, P1944, DOI 10.1016/j.ophtha.2013.06.010; Xu L, 2006, OPHTHALMOLOGY, V113, P1134, DOI 10.1016/j.ophtha.2006.01.035; AVILA MP, 1984, OPHTHALMOLOGY, V91, P1573; Buch H, 2004, OPHTHALMOLOGY, V111, P53, DOI 10.1016/j.ophtha.2003.05.010; Ruiz-Moreno JM, 2013, BRIT J OPHTHALMOL, V97, P1447, DOI 10.1136/bjophthalmol-2012-302973; Ohno-Matsui K, 2014, OPHTHALMOLOGY, V121, P1798, DOI 10.1016/j.ophtha.2014.03.035; Iwase A, 2006, OPHTHALMOLOGY, V113, P1354, DOI 10.1016/j.ophtha.2006.04.022; Vongphanit J, 2002, OPHTHALMOLOGY, V109, P704, DOI 10.1016/S0161-6420(01)01024-7; BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X; Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P653; [Anonymous], 1991, OPHTHALMOLOGY, V98, P786; Zheng YF, 2011, OPHTHALMOLOGY, V118, P1798, DOI 10.1016/j.ophtha.2011.02.014; Neelam K, 2012, PROG RETIN EYE RES, V31, P495, DOI 10.1016/j.preteyeres.2012.04.001; Ohno-Matsui K, 2003, BRIT J OPHTHALMOL, V87, P570, DOI 10.1136/bjo.87.5.570; Hayashi K, 2010, OPHTHALMOLOGY, V117, P1595, DOI 10.1016/j.ophtha.2009.11.003; Wolf S, 2014, OPHTHALMOLOGY, V121, P682, DOI 10.1016/j.ophtha.2013.10.023; Yoshida T, 2003, OPHTHALMOLOGY, V110, P1297, DOI 10.1016/S0161-6420(03)00461-5; Asakuma T, 2012, OPHTHALMOLOGY, V119, P1760, DOI 10.1016/j.ophtha.2012.02.034; Hsu WM, 2004, OPHTHALMOLOGY, V111, P62, DOI 10.1016/j.ophtha.2003.05.011; Hayashi K, 2012, RETINA-J RET VIT DIS, V32, P687, DOI 10.1097/IAE.0b013e3182278bae; Gao LQ, 2011, ARCH OPHTHALMOL-CHIC, V129, P1199, DOI 10.1001/archophthalmol.2011.230; Cedrone C, 2003, OPHTHALMOLOGY, V110, P584, DOI 10.1016/S0161-6420(02)01898-5; Chang L, 2013, AM J OPHTHALMOL, V155, P991, DOI 10.1016/j.ajo.2013.01.016; Cotter SA, 2006, OPHTHALMOLOGY, V113, P1574, DOI 10.1016/j.ophtha.2006.05.002; Curtin B J, 1977, Trans Am Ophthalmol Soc, V75, P67; Curtin B J, 1970, Trans Am Ophthalmol Soc, V68, P312; Krumpaszky HG, 1999, OPHTHALMOLOGICA, V213, P176, DOI 10.1159/000027415; Ohno-Matsui K, 2014, PATHOLOGIC MYOPIA, P177; Spaide RF, 2014, PATHOLOGIC MYOPIA, P167; Tokoro T, 1998, ATLAS POSTERIOR FUND, P5	30	1	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0002-9394	1879-1891		AM J OPHTHALMOL	Am. J. Ophthalmol.	MAY	2015	159	5					877	883		10.1016/j.ajo.2015.01.022		7	Ophthalmology	Ophthalmology	CG5VW	WOS:000353365000008		
J	Hasegawa, T; Masuda, N; Ogata, N				Hasegawa, Taiji; Masuda, Naonori; Ogata, Nahoko			Highly Reflective Line in Optical Coherence Tomography Images of Eyes With Macular Edema Associated With Branch Retinal Vein Occlusion	AMERICAN JOURNAL OF OPHTHALMOLOGY			English	Article							HYPERREFLECTIVE FOCI; INTRAVITREAL TRIAMCINOLONE; PHOTORECEPTOR LAYER; OUTER RETINA; BEVACIZUMAB; SECONDARY; INJECTION; VISION	PURPOSE: To determine whether, the highly reflective vertical lines seen in spectral-domain optical coherence tomographic (SD OCT) images, which we have termed track lines, after resolution of macular edema associated with branch retinal vein occlusion are related to the integrity of the photoreceptors. DESIGN: Retrospective, observational, cross-sectional study. METHODS: We reviewed the medical records of 59 eyes with resolved macular edema associated with branch retinal vein occlusion. The eyes were classified by the presence or absence of the track lines in the SD OCT images after the resolution of macular edema. The correlation between the presence of the track lines and the integrity of the photoreceptors was determined. RESULTS: Twenty-one of 59 (36%) eyes had track lines in the SD OCT images after a resolution of the macular edema during the follow-up period. At the final visit, 17 (81%) of 21 eyes with the track lines had an interrupted ellipsoid zone at the fovea, whereas 3 eyes (14%) had an intact ellipsoid zone and 1 eye (5%) had an absent ellipsoid zone (P < .0001). The percentage of eyes with a disrupted external limiting membrane at the initial visit was significantly higher in eyes with track lines (90%) than that in eyes without track lines (63%; P = .0324). CONCLUSIONS: The presence of highly reflective vertical lines in the SD OCT image is associated with a disrupted external limiting membrane before the resolution of macular edema and is associated with an interruption of the ellipsoid zone after resolution of macular edema. Thus, the vertical lines are useful markers of damage to the photoreceptors. (C) 2015 by Elsevier Inc. All rights reserved.	[Hasegawa, Taiji; Masuda, Naonori; Ogata, Nahoko] Nara Med Univ, Dept Ophthalmol, Kashihara, Nara 6348522, Japan	Hasegawa, T (reprint author), Nara Med Univ, Dept Ophthalmol, 840 Shijo Cho, Kashihara, Nara 6348522, Japan.	taijiha@naramed-u.ac.jp					Akagi-Kurashige Y, 2012, GRAEF ARCH CLIN EXP, V250, P1129, DOI 10.1007/s00417-012-1928-5; Amarsson A, 2000, INVEST OPHTH VIS SCI, V41, P877; Campochiaro PA, 2010, OPHTHALMOLOGY, V117, P1102, DOI 10.1016/j.ophtha.2010.02.021; Ota M, 2008, AM J OPHTHALMOL, V145, P273, DOI 10.1016/j.ajo.2007.09.019; Spaide RF, 2003, RETINA-J RET VIT DIS, V23, P343, DOI 10.1097/00006982-200306000-00009; Tsujikawa A, 2010, AM J OPHTHALMOL, V149, P291, DOI 10.1016/j.ajo.2009.09.007; Kang HM, 2013, GRAEF ARCH CLIN EXP, V251, P501, DOI 10.1007/s00417-012-2067-8; Marmor MF, 1999, DOC OPHTHALMOL, V97, P239, DOI 10.1023/A:1002192829817; Cekic O, 2005, RETINA-J RET VIT DIS, V25, P851; Yamaike N, 2008, OPHTHALMOLOGY, V115, P355, DOI 10.1016/j.ophtha.2007.04.052; Kondo M, 2009, RETINA-J RET VIT DIS, V29, P1242, DOI 10.1097/IAE.0b013e3181aa8e20; Rogers SL, 2010, OPHTHALMOLOGY, V117, P1094, DOI 10.1016/j.ophtha.2010.01.058; Scott IU, 2009, ARCH OPHTHALMOL-CHIC, V127, P1115, DOI 10.1001/archophthalmol.2009.233; Bolz M, 2009, OPHTHALMOLOGY, V116, P914, DOI 10.1016/j.ophtha.2008.12.039; Chung EJ, 2008, GRAEF ARCH CLIN EXP, V246, P1241, DOI 10.1007/s00417-008-0866-8; Chen SDM, 2006, AM J OPHTHALMOL, V141, P876, DOI 10.1016/j.ajo.2005.12.011; Esrick E, 2005, AM J OPHTHALMOL, V139, P653, DOI 10.1016/j.ajo.2004.11.011; Hasegawa T, 2014, AM J OPHTHALMOL, V157, P390, DOI 10.1016/j.ajo.2013.10.007; Kang JW, 2014, GRAEF ARCH CLIN EXP, V252, P1413, DOI 10.1007/s00417-014-2595-5; Mandelcorn MS, 2004, RETINA-J RET VIT DIS, V24, P348, DOI 10.1097/00006982-200406000-00002; Nishijima K, 2014, RETINA-J RET VIT DIS, V34, P732, DOI 10.1097/IAE.0000000000000005; Shin HJ, 2011, ACTA OPHTHALMOL, V89, P35; Uji A, 2012, AM J OPHTHALMOL, V153, P710, DOI 10.1016/j.ajo.2011.08.041	23	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0002-9394	1879-1891		AM J OPHTHALMOL	Am. J. Ophthalmol.	MAY	2015	159	5					925	933		10.1016/j.ajo.2015.01.033		9	Ophthalmology	Ophthalmology	CG5VW	WOS:000353365000013		
J	Suzuki, T; Ohashi, Y; Oshika, T; Goto, H; Hirakata, A; Fukushita, K; Miyata, K				Suzuki, Takashi; Ohashi, Yuichi; Oshika, Tetsuro; Goto, Hiroshi; Hirakata, Akito; Fukushita, Kimiko; Miyata, Kazunori		Japanese Ophthalmological Soc Hoya	Outbreak of Late-onset Toxic Anterior Segment Syndrome After Implantation of One-piece Intraocular Lenses	AMERICAN JOURNAL OF OPHTHALMOLOGY			English	Article							CATARACT-SURGERY; CORNEAL ENDOTHELIUM; SYNDROME UPDATE; COMMON CAUSES; INFLAMMATION; ENDOPHTHALMITIS; DETERGENTS; EXTRACTION; CHAMBER; RABBIT	PURPOSE: To describe clinical findings associated with an outbreak of toxic anterior segment syndrome (TASS) after implantation of 1-piece intraocular lenses (IOLs; HOYA iSert (R) 251 and 255; HOYA Co Ltd, Tokyo, Japan) contaminated with aluminum. DESIGN: Multicenter observational retrospective case series. METHODS: Cases developing TASS after IOL implantation from November 2011 to February 2013 were reported to the HOYA IOL-Related Endophthalmitis Investigation Committee. Infectious endophthalmitis was excluded. Data were collected on patient backgrounds, the time from IOL implantation to development of the first symptoms, clinical findings, treatment, and best-corrected visual acuity (BCVA) scores before and after treatment. BCVA data were converted into logMAR figures to allow for statistical analysis. RESULTS: We identified 251 cases of late-onset TASS in patients of mean age 72.85 years treated in 183 hospitals. Common clinical features included the presence of anterior chamber cells (99.2%), conjunctival injection (41.4%), fibrinous inflammation (26.7%), and hypopyon (22.7%). Mean BCVA at the onset of ocular inflammation was 0.253 +/- 0.424. The mean time from IOL implantation to development of the first symptoms was 38.44 +/- 32.29 days. Of all eyes, 142 were treated with steroids and antibiotics, and 109 underwent surgery, including washing of the anterior chamber, removal of the IOL, and vitrectomy. Mean BCVA after treatment was 0.036 +/- 0.242, significantly better than at the onset of ocular inflammation (P < .05). CONCLUSION: This is the first report of an outbreak of late-onset TASS after implantation of a particular type of IOL. (C) 2015 by Elsevier Inc. All rights reserved.	[Suzuki, Takashi; Ohashi, Yuichi] Ehime Univ, Grad Sch Med, Dept Ophthalmol, Matsuyama, Ehime 790, Japan; [Oshika, Tetsuro] Univ Tsukuba, Fac Med, Dept Ophthalmol, Tsukuba, Ibaraki, Japan; [Goto, Hiroshi] Tokyo Med Univ, Dept Ophthalmol, Tokyo 1608402, Japan; [Hirakata, Akito] Kyorin Univ, Sch Med, Dept Ophthalmol, Tokyo, Japan; [Fukushita, Kimiko] Karasuyama Eye Clin, Tokyo, Japan; [Miyata, Kazunori] Miyata Eye Hosp, Miyazaki, Japan	Suzuki, T (reprint author), Ehime Univ, Sch Med, Dept Ophthalmol, Toon, Ehime 7910295, Japan.	t-suzuki@m.ehime-u.ac.jp			Japanese Ophthalmological Society	the Japanese Ophthalmological Society.	Oshika T, 2007, ACTA OPHTHALMOL SCAN, V85, P848, DOI 10.1111/j.1600-0420.2007.00932.x; Peck CMC, 2010, J CATARACT REFR SURG, V36, P1073, DOI 10.1016/j.jcrs.2010.01.030; Bodnar Z, 2012, J CATARACT REFR SURG, V38, P1902, DOI 10.1016/j.jcrs.2012.06.053; Mamalis N, 2006, J CATARACT REFR SURG, V32, P324, DOI 10.1016/j.jcrs.2006.01.065; Unal M, 2006, J CATARACT REFR SURG, V32, P1696, DOI 10.1016/j.jcrs.2006.05.008; Kutty PK, 2008, J CATARACT REFR SURG, V34, P585, DOI 10.1016/j.jcrs.2007.11.037; Buzard K, 2010, J CATARACT REFR SURG, V36, P2195, DOI 10.1016/j.jcrs.2010.09.017; Calogero D, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.009; CARTER LM, 1973, EXP EYE RES, V17, P409, DOI 10.1016/0014-4835(73)90220-0; GONNERING R, 1979, INVEST OPHTH VIS SCI, V18, P373; Guzey M, 2002, OPHTHALMOLOGICA, V216, P113, DOI 10.1159/000048309; Holland SP, 2007, CURR OPIN OPHTHALMOL, V18, P4, DOI 10.1097/ICU.0b013e3280117d0c; Jehan FS, 2000, J CATARACT REFR SURG, V26, P1773, DOI 10.1016/S0886-3350(00)00726-4; KIM JH, 1987, J CATARACT REFR SURG, V13, P537; KREISLER KR, 1992, J CATARACT REFR SURG, V18, P106; Kumaran N, 2014, EYE, V28, P1382, DOI 10.1038/eye.2014.170; Liu H, 2001, J CATARACT REFR SURG, V27, P1746, DOI 10.1016/S0886-3350(01)01067-7; Lorenz K, 2014, J CATARACT REFR SURG, V40, P192, DOI 10.1016/j.jcrs.2013.07.041; Mamalis N, 2006, J CATARACT REFR SURG, V32, P181, DOI 10.1016/j.jcrs.2006.01.036; Mamalis N, 2010, J CATARACT REFR SURG, V36, P1067, DOI 10.1016/j.jcrs.2010.05.001; Mathys KC, 2008, J CATARACT REFR SURG, V34, P465, DOI 10.1016/j.jcrs.2007.10.047; MONSON MC, 1992, J CATARACT REFR SURG, V18, P184; Oshika T, 2014, IOL RS JAPANESE J CA, V28, P177; Parikh C, 2002, ARCH OPHTHALMOL-CHIC, V120, P165; RICHBURG FA, 1986, J CATARACT REFR SURG, V12, P248; Sengupta S, 2011, J CATARACT REFR SURG, V37, P1673, DOI 10.1016/j.jcrs.2011.03.053; Werner L, 2006, J CATARACT REFR SURG, V32, P227, DOI 10.1016/j.jcrs.2005.12.093	27	2	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0002-9394	1879-1891		AM J OPHTHALMOL	Am. J. Ophthalmol.	MAY	2015	159	5					934	939		10.1016/j.ajo.2015.01.023		6	Ophthalmology	Ophthalmology	CG5VW	WOS:000353365000014		
J	Murakami, Y; Yoshida, N; Ikeda, Y; Nakatake, S; Fujiwara, K; Notomi, S; Nabeshima, T; Nakao, S; Hisatomi, T; Enaida, H; Ishibashi, T				Murakami, Yusuke; Yoshida, Noriko; Ikeda, Yasuhiro; Nakatake, Shunji; Fujiwara, Kota; Notomi, Shoji; Nabeshima, Takahiro; Nakao, Shintaro; Hisatomi, Toshio; Enaida, Hiroshi; Ishibashi, Tatsuro			Relationship Between Aqueous Flare and Visual Function in Retinitis Pigmentosa	AMERICAN JOURNAL OF OPHTHALMOLOGY			English	Article							CHRONIC INFLAMMATORY REACTION; CYSTOID MACULAR EDEMA; RETINAL DEGENERATION; CELL-DEATH; PROTEIN-CONCENTRATION; TOPICAL DORZOLAMIDE; MOUSE MODEL; EYES; ACTIVATION; MICROGLIA	PURPOSE: To investigate the correlation between aqueous flare values and central visual function in patients with retinitis pigmentosa (RP). DESIGN: Retrospective, observational case series. METHODS: We retrospectively studied 160 patients diagnosed with typical RP and 59 control subjects. Aqueous flare values were measured by laser flare cell meter. The relationships between aqueous flare and best-corrected visual acuity (VA) and mean deviation (MD) of static perimetry tests were analyzed in RP patients. RESULTS: The aqueous flare values were significantly higher in the RP patients compared to the control subjects (10.6 +/- 7.9 vs 5.0 +/- 2.1 photon counts per millisecond [pc/ms], P < .0001). In the RP patients, the aqueous flare values were negatively correlated with VA (r = 0.359, P < .0001) and MD (r = -0.330, P < .0001). Age-subgroup analysis showed a significant correlation between aqueous flare and VA in the RP patients' 40s, 50s, and 60s and between aqueous flare and MD in the 30s, 40s, 50s, and 60s. The RP patients with MD values 15 decibels (dB) showed significantly higher levels of aqueous flare than those with MD values < -15 dB (12.0 +/- 6.2 vs 8.7 +/- 5.8, P = .0001). CONCLUSIONS: Aqueous flare is increased in RP patients and negatively correlates with central visual function. These results suggest a close relationship between inflammation and central vision loss in RP. (C) 2015 by Elsevier Inc. All rights reserved.	[Murakami, Yusuke; Yoshida, Noriko; Ikeda, Yasuhiro; Nakatake, Shunji; Fujiwara, Kota; Notomi, Shoji; Nabeshima, Takahiro; Nakao, Shintaro; Hisatomi, Toshio; Ishibashi, Tatsuro] Kyushu Univ, Grad Sch Med Sci, Dept Ophthalmol, Fukuoka 8128582, Japan; [Fujiwara, Kota] Akita Univ, Grad Sch Med, Dept Ophthalmol, Akita 010, Japan; [Enaida, Hiroshi] Saga Univ, Fac Med, Dept Ophthalmol, Saga 840, Japan	Ikeda, Y (reprint author), Kyushu Univ, Grad Sch Med Sci, Dept Ophthalmol, Fukuoka 8128582, Japan.	ymocl@pathol1.med.kyushu-u.ac.jp		Hisatomi, Toshio/0000-0003-2552-9595	Japanese Ministry of Education, Culture, Sports, Science, and Technology [25861637, 24659764]	This work was supported by the Japanese Ministry of Education, Culture, Sports, Science, and Technology, grants #25861637 (to Y.M.) and #24659764 (to T.I.). The authors indicate no conflict of interest associated with this study.	Fukuda S, 2013, STEM CELLS, V31, P2149, DOI 10.1002/stem.1469; Daiger SP, 2013, CLIN GENET, V84, P132, DOI 10.1111/cge.12203; Ladas JG, 2005, SURV OPHTHALMOL, V50, P27, DOI 10.1016/j.survophthal.2004.10.004; Ransohoff RM, 2012, J CLIN INVEST, V122, P1164, DOI 10.1172/JCI58644; OSHIKA T, 1989, JPN J OPHTHALMOL, V33, P237; Zeng HY, 2005, INVEST OPHTH VIS SCI, V46, P2992, DOI 10.1167/iovs.05-0118; Guo CR, 2012, EXP EYE RES, V104, P39, DOI 10.1016/j.exer.2012.08.013; Kohno H, 2014, J IMMUNOL, V192, P3816, DOI 10.4049/jimmunol.1301738; Hartong DT, 2006, LANCET, V368, P1795, DOI 10.1016/S0140-6736(06)69740-7; Zitvogel L, 2010, CELL, V140, P798, DOI 10.1016/j.cell.2010.02.015; Gupta N, 2003, EXP EYE RES, V76, P463, DOI 10.1016/S0014-4835(02)00332-9; Murakami Y, 2012, P NATL ACAD SCI USA, V109, P14598, DOI 10.1073/pnas.1206937109; Wright AF, 2010, NAT REV GENET, V11, P273, DOI 10.1038/nrg2717; Ikeda Y, 2013, BRIT J OPHTHALMOL, V97, P1187, DOI 10.1136/bjophthalmol-2012-303005; Yoshida N, 2013, OPHTHALMOLOGY, V120, pE5, DOI 10.1016/j.ophtha.2012.07.008; Fahim AT, 2000, GENEREVIEWS; Ikeda Y, 2012, GRAEF ARCH CLIN EXP, V250, P809, DOI 10.1007/s00417-011-1904-5; Kubota T, 1996, GRAEF ARCH CLIN EXP, V234, P285, DOI 10.1007/BF00220701; Kuchle M, 1998, GRAEF ARCH CLIN EXP, V236, P426, DOI 10.1007/s004170050101; NEWSOME DA, 1988, AM J OPHTHALMOL, V105, P596; NGUYEN NX, 1995, OPHTHALMOLOGICA, V209, P145; OSHIKA T, 1990, INVEST OPHTH VIS SCI, V31, P527; Sasahara M, 2008, AM J PATHOL, V172, P1693, DOI 10.2353/ajpath.2008.080024; SAWA M, 1988, JPN J OPHTHALMOL, V32, P132; Schroder S, 2012, RETINA-J RET VIT DIS, V32, P38, DOI 10.1097/IAE.0b013e3182173753; SHAH SM, 1991, BRIT J OPHTHALMOL, V75, P348, DOI 10.1136/bjo.75.6.348; Viringipurampeer I.A., 2013, INT J INFLAM, V2013; Yoshida N, 2013, OPHTHALMOLOGY, V120, P100, DOI 10.1016/j.ophtha.2012.07.006	28	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0002-9394	1879-1891		AM J OPHTHALMOL	Am. J. Ophthalmol.	MAY	2015	159	5					958	963		10.1016/j.ajo.2015.02.001		6	Ophthalmology	Ophthalmology	CG5VW	WOS:000353365000018		
J	Sekiyama, M; Roosita, K; Ohtsuka, R				Sekiyama, Makiko; Roosita, Katrin; Ohtsuka, Ryutaro			Developmental Stage-dependent Influence of Environmental Factors on Growth of Rural Sundanese Children in West Java, Indonesia	AMERICAN JOURNAL OF PHYSICAL ANTHROPOLOGY			English	Article						child growth; IGF-I; IGFBP-3; dietary intake; anemia; helminthiasis; Indonesia	IGF-BINDING PROTEIN-3; DAILY IRON SUPPLEMENTATION; FACTOR-I; PRESCHOOL-CHILDREN; WUCHERERIA-BANCROFTI; HELMINTH INFECTIONS; INTESTINAL HELMINTH; REFERENCE VALUES; FACTOR (IGF)-I; BONE TURNOVER	This study investigated the growth trajectories and the relative relevance levels of nutrition, disease, and hormonal status at various developmental stages among children in adverse environments to provide population-based empirical evidence for the life history theory. Three years of longitudinal anthropometric data in 1-year intervals were obtained from 418 boys and girls aged 0 to 12 years at recruitment. Following the final measurement, the main survey, which included blood and feces sampling, 3-h interval food consumption recall surveys for energy and nutrient intakes and anthropometry, was performed. Blood and feces were used for detecting, respectively, anemia and hormonal (IGF-I and IGFBP-3) levels as well as intestinal helminthiasis (Ascaris, Trichuris, and hookworm). The major findings of this study are summarized as follows: 1) the growth velocity of the subject children lagged behind international standards during childhood and juvenility but caught up during early adolescence; 2) diseases, both intestinal helminths and anemia, had significant effects on growth in childhood but not at older ages; and 3) hormonal status significantly affected growth in the children, with its highest significance in early adolescence. A larger growth than international standards in early adolescence likely follows programmed hormonal mechanisms after the onset of puberty. The onset of puberty might be associated with adequate amounts of nutrient intake and be mediated by hormonal function, because the IGF-IZ score was significantly correlated with energy and protein intakes at the transitional period from juvenility to adolescence, when puberty occurs. Am J Phys Anthropol 157:94-106, 2015. (c) 2015 Wiley Periodicals, Inc.	[Sekiyama, Makiko] Univ Tokyo, GPSS, Grad Sch Frontier Sci, Kashiwa, Chiba 2778563, Japan; [Roosita, Katrin] Bogor Agr Univ, Fac Human Ecol, Dept Community Nutr, Bogor 16680, Indonesia; [Ohtsuka, Ryutaro] Japan Wildlife Res Ctr, Tokyo 1308606, Japan	Sekiyama, M (reprint author), Univ Tokyo, GPSS, Grad Sch Frontier Sci, 5-1-5 Kashiwanoha, Kashiwa, Chiba 2778563, Japan.	sekiyama@k.u-tokyo.ac.jp			Japan Society for the Promotion of Science (JSPS)	Grant sponsor: Japan Society for the Promotion of Science (JSPS) Core University Program between The University of Tokyo and Bogor Agricultural University.	Alberti C, 2011, CLIN CHEM, V57, P1424, DOI 10.1373/clinchem.2011.169466; ANGELES IT, 1993, AM J CLIN NUTR, V58, P339; Rikken B, 1998, HORM RES, V50, P166, DOI 10.1159/000023268; Black RE, 2002, AM J CLIN NUTR, V76, P675; Nematian J, 2008, ANN TROP MED PARASIT, V102, P209, DOI 10.1179/136485908X267876; BLUM WF, 1993, J CLIN ENDOCR METAB, V76, P1610, DOI 10.1210/jc.76.6.1610; Gurven M, 2006, P ROY SOC B-BIOL SCI, V273, P835, DOI 10.1098/rspb.2005.3380; McDade TW, 2003, YEARB PHYS ANTHROPOL, V46, P100, DOI 10.1002/ajpa.10398; JUUL A, 1994, J CLIN ENDOCR METAB, V78, P744, DOI 10.1210/jc.78.3.744; Hadi H, 2000, AM J CLIN NUTR, V71, P507; Juul A, 2003, GROWTH HORM IGF RES, V13, P113, DOI 10.1016/S1096-6374(03)00038-8; Lofqvist C, 2001, J CLIN ENDOCR METAB, V86, P5870, DOI 10.1210/jc.86.12.5870; Hoppe C, 2004, AM J CLIN NUTR, V80, P447; Budek AZ, 2007, J NUTR, V137, P930; Sungthong R, 2002, J NUTR, V132, P418; Misra M, 2004, PEDIATRICS, V114, P1574, DOI 10.1542/peds.2004-0540; Bogin B, 2009, AM J HUM BIOL, V21, P567, DOI 10.1002/ajhb.20895; Ulijaszek SJ, 2006, FOOD NUTR BULL, V27, pS279; Norgan NG, 2012, HUMAN GROWTH AND DEVELOPMENT, 2ND EDITION, P123, DOI 10.1016/B978-0-12-383882-7.00006-4; Sekiyama M, 2012, ASIA PAC J CLIN NUTR, V21, P558; Bernstein RM, 2010, AM J PHYS ANTHROPOL, P46, DOI 10.1002/ajpa.21440; LAWLESS JW, 1994, J NUTR, V124, P645; Isojima T, 2012, ENDOCR J, V59, P771; Crompton DWT, 2002, ANNU REV NUTR, V22, P35, DOI 10.1146/annurev.nutr.22.120501.134539; Vucic V, 2013, NUTR REV, V71, P386, DOI 10.1111/nure.12037; Stoltzfus RJ, 2004, J NUTR, V134, P348; Beach MJ, 1999, AM J TROP MED HYG, V60, P479; Belgorosky A, 1998, HORM RES, V49, P226, DOI 10.1159/000023176; Bhargava Alok, 2003, Food and Nutrition Bulletin, V24, P332; Bogin B., 1999, PATTERNS HUMAN GROWT; de Icaya PM, 2000, ANN NUTR METAB, V44, P139; Department of Health Indonesia (Departemen Kesehatan RI Direktorat Jenderal Pembinaan Kesehatan Masyarakat), 1995, FOOD COMP TABL IND; desOnis M., 2007, B WORLD HEALTH ORGAN, V85, P660, DOI DOI 10.2471/BLT.07.043497; Dossa RAM, 2001, J NUTR, V131, P2874; DROOMERS M, 1995, EUR J CLIN NUTR, V49, P740; Ellison PT, 2012, HUMAN GROWTH AND DEVELOPMENT, 2ND EDITION, P81, DOI 10.1016/B978-0-12-383882-7.00004-0; Eveleth P.B., 1990, WORLDWIDE VARIATION; FAO/WHO/UNU Expert Consultation, 1985, WHO TECHNICAL REPORT, V724; Fox LM, 2005, AM J TROP MED HYG, V73, P115; Haas JD, 2006, FOOD NUTR BULL, V27, pS212; Hall A, 2008, MATERN CHILD NUTR, V4, P118, DOI 10.1111/j.1740-8709.2007.00127.x; Hardinsyah Briawan D., 1990, PENILAIAN PERENCANAA; Jaruratanasirikul Somchit, 1999, Journal of the Medical Association of Thailand, V82, P984; Jinabhai CC, 2001, PUBLIC HEALTH NUTR, V4, P1211, DOI 10.1079/PHN2001180; Juul A, 2001, HORM RES, V55, P94, DOI 10.1159/000063483; Kerver JM, 2010, AM J CLIN NUTR, V91, P643, DOI 10.3945/ajcn.2009.28205; Leigh SR., 2001, EVOL ANTHROPOL, V10, P455; McDade TW, 2008, AM J PHYS ANTHROPOL, V136, P478, DOI 10.1002/ajpa.20831; National Development Planning Board (Badan Perencanaan Pembangunan National), 1996, PROGR MAK TAMB AN SE; Nazaimoon WMW, 1996, CLIN ENDOCRINOL, V45, P79; Ohyama K., 2004, YAMANASHI NURS J, V3, P3; Pari HM, 2001, GIZI INDONESIA, V25, P1; Pegelow K., 1997, Southeast Asian Journal of Tropical Medicine and Public Health, V28, P173; Preece MA, 1984, HUMAN GROWTH DEV, P22; Rao MR, 2002, ACTA PAEDIATR, V91, P267, DOI 10.1080/08035250252833905; Rosenfeld RG, 2012, HUMAN GROWTH AND DEVELOPMENT, 2ND EDITION, P109, DOI 10.1016/B978-0-12-383882-7.00005-2; Sachdev HPS, 2006, PUBLIC HEALTH NUTR, V9, P904, DOI 10.1017/PHN2005918; Sari M, 2001, AM J CLIN NUTR, V73, P1034; Sekiyama M, 2004, J BIOSOC SCI, V37, P413; Statistics Bogor (Badan Pusat Statistik Kabupaten Bogor), 2013, KECAMATAN TAMANSARI; Stinson S., 2000, HUMAN BIOL EVOLUTION, P425; Stoltzfus RJ, 2001, NESTLE NUTR WORKS SE, V47, P257; Turan S, 2007, EUR J CLIN NUTR, V61, P752, DOI 10.1038/sj.ejcn.1602575; Weiner JS, 1981, PRACTICAL HUMAN BIOL; WHO Working Group, 1987, WHO TECHNICAL REPORT, V749; World Health Organization, 2001, IR DEF AN ASS PREV C; World Health Organization Multicentre Growth Reference Study Group, 2006, WHO CHILD GROWTH STA; Xu Shanshan, 2010, Endocr J, V57, P221	68	1	1	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0002-9483	1096-8644		AM J PHYS ANTHROPOL	Am. J. Phys. Anthropol.	MAY	2015	157	1					94	106		10.1002/ajpa.22692		13	Anthropology; Evolutionary Biology	Anthropology; Evolutionary Biology	CG6MA	WOS:000353414000008		
J	Abe, T; Ishii, D; Gorbacheva, V; Kohei, N; Tsuda, H; Tanaka, T; Dvorina, N; Nonomura, N; Takahara, S; Valujskikh, A; Baldwin, WM; Fairchild, RL				Abe, T.; Ishii, D.; Gorbacheva, V.; Kohei, N.; Tsuda, H.; Tanaka, T.; Dvorina, N.; Nonomura, N.; Takahara, S.; Valujskikh, A.; Baldwin, W. M., III; Fairchild, R. L.			Anti-huCD20 Antibody Therapy for Antibody-Mediated Rejection of Renal Allografts in a Mouse Model	AMERICAN JOURNAL OF TRANSPLANTATION			English	Article							ENDOTHELIAL-CELL ACTIVATION; KIDNEY-TRANSPLANTATION; ORGAN-TRANSPLANTATION; CARDIAC ALLOGRAFTS; HUMORAL REJECTION; INJURY; DEPOSITION; RECIPIENTS; IMMUNITY; FAILURE	We have reported that B6.CCR5(-/-) mice reject renal allografts with high serum donor-specific antibody (DSA) titers and marked C4d deposition in grafts, features consistent with antibody-mediated rejection (AMR). B6.huCD20/CCR5(-/-) mice, where human CD20 expression is restricted to B cells, rejected A/J renal allografts by day 26 posttransplant with DSA first detected in serum on day 5 posttransplant and increased thereafter. Recipient treatment with anti-huCD20 mAb prior to the transplant and weekly up to 7 weeks posttransplant promoted long-term allograft survival (>100 days) with low DSA titers. To investigate the effect of B cell depletion at the time serum DSA was first detected, recipients were treated with anti-huCD20 mAb on days 5, 8, and 12 posttransplant. This regimen significantly reduced DSA titers and graft inflammation on day 15 posttransplant and prolonged allograft survival >60 days. However, DSA returned to the titers observed in control treated recipients by day 30 posttransplant and histological analyses on day 60 posttransplant indicated severe interstitial fibrosis. These results indicate that anti-huCD20 mAb had the greatest effect as a prophylactic treatment and that the distinct kinetics of DSA responses accounts for acute renal allograft failure versus the development of fibrosis.	[Abe, T.; Ishii, D.; Kohei, N.; Tsuda, H.; Tanaka, T.; Valujskikh, A.; Baldwin, W. M., III; Fairchild, R. L.] Cleveland Clin Fdn, Glickman Urol & Kidney Inst, Cleveland, OH 44195 USA; [Abe, T.; Ishii, D.; Gorbacheva, V.; Kohei, N.; Tsuda, H.; Tanaka, T.; Dvorina, N.; Valujskikh, A.; Baldwin, W. M., III; Fairchild, R. L.] Cleveland Clin Fdn, Dept Immunol, Cleveland, OH 44195 USA; [Abe, T.; Nonomura, N.] Osaka Univ, Grad Sch Med, Dept Specif Organ Regulat Urol, Suita, Osaka, Japan; [Ishii, D.] Kitasato Univ, Dept Urol, Sagamihara, Kanagawa 228, Japan; [Takahara, S.] Osaka Univ, Grad Sch Med, Dept Adv Technol Transplantat, Suita, Osaka, Japan; [Baldwin, W. M., III; Fairchild, R. L.] Case Western Reserve Univ, Sch Med, Dept Pathol, Cleveland, OH 44106 USA	Fairchild, RL (reprint author), Cleveland Clin Fdn, Glickman Urol & Kidney Inst, 9500 Euclid Ave, Cleveland, OH 44195 USA.	fairchr@ccf.org			NIH [PO1 AI087506]; NIAID/NIH	The authors thank the staff of the Cleveland Clinic Biological Resources Unit for excellent care of the animals used in this study and Genentech for providing the human CD20 transgenic mice. The authors also thank members of the Fairchild and Valujskikh lab for helpful comments during the course of this work. This work was supported by grant NIH PO1 AI087506 from the NIAID/NIH to AV, WMB, and RLF.	Kohei N, 2012, AM J TRANSPLANT, V12, P469, DOI 10.1111/j.1600-6143.2011.03830.x; Trpkov K, 1996, TRANSPLANTATION, V61, P1586, DOI 10.1097/00007890-199606150-00007; Racusen LC, 2003, AM J TRANSPLANT, V3, P708, DOI 10.1034/j.1600-6143.2003.00072.x; Einecke G, 2009, AM J TRANSPLANT, V9, P2520, DOI 10.1111/j.1600-6143.2009.02799.x; ZHANG Z, 1995, MICROSURG, V16, P103, DOI 10.1002/micr.1920160212; Loupy A, 2012, NAT REV NEPHROL, V8, P348, DOI 10.1038/nrneph.2012.81; Barr TA, 2012, J EXP MED, V209, P1001, DOI 10.1084/jem.20111675; Uber WE, 2007, AM J TRANSPLANT, V7, P2064, DOI 10.1111/j.1600-6143.2007.01900.x; Colvin RB, 2005, NAT REV IMMUNOL, V5, P807, DOI 10.1038/nri1702; Taflin C, 2011, IMMUNOL LETT, V139, P1, DOI 10.1016/j.imlet.2011.04.014; Monsinjon T, 2003, FASEB J, V17, P1003, DOI 10.1096/fj.02-0737com; Takemoto SK, 2004, AM J TRANSPLANT, V4, P1033, DOI 10.1111/j.1600-6143.2004.00500.x; Zhang X, 2009, AM J TRANSPLANT, V9, P2459, DOI 10.1111/j.1600-6143.2009.02819.x; Albrecht EA, 2004, AM J PATHOL, V164, P849, DOI 10.1016/S0002-9440(10)63173-2; Regele H, 2002, J AM SOC NEPHROL, V13, P2371, DOI 10.1097/01.ASN.0000025780.03790.0F; Saadi S, 2000, CIRCULATION, V101, P1867; Solez K, 2007, AM J TRANSPLANT, V7, P518, DOI 10.1111/j.1600-6143.2006.01688.x; Bickerstaffa A, 2008, AM J TRANSPLANT, V8, P557, DOI 10.1111/j.1600-6143.2007.02125.x; Gloor J, 2008, AM J TRANSPLANT, V8, P1367, DOI 10.1111/j.1600-6143.2008.02262.x; Han WR, 1999, MICROSURG, V19, P272, DOI 10.1002/(SICI)1098-2752(1999)19:6<272::AID-MICR3>3.0.CO;2-L; Hattori Y, 2012, AM J TRANSPLANT, V12, P2017, DOI 10.1111/j.1600-6143.2012.04073.x; Loupy A, 2010, TRANSPLANTATION, V89, P1403, DOI 10.1097/TP.0b013e3181da1cc3; Murata K, 2007, AM J TRANSPLANT, V7, P2605, DOI 10.1111/j.1600-6143.2007.01971.x; Nozaki T, 2007, J IMMUNOL, V179, P5238; Saadi S, 2002, XENOTRANSPLANTATION, V9, P239, DOI 10.1034/j.1399-3089.2002.02042.x; Sellares J, 2012, AM J TRANSPLANT, V12, P389; Terasaki P, 2006, CLIN J AM SOC NEPHRO, V1, P400, DOI 10.2215/CJN.02311205	27	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1600-6135	1600-6143		AM J TRANSPLANT	Am. J. Transplant.	MAY	2015	15	5					1192	1204		10.1111/ajt.13150		13	Surgery; Transplantation	Surgery; Transplantation	CG5ML	WOS:000353335900013		
J	Tanaka, Y; Noda, K; Isse, K; Tobita, K; Maniwa, Y; Bhama, JK; D'Cunha, J; Bermudez, A; Luketich, JD; Shigemura, N				Tanaka, Y.; Noda, K.; Isse, K.; Tobita, K.; Maniwa, Y.; Bhama, J. K.; D'Cunha, J.; Bermudez, A.; Luketich, J. D.; Shigemura, N.			A Novel Dual Ex Vivo Lung Perfusion Technique Improves Immediate Outcomes in an Experimental Model of Lung Transplantation	AMERICAN JOURNAL OF TRANSPLANTATION			English	Article							BRONCHIAL ARTERY REVASCULARIZATION; ISCHEMIC TISSUE REVASCULARIZATION; BRONCHIOLITIS OBLITERANS SYNDROME; MICROVASCULAR GRAFT DYSFUNCTION; HEPATOCYTE GROWTH-FACTOR; AIRWAY COMPLICATIONS; PULMONARY TRANSPLANTATION; LIVER-TRANSPLANTATION; CHRONIC REJECTION; INJURY	The lungs are dually perfused by the pulmonary artery and the bronchial arteries. This study aimed to test the feasibility of dual-perfusion techniques with the bronchial artery circulation and pulmonary artery circulation synchronously perfused using ex vivo lung perfusion (EVLP) and evaluate the effects of dual-perfusion on posttransplant lung graft function. Using rat heart-lung blocks, we developed a dual-perfusion EVLP circuit (dual-EVLP), and compared cellular metabolism, expression of inflammatory mediators, and posttransplant graft function in lung allografts maintained with dual-EVLP, standard-EVLP, or cold static preservation. The microvasculature in lung grafts after transplant was objectively evaluated using microcomputed tomography angiography. Lung grafts subjected to dual-EVLP exhibited significantly better lung graft function with reduced proinflammatory profiles and more mitochondrial biogenesis, leading to better posttransplant function and compliance, as compared with standard-EVLP or static cold preservation. Interestingly, lung grafts maintained on dual-EVLP exhibited remarkably increased microvasculature and perfusion as compared with lungs maintained on standard-EVLP. Our results suggest that lung grafts can be perfused and preserved using dual-perfusion EVLP techniques that contribute to better graft function by reducing proinflammatory profiles and activating mitochondrial respiration. Dual-EVLP also yields better posttransplant graft function through increased microvasculature and better perfusion of the lung grafts after transplantation. This study explores a method of bronchial artery perfusion during ex vivo lung perfusion in pursuit of better preserving microcirculation in lung grafts for long-term transplant outcomes.	[Tanaka, Y.; Noda, K.; Bhama, J. K.; D'Cunha, J.; Bermudez, A.; Luketich, J. D.; Shigemura, N.] Univ Pittsburgh, Med Ctr, Dept Cardiothorac Surg, Pittsburgh, PA 15260 USA; [Isse, K.] Univ Pittsburgh, Dept Pathol, Div Transplantat, Pittsburgh, PA USA; [Isse, K.] Univ Pittsburgh, Thomas E Starzl Transplantat Inst, Pittsburgh, PA USA; [Tobita, K.] Univ Pittsburgh, Dept Dev Biol, Pittsburgh, PA USA; [Tobita, K.] UPMC, Childrens Hosp Pittsburgh, Rangos Res Ctr, Anim Imaging Core, Pittsburgh, PA USA; [Tanaka, Y.; Maniwa, Y.] Kobe Univ, Grad Sch Med, Div Thorac Surg, Kobe, Hyogo 657, Japan	Shigemura, N (reprint author), Univ Pittsburgh, Med Ctr, Dept Cardiothorac Surg, Pittsburgh, PA 15260 USA.	shigemuran@upmc.edu			Department of Cardiothoracic Surgery, University of Pittsburgh Medical Center	We thank Dr. Shannon Wyszomierski for editing the manuscript. This study was supported by research funds from the Department of Cardiothoracic Surgery, University of Pittsburgh Medical Center.	Santacruz Jose Fernando, 2009, Proc Am Thorac Soc, V6, P79, DOI 10.1513/pats.200808-094GO; Khan MA, 2013, ADV EXP MED BIOL, V735, P233, DOI 10.1007/978-1-4614-4118-2_16; Yusen RD, 2013, J HEART LUNG TRANSPL, V32, P965, DOI 10.1016/j.healun.2013.08.007; Autiero M, 2003, J THROMB HAEMOST, V1, P1356, DOI 10.1046/j.1538-7836.2003.00263.x; Cai L, 2007, STEM CELLS, V25, P3234, DOI 10.1634/stemcells.2007-0388; PUMP KK, 1972, CHEST, V62, P447, DOI 10.1378/chest.62.4.447; Snoeijs MG, 2010, AM J PHYSIOL-RENAL, V299, pF1134, DOI 10.1152/ajprenal.00158.2010; Lodhi SA, 2011, AM J TRANSPLANT, V11, P1226, DOI 10.1111/j.1600-6143.2011.03539.x; Verleden GM, 2014, J HEART LUNG TRANSPL, V33, P127, DOI 10.1016/j.healun.2013.10.022; MATSUMOTO Y, 1993, TRANSPLANTATION, V56, P69, DOI 10.1097/00007890-199307000-00012; Jiang X, 2011, J CLIN INVEST, V121, P2336, DOI 10.1172/JCI46192; Einecke G, 2009, AM J TRANSPLANT, V9, P2520, DOI 10.1111/j.1600-6143.2009.02799.x; Luttun A, 2002, NAT MED, V8, P831, DOI 10.1038/nm731; Cypel M, 2011, NEW ENGL J MED, V364, P1431, DOI 10.1056/NEJMoa1014597; Balabaud C, 2004, J HEPATOL, V41, P340, DOI 10.1016/j.jhep.2004.07.001; Boehler A, 1998, CHEST, V114, P1411, DOI 10.1378/chest.114.5.1411; Cicco G, 2005, ADV EXP MED BIOL, V566, P363; COURAUD L, 1992, EUR J CARDIO-THORAC, V6, P490, DOI 10.1016/1010-7940(92)90246-T; Dhillon GS, 2010, AM J RESP CRIT CARE, V182, P230, DOI 10.1164/rccm.200910-1573OC; Grossman EJ, 2009, TRANSL RES, V153, P153, DOI 10.1016/j.trsl.2009.01.005; Inci I, 2010, CURR OPIN ORGAN TRAN, V15, P578, DOI 10.1097/MOT.0b013e32833e1127; Kamler M, 2004, J HEART LUNG TRANSPL, V23, P763, DOI 10.1016/j.healun.2003.07.016; Luckraz H, 2006, ANN THORAC SURG, V82, P1212, DOI 10.1016/j.athoracsur.2006.03.070; Luckraz H, 2004, J HEART LUNG TRANSPL, V23, P527, DOI 10.1016/j.healun.2003.07.003; Magro CM, 2003, AM J TRANSPLANT, V3, P1155, DOI 10.1034/j.1600-6143.2003.00168.x; Mazzali M, 2003, KIDNEY INT, V63, P2088, DOI 10.1046/j.1523-1755.2003.00011.x; Nicolls MR, 2010, CURR OPIN ORGAN TRAN, V15, P563, DOI 10.1097/MOT.0b013e32833deca9; Noda K, 2014, EUR J CARDIO-THORAC, V45, pE54, DOI 10.1093/ejcts/ezt598; Norgaard MA, 1998, EUR J CARDIO-THORAC, V14, P311, DOI 10.1016/S1010-7940(98)00182-1; Olthoff KM, 2002, WORLD J SURG, V26, P831, DOI 10.1007/s00268-002-4060-6; Orens Jonathan B, 2009, Proc Am Thorac Soc, V6, P13, DOI 10.1513/pats.200807-072GO; PATTERSON GA, 1993, ANN THORAC SURG, V56, P807; Pettersson G, 1997, J HEART LUNG TRANSPL, V16, P320; Pettersson GB, 2010, CURR OPIN ORGAN TRAN, V15, P572, DOI 10.1097/MOT.0b013e32833e16fc; Pettersson GB, 2013, J THORAC CARDIOV SUR, V146, P894, DOI 10.1016/j.jtcvs.2013.04.030; Puhl G, 2004, J HEPATOL, V41, P299, DOI 10.1016/j.jhep.2004.04.017; Schreinemakers HH, 1990, ANN THORAC SURG, V49, P53; SCHREINEMAKERS HHJ, 1990, ANN THORAC SURG, V49, P44; Schwartz RS, 2011, NEW ENGL J MED, V364, P656, DOI 10.1056/NEJMra0910283; Shigemura N, 2005, CIRCULATION, V111, P1407, DOI 10.1161/01.CIR.0000158433.89103.85; Shigemura N, 2012, AM J TRANSPLANT, V12, P1249, DOI 10.1111/j.1600-6143.2011.03946.x; Suzuki T, 2003, ANAT EMBRYOL, V207, P95, DOI 10.1007/s00429-003-0332-7; Varela A, 1997, J THORAC CARDIOV SUR, V114, P1119, DOI 10.1016/S0022-5223(97)70029-1; Venuta F, 1999, J THORAC CARDIOV SUR, V118, P107, DOI 10.1016/S0022-5223(99)70149-2; Weder W, 2009, EUR J CARDIO-THORAC, V35, P293, DOI 10.1016/j.ejcts.2008.09.035; Wilkes DS, 2010, AM J RESP CRIT CARE, V182, P136, DOI 10.1164/rccm.201004-0508ED; Schafers HJ, 1996, EUR J CARDIO-THORAC, V10, P526; Wilson IC, 1996, EUR J CARDIO-THORAC, V10, P521, DOI 10.1016/S1010-7940(96)80418-0	48	1	1	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1600-6135	1600-6143		AM J TRANSPLANT	Am. J. Transplant.	MAY	2015	15	5					1219	1230		10.1111/ajt.13109		12	Surgery; Transplantation	Surgery; Transplantation	CG5ML	WOS:000353335900015		
J	Abe, Y; Ohkuri, T; Yoshitomi, S; Murakami, S; Ueda, T				Abe, Yoshito; Ohkuri, Takatoshi; Yoshitomi, Sachiko; Murakami, Shigeru; Ueda, Tadashi			Role of the osmolyte taurine on the folding of a model protein, hen egg white lysozyme, under a crowding condition	AMINO ACIDS			English	Article						Crowding; Lysozyme; NMR; Protein folding; Osmolyte, taurine	ENDOPLASMIC-RETICULUM STRESS; TRIMETHYLAMINE-N-OXIDE; AMYLOID AGGREGATION; DISORDERS; SUCROSE; CELLS; WATER	Taurine is one of the osmolytes that maintain the structure of proteins in cells exposed to denaturing environmental stressors. Recently, cryoelectron tomographic analysis of eukaryotic cells has revealed that their cytoplasms are crowded with proteins. Such crowding conditions would be expected to hinder the efficient folding of nascent polypeptide chains. Therefore, we examined the role of taurine on the folding of denatured and reduced lysozyme, as a model protein, under a crowding condition. The results confirmed that taurine had a better effect on protein folding than did beta-alanine, which has a similar chemical structure, when the protein to be folded was present at submillimolar concentration. NMR analyses further revealed that under the crowding condition, taurine had more interactions than did beta-alanine with the lysozyme molecule in both the folded and denatured states. We concluded that taurine improves the folding of the reduced lysozyme at submillimolar concentration to allow it to interact more favorably with the lysozyme molecule. Thus, the role of taurine, as an osmolyte in vivo, may be to assist in the efficient folding of proteins.	[Abe, Yoshito; Ohkuri, Takatoshi; Yoshitomi, Sachiko; Ueda, Tadashi] Kyushu Univ, Grad Sch Pharmaceut Sci, Fukuoka 8128582, Japan; [Ohkuri, Takatoshi] Sojo Univ, Fac Pharmaceut Sci, Kumamoto 8600082, Japan; [Murakami, Shigeru] Taisho Pharmaceut Co Ltd, Self Medicat Business, R&D Headquarters, Tokyo 1708633, Japan	Ueda, T (reprint author), Kyushu Univ, Grad Sch Pharmaceut Sci, Fukuoka 8128582, Japan.	ueda@phar.kyushu-u.ac.jp	Abe, Yoshito/D-8370-2012	Abe, Yoshito/0000-0002-0016-8490			YANCEY PH, 1982, SCIENCE, V217, P1214, DOI 10.1126/science.7112124; [Anonymous], 2014, BBA-MOL CELL RES, DOI DOI 10.1016/J.BBAMCR.2014.01.012; Hu CY, 2010, PROTEINS, V78, P695, DOI 10.1002/prot.22598; KITA Y, 1994, BIOCHEMISTRY-US, V33, P15178, DOI 10.1021/bi00254a029; Xiao C, 2008, DIABETOLOGIA, V51, P139, DOI 10.1007/s00125-007-0859-x; Fujii T, 2007, J BIOCHEM, V141, P699, DOI 10.1093/jb/mvm075; Athawale MV, 2005, BIOPHYS J, V89, P858, DOI 10.1529/biophysj.104.056671; Bounedjah O, 2012, J BIOL CHEM, V287, P2446, DOI 10.1074/jbc.M111.292748; TIMASHEFF SN, 1993, ANNU REV BIOPH BIOM, V22, P67, DOI 10.1146/annurev.bb.22.060193.000435; Doyle KM, 2011, J CELL MOL MED, V15, P2025, DOI 10.1111/j.1582-4934.2011.01374.x; SAXENA VP, 1970, BIOCHEMISTRY-US, V9, P5015; Oprescu AI, 2007, DIABETES, V56, P2927, DOI 10.2337/db07-0075; Emadi S, 2014, BIOCHEM BIOPH RES CO, V450, P1339, DOI 10.1016/j.bbrc.2014.06.133; Zhou HX, 2013, FEBS LETT, V587, P1053, DOI 10.1016/j.febslet.2013.01.064; Sun QR, 2014, BIOCHEM BIOPH RES CO, V447, P485, DOI 10.1016/j.bbrc.2014.04.019; Pan CL, 2012, AMINO ACIDS, V43, P845, DOI 10.1007/s00726-011-1141-6; Abe M, 2013, PROTEIN SCI, V22, P467, DOI 10.1002/pro.2228; GOLDBERG ME, 1991, BIOCHEMISTRY-US, V30, P2790, DOI 10.1021/bi00225a008; Medalia O, 2002, SCIENCE, V298, P1209, DOI 10.1126/science.1076184; Warskulat U, 2007, METHOD ENZYMOL, V428, P439, DOI 10.1016/S0076-6879(07)28025-5; ARAKAWA T, 1990, BIOCHEMISTRY-US, V29, P1924, DOI 10.1021/bi00459a037; Gazova Z, 2013, PROTEINS, V81, P994, DOI 10.1002/prot.24250; Ozcan L, 2012, ANNU REV MED, V63, P317, DOI 10.1146/annurev-med-043010-144749; LEE JC, 1981, J BIOL CHEM, V256, P7193; STURMAN JA, 1975, J NEUROCHEM, V25, P831, DOI 10.1111/j.1471-4159.1975.tb04414.x; BUCK M, 1995, BIOCHEMISTRY-US, V34, P13219, DOI 10.1021/bi00040a038; Dubey K, 2014, BIOCHEM BIOPH RES CO, V448, P480, DOI 10.1016/j.bbrc.2014.04.135; Gao MT, 2013, BIOTECHNOL PROGR, V29, P1316, DOI 10.1002/btpr.1766; Imoto T., 1972, ENZYMES, P665, DOI 10.1016/S1874-6047(08)60465-5; IRVING CS, 1980, J INORG BIOCHEM, V13, P137, DOI 10.1016/S0162-0134(00)80117-8; Ito T, 2010, J BIOMED SCI, V17, DOI 10.1186/1423-0127-17-S1-S20; Mine S, 1999, FEBS LETT, V448, P33, DOI 10.1016/S0014-5793(99)00332-4; Murakami S, 2014, AMINO ACIDS, V46, P73, DOI 10.1007/s00726-012-1432-6; Roysommuti S, 2014, AMINO ACIDS, V46, P57, DOI 10.1007/s00726-012-1417-5; Schaffer S, 2003, ADV EXP MED BIOL, V526, P307; Sturman J A, 1983, Prog Clin Biol Res, V125, P281; Ueda T, 2001, J BIOCHEM-TOKYO, V130, P491; UEDA T, 1990, J BIOCHEM-TOKYO, V108, P886; YAMADA H, 1994, J BIOCHEM-TOKYO, V116, P852	39	0	0	SPRINGER WIEN	WIEN	SACHSENPLATZ 4-6, PO BOX 89, A-1201 WIEN, AUSTRIA	0939-4451	1438-2199		AMINO ACIDS	Amino Acids	MAY	2015	47	5					909	915		10.1007/s00726-015-1918-0		7	Biochemistry & Molecular Biology	Biochemistry & Molecular Biology	CG1SI	WOS:000353053900005		
J	Matsuda, S; Katane, M; Maeda, K; Kaneko, Y; Saitoh, Y; Miyamoto, T; Sekine, M; Homma, H				Matsuda, Satsuki; Katane, Masumi; Maeda, Kazuhiro; Kaneko, Yuusuke; Saitoh, Yasuaki; Miyamoto, Tetsuya; Sekine, Masae; Homma, Hiroshi			Biosynthesis of daspartate in mammals: the rat and human homologs of mouse aspartate racemase are not responsible for the biosynthesis of daspartate	AMINO ACIDS			English	Article						Aspartate racemase; D-Aspartate; D-Amino acid; Amino acid racemase; Glutamate-oxaloacetate transaminase	AMINO-ACID ENANTIOMERS; HUMAN SERINE RACEMASE; GLUTAMATE TRANSPORTER; FUNCTIONAL-CHARACTERIZATION; L-CYSTEINE; BRAIN; RECEPTOR; OXIDASE; CELLS; IDENTIFICATION	d-Aspartate (d-Asp) has important physiological functions, and recent studies have shown that substantial amounts of free d-Asp are present in a wide variety of mammalian tissues and cells. Biosynthesis of d-Asp has been observed in several cultured rat cell lines, and a murine gene (glutamate-oxaloacetate transaminase 1-like 1, Got1l1) that encodes Asp racemase, a synthetic enzyme that produces d-Asp from l-Asp, was proposed recently. The product of this gene is homologous to mammalian glutamate-oxaloacetate transaminase (GOT). Here, we tested the hypothesis that rat and human homologs of mouse GOT1L1 are involved in Asp synthesis. The following two approaches were applied, since the numbers of attempts were unsuccessful to prepare soluble GOT1L1 recombinant proteins. First, the relationship between the d-Asp content and the expression levels of the mRNAs encoding GOT1L1 and d-Asp oxidase, a primary degradative enzyme of d-Asp, was examined in several rat and human cell lines. Second, the effect of knockdown of the Got1l1 gene on d-Asp biosynthesis during culture of the cells was determined. The results presented here suggest that the rat and human homologs of mouse GOT1L1 are not involved in d-Asp biosynthesis. Therefore, d-Asp biosynthetic pathway in mammals is still an urgent issue to be resolved.	[Matsuda, Satsuki; Katane, Masumi; Maeda, Kazuhiro; Kaneko, Yuusuke; Saitoh, Yasuaki; Miyamoto, Tetsuya; Sekine, Masae; Homma, Hiroshi] Kitasato Univ, Grad Sch Pharmaceut Sci, Lab Biomol Sci, Minato Ku, Tokyo 1088641, Japan	Homma, H (reprint author), Kitasato Univ, Grad Sch Pharmaceut Sci, Lab Biomol Sci, Minato Ku, 5-9-1 Shirokane, Tokyo 1088641, Japan.	hommah@pharm.kitasato-u.ac.jp			Japan Society for the Promotion of Science [24590090]; Kitasato University	This work was supported by a Grant-in-Aid for Scientific Research (24590090) from the Japan Society for the Promotion of Science and a Kitasato University Research Grant for Young Researchers (to M.K.).	Wolosker H, 1999, P NATL ACAD SCI USA, V96, P721, DOI 10.1073/pnas.96.2.721; KANAI Y, 1992, NATURE, V360, P467, DOI 10.1038/360467a0; Wolosker H, 2000, NEUROSCIENCE, V100, P183, DOI 10.1016/S0306-4522(00)00321-3; OLVERMAN HJ, 1988, NEUROSCIENCE, V26, P17, DOI 10.1016/0306-4522(88)90124-8; Ota N, 2012, AMINO ACIDS, V43, P1873, DOI 10.1007/s00726-012-1364-1; Katane M, 2010, CHEM BIODIVERS, V7, P1435, DOI 10.1002/cbdv.200900250; NIMURA N, 1986, J CHROMATOGR, V352, P169, DOI 10.1016/S0021-9673(01)83377-X; Hoffman HE, 2009, PROTEIN EXPRES PURIF, V63, P62, DOI 10.1016/j.pep.2008.09.003; Ohide H, 2011, J CHROMATOGR B, V879, P3162, DOI 10.1016/j.jchromb.2011.06.028; Wolosker H, 1999, P NATL ACAD SCI USA, V96, P13409, DOI 10.1073/pnas.96.23.13409; Errico F, 2012, AMINO ACIDS, V43, P1861, DOI 10.1007/s00726-012-1356-1; Katane M, 2013, J MED CHEM, V56, P1894, DOI 10.1021/jm3017865; Nishikawa T, 2011, J CHROMATOGR B, V879, P3169, DOI 10.1016/j.jchromb.2011.08.030; D'Aniello G, 2005, FERTIL STERIL, V84, P1444, DOI 10.1016/j.fertnstert.2005.05.019; PINES G, 1992, NATURE, V360, P464, DOI 10.1038/360464a0; Long ZQ, 2002, ARCH BIOCHEM BIOPHYS, V404, P92, DOI 10.1016/S0003-9861(02)00241-2; Katane M, 2010, CHEM BIODIVERS, V7, P1424, DOI 10.1002/cbdv.200900294; Kim PM, 2010, P NATL ACAD SCI USA, V107, P3175, DOI 10.1073/pnas.0914706107; Wang LP, 2011, J BIOL CHEM, V286, P13765, DOI 10.1074/jbc.M110.178228; Di Fiore MM, 2014, AMINO ACIDS, V46, P1805, DOI 10.1007/s00726-014-1759-2; Long ZQ, 1998, FEBS LETT, V434, P231, DOI 10.1016/S0014-5793(98)00986-7; Arriza JL, 1997, P NATL ACAD SCI USA, V94, P4155, DOI 10.1073/pnas.94.8.4155; Shibata K, 2003, COMP BIOCHEM PHYS B, V134, P307, DOI 10.1016/S1096-4959(02)00267-1; Wolosker H, 2007, MOL NEUROBIOL, V36, P152, DOI 10.1007/s12035-007-0038-6; De Miranda J, 2000, GENE, V256, P183, DOI 10.1016/S0378-1119(00)00356-5; Konno R, 2003, NEUROSCI LETT, V349, P111, DOI 10.1016/S0304-3940(03)00801-2; HASHIMOTO A, 1992, J CHROMATOGR-BIOMED, V582, P41, DOI 10.1016/0378-4347(92)80300-F; Katane M, 2011, J CHROMATOGR B, V879, P3108, DOI 10.1016/j.jchromb.2011.03.062; Long Z, 2000, BIOCHEM BIOPH RES CO, V276, P1143, DOI 10.1006/bbrc.2000.3573; D'Aniello G, 2007, HUM REPROD, V22, P3178, DOI 10.1093/humrep/dem328; FAGG GE, 1984, P NATL ACAD SCI-BIOL, V81, P6876, DOI 10.1073/pnas.81.21.6876; Strisovsky K, 2005, BIOCHEMISTRY-US, V44, P13091, DOI 10.1021/bi051201o	32	1	1	SPRINGER WIEN	WIEN	SACHSENPLATZ 4-6, PO BOX 89, A-1201 WIEN, AUSTRIA	0939-4451	1438-2199		AMINO ACIDS	Amino Acids	MAY	2015	47	5					975	985		10.1007/s00726-015-1926-0		11	Biochemistry & Molecular Biology	Biochemistry & Molecular Biology	CG1SI	WOS:000353053900011		
J	Ramkumar, S; Fujii, N; Sakaue, H; Fujii, N; Thankappan, B; Kumari, RP; Natarajaseenivasan, K; Anbarasu, K				Ramkumar, Srinivasagan; Fujii, Noriko; Sakaue, Hiroaki; Fujii, Norihiko; Thankappan, Bency; Kumari, Rasiah Pratheepa; Natarajaseenivasan, Kalimuthusamy; Anbarasu, Kumarasamy			Real-time heterogeneous protein-protein interaction between alpha A-crystallin N-terminal mutants and alpha B-crystallin using quartz crystal microbalance (QCM)	AMINO ACIDS			English	Article						Congenital cataract; alpha A-crystallin; Protein-protein interaction; QCM; Chaperone activity	CHAPERONE-LIKE FUNCTION; AUTOSOMAL-DOMINANT CATARACT; HEAT-SHOCK PROTEINS; CONGENITAL CATARACT; LENS CRYSTALLINS; GAMMA-CRYSTALLIN; SUBUNIT EXCHANGE; MUTATION; HYDROPHOBICITY; TRANSPARENCY	The lens transparency depends on higher concentration of lens proteins and their interactions. alpha-Crystallin is one of the predominant lens proteins, responsible for proper structural and functional architecture of the lens microenvironment, and any alteration of which results in cataract formation. The R12C, R21L, R49C and R54C are the most significant and prevalent alpha A-crystallin congenital cataract-causing mutants worldwide. Protein-protein interaction, crucial for lens proper structure and function, was posited to be lost due to point mutation and the elucidation of which could shed light on the molecular basis of cataract. In this conjuncture, we report quartz crystal microbalance (QCM) as a warranted technique for real-time analysis of protein-protein interaction between the N-terminal mutants of alpha A-crystallin and alpha B-crystallin. The biophysical characteristics of the mutated proteins were determined by size-exclusion HPLC, far-UV circular dichroism and fluorescence studies. Far-UV circular dichroism spectral analysis displayed slight modifications in beta-sheet of R54C mutant. Altered intrinsic tryptophan fluorescence and decreased bis-ANS fluorescence were observed in all the N-terminal mutations revealing the tertiary structural changes and decreased exposure of surface hydrophobicity. An emphatic fall in the chaperone activity was observed in the N-terminal mutants, R12C, R21L and R54C. QCM analysis revealed the occurrence of strong heterogeneous interaction between alpha A-crystallin and alpha B-crystallin. Nevertheless, decreased interactions were observed with the N-terminal mutants. In summary, the present study concludes that the loss of interactions between alpha A-crystallin N-terminal mutants and alpha B-crystallin signifies quaternary structural alterations due to mutation in the arginine residues.	[Ramkumar, Srinivasagan; Thankappan, Bency; Kumari, Rasiah Pratheepa; Anbarasu, Kumarasamy] Bharathidasan Univ, Dept Marine Biotechnol, Tiruchchirappalli 620024, Tamil Nadu, India; [Fujii, Noriko; Sakaue, Hiroaki; Fujii, Norihiko] Kyoto Univ, Inst Res Reactor, Kumatori, Osaka 5900494, Japan; [Natarajaseenivasan, Kalimuthusamy] Bharathidasan Univ, Sch Life Sci, Dept Microbiol, Tiruchchirappalli 620024, Tamil Nadu, India	Anbarasu, K (reprint author), Bharathidasan Univ, Dept Marine Biotechnol, Tiruchchirappalli 620024, Tamil Nadu, India.	anbumbt@bdu.ac.in			Department of Science and Technology (DST), New Delhi [SR/FT/LS-153/2008/(2010-2013), DST/INT/JSPS/P-119/(2011-2013)]; DST-INSPIRE; DST-PURSE	The authors gratefully acknowledge the financial assistance from Department of Science and Technology (DST), New Delhi as DST-YS (SR/FT/LS-153/2008/(2010-2013) and DST-JSPS-Indo-Japan co-operative collaboration project (DST/INT/JSPS/P-119/(2011-2013) sanctioned to the corresponding author (Dr. KA). The 5th and 6th authors thank DST-INSPIRE and DST-PURSE for fellowship.	Speight RE, 2012, J MOL RECOGNIT, V25, P451, DOI 10.1002/jmr.2209; Andley UP, 2002, J BIOL CHEM, V277, P10178, DOI 10.1074/jbc.M109211200; Reuel NF, 2012, CHEM SOC REV, V41, P5744, DOI 10.1039/c2cs35142k; Kore R, 2012, MOL CELL BIOCHEM, V362, P93, DOI 10.1007/s11010-011-1131-8; Liang JJN, 2004, PROTEIN SCI, V13, P2476, DOI 10.1110/ps.04815104; Sharma KK, 1998, J BIOL CHEM, V273, P15474, DOI 10.1074/jbc.273.25.15474; Evgrafov OV, 2004, NAT GENET, V36, P602, DOI 10.1038/ng1354; Bera S, 2002, BIOCHEMISTRY-US, V41, P12421, DOI 10.1021/bi0204140; Marx KA, 2003, BIOMACROMOLECULES, V4, P1099, DOI 10.1021/bm020116i; Liang JJ, 2006, PROTEIN SCI, V15, P1619, DOI 10.1110/ps.062216006; Cobb BA, 2000, BIOCHEMISTRY-US, V39, P15791, DOI 10.1021/bi001453j; Kundu M, 2007, BIOPOLYMERS, V86, P177, DOI 10.1002/bip.20716; HORWITZ J, 1992, P NATL ACAD SCI USA, V89, P10449, DOI 10.1073/pnas.89.21.10449; Fujii N, 2008, BBA-PROTEINS PROTEOM, V1784, P1507, DOI 10.1016/j.bbapap.2008.06.010; Wang KY, 2001, EUR J BIOCHEM, V268, P6335, DOI 10.1046/j.0014-2956.2001.02580.x; Hsu CD, 2006, INVEST OPHTH VIS SCI, V47, P2036, DOI 10.1167/iovs.05-0524; GROENEN PJTA, 1994, EUR J BIOCHEM, V225, P1, DOI 10.1111/j.1432-1033.1994.00001.x; Graw J, 2006, GRAEF ARCH CLIN EXP, V244, P912, DOI 10.1007/s00417-005-0234-x; INGOLIA TD, 1982, P NATL ACAD SCI-BIOL, V79, P2360, DOI 10.1073/pnas.79.7.2360; LIANG JN, 1991, EXP EYE RES, V53, P61, DOI 10.1016/0014-4835(91)90145-5; Wang Y, 2007, BIOCHEM BIOPH RES CO, V356, P998, DOI 10.1016/j.bbrc.2007.03.076; Reddy GB, 2006, IUBMB LIFE, V58, P632, DOI 10.1080/15216540601010096; Ponce A, 2005, MOL VIS, V11, P752; Brady JP, 1997, P NATL ACAD SCI USA, V94, P884, DOI 10.1073/pnas.94.3.884; Shroff NP, 2000, BIOCHEMISTRY-US, V39, P1420, DOI 10.1021/bi991656b; Bhattacharyya J, 2002, J PROTEIN CHEM, V21, P65, DOI 10.1023/A:1014187300930; Kumar MS, 2005, J BIOL CHEM, V280, P21726, DOI 10.1074/jbc.M500405200; Mackay DS, 2003, EUR J HUM GENET, V11, P784, DOI 10.1038/sj.ejhg.5201046; Hansen L, 2007, INVEST OPHTH VIS SCI, V48, P3937, DOI 10.1167/iovs.07-0013; Fu L, 2002, J BIOL CHEM, V277, P4255, DOI 10.1074/jbc.M110027200; Xia CH, 2006, INVEST OPHTH VIS SCI, V47, P3004, DOI 10.1167/iovs.06-0178; Ponce A, 2006, MOL VIS, V12, P879; KOENIG SH, 1992, BIOPHYS J, V61, P776; Bova MP, 2002, J BIOL CHEM, V277, P38468, DOI 10.1074/jbc.M205594200; Chen YH, 2011, BIOCHIMIE, V93, P314, DOI 10.1016/j.biochi.2010.10.003; Chen YLS, 2012, PEPTIDES, V36, P257, DOI 10.1016/j.peptides.2012.05.011; Kannan R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065610; Kumarasamy A, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003175; MACH H, 1990, J BIOL CHEM, V265, P4844; Peterson J, 2005, EXP EYE RES, V81, P680, DOI 10.1016/j.exer.2005.04.006; Raju I, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019876; Raju I, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031421; Raju I, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028085; Ramkumar S, 2013, MOL VIS, V7, P1002; ROEDERER JE, 1983, ANAL CHEM, V55, P2333, DOI 10.1021/ac00264a030; Santhoshkumar P, 2001, J BIOL CHEM, V276, P47094, DOI 10.1074/jbc.M107737200; SIEZEN RJ, 1983, BIOPHYS CHEM, V18, P181, DOI 10.1016/0301-4622(83)80030-1	47	1	1	SPRINGER WIEN	WIEN	SACHSENPLATZ 4-6, PO BOX 89, A-1201 WIEN, AUSTRIA	0939-4451	1438-2199		AMINO ACIDS	Amino Acids	MAY	2015	47	5					1035	1043		10.1007/s00726-015-1935-z		9	Biochemistry & Molecular Biology	Biochemistry & Molecular Biology	CG1SI	WOS:000353053900017		
J	Yokose, M; Mihara, T; Sugawara, Y; Goto, T				Yokose, M.; Mihara, T.; Sugawara, Y.; Goto, T.			The predictive ability of non-invasive haemodynamic parameters for hypotension during caesarean section: a prospective observational study	ANAESTHESIA			English	Article							HEART-RATE-VARIABILITY; SPINAL-ANESTHESIA; BLOOD-PRESSURE; DELIVERY; PHENYLEPHRINE; ENTROPY; INDEX; FLUCTUATION; INDUCTION; EPHEDRINE	Spinal anaesthesia for caesarean section induces hypotension, which may cause severe adverse effects. Our goal was to determine whether hypotension could be predicted by pulse oximetry parameters, such as the perfusion index and pleth variability index, heart rate, ratio of low-frequency to high-frequency components of heart rate variability, and entropy of heart rate variability, measured before the induction of anaesthesia. The predictive value of these parameters for detecting hypotension was assessed using logistic regression and the grey zone approach in 81 parturients. Logistic regression revealed heart rate to be the only independent predictor (OR 1.06; 95% CI 1.01-1.13; p=0.032). The grey zone for heart rate was in the range of 71-89bpm, and 60.5% of parturients were in the grey zone. Pre-anaesthetic heart rate, but not other parameters derived from pulse oximetry or heart rate variability, may be a prognostic factor for hypotension associated with spinal anaesthesia.	[Yokose, M.; Goto, T.] Yokohama City Univ, Sch Med, Dept Anaesthesiol & Crit Care Med, Yokohama, Kanagawa 232, Japan; [Mihara, T.] Kanagawa Childrens Med Ctr, Dept Anaesthesiol, Yokohama, Kanagawa, Japan; [Sugawara, Y.] Yokohama City Univ, Med Ctr, Dept Anaesthesiol, Yokohama, Kanagawa 232, Japan	Yokose, M (reprint author), Yokohama City Univ, Sch Med, Dept Anaesthesiol & Crit Care Med, Yokohama, Kanagawa 232, Japan.	yokose_p12@yahoo.co.jp					AKAIKE H, 1974, IEEE T AUTOMAT CONTR, VAC19, P716, DOI 10.1109/TAC.1974.1100705; Kee WDN, 2009, ANESTHESIOLOGY, V111, P506; YOUDEN WJ, 1950, CANCER, V3, P32, DOI 10.1002/1097-0142(1950)3:1<32::AID-CNCR2820030106>3.0.CO;2-3; Lima AP, 2002, CRIT CARE MED, V30, P1210; Palazzolo JA, 1998, AM J PHYSIOL-HEART C, V274, pH1099; Dyer RA, 2009, ANESTHESIOLOGY, V111, P753, DOI 10.1097/ALN.0b013e3181b437e0; Toyama S, 2013, BRIT J ANAESTH, V111, P235, DOI 10.1093/bja/aet058; Stewart A, 2010, ANESTH ANALG, V111, P1230, DOI 10.1213/ANE.0b013e3181f2eae1; Fujiwara Y, 2007, ACTA ANAESTH SCAND, V51, P1161, DOI 10.1111/j.1399-6576.2007.01435.x; Fujiwara Y, 2007, ANESTH ANALG, V104, P853, DOI 10.1213/01.ane.0000258756.41649.2d; Coste J, 2003, INT J EPIDEMIOL, V32, P304, DOI 10.1093/ije/dyg054; Kanaya N, 2003, ANESTHESIOLOGY, V98, P34, DOI 10.1097/00000542-200301000-00009; Hanss R, 2005, ANESTHESIOLOGY, V102, P1086, DOI 10.1097/00000542-200506000-00005; Armstrong L, 2007, ARCH DIS CHILD-FETAL, V92, P430; BONICA JJ, 1972, ANESTHESIOLOGY, V36, P219, DOI 10.1097/00000542-197203000-00006; Frolich MA, 2002, CAN J ANAESTH, V49, P185; Fujiwara Y, 2007, ANAESTHESIA, V62, P117, DOI 10.1111/j.1365-2044.2006.04933.x; Jeon YT, 2010, ANESTH ANALG, V111, P712, DOI 10.1213/ANE.0b013e3181e8137b; Keller G, 2008, CRIT CARE, V12, DOI 10.1186/cc6822	19	4	4	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0003-2409	1365-2044		ANAESTHESIA	Anaesthesia	MAY	2015	70	5					555	562		10.1111/anae.12992		8	Anesthesiology	Anesthesiology	CF8HZ	WOS:000352798500009		
J	Sato, T; Zaitsu, K; Tsuboi, K; Nomura, M; Kusano, M; Shima, N; Abe, S; Ishii, A; Tsuchihashi, H; Suzuki, K				Sato, Takako; Zaitsu, Kei; Tsuboi, Kento; Nomura, Masakatsu; Kusano, Maiko; Shima, Noriaki; Abe, Shuntaro; Ishii, Akira; Tsuchihashi, Hitoshi; Suzuki, Koichi			A preliminary study on postmortem interval estimation of suffocated rats by GC-MS/MS-based plasma metabolic profiling	ANALYTICAL AND BIOANALYTICAL CHEMISTRY			English	Article						Forensics; Postmortem interval (PMI); Metabolomics; Gas chromatography-tandem mass spectrometry; Plasma; Rat	TIME; DEATH; TEMPERATURE; NMR; METHAMPHETAMINE; SPECTROSCOPY; DISEASE; MODELS; BODIES; BRAIN	Estimation of postmortem interval (PMI) is an important goal in judicial autopsy. Although many approaches can estimate PMI through physical findings and biochemical tests, accurate PMI calculation by these conventional methods remains difficult because PMI is readily affected by surrounding conditions, such as ambient temperature and humidity. In this study, Sprague-Dawley (SD) rats (10 weeks) were sacrificed by suffocation, and blood was collected by dissection at various time intervals (0, 3, 6, 12, 24, and 48 h; n = 6) after death. A total of 70 endogenous metabolites were detected in plasma by gas chromatography-tandem mass spectrometry (GC-MS/MS). Each time group was separated from each other on the principal component analysis (PCA) score plot, suggesting that the various endogenous metabolites changed with time after death. To prepare a prediction model of a PMI, a partial least squares (or projection to latent structure, PLS) regression model was constructed using the levels of significantly different metabolites determined by variable importance in the projection (VIP) score and the Kruskal-Wallis test (P < 0.05). Because the constructed PLS regression model could successfully predict each PMI, this model was validated with another validation set (n = 3). In conclusion, plasma metabolic profiling demonstrated its ability to successfully estimate PMI under a certain condition. This result can be considered to be the first step for using the metabolomics method in future forensic casework.	[Sato, Takako; Tsuboi, Kento; Nomura, Masakatsu; Abe, Shuntaro; Tsuchihashi, Hitoshi; Suzuki, Koichi] Osaka Med Coll, Dept Legal Med, Takatsuki, Osaka 5688686, Japan; [Zaitsu, Kei; Kusano, Maiko; Ishii, Akira] Nagoya Univ, Grad Sch Med, Dept Legal Med & Bioeth, Showa Ku, Nagoya, Aichi 4668550, Japan; [Shima, Noriaki] Osaka Prefectural Police Headquarters, Forens Sci Lab, Chuo Ku, Osaka 5410053, Japan	Sato, T (reprint author), Osaka Med Coll, Dept Legal Med, 2-7 Daigakumachi, Takatsuki, Osaka 5688686, Japan.	leg017@art.osaka-med.ac.jp	Ishii, Akira/I-1965-2012		Japan Society for the Promotion of Science; Ministry of Education, Culture, Sports, Science and Technology, Japan [25460880]	This work was supported by Grants-in-Aid for Scientific Research from the Japan Society for the Promotion of Science and the Ministry of Education, Culture, Sports, Science and Technology, Japan (grant No. 25460880).	Althaus L, 1999, FORENSIC SCI INT, V99, P171, DOI 10.1016/S0379-0738(98)00188-1; Kim IY, 2010, BIOCHEM BIOPH RES CO, V403, P428, DOI 10.1016/j.bbrc.2010.11.048; Hansen J, 2014, FORENSIC SCI MED PAT, V10, P322, DOI 10.1007/s12024-014-9567-2; Mitsuhashi S, 2014, CURR OPIN BIOTECH, V26, P38, DOI 10.1016/j.copbio.2013.08.020; Rasmiena AA, 2013, CLIN SCI, V124, P289, DOI 10.1042/CS20120268; Warther S, 2012, INT J LEGAL MED, V126, P399, DOI 10.1007/s00414-011-0665-3; Shima N, 2011, TOXICOLOGY, V287, P29, DOI 10.1016/j.tox.2011.05.012; Madea B, 2006, FORENSIC SCI INT, V164, P87, DOI 10.1016/j.forsciint.2005.12.002; Poloz YO, 2009, INT J LEGAL MED, V123, P305, DOI 10.1007/s00414-009-0343-x; Mao SW, 2013, LEGAL MED-TOKYO, V15, P235, DOI 10.1016/j.legalmed.2013.03.004; Nicholson JK, 2012, NATURE, V491, P384, DOI 10.1038/nature11708; Pan ZZ, 2007, ANAL BIOANAL CHEM, V387, P525, DOI 10.1007/s00216-006-0687-8; Banaschak S, 2005, INT J LEGAL MED, V119, P77, DOI 10.1007/s00414-004-0495-7; Biermann FM, 2011, FORENSIC SCI INT, V210, P82, DOI 10.1016/j.forsciint.2011.02.007; Eriksson L, 2001, MULTI MEGAVARIATE 1, V2nd; Hirakawa Keiko, 2009, Leg Med (Tokyo), V11 Suppl 1, pS282, DOI 10.1016/j.legalmed.2009.02.007; Hotelling H., 1947, TECHNIQUES STAT ANAL, P111; Hu X, 2012, ANAL BIOANAL CHEM, V404, P887, DOI 10.1007/s00216-012-6129-x; Ith M, 2011, NMR BIOMED, V24, P791, DOI 10.1002/nbm.1623; Kaliszan M, 2013, LEGAL MED-TOKYO, V15, P278, DOI 10.1016/j.legalmed.2013.06.003; Katsumata Y, 1983, JPN J LEGAL MED, V37, P75; Kimura A, 2011, INT J LEGAL MED, V125, P385, DOI 10.1007/s00414-010-0527-4; Kobayashi T, 2014, BIOCHEM BIOPH RES CO, V445, P412, DOI 10.1016/j.bbrc.2014.02.021; Le Moyec L, 2012, ANAL BIOANAL CHEM, V404, P593, DOI 10.1007/s00216-012-6165-6; Mall G, 2005, INT J LEGAL MED, V119, P185, DOI 10.1007/s00414-004-0461-4; Sampaio-Silva F, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056507; Scheurer E, 2005, NMR BIOMED, V18, P163, DOI 10.1002/nbm.934; Seiboth B, 2011, APPL MICROBIOL BIOT, V89, P1665, DOI 10.1007/s00253-010-3071-8; Singh Dalbir, 2006, Legal Medicine, V8, P279, DOI 10.1016/j.legalmed.2006.06.004; Smolinska A, 2012, ANAL BIOANAL CHEM, V403, P947, DOI 10.1007/s00216-012-5871-4; Wells J.D., 2010, FORENSIC ENTOMOLOGY, P367; Zaitsu K, 2014, ANAL BIOANAL CHEM, V406, P1339, DOI 10.1007/s00216-013-7234-1; Zapico S C, 2013, CELL MOL LIFE SCI, V71, P2957	33	0	0	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	1618-2642	1618-2650		ANAL BIOANAL CHEM	Anal. Bioanal. Chem.	MAY	2015	407	13					3659	3665		10.1007/s00216-015-8584-7		7	Biochemical Research Methods; Chemistry, Analytical	Biochemistry & Molecular Biology; Chemistry	CG4CS	WOS:000353230400012		
J	Takenaka, N; Nihata, Y; Satoh, T				Takenaka, Nobuyuki; Nihata, Yuma; Satoh, Takaya			Immunofluorescent detection of the activation of the small GTPase Rac1 in mouse skeletal muscle fibers	ANALYTICAL BIOCHEMISTRY			English	Article						Activated form; Immunofluorescent microscopy; Rac1; Skeletal muscle; Small GTPase; Subcellular localization	TRANSLOCATION	The small GTPase Rac1 acts as a molecular switch of intracellular signaling in mammals. For understanding the regulatory mechanism, it is important to identify subcellular locations in which Rac1 is activated following multiple extracellular stimuli. However, it is difficult to detect Rac1 activation in situ in animal tissues, and thus a novel method is highly desirable. Here, we report a simple method to visualize the activation of endogenous Rac1 in mouse skeletal muscle fibers. In this assay, specific interaction between activated Rac1 and a binding polypeptide is detected by immunofluorescent microscopy. This approach is readily applicable to other small GTPases. (C) 2014 Elsevier Inc. All rights reserved.	[Takenaka, Nobuyuki; Nihata, Yuma; Satoh, Takaya] Osaka Prefecture Univ, Grad Sch Sci, Dept Biol Sci, Cell Biol Lab,Naka Ku, Sakai, Osaka 5998531, Japan	Satoh, T (reprint author), Osaka Prefecture Univ, Grad Sch Sci, Dept Biol Sci, Cell Biol Lab,Naka Ku, Sakai, Osaka 5998531, Japan.	tkysato@b.s.osakafu-u.ac.jp	Satoh, Takaya/K-2628-2014		Ministry of Education, Culture, Sports, Science, and Technology of Japan [26440103]; Naito Foundation	This work was supported by Grants-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science, and Technology of Japan (26440103) and the Naito Foundation.	Chiu TT, 2011, CELL SIGNAL, V23, P1546, DOI 10.1016/j.cellsig.2011.05.022; Tapon N, 1998, EMBO J, V17, P1395, DOI 10.1093/emboj/17.5.1395; Takai Y, 2001, PHYSIOL REV, V81, P153; Huang SH, 2007, CELL METAB, V5, P237, DOI 10.1016/j.cmet.2007.03.006; Raftopoulou M, 2004, DEV BIOL, V265, P23, DOI 10.1016/j.ydbio.2003.06.003; Ueda S, 2004, CELL SIGNAL, V16, P899, DOI 10.1016/j.cellsig.2004.01.007; Wennerberg K, 2002, J BIOL CHEM, V277, P47810, DOI 10.1074/jbc.M203816200; Ueda S, 2010, FASEB J, V24, P2254, DOI 10.1096/fj.09-137380; Ieguchi K, 2007, J BIOL CHEM, V282, P23296, DOI 10.1074/jbc.M700950200; Kanemura H, 2009, BIOCHEM BIOPH RES CO, V387, P754, DOI 10.1016/j.bbrc.2009.07.108; Satoh T., 2014, SMALL GTPASES, V5; Takenaka N, 2014, FEBS J, V281, P1493, DOI 10.1111/febs.12719; Ueda S, 2008, BIOL CELL, V100, P645, DOI 10.1042/BC20070160	13	1	1	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0003-2697	1096-0309		ANAL BIOCHEM	Anal. Biochem.	MAY 1	2015	476						5	7		10.1016/j.ab.2014.09.013		3	Biochemical Research Methods; Biochemistry & Molecular Biology; Chemistry, Analytical	Biochemistry & Molecular Biology; Chemistry	CG5VR	WOS:000353364500002		
J	Nakamura, H; Karakawa, S; Watanabe, A; Kawamata, Y; Kuwahara, T; Shimbo, K; Sakai, R				Nakamura, Hidehiro; Karakawa, Sachise; Watanabe, Akiko; Kawamata, Yasuko; Kuwahara, Tomomi; Shimbo, Kazutaka; Sakai, Ryosei			Measurement of N-15 enrichment of glutamine and urea cycle amino acids derivatized with 6-aminoquinolyl-N-hydroxysuccinimidyl carbamate using liquid chromatography-tandem quadrupole mass spectrometry	ANALYTICAL BIOCHEMISTRY			English	Article						Urea cycle amino acids; LC-MS/MS; Isotopic enrichment	TERM METABOLIC-FATE; PRECOLUMN DERIVATIZATION; HUMAN PLASMA; RAT-LIVER; IONIZATION; CITRULLINE; NITROGEN; ARGININE; ORNITHINE; ELECTRON	6-Aminoquinolyl-N-hydroxysuccinimidyl carbamate (AQC) is an amino acid-specific derivatizing reagent that has been used for sensitive amino acid quantification by liquid chromatography-tandem quadrupole mass spectrometry (LC-MS/MS). In this study, we aimed to evaluate the ability of this method to measure the isotopic enrichment of amino acids and to determine the positional N-15 enrichment of urea cycle amino acids (i.e., arginine, omithine, and citrulline) and glutamine. The distribution of the M and M + 1 isotopomers of each natural AQC-amino acid was nearly identical to the theoretical distribution. The standard deviation of the (M + 1)/M ratio for each amino acid in repeated measurements was approximately 0.1%, and the ratios were stable regardless of the injected amounts. Linearity in the measurements of N-15 enrichment was confirmed by measuring a series of N-15-labeled arginine standards. The positional N-15 enrichment of urea cycle amino acids and glutamine was estimated from the isotopic distribution of unique fragment ions generated at different collision energies. This method was able to identify their positional N-15 enrichment in the plasma of rats fed 15N-labeled glutamine. These results suggest the utility of LC-MS/MS detection of AQC-amino acids for the measurement of isotopic enrichment in N-15-labeled amino acids and indicate that this method is useful for the study of nitrogen metabolism in living organisms. (C) 2015 Elsevier Inc. All rights reserved.	[Nakamura, Hidehiro; Karakawa, Sachise; Watanabe, Akiko; Kawamata, Yasuko; Kuwahara, Tomomi; Shimbo, Kazutaka; Sakai, Ryosei] Ajinomoto, Inst Innovat, Kawasaki Ku, Kawasaki, Kanagawa 2108681, Japan	Sakai, R (reprint author), Ajinomoto, Inst Innovat, Kawasaki Ku, Kawasaki, Kanagawa 2108681, Japan.	ryosei_sakai@ajinomoto.com					Dookeran NN, 1996, J MASS SPECTROM, V31, P500, DOI 10.1002/(SICI)1096-9888(199605)31:5<500::AID-JMS327>3.0.CO;2-Q; Annesley TM, 2003, CLIN CHEM, V49, P1041, DOI 10.1373/49.7.1041; Amelung W, 2001, SOIL BIOL BIOCHEM, V33, P553, DOI 10.1016/S0038-0717(00)00195-4; Armenta JM, 2010, ANAL CHEM, V82, P548, DOI 10.1021/ac901790q; Boogers I, 2008, J CHROMATOGR A, V1189, P406, DOI 10.1016/j.chroma.2007.11.05; Shimbo K, 2009, RAPID COMMUN MASS SP, V23, P1483, DOI 10.1002/rcm.4026; Marini JC, 2011, RAPID COMMUN MASS SP, V25, P1291, DOI 10.1002/rcm.5007; Callejon RM, 2010, TALANTA, V81, P1143, DOI 10.1016/j.talanta.2010.02.040; Iwatani S, 2007, J BIOTECHNOL, V128, P93, DOI 10.1016/j.jbiotec.2006.09.004; Sharma G, 2014, AMINO ACIDS, V46, P1253, DOI 10.1007/s00726-014-1682-6; Nakamura H, 2013, AM J PHYSIOL-ENDOC M, V304, pE100, DOI 10.1152/ajpendo.00331.2012; CURTHOYS NP, 1995, ANNU REV NUTR, V15, P133, DOI 10.1146/annurev.nu.15.070195.001025; Fiechter G, 2011, J CHROMATOGR B, V879, P1353, DOI 10.1016/j.jchromb.2011.02.003; Bergen WG, 2009, J NUTR, V139, P821, DOI 10.3945/jn.109.104497; Bertolo RF, 2008, J NUTR, V138, p2032S; COOPER AJL, 1988, J BIOL CHEM, V263, P12268; COOPER AJL, 1987, J BIOL CHEM, V262, P1073; CORSO G, 1993, BIOL MASS SPECTROM, V22, P698, DOI 10.1002/bms.1200221205; DARMAUN D, 1986, AM J PHYSIOL, V251, pE117; GASKELL SJ, 1981, BIOMED MASS SPECTROM, V8, P125, DOI 10.1002/bms.1200080309; Gaudin Z, 2014, ANAL CHEM, V86, P1138, DOI 10.1021/ac403067w; JONES ME, 1985, J NUTR, V115, P509; Li QZ, 2012, KOREAN J PHYSIOL PHA, V16, P355, DOI 10.4196/kjpp.2012.16.5.355; NISSIM I, 1983, ANAL BIOCHEM, V131, P75, DOI 10.1016/0003-2697(83)90137-9; REYES AA, 1994, AM J PHYSIOL, V267, pF331; ROSENBLATT J, 1992, AM J PHYSIOL, V263, pE584; Rouge C, 2008, J CHROMATOGR B, V865, P40, DOI 10.1016/j.jchromb.2008.01.055; Smith PA, 2010, J CHROMATOGR A, V1217, P5444, DOI 10.1016/j.chroma.2010.06.043	28	0	0	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0003-2697	1096-0309		ANAL BIOCHEM	Anal. Biochem.	MAY 1	2015	476						67	77		10.1016/j.ab.2015.02.002		11	Biochemical Research Methods; Biochemistry & Molecular Biology; Chemistry, Analytical	Biochemistry & Molecular Biology; Chemistry	CG5VR	WOS:000353364500014		
J	Endo, A; Ueno, S; Yamada, S; Uwabe, C; Takakuwa, T				Endo, Aya; Ueno, Saki; Yamada, Shigehito; Uwabe, Chigako; Takakuwa, Tetsuya			Morphogenesis of the Spleen During the Human Embryonic Period	Anatomical Record-Advances in Integrative Anatomy and Evolutionary Biology			English	Article						spleen; dorsal mesogastrium; human embryo; morphogenesis	CROWN-RUMP LENGTH; CONGENITAL ASPLENIA; MAMMALIAN SPLEEN; DIFFERENTIATION; FETUSES; PANCREAS; MICE; CELL	We aimed to observe morphological changes in the spleen from the emergence of the primordium to the end of the embryonic period using histological serial sections of 228 samples. Between Carnegie stages (CSs) 14 and 17, the spleen was usually recognized as a bulge in the dorsal mesogastrium (DM), and after CS 20, the spleen became apparent. Intrasplenic folds were observed later. A high-density area was first recognized in 6 of the 58 cases at CS 16 and in all cases examined after CS 18. The spleen was recognized neither as a bulge nor as a high-density area at CS 13. The mesothelium was pseudostratified until CS 16 and was replaced with high columnar cells and then with low columnar cells. The basement membrane was obvious after CS 17. The mesenchymal cells differentiated from cells in the DM, and sinus formation started at CS 20. Hematopoietic cells were detected after CS 18. The vessels were observed at CS 14 in the DM. Hilus formation was observed after CS 20. The parallel entries of the arteries and veins were observed at CS 23. The rate of increase in spleen length in relation to that of stomach length along the cranial-caudal direction was 0.51 +/- 0.11, which remained constant during CSs 19 and 23, indicating that their growths were similar. These data may help to better understand the development of normal human embryos and to detect abnormal embryos in the early stages of development. Anat Rec, 298:820-826, 2015. (c) 2014 Wiley Periodicals, Inc.	[Endo, Aya; Ueno, Saki; Yamada, Shigehito; Takakuwa, Tetsuya] Kyoto Univ, Human Hlth Sci, Grad Sch Med, Kyoto 6068507, Japan; [Yamada, Shigehito; Uwabe, Chigako] Kyoto Univ, Grad Sch Med, Congenital Anomaly Res Ctr, Kyoto 6068507, Japan	Takakuwa, T (reprint author), Kyoto Univ, Human Hlth Sci, Grad Sch Med, Sakyo Ku, Shogoin Kawahara Cyo 53, Kyoto 6068507, Japan.	tez@hs.med.kyoto-u.ac.jp			Japan Society for the Promotion of Science; BIRD of the Japan Science and Technology Agency [22591199, 24119002, 25461642]	Grant sponsors: Japan Society for the Promotion of Science and BIRD of the Japan Science and Technology Agency; Grant numbers: 22591199, 24119002, and 25461642.	Gasser RF, 2014, DEV DYNAM, V243, P621, DOI 10.1002/dvdy.24110; Morohashi K, 1999, BLOOD, V93, P1586; Zangen D, 2014, J CLIN INVEST, V124, P2071, DOI 10.1172/JCI73186; VELLGUTH S, 1985, CELL TISSUE RES, V242, P579; Bolze A, 2013, SCIENCE, V340, P976, DOI 10.1126/science.1234864; Koss M, 2012, DEV CELL, V22, P913, DOI 10.1016/j.devcel.2012.02.009; Zaret KS, 2008, NAT REV GENET, V9, P329, DOI 10.1038/nrg2318; Brendolan A, 2007, BIOESSAYS, V29, P166, DOI 10.1002/bies.20528; Asayesh A, 2006, GENE DEV, V20, P2208, DOI 10.1101/gad.381906; Burn SF, 2008, DEV BIOL, V318, P303, DOI 10.1016/j.ydbio.2008.03.031; DJALDETTI M, 1979, BIOL NEONATE, V36, P133; Gasser RF, 1975, ATLAS HUMAN EMBRYOS, V1st; Holyoke EA, 1936, ANAT REC, V49, P243; Kaigai N, 2014, ANAT REC, V297, P791, DOI 10.1002/ar.22833; MERIDA-VELASCO J A, 1989, Archives d'Anatomie d'Histologie et d'Embryologie Normales et Experimentales, V72, P97; NISHIMUR.H, 1968, TERATOLOGY, V1, P281, DOI 10.1002/tera.1420010306; O'Rahilly R, 1987, DEV STAGES HUMAN EMB; Ono K, 1929, Z ZELLFORSCH, V10, P573; ROBERTS CWM, 1994, NATURE, V368, P747, DOI 10.1038/368747a0; Sabin FR, 1912, MANUAL HUMAN EMBRYOL, P745; SHIOTA K, 1991, Congenital Anomalies, V31, P67, DOI 10.1111/j.1741-4520.1991.tb00360.x; Thiel GA, 1921, AM J ANAT, V28, P279, DOI 10.1002/aja.1000280203; WEISS L, 1973, AM J ANAT, V136, P315, DOI 10.1002/aja.1001360306; WEISS L, 1974, AM J ANAT, V141, P393, DOI 10.1002/aja.1001410309; Yamada S, 2004, BIRTH DEFECTS RES A, V70, P495, DOI 10.1002/bdra.20048; ZAMBONI L, 1964, J ULTRA MOL STRUCT R, V11, P469, DOI 10.1016/S0022-5320(64)80077-0	26	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1932-8486	1932-8494		ANAT REC	Anat. Rec.	MAY	2015	298	5					820	826		10.1002/ar.23099		7	Anatomy & Morphology	Anatomy & Morphology	CG4FH	WOS:000353238900005		
J	Wang, MY; Brennan, CH; Lachlan, RF; Chittka, L				Wang, Mu-Yun; Brennan, Caroline H.; Lachlan, Robert F.; Chittka, Lars			Speed-accuracy trade-offs and individually consistent decision making by individuals and dyads of zebrafish in a colour discrimination task	ANIMAL BEHAVIOUR			English	Article						behavioural variation; Danio rerio; decision making; foraging; repeatability; social experience	BOLDNESS BEHAVIORAL SYNDROME; DANIO-RERIO; GREAT TITS; CRYPTIC PREDATORS; FORAGING SPEED; CONTEXT; MODEL; PERSONALITY; ECOLOGY; QUANTIFICATION	Speedeaccuracy trade-offs are well studied in human decision making, but we are only beginning to understand how such trade-offs affect other animals. Similarly, it is poorly understood how consistent individual differences in decision making are influenced by their social context. Here we investigated whether zebrafish, Danio rerio, show individual consistency ('personality') in speedeaccuracy trade-offs based on a colour discrimination task, and how pairs of fish with distinct personalities make consensus choices. The results showed that zebrafish exhibit between-individual speedeaccuracy trade-offs: some fish made 'careful', slow but accurate decisions, while others made swift but less accurate choices. We also found that these decision-making strategies were constant over time: fish retained the same strategy for 3 days. When testing pairs of careful and fast-and-inaccurate individuals, the combined choice strategy was intermediate in speed, but statistically indistinguishable from the careful individual, whereas accuracy of the dyad decision was moderately higher than that of each individual when tested singly, although this was again not significantly different from the more careful individual. For the first time, our study thus demonstrates that two individuals influence one another's speedeaccuracy tradeoff in decision making. (C) 2015 The Association for the Study of Animal Behaviour. Published by Elsevier Ltd. All rights reserved.	[Wang, Mu-Yun; Brennan, Caroline H.; Lachlan, Robert F.; Chittka, Lars] Queen Mary Univ London, Biol & Expt Psychol, Sch Biol & Chem Sci, London, England; [Wang, Mu-Yun] Univ Tokyo, Grad Sch Sci, Dept Biol Sci, Tokyo 113, Japan	Chittka, L (reprint author), Queen Mary Univ London, Biol & Expt Psychol, Sch Biol & Chem Sci, London, England.	l.chittka@qmul.ac.uk			Overseas Research Student Awards Scheme; Ministry of Education; National Science Council Taiwan [1003116013]	We thank Krishnna Rajaratnam and Samara Polwatta who helped with the experiment and video analysis. We also thank Fraser J. Combe for fish maintenance. M.Y.W. was supported by the Overseas Research Student Awards Scheme and the Ministry of Education and National Science Council Taiwan Studying Abroad Scholarship (grant number 1003116013).	Franks NR, 2003, P ROY SOC B-BIOL SCI, V270, P2457, DOI 10.1098/rspb.2003.2527; Harcourt JL, 2009, CURR BIOL, V19, P248, DOI 10.1016/j.cub.2008.12.051; Galton F, 1907, NATURE, V75, P450, DOI 10.1038/075450a0; SUBOSKI MD, 1990, J COMP PSYCHOL, V104, P101, DOI 10.1037//0735-7036.104.1.101; SCHOUTEN JF, 1967, ACTA PSYCHOL, V27, P143, DOI 10.1016/0001-6918(67)90054-6; DasGupta S, 2014, SCIENCE, V344, P901, DOI 10.1126/science.1252114; Mathur P, 2010, NEUROBIOL DIS, V40, P66, DOI 10.1016/j.nbd.2010.05.016; Sih A, 2004, Q REV BIOL, V79, P241, DOI 10.1086/422893; Spence R, 2008, ETHOLOGY, V114, P582, DOI 10.1111/j.1439-0310.2008.01515.x; Engeszer RE, 2004, CURR BIOL, V14, P881, DOI 10.1016/j.cub.2004.04.042; Verbeek MEM, 1996, BEHAVIOUR, V133, P945, DOI 10.1163/156853996X00314; Bisazza A, 2014, SCI REP-UK, V4, DOI 10.1038/srep04560; Dingemanse NJ, 2004, BEHAV ECOL, V15, P1023, DOI 10.1093/beheco/arh115; Lele Z, 1996, BIOTECHNOL ADV, V14, P57, DOI 10.1016/0734-9750(96)00004-3; LESSELLS CM, 1987, AUK, V104, P116; Bilotta J, 2001, INT J DEV NEUROSCI, V19, P621, DOI 10.1016/S0736-5748(01)00050-8; Leadbeater E, 2007, CURR BIOL, V17, pR703, DOI 10.1016/j.cub.2007.06.012; van Oers K, 2005, BEHAV ECOL, V16, P716, DOI 10.1093/beheco/ari045; Brown C, 2003, FISH FISH, V4, P280, DOI 10.1046/j.1467-2979.2003.00122.x; Dall SRX, 2005, TRENDS ECOL EVOL, V20, P187, DOI 10.1016/j.tree.2005.01.010; Wisenden BD, 2011, BEHAVIOUR, V148, P1443, DOI 10.1163/156853911X616530; Koolhaas JM, 1999, NEUROSCI BIOBEHAV R, V23, P925, DOI 10.1016/S0149-7634(99)00026-3; Spence R, 2008, BIOL REV, V83, P13, DOI 10.1111/j.1469-185X.2007.00030.x; Colwill RM, 2005, BEHAV PROCESS, V70, P19, DOI 10.1016/j.beproc.2005.03.001; Shadlen MN, 2013, NEURON, V80, P791, DOI 10.1016/j.neuron.2013.10.047; Grunwald DJ, 2002, NAT REV GENET, V3, P717, DOI 10.1038/nrg892; Norton WHJ, 2012, BEHAVIOUR, V149, P1063, DOI 10.1163/1568539X-00003012; Chittka L, 2009, TRENDS ECOL EVOL, V24, P400, DOI 10.1016/j.tree.2009.02.010; Reader SM, 2003, ANIM BEHAV, V66, P729, DOI 10.1006/anbe.2003.2252; Gosling SD, 2001, PSYCHOL BULL, V127, P45, DOI 10.1037//0033-2909.127.1.45; Pike TW, 2008, P ROY SOC B-BIOL SCI, V275, P2515, DOI 10.1098/rspb.2008.0744; Uchida N, 2003, NAT NEUROSCI, V6, P1224, DOI 10.1038/nn1142; Risner ML, 2006, VISION RES, V46, P2625, DOI 10.1016/j.visres.2005.12.014; Chittka L, 2003, NATURE, V424, P388, DOI 10.1038/424388a; Bogacz Rafal, 2010, Trends Neurosci, V33, P10, DOI 10.1016/j.tins.2009.09.002; Jandt JM, 2014, BIOL REV, V89, P48, DOI 10.1111/brv.12042; HAMILTON WD, 1971, J THEOR BIOL, V31, P295, DOI 10.1016/0022-5193(71)90189-5; Moretz JA, 2007, BEHAV ECOL, V18, P556, DOI 10.1093/beheco/arm011; Krause J, 2010, PHILOS T R SOC B, V365, P4099, DOI 10.1098/rstb.2010.0216; Mamuneas D, 2015, BEHAV ECOL, V26, P91, DOI 10.1093/beheco/aru160; Burns JG, 2008, ANIM BEHAV, V76, P911, DOI 10.1016/j.anbehav.2008.02.017; Miller N, 2007, BEHAV BRAIN RES, V184, P157, DOI 10.1016/j.bbr.2007.07.007; Reale D, 2007, BIOL REV, V82, P291, DOI 10.1111/j.1469-185X.2007.00010.x; Schuett W, 2009, ANIM BEHAV, V77, P1041, DOI 10.1016/j.anbehav.2008.12.024; Bumann D., 1993, BEHAVIOUR, V125, P3; Darrow KO, 2004, ZEBRAFISH, V1, P40, DOI 10.1089/154585404774101662; Dyer AG, 2004, J COMP PHYSIOL A, V190, P759, DOI 10.1007/s00359-004-0547-y; Ings TC, 2008, CURR BIOL, V18, P1520, DOI 10.1016/j.cub.2008.07.074; MAGURRAN AE, 1983, BEHAV ECOL SOCIOBIOL, V12, P147, DOI 10.1007/BF00343206; Marchetti C, 2000, ANIM BEHAV, V60, P131, DOI 10.1006/anbe.2000.1443; Nakayama S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043747; Ochiai T, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071685; PACHELLA RG, 1968, PSYCHON SCI, V12, P225; Proulx MJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0111540; Ruxton G.D., 2002, LIVING GROUPS; Snekser J. L., 2010, INT J COMP PSYCHOL, V23, P70; Surowiecki J., 2005, WISDOM CROWDS WHY MA; Thomson JD, 2001, COGNITIVE ECOLOGY OF POLLINATION: ANIMAL BEHAVIOUR AND FLORAL EVOLUTION, P191, DOI 10.1017/CBO9780511542268.011; Wang MY, 2013, ANIM BEHAV, V86, P859, DOI 10.1016/j.anbehav.2013.07.029; Weiss O., 2014, ANIMAL COGNITION, V18, P39	60	1	1	ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD	LONDON	24-28 OVAL RD, LONDON NW1 7DX, ENGLAND	0003-3472	1095-8282		ANIM BEHAV	Anim. Behav.	MAY	2015	103						277	283		10.1016/j.anbehav.2015.01.022		7	Behavioral Sciences; Zoology	Behavioral Sciences; Zoology	CG6AU	WOS:000353378200032		
J	Kotani, K; Ishii, J				Kotani, Kazuhiko; Ishii, Junnichi			High-sensitivity cardiac troponin I in the clinical setting: a rapidly developing field	ANNALS OF CLINICAL BIOCHEMISTRY			English	Letter							ASSAY		[Kotani, Kazuhiko] Jichi Med Univ, Dept Clin Lab Med, Shimotsuke, Tochigi 3290498, Japan; [Ishii, Junnichi] Fujita Hlth Univ, Sch Med, Dept Joint Res Lab Clin Med, Toyoake, Aichi, Japan	Kotani, K (reprint author), Jichi Med Univ, Dept Clin Lab Med, 3311-1 Yakushiji, Shimotsuke, Tochigi 3290498, Japan.	kazukotani@jichi.ac.jp					Apple FS, 2012, CLIN CHEM, V58, P1574, DOI 10.1373/clinchem.2012.192716; Barbier CE, 2014, CLIN CHEM, V60, P1327, DOI 10.1373/clinchem.2014.222430; Fraga OR, 2014, CLIN CHEM; Moretti M, 2015, ANN CLIN BIOCHEM, V52, P169, DOI 10.1177/0004563214529749; Vasikaran SD, 2012, ANN CLIN BIOCHEM, V49, P209, DOI 10.1258/acb.2012.012058	5	0	0	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0004-5632	1758-1001		ANN CLIN BIOCHEM	Ann. Clin. Biochem.	MAY	2015	52	3					414	415		10.1177/0004563215575036		3	Medical Laboratory Technology	Medical Laboratory Technology	CG3DI	WOS:000353157400017		
J	Postuma, RB; Iranzo, A; Hogl, B; Arnulf, I; Ferini-Strambi, L; Manni, R; Miyamoto, T; Oertel, W; Dauvilliers, Y; Ju, YE; Puligheddu, M; Sonka, K; Pelletier, A; Santamaria, J; Frauscher, B; Leu-Semenescu, S; Zucconi, M; Terzaghi, M; Miyamoto, M; Unger, MM; Carlander, B; Fantini, ML; Montplaisir, JY				Postuma, Ronald B.; Iranzo, Alex; Hogl, Birgit; Arnulf, Isabelle; Ferini-Strambi, Luigi; Manni, Raffaele; Miyamoto, Tomoyuki; Oertel, Wolfgang; Dauvilliers, Yves; Ju, Yo-El; Puligheddu, Monica; Sonka, Karel; Pelletier, Amelie; Santamaria, Juan; Frauscher, Birgit; Leu-Semenescu, Smaranda; Zucconi, Marco; Terzaghi, Michele; Miyamoto, Masayuki; Unger, Marcus M.; Carlander, Bertrand; Fantini, Maria-Livia; Montplaisir, Jacques Y.			Risk Factors for Neurodegeneration in Idiopathic Rapid Eye Movement Sleep Behavior Disorder: A Multicenter Study	ANNALS OF NEUROLOGY			English	Article							PARKINSONS-DISEASE DEMENTIA; LEWY BODIES; AUTONOMIC DYSFUNCTION; DIAGNOSTIC-PROCEDURES; DELAYED EMERGENCE; SYMPTOMS; PD	ObjectiveTo assess whether risk factors for Parkinson disease and dementia with Lewy bodies increase rate of defined neurodegenerative disease in idiopathic rapid eye movement (REM) sleep behavior disorder (RBD). MethodsTwelve centers administered a detailed questionnaire assessing risk factors for neurodegenerative synucleinopathy to patients with idiopathic RBD. Variables included demographics, lifestyle factors, pesticide exposures, occupation, comorbid conditions, medication use, family history, and autonomic/motor symptoms. After 4 years of follow-up, patients were assessed for dementia or parkinsonism. Disease risk was assessed with Kaplan-Meier analysis, and epidemiologic variables were compared between convertors and those still idiopathic using logistic regression. ResultsOf 305 patients, follow-up information was available for 279, of whom 93 (33.3%) developed defined neurodegenerative disease. Disease risk was 25% at 3 years and 41% after 5 years. Patients who converted were older (difference=4.5 years, p<0.001), with similar sex distribution. Neither caffeine, smoking, nor alcohol exposure predicted conversion. Although occupation was similar between groups, those who converted had a lower likelihood of pesticide exposure (occupational insecticide=2.3% vs 9.0%). Convertors were more likely to report family history of dementia (odds ratio [OR]=2.09), without significant differences in Parkinson disease or sleep disorders. Medication exposures and medical history were similar between groups. Autonomic and motor symptoms were more common among those who converted. Risk factors for primary dementia and parkinsonism were generally similar, except for a notably higher clonazepam use in dementia convertors (OR=2.6). InterpretationPatients with idiopathic RBD are at very high risk of neurodegenerative synucleinopathy. Risk factor profiles between convertors and nonconvertors have both important commonalities and differences. Ann Neurol 2015;77:830-839	[Postuma, Ronald B.; Pelletier, Amelie] McGill Univ, Montreal Gen Hosp, Dept Neurol, Montreal, PQ H3G 1A4, Canada; [Postuma, Ronald B.; Pelletier, Amelie; Montplaisir, Jacques Y.] Sacred Heart Hosp Montreal, Sleep Med Ctr Adv Studies, Montreal, PQ, Canada; [Iranzo, Alex; Santamaria, Juan] Hosp Clin Barcelona, August Pi & Sunyer Biomed Res Inst, Ctr Biomed Res Neurodegenerat Dis, Neurol Serv, Barcelona, Spain; [Hogl, Birgit; Frauscher, Birgit] Med Univ Innsbruck, Dept Neurol, A-6020 Innsbruck, Austria; [Arnulf, Isabelle; Leu-Semenescu, Smaranda] Univ Paris 06, Sleep Disorders Unit, Pitie Salpetriere Hosp, Publ Hosp Network Paris, Paris, France; [Arnulf, Isabelle; Leu-Semenescu, Smaranda] Univ Paris 06, French Natl Inst Hlth & Med Res, Inst Brain, Paris, France; [Arnulf, Isabelle; Leu-Semenescu, Smaranda] Univ Paris 06, Spine Res Ctr, Paris, France; [Ferini-Strambi, Luigi; Zucconi, Marco] Univ Vita Salute San Raffaele, Sleep Disorders Ctr, Milan, Italy; [Manni, Raffaele; Terzaghi, Michele] C Mondino Natl Neurol Inst, Pavia, Italy; [Miyamoto, Tomoyuki] Dokkyo Med Univ, Koshigaya Hosp, Dept Neurol, Saitama, Japan; [Oertel, Wolfgang; Unger, Marcus M.] Univ Marburg, Dept Neurol, Marburg, Germany; [Dauvilliers, Yves; Carlander, Bertrand] Gui de Chauliac Hosp, French Natl Inst Hlth & Med Res, Dept Neurol, Montpellier, France; [Ju, Yo-El] Washington Univ, Multidisciplinary Sleep Ctr, St Louis, MO USA; [Puligheddu, Monica; Fantini, Maria-Livia] Univ Cagliari, Dept Cardiovasc & Neurol Sci, Sleep Ctr, Cagliari, Italy; [Sonka, Karel] Charles Univ Prague, Fac Med 1, Dept Neurol, Prague, Czech Republic; [Sonka, Karel] Gen Univ Hosp, Prague, Czech Republic; [Miyamoto, Masayuki] Dokkyo Med Univ, Sch Med, Dept Neurol, Shimotsuga, Tochigi, Japan; [Fantini, Maria-Livia] Univ Auvergne, Dept Neurol, Clermont Ferrand, France	Postuma, RB (reprint author), L7 305 Montreal Gen Hosp, Dept Neurol, 1650 Cedar Ave, Montreal, PQ H3G 1A4, Canada.	ron.postuma@mcgill.ca			Fonds de la Recherche en Sante Quebec; Charles University [PRVOUK P26/LF1]	This study was funded by grants from the Fonds de la Recherche en Sante Quebec and Charles University (PRVOUK P26/LF1; K.S.).	Visser M, 2004, MOVEMENT DISORD, V19, P1306, DOI 10.1002/mds.20153; Postuma RB, 2012, NEUROLOGY, V79, P428, DOI 10.1212/WNL.0b013e31825dd383; Schenck CH, 1996, NEUROLOGY, V46, P388; Postuma RB, 2010, MOVEMENT DISORD, V25, P2304, DOI 10.1002/mds.23347; Postuma RB, 2009, NEUROLOGY, V72, P1296, DOI 10.1212/01.wnl.0000340980.19702.6e; Boeve BF, 2013, SLEEP MED, V14, P754, DOI 10.1016/j.sleep.2012.10.015; Wing YK, 2012, J NEUROL NEUROSUR PS, V83, P470, DOI 10.1136/jnnp-2011-301232; McKeith IG, 2005, NEUROLOGY, V65, P1863, DOI 10.1212/01.wnl.0000187889.17253.b1; Bender R, 2001, J CLIN EPIDEMIOL, V54, P343, DOI 10.1016/S0895-4356(00)00314-0; Ferini-Strambi L, 2014, J NEUROL, V261, P1112, DOI 10.1007/s00415-014-7317-8; Rolinski M, 2014, J NEUROL NEUROSUR PS, V85, P560, DOI 10.1136/jnnp-2013-306104; [Anonymous], 2013, MOV DISORD, V28, P1823; Schenck CH, 2013, SLEEP MED, V14, P795, DOI 10.1016/j.sleep.2013.02.016; Frauscher B, 2014, NEUROLOGY, V82, P1076, DOI 10.1212/WNL.0000000000000247; Postuma RB, 2012, BRAIN, V135, P1860, DOI 10.1093/brain/aws093; Schenck CH, 2013, SLEEP MED, V14, P744, DOI 10.1016/j.sleep.2012.10.009; Dubois B, 2007, MOVEMENT DISORD, V22, P2314, DOI 10.1002/mds.21844; Postuma RB, 2013, SLEEP, V36, P1579, DOI 10.5665/sleep.3102; Postuma RB, 2013, MOVEMENT DISORD, V28, P597, DOI 10.1002/mds.25445; [Anonymous], 2007, INT CLASS SLEEP DIS, V2nd; Barton BR, 2010, NEUROLOGY, V74, pA299; Billioti de Gage Sophie, 2014, BMJ, V349, pg5205, DOI 10.1136/bmj.g5205; Boot BP, 2013, NEUROLOGY, V81, P833, DOI 10.1212/WNL.0b013e3182a2cbd1; Chan DKY, 2000, J NEUROL NEUROSUR PS, V69, P117, DOI 10.1136/jnnp.69.1.117; Dauvilliers Y, 2013, NEUROLOGY, V80, P2233, DOI 10.1212/WNL.0b013e318296e967; Iranzo A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089741; Marras C, 2012, ANN NEUROL, V71, P362, DOI 10.1002/ana.22616; Nomura T, 2013, SLEEP MED, V14, P131, DOI 10.1016/j.sleep.2012.10.011; Postuma RB, 2015, NEUROLOGY; Romenets Silvia Rios, 2012, Mov Disord, V27, P996, DOI 10.1002/mds.25086	30	3	3	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0364-5134	1531-8249		ANN NEUROL	Ann. Neurol.	MAY	2015	77	5					830	839		10.1002/ana.24385		10	Clinical Neurology; Neurosciences	Neurosciences & Neurology	CG4EF	WOS:000353235400011		
J	Usami, S				Usami, Shin-ichi			Molecular Diagnosis of Deafness-A Preface	ANNALS OF OTOLOGY RHINOLOGY AND LARYNGOLOGY			English	Editorial Material									Shinshu Univ, Sch Med, Dept Otorhinolaryngol, Matsumoto, Nagano, Japan	Usami, S (reprint author), Shinshu Univ, Sch Med, Dept Otorhinolaryngol, Matsumoto, Nagano, Japan.	usami@shinshu-u.ac.jp						0	0	0	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0003-4894	1943-572X		ANN OTO RHINOL LARYN	Ann. Otol. Rhinol. Laryngol.	MAY	2015	124			1			5S	5S		10.1177/0003489415581802		1	Otorhinolaryngology	Otorhinolaryngology	CG6PA	WOS:000353422900001		
J	Nishio, S; Hattori, M; Moteki, H; Tsukada, K; Miyagawa, M; Naito, T; Yoshimura, H; Iwasa, Y; Mori, K; Shima, Y; Sakuma, N; Usami, S				Nishio, Shin-ya; Hattori, Mitsuru; Moteki, Hideaki; Tsukada, Keita; Miyagawa, Maiko; Naito, Takehiko; Yoshimura, Hidekane; Iwasa, Yoh-ichiro; Mori, Kentaro; Shima, Yutaka; Sakuma, Naoko; Usami, Shin-ichi			Gene Expression Profiles of the Cochlea and Vestibular Endorgans: Localization and Function of Genes Causing Deafness	ANNALS OF OTOLOGY RHINOLOGY AND LARYNGOLOGY			English	Article						deafness; gene expression; innmunocytochemistry; in situ hybridization; localization	NONSYNDROMIC HEARING-LOSS; AUTOSOMAL RECESSIVE DEAFNESS; HAIR CELL STEREOCILIA; MOUSE INNER-EAR; WAARDENBURG-HIRSCHSPRUNG-DISEASE; ACTIN-BINDING-PROTEIN; GENOTYPE-PHENOTYPE CORRELATION; BRANCHIOOTORENAL BOR SYNDROME; MESSENGER-RNA EXPRESSION; LANGE-NIELSEN-SYNDROME	Objectives: We sought to elucidate the gene expression profiles of the causative genes as well as the localization of the encoded proteins involved in hereditary hearing loss. Methods: Relevant articles (as of September 2014) were searched in PubMed databases, and the gene symbols of the genes reported to be associated with deafness were located on the Hereditary Hearing Loss Honnepage using localization, expression, and distribution as keywords. Results: Our review of the literature allowed us to systematize the gene expression profiles for genetic deafness in the inner ear, clarifying the unique functions and specific expression patterns of these genes in the cochlea and vestibular endorgans. Conclusions: The coordinated actions of various encoded molecules are essential for the normal development and maintenance of auditory and vestibular function.	[Nishio, Shin-ya; Hattori, Mitsuru; Moteki, Hideaki; Tsukada, Keita; Miyagawa, Maiko; Naito, Takehiko; Yoshimura, Hidekane; Iwasa, Yoh-ichiro; Mori, Kentaro; Shima, Yutaka; Sakuma, Naoko; Usami, Shin-ichi] Shinshu Univ, Sch Med, Dept Otorhinolaryngol, Matsumoto, Nagano 3908621, Japan; [Nishio, Shin-ya; Miyagawa, Maiko; Usami, Shin-ichi] Shinshu Univ, Sch Med, Dept Hearing Implant Sci, Matsumoto, Nagano 3908621, Japan; [Sakuma, Naoko] Yokohama City Univ, Sch Med, Dept Otorhinolaryngol & Head & Neck Surg, Yokohama, Kanagawa 232, Japan	Usami, S (reprint author), Shinshu Univ, Sch Med, Dept Otorhinolaryngol, 3-1-1 Asahi, Matsumoto, Nagano 3908621, Japan.	usami@shinshu-u.ac.jp			Health and Labour Sciences Research Grant for Research on Rare and Intractable Diseases from the Ministry of Health, Labour and Welfare of Japan; Ministry of Education, Science and Culture of Japan; Comprehensive Research on Disability Health and Welfare from the Ministry of Health, Labour and Welfare of Japan	The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This study was funded by a Health and Labour Sciences Research Grant for Research on Rare and Intractable Diseases and Comprehensive Research on Disability Health and Welfare from the Ministry of Health, Labour and Welfare of Japan (S.U.) and by a Grant-in-Aid for Scientific Research from the Ministry of Education, Science and Culture of Japan (S.U.).	Abdelhak S, 1997, NAT GENET, V15, P157, DOI 10.1038/ng0297-157; Adler HJ, 2003, HEARING RES, V184, P27, DOI 10.1016/S0378-5955(03)00192-8; Ahmed ZM, 2002, HUM GENET, V110, P527, DOI 10.1007/s00439-002-0732-4; Ben-Yosef T, 2003, HUM MOL GENET, V12, P2049, DOI 10.1093/hmg/ddg210; Wang L, 2012, HUM MOL GENET, V21, P692, DOI 10.1093/hmg/ddr503; Rost S, 2014, EUR J HUM GENET, V22, P208, DOI 10.1038/ejhg.2013.108; Goodyear RJ, 2002, J NEUROBIOL, V53, P212, DOI 10.1002/neu.10097; Lopez-Bigas N, 2001, HUM MOL GENET, V10, P947, DOI 10.1093/hmg/10.9.947; Everett LA, 1997, NAT GENET, V17, P411, DOI 10.1038/ng1297-411; Wang AH, 1998, SCIENCE, V280, P1447, DOI 10.1126/science.280.5368.1447; Zhang LP, 2014, HUM MUTAT, V35, P814, DOI 10.1002/humu.22558; Yan D, 2013, P NATL ACAD SCI USA, V110, P2228, DOI 10.1073/pnas.1222285110; Webb SW, 2011, DEVELOPMENT, V138, P1607, DOI 10.1242/dev.060061; Jenkinson EM, 2013, AM J HUM GENET, V92, P605, DOI 10.1016/j.ajhg.2013.02.013; Fasquelle L, 2011, J BIOL CHEM, V286, P17383, DOI 10.1074/jbc.M110.190652; Adato A, 2005, HUM MOL GENET, V14, P3921, DOI 10.1093/hmg/ddi416; Kikkawa Y, 2005, HUM MOL GENET, V14, P391, DOI 10.1093/hmg/ddi035; Edery P, 1996, NAT GENET, V12, P442, DOI 10.1038/ng0496-442; Qu Y, 2007, J COMP NEUROL, V504, P499, DOI 10.1002/cne.21459; Fettiplace R, 2014, PHYSIOL REV, V94, P951, DOI 10.1152/physrev.00038.2013; Pan BF, 2013, NEURON, V79, P504, DOI 10.1016/j.neuron.2013.06.019; Riazuddin S, 2006, AM J HUM GENET, V79, P1040, DOI 10.1086/510022; Adato A, 2002, EUR J HUM GENET, V10, P339, DOI 10.1038/sj.ejhg.5200831; Kubisch C, 1999, CELL, V96, P437, DOI 10.1016/S0092-8674(00)80556-5; Grillet N, 2009, NEURON, V62, P375, DOI 10.1016/j.neuron.2009.04.006; Schrauwen I, 2012, AM J HUM GENET, V91, P636, DOI 10.1016/j.ajhg.2012.08.018; Kurima K, 2002, NAT GENET, V30, P277, DOI 10.1038/ng842; Masuda M, 2011, NEUROSCIENCE, V197, P48, DOI 10.1016/j.neuroscience.2011.09.033; Kazmierczak P, 2007, NATURE, V449, P87, DOI 10.1038/nature06091; Borck G, 2011, AM J HUM GENET, V88, P127, DOI 10.1016/j.ajhg.2010.12.011; Delmaghani S, 2006, NAT GENET, V38, P770, DOI 10.1038/ng1829; Naz S, 2004, J MED GENET, V41, P591, DOI 10.1136/jmg.2004.018523; Donaudy F, 2004, AM J HUM GENET, V74, P770, DOI 10.1086/383285; Kharkovets T, 2000, P NATL ACAD SCI USA, V97, P4333, DOI 10.1073/pnas.97.8.4333; Ahmed ZM, 2011, AM J HUM GENET, V88, P19, DOI 10.1016/j.ajhg.2010.11.010; Hurd EA, 2010, DEVELOPMENT, V137, P3139, DOI 10.1242/dev.047894; Shin MJ, 2010, COMPARATIVE MED, V60, P288; Grillet N, 2009, AM J HUM GENET, V85, P328, DOI 10.1016/j.ajhg.2009.07.017; Usami S, 1999, HUM GENET, V104, P188, DOI 10.1007/s004390050933; Wayne S, 2001, HUM MOL GENET, V10, P195, DOI 10.1093/hmg/10.3.195; ATTIE T, 1995, HUM MOL GENET, V4, P2407, DOI 10.1093/hmg/4.12.2407; Rehman AU, 2014, AM J HUM GENET, V94, P144, DOI 10.1016/j.ajhg.2013.12.004; Walsh T, 2002, P NATL ACAD SCI USA, V99, P7518, DOI 10.1073/pnas.102091699; Yasunaga S, 1999, NAT GENET, V21, P363; Tan J, 2013, AM J PATHOL, V183, P49, DOI 10.1016/j.ajpath.2013.03.009; Kazmierczak P, 2012, TRENDS NEUROSCI, V35, P220, DOI 10.1016/j.tins.2011.10.007; Ain Q, 2007, HUM GENET, V122, P445, DOI 10.1007/s00439-007-0418-z; Stanchina L, 2006, DEV BIOL, V295, P232, DOI 10.1016/j.ydbio.2006.03.031; von Ameln S, 2012, AM J HUM GENET, V91, P919, DOI 10.1016/j.ajhg.2012.09.002; Wakaoka T, 2013, HEARING RES, V302, P17, DOI 10.1016/j.heares.2013.05.003; Mi HY, 2005, NUCLEIC ACIDS RES, V33, pD284, DOI 10.1093/nar/gki078; Kawashima Y, 2011, J CLIN INVEST, V121, P4796, DOI 10.1172/JCI60405; Ruf RG, 2003, J MED GENET, V40, P515, DOI 10.1136/jmg.40.7.515; Kelsell DP, 1997, NATURE, V387, P80, DOI 10.1038/387080a0; Collin RWJ, 2008, AM J HUM GENET, V82, P125, DOI 10.1016/j.ajhg.2007.09.008; Ahmed ZM, 2008, NAT GENET, V40, P1335, DOI 10.1038/ng.245; Schwander M, 2007, J NEUROSCI, V27, P2163, DOI 10.1523/JNEUROSCI.4975-06.2007; Horn HF, 2013, J CLIN INVEST, V123, P740, DOI 10.1172/JCI66911; Tyson J, 1997, HUM MOL GENET, V6, P2179, DOI 10.1093/hmg/6.12.2179; Kalatzis V, 1998, DEV DYNAM, V213, P486, DOI 10.1002/(SICI)1097-0177(199812)213:4<486::AID-AJA13>3.0.CO;2-L; Furness DN, 2013, P NATL ACAD SCI USA, V110, P13898, DOI 10.1073/pnas.1304644110; Holt JR, 2014, HEARING RES, V311, P17, DOI 10.1016/j.heares.2014.01.001; Robertson NG, 1998, NAT GENET, V20, P299; Yasunaga S, 2000, AM J HUM GENET, V67, P591, DOI 10.1086/303049; Ahmed M, 2012, DEV CELL, V22, P377, DOI 10.1016/j.devcel.2011.12.006; Hibino H, 1997, J NEUROSCI, V17, P4711; Robertson NG, 2008, HUM MOL GENET, V17, P3426, DOI 10.1093/hmg/ddn236; Watanabe A, 1998, NAT GENET, V18, P283, DOI 10.1038/ng0398-283; Hudspeth AJ, 2014, NAT REV NEUROSCI, V15, P600, DOI 10.1038/nrn3786; Nayak G, 2013, J CLIN INVEST, V123, P4036, DOI 10.1172/JCI69031; del Castillo I, 2002, NEW ENGL J MED, V346, P243, DOI 10.1056/NEJMoa012052; Furness DN, 2003, J NEUROSCI, V23, P11296; Oshima A, 2006, J MED GENET, V43, DOI 10.1136/jmg.2005.034397; Belyantseva IA, 2009, P NATL ACAD SCI USA, V106, P9703, DOI 10.1073/pnas.0900221106; Schraders M, 2012, AM J HUM GENET, V91, P883, DOI 10.1016/j.ajhg.2012.09.012; Bork JM, 2001, AM J HUM GENET, V68, P26, DOI 10.1086/316954; Lautermann J, 1998, CELL TISSUE RES, V294, P415, DOI 10.1007/s004410051192; Kwon TJ, 2014, HUM MOL GENET, V23, P1591, DOI 10.1093/hmg/ddt549; Knipper M, 2006, J PHYSIOL-LONDON, V576, P73, DOI 10.1113/jphysiol.2006.116889; [Anonymous], 2006, AM J HUM GENET, V78, P144; Belyantseva IA, 2003, P NATL ACAD SCI USA, V100, P13958, DOI 10.1073/pnas.2334417100; Peters LM, 2002, HUM MOL GENET, V11, P2877, DOI 10.1093/hmg/11.23.2877; Zheng WM, 2003, DEVELOPMENT, V130, P3989, DOI 10.1242/dev.00628; Seal RP, 2008, NEURON, V57, P263, DOI 10.1016/j.neuron.2007.11.032; Verpy E, 2001, NAT GENET, V29, P345, DOI 10.1038/ng726; Simmler MC, 2000, NAT GENET, V24, P139, DOI 10.1038/72793; Gillespie PG, 2009, CELL, V139, P33, DOI 10.1016/j.cell.2009.09.010; Ahmed ZM, 2003, HUM MOL GENET, V12, P3215, DOI 10.1093/hmg/ddg358; Liu XZ, 2010, AM J HUM GENET, V86, P65, DOI 10.1016/j.ajhg.2009.11.015; Rehman AU, 2010, AM J HUM GENET, V86, P378, DOI 10.1016/j.ajhg.2010.01.030; Belyantseva IA, 2000, J NEUROSCI, V20, part. no.; Yariz KO, 2012, AM J HUM GENET, V91, P872, DOI 10.1016/j.ajhg.2012.09.011; Verhoeven K, 1998, NAT GENET, V19, P60, DOI 10.1038/ng0598-60; Ye X, 2011, GENE EXPR PATTERNS, V11, P151, DOI 10.1016/j.gep.2010.10.007; McGee J, 2006, J NEUROSCI, V26, P6543, DOI 10.1523/JNEUROSCI.0693-06.2006; Zdebik AA, 2009, PHYSIOLOGY, V24, P307, DOI 10.1152/physiol.00018.2009; Beutner D, 2001, NEURON, V29, P681, DOI 10.1016/S0896-6273(01)00243-4; Steel KP, 2001, NAT GENET, V27, P143, DOI 10.1038/84758; Verpy E, 2000, NAT GENET, V26, P51; Michalski N, 2007, J NEUROSCI, V27, P6478, DOI 10.1523/JNEUROSCI.0342-07.2007; Miyagawa M, 2014, J HUM GENET, V59, P262, DOI 10.1038/jhg.2014.12; Coffin AB, 2007, HEARING RES, V224, P15, DOI 10.1016/j.heares.2006.11.004; Nin F, 2008, P NATL ACAD SCI USA, V105, P1751, DOI 10.1073/pnas.0711463105; Weston MD, 2011, DEV DYNAM, V240, P808, DOI 10.1002/dvdy.22591; Huebner AK, 2011, AM J HUM GENET, V88, P621, DOI 10.1016/j.ajhg.2011.04.007; Vahava O, 1998, SCIENCE, V279, P1950, DOI 10.1126/science.279.5358.1950; Shabbir MI, 2006, J MED GENET, V43, DOI 10.1136/jmg.2005.039834; TASSABEHJI M, 1994, NAT GENET, V8, P251, DOI 10.1038/ng1194-251; Liu XZ, 1997, NAT GENET, V16, P188, DOI 10.1038/ng0697-188; Walsh T, 2010, AM J HUM GENET, V87, P90, DOI 10.1016/j.ajhg.2010.05.010; Delmaghani S, 2012, HUM MOL GENET, V21, P3835, DOI 10.1093/hmg/dds212; Riazuddin S, 2012, NAT GENET, V44, P1265, DOI 10.1038/ng.2426; Zheng LL, 2000, CELL, V102, P377, DOI 10.1016/S0092-8674(00)00042-8; Lalwani AK, 2000, AM J HUM GENET, V67, P1121; Asamura K, 2005, NEUROSCIENCE, V132, P493, DOI 10.1016/j.neuroscience.2005.01.013; Forge A, 2003, J COMP NEUROL, V467, P207, DOI 10.1002/cne.10916; Cui GY, 2007, J PHYSIOL-LONDON, V585, P791, DOI 10.1113/jphysiol.2007.142307; Thomas PD, 2003, GENOME RES, V13, P2129, DOI 10.1101/gr.772403; Cheatham MA, 2014, J NEUROSCI, V34, P10325, DOI 10.1523/JNEUROSCI.1256-14.2014; Scott HS, 2001, NAT GENET, V27, P59; Schneider ME, 2006, J NEUROSCI, V26, P10243, DOI 10.1523/JNEUROSCI.2812-06.2006; Mburu P, 2003, NAT GENET, V34, P421, DOI 10.1038/ng1208; Kitajiri S, 2004, J CELL BIOL, V166, P559, DOI 10.1083/jcb.200402007; Ebermann I, 2010, J CLIN INVEST, V120, P1812, DOI 10.1172/JCI39715; Walsh T, 2010, AM J HUM GENET, V87, P101, DOI 10.1016/j.ajhg.2010.05.011; Zwaenepoel I, 2002, P NATL ACAD SCI USA, V99, P6240, DOI 10.1073/pnas.082515999; Johnson KR, 2010, HEARING RES, V268, P85, DOI 10.1016/j.heares.2010.05.002; Sacheli R, 2009, GENE EXPR PATTERNS, V9, P364, DOI 10.1016/j.gep.2009.01.003; Zheng J, 2000, NATURE, V405, P149, DOI 10.1038/35012009; Grati M, 2012, J NEUROSCI, V32, P14288, DOI 10.1523/JNEUROSCI.3071-12.2012; Santos-Cortez RLP, 2013, AM J HUM GENET, V93, P132, DOI 10.1016/j.ajhg.2013.05.018; Neyroud N, 1997, NAT GENET, V15, P186, DOI 10.1038/ng0297-186; Santos-Cortez RLP, 2014, HUM MOL GENET, V23, P3289, DOI 10.1093/hmg/ddu042; TASSABEHJI M, 1992, NATURE, V355, P635, DOI 10.1038/355635a0; Minowa O, 1999, SCIENCE, V285, P1408, DOI 10.1126/science.285.5432.1408; Wilcox ER, 2001, CELL, V104, P165, DOI 10.1016/S0092-8674(01)00200-8; SchulzeBahr E, 1997, NAT GENET, V17, P267, DOI 10.1038/ng1197-267; Grati M, 2011, P NATL ACAD SCI USA, V108, P11476, DOI 10.1073/pnas.1104161108; Azaiez H, 2014, HUM MUTAT, V35, P819, DOI 10.1002/humu.22557; Li XC, 1998, NAT GENET, V18, P215, DOI 10.1038/ng0398-215; Avenarius MR, 2012, THESIS U MICHIGAN; Behlouli A, 2014, ORPHANET J RARE DIS, V9, DOI 10.1186/1750-1172-9-55; Busch-Nentwich E, 2004, DEVELOPMENT, V131, P943, DOI 10.1242/dev.00961; Charizopoulou N, 2011, NAT COMMUN, V2, DOI 10.1038/ncomms1200; Cheng J, 2011, AM J HUM GENET, V89, P56, DOI 10.1016/j.ajhg.2011.05.027; Cosgrove D, 1996, HEARING RES, V97, P54; Cosgrove D, 1996, HEARING RES, V100, P21, DOI 10.1016/0378-5955(96)00114-1; Cosgrove D, 1998, HEARING RES, V121, P84, DOI 10.1016/S0378-5955(98)00069-0; Cryns K, 2003, HISTOCHEM CELL BIOL, V119, P247, DOI 10.1007/s00418-003-0495-6; Drescher MJ, 1997, MOL BRAIN RES, V45, P325, DOI 10.1016/S0169-328X(97)00007-7; Dulon D, 2009, J NEUROSCI, V29, P10474, DOI 10.1523/JNEUROSCI.1009-09.2009; El-Amraoui A, 2001, HEARING RES, V158, P151, DOI 10.1016/S0378-5955(01)00312-4; Everett LA, 1999, P NATL ACAD SCI USA, V96, P9727, DOI 10.1073/pnas.96.17.9727; Fang Q, 2012, JARO-J ASSOC RES OTO, V13, P173, DOI 10.1007/s10162-011-0302-3; Feng X, 2014, AUDIOL NEURO-OTOL, V19, P267, DOI 10.1159/000363683; Fransen E, 1999, BRIT J AUDIOL, V33, P297; Franz P, 1997, ACTA OTO-LARYNGOL, V117, P358, DOI 10.3109/00016489709113407; Furness DN, 2005, HEARING RES, V207, P22, DOI 10.1016/j.heares.2005.05.006; Furness DN, 1997, EUR J NEUROSCI, V9, P1961, DOI 10.1111/j.1460-9568.1997.tb00763.x; Gagnon LH, 2006, J NEUROSCI, V26, P10188, DOI 10.1523/JNEUROSCI.2166-06.2006; Geng RS, 2009, HUM MOL GENET, V18, P2748, DOI 10.1093/hmg/ddp210; Girotto G, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080323; Goodyear RJ, 2003, J NEUROSCI, V23, P9208; Guipponi M, 2008, HUM MUTAT, V29, P130, DOI 10.1002/humu.20617; Hertzano R, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000207; Hurd EA, 2011, HEARING RES, V282, P184, DOI 10.1016/j.heares.2011.08.005; Ishiyama A, 2009, HEARING RES, V254, P1, DOI 10.1016/j.heares.2009.03.014; Jaworek TJ, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003774; Kammerer R, 2012, J BIOL CHEM, V287, P21584, DOI 10.1074/jbc.M111.320481; Keller JP, 2014, J NEUROSCI, V34, P1325, DOI 10.1523/JNEUROSCI.4020-13.2014; Khan SY, 2007, HUM MUTAT, V28, P417, DOI 10.1002/humu.20469; Kim H, 2014, BIOCHEM BIOPH RES CO, V445, P608, DOI 10.1016/j.bbrc.2014.02.047; KIMBERLING WJ, 1990, GENOMICS, V7, P245, DOI 10.1016/0888-7543(90)90546-7; Kitajiri S, 2010, CELL, V141, P786, DOI 10.1016/j.cell.2010.03.049; Manji SSM, 2011, AM J PATHOL, V179, P903, DOI 10.1016/j.ajpath.2011.04.002; Manji SSM, 2012, AM J PATHOL, V180, P1560, DOI 10.1016/j.ajpath.2011.12.034; Marcotti W, 2012, EXP PHYSIOL, V97, P438, DOI 10.1113/expphysiol.2011.059303; McGuirt WT, 1999, NAT GENET, V23, P413; Melnick M, 2013, BIRTH DEFECTS RES A, V97, P69, DOI 10.1002/bdra.23105; Miyagawa M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040366; Mochizuki E, 2010, EXP ANIM TOKYO, V59, P57; Modamio-Hoybjor S, 2007, AM J HUM GENET, V80, P1076, DOI 10.1086/518311; Morozko EL, 2015, HUM MOL GENET, V24, P609, DOI 10.1093/hmg/ddu474; Morton CC, 2006, NEW ENGL J MED, V354, P2151, DOI 10.1056/NEJMra050700; Odeh H, 2010, AM J HUM GENET, V86, P148, DOI 10.1016/j.ajhg.2010.01.016; Oguchi T, 2012, HEARING RES, V292, P59, DOI 10.1016/j.heares.2012.07.005; Peng Z, 2013, BRAIN RES, V1537, P100, DOI 10.1016/j.brainres.2013.09.019; Pingault V, 1998, NAT GENET, V18, P171, DOI 10.1038/ng0298-171; Rebhan M, 1997, TRENDS GENET, V13, P163, DOI 10.1016/S0168-9525(97)01103-7; Robertson NG, 2001, HUM MOL GENET, V10, P2493, DOI 10.1093/hmg/10.22.2493; Robertson NG, 2006, HUM MOL GENET, V15, P1071, DOI 10.1093/hmg/ddl022; Roux I, 2006, CELL, V127, P227; Sakaguchi H, 2008, CELL MOTIL CYTOSKEL, V65, P528, DOI 10.1002/cm.20275; Sakaguchi H, 2009, CURR OPIN OTOLARYNGO, V17, P388, DOI 10.1097/MOO.0b013e3283303472; Salles FT, 2014, CYTOSKELETON, V71, P61, DOI 10.1002/cm.21159; Schmitz F, 2009, NEUROSCIENTIST, V15, P611, DOI 10.1177/1073858409340253; Schraders M, 2010, AM J HUM GENET, V86, P604, DOI 10.1016/j.ajhg.2010.02.015; Shpargel KB, 2004, ACTA OTO-LARYNGOL, V124, P242, DOI 10.1080/00016480410016162; Suzuki H, 2007, ACTA OTO-LARYNGOL, V127, P1292, DOI 10.1080/00016480701258739; Tachibana M, 1996, NAT GENET, V14, P50, DOI 10.1038/ng0996-50; Telang RS, 2010, PURINERG SIGNAL, V6, P263, DOI 10.1007/s11302-010-9195-6; Usami S, 2003, EUR J HUM GENET, V11, P744, DOI 10.1038/sj.ejhg.5201043; Usami S, 2008, NEUROSCIENCE, V154, P22, DOI 10.1016/j.neuroscience.2008.03.018; Wangemann P, 2004, BMC MED, V2, DOI 10.1186/1741-7015-2-30; Watanabe K, 2000, MOL BRAIN RES, V84, P141, DOI 10.1016/S0169-328X(00)00236-9; Wilson SM, 2001, GENOMICS, V74, P228, DOI 10.1006/geno.2001.6554; Wu L, 2013, DEV DYNAM, V242, P269, DOI 10.1002/dvdy.23917; Xiang MQ, 1997, P NATL ACAD SCI USA, V94, P9445, DOI 10.1073/pnas.94.17.9445; Yokoyama S, 2006, J BIOCHEM, V140, P491, DOI 10.1093/jb/mvj177; Zallocchi M, 2009, HEARING RES, V255, P109, DOI 10.1016/j.heares.2009.06.006; Zallocchi M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030573; Zehnder AF, 2005, ARCH OTOLARYNGOL, V131, P1007, DOI 10.1001/archotol.131.11.1007; Zhu M, 2003, AM J HUM GENET, V73, P1082, DOI 10.1086/379286	213	0	0	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0003-4894	1943-572X		ANN OTO RHINOL LARYN	Ann. Otol. Rhinol. Laryngol.	MAY	2015	124			1			6S	48S		10.1177/0003489415575549		43	Otorhinolaryngology	Otorhinolaryngology	CG6PA	WOS:000353422900002		
J	Nishio, S; Usami, S				Nishio, Shin-ya; Usami, Shin-ichi			Deafness Gene Variations in a 1120 Nonsyndromic Hearing Loss Cohort: Molecular Epidemiology and Deafness Mutation Spectrum of Patients in Japan	ANNALS OF OTOLOGY RHINOLOGY AND LARYNGOLOGY			English	Article						hearing loss; massively parallel DNA sequencing; next-generation DNA sequencer; molecular epidemiology	VARIANTS; CAPTURE; PHENOTYPE; GENOMES; PROTEIN	Objectives: To elucidate the molecular epidemiology of hearing loss in a large number of Japanese patients analyzed using massively parallel DNA sequencing (MPS) of target genes. Methods: We performed MPS of target genes using the Ion PGM system with the Ion AmpliSeq and HiSeq 2000 systems using SureSelect in 1389 samples (1120 nonsyndronnic hearing loss cases and 269 normal hearing controls). We filtered the variants identified using allele frequencies in a large number of controls and 12 predication program scores. Results: We identified 8376 kinds of variants in the 1389 samples, and 409 835 total variants were detected. After filtering the variants, we selected 2631 kinds of candidate variants. The number of GJB2 mutations was exceptionally high among these variants, followed by those in CDH23, SLC26A4, MYO 15A, COL11A2, MYO7A, and OTOF. Conclusions: We performed a large number of MPS analyses and clarified the genetic background of Japanese patients with hearing loss. This data set will be a powerful tool to discover rare causative gene mutations in highly heterogeneous monogenic diseases and reveal the genetic epidemiology of deafness.	[Nishio, Shin-ya; Usami, Shin-ichi] Shinshu Univ, Sch Med, Dept Otorhinolaryngol, Matsumoto, Nagano 3908621, Japan; [Nishio, Shin-ya; Usami, Shin-ichi] Shinshu Univ, Sch Med, Dept Hearing Implant Sci, Matsumoto, Nagano 3908621, Japan	Usami, S (reprint author), Shinshu Univ, Sch Med, Dept Otorhinolaryngol, 3-1-1 Asahi, Matsumoto, Nagano 3908621, Japan.	usami@shinshu-u.ac.jp			Health and Labour Sciences Research Grant for Research on Rare and Intractable Diseases from the Ministry of Health, Labour and Welfare of Japan [H24-Nanchitou(Nan)-Ippan-032]; Comprehensive Research on Disability Health and Welfare from the Ministry of Health, Labour and Welfare of Japan [H25-Kankaku-Ippan-002]; Ministry of Education, science and Culture of Japan [22249057]; Life Technologies Japan Ltd	The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This study was grant aided by a Health and Labour Sciences Research Grant for Research on Rare and Intractable Diseases (H24-Nanchitou(Nan)-Ippan-032) and Comprehensive Research on Disability Health and Welfare (H25-Kankaku-Ippan-002) from the Ministry of Health, Labour and Welfare of Japan (S.U.) and by a Grant-in-Aid for Scientific Research (A) (22249057) from the Ministry of Education, science and Culture of Japan (S.U.). This study was partially supported by Life Technologies Japan Ltd as a collaborative study (S.U.). The company had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Altshuler DM, 2012, NATURE, V491, P56, DOI 10.1038/nature11632; Tang WX, 2012, GENET TEST MOL BIOMA, V16, P536, DOI 10.1089/gtmb.2011.0187; Tsukada K, 2010, CLIN GENET, V78, P464, DOI 10.1111/j.1399-0004.2010.01407.x; Abe S, 2003, AM J HUM GENET, V72, P73, DOI 10.1086/345398; Li H, 2009, BIOINFORMATICS, V25, P1754, DOI 10.1093/bioinformatics/btp324; Shearer AE, 2010, P NATL ACAD SCI USA, V107, P21104, DOI 10.1073/pnas.1012989107; Schraders M, 2011, AM J HUM GENET, V88, P628, DOI 10.1016/j.ajhg.2011.04.012; Schrauwen I, 2013, AM J MED GENET A, V161A, P145, DOI 10.1002/ajmg.a.35737; Lin X, 2012, HEARING RES, V288, P67, DOI 10.1016/j.heares.2012.01.004; Rehman AU, 2010, AM J HUM GENET, V86, P378, DOI 10.1016/j.ajhg.2010.01.030; Miyagawa M, 2014, J HUM GENET, V59, P262, DOI 10.1038/jhg.2014.12; Landrum MJ, 2014, NUCLEIC ACIDS RES, V42, pD980, DOI 10.1093/nar/gkt1113; Walsh T, 2010, AM J HUM GENET, V87, P90, DOI 10.1016/j.ajhg.2010.05.010; Chang X, 2012, J MED GENET, V49, P433, DOI 10.1136/jmedgenet-2012-100918; Brownstein Z, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-9-r89; De Keulenaer S, 2012, BMC MED GENOMICS, V18, P17; Miyagawa M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071381; Miyagawa M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040366; Miyagawa M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0075793; Morton CC, 2006, NEW ENGL J MED, V354, P2151, DOI 10.1056/NEJMra050700; Mutai H, 2013, ORPHANET J RARE DIS, V8, DOI 10.1186/1750-1172-8-172; Narahara M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0100924; Nishio SY, 2015, GENET TEST MOL BIOMA; Oshima A, 2006, HUM MUTAT, V29, pE37; Shearer AE, 2014, AM J HUM GENET, V95, P445, DOI 10.1016/j.ajhg.2014.09.001; Usami S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031276; Van der Auwera GA, 2013, CURR PROTOC BIOINFOR, V11; Vona B, 2014, GENET MED, V16, P945, DOI 10.1038/gim.2014.65; Wang K, 2010, NUCLEIC ACIDS RES, V38, DOI 10.1093/nar/gkq603; Yoshimura H, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090688	30	1	1	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0003-4894	1943-572X		ANN OTO RHINOL LARYN	Ann. Otol. Rhinol. Laryngol.	MAY	2015	124			1			49S	60S		10.1177/0003489415575059		12	Otorhinolaryngology	Otorhinolaryngology	CG6PA	WOS:000353422900003		
J	Tsukada, K; Nishio, S; Hattori, M; Usami, S				Tsukada, Keita; Nishio, Shin-ya; Hattori, Mitsuru; Usami, Shin-ichi			Ethnic-Specific Spectrum of GJB2 and SLC26A4 Mutations: Their Origin and a Literature Review	ANNALS OF OTOLOGY RHINOLOGY AND LARYNGOLOGY			English	Article						GJB2; SLC26A4; mutation spectrum; c.35delG; c.235delC; p.H723R; Y-chromosome	SYNDROMIC HEARING-LOSS; CONNEXIN 26 GENE; ENLARGED VESTIBULAR AQUEDUCT; FREQUENT FOUNDER MUTATION; PENDRED-SYNDROME; IMPAIRED PATIENTS; 35DELG MUTATION; LARGE COHORT; PRELINGUAL DEAFNESS; MOLECULAR ANALYSIS	Objective: The mutation spectrum of the GJB2 and SLC26A4 genes, the 2 most common genes causing deafness, are known to be ethnic specific. In this study, the spectrum of the reported GJB2 and SLC26A4 mutations in different populations are reviewed and considered from a human migration perspective. Methods: Fifty-two and 17 articles on GJB2 and SLC26A4 mutations, respectively, were reviewed through the PubMed database from April 1996 to September 2014. The 4 most prevalent mutations were selected and compared. A cluster analysis was subsequently performed for these selected mutations. Results: The present review of frequent mutations shows the ethnic-specific GJB2 and SLC26A4 gene mutation spectrum. A cluster analysis of the GJB2 and SLC26A4 genes revealed similarities between ethnic populations. Conclusion: The mutation spectrum reviewed in this study clearly indicated that the frequent mutations in the GJB2 and SLC26A4 genes are consistent with the founder mutation hypothesis. A comparison with the Y-chromosome phylogenetic tree indicated that these mutations may have occurred during human migration.	[Tsukada, Keita; Nishio, Shin-ya; Hattori, Mitsuru; Usami, Shin-ichi] Shinshu Univ, Sch Med, Dept Otolaryngol, Matsumoto, Nagano 3908621, Japan; [Nishio, Shin-ya; Usami, Shin-ichi] Shinshu Univ, Sch Med, Dept Hearing Implant Sci, Matsumoto, Nagano 3908621, Japan	Usami, S (reprint author), Shinshu Univ, Sch Med, Dept Otolaryngol, 3-1-1 Asahi, Matsumoto, Nagano 3908621, Japan.	usami@shinshu-u.ac.jp			Health and Labour Sciences Research Grant for Research on Rare and Intractable Diseases from the Ministry of Health, Labour and Welfare, Japan [H24-Nanchitou(Nan)-Ippan-032]; Comprehensive Research on Disability Health and Welfare from the Ministry of Health, Labour and Welfare, Japan [H25-Kankaku-Ippan-002]; Ministry of Education, Culture, Sports, Science and Technology, Japan [22249057]	The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This study was supported by a Health and Labour Sciences Research Grant for Research on Rare and Intractable Diseases [H24-Nanchitou(Nan)-Ippan-032] and Comprehensive Research on Disability Health and Welfare (H25-Kankaku-Ippan-002) from the Ministry of Health, Labour and Welfare, Japan (S.U.), and by a Grant-in-Aid for Scientific Research (A) (22249057) from the Ministry of Education, Culture, Sports, Science and Technology, Japan (S.U.).	Abidi O, 2008, BIOCHEM BIOPH RES CO, V377, P971, DOI 10.1016/j.bbrc.2008.10.086; Al-Sebeih K, 2014, MED PRIN PRACT, V23, P74, DOI 10.1159/000348304; Ammar-Khodja F, 2009, EUR J MED GENET, V52, P174, DOI 10.1016/j.ejmg.2009.03.018; Kelley PM, 1998, AM J HUM GENET, V62, P792, DOI 10.1086/301807; Tsukada K, 2010, CLIN GENET, V78, P464, DOI 10.1111/j.1399-0004.2010.01407.x; Park HJ, 2003, J MED GENET, V40, P242, DOI 10.1136/jmg.40.4.242; Abidi O, 2007, INT J PEDIATR OTORHI, V71, P1239, DOI 10.1016/j.ijporl.2007.04.019; Tekin M, 2010, ANN HUM GENET, V74, P155, DOI 10.1111/j.1469-1809.2010.00564.x; Anwar S, 2009, J HUM GENET, V54, P266, DOI 10.1038/jhg.2009.21; Wilcox SA, 2000, HUM GENET, V106, P399, DOI 10.1007/s004390000273; Rendtorff ND, 2013, CLIN GENET, V84, P388, DOI 10.1111/cge.12074; Tekin M, 2007, AM J MED GENET A, V143A, P1583, DOI 10.1002/ajmg.a.31702; Coyle B, 1998, HUM MOL GENET, V7, P1105, DOI 10.1093/hmg/7.7.1105; Pourova R, 2010, ANN HUM GENET, V74, P299, DOI 10.1111/j.1469-1809.2010.00581.x; Han SH, 2008, J HUM GENET, V53, P1022, DOI 10.1007/s10038-008-0342-7; Bazazzadegan N, 2012, INT J PEDIATR OTORHI, V76, P1164, DOI 10.1016/j.ijporl.2012.04.026; Snoeckx RL, 2005, AM J HUM GENET, V77, P945, DOI 10.1086/497996; Ohtsuka A, 2003, HUM GENET, V112, P329, DOI 10.1007/s00439-002-0889-x; Radulescu L, 2012, INT J PEDIATR OTORHI, V76, P90, DOI 10.1016/j.ijporl.2011.10.007; D'Andrea P, 2002, BIOCHEM BIOPH RES CO, V296, P685, DOI 10.1016/S0006-291X(02)00891-4; Santos RLP, 2005, CLIN GENET, V67, P61, DOI 10.1111/j.1399-0004.2004.00379.x; Campbell C, 2001, HUM MUTAT, V17, P403, DOI 10.1002/humu.1116; Bajaj Y, 2008, CLIN OTOLARYNGOL, V33, P313, DOI 10.1111/j.1749-4486.2008.01754.x; de Moraes VCS, 2013, INT J PEDIATR OTORHI, V77, P410, DOI 10.1016/j.ijporl.2012.11.042; Albert S, 2006, EUR J HUM GENET, V14, P773, DOI 10.1038/sj.ejhg.5201611; Batissoco AC, 2009, EAR HEARING, V30, P1, DOI 10.1097/AUD.0b013e31819144ad; Shin JW, 2012, CLIN EXP OTORHINOLAR, V5, pS10, DOI 10.3342/ceo.2012.5.S1.S10; Padma G, 2009, J GENET, V88, P267, DOI 10.1007/s12041-009-0039-5; Joseph AY, 2009, INT J PEDIATR OTORHI, V73, P437, DOI 10.1016/j.ijporl.2008.11.010; Karafet TM, 2008, GENOME RES, V18, P830, DOI 10.1101/gr.7172008; Yuan YY, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049984; Miyagawa M, 2014, J HUM GENET, V59, P262, DOI 10.1038/jhg.2014.12; Putcha GV, 2007, GENET MED, V9, P413, DOI 10.1097/GIM.0b013e3180a03276; Al-Achkar W, 2011, MOL MED REP, V4, P331, DOI 10.3892/mmr.2011.428; Bruzzone R, 2003, FEBS LETT, V533, P79, DOI 10.1016/S0014-5793(02)03755-9; Najmabadi H, 2005, AM J MED GENET A, V133A, P132, DOI 10.1002/ajmg.a.30576; Van Laer L, 2001, J MED GENET, V38, P515, DOI 10.1136/jmg.38.8.515; Siem G, 2010, INT J AUDIOL, V49, P596, DOI 10.3109/14992021003743269; Hutchin T, 2005, CLIN GENET, V68, P506, DOI 10.1111/j.1399-0004.2005.00539.x; Jobling MA, 2003, NAT REV GENET, V4, P598, DOI 10.1038/nrg1124; Gravina LP, 2010, INT J PEDIATR OTORHI, V74, P250, DOI 10.1016/j.ijporl.2009.11.014; Guo YF, 2008, ACTA OTO-LARYNGOL, V128, P297, DOI 10.1080/00016480701767382; Arenas-Sordo MD, 2012, INT J PEDIATR OTORHI, V76, P1678, DOI 10.1016/j.ijporl.2012.08.005; Azaiez H, 2004, HUM MUTAT, V24, P305, DOI 10.1002/humu.20084; Bason L, 2002, CLIN GENET, V61, P459, DOI 10.1034/j.1399-0004.2002.610611.x; Borck G, 2003, J CLIN ENDOCR METAB, V88, P2916, DOI 10.1210/jc.2002-021334; Brownstein Z, 2009, PEDIATR RES, V66, P128, DOI 10.1203/PDR.0b013e3181aabd7f; Carlsson PI, 2012, ACTA OTO-LARYNGOL, V132, P1301, DOI 10.3109/00016489.2012.701018; Chan DK, 2014, LARYNGOSCOPE, V124, pE34, DOI 10.1002/lary.24332; Cifuentes L, 2013, BIOL RES, V46, P239, DOI 10.4067/S0716-97602013000300003; Dahl HH, 2013, PLOS ONE, V8; Dai P, 2009, PHYSIOL GENOMICS, V38, P281, DOI 10.1152/physiolgenomics.00047.2009; Dai P, 2008, J TRANSL MED, V6, DOI 10.1186/1479-5876-6-74; Dai P, 2009, J TRANSL MED, V7, DOI 10.1186/1479-5876-7-26; Danilenko N, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036354; Dzhemileva LU, 2011, ACTA NATURAE, V3, P52; Dzhemileva LU, 2010, J HUM GENET, V55, P749, DOI 10.1038/jhg.2010.101; Gasmelseed Nagla M A, 2004, Hum Mutat, V23, P206, DOI 10.1002/humu.9216; Hamelmann C, 2001, Hum Mutat, V18, P84, DOI 10.1002/humu.1156; Homoe P, 2012, INT J AUDIOL, V51, P433, DOI 10.3109/14992027.2012.660575; Imtiaz F, 2011, BMC MED GENET, V12, DOI 10.1186/1471-2350-12-91; Janecke AR, 2002, HUM GENET, V111, P145, DOI 10.1007/s00439-002-0762-y; Javidnia H, 2014, LARYNGOSCOPE, V124, pE373, DOI 10.1002/lary.24697; Kahrizi K, 2009, EUR J PEDIATR, V168, P651, DOI 10.1007/s00431-008-0809-8; Kokotas H, 2008, AM J MED GENET A, V146A, P2879, DOI 10.1002/ajmg.a.32546; Lopponen T, 2003, LARYNGOSCOPE, V113, P1758; Marlin S, 2005, ARCH OTOLARYNGOL, V131, P481, DOI 10.1001/archotol.131.6.481; Minarik G, 2012, INT J PEDIATR OTORHI, V76, P400, DOI 10.1016/j.ijporl.2011.12.020; MORTON NE, 1991, ANN NY ACAD SCI, V630, P16, DOI 10.1111/j.1749-6632.1991.tb19572.x; Nogueira C, 2011, GENET RES INT, DOI [10.4061/2011/587602., DOI 10.4061/2011/587602]; Pampanos A, 2002, INT J PEDIATR OTORHI, V65, P101, DOI 10.1016/S0165-5876(02)00177-5; Pera A, 2008, EUR J HUM GENET, V16, P888, DOI 10.1038/ejhg.2008.30; Popova DP, 2012, EUR ARCH OTO-RHINO-L, V269, P1589, DOI 10.1007/s00405-011-1817-2; Posukh O, 2005, BMC MED GENET, V6, DOI 10.1186/1471-2350-6-12; Rabionet R, 2000, HUM GENET, V106, P40, DOI 10.1007/s004390051007; RamShankar M, 2003, J MED GENET, V40, DOI 10.1136/jmg.40.5.e68; Sansovic I, 2009, GENET TEST MOL BIOMA, V13, P693, DOI 10.1089/gtmb.2009.0073; Santos RLP, 2005, INT J PEDIATR OTORHI, V69, P165, DOI 10.1016/j.ijport.2004.08.015; Seeman P, 2006, CLIN GENET, V69, P410, DOI 10.1111/j.1399-0004.2006.00602.x; Seeman P, 2004, CLIN GENET, V66, P152, DOI 10.1111/j.1399-0004.2004.00283.x; Snoeckx RL, 2005, AM J MED GENET A, V135A, P126, DOI 10.1002/ajmg.a.30726; Snoeckx Rikkert L, 2005, Hum Mutat, V26, P60, DOI 10.1002/humu.9350; Tamayo ML, 2009, INT J PEDIATR OTORHI, V73, P97, DOI 10.1016/j.ijporl.2008.10.001; Teek R, 2010, INT J PEDIATR OTORHI, V74, P1007, DOI 10.1016/j.ijporl.2010.05.026; Tekin M, 2003, CLIN GENET, V64, P371, DOI 10.1034/j.1399-0004.2003.00144.x; Trabelsi M, 2013, INT J PEDIATR OTORHI, V77, P714, DOI 10.1016/j.ijporl.2013.01.024; Wattanasirichaigoon D, 2004, CLIN GENET, V66, P452, DOI 10.1111/j.1399-0004.2004.00325.x; Wiszniewski W, 2001, GENET TEST, V5, P147, DOI 10.1089/109065701753145637; Wu CC, 2010, AUDIOL NEURO-OTOL, V15, P57, DOI 10.1159/000231567; Wu CC, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022314; Wu CC, 2005, LARYNGOSCOPE, V115, P1060, DOI 10.1097/01.MLG.0000163339.61909.D0; Ellis N, 2002, GENOME RES, V12, P339; Yan D, 2003, HUM GENET, V114, P44, DOI 10.1007/s00439-003-1018-1; Yao J, 2012, J TRANSL MED, V10, DOI 10.1186/1479-5876-10-136; Zainal SA, 2012, INT J PEDIATR OTORHI, V76, P1175, DOI 10.1016/j.ijporl.2012.04.027; Zoll Barbara, 2003, Hum Mutat, V21, P98, DOI 10.1002/humu.9098	96	2	2	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0003-4894	1943-572X		ANN OTO RHINOL LARYN	Ann. Otol. Rhinol. Laryngol.	MAY	2015	124			1			61S	76S		10.1177/0003489415575060		16	Otorhinolaryngology	Otorhinolaryngology	CG6PA	WOS:000353422900004		
J	Yoshimura, H; Hashimoto, T; Murata, T; Fukushima, K; Sugaya, A; Nishio, S; Usami, S				Yoshimura, Hidekane; Hashimoto, Takao; Murata, Toshinori; Fukushima, Kunihiro; Sugaya, Akiko; Nishio, Shin-ya; Usami, Shin-ichi			Novel ABHD12 Mutations in PHARC Patients: The Differential Diagnosis of Deaf-Blindness	ANNALS OF OTOLOGY RHINOLOGY AND LARYNGOLOGY			English	Article						PHARC; ABHD12; Usher syndrome; deaf-blindness; genetics of hearing loss	USHER-SYNDROME; SPECTRUM	Objective: This study examines ABHD12 mutation analysis in 2 PHARC patients, originally thought to be Usher syndrome. Methods: The ABHD12 gene of 2 patients, who suffered from deaf-blindness and dysfunctional central and peripheral nervous systems, were sequenced. Results: We identified that both cases carried the same novel splice site mutation in the ABHD12 gene. However, 1 had epilepsy and the other had peripheral neuropathy. Based on haplotype analysis, the mutation is likely not a hot spot, but rather could be attributable to a common ancestor. Conclusion: This study, shows that PHARC has phenotypic variability, even within a family, which is consistent with previous reports. Differential diagnosis of "deaf-blindness" diseases is crucial. Confirming the presence of associated symptoms is necessary for differentiating some deaf-blindness syndromes. In addition, mutation analysis is a useful tool for confirming the diagnosis.	[Yoshimura, Hidekane; Nishio, Shin-ya; Usami, Shin-ichi] Shinshu Univ, Sch Med, Dept Otorhinolaryngol, Matsumoto, Nagano 3908621, Japan; [Hashimoto, Takao] Aizawa Hosp, Dept Neurol, Matsumoto, Nagano, Japan; [Murata, Toshinori] Shinshu Univ, Sch Med, Dept Ophthalmol, Matsumoto, Nagano 3908621, Japan; [Sugaya, Akiko] Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Otorhinolaryngol Head & Neck Surg, Okayama 7008530, Japan; [Nishio, Shin-ya; Usami, Shin-ichi] Shinshu Univ, Sch Med, Dept Hearing Implant Sci, Matsumoto, Nagano 3908621, Japan; [Fukushima, Kunihiro] Fukuoka Univ, Sch Med, Dept Otorhinolaryngol, Fukuoka 81401, Japan	Usami, S (reprint author), Shinshu Univ, Sch Med, Dept Otorhinolaryngol, 3-1-1 Asahi, Matsumoto, Nagano 3908621, Japan.	usami@shinshu-u.ac.jp			Health and Labour Sciences Research Grant for Research on Rare and Intractable Diseases from the Ministry of Health, Labour and Welfare of Japan; Comprehensive Research on Disability Health and Welfare from the Ministry of Health, Labour and Welfare of Japan; Ministry of Education, Science and Culture of Japan	The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This study was supported by a Health and Labour Sciences Research Grant for Research on Rare and Intractable Diseases and Comprehensive Research on Disability Health and Welfare from the Ministry of Health, Labour and Welfare of Japan (S.U.), and by a Grant-in-Aid for Scientific Research from the Ministry of Education, Science and Culture of Japan (S.U.).	Laugel V, 2010, HUM MUTAT, V31, P113, DOI 10.1002/humu.21154; Fiskerstrand T, 2010, AM J HUM GENET, V87, P410, DOI 10.1016/j.ajhg.2010.08.002; Yan D, 2010, J HUM GENET, V55, P327, DOI 10.1038/jhg.2010.29; Chen DH, 2013, HUM MUTAT, V34, P1672, DOI 10.1002/humu.22437; Eisenberger T, 2012, ORPHANET J RARE DIS, V7, DOI 10.1186/1750-1172-7-59; Fiskerstrand T, 2009, NEUROLOGY, V72, P20, DOI 10.1212/01.wnl.0000333664.90605.23; Flynn P, 1965, J Neurol Sci, V2, P161, DOI 10.1016/0022-510X(65)90078-X; Maceluch Jaros Aw, 2006, Pediatr Endocrinol Rev, V4, P117; Nishiguchi KM, 2014, OPHTHALMOLOGY, V121, P1620, DOI 10.1016/j.ophtha.2014.02.008; van den Brink DM, 2003, AM J HUM GENET, V72, P471, DOI 10.1086/346093; Yoshimura H, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090688	11	0	0	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0003-4894	1943-572X		ANN OTO RHINOL LARYN	Ann. Otol. Rhinol. Laryngol.	MAY	2015	124			1			77S	83S		10.1177/0003489415574513		7	Otorhinolaryngology	Otorhinolaryngology	CG6PA	WOS:000353422900005		
J	Miyagawa, M; Nishio, S; Ichinose, A; Iwasaki, S; Murata, T; Kitajiri, S; Usami, S				Miyagawa, Maiko; Nishio, Shin-ya; Ichinose, Aya; Iwasaki, Satoshi; Murata, Takaaki; Kitajiri, Shin-ichiro; Usami, Shin-ichi			Mutational Spectrum and Clinical Features of Patients With ACTG1 Mutations Identified by Massively Parallel DNA Sequencing	ANNALS OF OTOLOGY RHINOLOGY AND LARYNGOLOGY			English	Article						ACTG1; DFNA20/26; hearing loss; massively parallel DNA sequencing; next generation sequencing; EAS	ELECTRIC-ACOUSTIC STIMULATION; HEARING-LOSS; GAMMA-ACTIN; GENETIC-VARIANTS; DFNA20/26 FAMILY; DEAFNESS GENES; HUMAN GENOMES; IMPAIRMENT; ISOFORMS	Objectives: ACTGI has been reported to be a causative gene for autosomal dominant sensorineural hearing loss, DFNA20/26. In this study we sought to clarify the detailed mutational spectrum, clinical features, and genotype-phenotype correlations. Methods: Massively parallel DNA sequencing (MPS) of 63 target candidate genes was used to screen 1120 Japanese hearing loss patients. Results: MPS screening successfully identified 4 ACTGI mutations in 5 families. The majority of patients showed high frequency involved progressive hearing loss, with the age of onset mostly in the first or second decade. One patient received electric acoustic stimulation (EAS), which showed a good outcome. Conclusions: Target exon-sequencing using MPS was proven to be a powerful new clinical diagnostic tool for the identification of rare causative genes such as ACTGI. The present clinical findings not only confirmed those previous reports but also provided important new clinical information.	[Miyagawa, Maiko; Nishio, Shin-ya; Ichinose, Aya; Usami, Shin-ichi] Shinshu Univ, Sch Med, Dept Otorhinolaryngol, Matsumoto, Nagano 3908621, Japan; [Miyagawa, Maiko; Nishio, Shin-ya; Iwasaki, Satoshi; Usami, Shin-ichi] Shinshu Univ, Sch Med, Dept Hearing Implant Sci, Matsumoto, Nagano 3908621, Japan; [Iwasaki, Satoshi] Int Univ Hlth & Welf, Mita Hosp, Dept Otorhinolaryngol, Tokyo, Japan; [Murata, Takaaki] Gunma Univ, Sch Med, Dept Otorhinolaryngol, Maebashi, Gumma 371, Japan; [Kitajiri, Shin-ichiro] Kyoto Univ, Grad Sch Med, Dept Otorhinolaryngol Head & Neck Surg, Kyoto, Japan	Usami, S (reprint author), Shinshu Univ, Sch Med, Dept Otorhinolaryngol, 3-1-1 Asahi, Matsumoto, Nagano 3908621, Japan.	usami@shinshu-u.ac.jp			Health and Labour Sciences Research Grant for Research on Rare and Intractable Diseases [H24-Nanchiou(Nan)-Ippan-032]; Comprehensive Research on Disability Health and Welfare from the Ministry of Health, Labour and Welfare of Japan [H25-Kankaku-Ippan-002]; Ministry of Education, Science and Culture of Japan [22249057]	The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This study was supported by a Health and Labour Sciences Research Grant for Research on Rare and Intractable Diseases (H24-Nanchiou(Nan)-Ippan-032) and Comprehensive Research on Disability Health and Welfare (H25-Kankaku-Ippan-002) from the Ministry of Health, Labour and Welfare of Japan (S.U.) and by a Grant-in-Aid for Scientific Research (A) (22249057) from the Ministry of Education, Science and Culture of Japan (S.U.).	Altshuler DM, 2012, NATURE, V491, P56, DOI 10.1038/nature11632; VANDEKERCKHOVE J, 1978, J MOL BIOL, V126, P783, DOI 10.1016/0022-2836(78)90020-7; Kumar P, 2009, NAT PROTOC, V4, P1073, DOI 10.1038/nprot.2009.86; Pollard KS, 2010, GENOME RES, V20, P110, DOI 10.1101/gr.097857.109; Morin M, 2009, HUM MOL GENET, V18, P3075, DOI 10.1093/hmg/ddp249; Cooper GM, 2005, GENOME RES, V15, P901, DOI 10.1101/gr.3577405; Belyantseva IA, 2009, P NATL ACAD SCI USA, V106, P9703, DOI 10.1073/pnas.0900221106; Schwarz JM, 2010, NAT METHODS, V7, P575, DOI 10.1038/nmeth0810-575; Khaitlina SY, 2001, INT REV CYTOL, V202, P35, DOI 10.1016/S0074-7696(01)02003-4; Chun S, 2009, GENOME RES, V19, P1553, DOI 10.1101/gr.092619.109; Adzhubei IA, 2010, NAT METHODS, V7, P248, DOI 10.1038/nmeth0410-248; von Ilberg CA, 2011, AUDIOL NEURO-OTOL, V16, P1, DOI 10.1159/000327765; Chang X, 2012, J MED GENET, V49, P433, DOI 10.1136/jmedgenet-2012-100918; Baek JI, 2012, ORPHANET J RARE DIS, V7, DOI 10.1186/1750-1172-7-60; de Heer AMR, 2009, ANN OTO RHINOL LARYN, V118, P382; Foo RY, 2013, DEV MED CHILD NEUROL, V55, P911, DOI 10.1111/dmcn.12157; Hofer D, 1997, J CELL SCI, V110, P765; Hu BH, 1997, HEARING RES, V110, P209, DOI 10.1016/S0378-5955(97)00075-0; LI HS, 1994, ORL J OTO-RHINO-LARY, V56, P61; Liu P, 2008, J GENET GENOMICS, V35, P553, DOI 10.1016/S1673-8527(08)60075-2; Miyagawa M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0075793; Morell RJ, 2000, GENOMICS, V63, P1, DOI 10.1006/geno.1999.6058; Mutai H, 2013, ORPHANET J RARE DIS, V8, DOI 10.1186/1750-1172-8-172; Narahara M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0100924; Park G, 2013, BMC GENOMICS, V14, DOI 10.1186/1471-2164-14-191; Rendtorff ND, 2006, EUR J HUM GENET, V14, P1097, DOI 10.1038/sj.ejhg.5201670; Riviere JB, 2012, NAT GENET, V26, pS1; Riviere JB, 2012, NAT GENET, V26, P440; Usami S, 2012, ACTA OTO-LARYNGOL, V132, P377, DOI 10.3109/00016489.2011.649493; Van Camp G, 2002, HUM MUTAT, V20, P15, DOI 10.1002/humu.10096; van Wijk E, 2003, J MED GENET, V40, P879, DOI 10.1136/jmg.40.12.879; Vona B, 2014, GENET MED, V16, P945, DOI 10.1038/gim.2014.65; Wang K, 2010, NUCLEIC ACIDS RES, V38, DOI 10.1093/nar/gkq603; Zhu M, 2003, AM J HUM GENET, V73, P1082, DOI 10.1086/379286	34	0	0	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0003-4894	1943-572X		ANN OTO RHINOL LARYN	Ann. Otol. Rhinol. Laryngol.	MAY	2015	124			1			84S	93S		10.1177/0003489415575057		10	Otorhinolaryngology	Otorhinolaryngology	CG6PA	WOS:000353422900006		
J	Yoshimura, H; Oshikawa, C; Nakayama, J; Moteki, H; Usami, S				Yoshimura, Hidekane; Oshikawa, Chie; Nakayama, Jun; Moteki, Hideaki; Usami, Shin-ichi			Identification of a Novel CLRN1 Gene Mutation in Usher Syndrome Type 3: Two Case Reports	ANNALS OF OTOLOGY RHINOLOGY AND LARYNGOLOGY			English	Article						CLRN1; Usher syndrome; deaf-blindness; massively parallel sequencing; genetics of hearing loss	SYNDROME TYPE-III; PHENOTYPIC VARIABILITY; CLARIN-1; VARIANTS; PROTEIN	Objective: This study examines the CLRNI gene mutation analysis in Japanese patients who were diagnosed with Usher syndrome type 3 (USH3) on the basis of clinical findings. Methods: Genetic analysis using massively parallel DNA sequencing (MPS) was conducted to search for 9 causative USH genes in 2 USH3 patients. Results: We identified the novel pathogenic mutation in the CLRNI gene in 2 patients. The missense mutation was confirmed by functional prediction software and segregation analysis. Both patients were diagnosed as having USH3 caused by the CLRNI gene mutation. Conclusion: This is the first report of USH3 with a CLRNI gene mutation in Asian populations. Validating the presence of clinical findings is imperative for properly differentiating among USH subtypes. In addition, mutation screening using MPS enables the identification of causative mutations in USH. The clinical diagnosis of this phenotypically variable disease can then be confirmed.	[Yoshimura, Hidekane; Moteki, Hideaki; Usami, Shin-ichi] Shinshu Univ, Sch Med, Dept Otorhinolaryngol, Matsumoto, Nagano 3908621, Japan; [Oshikawa, Chie] Kyushu Univ, Grad Sch Med Sci, Dept Otorhinolaryngol, Fukuoka 812, Japan; [Nakayama, Jun] Shiga Univ, Sch Med Sci, Dept Otorhinolaryngol, Otsu, Shiga, Japan; [Moteki, Hideaki; Usami, Shin-ichi] Shinshu Univ, Sch Med, Dept Hearing Implant Sci, Matsumoto, Nagano 3908621, Japan	Usami, S (reprint author), Shinshu Univ, Sch Med, Dept Otorhinolaryngol, 3-1-1 Asahi, Matsumoto, Nagano 3908621, Japan.	usami@shinshu-u.ac.jp			Health and Labour Sciences Research Grant for Research on Rare and Intractable Diseases; Comprehensive Research on Disability Health and Welfare from the Ministry of Health, Labour and Welfare of Japan; Ministry of Education, Science and Culture of Japan	The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This study was supported by a Health and Labour Sciences Research Grant for Research on Rare and Intractable Diseases and Comprehensive Research on Disability Health and Welfare from the Ministry of Health, Labour and Welfare of Japan (SU), and by a Grant-in-Aid for Scientific Research from the Ministry of Education, Science and Culture of Japan (SU).	Aller E, 2004, CLIN GENET, V66, P525, DOI 10.1111/j.1399-0004.2004.00352.x; Dreyer B, 2008, HUM MUTAT, V29, P451, DOI 10.1002/humu.9524; Adato A, 2002, EUR J HUM GENET, V10, P339, DOI 10.1038/sj.ejhg.5200831; Shearer AE, 2013, J MED GENET, V50, P627, DOI 10.1136/jmedgenet-2013-101749; Cremers FPM, 2007, J MED GENET, V44, P153, DOI 10.1136/jmg.2006.044784; Joensuu T, 2001, AM J HUM GENET, V69, P673, DOI 10.1086/323610; Fields RR, 2002, AM J HUM GENET, V71, P607, DOI 10.1086/342098; Chang X, 2012, J MED GENET, V49, P433, DOI 10.1136/jmedgenet-2012-100918; Ness SL, 2003, J MED GENET, V40, P767, DOI 10.1136/jmg.40.10.767; Yan D, 2010, J HUM GENET, V55, P327, DOI 10.1038/jhg.2010.29; Bonnet C, 2011, ORPHANET J RARE DIS, V6, DOI 10.1186/1750-1172-6-21; Geng RS, 2009, HUM MOL GENET, V18, P2748, DOI 10.1093/hmg/ddp210; Isosomppi J, 2009, MOL VIS, V15, P1806; Miyagawa M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071381; Miyagawa M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0075793; Pakarinen Leenamaija, 1995, International Ophthalmology, V19, P307, DOI 10.1007/BF00130927; PAKARINEN L, 1995, LARYNGOSCOPE, V105, P613, DOI 10.1288/00005537-199506000-00010; Sadeghi M, 2005, INT J AUDIOL, V44, P307, DOI 10.1080/14992020500060610; Wang K, 2010, NUCLEIC ACIDS RES, V38, DOI 10.1093/nar/gkq603; Yoshimura H, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090688; Zallocchi M, 2009, HEARING RES, V255, P109, DOI 10.1016/j.heares.2009.06.006	21	0	0	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0003-4894	1943-572X		ANN OTO RHINOL LARYN	Ann. Otol. Rhinol. Laryngol.	MAY	2015	124			1			94S	99S		10.1177/0003489415574069		6	Otorhinolaryngology	Otorhinolaryngology	CG6PA	WOS:000353422900007		
J	Tsukada, K; Ichinose, A; Miyagawa, M; Mori, K; Hattori, M; Nishio, S; Naito, Y; Kitajiri, S; Usami, S				Tsukada, Keita; Ichinose, Aya; Miyagawa, Maiko; Mori, Kentaro; Hattori, Mitsuru; Nishio, Shin-ya; Naito, Yasushi; Kitajiri, Shin-ichiro; Usami, Shin-ichi			Detailed Hearing and Vestibular Profiles in the Patients with COCH Mutations	ANNALS OF OTOLOGY RHINOLOGY AND LARYNGOLOGY			English	Article						COCH; DFNA9; progressive hearing loss; vestibular dysfunction; Massively Parallel Sequencing; next-generation sequencing	TEMPORAL BONE FINDINGS; INNER-EAR; DEAFNESS DISORDER; GENETIC-VARIANTS; DFNA9 DEAFNESS; HUMAN GENOMES; VWFA2 DOMAIN; LCCL DOMAIN; DYSFUNCTION; IDENTIFICATION	Objectives: To evaluate the clinical features of Japanese DFNA9 families with mutations of the COCH gene. Methods: Mutation screening was performed using targeted next-generation sequencing (NGS) for 63 previously reported deafness genes. The progression of hearing loss and vestibular dysfunction were evaluated by pure-tone audiometry, caloric testing, cVEMP, and computed dynamic posturography. Results: We detected I reported mutation of p.G88E and 2 novel mutations of p.I372T and p.C542R. The patients with the novel mutations of p.I372T and p.C542R within the vWFA2 domain showed early onset progressive hearing loss, and the patients with the p.G88E mutation showed late onset hearing loss and acute hearing deterioration over a short period. Vestibular symptoms were reported in the patients with p.G88E and p.C542R. Vestibular testing was performed for the family with the p.G88E mutation. Severe vestibular dysfunction was observed in the proband, and the proband's son showed unilateral semicircular canal dysfunction with mild hearing loss. Conclusions: Targeted exon resequencing of selected genes using NGS successfully identified mutations in the relatively rare deafness gene, COCH, in the Japanese population. The phenotype is compatible with that described in previous reports. Additional supporting evidence concerning progressive hearing loss and deterioration of vestibular function was obtained from our study.	[Tsukada, Keita; Ichinose, Aya; Miyagawa, Maiko; Mori, Kentaro; Hattori, Mitsuru; Nishio, Shin-ya; Usami, Shin-ichi] Shinshu Univ, Sch Med, Dept Otorhinolaryngol, Matsumoto, Nagano 3908621, Japan; [Miyagawa, Maiko; Nishio, Shin-ya; Usami, Shin-ichi] Shinshu Univ, Sch Med, Dept Hearing Implant Sci, Matsumoto, Nagano 3908621, Japan; [Naito, Yasushi] Kobe City Med Ctr Gen Hosp, Dept Otorhinolaryngol, Kobe, Hyogo, Japan; [Kitajiri, Shin-ichiro] Kyoto Univ, Grad Sch Med, Dept Otolaryngol Head & Neck Surg, Kyoto, Japan	Usami, S (reprint author), Shinshu Univ, Sch Med, Dept Otorhinolaryngol, 3-1-1 Asahi, Matsumoto, Nagano 3908621, Japan.	usami@shinshu-u.ac.jp			Health and Labour Sciences Research Grant for Research on Rare and Intractable Diseases [H24-Nanchiou(Nan)-Ippan-032]; Comprehensive Research on Disability Health and Welfare from the Ministry of Health, Labour and Welfare of Japan [H25-Kanakaku-Ippan-002]; Ministry of Education, Science and Culture of Japan [22249057]	The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This study was supported by a Health and Labour Sciences Research Grant for Research on Rare and Intractable Diseases (H24-Nanchiou(Nan)-Ippan-032) and Comprehensive Research on Disability Health and Welfare (H25-Kanakaku-Ippan-002) from the Ministry of Health, Labour and Welfare of Japan (S.U.), and by a Grant-in-Aid for Scientific Research (A) (22249057) from the Ministry of Education, Science and Culture of Japan (S.U.).	Altshuler DM, 2012, NATURE, V491, P56, DOI 10.1038/nature11632; Cho HJ, 2012, J MOL MED, V90, P1321, DOI 10.1007/s00109-012-0911-2; Dodson KM, 2012, AM J OTOLARYNG, V33, P590, DOI 10.1016/j.amjoto.2012.03.005; Gao J, 2013, CLIN GENET, V83, P477, DOI 10.1111/cge.12006; Merchant SN, 2000, ADV OTO-RHINO-LARYNG, V56, P212; Robertson NG, 1997, GENOMICS, V46, P345, DOI 10.1006/geno.1997.5067; Kumar P, 2009, NAT PROTOC, V4, P1073, DOI 10.1038/nprot.2009.86; Pollard KS, 2010, GENOME RES, V20, P110, DOI 10.1101/gr.097857.109; Robertson NG, 1998, NAT GENET, V20, P299; Cooper GM, 2005, GENOME RES, V15, P901, DOI 10.1101/gr.3577405; Schwarz JM, 2010, NAT METHODS, V7, P575, DOI 10.1038/nmeth0810-575; Liepinsh E, 2001, EMBO J, V20, P5347, DOI 10.1093/emboj/20.19.5347; Street VA, 2005, AM J MED GENET A, V139A, P86, DOI 10.1002/ajmg.a.30980; de Kok YJM, 1999, HUM MOL GENET, V8, P361, DOI 10.1093/hmg/8.2.361; Chun S, 2009, GENOME RES, V19, P1553, DOI 10.1101/gr.092619.109; Adzhubei IA, 2010, NAT METHODS, V7, P248, DOI 10.1038/nmeth0410-248; Chang X, 2012, J MED GENET, V49, P433, DOI 10.1136/jmedgenet-2012-100918; Baek JI, 2010, CLIN GENET, V77, P399, DOI 10.1111/j.1399-0004.2009.01362.x; Bischoff AMLC, 2005, OTOL NEUROTOL, V26, P918, DOI 10.1097/01.mao.0000185048.84641.e3; Bom SJH, 1999, LARYNGOSCOPE, V109, P1525, DOI 10.1097/00005537-199909000-00031; Chen DY, 2013, INT J PEDIATR OTORHI, V77, P1711, DOI 10.1016/j.ijporl.2013.07.031; Collin RWJ, 2006, AM J MED GENET A, V140A, P1791, DOI 10.1002/ajmg.a.31354; Gallant E, 2013, AM J OTOLARYNG, V34, P230, DOI 10.1016/j.amjoto.2012.11.002; Hildebrand MS, 2010, LARYNGOSCOPE, V120, P2489, DOI 10.1002/lary.21159; Ikezono T, 2001, BBA-MOL BASIS DIS, V1535, P258, DOI 10.1016/S0925-4439(00)00101-0; Kamarinos M, 2001, Hum Mutat, V17, P351, DOI 10.1002/humu.37; Kemperman MH, 2005, OTOL NEUROTOL, V26, P926, DOI 10.1097/01.mao.0000185062.12458.87; KHETARPAL U, 1991, ARCH OTOLARYNGOL, V117, P1032; KHETARPAL U, 1993, ARCH OTOLARYNGOL, V119, P106; Miyagawa M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0075793; MORTON NE, 1991, ANN NY ACAD SCI, V630, P16, DOI 10.1111/j.1749-6632.1991.tb19572.x; Nagy I, 2004, J MED GENET, V41, DOI 10.1136/jmg.2003.012286; Narahara M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0100924; Pauw RJ, 2007, ANN OTO RHINOL LARYN, V116, P349; Robertson NG, 2001, HUM MOL GENET, V10, P2493, DOI 10.1093/hmg/10.22.2493; Robertson NG, 2006, HUM MOL GENET, V15, P1071, DOI 10.1093/hmg/ddl022; Usami S, 2003, EUR J HUM GENET, V11, P744, DOI 10.1038/sj.ejhg.5201043; Vermeire K, 2006, OTOL NEUROTOL, V27, P44, DOI 10.1097/01.mao.0000187240.33712.01; Wang K, 2010, NUCLEIC ACIDS RES, V38, DOI 10.1093/nar/gkq603; Yuan HJ, 2008, CLIN GENET, V73, P391, DOI 10.1111/j.1399-0004.2008.00972.x	40	0	0	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0003-4894	1943-572X		ANN OTO RHINOL LARYN	Ann. Otol. Rhinol. Laryngol.	MAY	2015	124			1			100S	110S		10.1177/0003489415573074		11	Otorhinolaryngology	Otorhinolaryngology	CG6PA	WOS:000353422900008		
J	Iwasa, Y; Moteki, H; Hattori, M; Sato, R; Nishio, S; Takumi, Y; Usami, S				Iwasa, Yoh-ichiro; Moteki, Hideaki; Hattori, Mitsuru; Sato, Ririko; Nishio, Shin-ya; Takumi, Yutaka; Usami, Shin-ichi			Non-ocular Stickler Syndrome With a Novel Mutation in COL11A2 Diagnosed by Massively Parallel Sequencing in Japanese Hearing Loss Patients	ANNALS OF OTOLOGY RHINOLOGY AND LARYNGOLOGY			English	Article						hearing loss; genetics; COL11A2; autosonnal dominant; Stickler syndrome; massively parallel sequencing	WEISSENBACHER-ZWEYMULLER-SYNDROME; STOP CODON MUTATION; OTOSPONDYLOMEGAEPIPHYSEAL DYSPLASIA; GENETIC-VARIANTS; AFFECTED MEMBERS; HUMAN GENOMES; COLLAGEN-XI; LOCUS; DOMINANT; FAMILY	Objectives: This study aims to document the clinical features of patients with COLI IA2 mutations and to describe the usefulness of massively parallel sequencing. Methods: One thousand one hundred twenty (I I20) Japanese hearing loss patients from 53 ENT departments nationwide participated in this study. Massively parallel sequencing of 63 genes implicated in hearing loss was performed to identify the genetic causes in the Japanese hearing loss patients. Results: A novel mutation in COLI IA2 (c.3937_3948delCCCCCAGGGCCA) was detected in an affected family, and it was segregated in all hearing loss individuals. The clinical findings of this family were compatible with non-ocular Stickler syndrome. Orofacial features of mid-facial hypoplasia and slowly progressive mild to moderate hearing loss were also presented. Audiological examinations showed favorable auditory performance with hearing aid(s). Conclusion: This is the first case report of the genetic diagnosis of a non-ocular Stickler syndrome family in the Japanese population. We suggest that it is important to take both genetic analysis data and clinical symptoms into consideration to make an accurate diagnosis.	[Iwasa, Yoh-ichiro; Moteki, Hideaki; Hattori, Mitsuru; Sato, Ririko; Nishio, Shin-ya; Takumi, Yutaka; Usami, Shin-ichi] Shinshu Univ, Sch Med, Dept Otorhinolaryngol, Matsumoto, Nagano 3908621, Japan; [Moteki, Hideaki; Nishio, Shin-ya; Takumi, Yutaka; Usami, Shin-ichi] Shinshu Univ, Sch Med, Dept Hearing Implant Sci, Matsumoto, Nagano 3908621, Japan	Usami, S (reprint author), Shinshu Univ, Sch Med, Dept Hearing Implant Sci, Dept Otorhinolaryngol, 3-1-1 Asahi, Matsumoto, Nagano 3908621, Japan.	usami@shinshu-u.ac.jp			Health and Labour Sciences Research Grant for Research on Rare and Intractable Diseases; Comprehensive Research on Disability Health and Welfare from the Ministry of Health, Labour and Welfare of Japan; Ministry of Education, Science and Culture of Japan	The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This study was supported by a Health and Labour Sciences Research Grant for Research on Rare and Intractable Diseases and Comprehensive Research on Disability Health and Welfare from the Ministry of Health, Labour and Welfare of Japan (S.U.) and by a Grant-in-Aid for Scientific Research from the Ministry of Education, Science and Culture of Japan (S.U.).	Altshuler DM, 2012, NATURE, V491, P56, DOI 10.1038/nature11632; Acke FRE, 2012, ORPHANET J RARE DIS, V7, DOI 10.1186/1750-1172-7-84; STICKLER GB, 1965, MAYO CLIN PROC, V40, P433; Kumar P, 2009, NAT PROTOC, V4, P1073, DOI 10.1038/nprot.2009.86; Chen W, 2005, J MED GENET, V42, DOI 10.1136/jmg.2005.032615; Pollard KS, 2010, GENOME RES, V20, P110, DOI 10.1101/gr.097857.109; Cooper GM, 2005, GENOME RES, V15, P901, DOI 10.1101/gr.3577405; Schwarz JM, 2010, NAT METHODS, V7, P575, DOI 10.1038/nmeth0810-575; Chun S, 2009, GENOME RES, V19, P1553, DOI 10.1101/gr.092619.109; Adzhubei IA, 2010, NAT METHODS, V7, P248, DOI 10.1038/nmeth0410-248; VIKKULA M, 1995, CELL, V80, P431, DOI 10.1016/0092-8674(95)90493-X; Chang X, 2012, J MED GENET, V49, P433, DOI 10.1136/jmedgenet-2012-100918; Melkoniemi M, 2003, EUR J HUM GENET, V11, P265, DOI 10.1038/sj.ejhg.5200950; De Leenheer EMR, 2004, ANN OTO RHINOL LARYN, V113, P922; Harel T, 2005, AM J MED GENET A, V132A, P33, DOI 10.1002/ajmg.a.30371; Jain U, 2011, BMJ CASE REP, V2011; Jakkula E, 2005, OSTEOARTHR CARTILAGE, V13, P497, DOI 10.1016/j.joca.2005.02.005; Kayserili H, 2011, AM J MED GENET A, V155A, P180, DOI 10.1002/ajmg.a.33780; McGuirt WT, 1999, NAT GENET, V23, P413; Melkoniemi M, 2000, AM J HUM GENET, V66, P368, DOI 10.1086/302750; Miyagawa M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0075793; Narahara M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0100924; Pihlajamaa T, 1998, AM J MED GENET, V80, P115, DOI 10.1002/(SICI)1096-8628(19981102)80:2<115::AID-AJMG5>3.0.CO;2-O; Plantinga RF, 2007, JARO-J ASSOC RES OTO, V8, P1, DOI 10.1007/s10162-006-0060-9; Sirko-Osadsa D, 1998, J PEDIATR-US, V132, P368, DOI 10.1016/S0022-3476(98)70466-4; Temtamy SA, 2006, AM J MED GENET A, V140A, P1189, DOI 10.1002/ajmg.a.31205; Tokgoz-Yilmaz S, 2011, INT J PEDIATR OTORHI, V75, P433, DOI 10.1016/j.ijporl.2010.12.004; Tompson SW, 2012, AM J MED GENET A, V158A, P309, DOI 10.1002/ajmg.a.34406; van Beelen E, 2012, HEARING RES, V291, P15, DOI 10.1016/j.heares.2012.07.001; vanSteensel MAM, 1997, AM J MED GENET, V70, P315; Vuoristo MM, 2004, AM J MED GENET A, V130A, P160, DOI 10.1002/ajmg.a.30111; Wang K, 2010, NUCLEIC ACIDS RES, V38, DOI 10.1093/nar/gkq603	32	0	0	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0003-4894	1943-572X		ANN OTO RHINOL LARYN	Ann. Otol. Rhinol. Laryngol.	MAY	2015	124			1			111S	117S		10.1177/0003489415575044		7	Otorhinolaryngology	Otorhinolaryngology	CG6PA	WOS:000353422900009		
J	Miyagawa, M; Nishio, S; Hattori, M; Takumi, Y; Usami, S				Miyagawa, Maiko; Nishio, Shin-ya; Hattori, Mitsuru; Takumi, Yutaka; Usami, Shin-ichi			Germinal Mosaicism in a Family With BO Syndrome	ANNALS OF OTOLOGY RHINOLOGY AND LARYNGOLOGY			English	Article						EYA1; bronchiootorenal syndrome; Baha; next generation sequencing; germinal mosaicism	BRANCHIOOTORENAL SYNDROME; MUTATIONS; EYA1; GENE	Objectives: To clarify the existence of germinal mosaicism, we performed a genetic analysis of 2 siblings identified with an EYAI mutation associated with branchiooto (BO) syndrome but who were born from normal parents. Methods: Detailed data from the 2 affected siblings were collected for clinical diagnosis, with haplotype analysis also performed to prove germinal mosaicism. Results: The 2 sisters showed characteristic clinical features of BO syndrome (middle and inner ear anomalies, microtia, and auditory canal stenosis/atresia). Haplotype analysis confirmed the genetic relationship between the affected sisters and their parents. The younger sister with auditory canal atresia received a bone-anchored hearing aid (Baha), a transcutaneous bone conduction hearing device, resulting in a good hearing outcome. Conclusions: Based on the results of haplotype analysis, we proved that the BO syndrome in these cases was caused by germinal mosaicism of the EYAI gene in either the mother or father. We also demonstrated that the bone-conduction hearing implant is a good option for BO patients with complex outer, middle, and inner ear anomalies.	[Miyagawa, Maiko; Nishio, Shin-ya; Hattori, Mitsuru; Takumi, Yutaka; Usami, Shin-ichi] Shinshu Univ, Sch Med, Dept Otorhinolaryngol, Matsumoto, Nagano 3908621, Japan; [Miyagawa, Maiko; Nishio, Shin-ya; Takumi, Yutaka; Usami, Shin-ichi] Shinshu Univ, Sch Med, Dept Hearing Implant Sci, Matsumoto, Nagano 3908621, Japan	Usami, S (reprint author), Shinshu Univ, Sch Med, Dept Otorhinolaryngol, Matsumoto, Nagano 3908621, Japan.	usami@shinshu-u.ac.jp			Health and Labour Sciences Research Grant for Research on Rare and Intractable Diseases [H24-Nanchito(Nan)-Ippan-032]; Comprehensive Research on Disability Health and Welfare from the Ministry of Health, Labour and Welfare, Japan [H25-Kanakaku-Ippan-002]; Ministry of Education, Culture, Sports, Science and Technology, Japan [22249057]	The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This study was supported by a Health and Labour Sciences Research Grant for Research on Rare and Intractable Diseases (H24-Nanchito(Nan)-Ippan-032) and Comprehensive Research on Disability Health and Welfare (H25-Kanakaku-Ippan-002) from the Ministry of Health, Labour and Welfare, Japan (S.U.) and by a Grant-in-Aid for Scientific Research (A) (22249057) from the Ministry of Education, Culture, Sports, Science and Technology, Japan (S.U.).	FRASER FC, 1980, AM J MED GENET, V7, P341, DOI 10.1002/ajmg.1320070316; Kochhar A, 2007, AM J MED GENET A, V143A, P1671, DOI 10.1002/ajmg.a.31561; Kumar P, 2009, NAT PROTOC, V4, P1073, DOI 10.1038/nprot.2009.86; Pollard KS, 2010, GENOME RES, V20, P110, DOI 10.1101/gr.097857.109; Schwarz JM, 2010, NAT METHODS, V7, P575, DOI 10.1038/nmeth0810-575; Chun S, 2009, GENOME RES, V19, P1553, DOI 10.1101/gr.092619.109; Adzhubei IA, 2010, NAT METHODS, V7, P248, DOI 10.1038/nmeth0410-248; Chang EH, 2004, HUM MUTAT, V23, P582, DOI 10.1002/humu.20048; Brophy PD, 2013, HUM GENET, V132, P1339, DOI 10.1007/s00439-013-1338-8; FITCH N, 1976, AM J DIS CHILD, V130, P1356; Miyagawa M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071381; Orten DJ, 2008, HUM MUTAT, V29, P537, DOI 10.1002/humu.20691; Sun Y, 2009, AM J MED GENET A, V149A, P776, DOI 10.1002/ajmg.a.32706; Takumi Y, 2008, LARYNGOSCOPE, V118, P1824, DOI 10.1097/MLG.0b013e31817f4cf6; Usami S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031276	15	0	0	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0003-4894	1943-572X		ANN OTO RHINOL LARYN	Ann. Otol. Rhinol. Laryngol.	MAY	2015	124			1			118S	122S		10.1177/0003489415575062		5	Otorhinolaryngology	Otorhinolaryngology	CG6PA	WOS:000353422900010		
J	Moteki, H; Yoshimura, H; Azaiez, H; Booth, KT; Shearer, AE; Sloan, CM; Kolbe, DL; Murata, T; Smith, RJH; Usami, S				Moteki, Hideaki; Yoshimura, Hidekane; Azaiez, Hela; Booth, Kevin T.; Shearer, A. Eliot; Sloan, Christina M.; Kolbe, Diana L.; Murata, Toshinori; Smith, Richard J. H.; Usami, Shin-ichi			USH2 Caused by GPR98 Mutation Diagnosed by Massively Parallel Sequencing in Advance of the Occurrence of Visual Symptoms	ANNALS OF OTOLOGY RHINOLOGY AND LARYNGOLOGY			English	Article						hearing loss; genetics; GPR98; Usher syndrome; massively parallel sequencing	ANKLE-LINK COMPLEX; SYNDROME TYPE-2; ENRICHMENT; GENES; MYO7A; VLGR1	Objective: We present 2 patients who were identified with mutations in the GPR98 gene that causes Usher syndrome type 2 (USH2). Methods: One hundred ninety-four (194) Japanese subjects from unrelated families were enrolled in the study. Targeted genomic enrichment and massively parallel sequencing of all known nonsyndromic hearing loss genes were used to identify the genetic causes of hearing loss. Results: We identified causative mutations in the GPR98 gene in 1 family (2 siblings). The patients had moderate sloping hearing loss, and no progression was observed over a period of 10 years. Fundus examinations were normal. However, electroretinograms revealed impaired responses in both patients. Conclusion: Early diagnosis of Usher syndrome has many advantages for patients and their families. This study supports the use of comprehensive genetic diagnosis for Usher syndrome, especially prior to the onset of visual symptoms, to provide the highest chance of diagnostic success in early life stages.	[Moteki, Hideaki; Yoshimura, Hidekane; Usami, Shin-ichi] Shinshu Univ, Sch Med, Dept Otorhinolaryngol, Matsumoto, Nagano 3908621, Japan; [Moteki, Hideaki; Azaiez, Hela; Booth, Kevin T.; Shearer, A. Eliot; Sloan, Christina M.; Kolbe, Diana L.; Smith, Richard J. H.] Univ Iowa Hosp & Clin, Dept Otolaryngol Head & Neck Surg, Mol Otolaryngol & Renal Res Labs, Iowa City, IA 52242 USA; [Moteki, Hideaki; Usami, Shin-ichi] Shinshu Univ, Sch Med, Dept Hearing Implant Sci, Matsumoto, Nagano 3908621, Japan; [Murata, Toshinori] Shinshu Univ, Sch Med, Dept Ophthalmol, Matsumoto, Nagano 3908621, Japan	Usami, S (reprint author), Shinshu Univ, Sch Med, Dept Otorhinolaryngol, 3-1-1 Asahi, Matsumoto, Nagano 3908621, Japan.	usami@shinshu-u.ac.jp			NIDCD [DC003544, DC002842, DC012049]	The author(s) disclosed receipt of the following fmancial support for the research, authorship, and/or publication of this article: This work was supported by NIDCD RO1s DC003544, DC002842, and DC012049 to R.J.H.S.	Shearer AE, 2013, J MED GENET, V50, P627, DOI 10.1136/jmedgenet-2013-101749; Weston MD, 2004, AM J HUM GENET, V74, P357, DOI 10.1086/381685; Kimberling WJ, 2010, GENET MED, V12, P512, DOI 10.1097/GIM.0b013e3181e5afb8; Li H, 2009, BIOINFORMATICS, V25, P1754, DOI 10.1093/bioinformatics/btp324; Abadie C, 2012, CLIN GENET, V82, P433, DOI 10.1111/j.1399-0004.2011.01772.x; Besnard T, 2012, HUM MUTAT, V33, P504, DOI 10.1002/humu.22004; McGee J, 2006, J NEUROSCI, V26, P6543, DOI 10.1523/JNEUROSCI.0693-06.2006; Michalski N, 2007, J NEUROSCI, V27, P6478, DOI 10.1523/JNEUROSCI.0342-07.2007; McKenna A, 2010, GENOME RES, V20, P1297, DOI 10.1101/gr.107524.110; Yan D, 2010, J HUM GENET, V55, P327, DOI 10.1038/jhg.2010.29; Bonnet C, 2011, ORPHANET J RARE DIS, V6, DOI 10.1186/1750-1172-6-21; Frommolt P, 2012, HUM MUTAT, V33, P635, DOI 10.1002/humu.22036; Garcia-Garcia G, 2013, MOL VIS, V19, P367; Hilgert N, 2009, J MED GENET, V46, P272, DOI 10.1136/jmg.2008.060947; Jacobson SG, 2008, HUM MOL GENET, V17, P2405, DOI 10.1093/hmg/ddn140; Le Quesne SP, 2012, J MED GENET, V49, P27, DOI DOI 10.1136/JMEDGENET-2011-100468; Liu XZ, 2008, INT J PEDIATR OTORHI, V72, P841, DOI 10.1016/j.ijporl.2008.02.013; Miyagawa M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071381; Nakanishi H, 2009, CLIN GENET, V76, P383, DOI 10.1111/j.1399-0004.2009.01257.x; Shearer AE, 2012, BMC BIOTECHNOL, V12, DOI 10.1186/1472-6750-12-20; Tsilou ET, 2002, ACTA OPHTHALMOL SCAN, V80, P196, DOI 10.1034/j.1600-0420.2002.800215.x; Yoshimura H, 2013, INT J PEDIATR OTORHI, V77, P298, DOI 10.1016/j.ijporl.2012.11.007	22	0	0	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0003-4894	1943-572X		ANN OTO RHINOL LARYN	Ann. Otol. Rhinol. Laryngol.	MAY	2015	124			1			123S	128S		10.1177/0003489415574070		6	Otorhinolaryngology	Otorhinolaryngology	CG6PA	WOS:000353422900011		
J	Mori, K; Miyanohara, I; Moteki, H; Nishio, S; Kurono, Y; Usami, S				Mori, Kentaro; Miyanohara, Ikuyo; Moteki, Hideaki; Nishio, Shin-ya; Kurono, Yuichi; Usami, Shin-ichi			Novel Mutations in GRXCRI at DFNB25 Lead to Progressive Hearing Loss and Dizziness	ANNALS OF OTOLOGY RHINOLOGY AND LARYNGOLOGY			English	Article						hearing loss; genetics; dizziness; GRXCRI; massively parallel sequencing	GENETIC-VARIANTS; HUMAN GENOMES; SEQUENCE	Objective: We identified 2 patients in 1 family who had novel mutations in GRXCRI, which caused progressive hearing loss. Methods: One thousand one hundred twenty Japanese hearing loss patients with sensorineural hearing loss from unrelated families were enrolled in this study. Targeted genomic enrichment with massively parallel sequencing of all known nonsyndromic hearing loss genes was used to identify the genetic causes of hearing loss. Results: In this study, 2 affected individuals with compound heterozygous mutations-c.439C>T (p.R147C) and c.784C>T (p.R262X)-in GRXCRI were identified. The proband had moderate to severe hearing loss and suffered from dizziness with bilateral canal paralysis. Conclusion: Our cases are the first identified in the Japanese population and are consistent with previously reported cases. The frequency of mutations in GRXCRI seems to be extremely rare. This study underscores the importance of using comprehensive genetic testing for hearing loss. Furthermore, longitudinal audiologic assessment and precise vestibular testing are necessary for a better understanding of the mechanisms of hearing loss and vestibular dysfunction caused by GRXCRI mutations.	[Mori, Kentaro; Moteki, Hideaki; Nishio, Shin-ya; Usami, Shin-ichi] Shinshu Univ, Sch Med, Dept Otolaryngol, Matsumoto, Nagano 3908621, Japan; [Miyanohara, Ikuyo; Kurono, Yuichi] Kagoshima Univ, Grad Sch Med & Dent Sci, Dept Otolaryngol Head & Neck Surg, Kagoshima 890, Japan; [Moteki, Hideaki; Nishio, Shin-ya; Usami, Shin-ichi] Shinshu Univ, Sch Med, Dept Hearing Implant Sci, Matsumoto, Nagano 3908621, Japan	Usami, S (reprint author), Shinshu Univ, Sch Med, 3-1-1 Asahi, Matsumoto, Nagano 3908621, Japan.	usami@shinshu-u.ac.jp			Ministry of Health, Labour and Welfare of Japan; Ministry of Education, Science and Culture of Japan	The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This study was supported by a Health and Labour Sciences Research Grant for Research on Rare and Intractable Diseases and Comprehensive Research on Disability Health and Welfare from the Ministry of Health, Labour and Welfare of Japan (S.U.), and by a Grant-in-Aid for Scientific Research from the Ministry of Education, Science and Culture of Japan (S.U.).	Altshuler DM, 2012, NATURE, V491, P56, DOI 10.1038/nature11632; Shearer AE, 2013, J MED GENET, V50, P627, DOI 10.1136/jmedgenet-2013-101749; Shearer AE, 2010, P NATL ACAD SCI USA, V107, P21104, DOI 10.1073/pnas.1012989107; Shelton MD, 2005, ANTIOXID REDOX SIGN, V7, P348, DOI 10.1089/ars.2005.7.348; Kumar P, 2009, NAT PROTOC, V4, P1073, DOI 10.1038/nprot.2009.86; Pollard KS, 2010, GENOME RES, V20, P110, DOI 10.1101/gr.097857.109; Cooper GM, 2005, GENOME RES, V15, P901, DOI 10.1101/gr.3577405; Schwarz JM, 2010, NAT METHODS, V7, P575, DOI 10.1038/nmeth0810-575; Smith RJH, 2005, LANCET, V365, P879, DOI 10.1016/S0140-6736(05)71047-3; Chun S, 2009, GENOME RES, V19, P1553, DOI 10.1101/gr.092619.109; Adzhubei IA, 2010, NAT METHODS, V7, P248, DOI 10.1038/nmeth0410-248; Bordoli L, 2009, NAT PROTOC, V4, P1, DOI 10.1038/nprot.2008.197; Chang X, 2012, J MED GENET, V49, P433, DOI 10.1136/jmedgenet-2012-100918; Hilgert N, 2009, MUTAT RES-REV MUTAT, V681, P189, DOI 10.1016/j.mrrev.2008.08.002; Beyer LA, 2000, J NEUROCYTOL, V29, P227, DOI 10.1023/A:1026515619443; Miyagawa M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040366; Miyagawa M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0075793; Morton CC, 2006, NEW ENGL J MED, V354, P2151, DOI 10.1056/NEJMra050700; Narahara M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0100924; Odeh H, 2010, AM J HUM GENET, V86, P148, DOI 10.1016/j.ajhg.2010.01.016; Schraders M, 2010, AM J HUM GENET, V86, P138, DOI 10.1016/j.ajhg.2009.12.017; Wang K, 2010, NUCLEIC ACIDS RES, V38, DOI 10.1093/nar/gkq603	22	0	0	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0003-4894	1943-572X		ANN OTO RHINOL LARYN	Ann. Otol. Rhinol. Laryngol.	MAY	2015	124			1			129S	134S		10.1177/0003489415575061		6	Otorhinolaryngology	Otorhinolaryngology	CG6PA	WOS:000353422900012		
J	Mori, K; Moteki, H; Kobayashi, Y; Azaiez, H; Booth, KT; Nishio, S; Sato, H; Smith, RJH; Usami, S				Mori, Kentaro; Moteki, Hideaki; Kobayashi, Yumiko; Azaiez, Hela; Booth, Kevin T.; Nishio, Shin-ya; Sato, Hiroaki; Smith, Richard J. H.; Usami, Shin-ichi			Mutations in LOXHDI Gene Cause Various Types and Severities of Hearing Loss	ANNALS OF OTOLOGY RHINOLOGY AND LARYNGOLOGY			English	Article						hearing loss; genetics; LOXHDI; DFNB77; massively parallel sequencing	SEQUENCING DATA; HUMAN GENOMES; VARIANTS; PERFORMANCE; ENRICHMENT; DEAFNESS	Objective: We present 2 families that were identified with novel mutations in LOXHDI as a cause of nonprogressive hearing loss. Methods: One thousand three hundred fourteen (1314) Japanese subjects with sensorineural hearing loss from unrelated families were enrolled in the study. Targeted genomic enrichment and massively parallel sequencing of all known nonsyndromic hearing loss genes were performed to identify the genetic cause of hearing loss. Results: Two patients in I family affected with homozygous mutation c.879+IG>A in LOXHDI showed profound congenital hearing loss, whereas 2 patients in another family with compound heterozygous mutations, c.5869G>T (p.E1957X) and c.4480C>T (p.R1494X), showed moderate to severe hearing loss. Conclusion: Mutations in LOXHDI are extremely rare, and these cases are the first identified in a Japanese population. The genotype-phenotype correlation in LOXHDI is still unclear. The differences in phenotypes in each patient might be the result of the nature of the mutations or the location on the gene, or be influenced by a genetic modifier.	[Mori, Kentaro; Moteki, Hideaki; Nishio, Shin-ya; Usami, Shin-ichi] Shinshu Univ, Sch Med, Dept Otolaryngol, Matsumoto, Nagano 3908621, Japan; [Moteki, Hideaki; Nishio, Shin-ya; Usami, Shin-ichi] Shinshu Univ, Sch Med, Dept Hearing Implant Sci, Matsumoto, Nagano 3908621, Japan; [Moteki, Hideaki; Azaiez, Hela; Booth, Kevin T.; Smith, Richard J. H.] Univ Iowa Hosp & Clin, Dept Otolaryngol Head & Neck Surg, Mol Otolaryngol & Renal Res Labs, Iowa City, IA 52242 USA; [Kobayashi, Yumiko; Sato, Hiroaki] Iwate Med Univ, Sch Med, Dept Otolaryngol, Morioka, Iwate, Japan	Usami, S (reprint author), Shinshu Univ, Sch Med, Dept Otolaryngol, 3-1-1 Asahi, Matsumoto, Nagano 3908621, Japan.	usami@shinshu-u.ac.jp			NIDCD [DC003544, DC002842, DC012049]; Ministry of Health, Labour and Welfare of Japan; Ministry of Education, Science and Culture of Japan	The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by NIDCD RO1s DC003544, DC002842 and DC012049 to R.J.H.S. This study also was supported by a Health and Labour Sciences Research Grant for Research on Rare and Intractable Diseases and Comprehensive Research on Disability Health and Welfare from the Ministry of Health, Labour and Welfare of Japan (S.U.) and by a Grant-in-Aid for Scientific Research from the Ministry of Education, Science and Culture of Japan (S.U.).	Altshuler DM, 2012, NATURE, V491, P56, DOI 10.1038/nature11632; Shearer AE, 2013, J MED GENET, V50, P627, DOI 10.1136/jmedgenet-2013-101749; Li H, 2009, BIOINFORMATICS, V25, P1754, DOI 10.1093/bioinformatics/btp324; Grillet N, 2009, AM J HUM GENET, V85, P328, DOI 10.1016/j.ajhg.2009.07.017; Kumar P, 2009, NAT PROTOC, V4, P1073, DOI 10.1038/nprot.2009.86; Eppsteiner RW, 2012, HEARING RES, V292, P51, DOI 10.1016/j.heares.2012.08.007; Vozzi D, 2014, GENE, V542, P209, DOI 10.1016/j.gene.2014.03.033; Pollard KS, 2010, GENOME RES, V20, P110, DOI 10.1101/gr.097857.109; Cooper GM, 2005, GENOME RES, V15, P901, DOI 10.1101/gr.3577405; Schwarz JM, 2010, NAT METHODS, V7, P575, DOI 10.1038/nmeth0810-575; McKenna A, 2010, GENOME RES, V20, P1297, DOI 10.1101/gr.107524.110; Chun S, 2009, GENOME RES, V19, P1553, DOI 10.1101/gr.092619.109; Adzhubei IA, 2010, NAT METHODS, V7, P248, DOI 10.1038/nmeth0410-248; Riazuddin SA, 2012, AM J HUM GENET, V90, P533, DOI 10.1016/j.ajhg.2012.01.013; Chang X, 2012, J MED GENET, V49, P433, DOI 10.1136/jmedgenet-2012-100918; Hilgert N, 2009, MUTAT RES-REV MUTAT, V681, P189, DOI 10.1016/j.mrrev.2008.08.002; Diaz-Horta O, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050628; Edvardson S, 2011, AM J MED GENET A, V155A, P1170, DOI 10.1002/ajmg.a.33972; Frommolt P, 2012, HUM MUTAT, V33, P635, DOI 10.1002/humu.22036; Mchugh RK, 2006, ANAT REC PART A, V288A, P370, DOI 10.1002/ar.a.20297; Miyagawa M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0075793; Narahara M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0100924; Shearer AE, 2012, BMC BIOTECHNOL, V12, DOI 10.1186/1472-6750-12-20; Stehouwer Marilette, 2011, Clin Ophthalmol, V5, P1297, DOI 10.2147/OPTH.S23091; Wang K, 2010, NUCLEIC ACIDS RES, V38, DOI 10.1093/nar/gkq603	25	1	1	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0003-4894	1943-572X		ANN OTO RHINOL LARYN	Ann. Otol. Rhinol. Laryngol.	MAY	2015	124			1			135S	141S		10.1177/0003489415574067		7	Otorhinolaryngology	Otorhinolaryngology	CG6PA	WOS:000353422900013		
J	Ichinose, A; Moteki, H; Hattori, M; Nishio, S; Usami, S				Ichinose, Aya; Moteki, Hideaki; Hattori, Mitsuru; Nishio, Shin-ya; Usami, Shin-ichi			Novel Mutations in LRTOMT Associated With Moderate Progressive Hearing Loss in Autosomal Recessive Inheritance	ANNALS OF OTOLOGY RHINOLOGY AND LARYNGOLOGY			English	Article						hearing loss; genetics; LRTOMT; DFNB63; massively parallel sequencing	NONSYNDROMIC DEAFNESS; LOCUS DFNB63; IMPAIRMENT; HUMANS; GENE	Objective: We present a patient who was identified with novel mutations in the LRTOMT gene and describe the clinical features of the phenotype including serial audiological findings. Methods: One hundred six Japanese patients with mild to moderate sensorineural hearing loss from unrelated and nonconsanguineous families were enrolled in the study. Targeted genomic enrichment and massively parallel sequencing of all known nonsyndromic hearing loss genes were performed to identify the genetic cause of hearing loss. Results: Compound heterozygotes with a novel frame-shift mutation and a missense mutation were identified in the LRTOMT gene. The mutated residues were segregated in both alleles of LRTOMT, present within the LRTOMT2 protein coding region. The patient had moderate sloping hearing loss at high frequencies, which progressed at 1000 Hz and higher frequencies over a period of 6 years. Conclusion: Hearing loss caused by mutations in the LRTOMT gene is extremely rare. This is the first case report of a compound heterozygous mutation in a nonconsanguineous family.	[Ichinose, Aya; Moteki, Hideaki; Hattori, Mitsuru; Nishio, Shin-ya; Usami, Shin-ichi] Shinshu Univ, Sch Med, Dept Otorhinolaryngol, Matsumoto, Nagano 3908621, Japan; [Moteki, Hideaki; Nishio, Shin-ya; Usami, Shin-ichi] Shinshu Univ, Sch Med, Dept Hearing Implant Sci, Matsumoto, Nagano 3908621, Japan	Usami, S (reprint author), Shinshu Univ, Sch Med, 3-1-1 Asahi, Matsumoto, Nagano 3908621, Japan.	usami@shinshu-u.ac.jp			Ministry of Health, Labour and Welfare of Japan; Ministry of Education, Science and Culture of Japan	The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This study was supported by a Health and Labour Sciences Research Grant for Research on Rare and Intractable Diseases and Comprehensive Research on Disability Health and Welfare from the Ministry of Health, Labour and Welfare of Japan (S.U.), and by a Grant-in-Aid for Scientific Research from the Ministry of Education, Science and Culture of Japan (S.U.).	Charif M, 2012, MOL BIOL REP, V39, P11011, DOI 10.1007/s11033-012-2003-3; Li H, 2009, BIOINFORMATICS, V25, P1754, DOI 10.1093/bioinformatics/btp324; Ahmed ZM, 2008, NAT GENET, V40, P1335, DOI 10.1038/ng.245; Babanejad M, 2012, AM J MED GENET A, V158A, P2485, DOI 10.1002/ajmg.a.35572; Adzhubei IA, 2010, NAT METHODS, V7, P248, DOI 10.1038/nmeth0410-248; Du X, 2008, P NATL ACAD SCI USA, V105, P14609, DOI 10.1073/pnas.0807219105; Kalay E, 2007, J MOL MED-JMM, V85, P397, DOI 10.1007/s00109-006-0136-3; Khan SY, 2007, HUM GENET, V120, P789, DOI 10.1007/s00439-006-0275-1; Taghizadeh Seyyed Hossein, 2013, Int J Mol Cell Med, V2, P41; Tlili A, 2007, ANN HUM GENET, V71, P271, DOI 10.1111/j.1469-1809.2006.00337.x; Vanwesemael M, 2011, AM J MED GENET A, V155A, P2021, DOI 10.1002/ajmg.a.34096	11	0	0	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0003-4894	1943-572X		ANN OTO RHINOL LARYN	Ann. Otol. Rhinol. Laryngol.	MAY	2015	124			1			142S	147S		10.1177/0003489415575043		6	Otorhinolaryngology	Otorhinolaryngology	CG6PA	WOS:000353422900014		
J	Miyagawa, M; Nishio, S; Kumakawa, K; Usami, S				Miyagawa, Maiko; Nishio, Shin-ya; Kumakawa, Kozo; Usami, Shin-ichi			Massively Parallel DNA Sequencing Successfully Identified Seven Families With Deafness-Associated MYO6 Mutations: The Mutational Spectrum and Clinical Characteristics	ANNALS OF OTOLOGY RHINOLOGY AND LARYNGOLOGY			English	Article						MYO6; DFNA22; DFNB37; hearing loss; genetics; massively parallel DNA; next generation sequencing	NONSYNDROMIC HEARING-LOSS; MYOSIN-VI; UNCONVENTIONAL MYOSINS; GENETIC-VARIANTS; HUMAN GENOMES; HAIR-CELLS	Objectives: To elucidate the involvement of MYO6 mutations, known to be responsible for DFNA22/DFNB37, in Japanese hearing loss patients through the use of genetic analysis. Methods: Genomic variations responsible for hearing loss were identified by massively parallel DNA sequencing (MPS) of 63 target candidate genes in 1120 Japanese hearing loss patients, and the detailed clinical features for the patients with MYO6 mutations were collected and analyzed. Results: Four mutations were successfully found in 7 families exhibiting autosomal dominant inheritance. All of the patients showed progressive hearing loss, but hearing type and onset age varied. Further, none of the affected patients showed any associated symptoms, such as hypertrophic cardiomyopathy or retinitis pigmentosa. Conclusions: MPS is powerful tool for the identification of rare causative deafness gene mutations, such as MYO6. The clinical characteristics noted in the present study not only confirmed the findings of previous reports but provided important new clinical information.	[Miyagawa, Maiko; Nishio, Shin-ya; Usami, Shin-ichi] Shinshu Univ, Sch Med, Dept Otorhinolaryngol, Matsumoto, Nagano 3908621, Japan; [Miyagawa, Maiko; Nishio, Shin-ya; Usami, Shin-ichi] Shinshu Univ, Sch Med, Dept Hearing Implant Sci, Matsumoto, Nagano 3908621, Japan; [Kumakawa, Kozo] Toranomon Gen Hosp, Dept Otorhinolaryngol, Tokyo, Japan	Usami, S (reprint author), Shinshu Univ, Sch Med, Dept Otorhinolaryngol, 3-1-1 Asahi, Matsumoto, Nagano 3908621, Japan.	usami@shinshu-u.ac.jp			Health and Labour Sciences Research Grant for Research on Rare and Intractable Diseases from the Ministry of Health, Labour and Welfare of Japan [H24-Nanchiou(Nan)-Ippan-032]; Ministry of Education, Science and Culture of Japan [22249057]; Comprehensive Research on Disability Health and Welfare from the Ministry of Health, Labour and Welfare of Japan [H25-Kankaku-Ippan-002]	The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This study was supported by a Health and Labour Sciences Research Grant for Research on Rare and Intractable Diseases, (H24-Nanchiou(Nan)-Ippan-032) and Comprehensive Research on Disability Health and Welfare (H25-Kankaku-Ippan-002) from the Ministry of Health, Labour and Welfare of Japan (S.U.) and by a Grant-in-Aid for Scientific Research (A) (22249057) from the Ministry of Education, Science and Culture of Japan (S.U.).	Altshuler DM, 2012, NATURE, V491, P56, DOI 10.1038/nature11632; Friedman TB, 1999, AM J MED GENET, V89, P147, DOI 10.1002/(SICI)1096-8628(19990924)89:3<147::AID-AJMG5>3.0.CO;2-6; Shearer AE, 2010, P NATL ACAD SCI USA, V107, P21104, DOI 10.1073/pnas.1012989107; Kumar P, 2009, NAT PROTOC, V4, P1073, DOI 10.1038/nprot.2009.86; Pollard KS, 2010, GENOME RES, V20, P110, DOI 10.1101/gr.097857.109; Ahmed ZM, 2003, AM J HUM GENET, V72, P1315, DOI 10.1086/375122; Self T, 1999, DEV BIOL, V214, P331, DOI 10.1006/dbio.1999.9424; Cooper GM, 2005, GENOME RES, V15, P901, DOI 10.1101/gr.3577405; Melchionda S, 2001, AM J HUM GENET, V69, P635, DOI 10.1086/323156; Schwarz JM, 2010, NAT METHODS, V7, P575, DOI 10.1038/nmeth0810-575; Mohiddin SA, 2004, J MED GENET, V41, P309, DOI 10.1136/jmg.2003.011973; Breckler J, 2000, EXP EYE RES, V70, P121, DOI 10.1006/exer.1999.0758; Chun S, 2009, GENOME RES, V19, P1553, DOI 10.1101/gr.092619.109; Adzhubei IA, 2010, NAT METHODS, V7, P248, DOI 10.1038/nmeth0410-248; Hasson T, 1997, J CELL BIOL, V137, P1287, DOI 10.1083/jcb.137.6.1287; Chang X, 2012, J MED GENET, V49, P433, DOI 10.1136/jmedgenet-2012-100918; AVRAHAM KB, 1995, NAT GENET, V11, P369, DOI 10.1038/ng1295-369; Choi BY, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068692; Hasson T, 2003, J CELL SCI, V116, P3453, DOI 10.1242/jcs.00669; Hilgert N, 2008, EUR J HUM GENET, V16, P593, DOI 10.1038/sj.ejhg.5202000; Kwon TJ, 2014, OPEN BIOL, V4, DOI 10.1098/rsob.140107; Miyagawa M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071381; Miyagawa M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0075793; Narahara M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0100924; Oonk AMM, 2013, HEARING RES, V299, P88, DOI 10.1016/j.heares.2012.12.015; Sanggaard KM, 2008, AM J MED GENET A, V146A, P1017, DOI 10.1002/ajmg.a.32174; VanCamp G, 1997, AM J HUM GENET, V60, P758; Vona B, 2014, GENET MED, V16, P945, DOI 10.1038/gim.2014.65; Wang K, 2010, NUCLEIC ACIDS RES, V38, DOI 10.1093/nar/gkq603; Yang T, 2013, ORPHANET J RARE DIS, V8, DOI 10.1186/1750-1172-8-85	30	0	0	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0003-4894	1943-572X		ANN OTO RHINOL LARYN	Ann. Otol. Rhinol. Laryngol.	MAY	2015	124			1			148S	157S		10.1177/0003489415575055		10	Otorhinolaryngology	Otorhinolaryngology	CG6PA	WOS:000353422900015		
J	Miyagawa, M; Nishio, S; Hattori, M; Moteki, H; Kobayashi, Y; Sato, H; Watanabe, T; Naito, Y; Oshikawa, C; Usami, S				Miyagawa, Maiko; Nishio, Shin-ya; Hattori, Mitsuru; Moteki, Hideaki; Kobayashi, Yumiko; Sato, Hiroaki; Watanabe, Tomoo; Naito, Yasushi; Oshikawa, Chie; Usami, Shin-ichi			Mutations in the MYO15A Gene Are a Significant Cause of Nonsyndromic Hearing Loss: Massively Parallel DNA Sequencing-Based Analysis	ANNALS OF OTOLOGY RHINOLOGY AND LARYNGOLOGY			English	Article						MYOI5A; DFNB3; autosomal recessive hearing loss; massively parallel DNA sequencing; next generation sequencing; cochlear implant	UNCONVENTIONAL MYOSIN; DEAFNESS; VARIANTS; FAMILIES; DFNB3; POPULATION; GENOMES; MY015A; DOMAIN	Objectives: Screening for MYO15A mutations was carried out using a large cohort to clarify the frequency and clinical characteristics of patients with MYO15A (DFNB3) mutations in a hearing loss population. Methods: Genetic analysis of 63 previously reported deafness genes based on massively parallel DNA sequencing (MPS) in 1120 Japanese hearing loss patients from 53 otorhinolaryngology departments was performed. Detailed clinical features of the patients with MYO15A mutations were then collected and analyzed. Results: Eleven patients from 10 families were found to have compound heterozygosity for MYO15A. Audiogranns showed profound or high frequency hearing loss, with some patients showing progressive hearing loss. Age at onset was found to vary from 0 to 14 years, which seemed to be associated with the mutation. Four children underwent bilateral cochlear implantation for congenital hearing loss, with all showing good results. Conclusion: Mutations in the MYO15A gene are a notable cause of nonsyndromic hearing loss. MPS technology successfully detected mutations in relatively rare deafness genes such as MY015A.	[Miyagawa, Maiko; Nishio, Shin-ya; Hattori, Mitsuru; Moteki, Hideaki; Usami, Shin-ichi] Shinshu Univ, Sch Med, Dept Otorhinolaryngol, Matsumoto, Nagano 3908621, Japan; [Miyagawa, Maiko; Nishio, Shin-ya; Moteki, Hideaki; Usami, Shin-ichi] Shinshu Univ, Sch Med, Dept Hearing Implant Sci, Matsumoto, Nagano 3908621, Japan; [Kobayashi, Yumiko; Sato, Hiroaki] Iwate Med Univ, Dept Otolaryngol Head & Neck Surg, Morioka, Iwate 020, Japan; [Watanabe, Tomoo] Yamagata Univ, Fac Med, Dept Otolaryngol, Yamagata 990, Japan; [Watanabe, Tomoo] Yamagata Univ, Fac Med, Dept Head, Yamagata 990, Japan; [Watanabe, Tomoo] Yamagata Univ, Fac Med, Dept Neck Surg, Yamagata 990, Japan; [Naito, Yasushi] Kobe City Med Ctr Gen Hosp, Dept Otolaryngol, Kobe, Hyogo, Japan; [Oshikawa, Chie] Kyushu Univ, Grad Sch Med Sci, Dept Otorhinolaryngol, Fukuoka 812, Japan	Usami, S (reprint author), Shinshu Univ, Sch Med, Dept Otorhinolaryngol, 3-1-1 Asahi, Matsumoto, Nagano 3908621, Japan.	usami@shinshu-u.ac.jp			Health and Labour Sciences Research Grant for Research on Rare and Intractable Diseases [H24-Nanchiou(Nan)-Ippan-032]; Ministry of Health, Labour and Welfare, Japan [H25-Kankaku-Ippan-002]; Ministry of Education, Culture, Sports, Science and Technology, Japan [22249057]	The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This study was supported by a Health and Labour Sciences Research Grant for Research on Rare and Intractable Diseases (H24-Nanchiou(Nan)-Ippan-032) and Comprehensive Research on Disability Health and Welfare (H25-Kankaku-Ippan-002) from the Ministry of Health, Labour and Welfare, Japan (S.U.) and by a Grant-in-Aid for Scientific Research (A) (22249057) from the Ministry of Education, Culture, Sports, Science and Technology, Japan (S.U.).	Altshuler DM, 2012, NATURE, V491, P56, DOI 10.1038/nature11632; Wang AH, 1998, SCIENCE, V280, P1447, DOI 10.1126/science.280.5368.1447; Liburd N, 2001, HUM GENET, V109, P535, DOI 10.1007/s004390100604; Kalay E, 2007, AM J MED GENET A, V143A, P2382, DOI 10.1002/ajmg.a.31937; Kumar P, 2009, NAT PROTOC, V4, P1073, DOI 10.1038/nprot.2009.86; Shearer AE, 2009, LARYNGOSCOPE, V119, P727, DOI 10.1002/lary.20116; Lezirovitz K, 2008, EUR J HUM GENET, V16, P89, DOI 10.1038/sj.ejhg.5201917; Krendel M, 2005, PHYSIOLOGY, V20, P239, DOI 10.1152/physiol.00014.2005; Nal N, 2007, HUM MUTAT, V28, P1014, DOI 10.1002/humu.20556; Probst FJ, 1998, SCIENCE, V280, P1444, DOI 10.1126/science.280.5368.1444; Cooper GM, 2005, GENOME RES, V15, P901, DOI 10.1101/gr.3577405; Duman D, 2011, GENET TEST MOL BIOMA, V15, P29, DOI 10.1089/gtmb.2010.0120; Fattahi Z, 2012, AM J MED GENET A, V158A, P1857, DOI 10.1002/ajmg.a.34411; Schwarz JM, 2010, NAT METHODS, V7, P575, DOI 10.1038/nmeth0810-575; Bashir R, 2012, EUR J MED GENET, V55, P99, DOI 10.1016/j.ejmg.2011.12.003; Reva B, 2011, NUCLEIC ACIDS RES, V39, pE118, DOI 10.1093/nar/gkr407; Wagatsuma M, 2007, CLIN GENET, V72, P339, DOI 10.1111/j.1399-0004.2007.00833.x; Belguith H, 2009, GENET TEST MOL BIOMA, V13, P147, DOI 10.1089/gtmb.2008.0077; Shihab HA, 2013, HUM MUTAT, V34, P57, DOI 10.1002/humu.22225; Adzhubei IA, 2010, NAT METHODS, V7, P248, DOI 10.1038/nmeth0410-248; Cengiz FB, 2010, GENET TEST MOL BIOMA, V14, P543, DOI 10.1089/gtmb.2010.0039; Chang X, 2012, J MED GENET, V49, P433, DOI 10.1136/jmedgenet-2012-100918; Brownstein Z, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-9-r89; Diaz-Horta O, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050628; Imtiaz F, 2011, BMC MED GENET, V12, DOI 10.1186/1471-2350-12-91; Miyagawa M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0075793; Narahara M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0100924; Shearer AE, 2014, AM J HUM GENET, V95, P445, DOI 10.1016/j.ajhg.2014.09.001; Usami S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031276; Wang K, 2010, NUCLEIC ACIDS RES, V38, DOI 10.1093/nar/gkq603; Wilson BS, 1997, BRIT J AUDIOL, V31, P205; Woo HM, 2013, BMC MED GENET, V14, DOI 10.1186/1471-2350-14-72; Yang T, 2013, ORPHANET J RARE DIS, V14, P85; Yano T, 2013, J CLIN CASE REP, V3, P319	34	1	1	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0003-4894	1943-572X		ANN OTO RHINOL LARYN	Ann. Otol. Rhinol. Laryngol.	MAY	2015	124			1			158S	168S		10.1177/0003489415575058		11	Otorhinolaryngology	Otorhinolaryngology	CG6PA	WOS:000353422900016		
J	Moteki, H; Shearer, AE; Izumi, S; Kubota, Y; Azaiez, H; Booth, KT; Sloan, CM; Kolbe, DL; Smith, RJH; Usami, S				Moteki, Hideaki; Shearer, A. Eliot; Izumi, Shuji; Kubota, Yamato; Azaiez, Hela; Booth, Kevin T.; Sloan, Christina M.; Kolbe, Diana L.; Smith, Richard J. H.; Usami, Shin-ichi			De Novo Mutation in X-Linked Hearing Loss-Associated POU3F4 in a Sporadic Case of Congenital Hearing Loss	ANNALS OF OTOLOGY RHINOLOGY AND LARYNGOLOGY			English	Article						hearing loss; genetics; POU3F4; cochlear implant; massively parallel sequencing	DEAFNESS TYPE-3 DFN3; INNER-EAR; MISSENSE MUTATION; MIXED DEAFNESS; CHINESE FAMILY; GENE; IDENTIFICATION; UPSTREAM; MISLOCALIZATION; ENRICHMENT	Objectives: In this report, we present a male patient with no family history of hearing loss, in whom we identified a novel de novo mutation in the POU3F4 gene. Methods: One hundred ninety-four (194) Japanese subjects from unrelated and nonconsanguineous families were enrolled in this study. We used targeted genomic enrichment and massively parallel sequencing of all known nonsyndromic hearing loss genes for identifying the genetic causes of hearing loss. Results: A novel de novo frameshift mutation of POU3F4 to c.727_728insA (p.N244KfsX26) was identified. The patient was a 7-year-old male with congenital progressive hearing loss and inner ear deformity. Although the patient had received a cochlear implant, auditory skills were still limited. The patient also exhibited developmental delays similar to those previously associated with POU3F4 mutation. Conclusion: This is the first report of a mutation in POU3F4 causing hearing loss in a Japanese patient without a family history of hearing loss. This study underscores the importance of comprehensive genetic testing of patients with hearing loss for providing accurate prognostic information and guiding the optimal management of patient rehabilitation.	[Moteki, Hideaki; Usami, Shin-ichi] Shinshu Univ, Sch Med, Dept Otorhinolaryngol, Matsumoto, Nagano 3908621, Japan; [Moteki, Hideaki; Shearer, A. Eliot; Azaiez, Hela; Booth, Kevin T.; Sloan, Christina M.; Kolbe, Diana L.; Smith, Richard J. H.] Univ Iowa Hosp & Clin, Dept Otolaryngol Head & Neck Surg, Mol Otolaryngol & Renal Res Labs, Iowa City, IA 52242 USA; [Izumi, Shuji; Kubota, Yamato] Niigata Univ, Fac Med, Dept Otolaryngol Head & Neck Surg, Niigata, Japan; [Moteki, Hideaki; Usami, Shin-ichi] Shinshu Univ, Sch Med, Dept Hearing Implant Sci, Matsumoto, Nagano 3908621, Japan	Usami, S (reprint author), Shinshu Univ, Sch Med, Dept Otorhinolaryngol, Dept Hearing Implant Sci, 3-1-1 Asahi, Matsumoto, Nagano 3908621, Japan.	usami@shinshu-u.ac.jp			NIDCD [RO1s DC003544, DC002842, DC012049]	The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by NIDCD RO1s DC003544, DC002842, and DC012049 to R.J.H.S.	Anger GJ, 2014, AM J AUDIOL, V23, P1, DOI 10.1044/1059-0889(2013/13-0018); Stankovic KM, 2010, ANN OTO RHINOL LARYN, V119, P815; Shearer AE, 2013, J MED GENET, V50, P627, DOI 10.1136/jmedgenet-2013-101749; Parzefall T, 2013, HUM MUTAT, V34, P1102, DOI 10.1002/humu.22339; PHELPS PD, 1991, NEURORADIOLOGY, V33, P326; Li H, 2009, BIOINFORMATICS, V25, P1754, DOI 10.1093/bioinformatics/btp324; Shearer AE, 2010, P NATL ACAD SCI USA, V107, P21104, DOI 10.1073/pnas.1012989107; Petersen MB, 2008, CLIN GENET, V73, P14, DOI 10.1111/j.1399-0004.2007.00913.x; deKok YJM, 1996, HUM MOL GENET, V5, P1229, DOI 10.1093/hmg/5.9.1229; Naranjo S, 2010, HUM GENET, V128, P411, DOI 10.1007/s00439-010-0864-x; McKenna A, 2010, GENOME RES, V20, P1297, DOI 10.1101/gr.107524.110; Arellano B, 2000, ARCH OTOLARYNGOL, V126, P1065; BITNERGLINDZICZ M, 1995, HUM MOL GENET, V4, P1467, DOI 10.1093/hmg/4.8.1467; Choi BY, 2013, HUM MUTAT, V34, P309, DOI 10.1002/humu.22232; Choi JW, 2015, OTOL NEUROTOL, V36, P184, DOI 10.1097/MAO.0000000000000343; DEKOK YJM, 1995, HUM MOL GENET, V4, P2145; deKok YJM, 1997, HUM MUTAT, V10, P207; Friedman RA, 1997, ANN OTO RHINOL LARYN, V106, P320; Frommolt P, 2012, HUM MUTAT, V33, P635, DOI 10.1002/humu.22036; Hagiwara H, 1998, LARYNGOSCOPE, V108, P1544, DOI 10.1097/00005537-199810000-00022; Hildebrand MS, 2007, AM J MED GENET A, V143A, P2564, DOI 10.1002/ajmg.a.31995; Lee HK, 2009, CLIN GENET, V75, P572, DOI 10.1111/j.1399-0004.2009.01181.x; Lee HK, 2009, PHYSIOL GENOMICS, V39, P195, DOI 10.1152/physiolgenomics.00100.2009; Li JZ, 2010, J GENET GENOMICS, V37, P787, DOI 10.1016/S1673-8527(09)60096-5; Schild C, 2011, OTOL NEUROTOL, V32, P690, DOI 10.1097/MAO.0b013e318210b749; Shearer AE, 2012, BMC BIOTECHNOL, V12, DOI 10.1186/1472-6750-12-20; Song MH, 2010, CLIN GENET, V78, P524, DOI 10.1111/j.1399-0004.2010.01426.x; Stanton SG, 2014, AM J AUDIOL, V23, P190, DOI 10.1044/2014_AJA-13-0040; Vore AP, 2005, ARCH OTOLARYNGOL, V131, P1057, DOI 10.1001/archotol.131.12.1057; Wang QJ, 2006, LARYNGOSCOPE, V116, P944, DOI 10.1097/01.MLG.0000215285.53045.24	30	0	0	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0003-4894	1943-572X		ANN OTO RHINOL LARYN	Ann. Otol. Rhinol. Laryngol.	MAY	2015	124			1			169S	176S		10.1177/0003489415575042		8	Otorhinolaryngology	Otorhinolaryngology	CG6PA	WOS:000353422900017		
J	Moteki, H; Azaiez, H; Booth, KT; Hattori, M; Sato, A; Sato, Y; Motobayashi, M; Sloan, CM; Kolbe, DL; Shearer, AE; Smith, RJH; Usami, S				Moteki, Hideaki; Azaiez, Hela; Booth, Kevin T.; Hattori, Mitsuru; Sato, Ai; Sato, Yoshihiko; Motobayashi, Mitsuo; Sloan, Christina M.; Kolbe, Diana L.; Shearer, A. Eliot; Smith, Richard J. H.; Usami, Shin-ichi			Hearing Loss Caused by a P2RX2 Mutation Identified in a MELAS Family With a Coexisting Mitochondrial 3243AG Mutation	ANNALS OF OTOLOGY RHINOLOGY AND LARYNGOLOGY			English	Article						hearing loss; genetics; P2X2; MELAS; massively parallel sequencing	DNA MUTATIONS; DEAFNESS; ENRICHMENT; COCHLEA; LOCUS	Objectives: We present a family with a mitochondrial DNA 3243A>G mutation resulting in mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes (MELAS), of which some members have hearing loss in which a novel mutation in the P2RX2 gene was identified. Methods: One hundred ninety-four (194) Japanese subjects from unrelated families were enrolled in the study. Targeted genomic enrichment and massively parallel sequencing of all known nonsyndromic hearing loss genes were performed to identify the genetic causes of hearing loss. Results: A novel mutation in the P2RX2 gene that corresponded to c.601G>A (p.Asp201Tyr) was identified. Two patients carried the mutation and had severe sensorineural hearing loss, while other members with MELAS (who did not carry the P2RX2 mutation) had normal hearing. Conclusion: This is the first case report of a diagnosis of hearing loss caused by P2RX2 mutation in patients with MELAS. A potential explanation is that a decrease in adenosine triphosphate (ATP) production due to MELAS with a mitochondrial 3243A>G mutation might suppress activation of P2X2 receptors. We also suggest that hearing loss caused by the P2RX2 mutation might be influenced by the decrease in ATP production due to MELAS.	[Moteki, Hideaki; Hattori, Mitsuru; Usami, Shin-ichi] Shinshu Univ, Sch Med, Dept Otorhinolaryngol, Matsumoto, Nagano 3908621, Japan; [Moteki, Hideaki; Azaiez, Hela; Booth, Kevin T.; Sloan, Christina M.; Kolbe, Diana L.; Shearer, A. Eliot; Smith, Richard J. H.] Univ Iowa Hosp & Clin, Dept Otolaryngol Head & Neck Surg, Mol Otolaryngol & Renal Res Labs, Iowa City, IA 52242 USA; [Moteki, Hideaki; Usami, Shin-ichi] Shinshu Univ, Sch Med, Dept Hearing Implant Sci, Matsumoto, Nagano 3908621, Japan; [Sato, Ai; Sato, Yoshihiko] Shinshu Univ, Sch Med, Dept Internal Med, Div Diabet Endocrinol & Metab, Matsumoto, Nagano 3908621, Japan; [Motobayashi, Mitsuo] Shinshu Univ, Sch Med, Dept Pediat, Matsumoto, Nagano 3908621, Japan	Usami, S (reprint author), Shinshu Univ, Sch Med, Dept Otorhinolaryngol, 3-1-1 Asahi, Matsumoto, Nagano 3908621, Japan.	usami@shinshu-u.ac.jp			NIDCD [RO1s DC003544, DC002842, DC012049]	The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by NIDCD RO1s DC003544, DC002842, and DC012049 to R.J.H.S.	Yan D, 2013, P NATL ACAD SCI USA, V110, P2228, DOI 10.1073/pnas.1222285110; Housley GD, 1999, J NEUROSCI, V19, P8377; VANDENOUWELAND JMW, 1992, NAT GENET, V1, P368, DOI 10.1038/ng0892-368; Shearer AE, 2013, J MED GENET, V50, P627, DOI 10.1136/jmedgenet-2013-101749; Faletra F, 2014, GENE, V534, P236, DOI 10.1016/j.gene.2013.10.052; Blanton SH, 2002, J MED GENET, V39, P567, DOI 10.1136/jmg.39.8.567; Li H, 2009, BIOINFORMATICS, V25, P1754, DOI 10.1093/bioinformatics/btp324; Shearer AE, 2010, P NATL ACAD SCI USA, V107, P21104, DOI 10.1073/pnas.1012989107; Petersen MB, 2002, CLIN GENET, V62, P1, DOI 10.1034/j.1399-0004.2002.620101.x; Zhao HB, 2005, P NATL ACAD SCI USA, V102, P18724, DOI 10.1073/pnas.0506481102; Zhu Y, 2010, PURINERG SIGNAL, V6, P221, DOI 10.1007/s11302-010-9184-9; Smith RJH, 2005, LANCET, V365, P879, DOI 10.1016/S0140-6736(05)71047-3; McKenna A, 2010, GENOME RES, V20, P1297, DOI 10.1101/gr.107524.110; Housley GD, 2009, TRENDS NEUROSCI, V32, P128, DOI 10.1016/j.tins.2009.01.001; Housley GD, 2013, P NATL ACAD SCI USA, V110, P7494, DOI 10.1073/pnas.1222295110; Frommolt P, 2012, HUM MUTAT, V33, P635, DOI 10.1002/humu.22036; Jacobs HT, 2005, EUR J HUM GENET, V13, P26, DOI 10.1038/sj.ejhg.5201250; Scuderi C, 2010, MITOCHONDRION, V10, P548, DOI 10.1016/j.mito.2010.04.004; Shearer AE, 2012, BMC BIOTECHNOL, V12, DOI 10.1186/1472-6750-12-20; Telang RS, 2010, PURINERG SIGNAL, V6, P263, DOI 10.1007/s11302-010-9195-6; WHO, PREV BLINDN DEAFN ES; Yan D, 2005, J HUM GENET, V50, P516, DOI 10.1007/s10038-005-0286-0	22	1	1	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0003-4894	1943-572X		ANN OTO RHINOL LARYN	Ann. Otol. Rhinol. Laryngol.	MAY	2015	124			1			177S	183S		10.1177/0003489415575045		7	Otorhinolaryngology	Otorhinolaryngology	CG6PA	WOS:000353422900018		
J	Sakuma, N; Moteki, H; Azaiez, H; Booth, KT; Takahashi, M; Arai, Y; Shearer, AE; Sloan, CM; Nishio, S; Kolbe, DL; Iwasaki, S; Oridate, N; Smith, RJH; Usami, S				Sakuma, Naoko; Moteki, Hideaki; Azaiez, Hela; Booth, Kevin T.; Takahashi, Masahiro; Arai, Yasuhiro; Shearer, A. Eliot; Sloan, Christina M.; Nishio, Shin-ya; Kolbe, Diana L.; Iwasaki, Satoshi; Oridate, Nobuhiko; Smith, Richard J. H.; Usami, Shin-ichi			Novel PTPRQ Mutations Identified in Three Congenital Hearing Loss Patients With Various Types of Hearing Loss	ANNALS OF OTOLOGY RHINOLOGY AND LARYNGOLOGY			English	Article						hearing loss; PTPRQ; DFNB84; massively parallel DNA sequencing	INOSITOL LIPID PHOSPHATASE; GENETIC-VARIANTS; SEQUENCING DATA; HUMAN GENOMES; ENRICHMENT; END	Objectives: We present 3 patients with congenital sensorineural hearing loss (SNHL) caused by novel PTPRQ mutations, including clinical manifestations and phenotypic features. Methods: Two hundred twenty (220) Japanese subjects with SNHL from unrelated and nonconsanguineous families were enrolled in the study. Targeted genomic enrichment with massively parallel DNA sequencing of all known nonsyndromic hearing loss genes was performed to identify the genetic cause of hearing loss. Results: Four novel causative PTPRQ mutations were identified in 3 cases. Case I had progressive profound SNHL with a homozygous nonsense mutation. Case 2 had nonprogressive profound SNHL with a compound heterozygous mutation (nonsense and missense mutation). Case 3 had nonprogressive moderate SNHL with a compound heterozygous mutation (missense and splice site mutation). Caloric test and vestibular evoked myogenic potential (VEMP) test showed vestibular dysfunction in Case I. Conclusion: Hearing loss levels and progression among the present cases were varied, and there seem to be no obvious correlations between genotypes and the phenotypic features of their hearing loss. The PTPRQ mutations appeared to be responsible for vestibular dysfunction.	[Sakuma, Naoko; Takahashi, Masahiro; Arai, Yasuhiro; Oridate, Nobuhiko] Yokohama City Univ, Sch Med, Dept Otorhinolaryngol & Head & Neck Surg, Yokohama, Kanagawa 232, Japan; [Sakuma, Naoko; Moteki, Hideaki; Nishio, Shin-ya; Usami, Shin-ichi] Shinshu Univ, Sch Med, Dept Otorhinolaryngol, Matsumoto, Nagano 3908621, Japan; [Moteki, Hideaki; Azaiez, Hela; Booth, Kevin T.; Shearer, A. Eliot; Sloan, Christina M.; Kolbe, Diana L.; Smith, Richard J. H.] Univ Iowa Hosp & Clin, Dept Otolaryngol Head & Neck Surg, Mol Otolaryngol & Renal Res Labs, Iowa City, IA 52242 USA; [Moteki, Hideaki; Nishio, Shin-ya; Iwasaki, Satoshi; Usami, Shin-ichi] Shinshu Univ, Sch Med, Dept Hearing Implant Sci, Matsumoto, Nagano 3908621, Japan; [Iwasaki, Satoshi] Int Univ Hlth & Welf, Mita Hosp, Dept Otorhinolaryngol, Minato Ku, Tokyo, Japan	Usami, S (reprint author), Shinshu Univ, Sch Med, Dept Otorhinolaryngol, 3-1-1 Asahi, Matsumoto, Nagano 3908621, Japan.	usami@shinshu-u.ac.jp			NIDCD [RO1s DC003544, DC002842, DC012049]; Health and Labour Sciences Research Grant for Research on Rare and Intractable Diseases and Comprehensive Research on Disability Health and Welfare from the Ministry of Health, Labour and Welfare of Japan; Ministry of Education, Science and Culture of Japan	The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by NIDCD RO1s DC003544, DC002842, and DC012049 to R.J.H.S. This study was also supported by a Health and Labour Sciences Research Grant for Research on Rare and Intractable Diseases and Comprehensive Research on Disability Health and Welfare from the Ministry of Health, Labour and Welfare of Japan (S.U.) and by a Grant-in-Aid for Scientific Research from the Ministry of Education, Science and Culture of Japan (S.U.).	Altshuler DM, 2012, NATURE, V491, P56, DOI 10.1038/nature11632; Shearer AE, 2013, J MED GENET, V50, P627, DOI 10.1136/jmedgenet-2013-101749; Li H, 2009, BIOINFORMATICS, V25, P1754, DOI 10.1093/bioinformatics/btp324; Shearer AE, 2010, P NATL ACAD SCI USA, V107, P21104, DOI 10.1073/pnas.1012989107; Kumar P, 2009, NAT PROTOC, V4, P1073, DOI 10.1038/nprot.2009.86; Goodyear RJ, 2012, J NEUROSCI, V32, P2762, DOI 10.1523/JNEUROSCI.3635-11.2012; Pollard KS, 2010, GENOME RES, V20, P110, DOI 10.1101/gr.097857.109; Cooper GM, 2005, GENOME RES, V15, P901, DOI 10.1101/gr.3577405; Schwarz JM, 2010, NAT METHODS, V7, P575, DOI 10.1038/nmeth0810-575; McKenna A, 2010, GENOME RES, V20, P1297, DOI 10.1101/gr.107524.110; Chun S, 2009, GENOME RES, V19, P1553, DOI 10.1101/gr.092619.109; Adzhubei IA, 2010, NAT METHODS, V7, P248, DOI 10.1038/nmeth0410-248; Chang X, 2012, J MED GENET, V49, P433, DOI 10.1136/jmedgenet-2012-100918; Frommolt P, 2012, HUM MUTAT, V33, P635, DOI 10.1002/humu.22036; Goodyear RJ, 2003, J NEUROSCI, V23, P9208; Hirono M, 2004, NEURON, V44, P309, DOI 10.1016/j.neuron.2004.09.020; Miyagawa M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0075793; Narahara M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0100924; Oganesian A, 2003, P NATL ACAD SCI USA, V100, P7563, DOI 10.1073/pnas.1336511100; Sakaguchi H, 2008, CELL MOTIL CYTOSKEL, V65, P528, DOI 10.1002/cm.20275; Schraders M, 2010, AM J HUM GENET, V86, P604, DOI 10.1016/j.ajhg.2010.02.015; Shahin H, 2010, J MED GENET, V47, P643, DOI 10.1136/jmg.2009.075697; Shearer AE, 2012, BMC BIOTECHNOL, V12, DOI 10.1186/1472-6750-12-20; Takenawa T, 2001, BBA-MOL CELL BIOL L, V1533, P190, DOI 10.1016/S1388-1981(01)00165-2; Wang K, 2010, NUCLEIC ACIDS RES, V38, DOI 10.1093/nar/gkq603	25	0	0	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0003-4894	1943-572X		ANN OTO RHINOL LARYN	Ann. Otol. Rhinol. Laryngol.	MAY	2015	124			1			184S	192S		10.1177/0003489415575041		9	Otorhinolaryngology	Otorhinolaryngology	CG6PA	WOS:000353422900019		
J	Miyagawa, M; Nishio, S; Sakurai, Y; Hattori, M; Tsukada, K; Moteki, H; Kojima, H; Usami, S				Miyagawa, Maiko; Nishio, Shin-ya; Sakurai, Yuika; Hattori, Mitsuru; Tsukada, Keita; Moteki, Hideaki; Kojima, Hiromi; Usami, Shin-ichi			The Patients Associated With TMPRSS3 Mutations Are Good Candidates for Electric Acoustic Stimulation	ANNALS OF OTOLOGY RHINOLOGY AND LARYNGOLOGY			English	Article						TMPRSS3; DFNB8/10; high-frequency hearing loss; massively parallel DNA sequencing; next generation sequencing; EAS	AUTOSOMAL RECESSIVE DEAFNESS; HEARING-LOSS; MISSENSE MUTATIONS; GENETIC-VARIANTS; HUMAN GENOMES; FAMILIES; PHENOTYPE; SEQUENCE; PROTEIN; FUTURE	Objectives: To clarify the frequency of TMPRSS3 mutations in the hearing loss population, genetic analysis was performed, and detailed clinical characteristics were collected. Optical intervention for patients with TMPRSS3 mutations was also discussed. Methods: Massively parallel DNA sequencing (MPS) was applied for the target exon-sequencing of 63 deafness genes in a population of 1 120 Japanese hearing loss patients. Results: Hearing loss in 5 patients was found to be caused by compound heterozygous TMPRSS3 mutations, and their detailed clinical features were collected and analyzed. Typically, all of the patients showed ski slope type audiogranns and progressive hearing loss. Three of the 5 patients received electric acoustic stimulation (EAS), which showed good results. Further, the onset age was found to vary, and there were some correlations between genotype and phenotype (onset age). Conclusions: MPS is a powerful tool for the identification of rare causative deafness genes, such as TMPRSS3. The present clinical characteristics not only confirmed the findings from previous studies but also provided clinical evidence that EAS is beneficial for patients possessing TMPRSS3 mutations.	[Miyagawa, Maiko; Nishio, Shin-ya; Hattori, Mitsuru; Tsukada, Keita; Moteki, Hideaki; Usami, Shin-ichi] Shinshu Univ, Sch Med, Dept Otorhinolaryngol, Matsumoto, Nagano 3908621, Japan; [Miyagawa, Maiko; Nishio, Shin-ya; Moteki, Hideaki; Usami, Shin-ichi] Shinshu Univ, Sch Med, Dept Hearing Implant Sci, Matsumoto, Nagano 3908621, Japan; [Sakurai, Yuika; Kojima, Hiromi] Jikei Univ, Sch Med, Dept Otorhinolaryngol, Tokyo, Japan	Usami, S (reprint author), Shinshu Univ, Sch Med, Dept Otorhinolaryngol, 3-1-1 Asahi, Matsumoto, Nagano 3908621, Japan.	usami@shinshu-u.ac.jp			Health and Labour Sciences Research Grant for Research on Rare and Intractable Diseases [H24-Nanchiou(Nan)-Ippan-032]; Comprehensive Research on Disability Health and Welfare from the Ministry of Health, Labour and Welfare of Japan [H25-Kankaku-Ippan-002]; Ministry of Education, Science and Culture of Japan [22249057]	The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This study was supported by a Health and Labour Sciences Research Grant for Research on Rare and Intractable Diseases (H24-Nanchiou(Nan)-Ippan-032) and Comprehensive Research on Disability Health and Welfare (H25-Kankaku-Ippan-002) from the Ministry of Health, Labour and Welfare of Japan (S.U.) and by a Grant-in-Aid for Scientific Research (A) (22249057) from the Ministry of Education, Science and Culture of Japan (S.U.).	Altshuler DM, 2012, NATURE, V491, P56, DOI 10.1038/nature11632; Ahmed Zubair M, 2004, BMC Med Genet, V5, P24, DOI 10.1186/1471-2350-5-24; Fasquelle L, 2011, J BIOL CHEM, V286, P17383, DOI 10.1074/jbc.M110.190652; Usami SI, 2014, ACTA OTO-LARYNGOL, V134, P717, DOI 10.3109/00016489.2014.894254; Weegerink NJD, 2011, JARO-J ASSOC RES OTO, V12, P753, DOI 10.1007/s10162-011-0282-3; Kumar P, 2009, NAT PROTOC, V4, P1073, DOI 10.1038/nprot.2009.86; Eppsteiner RW, 2012, HEARING RES, V292, P51, DOI 10.1016/j.heares.2012.08.007; Masmoudi S, 2001, HUM MUTAT, V18, P101, DOI 10.1002/humu.1159; Pollard KS, 2010, GENOME RES, V20, P110, DOI 10.1101/gr.097857.109; Charif M, 2012, BIOCHEM BIOPH RES CO, V419, P643, DOI 10.1016/j.bbrc.2012.02.066; Cooper GM, 2005, GENOME RES, V15, P901, DOI 10.1101/gr.3577405; Schwarz JM, 2010, NAT METHODS, V7, P575, DOI 10.1038/nmeth0810-575; Smith RJH, 2005, LANCET, V365, P879, DOI 10.1016/S0140-6736(05)71047-3; Scott HS, 2001, NAT GENET, V27, P59; Chun S, 2009, GENOME RES, V19, P1553, DOI 10.1101/gr.092619.109; Adzhubei IA, 2010, NAT METHODS, V7, P248, DOI 10.1038/nmeth0410-248; Wattenhofer M, 2002, J MOL MED-JMM, V80, P124, DOI 10.1007/s00109-001-0310-6; von Ilberg CA, 2011, AUDIOL NEURO-OTOL, V16, P1, DOI 10.1159/000327765; Chung J, 2014, J MOL MED, V92, P651, DOI 10.1007/s00109-014-1128-3; Chang X, 2012, J MED GENET, V49, P433, DOI 10.1136/jmedgenet-2012-100918; Ben-Yosef T, 2001, J MED GENET, V38, P396, DOI 10.1136/jmg.38.6.396; Elbracht M, 2007, J MED GENET, V44, DOI 10.1136/jmg.2007.049122; Guipponi M, 2008, HUM MUTAT, V29, P130, DOI 10.1002/humu.20617; Guipponi M, 2002, HUM MOL GENET, V11, P2829, DOI 10.1093/hmg/11.23.2829; Lee K, 2012, CLIN GENET, V82, P56, DOI 10.1111/j.1399-0004.2011.01695.x; Liu W, 2015, NEUROSCIENCE, V284, P470, DOI 10.1016/j.neuroscience.2014.09.059; Miyagawa M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071381; Miyagawa M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0075793; Narahara M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0100924; Tsukada K, AUDIOL NEUR IN PRESS; Wang K, 2010, NUCLEIC ACIDS RES, V38, DOI 10.1093/nar/gkq603; Wattenhofer M, 2005, HUM GENET, V117, P528, DOI 10.1007/s00439-005-1332-x; Wilson BS, 1997, BRIT J AUDIOL, V31, P205	33	0	0	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0003-4894	1943-572X		ANN OTO RHINOL LARYN	Ann. Otol. Rhinol. Laryngol.	MAY	2015	124			1			193S	204S		10.1177/0003489415575056		12	Otorhinolaryngology	Otorhinolaryngology	CG6PA	WOS:000353422900020		
J	Yabe, T; Tsuda, T; Hirose, S; Ozawa, T				Yabe, Tetsuji; Tsuda, Tomoyuki; Hirose, Shunsuke; Ozawa, Toshiyuki			Intraoperative Adjustment of Eyelid Level in Aponeurotic Blepharoptosis Surgery	ANNALS OF PLASTIC SURGERY			English	Article						aponeurotic blepharoptosis surgery; eyelid level; adjustment	SMALL-INCISION; LEVATOR APONEUROSIS; PTOSIS SURGERY; REPAIR; HEIGHT	There have been numerous reports on the use of aponeurotic surgery to correct involutional blepharoptosis. However, it is still difficult to determine optimal eyelid level during operation. Here we present our new method to adjust eyelid level intraoperatively. After the aponeurosis was temporally sutured to the tarsus, while still in the supine position, the patient was asked to look up, and the position of the eyelid margin was confirmed. The margin should be located above the pupil but within the cornea while the patient gazes up. And it is ideal if the eyelid position is located in the upper half of this range. Although 3 of 29 patients were reoperated on in the follow-up period, only 1 patient required readjustment in the perioperative period. Our method is simple, easy and reduces operative time, because it is not necessary to change patient position during the operation.	[Yabe, Tetsuji; Tsuda, Tomoyuki; Hirose, Shunsuke] Ishikiri Seiki Hosp, Dept Plast & Reconstruct Surg, Higashiosaka, Osaka 5798026, Japan; [Ozawa, Toshiyuki] Osaka City Univ, Sch Med, Dept Plast & Reconstruct Surg, Osaka 545, Japan	Yabe, T (reprint author), Ishikiri Seiki Hosp, Dept Plast Surg, 18-28 Yayoi Cho, Higashiosaka, Osaka 5798026, Japan.	yabe@msic.med.osaka-cu.ac.jp					Tucker SM, 1999, OPHTHALMOLOGY, V106, P517, DOI 10.1016/S0161-6420(99)90110-0; JONES LT, 1975, ARCH OPHTHALMOL-CHIC, V93, P629; ANDERSON RL, 1979, ARCH OPHTHALMOL-CHIC, V97, P1123; Frueh BR, 2004, OPHTHALMOLOGY, V111, P2158, DOI 10.1016/j.ophtha.2004.07.019; BERLIN AJ, 1989, OPHTHALMOLOGY, V96, P1033; Lucarelli MJ, 1999, AM J OPHTHALMOL, V127, P637, DOI 10.1016/S0002-9394(99)00064-1; McCulley TJ, 2003, OPHTHALMIC PLAST REC, V19, P388, DOI 10.1097/01.IOP.0000087071.78407.9A; Baroody M, 2004, ANN PLAS SURG, V52, P558, DOI 10.1097/01.sap.0000123354.69226.45; Bartley G B, 1996, Trans Am Ophthalmol Soc, V94, P165; DOXANAS MT, 1992, OPHTHALMIC SURG LAS, V23, P512; Emsen Ilteris Murat, 2008, J Craniofac Surg, V19, P669, DOI 10.1097/SCS.0b013e31806901b8; Holmstrom H, 2002, SCAND J PLAST RECONS, V36, P160; Lee IJ, 2011, J CRANIOFAC SURG, V22, P2284, DOI 10.1097/SCS.0b013e31823278a6; LINBERG JV, 1988, OPHTHALMOLOGY, V95, P1046; Liu F, 2012, AESTHET PLAST SURG, V36, P41, DOI 10.1007/s00266-011-9775-z; McDonald Hector, 2007, Semin Plast Surg, V21, P41, DOI 10.1055/s-2007-967747; Park DH, 2006, ANN PLAS SURG, V57, P376, DOI 10.1097/01.sap.0000237056.72643.20	17	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0148-7043	1536-3708		ANN PLAS SURG	Ann. Plast. Surg.	MAY	2015	74	5					520	523		10.1097/SAP.0b013e3182978885		4	Surgery	Surgery	CG7IA	WOS:000353475100002		
J	Akita, S; Mitsukawa, N; Kuriyama, M; Kubota, Y; Hasegawa, M; Tokumoto, H; Ishigaki, T; Togawa, T; Kuyama, J; Satoh, K				Akita, Shinsuke; Mitsukawa, Nobuyuki; Kuriyama, Motone; Kubota, Yoshitaka; Hasegawa, Masakazu; Tokumoto, Hideki; Ishigaki, Tatsuya; Togawa, Takashi; Kuyama, Junpei; Satoh, Kaneshige			Comparison of Vascularized Supraclavicular Lymph Node Transfer and Lymphaticovenular Anastomosis for Advanced Stage Lower Extremity Lymphedema	ANNALS OF PLASTIC SURGERY			English	Article						lymphedema; lymphaticovenular anastomosis; vascularized supraclavicular lymph node transfer	INDOCYANINE GREEN LYMPHOGRAPHY; CANCER-RELATED LYMPHEDEMA; UPPER-LIMB LYMPHEDEMA; OBSTRUCTIVE LYMPHEDEMA; POSTMASTECTOMY LYMPHEDEMA; PERIPHERAL LYMPHEDEMA; LEG LYMPHEDEMA; FLAP TRANSFER; SECONDARY; OUTCOMES	Background Vascularized lymph node transfer has become a popular surgical option to improve lower extremity lymphedema (LEL), although potential donor sites are limited. The free supraclavicular flap with deep cervical lymph nodes has been recently associated with a minimal risk of secondary lymphedema caused by donor site dissection. However, the effectiveness of this procedure has not yet been evaluated. Methods Vascularized supraclavicular lymph node transfer (VSLNT) was performed for patients with International Society of Lymphology late stage II or more severe LEL. The results were compared with lymphaticovenular anastomosis (LVA) performed for patients with the same stages of severity. To evaluate improvement in lymphatic function, indocyanine green lymphography and lymphoscintigraphy were performed. Results Vascularized supraclavicular lymph node transfer was performed in 13 limbs of 13 patients. The results were compared with 43 limbs of 33 patients who underwent multiple LVA. No severe complications were observed in either group. Improvement in lymphatic function, as measured by the LEL index, was 26.5 4.4 and 21.2 +/- 2.0 in the VSLNT and LVA groups, respectively. Lymphatic function was improved in 7 cases in the VSLNT group and 10 cases in the LVA group. Conclusions Vascularized supraclavicular lymph node transfer is an effective technique for the treatment of advanced stage LEL. Lymphaticovenular anastomosis is also effective, but to a lesser degree than VSLNT. However, LVA is less invasive and requires a shorter hospital stay.	[Akita, Shinsuke; Tokumoto, Hideki] Chiba Canc Ctr, Dept Plast & Reconstruct Surg, Chiba, Chiba 2608717, Japan; [Mitsukawa, Nobuyuki; Kubota, Yoshitaka; Hasegawa, Masakazu; Ishigaki, Tatsuya; Satoh, Kaneshige] Chiba Canc Ctr, Dept Plast Reconstruct & Aesthet Surg, Fac Med, Chiba, Chiba 2608717, Japan; [Kuriyama, Motone] Kochi Med Sch Hosp, Dept Plast & Reconstruct Surg, Nankoku, Kochi, Japan; [Togawa, Takashi; Kuyama, Junpei] Chiba Canc Ctr, Div Nucl Med, Chiba, Chiba 2608717, Japan	Akita, S (reprint author), Chiba Canc Ctr, Dept Plast & Reconstruct Surg, Chuo Ku, 666-2 Nitona Cho, Chiba, Chiba, Japan.	shinsukeakitaprs@gmail.com					Akita S, 2013, PLAST RECONSTR SURG, V132, P1008, DOI 10.1097/PRS.0b013e31829fe12f; Althubaiti GA, 2013, PLAST RECONSTR SURG, V131, p133E, DOI 10.1097/PRS.0b013e318272a1b4; Maegawa J, 2012, J VASC SURG, V55, P753, DOI 10.1016/j.jvs.2011.08.062; Yamamoto T, 2011, PLAST RECONSTR SURG, V127, P1987, DOI 10.1097/PRS.0b013e31820cf5c6; Jeltsch M, 1997, SCIENCE, V276, P1423, DOI 10.1126/science.276.5317.1423; Basta MN, 2014, PLAST RECONSTR SURG, V133, P905, DOI 10.1097/PRS.0000000000000010; Damstra RJ, 2009, BREAST CANCER RES TR, V113, P199, DOI 10.1007/s10549-008-9932-5; Brorson H, 1998, PLAST RECONSTR SURG, V102, P1058, DOI 10.1097/00006534-199809040-00021; OBRIEN BM, 1990, PLAST RECONSTR SURG, V85, P562, DOI 10.1097/00006534-199004000-00011; Becker C, 2012, CLIN PLAST SURG, V39, P385, DOI 10.1016/j.cps.2012.08.002; Demirtas Y, 2010, J RECONSTR MICROSURG, V26, P137, DOI 10.1055/s-0029-1243299; Becker C, 2006, ANN SURG, V243, P313, DOI 10.1097/01.sla.0000201258.10304.16; Lin CH, 2009, PLAST RECONSTR SURG, V123, P1265, DOI 10.1097/PRS.0b013e31819e6529; Gharb BB, 2011, ANN PLAS SURG, V67, P589, DOI 10.1097/SAP.0b013e3181f88e8a; CHEN HC, 1990, BRIT J PLAST SURG, V43, P578, DOI 10.1016/0007-1226(90)90123-H; Honkonen KM, 2013, ANN SURG, V257, P961, DOI 10.1097/SLA.0b013e31826ed043; Cheng MH, 2013, PLAST RECONSTR SURG, V131, P1286, DOI 10.1097/PRS.0b013e31828bd3b3; Chang DW, 2010, PLAST RECONSTR SURG, V126, P752, DOI 10.1097/PRS.0b013e3181e5f6a9; Olszewski WL, 2013, EUR J VASC ENDOVASC, V45, P282, DOI 10.1016/j.ejvs.2012.11.025; OBRIEN BM, 1977, PLAST RECONSTR SURG, V60, P197; Maegawa J, 2010, MICROSURG, V30, P437, DOI 10.1002/micr.20772; Koshima I, 2003, J RECONSTR MICROSURG, V19, P209; Koshima I, 2000, J RECONSTR MICROSURG, V16, P437; Lahteenvuo M, 2011, CIRCULATION, V123, P613, DOI 10.1161/CIRCULATIONAHA.110.965384; Akita S, 2014, J PLAST RECONSTR AES, V67, P520, DOI 10.1016/j.bjps.2013.12.056; Koshima I, 2004, ANN PLAS SURG, V53, P261, DOI 10.1097/01.sap.0000120319.89926.07; Cheng MH, 2012, GYNECOL ONCOL, V126, P93, DOI 10.1016/j.ygyno.2012.04.017; Saaristo AM, 2012, ANN SURG, V255, P468, DOI 10.1097/SLA.0b013e3182426757; Akita S, 2013, J PLAST RECONSTR AES, V66, P792, DOI 10.1016/j.bjps.2013.02.023; Yamamoto T, 2014, MICROSURG, V34, P308, DOI 10.1002/micr.22187; Yamamoto T, 2011, ANN PLAS SURG, V67, P637, DOI 10.1097/SAP.0b013e318208fd75; Saito Y, 2006, CIRCULATION, V114, P1177, DOI 10.1161/CIRCULATIONAHA.105.602953; Auba C, 2012, MICROSURG, V32, P261, DOI 10.1002/micr.20980; BECKER C, 1988, J MAL VASCUL, V13, P119; Brorson H, 2003, Scand J Surg, V92, P287; Granzow JW, 2014, ANN SURG ONCOL, V21, P1189, DOI 10.1245/s10434-014-3515-y; Granzow JW, 2014, ANN SURG ONCOL, V21, P1195, DOI 10.1245/s10434-014-3518-8; International Society of Lymphology, 2013, LYMPHOLOGY, V46, P1; IPSEN T, 1988, SCAND J PLAST RECONS, V22, P233; Ito R, 2014, PLAST RECONSTR SURG, V134, P548, DOI 10.1097/PRS.0000000000000383; Mihara M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041126; Nagase Takashi, 2005, Int J Clin Oncol, V10, P304, DOI 10.1007/s10147-005-0518-5; Saito Y, 2013, BIOMED RES INT, DOI 10.1155/2013/804675; Yamamoto N, 2014, ANN PLAST SURG; Yamamoto T, 2011, PLAST RECONSTR SURG, V128, p314E, DOI 10.1097/PRS.0b013e3182268da8; Yamamoto T, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059523; Yamamoto T, 2014, MICROSURG, V34, P404, DOI 10.1002/micr.22215; Yamamoto T, 2013, ANN PLAS SURG, V70, P47, DOI 10.1097/SAP.0b013e3182275d23	48	1	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0148-7043	1536-3708		ANN PLAS SURG	Ann. Plast. Surg.	MAY	2015	74	5					573	579		10.1097/SAP.0000000000000513		7	Surgery	Surgery	CG7IA	WOS:000353475100011		
J	Kataoka, N; Matsutani, M; Yakushi, T; Matsushita, K				Kataoka, Naoya; Matsutani, Minenosuke; Yakushi, Toshiharu; Matsushita, Kazunobu			Efficient Production of 2,5-Diketo-D-Gluconate via Heterologous Expression of 2-Ketogluconate Dehydrogenase in Gluconobacter japonicus	APPLIED AND ENVIRONMENTAL MICROBIOLOGY			English	Article							D-GLUCONATE DEHYDROGENASE; D-SORBITOL DEHYDROGENASE; L-ASCORBATE SYNTHESIS; CYTOCHROME-C COMPLEX; ACETIC-ACID BACTERIA; 2-KETO-D-GLUCONATE DEHYDROGENASE; GLYCEROL DEHYDROGENASE; FRUCTOSE DEHYDROGENASE; MOLECULAR-PROPERTIES; MAXIMUM-LIKELIHOOD	2,5-Diketo-D-gluconate (2,5DKG) is a compound that can be the intermediate for D-tartrate and also vitamin C production. Although Gluconobacter oxydans NBRC3293 produces 2,5DKG from D-glucose via D-gluconate and 2-keto-D-gluconate (2KG), with accumulation of the product in the culture medium, the efficiency of 2,5DKG production is unsatisfactory because there is a large amount of residual D-gluconate at the end of the biotransformation process. Oxidation of 2KG to 2,5DKG is catalyzed by a membrane-bound flavoprotein-cytochrome c complex: 2-keto-gluconate dehydrogenase (2KGDH). Here, we studied the kgdSLC genes encoding 2KGDH in G. oxydans NBRC3293 to improve 2,5DKG production by Gluconobacter spp. The kgdS, kgdL, and kgdC genes correspond to the small, large, and cytochrome subunits of 2KGDH, respectively. The kgdSLC genes were cloned into a broad-host-range vector carrying a DNA fragment of the putative promoter region of the membrane-bound alcohol dehydrogenase gene of G. oxydans for expression in Gluconobacter spp. According to our results, 2KGDH that was purified from the recombinant Gluconobacter cells showed characteristics nearly the same as those reported previously. We also expressed the kgdSLC genes in a mutant strain of Gluconobacter japonicus NBRC3271 (formerly Gluconobacter dioxyacetonicus IFO3271) engineered to produce 2KG efficiently from a mixture of D-glucose and D-gluconate. This mutant strain consumed almost all of the starting materials (D-glucose and D-gluconate) to produce 2,5DKG quantitatively as a seemingly unique metabolite. To our knowledge, this is the first report of a Gluconobacter strain that produces 2,5DKG efficiently and homogeneously.	[Kataoka, Naoya; Matsutani, Minenosuke; Yakushi, Toshiharu; Matsushita, Kazunobu] Yamaguchi Univ, Fac Agr, Dept Biol Chem, Yoshida, Yamaguchi, Japan; [Kataoka, Naoya; Yakushi, Toshiharu; Matsushita, Kazunobu] Yamaguchi Univ, Res Ctr Thermotolerant Microbial Resources, Yoshida, Yamaguchi, Japan	Yakushi, T (reprint author), Yamaguchi Univ, Fac Agr, Dept Biol Chem, Yoshida, Yamaguchi, Japan.	juji@yamaguchi-u.ac.jp					C elegans Sequencing Consortium, 1998, SCIENCE, V282, P2012, DOI 10.1126/science.282.5396.2012; ANDERSON S, 1985, SCIENCE, V230, P144, DOI 10.1126/science.230.4722.144; FIGURSKI DH, 1979, P NATL ACAD SCI USA, V76, P1648, DOI 10.1073/pnas.76.4.1648; AMEYAMA M, 1981, J BACTERIOL, V145, P814; Castresana J, 2000, MOL BIOL EVOL, V17, P540; Toyama H, 2005, BIOSCI BIOTECH BIOCH, V69, P1120, DOI 10.1271/bbb.69.1120; MCINTIRE W, 1985, BIOCHEM J, V231, P651; Sugisawa T, 2002, BIOSCI BIOTECH BIOCH, V66, P57, DOI 10.1271/bbb.66.57; Tamura K, 2007, MOL BIOL EVOL, V24, P1596, DOI 10.1093/molbev/msm092; Talavera G, 2007, SYSTEMATIC BIOL, V56, P564, DOI 10.1080/10635150701472164; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; Stamatakis A, 2006, BIOINFORMATICS, V22, P2688, DOI 10.1093/bioinformatics/btl446; Bremus C, 2006, J BIOTECHNOL, V124, P196, DOI 10.1016/j.jbiotec.2006.01.010; Krogh A, 2001, J MOL BIOL, V305, P567, DOI 10.1006/jmbi.2000.4315; DULLEY JR, 1975, ANAL BIOCHEM, V64, P136, DOI 10.1016/0003-2697(75)90415-7; Dym O, 2001, PROTEIN SCI, V10, P1712, DOI 10.1110/ps.12801; SHINAGAWA E, 1981, AGR BIOL CHEM TOKYO, V45, P1079; Miyazaki T, 2002, BIOSCI BIOTECH BIOCH, V66, P262, DOI 10.1271/bbb.66.262; Shinagawa E, 2009, BIOSCI BIOTECH BIOCH, V73, P241, DOI 10.1271/bbb.80554; Kawai S, 2013, APPL ENVIRON MICROB, V79, P1654, DOI 10.1128/AEM.03152-12; Saichana I, 2009, APPL ENVIRON MICROB, V75, P4240, DOI 10.1128/AEM.00640-09; BOYER HW, 1969, J MOL BIOL, V41, P459, DOI 10.1016/0022-2836(69)90288-5; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; Berks BC, 2005, CURR OPIN MICROBIOL, V8, P174, DOI 10.1016/j.mib.2005.02.010; Toyama H, 2007, APPL ENVIRON MICROB, V73, P6551, DOI 10.1128/AEM.00493-07; GOODHEW CF, 1986, BIOCHIM BIOPHYS ACTA, V852, P288, DOI 10.1016/0005-2728(86)90234-3; PUGSLEY AP, 1993, MICROBIOL REV, V57, P50; Edgar RC, 2004, NUCLEIC ACIDS RES, V32, P1792, DOI 10.1093/nar/gkh340; Matsushita K, 2003, APPL ENVIRON MICROB, V69, P1959, DOI 10.1128/AEM.69.4.1959-1966.2003; AMEYAMA M, 1985, AGR BIOL CHEM TOKYO, V49, P1001; SHINAGAWA E, 1984, AGR BIOL CHEM TOKYO, V48, P1517; Adachi O, 2010, BIOSCI BIOTECH BIOCH, V74, P2555, DOI 10.1271/bbb.100698; Tamura K, 2011, MOL BIOL EVOL, V28, P2731, DOI 10.1093/molbev/msr121; Edgar RC, 2004, BMC BIOINFORMATICS, V5, P1, DOI 10.1186/1471-2105-5-113; GRINDLEY JF, 1988, APPL ENVIRON MICROB, V54, P1770; Habe H, 2009, APPL ENVIRON MICROB, V75, P7760, DOI 10.1128/AEM.01535-09; Hoshino T, 2014, Japanese patent, Patent No. 113105; Matsushita K, 1996, J BIOL CHEM, V271, P4850; MATSUSHITA K, 1994, ADV MICROB PHYSIOL, V36, P247, DOI 10.1016/S0065-2911(08)60181-2; MATSUSHITA K, 1989, J BIOCHEM-TOKYO, V105, P633; Pappenberger G, 2014, ADV BIOCHEM ENG BIOT, V143, P143, DOI 10.1007/10_2013_243; Pujol CJ, 2000, J BACTERIOL, V182, P2230, DOI 10.1128/JB.182.8.2230-2237.2000; SHINAGAWA E, 1976, AGR BIOL CHEM TOKYO, V40, P475; SONOYAMA T, 1982, APPL ENVIRON MICROB, V43, P1064; Sulo P, 2001, BIOTECHNOL LETT, V23, P693, DOI 10.1023/A:1010360603287	45	0	0	AMER SOC MICROBIOLOGY	WASHINGTON	1752 N ST NW, WASHINGTON, DC 20036-2904 USA	0099-2240	1098-5336		APPL ENVIRON MICROB	Appl. Environ. Microbiol.	MAY	2015	81	10					3552	3560		10.1128/AEM.04176-14		9	Biotechnology & Applied Microbiology; Microbiology	Biotechnology & Applied Microbiology; Microbiology	CG5MV	WOS:000353336900028		
J	Nakashima, Y				Nakashima, Yoshito			Development of a Single-Sided Nuclear Magnetic Resonance Scanner for the In Vivo Quantification of Live Cattle Marbling	APPLIED MAGNETIC RESONANCE			English	Article							TIME-DOMAIN NMR; FAT-CONTENT; UNILATERAL NMR; IMAGE-ANALYSIS; MEAT QUALITY; GROWTH; STEERS; PRODUCTS; MUSCLE; BEEF	Non-invasive in vivo marbling quantification helps owners to choose the optimum nutritional management for growing cattle and buyers to more precisely evaluate grown cattle at auctions. When using time-domain proton nuclear magnetic resonance (NMR) relaxometry, it is possible to quantify muscle and fat separately by taking advantage of the difference in the spin spin relaxation time (T2) between water molecules in muscles and fat molecules, which would contribute to the noninvasive and objective determination of marbling scores. With this in mind, we developed a prototype NMR scanner (4.1 MHz for protons) using an original singlesided magnetic circuit and a plane radio frequency (RF) coil for use in the noninvasive quantification of water and fat in live cattle. The sensed region of the developed scanner is compact and almost cubical (19 x 19 x 16 mm(3)) while the investigation depth (the distance from the RF coil to the center of the sensed region) has been lengthened to 30 mm, which is sufficient for the in vivo trapezius muscle measurement of live cattle. Measurements of 17 samples of beef meat blocks kept at 39 C were taken in a laboratory to successfully obtain the calibration lines used to convert the NMR signals into water and fat weight fractions at correlation coefficients in excess of 0.9. We also showed that each meat sample could be measured in about 10 s with a measurement error as small as approximately 10 wt%. Accordingly, we believe that our prototype scanner would be useful for in vivo marbling measurements of live cattle trapezius muscles.	Natl Inst Adv Ind Sci & Technol, Tsukuba, Ibaraki 3058567, Japan	Nakashima, Y (reprint author), Natl Inst Adv Ind Sci & Technol, Cent 7,1-1-1 Higashi, Tsukuba, Ibaraki 3058567, Japan.	nakashima.yoshito@aist.go.jp	NAKASHIMA, Yoshito/A-1504-2010		High-Tech Monodukuri Project of the National Institute of Advanced Industrial Science and Technology (AIST), Japan	Comments by an anonymous reviewer were helpful. I thank Dr. S. Utsuzawa (New Mexico Resonance) for his very important contribution to the development of the software/hardware of the NMR apparatus. The FFC NMR measurements in Fig. ESM_10 were performed by Dr. G. Ferrante at Stelar Srl. This study was financially supported by the High-Tech Monodukuri Project of the National Institute of Advanced Industrial Science and Technology (AIST), Japan.	van Duynhoven J, 2010, ANNU REP NMR SPECTRO, V69, P145, DOI 10.1016/S0066-4103(10)69003-5; Grunert KG, 2004, MEAT SCI, V66, P259, DOI 10.1016/S0309-1740(03)00130-X; Hurlimann MD, 2000, J MAGN RESON, V143, P120, DOI 10.1006/jmre.1999.1967; Blumich B, 2008, PROG NUCL MAG RES SP, V52, P197, DOI 10.1016/j.pnmrs.2007.10.002; Bertram HC, 2004, ANNU REP NMR SPECTRO, V53, P157, DOI 10.1016/S0066-4103(04)53003-X; Ferrante G, 2005, ADV INORG CHEM, V57, P405, DOI 10.1016/S0898-8838(05)57009-0; Pethick DW, 2004, AUST J EXP AGR, V44, P705, DOI 10.1071/EA02165; Nakamura T, 2007, CONCEPT MAGN RESON B, V31B, P65, DOI 10.1002/cmr.b.20083; DAMADIAN R, 1971, SCIENCE, V171, P1151, DOI 10.1126/science.171.3976.1151; Pearce KL, 2011, MEAT SCI, V89, P111, DOI 10.1016/j.meatsci.2011.04.007; Purchas RW, 2002, J ANIM SCI, V80, P3211; Biasibetti E, 2012, ANIMAL, V6, P1839, DOI 10.1017/S175173111200081X; Casanova F, 2011, SINGLE-SIDED NMR, P1, DOI 10.1007/978-3-642-16307-4; Coates G.R., 2001, NMR LOGGING PRINCIPL; Fukushima E., 2002, US patent, Patent No. 6489872; Guthausen A, 2004, J AM OIL CHEM SOC, V81, P727, DOI 10.1007/s11746-004-0969-5; Hashimoto D., 2014, NIHON CHIKUSAN GAKKA, V85, P51; Ikehira H., 2008, RADIOL SCI, V51, P17; Irie M, 2012, ASIAN AUSTRAL J ANIM, V25, P592, DOI 10.5713/ajas.2011.11204; Ishizuka Y., 2008, NIHON CHIKUSAN GAKKA, V79, P497; Kumagai H., 2000, Asian-Australasian Journal of Animal Sciences, V13, P346; Miyajima T., 2009, B BEEF CATTLE SCI, P41; Nakashima Y, 2004, J NUCL SCI TECHNOL, V41, P981, DOI 10.3327/jnst.41.981; Nakashima Y., 2007, 108 M JAP SOC AN SCI; Nakashima Y., 2008, J JPN SOC IRRIG DRAI, V76, P795; Osawa T, 2008, J ANIM SCI, V86, P40, DOI 10.2527/jas.2007-0359; Perlo J, 2004, J MAGN RESON, V166, P228, DOI 10.1016/j.jmr.2003.10.018; Petrov OV, 2008, FOOD RES INT, V41, P758, DOI 10.1016/j.foodres.2008.05.010; Short RE, 1999, J ANIM SCI, V77, P2406; Todt H, 2006, FOOD CHEM, V96, P436, DOI 10.1016/j.foodchem.2005.04.032; Veliyulin E, 2005, J SCI FOOD AGR, V85, P1299, DOI 10.1002/jsfa.2117; Veliyulin E, 2008, J SCI FOOD AGR, V88, P2563, DOI 10.1002/jsfa.3391	32	0	0	SPRINGER WIEN	WIEN	SACHSENPLATZ 4-6, PO BOX 89, A-1201 WIEN, AUSTRIA	0937-9347	1613-7507		APPL MAGN RESON	Appl. Magn. Reson.	MAY	2015	46	5					593	606		10.1007/s00723-015-0657-4		14	Physics, Atomic, Molecular & Chemical; Spectroscopy	Physics; Spectroscopy	CG7EC	WOS:000353464200010		
J	Kaneshima, K; Sugiura, M; Tamura, K; Ishii, N; Itatani, J				Kaneshima, Keisuke; Sugiura, Muneo; Tamura, Koichi; Ishii, Nobuhisa; Itatani, Jiro			Ultrabroadband infrared chirped mirrors characterized by a white-light Michelson interferometer	APPLIED PHYSICS B-LASERS AND OPTICS			English	Article							GROUP-DELAY MEASUREMENT; FEMTOSECOND LASERS; PULSE AMPLIFIER; DISPERSION; GENERATION; DIFFERENTIATION; COMPRESSION	We fabricated and characterized a pair of ultrabroadband chirped mirrors (CMs) in the infrared. These mirrors provide smooth control of the spectral phases in the wavelength range 1200-2200 nm, nearly one octave of a bandwidth. A scanning-type white-light Michelson interferometer was developed to measure spectral dispersion. We confirmed that the dispersion of the CMs well reproduced the designed dispersion. Furthermore, the CMs' damage threshold was measured to be >390 mJ/cm(2) for 10-fs pulses, which corresponds to >37 TW/cm(2).	[Kaneshima, Keisuke; Ishii, Nobuhisa; Itatani, Jiro] Univ Tokyo, Inst Solid State Phys, Kashiwa, Chiba 2778581, Japan; [Sugiura, Muneo; Tamura, Koichi] Tokai Opt Co Ltd, Opt Prod Div, Okazaki, Aichi 4442106, Japan	Kaneshima, K (reprint author), Univ Tokyo, Inst Solid State Phys, 5-1-5 Kashiwanoha, Kashiwa, Chiba 2778581, Japan.	kaneshima@issp.u-tokyo.ac.jp			Japan Society for the Promotion of Science [23226003, 25790063]	This research was partially supported by Grant-in-Aid for Scientific Research (S) Grant Number 23226003, Grant-in-Aid for Young Scientists (B) Grant Number 25790063, and Program for Leading Graduate Schools (MERIT) by Japan Society for the Promotion of Science.	NAGANUMA K, 1990, OPT LETT, V15, P393, DOI 10.1364/OL.15.000393; Moses J, 2009, OPT LETT, V34, P1639, DOI 10.1364/OL.34.001639; Kartner FX, 2001, J OPT SOC AM B, V18, P882, DOI 10.1364/JOSAB.18.000882; Takahashi EJ, 2010, PHYS REV LETT, V104, DOI 10.1103/PhysRevLett.104.233901; Gu X, 2009, OPT EXPRESS, V17, P62, DOI 10.1364/OE.17.000062; CORKUM PB, 1993, PHYS REV LETT, V71, P1994, DOI 10.1103/PhysRevLett.71.1994; Lepetit L, 1995, J OPT SOC AM B, V12, P2467, DOI 10.1364/JOSAB.12.002467; SAVITZKY A, 1964, ANAL CHEM, V36, P1627, DOI 10.1021/ac60214a047; Giguere M, 2009, OPT LETT, V34, P1894, DOI 10.1364/OL.34.001894; GORRY PA, 1990, ANAL CHEM, V62, P570, DOI 10.1021/ac00205a007; SZIPOCS R, 1994, OPT LETT, V19, P201, DOI 10.1364/OL.19.000201; Nisoli M, 1997, OPT LETT, V22, P522, DOI 10.1364/OL.22.000522; REYNAUD F, 1989, OPT LETT, V14, P275, DOI 10.1364/OL.14.000275; Corkum PB, 2007, NAT PHYS, V3, P381, DOI 10.1038/nphys620; Hentschel M, 2001, NATURE, V414, P509, DOI 10.1038/35107000; Schmidt BE, 2010, APPL PHYS LETT, V96, DOI 10.1063/1.3359458; Ishii N, 2012, OPT LETT, V37, P4182, DOI 10.1364/OL.37.004182; Popmintchev T, 2012, SCIENCE, V336, P1287, DOI 10.1126/science.1218497; Diddams S, 1996, J OPT SOC AM B, V13, P1120, DOI 10.1364/JOSAB.13.001120; Fuji T, 1998, REV SCI INSTRUM, V69, P2854, DOI 10.1063/1.1149024; Imran T, 2004, REV SCI INSTRUM, V75, P2266, DOI 10.1063/1.1763257; Ishii N, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4331; KOVACS AP, 1995, OPT LETT, V20, P788; MALITSON IH, 1963, APPL OPTICS, V2, P1103, DOI 10.1364/AO.2.001103; Trubetskov MK, 2013, OPT EXPRESS, V21, P6658, DOI 10.1364/OE.21.006658	25	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0946-2171	1432-0649		APPL PHYS B-LASERS O	Appl. Phys. B-Lasers Opt.	MAY	2015	119	2					347	353		10.1007/s00340-015-6076-2		7	Optics; Physics, Applied	Optics; Physics	CG5RB	WOS:000353350400015		
J	Suzuki, A				Suzuki, Akira			When a Tree House No Longer Says 'House', Are We Virtually There?	ARCHITECTURAL DESIGN			English	Article									Musashino Art Univ, Architecture, Kodaira, Tokyo, Japan	Suzuki, A (reprint author), Musashino Art Univ, Architecture, Kodaira, Tokyo, Japan.						Isozaki Arata, 1971, TOWARDS SPACE, P132; Isozaki Arata, 1991, OSAKA FOLLIES TYPES, P7	2	0	0	WILEY PERIODICALS, INC	SAN FRANCISCO	ONE MONTGOMERY ST, SUITE 1200, SAN FRANCISCO, CA 94104 USA	0003-8504	1554-2769		ARCHIT DESIGN	Archit. Des.	MAY-JUN	2015	85	3			SI		86	91		10.1002/ad.1905		6	Architecture	Architecture	CF8KG	WOS:000352807400013		
J	Ogura, K; Sakuraba, M; Miyamoto, S; Fujiwara, T; Chuman, H; Kawai, A				Ogura, Koichi; Sakuraba, Minoru; Miyamoto, Shimpei; Fujiwara, Tomohiro; Chuman, Hirokazu; Kawai, Akira			Pelvic ring reconstruction with a double-barreled free vascularized fibula graft after resection of malignant pelvic bone tumor	ARCHIVES OF ORTHOPAEDIC AND TRAUMA SURGERY			English	Article						Internal hemipelvectomy; Pelvic ring reconstruction; Vascularized fibula graft; Complication	INTERNAL HEMIPELVECTOMY; ALLOGRAFTS; FLAP	In patients undergoing limb-salvage internal hemipelvectomy, pelvic ring reconstruction is mandatory to maintain the stability of the pelvis and the spinal column, which finally expected to achieve a good functional outcome. However, no optimal reconstruction method has been established. In addition, no previous reports have highlighted the long-term complications of pelvic ring reconstruction after internal hemipelvectomy. We aimed to analyze the outcome of pelvic ring reconstruction using a double-barreled free vascularized fibula graft (VFG) after internal hemipelvectomy with special reference to long-term complications. We conducted a retrospective review of 9 consecutive patients (5 male, 4 female; mean age 31 years) who underwent pelvic ring reconstruction using a double-barreled free VFG after internal hemipelvectomy (P1, n = 4; P1 + 4, n = 3; P1 + 2, n = 2) at our institution between 1998 and 2013. The mean follow-up period was 55 months (range 3-131 months). The mean length of the bone defect was 9 cm. The methods of fixation included a Cotrel-Dubosset rod (n = 4), screw (n = 3), and screw and plate (n = 2). Bone union was achieved in 5 of 8 patients (63 %) over a 1-year follow-up. The mean period required for bone union was 5.4 months (range 3-7 months). There were 3 early postoperative complications: 2 deep infections resulting in graft removal and 1 implant failure resulting in non-union. Among 3 patients, 2 developed scoliosis within 5 years. One patient developed lumbar disc hernia as a result of scoliosis, for which surgical intervention was required. The mean Musculoskeletal Tumor Society score was 57 % at the last follow-up. In conclusion, this reconstruction method can achieve an early and high rate of bone union and provide good functional outcome. However, follow-up with careful attention to postoperative complications, including deep infection in the early postoperative period and spinal deformity in the long term, is necessary.	[Ogura, Koichi; Fujiwara, Tomohiro; Chuman, Hirokazu; Kawai, Akira] Natl Canc Ctr, Dept Musculoskeletal Oncol, Chuo Ku, Tokyo 1040045, Japan; [Sakuraba, Minoru; Miyamoto, Shimpei] Natl Canc Ctr, Dept Plast & Reconstruct Surg, Chuo Ku, Tokyo 1040045, Japan	Kawai, A (reprint author), Natl Canc Ctr, Dept Musculoskeletal Oncol, Chuo Ku, 5-1-1 Tsukiji, Tokyo 1040045, Japan.	akawai@ncc.go.jp			Ministry of Education and Science [22390296]; National Cancer Center Research and Development Fund [23-A-10]	This study was funded by a Grant-in-Aid for Scientific Research from the Ministry of Education and Science (B, No. 22390296), and by the National Cancer Center Research and Development Fund (23-A-10).	Akiyama T, 2010, J BONE JOINT SURG BR, V92B, P999, DOI 10.1302/0301-620X.92B7.23497; Nishida J, 2006, CLIN ORTHOP RELAT R, P145, DOI 10.1097/01.blo.0000203485.90711.1b; Mankin HJ, 2005, CLIN ORTHOP RELAT R, P210, DOI 10.1097/01.blo.0000150371.77314.52; OCONNOR MI, 1989, J BONE JOINT SURG AM, V71A, P481; AHO AJ, 1994, CLIN ORTHOP RELAT R, P200; ENNEKING WF, 1993, CLIN ORTHOP RELAT R, P241; Beadel GP, 2005, CLIN ORTHOP RELAT R, P22, DOI 10.1097/01.blo.0000180046.97466.bc; Chang DW, 2008, PLAST RECONSTR SURG, V121, P1993, DOI 10.1097/PRS.0b013e3181706ff2; ENNEKING W, 1990, Chirurgia degli Organi di Movimento, V75, P217; HARRINGTON KD, 1992, J BONE JOINT SURG AM, V74A, P331; HUTH JF, 1988, ARCH SURG-CHICAGO, V123, P1121; Langlais F, 2001, CLIN ORTHOP RELAT R, P178; Nassif NA, 2013, CLIN ORTHOP RELAT R, V471, P947, DOI 10.1007/s11999-012-2643-6; Ogura K, 2014, BONE JOINT J, V96B, P270, DOI 10.1302/0301-620X.96B2.32514; Sabourin M, 2009, ORTHOP TRAUMATOL-SUR, V95, P284, DOI 10.1016/j.otsr.2009.04.008; Sakuraba M, 2005, PLAST RECONSTR SURG, V116, P1340, DOI 10.1097/01.prs.0000181736.85276-78	16	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0936-8051	1434-3916		ARCH ORTHOP TRAUM SU	Arch. Orthop. Trauma Surg.	MAY	2015	135	5					619	625		10.1007/s00402-015-2197-7		7	Orthopedics; Surgery	Orthopedics; Surgery	CG4XG	WOS:000353291800005		
J	Takata, Y; Nakase, J; Numata, H; Oshima, T; Tsuchiya, H				Takata, Yasushi; Nakase, Junsuke; Numata, Hitoaki; Oshima, Takeshi; Tsuchiya, Hiroyuki			Repair and augmentation of a spontaneous patellar tendon rupture in a patient with Ehlers-Danlos syndrome: a case report	ARCHIVES OF ORTHOPAEDIC AND TRAUMA SURGERY			English	Article						Patellar tendon rupture; Ehlers-Danlos syndrome; Augmentation; Repair; Hamstrings		Disruption of the knee extensor mechanism is a serious disorder that requires prompt treatment. It often occurs in the form of a patellar tendon rupture. It may occur in association with systemic disease or after administration of corticosteroids or fluoroquinolones. These conditions can cause tendon weakness, and consequent ruptures usually require both repair and augmentation. This paper reports on repair and augmentation for treating patellar tendon rupture in patients with Ehlers-Danlos syndrome (EDS). We report a patellar tendon rupture in a 27-year-old man with EDS, which occurred in the midsubstance of the patella. As the patient has tendon weakness, extensive repair will increase the risk of patella baja, and the use of end-to-end suturing technique alone will not be enough to prevent a rupture recurring; however, augmentation could be used to address the tendon weakness. Repair of the rupture and augmentation with hamstring tendon was performed. One year after the surgery, the patient was able to move his knee joint without pain and had an active range of motion of 0A degrees (passive 20A degrees)-145A degrees. He was able to perform a straight leg raise without an extension lag. Repair and augmentation with hamstring tendon was an effective treatment option for patellar tendon rupture in a patient with EDS.	[Takata, Yasushi; Nakase, Junsuke; Numata, Hitoaki; Oshima, Takeshi; Tsuchiya, Hiroyuki] Kanazawa Univ, Grad Sch Med Sci, Dept Orthopaed Surg, Kanazawa, Ishikawa 9208641, Japan	Takata, Y (reprint author), Kanazawa Univ, Grad Sch Med Sci, Dept Orthopaed Surg, 13-1 Takara Machi, Kanazawa, Ishikawa 9208641, Japan.	y.takata.14@gmail.com					Beighton P, 1998, AM J MED GENET, V77, P31, DOI 10.1002/(SICI)1096-8628(19980428)77:1<31::AID-AJMG8>3.0.CO;2-O; PEIRO A, 1975, ACTA ORTHOP SCAND, V46, P700; SIWEK CW, 1981, J BONE JOINT SURG AM, V63, P932; Tashiro T, 2003, AM J SPORT MED, V31, P522, DOI 10.1177/31.4.522; Nielsen RH, 2014, FASEB J, V28, P4668, DOI 10.1096/fj.14-249656; Bedi A, 2010, ROCKWOOD GREENS FRAC, V7th, P1772; Chen CH, 1999, ORTHOPEDICS, V22, P1177; Clark SC, 1995, J ACCID EMERG MED, V12, P300; Greis PE, 2005, ORTHOPEDICS, V28, P765; Iacono V, 2010, KNEE SURG SPORT TR A, V18, P1116, DOI 10.1007/s00167-009-1022-7; Lu Michael, 2012, J Emerg Med, V43, pe35, DOI 10.1016/j.jemermed.2009.08.054; Maffulli Nicola, 2013, J Bone Joint Surg Am, V95, pe1231, DOI 10.2106/JBJS.L.01462; Malfait F, 2011, GENEREVIEWS; Matziolis G, 2003, UNFALLCHIRURG, V106, P1051, DOI 10.1007/s00113-003-0651-4; Mihalko WM, 2010, CLIN BIOMECH, V25, P348, DOI 10.1016/j.clinbiomech.2010.01.003; Moretti Biagio, 2008, Chir Organi Mov, V91, P51, DOI 10.1007/s12306-007-0009-0; MORGAN J, 1974, ARTHRITIS RHEUM, V17, P1033, DOI 10.1002/art.1780170616; Stinner DJ, 2010, MIL MED, V175, P457; Sullivan R L, 1986, Wis Med J, V85, P12; Van der Bracht H, 2009, ACTA ORTHOP BELG, V75, P417; VANGLABBEEK F, 1992, J TRAUMA, V33, P790	21	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0936-8051	1434-3916		ARCH ORTHOP TRAUM SU	Arch. Orthop. Trauma Surg.	MAY	2015	135	5					639	644		10.1007/s00402-015-2179-9		6	Orthopedics; Surgery	Orthopedics; Surgery	CG4XG	WOS:000353291800008		
J	Ito, J; Takakubo, Y; Sasaki, K; Sasaki, J; Owashi, K; Takagi, M				Ito, Juji; Takakubo, Yuya; Sasaki, Kan; Sasaki, Junya; Owashi, Kazuya; Takagi, Michiaki			Prevention of excessive postoperative sliding of the short femoral nail in femoral trochanteric fractures	ARCHIVES OF ORTHOPAEDIC AND TRAUMA SURGERY			English	Article						Trochanteric fracture; Intramedullary nail; Sliding; Cut-out	HIP-FRACTURES; FIXATION; FAILURE; REDUCTION	Lag screw cut-out is one of the major postoperative complications on femoral trochanteric fractures. However, precise analyses of excessive sliding and lag screw cut-out were limited. The purpose of this study was to investigate the factors that induce this unfavorable event. From April 2010 to April 2013, 226 patients were operated in our institute using a short femoral nail. Among them, 177 patients (29 males and 148 females) with a mean age of 84 years (60-97 years), who were followed up > 3 months, were included in this study. The postoperative sliding distance, fracture type (AO/OTA classification), tip-apex distance (TAD), reduction pattern in the postoperative X-ray (antero-posterior and lateral views), bone quality (canal flare and cortical indices), walking ability at the time of pre-injury and final follow-up, and complications were investigated retrospectively. The mean sliding distance was 3.7 mm, and one cut-out case (0.6 %) was observed. The sliding distance of the AO/OTA 31-A2 fractures was significantly longer than that of the A1 fractures (p < 0.0001). Regarding the reduction pattern, the sliding distance of the intramedullary type was longer than that of the extramedullary and anatomical types in the lateral view (p < 0.01, p < 0.001, respectively). Further, even in the medial and anatomical types, where the reduction patterns are recommended in the antero-posterior view, the sliding distance of the intramedullary type was significantly longer than that of the anatomical type in the lateral view. There was no correlation of bone quality with the sliding distance. Because the sliding distance increased in the intramedullary type in the lateral view of unstable fractures, an accurate reduction in the lateral view at surgery is important, particularly in unstable fractures.	[Ito, Juji; Sasaki, Junya; Owashi, Kazuya] Nihonkai Gen Hosp, Dept Orthopaed Surg, Sakata, Yamagata 9988501, Japan; [Ito, Juji; Takakubo, Yuya; Sasaki, Kan; Takagi, Michiaki] Yamagata Univ, Fac Med, Dept Orthopaed Surg, Yamagata 9909585, Japan	Ito, J (reprint author), Nihonkai Gen Hosp, Dept Orthopaed Surg, 30 Akihocho, Sakata, Yamagata 9988501, Japan.	indigo.cross@gmail.com					BAUMGAERTNER MR, 1995, J BONE JOINT SURG AM, V77A, P1058; DAVIS TRC, 1990, J BONE JOINT SURG BR, V72, P26; Marsh JL, 2007, J ORTHOP TRAUMA, V21, pS1; SALVATI EA, 1973, J BONE JOINT SURG AM, VA 55, P516; Norris R, 2012, INJURY, V43, P706, DOI 10.1016/j.injury.2011.10.027; Carr JB, 2007, J ORTHOP TRAUMA, V21, P485, DOI 10.1097/BOT.0b013e31804797cf; Buciuto R, 2001, J TRAUMA, V50, P545, DOI 10.1097/00005373-200103000-00022; Choo SK, 2010, J KOREAN HIP SOC, V22, P79; EBBINGHAUS S, 1991, UPSALA J MED SCI, V96, P235; Gruen T, 1997, Acta Orthop Belg, V63 Suppl 1, P20; Japanese Orthopaedic Association (JOA), 2011, CLIN PRACT GUID DIAG, V2nd, P26; LARSSON S, 1990, CLIN ORTHOP RELAT R, P130; NOBLE PC, 1988, CLIN ORTHOP RELAT R, P148; Orimo H, 2009, ARCH OSTEOPOROS, V4, P71; Parker MJ, 1996, ACTA ORTHOP SCAND, V67, P329; Tsukada S, 2012, ARCH ORTHOP TRAUM SU, V132, P839, DOI 10.1007/s00402-012-1484-9; Williams WW, 1992, INJURY, V23, P91	17	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0936-8051	1434-3916		ARCH ORTHOP TRAUM SU	Arch. Orthop. Trauma Surg.	MAY	2015	135	5					651	657		10.1007/s00402-015-2200-3		7	Orthopedics; Surgery	Orthopedics; Surgery	CG4XG	WOS:000353291800010		
J	Pedrosa, AR; Trindade, A; Fernandes, AC; Carvalho, C; Gigante, J; Tavares, AT; Dieguez-Hurtado, R; Yagita, H; Adams, RH; Duarte, A				Pedrosa, Ana-Rita; Trindade, Alexandre; Fernandes, Ana-Carina; Carvalho, Catarina; Gigante, Joana; Tavares, Ana Teresa; Dieguez-Hurtado, Rodrigo; Yagita, Hideo; Adams, Ralf H.; Duarte, Antonio			Endothelial Jagged1 Antagonizes Dll4 Regulation of Endothelial Branching and Promotes Vascular Maturation Downstream of Dll4/Notch1	ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY			English	Article						angiogenesis modulators; Jagged1 protein; Notch proteins; wound healing	SMOOTH-MUSCLE DIFFERENTIATION; NOTCH LIGAND JAGGED1; EXPRESSION; ANGIOGENESIS; CELLS; RECEPTOR; PATHWAY; MICE	Objective-Notch signaling controls cardiovascular development and has been associated with several pathological conditions. Among its ligands, Jagged1 and Dll4 were shown to have opposing effects in developmental angiogenesis, but the underlying mechanism and the role of Jagged1/Notch signaling in adult angiogenesis remain incompletely understood. The current study addresses the importance of endothelial Jagged1-mediated Notch signaling in the context of adult physiological angiogenesis and the interactions of Jagged1 and Dll4 on angiogenic response and vascular maturation processes. Approach and Results-The role of endothelial Jagged1 in wound healing kinetics and angiogenesis was investigated with endothelial-specific Jag1 gain-of-function and loss-of-function mouse mutants (eJag1OE and eJag1cKO). To study the interactions between the 2 Notch ligands, genetic mouse models were combined with pharmacological inhibition of Dll4 or Jagged1, respectively. Jagged1 overexpression in endothelial cells increased vessel density, maturation, and perfusion, thus accelerating wound healing. The opposite effect was seen in eJag1cKO animals. Interestingly, Dll4 blockade in these animals led to an increase in vascular density but induced a greater decrease in perivascular cell coverage. However, Jagged1 inhibition in Dll4 gain-of-function (eDll4OE) mutants, with reduced angiogenesis, further diminished angiogenic growth and hampered perivascular cell coverage. Our findings suggest that as Dll4 blocks endothelial activation through Notch1 signaling, it also induces Jagged1 expression. Jagged1 then blocks Dll4 signaling through Notch1, allowing endothelial activation by vascular endothelial growth factor and endothelial layer growth. Jagged1 also initiates maturation of the newly formed vessels, possibly by binding and activating endothelial Notch4. Importantly, mice administered with a Notch4 agonistic antibody mimicked the mural cell phenotype of eJag1OE mutants without affecting angiogenic growth, which is thought to be Notch1 dependent. Conclusions-Endothelial Jagged1 is likely to operate downstream of Dll4/Notch1 signaling to activate Notch4 and regulate vascular maturation. Thus, Jagged1 not only counteracts Dll4/Notch in the endothelium but also generates a balance between angiogenic growth and maturation processes in vivo.	[Pedrosa, Ana-Rita; Trindade, Alexandre; Fernandes, Ana-Carina; Carvalho, Catarina; Gigante, Joana; Tavares, Ana Teresa; Duarte, Antonio] Univ Lisbon, CIISA, P-1699 Lisbon, Portugal; [Trindade, Alexandre; Tavares, Ana Teresa] Inst Gulbenkian Ciencias, Oeiras, Portugal; [Dieguez-Hurtado, Rodrigo; Adams, Ralf H.] Max Planck Inst Mol Biomed, Dept Tissue Morphogenesis, Dept Tissue Morphogenesis, D-48149 Munster, Germany; [Dieguez-Hurtado, Rodrigo; Adams, Ralf H.] Univ Munster, Fac Med, D-48149 Munster, Germany; [Yagita, Hideo] Juntendo Univ, Sch Med, Dept Immunol, Tokyo 113, Japan	Duarte, A (reprint author), Fac Med Vet, Av Univ Tecn, P-1300477 Lisbon, Portugal.	adtrindade@fmv.ulisboa.pt; aduarte@fmv.ulisboa.pt	Trindade, Alexandre/J-3606-2013; Tavares, Ana Teresa/I-3086-2013; 	Trindade, Alexandre/0000-0002-3104-9259; Tavares, Ana Teresa/0000-0002-3495-5513; Duarte, Antonio/0000-0002-9255-3635	Portuguese Foundation for Science and Technology [PTDC\/SAU-ONC/116164/2009, PTDC/SAU-OSM/102468/2008, PTDC/CVT/115703/2009]; European Union [317250]; CIISA - FCT [PEst-OE/AGR/U10276/2014];  [SFRH /BD/44964 /2008]	This study was supported by the Portuguese Foundation for Science and Technology (grants PTDC vertical bar/SAU-ONC/116164/2009, PTDC/SAU-OSM/102468/2008, PTDC/CVT/115703/2009 and by the individual PhD grant SFRH /BD/44964 /2008). R. Dieguez-Hurtado has received funding from the People Programme (Marie Curie Actions) of the European Union's Seventh Framework Programme FP7/2007 to 2013/under REA grant agreement no. 317250. CIISA has provided support (Project PEst-OE/AGR/U10276/2014, funded by FCT).	Shutter JR, 2000, GENE DEV, V14, P1313; SWIATEK PJ, 1994, GENE DEV, V8, P707, DOI 10.1101/gad.8.6.707; Eming SA, 2007, PROG HISTOCHEM CYTO, V42, P115, DOI 10.1016/j.proghi.2007.06.001; Li L, 1996, CIRC RES, V78, P188; Schweisguth F, 2004, CURR BIOL, V14, pR129, DOI [10.1016/j.cub.2004.01.023, 10.1016/S0960-9822(04)00038-7]; Claxton S, 2004, GENE EXPR PATTERNS, V5, P123, DOI 10.1016/j.modgep.2004.05.004; High FA, 2008, P NATL ACAD SCI USA, V105, P1955, DOI 10.1073/pnas.0709663105; Thomas M, 2009, ANGIOGENESIS, V12, P125, DOI 10.1007/s10456-009-9147-3; Jin S, 2008, CIRC RES, V102, P1483, DOI 10.1161/CIRCRESAHA.107.167965; Manderfield LJ, 2012, CIRCULATION, V125, P314, DOI 10.1161/CIRCULATIONAHA.111.047159; Doi H, 2006, J BIOL CHEM, V281, P28555, DOI 10.1074/jbc.M602749200; Xue YZ, 1999, HUM MOL GENET, V8, P723, DOI 10.1093/hmg/8.5.723; Benedito R, 2009, CELL, V137, P1124, DOI 10.1016/j.cell.2009.03.025; Duarte A, 2004, GENE DEV, V18, P2474, DOI 10.1101/gad.1239004; Liu H, 2009, CIRC RES, V104, P466, DOI 10.1161/CIRCRESAHA.108.184846; Trindade A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029863; Carmeliet P, 2003, NAT MED, V9, P653, DOI 10.1038/nm0603-653; High FA, 2007, J CLIN INVEST, V117, P353, DOI 10.1172/JCI30070; Villa N, 2001, MECH DEVELOP, V108, P161, DOI 10.1016/S0925-4773(01)00469-5; Benedito R, 2008, BMC DEV BIOL, V8, DOI 10.1186/1471-213X-8-117; Emuss V, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000616; Uyttendaele H, 2000, MICROVASC RES, V60, P91, DOI 10.1006/mvre.2000.2254; Winkler EA, 2010, MOL NEURODEGENER, V5, DOI 10.1186/1750-1326-5-32; Yoon CH, 2014, J MOL CELL CARDIOL, V69, P52, DOI 10.1016/j.yjmcc.2013.12.006	24	3	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1079-5642	1524-4636		ARTERIOSCL THROM VAS	Arterioscler. Thromb. Vasc. Biol.	MAY	2015	35	5					1134	1146		10.1161/ATVBAHA.114.304741		13	Hematology; Peripheral Vascular Disease	Hematology; Cardiovascular System & Cardiology	CG5MF	WOS:000353335300012		
J	Noda, T; Maeda, K; Hayano, S; Asai, N; Enomoto, A; Takahashi, M; Murohara, T				Noda, Tomonori; Maeda, Kengo; Hayano, Shinji; Asai, Naoya; Enomoto, Atsushi; Takahashi, Masahide; Murohara, Toyoaki			New Endoplasmic Reticulum Stress Regulator, Gipie, Regulates the Survival of Vascular Smooth Muscle Cells and the Neointima Formation After Vascular Injury	ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY			English	Article						atherosclerosis; endoplasmic reticulum stress; neointima; vascular smooth muscle cell	UNFOLDED PROTEIN RESPONSE; RAT CAROTID-ARTERY; ACCELERATES REENDOTHELIALIZATION; MOLECULAR CHAPERONES; PROCOLLAGEN; RESTENOSIS; DISEASES; GIRDIN; GROWTH; HSP47	Objective-The accumulation of unfolded protein in the endoplasmic reticulum (ER) initiates an adaptive stress response, termed the unfolded protein response. Previous studies suggested that ER stress might be involved in the formation of neointima after vascular injury. We recently discovered a novel regulator of ER stress, 78-kDa glucose-regulated protein-interacting protein induced by ER stress (Gipie). The objective of this study was to elucidate the role of Gipie using models of vascular disease. Approach and Results-We investigated the functions of Gipie in cultured vascular smooth muscle cells (VSMCs) and in a vascular injury model of a rat carotid artery. The expression of Gipie was predominantly detected in synthetic VSMCs and to a much lesser extent in contractile VSMCs, which was augmented by treatment with thapsigargin. Gipie knockdown increased the phosphorylation levels of c-Jun N-terminal kinase and the number of apoptotic cells under ER stress. Moreover, Gipie knockdown decreased the mature form of collagen I in synthetic VSMCs. The expression of Gipie was rarely detected in the medial VSMCs of the intact carotid artery, whereas it was detected in most of the neointimal cells and some of the medial VSMCs after balloon injury. Depletion of Gipie in the rat carotid artery attenuated the neointimal thickening, which was accompanied by increased cell death in the neointima. Conversely, overexpression of Gipie augmented the neointimal thickening. Conclusions-Gipie participates in the ER stress response in VSMCs and plays an important role in neointima formation after vascular injury.	[Noda, Tomonori; Maeda, Kengo; Hayano, Shinji; Murohara, Toyoaki] Nagoya Univ, Grad Sch Med, Dept Cardiol, Nagoya, Aichi 4668550, Japan; [Asai, Naoya; Enomoto, Atsushi; Takahashi, Masahide] Nagoya Univ, Grad Sch Med, Dept Pathol, Nagoya, Aichi 4668550, Japan	Maeda, K (reprint author), Nagoya Univ, Grad Sch Med, Dept Cardiol, Showa Ku, 65 Tsurumai Cho, Nagoya, Aichi 4668550, Japan.	maedaken@med.nagoya-u.ac.jp	Murohara, Toyoaki/M-4958-2014		Ministry of Education, Culture, Sports, Science, and Technology of Japan	This work was supported by a Grant-in-Aid for Scientific Research (C) from the Ministry of Education, Culture, Sports, Science, and Technology of Japan (to K. Maeda).	Alfonso F, 2014, J AM COLL CARDIOL, V63, P2659, DOI 10.1016/j.jacc.2014.02.545; Iwakoshi NN, 2003, NAT IMMUNOL, V4, P321, DOI 10.1038/ni907; Tabas I, 2010, CIRC RES, V107, P839, DOI 10.1161/CIRCRESAHA.110.224766; BOCHATONPIALLAT ML, 1995, AM J PATHOL, V146, P1059; Viana RJS, 2012, MOL NEUROBIOL, V46, P522, DOI 10.1007/s12035-012-8301-x; Ron D, 2007, NAT REV MOL CELL BIO, V8, P519, DOI 10.1038/nrm2199; Enomoto A, 2005, DEV CELL, V9, P389, DOI 10.1016/j.devcel.2005.08.001; Rutkowski DT, 2010, J CELL BIOL, V189, P783, DOI 10.1083/jcb.201003138; Levi F, 2002, HEART, V88, P119, DOI 10.1136/heart.88.2.119; Ogata M, 2006, MOL CELL BIOL, V26, P9220, DOI 10.1128/MCB.01453-06; Mauri L, 2008, CIRCULATION, V118, P1817, DOI 10.1161/CIRCULATIONAHA.108.781377; Kim I, 2008, NAT REV DRUG DISCOV, V7, P1013, DOI 10.1038/nrd2755; Lamande SR, 1999, SEMIN CELL DEV BIOL, V10, P455, DOI 10.1006/scdb.1999.0317; Back SH, 2009, CELL METAB, V10, P13, DOI 10.1016/j.cmet.2009.06.002; CLOWES AW, 1985, CIRC RES, V56, P139; Kimata Y, 2007, J CELL BIOL, V179, P75, DOI 10.1083/jcb.200704166; Lee J, 2014, J BIOL CHEM, V289, P1203, DOI 10.1074/jbc.R113.534743; Numaguchi Y, 1999, ARTERIOSCL THROM VAS, V19, P727; CLOWES AW, 1983, LAB INVEST, V49, P327; Satoh M, 1996, J CELL BIOL, V133, P469, DOI 10.1083/jcb.133.2.469; Walter P, 2011, SCIENCE, V334, P1081, DOI 10.1126/science.1209038; ASAHARA T, 1995, CIRCULATION, V91, P2793; Miyake H, 2011, CIRC RES, V108, P1170, DOI 10.1161/CIRCRESAHA.110.236174; FERREIRA LR, 1994, J CELL BIOCHEM, V56, P518, DOI 10.1002/jcb.240560412; GIMONA M, 1990, FEBS LETT, V274, P159, DOI 10.1016/0014-5793(90)81353-P; Matsushita E, 2011, MOL BIOL CELL, V22, P736, DOI 10.1091/mbc.E10-08-0724; Weng L, 2014, EMBO J, V33, P2098, DOI 10.15252/embj.201488289; WILCOX JN, 1993, AM J CARDIOL, V72, pE88, DOI 10.1016/0002-9149(93)91043-H	28	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1079-5642	1524-4636		ARTERIOSCL THROM VAS	Arterioscler. Thromb. Vasc. Biol.	MAY	2015	35	5					1246	1253		10.1161/ATVBAHA.114.304923		8	Hematology; Peripheral Vascular Disease	Hematology; Cardiovascular System & Cardiology	CG5MF	WOS:000353335300023		
J	Nojiri, S; Odintsov, SD				Nojiri, Shin'ichi; Odintsov, Sergei D.			Inflation without self-reproduction in F(R) gravity	ASTROPHYSICS AND SPACE SCIENCE			English	Article						Inflation; Modified gravity; Multiverse	PROBE WMAP OBSERVATIONS; OBSERVATIONS COSMOLOGICAL INTERPRETATION; CONSISTENT; RECONSTRUCTION; MODELS	We investigate inflation in frames of two classes of F(R) gravity and check its consistency with Planck data. It is shown that F(R) inflation without self-reproduction may be constructed in close analogy with the corresponding scalar example proposed by Mukhanov for the resolution of the problems of multiverse, predictability and initial conditions.	[Nojiri, Shin'ichi] Nagoya Univ, Kobayashi Maskawa Inst Origin Particles & Univers, Nagoya, Aichi 4648602, Japan; [Nojiri, Shin'ichi] Nagoya Univ, Dept Phys, Nagoya, Aichi 4648602, Japan; [Odintsov, Sergei D.] CSIC, ICE CSIC IEEC, Fac Ciencies, Bellaterra 08193, Barcelona, Spain; [Odintsov, Sergei D.] ICREA, Barcelona, Spain; [Odintsov, Sergei D.] Natl Res Tomsk State Univ, Tomsk 634050, Russia; [Odintsov, Sergei D.] Tomsk State Pedag Univ, Tomsk 634061, Russia	Nojiri, S (reprint author), Nagoya Univ, Kobayashi Maskawa Inst Origin Particles & Univers, Nagoya, Aichi 4648602, Japan.	nojiri@phys.nagoya-u.ac.jp			JSPS [22224003, 23540296]; MINECO (Spain) [FIS2010-15640, FIS2013-44881]	We are grateful to A. Linde and V. Mukhanov for very useful discussion. The work is supported by the JSPS Grant-in-Aid for Scientific Research (S) # 22224003 and (C) # 23540296 (S.N.) and in part by MINECO (Spain), projects FIS2010-15640 and FIS2013-44881 (S.D.O.).	Nojiri S, 2007, PHYS LETT B, V657, P238, DOI 10.1016/j.physletb.2007.10.027; Komatsu E, 2009, ASTROPHYS J SUPPL S, V180, P330, DOI 10.1088/0067-0049/180/2/330; Nojiri S, 2007, INT J GEOM METHODS M, V4, P115, DOI 10.1142/S0219887807001928; Nojiri S, 2008, PHYS REV D, V77, DOI 10.1103/PhysRevD.77.026007; Cognola G, 2008, PHYS REV D, V77, DOI 10.1103/PhysRevD.77.046009; Bamba K, 2014, PHYS LETT B, V737, P374, DOI 10.1016/j.physletb.2014.09.014; Spergel DN, 2007, ASTROPHYS J SUPPL S, V170, P377, DOI 10.1086/513700; Capozziello S, 2011, PHYS REP, V509, P167, DOI 10.1016/j.physrep.2011.09.003; Hu W, 2007, PHYS REV D, V76, DOI 10.1103/PhysRevD.76.064004; Nojiri S, 2006, PHYS REV D, V74, DOI 10.1103/PhysRevD.74.046004; Appleby SA, 2007, PHYS LETT B, V654, P7, DOI 10.1016/j.physletb.2007.08.037; Nojiri S, 2011, PHYS REP, V505, P59, DOI 10.1016/j.physrep.2011.04.001; Nojiri S, 2009, PHYS LETT B, V681, P74, DOI 10.1016/j.physletb.2009.09.045; Capozziello S., 2014, ARXIV14112822GRQC; Capozziello S, 2011, FUND THEOR PHYS, V170, P1, DOI 10.1007/978-94-007-0165-6_1; Faraoni V., 2004, COSMOLOGY SCALAR TEN; Fujii Y., 2003, SCALAR TENSOR THEORY; Gorbunov D. S., 2011, INTRO THEORY EARLY U; Hinshaw G, 2013, ASTROPHYS J SUPPL S, V208, DOI 10.1088/0067-0049/208/2/19; Komatsu E, 2011, ASTROPHYS J SUPPL S, V192, DOI 10.1088/0067-0049/192/2/18; Linde A., 2014, ARXIV14020526HEPTH; Mukhanov V, 2013, EUR PHYS J C, V73, DOI 10.1140/epjc/s10052-013-2486-7; Mukhanov V., 2005, PHYS FDN COSMOLOGY; Nojiri S, 2003, PHYS REV D, V68, DOI 10.1103/PhysRevD.68.123512; Spergel DN, 2003, ASTROPHYS J SUPPL S, V148, P175, DOI 10.1086/377226	25	2	2	SPRINGER	DORDRECHT	VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS	0004-640X	1572-946X		ASTROPHYS SPACE SCI	Astrophys. Space Sci.	MAY	2015	357	1							39	10.1007/s10509-015-2288-5		5	Astronomy & Astrophysics	Astronomy & Astrophysics	CF8ZI	WOS:000352850400039		
J	Ando, K; Kondo, F; Yamaguchi, N; Tachi, M; Fukayama, M; Yoshikawa, K; Gosho, M; Fujiwara, Y; Okada, S				Ando, Kazuo; Kondo, Fumio; Yamaguchi, Naoko; Tachi, Masahiko; Fukayama, Minoru; Yoshikawa, Kazuhiro; Gosho, Masahiko; Fujiwara, Yoshihiro; Okada, Shoshiro			Centrally administered isoproterenol induces sympathetic outflow via brain prostaglandin E-2-mediated mechanisms in rats	AUTONOMIC NEUROSCIENCE-BASIC & CLINICAL			English	Article						beta-Adrenoceptor; Prostaglandin E-2; Plasma noradrenaline; Hypothalamic paraventricular nucleus	CENTRAL-NERVOUS-SYSTEM; HYPOTHALAMIC PARAVENTRICULAR NUCLEUS; CORTICOTROPIN-RELEASING-FACTOR; BETA-ADRENERGIC-RECEPTORS; ADRENOMEDULLARY OUTFLOW; THROMBOXANE A(2); BLOOD-PRESSURE; NORADRENERGIC CONTROL; CONSCIOUS RATS; ACTIVATION	Brain beta-adrenoceptor stimulation can induce elevations of plasma levels of noradrenaline. However, there have been no detailed studies related to signaling pathways downstream of beta-adrenoceptors responsible for central sympathetic outflow. In the present study, we pharmacologically examined the possibility that centrally administered isoproterenol can induce elevations of plasma noradrenaline levels in a brain prostaglandin-dependent manner. In addition, we also examined whether or not intracerebroventricular administration of isoproterenol could release endogenously synthesized prostaglandin (PG) E-2 in the hypothalamic paraventricular nucleus (PVN) by using the brain microdialysis technique combined with liquid chromatography-ion trap tandem mass spectrometry (LC-ITMSn). Under urethane anesthesia, a femoral venous line was inserted for infusion of saline and a femoral arterial line was inserted for collecting blood samples. Next, animals were placed in a stereotaxic apparatus for application of test agents. Catecholamines in the plasma were extracted by alumina absorption and were assayed by high-performance liquid chromatography with electrochemical detection. Quantification of PGE(2) in rat PVN microdialysates was performed by the LC-ITMSn method. We demonstrated that centrally administered isoproterenol-induced elevations of plasma noradrenaline could be mediated via activation of beta-adrenoceptors and the downstream phospholipase A(2)-cyclooxygenase pathway. Furthermore, PGE(2) in the PVN and the PGE(2) receptor EP3 subtype appear to play an important role in the process. Our results suggest that central isoproterenol-induced sympathetic outflow is mediated via brain PGE(2) in a PGE(2) receptor EP3 subtype-dependent manner. (C) 2014 Elsevier B.V. All rights reserved.	[Ando, Kazuo; Fujiwara, Yoshihiro] Aichi Med Univ, Sch Med, Dept Anesthesiol, Nagakute, Aichi 4801195, Japan; [Kondo, Fumio; Yamaguchi, Naoko; Tachi, Masahiko; Okada, Shoshiro] Aichi Med Univ, Sch Med, Dept Pharmacol, Nagakute, Aichi 4801195, Japan; [Fukayama, Minoru; Yoshikawa, Kazuhiro; Gosho, Masahiko] Aichi Med Univ, Adv Med Res Ctr, Nagakute, Aichi 4801195, Japan	Okada, S (reprint author), Aichi Med Univ, Sch Med, Dept Pharmacol, 1-1 Yazakokarimata, Nagakute, Aichi 4801195, Japan.	okadas@aichi-med-u.ac.jp			Ministry of Education, Culture, Sports, Science, and Technology, Japan [24590903, S1101027]	This work was supported in part by a Grant-in-Aid for Scientific Research (no. 24590903 to S.O.) and by a Strategic Research Foundation Grant-aided Project for Private Universities grant (S1101027) from the Ministry of Education, Culture, Sports, Science, and Technology, Japan.	Vane JR, 1998, ANNU REV PHARMACOL, V38, P97, DOI 10.1146/annurev.pharmtox.38.1.97; Okada S, 2002, BRAIN RES, V939, P26, DOI 10.1016/S0006-8993(02)02540-4; KOEPKE JP, 1985, HYPERTENSION, V7, P350; Furuyashiki T, 2011, NAT REV ENDOCRINOL, V7, P163, DOI 10.1038/nrendo.2010.194; Burke JE, 2009, CARDIOVASC DRUG THER, V23, P49, DOI 10.1007/s10557-008-6132-9; IRVINE RF, 1982, BIOCHEM J, V204, P3; Borda ES, 1998, PROSTAG LEUKOTR ESS, V58, P85, DOI 10.1016/S0952-3278(98)90145-4; Docherty JR, 1998, EUR J PHARMACOL, V361, P1, DOI 10.1016/S0014-2999(98)00682-7; Elenkov IJ, 2000, PHARMACOL REV, V52, P595; AXELROD J, 1990, BIOCHEM SOC T, V18, P503; BHARGAVA KP, 1972, BRIT J PHARMACOL, V45, P596; BROWN MR, 1982, ENDOCRINOLOGY, V111, P928; DAY MD, 1973, NATURE-NEW BIOL, V242, P30; ESLER MD, 1995, CLIN EXP HYPERTENS, V17, P409, DOI 10.3109/10641969509087081; GAGNON D. J., 1967, INT J NEUROPHARMACOL, V6, P245; ISAAC L, 1980, J CARDIOVASC PHARM, V2, pS5, DOI 10.1097/00005344-198000021-00002; KORTE SM, 1993, HORM BEHAV, V27, P167, DOI 10.1006/hbeh.1993.1013; LEVINE L, 1979, P NATL ACAD SCI USA, V76, P6632, DOI 10.1073/pnas.76.12.6632; Murakami Y, 2002, EUR J PHARMACOL, V452, P289, DOI 10.1016/S0014-2999(02)02308-7; Okada S, 2002, EUR J PHARMACOL, V457, P29, DOI 10.1016/S0014-2999(02)02652-3; Okada S, 2003, EUR J PHARMACOL, V467, P125, DOI 10.1016/S0014-2999(03)01629-7; Okada S, 2000, NEUROSCIENCE, V96, P585, DOI 10.1016/S0306-4522(99)00598-9; Okada S, 2010, EUR J PHARMACOL, V640, P55, DOI 10.1016/j.ejphar.2010.04.038; Paxinos G., 1997, RAT BRAIN STEREOTAXI; Rauls RA, 2005, BRAIN RES, V1048, P98, DOI 10.1016/j.brainres.2005.04.057; SCRIABINE A, 1976, ANNU REV PHARMACOL, V16, P113, DOI 10.1146/annurev.pa.16.040176.000553; STRUTHERS AD, 1985, EUR J CLIN PHARMACOL, V28, P3, DOI 10.1007/BF00543703; Tachi M, 2014, AUTON NEUROSCI-BASIC, V181, P49, DOI 10.1016/j.autneu.2013.12.013; Tan Y, 2003, BRAIN RES, V968, P122, DOI 10.1016/S0006-8993(03)02226-1; WEIS MT, 1985, J PHARMACOL EXP THER, V235, P178; Yalcin M, 2006, NEUROPEPTIDES, V40, P207, DOI 10.1016/j.npep.2006.01.003; Yamaguchi K, 2013, NEUROSCI RES, V76, P213, DOI 10.1016/j.neures.2013.05.005; YOKOTANI K, 1995, BRIT J PHARMACOL, V115, P672; Yokotani K, 2000, EUR J PHARMACOL, V398, P341, DOI 10.1016/S0014-2999(00)00276-4; Yorimitsu M, 2008, LIFE SCI, V82, P487, DOI 10.1016/j.lfs.2007.12.006; Zhang ZH, 2011, AM J PHYSIOL-HEART C, V301, pH1559, DOI 10.1152/ajpheart.00262.2011	36	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	1566-0702	1872-7484		AUTON NEUROSCI-BASIC	Auton. Neurosci-Basic Clin.	MAY	2015	189						1	7		10.1016/j.autneu.2014.12.002		7	Neurosciences	Neurosciences & Neurology	CG6QP	WOS:000353427400001		
J	Matsukawa, K; Ishii, K; Ishida, T; Nagai, A; Liang, N				Matsukawa, Kanji; Ishii, Kei; Ishida, Tomoko; Nagai, Atsushi; Liang, Nan			Stimulation of the mesencephalic ventral tegmental area blunts the sensitivity of cardiac baroreflex in decerebrate cats	AUTONOMIC NEUROSCIENCE-BASIC & CLINICAL			English	Article						Cardiac baroreflex sensitivity; Ventral tegmental area; Substantia nigra; Central command; Exercise	SPONTANEOUS MOTOR-ACTIVITY; CAROTID-SINUS BARORECEPTORS; NUCLEUS-TRACTUS-SOLITARIUS; VOLUNTARY STATIC EXERCISE; CENTRAL COMMAND BLUNTS; HEART RATE REFLEX; SUBSTANTIA-NIGRA; HORSERADISH-PEROXIDASE; OVERGROUND LOCOMOTION; PERIAQUEDUCTAL GRAY	We have examined for the first time whether electrical stimulation of the mesencephalic ventral tegmental area (VTA) or the substantia nigra (SN) was capable of suppressing cardiac baroreflex sensitivity in decerebrate cats. After decerebration was performed by electrocoagulation at the precollicular-premammillary level and inhalation anesthesia was stopped, the animals were able to show spontaneous motor activity intermittently. Electrical stimulations of the mesencephalic areas (the VTA and SN) for 30s were conducted with a monopolar tungsten microelectrode (current intensity of pulse trains, 50-100 mu A; frequency, 40-50 Hz; pulse duration, 0.5-1.0 ms), without producing tibial motor discharge. Stimulation of the VTA evoked the significant increases in heart rate (HR, 12 +/- 2 beats/min) and mean arterial blood pressure (MAP, 12 +/- 3 mm Hg). When the baroreflex bradycardia and the slope of the cardiac baroreflex curve were examined using a pressor response with brief occlusion of the abdominal aorta, the VTA stimulation blunted both the baroreflex bradycardia and the maximal slope of the baroreflex MAP-HR curve by 63-74% in the same manner as spontaneously-evoked motor activity. In contrast, stimulation of the SN elicited no modulation of cardiac baroreflex. It is likely that stimulation of the mesencephalic VIA suppresses cardiac baroreflex sensitivity and has the similar features of the effects on the cardiac baroreflex function as those during spontaneously-evoked motor activity. (C) 2014 Elsevier B.V. All rights reserved.	[Matsukawa, Kanji; Ishii, Kei; Ishida, Tomoko; Nagai, Atsushi; Liang, Nan] Hiroshima Univ, Grad Sch Biomed & Hlth Sci, Dept Integrat Physiol, Minami Ku, Hiroshima 7348551, Japan	Matsukawa, K (reprint author), Hiroshima Univ, Grad Sch Biomed & Hlth Sci, Dept Integrat Physiol, Minami Ku, Kasumi 1-2-3, Hiroshima 7348551, Japan.	matsuk@hiroshima-u.ac.jp			Japan Society for the Promotion of Science [90165788, 25560262]	This study was supported by Grants-in-Aid for Scientific Research (B) (90165788) and for Exploratory Research from the Japan Society for the Promotion of Science (25560262).	OADES RD, 1987, BRAIN RES REV, V12, P117, DOI 10.1016/0165-0173(87)90011-7; Kirouac GJ, 1997, AM J PHYSIOL-HEART C, V273, pH2549; Nakamoto T, 2011, J APPL PHYSIOL, V110, P1342, DOI 10.1152/japplphysiol.01233.2010; GOODWIN GM, 1972, J PHYSIOL-LONDON, V226, P173; Cornish JL, 1997, NEUROSCIENCE, V81, P69, DOI 10.1016/S0306-4522(97)00157-7; Kirouac GJ, 2004, J COMP NEUROL, V469, P170, DOI 10.1002/cne.11005; VANDOMBURG PHMF, 1991, ADV ANAT EMBRYOL CEL, V121, P1; BECKSTEAD RM, 1979, BRAIN RES, V175, P191, DOI 10.1016/0006-8993(79)91001-1; GUSTAFSSON B, 1976, J PHYSIOL-LONDON, V258, P33; RANCK JB, 1975, BRAIN RES, V98, P417, DOI 10.1016/0006-8993(75)90364-9; Haber SN, 1997, CRIT REV NEUROBIOL, V11, P323; ELDRIDGE FL, 1981, SCIENCE, V211, P844, DOI 10.1126/science.7466362; BARONE FC, 1981, BRAIN RES BULL, V7, P75, DOI 10.1016/0361-9230(81)90101-5; Berman AL, 1968, BRAIN STEM CAT CYTOA; Bristow J.D., 1969, J PHYSL, V202, p84P; Deschamps K, 2005, BRIT J PHARMACOL, V145, P712, DOI 10.1038/sj.bjp.0706249; GANDEVIA SC, 1993, J PHYSIOL-LONDON, V470, P85; Gracia-Rill E., 1986, BRAIN RES, V396, P47; HILTON SM, 1963, J PHYSIOL-LONDON, V165, pP56; Komine H, 2003, AM J PHYSIOL-HEART C, V285, pH516, DOI 10.1152/ajpheart.00013.2003; Matsukawa K, 2012, EXP PHYSIOL, V97, P20, DOI 10.1113/expphysiol.2011.057661; Matsukawa K, 2006, AM J PHYSIOL-HEART C, V290, pH200, DOI 10.1152/ajpheart.00013.2005; Matsukawa K, 2011, J PHYSIOL SCI, V61, P293, DOI 10.1007/s12576-011-0149-8; Matsukawa K, 2014, J PHYSIOL SCI, V64, P291, DOI 10.1007/s12576-014-0318-7; Matsukawa K, 2014, AM J PHYSIOL-REG I, V306, pR735, DOI 10.1152/ajpregu.00538.2013; Matsukawa K, 1998, AM J PHYSIOL-HEART C, V275, pH1115; Matsukawa K, 2013, AUTON NEUROSCI-BASIC, V179, P75, DOI 10.1016/j.autneu.2013.07.008; Matsukawa K, 2012, AM J PHYSIOL-HEART C, V303, pH464, DOI 10.1152/ajpheart.01133.2011; MIFFLIN SW, 1988, J PHYSIOL-LONDON, V399, P369; MITCHELL JH, 1990, MED SCI SPORT EXER, V22, P141; Mitchell JH, 2013, EXP PHYSIOL, V98, P867, DOI 10.1113/expphysiol.2012.071001; Murata J, 2004, J APPL PHYSIOL, V97, P1371, DOI 10.1152/japplphysiol.00307.2004; NOSAKA S, 1989, PFLUG ARCH EUR J PHY, V413, P656, DOI 10.1007/BF00581817; NOSAKA S, 1993, PFLUG ARCH EUR J PHY, V424, P266, DOI 10.1007/BF00384352; Sadamoto T, 1997, J APPL PHYSIOL, V83, P1454; Sevoz-Couche C, 2003, J NEUROPHYSIOL, V90, P2521, DOI 10.1152/jn.00275.2003; SIMON H, 1979, BRAIN RES, V178, P17, DOI 10.1016/0006-8993(79)90085-4; Snider R. S., 1961, STEREOTAXIC ATLAS CA; STAESSEN J, 1987, AM HEART J, V114, P765, DOI 10.1016/0002-8703(87)90787-3; TAN E, 1983, CLIN EXP PHARMACOL P, V10, P305, DOI 10.1111/j.1440-1681.1983.tb00202.x	40	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	1566-0702	1872-7484		AUTON NEUROSCI-BASIC	Auton. Neurosci-Basic Clin.	MAY	2015	189						16	24		10.1016/j.autneu.2014.12.005		9	Neurosciences	Neurosciences & Neurology	CG6QP	WOS:000353427400003		
J	Shiina, T; Naitou, K; Nakamori, H; Sakai, H; Shimizu, Y				Shiina, Takahiko; Naitou, Kiyotada; Nakamori, Hiroyuki; Sakai, Hiroki; Shimizu, Yasutake			Regulation of longitudinal esophageal motility in the house musk shrew (Suncus murinus)	AUTONOMIC NEUROSCIENCE-BASIC & CLINICAL			English	Article						Esophagus; Histamine; Mast cell; Prostaglandin; Serotonin	STRIATED-MUSCLE CONTRACTIONS; MAST-CELL ACTIVATION; GASTROINTESTINAL-TRACT; C FIBERS; EMESIS; NEURONS; NEUROCHEMISTRY; PHARMACOLOGY; TACHYKININS; RECEPTOR	Suncus murinus (house musk shrew; suncus) is a species of insectivore that has an ability to vomit. Although longitudinal movement of the esophagus would be related to the emetic response, regulatory mechanisms for the suncus esophageal motility are unclear. Therefore, the aim of the present study was to clarify components that regulate esophageal motility in the suncus. An isolated segment of the suncus esophagus was placed in an organ bath, and longitudinal mechanical responses were recorded using a force transducer. Electrical stimulation of the vagus trunk evoked a biphasic contractile response. The first phase of the contractile response was blocked by alpha-bungarotoxin, a blocker of nicotinic acetylcholine receptors on striated muscle cells, whereas the second one was blocked by atropine, a blocker of muscarinic acetylcholine receptors on smooth muscle cells. Next, we investigated whether mast cells are involved in motor functions of the suncus esophagus. Application of a mast cell stimulator, compound 48/80, elicited contractile responses, which was resistant to tetrodotoxin. Exogenous application of serotonin and histamine induced contractile responses. The mast cell activation-mediated contraction was abolished by double desensitization by serotonin and histamine and pre-treatment with indomethacin, a cyclooxygenase inhibitor. The findings show that cholinergic and non-cholinergic transmitters induce longitudinal contraction in the suncus esophagus, which might contribute to esophageal shortening during emesis. Cholinergic transmitters are derived from vagal efferents, and non-cholinergic transmitters, which are thought to be serotonin, histamine and prostaglandins, are released from mast cells. (C) 2015 Elsevier B.V. All rights reserved.	[Shiina, Takahiko; Naitou, Kiyotada; Nakamori, Hiroyuki; Shimizu, Yasutake] Gifu Univ, United Grad Sch Vet Sci, Dept Vet Basic Sci, Physiol Lab, Gifu 5011193, Japan; [Sakai, Hiroki] Gifu Univ, United Grad Sch Vet Sci, Dept Pathogenet Vet Sci, Pathol Lab, Gifu 5011193, Japan	Shiina, T (reprint author), Gifu Univ, United Grad Sch Vet Sci, Dept Vet Basic Sci, Physiol Lab, 1-1 Yanagido, Gifu 5011193, Japan.	tshiina@gifu-u.ac.jp			Ministry of Education, Culture, Sports, Science, and Technology of Japan [20780206, 23780291]	This work was supported in part by Grants-in-Aid for Scientific Research (KAKENHI) from the Ministry of Education, Culture, Sports, Science, and Technology of Japan [Research Project Numbers: 20780206 and 23780291]. The authors are indebted to Ms. Ayako Takahashi and Ms. Noriko Endo (Gifu University, Japan) for their technical supports.	Andrews P, 1996, EUR J PHARMACOL, V307, P305, DOI 10.1016/0014-2999(96)00275-0; Andrews P.L.R., 2003, NEUROGASTROENT MOTIL, V15, P25; Andrews P.LR., 1995, PHYSIOL ZOOL, V68, P61; Ono HK, 2012, FEMS IMMUNOL MED MIC, V64, P392, DOI 10.1111/j.1574-695X.2011.00924.x; Endo T, 2000, TOXICOLOGY, V153, P189, DOI 10.1016/S0300-483X(00)00314-0; Zhang SZ, 2013, AM J PHYSIOL-GASTR L, V304, pG908, DOI 10.1152/ajpgi.00448.2012; Andrews PLR, 2006, AUTON NEUROSCI-BASIC, V125, P100, DOI 10.1016/j.autneu.2006.01.008; Chan SW, 2014, NEUROPHARMACOLOGY, V83, P71, DOI 10.1016/j.neuropharm.2014.03.016; Hornby PJ, 2001, AM J MED, V111, P106, DOI 10.1016/S0002-9343(01)00849-X; De Winter BY, 2012, BBA-MOL BASIS DIS, V1822, P66, DOI 10.1016/j.bbadis.2011.03.016; Bischoff SC, 2009, SEMIN IMMUNOPATHOL, V31, P185, DOI 10.1007/s00281-009-0165-4; Bieger D., 1985, PHARM PROPERTIES MEC, V84, P93; Bieger D., 2006, NEURAL CIRCUITS MEDI, DOI DOI 10.1038/GIM01074; Boudaka A, 2009, NEUROGASTROENT MOTIL, V21, P180, DOI 10.1111/j.1365-2982.2008.01224.x; Cheng FHM, 2008, NEUROPEPTIDES, V42, P671, DOI 10.1016/j.npep.2008.05.002; CHRISTENSEN J, 1975, ANNU REV PHARMACOL, V15, P243, DOI 10.1146/annurev.pa.15.040175.001331; Clouse RE, 2006, PHYSIOLOGY OF THE GASTROINTESTINAL TRACT, VOLS 1 AND 2, 4TH EDITION, P913; Frieri M, 2013, CURR ALLERGY ASTHM R, V13, P27, DOI 10.1007/s11882-012-0322-z; FUKUDA H, 1991, NEUROSCI RES, V12, P471; Furness JB, 2006, ENTERIC NERVOUS SYSTEM, P1; Hansen MB, 2003, PHYSIOL RES, V52, P1; Hempfling C., 2011, NEUROGASTROENT MOTIL, V24, pe67; Hempfling C, 2009, AUTON NEUROSCI-BASIC, V151, P135, DOI 10.1016/j.autneu.2009.08.006; Hyland NP, 2001, J COMP NEUROL, V430, P222, DOI 10.1002/1096-9861(20010205)430:2<222::AID-CNE1027>3.0.CO;2-Y; ITO C, 1995, EUR J PHARMACOL, V285, P37, DOI 10.1016/0014-2999(95)00372-R; Izumi N, 2003, J PHYSIOL-LONDON, V551, P287, DOI 10.1113/jphysiol.2003.044669; LANG IM, 1990, CAN J PHYSIOL PHARM, V68, P242; Paterson WG, 2007, GUT, V56, P1347, DOI 10.1136/gut.2006.115881; Saito R, 2003, J PHARMACOL SCI, V91, P87; Shea-Donohue Terez, 2010, Curr Gastroenterol Rep, V12, P349, DOI 10.1007/s11894-010-0132-1; Shiina T, 2006, NEUROSCIENCE, V139, P495, DOI 10.1016/j.neuroscience.2005.12.027; Shiina T, 2012, AUTON NEUROSCI-BASIC, V168, P25, DOI 10.1016/j.autneu.2012.01.003; Shima T, 2014, AM J PHYSIOL-GASTR L, V306, pG811, DOI 10.1152/ajpgi.00250.2013; Smith JE, 2002, EXP PHYSIOL, V87, P563, DOI 10.1113/eph8702424; Tsutsui C, 2009, PEPTIDES, V30, P318, DOI 10.1016/j.peptides.2008.10.006; Uchino M, 2002, AUTON NEUROSCI-BASIC, V100, P32, DOI 10.1016/S1566-0702(02)00141-8; UENO S, 1987, LIFE SCI, V41, P513, DOI 10.1016/0024-3205(87)90229-3; Worl J, 2005, HISTOCHEM CELL BIOL, V123, P117, DOI 10.1007/s00418-005-0764-7; Yu S, 2007, AM J PHYSIOL-GASTR L, V293, pG850, DOI 10.1152/ajpgi.00277.2007; Zhang SZ, 2014, AM J PHYSIOL-GASTR L, V306, pG200, DOI 10.1152/ajpgi.00142.2013	40	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	1566-0702	1872-7484		AUTON NEUROSCI-BASIC	Auton. Neurosci-Basic Clin.	MAY	2015	189						37	42		10.1016/j.autneu.2015.02.003		6	Neurosciences	Neurosciences & Neurology	CG6QP	WOS:000353427400006		
J	Kubota, S; Endo, Y; Kubota, M; Ishizuka, Y; Furudate, T				Kubota, Satoshi; Endo, Yutaka; Kubota, Mitsue; Ishizuka, Yusuke; Furudate, Takuya			Effects of trunk posture in Fowler's position on hemodynamics	AUTONOMIC NEUROSCIENCE-BASIC & CLINICAL			English	Article						Cardiovascular regulation; Impedance cardiography; Systolic time intervals	SYSTOLIC-TIME INTERVALS; CARDIOVASCULAR REGULATION; IMPEDANCE CARDIOGRAPHY; SPECTRAL-ANALYSIS; BLOOD-PRESSURE; BODY POSITION; STROKE VOLUME; HEART-RATE; STRESS; RESPONSES	We speculated that stroke volume would be higher and heart rate would be lower when the head and upper trunk were mainly upright in the Fowler's position. We therefore analyzed the effects of three trunk postures in Fowler's position on heart rate, blood pressure and circulatory volume. Heart rate (HR), blood pressure (BP), stroke volume (SV), cardiac output (Q), systemic vascular resistance (SVR), ejection time (ET) and pre-ejection period (PEP) were measured in 10 healthy male volunteers (mean age +/- SEM, 20.7 +/- 0.5 y; range, 19-23 y) while in three trunk postures in Fowler's position. Stroke volume and Q were measured using impedance cardiography. The three trunk postures were 30 degrees of lower and upper trunk inclination (WT30 degrees), 30 degrees and 60 degrees of lower and upper trunk inclination (UT 60 degrees), respectively and 60 degrees of upper and lower trunk inclination (WT60 degrees). Both SV and ET were significantly higher and HR and PEP were lower at UT60 degrees than at WT60 degrees (p<0.01) whereas these values did not significantly differ between WT30 degrees and UT60 degrees (p > 0.05). None of Q SVR and BP significantly differed among the three conditions (p > 0.05). These findings suggested that SV and preload are higher when the upper trunk is upright (UT60 degrees) than when the entire trunk is upright (WT60 degrees) while in Fowler's position. In addition, Q might be maintained without increasing HR through vagal withdrawal when only the upper trunk is upright in healthy young males in Fowler's position. (C) 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).	[Kubota, Satoshi; Endo, Yutaka; Kubota, Mitsue] Int Univ Hlth & Welf, Sch Nursing & Rehabil Sci Odawara, Odawara, Kanagawa 2508588, Japan; [Ishizuka, Yusuke] New Life Yugawara, Yugawara, Kanagawa, Japan; [Furudate, Takuya] Social Welf Corp Keiroen, Ueda, Nagano, Japan	Kubota, S (reprint author), Int Univ Hlth & Welf, Sch Nursing & Rehabil Sci Odawara, Dept Occupat Therapy, 1-2-25 Shiroyama, Odawara, Kanagawa 2508588, Japan.	satoshi@iuhw.ac.jp			JSPS KAKENHI [22792159]	We thank Sumiko Yamamoto for the critical and valuable advice. This study was supported by JSPS KAKENHI Grant Number 22792159. The experiments complied with the current laws of the country in which they were performed.	O'Leary DD, 2003, EXP PHYSIOL, V88, P769, DOI 10.1113/eph8802632; Cowie DA, 2004, ANESTH ANALG, V98, P40, DOI 10.1213/01.ANE.0000093388.17298.90; Reesink KD, 2007, J APPL PHYSIOL, V102, P2128, DOI 10.1152/japplphysiol.01206.2006; SAUL JP, 1991, AM J PHYSIOL, V261, pH1231; PAGANI M, 1986, CIRC RES, V59, P178; LEWIS RP, 1977, CIRCULATION, V56, P146; Bernstein DP, 2005, MED BIOL ENG COMPUT, V43, P443, DOI 10.1007/BF02344724; POMERANZ B, 1985, AM J PHYSIOL, V248, pH151; Boudoulas P.F.B.a.H., 1986, CARDIOTONIC DRUGS CL, V7, P5; Bundgaard-Nielsen M, 2009, BRIT J ANAESTH, V102, P756, DOI 10.1093/bja/aep083; Carol T., 2008, ACTIVITY FUNDAMENTAL, P1290; Chan Gregory S H, 2007, J Clin Monit Comput, V21, P283, DOI 10.1007/s10877-007-9086-8; Cicolini G, 2010, J CLIN NURS, V19, P3581, DOI 10.1111/j.1365-2702.2010.03418.x; Cicolini G, 2011, AM J HYPERTENS, V24, P1073, DOI 10.1038/ajh.2011.106; Cybulski G., 2011, IMPEDANCE CARDIOGRAP, V76, P7; Cybulski G, 2004, MED BIOL ENG COMPUT, V42, P707, DOI 10.1007/BF02347554; DRISCOLL A, 1995, HEART LUNG, V24, P38, DOI 10.1016/S0147-9563(05)80093-7; Fu Q, 2005, AM J PHYSIOL-REG I, V289, pR109, DOI 10.1152/ajpregu.00013.2005; GUAZZI M, 1995, J AM COLL CARDIOL, V26, P1732, DOI 10.1016/0735-1097(95)00370-3; Her C, 1999, CRIT CARE MED, V27, P2703, DOI 10.1097/00003246-199912000-00017; Kubota S, 2013, J PHYSIOL SCI, V63, P369, DOI 10.1007/s12576-013-0273-8; Metzler DJ, 1996, AM J NURS, V96, P33, DOI 10.2307/3465158; Potter PA, 2009, MOBILITY IMMOBILITY, P898; RANKIN LS, 1975, CIRCULATION, V51, P910; Rauen CA, 2009, CRIT CARE NURSE, V29, P46, DOI 10.4037/ccn2009287; Rowell LB., 1993, REFLEX CONTROL ORTHO, P3; Shih FJ, 1999, INT J NURS STUD, V36, P497, DOI 10.1016/S0020-7489(99)00033-4; Shoemaker JK, 2001, AM J PHYSIOL-HEART C, V281, pH2028; STAFFORD RW, 1970, CIRCULATION, V41, P485; Steinberg F., 1980, IMMOBILIZED PATIENT, P11; Wilson A E, 1996, Am J Crit Care, V5, P264	31	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	1566-0702	1872-7484		AUTON NEUROSCI-BASIC	Auton. Neurosci-Basic Clin.	MAY	2015	189						56	59		10.1016/j.autneu.2015.01.002		4	Neurosciences	Neurosciences & Neurology	CG6QP	WOS:000353427400009		
J	Zhang, H; Kovacs-Nolan, J; Kodera, T; Eto, Y; Mine, Y				Zhang, Hua; Kovacs-Nolan, Jennifer; Kodera, Tomohiro; Eto, Yuzuru; Mine, Yoshinori			gamma-Glutamyl cysteine and gamma-glutamyl valine inhibit TNF-alpha signaling in intestinal epithelial cells and reduce inflammation in a mouse model of colitis via allosteric activation of the calcium-sensing receptor	BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE			English	Article						Inflammatory bowel disease (IBD); Tumor necrosis factor (TNF); Intestinal epithelium; Dextran sodium sulfate (DSS) colitis; gamma-Glutamyl dipeptides; Calcium-sensing receptor (CaSR)	NF-KAPPA-B; PROTEIN-COUPLED RECEPTORS; GASTROINTESTINAL-TRACT; ULCERATIVE-COLITIS; CROHNS-DISEASE; BOWEL-DISEASE; BETA-ARRESTIN; CACO-2 CELLS; PATHWAY; KINASE	Background: The extracellular calcium-sensing receptor (CaSR) is distributed throughout the gastrointestinal tract, and its activation has been shown to promote intestinal homeostasis, suggesting that CaSR may be a promising target for novel therapies to prevent chronic intestinal inflammation such as inflammatory bowel disease (IBD). The gamma-glutamyl dipeptides gamma-glutamyl cysteine (gamma-EC) and gamma-glutamyl valine (gamma-EV) are dietary flavor enhancing compounds, and have been shown to activate CaSR via allosteric ligand binding. The aim of this study was to examine the anti-inflammatory effects of gamma-EC and gamma-EV in vitro in intestinal epithelial cells and in a mouse model of intestinal inflammation. Results: In vitro, treatment of Caco-2 cells with gamma-EC and gamma-EV resulted in the CaSR-mediated reduction of TNF-alpha-stimulated pro-inflammatory cytokines and chemokines including IL-8, IL-6, and IL-1 beta, and inhibited phosphorylation of JNK and I kappa B alpha, while increasing expression of IL-10. In vivo, using a mouse model of dextran sodium sulfate (DSS)-induced colitis, gamma-EC and gamma-EV treatment ameliorated DSS-induced clinical signs, weight loss, colon shortening and histological damage. Moreover, gamma-EC and gamma-EV reduced the expression of TNF-alpha, IL-6, IL-1 beta, and IL-17, and increased the expression of IL-10 in the colon, in a CaSR-dependent manner. The CaSR-mediated anti-inflammatory effects of gamma-EC were abrogated in beta-arrestin2 knock-down Caco-2 cells, and involvement of beta-arrestin2 was found to inhibit TNF-alpha-dependent signaling via cross-talk with the TNF-a receptor (TNFR). Conclusions: Thus CaSR activation by gamma-EC and gamma-EV can aid in maintaining intestinal homeostasis and reducing inflammation in chronic inflammatory conditions such as IBD. (C) 2015 Elsevier B.V. All rights reserved.	[Zhang, Hua; Kovacs-Nolan, Jennifer; Mine, Yoshinori] Univ Guelph, Dept Food Sci, Guelph, ON N1G 2W1, Canada; [Kodera, Tomohiro; Eto, Yuzuru] Ajinomoto Co Inc, Kawasaki Ku, Kawasaki, Kanagawa 2108681, Japan	Mine, Y (reprint author), Univ Guelph, Dept Food Sci, Guelph, ON N1G 2W1, Canada.	ymine@uoguelph.ca			Advanced Foods and Materials Network (AFMNet), part of the Networks of Centres of Excellence (NCE), Canada	We thank Dr. Prithy Rupa, Annette Morrison, Maka Natsvlishvili, and Jackie Rombeek for their assistance with the animal studies. This study was supported by the Advanced Foods and Materials Network (AFMNet), part of the Networks of Centres of Excellence (NCE), Canada.	Allen Sara, 2000, Methods in Cell Science, V22, P305, DOI 10.1023/A:1017585308255; Treede I, 2007, J BIOL CHEM, V282, P27155, DOI 10.1074/jbc.M704408200; Ohsu T, 2010, J BIOL CHEM, V285, P1016, DOI 10.1074/jbc.M109.029165; Wu GY, 2004, J NUTR, V134, P489; Dunkel A, 2007, J AGR FOOD CHEM, V55, P6712, DOI 10.1021/jf071276u; Chen GQ, 2002, SCIENCE, V296, P1634, DOI 10.1126/science.1071924; Kallay E, 1997, BIOCHEM BIOPH RES CO, V232, P80, DOI 10.1006/bbrc.1997.6225; Young D, 2012, J NUTR, V142, P363, DOI 10.3945/jn.111.149104; Mundy GR, 2002, NAT REV CANCER, V2, P584, DOI 10.1038/nrc867; Brown EM, 2001, PHYSIOL REV, V81, P239; Witherow DS, 2004, P NATL ACAD SCI USA, V101, P8603, DOI 10.1073/pnas.0402851101; Pierce KL, 2001, NAT REV NEUROSCI, V2, P727, DOI 10.1038/35094577; Shibuya H, 1996, SCIENCE, V272, P1179, DOI 10.1126/science.272.5265.1179; Pan MH, 2011, MOL NUTR FOOD RES, V55, P32, DOI 10.1002/mnfr.201000412; Wang C, 2001, NATURE, V412, P346, DOI 10.1038/35085597; Oh DY, 2010, CELL, V142, P687, DOI 10.1016/j.cell.2010.07.041; Conigrave AD, 2006, AM J PHYSIOL-GASTR L, V291, pG753, DOI 10.1152/ajpgi.00189.2006; Feng JY, 2010, P NATL ACAD SCI USA, V107, P17791, DOI 10.1073/pnas.1009078107; Ninomiya-Tsuji J, 1999, NATURE, V398, P252; OKAYASU I, 1990, GASTROENTEROLOGY, V98, P694; Strober W, 2007, J CLIN INVEST, V117, P514, DOI 10.1172/JCI30587; Wang MH, 2006, J BIOL CHEM, V281, P8864, DOI 10.1074/jbc.M512865200; Broom OJ, 2009, CLIN EXP IMMUNOL, V158, P272, DOI 10.1111/j.1365-2249.2009.04033.x; Bouwmeester T, 2004, NAT CELL BIOL, V6, P97, DOI 10.1038/ncb1086; Nakajima S, 2010, REGUL PEPTIDES, V159, P148, DOI 10.1016/j.regpep.2009.11.007; Rodriguez-Ramiro I, 2013, BRIT J NUTR, V110, P206, DOI 10.1017/S0007114512004862; Saidak Z, 2009, ENDOCR REV, V30, P178, DOI 10.1210/er.2008-0041; Sartor RB, 2006, NAT CLIN PRACT GASTR, V3, P390, DOI 10.1038/ncpgasthep0528; Wallach D, 1999, ANNU REV IMMUNOL, V17, P331, DOI 10.1146/annurev.immunol.17.1.331; DiDonato JA, 1997, NATURE, V388, P548; Garside P, 1999, CLIN EXP IMMUNOL, V118, P337; Chen ZJJ, 2005, NAT CELL BIOL, V7, P758, DOI 10.1038/ncb0805-758; Nemeth EF, 2001, J PHARMACOL EXP THER, V299, P323; Bhattacharyya S, 2009, INFLAMM BOWEL DIS, V15, P673, DOI 10.1002/ibd.20821; Bookout Angie L, 2003, Nucl Recept Signal, V1, pe012; Broadhead GK, 2011, J BIOL CHEM, V286, P8786, DOI 10.1074/jbc.M110.149724; Cheng SX, 2002, AM J PHYSIOL-GASTR L, V283, pG240, DOI 10.1152/ajpgi.00500.2001; Fujita T, 2011, J INVEST DERMATOL, V131, P1660, DOI 10.1038/jid.2011.123; Gama L, 1997, AM J PHYSIOL-CELL PH, V273, pC1168; Gao I.I., 2004, MOL CELL, V14, P303; Geibel JP, 2009, ANNU REV PHYSIOL, V71, P205, DOI 10.1146/annurev.physiol.010908.163128; Hebert S.C., 2004, CELL CALCIUM, V35, P293; Katayama S., 2007, J AGR FOOD CHEM, V17, P8458; Kelly JC, 2011, FRONT PHYSIOL, V2, DOI 10.3389/fphys.2011.00017; Kovacs-Nolan J, 2012, BBA-GEN SUBJECTS, V1820, P1753, DOI 10.1016/j.bbagen.2012.07.007; KUHN R, 1993, CELL, V75, P263, DOI 10.1016/0092-8674(93)80068-P; Magro F., 2010, BIODRUGS S, VS1, P3; Maxwell J. R, 2009, CURR PROTOC PHARM, VS47; Nishitani Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062441; Nishiuchi H, 2013, J BIOSCI BIOENG, V115, P50, DOI 10.1016/j.jbiosc.2012.08.009; Pacheco LI., 2008, AM J PHYSIOL-GASTR L, V295, pG748; Pi M, 2005, MOL ENDOCRINOL, V19, P1078, DOI 10.1210/me.2004-0450; Plevy SE, 1997, J IMMUNOL, V159, P6276; Treede I, 2009, BMC GASTROENTEROL, V9, DOI 10.1186/1471-230X-9-53	54	3	3	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0925-4439	0006-3002		BBA-MOL BASIS DIS	Biochim. Biophys. Acta-Mol. Basis Dis.	MAY	2015	1852	5					792	804		10.1016/j.bbadis.2014.12.023		13	Biochemistry & Molecular Biology; Biophysics; Cell Biology	Biochemistry & Molecular Biology; Biophysics; Cell Biology	CG3JJ	WOS:000353176200010		
J	Kawai, N; Hirasaka, K; Maeda, T; Haruna, M; Shiota, C; Ochi, A; Abe, T; Kohno, S; Ohno, A; Teshima-Kondo, S; Mori, H; Tanaka, E; Nikawa, T				Kawai, Nobuhiko; Hirasaka, Katsuya; Maeda, Tasuku; Haruna, Marie; Shiota, Chieko; Ochi, Arisa; Abe, Tomoki; Kohno, Shohei; Ohno, Ayako; Teshima-Kondo, Sigetada; Mori, Hiroyo; Tanaka, Eiji; Nikawa, Takeshi			Prevention of skeletal muscle atrophy in vitro using anti-ubiquitination oligopeptide carried by atelocollagen	BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH			English	Article						Muscle atrophy; Ubiquitin ligase; IGF-1 signaling; Starvation	FOXO TRANSCRIPTION FACTORS; SMALL INTERFERING RNA; CBL-B; PROTEIN; CELLS; DELIVERY; PATHWAY; VIVO; ACTIVATION; EXPRESSION	Skeletal muscle atrophy occurs when the rate of protein degradation exceeds that of protein synthesis in various catabolic conditions, such as fasting, disuse, aging, and chronic diseases. Insulin-like growth factor-1 (IGF-1) signaling stimulates muscle growth and suppresses muscle protein breakdown. In atrophied muscles, ubiquitin ligase, Cbl-b, increases and stimulates the ubiquitination and degradation of IRS-1, an intermediate in IGF-1 signaling pathway, resulting in IGF-1 resistance. In this study, we evaluated the efficacy of atelocollagen (ATCOL)-transported anti-ubiquitination oligopeptide (Cblin: Cbl-b inhibitor) (consisting of tyrosine phosphorylation domain of IRS-1) in starved C2C12 myotubes. The amount of IRS-1 protein was lower in starved versus unstarved myotubes. The Cblin-ATCOL complex inhibited IRS-1 degradation in a concentration-dependent manner. Myotubes incubated with Cblin-ATCOL complex showed significant resistance to starvation-induced atrophy (p < 0.01). Furthermore, the Cblin-ATCOL complex significantly inhibited any decrease in Akt phosphorylation (p < 0.01) and localization of FOX03a to the nucleus in starved myotubes. These results suggest that Cblin prevented starvation-induced C2C12 myotube atrophy by maintaining the IGF-1/Akt/FOXO signaling. Therefore, attachment of anti-ubiquitination oligopeptide, Cblin, to ATCOL enhances its delivery to myotubes and could be a potentially effective strategy in the treatment of atrophic myopathies. (C) 2015 Elsevier B.V. All rights reserved.	[Kawai, Nobuhiko; Shiota, Chieko; Ochi, Arisa; Abe, Tomoki; Kohno, Shohei; Ohno, Ayako; Teshima-Kondo, Sigetada; Nikawa, Takeshi] Univ Tokushima, Grad Sch, Dept Nutr Physiol, Inst Hlth Biosci, Tokushima 7708504, Japan; [Kawai, Nobuhiko; Maeda, Tasuku; Haruna, Marie; Shiota, Chieko; Mori, Hiroyo; Tanaka, Eiji] Univ Tokushima, Grad Sch, Dept Orthodont & Dentofacial Orthoped, Inst Hlth Biosci, Tokushima 7708504, Japan; [Hirasaka, Katsuya] Nagasaki Univ, Grad Sch Fisheries Sci & Environm Studies, Nagasaki 852, Japan	Kawai, N (reprint author), Univ Tokushima, Grad Sch, Dept Orthodont & Dentofacial Orthoped, Inst Hlth Biosci, 3-18-15 Kuramoto Cho, Tokushima 7708504, Japan.	kamo@tokushima-u.ac.jp			Ministry of Education, Culture, Sports, Science and Technology, Japan [24792289]	This research was supported by grant no. 24792289 for Science Research from the Ministry of Education, Culture, Sports, Science and Technology, Japan.	Sandri M, 2013, BIOGERONTOLOGY, V14, P303, DOI 10.1007/s10522-013-9432-9; KEANE MM, 1995, ONCOGENE, V10, P2367; Thien CBF, 2001, NAT REV MOL CELL BIO, V2, P294, DOI 10.1038/35067100; Honma K, 2001, BIOCHEM BIOPH RES CO, V289, P1075, DOI 10.1006/bbrc.2001.6133; Schiaffino S, 2013, FEBS J, V280, P4294, DOI 10.1111/febs.12253; Sandri M, 2004, CELL, V117, P399, DOI 10.1016/S0092-8674(04)00400-3; Zhao J, 2007, CELL METAB, V6, P472, DOI 10.1016/j.cmet.2007.11.004; Nakao R, 2009, MOL CELL BIOL, V29, P4798, DOI 10.1128/MCB.01347-08; McPherron AC, 1997, NATURE, V387, P83, DOI 10.1038/387083a0; Ohnuki Y, 2013, J PHARMACOL SCI, V123, P36, DOI 10.1254/jphs.12271FP; Frohlich E, 2012, INT J NANOMED, V7, P5577, DOI 10.2147/IJN.S36111; Ochiya T, 1999, NAT MED, V5, P707; Minakuchi Y, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh093; Takeshita F, 2005, P NATL ACAD SCI USA, V102, P12177, DOI 10.1073/pnas.0501753102; Bodine SC, 2001, SCIENCE, V294, P1704, DOI 10.1126/science.1065874; CHOMCZYNSKI P, 1995, BIOTECHNIQUES, V19, P942; Calnan DR, 2008, ONCOGENE, V27, P2276, DOI 10.1038/onc.2008.21; Chvapil M, 1973, Int Rev Connect Tissue Res, V6, P1; Esposito DL, 2001, ENDOCRINOLOGY, V142, P2833, DOI 10.1210/en.142.7.2833; FUJIMURA K, 1995, BIOCHEM BIOPH RES CO, V208, P316, DOI 10.1006/bbrc.1995.1340; Gomes M.D., 2001, P NATL ACAD SCI USA, V98, P1440; Hirasaka K, 2007, DIABETES, V56, P2511, DOI 10.2337/db06-1768; Kawakami E, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064719; Li JJ, 2011, CELL PHYSIOL BIOCHEM, V27, P463, DOI 10.1159/000329967; MILLER JM, 1964, ARCH SURG-CHICAGO, V88, P167; Nikawa T, 2004, FASEB J, V18, P522, DOI 10.1096/fj.03-0419fje; Paul PK, 2012, MOL CELL BIOL, V32, P1248, DOI 10.1128/MCB.06351-11; Stitt TN, 2004, MOL CELL, V14, P395, DOI 10.1016/S1097-2765(04)00211-4	28	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0167-4889	0006-3002		BBA-MOL CELL RES	Biochim. Biophys. Acta-Mol. Cell Res.	MAY	2015	1853	5					873	880		10.1016/j.bbamcr.2015.01.024		8	Biochemistry & Molecular Biology; Cell Biology	Biochemistry & Molecular Biology; Cell Biology	CG3JO	WOS:000353176700001		
J	Sato, M; Arakawa, T; Nam, YW; Nishimoto, M; Kitaoka, M; Fushinobu, S				Sato, Mayo; Arakawa, Takatoshi; Nam, Young-Woo; Nishimoto, Mamoru; Kitaoka, Motomitsu; Fushinobu, Shinya			Open-close structural change upon ligand binding and two magnesium ions required for the catalysis of N-acetylhexosamine 1-kinase	BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS			English	Article						Crystal structure; Anomeric sugar kinase; Conformational change; Magnesium ion; Protein kinase; Bifidobacterium longum	DEPENDENT PROTEIN-KINASE; CRYSTAL-STRUCTURES; BIFIDOBACTERIA; PHOSPHOTRANSFERASE; IDENTIFICATION; SPECIFICITY; COMPLEXES; MECHANISM; SUBUNIT; LONGUM	Infant gut-associated bifidobacteria possess a metabolic pathway to utilize lacto-N-biose (Gal-beta 1,3-G1cNAc) and galacto-N-biose (Gal-beta 1,3-GalNAc) from human milk and glycoconjugates specifically. In this pathway, N-acetylhexosamine 1-kinase (NahK) catalyzes the phosphorylation of GlcNAc or GalNAc at the anomeric Cl position with ATP. Crystal structures of NahK have only been determined in the closed state. In this study, we determined open state structures of NahK in three different forms (apo, ADP complex, and ATP complex). A comparison of the open and closed state structures revealed an induced fit structural change defined by two rigid domains. ATP binds to the small N-terminal domain, and binding of the N-acetylhexosamine substrate to the large C-terminal domain induces a closing conformational change with a rotation angle of 16 degrees. In the nucleotide binding site, two magnesium ions bridging the alpha-gamma and beta-gamma phosphates were identified. A mutational analysis indicated that a residue coordinating both of the two magnesium ions (Asp228) is essential for catalysis. The involvement of two magnesium ions in the catalytic machinery is structurally similar to the catalytic structures of protein kinases and aminoglycoside phosphotransferases, but distinct from the structures of other anomeric kinases or sugar 6-kinases. These findings help to elucidate the possible evolutionary adaptation of substrate specificities and induced fit mechanism. (C) 2015 Elsevier B.V. All rights reserved.	[Sato, Mayo; Arakawa, Takatoshi; Nam, Young-Woo; Fushinobu, Shinya] Univ Tokyo, Dept Biotechnol, Tokyo 1138657, Japan; [Nishimoto, Mamoru; Kitaoka, Motomitsu] Natl Agr & Food Res Org, Natl Food Res Inst, Tsukuba, Ibaraki 3058642, Japan	Fushinobu, S (reprint author), Univ Tokyo, Dept Biotechnol, Bunkyo Ku, 1-1-1 Yayoi, Tokyo 1138657, Japan.	asfushi@mail.ecc.u-tokyo.ac.jp	Fushinobu, Shinya/E-4987-2011	Fushinobu, Shinya/0000-0003-1346-6435	Platform for Drug Discovery, Informatics, and Structural Life Science - Ministry of Education, Culture, Sports, Science and Technology, Japan; Science and Technology Research Promotion Program for Agriculture, Forestry, Fisheries and Food Industry [25010A]	We thank the staff of the Photon Factory for the X-ray data collection. This work was supported in part by Platform for Drug Discovery, Informatics, and Structural Life Science funded by the Ministry of Education, Culture, Sports, Science and Technology, Japan. This study was supported by Science and Technology Research Promotion Program for Agriculture, Forestry, Fisheries and Food Industry (25010A).	ANDERSON CM, 1979, SCIENCE, V204, P375, DOI 10.1126/science.220706; Thoden JB, 2005, J BIOL CHEM, V280, P32784, DOI 10.1074/jbc.M505730200; Liu Y, 2015, CARBOHYD RES, V401, P1, DOI 10.1016/j.carres.2014.10.014; Picard C, 2005, ALIMENT PHARM THERAP, V22, P495, DOI 10.1111/j.1365-2036.2005.02615.x; Adams PD, 2010, ACTA CRYSTALLOGR D, V66, P213, DOI 10.1107/S0907444909052925; Cheek S, 2002, J MOL BIOL, V320, P855, DOI 10.1016/S0022-2836(02)00538-7; Finn RD, 2014, NUCLEIC ACIDS RES, V42, pD222, DOI 10.1093/nar/gkt1223; Fushinobu S, 2010, BIOSCI BIOTECH BIOCH, V74, P2374, DOI 10.1271/bbb.100494; Kitaoka M, 2005, APPL ENVIRON MICROB, V71, P3158, DOI 10.1128/AEM.71.6.3158-3162.2005; Nishimasu H, 2007, J BIOL CHEM, V282, P9923, DOI 10.1074/jbc.M610678200; Adams JA, 2001, CHEM REV, V101, P2271, DOI 10.1021/cr000230w; ARMSTRONG RN, 1979, BIOCHEMISTRY-US, V18, P1230, DOI 10.1021/bi00574a018; Kapelyukh Y, 2008, DRUG METAB DISPOS, V36, P2136, DOI 10.1124/dmd.108.021733; Emsley P, 2010, ACTA CRYSTALLOGR D, V66, P486, DOI 10.1107/S0907444910007493; Li YH, 2011, MOLECULES, V16, P6396, DOI 10.3390/molecules16086396; Sela DA, 2010, TRENDS MICROBIOL, V18, P298, DOI 10.1016/j.tim.2010.03.008; Sahun-Roncero M, 2013, CHEMBIOCHEM, V14, P1291, DOI 10.1002/cbic.201300195; Nishimoto M, 2007, APPL ENVIRON MICROB, V73, P6444, DOI 10.1128/AEM.01425-07; Burk DL, 2001, BIOCHEMISTRY-US, V40, P8756, DOI 10.1021/bi010504p; Fong DH, 2010, J BIOL CHEM, V285, P9545, DOI 10.1074/jbc.M109.038364; Grueninger D, 2006, J MOL BIOL, V359, P787, DOI 10.1016/j.jmb.2006.04.013; Hayward S, 2004, J MOL BIOL, V339, P1001, DOI 10.1016/j.jmb.2004.04.004; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; Malito E, 2006, J MOL BIOL, V364, P136, DOI 10.1016/j.jmb.2006.08.084; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Scheeff ED, 2005, PLOS COMPUT BIOL, V1, P359, DOI 10.1037/journal.pcbi.0010049; Thoden JB, 2005, J BIOL CHEM, V280, P9662, DOI 10.1074/jbc.M412916200; Wang KC, 2014, ACTA CRYSTALLOGR D, V70, P1401, DOI 10.1107/S1399004714004209; ZHENG JH, 1993, BIOCHEMISTRY-US, V32, P2154, DOI 10.1021/bi00060a005	29	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	1570-9639	0006-3002		BBA-PROTEINS PROTEOM	BBA-Proteins Proteomics	MAY	2015	1854	5					333	340		10.1016/j.bbapap.2015.01.011		8	Biochemistry & Molecular Biology; Biophysics	Biochemistry & Molecular Biology; Biophysics	CG2FF	WOS:000353089600003		
J	Suzuki, R; Koide, K; Hayashi, M; Suzuki, T; Sawada, T; Ohdan, T; Takahashi, H; Nakamura, Y; Fujita, N; Suzuki, E				Suzuki, Ryuichiro; Koide, Keiichi; Hayashi, Mari; Suzuki, Tomoko; Sawada, Takayuki; Ohdan, Takashi; Takahashi, Hidekazu; Nakamura, Yasunori; Fujita, Naoko; Suzuki, Eiji			Functional characterization of three (GH13) branching enzymes involved in cyanobacterial starch biosynthesis from Cyanobacterium sp NBRC 102756	BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS			English	Article						Branching enzyme; Cyanobacteria; Glycogen; Amylopectin; Cyanobacterial starch	ALPHA-AMYLASE FAMILY; RICE ENDOSPERM; ESCHERICHIA-COLI; AMYLOPECTIN BIOSYNTHESIS; GLYCOGEN-METABOLISM; SPECIFICITY; EVOLUTION; SEQUENCE; ISOFORMS; GENE	Starch and glycogen are widespread storage polysaccharides in bacteria, plants, and animals. Recently, some cyanobacteria were found to accumulate water-insoluble alpha-glucan similar to amylopectin rather than glycogen, the latter of which is more commonly produced in these organisms. The amylopectin-producing species including Cyanobacterium sp. NBRC 102756 invariably have three branching enzyme (BE) homologs, BE1, BE2, and BE3, all belonging to the glycoside hydrolase family 13. Multiple BE isoforms in prokaryotes have not been previously studied. In the present work, we carried out functional characterization of these enzymes expressed in Escherichia colt. The recombinant enzymes were all active, although the specific activity of BE3 was much lower than those of BE1 and BE2. After the incubation of the enzymes with amylopectin or amylose, the reaction products were analyzed by fluorophore-assisted carbohydrate capillary electrophoresis method. BE1 and BE2 showed similar chain-length preference to BEIIb isoform of rice (Oryza sativa L), while the catalytic specificity of BE3 was similar to that of rice BEI. These results indicate that starch-producing cyanobacteria have both type-I BE (BE3) and type-II BEs (BE1 and BE2) in terms of chain-length preferences, as is the case of plants. All BE isoforms were active against phosphorylase limit dextrin, in which outer branches had been uniformly diminished to 4 glucose residues. Based on its catalytic properties, BE3 was assumed to have a role to transfer the glucan chain bearing branch(es) to give rise to a newly growing unit, or cluster as observed in amylopectin molecule. (C) 2015 Elsevier B.V. All rights reserved.	[Suzuki, Ryuichiro; Koide, Keiichi; Hayashi, Mari; Takahashi, Hidekazu; Nakamura, Yasunori; Fujita, Naoko; Suzuki, Eiji] Akita Prefectural Univ, Fac Bioresource Sci, Dept Biol Prod, Akita, Akita 0100195, Japan; [Suzuki, Tomoko; Sawada, Takayuki; Ohdan, Takashi] Akita Prefectural Univ, Fac Bioresource Sci, Ctr Biotechnol, Akita, Akita 0100195, Japan	Suzuki, R (reprint author), Akita Prefectural Univ, Fac Bioresource Sci, Dept Biol Prod, Akita, Akita 0100195, Japan.	ryuichi@akita-pu.ac.jp; esuzuki@akita-pu.ac.jp		Nakamura, Yasunori/0000-0001-7660-0078	Program for Promotion of Basic and Applied Researches for Innovations in Bio-oriented Industry (BRAIN, Japan); Shimadzu Science Foundation [120003]; JSPS KAKENHI [25440193]	The authors would like to thank Enago (www.enago.jp) for the English language review. The authors also thank Hayashibara Co. for providing Pseudomonas isoamylase. This work was supported by grants from the Program for Promotion of Basic and Applied Researches for Innovations in Bio-oriented Industry (BRAIN, Japan), Shimadzu Science Foundation (120003), and JSPS KAKENHI Grant Number 25440193.	Abe J, 1999, APPL ENVIRON MICROB, V65, P4163; Kuriki T, 1997, J BIOL CHEM, V272, P28999, DOI 10.1074/jbc.272.46.28999; Abad MC, 2002, J BIOL CHEM, V277, P42164, DOI 10.1074/jbc.M205746200; Larkin MA, 2007, BIOINFORMATICS, V23, P2947, DOI 10.1093/bioinformatics/btm404; Palomo M, 2011, J BIOL CHEM, V286, P3520, DOI 10.1074/jbc.M110.179515; Nakamura Y, 2010, PLANT CELL PHYSIOL, V51, P776, DOI 10.1093/pcp/pcq035; Nishi A, 2001, PLANT PHYSIOL, V127, P459, DOI 10.1104/pp.127.2.459; Ball S, 2011, J EXP BOT, V62, P1775, DOI 10.1093/jxb/erq411; MacGregor EA, 2001, BBA-PROTEIN STRUCT M, V1546, P1, DOI 10.1016/S0167-4838(00)00302-2; Kuriki T, 1999, J BIOSCI BIOENG, V87, P557, DOI 10.1016/S1389-1723(99)80114-5; Dauvillee D, 2005, J BACTERIOL, V187, P1465, DOI 10.1128/JB.187.4.1465-1473.2005; Deschamps P, 2008, MOL BIOL EVOL, V25, P536, DOI 10.1093/molbev/msm280; Kubo A, 1999, PLANT PHYSIOL, V121, P399, DOI 10.1104/pp.121.2.399; Roussel X, 2013, BBA-GEN SUBJECTS, V1830, P2167, DOI 10.1016/j.bbagen.2012.09.022; Fujita N, 2007, PLANT PHYSIOL, V144, P2009, DOI 10.1104/pp.107.102533; Murakami T, 2006, J BACTERIOL, V188, P5915, DOI 10.1128/JB.00390-06; Devillers CH, 2003, ARCH BIOCHEM BIOPHYS, V418, P34, DOI 10.1016/S0003-9861(03)00341-2; Gouet P, 1999, BIOINFORMATICS, V15, P305, DOI 10.1093/bioinformatics/15.4.305; Fujita N, 2011, J EXP BOT, V62, P4819, DOI 10.1093/jxb/err125; Santos CR, 2011, PROTEINS, V79, P547, DOI 10.1002/prot.22902; Gallant DJ, 1997, CARBOHYD POLYM, V32, P177, DOI 10.1016/S0144-8617(97)00008-8; Palomo M, 2009, APPL ENVIRON MICROB, V75, P1355, DOI 10.1128/AEM.02141-08; Pal K, 2010, J BIOL CHEM, V285, P20897, DOI 10.1074/jbc.M110.121707; Thompson DB, 2000, CARBOHYD POLYM, V43, P223, DOI 10.1016/S0144-8617(00)00150-8; Stam MR, 2006, PROTEIN ENG DES SEL, V19, P555, DOI 10.1093/protein/gzl044; Janecek S, 2002, BIOLOGIA, V57, P29; Nakamura Y, 2005, PLANT CELL PHYSIOL, V46, P539, DOI 10.1093/pcp/pci045; Ball SG, 2003, ANNU REV PLANT BIOL, V54, P207, DOI 10.1146/annurev.arplant.54.031902.134927; BOYER CD, 1978, CARBOHYD RES, V61, P321, DOI 10.1016/S0008-6215(00)84492-4; Cantarel BL, 2009, NUCLEIC ACIDS RES, V37, pD233, DOI 10.1093/nar/gkn663; Cenci U, 2013, PLANT CELL, V25, P3961, DOI 10.1105/tpc.113.118174; Colleoni C., 2012, SYNTHESIS BREAKDOWN, V5, P217; Fasman G. D., 1989, PREDICTION PROTEIN S, P599; Fujita N., 2014, AGRIBIOSCI MONOGR, V4, P1; Hamada S, 2002, J BIOL CHEM, V277, P16538, DOI [10.1074/jbc.M110497200, 10.1074/jbc.M110467200]; Hilden I, 2000, EUR J BIOCHEM, V267, P2150, DOI 10.1046/j.1432-1327.2000.01221.x; Machovic M, 2008, BIOLOGIA, V63, P1057, DOI 10.2478/s11756-008-0162-4; Min HT, 2010, APPL ENVIRON MICROB, V76, P7641, DOI 10.1128/AEM.01456-10; Nakamura Y, 1997, PLANT J, V12, P143, DOI 10.1046/j.1365-313X.1997.12010143.x; Nakamura Y, 2002, PLANT CELL PHYSIOL, V43, P718, DOI 10.1093/pcp/pcf091; Nakamura Y., 2011, J APPL GLYCOSCI, V58, P119; Nozaki K, 2001, BIOSCI BIOTECH BIOCH, V65, P1141, DOI 10.1271/bbb.65.1141; Ohdan T., 2011, Journal of Applied Glycoscience, V58, P19; O'Shea MG, 1998, CARBOHYD RES, V307, P1, DOI 10.1016/S0008-6215(97)10085-4; Sawada T., 2013, J APPL GLYCOSCI, V60, P69; Sawada T, 2014, ARCH BIOCHEM BIOPHYS, V562, P9, DOI 10.1016/j.abb.2014.07.032; Sawada T, 2009, PLANT CELL PHYSIOL, V50, P1062, DOI 10.1093/pcp/pcp058; Schlager B, 2012, BMC BIOTECHNOL, V12, DOI 10.1186/1472-6750-12-95; Suzuki E, 2010, APPL ENVIRON MICROB, V76, P3153, DOI 10.1128/AEM.00397-08; Suzuki E, 2007, BBA-GEN SUBJECTS, V1770, P763, DOI 10.1016/j.bbagen.2007.01.006; Suzuki E, 2013, PLANT CELL PHYSIOL, V54, P465, DOI 10.1093/pcp/pcs190; Suzuki E., 2013, J APPL GLYCOSCI, V60, P21; TAKEDA Y, 1984, CARBOHYD RES, V132, P83, DOI 10.1016/0008-6215(84)85066-1; Ustumi Y., 2006, PLANTA, V225, P75; Vu NT, 2008, BIOSCI BIOTECH BIOCH, V72, P2858, DOI 10.1271/bbb.80325; Welkie DG, 2013, PHOTOSYNTH RES, V118, P25, DOI 10.1007/s11120-013-9941-z; YAMANOUCHI H, 1992, PLANT CELL PHYSIOL, V33, P985	57	1	1	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	1570-9639	0006-3002		BBA-PROTEINS PROTEOM	BBA-Proteins Proteomics	MAY	2015	1854	5					476	484		10.1016/j.bbapap.2015.02.012		9	Biochemistry & Molecular Biology; Biophysics	Biochemistry & Molecular Biology; Biophysics	CG2FF	WOS:000353089600017		
J	Miyakawa, M; Zukeran, G; Wada, Y; Akama, K				Miyakawa, Miho; Zukeran, Gosuke; Wada, Yuko; Akama, Kuniko			Conserved C272/278 in b domain regulate the function of PDI-P5 to make lysozymes trypsin-resistant forms via significant intermolecular disulfide cross-linking	BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS			English	Article						Protein disulfide isomerase-P5; PDIA6; Sulfhydryl oxidase activity; Protein regulation; Intermolecular disulfide cross-linking	ENDOPLASMIC-RETICULUM; ISOMERASE FAMILY; STORAGE PROTEINS; OXIDOREDUCTASE; MEMBER; P5	Protein disulfide isomerase-P5 (P5) is thought to have important functions as an oxidoreductase, however, molecular functions of P5 have not been fully elucidated. We have reported that P5 has insulin reductase activity and inhibits lysozyme refolding by formation of lysozyme multimers with hypermolecular mass inactivated by intermolecular disulfides (hyLYS) in oxidative refolding of reduced denatured lysozyme. To explore the role of each domain of P5, we investigated the effects of domain deletion and Cys-Ala mutants of P5 on insulin reduction and the oxidative refolding of the lysozyme. The mutants of catalytic cysteines, C36/39A, C171/174A, and C36/39/171/174A inhibited the lysozyme refolding almost similarly to P5, and even b domain without catalytic cysteines showed moderate inhibitory effect, suggesting that the b domain played a key role in the inhibition. Western blotting analysis of the refolding products indicated that the catalytic cysteines in both the a and a' domains cross-linked lysozyme comparably to form hyLYS resistant to trypsin, in which b domain was suggested to capture lysozyme for the significant sulfhydryl oxidation. The mutant of the conserved cysteines in b domain, C272/278A, did not form hyLYS, however, showed predominant reductase activity, implying that P5 functioned as a potent sulfhydryl oxidase and a predominant reductase depending on the circumstance around C272/278. These results provide new insight into the molecular basis of P5 function. (C) 2015 Elsevier B.V. All rights reserved.	[Miyakawa, Miho; Zukeran, Gosuke; Akama, Kuniko] Chiba Univ, Grad Sch Sci, Chiba 2638522, Japan; [Wada, Yuko] Chiba Univ, Fac Sci, Dept Chem, Chiba 2638522, Japan; [Akama, Kuniko] Chiba Univ, Ctr Gen Educ, Chiba 2638522, Japan	Akama, K (reprint author), Chiba Univ, Ctr Gen Educ, Grad Sch Sci, Inage Ku, 1-33 Yayoi Cho, Chiba 2638522, Japan.	akama@faculty.chiba-u.jp			Chiba University [190C14, 330C02]	We would like to thank Prof. Tadashi Baba (University of Tsukuba, Japan) for his encouragement, Dr. Michio Ogasawara and Dr. Asako G Terasaki for their kindness and sharing instruments (Chiba University). This work was supported by Grants-in-Aid from Chiba University (190C14 and 330C02).	Onda Y, 2011, PLANT CELL, V23, P210, DOI 10.1105/tpc.110.079509; Ferrari DM, 1999, BIOCHEM J, V339, P1, DOI 10.1042/0264-6021:3390001; Tian G, 2006, CELL, V124, P61, DOI 10.1016/j.cell.2005.10.044; Ellgaard L, 2005, EMBO REP, V6, P28, DOI 10.1038/sj.embor.7400311; Kaiser BK, 2007, NATURE, V447, P482, DOI 10.1038/nature05768; PUIG A, 1994, J BIOL CHEM, V269, P7764; HOLMGREN A, 1979, J BIOL CHEM, V254, P9627; Anelli T, 2002, EMBO J, V21, P835, DOI 10.1093/emboj/21.4.835; Jordan PA, 2005, BLOOD, V105, P1500, DOI 10.1182/blood-2004-02-0608; Araki K, 2013, J CELL BIOL, V202, P861, DOI 10.1083/jcb.201303027; Jessop CE, 2009, J CELL SCI, V122, P4287, DOI 10.1242/jcs.059154; Karala AR, 2010, FEBS J, V277, P2454, DOI 10.1111/j.1742-4658.2010.07660.x; Gumireddy K, 2007, P NATL ACAD SCI USA, V104, P6696, DOI 10.1073/pnas.0701145104; Akama K, 2010, BBA-PROTEINS PROTEOM, V1804, P1272, DOI 10.1016/j.bbapap.2010.02.004; Hatahet F, 2009, ANTIOXID REDOX SIGN, V11, P2807, DOI 10.1089/ARS.2009.2466; Eletto D, 2014, MOL CELL, V53, P562, DOI 10.1016/j.molcel.2014.01.004; D'Ambrosio K, 2006, J MOL BIOL, V362, P743, DOI 10.1016/j.jmb.2006.07.038; FREEDMAN RB, 1995, CURR OPIN STRUC BIOL, V5, P85, DOI 10.1016/0959-440X(95)80013-Q; Groenendyk J, 2014, SCI SIGNAL, V7, DOI 10.1126/scisignal.2004983; Hatahet F, 2007, FEBS J, V274, P5223, DOI 10.1111/j.1742-4658.2007.06058.x; Hoshijima K, 2002, GENE DEV, V16, P2518, DOI 10.1101/gad.1001302; Kikuchi M, 2002, J BIOCHEM, V132, P451; Kimura T, 2008, J BIOCHEM, V144, P187, DOI 10.1093/jb/mvn057; Onda Yayoi, 2013, Plant Signal Behav, V8, pe23075, DOI 10.4161/psb.23075; Pedone E., 2006, MOL BIOL, V356, P155; Pedone E, 2004, EUR J BIOCHEM, V271, P3437, DOI 10.1111/j.1432-1033.2004.04282.x; Toda Tosifusa, 1997, Japanese Journal of Electrophoresis, V41, P13; UEDA Y, 1993, GENE, V129, P129; van Lith M, 2005, J BIOL CHEM, V280, P1376, DOI 10.1074/jbc.M408651200; Wadahama H, 2008, FEBS J, V275, P399, DOI 10.1111/j.1742-4658.2007.06199.x; Zheng L, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh110	31	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	1570-9639	0006-3002		BBA-PROTEINS PROTEOM	BBA-Proteins Proteomics	MAY	2015	1854	5					485	491		10.1016/j.bbapap.2015.02.014		7	Biochemistry & Molecular Biology; Biophysics	Biochemistry & Molecular Biology; Biophysics	CG2FF	WOS:000353089600018		
J	Singh, SB; Kaelin, DE; Wu, J; Miesel, L; Tan, CM; Black, T; Nargund, R; Meinke, PT; Olsen, DB; Lagrutta, A; Lu, J; Patel, S; Rickert, KW; Smith, RF; Soisson, S; Sherer, E; Joyce, LA; Wei, CQ; Peng, XJ; Wang, X; Fukuda, H; Kishii, R; Takei, M; Takano, H; Shibasaki, M; Yajima, M; Nishimura, A; Shibata, T; Fukuda, Y				Singh, Sheo B.; Kaelin, David E.; Wu, Jin; Miesel, Lynn; Tan, Christopher M.; Black, Todd; Nargund, Ravi; Meinke, Peter T.; Olsen, David B.; Lagrutta, Armando; Lu, Jun; Patel, Sangita; Rickert, Keith W.; Smith, Robert F.; Soisson, Stephen; Sherer, Edward; Joyce, Leo A.; Wei, Changqing; Peng, Xuanjia; Wang, Xiu; Fukuda, Hideyuki; Kishii, Ryuta; Takei, Masaya; Takano, Hisashi; Shibasaki, Mitsuhito; Yajima, Masanobu; Nishimura, Akinori; Shibata, Takeshi; Fukuda, Yasumichi			Tricyclic 1,5-naphthyridinone oxabicyclooctane-linked novel bacterial topoisomerase inhibitors as broad-spectrum antibacterial agents-SAR of left-hand-side moiety (Part-2)	BIOORGANIC & MEDICINAL CHEMISTRY LETTERS			English	Article						Antibacterial; Broad-spectrum; Bacterial to poisomerase inhibitors; Gyrase inhibitors; ParC inhibitors; Tricyclic-1,5-naphthyridinone	IIA TOPOISOMERASES; POTENT INHIBITORS; DERIVATIVES	Novel bacterial topoisomerase inhibitors (NBTIs) represent a new class of broad-spectrum antibacterial agents targeting bacterial Gyrase A and ParC and have potential utility in combating antibiotic resistance. A series of novel oxabicyclooctane-linked NBTIs with new tricyclic-1,5-naphthyridinone left hand side moieties have been described. Compounds with a (R)-hydroxy-1,5-naphthyridinone moiety (7) showed potent antibacterial activity (e.g., Staphylococcus aureus MIC 0.25 mu g/mL), acceptable Gram-positive and Gram-negative spectrum with rapidly bactericidal activity. The compound 7 showed intravenous and oral efficacy (ED50) at 3.2 and 27 mg/kg doses, respectively, in a murine model of bacteremia. Most importantly they showed significant attenuation of functional hERG activity (IC50 > 170 mu M). In general, lower logD attenuated hERG activity but also reduced Gram-negative activity. The co-crystal structure of a hydroxy-tricyclic NBTI bound to a DNA-gyrase complex exhibited a binding mode that show enantiomeric preference for R isomer and explains the activity and SAR. The discovery, synthesis, SAR and X-ray crystal structure of the left-hand-side tricyclic 1,5-naphthyridinone based oxabicyclooctane linked NBTIs are described. (C) 2015 Elsevier Ltd. All rights reserved.	[Singh, Sheo B.; Kaelin, David E.; Wu, Jin; Miesel, Lynn; Tan, Christopher M.; Black, Todd; Nargund, Ravi] Merck Res Labs, Kenilworth, NJ 07033 USA; [Meinke, Peter T.; Sherer, Edward; Joyce, Leo A.] Merck Res Labs, Rahway, NJ 07065 USA; [Olsen, David B.; Lagrutta, Armando; Lu, Jun; Patel, Sangita; Rickert, Keith W.; Smith, Robert F.; Soisson, Stephen] Merck Res Labs, West Point, PA 19486 USA; [Wei, Changqing; Peng, Xuanjia; Wang, Xiu] WuXi AppTec, Shanghai, Peoples R China; [Fukuda, Hideyuki; Kishii, Ryuta; Takei, Masaya; Takano, Hisashi; Shibasaki, Mitsuhito; Yajima, Masanobu; Nishimura, Akinori; Shibata, Takeshi; Fukuda, Yasumichi] Kyorin Pharmaceut Co Ltd, Nogi, Tochigi 3290114, Japan	Singh, SB (reprint author), SBS Pharma Consulting LLC, Edison, NJ 08820 USA.	sheo.singh.215@gmail.com; yasumichi.fukuda@gmail.com					Miles TJ, 2013, BIOORG MED CHEM LETT, V23, P5437, DOI 10.1016/j.bmcl.2013.07.013; Klevens RM, 2007, JAMA-J AM MED ASSOC, V298, P1763, DOI 10.1001/jama.298.15.1763; Black MT, 2008, ANTIMICROB AGENTS CH, V52, P3339, DOI 10.1128/AAC.00496-08; Mitton-Fry MJ, 2013, BIOORG MED CHEM LETT, V23, P2955, DOI 10.1016/j.bmcl.2013.03.047; Miles TJ, 2011, BIOORG MED CHEM LETT, V21, P7483, DOI 10.1016/j.bmcl.2011.09.114; Reck F, 2011, J MED CHEM, V54, P7834, DOI 10.1021/jm2008826; Gomez L, 2007, BIOORG MED CHEM LETT, V17, P2723, DOI 10.1016/j.bmcl.2007.03.003; Bax BD, 2010, NATURE, V466, P935, DOI 10.1038/nature09197; Mayer C, 2014, CHEM REV, V114, P2313, DOI 10.1021/cr4003984; Zhanel GG, 2010, ANTIMICROB AGENTS CH, V54, P4684, DOI 10.1128/AAC.00469-10; Reck F, 2012, J MED CHEM, V55, P6916, DOI 10.1021/jm300690s; Black MT, 2009, CURR OPIN INVEST DR, V10, P804; Singh SB, 2014, ACS MED CHEM LETT, V5, P609, DOI 10.1021/ml500069w; Miles TJ, 2011, BIOORG MED CHEM LETT, V21, P7489, DOI 10.1016/j.bmcl.2011.09.117; Wiener JJM, 2007, BIOORG MED CHEM LETT, V17, P2718, DOI 10.1016/j.bmcl.2007.03.004; Bisacchi GS, 2009, ANNU REP MED CHEM, V44, P379, DOI 10.1016/S0065-7743(09)04419-4; Sherer EC, 2014, J MED CHEM, V57, P477, DOI 10.1021/jm401600u	17	3	3	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0960-894X	1464-3405		BIOORG MED CHEM LETT	Bioorg. Med. Chem. Lett.	MAY 1	2015	25	9					1831	1835		10.1016/j.bmcl.2015.03.044		5	Chemistry, Medicinal; Chemistry, Organic	Pharmacology & Pharmacy; Chemistry	CG3UL	WOS:000353205000003		
J	Chiba, M; Fujimoto, C; Sakai, R; Oikawa, M				Chiba, Manami; Fujimoto, Chikako; Sakai, Ryuichi; Oikawa, Masato			Structure-activity relationships of IKM-159: Diverted synthesis and biological evaluation of a series of C5-oxy analogs	BIOORGANIC & MEDICINAL CHEMISTRY LETTERS			English	Article						Diverted synthesis; Ionotropic glutamate receptor; Glutamate analogs; Domino metathesis reaction; Anti-Wacker reaction	REGIOSELECTIVE DOMINO METATHESIS; OXIDATIVE CYCLIZATION; GLUTAMATE ANALOGS; 7-OXANORBORNENES; ALDEHYDES	Ligands for neuronal receptors are important for understanding the biological functions as well as for treatment of neuronal diseases associated with. Here, we report diverted synthesis and biological evaluation of four C-ring analogs of IKM-159, a subtype-selective inhibitor for (S)-2-amino-3-(3-hydroxy-5-methyl-4-isoxazolyl) propionic acid (AMPA)-type ionotropic glutamate receptor. Starting from iodinated 7-oxanorbornene 7, those analogs 3-6 were successfully synthesized in 7.0-33% yields over 8-11 steps via a common intermediate 13. Intracerebroventricular injection of those analogs on mice showed that introduction of oxo group on the C-ring (analogs 4, 5) or cleavage of the C-ring (analog 6) caused significant loss of the activity, while the ether analog 3 still retain the suppressed motor activity, indicating the importance of the C-ring in the neuronal activity of IKM-159. (C) 2015 Elsevier Ltd. All rights reserved.	[Chiba, Manami; Fujimoto, Chikako; Oikawa, Masato] Yokohama City Univ, Kanazawa Ku, Yokohama, Kanagawa 2360027, Japan; [Sakai, Ryuichi] Hokkaido Univ, Fac Fisheries Sci, Hakodate, Hokkaido 0418611, Japan	Oikawa, M (reprint author), Yokohama City Univ, Kanazawa Ku, Seto 22-2, Yokohama, Kanagawa 2360027, Japan.	moikawa@yokohama-cu.ac.jp	Oikawa, Masato/E-9411-2010	Oikawa, Masato/0000-0002-3919-811X	Ministry of Education, Science, Sports, Culture and Technology, Japan [26282216]	Financial support (a Grant-in-Aid for Scientific Research (26282216)) from the Ministry of Education, Science, Sports, Culture and Technology, Japan, is gratefully acknowledged.	Ikoma M, 2008, TETRAHEDRON, V64, P2740, DOI 10.1016/j.tet.2008.01.067; Krishnudu K, 1996, TETRAHEDRON LETT, V37, P6007, DOI 10.1016/0040-4039(96)01261-0; DALCANALE E, 1986, J ORG CHEM, V51, P567, DOI 10.1021/jo00354a037; BAL BS, 1981, TETRAHEDRON, V37, P2091, DOI 10.1016/S0040-4020(01)97963-3; Riedel G, 2003, BEHAV BRAIN RES, V140, P1, DOI 10.1016/S0166-4328(02)00272-3; Banda G, 2006, TETRAHEDRON-ASYMMETR, V17, P1684, DOI 10.1016/j.tetasy.2006.06.012; Gill MB, 2010, BRIT J PHARMACOL, V160, P1417, DOI 10.1111/j.1476-5381.2010.00784.x; Ikoma M, 2008, EUR J ORG CHEM, P5215, DOI 10.1002/ejoc.200800704; Juknaite L, 2013, J MED CHEM, V56, P2283, DOI 10.1021/jm301590z; KRAUS GA, 1980, J ORG CHEM, V45, P1175, DOI 10.1021/jo01294a058; LINZ G, 1989, TETRAHEDRON LETT, V30, P5599, DOI 10.1016/S0040-4039(01)93809-2; Louie J, 2002, ORGANOMETALLICS, V21, P2153, DOI 10.1021/om011037a; Mereyala HB, 1997, J CHEM SOC PERK T 1, P3567, DOI 10.1039/a703905k; Oikawa M, 2009, EUR J ORG CHEM, P5531, DOI 10.1002/ejoc.200900580; Oikawa M, 2010, BIOORGAN MED CHEM, V18, P3795, DOI 10.1016/j.bmc.2010.04.044; Oikawa M, 2013, SYNTHESIS-STUTTGART, V45, P3106, DOI 10.1055/s-0033-1338543; Zhan Z.-Y., 2007, PCT WO, Patent No. [2007/003135A1, 2007003135]	17	0	0	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0960-894X	1464-3405		BIOORG MED CHEM LETT	Bioorg. Med. Chem. Lett.	MAY 1	2015	25	9					1869	1871		10.1016/j.bmcl.2015.03.037		3	Chemistry, Medicinal; Chemistry, Organic	Pharmacology & Pharmacy; Chemistry	CG3UL	WOS:000353205000009		
J	Sakudo, A; Chou, H; Ikuta, K; Nagatsu, M				Sakudo, Akikazu; Chou, Han; Ikuta, Kazuyoshi; Nagatsu, Masaaki			Integration of antibody by surface functionalization of graphite-encapsulated magnetic beads using ammonia gas plasma technology for capturing influenza A virus	BIOORGANIC & MEDICINAL CHEMISTRY LETTERS			English	Article						Influenza virus; Capture; Gas plasma; Amino group; Magnetic beads	IMMOBILIZATION; NANOPARTICLES; PARTICLES; PCR	Antibody-integrated magnetic beads have been functionalized for influenza A virus capture. First, ammonia plasma produced by a radio frequency power source was reacted with the surface of graphite-encapsulated magnetic beads to introduce amino groups. Anti-influenza A virus hemagglutinin antibody was then anchored by its surface sulfide groups to the amino groups on the beads via N-succinimidyl 3-(2-pyridyldithio) propionate. After incubation with influenza A virus, adsorption of the virus to the beads was confirmed by immunochromatography, polymerase chain reaction (PCR), enzyme-linked immunosorbent assay (ELISA), and inoculation of chicken embryonated eggs, indicating that virus infectivity is maintained and that the proposed method is useful for the enhanced detection and isolation of influenza A virus. (C) 2015 Elsevier Ltd. All rights reserved.	[Sakudo, Akikazu] Univ Ryukyus, Fac Med, Sch Hlth Sci, Lab Biometabol Chem, Nishihara, Okinawa 9030215, Japan; [Chou, Han; Nagatsu, Masaaki] Shizuoka Univ, Grad Sch Engn, Naka Ku, Hamamatsu, Shizuoka 4328561, Japan; [Ikuta, Kazuyoshi] Osaka Univ, Res Fdn Microbial Dis, Kanonji Inst, Kanonji, Kagawa, Japan; [Nagatsu, Masaaki] Shizuoka Univ, Grad Sch Sci & Technol, Naka Ku, Hamamatsu, Shizuoka 4328561, Japan	Sakudo, A (reprint author), Univ Ryukyus, Fac Med, Sch Hlth Sci, Lab Biometabol Chem, 207 Uehara, Nishihara, Okinawa 9030215, Japan.	sakudo@med.u-ryukyu.ac.jp			Bio-oriented Technology Research Advancement Institution (BRAIN); Science and Technology Research Promotion Program for Agriculture, Forestry, Fisheries and Food Industry; Kieikai Research Foundation; Japan Society for the Promotion of Science [21110010, 22110514, 24110717, 25246029]	This work was supported by a Grant-in-Aid for the Promotion of Basic Research Activities for Innovative Biosciences from the Bio-oriented Technology Research Advancement Institution (BRAIN), the Science and Technology Research Promotion Program for Agriculture, Forestry, Fisheries and Food Industry, and a Grant-in-Aid from Kieikai Research Foundation as well as a Grant-in-Aid for Scientific Research (No. 21110010, 22110514, 24110717, and 25246029) from the Japan Society for the Promotion of Science.	PLAPP BV, 1971, J BIOL CHEM, V246, P939; OKUNO Y, 1993, J VIROL, V67, P2552; Poplawska M, 2014, CARBON, V74, P180, DOI 10.1016/j.carbon.2014.03.022; Nagatsu M, 2006, CARBON, V44, P3336, DOI 10.1016/j.carbon.2006.06.005; Chen XW, 2006, TALANTA, V69, P681, DOI 10.1016/j.talanta.2005.11.001; Dwyer DE, 2006, MED J AUSTRALIA, V185, pS48; HAMELIN C, 1979, J GEN VIROL, V42, P193, DOI 10.1099/0022-1317-42-1-193; Nicholson KG, 1998, TXB INFLUENZA; NOVOTNY J, 1992, ACTA VIROL, V36, P483; Palese P., 2006, FIELDS VIROLOGY, P1647; Roth WK, 1999, LANCET, V353, P359, DOI 10.1016/S0140-6736(98)06318-1; SAITO Y, 1993, CHEM PHYS LETT, V212, P379, DOI 10.1016/0009-2614(93)89341-E; Sakudo A., 2015, BIOORG MED CHEM LETT, V1018, P25; Saraswati T. E., 2014, JPN J APPL PHYS, V53, P1; Saraswati TE, 2012, CARBON, V50, P1253, DOI 10.1016/j.carbon.2011.10.044; Spackman Erica, 2008, V436, P1, DOI 10.1007/978-1-59745-279-3_1; Vabret A, 2000, J CLIN VIROL, V17, P167, DOI 10.1016/S1386-6532(00)00095-0	17	0	0	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0960-894X	1464-3405		BIOORG MED CHEM LETT	Bioorg. Med. Chem. Lett.	MAY 1	2015	25	9					1876	1879		10.1016/j.bmcl.2015.03.036		4	Chemistry, Medicinal; Chemistry, Organic	Pharmacology & Pharmacy; Chemistry	CG3UL	WOS:000353205000011		
J	Endo, Y; Kawai, K; Asano, T; Amano, S; Asanuma, Y; Sawada, K; Onodera, Y; Ueo, N; Takahashi, N; Sonoda, Y; Kamei, N; Irie, T				Endo, Yusuke; Kawai, Kentaro; Asano, Takeshi; Amano, Seiji; Asanuma, Yoshihito; Sawada, Keisuke; Onodera, Yuuta; Ueo, Noriko; Takahashi, Nobuaki; Sonoda, Yo; Kamei, Noriyuki; Irie, Tetsumi			2-(Isopropylamino)thieno[3,2-d]pyrimidin-4(3H)-one derivatives as selective phosphodiesterase 7 inhibitors with potent in vivo efficacy	BIOORGANIC & MEDICINAL CHEMISTRY LETTERS			English	Article						Phosphodiesterase; Thienopyrimidinone; T-cell; Aqueous solubility; Anti-inflammation	DRUG DISCOVERY; EFFICIENCY	A new series of thienopyrimidinones is synthesized and evaluated as selective phosphodiesterase 7 (PDE7) inhibitors for the treatment of inflammatory diseases. The modification of the substituents on thienopyrimidinone revealed that an isopropylamino group at the 2-position was favorable for aqueous solubility. The introduction of 3-pyrrolidines at the 7-position resulted in good solubility, highly potent activity, and good PDE7 selectivity. Among the synthesized compounds, compound 46 exhibited the greatest inhibition of ear edema in a phorbol ester-induced mouse model. (C) 2015 Elsevier Ltd. All rights reserved.	[Endo, Yusuke; Kawai, Kentaro; Asano, Takeshi; Amano, Seiji; Asanuma, Yoshihito; Sawada, Keisuke; Onodera, Yuuta; Ueo, Noriko; Takahashi, Nobuaki; Sonoda, Yo; Kamei, Noriyuki] Kaken Pharmaceut Co Ltd, Drug Res Ctr, Yamashina Ku, Kyoto 6078042, Japan; [Irie, Tetsumi] Kumamoto Univ, Dept Clin Chem & Informat, Chuo Ku, Kumamoto 8620973, Japan	Endo, Y (reprint author), Kaken Pharmaceut Co Ltd, Drug Res Ctr, Yamashina Ku, 14 Shinomiya Minamigawara Cho, Kyoto 6078042, Japan.	endo_yusuke@kaken.co.jp					Barluenga J, 2011, ANGEW CHEM INT EDIT, V50, P7486, DOI 10.1002/anie.201007961; Abad-Zapatero C, 2005, DRUG DISCOV TODAY, V10, P464, DOI 10.1016/S1359-6446(05)03386-6; Kawai K, 2014, J MED CHEM, V57, P9844, DOI 10.1021/jm5008215; Reynolds CH, 2008, J MED CHEM, V51, P2432, DOI 10.1021/jm701255b; Ishikawa M, 2011, J MED CHEM, V54, P1539, DOI 10.1021/jm101356p; Goto M, 2010, EUR J PHARMACOL, V633, P93, DOI 10.1016/j.ejphar.2010.01.024; Houslay MD, 2005, DRUG DISCOV TODAY, V10, P1503, DOI 10.1016/S1359-6446(05)03622-6; DeNinno MP, 2012, BIOORG MED CHEM LETT, V22, P6794, DOI 10.1016/j.bmcl.2012.09.028; Endo Y., 2015, MED CHEM LETT, V25, P649; Lee R, 2002, CELL SIGNAL, V14, P277, DOI 10.1016/S0898-6568(01)00250-9; Li LS, 1999, SCIENCE, V283, P848, DOI 10.1126/science.283.5403.848; Walker MA, 2014, EXPERT OPIN DRUG DIS, V9, P1421, DOI 10.1517/17460441.2014.960839	12	0	0	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0960-894X	1464-3405		BIOORG MED CHEM LETT	Bioorg. Med. Chem. Lett.	MAY 1	2015	25	9					1910	1914		10.1016/j.bmcl.2015.03.031		5	Chemistry, Medicinal; Chemistry, Organic	Pharmacology & Pharmacy; Chemistry	CG3UL	WOS:000353205000018		
J	Kakizawa, T; Ota, Y; Itoh, Y; Tsumoto, H; Suzuki, T				Kakizawa, Taeko; Ota, Yosuke; Itoh, Yukihiro; Tsumoto, Hiroki; Suzuki, Takayoshi			Histone H3 peptide based LSD1-selective inhibitors	BIOORGANIC & MEDICINAL CHEMISTRY LETTERS			English	Article						Histone H3; Peptide; Lysine-specific demethylase 1 (LSD1); Inhibitor	DEMETHYLASE LSD1; METHYLATION; INACTIVATOR; MECHANISM; OXIDASE	A series of candidates for the histone H3 peptide based LSD1-selective inhibitor were designed and synthesized. Among peptides 1a-c and 2a-c, peptide 1a, which has a phenylcyclopropylamine (PCPA) moiety at Lys-4 of the 21 amino acid residues of histone H3, was the most potent LSD1-selective inhibitor. Truncation studies of peptide 1a revealed the significance of the peptide sequence length. These findings will be useful for the further development of histone H3 peptide based LSD1-selective inhibitors. (C) 2015 Elsevier Ltd. All rights reserved.	[Kakizawa, Taeko] Waseda Univ, Sch Adv Sci & Engn, Dept Chem & Biochem, Shinjuku Ku, Tokyo 1698555, Japan; [Ota, Yosuke; Itoh, Yukihiro; Suzuki, Takayoshi] Kyoto Prefectural Univ Med, Grad Sch Med Sci, Sakyo Ku, Kyoto 6060823, Japan; [Tsumoto, Hiroki] Tokyo Metropolitan Inst Gerontol, Res Team Mech Aging, Itabashi Ku, Tokyo 1730015, Japan; [Suzuki, Takayoshi] Japan Sci & Technol Agcy JST, CREST, Kawaguchi, Saitama 3320012, Japan	Suzuki, T (reprint author), Kyoto Prefectural Univ Med, Grad Sch Med Sci, Sakyo Ku, 1-5 Shimogamohangi Cho, Kyoto 6060823, Japan.	suzukit@koto.kpu-m.ac.jp			Waseda University Grant for Special Research Projects [2014K-6139]; JST CREST Program; Takeda Science Foundation; Terumo Life Science Foundation; Mochida Memorial Foundation for Medical and Pharmaceutical Research; MEXT (Ministry of Education, Culture, Sports, Science and Technology) [26460159]	We thank Professor Takaki Koide and Dr. Miki Suzuki for technical support. This work is supported in part by a Grant-in-Aid for Scientific Research (T.K.; C, 26460159) from MEXT (The Ministry of Education, Culture, Sports, Science and Technology), Waseda University Grant for Special Research Projects (T.K.; project number 2014K-6139), JST CREST Program (T.S.),Takeda Science Foundation (T.S.), Terumo Life Science Foundation (T.S.), and Mochida Memorial Foundation for Medical and Pharmaceutical Research (T.S.).	Suzuki T, 2011, J MED CHEM, V54, P8236, DOI 10.1021/jm201048w; Kontaki H, 2010, MOL CELL, V39, P152, DOI 10.1016/j.molcel.2010.06.006; Tsukada Y, 2006, NATURE, V439, P811, DOI 10.1038/nature04433; Schulte JH, 2009, CANCER RES, V69, P2065, DOI 10.1158/0008-5472.CAN-08-1735; Shi YJ, 2004, CELL, V119, P941, DOI 10.1016/j.cell.2004.12.012; Wichitnithad W, 2011, BIOORGAN MED CHEM, V19, P7482, DOI 10.1016/j.bmc.2011.10.038; Itoh Y, 2013, MOL BIOSYST, V9, P873, DOI 10.1039/c3mb25410k; Shi LH, 2013, NAT MED, V19, P291, DOI 10.1038/nm.3101; Culhane JC, 2006, J AM CHEM SOC, V128, P4536, DOI 10.1021/ja0602748; Schenk T, 2012, NAT MED, V18, P605, DOI 10.1038/nm.2661; Culhane JC, 2010, J AM CHEM SOC, V132, P3164, DOI 10.1021/ja909996p; Szewczuk LM, 2007, BIOCHEMISTRY-US, V46, P6892, DOI 10.1021/bi700414b; Metzger E, 2005, NATURE, V437, P436, DOI 10.1038/nature04020; Ogasawara D, 2013, ANGEW CHEM INT EDIT, V52, P8620, DOI 10.1002/anie.201303999; Yang JB, 2010, P NATL ACAD SCI USA, V107, P21499, DOI 10.1073/pnas.1016147107; Liang Y, 2009, NAT MED, V15, P1312, DOI 10.1038/nm.2051; Jing H., 2007, NATURE, V449, P105; Jing W., 2009, NAT GENET, V41, P125; Yang MJ, 2007, NAT STRUCT MOL BIOL, V14, P535, DOI 10.1038/nsmb1255	19	0	0	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0960-894X	1464-3405		BIOORG MED CHEM LETT	Bioorg. Med. Chem. Lett.	MAY 1	2015	25	9					1925	1928		10.1016/j.bmcl.2015.03.030		4	Chemistry, Medicinal; Chemistry, Organic	Pharmacology & Pharmacy; Chemistry	CG3UL	WOS:000353205000021		
J	Sasaki, T; Li, W; Higai, K; Koike, K				Sasaki, Tatsunori; Li, Wei; Higai, Koji; Koike, Kazuo			Canthinone alkaloids are novel protein tyrosine phosphatase 1B inhibitors	BIOORGANIC & MEDICINAL CHEMISTRY LETTERS			English	Article						Protein tyrosine phosphatase 1B; Canthinone; Picrasidine L; Diabetes	PTP1B; FLAVONOIDS; OBESITY	Considerable attention has been paid to protein tyrosine phosphatase 1B (PTP1B) inhibitors as a potential therapy for diabetes. Screening of a natural compound library resulted in six canthinone alkaloids, namely, picrasidine L (1), 3,4-dimethyl-canthin-5,6-dione (2), 4-ethyl-3-methyl-canthin-5,6-dione (3), eurycomine E (4), 5-methoxy-canthin-6-one (5), and 5-acethoxy-canthin-6-one (6), as novel PTP1B inhibitors. Among these, 1 is the competitive PTP1B inhibitor with the best inhibitory selectivity between PTP1B and other PTPs and was shown to promote activity in the insulin signaling pathway in cell-based assays. Molecular docking simulations and structure-activity relationship analysis of 1 will add to its potential as a lead compound in future anti-insulin-resistant drug developments. (C) 2015 Elsevier Ltd. All rights reserved.	[Sasaki, Tatsunori; Li, Wei; Higai, Koji; Koike, Kazuo] Toho Univ, Fac Pharmaceut Sci, Funabashi, Chiba 2748510, Japan	Li, W (reprint author), Toho Univ, Fac Pharmaceut Sci, Miyama 2-2-1, Funabashi, Chiba 2748510, Japan.	liwei@phar.toho-u.ac.jp			Ministry of Education, Culture, Sports, Science and Technology of Japan [23790025]; Sasakawa Scientific Research Grant from The Japan Science Society [25-316]	The research was partially supported by a Grant-in-Aid for Young Scientists (B) (No. 23790025) from the Ministry of Education, Culture, Sports, Science and Technology of Japan, and the Sasakawa Scientific Research Grant (No. 25-316) from The Japan Science Society.	Li W, 2013, BIOORG MED CHEM LETT, V23, P5836, DOI 10.1016/j.bmcl.2013.08.102; Yip SC, 2010, TRENDS BIOCHEM SCI, V35, P442, DOI 10.1016/j.tibs.2010.03.004; Zhang S, 2007, DRUG DISCOV TODAY, V12, P373, DOI 10.1016/j.drudis.2007.03.011; Li SP, 2010, BIOORG MED CHEM LETT, V20, P5398, DOI 10.1016/j.bmcl.2010.07.110; Tonks NK, 2003, FEBS LETT, V546, P140, DOI 10.1016/S0014-5793(03)00603-3; Kennedy BP, 1999, BIOMED PHARMACOTHER, V53, P466, DOI 10.1016/S0753-3322(00)88105-6; Zhang ZY, 2002, ANNU REV PHARMACOL, V42, P209, DOI 10.1146/annurev.pharmtox.42.083001.144616; Elchebly M, 1999, SCIENCE, V283, P1544, DOI 10.1126/science.283.5407.1544; Jiang CS, 2012, ACTA PHARMACOL SIN, V33, P1217, DOI 10.1038/aps.2012.90; Taylor SD, 2004, EXPERT OPIN INV DRUG, V13, P199, DOI 10.1517/eoid.13.3.199.27347; Sasaki T, 2011, CHEM PHARM BULL, V59, P1396, DOI 10.1248/cpb.59.1396; Byon C. H. J., 1998, J MOL CELL BIOCH, V182, P101; Sasaki T, 2014, PLANTA MED, V80, P557, DOI 10.1055/s-0034-1368400; Tabernero L, 2008, FEBS J, V275, P867, DOI 10.1111/j.1742-4658.2008.06251.x	14	3	3	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0960-894X	1464-3405		BIOORG MED CHEM LETT	Bioorg. Med. Chem. Lett.	MAY 1	2015	25	9					1979	1981		10.1016/j.bmcl.2015.03.014		3	Chemistry, Medicinal; Chemistry, Organic	Pharmacology & Pharmacy; Chemistry	CG3UL	WOS:000353205000032		
J	Nakashima, K; Tanaka, T; Murata, H; Kaburagi, K; Inoue, M				Nakashima, Ken-ichi; Tanaka, Toshiyuki; Murata, Hiroko; Kaburagi, Kouichi; Inoue, Makoto			Xanthones from the roots of Maclura cochinchinensis var. gerontogea and their retinoic acid receptor-alpha agonistic activity	BIOORGANIC & MEDICINAL CHEMISTRY LETTERS			English	Article						Maclura cochinchinensis var. gerontogea; Moraceae; Xanthone; Retinoic acid receptor-alpha; Bioactive natural compound	RESCUES MEMORY DEFICITS; CUDRANIA-COCHINCHINENSIS; ISOPRENYLATED XANTHONES; MORACEAE PLANTS; ALZHEIMERS-DISEASE; MOUSE MODEL; BARK; CONSTITUENTS; COMPONENTS; TRICUSPIDATA	A new xanthone (1) and a new naturally occurring xanthone (2) were isolated from the roots of Maclura cochinchinensis (Lour.) Corner var. gerontogea (Sieb. et Zucc.) Ohashi together with 10 known xanthones (3-12). Their structures were established by spectroscopic analyses including 1D and 2D NMR. Their retinoic acid receptor-alpha agonistic activity was evaluated using a luciferase reporter assay. Compound 2, gerontoxanthone A (3), gerontoxanthone B (4), and cudraxanthone I (11) showed moderate concentration- dependent activity. Furthermore, these four xanthones synergistically increased transcriptional activity in this assay in the presence of bexarotene, an RXR agonist. (C) 2015 Elsevier Ltd. All rights reserved.	[Nakashima, Ken-ichi; Inoue, Makoto] Aichi Gakuin Univ, Sch Pharm, Lab Med Resources, Chikusa Ku, Nagoya, Aichi 4648650, Japan; [Tanaka, Toshiyuki] Gifu Pharmaceut Univ, Lab Nat Resources, Gifu, Gifu 5011196, Japan; [Murata, Hiroko] Setsunan Univ, Fac Pharmaceut Sci, Hirakata, Osaka 5730101, Japan	Inoue, M (reprint author), Aichi Gakuin Univ, Sch Pharm, Lab Med Resources, Chikusa Ku, 1-100 Kusumoto Cho, Nagoya, Aichi 4648650, Japan.	minoue@dpc.aichi-gakuin.ac.jp	Tanaka, Toshiyuki/C-6827-2014				Ding Y, 2008, J NEUROSCI, V28, P11622, DOI 10.1523/JNEUROSCI.3153-08.2008; Obulesu M, 2011, NEUROCHEM INT, V59, P535, DOI 10.1016/j.neuint.2011.04.004; Matsumoto A, 2007, BIOCHEM PHARMACOL, V74, P256, DOI 10.1016/j.bcp.2007.04.014; Tanabe H, 2014, BIOORGAN MED CHEM, V22, P3204, DOI 10.1016/j.bmc.2014.03.047; Peres V, 2000, PHYTOCHEMISTRY, V55, P683, DOI 10.1016/S0031-9422(00)00303-4; Botling J, 1997, J BIOL CHEM, V272, P9443; CHANG CH, 1989, PHYTOCHEMISTRY, V28, P595, DOI 10.1016/0031-9422(89)80058-5; CHANG CH, 1995, PHYTOCHEMISTRY, V40, P945, DOI 10.1016/0031-9422(95)00277-E; HANO Y, 1990, HETEROCYCLES, V31, P1345; HANO Y, 1990, PLANTA MED, V56, P478, DOI 10.1055/s-2006-961016; HANO Y, 1991, PLANTA MED, V57, P172, DOI 10.1055/s-2006-960059; Hou AJ, 2001, J NAT PROD, V64, P65, DOI 10.1021/np000406p; Inoue M, 2014, J NAT PROD, V77, P1670, DOI 10.1021/np5002016; Kobayashi M, 1997, CHEM PHARM BULL, V45, P1615; Lin CC, 1999, AM J CHINESE MED, V27, P227, DOI 10.1142/S0192415X99000264; MESQUITA AA, 1968, ANAL CHIM ACTA, V42, P311; MURTI VVS, 1972, PHYTOCHEMISTRY, V11, P2089, DOI 10.1016/S0031-9422(00)90178-X; Nakashima K, 2014, BBA-GEN SUBJECTS, V1840, P3034, DOI 10.1016/j.bbagen.2014.06.011; Nakashima K, 2011, HETEROCYCLES, V83, P1603, DOI 10.3987/COM-11-12228; Sodhi RK, 2013, PROG NEURO-PSYCHOPH, V40, P38, DOI 10.1016/j.pnpbp.2012.09.012; Wang CJ, 2013, J BIOMED SCI, V20, DOI 10.1186/1423-0127-20-55	21	0	0	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0960-894X	1464-3405		BIOORG MED CHEM LETT	Bioorg. Med. Chem. Lett.	MAY 1	2015	25	9					1998	2001		10.1016/j.bmcl.2015.02.075		4	Chemistry, Medicinal; Chemistry, Organic	Pharmacology & Pharmacy; Chemistry	CG3UL	WOS:000353205000037		
J	Ishioka, J; Saito, K; Kijima, T; Nakanishi, Y; Yoshida, S; Yokoyama, M; Matsuoka, Y; Numao, N; Koga, F; Masuda, H; Fujii, Y; Sakai, Y; Arisawa, C; Okuno, T; Nagahama, K; Kamata, S; Sakura, M; Yonese, J; Morimoto, S; Noro, A; Tsujii, T; Kitahara, S; Gotoh, S; Higashi, Y; Kihara, K				Ishioka, Junichiro; Saito, Kazutaka; Kijima, Toshiki; Nakanishi, Yasukazu; Yoshida, Soichiro; Yokoyama, Minato; Matsuoka, Yoh; Numao, Noboru; Koga, Fumitaka; Masuda, Hitoshi; Fujii, Yasuhisa; Sakai, Yasuyuki; Arisawa, Chizuru; Okuno, Tetsuo; Nagahama, Katsuhi; Kamata, Shigeyoshi; Sakura, Mizuaki; Yonese, Junji; Morimoto, Shinji; Noro, Akira; Tsujii, Toshihiko; Kitahara, Satoshi; Gotoh, Shuichi; Higashi, Yotsuo; Kihara, Kazunori			Risk stratification for bladder recurrence of upper urinary tract urothelial carcinoma after radical nephroureterectomy	BJU INTERNATIONAL			English	Article						upper tract urothelial carcinoma; radical nephroureterectomy; bladder recurrence	TRANSITIONAL-CELL CARCINOMA; DECISION CURVE ANALYSIS; INTRAVESICAL RECURRENCE; PREDICTION MODELS; COMPETING RISK; CANCER; MULTICENTER; PROGRESSION; PROGNOSIS; ORIGIN	Objectives To identify risk factors and develop a model for predicting recurrence of upper urinary tract urothelial carcinoma (UTUC) in the bladder in patients without a history of bladder cancer after radical nephroureterectomy (RNU). Patients and Methods We retrospectively reviewed 754 patients with UTUC without prior or concurrent bladder cancer or distant metastasis at 13 institutions in Japan. Univariate and multivariate Fine and Gray competing risks proportional hazards models were used to examine the cumulative incidence of bladder recurrence of UTUC. A risk stratification model and a nomogram were constructed. Two prediction models were compared using the concordance index (c-index) focusing on predictive accuracy and decision-curve analysis, which indicate whether a model is appropriate for decision-making and determining subsequent patient prognosis. Results The cumulative incidence rates of bladder UTUC recurrence at 1 and 5 years were 15 and 29%, respectively; the median time to bladder UTUC recurrence was 10 months. Multivariate analysis showed that papillary tumour architecture, absence of lymphovascular invasion and higher pathological T stage were both predictive factors for bladder cancer recurrence. The predictive accuracy of the risk stratification model and the nomogram for bladder cancer recurrence were not different (c-index: 0.60 and 0.62). According to the decision-curve analysis, the risk stratification was an acceptable model because the net benefit of the risk stratification was equivalent to that of the nomogram. The overall cumulative incidence rates of bladder cancer 5 years after RNU were 10, 26 and 44% in the low-, intermediate-and high-risk groups, respectively. Conclusions We identified risk factors and developed a risk stratification model for UTUC recurrence in the bladder after RNU. This model could be used to provide both an individualised strategy to prevent recurrence and a risk-stratified surveillance protocol.	[Ishioka, Junichiro; Saito, Kazutaka; Kijima, Toshiki; Nakanishi, Yasukazu; Yoshida, Soichiro; Yokoyama, Minato; Matsuoka, Yoh; Numao, Noboru; Koga, Fumitaka; Masuda, Hitoshi; Fujii, Yasuhisa; Tsujii, Toshihiko; Kihara, Kazunori] Tokyo Med & Dent Univ, Grad Sch, Dept Urol, Tokyo 1138519, Japan; [Sakai, Yasuyuki] Natl Canc Ctr Hosp East, Dept Urol, Chiba, Japan; [Arisawa, Chizuru] East Tokyo Metropolitan Hosp, Dept Urol, Tokyo, Japan; [Okuno, Tetsuo] JA Toride Med Ctr, Dept Urol, Ibaraki, Japan; [Nagahama, Katsuhi] Kounodai Hosp, Natl Ctr Global Hlth & Med, Dept Urol, Chiba, Japan; [Kamata, Shigeyoshi] Soka Municipal Hosp, Dept Urol, Saitama, Japan; [Sakura, Mizuaki; Yonese, Junji] Japanese Fdn Canc Res, Canc Inst Hosp, Dept Urol, Tokyo, Japan; [Morimoto, Shinji] Tsuchiura Kyodo Gen Hosp, Dept Urol, Ibaraki, Japan; [Noro, Akira] Saitama Red Cross Hosp, Dept Urol, Saitama, Japan; [Tsujii, Toshihiko] Tokyo Metropolitan Otsuka Hosp, Dept Urol, Tokyo, Japan; [Kitahara, Satoshi] Tama Nanbu Chiiki Hosp, Dept Urol, Tokyo, Japan; [Gotoh, Shuichi] Hamamatsu Med Ctr, Dept Urol, Shizuoka, Japan; [Higashi, Yotsuo] Saitama Canc Ctr, Dept Urol, Saitama, Japan	Ishioka, J (reprint author), Tokyo Med & Dent Univ, Grad Sch, Dept Urol, Bunkyo Ku, 1-5-45 Yushima, Tokyo 1138519, Japan.	ishiuro@tmd.ac.jp			Sony Corporation (Tokyo, Japan)	K. K. received research funding from Sony Corporation (Tokyo, Japan), but the sponsor had no control over the interpretation, writing, or publication of this work. All the other authors have no conflict of interest to declare.	O'Brien T, 2011, EUR UROL, V60, P703, DOI 10.1016/j.eururo.2011.05.064; Xylinas E, 2013, WORLD J UROL, V31, P61, DOI 10.1007/s00345-012-0957-3; Fritsche HM, 2012, UROL ONCOL-SEMIN ORI, V30, P666, DOI 10.1016/j.urolonc.2010.07.010; Kikuchi E, 2009, J CLIN ONCOL, V27, P612, DOI 10.1200/JCO.2008.17.2361; Vickers AJ, 2006, MED DECIS MAKING, V26, P565, DOI 10.1177/0272989X06295361; Hernandez V, 2011, WORLD J UROL, V29, P409, DOI 10.1007/s00345-010-0635-2; Habuchi T, 2005, INT J UROL, V12, P709, DOI 10.1111/j.1442-2042.2005.01155.x; Sylvester RJ, 2006, EUR UROL, V49, P466, DOI 10.1016/j.eururo.2005.12.031; Kauffman EC, 2008, EXPERT REV ANTICANC, V8, P75, DOI 10.1586/14737140.8.1.75; Novara G, 2008, BJU INT, V101, P1368, DOI 10.1111/j.1464-410X.2008.07438.x; Kusuda Y, 2013, UROL ONCOL-SEMIN ORI, V31, P899, DOI 10.1016/j.urolonc.2011.06.014; Southern DA, 2006, J CLIN EPIDEMIOL, V59, P1110, DOI 10.1016/j.jclinepi.2006.07.002; Pieras E, 2010, BJU INT, V106, P1319, DOI 10.1111/j.1464-410X.2010.09341.x; Fernandez-Gomez J, 2011, EUR UROL, V60, P423, DOI 10.1016/j.eururo.2011.05.033; Kamihira O, 2009, EUR UROL, V55, P1397, DOI 10.1016/j.eururo.2009.03.003; Saito K, 2007, J UROLOGY, V178, P2291, DOI 10.1016/j.juro.2007.08.019; Huang WW, 2009, PATHOL INT, V59, P642, DOI 10.1111/j.1440-1827.2009.02420.x; Matsui Y, 2005, UROLOGY, V65, P279, DOI 10.1016/j.urology.2004.09.021; Fine JP, 1999, J AM STAT ASSOC, V94, P496, DOI 10.2307/2670170; Terakawa T, 2008, UROLOGY, V71, P123, DOI 10.1016/j.urology.2007.08.054; Li CC, 2008, EUR UROL, V54, P1127, DOI 10.1016/j.eururo.2008.01.054; Ishioka J, 2012, BRIT J CANCER, V107, P1031, DOI 10.1038/bjc.2012.254; Azemar MD, 2011, UROL ONCOL-SEMIN ORI, V29, P130, DOI 10.1016/j.urolonc.2009.06.003; HARRIS AL, 1992, NEW ENGL J MED, V326, P759, DOI 10.1056/NEJM199203123261108; HARRELL FE, 1982, JAMA-J AM MED ASSOC, V247, P2543, DOI 10.1001/jama.247.18.2543; Kihara K, 2009, INT J UROL, V16, P791, DOI 10.1111/j.1442-2042.2009.02366.x; Mostofi FK, 1973, INT HISTOLOGICAL CLA, V10; NCCN Clinical Practice Guidelines in Oncology, 2012, NCCN CLIN PRACT GUID; Roobol MJ, 2010, EUR UROL, V60, P931; SAITO K, 2010, EUR UROL SUPPL, V9, P335; Sobin LH, 2002, TNM CLASSIFICATION M; Vickers AJ, 2008, BMC MED INFORM DECIS, V8, DOI 10.1186/1472-6947-8-53	32	1	1	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1464-4096	1464-410X		BJU INT	BJU Int.	MAY	2015	115	5					705	712		10.1111/bju.12707		8	Urology & Nephrology	Urology & Nephrology	CG4CT	WOS:000353230500010		
J	Ling, S; Jehee, JFM; Pestilli, F				Ling, Sam; Jehee, Janneke F. M.; Pestilli, Franco			A review of the mechanisms by which attentional feedback shapes visual selectivity	Brain Structure & Function			English	Review						Neuroimaging; Attention; Psychophysics; Visual system; Electrophysiology; Orientation; Motion	HUMAN EXTRASTRIATE CORTEX; CATS STRIATE CORTEX; MACAQUE AREA V4; ORIENTATION SELECTIVITY; SPATIAL ATTENTION; RECEPTIVE-FIELDS; LETTER IDENTIFICATION; POPULATION CODES; NORMALIZATION MODEL; COVERT ATTENTION	The glut of information available for the brain to process at any given moment necessitates an efficient attentional system that can 'pick and choose' what information receives prioritized processing. A growing body of work, spanning numerous methodologies and species, reveals that one powerful way in which attending to an item separates the wheat from the chaff is by altering a basic response property in the brain: neuronal selectivity. Selectivity is a cornerstone response property, largely dictating our ability to represent and interact with the environment. Although it is likely that selectivity is altered throughout many brain areas, here we focus on how directing attention to an item affects selectivity in the visual system, where this response property is generally more well characterized. First, we review the neural architecture supporting selectivity, and then discuss the various changes that could occur in selectivity for an attended item. In a survey of the literature, spanning neurophysiology, neuroimaging and psychophysics, we reveal that there is general convergence regarding the manner with which selectivity is shaped by attentional feedback. In a nutshell, the literature suggests that the type of changes in selectivity that manifest appears to depend on the type of attention being deployed: whereas directing spatial attention towards an item only alters spatial selectivity, directing feature-based attention can alter the selectivity of attended features.	[Ling, Sam] Boston Univ, Dept Psychol & Brain Sci, Boston, MA 02215 USA; [Ling, Sam] Boston Univ, Ctr Computat Neurosci & Neural Technol, Boston, MA 02215 USA; [Ling, Sam; Jehee, Janneke F. M.] Radboud Univ Nijmegen, Donders Inst Brain Cognit & Behav, NL-6525 ED Nijmegen, Netherlands; [Pestilli, Franco] Stanford Univ, Dept Psychol, Stanford, CA 94305 USA; [Pestilli, Franco] RIKEN Brain Sci Inst, Wako, Saitama 3150198, Japan	Ling, S (reprint author), Boston Univ, Dept Psychol & Brain Sci, Boston, MA 02215 USA.	samling@bu.edu; franco.pestilli@stanford.edu			EU [256456]; Italian Academy for Advanced Studies in America, Columbia University; National Institute of Mental Health [T32-MH05174]; National Eye Institute [T32-EY1393309]; National Science Foundation [BCS1228397]	We thank Randolph Blake, Brian Wandell, Vincent Ferrera and Frank Tong for generous support and advice, and Hiromasa Takemura, Jocelyn Sy, and Rosemary Le for comments on early drafts of the manuscript. This work was supported by EU FP7-PEOPLE-2009-RG Grant 256456 to Janneke Jehee, by training grants awarded by The Italian Academy for Advanced Studies in America, Columbia University, the National Institute of Mental Health (T32-MH05174) and National Eye Institute (T32-EY1393309) to Franco Pestilli, and by a research grant awarded by the National Science Foundation (BCS1228397) to Brian Wandell.	Anderson DE, 2013, J NEUROSCI, V33, P9273, DOI 10.1523/JNEUROSCI.0239-13.2013; Mitchell JF, 2009, NEURON, V63, P879, DOI 10.1016/j.neuron.2009.09.013; Carrasco M, 2004, NAT NEUROSCI, V7, P308, DOI 10.1038/nn1194; Cohen MR, 2009, NAT NEUROSCI, V12, P1594, DOI 10.1038/nn.2439; Finn IM, 2007, NEURON, V54, P137, DOI 10.1016/j.neuron.2007.02.029; Kamitani Y, 2005, NAT NEUROSCI, V8, P679, DOI 10.1038/nn1444; Abbott LF, 1999, NEURAL COMPUT, V11, P91, DOI 10.1162/089976699300016827; Bhatt R, 2007, VISION RES, V47, P3173, DOI 10.1016/j.visres.2007.07.013; Muller NG, 2005, VISION RES, V45, P1129, DOI 10.1016/j.visres.2004.11.003; Krekelberg B, 2006, TRENDS NEUROSCI, V29, P250, DOI 10.1016/j.tins.2006.02.008; Kanwisher N, 1997, J COGNITIVE NEUROSCI, V9, P133, DOI 10.1162/jocn.1997.9.1.133; Yeshurun Y, 1998, NATURE, V396, P72; Maunsell JHR, 2006, TRENDS NEUROSCI, V29, P317, DOI 10.1016/j.tins.2006.04.001; Scolari M, 2009, J NEUROSCI, V29, P11933, DOI 10.1523/JNEUROSCI.5642-08.2009; LEGGE GE, 1980, J OPT SOC AM, V70, P1458, DOI 10.1364/JOSA.70.001458; Murray SO, 2004, NAT NEUROSCI, V7, P70, DOI 10.1038/nn1161; Hopf JM, 2000, CEREB CORTEX, V10, P1233, DOI 10.1093/cercor/10.12.1233; Paltoglou AE, 2012, J NEUROPHYSIOL, V107, P1260, DOI 10.1152/jn.00776.2011; Ling S, 2009, VISION RES, V49, P1194, DOI 10.1016/j.visres.2008.05.025; Scolari M, 2010, J NEUROPHYSIOL, V104, P2266, DOI 10.1152/jn.00273.2010; Hopf JM, 2006, P NATL ACAD SCI USA, V103, P1053, DOI 10.1073/pnas.0507746103; Busse L, 2005, P NATL ACAD SCI USA, V102, P18751, DOI 10.1073/pnas.0507704102; Jehee JFM, 2011, J NEUROSCI, V31, P8210, DOI 10.1523/JNEUROSCI.6153-09.2011; Serences JT, 2009, NEUROIMAGE, V44, P223, DOI 10.1016/j.neuroimage.2008.07.043; Chen YZ, 2012, NEURON, V74, P557, DOI 10.1016/j.neuron.2012.03.033; SOLOMON JA, 1994, NATURE, V369, P395, DOI 10.1038/369395a0; SCLAR G, 1982, EXP BRAIN RES, V46, P457; SHIU LP, 1992, PERCEPT PSYCHOPHYS, V52, P582, DOI 10.3758/BF03206720; Talgar CP, 2004, J VISION, V4, P22, DOI 10.1167/4.1.3; Hopf JM, 2000, CLIN NEUROPHYSIOL, V111, P1241, DOI 10.1016/S1388-2457(00)00313-8; Lee DK, 1999, NAT NEUROSCI, V2, P375; McAlonan K, 2008, NATURE, V456, P391, DOI 10.1038/nature07382; O'Connor DH, 2002, NAT NEUROSCI, V5, P1203, DOI 10.1038/nn957; MALACH R, 1995, P NATL ACAD SCI USA, V92, P8135, DOI 10.1073/pnas.92.18.8135; McAdams CJ, 1999, J NEUROSCI, V19, P431; Jin JZ, 2011, NAT NEUROSCI, V14, P232, DOI 10.1038/nn.2729; Saenz M, 2003, VISION RES, V43, P629, DOI 10.1016/S0042-6989(02)00595-3; Clifford CWG, 2007, VISION RES, V47, P3125, DOI 10.1016/j.visres.2007.08.023; David SV, 2008, NEURON, V59, P509, DOI 10.1016/j.neuron.2008.07.001; Schwartz O, 2007, NAT REV NEUROSCI, V8, P522, DOI 10.1038/nrn2155; Chung S, 1998, NEURON, V20, P1177, DOI 10.1016/S0896-6273(00)80498-5; Kanwisher N, 1997, J NEUROSCI, V17, P4302; Anderson JS, 2000, SCIENCE, V290, P1968, DOI 10.1126/science.290.5498.1968; McLaughlin D, 2000, P NATL ACAD SCI USA, V97, P8087, DOI 10.1073/pnas.110135097; Herrmann K, 2010, NAT NEUROSCI, V13, P1554, DOI 10.1038/nn.2669; Priebe NJ, 2006, NAT NEUROSCI, V9, P552, DOI 10.1038/nn1660; Ling S, 2009, CURR BIOL, V19, P1458, DOI 10.1016/j.cub.2009.06.069; Series P, 2004, NAT NEUROSCI, V7, P1129, DOI 10.1038/nn1321; Womelsdorf T, 2008, J NEUROSCI, V28, P8934, DOI 10.1523/JNEUROSCI.4030-07.2008; Majaj NJ, 2002, VISION RES, V42, P1165, DOI 10.1016/S0042-6989(02)00045-7; Pestilli F, 2011, NEURON, V72, P832, DOI 10.1016/j.neuron.2011.09.025; Briggs F, 2013, NATURE, V499, P476, DOI 10.1038/nature12276; Dragoi V, 2000, NEURON, V28, P287, DOI 10.1016/S0896-6273(00)00103-3; Serences JT, 2007, NEURON, V55, P301, DOI 10.1016/j.neuron.2007.06.015; HUBEL DH, 1962, J PHYSIOL-LONDON, V160, P106; Reynolds JH, 2000, NEURON, V26, P703, DOI 10.1016/j.neuron.2009.01.002; Averbeck BB, 2006, NAT REV NEUROSCI, V7, P358, DOI 10.1038/nrn1888; Bejjanki VR, 2011, NAT NEUROSCI, V14, P642, DOI 10.1038/nn.2796; Ringach DL, 1997, NATURE, V387, P281, DOI 10.1038/387281a0; Liu TS, 2011, J NEUROSCI, V31, P4484, DOI 10.1523/JNEUROSCI.5745-10.2011; Wyart V, 2012, P NATL ACAD SCI USA, V109, P3593, DOI 10.1073/pnas.1120118109; Cutzu F, 2003, VISION RES, V43, P205, DOI 10.1016/S0042-6989(02)00491-1; Saenz M, 2002, NAT NEUROSCI, V5, P631, DOI 10.1038/nn876; Liu TS, 2011, VISION RES, V51, P26, DOI 10.1016/j.visres.2010.09.023; Grill-Spector K, 2003, CURR OPIN NEUROBIOL, V13, P159, DOI 10.1016/S0959-4388(03)00040-0; Shamir M, 2004, NEURAL COMPUT, V16, P1105, DOI 10.1162/089976604773717559; Liu T, 2007, NEURON, V55, P313, DOI 10.1016/j.neuron.2007.06.030; Connor CE, 1996, J NEUROPHYSIOL, V75, P1306; Kohn A, 2004, NAT NEUROSCI, V7, P764, DOI 10.1038/nn1267; Buracas GT, 2007, J NEUROSCI, V27, P93, DOI 10.1523/JNEUROSCI.3162-06.2007; Sompolinsky H, 1997, CURR OPIN NEUROBIOL, V7, P514, DOI 10.1016/S0959-4388(97)80031-1; Ferster D, 2000, ANNU REV NEUROSCI, V23, P441, DOI 10.1146/annurev.neuro.23.1.441; Kohn A, 2003, NEURON, V39, P681, DOI 10.1016/S0896-6273(03)00438-0; Tootell RBH, 1998, P NATL ACAD SCI USA, V95, P811, DOI 10.1073/pnas.95.3.811; Anderson JS, 2000, J NEUROPHYSIOL, V84, P909; MANGUN GR, 1988, ELECTROEN CLIN NEURO, V70, P417, DOI 10.1016/0013-4694(88)90019-3; Baldassi S, 2005, J VISION, V5, P556, DOI 10.1167/5.6.7; BLAKE R, 1985, VISION RES, V25, P1459, DOI 10.1016/0042-6989(85)90224-X; BLAKEMOR.C, 1969, J PHYSIOL-LONDON, V203, P237; Busse L, 2008, J VIS, V8, P1, DOI [10.1167/8.9.2.Introduction, DOI 10.1167/8.9.2]; Carrasco M, 2006, PERCEPT PSYCHOPHYS, V68, P1004, DOI 10.3758/BF03193361; Conner CE, 1997, J NEUROSCI, V17, P3201; Eckstein MP, 2004, VISION RES, V44, P1193, DOI 10.1016/j.visres.2003.10.026; Eckstein Miguel P, 2002, J Vis, V2, p1x; Fischer J, 2009, CURR BIOL, V19, P1356, DOI 10.1016/j.cub.2009.06.059; Golla H, 2004, VISION RES, V44, P1589, DOI 10.1016/j.visres.2004.01.009; Hara Y, 2014, FRONT COMPUT NEUROSC, V8, DOI 10.3389/fncom.2014.00012; Hegde J, 2009, J NEUROPHYSIOL, V102, P2245, DOI 10.1152/jn.00216.2009; HUBEL DH, 1959, J PHYSIOL-LONDON, V148, P574; Jha AP, 2000, CONTROL COGNITIVE PR, VXVIII, P125; Ling S, 2007, PERCEPT PSYCHOPHYS, V69, P1051, DOI 10.3758/BF03193943; Ling S, 2012, NEURON, V75, P533; Murray SO, 2008, J VISION, V8, DOI 10.1167/8.10.2; Neri P, 2004, VISION RES, V44, P3053, DOI 10.1016/j.visres.2004.07.014; Niebergall R, 2011, NEURON, V72, P1067, DOI 10.1016/j.neuron.2011.10.013; Prinzmetal W, 2008, PERCEPT PSYCHOPHYS, V70, P1139, DOI 10.3758/PP.70.7.1139; Pugh MC, 2000, J COMPUT NEUROSCI, V8, P143, DOI 10.1023/A:1008921231855; Saproo S, 2010, J NEUROPHYSIOL, V104, P885, DOI 10.1152/jn.00369.2010; Schneider KA, 2008, J VISION, V8, DOI 10.1167/8.15.3; Shalev L, 2002, EUR J COGN PSYCHOL, V14, P3, DOI 10.1080/09541440143000005; SPITZER H, 1988, SCIENCE, V240, P338, DOI 10.1126/science.3353728; Tombu M, 2008, PERCEPT PSYCHOPHYS, V70, P30, DOI 10.3758/PP.70.1.30; Valsecchi M, 2010, ATTEN PERCEPT PSYCHO, V72, P637, DOI 10.3758/APP.72.3.637; Verghese P, 2012, J NEUROSCI, V32, P16379, DOI 10.1523/JNEUROSCI.1174-12.2012; Yeshurun Y, 2008, VISION RES, V48, P80, DOI 10.1016/j.visres.2007.10.015	105	0	0	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	1863-2653	1863-2661		BRAIN STRUCT FUNCT	Brain Struct. Funct.	MAY	2015	220	3					1237	1250		10.1007/s00429-014-0818-5		14	Anatomy & Morphology; Neurosciences	Anatomy & Morphology; Neurosciences & Neurology	CG7VX	WOS:000353515200001		
J	Ohmura, N; Kawasaki, K; Satoh, T; Hata, Y				Ohmura, Nami; Kawasaki, Kazuha; Satoh, Takemasa; Hata, Yoshio			In vivo electroporation to physiologically identified deep brain regions in postnatal mammals	Brain Structure & Function			English	Article						Electroporation; Lateral geniculate nucleus; Visual cortex; Cat; Gene transfer	SINGLE-CELL ELECTROPORATION; GENE-TRANSFER; CEREBRAL-CORTEX; MOUSE-BRAIN; NEURONS; DELIVERY; RECORDINGS; NEOCORTEX; SYSTEM; DNA	Genetic manipulation is widely used to research the central nervous system (CNS). The manipulation of molecular expression in a small number of neurons permits the detailed investigation of the role of specific molecules on the function and morphology of the neurons. Electroporation is a broadly used technique for gene transfer in the CNS. However, the targeting of gene transfer using electroporation in postnatal animals was restricted to the cortex, hippocampus, or the region facing the ventricle in previous reports. Electroporation targeting of deep brain structures, such as the thalamus, has been difficult. We introduce a novel electroporation technique that enables gene transfer to a physiologically identified deep brain region using a glass pipette. We recorded neural activity in young-adult mice to identify the location of the lateral geniculate nucleus (LGN) of the thalamus, using a glass pipette electrode containing the plasmid DNA encoding enhanced green fluorescent protein (EGFP). The location of the LGN was confirmed by monitoring visual responses, and the plasmid solution was pressure-injected into the recording site. Voltage pulses were delivered through the glass pipette electrode. Several EGFP-labeled somata and dendrites were observed in the LGN after a few weeks, and labeled axons were found in the visual cortex. The EGFP-expressing structures were observed in detail sufficient to reconstruct their morphology in three dimensions. We further confirmed the applicability of this technique in cats. This method should be useful for the transfer of various genes into cells in physiologically identified brain regions in rodents and gyrencephalic mammals.	[Ohmura, Nami; Hata, Yoshio] Tottori Univ, Grad Sch Med Sci, Inst Regenerat Med & Biofunct, Div Integrat Biosci, Yonago, Tottori 6838503, Japan; [Kawasaki, Kazuha; Satoh, Takemasa; Hata, Yoshio] Tottori Univ, Fac Med, Sch Life Sci, Div Neurobiol, Yonago, Tottori 683, Japan	Hata, Y (reprint author), Tottori Univ, Grad Sch Med Sci, Inst Regenerat Med & Biofunct, Div Integrat Biosci, 86 Nishicho, Yonago, Tottori 6838503, Japan.	yhata@med.tottori-u.ac.jp			MEXT KAKENHI [22115010]; JSPS KAKENHI [24650208]	We thank Dr. Yasuaki Shirayoshi (Tottori Univ., Japan) for providing plasmids, pCAG-EGFP. This work was supported by MEXT KAKENHI Grant Number 22115010 (Y.H.) and JSPS KAKENHI Grant Number 24650208 (Y.H., T.S.).	Akaneya Y, 2005, J NEUROPHYSIOL, V93, P594, DOI 10.1152/jn.00161.2004; De la Rossa A, 2013, NAT NEUROSCI, V16, P193, DOI 10.1038/nn.3299; Antonini A, 1999, J NEUROSCI, V19, P4388; Schindelin J, 2012, NAT METHODS, V9, P676, DOI [10.1038/nmeth.2019, 10.1038/NMETH.2019]; Hensch TK, 2004, ANNU REV NEUROSCI, V27, P549, DOI 10.1146/annurev.neuro.27.070203.144327; Cohen L, 2013, P NATL ACAD SCI USA, V110, P5665, DOI 10.1073/pnas.1214434110; Barnabe-Heider F, 2008, NAT METHODS, V5, P189, DOI [10.1038/nmeth.1174, 10.1038/NMETH.1174]; Judkewitz B, 2009, NAT PROTOC, V4, P862, DOI 10.1038/nprot.2009.56; Preibisch S, 2009, BIOINFORMATICS, V25, P1463, DOI 10.1093/bioinformatics/btp184; Kitamura K, 2008, NAT METHODS, V5, P61, DOI 10.1038/NMETH1150; Furuta T, 2001, J HISTOCHEM CYTOCHEM, V49, P1497; Karra D, 2010, J NEUROSCI, V30, P6171, DOI 10.1523/JNEUROSCI.0183-10.2010; Haas K, 2001, NEURON, V29, P583, DOI 10.1016/S0896-6273(01)00235-5; Huang ZJ, 2013, ANNU REV NEUROSCI, V36, P183, DOI 10.1146/annurev-neuro-062012-170307; De Vry J, 2010, PROG NEUROBIOL, V92, P227, DOI 10.1016/j.pneurobio.2010.10.001; Tabata H, 2001, NEUROSCIENCE, V103, P865, DOI 10.1016/S0306-4522(01)00016-1; Borrell V, 2010, J NEUROSCI METH, V186, P186, DOI 10.1016/j.jneumeth.2009.11.016; Boutin C, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001883; Chesler AT, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001517; De Vry J, 2010, MOL THER, V18, P1183, DOI 10.1038/mt.2010.62; Kondoh T, 2000, NEUROL MED-CHIR, V40, P618, DOI 10.2176/nmc.40.618; Mizuno H, 2010, EUR J NEUROSCI, V31, P410, DOI 10.1111/j.1460-9568.2009.07070.x; Molotkov DA, 2010, J VISUALIZED EXPT, DOI [10.3791/2244, DOI 10.3791/2244]; Oyama K, 2013, J NEUROSCI METH, V218, P139, DOI 10.1016/j.jneumeth.2013.06.004; Portera-Cailliau C, 2005, PLOS BIOL, V3, P1473, DOI 10.1371/journal.pbio.0030272; Washbourne P, 2002, CURR OPIN NEUROBIOL, V12, P566, DOI 10.1016/S0959-4388(02)00365-3	26	1	1	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	1863-2653	1863-2661		BRAIN STRUCT FUNCT	Brain Struct. Funct.	MAY	2015	220	3					1307	1316		10.1007/s00429-014-0724-x		10	Anatomy & Morphology; Neurosciences	Anatomy & Morphology; Neurosciences & Neurology	CG7VX	WOS:000353515200006		
J	Edwards, IJ; Lall, VK; Paton, JF; Yanagawa, Y; Szabo, G; Deuchars, SA; Deuchars, J				Edwards, I. J.; Lall, V. K.; Paton, J. F.; Yanagawa, Y.; Szabo, G.; Deuchars, S. A.; Deuchars, J.			Neck muscle afferents influence oromotor and cardiorespiratory brainstem neural circuits	Brain Structure & Function			English	Article						Proprioception; Autonomic; Immunohistochemistry; Electrophysiology	VESICULAR GLUTAMATE TRANSPORTERS; CERVICAL PRIMARY AFFERENTS; NUCLEUS-TRACTUS-SOLITARII; NITRIC-OXIDE SYNTHASE; SPINAL-CORD; MEDULLA-OBLONGATA; DORSAL-HORN; RAT MEDULLA; PROJECTIONS; NEURONS	Sensory information arising from the upper neck is important in the reflex control of posture and eye position. It has also been linked to the autonomic control of the cardiovascular and respiratory systems. Whiplash associated disorders (WAD) and cervical dystonia, which involve disturbance to the neck region, can often present with abnormalities to the oromotor, respiratory and cardiovascular systems. We investigated the potential neural pathways underlying such symptoms. Simulating neck afferent activity by electrical stimulation of the second cervical nerve in a working heart brainstem preparation (WHBP) altered the pattern of central respiratory drive and increased perfusion pressure. Tracing central targets of these sensory afferents revealed projections to the intermedius nucleus of the medulla (InM). These anterogradely labelled afferents co-localised with parvalbumin and vesicular glutamate transporter 1 indicating that they are proprioceptive. Anterograde tracing from the InM identified projections to brain regions involved in respiratory, cardiovascular, postural and oro-facial behaviours-the neighbouring hypoglossal nucleus, facial and motor trigeminal nuclei, parabrachial nuclei, rostral and caudal ventrolateral medulla and nucleus ambiguus. In brain slices, electrical stimulation of afferent fibre tracts lateral to the cuneate nucleus monosynaptically excited InM neurones. Direct stimulation of the InM in the WHBP mimicked the response of second cervical nerve stimulation. These results provide evidence of pathways linking upper cervical sensory afferents with CNS areas involved in autonomic and oromotor control, via the InM. Disruption of these neuronal pathways could, therefore, explain the dysphagic and cardiorespiratory abnormalities which may accompany cervical dystonia and WAD.	[Edwards, I. J.; Lall, V. K.; Deuchars, S. A.; Deuchars, J.] Univ Leeds, Sch Biomed Sci, Leeds LS2 9JT, W Yorkshire, England; [Paton, J. F.] Univ Bristol, Bristol Heart Inst, Sch Physiol & Pharmacol, Bristol BS8 1TD, Avon, England; [Yanagawa, Y.] Gunma Univ, Grad Sch Med, Dept Genet & Behav Neurosci, JST,CREST, Maebashi, Gumma 3718511, Japan; [Szabo, G.] Inst Expt Med, Dept Gene Technol & Dev Neurobiol, H-1450 Budapest, Hungary	Edwards, IJ (reprint author), Univ Leeds, Sch Biomed Sci, Leeds LS2 9JT, W Yorkshire, England.	i.j.edwards@leeds.ac.uk; J.Deuchars@leeds.ac.uk		Deuchars, Jim/0000-0002-4445-654X; Paton, Julian/0000-0001-7410-2913	Biotechnology and Biological Sciences Research Council [BB/F006594/1]; British Heart Foundation [PG/08/120/26338]; MEXT, Japan	We acknowledge the contributions of Mrs Brenda Frater to this work. This work was supported by the Biotechnology and Biological Sciences Research Council (BB/F006594/1 to SAD and JD), the British Heart Foundation (PG/08/120/26338 to SAD) and Grants-in-Aid for Scientific Research from the MEXT, Japan (YY).	Alipour M, 2002, BRAIN BEHAV EVOLUT, V60, P101, DOI 10.1159/000065205; Alvarez FJ, 2004, J COMP NEUROL, V472, P257, DOI 10.1002/cne.20012; Hughes DI, 2012, J PHYSIOL-LONDON, V590, P3927, DOI 10.1113/jphysiol.2012.235655; RICHMOND FJR, 1975, J NEUROPHYSIOL, V38, P1312; Tamamaki N, 2003, J COMP NEUROL, V467, P60, DOI 10.1002/cne.10905; Aizawa H, 2012, J COMP NEUROL, V520, P4051, DOI 10.1002/cne.23167; Oka A, 2013, BRAIN RES, V1540, P48, DOI 10.1016/j.brainres.2013.10.009; Miyazaki Y, 2012, NAT MED, V18, P1136, DOI 10.1038/nm.2791; PFALLER K, 1988, J COMP NEUROL, V268, P91, DOI 10.1002/cne.902680110; Muller M, 2012, J NEUROSCI, V32, P14885, DOI 10.1523/JNEUROSCI.2849-12.2012; Arber S, 2000, CELL, V101, P485, DOI 10.1016/S0092-8674(00)80859-4; Gabriel R, 2004, CELL TISSUE RES, V315, P181, DOI 10.1007/s00441-003-0785-2; Jager C, 2013, NEUROSCIENCE, V238, P168, DOI 10.1016/j.neuroscience.2013.02.014; Todd AJ, 2003, EUR J NEUROSCI, V17, P13, DOI 10.1046/j.1460-9568.2003.02406.x; NOMURA S, 1985, BRAIN RES, V359, P311, DOI 10.1016/0006-8993(85)91442-8; ROSS CA, 1985, J COMP NEUROL, V242, P511, DOI 10.1002/cne.902420405; Kulkarni V, 2001, NEUROL INDIA, V49, P355; Castillo-Ruiz A, 2013, NEUROSCIENCE, V250, P352, DOI 10.1016/j.neuroscience.2013.07.007; Atkinson L, 2003, NEUROSCIENCE, V118, P115, DOI 10.1016/S0306-4522(02)00946-6; BECKMAN ME, 1991, BRAIN RES, V557, P265, DOI 10.1016/0006-8993(91)90143-J; Bolton PS, 1998, BRAIN RES BULL, V47, P413, DOI 10.1016/S0361-9230(98)00094-X; Bolton PS, 2000, BRAIN RES BULL, V53, P45, DOI 10.1016/S0361-9230(00)00307-5; Boscan P, 2002, NEUROSCIENCE, V110, P319, DOI 10.1016/S0306-4522(01)00585-1; Brooke RE, 2006, BRAIN RES, V1070, P101, DOI 10.1016/j.brainres.2005.10.102; Brooke RE, 2010, BRAIN RES, V1345, P45, DOI 10.1016/j.brainres.2010.05.020; CARLETON SC, 1983, BRAIN RES, V278, P29, DOI 10.1016/0006-8993(83)90223-8; Dauvergne C, 2001, NEUROSCI LETT, V311, P109, DOI 10.1016/S0304-3940(01)02150-4; EDNEY DP, 1986, J COMP NEUROL, V250, P389, DOI 10.1002/cne.902500311; Edwards IJ, 2009, J CHEM NEUROANAT, V38, P166, DOI 10.1016/j.jchemneu.2009.01.001; Edwards IJ, 2007, J NEUROSCI, V27, P8324, DOI 10.1523/JNEUROSCI.0638-07.2007; Herbison AE, 1996, J NEUROENDOCRINOL, V8, P73, DOI 10.1111/j.1365-2826.1996.tb00688.x; IMAMURA J, 1986, NEUROSCI LETT, V70, P46, DOI 10.1016/0304-3940(86)90435-0; Lopez-Bendito G, 2004, CEREB CORTEX, V14, P1122, DOI 10.1093/cercor/bhh072; Melone M, 2005, J COMP NEUROL, V492, P495, DOI 10.1002/cne.20743; Menegola M, 2008, NEUROSCIENCE, V154, P953, DOI 10.1016/j.neuroscience.2008.04.022; Messanvi F, 2013, FRONT NEUROANAT, V7, DOI 10.3389/fnana.2013.00041; Milligan CJ, 2006, BRAIN RES, V1081, P79, DOI 10.1016/j.brainres.2006.01.019; Milnerwood AJ, 2012, NEUROBIOL DIS, V48, P40, DOI 10.1016/j.nbd.2012.05.013; Mura A, 2000, NEUROSCIENCE, V98, P501, DOI 10.1016/S0306-4522(00)00154-8; NEUHUBER WL, 1989, J COMP NEUROL, V280, P231, DOI 10.1002/cne.902800206; Ohno K, 2001, P NATL ACAD SCI USA, V98, P2017, DOI 10.1073/pnas.98.4.2017; PFISTER J, 1984, ANAT EMBRYOL, V169, P79, DOI 10.1007/BF00300589; Ponti G, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002366; Popratiloff AS, 2001, J COMP NEUROL, V433, P364, DOI 10.1002/cne.1145; Potts JT, 2000, BRAIN RES BULL, V53, P59, DOI 10.1016/S0361-9230(00)00309-9; PRIHODA M, 1991, J COMP NEUROL, V308, P418, DOI 10.1002/cne.903080309; She K, 2012, J BIOL CHEM, V287, P27432, DOI 10.1074/jbc.M112.345108; STECHISON MT, 1986, J COMP NEUROL, V246, P555, DOI 10.1002/cne.902460411; Stevens HE, 2010, J NEUROSCI, V30, P5590, DOI 10.1523/JNEUROSCI.5837-09.2010; Watson C, 1998, STEREOTAXIC COORDINA; Yang S, 2012, J ANAT, V221, P303, DOI 10.1111/j.1469-7580.2012.01546.x	51	0	0	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	1863-2653	1863-2661		BRAIN STRUCT FUNCT	Brain Struct. Funct.	MAY	2015	220	3					1421	1436		10.1007/s00429-014-0734-8		16	Anatomy & Morphology; Neurosciences	Anatomy & Morphology; Neurosciences & Neurology	CG7VX	WOS:000353515200013		
J	Yokota, R; Aihara, K; Kanzaki, R; Takahashi, H				Yokota, Ryo; Aihara, Kazuyuki; Kanzaki, Ryohei; Takahashi, Hirokazu			Learning-Stage-Dependent Plasticity of Temporal Coherence in the Auditory Cortex of Rats	BRAIN TOPOGRAPHY			English	Article						Auditory cortex; First spike latency; Local field potentials; Temporal coherence; Learning; Plasticity	VISUAL-CORTEX; CORTICAL PLASTICITY; FIELD POTENTIALS; NUCLEUS BASALIS; SINGLE NEURONS; FREQUENCY; MODULATION; RESPONSES; REPRESENTATION; ACETYLCHOLINE	Temporal coherence among neural populations may contribute importantly to signal encoding, specifically by providing an optimal tradeoff between encoding reliability and efficiency. Here, we considered the possibility that learning modulates the temporal coherence among neural populations in association with well-characterized map plasticity. We previously demonstrated that, in appetitive operant conditioning tasks, the tone-responsive area globally expanded during the early stage of learning, but shrank during the late stage. The present study further showed that phase locking of the first spike to band-specific oscillations of local field potentials (LFPs) significantly increased during the early stage of learning but decreased during the late stage, suggesting that neurons in A1 were more synchronously activated during early learning, whereas they were more asynchronously activated once learning was completed. Furthermore, LFP amplitudes increased during early learning but decreased during later learning. These results suggest that, compared to na < ve encoding, early-stage encoding is more reliable but energy-consumptive, whereas late-stage encoding is more energetically efficient. Such a learning-stage-dependent encoding strategy may underlie learning-induced, non-monotonic map plasticity. Accumulating evidence indicates that the cholinergic system is likely to be a shared neural substrate of the processes for perceptual learning and attention, both of which modulate neural encoding in an adaptive manner. Thus, a better understanding of the links between map plasticity and modulation of temporal coherence will likely lead to a more integrated view of learning and attention.	[Yokota, Ryo; Kanzaki, Ryohei; Takahashi, Hirokazu] Univ Tokyo, Res Ctr Adv Sci & Technol, Meguro Ku, Tokyo 1538904, Japan; [Yokota, Ryo; Aihara, Kazuyuki] Univ Tokyo, Inst Ind Sci, Meguro Ku, Tokyo 1538505, Japan; [Yokota, Ryo] Univ Tokyo, FIRST, Aihara Innovat Math Modelling Project, Japan Sci & Technol Agcy,Meguro Ku, Tokyo 1538505, Japan; [Takahashi, Hirokazu] Japan Sci & Technol Agcy, Precursory Res Embryon Sci & Technol, Kawaguchi, Saitama 3320012, Japan	Takahashi, H (reprint author), Univ Tokyo, Res Ctr Adv Sci & Technol, Meguro Ku, Komaba 4-6-1, Tokyo 1538904, Japan.	takahashi@i.u-tokyo.ac.jp			Strategic Information and Communications R&D Promotion Programme (SCOPE) [121803022]; KAKENHI [25135710]; Aihara Innovative Mathematical Modelling Project; Japan Society for the Promotion of Science (JSPS); Council for Science and Technology Policy (CSTP)	This research is partially supported by Strategic Information and Communications R&D Promotion Programme (SCOPE; 121803022), KAKENHI (25135710) and the Aihara Innovative Mathematical Modelling Project, the Japan Society for the Promotion of Science (JSPS) through the "Funding Program for World-Leading Innovative R&D on Science and Technology (FIRST Program)," initiated by the Council for Science and Technology Policy (CSTP).	Chalk M, 2010, NEURON, V66, P114, DOI 10.1016/j.neuron.2010.03.013; EDELMAN GM, 1993, NEURON, V10, P115, DOI 10.1016/0896-6273(93)90304-A; Butt AE, 2009, NEUROBIOL LEARN MEM, V92, P400, DOI 10.1016/j.nlm.2009.05.006; Kilgard MP, 1998, SCIENCE, V279, P1714, DOI 10.1126/science.279.5357.1714; Montemurro MA, 2008, CURR BIOL, V18, P375, DOI 10.1016/j.cub.2008.02.023; Conner JM, 2003, NEURON, V38, P819, DOI 10.1016/S0896-6273(03)00288-5; Bieszczad KM, 2010, NEUROBIOL LEARN MEM, V93, P229, DOI 10.1016/j.nlm.2009.10.003; Hsieh CY, 2000, BRAIN RES, V880, P51, DOI 10.1016/S0006-8993(00)02766-9; Kimura F, 1999, EUR J NEUROSCI, V11, P3597, DOI 10.1046/j.1460-9568.1999.00779.x; Rasch M, 2009, J NEUROSCI, V29, P13785, DOI 10.1523/JNEUROSCI.2390-09.2009; Froemke RC, 2007, NATURE, V450, P425, DOI 10.1038/nature06289; Chase SM, 2007, P NATL ACAD SCI USA, V104, P5175, DOI 10.1073/pnas.0610368104; Wu GYK, 2011, NEUROSCI BIOBEHAV R, V35, P2094, DOI 10.1016/j.neubiorev.2011.05.004; Rutkowski RG, 2003, HEARING RES, V181, P116, DOI 10.1016/S0378-5955(03)00182-5; Zhang LI, 2003, NATURE, V424, P201, DOI 10.1038/nature01796; Takahashi H, 2011, NEUROSCIENCE, V199, P243, DOI 10.1016/j.neuroscience.2011.09.046; Rutkowski RG, 2005, P NATL ACAD SCI USA, V102, P13664, DOI 10.1073/pnas.0506838102; Froemke RC, 2013, NAT NEUROSCI, V16, P79, DOI 10.1038/nn.3274; Fell J, 2011, NAT REV NEUROSCI, V12, P105, DOI 10.1038/nrn2979; Recanzone GH, 2000, J NEUROPHYSIOL, V83, P2315; Headley DB, 2013, J NEUROSCI, V33, P5705, DOI 10.1523/JNEUROSCI.4915-12.2013; Logothetis NK, 2002, PHILOS T ROY SOC B, V357, P1003, DOI 10.1098/rstb.2002.1114; Fries P, 2001, SCIENCE, V291, P1560, DOI 10.1126/science.1055465; Kruglikov I, 2008, NEURON, V58, P911, DOI 10.1016/j.neuron.2008.04.024; Disney AA, 2007, NEURON, V56, P701, DOI 10.1016/j.neuron.2007.09.034; RECANZONE GH, 1993, J NEUROSCI, V13, P87; Goard M, 2009, NAT NEUROSCI, V12, P1444, DOI 10.1038/nn.2402; Bakin JS, 1996, P NATL ACAD SCI USA, V93, P11219, DOI 10.1073/pnas.93.20.11219; Polley DB, 2007, J NEUROPHYSIOL, V97, P3621, DOI 10.1152/jn.01298.2006; Katzner S, 2009, NEURON, V61, P35, DOI 10.1016/j.neuron.2008.11.016; Logothetis NK, 2001, NATURE, V412, P150, DOI 10.1038/35084005; Qin L, 2008, J NEUROPHYSIOL, V99, P2305, DOI 10.1152/jn.01125.2007; Gil Z, 1997, NEURON, V19, P679, DOI 10.1016/S0896-6273(00)80380-3; Linden H, 2011, NEURON, V72, P859, DOI 10.1016/j.neuron.2011.11.006; Bao SW, 2001, NATURE, V412, P79, DOI 10.1038/35083586; Buonomano DV, 1998, ANNU REV NEUROSCI, V21, P149, DOI 10.1146/annurev.neuro.21.1.149; BARFIELD RJ, 1972, SCIENCE, V176, P1349, DOI 10.1126/science.176.4041.1349; BLANCHARD RJ, 1991, PHYSIOL BEHAV, V50, P967, DOI 10.1016/0031-9384(91)90423-L; Disney AA, 2012, J NEUROPHYSIOL, V108, P1907, DOI 10.1152/jn.00188.2012; Fisher N. I., 1993, STAT ANAL CIRCULAR D; Funamizu A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063655; Godey B, 2005, J NEUROPHYSIOL, V94, P1299, DOI 10.1152/jn.00950.2004; Heil P, 1997, J NEUROPHYSIOL, V77, P2626; HEIL P, 1992, J COMP PHYSIOL A, V171, P583; Heil P, 1997, J NEUROPHYSIOL, V77, P2642; Kilgard MP, 2012, TRENDS NEUROSCI, V35, P715, DOI 10.1016/j.tins.2012.09.002; Mitzdorf U., 1985, AM PHYSL SOC, V65, P37; Oldford E, 2003, NEUROSCIENCE, V117, P769, DOI 10.1016/S0306-4522(02)00663-2; SCHREINER CE, 1992, EXP BRAIN RES, V92, P105; Takahashi H, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068705; Takahashi H, 2010, BIOSYSTEMS, V101, P37, DOI 10.1016/j.biosystems.2010.04.003; Takahashi H, 2004, NEUROREPORT, V15, P2061, DOI 10.1097/00001756-200409150-00013; Tan XD, 2008, HEARING RES, V235, P90, DOI 10.1016/j.heares.2007.10.002; Yin PB, 2011, J NEUROPHYSIOL, V105, P582, DOI 10.1152/jn.00621.2010; Yokota R, 2012, NEUROSCIENCE, V223, P377, DOI 10.1016/j.neuroscience.2012.07.051	55	0	0	SPRINGER	DORDRECHT	VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS	0896-0267	1573-6792		BRAIN TOPOGR	Brain Topogr.	MAY	2015	28	3			SI		401	410		10.1007/s10548-014-0359-5		10	Clinical Neurology; Neurosciences	Neurosciences & Neurology	CG5RQ	WOS:000353352100003		
J	Noguchi, Y; Fujiwara, M; Hamano, S				Noguchi, Yasuki; Fujiwara, Mana; Hamano, Saki			Temporal Evolution of Neural Activity Underlying Auditory Discrimination of Frequency Increase and Decrease	BRAIN TOPOGRAPHY			English	Article						Electroencephalography; Auditory-evoked potentials; P1; N1; P2	MISMATCH NEGATIVITY MMN; EVOKED-POTENTIALS; DIRECTION SELECTIVITY; PITCH DISCRIMINATION; DEVIANCE DIRECTION; CORTEX; PERCEPTION; MECHANISMS; MUSICIANS; LOCALIZATION	Discriminating a direction of frequency change is an important ability of the human auditory system, although temporal dynamics of neural activity underlying this discrimination remains unclear. In the present study, we recorded auditory-evoked potentials when human subjects explicitly judged a direction of a relative frequency change between two successive tones. A comparison of two types of trials with ascending and descending tone pairs revealed that neural activity discriminating a direction of frequency changes appeared as early as the P1 component of auditory-evoked potentials (latency 50 ms). Those differences between the ascending and descending trials were also observed in subsequent electroencephalographic components such as the N1 (100 ms) and P2 (200 ms). Furthermore, amplitudes of the P2 were significantly modulated by behavioral responses (upward/downward judgments) of subjects in the direction discrimination task, while those of the P1 were not. Those results indicate that, while the neural responses encoding a direction of frequency changes can be observed in an early component of electroencephalographic responses (50 ms after the change), the activity associated (correlated) with behavioral judgments evolves over time, being shaped in a later time period (around 200 ms) of the auditory processing.	[Noguchi, Yasuki; Fujiwara, Mana; Hamano, Saki] Kobe Univ, Dept Psychol, Grad Sch Humanities, Nada Ku, Kobe, Hyogo 6578501, Japan	Noguchi, Y (reprint author), Kobe Univ, Dept Psychol, Grad Sch Humanities, Nada Ku, 1-1 Rokkodai Cho, Kobe, Hyogo 6578501, Japan.	ynoguchi@lit.kobe-u.ac.jp			Japan Society for the Promotion of Science	This work was supported by Grants from the Japan Society for the Promotion of Science for Young Scientists to Y.N.	Fishman YI, 2014, BRAIN TOPOGR, V27, P500, DOI 10.1007/s10548-013-0337-3; McDermott JH, 2008, CURR OPIN NEUROBIOL, V18, P452, DOI 10.1016/j.conb.2008.09.005; Brainard DH, 1997, SPATIAL VISION, V10, P433, DOI 10.1163/156856897X00357; Stefanics G, 2009, CLIN NEUROPHYSIOL, V120, P304, DOI 10.1016/j.clinph.2008.11.020; Crowley KE, 2004, CLIN NEUROPHYSIOL, V115, P732, DOI 10.1016/j.clinph.2003.11.021; Stewart L, 2006, BRAIN, V129, P2533, DOI 10.1093/brain/awl171; Schreiner CE, 2000, ANNU REV NEUROSCI, V23, P501, DOI 10.1146/annurev.neuro.23.1.501; Kuo RI, 2012, NEURON, V73, P1016, DOI 10.1016/j.neuron.2011.11.035; ZATORRE RJ, 1994, J NEUROSCI, V14, P1908; Peretz I, 2002, NEURON, V33, P185, DOI 10.1016/S0896-6273(01)00580-3; Naatanen R, 2014, BRAIN TOPOGR, V27, P451, DOI 10.1007/s10548-014-0374-6; Bosnyak DJ, 2004, CEREB CORTEX, V14, P1088, DOI 10.1093/cercor/bhh068; Pratt H, 2008, CLIN NEUROPHYSIOL, V119, P376, DOI 10.1016/j.clinph.2007.10.016; Pelli DG, 1997, SPATIAL VISION, V10, P437, DOI 10.1163/156856897X00366; Godey B, 2001, CLIN NEUROPHYSIOL, V112, P1850, DOI 10.1016/S1388-2457(01)00636-8; Karanasiou IS, 2011, J INTEGR NEUROSCI, V10, P525, DOI 10.1142/S0219635211002841; Tremblay K, 2001, EAR HEARING, V22, P79, DOI 10.1097/00003446-200104000-00001; Tong YX, 2009, BRAIN RES, V1297, P80, DOI 10.1016/j.brainres.2009.07.089; Zhang LI, 2003, NATURE, V424, P201, DOI 10.1038/nature01796; Shahin A, 2003, J NEUROSCI, V23, P5545; Okamoto H, 2009, CEREB CORTEX, V19, P2290, DOI 10.1093/cercor/bhn245; Doupe AJ, 1999, ANNU REV NEUROSCI, V22, P567, DOI 10.1146/annurev.neuro.22.1.567; Johnsrude IS, 2000, BRAIN, V123, P155, DOI 10.1093/brain/123.1.155; Foxton JM, 2004, BRAIN, V127, P801, DOI 10.1093/brain/awh105; Rao A, 2010, HEARING RES, V268, P123, DOI 10.1016/j.heares.2010.05.013; Pratt H, 2009, CLIN NEUROPHYSIOL, V120, P360, DOI 10.1016/j.clinph.2008.10.158; Marie C, 2011, J COGNITIVE NEUROSCI, V23, P294, DOI 10.1162/jocn.2010.21413; Peter V, 2010, NEUROSCI LETT, V482, P71, DOI 10.1016/j.neulet.2010.07.010; Atienza M, 2002, LEARN MEMORY, V9, P138, DOI 10.1101/lm.46502; Butler BE, 2012, FRONT PSYCHOL, V3, DOI 10.3389/fpsyg.2012.00180; Carral V, 2005, NEUROREPORT, V16, P301, DOI 10.1097/00001756-200502280-00020; Holy TE, 2005, PLOS BIOL, V3, P2177, DOI 10.1371/journal.pbio.0030386; Inui K, 2010, BMC NEUROSCI, V11, DOI 10.1186/1471-2202-11-80; Kuriki S, 2006, J NEUROSCI, V26, P4046, DOI 10.1523/JNEUROSCI.3907-05.2006; MENDELSON JR, 1985, BRAIN RES, V327, P331, DOI 10.1016/0006-8993(85)91530-6; Ruusuvirta TT, 2012, NEUROREPORT, V23, P220, DOI 10.1097/WNR.0b013e32834fe71d; Selezneva E, 2006, CURR BIOL, V16, P2428, DOI 10.1016/j.cub.2006.10.027; Tramo MJ, 2005, ANN NY ACAD SCI, V1060, P148, DOI 10.1196/annals.1360.011; Wang XQ, 2000, P NATL ACAD SCI USA, V97, P11843, DOI 10.1073/pnas.97.22.11843; Yvert B, 2005, NEUROIMAGE, V28, P140, DOI 10.1016/j.neuroimage.2005.05.056	40	0	0	SPRINGER	DORDRECHT	VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS	0896-0267	1573-6792		BRAIN TOPOGR	Brain Topogr.	MAY	2015	28	3			SI		437	444		10.1007/s10548-014-0410-6		8	Clinical Neurology; Neurosciences	Neurosciences & Neurology	CG5RQ	WOS:000353352100006		
J	Keceli, S; Okamoto, H; Kakigi, R				Keceli, Sumru; Okamoto, Hidehiko; Kakigi, Ryusuke			Hierarchical Neural Encoding of Temporal Regularity in the Human Auditory Cortex	BRAIN TOPOGRAPHY			English	Article						Auditory steady state response (ASSR); Auditory sustained field (SF); Magnetoencephalography (MEG); Periodic noise; Temporal integration window	STEADY-STATE RESPONSES; AMPLITUDE-MODULATION; CORTICAL ACTIVITY; SPEECH RECEPTION; EVOKED FIELD; INTEGRATION; LATERALIZATION; MULTIPLE; STIMULI; SOUNDS	Temporal regularity provides an important cue for the identification of natural sounds. Here, we measured auditory evoked cortical magnetic fields to investigate the neural processing of temporal regularity that cannot be tonotopically represented in the auditory periphery. Auditory steady state responses (ASSR) and sustained fields (SF) elicited by 40 Hz amplitude modulated periodic and non-periodic noises were analyzed. Periodic noises of 40-, 20-, and 5-Hz were prepared in the form of repeating frozen noises where the same noise segment appears at either each period (40 Hz), every second period (20 Hz), or every eighth period (5 Hz) of amplitude modulation. Compared to non-periodic white noises, periodic noises with repetition rates of 5-, 20-, and 40-Hz caused significantly increased SF amplitudes in both hemispheres. ASSR amplitudes were significantly enhanced for 20- and 40-Hz periodic noises in the right hemisphere while no enhancement was observed for periodic noises in the left hemisphere. The observed variation of the regularity effect between evoked response components and hemispheres may reflect the differences in the temporal integration window lengths adopted between ASSR and SF generators and also between the right and left auditory pathways.	[Keceli, Sumru; Okamoto, Hidehiko; Kakigi, Ryusuke] Natl Inst Physiol Sci, Dept Integrat Physiol, Okazaki, Aichi 4448585, Japan; [Keceli, Sumru; Okamoto, Hidehiko; Kakigi, Ryusuke] Grad Univ Adv Studies SOKENDAI, Sch Life Sci, Dept Physiol Sci, Hayama, Kanagawa 2400193, Japan	Keceli, S (reprint author), Natl Inst Physiol Sci, Dept Integrat Physiol, Nishigoh Naka 38, Okazaki, Aichi 4448585, Japan.	sumru@nips.ac.jp			College Women's Association of Japan; Japan Society for the Promotion of Science for Young Scientists [23689070]; Strategic Research Program for Brain Sciences	We thank Yasuyuki Takeshima for technical support and Nurhan Erbil and Henning Teismann for their helpful comments. This study was supported in part by a scholarship award to the author SK from the College Women's Association of Japan and in part by "Japan Society for the Promotion of Science for Young Scientists (23689070)" and "Strategic Research Program for Brain Sciences" (Development of biomarker candidates for social behavior).	Patel AD, 2001, NAT NEUROSCI, V4, P839, DOI 10.1038/90557; TESCHE CD, 1995, ELECTROEN CLIN NEURO, V95, P189, DOI 10.1016/0013-4694(95)00064-6; Gutschalk A, 2011, NEUROIMAGE, V56, P1578, DOI 10.1016/j.neuroimage.2011.02.026; Zatorre RJ, 2001, CEREB CORTEX, V11, P946, DOI 10.1093/cercor/11.10.946; HARI R, 1989, J ACOUST SOC AM, V86, P1033, DOI 10.1121/1.398093; GALAMBOS R, 1981, P NATL ACAD SCI-BIOL, V78, P2643, DOI 10.1073/pnas.78.4.2643; ZATORRE RJ, 1994, J NEUROSCI, V14, P1908; Ross B, 2002, HEARING RES, V165, P68, DOI 10.1016/S0378-5955(02)00285-X; Dau T, 1996, J ACOUST SOC AM, V99, P3615, DOI 10.1121/1.414959; Chi T, 2005, J ACOUST SOC AM, V118, P887, DOI 10.1121/1.1945807; PANTEV C, 1994, ELECTROEN CLIN NEURO, V90, P82, DOI 10.1016/0013-4694(94)90115-5; Gunji A, 2003, NEUROSCI LETT, V348, P13, DOI 10.1016/S0304-3940(03)00640-2; VIEMEISTER NF, 1991, J ACOUST SOC AM, V90, P858, DOI 10.1121/1.401953; Ross B, 2005, J NEUROPHYSIOL, V94, P4082, DOI 10.1152/jn.00469.2005; EULITZ C, 1995, J NEUROSCI, V15, P2748; Ross B, 2004, J ACOUST SOC AM, V115, P2193, DOI 10.1121/1.1694996; Boemio A, 2005, NAT NEUROSCI, V8, P389, DOI 10.1038/nn1409; Ross B, 2000, J ACOUST SOC AM, V108, P679, DOI 10.1121/1.429600; OLDFIELD RC, 1971, NEUROPSYCHOLOGIA, V9, P97, DOI 10.1016/0028-3932(71)90067-4; Yrttiaho S, 2009, J ACOUST SOC AM, V125, P3177, DOI 10.1121/1.3097471; Shaw ME, 2013, NEUROIMAGE, V74, P22, DOI 10.1016/j.neuroimage.2013.02.002; Szymanski MD, 2001, J NEUROSURG, V94, P445, DOI 10.3171/jns.2001.94.3.0445; Ross B, 2005, CEREB CORTEX, V15, P2029, DOI 10.1093/cercor/bhi078; Okamoto H, 2011, J COGNITIVE NEUROSCI, V23, P1855, DOI 10.1162/jocn.2010.21521; DRULLMAN R, 1994, J ACOUST SOC AM, V95, P2670, DOI 10.1121/1.409836; DRULLMAN R, 1994, J ACOUST SOC AM, V95, P1053, DOI 10.1121/1.408467; John MS, 2001, AUDIOL NEURO-OTOL, V6, P12, DOI 10.1159/000046805; Gutschalk A, 2002, NEUROIMAGE, V15, P207, DOI 10.1006/nimg.2001.0949; HOLM S, 1979, SCAND J STAT, V6, P65; TALLAL P, 1993, ANN NY ACAD SCI, V682, P27, DOI 10.1111/j.1749-6632.1993.tb22957.x; Dau T, 1997, J ACOUST SOC AM, V102, P2906, DOI 10.1121/1.420345; Supin AY, 1999, J ACOUST SOC AM, V106, P2800, DOI 10.1121/1.428105; Alho K, 1998, NEUROSCI LETT, V258, P9, DOI 10.1016/S0304-3940(98)00836-2; Zatorre RJ, 2002, TRENDS COGN SCI, V6, P37, DOI 10.1016/S1364-6613(00)01816-7; Poeppel D, 2003, SPEECH COMMUN, V41, P245, DOI 10.1016/S0167-6393(02)00107-3; Pantev C, 1996, HEARING RES, V101, P62, DOI 10.1016/S0378-5955(96)00133-5; Belin P, 1998, J COGNITIVE NEUROSCI, V10, P536, DOI 10.1162/089892998562834; PATTERSON RD, 1995, J ACOUST SOC AM, V98, P1890, DOI 10.1121/1.414456; Chi TS, 1999, J ACOUST SOC AM, V106, P2719, DOI 10.1121/1.428100; De Boer E, 1985, AUDITORY TIME CONSTA, P141; Engelien A, 2000, HEARING RES, V148, P153, DOI 10.1016/S0378-5955(00)00148-9; Griffiths TD, 2001, NAT NEUROSCI, V4, P633, DOI 10.1038/88459; HARI R, 1989, EXP BRAIN RES, V74, P463; Hewson-Stoate N, 2006, EUR J NEUROSCI, V24, P2661, DOI 10.1111/j.1460-9568.2006.05096.x; Keceli S, 2012, BMC NEUROSCI, V13, DOI 10.1186/1471-2202-13-7; MAKELA JP, 1987, ELECTROEN CLIN NEURO, V66, P539, DOI 10.1016/0013-4694(87)90101-5; Moore B., 2003, INTRO PSYCHOL HEARIN; Patterson R. D., 2000, Journal of the Acoustical Society of Japan (E), V21, DOI 10.1250/ast.21.183; PICTON TW, 1987, J ACOUST SOC AM, V82, P165, DOI 10.1121/1.395560; PICTON TW, 1978, ELECTROEN CLIN NEURO, V45, P198, DOI 10.1016/0013-4694(78)90004-4; Seither-Preisler A, 2006, HEARING RES, V218, P50, DOI 10.1016/j.heares.2006.04.005; Wang KS, 1994, IEEE T SPEECH AUDI P, V2, P421; Warren RM, 2008, AUDITORY PERCEPTION: AN ANALYSIS AND SYNTHESIS, 3RD EDITION, P1	53	0	0	SPRINGER	DORDRECHT	VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS	0896-0267	1573-6792		BRAIN TOPOGR	Brain Topogr.	MAY	2015	28	3			SI		459	470		10.1007/s10548-013-0300-3		12	Clinical Neurology; Neurosciences	Neurosciences & Neurology	CG5RQ	WOS:000353352100008		
J	Okamoto, H; Kakigi, R				Okamoto, Hidehiko; Kakigi, Ryusuke			Hemispheric Asymmetry of Auditory Mismatch Negativity Elicited by Spectral and Temporal Deviants: A Magnetoencephalographic Study	BRAIN TOPOGRAPHY			English	Article						Auditory evoked response; Hemispheric laterality; Magnetoencephalography (MEG); Mismatch negativity (MMNm)	SPEECH RECEPTION; CORTEX; LATERALIZATION; SOUNDS; PITCH; MEG; SPECIALIZATION; SENSITIVITY; PERCEPTION; RELEVANCE	One of the major challenges in human brain science is the functional hemispheric asymmetry of auditory processing. Behavioral and neurophysiological studies have demonstrated that speech processing is dominantly handled in the left hemisphere, whereas music processing dominantly occurs in the right. Using magnetoencephalography, we measured the auditory mismatch negativity elicited by band-pass filtered click-trains, which deviated from frequently presented standard sound signals in a spectral or temporal domain. The results showed that spectral and temporal deviants were dominantly processed in the right and left hemispheres, respectively. Hemispheric asymmetry was not limited to high-level cognitive processes, but also originated from the pre-attentive neural processing stage represented by mismatch negativity.	[Okamoto, Hidehiko; Kakigi, Ryusuke] Natl Inst Nat Sci, Natl Inst Physiol Sci, Dept Integrat Physiol, Okazaki, Aichi 4448585, Japan	Okamoto, H (reprint author), Natl Inst Nat Sci, Natl Inst Physiol Sci, Dept Integrat Physiol, 38 Nishigo Naka, Okazaki, Aichi 4448585, Japan.	hokamoto@nips.ac.jp			Japan Society for the Promotion of Science for Young Scientists [23689070]; Strategic Research Program for Brain Sciences (Development of biomarker candidates for social behavior); Sound Technology Promotion Foundation	We thank Y. Takeshima for technical help and our test subjects for their diligent collaboration. This study was supported by the "Japan Society for the Promotion of Science for Young Scientists (23689070)", "Strategic Research Program for Brain Sciences (Development of biomarker candidates for social behavior)", and "Sound Technology Promotion Foundation".	TESCHE CD, 1995, ELECTROEN CLIN NEURO, V95, P189, DOI 10.1016/0013-4694(95)00064-6; Zatorre RJ, 2001, CEREB CORTEX, V11, P946, DOI 10.1093/cercor/11.10.946; Kujala T, 2007, BIOL PSYCHOL, V74, P1, DOI 10.1016/j.biopsycho.2006.06.001; ZATORRE RJ, 1994, J NEUROSCI, V14, P1908; NAATANEN R, 1978, ACTA PSYCHOL, V42, P313, DOI 10.1016/0001-6918(78)90006-9; SHANNON RV, 1995, SCIENCE, V270, P303, DOI 10.1126/science.270.5234.303; Naatanen R, 2007, CLIN NEUROPHYSIOL, V118, P2544, DOI 10.1016/j.clinph.2007.04.026; VOS PG, 1989, MUSIC PERCEPT, V6, P383; EULITZ C, 1995, J NEUROSCI, V15, P2748; Boemio A, 2005, NAT NEUROSCI, V8, P389, DOI 10.1038/nn1409; OLDFIELD RC, 1971, NEUROPSYCHOLOGIA, V9, P97, DOI 10.1016/0028-3932(71)90067-4; Szymanski MD, 2001, J NEUROSURG, V94, P445, DOI 10.3171/jns.2001.94.3.0445; Okamoto H, 2009, CEREB CORTEX, V19, P2290, DOI 10.1093/cercor/bhn245; DRULLMAN R, 1994, J ACOUST SOC AM, V95, P2670, DOI 10.1121/1.409836; DRULLMAN R, 1994, J ACOUST SOC AM, V95, P1053, DOI 10.1121/1.408467; Shtyrov Y, 2000, NEUROIMAGE, V12, P657, DOI 10.1006/nimg.2000.0646; TALLAL P, 1993, ANN NY ACAD SCI, V682, P27, DOI 10.1111/j.1749-6632.1993.tb22957.x; Alho K, 1998, NEUROSCI LETT, V258, P9, DOI 10.1016/S0304-3940(98)00836-2; Zatorre RJ, 2002, TRENDS COGN SCI, V6, P37, DOI 10.1016/S1364-6613(00)01816-7; Jamison HL, 2006, CEREB CORTEX, V16, P1266, DOI 10.1093/cercor/bhj068; Belin P, 2000, NATURE, V403, P309, DOI 10.1038/35002078; Poeppel D, 2003, SPEECH COMMUN, V41, P245, DOI 10.1016/S0167-6393(02)00107-3; Belin P, 1998, J COGNITIVE NEUROSCI, V10, P536, DOI 10.1162/089892998562834; ALHO K, 1995, EAR HEARING, V16, P38, DOI 10.1097/00003446-199502000-00004; Griffiths TD, 1999, NEUROREPORT, V10, P3825, DOI 10.1097/00001756-199912160-00019; Bendor D, 2007, NAT NEUROSCI, V10, P763, DOI 10.1038/nn1888; Broca P., 1861, B SOC ANAT PARIS, V36, P330; Hillebrand A, 2002, NEUROIMAGE, V16, P638, DOI 10.1006/nimg.2002.1102; Joos M, 1948, LANGUAGE MONOGRAPH, V23; Lappe C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061296; Moore B., 2003, INTRO PSYCHOL HEARIN; NAATANEN R, 1987, PSYCHOPHYSIOLOGY, V24, P375, DOI 10.1111/j.1469-8986.1987.tb00311.x; Okamoto H, 2012, FRONT PSYCHOL, V3, DOI 10.3389/fpsyg.2012.00149; Sakai M, 2009, BRAIN RES, V1265, P80, DOI 10.1016/j.brainres.2009.01.064; Tervaniemi M, 1999, NEUROIMAGE, V9, P330, DOI 10.1006/nimg.1999.0405; Warrier CM, 2002, PERCEPT PSYCHOPHYS, V64, P198, DOI 10.3758/BF03195786; Wernicke C, 1874, SYMPTOMENKOMPLEX PSY	37	1	1	SPRINGER	DORDRECHT	VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS	0896-0267	1573-6792		BRAIN TOPOGR	Brain Topogr.	MAY	2015	28	3			SI		471	478		10.1007/s10548-013-0347-1		8	Clinical Neurology; Neurosciences	Neurosciences & Neurology	CG5RQ	WOS:000353352100009		
J	Yoshida, S; Kobayashi, Y; Nakama, T; Zhou, Y; Ishikawa, K; Arita, R; Nakao, S; Miyazaki, M; Sassa, Y; Oshima, Y; Izuhara, K; Kono, T; Ishibashi, T				Yoshida, Shigeo; Kobayashi, Yoshiyuki; Nakama, Takahito; Zhou, Yedi; Ishikawa, Keijiro; Arita, Ryoichi; Nakao, Shintaro; Miyazaki, Masanori; Sassa, Yukio; Oshima, Yuji; Izuhara, Kenji; Kono, Toshihiro; Ishibashi, Tatsuro			Increased expression of M-CSF and IL-13 in vitreous of patients with proliferative diabetic retinopathy: implications for M2 macrophage-involving fibrovascular membrane formation	BRITISH JOURNAL OF OPHTHALMOLOGY			English	Article							OXYGEN-INDUCED RETINOPATHY; ENDOTHELIAL GROWTH-FACTOR; MOUSE MODEL; RETINAL NEOVASCULARIZATION; PERIOSTIN; VITREORETINOPATHY; INTERLEUKIN-13; ANGIOGENESIS; POLARIZATION; INVOLVEMENT	Purpose We recently demonstrated that M2 macrophages were involved in the development of fibrovascular membranes (FVM) associated with proliferative diabetic retinopathy (PDR) possibly through the induction of periostin. The purpose of this study was to determine whether macrophage colony-stimulating factor (M-CSF) and interleukin (IL)-13, inducers of the M2 polarisation of macrophages from monocytes, are elevated in the vitreous of patients with PDR, and whether M2-polarised macrophages induce periostin production. Methods We measured the levels of M-CSF, granulocyte-macrophage colony-stimulating factor (GM-CSF), IL-4, IL-13, soluble (s) CD163, periostin and vascular endothelial growth factor by sandwich ELISA in vitreous samples collected from 61 eyes of 47 patients with PDR, and 39 eyes of 36 patients with non-diabetic ocular diseases (control group). Human monocytes were polarised in vitro with GM-CSF, interferon-gamma, and lipopolysaccharide for M1 macrophages, and M-CSF, IL-4, and IL-13 for M2 macrophages. Quantitative real-time PCR was used to determine the mRNA level of periostin. Results The concentrations of M-CSF and IL-13 in the vitreous were significantly higher in patients with PDR than in non-diabetic controls (p<0.0001). There was a strong positive correlation between the vitreous concentrations of M-CSF and sCD163 and periostin. The mean vitreous level of IL-13 was significantly higher in eyes with FVMs than in those without FVMs (epicentre only). In vitro studies showed that M2-polarlised macrophages significantly increased the expression of the mRNA of periostin. Conclusions These findings indicate that the M2 polarisation of macrophages is induced by M-CSF and IL-13 in diabetic retinas. The presence of M-CSF and IL-13 would then promote FVM formation by periostin production.	[Yoshida, Shigeo; Kobayashi, Yoshiyuki; Nakama, Takahito; Zhou, Yedi; Ishikawa, Keijiro; Arita, Ryoichi; Nakao, Shintaro; Miyazaki, Masanori; Sassa, Yukio; Oshima, Yuji; Ishibashi, Tatsuro] Kyushu Univ, Dept Ophthalmol, Grad Sch Med Sci, Fukuoka 8128582, Japan; [Izuhara, Kenji] Saga Med Sch, Dept Biomol Sci, Div Med Biochem, Saga, Japan; [Kono, Toshihiro] Fukuoka Univ, Dept Ophthalmol, Chikushi Hosp, Fukuoka 81401, Japan	Yoshida, S (reprint author), Kyushu Univ, Dept Ophthalmol, Grad Sch Med Sci, Fukuoka 8128582, Japan.	yosida@eye.med.kyushu-u.ac.jp			JSPS KAKENHI [26293374, 24249083, 26670757]; Takeda Science Foundation	Masayo Eto provided excellent technical help. This work was supported in part by JSPS KAKENHI Grant Numbers 26293374, 24249083 and 26670757 and Takeda Science Foundation.	Hiscott P, 2000, EYE, V14, P549; Ishikawa K, 2012, LAB INVEST, V92, P91, DOI 10.1038/labinvest.2011.141; Sica A, 2012, J CLIN INVEST, V122, P787, DOI 10.1172/JCI59643; Yoshida S, 1997, MOL CELL BIOL, V17, P4015; Snead DRJ, 2008, EYE, V22, P1310, DOI 10.1038/eye.2008.36; ELNER SG, 1995, CURR EYE RES, V14, P1045, DOI 10.3109/02713689508998529; Ishikawa K, 2010, INVEST OPHTH VIS SCI, V51, P4307, DOI 10.1167/iovs.09-4605; Martinon F, 2009, ANNU REV IMMUNOL, V27, P229, DOI 10.1146/annurev.immunol.021908.132532; Adamis AP, 2002, BRIT J OPHTHALMOL, V86, P363, DOI 10.1136/bjo.86.4.363; PIERCE EA, 1995, P NATL ACAD SCI USA, V92, P905, DOI 10.1073/pnas.92.3.905; Sivaprasad S, 2012, SURV OPHTHALMOL, V57, P347, DOI 10.1016/j.survophthal.2012.01.004; ZURAWSKI SM, 1993, EMBO J, V12, P2663; Verreck FAW, 2006, J LEUKOCYTE BIOL, V79, P285, DOI 10.1189/jlb.0105015; Mantovani A, 2013, J PATHOL, V229, P176, DOI 10.1002/path.4133; Ishikawa K, 2014, FASEB J, V28, P131, DOI 10.1096/fj.13-229740; Yoshida S, 2003, J LEUKOCYTE BIOL, V73, P137, DOI 10.1189/jlb.0302117; Asato R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054191; Kobayashi Y, 2015, BRIT J OPHTHALMOL, V99, P451, DOI [10.1136/bjophthalmol-2014-305321, 10.1136/bjophthalmo1-2014-305321]; Liu W, 2009, CURR EYE RES, V34, P123, DOI 10.1080/02713680802650369; O'Reilly S, 2013, BIOFACTORS, V39, P593, DOI 10.1002/biof.1117; Saini A, 1996, METABOLISM, V45, P1125, DOI 10.1016/S0026-0495(96)90012-8; Simó Rafael, 2006, Curr Diabetes Rev, V2, P71, DOI 10.2174/157339906775473671; SUNDERKOTTER C, 1991, PHARMACOL THERAPEUT, V51, P195, DOI 10.1016/0163-7258(91)90077-Y; Yoshida S, 2011, INVEST OPHTH VIS SCI, V52, P5670, DOI 10.1167/iovs.10-6625; Yoshida S, 2012, INVEST OPHTH VIS SCI, V53, P6997, DOI 10.1167/iovs.12-9671	25	2	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0007-1161	1468-2079		BRIT J OPHTHALMOL	Br. J. Ophthalmol.	MAY	2015	99	5					629	634		10.1136/bjophthalmol-2014-305860		6	Ophthalmology	Ophthalmology	CG5BR	WOS:000353305800012		
J	Fukuda, K; Ishida, W; Harada, Y; Wakasa, Y; Takagi, H; Takaiwa, F; Fukushima, A				Fukuda, Ken; Ishida, Waka; Harada, Yosuke; Wakasa, Yuhya; Takagi, Hidenori; Takaiwa, Fumio; Fukushima, Atsuki			Prevention of allergic conjunctivitis in mice by a rice-based edible vaccine containing modified Japanese cedar pollen allergens	BRITISH JOURNAL OF OPHTHALMOLOGY			English	Article							ORAL IMMUNOTHERAPY; POLLINOSIS; TOLERANCE; RESPONSES; SEED	Background/aims To determine whether oral immunotherapy with transgenic rice seeds expressing hypoallergenic modified antigens suppresses cedar pollen-induced allergic conjunctivitis by eliciting immune tolerance in mice. Methods BALB/c mice were fed once a day for 20 days with 220 mg of transgenic rice expressing modified Japanese cedar pollen allergens Cry j 1 and Cry j 2 or with non-transgenic rice seeds as a control. They were then sensitised with two intraperitoneal injections of Japanese cedar pollen in alum before challenge twice with pollen in eye drops. Twenty-four hours after the second challenge, the conjunctiva, spleen, and blood were isolated for histological analysis, cytokine production assays, and measurement of serum immunoglobulin E concentrations, respectively. Results The numbers of eosinophils and total inflammatory cells in the conjunctiva were significantly lower in mice fed the transgenic rice than in those fed non-transgenic rice. The clinical score evaluated at 15 min after antigen challenge was also significantly lower in mice fed the transgenic rice than in those fed non-transgenic rice. The serum concentrations of both total and allergen-specific immunoglobulin E were also significantly lower in mice fed the transgenic rice. Oral vaccination with transgenic rice resulted in significant down-regulation of the allergen-induced production of interleukin (IL)-2, IL-4, IL-5, IL-12p70, interferon-gamma, and IL-17A by splenocytes. Conclusions Oral immunotherapy with transgenic rice expressing modified Japanese cedar pollen allergens suppressed pollen-induced experimental allergic conjunctivitis in mice by eliciting immune tolerance. This novel prophylactic approach is potentially safe and effective for allergen-specific oral immunotherapy in allergic conjunctivitis.	[Fukuda, Ken; Ishida, Waka; Harada, Yosuke; Fukushima, Atsuki] Kochi Med Sch, Dept Ophthalmol & Visual Sci, Nankoku, Kochi 7838505, Japan; [Wakasa, Yuhya; Takagi, Hidenori; Takaiwa, Fumio] Natl Inst Agrobiol Sci, Funct Transgen Crop Res Unit, Tsukuba, Ibaraki, Japan	Fukuda, K (reprint author), Kochi Med Sch, Dept Ophthalmol & Visual Sci, Oko Cho, Nankoku, Kochi 7838505, Japan.	k.fukuda@kochi-u.ac.jp			Ministry of Agriculture, Forestry, and Fisheries of Japan	This study was supported by "Agri-Health Translational Research Projects" of the Ministry of Agriculture, Forestry, and Fisheries of Japan to FT.	Wakasa Y, 2013, PLANT BIOTECHNOL J, V11, P66, DOI 10.1111/pbi.12007; HASHIMOTO M, 1995, CLIN EXP ALLERGY, V25, P848, DOI 10.1111/j.1365-2222.1995.tb00027.x; Magone MT, 1998, CLIN IMMUNOL IMMUNOP, V87, P75, DOI 10.1006/clin.1997.4507; Bohle B, 2007, J ALLERGY CLIN IMMUN, V120, P707, DOI 10.1016/j.jaci.2007.06.013; Takaiwa F, 2011, HUM VACCINES, V7, P357, DOI 10.4161/hv.7.3.14302; Ishida W, 2013, BRIT J OPHTHALMOL, V97, P492, DOI 10.1136/bjophthalmol-2012-302639; Faria AMC, 2005, IMMUNOL REV, V206, P232, DOI 10.1111/j.0105-2896.2005.00280.x; Takaiwa F, 2013, IMMUNOTHERAPY-UK, V5, P301, DOI [10.2217/imt.13.4, 10.2217/IMT.13.4]; Fukushima A, 2006, BRIT J OPHTHALMOL, V90, P1535, DOI 10.1136/bjo.2006.100180; Fukushima A, 2007, BIOL PHARM BULL, V30, P1745, DOI 10.1248/bpb.30.1745; Fukushima A, 2006, INVEST OPHTH VIS SCI, V47, P657, DOI 10.1167/iovs.05-1064; Fukushima A, 2005, J IMMUNOL, V175, P4897; Midoro-Horiuti T, 2006, MOL IMMUNOL, V43, P509, DOI 10.1016/j.molimm.2005.05.006; Okamoto Yoshitaka, 2009, Allergology International, V58, P155, DOI 10.2332/allergolint.08-RAI-0074; Takagi H, 2005, P NATL ACAD SCI USA, V102, P17525, DOI 10.1073/pnas.0503428102	15	2	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0007-1161	1468-2079		BRIT J OPHTHALMOL	Br. J. Ophthalmol.	MAY	2015	99	5					705	709		10.1136/bjophthalmol-2014-305842		5	Ophthalmology	Ophthalmology	CG5BR	WOS:000353305800027		
J	Matsushita, K; Kobori, Y; Kamada, S; Yamaguchi, H				Matsushita, K.; Kobori, Y.; Kamada, S.; Yamaguchi, H.			Easily manoeuvrable osteotome for pterygomaxillary disjunction	BRITISH JOURNAL OF ORAL & MAXILLOFACIAL SURGERY			English	Article						Le Fort I osteotomy; Pterygomaxillary disjunction; Swan's neck osteotome			[Matsushita, K.; Kobori, Y.; Kamada, S.; Yamaguchi, H.] Hokkaido Univ, Grad Sch Dent Med, Dept Oral & Maxillofacial Surg, Div Oral Pathobiol Sci,Kita Ku, Sapporo, Hokkaido 0608586, Japan	Matsushita, K (reprint author), Hokkaido Univ, Grad Sch Dent Med, Dept Oral & Maxillofacial Surg, Div Oral Pathobiol Sci,Kita Ku, N13 W7, Sapporo, Hokkaido 0608586, Japan.	matsushi@dcn.hokudai.ac.jp					LANIGAN DT, 1990, J ORAL MAXIL SURG, V48, P561; WIKKELING OME, 1975, INT J ORAL MAXILLOF, V4, P99, DOI 10.1016/S0300-9785(75)80001-9	2	0	0	CHURCHILL LIVINGSTONE	EDINBURGH	JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE, LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND	0266-4356	1532-1940		BRIT J ORAL MAX SURG	Br. J. Oral Maxillofac. Surg.	MAY	2015	53	5					474	475		10.1016/j.bjoms.2015.02.007		2	Dentistry, Oral Surgery & Medicine; Surgery	Dentistry, Oral Surgery & Medicine; Surgery	CG3ZE	WOS:000353218100017		
J	Yoda, T; Sato, T				Yoda, Tetsuya; Sato, Tsuyoshi			Re: Limited mouth opening of unknown cause cured by diagnostic coronoidectomy: a new clinical entity? Br J Oral Maxillofac Surg 2015:53(3):230-4	BRITISH JOURNAL OF ORAL & MAXILLOFACIAL SURGERY			English	Letter							TENDON-APONEUROSIS HYPERPLASIA		[Yoda, Tetsuya; Sato, Tsuyoshi] Saitama Med Univ, Dept Oral & Maxillofacial Surg, Saitama, Japan	Sato, T (reprint author), Saitama Med Univ, Dept Oral & Maxillofacial Surg, 38 Moro Hongou, Moroyama, Saitama 3500495, Japan.	yoda@saitama-med.ac.jp; tsato@saitama-med.ac.jp					Nakamoto A, 2014, INT J ORAL MAX SURG, V43, P113, DOI 10.1016/j.ijom.2013.06.004; Sato T, 2014, ORAL DIS, V20, P404, DOI 10.1111/odi.12140; Yoda T, 2009, INT J ORAL MAX SURG, V38, P1143, DOI 10.1016/j.ijom.2009.07.002	3	0	0	CHURCHILL LIVINGSTONE	EDINBURGH	JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE, LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND	0266-4356	1532-1940		BRIT J ORAL MAX SURG	Br. J. Oral Maxillofac. Surg.	MAY	2015	53	5					476	477		10.1016/j.bjoms.2015.02.016		3	Dentistry, Oral Surgery & Medicine; Surgery	Dentistry, Oral Surgery & Medicine; Surgery	CG3ZE	WOS:000353218100019		
J	Kimura, M; Sakai, A; Sakamoto, A; Suzuki, H				Kimura, M.; Sakai, A.; Sakamoto, A.; Suzuki, H.			Glial cell line-derived neurotrophic factor-mediated enhancement of noradrenergic descending inhibition in the locus coeruleus exerts prolonged analgesia in neuropathic pain	BRITISH JOURNAL OF PHARMACOLOGY			English	Article							CONCISE GUIDE; IN-VIVO; TYROSINE-HYDROXYLASE; RAT MODEL; ADHESION MOLECULE; ARRIVE GUIDELINES; RECEPTOR-ALPHA; NERVE LIGATION; SPINAL-CORD; NEURONS	Background and PurposeThe locus coeruleus (LC) is the principal nucleus containing the noradrenergic neurons and is a major endogenous source of pain modulation in the brain. Glial cell line-derived neurotrophic factor (GDNF), a well-established neurotrophic factor for noradrenergic neurons, is a major pain modulator in the spinal cord and primary sensory neurons. However, it is unknown whether GDNF is involved in pain modulation in the LC. Experimental ApproachRats with chronic constriction injury (CCI) of the left sciatic nerve were used as a model of neuropathic pain. GDNF was injected into the left LC of rats with CCI for 3 consecutive days and changes in mechanical allodynia and thermal hyperalgesia were assessed. The (2)-adrenoceptor antagonist yohimbine was injected intrathecally to assess the involvement of descending inhibition in GDNF-mediated analgesia. The MEK inhibitor U0126 was used to investigate whether the ERK signalling pathway plays a role in the analgesic effects of GDNF. Key ResultsBoth mechanical allodynia and thermal hyperalgesia were attenuated 24h after the first GDNF injection. GDNF increased the noradrenaline content in the dorsal spinal cord. The analgesic effects continued for at least 3 days after the last injection. Yohimbine abolished these effects of GDNF. The analgesic effects of GDNF were partly, but significantly, inhibited by prior injection of U0126 into the LC. Conclusions and ImplicationsGDNF injection into the LC exerts prolonged analgesic effects on neuropathic pain in rats by enhancing descending noradrenergic inhibition.	[Kimura, M.; Sakamoto, A.] Nippon Med Sch, Dept Anesthesiol, Grad Sch Med, Tokyo 113, Japan; [Sakai, A.; Suzuki, H.] Nippon Med Sch, Dept Pharmacol, Grad Sch Med, Tokyo 113, Japan	Suzuki, H (reprint author), Nippon Med Sch, Grad Sch Med, Dept Pharmacol, Bunkyo Ku, 1-1-5 Sendagi, Tokyo 1138602, Japan.	hsuzuki@nms.ac.jp			Japan Society for the Promotion of Science [22791457]; Ministry of Education, Culture, Sports, Science and Technology, Japan [S0801035]	We thank Drs. Masatoshi Nagano and Motoyo Maruyama for technical assistance in the HPLC assay and Dr. Yumi Muto for histological preparation. This work was supported by a Grant-in-Aid for Encouragement of Young Scientists (B) (22791457 to A.S.) from the Japan Society for the Promotion of Science and a Ministry of Education, Culture, Sports, Science and Technology-Supported Program for the Strategic Research Foundation at Private Universities, 2008-2012 (S0801035 to H.S.), Japan.	Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; Alexander SPH, 2013, BRIT J PHARMACOL, V170, P1459, DOI 10.1111/bph.12445; Pertovaara A, 2013, EUR J PHARMACOL, V716, P2, DOI 10.1016/j.ejphar.2013.01.067; FUNG SJ, 1991, PROG BRAIN RES, V88, P395; Yang F, 2001, NAT NEUROSCI, V4, P1071, DOI 10.1038/nn734; Pertovaara A, 2006, PROG NEUROBIOL, V80, P53, DOI 10.1016/j.pneurobio.2006.08.001; EISENACH JC, 1995, PAIN, V61, P391, DOI 10.1016/0304-3959(94)00209-W; Arenas E, 1995, NEURON, V15, P1465, DOI 10.1016/0896-6273(95)90024-1; Kilkenny C, 2010, BRIT J PHARMACOL, V160, P1577, DOI 10.1111/j.1476-5381.2010.00872.x; Alexander SPH, 2013, BRIT J PHARMACOL, V170, P1797, DOI 10.1111/bph.12451; Malin SA, 2006, J NEUROSCI, V26, P8588, DOI 10.1523/JNEUROSCI.1726-06.2006; Millan MJ, 2002, PROG NEUROBIOL, V66, P355, DOI 10.1016/S0301-0082(02)00009-6; Alexander SPH, 2013, BRIT J PHARMACOL, V170, P1676, DOI 10.1111/bph.12449; Pascual A, 2008, NAT NEUROSCI, V11, P755, DOI 10.1038/nn.2136; Bennett DLH, 1998, J NEUROSCI, V18, P3059; Airaksinen MS, 2002, NAT REV NEUROSCI, V3, P383, DOI 10.1038/nrn812; Bogen O, 2008, EUR J NEUROSCI, V28, P12, DOI 10.1111/j.1460-9568.2008.06308.x; Brightwell JJ, 2009, NEUROSCIENCE, V160, P174, DOI 10.1016/j.neuroscience.2009.02.023; Alba-Delgado C, 2012, PAIN, V153, P1438, DOI 10.1016/j.pain.2012.03.034; Boucher TJ, 2000, SCIENCE, V290, P124, DOI 10.1126/science.290.5489.124; Alexander SPH, 2013, BRIT J PHARMACOL, V170, P1607, DOI 10.1111/bph.12447; Bradbury EJ, 1998, MOL CELL NEUROSCI, V12, P256, DOI 10.1006/mcne.1998.0719; Viisanen H, 2007, NEUROSCIENCE, V146, P1785, DOI 10.1016/j.neuroscience.2007.03.016; Wei H, 2013, BASIC CLIN PHARMACOL, V112, P90, DOI 10.1111/j.1742-7843.2012.00930.x; BENNETT GJ, 1988, PAIN, V33, P87, DOI 10.1016/0304-3959(88)90209-6; Takekoshi K, 2001, ENDOCRINOLOGY, V142, P290, DOI 10.1210/en.142.1.290; Daubner SC, 2011, ARCH BIOCHEM BIOPHYS, V508, P1, DOI 10.1016/j.abb.2010.12.017; Ackerman LL, 2003, J PAIN SYMPTOM MANAG, V26, P668, DOI 10.1016/S0885-3924(03)00144-1; Pawson AJ, 2014, NUCLEIC ACIDS RES, V42, pD1098, DOI 10.1093/nar/gkt1143; Trupp M, 1997, J NEUROSCI, V17, P3554; WEST WL, 1993, BRAIN RES, V626, P127, DOI 10.1016/0006-8993(93)90571-4; McGrath JC, 2010, BRIT J PHARMACOL, V160, P1573, DOI 10.1111/j.1476-5381.2010.00873.x; Borges GS, 2013, EUR J PAIN, V17, P35, DOI 10.1002/j.1532-2149.2012.00181.x; Black MA, 2009, EUR J NEUROSCI, V30, P2190, DOI 10.1111/j.1460-9568.2009.07000.x; Bravo L, 2013, PAIN, V154, P2014, DOI 10.1016/j.pain.2013.06.021; Christophersen NS, 2007, EXP NEUROL, V204, P791, DOI 10.1016/j.expneurol.2007.01.014; CLARK FM, 1991, BRAIN RES, V538, P231, DOI 10.1016/0006-8993(91)90435-X; O'Connor AB, 2009, AM J MED, V122, pS22, DOI 10.1016/j.amjmed.2009.04.007; Dworkin RH, 2010, MAYO CLIN PROC, V85, pS3, DOI 10.4065/mcp.2009.0649; Feng XM, 2009, EUR J PHARMACOL, V614, P38, DOI 10.1016/j.ejphar.2009.04.044; Glazner GW, 1998, J COMP NEUROL, V391, P42, DOI 10.1002/(SICI)1096-9861(19980202)391:1<42::AID-CNE4>3.0.CO;2-R; Golden JP, 1998, J COMP NEUROL, V398, P139, DOI 10.1002/(SICI)1096-9861(19980817)398:1<139::AID-CNE9>3.0.CO;2-2; Guo Z, 1998, J NEUROSCI, V18, P8163; Hayashida KI, 2008, ANESTHESIOLOGY, V109, P1077, DOI 10.1097/ALN.0b013e31818dac9c; Hentall ID, 2003, J NEUROPHYSIOL, V89, P2943, DOI 10.1152/jn.00608.2002; Howorth PW, 2009, J COMP NEUROL, V512, P141, DOI 10.1002/cne.21879; JONES SL, 1986, BRAIN RES, V364, P315, DOI 10.1016/0006-8993(86)90844-9; Muto Y, 2012, BRIT J PHARMACOL, V166, P1047, DOI 10.1111/j.1476-5381.2011.01820.x; Pascual A, 2011, J MOL ENDOCRINOL, V46, pR83, DOI 10.1530/JME-10-0125; Paxinos G, 1998, RAT BRAIN STEREOTAXI; Peterziel H, 2002, J CELL BIOL, V159, P157, DOI 10.1083/jcb.200203115; Saade NE, 2008, PROG NEUROBIOL, V86, P22, DOI 10.1016/j.pneurobio.2008.06.002; Sakai A, 2008, PAIN, V137, P378, DOI 10.1016/j.pain.2007.09.020; Sarabi A, 2003, NEUROSCIENCE, V116, P261, DOI 10.1016/S0306-4522(02)00559-6; Takasu K, 2011, J PAIN, V12, P1130, DOI 10.1016/j.jpain.2011.04.003; Takeda M, 2010, BRAIN BEHAV IMMUN, V24, P72, DOI 10.1016/j.bbi.2009.08.002; Takeuchi Y, 2007, NEUROPHARMACOLOGY, V53, P842, DOI 10.1016/j.neuropharm.2007.08.013; Wang J, 2003, NEUROSIGNALS, V12, P78, DOI 10.1159/000071817; Wang R, 2003, NEUROSCIENCE, V121, P815, DOI 10.1016/S0306-4522(03)00491-3; Weinbroum AA, 2001, EUR J SURG, V167, P563; Xu B, 2012, MOL PAIN, V8, DOI 10.1186/1744-8069-8-15; YAKSH TL, 1985, EUR J PHARMACOL, V117, P81, DOI 10.1016/0014-2999(85)90474-1; ZIMMERMANN M, 1983, PAIN, V16, P109, DOI 10.1016/0304-3959(83)90201-4	63	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0007-1188	1476-5381		BRIT J PHARMACOL	Br. J. Pharmacol.	MAY	2015	172	10					2469	2478		10.1111/bph.13073		10	Pharmacology & Pharmacy	Pharmacology & Pharmacy	CG6EQ	WOS:000353389600005		
J	Cingolani, S; Jeanjean, L; Tanaka, K				Cingolani, Silvia; Jeanjean, Louis; Tanaka, Kazunaga			Multiplicity of positive solutions of nonlinear Schrodinger equations concentrating at a potential well	CALCULUS OF VARIATIONS AND PARTIAL DIFFERENTIAL EQUATIONS			English	Article							PERTURBED ELLIPTIC-EQUATIONS; SEMICLASSICAL STATES; STANDING WAVES; BOUND-STATES; R-N; GENERAL NONLINEARITY; FIELD-EQUATIONS; DOMAIN TOPOLOGY; EXISTENCE; POINTS	We consider singularly perturbed nonlinear Schrodinger equations where and is a nonlinear term which satisfies the so-called Berestycki-Lions conditions. We assume that there exists a bounded domain such that and we set . For small we prove the existence of at least solutions to (0.1) concentrating, as around . We remark that, under our assumptions of , the search of solutions to (0.1) cannot be reduced to the study of the critical points of a functional restricted to a Nehari manifold.	[Cingolani, Silvia] Politecn Bari, Dipartimento Meccan Matemat & Management, I-70125 Bari, Italy; [Jeanjean, Louis] Univ Franche Comte, Math Lab, CNRS, UMR 6623, F-25030 Besancon, France; [Tanaka, Kazunaga] Waseda Univ, Sch Sci & Engn, Dept Math, Shinjuku Ku, Tokyo 1698555, Japan	Cingolani, S (reprint author), Politecn Bari, Dipartimento Meccan Matemat & Management, Via E Orabona 4, I-70125 Bari, Italy.	silvia.cingolani@poliba.it; louis.jeanjean@univ-fcomte.fr; kazunaga@waseda.jp					Jeanjean L, 2004, CALC VAR PARTIAL DIF, V21, P287, DOI 10.1007/s00526-003-026-6; Cortazar C, 1998, ARCH RATION MECH AN, V142, P127, DOI 10.1007/s002050050086; Davila J, 2013, P LOND MATH SOC, V106, P318, DOI 10.1112/plms/pds038; Byeon J, 2013, J EUR MATH SOC, V15, P1859, DOI 10.4171/JEMS/407; BENCI V, 1991, ARCH RATION MECH AN, V114, P79, DOI 10.1007/BF00375686; Del Pino M, 1998, ANN I H POINCARE-AN, V15, P127, DOI 10.1016/S0294-1449(97)89296-7; del Pino M, 2002, MATH ANN, V324, P1, DOI 10.1007/s002080200327; Cingolani S, 2000, J DIFFER EQUATIONS, V160, P118, DOI 10.1006/jdeq.1999.3662; Ambrosetti A, 2001, ARCH RATION MECH AN, V159, P253, DOI 10.1007/s002050100152; Byeon J, 2007, ARCH RATION MECH AN, V185, P185, DOI 10.1007/s00205-006-0019-3; Ambrosetti A, 2003, COMMUN MATH PHYS, V235, P427, DOI 10.1007/s00220-003-0811-y; Cingolani S, 2003, J DIFFER EQUATIONS, V188, P52, DOI 10.1016/S0022-0396(02)00058-X; WANG XF, 1993, COMMUN MATH PHYS, V153, P229, DOI 10.1007/BF02096642; delPino M, 1997, J FUNCT ANAL, V149, P245, DOI 10.1006/jfan.1996.3085; Cingolani S, 2009, ESAIM CONTR OPTIM CA, V15, P653, DOI 10.1051/cocv:2008055; BERESTYCKI H, 1983, ARCH RATION MECH AN, V82, P313; Dancer EN, 2009, J DIFFER EQUATIONS, V246, P3077, DOI 10.1016/j.jde.2009.01.030; Gui CF, 1996, COMMUN PART DIFF EQ, V21, P787, DOI 10.1080/03605309608821208; Byeon J, 2008, COMMUN PART DIFF EQ, V33, P1113, DOI 10.1080/03605300701518174; Byeon J, 2002, ARCH RATION MECH AN, V165, P295, DOI 10.1007/s00205-002-0225-6; Jeanjean L, 2003, P AM MATH SOC, V131, P2399, DOI 10.1090/S0002-9939-02-06821-1; Del Pino M, 2007, COMMUN PUR APPL MATH, V60, P113, DOI 10.1002/cpa.20135; d'Avenia P, 2012, J FUNCT ANAL, V262, P4600, DOI 10.1016/j.jfa.2012.03.009; Cingolani S, 2002, J MATH ANAL APPL, V275, P108, DOI 10.1016/S0022-247X(02)00278-0; Ambrosetti A, 1997, ARCH RATION MECH AN, V140, P285, DOI 10.1007/s002050050067; BAHRI A, 1988, COMMUN PUR APPL MATH, V41, P253, DOI 10.1002/cpa.3160410302; Bartsch T, 2005, TOPOL METHOD NONL AN, V26, P109; Bartsch T., 2012, COMMUNICATION; Benci V., 1991, NONLINEAR ANAL TRIBU, P93; BENCI V, 1994, CALC VAR PARTIAL DIF, V2, P29, DOI 10.1007/BF01234314; Byeon J., 2014, MEM AM MATH SOC, V229; CERAMI G, 1992, NONLINEAR ANAL-THEOR, V18, P109, DOI 10.1016/0362-546X(92)90089-W; Cingolani S, 1998, P ROY SOC EDINB A, V128, P1249; Cingolani S., 1997, TOPOL METHOD NONL AN, V10, P1; Dancer E. N., 1999, ADV DIFF EQUATIONS, V4, P347; Dancer E. N., 1998, ABSTR APPL ANAL, V3, P293, DOI 10.1155/S1085337598000578; Dancer E. N., 1999, TOPOL METHOD NONL AN, V4, P347; Dancer EN, 2000, DISCRET CONTIN DYN S, V6, P39; delPino M, 1996, CALC VAR PARTIAL DIF, V4, P121, DOI 10.1007/s005260050031; FLOER A, 1986, J FUNCT ANAL, V69, P397, DOI 10.1016/0022-1236(86)90096-0; Fournier G., 1989, ANN I H POINCARE-AN, V6, P259; Fournier G., 1990, NODEA-NONLINEAR DIFF, V4, P95; KANG X., 2000, ADV DIFFERENTIAL EQU, V5, P899; LI Y. Y., 1997, ADV DIFFERENTIAL EQU, V2, P955; OH YG, 1990, COMMUN MATH PHYS, V131, P223, DOI 10.1007/BF02161413; OH YG, 1988, COMMUN PART DIFF EQ, V13, P1499, DOI 10.1080/03605308808820585; RABINOWITZ PH, 1992, Z ANGEW MATH PHYS, V43, P270, DOI 10.1007/BF00946631; Spanier E.H., 1966, ALGEBRAIC TOPOLOGY	48	0	0	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	0944-2669	1432-0835		CALC VAR PARTIAL DIF	Calc. Var. Partial Differ. Equ.	MAY	2015	53	1-2					413	439		10.1007/s00526-014-0754-5		27	Mathematics, Applied; Mathematics	Mathematics	CF9PE	WOS:000352896500016		
J	Kimijima, A; Nakagawa, K; Ogawa, T				Kimijima, Atsushi; Nakagawa, Kazushige; Ogawa, Takayoshi			Threshold of global behavior of solutions to a degenerate drift-diffusion system in between two critical exponents	CALCULUS OF VARIATIONS AND PARTIAL DIFFERENTIAL EQUATIONS			English	Article							KELLER-SEGEL SYSTEM; NONLINEAR SCHRODINGER-EQUATION; WELL-POSEDNESS; BLOW-UP; MODELING CHEMOTAXIS; PARABOLIC EQUATION; POISSON SYSTEM; KINETIC-THEORY; TIME BEHAVIOR; EXISTENCE	We consider large time behavior of weak solutions to degenerate drift-diffusion system related to Keller-Segel system. <Equation ID="Equ56"> <MediaObject> </MediaObject> </Equation>where and . There exist two critical diffusion exponents and and for those cases, large time behavior of solutions is classified by the invariant norms of initial data. We consider the case of the intermediate exponent and classify the global existence and finite time blow up of weak solutions by the combination of invariant norms of initial data. Besides we show that the threshold value which classifies the behavior of solutions is characterized by the best possible constant of the modified Hardy-Littlewood-Sobolev inequality: <Equation ID="Equ57"> <MediaObject> </MediaObject> </Equation>where and it is given by the radial stationary solution of the system. Here the result is continuous analogue of the known critical cases (Blanchet et al., Calc Var Partial Diff Equ 35:133-168, 2009 and Ogawa, Disc Contin Dyn Syst Ser S 4:875-886, 2011). Analogous result has been obtained in the theory of nonlinear Schrodinger equations. The global behavior of the weak solution is also given and the solution converges to the self-similar Barenbratt solution as time parameter goes to infinity.	[Kimijima, Atsushi; Ogawa, Takayoshi] Tohoku Univ, Math Inst, Sendai, Miyagi 9808578, Japan; [Nakagawa, Kazushige] Fukushima Univ, Fac Symbiot Syst Sci, Fukushima 9601296, Japan	Nakagawa, K (reprint author), Fukushima Univ, Fac Symbiot Syst Sci, Fukushima 9601296, Japan.	knakagawa@sss.fukushima-u.ac.jp; ogawa@math.tohoku.ac.jp			JSPS [20244009, 25220702]; Graduate School of Science, Tohoku University	The authors would like to express their thanks to referees for helpful comment to improve the original manuscript. The work of Takayoshi Ogawa is partially supported by JSPS grant in aid for scientific research, Basic Research (A) #20244009 and Basic Research (S) #25220702. The work of Kazushige Nakagawa is partially supported by Intensive Research Fund for Young Researchers from Graduate School of Science, Tohoku University.	Diaz JI, 2001, NONLINEAR ANAL-REAL, V2, P305; Biler P, 2000, ANN HENRI POINCARE, V1, P461, DOI 10.1007/s000230050003; Senba T, 2002, J FUNCT ANAL, V191, P17, DOI 10.1006/jfan.2001.3802; Otto F, 2001, COMMUN PART DIFF EQ, V26, P101, DOI 10.1081/PDE-100002243; Nagai T, 2001, J INEQUAL APPL, V6, P37, DOI 10.1155/S1025583401000042; WIEGNER M, 1986, ANN MAT PUR APPL, V145, P385, DOI 10.1007/BF01790549; KELLER EF, 1970, J THEOR BIOL, V26, P399, DOI 10.1016/0022-5193(70)90092-5; Kenig CE, 2006, INVENT MATH, V166, P645, DOI 10.1007/s00222-006-0011-4; NAGAI T, 1983, J MATH SOC JPN, V35, P539; WEINSTEIN MI, 1983, COMMUN MATH PHYS, V87, P567, DOI 10.1007/BF01208265; Blanchet A, 2009, CALC VAR PARTIAL DIF, V35, P133, DOI 10.1007/s00526-008-0200-7; Kozono H, 2008, INDIANA U MATH J, V57, P1467, DOI 10.1512/iumj.2008.57.3316; JAGER W, 1992, T AM MATH SOC, V329, P819, DOI 10.2307/2153966; Duyckaerts T, 2010, REV MAT IBEROAM, V26, P1; Carrillo JA, 2000, INDIANA U MATH J, V49, P113; Biler P., 2004, BANACH CTR PUBL, V66, P61; BILER P., 1998, ADV MATH SCI APPL, V8, P715; BILER P, 1994, NONLINEAR ANAL-THEOR, V23, P1189, DOI 10.1016/0362-546X(94)90101-5; Blanchet A., 2006, ELECT J DIFFERENTIAL, V44, P1; Chen L, 2012, SIAM J MATH ANAL, V44, P1077, DOI 10.1137/110839102; Diaz J. I., 1996, JPN J IND APPL MATH, V13, P385; DIBENEDETTO E, 1985, J REINE ANGEW MATH, V363, P217; Feireisl E, 2007, J MATH PURE APPL, V88, P325, DOI 10.1016/j.matpur.2007.07.002; Holmer J, 2008, COMMUN MATH PHYS, V282, P435, DOI 10.1007/s00220-008-0529-y; Ishida S., 2012, J DIFFER EQUATIONS, V252, P2464; JUNGEL A, 1995, MATH MOD METH APPL S, V5, P497, DOI 10.1142/S0218202595000292; Kenig C, 2008, ACTA MATH-DJURSHOLM, V201, P147, DOI 10.1007/s11511-008-0031-6; Kobayashi T, 2013, INDIANA U MATH J, V62, P1021; Kurokiba M, 2008, J MATH ANAL APPL, V342, P1052, DOI 10.1016/j.jmaa.2007.11.017; Kurokiba M., 2003, DIFFERENTIAL INTEGRA, V16, P427; Lieb E., 2001, AM MATH SOC GSM, V14; LIEB EH, 1983, ANN MATH, V118, P349, DOI 10.2307/2007032; Mizuno M., 2013, J MATH SCI-U TOKYO, V20, P1; MOCK MS, 1974, SIAM J MATH ANAL, V5, P597, DOI 10.1137/0505061; Nagai T, 2011, COMMUN CONTEMP MATH, V13, P795, DOI 10.1142/S0219199711004440; Nagai T., 1995, ADV MATH SCI APPL, V5, P581; Nagai T, 1997, NONLINEAR ANAL-THEOR, V30, P5381, DOI 10.1016/S0362-546X(97)00395-7; Nagai T, 1997, FUNKC EKVACIOJ-SER I, V40, P411; Nagai T., 2000, HIROSHIMA MATH J, V30, P463; Ogawa T, 2008, DIFFER INTEGRAL EQU, V21, P1113; Ogawa T., 2011, DISCRETE CONT DYN S, V4, P875; Ogawa T., 2006, BANACH CTR PUBL, V74, P161; SENBA T., 2001, ADV DIFFERENTIAL EQU, V6, P21; Senba T., 2003, ADV DIFFERENTIAL EQU, V8, P787; Sugiyama Y, 2006, DIFFER INTEGRAL EQU, V19, P841; Sugiyama Y., 2007, ADV DIFF EQNS, V12, P121; Suzuki T, 2009, DIFFER INTEGRAL EQU, V22, P1153; Suzuki T, 2005, PROGR NONLINEAR DIFF, V62; Suzuki T, 2009, ADV DIFFERENTIAL EQU, V14, P433; Talenti G., 1976, MATH JPN, V110, P353; Tsutsumi M., 1972, PUBL RES I MATH SCI, V8, P211, DOI 10.2977/prims/1195193108; Vazquez J. L., 2006, OXFORD MATH MONOGRAP; Yagi A., 1997, MATH JPN, V45, P241	53	0	0	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	0944-2669	1432-0835		CALC VAR PARTIAL DIF	Calc. Var. Partial Differ. Equ.	MAY	2015	53	1-2					441	472		10.1007/s00526-014-0755-4		32	Mathematics, Applied; Mathematics	Mathematics	CF9PE	WOS:000352896500017		
J	Jensen-Jarolim, E; Fazekas, J; Singer, J; Hofstetter, G; Oida, K; Matsuda, H; Tanaka, A				Jensen-Jarolim, Erika; Fazekas, Judit; Singer, Josef; Hofstetter, Gerlinde; Oida, Kumiko; Matsuda, Hiroshi; Tanaka, Akane			Crosstalk of carcinoembryonic antigen and transforming growth factor-beta via their receptors: comparing human and canine cancer	CANCER IMMUNOLOGY IMMUNOTHERAPY			English	Review						Carcinoembryonic antigen (CEA); CEA-receptor (CEAR); Transforming growth factor beta (TGF-beta); Cancer immunology; Regulatory; Nuclear factor kappa-B (NF kappa B)	NF-KAPPA-B; REGULATORY T-CELLS; TGF-BETA; COLORECTAL-CANCER; STEM-CELLS; MESENCHYMAL TRANSITION; COMPARATIVE ONCOLOGY; STROMAL CELLS; METASTASIS; BREAST	There is accumulating evidence that the transforming growth factor beta (TGF-beta) and nuclear factor kappa-B (NF kappa B) pathways are tightly connected and play a key role in malignant transformation in cancer. Immune infiltration by regulatory T- and B-lymphocytes (Tregs, Bregs) has recently gained increased attention for being an important source of TGF-beta. There is a plethora of studies examining the pro-tumorigenic functions of carcinoembryonic antigen (CEA), but its receptor CEAR is far less studied. So far, there is a single connecting report that TGF-beta also may signal through CEAR. The crosstalk between cancer tissues is further complicated by the expression of CEAR and TGF-beta receptors in stromal cells, and implications of TGF-beta in epithelial-mesenchymal transition. Furthermore, tumor-infiltrating Tregs and Bregs may directly instruct cancer cells by secreting TGF-beta binding to their CEAR. Therefore, both TGF-beta and CEA may act synergistically in breast cancer and cause disease progression, and NF kappa B could be a common crossing point between their signaling. CEAR, TGF-beta 1-3, TGF-beta-R types I-III and NF kappa B class I and II molecules have an outstanding human-canine sequence identity, and only a canine CEA homolog has not yet been identified. For these reasons, the dog may be a valid translational model patient for investigating the crosstalk of the interconnected CEA and TGF-beta networks.	[Jensen-Jarolim, Erika; Fazekas, Judit; Singer, Josef; Hofstetter, Gerlinde] Med Univ Vienna, Dept Comparat Med Comparat Immunol & Oncol, Univ Vet Med Vienna, Inst Pathophysiol & Allergy Res,Messerli Res Inst, A-1090 Vienna, Austria; [Jensen-Jarolim, Erika; Fazekas, Judit; Singer, Josef; Hofstetter, Gerlinde] Univ Vienna, A-1090 Vienna, Austria; [Oida, Kumiko; Matsuda, Hiroshi; Tanaka, Akane] Tokyo Univ Agr & Technol, Comparat Anim Med, Div Anim Life Sci, Inst Agr, Fuchu, Tokyo, Japan	Jensen-Jarolim, E (reprint author), Med Univ Vienna, Dept Comparat Med Comparat Immunol & Oncol, Univ Vet Med Vienna, Inst Pathophysiol & Allergy Res,Messerli Res Inst, AKH 4Q,Waehringer Guertel 18-20, A-1090 Vienna, Austria.	erika.jensen-jarolim@meduniwien.ac.at			Austrian Science Fund (FWF) [P23398-B11]; Cell Communication in Health and Disease (CCHD) PhD Program of the Austrian Science Fund (FWF) [W1205-B09]	The authors were supported by Project P23398-B11 of the Austrian Science Fund (FWF), Judit Fazekas by the Cell Communication in Health and Disease (CCHD) PhD Program W1205-B09 of the Austrian Science Fund (FWF). We would like to thank Mrs. Amelia Wein for proofreading the manuscript.	Adeegbe DO, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00190; Pasparakis M, 2006, CELL DEATH DIFFER, V13, P861, DOI 10.1038/sj.cdd.4401870; Thomas P, 2011, CLIN EXP METASTAS, V28, P923, DOI 10.1007/s10585-011-9419-3; Singh A, 2010, ONCOGENE, V29, P4741, DOI 10.1038/onc.2010.215; Jemal A, 2011, CA-CANCER J CLIN, V61, P69, DOI 10.3322/caac.20107; Cufi S, 2010, CELL CYCLE, V9, P4461, DOI 10.4161/cc.9.22.14048; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; Muller MM, 2005, BLOOD, V105, P3925, DOI 10.1182/blood-2004-09-3618; Olkhanud PB, 2011, CANCER RES, V71, P3505, DOI 10.1158/0008-5472.CAN-10-4316; Iwanicki-Caron I, 2008, J CLIN ONCOL, V26, P3681, DOI 10.1200/JCO.2007.15.0904; Huang T, 2011, EMBO J, V30, P1263, DOI 10.1038/emboj.2011.54; Lindner S, 2013, CANCER RES, V73, P2468, DOI 10.1158/0008-5472.CAN-12-3450; Lindblad-Toh K, 2005, NATURE, V438, P803, DOI 10.1038/nature04338; Thomas SN, 2008, J BIOL CHEM, V283, P15647, DOI 10.1074/jbc.M800543200; Egenvall A, 2005, PREV VET MED, V69, P109, DOI 10.1016/j.prevetmed.2005.01.014; Dunning NL, 2011, CANCER IMMUNOL IMMUN, V60, P1181, DOI 10.1007/s00262-011-1065-8; Singer J, 2012, MOL IMMUNOL, V50, P200, DOI 10.1016/j.molimm.2012.01.002; Chen LF, 2012, IMMUNITY, V37, P930, DOI 10.1016/j.immuni.2012.07.016; Gingery A, 2008, EXP CELL RES, V314, P2725, DOI 10.1016/j.yexcr.2008.06.006; Elliott RL, 2005, J CLIN ONCOL, V23, P2078, DOI 10.1200/JCO.2005.02.047; Mele V, 2014, INT J CANCER, V134, P2583, DOI 10.1002/ijc.28598; Ear T, 2010, J IMMUNOL, V184, P3897, DOI 10.4049/jimmunol.0902958; Moo-Young TA, 2009, J IMMUNOTHER, V32, P12, DOI 10.1097/CJI.0b013e318189f13c; Naugler WE, 2008, CURR OPIN GENET DEV, V18, P19, DOI 10.1016/j.gde.2008.01.020; Li QX, 2013, ONCOL REP, V30, P1215, DOI 10.3892/or.2013.2570; Palermo NY, 2012, J PEPT SCI, V18, P252, DOI 10.1002/psc.2393; Calon A, 2012, CANCER CELL, V22, P571, DOI 10.1016/j.ccr.2012.08.013; Zhang J, 2014, TUMOR BIOL, V35, P379, DOI 10.1007/s13277-013-1053-z; Hart PJ, 2002, NAT STRUCT BIOL, V9, P203, DOI 10.1038/nsb766; Taylor MA, 2013, J CLIN INVEST, V123, P150, DOI 10.1172/JCI64946; Zebhauser R, 2005, GENOMICS, V86, P566, DOI 10.1016/j.ygeno.2005.07.008; Triozzi PL, 2011, CANCER GENE THER, V18, P850, DOI 10.1038/cgt.2011.54; Oeckinghaus A, 2011, NAT IMMUNOL, V12, P695, DOI 10.1038/ni.2065; Freudlsperger C, 2013, ONCOGENE, V32, P1549, DOI 10.1038/onc.2012.171; Bajenova O, 2014, EXP CELL RES, V324, P115, DOI 10.1016/j.yexcr.2014.04.007; Bajenova OV, 2001, J BIOL CHEM, V276, P31067, DOI 10.1074/jbc.M104093200; Bast RC, 2001, J CLIN ONCOL, V19, P1865; Biragyn A, 2014, METHODS MOL BIOL, V1190, P271, DOI 10.1007/978-1-4939-1161-5_19; Carvalho MI, 2014, BIOMED RES INT, DOI 10.1155/2014/130894; Gupta Devendra Kumar, 2014, Cancer Growth Metastasis, V7, P1, DOI 10.4137/CGM.S14205; Han SU, 2008, ONCOGENE, V27, P675, DOI 10.1038/sj.onc.1210686; HOSTETTER RB, 1990, J NATL CANCER I, V82, P380, DOI 10.1093/jnci/82.5.380; Kammerer R, 2007, BMC EVOL BIOL, V7, DOI 10.1186/1471-2148-7-196; Kammerer R, 1996, INT J CANCER, V68, P457, DOI 10.1002/(SICI)1097-0215(19961115)68:4<457::AID-IJC10>3.0.CO;2-2; Kim JH, 2012, VET J, V193, P222, DOI 10.1016/j.tvjl.2011.10.022; Laguinge L, 2005, ANTICANCER RES, V25, P23; Lee C, 2014, BIOMED RES INT, DOI 10.1155/2014/502093; Li Y, 2010, CANCER RES, V70, P8159, DOI 10.1158/0008-5472.CAN-10-1073; Muturi HT, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074654; Neil JR, 2008, CANCER RES, V68, P1462, DOI 10.1158/0008-5472.CAN-07-3094; Ogoshi K, 1998, CANCER IMMUNOL IMMUN, V46, P14, DOI 10.1007/s002620050454; Oida K, 2014, SCI REP-UK, V4, DOI 10.1038/srep04057; O'Neill K, 2009, J VET INTERN MED, V23, P875, DOI 10.1111/j.1939-1676.2009.0333.x; Pinheiro D, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0105027; Riccardo F, 2015, CANCER IMMUNOL IMMUN, V64, P137, DOI 10.1007/s00262-014-1645-5; Richter S, 2010, CHLOE, V41, P7; Singer J, 2014, MOL CANCER THER, V13, P1777, DOI 10.1158/1535-7163.MCT-13-0288; The American Veterinary Medical Association, ONE HLTH NEW PROF IM; Vannucci L., 2014, CANC MICROENVIRON, DOI [10.1007/s12307-014-0150-x, DOI 10.1007/S12307-014-0150-X]; Wagner Siegfried, 2013, Frontiers in Genetics, V4, P46, DOI 10.3389/fgene.2013.00046; Weichselbaumer M, 2011, PLOS CURR, V3, DOI [10.1371/currents.RRN1223, DOI 10.1371/CURRENTS.RRN1223]; Whiteside TL, 2014, CANCER IMMUNOL IMMUN, V63, P67, DOI 10.1007/s00262-013-1490-y; Witzens-Harig M, 2013, BLOOD, V121, P4493, DOI 10.1182/blood-2012-05-429415; Zhao Hui-min, 2010, Zhonghua Wei Chang Wai Ke Za Zhi, V13, P608	64	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0340-7004	1432-0851		CANCER IMMUNOL IMMUN	Cancer Immunol. Immunother.	MAY	2015	64	5					531	537		10.1007/s00262-015-1684-6		7	Oncology; Immunology	Oncology; Immunology	CG4CX	WOS:000353231000001		
J	Diletti, R; Garcia-Garcia, HM; Bourantas, C; Van Mieghem, NM; van Geuns, RJ; Muramatsu, T; Zhang, YJ; Mauri, L; Belardi, J; Silber, S; Widimsky, P; Leon, M; Windecker, S; Meredith, I; Neumann, FJ; Yeung, AC; Saito, S; Liu, ML; van Leeuwen, F; Serruys, PW				Diletti, Roberto; Garcia-Garcia, Hector M.; Bourantas, Christos; Van Mieghem, Nicolas M.; van Geuns, Robert Jan; Muramatsu, Takashi; Zhang, Yao-Jun; Mauri, Laura; Belardi, Jorge; Silber, Sigmund; Widimsky, Petr; Leon, Martin; Windecker, Stephan; Meredith, Ian; Neumann, Franz-Josef; Yeung, Alan C.; Saito, Shigeru; Liu, Minglei; van Leeuwen, Frank; Serruys, Patrick W.			Impact of Body Mass Index on Long-Term Clinical Outcomes After Second-Generation Drug Eluting Stent Implantation: Insights From the International Global RESOLUTE Program	CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS			English	Article						obesity paradox; coronary artery disease; zotarolimus eluting stents	PERCUTANEOUS CORONARY INTERVENTION; OBESITY PARADOX; HEART-FAILURE; CARDIOVASCULAR RISK; ARTERY-DISEASE; WEIGHT-LOSS; REVERSE EPIDEMIOLOGY; FOLLOW-UP; MULTICENTER; MEN	BackgroundAn increased body mass index (BMI) is associated with a high risk of cardiovascular disease and reduction in life expectancy. However, several studies reported improved clinical outcomes in obese patients treated for cardiovascular diseases. The aim of the present study is to investigate the impact of BMI on long-term clinical outcomes after implantation of zotarolimus eluting stents. MethodsIndividual patient data were pooled from the RESOLUTE Clinical Program comprising five trials worldwide. The study population was sorted according to BMI tertiles and clinical outcomes were evaluated at 2-year follow-up. ResultsData from a total of 5,127 patients receiving the R-ZES were included in the present study. BMI tertiles were as follow: I tertile ( 25.95 kg/m(2)Low or normal weight) 1,727 patients; II tertile (>25.9529.74 kg/m(2)overweight) 1,695 patients, and III tertile (>29.74 kg/m(2)obese) 1,705 patients. At 2-years follow-up no difference was found for patients with high BMI (III tertile) compared with patients with normal or low BMI (I tertile) in terms of target lesion failure (I-III tertile, HR [95% CI]=0.89 [0.69, 1.14], P=0.341; major adverse cardiac events (I-III tertile, HR [95% CI]=0.90 [0.72, 1.14], P=0.389; cardiac death (I-III tertile, HR [95% CI]=1.20 [0.73, 1.99], P=0.476); myocardial infarction (I-III tertile, HR [95% CI]=0.86 [0.55, 1.35], P=0.509; clinically-driven target lesion revascularization (I-III tertile, HR [95% CI]=0.75 [0.53, 1.08], P=0.123; definite or probable stent thrombosis (I-III tertile, HR [95% CI]=0.98 [0.49, 1.99], P=0.964. ConclusionsIn the present study, the patients' body mass index was found to have no impact on long-term clinical outcomes after coronary artery interventions. (c) 2015 Wiley Periodicals, Inc.	[Diletti, Roberto; Garcia-Garcia, Hector M.; Bourantas, Christos; Van Mieghem, Nicolas M.; van Geuns, Robert Jan; Muramatsu, Takashi; Zhang, Yao-Jun; Serruys, Patrick W.] Erasmus MC, Intervent Cardiol Dept, Thoraxctr, NL-3015 CE Rotterdam, Netherlands; [Garcia-Garcia, Hector M.] Cardialysis BV, Rotterdam, Netherlands; [Mauri, Laura] Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Cardiovasc Med, Boston, MA 02115 USA; [Belardi, Jorge] Cardiovasc Inst Buenos Aires, Dept Intervent Cardiol & Endovasc Therapeut, Buenos Aires, DF, Argentina; [Silber, Sigmund] Heart Ctr Isar, Dept Intervent Cardiol, Munich, Germany; [Widimsky, Petr] Charles Univ Prague, Dept Intervent Cardiol, Cardioctr Kralovske Vinohrady, Prague, Czech Republic; [Leon, Martin] Columbia Univ, Med Ctr, New York Presbyterian Hosp, New York, NY USA; [Windecker, Stephan] Univ Hosp Bern, Dept Cardiol, CH-3010 Bern, Switzerland; [Meredith, Ian] MonashHeart, Dept Intervent Cardiol, Melbourne, Vic, Australia; [Meredith, Ian] Monash Univ, Melbourne, Vic 3004, Australia; [Neumann, Franz-Josef] Heart Ctr Bad Krozingen, Bad Krozingen, Germany; [Yeung, Alan C.] Stanford Univ, Sch Med, Palo Alto, CA 94304 USA; [Saito, Shigeru] Shonan Kamakura Gen Hosp, Kamakura, Kanagawa, Japan; [Liu, Minglei; van Leeuwen, Frank] Medtronic, Santa Rosa, CA USA	Diletti, R (reprint author), Erasmus MC, Intervent Cardiol Dept, S Gravendijkwal 230, NL-3015 CE Rotterdam, Netherlands.	r.diletti@erasmusmc.nl	Diletti, Roberto/P-2214-2014		Medtronic	Contract grant sponsor: Medtronic.	Andreotti F, 2009, EUR HEART J, V30, P752, DOI 10.1093/eurheartj/ehp081; Calle EE, 1999, NEW ENGL J MED, V341, P1097, DOI 10.1056/NEJM199910073411501; Sibbing D, 2007, AM J CARDIOL, V100, P203, DOI 10.1016/j.amjcard.2007.02.081; Fontaine KR, 2003, JAMA-J AM MED ASSOC, V289, P187, DOI 10.1001/jama.289.2.187; Feldman AM, 2000, J AM COLL CARDIOL, V35, P537, DOI 10.1016/S0735-1097(99)00600-2; Strandberg TE, 2009, EUR HEART J, V30, P1720, DOI 10.1093/eurheartj/ehp162; Das SR, 2011, J AM COLL CARDIOL, V58, P2642, DOI 10.1016/j.jacc.2011.09.030; Dorresteijn JAN, 2012, OBES REV, V13, P17, DOI 10.1111/j.1467-789X.2011.00914.x; Uretsky S, 2007, AM J MED, V120, P863, DOI 10.1016/j.amjmed.2007.05.011; Lavie CJ, 2009, J AM COLL CARDIOL, V53, P1925, DOI 10.1016/j.jacc.2008.12.068; Curtis JP, 2005, ARCH INTERN MED, V165, P55, DOI 10.1001/archinte.165.1.55; Wang ZJ, 2009, HEART, V95, P1587, DOI 10.1136/hrt.2009.172395; Lancefield T, 2010, JACC-CARDIOVASC INTE, V3, P660, DOI 10.1016/j.jcin.2010.03.018; Gruberg L, 2002, J AM COLL CARDIOL, V39, P578, DOI 10.1016/S0735-1097(01)01802-2; Galal W, 2008, CHEST, V134, P925, DOI 10.1378/chest.08-0418; Zamboni M, 2005, INT J OBESITY, V29, P1011, DOI 10.1038/sj.ijo.0803005; Buonamici P, 2007, J AM COLL CARDIOL, V49, P2312, DOI 10.1016/j.jacc.2007.01.094; Lavie CJ, 2009, AM J MED, V122, P1106, DOI 10.1016/j.amjmed.2009.06.006; Hastie CE, 2010, EUR HEART J, V31, P222, DOI 10.1093/eurheartj/ehp317; Hughes VA, 2002, AM J CLIN NUTR, V76, P473; Engeli S, 2005, HYPERTENSION, V45, P356, DOI 10.1161/01.HYP.0000154361.47683.d3; Akin I, 2012, JACC-CARDIOVASC INTE, V5, P162, DOI 10.1016/j.jcin.2011.09.021; Meredith IT, 2009, JACC-CARDIOVASC INTE, V2, P977, DOI 10.1016/j.jcin.2009.07.007; Wilson PWF, 2002, ARCH INTERN MED, V162, P1867, DOI 10.1001/archinte.162.16.1867; Mauri L, 2010, JACC-CARDIOVASC INTE, V3, P1240, DOI 10.1016/j.jcin.2010.08.021; Sorkin JD, 1999, AM J EPIDEMIOL, V150, P969; Boden WE, 2007, NEW ENGL J MED, V356, P1503, DOI 10.1056/NEJMoa070829; Eilat-Adar Sigal, 2005, Am J Epidemiol, V161, P352, DOI 10.1093/aje/kwi045; HUBERT HB, 1983, CIRCULATION, V67, P968; Johnson WD, 2011, AM J MED, V124, P931, DOI 10.1016/j.amjmed.2011.04.033; Kenchaiah S, 2002, NEW ENGL J MED, V347, P305, DOI 10.1056/NEJMoa020245; Lavie Carl J, 2008, J Cardiometab Syndr, V3, P136, DOI 10.1111/j.1559-4572.2008.00002.x; Lavie CJ, 2005, EUR HEART J, V26, P5, DOI 10.1093/eurheartj/ehi022; Martin-Ponce E, 2010, CLIN NUTR, V29, P501, DOI 10.1016/j.clnu.2009.12.009; Rubinshtein R, 2006, AM J CARDIOL, V97, P1277, DOI 10.1016/j.amjcard.2005.11.061; Sarno G, 2011, AM J CARDIOL, V108, P195, DOI 10.1016/j.amjcard.2011.03.023; Schenkeveld L, 2012, BMJ OPEN, V2, DOI 10.1136/bmjopen-2011-000535; Steinberg BA, 2007, AM J CARDIOL, V100, P1331, DOI 10.1016/j.amjcard.2007.06.019; Tamminen M, 2003, INT J OBESITY, V27, P907, DOI 10.1038/sj.ijo.0802312	39	1	1	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1522-1946	1522-726X		CATHETER CARDIO INTE	Catheter. Cardiovasc. Interv.	MAY	2015	85	6					952	958		10.1002/ccd.25828		7	Cardiac & Cardiovascular Systems	Cardiovascular System & Cardiology	CG5UG	WOS:000353360800005		
J	Lim, WH; Koo, BK; Nam, CW; Doh, JH; Park, JJ; Yang, HM; Park, KW; Kim, HS; Takashima, H; Waseda, K; Amano, T; Kato, D; Kurita, A; Oi, M; Toyofuku, M; van Nunen, L; Pijls, NHJ				Lim, Woo-Hyun; Koo, Bon-Kwon; Nam, Chang-Wook; Doh, Joon-Hyung; Park, Jin Joo; Yang, Han-Mo; Park, Kyung Woo; Kim, Hyo-Soo; Takashima, Hiroaki; Waseda, Katsuhisa; Amano, Tetsuya; Kato, Daiki; Kurita, Akiyoshi; Oi, Maki; Toyofuku, Mamoru; van Nunen, Lokien; Pijls, Nico H. J.			Variability of Fractional Flow Reserve According to the Methods of Hyperemia Induction	CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS			English	Article						fractional flow reserve; variability; hyperemia	PERCUTANEOUS CORONARY INTERVENTION; ARTERY-DISEASE; CARDIAC-CATHETERIZATION; MEDICAL THERAPY; STENOSIS; REVASCULARIZATION; EFFICACY	ObjectivesWe performed this study to evaluate the variability of fractional flow reserve (FFR) values which were measured from various methods of hyperemia induction. BackgroundConcerns have been raised regarding the variability of FFR due to different routes for hyperemic agent administration and different hyperemic agents targeting different receptors to induce maximal hyperemia. MethodsA total of 656 intermediate coronary lesions from 628 patients with coronary artery disease were analyzed. Among them, 238 lesions underwent FFR measurement with hyperemia induced by both intravenous (IV) and intracoronary (IC) adenosine administration, 318 by IV adenosine/adenosine triphosphate (ATP) and IC nicorandil injection, and 100 by IV adenosine and regadenoson infusion. ResultsExcellent correlation and close classification agreement (FFR0.80) were observed between IV vs. IC adenosine (r=0.980, CA=92.9%, Cohen's Kappa=0.887, P<0.001), between IV adenosine/ATP vs. IC nicorandil (r=0.962, CA=91.2%, Cohen's Kappa=0.817, P<0.001), and between IV adenosine vs. regadenoson (r=0.990, CA=100%, Cohen's Kappa=1.000, P<0.001). When changes in blood pressure (BP) or heart rate (HR) were compared with changes in FFR (FFR) between IV adenosine/ATP and IC nicorandil administration, there were no significant correlations between BP and FFR nor between HR and FFR (r=-0.122, P=0.076; r=0.036, P=0.605, respectively). ConclusionsThis study suggests that the measurement of FFR is reproducible regardless of the hemodynamic changes, hyperemic agents used, or the route of administration. (c) 2014 Wiley Periodicals, Inc.	[Lim, Woo-Hyun; Koo, Bon-Kwon; Yang, Han-Mo; Park, Kyung Woo; Kim, Hyo-Soo] Seoul Natl Univ Hosp, Dept Internal Med, Seoul 110744, South Korea; [Lim, Woo-Hyun; Koo, Bon-Kwon; Yang, Han-Mo; Park, Kyung Woo; Kim, Hyo-Soo] Seoul Natl Univ Hosp, Cardiovasc Ctr, Seoul 110744, South Korea; [Nam, Chang-Wook] Keimyung Univ, Dongsan Med Ctr, Dept Internal Med, Div Cardiol, Taegu, South Korea; [Doh, Joon-Hyung] Inje Univ, Ilsan Paik Hosp, Dept Internal Med, Div Cardiol, Goyang, South Korea; [Park, Jin Joo] Seoul Natl Univ, Bundang Hosp, Cardiovasc Ctr, Songnam, South Korea; [Takashima, Hiroaki; Waseda, Katsuhisa; Amano, Tetsuya; Kato, Daiki; Kurita, Akiyoshi] Aichi Med Univ, Dept Cardiol, Nagakute, Aichi 48011, Japan; [Oi, Maki; Toyofuku, Mamoru; van Nunen, Lokien] Japanese Red Cross Soc, Wakayama Med Ctr, Div Cardiol, Wakayama, Japan; [Pijls, Nico H. J.] Catharina Hosp, Dept Cardiol, Eindhoven, Netherlands	Koo, BK (reprint author), Seoul Natl Univ, Coll Med, Med Cardiol, 101 Daehang Ro, Seoul 110744, South Korea.	bkkoo@snu.ac.kr			St. Jude Medical	Koo BK has received honorarium and research grants from St. Jude Medical. However, the company was not involved in this study and the honorarium was not related to this study. Pijls NH has served as a consultant for St. Jude Medical and received institutional research grants from St. Jude Medical. All other authors have reported that they have no relationships relevant to the content of this article to disclose.	Tonino PAL, 2009, NEW ENGL J MED, V360, P213, DOI 10.1056/NEJMoa0807611; Pijls NHJ, 2007, J AM COLL CARDIOL, V49, P2105, DOI 10.1016/j.jacc.2007.01.087; Kern MJ, 2006, CIRCULATION, V114, P1321, DOI 10.1161/CIRCULATIONAHA.106.177276; Park JJ, 2013, INT J CARDIOL, V168, P4070, DOI 10.1016/j.ijcard.2013.07.030; Montalescot G, 2013, EUR HEART J, V34, P2949, DOI 10.1093/eurheartj/eht296; PIJLS NHJ, 1993, CIRCULATION, V87, P1354; Seo MK, 2012, CIRC-CARDIOVASC INTE, V5, P401, DOI 10.1161/CIRCINTERVENTIONS.111.965392; Shaw LJ, 2008, CIRCULATION, V117, P1283, DOI 10.1161/CIRCULATIONAHA.107.743963; van de Hoef TP, 2013, NAT REV CARDIOL, V10, P439, DOI 10.1038/nrcardio.2013.86; Hachamovitch R, 2003, CIRCULATION, V107, P2900, DOI 10.1161/01.CIR.0000072790.23090.41; Spaan JAE, 2006, CIRCULATION, V113, P446, DOI 10.1161/CIRCULATIONAHA.105.587196; Jang HJ, 2013, EUR HEART J, V34, P2055, DOI 10.1093/eurheartj/eht040; DesBruyne B, 2012, NEW ENGL J MED, V367, P991, DOI DOI 10.1056/NEJMOA1205361]; Kato D, 2014, HEART VESSELS, P19; Petraco R, 2013, JACC-CARDIOVASC INTE, V6, P222, DOI 10.1016/j.jcin.2012.10.014; van de Hoef TP, 2014, HEART, V100, P951, DOI 10.1136/heartjnl-2013-305124; vansNunen LX, 2014, EUROINTERVENTION, P10	17	4	4	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1522-1946	1522-726X		CATHETER CARDIO INTE	Catheter. Cardiovasc. Interv.	MAY	2015	85	6					970	976		10.1002/ccd.25752		7	Cardiac & Cardiovascular Systems	Cardiovascular System & Cardiology	CG5UG	WOS:000353360800009		
J	Nishida-Aoki, N; Ochiya, T				Nishida-Aoki, Nao; Ochiya, Takahiro			Interactions between cancer cells and normal cells via miRNAs in extracellular vesicles	CELLULAR AND MOLECULAR LIFE SCIENCES			English	Review						Extracellular RNA; Extracellular vesicle (EV); Exosome; MicroRNA (miRNA); Cancer; Cancer therapy	TUMOR-DERIVED EXOSOMES; DOUBLE-STRANDED-RNA; PROSTATE-CANCER; MEDIATED ENDOCYTOSIS; CIRCULATING MICRORNA; CAENORHABDITIS-ELEGANS; DIAGNOSTIC BIOMARKERS; TRANSFERRIN RECEPTOR; GENETIC INTERFERENCE; PREMETASTATIC NICHE	MicroRNAs (miRNAs) exhibit many functions in biological activities. Recent studies have shown that miRNAs exist outside cells and are transferred between cells. Extracellular miRNAs are protected from ribonucleases found in body fluids through binding to specific proteins or by being encapsulated in lipid bilayer vesicles. Here, we review the mechanisms of the secretion and uptake as well as the functions of extracellular miRNAs, particularly those encapsulated in extracellular vesicles. Extracellular vesicles are related to cancer progression, and some miRNAs in extracellular vesicles are associated with cancer cells. We describe the transfer of cancer-related miRNAs between cancer cells and non-cancerous cells. Finally, we discuss the anticipated applications of miRNAs present in extracellular vesicles in diagnostics and therapeutics.	[Nishida-Aoki, Nao; Ochiya, Takahiro] Natl Canc Ctr, Res Inst, Div Mol & Cellular Med, Chuo Ku, Tokyo 1040045, Japan	Ochiya, T (reprint author), Natl Canc Ctr, Res Inst, Div Mol & Cellular Med, Chuo Ku, 5-1-1 Tsukiji, Tokyo 1040045, Japan.	tochiya@ncc.go.jp			Ministry of Health, Labor, and Welfare, Japan; Program for Promotion of Fundamental Studies in Health Sciences of the National Institute of Biomedical Innovation; New Energy and Industrial Technology Development Organization (NEDO); Japan Society for the Promotion of Science through the Funding Program for World-Leading Innovative R&D on Science and Technology (FIRST Program); Council for Science and Technology Policy;  [269202]	This work was supported in part by a Grant-in-Aid for the Third-Term Comprehensive 10-Year Strategy for Cancer Control from the Ministry of Health, Labor, and Welfare, Japan; the Program for Promotion of Fundamental Studies in Health Sciences of the National Institute of Biomedical Innovation; the New Energy and Industrial Technology Development Organization (NEDO); the Japan Society for the Promotion of Science through the Funding Program for World-Leading Innovative R&D on Science and Technology (FIRST Program) initiated by the Council for Science and Technology Policy; and a Grant-in-Aid for JSPS Fellows (No. 269202). The authors declare that they have no competing interests.	Aalberts M, 2012, BIOL REPROD, V86, DOI 10.1095/biolreprod.111.095760; Andreu Z, 2015, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00442; Christianson HC, 2013, P NATL ACAD SCI USA, V110, P17380, DOI 10.1073/pnas.1304266110; Tian T, 2014, J BIOL CHEM, V289, P22258, DOI 10.1074/jbc.M114.588046; Lee I, 2009, GENOME RES, V19, P1175, DOI 10.1101/gr.089367.108; Turchinovich A, 2012, RNA BIOL, V9, P1066, DOI 10.4161/rna.21083; Grange C, 2011, CANCER RES, V71, P5346, DOI 10.1158/0008-5472.CAN-11-0241; Parolini I, 2009, J BIOL CHEM, V284, P34211, DOI 10.1074/jbc.M109.041152; Turchinovich A, 2011, NUCLEIC ACIDS RES, V39, P7223, DOI 10.1093/nar/gkr254; Zhang YJ, 2010, MOL CELL, V39, P133, DOI 10.1016/j.molcel.2010.06.010; Alderton GK, 2012, NAT REV CANCER, V12, P447, DOI 10.1038/nrc3304; Iorio MV, 2012, CANCER J, V18, P215, DOI 10.1097/PPO.0b013e318250c001; Kosaka N, 2012, J BIOL CHEM, V287, P1397, DOI 10.1074/jbc.M111.288662; Akers JC, 2013, J NEURO-ONCOL, V113, P1, DOI 10.1007/s11060-013-1084-8; Zhuang GL, 2012, EMBO J, V31, P3513, DOI 10.1038/emboj.2012.183; Yang M, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-117; [Anonymous], 2014, SCI SIGNAL, DOI [DOI 10.1126/SCISIGNAL.2005231, 10.1126/scisignal.2005231]; Wang K, 2010, NUCLEIC ACIDS RES, V38, P7248, DOI 10.1093/nar/gkq601; Berezikov E, 2005, CELL, V120, P21, DOI 10.1016/j.cell.2004.12.031; van Niel G, 2011, DEV CELL, V21, P708, DOI 10.1016/j.devcel.2011.08.019; Feng D, 2010, TRAFFIC, V11, P675, DOI 10.1111/j.1600-0854.2010.01041.x; Chairoungdua A, 2010, J CELL BIOL, V190, P1079, DOI 10.1083/jcb.201002049; Kosaka N, 2010, J BIOL CHEM, V285, P17442, DOI 10.1074/jbc.M110.107821; Skog J, 2008, NAT CELL BIOL, V10, P1470, DOI 10.1038/ncb1800; Raposo G, 2013, J CELL BIOL, V200, P373, DOI 10.1083/jcb.201211138; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Bobrie A, 2011, TRAFFIC, V12, P1659, DOI 10.1111/j.1600-0854.2011.01225.x; Choi DS, 2013, PROTEOMICS, V13, P1554, DOI 10.1002/pmic.201200329; Montecalvo A, 2012, BLOOD, V119, P756, DOI 10.1182/blood-2011-02-338004; Chen C, 2010, LAB CHIP, V10, P505, DOI 10.1039/b916199f; TRAMS EG, 1981, BIOCHIM BIOPHYS ACTA, V645, P63, DOI 10.1016/0005-2736(81)90512-5; Svensson KJ, 2013, J BIOL CHEM, V288, P17713, DOI 10.1074/jbc.M112.445403; Rupp AK, 2011, GYNECOL ONCOL, V122, P437, DOI 10.1016/j.ygyno.2011.04.035; Rana S, 2013, NEOPLASIA, V15, P281, DOI 10.1593/neo.122010; Asangani IA, 2008, ONCOGENE, V27, P2128, DOI 10.1038/sj.onc.1210856; Chen X, 2008, CELL RES, V18, P997, DOI 10.1038/cr.2008.282; ROMANO N, 1992, MOL MICROBIOL, V6, P3343, DOI 10.1111/j.1365-2958.1992.tb02202.x; Karrison TG, 1999, J NATL CANCER I, V91, P80, DOI 10.1093/jnci/91.1.80; Takamizawa J, 2004, CANCER RES, V64, P3753, DOI 10.1158/0008-5472.CAN-04-0637; HARDING C, 1983, J CELL BIOL, V97, P329, DOI 10.1083/jcb.97.2.329; Hessvik NP, 2012, BBA-GENE REGUL MECH, V1819, P1154, DOI 10.1016/j.bbagrm.2012.08.016; Katzmann DJ, 2001, CELL, V106, P145, DOI 10.1016/S0092-8674(01)00434-2; Elmore S, 2007, TOXICOL PATHOL, V35, P495, DOI 10.1080/01926230701320337; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; Kosaka N, 2010, CANCER SCI, V101, P2087, DOI 10.1111/j.1349-7006.2010.01650.x; Kosaka N, 2013, ADV DRUG DELIVER REV, V65, P376, DOI 10.1016/j.addr.2012.07.011; Stuffers S, 2009, TRAFFIC, V10, P925, DOI 10.1111/j.1600-0854.2009.00920.x; Zubakov D, 2010, INT J LEGAL MED, V124, P217, DOI 10.1007/s00414-009-0402-3; Fabbri M, 2012, P NATL ACAD SCI USA, V109, pE2110, DOI 10.1073/pnas.1209414109; Kim VN, 2005, NAT REV MOL CELL BIO, V6, P376, DOI 10.1038/nrm1644; Zhou WY, 2014, CANCER CELL, V25, P501, DOI 10.1016/j.ccr.2014.03.007; Wolfers J, 2001, NAT MED, V7, P297, DOI 10.1038/85438; Ohno S, 2013, MOL THER, V21, P185, DOI 10.1038/mt.2012.180; Meng FY, 2007, GASTROENTEROLOGY, V133, P647, DOI 10.1053/j.gastro.2007.05.022; Kowal J, 2014, CURR OPIN CELL BIOL, V29, P116, DOI 10.1016/j.ceb.2014.05.004; Valadi H, 2007, NAT CELL BIOL, V9, P654, DOI 10.1038/ncb1596; Taylor DD, 2011, METHODS MOL BIOL, V728, P235, DOI 10.1007/978-1-61779-068-3_15; Tejera E, 2013, MOL BIOL CELL, V24, P261, DOI 10.1091/mbc.E12-09-0642; Tian TA, 2010, J CELL BIOCHEM, V111, P488, DOI 10.1002/jcb.22733; Wahlgren J, 2012, NUCLEIC ACIDS RES, V40, DOI 10.1093/nar/gks463; Rosell R, 2009, CLIN LUNG CANCER, V10, P8, DOI 10.3816/CLC.2009.n.001; Vickers KC, 2011, NAT CELL BIOL, V13, P423, DOI 10.1038/ncb2210; Kosaka N, 2013, J BIOL CHEM, V288, P10849, DOI 10.1074/jbc.M112.446831; Taylor DD, 2008, GYNECOL ONCOL, V110, P13, DOI 10.1016/j.ygyno.2008.04.033; Hessels D, 2013, ASIAN J ANDROL, V15, P333, DOI 10.1038/aja.2013.6; Zhou Q, 2012, INT J BIOL SCI, V8, P118, DOI 10.7150/ijbs.8.118; Gastpar R, 2005, CANCER RES, V65, P5238, DOI 10.1158/0008-5472.CAN-04-3804; Lai EC, 2002, NAT GENET, V30, P363, DOI 10.1038/ng865; Morelli AE, 2004, BLOOD, V104, P3257, DOI 10.1182/blood-2004-03-0824; PAN BT, 1983, CELL, V33, P967, DOI 10.1016/0092-8674(83)90040-5; Park NJ, 2009, CLIN CANCER RES, V15, P5473, DOI 10.1158/1078-0432.CCR-09-0736; Pegtel DM, 2010, P NATL ACAD SCI USA, V107, P6328, DOI 10.1073/pnas.0914843107; Alvarez-Erviti L, 2011, NAT BIOTECHNOL, V29, P341, DOI 10.1038/nbt.1807; Hanke Merle, 2010, Urol Oncol, V28, P655, DOI 10.1016/j.urolonc.2009.01.027; Franzen CA, 2014, BIOMED RES INT, DOI 10.1155/2014/619829; JOHNSTONE RM, 1987, J BIOL CHEM, V262, P9412; Weber JA, 2010, CLIN CHEM, V56, P1733, DOI 10.1373/clinchem.2010.147405; Fitzner D, 2011, J CELL SCI, V124, P447, DOI 10.1242/jcs.074088; Yoo AS, 2009, NATURE, V460, P642, DOI 10.1038/nature08139; Zhang HG, 2011, CLIN CANCER RES, V17, P959, DOI 10.1158/1078-0432.CCR-10-1489; Jansson MD, 2012, MOL ONCOL, V6, P590, DOI 10.1016/j.molonc.2012.09.006; Trajkovic K, 2008, SCIENCE, V319, P1244, DOI 10.1126/science.1153124; Rabinowits G, 2009, CLIN LUNG CANCER, V10, P42, DOI 10.3816/CLC.2009.n.006; Bobrie A, 2012, CANCER RES, V72, P4920, DOI 10.1158/0008-5472.CAN-12-0925; Mitchell P, 1997, CELL, V91, P457, DOI 10.1016/S0092-8674(00)80432-8; Agaoglu FY, 2011, TUMOR BIOL, V32, P583, DOI 10.1007/s13277-011-0154-9; Cocucci E, 2009, TRENDS CELL BIOL, V19, P43, DOI 10.1016/j.tcb.2008.11.003; Mitchell PS, 2008, P NATL ACAD SCI USA, V105, P10513, DOI 10.1073/pnas.0804549105; Arroyo JD, 2011, P NATL ACAD SCI USA, V108, P5003, DOI 10.1073/pnas.1019055108; Benetti R, 2008, NAT STRUCT MOL BIOL, V15, P268, DOI 10.1038/nsmb.1399; BLANK A, 1981, BIOCHEMISTRY-US, V20, P2261, DOI 10.1021/bi00511a030; Chen WX, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0095240; Choi DS, 2014, MASS SPECTROM REV, DOI [10.1002/mas.21420, DOI 10.1002/MAS.21420]; Clayton A, 2012, ONCOIMMUNOLOGY, V1, P78, DOI 10.4161/onci.1.1.17826; Crescitelli R., 2013, J EXTRACELLUL VESICL, V2, P20677, DOI DOI 10.3402/JEV.V2I0.20677; Escrevente C, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-108; Fruhbeis C, 2013, PLOS BIOL, V11, DOI 10.1371/journal.pbio.1001604; Gaidatzis D, 2007, BMC BIOINFORMATICS, V8, DOI 10.1186/1471-2105-8-69; Gilad S, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003148; Gould Stephen J, 2013, J Extracell Vesicles, V2, DOI 10.3402/jev.v2i0.20389; Griffiths-Jones S, 2006, NUCLEIC ACIDS RES, V34, pD140, DOI 10.1093/nar/gkj112; Hessvik Nina Pettersen, 2013, Frontiers in Genetics, V4, P36, DOI 10.3389/fgene.2013.00036; Hu Guoku, 2012, Frontiers in Genetics, V3, P56, DOI 10.3389/fgene.2012.00056; Huang XY, 2013, BMC GENOMICS, V14, DOI 10.1186/1471-2164-14-319; Hunter MP, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003694; Jenjaroenpun P, 2013, PEERJ, V1, DOI 10.7717/peerj.201; Kalra H, 2012, PLOS BIOL, V10, DOI 10.1371/journal.pbio.1001450; Kim D.-K., 2013, J EXTRACELL VESICLES, V2, P20384, DOI DOI 10.3402/JEV.V2I0.20384; Kosaka Nobuyoshi, 2010, Silence, V1, P7, DOI 10.1186/1758-907X-1-7; Kosaka Nobuyoshi, 2013, Frontiers in Genetics, V4, P173, DOI 10.3389/fgene.2013.00173; Kruger S, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-44; Lai CPK, 2012, FRONT PHYSIOL, V3, DOI 10.3389/fphys.2012.00228; LEE RC, 1993, CELL, V75, P843, DOI 10.1016/0092-8674(93)90529-Y; Marleau AM, 2012, J TRANSL MED, V10, DOI 10.1186/1479-5876-10-134; Mittelbrunn M, 2011, NAT COMMUN, V2, DOI 10.1038/ncomms1285; Montgomery MK, 1998, P NATL ACAD SCI USA, V95, P15502, DOI 10.1073/pnas.95.26.15502; Mulcahy L. A., 2014, J EXTRACELL VESICLES, V4, DOI [10.3402/jev.v3.24641, DOI 10.3402/JEV.V3.24641]; NAPOLI C, 1990, PLANT CELL, V2, P279, DOI 10.1105/tpc.2.4.279; Noerholm M, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-22; Ogata-Kawata H, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092921; Ohshima K, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013247; Pigati L, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013515; Qin Q, 2014, J EXP CLIN CANC RES, V33, DOI 10.1186/1756-9966-33-50; Tickner Jacob A, 2014, Front Oncol, V4, P127, DOI 10.3389/fonc.2014.00127; Roma-Rodrigues C., 2014, BIOMED RES INT, V2014, DOI [DOI 10.1155/2014/179486, 10.1155/2014/179486]; Shtam TA, 2013, CELL COMMUN SIGNAL, V11, DOI 10.1186/1478-811X-11-88; Simpson RJ, 2012, J PROTEOM BIOINFORM, V05, P10000, DOI [10.4172/jpb.10000e10, DOI 10.4172/JPB.10000E10]; Stroynowska-Czerwinska A, 2014, CELL MOL LIFE SCI, V71, P2253, DOI 10.1007/s00018-013-1551-6; Thery C, 2011, F1000 PRIME REP, V3, DOI [10.3410/B3-15, DOI 10.3410/B3-15]; VANDERKROL AR, 1990, PLANT CELL, V2, P291, DOI 10.1105/tpc.2.4.291; Villarroya-Beltri C, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3980	131	1	1	SPRINGER BASEL AG	BASEL	PICASSOPLATZ 4, BASEL, 4052, SWITZERLAND	1420-682X	1420-9071		CELL MOL LIFE SCI	Cell. Mol. Life Sci.	MAY	2015	72	10					1849	1861		10.1007/s00018-014-1811-0		13	Biochemistry & Molecular Biology; Cell Biology	Biochemistry & Molecular Biology; Cell Biology	CG4DA	WOS:000353231300002		
J	Mikawa, T; LLeonart, ME; Takaori-Kondo, A; Inagaki, N; Yokode, M; Kondoh, H				Mikawa, Takumi; LLeonart, Matilde E.; Takaori-Kondo, Akifumi; Inagaki, Nobuya; Yokode, Masayuki; Kondoh, Hiroshi			Dysregulated glycolysis as an oncogenic event	CELLULAR AND MOLECULAR LIFE SCIENCES			English	Review						Warburg effect; Cancer; HIF-1; Sirtuin; Myc; PGAM	HYPOXIA-INDUCIBLE FACTOR; PYRUVATE-KINASE M2; HISTONE DEACETYLASE SIRT6; ACTIVATED PROTEIN-KINASE; CANCER-CELL METABOLISM; TUMOR-SUPPRESSOR; PHOSPHOGLYCERATE MUTASE; LIFE-SPAN; GLUCOSE-METABOLISM; AEROBIC GLYCOLYSIS	Enhanced glycolysis in cancer, called the Warburg effect, is a well-known feature of cancer metabolism. Recent advances revealed that the Warburg effect is coupled to many other cancer properties, including adaptation to hypoxia and low nutrients, immortalisation, resistance to oxidative stress and apoptotic stimuli, and elevated biomass synthesis. These linkages are mediated by various oncogenic molecules and signals, such as c-Myc, p53, and the insulin/Ras pathway. Furthermore, several regulators of glycolysis have been recently identified as oncogene candidates, including the hypoxia-inducible factor pathway, sirtuins, adenosine monophosphate-activated kinase, glycolytic pyruvate kinase M2, phosphoglycerate mutase, and oncometabolites. The interplay between glycolysis and oncogenic events will be the focus of this review.	[Mikawa, Takumi; Inagaki, Nobuya; Kondoh, Hiroshi] Kyoto Univ, Grad Sch Med, Dept Diabet Endocrinol & Nutr, Kyoto 6068507, Japan; [LLeonart, Matilde E.] Hosp Vall deHebron, Dept Pathol, Barcelona 08035, Spain; [Takaori-Kondo, Akifumi] Kyoto Univ, Grad Sch Med, Dept Hematol, Kyoto 6068507, Japan; [Takaori-Kondo, Akifumi] Kyoto Univ, Grad Sch Med, Dept Oncol, Kyoto 6068507, Japan; [Yokode, Masayuki] Kyoto Univ Hosp, Dept Clin Innovat Med, Translat Res Ctr, Kyoto 6068507, Japan; [Kondoh, Hiroshi] Kyoto Univ Hosp, Geriatr Unit, Kyoto 6068507, Japan	Kondoh, H (reprint author), Kyoto Univ Hosp, Geriatr Unit, Kyoto 6068507, Japan.	hkondoh@kuhp.kyoto-u.ac.jp					Mikawa T, 2014, J CELL BIOL, V204, P729, DOI 10.1083/jcb.201306149; Kwon OH, 2012, BIOCHEM BIOPH RES CO, V423, P38, DOI 10.1016/j.bbrc.2012.05.063; Papandreou I, 2006, CELL METAB, V3, P187, DOI 10.1016/j.cmet.2006.01.012; Zhong L, 2010, CELL, V140, P280, DOI 10.1016/j.cell.2009.12.041; Shim H, 1997, P NATL ACAD SCI USA, V94, P6658, DOI 10.1073/pnas.94.13.6658; David CJ, 2010, NATURE, V463, P364, DOI 10.1038/nature08697; Ro TB, 2013, EXP HEMATOL, V41, P646, DOI 10.1016/j.exphem.2013.03.002; Hart GW, 2011, ANNU REV BIOCHEM, V80, P825, DOI 10.1146/annurev-biochem-060608-102511; Elvidge GP, 2006, J BIOL CHEM, V281, P15215, DOI 10.1074/jbc.M511408200; Fukuda R, 2002, J BIOL CHEM, V277, P38205, DOI 10.1074/jbc.M203781200; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Gatenby RA, 2004, NAT REV CANCER, V4, P891, DOI 10.1038/nrc1478; Israelsen WJ, 2013, CELL, V155, P397, DOI 10.1016/j.cell.2013.09.025; Lee JW, 2008, INT J BIOCHEM CELL B, V40, P1043, DOI 10.1016/j.biocel.2007.11.009; LEACH FS, 1993, CANCER RES, V53, P2231; Kim JW, 2006, CELL METAB, V3, P177, DOI 10.1016/j.cmet.2006.02.002; Granchi C, 2012, CHEMMEDCHEM, V7, P1318, DOI 10.1002/cmdc.201200176; Shin JY, 2013, CELL REP, V5, P654, DOI 10.1016/j.celrep.2013.10.007; Wu N, 2013, MOL CELL, V49, P1167, DOI 10.1016/j.molcel.2013.01.035; Sebastian C, 2012, CELL, V151, P1185, DOI 10.1016/j.cell.2012.10.047; Zhao D, 2013, CANCER CELL, V23, P464, DOI 10.1016/j.ccr.2013.02.005; Lim JH, 2010, MOL CELL, V38, P864, DOI 10.1016/j.molcel.2010.05.023; Xu YP, 2014, CANCER RES, V74, P3630, DOI 10.1158/0008-5472.CAN-13-3615; Xu W, 2011, CANCER CELL, V19, P17, DOI 10.1016/j.ccr.2010.12.014; Kamura T, 2000, P NATL ACAD SCI USA, V97, P10430, DOI 10.1073/pnas.190332597; Parrinello S, 2003, NAT CELL BIOL, V5, P741, DOI 10.1038/ncb1024; Sherr CJ, 2002, CANCER CELL, V2, P103, DOI 10.1016/S1535-6108(02)00102-2; Covello KL, 2006, GENE DEV, V20, P557, DOI 10.1101/gad.1399906; Prabhakar NR, 2012, PHYSIOL REV, V92, P967, DOI 10.1152/physrev.00030.2011; Altenberg B, 2004, GENOMICS, V84, P1014, DOI 10.1016/j.ygeno.2004.08.010; BelAiba RS, 2007, MOL BIOL CELL, V18, P4691, DOI 10.1091/mbc.E07-04-0391; Kondoh H, 2005, CANCER RES, V65, P177; Kawauchi K, 2008, NAT CELL BIOL, V10, P611, DOI 10.1038/ncb1724; Jones RG, 2005, MOL CELL, V18, P283, DOI 10.1016/j.molcel.2005.03.027; Yang WW, 2011, NATURE, V480, P118, DOI 10.1038/nature10598; Kim JW, 2004, MOL CELL BIOL, V24, P5923, DOI 10.1128/MCB.24.13.5923-5936.2004; Mathupala SP, 2006, ONCOGENE, V25, P4777, DOI 10.1038/sj.onc.1209603; Hitosugi T, 2012, CANCER CELL, V22, P585, DOI 10.1016/j.ccr.2012.09.020; Gao XL, 2012, MOL CELL, V45, P598, DOI 10.1016/j.molcel.2012.01.001; Lv L, 2013, MOL CELL, V52, P340, DOI 10.1016/j.molcel.2013.09.004; Yeung SJ, 2008, CELL MOL LIFE SCI, V65, P3981, DOI 10.1007/s00018-008-8224-x; Onodera Y, 2014, J CLIN INVEST, V124, P367, DOI 10.1172/JCI63146; Shalom-Barak T, 2002, J BIOL CHEM, V277, P40659, DOI 10.1074/jbc.M206650200; Macheda ML, 2005, J CELL PHYSIOL, V202, P654, DOI 10.1002/jcp.20166; Chen HC, 2012, ANN SURG ONCOL, V19, P2011, DOI 10.1245/s10434-011-2159-4; Yang WW, 2012, CELL, V150, P685, DOI 10.1016/j.cell.2012.07.018; Helmlinger G, 1997, NAT MED, V3, P177, DOI 10.1038/nm0297-177; Gerald D, 2004, CELL, V118, P781, DOI 10.1016/j.cell.2004.08.025; Lv L, 2011, MOL CELL, V42, P719, DOI 10.1016/j.molcel.2011.04.025; Tao RD, 2010, MOL CELL, V40, P893, DOI 10.1016/j.molcel.2010.12.013; Itamochi H, 2008, CANCER SCI, V99, P653, DOI 10.1111/j.1349-7006.2008.00747.x; Yang F, 2014, MOL CELL, V53, P88, DOI 10.1016/j.molcel.2013.11.004; Sano H, 2003, J BIOL CHEM, V278, P14599, DOI 10.1074/jbc.C300063200; Li TT, 2014, J BIOL CHEM, V289, P3775, DOI 10.1074/jbc.M113.531640; Rios M, 2013, CANCER RES, V73, P2628, DOI 10.1158/0008-5472.CAN-12-0861; Imai S, 2000, NATURE, V403, P795; Kondoh H, 2007, ANTIOXID REDOX SIGN, V9, P293, DOI 10.1089/ars.2006.1467; Hubbi ME, 2013, J BIOL CHEM, V288, P20768, DOI 10.1074/jbc.M113.476903; Burns DM, 2008, GENE DEV, V22, P3449, DOI 10.1101/gad.1697808; Kim HS, 2010, CANCER CELL, V17, P41, DOI 10.1016/j.ccr.2009.11.023; Finley LWS, 2011, CANCER CELL, V19, P416, DOI 10.1016/j.ccr.2011.02.014; Bingham C, 2004, NEPHROL DIAL TRANSPL, V19, P2703, DOI 10.1093/ndt/gfh348; Jiang YH, 2014, MOL CELL, V53, P75, DOI 10.1016/j.molcel.2013.11.001; Jeong SM, 2014, J BIOL CHEM, V289, P4135, DOI 10.1074/jbc.M113.525949; Kaelin WG, 1998, TRENDS GENET, V14, P423, DOI 10.1016/S0168-9525(98)01558-3; Iyer NV, 1998, GENE DEV, V12, P149, DOI 10.1101/gad.12.2.149; Li ZW, 2014, BBA-REV CANCER, V1846, P285, DOI 10.1016/j.bbcan.2014.07.008; Yecies JL, 2011, J MOL MED-JMM, V89, P221, DOI 10.1007/s00109-011-0726-6; REIFENBERGER G, 1993, CANCER RES, V53, P2736; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Mathupala SP, 1997, J BIOL CHEM, V272, P22776, DOI 10.1074/jbc.272.36.22776; Feng ZH, 2010, TRENDS CELL BIOL, V20, P427, DOI 10.1016/j.tcb.2010.03.004; Kanfi Y, 2012, NATURE, V483, P218, DOI 10.1038/nature10815; Lu HS, 2002, J BIOL CHEM, V277, P23111, DOI 10.1074/jbc.M202487200; Maxwell PH, 1999, NATURE, V399, P271; Canto C, 2009, CURR OPIN LIPIDOL, V20, P98, DOI 10.1097/MOL.0b013e328328d0a4; Isaacs JS, 2005, CANCER CELL, V8, P143, DOI 10.1016/j.ccr.2005.06.017; Gariboldi MB, 2010, BIOCHEM PHARMACOL, V80, P455, DOI 10.1016/j.bcp.2010.05.011; Pedersen PL, 2007, J BIOENERG BIOMEMBR, V39, P211, DOI 10.1007/s10863-007-9094-x; Discher DJ, 1998, J BIOL CHEM, V273, P26087, DOI 10.1074/jbc.273.40.26087; Keller KE, 2012, SCIENCE, V338, P1069, DOI 10.1126/science.1224409; Liang JY, 2013, CANCER RES, V73, P2929, DOI 10.1158/0008-5472.CAN-12-3876; Sowter HM, 2003, CANCER RES, V63, P6130; Hallows WC, 2012, J BIOL CHEM, V287, P3850, DOI 10.1074/jbc.M111.317404; Schafer D, 1997, FEBS LETT, V417, P325, DOI 10.1016/S0014-5793(97)01314-8; Bouche C, 2004, ENDOCR REV, V25, P807, DOI 10.1210/er.2003-0026; Ying HQ, 2012, CELL, V149, P656, DOI 10.1016/j.cell.2012.01.058; Maynard MA, 2007, CELL MOL LIFE SCI, V64, P2170, DOI 10.1007/s00018-007-7082-2; Bensaad K, 2006, CELL, V126, P107, DOI 10.1016/j.cell.2006.05.036; Luo WB, 2011, CELL, V145, P732, DOI 10.1016/j.cell.2011.03.054; Koshiji M, 2004, EMBO J, V23, P1949, DOI 10.1038/sj.emboj.7600196; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; WARBURG O, 1956, SCIENCE, V124, P269; Brown DR, 1998, EMBO J, V17, P2513, DOI 10.1093/emboj/17.9.2513; Collado M, 2005, NATURE, V436, P642, DOI 10.1038/436642a; Faubert B, 2013, CELL METAB, V17, P113, DOI 10.1016/j.cmet.2012.12.001; McCay CM, 1934, SCI MON, V39, P405; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; Duvel K, 2010, MOL CELL, V39, P171, DOI 10.1016/j.molcel.2010.06.022; Manfredi JJ, 2010, GENE DEV, V24, P1580, DOI 10.1101/gad.1941710; Geng H, 2011, J BIOL CHEM, V286, P38095, DOI 10.1074/jbc.M111.257055; Kim HS, 2011, CANCER CELL, V20, P487, DOI 10.1016/j.ccr.2011.09.004; Elstrom RL, 2004, CANCER RES, V64, P3892, DOI 10.1158/0008-5472.CAN-03-2904; Koppenol WH, 2011, NAT REV CANCER, V11, P325, DOI 10.1038/nrc3038; Molli PR, 2009, ONCOGENE, V28, P2545, DOI 10.1038/onc.2009.119; Cha EJ, 2009, CLIN CANCER RES, V15, P4453, DOI 10.1158/1078-0432.CCR-08-3329; Giovannucci E, 2010, DIABETES CARE, V33, P1674, DOI 10.2337/dc10-0666; Mathupala SP, 2009, SEMIN CANCER BIOL, V19, P17, DOI 10.1016/j.semcancer.2008.11.006; Clower CV, 2010, P NATL ACAD SCI USA, V107, P1894, DOI 10.1073/pnas.0914845107; Satoh A, 2013, CELL METAB, V18, P416, DOI 10.1016/j.cmet.2013.07.013; Osthus RC, 2000, J BIOL CHEM, V275, P21797, DOI 10.1074/jbc.C000023200; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Yuan J, 2009, J CELL BIOL, V185, P203, DOI 10.1083/jcb.200809167; Chan DA, 2005, MOL CELL BIOL, V25, P6415, DOI 10.1128/MCB.25.15.6415-6426.2005; Selak MA, 2005, CANCER CELL, V7, P77, DOI 10.1016/j.ccr.2004.11.022; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Baba T, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4634; Banaszak K, 2011, J MOL BIOL, V407, P284, DOI 10.1016/j.jmb.2011.01.019; CHEN Q, 1994, P NATL ACAD SCI USA, V91, P4130, DOI 10.1073/pnas.91.10.4130; COOPER JA, 1983, NATURE, V302, P218, DOI 10.1038/302218a0; Durany N, 1997, BRIT J CANCER, V75, P969, DOI 10.1038/bjc.1997.168; Elvert G, 2003, J BIOL CHEM, V278, P7520, DOI 10.1074/jbc.M211298200; Ganapathy-Kanniappan S, 2012, ONCOTARGET, V3, P940; Gitenay D, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.63; Hasawi N. A., 2014, CR REV ONCOL HEM, V92, P312, DOI DOI 10.1016/J.CRITREVONC.2014.05.007; Hitosugi T, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.2000431; Hitosugi T, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2759; Jang M, 2013, EXP MOL MED, V45, DOI 10.1038/emm.2013.85; Jung JW, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028068; Kennedy KM, 2010, FUTURE ONCOL, V6, P127, DOI [10.2217/fon.09.145, 10.2217/FON.09.145]; Le Bras A, 2007, ONCOGENE, V26, P7480, DOI 10.1038/sj.onc.1210566; Menon S, 2008, Oncogene, V27 Suppl 2, pS43, DOI 10.1038/onc.2009.352; Musi N, 2003, ACTA PHYSIOL SCAND, V178, P337, DOI 10.1046/j.1365-201X.2003.01168.x; Noguchi A, 2014, CANCER MED-US, V3, P1553, DOI 10.1002/cam4.310; Okamoto T, 2015, MOL CARCINOGEN, V54, P35, DOI 10.1002/mc.22072; Okuda J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072173; Panasyuk G, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms1667; Singh PK, 2011, MOL CELL PHARM, V3, P125; Sun J, 2009, ONCOGENE, V28, P3132, DOI 10.1038/onc.2009.167; TARUI S, 1995, MUSCLE NERVE, pS2; Tsusaka T, 2014, GENES CELLS, V19, P766, DOI 10.1111/gtc.12176; Tunduguru R, 2014, BIOCHEM PHARMACOL, V92, P380, DOI 10.1016/j.bcp.2014.08.033; Vander Heiden Matthew G, 2010, Science, V329, P1492, DOI 10.1126/science.1188015; Vander Heiden MG, 2009, SCIENCE, V324, P1029, DOI DOI 10.1126/SCIENCE.1160809; Zwaans BMM, 2014, DIS MODEL MECH, V7, P1023, DOI 10.1242/dmm.016287	145	1	1	SPRINGER BASEL AG	BASEL	PICASSOPLATZ 4, BASEL, 4052, SWITZERLAND	1420-682X	1420-9071		CELL MOL LIFE SCI	Cell. Mol. Life Sci.	MAY	2015	72	10					1881	1892		10.1007/s00018-015-1840-3		12	Biochemistry & Molecular Biology; Cell Biology	Biochemistry & Molecular Biology; Cell Biology	CG4DA	WOS:000353231300004		
J	Hirakawa, K; Ito, H				Hirakawa, Kazutaka; Ito, Hiroki			Rhodamine-6G can photosensitize folic acid decomposition through electron transfer	CHEMICAL PHYSICS LETTERS			English	Article							ACTIVE-SITE; DNA-DAMAGE; DIFFUSION; METHOTREXATE; FLUOROMETRY; THERAPY; ENZYME	Rhodamine-6G photosensitized folic acid decomposition in aqueous solution, and its quantum yield in the presence of 10 mu M folic acid was 9.9 x 10(-6). A possible mechanism of this photodecomposition is direct oxidation through an electron transfer from folic acid to rhodamine-6G. The fluorescence lifetime of rhodamine-6G was slightly decreased by folic acid, suggesting electron transfer in the excited singlet state of rhodamine-6G. The quenching rate coefficient estimated from the Stern-Volmer plot of the fluorescence quenching supported that this electron transfer proceeds as a diffusion-controlled reaction. The quantum yields of the electron transfer and the following reaction could be determined. (C) 2015 Elsevier B.V. All rights reserved.	[Hirakawa, Kazutaka; Ito, Hiroki] Shizuoka Univ, Grad Sch Engn, Dept Appl Chem & Biochem Engn, Naka Ku, Hamamatsu, Shizuoka 4328561, Japan; [Hirakawa, Kazutaka] Shizuoka Univ, Grad Sch Sci & Technol, Dept Optoelect & Nanostruct Sci, Naka Ku, Hamamatsu, Shizuoka 4328561, Japan	Hirakawa, K (reprint author), Shizuoka Univ, Grad Sch Engn, Dept Appl Chem & Biochem Engn, Naka Ku, Johoku 3-5-1, Hamamatsu, Shizuoka 4328561, Japan.	hirakawa.kazutaka@shizuoka.ac.jp			JSPS KAKENHI [23750186]	This work was supported by JSPS KAKENHI grant Number 23750186.	Hirakawa K, 2006, ANAL BIOANAL CHEM, V386, P244, DOI 10.1007/s00216-006-0649-1; Wilson WR, 2011, NAT REV CANCER, V11, P393, DOI 10.1038/nrc3064; Perez-Lustres JL, 2007, J AM CHEM SOC, V129, P5408, DOI 10.1021/ja0664990; GETZOFF ED, 1992, NATURE, V358, P347, DOI 10.1038/358347a0; Hirakawa K, 2012, J PHYS CHEM B, V116, P3037, DOI 10.1021/jp300142e; SHARP K, 1987, SCIENCE, V236, P1460, DOI 10.1126/science.3589666; Hirakawa K, 2014, CHEM RES TOXICOL, V27, P649, DOI 10.1021/tx400475c; KUBIN RF, 1982, J LUMIN, V27, P455; CHOU KC, 1982, J AM CHEM SOC, V104, P1409, DOI 10.1021/ja00369a043; Idris NM, 2012, NAT MED, V18, P1580, DOI 10.1038/nm.2933; Boussicault F, 2008, CHEM REV, V108, P2622, DOI 10.1021/cr0680787; Burgess D. J., 2012, NAT REV CANCER, V12, P737; Butzbach K, 2013, FREE RADICAL BIO MED, V65, P821, DOI 10.1016/j.freeradbiomed.2013.08.168; Cadet J., 2014, INT J RADIAT BIOL, V90, P423; Dolmans D.E.J.G.J., 2003, NAT REV CANCER, V3, P381; Hirakawa K., 2011, TRENDS PHOTOCHEM PHO, V13, P29; Hirakawa K, 2003, ARCH BIOCHEM BIOPHYS, V410, P261, DOI 10.1016/S0003-9861(02)00722-1; Hirakawa K, 2009, ANAL BIOANAL CHEM, V393, P999, DOI 10.1007/s00216-008-2522-x; Hirakawa K., 2008, NEW RES DNA DAMAGE, P197; Joseph J, 2010, CHEM COMMUN, V46, P7872, DOI 10.1039/c0cc02118k; Li GF, 2012, J PHYS CHEM B, V116, P3467, DOI 10.1021/jp300392a; Magde D., 2002, PHOTOCHEM PHOTOBIOL, V75, P327; Martin CB, 2009, J PHOTOCH PHOTOBIO A, V208, P1, DOI 10.1016/j.jphotochem.2009.07.025; Molavian HR, 2009, CANCER RES, V69, P9141, DOI 10.1158/0008-5472.CAN-09-2112; Pedzinski T, 2002, J PHOTOCH PHOTOBIO A, V150, P21, DOI 10.1016/S1010-6030(02)00028-X; POE M, 1977, J BIOL CHEM, V252, P3724; REMBOLD H., 1964, P465; Song QH, 2007, J PHOTOCH PHOTOBIO A, V185, P51, DOI 10.1016/j.jphotochem.2006.05.009; Tyagi A, 2010, CHEM PHYS, V367, P83, DOI 10.1016/j.chemphys.2009.10.026; Yasui S, 2008, J PHYS ORG CHEM, V21, P541, DOI 10.1002/poc.1313	30	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0009-2614	1873-4448		CHEM PHYS LETT	Chem. Phys. Lett.	MAY 1	2015	627						26	29		10.1016/j.cplett.2015.03.030		4	Chemistry, Physical; Physics, Atomic, Molecular & Chemical	Chemistry; Physics	CG7VP	WOS:000353514300005		
J	Takasu, Y; Matsumoto, S; Fujii, Y; Nishio, I				Takasu, Yuichi; Matsumoto, Satoru; Fujii, Yasuhiro; Nishio, Izumi			Raman study of the low temperature behavior of tetrahydrofuran molecule in the cage of clathrate hydrate	CHEMICAL PHYSICS LETTERS			English	Article							THERMAL-CONDUCTIVITY	Vibrational modes of a tetrahydrofuran (THF) in a clathrate hydrate (CH) are studied by Raman spectroscopy. Especially, we focused on around 900 cm(-1), where a CCCC stretching mode of THF is mainly observed. An asymmetric peak around 900 cm(-1), which shows a major CCCC stretching mode of THF with a minor tailing above 150K, is observed as clear four modes below 40K. We concluded that the peak-splitting is attributed to a restriction of vibrational motions of the guest molecule by the CH-cage wall at low temperature due to a deformation of a force field of the CH-cage for the guest molecule. (C) 2015 Elsevier B.V. All rights reserved.	[Takasu, Yuichi] St Marianna Univ, Sch Med, Dept Phys, Sagamihara, Kanagawa 2168511, Japan; [Matsumoto, Satoru; Nishio, Izumi] Aoyama Gakuin Univ, Coll Sci & Engn, Dept Math & Phys, Sagamihara, Kanagawa 2525258, Japan; [Fujii, Yasuhiro] Ritsumeikan Univ, Coll Sci & Engn, Dept Phys Sci, Kyoto, Shiga 5258577, Japan	Takasu, Y (reprint author), St Marianna Univ, Sch Med, Dept Phys, Sagamihara, Kanagawa 2168511, Japan.	ytakasu@marianna-u.ac.jp	Fujii, Yasuhiro/D-3025-2013	Fujii, Yasuhiro/0000-0002-9522-6103			Alavi S, 2006, J CHEM PHYS, V124, DOI 10.1063/1.2141506; Andersson O, 1996, J PHYS CHEM SOLIDS, V57, P125, DOI 10.1016/0022-3697(95)00157-3; TSE JS, 1988, J PHYS CHEM-US, V92, P5006, DOI 10.1021/j100328a036; Gao SQ, 2005, J PHYS CHEM B, V109, P19090, DOI 10.1021/jp052071w; Sloan ED, 2003, NATURE, V426, P353, DOI 10.1038/nature02135; Florusse LJ, 2004, SCIENCE, V306, P469, DOI 10.1126/science.1102076; Kulig W, 2011, J PHYS CHEM A, V115, P6149, DOI 10.1021/jp111245z; Lee H, 2005, NATURE, V434, P743, DOI 10.1038/nature03457; Makino T, 2005, J CHEM ENG DATA, V50, P2058, DOI 10.1021/je0502694; Kirschgen TM, 2003, PHYS CHEM CHEM PHYS, V5, P5243, DOI 10.1039/b212471h; Conrad H, 2009, PHYS REV LETT, V103, DOI 10.1103/PhysRevLett.103.218301; Alavi S, 2009, J CHEM PHYS, V130, DOI 10.1063/1.3124187; BERTIE JE, 1978, J CHEM PHYS, V69, P4105, DOI 10.1063/1.437089; CADIOLI B, 1993, J PHYS CHEM-US, V97, P7844, DOI 10.1021/j100132a010; KLUG DD, 1973, CAN J CHEM, V51, P4062, DOI 10.1139/v73-605; Krivchikov AI, 2005, PHYS CHEM CHEM PHYS, V7, P728, DOI 10.1039/b418602h; Prasad PSR, 2007, SPECTROCHIM ACTA A, V68, P1096, DOI 10.1016/j.saa.2007.06.049; Subramanian S., 2002, J PHYS CHEM B, V106, P4348; Tombari E., 2001, J CHEM PHYS, V121; Tulk C.A., 1998, J PHYS CHEM A, V102, P8734; Verges M. B., 2001, J PHYS CHEM B, V105, P2699; YAMAMURO O, 1995, PHYSICA B, V213, P405, DOI 10.1016/0921-4526(95)00171-5	22	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0009-2614	1873-4448		CHEM PHYS LETT	Chem. Phys. Lett.	MAY 1	2015	627						39	43		10.1016/j.cplett.2015.03.037		5	Chemistry, Physical; Physics, Atomic, Molecular & Chemical	Chemistry; Physics	CG7VP	WOS:000353514300008		
J	Shoji, M; Isobe, H; Yamanaka, S; Suga, M; Akita, F; Shen, JR; Yamaguchi, K				Shoji, Mitsuo; Isobe, Hiroshi; Yamanaka, Shusuke; Suga, Michihiro; Akita, Fusamichi; Shen, Jian-Ren; Yamaguchi, Kizashi			On the guiding principles for lucid understanding of the damage-free S-1 structure of the CaMn4O5 cluster in the oxygen evolving complex of photosystem II	CHEMICAL PHYSICS LETTERS			English	Editorial Material							RESOLUTION CRYSTAL-STRUCTURE; 1.9 ANGSTROM; MANGANESE COMPLEX; MN-CLUSTER; STATES; MODEL; EXAFS; WATER; CRYSTALLOGRAPHY; CAMN4O5(H2O)(4)	Several key concepts and geometrical rules for the Mn-Mn and Mn-O distances of the CaMn4O5 cluster in the oxygen evolving complex (OEC) of photosystem II (PSII) by previous and present theoretical calculations were examined for a clear understanding of the damage-free Si structure revealed by X-ray free electron laser (XFEL). A simple equation to estimate the Mn-a-Mn-b distance in relation to the Mn-a-O(5) distance was derived taking into consideration the Jahn-Teller (JT) effects for Mn centers, indicating that the XFEL structure is regarded as a slightly right-elongated quasi-central structure in contradiction to a right-opened structure proposed by the EXAFS measurements. (C) 2015 Elsevier B.V. All rights reserved.	[Shoji, Mitsuo] Univ Tsukuba, Ctr Computat Sci, Tsukuba, Ibaraki 3058577, Japan; [Isobe, Hiroshi; Suga, Michihiro; Akita, Fusamichi; Shen, Jian-Ren] Okayama Univ, Grad Sch Nat Sci & Technol, Photosynth Res Ctr, Okayama 7008530, Japan; [Yamanaka, Shusuke] Osaka Univ, Grad Sch Sci, Toyonaka, Osaka 5600043, Japan; [Yamaguchi, Kizashi] Osaka Univ, Insitute NanoSci Design, Toyonaka, Osaka 5608531, Japan; [Yamaguchi, Kizashi] Handairigaku Technores, Toyonaka, Osaka 5600043, Japan	Yamaguchi, K (reprint author), Osaka Univ, Insitute NanoSci Design, Toyonaka, Osaka 5608531, Japan.	yama@chem.sci.osaka-u.ac.jp	Shen, Jian-Ren/B-2558-2011; Akita, Fusamichi/C-2034-2015	Akita, Fusamichi/0000-0003-0537-6157	MEXT, Japan [24000018]	Numerical calculations of the present work were carried out under the support of a Grants-in-Aid for Specially Promoted Research (No. 24000018) from MEXT, Japan.	Grundmeier A, 2012, BBA-BIOENERGETICS, V1817, P88, DOI 10.1016/j.bbabio.2011.07.004; Shoji M, 2015, CHEM PHYS LETT, V623, P1, DOI 10.1016/j.cplett.2015.01.030; Li XC, 2013, INT J QUANTUM CHEM, V113, P474, DOI 10.1002/qua.24143; Kern J, 2012, P NATL ACAD SCI USA, V109, P9721, DOI 10.1073/pnas.1204598109; Yamanaka S, 2012, ADV QUANTUM CHEM, V64, P121, DOI 10.1016/B978-0-12-396498-4.00016-8; Ferreira KN, 2004, SCIENCE, V303, P1831, DOI 10.1126/science.1093087; Hirata K, 2014, NAT METHODS, V11, P734, DOI [10.1038/nmeth.2962, 10.1038/NMETH.2962]; Rivalta I, 2012, CURR OPIN CHEM BIOL, V16, P11, DOI 10.1016/j.cbpa.2012.03.003; Gatt P, 2012, ANGEW CHEM INT EDIT, V51, P12025, DOI 10.1002/anie.201206316; Kanda K, 2011, CHEM PHYS LETT, V506, P98, DOI 10.1016/j.cplett.2011.02.030; Biesiadka J, 2004, PHYS CHEM CHEM PHYS, V6, P4733, DOI 10.1039/b406989g; Yamanaka S, 2012, INT J QUANTUM CHEM, V112, P321, DOI 10.1002/qua.23261; Yano J, 2005, P NATL ACAD SCI USA, V102, P12047, DOI 10.1073/pnas.0505207102; Dau H, 2008, PHILOS T R SOC B, V363, P1237, DOI 10.1098/rstb.2007.2220; Galstyan A, 2012, J AM CHEM SOC, V134, P7442, DOI 10.1021/ja300254n; Chapman HN, 2011, NATURE, V470, P73, DOI 10.1038/nature09750; Isobe H, 2012, DALTON T, V41, P13727, DOI 10.1039/c2dt31420g; Yamaguchi K, 2013, INT J QUANTUM CHEM, V113, P525, DOI 10.1002/qua.24117; Yachandra VK, 1996, CHEM REV, V96, P2927, DOI 10.1021/cr950052k; Shoji M, 2015, MOL PHYS, V113, P359, DOI 10.1080/00268976.2014.960021; Suga M, 2015, NATURE, V517, P99, DOI 10.1038/nature13991; Umena Y, 2011, NATURE, V473, P55, DOI 10.1038/nature09913; Pal R, 2013, BIOCHEMISTRY-US, V52, P7703, DOI 10.1021/bi401214v; Shoji M, 2013, CATAL SCI TECHNOL, V3, P1831, DOI 10.1039/c3cy00051f; Siegbahn PEM, 2008, CHEM-EUR J, V14, P8290, DOI 10.1002/chem.200800445; Guskov A, 2009, NAT STRUCT MOL BIOL, V16, P334, DOI 10.1038/nsmb.1559; Guskov A, 2010, CHEMPHYSCHEM, V11, P1160, DOI 10.1002/cphc.200900901; Boutet S, 2012, SCIENCE, V337, P362, DOI 10.1126/science.1217737; Yamaguchi K, 2013, INT J QUANTUM CHEM, V113, P453, DOI 10.1002/qua.24280; Yano J, 2005, J AM CHEM SOC, V127, P14974, DOI 10.1021/ja054873a; Loll B, 2005, NATURE, V438, P1040, DOI 10.1038/nature04224; Petrie S, 2012, PHYS CHEM CHEM PHYS, V14, P11333, DOI 10.1039/c2cp41020f; Luber S, 2011, BIOCHEMISTRY-US, V50, P6308, DOI 10.1021/bi200681q; Krivanek R, 2007, BBA-BIOENERGETICS, V1767, P520, DOI 10.1016/j.bbabio.2007.02.013; Berg J. M., 2007, BIOCHEMISTRY; Glockner G., 2013, J BIOL CHEM, V288, P22607; Isobe H, 2014, PHYS CHEM CHEM PHYS, V16, P11911, DOI 10.1039/c4cp00282b; Kutpitz C., 2014, NATURE, V513, P261; Nelson D. L., 2008, LEHNINGER PRINCIPLES; Neutze R, 2000, NATURE, V406, P753, DOI [10.1038/35021099, DOI 10.1038/35021099]; Siegbahn P.E.M., 2013, BIOCHIM BIOPHYS ACTA, V1827, P1003; Siegbalm P.E.M., 2011, J PHOTOCHEM PHOTOBIO, V104, P94; Yamaguchi K., 1986, APPL QUANTUM CHEM, P155; Yamaguchi K., 1983, J MOL STRUC-THEOCHEM, V103, P101; Yamaguchi K, 2014, MOL PHYS, V112, P485, DOI 10.1080/00268976.2013.842009	45	2	2	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0009-2614	1873-4448		CHEM PHYS LETT	Chem. Phys. Lett.	MAY 1	2015	627						44	52		10.1016/j.cplett.2015.03.033		9	Chemistry, Physical; Physics, Atomic, Molecular & Chemical	Chemistry; Physics	CG7VP	WOS:000353514300009		
J	Hasegawa, T				Hasegawa, Takeshi			Understanding of the intrinsic difference between normal- and perfluoro-alkyl compounds toward total understanding of material properties	CHEMICAL PHYSICS LETTERS			English	Article								Molecular interaction of perfluoroalkyl (Rf) compounds has long been discussed on an extended theory of normal alkyl compounds. When Rf-specific bulk properties depending on the molecular packing structure are taken into account, however, the conventional polarizability theory has a big inconsistency especially with the high melting point. Here, we present a new viewpoint to totally uniform the conventional theories for systematically accounting for the bulk properties of Rf compounds. With the organized theoretical framework, the conventional understanding based on polarizability proves to be partly true, but it misses the molecular orientation effect, which is specifically necessary for the Rf compounds. (C) 2015 Elsevier B.V. All rights reserved.	Kyoto Univ, Inst Chem Res, Div Environm Chem, Lab Solut & Interface Chem, Uji, Kyoto 6110011, Japan	Hasegawa, T (reprint author), Kyoto Univ, Inst Chem Res, Div Environm Chem, Lab Solut & Interface Chem, Uji, Kyoto 6110011, Japan.	htakeshi@scl.kyoto-u.ac.jp			Japan Society for the Promotion of Science [26620118 (TH)]	This work was financially supported by a Grant-in-Aid for challenging Exploratory Research (No. 26620118 (TH)) from Japan Society for the Promotion of Science.	GROH W, 1991, MACROMOLECULES, V24, P6660, DOI 10.1021/ma00025a016; STARKWEATHER HW, 1986, MACROMOLECULES, V19, P1131, DOI 10.1021/ma00158a034; Krafft MP, 2009, CHEM REV, V109, P1714, DOI 10.1021/cr800260k; MILLER KJ, 1990, J AM CHEM SOC, V112, P8533, DOI 10.1021/ja00179a044; Skrabania K, 2010, MACROMOLECULES, V43, P271, DOI 10.1021/ma901913f; Hasegawa T, 2014, CHEMPLUSCHEM, V79, P1421, DOI 10.1002/cplu.201402156; Huheey J.E., 1978, INORGANIC CHEM; Jackson J. D., 1999, CLASSICAL ELECTRODYN; Keesom W. H., 1912, COMMUNICATIONS PH SB, V24B, P23; London F., 1937, T FARADAY SOC, V33, P8, DOI [DOI 10.1039/TF937330008B, 10.1039/tf937330008b]; MINKIN VI, 1970, DIPOLE MOMENTS ORGAN; Thomas R. R., 1999, FLUOROPOLYMERS, V2	12	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0009-2614	1873-4448		CHEM PHYS LETT	Chem. Phys. Lett.	MAY 1	2015	627						64	66		10.1016/j.cplett.2015.03.046		3	Chemistry, Physical; Physics, Atomic, Molecular & Chemical	Chemistry; Physics	CG7VP	WOS:000353514300012		
J	Ara, M; Tomita, K; Tada, H				Ara, Masato; Tomita, Kensuke; Tada, Hirokazu			Growth of crystalline silicon nanotubes under hydrothermal condition	CHEMICAL PHYSICS LETTERS			English	Article							NANOWIRES	Silicon nanotubes (SiNTs) were prepared from silicon monoxide using a hydrothermal method without solid templates. The structure of the products was investigated by transmission electron microscopy, which showed that SiNTs had diamond cubic crystalline structures and capsule-like structures at the tip of them. It was speculated that several hundred nanometer-sized water droplets condensed in the vessel acted as cores for the growth of SiNTs. (C) 2015 Elsevier B.V. All rights reserved.	[Ara, Masato; Tomita, Kensuke; Tada, Hirokazu] Osaka Univ, Grad Sch Engn Sci, Toyonaka, Osaka 5608531, Japan	Ara, M (reprint author), Osaka Univ, Grad Sch Engn Sci, Toyonaka, Osaka 5608531, Japan.	ara@molectronics.jp			MEXT [25110012]; JSPS [26790013]; MEXT Nanotechnology Platform Program (Molecule and Material Synthesis) [2011B7422]	This work was supported by MEXT Grant-in-Aid for Scientific Research on Innovative Areas (No. 25110012) and JSPS Grant-in-Aid for Young Scientists (B) (No. 26790013). Part of this work was performed at the BL07LSU of SPring-8 with the approval of the Japan Synchrotron Radiation Research Institute (JASRI) (Proposal No. 2011B7422) and the Institute for Molecular Science supported by MEXT Nanotechnology Platform Program (Molecule and Material Synthesis).	Hu JQ, 2004, ANGEW CHEM INT EDIT, V43, P63, DOI 10.1002/anie.200352483; Li CP, 2003, ADV MATER, V15, P607, DOI 10.1002/adma.200304409; Yoo JK, 2012, ADV MATER, V24, P5452, DOI 10.1002/adma.201201601; Chen BS, 2010, ADV FUNCT MATER, V20, P3791, DOI 10.1002/adfm.201001190; Boukai AI, 2008, NATURE, V451, P168, DOI 10.1038/nature06458; Song T, 2010, NANO LETT, V10, P1710, DOI 10.1021/nl100086e; Cui Y, 2001, SCIENCE, V291, P851, DOI 10.1126/science.291.5505.851; McAlpine MC, 2003, NANO LETT, V3, P1531, DOI 10.1021/nl0346427; Sha J, 2002, ADV MATER, V14, P1219, DOI 10.1002/1521-4095(20020903)14:17<1219::AID-ADMA1219>3.0.CO;2-T; Chan CK, 2010, ACS NANO, V4, P1443, DOI 10.1021/nn901409q; Baldwin RK, 2002, CHEM COMMUN, P1822, DOI 10.1039/b205301b; Li Z, 2004, NANO LETT, V4, P245, DOI 10.1021/nl034958e; Castrucci P, 2012, NANOSCALE, V4, P5195, DOI 10.1039/c2nr30910f; Chen BS, 2010, ACS NANO, V4, P7105, DOI 10.1021/nn102689z; Jeong SY, 2003, ADV MATER, V15, P1172, DOI 10.1002/adma.200304898; Koo SM, 2005, NANOTECHNOLOGY, V16, P1482, DOI 10.1088/0957-4484/16/9/011; Li YS, 2012, MATER LETT, V72, P122, DOI 10.1016/j.matlet.2011.12.088; Mbenkum BN, 2010, ACS NANO, V4, P1805, DOI 10.1021/nn900969y; Romans ST, 2005, PHYS CHEM CHEM PHYS, V7, P2610; Shpaisman N, 2012, J PHYS CHEM C, V116, P8000, DOI 10.1021/jp2037944; Tang YH, 2005, PHYS REV LETT, V95, DOI 10.1103/PhysRevLett.95.116102; Wu HW, 2007, APPL PHYS LETT, V90, DOI 10.1063/1.2432273; Zhou M, 2009, J APPL PHYS, V106, DOI 10.1063/1.3273362	23	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0009-2614	1873-4448		CHEM PHYS LETT	Chem. Phys. Lett.	MAY 1	2015	627						87	89		10.1016/j.cplett.2015.03.042		3	Chemistry, Physical; Physics, Atomic, Molecular & Chemical	Chemistry; Physics	CG7VP	WOS:000353514300017		
J	Hayashi, G; Sakamoto, R; Okamoto, A				Hayashi, Gosuke; Sakamoto, Ryosuke; Okamoto, Akimitsu			2-Oxazoline Formation for Selective Chemical Labeling of 5-Hydroxylysine	Chemistry-An Asian Journal			English	Article						hydroxylysine; oxazoline formation; peptide labeling; posttranslational modification; proteomics	HISTONE MODIFICATIONS; HYDROXYLATION; JMJD6; GLYCOSYLATION; LIGATION; DOMAIN	Hydroxylation of lysine, one of posttranslational modifications of proteins, generates 5-hydroxylysine (Koh) and plays a crucial role in regulating protein functions in cellular activity. We have developed a chemical labeling method of Koh. The 1,2-aminoalcohol moiety of Koh in synthetic peptide sequences was trapped by an alkyne-containing benzimidate to form a 2-oxazoline ring. An additional ammonia treatment process removed the undesirable amidine residue formed between benzimidate and lysine. During the ammonia treatment, the oxazoline residue formed at Koh mainly remained intact, and the ring opening to the amide form was observed for only part of oxazoline, indicating that the chemical labeling is amino acid selective. Azide-substituted biotin or fluorescent dye was attached to the peptide through Huisgen cycloaddition at Koh and converted into an alkyne-labeled oxazoline form. The Koh-labeling assay could provide a platform to enhance proteomic research of lysine hydroxylation.	[Hayashi, Gosuke; Sakamoto, Ryosuke; Okamoto, Akimitsu] Univ Tokyo, Dept Chem & Biotechnol, Bunkyo Ku, Tokyo 1138656, Japan; [Okamoto, Akimitsu] Univ Tokyo, Res Ctr Adv Sci & Technol, Meguro Ku, Tokyo 1538904, Japan	Okamoto, A (reprint author), Univ Tokyo, Dept Chem & Biotechnol, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1138656, Japan.	okamoto@chembio.t.u-tokyo.ac.jp					Kouzarides T, 2007, CELL, V128, P693, DOI 10.1016/j.cell.2007.02.005; Weake VM, 2008, MOL CELL, V29, P653, DOI 10.1016/j.molcel.2008.02.014; Mantri M, 2010, J MOL BIOL, V401, P211, DOI 10.1016/j.jmb.2010.05.054; Webby CJ, 2009, SCIENCE, V325, P90, DOI 10.1126/science.1175865; Unoki M, 2013, J BIOL CHEM, V288, P6053, DOI 10.1074/jbc.M112.433284; Lin HN, 2012, ACS CHEM BIOL, V7, P947, DOI 10.1021/cb3001793; Greer EL, 2012, NAT REV GENET, V13, P343, DOI 10.1038/nrg3173; Suganuma T, 2011, ANNU REV BIOCHEM, V80, P473, DOI 10.1146/annurev-biochem-061809-175347; Wang Y, 2002, J BIOL CHEM, V277, P19521, DOI 10.1074/jbc.M200601200; Chatterjee C, 2010, J BIOL CHEM, V285, P11045, DOI 10.1074/jbc.R109.080291; Arnesen T, 2009, P NATL ACAD SCI USA, V106, P8157, DOI 10.1073/pnas.0901931106; Dhall A, 2011, ACS CHEM BIOL, V6, P987, DOI 10.1021/cb200142c; Hu LL, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015917; Mantri M, 2011, CHEMBIOCHEM, V12, P531, DOI 10.1002/cbic.201000641; Ritchie MA, 2013, INT J MASS SPECTROM, V345, P132, DOI 10.1016/j.ijms.2012.08.015; Schwekendiek K, 2006, SYNTHESIS-STUTTGART, P2996, DOI 10.1055/s-2006-950198; Spetzler JC, 2002, TETRAHEDRON LETT, V43, P2303, DOI 10.1016/S0040-4039(02)00230-7; Tung CL, 2014, CHEM COMMUN, V50, P5298, DOI 10.1039/c3cc47465h; WILEY RH, 1949, CHEM REV, V44, P447, DOI 10.1021/cr60139a002; Yadav VK, 2005, EUR J ORG CHEM, P452; Yamauchi Mitsuo, 2012, Essays Biochem, V52, P113, DOI 10.1042/bse0520113	21	0	0	WILEY-V C H VERLAG GMBH	WEINHEIM	BOSCHSTRASSE 12, D-69469 WEINHEIM, GERMANY	1861-4728	1861-471X		CHEM-ASIAN J	Chem.-Asian J.	MAY	2015	10	5					1138	1141		10.1002/asia.201500172		4	Chemistry, Multidisciplinary	Chemistry	CG5PB	WOS:000353343800006		
J	Saito, N; Sun, ZD; Sato, Y				Saito, Nozomi; Sun, Zhongdong; Sato, Yoshihiro			Nickel-Promoted Highly Regioselective Carboxylation of Aryl Ynol Ether and Its Application to the Synthesis of Chiral beta-Aryloxypropionic Acid Derivatives	Chemistry-An Asian Journal			English	Article						asymmetric catalysis; carbon dioxide; nickel; rhodium; ynol ether	NICKEL(0)-MEDIATED SEQUENTIAL ADDITION; CATALYZED DIRECT CARBOXYLATION; METAL-FREE SYNTHESIS; ALPHA-AMINO-ACIDS; ONE-POT SYNTHESIS; CARBON-DIOXIDE; ASYMMETRIC-SYNTHESIS; VINYL ETHERS; STEREOSELECTIVE-SYNTHESIS; ENANTIOSELECTIVE HYDROGENATION	Nickel(0)-promoted carboxylation of aryl ynol ether proceeded in a highly regioselective manner to produce -substituted--aryloxyacrylic acid derivatives. The -substituted--aryloxyacrylic acids were transformed into the corresponding -aryloxypropionic acid derivative as an optically active form via rhodium-catalyzed asymmetric hydrogenation.	[Saito, Nozomi; Sun, Zhongdong; Sato, Yoshihiro] Hokkaido Univ, Fac Pharmaceut Sci, Sapporo, Hokkaido 0600812, Japan; [Sato, Yoshihiro] ACT C Japan Sci & Technol Agcy JST, Sapporo, Hokkaido 0600812, Japan	Saito, N (reprint author), Hokkaido Univ, Fac Pharmaceut Sci, Sapporo, Hokkaido 0600812, Japan.	nozomi-s@pharm.hokudai.ac.jp; biyo@pharm.hokudai.ac.jp	Sato, Yoshihiro/E-8900-2012	Sato, Yoshihiro/0000-0003-2540-5525	JSPS [26460002, 26293001]; MEXT, Japan [23105501, 25105701]; Otsuka Toshimi Scholarship Foundation	This work was partly supported by a Grant-in-Aid for Scientific Research (C) (No. 26460002) and a Grant-in-Aid for Scientific Research (B) (No. 26293001) from JSPS and by a Grant-in-Aid for Scientific Research on Innovative Areas "Molecular Activation Directed toward Straightforward Synthesis" (Nos. 23105501 and 25105701) from MEXT, Japan. ZS acknowledges Otsuka Toshimi Scholarship Foundation for financial support.	Mita T, 2013, CHEM-EUR J, V19, P1123, DOI 10.1002/chem.201202332; Hendriksen C, 2014, CHEM-EUR J, V20, P12037, DOI 10.1002/chem.201404082; Mita T, 2014, ORG LETT, V16, P14, DOI 10.1021/ol403099f; Takimoto M, 2001, J AM CHEM SOC, V123, P2895, DOI 10.1021/ja004004f; Shimizu K, 2005, ORG LETT, V7, P195, DOI 10.1021/ol047912g; Lejkowski ML, 2012, CHEM-EUR J, V18, P14017, DOI 10.1002/chem.201201757; Duong HA, 2013, ORG LETT, V15, P4034, DOI 10.1021/ol4019375; Jouvin K, 2012, ORGANOMETALLICS, V31, P7933, DOI 10.1021/om3005614; Leon T, 2013, J AM CHEM SOC, V135, P1221, DOI 10.1021/ja311045f; Mita T, 2013, CHEM COMMUN, V49, P5601, DOI 10.1039/c3cc42675k; Zhang WH, 2014, ANGEW CHEM INT EDIT, V53, P8980, DOI 10.1002/anie.201405036; Tran V, 2011, ORG LETT, V13, P6588, DOI 10.1021/ol202989c; Cokoja M, 2011, ANGEW CHEM INT EDIT, V50, P8510, DOI 10.1002/anie.201102010; Huang K, 2011, CHEM SOC REV, V40, P2435, DOI 10.1039/c0cs00129e; Kawasaki M, 2003, TETRAHEDRON-ASYMMETR, V14, P1529, DOI 10.1016/S0957-4166(03)00277-5; Fujihara T, 2014, ORG LETT, V16, P4960, DOI 10.1021/ol502538r; Takimoto M, 2011, SYNLETT, P1423, DOI 10.1055/s-0030-1260565; Stewart GW, 2012, ORG LETT, V14, P5440, DOI 10.1021/ol302518y; Tsuji Y, 2012, CHEM COMMUN, V48, P9956, DOI 10.1039/c2cc33848c; Kesteleyn B, 2013, BIOORG MED CHEM LETT, V23, P310, DOI 10.1016/j.bmcl.2012.10.095; Zhu SF, 2012, ANGEW CHEM INT EDIT, V51, P8872, DOI 10.1002/anie.201204363; Takimoto M, 2001, ORG LETT, V3, P3345, DOI 10.1021/ol016585z; Feng XJ, 2013, ORG LETT, V15, P108, DOI 10.1021/ol303135e; Nogi K, 2014, CHEM COMMUN, V50, P13052, DOI 10.1039/c4cc03644a; Miles WH, 2001, TETRAHEDRON, V57, P9925, DOI 10.1016/S0040-4020(01)01012-2; Mita T, 2014, ORG LETT, V16, P2200, DOI 10.1021/ol500701n; Mita T, 2012, ORG LETT, V14, P3462, DOI 10.1021/ol301431d; Takimoto M, 2003, ORG LETT, V5, P2599, DOI 10.1021/ol034480l; Murakami M, 2007, CHEM LETT, V36, P476, DOI 10.1246/cl.2007.476; Riduan SN, 2010, DALTON T, V39, P3347, DOI 10.1039/b920163g; Takimoto M, 2013, CHEM-EUR J, V19, P11439, DOI 10.1002/chem.201301456; Mita T, 2012, J ORG CHEM, V77, P2159, DOI 10.1021/jo202597p; Tekavec TN, 2004, TETRAHEDRON, V60, P7431, DOI 10.1016/j.tet.2004.06.025; Martin R, 2011, CHEMSUSCHEM, V4, P1259, DOI 10.1002/cssc.201100102; Zhu Y, 2008, ADV SYNTH CATAL, V350, P979, DOI 10.1002/adsc.200700546; Gray VJ, 2014, J ORG CHEM, V79, P5869, DOI 10.1021/jo500814y; Jouvin K, 2012, ORG LETT, V14, P1652, DOI 10.1021/ol300491d; Hase S, 2013, ORGANOMETALLICS, V32, P5285, DOI 10.1021/om400949m; Gray VJ, 2012, CHEM-EUR J, V18, P15582, DOI 10.1002/chem.201203015; Verrier C, 2012, ORG LETT, V14, P5122, DOI 10.1021/ol302392k; Marhefka CA, 2004, J MED CHEM, V47, P993, DOI 10.1021/jm030336u; Kawasaki M, 2008, J MOL CATAL B-ENZYM, V54, P93, DOI 10.1016/j.molcatb.2007.12.022; Mita T, 2012, ORG LETT, V14, P6202, DOI 10.1021/ol302952r; Cai HT, 2011, CHEM COMMUN, V47, P8682, DOI 10.1039/c1cc13424h; Mejuch T, 2011, ORG LETT, V13, P3604, DOI 10.1021/ol201221d; Bai YH, 2013, CHEM COMMUN, V49, P7650, DOI 10.1039/c3cc43793k; Correa A, 2009, ANGEW CHEM INT EDIT, V48, P6201, DOI 10.1002/anie.200900667; Yamasaki R, 2010, J ORG CHEM, V75, P480, DOI 10.1021/jo902251m; Cui WJ, 2013, J ORG CHEM, V78, P9815, DOI 10.1021/jo401523m; Saito N, 2011, ORG LETT, V13, P2718, DOI 10.1021/ol200812y; Correa A, 2014, J AM CHEM SOC, V136, P1062, DOI 10.1021/ja410883p; Louie J, 2002, J AM CHEM SOC, V124, P15188, DOI 10.1021/ja027438e; Alford JS, 2014, J AM CHEM SOC, V136, P10266, DOI 10.1021/ja5058967; Marzo L, 2013, EUR J ORG CHEM, V2013, P4405, DOI 10.1002/ejoc.201300395; Saito S, 1999, J ORG CHEM, V64, P3975, DOI 10.1021/jo982443f; Yabuuchi T, 2000, J ORG CHEM, V65, P397, DOI 10.1021/jo991218a; Saito N, 2012, ORG LETT, V14, P1914, DOI 10.1021/ol300571b; Cui WJ, 2014, J ORG CHEM, V79, P3487, DOI 10.1021/jo5002356; Mikkelsen M, 2010, ENERG ENVIRON SCI, V3, P43, DOI 10.1039/b912904a; Sasano K, 2013, J AM CHEM SOC, V135, P10954, DOI 10.1021/ja405503y; Takimoto M, 2004, J AM CHEM SOC, V126, P5956, DOI 10.1021/ja049506y; Mita T, 2013, CHEM-ASIAN J, V8, P2970, DOI 10.1002/asia.201300930; Li SH, 2011, ANGEW CHEM INT EDIT, V50, P2578, DOI 10.1002/anie.201007128; Yu B, 2013, GREEN CHEM, V15, P2401, DOI 10.1039/c3gc40896e; Zhu Y, 2012, RSC ADV, V2, P4728, DOI 10.1039/c2ra01350a; Saito N, 2013, ADV SYNTH CATAL, V355, P853, DOI 10.1002/adsc.201201111; Saito N, 2008, ORG LETT, V10, P3829, DOI 10.1021/ol801534e; Liu Y, 2014, J AM CHEM SOC, V136, P11212, DOI [10.1021/ja5064586, 10.1021/ja05064586]; Tran V, 2012, ORG LETT, V14, P6100, DOI 10.1021/ol303026v; Mita T, 2014, ORG LETT, V16, P3028, DOI 10.1021/ol501143c; Aoki M, 2007, ORG LETT, V9, P1251, DOI 10.1021/ol070038h; Aoki M, 2004, CHEM COMMUN, P2568, DOI 10.1039/b411802b; Beliaev A, 2012, ORG PROCESS RES DEV, V16, P704, DOI 10.1021/op300012d; Cokoja M., 2011, ANGEW CHEM, V123, P8662, DOI DOI 10.1002/ANGE.201102010; Correa A., 2009, ANGEW CHEM, V721, P6317; Franchini C, 2003, J MED CHEM, V46, P5238, DOI 10.1021/jm030865y; Hanna R, 2011, TETRAHEDRON, V67, P92, DOI 10.1016/j.tet.2010.11.024; Huguet N, 2014, CHEM-EUR J, V20, P16858, DOI 10.1002/chem.201405528; Kamata M, 2012, J MED CHEM, V55, P2353, DOI 10.1021/jm201596h; Kanno H, 1996, BIOORG MED CHEM LETT, V6, P65, DOI 10.1016/0960-894X(95)00551-4; Langer J, 2012, POLYHEDRON, V32, P60, DOI 10.1016/j.poly.2011.05.047; Levin A, 2010, SYNLETT, P329, DOI 10.1055/s-0029-1219221; Li S., 2011, ANGEW CHEM, V123, P2626, DOI 10.1002/ange.201007128; Liantonio A, 2003, BRIT J PHARMACOL, V139, P1255, DOI 10.1038/sj.bjp.0705364; LOUBINOUX B, 1992, TETRAHEDRON LETT, V33, P2145, DOI 10.1016/0040-4039(92)88162-X; Mita T, 2011, ANGEW CHEM INT EDIT, V50, P1393, DOI 10.1002/anie.201006422; Mita T., 2012, SYNTHESIS-STUTTGART, P194; Mita T., 2014, SYNLETT, P1291; Mita T, 2011, ORG LETT, V13, P2354, DOI 10.1021/ol200599d; Mizuno T, 2011, EUR J ORG CHEM, P2606, DOI 10.1002/ejoc.201100147; Nishi T., 2011, [No title captured], Patent No. [WO2011024933, 2011024933, W02011024933]; Omae I, 2012, COORDIN CHEM REV, V256, P1384, DOI 10.1016/j.ccr.2012.03.017; Saito N, 2011, HETEROCYCLES, V82, P1181, DOI 10.3987/COM-10-S(E)122; Saito N, 2014, SYNLETT, V25, P736, DOI 10.1055/s-0033-1340628; Shimizu K, 2003, ORG LETT, V5, P2323, DOI 10.1021/ol034670w; Sosa JR, 2008, ORG LETT, V10, P5091, DOI 10.1021/ol802147h; Suga T, 2014, CHEM COMMUN, V50, P14360, DOI 10.1039/c4cc06188h; Takimoto M, 2005, SYNLETT, P2019, DOI 10.1055/s-2005-872225; Takimoto M, 2004, SYNTHESIS-STUTTGART, P791, DOI 10.1055/s-2004-815985; Takimoto M., 2005, MODERN ORGANONICKEL, P205; Takimoto M, 2006, TETRAHEDRON, V62, P7589, DOI 10.1016/j.tet.2006.03.121; Takimoto M, 2005, TETRAHEDRON LETT, V46, P5173, DOI 10.1016/j.tetlet.2005.05.129; Tran-Vu H., 2013, ACS CATAL, V3, P2417; Yu B., 2013, UTILIZATION, V1, P60; Zhang W., 2014, ANGEW CHEM, V126, P9126; Zhu S.-F., 2012, ANGEW CHEM, V124, P9002	106	2	2	WILEY-V C H VERLAG GMBH	WEINHEIM	BOSCHSTRASSE 12, D-69469 WEINHEIM, GERMANY	1861-4728	1861-471X		CHEM-ASIAN J	Chem.-Asian J.	MAY	2015	10	5					1170	1176		10.1002/asia.201403399		7	Chemistry, Multidisciplinary	Chemistry	CG5PB	WOS:000353343800012		
J	Aoki, M; Sakamoto, Y; Miwa, T; Yoshida, K; Kishi, K				Aoki, Marie; Sakamoto, Yoshiaki; Miwa, Tomoru; Yoshida, Kazunari; Kishi, Kazuo			The GETA technique: a novel technique protecting the dura against the distractors for early cranial expansion	CHILDS NERVOUS SYSTEM			English	Article						Craniosynostosis; Distraction osteogenesis; Posterior distraction; Fronto-orbital advancement	VAULT EXPANSION; OSTEOGENESIS	Posterior cranial vault distraction profoundly enlarges intracranial volume. To perform this procedure during the first year of life, the cranium is too thin to fix the distractors. Sometimes, the screws penetrate the bone, which risks scratching the dura during distraction. To solve this problem, we developed an implant fixation technique using bioabsorbable screws and plates, and named it the GETA technique. In cases in which the bone is thinner than the screws, a resorbable sheet is placed between the bone and the dura to protect the dura from the tips of the screws. We used this technique for cranial distraction in four patients, with satisfactory results and without complications. The technique described here allows craniofacial surgeons to fix the distractors without injuring the dura.	[Aoki, Marie; Sakamoto, Yoshiaki; Kishi, Kazuo] Keio Univ, Sch Med, Dept Plast & Reconstruct Surg, Shinjuku Ward, Tokyo 1608582, Japan; [Miwa, Tomoru; Yoshida, Kazunari] Keio Univ, Sch Med, Dept Neurosurg, Shinjuku Ward, Tokyo 1608582, Japan	Sakamoto, Y (reprint author), Keio Univ, Sch Med, Dept Plast & Reconstruct Surg, Shinjuku Ward, 35 Shinanomachi, Tokyo 1608582, Japan.	ysakamoto@z8.keio.jp					Steinbacher DM, 2011, PLAST RECONSTR SURG, V127, P792, DOI 10.1097/PRS.0b013e318200ab83; White N, 2009, CHILD NERV SYST, V25, P231, DOI 10.1007/s00381-008-0758-6; Nakajima H, 2012, J PLAST RECONSTR AES, V65, P61, DOI 10.1016/j.bjps.2011.08.009; Arnaud E, 2012, CHILD NERV SYST, V28, P1545, DOI 10.1007/s00381-012-1843-4; Komuro Y, 2011, J CRANIOFAC SURG, V22, P269, DOI 10.1097/SCS.0b013e3181f7dc08	5	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0256-7040	1433-0350		CHILD NERV SYST	Childs Nerv. Syst.	MAY	2015	31	5					773	776		10.1007/s00381-015-2661-2		4	Clinical Neurology; Pediatrics; Surgery	Neurosciences & Neurology; Pediatrics; Surgery	CG3WR	WOS:000353210800019		
J	Fujihara, A; Maeda, N; Hayakawa, S				Fujihara, Akimasa; Maeda, Naoto; Hayakawa, Shigeo			Enantioselective Photolysis and Quantitative Chiral Analysis of Tryptophan Complexed With Alkali-Metalized L-Serine in the Gas Phase	CHIRALITY			English	Article						chiral recognition; amino acid; chiral auxiliary; optical purity; quantitative analysis	ENANTIOMER-SELECTIVE PHOTOLYSIS; SONIC SPRAY IONIZATION; MASS-SPECTROMETRY; AMINO-ACIDS; RECOGNITION; HOMOCHIRALITY; DISSOCIATION; CLUSTERS; SPACE	The enantioselective photolysis of a cold gas-phase noncovalent complex of tryptophan with alkali-metalized L-serine, M+(L-Ser)(Trp) (M = Na and Li), was examined using a tandem mass spectrometer containing a variable-temperature ion trap. CO2 loss from Trp in the clusters was enantiomerically selective in ultraviolet excitation with linearly polarized light. M+(L-Ser) promoted the enantioselective photolysis of Trp as a chiral auxiliary. The enantioselective photolysis of the D-enantiomer was applied to a quantitative chiral analysis, in which the optical purity of tryptophan could be determined by measuring the relative abundance ratio R of the enantioselective CO2 loss to the chiral-independent evaporation of L-Ser in a single photodissociation mass spectrum of M+(L-Ser)(Trp). Chirality 27:349-352, 2015. (c) 2015 Wiley Periodicals, Inc.	[Fujihara, Akimasa; Maeda, Naoto; Hayakawa, Shigeo] Osaka Prefecture Univ, Grad Sch Sci, Dept Chem, Sakai, Osaka 5998531, Japan	Fujihara, A (reprint author), Osaka Prefecture Univ, Grad Sch Sci, Dept Chem, Naka Ku, 1-1 Gakuen Cho, Sakai, Osaka 5998531, Japan.	fujihara@c.s.osakafu-u.ac.jp			JSPS KAKENHI; Iwatani Naoji Foundation; Kurata Memorial Hitachi Science and Technology Foundation [23750021]	Contract grant sponsor: JSPS KAKENHI, Iwatani Naoji Foundation and Kurata Memorial Hitachi Science and Technology Foundation; Contract grant number: 23750021	Bailey J, 1998, SCIENCE, V281, P672, DOI 10.1126/science.281.5377.672; Cronin JR, 1997, SCIENCE, V275, P951, DOI 10.1126/science.275.5302.951; SAWADA M, 1995, J AM CHEM SOC, V117, P7726, DOI 10.1021/ja00134a017; Maruoka K, 2003, CHEM REV, V103, P3013, DOI 10.1021/cr020020e; Meinert C, 2011, PHYS LIFE REV, V8, P307, DOI 10.1016/j.plrev.2011.08.005; Fujihara A, 2015, J MASS SPECTROM, V50, P451, DOI 10.1002/jms.3547; Ruiz-Mirazo K, 2014, CHEM REV, V114, P285, DOI 10.1021/cr2004844; Ehrenfreund P, 2001, ASTROPHYS J, V550, pL95, DOI 10.1086/319491; Scriba GKE, 2012, CHROMATOGRAPHIA, V75, P815, DOI 10.1007/s10337-012-2261-1; List B, 2002, TETRAHEDRON, V58, P5573, DOI 10.1016/S0040-4020(02)00516-1; Nanita SC, 2006, ANGEW CHEM INT EDIT, V45, P554, DOI 10.1002/anie.200501328; Zehnacker A, 2008, ANGEW CHEM INT EDIT, V47, P6970, DOI 10.1002/anie.200800957; Chu IH, 1993, J AM CHEM SOC, V115, P4318; Fujihara A, 2014, EUR PHYS J D, V68, DOI 10.1140/epjd/e2014-50302-5; Fujihara A, 2014, ORIGINS LIFE EVOL B, V44, P67, DOI 10.1007/s11084-014-9370-9; Fujihara A, 2014, CHEM PHYS LETT, V610-611, P228; Fuke K, 2012, REV SCI INSTRUM, V83; Gerbaux P, 2008, CHEM-EUR J, V14, P11039, DOI 10.1002/chem.200801372; HIRABAYASHI A, 1994, ANAL CHEM, V66, P4557, DOI 10.1021/ac00096a025; Nagata H, 2009, B CHEM SOC JPN, V82, P219, DOI 10.1246/bcsj.82.219; Schug KA, 2005, J AM SOC MASS SPECTR, V16, P825, DOI 10.1016/j.jasms.2005.02.008; Takats Z, 2003, ANAL CHEM, V75, P1514, DOI 10.1021/ac0260793; Tao WA, 2000, J AM CHEM SOC, V122, P10598; Wu L, 2013, ANAL CHEM, V85, P4869; Yao ZP, 2000, ANAL CHEM, V72, P5394	25	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0899-0042	1520-636X		CHIRALITY	Chirality	MAY	2015	27	5					349	352		10.1002/chir.22442		4	Chemistry, Medicinal; Chemistry, Analytical; Chemistry, Organic; Pharmacology & Pharmacy	Pharmacology & Pharmacy; Chemistry	CG5NU	WOS:000353339600005		
J	Aizawa, SI; Kidani, T; Takada, S; Ofusa, Y				Aizawa, Sen-Ichi; Kidani, Takahiro; Takada, Sayuri; Ofusa, Yumika			Simple Resolution of Enantiomeric NMR Signals of alpha-Amino Acids by Using Samarium(III) Nitrate With L-Tartarate	CHIRALITY			English	Article						C-13 and H-1 NMR; chiral shift reagent; L-tartaric acid; samarium(III) complex; simultaneous analysis	CHIRAL SHIFT-REAGENT; AQUEOUS-SOLUTION; COMPLEX; PROPYLENEDIAMINETETRAACETATOEUROPIUM(III); H-1; ION	Readily available L-tartaric acid, which is a bidentate ligand with two chiral centers forming a seven-membered chelate ring, was applied to the chiral ligand for the chiral nuclear magnetic resonance (NMR) shift reagent of samarium(III) formed in situ. This simple method does not cause serious signal broadening in the high magnetic field. Enantiomeric C-13 and H-1 NMR signals and enantiotopic H-1 NMR signals of -amino acids were successfully resolved at pH8.0 and the 1:3 molar ratio of Sm(NO3)(3):L-tartaric acid. It is elucidated that the enantiomeric signal resolution is attributed to the anisotropic magnetic environment for the enantiomers induced by the chiral L-tartarato samarium(III) complex rather than differences in stability of the diastereomeric substrate adducts. The present C-13 NMR signal resolution was also effective for the practical simultaneous analysis of plural kinds of DL-amino acids. Chirality 27:353-357, 2015.(c) 2015 Wiley Periodicals, Inc.	[Aizawa, Sen-Ichi; Kidani, Takahiro; Takada, Sayuri; Ofusa, Yumika] Toyama Univ, Grad Sch Sci & Engn, Toyama 9308555, Japan	Aizawa, SI (reprint author), Toyama Univ, Grad Sch Sci & Engn, 3190 Gofuku, Toyama 9308555, Japan.	saizawa@eng.u-toyama.ac.jp					Inamoto A, 2000, ORG LETT, V2, P3543, DOI 10.1021/ol006379b; GOERING HL, 1974, J AM CHEM SOC, V96, P1493, DOI 10.1021/ja00812a036; GOERING HL, 1971, J AM CHEM SOC, V93, P5913, DOI 10.1021/ja00751a065; Dickins RS, 2001, CHEM COMMUN, P2308, DOI 10.1039/b106262j; FRASER RR, 1971, J CHEM SOC CHEM COMM, P1450, DOI 10.1039/c29710001450; Hazama R, 1996, CHEM COMMUN, P15, DOI 10.1039/cc9960000015; KABUTO C, 1993, J CHEM SOC CHEM COMM, P381, DOI 10.1039/c39930000381; KABUTO K, 1987, J CHEM SOC CHEM COMM, P670, DOI 10.1039/c39870000670; KABUTO K, 1984, J CHEM SOC CHEM COMM, P316, DOI 10.1039/c39840000316; KIDO J, 1991, J ORG CHEM, V56, P1412, DOI 10.1021/jo00004a014; Kodama S, 2013, ELECTROPHORESIS, V34, P1327, DOI 10.1002/elps.201200645; Lisowski J, 1999, MAGN RESON CHEM, V37, P287, DOI 10.1002/(SICI)1097-458X(199904)37:4<287::AID-MRC455>3.3.CO;2-R; Omata K, 2004, TETRAHEDRON-ASYMMETR, V15, P2351, DOI 10.1016/j.tetasy.2004.06.021; Takemura M, 2001, B CHEM SOC JPN, V74, P707, DOI 10.1246/bcsj.74.707; Watanabe M, 2001, CHEM LETT, P4, DOI 10.1246/cl.2001.4	15	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0899-0042	1520-636X		CHIRALITY	Chirality	MAY	2015	27	5					353	357		10.1002/chir.22443		5	Chemistry, Medicinal; Chemistry, Analytical; Chemistry, Organic; Pharmacology & Pharmacy	Pharmacology & Pharmacy; Chemistry	CG5NU	WOS:000353339600006		
J	Furuchi, T; Tazawa, A; Numajiri, S; Niitsu, M				Furuchi, Takemitsu; Tazawa, Ayano; Numajiri, Sachihiko; Niitsu, Masaru			Quantitative Analysis of Structural Isomers of Linear Pentaamines by GC-MS	CHROMATOGRAPHIA			English	Article						Gas chromatography-mass spectrometry; Quantitative analysis; Long linear polyamine; Pentaamine	POLYAMINES; HEXAAMINES	Structural isomers of long linear polyamines are often highly difficult to differentially quantify due to their structural similarities. In this study, we focused on pentaamines, aminopropylcanavalmine [H2N(CH2)(3)NH(CH2)(4)NH(CH2)(3)NH(CH2)(4)NH2, (3-4-3-4)] and N (1)-aminopropyl-N (8)-aminobutylspermidine [H2N(CH2)(3)NH(CH2)(3)NH(CH2)(4)NH(CH2)(4)NH2, (3-3-4-4)], which have never been separated. We analyzed a mixture of the heptafluorobutyryl derivatives of these pentaamines by gas chromatography-mass spectrometry (GC-MS) and found that the polyamine content and intensity of the unique fragment ions detected in MS spectra exhibited a strong correlation. The calibration curves of appropriate combinations of the peak intensities versus pentaamine mixing ratios showed high linearity (r > 0.99) in the mixing ratio range of 0-2.33. These data indicated that the pentaamine content in the pentaamine mixed solutions could be determined using appropriate calibration curves. Therefore, this method can potentially be applied to measure the pentaamine content of biological samples.	[Furuchi, Takemitsu; Tazawa, Ayano; Numajiri, Sachihiko; Niitsu, Masaru] Josai Univ, Fac Pharmaceut Sci, Sakado, Saitama 3500295, Japan	Furuchi, T (reprint author), Josai Univ, Fac Pharmaceut Sci, Sakado, Saitama 3500295, Japan.	tfuruchi@josai.ac.jp					NIITSU M, 1986, CHEM PHARM BULL, V34, P1032; NIITSU M, 1993, J CHROMATOGR, V641, P115, DOI 10.1016/0021-9673(93)83465-5; HAMANA K, 1990, FEMS MICROBIOL LETT, V68, P27; HAMANA K, 1991, PHYTOCHEMISTRY, V30, P3319, DOI 10.1016/0031-9422(91)83201-U; HAMANA K, 1991, COMP BIOCHEM PHYS B, V100, P59, DOI 10.1016/0305-0491(91)90084-Q; HAMANA K, 1991, COMP BIOCHEM PHYS B, V100, P399, DOI 10.1016/0305-0491(91)90393-R; Igarashi Kazuei, 2010, Int J Biochem Cell Biol, V42, P39, DOI 10.1016/j.biocel.2009.07.009; Knott JM, 2009, FEBS LETT, V583, P3519, DOI 10.1016/j.febslet.2009.10.014; MATSUZAKI S, 1990, PHYTOCHEMISTRY, V29, P1311, DOI 10.1016/0031-9422(90)85449-P; Morgan DML, 1999, MOL BIOTECHNOL, V11, P229, DOI 10.1007/BF02788682; Niitsu M, 2014, INT J PLANT BIOL RES, V2, P1022; Okada K, 2014, J BACTERIOL, V196, P1866, DOI 10.1128/JB.01515-14; OSHIMA T, 1982, J BIOL CHEM, V257, P9913; OSHIMA T, 1983, J BIOCHEM-TOKYO, V93, P1455; Tzouros M, 2005, TOXICON, V46, P350, DOI 10.1016/j.toxicon.2005.04.018	15	0	0	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	0009-5893	1612-1112		CHROMATOGRAPHIA	Chromatographia	MAY	2015	78	9-10					723	727		10.1007/s10337-015-2868-0		5	Biochemical Research Methods; Chemistry, Analytical	Biochemistry & Molecular Biology; Chemistry	CG4HI	WOS:000353245800013		
J	Tanida, S; Inoue, N; Kobayashi, K; Naganuma, M; Hirai, F; Iizuka, B; Watanabe, K; Mitsuyama, K; Inoue, T; Ishigatsubo, Y; Suzuki, Y; Nagahori, M; Motoya, S; Nakamura, S; Arora, V; Robinson, AM; Thakkar, RB; Hibi, T				Tanida, Satoshi; Inoue, Nagamu; Kobayashi, Kiyonori; Naganuma, Makoto; Hirai, Fumihito; Iizuka, Bunei; Watanabe, Kenji; Mitsuyama, Keiichi; Inoue, Takuya; Ishigatsubo, Yoshiaki; Suzuki, Yasuo; Nagahori, Masakazu; Motoya, Satoshi; Nakamura, Shiro; Arora, Vipin; Robinson, Anne M.; Thakkar, Roopal B.; Hibi, Toshifumi			Adalimumab for the Treatment of Japanese Patients With Intestinal Behcet's Disease	CLINICAL GASTROENTEROLOGY AND HEPATOLOGY			English	Article						Autoimmunity; Anti-TNF Agent; Endoscopy; Japan	FACTOR-ALPHA ANTIBODY; CROHNS-DISEASE; CLINICAL REMISSION; TNF-ALPHA; INFLIXIMAB; MAINTENANCE; THERAPY; INDUCTION; EFFICACY; TRIAL	BACKGROUND & AIMS: Behcet's disease is a chronic, relapsing inflammatory disease that can involve the mouth, skin, eyes, genitals, and intestines. Active intestinal Behcet's disease can be complicated by gastrointestinal (GI) bleeding and perforation. We performed a multicenter, open-label, uncontrolled study to evaluate the efficacy and safety of adalimumab, a fully human monoclonal antibody against tumor necrosis factor a, in patients with intestinal Behcet's disease who were refractory to corticosteroid and/or immunomodulator therapies. METHODS: The study was conducted at 12 sites in Japan, from November 2010 through October 2012. Twenty patients were given 160 mg adalimumab at the start of the study and 80 mg 2 weeks later, followed by 40 mg every other week for 52 weeks; for some patients, the dose was increased to 80 mg every other week. A composite efficacy index, combining GI symptom and endoscopic assessments, was used to evaluate efficacy. The primary efficacy end point was the percentage of patients with scores of 1 or lower for GI symptom and endoscopic assessments at week 24. Secondary end points included complete remission and resolution of non-GI Behcet's-related symptoms. RESULTS: Nine patients (45%) had GI symptom and endoscopic assessment scores of 1 or lower at week 24 of treatment, and 12 patients (60%) had these scores by week 52. Four patients (20%) achieved complete remission at weeks 24 and 52. Individual global GI symptom and endoscopic scores improved for most patients at weeks 24 and 52. Two thirds of patients with oral aphthous ulcers, skin symptoms, and genital ulcers, and 88% of patients with erythema nodosum had complete resolution of these conditions at week 52. A total of 9 of 13 patients (69%) taking steroids at baseline were able to taper (n = 1) or completely discontinue steroids (n = 8) during the study. No new safety signals were observed. CONCLUSIONS: Adalimumab is a potentially effective treatment for intestinal Behcet's disease in Japanese patients who are refractory to conventional treatments.	[Tanida, Satoshi] Nagoya City Univ, Grad Sch Med Sci, Aichi, Japan; [Inoue, Nagamu; Naganuma, Makoto] Keio Univ, Sch Med, Tokyo, Japan; [Kobayashi, Kiyonori] Kitasato Univ, East Hosp, Kanagawa, Japan; [Hirai, Fumihito] Fukuoka Univ, Chikushi Hosp, Fukuoka 81401, Japan; [Iizuka, Bunei] Tokyo Womens Med Univ, Tokyo, Japan; [Watanabe, Kenji] Osaka City Univ Hosp, Osaka, Japan; [Mitsuyama, Keiichi] Kurume Univ, Sch Med, Kurume, Fukuoka 830, Japan; [Inoue, Takuya] Osaka Med Coll, Osaka, Japan; [Ishigatsubo, Yoshiaki] Yokohama City Univ, Grad Sch Med, Yokohama, Kanagawa 232, Japan; [Suzuki, Yasuo] Toho Univ, Med Ctr, Sakura Hosp, Chiba 2748510, Japan; [Nagahori, Masakazu] Tokyo Med & Dent Univ, Tokyo, Japan; [Motoya, Satoshi] Sapporo Kosei Gen Hosp, IBD Ctr, Sapporo, Hokkaido, Japan; [Nakamura, Shiro] Hyogo Coll Med, Hyogo, Japan; [Arora, Vipin; Robinson, Anne M.; Thakkar, Roopal B.] AbbVie, N Chicago, IL USA; [Hibi, Toshifumi] Kitasato Univ, Kitasato Inst Hosp, Tokyo, Japan	Hibi, T (reprint author), Kitasato Univ, Kitasato Inst Hosp, Minami Ku, 1-15-1 Kitasato, Sagamihara, Kanagawa 2520374, Japan.	thibi@insti.kitasato-u.ac.jp			AbbVie Inc; Eisai Co, Ltd.	This study was funded by AbbVie Inc and Eisai Co, Ltd.	Byeon JS, 2007, DIS COLON RECTUM, V50, P672, DOI 10.1007/s10350-006-0813-x; Colombel JF, 2007, GASTROENTEROLOGY, V132, P52, DOI 10.1053/j.gastro.2007.11.041; Irvine EJ, 1999, J PEDIATR GASTR NUTR, V28, pS23, DOI 10.1097/00005176-199904001-00003; Ariyachaipanich A, 2009, INFLAMM BOWEL DIS, V15, P1769, DOI 10.1002/ibd.20869; KASAHARA Y, 1981, DIS COLON RECTUM, V24, P103, DOI 10.1007/BF02604297; Jung YS, 2011, INFLAMM BOWEL DIS, V17, P1594, DOI 10.1002/ibd.21517; Watanabe M, 2012, J CROHNS COLITIS, V6, P160, DOI 10.1016/j.crohns.2011.07.013; Comarmond C, 2013, IMMUNOTHERAPY-UK, V5, P743, DOI 10.2217/imt.13.66; Burmester GR, 2013, ANN RHEUM DIS, V72, P517, DOI 10.1136/annrheumdis-2011-201244; Kram MT, 2003, DIS COLON RECTUM, V46, P118, DOI 10.1097/01.DCR.0000044733.59705.44; Naganuma M, 2008, INFLAMM BOWEL DIS, V14, P1259, DOI 10.1002/ibd.20457; [Anonymous], 2013, HUMIRA; Samsa G, 1999, PHARMACOECONOMICS, V15, P141, DOI 10.2165/00019053-199915020-00003; Evereklioglu C, 2002, MEDIAT INFLAMM, V11, P87, DOI 10.1080/09629350220131935; Lee Jung Hoon, 2007, Korean Journal of Internal Medicine, V22, P24; Marshall SE, 2004, BEST PRACT RES CL RH, V18, P291, DOI 10.1016/j.berh.2004.02.008; [Anonymous], 2013, HUMIRA SUMM PROD CHA; Cheon JH, 2011, INFLAMM BOWEL DIS, V17, P605, DOI 10.1002/ibd.21313; Hassard PV, 2001, GASTROENTEROLOGY, V120, P995, DOI 10.1053/gast.2001.22556; Travis SPL, 2001, GUT, V49, P725, DOI 10.1136/gut.49.5.725; Kinoshita H, 2013, INTERNAL MED, V52, P1855, DOI 10.2169/internalmedicine.52.0589; Ju JH, 2007, CLIN RHEUMATOL, V26, P1383, DOI 10.1007/s10067-006-0410-3; Hanauer SB, 2006, GASTROENTEROLOGY, V130, P323, DOI 10.1053/j.gastro.2005.11.030; Hisamatsu T, 2014, J GASTROENTEROL, V49, P156, DOI 10.1007/s00535-013-0872-4; Iwata S, 2009, RHEUMATOLOGY, V48, P1012, DOI 10.1093/rheumatology/kep126; Kurata M, 2006, HEPATO-GASTROENTEROL, V53, P60; Lee HJ, 2012, WORLD J GASTROENTERO, V18, P5771, DOI 10.3748/wjg.v18.i40.5771; Matsuda T, 2002, NIHONIGAKUKAN; Saadoun D, 2012, ORPHANET J RARE DIS, V7, DOI 10.1186/1750-1172-7-20; Sandborn WJ, 2012, GASTROENTEROLOGY, V142, P257, DOI 10.1053/j.gastro.2011.10.032; Tugal-Tutkun Ilknur, 2009, Middle East Afr J Ophthalmol, V16, P219, DOI 10.4103/0974-9233.58425	31	3	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1542-3565	1542-7714		CLIN GASTROENTEROL H	Clin. Gastroenterol. Hepatol.	MAY	2015	13	5					940	U444		10.1016/j.cgh.2014.08.042		12	Gastroenterology & Hepatology	Gastroenterology & Hepatology	CG1XN	WOS:000353069000024		
J	Kodera, H; Ando, N; Yuasa, I; Wada, Y; Tsurusaki, Y; Nakashima, M; Miyake, N; Saitoh, S; Matsumoto, N; Saitsu, H				Kodera, H.; Ando, N.; Yuasa, I.; Wada, Y.; Tsurusaki, Y.; Nakashima, M.; Miyake, N.; Saitoh, S.; Matsumoto, N.; Saitsu, H.			Mutations in COG2 encoding a subunit of the conserved oligomeric golgi complex cause a congenital disorder of glycosylation	CLINICAL GENETICS			English	Article						COG complex; COG2; congenital disorders of glycosylation; endosomal transportation system	DE-NOVO MUTATIONS; EPILEPTIC ENCEPHALOPATHY; DEFICIENCY REVEALS; MASS-SPECTROMETRY; GENE; PATIENT; CDG; PHENOTYPE	The conserved oligomeric Golgi (COG) complex is involved in intra-Golgi retrograde trafficking, and mutations in six of its eight subunits have been reported in congenital disorders of glycosylation (CDG). Here we report a patient showing severe acquired microcephaly, psychomotor retardation, seizures, liver dysfunction, hypocupremia, and hypoceruloplasminemia. Analysis of his serum glycoproteins revealed defects in both sialylation and galactosylation of glycan termini. Trio-based whole-exome sequencing identified two heterozygous mutations in COG2: a de novo frameshift mutation [c.701dup (p.Tyr234*)] and a missense mutation [c.1900T>G (p.Trp634Gly)]. Sequencing of cloned reverse-transcription polymerase chain reaction (RT-PCR) products revealed that both mutations were located on separate alleles, as expected, and that the mutant transcript harboring the frameshift mutation underwent degradation. The c.1900T>G (p.Trp634Gly) mutation is located in a domain highly conserved among vertebrates and was absent from both the public database and our control exomes. Protein expression of COG2, along with COG3 and COG4, was decreased in fibroblasts from the patient. Our data strongly suggest that these compound heterozygous mutations in COG2 are causative of CDG.	[Kodera, H.; Tsurusaki, Y.; Nakashima, M.; Miyake, N.; Matsumoto, N.; Saitsu, H.] Yokohama City Univ, Grad Sch Med, Dept Human Genet, Kanazawa Ku, Yokohama, Kanagawa 232, Japan; [Ando, N.; Saitoh, S.] Nagoya City Univ, Grad Sch Med Sci, Dept Pediat & Neonatol, Nagoya, Aichi, Japan; [Yuasa, I.] Tottori Univ, Fac Med, Div Legal Med, Yonago, Tottori 683, Japan; [Wada, Y.] Osaka Med Ctr, Dept Mol Med, Osaka, Japan; [Wada, Y.] Res Inst Maternal & Child Hlth, Izumi Ku, Osaka, Japan	Matsumoto, N (reprint author), Yokohama City Univ, Grad Sch Med, Dept Human Genet, Kanazawa Ku, Yokohama, Kanagawa 232, Japan.	naomat@yokohama-cu.ac.jp; hsaitsu@yokohama-cu.ac.jp			Ministry of Health, Labour and Welfare of Japan; Japan Society for the Promotion of Science [23390081, 25293085, 25293235, 13313587]; Takeda Science Foundation; Fund for Creation of Innovation Centers for Advanced Interdisciplinary Research Areas Program in the Project for Developing Innovation Systems; Strategic Research Program for Brain Sciences [11105137]; Ministry of Education, Culture, Sports, Science and Technology of Japan [12024421]	We would like to thank the patient and his family for their participation in this study. We also thank Nobuko Watanabe for her excellent technical assistance. This work was supported by the Ministry of Health, Labour and Welfare of Japan; the Japan Society for the Promotion of Science (a Grant-in-Aid for Scientific Research (B) from (23390081, 25293085, 25293235), a Grant-in-Aid for Scientific Research (A) (13313587)); the Takeda Science Foundation; the Fund for Creation of Innovation Centers for Advanced Interdisciplinary Research Areas Program in the Project for Developing Innovation Systems; the Strategic Research Program for Brain Sciences (11105137); and a Grant-in-Aid for Scientific Research on Innovative Areas (Transcription Cycle) from the Ministry of Education, Culture, Sports, Science and Technology of Japan (12024421)	Foulquier F, 2006, P NATL ACAD SCI USA, V103, P3764, DOI 10.1073/pnas.0507685103; Wu XH, 2004, NAT MED, V10, P518, DOI 10.1038/nm1041; Saitsu H, 2010, EPILEPSIA, V51, P2397, DOI 10.1111/j.1528-1167.2010.02728.x; Shaheen R, 2013, J MED GENET, V50, P431, DOI 10.1136/jmedgenet-2013-101527; Saitsu H, 2013, NAT GENET, V45, P445, DOI 10.1038/ng.2562; Lees JA, 2010, NAT STRUCT MOL BIOL, V17, P1292, DOI 10.1038/nsmb.1917; Zeevaert R, 2009, HUM MOL GENET, V18, P517, DOI 10.1093/hmg/ddn379; Koch M, 2003, J BIOL CHEM, V278, P43236, DOI 10.1074/jbc.M302112200; Reynders E, 2011, GLYCOBIOLOGY, V21, P853, DOI 10.1093/glycob/cwq179; Srour M, 2010, SCIENCE, V328, P592, DOI 10.1126/science.1186463; Lubbehusen J, 2010, HUM MOL GENET, V19, P3623, DOI 10.1093/hmg/ddq278; Freeze HH, 2013, J BIOL CHEM, V288, P6936, DOI 10.1074/jbc.R112.429274; Morava E, 2007, EUR J HUM GENET, V15, P638, DOI 10.1038/sj.ejhg.5201813; Ng BG, 2011, MOL GENET METAB, V102, P364, DOI 10.1016/j.ymgme.2010.11.161; Kranz C, 2007, HUM MOL GENET, V16, P731, DOI 10.1093/hmg/ddm028; Reynders E, 2009, HUM MOL GENET, V18, P3244, DOI 10.1093/hmg/ddp262; Kodera H, 2013, HUM MUTAT, V34, P1708, DOI 10.1002/humu.22446; Foulquier F, 2007, HUM MOL GENET, V16, P717, DOI 10.1093/hmg/ddl476; Wada Y, 2004, ANAL CHEM, V76, P6560, DOI 10.1021/ac049062o; Paesold-Burda P, 2009, HUM MOL GENET, V18, P4350, DOI 10.1093/hmg/ddp389; Fung CW, 2012, JIMD REP, V3, P67, DOI 10.1007/8904_2011_61; Foulquier F, 2009, BBA-MOL BASIS DIS, V1792, P896, DOI 10.1016/j.bbadis.2008.10.020; Goriounov D, 2003, J CELL SCI, V116, P1045, DOI 10.1242/jcs.00272; Huybrechts S, 2012, JIMD REP, V4, P103, DOI 10.1007/8904_2011_79; Jaeken J, 2003, J INHERIT METAB DIS, V26, P99, DOI 10.1023/A:1024431131208; Jones MA, 2013, MOL GENET METAB, V110, P78, DOI 10.1016/j.ymgme.2013.05.012; Wada Y, 2012, GLYCOBIOLOGY, V22, P1140, DOI 10.1093/glycob/cws086; Zeevaert R, 2008, MOL GENET METAB, V93, P15, DOI 10.1016/j.ymgme.2007.08.118	28	2	2	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0009-9163	1399-0004		CLIN GENET	Clin. Genet.	MAY	2015	87	5					455	460		10.1111/cge.12417		6	Genetics & Heredity	Genetics & Heredity	CF8GS	WOS:000352794800009		
J	Tham, E; Nishimura, G; Geiberger, S; Horemuzova, E; Nilsson, D; Lindstrand, A; Hammarsjo, A; Armenio, M; Makitie, O; Zabel, B; Nordgren, A; Nordenskjold, M; Grigelioniene, G				Tham, E.; Nishimura, G.; Geiberger, S.; Horemuzova, E.; Nilsson, D.; Lindstrand, A.; Hammarsjo, A.; Armenio, M.; Makitie, O.; Zabel, B.; Nordgren, A.; Nordenskjold, M.; Grigelioniene, G.			Autosomal recessive mutations in the COL2A1 gene cause severe spondyloepiphyseal dysplasia	CLINICAL GENETICS			English	Letter							PHENOTYPIC SPECTRUM		[Tham, E.; Nilsson, D.; Lindstrand, A.; Hammarsjo, A.; Armenio, M.; Makitie, O.; Nordgren, A.; Nordenskjold, M.; Grigelioniene, G.] Karolinska Inst, Dept Mol Med & Surg, Stockholm, Sweden; [Tham, E.; Nilsson, D.; Lindstrand, A.; Hammarsjo, A.; Armenio, M.; Makitie, O.; Nordgren, A.; Nordenskjold, M.; Grigelioniene, G.] Karolinska Inst, Ctr Mol Med, Stockholm, Sweden; [Tham, E.; Nilsson, D.; Lindstrand, A.; Hammarsjo, A.; Armenio, M.; Makitie, O.; Nordgren, A.; Nordenskjold, M.; Grigelioniene, G.] Karolinska Univ Hosp, Dept Clin Genet, S-17176 Stockholm, Sweden; [Nishimura, G.] Tokyo Metropolitan Childrens Med Ctr, Dept Pediat Imaging, Tokyo, Japan; [Geiberger, S.] Karolinska Univ Hosp, Dept Pediat Radiol, S-17176 Stockholm, Sweden; [Horemuzova, E.] Karolinska Inst, Dept Womens & Childrens Hlth, Stockholm, Sweden; [Horemuzova, E.] Karolinska Univ Hosp, Paediat Endocrinol Unit, S-17176 Stockholm, Sweden; [Nilsson, D.] Karolinska Inst, Sci Life Lab, Solna, Sweden; [Makitie, O.] Folkhalsan Inst Genet, Helsinki, Finland; [Makitie, O.] Univ Helsinki, Helsinki, Finland; [Zabel, B.] Freiburg Univ Hosp, Ctr Paediat & Adolescent Med, Pediat Genet Div, Freiburg, Germany	Grigelioniene, G (reprint author), Karolinska Univ Hosp, Dept Clin Genet, S-17176 Stockholm, Sweden.	Giedre.Grigelioniene@ki.se	Nilsson, Daniel/B-8365-2009; Lindstrand, Anna/J-3566-2012	Nilsson, Daniel/0000-0001-5831-385X; Lindstrand, Anna/0000-0003-0806-5602			Hoornaert KP, 2006, J MED GENET, V43, P406, DOI 10.1136/jmg.2005.035717; Baker S, 2011, AM J MED GENET A, V155A, P1668, DOI 10.1002/ajmg.a.34071; Nishimura G, 2005, HUM MUTAT, V26, P36, DOI 10.1002/humc.20179; Donahue LR, 2003, J BONE MINER RES, V18, P1612, DOI 10.1359/jbmr.2003.18.9.1612; Barat-Houari M, 2014, SKELETAL DYSPLASIA P; Liang GY, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0086894; Melkoniemi M, 2000, AM J HUM GENET, V66, P368, DOI 10.1086/302750	7	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0009-9163	1399-0004		CLIN GENET	Clin. Genet.	MAY	2015	87	5					496	498		10.1111/cge.12466		3	Genetics & Heredity	Genetics & Heredity	CF8GS	WOS:000352794800017		
J	Nakamura, H; Saji, H; Shinmyo, T; Tagaya, R; Kurimoto, N; Koizumi, H; Takagi, M				Nakamura, Haruhiko; Saji, Hisashi; Shinmyo, Takuo; Tagaya, Rie; Kurimoto, Noriaki; Koizumi, Hirotaka; Takagi, Masayuki			Association of IASLC/ATS/ERS Histologic Subtypes of Lung Adenocarcinoma With Epidermal Growth Factor Receptor Mutations in 320 Resected Cases	Clinical Lung Cancer			English	Article						Adenocarcinoma; Disease-free survival; EGFR; Lung cancer; Overall survival	RESPIRATORY SOCIETY CLASSIFICATION; INTERNATIONAL-ASSOCIATION; PROGNOSTIC VALUE; EGFR MUTATIONS; EXON 19; CANCER; GEFITINIB; SURVIVAL; HETEROGENEITY; DIAGNOSIS	In the new international pathologic classification of lung adenocarcinoma proposed in 2011, the epidermal growth factor receptor (EGFR) gene mutation was found in all subtypes. The mutation positivity was greatest in the acinar predominant type and lowest in the solid predominant type. However, the mutation assay is essential in all resected cases to identify patients suitable for EGFR-tyrosine kinase inhibitor therapy. Background: The relationships between the subtypes defined by the new international histologic classification of lung adenocarcinoma (IASLC/ATS/ERS) and epidermal growth factor receptor (EGFR) mutations were studied. Patients and Methods: We retrospectively reviewed 320 patients with lung adenocarcinoma (162 women, 158 men; mean age, 69 years) who had undergone complete resection, focusing on the new histologic subtypes and EGFR mutations. The clinical stage was IA in 196 patients, IB in 95, IIA in 10, IIB in 10, IIIA in 6, and IV in 3. Results: The most prevalent subtype was papillary (35.0%), followed by acinar (29.4%), lepidic (13.1%), solid (7.2%), adenocarcinoma in situ (6.6%), minimally invasive adenocarcinoma (6.3%), micropapillary (1.6%), and invasive mucinous adenocarcinoma (1.0%). These subtypes were predictive for both postoperative disease-free and overall survival. EGFR mutations, detected in 40.6% of all cases, were most frequent in acinar (48.4%), followed by minimally invasive adenocarcinoma (45.0%) and papillary (43.8%). They were least frequent in the solid subtype (17.4%). EGFR mutation status did not affect postoperative disease-free or overall survival. Conclusion: The outcome after complete resection for lung adenocarcinoma was predicted by the proposed subtype classification. Because EGFR mutations were found in all subtypes, mutation analyses are essential to identify patients with postoperative relapse who would benefit from EGFR-tyrosine kinase inhibitor therapy.	[Nakamura, Haruhiko; Saji, Hisashi; Shinmyo, Takuo; Tagaya, Rie; Kurimoto, Noriaki] St Marianna Univ, Sch Med, Dept Chest Surg, Kawasaki, Kanagawa 2168511, Japan; [Koizumi, Hirotaka; Takagi, Masayuki] St Marianna Univ, Sch Med, Dept Pathol, Kawasaki, Kanagawa 2168511, Japan	Nakamura, H (reprint author), St Marianna Univ, Sch Med, Dept Chest Surg, Miyamae Ku, 2-16-1 Sugao, Kawasaki, Kanagawa 2168511, Japan.	h-nakamura@marianna-u.ac.jp					Nagai Y, 2005, CANCER RES, V65, P7276, DOI 10.1158/0008-5472.CAN-05-0331; Goldstraw P, 2007, J THORAC ONCOL, V2, P706, DOI 10.1097/JTO.0b013e31812f3c1a; Jackman DM, 2006, CLIN CANCER RES, V12, P3908, DOI 10.1158/1078-0432.CCR-06-0462; Nakamura H, 2014, SURG TODAY, V44, P1004, DOI 10.1007/s00595-013-0636-z; Russell PA, 2013, J THORAC ONCOL, V8, P461, DOI 10.1097/JTO.0b013e3182828fb8; FREEMAN GH, 1951, BIOMETRIKA, V38, P141, DOI 10.2307/2332323; Tsuta K, 2013, LUNG CANCER, V81, P371, DOI 10.1016/j.lungcan.2013.06.012; Lee HJ, 2013, RADIOLOGY, V268, P254, DOI 10.1148/radiol.13112553; Lee VHF, 2013, J THORAC ONCOL, V8, P1148, DOI 10.1097/JTO.0b013e31829f684a; Tomonaga N, 2013, CLIN LUNG CANCER, V14, P521, DOI 10.1016/j.cllc.2013.04.005; Hung JJ, 2013, ANN SURG, V258, P1079, DOI 10.1097/SLA.0b013e31828920c0; Rosell R, 2009, NEW ENGL J MED, V361, P958, DOI 10.1056/NEJMoa0904554; Mansuet-Lupo A, 2014, CHEST, V146, P633, DOI 10.1378/chest.13-2499; Gu J, 2013, J SURG ONCOL, V107, P474, DOI 10.1002/jso.23259; Warth A, 2012, VIRCHOWS ARCH, V461, P185, DOI 10.1007/s00428-012-1263-6; Gahr S, 2013, BRIT J CANCER, V109, P1821, DOI 10.1038/bjc.2013.511; Travis WD, 2013, ARCH PATHOL LAB MED, V137, P685, DOI 10.5858/arpa.2012-0264-RA; Nakamura H, 2010, ANTICANCER RES, V30, P5233; Russell PA, 2011, J THORAC ONCOL, V6, P1496, DOI 10.1097/JTO.0b013e318221f701; Song Z, 2013, EJSO-EUR J SURG ONC, V39, P1262, DOI 10.1016/j.ejso.2013.08.026; Won YW, 2011, J CLIN PATHOL, V64, P947, DOI 10.1136/jclinpath-2011-200169; Yoshizawa A, 2013, J THORAC ONCOL, V8, P52, DOI 10.1097/JTO.0b013e3182769aa8; Yoshizawa A, 2011, MODERN PATHOL, V24, P653, DOI 10.1038/modpathol.2010.232; Izar B, 2013, ANN THORAC SURG, V96, P962, DOI 10.1016/j.athoracsur.2013.05.091; Hwang DH, 2014, ARCH PATHOL LAB MED, V138, P626, DOI 10.5858/arpa.2013-0179-OA; Paez JG, 2004, SCIENCE, V304, P1497, DOI 10.1126/science.1099314; Warth A, 2012, J CLIN ONCOL, V30, P1438, DOI 10.1200/JCO.2011.37.2185; Lynch TJ, 2004, NEW ENGL J MED, V350, P2129, DOI 10.1056/NEJMoa040938; Zhang Y, 2012, CLIN CANCER RES, V18, P1947, DOI 10.1158/1078-0432.CCR-11-2511; Jeon JH, 2014, EUR J CARDIOTHORAC S; Lin MW, 2014, J SURG ONCOL, V110, P99, DOI 10.1002/jso.23628; Liu WS, 2014, MED ONCOL, V31, DOI 10.1007/s12032-013-0771-9; Miyazawa H, 2008, CANCER SCI, V99, P595, DOI 10.1111/j.1349-7006.2007.00706.x; Sun JM, 2011, J CANCER RES CLIN, V137, P687, DOI 10.1007/s00432-010-0928-2	34	1	2	CIG MEDIA GROUP, LP	DALLAS	3500 MAPLE AVENUE, STE 750, DALLAS, TX 75219-3931 USA	1525-7304	1938-0690		CLIN LUNG CANCER	Clin. Lung Cancer	MAY	2015	16	3					209	215		10.1016/j.cllc.2014.10.004		7	Oncology	Oncology	CG5RC	WOS:000353350500006		
J	Okuma, Y; Hosomi, Y; Takahashi, S; Maeda, Y; Okamura, T; Hishima, T				Okuma, Yusuke; Hosomi, Yukio; Takahashi, Satoshi; Maeda, Yoshiharu; Okamura, Tatsuru; Hishima, Tsunekazu			Response to Cytotoxic Chemotherapy in Patients Previously Treated With Palliative-Intent Chemotherapy for Advanced Thymic Carcinoma	Clinical Lung Cancer			English	Article						Chemotherapy; Rare cancer; Refractory; Response; Survival; Thymic carcinoma	CLINICAL-PRACTICE GUIDELINES; PHASE-II; COMBINATION CHEMOTHERAPY; EPITHELIAL TUMORS; NEUROENDOCRINE TUMORS; METASTATIC THYMOMA; INTERGROUP TRIAL; LUNG-CANCER; MALIGNANCIES; CISPLATIN	We retrospectively investigated the outcome of chemotherapy in 23 patients with refractory thymic carcinoma because there are few published data concerning this. The response rates to second-, third-, and fourth-line chemotherapy were 39.1%, 23.1%, and 25.0%, respectively, and the median survival time was 18.8 months. Single agents can be beneficial as second-or later-lines of chemotherapy for thymic carcinoma. Background: Clinical efficacy of second-and later-line chemotherapy for patients with thymic carcinoma previously treated with chemotherapy remains uncertain; limited data are available about this carcinoma because of its rarity. The aim of this study was to investigate effective chemotherapy for patients with thymic carcinoma previously treated with chemotherapy using a retrospective analysis of responses and times to event. Patients and Methods: We conducted a retrospective review of the medical records of 23 advanced thymic carcinoma patients previously treated with palliative-intent chemotherapy between 1980 and 2014 in our institution. Clinical demographic characteristics, agents, response, and time to treatment failure for each treatment line and overall survival were reviewed. Factors expected to be associated with survival rates were analyzed. Differences in survival were assessed using Kaplan-Meier analysis and univariate and multivariate Cox proportional hazards regression analyses. Results: The study included 13 men (56.5%) and 10 women (43.5%). The median age at diagnosis was 58.5 years. The most common histological sub-types were squamous cell carcinoma (16 patients [69.6%]), followed by neuroendocrine carcinoma (4 patients [17.4%]). The objective response rates of first-, second-, third-, and fourth-line chemotherapy were 60.9%, 39.1%, 23.1%, and 25.0%, respectively. The median survival time was 18.8 months (95% confidence interval, 7.5-40.9 months). Uni- and multivariate analyses of all assessed variables failed to identify any statistically significant indicators of overall survival. Conclusion: Patients with thymic carcinoma previously treated with palliative-intent chemotherapy might respond to second-or later-lines of cytotoxic chemotherapy.	[Okuma, Yusuke; Hosomi, Yukio; Takahashi, Satoshi; Okamura, Tatsuru] Tokyo Metropolitan Canc & Infect Dis Ctr, Dept Thorac Oncol & Resp Med, Komagome Hosp, Tokyo 1138677, Japan; [Okuma, Yusuke] Jikei Univ, Sch Med, Res Ctr Med Sci, Div Oncol, Tokyo, Japan; [Maeda, Yoshiharu] Tokyo Metropolitan Canc & Infect Dis Ctr, Dept Chemotherapy, Bunkyo Ku, Tokyo, Japan; [Hishima, Tsunekazu] Tokyo Metropolitan Canc & Infect Dis Ctr, Komagome Hosp, Dept Pathol, Tokyo 1138677, Japan	Okuma, Y (reprint author), Tokyo Metropolitan Canc & Infect Dis Ctr, Dept Thorac Oncol & Resp Med, Komagome Hosp, Bunkyo Ku, 3-18-22 Honkomagome, Tokyo 1138677, Japan.	y-okuma@cick.jp					Giaccone G, 1996, J CLIN ONCOL, V14, P814; SUSTER S, 1991, CANCER, V67, P1025, DOI 10.1002/1097-0142(19910215)67:4<1025::AID-CNCR2820670427>3.0.CO;2-F; Crona J, 2013, LUNG CANCER, V79, P289, DOI 10.1016/j.lungcan.2012.12.001; Oberg K, 2004, ANN ONCOL, V15, P966, DOI 10.1093/annonc/mdh216; Masters GA, 2003, J CLIN ONCOL, V21, P1550, DOI 10.1200/JCO.2003.09.130; Girard N, 2009, CLIN CANCER RES, V15, P6790, DOI 10.1158/1078-0432.CCR-09-0644; Agatsuma T, 2011, J THORAC ONCOL, V6, P2130, DOI 10.1097/JTO.0b013e31822e71c0; Bisagni G, 2009, J THORAC ONCOL, V4, P773, DOI 10.1097/JTO.0b013e3181a52e25; Koizumi T, 2002, AM J CLIN ONCOL-CANC, V25, P266, DOI 10.1097/00000421-200206000-00012; Schirosi L, 2012, ANN ONCOL, V23, P2409, DOI 10.1093/annonc/mdr626; Giaccone G, 2011, J CLIN ONCOL, V29, P2052, DOI 10.1200/JCO.2010.32.4467; Okuma Y, 2010, LUNG CANCER, V70, P357, DOI 10.1016/j.lungcan.2010.09.004; de Jong WK, 2008, EUR J CANCER, V44, P123, DOI 10.1016/j.ejca.2007.11.004; Lemma GL, 2011, J CLIN ONCOL, V29, P2060, DOI 10.1200/JCO.2010.32.9607; Gaur P, 2010, ANN SURG, V251, P1117, DOI 10.1097/SLA.0b013e3181dd4ec4; Okuma Y, 2013, LUNG CANCER, V80, P75, DOI 10.1016/j.lungcan.2012.12.012; Strobel P, 2010, BRIT J CANCER, V103, P196, DOI 10.1038/sj.bjc.6605740; Strobel P, 2004, NEW ENGL J MED, V350, P2625, DOI 10.1056/NEJM200406173502523; Engels EA, 2003, INT J CANCER, V105, P546, DOI 10.1002/ijc.11099; Hirabayashi H, 1997, INT J CANCER, V73, P639; Girard N, 2010, J THORAC ONCOL, V5, P1439, DOI 10.1097/JTO.0b013e3181e392a8; Kelly RJ, 2011, J CLIN ONCOL, V29, P4820, DOI 10.1200/JCO.2011.36.0487; SUSTER S, 1990, AM J SURG PATHOL, V14, P284, DOI 10.1097/00000478-199003000-00010; Ettinger DS, 2013, J NATL COMPR CANC NE, V11, P562; LOEHRER PJ, 1994, J CLIN ONCOL, V12, P1164; Palmieri G, 2010, ANN ONCOL, V21, P1168, DOI 10.1093/annonc/mdp483; Oberg K, 2012, ANN ONCOL, V23, P120, DOI 10.1093/annonc/mds267; Igawa S, 2010, LUNG CANCER, V67, P194, DOI 10.1016/j.lungcan.2009.03.031; Loehrer PJ, 1997, J CLIN ONCOL, V15, P3093; Li XF, 2009, MED ONCOL, V26, P157, DOI 10.1007/s12032-008-9100-0; Besse B, 2014, ASCO M ABSTR, P32; Girard N, 2011, J THORAC ONCOL, V6, pS1749, DOI 10.1097/JTO.0b013e31821ea5f7; Girard N, 2012, EXPERT REV ANTICANC, V12, P685, DOI [10.1586/era.12.29, 10.1586/ERA.12.29]; Girard N, 2011, THORAC SURG CLIN, V21, P99, DOI 10.1016/j.thorsurg.2010.08.011; Girard N, 2010, J THORAC ONCOL, V5, pS291, DOI 10.1097/JTO.0b013e3181f209b9; Highley MS, 1999, J CLIN ONCOL, V17, P2737; Hirai F, 2013, JPN J CLIN ONCOL, V43, P1018, DOI 10.1093/jjco/hyt106; Hsu CH, 1997, ANTICANCER RES, V17, P1331; Huang J, 2010, J THORAC ONCOL, V5, P2017, DOI 10.1097/JTO.0b013e3181f13682; Komatsu Y, 2006, ANTICANCER RES, V26, P4851; Kuo T, 2000, HISTOPATHOLOGY, V36, P403; Loehrer PJ, 2006, AM SOC CLIN ONCOL, V24, P7079; Masaoka A, 2010, J THORAC ONCOL, V5, pS304, DOI 10.1097/JTO.0b013e3181f20c05; Oguri T, 2004, CHEMOTHERAPY, V50, P279, DOI 10.1159/000082626; Okuma Y, 2011, LUNG CANCER, V74, P492, DOI 10.1016/j.lungcan.2011.05.013; Palmieri Giovannella, 2012, World J Clin Oncol, V3, P111, DOI 10.5306/wjco.v3.i7.111; Rajan A, 2014, LANCET ONCOL, V15, P191, DOI 10.1016/S1470-2045(13)70596-5; Schmitt J, 2010, J THORAC ONCOL, V5, pS357, DOI 10.1097/JTO.0b013e3181f21129; Takeda K, 2013, J CLIN ONCOL, V31l; Thomas A, 2014, ASCO M ABSTR, V32, P7525; Travis WD, 2004, WHO CLASSIFICATION T; Umemura S, 2002, JPN J CLIN ONCOL, V32, P262, DOI 10.1093/jjco/hyf059; Zucali PA, 2014, ASCO M ABSTR, V32, P7527	53	0	0	CIG MEDIA GROUP, LP	DALLAS	3500 MAPLE AVENUE, STE 750, DALLAS, TX 75219-3931 USA	1525-7304	1938-0690		CLIN LUNG CANCER	Clin. Lung Cancer	MAY	2015	16	3					221	227		10.1016/j.cllc.2014.10.006		7	Oncology	Oncology	CG5RC	WOS:000353350500008		
J	Gaertner, FC; Okamoto, S; Shiga, T; Ito, YM; Uchiyama, Y; Manabe, O; Hattori, N; Tamaki, N				Gaertner, Florian C.; Okamoto, Shozo; Shiga, Tohru; Ito, Yoichi M.; Uchiyama, Yuko; Manabe, Osamu; Hattori, Naoya; Tamaki, Nagara			FDG PET Performed at Thyroid Remnant Ablation Has a Higher Predictive Value for Long-Term Survival of High-Risk Patients With Well-Differentiated Thyroid Cancer Than Radioiodine Uptake	CLINICAL NUCLEAR MEDICINE			English	Article						differentiated thyroid cancer; radioiodine therapy; thyroid remnant ablation; FDG PET; radioiodine uptake; overall survival	EMISSION-TOMOGRAPHY; F-18 FDG; I-131; CARCINOMA; THERAPY; PROGNOSIS; RECURRENT	Purpose: The predictive value of FDG PET at thyroid remnant ablation was evaluated in comparison to radioiodine uptake in high-risk patients with differentiated thyroid cancer. Patients and Methods: One hundred forty-one patients who underwent radioiodine therapy (RIT) after total thyroidectomy and received at least 1 further RIT due to suspected metastases were retrospectively analyzed. Patients had not received RIT previously. FDG PET was performed before thyroid remnant ablation. Thyroid-stimulating hormone-stimulated serum thyroglobulin (Tg) was measured for biochemical response assessment (change of Tg between the first and second RIT, Delta Tg). Results: Biochemical response could be evaluated in 80 patients; survival data could be obtained for 88 patients (maximum, 124 months). Biochemical response was significantly better in patients with radioiodine-positive metastases compared with patients with radioiodine-negative metastases (median Delta Tg I+, 55.8% vs I-, 112.6%; P < 0.01). Regarding survival, deaths occurred later in patients with radioiodine-positive metastases compared with radioiodine-negative patients; however, there was no significant difference regarding overall survival (I+, 61.3% vs I-, 58.2%; P > 0.05). Patients with FDG-positive metastases at thyroid remnant ablation showed a poorer biochemical response compared with patients with FDG-negative metastases (median Delta Tg FDG+, 77.5% vs FDG-, 53.2%; P < 0.05), and these groups also differed significantly regarding survival (overall survival FDG+, 48.5% vs FDG-, 100%, P < 0.05). Conclusions: At thyroid remnant ablation, FDG PET is more predictive for long-term survival, whereas radioiodine uptake is more important for short-term response. FDG PET performed at thyroid remnant ablation might represent a useful tool for management of high-risk patients with differentiated thyroid cancer.	[Gaertner, Florian C.; Okamoto, Shozo; Shiga, Tohru; Uchiyama, Yuko; Manabe, Osamu; Hattori, Naoya; Tamaki, Nagara] Hokkaido Univ, Grad Sch Med, Dept Nucl Med, Sapporo, Hokkaido 0608638, Japan; [Gaertner, Florian C.] Tech Univ Munich, Klinikum Rechts Isar, Dept Nucl Med, D-80290 Munich, Germany; [Gaertner, Florian C.] Univ Hosp Bonn, Dept Nucl Med, Bonn, Germany; [Ito, Yoichi M.] Hokkaido Univ, Grad Sch Med, Dept Biostat, Sapporo, Hokkaido 0608638, Japan	Shiga, T (reprint author), Hokkaido Univ, Grad Sch Med, Dept Nucl Med, Kita Ku, N-15,W-7, Sapporo, Hokkaido 0608638, Japan.	tshiga@med.hokudai.ac.jp			Japanese-German Radiological Affiliation; Deutsche Rontgengesellschaft	Supported by a grant to F.C.G. by the Japanese-German Radiological Affiliation and by the Deutsche Rontgengesellschaft.	Al-Zahrani AS, 2008, EUR J ENDOCRINOL, V158, P683, DOI 10.1530/EJE-07-0903; Moon SH, 2013, ENDOCR RES, V38, P77, DOI 10.3109/07435800.2012.713426; Reske SN, 2001, EUR J NUCL MED, V28, P1707, DOI 10.1007/s002590100626; Lee JW, 2013, J NUCL MED, V54, P1230, DOI 10.2967/jnumed.112.117119; Deandreis D, 2011, ENDOCR-RELAT CANCER, V18, P159, DOI 10.1677/ERC-10-0233; Wang WP, 2000, J CLIN ENDOCR METAB, V85, P1107, DOI 10.1210/jc.85.3.1107; Schonberger J, 2002, THYROID, V12, P747, DOI 10.1089/105072502760339307; Luster M, 2008, EUR J NUCL MED MOL I, V35, P1941, DOI 10.1007/s00259-008-0883-1; Davies L, 2006, JAMA-J AM MED ASSOC, V295, P2164, DOI 10.1001/jama.295.18.2164; Stokkel MPM, 2006, Q J NUCL MED MOL IM, V50, P78; McDougall IR, 2011, SEMIN NUCL MED, V41, P105, DOI 10.1053/j.semnuclmed.2010.10.004; Iwano S, 2012, ANN NUCL MED, V26, P207, DOI 10.1007/s12149-011-0559-y; FEINE U, 1995, NUKLEARMED, V34, P127; Lawless J. F., 2003, STAT MODELS METHODS; Nanni C, 2006, BIOMED PHARMACOTHER, V60, P409, DOI 10.1016/j.biopha.2006.07.008; Pellegriti G, 2013, J CANC EPIDEMIOL, V2013, DOI [DOI 10.1155/2013/965212, 10.1155/2013/965212]; Piccardo A, 2014, EUR J NUCL MED MOL I, V41, P1482, DOI 10.1007/s00259-014-2774-y; Robbins RJ, 2006, J CLIN ENDOCR METAB, V91, P498, DOI 10.1210/jc.2005-1534; Rosenbaum-Krumme SJ, 2012, EUR J NUCL MED MOL I, V39, P1373, DOI 10.1007/s00259-012-2065-4; Shiga T, 2001, J NUCL MED, V42, P414; Yoshio K, 2011, CLIN NUCL MED, V36, P113, DOI 10.1097/RLU.0b013e318203bb6c	21	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0363-9762	1536-0229		CLIN NUCL MED	Clin. Nucl. Med.	MAY	2015	40	5					378	383				6	Radiology, Nuclear Medicine & Medical Imaging	Radiology, Nuclear Medicine & Medical Imaging	CG1RL	WOS:000353051100011		
J	Koyama, M; Koizumi, M; Umayahara, K; Takeshima, N; Takahashi, S				Koyama, Masamichi; Koizumi, Mitsuru; Umayahara, Kenji; Takeshima, Nobuhiro; Takahashi, Shunji			Radiation-Induced Osteosarcoma Might Mimic Metastatic Bone Lesions A Case With Bone Scan and FDG PET/CT Imaging	CLINICAL NUCLEAR MEDICINE			English	Editorial Material						radiation-induced osteosarcoma; FDG PET/CT; bone scan	SARCOMA		[Koyama, Masamichi; Koizumi, Mitsuru] Canc Inst Hosp JFCR, Dept Nucl Med, Tokyo 1358550, Japan; [Umayahara, Kenji; Takeshima, Nobuhiro] Canc Inst Hosp JFCR, Dept Gynecol Oncol, Tokyo 1358550, Japan; [Takahashi, Shunji] Canc Inst Hosp JFCR, Dept Comprehens Med Oncol, Tokyo 1358550, Japan	Koyama, M (reprint author), Canc Inst Hosp JFCR, Dept Nucl Med, Koto Ku, 3-8-31 Ariake, Tokyo 1358550, Japan.	masamichi.koyama@jfcr.or.jp					CAHAN WG, 1948, CANCER, V1, P3, DOI 10.1002/1097-0142(194805)1:1<3::AID-CNCR2820010103>3.0.CO;2-7; Lagrange JL, 2000, RADIOLOGY, V216, P197; ARLEN M, 1971, CANCER, V28, P1087, DOI 10.1002/1097-0142(1971)28:5<1087::AID-CNCR2820280502>3.0.CO;2-F; HUVOS AG, 1985, CANCER, V55, P1244, DOI 10.1002/1097-0142(19850315)55:6<1244::AID-CNCR2820550617>3.0.CO;2-1; Berrington de Gonzalez A, 2012, CLIN SARCOMA RES, V2, P18; McHugh JB, 2006, CANCER, V107, P554, DOI 10.1002/cncr.22019; Patel AJ, 2011, CANCER-AM CANCER SOC, V117, P2120, DOI 10.1002/cncr.25734; SALVATI M, 1993, CANCER, V71, P2210, DOI 10.1002/1097-0142(19930401)71:7<2210::AID-CNCR2820710708>3.0.CO;2-W; Tonakie A, 2006, CLIN NUCL MED, V31, P5, DOI 10.1097/01.rlu.0000190891.59706.4d	9	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0363-9762	1536-0229		CLIN NUCL MED	Clin. Nucl. Med.	MAY	2015	40	5					427	429				3	Radiology, Nuclear Medicine & Medical Imaging	Radiology, Nuclear Medicine & Medical Imaging	CG1RL	WOS:000353051100024		
J	Norikane, T; Yamamoto, Y; Maeda, Y; Noma, T; Nishiyama, Y				Norikane, Takashi; Yamamoto, Yuka; Maeda, Yukito; Noma, Takahisa; Nishiyama, Yoshihiro			F-18-FLT PET Imaging in a Patient With Sarcoidosis With Cardiac Involvement	CLINICAL NUCLEAR MEDICINE			English	Editorial Material						cardiac sarcoidosis; FLT; PET	PROLIFERATION		[Norikane, Takashi; Yamamoto, Yuka; Maeda, Yukito; Nishiyama, Yoshihiro] Kagawa Univ, Dept Radiol, Fac Med, Miki, Kagawa 7610793, Japan; [Noma, Takahisa] Kagawa Univ, Dept Cardiorenal & Cerebrovasc Med, Fac Med, Miki, Kagawa 7610793, Japan	Yamamoto, Y (reprint author), Kagawa Univ, Dept Radiol, Fac Med, 1750-1 Ikenobe, Miki, Kagawa 7610793, Japan.	yuka@kms.ac.jp					Manabe O, 2013, EUR J NUCL MED MOL I, V40, P1558, DOI 10.1007/s00259-013-2460-5; Schatka I, 2014, J NUCL MED, V55, P99, DOI 10.2967/jnumed.112.115121; Sobic-Saranovic D, 2013, SEMIN NUCL MED, V43, P404, DOI 10.1053/j.semnuclmed.2013.06.007; Shields AF, 1998, NAT MED, V4, P1334, DOI 10.1038/3337; Newman LS, 1997, NEW ENGL J MED, V336, P1224, DOI 10.1056/NEJM199704243361706; Kim SK, 2010, CLIN NUCL MED, V35, P67; Morooka M, 2014, EJNMMI RES, V4, DOI 10.1186/2191-219X-4-1; Ohira Hiroshi, 2011, Eur J Nucl Med Mol Imaging, V38, P1773, DOI 10.1007/s00259-011-1832-y; VANDERGAAG RD, 1983, J PATHOL, V139, P239, DOI 10.1002/path.1711390302; Zhao S, 2008, J NUCL MED, V49, P135, DOI 10.2967/jnumed.107.044578	10	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0363-9762	1536-0229		CLIN NUCL MED	Clin. Nucl. Med.	MAY	2015	40	5					433	434				2	Radiology, Nuclear Medicine & Medical Imaging	Radiology, Nuclear Medicine & Medical Imaging	CG1RL	WOS:000353051100026		
J	Katada, H; Yukawa, N; Urushihara, H; Tanaka, S; Mimori, T; Kawakami, K				Katada, Hirotaka; Yukawa, Naoichiro; Urushihara, Hisashi; Tanaka, Shiro; Mimori, Tsuneyo; Kawakami, Koji			Prescription patterns and trends in anti-rheumatic drug use based on a large-scale claims database in Japan	CLINICAL RHEUMATOLOGY			English	Article						Anti-rheumatic drugs; Claims database; Drug utilization study; Prescription patterns; Rheumatoid arthritis	EARLY RHEUMATOID-ARTHRITIS; PROSPECTIVE FOLLOW-UP; POSTMARKETING SURVEILLANCE; METHOTREXATE TREATMENT; RADIOGRAPHIC DAMAGE; DISEASE-ACTIVITY; CONTROLLED-TRIAL; THERAPY; MANAGEMENT; SAFETY	This drug utilization study aimed to investigate prescription patterns and trends for anti-rheumatic drug use in Japanese patients with rheumatoid arthritis (RA), clarifying if patients with RA in Japan are being treated according to EULAR recommendations and ACR guidelines. We used a large-scale claims database consisting of the medical claims of employee health insurance recipients, which included approximately one million insured people. The claims data for incident 5,126 patients with diagnosis codes of RA between January 1, 2005 and October 31, 2011 were analyzed. The number of patients who received disease modifying antirheumatic drugs (DMARDs) including biologics as initial therapy was 629 (12.3 %), while the others received non-DMARD therapy only. During the study period, use of methotrexate (MTX) and biologics as first-line drugs increased from 1.9 to 8.0 % and from 0 to 1.6 %, respectively (p < 0.001 for both), while that of non-steroidal anti-inflammatory drugs (NSAIDs) decreased (p = 0.004). Time from first RA diagnosis to the start of treatment with DMARDs decreased significantly from 2005 to 2010. These findings suggest that many early RA patients in Japan do not yet receive aggressive treatment, albeit that this prescribing practice has gradually changed to better comply with clinical recommendations. The current, obsolete Japanese RA guidelines require urgent updating to reflect the most recent knowledge and care with effective treatment modalities.	[Katada, Hirotaka; Urushihara, Hisashi; Tanaka, Shiro; Kawakami, Koji] Kyoto Univ, Grad Sch Med & Publ Hlth, Dept Pharmacoepidemiol, Sakyo Ku, Kyoto 6068051, Japan; [Yukawa, Naoichiro; Mimori, Tsuneyo] Kyoto Univ, Grad Sch Med, Dept Rheumatol & Clin Immunol, Sakyo Ku, Kyoto 6068051, Japan	Kawakami, K (reprint author), Kyoto Univ, Grad Sch Med & Publ Hlth, Dept Pharmacoepidemiol, Sakyo Ku, Yoshidakonoe Cho, Kyoto 6068051, Japan.	hirotaka.katada@takeda.com; naoichiy@kuhp.kyoto-u.ac.jp; urushihara.hisashi.2s@kyoto-u.ac.jp; tanaka.shiro.8n@kyoto-u.ac.jp; mimorit@kuhp.kyoto-u.ac.jp; kawakami.koji.4e@kyoto-u.ac.jp			Canon Inc.; Olympus Co.; Kyowa Hakko Kirin Co., Ltd; Kaken Pharmaceutical Co., Ltd; Novartis K.K.; Otsuka Pharmaceuticals Co., Ltd.; Eisai Co., Ltd.; Bristol-Myers Squibb K.K.; Chugai Pharmaceutical Co., Ltd.; Asahi Kasei Pharma Co.; Astellas Pharma Inc.; Eli Lilly Japan	KK received paid consultancy from Canon Inc., Olympus Co., Kyowa Hakko Kirin Co., Ltd, Kaken Pharmaceutical Co., Ltd, Novartis K.K., Otsuka Pharmaceuticals Co., Ltd. TM received grants from Eisai Co., Ltd., Bristol-Myers Squibb K.K., Chugai Pharmaceutical Co., Ltd., Asahi Kasei Pharma Co., Astellas Pharma Inc. HUreceived paid consultancy from Eli Lilly Japan. The other authors declare no conflict of interest.	Smolen JS, 2010, ANN RHEUM DIS, V69, P964, DOI 10.1136/ard.2009.126532; Takeuchi T, 2008, ANN RHEUM DIS, V67, P189, DOI 10.1136/ard.2007.072967; Nell VPK, 2004, RHEUMATOLOGY, V43, P906, DOI 10.1093/rheumatology/keh199; Imokawa S, 2000, EUR RESPIR J, V15, P373, DOI 10.1034/j.1399-3003.2000.15b25.x; Yamanaka H, 2013, MOD RHEUMATOL, V23, P1, DOI 10.1007/s10165-012-0702-1; Singh JA, 2012, ARTHRIT CARE RES, V64, P625, DOI 10.1002/acr.21641; GutierrezUrena S, 1996, ARTHRITIS RHEUM, V39, P272, DOI 10.1002/art.1780390214; TARONE RE, 1977, BIOMETRIKA, V64, P156, DOI 10.1093/biomet/64.1.156; Capell HA, 2004, ANN RHEUM DIS, V63, P797, DOI 10.1136/ard.2003.014050; FUCHS HA, 1989, J RHEUMATOL, V16, P585; van Dongen H, 2007, ARTHRITIS RHEUM, V56, P1424, DOI 10.1002/art.22525; Smolen JS, 2014, ANN RHEUM DIS, V73, P492, DOI 10.1136/annrheumdis-2013-204573; Schneeweiss S, 2010, PHARMACOEPIDEM DR S, V19, P858, DOI 10.1002/pds.1926; Koike T, 2009, J RHEUMATOL, V36, P898, DOI 10.3899/jrheum.080791; VANDERHEIJDE DMFM, 1992, ARTHRITIS RHEUM, V35, P26; BUCHBINDER R, 1993, J RHEUMATOL, V20, P639; Chugai Pharmaceutical Company, PACK INS ACT; de Thurah A, 2010, SCAND J RHEUMATOL, V39, P19, DOI 10.3109/03009740903185987; Fex E, 1996, BRIT J RHEUMATOL, V35, P1106; Hashimoto S, 2012, EUR REV MED PHARMACO, V16, P235; Iikuni N, 2008, RHEUMATOLOGY, V47, P519, DOI 10.1093/rheumatology/ken047; Japan College of Rheumatology, 2008, GUID AD; Japan College of Rheumatology, 2010, GUID AB; Japan College of Rheumatology, 2012, GUID TOC; Kita F, 2010, J CLIN PHARM THER, V35, P87, DOI 10.1111/j.1365-2710.2009.01074.x; Landau S, 2004, HDB STAT ANAL USING; Mitsubishi Tanabe Pharmaceutical Company, PACK INS REM; Morrison E, 2006, RHEUMATOLOGY, V45, P1058, DOI 10.1093/rheumatology/kel230; Nakajima A, 2011, MOD RHEUMATOL, V21, P594, DOI 10.1007/s10165-011-0457-0; Ochi T, 2013, GUIDELINES MANAGEMEN; Pfizer Inc, PACK INS METH; Pincus T., 2003, CLIN EXP RHEUMAT S31, V21, P179; Sakai R, 2012, ANN RHEUM DIS, V71, P1820, DOI 10.1136/annrheumdis-2011-200838; SMYTH CJ, 1968, MED CLIN N AM, V52, P687; Statistics Bureau Director-General for Policy Planning (Statistical Standards) and Statistical Research and Training Institute, DIV 87 DRUGS REL COM; Takeda Pharmaceutical Company, PACK INS ENBR; Tanaka E, 2012, RHEUMATOL INT, V32, P749, DOI 10.1007/s00296-010-1638-4; Urushihara H, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028483; Yamanaka H, 2006, MOD RHEUMATOL, V16, P75; Yamanaka Hisashi, 2007, Mod Rheumatol, V17, P98, DOI 10.1007/s10165-006-0546-7; Yasui T, 2010, MOD RHEUMATOL, V20, P233, DOI 10.1007/s10165-009-0262-1; Yazici Yusuf, 2008, Bull NYU Hosp Jt Dis, V66, P77	42	0	0	SPRINGER LONDON LTD	LONDON	236 GRAYS INN RD, 6TH FLOOR, LONDON WC1X 8HL, ENGLAND	0770-3198	1434-9949		CLIN RHEUMATOL	Clin. Rheumatol.	MAY	2015	34	5					949	956		10.1007/s10067-013-2482-1		8	Rheumatology	Rheumatology	CG5SC	WOS:000353353400019		
J	Zhao, YY; Yuan, Y; Chen, Y; Jiang, L; Liao, RJ; Wang, L; Zhang, XN; Ohtsu, H; Hu, WW; Chen, Z				Zhao, Yan-Yan; Yuan, Yang; Chen, Ying; Jiang, Lei; Liao, Ru-Jia; Wang, Lu; Zhang, Xiang-Nan; Ohtsu, Hiroshi; Hu, Wei-Wei; Chen, Zhong			Histamine Promotes Locomotion Recovery After Spinal Cord Hemisection via Inhibiting Astrocytic Scar Formation	CNS Neuroscience & Therapeutics			English	Article						Astrocyte; Histamine; Scar; Spinal cord injury	REACTIVE ASTROCYTES; FUNCTIONAL RECOVERY; GLIAL SCAR; AXONAL REGENERATION; INJURY; RECEPTORS; NEURONS; RATS; MICE; DEGENERATION	AimThis study investigated whether histamine could play a protective role in pathophysiological response of spinal cord injury (SCI) and regulate the glial scar formation. MethodsFunctional assessment and histological analyses were performed to investigate the effect of histamine after SCI. Histidine decarboxylase knockout (HDC-/-) mice were used to confirm the action of histamine. Selective antagonists for H1 and H2 receptors were utilized in vivo and in vitro to verify the functional properties of histamine on astrogliosis. ResultsThe local administration of histamine significantly attenuated the tissue damage and glial scar formation after SCI. In particular, the astrogliosis and neurocan expression found around the lesion were significantly suppressed by histamine. Immunofluorescent staining for neurofilament showed that histamine promoted axonal growth across the glial scar. The HDC-/- mice, lacking in endogenous histamine, showed lower behavior score, increased lesion size and astrogliosis, as compared with the wild types. The effect of histamine on locomotor recovery and reactive astrogliosis is reversed by H1 receptor antagonist but not H2 receptor antagonist. ConclusionsOur results indicate that histamine significantly improved the chronic locomotor recovery via attenuating astrogliosis after SCI by stimulating histamine H1 receptor. This study highlights a therapeutic potential of histamine and its related drugs for SCI.	[Zhao, Yan-Yan; Yuan, Yang; Chen, Ying; Jiang, Lei; Liao, Ru-Jia; Wang, Lu; Zhang, Xiang-Nan; Hu, Wei-Wei; Chen, Zhong] Zhejiang Univ, Zhejiang Prov Key Lab Neurobiol, Coll Pharmaceut Sci, Dept Pharmacol,Key Lab Med Neurobiol,Minist Hlth, Hangzhou 310058, Zhejiang, Peoples R China; [Ohtsu, Hiroshi] Tohoku Univ, Sch Med, Dept Engn, Aoba Ku, Sendai, Miyagi 980, Japan	Chen, Z (reprint author), Zhejiang Univ, Dept Pharmacol, Coll Pharmaceut Sci, Hangzhou 310058, Zhejiang, Peoples R China.	huww@zju.edu.cn; chenzhong@zju.edu.cn			National Natural Science Foundation of China [81030061, 81273490, 81273506, 81473186]; National Basic Research of China 973 Program [2011CB504403]; Program for Zhejiang Leading Team of ST Innovation [2011R50014]	This work was supported by the National Natural Science Foundation of China (81030061, 81273490, 81273506, 81473186), the National Basic Research of China 973 Program (2011CB504403), and the Program for Zhejiang Leading Team of S&T Innovation (2011R50014).	Cho SK, 2012, J BONE JOINT SURG AM, V94A, P1952, DOI 10.2106/JBJS.K.00632; Dai H, 2006, J NEUROCHEM, V96, P1390, DOI 10.1111/j.4171-4159.2005.03633.x; Ribotta MG, 2004, ACT NEUR S, V89, P87; Silver J, 2004, NAT REV NEUROSCI, V5, P146, DOI 10.1038/nrn1326; Okada S, 2006, NAT MED, V12, P829, DOI 10.1038/nm1425; Apostolova I, 2006, J NEUROSCI, V26, P7849, DOI 10.1523/JNEUROSCI.1526-06.2006; Wu Q, 2014, MOL NEUROBIOL, V49, P1327, DOI 10.1007/s12035-013-8607-3; HOSLI L, 1984, NEUROSCI LETT, V48, P287, DOI 10.1016/0304-3940(84)90052-1; Tian DS, 2006, J NEUROSCI RES, V84, P1053, DOI 10.1002/jnr.20999; Adachi N, 2002, BRAIN RES, V926, P172, DOI 10.1016/S0006-8993(01)03107-9; BASSO DM, 1995, J NEUROTRAUM, V12, P1, DOI 10.1089/neu.1995.12.1; Jefferson SC, 2011, J NEUROSCI, V31, P5710, DOI 10.1523/JNEUROSCI.4459-10.2011; Yiu G, 2006, NAT REV NEUROSCI, V7, P617, DOI 10.1038/nrn1956; Fang Q, 2014, NEUROPHARMACOLOGY, V77, P156, DOI 10.1016/j.neuropharm.2013.06.012; Faulkner JR, 2004, J NEUROSCI, V24, P2143, DOI 10.1523/JNEUROSCI.3547-03.2004; Liu FT, 2014, CNS NEUROSCI THER, V20, P778, DOI 10.1111/cns.12258; Schwab ME, 1996, PHYSIOL REV, V76, P319; Bundesen LQ, 2003, J NEUROSCI, V23, P7789; Hu R, 2010, J NEUROSURG-SPINE, V13, P169, DOI 10.3171/2010.3.SPINE09190; Sofroniew MV, 2005, NEUROSCIENTIST, V11, P400, DOI 10.1177/1073858405278321; Huang X, 2009, J NEUROL SCI, V277, P87, DOI 10.1016/j.jns.2008.10.022; Wang XF, 2013, NEUROSCI LETT, V549, P69, DOI 10.1016/j.neulet.2013.06.013; Hamami G, 2004, EUR J PHARMACOL, V484, P167, DOI 10.1016/j.ejphar.2003.11.006; Basso DM, 2006, J NEUROTRAUM, V23, P635, DOI 10.1089/neu.2006.23.635; Pekny M, 2005, GLIA, V50, P427, DOI 10.1002/glia.20207; Hu WW, 2012, ACS CHEM NEUROSCI, V3, P238, DOI 10.1021/cn200126p; Carman-Krzan M, 2000, PFLUG ARCH EUR J PHY, V439, pR131, DOI 10.1007/s004240000117; Karimi-Abdolrezaee S, 2006, J NEUROSCI, V26, P3377, DOI 10.1523/JNEUROSCI.4184-05.2006; Kuruvilla A, 1985, Cent Nerv Syst Trauma, V2, P61; Loers G, 2014, BIOCHEM J, V460, P437, DOI 10.1042/BJ20131677; NAFTCHI NE, 1974, J NEUROSURG, V40, P52, DOI 10.3171/jns.1974.40.1.0052; Rangasamy SB, 2013, SYNAPSE, V67, P427, DOI 10.1002/syn.21645; Sharma HS, 2006, ACT NEUR S, V96, P316; Wang RR, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037574; Winkler T, 1995, Inflamm Res, V44 Suppl 1, pS44, DOI 10.1007/BF01674388; Yuan YM, 2012, BRIT J PHARMACOL, V166, P749, DOI 10.1111/j.1476-5381.2011.01804.x	36	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1755-5930	1755-5949		CNS NEUROSCI THER	CNS Neurosci. Ther.	MAY	2015	21	5					454	462		10.1111/cns.12379		9	Neurosciences; Pharmacology & Pharmacy	Neurosciences & Neurology; Pharmacology & Pharmacy	CG4DH	WOS:000353232200008		
J	Murugaboopathy, S; Matsuoka, H				Murugaboopathy, Sivanantham; Matsuoka, Hideki			Salt-dependent surface activity and micellization behaviour of zwitterionic amphiphilic diblock copolymers having carboxybetaine	COLLOID AND POLYMER SCIENCE			English	Article						Non-surface activity; Carboxybetaine; Zwitterionic polymer; Block copolymer; Polymer micelle	CHAIN-LENGTH DEPENDENCE; BLOCK-COPOLYMERS; AQUEOUS-SOLUTION; NEUTRON REFLECTIVITY; ASSOCIATION BEHAVIOR; AIR/WATER INTERFACE; WATER; MICELLES; TRANSITION; ADSORPTION	Zwitterionic amphiphilic diblock copolymers having n-butylacrylate(n-BA) and carboxybetaine as hydrophobic and hydrophilic blocks, respectively, with various chain lengths were synthesized by the reversible addition-fragmentation chain transfer (RAFT) polymerization method. The effects of salt and chain length on the solution behaviour of zwitterionic amphiphilic diblock copolymers were investigated using surface tension, static light scattering (SLS), dynamic light scattering (DLS) and fluorescence spectroscopic measurements. Surface tension measurements revealed that zwitterionic amphiphilic diblock copolymers undergo transition from surface active to non-surface active after addition of salt. This may be due to the transition from zwitterionic (almost zero charge) to ionic nature of the betaine block by addition of small amount of salt followed by an increase of solvent power of salt solution. Foam formation behaviour decreased with increasing chain length. The critical micelle concentration was decreased drastically by the presence of a small amount of salt, which reflected the non-surface active nature of block copolymer. Increase in values of hydrodynamic radii with increase in salt is attributed to stretching of the hydrophilic chain due to the ionic nature of the block chain and the increase of solvent power. Aggregation number (N (agg) ) and the second virial coefficient (A (2)) decreased with the increase in chain length as well as after addition of salt. Packing parameters of block copolymer micelles were less than 0.3 which implies that the micellar shape is spherical. Some unique aspects of zwitterionic polymer were elucidated, which are largely different from simple ionic (anionic and cationic) polymers.	[Murugaboopathy, Sivanantham; Matsuoka, Hideki] Kyoto Univ, Dept Polymer Chem, Kyoto 6158510, Japan	Matsuoka, H (reprint author), Kyoto Univ, Dept Polymer Chem, Kyoto 6158510, Japan.	matsuoka@star.polym.kyoto-u.ac.jp			Global Centre of Excellence (GCOE), GCOE for International Center for Integrated Research and Advanced Education in Material Science; Ministry of Education, Culture, Sports, Science and Technology of Japan [20106006]	M. Sivanantham gratefully acknowledges the Global Centre of Excellence (GCOE), GCOE for International Center for Integrated Research and Advanced Education in Material Science, for providing post-doctoral fellowship. We thank Dr. Yoshiyuki Saruwatari (Osaka Organic Chemical Industry) for kind donation of carboxybetaine monomer. This work was supported by a grant-in-aid for the Scientific Research on Innovative Areas "Molecular Soft-Interface Science" (20106006) from the Ministry of Education, Culture, Sports, Science and Technology of Japan, to which our sincere gratitude is due.	An SW, 1998, J PHYS CHEM B, V102, P387, DOI 10.1021/jp971277x; An SW, 1998, MACROMOLECULES, V31, P7877, DOI 10.1021/ma980548e; Tuzar Z, 1997, MACROMOLECULES, V30, P2509, DOI 10.1021/ma9615617; Stenzel MH, 2004, MACROMOL BIOSCI, V4, P445, DOI 10.1002/mabi.200300113; Ghosh A, 2014, LANGMUIR, V30, P3319, DOI 10.1021/la403042p; Garnier S, 2006, LANGMUIR, V22, P4044, DOI 10.1021/la0600595; Jiang W, 2006, J CHROMATOGR A, V1127, P82, DOI 10.1016/j.chroma.2006.05.080; Nagarajan R, 2002, LANGMUIR, V18, P31, DOI 10.1021/la010831y; Mitsukami Y, 2001, MACROMOLECULES, V34, P2248, DOI 10.1021/ma0018087; Netz RR, 2003, PHYS REP, V380, P1, DOI 10.1016/S0370-1573(03)00118-2; AMIEL C, 1995, MACROMOLECULES, V28, P3125, DOI 10.1021/ma00113a015; ZIMM BH, 1948, J CHEM PHYS, V16, P1099, DOI 10.1063/1.1746740; Shrivastava S, 2014, LANGMUIR, V30, P3957, DOI 10.1021/la4049677; XU RL, 1991, MACROMOLECULES, V24, P87, DOI 10.1021/ma00001a014; Yusa SI, 2005, BIOMACROMOLECULES, V6, P663, DOI 10.1021/bm0495553; Lowe AB, 1999, MACROMOLECULES, V32, P2141, DOI 10.1021/ma980543h; Eghbali E, 2006, LANGMUIR, V22, P4766, DOI 10.1021/la053272u; Berne B, 1976, DYNAMIC LIGHT SCATTE, P174; Ghosh A, 2011, LANGMUIR, V27, P9237, DOI 10.1021/la201550a; Ghosh A, 2013, J CHEM BIOL INTERFAC, V1, P41; Inayama R, COMMUNICATION; Israelachvili J. N., 1991, INTERMOLECULAR SURFA; Kaewsaiha P, 2007, LANGMUIR, V23, P9162, DOI 10.1021/la7003672; Kaewsaiha P, 2005, LANGMUIR, V21, P9938, DOI 10.1021/la051584r; Katagiri K, 2004, COLLOID SURFACE B, V38, P149, DOI 10.1016/j.colsurfb.2004.05.019; Kerker M, 1969, SCATTERING LIGHT OTH, P434; Marques CM, 1988, MACROMOLECULES, V21, P9938; MARQUES CM, 1989, MACROMOLECULES, V22, P1454, DOI 10.1021/ma00193a075; Matsumoto K, 2004, LANGMUIR, V20, P7270, DOI 10.1021/la049371+; Matsuoka H, 2004, LANGMUIR, V20, P7412, DOI 10.1021/la0492153; Matsuoka H, 2003, MACROMOLECULES, V36, P5321, DOI 10.1021/ma0215161; Matsuoka H., 2013, MATEC WEB C, V4; Nayak RR, 2011, IOP CONF SER-MAT SCI, V24, DOI 10.1088/1757-899X/24/1/012024; OAE S, 1972, TETRAHEDRON, V28, P3203, DOI 10.1016/S0040-4020(01)93661-0; Onsager L, 1934, J CHEM PHYS, V2, DOI 10.1063/1.1749522; Parker AP, 2005, COLLOID SURFACE B, V46, P204, DOI 10.1016/j.colsurfb.2005.11.009; Selb J, 1980, POLYM AMINES AMMONIU, P205; WITTMER J, 1993, MACROMOLECULES, V26, P2691, DOI 10.1021/ma00063a009	38	1	1	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0303-402X	1435-1536		COLLOID POLYM SCI	Colloid Polym. Sci.	MAY	2015	293	5					1317	1328		10.1007/s00396-015-3503-1		12	Chemistry, Physical; Polymer Science	Chemistry; Polymer Science	CG5QJ	WOS:000353348000002		
J	Tamai, T; Watanabe, M; Mitamura, K				Tamai, Toshiyuki; Watanabe, Mitsuru; Mitamura, Koji			Modification of PEN and PET film surfaces by plasma treatment and layer-by-layer assembly of polyelectrolyte multilayer thin films	COLLOID AND POLYMER SCIENCE			English	Article						Polymer surface modification; Plasma treatment; Layer-by-layer assembly; Polyelectrolyte multilayer thin film; Polyethylene naphthalate; Polyethylene terephthalate	SILICA NANOPARTICLE; FORCE MICROSCOPY; DEPOSITION; POLYMERIZATION; TEREPHTHALATE; ACTIVATION; MORPHOLOGY; PATTERNS; COPPER; UV	The surfaces of polyethylene naphthalate and polyethylene terephthalate films were modified by plasma treatment, layer-by-layer (LbL) assembly of polyelectrolyte multilayer thin films and subsequent deposition of SiO2 particles. Plasma treatment rendered the film surfaces hydrophilic and led to the formation of fibrillar patterns. The plasma-treated film surfaces were compatible with multilayers acquired via LbL assembly, and the outer adsorbed polyelectrolyte layer determined the charge of the multilayer surfaces. Negatively charged SiO2 particles were adsorbed to the positively charged surface of the multilayers. This process is potentially applicable to surface modifications of polymer materials by charged compounds.	[Tamai, Toshiyuki; Watanabe, Mitsuru; Mitamura, Koji] Osaka Municipal Tech Res Inst, Joto Ku, Osaka 5368553, Japan	Tamai, T (reprint author), Osaka Municipal Tech Res Inst, Joto Ku, 1-6-50 Morinomiya, Osaka 5368553, Japan.	tositama@omtri.or.jp			MEXT of Japan [25410135]	This study was partly supported by a Grant-in-Aid for Scientific Research (C) (25410135) from the MEXT of Japan. We would also like to thank Nissan Chemical Co., Ltd. for a gift of colloidal silica.	ALLEN NS, 1978, J APPL POLYM SCI, V22, P2085, DOI 10.1002/app.1978.070220801; Chen W, 1997, MACROMOLECULES, V30, P78, DOI 10.1021/ma961096d; Lvov Y, 1997, LANGMUIR, V13, P6195, DOI 10.1021/la970517x; Wang TC, 2001, LANGMUIR, V17, P6610, DOI 10.1021/la010755z; Hagen DA, 2014, ACS MACRO LETT, V3, P663, DOI 10.1021/mz500276r; Caruso F, 1998, J AM CHEM SOC, V120, P8523, DOI 10.1021/ja9815024; Yang P, 2014, ACS APPL MATER INTER, V6, P3759, DOI 10.1021/am405857m; Ohno K, 2010, MACROMOLECULES, V43, P5569, DOI 10.1021/ma10013258; Beake BD, 1998, J MATER CHEM, V8, P1735, DOI 10.1039/a801194j; Lee I, 2013, LANGMUIR, V29, P2476, DOI 10.1021/la304123b; Wohlfart E, 2010, MACROMOLECULES, V43, P9908, DOI 10.1021/ma101889s; Nie HY, 1999, APPL SURF SCI, V144-45, P627, DOI 10.1016/S0169-4332(98)00879-4; Srivastava S, 2008, ACCOUNTS CHEM RES, V41, P1831, DOI 10.1021/ar8001377; Matsusaki M, 2012, ADV MATER, V24, P454, DOI 10.1002/adma.201103698; Teshima K, 2003, LANGMUIR, V19, P10624, DOI 10.1021/la034265d; DECHER G, 1992, THIN SOLID FILMS, V210, P831, DOI 10.1016/0040-6090(92)90417-A; Gonzalez E, 2008, LANGMUIR, V24, P12636, DOI 10.1021/la802296c; Ayres N, 2010, POLYM CHEM-UK, V1, P769, DOI 10.1039/b9py00246d; Farhan T, 2004, EUR POLYM J, V40, P1599, DOI 10.1016/j.eurpolymj.2004.05.001; Fleischman MS, 2012, SURF COAT TECH, V206, P3923, DOI 10.1016/j.surfcoat.2012.03.062; Friebe A, 2007, LANGMUIR, V23, P10316, DOI 10.1021/la7016962; Kim YJ, 2009, APPL SURF SCI, V255, P3648, DOI 10.1016/j.apsusc.2008.10.009; Kimura M, 2010, ACS APPL MATER INTER, V2, P3714, DOI 10.1021/am100853t; Powell HM, 2003, LANGMUIR, V19, P9071, DOI 10.1021/la0349368; RICHARDS RR, 1974, J POLYM SCI POL PHYS, V12, P89, DOI 10.1002/pol.1974.180120108; Tamai T, 2000, MACROMOLECULES, V33, P2881, DOI 10.1021/ma990948h; Tamai T, 2012, CHEM LETT, V41, P277, DOI 10.1246/cl.2012.277; Wang F, 2009, LANGMUIR, V25, P4384, DOI 10.1021/la8033758; Yang GH, 2001, LANGMUIR, V17, P211, DOI 10.1021/la0009689	29	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0303-402X	1435-1536		COLLOID POLYM SCI	Colloid Polym. Sci.	MAY	2015	293	5					1349	1356		10.1007/s00396-015-3518-7		8	Chemistry, Physical; Polymer Science	Chemistry; Polymer Science	CG5QJ	WOS:000353348000005		
J	Ohshima, H				Ohshima, Hiroyuki			Electroosmotic flow on an arbitrarily charged planar surface	COLLOID AND POLYMER SCIENCE			English	Article						Electroosmotic flow; Arbitrarily charged surface; Nonuniformly charged surface; Sinusoidally charged surface; Discrete charge effect	APPROXIMATE ANALYTIC-EXPRESSION; SPHERICAL COLLOIDAL PARTICLE; UNIVALENT SALT-SOLUTIONS; ELECTROPHORETIC MOBILITY; ELCTROOSMOSIS; FIELD; CYLINDERS; FORCES	A general expression for the electroosmotic flow on an arbitrarily (i.e., both uniformly and nonuniformly) charged planar surface under an applied static electric field is derived. We treat the case in which the applied field is weak so that the flow is slow enough to obey the Stokes approximation at low Reynolds numbers and the electric potential is low enough to obey the linearized Poisson-Boltzmann equation. As examples, the flow around a sinusoidally charged planar surface and that around a charged planar surface carrying a square lattice of point charges are considered. The latter is related to the discrete-charge effect upon the electroosmotic flow.	Tokyo Univ Sci, Fac Pharmaceut Sci, Noda, Chiba 2788510, Japan	Ohshima, H (reprint author), Tokyo Univ Sci, Fac Pharmaceut Sci, 2641 Yamazaki, Noda, Chiba 2788510, Japan.	ohshima@rs.noda.tus.ac.jp					MIKLAVIC SJ, 1994, J PHYS CHEM-US, V98, P9022, DOI 10.1021/j100087a034; AJDARI A, 1995, PHYS REV LETT, V75, P755, DOI 10.1103/PhysRevLett.75.755; Ajdari A, 1996, PHYS REV E, V53, P4996, DOI 10.1103/PhysRevE.53.4996; OHSHIMA H, 1983, J CHEM SOC FARAD T 2, V79, P1613, DOI 10.1039/f29837901613; ANDERSON JL, 1985, J COLLOID INTERF SCI, V105, P45, DOI 10.1016/0021-9797(85)90345-5; DUKHIN SS, 1993, ADV COLLOID INTERFAC, V44, P1, DOI 10.1016/0001-8686(93)80021-3; Stroock AD, 2000, PHYS REV LETT, V84, P3314, DOI 10.1103/PhysRevLett.84.3314; Erickson D, 2002, LANGMUIR, V18, P8949, DOI 10.1021/la025942r; Delgado AV, 2000, ELECTROKINETICS ELEC; Dukhin A. S., 2002, ULTRASOUND CHARACTER; Dukhin SS, 1974, SURFACE COLLOID SCI, V2; Erickson D, 2003, J PHYS CHEM B, V107, P12212, DOI 10.1021/jp027724c; Ghosh CS, 2013, PHYS REV E, VE88; Hsu JP, 2011, J PHYS CHEM C, V115, P12592, DOI 10.1021/jp200559z; Hunter R. J., 1989, FDN COLLOID SCI, V2; Long P, 1998, PHYS REV LETT, V81, P1529; Lyklema J., 1995, FUNDAMENTALS INTERFA, VII; Masliyah J. H., 2006, ELECTROKINETIC COLLO; Miklavic SJ, 1999, J COLLOID INTERF SCI, V216, P329; NELSON AP, 1975, J THEOR BIOL, V55, P13, DOI 10.1016/S0022-5193(75)80106-8; OBRIEN RW, 1978, J CHEM SOC FARAD T 2, V74, P1607, DOI 10.1039/f29787401607; Ohshima H, 2006, INTERFACE SCI TECHNO, V12, P1; Ohshima H, 2014, COLLOID POLYM SCI, V292, P749, DOI 10.1007/s00396-013-3132-5; Ohshima H, 2014, COLLOID POLYM SCI, V292, P1227, DOI 10.1007/s00396-014-3171-6; Ohshima H, 2010, BIOPHYSICAL CHEM BIO; Ohshima H, 2014, COLLOID POLYM SCI, V292, P1457, DOI 10.1007/s00396-014-3193-0; Ohshima H, 1998, ELECT PHENOMENA INTE; Ohshima H, 2012, ELECT PHENOMENA INTE; Ohshima H, 2014, COLLOID POLYM SCI, V292, P757, DOI 10.1007/s00396-013-3160-1; Petrov AG, 1993, PMM-J APPL MATH MEC, V57, P577, DOI 10.1016/0021-8928(93)90138-C; Richmond P, 1974, J CHEM SOC FARADAY T, V2, P1154; Richmond P, 1974, J CHEM SOC FARADAY T, V2, P1066; Spasic A, 2005, FINELY DISPERSED PAR; STIGTER D, 1978, J PHYS CHEM-US, V82, P1424, DOI 10.1021/j100501a020; STIGTER D, 1978, J PHYS CHEM-US, V82, P1417, DOI 10.1021/j100501a019; van de Ven TGM, 1989, COLLOID HYDRODYNAMIC	36	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0303-402X	1435-1536		COLLOID POLYM SCI	Colloid Polym. Sci.	MAY	2015	293	5					1401	1408		10.1007/s00396-015-3520-0		8	Chemistry, Physical; Polymer Science	Chemistry; Polymer Science	CG5QJ	WOS:000353348000010		
J	Sae-heng, K; Iso, N; Kosugi, K; Kawahara, S				Sae-heng, Kewwarin; Iso, Noriaki; Kosugi, Kenichiro; Kawahara, Seiichi			Prevulcanization of isoprene rubber latex	COLLOID AND POLYMER SCIENCE			English	Article						Isoprene rubber; Prevulcanization; NMR; Kinetics; Activation energy	STATE C-13 NMR; VULCANIZED NATURAL-RUBBER; SPECTROSCOPY; TEMPERATURE	Prevulcanization of isoprene rubber (IR) latex was investigated by latex-state C-13-NMR spectroscopy to understand its mechanism in latex stage. The prevulcanization was carried out at 50 to 90 A degrees C with sulfur (S) and zinc-dibutyldithiocarbamate (ZDBC) as vulcanizing agents. The prevulcanized IR latex was subjected to latex-state C-13-NMR spectroscopy. The signal at 44 ppm was assigned to secondary carbons adjacent to carbons linking to S atoms, whereas the signal at 58 ppm was assigned to tertiary and quaternary carbons linking to S atoms. The time evolution of the small signals at 44 and 58 ppm was investigated at various temperatures, and kinetic constants were determined at each temperature. The activation energy of the prevulcanization of IR latex was estimated from the kinetic constants to be about 80 kJ/mol.	[Sae-heng, Kewwarin; Iso, Noriaki; Kosugi, Kenichiro; Kawahara, Seiichi] Nagaoka Univ Technol, Dept Mat Sci & Technol, Fac Engn, Nagaoka, Niigata 9402188, Japan	Kawahara, S (reprint author), Nagaoka Univ Technol, Dept Mat Sci & Technol, Fac Engn, Nagaoka, Niigata 9402188, Japan.	kawahara@mst.nagaokaut.ac.jp			Japanese Government (Monbugakusho) scholarship from The Ministry of Education, Science and Culture, Japan	This work was supported by Japanese Government (Monbugakusho) scholarship from The Ministry of Education, Science and Culture, Japan and research work is done in Nagaoka University of Technology, Japan.	Ang T. T., 1979, Plastics and Rubber Materials and Applications, V4; Kawahara S, 2009, POLYMER, V50, P1626, DOI 10.1016/j.polymer.2009.01.062; Sasidharan KK, 2005, J APPL POLYM SCI, V97, P1804, DOI 10.1002/app.21918; Flory PJ, 1943, J CHEM PHYS, V11, P521, DOI 10.1063/1.1723792; Chaikumpollert O, 2012, POLYM J, V44, P772, DOI 10.1038/pj.2012.112; Claramma NM, 1997, J APPL POLYM SCI, V65, P1913, DOI 10.1002/(SICI)1097-4628(19970906)65:10<1913::AID-APP8>3.0.CO;2-I; Coran AY, 1994, VULCANIZATION, V2nd; FITCH RM, 1979, J COLLOID INTERF SCI, V71, P107, DOI 10.1016/0021-9797(79)90225-X; Fossey J., 1995, FREE RADICAL ORGANIC; Gambhir PN, 1993, J RUBBER RES, V8, P208; Ho CC, 1999, LANGMUIR, V15, P6208, DOI 10.1021/la981601v; Houston PL, 2001, CHEM KINETIC REACTIO; Kawahara S, 2001, RUBBER CHEM TECHNOL, V74, P295, DOI 10.5254/1.3544951; Kawahara S, 1999, RUBBER CHEM TECHNOL, V72, P844, DOI 10.5254/1.3538836; Kawahara S, 2007, RUBBER CHEM TECHNOL, V80, P751, DOI 10.5254/1.3539414; Kooyman E. C., 1967, PURE APPL CHEM, V15, P81, DOI 10.1351/pac196715010081; Mori M, 1997, RUBBER CHEM TECHNOL, V70, P671, DOI 10.5254/1.3538453; Mori M, 2003, RUBBER CHEM TECHNOL, V76, P1259, DOI 10.5254/1.3547801; Parker DD, 1998, J APPL POLYM SCI, V70, P1371; Ukawa J, 2007, J POLYM SCI POL PHYS, V45, P1003, DOI 10.1002/polb.21076	20	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0303-402X	1435-1536		COLLOID POLYM SCI	Colloid Polym. Sci.	MAY	2015	293	5					1457	1464		10.1007/s00396-015-3513-z		8	Chemistry, Physical; Polymer Science	Chemistry; Polymer Science	CG5QJ	WOS:000353348000015		
J	Takeoka, H; Hamasaki, H; Harada, Y; Nakamura, Y; Fujii, S				Takeoka, Hiroaki; Hamasaki, Hiroyuki; Harada, Yoshiyuki; Nakamura, Yoshinobu; Fujii, Syuji			Synthesis and characterization of polypyrrole-platinum nanocomposite-coated latex particles	COLLOID AND POLYMER SCIENCE			English	Article						Nanocomposite; Core-shell morphology; Particle; Dispersibility; Conducting polymer; Platinum	SEEDED DISPERSION POLYMERIZATION; SURFACE CHARACTERIZATION; POLYSTYRENE LATEXES; COAXIAL NANOCABLES; POLYANILINE; COMPOSITES; NANOSPHERES; CATALYST; PYRROLE; SPECTRA	Deposition of polypyrrole-platinum (PPy-Pt) nanocomposite from aqueous solution onto micrometer-sized polystyrene (PS) particles was conducted. The PS seed particles and resulting composite particles were extensively characterized with respect to particle size and size distribution, morphology, surface/bulk chemical compositions, and conductivity. PPy-Pt nanocomposite loading onto the PS seed latex particles was systematically controlled over a wide range (5.7-36.6 wt%) by changing the weight ratio of the PS latex and PPy-Pt nanocomposite. Pt loading was also controlled between 2.94 and 18.8 wt%. The conductivity of pressed pellets increased with the PPy-Pt nanocomposite loading, and conductivities were ranged from 4.62 x 10(-8) to 9.56 x 10(-11) S cm(-1). Hollow capsule and broken egg-shell morphologies were observed by scanning/transmission electron microscopy after extraction of the PS component from the composite particles, which confirmed a PS core and PPy-Pt nanocomposite shell morphology. Transmission electron microscopy confirmed that nanometer-sized Pt particles were distributed in the shell.	[Takeoka, Hiroaki; Hamasaki, Hiroyuki; Nakamura, Yoshinobu; Fujii, Syuji] Osaka Inst Technol, Dept Appl Chem, Fac Engn, Asahi Ku, Osaka 5358585, Japan; [Harada, Yoshiyuki; Nakamura, Yoshinobu] Osaka Inst Technol, Nanomat Microdevices Res Ctr, Asahi Ku, Osaka 5358585, Japan	Fujii, S (reprint author), Osaka Inst Technol, Dept Appl Chem, Fac Engn, Asahi Ku, 5-16-1 Omiya, Osaka 5358585, Japan.	syuji.fujii@oit.ac.jp			Ministry of Education, Culture, Sports, Science and Technology of Japan	A Rabbit Science Co., Ltd, is thanked for elemental microanalysis studies. Prof. K. Akamatsu and Dr. T. Tsuruoka are thanked for TEM studies. This work was supported by a Grant-in-Aid for Scientific Research on Innovative Areas "New Polymeric Materials Based on Element-Blocks," "Engineering Neo-Biomimetics," and "Molecular Soft-Interface Science" from the Ministry of Education, Culture, Sports, Science and Technology of Japan.	TIAN ZQ, 1991, J ELECTROANAL CHEM, V308, P357, DOI 10.1016/0022-0728(91)85083-2; Henry MC, 2001, J ELECTROCHEM SOC, V148, pD155, DOI 10.1149/1.1405802; Fujii S, 2010, LANGMUIR, V26, P6230, DOI 10.1021/la9039545; Fujii S, 2007, J MATER CHEM, V17, P3777, DOI 10.1039/b709413b; Lascelles SF, 1997, J MATER CHEM, V7, P1349, DOI 10.1039/a700236j; Pillalamarri SK, 2005, CHEM MATER, V17, P5941, DOI 10.1021/cm050827y; TUINSTRA F, 1970, J CHEM PHYS, V53, P1126, DOI 10.1063/1.1674108; Fujii S, 2010, CHEM COMMUN, V46, P7217, DOI 10.1039/c0cc02005b; Fujii S, 2012, LANGMUIR, V28, P2436, DOI 10.1021/la204324f; Drelinkiewicz A, 2000, CATAL LETT, V64, P41, DOI 10.1023/A:1019078718474; Chen AH, 2005, CHEM COMMUN, P1863, DOI 10.1039/b417744d; Vasilyeva SV, 2008, J PHYS CHEM C, V112, P19878, DOI 10.1021/jp805423t; Gangopadhyay R, 2000, CHEM MATER, V12, P608, DOI 10.1021/cm990537f; Selvan ST, 1998, ADV MATER, V10, P132, DOI 10.1002/(SICI)1521-4095(199801)10:2<132::AID-ADMA132>3.0.CO;2-Y; Perruchot C, 1996, LANGMUIR, V12, P3245, DOI 10.1021/la960057s; Lascelles SF, 1997, J MATER CHEM, V7, P1339, DOI 10.1039/a700237h; Radford PT, 2001, ANAL CHIM ACTA, V449, P199, DOI 10.1016/S0003-2670(01)01343-5; Attia MF, 2013, J COLLOID INTERF SCI, V393, P130, DOI 10.1016/j.jcis.2012.11.008; BJORKLUND RB, 1986, J CHEM SOC CHEM COMM, P1293, DOI 10.1039/c39860001293; Chen AH, 2005, J PHYS CHEM B, V109, P18283, DOI 10.1021/jp053247x; Fujii S, 2008, J ADH SOC JPN, V44, P12; Fujii S, 2013, APPL SURFACE SCI NAN, V11, P303; Hamasaki H, 2012, CHEM LETT, V41, P1658, DOI 10.1246/cl.2012.1658; Han CC, 1998, CHEM COMMUN, P2087, DOI 10.1039/a805057k; JONES CH, 1991, SPECTROCHIM ACTA A, V47, P1293, DOI 10.1016/0584-8539(91)80218-8; Khan AM, 2001, J MATER CHEM, V11, P2363; Kitani A, 2001, SYNTHETIC MET, V121, P1301, DOI 10.1016/S0379-6779(00)01522-8; Lovell P. A., 1997, EMULSION POLYM EMULS; Mangeney C, 2006, LANGMUIR, V22, P10163, DOI 10.1021/la060910f; Mravcakova M, 2007, SYNTHETIC MET, V157, P347, DOI 10.1016/j.synthmet.2007.04.005; NYQUIST RA, 1992, APPL SPECTROSC, V46, P981, DOI 10.1366/0003702924124321; Okubo M, 1999, COLLOID POLYM SCI, V277, P875, DOI 10.1007/s003960050464; Okubo M, 2001, COLLOID POLYM SCI, V279, P139, DOI 10.1007/s003960000405; Okubo M, 2000, COLLOID POLYM SCI, V278, P559, DOI 10.1007/s003960050555; Pourbaix M., 1966, ATLAS ELECTROCHEMICA; TADAYYONI MA, 1991, APPL SPECTROSC, V45, P1613, DOI 10.1366/0003702914335166; VENKATACHALAM RS, 1988, J POLYM SCI POL PHYS, V26, P2447, DOI 10.1002/polb.1988.090261205; Vetter CA, 2011, LANGMUIR, V27, P13719, DOI 10.1021/la202947e	38	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0303-402X	1435-1536		COLLOID POLYM SCI	Colloid Polym. Sci.	MAY	2015	293	5					1483	1493		10.1007/s00396-015-3534-7		11	Chemistry, Physical; Polymer Science	Chemistry; Polymer Science	CG5QJ	WOS:000353348000018		
J	Takakura, Y; Ikeda, S; Imaoka, Y; Urushihara, T; Itamoto, T				Takakura, Y.; Ikeda, S.; Imaoka, Y.; Urushihara, T.; Itamoto, T.			An elevated preoperative serum carbohydrate antigen 19-9 level is a significant predictor for peritoneal dissemination and poor survival in colorectal cancer	Colorectal Disease			English	Article						Colorectal cancer; CA19-9; peritoneal dissemination	GASTROINTESTINAL CANCER; CLINICAL-SIGNIFICANCE; PROGNOSTIC VALUE; CA19-9; CEA; CARCINOMATOSIS; RECURRENCE; MANAGEMENT; CELLS; RISK	AimMany studies support the role of carcinoembryonic antigen (CEA) as a strong indicator of the status of colorectal cancer patients, but evidence for carbohydrate antigen 19-9 (CA19-9) is poor. For this reason the study aimed to evaluate the prognostic value of preoperative serum CA19-9 levels in colorectal cancer patients. MethodIn all, 1190 colorectal cancer patients were included in this study, of whom 955 underwent a potentially curative resection. These were analysed for recurrence and survival. The 255 patients with Stage IV disease were analysed for metastatic status. ResultsPatients with an elevated preoperative CEA with Stage II and III disease showed a significantly poorer survival than those with normal levels. In contrast patients with elevated preoperative CA19-9 levels were associated with a significantly poorer survival irrespective of disease stage. Of the 255 patients with Stage IV disease, 92 (39.1%) had peritoneal dissemination at laparotomy observed more frequently in patients with an elevated CA19-9 (47.9%). Of the 955 patients having a curative resection, 18 (1.9%) developed peritoneal dissemination. In multivariate analysis, an elevated preoperative CA19-9 level was a significant risk factor for postoperative peritoneal recurrence. ConclusionAfter curative surgery for colorectal cancer the preoperative CA19-9 level is a strong prognostic indicator of higher risk of peritoneal dissemination.	[Takakura, Y.; Ikeda, S.; Imaoka, Y.; Urushihara, T.; Itamoto, T.] Hiroshima Prefectural Hosp, Dept Gastrointestinal Surg, Hiroshima, Japan; [Urushihara, T.; Itamoto, T.] Hiroshima Univ, Fac Med, Hiroshima, Japan	Takakura, Y (reprint author), Hiroshima Prefectural Hosp, Dept Gastrointestinal Surg, Minami Ku, 1-5-54 Ujina Kanda, Hiroshima, Japan.	ytaka0621@gmail.com					Yakabe T, 2010, ANN SURG ONCOL, V17, P2349, DOI 10.1245/s10434-010-1004-5; Schott A, 1998, ANN SURG, V227, P372, DOI 10.1097/00000658-199803000-00009; Morita S, 2004, DIS COLON RECTUM, V47, P227, DOI 10.1007/s10350-003-0041-6; KOPROWSKI H, 1979, SOMAT CELL GENET, V5, P957, DOI 10.1007/BF01542654; Elias D, 2011, ANN SURG, V254, P289, DOI 10.1097/SLA.0b013e31822638f6; Yu JH, 2013, NAT MATER, V12, P359, DOI [10.1038/nmat3565, 10.1038/NMAT3565]; Lin PC, 2012, INT J COLORECTAL DIS, V27, P1333, DOI 10.1007/s00384-012-1447-1; Kerscher AG, 2013, BRIT J CANCER, V108, P1432, DOI 10.1038/bjc.2013.82; Chen CC, 2005, J SURG RES, V124, P169, DOI 10.1016/j.jss.2004.08.013; Elias D, 2010, J CLIN ONCOL, V28, P63, DOI 10.1200/JCO.2009.23.9285; Reiter W, 2000, ANTICANCER RES, V20, P5195; Park IJ, 2009, ANTICANCER RES, V29, P4303; BERG EL, 1992, BIOCHEM BIOPH RES CO, V184, P1048, DOI 10.1016/0006-291X(92)90697-J; Elias D, 2010, ANN SURG, V251, P896, DOI 10.1097/SLA.0b013e3181d9765d; IITSUKA Y, 1979, CANCER, V44, P1476, DOI 10.1002/1097-0142(197910)44:4<1476::AID-CNCR2820440442>3.0.CO;2-R; Locker GY, 2006, J CLIN ONCOL, V24, P5313, DOI 10.1200/JCO.2006.08.2644; MAGNANI JL, 1982, J BIOL CHEM, V257, P4365; NAKAJIMA T, 1978, Acta Cytologica, V22, P225; Nakayama T, 1997, J SURG ONCOL, V66, P238; Nakayama T, 1997, ANTICANCER RES, V17, P1379; Yang SH, 2004, J SURG ONCOL, V87, P167, DOI 10.1002/jso.20109; Yu H, 2013, J KOREAN SURG SOC, V84, P231, DOI 10.4174/jkss.2013.84.4.231	22	1	1	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1462-8910	1463-1318		COLORECTAL DIS	Colorectal Dis.	MAY	2015	17	5					417	425		10.1111/codi.12865		84	Gastroenterology & Hepatology; Surgery	Gastroenterology & Hepatology; Surgery	CG8NO	WOS:000353565100001		
J	Akiyoshi, T; Ogura, A; Sakura, M; Ueno, M				Akiyoshi, T.; Ogura, A.; Sakura, M.; Ueno, M.			Laparoscopic anterior pelvic exenteration for advanced sigmoid colon cancer - a video vignette	Colorectal Disease			English	Letter									[Akiyoshi, T.; Ogura, A.; Ueno, M.] Japanese Fdn Canc Res, Canc Inst Hosp, Dept Surg Gastroenterol, Gastroenterol Ctr,Koto Ku, Tokyo 1358550, Japan; [Sakura, M.] Japanese Fdn Canc Res, Canc Inst Hosp, Dept Urol, Koto Ku, Tokyo 1358550, Japan	Akiyoshi, T (reprint author), Japanese Fdn Canc Res, Canc Inst Hosp, Dept Surg Gastroenterol, Gastroenterol Ctr,Koto Ku, 3-8-31 Ariake, Tokyo 1358550, Japan.	takashi.akiyoshi@jfcr.or.jp					Martinez A, 2011, GYNECOL ONCOL, V120, P374, DOI 10.1016/j.ygyno.2010.11.032; Pruthi RS, 2008, J ENDOUROL, V22, P2397, DOI 10.1089/end.2008.0108	2	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1462-8910	1463-1318		COLORECTAL DIS	Colorectal Dis.	MAY	2015	17	5					454	454		10.1111/codi.12928		1	Gastroenterology & Hepatology; Surgery	Gastroenterology & Hepatology; Surgery	CG8NO	WOS:000353565100022		
J	Kishi, T; Matsuda, Y; Mukai, T; Matsunaga, S; Yasue, I; Fujita, K; Okochi, T; Hirano, S; Kajio, Y; Funahashi, T; Akamatsu, K; Ino, K; Okuda, M; Tabuse, H; Iwata, N				Kishi, Taro; Matsuda, Yuki; Mukai, Tomohiko; Matsunaga, Shinji; Yasue, Ichiro; Fujita, Kiyoshi; Okochi, Tomo; Hirano, Shigeki; Kajio, Yusuke; Funahashi, Toshihiko; Akamatsu, Kaku; Ino, Kei; Okuda, Momoko; Tabuse, Hideaki; Iwata, Nakao			A cross-sectional survey to investigate the prevalence of pain in Japanese patients with major depressive disorder and schizophrenia	COMPREHENSIVE PSYCHIATRY			English	Article							SYMPTOMS; SMOKING; SCALE	We conducted a cross-sectional survey to assess the prevalence of physical pain in Japanese major depressive disorder (MDD) and schizophrenia (SZ) patients as well as in healthy controls (HCs). We also examined the association between their psychopathology and characteristics of pain according to a face-to-face survey by an experienced psychiatrist and psychologist. We analyzed 233 HCs, 94 MDD patients, and 75 SZ patients using the McGill Pain Questionnaire (MPQ) and SF-8 (all participants), the Hamilton Depression Rating Scale 21 items (MDD patients), and the Positive and Negative Symptom Scale (SZ patients). Although MDD patients experienced more pain than HCs, there was no difference in the prevalence of pain between SZ patients and HCs. Moreover, HCs with pain did not have higher SF-8 total scores than those without pain, whereas both MDD and SZ patients with pain had higher SF-8 total scores than those without pain. The severity of psychopathology in MDD and SZ patients was also positively associated with both the prevalence of pain and MPQ scores. MPQ scores were also associated with positive symptoms in SZ patients. Considering these results, physicians need to query MDD patients about physical pain during examination if they are to ensure a favorable and quick response to treatment. The severity of positive symptoms (i.e., clinical status) in SZ patients might also be associated with pain sensitivity, and warrants further investigation. (C) 2015 Elsevier Inc. All rights reserved.	[Kishi, Taro; Matsuda, Yuki; Mukai, Tomohiko; Matsunaga, Shinji; Iwata, Nakao] Fujita Hlth Univ, Sch Med, Dept Psychiat, Toyoake, Aichi 4701192, Japan; [Yasue, Ichiro; Fujita, Kiyoshi] Okehazama Hosp, Dept Psychiat, Toyoake, Aichi 4701168, Japan; [Okochi, Tomo; Hirano, Shigeki] Toyota Mem Hosp, Dept Psychiat, Toyota, Aichi 4718513, Japan; [Kajio, Yusuke; Funahashi, Toshihiko] Jindai Hosp, Dept Psychiat, Toyota, Aichi 4700361, Japan; [Akamatsu, Kaku] Jindai Clin, Dept Psychiat, Nagoya, Aichi 4700361, Japan; [Ino, Kei; Okuda, Momoko; Tabuse, Hideaki] Holy Cross Hosp, Dept Psychiat, Toki, Gifu 5095142, Japan	Kishi, T (reprint author), Fujita Hlth Univ, Sch Med, Dept Psychiat, Toyoake, Aichi 4701192, Japan.	tarok@fujita-hu.ac.jp			Eli Lilly Japan K.K	This study was funded by Eli Lilly Japan K.K.	Allen SS, 2014, ADDICT BEHAV, V39, P901, DOI 10.1016/j.addbeh.2014.01.029; Simon GE, 1999, NEW ENGL J MED, V341, P1329, DOI 10.1056/NEJM199910283411801; KAY SR, 1987, SCHIZOPHRENIA BULL, V13, P261; Aguera-Ortiz L, 2011, J AFFECT DISORDERS, V130, P106, DOI 10.1016/j.jad.2010.10.022; Engels G, 2014, J PAIN, V15, P457, DOI 10.1016/j.jpain.2013.11.005; Bartley EJ, 2013, BRIT J ANAESTH, V111, P52, DOI 10.1093/bja/aet127; McCormick Z, 2014, PAIN MED, V15, P292, DOI 10.1111/pme.12283; Bair MJ, 2004, PSYCHOSOM MED, V66, P17, DOI 10.1097/01.PSY.0000106883.94059.C5; Goesling J, 2012, PAIN, V153, P1749, DOI 10.1016/j.pain.2012.05.014; MELZACK R, 1975, PAIN, V1, P277, DOI 10.1016/0304-3959(75)90044-5; Fukuhara S, 2004, MANUAL SF 8 JAPANESE; HAMILTON M, 1960, J NEUROL NEUROSUR PS, V23, P56, DOI 10.1136/jnnp.23.1.56; Ney JP, 2013, PAIN MED, V14, P706, DOI 10.1111/pme.12091; Shimodera S, 2012, COMPR PSYCHIAT, V53, P843, DOI 10.1016/j.comppsych.2011.11.004; Singh Manpreet K, 2006, J Psychiatr Pract, V12, P90, DOI 10.1097/00131746-200603000-00004	15	0	0	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0010-440X	1532-8384		COMPR PSYCHIAT	Compr. Psychiat.	MAY	2015	59						91	97		10.1016/j.comppsych.2015.02.004		7	Psychiatry	Psychiatry	CG4KL	WOS:000353253900013		
J	Kawakami, N; Yoshida, F				Kawakami, Naoaki; Yoshida, Fujio			Perceiving a story outside of conscious awareness: When we infer narrative attributes from subliminal sequential stimuli	CONSCIOUSNESS AND COGNITION			English	Article						Unconscious processes; Priming; Subliminal; Implicit measure; Story perception	IMPLICIT ASSOCIATION TEST; PERCEPTION; BEHAVIOR; INFANTS	Perceiving a story behind successive movements plays an important role in our lives. From a general perspective, such higher mental activity would seem to depend on conscious processes. Using a subliminal priming paradigm, we demonstrated that such story perception occurs without conscious awareness. In the experiments, participants were subliminally presented with sequential pictures that represented a story in which one geometrical figure was chased by the other figure, and in which one fictitious character defeated the other character in a tug-of-war. Although the participants could not report having seen the pictures, their automatic mental associations (i.e., associations that are activated unintentionally, difficult to control, and not necessarily endorsed at a conscious level) were shifted to line up with the story. The results suggest that story perception operates outside of conscious awareness. Implications for research on the unconscious were also briefly discussed. (C) 2014 Elsevier Inc. All rights reserved.	[Kawakami, Naoaki; Yoshida, Fujio] Univ Tsukuba, Ibaraki 3058572, Japan	Kawakami, N (reprint author), Univ Tsukuba, Fac Human Sci, Ibaraki 3058572, Japan.	aki-kawa@human.tsukuba.ac.jp					Hassin RR, 2013, PERSPECT PSYCHOL SCI, V8, P195, DOI 10.1177/1745691612460684; Uleman JS, 1996, ADV EXP SOC PSYCHOL, V28, P211, DOI 10.1016/S0065-2601(08)60239-7; Kovacs AM, 2010, SCIENCE, V330, P1830, DOI 10.1126/science.1190792; Tremoulet PD, 2000, PERCEPTION, V29, P943, DOI 10.1068/p3101; Custers R, 2010, SCIENCE, V329, P47, DOI 10.1126/science.1188595; Heider F, 1944, AM J PSYCHOL, V57, P243, DOI 10.2307/1416950; Aarts H, 2008, SCIENCE, V319, P1639, DOI 10.1126/science.1150432; Gawronski B, 2006, PSYCHOL BULL, V132, P692, DOI 10.1037/0033-2909.132.5.692; Kouider S, 2007, PHILOS T R SOC B, V362, P857, DOI 10.1098/rstb.2007.2093; Gawronski B, 2007, J EXP SOC PSYCHOL, V43, P221, DOI 10.1016/j.jesp.2006.04.001; Sklar AY, 2012, P NATL ACAD SCI USA, V109, P19614, DOI 10.1073/pnas.1211645109; Greenwald AG, 2002, J PERS SOC PSYCHOL, V83, P367, DOI 10.1037//0022-3514.83.2.367; Greenwald AG, 2003, J PERS SOC PSYCHOL, V85, P197, DOI 10.1037/0022-3514.85.2.197; Rothermund K, 2004, J EXP PSYCHOL GEN, V133, P139, DOI 10.1037/0096-3445.133.2.139; Dijksterhuis A, 2006, PERSPECT PSYCHOL SCI, V1, P95, DOI 10.1111/j.1745-6916.2006.00007.x; Greenwald AG, 1996, SCIENCE, V273, P1699, DOI 10.1126/science.273.5282.1699; Ric F, 2012, J EXP PSYCHOL GEN, V141, P222, DOI 10.1037/a0024608; Dell'Acqua R, 1999, COGNITION, V73, pB1, DOI 10.1016/S0010-0277(99)00049-9; Guldenpenning I, 2011, EXP BRAIN RES, V213, P383, DOI 10.1007/s00221-011-2788-7; Hassin RR, 2005, J EXP SOC PSYCHOL, V41, P129, DOI 10.1016/j.jesp.2004.06.008; Hamlin JK, 2007, NATURE, V450, P557, DOI 10.1038/nature06288; Naccache L, 2005, P NATL ACAD SCI USA, V102, P7713, DOI 10.1073/pnas.05005742102; Greenwald AG, 1998, J PERS SOC PSYCHOL, V74, P1464, DOI 10.1037/0022-3514.74.6.1464; Hassin R. R., 2005, NEW UNCONSCIOUS, P196; Kiesel A, 2009, J EXP PSYCHOL LEARN, V35, P292, DOI 10.1037/a0014499; van Gaal S, 2014, PHILOS T R SOC B, V369, DOI 10.1098/rstb.2013.0212; Wilson T.D., 2002, STRANGERS OURSELVES; WINTER L, 1984, J PERS SOC PSYCHOL, V47, P237, DOI 10.1037/0022-3514.47.2.237	28	0	0	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	1053-8100	1090-2376		CONSCIOUS COGN	Conscious. Cogn.	MAY	2015	33						53	66		10.1016/j.concog.2014.12.001		14	Psychology, Experimental	Psychology	CG0AA	WOS:000352927800006		
J	Sathiparan, N; Meguro, K				Sathiparan, Navaratnarajah; Meguro, Kimiro			Strengthening of adobe houses with arch roofs using tie-bars and polypropylene band mesh	CONSTRUCTION AND BUILDING MATERIALS			English	Article						Adobe; Arches; Earthquake; PP-band; Tie-bars; Shaking table test	REINFORCED POLYMER STRIPS; MASONRY ARCHES; TABLE TESTS; BEHAVIOR; MODELS	The purpose of this study was to compare the effects of strengthening adobe houses with an arch roof using polypropylene band (PP-band) mesh with or without tie-bars. To this end, an experimental analysis was conducted on scale models of adobe houses. In one test, an arch roof was retrofitted with only a PP-band mesh. In the second test, in addition to being retrofitted with PP-band mesh, tie-bars were used for horizontal support at roof level. These two PP-band retrofitted house models and house model with tie-bars only were subjected to sinusoid loading until the point of collapse or the capacity of the shaking table was exceeded. Results collected during the analyses were significant in assessing the capability of these retrofitting methods to support dynamic loads, increasing the collapse load, stiffness and ductility and dissipate energy. (C) 2015 Elsevier Ltd. All rights reserved.	[Sathiparan, Navaratnarajah] Univ Ruhuna, Dept Civil & Environm Engn, Galle, Sri Lanka; [Sathiparan, Navaratnarajah] Univ Tokyo, Inst Ind Sci, Tokyo 1138654, Japan; [Meguro, Kimiro] Univ Tokyo, Inst Ind Sci, ICUS, Tokyo 1138654, Japan	Sathiparan, N (reprint author), Univ Ruhuna, Dept Civil & Environm Engn, Galle, Sri Lanka.	nsakthiparan@yahoo.com	Sathiparan, Navaratnarajah/M-1485-2015	Sathiparan, Navaratnarajah/0000-0001-8570-0580	Ministry of Education, Culture, Sports, Science, and Technology of Japan	The authors acknowledge the Ministry of Education, Culture, Sports, Science, and Technology of Japan for extending financial support undertaking the research work. Authors wish to acknowledge Dr. Paola Mayorca for providing essential guidelines in the experimental campaign.	Shedid MT, 2009, ENG STRUCT, V31, P2032, DOI 10.1016/j.engstruct.2009.03.006; Foraboschi P, 2004, J COMPOS CONSTR, V8, P191, DOI 10.1061/(ASCE)1090-0268(2004)8:3(191); Borri A, 2009, J COMPOS CONSTR, V13, P468, DOI 10.1061/(ASCE)CC.1943-5614.0000030; Bati SB, 2008, MATER STRUCT, V41, P1291, DOI 10.1617/s11527-007-9328-8; Bednarz L, 2011, AUTOMAT CONSTR, V20, P741, DOI 10.1016/j.autcon.2011.01.005; Garmendia L, 2014, INT J ARCHIT HERIT, V8, P627, DOI 10.1080/15583058.2012.704480; TOMAZEVIC M, 1992, EARTHQUAKE ENG STRUC, V21, P945, DOI 10.1002/eqe.4290211102; Dizhur D, 2014, ENG STRUCT, V59, P330, DOI 10.1016/j.engstruct.2013.10.026; Benjamin J. R., 1988, NP5930 EPRI; Boughton BW, 1997, BRIDGE MODIFICATION, P122; Calderini C, 2015, B EARTHQ ENG, V13, P279, DOI 10.1007/s10518-014-9678-x; Cancelliere I, 2010, ENG STRUCT, V32, P776, DOI 10.1016/j.engstruct.2009.12.005; Dizhur D, 2013, J COMPOS CONSTR, V17, DOI 10.1061/(ASCE)CC.1943-5614.0000400; EIGawady MA, 2006, J COMPOS CONSTR, V10, P50; Garmendia L, 2011, CONSTR BUILD MATER, V25, P4374, DOI 10.1016/j.conbuildmat.2011.03.065; Grande E, 2011, BRIDGE MODIFICATION, V4, P585; Griffith MC, 2013, CONSTR BUILD MATER, V49, P1032, DOI 10.1016/j.conbuildmat.2012.06.065; Grunthal G, 2001, EUROPEAN MACROSEISMI; Japan Bank for International Cooperation (JBIC) International Center for Urban Safety Engineering & OYO International Corporation, 2007, PIL STUD KNOWL ASS V; Lourenco P.B., 1996, THESIS DELFT U TECHN; Mayorca P, 2009, B EARTHQ RESISTANT S, V42, P121; Oliveira DV, 2010, J COMPOS CONSTR, V14, P312, DOI 10.1061/(ASCE)CC.1943-5614.0000086; Sakai Y, 2004, J STRUCT CONSTR ENG, V58, P71; Sathiparan N., 2013, CONSTRUCTII, V14, P3; Sathiparan N, 2013, B EARTHQ ENG, V11, P2177, DOI 10.1007/s10518-013-9502-z; Sathiparan N, 2012, EARTHQ SPECTRA, V28, P277, DOI 10.1193/1.3675357; Sathiparan N, 2014, B EARTHQ ENG, V12, P1805, DOI 10.1007/s10518-014-9587-z; Tao Y, 2011, ENG STRUCT, V33, P1594, DOI 10.1016/j.engstruct.2011.01.029; Valluzzi MR, 2001, J COMPOS CONSTR, V5, P163, DOI 10.1061/(ASCE)1090-0268(2001)5:3(163)	29	0	0	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0950-0618	1879-0526		CONSTR BUILD MATER	Constr. Build. Mater.	MAY 1	2015	82						360	375		10.1016/j.conbuildmat.2015.02.071		16	Construction & Building Technology; Engineering, Civil; Materials Science, Multidisciplinary	Construction & Building Technology; Engineering; Materials Science	CG2FL	WOS:000353090200037		
J	Ishikawa, S; Hashizume, K; Nishigori, H; Tezuka, Y; Sanbe, A; Kurosaka, D				Ishikawa, Sayano; Hashizume, Kouhei; Nishigori, Hideo; Tezuka, Yu; Sanbe, Atsushi; Kurosaka, Daijiro			Effect of Astaxanthin on Cataract Formation Induced by Glucocorticoids in the Chick Embryo	CURRENT EYE RESEARCH			English	Article						Astaxanthin; cataract; chick embryo; glucocorticoid; oxidative stress	CIGARETTE-SMOKING; IN-VIVO; METABOLIC-CHANGES; CAROTENOIDS; ANTIOXIDANT; RISK; MODEL; MICE; ASSOCIATION; INSULIN	Purpose: To examine whether astaxanthin (AST) prevent the cataract formation induced by glucocorticoid in chick embryo. Materials and methods: Hydrocortisone hemisuccinate sodium (HC) (0.5 mu mol/egg) was administered directly into the air chamber in the egg shell of chick embryo day 15. The eggs were then kept in an incubator at same conditions and administered 100 mu L of 50 (HC + AST50 group), 80 (HC + AST80 group), 100 (HC + AST100 group) mg/mL of AST solutions dissolved in dimethyl sulfoxide (DMSO) 3 h after administration of HC. In addition, non-HC treated group (treated with physiological saline without HC and 100 mu L of DMSO), HC-alone group (treated with 0.5 mu mol of HC and 100 mu L of DMSO), and AST100 group (treated with physiological saline without HC and 100 mu L of DMSO) were also incorporated. After 48 h of treatment, lenses were removed from embryo and classified into five stages according to developed opacity. The amounts of reduced glutathione in the lenses and the blood glucose levels were measured. Results: The average scores of lens opacitiy were 2.63 +/- 1.02 nmol/lens (HC-alone), 2.78 +/- 0.97 nmol/lens (HC + AST50), 2.22 +/- 1.20 nmol/lens (HC + AST80) and 1.84 +/- 0.83 nmol/lens (HC + AST100; p<0.05), respectively. Administration of AST decreased the lens opacity dose-dependently. The amounts of reduced glutathione in lenses were 11.6 +/- 2.8 nmol/lens (HC-alone), 11.3 +/- 2.7 nmol/lens (HC + AST50), 13.4 +/- 2.4 nmol/lens (HC + AST80) and 13.7 +/- 3.1 nmol/lens (HC + AST100; p<0.05), respectively. Higher levels of AST prevented loss of reduced glutathione from the lens. Conclusion: These findings support that AST protects glucocorticoid-induced cataract in chick embryo.	[Ishikawa, Sayano; Hashizume, Kouhei; Kurosaka, Daijiro] Iwate Med Univ, Sch Med, Dept Ophthalmol, Morioka, Iwate 020, Japan; [Nishigori, Hideo; Tezuka, Yu; Sanbe, Atsushi] Iwate Med Univ, Sch Pharm, Dept Pharmacotherapeut, Yahaba, Iwate, Japan	Hashizume, K (reprint author), Iwate Med Univ, Sch Med, Dept Ophthalmol, Morioka, Iwate 020, Japan.	hassixi9898@yahoo.co.jp					Sanmartin-Suarez C, 2011, J PHARMACOL TOX MET, V63, P209, DOI 10.1016/j.vascn.2010.10.004; TANAKA T, 1995, CANCER RES, V55, P4059; KRINSKY NI, 1989, FREE RADICAL BIO MED, V7, P617, DOI 10.1016/0891-5849(89)90143-3; Hiller R, 1997, ARCH OPHTHALMOL-CHIC, V115, P1113; Chew BP, 1999, ANTICANCER RES, V19, P1849; TAYLOR HR, 1988, NEW ENGL J MED, V319, P1429, DOI 10.1056/NEJM198812013192201; Guerin M, 2003, TRENDS BIOTECHNOL, V21, P210, DOI 10.1016/S0167-7799(03)00078-7; Lee SJ, 2003, MOL CELLS, V16, P97; Naguib YMA, 2000, J AGR FOOD CHEM, V48, P1150, DOI 10.1021/jf991106k; Kelly SP, 2005, J CATARACT REFR SURG, V31, P2395, DOI 10.1016/j.jcrs.2005.06.039; Krishnaiah S, 2005, INVEST OPHTH VIS SCI, V46, P58, DOI 10.1167/iovs.04-0089; Suzuki Y, 2006, EXP EYE RES, V82, P275, DOI 10.1016/j.exer.2005.06.023; Higuera-Ciapara I, 2006, CRIT REV FOOD SCI, V46, P185, DOI 10.1080/10408690590957188; Naito Y, 2004, BIOFACTORS, V20, P49; CHRISTEN WG, 1992, JAMA-J AM MED ASSOC, V268, P989; Liao JH, 2009, CHEM RES TOXICOL, V22, P518, DOI 10.1021/tx800378z; Ohgami K, 2003, INVEST OPHTH VIS SCI, V44, P2694, DOI 10.1167/iovs.02-0822; Bhuvaneswari S, 2012, CAN J PHYSIOL PHARM, V90, P1544, DOI 10.1139/y2012-119; Fukuzawa K, 1998, LIPIDS, V33, P751, DOI 10.1007/s11745-998-0266-y; HANKINSON SE, 1992, JAMA-J AM MED ASSOC, V268, P994, DOI 10.1001/jama.268.8.994; Hashimoto H, 2013, J CLIN BIOCHEM NUTR, V53, P1, DOI 10.3164/jcbn.13-6; HILLER R, 1977, AM J EPIDEMIOL, V105, P450; Jacques PF, 1991, AM J CLIN NUTR, V53, P352; Kawada H, 2009, JPN J OPHTHALMOL, V53, P531, DOI 10.1007/s10384-009-0695-2; Kobayashi M, 2000, APPL MICROBIOL BIOT, V54, P550; Kosano H, 2001, EXP EYE RES, V72, P643, DOI 10.1006/exer.2001.0997; Lee J, 1998, ANTIGONISH REV, P50; LEE JW, 1995, J OCUL PHARMACOL TH, V11, P533, DOI 10.1089/jop.1995.11.533; McCarty Catherine A, 2002, Clin Exp Optom, V85, P91; MIKI W, 1982, COMP BIOCHEM PHYS B, V71, P7, DOI 10.1016/0305-0491(82)90167-5; Murakami I, 1996, EXP EYE RES, V63, P673, DOI 10.1006/exer.1996.0161; NISHIGORI H, 1985, EXP EYE RES, V40, P445, DOI 10.1016/0014-4835(85)90157-5; Nishigori H, 2004, LIFE SCI, V75, P3027, DOI 10.1016/j.lfs.2004.04.050; NISHIGORI H, 1983, EXP EYE RES, V36, P617, DOI 10.1016/0014-4835(83)90055-6; NISHIGORI H, 1984, INVEST OPHTH VIS SCI, V25, P1051; NISHIGORI H, 1989, LIFE SCI, V45, P593, DOI 10.1016/0024-3205(89)90044-1; NISHIGORI H, 1989, EXP EYE RES, V49, P515, DOI 10.1016/S0014-4835(89)80050-8; SETOGAWA T, 1994, EXP EYE RES, V58, P689, DOI 10.1006/exer.1994.1066; Sies H, 1991, AM J MED, V91, p31S, DOI 10.1016/0002-9343(91)90281-2; SORBYE H, 1993, DIGEST DIS SCI, V38, P1243, DOI 10.1007/BF01296073; Varma SD., 1991, AM J CLIN NUTR, V53, P335; Waagbo R, 2003, J FISH DIS, V26, P213, DOI 10.1046/j.1365-2761.2003.00449.x; Watanabe H, 2000, INVEST OPHTH VIS SCI, V41, P1846; WEST S, 1989, ARCH OPHTHALMOL-CHIC, V107, P1166	44	0	0	INFORMA HEALTHCARE	LONDON	TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND	0271-3683	1460-2202		CURR EYE RES	Curr. Eye Res.	MAY	2015	40	5					535	540		10.3109/02713683.2014.935445		6	Ophthalmology	Ophthalmology	CG8RS	WOS:000353579400011		
J	Asami, Y; Nakahara, T; Asano, D; Kurauchi, Y; Mori, A; Sakamoto, K; Ishii, K				Asami, Yasuyuki; Nakahara, Tsutomu; Asano, Daiki; Kurauchi, Yuki; Mori, Asami; Sakamoto, Kenji; Ishii, Kunio			Age-Dependent Changes in the Severity of Capillary Degeneration in Rat Retina Following N-Methyl-D-Aspartate-Induced Neurotoxicity	CURRENT EYE RESEARCH			English	Article						Age; endothelial cells; excitotoxicity; retinal neuronal cells; retinal blood vessels	MODEL; SIMILARITIES; ANGIOGENESIS; VASCULATURE; ISCHEMIA; NEURONS; MK-801	Purpose: Previous studies have shown that injury to the retinal vasculature, including capillary degeneration, occurs following N-methyl-D-aspartate (NMDA)-induced neuronal cell loss, but it is unclear whether there are age-dependent differences in the severity of vascular damage. The purpose of the present study was to determine age-related changes in retinal capillary degeneration in NMDA-induced retinal damage rat model. Materials and Methods: A single intravitreal injection of NMDA (200 nmol/eye) was performed in 1-, 2-, 3-, 7- and 15-week-old male Sprague-Dawley rats. Seven days after NMDA injection, damage to retinal neurons and blood vessels were assessed by measuring the number of cells in the ganglion cell layer and the length of empty basement membrane sleeves, left behind by regressing endothelial cells, respectively. Results: At all ages examined, the NMDA-induced neurotoxicity exhibited similar levels of ganglion cell death. However, the degeneration of capillaries in NMDA-treated retina was severe during the early stages of retinal vascular development, and the degree of capillary degeneration decreased with age. Conclusion: The degree of retinal capillary degeneration in NMDA-induced retinal damage rat model decreases in an age-dependent manner. Retinal capillaries may be resistant to retinal neuronal damage in young adults.	[Asami, Yasuyuki; Nakahara, Tsutomu; Asano, Daiki; Mori, Asami; Sakamoto, Kenji; Ishii, Kunio] Kitasato Univ, Sch Pharmaceut Sci, Dept Mol Pharmacol, Tokyo 1088641, Japan; [Kurauchi, Yuki] Kumamoto Univ, Program Leading Grad Sch HIGO Hlth Life Sci Inter, Kumamoto, Japan	Nakahara, T (reprint author), Kitasato Univ, Sch Pharmaceut Sci, Dept Mol Pharmacol, Minato Ku, 5-9-1 Shirokane, Tokyo 1088641, Japan.	nakaharat@pharm.kitasato-u.ac.jp			Ministry of Education, Culture, Sports, Science and Technology of Japan [23122517, 25122712, 20590090, 23590112]	The authors report no conflicts of interest. This study was supported by Grants-in-Aid for Scientific Research on Innovative Areas (No. 23122517, T.N.; 25122712, T.N.) and Grants-in-Aid for Scientific Research (C) from the Ministry of Education, Culture, Sports, Science and Technology of Japan (No. 20590090 and No. 23590112, T.N.).	Al-Gayyar MMH, 2010, AM J PATHOL, V177, P1187, DOI 10.2353/ajpath.2010.091289; Ozaki H, 2000, AM J PATHOL, V156, P697, DOI 10.1016/S0002-9440(10)64773-6; Lam TT, 1999, INVEST OPHTH VIS SCI, V40, P2391; Stahl A, 2010, INVEST OPHTH VIS SCI, V51, P2813, DOI 10.1167/iovs.10-5176; Vorwerk CK, 1997, INVEST OPHTH VIS SCI, V38, P2038; Saint-Geniez M, 2004, INT J DEV BIOL, V48, P1045, DOI 10.1387/ijdb.041895ms; Guerin MB, 2011, CLIN EXP OPHTHALMOL, V39, P243, DOI 10.1111/j.1442-9071.2011.02496.x; Ueda K, 2013, EUR J PHARMACOL, V699, P188, DOI 10.1016/j.ejphar.2012.11.054; Nakazawa T, 2007, J NEUROCHEM, V100, P1018, DOI 10.1111/j.1471-4159.2006.04274.x; STONE J, 1995, J NEUROSCI, V15, P4738; Gu XL, 2002, INVEST OPHTH VIS SCI, V43, P496; Morizane C, 1997, EUR J PHARMACOL, V328, P45, DOI 10.1016/S0014-2999(97)83026-9; Hernandez C, 2012, CURR DIABETES REP, V12, P329, DOI 10.1007/s11892-012-0284-5; Sapieha P, 2008, NAT MED, V14, P1067, DOI 10.1038/nm.1873; Tsuda Y, 2012, BIOL PHARM BULL, V35, P2209; Fruttiger M, 1996, NEURON, V17, P1117, DOI 10.1016/S0896-6273(00)80244-5; Solberg Y, 1997, INVEST OPHTH VIS SCI, V38, P1380; Zheng L, 2007, INVEST OPHTH VIS SCI, V48, P361, DOI 10.1167/iovs.06-0510; Lam TT, 1997, J OCUL PHARMACOL TH, V13, P129, DOI 10.1089/jop.1997.13.129; Izumi Y, 1995, NEUROBIOL DIS, V2, P139, DOI 10.1006/nbdi.1995.0015; Sha O, 2008, NEUROEMBRYOL AGING, V4, P183; SILIPRANDI R, 1992, VISUAL NEUROSCI, V8, P567; Ueda K, 2010, NEUROSCI LETT, V485, P55, DOI 10.1016/j.neulet.2010.08.061	23	0	0	INFORMA HEALTHCARE	LONDON	TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND	0271-3683	1460-2202		CURR EYE RES	Curr. Eye Res.	MAY	2015	40	5					549	553		10.3109/02713683.2014.933851		5	Ophthalmology	Ophthalmology	CG8RS	WOS:000353579400013		
J	Kamiya, A; Chikada, H				Kamiya, Akihide; Chikada, Hiromi			Human pluripotent stem cell-derived cholangiocytes: current status and future applications	CURRENT OPINION IN GASTROENTEROLOGY			English	Review						cholangiocyte; embryonic stem cell; hepatic progenitor cell; inducible pluripotent stem cell	POLYCYSTIC LIVER-DISEASE; FUNCTIONAL HUMAN LIVER; ORGAN BUD TRANSPLANT; PROGENITOR CELLS; FATE DECISION; BIPOTENT PROGENITOR; DIFFERENTIATION; CULTURE; FIBROBLASTS; EXPRESSION	Purpose of review Pluripotent stem cells, such as embryonic stem cells and inducible pluripotent stem (iPS) cells, have high proliferative multipotency for differentiation into mature functional cells that are useful for treatment and basic research on several diseases. Cholangiocytes are differentiated from fetal hepatic progenitor cells (hepatoblasts) and are important for transport of bile acids that are synthesized by mature hepatocytes in the liver. However, the molecular mechanisms of development and function of human cholangiocytes remain unknown. This review mentions the potential of human cholangiocytic culture from pluripotent stem cells to contribute to the analyses of the human bile duct system and diseases. Recent findings Recent studies found that human hepatic cholangiocytic cells can be differentiated from human embryonic stem and iPS cells in a suitable culture condition. Cholangiocytic cysts have epithelial cell polarity formed in a three-dimensional cell culture system using extracellular matrices. Summary Disease pathogenesis was elucidated in vitro using differentiated cells from disease-related iPS cells. Using genome-editing enzymes, iPS cells with disease-specific gene mutations can be easily and rapidly established. These disease-related iPS cells and cholangiocytic culture system may be useful for analyses and drug screening of human bile duct diseases.	[Kamiya, Akihide; Chikada, Hiromi] Tokai Univ, Inst Innovat Sci & Technol, Lab Stem Cell Therapy, Isehara, Kanagawa 2591193, Japan	Kamiya, A (reprint author), Tokai Univ, Inst Innovat Sci & Technol, Lab Stem Cell Therapy, 143 Shimokasuya, Isehara, Kanagawa 2591193, Japan.	kamiyaa@tokai-u.jp			Ministry of Education, Culture, Sports, Science and Technology of Japan; Ministry of Heath, Labour and Welfare of Japan	The studies described in this review article were supported in part by the Grants-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology of Japan, and the Ministry of Heath, Labour and Welfare of Japan.	Rossi JM, 2001, GENE DEV, V15, P1998, DOI 10.1101/gad.904601; Oikawa T, 2009, GASTROENTEROLOGY, V136, P1000, DOI 10.1053/j.gastro.2008.11.018; Dianat N, 2014, HEPATOLOGY, V60, P700, DOI 10.1002/hep.27165; Gerbal-Chaloin S, 2014, AM J PATHOL, V184, P332, DOI 10.1016/j.ajpath.2013.09.026; Okada K, 2012, STEM CELLS DEV, V21, P1124, DOI 10.1089/scd.2011.0229; EVANS MJ, 1981, NATURE, V292, P154, DOI 10.1038/292154a0; Tanimizu N, 2007, MOL BIOL CELL, V18, P1472, DOI 10.1091/mbc.E06-09-0848; Takebe T, 2013, NATURE, V499, P481, DOI 10.1038/nature12271; Davila S, 2004, NAT GENET, V36, P575, DOI 10.1038/ng1357; Lu HF, 2005, ACTA BIOMATER, V1, P399, DOI 10.1016/j.actbio.2005.04.003; Lemaigre FP, 2009, GASTROENTEROLOGY, V137, P62, DOI 10.1053/j.gastro.2009.03.035; Cerec V, 2007, HEPATOLOGY, V45, P957, DOI 10.1002/hep.21536; Egawa N, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3004052; Kamiya A, 1999, EMBO J, V18, P2127, DOI 10.1093/emboj/18.8.2127; KOIDE N, 1989, BIOCHEM BIOPH RES CO, V161, P385, DOI 10.1016/0006-291X(89)91609-4; Takayama K, 2014, DEVELOPMENT, V141, P91, DOI 10.1242/dev.103168; Antoniou A, 2009, GASTROENTEROLOGY, V136, P2325, DOI 10.1053/j.gastro.2009.02.051; Takahashi K, 2007, CELL, V131, P861, DOI 10.1016/j.cell.2007.11.019; Gaj T, 2013, TRENDS BIOTECHNOL, V31, P397, DOI 10.1016/j.tibtech.2013.04.004; Jung JN, 1999, SCIENCE, V284, P1998, DOI 10.1126/science.284.5422.1998; Takayama K, 2013, STEM CELL REP, V1, P322, DOI 10.1016/j.stemcr.2013.08.006; Clotman F, 2005, GENE DEV, V19, P1849, DOI 10.1101/gad.340305; Zong YW, 2009, DEVELOPMENT, V136, P1727, DOI 10.1242/dev.029140; PERRY ST, 1983, J CELL BIOCHEM, V21, P47, DOI 10.1002/jcb.240210107; Takebe T, 2014, NAT PROTOC, V9, P396, DOI 10.1038/nprot.2014.020; Zhao R, 2005, HEPATOLOGY, V41, P956, DOI 10.1002/hep.20691; Yamasaki H, 2006, DEVELOPMENT, V133, P4233, DOI 10.1242/dev.02591; Si-Tayeb K, 2010, HEPATOLOGY, V51, P297, DOI 10.1002/hep.23354; Drenth JPH, 2003, NAT GENET, V33, P345, DOI 10.1038/ng1104; Douarin N M, 1975, Med Biol, V53, P427; Everson GT, 2004, HEPATOLOGY, V40, P774, DOI 10.1002/hep.20431; HOUSSAINT E, 1980, CELL DIFFER DEV, V9, P269, DOI 10.1016/0045-6039(80)90026-3; Kamiya A, 2009, GASTROENTEROLOGY, V137, P1114, DOI 10.1053/j.gastro.2009.06.001; Tanimizu N, 2014, DEVELOPMENT, V141, P4448, DOI 10.1242/dev.113654; Yanagida A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067541; Zhao DX, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006468	36	1	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0267-1379	1531-7056		CURR OPIN GASTROEN	Curr. Opin. Gastroenterol.	MAY	2015	31	3					233	238		10.1097/MOG.0000000000000180		6	Gastroenterology & Hepatology	Gastroenterology & Hepatology	CG5EA	WOS:000353312700009		
J	Suzuki, A				Suzuki, Atsushi			Evidence of cell-fate conversion from hepatocytes to cholangiocytes in the injured liver: in-vivo genetic lineage-tracing approaches	CURRENT OPINION IN GASTROENTEROLOGY			English	Review						chronic liver injury; intrahepatic cholangiocarcinoma; liver; Notch signaling; progenitor cell	HEPATIC PROGENITOR CELLS; INTRAHEPATIC CHOLANGIOCARCINOMA; MOUSE-LIVER; HEPATOCELLULAR-CARCINOMA; STEM-CELLS; REGENERATION; THIOACETAMIDE; MICE; DIFFERENTIATION; HOMEOSTASIS	Purpose of review Recently, it has been suggested that hepatocytes can potentially convert their fate into that of cholangiocytes when the liver receives an injury. This review concisely summarizes these new findings, especially those obtained in studies using cell-lineage tracing methods. Recent findings Recent advances in technologies using mutant mice with a tamoxifen-inducible Cre/loxP system have allowed heritable labeling of a particular type of cell and enabled us to follow the fate of their progeny. This is generally known as 'genetic lineage-tracing', and has been applied in various studies that require tracking of the fate of cells in living mice. Previous studies using these methods have revealed that hepatocytes themselves can give rise to cholangiocytes through Notch-mediated cell-fate conversion from hepatocytes to cholangiocytes in injured liver tissue and at the onset of liver cancer. Summary Intensive studies using in-vivo genetic lineage-tracing approaches have provided new insights into the nature of cellular identity and plasticity in the liver, which will contribute to the development of new therapeutic strategies for liver diseases.	[Suzuki, Atsushi] Kyushu Univ, Med Inst Bioregulat, Div Organogenesis & Regenerat, Fukuoka 8128582, Japan; [Suzuki, Atsushi] Japan Sci & Technol Agcy, Core Res Evolut Sci & Technol CREST, Saitama, Japan	Suzuki, A (reprint author), Kyushu Univ, Med Inst Bioregulat, Div Organogenesis & Regenerat, Higashi Ku, 3-1-1 Maidashi, Fukuoka 8128582, Japan.	suzukicks@bioreg.kyushu-u.ac.jp					Blechacz B, 2008, HEPATOLOGY, V48, P308, DOI 10.1002/hep.22310; Libbrecht L, 2002, SEMIN CELL DEV BIOL, V13, P389, DOI 10.1016/S1084-9521(02)00125-8; Fan B, 2012, J CLIN INVEST, V122, P2911, DOI 10.1172/JCI63212; Suzuki A, 2008, HEPATOLOGY, V48, P1964, DOI 10.1002/hep.22558; Lee CH, 2009, BRIT J CANCER, V100, P1765, DOI 10.1038/sj.bjc.6605063; Gatto M, 2010, DIGEST LIVER DIS, V42, P253, DOI 10.1016/j.dld.2009.12.008; DESMET V, 1995, PATHOL RES PRACT, V191, P513; Okabe M, 2009, DEVELOPMENT, V136, P1951, DOI 10.1242/dev.031369; Furuyama K, 2011, NAT GENET, V43, P34, DOI 10.1038/ng.722; Malato Y, 2011, J CLIN INVEST, V121, P4850, DOI 10.1172/JCI59261; Lemaigre FP, 2009, GASTROENTEROLOGY, V137, P62, DOI 10.1053/j.gastro.2009.03.035; Espanol-Suner R, 2012, GASTROENTEROLOGY, V143, P1564, DOI 10.1053/j.gastro.2012.08.024; HUNTER AL, 1977, J PHARMACOL EXP THER, V200, P439; Shin S, 2011, GENE DEV, V25, P1185, DOI 10.1101/gad.2027811; ANUNDI I, 1993, BIOCHEM PHARMACOL, V45, P1251, DOI 10.1016/0006-2952(93)90277-4; Sekiya S, 2012, J CLIN INVEST, V122, P3914, DOI 10.1172/JCI63065; Si-Tayeb K, 2010, DEV CELL, V18, P175, DOI 10.1016/j.devcel.2010.01.011; Yanger K, 2013, GENE DEV, V27, P719, DOI 10.1101/gad.207803.112; Zong YW, 2009, DEVELOPMENT, V136, P1727, DOI 10.1242/dev.029140; Wang T, 2000, J PHARMACOL EXP THER, V294, P473; Sekiya S, 2014, AM J PATHOL, V184, P1468, DOI 10.1016/j.ajpath.2014.01.005; Dumble ML, 2002, CARCINOGENESIS, V23, P435, DOI 10.1093/carcin/23.3.435; Michalopoulos GK, 2005, HEPATOLOGY, V41, P535, DOI 10.1002/hep.20600; Shaib YH, 2005, GASTROENTEROLOGY, V128, P620, DOI 10.1053/j.gastro.2004.12.048; Sempoux C, 2011, SEMIN LIVER DIS, V31, P49, DOI 10.1055/s-0031-1272839; Dorrell C, 2011, GENE DEV, V25, P1193, DOI 10.1101/gad.2029411; Duncan AW, 2009, GASTROENTEROLOGY, V137, P466, DOI 10.1053/j.gastro.2009.05.044; Miyajima A, 2014, CELL STEM CELL, V14, P561, DOI 10.1016/j.stem.2014.04.010; OINONEN T, 1993, FEBS LETT, V327, P237, DOI 10.1016/0014-5793(93)80176-U; PORTER WR, 1978, DRUG METAB DISPOS, V6, P379; Suzuki A, 2013, CURR OPIN GENET DEV, V23, P579, DOI 10.1016/j.gde.2013.04.006; Takashima Y, HEPATOLOGY	32	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0267-1379	1531-7056		CURR OPIN GASTROEN	Curr. Opin. Gastroenterol.	MAY	2015	31	3					247	251		10.1097/MOG.0000000000000172		5	Gastroenterology & Hepatology	Gastroenterology & Hepatology	CG5EA	WOS:000353312700011		
J	Takahashi, N; Takahashi, K; Kobayashi, M; Yada, Y; Koike, Y; Kono, Y				Takahashi, Naoto; Takahashi, Kayo; Kobayashi, Mami; Yada, Yukari; Koike, Yasunori; Kono, Yumi			Constitutively high-level expression of TGF beta isoforms in cord blood and its relationship to perinatal findings	CYTOKINE			English	Article						TGF beta; Isoforms; Cord blood; Newborn infants; Cytokine profile	TRANSFORMING GROWTH-FACTOR-BETA-1; ALLERGIC MOTHERS; GROWTH-FACTORS; FETAL-GROWTH; PREMATURITY; CYTOKINES; CHILDREN; HEALTHY; CELLS; MILK	Background: The clinical significance of TGF beta isoforms in cord blood is not well understood. Methods: We obtained cord blood samples from 37 term infants and 85 preterm infants who were born in several clinical settings. The serum levels of 3 TGF beta isoforms and of the other 17 cytokines in cord blood were investigated using cytometric bead array technology. Results: Very high levels of TGF beta 1and TGF beta 2 isoforms compared to the level of other cytokines were found; mean levels were 44,180 and 1871 pg/mL, respectively. The levels of all 3 isoforms of TGF beta were significantly correlated with birth weight, and the levels of TGF beta 1 and TGF beta 3 were correlated with gestational age. The levels of TGF beta 1 and beta 2 isoforms were strongly correlated with each other, but not with levels of other cytokines. The levels of TGF beta 1 and TGF beta 2 were ignificantly higher in male infants and significantly lower in infants with fetal growth restriction. The prevalence of chronic lung disease was related to a low level of TGF beta 1, and that of patent ductus arteriosus was related to a high level of TGF beta 1 in preterm infants. Conclusions: TGF beta 1 and TGF beta 2 appeared to play a significant role in physiological and pathological conditions in the fetus. TGF beta isoform levels appear to be regulated independently of those of other cytokines and do not appear to be influenced by inflammation in the fetal period. The role of TGF beta 3 in cord blood and the postnatal chronological changes of the TGF beta isoforms should be investigated in the future. 0 2015 Elsevier Ltd. All rights reserved.	[Takahashi, Naoto] Univ Tokyo, Dept Pediat, Bunkyo Ku, Tokyo 1138655, Japan; [Takahashi, Naoto; Kobayashi, Mami; Yada, Yukari; Koike, Yasunori; Kono, Yumi] Jichi Med Univ, Sch Med, Dept Pediat, Shimotsuke, Tochigi 3290498, Japan; [Takahashi, Kayo] Jichi Med Univ, Sch Med, Dept Obstet & Gynecol, Shimotsuke, Tochigi 3290498, Japan	Takahashi, N (reprint author), Univ Tokyo, Dept Pediat, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1138655, Japan.	tnaoto-tky@umin.ac.jp			Japan Society for the Promotion of Sciences (JSPS) [22390215]; Japanese Ministry of Welfare and Labor [H25-Health Research on Children, Youth and Families-Ippan-005]	This research was supported by Japan Society for the Promotion of Sciences (JSPS) Grant-in-Aid for Scientific Research [KAKENHI] Grant No. 22390215 and Health and Labour Sciences Research Grants from the Japanese Ministry of Welfare and Labor Grant No. H25-Health Research on Children, Youth and Families-Ippan-005.	Rautava S, 2009, BREASTFEED MED, V4, P4, DOI 10.1089/bfm.2009.0004; Oddy WH, 2010, PEDIATR ALLERGY IMMU, V21, P47, DOI 10.1111/j.1399-3038.2009.00913.x; Penttila IA, 1998, PEDIATR RES, V44, P524, DOI 10.1203/00006450-199810000-00010; LETTERIO JJ, 1994, SCIENCE, V264, P1936, DOI 10.1126/science.8009224; Oshimori N, 2012, CELL STEM CELL, V11, P751, DOI 10.1016/j.stem.2012.11.001; Briana DD, 2012, CYTOKINE, V60, P157, DOI 10.1016/j.cyto.2012.06.005; Prokesova L, 2006, PEDIATR ALLERGY IMMU, V17, P175, DOI 10.1111/j.1399-3038.2006.00395.x; Sood BG, 2010, PEDIATR RES, V67, P394, DOI 10.1203/PDR.0b013e3181d01a36; Prossler J, 2014, CYTOKINE, V68, P9, DOI 10.1016/j.cyto.2014.03.001; Balossini V, 2009, ACTA PAEDIATR, V98, P812, DOI 10.1111/j.1651-2227.2008.01194.x; Hrdy J, 2010, FOLIA MICROBIOL, V55, P515, DOI 10.1007/s12223-010-0085-7; Kotecha S, 1996, J PEDIATR-US, V128, P464, DOI 10.1016/S0022-3476(96)70355-4; Kumar P, 2011, EARLY HUM DEV, V87, P559, DOI 10.1016/j.earlhumdev.2011.04.013; Ostlund E, 2002, OBSTET GYNECOL, V100, P567, DOI 10.1016/S0029-7844(02)02173-7; Soleymaninejadian E, 2012, AM J REPROD IMMUNOL, V67, P1, DOI 10.1111/j.1600-0897.2011.01069.x; Speer CP, 2006, J PERINATOL, V26, pS57, DOI 10.1038/sj.jp.7211476; Takahashi N, 2010, CYTOKINE, V49, P331, DOI 10.1016/j.cyto.2009.11.024	17	0	0	ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD	LONDON	24-28 OVAL RD, LONDON NW1 7DX, ENGLAND	1043-4666	1096-0023		CYTOKINE	Cytokine	MAY	2015	73	1					101	107		10.1016/j.cyto.2015.01.024		7	Biochemistry & Molecular Biology; Cell Biology; Immunology	Biochemistry & Molecular Biology; Cell Biology; Immunology	CG2AY	WOS:000353078500015		
J	Park, E; Ch, HB; Takimoto, K				Park, Eulsoon; Ch, Hong-Baek; Takimoto, Koichi			Effective gene delivery into adipose-derived stem cells: transfection of cells in suspension with the use of a nuclear localization signal peptide-conjugated polyethylenimine	CYTOTHERAPY			English	Article						adipose tissue; adult stem cell; polyethylenimine; transfection	PROTEIN-PRODUCTION; DIFFERENTIATION; PLURIPOTENCY; EXPRESSION	Background aims. Adipose-derived stem cells have the ability to turn into several clinically important cell types. However, it is difficult to transfect these cells with the use of conventional cationic lipid-based reagents. Polyethylenimine (PEI) is considered to be an inexpensive and effective tool for delivery of nucleic acids into mammalian cells. Methods. We used a linear PEI conjugated with the nuclear localization signal (NLS) peptide of Simian vacuolating virus 40 large T antigen (PEI-NLS) for transfection of plasmid DNA into adipose-derived cells. We also tested if transfection of cells in suspension might improve the degree and duration of exogenous gene expression. Results. Transfection of cells in suspension with the use of a PEI conjugated with an NLS peptide resulted in high levels of reporter gene expression for an extended period of time in clonal 3T3-L1 preadipocytes and native human adipose-derived stem cells. The reporter gene expression increased for 3 days after the addition of the PEI-NLS peptide-DNA mixture in cell suspension and remained significant for at least 7 days. Cell density did not influence the level of reporter gene expression. Thus, the suspension method with the use of an NLS peptide conjugated PEI leads to a robust and sustained expression of exogenous genes in adipose-derived cells. Conclusions. The devised transfection method may be useful for reprogramming of adipose-derived stem cells and cell-based therapy.	[Park, Eulsoon; Takimoto, Koichi] Nagaoka Univ Technol, Dept Bioengn, Nagaoka, Niigata 9402188, Japan; [Ch, Hong-Baek] Nagaoka Univ Technol, Extreme Energy Dens Res Inst, Nagaoka, Niigata 94021, Japan	Takimoto, K (reprint author), Nagaoka Univ Technol, Dept Bioengn, 1603-1 Kamitomioka, Nagaoka, Niigata 9402188, Japan.	koichi@vos.nagaokaut.ac.jp					Brunner S, 2002, MOL THER, V5, P80, DOI 10.1006/mthe.2001.0509; Lungwitz U, 2005, EUR J PHARM BIOPHARM, V60, P247, DOI 10.1016/j.ejpb.2004.11.011; Hanna JH, 2010, CELL, V143, P508, DOI 10.1016/j.cell.2010.10.008; Durocher Y, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.2.e9; Vierbuchen T, 2012, MOL CELL, V47, P827, DOI 10.1016/j.molcel.2012.09.008; Hu QL, 2012, BIOMATERIALS, V33, P1135, DOI 10.1016/j.biomaterials.2011.10.023; Yamano S, 2014, BIOMATERIALS, V35, P1705, DOI 10.1016/j.biomaterials.2013.11.012; Yoshida Y, 2012, CIRC RES, V111, P3, DOI 10.1161/CIRCRESAHA.112.271445; Chambers SM, 2011, CELL, V145, P827, DOI 10.1016/j.cell.2011.05.036; Sugii S, 2010, P NATL ACAD SCI USA, V107, P3558, DOI 10.1073/pnas.0910172106; Watanabe A, 2013, PHILOS T R SOC B, V368, DOI 10.1098/rstb.2012.0292; Gimble JM, 2003, CYTOTHERAPY, V5, P362, DOI 10.1080/14653240310003026; Baldi L, 2005, BIOTECHNOL PROGR, V21, P148, DOI 10.1021/bp049830x; Tait AS, 2004, BIOTECHNOL BIOENG, V88, P707, DOI 10.1002/bit.20265; Chen JX, 2012, CIRC RES, V111, P50, DOI 10.1161/CIRCRESAHA.112.270264; Neu M, 2005, J GENE MED, V7, P992, DOI 10.1002/jgm.773; Godbey WT, 1999, J BIOMED MATER RES, V45, P268, DOI 10.1002/(SICI)1097-4636(19990605)45:3<268::AID-JBM15>3.0.CO;2-Q; Bunnell Bruce A., 2008, V456, P155, DOI 10.1007/978-1-59745-245-8_12; Takimoto K, 2002, J BIOL CHEM, V277, P26904, DOI 10.1074/jbc.M203651200; Yamano S, 2011, J CONTROL RELEASE, V152, P278, DOI 10.1016/j.jconrel.2011.02.004	20	0	0	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	1465-3249	1477-2566		CYTOTHERAPY	Cytotherapy	MAY	2015	17	5					536	542		10.1016/j.jcyt.2014.11.008		7	Cell & Tissue Engineering; Biotechnology & Applied Microbiology; Cell Biology; Hematology; Medicine, Research & Experimental	Cell Biology; Biotechnology & Applied Microbiology; Hematology; Research & Experimental Medicine	CG5VQ	WOS:000353364400003		
J	Shimazu, T; Mori, Y; Takahashi, A; Tsunoda, H; Tojo, A; Nagamura-Inoue, T				Shimazu, Takahisa; Mori, Yuka; Takahashi, Atsuko; Tsunoda, Hajime; Tojo, Arinobu; Nagamura-Inoue, Tokiko			Serum- and xeno-free cryopreservation of human umbilical cord tissue as mesenchymal stromal cell source	CYTOTHERAPY			English	Article						cryopreservation; immunosuppression; mesenchymal stromal cell; umbilical cord	THERAPY POSITION STATEMENT; STEM-CELLS; BONE-MARROW; INTERNATIONAL-SOCIETY; EXPANSION	Background aims. Human umbilical cord (UC) has become a notable source for mesenchymal stromal cells (MSCs) that can migrate to areas of inflammation and damaged tissue and can suppress excess immune reactions and to repair, respectively. Although UC is a solid tissue, there are several advantages, including repeatable uses from the same donor sample when needed and the possibility of future explorations for cells with unknown potential, if we could cryopreserve the UC as a living tissue material. However, because the cryoprotectants in the previous reports included animal- or allogeneic human-derived serum or no serum, the frozen-thawed UC-MSCs were inferior to fresh UC-MSCs in cell proliferation. The objective of this study was to find a suitable cryopreservation method of UC for clinical use. Methods. The UC was cut in cross-section and incised longitudinally, immersed in the cryoprotectant and frozen slowly. Later, it was thawed and minced rapidly, and the fragments of UC were cultured by improved explant method. Results. The highest yield of cells was obtained from frozen-thawed UC with serum- and xeno-free cryoprotectant, STEM-CELLBANKER, when compared with others. The cells derived from frozen-thawed UC stored in STEM-CELLBANKER expressed the phenotypes of MSCs, retained the immunosuppressive properties in allogeneic mixed lymphocyte reactions and the differentiation potentials (into adipocyte and chondrocytes) comparable to those derived from fresh UC. Conclusions. UC can be cryopreserved in serum- and xeno-free cryoprotectant as a living tissue while keeping its growth and functions equivalent to fresh UC. Our method is simple and feasible for clinical use.	[Shimazu, Takahisa; Mori, Yuka; Takahashi, Atsuko; Tojo, Arinobu; Nagamura-Inoue, Tokiko] Univ Tokyo, Dept Cell Proc & Transfus, Inst Med Sci, Tokyo 1088639, Japan; [Tsunoda, Hajime] NTT Med Ctr Tokyo Hosp, Dept Obstet, Tokyo, Japan; [Tojo, Arinobu] Univ Tokyo, Div Mol Therapy, Inst Med Sci, Ctr Adv Med Res, Tokyo 1088639, Japan	Nagamura-Inoue, T (reprint author), Univ Tokyo, Dept Cell Proc & Transfus, Inst Med Sci, Minato Ku, 4-6-1Shirokanedai, Tokyo 1088639, Japan.	tokikoni@ims.u-tokyo.ac.jp			Ministry of Health, Labor and Welfare [H24-Intractable disease-016, H26-Regeneration-010]; University of Tokyo; Wanbishi Archives Cor.	This study was supported by Grants-in-Aid for Scientific Research from the Ministry of Health, Labor and Welfare (H24-Intractable disease-016 and H26-Regeneration-010). The study was partially supported by a joint research study of the University of Tokyo with Wanbishi Archives Cor. for the employment of T. Shimazu. We thank Mr K. Saze, Mr T. Sato and Dr H. Kodama of ZENOAQ Resource Co, Ltd, Japan, for their assistance with valuable information. We also thank the staff of the NTT Medical Center Hospital, Tokyo, for their assistance with the collection of UC and CB.	Al-Saqi SH, 2014, CELL TISSUE BANK, P1; Gnecchi Massimiliano, 2009, V482, P281, DOI 10.1007/978-1-59745-060-7_18; in't Anker PS, 2004, STEM CELLS, V22, P1338, DOI 10.1634/stemcells.2004-0058; Jin JL, 2013, CURR NEUROVASC RES, V10, P11; Horwitz EM, 2005, CYTOTHERAPY, V7, P393, DOI 10.1080/14653240500319234; RUBINSTEIN P, 1995, P NATL ACAD SCI USA, V92, P10119, DOI 10.1073/pnas.92.22.10119; Roy S, 2014, CRYOBIOLOGY, V68, P467, DOI 10.1016/j.cryobiol.2014.03.010; Seshareddy K, 2008, METHOD CELL BIOL, V86, P101, DOI 10.1016/S0091-679X(08)00006-X; Han YF, 2013, CYTOTECHNOLOGY, V65, P819, DOI 10.1007/s10616-012-9528-0; Hsieh JY, 2010, STEM CELLS DEV, V19, P1895, DOI 10.1089/scd.2009.0485; Salehinejad P, 2012, IN VITRO CELL DEV-AN, V48, P75, DOI 10.1007/s11626-011-9480-x; Ishige I, 2009, INT J HEMATOL, V90, P261, DOI 10.1007/s12185-009-0377-3; Dominici M, 2006, CYTOTHERAPY, V8, P315, DOI 10.1080/14653240600855905; Holm F, 2010, HUM REPROD, V25, P1271, DOI 10.1093/humrep/deq040; Tong CK, 2011, CELL BIOL INT, V35, P221, DOI 10.1042/CBI20100326; Bieback Karen, 2007, Curr Stem Cell Res Ther, V2, P310, DOI 10.2174/157488807782793763; Ennis J, 2008, METHOD CELL BIOL, V86, P121, DOI 10.1016/S0091-679X(08)00007-1; Gruber HE, 2010, TISSUE ENG PT A, V16, P2843, DOI 10.1089/ten.TEA.2009.0709; He HP, 2014, TISSUE ENG PT A, V20, P1314, DOI [10.1089/ten.TEA.2013.0333, 10.1089/ten.tea.2013.0333]; Illouz S, 2008, TRANSPL P, V40, P1706, DOI 10.1016/j.transproceed.2008.01.064; Margossian T, 2012, BIO-MED MATER ENG, V22, P243, DOI 10.3233/BME-2012-0714; Mori Y, 2015, TISSUE ENG PART C-ME, V21, P1; Prasanna SJ, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009016; Saliem Mohammed, 2012, World J Hepatol, V4, P176, DOI 10.4254/wjh.v4.i5.176; Santos JM, 2013, J TRANSL MED, V11, DOI 10.1186/1479-5876-11-18; Wang L, 2013, CASE REP TRANSPLANT, V2013, DOI DOI 10.1155/2013/146347; Wei L, 2014, J TRANSL MED, V12, DOI 10.1186/s12967-014-0246-6	27	1	1	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	1465-3249	1477-2566		CYTOTHERAPY	Cytotherapy	MAY	2015	17	5					593	600		10.1016/j.jcyt.2015.03.604		8	Cell & Tissue Engineering; Biotechnology & Applied Microbiology; Cell Biology; Hematology; Medicine, Research & Experimental	Cell Biology; Biotechnology & Applied Microbiology; Hematology; Research & Experimental Medicine	CG5VQ	WOS:000353364400008		
J	Yokoyama, Y; Watanabe, K; Ito, H; Nishishita, M; Sawada, K; Okuyama, Y; Okazaki, K; Fujii, H; Nakase, H; Masuda, T; Fukunaga, K; Andoh, A; Nakamura, S				Yokoyama, Yoko; Watanabe, Kenji; Ito, Hiroaki; Nishishita, Masakazu; Sawada, Koji; Okuyama, Yusuke; Okazaki, Kazuichi; Fujii, Hisao; Nakase, Hiroshi; Masuda, Tsutomu; Fukunaga, Ken; Andoh, Akira; Nakamura, Shiro			Factors associated with treatment outcome, and long-term prognosis of patients with ulcerative colitis undergoing selective depletion of myeloid lineage leucocytes: a prospective multicenter study	CYTOTHERAPY			English	Article						long-term prognosis; myeloid lineage leucocytes; platelets; predictive factor of response to therapy; ulcerative colitis	INFLAMMATORY-BOWEL-DISEASE; MONOCYTE ADSORPTIVE APHERESIS; JAPANESE PATIENTS; CROHNS-DISEASE; CORTICOSTEROID-THERAPY; INTENSIVE GRANULOCYTE; PROSPECTIVE COHORT; CLINICAL-RESPONSE; INFLIXIMAB; LEUCOCYTAPHERESIS	Background. Patients with ulcerative colitis (UC) have elevated/activated myeloid lineage leucocytes and may respond favorably to adsorptive granulocyte/monocyte apheresis (GMA). However, there are patients who respond well to GMA, and patients who do not benefit. Therefore, predictive factors of GMA efficacy need to be defined. Methods. In a prospective multicenter setting, 200 UC patients at 32 institutes received one GMA session per week over 10 weeks. Patients who achieved remission were followed for 12 months. The Clinical Activity Index (CAI) <= 3 meant remission, and response meant CAI decreased by >= 3. Quality of life was evaluated by the Inflammatory Bowel Disease Questionnaire (IBDQ). Results. After final GMA, remission, response and no response rates were 67.0%, 15.0% and 18%, respectively. The remission group had a significant decrease in myeloid leucocytes and platelets. Corticosteroid dose decreased (P < 0.001); 49 Of 97 patients on corticosteroids became steroid-free. Baseline CAI was lower in the remission group versus non-remission (P < 0.01), whereas IBDQ was higher in the remission group versus non-remission (P < 0.05). After 12 months, 52 of 134 patients had maintained remission. Disease duration was longer in the relapsed group versus maintained remission group (P = 0.041). Male gender, first UC episode and corticosteroid responder were significant factors for maintaining remission, whereas corticosteroid dependent UC was associating with relapse. Discussion. Selective myeloid leucocyte depletion was effective for remission induction and improving patients' quality of life. Baseline demographics such as disease activity level, duration and corticosteroid dependency appear to predict response to GMA. Additionally, patients with a first UC episode who were drug naive responded well to GMA and achieved a favorable long-term disease course by avoiding pharmacologics from an early stage of their inflammatory bowel disease. These findings should help to end unnecessary use of medical resources by targeting GMA to patients who may respond well.	[Yokoyama, Yoko; Fukunaga, Ken; Nakamura, Shiro] Hyogo Coll Med, Div Internal Med, Dept Inflammatory Bowel Dis, Nishinomiya, Hyogo 6638501, Japan; [Watanabe, Kenji] Osaka City Gen Hosp, Dept Gastroenterol, Osaka, Japan; [Ito, Hiroaki] Kinshukai Infus Clin, Osaka, Japan; [Nishishita, Masakazu] Nishishita Intestinal Hosp, Osaka, Japan; [Sawada, Koji] Dojima Digest Tract Internal Med Clin, Osaka, Japan; [Okuyama, Yusuke] Japan Red Cross Kyoto Daiichi Hosp, Dept Gastroenterol, Kyoto, Japan; [Okazaki, Kazuichi] Kansai Med Univ, Dept Gastroenterol & Hepatol, Osaka, Japan; [Fujii, Hisao] Nara Med Univ, Dept Endoscopy & Ultrasound, Nara, Japan; [Nakase, Hiroshi] Kyoto Univ, Grad Sch Med, Div Gastroenterol & Hepatol, Kyoto, Japan; [Masuda, Tsutomu] Ikoma Clin, Gastroenterol & Proctol, Osaka, Japan; [Andoh, Akira] Shiga Univ, Sch Med, Div Gastroenterol, Hikone, Shiga, Japan; [Fukunaga, Ken] Chyokyu Hosp, Himeji, Hyogo, Japan	Yokoyama, Y (reprint author), Hyogo Coll Med, Div Internal Med, Dept Inflammatory Bowel Dis, 1-1 Mukogawa, Nishinomiya, Hyogo 6638501, Japan.	yoko0502@hyo-med.ac.jp					Akerkar GA, 1997, AM J GASTROENTEROL, V92, P461; Colombel JF, 2011, GASTROENTEROLOGY, V141, P1194, DOI 10.1053/j.gastro.2011.06.054; Hanai H, 2011, CLIN EXP IMMUNOL, V163, P50, DOI 10.1111/j.1365-2249.2010.04279.x; Reinisch W, 2012, INFLAMM BOWEL DIS, V18, P201, DOI 10.1002/ibd.21697; Lichtenstein GR, 2012, AM J GASTROENTEROL, V107, P1409, DOI 10.1038/ajg.2012.218; LICHTIGER S, 1994, NEW ENGL J MED, V330, P1841, DOI 10.1056/NEJM199406303302601; Hanai H, 2003, CLIN GASTROENTEROL H, V1, P28, DOI 10.1053/jcgh.2003.50005; Sakuraba A, 2009, AM J GASTROENTEROL, V104, P2990, DOI 10.1038/ajg.2009.453; MATTS SG, 1961, Q J MED, V30, P393; Saniabadi AR, 2007, TRANSFUS APHER SCI, V37, P191, DOI 10.1016/j.transci.2007.08.003; Faubion WA, 2001, GASTROENTEROLOGY, V121, P255, DOI 10.1053/gast.2001.26279; Hibi T, 2009, DIGEST LIVER DIS, V41, P570, DOI 10.1016/j.dld.2008.11.020; Ali T, 2009, AM J MED, V122, P599, DOI 10.1016/j.amjmed.2009.01.022; Leone V, 2013, J GASTROENTEROL, V48, P315, DOI 10.1007/s00535-013-0777-2; MCCARTHY DA, 1991, CLIN EXP IMMUNOL, V86, P489; Yamamoto T, 2012, J CROHNS COLITIS, V6, P750, DOI 10.1016/j.crohns.2011.12.009; Sands BE, 2008, GASTROENTEROLOGY, V135, P400, DOI 10.1053/j.gastro.2008.04.023; GUYATT G, 1989, GASTROENTEROLOGY, V96, P804; Yokoyama Y, 2007, DIGEST DIS SCI, V52, P2725, DOI 10.1007/s10620-006-9560-z; Xavier RJ, 2007, NATURE, V448, P427, DOI 10.1038/nature06005; Saniabadi AR, 2003, THER APHER DIAL, V7, P48, DOI 10.1046/j.1526-0968.2003.00012.x; Bewtra M, 2010, EXPERT REV CLIN IMMU, V6, P621, DOI [10.1586/eci.10.36, 10.1586/ECI.10.36]; Bratcher JM, 2006, EXPERT OPIN DRUG SAF, V5, P9, DOI 10.1517/14740338.5.1.9; Cabriada JL, 2012, J GASTROENTEROL, V47, P359, DOI 10.1007/s00535-011-0499-2; Fukuchi T, 2013, J CROHNS COLITIS, V7, P803, DOI 10.1016/j.crohns.2012.12.003; Kawakami A, 2013, J GASTROENTEROL, V48, P1006, DOI 10.1007/s00535-012-0721-x; Yokoyama Y, 2013, BMC GASTROENTEROL, V13, DOI 10.1186/1471-230X-13-27; Kuwahara E, 2012, J GASTROENTEROL, V47, P961, DOI 10.1007/s00535-012-0558-3; Mizoguchi A, 2008, J GASTROENTEROL, V43, P1; PODOLSKY DK, 1991, NEW ENGL J MED, V325, P928, DOI 10.1056/NEJM199109263251306; Sacco Rodolfo, 2013, J Crohns Colitis, V7, pe692, DOI 10.1016/j.crohns.2013.06.012; Sacco R, 2014, EXPERT REV GASTROENT, V27, P1; Suzuki Y, 2014, J GASTROENTEROL, V49, P283, DOI 10.1007/s00535-013-0922-y; Suzuki Y, 2006, DIGEST DIS SCI, V51, P2031, DOI 10.1007/s10620-006-9199-9; Suzuki Y, 2004, DIGEST DIS SCI, V49, P565, DOI 10.1023/B:DDAS.0000026299.43792.ae; Takahashi H, 2013, ARCH GYNECOL OBSTET, V288, P341, DOI 10.1007/s00404-013-2748-5; Tanaka T, 2010, GASTROEN CLIN BIOL, V34, P687, DOI 10.1016/j.gcb.2010.08.007; Tanaka T, 2013, BMC GASTROENTEROL, V13, DOI 10.1186/1471-230X-13-130; THOMAS TPL, 1984, GERONTOLOGY, V30, P60; Yamamoto T, 2015, ALIMENT PHARM THER, V41, P35; Yamamoto T, 2010, INFLAMM BOWEL DIS, V16, P1905, DOI 10.1002/ibd.21260; Yarur AJ, 2014, WORLD J GASTROENTERO, V20, P3475, DOI 10.3748/wjg.v20.i13.3475	42	0	0	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	1465-3249	1477-2566		CYTOTHERAPY	Cytotherapy	MAY	2015	17	5					680	688		10.1016/j.jcyt.2015.02.007		9	Cell & Tissue Engineering; Biotechnology & Applied Microbiology; Cell Biology; Hematology; Medicine, Research & Experimental	Cell Biology; Biotechnology & Applied Microbiology; Hematology; Research & Experimental Medicine	CG5VQ	WOS:000353364400015		
J	Hashimoto, M; Imazato, S				Hashimoto, Masanori; Imazato, Satoshi			Cytotoxic and genotoxic characterization of aluminum and silicon oxide nanoparticles in macrophages	DENTAL MATERIALS			English	Article						Oxide-nanoparticle; Aluminum; Silica; Macrophage; Cytotoxicity; Genotoxicity; Comet assay; SEM; TEM; Confocal microscopy	SILVER NANOPARTICLES; CELLULAR UPTAKE; NANO SILICA; HUMAN-CELLS; TOXICITY; PARTICLES; RESPONSES; RELEASE; IONS	Objective. Although aluminum oxide and silicon oxide nanoparticles are currently available as dental materials, there is a lack of basic information concerning their biocompatibility. This study evaluates the biological responses of cultured macrophages (RAW264) to aluminum oxide (Al(2)O(3)NPs) and silicon oxide nanoparticles (SiO(2)NPs) by analyzing cytotoxicity and genotoxicity. Methods. The nanoparticles are amorphous and spherical, with diameters of 13 nm for the Al(2)O(3)NPs and 12 nm for the SiO(2)NPs. The cultured RAW264 are exposed to the nanoparticles (NPs) and examined for cytotoxicity using the WST-8 cell viability and Hoechst/PI apoptosis assay, for genotoxicity by micronucleus analysis, for changes in nuclear shape (deformed nuclei) and for comet assay using confocal microscopy, and micromorphological analysis is done using scanning and transmission electron microscopes. Results. Nuclei and DNA damage because of exposure to both types of NPs is observed by inmunostaining genotoxicity testing. The cytotoxicity and genotoxicity are well correlated in this study. Numerous NPs are observed as large aggregates in vesicles, but less or nonexistent NP internalization is seen in the nucleus or cytoplasm. These morphological results suggest that a primary cause of cell disruption is the chemical changes of the NPs in the low pH of vesicles (i.e., ionization of Al2O3 or SiO2) for both types of oxide NPs. Significance. Although further research on the elution of NP concentrations on cell or tissue activity under simulated clinical conditions is required, NP concentrations over 200 mu g/mL are large enough to induce cytotoxic and genotoxic effects to cells. (C) 2015 Academy of Dental Materials. Published by Elsevier Ltd. All rights reserved.	[Hashimoto, Masanori; Imazato, Satoshi] Osaka Univ, Grad Sch Dent, Dept Biomat Sci, Suita, Osaka 5650871, Japan	Hashimoto, M (reprint author), Osaka Univ, Grad Sch Dent, Dept Biomat Sci, 1-8 Yamadaoka, Suita, Osaka 5650871, Japan.	masanori-h@mue.biglobe.ne.jp			Japan Society for the Promotion of Science (JSPS) [26462953, 24659846]	This work was supported in part by Grants-in-Aid for Scientific Research (C) (Nos. 26462953 and 24659846) from the Japan Society for the Promotion of Science (JSPS). The authors wish to express appreciation for laboratory support from Dr. H. Toshima and Prof. K. Endo (Health Sciences University of Hokkaido, Japan).	Akbari M, 2013, J ENDODONT, V39, P1448, DOI 10.1016/j.joen.2013.06.035; Tsaousi A, 2010, MUTAT RES-GEN TOX EN, V697, P1, DOI 10.1016/j.mrgentox.2010.01.012; Kittler S, 2010, CHEM MATER, V22, P4548, DOI 10.1021/cm100023p; Schaeublin NM, 2011, NANOSCALE, V3, P410, DOI 10.1039/c0nr00478b; Studer AM, 2010, TOXICOL LETT, V197, P169, DOI 10.1016/j.toxlet.2010.05.012; Gu YJ, 2009, TOXICOL APPL PHARM, V237, P196, DOI 10.1016/j.taap.2009.03.009; Brunner TJ, 2006, ENVIRON SCI TECHNOL, V40, P4374, DOI 10.1021/es052069i; Asati A, 2010, ACS NANO, V4, P5321, DOI 10.1021/nn100816s; Di Virgilio AL, 2010, J HAZARD MATER, V177, P711, DOI 10.1016/j.jhazmat.2009.12.089; Radziun E, 2011, TOXICOL IN VITRO, V25, P1694, DOI 10.1016/j.tiv.2011.07.010; Choi J, 2009, J APPL TOXICOL, V29, P52, DOI 10.1002/jat.1382; Azqueta A, 2011, MUTAGENESIS, V26, P393, DOI 10.1093/mutage/geq105; Khang D, 2009, ACTA BIOMATER, V5, P1425, DOI 10.1016/j.actbio.2009.01.031; Jeong YS, 2011, BIOMATERIALS, V32, P7217, DOI 10.1016/j.biomaterials.2011.06.020; Greulich C, 2009, LANGENBECK ARCH SURG, V394, P495, DOI 10.1007/s00423-009-0472-1; Atai M, 2012, DENT MATER, V28, P133, DOI 10.1016/j.dental.2011.10.015; Foldbjerg R, 2009, TOXICOL LETT, V190, P156, DOI 10.1016/j.toxlet.2009.07.009; Tsoli M, 2005, SMALL, V1, P841, DOI 10.1002/smll.200500104; Liu JY, 2010, ENVIRON SCI TECHNOL, V44, P2169, DOI 10.1021/es9035557; AshaRani PV, 2009, ACS NANO, V3, P279, DOI 10.1021/nn800596w; Besinis A, 2012, DENT MATER, V28, P1012, DOI 10.1016/j.dental.2012.05.007; Simon-Deckers A, 2008, TOXICOLOGY, V253, P137, DOI 10.1016/j.tox.2008.09.007; Di Virgilio AL, 2010, J BIOMED MATER RES A, V92A, P80, DOI 10.1002/jbm.a.32339; Huhn D, 2013, ACS NANO, V4, P3253; Husheng J., 2008, DENT MATER, V24, P244; Luo Z, 2013, J BIOMED MATER RES, V102, P3781; Mantri Sneha S, 2013, J Nat Sci Biol Med, V4, P39, DOI 10.4103/0976-9668.107258; Mohamed BM, 2011, J NANOBIOTECHNOL, V9, DOI 10.1186/1477-3155-9-29	28	0	0	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0109-5641	1879-0097		DENT MATER	Dent. Mater.	MAY	2015	31	5					556	564		10.1016/j.dental.2015.02.009		9	Dentistry, Oral Surgery & Medicine; Materials Science, Biomaterials	Dentistry, Oral Surgery & Medicine; Materials Science	CG1XL	WOS:000353068700010		
J	Kato, E; Sakurai, K; Yamada, M				Kato, Eiji; Sakurai, Kaoru; Yamada, Masahiro			Periodontal-like gingival connective tissue attachment on titanium surface with nano-ordered spikes and pores created by alkali-heat treatment	DENTAL MATERIALS			English	Article						Fibroblasts; Gingival fiber; Nanotopography; Peri-implant tissue; Surface modification	MECHANICAL-PROPERTIES; TREATED TITANIUM; BONE-FORMATION; CELL-ADHESION; OSTEOBLASTIC DIFFERENTIATION; CHEMICAL-COMPOSITION; HISTOLOGIC EVIDENCE; DENTAL IMPLANT; STEM-CELLS; SOFT	Objectives. Establishment of periodontal-like connective tissue attachment is one of the outstanding issues in implant dentistry. Organized nanotopographic titanium surface may acquire periodontal-like connective tissue attachment with activation of fibroblastic function. This study aimed to evaluate gingival fibroblastic function and connective tissue attachment on two types of nanotopographic titanium surface created by alkali-heat (AH) treatment. Methods. Commercially pure titanium turned discs with or without acid-etching or two types of AH treatment, underwent scanning electron microscopic evaluation in surface topography. Rat gingival fibroblasts cultured on the discs evaluated in terms of cellular adhesion, collagen synthesis and physicochemical binding strength of deposited collagen on the surfaces. Turned or the AH-treated pure titanium mini-implants were placed on the hard palatal plate of rabbits and underwent histological evaluation at 8 weeks postoperatively. Results. Both AH-treated surfaces were characterized by numerous well-organized fine nanospikes with crevasses and nanoholes, and uniform shaggy-like nanotopography with a sponge-like inner network, respectively. These nanotopographic surfaces enhanced cellular adhesion and collagen synthesis and toughened binding strength of deposited collagen sufficiently to resist against experimental overloading and inflammatory conditions by inclusion of collagen fibers into the surface, as compared with turned or acid-etched surfaces. The AH-treated mini-implants yielded inclusion of gingival connective tissue into the nanotopographic surface structure, with collagen fiber directions mimicking periodontal tissue in the transmucosal area. These features were not seen on turned surface implants. Significance. The well-organized nanotopographic titanium surface with nanospikes and pores by the AH treatment enhanced gingival fibroblastic collagen synthesis and acquired periodontal-like connective tissue attachment with substantial detachment resistance. (C) 2015 Academy of Dental Materials. Published by Elsevier Ltd. All rights reserved.	[Kato, Eiji; Sakurai, Kaoru; Yamada, Masahiro] Tokyo Dent Coll, Dept Removable Prosthodont & Gerodontol, Tokyo 1010061, Japan; [Yamada, Masahiro] Tokyo Dent Coll, Oral Hlth Sci Ctr, Tokyo 1010061, Japan	Yamada, M (reprint author), Tokyo Dent Coll, Dept Removable Prosthodont & Gerodontol, Chiyoda Ku, 2-9-18 Misaki Chou, Tokyo 1010061, Japan.	masayamada1020@gmail.com			 [26462978]	The author would like to thank research associate Eiko Watanabe of the Oral Health Science Center for her assistance with the evaluation of chemical composition by EPMA. This research was supported by Grant-in-Aid for Scientific Research (C) of Japan, 2014-2016 (grant number 26462978).	Abarrategi A, 2008, BIOMATERIALS, V29, P94, DOI 10.1016/j.biomaterials.2007.09.021; Albuschies J, 2013, SCI REP-UK, V3, DOI 10.1038/srep01658; Berglundh T, 1991, CLIN ORAL IMPLAN RES, V2, P81, DOI 10.1034/j.1600-0501.1991.020206.x; Shin SY, 2010, CLIN ORAL IMPLAN RES, V21, P804, DOI 10.1111/j.1600-0501.2010.01917.x; Usui Y, 2008, SMALL, V4, P240, DOI 10.1002/smll.200700670; Kim HM, 1996, J BIOMED MATER RES, V32, P409, DOI 10.1002/(SICI)1097-4636(199611)32:3<409::AID-JBM14>3.0.CO;2-B; Mathieu PS, 2012, TISSUE ENG PART B-RE, V18, P436, DOI [10.1089/ten.TEB.2012.0014, 10.1089/ten.teb.2012.0014]; Nevins M, 2008, INT J PERIODONT REST, V28, P111; Kubo K, 2009, BIOMATERIALS, V30, P5319, DOI 10.1016/j.biomaterials.2009.06.021; Miyazaki T, 2002, BIOMATERIALS, V23, P827, DOI 10.1016/S0142-9612(01)00188-0; Tang DD, 2008, J CARDIOVASC PHARM T, V13, P130, DOI 10.1177/1074248407313737; Nishiguchi S, 2003, J BIOMED MATER RES A, V67A, P26, DOI 10.1002/jbm.a.10540; Schierano G, 2002, CLIN ORAL IMPLAN RES, V13, P460, DOI 10.1034/j.1600-0501.2002.130503.x; Ruoslahti E, 1996, EXP CELL RES, V227, P1, DOI 10.1006/excr.1996.0243; Ballo A, 2011, INT J NANOMED, V6, P3415, DOI 10.2147/IJN.S25867; Cochran DL, 1997, J PERIODONTOL, V68, P186, DOI 10.1902/jop.1997.68.2.186; Att W, 2009, ACTA BIOMATER, V5, P391, DOI 10.1016/j.actbio.2008.07.021; Chen GC, 2005, MOL CELL BIOL, V25, P979, DOI 10.1128/MCB.25.3.979-987.2005; Yao C, 2008, J BIOMED MATER RES A, V85A, P157, DOI 10.1002/jbm.a.31551; Ho SP, 2010, BIOMATERIALS, V31, P6635, DOI 10.1016/j.biomaterials.2010.05.024; Rompen E, 2006, CLIN ORAL IMPLAN RES, V17, P55, DOI 10.1111/j.1600-0501.2006.01367.x; Abrahamsson I, 1996, CLIN ORAL IMPLAN RES, V7, P212, DOI 10.1034/j.1600-0501.1996.070303.x; Yang L, 2009, J BIOMED MATER RES A, V91A, P548, DOI 10.1002/jbm.a.32227; BERGLUNDH T, 1994, J CLIN PERIODONTOL, V21, P189, DOI 10.1111/j.1600-051X.1994.tb00302.x; Cooper LF, 2006, BIOMATERIALS, V27, P926, DOI 10.1016/j.biomaterials.2005.07.009; Huang S, 2000, EXP CELL RES, V261, P91, DOI 10.1006/excr.2000.5044; SCHROEDER A, 1981, J MAXILLOFAC SURG, V9, P15, DOI 10.1016/S0301-0503(81)80007-0; Jiang HM, 2005, MOL BIOL CELL, V16, P5070, DOI 10.1091/mbc.E05-01-0007; Ho SP, 2004, J BIOMED MATER RES A, V70A, P480, DOI 10.1002/jbm.a.30105; Padmanabhan J, 2014, ACS NANO, V8, P4366, DOI 10.1021/nn501874q; Teo BKK, 2013, ACS NANO, V7, P4785, DOI 10.1021/nn304966z; Lyu ZL, 2014, NANOSCALE, V6, P6959, DOI 10.1039/c4nr01540a; Ho SP, 2009, ACTA BIOMATER, V5, P707, DOI 10.1016/j.actbio.2008.08.013; Nevins M, 2010, INT J PERIODONT REST, V30, P245; Nishio K, 2000, J BIOMED MATER RES, V52, P652, DOI 10.1002/1097-4636(20001215)52:4<652::AID-JBM9>3.0.CO;2-W; Buser D, 1992, J PERIODONTOL, V63, P725; Butz F, 2005, J BIOMED MATER RES A, V74A, P164, DOI 10.1002/jbm.a.30281; CHAVRIER C, 1994, CLIN ORAL IMPLAN RES, V5, P117, DOI 10.1034/j.1600-0501.1994.050301.x; DEPORTER DA, 1988, J DENT RES, V67, P1190, DOI 10.1177/00220345880670090801; Divya Rani VV, 2009, NANOTECHNOLOGY, V70; Dreier B, 2013, AM J PHYSIOL-CELL PH, V305, pC290, DOI 10.1152/ajpcell.00264.2012; Ellingsen JE, 2004, INT J ORAL MAX IMPL, V19, P659; GARGIULO A. W., 1961, ORAL SURG ORAL MED AND ORAL PATHOL, V14, P474, DOI 10.1016/0030-4220(61)90116-5; Ho SP, 2009, DENT MATER, V25, P1195, DOI 10.1016/j.dental.2009.04.005; Kubo K, 2008, J BIOMED MATER RES A, V87A, P380, DOI 10.1002/jbm.a.31791; Liou YR, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089767; LISTGARTEN MA, 1992, J DENT RES, V71, P364, DOI 10.1177/00220345920710020401; Mendonca G, 2008, BIOMATERIALS, V29, P3827; Muramatsu K, 2003, J BIOMED MATER RES A, V65A, P409, DOI 10.1002/jbm.a.10494; Nakamura HK, 2007, J DENT RES, V86, P147; Nichols HL, 2007, J BIOMED MATER RES A, V82A, P373, DOI 10.1002/jbm.a.31066; Raimondo T, 2010, INT J NANOMED, V5, P647, DOI 10.2147/IJN.S13047; ROSALES C, 1995, BBA-REV CANCER, V1242, P77, DOI 10.1016/0304-419X(95)00005-Z; Salasznyk RM, 2007, EXP CELL RES, V313, P27; Samwatari L, 2005, J BONE MINER RES, V20, P2002; Sato N, 2009, DENT MATER, V25, P1532, DOI 10.1016/j.dental.2009.07.006; Sculean A, 2014, J CLIN PERIODONTOL, V41, pS6, DOI 10.1111/jcpe.12206; STERN IB, 1981, J PERIODONTOL, V52, P465; Stewart ML, 2006, INT ENDOD J, V39, P81; Ueno T, 2011, BIOMATERIALS, V32, P7297, DOI 10.1016/j.biomaterials.2011.06.033	60	0	0	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0109-5641	1879-0097		DENT MATER	Dent. Mater.	MAY	2015	31	5					E116	E130		10.1016/j.dental.2015.01.014		15	Dentistry, Oral Surgery & Medicine; Materials Science, Biomaterials	Dentistry, Oral Surgery & Medicine; Materials Science	CG1XL	WOS:000353068700002		
J	Sheng, GJ				Sheng, Guojun			Epiblast morphogenesis before gastrulation	DEVELOPMENTAL BIOLOGY			English	Article						Amniote; Epiblast; Morphogenesis; Hypoblast; Trophoblast; Mesenchymal-epithelial transition	EMBRYONIC STEM-CELLS; STREAK FORMATION; RHESUS-MONKEY; E-CADHERIN; PLURIPOTENCY; BLASTOCYST; BOVINE; IMPLANTATION; TROPHOBLAST; MAMMALS	The epiblast is a single cell-layered epithelium which generates through gastrulation all tissues in an amniote embryo proper. Specification of the epiblast as a cell lineage in early development is coupled with that of the trophoblast and hypoblast, two lineages dedicated to forming extramebryonic tissues. The complex relationship between molecular specification and morphogenetic segregation of these three lineages is not well understood. In this review I will compare the ontogeny of epithelial epiblast in different amniote groups and emphasize the diversity in cell biological mechanisms employed by each group to reach this conserved epithelial structure as the pre-requisite for gastrulation. The limitations of associating cell fate with cell shape and position will also be discussed. In most amniote groups, bipotential precursors for the epiblast and hypoblast, similar to the inner cell mass in the eutherian mammals, are not associated with an apolar, inside location in the blastocyst. Conversely, a blastocyst cell with epithelial morphology and superficial location is not indicative of its trophoblast fate. The polar trophoblast is absent in all amniotes except for the eutherian mammals. In the avian, reptilian and eutherian groups, epithelialization of the epiblast occurs after its fate specification and involves a mesenchymal-to-epithelial transition (MET) process, whereas in the monotremes and marsupials, preepiblast cells adopt an epithelial morphology prior to their commitment to the epiblast fate. The conservation of an epithelialized epiblast is viewed as an adaptation to evolutionary constraints placed on pre-gastrulation ectoderm in the ancestral amniote. The relationship between epiblast MET and epiblast pluripontency will also be discussed. Whether such an MET/epithelialization process is advantageous for the self-renewal and/or differentiation of human epiblast stem cells in vitro is unclear. (C) 2014 Elsevier Inc. All rights reserved.	RIKEN, Ctr Dev Biol, Lab Early Embryogenesis, Kobe, Hyogo 6500047, Japan	Sheng, GJ (reprint author), RIKEN, Ctr Dev Biol, Lab Early Embryogenesis, Kobe, Hyogo 6500047, Japan.	sheng@cdb.riken.jp	Sheng, Guojun/I-4900-2015				Alev C, 2013, METHODS MOL BIOL, V1074, P151, DOI 10.1007/978-1-62703-628-3_12; Selwood L, 2006, BIOESSAYS, V28, P128, DOI 10.1002/bies.20360; Niakan KK, 2012, DEVELOPMENT, V139, P829, DOI 10.1242/dev.060426; Kuijk EW, 2012, DEVELOPMENT, V139, P871, DOI 10.1242/dev.071688; EYALGILADI H, 1976, DEV BIOL, V49, P321, DOI 10.1016/0012-1606(76)90178-0; Posfai E, 2014, CURR TOP DEV BIOL, V107, P1, DOI 10.1016/B978-0-12-416022-4.00001-9; Chiari Y, 2012, BMC BIOL, V10, DOI 10.1186/1741-7007-10-65; Romiguier J, 2013, MOL BIOL EVOL, V30, P2134, DOI 10.1093/molbev/mst116; Oestrup O, 2009, REPROD DOMEST ANIM, V44, P39, DOI 10.1111/j.1439-0531.2009.01482.x; Schrode N, 2013, GENESIS, V51, P219, DOI 10.1002/dvg.22368; Berg DK, 2011, DEV CELL, V20, P244, DOI 10.1016/j.devcel.2011.01.003; LUCKETT WP, 1975, AM J ANAT, V144, P149, DOI 10.1002/aja.1001440204; WIMSATT WA, 1975, BIOL REPROD, V12, P1, DOI 10.1095/biolreprod12.1.1; Wolf XA, 2011, DEV DYNAM, V240, P204, DOI 10.1002/dvdy.22491; del Valle I, 2013, DEVELOPMENT, V140, P1684, DOI 10.1242/dev.088690; Blomberg L, 2008, REPRODUCTION, V135, P181, DOI 10.1530/REP-07-0355; Nakaya Y, 2008, DEV GROWTH DIFFER, V50, P755, DOI 10.1111/j.1440-169X.2008.01070.x; Alev C, 2013, DEVELOPMENT, V140, P2691, DOI 10.1242/dev.094318; Gandolfi F, 2012, REPROD DOMEST ANIM, V47, P11, DOI 10.1111/j.1439-0531.2012.02106.x; Lavial F, 2007, DEVELOPMENT, V134, P3549, DOI 10.1242/dev.006569; Sheng GJ, 2014, DEV DYNAM, V243, P357, DOI 10.1002/dvdy.24087; Vejlsted M, 2005, BIOL REPROD, V72, P678, DOI 10.1095/biolreprod.104.034348; Degrelle SA, 2005, DEV BIOL, V288, P448, DOI 10.1016/j.ydbio.2005.09.043; Nakaya Y, 2013, CANCER LETT, V341, P9, DOI 10.1016/j.canlet.2013.02.037; Sokol SY, 2011, DEVELOPMENT, V138, P4341, DOI 10.1242/dev.066209; Esteban MA, 2012, CURR OPIN GENET DEV, V22, P423, DOI 10.1016/j.gde.2012.09.004; Stephenson RO, 2010, DEVELOPMENT, V137, P3383, DOI 10.1242/dev.050195; Shin M, 2011, MECH DEVELOP, V128, P268, DOI 10.1016/j.mod.2011.03.001; Frankenberg S, 2013, DEVELOPMENT, V140, P965, DOI 10.1242/dev.091629; Pieters T, 2014, J CELL SCI, V127, P2603, DOI 10.1242/jcs.146720; BETTERIDGE KJ, 1988, THERIOGENOLOGY, V29, P155, DOI 10.1016/0093-691X(88)90038-6; Artus J., 2014, CELL MOL LIFE SCI; Bedzhov I, 2014, CELL, V156, P1032, DOI 10.1016/j.cell.2014.01.023; Bedzhov I, 2013, STEM CELL RES, V11, P1250, DOI 10.1016/j.scr.2013.08.009; Bertocchini F, 2013, DEV GROWTH DIFFER, V55, P52, DOI 10.1111/dgd.12014; Boroviak T, 2014, NAT CELL BIOL, V16, P513, DOI 10.1038/ncb2965; Chiappe LM, 2004, ORNITOL NEOTROP, V15, P101; De Paepe C., 2012, HUM REPROD, V28, P740; Ferner K, 2011, RESP PHYSIOL NEUROBI, V178, P39, DOI 10.1016/j.resp.2011.03.029; Flechon JE, 2004, GENESIS, V38, P13, DOI 10.1002/gene.10244; Flynn T. T., 1939, T ZOOL SOC LONDON, V24, P445; Flynn T. T., 1947, Transactions of the Zoological Society of London, V26, P1; Frankenberg S, 2013, BMC BIOL, V11, DOI 10.1186/1741-7007-11-56; Goetz R. H., 1939, BIOMORPHOSIS, V1, P67; Hall V.J., 2014, STEM CELLS DEV; Johnson MH, 1996, REPROD FERT DEVELOP, V8, P759, DOI 10.1071/RD9960759; LUCKETT WP, 1978, AM J ANAT, V152, P59, DOI 10.1002/aja.1001520106; Morrison JT, 2013, EVOL DEV, V15, P171, DOI 10.1111/ede.12031; Niakan K. K., 2012, DEV BIOL, V375, P54; Permute B., 2010, DEV DYNAM, V239, P620; Scerbo P, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0085104; SELWOOD L, 1992, CURR TOP DEV BIOL, V27, P175, DOI 10.1016/S0070-2153(08)60535-9; Sheng GJ, 2012, ANN NY ACAD SCI, V1271, P97, DOI 10.1111/j.1749-6632.2012.06726.x; Stephenson RO, 2012, COLD SPRING HARBOR P, P4; Tapia N, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms2229; Van de Horst C. J., 1949, T R SOC S AFR, V32, P435; Van der Horst C. J., 1942, S AFRICAN JOUR MED SCI, V7, P55; Vogler H., 1987, HUMAN BLASTOGENESIS; WILLIAMS BS, 1990, ANAT REC, V227, P211, DOI 10.1002/ar.1092270210; WILSON JT, 1907, PHIL T R SOC LONDO B, V199, P31; Yatskievych TA, 1999, MECH DEVELOP, V80, P107, DOI 10.1016/S0925-4773(98)00204-4	61	1	1	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0012-1606	1095-564X		DEV BIOL	Dev. Biol.	MAY 1	2015	401	1			SI		17	24		10.1016/j.ydbio.2014.10.003		8	Developmental Biology	Developmental Biology	CG5VS	WOS:000353364600003		
J	Araneta, MRG; Kanaya, AM; Hsu, WC; Chang, HK; Grandinetti, A; Boyko, EJ; Hayashi, T; Kahn, SE; Leonetti, DL; McNeely, MJ; Onishi, Y; Sato, KK; Fujimoto, WY				Araneta, Maria Rosario G.; Kanaya, Alka M.; Hsu, William C.; Chang, Healani K.; Grandinetti, Andrew; Boyko, Edward J.; Hayashi, Tomoshige; Kahn, Steven E.; Leonetti, Donna L.; McNeely, Marguerite J.; Onishi, Yukiko; Sato, Kyoko K.; Fujimoto, Wilfred Y.			Optimum BMI Cut Points to Screen Asian Americans for Type 2 Diabetes	DIABETES CARE			English	Article							IMPAIRED GLUCOSE-TOLERANCE; JAPANESE-AMERICANS; PACIFIC ISLANDERS; NATIVE HAWAIIANS; RISK; PREVALENCE; WOMEN; COMPLICATIONS; INTOLERANCE; FILIPINO	OBJECTIVEAsian Americans manifest type 2 diabetes at low BMI levels but may not undergo diagnostic testing for diabetes if the currently recommended BMI screening cut point of 25 kg/m(2) is followed. We aimed to ascertain an appropriate lower BMI cut point among Asian-American adults without a prior diabetes diagnosis.RESEARCH DESIGN AND METHODSWe consolidated data from 1,663 participants, ages 45 years, without a prior diabetes diagnosis, from population- and community-based studies, including the Mediators of Atherosclerosis in South Asians Living in America study, the North Kohala Study, the Seattle Japanese American Community Diabetes Study, and the University of California San Diego Filipino Health Study. Clinical measures included a 2-h 75-g oral glucose tolerance test, BMI, and glycosylated hemoglobin (HbA(1c)).RESULTSMean age was 59.7 years, mean BMI was 25.4 kg/m(2), 58% were women, and type 2 diabetes prevalence (American Diabetes Association 2010 criteria) was 16.9%. At BMI 25 kg/m(2), sensitivity (63.7%), specificity (52.8%), and Youden index (0.16) values were low; limiting screening to BMI 25 kg/m(2) would miss 36% of Asian Americans with type 2 diabetes. For screening purposes, higher sensitivity is desirable to minimize missing cases, especially if the diagnostic test is relatively simple and inexpensive. At BMI 23 kg/m(2), sensitivity (84.7%) was high in the total sample and by sex and Asian-American subgroup and would miss only approximate to 15% of Asian Americans with diabetes.CONCLUSIONSThe BMI cut point for identifying Asian Americans who should be screened for undiagnosed type 2 diabetes should be <25 kg/m(2), and 23 kg/m(2) may be the most practical.	[Araneta, Maria Rosario G.] Univ Calif San Diego, Dept Family & Prevent Med, La Jolla, CA 92093 USA; [Kanaya, Alka M.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA; [Hsu, William C.] Harvard Univ, Sch Med, Joslin Diabet Ctr, Boston, MA 02115 USA; [Chang, Healani K.; Grandinetti, Andrew] Univ Hawaii Manoa, Honolulu, HI 96822 USA; [Boyko, Edward J.] Vet Affairs Puget Sound Hlth Care Syst, Seattle Epidemiol Res & Informat Ctr, Seattle, WA USA; [Boyko, Edward J.; Kahn, Steven E.] Vet Affairs Puget Sound Hlth Care Syst, Dept Med, Seattle, WA USA; [Boyko, Edward J.; Kahn, Steven E.; McNeely, Marguerite J.; Fujimoto, Wilfred Y.] Univ Washington, Dept Med, Seattle, WA USA; [Hayashi, Tomoshige; Sato, Kyoko K.] Osaka City Univ, Grad Sch Med, Dept Prevent Med & Environm Hlth, Osaka 558, Japan; [Leonetti, Donna L.] Univ Washington, Dept Anthropol, Seattle, WA 98195 USA; [Onishi, Yukiko] Asahi Life Fdn, Inst Adult Dis, Tokyo, Japan	Araneta, MRG (reprint author), Univ Calif San Diego, Dept Family & Prevent Med, La Jolla, CA 92093 USA.	haraneta@ucsd.edu	Hayashi, Tomoshige/N-8508-2015		National Institutes of Health [DK-31801, R03-DK-60575, HL-093009, K24-HL-112827, DK-31170, DK-02654, DK-02860, DK-48152, DK-50703, DK-55460, DK-17047, DK-35876, HL-07028, HL-49293, RR-00037, HL-29393, U01-HL-079163, G12-RR-03061]; Department of Veterans Affairs	This work was supported by the National Institutes of Health (DK-31801, R03-DK-60575, HL-093009, K24-HL-112827, DK-31170, DK-02654, DK-02860, DK-48152, DK-50703, DK-55460, DK-17047, DK-55460, DK-35876, HL-07028, HL-49293, RR-00037, HL-29393, U01-HL-079163, and G12-RR-03061) and the Department of Veterans Affairs.	American Diabetes Association, 2014, DIABETES CARE S1, V37, pS14, DOI [DOI 10.2337/DC14-S014, 10.2337/dc14-S014]; FUJIMOTO WY, 1987, DIABETES, V36, P721, DOI 10.2337/diabetes.36.6.721; Wild S, 2004, DIABETES CARE, V27, P1047, DOI 10.2337/diacare.27.5.1047; Araneta MRG, 2002, DIABETES CARE, V25, P494, DOI 10.2337/diacare.25.3.494; Karter AJ, 2013, DIABETES CARE, V36, P574, DOI 10.2337/dc12-0722; Gregg EW, 2014, NEW ENGL J MED, V370, P1514, DOI 10.1056/NEJMoa1310799; Kanaya AM, 2013, CLIN CARDIOL, V36, P713, DOI 10.1002/clc.22219; Ntuk UE, 2014, DIABETES CARE, V37, P2500, DOI 10.2337/dc13-2966; Nathan DM, 2007, DIABETES CARE, V30, P753, DOI 10.2337/dc07-9920; Chiu M, 2011, DIABETES CARE, V34, P1741, DOI 10.2337/dc10-2300; Kanaya AM, 2014, DIABETES CARE, V37, P1621, DOI 10.2337/dc13-2656; Fujimoto WY, 2012, J DIABETES INVEST, V3, P212, DOI 10.1111/j.2040-1124.2012.00195.x; Araneta MRG, 2005, OBES RES, V13, P1458, DOI 10.1038/oby.2005.176; Araneta MRG, 2010, DIABETES CARE, V33, P2626, DOI [10.2337/dc10-0958, 10.2337/dc10.0958]; Wander PL, 2013, DIABETES CARE, V36, P289, DOI 10.2337/dc12-0198; Barba C, 2004, LANCET, V363, P157; FUJIMOTO WY, 1991, DIABETES RES CLIN PR, V13, P119, DOI 10.1016/0168-8227(91)90042-C; FUJIMOTO WY, 1994, DIABETOLOGIA, V37, P524; Grandinetti A, 2007, ETHNIC DIS, V17, P250; Hsu WC, 2012, DIABETES CARE, V35, P1189, DOI 10.2337/dc12-0212; International Diabetes Federation, 2013, IDF DIAB ATL; Staimez Lisa R, 2013, Curr Diabetes Rev, V9, P312	22	1	1	AMER DIABETES ASSOC	ALEXANDRIA	1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA	0149-5992	1935-5548		DIABETES CARE	Diabetes Care	MAY	2015	38	5					814	820		10.2337/dc14-2071		7	Endocrinology & Metabolism	Endocrinology & Metabolism	CG7SP	WOS:000353505600021		
J	Hayashi, A; Takemoto, M; Shoji, M; Hattori, A; Sugita, K; Yokote, K				Hayashi, Aiko; Takemoto, Minoru; Shoji, Mayumi; Hattori, Akiko; Sugita, Katsuo; Yokote, Koutaro			Pioglitazone Improves Fat Tissue Distribution and Hyperglycemia in a Case of Cockayne Syndrome With Diabetes	DIABETES CARE			English	Letter									[Hayashi, Aiko; Takemoto, Minoru; Shoji, Mayumi; Hattori, Akiko; Yokote, Koutaro] Chiba Univ, Grad Sch Med, Dept Clin Cell Biol & Med, Chuo Ku, Chiba, Chiba, Japan; [Hayashi, Aiko; Takemoto, Minoru; Shoji, Mayumi; Hattori, Akiko; Yokote, Koutaro] Chiba Univ Hosp, Dept Med, Div Diabet Metab & Endocrinol, Chuo Ku, Chiba, Chiba, Japan; [Sugita, Katsuo] Chiba Univ Hosp, Dept Pediat, Chuo Ku, Chiba, Chiba, Japan	Takemoto, M (reprint author), Chiba Univ, Grad Sch Med, Dept Clin Cell Biol & Med, Chuo Ku, Chiba, Chiba, Japan.	minoru.takemoto@faculty.chiba-u.jp					NANCE MA, 1992, AM J MED GENET, V42, P68, DOI 10.1002/ajmg.1320420115; Cockayne E A, 1936, Arch Dis Child, V11, P1; Inoue T, 1997, INTERNAL MED, V36, P565; MIYAUCHI H, 1994, J AM ACAD DERMATOL, V30, P329, DOI 10.1016/S0190-9622(94)70034-6; Shirasaki N, 1986, No To Shinkei, V38, P871	5	0	0	AMER DIABETES ASSOC	ALEXANDRIA	1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA	0149-5992	1935-5548		DIABETES CARE	Diabetes Care	MAY	2015	38	5					E76	E76		10.2337/dc14-2944		1	Endocrinology & Metabolism	Endocrinology & Metabolism	CG7SP	WOS:000353505600005		
J	Katsuyama, T; Sada, KE; Namba, S; Watanabe, H; Katsuyama, E; Yamanari, T; Wada, J; Makino, H				Katsuyama, Takayuki; Sada, Ken-Ei; Namba, Sayaka; Watanabe, Haruki; Katsuyama, Eri; Yamanari, Toshio; Wada, Jun; Makino, Hirofumi			Risk factors for the development of glucocorticoid-induced diabetes mellitus	DIABETES RESEARCH AND CLINICAL PRACTICE			English	Article						Glucocorticoid-induced diabetes mellitus; Risk factor; Rheumatic disease; Renal disease	CORTICOSTEROID-THERAPY; INDUCED HYPERGLYCEMIA; RHEUMATOID-ARTHRITIS; INSULIN-RESISTANCE; DISEASES; MANAGEMENT; PREVALENCE; DIAGNOSIS; GLUCOSE; KIDNEY	Aims: To evaluate the incidence of glucocorticoid-induced diabetes mellitus (GC-DM) by repeated measurements of the postprandial glucose and detect predictors for the development of GC-DM. Methods: Inpatients with rheumatic or renal disease who received glucocorticoid therapy were enrolled in this study. We compared the clinical and laboratory parameters of the GC-DM group with the non-GC-DM group and performed a multivariate analysis to identify risk factors. Results: During a four-week period, 84 of the 128 patients (65.6%) developed GC-DM. All patients were diagnosed based on the detection of postprandial hyperglycemia. The GC-DM group had an older age (65.2 vs. 50.4 years, p < 0.0001), higher levels of fasting plasma glucose (93.3 vs. 89.0 mg/dl, p = 0.027) and HbA1c (5.78 vs. 5.50%, 39.7 vs. 36.6 mmol/mol, p = 0.001) and lower eGFR values (54.0 vs. 77.1 ml/min/1.73 m(2), p = 0.0003) than the non-GC-DM group. According to the multivariate analysis, an older age (more than or equal to 65 years), higher HbA1c level (more than or equal to 6.0%) and lower eGFR (<40 ml/min/1.73 m(2)) were identified as independent risk factors for GC-DM (OR 2.95, 95% CI 1.15-7.92, OR: 3.05, 95% CI 1.11-9.21, OR: 3.42, 95% CI: 1.22-10.8, respectively). The risk ratio for the development of GC-DM in the patients with at least one of these three risk factors was 2.28. The dose of glucocorticoids was not statistically related to the development of GC-DM. Conclusions: Patients with an older age, higher HbA1c level and lower eGFR require close monitoring for the development of GC-DM, regardless of the dose of glucocorticoids being administered. (C) 2015 Elsevier Ireland Ltd. All rights reserved.	[Katsuyama, Takayuki; Sada, Ken-Ei; Namba, Sayaka; Watanabe, Haruki; Katsuyama, Eri; Yamanari, Toshio; Wada, Jun; Makino, Hirofumi] Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Med & Clin Sci, Kita Ku, Okayama 7008558, Japan	Sada, KE (reprint author), Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Med & Clin Sci, Kita Ku, 2-5-1 Shikata Cho, Okayama 7008558, Japan.	sadakenn@md.okayama-u.ac.jp	SADA, KENEI/B-2305-2011; Wada, Jun/B-2023-2011	Wada, Jun/0000-0003-1468-5170	Astellas; Boehringer Ingelheim; Daiichi Sankyo; Dainippon Sumitomo; Kyowa Hakko Kirin; Mochida; MSD; Novartis; Novo Nordisk; Pfizer; Takeda; Tanabe Mitsubishi	J.W. is a consultant for Astellas and Boehringer Ingelheim and receives speaker honoraria from Novartis, Boehringer Ingelheim and Novo Nordisk. H.M. is a consultant for AbbVie, Astellas and Teijin, receives speaker honoraria from Astellas, Boehringer Ingelheim, Chugai, Daiichi Sankyo, Dainippon Sumitomo, Kyowa Hakko Kirin, MSD, Novartis, Pfizer, Takeda, and Tanabe Mitsubishi and receives grant support from Astellas, Boehringer Ingelheim, Daiichi Sankyo, Dainippon Sumitomo, Kyowa Hakko Kirin, Mochida, MSD, Novartis, Novo Nordisk, Pfizer, Takeda and Tanabe Mitsubishi.	ARNER P, 1983, DIABETES CARE, V6, P23, DOI 10.2337/diacare.6.1.23; Morgan SA, 2009, DIABETES, V58, P2506, DOI 10.2337/db09-0525; Clement S, 2004, DIABETES CARE, V27, P553, DOI 10.2337/diacare.27.2.553; Sethi S, 2012, NEW ENGL J MED, V366, P1119, DOI 10.1056/NEJMra1108178; Drucker DJ, 2006, LANCET, V368, P1696, DOI 10.1016/S0140-6736(06)69705-5; Uzu T, 2007, NEPHRON CLIN PRACT, V105, pC54, DOI 10.1159/000097598; Hogan J, 2013, J AM SOC NEPHROL, V24, P702, DOI 10.1681/ASN.2012070734; Rohrmeier C, 2013, EUR ARCH OTO-RHINO-L, V270, P1255, DOI 10.1007/s00405-012-2134-0; Hahn BH, 2012, ARTHRIT CARE RES, V64, P797, DOI 10.1002/acr.21664; Delaunay F, 1997, J CLIN INVEST, V100, P2094, DOI 10.1172/JCI119743; Tatsuno I, 2011, DIABETES RES CLIN PR, V93, pE18, DOI 10.1016/j.diabres.2011.03.005; Hellmich B, 2007, ANN RHEUM DIS, V66, P605, DOI 10.1136/ard.2006.062711; Clore JN, 2009, ENDOCR PRACT, V15, P469, DOI 10.4158/EP08331.RAR; Ponticelli C, 2014, CLIN J AM SOC NEPHRO, V9, P609, DOI 10.2215/CJN.04160413; Dimitriadis G, 1997, BIOCHEM J, V321, P707; Carstens PO, 2014, CLIN EXP IMMUNOL, V175, P349, DOI 10.1111/cei.12194; Donihi Amy Calabrese, 2006, Endocr Pract, V12, P358; Gonzalez-Gonzalez JG, 2013, DIABETOL METAB SYNDR, V5, DOI 10.1186/1758-5996-5-18; Ito S, 2014, MOD RHEUMATOL, V24, P52, DOI 10.3109/14397595.2013.852855; Iwamoto T, 2004, PHARMACOTHERAPY, V24, P508, DOI 10.1592/phco.24.5.508.33355; Kim SY, 2011, J KOREAN MED SCI, V26, P264, DOI 10.3346/jkms.2011.26.2.264; Koppe L, 2014, NEPHROL DIAL TRANSPL, V29, P1666, DOI 10.1093/ndt/gft435; Lee CTC, 2014, CLIN ENDOCRINOL, V81, P536, DOI 10.1111/cen.12390; Panthakalam S, 2004, SCOT MED J, V49, P139; Raul Ariza-Andraca C, 1998, ARCH MED RES, V29, P259; Shikuma CM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090330; WHITWORTH JA, 1989, CLIN ENDOCRINOL, V31, P355, DOI 10.1111/j.1365-2265.1989.tb01259.x; Yanai Hidekatsu, 2010, World J Diabetes, V1, P99, DOI 10.4239/wjd.v1.i3.99; Yuen KCJ, 2012, CLIN ENDOCRINOL, V77, P224, DOI 10.1111/j.1365-2265.2011.04242.x; Zhu LY, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067613	30	0	0	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0168-8227	1872-8227		DIABETES RES CLIN PR	Diabetes Res. Clin. Pract.	MAY	2015	108	2					273	279		10.1016/j.diabres.2015.02.010		7	Endocrinology & Metabolism	Endocrinology & Metabolism	CG3YJ	WOS:000353215500014		
J	Kusunoki, Y; Katsuno, T; Nakae, R; Watanabe, K; Akagami, T; Ochi, F; Tokuda, M; Murai, K; Miuchi, M; Miyagawa, J; Namba, M				Kusunoki, Yoshiki; Katsuno, Tomoyuki; Nakae, Rie; Watanabe, Kahori; Akagami, Takafumi; Ochi, Fumihiro; Tokuda, Masaru; Murai, Kazuki; Miuchi, Masayuki; Miyagawa, Jun-ichiro; Namba, Mitsuyoshi			Evaluation of blood glucose fluctuation in Japanese patients with type 1 diabetes mellitus by self-monitoring of blood glucose and continuous glucose monitoring	DIABETES RESEARCH AND CLINICAL PRACTICE			English	Article						Self-monitoring of blood glucose; Continuous glucose monitoring; Type 1 diabetes mellitus; Glycemic excursion; Hypoglycemia	SEVERE HYPOGLYCEMIA; GLYCEMIC CONTROL; OXIDATIVE STRESS; BED SYNDROME; VARIABILITY; INDEX; COMPLICATIONS; ASSOCIATION; UNAWARENESS; HEMOGLOBIN	Aims: Accurate assessment of blood glucose fluctuation is essential for managing blood glucose control while avoiding hypoglycemia in patients with diabetes mellitus. In this study, blood glucose was measured by continuous glucose monitoring (CGM) in patients with type 1 diabetes mellitus (T1DM) whom self-monitoring of blood glucose (SMBG) was carried out three or more times per day, and evaluation was performed using blood glucose fluctuation parameters obtained by CGM and SMBG. Methods: Twenty-nine insulin-depleted patients with T1DM were enrolled. Their blood glucose fluctuations were measured at the same time by SMBG and CGM, and the correlations were evaluated. Results: Correlations were found between the following values obtained by SMBG and CGM: mean and standard deviation of blood glucose levels, average daily risk range, Morbus value and high-blood-glucose index. The hypoglycemia duration and the nocturnal hypoglycemia duration showed no correlation with any of the blood glucose fluctuation parameters obtained by SMBG. Conclusions: The findings suggest that routine SMBG and glycated hemoglobin (HbA1c) measurement are sufficient for evaluation of hyperglycemia in T1DM. On the other hand, blood glucose fluctuation parameters obtained by SMBG and HbA1c have been shown to have no correlations with either hypoglycemia duration or nocturnal hypoglycemia duration. (C) 2015 Elsevier Ireland Ltd. All rights reserved.	[Kusunoki, Yoshiki; Nakae, Rie; Watanabe, Kahori; Akagami, Takafumi; Ochi, Fumihiro; Tokuda, Masaru; Murai, Kazuki; Miuchi, Masayuki; Miyagawa, Jun-ichiro; Namba, Mitsuyoshi] Hyogo Coll Med, Dept Internal Med, Div Diabet Endocrinol & Metab, Nishinomiya, Hyogo 6638501, Japan; [Katsuno, Tomoyuki] Hyogo Coll Med, Div Innovat Diabet Treatment, Nishinomiya, Hyogo 6638501, Japan	Kusunoki, Y (reprint author), Hyogo Coll Med, Dept Internal Med, Div Diabet Endocrinol & Metab, 1-1 Mukogawa Cho, Nishinomiya, Hyogo 6638501, Japan.	ykusu@hyo-med.ac.jp					ADVANCE Collaborative Group, 2008, NEW ENGL J MED, V358, P2560, DOI [10.1056/NEJMoa0802987, DOI 10.1056/NEJM0A0802987]; American Diabetes Association, 2014, DIABETES CARE S1, V37, pS14, DOI [DOI 10.2337/DC14-S014, 10.2337/dc14-S014]; Ceriello A, 2003, DIABETES CARE, V26, P1589, DOI 10.2337/diacare.26.5.1589; Skyler JS, 2009, DIABETES CARE, V32, P187, DOI 10.2337/dc08-9026; Kovatchev BP, 1998, DIABETES CARE, V21, P1870, DOI 10.2337/diacare.21.11.1870; Duckworth W, 2009, NEW ENGL J MED, V360, P129, DOI 10.1056/NEJMoa0808431; Monnier L, 2006, JAMA-J AM MED ASSOC, V295, P1681, DOI 10.1001/jama.295.14.1681; Pickup JC, 2008, DIABETIC MED, V25, P765, DOI 10.1111/j.1464-5491.2008.02486.x; Nathan DM, 2007, DIABETOLOGIA, V50, P2239, DOI 10.1007/s00125-007-0803-0; Kovatchev BP, 2006, DIABETES CARE, V29, P2433, DOI 10.2337/dc06-1085; SERVICE FJ, 1980, DIABETES CARE, V3, P58, DOI 10.2337/diacare.3.1.58; Patton SR, 2012, DIABETES TECHNOL THE, V14, P239, DOI 10.1089/dia.2011.0169; Yaffe K, 2013, JAMA INTERN MED, V173, P1300, DOI 10.1001/jamainternmed.2013.6176; SERVICE FJ, 1970, DIABETES, V19, P644; Tsujimoto T, 2014, DIABETES CARE, V37, P217, DOI 10.2337/dc13-0701; Sartore G, 2012, ACTA DIABETOL, V49, pS153, DOI 10.1007/s00592-012-0391-4; Gill G, 2009, DIABETOLOGIA, V52, P42, DOI 10.1007/s00125-008-1177-7; Gerstein HC, 2008, NEW ENGL J MED, V358, P2545; Boyle PJ, 1995, NEW ENGL J MED, V333, P1726, DOI 10.1056/NEJM199512283332602; Choudhary P, 2013, DIABETES CARE, V36, P4160, DOI 10.2337/dc13-0939; Cryer PE, 2005, DIABETES, V54, P3592, DOI 10.2337/diabetes.54.12.3592; Benjamini Y, 1995, J R STAT SOC B, V57, P57, DOI DOI 10.2307/2346101; Borg R, 2010, DIABETES, V59, P1585, DOI 10.2337/db09-1774; Goto A, 2013, BMJ-BRIT MED J, V29, P347; Hanas R, 1997, LANCET, V350, P492, DOI 10.1016/S0140-6736(05)63081-4; HELLER SR, 1991, DIABETES, V40, P223, DOI 10.2337/diabetes.40.2.223; Kim SK, 2011, ENDOCR J, V58, P535; Martin M, 2002, BMJ-BRIT MED J, V324, P704; McCall AL, 2006, DIABETES TECHNOL THE, V8, P644, DOI 10.1089/dia.2006.8.644; Risso A, 2001, AM J PHYSIOL-ENDOC M, V281, pE924; Rodbard D, 2009, DIABETES TECHNOL THE, V11, pS55, DOI 10.1089/dia.2008.0132; SCHLICHT.J, 1965, ACTA MED SCAND, V177, P95; SVENDSEN PA, 1982, DIABETOLOGIA, V23, P403; The Diabetes Control and Complications Trial Research Group, 1995, DIABETES, V44, P968; The Diabetes Control and Complications Trial Research Group, 1993, NEW ENGL J MED, V329, P977, DOI [10.1056/NEJM199309303291401, DOI 10.1056/NEJM199309303291401]; UK Prospective Diabetes Study (UKPDS) Group, 1998, LANCET, V352, P837, DOI DOI 10.1016/S0140-6736(98)07019-6; WOJCICKI JM, 1995, HORM METAB RES, V27, P41, DOI 10.1055/s-2007-979906	37	0	0	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0168-8227	1872-8227		DIABETES RES CLIN PR	Diabetes Res. Clin. Pract.	MAY	2015	108	2					342	349		10.1016/j.diabres.2015.01.040		8	Endocrinology & Metabolism	Endocrinology & Metabolism	CG3YJ	WOS:000353215500023		
J	Home, PD; Dain, MP; Freemantle, N; Kawamori, R; Pfohl, M; Brette, S; Pilorget, V; Scherbaum, WA; Vespasiani, G; Vincent, M; Balkau, B				Home, Philip D.; Dain, Marie-Paule; Freemantle, Nick; Kawamori, Ryuzo; Pfohl, Martin; Brette, Sandrine; Pilorget, Valerie; Scherbaum, Werner A.; Vespasiani, Giacomo; Vincent, Maya; Balkau, Beverley			Four-year evolution of insulin regimens, glycaemic control, hypoglycaemia and body weight after starting insulin therapy in type 2 diabetes across three continents	DIABETES RESEARCH AND CLINICAL PRACTICE			English	Article						CREDIT; Non-interventional study; Insulin regimens; Glucose-lowering mediations; Glycaemic control; Hypoglycaemia	SUPPORTED ORAL-THERAPY; BASAL INSULIN; OBSERVATIONAL DATABASE; NPH INSULIN; PEOPLE; DURATION; PERSISTENCE; GLARGINE; EFFICACY; OUTCOMES	Aims: It is of interest to understand how insulin therapy currently evolves in clinical practice, in the years after starting insulin in people with type 2 diabetes. We aimed to describe this evolution prospectively over 4 years, to assist health care planning. Methods: People who had started any insulin were identified from 12 countries on three continents. Baseline, then yearly follow-up, data were extracted from clinical records over 4 years. Results: Of the 2999 eligible people, 2272 were followed over 4 years. When starting insulin, mean (SD) duration of diabetes was 10.6 (7.8) years, HbA1c 9.5 (2.0)% (80 [22] mmol/mol) and BMI 29.3 (6.3) kg/m(2). Initial insulin therapy was basal 52%, premix 23%, mealtime + basal 14%, mealtime 8% and other 3%; at 4 years, 30%, 25%, 33%, 2% and 5%, respectively, with 5% not on insulin. Insulin dose was 20.2 U/day at the start and 45.8 U/day at year 4. There were 1258 people (55%) on their original regimen at 4 years, and this percentage differed according to baseline insulin regimen. HbA1c change was -2.0 (2.2)% (-22 [24] mmol/mol) and was similar by final insulin regimen. Hypoglycaemia prevalence was <20% in years 1-4. Body weight change was mostly in year 1, and was very variable, mean +2.7 (7.5) kg at year 4. Conclusion: Different insulin regimens were started in people with differing characteristics, and they evolved differently; insulin dose, hypoglycaemia and body weight change were diverse and largely independent of regimen. (C) 2015 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).	[Home, Philip D.] Newcastle Univ, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England; [Dain, Marie-Paule; Pilorget, Valerie; Vincent, Maya] Sanofi, Paris, France; [Freemantle, Nick] UCL, Dept Primary Care & Populat Hlth, London WC1E 6BT, England; [Kawamori, Ryuzo] Juntendo Univ, Dept Med, Tokyo, Japan; [Pfohl, Martin] Evangel Bethesda Krankenhaus Duisburg GmbH, Duisburg, Germany; [Brette, Sandrine] Lincoln, Boulogne, France; [Scherbaum, Werner A.] Univ Dusseldorf, Univ Hosp Dusseldorf, Dusseldorf, Germany; [Vespasiani, Giacomo] Madonna Soccorso Hosp, Diabetol & Metab Disorders Ctr, San Benedetto Tronto, Italy; [Balkau, Beverley] Univ Paris 11, INSERM, UMRS 1018, U1018, F-94807 Villejuif, France	Home, PD (reprint author), Sch Med, Inst Cellular Med Diabet, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.	philip.home@ncl.ac.uk			Sanofi; Eli Lilly; Medtronic; Novo Nordisk; Pfizer; Servier	This study was supported by Sanofi. Editorial support was provided by Tom Claus, Ph.D., of PPSI (a PAREXEL company) and was funded by Sanofi.; P.D.H., either personally or through institutions with which he is associated, receives funding for research, advisory and educational activities from most insulin and oral-agent manufacturers, including Sanofi. N.F. has received research grants and served as consultant to Eli Lilly, Medtronic, Novo Nordisk, Pfizer and Sanofi, and has served on speaker bureaus for Novo Nordisk and Sanofi. R.K. has received honoraria for lectures from Eli Lilly, Novo Nordisk and Sanofi. M.P. has served on advisory boards for Boehringer Ingelheim, Eli Lilly, Novo Nordisk and Sanofi, on speaker bureaus for Novo Nordisk and Sanofi, and received research grants from Eli Lilly, Medtronic, Novo Nordisk, Pfizer and Sanofi. W.A.S. has no conflicts to declare. G.V. has served on advisory boards for Sanofi, speaker bureaus for Lifescan and Novo Nordisk, and as consultant for Meteda. B.B. has served on advisory bureaus for Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly and Sanofi, and received a research grant from Servier. M.-P.D., V.P. and M.V. are employees of Sanofi. S.B. is a consultant to Sanofi.	DeFronzo RA, 2010, DIABETIC MED, V27, P309, DOI 10.1111/j.1464-5491.2010.02941.x; Valensi P, 2009, INT J CLIN PRACT, V63, P522, DOI 10.1111/j.1742-1241.2009.02002.x; Riddle MC, 2003, DIABETES CARE, V26, P3080, DOI 10.2337/diacare.26.11.3080; Little RR, 2001, CLIN CHEM, V47, P1985; Jeppsson JO, 2002, CLIN CHEM LAB MED, V40, P78, DOI 10.1515/CCLM.2002.016; Khunti K, 2012, DIABETES OBES METAB, V14, P654, DOI 10.1111/j.1463-1326.2012.01602.x; Home P, 2011, DIABETES RES CLIN PR, V94, P352, DOI 10.1016/j.diabres.2011.10.021; Hall GC, 2013, DIABETIC MED, V30, P681, DOI 10.1111/dme.12137; Balkau B, 2014, DIABETES CARE, V37, P2108, DOI 10.2337/dc13-3010; Pfohl M, 2010, INT J CLIN PHARM TH, V48, P761; Meneghini LF, 2009, CURR MED RES OPIN, V25, P1029, DOI 10.1185/03007990902840871 ; Deacon CF, 2012, DIABETES OBES METAB, V14, P762, DOI 10.1111/j.1463-1326.2012.01603.x; Quinzler R, 2012, INT J CLIN PHARM TH, V50, P24, DOI 10.5414/CP201572; Gerstein HC, 2008, NEW ENGL J MED, V358, P2545; Holman RR, 2007, NEW ENGL J MED, V357, P1716, DOI 10.1056/NEJMoa075392; Eliasson Björn, 2014, Diabetes Ther, V5, P243, DOI 10.1007/s13300-014-0068-9; Fonseca V, 2010, CURR MED RES OPIN, V26, P1621, DOI 10.1185/03007995.2010.485087; Freemantle N, 2012, DIABETES OBES METAB, V14, P901, DOI 10.1111/j.1463-1326.2012.01613.x; Gerstein HC, 2012, NEW ENGL J MED, V367, P319, DOI 10.1056/NEJMoa1203858; Gordon J, 2010, INT J CLIN PRACT, V64, P1609, DOI 10.1111/j.1742-1241.2010.02520.x; Hall GC, 2012, PHARMACOEPIDEM DR S, V21, P305, DOI 10.1002/pds.2345; Hall GC, 2011, DIABETES RES CLIN PR, V94, P442, DOI 10.1016/j.diabres.2011.09.003; International Diabetes Federation, 2014, DIABETES RES CLIN PR, V104, P1; Inzucchi SE, 2012, DIABETES CARE, V35, P1364, DOI [10.2337/dc12-0413, 10.2337/dc12-041.3]; Karter AJ, 2007, AM J MANAG CARE, V13, P598; NICE, BLOOD GLUC LOW THER; Raz I, 2013, DIABETES CARE, V36, pS139, DOI 10.2337/dcS13-2035; Strojek K, 2009, CURR MED RES OPIN, V25, P2887, DOI 10.1185/03007990903354674; UK Hypoglycaemia Stzzudy Group, 2007, DIABETOLOGIA, V50, P1140; Turner RC, 1998, LANCET, V352, P837; (UKPDS) UKPDS, 1995, BRIT MED J, V310, P83	31	0	0	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0168-8227	1872-8227		DIABETES RES CLIN PR	Diabetes Res. Clin. Pract.	MAY	2015	108	2					350	359		10.1016/j.diabres.2015.01.030		10	Endocrinology & Metabolism	Endocrinology & Metabolism	CG3YJ	WOS:000353215500024		
J	Tokumoto, S; Hamamoto, Y; Fujimoto, K; Yamaguchi, E; Okamura, E; Honjo, S; Ikeda, H; Wada, Y; Hamasaki, A; Koshiyama, H				Tokumoto, S.; Hamamoto, Y.; Fujimoto, K.; Yamaguchi, E.; Okamura, E.; Honjo, S.; Ikeda, H.; Wada, Y.; Hamasaki, A.; Koshiyama, H.			Correlation of circulating betatrophin concentrations with insulin secretion capacity, evaluated by glucagon stimulation tests	DIABETIC MEDICINE			English	Article							IDENTIFICATION; INDIVIDUALS; GLUCOSE	AimTo investigate the relationship between plasma betatrophin concentrations and insulin secretion capacity in people with Type 2 diabetes. MethodsGlucagon stimulation tests (1mg) were performed in 70 people with Type 2 diabetes after an overnight fast. Plasma betatrophin concentrations were measured using an enzyme-linked immunosorbent assay. Insulin secretion capacity was evaluated by measuring increments of C-peptide concentration in response to glucagon stimulation, and creatinine clearance was determined by comparing creatinine concentrations in serum and 24-h urine samples. ResultsPlasma betatrophin concentrations were positively correlated with duration of Type 2 diabetes (r=0.34, P=0.003), and negatively correlated with increments of C-peptide concentration (r=0.37, P=0.001) and creatinine clearance (r=0.37, P=0.001). The correlation with increments of C-peptide concentration remained significant after adjustment for age and duration of Type 2 diabetes (r=0.25, P=0.037). Multivariate analysis identified age and increments of C-peptide concentration as independent factors associated with plasma betatrophin levels. ConclusionPlasma betatrophin levels inversely correlate with insulin secretion capacity, suggesting that betatrophin levels are regulated by insulin secretion capacity in humans. What's new? Betatrophin has recently been identified as a potential stimulator of -cell mass expansion in mice; however, the pathophysiological role of betatrophin in people with diabetes is still unknown. This is the first report to show that betatrophin concentrations correlate negatively with insulin secretion capacity and positively with duration of Type 2 diabetes.	[Tokumoto, S.; Hamamoto, Y.; Fujimoto, K.; Yamaguchi, E.; Okamura, E.; Honjo, S.; Ikeda, H.; Wada, Y.; Hamasaki, A.; Koshiyama, H.] Kitano Hosp, Med Res Inst, Tazuke Kofukai Fdn, Ctr Diabet & Endocrinol, Osaka, Japan	Hamamoto, Y (reprint author), Kitano Hosp, Med Res Inst, Tazuke Kofukai Fdn, Ctr Diabet & Endocrinol, Osaka, Japan.	hamamoto@kitano-hp.or.jp					LINDEMAN RD, 1985, J AM GERIATR SOC, V33, P278; Yi P, 2013, CELL, V153, P747, DOI 10.1016/j.cell.2013.04.008; Fenzl A, 2014, DIABETOLOGIA, V57, P1204, DOI 10.1007/s00125-014-3208-x; Espes D, 2014, DIABETOLOGIA, V57, P50, DOI 10.1007/s00125-013-3071-1; Quagliarini F, 2012, P NATL ACAD SCI USA, V109, P19751, DOI 10.1073/pnas.1217552109; Fukushima M, 2004, METABOLISM, V53, P831, DOI 10.1016/j.metabol.2004.02.012; Zhang R, 2012, BIOCHEM BIOPH RES CO, V424, P786, DOI 10.1016/j.bbrc.2012.07.038; Gomez-Ambrosi J, 2014, J CLIN ENDOCR METAB, V99, pE2004, DOI 10.1210/jc.2014-1568; Jiao Y, 2014, DIABETES, V63, P1283, DOI 10.2337/db13-1435; Dong XY, 2004, INT J CANCER, V112, P239, DOI 10.1002/ijc.20363; Ren G, 2012, AM J PHYSIOL-ENDOC M, V303, pE334, DOI 10.1152/ajpendo.00084.2012; Funakoshi S, 2008, DIABETES RES CLIN PR, V82, P353, DOI 10.1016/j.diabres.2008.09.010; Habener JF, 2005, JOSLINS DIABETES MEL, P179; Hu H, 2014, DIABETES CARE, V37, P2718, DOI 10.2337/dc14-0602; Wasen E, 2004, DIABETES CARE, V27, P2648, DOI 10.2337/diacare.27.11.2648	15	3	3	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0742-3071	1464-5491		DIABETIC MED	Diabetic Med.	MAY	2015	32	5					653	656		10.1111/dme.12696		4	Endocrinology & Metabolism	Endocrinology & Metabolism	CG4BE	WOS:000353224800012		
J	Heianza, Y; Kato, K; Kodama, S; Ohara, N; Suzuki, A; Tanaka, S; Hanyu, O; Sato, K; Sone, H				Heianza, Y.; Kato, K.; Kodama, S.; Ohara, N.; Suzuki, A.; Tanaka, S.; Hanyu, O.; Sato, K.; Sone, H.			Risk of the development of Type 2 diabetes in relation to overall obesity, abdominal obesity and the clustering of metabolic abnormalities in Japanese individuals: does metabolically healthy overweight really exist? The Niigata Wellness Study	DIABETIC MEDICINE			English	Article							BODY-MASS INDEX; CORONARY-HEART-DISEASE; CARDIOVASCULAR-DISEASE; NORMAL-WEIGHT; FATTY LIVER; IMPACT; METAANALYSIS; POPULATION; MELLITUS; COHORT	AimsWe investigated the risk of developing diabetes across various metabolic phenotypes by considering the presence of overall adiposity or abdominal adiposity and the number of metabolic abnormalities and aimed to clarify whether a healthy overweight' phenotype, that is, overweight with no metabolic abnormalities, was protective of the development of diabetes. MethodsWe studied 29564 Japanese individuals without diabetes. The 5-year incidence of diabetes was assessed according to a combination of either overweight (BMI25.0kg/m(2)) or abdominal obesity (waist circumference 90cm in men and 80cm in women) and the number of metabolic factors present (hypertension, elevated triglyceride concentration, low HDL cholesterol concentration and impaired fasting glucose). ResultsA total of 1188 individuals developed diabetes. Compared with normal weight individuals with none of the four metabolic abnormalities, in overweight individuals with none of the four abnormalities there was an odds ratio (OR) of 2.32 [95% confidence interval (CI) 1.50, 3.59] for diabetes; having any one metabolic abnormality increased the risk of developing diabetes among normal weight individuals [OR 3.23 (2.55, 4.10)] and overweight individuals [OR 5.00 (3.77, 6.63)]. Among overweight individuals, the presence of impaired fasting glucose alone substantially elevated the risk of diabetes by 8.98-fold (5.52, 14.6) in comparison with the absence of the four metabolic factors. ConclusionsBeing healthy overweight' was associated with a higher OR of developing future diabetes among Japanese individuals than normal weight individuals with no metabolic abnormalities, and being overweight with one or more abnormalities had a further elevated OR compared with healthy overweight' people. What's new Japanese men and women who were healthy overweight', that is, overweight with none of the four metabolic abnormalities, were at risk of developing diabetes in comparison with those who were metabolically healthy and of normal weight. Each additional metabolic abnormality (hypertension, elevated triglycerides, low HDL cholesterol and impaired fasting glucose) increased the risk of developing Type2 diabetes in all four groups of people: overweight, abdominal adiposity, normal weight and normal abdominal adiposity.	[Heianza, Y.; Suzuki, A.; Hanyu, O.; Sone, H.] Niigata Univ, Dept Internal Med, Niigata, Japan; [Kato, K.; Kodama, S.; Ohara, N.] Niigata Univ, Grad Sch Med & Dent Sci, Dept Lab Med & Clin Epidemiol Prevent Noncommun D, Niigata, Japan; [Kato, K.; Sato, K.; Sone, H.] Niigata Assoc Occupat Hlth, Niigata, Japan; [Tanaka, S.] Kyoto Univ, Grad Sch Med & Publ Hlth, Dept Pharmacoepidemiol, Kyoto, Japan	Sone, H (reprint author), Niigata Univ, Dept Internal Med, Niigata, Japan.	sone@med.niigata-u.ac.jp			Ministry of Health, Labour and Welfare, Japan; Japan Society for the Promotion of Science	This work is financially supported in part by the Ministry of Health, Labour and Welfare, Japan. H. Sone and Y. Heianza are recipients of a Grant-in-Aid for Scientific Research from the Japan Society for the Promotion of Science. The sponsors had no role in the design and conduct of the study.	American Diabetes Association, 2010, DIABETES CARE S1, V33, pS62, DOI DOI 10.2337/DC10-S062; Jung HS, 2014, OBESITY, V22, P1880, DOI 10.1002/oby.20751; Primeau V, 2011, INT J OBESITY, V35, P971, DOI 10.1038/ijo.2010.216; Guo FJ, 2014, OBESITY, V22, P110, DOI 10.1002/oby.20585; Hwang LC, 2012, ASIA PAC J CLIN NUTR, V21, P227; Arnlov J, 2011, DIABETES CARE, V34, P61, DOI 10.2337/dc10-0955; Pataky Z, 2010, INT J OBESITY, V34, pS18, DOI 10.1038/ijo.2010.235; Appleton SL, 2013, DIABETES CARE, V36, P2388, DOI 10.2337/dc12-1971; Meigs JB, 2006, J CLIN ENDOCR METAB, V91, P2906, DOI 10.1210/jc.2006-0594; Bell JA, 2014, OBES REV, V15, P504, DOI 10.1111/obr.12157; Mukai N, 2009, DIABETES CARE, V32, P2288, DOI 10.2337/dc09-0896; Sung KC, 2012, DIABETES CARE, V35, P717, DOI 10.2337/dc11-1853; Stefan N, 2013, LANCET DIABETES ENDO, V1, P152, DOI 10.1016/S2213-8587(13)70062-7; Aung K, 2014, J CLIN ENDOCR METAB, V99, P462, DOI 10.1210/jc.2013-2832; Kashiwagi A, 2012, J DIABETES INVEST, V3, P39, DOI 10.1111/j.2040-1124.2012.00207.x; Bo S, 2012, AM J CLIN NUTR, V96, P962, DOI 10.3945/ajcn.112.040006; Wilson PWF, 2005, CIRCULATION, V112, P3066, DOI 10.1161/CIRCULATIONAHA.105.539528; Chan JCN, 2009, JAMA-J AM MED ASSOC, V301, P2129, DOI 10.1001/jama.2009.726; Sattar N, 2003, CIRCULATION, V108, P414, DOI 10.1161/01.CIR.0000080897.52664.94; Alberti KGMM, 2009, CIRCULATION, V120, P1640, DOI 10.1161/CIRCULATIONAHA.109.192644; Wannamethee SG, 2005, ARCH INTERN MED, V165, P2644, DOI 10.1001/archinte.165.22.2644; Kim CH, 2012, METAB SYNDR RELAT D, V10, P321, DOI 10.1089/met.2011.0143; Soriguer F, 2013, J CLIN ENDOCR METAB, V98, P2318, DOI 10.1210/jc.2012-4253; Kramer CK, 2013, ANN INTERN MED, V159, P758, DOI 10.7326/0003-4819-159-11-201312030-00008; Cugati S, 2007, MED J AUSTRALIA, V186, P131; Hadaegh F, 2011, BMC PUBLIC HEALTH, V11, DOI 10.1186/1471-2458-11-383; Heianza Y, 2014, J CLIN ENDOCR METAB, V99, P2952, DOI 10.1210/jc.2013-4427; Hinnouho GM, 2014, EUR HEART J, V36, P551; International Diabetes Foundation IDF, 2006, IDF CONS WORLDW DEF; Wassink AMJ, 2011, DIABETIC MED, V28, P932, DOI 10.1111/j.1464-5491.2011.03318.x	30	1	1	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0742-3071	1464-5491		DIABETIC MED	Diabetic Med.	MAY	2015	32	5					665	672		10.1111/dme.12646		8	Endocrinology & Metabolism	Endocrinology & Metabolism	CG4BE	WOS:000353224800014		
J	Kinoshita, Y; Takasu, K; Kobayashi, TK; Yuri, T; Tsubura, A; Shikata, N				Kinoshita, Yuichi; Takasu, Kosho; Kobayashi, Tadao K.; Yuri, Takashi; Tsubura, Airo; Shikata, Nobuaki			Diagnosis of Intraocular Lesions Using Vitreous Humor and Intraocular Perfusion Fluid Cytology: Experience with 83 Cases	DIAGNOSTIC CYTOPATHOLOGY			English	Article						intraocular cytology; pars plana vitrectomy; vitreous humor; intraocular perfusion fluid	NEEDLE-ASPIRATION BIOPSY; LYMPHOMA; UVEITIS; TUMORS; SARCOIDOSIS; VITRECTOMY; SPECIMENS; FEATURES; OUTCOMES	ObjectiveThe objective of the study was to evaluate the use of vitreous humor and/or intraocular perfusion fluid (IPF) from pars plana vitrectomy as a diagnostic and therapeutic procedure for intraocular diseases. MethodsThe cytologic findings with respect to the clinical data, the anatomical findings, and the final diagnosis in 83 cases that underwent intraocular cytologic examinations at the Kansai Medical University Takii Hospital were evaluated. For cytologic examination, the Papanicolaou stain, Giemsa stain, and in some cases, molecular biology and immunocytochemical techniques were used. ResultsMost of the clinical diagnoses were uveitis or endophthalmitis. Sixty-eight cases (81.9%) were negative on cytodiagnosis, while 15 cases (18.9%) were positive or suspicious for malignancy. Negative cases included infections and intraocular sarcoidosis (IOS), and all of the positive or suspicious cases were intraocular lymphomas. Some of these latter cases were also diagnosed using immunocytochemical staining or molecular biological procedures as ancillary techniques, performed using vitreous body cytology from IPF. ConclusionsAn early diagnosis and treatment of intraocular diseases is necessary to maintain an acceptable degree of quality of life. For an accurate diagnosis, it is necessary to understand the anatomy of the eye. Giemsa staining is recommended in addition to Papanicolaou staining for cytologic diagnostic evaluation of intraocular diseases. Furthermore, for the diagnosis of clonality in intraocular lymphomas, it is often necessary to use ancillary molecular biological procedures, using vitreous fluid. Diagn. Cytopathol. 2015;43:353-359. (c) 2014 Wiley Periodicals, Inc.	[Kinoshita, Yuichi; Yuri, Takashi; Tsubura, Airo] Kansai Med Univ, Dept Pathol 2, Hirakata, Osaka 5731010, Japan; [Kinoshita, Yuichi; Takasu, Kosho; Shikata, Nobuaki] Kansai Med Univ, Takii Hosp, Div Diagnost Cytopathol & Histopathol, Moriguchi, Osaka 570, Japan; [Takasu, Kosho] Hyogo Kenritsu Amagasaki Hosp, Div Surg Pathol, Amagasaki, Hyogo, Japan; [Kobayashi, Tadao K.] Osaka Univ, Grad Sch Med & Hlth Sci, Canc Educ & Res Ctr, Osaka, Japan	Kinoshita, Y (reprint author), Kansai Med Univ, Dept Pathol 2, Shinmachi 2-5-1, Hirakata, Osaka 5731010, Japan.	kinoshyu@takii.kmu.ac.jp					SHIELDS JA, 1995, AM J OPHTHALMOL, V119, P422; Akpek EK, 1999, OPHTHALMOLOGY, V106, P1805, DOI 10.1016/S0161-6420(99)90341-X; Biscotti CV, 2011, FNA CYTOLOGY OPHTHAL, P99; Cao XG, 2011, ACTA OPHTHALMOL, V89, pE149, DOI 10.1111/j.1755-3768.2009.01797.x; Caya J G, 1985, Diagn Cytopathol, V1, P267, DOI 10.1002/dc.2840010404; Chan Chi-Chao, 2004, Cancer Control, V11, P285; Decaussin M, 1998, DIAGN CYTOPATHOL, V19, P190, DOI 10.1002/(SICI)1097-0339(199809)19:3<190::AID-DC7>3.0.CO;2-H; Eide N, 2009, ACTA OPHTHALMOL, V87, P588, DOI 10.1111/j.1755-3768.2009.01637.x; Engel H M, 1981, Retina, V1, P121; Glasgow BJ, 1992, OCULAR CYTOPATHOLOGY; Halm CJ, 1993, SURV OPHTHALMOL, V38, P229; Harbort CP, 2009, OCUL IMMUNOL INFLAMM, V17, P160; Hoffman PM, 2003, EYE, V17, P513, DOI 10.1038/sj.eye.6700378; Jahnke K, 2006, GRAEF ARCH CLIN EXP, V244, P663, DOI 10.1007/s00417-005-0138-9; JAKOBIEC FA, 1979, OPHTHALMOLOGY, V86, P1662; Kaneko C, 2010, DIAGN CYTOPATHOL, V38, P652, DOI 10.1002/dc.21280; Kinoshita Y, 2012, DIAGN CYTOPATHOL, V40, P210, DOI 10.1002/dc.21540; KINOSHITA Y, 2011, J JPN SOC CLIN CYTOL, V50, P320; Kinoshita Y, 2012, DIAGN CYTOPATHOL, V40, P604, DOI 10.1002/dc.21596; Kobayashi TK, 1996, CYTOPATHOLOGY, V1, P97; Liu K, 1999, ACTA CYTOL, V43, P201; Margolis R, 2007, OPHTHALMOLOGY, V114, P1893, DOI 10.1016/j.ophtha.2007.01.038; Matsuo T, 2001, ARCH OPHTHALMOL-CHIC, V119, P125; Mruthyunjaya JM, 2002, OPHTHALMOLOGY, V109, P1123; Norimatsu Y, 2010, DIAGN CYTOPATHOL, V38, P702, DOI 10.1002/dc.21279; Shen SC, 2007, J CATARACT REFR SURG, V33, P336, DOI 10.1016/j.jcrs.2006.09.032; Trichopoulos N, 2006, GRAEF ARCH CLIN EXP, V244, P524, DOI 10.1007/s00417-005-0113-5; Verbraeken H, 1996, GRAEF ARCH CLIN EXP, V234, P288, DOI 10.1007/BF00220702; Wang YJ, 2011, INT J MOL SCI, V12, P5684, DOI 10.3390/ijms12095684; WHITCUP SM, 1993, OPHTHALMOLOGY, V100, P1399; Wittenberg LA, 2008, OPHTHALMOLOGY, V115, P1944, DOI 10.1016/j.ophtha.2008.05.022; Yasuhara T, 2005, ACTA OPHTHALMOL SCAN, V83, P364, DOI 10.1111/j.1600-0420.2005.00449.x; Zardiver RA, 2004, OPHTHALMOLOGY, V111, P1762	33	1	1	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	8755-1039	1097-0339		DIAGN CYTOPATHOL	Diagn. Cytopathol.	MAY	2015	43	5					353	359		10.1002/dc.23222		7	Medical Laboratory Technology; Pathology	Medical Laboratory Technology; Pathology	CG4AQ	WOS:000353222800001		
J	Tone, K; Kojima, K; Hoshiai, K; Kijima, H; Kurose, A				Tone, Kiyoshi; Kojima, Keiko; Hoshiai, Keita; Kijima, Hiroshi; Kurose, Akira			Utility of Intraoperative Cytology of Resection Margins in Biliary Tract and Pancreas Tumors	DIAGNOSTIC CYTOPATHOLOGY			English	Article						biliary tract tumor; pancreas tumor; resection margin; intraoperative cytology; frozen section	ULTRAFAST PAPANICOLAOU STAIN; ASPIRATION BIOPSY SPECIMENS; INTRAEPITHELIAL NEOPLASIA; EXTRAHEPATIC CHOLANGIOCARCINOMA; SURGICAL PATHOLOGY; IMPRINT CYTOLOGY; DIAGNOSIS; CARCINOMA; ADENOCARCINOMA; CLASSIFICATION	BackgroundIntraoperative diagnosis of resection margins in the biliary tract and pancreas tumors is important in deciding extent of resection; however, diagnosis based solely on frozen sections is sometimes difficult. Therefore, we investigated the usefulness of intraoperative cytology (IC) combined with frozen section (FS) histology. We present the results with a discussion of the value of this combination and its associated problems. MethodsWe examined 80 bile duct resection margin specimens from 42 patients, and 34 pancreatic resection margin specimens from 29 patients, who underwent intraoperative diagnosis of resection margins during surgery for biliary tract or pancreatic tumors between October 2012 and January 2014. IC was performed on imprint specimens prepared from surfaces of margins being examined. The results were compared with FS and final histology of operative materials. ResultsIn IC, excluding cases with insufficient material, the results for bile duct margins; sensitivity was 96.7%, specificity 100% and accuracy 98.7%. The results for pancreatic margins; sensitivity was 100%, specificity 92.9%, and accuracy 93.3%. In FS, the results for bile duct margins; sensitivity was 96.8%, specificity 100%, and accuracy 98.8%. The results for pancreatic margins; sensitivity was 66.7%, specificity 100%, and accuracy 97.1%. ConclusionIC is quick, highly accurate and very easy to perform. This study even included a specimen for which only IC led to an accurate diagnosis. IC used in combination with FS can achieve intraoperative diagnosis with high overall accuracy. Diagn. Cytopathol. 2015;43:366-373. (c) 2014 Wiley Periodicals, Inc.	[Tone, Kiyoshi; Kojima, Keiko; Hoshiai, Keita; Kurose, Akira] Hirosaki Univ Hosp, Dept Pathol, Hirosaki, Aomori 0368563, Japan; [Kijima, Hiroshi] Hirosaki Univ, Grad Sch Med, Dept Pathol & Biosci, Hirosaki, Aomori, Japan; [Kurose, Akira] Hirosaki Univ, Grad Sch Med, Dept Anat Pathol, Hirosaki, Aomori, Japan	Tone, K (reprint author), Hirosaki Univ Hosp, Dept Pathol, 53 Honcho, Hirosaki, Aomori 0368563, Japan.	ki-tone@cc.hirosaki-u.ac.jp					Akamatsu Nobuhisa, 2011, World J Clin Oncol, V2, P94, DOI 10.5306/wjco.v2.i2.94; Cioc AM, 2002, ARCH PATHOL LAB MED, V126, P1169; Kinney T, 2010, SURG CLIN N AM, V90, P235, DOI 10.1016/j.suc.2009.12.003; Hruban RH, 2001, AM J SURG PATHOL, V25, P579, DOI 10.1097/00000478-200105000-00003; Nakaizumi A, 1997, DIGEST DIS SCI, V42, P1796, DOI 10.1023/A:1018842305690; Lechago J, 2005, ARCH PATHOL LAB MED, V129, P1610; Hruban RH, 2004, AM J SURG PATHOL, V28, P977, DOI 10.1097/01.pas.0000126675.59108.80; SILVERMAN JF, 1989, ACTA CYTOL, V33, P791; YANG GCH, 1995, ACTA CYTOL, V39, P55; Dudgeon LS, 1927, BRIT J SURG, V15, P250, DOI 10.1002/bjs.1800155810; GUARDA LA, 1990, DIAGN CYTOPATHOL, V6, P235, DOI 10.1002/dc.2840060403; Hara H, 2008, AM J CLIN PATHOL, V129, P115, DOI 10.1309/PHV2244LC8BOP7TR; Hara H, 2005, ACTA CYTOL, V49, P611, DOI 10.1159/000326248; Higuchi R, 2010, SURGERY, V148, P7, DOI 10.1016/j.surg.2009.11.018; Hysell C, 2007, CANCER CYTOPATHOL, V111, P351; Jarboe EA, 2011, DIAGN CYTOPATHOL, V39, P575, DOI 10.1002/dc.21430; KIM K, 1990, DIAGN CYTOPATHOL, V6, P304, DOI 10.1002/dc.2840060503; KONTOZOGLOU TE, 1991, ACTA CYTOL, V35, P154; Layfield LJ, 2010, ANN DIAGN PATHOL, V14, P140, DOI 10.1016/j.anndiagpath.2009.12.007; Lin F, 2003, CANCER CYTOPATHOL, V99, P44, DOI 10.1002/cncr.11012; MAIR S, 1991, AM J CLIN PATHOL, V96, P8; Ojima H, 2009, CANCER SCI, V100, P62, DOI 10.1111/j.1349-7006.2008.01009.x; Omiya H, 2006, ACTA CYTOL, V50, P444; Otero JCR, 2008, J HEPATO-BILIARY-PAN, V15, P157, DOI 10.1007/s00534-007-1253-2; OWINGS RM, 1984, HUM PATHOL, V15, P605; Pitman MB, 2010, DIAGNOSTIC CYTOPATHO, V3rd, P333; Sasaki R, 2007, WORLD J SURG, V31, P1788, DOI 10.1007/s00268-007-9102-7; SCOPA CD, 1990, DIAGN CYTOPATHOL, V6, P5, DOI 10.1002/dc.2840060103; Scucchi LF, 1997, ACTA CYTOL, V41, P1489; Wakai T, 2005, CANCER, V103, P1210, DOI 10.1002/cncr.20906; Yamaguchi Koji, 2005, HPB (Oxford), V7, P135, DOI 10.1080/13651820510028873; YANG GCH, 1994, ACTA CYTOL, V38, P37; Yang GCH, 1997, ACTA CYTOL, V41, P1513	33	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	8755-1039	1097-0339		DIAGN CYTOPATHOL	Diagn. Cytopathol.	MAY	2015	43	5					366	373		10.1002/dc.23240		8	Medical Laboratory Technology; Pathology	Medical Laboratory Technology; Pathology	CG4AQ	WOS:000353222800003		
J	Yorita, K; Ishihara, A; Tokumitsu, T; Minematsu, E; Ohno, A; Ikejiri, H; Kataoka, H				Yorita, Kenji; Ishihara, Akira; Tokumitsu, Takako; Minematsu, Eiko; Ohno, Akinobu; Ikejiri, Hiroshi; Kataoka, Hiroaki			A Case of a Pleomorphic Hyalinizing Angiectatic Tumor of Soft Parts with Intracytoplasmic Hemosiderin Pigment Apparent upon Fine-Needle Aspiration Cytology	DIAGNOSTIC CYTOPATHOLOGY			English	Article						intracytoplasmic hemosiderin pigments; pleomorphic hyalinizing angiectatic tumor of soft parts; satellite lesions; tumor encapsulation	FIBROHISTIOCYTIC LIPOMATOUS LESION; FEATURES	Pleomorphic hyalinizing angiectatic tumors of soft parts are extremely rare low-grade mesenchymal lesions that frequently occur subcutaneously, especially in the lower extremity. The tumor is histologically characterized by sheets of plump, spindled or rounded cells, and clusters of ectatic blood vessels. It also has a number of previously characterized cytological features such as pleomorphic cells, intranuclear pseudoinclusion, and intracytoplasmic hemosiderin pigments. However, intracytoplasmic hemosiderin has not been carefully evaluated in cytology specimens. Here, we report the case of a 56-year-old Japanese man with an encapsulated pleomorphic hyalinizing angiectatic tumor of soft parts that included fine and coarse hemosiderin-laden tumor cells. The tumor was clinically followed up as a hematoma, but malignant tumors, including malignant melanoma, were suspected because aspiration cytology specimens contained pleomorphic cells with intracytoplasmic brown pigments. The tumor was closely associated with an intratumoral hematoma and a few microscopic satellite lesions. Pleomorphic hyalinizing angiectatic tumor of soft parts should be included in the differential cytological diagnosis of soft tissue tumors if the three cytological features described earlier are present. Enucleation therapy could facilitate local recurrence, as the tumor may have the potential to infiltrate surrounding soft tissue or form satellite lesions. Diagn. Cytopathol. 2015;43:407-411. (c) 2014 The Authors. Diagnostic Cytopathology Published by Wiley Periodicals, Inc.	[Yorita, Kenji; Kataoka, Hiroaki] Miyazaki Univ, Sect Oncopathol & Regenerat Biol, Dept Pathol, Fac Med, Kiyotake, Miyazaki 8891692, Japan; [Ishihara, Akira] Miyazaki Prefectural Nobeoka Hosp, Dept Anat Pathol, Miyazaki, Miyazaki, Japan; [Tokumitsu, Takako; Minematsu, Eiko; Ohno, Akinobu] Univ Miyazaki Hosp, Dept Pathol Div, Miyazaki, Japan; [Ikejiri, Hiroshi] Miyazaki Univ, Fac Med, Dept Orthoped Surg, Miyazaki, Japan	Yorita, K (reprint author), Miyazaki Univ, Sect Oncopathol & Regenerat Biol, Dept Pathol, Fac Med, 5200 Kihara, Kiyotake, Miyazaki 8891692, Japan.	kenji_yorita@med.miyazaki-u.ac.jp					Murali R, 2011, AM J CLIN PATHOL, V136, P739, DOI 10.1309/AJCP5NK0FJCGHTFM; Tallarigo F, 2009, PATHOL RES PRACT, V205, P69, DOI 10.1016/j.prp.2008.07.010; Cimino-Mathews A, 2011, DIAGN CYTOPATHOL, V39, P214, DOI 10.1002/dc.21403; El-Tal AEK, 2006, J CUTAN PATHOL, V33, P361, DOI 10.1111/j.0303-6987.2006.00416.x; Folpe AL, 2004, AM J SURG PATHOL, V28, P1417, DOI 10.1097/01.pas.0000141406.02581.fb; Fukunaga M, 1997, PATHOL INT, V47, P784, DOI 10.1111/j.1440-1827.1997.tb04458.x; Guillou L, 2000, AM J SURG PATHOL, V24, P971, DOI 10.1097/00000478-200007000-00008; Husek K, 2001, Cesk Patol, V37, P177; Kazakov DV, 2007, PATHOL INT, V57, P281, DOI 10.1111/j.1440-1827.2007.02094.x; Ke Q, 2007, CHINESE MED J-PEKING, V120, P876; Lin O, 2005, DIAGN CYTOPATHOL, V32, P238, DOI 10.1002/dc.20219; Lin O, 2008, COMPREHENSIVE CYTOPA, V3 rd, P472; Luzar B, 2006, PATHOL INT, V56, P283, DOI 10.1111/j.1440-1827.2006.01955.x; Marshall-Taylor C, 2000, MODERN PATHOL, V13, P1192, DOI 10.1038/modpathol.3880221; Matsumoto K, 2002, PATHOL INT, V52, P664, DOI 10.1046/j.1440-1827.2002.01406.x; Peng HC, 2010, J FORMOS MED ASSOC, V109, P616, DOI 10.1016/S0929-6646(10)60100-3; Silverman JS, 1997, J CUTAN PATHOL, V24, P377, DOI 10.1111/j.1600-0560.1997.tb00807.x; Smith MEF, 1996, AM J SURG PATHOL, V20, P21, DOI 10.1097/00000478-199601000-00002; Wei S, 2012, HUM PATHOL, V43, P121, DOI 10.1016/j.humpath.2011.02.023	19	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	8755-1039	1097-0339		DIAGN CYTOPATHOL	Diagn. Cytopathol.	MAY	2015	43	5					407	411		10.1002/dc.23233		5	Medical Laboratory Technology; Pathology	Medical Laboratory Technology; Pathology	CG4AQ	WOS:000353222800012		
J	Kinoshita, T				Kinoshita, Tamotu			ON SECOND ORDER WEAKLY HYPERBOLIC EQUATIONS WITH OSCILLATING COEFFICIENTS	Differential and Integral Equations			English	Article							GEVREY-WELL-POSEDNESS; NON-LIPSCHITZ COEFFICIENTS; NONREGULAR COEFFICIENTS; OPERATORS	We study well-posedness issues in Gevrey classes for the Cauchy problem for wave equations of the form partial derivative(2)(t)u-a(t)partial derivative(2)(x)u = 0. lathe strictly hyperbolic case a(t) >= c(> 0), Colombini, De Giorgi and Spagnolo have shown that it is sufficient to assume Holder regularity of the coefficients in order to prove Gevrey well-posedness. Recently, assumptions bearing on the oscillations of the coefficient have been imposed in the literature in order to guarantee well-posedness. In the weakly hyperbolic case a(t) >= 0, Colombini, Jannelli and Spagnolo proved well-posedness in Gevrey classes of order 1 <= s <= s(0) = 1 + (k + alpha)/2. In this paper, we put forward condition vertical bar a'(t)vertical bar <= Ca(t)(p)/t(q) that bears both on the oscillations and the degree of degeneracy of the coefficient. we show that under such a condition, Gevrey well-posalness holds for 1 <= s < qs(0)/{(k + alpha)(1 - p) + q - 1} if q >= 3 - 2p. In particular, this improves on the result (corresponding to the case p = 0) of Colombini, Del Santo and Kinoshita.	Univ Tsukuba, Inst Math, Tsukuba, Ibaraki 3058571, Japan	Kinoshita, T (reprint author), Univ Tsukuba, Inst Math, Tsukuba, Ibaraki 3058571, Japan.						Cicognani M., 2003, TSUKUBA J MATH, V27, P1; Colombini F., 1983, ANN SCUOLA NORM SUP, V10, P291; Colombini F., 1982, ACTA MATH, V148, P291; Colombini F, 2003, J MATH ANAL APPL, V282, P410, DOI 10.1016/S0022-247X(03)00164-1; Colombini F, 2002, ANN SCUOLA NORM-SCI, V1, P327; Colombini F, 2002, J MATH PURE APPL, V81, P641, DOI 10.1016/S0021-7824(01)01252-1; Colombini F., 1979, ANN SCUOLA NORMALE S, p[6, 511]; Colombini F, 2004, MATH SCAND, V94, P267; D'Ancona P., 1988, PUBL RIMS KYOTO U, V24, P243; Fukuda N., 2014, REND I MAT U TRIESTE, V45, P97; JANNELLI E, 1984, J MATH KYOTO U, V24, P763; Kinoshita T., 2003, BANACH CTR PUBLICATI, V60, P121; Kinoshita T, 2005, ADV DIFFERENTIAL EQU, V10, P191; NISHITANI T, 1983, B SCI MATH, V107, P113	14	0	0	KHAYYAM PUBL CO INC	ATHENS	PO BOX 429, ATHENS, OH 45701 USA	0893-4983			DIFFER INTEGRAL EQU	Differ. Integral Equ.	MAY-JUN	2015	28	5-6					581	600				20	Mathematics, Applied; Mathematics	Mathematics	CG6PE	WOS:000353423300008		
J	Imanishi, J; Tanaka, H; Sawa, T; Motoji, Y; Miyoshi, T; Mochizuki, Y; Fukuda, Y; Tatsumi, K; Matsumoto, K; Okita, Y; Hirata, K				Imanishi, Junichi; Tanaka, Hidekazu; Sawa, Takuma; Motoji, Yoshiki; Miyoshi, Tatsuya; Mochizuki, Yasuhide; Fukuda, Yuko; Tatsumi, Kazuhiro; Matsumoto, Kensuke; Okita, Yutaka; Hirata, Ken-ichi			Association of Left Atrial Booster-Pump Function with Heart Failure Symptoms in Patients with Severe Aortic Stenosis and Preserved Left Ventricular Ejection Fraction	ECHOCARDIOGRAPHY-A JOURNAL OF CARDIOVASCULAR ULTRASOUND AND ALLIED TECHNIQUES			English	Article						aortic stenosis; echocardiography; left atrium; strain rate imaging	ACUTE MYOCARDIAL-INFARCTION; DIASTOLIC FUNCTION; VALVE STENOSIS; EXERCISE CAPACITY; DILATED CARDIOMYOPATHY; SPECKLE-TRACKING; FILLING PRESSURE; EUROPEAN-SOCIETY; DISEASE; STRAIN	BackgroundIdentification of heart failure (HF) symptoms in patients with severe aortic stenosis (AS) and preserved left ventricular (LV) ejection fraction (EF) is clinically important, but assessment of HF symptoms is challenging. It was recently reported that resting left atrium (LA) functions are related to exercise performance and are also important prognostic markers for patients with HF. The aim of this study was to assess the association of the HF symptoms with LA function in patients with severe AS and preserved LVEF. MethodsWe retrospectively studied 40 patients with severe AS and preserved LVEF (all 50%) who were referred for aortic valve replacement (AVR). LA reservoir (SR-LAs), conduit (SR-LAe), and booster-pump (SR-LAa) functions were determined as the averaged global LA speckle tracking longitudinal strain rate from apical four- and two-chamber views. Twenty patients were symptomatic and 20 asymptomatic. ResultsAortic stenosis severity was similar for the 2 groups. Symptomatic status was associated with age, LV mass index, hemoglobin, B-type natriuretic peptide, LV end-systolic volume index, LVEF, LA volume index, SR-LAs, SR-LAe, and SR-LAa. Importantly, multivariate logistic regression analysis revealed that SR-LAa was the only independent determinant of symptomatic status (OR=0.242, P=0.002). Furthermore, significant improvement of SR-LAa was observed along with the reduction in LA volume index and LV mass index after AVR. ConclusionsSR-LAa was found to be associated with the HF symptoms. Characterization of LA booster-pump function may be useful for the assessment of the symptomatic status in patients with severe AS patients and limited physical activity.	[Imanishi, Junichi; Tanaka, Hidekazu; Sawa, Takuma; Motoji, Yoshiki; Miyoshi, Tatsuya; Mochizuki, Yasuhide; Fukuda, Yuko; Tatsumi, Kazuhiro; Matsumoto, Kensuke; Hirata, Ken-ichi] Kobe Univ, Grad Sch Med, Dept Internal Med, Div Cardiovasc Med, Kobe, Hyogo 6500017, Japan; [Okita, Yutaka] Kobe Univ, Grad Sch Med, Dept Surg, Div Cardiovasc Med, Kobe, Hyogo 6500017, Japan	Tanaka, H (reprint author), Kobe Univ, Grad Sch Med, Dept Internal Med, Div Cardiovasc Med,Chuo Ku, 7-5-2 Kusunoki Cho, Kobe, Hyogo 6500017, Japan.	tanakah@med.kobe-u.ac.jp					Bonow RO, 2006, CIRCULATION, V114, pE84, DOI 10.1161/CIRCULATIONAHA.106.176857; Nagueh SF, 2009, J AM SOC ECHOCARDIOG, V22, P107, DOI 10.1016/j.echo.2008.11.023; Modesto KM, 2005, EUR HEART J, V26, P173, DOI 10.1093/eurheartj/ehi040; Nishimura RA, 2014, J AM COLL CARDIOL, V63, P2438, DOI 10.1016/j.jacc.2014.02.537; Beinart R, 2004, J AM COLL CARDIOL, V44, P327, DOI 10.1016/j.jacc.2004.03.062; Lancellotti P, 2010, AM J CARDIOL, V105, P383, DOI 10.1016/j.amjcard.2009.09.043; Inaba Y, 2005, J AM SOC ECHOCARDIOG, V18, P729, DOI 10.1016/j.echo.2004.12.005; Moller JE, 2003, CIRCULATION, V107, P2207, DOI 10.1161/01.CIR.0000066318.21784.43; Mondillo S, 2011, J AM SOC ECHOCARDIOG, V24, P898, DOI 10.1016/j.echo.2011.04.014; Amato MCM, 2001, HEART, V86, P381, DOI 10.1136/heart.86.4.381; Vahanian A, 2007, EUR HEART J, V28, P230, DOI 10.1093/eurheartj/ehl428; Serri K, 2006, J AM COLL CARDIOL, V47, P1175, DOI 10.1016/j.jacc.2005.10.061; Lang RM, 2005, J AM SOC ECHOCARDIOG, V18, P1440, DOI 10.1016/j.echo.2005.10.005; Kokubu N, 2007, HYPERTENS RES, V30, P13, DOI 10.1291/hypres.30.13; Baumgartner H, 2009, J AM SOC ECHOCARDIOG, V22, P1, DOI 10.1016/j.echo.2008.11.029; Pellikka PA, 2005, CIRCULATION, V111, P3290, DOI 10.1161/CIRCULATIONAHA.104.495903; Cohen-Solal A, 1999, EUR HEART J, V20, P931, DOI 10.1053/euhj.1998.1473; Briand M, 2005, J AM COLL CARDIOL, V46, P291, DOI 10.1016/j.jacc.2004.10.081; Wakami K, 2009, J AM SOC ECHOCARDIOG, V22, P847, DOI 10.1016/j.echo.2009.04.026; Rossi A, 2002, J AM COLL CARDIOL, V40, P1425, DOI 10.1016/S0735-1097(02)02305-7; Di Salvo G, 2005, CIRCULATION, V112, P387, DOI 10.1161/CIRCULATIONAHA.104.463125; Cioffi G, 2012, ECHOCARDIOGR-J CARD, V29, P1038, DOI 10.1111/j.1540-8175.2012.01744.x; Dahl JS, 2014, CIRC-CARDIOVASC IMAG, V7, P142, DOI 10.1161/CIRCIMAGING.113.000636; Dalsgaard M, 2013, ECHOCARDIOGR-J CARD, V30, P1008, DOI 10.1111/echo.12184; Donal E, 2008, J AM SOC ECHOCARDIOG, V21, P703, DOI 10.1016/j.echo.2007.10.002; HEIDENRE.FP, 1970, J CLIN INVEST, V49, P1605, DOI 10.1172/JCI106378; Hung MJ, 2004, ECHOCARDIOGR-J CARD, V21, P593, DOI 10.1111/j.0742-2822.2004.03154.x; Imanishi J, 2014, INT J CARDIOVAS IMAG, V30, P295, DOI 10.1007/s10554-013-0346-z; Jikuhara T, 1997, CHEST, V111, P922, DOI 10.1378/chest.111.4.922; LAVINE SJ, 1989, AM J CARDIOL, V64, P61, DOI 10.1016/0002-9149(89)90654-1; Morris DA, 2012, CIRC-HEART FAIL, V5, P610, DOI 10.1161/CIRCHEARTFAILURE.112.966564; O'Connor K, 2010, AM J CARDIOL, V106, P1157, DOI 10.1016/j.amjcard.2010.06.029; PACKER M, 1990, CIRCULATION, V81, P78; Rosenhek R, 2000, NEW ENGL J MED, V343, P611, DOI 10.1056/NEJM200008313430903; Terzi S, 2005, INT HEART J, V46, P123, DOI 10.1536/ihj.46.123; Toutouzas K, 1996, AM J CARDIOL, V78, P1314, DOI 10.1016/S0002-9149(96)00622-4; Vahanian A, 2012, EUR J CARDIO-THORAC, V42, pS1, DOI 10.1093/ejcts/ezs455	37	1	1	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0742-2822	1540-8175		ECHOCARDIOGR-J CARD	Echocardiography-J. Cardiovasc. Ultrasound Allied Tech.	MAY	2015	32	5					758	767		10.1111/echo.12733		10	Cardiac & Cardiovascular Systems	Cardiovascular System & Cardiology	CG6CN	WOS:000353383200006		
J	Orii, M; Hirata, K; Tanimoto, T; Shiono, Y; Shimamura, K; Ishibashi, K; Yamano, T; Ino, Y; Kitabata, H; Yamaguchi, T; Kubo, T; Imanishi, T; Akasaka, T				Orii, Makoto; Hirata, Kumiko; Tanimoto, Takashi; Shiono, Yasutsugu; Shimamura, Kunihiro; Ishibashi, Kohei; Yamano, Takashi; Ino, Yasushi; Kitabata, Hironori; Yamaguchi, Tomoyuki; Kubo, Takashi; Imanishi, Toshio; Akasaka, Takashi			Two-Dimensional Speckle Tracking Echocardiography for the Prediction of Reversible Myocardial Dysfunction after Acute Myocardial Infarction: Comparison with Magnetic Resonance Imaging	ECHOCARDIOGRAPHY-A JOURNAL OF CARDIOVASCULAR ULTRASOUND AND ALLIED TECHNIQUES			English	Article						strain; myocardial infarction; cardiac magnetic resonance imaging	PRIMARY PERCUTANEOUS INTERVENTION; LEFT-VENTRICULAR FUNCTION; CANINE LEFT-VENTRICLE; LONGITUDINAL STRAIN; TRANSMURAL EXTENT; EUROPEAN-SOCIETY; DEFORMATION; FIBER; IMPROVEMENT; ENHANCEMENT	BackgroundWe aimed to determine the predictive value of longitudinal, circumferential, and radial strains by two-dimensional speckle tracking echocardiography (2DSTE) for improvement in cardiac function after acute myocardial infarction (AMI) compared with that of contrast-enhanced cardiac magnetic resonance imaging (ceMRI). MethodsIn 35 patients with first-time AMI, myocardial viability was assessed to predict recovery of function at follow-up (72months), prospectively. For each left ventricular segment, each peak strains were determined using 2DSTE, and the relative extent of hyperenhancement was assessed using ceMRI. ResultsOf 176 segments with impaired function early after AMI, 99 segments showed regional recovery. Compared with segments showing functional improvement, those that failed to recover had lower peak radial (20 +/- 16% vs. 32 +/- 21%; P<0.001), circumferential (-10 +/- 5% vs. -20 +/- 6%; P<0.001), and longitudinal (-10 +/- 5% vs. -14 +/- 5%; P<0.001) strain and a greater extent of hyperenhancement (71 +/- 22% vs. 27 +/- 20%; P<0.001). Among strain parameters, circumferential strain yielded greater area under the curve (AUC; 0.899) than radial and longitudinal strain (0.682 and 0.718, respectively). The predictive value of circumferential strain (sensitivity 81.0%, specificity 79.6%, at a cutoff value of -14.3%) could be comparable to that of hyperenhancement (sensitivity 86.2%, specificity 83.9%, AUC 0.921, at a cutoff value of 47%) (P=0.439). ConclusionCircumferential strain can identify reversible myocardial dysfunction after AMI with a diagnostic ability comparable to that of ceMRI.	[Orii, Makoto; Hirata, Kumiko; Tanimoto, Takashi; Shiono, Yasutsugu; Shimamura, Kunihiro; Ishibashi, Kohei; Yamano, Takashi; Ino, Yasushi; Kitabata, Hironori; Yamaguchi, Tomoyuki; Kubo, Takashi; Imanishi, Toshio; Akasaka, Takashi] Wakayama Med Univ, Dept Cardiovasc Med, Wakayama 6418510, Japan	Hirata, K (reprint author), Wakayama Med Univ, Dept Cardiovasc Med, 811-1 Kimiidera, Wakayama 6418510, Japan.	hiratakumiko@aol.com					Chan J, 2006, J AM COLL CARDIOL, V48, P2026, DOI 10.1016/j.jacc.2006.07.050; WALDMAN LK, 1985, CIRC RES, V57, P152; WALDMAN LK, 1988, CIRC RES, V63, P550; GAUDRON P, 1993, CIRCULATION, V87, P755; Kim RJ, 2000, NEW ENGL J MED, V343, P1445, DOI 10.1056/NEJM200011163432003; Langeland S, 2005, CIRCULATION, V112, P2157, DOI 10.1161/CIRCULATIONAHA.105.554006; Bochenek T, 2011, J AM SOC ECHOCARDIOG, V24, P1342, DOI 10.1016/j.echo.2011.09.003; Ersboll M, 2012, J AM SOC ECHOCARDIOG, V25, P1280, DOI 10.1016/j.echo.2012.09.006; Ryf S, 2006, J CARDIOV MAGN RESON, V8, P445, DOI 10.1080/10976640600599494; Amundsen BH, 2006, J AM COLL CARDIOL, V47, P789, DOI 10.1016/j.jacc.2005.10.040; Sjoli B, 2009, JACC-CARDIOVASC IMAG, V2, P24, DOI 10.1016/j.jcmg.2008.10.007; Tanimoto T, 2010, CIRCULATION, V122, P2281, DOI 10.1161/CIRCULATIONAHA.109.935338; Munk K, 2012, J AM SOC ECHOCARDIOG, V25, P644, DOI 10.1016/j.echo.2012.02.003; Lang RM, 2005, J AM SOC ECHOCARDIOG, V18, P1440, DOI 10.1016/j.echo.2005.10.005; RADEMAKERS FE, 1994, CIRCULATION, V89, P1174; Kitabata H, 2009, JACC-CARDIOVASC IMAG, V2, P263, DOI 10.1016/j.jcmg.2008.11.013; Asanuma T, 2012, JACC-CARDIOVASC IMAG, V5, P1, DOI 10.1016/j.jcmg.2011.09.019; Kim RJ, 1999, CIRCULATION, V100, P1992; Beek AM, 2003, J AM COLL CARDIOL, V42, P895, DOI 10.1016/S0735-1097(03)00835-0; Alpert JS, 2000, J AM COLL CARDIOL, V36, P959; Mor-Avi V, 2011, J AM SOC ECHOCARDIOG, V24, P277, DOI 10.1016/j.echo.2011.01.015; Mollema SA, 2010, CIRC-CARDIOVASC IMAG, V3, P15, DOI 10.1161/CIRCIMAGING.108.802785; Choi KA, 2001, CIRCULATION, V104, P1101, DOI 10.1161/hc3501.096798; Geyer H, 2010, J AM SOC ECHOCARDIOG, V23, P351, DOI 10.1016/j.echo.2010.02.015; MacGowan GA, 1997, CIRCULATION, V96, P535; Park YH, 2008, J AM SOC ECHOCARDIOG, V21, P262, DOI 10.1016/j.echo.2007.08.026; Hung CL, 2010, J AM COLL CARDIOL, V56, P1812, DOI 10.1016/j.jacc.2010.06.044; Reisner SA, 2004, J AM SOC ECHOCARDIOG, V17, P630, DOI 10.1016/j.echo.2004.02.011; Gjesdal O, 2008, CIRC-CARDIOVASC IMAG, V1, P189, DOI 10.1161/CIRCIMAGING.108.784900; BRUNVAND H, 1995, CARDIOVASC RES, V30, P138; GREENBAUM RA, 1981, BRIT HEART J, V45, P248; HANLEY JA, 1983, RADIOLOGY, V148, P839; Neizel M, 2009, CIRC-CARDIOVASC IMAG, V2, P116, DOI 10.1161/CIRCIMAGING.108.789032; Ripa RS, 2007, AM HEART J, V154, P929, DOI 10.1016/j.ahj.2007.06.038; SABIA P, 1991, CIRCULATION, V84, pI85; Sciagra R, 2002, J NUCL MED, V43, P8; Torrent-Guasp F, 2001, Semin Thorac Cardiovasc Surg, V13, P301	37	1	1	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0742-2822	1540-8175		ECHOCARDIOGR-J CARD	Echocardiography-J. Cardiovasc. Ultrasound Allied Tech.	MAY	2015	32	5					768	778		10.1111/echo.12726		11	Cardiac & Cardiovascular Systems	Cardiovascular System & Cardiology	CG6CN	WOS:000353383200007		
J	Teramachi, Y; Suda, K; Yoshimoto, H; Kishimoto, S; Kudo, Y; Iemura, M				Teramachi, Yozo; Suda, Kenji; Yoshimoto, Hironaga; Kishimoto, Shintaro; Kudo, Yoshiyuki; Iemura, Motofumi			Transpulmonary Echocardiography to Guide Stent Implantation into Coarctation of the Aorta	ECHOCARDIOGRAPHY-A JOURNAL OF CARDIOVASCULAR ULTRASOUND AND ALLIED TECHNIQUES			English	Article						intracardiac echocardiography; hypertension; endovascular treatment	INTRACARDIAC ECHOCARDIOGRAPHY; VALVE-REPLACEMENT	Although stent implantation into aortic coarctation has been performed solely under fluoroscopy, we successfully applied intracardiac echocardiography to guide this procedure in a 13-year-old patient. Placing an intracardiac echocardiographic catheter in the left pulmonary artery facing upward, we readily visualized the precise anatomy of coarctation, measured the pressure gradient, and monitored the stent inflation process. This report suggests a new application of intracardiac echocardiography for intervention with structural and vascular diseases other than interatrial septum.	[Teramachi, Yozo; Iemura, Motofumi] St Marys Hosp, Dept Pediat Cardiol, Kurume, Fukuoka, Japan; [Suda, Kenji; Yoshimoto, Hironaga; Kishimoto, Shintaro; Kudo, Yoshiyuki] Kurume Univ, Sch Med, Pediat & Child Hlth, Kurume, Fukuoka 8300011, Japan	Suda, K (reprint author), Kurume Univ, Sch Med, Dept Pediat & Child Hlth, Asahi Machi 67, Kurume, Fukuoka 8300011, Japan.	suda_kenji@med.kurume-u.ac.jp					Hijazi ZM, 2001, CATHETER CARDIO INTE, V52, P194, DOI 10.1002/1522-726X(200102)52:2<194::AID-CCD1046>3.0.CO;2-4; Bartel T, 2011, J AM SOC ECHOCARDIOG, V24, P966, DOI 10.1016/j.echo.2011.04.009; Ali S, 2011, ECHOCARDIOGR-J CARD, V28, P582, DOI 10.1111/j.1540-8175.2011.01395.x; Awad SM, 2015, PEDIATR CARDIOL, V36, P76, DOI 10.1007/s00246-014-0967-6; Bartel T, 2014, EUR HEART J, V35, P69, DOI 10.1093/eurheartj/eht411; Butera Gianfranco, 2010, J Invasive Cardiol, V22, pE209; DUFFY CI, 1994, CHEST, V105, P286, DOI 10.1378/chest.105.1.286; Inohara T, 2014, J INVASIVE CARDIOL, V26, pE95; Vaina Sophia, 2006, EuroIntervention, V1, P454	9	1	1	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0742-2822	1540-8175		ECHOCARDIOGR-J CARD	Echocardiography-J. Cardiovasc. Ultrasound Allied Tech.	MAY	2015	32	5					872	874		10.1111/echo.12896		3	Cardiac & Cardiovascular Systems	Cardiovascular System & Cardiology	CG6CN	WOS:000353383200021		
J	Fishman, T; Schandl, H; Tanikawa, H				Fishman, Tomer; Schandl, Heinz; Tanikawa, Hiroki			The socio-economic drivers of material stock accumulation in Japan's prefectures	ECOLOGICAL ECONOMICS			English	Article						Material stock analysis; Japan; Construction materials; IPAT; Panel regression analysis; Sodo-economic metabolism	MATERIAL FLOW-ANALYSIS; IN-USE STOCKS; MATERIAL EFFICIENCY; METAL STOCKS; GROWTH; CONSTRUCTION; METABOLISM; BUILDINGS; IMPACT; LIFE	Physical economy research has, thus far, focused on the throughput of materials that underpin economic development. The role of stocks of buildings and infrastructure has remained underexplored, yet it is the physical stock that provides service to society. To fill this gap, this research investigates stock dynamics in Japan in relation to population and economic drivers using panel regression and IPAT analyses for the past five decades. We recognize characteristic changes in the strength and relative influence of the drivers throughout time, in different subnational regions, and on the dynamics of buildings compared to transportation infrastructure. We find that material stock accumulation mainly occurred due to growth in economic activity, specifically by tertiary sector demand. Apart from a period of government-driven stock accumulation in the 1990s to stimulate economic growth, as economic and population growth slowed stock accumulation dynamics also changed signaling a new stock saturation trend. Migration from rural to urban areas has recently become an influential driver, leaving behind underused buildings and roads. This analysis provides a case study on how socio-economic drivers and stock accumulation interacted and changed while the country matured, which may have implications for understanding stock dynamics in rapidly industrializing economies. (C) 2015 Elsevier B.V. All rights reserved.	[Fishman, Tomer; Schandl, Heinz; Tanikawa, Hiroki] Nagoya Univ, Grad Sch Environm Studies, Nagoya, Aichi 4648601, Japan; [Fishman, Tomer; Schandl, Heinz] CSIRO, Clayton, Vic, Australia; [Schandl, Heinz] Australian Natl Univ, Sch Sociol, Canberra, ACT, Australia	Fishman, T (reprint author), Nagoya Univ, Grad Sch Environm Studies, Chikusa Ku, D2-1 510 Furo Cho, Nagoya, Aichi 4648601, Japan.	tomer.fishman@nagoya-u.jp	Schandl, Heinz/C-5055-2008; Tanikawa, Hiroki/G-8033-2012; Fishman, Tomer/C-9772-2015	Fishman, Tomer/0000-0003-4405-2382	Environment Research and Technology Development Fund of the Ministry of the Environment, Japan [1-1402]; CSIRO National Outlook Project (ANO)	This research was financially supported by the Environment Research and Technology Development Fund (1-1402) of the Ministry of the Environment, Japan, and has been supported by the CSIRO National Outlook Project (ANO). We wish to thank Steve Hatfield-Dodds, director of the ANO, for his ongoing support. The authors are grateful to Karin Hosking for editing the manuscript.	ADRIAANSE A., 1997, RESOURCE FLOWS MAT B; Huang T, 2013, RESOUR CONSERV RECY, V72, P91, DOI 10.1016/j.resconrec.2012.12.013; BHARGAVA A, 1982, REV ECON STUD, V49, P533, DOI 10.2307/2297285; Kovanda J, 2011, ECOL INDIC, V11, P1375, DOI 10.1016/j.ecolind.2011.02.016; Steinberger JK, 2010, ECOL ECON, V69, P1148, DOI 10.1016/j.ecolecon.2009.12.009; Fischer-Kowalski M, 2011, J IND ECOL, V15, P855, DOI 10.1111/j.1530-9290.2011.00366.x; Gerst MD, 2009, ENVIRON SCI TECHNOL, V43, P6320, DOI 10.1021/es900845v; Hatayama H, 2010, ENVIRON SCI TECHNOL, V44, P6457, DOI 10.1021/es100044n; Muller E, 2014, ENVIRON SCI TECHNOL, V48, P2102, DOI 10.1021/es403506a; York R, 2003, ECOL ECON, V46, P351, DOI 10.1016/S0921-8009(03)00188-5; Hashimoto S, 2009, WASTE MANAGE, V29, P2859, DOI 10.1016/j.wasman.2009.06.011; Krausmann F, 2011, J IND ECOL, V15, P877, DOI 10.1111/j.1530-9290.2011.00376.x; Kennedy C, 2011, ENVIRON POLLUT, V159, P1965, DOI 10.1016/j.envpol.2010.10.022; Bettencourt LMA, 2007, P NATL ACAD SCI USA, V104, P7301, DOI 10.1073/pnas.0610172104; Muller DB, 2006, ECOL ECON, V59, P142, DOI 10.1016/j.ecolecon.2005.09.025; Hashimoto S, 2007, WASTE MANAGE, V27, P1725, DOI 10.1016/j.wasman.2006.10.009; Schandl H, 2010, GLOBAL ENVIRON CHANG, V20, P636, DOI 10.1016/j.gloenvcha.2010.06.003; Krausmann F, 2008, J IND ECOL, V12, P637, DOI 10.1111/j.1530-9290.2008.00065.x; Steinberger JK, 2011, ENVIRON SCI TECHNOL, V45, P1169, DOI 10.1021/es1028537; Bergsdal H, 2007, BUILD RES INF, V35, P557, DOI 10.1080/09613210701287588; Norman J, 2006, J URBAN PLAN D-ASCE, V132, P10, DOI 10.1061/(ASCE)0733-9488(2006)132:1(10); Pauliuk S, 2014, GLOBAL ENVIRON CHANG, V24, P132, DOI 10.1016/j.gloenvcha.2013.11.006; Fishman T, 2014, J IND ECOL, V18, P407, DOI 10.1111/jiec.12114; Schandl H, 2012, J IND ECOL, V16, P352, DOI 10.1111/j.1530-9290.2011.00420.x; EHRLICH PR, 1971, SCIENCE, V171, P1212, DOI 10.1126/science.171.3977.1212; Hu MM, 2010, RESOUR CONSERV RECY, V54, P591, DOI 10.1016/j.resconrec.2009.10.016; Tanikawa H, 2009, BUILD RES INF, V37, P483, DOI 10.1080/09613210903169394; Krausmann F, 2009, ECOL ECON, V68, P2696, DOI 10.1016/j.ecolecon.2009.05.007; West J, 2013, ECOL ECON, V94, P19, DOI 10.1016/j.ecolecon.2013.06.015; Muller DB, 2011, ENVIRON SCI TECHNOL, V45, P182, DOI 10.1021/es102273t; Kennedy C, 2007, J IND ECOL, V11, P43, DOI 10.1162/jie.2007.1107; Gordon RB, 2006, P NATL ACAD SCI USA, V103, P1209, DOI 10.1073/pnas.0509498103; De Hoyos RE, 2006, STATA J, V6, P482; Muller DB, 2013, ENVIRON SCI TECHNOL, V47, P11739, DOI 10.1021/es402618m; Gierlinger S, 2012, J IND ECOL, V16, P365, DOI 10.1111/j.1530-9290.2011.00404.x; Kohler N, 2007, BUILD RES INF, V35, P351, DOI 10.1080/09613210701308962; Liu G, 2013, ENVIRON SCI TECHNOL, V47, P4882, DOI 10.1021/es305108p; Bringezu S, 2004, ECOL ECON, V51, P97, DOI 10.1016/j.ecolecon.2004.04.010; Baltagi BH, 2011, SPRING TEXT BUS ECON, P1, DOI 10.1007/978-3-642-20059-5; COMMONER B, 1971, ENVIRONMENT, V13, P2; Davidson R., 2004, ECONOMETRIC THEORY M; Douglas I., 2000, J IND ECOL, V4, P9, DOI DOI 10.1162/108819800569771; Drukker D.M., 2003, STATA J, V3, P168; Hammond GP, 2008, P I CIVIL ENG-ENERGY, V161, P87, DOI DOI 10.1680/ENER.2008.161.2.87; Herendeen R. A., 1998, ECOLOGICAL NUMERACY; Horvath A, 2004, ANNU REV ENV RESOUR, V29, P181, DOI 10.1146/annurev.energy.29.062403.102215; Humbert S., 2007, INT J LIFE CYCLE ASS, P12; IPCC, 2014, CLIM CHANG 2014 MIT; Lawson N., 2001, ENV MANAGEMENT HLTH, V12, P146, DOI 10.1108/09566160110389898; Maddison A., 2008, HIST STAT WORLD EC; OECD, 2014, OECD STAT EXTR; Okina K., 2001, MONETARY EC STUDIES, V19, P395; Statistics Bureau of Japan, 2014, REG STAT; Steinberger JK, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070385; Tanikawa H., 2015, J IND ECOL IN PRESS; Vieira PS, 2008, ENVIRON SCI TECHNOL, V42, P4663, DOI 10.1021/es071345l; West J, 2014, ECOL ECON, V105, P211, DOI 10.1016/j.ecolecon.2014.06.013; Wiedenhofer D., 2015, J IND ECOL	58	1	1	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0921-8009	1873-6106		ECOL ECON	Ecol. Econ.	MAY	2015	113						76	84		10.1016/j.ecolecon.2015.03.001		9	Ecology; Economics; Environmental Sciences; Environmental Studies	Environmental Sciences & Ecology; Business & Economics	CG2IA	WOS:000353096900007		
J	Kohno, S; Bernhard, MC; Katsu, Y; Zhu, J; Bryan, TA; Doheny, BM; Iguchi, T; Guillette, LJ				Kohno, Satomi; Bernhard, Melissa C.; Katsu, Yoshinao; Zhu, Jianguo; Bryan, Teresa A.; Doheny, Brenna M.; Iguchi, Taisen; Guillette, Louis J., Jr.			Estrogen Receptor 1 (ESR1; ER alpha), not ESR2 (ER beta), Modulates Estrogen-Induced Sex Reversal in the American Alligator, a Species With Temperature-Dependent Sex Determination	ENDOCRINOLOGY			English	Article							EARED SLIDER TURTLE; ENDOCRINE DISRUPTING CONTAMINANTS; MOLECULAR-CLONING; TRACHEMYS-SCRIPTA; ENVIRONMENTAL CONTAMINANTS; FUNCTIONAL-CHARACTERIZATION; EXPRESSION PATTERNS; DAX1 EXPRESSION; CHICK-EMBRYO; MISSISSIPPIENSIS	All crocodilians and many turtles exhibit temperature-dependent sex determination where the temperature of the incubated egg, during a thermo-sensitive period (TSP), determines the sex of the offspring. Estrogens play a critical role in sex determination in crocodilians and turtles, as it likely does in most nonmammalian vertebrates. Indeed, administration of estrogens during the TSP induces male to female sex reversal at a male-producing temperature (MPT). However, it is not clear how estrogens override the influence of temperature during sex determination in these species. Most vertebrates have 2 forms of nuclear estrogen receptor (ESR): ESR1 (ER alpha) and ESR2 (ER beta). However, there is no direct evidence concerning which ESR is involved in sex determination, because a specific agonist or antagonist for each ESR has not been tested in nonmammalian species. We identified specific pharmaceutical agonists for each ESR using an in vitro transactivation assay employing American alligator ESR1 and ESR2; these were4,4',4 ''-(4-propyl-[1H]-pyrazole-1,3,5-triyl)trisphenol (PPT) and 7-bromo-2-(4-hydroxyphenyl)-1,3-benzoxazol-5-ol (WAY 200070), respectively. Alligator eggs were exposed to PPT or WAY 200070 at a MPT just before the TSP, and their sex was examined at the last stage of embryonic development. Estradiol-17 beta and PPT, but not WAY 200070, induced sex reversal at a MPT. PPT-exposed embryos exposed to the highest dose (5.0 mu g/g egg weight) exhibited enlargement and advanced differentiation of the Mullerian duct. These results indicate that ESR1 is likely the principal ESR involved in sex reversal as well as embryonic Mullerian duct survival and growth in American alligators.	[Kohno, Satomi; Zhu, Jianguo; Bryan, Teresa A.; Guillette, Louis J., Jr.] Med Univ S Carolina, Dept Obstet & Gynecol, Charleston, SC 29425 USA; [Kohno, Satomi; Bernhard, Melissa C.; Bryan, Teresa A.; Doheny, Brenna M.; Guillette, Louis J., Jr.] Hollings Marine Lab, Marine Biomed & Environm Sci Ctr, Charleston, SC 29412 USA; [Bernhard, Melissa C.] Coll Charleston, Grad Program Marine Biol, Charleston, SC 29412 USA; [Katsu, Yoshinao] Hokkaido Univ, Grad Sch Life Sci, Sapporo, Hokkaido 0600808, Japan; [Katsu, Yoshinao] Hokkaido Univ, Dept Biol Sci, Sapporo, Hokkaido 0600808, Japan; [Bryan, Teresa A.] Univ Florida, Dept Biol, Gainesville, FL 32611 USA; [Iguchi, Taisen] Natl Inst Nat Sci, Natl Inst Basic Biol, Okazaki Inst Integrat Biosci, Okazaki, Aichi 4448585, Japan; [Iguchi, Taisen] Grad Univ Adv Studies SOKENDAI, Dept Basic Biol, Okazaki, Aichi 4448585, Japan	Kohno, S (reprint author), Med Univ S Carolina, Dept Obstet & Gynecol, 331 Ft Johnson Rd, Charleston, SC 29412 USA.	kohno@musc.edu			Gulf of Mexico Research Initiative; National Institute of Standards and Technology; South Carolina Centers of Economic Excellence for Marine Genomics; Ministry of Education, Culture, Sports, Science and Technology of Japan [17052032, 20570064, 21510068, 19370027]; National Institute for Basic Biology	This work was supported by the Gulf of Mexico Research Initiative (S.K. and L.J.G.); a grant from the National Institute of Standards and Technology (L.J.G. and S.K.); the South Carolina Centers of Economic Excellence for Marine Genomics (L.J.G.); Grants-in-Aid for Scientific Research 17052032 (to Y.K.), 20570064 (to Y.K.), 21510068 (to Y.K.), and 19370027 (to T.I.) from the Ministry of Education, Culture, Sports, Science and Technology of Japan; and a grant from the National Institute for Basic Biology (T.I.).	Akazome Y, 1999, J REPROD FERTIL, V115, P9; Tremblay GB, 1997, MOL ENDOCRINOL, V11, P353, DOI 10.1210/me.11.3.353; Hamlin HJ, 2011, BIRTH DEFECTS RES C, V93, P19, DOI 10.1002/bdrc.20202; MerchantLarios H, 1997, GEN COMP ENDOCR, V107, P373, DOI 10.1006/gcen.1997.6946; Schmidt D, 2004, DEVELOPMENT, V131, P933, DOI 10.1242/dev.00969; Ramsey M, 2009, SEMIN CELL DEV BIOL, V20, P283, DOI 10.1016/j.semcdb.2008.10.004; Kohno S, 2010, SEX DEV, V4, P73, DOI 10.1159/000260374; Smith CA, 2004, BIOESSAYS, V26, P120, DOI 10.1002/bies.10400; BULL JJ, 1988, GEN COMP ENDOCR, V70, P425, DOI 10.1016/0016-6480(88)90117-7; Kohno S, 2003, GEN COMP ENDOCR, V132, P485, DOI 10.1016/S0016-6480(03)00140-0; Filice E, 2009, J PHYSIOL PHARMACOL, V60, P3; Devlin RH, 2002, AQUACULTURE, V208, P191, DOI 10.1016/S0044-8486(02)00057-1; Ramsey M, 2007, SEX DEV, V1, P181, DOI 10.1159/000102107; Yao HHC, 2005, J BIOCHEM, V138, P5, DOI 10.1093/jb/mvi097; Couse JF, 1999, ENDOCR REV, V20, P358, DOI 10.1210/er.20.3.358; Thomas P, 2006, J STEROID BIOCHEM, V102, P175, DOI 10.1016/j.jsbmb.2006.09.017; Zheng P, 2007, SEMIN REPROD MED, V25, P243, DOI 10.1055/s-2007-980218; Nakamura T, 2008, TOXICOLOGY, V253, P117, DOI 10.1016/j.tox.2008.09.006; Wakeling AE, 2000, ENDOCR-RELAT CANCER, V7, P17, DOI 10.1677/erc.0.0070017; Jordan BK, 2001, AM J HUM GENET, V68, P1102, DOI 10.1086/320125; Kobayashi A, 2003, NAT REV GENET, V4, P969, DOI 10.1038/nrg1225; LANG JW, 1994, J EXP ZOOL, V270, P28, DOI 10.1002/jez.1402700105; Crain DA, 1997, ENVIRON HEALTH PERSP, V105, P528, DOI 10.1289/ehp.97105528; Weiser MJ, 2009, ENDOCRINOLOGY, V150, P1817, DOI 10.1210/en.2008-1355; Chimento A, 2010, MOL CELL ENDOCRINOL, V320, P136, DOI 10.1016/j.mce.2010.01.035; Razandi M, 1999, MOL ENDOCRINOL, V13, P307, DOI 10.1210/me.13.2.307; Uhlenhaut NH, 2009, CELL, V139, P1130, DOI 10.1016/j.cell.2009.11.021; McLachlan JA, 2001, ENDOCR REV, V22, P319, DOI 10.1210/er.22.3.319; Hanley NA, 2000, MECH DEVELOP, V91, P403, DOI 10.1016/S0925-4773(99)00307-X; Urushitani H, 2011, MOL CELL ENDOCRINOL, V333, P190, DOI 10.1016/j.mce.2010.12.025; Kuo J, 2010, J NEUROSCI, V30, P12950, DOI 10.1523/JNEUROSCI.1158-10.2010; Pennetier S, 2004, BIOL REPROD, V71, P1359, DOI 10.1095/biolreprod.104.030288; Guillette LJ, 2000, AM ZOOL, V40, P438, DOI 10.1668/0003-1569(2000)040[0438:AAEDCA]2.0.CO;2; Yao HHC, 2004, DEV DYNAM, V230, P210, DOI 10.1002/dvdy.20042; Thornton JW, 2001, P NATL ACAD SCI USA, V98, P5671, DOI 10.1073/pnas.091553298; Pieau C, 2004, J ENDOCRINOL, V181, P367, DOI 10.1677/joe.0.1810367; Barske LA, 2010, DEV BIOL, V341, P305, DOI 10.1016/j.ydbio.2010.02.010; Revankar CM, 2005, SCIENCE, V307, P1625, DOI 10.1126/science.1106943; Milnes MR, 2002, ENVIRON HEALTH PERSP, V110, P393; FERGUSON MWJ, 1983, J ZOOL, V200, P143; Shoemaker-Daly CM, 2010, DEV DYNAM, V239, P1061, DOI 10.1002/dvdy.22266; Kuiper GGJM, 1997, ENDOCRINOLOGY, V138, P863, DOI 10.1210/en.138.3.863; AUSTIN HB, 1991, GEN COMP ENDOCR, V84, P300, DOI 10.1016/0016-6480(91)90053-9; Biau S, 2007, ANAL BIOANAL CHEM, V387, P1397, DOI 10.1007/s00216-006-0870-y; CREWS D, 1989, GEN COMP ENDOCR, V76, P159, DOI 10.1016/0016-6480(89)90042-7; Crews D, 2003, EVOL DEV, V5, P50, DOI 10.1046/j.1525-142X.2003.03008.x; Diamanti-Kandarakis E, 2009, ENDOCR REV, V30, P293, DOI 10.1210/er.2009-0002; DOURNON C, 1990, International Journal of Developmental Biology, V34, P81; Ferguson M.W.J., 1985, Biology of Reptilia, V14, P329; HUTSON JM, 1982, J PEDIATR SURG, V17, P953, DOI 10.1016/S0022-3468(82)80474-0; Katsu Y, 2008, ENDOCRINOLOGY, V149, P161, DOI 10.1210/en.2007-0938; Katsu Y, 2010, ENDOCRINOLOGY, V151, P5710, DOI 10.1210/en.2010-0356; Katsu Y, 2004, GEN COMP ENDOCR, V136, P122, DOI 10.1016/j.ygcen.2003.11.008; Katsu Y, 2010, GEN COMP ENDOCR, V168, P496, DOI 10.1016/j.ygcen.2010.06.010; Kohno S, 2013, ENDOCRINE DISRUPTERS, P245, DOI [10.1002/9781118355961.ch9, DOI 10.1002/9781118355961.CH9]; Kohno S, 2008, AQUAT TOXICOL, V88, P95, DOI 10.1016/j.aquatox.2008.03.006; Matsumoto Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063599; Matsumoto Y, 2014, ENDOCRINOLOGY, V55, P4168; Matter JM, 1998, CHEMOSPHERE, V37, P1905, DOI 10.1016/S0045-6535(98)00257-4; Milnes MR, 2008, BIOSCIENCE, V58, P1027, DOI 10.1641/B581106; Milnes MR, 2005, GEN COMP ENDOCR, V144, P257, DOI 10.1016/j.ygcen.2005.06.013; Moore BC, 2010, SEX DEV, V4, P62, DOI 10.1159/000277934; Moore BC, 2011, J STEROID BIOCHEM, V127, P58, DOI 10.1016/j.jsbmb.2011.01.004; Navarro-Martin L, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002447; Parrott B.B., 2014, BIOL REPROD, V90, P1; Pfaffl MW, 2004, A Z QUANTITATIVE PCR, P87; Pieau C, 1996, BIOESSAYS, V18, P19, DOI 10.1002/bies.950180107; Rooney AA, 1998, THESIS U FLORIDA GAI; Rooney AA, 2000, ENVIRONMENTAL ENDOCRINE DISRUPTERS: AN EVOLUTIONARY PERSPECTIVE, P82; SMITH CA, 1995, DIFFERENTIATION, V58, P281, DOI 10.1046/j.1432-0436.1995.5840281.x; Swain A, 1996, NAT GENET, V12, P404, DOI 10.1038/ng0496-404; WIBBELS T, 1991, J EXP ZOOL, V260, P130, DOI 10.1002/jez.1402600117; Willingham E, 1999, GEN COMP ENDOCR, V113, P429, DOI 10.1006/gcen.1998.7221	73	2	2	ENDOCRINE SOC	WASHINGTON	2055 L ST NW, SUITE 600, WASHINGTON, DC 20036 USA	0013-7227	1945-7170		ENDOCRINOLOGY	Endocrinology	MAY	2015	156	5					1887	1899		10.1210/en.2014-1852		13	Endocrinology & Metabolism	Endocrinology & Metabolism	CG4RO	WOS:000353274500029		
J	Kodama, M; Suda, M; Sakamoto, D; Iwasaki, T; Matsuo, Y; Uno, Y; Matsuda, Y; Nakamura, Y; Maekawa, S; Katsu, Y; Nakamura, M				Kodama, Maho; Suda, Mari; Sakamoto, Daiki; Iwasaki, Takehiro; Matsuo, Yasuki; Uno, Yoshinobu; Matsuda, Yoichi; Nakamura, Yoriko; Maekawa, Shun; Katsu, Yoshinao; Nakamura, Masahisa			Molecular Cloning and Characterization of Anti-Mullerian Hormone (AMH) from the Japanese Wrinkled Frog, Rana rugosa	ENDOCRINOLOGY			English	Article							INHIBITING SUBSTANCE; SEX-DIFFERENTIATION; SOX9 EXPRESSION; GENE; PROTEIN; GONADS; MEDAKA; TESTIS; FISH	The role of anti-Mullerian hormone (AMH) during gonad development has been studied extensively in many species of mammal, bird, reptile, and fish but remains unresolved in amphibians. In male mammalian embryos, Sox9 activates AMH expression, which initiates regression of the Mullerian ducts. However, Sox9 (Sry-related HMG box 9) is unlikely to initiate AMH in chicken, because AMH precedes Sox9 expression in this species. To clarify whether AMH is involved in testicular differentiation in amphibians, we cloned the full-length AMH cDNA from the Japanese wrinkled frog, Rana rugosa. The AMH gene, which appears to be autosomal, is exclusively expressed in the testis of adult frog among 8 different tissues examined; Sertoli cells are probably responsible for its expression. AMH expression was found in the undifferentiated gonad of both male and female tadpoles, increasing in the differentiating testis. Moreover, we observed consensus binding sites for Sox9 in the 5'-flanking region of the AMH gene. Sox9 stimulated statistically significant AMH expression in luciferase reporter assays when coexpressed in Xenopus kidney-derived A6 cells. However, Sox9 expression showed no sexual dimorphism when AMH expression was up-regulated in the developing testis. These results, taken together, suggest that AMH is probably involved in testicular differentiation in R. rugosa, although an additional, perhaps tissue-specific, transcription factor may be required for the regulation of AMH transcription.	[Kodama, Maho; Suda, Mari; Sakamoto, Daiki; Iwasaki, Takehiro; Matsuo, Yasuki; Maekawa, Shun; Nakamura, Masahisa] Waseda Univ, Fac Educ & Integrated Arts & Sci, Dept Biol, Shinjuku Ku, Tokyo 1628480, Japan; [Uno, Yoshinobu; Matsuda, Yoichi] Nagoya Univ, Grad Sch Bioagr Sci, Dept Appl Mol Biosci, Lab Anim Genet,Chikusa Ku, Nagoya, Aichi 4648601, Japan; [Nakamura, Yoriko] Ehime Univ, Fac Educ, Dept Sci Educ, Matsuyama, Ehime 7908577, Japan; [Katsu, Yoshinao] Hokkaido Univ, Fac Sci, Lab Reprod & Dev Biol, Sapporo, Hokkaido 0600810, Japan	Nakamura, M (reprint author), Waseda Univ, Fac Educ & Integrated Arts & Sci, Dept Biol, Shinjuku Ku, 2-2 Wakamatsu, Tokyo 1628480, Japan.	nakamra@waseda.jp			Ministry of Education, Science, and Culture of Japan [22370027]	This work was supported by the Ministry of Education, Science, and Culture of Japan Grantin Aid 22370027.	Trbovich AM, 2001, P NATL ACAD SCI USA, V98, P3393, DOI 10.1073/pnas.051632298; Ijiri S, 2008, BIOL REPROD, V78, P333, DOI 10.1095/biolreprod.107.064246; Matsuda M, 2002, NATURE, V417, P559, DOI 10.1038/nature751; Oreal E, 1998, DEV DYNAM, V212, P522, DOI 10.1002/(SICI)1097-0177(199808)212:4<522::AID-AJA5>3.0.CO;2-J; Kent J, 1996, DEVELOPMENT, V122, P2813; Sekido R, 2008, NATURE, V453, P930, DOI 10.1038/nature06944; MATSUDA Y, 1995, ELECTROPHORESIS, V16, P261, DOI 10.1002/elps.1150160142; CATE RL, 1986, CELL, V45, P685, DOI 10.1016/0092-8674(86)90783-X; Urushitani H, 2011, MOL CELL ENDOCRINOL, V333, P190, DOI 10.1016/j.mce.2010.12.025; daSilva SM, 1996, NAT GENET, V14, P62, DOI 10.1038/ng0996-62; Mertin S, 1999, NUCLEIC ACIDS RES, V27, P1359, DOI 10.1093/nar/27.5.1359; TAYLOR AC, 1946, ANAT REC, V94, P7, DOI 10.1002/ar.1090940103; Oshima Y, 2009, GENE, V445, P38, DOI 10.1016/j.gene.2009.05.011; Rey R, 2003, MOL CELL ENDOCRINOL, V211, P21, DOI 10.1016/j,mce.2003.09.007; Kluver N, 2007, DEV DYNAM, V236, P271, DOI 10.1002/dvdy.20997; Iwade R, 2008, GEN COMP ENDOCR, V155, P79, DOI 10.1016/j.ygcen.2007.02.032; Rodriguez-Mari A, 2005, GENE EXPR PATTERNS, V5, P655, DOI 10.1016/j.modgep.2005.02.008; Brennan J, 2004, NAT REV GENET, V5, P509, DOI 10.1038/nrg1381; De Santa B. P., 1998, MOL CELL BIOL, V18, P6653; Isomura T, 2011, GEN COMP ENDOCR, V170, P207, DOI 10.1016/j.ygcen.2010.10.015; Nishioka Midori, 1993, Scientific Report of the Laboratory for Amphibian Biology Hiroshima University, V12, P55; Ohtani H, 2003, COMP BIOCHEM PHYS C, V134, P215, DOI 10.1016/S1532-0456(02)00252-1; PICARD JY, 1978, MOL CELL ENDOCRINOL, V12, P17, DOI 10.1016/0303-7207(78)90098-9; Saotome K, 2010, J EXP ZOOL PART A, V313A, P452, DOI 10.1002/jez.617; Saotome K, 2010, J EXP ZOOL PART A, V313A, P369, DOI 10.1002/jez.607; Shumway W, 1940, ANAT REC, V78, P139, DOI 10.1002/ar.1090780202; SINCLAIR AH, 1990, NATURE, V346, P240, DOI 10.1038/346240a0; Suda M, 2011, COMP BIOCHEM PHYS B, V160, P54, DOI [10.1016/j.cbpb.2011.05.007, 10.1016/j.cbpb.2011.05.008]; Uno Y, 2008, CHROMOSOME RES, V16, P637, DOI 10.1007/s10577-008-1217-7; Yokoyama S, 2009, J EXP ZOOL PART A, V311A, P1	30	1	1	ENDOCRINE SOC	WASHINGTON	2055 L ST NW, SUITE 600, WASHINGTON, DC 20036 USA	0013-7227	1945-7170		ENDOCRINOLOGY	Endocrinology	MAY	2015	156	5					1914	1923		10.1210/en.2013-2053		10	Endocrinology & Metabolism	Endocrinology & Metabolism	CG4RO	WOS:000353274500031		
J	Diamond, ML; de Wit, CA; Molander, S; Scheringer, M; Backhaus, T; Lohmann, R; Arvidsson, R; Bergman, A; Hauschild, M; Holoubek, I; Persson, L; Suzuki, N; Vighi, M; Zetzsch, C				Diamond, Miriam L.; de Wit, Cynthia A.; Molander, Sverker; Scheringer, Martin; Backhaus, Thomas; Lohmann, Rainer; Arvidsson, Rickard; Bergman, Ake; Hauschild, Michael; Holoubek, Ivan; Persson, Linn; Suzuki, Noriyuki; Vighi, Marco; Zetzsch, Cornelius			Exploring the planetary boundary for chemical pollution	ENVIRONMENT INTERNATIONAL			English	Review						Planetary boundary; Chemical pollution; Chemical emissions; Stockholm Convention; Tipping point; Global threshold; Pollution controls; Ecosystem health protection; Human health protection; Chemical management	PERSISTENT ORGANIC POLLUTANTS; MULTIPLE CHEMICALS; RISK-ASSESSMENT; EMISSIONS; EXPOSURE; CHALLENGE; PHARMACEUTICALS; ENVIRONMENT; GROWTH; WATER	Rockstrom et al. (2009a, 2009b) have warned that humanity must reduce anthropogenic impacts defined by nine planetary boundaries if "unacceptable global change" is to be avoided. Chemical pollution was identified as one of those boundaries for which continued impacts could erode the resilience of ecosystems and humanity. The central concept of the planetary boundary (or boundaries) for chemical pollution (PBCP or PBCPs) is that the Earth has a finite assimilative capacity for chemical pollution, which includes persistent as well as readily degradable chemicals released at local to regional scales, which in aggregate threaten ecosystem and human viability. The PBCP allows humanity to explicitly address the increasingly global aspects of chemical pollution throughout a chemical's life cycle and the need for a global response of internationally coordinated control measures. We submit that sufficient evidence shows stresses on ecosystem and human health at local to global scales, suggesting that conditions are transgressing the safe operating space delimited by a PBCP. As such, current local to global pollution control measures are insufficient. However, while the PBCP is an important conceptual step forward, at this point single or multiple PBCPs are challenging to operationalize due to the extremely large number of commercial chemicals or mixtures of chemicals that cause myriad adverse effects to innumerable species and ecosystems, and the complex linkages between emissions, environmental concentrations, exposures and adverse effects. As well, the normative nature of a PBCP presents challenges of negotiating pollution limits amongst societal groups with differing viewpoints. Thus, a combination of approaches is recommended as follows: develop indicators of chemical pollution, for both control and response variables, that will aid in quantifying a PBCP(s) and gauging progress towards reducing chemical pollution; develop new technologies and technical and social approaches to mitigate global chemical pollution that emphasize a preventative approach; coordinate pollution control and sustainability efforts; and facilitate implementation of multiple (and potentially decentralized) control efforts involving scientists, civil society, government, non-governmental organizations and international bodies. (C) 2015 Elsevier Ltd. All rights reserved.	[Diamond, Miriam L.] Univ Toronto, Ctr Earth Sci, Toronto, ON M5S 3B1, Canada; [de Wit, Cynthia A.] Stockholm Univ, Dept Environm Sci & Analyt Chem ACES, SE-10691 Stockholm, Sweden; [Molander, Sverker; Arvidsson, Rickard] Chalmers, Environm & Energy Dept, Environm Syst Anal, SE-41296 Gothenburg, Sweden; [Scheringer, Martin] ETH, Inst Chem & Bioengn, CH-8093 Zurich, Switzerland; [Scheringer, Martin] Univ Luneburg, D-21335 Luneburg, Germany; [Backhaus, Thomas] Univ Gothenburg, Dept Biol & Environm Sci, SE-40530 Gothenburg, Sweden; [Lohmann, Rainer] Univ Rhode Isl, Grad Sch Oceanog, Narragansett, RI 02882 USA; [Bergman, Ake] Swedish Toxicol Sci Res Ctr Swetox, Uppsala, Sweden; [Hauschild, Michael] Tech Univ Denmark DTU, Dept Engn Management, DK-2800 Lyngby, Denmark; [Holoubek, Ivan] Masaryk Univ, Fac Sci, Res Ctr Tox Cpds Environm RECETOX, Brno 62500, Czech Republic; [Persson, Linn] Stockholm Environm Inst, Stockholm, Sweden; [Suzuki, Noriyuki] Natl Inst Environm Studies, Ctr Environm Risk Res, Strateg Risk Management Res Sect, Tsukuba, Ibaraki 3058506, Japan; [Vighi, Marco] Univ Milano Bicocca, Dept Earth & Environm Sci, I-20126 Milan, Italy; [Zetzsch, Cornelius] Univ Bayreuth, Forschungsstelle Atmosphar Chem, D-95448 Bayreuth, Germany	Diamond, ML (reprint author), Univ Toronto, Ctr Earth Sci, 22 Russell St, Toronto, ON M5S 3B1, Canada.		de Wit, Cynthia/J-8063-2012; Molander, Sverker/E-1462-2012; Hauschild, Michael/G-4335-2011; QSA, DTU/J-4787-2014	Molander, Sverker/0000-0002-9081-8847; 	Swedish Research Council FORMAS [2011-2171]; International Panel on Chemical Pollution	The authors gratefully acknowledge financial support by the Swedish Research Council FORMAS (grant no. 2011-2171) and the International Panel on Chemical Pollution, which funded a workshop on this topic.	AMAP (Arctic Monitoring and Assessment Programme), 2009, AMAP ASS 2009 HUM HL, P254; AMAP (Arctic Monitoring and Assessment Programme), 2004, AMAP ASS 2002 PERS O, P310; [Anonymous], 2004, HDB 1979 CONV LONG R; Lenton TM, 2008, P NATL ACAD SCI USA, V105, P1786, DOI 10.1073/pnas.0705414105; Baccarelli A, 2009, CURR OPIN PEDIATR, V21, P243, DOI 10.1097/MOP.0b013e32832925cc; Peck AM, 2004, ENVIRON SCI TECHNOL, V38, P367, DOI 10.1021/es034769y; Kolpin DW, 2002, ENVIRON SCI TECHNOL, V36, P1202, DOI 10.1021/es011055j; Doney SC, 2014, OCEANOGRAPHY, V27, P108; Howard PH, 2010, ENVIRON SCI TECHNOL, V44, P2277, DOI 10.1021/es903383a; Gerten D, 2013, CURR OPIN ENV SUST, V5, P551, DOI 10.1016/j.cosust.2013.11.001; Torres JPM, 2013, ENVIRON SCI POLLUT R, V20, P1951, DOI 10.1007/s11356-012-1089-4; Strempel S, 2012, ENVIRON SCI TECHNOL, V46, P5680, DOI 10.1021/es3002713; Henry M, 2012, SCIENCE, V336, P348, DOI 10.1126/science.1215039; Hooper DU, 2012, NATURE, V486, P105, DOI 10.1038/nature11118; Fries E, 2011, J ENVIRON MONITOR, V13, P2692, DOI 10.1039/c1em10538h; Kortenkamp A, 2007, ENVIRON HEALTH PERSP, V115, P98, DOI 10.1289/ehp.9357; Brook BW, 2013, TRENDS ECOL EVOL, V28, P396, DOI 10.1016/j.tree.2013.01.016; Breivik K, 2014, ENVIRON SCI TECHNOL, V48, P8735, DOI 10.1021/es5021313; Meek ME, 2011, REGUL TOXICOL PHARM, V60, pS1, DOI 10.1016/j.yrtph.2011.03.010; Stillerman KP, 2008, REPROD SCI, V15, P631, DOI 10.1177/1933719108322436; Weber R, 2011, WASTE MANAGE RES, V29, P107, DOI 10.1177/0734242X10390730; Csiszar SA, 2013, ENVIRON SCI TECHNOL, V47, P436, DOI 10.1021/es3033023; Tapparo A, 2012, ENVIRON SCI TECHNOL, V46, P2592, DOI 10.1021/es2035152; Diaz RJ, 2008, SCIENCE, V321, P926, DOI 10.1126/science.1156401; Schmidt CW, 2006, ENVIRON HEALTH PERSP, V114, pA232; Abdullah HM, 2013, ENVIRON MONIT ASSESS, V185, P3839, DOI 10.1007/s10661-012-2833-4; Kortenkamp A, 2008, INT J ANDROL, V31, P233, DOI 10.1111/j.1365-2605.2007.00862.x; Fromme H, 2002, WATER RES, V36, P1429, DOI 10.1016/S0043-1354(01)00367-0; Breivik K, 2011, ENVIRON SCI TECHNOL, V45, P9154, DOI 10.1021/es202320c; Oaks JL, 2004, NATURE, V427, P630, DOI 10.1038/nature02317; Gioia R, 2011, ENVIRON SCI TECHNOL, V45, P1349, DOI 10.1021/es1025239; Adu-Kumi S, 2012, ENVIRON SCI POLLUT R, V19, P1963, DOI 10.1007/s11356-012-1013-y; Weber R, 2013, ENVIRON SCI POLLUT R, V20, P1901, DOI 10.1007/s11356-012-1247-8; Lenzen M, 2012, NATURE, V486, P109, DOI 10.1038/nature11145; Klanova J, 2009, J ENVIRON MONITOR, V11, P1952, DOI 10.1039/b913415h; Egeghy PP, 2012, SCI TOTAL ENVIRON, V414, P159, DOI 10.1016/j.scitotenv.2011.10.046; Doney SC, 2009, ANNU REV MAR SCI, V1, P169, DOI 10.1146/annurev.marine.010908.163834; Scheringer M, 2012, ATMOS POLLUT RES, V3, P383, DOI 10.5094/APR.2012.044; Kortenkamp A, 2007, ENVIRON HEALTH PERSP, V115, P106, DOI 10.1289/ehp.9358; Grandjean P, 2006, LANCET, V368, P2167, DOI 10.1016/S0140-6736(06)69665-7; Barnosky AD, 2012, NATURE, V486, P52, DOI 10.1038/nature11018; Wang DG, 2013, CHEMOSPHERE, V93, P711, DOI 10.1016/j.chemosphere.2012.10.041; Muir DCG, 2006, ENVIRON SCI TECHNOL, V40, P7157, DOI 10.1021/es061677a; Diamond ML, 2010, ENVIRON SCI TECHNOL, V44, P2777, DOI 10.1021/es9012036; Wilson MP, 2009, ENVIRON HEALTH PERSP, V117, P1202, DOI 10.1289/ehp.0800404; Carpenter SR, 2011, ENVIRON RES LETT, V6, DOI 10.1088/1748-9326/6/1/014009; Rosi-Marshall EJ, 2013, ECOL APPL, V23, P583, DOI 10.1890/12-0491.1; Howard PH, 2011, ENVIRON SCI TECHNOL, V45, P6938, DOI 10.1021/es201196x; Letcher RJ, 2010, SCI TOTAL ENVIRON, V408, P2995, DOI 10.1016/j.scitotenv.2009.10.038; Whitehorn PR, 2012, SCIENCE, V336, P351, DOI 10.1126/science.1215025; MAY RM, 1977, NATURE, V269, P471, DOI 10.1038/269471a0; Rockstrom J, 2009, NATURE, V461, P472, DOI 10.1038/461472a; Azar C, 1997, SCIENCE, V276, P1818, DOI 10.1126/science.276.5320.1818; Bollati V, 2010, HEREDITY, V105, P105, DOI 10.1038/hdy.2010.2; Backhaus T, 2010, HAZARD RISK ASSESSME; Bouwman H, 2012, ENVIRON RES, V118, P53, DOI 10.1016/j.envres.2012.05.009; Brunner P.H., 2001, ENCY GLOBAL ENV CHAN, V3, P54; Clean Production Action, 2015, CLEAN PROD ACT; Conklin J., 2005, DIALOGUE MAPPING BUI; ECA (European Chemicals Agency), 2013, PRER SUBST; EFSA (European Food Safety Authority), 2013, EFSA ID RISKS BEES N; Ellerman A.D., 2003, ABSOLUTE VS INTENSIT; Erisman J.W., 2013, PHILOS T R SOC B, V368; Gawor A, 2014, ENVIRON SCI-PROC IMP, V16, P404, DOI 10.1039/c3em00499f; Gee D., 2013, LATE LESSONS EARLY W; Gee D, 2006, ENVIRON HEALTH PERSP, V114, P152, DOI 10.1289/ehp.8134; Gottesfeld P, 2011, ENERG POLICY, V39, P4939, DOI 10.1016/j.enpol.2011.06.021; Gottesfeld P, 2013, NEW SCI, V218, P26; Harremoes P, 1998, WATER SCI TECHNOL, V37, P9, DOI 10.1016/S0273-1223(98)00051-1; Harremoes P., 2001, LATE LESSONS EARLY W; Horn Robert E., 2007, NEW TOOLS RESOLVING; International Energy agency (IEA), 2014, WORLD EN OUTL 2014; Kortenkamp A., 2009, STATE ART REPORT MIX; Mani M., 2012, ANAL PHYS MONETARY L; OECD (Organization for Economic Cooperation and Development), 1991, COR SET IND ENV PERF; Persson LM, 2013, ENVIRON SCI TECHNOL, V47, P12619, DOI 10.1021/es402501c; Rockstrom J, 2009, ECOL SOC, V14; SAICM (The Strategic Approach to International Chemicals Management), 2006, TEXTS RES INT C CHEM; SCENIHR (Scientific Committee on Emerging and Newly Identified Health Risks) SCCS (Scientific Committee on Consumer Safety) SCHER (Scientific Committee on Health and Environmental Risks), 2012, DG HLTH CONS; Sindiku O., 2014, ENV SCI POLLUT RES; Skelton A, 2011, ENVIRON SCI TECHNOL, V45, P10516, DOI 10.1021/es202313e; Steffen W., 2015, SCIENCE; Stockholm Convention, 2008, CONV TEXT; Stockholm Convention, 2012, SUCC STOR STOCKH CON; Turk M, 2007, ENVIRON CHEM LETT, V5, P109, DOI 10.1007/s10311-006-0091-9; UNEP (United Nations Environment Programme), 2013, GC GLOB CHEM OUTL SO; UNEP (United Nations Environment Programme), 2010, MONTR PROT SUBST DEP; UNEP (United Nations Environment Programme), 2015, MIN CONV AGR NAT; UNEP (United Nations Environment Programme) WHO (World Health Organisation) CVUA (The State Institute for Chemical Veterinary Analysis of Food) MTM Research Centre, 2013, HUM EXP POPS GLOB PO; United Nations Environment Programme (UNEP), 2012, GLOB ENV OUTL 5 ENV; U.S. EPA (United States Environmental Protection Agency), 2014, DES ENV; Voeroesmarty C.J., 2010, NATURE, V467, P555, DOI DOI 10.1038/NATURE0944020882010; World Health Organization, 2013, STAT SCI END DISR CH	93	6	6	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0160-4120	1873-6750		ENVIRON INT	Environ. Int.	MAY	2015	78						8	15		10.1016/j.envint.2015.02.001		8	Environmental Sciences	Environmental Sciences & Ecology	CG2GH	WOS:000353092400002		
J	Tran, TM; Abualnaja, KO; Asimakopoulos, AG; Covaci, A; Gevao, B; Johnson-Restrepo, B; Kumosani, TA; Malarvannan, G; Minh, TB; Moon, HB; Nakata, H; Sinha, RK; Kannan, K				Tri Manh Tran; Abualnaja, Khalid O.; Asimakopoulos, Alexandros G.; Covaci, Adrian; Gevao, Bondi; Johnson-Restrepo, Boris; Kumosani, Taha A.; Malarvannan, Govindan; Tu Binh Minh; Moon, Hyo-Bang; Nakata, Haruhiko; Sinha, Ravindra K.; Kannan, Kurunthachalam			A survey of cyclic and linear siloxanes in indoor dust and their implications for human exposures in twelve countries	ENVIRONMENT INTERNATIONAL			English	Article						Siloxanes; Dust; Exposure; D5; Silicone	WATER TREATMENT PLANTS; OCTAMETHYLCYCLOTETRASILOXANE D-4; WASTE-WATER; VOLATILE METHYLSILOXANES; REPRODUCTIVE TOXICITY; PERSONAL-CARE; UNITED-STATES; IN-VITRO; RATS; INHALATION	Siloxanes are used widely in a variety of consumer products, including cosmetics, personal care products, medical and electrical devices, cookware, and building materials. Nevertheless, little is known on the occurrence of siloxanes in indoor dust. In this survey, five cyclic (D3-D7) and 11 linear (L4-L14) siloxanes were determined in 310 indoor dust samples collected from 12 countries. Dust samples collected from Greece contained the highest concentrations of total cyclic siloxanes (TCSi), ranging from 118 to 25,100 ng/g (median: 1380), and total linear siloxanes (TLSi), ranging from 129 to 4990 ng/g (median: 772). The median total siloxane (TSi) concentrations in dust samples from 12 countries were in the following decreasing order: Greece (2970 ng/g), Kuwait (2400), South Korea (1810), Japan (1500), the USA (1220), China (1070), Romania (538), Colombia (230), Vietnam (206), Saudi Arabia (132), India (116), and Pakistan (68.3). TLSi concentrations as high as 42,800 ng/g (Kuwait) and TCSi concentrations as high as 25,000 ng/g (Greece) were found in indoor dust samples. Among the 16 siloxanes determined, decamethylcyclopentasiloxane (D5) was found at the highest concentration in dust samples from all countries, except for Japan and South Korea, with a predominance of L11; Kuwait, with L10; and Pakistan and Romania, with L12. The composition profiles of 16 siloxanes in dust samples varied by country. TCSi accounted for a major proportion of TSi concentrations in dust collected from Colombia (90%), India (80%) and Saudi Arabia (70%), whereas TLSi predominated in samples collected from Japan (89%), Kuwait (85%), and South Korea (78%). Based on the measured median TSi concentrations in indoor dust, we estimated human exposure doses through indoor dust ingestion for various age groups. The exposure doses ranged from 0.27 to 11.9 ng/kg-bw/d for toddlers and 0.06 to 2.48 ng/kg-bw/d for adults. (C) 2015 Elsevier Ltd. All rights reserved.	[Tri Manh Tran; Asimakopoulos, Alexandros G.; Kannan, Kurunthachalam] SUNY Albany, New York State Dept Hlth, Wadsworth Ctr, Albany, NY 12201 USA; [Tri Manh Tran; Asimakopoulos, Alexandros G.; Kannan, Kurunthachalam] SUNY Albany, Dept Environm Hlth Sci, Sch Publ Hlth, Albany, NY 12201 USA; [Tri Manh Tran; Tu Binh Minh] Vietnam Natl Univ, Hanoi Univ Sci, Fac Chem, Hanoi, Vietnam; [Abualnaja, Khalid O.; Kumosani, Taha A.; Kannan, Kurunthachalam] King Abdulaziz Univ, Fac Sci, Dept Biochem, Expt Biochem Unit,King Fand Med Res Ctr, Jeddah, Saudi Arabia; [Abualnaja, Khalid O.; Kannan, Kurunthachalam] King Abdulaziz Univ, Bioact Nat Prod Res Grp, Jeddah, Saudi Arabia; [Covaci, Adrian; Malarvannan, Govindan] Univ Antwerp, Toxicol Ctr, B-2610 Wilrijk Antwerp, Belgium; [Gevao, Bondi] Kuwait Inst Sci Res, Environm & Life Sci Ctr, Environm Management Program, Safat 13109, Kuwait; [Johnson-Restrepo, Boris] Univ Cartagena, Sede San Pablo, Environm & Chem Grp, Bolivar 130015, Colombia; [Kumosani, Taha A.] King Abdulaziz Univ, Prod Bioprod Ind Applicat Res Grp, Jeddah, Saudi Arabia; [Moon, Hyo-Bang] Hanyang Univ, Coll Sci & Technol, Dept Marine Sci & Convergent Technol, Ansan, South Korea; [Nakata, Haruhiko] Kumamoto Univ, Grad Sch Sci & Technol, Kumamoto 8608555, Japan; [Sinha, Ravindra K.] Univ Patna, Dept Zool, Patna 800005, Bihar, India	Kannan, K (reprint author), Wadsworth Ctr, Empire State Pl,POB 509, Albany, NY 12201 USA.	kkannan@wadsworth.org			Colombian National Science and Technology System; Centers for Disease Control and Prevention (CDC, Atlanta, GA) [1U38EH000464-01]	The authors thank Pierina Maza-Anaya, a youth research fellow supported by the Colombian National Science and Technology System, for helping with the collection of dust samples from Colombia; Dr. Dilip Kumar Kedia helped with the collection of dust samples from India. This study was funded by a grant (1U38EH000464-01) from the Centers for Disease Control and Prevention (CDC, Atlanta, GA) to Wadsworth Center, New York State Department of Health. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the CDC.	Lee S, 2014, SCI TOTAL ENVIRON, V497, P106, DOI 10.1016/j.scitotenv.2014.07.083; McKim JM, 2001, TOXICOL SCI, V63, P37, DOI 10.1093/toxsci/63.1.37; Quinn AL, 2007, TOXICOL SCI, V96, P145, DOI 10.1093/toxsci/kfl185; Zhang ZF, 2011, ARCH ENVIRON CON TOX, V60, P204, DOI 10.1007/s00244-010-9619-x; Wang DG, 2013, CHEMOSPHERE, V93, P766, DOI 10.1016/j.chemosphere.2012.10.047; Horii Y, 2008, ARCH ENVIRON CON TOX, V55, P701, DOI 10.1007/s00244-008-9172-z; Wang R, 2009, ENVIRON INT, V35, P900, DOI 10.1016/j.envint.2009.03.009; Bletsou AA, 2013, ENVIRON SCI TECHNOL, V47, P1824, DOI 10.1021/es304369b; Guo Y, 2011, ENVIRON SCI TECHNOL, V45, P3788, DOI 10.1021/es2002106; Pieri F, 2013, ENVIRON INT, V59, P363, DOI 10.1016/j.envint.2013.06.006; Lu Y, 2011, ENVIRON POLLUT, V159, P3522, DOI 10.1016/j.envpol.2011.08.015; Reddy MB, 2007, TOXICOL SCI, V99, P422, DOI 10.1093/toxsci/kfm174; Lu Y, 2010, ENVIRON SCI TECHNOL, V44, P6081, DOI 10.1021/es101368n; Yucuis RA, 2013, CHEMOSPHERE, V92, P905, DOI 10.1016/j.chemosphere.2013.02.051; He B, 2003, TOXICOL APPL PHARM, V192, P254, DOI 10.1016/S0041-008X(03)00282-5; Liao CY, 2012, ENVIRON SCI TECHNOL, V46, P9138, DOI 10.1021/es302004w; Jovanovic ML, 2008, REGUL TOXICOL PHARM, V50, P239, DOI 10.1016/j.yrtph.2007.11.003; Badjagbo K, 2009, ANAL CHEM, V81, P7288, DOI 10.1021/ac901088f; Brooke DN, 2009, ENV RISK ASSESSMENT; Bums-Naas LA, 1998, TOXICOL SCI, V43, P28; Burns-Naas LA, 2002, INT J TOXICOL, V21, P39, DOI 10.1080/10915810252826000; Environment Canada Health Canada, 2011, SCREEN ASS CHALL SIL; Kawamura Y, 2001, J FOOD HYG SOC JPN, V42, P316; Meeks RG, 2007, REPROD TOXICOL, V23, P192, DOI 10.1016/j.reprotox.2006.12.005; Quinn AL, 2007, REPROD TOXICOL, V23, P532, DOI 10.1016/j.reprotox.2007.02.005; Sanchis J, 2013, SCI TOTAL ENVIRON, V443, P530, DOI 10.1016/j.scitotenv.2012.10.047; Siddiqui WH, 2007, REPROD TOXICOL, V23, P202, DOI 10.1016/j.reprotox.2006.11.011; U.S. Environmental Protection Agency, 2008, CHILD SPEC EXP FACT; WATTS RJ, 1995, WATER RES, V29, P2405, DOI 10.1016/0043-1354(95)00067-U	29	0	0	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0160-4120	1873-6750		ENVIRON INT	Environ. Int.	MAY	2015	78						39	44		10.1016/j.envint.2015.02.011		6	Environmental Sciences	Environmental Sciences & Ecology	CG2GH	WOS:000353092400006		
J	Yorifuji, T; Kashima, S; Doi, H				Yorifuji, Takashi; Kashima, Saori; Doi, Hiroyuki			Outdoor air pollution and term low birth weight in Japan (vol 74, pg 106, 2014)	ENVIRONMENT INTERNATIONAL			English	Correction									[Yorifuji, Takashi] Okayama Univ, Grad Sch Environm & Life Sci, Dept Human Ecol, Okayama 7008530, Japan; [Kashima, Saori] Hiroshima Univ, Inst Biomed & Hlth Sci, Dept Publ Hlth & Publ Policy, Hiroshima 730, Japan; [Doi, Hiroyuki] Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Epidemiol, Okayama 7008530, Japan	Yorifuji, T (reprint author), Okayama Univ, Grad Sch Environm & Life Sci, Dept Human Ecol, Kita Ku, 3-1-1 Tsushima Naka, Okayama 7008530, Japan.	yorichan@md.okayama-u.ac.jp					Yorifuji T, 2015, ENVIRON INT, V74, P106, DOI 10.1016/j.envint.2014.09.003	1	0	0	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0160-4120	1873-6750		ENVIRON INT	Environ. Int.	MAY	2015	78						95	96		10.1016/j.envint.2015.02.016		2	Environmental Sciences	Environmental Sciences & Ecology	CG2GH	WOS:000353092400012		
J	Narihiro, T; Nobu, MK; Kim, NK; Kamagata, Y; Liu, WT				Narihiro, Takashi; Nobu, Masaru K.; Kim, Na-Kyung; Kamagata, Yoichi; Liu, Wen-Tso			The nexus of syntrophy-associated microbiota in anaerobic digestion revealed by long-term enrichment and community survey	ENVIRONMENTAL MICROBIOLOGY			English	Article							WASTE-WATER TREATMENT; METHANOGENIC GRANULAR SLUDGES; RDNA SEQUENCE-ANALYSIS; RICE FIELD SOIL; SP-NOV.; GEN.-NOV.; FILAMENTOUS BACTERIA; OXIDIZING BACTERIUM; PHYLUM CHLOROFLEXI; TREATMENT SYSTEMS	Anaerobic digestion (AD) processes are known to effectively convert organic waste to CO2 and CH4, but much of the microbial ecology remains unclear. Specifically, we have limited insights into symbiotic syntroph and methanogen (syntrophy') acid degradation, although they are essential for preventing process deterioration. Also, we often observed many uncharacterized or uncultivated organisms, but poorly understood their role(s) in relation to syntrophy. To define syntrophy-associated populations, this study enriched methanogenic communities with propionate, butyrate, benzoate, acetate, formate and H-2 from two different inocula over 3 years. 16S pyrotag analysis revealed core populations of known syntrophs (six clades) and methanogens (nine clades) associated with acid degradation, and evidence for substrate- and/or inoculum-dependent specificity in syntrophic partnerships. Based on comprehensive re-evaluation of publically available microbial community data for AD, the known syntrophs and methanogens identified were clearly representatives of the AD-associated syntrophs and methanogens. In addition, uncultivated clades related to Bacteroidetes, Firmicutes, Actinobacteria and Chloroflexi were ubiquitously found in AD and enrichments. These organisms may be universally involved in AD syntrophic degradation, but only represented <23% of the yet-to-be-cultivated organisms (89 of 390 clades). Thus, the contribution of these uncultured organisms in AD remains unclear and warrants further investigation.	[Narihiro, Takashi; Nobu, Masaru K.; Kim, Na-Kyung; Liu, Wen-Tso] Univ Illinois, Dept Civil & Environm Engn, Urbana, IL 61801 USA; [Narihiro, Takashi; Kamagata, Yoichi] Natl Inst Adv Ind Sci & Technol, Bioprod Res Inst, Tsukuba, Ibaraki 3058566, Japan; [Kamagata, Yoichi] Natl Inst Adv Ind Sci & Technol, Bioprod Res Inst, Sapporo, Hokkaido 0628517, Japan	Liu, WT (reprint author), Univ Illinois, Dept Civil & Environm Engn, 205 North Mathews Ave, Urbana, IL 61801 USA.	wtliu@illinois.edu	Liu, Wen-Tso/C-8788-2011	Liu, Wen-Tso/0000-0002-8700-9803	PepsiCo; JSPS KAKENHI [26630250]	We are grateful to Lin Ye, Hideyuki Tamaki, Xiang-Kun Li and Xiang-Zheng Li for technical assistance. We also thank Alexander V. Ulanov and Chris L. Wright at the Roy J. Carver Biotechnology Center, the University of Illinois at Urbana-Champaign for pyrosequencing and GC-MS analyses respectively. This research was partly supported by PepsiCo to WTL and JSPS KAKENHI to TN (Grant Number 26630250). The authors declare no conflict of interest.	Godon JJ, 1997, APPL ENVIRON MICROB, V63, P2802; Lykidis A, 2011, ISME J, V5, P122, DOI 10.1038/ismej.2010.125; Diaz EE, 2006, APPL ENVIRON MICROB, V72, P4942, DOI 10.1128/AEM.02985-05; Yamada T, 2007, INT J SYST EVOL MICR, V57, P2299, DOI 10.1099/ijs.0.65098-0; Yamada T, 2006, INT J SYST EVOL MICR, V56, P1331, DOI 10.1099/ijs.0.64169-0; Hori T, 2007, APPL ENVIRON MICROB, V73, P101, DOI 10.1128/AEM.01676-06; Sieber JR, 2012, ANNU REV MICROBIOL, V66, P429, DOI 10.1146/annurev-micro-090110-102844; Haas BJ, 2011, GENOME RES, V21, P494, DOI 10.1101/gr.112730.110; Hattori S, 2000, INT J SYST EVOL MICR, V50, P1601; Werner JJ, 2011, P NATL ACAD SCI USA, V108, P4158, DOI 10.1073/pnas.1015676108; Liu H, 2012, WATER RES, V46, P799, DOI 10.1016/j.watres.2011.11.047; Chong SH, 2012, WATER RES, V46, P3434, DOI 10.1016/j.watres.2012.03.066; LETTINGA G, 1995, ANTON LEEUW INT J G, V67, P3, DOI 10.1007/BF00872193; Nelson MC, 2011, BIORESOURCE TECHNOL, V102, P3730, DOI 10.1016/j.biortech.2010.11.119; McDonald D, 2012, ISME J, V6, P610, DOI 10.1038/ismej.2011.139; Perkins SD, 2011, WATER SCI TECHNOL, V64, P1406, DOI 10.2166/wst.2011.552; Ludwig W, 2004, NUCLEIC ACIDS RES, V32, P1363, DOI 10.1093/nar/gkh293; Cole JR, 2009, NUCLEIC ACIDS RES, V37, pD141, DOI 10.1093/nar/gkn879; Schink B, 1997, MICROBIOL MOL BIOL R, V61, P262; Ariesyady HD, 2007, WATER RES, V41, P1554, DOI 10.1016/j.watres.2006.12.036; Narihiro T, 2009, MICROBES ENVIRON, V24, P88, DOI 10.1264/jsme2.ME08561; Chouari R, 2005, ENVIRON MICROBIOL, V7, P1104, DOI 10.1111/j.1462-2920.2005.00795.x; Sakai S, 2009, APPL ENVIRON MICROB, V75, P4892, DOI 10.1128/AEM.02835-08; Caporaso JG, 2010, BIOINFORMATICS, V26, P266, DOI 10.1093/bioinformatics/btp636; Lee SH, 2013, BIORESOURCE TECHNOL, V145, P25, DOI 10.1016/j.biortech.2013.02.070; Krzywinski M, 2009, GENOME RES, V19, P1639, DOI 10.1101/gr.092759.109; Sekiguchi Y, 2001, APPL ENVIRON MICROB, V67, P5740, DOI 10.1128/AEM.67.12.5740-5749.2001; Narihiro T, 2009, ISME J, V3, P522, DOI 10.1038/ismej.2009.4; Caporaso JG, 2010, NAT METHODS, V7, P335, DOI 10.1038/nmeth.f.303; Chen SY, 2005, INT J SYST EVOL MICR, V55, P2257, DOI 10.1099/ijs.0.63807-0; Ito T, 2011, ISME J, V5, P1844, DOI 10.1038/ismej.2011.59; Chouari R, 2005, APPL ENVIRON MICROB, V71, P2145, DOI 10.1128/AEM.71.4.2145-2153.2005; Hamady M, 2010, ISME J, V4, P17, DOI 10.1038/ismej.2009.97; Chen CL, 2009, MICROBES ENVIRON, V24, P144, DOI 10.1264/jsme2.ME09109; Sundberg C, 2013, FEMS MICROBIOL ECOL, V85, P612, DOI 10.1111/1574-6941.12148; Hori T, 2006, APPL ENVIRON MICROB, V72, P1623, DOI 10.1128/AEM.72.2.1623-1630.2006; Balk M, 2002, INT J SYST EVOL MICR, V52, P1361, DOI 10.1099/ijs.0.02165-0; Speece RE, 2006, WATER ENVIRON RES, V78, P460, DOI 10.2175/106143006X95492; Kampmann K, 2012, APPL ENVIRON MICROB, V78, P2106, DOI 10.1128/AEM.06394-11; Angelidaki I, 2003, ADV BIOCHEM ENG BIOT, V82, P1; Narihiro T, 2007, CURR OPIN BIOTECH, V18, P273, DOI 10.1016/j.copbio.2007.04.003; Ito T, 2012, BIORESOURCE TECHNOL, V123, P599, DOI 10.1016/j.biortech.2012.07.108; Imachi H, 2008, INT J SYST EVOL MICR, V58, P294, DOI 10.1099/ijs.0.65394-0; Baena S, 1998, ANAEROBE, V4, P241, DOI 10.1006/anae.1998.0170; Hatamoto M, 2007, INT J SYST EVOL MICR, V57, P2137, DOI 10.1099/ijs.0.64981-0; Arbeli Z, 2006, WATER RES, V40, P3653, DOI 10.1016/j.watres.2006.06.017; Latif MA, 2011, WATER RES, V45, P4683, DOI 10.1016/j.watres.2011.05.049; Edgar RC, 2010, BIOINFORMATICS, V26, P2460, DOI 10.1093/bioinformatics/btq461; Sekiguchi Y, 2003, INT J SYST EVOL MICR, V53, P1843, DOI 10.1099/ijs.0.02699-0; Wu JH, 2001, MICROBIOL-UK, V147, P373; Chen CL, 2004, MICROBIOL-SGM, V150, P3429, DOI 10.1099/mic.0.27193-0; Dolfing J, 2008, APPL ENVIRON MICROB, V74, P6126, DOI 10.1128/AEM.01428-08; Riviere D, 2009, ISME J, V3, P700, DOI 10.1038/ismej.2009.2; Yamada T, 2007, ISME J, V1, P246, DOI 10.1038/ismej.2007.28; Fernandez N, 2008, MICROB ECOL, V56, P121, DOI 10.1007/s00248-007-9330-2; Sakai S, 2012, INT J SYST EVOL MICR, V62, P1389, DOI 10.1099/ijs.0.035048-0; Angenent LT, 2001, WATER RES, V35, P1739, DOI 10.1016/S0043-1354(00)00447-4; Schnurer A, 1996, INT J SYST BACTERIOL, V46, P1145; Liu YC, 2008, ANN NY ACAD SCI, V1125, P171, DOI 10.1196/annals.1419.019; GOOD IJ, 1953, BIOMETRIKA, V40, P237, DOI 10.2307/2333344; Chen CL, 2008, WATER RES, V42, P1963, DOI 10.1016/j.watres.2007.11.037; Bialek K, 2012, MICROB BIOTECHNOL, V5, P738, DOI 10.1111/j.1751-7915.2012.00364.x; Camacho C, 2009, BMC BIOINFORMATICS, V10, DOI 10.1186/1471-2105-10-421; Colwell R.K., 2013, ESTIMATES STAT ESTIM; DSMZ, 2014, CAT MICR; ENDO G, 1988, WATER SCI TECHNOL, V20, P205; FELSENSTEIN J, 1985, EVOLUTION, V39, P783, DOI 10.2307/2408678; Lacroix N, 2014, WASTE MANAGE RES, V32, P608, DOI 10.1177/0734242X14538308; Li P, 2010, WATER SCI TECHNOL, V61, P243, DOI 10.2166/wst.2010.807; McKeown RM, 2012, CURR OPIN BIOTECH, V23, P444, DOI 10.1016/j.copbio.2011.11.025; MIN H, 1989, APPL ENVIRON MICROB, V55, P488; Nobu M. K., 2014, GENOME ANNOUNC, V2; Nobu MK, 2014, ENVIRON MICROBIOL, DOI [10.1111/1462-2920.12444, DOI 10.1111/1462-2920.12444]; Panichnumsin P, 2012, WATER SCI TECHNOL, V66, P1590, DOI 10.2166/wst.2012.358; R DEVELOPMENT CORE TEAM, 2005, R LANG ENV STAT COMP; SAITOU N, 1987, MOL BIOL EVOL, V4, P406; Schink B., 2013, SYNTROPHISM PROKARYO; Sekiguchi Y, 2000, INT J SYST EVOL MICR, V50, P771; Sekiguchi Y, 2004, STRICT AND FACULTATIVE ANAEROBES: MEDICAL AND ENVIRONMENTAL ASPECTS, P361; Tamaki H, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025263; Tian JQ, 2010, INT J SYST EVOL MICR, V60, P2165, DOI 10.1099/ijs.0.019273-0; vansLier J. B., 2008, ANAEROBIC WASTEWATER; Vanwonterghem I., 2014, ISME J, DOI [10.1038/ismej.2014.1050, DOI 10.1038/ISMEJ.2014.1050]; Wang Y, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007401; Wu JH, 2001, J BIOSCI BIOENG, V91, P449, DOI 10.1263/jbb.91.449; Yamada T, 2011, APPL ENVIRON MICROB, V77, P2081, DOI 10.1128/AEM.02475-10	86	3	3	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1462-2912	1462-2920		ENVIRON MICROBIOL	Environ. Microbiol.	MAY	2015	17	5					1707	1720		10.1111/1462-2920.12616		14	Microbiology	Microbiology	CG7TD	WOS:000353507100018		
J	Kato, S; Ikehata, K; Shibuya, T; Urabe, T; Ohkuma, M; Yamagishi, A				Kato, Shingo; Ikehata, Kei; Shibuya, Takazo; Urabe, Tetsuro; Ohkuma, Moriya; Yamagishi, Akihiko			Potential for biogeochemical cycling of sulfur, iron and carbon within massive sulfide deposits below the seafloor	ENVIRONMENTAL MICROBIOLOGY			English	Article							SOUTHERN MARIANA TROUGH; MOLAL THERMODYNAMIC PROPERTIES; LEPIDOCROCITE GAMMA-FEOOH; GOETHITE ALPHA-FEOOH; RIBOSOMAL-RNA GENES; HIGH-PRESSURES; HYDROTHERMAL SYSTEMS; HIGH-THROUGHPUT; INDEPENDENT CHARACTERIZATION; MAGHEMITE GAMMA-FE2O3	Seafloor massive sulfides are a potential energy source for the support of chemosynthetic ecosystems in dark, deep-sea environments; however, little is known about microbial communities in these ecosystems, especially below the seafloor. In the present study, we performed culture-independent molecular analyses of sub-seafloor sulfide samples collected in the Southern Mariana Trough by drilling. The depth for the samples ranged from 0.52m to 2.67m below the seafloor. A combination of 16S rRNA and functional gene analyses suggested the presence of chemoautotrophs, sulfur-oxidizers, sulfate-reducers, iron-oxidizers and iron-reducers. In addition, mineralogical and thermodynamic analyses are consistent with chemosynthetic microbial communities sustained by sulfide minerals below the seafloor. Although distinct bacterial community compositions were found among the sub-seafloor sulfide samples and hydrothermally inactive sulfide chimneys on the seafloor collected from various areas, we also found common bacterial members at species level including the sulfur-oxidizers and sulfate-reducers, suggesting that the common members are widely distributed within massive sulfide deposits on and below the seafloor and play a key role in the ecosystem function.	[Kato, Shingo; Yamagishi, Akihiko] Tokyo Univ Pharm & Life Sci, Dept Mol Biol, Hachioji, Tokyo 1920392, Japan; [Kato, Shingo; Ohkuma, Moriya] RIKEN BioResource Ctr, Japan Collect Microorganisms, Tsukuba, Ibaraki 3050074, Japan; [Ikehata, Kei] Univ Tsukuba, Fac Life & Environm Sci, Tsukuba, Ibaraki 3058572, Japan; [Shibuya, Takazo] Japan Agcy Marine Earth Sci & Technol JAMSTEC, SRRP, Yokosuka, Kanagawa 2370061, Japan; [Shibuya, Takazo] Japan Agcy Marine Earth Sci & Technol JAMSTEC, PEL, Yokosuka, Kanagawa 2370061, Japan; [Urabe, Tetsuro] Univ Tokyo, Dept Earth & Planetary Sci, Bunkyo Ku, Tokyo 1130033, Japan	Yamagishi, A (reprint author), Tokyo Univ Pharm & Life Sci, Dept Mol Biol, 1432-1 Horinouchi, Hachioji, Tokyo 1920392, Japan.	yamagish@toyaku.ac.jp	Ohkuma, Moriya/A-8100-2011		TAIGA project - Ministry of Education, Culture, Sports, Science and Technology (MEXT), Japan [20109006]; RIKEN Special Post-doctoral Researchers Program;  [24770032]	We would like to thank the crew of R/V Hakurei-Maru No. 2, the operation team of BMS and the scientific colleagues for their professional skills and careful consideration for collecting core samples during the TAIGA10 cruise. We are grateful to the Support Unit for Bio-Material Analysis in RIKEN BSI Research Resources Center (RRC) for DNA sequencing. We would like to thank two anonymous reviewers for their helpful comments and suggestions. This research was supported by the 'TAIGA project', which was funded by a Grant-in-Aid for Scientific Research on Innovative Areas (#20109006) from the Ministry of Education, Culture, Sports, Science and Technology (MEXT), Japan, by a Grant-in-Aid for Young Scientists (B) (#24770032), and partially by the RIKEN Special Post-doctoral Researchers Program. The authors have no conflict of interest to declare.	SHOCK EL, 1995, GEOCHIM COSMOCHIM AC, V59, P1497, DOI 10.1016/0016-7037(95)00058-8; Clark DA, 1996, MICROBIOL-UK, V142, P785; Meyer B, 2007, APPL ENVIRON MICROB, V73, P7664, DOI 10.1128/AEM.01272-07; Alfreider A, 2003, MICROB ECOL, V45, P317, DOI 10.1007/s00248-003-2004-9; Yao WS, 1996, MAR CHEM, V52, P1, DOI 10.1016/0304-4203(95)00072-0; Baker BJ, 2003, FEMS MICROBIOL ECOL, V44, P139, DOI 10.1016/S0168-6496(03)00028-X; McAllister SM, 2011, APPL ENVIRON MICROB, V77, P5445, DOI 10.1128/AEM.00533-11; Shade A, 2012, ENVIRON MICROBIOL, V14, P4, DOI 10.1111/j.1462-2920.2011.02585.x; Nitahara S, 2011, FEMS MICROBIOL LETT, V321, P121, DOI 10.1111/j.1574-6968.2011.02323.x; Castresana J, 2000, MOL BIOL EVOL, V17, P540; Herlemann DPR, 2011, ISME J, V5, P1571, DOI 10.1038/ismej.2011.41; Mason OU, 2007, ENVIRON MICROBIOL, V9, P2539, DOI 10.1111/j.1462-2920.2007.01372.x; Teske A, 2000, APPL ENVIRON MICROB, V66, P3125, DOI 10.1128/AEM.66.8.3125-3133.2000; Osorio H, 2013, APPL ENVIRON MICROB, V79, P2172, DOI 10.1128/AEM.03057-12; Lee ZMP, 2009, NUCLEIC ACIDS RES, V37, pD489, DOI 10.1093/nar/gkn689; Kakegawa T, 2008, RESOUR GEOL, V58, P249, DOI 10.1111/j.1751-3928.2008.00060.x; Shock EL, 1997, GEOCHIM COSMOCHIM AC, V61, P907, DOI 10.1016/S0016-7037(96)00339-0; Baker BJ, 2006, SCIENCE, V314, P1933, DOI 10.1126/science.1132690; Rice P, 2000, TRENDS GENET, V16, P276, DOI 10.1016/S0168-9525(00)02024-2; Emerson D, 2010, ANNU REV MICROBIOL, V64, P561, DOI 10.1146/annurev.micro.112408.134208; Sverjensky DA, 1997, GEOCHIM COSMOCHIM AC, V61, P1359, DOI 10.1016/S0016-7037(97)00009-4; SHOCK EL, 1989, GEOCHIM COSMOCHIM AC, V53, P2157, DOI 10.1016/0016-7037(89)90341-4; Baker BJ, 2010, P NATL ACAD SCI USA, V107, P8806, DOI 10.1073/pnas.0914470107; Suzuki MT, 2000, APPL ENVIRON MICROB, V66, P4605, DOI 10.1128/AEM.66.11.4605-4614.2000; HELGESON HC, 1969, AM J SCI, V267, P729; Marumo K, 2008, RESOUR GEOL, V58, P220, DOI 10.1111/j.1751-3928.2008.00059.x; Guindon S, 2010, SYST BIOL, V59, P307, DOI 10.1093/sysbio/syq010; Takai K, 2000, APPL ENVIRON MICROB, V66, P5066, DOI 10.1128/AEM.66.11.5066-5072.2000; HELGESON HC, 1974, AM J SCI, V274, P1199; Herzig PM, 1995, ORE GEOL REV, V10, P95, DOI 10.1016/0169-1368(95)00009-7; Holmes DE, 2004, APPL ENVIRON MICROB, V70, P1234, DOI 10.1128/AEM.70.2.1234-1237.2004; Schippers A, 2002, GEOCHIM COSMOCHIM AC, V66, P85, DOI 10.1016/S0016-7037(01)00745-1; Kato S, 2012, EXTREMOPHILES, V16, P277, DOI 10.1007/s00792-011-0428-6; SHOCK EL, 1988, GEOCHIM COSMOCHIM AC, V52, P2009, DOI 10.1016/0016-7037(88)90181-0; Caporaso JG, 2010, NAT METHODS, V7, P335, DOI 10.1038/nmeth.f.303; McCollom TM, 2009, GEOCHIM COSMOCHIM AC, V73, P856, DOI 10.1016/j.gca.2008.10.032; Finster K, 2008, J SULFUR CHEM, V29, P281, DOI 10.1080/17415990802105770; Button DK, 2001, APPL ENVIRON MICROB, V67, P1636, DOI 10.1128/AEM.67.4.1636-1645.2001; JORGENSEN BB, 1977, LIMNOL OCEANOGR, V22, P814; McCollom TM, 1997, GEOCHIM COSMOCHIM AC, V61, P4375, DOI 10.1016/S0016-7037(97)00241-X; Tabita FR, 2008, J EXP BOT, V59, P1515, DOI 10.1093/jxb/erm361; Campbell BJ, 2003, APPL ENVIRON MICROB, V69, P5070, DOI 10.1128/AEM.69.9.5070-5078.2003; Santelli CM, 2008, NATURE, V453, P653, DOI 10.1038/nature06899; Kato S, 2009, ENVIRON MICROBIOL, V11, P3210, DOI 10.1111/j.1462-2920.2009.02031.x; Klindworth A, 2013, NUCLEIC ACIDS RES, V41, DOI 10.1093/nar/gks808; Kato S, 2010, APPL ENVIRON MICROB, V76, P2968, DOI 10.1128/AEM.00478-10; Hannington M, 2011, GEOLOGY, V39, P1155, DOI 10.1130/G32468.1; HUMPHRIS SE, 1995, NATURE, V377, P713, DOI 10.1038/377713a0; Kato S, 2009, ENVIRON MICROBIOL, V11, P2094, DOI 10.1111/j.1462-2920.2009.01930.x; Cole JR, 2014, NUCLEIC ACIDS RES, V42, pD633, DOI 10.1093/nar/gkt1244; Toner BM, 2013, GEOMICROBIOL J, V30, P313, DOI 10.1080/01490451.2012.688925; Klein F, 2009, GEOCHIM COSMOCHIM AC, V73, P6868, DOI 10.1016/j.gca.2009.08.021; DELONG EF, 1994, NATURE, V371, P695, DOI 10.1038/371695a0; THAMDRUP B, 1993, APPL ENVIRON MICROB, V59, P101; Majzlan J, 2003, AM MINERAL, V88, P846; Podosokorskaya OA, 2013, ENVIRON MICROBIOL, V15, P1759, DOI 10.1111/1462-2920.12067; HAYMON RM, 1981, EARTH PLANET SC LETT, V53, P363, DOI 10.1016/0012-821X(81)90041-8; Edgar RC, 2004, NUCLEIC ACIDS RES, V32, P1792, DOI 10.1093/nar/gkh340; Schloss PD, 2009, APPL ENVIRON MICROB, V75, P7537, DOI 10.1128/AEM.01541-09; Majzlan J, 2003, AM MINERAL, V88, P855; Canfield DE, 2010, SCIENCE, V330, P1375, DOI 10.1126/science.1196889; Sekiguchi Y, 2008, INT J SYST EVOL MICR, V58, P2541, DOI 10.1099/ijs.0.2008/000893-0; Hallberg KB, 2011, EXTREMOPHILES, V15, P271, DOI 10.1007/s00792-011-0359-2; MOSES CO, 1987, GEOCHIM COSMOCHIM AC, V51, P1561, DOI 10.1016/0016-7037(87)90337-1; Karner MB, 2001, NATURE, V409, P507, DOI 10.1038/35054051; Darriba D, 2011, BIOINFORMATICS, V27, P1164, DOI 10.1093/bioinformatics/btr088; Ashelford KE, 2006, APPL ENVIRON MICROB, V72, P5734, DOI 10.1128/AEM.00556-06; You CF, 1998, NATURE, V394, P668; Bethke CM., 2008, GEOCHEMICAL BIOGEOCH; Campbell BJ, 2004, APPL ENVIRON MICROB, V70, P6282, DOI 10.1128/AEM.70.10.6282-6289.2004; Cleverley JS, 2005, COMPUT GEOSCI-UK, V31, P756, DOI 10.1016/j.cageo.2005.01.007; Drummond S. E., 1981, THESIS PENNSYLVANIA; Emerson D, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000667; HELGESON HC, 1978, AM J SCI, V278, P1; Ikehata K., SUBSEAFLOOR IN PRESS; Ishibashi J., SUBSEAFLOOR IN PRESS; Ishibashi J., SUBSEAFLOOR IN PRESS; Jogler C, 2010, ENVIRON MICROBIOL, V12, P2466, DOI 10.1111/j.1462-2920.2010.02220.x; JOHNSON JW, 1992, COMPUT GEOSCI, V18, P899, DOI 10.1016/0098-3004(92)90029-Q; Kato S., SUBSEAFLOOR IN PRESS; Kato S, 2011, FEMS MICROBIOL LETT, V319, P34, DOI 10.1111/j.1574-6968.2011.02267.x; LALOU C, 1995, J GEOPHYS RES-SOL EA, V100, P17855, DOI 10.1029/95JB01858; Lane D., 1991, 16S 23S RRNA SEQUENC; Lefevre CT, 2011, ENVIRON MICROBIOL, V13, P538, DOI 10.1111/j.1462-2920.2010.02361.x; Lucker S, 2013, FRONT MICROBIOL, V4, DOI 10.3389/fmicb.2013.00027; Nakagawa S, 2008, FEMS MICROBIOL ECOL, V65, P1, DOI 10.1111/j.1574-6941.2008.00502.x; Nylander J.A.A, 2004, MRAIC PL PROGRAM DIS; Rassa AC, 2009, GEOMICROBIOL J, V26, P623, DOI 10.1080/01490450903263350; Suzuki Y, 2004, MICROB ECOL, V47, P186, DOI 10.1007/s00248-003-1014-y; Sylvan JB, 2012, MBIO, V3, DOI 10.1128/mBio.00279-11; Sylvan JB, 2013, FRONT MICROBIOL, V4, DOI 10.3389/fmicb.2013.00061; Takamasa A, 2013, QUAT GEOCHRONOL, V15, P38, DOI 10.1016/j.quageo.2012.12.002; WIRSEN CO, 1993, J GEOPHYS RES-SOL EA, V98, P9693, DOI 10.1029/92JB01556; Yoshikawa S, 2012, MAR GEOL, V303, P172, DOI 10.1016/j.margeo.2012.02.013; Zierenberg RA, 1998, NATURE, V392, P485, DOI 10.1038/33126	95	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1462-2912	1462-2920		ENVIRON MICROBIOL	Environ. Microbiol.	MAY	2015	17	5					1817	1835		10.1111/1462-2920.12648		19	Microbiology	Microbiology	CG7TD	WOS:000353507100026		
J	Song, Y; Ichinose, T; Morita, K; Nakanishi, T; Kanazawa, T; Yoshida, Y				Song, Yuan; Ichinose, Takamichi; Morita, Kentaro; Nakanishi, Tsukasa; Kanazawa, Tamotsu; Yoshida, Yasuhiro			Asian Sand Dust Causes Subacute Peripheral Immune Modification with NF-kappa B Activation	ENVIRONMENTAL TOXICOLOGY			English	Article						asian sand dust; NF-B; splenocytes; CD4(+) cells; CD11b(+) cells	AIR-POLLUTION; EPITHELIAL-CELLS; DAILY MORTALITY; STORM EVENTS; DNA-DAMAGE; TAIWAN; INFLAMMATION; TAIPEI; ICAM-1; GENE	Asian sand dust (ASD), a type of particulate matter found in Asia, migrates to East Asia. The increased airborne spread of ASD has led to concerns regarding possible adverse health effects. Our group previously reported that ASD induces lung inflammation in mice, but it is still unclear whether ASD affects lymphoid organs. In this study, we investigated the effect of ASD on splenocytes in a mouse model of ASD exposure. ICR mice were intratracheally administered a single dose of normal saline (control) or ASD and were subsequently sacrificed 1 or 3 days later. TNF- production in bronchoalveolar lavage fluids was higher at day 1, but not at day 3, after ASD administration. The enzyme-linked immunosorbent assay results showed that ASD administration increased mitogen-induced IL-2, TNF-, and IL-6 production in splenocytes. Additionally, cell viability assay showed enhanced splenocyte proliferation at day 3, but not at day 1, after ASD administration. The electrophoretic mobility shift assay results demonstrated that nuclear factor B (NF-B) was activated in splenocytes on day 3, but not on day 1. In particular, NF-B activation was detected in CD4(+) and CD11b(+) cells on day 3. These results suggest that ASD induces subacute inflammatory responses with NF-B activation in the spleen, in contrast to acute inflammation in the lungs. (c) 2013 Wiley Periodicals, Inc. Environ Toxicol 30: 549-558, 2015.	[Song, Yuan; Morita, Kentaro; Nakanishi, Tsukasa; Kanazawa, Tamotsu; Yoshida, Yasuhiro] Univ Occupat & Environm Hlth, Sch Med, Dept Immunol & Parasitol, Yahatanishi Ku, Kitakyushu, Fukuoka 8078555, Japan; [Ichinose, Takamichi] Oita Univ Nursing & Hlth Sci, Dept Hlth Sci, Oita 8701201, Japan	Yoshida, Y (reprint author), Univ Occupat & Environm Hlth, Sch Med, Dept Immunol & Parasitol, Yahatanishi Ku, 1-1 Iseigaoka, Kitakyushu, Fukuoka 8078555, Japan.	freude@med.uoeh-u.ac.jp			Ministry of the Environment, Government of Japan [ERTDF C-1155]; Japan Society for the Promotion of Science [24390159]	Contract grant sponsor: Grant-in-Aid for the Environment Research and Technology Development Fund from the Ministry of the Environment, Government of Japan.; Contract grant number: ERTDF C-1155; Contract grant sponsor: Grant-in-Aid for Scientific Research (B) from the Japan Society for the Promotion of Science.; Contract grant number: 24390159.	Andreakos E, 2003, EXPERT OPIN BIOL TH, V3, P435, DOI 10.1517/14712598.3.3.435; Liu JL, 2011, INT J ONCOL, V39, P915, DOI 10.3892/ijo.2011.1125; Kleinman MT, 2008, TOXICOL LETT, V178, P127, DOI 10.1016/j.toxlet.2008.03.001; GONDO Y, 1994, BIOCHEM BIOPH RES CO, V202, P830, DOI 10.1006/bbrc.1994.2005; Karin M, 2002, NAT IMMUNOL, V3, P221, DOI 10.1038/ni0302-221; Ichinose T, 2008, ARCH ENVIRON CON TOX, V55, P348, DOI 10.1007/s00244-007-9128-8; Brook RD, 2010, CIRCULATION, V121, P2331, DOI 10.1161/CIR.0b013e3181dbece1; Oshima H, 2012, J GASTROENTEROL, V47, P97, DOI 10.1007/s00535-011-0523-6; Brown DM, 2007, AM J PHYSIOL-LUNG C, V292, pL1444, DOI 10.1152/ajplung.00162.2006; Ding N, 2011, CANCER-AM CANCER SOC, V117, P2735, DOI 10.1002/cncr.25711; Maki T, 2010, SCI TOTAL ENVIRON, V408, P4556, DOI 10.1016/j.scitotenv.2010.04.002; Chen F, 2001, AM J PATHOL, V159, P387, DOI 10.1016/S0002-9440(10)61708-7; Kwon HJ, 2002, ENVIRON RES, V90, P1, DOI 10.1006/enrs.2002.4377; Wan FY, 2010, CELL RES, V20, P24, DOI 10.1038/cr.2009.137; Ichinose T, 2008, INHAL TOXICOL, V20, P685, DOI 10.1080/08958370801935133 ; Yang CY, 2005, INHAL TOXICOL, V17, P817, DOI 10.1080/08958370500241254; DUCE RA, 1980, SCIENCE, V209, P1522, DOI 10.1126/science.209.4464.1522; Chan CC, 2008, ENVIRON RES, V106, P393, DOI 10.1016/j.envres.2007.09.006; Cardus A, 2013, CARDIOVASC RES, V97, P571, DOI 10.1093/cvr/cvs352; Strak M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058944; Chen YS, 2004, ENVIRON RES, V95, P151, DOI 10.1016/j.envres.2003.08.008; Bell ML, 2008, OCCUP ENVIRON MED, V65, P104, DOI 10.1136/oem.2006.031500; Hiyoshi K, 2005, ENVIRON RES, V99, P361, DOI 10.1016/j.envres.2005.03.008; Ichinose T, 2003, TOXICOL APPL PHARM, V187, P29, DOI 10.1016/S0041-008X(02)00038-8; Rodier F, 2009, NAT CELL BIOL, V11, P973, DOI 10.1038/ncb1909; Pope CA, 2006, CIRCULATION, V114, P2443, DOI 10.1161/CIRCULATIONAHA.106.636977; Yoshida Y, 2004, J BIOL CHEM, V279, P1768, DOI 10.1074/jbc.M311498200; Hubbard AK, 2002, AM J PHYSIOL-LUNG C, V282, pL968, DOI 10.1152/ajplung.00327.2001; Ding N, 2011, J HAZARD MATER, V194, P324, DOI 10.1016/j.jhazmat.2011.07.101; Essani NA, 1997, SHOCK, V7, P90, DOI 10.1097/00024382-199702000-00003; Farina F, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056636; Kish L, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062220; Melotti P, 2001, GENE THER, V8, P1436, DOI 10.1038/sj.gt.3301533; Takizawa H, 2000, CLIN EXP IMMUNOL, V120, P356, DOI 10.1046/j.1365-2249.2000.01213.x; Yoshida Y, 2009, CHEM-BIOL INTERACT, V177, P137, DOI 10.1016/j.cbi.2008.10.053	35	1	1	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1520-4081	1522-7278		ENVIRON TOXICOL	Environ. Toxicol.	MAY	2015	30	5					549	558		10.1002/tox.21931		10	Environmental Sciences; Toxicology; Water Resources	Environmental Sciences & Ecology; Toxicology; Water Resources	CG8IN	WOS:000353550900005		
J	Shehzad, T; Okuno, K				Shehzad, Tariq; Okuno, Kazutoshi			QTL mapping for yield and yield-contributing traits in sorghum (Sorghum bicolor (L.) Moench) with genome-based SSR markers	EUPHYTICA			English	Article						Quantitative trait loci; Single-QTL method; Multiple-QTL method; Yield; Yield components	FLOWERING DROUGHT TOLERANCE; SUGAR-RELATED TRAITS; GRAIN-SORGHUM; STAY-GREEN; EXPERIMENTAL CROSSES; LOCI; IDENTIFICATION; POPULATIONS; ASSOCIATION; MODELS	In recent years, sorghum (Sorghum bicolor (L.) Moench) has gained attention as a food, feed, and biofuel crop, but yield improvements have lagged behind those in other crops. Here, we investigated quantitative trait loci (QTLs) associated with yield and yield-related traits in sorghum. We measured eight morphological traits related to yield potential in an F-2 and F-2:3 population derived from a cross between African and Japanese sorghum landraces, and we developed a genetic linkage map of 137 sorghum genome-based simple sequence repeat markers. The total map length was 1,239.2 cM, with an average distance of 9.9 cM between adjacent markers. By using both single- and multiple-QTL approaches to identify the chromosomal regions controlling these traits, we identified a total of 52 QTLs associated with the eight traits (culm length, number of tillers, panicle length, culm diameter, leaf length, leaf width, grain weight/panicle, and 100-grain weight) using F-2 phenotypic values while 25 QTLs were confirmed in the F-2:3 population. The percentage phenotypic variation explained by individual QTLs ranged from 3.1 to 36.3 % in the F-2 and 2.1 to 30.4 % in the F-2:3 population. Most of the traits were significantly correlated with one another (P < 0.05). Ten QTLs had a significant association with more than one trait. A QTL for culm length was mapped to the same region of chromosome 7 as the dw3 gene for plant height. The major QTLs identified here are expected to provide useful information toward understanding the genetic mechanisms of important agronomic traits related to yield in sorghum.	[Shehzad, Tariq] Univ Tsukuba, Fac Life & Environm Sci, Tsukuba, Ibaraki 3058572, Japan; [Shehzad, Tariq; Okuno, Kazutoshi] Univ Tsukuba, Alliance Res North Africa ARENA, Tsukuba, Ibaraki 3058572, Japan	Shehzad, T (reprint author), Univ Tsukuba, Fac Life & Environm Sci, Tennodai 1-1-1, Tsukuba, Ibaraki 3058572, Japan.	shehzad.tariq.gb@u.tsukuba.ac.jp					Broman KW, 2003, BIOINFORMATICS, V19, P889, DOI 10.1093/bioinformatics/btg112; Yandell BS, 2007, BIOINFORMATICS, V23, P641, DOI 10.1093/bioinformatics/btm011; Yi NJ, 2007, GENETICS, V176, P1865, DOI 10.1534/genetics.107.071365; Xu WW, 2000, GENOME, V43, P461; Feltus FA, 2006, THEOR APPL GENET, V112, P1295, DOI 10.1007/s00122-006-0232-3; Tao YZ, 2000, THEOR APPL GENET, V100, P1225, DOI 10.1007/s001220051428; Childs KL, 1997, PLANT PHYSIOL, V113, P611, DOI 10.1104/pp.113.2.611; Crasta OR, 1999, MOL GEN GENET, V262, P579, DOI 10.1007/s004380051120; Ritter KB, 2008, MOL BREEDING, V22, P367, DOI 10.1007/s11032-008-9182-6; Hart GE, 2001, THEOR APPL GENET, V103, P1232, DOI 10.1007/s001220100582; Srinivas G, 2009, THEOR APPL GENET, V118, P1439, DOI 10.1007/s00122-009-0993-6; Yonemaru J, 2009, DNA RES, V16, P187, DOI 10.1093/dnares/dsp005; Shiringani AL, 2010, THEOR APPL GENET, V121, P323, DOI 10.1007/s00122-010-1312-y; ZENG ZB, 1994, GENETICS, V136, P1457; Multani DS, 2003, SCIENCE, V302, P81, DOI 10.1126/science.1086072; Rami JF, 1998, THEOR APPL GENET, V97, P605, DOI 10.1007/s001220050936; Haussmann BIG, 2002, THEOR APPL GENET, V106, P133, DOI 10.1007/s00122-002-1012-3; Tuinstra MR, 1997, MOL BREEDING, V3, P439, DOI 10.1023/A:1009673126345; Bhattramakki D, 2000, GENOME, V43, P988, DOI 10.1139/gen-43-6-988; Falconer DS, 1996, INTRO QUALITATIVE GE, V4th; HANSON C. H., 1956, AGRON JOUR, V48, P268; Lander ES, 1987, GENOMICS, V1, P74; SAS Institute, 2002, JMP STAT GRAPH GUID; Shehzad T, 2009, BREEDING SCI, V59, P217, DOI 10.1270/jsbbs.59.217; Shehzad T, 2009, GENET RESOUR CROP EV, V56, P809, DOI 10.1007/s10722-008-9403-1; Tuinstra MR, 1996, CROP SCI, V36, P1337	26	1	1	SPRINGER	DORDRECHT	VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS	0014-2336	1573-5060		EUPHYTICA	Euphytica	MAY	2015	203	1					17	31		10.1007/s10681-014-1243-9		15	Agronomy; Plant Sciences; Horticulture	Agriculture; Plant Sciences	CF9AA	WOS:000352852600002		
J	Koide, Y; Kawasaki-Tanaka, A; Odjo, T; Obara, M; Yanagihara, S; Fukuta, Y				Koide, Yohei; Kawasaki-Tanaka, Akiko; Odjo, Theophile; Obara, Mitsuhiro; Yanagihara, Seiji; Fukuta, Yoshimichi			Identification of QTLs and candidate genes for days to heading in an upland New Rice for Africa (NERICA) variety	EUPHYTICA			English	Article						Days to heading; QTL; Rice; Upland NERICA10	QUANTITATIVE TRAIT LOCUS; ORYZA-GLABERRIMA STEUD; FLOWERING-TIME; ARTIFICIAL SELECTION; CULTIVATED RICE; SATIVA L.; HD3A; DATE; ARABIDOPSIS; EHD1	To produce rice varieties adaptable to unfavorable environments in Africa, New Rice for Africa (NERICA) varieties have been developed by inter-specific crossings. The basic idea of NERICA was to combine the useful characteristics of the African rice species Oryza glaberrima and an Asian rice species, Oryza sativa. However, the genetic basis of the agronomic characteristics of NERICA varieties is not fully understood. We performed a QTL analysis to examine the genetic basis of days to heading (DTH) in an upland variety, NERICA10. We found that NERICA10 had weaker photoperiod sensitivity (PS) and shorter DTH under long day-length conditions than its parental varieties. We then examined QTLs controlling DTH under natural long-day-length conditions by using segregating populations. We found three QTLs for DTH, on chromosomes 4, 6, and 8. Among them, qDTH8.1, located on chromosome 8, had the strongest effect. By comparing nucleotide sequences, we found that NERICA10 had a loss of the functional allele of DTH8, which was located in the candidate region of qDTH8.1. These results suggested that loss of function of DTH8 is the causal factor of weakened PS in NERICA10. The information on these QTLs will be useful for improving rice varieties for better adaption to African conditions.	[Koide, Yohei; Kawasaki-Tanaka, Akiko; Obara, Mitsuhiro; Yanagihara, Seiji; Fukuta, Yoshimichi] JIRCAS, Tsukuba, Ibaraki 3058686, Japan; [Koide, Yohei] Kyoto Univ, Hakubi Ctr Adv Res, Grad Sch Agr, Sakyo Ku, Kyoto 6068502, Japan; [Odjo, Theophile] Univ Abomey Calavi, Fac Agr Sci, Cotonou, Benin	Fukuta, Y (reprint author), JIRCAS, Ohwashi 1-1, Tsukuba, Ibaraki 3058686, Japan.	zen@jircas.affrc.go.jp			Japan Society for the Promotion of Science for Young Scientists [22-6429]	Y.K. thanks Drs. N. Kobayashi, D. Fujita, T. Abiko, K. Matsubara, K. Onishi, and N. Uwatoko for their invaluable suggestions and warm encouragement. This paper reports the results obtained in the JIRCAS projects "Development of rice production technologies in Africa'' and "Rice innovation for environmentally sustainable production systems.'' Financial support was also provided by a Research Fellowship of the Japan Society for the Promotion of Science for Young Scientists (22-6429 to Y.K.).	ALLARD R. W., 1956, HILGARDIA, V24, P235; Semagn K, 2006, AFR J BIOTECHNOL, V5, P800; Yano M, 1997, THEOR APPL GENET, V95, P1025, DOI 10.1007/s001220050658; Saito H, 2012, PLANT CELL PHYSIOL, V53, P717, DOI 10.1093/pcp/pcs029; Tamaki S, 2007, SCIENCE, V316, P1033, DOI 10.1126/science.1141753; Huang CL, 2012, PLANT J, V70, P769, DOI 10.1111/j.1365-313X.2012.04915.x; Yano M, 1997, PLANT MOL BIOL, V35, P145, DOI 10.1023/A:1005764209331; Izawa T, 2007, J EXP BOT, V58, P3091, DOI 10.1093/jxb/erm159; Doi K, 2004, GENE DEV, V18, P926, DOI 10.1101/gad.1189604; Fujino K, 2013, THEOR APPL GENET, V126, P611, DOI 10.1007/s00122-012-2005-5; Izawa T, 2002, GENE DEV, V16, P2006, DOI 10.1101/gad.999202; Hayama R, 2003, NATURE, V422, P719, DOI 10.1038/nature01549; Thomson MJ, 2003, THEOR APPL GENET, V107, P479, DOI 10.1007/s00122-003-1270-8; Kojima S, 2002, PLANT CELL PHYSIOL, V43, P1096, DOI 10.1093/pcp/pcf156; Sarla N, 2005, CURR SCI INDIA, V89, P955; Komiya R, 2008, DEVELOPMENT, V135, P767, DOI 10.1242/dev.008631; Matsubara K, 2012, PLANT CELL PHYSIOL, V53, P709, DOI 10.1093/pcp/pcs028; Monna L, 2002, DNA RES, V9, P11, DOI 10.1093/dnares/9.1.11; McCouch SR, 2002, DNA RES, V9, P199, DOI 10.1093/dnares/9.6.199; Wei XJ, 2010, PLANT PHYSIOL, V153, P1747, DOI 10.1104/pp.110.156943; Fukuta Y, 2012, BREEDING SCI, V62, P27, DOI 10.1270/jsbbs.62.27; Tsuji H, 2011, CURR OPIN PLANT BIOL, V14, P45, DOI 10.1016/j.pbi.2010.08.016; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Bian XF, 2011, PLANT CELL REP, V30, P2243, DOI 10.1007/s00299-011-1129-4; Yano M, 2000, PLANT CELL, V12, P2473, DOI 10.1105/tpc.12.12.2473; Hagiwara WE, 2009, MOL ECOL, V18, P1537, DOI 10.1111/j.1365-294X.2009.04119.x; Takahashi Y, 2009, P NATL ACAD SCI USA, V106, P4555, DOI 10.1073/pnas.0812092106; Asante MD, 2010, MOL BREEDING, V26, P419, DOI 10.1007/s11032-009-9382-8; Cissoko M, 2011, NEW PHYTOL, V192, P952, DOI 10.1111/j.1469-8137.2011.03846.x; Doi K, 1998, BREEDING SCI, V48, P395; Hall T. A., 1999, NUCL ACIDS S SER, V4, P95, DOI DOI 10.1111/J.1469-8137.2009.02874.X; Jones MP, 1997, BREEDING SCI, V47, P395; Jones M.P., 1997, EUPHYTICA, V92, P237; Kang DongJin, 2012, Journal of Crop Science and Biotechnology, V15, P25, DOI 10.1007/s12892-011-0083-6; Kosambi D. D., 1944, ANN EUGENICS, V12, P172; Monna L, 2002, THEOR APPL GENET, V104, P772, DOI 10.1007/s00122-001-0813-0; Oikeh SO, 2008, AGRON J, V100, P735, DOI 10.2134/agronj2007.0212; Saito K, 2012, CROP SCI, V52, P484, DOI 10.2135/cropsci2010.12.0734; Somado EA, 2008, COTONOU BENIN AFRICA, P210; Wang S, 2011, WINDOWS QTL CARTOGRA	40	0	0	SPRINGER	DORDRECHT	VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS	0014-2336	1573-5060		EUPHYTICA	Euphytica	MAY	2015	203	1					153	164		10.1007/s10681-014-1289-8		12	Agronomy; Plant Sciences; Horticulture	Agriculture; Plant Sciences	CF9AA	WOS:000352852600012		
J	Nishikawa, K; Fujitani, K; Inagaki, H; Akamaru, Y; Tokunaga, S; Takagi, M; Tamura, S; Sugimoto, N; Shigematsu, T; Yoshikawa, T; Ishiguro, T; Nakamura, M; Morita, S; Miyashita, Y; Tsuburaya, A; Sakamoto, J; Tsujinaka, T				Nishikawa, Kazuhiro; Fujitani, Kazumasa; Inagaki, Hitoshi; Akamaru, Yusuke; Tokunaga, Shinya; Takagi, Masakazu; Tamura, Shigeyuki; Sugimoto, Naotoshi; Shigematsu, Tadashi; Yoshikawa, Takaki; Ishiguro, Tohru; Nakamura, Masato; Morita, Satoshi; Miyashita, Yumi; Tsuburaya, Akira; Sakamoto, Junichi; Tsujinaka, Toshimasa			Randomised phase III trial of second-line irinotecan plus cisplatin versus irinotecan alone in patients with advanced gastric cancer refractory to S-1 monotherapy: TRICS trial	EUROPEAN JOURNAL OF CANCER			English	Article						Phase III; Gastric cancer; Combination chemotherapy; Second-line; Irinotecan; Cisplatin; Fluoropyrimidine; S-1	ADJUVANT CHEMOTHERAPY; SUPPORTIVE CARE; OPEN-LABEL; ADENOCARCINOMA; FLUOROPYRIMIDINE; COMBINATION; PACLITAXEL; DOCETAXEL; THERAPY	Aim: The optimal second-line regimen for treating advanced gastric cancer (AGC) remains unclear. While irinotecan (CPT-11) plus cisplatin (CDDP) combination therapy and CPT-11 monotherapy have been explored in the second-line setting, the superiority of second-line platinum-based therapies for AGC patients initially treated with S-1 monotherapy has not yet been evaluated; therefore, we aimed to examine the survival benefit of CPT-11/CDDP combination over CPT-11 monotherapy. Methods: AGC patients showing progression after S-1 monotherapy for advanced cancer or recurrence within 6 months after completion of S-1 adjuvant therapy were randomly allocated to CPT-11/CDDP (CPT-11, 60 mg/m(2); CDDP, 30 mg/m(2) , q2w) or CPT-11 (150 mg/m(2), q2w). Results: Sixty-eight advanced and 95 recurrent cases were evaluated. The median overall survivals were 13.9 (95% confidence interval [CI]: 10.8-17.6) and 12.7 (95% CI: 10.3-17.2) months for CPT-11/CDDP and CPT-11, respectively (hazard ratio: 0.834; 95% CI: 0.596-1.167, P = 0.288). No significant differences were observed in the secondary end-points, including progression-free survival (4.6 [95% CI: 3.4-5.9] versus 4.1 [95% CI: 3.3-4.9] months) and response rate (16.9% [95% CI: 8.8-28.3] versus 15.4% [95% CI: 7.6-26.5]). The incidences of grade 3-4 anaemia (16% versus 4%) and elevated serum lactate dehydrogenase levels (5% versus 0%) were higher for CPT-11/CDDP than for CPT-11. Exploratory subgroup analysis revealed that CPT-11/CDDP was significantly more effective for intestinal-type AGC, compared with CPT-11 (overall survival: 15.8 versus 14.0 months; P = 0.019). Conclusion: No survival benefit was observed upon adding CDDP to CPT-11 after S-1 monotherapy failure. (C) 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CCBY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).	[Nishikawa, Kazuhiro] Osaka Natl Hosp, Dept Surg, Chuo Ku, Osaka 5400006, Japan; [Fujitani, Kazumasa] Osaka Gen Med Ctr, Dept Surg, Sumiyoshi Ku, Osaka 5580056, Japan; [Inagaki, Hitoshi] Gifu Cent Hosp, Dept Surg, Gifu 5011151, Japan; [Akamaru, Yusuke] Osaka Kose Nenkin Hosp, Dept Surg, Fukushima Ku, Osaka 5530007, Japan; [Tokunaga, Shinya] Osaka City Gen Hosp, Dept Clin Oncol, Miyakojima Ku, Osaka 5340021, Japan; [Takagi, Masakazu] Shizuoka Prefectural Gen Hosp, Dept Surg, Aoi Ku, Shizuoka 4200881, Japan; [Tamura, Shigeyuki] Kansai Rosai Hosp, Dept Surg, Amagasaki, Hyogo 5370025, Japan; [Sugimoto, Naotoshi] Osaka Med Ctr Canc & Cardiovasc Dis, Dept Clin Oncol, Higashinari Ku, Osaka 5370025, Japan; [Shigematsu, Tadashi] Saiseikai Shiga Prefectural Hosp, Dept Gastroenterol, Ritto 5203046, Japan; [Yoshikawa, Takaki] Kanagawa Canc Ctr, Dept Gastrointestinal Surg, Asahi Ku, Yokohama, Kanagawa 2410815, Japan; [Ishiguro, Tohru] Saitama Med Ctr, Dept Digest Tract & Gen Surg, Kawagoe, Saitama 3500844, Japan; [Nakamura, Masato] Aizawa Hosp, Ctr Comprehens Canc, Matsumoto, Nagano 3900814, Japan; [Morita, Satoshi] Kyoto Univ, Grad Sch Med, Dept Biomed Stat & Bioinformat, Sakyo Ku, Kyoto 6068397, Japan; [Miyashita, Yumi] Epidemiol & Clin Res Informat Network, Date Ctr, Sakyo Ku, Kyoto 6068392, Japan; [Tsuburaya, Akira] Yokohama City Univ, Med Ctr, Dept Gastroenterol Ctr, Minami Ku, Yokohama, Kanagawa 2320024, Japan; [Sakamoto, Junichi] Tokai Cent Hosp, Kakamigahara 5048601, Japan; [Tsujinaka, Toshimasa] Kaizuka City Hosp, Kaizuka 5970015, Japan	Nishikawa, K (reprint author), Osaka Natl Hosp, Dept Surg, Chuo Ku, 2-1-14 Houenzaka, Osaka 5400006, Japan.	kazuno13@hotmail.co.jp; fujitani@gh.opho.jp; hinagaki@skhosp.or.jp; akamaru@ka3.so-net.ne.jp; s-tokunaga@hospital.city.osaka.jp; masakazu-takagi@i.shizuoka-pho.jp; stamura@kanrou.net; sugimoto-na2@mc.pref.osaka.jp; bssjh242@yahoo.co.jp; yoshikawat@kcch.jp; itoru@saitama-med.ac.jp; geka-dr7@ai-hosp.or.jp; smorita@kuhp.kyoto-u.ac.jp; miya@ecrin.or.jp; tuburayaa@gmail.com; sakamjun@tokaihp.jp; tsujinaka@hosp.kaizuka.osaka.jp			non-profit organisation Epidemiological & Clinical Research Information Network (ECRIN)	We thank the investigators from the following institutions who enrolled patients for this trial. Furthermore, we deeply appreciate all patients who participated in the trial, TRial of Irinoecan based Chemotherpy for S-1 failed Stomach cancer (TRICS trial). This work was supported, in part, by the non-profit organisation Epidemiological & Clinical Research Information Network (ECRIN).	Altinbas M, 2005, MED ONCOL, V22, P153, DOI 10.1385/MO:22:2:153; Koizumi W, 2008, LANCET ONCOL, V9, P215, DOI [10.1016/S1470-2045(08)70035-4, 10.1016/S1470-204S(08)70035-4]; Chun JH, 2004, JPN J CLIN ONCOL, V34, P8, DOI 10.1093/jjco/hyh006; Higuchi K, 2014, EUR J CANCER, V50, P1437, DOI 10.1016/j.ejca.2014.01.020; Boku N, 2009, LANCET ONCOL, V10, P1063, DOI 10.1016/S1470-2045(09)70259-1; Hironaka S, 2013, J CLIN ONCOL, V31, P4438, DOI 10.1200/JCO.2012.48.5805; Sasako M, 2011, J CLIN ONCOL, V29, P4387, DOI 10.1200/JCO.2011.36.5908; Kim HS, 2013, ANN ONCOL, V24, P2850, DOI 10.1093/annonc/mdt351; Cunningham D, 2008, NEW ENGL J MED, V358, P36, DOI 10.1056/NEJMoa073149; Fuchs CS, 2014, LANCET, V383, P31, DOI 10.1016/S0140-6736(13)61719-5; Van Cutsem E, 2006, J CLIN ONCOL, V24, P4991, DOI 10.1200/JCO.2006.06.8429; Ford HER, 2014, LANCET ONCOL, V15, P78, DOI 10.1016/S1470-2045(13)70549-7; Kang JH, 2012, J CLIN ONCOL, V30, P1513, DOI 10.1200/JCO.2011.39.4585; Thuss-Patience PC, 2011, EUR J CANCER, V47, P2306, DOI 10.1016/j.ejca.2011.06.002; Wilson D, 2005, CLIN ONCOL-UK, V17, P81, DOI 10.1016/j.clon.2004.10.006; Ferlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210; Iacovelli R, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0108940; Koizumi W, 2005, ANTICANCER RES, V25, P1257; Sakuramoto S, 2007, NEW ENGL J MED, V357, P1810, DOI 10.1056/NEJMoa072252; Sato A, 2001, CANCER CHEMOTH PHARM, V47, P380, DOI 10.1007/s002800000233; Van Cutsem Eric, 2002, Gastric Cancer, V5 Suppl 1, P17; Wilke H, 2014, LANCET ONCOL, V15, P1224, DOI 10.1016/S1470-2045(14)70420-6	22	2	2	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0959-8049	1879-0852		EUR J CANCER	Eur. J. Cancer	MAY	2015	51	7					808	816		10.1016/j.ejca.2015.02.009		9	Oncology	Oncology	CG1LT	WOS:000353034800003		
J	Kimura, SI; Murata, T; Akahoshi, Y; Nakano, H; Ugai, T; Wada, H; Yamasaki, R; Ishihara, Y; Kawamura, K; Sakamoto, K; Ashizawa, M; Sato, M; Terasako-Saito, K; Nakasone, H; Kikuchi, M; Yamazaki, R; Kako, S; Kanda, J; Tanihara, A; Nishida, J; Kanda, Y				Kimura, S-I.; Murata, T.; Akahoshi, Y.; Nakano, H.; Ugai, T.; Wada, H.; Yamasaki, R.; Ishihara, Y.; Kawamura, K.; Sakamoto, K.; Ashizawa, M.; Sato, M.; Terasako-Saito, K.; Nakasone, H.; Kikuchi, M.; Yamazaki, R.; Kako, S.; Kanda, J.; Tanihara, A.; Nishida, J.; Kanda, Y.			Economic evaluation of a preemptive treatment strategy for invasive fungal infection in neutropenic patients with hematological diseases	EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES			English	Article							LIPOSOMAL AMPHOTERICIN-B; EMPIRICAL ANTIFUNGAL THERAPY; CLINICAL-PRACTICE GUIDELINES; RANDOMIZED CONTROLLED-TRIAL; CELL TRANSPLANT RECIPIENTS; PERSISTENT FEVER; HIGH-RISK; PULMONARY ASPERGILLOSIS; GALACTOMANNAN; AMERICA	We compared the expected medical costs of empirical and preemptive treatment strategies for invasive fungal infection in neutropenic patients with hematological diseases. Based on the results of two clinical trials with different backgrounds reported by Oshima et al. [J Antimicrob Chemother 60(2):350-355; Oshima study] and Cordonnier et al. [Clin Infect Dis 48(8):1042-1051; PREVERT study], we developed a decision tree model that represented the outcomes of empirical and preemptive treatment strategies, and estimated the expected medical costs of medications and examinations in the two strategies. We assumed that micafungin was started in the empirical group at 5 days after fever had developed, while voriconazole was started in the preemptive group only when certain criteria, such as positive test results of imaging studies and/or serum markers, were fulfilled. When we used an incidence of positive test results of 6.7 % based on the Oshima study, the expected medical costs of the empirical and preemptive groups were 288,198 and 150,280 yen, respectively. Even in the case of the PREVERT study, in which the incidence of positive test results was 32.9 %, the expected medical costs in the empirical and preemptive groups were 291,871 and 284,944 yen, respectively. A sensitivity analysis indicated that the expected medical costs in the preemptive group would exceed those in the empirical group when the incidence of positive test results in the former was over 34.4 %. These results suggest that a preemptive treatment strategy can be expected to reduce medical costs compared with empirical therapy in most clinical settings.	[Kimura, S-I.; Akahoshi, Y.; Nakano, H.; Ugai, T.; Wada, H.; Yamasaki, R.; Ishihara, Y.; Kawamura, K.; Sakamoto, K.; Ashizawa, M.; Sato, M.; Terasako-Saito, K.; Nakasone, H.; Kikuchi, M.; Yamazaki, R.; Kako, S.; Kanda, J.; Tanihara, A.; Nishida, J.; Kanda, Y.] Jichi Med Univ, Div Hematol, Saitama Med Ctr, Omiya Ku, Saitama, Saitama 3308503, Japan; [Murata, T.] CRECON Res & Consulting Inc, Tokyo, Japan	Kanda, Y (reprint author), Jichi Med Univ, Div Hematol, Saitama Med Ctr, Omiya Ku, 1-847 Amanuma, Saitama, Saitama 3308503, Japan.	ycanda-tky@umin.ac.jp			Pfizer Inc.	This study was supported in part by funding from Pfizer Inc.	Walsh TJ, 1999, NEW ENGL J MED, V340, P764, DOI 10.1056/NEJM199903113401004; VONEIFF M, 1995, RESPIRATION, V62, P341; Freifeld AG, 2011, CLIN INFECT DIS, V52, pE56, DOI 10.1093/cid/cir073; Tan BH, 2011, INT J INFECT DIS, V15, pE350, DOI 10.1016/j.ijid.2011.01.011; Safdar A, 2011, CLIN INFECT DIS, V53, P798, DOI 10.1093/cid/cir492; Morrissey CO, 2013, LANCET INFECT DIS, V13, P519, DOI 10.1016/S1473-3099(13)70076-8; Oshima K, 2007, J ANTIMICROB CHEMOTH, V60, P350, DOI 10.1093/jac/dkm217; Walsh TJ, 2008, CLIN INFECT DIS, V46, P327, DOI 10.1086/525258; Herbrecht R, 2002, NEW ENGL J MED, V347, P408, DOI 10.1056/NEJMoa020191; Hebart H, 2009, BONE MARROW TRANSPL, V43, P553, DOI 10.1038/bmt.2008.355; Pappas PG, 2009, CLIN INFECT DIS, V48, P503, DOI 10.1086/596757; Walsh TJ, 2002, NEW ENGL J MED, V346, P225, DOI 10.1056/NEJM200201243460403; Walsh TJ, 2004, NEW ENGL J MED, V351, P1391, DOI 10.1056/NEJMoa040446; Maertens J, 2005, CLIN INFECT DIS, V41, P1242, DOI 10.1086/496927; Greene RE, 2007, CLIN INFECT DIS, V44, P373, DOI 10.1086/509917; Kontoyiannis DP, 2010, CLIN INFECT DIS, V50, P1091, DOI 10.1086/651263; PIZZO PA, 1982, AM J MED, V72, P101, DOI 10.1016/0002-9343(82)90594-0; Yamaguchi M, 2011, ANN HEMATOL, V90, P1209, DOI 10.1007/s00277-011-1277-1; Kuse ER, 2007, LANCET, V369, P1519, DOI 10.1016/S0140-6736(07)60605-9; Cordonnier C, 2009, CLIN INFECT DIS, V48, P1042, DOI 10.1086/597395; Kimura S, 2014, HEMATOLOGY, V19, P107, DOI 10.1179/1607845413Y.0000000103; Kimura SI, 2010, BIOL BLOOD MARROW TR, V16, P1355, DOI 10.1016/j.bbmt.2010.04.012; Pagano L, 2006, HAEMATOL-HEMATOL J, V91, P1068	23	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0934-9723	1435-4373		EUR J CLIN MICROBIOL	Eur. J. Clin. Microbiol. Infect. Dis.	MAY	2015	34	5					951	961		10.1007/s10096-014-2311-8		11	Infectious Diseases; Microbiology	Infectious Diseases; Microbiology	CG7GK	WOS:000353470600013		
J	Kitagawa, K; Iwama, S; Fukui, S; Sunaoka, Y; Yazawa, H; Usami, A; Naramoto, M; Uchida, T; Saito, S; Mizunaga, H				Kitagawa, Kenji; Iwama, Shintaro; Fukui, Sho; Sunaoka, Yuuki; Yazawa, Hayato; Usami, Atsushi; Naramoto, Masaaki; Uchida, Takanori; Saito, Satoshi; Mizunaga, Hiromi			Effects of components of the leaf area distribution on drag relations for Cryptomeria japonica and Chamaecyparis obtusa	EUROPEAN JOURNAL OF FOREST RESEARCH			English	Article						Drag coefficient; Streamlining; Gap fraction; Leaf area distribution	WIND-TUNNEL MEASUREMENTS; SCOTS PINE; MECHANICAL STABILITY; NORWAY SPRUCE; TREES; DAMAGE; STANDS; MODEL; FORESTS; JAPAN	The objectives of this study were to clarify the effects of components of the leaf area distribution on the drag coefficient of crowns and streamlining (e.g., leaf area index; LAI, outline of the crown shape, and clumpiness) and to contribute to the accumulation of data on drag relations by quantifying data for Chamaecyparis obtusa and Cryptomeria japonica. We conducted drag experiments while simultaneously capturing dynamic crown images for 28 Ch. obtusa crowns and 13 Cr. japonica crowns to analyze the relationships between the leaf area distribution components and drag coefficient or streamlining. The static drag coefficient increased with the LAI for Ch. obtusa and with decreasing clumpiness for Cr. japonica. The reduction rate of the static drag coefficient decreased with increasing clumpiness for Ch. obtusa and with a combination of increasing LAI and decreasing clumpiness for Cr. japonica. The reduction rate of the static drag coefficient had a clear relationship with the decreasing rate of the dynamic crown projected area of obstacles (foliage elements, branches, and stems) calculated from captured video images under windy conditions for Cr. japonica, while Ch. obtusa did not show clear relationship between them. The drag coefficients assuming non-porous crown; C (max) estimated by simple model combining LAI and clumpiness were approximately 1.0 in Ch. obtusa and 0.5 in Cr. japonica and were equivalent to the dynamic drag coefficients from video image under windy condition. The combination of LAI and clumpiness provided simple estimation for drag relations and enable to link crown structure to wind damage easier.	[Kitagawa, Kenji] Gifu Univ, United Grad Sch Agr Sci, Gifu 5011193, Japan; [Iwama, Shintaro; Fukui, Sho; Sunaoka, Yuuki; Yazawa, Hayato; Usami, Atsushi; Naramoto, Masaaki; Mizunaga, Hiromi] Shizuoka Univ, Grad Sch Agr Sci, Shizuoka 4228529, Japan; [Uchida, Takanori] Kyushu Univ, Appl Mech Res Inst, Kasuga, Fukuoka 8168580, Japan; [Saito, Satoshi] Forestry & Forest Prod Res Inst, Tsukuba, Ibaragi 3058687, Japan	Mizunaga, H (reprint author), Shizuoka Univ, Grad Sch Agr Sci, 836 Ohya, Shizuoka 4228529, Japan.	mizunaga.hiromi@shizuoka.ac.jp	Kyushu, RIAM/F-4018-2015		Japan Society for the Promotion of Science (KAKENHI) [23405024, 23580202]	We are grateful to the staff at Fuji International Speedway Co., Ltd. for their kind support. We thank also Dr. Wang and Dr. Kamimura for their encouragement. Funding for this research was provided by the Japan Society for the Promotion of Science (KAKENHI Grant Numbers 23405024 and 23580202).	Iio A, 2011, AGR FOREST METEOROL, V151, P461, DOI 10.1016/j.agrformet.2010.12.003; Oouchi K, 2006, J METEOROL SOC JPN, V84, P259, DOI 10.2151/jmsj.84.259; SMOLANDER H, 1994, TREE PHYSIOL, V14, P971; Peltola H, 1999, CAN J FOREST RES, V29, P647, DOI 10.1139/cjfr-29-6-647; Nicoll BC, 2005, CAN J FOREST RES, V35, P2360, DOI 10.1139/X05-157; Gardiner B, 2000, ECOL MODEL, V129, P1, DOI 10.1016/S0304-3800(00)00220-9; WANG YP, 1990, TREE PHYSIOL, V7, P297; NILSON T, 1971, AGR METEOROL, V8, P25, DOI 10.1016/0002-1571(71)90092-6; Pavlis Michael, 2008, Arboriculture & Urban Forestry, V34, P207; Chen JM, 2005, REMOTE SENS ENVIRON, V97, P447, DOI 10.1016/j.rse.2005.05.003; Beland M, 2014, AGR FOREST METEOROL, V184, P82, DOI 10.1016/j.agrformet.2013.09.005; Peltola H, 2000, FOREST ECOL MANAG, V135, P143, DOI 10.1016/S0378-1127(00)00306-6; Achim A, 2005, FOREST ECOL MANAG, V204, P35, DOI 10.1016/j.foreco.2004.07.072; Meehl GA, 2007, CLIMATE CHANGE 2007: THE PHYSICAL SCIENCE BASIS, P747; Peltola HM, 2006, AM J BOT, V93, P1501, DOI 10.3732/ajb.93.10.1501; Baret F, 2004, SIMPLE METHOD CALIBR; Brunner A, 1998, FOREST ECOL MANAG, V107, P19, DOI 10.1016/S0378-1127(97)00325-3; Chiba Y, 2000, FOREST ECOL MANAG, V135, P123, DOI 10.1016/S0378-1127(00)00304-2; Cucchi V, 2005, FOREST ECOL MANAG, V213, P184, DOI 10.1016/j.foreco.2005.03.019; HEDDEN RL, 1995, CAN J FOREST RES, V25, P704, DOI 10.1139/x95-078; Iio A, 2013, GLOBAL ECOL BIOGEOGR, V23, P274; Kamimura K, 2008, FORESTRY, V81, P429, DOI 10.1093/forestry/cpn029; Kamimura K, 2012, EUR J FOREST RES, V131, P219, DOI 10.1007/s10342-011-0508-2; Kamiyama K, 2004, J ENV ENG ARCHIT I J, V578, P71; Kane B, 2008, CAN J FOREST RES, V38, P1275, DOI 10.1139/X07-225; Kane B, 2006, CAN J FOREST RES, V36, P1951, DOI 10.1139/X06-086; Kitagawa K, 2010, JPN J FOR ENV, V52, P57; Kuboyama H, 2000, SILVA FENN, V34, P155, DOI 10.14214/sf.637; Mandelbrot B. B., 1983, FRACTAL GEOMETRY NAT; MAYHEAD GJ, 1973, AGR METEOROL, V12, P123, DOI 10.1016/0002-1571(73)90013-7; Mizoue N., 1994, Journal of the Japanese Forestry Society, V76, P242; Mizunaga H., 2013, Journal of Sustainable Forestry, V32, P266, DOI 10.1080/10549811.2013.763150; Mizunaga H, 2007, CAN J FOREST RES, V37, P1545, DOI 10.1139/X07-124; Mizunaga H, 1996, THESIS GIFU U GIFU J; Mizunaga H, 2000, FOREST ECOL MANAG, V126, P309, DOI 10.1016/S0378-1127(99)00102-4; Nakao H, 1993, B KYUSYU U, V68, P11; OOHATA S-I, 1979, Japanese Journal of Ecology, V29, P323; Peltola Heli, 1993, Silva Fennica, V27, P99; Rudnicki M, 2004, CAN J FOREST RES, V34, P666, DOI 10.1139/X03-233; STENBERG P, 1994, TREE PHYSIOL, V14, P981; Suzuki Satoru, 2009, Bulletin of the Forestry and Forest Products Research Institute, V8, P71; Takayasu H, 1986, FRACTALS; Torita H., 2010, Journal of the Japanese Forest Society, V92, P127; Uchida T, 2008, J WIND ENG IND AEROD, V96, P2121, DOI 10.1016/j.jweia.2008.02.047; Urata T, 2012, J FOREST RES-JPN, V17, P65, DOI 10.1007/s10310-011-0249-6; Vollsinger S, 2005, CAN J FOREST RES, V35, P1238, DOI 10.1139/x05-051; Yamamoto K, 2003, LIA WIN32	47	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1612-4669	1612-4677		EUR J FOREST RES	Eur. J. For. Res.	MAY	2015	134	3					403	414		10.1007/s10342-014-0859-6		12	Forestry	Forestry	CG1UL	WOS:000353060100002		
J	Bakir-Gungor, B; Remmers, EF; Meguro, A; Mizuki, N; Kastner, DL; Gul, A; Sezerman, OU				Bakir-Gungor, Burcu; Remmers, Elaine F.; Meguro, Akira; Mizuki, Nobuhisa; Kastner, Daniel L.; Gul, Ahmet; Sezerman, Osman U.			Identification of possible pathogenic pathways in Behcet's disease using genome-wide association study data from two different populations	EUROPEAN JOURNAL OF HUMAN GENETICS			English	Article							SUSCEPTIBILITY LOCI; T-CELLS; VARIANTS; COAGULATION; ACTIVATION; IL23R-IL12RB2; MUTATIONS; MEDICINE; RISK; IL10	Behcet's disease (BD) is a multi-system inflammatory disorder of unknown etiology. Two recent genome-wide association studies (GWASs) of BD confirmed a strong association with the MHC class I region and identified two non-HLA common genetic variations. In complex diseases, multiple factors may target different sets of genes in the same pathway and thus may cause the same disease phenotype. We therefore hypothesized that identification of disease-associated pathways is critical to elucidate mechanisms underlying BD, and those pathways may be conserved within and across populations. To identify the disease-associated pathways, we developed a novel methodology that combines nominally significant evidence of genetic association with current knowledge of biochemical pathways, protein-protein interaction networks, and functional information of selected SNPs. Using this methodology, we searched for the disease-related pathways in two BD GWASs in Turkish and Japanese case-control groups. We found that 6 of the top 10 identified pathways in both populations were overlapping, even though there were few significantly conserved SNPs/genes within and between populations. The probability of random occurrence of such an event was 2.24E -39. These shared pathways were focal adhesion, MAPK signaling, TGF-beta signaling, ECM-receptor interaction, complement and coagulation cascades, and proteasome pathways. Even though each individual has a unique combination of factors involved in their disease development, the targeted pathways are expected to be mostly the same. Hence, the identification of shared pathways between the Turkish and the Japanese patients using GWAS data may help further elucidate the inflammatory mechanisms in BD pathogenesis.	[Bakir-Gungor, Burcu] Bahcesehir Univ, Dept Genet & Bioinformat, Fac Arts & Sci, Istanbul, Turkey; [Bakir-Gungor, Burcu] Abdullah Gul Univ, Fac Engn & Nat Sci, Dept Comp Engn, Kayseri, Turkey; [Remmers, Elaine F.; Kastner, Daniel L.] NHGRI, Inflammatory Dis Sect, NIH, Bethesda, MD 20892 USA; [Meguro, Akira; Mizuki, Nobuhisa] Yokohama City Univ, Sch Med, Dept Ophthalmol, Yokohama, Kanagawa 232, Japan; [Gul, Ahmet] Istanbul Univ, Dept Internal Med, Div Rheumatol, Istanbul, Turkey; [Sezerman, Osman U.] Sabanci Univ, Fac Engn & Nat Sci, Biol Sci & Bioengn, Istanbul, Turkey	Bakir-Gungor, B (reprint author), Abdullah Gul Univ, Fac Engn & Nat Sci, Dept Comp Engn, Kayseri, Turkey.	burcub@gatech.edu			Intensified Cooperation (IntenC): Promotion of German-Turkish Higher Education Research Grant of The Scientific and Technological Research Council of Turkey (TUBITAK) [109S218]; Abdullah Gul University Support Foundation (AGUV)	This work was supported by the Intensified Cooperation (IntenC): Promotion of German-Turkish Higher Education Research Grant of The Scientific and Technological Research Council of Turkey (TUBITAK; 109S218). The Abdullah Gul University Support Foundation (AGUV) supported the work of BB-G.	O'Shea JJ, 2013, NEW ENGL J MED, V368, P161, DOI 10.1056/NEJMra1202117; Fridley BL, 2011, EUR J HUM GENET, V19, P837, DOI 10.1038/ejhg.2011.57; de las Fuentes L, 2012, EUR J HUM GENET, V20, P1168, DOI 10.1038/ejhg.2012.66; Hugot JP, 2001, NATURE, V411, P599, DOI 10.1038/35079107; HAMPTON KK, 1991, THROMB HAEMOSTASIS, V66, P292; Visscher PM, 2012, AM J HUM GENET, V90, P7, DOI 10.1016/j.ajhg.2011.11.029; Bebek G, 2012, BRIEF BIOINFORM, V13, P446, DOI 10.1093/bib/bbr075; Remmers EF, 2010, NAT GENET, V42, P698, DOI 10.1038/ng.625; Liu CT, 2012, GENE, V511, P358, DOI 10.1016/j.gene.2012.09.075; de Chambrun MP, 2012, AUTOIMMUN REV, V11, P687, DOI 10.1016/j.autrev.2011.11.026; Cho JH, 2011, NEW ENGL J MED, V365, P1612, DOI 10.1056/NEJMra1100030; Baranzini SE, 2009, HUM MOL GENET, V18, P2078, DOI 10.1093/hmg/ddp120; Noubade R, 2011, BLOOD, V118, P3290, DOI 10.1182/blood-2011-02-336552; Peng G, 2010, EUR J HUM GENET, V18, P111, DOI 10.1038/ejhg.2009.115; Palmer CNA, 2006, NAT GENET, V38, P441, DOI 10.1038/ng1767; Rosenberg NA, 2010, NAT REV GENET, V11, P356, DOI 10.1038/nrg2760; Torkamani A, 2008, GENOMICS, V92, P265, DOI 10.1016/j.ygeno.2008.07.011; Hughes T, 2013, NAT GENET, V45, P319, DOI 10.1038/ng.2551; Gul A, 1996, BRIT J RHEUMATOL, V35, P1178; Kirino Y, 2013, P NATL ACAD SCI USA, V110, P8134, DOI 10.1073/pnas.1306352110; Saccone SF, 2010, NUCLEIC ACIDS RES, V38, pW201, DOI 10.1093/nar/gkq513; Kirino Y, 2013, NAT GENET, V45, P202, DOI 10.1038/ng.2520; Barabasi AL, 2011, NAT REV GENET, V12, P56, DOI 10.1038/nrg2918; Lu L, 2010, J IMMUNOL, V184, P4295, DOI 10.4049/jimmunol.0903418; Wu JM, 2009, NAT METHODS, V6, P75, DOI [10.1038/nmeth.1282, 10.1038/NMETH.1282]; Hamzaoui K, 2011, CLIN EXP RHEUMATOL, V29, pS71; Cirulli ET, 2010, NAT REV GENET, V11, P415, DOI 10.1038/nrg2779; Calabrese R, 2009, HUM MUTAT, V30, P1237, DOI 10.1002/humu.21047; Bakir-Gungor B, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026277; Bakir-Gungor B, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057022; Bakir-Gungor B, 2013, BIOINFORMATICS, V30, P1287; Bakir-Gungor B, 2012, THESIS SABANCI U IST; Bakir-Gungor B, 2012, PROTOC EXCH, V2012, DOI [10.1038/protex.2012.019, DOI 10.1038/PROTEX.2012.019]; Bakir-Gungor B, 2013, EPILEPSY RES, V105, P92, DOI 10.1016/j.eplepsyres.2013.02.008; Batioglu F, 2003, ACTA OPHTHALMOL SCAN, V81, P283, DOI 10.1034/j.1600-0420.2003.00068.x; Beyan E, 2005, AM J HEMATOL, V79, P70, DOI 10.1002/ajh.20317; Cho DY, 2012, PLOS COMPUT BIOL, V8, DOI 10.1371/journal.pcbi.1002820; Demirer S, 2000, EUR J VASC ENDOVASC, V19, P570, DOI 10.1053/ejvs.2000.1091; Espinosa G, 2002, AM J MED, V112, P37, DOI 10.1016/S0002-9343(01)01048-8; Gul A, 2001, CLIN EXP RHEUMATOL, V19, pS6; Haznedaroglu IC, 1996, J INTERN MED, V240, P181, DOI 10.1046/j.1365-2796.1996.396853000.x; Ideker Trey, 2002, Bioinformatics, V18 Suppl 1, pS233; Kim Yoo-Ah, 2013, Frontiers in Genetics, V3, DOI 10.3389/fgene.2012.00227; Mizuki N, 2010, NAT GENET, V42, P703, DOI 10.1038/ng.624; Ozoran K, 1995, SCAND J RHEUMATOL, V24, P376; Polgar N, 2012, INT J IMMUNOGENET, V39, P247, DOI 10.1111/j.1744-313X.2012.01084.x; Ricart JM, 2006, THROMB HAEMOSTASIS, V95, P618, DOI 10.1160/TH05-10-0659; Schadt EE, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3002132; Seng KC, 2008, EUR J HUM GENET, V16, P554, DOI 10.1038/ejhg.2008.12; Shahneh FZ, 2013, ADV PHARM B, V3, P9; Shang H, 2011, CHINESE J PHYSIOL, V54, P235, DOI 10.4077/CJP.2011.AMM042; Shimizu J, 2012, AUTOIMMUNE DIS, V2012; Shimizu J, 2012, CLIN EXP RHEUMATOL, V30, pS35; Stranger BE, 2012, GENOME MED, V4, DOI 10.1186/gm328; Ture-Ozdemir F, 2013, RHEUMATOLOGY, V52, P800, DOI 10.1093/rheumatology/kes399	55	2	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1018-4813	1476-5438		EUR J HUM GENET	Eur. J. Hum. Genet.	MAY	2015	23	5					678	687		10.1038/ejhg.2014.158		10	Biochemistry & Molecular Biology; Genetics & Heredity	Biochemistry & Molecular Biology; Genetics & Heredity	CG1JF	WOS:000353028200021		
J	Tanaka, M; Yamamoto, H; Yoshida, M; Matsuo, M; Lahjie, AM				Tanaka, Midori; Yamamoto, Hiroyuki; Yoshida, Masato; Matsuo, Miyuki; Lahjie, Abubakar M.			Retarded recovery of remaining growth stress in Agathis wood specimen caused by drying and subsequent re-swelling treatments	European Journal of Wood and Wood Products			English	Article							COMPRESSION WOOD; MICROFIBRIL ANGLE; CELL-WALLS; SHRINKAGE; SPRUCE; MATURATION; LIGNIN	A wood block often changes its original dimension when it is kept in hot water. This is because the locked-in component of the growth stress is released by hygrothermal softening of the cell wall matrix. However, it is still unknown whether or not heating is a necessary requirement for the release of the visco-elastic locked-in component of the growth stress (GS). To solve this question, Agathis green specimen was treated by drying and re-swelling at room temperature, followed by boiling at 120 A degrees C and 0.2 MPa. Then dimensions of green, re-swollen, and boiled specimens were measured at room temperature. Based on the obtained data, it was discussed whether the drying and subsequent re-swelling treatments release the visco-elastic locked-in component of the GS in green wood. The following conclusions were obtained. Locked-in component is released in part by the drying and subsequent re-swelling treatments without heating. After repeating the drying and subsequent re-swelling treatments, viscoelastic components are gradually released; however, rapid or complete release is made by boiling in hot water.	[Tanaka, Midori; Yamamoto, Hiroyuki; Yoshida, Masato; Matsuo, Miyuki] Nagoya Univ, Grad Sch Bioagr Sci, Chikusa Ku, Nagoya, Aichi 4648601, Japan; [Lahjie, Abubakar M.] Univ Mulawarman, Fac Forestry, Samarinda, Indonesia	Yamamoto, H (reprint author), Nagoya Univ, Grad Sch Bioagr Sci, Chikusa Ku, Nagoya, Aichi 4648601, Japan.	hiro@agr.nagoya-u.ac.jp			Toyotex Co. Ltd, Takamatsu, Japan	The authors would like to thank Mr. Suhendri, a private forester, in Tenggarong, East Kalimantan, Indonesia, for giving us the chance of field measurement in his Agathis arboretum. The authors also express appreciation for financial support from the late Akiyoshi Tsukada, the former president of Toyotex Co. Ltd, Takamatsu, Japan.	Altaner CM, 2009, WOOD SCI TECHNOL, V43, P279, DOI 10.1007/s00226-008-0226-1; Altaner C, 2007, HOLZFORSCHUNG, V61, P311, DOI 10.1515/HF.2007.049; GRIL J, 1994, ANN SCI FOREST, V51, P329, DOI 10.1051/forest:19940311; Clair B, 2012, HOLZFORSCHUNG, V66, P349, DOI [10.1515/HF.2011.159, 10.1515/hf.2011.159]; Brennan M, 2012, CELLULOSE, V19, P1385, DOI 10.1007/s10570-012-9697-1; Yamamoto H, 2001, WOOD SCI TECHNOL, V35, P167, DOI 10.1007/s002260000074; ARCHER RR, 1974, WOOD SCI TECHNOL, V8, P184; Archer RR, 1987, GROWTH STRESSES STRA; Brennan M, 2014, HOLZFORSCHUNG, V68, P505, DOI 10.1515/hf-2013-0110; CAVE I. D., 1966, FOREST PRODJ, V16, P37; HARRIS JM, 1965, HOLZFORSCHUNG, V19, P144, DOI 10.1515/hfsg.1965.19.5.144; Kubler H, 1987, FOR PROD ABSTR, V10, P61; Leonardon M, 2010, EUR J WOOD WOOD PROD, V68, P87, DOI 10.1007/s00107-009-0355-8; Megraw R, 1998, MICROFIBRIL ANGLE WO, P27; MEYLAN BA, 1972, WOOD SCI TECHNOL, V6, P293; Meylan B. A., 1968, Forest Products Journal, V18, P75; Okuyama T., 1975, Mokuzai Gakkaishi (Journal of the Japan Wood Research Society), V21, P335; Ormarsson S, 2009, WOOD SCI TECHNOL, V43, P387, DOI 10.1007/s00226-008-0209-2; Tanaka M, 2014, HOLZFORSCHUNG, V68, P823, DOI 10.1515/hf-2013-0153; Timell T.E., 1986, COMPRESSION WOOD GYM; WESTERMARK U, 1985, WOOD SCI TECHNOL, V19, P223; Xu P, 2009, WOOD SCI TECHNOL, V43, P423, DOI 10.1007/s00226-008-0228-z; Yamamoto H, 1998, WOOD SCI TECHNOL, V32, P171; YAMAMOTO H, 1991, MOKUZAI GAKKAISHI, V37, P94; Yamashita S, 2009, PLANT SCI, V176, P729, DOI 10.1016/j.plantsci.2009.02.017; Yokota T., 1962, Forest Products Journal, V12, P43	26	1	1	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0018-3768	1436-736X		EUR J WOOD WOOD PROD	Eur. J. Wood Wood Prod.	MAY	2015	73	3					289	298		10.1007/s00107-015-0880-6		10	Forestry; Materials Science, Paper & Wood	Forestry; Materials Science	CG4YA	WOS:000353294300002		
J	Kubojima, Y; Sonoda, S				Kubojima, Yoshitaka; Sonoda, Satomi			Measuring Young's modulus of a wooden bar using longitudinal vibration without measuring its weight	European Journal of Wood and Wood Products			English	Article								This study aimed at developing a simple measuring method to determine Young's modulus of a wooden bar by measuring its longitudinal vibration without measuring its weight. Before and after attaching an iron piece to a wooden bar, a free-free longitudinal vibration test was performed to obtain Young's modulus. Young's modulus was calculated by substituting the ratio of the resonance frequencies of a wooden rectangular bar with and without attached iron piece into the frequency equation. The calculated results resembled the experimental values without the iron piece.	[Kubojima, Yoshitaka] Forestry & Forest Prod Res Inst, Tsukuba, Ibaraki 305, Japan; [Sonoda, Satomi] Toyama Prefectural Agr Forestry & Fisheries Res C, Toyama, Japan	Kubojima, Y (reprint author), Forestry & Forest Prod Res Inst, Tsukuba, Ibaraki 305, Japan.	kubojima@ffpri.affrc.go.jp			Forestry and Forest Products Research Institute [201402]	This work was financially supported by the Research Grant No. 201402 of the Forestry and Forest Products Research Institute.	Arima T, 1990, J SOC MAT SCI JPN, V39, P1228; Kubojima Y, 2014, BIORESOURCES, V9, P5088; Yamasaki M, 2010, J WOOD SCI, V56, P269, DOI 10.1007/s10086-010-1108-3; Yamasaki M, 2010, J WOOD SCI, V56, P380, DOI 10.1007/s10086-010-1114-5	4	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0018-3768	1436-736X		EUR J WOOD WOOD PROD	Eur. J. Wood Wood Prod.	MAY	2015	73	3					399	401		10.1007/s00107-015-0884-2		3	Forestry; Materials Science, Paper & Wood	Forestry; Materials Science	CG4YA	WOS:000353294300013		
J	Ishii, K; Takeuchi, H; Fukunaga, K; Hirano, Y; Suda, K; Hagiwara, T; Miyasho, T; Yamada, S; Nakamura, R; Takahashi, T; Wada, N; Kawakubo, H; Saikawa, Y; Omori, T; Betsuyaku, T; Ichihara, A; Kitagawa, Y				Ishii, Kenjiro; Takeuchi, Hiroya; Fukunaga, Koichi; Hirano, Yuki; Suda, Koichi; Hagiwara, Tomoko; Miyasho, Taku; Yamada, Shingo; Nakamura, Rieko; Takahashi, Tsunehiro; Wada, Norihito; Kawakubo, Hirofumi; Saikawa, Yoshiro; Omori, Tai; Betsuyaku, Tomoko; Ichihara, Atsuhiro; Kitagawa, Yuko			Attenuation of lipopolysaccharide-induced acute lung injury after (pro)renin receptor blockade	EXPERIMENTAL LUNG RESEARCH			English	Article						acute lung injury; (pro)renin receptor blocker; prorenin; renin-angiotensin system	RESPIRATORY-DISTRESS-SYNDROME; NONPROTEOLYTICALLY ACTIVATED PRORENIN; RENIN-ANGIOTENSIN SYSTEM; DECOY PEPTIDE; INFLAMMATION; INHIBITION; SEPSIS; PROTECTS; MEDIATOR; THERAPY	Purpose/Aim: We performed a randomized, prospective animal study to investigate whether inhibiting the renin-angiotensin system with a (pro)renin receptor blocker (PRRB) prevents acute lung injury (ALI) in a rodent model. Materials: We used Thirty-six male Sprague-Dawley rats. We administered lipopolysaccharide (LPS; 2 mg/kg) intratracheally with or without PRRB pretreatment (1 mg/kg/d). Methods: We performed bronchoalveolar lavage (BAL) and lung removal at 4 h after LPS administration and measured levels of inflammatory cytokines, high mobility group box 1 (HMGB-1) protein, and total protein in bronchoalveolar lavage fluid (BALF). Myeloperoxidase (MPO) activity was detected in lung tissue homogenates using a sensitive ELISA. We performed hematoxylin and eosin staining and immunohistochemical staining for nonproteolytically activated prorenin in the left lung. Results: The PRRB decreased leukocyte counts and total protein, tumor necrosis factor (TNF)-alpha, interleukin (IL)-1 beta, IL-2, IL-6, and IL-10 levels in the BALF and MPO activity in lung tissue. The PRRB reduced interstitial edema, hemorrhage, and the neutrophil count in the lung tissues. Consistent with the reduction in lung tissue damage, immunohistochemical staining showed that the PRRB decreased the amount of nonproteolytically activated prorenin. Conclusions: The PRRB blocked LPS-induced inflammatory response in the lung and protected against ALI. Therefore, it is a potential therapeutic agent for preventing ALI.	[Ishii, Kenjiro; Takeuchi, Hiroya; Hirano, Yuki; Suda, Koichi; Hagiwara, Tomoko; Nakamura, Rieko; Takahashi, Tsunehiro; Wada, Norihito; Kawakubo, Hirofumi; Saikawa, Yoshiro; Omori, Tai; Kitagawa, Yuko] Keio Univ, Sch Med, Dept Surg, Tokyo 1608582, Japan; [Fukunaga, Koichi; Betsuyaku, Tomoko] Keio Univ, Sch Med, Dept Resp Med, Tokyo 1608582, Japan; [Miyasho, Taku] Rakuno Gakuen Univ, Sch Vet Med, Sapporo, Hokkaido, Japan; [Yamada, Shingo] Shino Test Corp, Cent Inst, Kanagawa, Japan; [Ichihara, Atsuhiro] Tokyo Womens Med Univ, Dept Med 2, Tokyo, Japan	Takeuchi, H (reprint author), Keio Univ, Sch Med, Dept Surg, Shinjuku Ku, 35 Shinanomachi, Tokyo 1608582, Japan.	htakeuchi@a6.keio.jp					Abd El-Aziz M. A., 2001, Journal of Applied Toxicology, V21, P469, DOI 10.1002/jat.782; Seki H, 2010, J IMMUNOL, V184, P836, DOI 10.4049/jimmunol.0901809; Ichihara A, 2004, J CLIN INVEST, V114, P1128, DOI 10.1172/JCl200421398; Suzuki Y, 2003, INT J BIOCHEM CELL B, V35, P881, DOI 10.1016/S1357-2725(02)00271-6; Abraham E, 2000, J IMMUNOL, V165, P2950; Nguyen G, 2002, J CLIN INVEST, V109, P1417, DOI 10.1172/JCI200214276; Suzuki F, 2003, J BIOL CHEM, V278, P22217, DOI 10.1074/jbc.M302579200; Bhatia M, 2004, J PATHOL, V202, P145, DOI 10.1002/path.1491; Zhang H, 2005, ARCH BIOCHEM BIOPHYS, V441, P75, DOI 10.1016/j.abb.2005.06.022; Kinouchi K, 2010, CIRC RES, V107, P30, DOI 10.1161/CIRCRESAHA.110.224667; Riedemann NC, 2003, J CLIN INVEST, V112, P460, DOI 10.1172/JCI200319523; Jerng JS, 2006, CRIT CARE MED, V34, P1001, DOI 10.1097/01.CCM.0000206107.92476.39; Imai Y, 2005, NATURE, V436, P112, DOI 10.1038/nature03712; Ichihara A, 2006, J AM SOC NEPHROL, V17, P2495, DOI 10.1681/ASN.2005121278; Stojiljkovic L, 2007, CURR PHARM DESIGN, V13, P1335, DOI 10.2174/138161207780618768; Lehr HA, 2000, J PATHOL, V190, P373; Ueno H, 2004, AM J RESP CRIT CARE, V170, P1310, DOI 10.1164/rccm.200402-1880C; Griffin KA, 2003, HYPERTENSION, V41, P201, DOI 10.1161/01.HYP.0000049881.25304.73; Hagiwara S, 2009, CRIT CARE MED, V37, P626, DOI 10.1097/CCM.0b013e3181958d91; Wang H, 2004, J INTERN MED, V255, P320, DOI 10.1111/j.1365-2796.2003.01302.x; Wyncoll DLA, 1999, LANCET, V354, P497, DOI 10.1016/S0140-6736(98)08129-X; Arndt PG, 2006, J IMMUNOL, V177, P7233; Genctoy G, 2005, ARTIF ORGANS, V29, P174, DOI 10.1111/j.1525-1594.2005.29029.x; Hirano Y, 2013, J SURG RES IN PRESS; Ichihara A, 2010, J PHARMACOL SCI, V113, P296, DOI 10.1254/jphs.10R04FM; Ichihara A, 2009, J PHARMACOL SCI, V109, P20, DOI 10.1254/jphs.08R07FM; Kinouchi K, 2011, FRONT BIOSCI-LANDMRK, V16, P3216, DOI 10.2741/3907; LUETSCHER JA, 1985, NEW ENGL J MED, V312, P1412, DOI 10.1056/NEJM198505303122202; NurunNabi AHM, 2009, BIOCHIM BIOPHYS ACTA, V1794, P1838; NurunNabi AHM, 2009, INT J MOL MED, V24, P83; Satofuka S, 2007, INVEST OPHTH VIS SCI, V48, P422, DOI 10.1167/iovs.06-0534; Zhang JD, 2008, AM J PHYSIOL-ENDOC M, V295, pE810, DOI 10.1152/ajpendo.90264.2008	32	1	1	INFORMA HEALTHCARE	LONDON	TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND	0190-2148	1521-0499		EXP LUNG RES	Exp. Lung Res.	MAY	2015	41	4					199	207		10.3109/01902148.2014.993444		9	Respiratory System	Respiratory System	CG3WK	WOS:000353210100003		
J	Takano, M; Kawami, M; Aoki, A; Yumoto, R				Takano, Mikihisa; Kawami, Masashi; Aoki, Ayako; Yumoto, Ryoko			Receptor-mediated endocytosis of macromolecules and strategy to enhance their transport in alveolar epithelial cells	EXPERT OPINION ON DRUG DELIVERY			English	Review						albumin; alveolar epithelial cells; cationic poly(amino acid)s; clathrin; endocytosis; endocytosis receptor; insulin; intracellular trafficking; megalin	RESPIRATORY-DISTRESS-SYNDROME; BRONCHOALVEOLAR LAVAGE FLUID; ALBUMIN-BINDING PROTEIN; RENAL PROXIMAL TUBULE; ACUTE LUNG INJURY; RT-PCR ANALYSIS; ENDOTHELIAL-CELLS; DRUG-DELIVERY; IN-VITRO; PULMONARY DELIVERY	Introduction: Pulmonary delivery is an attractive administration route for therapeutic proteins and peptides. In this context, endocytosis/transcytosis at the distal lung epithelial barrier is an important process in the pulmonary absorption of therapeutic macromolecules. The alveolar epithelium is comprised of type I and type II cells. Understanding the transport mechanisms in these cells is essential for the development of efficient pulmonary delivery systems of therapeutic macromolecules. Areas covered: Endocytic pathways for albumin and insulin in alveolar epithelial cells and possible receptors for the endocytosis are discussed. Strategies to enhance the endocytosis and pulmonary absorption of macromolecules are also discussed, by focusing on the effects of cationic poly(amino acid)s. Expert opinion: Although the surface area occupied by type II cells in alveoli is much smaller than that covered by type I cells, type II cells may significantly contribute to the endocytosis/transcytosis of macromolecules such as albumin. Identification of the receptors involved in the cellular uptake of each macromolecule is prerequisite for the understanding and regulation of its transport into and across alveolar epithelial cells. Establishment of novel in-vitro culture cell models of type I and type II cells would be a great help for the future advance of this research field.	[Takano, Mikihisa; Kawami, Masashi; Aoki, Ayako; Yumoto, Ryoko] Hiroshima Univ, Grad Sch Biomed & Hlth Sci, Dept Pharmaceut & Therapeut, Minami Ku, Hiroshima 7348553, Japan	Takano, M (reprint author), Hiroshima Univ, Grad Sch Biomed & Hlth Sci, Dept Pharmaceut & Therapeut, Minami Ku, 1-2-3 Kasumi, Hiroshima 7348553, Japan.	takanom@hiroshima-u.ac.jp					RENNARD SI, 1986, J APPL PHYSIOL, V60, P532; Paranjpe M, 2014, INT J MOL SCI, V15, P5852, DOI 10.3390/ijms15045852; EVANS MJ, 1975, EXP MOL PATHOL, V22, P142, DOI 10.1016/0014-4800(75)90059-3; Scheuch G, 2006, ADV DRUG DELIVER REV, V58, P996, DOI 10.1016/j.addr.2006.07.009; Uhal BD, 1997, AM J PHYSIOL-LUNG C, V272, pL1031; Salomon JJ, 2014, MOL PHARMACEUT, V11, P995, DOI 10.1021/mp4006535; Tenten V, 2013, J AM SOC NEPHROL, V24, P1966, DOI 10.1681/ASN.2013010018; Mayor S, 2007, NAT REV MOL CELL BIO, V8, P603, DOI 10.1038/nrm2216; Khalil IA, 2006, J BIOL CHEM, V281, P3544, DOI 10.1074/jbc.M503202200; van den Bogaard EHJ, 2009, PHARM RES-DORD, V26, P1172, DOI 10.1007/s11095-009-9838-x; Takano M, 2004, EUR J PHARMACOL, V502, P149, DOI 10.1016/j.ejphar.2004.08.041; Buchackert Y, 2012, J PHYSIOL-LONDON, V590, P5167, DOI 10.1113/jphysiol.2012.233403; LIEBER M, 1976, INT J CANCER, V17, P62, DOI 10.1002/ijc.2910170110; Mehanna MM, 2014, J CONTROL RELEASE, V187, P183, DOI 10.1016/j.jconrel.2014.05.038; Groneberg DA, 2002, THORAX, V57, P55, DOI 10.1136/thorax.57.1.55; SCHNITZER JE, 1994, J BIOL CHEM, V269, P6072; Christensen EI, 2001, AM J PHYSIOL-RENAL, V280, pF562; Kemp SJ, 2008, AM J RESP CELL MOL, V39, P591, DOI 10.1165/rcmb.2007-0334OC; Takano M, 2006, PHARMACOL THERAPEUT, V109, P137, DOI 10.1016/j.pharmthera.2005.06.005; Murakami T, 2008, EXPERT OPIN DRUG MET, V4, P923, DOI [10.1517/17425255.4.7.923 , 10.1517/17425250802196512]; Fehrenbach H, 2001, RESPIR RES, V2, P33, DOI 10.1186/rr36; Endter S, 2009, J PHARM PHARMACOL, V61, P583, DOI 10.1211/jpp/61.05.0006; Sporty JL, 2008, EXPERT OPIN DRUG MET, V4, P333, DOI 10.1517/17425255.4.4.333 ; Amet N, 2010, J CONTROL RELEASE, V141, P177, DOI 10.1016/j.jconrel.2009.09.007; John TA, 2001, J PHYSIOL-LONDON, V533, P547, DOI 10.1111/j.1469-7793.2001.0547a.x; Nagai M, 2003, MOL BIOL CELL, V14, P4984, DOI 10.1091/mbc.E03-06-0385; Stearns RC, 2001, AM J RESP CELL MOL, V24, P108; Hastings RH, 2004, AM J PHYSIOL-LUNG C, V286, pL679, DOI 10.1152/ajplung.00205.2003; Vogel SM, 2001, AM J PHYSIOL-LUNG C, V281, pL1512; Sung JC, 2007, TRENDS BIOTECHNOL, V25, P563, DOI 10.1016/j.tibtech.2007.09.005; Kim KJ, 2003, AM J PHYSIOL-LUNG C, V284, pL247, DOI 10.1152/ajplung.00235.2002; Bahhady R, 2008, EUR J PHARM BIOPHARM, V69, P808, DOI [10.1016/j.ejpb.2008.01.028, 10.1016/j.ejpb.2008-01.028]; Widera A, 2003, PHARMACEUT RES, V20, P1231, DOI 10.1023/A:1025005232421; Demling N, 2006, CELL TISSUE RES, V323, P475, DOI 10.1007/s00441-005-0069-0; Leheste JR, 1999, AM J PATHOL, V155, P1361, DOI 10.1016/S0002-9440(10)65238-8; Wang ZY, 2004, INT J PHARM, V269, P451, DOI 10.1016/j.ijpharm.2003.09.033; Yumoto R, 2006, AM J PHYSIOL-LUNG C, V290, pL946, DOI 10.1152/ajplung.00173.2005; Kavimandan NJ, 2006, BIOMATERIALS, V27, P3846, DOI 10.1016/j.biomaterials.2006.02.026; SCHNITZER JE, 1994, J CELL BIOL, V127, P1217, DOI 10.1083/jcb.127.5.1217; BACHOFEN M, 1977, AM REV RESPIR DIS, V116, P589; Matsukawa Y, 2000, J DRUG TARGET, V7, P335; [Anonymous], FDA NEWS RELEASE FDA; Shah M, 2013, J CELL BIOL, V202, P113, DOI 10.1083/jcb.201211110; Codrons V, 2004, J PHARM SCI-US, V93, P1241, DOI 10.1002/jps.20053; CLARK JG, 1995, ANN INTERN MED, V122, P17; Eckle T, 2008, J CLIN INVEST, V118, P3301, DOI 10.1172/JCI34203; Owens DR, 2002, NAT REV DRUG DISCOV, V1, P529, DOI 10.1038/nrd836; GREENWALT DE, 1992, BLOOD, V80, P1105; Campbell L, 2003, J PHARMACOL EXP THER, V304, P441, DOI 10.1124/jpet.102.042994; Ikehata M, 2008, PHARM RES-DORDR, V25, P913, DOI 10.1007/s11095-007-9426-x; Brewer PD, 2014, J BIOL CHEM, V289, P17280, DOI 10.1074/jbc.M114.555714; Agu RU, 2001, RESPIR RES, V2, P198; Kirchhausen T, 2008, METHOD ENZYMOL, V438, P77, DOI 10.1016/S0076-6879(07)38006-3; Birn H, 2000, J CLIN INVEST, V105, P1353, DOI 10.1172/JCI8862; Groneberg DA, 2001, AM J PATHOL, V158, P707, DOI 10.1016/S0002-9440(10)64013-8; Takano M, 2013, LIFE SCI, V93, P630, DOI 10.1016/j.lfs.2013.08.008; Tiruppathi C, 1997, J BIOL CHEM, V272, P25968, DOI 10.1074/jbc.272.41.25968; Ware LB, 2001, AM J RESP CRIT CARE, V163, P1376; Matthay MA, 2002, PHYSIOL REV, V82, P569, DOI 10.1152/physrev.00003.2002; Bur M, 2006, EUR J PHARM SCI, V28, P196, DOI 10.1016/j.ejps.2006.02.002; Bosquillon C, 2004, J CONTROL RELEASE, V96, P233, DOI 10.1016/j.jconrel.2004.01.027; Baginski L, 2012, PHARM RES-DORDR, V29, P1425, DOI 10.1007/s11095-012-0688-6; Baginski L, 2012, PHARM RES-DORDR, V29, P332, DOI 10.1007/s11095-011-0553-z; Baginski L, 2011, J AEROSOL MED PULM D, V24, P89, DOI 10.1089/jamp.2010.0842; Baines RJ, 2012, AM J PHYSIOL-RENAL, V303, pF1006, DOI 10.1152/ajprenal.00021.2012; Borok Z, 1998, AM J PHYSIOL-LUNG C, V274, pL149; COLTHORPE P, 1992, PHARMACEUT RES, V9, P764, DOI 10.1023/A:1015851521551; CORDONCARDO C, 1990, J HISTOCHEM CYTOCHEM, V38, P1277; Cui SY, 1996, AM J PHYSIOL-RENAL, V271, pF900; de Galan BE, 2006, NETH J MED, V64, P319; Di Guglielmo GM, 1998, MOL CELL BIOCHEM, V182, P59, DOI 10.1023/A:1006883311233; Dobbs LG, 1997, AM J PHYSIOL-LUNG C, V273, pL347; Dobrinskikh E, 2014, AM J PHYSIOL-RENAL, V306, pF941, DOI 10.1152/ajprenal.00532.2013; DRISCOLL KE, 1995, IN VITRO CELL DEV-AN, V31, P516; Endter S, 2007, CELL TISSUE RES, V328, P77, DOI 10.1007/s00441-006-0346-6; FARQUHAR MG, 1995, J AM SOC NEPHROL, V6, P35; Ferkol T, 2003, AM J RESP CRIT CARE, V167, P1374, DOI 10.1164/rccm.200209-1119OC; Hammad SM, 2000, J BIOL CHEM, V275, P12003, DOI 10.1074/jbc.275.16.12003; Horalkova L, 2009, EUR J PHARM SCI, V36, P444, DOI 10.1016/j.ejps.2008.11.010; Hu G, 2008, CIRC RES, V102, pE120, DOI 10.1161/CIRCRESAHA.107.167486; Ikehata M, 2009, BIOL PHARM BULL, V32, P1765; John TA, 2003, AM J PHYSIOL-LUNG C, V284, pL187, DOI 10.1152/ajplung.00152.2002; KIM KJ, 1985, J APPL PHYSIOL, V59, P1290; Kim KJ, 2004, AM J PHYSIOL-LUNG C, V287, pL616, DOI 10.1152/ajplung.00121.2004; Kim KJ, 2003, AM J PHYSIOL-LUNG C, V284, pL458, DOI 10.1152/ajplung.00237.2002; Kolleck I, 2002, AM J RESP CELL MOL, V27, P57; Kooijman EE, 2011, AM J PHYSIOL-LUNG C, V301, pL804, DOI 10.1152/ajplung.00445.2010; Kozyraki R, 2001, J MOL MED-JMM, V79, P161, DOI 10.1007/s001090100193; Nadkarni PP, 2011, DIABETES OBES METAB, V13, P408, DOI 10.1111/j.1463-1326.2011.01363.x; Nagai J, 2013, HUMAN SERUM ALBUMIN, P122; Natsume H, 1999, INT J PHARM, V185, P1, DOI 10.1016/S0378-5173(99)00100-3; Nelson N, 1999, PHYSIOL REV, V79, P361; Oda K, 2012, DRUG METAB PHARMACOK, V27, P570, DOI 10.2133/dmpk.DMPK-12-RG-002; Oda K, 2011, EUR J PHARMACOL, V672, P62, DOI 10.1016/j.ejphar.2011.10.003; Owens DR, 2003, DIABETIC MED, V20, P886, DOI 10.1046/j.1464-5491.2003.01076.x; Park SH, 2007, INT J PHARM, V339, P205, DOI 10.1016/j.ijpharm.2007.03.003; Patton JS, 2010, J AEROSOL MED PULM D, V23, pS71, DOI 10.1089/jamp.2010.0836; Patton JS, 1996, ADV DRUG DELIVER REV, V19, P3, DOI 10.1016/0169-409X(95)00113-L; Pedersen LRE, 2012, ACTA PHYSIOL, V206, P142, DOI 10.1111/j.1748-1716.2012.02459.x; Ramsay E, 2000, INT J PHARM, V210, P97, DOI 10.1016/S0378-5173(00)00571-8; Sakagami M, 2006, PHARM RES, V23, P270, DOI 10.1007/s11095-005-9226-0; Sasaki Y, 2001, BIOCHEM BIOPH RES CO, V282, P212, DOI 10.1006/bbrc.2001.4557; Saumon G, 2001, PFLUG ARCH EUR J PHY, V441, P559, DOI 10.1007/s004240000457; SCHNITZER JE, 1988, P NATL ACAD SCI USA, V85, P6773, DOI 10.1073/pnas.85.18.6773; Shen ZC, 1999, INT J PHARM, V192, P115, DOI 10.1016/S0378-5173(99)00295-1; Tagawa M, 2008, DRUG METAB PHARMACOK, V23, P318, DOI 10.2133/dmpk.23.318; Takano M, 2013, MEMBRANE, V38, P246; Takano Mikihisa, 2011, Membrane, V36, P145; Tiruppathi C, 1996, P NATL ACAD SCI USA, V93, P250, DOI 10.1073/pnas.93.1.250; van der Deen M, 2005, RESP RES, V6, DOI 10.1186/1465-9921-6-59; WAN JS, 1990, J CELL PHYSIOL, V145, P9, DOI 10.1002/jcp.1041450103; Yamada K, 2005, J PHARM SCI-US, V94, P2432, DOI 10.1002/jps.20454; YAMAHARA H, 1994, EUR J PHARM BIOPHARM, V40, P294; Yumoto R, 2013, DRUG METAB PHARMACOK, V28, P159, DOI 10.2133/dmpk.DMPK-12-NT-056; Yumoto R, 2012, DRUG METAB PHARMACOK, V27, P336, DOI 10.2133/dmpk.DMPK-11-RG-127	115	1	1	INFORMA HEALTHCARE	LONDON	TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND	1742-5247	1744-7593		EXPERT OPIN DRUG DEL	Expert Opin. Drug Deliv.	MAY	2015	12	5					813	825		10.1517/17425247.2015.992778		13	Pharmacology & Pharmacy	Pharmacology & Pharmacy	CG3WA	WOS:000353209100009		
J	Miura, Y; Azuma, A				Miura, Yukiko; Azuma, Arata			Pirfenidone: an orphan drug for treating idiopathic pulmonary fibrosis	Expert Opinion on Orphan Drugs			English	Article						an antifibrotic agent; idiopathic pulmonary fibrosis; pirfenidone; TGF-beta	INTERSTITIAL LUNG-DISEASE; PLACEBO-CONTROLLED TRIAL; INTERFERON GAMMA-1B; ANTIFIBROTIC AGENT; VITAL CAPACITY; DOUBLE-BLIND; SCLERODERMA; EFFICACY; METAANALYSIS; NINTEDANIB	Introduction: Idiopathic pulmonary fibrosis (IPF) is a chronic progressive fibrotic lung disease with a poor prognosis. With advances in understanding of its pathogenesis, antifibrotic agents were proven to be effective. Pirfenidone slows the progression of IPF and fortunately it has resulted in survival benefit. Areas covered: Randomized clinical trials of pirfenidone showed a significant reduction in the decline of lung function. In 2014 May, the pooled analysis of the results of the Assessment of Pirfenidone to Confirm Efficacy and Safety in IPF trial combined with CAPACITY trials revealed a mortality benefit, which was the first in the history of IPF. Expert opinion: Pirfenidone is slow acting and is not approved for severe patients except in Japan. The prevalence of its use and compliance are current issues. An important task after marketing is to identify appropriate candidates for its use and the correct time of initiation, in addition to establishing criteria to evaluate its therapeutic benefits. Furthermore, it is desirable to widen the approval of this novel drug for other fibrotic diseases. We need to investigate other unknown therapeutic benefits associated with prognosis other than inhibition of declines in vital capacity.	[Miura, Yukiko; Azuma, Arata] Nippon Med Sch, Grad Sch Med, Dept Pulm Med & Oncol, Bunkyo Ku, Tokyo 1138603, Japan; [Miura, Yukiko] Natl Hosp Org, Ibarakihigashi Hosp, Dept Resp Med, Tokyo, Japan	Azuma, A (reprint author), Nippon Med Sch, Grad Sch Med, Dept Pulm Med & Oncol, Bunkyo Ku, 1-1-5 Sendagi, Tokyo 1138603, Japan.	azuma_arata@yahoo.co.jp					[American Thoracic Society International Consensus Statement American Thoracic Society (ATS) and the European Respiratory Society (ERS)], 2000, AM J RESP CRIT CARE, V161, P646; Richeldi L, 2012, THORAX, V67, P407, DOI 10.1136/thoraxjnl-2011-201184; King TE, 2009, LANCET, V374, P222, DOI 10.1016/S0140-6736(09)60551-1; King TE, 2014, NEW ENGL J MED, V370, P2083, DOI 10.1056/NEJMoa1402582; Lee JS, 2010, AM J MED, V123, P304, DOI 10.1016/j.amjmed.2009.07.033; Strieter RM, 2009, CHEST, V136, P1364, DOI 10.1378/chest.09-0510; Di Sario A, 2004, DIGEST LIVER DIS, V36, P744, DOI 10.1016/j.dld.2004.05.012; Armanios MY, 2007, NEW ENGL J MED, V356, P1317, DOI 10.1056/NEJMoa066157; Taskar Varsha S, 2006, Proc Am Thorac Soc, V3, P293, DOI 10.1513/pats.200512-131TK; McCormick LL, 1999, J IMMUNOL, V163, P5693; Kozono S, 2013, CANCER RES, V73, P2345, DOI 10.1158/0008-5472.CAN-12-3180; Liu HZ, 2005, AM J TRANSPLANT, V5, P1256, DOI 10.1111/j/1600-6143.2005.00876.x; Taniguchi H, 2010, EUR RESPIR J, V35, P821, DOI 10.1183/09031936.00005209; Noble PW, 2011, LANCET, V377, P1760, DOI 10.1016/S0140-6736(11)60405-4; Yamazaki T, 2012, HYPERTENS RES, V35, P34, DOI 10.1038/hr.2011.139; Raghu G, 2004, NEW ENGL J MED, V350, P125, DOI 10.1056/NEJMoa030511; Vancheri C, 2010, EUR RESPIR J, V35, P496, DOI 10.1183/09031936.00077309; [Anonymous], 2014, FDA APPR ESBR TREAT; Richeldi L, 2014, NEW ENGL J MED, V370, P2071, DOI 10.1056/NEJMoa1402584; Raghu G, 1999, AM J RESP CRIT CARE, V159, P1061; [Anonymous], 2013, PIRF TREAT ID PULM F; Azuma A, 2005, AM J RESP CRIT CARE, V171, P1040, DOI 10.1164/rccm.200404-571OC; Sharma K, 2011, J AM SOC NEPHROL, V22, P1144, DOI 10.1681/ASN.2010101049; Nakazato H, 2002, EUR J PHARMACOL, V446, P177, DOI 10.1016/S0014-2999(02)01758-2; Rubino CM, 2009, PULM PHARMACOL THER, V22, P279, DOI 10.1016/j.pupt.2009.03.003; Nagai S, 2002, INTERNAL MED, V41, P1118, DOI 10.2169/internalmedicine.41.1118; Antoniou KM, 2004, SARCOIDOSIS VASC DIF, V21, P105; Arai Toru, 2014, Respir Investig, V52, P136, DOI 10.1016/j.resinv.2013.09.002; Armendariz-Borunda J, 2012, ANN PLAS SURG, V68, P22, DOI 10.1097/SAP.0b013e31821b6d08; Azuma A, 2011, RESP RES, V12, DOI 10.1186/1465-9921-12-143; Burghardt I, 2007, BIOCHEM BIOPH RES CO, V354, P542, DOI 10.1016/j.bbrc.2007.01.012; Chiba H, 2012, LUNG PERSPECTIVCES, V20, P243; Gross TJ, 2001, NEW ENGL J MED, V345, P517, DOI 10.1056/NEJMra003200; Inoue Y, 2013, 2013 RES INT C BARC; Itoh T, 2012, JPN PHARMACOL THER, V40, P405; Iwasawa T, 2014, EUR J RADIOL, V83, P32, DOI [10.1016/j.ejrad.2012.02.014, 10.1016/j.ejrad.2013.02.014]; Iwata T, 2014, SURG TODAY; Jeon K, 2006, RESP MED, V100, P451, DOI 10.1016/j.rmed.2005.06.013; Ley Brett, 2013, Clin Epidemiol, V5, P483, DOI 10.2147/CLEP.S54815; Loeh B, 2015, AM J RESP CRIT CARE, V191, P110, DOI 10.1164/rccm.201406-1106LE; Loveman E, 2014, BMC PHARMACOL TOXICO, V15, DOI 10.1186/2050-6511-15-63; MARGOLIN SB, 1994, FASEB J, V8, pA382; Miura Y, 2014, SARCOIDOSIS VASC DIF, V31, P235; Miura Y, 2014, AM J RESP CRIT CARE, pA6581; Miura Y, 2014, 2014 ERS INT C 9 SEP; Nannini C, 2008, ARTHRITIS RES THER, V10, DOI 10.1186/ar2534; Noth I, 2013, LANCET RESP MED, V1, P309, DOI 10.1016/S2213-2600(13)70045-6; Ogura T., 2014, EUR RESP J; Oku H, 2008, EUR J PHARMACOL, V590, P400, DOI 10.1016/j.ejphar.2008.06.046; Okuda R, 2013, RESP MED, V107, P1431, DOI 10.1016/j.rmed.2013.06.011; Raghu G, 2011, AM J RESP CRIT CARE, V183, P788, DOI 10.1164/rccm.2009-040GL; Reck M, 2014, LANCET ONCOL, V15, P143, DOI 10.1016/S1470-2045(13)70586-2; Sakamoto S, 2013, INTERNAL MED, V52, P2495, DOI 10.2169/internalmedicine.52.8498; Shi Q, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028134; Shimizu T, 1998, KIDNEY INT, V54, P99, DOI 10.1046/j.1523-1755.1998.00962.x; Shimizu Y, 2014, J BIOL REG HOMEOS AG, V28, P433; Spagnolo P, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003134.pub2; Taniguchi H, 2011, RESP RES, V12, DOI 10.1186/1465-9921-12-93; Udwadia Zarir F, 2015, Lung India, V32, P50, DOI 10.4103/0970-2113.148451; Wells AU, 2014, PRESSE MED, V43, pE329, DOI 10.1016/j.lpm.2014.08.002	60	0	0	INFORMA HEALTHCARE	LONDON	TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND	2167-8707			EXPERT OPIN ORPHAN D	Exp. Opin. Orphan Drugs	MAY	2015	3	5					587	597		10.1517/21678707.2015.1029453		11	Pharmacology & Pharmacy	Pharmacology & Pharmacy	CG6LK	WOS:000353412200009		
J	Koh, KK; Sakuma, I; Hayashi, T; Kim, SH; Chung, WJ				Koh, Kwang Kon; Sakuma, Ichiro; Hayashi, Toshio; Kim, Sang Hyun; Chung, Wook-Jin			Renin-angiotensin system inhibitor and statins combination therapeutics - what have we learnt?	EXPERT OPINION ON PHARMACOTHERAPY			English	Editorial Material						cardiovascular disease; hypercholesterolemia; hypertension; renin-angiotensin system inhibitors; statins	HYPERCHOLESTEROLEMIC PATIENTS; CARDIOVASCULAR-DISEASE; HYPERTENSIVE PATIENTS; SIMVASTATIN; PREVENTION; THERAPY; DENSITY	Hypercholesterolemia and hypertension are the most common risk factors for cardiovascular disease (CVD). Updated guidelines emphasize target reduction of overall cardiovascular risks. Hypercholesterolemia and hypertension have a synergistic deleterious effect on insulin resistance and endothelial dysfunction. Unregulated renin-angiotensin system (RAS) is important in the pathogenesis of atherosclerosis. Statins are the most important in patients with hypercholesterolemia to prevent CVD by lowering low-density lipoprotein-cholesterol, improving endothelial dysfunction, and other anti-atherosclerotic effects. Unfortunately, statin therapy dose-dependently causes insulin resistance and increases the risk of type 2 diabetes mellitus. RAS inhibitors improve both endothelial dysfunction and insulin resistance in addition to blood pressure lowering. Further, cross-talk between hypercholesterolemia and RAS exists at multiple steps of insulin resistance and endothelial dysfunction. In this regard, combined therapy with statins and RAS inhibitors demonstrates additive/synergistic beneficial effects on endothelial dysfunction and insulin resistance in addition to lowering both cholesterol levels and blood pressure and it did reduce cardiovascular events when compared with either monotherapy in patients. This is mediated by both distinct and interrelated mechanisms. Therefore, combined therapy with statins and RAS inhibitors may be important in developing optimal management strategies in patients with hypertension, hypercholesterolemia, diabetes, metabolic syndrome or obesity to prevent or treat CVD.	[Koh, Kwang Kon; Chung, Wook-Jin] Gachon Univ, Gil Hosp, Div Cardiol, Vasc Med & Atherosclerosis Unit, Inchon, South Korea; [Koh, Kwang Kon; Chung, Wook-Jin] Gachon Cardiovasc Res Inst, Inchon, South Korea; [Sakuma, Ichiro] Hokko Mem Clin, Cardiovasc Med, Sapporo, Hokkaido, Japan; [Hayashi, Toshio] Nagoya Univ, Grad Sch Med, Dept Geriatr, Nagoya, Aichi 4648601, Japan; [Kim, Sang Hyun] Seoul Natl Univ, Coll Med, Div Cardiol, Seoul, South Korea	Koh, KK (reprint author), Gachon Univ, Gil Hosp, Div Cardiol, Vasc Med & Atherosclerosis Unit, 774 Beongil 21, Inchon, South Korea.	kwangk@gilhospital.com					Egan BM, 2013, CIRCULATION, V128, P29, DOI 10.1161/CIRCULATIONAHA.112.000500; Koh KK, 2004, CIRCULATION, V110, P3687, DOI 10.1161/01.CIR.0000143085.86697.13; Koh KK, 2010, J AM COLL CARDIOL, V55, P1209, DOI 10.1016/j.jacc.2009.10.053; Koh KK, 2003, J AM COLL CARDIOL, V42, P905, DOI 10.1016/S0735-1097(03)00846-5; Ridker PM, 2012, LANCET, V380, P565, DOI 10.1016/S0140-6736(12)61190-8; Stone NJ, 2014, CIRCULATION, V129, pS1, DOI 10.1161/01.cir.0000437738.63853.7a; Abuissa H, 2005, J AM COLL CARDIOL, V46, P821, DOI 10.1016/j.jacc.2005.05.051; Koh KK, 2000, CARDIOVASC RES, V47, P648, DOI 10.1016/S0008-6363(00)00146-2; Koh KK, 2010, INT J CARDIOL, V140, P73, DOI 10.1016/j.ijcard.2008.11.017; Lee HY, 2014, CIRC J, V78, P281, DOI 10.1253/circj.CJ-13-1494; Nickenig G, 1999, CIRCULATION, V100, P2131; Nickenig G, 1997, CIRCULATION, V95, P473; Koh KK, 2008, DIABETES CARE, V31, P776, DOI 10.2337/dc07-2199; Lim S, 2013, INT J CARDIOL, V167, P1696, DOI 10.1016/j.ijcard.2012.10.037; Koh KK, 2005, HYPERTENSION, V45, P1088, DOI 10.1161/01.HYP.0000166722.91714.ba; Athyros VG, 2004, J HUM HYPERTENS, V18, P781, DOI 10.1038/sj.jhh.1001748; Koh KK, 2013, DIABETES, V62, P3547, DOI 10.2337/db13-0566; Athyros VG, 2014, CURR PHARM DESIGN, V20, P6299; Go AS, 2014, J AM COLL CARDIOL, V63, P1230, DOI 10.1016/j.jacc.2013.11.007; Koh KK, 2013, INT J CARDIOL, V166, P509, DOI 10.1016/j.ijcard.2011.11.028; Oh PC, 2013, KOREAN CIRC J, V43, P527, DOI 10.4070/kcj.2013.43.8.527; Sim DS, 2013, KOREAN CIRC J, V43, P100, DOI 10.4070/kcj.2013.43.2.100	22	1	2	INFORMA HEALTHCARE	LONDON	TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND	1465-6566	1744-7666		EXPERT OPIN PHARMACO	Expert Opin. Pharmacother.	MAY	2015	16	7					949	953		10.1517/14656566.2015.1019464		5	Pharmacology & Pharmacy	Pharmacology & Pharmacy	CG3FZ	WOS:000353165100002		
J	Chung, SJ; Kim, JM; Kim, JW; Jeon, BS; Singh, P; Thierfelder, S; Ikeda, J; Bauer, L				Chung, Sun Ju; Kim, Jong-Min; Kim, Jae Woo; Jeon, Beom Seok; Singh, Pritibha; Thierfelder, Stephan; Ikeda, Junji; Bauer, Lars		Asia Pacific Rotigotine Switching	Switch from oral pramipexole or ropinirole to rotigotine transdermal system in advanced Parkinson's disease: an open-label study	EXPERT OPINION ON PHARMACOTHERAPY			English	Review						Parkinson's disease; pramipexole; ropinirole; rotigotine transdermal system; safety	DOPAMINE AGONISTS; OVERNIGHT SWITCH; CONTROLLED-TRIAL; DOUBLE-BLIND; RECEPTOR; PATCH; MANAGEMENT; PROFILE	Objective: Investigate safety, feasibility and efficacy of switching therapy in patients with advanced-stage Parkinson's disease (PD) inadequately controlled with pramipexole (<= 3.5 mg/day) or ropinirole (<= 14 mg/day) to rotigotine transdermal system (<= 14 mg/24 h; dose adjustments <= 16 mg/24 h permitted). Methods: PD0009 (ClinicalTrials. gov: NCT01711866) was an open-label study in patients with advanced-stage PD receiving levodopa, and experiencing sleep disturbance or early-morning motor impairment. Pramipexole/ropinirole was switched to equivalent dose rotigotine overnight or in two stages. During the 4-week treatment period rotigotine dose adjustments were permitted (up to 16 mg/24 h). Primary variable: Clinical Global Impressions (CGI) item 4: side effects (assessing safety) at end of treatment. Results: 79/87 (91%) patients completed the study; 2 (2%) withdrew due to adverse events (AEs). Most (84; 97%) had CGI item 4 score < 3 indicating switch did not interfere with functioning; three experienced drug-related AEs interfering with functioning (score = 3). 62% patients improved on Patient Global Impression of Change, assessing effectiveness. AEs occurring >= 5%: application site pruritus (10%), application site erythema (7%), dizziness (7%), dyskinesia (7%), erythema (6%), pruritus (6%). Unified Parkinson's Disease Rating Scale II and III, Parkinson's Disease Sleep Scale-2 and Pittsburgh Sleep Quality Index were unchanged. Numerical improvements in 'off' time, awakenings and nocturias were observed. Conclusions: Switch from pramipexole or ropinirole to rotigotine (up to 14 mg/24 h) was feasible and possibly associated with some benefit.	[Chung, Sun Ju] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Neurol, Seoul, South Korea; [Kim, Jong-Min] Seoul Natl Univ, Bundang Hosp, Dept Neurol, Songnam, South Korea; [Kim, Jae Woo] Dong A Univ, Med Ctr, Dept Neurol, Busan, South Korea; [Jeon, Beom Seok] Seoul Natl Univ Hosp, Dept Neurol, Seoul 110744, South Korea; [Singh, Pritibha; Thierfelder, Stephan; Bauer, Lars] UCB Pharma, D-40789 Monheim, Germany; [Ikeda, Junji] Otsuka Pharmaceut Co Ltd, Tokyo, Japan	Bauer, L (reprint author), UCB Pharma, Alfred Nobel Str 10, D-40789 Monheim, Germany.	lars.bauer@ucb.com			UCB Pharma, Monheim am Rhein, Germany; Otsuka Pharmaceutical Co., Ltd, Tokyo, Japan; UCB Pharma, Brussels, Belgium; Korean Ministry of Health; Seoul National University Hospital; Lundbeck; Novartis; Ipsen; Samil; AbbVie	This study was supported by UCB Pharma, Monheim am Rhein, Germany and Otsuka Pharmaceutical Co., Ltd, Tokyo, Japan. Writing and editorial assistance was funded by UCB Pharma, Brussels, Belgium and carried out by Emily Thompson, PhD, Evidence Scientific Solutions, London, UK. JH Kim, SJ Chung, BS Jeon and JW Kim received grant payments from the sponsor for enrolling patients in the study. L Bauer is an employee of UCB Pharma, Monheim am Rhein, Germany and holds stock from this employment. BS Jeon received research grant support from Korean Ministry of Health, Seoul National University Hospital, Lundbeck, Novartis, Ipsen, Samil and AbbVie; has served as a paid consultant for Lundbeck and has received honoraria from Ipsen. P Singh and S Thierfelder are employees of UCB Pharma, Monheim am Rhein, Germany. J Ikeda is an employee of Otsuka Pharmaceutical Co., Ltd, Tokyo, Japan. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.	Trenkwalder C, 2011, MOVEMENT DISORD, V26, P90, DOI 10.1002/mds.23441; Scheller D, 2009, N-S ARCH PHARMACOL, V379, P73, DOI 10.1007/s00210-008-0341-4; Giladi N, 2007, MOVEMENT DISORD, V22, P2398, DOI 10.1002/mds.21741; LeWitt PA, 2007, CLIN NEUROPHARMACOL, V30, P256; Elshoff JP, 2012, CLIN THER, V34, P966, DOI 10.1016/j.clinthera.2012.02.008; Watts RL, 2007, NEUROLOGY, V68, P272, DOI 10.1212/01.wnl.0000252355.79284.22; Millan MJ, 2002, J PHARMACOL EXP THER, V303, P791, DOI 10.1124/jpet.102.039867; Olanow CW, 2001, NEUROLOGY, V56, pS1; Radad K, 2005, PHARMACOL REP, V57, P701; LeWitt PA, 2007, NEUROLOGY, V68, P1262, DOI 10.1212/01.wnl.0000259516.61938.bb; Poewe WH, 2007, LANCET NEUROL, V6, P513, DOI 10.1016/S1471-4422(07)70108-4; Tomlinson CL, 2010, MOVEMENT DISORD, V25, P2649, DOI 10.1002/mds.23429; Canesi M, 1999, J NEURAL TRANSM, V106, P925, DOI 10.1007/s007020050212; Ferreira JJ, 2013, EUR J NEUROL, V20, P5, DOI 10.1111/j.1468-1331.2012.03866.x; Goetz CG, 1999, NEUROLOGY, V52, P1227; Junghanns S, 2004, J NEUROL, V251, P19, DOI 10.1007/s00415-004-1605-7; Kim HJ, 2011, BMC NEUROL, V11, DOI 10.1186/1471-2377-11-100; Reichmann H, 2003, J NEURAL TRANSM, V110, P1393, DOI 10.1007/s00702-003-0081-z; Thobois S, 2006, CLIN THER, V28, P1, DOI 10.1016/j.clinthera.2005.12.003	19	0	0	INFORMA HEALTHCARE	LONDON	TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND	1465-6566	1744-7666		EXPERT OPIN PHARMACO	Expert Opin. Pharmacother.	MAY	2015	16	7					961	970		10.1517/14656566.2015.1030336		10	Pharmacology & Pharmacy	Pharmacology & Pharmacy	CG3FZ	WOS:000353165100004		
J	Kadowaki, T; Marubayashi, F; Yokota, S; Katoh, M; Iijima, H				Kadowaki, Takashi; Marubayashi, Fuyuhiko; Yokota, Shoko; Katoh, Makoto; Iijima, Hiroaki			Safety and efficacy of teneligliptin in Japanese patients with type 2 diabetes mellitus: a pooled analysis of two Phase III clinical studies	EXPERT OPINION ON PHARMACOTHERAPY			English	Review						co-administration; Japanese; Phase III; pooled analysis; teneligliptin; type 2 diabetes	DIPEPTIDYL PEPTIDASE-4 INHIBITORS; METAANALYSIS; COMBINATION; REDUCTION	Objective: To assess the safety and efficacy of long-term administration of teneligliptin alone and in combination with oral antidiabetic drugs in Japanese type 2 diabetes mellitus (T2DM) patients with insufficient glycemic control. Methods: This post-hoc pooled analysis used data from two Phase III clinical studies involving 702 Japanese patients. We evaluated teneligliptin as monotherapy and combined with a sulfonylurea, glinide, biguanide, or a-glucosidase inhibitor. Safety measures included adverse events (AEs), adverse reactions and hypoglycemia. The main efficacy measure was the change in glycated hemoglobin (HbA(1c)) from baseline. Results: Incidences of AEs and adverse reactions were similar among the teneligliptin monotherapy group and all combination therapy groups except the combination with sulfonylurea. Hypoglycemia was more frequent in the sulfonylurea combination therapy group than in other groups. Teneligliptin administered once daily as monotherapy or combination therapy resulted in a decrease in HbA1c, which was maintained for 52 weeks. Bodyweight showed no change or a slight increase at the end of 52 weeks in all groups. Conclusions: This pooled analysis provides evidence for the safety and efficacy of long-term use of teneligliptin as monotherapy or combination therapy in Japanese T2DM patients.	[Kadowaki, Takashi] Univ Tokyo, Grad Sch Med, Dept Metab Dis, Tokyo, Japan; [Marubayashi, Fuyuhiko] Mitsubishi Tanabe Pharma Corp, Dev Div, Clin Res Dept 2, Tokyo, Japan; [Yokota, Shoko] Mitsubishi Tanabe Pharma Corp, Dev Div, Data Sci Dept, Tokyo, Japan; [Katoh, Makoto] Mitsubishi Tanabe Pharma Corp, Pharmacovigilance & Qual Assurance Div, Med Affairs Dept, Tokyo, Japan; [Iijima, Hiroaki] Mitsubishi Tanabe Pharma Corp, Pharmacovigilance & Qual Assurance Div, Med Affairs Dept, Yodogawa Ku, Osaka 5328505, Japan	Iijima, H (reprint author), Mitsubishi Tanabe Pharma Corp, Pharmacovigilance & Qual Assurance Div, Med Affairs Dept, 3-16-89 Kashima, Osaka 5328505, Japan.	Iijima.Hiroaki@mm.mt-pharma.co.jp			MSD K.K.; Nippon Boehringer Ingelheim Co., Ltd.; AstraZeneca K.K.; Chugai Pharmaceutical Co., Ltd.; Daiichi Sankyo Co., Ltd.; Mitsubishi Tanabe Pharma Corporation; Ono Pharmaceutical Co., Ltd.; Sanofi K.K.; Takeda Pharmaceutical Co., Ltd.; Mitsubishi Tanabe Pharma Corporation, Tokyo, Japan	T Kadowaki was the independent medical adviser for this study and is on the Advisory Panel of Daiichi Sankyo Co., Ltd., Mitsubishi Tanabe Pharma Corporation, Nippon Boehringer Ingelheim Co., Ltd., Novo Nordisk Pharma Ltd., Taisho Pharmaceutical Co., Ltd. and Takeda Pharmaceutical Co., Ltd.; has received consulting fees from MSD K.K. and Nippon Boehringer Ingelheim Co., Ltd.; has received research support from AstraZeneca K.K., Chugai Pharmaceutical Co., Ltd., Daiichi Sankyo Co., Ltd., Mitsubishi Tanabe Pharma Corporation, MSD K.K., Ono Pharmaceutical Co., Ltd., Sanofi K.K. and Takeda Pharmaceutical Co., Ltd.; and is on speakers bureaus for Astellas Pharma Inc., AstraZeneca K.K., Daiichi Sankyo Co., Ltd., Eli Lilly Japan K.K., Kowa Company, Ltd., Kyowa Hakko Kirin Co., Ltd., Mitsubishi Tanabe Pharma Corporation, MSD K.K., Nippon Boehringer Ingelheim Co., Ltd., Novartis Pharma K.K., Ono Pharmaceutical Co., Ltd., Sanofi K.K., Sanwa Kagaku Kenkyusho Co., Ltd., Sumitomo Dainippon Pharma Co., Ltd., Taisho Pharmaceutical Co., Ltd. and Takeda Pharmaceutical Co., Ltd. All other authors are employees of Mitsubishi Tanabe Pharma Corporation. This study was funded by Mitsubishi Tanabe Pharma Corporation, Tokyo, Japan. Medical writing support was provided by Helen Roberton and Nicholas Smith, PhD from Edanz Group Ltd and was funded by Mitsubishi Tanabe Pharma Corporation. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.	Kadowaki T, 2013, J DIABETES INVEST, V4, P576, DOI 10.1111/jdi.12092; Drucker DJ, 2006, LANCET, V368, P1696, DOI 10.1016/S0140-6736(06)69705-5; Kim YG, 2013, DIABETOLOGIA, V56, P696, DOI 10.1007/s00125-012-2827-3; Nabeno M, 2013, BIOCHEM BIOPH RES CO, V434, P191, DOI 10.1016/j.bbrc.2013.03.010; Park H, 2012, ANN PHARMACOTHER, V46, P1453, DOI 10.1345/aph.1R041; Filippatos TD, 2014, EXPERT OPIN DRUG MET, V10, P787, DOI 10.1517/17425255.2014.907274; Goda M, 2013, DRUG TODAY, V49, P615, DOI 10.1358/dot.2013.49.10.2035882; Kadowaki T, 2013, DIABETES OBES METAB, V15, P810, DOI 10.1111/dom.12092; Russell S, 2013, INT J CLIN PHARM-NET, V35, P159, DOI 10.1007/s11096-012-9729-9; Yabe D, 2014, J DIABETES INVEST, V5, P475, DOI 10.1111/jdi.12229; Eto T, 2012, DIABETES OBES METAB, V14, P1040, DOI 10.1111/j.1463-1326.2012.01662.x; Scirica BM, 2013, NEW ENGL J MED, V369, P1317, DOI 10.1056/NEJMoa1307684; Drucker DJ, 2007, J CLIN INVEST, V117, P24, DOI 10.1172/JCI30076; Kadowaki T, 2014, DIABETES OBES METAB, V16, P418, DOI [10.1111/dom.12235, 10.1111/dom.12233]; Nakamaru Y, 2014, XENOBIOTICA, V44, P242, DOI 10.3109/00498254.2013.816891; White WB, 2013, NEW ENGL J MED, V369, P1327, DOI 10.1056/NEJMoa1305889; Halabi A, 2014, CLIN PHARM DRUG DEV, V3, P290, DOI 10.1002/cpdd.89; Halabi A, 2013, CLIN PHARM DRUG DEV, V2, P246, DOI 10.1002/cpdd.29; Japan Diabetes Society, 2013, EV BAS PRACT GUID TR; Kinoshita S, 2015, EXPERT OPIN DRUG MET, V11, P7, DOI 10.1517/17425255.2015.982531; Konya H, 2014, THER CLIN RISK MANAG, V10, P547, DOI 10.2147/TCRM.S46076; Maeda H, 2012, DIABETES RES CLIN PR, V95, pE20, DOI 10.1016/j.diabres.2011.10.011; Morishita R, 2015, EXPERT OPIN PHARMACO, V16, P417, DOI 10.1517/14656566.2015.1000301; Otsuki H, 2014, INT UROL NEPHROL, V46, P427, DOI 10.1007/s11255-013-0552-6; Scheen AJ, 2015, EXPERT OPIN PHARMACO, V16, P43, DOI 10.1517/14656566.2015.978289; Tanaka S, 2014, DIABETES TECHNOL THE, V16, P1; Tsuchimochi W, 2015, ENDOCR J, V62, P13, DOI 10.1507/endocrj.EJ14-0393	27	2	2	INFORMA HEALTHCARE	LONDON	TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND	1465-6566	1744-7666		EXPERT OPIN PHARMACO	Expert Opin. Pharmacother.	MAY	2015	16	7					971	981		10.1517/14656566.2015.1032249		11	Pharmacology & Pharmacy	Pharmacology & Pharmacy	CG3FZ	WOS:000353165100005		
J	Tanaka, K; Yamaguchi, T; Hara, M				Tanaka, Keiichi; Yamaguchi, Tomonobu; Hara, Masako			Iguratimod for the treatment of rheumatoid arthritis in Japan	Expert Review of Clinical Immunology			English	Article						DMARD; iguratimod; rheumatoid arthritis; T-614	PLACEBO-CONTROLLED TRIAL; MODIFYING ANTIRHEUMATIC DRUG; KAPPA-B ACTIVATION; DOUBLE-BLIND; ANTIINFLAMMATORY AGENT; CYTOKINE PRODUCTION; SYNOVIAL-CELLS; METHOTREXATE; T-614; THERAPY	Iguratimod (IGU), a small-molecule compound, was developed as a disease-modifying antirheumatic drug in Japan. The pharmacological studies showed that inhibition of the production of cytokines and immunoglobulins mainly contributes to its improvement effect on animal arthritis models. The first clinical study of IGU in Japanese patients with rheumatoid arthritis was started in 1992 and Phase III studies were started in 1998. From the results of Phase II studies, a dose-escalating regimen was recommended to relieve the side effects. In a double-blind study comparing the efficacy and safety of the drug with those of placebo and salazosulfapyridine, it was confirmed that IGU was superior to placebo and was not inferior to salazosulfapyridine. Furthermore, a double-blind controlled trial of IGU in combination with methotrexate revealed an efficacious and manageable safety profile. IGU would be widely used as a new option for rheumatoid arthritis treatment and combination drug with methotrexate.	[Tanaka, Keiichi] Toyama Chem Co Ltd, Res Labs, Toyama 9308508, Japan; [Yamaguchi, Tomonobu] Toyama Chem Co Ltd, Dept Clin Res, Tokyo, Japan; [Hara, Masako] Tokyo Womens Med Univ, Inst Rheumatol, Tokyo, Japan	Tanaka, K (reprint author), Toyama Chem Co Ltd, Res Labs, Toyama 9308508, Japan.	keiichi_tanaka@toyama-chemical.co.jp			Toyama Chemical Co., Ltd.; Eisai Co., Ltd.	The authors were supported by Toyama Chemical Co., Ltd. and Eisai Co., Ltd. K Tanaka and T Yamaguchi are employees of Toyama Chemical Co., Ltd. M Hara served for consultancy to Eisai Co., Ltd. and Toyama Chemical Co., Ltd. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.	Kwoh CK, 2002, ARTHRITIS RHEUM-US, V46, P328; Smolen JS, 2010, ANN RHEUM DIS, V69, P964, DOI 10.1136/ard.2009.126532; Tanaka K, 2003, RHEUMATOLOGY, V42, P1365, DOI 10.1093/rheumatology/keg381; Kawakami A, 1999, J LAB CLIN MED, V133, P566, DOI 10.1016/S0022-2143(99)90186-5; Smolen JS, 2010, ANN RHEUM DIS, V69, P631, DOI 10.1136/ard.2009.123919; Moreland LW, 2012, ARTHRITIS RHEUM-US, V64, P2824, DOI 10.1002/art.34498; Mucke HAM, 2012, DRUG TODAY, V48, P577, DOI 10.1358/dot.2012.48.9.1855758; Feldmann M, 2008, IMMUNOL REV, V223, P7, DOI 10.1111/j.1600-065X.2008.00626.x; O'Dell JR, 2013, NEW ENGL J MED, V369, P307, DOI 10.1056/NEJMoa1303006; Aikawa Y, 2002, INFLAMM RES, V51, P188, DOI 10.1007/PL00000291; van Vollenhoven RF, 2012, LANCET, V379, P1712, DOI 10.1016/S0140-6736(12)60027-0; Wang QT, 2011, INT ARCH ALLERGY IMM, V155, P205, DOI 10.1159/000321185; Edwards JCW, 2001, RHEUMATOLOGY, V40, P205, DOI 10.1093/rheumatology/40.2.205; WELLS GA, 1993, J RHEUMATOL, V20, P557; Scott DL, 2010, LANCET, V376, P1094, DOI 10.1016/S0140-6736(10)60826-4; Kremer JM, 2002, ANN INTERN MED, V137, P726; Emery P, 2000, RHEUMATOLOGY, V39, P655, DOI 10.1093/rheumatology/39.6.655; Okamura K, 2015, MOD RHEUMATOL, V25, P235, DOI 10.3109/14397595.2014.938401; Benoist C, 2000, ARTHRITIS RES, V2, P90, DOI 10.1186/ar73; Brown KD, 2008, ARTHRITIS RES THER, V10, DOI 10.1186/ar2457; Felson DT, 2011, ARTHRITIS RHEUM-US, V63, P573, DOI 10.1002/art.30129; FRIES JF, 1986, ARTHRITIS RHEUM, V29, P1, DOI 10.1002/art.1780290101; Kwoh CK, 1996, ARTHRITIS RHEUM, V39, P713; Hara M, 2014, MOD RHEUMATOL, V24, P410, DOI 10.3109/14397595.2013.843756; Hara M, 2007, MOD RHEUMATOL, V17, P10; Hara Masako, 2007, Mod Rheumatol, V17, P1, DOI 10.1007/s10165-006-0542-y; Inaba T, 2000, CHEM PHARM BULL, V48, P131; Ishiguro N, 2013, MOD RHEUMATOL, V23, P430, DOI 10.1007/s10165-012-0724-8; Japan College of Rheumatology, 2014, GUID MAN RHEUM ARTHR; Japan College of Rheumatology, 2011, GUID TREATM METH MTX; Kohno M, 2001, J RHEUMATOL, V28, P2591; Luo Q, 2013, J IMMUNOL, V191, P4969, DOI 10.4049/jimmunol.1300832; Müller-Ladner Ulf, 2002, Curr Rheumatol Rep, V4, P201, DOI 10.1007/s11926-002-0066-1; Murao H, 2008, INT J RHEUM DIS S1, V11, pA112; Panayi G. S., 2005, RHEUMATOLOGY S2, V44, pii3; Rasheed Z, 2008, CURR RHEUMATOL REV, V4, P246, DOI 10.2174/157339708786263915; Saitoh T, 2000, RHEUMATIKA, V23, P571; TANAKA K, 1995, JPN J PHARMACOL, V67, P305, DOI 10.1254/jjp.67.305; Tanaka K, 2009, RHEUMATOL REP, V1, pe4; TANAKA K, 1992, J PHARMACOBIO-DYNAM, V15, P649; TANAKA K, 1992, ARZNEIMITTEL-FORSCH, V42-2, P945	41	0	0	EXPERT REVIEWS	LONDON	UNITEC HOUSE, 3RD FL, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON N3 1QB, ENGLAND	1744-666X	1744-8409		EXPERT REV CLIN IMMU	Expert Rev. Clin. Immunol.	MAY	2015	11	5					565	573		10.1586/1744666X.2015.1027151		9	Immunology	Immunology	CG4FI	WOS:000353239000003		
J	Iino, H; Hikima, T; Nishida, Y; Yamamoto, M; Kuramitsu, S; Fukui, K				Iino, Hitoshi; Hikima, Takaaki; Nishida, Yuya; Yamamoto, Masaki; Kuramitsu, Seiki; Fukui, Kenji			Small-angle X-ray scattering analysis reveals the ATP-bound monomeric state of the ATPase domain from the homodimeric MutL endonuclease, a GHKL phosphotransferase superfamily protein	EXTREMOPHILES			English	Article						DNA mismatch repair; Endonuclease; GHKL superfamily; ATPase; Small-angle X-ray scattering	DNA-MISMATCH-REPAIR; N-TERMINAL DOMAINS; CONFORMATIONAL-CHANGES; CRYSTAL-STRUCTURE; SWISS-MODEL; CANCER; ALPHA; SYSTEM; HSP90; ACTIVATION	DNA mismatch repair is an excision system that removes mismatched bases chiefly generated by replication errors. In this system, MutL endonucleases direct the excision reaction to the error-containing strand of the duplex by specifically incising the newly synthesized strand. Both bacterial homodimeric and eukaryotic heterodimeric MutL proteins belong to the GHKL ATPase/kinase superfamily that comprises the N-terminal ATPase and C-terminal dimerization regions. Generally, the GHKL proteins show large ATPase cycle-dependent conformational changes, including dimerization-coupled ATP binding of the N-terminal domain. Interestingly, the ATPase domain of human PMS2, a subunit of the MutL heterodimer, binds ATP without dimerization. The monomeric ATP-bound state of the domain has been thought to be characteristic of heterodimeric GHKL proteins. In this study, we characterized the ATP-bound state of the ATPase domain from the Aquifex aeolicus MutL endonuclease, which is a homodimeric GHKL protein unlike the eukaryotic MutL. Gel filtration, dynamic light scattering, and small-angle X-ray scattering analyses clearly showed that the domain binds ATP in a monomeric form despite its homodimeric nature. This indicates that the uncoupling of dimerization and ATP binding is a common feature among bacterial and eukaryotic MutL endonucleases, which we suggest is closely related to the molecular mechanisms underlying mismatch repair.	[Iino, Hitoshi; Hikima, Takaaki; Yamamoto, Masaki] Harima Inst, RIKEN SPring Ctr 8, Sayo, Hyogo 6795148, Japan; [Nishida, Yuya; Kuramitsu, Seiki] Osaka Univ, Grad Sch Sci, Dept Biol Sci, Toyonaka, Osaka 5600043, Japan; [Fukui, Kenji] Osaka Med Coll, Dept Biochem, Takatsuki, Osaka 5698686, Japan	Fukui, K (reprint author), Osaka Med Coll, Dept Biochem, 2-7 Daigaku Machi, Takatsuki, Osaka 5698686, Japan.	k.fukui@art.osaka-med.ac.jp	Yamamoto, Masaki/B-7844-2015	Yamamoto, Masaki/0000-0002-1311-1768	Management Expenses Grants	The authors thank Kayoko Matsumoto for the experiment involving overexpression of the proteins, Aimi Osaki for the assistance of protein purifications. Authors also thank Masao Inoue for his critical reading of this manuscript. The SAXS experiments in this study were performed at BL45XU in SPring-8 (Proposals 20110033 and 20120009). This work was supported by Management Expenses Grants from the government to RIKEN.	Pillon MC, 2011, DNA REPAIR, V10, P87, DOI 10.1016/j.dnarep.2010.10.003; Kunkel TA, 2005, ANNU REV BIOCHEM, V74, P681, DOI 10.1146/annurev.biochem.74.082803.133243; Yokoyama S, 2000, NAT STRUCT BIOL, V7, P943, DOI 10.1038/80712; Kadyrov FA, 2006, CELL, V126, P297, DOI 10.1016/j.cell.2006.05.039; Volkov VV, 2003, J APPL CRYSTALLOGR, V36, P860, DOI 10.1107/S0021889803000268; Aarnio M, 1999, INT J CANCER, V81, P214, DOI 10.1002/(SICI)1097-0215(19990412)81:2<214::AID-IJC8>3.0.CO;2-L; Fukui K, 2008, J BIOL CHEM, V283, P12136, DOI 10.1074/jbc.M800110200; Wriggers W, 2001, J STRUCT BIOL, V133, P193, DOI 10.1006/jsbi.2000.4350; Miyaki M, 1997, ONCOGENE, V15, P2877, DOI 10.1038/sj.onc.1201668; SVERGUN DI, 1992, J APPL CRYSTALLOGR, V25, P495, DOI 10.1107/S0021889892001663; Li GM, 2008, CELL RES, V18, P85, DOI 10.1038/cr.2007.115; Kadyrov FA, 2007, J BIOL CHEM, V282, P37181, DOI 10.1074/jbc.M707617200; Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084; Pillon MC, 2010, MOL CELL, V39, P145, DOI 10.1016/j.molcel.2010.06.027; Yamamoto T, 2011, J BIOL CHEM, V286, P42337, DOI 10.1074/jbc.M111.277335; Jiricny J, 2000, CURR OPIN GENET DEV, V10, P157, DOI 10.1016/S0959-437X(00)00066-6; Konarev PV, 2003, J APPL CRYSTALLOGR, V36, P1277, DOI 10.1107/S0021889803012779; Fujisawa T, 2000, J APPL CRYSTALLOGR, V33, P797, DOI 10.1107/S002188980000131X; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; Genschel J, 2002, J BIOL CHEM, V277, P13302, DOI 10.1074/jbc.M111854200; Schwede T, 2003, NUCLEIC ACIDS RES, V31, P3381, DOI 10.1093/nar/gkg520; Svergun D, 1995, J APPL CRYSTALLOGR, V28, P768, DOI 10.1107/S0021889895007047; Sacho EJ, 2008, MOL CELL, V29, P112, DOI 10.1016/j.molcel.2007.10.030; Arana ME, 2010, DNA REPAIR, V9, P448, DOI 10.1016/j.dnarep.2010.01.010; Ban C, 1998, CELL, V95, P541, DOI 10.1016/S0092-8674(00)81621-9; Kozin MB, 2001, J APPL CRYSTALLOGR, V34, P33, DOI 10.1107/S0021889800014126; Dutta R, 2000, TRENDS BIOCHEM SCI, V25, P24, DOI 10.1016/S0968-0004(99)01503-0; Ban C, 1999, CELL, V97, P85, DOI 10.1016/S0092-8674(00)80717-5; Svergun DI, 2001, BIOPHYS J, V80, P2946; Guarne A, 2004, EMBO J, V23, P4134, DOI 10.1038/sj.emboj.7600412; Svergun DI, 2011, CRYSTALLOGR REP+, V56, P725, DOI 10.1134/S1063774511050221; Iyer RR, 2006, CHEM REV, V106, P302, DOI 10.1021/cr0404794; LYNCH HT, 1985, CANCER, V56, P939, DOI 10.1002/1097-0142(19850815)56:4<939::AID-CNCR2820560440>3.0.CO;2-T; Kiefer F, 2009, NUCLEIC ACIDS RES, V37, pD387, DOI 10.1093/nar/gkn750; Modrich P, 1996, ANNU REV BIOCHEM, V65, P101, DOI 10.1146/annurev.bi.65.070196.000533; Zhang YB, 2005, CELL, V122, P693, DOI 10.1016/j.cell.2005.06.027; Modrich P, 2006, J BIOL CHEM, V281, P30305, DOI 10.1074/jbc.R600022200; Pluciennik A, 2010, P NATL ACAD SCI USA, V107, P16066, DOI 10.1073/pnas.1010662107; WIGLEY DB, 1991, NATURE, V351, P624, DOI 10.1038/351624a0; Bergerat A, 1997, NATURE, V386, P414, DOI 10.1038/386414a0; Prodromou C, 1997, CELL, V90, P65, DOI 10.1016/S0092-8674(00)80314-1; Prodromou C, 2000, EMBO J, V19, P4383, DOI 10.1093/emboj/19.16.4383; Dzantiev L, 2004, MOL CELL, V15, P31, DOI 10.1016/j.molcel.2004.06.016; Arai R, 2004, PROTEINS, V57, P829, DOI 10.1002/prot.20244; Ban C, 1998, EMBO J, V17, P1526, DOI 10.1093/emboj/17.5.1526; Correa EME, 2011, DNA REPAIR, V10, P1106, DOI 10.1016/j.dnarep.2011.08.007; Duppatla V, 2009, BIOCHEM J, V423, P265, DOI 10.1042/BJ20090626; FISHEL R, 1995, CURR OPIN GENET DEV, V5, P382, DOI 10.1016/0959-437X(95)80055-7; Friedberg EC, 2006, DNA REPAIR AND MUTAG; Fukui K, 2011, DNA REPAIR PATHWAYS, P123; Fukui K., 2010, J NUCL ACIDS, V2010; Guarne A, 2001, EMBO J, V20, P5521, DOI 10.1093/emboj/20.19.5521; Iino H, 2011, BIOSCIENCE REP, V31, P309, DOI 10.1042/BSR20100116; Kim TG, 2009, J BIOCHEM, V145, P199, DOI 10.1093/jb/mvn157; KURAMITSU S, 1990, BIOCHEMISTRY-US, V29, P5469, DOI 10.1021/bi00475a010; Maruya M, 1999, J MOL BIOL, V285, P903, DOI 10.1006/jmbi.1998.2349; Mauris J, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007175; Morita R, 2010, J NUCL ACIDS, V2010; Niedziela-Majka A, 2011, BIOCHEMISTRY-US, V50, P7868, DOI 10.1021/bi200753b; PUGH BF, 1988, J BIOL CHEM, V263, P76; Terasawa K, 2005, J BIOCHEM, V137, P443, DOI 10.1093/jb/vmvi056; Yang W, 2007, DNA REPAIR, V6, P135, DOI 10.1016/j.dnarep.2006.10.021	62	0	0	SPRINGER JAPAN KK	TOKYO	CHIYODA FIRST BLDG EAST, 3-8-1 NISHI-KANDA, CHIYODA-KU, TOKYO, 101-0065, JAPAN	1431-0651	1433-4909		EXTREMOPHILES	Extremophiles	MAY	2015	19	3					643	656		10.1007/s00792-015-0745-2		14	Biochemistry & Molecular Biology; Microbiology	Biochemistry & Molecular Biology; Microbiology	CG4XY	WOS:000353294100008		
J	Hirooka, Y; Homma, K; Maki, M; Sekiguchi, K				Hirooka, Yoshihiro; Homma, Koki; Maki, Masayasu; Sekiguchi, Kosuke			Applicability of synthetic aperture radar (SAR) to evaluate leaf area index (LAI) and its growth rate of rice in farmers' fields in Lao PDR	FIELD CROPS RESEARCH			English	Article						Back scattering coefficient (BSC); Farmers' fields; LAI; NDVI; Rice; Synthetic aperture radar (SAR)	PADDY FIELDS; SATELLITE; CROP	Rice is the most important crop in Lao People's Democratic Republic (Lao PDR). Synthetic aperture radar (SAR) is proposed as a more suitable method to evaluate rice growth in this area because it is independent from cloud and solar illumination. This study analyzed the relationship between the back scattering coefficient (BSC) in SAR images and leaf area index (LAI) of rice. Here, we discuss the applicability of SAR to estimate LAI and its growth rate in farmers' fields in Lao PDR. 30 farmers' paddy fields were selected for surveying throughout the growth period in the wet season of 2013, and both LAI and normalized difference vegetation index (NDVI) were measured at 4 time periods before the heading period for each field. X-band SAR images from the COSMO-SkyMed system (SAR) were used in this study. BSC was significantly correlated with LAI and NDVI. BSC at 28 of 30 fields was positively correlated with days after transplanting (DAT), and 10 of these results were significant. The increased rate in BSC obtained at the fields where BSC and DAT had a significant correlation, were significantly correlated with that in LAI. This finding suggests that if SAR images demonstrate significant increases of BSC against DAT, the increased rate may also represent LAI growth rate, although uncontrollable water levels and weeds occasionally interrupt observation. This study demonstrates the capacity of SAR to evaluate rice production in developing countries. (C) 2015 Elsevier B.V. All rights reserved.	[Hirooka, Yoshihiro; Homma, Koki] Kyoto Univ, Grad Sch Agr, Kyoto 6068502, Japan; [Maki, Masayasu; Sekiguchi, Kosuke] Kyoto Univ, Grad Sch Engn, Kyoto 6158530, Japan; [Maki, Masayasu] Tohoku Inst Technol, Fac Engn, Sendai, Miyagi 9828577, Japan	Homma, K (reprint author), Kyoto Univ, Grad Sch Agr, Kyoto 6068502, Japan.	homma@kais.kyoto-u.ac.jp		Homma, Koki/0000-0002-6285-6635	Ministry of the Environment, Japan [E-1104]; green network of excellence, Ministry of Education, Culture, Sport, Science and Technology, Japan; Japan Society for the Promotion of Science	This research was supported by the Environmental Research & Technology Development Fund (E-1104: Development and Practice of Advanced Basin Model in Asia: Toward Adaptation of Climate Changes (FY2011-FY2013), Ministry of the Environment, Japan), by the green network of excellence, Ministry of Education, Culture, Sport, Science and Technology, Japan and by Japan Society for the Promotion of Science.	Moran MS, 2002, REMOTE SENS ENVIRON, V79, P243, DOI 10.1016/S0034-4257(01)00276-0; Yamaguchi Y, 2005, IEEE T GEOSCI REMOTE, V43, P1699, DOI 10.1109/TGRS.2005.852084; Capodici F, 2013, REMOTE SENS-BASEL, V5, P1389, DOI 10.3390/rs5031389; Liew SC, 1998, IEEE T GEOSCI REMOTE, V36, P1412; Inoue Y, 2014, REMOTE SENS ENVIRON, V140, P257, DOI 10.1016/j.rse.2013.09.001; Martinez JM, 2007, REMOTE SENS ENVIRON, V108, P209, DOI 10.1016/j.rse.2006.11.012; Bamler R, 2000, SURV GEOPHYS, V21, P147, DOI 10.1023/A:1006790026612; Bell R.W., 2003, CARDI INT C RES WAT, P161; Chakraborty M, 2005, ISPRS J PHOTOGRAMM, V59, P310, DOI 10.1016/j.isprsjprs.2005.05.001; Fukai S, 1999, FIELD CROP RES, V64, P121, DOI 10.1016/S0378-4290(99)00055-6; Gauthier Y, 1998, INT J REMOTE SENS, V19, P2001, DOI 10.1080/014311698215117; Hirooka Y., 2015, J AGR METEO IN PRESS; Inamura Tatsuya, 2003, Weed Biology and Management, V3, P213, DOI 10.1046/j.1444-6162.2003.00106.x; Inthavong T, 2011, FIELD CROP RES, V121, P291, DOI 10.1016/j.fcr.2010.12.019; Kosaka Y, 2006, AGROFOREST SYST, V67, P1, DOI 10.1007/s10457-005-1109-1; Maclean J. L., 2002, RICE ALMANAC, P1; Maki M., 2015, J AGR METER IN PRESS; Miyagawa S, 2013, PLANT PROD SCI, V16, P325, DOI 10.1626/pps.16.325; Miyaoka K, 2013, IEEE GEOSCI REMOTE S, V10, P1507, DOI 10.1109/LGRS.2013.2261049; LEE JS, 1980, IEEE T PATTERN ANAL, V2, P165; Schiller J.M., 2006, RICE IN LAOS, P1	21	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0378-4290	1872-6852		FIELD CROP RES	Field Crop. Res.	MAY	2015	176						119	122		10.1016/j.fcr.2015.02.022		4	Agronomy	Agriculture	CG6QD	WOS:000353426100012		
J	Ludwiczuk, A; Asakawa, Y				Ludwiczuk, Agnieszka; Asakawa, Yoshinori			Chemotaxonomic value of essential oil components in liverwort species. A review	FLAVOUR AND FRAGRANCE JOURNAL			English	Review						liverworts; chemotaxonomy; essential oil components; chemical markers	SESQUITERPENE CONSTITUENTS; REBOULIA-HEMISPHAERICA; CONOCEPHALUM-CONICUM; VOLATILE COMPONENTS; LOPHOCOLEA-HETEROPHYLLA; CHEMICAL-CONSTITUENTS; EUROPEAN LIVERWORTS; LEPIDOZIA-FAURIANA; SCAPANIA-UNDULATA; PLAGIOCHILA	A number of liverwort species are known to emit volatile terpenoids and simple aromatic compounds when crushed. The characteristic odour of these spore-forming plants is associated with oil body constituents. Secondary metabolites, which constitute the oil bodies, are also of value for taxonomic investigations. Liverworts have yielded a rich array of secondary metabolites. Many of these compounds are characterized by unique structures, and some of them have not been found in any other plants, fungi, or marine organisms. Gas chromatographic profiling of the volatile extracts obtained from the liverworts has been applied with success in differentiating liverworts species, and also used to resolve the taxonomic problems at genus and family level. Due to the fact that liverworts are morphologically very small and it is difficult to collect a sufficient amount of plant material, there are few research data on the composition of the essential oils obtained from these plants. Nevertheless, the available data indicate that, as in the case of aromatic plants, the components present in essential oils obtained from the liverworts can be used in chemosystematic studies of this plant group. The aim of this paper is to show whether: (i) there are differences in the essential oils composition between different liverwort species; (ii) it is possible to find chemical markers characteristic for the analysed liverwort species; and (iii) the data derived from an analysis of the essential oils are in accordance with the data received from volatile extracts. Copyright (c) 2015 John Wiley & Sons, Ltd.	[Ludwiczuk, Agnieszka] Med Univ Lublin, Chair & Dept Pharmacognosy, Med Plant Unit, PL-20093 Lublin, Poland; [Asakawa, Yoshinori] Tokushima Bunri Univ, Fac Pharmaceut Sci, Tokushima 7708514, Japan	Ludwiczuk, A (reprint author), Med Univ Lublin, Chair & Dept Pharmacognosy, Med Plant Unit, 1 Chodzki Str, PL-20093 Lublin, Poland.	aludwiczuk@pharmacognosy.org					Adams RP, 2000, BIOCHEM SYST ECOL, V28, P515, DOI 10.1016/S0305-1978(99)00089-7; Adio AM, 2002, PHYTOCHEMISTRY, V61, P79; Adio AM, 2007, TETRAHEDRON-ASYMMETR, V18, P1693, DOI 10.1016/j.tetasy.2007.06.036; Adio AM, 2005, PHYTOCHEMISTRY, V66, P599, DOI 10.1016/j.phytochem.2005.01.015; Adio AM, 2004, PHYTOCHEMISTRY, V65, P199, DOI 10.1016/j.phytochem.2003.10.018; Adio AM, 2003, PHYTOCHEMISTRY, V64, P637, DOI 10.1016/S0031-9422(03)00298-X; Adio AM, 2007, TETRAHEDRON-ASYMMETR, V18, P1245, DOI 10.1016/j.tetasy.2007.05.020; ANDERSEN NH, 1973, PHYTOCHEMISTRY, V12, P2709, DOI 10.1016/0031-9422(73)85085-X; ANDERSEN NH, 1977, PHYTOCHEMISTRY, V16, P1727, DOI 10.1016/0031-9422(71)85080-X; ANDERSEN NH, 1977, PHYTOCHEMISTRY, V16, P1731, DOI 10.1016/0031-9422(71)85081-1; Schmiderer C, 2013, BIOCHEM SYST ECOL, V51, P70, DOI 10.1016/j.bse.2013.08.007; Bickford D, 2007, TRENDS ECOL EVOL, V22, P148, DOI 10.1016/j.tree.2006.11.004; Tesso H, 2005, PHYTOCHEMISTRY, V66, P941, DOI 10.1016/j.phytochem.2005.03.003; Tistaert C, 2011, ANAL CHIM ACTA, V690, P148, DOI 10.1016/j.aca.2011.02.023; Salgueiro L, 2010, FLAVOUR FRAG J, V25, P253, DOI 10.1002/ffj.1973; Crandall-Stotler B., 2009, Edinburgh Journal of Botany, V66, P155, DOI 10.1017/S0960428609005393; Asakawa Y, 2004, PHYTOCHEMISTRY, V65, P623, DOI 10.1016/j.phytochem.2004.01.003; Ludwiczuk A, 2013, NAT PROD COMMUN, V8, P1515; Asakawa Y., 1995, PROG CH ORG NAT PROD, V65, P1; ASAKAWA Y, 1982, PROG CH ORG NAT PROD, V42, P1; Asakawa Y, 2001, HETEROCYCLES, V54, P1057; Asakawa Y., 2013, 44 INT S ESS OILS IS, P51; Asakawa Yoshinori, 2013, Prog Chem Org Nat Prod, V95, P1; Asakawa Y, 2013, PHYTOCHEMISTRY, V91, P52, DOI 10.1016/j.phytochem.2012.04.012; BENESOVA V, 1971, TETRAHEDRON LETT, P2679; Figueiredo AC, 2009, FLAVOUR FRAG J, V24, P316, DOI 10.1002/ffj.1943; Figueiredo AC, 2010, FLAVOUR FRAG J, V25, P219, DOI 10.1002/ffj.1998; Figueiredo AC, 2005, FLAVOUR FRAG J, V20, P703, DOI 10.1002/ffj.1627; Figueiredo AC, 2006, FLAVOUR FRAG J, V21, P534, DOI 10.1002/ffj.1611; Flegel M, 2000, PLANT BIOLOGY, V2, P208, DOI 10.1055/s-2000-9156; Fujita Y., 1956, NIPPON KAGAKU ZASSHI, V77, P400; Furusawa M, 2006, CHEM PHARM BULL, V54, P996, DOI 10.1248/cpb.54.996; Hackl T, 2006, PHYTOCHEMISTRY, V67, P778, DOI 10.1016/j.phytyochem.2006.01.001; Harrison L. J., 1983, THESIS U GLASGOW UK; He XL, 2013, CRIT REV PLANT SCI, V32, P293, DOI 10.1080/07352689.2013.765765; Heinrichs J, 2011, AM J BOT, V98, P1252, DOI 10.3732/ajb.1100115; Heinrichs J, 2003, PLANT SYST EVOL, V242, P205, DOI 10.1007/s00606-003-0063-5; HUNECK S, 1967, PHYTOCHEMISTRY, V6, P383, DOI 10.1016/S0031-9422(00)86295-0; Jones W. P., 2006, METHODS BIOTECHNOLOG, V20, P323; Lu RH, 2003, PHYTOCHEMISTRY, V63, P581, DOI 10.1016/S0031-9422(03)00188-2; Ludwiczuk A, 2013, PHYTOCHEMISTRY, V95, P234, DOI 10.1016/j.phytochem.2013.06.011; Ludwiczuk A, 2014, PHYTOCHEM LETT, V10, pXCIX, DOI 10.1016/j.phytol.2014.05.015; Ludwiczuk A, 2014, J AOAC INT, V97, P1234, DOI 10.5740/jaoacint.SGELudwiczuk; Ludwiczuk A, 2011, NAT PROD COMMUN, V6, P315; Ludwiczuk A, 2008, NAT PROD COMMUN, V3, P133; Ludwiczuk A., 2010, TROPIC BRYOL, V31, P33; MATSUO A, 1971, TETRAHEDRON, V27, P2757, DOI 10.1016/S0040-4020(01)98065-2; MATSUO A, 1973, B CHEM SOC JPN, V46, P1010, DOI 10.1246/bcsj.46.1010; Melching S, 1999, PHYTOCHEMISTRY, V51, P517, DOI 10.1016/S0031-9422(98)00769-9; Muller K., 1905, PHYSIOL CHEM PHYS M, V45, P299; NAGASHIMA F, 1993, PHYTOCHEMISTRY, V33, P1445, DOI 10.1016/0031-9422(93)85107-3; ODRZYKOSKI IJ, 1991, PLANT SYST EVOL, V178, P135; OHTA Y, 1977, TETRAHEDRON, V33, P617, DOI 10.1016/0040-4020(77)80301-3; Paul C, 2001, PHYTOCHEMISTRY, V58, P789, DOI 10.1016/S0031-9422(01)00322-3; RIECK A, 1995, PHYTOCHEMISTRY, V40, P847, DOI 10.1016/0031-9422(95)00355-B; Rieck A, 1996, PHYTOCHEMISTRY, V43, P1055, DOI 10.1016/S0031-9422(96)00372-X; Rycroft DS, 2004, J BRYOL, V26, P37, DOI 10.1179/03736680325001643; Sandasi M, 2013, BIOCHEM SYST ECOL, V51, P142, DOI 10.1016/j.bse.2013.08.028; Schuster R.M., 1992, J HATTORI BOT LAB, V72, P163; Schuster RM, 1992, J HATTORI BOT LAB, V72, P151; SHU YF, 1994, PHYTOCHEMISTRY, V37, P773, DOI 10.1016/S0031-9422(00)90356-X; Shy HS, 2006, J ASIAN NAT PROD RES, V8, P723, DOI 10.1080/10286020500247392; Tabacchi R., 1992, P 12 INT C FLAV FRAG, P134; TOYOTA M, 1990, PHYTOCHEMISTRY, V29, P2334, DOI 10.1016/0031-9422(90)83066-A; Toyota M, 1999, PHYTOCHEMISTRY, V52, P105, DOI 10.1016/S0031-9422(99)00137-5; Toyota M., 1996, PHYTOCHEMISTRY, V41, P83; vons Reu S. H., 2004, PHYTOCHEMISTRY, V65, P2277; Warmers U, 1999, PHYTOCHEMISTRY, V52, P1501, DOI 10.1016/S0031-9422(99)00205-8; Warmers U, 1999, PHYTOCHEMISTRY, V52, P99, DOI 10.1016/S0031-9422(99)00123-5; Warmers U, 1998, PHYTOCHEMISTRY, V49, P1723, DOI 10.1016/S0031-9422(98)00283-0; WATERMAN PG, 1987, NAT PROD REP, V4, P175, DOI 10.1039/np9870400175; WEI HC, 1995, PHYTOCHEMISTRY, V39, P91, DOI 10.1016/0031-9422(94)00860-V; Weston RJ, 2010, BIOCHEM SYST ECOL, V38, P691, DOI 10.1016/j.bse.2010.04.009; Wikstrom N., 2009, TIMETREE LIFE, P146	74	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0882-5734	1099-1026		FLAVOUR FRAG J	Flavour Frag. J.	MAY	2015	30	3					189	196		10.1002/ffj.3236		8	Chemistry, Applied; Food Science & Technology	Chemistry; Food Science & Technology	CG3ZP	WOS:000353219500001		
J	Ogura, T; Onda, S; Sano, T; Takagi, W; Kitano, M; Masuda, D; Imoto, A; Fukunishi, S; Higuchi, K				Ogura, Takeshi; Onda, Saori; Sano, Tatsushi; Takagi, Wataru; Kitano, Masayuki; Masuda, Daisuke; Imoto, Akira; Fukunishi, Shinya; Higuchi, Kazuhide			EUS-Guided Antegrade Balloon Dilation From Right Hepatic Duct Combined With Retrograde Rendezvous Stent Placement	GASTROENTEROLOGY			English	Editorial Material							OBSTRUCTION		[Ogura, Takeshi; Onda, Saori; Sano, Tatsushi; Takagi, Wataru; Masuda, Daisuke; Imoto, Akira; Fukunishi, Shinya; Higuchi, Kazuhide] Osaka Med Coll, Dept Internal Med 2, Takatsuki, Osaka 5698686, Japan; [Kitano, Masayuki] Kinki Univ, Fac Med, Dept Gastroenterol & Hepatol, Osaka, Japan	Ogura, T (reprint author), Osaka Med Coll, Dept Internal Med 2, 2-7 Daigakuchou, Takatsuki, Osaka 5698686, Japan.	oguratakeshi0411@yahoo.co.jp					Itoi T, 2011, J HEPATO-BIL-PAN SCI, V18, P664, DOI 10.1007/s00534-011-0410-9; Park SJ, 2013, GASTROINTEST ENDOSC, V78, P374, DOI 10.1016/j.gie.2013.04.183; Hara K, 2013, ENDOSCOPY, V45, P392, DOI 10.1055/s-0032-1326076; Isayama H, 2013, J HEPATO-BIL-PAN SCI, V20, P413, DOI 10.1007/s00534-012-0577-8; Ogura T, 2015, ENDOSCOPY, V47, P72, DOI 10.1055/s-0034-1378111; Paik WH, 2014, WORLD J GASTROENTERO, V20, P5051, DOI 10.3748/wjg.v20.i17.5051	6	0	0	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0016-5085	1528-0012		GASTROENTEROLOGY	Gastroenterology	MAY	2015	148	5					901	903		10.1053/j.gastro.2015.03.007		3	Gastroenterology & Hepatology	Gastroenterology & Hepatology	CG5MJ	WOS:000353335700017		
J	Mizutani, Y; Nakamura, M; Goto, H				Mizutani, Yasuyuki; Nakamura, Masanao; Goto, Hidemi			An Unusual Cause of Obscure Gastrointestinal Bleeding	GASTROENTEROLOGY			English	Editorial Material							INFLAMMATORY FIBROID POLYPS		[Mizutani, Yasuyuki; Nakamura, Masanao; Goto, Hidemi] Nagoya Univ, Grad Sch Med, Dept Gastroenterol & Hepatol, Nagoya, Aichi 4648601, Japan	Mizutani, Y (reprint author), Nagoya Univ, Grad Sch Med, Dept Gastroenterol & Hepatol, Nagoya, Aichi 4648601, Japan.						Wysocki AP, 2007, DIGEST SURG, V24, P162, DOI 10.1159/000102099; ANTHONY PP, 1984, GUT, V25, P854, DOI 10.1136/gut.25.8.854; TADA S, 1991, AM J GASTROENTEROL, V86, P1247	3	0	0	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0016-5085	1528-0012		GASTROENTEROLOGY	Gastroenterology	MAY	2015	148	5					908	909		10.1053/j.gastro.2014.12.048		2	Gastroenterology & Hepatology	Gastroenterology & Hepatology	CG5MJ	WOS:000353335700020		
J	Namikawa, T; Kobayashi, M; Hanazaki, K				Namikawa, Tsutomu; Kobayashi, Michiya; Hanazaki, Kazuhiro			An Unusual Giant Duodenal Mass Lesion	GASTROENTEROLOGY			English	Editorial Material									[Namikawa, Tsutomu; Kobayashi, Michiya; Hanazaki, Kazuhiro] Kochi Med Sch, Dept Surg, Kochi, Japan	Namikawa, T (reprint author), Kochi Med Sch, Dept Surg, Kochi, Japan.						Patel ND, 2006, AM J ROENTGENOL, V187, P715, DOI 10.2214/AJR.05.0564; Kim K, 2013, DIGEST DIS SCI, V58, P194, DOI 10.1007/s10620-012-2320-3; Wang YP, 2013, GASTROENTEROLOGY, V145, P261	3	0	0	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0016-5085	1528-0012		GASTROENTEROLOGY	Gastroenterology	MAY	2015	148	5					E5	E6		10.1053/j.gastro.2014.10.049		2	Gastroenterology & Hepatology	Gastroenterology & Hepatology	CG5MJ	WOS:000353335700003		
J	Yamaguchi, T; Hasegawa, K; Kokudo, N				Yamaguchi, Takamune; Hasegawa, Kiyoshi; Kokudo, Norihiro			An Unusual Cause of Ascites	GASTROENTEROLOGY			English	Editorial Material									[Yamaguchi, Takamune; Hasegawa, Kiyoshi; Kokudo, Norihiro] Univ Tokyo, Grad Sch Med, Dept Surg, Hepatobiliary Pancreat Surg Div, Tokyo, Japan	Yamaguchi, T (reprint author), Univ Tokyo, Grad Sch Med, Dept Surg, Hepatobiliary Pancreat Surg Div, Tokyo, Japan.						Goshima S, 2004, J MAGN RESON IMAGING, V20, P66, DOI 10.1002/jmri.20055; Nojiri K, 2011, CLIN GASTROENTEROL H, V9, pE31, DOI 10.1016/j.cgh.2010.10.025; Vathey JN, 1997, GASTROENTEROLOGY, V113, P1390	3	0	0	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0016-5085	1528-0012		GASTROENTEROLOGY	Gastroenterology	MAY	2015	148	5					E3	E4		10.1053/j.gastro.2014.10.050		2	Gastroenterology & Hepatology	Gastroenterology & Hepatology	CG5MJ	WOS:000353335700002		
J	Hirano, T; Kusin, K; Limin, S; Osaki, M				Hirano, Takashi; Kusin, Kitso; Limin, Suwido; Osaki, Mitsuru			Evapotranspiration of tropical peat swamp forests	GLOBAL CHANGE BIOLOGY			English	Article						disturbances; drainage; eddy covariance; energy balance; ENSO; fire; groundwater level; smoke; Southeast Asia	FREQUENCY-RESPONSE CORRECTIONS; CARBON-DIOXIDE EMISSIONS; EDDY COVARIANCE SYSTEMS; RAIN-FOREST; FLUX MEASUREMENTS; ENERGY-BALANCE; CLIMATE-CHANGE; WATER; INDONESIA; PEATLANDS	In Southeast Asia, peatland is widely distributed and has accumulated a massive amount of soil carbon, coexisting with peat swamp forest (PSF). The peatland, however, has been rapidly degraded by deforestation, fires, and drainage for the last two decades. Such disturbances change hydrological conditions, typically groundwater level (GWL), and accelerate oxidative peat decomposition. Evapotranspiration (ET) is a major determinant of GWL, whereas information on the ET of PSF is limited. Therefore, we measured ET using the eddy covariance technique for 4-6years between 2002 and 2009, including El Nino and La Nina events, at three sites in Central Kalimantan, Indonesia. The sites were different in disturbance degree: a PSF with little drainage (UF), a heavily drained PSF (DF), and a drained burnt ex-PSF (DB); GWL was significantly lowered at DF, especially in the dry season. The ET showed a clear seasonal variation with a peak in the mid-dry season and a large decrease in the late dry season, mainly following seasonal variation in net radiation (R-n). The R-n drastically decreased with dense smoke from peat fires in the late dry season. Annual ET forced to close energy balance for 4years was 1636 +/- 53, 1553 +/- 117, and 1374 +/- 75mmyr(-1) (mean +/- 1 standard deviation), respectively, at UF, DF, and DB. The undrained PSF (UF) had high and rather stable annual ET, independently of El Nino and La Nina events, in comparison with other tropical rainforests. The minimum monthly-mean GWL explained 80% of interannual variation in ET for the forest sites (UF and DF); the positive relationship between ET and GWL indicates that drainage by a canal decreased ET at DF through lowering GWL. In addition, ET was decreased by 16% at DB in comparison with UF chiefly because of vegetation loss through fires.	[Hirano, Takashi; Limin, Suwido; Osaki, Mitsuru] Hokkaido Univ, Res Fac Agr, Sapporo, Hokkaido 0608589, Japan; [Kusin, Kitso] Univ Palangkaraya, CIMTROP, Palangkaraya 73112, Indonesia	Hirano, T (reprint author), Hokkaido Univ, Res Fac Agr, Sapporo, Hokkaido 0608589, Japan.	hirano@env.agr.hokudai.ac.jp	Hirano, Takashi/A-4557-2012		JSPS Core University Program; JSPS KAKENHI [13375011, 15255001, 18403001, 21255001, 25257401]; JST-JICA Project (SATREPS) (Wild Fire and Carbon Management in Peat-Forest in Indonesia)	This work was supported by JSPS Core University Program, JSPS KAKENHI (nos. 13375011, 15255001, 18403001, 21255001, and 25257401), and the JST-JICA Project (SATREPS) (Wild Fire and Carbon Management in Peat-Forest in Indonesia).	Giambelluca TW, 2009, AGR FOREST METEOROL, V149, P230, DOI 10.1016/j.agrformet.2008.08.004; Hirano T, 2012, GLOBAL CHANGE BIOL, V18, P3410, DOI 10.1111/j.1365-2486.2012.02793.x; Vickers D, 1997, J ATMOS OCEAN TECH, V14, P512, DOI 10.1175/1520-0426(1997)014<0512:QCAFSP>2.0.CO;2; Twine TE, 2000, AGR FOREST METEOROL, V103, P279, DOI 10.1016/S0168-1923(00)00123-4; Limpens J, 2008, BIOGEOSCIENCES, V5, P1475; Hamada JI, 2002, J METEOROL SOC JPN, V80, P285, DOI 10.2151/jmsj.80.285; Sakai RK, 2004, GLOBAL CHANGE BIOL, V10, P895, DOI 10.1111/j.1529-8817.2003.00773.x; Li ZH, 2010, HYDROL PROCESS, V24, P2405, DOI 10.1002/hyp.7643; Iwata Hiroki, 2012, Journal of Agricultural Meteorology, V68, P175, DOI 10.2480/agrmet.68.3.2; Massman WJ, 2001, AGR FOREST METEOROL, V107, P247, DOI 10.1016/S0168-1923(00)00237-9; Jauhiainen J, 2012, BIOGEOSCIENCES, V9, P617, DOI 10.5194/bg-9-617-2012; Miettinen J, 2012, GCB BIOENERGY, V4, P908, DOI 10.1111/j.1757-1707.2012.01172.x; WEBB EK, 1980, Q J ROY METEOR SOC, V106, P85, DOI 10.1002/qj.49710644707; Loescher HW, 2005, J HYDROL, V315, P274, DOI 10.1016/j.jhydrol.2005.03.040; Couwenberg J, 2010, GLOBAL CHANGE BIOL, V16, P1715, DOI 10.1111/j.1365-2486.2009.02016.x; Page SE, 2011, GLOBAL CHANGE BIOL, V17, P798, DOI 10.1111/j.1365-2486.2010.02279.x; PRIESTLEY CHB, 1972, MON WEATHER REV, V100, P81, DOI 10.1175/1520-0493(1972)100<0081:OTAOSH>2.3.CO;2; Hasler N, 2007, J HYDROMETEOROL, V8, P380, DOI 10.1175/JHM587.1; Spracklen DV, 2012, NATURE, V489, P282, DOI 10.1038/nature11390; Harris NL, 2012, SCIENCE, V336, P1573, DOI 10.1126/science.1217962; Ryu Y, 2008, J GEOPHYS RES-ATMOS, V113, DOI 10.1029/2007JD009263; Fisher JB, 2009, GLOBAL CHANGE BIOL, V15, P2694, DOI 10.1111/j.1365-2486.2008.01813.x; Hooijer A, 2010, BIOGEOSCIENCES, V7, P1505, DOI 10.5194/bg-7-1505-2010; Hirano T, 2007, GLOBAL CHANGE BIOL, V13, P412, DOI 10.1111/j.1365-2486.2006.01301.x; Sundari Siti, 2012, Journal of Agricultural Meteorology, V68, P121; Hooijer A, 2012, BIOGEOSCIENCES, V9, P1053, DOI 10.5194/bg-9-1053-2012; FLINT AL, 1991, AGR FOREST METEOROL, V56, P247, DOI 10.1016/0168-1923(91)90094-7; Hirano T, 2005, PHYTON-ANN REI BOT A, V45, P67; Tanaka N, 2008, AGR FOREST METEOROL, V148, P807, DOI 10.1016/j.agrformet.2008.01.011; Sun G, 2001, FOREST ECOL MANAG, V143, P227, DOI 10.1016/S0378-1127(00)00520-X; HIGNETT P, 1992, BOUND-LAY METEOROL, V61, P175, DOI 10.1007/BF02034000; Malhi Y, 2002, J GEOPHYS RES-ATMOS, V107, DOI 10.1029/2001JD000623; Miettinen J, 2012, FRONT ECOL ENVIRON, V10, P124, DOI 10.1890/100236; Dommain R, 2011, QUATERNARY SCI REV, V30, P999, DOI 10.1016/j.quascirev.2011.01.018; Moore S, 2013, NATURE, V493, P660, DOI 10.1038/nature11818; Bonan GB, 2008, SCIENCE, V320, P1444, DOI 10.1126/science.1155121; Page SE, 2002, NATURE, V420, P61, DOI 10.1038/nature01131; Lewis SL, 2006, PHILOS T R SOC B, V361, P195, DOI 10.1098/rstb.2005.1711; Dore S, 2010, ECOL APPL, V20, P663, DOI 10.1890/09-0934.1; Page SE, 2004, J QUATERNARY SCI, V19, P625, DOI 10.1002/jqs.884; Borma LS, 2009, J GEOPHYS RES, V114; BOSCH JM, 1982, J HYDROL, V55, P3, DOI 10.1016/0022-1694(82)90117-2; Bozkurt S, 2001, EARTH-SCI REV, V53, P95, DOI 10.1016/S0012-8252(00)00036-2; das Rocha H. R., 2004, ECOL APPL, V14, P22, DOI [10.1890/02-6001, DOI 10.1890/02-6001]; Davidson E, 2011, FOREST SCI, V57, P51; Herrera A., 2013, FRONT PLANT SCI, V4, P1; Hirano T, 2014, GLOBAL CHANGE BIOL, V20, P555, DOI 10.1111/gcb.12296; Humphreys ER, 2006, J GEOPHYS RES, V111; Hutyra LR, 2007, J GEOPHYS RES-BIOGEO, V112, DOI 10.1029/2006JG000365; JARVIS PG, 1986, ADV ECOL RES, V15, P1, DOI 10.1016/S0065-2504(08)60119-1; Komatsu H, 2012, J HYDROL, V420, P380, DOI 10.1016/j.jhydrol.2011.12.030; Kosugi Y, 2012, J FOREST RES-JPN, V17, P227, DOI 10.1007/s10310-010-0235-4; Kozlowski KK, 1997, TREE PHYSL MONOGRAPH, V1, P1; Kume T, 2011, AGR FOREST METEOROL, V151, P1183, DOI 10.1016/j.agrformet.2011.04.005; Massman WJ, 2000, AGR FOREST METEOROL, V104, P185, DOI 10.1016/S0168-1923(00)00164-7; Monteith J L, 1965, Symp Soc Exp Biol, V19, P205; Nesptad DC, 1994, NATURE, V372, P666; Sulistiyanto Y, 2004, THESIS U NOTTINGHAM; Takahashi H, 2011, 3 INT WORKSH WILD FI, P49; vons Randow C., 2004, THEORETICAL APPL CLI, V78, P5, DOI [10.1007/s00704-004-0041-z, DOI 10.1007/S00704-004-0041-Z]; von Randow RCS, 2012, THEOR APPL CLIMATOL, V109, P205, DOI 10.1007/s00704-011-0570-1; Foken T, 1996, AGR FOREST METEOROL, V78, P83, DOI 10.1016/0168-1923(95)02248-1; Wilczak JM, 2001, BOUND-LAY METEOROL, V106, P85	63	1	1	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1354-1013	1365-2486		GLOBAL CHANGE BIOL	Glob. Change Biol.	MAY	2015	21	5					1914	1927		10.1111/gcb.12653		14	Biodiversity Conservation; Ecology; Environmental Sciences	Biodiversity & Conservation; Environmental Sciences & Ecology	CG3ZX	WOS:000353220500014		
J	Fujita, S; Furuya, M; Magnant, C				Fujita, Shinya; Furuya, Michitaka; Magnant, Colton			General Bounds on Rainbow Domination Numbers	GRAPHS AND COMBINATORICS			English	Article						Rainbow domination number; k-rainbow dominating function; Minimum degree	GRAPHS	A k-rainbow dominating function of a graph G is a function f from the vertices V(G) to such that, for all , either or . The k-rainbow domination number of a graph G is then defined to be the minimum weight of a k-rainbow dominating function. In this work, we prove sharp upper bounds on the k-rainbow domination number for all values of k. Furthermore, we also consider the problem with minimum degree restrictions on the graph.	[Fujita, Shinya] Yokohama City Univ, Int Coll Arts & Sci, Kanazawa Ku, Yokohama, Kanagawa 2360027, Japan; [Furuya, Michitaka] Tokyo Univ Sci, Dept Math Informat Sci, Shinjuku Ku, Tokyo 1628601, Japan; [Magnant, Colton] Georgia So Univ, Dept Math Sci, Statesboro, GA 30460 USA	Furuya, M (reprint author), Tokyo Univ Sci, Dept Math Informat Sci, Shinjuku Ku, 1-3 Kagurazaka, Tokyo 1628601, Japan.	shinya.fujita.ph.d@gmail.com; michitaka.furuya@gmail.com; dr.colton.magnant@gmail.com			Japan Society for the Promotion of Science [20740095]	S. Fujita is supported by the Japan Society for the Promotion of Science Grant-in-Aid for Young Scientists (B) (20740095).	Bresar B, 2008, TAIWAN J MATH, V12, P213; Caro Y., 1990, INT J MATH MATH SCI, V13, P205, DOI 10.1155/S016117129000031X; CARO Y, 1985, ARS COMBINATORIA, V20, P167; Chang GJ, 2010, DISCRETE APPL MATH, V158, P8, DOI 10.1016/j.dam.2009.08.010; Chartrand G., 2005, GRAPHS DIGRAPHS; Haynes T.W., 1998, FUNDAMENTALS DOMINAT; MCCUAIG W, 1989, J GRAPH THEOR, V13, P749, DOI 10.1002/jgt.3190130610; Ore O., 1962, AM MATH SOC C PUBLIC, VXXXVIII; Reed B., 1996, COMB PROBAB COMPUT, V5, P277; Wu YJ, 2013, GRAPH COMBINATOR, V29, P1125, DOI 10.1007/s00373-012-1158-y; Xing HM, 2006, CZECH MATH J, V56, P1049, DOI 10.1007/s10587-006-0079-4	11	0	0	SPRINGER JAPAN KK	TOKYO	CHIYODA FIRST BLDG EAST, 3-8-1 NISHI-KANDA, CHIYODA-KU, TOKYO, 101-0065, JAPAN	0911-0119	1435-5914		GRAPH COMBINATOR	Graphs Comb.	MAY	2015	31	3					601	613		10.1007/s00373-013-1394-9		13	Mathematics	Mathematics	CG4DM	WOS:000353232900009		
J	Takahashi, S; Miyashita, T; Hoshikawa, H; Haba, R; Togami, T; Shibata, T				Takahashi, Shigeo; Miyashita, Takenori; Hoshikawa, Hiroshi; Haba, Reiji; Togami, Taro; Shibata, Toru			Accelerated hyperfractionated radiotherapy for small cell carcinoma of the nasopharynx	HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK			English	Article						small cell carcinoma; accelerated hyperfractionation; twice daily; cisplatin and etoposide regimen; concurrent chemoradiation	LUNG-CANCER	BackgroundThe purpose of this study was to report the treatment outcome of a patient with nasopharyngeal small cell carcinoma. MethodsThe patient received concurrent chemoradiotherapy (CRT). Chemotherapy consisted of 4 cycles of cisplatin and etoposide. Accelerated hyperfractionated radiotherapy (RT) was performed with a dose of 45 Gy in 30 fractions over 3 weeks for the nasopharynx and upper neck region, whereas conventional fractionated RT was performed with a dose of 50 Gy in 25 fractions over 5 weeks for the lower neck region. ResultsComplete response was achieved 1 month after the completion of CRT. Prophylactic cranial irradiation was not performed. Isolated brain metastasis was diagnosed 18 months after the completion of CRT. Finally, the patient died because of the brain and cord metastases 32 months after the completion of CRT. ConclusionThe administration of prophylactic cranial irradiation may be considered for nasopharyngeal small cell carcinoma. (c) 2015 Wiley Periodicals, Inc. Head Neck37: E63-E65, 2015	[Takahashi, Shigeo; Togami, Taro; Shibata, Toru] Kagawa Univ Hosp, Dept Radiat Oncol, Miki, Kagawa 7610793, Japan; [Miyashita, Takenori; Hoshikawa, Hiroshi] Kagawa Univ Hosp, Dept Otolaryngol Head & Neck Surg, Miki, Kagawa 7610793, Japan; [Haba, Reiji] Kagawa Univ Hosp, Dept Diagnost Pathol, Miki, Kagawa 7610793, Japan	Takahashi, S (reprint author), Kagawa Univ Hosp, Dept Radiat Oncol, 1750-1 Ikenobe, Miki, Kagawa 7610793, Japan.	shigeot@med.kagawa-u.ac.jp					Auperin A, 1999, NEW ENGL J MED, V341, P476, DOI 10.1056/NEJM199908123410703; LEVENSON RM, 1981, J NATL CANCER I, V67, P607; Turrisi AT, 1999, NEW ENGL J MED, V340, P265, DOI 10.1056/NEJM199901283400403; Hatoum GF, 2009, INT J RADIAT ONCOL, V74, P477, DOI 10.1016/j.ijrobp.2008.08.014; Lee LY, 2011, INT J SURG PATHOL, V19, P199, DOI 10.1177/1066896908316904; Lin IH, 2007, ACTA OTO-LARYNGOL, V127, P206, DOI 10.1080/00016480500401027; NCCN. org, 2014, SMALL CELL LUNG CANC; Schild SE, 2012, CLIN RAD ONCOLOGY, P795; Walenkamp AME, 2009, CANCER TREAT REV, V35, P228, DOI 10.1016/j.ctrv.2008.10.007	9	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1043-3074	1097-0347		HEAD NECK-J SCI SPEC	Head Neck-J. Sci. Spec. Head Neck	MAY	2015	37	5					E63	E65		10.1002/hed.23888		3	Otorhinolaryngology; Surgery	Otorhinolaryngology; Surgery	CG6MF	WOS:000353414600001		
J	Usui, E; Miyazaki, S; Taniguchi, H; Ichihara, N; Kanaji, Y; Takagi, T; Iwasawa, J; Kuroi, A; Nakamura, H; Hachiya, H; Isobe, M; Hirao, K; Iesaka, Y				Usui, Eisuke; Miyazaki, Shinsuke; Taniguchi, Hiroshi; Ichihara, Noboru; Kanaji, Yoshihisa; Takagi, Takamitsu; Iwasawa, Jin; Kuroi, Akio; Nakamura, Hiroaki; Hachiya, Hitoshi; Isobe, Mitsuaki; Hirao, Kenzo; Iesaka, Yoshito			Recurrence after "long-term success" in catheter ablation of paroxysmal atrial fibrillation	HEART RHYTHM			English	Article						Very late recurrence; Long-term success; Atrial fibrillation; Catheter ablation; Pulmonary vein isolation	PULMONARY VEINS; FOLLOW-UP; SUBSTRATE; CARDIOMYOPATHY; CONDUCTION; UTILITY	BACKGROUND The latest guidelines define "long-term success" as freedom from atrial arrhythmia recurrence more than 36 months after procedures without any antiarrhythmic drug therapy. OBJECTIVE The purpose of this study was to investigate the clinical outcomes and procedural findings in patients with recurrence beyond "long-term success." METHODS Among patients who underwent pulmonary vein (PV) antrum isolation for drug-refractory symptomatic paroxysmal atrial fibrillation (AF), 37 in whom recurrent arrhythmias were observed during annual follow-up after "long-term success" and who underwent repeat procedures for recurrent arrhythmias were included in the study. RESULTS The time from the Latest procedure to recurrence was a median of 61 ([25th, 75th percentiles]: [51-77.5]) months. Recurrent arrhythmia type was paroxysmal in 22 patients (59.5%) and persistent in 15 (40.5%). Recurrent arrhythmias were atrial tachycardia (AT) in 13 patients (35.1%), including 8 with AT unrelated to PVs. Repeat procedures were performed a median of 2.0 [1.0-4.0] months after identifying recurrent episodes. Recovered PV conduction was found in 29 patients (78.4%) and non-PV foci in 4 (10.8%). Freedom from recurrence 1 year after repeat procedures was 63.3%. Seven patients (18.9%) underwent further repeat procedures a median of 7.0 [2.0-28.0] months after repeat procedures and had no PV reconnections. In total, AF/AT unrelated to PVs was present in 24 patients (64.9%). In contrast, arrhythmias related to PVs were observed in 2 patients (5.4%) during a total of 46 repeat procedures after "long-term success." CONCLUSION Although PV reconnections were commonly found even after "long-term success," AF/AT unrelated to PVs was assumed to be present in the majority of this population.	[Usui, Eisuke; Miyazaki, Shinsuke; Taniguchi, Hiroshi; Ichihara, Noboru; Kanaji, Yoshihisa; Takagi, Takamitsu; Iwasawa, Jin; Kuroi, Akio; Nakamura, Hiroaki; Hachiya, Hitoshi; Iesaka, Yoshito] Tsuchiura Kyodo Hospital, Ctr Cardiovasc, Tsuchiura, Ibaraki 3000053, Japan; [Isobe, Mitsuaki] Tokyo Med & Dent Univ, Dept Cardiovasc Med, Tokyo, Japan; [Hirao, Kenzo] Tokyo Med & Dent Univ, Heart Rhythm Ctr, Tokyo, Japan	Miyazaki, S (reprint author), Tsuchiura Kyodo Hospital, Div Cardiol, Ctr Cardiovasc, 11-7 Manabeshin Machi, Tsuchiura, Ibaraki 3000053, Japan.	mshinsuke@k3.dion.ne.jp					Arentz T, 2007, CIRCULATION, V115, P3057, DOI 10.1161/CIRCULATIONAHA.107.690578; Badger TJ, 2009, HEART RHYTHM, V6, P161, DOI 10.1016/j.hrthm.2008.10.042; Stiles MK, 2009, J AM COLL CARDIOL, V53, P1182, DOI 10.1016/j.jacc.2008.11.054; Kottkamp H, 2013, EUR HEART J, V34, P2731, DOI 10.1093/eurheartj/eht194; Liu XP, 2006, J CARDIOVASC ELECTR, V17, P1263, DOI 10.1111/j.1540-8167.2006.00621.x; Weerasooriya R, 2011, J AM COLL CARDIOL, V57, P160, DOI 10.1016/j.jacc.2010.05.061; Shah D, 2000, CIRCULATION, V102, P1517; Haissaguerre M, 1998, NEW ENGL J MED, V339, P659, DOI 10.1056/NEJM199809033391003; Jiang RH, 2014, HEART RHYTHM, V11, P969, DOI [10.1016/j.hrthm.2014.03.015, 10.1016/j.hrthm.2014.0.3.015]; Miyazaki S, 2013, HEART RHYTHM, V10, P629, DOI 10.1016/j.hrthm.2012.12.032; Oakes RS, 2009, CIRCULATION, V119, P1758, DOI 10.1161/CIRCULATIONAHA.108.811877; Nault I, 2010, EUR HEART J, V31, P1046, DOI 10.1093/eurheartj/ehq079; Calkins H, 2012, HEART RHYTHM, V9, P632, DOI 10.1016/j.hrthm.2011.12.016; Miyazaki S, 2011, HEART, V97, P668, DOI 10.1136/hrt.2009.186874; Hachiya H, 2007, J CARDIOVASC ELECTR, V18, P1; Kottkamp H, 2012, J CARDIOVASC ELECTR, V23, P797, DOI 10.1111/j.1540-8167.2012.02341.x; Takagi T, 2014, CIRC J, V78, P2637, DOI 10.1253/circj.CJ-14-0610; Takahashi A, 2002, CIRCULATION, V105, P2998, DOI 10.1161/01.CIR.0000019585.91146.AB; Teh AW, 2012, HEART RHYTHM, V9, P473, DOI 10.1016/j.hrthm.2011.11.013; Uchiyama T, 2013, CIRC J, V77, P2722, DOI 10.1253/circj.CJ-13-0468; Wittkampf FH, 1989, CIRCULATION, V80, P962	21	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1547-5271	1556-3871		HEART RHYTHM	Heart Rhythm	MAY	2015	12	5					893	898		10.1016/j.hrthm.2015.01.043		6	Cardiac & Cardiovascular Systems	Cardiovascular System & Cardiology	CG5LK	WOS:000353333100010		
J	Auricchio, A; Schloss, EJ; Kurita, T; Meijer, A; Gerritse, B; Zweibel, S; AlSmadi, FM; Leng, CT; Sterns, LD				Auricchio, Angelo; Schloss, Edward J.; Kurita, Takashi; Meijer, Albert; Gerritse, Bart; Zweibel, Steven; AlSmadi, Faisal M.; Leng, Charles T.; Sterns, Laurence D.		PainFree SST Investigators	Low inappropriate shock rates in patients with single- and dual/triple-chamber implantable cardioverter-defibrillators using a novel suite of detection algorithms: Pain Free SST trial primary results	HEART RHYTHM			English	Article						Implantable cardioverter-defibrillator; Cardiac resynchronization therapy; Heart failure; Atrial fibrillation; Inappropriate shock	QUALITY-OF-LIFE; HEART-FAILURE; DISCRIMINATION ALGORITHMS; COMPETING RISK; THERAPY; PERFORMANCE; PREVENTION; REDUCTION; SAFETY	BACKGROUND The benefits of implantable cardioverterdefibrillators (ICDs) have been well demonstrated in many clinical trials, and ICD shocks for ventricular tachyarrhythmias save Lives. However, inappropriate and unnecessary shock delivery remains a significant clinical issue with considerable consequences for patients and the healthcare system. OBJECTIVE The purpose of the PainFree SmartShock Technology (SST) study was to investigate new-generation ICDs to reduce inappropriate and unnecessary shocks through novel discrimination algorithms with modern programming strategies. METHODS This prospective, multicenter clinical trial enrolled 2790 patients with approved indication for ICD implantation (79% male, mean age 65 years; 69 /a primary prevention indication, 27% singlechamber ICD, 33% replacement or upgrade). Patients were followed for a minimum of 12 months, and mean follow-up was 22 months. The primary end-point of the study was the percentage of patients remaining free of inappropriate shocks at 1 year postimplant, analyzed separately for dual/triple-chamber ICDs (N = 2019) and single-chamber ICDs (N = 751). RESULTS The inappropriate shock rate at 1 year was 1.5% for patients with dual/triple-chamber ICDs and 2.5% for patients with single-chamber devices. Two years postimplant, the inappropriate shock rate was 2.8% for patients with dual-/triple chamber ICDs and 3.7% for those with single-chamber ICDs. The most common cause of an inappropriate shock in both groups was atrial fibrillation or flutter. CONCLUSION In a large patient cohort receiving ICDs for primary or secondary prevention, the adoption of novel enhanced detection algorithms in conjunction with routine implementation of modern programming strategies Led to a very Low inappropriate shock rate.	[Auricchio, Angelo] Fdn Cardioctr Ticino, CH-6900 Lugano, Switzerland; [Schloss, Edward J.] Christ Hosp, Ohio Heart & Vasc Ctr, Cincinnati, OH USA; [Kurita, Takashi] Kinki Univ, Sch Med, Osaka 589, Japan; [Meijer, Albert] Catharina Hosp, Eindhoven, Netherlands; [Gerritse, Bart] Medtron Bakken Res Ctr, Maastricht, Netherlands; [Zweibel, Steven] Hartford Hosp, Hartford, CT 06115 USA; [AlSmadi, Faisal M.] Prince Sahnan Heart Ctr King Fahad Med City, Riyadh, Saudi Arabia; [Leng, Charles T.] Univ Penn, Philadelphia, PA 19104 USA; [Sterns, Laurence D.] Royal Jubilee Hosp, Victoria, BC, Canada	Auricchio, A (reprint author), Fdn Cardioctr Ticino, Via Tesserete 48, CH-6900 Lugano, Switzerland.	angelo.auricchio@cardiocentro.org			Medtronic Inc, Minneapolis, Minnesota; Medtronic; Sorin; St. Jude Medical; Boston Scientific	This study was funded by Medtronic Inc, Minneapolis, Minnesota. Dr. Auricchio is a consultant 'for Medtronic, Biotronik, Sorin, and Cordis Biologics Delivery Systems; and receives Speaker fees from Medtronic and Sorin. Dr. Schloss is a consultant for Medtronic and Boston Scientific; and receives Speaker fees from Medtronic. Dr. Kmita is a consultant for Medtronic, St. Jude Medical, and Boston Scientific; and receives Speaker fees from Medtronic and St. Jude Medical. Dr. Meijer receives fellowship support from, and is a consultant for, Medtronic. Mr. Gerritse is a Medtronic employee. Dr. Zweibei receives research grants from, and is a consultant for, Medtronic. Dr. Sterns is a consultant l'or Medtronic, Boston Scientific, and St. Jude Medical; and receives Speaker fees from Medtronic. This study is registered at www.clinicakrials.gov No. NCT00982397. The full list of investigators and their institutions is given in Appendix A.	Ruwald ACH, 2013, J CARDIOVASC ELECTR, V24, P672, DOI 10.1111/jce.12099; Wilkoff BL, 2008, J AM COLL CARDIOL, V52, P541, DOI 10.1016/j.jacc.2008.05.011; GRAY RJ, 1988, ANN STAT, V16, P1141, DOI 10.1214/aos/1176350951; Brignole M, 2013, EUR HEART J, V34, P2281, DOI 10.1093/eurheartj/eht150; Theuns DAMJ, 2008, INT J CARDIOL, V125, P352, DOI 10.1016/j.ijcard.2007.02.041; Wilkoff BL, 2006, J AM COLL CARDIOL, V48, P330, DOI 10.1016/j.jacc.2006.03.037; Mishkin JD, 2009, J AM COLL CARDIOL, V54, P1993, DOI 10.1016/j.jacc.2009.07.039; Fine JP, 1999, J AM STAT ASSOC, V94, P496, DOI 10.2307/2670170; Schron EB, 2002, CIRCULATION, V105, P589, DOI 10.1161/hc0502.103330; Daubert JP, 2008, J AM COLL CARDIOL, V51, P1357, DOI 10.1016/j.jacc.2007.09.073; Auricchio A, 2011, EUROPACE, V13, P1484, DOI 10.1093/europace/eur133; Bardy GH, 2005, NEW ENGL J MED, V352, P225, DOI 10.1056/NEJMoa043399; Freedenberg V, 2011, HEART FAIL CLIN, V7, P59, DOI 10.1016/j.hfc.2010.08.008; Gasparini M, 2013, JAMA-J AM MED ASSOC, V309, P1903, DOI 10.1001/jama.2013.4598; Moss AJ, 2012, NEW ENGL J MED, V367, P2275, DOI 10.1056/NEJMoa1211107; Passman R, 2007, ARCH INTERN MED, V167, P2226, DOI 10.1001/archinte.167.20.2226; Volosin KJ, 2011, J CARDIOVASC ELECTR, V22, P280, DOI 10.1111/j.1540-8167.2010.01918.x; White IR, 2010, STAT MED, V30, P377, DOI DOI 10.1002/SIM.4067; Wollmann CG, 2014, PACE, V37, P1198, DOI 10.1111/pace.12390	19	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1547-5271	1556-3871		HEART RHYTHM	Heart Rhythm	MAY	2015	12	5					926	936		10.1016/j.hrthm.2015.01.017		11	Cardiac & Cardiovascular Systems	Cardiovascular System & Cardiology	CG5LK	WOS:000353333100014		
J	Chong, E; Chang, SL; Hsiao, YW; Singhal, R; Liu, SH; Leha, T; Lin, WY; Hsu, CP; Chen, YC; Chen, YJ; Wu, TJ; Higa, S; Chen, SA				Chong, Eric; Chang, Shih-Lin; Hsiao, Ya-Wen; Singhal, Rahul; Liu, Shuen-Hsin; Leha, Trung; Lin, Wen-Yu; Hsu, Chiao-Po; Chen, Yao-Chang; Chen, Yi-Jen; Wu, Tsu-Juey; Higa, Satoshi; Chen, Shih-Ann			Resveratrol, a red wine antioxidant, reduces atrial fibrillation susceptibility in the failing heart by PI3K/AKT/eNOS signaling pathway activation	HEART RHYTHM			English	Article						Resveratrol; Atrial fibrillation; Ion channel; Signaling path way	DOWN-REGULATION; MESSENGER-RNA; RAT HEARTS; FAILURE; ARRHYTHMOGENESIS; EXPRESSION; ISCHEMIA; PROTECTS	BACKGROUND Resveratrol has shown benefits in reducing ventricular remodeling and arrhythmias. OBJECTIVE This study aimed to assess the therapeutic efficacy of resveratrol in reducing atrial fibrillation (AF) in a heart failure (HE) model and to explore the underlying mechanisms. METHODS HF rabbits were created 4 weeks after undergoing coronary ligation. Group 1 (n = 6) was divided into subgroups of (a) normal rabbits, (b) HF sham rabbits, and (c) HF rabbits treated for 1 week with intraperitoneal injections of resveratrol, (d) resveratrol plus wortmannin, or (e) resveratrol plus diphenyleneiodonium chloride (DPI). All rabbits underwent epicardial catheter stimulation. Collagen content, messenger RNA and protein expression in ion channels, and phosphoinositide 3-kinase (PI3K)/AKT/endothelial nitric oxide synthase (eNOS) signaling pathways were studied in Left atrial appendage (LAA) preparations. To investigate acute drug effects on left atrial electrophysiology, groups 2 a through 2e (n = 6 per group) were subjected to Langendorff perfusion. RESULTS Higher AF inducibility was found in the HF group and groups that were given PI3K and eNOS inhibitors than in the normal and resveratrol-treated groups (P < .001). Histologic analysis of the LAA revealed a decrease in fibrosis in resveratrol-treated groups compared with the HF group (8.95% +/- 1.53% vs 26.62% +/- 2.19%, P < .001). In real-time polymerase chain reaction analysis, ion channels including Kv1.4, Kv1.5, KvLQT1, Kir2.1, Nav1.5, Cav1.2, NCX, SERCA2a, and phospholamban were upregdated by resveratrol. PI3K, AKT, and eNOS messenger RNA and protein expression were upregdated by resveratrol but were inhibited by the coadministration of wortmannin and DPI. CONCLUSION Resveratrol decreases left atrial fibrosis and regulates variation in ion channels to reduce AF through the PI3K/AKT/eNOS signaling pathway.	[Chong, Eric; Chang, Shih-Lin; Singhal, Rahul; Liu, Shuen-Hsin; Leha, Trung; Lin, Wen-Yu; Hsu, Chiao-Po; Wu, Tsu-Juey; Chen, Shih-Ann] Natl Yang Ming Univ Sch Med, Dept Med, Taipei, Taiwan; [Chong, Eric; Chang, Shih-Lin; Hsiao, Ya-Wen; Singhal, Rahul; Liu, Shuen-Hsin; Leha, Trung; Lin, Wen-Yu; Chen, Shih-Ann] Taipei Vet Gen Hosp, Div Cardiol, Taipei, Taiwan; [Hsu, Chiao-Po] Taipei Vet Gen Hosp, Div Cardiovasc Surg, Taipei, Taiwan; [Chen, Yao-Chang] Natl Def Med Ctr, Dept Biomed Engn, Taipei, Taiwan; [Chen, Yi-Jen] Taipei Med Univ, Grad Inst Clin Med, Coll Med, Taipei, Taiwan; [Chen, Yi-Jen] Taipei Med Univ, Wan Fang Hosp, Dept Internal Med, Div Cardiovasc Med, Taipei, Taiwan; [Wu, Tsu-Juey] Taichung Vet Gen Hosp, Div Cardiol, Taichung, Taiwan; [Higa, Satoshi] Makiminato Cent Hosp, Div Cardiovasc Med, Cardiac Electrophysiol & Pacing Lab, Okinawa, Japan	Chen, SA (reprint author), Vet Gen Hosp Taipei, Div Cardiol, 201 Sec 2,Shih Pai Rd, Taipei, Taiwan.	epsachen@ms41.hinet.net			National Science Council of Taiwan [100-2314-B-075-046-MY3, 101-2314-B-010-057-MY3, 101-2314-B-075-056-MY3]; Taipei Veterans General Hospital [V102C-054, V102E7-002, VGLIUST102-G1-1-1]; International Center of Excellence in Advanced Bioengineering - Taiwan National Science Council I-RiCE Program [NSC-99-2911-I-009-101, NSC 99-2314-B-075-032, NSC 99-2314-B-016-034-MY3]; Foundation for the Development of Internal Medicine in Okinawa [26-02-001, 2602-002, 26-02-003]	This study was supported by National Science Council of Taiwan grants 100-2314-B-075-046-MY3, 101-2314-B-010-057-MY3, and 101-2314-B-075-056-MY3; Taipei Veterans General Hospital grants V102C-054, V102E7-002, and VGLIUST102-G1-1-1; International Center of Excellence in Advanced Bioengineering sponsored by the Taiwan National Science Council I-RiCE Program under grant number NSC-99-2911-I-009-101, NSC 99-2314-B-075-032, and NSC 99-2314-B-016-034-MY3; and the Foundation for the Development of Internal Medicine in Okinawa (26-02-001, 2602-002, and 26-02-003). Drs Chong, Chang, and IIsiao contributed equally to this work.	Yeh YH, 2008, CIRC-ARRHYTHMIA ELEC, V1, P93, DOI 10.1161/CIRCEP.107.754788; Shioi T, 2002, MOL CELL BIOL, V22, P2799, DOI 10.1128/MCB.22.8.2799-2809.2002; Carnicer R, 2013, ANTIOXID REDOX SIGN, V18, P1078, DOI 10.1089/ars.2012.4824; Chen LY, 2007, HEART RHYTHM, V4, pS1, DOI 10.1016/j.hrthm.2006.12.018; Nishida K, 2011, CIRCULATION, V123, P137, DOI 10.1161/CIRCULATIONAHA.110.972778; Wu Y, 2013, ANTI-CANCER AGENT ME, V13, P1032; Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655; Kaab S, 1998, CIRCULATION, V98, P1383; Li DS, 2000, CIRCULATION, V101, P2631; Dobrev D, 2010, LANCET, V375, P1212, DOI 10.1016/S0140-6736(10)60096-7; WANG Q, 1995, CELL, V80, P805, DOI 10.1016/0092-8674(95)90359-3; Chen YJ, 2001, CIRCULATION, V104, P2849, DOI 10.1161/hc4801.099736; Lin RCY, 2010, ARTERIOSCL THROM VAS, V30, P724, DOI 10.1161/ATVBAHA.109.201988; Pretorius L, 2009, AM J PATHOL, V175, P998, DOI 10.2353/ajpath.2009.090126; Hung LM, 2000, CARDIOVASC RES, V47, P549, DOI 10.1016/S0008-6363(00)00102-4; Birner C, 2012, N-S ARCH PHARMACOL, V385, P473, DOI 10.1007/s00210-011-0723-x; Cai H, 2002, CIRCULATION, V106, P2854, DOI 10.1161/01.CIR.0000039327.11661.16; Chang SL, 2011, J CARDIOVASC ELECTR, V22, P1378, DOI 10.1111/j.1540-8167.2011.02126.x; Dernek S, 2004, SCAND CARDIOVASC J, V38, P245, DOI 10.1080/14017430410035476; Gao G, 2011, CIRCULATION, V124, P1124, DOI 10.1161/CIRCULATIONAHA.111.044495; Ghigo Alessandra, 2011, Curr Heart Fail Rep, V8, P168, DOI 10.1007/s11897-011-0059-3; Hu ST, 2011, PHYSIOL RES, V60, P27; Hung LM, 2002, BRIT J PHARMACOL, V135, P1627, DOI 10.1038/sj.bjp.0704637; Lu Z, 2012, SCI TRANSL MED, V4, P131; McMullen JR, 2007, P NATL ACAD SCI USA, V104, P612, DOI 10.1073/pnas.0606663104; Nattel S, 2002, NATURE, V415, P219, DOI 10.1038/415219a; Pye MP, 1996, CARDIOVASC RES, V31, P873; Speranza Lorenza, 2013, Front Biosci (Elite Ed), V5, P551; Wen Q, 2012, J CELL MOL MED, V16, P1260, DOI 10.1111/j.1582-4934.2011.01407.x; Wu CYC, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024404; Zhang Q, 2012, CELL BIOL INT, V36, P419, DOI 10.1042/CBI20100900	31	2	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1547-5271	1556-3871		HEART RHYTHM	Heart Rhythm	MAY	2015	12	5					1046	1056		10.1016/j.hrthm.2015.01.044		11	Cardiac & Cardiovascular Systems	Cardiovascular System & Cardiology	CG5LK	WOS:000353333100029		
J	Kaneko, Y; Nakajima, T; Irie, T; Kurabayashi, M				Kaneko, Yoshiaki; Nakajima, Tadashi; Irie, Tadanobu; Kurabayashi, Masahiko			Shortening of retrograde conduction time over slow pathway after atrial stimulation	HEART RHYTHM			English	Editorial Material						Atrioventricular node; Slow pathway; Peeling back; Electro-physiological study	ACCESSORY ATRIOVENTRICULAR PATHWAYS; CONCEALED CONDUCTION		[Kaneko, Yoshiaki; Nakajima, Tadashi; Irie, Tadanobu; Kurabayashi, Masahiko] Gunma Univ Grad Sch Med, Dept Med & Biol Sci, Maebashi, Gumma 3718511, Japan	Kaneko, Y (reprint author), Gunma Univ Grad Sch Med, Dept Med & Biol Sci, 3-39-22 Showa Machi, Maebashi, Gumma 3718511, Japan.	kanekoy@gunma-u.ac.jp					MOE GK, 1968, CIRCULATION, V38, P5; MOORE EN, 1971, CIRC RES, V29, P29; SHENASA M, 1983, CIRCULATION, V67, P651; SUZUKI F, 1989, PACE, V12, P591, DOI 10.1111/j.1540-8159.1989.tb02705.x; Tanaka K, 1997, PACE, V20, P1342, DOI 10.1111/j.1540-8159.1997.tb06789.x	5	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1547-5271	1556-3871		HEART RHYTHM	Heart Rhythm	MAY	2015	12	5					1097	1099		10.1016/j.hrthm.2014.12.032		3	Cardiac & Cardiovascular Systems	Cardiovascular System & Cardiology	CG5LK	WOS:000353333100035		
J	Sugawara, M; Komatsu, Y; Beer, H				Sugawara, M.; Komatsu, Y.; Beer, H.			Three-dimensional freezing of flowing water in a tube cooled by air flow	HEAT AND MASS TRANSFER			English	Article							LIQUID SOLIDIFICATION	The 3-D freezing of flowing water in a copper tube cooled by air flow is investigated by means of a numerical analysis. The air flows normal to the tube axis. Several parameters as inlet water mean velocity w (m) , inlet water temperature T (ia""t) , air flow temperature T (a) and air flow velocity u (a) are selected in the calculations to adapt it to a winter season actually encountered. The numerical results present the development of the ice layer mean thickness and its 3-D morphologies as well as the critical ice layer thickness in the tube choked by the ice layer.	[Sugawara, M.] Akita Univ, Fac Engn & Resource Sci, Mineral Ind Museum, Akita 0108502, Japan; [Komatsu, Y.] Akita Univ, Fac Engn & Resource Sci, Dept Mech Engn, Akita 0108502, Japan; [Beer, H.] Tech Univ Darmstadt, Inst Tech Thermodynam, D-64287 Darmstadt, Germany	Sugawara, M (reprint author), Akita Univ, Fac Engn & Resource Sci, Mineral Ind Museum, Akita 0108502, Japan.	sugawara@ipc.akita-u.ac.jp					Chiba R., 2006, Transactions of the Japan Society of Refrigerating and Air Conditioning Engineers, V23; Chida K., 1983, HEAT TRANSFER JAP RE, V81, P81; Eckert E.R.G., 1952, Transactions of the ASME, V74; Hausen H., 1943, Z VER DEUT INGR BEIH, V4, P91; HIBBERT SE, 1988, INT J HEAT MASS TRAN, V31, P1785, DOI 10.1016/0017-9310(88)90193-7; LEE SL, 1989, CAN J CHEM ENG, V67, P569; Lin Sui, 2003, ASME J HEAT TRANSF, V125, P1123; London AL, 1943, T ASME, P771; McAdams W H, 1954, HEAT TRANSMISSION; Sadeghipour MS, 1984, INT J ENG SCI, V22, P134; Sugawara M, 2010, HEAT MASS TRANSFER, V46, P1307, DOI 10.1007/s00231-010-0651-1; SUGAWARA M, 1983, WARME STOFFUBERTRAG, V17, P187, DOI 10.1007/BF02570529; Sugawara M, 2011, HEAT MASS TRANSFER, V47, P139, DOI 10.1007/s00231-010-0676-5; Sugawara M, 2009, HEAT MASS TRANSFER, V45, P1223, DOI 10.1007/s00231-009-0492-y; Toda S, 1986, 8TH P INT HEAT TRANS, V4, P1745; Weigand B, 1997, HEAT MASS TRANSFER, V32, P341, DOI 10.1007/s002310050131; YEOW YL, 1990, IND ENG CHEM RES, V29, P896, DOI 10.1021/ie00101a027; ZERKLE RD, 1968, J HEAT TRANSF, V90, P183	18	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0947-7411	1432-1181		HEAT MASS TRANSFER	Heat Mass Transf.	MAY	2015	51	5					703	711		10.1007/s00231-014-1444-8		9	Thermodynamics; Mechanics	Thermodynamics; Mechanics	CG3YG	WOS:000353215200010		
J	Arai, Y; Yamashita, K; Mizugishi, K; Nishikori, M; Hishizawa, M; Kondo, T; Kitano, T; Kawabata, H; Kadowaki, N; Takaori-Kondo, A				Arai, Yasuyuki; Yamashita, Kouhei; Mizugishi, Kiyomi; Nishikori, Momoko; Hishizawa, Masakatsu; Kondo, Tadakazu; Kitano, Toshiyuki; Kawabata, Hiroshi; Kadowaki, Norimitsu; Takaori-Kondo, Akifumi			Risk factors for late-onset neutropenia after rituximab treatment of B-cell lymphoma	Hematology			English	Article						Non-Hodgkin lymphoma; CD20; Neutrophil; Adverse effect; Infection	NON-HODGKINS-LYMPHOMA; POSSIBLE MECHANISMS; BONE-MARROW; TRANSPLANTATION; THERAPY; DEPLETION; CHEMOTHERAPY; POLYMORPHISM; SERIES	Objectives: Late-onset neutropenia after rituximab (RTX) therapy (R-LON) has been widely reported, but clinical studies on a large number of cases are limited. In this study, we aimed to investigate the incidence and risk factors of R-LON. Patients and methods: In this study, we retrospectively analyzed data of 213 enrolled B-cell lymphoma patients (male 114; female 99) treated with RTX at a single institution. R-LON was defined as otherwise unexplained grade III-IV neutropenia after RTX. The median age of the patients was 62 years, and 129 of them were initially diagnosed at advanced stages (stage III-IV). Results: R-LON occurred in 19 patients within a median of 121 (range, 49-474) days after the last RTX administration. The 1-year cumulative incidence was 9.0%. On univariate analysis, older age (>60 years), advanced stage, and purine analog or methotrexate administration were significant or borderline significant risk factors for R-LON, whereas sex, disease type, bone marrow invasion, combination with cytotoxic chemotherapeutic drugs, intensified therapy (compared with R-CHOP), prior autologous transplantation, and repeated RTX administration were not. On multivariate analysis, older age (hazard ratio (HR), 2.95) and advanced stage (HR, 3.56) were significant risk factors. Treatment with granulocyte colony-stimulating factor was feasible in grade IV R-LON patients with high risk of infection. Discussion and conclusion: Careful follow-up is therefore necessary after B-cell lymphoma treatment, especially in high-risk patients with advanced disease or of older age.	[Arai, Yasuyuki; Yamashita, Kouhei; Mizugishi, Kiyomi; Nishikori, Momoko; Hishizawa, Masakatsu; Kondo, Tadakazu; Kitano, Toshiyuki; Kawabata, Hiroshi; Kadowaki, Norimitsu; Takaori-Kondo, Akifumi] Kyoto Univ, Dept Hematol & Oncol, Grad Sch Med, Kyoto 6068507, Japan	Yamashita, K (reprint author), Kyoto Univ, Dept Hematol & Oncol, Grad Sch Med, Sakyo Ku, 54 Shogoin Kawahara Cho, Kyoto 6068507, Japan.	kouhei@kuhp.kyoto-u.ac.jp					Geiger H, 2009, TRENDS IMMUNOL, V30, P360, DOI 10.1016/j.it.2009.03.010; Nitta E, 2007, ANN ONCOL, V18, P364, DOI 10.1093/annonc/mdl393; Martin C, 2003, IMMUNITY, V19, P583, DOI 10.1016/S1074-7613(03)00263-2; Metcalf D, 2010, NAT REV CANCER, V10, P425, DOI 10.1038/nrc2843; Weng WK, 2010, J CLIN ONCOL, V28, P279, DOI 10.1200/JCO.2009.25.0274; Kewalramani T, 2004, BLOOD, V103, P3684, DOI 10.1182/blood-2003-11-3911; Tesfa D, 2011, ARTHRITIS RHEUM-US, V63, P2209, DOI 10.1002/art.30427; Tesfa D, 2011, EXPERT REV HEMATOL, V4, P619, DOI 10.1586/EHM.11.62; Wolach O, 2012, CURR OPIN HEMATOL, V19, P32, DOI 10.1097/MOH.0b013e32834da987; Tokoyoda K, 2004, IMMUNITY, V20, P707, DOI 10.1016/j.immuni.2004.05.001; Gregersen JW, 2012, NAT REV NEPHROL, V8, P505, DOI 10.1038/nrneph.2012.141; Pels H, 2003, J CLIN ONCOL, V21, P4489, DOI 10.1200/JCO.2003.04.056; Wolach O, 2010, MEDICINE, V89, P308, DOI 10.1097/MD.0b013e3181f2caef; Dunleavy K, 2005, BLOOD, V106, P795, DOI 10.1182/blood-2004-08-3198; De La Torre I, 2012, RHEUMATOLOGY, V51, P833, DOI 10.1093/rheumatology/ker417; Ram R, 2009, LEUKEMIA LYMPHOMA, V50, P1083, DOI 10.1080/10428190902934944; Fehr T, 2012, CURR OPIN ORGAN TRAN, V17, P376, DOI 10.1097/MOT.0b013e328355f013; Cairoli R, 2004, HAEMATOLOGICA, V89, P361; Cattaneo C, 2006, LEUKEMIA LYMPHOMA, V47, P1013, DOI 10.1080/10428190500473113; Hincks I, 2011, BRIT J HAEMATOL, V153, P411, DOI 10.1111/j.1365-2141.2010.08563.x; Hirayama Y, 2009, INTERNAL MED, V48, P57, DOI 10.2169/internalmedicine.48.1368; Johnson P, 2003, SEMIN ONCOL, V30, P3, DOI 10.1053/sonc.2003.50025; Keane C, 2012, INTERN MED J, V42, P1113, DOI 10.1111/j.1445-5994.2011.02587.x; Lemieux B, 2004, BONE MARROW TRANSPL, V33, P921, DOI 10.1038/sj.bmt.1704467; Li SC, 2010, AM J HEMATOL, V85, P810, DOI 10.1002/ajh.21818; Molina A, 2008, ANNU REV MED, V59, P237, DOI 10.1146/annurev.med.59.060906.220345; Okamoto M, 1994, Rinsho Ketsueki, V35, P635; Tesfa D, 2008, MED ONCOL, V25, P374, DOI 10.1007/s12032-008-9049-z; Tesfa D, 2009, AM J HEMATOL, V84, P428, DOI 10.1002/ajh.21433	29	1	1	MANEY PUBLISHING	LEEDS	STE 1C, JOSEPHS WELL, HANOVER WALK, LEEDS LS3 1AB, W YORKS, ENGLAND	1024-5332	1607-8454		HEMATOLOGY	Hematology	MAY	2015	20	4					196	202		10.1179/1607845414Y.0000000188		7	Hematology	Hematology	CG6OV	WOS:000353422400003		
J	Ishibashi, N; Maebayashi, T; Aizawa, T; Sakaguchi, M; Abe, O; Saito, T; Tanaka, Y				Ishibashi, Naoya; Maebayashi, Toshiya; Aizawa, Takuya; Sakaguchi, Masakuni; Abe, Osamu; Saito, Tsutomu; Tanaka, Yoshiaki			Myelosuppression toxicity of palliative splenic irradiation in myelofibrosis and malignant lymphoma	Hematology			English	Article						Splenic irradiation; Myelosuppression; Toxicity; Myelofibrosis; Malignant lymphoma	MYELOID METAPLASIA; IDIOPATHIC MYELOFIBROSIS; RADIOTHERAPY; MANAGEMENT; DISORDERS; LEUKEMIA; SPLENECTOMY; HYDROXYUREA; EFFICACY	Objectives: Distinctive splenomegaly resulting from extramedullary hematopoiesis and infiltration of neoplastic cells is observed in some patients with myelofibrosis (MF) or malignant lymphoma. Palliative splenic irradiation is known to be effective for such patients and is widely performed. However, little is known about the biological mechanism of palliative splenic irradiation. Various reports have focused on irradiation doses, in terms of efficacy and safety. We examined the toxicity of myelosuppression and the timing of the platelet, white blood cell, and red blood cell count nadirs within 3 months after the start of irradiation in a total of eight patients with MF or malignant lymphoma, all of whom underwent palliative splenic irradiation at our hospital between 2004 and 2013. Methods: Five patients with idiopathic MF and three patients with non-Hodgkin's lymphoma (NHL) treated with splenic irradiation between 2004 and 2013. Of the three patients with NHL, two had diffuse large B-cell lymphoma and one had mantle cell lymphoma. There were four male and four female patients, with median age of 61 years (range, 51-73). Patients with MF received irradiation at 20-100 cGy per fraction dose; four patients received irradiation five times a week and one patient received irradiation three times a week. In three of these patients, the irradiation dose was gradually increased while observing for hematotoxicity. Patients with NHL received irradiation at a fraction dose of 150-200 cGy, and all received irradiation five times a week. Irradiation was terminated when we judged symptoms to be alleviated, splenomegaly reduced, or efficacy to be poor. With regard to the total irradiation dose, 175, 320, 400, 600, and 640 cGy were given to one MF patient each, and 1050 and 3000 cGy were given to one and two NHL patients, respectively. Results: Symptoms diminished or disappeared in five of the six symptomatic patients (83%). A reduction in the size of the spleen was confirmed in five of six patients (83%) with splenomegaly. For MF, the platelet count nadir was observed at week 3 in two patients, week 5 in two, and week 6 in one patient. For NHL, it was observed at week 1 in one patient, week 4 in one, and week 9 in one patient. For MF, the white blood cell count nadir was observed in at week 2 in one patient, week 3 in two, and week 5 in two patients. For NHL, it was observed at week 1 in one patient and week 4 in two patients. For MF, the red blood cell count nadir was observed at week 1 in two patients, week 3 in one, week 7 in one, and week 8 in one patient. For NHL patients, it was observed at week 1 in one patient, week 4 in one, and week 9 in one patient. Discussion: There was a trend for the nadir to be steeper in patients with MF than in those with NHL. With regard to the total dose, symptoms diminished at the minimum dose of 175 cGy in MF patients, whereas the maximum dose of 3000 cGy was not effective in NHL patients. These observations suggest that a splenic lesion in NHL patients may be the primary site of neoplastic cell infiltration and that extramedullary hematopoiesis may not necessarily occur in the spleen. Conclusion: Although palliative irradiation of splenic lesions in patients with MF or NHL is safe and effective, optimal irradiation doses may differ for MF and NHL. More cases need to be accumulated to elucidate these differences.	[Ishibashi, Naoya; Maebayashi, Toshiya; Aizawa, Takuya; Sakaguchi, Masakuni; Abe, Osamu] Nihon Univ, Sch Med, Dept Radiol, Tokyo 1738610, Japan; [Saito, Tsutomu] Sonoda Med Corp, Radiol Clin, Tokyo, Japan; [Tanaka, Yoshiaki] Kawasaki Saiwai Hosp, Dept Radiat Oncol, Kawasaki, Kanagawa, Japan	Ishibashi, N (reprint author), Nihon Univ, Sch Med, Dept Radiol, Itabashi Ku, 30-1 Oyaguchi Kami Cho, Tokyo 1738610, Japan.	ishibashi.naoya@nihon-u.ac.jp					Weinmann M, 2001, RADIOTHER ONCOL, V58, P235, DOI 10.1016/S0167-8140(00)00316-9; Santos FPS, 2014, LEUKEMIA LYMPHOMA, V55, P121, DOI 10.3109/10428194.2013.794269; James C, 2005, NATURE, V434, P1144, DOI 10.1038/nature03546; WEINSTEIN IM, 1991, BLOOD REV, V5, P98, DOI 10.1016/0268-960X(91)90041-A; Kriz J, 2011, STRAHLENTHER ONKOL, V187, P221, DOI 10.1007/s00066-011-2252-4; PARMENTIER C, 1977, INT J RADIAT ONCOL, V2, P1075; Lavrenkov K, 2012, LEUKEMIA LYMPHOMA, V53, P430, DOI 10.3109/10428194.2011.614708; Ito T, 2012, TOHOKU J EXP MED, V228, P295, DOI 10.1620/tjem.228.295; WAGNER H, 1986, CANCER, V58, P1204, DOI 10.1002/1097-0142(19860915)58:6<1204::AID-CNCR2820580605>3.0.CO;2-G; Franco V, 2003, BLOOD, V101, P2464, DOI 10.1182/blood-2002-07-2216; Elliott MA, 1998, BRIT J HAEMATOL, V103, P505, DOI 10.1046/j.1365-2141.1998.00998.x; Mesa RA, 2006, CANCER, V107, P361, DOI 10.1002/cncr.22021; Pardanani AD, 2006, BLOOD, V108, P3472, DOI 10.1182/blood-2006-04-018879; Bouabdallah R, 2000, LEUKEMIA RES, V24, P491, DOI 10.1016/S0145-2126(00)00018-7; BYHARDT RW, 1975, CANCER, V35, P1621, DOI 10.1002/1097-0142(197506)35:6<1621::AID-CNCR2820350622>3.0.CO;2-U; Elliott MA, 1999, BLOOD REV, V13, P163, DOI 10.1054/blre.1999.0110; LOFVENBERG E, 1990, EUR J HAEMATOL, V44, P33; McFarland JT, 2003, AM J CLIN ONCOL-CANC, V26, P178, DOI 10.1097/00000421-200304000-00016; Pardanani A, 2010, AM J HEMATOL, V85, P715, DOI 10.1002/ajh.21799	19	0	0	MANEY PUBLISHING	LEEDS	STE 1C, JOSEPHS WELL, HANOVER WALK, LEEDS LS3 1AB, W YORKS, ENGLAND	1024-5332	1607-8454		HEMATOLOGY	Hematology	MAY	2015	20	4					203	207		10.1179/1607845414Y.0000000192		5	Hematology	Hematology	CG6OV	WOS:000353422400004		
J	Chayama, K; Notsumata, K; Kurosaki, M; Sato, K; Rodrigues, L; Setze, C; Badri, P; Pilot-Matias, T; Vilchez, RA; Kumada, H				Chayama, Kazuaki; Notsumata, Kazuo; Kurosaki, Masayuki; Sato, Ken; Rodrigues, Lino, Jr.; Setze, Carolyn; Badri, Prajakta; Pilot-Matias, Tami; Vilchez, Regis A.; Kumada, Hiromitsu			Randomized Trial of Interferon- and Ribavirin-Free Ombitasvir/Paritaprevir/Ritonavir in Treatment-Experienced Hepatitis C Virus-Infected Patients	HEPATOLOGY			English	Article							GENOTYPE 1 INFECTION; HCV; DASABUVIR; ABT-450/R-OMBITASVIR; JAPAN; TELAPREVIR; SOFOSBUVIR; EPIDEMIOLOGY; RETREATMENT; BOCEPREVIR	Approximately 2 million Japanese individuals are infected with hepatitis C virus and are at risk for cirrhosis, end-stage liver disease, and hepatocellular carcinoma. Patients in whom interferon (IFN)/ribavirin (RBV) therapy has failed remain at risk as effective therapeutic options are limited. This phase 2, randomized, open-label study evaluated an IFN- and RBV-free regimen of once-daily ombitasvir (ABT-267), an NS5A inhibitor, plus paritaprevir (ABT-450), an NS3/4A protease inhibitor dosed with ritonavir (paritaprevir/ritonavir), in pegylated IFN/RBV treatment-experienced Japanese patients with hepatitis C virus subtype 1b or genotype 2 infection. Patients without cirrhosis (aged 18-75 years) with subtype 1b infection received ombitasvir 25 mg plus paritaprevir/ritonavir 100/100 mg or 150/100 mg for 12 or 24 weeks; patients with genotype 2 infection received ombitasvir 25 mg plus paritaprevir/ritonavir 100/100 mg or 150/100 mg for 12 weeks. Sustained virologic response (SVR) at posttreatment week 24 (SVR24) was the primary endpoint. Adverse events were collected throughout the study. One hundred ten patients received 1 dose of study medication. In the subtype 1b cohort, SVR24 rates were high (88.9%-100%) regardless of paritaprevir dose or treatment duration. In the genotype 2 cohort, SVR24 rates were 57.9% and 72.2% with 100 mg and 150 mg of paritaprevir, respectively. The SVR24 rate was higher in patients with subtype 2a (90%) than 2b (27%). Concordance between SVR12 and SVR24 was 100%. The most common adverse events overall were nasopharyngitis (29%) and headache (14%). Conclusion: In this difficult-to-treat population of patients in whom prior pegylated IFN/RBV had failed, ombitasvir/paritaprevir/ritonavir demonstrated potent antiviral activity with a favorable safety profile among Japanese patients with hepatitis C virus genotype 1b or 2a infection. (Hepatology 2015;61:1523-1532)	[Chayama, Kazuaki] Hiroshima Univ, Dept Gastroenterol & Metab, Hiroshima 7348551, Japan; [Notsumata, Kazuo] Fukui Ken Saiseikai Hosp, Dept Internal Med, Fukui, Japan; [Kurosaki, Masayuki] Musashino Red Cross Hosp, Dept Gastroenterol & Hepatol, Musashino, Tokyo, Japan; [Sato, Ken] Gunma Univ, Grad Sch Med, Dept Med & Mol Sci, Maebashi, Gumma 371, Japan; [Rodrigues, Lino, Jr.; Setze, Carolyn; Badri, Prajakta; Pilot-Matias, Tami; Vilchez, Regis A.] AbbVie Inc, N Chicago, IL USA; [Kumada, Hiromitsu] Toranomon Gen Hosp, Dept Hepatol, Tokyo, Japan	Chayama, K (reprint author), Hiroshima Univ, Inst Biomed & Hlth Sci, Dept Gastroenterol & Metab, Minami Ku, 1-2-3 Kasumi, Hiroshima 7348551, Japan.	chayama@hiroshima-u.ac.jp			AbbVie	We acknowledge Travis Yanke, Melissa Cook, Christine Collins, Rajeev M. Menon, Gretja Schnell, Rakesh Tripathi, Jill Beyer, Thomas Reisch, and Takuma Matsuda at AbbVie for assistance provided in the preparation and execution of the study. Editorial and medical writing support was provided by Jillian Gee, Ph.D., C.M.P.P., at Complete Publication Solutions, LLC; this study was funded by AbbVie.	El-Serag HB, 2012, GASTROENTEROLOGY, V142, P1264, DOI 10.1053/j.gastro.2011.12.061; Afdhal N, 2014, NEW ENGL J MED, V370, P1483, DOI 10.1056/NEJMoa1316366; Akuta N, 2012, J MED VIROL, V84, P1593, DOI 10.1002/jmv.23368; Poordad F, 2011, NEW ENGL J MED, V364, P1195, DOI 10.1056/NEJMoa1010494; Hayashi N, 2014, J HEPATOL, V61, P219, DOI 10.1016/j.jhep.2014.04.004; Ferenci P, 2014, NEW ENGL J MED, V370, P1983, DOI 10.1056/NEJMoa1402338; Jacobson IM, 2013, NEW ENGL J MED, V368, P1867, DOI 10.1056/NEJMoa1214854; Chung H, 2010, INTERVIROLOGY, V53, P39, DOI 10.1159/000252782; Kawaoka T, 2011, J HEPATOL, V54, P408, DOI 10.1016/j.jhep.2010.07.032; Dore GJ, 2014, J VIRAL HEPATITIS, V21, P1, DOI 10.1111/jvh.12253; Zeuzem S, 2011, NEW ENGL J MED, V364, P2417, DOI 10.1056/NEJMoa1013086; Manns M, 2014, LANCET, V384, P1597, DOI 10.1016/S0140-6736(14)61059-X; Jacobson IM, 2011, NEW ENGL J MED, V364, P2405, DOI 10.1056/NEJMoa1012912; Koletzki D, 2010, CLIN CHEM LAB MED, V48, P1095, DOI 10.1515/CCLM.2010.236; Kumada H, 2012, J HEPATOL, V56, P78, DOI 10.1016/j.jhep.2011.07.016; Bacon BR, 2011, NEW ENGL J MED, V364, P1207, DOI 10.1056/NEJMoa1009482; Andreone P, 2014, GASTROENTEROLOGY, V147, P359, DOI 10.1053/j.gastro.2014.04.045; Feld JJ, 2014, NEW ENGL J MED, V370, P1594, DOI 10.1056/NEJMoa1315722; Hayashi N, 2014, J GASTROENTEROL, V49, P138, DOI 10.1007/s00535-013-0875-1; Kowdley KV, 2014, NEW ENGL J MED, V370, P222, DOI 10.1056/NEJMoa1306227; Krishnan P, 2015, ANTIMICROB AGENTS CH, V59, P979, DOI 10.1128/AAC.04226-14; Lawitz E, 2013, HEPATOLOGY, V58, p244A; Lawitz E, 2015, J INFECTION, V70, P197, DOI 10.1016/j.jinf.2014.09.008; Menon RM, 2009, GLOBAL ANTIVIRAL J, V5, P53; Moriya T, 1999, INTERVIROLOGY, V42, P153, DOI 10.1159/000024974; Pilot-Matias T, 2015, ANTIMICROB AGENTS CH, V59, P988, DOI 10.1128/AAC.04227-14; Poordad F, 2014, NEW ENGL J MED, V370, P1973, DOI 10.1056/NEJMoa1402869; Sakamoto N, 2011, J MED VIROL, V83, P871, DOI 10.1002/jmv.22038; Wu S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073615; Zeuzem S, 2014, NEW ENGL J MED, V370, P1993, DOI 10.1056/NEJMoa1316145; Zeuzem S, 2014, NEW ENGL J MED, V370, P1604, DOI 10.1056/NEJMoa1401561	31	5	5	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0270-9139	1527-3350		HEPATOLOGY	Hepatology	MAY	2015	61	5					1523	1532		10.1002/hep.27705		10	Gastroenterology & Hepatology	Gastroenterology & Hepatology	CG4DR	WOS:000353233500013		
J	Hatano, R; Akiyama, K; Tamura, A; Hosogi, S; Marunaka, Y; Caplan, MJ; Ueno, Y; Tsukita, S; Asano, S				Hatano, Ryo; Akiyama, Kaori; Tamura, Atsushi; Hosogi, Shigekuni; Marunaka, Yoshinori; Caplan, Michael J.; Ueno, Yoshiyuki; Tsukita, Sachiko; Asano, Shinji			Knockdown of Ezrin Causes Intrahepatic Cholestasis by the Dysregulation of Bile Fluidity in the Bile Duct Epithelium in Mice	HEPATOLOGY			English	Article							PRIMARY SCLEROSING CHOLANGITIS; PRIMARY BILIARY-CIRRHOSIS; CYSTIC-FIBROSIS; CHOLANGIOCYTES; CYTOSKELETAL; TRAFFICKING; PROTEINS; RADIXIN; MOESIN; CFTR	Cholangiopathies share common features, including bile duct proliferation, periportal fibrosis, and intrahepatic cholestasis. Damage of biliary epithelium by autoimunne disorder, virus infection, toxic compounds, and developmental abnormalities causes severe progressive hepatic disorders responsible for high mortality. However, the etiologies of these cholestatic diseases remain unclear because useful models to study the pathogenic mechanisms are not available. In the present study, we have found that ezrin knockdown (Vil2(kd/kd)) mice develop severe intrahepatic cholestasis characterized by extensive bile duct proliferation, periductular fibrosis, and intrahepatic bile acid accumulation without developmental defects of bile duct morphology and infiltration of inflammatory cells. Ezrin is a membrane cytoskeletal cross-linker protein, which is known to interact with transporters, scaffold proteins, and actin cytoskeleton at the plasma membrane. We found that the normal apical membrane localizations of several transport proteins including cystic fibrosis transmembrane conductance regulator (CFTR), anion exchanger 2 (AE-2), aquaporin 1 (AQP1), and Na+/H+ exchanger regulatory factor were disturbed in bile ducts of Vil2(kd/kd) mice. Stable expression of a dominant negative form of ezrin in immortalized mouse cholangiocytes also led to the reduction of the surface expression of CFTR, AE-2, and AQP1. Reduced surface expression of these transport proteins was accompanied by reduced functional expression, as evidenced by the fact these cells exhibited decreased CFTR-mediated Cl- efflux activity. Furthermore, bile flow and biliary HCO3- concentration were also significantly reduced in Vil2(kd/kd) mice. Conclusion: Dysfunction of ezrin mimics important aspects of the pathological mechanisms responsible for cholangiopathies. The Vil2(kd/kd) mouse may be a useful model to exploit in the development and testing of potential therapies for cholangiopathies. (Hepatology 2015;61:1660-1671)	[Hatano, Ryo; Akiyama, Kaori; Asano, Shinji] Ritsumeikan Univ, Dept Mol Physiol, Coll Pharmaceut Sci, Kusatsu, Shiga 5258577, Japan; [Tamura, Atsushi; Tsukita, Sachiko] Osaka Univ, Grad Sch Frontier Biosci, Biol Sci Lab, Osaka, Japan; [Hosogi, Shigekuni; Marunaka, Yoshinori] Osaka Univ, Grad Sch Med, Osaka, Japan; [Hosogi, Shigekuni; Marunaka, Yoshinori] Kyoto Prefectural Univ Med, Dept Mol Cell Physiol & Bioion, Kyoto, Japan; [Caplan, Michael J.] Yale Univ, Sch Med, Dept Cellular & Mol Physiol, New Haven, CT 06510 USA; [Ueno, Yoshiyuki] Yamagata Univ, Sch Med, Dept Gastroenterol, Yamagata 99023, Japan	Hatano, R (reprint author), Ritsumeikan Univ, Dept Mol Physiol, Coll Pharmaceut Sci, 1-1-1 Noji Higashi, Kusatsu, Shiga 5258577, Japan.	hatanori@fc.ritsumei.ac.jp					Esteller A, 2008, WORLD J GASTROENTERO, V14, P5641, DOI 10.3748/wjg.14.5641; Hatano R, 2013, KIDNEY INT, V83, P41, DOI 10.1038/ki.2012.308; Boonstra K, 2012, J HEPATOL, V56, P1181, DOI 10.1016/j.jhep.2011.10.025; Guggino WB, 2006, NAT REV MOL CELL BIO, V7, P426, DOI 10.1038/nrm1949; Strazzabosco M, 2000, J GASTROEN HEPATOL, V15, P244, DOI 10.1046/j.1440-1746.2000.02091.x; Karlsen TH, 2013, J HEPATOL, V59, P571, DOI 10.1016/j.jhep.2013.03.015; Ramel D, 2013, NAT CELL BIOL, V15, P317, DOI 10.1038/ncb2681; Tietz PS, 2003, J BIOL CHEM, V278, P20413, DOI 10.1074/jbc.M302108200; Herrmann U, 2010, BEST PRACT RES CL GA, V24, P585, DOI 10.1016/j.bpg.2010.08.003; Tamura A, 2005, J CELL BIOL, V169, P21, DOI 10.1083/jcb.200410083; Banales JM, 2006, WORLD J GASTROENTERO, V12, P3496; Dransfield DT, 1997, EMBO J, V16, P35, DOI 10.1093/emboj/16.1.35; Okayama T, 2008, BBA-MOL BASIS DIS, V1782, P542, DOI 10.1016/j.bbadis.2008.06.006; Naren AP, 2003, P NATL ACAD SCI USA, V100, P342, DOI 10.1073/pnas.0135434100; Kikuchi S, 2002, NAT GENET, V31, P320, DOI 10.1038/ng905; Salas JT, 2008, GASTROENTEROLOGY, V134, P1482, DOI 10.1053/j.gastro.2008.02.020; SATO N, 1992, J CELL SCI, V103, P131; Frizzell RA, 2012, CSH PERSPECT MED, V2, DOI 10.1101/cshperspect.a009563; Hayashi H, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055623; Mano Y, 1998, LAB INVEST, V78, P1467; Tietz PS, 2006, BIOL CELL, V98, P43, DOI 10.1042/BC20040089	21	2	2	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0270-9139	1527-3350		HEPATOLOGY	Hepatology	MAY	2015	61	5					1660	1671		10.1002/hep.27565		12	Gastroenterology & Hepatology	Gastroenterology & Hepatology	CG4DR	WOS:000353233500025		
J	Kumada, H; Hayashi, N; Izumi, N; Okanoue, T; Tsubouchi, H; Yatsuhashi, H; Kato, M; Rito, K; Komada, Y; Seto, C; Goto, S				Kumada, Hiromitsu; Hayashi, Norio; Izumi, Namiki; Okanoue, Takeshi; Tsubouchi, Hirohito; Yatsuhashi, Hiroshi; Kato, Mai; Rito, Ki; Komada, Yuji; Seto, Chiharu; Goto, Shoichiro			Simeprevir (TMC435) once daily with peginterferon-alpha-2b and ribavirin in patients with genotype 1 hepatitis C virus infection: The CONCERTO-4 study	HEPATOLOGY RESEARCH			English	Article						chronic hepatitis C; direct-acting antiviral; protease inhibitor; simeprevir (TMC435); sustained virologic response	PLUS RIBAVIRIN; PROTEASE INHIBITOR; RANDOMIZED-TRIAL; HCV; TELAPREVIR; JAPAN; ASSOCIATION; BOCEPREVIR; RESISTANCE	AimThe efficacy and safety of simeprevir in combination with peginterferon--2b and ribavirin (PEG IFN--2b/RBV) were investigated in patients infected with hepatitis C virus (HCV) genotype 1 who were treatment-naive or had previously received interferon (IFN)-based therapy. MethodsCONCERTO-4 (NCT01366638) was an open-label, non-comparative, multicenter study of once-daily simeprevir (TMC435) 100mg in combination with PEG IFN--2b/RBV in treatment-naive and -experienced patients (prior relapsers or non-responders to IFN-based therapy) with chronic HCV genotype 1 infection. Twelve-week combination treatment was followed by 24/48-week response-guided PEG IFN--2b/RBV therapy for treatment-naive patients and prior relapsers, and 48-week PEG IFN--2b/RBV therapy for prior non-responders. Patients were followed for 72 weeks after treatment initiation. The proportions of patients with sustained viral response (SVR; undetectable HCV RNA) at treatment end and 12 weeks after the last treatment (SVR12) were among the major efficacy end-points. Safety, including adverse events (AE), was monitored. ResultsOf the 79 patients treated, the proportion achieving SVR12 was highest among treatment-naive patients (91.7%) and prior relapsers (100%) versus 38.5% of prior non-responders. All treatment-naive patients and prior non-responders who achieved SVR12 also achieved SVR at treatment end and 24 weeks after last dose; 96.6% of prior relapsers achieved both end-points. Most AE were of grade 1 or 2 severity. Grade 3 AE occurred in 17 patients, most frequently neutropenia (6.3%). ConclusionSimeprevir combined with PEG IFN--2b/RBV was effective in patients infected with HCV genotype 1, both for initial treatment of naive patients and for retreatment of patients in whom previous IFN-based therapy had failed.	[Kumada, Hiromitsu] Janssen Pharmaceut KK, Toranomon Hosp, Tokyo, Japan; [Izumi, Namiki] Janssen Pharmaceut KK, Musashino Red Cross Hosp, Tokyo, Japan; [Kato, Mai; Rito, Ki; Seto, Chiharu; Goto, Shoichiro] Janssen Pharmaceut KK, Res & Dev, Div Clin Sci, Tokyo, Japan; [Komada, Yuji] Janssen Pharmaceut KK, Japan Clin Operat Div, Res & Dev, Tokyo, Japan; [Hayashi, Norio] Kansai Rosai Hosp, Kobe, Hyogo, Japan; [Okanoue, Takeshi] Saiseikai Suita Hosp, Osaka, Japan; [Tsubouchi, Hirohito] Kagoshima Univ, Med & Dent Hosp, Kagoshima, Japan; [Yatsuhashi, Hiroshi] Natl Hosp Org, Nagasaki Med Ctr, Nagasaki, Japan	Goto, S (reprint author), Janssen Pharmaceut KK, Div Clin Sci, Res & Dev, Chiyoda Ku, 5-2 Nishi Kanda 3 Chome, Tokyo 1010065, Japan.	sgoto2@its.jnj.com			Janssen Pharmaceutical; Janssen Research and Development	THE AUTHORS WOULD like to thank all patients, their families, investigators and their staff at the following 14 study sites. The principal investigators for the study sites are listed below (alphabetical order): Eiji Mita (National Hospital Organization Osaka National Hospital); Harumasa Yoshihara (Osaka Rosai Hospital); Hideki Hagiwara (Kansai Rosai Hospital); Hiromitsu Kumada (Toranomon Hospital); Hiroshi Yatsuhashi (National Hospital Organization Nagasaki Medical Center); Kazuhiko Koike (The University of Tokyo Hospital); Kazuhiro Katayama (Osaka Medical Center for Cancer and Cardiovascular Diseases); Norifumi Kawada (Osaka City University Hospital); Tetsuo Takehara (Osaka University Hospital); Toru Ishikawa (Saiseikai Niigata Daini Hospital); Toshifumi Ito (Osaka Koseinenkin Hospital); Yasuharu Imai (Ikeda Municipal Hospital); Yoshiyasu Karino (Sapporo Kosei General Hospital); Yutaka Sasaki (Kumamoto University Hospital). This study was funded by Janssen Pharmaceutical K. K., and medical writing and editorial support was provided by Jennifer Coward on behalf of Complete Medical Communications and was funded by Janssen Research and Development.	Manns M, 2011, ANTIVIR THER, V16, P1021, DOI 10.3851/IMP1894; Yuen MF, 2009, J GASTROEN HEPATOL, V24, P346, DOI 10.1111/j.1440-1746.2009.05784.x; Rauch A, 2010, GASTROENTEROLOGY, V138, P1338, DOI 10.1053/j.gastro.2009.12.056; Manns MP, 2001, LANCET, V358, P958, DOI 10.1016/S0140-6736(01)06102-5; Lenz O, 2010, ANTIMICROB AGENTS CH, V54, P1878, DOI 10.1128/AAC.01452-09; Kieffer TL, 2010, J ANTIMICROB CHEMOTH, V65, P202, DOI 10.1093/jac/dkp388; Poordad F, 2011, NEW ENGL J MED, V364, P1195, DOI 10.1056/NEJMoa1010494; Fried MW, 2002, NEW ENGL J MED, V347, P975, DOI 10.1056/NEJMoa020047; Izumi N, 2014, J GASTROENTEROL, V49, P941, DOI 10.1007/s00535-014-0949-8; Chung H, 2010, INTERVIROLOGY, V53, P39, DOI 10.1159/000252782; Sherman KE, 2011, NEW ENGL J MED, V365, P1014, DOI 10.1056/NEJMoa1014463; Zeuzem S, 2011, NEW ENGL J MED, V364, P2417, DOI 10.1056/NEJMoa1013086; McHutchison JG, 2009, NEW ENGL J MED, V360, P1827, DOI 10.1056/NEJMoa0806104; Fried MW, 2013, HEPATOLOGY, V58, P1918, DOI 10.1002/hep.26641; Ghany MG, 2011, HEPATOLOGY, V54, P1433, DOI 10.1002/hep.24641; Lavanchy D, 2009, LIVER INT, V29, P74, DOI 10.1111/j.1478-3231.2008.01934.x; Jacobson IM, 2011, NEW ENGL J MED, V364, P2405, DOI 10.1056/NEJMoa1012912; Hayashi N, 2012, J VIRAL HEPATITIS, V19, pE134, DOI 10.1111/j.1365-2893.2011.01528.x; Kumada H, 2012, J HEPATOL, V56, P78, DOI 10.1016/j.jhep.2011.07.016; Hadziyannis SJ, 2004, ANN INTERN MED, V140, P346; Bacon BR, 2011, NEW ENGL J MED, V364, P1207, DOI 10.1056/NEJMoa1009482; Kuboki M, 2007, J GASTROEN HEPATOL, V22, P645, DOI 10.1111/j.1440-1746.2007.04834.x; Reesink HW, 2010, GASTROENTEROLOGY, V138, P913, DOI 10.1053/j.gastro.2009.10.033; Moreno C, 2012, J HEPATOL, V56, P1247, DOI 10.1016/j.jhep.2011.12.033; Editors of the Drafting Committee for Hepatitis Management Guidelines: the Japan Society of Hepatology, 2013, HEPATOL RES, V43, P1; European Assoc Study L, 2011, J HEPATOL, V55, P245, DOI DOI 10.1016/J.JHEP.2011.02.023]; Hayashi N, 2014, J GASTROENTEROL, V49, P138, DOI 10.1007/s00535-013-0875-1; Hayashi N, 2014, J HEPATOL; Iino S, 2004, KANTANSUI, V49, P1099; Kong Y, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0052158; Manns M, 2014, LANCET; Zeuzem S, 2014, GASTROENTEROLOGY, V146, P430, DOI 10.1053/j.gastro.2013.10.058	32	4	5	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1386-6346	1872-034X		HEPATOL RES	Hepatol. Res.	MAY	2015	45	5					501	513		10.1111/hepr.12375		13	Gastroenterology & Hepatology	Gastroenterology & Hepatology	CG6FZ	WOS:000353394200001		
J	Otsuji, K; Takai, K; Nishigaki, Y; Shimizu, S; Hayashi, H; Imai, K; Suzuki, Y; Hanai, T; Ideta, T; Miyazaki, T; Tomita, E; Shimizu, M; Moriwaki, H				Otsuji, Kentarou; Takai, Koji; Nishigaki, Yoichi; Shimizu, Shougo; Hayashi, Hideki; Imai, Kenji; Suzuki, Yusuke; Hanai, Tatsunori; Ideta, Takayasu; Miyazaki, Tsuneyuki; Tomita, Eiichi; Shimizu, Masahito; Moriwaki, Hisataka			Efficacy and safety of cisplatin versus miriplatin in transcatheter arterial chemoembolization and transarterial infusion chemotherapy for hepatocellular carcinoma: A randomized controlled trial	HEPATOLOGY RESEARCH			English	Article						cisplatin; efficacy; hepatocellular carcinoma; miriplatin; outcome; randomized controlled trial; safety	LIPIODOL SUSPENSION; PHASE-II; EPIRUBICIN; THERAPY; CANCER; AGENT	AimTranscatheter arterial chemoembolization (TACE) and transarterial infusion chemotherapy (TAI) are the main therapeutic strategies for treatment of advanced hepatocellular carcinoma (HCC). We conducted a randomized controlled trial to compare the efficacy and safety of cisplatin and miriplatin in TACE and TAI. MethodsPatients with HCC of indication for TACE or TAI were randomly assigned to receive either cisplatin or miriplatin (49 patients per group) between April 2010 and May 2013. The primary end-point was the therapeutic effect (TE) 3months after initial treatment, and the secondary end-point was overall survival. ResultsTE could be evaluated in 26 patients of the cisplatin group and 20 patients of the miriplatin group. In the cisplatin group, 11 (42.3%) and 15 (57.7%) patients were classified as showing TE3+4 and TE1+2, respectively, while in the miriplatin group, each number was nine (45.0%) and 11 (55.0%) (P=0.8551). Furthermore, no significant difference in overall survival was found between two groups for all patients (P=0.905) or those treated only with TAI (10 in the cisplatin group and eight in the miriplatin group; P=0.695). TE3+4 group showed better overall survival than TE1+2 group (P=0.0263). Grade 4 or higher adverse event did not occur in either group. Creatinine levels in the cisplatin group rose 3 days after TACE or TAI (P=0.0397). ConclusionCisplatin and miriplatin had equal efficacy for TACE and TAI, but cisplatin should be avoided for patients with renal dysfunction or inadequate hydration. Good TE improved overall survival.	[Otsuji, Kentarou; Takai, Koji; Imai, Kenji; Hanai, Tatsunori; Ideta, Takayasu; Miyazaki, Tsuneyuki; Shimizu, Masahito; Moriwaki, Hisataka] Gifu Univ, Grad Sch Med, Dept Gastroenterol & Internal Med, Gifu 5011194, Japan; [Nishigaki, Yoichi; Hayashi, Hideki; Suzuki, Yusuke; Tomita, Eiichi] Gifu Municipal Hosp, Gifu, Japan; [Shimizu, Shougo] Gifu Prefectural Gen Med Ctr, Gifu, Japan	Takai, K (reprint author), Gifu Univ, Grad Sch Med, Dept Gastroenterol & Internal Med, 1-1 Yanagido, Gifu 5011194, Japan.	koz@gifu-u.ac.jp					Ando E, 2002, CANCER, V95, P588, DOI 10.1002/cncr.10694; Llovet JM, 2003, HEPATOLOGY, V37, P429, DOI 10.1053/jhep.2003.50047; FALKSON G, 1987, CANCER, V60, P2141, DOI 10.1002/1097-0142(19871101)60:9<2141::AID-CNCR2820600903>3.0.CO;2-4; Llovet JM, 2008, NEW ENGL J MED, V359, P378, DOI 10.1056/NEJMoa0708857; Llovet JM, 2003, LANCET, V362, P1907, DOI 10.1016/S0140-6736(03)14964-1; Ikeda M, 2004, ONCOLOGY-BASEL, V66, P24, DOI 10.1159/000076331; Jemal A, 2008, CA-CANCER J CLIN, V58, P71, DOI 10.3322/CA.2007.0010; SHIBATA J, 1989, CANCER, V64, P1586, DOI 10.1002/1097-0142(19891015)64:8<1586::AID-CNCR2820640805>3.0.CO;2-E; Ueda T, 2013, HEPATOL RES, V43, P1071, DOI 10.1111/hepr.12212; [Anonymous], 2010, HEPATOL RES S1, V40, P2; Marelli L, 2007, CARDIOVASC INTER RAD, V30, P6, DOI 10.1007/s00270-006-0062-3; Kudo M, 2010, HEPATOL RES, V40, P686, DOI 10.1111/j.1872-034X.2010.00674.x; Fujiyamas S, 2003, BRIT J CANCER, V3, P1614; Iwazawa Jin, 2012, Cancer Manag Res, V4, P113, DOI 10.2147/CMAR.S30431; Kasai K, 2010, WORLD J GASTROENTERO, V16, P3437, DOI 10.3748/wjg.v16.i27.3437; Kora S, 2013, CARDIOVASC INTER RAD, V36, P1023, DOI 10.1007/s00270-012-0537-3; MAEDA M, 1986, JPN J CANCER RES, V77, P523; Miyayama S, 2012, JPN J RADIOL, V30, P263, DOI 10.1007/s11604-011-0043-6; Oguro S, 2012, JPN J RADIOL, V30, P735, DOI 10.1007/s11604-012-0116-1; Okabe K, 2011, ANTICANCER RES, V31, P2983; Okusaka T, 2009, J HEPATOL, V51, P1030, DOI 10.1016/j.jhep.2009.09.004; Okusaka T, 2012, INVEST NEW DRUG, V30, P2015, DOI 10.1007/s10637-011-9776-4; Ruggebergs JU, 2007, VACCINE, V1, P5675; Sahara S, 2010, JPN J RADIOL, V28, P362, DOI 10.1007/s11604-010-0436-y; SASAKI Y, 1987, CANCER, V60, P1194, DOI 10.1002/1097-0142(19870915)60:6<1194::AID-CNCR2820600607>3.0.CO;2-T; Seko Y, 2013, HEPATOL RES, V43, P942, DOI 10.1111/hepr.12041; Yamanaka K, 2011, HEPATOL RES, V41, P303, DOI 10.1111/j.1872-034X.2010.00770.x; Yodono H, 2011, ANTI-CANCER DRUG, V22, P277, DOI 10.1097/CAD.0b013e328342231d	28	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1386-6346	1872-034X		HEPATOL RES	Hepatol. Res.	MAY	2015	45	5					514	522		10.1111/hepr.12376		9	Gastroenterology & Hepatology	Gastroenterology & Hepatology	CG6FZ	WOS:000353394200002		
J	Tatsumi, A; Maekawa, S; Sato, M; Komatsu, N; Miura, M; Amemiya, F; Nakayama, Y; Inoue, T; Sakamoto, M; Enomoto, N				Tatsumi, Akihisa; Maekawa, Shinya; Sato, Mitsuaki; Komatsu, Nobutoshi; Miura, Mika; Amemiya, Fumitake; Nakayama, Yasuhiro; Inoue, Taisuke; Sakamoto, Minoru; Enomoto, Nobuyuki			Liver stiffness measurement for risk assessment of hepatocellular carcinoma	HEPATOLOGY RESEARCH			English	Article						FibroScan; hepatocellular carcinoma; liver fibrosis	CHRONIC HEPATITIS-C; CHRONIC VIRAL-HEPATITIS; TRANSIENT ELASTOGRAPHY; INTERFERON THERAPY; DISEASE; FIBROSIS; CIRRHOSIS; JAPAN	AimLiver fibrosis is a risk factor for hepatocellular carcinoma (HCC), but at what fibrotic stage the risk for HCC is increased has been poorly investigated quantitatively. This study aimed to determine the appropriate cut-off value of liver stiffness for HCC concurrence by FibroScan, and its clinical significance in hepatitis B virus (HBV), hepatitis C virus (HCV) and non-B, non-C (NBNC) liver disease. MethodsSubjects comprised 1002 cases (246 with HCC and 756 without HCC) with chronic liver disease (HBV, 104; HCV, 722; and NBNC, 176). ResultsLiver stiffness was significantly greater in all groups with HCC, and the determined cut-off value for HCC concurrence was more than 12.0kPa in those with HCV, more than 8.5kPa in those with HBV and more than 12.0kPa in those with NBNC. Liver stiffness of more than 12.0kPa was an independent risk factor for new HCC development in HCV. For HCV, risk factors for HCC concurrence were old age, male sex, low albumin, low platelets and liver stiffness, while for HBV they were old age, low platelets and liver stiffness, and for NBNC they were old age, elevated -fetoprotein and liver stiffness. ConclusionLiver stiffness cut-off values and their association with HCC concurrence were different depending on the etiology. In HCV, liver stiffness of more than 12.0kPa was an independent risk factor for new HCC development. Collectively, determining the fibrotic cut-off values for HCC concurrence would be important in evaluating HCC risks.	[Tatsumi, Akihisa; Maekawa, Shinya; Sato, Mitsuaki; Komatsu, Nobutoshi; Miura, Mika; Nakayama, Yasuhiro; Inoue, Taisuke; Sakamoto, Minoru; Enomoto, Nobuyuki] Univ Yamanashi, Dept Med 1, Chuo Ku, Yamanashi 4093898, Japan; [Amemiya, Fumitake] Kofu Municipal Hosp, Dept Gastroenterol Med, Kofu, Yamanashi, Japan	Enomoto, N (reprint author), Univ Yamanashi, Dept Med 1, Chuo Ku, 1110 Shimokato, Yamanashi 4093898, Japan.	enomoto@yamanashi.ac.jp			Ministry of Education, Science, Sports and Culture of Japan [23390195, 23791404, 24590964, 24590965]; Ministry of Health, Labour and Welfare of Japan [H23-kanen-001, H23-kanen-004, H23-kanen-006, H24-kanen-002, H24-kanen-004, H25-kanen-006]	This study was supported in part by Grants-in-Aid from the Ministry of Education, Science, Sports and Culture of Japan (23390195, 23791404, 24590964 and 24590965), and in part by Grants-in-Aid from the Ministry of Health, Labour and Welfare of Japan (H23-kanen-001, H23-kanen-004, H23-kanen-006, H24-kanen-002, H24-kanen-004 and H25-kanen-006).	Abenavoli L, 2012, ANN HEPATOL, V11, P172; Wong VWS, 2010, HEPATOLOGY, V51, P454, DOI 10.1002/hep.23312; Arase Y, 2013, HEPATOLOGY, V57, P964, DOI 10.1002/hep.26087; Jemal A, 2011, CA-CANCER J CLIN, V61, P69, DOI 10.3322/caac.20107; Jung KS, 2011, HEPATOLOGY, V53, P885, DOI 10.1002/hep.24121; Lupsor M, 2008, J GASTROINTEST LIVER, V17, P155; Lewis S, 2013, AM J ROENTGENOL, V200, pW610, DOI 10.2214/AJR.12.9151; Asahina Y, 2013, HEPATOLOGY, V58, P1253, DOI 10.1002/hep.26442; Kudo M, 2011, DIGEST DIS, V29, P339, DOI 10.1159/000327577; Sandrin L, 2003, ULTRASOUND MED BIOL, V29, P1705, DOI 10.1016/j.ultrasmedbio.2003.07.001; Reddy SK, 2012, HEPATOLOGY, V55, P1809, DOI 10.1002/hep.25536; Boursier J, 2013, HEPATOLOGY, V57, P1182, DOI 10.1002/hep.25993; Asahina Y, 2010, HEPATOLOGY, V52, P518, DOI 10.1002/hep.23691; El-Serag HB, 2002, HEPATOLOGY, V36, pS74, DOI 10.1053/jhep.2002.36807; Wang HM, 2013, LIVER INT, V33, P756, DOI 10.1111/liv.12118; Masuzaki R, 2009, HEPATOLOGY, V49, P1954, DOI 10.1002/hep.22870; Yoneda M, 2008, DIGEST LIVER DIS, V40, P371, DOI 10.1016/j.dld.2007.10.019; Starley BQ, 2010, HEPATOLOGY, V51, P1820, DOI 10.1002/hep.23594; Castera L, 2011, HEPATOL INT, V5, P625, DOI 10.1007/s12072-010-9240-0; Akima T, 2011, HEPATOL RES, V41, P965, DOI 10.1111/j.1872-034X.2011.00846.x; Yoshida H, 1999, ANN INTERN MED, V131, P174; Ikeda K, 1998, J HEPATOL, V28, P930, DOI 10.1016/S0168-8278(98)80339-5; Masuzaki R, 2008, J CLIN GASTROENTEROL, V42, P839; TAKANO S, 1995, HEPATOLOGY, V21, P650; Cardoso AC, 2011, GUT, V60, P759, DOI 10.1136/gut.2010.220863; Castera L, 2009, HEPATOLOGY, V49, P1793, DOI 10.1002/hep.22981; Chon YE, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044930; de Oliveria Andrade LJ, 2009, J GLOB INFECT DIS, V1, P33, DOI DOI 10.4103/0974-777X.52979; El-Serag HB, 2011, NEW ENGL J MED, V365, P1118, DOI 10.1056/NEJMra1001683; Inoue A, 2000, J Epidemiol, V10, P234; Jung Kyu Sik, 2012, Clin Mol Hepatol, V18, P163, DOI 10.3350/cmh.2012.18.2.163; Kims BK, 2013, WORLD J GASTROENTERO, V19, P1890; Kuos YH, 2010, HEPATOL INT, V4, P700; Masuzaki R, 2008, CAN J GASTROENTEROL, V22, P753	34	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1386-6346	1872-034X		HEPATOL RES	Hepatol. Res.	MAY	2015	45	5					523	532		10.1111/hepr.12377		10	Gastroenterology & Hepatology	Gastroenterology & Hepatology	CG6FZ	WOS:000353394200003		
J	Ishitobi, T; Hyogo, H; Kan, H; Hiramatsu, A; Arihiro, K; Aikata, H; Chayama, K				Ishitobi, Tomokazu; Hyogo, Hideyuki; Kan, Hiromi; Hiramatsu, Akira; Arihiro, Koji; Aikata, Hiroshi; Chayama, Kazuaki			Eicosapentaenoic acid/arachidonic acid ratio as a possible link between non-alcoholic fatty liver disease and cardiovascular disease	HEPATOLOGY RESEARCH			English	Article						cardiovascular disease; eicosapentaenoic acid; arachidonic acid; non-alcoholic fatty liver disease	DIABETES-MELLITUS; FOLLOW-UP; STEATOHEPATITIS; GLUCOSE; THICKNESS; COMMITTEE; TISSUE; CELLS; RISK; MEN	AimThe main causes of mortality from non-alcoholic fatty liver disease (NAFLD) are cardiovascular disease (CVD) and malignancy. Eicosapentaenoic acid (EPA)/arachidonic acid (AA) ratio is known to be associated with CVD. However, a possible link between EPA/AA ratio and NAFLD is not well known. In this study, we investigated EPA/AA ratio in Japanese patients with NAFLD. MethodsTwo hundred and fifty-four patients with biopsy-proven NAFLD were retrospectively enrolled. Serum EPA/AA ratios were examined for each generation (<35, 35-44, 45-54, 55-64, 65 years), and the differences of EPA/AA ratios were evaluated based on steatotic grades and fibrotic stages. ResultsEPA/AA ratio in NAFLD patients was decreased compared to that reported in age-matched healthy controls. EPA/AA ratio, body mass index, total cholesterol, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol and steatotic grades in younger NAFLD patients were significantly worse than those in older NAFLD patients. Fasting glucose, hemoglobin A1c and fibrotic stages in older NAFLD patients were significantly higher than those in younger NAFLD patients. No relation was found between EPA/AA ratio and histological findings. ConclusionEPA/AA ratio was lower in NAFLD, especially in younger NAFLD patients. Considering the high mortality from CVD in NAFLD patients, low EPA/AA ratio in young age may influence the increased prevalence of CVD in their older age. EPA/AA ratio is suggested to be a possible link between NAFLD and CVD, and would become a useful marker for CVD in NAFLD.	[Ishitobi, Tomokazu; Hyogo, Hideyuki; Kan, Hiromi; Hiramatsu, Akira; Aikata, Hiroshi; Chayama, Kazuaki] Hiroshima Univ Hosp, Dept Gastroenterol & Metab, Hiroshima, Japan; [Arihiro, Koji] Hiroshima Univ Hosp, Dept Pathol, Hiroshima, Japan	Hyogo, H (reprint author), Hiroshima Univ, Dept Gastroenterol & Metab, Minami Ku, 1-2-3 Kasumi, Hiroshima 7348551, Japan.	hidehyogo@hiroshima-u.ac.jp					Kleiner DE, 2005, HEPATOLOGY, V41, P1313, DOI 10.1002/hep.20701; Iwamoto K, 2008, J GASTROENTEROL, V43, P298, DOI 10.1007/s00535-007-2152-7; MATTHEWS DR, 1985, DIABETOLOGIA, V28, P412, DOI 10.1007/BF00280883; Yanagisawa N, 2010, J ATHEROSCLER THROMB, V17, P285; Brunt EM, 1999, AM J GASTROENTEROL, V94, P2467, DOI 10.1111/j.1572-0241.1999.01377.x; Seino Y, 2010, J DIABETES INVEST, V1, P212, DOI 10.1111/j.2040-1124.2010.00074.x; Oya J, 2010, EUR J CLIN NUTR, V64, P1179, DOI 10.1038/ejcn.2010.139; Eguchi Y, 2012, J GASTROENTEROL, V47, P586, DOI 10.1007/s00535-012-0533-z; Paradis V, 2001, HEPATOLOGY, V34, P738, DOI 10.1053/jhep.2001.28055; Targher G, 2006, DIABETES CARE, V29, P1325, DOI 10.2337/dc06-0135; James O, 1999, LANCET, V353, P1634; Teli MR, 1995, HEPATOLOGY, V22, P1714, DOI 10.1016/0270-9139(95)90196-5; Toshimitsu K, 2007, NUTRITION, V23, P46, DOI 10.1016/j.nut.2006.09.004; Dam-Larsen S, 2004, GUT, V53, P750, DOI 10.1136/gut.2003.019984; Hashimoto E, 2011, J GASTROENTEROL, V46, P63, DOI 10.1007/s00535-010-0311-8; Hyogo H, 2008, METABOLISM, V57, P1711, DOI 10.1016/j.metabol.2008.07.030; Kimura Y, 2011, J GASTROEN HEPATOL, V26, P517, DOI 10.1111/j.1440-1746.2010.06567.x; Fracanzani AL, 2008, AM J MED, V121, P72, DOI 10.1016/j.amjmed.2007.08.041; Soderberg C, 2010, HEPATOLOGY, V51, P595, DOI 10.1002/hep.23314; Scorletti E, 2011, ENDOCRINE, V40, P332, DOI 10.1007/s12020-011-9530-x; Tanaka N, 2008, J CLIN GASTROENTEROL, V42, P413, DOI 10.1097/MCG.0b013e31815591aa; Targher G, 2010, NEW ENGL J MED, V363, P1341, DOI 10.1056/NEJMra0912063; Jimba S, 2005, DIABETIC MED, V22, P1141, DOI 10.1111/j.1464-5491.2005.01582.x; Corporeaus C, 2006, AM J PHYSIOL-ENDOC M, V290, P78; Hirai K, 2000, Environ Health Prev Med, V5, P60, DOI 10.1007/BF02932005; Hyogos H, 2013, CURR PHARM DESIGN, V20, P2403; Nathan DM, 2009, DIABETES CARE, V32, P1327, DOI 10.2337/dc09-9033; Matteonis CA, 2007, LANCET, V369, P1090; Nakahara T., 2013, J GASTROENTEROL; Neuschwander-Tetri BA, 2003, HEPATOLOGY, V37, P1202, DOI 10.1053/jhep.2003.50193; Patterson E, 2012, J NUTR METAB, V2012, DOI DOI 10.1155/2012/539426; Targher G, 2005, DIABETIC MED, V22, P1354, DOI 10.1111/j.1464-5491.2005.01646.x; The World Medical Association Inc., 2008, ETH PRINC MED RES IN; Yokoyamas M, 2007, LANCET, V370, P220	34	1	1	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1386-6346	1872-034X		HEPATOL RES	Hepatol. Res.	MAY	2015	45	5					533	539		10.1111/hepr.12382		7	Gastroenterology & Hepatology	Gastroenterology & Hepatology	CG6FZ	WOS:000353394200004		
J	Sanuki, N; Takeda, A; Oku, Y; Eriguchi, T; Nishimura, S; Aoki, Y; Kunieda, E				Sanuki, Naoko; Takeda, Atsuya; Oku, Yohei; Eriguchi, Takahisa; Nishimura, Shuichi; Aoki, Yosuke; Kunieda, Etsuo			Influence of liver toxicities on prognosis after stereotactic body radiation therapy for hepatocellular carcinoma	HEPATOLOGY RESEARCH			English	Article						hepatocellular carcinoma; liver cirrhosis; radiation-induced liver disease; stereotactic ablative body radiotherapy	PROTON-BEAM THERAPY; TRANSARTERIAL CHEMOEMBOLIZATION; CONFORMAL RADIOTHERAPY; HEPATIC TOXICITY; RISK-FACTORS; DISEASE; CANCER; PREDICTION; CIRRHOSIS; FAILURE	AimTo better define clinically relevant non-classic radiation-induced liver disease (RILD) following stereotactic body radiotherapy (SBRT) in patients with small hepatocellular carcinoma (HCC). MethodsWe retrospectively evaluated the influence of acute liver toxicities on fatal hepatic failure in HCC patients treated with SBRT. Between April 2006 and February 2012, 194 HCC were treated with SBRT. Among them, patients followed up for more than 6 months were eligible. Laboratory results and Child-Pugh (CP) scores were obtained before treatment and at monthly follow-up visits. Toxicities were evaluated by the Common Terminology Criteria for Adverse Events version 4.0. Possible definitions of RILD were evaluated with respect to fatal hepatic failure within 12 months. ResultsOne hundred and eighty HCC were evaluated with a median follow-up of 28.2 months. Fatal hepatic failure within 12 months occurred in eight patients (4%). On univariate analysis, grade 3 or more elevated transaminases, CP score of 8 or more, and/or grade 3 or more decreased platelet count significantly predicted fatal hepatic failure within 12 months. Combinations of these factors (i.e. having at least one criterion) also predicted fatal hepatic failure within 12 months (16% with criteria vs 1% without criteria). Two-year overall survival rates for patients with and without RILD was 64.9% and 83.8% (P<0.001), respectively. ConclusionWe identified three criteria that affected overall survival in HCC patients treated with SBRT. Further prospective studies are warranted to validate the safety and effect of SBRT for HCC.	[Sanuki, Naoko; Takeda, Atsuya; Oku, Yohei; Eriguchi, Takahisa; Nishimura, Shuichi; Aoki, Yosuke] Ofuna Chuo Hosp, Radiat Oncol Ctr, Kamakura, Kanagawa, Japan; [Sanuki, Naoko; Takeda, Atsuya; Oku, Yohei; Kunieda, Etsuo] Tokai Univ, Dept Radiat Oncol, Isehara, Kanagawa 2591193, Japan	Kunieda, E (reprint author), Tokai Univ, Dept Radiat Oncol, 143 Shimokasuya, Isehara, Kanagawa 2591193, Japan.	kunieda-mi@umin.ac.jp					Takeda A, 2012, BRIT J RADIOL, V85, P636, DOI 10.1259/bjr/71635286; Takeda A, 2008, HEPATOL RES, V38, P60, DOI 10.1111/j.1872-034X.2007.00084.x; Trevisani F, 2001, J CLIN GASTROENTEROL, V32, P383, DOI 10.1097/00004836-200105000-00005; Facciuto ME, 2012, J SURG ONCOL, V105, P692, DOI 10.1002/jso.22104; REED GB, 1966, AM J PATHOL, V48, P597; Guha C, 2011, SEMIN RADIAT ONCOL, V21, P256, DOI 10.1016/j.semradonc.2011.05.003; Andolino DL, 2011, INT J RADIAT ONCOL, V81, pE447, DOI 10.1016/j.ijrobp.2011.04.011; Liang SX, 2011, RADIOTHER ONCOL, V98, P265, DOI 10.1016/j.radonc.2010.10.014; Hsin IF, 2011, J CLIN GASTROENTEROL, V45, P556, DOI 10.1097/MCG.0b013e318210ff17; Son SH, 2010, INT J RADIAT ONCOL, V78, P1073, DOI 10.1016/j.ijrobp.2009.09.009; Cardenes HR, 2010, CLIN TRANSL ONCOL, V12, P218, DOI 10.1007/s12094-010-0492-x; Louis C, 2010, TECHNOL CANCER RES T, V9, P479; Cheng JCH, 2004, INT J RADIAT ONCOL, V60, P1502, DOI 10.1016/j.ijrobp.2004.05.048; Forner A, 2010, SEMIN LIVER DIS, V30, P61, DOI 10.1055/s-0030-1247133; INGOLD JA, 1965, AMER J ROENTGENOL RA, V93, P200; Chiba T, 2005, CLIN CANCER RES, V11, P3799, DOI 10.1158/1078-0432.CCR-04-1350; Liang SX, 2006, INT J RADIAT ONCOL, V65, P426, DOI 10.1016/j.ijrobp.2005.12.031; Kim TH, 2007, INT J RADIAT ONCOL, V67, P225, DOI 10.1016/j.ijrobp.2006.08.015; Dawson LA, 2011, SEMIN RADIAT ONCOL, V21, P241, DOI 10.1016/j.semradonc.2011.05.009; LAWRENCE TS, 1995, INT J RADIAT ONCOL, V31, P1237, DOI 10.1016/0360-3016(94)00418-K; Xu ZY, 2006, INT J RADIAT ONCOL, V65, P189, DOI 10.1016/j.ijrobp.2005.11.034; European Association For The Study Of The Liver; European Organisation For Research And Treatment Of Cancer, 2012, J HEPATOL, V56, P908, DOI DOI 10.1016/J.JHEP.2011.12.001; Katsushima S, 1997, DIGESTION, V58, P189; Kwon JH, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-475; Nakayama H, 2009, CANCER, V115, P5499, DOI 10.1002/cncr.24619; Oku Yohei, 2014, Pract Radiat Oncol, V4, pe7, DOI 10.1016/j.prro.2013.04.001; Pans CC, 2010, INT J RADIAT ONCOL, V76, pS94; Sanukis N, 2014, ACTA ONCOL, V58, P399; The National Cancer Institute, 2010, COMM TERM CRIT ADV E; Tses RV, 2008, J CLIN ONCOL, V26, P657	30	1	1	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1386-6346	1872-034X		HEPATOL RES	Hepatol. Res.	MAY	2015	45	5					540	547		10.1111/hepr.12383		8	Gastroenterology & Hepatology	Gastroenterology & Hepatology	CG6FZ	WOS:000353394200005		
J	Shima, T; Seki, K; Umemura, A; Ogawa, R; Horimoto, R; Oya, H; Sendo, R; Mizuno, M; Okanoue, T				Shima, Toshihide; Seki, Kojiro; Umemura, Atsushi; Ogawa, Rie; Horimoto, Ryuji; Oya, Hirohisa; Sendo, Rei; Mizuno, Masayuki; Okanoue, Takeshi			Influence of lifestyle-related diseases and age on the development and progression of non-alcoholic fatty liver disease	HEPATOLOGY RESEARCH			English	Article						aging; lifestyle-related disease; non-alcoholic fatty liver disease; non-alcoholic steatohepatitis	CLINICAL SCORING SYSTEM; HEPATOCELLULAR-CARCINOMA; FOLLOW-UP; STEATOHEPATITIS; FIBROSIS; JAPAN; RISK; CANCER; ELASTOGRAPHY; ASSOCIATION	AimAlthough non-alcoholic fatty liver disease (NAFLD) is the hepatic manifestation of metabolic syndrome, the clinical association between non-alcoholic steatohepatitis (NASH) and lifestyle-related diseases such as obesity, type 2 diabetes mellitus (DM), hypertension (HT) and dyslipidemia (DL) has not been clarified. We studied the influence of lifestyle-related diseases and age on the development and progression of NAFLD. MethodsWe enrolled 550 patients with biopsy-proven NAFLD (284 men, 266 women; average age, 52 and 62 years, respectively). The effect of lifestyle-related diseases and age (49 vs 50 years) on the frequency of NASH and advanced fibrosis (stage 3) was studied. ResultsPrevalence of obesity, DM, HT and DL in male and female NASH patients was 75%/67%, 53%/54%, 66%/77% and 85/79%, respectively. DM patients had a higher frequency of NASH in the older male NAFLD group and a higher frequency of advanced fibrosis in the older female NASH group. With the increasing number of complicating lifestyle-related diseases, the rate of NASH increased in male NAFLD patients. In both sexes, aging resulted in the development of NASH and progression of liver fibrosis. Multivariate logistic regression analysis revealed that age and DM were significantly associated with the development of NASH in male NAFLD patients and progression of fibrosis in female NASH patients. ConclusionAge is strongly associated with the development and progression of NASH. Type 2 DM may play the most crucial role among lifestyle-related diseases in the development and progression of NASH.	[Shima, Toshihide; Seki, Kojiro; Umemura, Atsushi; Ogawa, Rie; Horimoto, Ryuji; Oya, Hirohisa; Sendo, Rei; Mizuno, Masayuki; Okanoue, Takeshi] Saiseikai Suita Hosp, Dept Gastroenterol & Hepatol, Suita, Osaka 5640013, Japan	Okanoue, T (reprint author), Saiseikai Suita Hosp, Dept Gastroenterol & Hepatol, 1-2 Kawazonocho, Suita, Osaka 5640013, Japan.	okanoue@suita.saiseikai.or.jp			Ministry of Labor and Welfare Japan [H20-Hepatitis general-008, H24-Hepatitis general-006]	THIS STUDY WAS supported by a grant from the Ministry of Labor and Welfare Japan (T. O. H20-Hepatitis general-008, H24-Hepatitis general-006].	Adams LA, 2005, GASTROENTEROLOGY, V129, P113, DOI 10.1053/j.gastro.2005.04.014; Kasuga M, 2013, CANCER SCI, V104, P965, DOI 10.1111/cas.12203; Kamada Y, 2011, AM J PHYSIOL-GASTR L, V301, pG1031, DOI 10.1152/ajpgi.00211.2011; Brunt EM, 1999, AM J GASTROENTEROL, V94, P2467, DOI 10.1111/j.1572-0241.1999.01377.x; Angulo P, 2007, HEPATOLOGY, V45, P846, DOI 10.1002/hep.21496; Speliotes EK, 2010, HEPATOLOGY, V51, P1979, DOI 10.1002/hep.23593; Ikai I, 2010, HEPATOL RES, V40, P1043, DOI 10.1111/j.1872-034X.2010.00731.x; Eguchi Y, 2012, J GASTROENTEROL, V47, P586, DOI 10.1007/s00535-012-0533-z; Sumida Y, 2011, J GASTROENTEROL, V46, P257, DOI 10.1007/s00535-010-0305-6; Tilg H, 2010, HEPATOLOGY, V52, P1836, DOI 10.1002/hep.24001; Chalasani N, 2012, HEPATOLOGY, V55, P2005, DOI 10.1002/hep.25762; Matteoni CA, 1999, GASTROENTEROLOGY, V116, P1413, DOI 10.1016/S0016-5085(99)70506-8; Hotta Nigishi, 2007, Journal of the Japan Diabetes Society, V50, P47; Welzel TM, 2011, HEPATOLOGY, V54, P463, DOI 10.1002/hep.24397; Loomba R, 2012, HEPATOLOGY, V56, P943, DOI 10.1002/hep.25772; Chen J, 2011, RADIOLOGY, V259, P749, DOI 10.1148/radiol.11101942; Harrison SA, 2008, GUT, V57, P1441, DOI 10.1136/gut.2007.146019; Fontana L, 2013, HEPATOLOGY, V57, P995, DOI 10.1002/hep.26099; Kawamura Y, 2012, AM J GASTROENTEROL, V107, P253, DOI 10.1038/ajg.2011.327; Yang JD, 2014, HEPATOLOGY, V59, P1406, DOI 10.1002/hep.26761; Ochi H, 2012, HEPATOLOGY, V56, P1271, DOI 10.1002/hep.25756; Fallo F, 2008, J HYPERTENS, V26, P2191, DOI 10.1097/HJH.0b013e32830dfe4b; Umemura T, 2009, J GASTROENTEROL, V44, P102, DOI 10.1007/s00535-008-2251-0; El-Serag HB, 2004, GASTROENTEROLOGY, V126, P460, DOI 10.1053/j.gastro.2003.10.065; Kawaguchi T, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038322; Miyaaki H, 2008, LIVER INT, V28, P519, DOI 10.1111/j.1478-3231.2007.01614.x; Neuschwander-Tetri Brent A, 2010, Hepatology, V52, P913, DOI 10.1002/hep.23784; Okanoue T, 2013, NONALCOHOLIC FATTY L, P217; Shiga T, 2009, J GASTROENTEROL, V44, P757, DOI 10.1007/s00535-009-0059-1; Shima T, 2013, J GASTROENTEROL, V48, P515, DOI 10.1007/s00535-012-0653-5; Tobias DK, 2014, NEW ENGL J MED, V370, P233, DOI 10.1056/NEJMoa1304501	31	1	1	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1386-6346	1872-034X		HEPATOL RES	Hepatol. Res.	MAY	2015	45	5					548	559		10.1111/hepr.12384		12	Gastroenterology & Hepatology	Gastroenterology & Hepatology	CG6FZ	WOS:000353394200006		
J	Kuroda, H; Kakisaka, K; Oikawa, T; Onodera, M; Miyamoto, Y; Sawara, K; Endo, R; Suzuki, K; Takikawa, Y				Kuroda, Hidekatsu; Kakisaka, Keisuke; Oikawa, Takayoshi; Onodera, Mio; Miyamoto, Yasuhiro; Sawara, Kei; Endo, Ryujin; Suzuki, Kazuyuki; Takikawa, Yasuhiro			Liver stiffness measured by acoustic radiation force impulse elastography reflects the severity of liver damage and prognosis in patients with acute liver failure	HEPATOLOGY RESEARCH			English	Article						acoustic radiation force impulse elastography; acute liver failure; liver stiffness; prognosis; shear wave velocity	FULMINANT HEPATIC-FAILURE; TRANSIENT ELASTOGRAPHY; NONINVASIVE ASSESSMENT; FIBROSIS; JAPAN; DISEASES; TRANSPLANTATION; RECOMMENDATIONS; TOMOGRAPHY; VOLUME	AimWe measured liver stiffness (LS) in patients with acute liver failure (ALF) using acoustic radiation force impulse (ARFI) elastography and investigated the usefulness of measuring LS for predicting the prognosis of ALF patients. MethodsFrom April 2010 to December 2013, we evaluated 63 patients with acute liver disease. The subjects included 41 patients with acute hepatitis (AH), 16 patients with severe AH (SAH), who had no hepatic encephalopathy despite plasma prothrombin time of 40% or less, and six patients with fulminant hepatitis (FH) diagnosed according to the criteria of the Japanese Study Group. The relationships among shear wave velocity (SWV), clinical diagnosis, liver function tests and prognosis were evaluated. Receiver-operator curve (ROC) analysis was performed to investigate whether ARFI elastography exhibits potential usefulness for the prediction of FH. ResultsThe mean SWV on admission were 1.980.55, 2.61 +/- 0.58 and 3.66 +/- 0.86m/s in the AH, SAH and FH groups, respectively. The SWV was significantly higher in the FH group than in the other groups (P<0.001), and in the SAH group than in the AH group (P=0.002). The area under the ROC for predicting FH was 0.924 (sensitivity, 83.3%; specificity, 93.0%). The SWV was significantly increased in non-survivors, while remaining decreased in survivors (P=0.002). ConclusionThe SWV measured by ARFI elastography reflects severity of liver damage, and serial changes in SWV predict the prognosis of ALF patients. The SWV is an early and precise biomarker of FH.	[Kuroda, Hidekatsu; Kakisaka, Keisuke; Oikawa, Takayoshi; Onodera, Mio; Miyamoto, Yasuhiro; Sawara, Kei; Endo, Ryujin; Suzuki, Kazuyuki; Takikawa, Yasuhiro] Iwate Med Univ, Div Gastroenterol & Hepatol, Dept Internal Med, Morioka, Iwate 0208505, Japan; [Suzuki, Kazuyuki] Morika Univ, Depy Nutr Sci, Takizawa, Iwate, Japan	Kuroda, H (reprint author), Iwate Med Univ, Div Gastroenterol & Hepatol, Dept Internal Med, 19-1 Uchimaru, Morioka, Iwate 0208505, Japan.	hikuro@iwate-med.ac.jp					Als K, 2011, CRIT CARE, V15, pR266; Bota S, 2013, LIVER INT, V33, P1138, DOI 10.1111/liv.12240; Yamagishi Y, 2009, J GASTROENTEROL, V44, P615, DOI 10.1007/s00535-009-0045-7; Mochida S, 2011, HEPATOL RES, V41, P805, DOI 10.1111/j.1872-034X.2011.00860.x; Sagir A, 2008, HEPATOLOGY, V47, P592, DOI 10.1002/hep.22056; OGRADY JG, 1989, GASTROENTEROLOGY, V97, P439; Fujiwara K, 2008, HEPATOL RES, V38, P646, DOI 10.1111/j.1872-034X.2008.00322.x; Friedrich-Rust M, 2009, RADIOLOGY, V252, P595, DOI 10.1148/radiol.2523081928; Yoneda M, 2010, RADIOLOGY, V256, P640, DOI 10.1148/radiol.10091662; Dechene A, 2010, HEPATOLOGY, V52, P1008, DOI 10.1002/hep.23754; Arena U, 2008, HEPATOLOGY, V47, P380, DOI 10.1002/hep.22007; Nightingale K, 2003, ULTRASOUND MED BIOL, V29, P1715, DOI 10.1016/j.ultrasmedbio.2003.08.008; Takikawa Y, 2008, HEPATOL RES, V38, pS14, DOI 10.1111/j.1872-034X.2008.00421.x; URATA K, 1995, HEPATOLOGY, V21, P1317, DOI 10.1016/0270-9139(95)90053-5; Ziol M, 2005, HEPATOLOGY, V41, P48, DOI 10.1002/hep.20506; Wang HM, 2013, LIVER INT, V33, P756, DOI 10.1111/liv.12118; Stravitz RT, 2007, CRIT CARE MED, V35, P2498, DOI 10.1097/01.CCM.0000287592.94554.5F; Di Marco V, 2011, GUT, V60, P1023, DOI 10.1136/gut.2010.228478; Cobbold JFL, 2008, HEPATOLOGY, V47, P370, DOI 10.1002/hep.22200; Chen X, 2013, ULTRASOUND MED BIOL, V39, P2091, DOI 10.1016/j.ultrasmedbio.2013.05.020; Dufour DR, 2000, CLIN CHEM, V46, P2050; Takikawa Y, 2009, J HEPATOL, V51, P1021, DOI 10.1016/j.jhep.2009.09.011; HENDERSON JM, 1981, RADIOLOGY, V141, P525; Hirooka M, 2011, RADIOLOGY, V261, P960, DOI 10.1148/radiol.11110156; Itai Y, 1997, RADIOLOGY, V202, P379; Kims SU, 2009, LIVER INT, V29, P810; Kremers WK, 2004, HEPATOLOGY, V39, P764, DOI 10.1002/hep.20083; Kuroda H, 2010, HEPATO-GASTROENTEROL, V57, P1203; Kuroda H, 2012, J CLIN ULTRASOUND, V40, P99, DOI 10.1002/jcu.20893; Lees WM, 2008, HEPATOLOGY, V47, P1401; Murakami T, 1996, RADIOLOGY, V198, P239; Polsons J, 2005, HEPATOLOGY, V41, P1180; Ryder SD, 2001, BRIT MED J, V322, P151, DOI 10.1136/bmj.322.7279.151; Sato S, 1983, Gastroenterol Jpn, V18, P128; SEKIYAMA K, 1994, DIGEST DIS SCI, V39, P240, DOI 10.1007/BF02090192; Taylor-Robinson SD, 2010, EUR J GASTROEN HEPAT, V22, P133, DOI 10.1097/MEG.0b013e328334250a; TREY C, 1968, NEW ENGL J MED, V279, P798, DOI 10.1056/NEJM196810102791504; TSUBOUCHI H, 1991, HEPATOLOGY, V13, P1; WILLIAMS R, 1994, HEPATOLOGY, V20, pS5, DOI 10.1016/0270-9139(94)90265-8; Yes XP, 2012, J ULTRAS MED, V31, P1245	40	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1386-6346	1872-034X		HEPATOL RES	Hepatol. Res.	MAY	2015	45	5					571	577		10.1111/hepr.12389		7	Gastroenterology & Hepatology	Gastroenterology & Hepatology	CG6FZ	WOS:000353394200008		
J	Ito, T; Okubo, H; Kokubu, S; Miyazaki, A; Ando, H; Fujimura, A; Watanabe, S				Ito, Tomoyasu; Okubo, Hironao; Kokubu, Shigehiro; Miyazaki, Akihisa; Ando, Hitoshi; Fujimura, Akio; Watanabe, Sumio			Radiofrequency ablation combined with chemolipiodolization in a porcine liver: Comparison of the pharmacokinetic analysis with cisplatin powder and miriplatin	HEPATOLOGY RESEARCH			English	Article						chemolipiodolization; cisplatin; hepatocellular carcinoma; miriplatin; pharmacokinetics; radiofrequency ablation	TRANSCATHETER ARTERIAL CHEMOEMBOLIZATION; STAGE HEPATOCELLULAR-CARCINOMA; PLATINUM AGENTS; CHEMOTHERAPY; SM-11355; THERAPY; PLASMA; TRIAL	AimTo compare the pharmacokinetics of radiofrequency (RF) ablation with chemolipiodolization using cisplatin (CDDP) powder and miriplatin (MPT) in a porcine liver. MethodsTwelve pigs were divided equally into four groups. After each CDDP powder-lipiodol suspension (n=6; groups A and B) or MPT-lipiodol suspension (n=6; groups C and D) was injected into the lateral left artery, one RF ablation was performed at the lateral left lobe of each pig. Six pigs (groups A and C) were killed on the same day as treatment, whereas the other pigs (groups B and D) were killed 7 days after the treatment. The platinum concentrations in venous blood were assayed at 15, 60 and 120min, and 7 days after treatment. The platinum concentrations in the ablated area and the surrounding liver were also examined. ResultsPlasma platinum concentrations of the CDDP group peaked at 15min, and then gradually diminished over time (g units), while plasma platinum levels in the MPT group gradually increased over time (ng units). Liver tissue platinum concentrations of the CDDP group were significantly lower in non-ablative areas than in ablated areas at days 0 and 7, while liver concentrations of the MPT group were significantly higher in non-ablative areas than in ablated areas at day 7. ConclusionMPT may be a suitable chemotherapeutic agent to stagnate platinum in the surrounding liver.	[Ito, Tomoyasu; Okubo, Hironao; Kokubu, Shigehiro; Miyazaki, Akihisa] Juntendo Univ, Nerima Hosp, Dept Gastroenterol, Tokyo 1778521, Japan; [Ando, Hitoshi; Fujimura, Akio] Juntendo Univ, Sch Med, Dept Gastroenterol, Tokyo 1778521, Japan; [Watanabe, Sumio] Jichi Med Univ, Dept Pharmacol, Sch Med, Div Clin Pharmacol, Shimotsuke, Tochigi, Japan	Okubo, H (reprint author), Juntendo Univ, Nerima Hosp, Dept Gastroenterol, Nerima Ku, 3-1-10 Takanodai, Tokyo 1778521, Japan.	drokubo@juntendo-nerima.jp					Yamakado K, 2008, RADIOLOGY, V247, P260, DOI 10.1148/radiol.2471070818; Livraghi T, 2003, RADIOLOGY, V226, P441, DOI 10.1148/radiol.2262012198; Kagawa T, 2010, CANCER-AM CANCER SOC, V116, P3638, DOI 10.1002/cncr.25142; Peng ZW, 2013, J CLIN ONCOL, V31, P426, DOI 10.1200/JCO.2012.42.9936; Yamanaka T, 2012, JPN J RADIOL, V30, P553, DOI 10.1007/s11604-012-0087-2; Sasaki A, 2005, CANCER, V103, P299, DOI 10.1002/cncr.20797; Yasui K, 2013, HEPATOL RES, V43, P1093, DOI 10.1111/hepr.12059; Morimoto M, 2010, CANCER-AM CANCER SOC, V116, P5452, DOI 10.1002/cncr.25314; DALEYYATES PT, 1984, BIOCHEM PHARMACOL, V33, P3063, DOI 10.1016/0006-2952(84)90610-5; Gibby WA, 2004, INVEST RADIOL, V39, P138, DOI 10.1097/01.rli.0000112789.57341.01; SHIBATA J, 1989, CANCER, V64, P1586, DOI 10.1002/1097-0142(19891015)64:8<1586::AID-CNCR2820640805>3.0.CO;2-E; Ueda T, 2013, HEPATOL RES, V43, P1071, DOI 10.1111/hepr.12212; OKUDA K, 1985, CANCER, V56, P918, DOI 10.1002/1097-0142(19850815)56:4<918::AID-CNCR2820560437>3.0.CO;2-E; MATSUI O, 1993, RADIOLOGY, V188, P79; Ishikawa T, 2011, CANCER-AM CANCER SOC, V117, P4018, DOI 10.1002/cncr.25989; Kishimoto S, 2000, BIOL PHARM BULL, V23, P344; Kishimoto S, 2000, BIOL PHARM BULL, V23, P637; Nakashimas Y, 2003, HEPATOL RES, V226, P142; Okusaka T, 2012, INVEST NEW DRUG, V30, P2015, DOI 10.1007/s10637-011-9776-4; TAKAHASHI K, 1985, JPN J CANCER RES, V76, P68; Watanabe S, 2012, CARDIOVASC INTER RAD, V35, P399, DOI 10.1007/s00270-011-0172-4; Yamanakas T, 2013, CARDIOVASC INTERVENT; Yamashita Y, 2010, CANCER CHEMOTH PHARM, V65, P301, DOI 10.1007/s00280-009-1034-5	23	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1386-6346	1872-034X		HEPATOL RES	Hepatol. Res.	MAY	2015	45	5					589	594		10.1111/hepr.12387		6	Gastroenterology & Hepatology	Gastroenterology & Hepatology	CG6FZ	WOS:000353394200010		
J	Hokuto, D; Yamato, I; Nomi, T; Yasuda, S; Obara, S; Yamada, T; Chihiro, K; Nakajima, Y				Hokuto, Daisuke; Yamato, Ichiro; Nomi, Takeo; Yasuda, Satoshi; Obara, Shinsaku; Yamada, Takatsugu; Chihiro, Kawaguchi; Nakajima, Yoshiyuki			Eosinophilic cholangitis coexisted with idiopathic thrombocytopenic purpura: Report of a case	HEPATOLOGY RESEARCH			English	Article						eosinophilic cholangitis; eosinophilic cholecystitis; idiopathic thrombocytopenic purpura	SCLEROSING CHOLANGITIS; HYPEREOSINOPHILIC SYNDROME; CHOLANGIOPATHY; DISEASE; GASTROENTERITIS; MANIFESTATION; OBSTRUCTION; COLITIS	Eosinophilic cholangitis is a rare disease of which only 31 cases have been reported. Eosinophilic infiltration causes stricture of the bile duct diffusely or locally, and the imaging of eosinophilic cholangitis resembles primary sclerosing cholangitis or cancer of the bile tract. For eosinophilic cholangitis, treatment with steroid is effective and the prognosis is good. Therefore, its accurate diagnosis is very important. Here, we describe a patient with eosinophilic cholangitis who was also diagnosed with idiopathic thrombocytopenic purpura (ITP). He was treated for ITP using prednisolone, the unexpected sudden interruption of which caused severe deterioration of eosinophilic cholangitis and acute cholecystitis. Cholecystectomy and choledochojejunostomy were performed, and the addition of treatment by prednisolone resulted in a good clinical course. This is the first report on eosinophilic cholangitis coexisting with ITP.	[Hokuto, Daisuke; Yamato, Ichiro; Nomi, Takeo; Yasuda, Satoshi; Obara, Shinsaku; Yamada, Takatsugu; Chihiro, Kawaguchi; Nakajima, Yoshiyuki] Nara Med Univ, Dept Surg, Kashihara, Nara 6348522, Japan	Hokuto, D (reprint author), Nara Med Univ, Dept Surg, 840 Shijo Cho, Kashihara, Nara 6348522, Japan.	hokuto@naramed-u.ac.jp					Al-Abdulla NA, 2000, HEPATO-GASTROENTEROL, V47, P359; BUTLER TW, 1985, AM J GASTROENTEROL, V80, P572; Chen WH, 2009, J HEPATO-BILIARY-PAN, V16, P242, DOI 10.1007/s00534-008-0041-y; Dubay D, 2010, CLIN GASTROENTEROL H, V8, pXXII, DOI 10.1016/j.cgh.2010.02.006; Duseja A, 2005, DIGEST DIS SCI, V50, P1422, DOI 10.1007/s10620-005-2856-6; Miura F, 2009, WORLD J GASTROENTERO, V15, P1394, DOI 10.3748/wjg.15.1394; GRAUER L, 1993, AM J GASTROENTEROL, V88, P1764; Horiuchi K, 2009, INTERNAL MED, V48, P1377, DOI 10.2169/internalmedicine.48.2223; Iwamuro M, 2009, INTERNAL MED, V48, P1143, DOI 10.2169/internalmedicine.48.1892; Jeyamani R, 2007, Indian J Gastroenterol, V26, P190; Jimenez-Saenz M, 2003, DIGEST DIS SCI, V48, P624, DOI 10.1023/A:1022521707420; Kimura Yoshito, 2013, Nihon Shokakibyo Gakkai Zasshi, V110, P271; Kroemer A, 2012, Z GASTROENTEROL, V50, P766, DOI 10.1055/s-0031-1299110; Matsumoto N, 2007, WORLD J GASTROENTERO, V13, P1995; Nashed C, 2010, HPB SURG, V2010; Papadopoulos AA, 2005, GUT, V54, P1822, DOI 10.1136/gut.2005.075077; PLATT ML, 1990, J UROLOGY, V144, P127; Raptou G, 2009, PATHOL INT, V59, P395, DOI 10.1111/j.1440-1827.2009.02383.x; Rodgers M S, 2001, HPB (Oxford), V3, P235, DOI 10.1080/136518201753242280; ROSENGART TK, 1990, AM J GASTROENTEROL, V85, P582; SCHEURLEN M, 1992, J CLIN GASTROENTEROL, V14, P59, DOI 10.1097/00004836-199201000-00015; SCHOONBROODT D, 1995, DIGEST DIS SCI, V40, P308, DOI 10.1007/BF02065415; Seow-En I, 2014, BMJ CASE REP, DOI [10.1136/bcr-2013-202225, DOI 10.1136/BCR-2013-202225]; Shanti CM, 2001, SURGERY, V130, P104, DOI 10.1067/msy.2001.113285; Song HH, 1997, J COMPUT ASSIST TOMO, V21, P251, DOI 10.1097/00004728-199703000-00015; Sussman DA, 2008, EUR J GASTROEN HEPAT, V20, P574, DOI 10.1097/MEG.0b013e3282f1cc11; Tenner S, 1997, GASTROINTEST ENDOSC, V45, P307, DOI 10.1016/S0016-5107(97)70277-3; Vainer E, 2014, ENDOSCOPY, V46, pE95, DOI 10.1055/s-0033-1359137; Vauthey Jean-Nicolas, 2003, Radiology, V227, P107, DOI 10.1148/radiol.2271010938	29	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1386-6346	1872-034X		HEPATOL RES	Hepatol. Res.	MAY	2015	45	5					595	600		10.1111/hepr.12380		6	Gastroenterology & Hepatology	Gastroenterology & Hepatology	CG6FZ	WOS:000353394200011		
J	Tsunoda, T; Inui, A; Kawamoto, M; Sogo, T; Komatsu, H; Kasahara, M; Nakazawa, A; Fujisawa, T				Tsunoda, Tomoyuki; Inui, Ayano; Kawamoto, Manari; Sogo, Tsuyoshi; Komatsu, Haruki; Kasahara, Mureo; Nakazawa, Atsuko; Fujisawa, Tomoo			Neonatal liver failure owing to gestational alloimmune liver disease without iron overload	HEPATOLOGY RESEARCH			English	Article						C5b-9; gestational alloimmune liver disease; liver failure; liver transplantation; membrane attack complex; neonatal hemochromatosis	5-BETA-REDUCTASE DEFICIENCY; HEMOCHROMATOSIS; TRANSPLANTATION; EXPERIENCE; FETAL	Although neonatal hemochromatosis (NH) is a well-known cause of liver failure during the neonatal period and iron deposition in extrahepatic tissues is considered essential in the diagnosis of NH, there is no consensus regarding the pathology or diagnostic criteria of NH. Recent studies of immunohistochemical assays have shown that the C5b-9 complex (the terminal membrane attack complement complex) is strongly expressed in the liver of NH cases, suggesting that a gestational alloimmune mechanism is the cause of liver injury. The patient was a low birthweight primiparous male born at 37 weeks of gestation by vaginal delivery. Blood tests 3h after birth showed signs of liver failure, including high transferrin saturation, resembling the clinical characteristics of NH. However, magnetic resonance imaging and a lip biopsy showed no obvious iron deposition outside the liver. The patient was refractory to exchange transfusion and immunoglobulin therapy but was successfully treated by liver transplantation. Histologically, the explanted liver showed established cirrhosis, with large amounts of human C5b-9 in the residual hepatocytes, suggesting the alloimmune mechanism of liver injury was the cause of his liver failure. Liver failure caused by a gestational alloimmune mechanism should be considered in patients with antenatal liver failure, even without obvious extrahepatic siderosis.	[Tsunoda, Tomoyuki; Inui, Ayano; Kawamoto, Manari; Sogo, Tsuyoshi; Fujisawa, Tomoo] Saiseikai Yokohama Eastern Hosp, Dept Pediat Hepatol & Gastroenterol, Yokohama, Kanagawa, Japan; [Komatsu, Haruki] Toho Univ, Med Ctr, Sakura Hosp, Dept Pediat, Sakura, Japan; [Kasahara, Mureo] Natl Ctr Child Hlth & Dev, Dept Transplant Surg, Tokyo, Japan; [Nakazawa, Atsuko] Natl Ctr Child Hlth & Dev, Dept Pathol, Tokyo, Japan	Tsunoda, T (reprint author), 3-6-1 Shimosueyoshi, Yokohama, Kanagawa 2308765, Japan.	ttsunoda1982@yahoo.co.jp			Merck Sharp and Dohme; Merck; Astellas Pharma	A. I. received lecture fees from Merck Sharp and Dohme. T. F. received lecture fees from Merck and Astellas Pharma. We have no other conflicts of interest and no financial relationships to disclose.	Durand P, 2001, J PEDIATR-US, V139, P871, DOI 10.1067/mpd.2001.119989; Rand EB, 2009, J PEDIATR-US, V155, P566, DOI 10.1016/j.jpeds.2009.04.012; Ueki I, 2009, J GASTROEN HEPATOL, V24, P776, DOI 10.1111/j.1440-1746.2008.05669.x; Debray FG, 2012, PEDIATRICS, V129, pE1076, DOI 10.1542/peds.2011-0568; HOOGSTRATEN J, 1990, GASTROENTEROLOGY, V98, P1699; Pans X, 2010, HEPATOLOGY, V51, P2061; Rodrigues F, 2005, LIVER TRANSPLANT, V11, P1417, DOI 10.1002/lt.20497; SHNEIDER BL, 1994, J PEDIATR-US, V124, P234, DOI 10.1016/S0022-3476(94)70310-8; Whitington PF, 2004, LANCET, V364, P1690, DOI 10.1016/S0140-6736(04)17356-X; Whitington PF, 2012, SEMIN LIVER DIS, V32, P325, DOI 10.1055/s-0032-1329901; Whitington PF, 2005, J PEDIATR GASTR NUTR, V40, P544, DOI 10.1097/01.MPG.0000162004.44971.92; Whitington PF, 2006, HEPATOLOGY, V43, P654, DOI 10.1002/hep.21129	12	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1386-6346	1872-034X		HEPATOL RES	Hepatol. Res.	MAY	2015	45	5					601	605		10.1111/hepr.12381		5	Gastroenterology & Hepatology	Gastroenterology & Hepatology	CG6FZ	WOS:000353394200012		
J	Milward, P				Milward, Peter			Henry VIII and His Afterlives: Literature, Politics, and Art	HEYTHROP JOURNAL			English	Book Review									[Milward, Peter] Sophia Univ, Tokyo 102, Japan	Milward, P (reprint author), Sophia Univ, Tokyo 102, Japan.						RANKIN M, 2013, HENRY VIII HIS AFTER	1	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0018-1196	1468-2265		HEYTHROP J	Heythrop J.	MAY	2015	56	3					475	476		10.1111/heyj.12249_21		2	Philosophy; Religion	Philosophy; Religion	CG1UC	WOS:000353059100029		
J	Milward, P				Milward, Peter			Rethinking Shakespeare's Political Philosophy: From Lear to Leviathan	HEYTHROP JOURNAL			English	Book Review									[Milward, Peter] Sophia Univ, Tokyo 102, Japan	Milward, P (reprint author), Sophia Univ, Tokyo 102, Japan.						Schulman A, 2014, EDINB CRIT STUD SHAK, P1	1	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0018-1196	1468-2265		HEYTHROP J	Heythrop J.	MAY	2015	56	3					476	478		10.1111/heyj.12249_22		3	Philosophy; Religion	Philosophy; Religion	CG1UC	WOS:000353059100030		
J	Seubert, J; Ohla, K; Yokomukai, Y; Kellermann, T; Lundstrom, JN				Seubert, Janina; Ohla, Kathrin; Yokomukai, Yoshiko; Kellermann, Thilo; Lundstrom, Johan N.			Superadditive Opercular Activation to Food Flavor is Mediated by Enhanced Temporal and Limbic Coupling	HUMAN BRAIN MAPPING			English	Article						olfaction; taste; flavor; multisensory; fMRI; food perception	HUMAN OLFACTORY CORTEX; KLUVER-BUCY-SYNDROME; HUMAN BRAIN; ORBITOFRONTAL CORTEX; ODOR DISCRIMINATION; MULTISENSORY INTEGRATION; GUSTATORY RESPONSES; CINGULATE CORTICES; NEURAL RESPONSES; MACAQUE MONKEY	Food perception is characterized by a transition from initially separate sensations of the olfactory and gustatory properties of the object toward their combined sensory experience during consumption. The holistic flavor experience, which occurs as the smell and taste merge, extends beyond the mere addition of the two chemosensory modalities, being usually perceived as more object-like, intense and rewarding. To explore the cortical mechanisms which give rise to olfactory-gustatory binding during natural food consumption, brain activation during consumption of a pleasant familiar beverage was contrasted with presentation of its taste and orthonasal smell alone. Convergent activation to all presentation modes was observed in executive and chemosensory association areas. Flavor, but not orthonasal smell or taste alone, stimulated the frontal operculum, supporting previous accounts of its central role in the formation of the flavor percept. A functional dissociation was observed in the insula: the anterior portion was characterized by sensory convergence, while mid-dorsal sections activated exclusively to the combined flavor stimulus. psycho-physiological interaction analyses demonstrated increased neural coupling between the frontal operculum and the anterior insula during flavor presentation. Connectivity was also increased with the lateral entorhinal cortex, a relay to memory networks and central node for contextual modulation of olfactory processing. These findings suggest a central role of the insular cortex in the transition from mere detection of chemosensory convergence to a superadditive flavor representation. The increased connections between the frontal operculum and medial temporal memory structures during combined olfactory-gustatory stimulation point to a potential mechanism underlying the acquisition and modification of flavor preferences. Hum Brain Mapp 36:1662-1676, 2015. (c) 2014 Wiley Periodicals, Inc.	[Seubert, Janina; Lundstrom, Johan N.] Karolinska Inst, Dept Clin Neurosci, S-17177 Stockholm, Sweden; [Seubert, Janina; Ohla, Kathrin; Lundstrom, Johan N.] Monell Chem Senses Ctr, Cognit Neuroimaging Lab, Philadelphia, PA 19104 USA; [Seubert, Janina] Karolinska Inst, Aging Res Ctr, S-17177 Stockholm, Sweden; [Seubert, Janina] Stockholm Univ, S-10691 Stockholm, Sweden; [Ohla, Kathrin] German Inst Human Nutr Potsdam Rehbrucke, Nuthetal, Germany; [Yokomukai, Yoshiko] Kirin Co Ltd, Tokyo, Japan; [Kellermann, Thilo] Rhein Westfal TH Aachen, Dept Psychiat Psychotherapy & Psychosomat Med, Aachen, Germany; [Kellermann, Thilo] JARA Brain Translat Brain Med, Aachen, Germany; [Lundstrom, Johan N.] Univ Penn, Dept Psychol, Philadelphia, PA 19104 USA	Seubert, J (reprint author), Karolinska Inst, Psychol Div, Dept Clin Neurosci, Nobels Vag 9, S-17177 Stockholm, Sweden.	janina.seubert@ki.se	Kellermann, Thilo/B-1712-2012; Lundstrom, Johan/E-9482-2014	Lundstrom, Johan/0000-0002-3529-8981	Knut and Allice Wallenberg Foundation [KAW 2012.0141]; Swedish Research Council [VR2014-1346, VR2014-1384]; German Research Foundation (DFG) [SE 2147/1-1]	Contract grant sponsor: Knut and Allice Wallenberg Foundation; Contract grant number: KAW 2012.0141; Contract grant sponsor: Swedish Research Council; Contract grant number: VR2014-1346 (J.N.L.); Contract grant sponsor: German Research Foundation; Contract grant number: DFG; SE 2147/1-1; Contract grant sponsor: Swedish Research Council; Contract grant number: VR2014-1384 (J.S.)	Boesveldt S, 2010, BIOL PSYCHOL, V84, P313, DOI 10.1016/j.biopsycho.2010.03.006; McCabe C, 2007, EUR J NEUROSCI, V25, P1855, DOI 10.1111/j.1460-9568.2007.05445.x; ZATORRE RJ, 1992, NATURE, V360, P339, DOI 10.1038/360339a0; YAXLEY S, 1990, J NEUROPHYSIOL, V63, P689; Lim J, 2008, CHEM SENSES, V33, P137, DOI 10.1093/chemse/bjm070; Small DM, 2008, NEURON, V57, P786, DOI 10.1016/j.neuron.2008.01.021; Gottfried JA, 2005, BRAIN RES REV, V50, P287, DOI 10.1016/j.brainreserv.2005.08.004; Cerf-Ducastel B, 2001, CHEM SENSES, V26, P625, DOI 10.1093/chemse/26.6.625; Nichols T, 2005, NEUROIMAGE, V25, P653, DOI 10.1016/j.neuroimage.2004.12.005; Cerf-Ducastel B, 2001, CHEM SENSES, V26, P371, DOI 10.1093/chemse/26.4.371; Driver J, 2008, NEURON, V57, P11, DOI 10.1016/j.neuron.2007.12.013; Volkow ND, 2011, TRENDS COGN SCI, V15, P37, DOI 10.1016/j.tics.2010.11.001; Grabenhorst F, 2008, CEREB CORTEX, V18, P1549, DOI 10.1093/cercor/bhm185; Small DM, 2001, BRAIN, V124, P1720, DOI 10.1093/brain/124.9.1720; Landis BN, 2009, J NEUROL, V256, P242, DOI 10.1007/s00415-009-0088-y; Hummel T, 2007, EUR ARCH OTO-RHINO-L, V264, P237, DOI 10.1007/s00405-006-0173-0; Glascher J, 2009, NEUROINFORMATICS, V7, P73, DOI 10.1007/s12021-008-9042-x; Guest S, 2007, PHYSIOL BEHAV, V92, P975, DOI 10.1016/j.physbeh.2007.07.004; YAMAMOTO T, 1985, J NEUROPHYSIOL, V53, P1356; Kerr KM, 2007, HIPPOCAMPUS, V17, P697, DOI 10.1002/hipo.20315; TODRANK J, 1991, PHYSIOL BEHAV, V50, P1027, DOI 10.1016/0031-9384(91)90432-N; Ashburner J, 2005, NEUROIMAGE, V26, P839, DOI 10.1016/j.neuroimage.2005.02.018; Frey S, 1999, EUR J NEUROSCI, V11, P2985, DOI 10.1046/j.1460-9568.1999.00738.x; Haase L, 2009, NEUROIMAGE, V44, P1008, DOI 10.1016/j.neuroimage.2008.09.044; Kurth F, 2010, BRAIN STRUCT FUNCT, V214, P519, DOI 10.1007/s00429-010-0255-z; Iannilli E, 2014, NEUROSCIENCE, V273, P92, DOI 10.1016/j.neuroscience.2014.05.017; Sobel N, 1998, NATURE, V392, P282, DOI 10.1038/32654; ROLLS ET, 1994, J NEUROSCI, V14, P5437; Zald DH, 1998, BRAIN, V121, P1143, DOI 10.1093/brain/121.6.1143; Savic I, 2000, NEUROREPORT, V11, P2861, DOI 10.1097/00001756-200009110-00007; Beauchamp MS, 2005, NEUROINFORMATICS, V3, P93, DOI 10.1385/NI:03:02:93; Veldhuizen MG, 2007, CHEM SENSES, V32, P569, DOI 10.1093/chemse/bjm025; Yeomans MR, 2006, J EXP PSYCHOL ANIM B, V32, P215, DOI 10.1037/0097-7403.32.3.215; CARMICHAEL ST, 1994, J COMP NEUROL, V346, P403, DOI 10.1002/cne.903460306; Seubert J, 2010, NEUROIMAGE, V53, P746, DOI 10.1016/j.neuroimage.2010.07.012; Patterson K, 2007, NAT REV NEUROSCI, V8, P976, DOI 10.1038/nrn2277; Stice E, 2011, CURR TOP BEHAV NEURO, V6, P81, DOI 10.1007/7854_2010_89; MESULAM MM, 1982, J COMP NEUROL, V212, P1, DOI 10.1002/cne.902120102; Deen B, 2011, CEREB CORTEX, V21, P1498, DOI 10.1093/cercor/bhq186; Hummel T, 1997, CHEM SENSES, V22, P39, DOI 10.1093/chemse/22.1.39; Chapuis J, 2013, J NEUROSCI, V33, P13449, DOI 10.1523/JNEUROSCI.1387-13.2013; Small DM, 1997, NEUROREPORT, V8, P3913, DOI 10.1097/00001756-199712220-00014; Auvray M, 2008, CONSCIOUS COGN, V17, P1016, DOI 10.1016/j.concog.2007.06.005; O'Doherty J, 2001, J NEUROPHYSIOL, V85, P1315; Dalton P, 2000, NAT NEUROSCI, V3, P431, DOI 10.1038/74797; EVANS AC, 1993, NUCLEAR SCIENCE SYMPOSIUM & MEDICAL IMAGING CONFERENCE, VOLS 1-3, P1813; Rolls ET, 2003, CEREB CORTEX, V13, P308, DOI 10.1093/cercor/13.3.308; Friston KJ, 1997, NEUROIMAGE, V6, P218, DOI 10.1006/nimg.1997.0291; Small DM, 2005, EXP BRAIN RES, V166, P345, DOI 10.1007/s00221-005-2376-9; Olofsson JK, 2013, BRAIN, V136, P1245, DOI 10.1093/brain/awt019; Zald DH, 1997, P NATL ACAD SCI USA, V94, P4119, DOI 10.1073/pnas.94.8.4119; Wicker B, 2003, NEURON, V40, P655, DOI 10.1016/S0896-6273(03)00679-2; Uncapher MR, 2009, J NEUROSCI, V29, P8270, DOI 10.1523/JNEUROSCI.1043-09.2009; Nakamura K, 1996, BEHAV BRAIN RES, V77, P53, DOI 10.1016/0166-4328(95)00227-8; Calvert GA, 1999, NEUROREPORT, V10, P2619, DOI 10.1097/00001756-199908200-00033; Small DM, 2005, NEURON, V47, P593, DOI 10.1016/j.neuron.2005.07.022; Lundstrom JN, 2010, INT J PSYCHOPHYSIOL, V78, P179, DOI 10.1016/j.ijpsycho.2010.07.007; Craig AD, 2000, NAT NEUROSCI, V3, P184, DOI 10.1038/72131; Petrovich GD, 2005, J NEUROSCI, V25, P8295, DOI 10.1523/JNEUROSCI.2480-05.2005; Veldhuizen MG, 2011, HUM BRAIN MAPP, V32, P2256, DOI 10.1002/hbm.21188; Small DM, 1999, NEUROREPORT, V10, P7, DOI 10.1097/00001756-199901180-00002; Adolphs R, 2003, BRAIN COGNITION, V52, P61, DOI 10.1016/S0278-2626(03)00009-5; Angelaki DE, 2009, CURR OPIN NEUROBIOL, V19, P452, DOI 10.1016/j.conb.2009.06.008; Shepherd GM, 2006, NATURE, V444, P316, DOI 10.1038/nature05405; Seubert J, 2013, NEUROIMAGE, V66, P333, DOI 10.1016/j.neuroimage.2012.10.030; Lundstrom JN, 2011, ACS CHEM NEUROSCI, V2, P5, DOI 10.1021/cn1000843; Poellinger A, 2001, NEUROIMAGE, V13, P547, DOI 10.1006/nimg.2000.0713; BARTOSHUK LM, 1964, SCIENCE, V143, P967, DOI 10.1126/science.143.3609.967; Baxter MG, 2009, NEURON, V61, P667, DOI 10.1016/j.neuron.2009.02.007; Biella GR, 2007, PFLUG ARCH EUR J PHY, V455, P515, DOI 10.1007/s00424-007-0299-y; desAraujo IE, 2009, INT J OBES S2, V33, pS34; desAraujo IE, 2003, EUR J NEUROSCI, V18, P2059; Green BG, 2003, PHYSIOL BEHAV, V79, P811, DOI 10.1016/S0031-9384(03)00213-0; Haase L, 2007, J NEUROSCI METH, V159, P98, DOI 10.1016/j.jneumeth.2006.07.009; HOREL JA, 1975, BRAIN RES, V94, P347, DOI 10.1016/0006-8993(75)90067-0; Kadohisa M, 2005, CHEM SENSES, V30, P401, DOI 10.1093/chemse/bji036; KLING AS, 1993, BEHAV BRAIN RES, V56, P161, DOI 10.1016/0166-4328(93)90034-N; Mai J, 2008, ATLAS HUMAN BRAIN; Miller SS, 2013, CHEM SENSES, V38, P167, DOI 10.1093/chemse/bjs086; MURPHY C, 1977, SENS PROCESS, V1, P204; Petrides M, 2005, PHILOS T ROY SOC B, V360, P781, DOI 10.1098/rstb.2005.1631; Rolls ET, 2010, NEUROSCI BIOBEHAV R, V34, P237, DOI 10.1016/j.neubiorev.2008.03.010; ROOM P, 1984, EXP BRAIN RES, V56, P488; Small DM, 2012, NEURAL BASES MULTISE; Small DM, 1997, J NEUROSCI, V17, P5136; SMITHSWINTOSKY VL, 1991, J NEUROPHYSIOL, V66, P1156; Stanford TR, 2007, NEUROREPORT, V18, P787, DOI 10.1097/WNR.0b013e3280c1e315; Stevenson RJ, 2013, PSYCHOL BULL, V140, P487; Suzuki WA, 2009, NEURON, V61, P678, DOI 10.1016/j.neuron.2009.02.009	89	1	1	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1065-9471	1097-0193		HUM BRAIN MAPP	Hum. Brain Mapp.	MAY	2015	36	5					1662	1676		10.1002/hbm.22728		15	Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	CG1XH	WOS:000353068300003		
J	Takeuchi, H; Taki, Y; Sekiguchi, A; Hashizume, H; Nouchi, R; Sassa, Y; Kotozaki, Y; Miyauchi, CM; Yokoyama, R; Iizuka, K; Nakagawa, S; Nagase, T; Kunitoki, K; Kawashima, R				Takeuchi, Hikaru; Taki, Yasuyuki; Sekiguchi, Atsushi; Hashizume, Hiroshi; Nouchi, Rui; Sassa, Yuko; Kotozaki, Yuka; Miyauchi, Carlos Makoto; Yokoyama, Ryoichi; Iizuka, Kunio; Nakagawa, Seishu; Nagase, Tomomi; Kunitoki, Keiko; Kawashima, Ryuta			Mean Diffusivity of Globus Pallidus Associated with Verbal Creativity Measured by Divergent Thinking and Creativity-Related Temperaments in Young Healthy Adults	HUMAN BRAIN MAPPING			English	Article						mean diffusivity; creativity; divergent thinking; novelty seeking; harm avoidance; dopamine	VOXEL-BASED MORPHOMETRY; WHITE-MATTER STRUCTURES; RESTING FUNCTIONAL CONNECTIVITY; EMOTIONAL INTELLIGENCE EVIDENCE; NOVELTY-SEEKING PERSONALITY; WORKING-MEMORY PERFORMANCE; MEDIAL PREFRONTAL CORTEX; PARKINSONS-DISEASE; REGIONAL GRAY; CHARACTER INVENTORY	Recent investigations revealed mean diffusivity (MD) in gray matter and white matter areas is correlated with individual cognitive differences in healthy subjects and show unique properties and sensitivity that other neuroimaging tools donot have. In this study, we tested the hypothesis that the MD in the dopaminergic system is associated with individual differences in verbal creativity measured by divergent thinking (VCDT) and novelty seeking based on prior studies suggesting associations between these and dopaminergic functions. We examined this issue in a large sample of right-handed healthy young adults. We used analyses of MD and a psychological measure of VCDT, as well as personality measures of the Temperament and Character Inventory (TCI). Our results revealed associations between higher VCDT and lower MD in the bilateral globus pallidus. Furthermore, not only higher novelty seeking, but also lower harm avoidance, higher self-directedness, and higher self-transcendence were robustly associated with lower MD in the right globus pallidus, whereas higher persistence was associated with lower MD in the left globus pallidus. These personality variables were also associated with VCDT. The globus pallidus receives the dopaminergic input from the substantia nigra and plays a key role in motivation which is critically linked to dopamine. These results suggested the MD in the globus pallidus, underlie the association between VCDT and multiple personalities in TCI including novelty seeking. Hum Brain Mapp 36:1808-1827, 2015. (c) 2015 Wiley Periodicals, Inc.	[Takeuchi, Hikaru; Taki, Yasuyuki; Hashizume, Hiroshi; Sassa, Yuko; Kawashima, Ryuta] Tohoku Univ, Div Dev Cognit Neurosci, IDAC, Sendai, Miyagi 9808575, Japan; [Taki, Yasuyuki] Tohoku Univ, Tohoku Med Megabank Org, Div Meidcal Neuroimaging Anal, Dept Community Med Supports, Sendai, Miyagi 9808575, Japan; [Taki, Yasuyuki; Sekiguchi, Atsushi] Tohoku Univ, Dept Radiol & Nucl Med, Inst Dev Aging & Canc, Sendai, Miyagi 9808575, Japan; [Sekiguchi, Atsushi; Miyauchi, Carlos Makoto; Yokoyama, Ryoichi; Iizuka, Kunio; Nakagawa, Seishu; Kawashima, Ryuta] Tohoku Univ, Dept Funct Brain Imaging, Inst Dev Aging & Canc, Sendai, Miyagi 9808575, Japan; [Nouchi, Rui] Tohoku Univ, Int Res Inst Disaster Sci, Human & Social Response Res Div, Sendai, Miyagi 9808575, Japan; [Kotozaki, Yuka; Kawashima, Ryuta] Tohoku Univ, Inst Dev Aging & Canc, Smart Ageing Int Res Ctr, Sendai, Miyagi 9808575, Japan; [Yokoyama, Ryoichi] Japan Soc Promot Sci, Tokyo, Japan; [Nagase, Tomomi; Kunitoki, Keiko] Tohoku Univ, Fac Med, Sendai, Miyagi 9808575, Japan	Takeuchi, H (reprint author), Tohoku Univ, Div Dev Cognit Neurosci, IDAC, Aoba Ku, 4-1 Seiryo Cho, Sendai, Miyagi 9808575, Japan.	takehi@idac.tohoku.ac.jp			JST/RISTEX; JST/CREST; Ministry of Education, Culture, Sports, Science, and Technology [KAKENHI 23700306, KAKENHI 25700012]	Contract grant sponsor: JST/RISTEX, JST/CREST; Contract grant sponsor: The Ministry of Education, Culture, Sports, Science, and Technology; Contract grant number: KAKENHI 23700306; KAKENHI 25700012	AKAIKE H, 1974, IEEE T AUTOMAT CONTR, VAC19, P716, DOI 10.1109/TAC.1974.1100705; Chermahini SA, 2012, FRONT HUM NEUROSCI, V6, DOI 10.3389/fnhum.2012.00319; Sagi Y, 2012, NEURON, V73, P1195, DOI 10.1016/j.neuron.2012.01.025; Hansenne M, 2005, J PERS ASSESS, V85, P40, DOI 10.1207/s15327752jpa8501_04; Takeuchi H, 2012, NEUROIMAGE, V59, P2899, DOI 10.1016/j.neuroimage.2011.09.064; Schinka JA, 2002, AM J MED GENET, V114, P643, DOI 10.1002/ajmg.10649; Moseley M, 2002, BRAIN COGNITION, V50, P396, DOI 10.1016/S0278-2626(02)00524-9; Kaasinen V, 2001, P NATL ACAD SCI USA, V98, P13272, DOI 10.1073/pnas.231313198; Seppi K, 2004, MOVEMENT DISORD, V19, P1438, DOI 10.1002/mds.20229; Prabhu V, 2008, CREATIVITY RES J, V20, P53, DOI 10.1080/10400410701841955; Maldjian JA, 2003, NEUROIMAGE, V19, P1233, DOI 10.1016/S1053-8119(03)00169-1; Hillman CH, 2008, NAT REV NEUROSCI, V9, P58, DOI 10.1038/nrn2298; Razek AAKA, 2011, ACAD RADIOL, V18, P70, DOI 10.1016/j.acra.2010.08.023; Takeuchi H, 2014, BRAIN STRUCT FUNCT, V219, P71, DOI 10.1007/s00429-012-0485-3; Takeuchi H, 2010, NEUROIMAGE, V51, P578, DOI 10.1016/j.neuroimage.2010.02.078; Yasuno F, 2001, NEUROSCI LETT, V300, P59, DOI 10.1016/S0304-3940(01)01552-X; Takeuchi H, 2013, NEUROIMAGE, V77, P222, DOI 10.1016/j.neuroimage.2013.04.004; Kantarci K, 2001, RADIOLOGY, V219, P101; Laricchiuta D, 2014, BRAIN STRUCT FUNCT, V219, P793, DOI 10.1007/s00429-013-0535-5; Kijima N, 2000, PSYCHOL REP, V86, P1050, DOI 10.2466/PR0.86.3.1050-1058; Dietrich A, 2007, METHODS, V42, P22, DOI 10.1016/j.ymeth.2006.12.009; Fjell AM, 2012, NEUROIMAGE, V61, P195, DOI 10.1016/j.neuroimage.2012.03.007; Taki Y, 2013, HUM BRAIN MAPP, V34, P1842, DOI 10.1002/hbm.22027; Liao W, 2010, NEUROIMAGE, V52, P1549, DOI 10.1016/j.neuroimage.2010.05.010; Smith SM, 2009, NEUROIMAGE, V44, P83, DOI 10.1016/j.neuroimage.2008.03.061; Takeuchi H, 2013, HUM BRAIN MAPP, V34, P1025, DOI 10.1002/hbm.21492; Nusbaum AO, 2001, AM J NEURORADIOL, V22, P136; Laakso A, 2003, AM J PSYCHIAT, V160, P904, DOI 10.1176/appi.ajp.160.5.904; Heilman KM, 2003, NEUROCASE, V9, P369, DOI 10.1076/neur.9.5.369.16553; Mardaga S, 2007, PERS INDIV DIFFER, V42, P715, DOI 10.1016/j.paid.2006.08.013; Taylor KS, 2009, HUM BRAIN MAPP, V30, P2731, DOI 10.1002/hbm.20705; LINDVALL O, 1979, BRAIN RES, V172, P169, DOI 10.1016/0006-8993(79)90907-7; Haber SN, 2009, BRAIN RES BULL, V78, P69, DOI 10.1016/j.brainresbull.2008.09.013; Takeuchi H, 2011, J NEUROSCI, V31, P12139, DOI 10.1523/JNEUROSCI.2948-11.2011; Takeuchi H, 2011, NEUROIMAGE, V55, P681, DOI 10.1016/j.neuroimage.2010.11.052; Ashby FG, 1999, PSYCHOL REV, V106, P529, DOI 10.1037/0033-295X.106.3.529; OLDFIELD RC, 1971, NEUROPSYCHOLOGIA, V9, P97, DOI 10.1016/0028-3932(71)90067-4; CLONINGER CR, 1993, ARCH GEN PSYCHIAT, V50, P975; Takeuchi H, 2012, REV NEUROSCIENCE, V23, P289, DOI 10.1515/revneuro-2012-0035; Ellenbroek BA, 1996, NEUROSCIENCE, V75, P535, DOI 10.1016/0306-4522(96)00307-7; Maldjian JA, 2004, NEUROIMAGE, V21, P450, DOI 10.1016/j.neuroimage.2003.09.032; Haruno M, 2006, J NEUROPHYSIOL, V95, P948, DOI 10.1152/jn.00382.2005; Benjamini Y, 2006, BIOMETRIKA, V93, P491, DOI 10.1093/biomet/93.3.491; Takeuchi H, 2010, J NEUROSCI, V30, P3297, DOI 10.1523/JNEUROSCI.4611-09.2010; Peran P, 2010, BRAIN, V133, P3423, DOI 10.1093/brain/awq212; Takeuchi H, 2011, NEUROPSYCHOLOGIA, V49, P3466, DOI 10.1016/j.neuropsychologia.2011.08.022; Kanai R, 2011, NAT REV NEUROSCI, V12, P231, DOI 10.1038/nrn3000; Abe M, 2014, P NATL ACAD SCI USA, V111, P4608, DOI 10.1073/pnas.1320223111; Frank GK, 2005, BIOL PSYCHIAT, V58, P908, DOI 10.1016/j.biopsych.2005.05.003; Chermahini SA, 2010, COGNITION, V115, P458, DOI 10.1016/j.cognition.2010.03.007; Takeuchi H, 2011, HUM BRAIN MAPP, V32, P1497, DOI 10.1002/hbm.21122; Charlton RA, 2008, NEUROBIOL AGING, V29, P1547, DOI 10.1016/j.neurobiolaging.2007.03.017; GLICK SD, 1982, BRAIN RES, V234, P53, DOI 10.1016/0006-8993(82)90472-3; Jung RE, 2010, HUM BRAIN MAPP, V31, P398, DOI 10.1002/hbm.20874; Kaasinen V, 2004, MOVEMENT DISORD, V19, P1348, DOI 10.1002/mds.20191; King LA, 1996, J RES PERS, V30, P189, DOI 10.1006/jrpe.1996.0013; Takeuchi H, 2010, NEUROIMAGE, V51, P11, DOI 10.1016/j.neuroimage.2010.02.035; Ni JM, 2010, EUR J RADIOL, V75, P134, DOI 10.1016/j.ejrad.2009.04.028; Kulisevsky J, 2009, J NEUROL, V256, P816, DOI 10.1007/s00415-009-5001-1; Casanova R, 2007, NEUROIMAGE, V34, P137, DOI 10.1016/j.neuroimage.2006.09.011; Sassa Y, 2012, NEUROIMAGE, V60, P2035, DOI 10.1016/j.neuroimage.2012.02.021; Seeley WW, 2007, J NEUROSCI, V27, P2349, DOI 10.1523/JNEUROSCI.5587-06.2007; Suhara T, 2001, NEUROIMAGE, V13, P891, DOI 10.1006/nimg.2001.0761; Kim JH, 2011, BIOL PSYCHOL, V87, P164, DOI 10.1016/j.biopsycho.2011.02.011; Tomer R, 2004, J NEUROL NEUROSUR PS, V75, P972, DOI 10.1136/jnnp.2003.024885; Fink A, 2014, BRAIN STRUCT FUNCT, V219, P1263, DOI 10.1007/s00429-013-0564-0; Cheng NN, 1996, BRAIN RES, V743, P278, DOI 10.1016/S0006-8993(96)01056-6; Andreone N, 2007, BRIT J PSYCHIAT, V191, P113, DOI 10.1192/bjp.jp.105.020990; Depue RA, 1999, BEHAV BRAIN SCI, V22, P491; Taki Y, 2011, HUM BRAIN MAPP, V32, P1973, DOI 10.1002/hbm.21163; Liu X, 2011, NEUROSCI BIOBEHAV R, V35, P1219, DOI 10.1016/j.neubiorev.2010.12.012; CLONINGER CR, 1994, CURR OPIN NEUROBIOL, V4, P266, DOI 10.1016/0959-4388(94)90083-3; Takeuchi H, 2012, CEREB CORTEX, V22, P2921, DOI 10.1093/cercor/bhr371; Flaherty AW, 2005, J COMP NEUROL, V493, P147, DOI 10.1002/cne.20768; Assaf Y, 2008, J MOL NEUROSCI, V34, P51, DOI 10.1007/s12031-007-0029-0; Bjornebekk A, 2012, CEREB CORTEX, V22, P2672, DOI 10.1093/cercor/bhr345; Bodi N, 2009, BRAIN, V132, P2385, DOI 10.1093/brain/awp094; Carson SH, 2003, J PERS SOC PSYCHOL, V85, P499, DOI 10.1037/0022-3514.85.3.499; Chavez-Eakle RA, 2006, CREATIVITY RES J, V18, P27, DOI 10.1207/s15326934crj1801_4; Cloninger C. R., 1985, PSYCHIAT DEV, V4, P167; Cooper SH, 1998, J PERS, V66, P947, DOI 10.1111/1467-6494.00038; Csikszentmihalyi M., 1997, CREATIVITY FLOW PSYC; DisGiovanni G, 2008, SEROTONIN DOPAMINE I; Drago V, 2009, J NEUROL SCI, V276, P179, DOI 10.1016/j.jns.2008.09.026; Ettinger U, 2006, PSYCHIAT CLIN NEUROS, V60, P764, DOI 10.1111/j.1440-1819.2006.01594.x; EYSENCK HJ, 1993, PERCEPT MOTOR SKILL, V76, P837; Gansier DA, 2011, NEUROPSYCHOLOGIA, V49, P2527, DOI 10.1016/j.neuropsychologia.2011.05.001; Greenstein B., 2000, COLOR ATLAS NEUROSCI; Guilford J.P., 1967, NATURE HUMAN INTELLI; Horino M, 1991, JAPANESE J ED PSYCHO, V39, P308; Jung RE, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009818; Jung RE, 2009, J NEUROSCI, V29, P5319, DOI 10.1523/JNEUROSCI.0588-09.2009; Jung-Beeman M, 2004, PLOS BIOL, V2, P500, DOI 10.1371/journal.pbio.0020097; KAHN RS, 1993, PSYCHOPHARMACOLOGY, V112, pS1, DOI 10.1007/BF02245002; Kaplan Frederic, 2007, Front Neurosci, V1, P225, DOI 10.3389/neuro.01.1.1.017.2007; KELLAND MD, 1990, J PHARMACOL EXP THER, V253, P803; Kijimas N, 1996, ARCH PSYCHIAT DIAGN, V7, P379; Kim KH, 2008, J CREATIVE BEHAV, V42, P106; Kirrane R M, 2000, Curr Psychiatry Rep, V2, P62, DOI 10.1007/s11920-000-0044-0; KLINE P, 1986, J GENET PSYCHOL, V147, P183; KOOISTRA CA, 1988, NEUROLOGY, V38, P388; LesBihan D, 2001, J MAGN RESON IMAGING, V13, P534; Mayseless N, 2013, FRONT HUM NEUROSCI, V7, DOI 10.3389/fnhum.2013.00502; Mcnab F, 2008, NAT NEUROSCI, V11, P103, DOI 10.1038/nn2024; McNair D. M., 1992, PROFILE MOOD STATES; O'Reilly T, 2001, PERS INDIV DIFFER, V31, P1067, DOI 10.1016/S0191-8869(00)00204-X; Pelissolo A, 2000, PSYCHIAT RES, V94, P67, DOI 10.1016/S0165-1781(00)00127-X; Picerni E, 2013, FRONT BEHAV NEUROSCI, V7, DOI 10.3389/fnbeh.2013.00133; Piras F, 2010, NEUROSCIENCE, V171, P496, DOI 10.1016/j.neuroscience.2010.09.006; Raven JC, 1993, MANUAL RAVENS PROGR; Shimonaka Y, 2007, JPN J EDUC PSYCHOL, V55, P231; Society_For_Creative_Minds, 1969, MAN S A CREAT TEST; Swerdlow NR, 2003, PSYCHOPHARMACOLOGY, V169, P314, DOI 10.1007/s00213-002-1325-6; Takeuchi H, 2013, FRONT HUM NEUROSCI, V7, DOI 10.3389/fnhum.2013.00875; Takeuchi H, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023175; Takeuchi H, 2013, NEURAL BASES INDIVID; Takeuchi H, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025532; Takeuchi Hikaru, 2014, Front Syst Neurosci, V8, P200, DOI 10.3389/fnsys.2014.00200; Taki Y, 2011, NEUROIMAGE, V60, P471; Taki Y., 2011, NEUROIMAGE, V59, P1023, DOI DOI 10.1016/J.NEUR0IMAGE.2011.08.092; Tanaka M, 2009, MED EDUC, V43, P384, DOI 10.1111/j.1365-2923.2008.03279.x; TORK I, 1990, ANN NY ACAD SCI, V600, P9, DOI 10.1111/j.1749-6632.1990.tb16870.x; Torrance E. P., 1966, TORRANCE TESTS CREAT; Watanabe T, 1998, JPN J PSYCHOL, V68, P478; Wei DT, 2014, CORTEX, V51, P92, DOI 10.1016/j.cortex.2013.09.004; Zeki S, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003556; Zhu FF, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079272	127	1	1	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1065-9471	1097-0193		HUM BRAIN MAPP	Hum. Brain Mapp.	MAY	2015	36	5					1808	1827		10.1002/hbm.22739		20	Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	CG1XH	WOS:000353068300014		
J	Dang, GT; Kawaharamura, T; Furuta, M; Allen, MW				Dang, Giang T.; Kawaharamura, Toshiyuki; Furuta, Mamoru; Allen, Martin W.			Metal-Semiconductor Field-Effect Transistors With In-Ga-Zn-O Channel Grown by Nonvacuum-Processed Mist Chemical Vapor Deposition	IEEE ELECTRON DEVICE LETTERS			English	Article						IGZO; AgO; MESFETs; mist CVD	THIN-FILM TRANSISTORS; PERFORMANCE; BOTTOM	In-Ga-Zn-O (IGZO) thin films (TFs) were grown by cost-effective nonvacuum solution-processed mist chemical vapor deposition. High quality AgOx Schottky contacts (SCs) were fabricated on these IGZO TFs with rectification ratios and barrier heights as high as 7.9 x 10(7) and 1 eV, respectively, combined with ideality factors as low as 1.32. These SCs were subsequently used as gate contacts in the production of metal-semiconductor field-effect transistors (MESFETs) with excellent switching and stability characteristics. For example, typical (W/L 785 mu m/5 mu m) MESFETs were capable of providing ON-currents up to 245 mu A, combined with a large ON/OFF ratio of 3.8 x 10(7). A mobility of 3.2 cm(2)/(V.s) and a low subthreshold swing of 356 mV/decade were achieved in the W/L 524 mu m/10 mu m transistors. Under positive bias stress, these MESFETs were highly stable, demonstrating the feasibility of using a combination of mist chemical vapor deposition grown IGZO and AgOx SCs to produce stable, low power consumption, and low-cost switching devices.	[Dang, Giang T.; Allen, Martin W.] Univ Canterbury, MacDiarmid Inst Adv Mat & Nanotechnol, Dept Elect & Comp Engn, Christchurch 8041, New Zealand; [Kawaharamura, Toshiyuki; Furuta, Mamoru] Kochi Univ Technol, Ctr Nanotechnol, Res Inst, Kochi 7800003, Japan; [Furuta, Mamoru] Kochi Univ Technol, Dept Environm Sci & Engn, Kochi 7800003, Japan	Dang, GT (reprint author), Univ Canterbury, MacDiarmid Inst Adv Mat & Nanotechnol, Dept Elect & Comp Engn, Christchurch 8041, New Zealand.	giang.dang@canterbury.ac.nz			MacDiarmid Institute for Advanced Materials and Nanotechnology, New Zealand	This work was supported by the MacDiarmid Institute for Advanced Materials and Nanotechnology, New Zealand. The review of this letter was arranged by Editor A. Nathan.	Allen MW, 2009, APPL PHYS LETT, V94, DOI 10.1063/1.3089871; Lee DH, 2011, IEEE ELECTR DEVICE L, V32, P1695, DOI 10.1109/LED.2011.2167123; Lee DH, 2012, ECS SOLID STATE LETT, V1, pQ8, DOI 10.1149/2.008201ssl; Chung HJ, 2008, ELECTROCHEM SOLID ST, V11, pH51, DOI 10.1149/1.2826332; Kaczmarski J, 2014, PHYS STATUS SOLIDI-R, V8, P625, DOI 10.1002/pssr.201409124; Allen MW, 2007, APPL PHYS LETT, V91, DOI 10.1063/1.2768028; Jiang JX, 2014, IEEE ELECTR DEVICE L, V35, P933, DOI 10.1109/LED.2014.2336880; Fortunato E, 2012, ADV MATER, V24, P2945, DOI 10.1002/adma.201103228; Kawaharamura T, 2012, JPN J APPL PHYS, V51, DOI 10.1143/JJAP.51.040207; Frenzel H, 2013, PHYS STATUS SOLIDI-R, V7, P605, DOI 10.1002/pssr.201307259; Chasin A, 2013, IEEE T ELECTRON DEV, V60, P3407, DOI 10.1109/TED.2013.2275250; Chasin A, 2012, APPL PHYS LETT, V101, DOI 10.1063/1.4752009; Elzwawi S., 2012, APPL PHYS LETT, V101; Furuta M, 2014, J DISP TECHNOL, V10, P934, DOI 10.1109/JDT.2013.2294967; Kawaharamura T, 2014, JPN J APPL PHYS, V53, DOI 10.7567/JJAP.53.05FF08; Lorenz M., 2010, APPL PHYS LETT, V97	16	2	2	IEEE-INST ELECTRICAL ELECTRONICS ENGINEERS INC	PISCATAWAY	445 HOES LANE, PISCATAWAY, NJ 08855-4141 USA	0741-3106	1558-0563		IEEE ELECTR DEVICE L	IEEE Electron Device Lett.	MAY	2015	36	5					463	465		10.1109/LED.2015.2412124		3	Engineering, Electrical & Electronic	Engineering	CG8NZ	WOS:000353566300014		
J	Hisamoto, D; Yoshimoto, H; Tega, N				Hisamoto, Digh; Yoshimoto, Hiroyuki; Tega, Naoki			Modified Interface State Charge Model for 4H-SiC Power MOSFETs	IEEE ELECTRON DEVICE LETTERS			English	Article						Silicon carbide; 4H-SiC; interface state; power MOSFETs		We propose a modified model for interface-state charges to comprehend the device characteristics of 4H-SiC MOSFETs. Device characteristics, such as channel current and channel capacitance, and their dependence on temperature were intuitionally expected by regarding interface-state charges at the conduction band edge as stagnation. We also found that the observed mobility was underestimated through conventional experimental methods compared with actual channel mobility due to stagnant carriers.	[Hisamoto, Digh; Yoshimoto, Hiroyuki; Tega, Naoki] Hitachi Ltd, Cent Res Lab, Kokubunji, Tokyo 1858601, Japan	Hisamoto, D (reprint author), Hitachi Ltd, Cent Res Lab, Kokubunji, Tokyo 1858601, Japan.	dai.hisamoto.pd@hitachi.com			Central Research Laboratory, Hitachi, Ltd., Kokubunji, Japan	This work was supported by the Central Research Laboratory, Hitachi, Ltd., Kokubunji, Japan. The review of this letter was arranged by Editor K.-S. Chang-Liao.	Yano H, 1999, IEEE T ELECTRON DEV, V46, P504, DOI 10.1109/16.748869; Fukuda K, 2004, APPL PHYS LETT, V84, P2088, DOI 10.1063/1.1682680; Matsushita Y, 2012, PHYS REV LETT, V108, DOI 10.1103/PhysRevLett.108.246404; Okamoto D, 2008, IEEE T ELECTRON DEV, V55, P2013, DOI 10.1109/TED.2008.926639; Chokawa K, 2013, MATER SCI FORUM, V740-742, P469, DOI 10.4028/www.scientific.net/MSF.740-742.469; Chung GY, 2000, APPL PHYS LETT, V76, P1713, DOI 10.1063/1.126167; Yano H, 2002, APPL PHYS LETT, V81, P301, DOI 10.1063/1.1492313; Arnold E, 2001, IEEE T ELECTRON DEV, V48, P1870, DOI 10.1109/16.944171; Saks NS, 2000, APPL PHYS LETT, V77, P3281, DOI 10.1063/1.1326046; Potbhare S, 2008, IEEE T ELECTRON DEV, V55, P2061, DOI 10.1109/TED.2008.926668; Shiraishi K., 2014, IEEE IEDM, P2131; Yoshioka H, 2012, J APPL PHYS, V111, DOI 10.1063/1.3673572	12	0	0	IEEE-INST ELECTRICAL ELECTRONICS ENGINEERS INC	PISCATAWAY	445 HOES LANE, PISCATAWAY, NJ 08855-4141 USA	0741-3106	1558-0563		IEEE ELECTR DEVICE L	IEEE Electron Device Lett.	MAY	2015	36	5					490	492		10.1109/LED.2015.2411751		3	Engineering, Electrical & Electronic	Engineering	CG8NZ	WOS:000353566300023		
J	Marnay, C; Aki, H; Hirose, K; Kwasinski, A; Ogura, S; Shinji, T				Marnay, Chris; Aki, Hirohisa; Hirose, Keiichi; Kwasinski, Alexis; Ogura, Saori; Shinji, Takao			Japan's Pivot to Resilience	IEEE Power & Energy Magazine			English	Article									[Marnay, Chris] Univ Calif Berkeley, Lawrence Berkeley Natl Lab, Berkeley, CA 94720 USA; [Aki, Hirohisa] Natl Inst Adv Ind Sci & Technol, Tsukuba, Ibaraki, Japan; [Hirose, Keiichi] NTT Facil, Tokyo, Japan; [Kwasinski, Alexis] Univ Pittsburgh, Pittsburgh, PA 15260 USA; [Ogura, Saori] Univ Calif Berkeley, Berkeley, CA 94720 USA; [Shinji, Takao] Tokyo Gas, Tokyo, Japan	Marnay, C (reprint author), Univ Calif Berkeley, Lawrence Berkeley Natl Lab, Berkeley, CA 94720 USA.				U.S. National Science Foundation under a CAREER ECCS [0845828]	The authors have benefitted from valuable input as well as graphics and other materials from several sources. They particularly recognize the following: Andrea Mammoli at the University of New Mexico, Alex McEachern at Power Standards Laboratory, Kimio Morino at Shimizu Corp., and Satoshi Morozumi at NEDO. Joe Eto of Lawrence Berkeley National Laboratory reviewed a draft of the article and provided helpful input. Chris Marnay's participation is supported by the U.S. Department of Energy and the U.S. Trade Development Administration. Alexis Kwasinski's contribution is funded by the U.S. National Science Foundation under a CAREER ECCS award #0845828.		0	0	0	IEEE-INST ELECTRICAL ELECTRONICS ENGINEERS INC	PISCATAWAY	445 HOES LANE, PISCATAWAY, NJ 08855-4141 USA	1540-7977	1558-4216		IEEE POWER ENERGY M	IEEE Power Energy Mag.	MAY-JUN	2015	13	3					44	57		10.1109/MPE.2015.2397333		14	Engineering, Electrical & Electronic	Engineering	CG9LH	WOS:000353636100007		
J	Wang, YQ; Hori, Y; Hara, S; Doyle, FJ				Wang, Yongqiang; Hori, Yutaka; Hara, Shinji; Doyle, Francis J., III			Collective Oscillation Period of Inter-Coupled Biological Negative Cyclic Feedback Oscillators	IEEE TRANSACTIONS ON AUTOMATIC CONTROL			English	Article						Collective period; cyclic feedback oscillators; multivariable harmonic balance technique; oscillator networks	CELLULAR CONTROL PROCESSES; CIRCADIAN CLOCK; GENE; EXISTENCE; NETWORKS; SYSTEMS; SYNCHRONIZATION; DYNAMICS	A number of biological rhythms originate from networks comprised of multiple cellular oscillators. But analytical results are still lacking on the collective oscillation period of inter-coupled gene regulatory oscillators, which, as has been reported, may be different from that of an autonomous oscillator. Based on cyclic feedback oscillators, we analyze the collective oscillation pattern of coupled cellular oscillators. First we give a condition under which the oscillator network exhibits oscillatory and synchronized behavior. Then we estimate the collective oscillation period based on a novel multivariable harmonic balance technique. Analytical results are derived in terms of biochemical parameters, thus giving insight into the basic mechanism of biological oscillation and providing guidance in synthetic biology design.	[Wang, Yongqiang] Univ Calif Santa Barbara, Inst Collaborat Biotechnol, Santa Barbara, CA 93106 USA; [Hori, Yutaka] CALTECH, Comp & Math Sci, Pasadena, CA 91125 USA; [Hara, Shinji] Univ Tokyo, Dept Informat Phys & Comp, Tokyo 1138656, Japan; [Doyle, Francis J., III] Univ Calif Santa Barbara, Dept Chem Engn, Santa Barbara, CA 93106 USA	Wang, YQ (reprint author), Clemson Univ, Dept Elect & Comp Engn, Clemson, SC 29634 USA.	yongqiw@clemson.edu; yhori@caltech.edu; Shinji_hara@ipc.i.u-tokyo.ac.jp; frank.doyle@icb.ucsb.edu			NIH [GM096873]; ICB from U.S. ARO [W911NF-09-0001]; JSPS [23-9203]; JSPS fellowship for Research Abroad; GASR [21246067]	This work was supported in part by the NIH under Grant GM096873, the ICB under Grant W911NF-09-0001 from U.S. ARO, the JSPS under Grant 23-9203, the JSPS fellowship for Research Abroad (Y.H.), and the GASR (A) under Grant 21246067. A special case of the work (inter-coupled Goodwin oscillators) was published in IEEE CDC 2012 [1]. Recommended by Associate Editor F. Blanchini.	Popovych OV, 2011, PROG BIOPHYS MOL BIO, V105, P98, DOI 10.1016/j.pbiomolbio.2010.09.018; Novak B, 2008, NAT REV MOL CELL BIO, V9, P981, DOI 10.1038/nrm2530; Pogromsky A, 1999, INT J BIFURCAT CHAOS, V9, P629, DOI 10.1142/S0218127499000444; To TL, 2007, BIOPHYS J, V92, P3792, DOI 10.1529/biophysj.106.094086; Olfati-Saber R, 2007, P IEEE, V95, P215, DOI 10.1109/JPROC.2006.887293; Hamadeh A, 2012, IEEE T AUTOMAT CONTR, V57, P478, DOI 10.1109/TAC.2011.2164015; [Anonymous], 1978, PROGR THEORET BIOL; Hori Y, 2011, AUTOMATICA, V47, P1203, DOI 10.1016/j.automatica.2011.02.042; Herrgen L, 2010, CURR BIOL, V20, P1244, DOI 10.1016/j.cub.2010.06.034; Liu C, 1997, CELL, V91, P855, DOI 10.1016/S0092-8674(00)80473-0; Bagheri N, 2008, J R SOC INTERFACE, V5, pS17, DOI 10.1098/rsif.2008.0045.focus; El Samad H, 2005, P AMER CONTR CONF, P4405, DOI 10.1109/ACC.2005.1470689; Fall C. P., 2005, COMPUTATIONAL CELL B; Glad T., 2000, CONTROL THEORY MULTI; GRIFFITH JS, 1968, J THEOR BIOL, V20, P202, DOI 10.1016/0022-5193(68)90189-6; Hori Y, 2013, AUTOMATICA, V49, P2581, DOI 10.1016/j.automatica.2013.04.020; HUNDING A, 1974, BIOPHYS STRUCT MECH, V1, P47, DOI 10.1007/BF01022559; Iwasaki T, 2008, AUTOMATICA, V44, P3061, DOI 10.1016/j.automatica.2008.05.024; Johnson C. R., 1985, MATRIX ANAL; Khalil H.K., 2002, NONLINEAR SYSTEMS; MacDonald N., 1978, TIME LAGS BIOL MODEL; Rapp P., 1976, MATH BIOL, V25, P203; Stephanopoulos N., 1998, METABOLIC ENG PRINCI; TURING AM, 1952, PHILOS T ROY SOC B, V237, P37, DOI 10.1098/rstb.1952.0012; TYSON JJ, 1979, J THEOR BIOL, V80, P27, DOI 10.1016/0022-5193(79)90177-2; TYSON JJ, 1975, J MATH BIOL, V1, P311; Wang Y. Q., COLLECTIVE OSCILLATI; Wang YQ, 2014, IEEE T AUTOMAT CONTR, V59, P211, DOI 10.1109/TAC.2013.2270072; Wang YQ, 2012, IEEE DECIS CONTR P, P1627; Wunsche HJ, 2005, PHYS REV LETT, V94, DOI 10.1103/PhysRevLett.94.163901	30	1	1	IEEE-INST ELECTRICAL ELECTRONICS ENGINEERS INC	PISCATAWAY	445 HOES LANE, PISCATAWAY, NJ 08855-4141 USA	0018-9286	1558-2523		IEEE T AUTOMAT CONTR	IEEE Trans. Autom. Control	MAY	2015	60	5					1392	1397		10.1109/TAC.2014.2342072		6	Automation & Control Systems; Engineering, Electrical & Electronic	Automation & Control Systems; Engineering	CG7TN	WOS:000353508100020		
J	Kodama, C; Ichikawa, H; Nakayama, K; Nakajima, F; Nojima, S; Kotani, T; Ihara, T; Takahashi, A				Kodama, Chikaaki; Ichikawa, Hirotaka; Nakayama, Koichi; Nakajima, Fumiharu; Nojima, Shigeki; Kotani, Toshiya; Ihara, Takeshi; Takahashi, Atsushi			Self-Aligned Double and Quadruple Patterning Aware Grid Routing Methods	IEEE TRANSACTIONS ON COMPUTER-AIDED DESIGN OF INTEGRATED CIRCUITS AND SYSTEMS			English	Article						Design for manufacturing; lithography; routing; self-aligned double patterning (SADP); self-aligned quadruple patterning (SAQP)	LAYOUT DECOMPOSITION; MINIMIZATION; LITHOGRAPHY	Although self-aligned double and quadruple patterning (SADP, SAQP) have promising processes for sub-20 nm node advanced technologies and beyond, not all layouts are compatible with them. In advanced technologies, feasible wafer image should be generated effectively by utilizing SADP and SAQP where a wafer image is determined by a selected mandrel pattern. However, predicting a mandrel pattern is not easy since it is different from the wafer image (or target pattern). In this paper, we propose new routing methods for spacer-is-dielectric (SID)-type SADP, SID-type SAQP, and spacer-is-metal (SIM)-type SADP to generate a feasible layout satisfying the connection requirements. Routing algorithms comprising simple connecting and cutting rules are performed on a new grid structure where two (SID-type SADP) or three colors (SID-type SAQP and SIM-type SADP) are assigned alternately to grid-nodes. Then a mandrel pattern is selected without complex coloring or decomposition methods. Also, we try to reduce hotspots (potentially defective regions) by the proposed dummy pattern flipping for SID-type SADP. In experiments, feasible layouts meeting the connection requirements are generated and the effectiveness of the proposed framework is confirmed.	[Kodama, Chikaaki; Nakayama, Koichi; Nakajima, Fumiharu; Nojima, Shigeki; Kotani, Toshiya] Toshiba Co Ltd, Semicond & Storage Prod Co, Yokohama, Kanagawa 2478585, Japan; [Ichikawa, Hirotaka] Toshiba Microelect Corp, Kawasaki, Kanagawa 2108538, Japan; [Ihara, Takeshi; Takahashi, Atsushi] Tokyo Inst Technol, Grad Sch Sci & Engn, Dept Commun & Comp Engn, Tokyo 1528550, Japan	Kodama, C (reprint author), Toshiba Co Ltd, Semicond & Storage Prod Co, Yokohama, Kanagawa 2478585, Japan.	chikaaki1.kodama@toshiba.co.jp; hirotaka.ichikawa@glb.toshiba.co.jp; atsushi@eda.ce.titech.ac.jp					Bencher C, 2011, PROC SPIE, V7970, DOI 10.1117/12.881293; Ban YC, 2011, DES AUT CON, P789; Cabral Jr C., 2010, P 2010 ADV MET C ALB, P136; Du Y., 2013, P ACM IEEE DAC, P1; Gao JR, 2012, ISPD 12: PROCEEDINGS OF THE 2012 INTERNATIONAL SYMPOSIUM ON PHYSICAL DESIGN, P25; Hsu CH, 2011, IEEE T COMPUT AID D, V30, P284, DOI 10.1109/TCAD.2010.2079990; Kahng AB, 2010, IEEE T COMPUT AID D, V29, P939, DOI 10.1109/TCAD.2010.2048374; Kodama C., P 2013 IEEE ACM AS S, P267; Li QA, 2010, P SOC PHOTO-OPT INS, V7823, DOI 10.1117/12.864302; Ma YS, 2010, P SOC PHOTO-OPT INS, V7641, DOI 10.1117/12.848387; McMurchie L., P 1995 3 INT ACM S F, P111; Mirsaeedi M, 2011, PROC SPIE, V7974, DOI 10.1117/12.877601; Nakayama K, 2012, PROC SPIE, V8327, DOI 10.1117/12.916678; SAIT S, 1995, VLSI PHYS DESIGN AUT; Smayling MC, 2014, PROC SPIE, V9052, DOI 10.1117/12.2045667; Xu P, 2011, PROC SPIE, V7973, DOI 10.1117/12.881547; Yuan K, 2010, IEEE T COMPUT AID D, V29, P185, DOI 10.1109/TCAD.2009.2035577; Zhang HB, 2011, DES AUT CON, P71	18	0	0	IEEE-INST ELECTRICAL ELECTRONICS ENGINEERS INC	PISCATAWAY	445 HOES LANE, PISCATAWAY, NJ 08855-4141 USA	0278-0070	1937-4151		IEEE T COMPUT AID D	IEEE Trans. Comput-Aided Des. Integr. Circuits Syst.	MAY	2015	34	5					753	765		10.1109/TCAD.2015.2404878		13	Computer Science, Hardware & Architecture; Computer Science, Interdisciplinary Applications; Engineering, Electrical & Electronic	Computer Science; Engineering	CG7TX	WOS:000353509300006		
J	Wang, YB; Fang, HZ; Sahinoglu, Z; Wada, T; Hara, S				Wang, Yebin; Fang, Huazhen; Sahinoglu, Zafer; Wada, Toshihiro; Hara, Satoshi			Adaptive Estimation of the State of Charge for Lithium-Ion Batteries: Nonlinear Geometric Observer Approach	IEEE TRANSACTIONS ON CONTROL SYSTEMS TECHNOLOGY			English	Article						Adaptive estimation; geometric method; lithium-ion (Li+) batteries; nonlinear systems; state of charge (SoC)	LINEARIZABLE ERROR DYNAMICS; SINGLE-PARTICLE MODEL; BLOCK-TRIANGULAR FORM; MANAGEMENT-SYSTEMS; PARAMETER-ESTIMATION; OUTPUT INJECTION; INSERTION CELL; DESIGN; TRANSFORMATIONS; DISCHARGE	This paper considers the state of charge (SoC) and parameter estimation of lithium-ion batteries. Different from various prior arts, where estimation is based on local linearization of a nonlinear battery model, nonlinear geometric observer approach is followed to design adaptive observers for the SoC and parameter estimation based on nonlinear battery models. A major advantage of the proposed approach is the possibility to establish the exponential stability of the resultant error dynamics of state and parameter estimation. The proposed adaptive observers are shown to be robust with respect to unmodeled process uncertainties. Analysis also shows the design tradeoff between the convergence rate and the robustness of the estimation error dynamics with respect to the measurement noise. Simulation and experimental results validate the effectiveness and main advantages of the proposed approach. Error analysis is presented and explains the experimental results.	[Wang, Yebin; Fang, Huazhen; Sahinoglu, Zafer] Mitsubishi Elect Res Labs, Cambridge, MA 02139 USA; [Wada, Toshihiro; Hara, Satoshi] Mitsubishi Electr Corp, Adv Technol Res & Dev Ctr, Amagasaki, Hyogo 6618661, Japan	Wang, YB (reprint author), Mitsubishi Elect Res Labs, Cambridge, MA 02139 USA.	yebinwang@ieee.org; fang@ku.edu; zafer@merl.com; wada.toshihiro@bx.mitsubishielectric.co.jp; hara.satoshi@cb.mitsubishielectric.co.jp					Barbarisi O, 2006, CONTROL ENG PRACT, V14, P267, DOI 10.1016/j.conengprac.2005.03.027; Pop V, 2005, MEAS SCI TECHNOL, V16, pR93, DOI 10.1088/0957-0233/16/12/R01; Kim IS, 2006, J POWER SOURCES, V163, P584, DOI 10.1016/j.jpowsour.2006.09.006; Santhanagopalan S, 2010, INT J ENERG RES, V34, P152, DOI 10.1002/er.1655; MARINO R, 1992, IEEE T AUTOMAT CONTR, V37, P1239, DOI 10.1109/9.151117; Plett GL, 2004, J POWER SOURCES, V134, P277, DOI 10.1016/j jpowsour.2004.02.033; Besancon G, 1999, IEEE T AUTOMAT CONTR, V44, P1975, DOI 10.1109/9.793789; Milocco RH, 2014, J POWER SOURCES, V246, P609, DOI 10.1016/j.jpowsour.2013.08.006; Respondek W, 2004, AUTOMATICA, V40, P277, DOI 10.1016/j.automatica.2003.09.012; Nishi Y, 2001, J POWER SOURCES, V100, P101, DOI 10.1016/S0378-7753(01)00887-4; Coleman M, 2007, IEEE T IND ELECTRON, V54, P2550, DOI 10.1109/TIE.2007.899926; KRENER AJ, 1983, SYST CONTROL LETT, V3, P47, DOI 10.1016/0167-6911(83)90037-3; FULLER TF, 1994, J ELECTROCHEM SOC, V141, P1, DOI 10.1149/1.2054684; Santhanagopalan S, 2006, J POWER SOURCES, V156, P620, DOI 10.1016/j.jpowsour.2005.05.070; Farza M, 2009, AUTOMATICA, V45, P2292, DOI 10.1016/j.automatica.2009.06.008; DOYLE M, 1993, J ELECTROCHEM SOC, V140, P1526, DOI 10.1149/1.2221597; Smith K, 2006, J POWER SOURCES, V161, P628, DOI 10.1016/j.jpowsour.2006.03.050; Moura SJ, 2012, P AMER CONTR CONF, P559; Plett GL, 2006, J POWER SOURCES, V161, P1369, DOI 10.1016/j.jpowsour.2006.06.004; Klein R, 2013, IEEE T CONTR SYST T, V21, P289, DOI 10.1109/TCST.2011.2178604; ATLUNG S, 1979, J ELECTROCHEM SOC, V126, P1311, DOI 10.1149/1.2129269; Back J, 2006, AUTOMATICA, V42, P2195, DOI 10.1016/j.automatica.2006.07.009; BASTIN G, 1988, IEEE T AUTOMAT CONTR, V33, P650, DOI 10.1109/9.1273; BORNARD G, 1991, PROCEEDINGS OF THE 30TH IEEE CONFERENCE ON DECISION AND CONTROL, VOLS 1-3, P1494, DOI 10.1109/CDC.1991.261650; Chaturvedi NA, 2010, IEEE CONTR SYST MAG, V30, P49, DOI 10.1109/MCS.2010.936293; Chiasson J, 2005, IEEE T CONTR SYST T, V13, P465, DOI 10.1109/TCST.2004.839571; Di Domenico D., 2008, P IEEE INT C CONTR A, P702; Fang H., 2013, P AM CONTR C, P3491; Fang HZ, 2014, J POWER SOURCES, V254, P258, DOI 10.1016/j.jpowsour.2013.12.005; GAUTHIER JP, 1992, IEEE T AUTOMAT CONTR, V37, P875, DOI 10.1109/9.256352; Gevers M., 1986, Analysis and Optimization of Systems. Proceedings of the Seventh International Conference; Guay M., 2001, P NOLCOS ST PET RUSS, P1443; Guo M, 2011, J ELECTROCHEM SOC, V158, pA122, DOI 10.1149/1.3521314; HERMANN R, 1977, IEEE T AUTOMAT CONTR, V22, P728, DOI 10.1109/TAC.1977.1101601; Hu Y, 2012, J POWER SOURCES, V198, P338, DOI 10.1016/j.jpowsour.2011.09.058; Kazantzis N, 1997, IEEE DECIS CONTR P, P4802, DOI 10.1109/CDC.1997.649779; Khalil H.K., 2002, NONLINEAR SYSTEMS; KRENER AJ, 1985, SIAM J CONTROL OPTIM, V23, P197, DOI 10.1137/0323016; Lynch AF, 2001, IEEE T AUTOMAT CONTR, V46, P927, DOI 10.1109/9.928597; Marino R, 2010, ADV IND CONTROL, P1, DOI 10.1007/978-1-84996-284-1; Marino Riccardo, 1995, NONLINEAR CONTROL DE; McIntyre M, 2006, P AMER CONTR CONF, V1-12, P5740, DOI 10.1109/ACC.2006.1657640; Nocedal J, 2006, SPRINGER SER OPER RE, P1, DOI 10.1007/978-0-387-40065-5; Rahimian SK, 2013, J POWER SOURCES, V224, P180, DOI 10.1016/j.jpowsour.2012.09.084; RUDOLPH J, 1994, SYST CONTROL LETT, V23, P1, DOI 10.1016/0167-6911(94)90075-2; Schaffner J, 1999, INT J SYST SCI, V30, P1131, DOI 10.1080/002077299291750; Seber G. A. F., 2003, NONLINEAR REGRESSION; Shim H, 2001, SYST CONTROL LETT, V42, P233, DOI 10.1016/S0167-6911(00)00098-0; Smith K. A., 2008, P IEEE INT C CONTR A, P714, DOI DOI 10.1109/CCA.2008.4629589; Verbrugge M, 2004, J POWER SOURCES, V126, P236, DOI 10.1016/j.jpowsour.2003.08.042; Wang Y., 2013, P IEEE C DEC CONTR, P4405; Wang Y., 2008, THESIS U ALBERTA EDM; Wang Y, 2008, INT J CONTROL, V81, P177, DOI 10.1080/00207170701487771; Wang YB, 2009, SYST CONTROL LETT, V58, P346, DOI 10.1016/j.sysconle.2008.12.005; Wang YB, 2006, IEEE T AUTOMAT CONTR, V51, P1803, DOI 10.1109/TAC.2006.884996; Wang YB, 2010, IEEE T AUTOMAT CONTR, V55, P966, DOI 10.1109/TAC.2010.2041616	56	3	3	IEEE-INST ELECTRICAL ELECTRONICS ENGINEERS INC	PISCATAWAY	445 HOES LANE, PISCATAWAY, NJ 08855-4141 USA	1063-6536	1558-0865		IEEE T CONTR SYST T	IEEE Trans. Control Syst. Technol.	MAY	2015	23	3					948	962		10.1109/TCST.2014.2356503		15	Automation & Control Systems; Engineering, Electrical & Electronic	Automation & Control Systems; Engineering	CG7YL	WOS:000353523700010		
J	Ando, Y; Takenaka, I; Takahashi, H; Sasaoka, C				Ando, Yuji; Takenaka, Isao; Takahashi, Hidemasa; Sasaoka, Chiaki			Correlation Between Epitaxial Layer Quality and Drain Current Stability of GaN/AlGaN/GaN Heterostructure Field-Effect Transistors	IEEE TRANSACTIONS ON ELECTRON DEVICES			English	Article						GaN; heterostructure field-effect transistor (HFET); instability	LEVEL TRANSIENT SPECTROSCOPY; MG-DOPED GAN; YELLOW LUMINESCENCE; ACCEPTOR LEVELS; DEEP LEVELS; CARBON; TRAPS; DLTS; DISLOCATIONS; RELIABILITY	Stability of current-voltage characteristics was investigated for GaN/AlGaN/GaN heterostructure field-effect transistors, which were fabricated using epiwafers with different yellow luminescence (YL)-to-band edge (BE) ratios in photoluminescence spectrum and full-width at half-maximum (FWHM) values of X-ray rocking curves. After application of a long-term high-voltage OFF-state stress, they exhibited a temporary reduction of drain current (I-d) accompanied by a positive threshold voltage shift with a long recovery time (>1 h at room temperature). To study the mechanism of this instability, transient of I-d just after removing the stress was measured under the subthreshold condition for different ambient temperatures (-20 degrees C to 200 degrees C). An isothermal capacitance transient spectroscopy-like analysis applied to the transient signal indicated that electron traps with an activation energy of 0.3-0.5 eV and a density of the order of 10(11) cm(-2) are responsible for this phenomenon. The emission rate of these electron traps increased when the YL/BE ratio was reduced, while the trap density decreased when the FWHM values were reduced. These results suggest that the long-term I-d transient can be minimized by reducing both of these parameters.	[Ando, Yuji; Takenaka, Isao; Takahashi, Hidemasa; Sasaoka, Chiaki] Renesas Syst Design Co Ltd, Otsu, Shiga 5208555, Japan	Ando, Y (reprint author), Renesas Syst Design Co Ltd, Otsu, Shiga 5208555, Japan.	yuji.ando.ry@renesas.com; isao.takenaka.jc@renesas.com; hidemasa.takahashi.ym@renesas.com; chiaki.sasaoka.xe@renesas.com					Ando Y., 2005, IEDM, P576, DOI 10.1109/IEDM.2005.1609412; Ando Y, 2013, IEEE T ELECTRON DEV, V60, P4125, DOI 10.1109/TED.2013.2284285; GLASER ER, 1995, PHYS REV B, V51, P13326, DOI 10.1103/PhysRevB.51.13326; Meneghesso G, 2008, IEEE T DEVICE MAT RE, V8, P332, DOI 10.1109/TDMR.2008.923743; Seager CH, 2002, J APPL PHYS, V92, P6553, DOI 10.1063/1.1518794; Hofmann DM, 1995, PHYS REV B, V52, P16702, DOI 10.1103/PhysRevB.52.16702; Koley G, 2003, IEEE T ELECTRON DEV, V50, P886, DOI 10.1109/TED.2003.812489; Wright AF, 2002, J APPL PHYS, V92, P2575, DOI 10.1063/1.1498879; BLIGHT SR, 1986, IEEE T ELECTRON DEV, V33, P1447, DOI 10.1109/T-ED.1986.22693; Armstrong A, 2005, J APPL PHYS, V98, DOI 10.1063/1.2005379; Bisi D, 2013, IEEE T ELECTRON DEV, V60, P3166, DOI 10.1109/TED.2013.2279021; Hasegawa H, 2003, J VAC SCI TECHNOL B, V21, P1844, DOI 10.1116/1.1589520; Ando Y, 2003, IEEE ELECTR DEVICE L, V24, P289, DOI 10.1109/LED.2003.812532; Okino T, 2004, IEEE ELECTR DEVICE L, V25, P523, DOI 10.1109/LED.2004.832788; LANG DV, 1974, J APPL PHYS, V45, P3023, DOI 10.1063/1.1663719; Marso M, 2003, APPL PHYS LETT, V82, P633, DOI 10.1063/1.1540239; Mishra UK, 2008, P IEEE, V96, P287, DOI 10.1109/JPROC.2007.911060; Elsner J, 1998, PHYS REV B, V58, P12571, DOI 10.1103/PhysRevB.58.12571; Cho HK, 2003, J APPL PHYS, V94, P1485, DOI 10.1063/1.1586981; Joh J, 2011, IEEE T ELECTRON DEV, V58, P132, DOI 10.1109/TED.2010.2087339; Chini A, 2009, 2009 EUROPEAN MICROWAVE INTEGRATED CIRCUITS CONFERENCE (EUMIC 2009), P132; Chini A, 2009, ELECTRON LETT, V45, P426, DOI 10.1049/el.2009.0533; Fang Z.-Q., 2009, J APPL PHYS, V105; KATO M, 2008, B NATL MUS NAT SCI S, V34, P1; Lyons J. L., 2010, APPL PHYS LETT, V97; Miczek M., 2008, J APPL PHYS, V103; Nakano Y, 2002, J APPL PHYS, V92, P5590, DOI 10.1063/1.1512681; Nakano Y, 2001, APPL PHYS LETT, V79, P1631, DOI 10.1063/1.1401779; OGINO T, 1980, JPN J APPL PHYS, V19, P2395, DOI 10.1143/JJAP.19.2395; OKUSHI H, 1981, JPN J APPL PHYS, V20, pL549, DOI 10.1143/JJAP.20.L549; Ota K., 2009, IEDM, P1; Polyakov AY, 1996, J APPL PHYS, V80, P6349, DOI 10.1063/1.363653; Rao H., 2010, J APPL PHYS, V108; Saadaoui S., 2012, J APPL PHYS, V111; Sasikumar A., 2013, APPL PHYS LETT, V103; Soh CB, 2004, J PHYS-CONDENS MAT, V16, P6305, DOI 10.1088/0953-8984/16/34/027; Sozza A., 2005, IEDM, P590, DOI 10.1109/IEDM.2005.1609416; Stoklas R., 2008, APPL PHYS LETT, V93; Sze S. M., 1981, PHYS SEMICONDUCTOR D; Tapajna M., 2010, APPL PHYS LETT, V97; Usui A., 2001, P MAT RES SOC S, V639; Verzellesi Giovanni, 2014, IEEE Electron Device Letters, V35, DOI 10.1109/LED.2014.2304680; Zhang K., 2013, J APPL PHYS, V113	43	0	0	IEEE-INST ELECTRICAL ELECTRONICS ENGINEERS INC	PISCATAWAY	445 HOES LANE, PISCATAWAY, NJ 08855-4141 USA	0018-9383	1557-9646		IEEE T ELECTRON DEV	IEEE Trans. Electron Devices	MAY	2015	62	5					1440	1447		10.1109/TED.2015.2410345		8	Engineering, Electrical & Electronic; Physics, Applied	Engineering; Physics	CG8NJ	WOS:000353564600011		
J	Yamaji, M; Jonishi, A; Tanaka, T; Sumida, H; Hashimoto, Y				Yamaji, Masaharu; Jonishi, Akihiro; Tanaka, Takahide; Sumida, Hitoshi; Hashimoto, Yoshio			A 600 V High-Voltage IC Technique With a New Self-Shielding Structure for High Noise Tolerance and Die Shrink	IEEE TRANSACTIONS ON ELECTRON DEVICES			English	Article						600 V; high-voltage IC (HVIC); noise tolerance; self-shielding	SOI	A novel 600 V high-voltage IC (HVIC) featuring a high noise tolerance is proposed. The purpose of the proposed HVIC is to achieve the high noise tolerance without an increase of the fabrication cost. The basic device concept is to arrange a P-separation layer around the high-side control part, which is called a new self-shielding structure, to reduce a hole current injection under the condition of negative transient voltage noise. By applying the new self-shielding structure in the HVIC, more than 3x higher noise tolerance (-95 V/1 mu s) and 20% die shrink can be obtained compared with a conventional HVIC, without additional fabrication process. This means the noise tolerance of the fabricated HVIC with proposed structure is high enough to be applied to over 600 V/50-A class power conversion applications. In this paper, the new self-shielding concept of the proposed 600 V-class HVIC is presented with the simulation and experimental results.	[Yamaji, Masaharu; Jonishi, Akihiro; Tanaka, Takahide; Sumida, Hitoshi] Fuji Elect Co Ltd, Dept Device Dev, Dev Div, Elect Devices Business Grp, Matsumoto, Nagano 3900821, Japan; [Hashimoto, Yoshio] Shinshu Univ, Inst Carbon Sci & Technol, Nagano 3808553, Japan	Yamaji, M (reprint author), Fuji Elect Co Ltd, Dept Device Dev, Dev Div, Elect Devices Business Grp, Matsumoto, Nagano 3900821, Japan.	yamaji-masaharu-m@fujielectric.com; jonishi-akihiro@fujielectric.com; tanaka-takahide@fujielectric.com; sumida-hitoshi@fujielectric.com; hashimt@shinshu-u.ac.jp					Akiyama H., 2004, Proceedings of the 16th International Symposium on Power Semiconductor Devices & IC's; Sun WF, 2012, PROC INT SYMP POWER, P193; Kim SL, 2005, INT SYM POW SEMICOND, P143; Arad E. O., 2012, P IEEE 27 CONV EL EL, P1; Fujihira T, 1996, JPN J APPL PHYS 1, V35, P5655, DOI 10.1143/JJAP.35.5655; Jizhi L., 2009, J SEMICOND, V30; Kim JJ, 2002, IEEE POWER ELECTRON, P626; Kong MF, 2013, IEEE T ELECTRON DEV, V60, P2318, DOI 10.1109/TED.2013.2263578; Luo XR, 2010, IEEE T ELECTRON DEV, V57, P3033, DOI 10.1109/TED.2010.2066279; Luo XR, 2009, IEEE ELECTR DEVICE L, V30, P1093, DOI 10.1109/LED.2009.2028249; Moon NC, 2013, PROC INT SYMP POWER, P151; Nolhier N, 1996, CAS '96 PROCEEDINGS - 1996 INTERNATIONAL SEMICONDUCTOR CONFERENCE, 19TH EDITION, VOLS 1 AND 2, P267, DOI 10.1109/SMICND.1996.557368; Pawel S, 2005, INT SYM POW SEMICOND, P55; Qiao M., 2006, P 8 INT C SOL STAT I, P248; Shimizu K, 2008, INT SYM POW SEMICOND, P311; Takahashi T, 2007, INT SYM POW SEMICOND, P69, DOI 10.1109/ISPSD.2007.4294934; Terashima T., 1993, Proceedings of the 5th International Symposium on Power Semiconductor Devices and ICs ISPSD '93 (Cat. No.93CH3314-2), DOI 10.1109/ISPSD.1993.297076; Venturato M, 2012, PROC INT SYMP POWER, P397, DOI 10.1109/ISPSD.2012.6229105; Watabe K, 1998, IEEE J SOLID-ST CIRC, V33, P1423, DOI 10.1109/4.711342; Yamaji M., 2012, J ENERGY POWER ENG, V6, P1515; Yamaji Masaharu, 2012, Proceedings of the PCIM ASIA 2012. International Conference and Exhibition for Power Electronics, Intelligent Motion, Renewable Energy and Energy Management; Yamamoto M., 2012, PCIM EUR 2012 8 10 M, P466; Yamazaki T, 2006, JPN J APPL PHYS 1, V45, P43, DOI 10.1143/JJAP.45.43; Yamazaki T., 1999, P 11 INT S POW SEM D, P333; Yoshino M, 2013, PROC INT SYMP POWER, P77, DOI 10.1109/ISPSD.2013.6694401; Yunwu Z., 2013, J SEMICOND, V34	26	0	0	IEEE-INST ELECTRICAL ELECTRONICS ENGINEERS INC	PISCATAWAY	445 HOES LANE, PISCATAWAY, NJ 08855-4141 USA	0018-9383	1557-9646		IEEE T ELECTRON DEV	IEEE Trans. Electron Devices	MAY	2015	62	5					1524	1529		10.1109/TED.2015.2414923		6	Engineering, Electrical & Electronic; Physics, Applied	Engineering; Physics	CG8NJ	WOS:000353564600024		
J	Nishi, Y; Fleck, K; Bottger, U; Waser, R; Menzel, S				Nishi, Yoshifumi; Fleck, Karsten; Boettger, Ulrich; Waser, Rainer; Menzel, Stephan			Effect of RESET Voltage on Distribution of SET Switching Time of Bipolar Resistive Switching in a Tantalum Oxide Thin Film	IEEE TRANSACTIONS ON ELECTRON DEVICES			English	Article						Bipolar resistive switching; nonvolatile memory; switching statistics	PARAMETER VARIATION; KINETICS; PREDICTION; BREAKDOWN; ORIGIN; MODEL	The distribution of SET switching time of bipolar switching tantalum oxide thin films is studied using pulse measurement techniques. SET switching times are measured by repeating SET and RESET operations in a single cell. It is found that the distribution measured with a high RESET voltage can be well described by a steep Weibull distribution with a shape parameter >1, but lowering the RESET voltage results in a broad distribution at high cumulative frequencies. Statistical analysis shows that this broadening of the distribution can be attributed to the variation of initial conditions for SET, whereas a steep Weibull distribution points to an aging process leading to SET under a voltage stress. It is also shown that although the power of the leakage current before SET determines the fastest limit of the SET switching speed, those SET in the broadened distributions are delayed due to gradual current increase prior to the SET. The waiting time for the start of the gradual current increase has a correlation with the power of the leakage current, showing that Joule heating effect is still a significant factor in the SET mechanism even if the SET time distribution is broadened due to the variation of initial states programmed by low RESET voltages.	[Nishi, Yoshifumi; Waser, Rainer] Rhein Westfal TH Aachen, Inst Werkstoffe Elektrotech 2, D-52062 Aachen, Germany; [Fleck, Karsten; Boettger, Ulrich] Rhein Westfal TH Aachen, Inst Werkstoffe Elektrotech 2, D-52074 Aachen, Germany; [Fleck, Karsten; Boettger, Ulrich; Waser, Rainer; Menzel, Stephan] JARA Fundamentals Future Informat Technol, D-52425 Julich, Germany; [Waser, Rainer] Forschungszentrum Julich, Peter Grunberg Inst, D-52425 Julich, Germany; [Menzel, Stephan] Forschungszentrum Julich, Peter Grunberg Inst, D-52428 Julich, Germany	Nishi, Y (reprint author), Toshiba Co Ltd, Corp Res & Dev Ctr, Adv LSI Technol Lab, Kawasaki, Kanagawa 2128582, Japan.	yoshifumi.nishi@toshiba.co.jp; fleck@iwe.rwth-aachen.de; boettger@iwe.rwth-aachen.de; waser@iwe.rwth-aachen.de; st.menzel@fz-juelich.de			Deutsche Forschungsgemeinschaft [SFB 917]	This work was supported by the Deutsche Forschungsgemeinschaft under Grant SFB 917. The review of this paper was arranged by Editor G.-H. Koh.	Luo WC, 2013, IEEE T ELECTRON DEV, V60, P3760, DOI 10.1109/TED.2013.2281991; Yu SM, 2012, IEEE T ELECTRON DEV, V59, P1183, DOI 10.1109/TED.2012.2184544; Menzel S, 2011, ADV FUNCT MATER, V21, P4487, DOI 10.1002/adfm.201101117; Yang JJ, 2009, NANOTECHNOLOGY, V20, DOI 10.1088/0957-4484/20/21/215201; Nishi Y, 2014, IEEE ELECTR DEVICE L, V35, P259, DOI 10.1109/LED.2013.2294868; Larentis S, 2012, IEEE T ELECTRON DEV, V59, P2468, DOI 10.1109/TED.2012.2202320; Guan XM, 2012, IEEE T ELECTRON DEV, V59, P1172, DOI 10.1109/TED.2012.2184545; Waser R, 2009, ADV MATER, V21, P2632, DOI 10.1002/adma.200900375; Cao M. G., 2012, APPL PHYS LETT, V101; Jeong D. S., 2008, J APPL PHYS, V104; Kalbfleisch J.D., 1980, STAT ANAL FAILURE TI; Kim S, 2013, SCI REP-UK, V3, DOI 10.1038/srep01680; Long S., 2012, J APPL PHYS, V111; Medeiros-Ribeiro G., 2011, NANOTECHNOLOGY, V22; Monsieur F., 2002, P INT REL PHYS S, P45; Nishi Y, 2013, PROC EUR S-STATE DEV, P174; Sahhaf S, 2007, INT EL DEVICES MEET, P501, DOI 10.1109/IEDM.2007.4418984; Schmelzer S., 2013, THESIS RWTH AACHEN U; Siemon A., 2014, P IEEE INT S CIRC SY, P1420; STAPPER CH, 1973, IEEE T ELECTRON DEV, VED20, P655, DOI 10.1109/T-ED.1973.17719; Tous Santi, 2008, IEEE Electron Device Letters, V29, DOI 10.1109/LED.2008.2001178; Tous S., 2011, J APPL PHYS, V109; Wei Z., 2008, P 19 INT C PATT REC, P1; Wei Z., 2011, P IEEE INT EL DEV M; Wu EY, 2000, IEEE T ELECTRON DEV, V47, P2301, DOI 10.1109/16.887012; Wu EY, 2013, APPL PHYS LETT, V103, DOI 10.1063/1.4824035; Yang J. J., 2010, APPL PHYS LETT, V97	27	0	0	IEEE-INST ELECTRICAL ELECTRONICS ENGINEERS INC	PISCATAWAY	445 HOES LANE, PISCATAWAY, NJ 08855-4141 USA	0018-9383	1557-9646		IEEE T ELECTRON DEV	IEEE Trans. Electron Devices	MAY	2015	62	5					1561	1567		10.1109/TED.2015.2411748		7	Engineering, Electrical & Electronic; Physics, Applied	Engineering; Physics	CG8NJ	WOS:000353564600029		
J	Liu, GY; Yokoyama, S				Liu, Gongyi; Yokoyama, Shin-ichiro			Proposal for a Quantitative Skill Risk Evaluation Method Using Fault Tree Analysis	IEEE TRANSACTIONS ON ENGINEERING MANAGEMENT			English	Article						Collaborative filtering; control chart; fault tree analysis (FTA); project management; project team; risk analysis; skill management; skill shortage	RESOURCE-ALLOCATION; SOFTWARE PROJECTS; TEAMS	Project teams must be comprised of skilled individuals; however, project managers often face challenges when assigned team members have a shortage of skills. This potential for a project team's shortage of skill is expressed as project skill risk in this paper. When this occurs, project managers must identify the project team's skill status and take appropriate action. Hence, project managers should understand the skill status of a team and monitor this status in a timely manner, especially for a project that requires expertise. In addition, by understanding skill similarity among team members, project managers can reduce project skill risk. The method proposed in this study creates a systematized quantitative process to evaluate project skill risk in order to generate an objective understanding of team skill status so that decisions can be made proactively during the project planning and execution phases. The proposed method uses a skill risk fault tree and skill risk control chart. The skill risk fault tree is used to evaluate quantitative risk, whereas the skill risk control chart is used to visualize skill risk status. The proposed method incorporates skill similarity to allow for flexibility in project skill risk-related actions. The feasibility and efficiency of the proposed method are then verified through a case study involving an information technology system infrastructure transition project.	[Liu, Gongyi] IBM Japan Ltd, GTS IS MR Automat Delivery 2, Tokyo 1358511, Japan; [Yokoyama, Shin-ichiro] Tokyo City Univ, Fac Knowledge Engn, Tokyo 1588557, Japan	Liu, GY (reprint author), IBM Japan Ltd, GTS IS MR Automat Delivery 2, Tokyo 1358511, Japan.	lkougi@gmail.com; yokoyama@ims.tcu.ac.jp					Aljassmi H, 2013, J CONSTR ENG M, V139, P870, DOI 10.1061/(ASCE)CO.1943-7862.0000653; Andre M, 2011, INFORM SOFTWARE TECH, V53, P259, DOI 10.1016/j.infsof.2010.11.011; Cerpa N, 2009, COMMUN ACM, V52, P130, DOI 10.1145/1610252.1610286; Fitzpatrick EL, 2005, COMPUT IND ENG, V48, P593, DOI 10.1016/j.cie.2004.12.014; Hoegl M, 2001, ORGAN SCI, V12, P435, DOI 10.1287/orsc.12.4.435.10635; Correia I, 2012, OR SPECTRUM, V34, P635, DOI 10.1007/s00291-010-0233-0; Barreto A, 2008, COMPUT OPER RES, V35, P3073, DOI 10.1016/j.cor.2007.01.010; Campbell GM, 1999, MANAGE SCI, V45, P722, DOI 10.1287/mnsc.45.5.722; Heimerl C, 2010, OR SPECTRUM, V32, P343, DOI 10.1007/s00291-009-0169-4; [Anonymous], 1975, NUREG75014; Otero LD, 2009, COMPUT IND ENG, V56, P1333, DOI 10.1016/j.cie.2008.08.002; Herlocker J., 1999, P 22 ANN INT ACM SIG, V54, P230, DOI DOI 10.1145/312624.312682; Hung CL, 2011, IN C IND ENG ENG MAN, P879, DOI 10.1109/IEEM.2011.6118042; Kang D, 2011, SOFTWARE PRACT EXPER, V41, P551, DOI 10.1002/spe.1030; Krysinski M., 2005, P IEEE INT C ENG MAN, V2, P710, DOI 10.1109/IEMC.2005.1559241; La S., 2008, P INT C RISK MAN ENG, P393; Limnios N., 2008, FAULT TREES; Liu G., 2014, J SOC PROJECT MANAGE, V16, P46; Noble P., 2012, PHARM ENG, V32, P74; Patanakul P., 2010, P INT CTR MAN ENG TE, P1571; Project Management Institute, 2013, GUID PROJ MAN BOD KN; Schwarzkopf AB, 2004, COMMUN ACM, V47, P83, DOI 10.1145/962081.962084; Silva LCE, 2013, INT J PROJ MANAG, V31, P100, DOI 10.1016/j.ijproman.2012.06.008; Tong T. K. L., 2003, Engineering Construction and Architectural Management, V10, DOI 10.1108/09699980310466613; Tseng T.-L., 2004, International Journal of Project Management, V22, DOI 10.1016/S0263-7863(03)00058-9; Tuckman W. B., 1977, GROUP ORGAN STUD, V2, P419; Varvell T, 2004, J MANAGE ENG, V20, P141, DOI 10.1061/(ASCE)0742-597X(2004)20:4(141); Verma V. K., 1997, HUMAN ASPECTS PROJEC, VThree; Yang LJ, 2011, APPL MECH MATER, V48-49, P48, DOI 10.4028/www.scientific.net/AMM.48-49.48; Yang TH, 2012, INT C MANAGE SCI ENG, P372, DOI 10.1109/ICMSE.2012.6414208; Yannibelli V, 2013, ENG OPTIMIZ, V45, P45, DOI 10.1080/0305215X.2012.658782; Zakarian A, 1999, IIE TRANS, V31, P85, DOI 10.1080/07408179908969808; Zeng YJ, 2013, ENTERP INF SYST-UK, V7, P332, DOI 10.1080/17517575.2012.690049; Zhang X. H., 2009, P IEEE INT C COMM DR, P1, DOI 10.1145/1645413.1645420	34	0	0	IEEE-INST ELECTRICAL ELECTRONICS ENGINEERS INC	PISCATAWAY	445 HOES LANE, PISCATAWAY, NJ 08855-4141 USA	0018-9391	1558-0040		IEEE T ENG MANAGE	IEEE Trans. Eng. Manage.	MAY	2015	62	2					266	279		10.1109/TEM.2015.2413357		14	Business; Engineering, Industrial; Management	Business & Economics; Engineering	CG1WP	WOS:000353066500013		
J	Tan, SC; Watada, J; Ibrahim, Z; Khalid, M				Tan, Shing Chiang; Watada, Junzo; Ibrahim, Zuwairie; Khalid, Marzuki			Evolutionary Fuzzy ARTMAP Neural Networks for Classification of Semiconductor Defects	IEEE TRANSACTIONS ON NEURAL NETWORKS AND LEARNING SYSTEMS			English	Article						Hybrid genetic algorithms (GAs) imbalanced data classification; supervised adaptive resonance theory (ART) neural networks; wafer defect detection	SUPPORT VECTOR MACHINES; IMBALANCED DATA; UNBALANCED DATASETS; PATTERN-RECOGNITION; SYSTEM; CLASSIFIERS; ALGORITHMS; PREDICTION; ENSEMBLES; SELECTION	Wafer defect detection using an intelligent system is an approach of quality improvement in semiconductor manufacturing that aims to enhance its process stability, increase production capacity, and improve yields. Occasionally, only few records that indicate defective units are available and they are classified as a minority group in a large database. Such a situation leads to an imbalanced data set problem, wherein it engenders a great challenge to deal with by applying machine-learning techniques for obtaining effective solution. In addition, the database may comprise overlapping samples of different classes. This paper introduces two models of evolutionary fuzzy ARTMAP (FAM) neural networks to deal with the imbalanced data set problems in a semiconductor manufacturing operations. In particular, both the FAM models and hybrid genetic algorithms are integrated in the proposed evolutionary artificial neural networks (EANNs) to classify an imbalanced data set. In addition, one of the proposed EANNs incorporates a facility to learn overlapping samples of different classes from the imbalanced data environment. The classification results of the proposed evolutionary FAM neural networks are presented, compared, and analyzed using several classification metrics. The outcomes positively indicate the effectiveness of the proposed networks in handling classification problems with imbalanced data sets.	[Tan, Shing Chiang] Multimedia Univ, Fac Informat Sci & Technol, Bukit Beruang 75450, Malaysia; [Watada, Junzo] Waseda Univ, Grad Sch Informat Prod & Syst, Kitakyushu, Fukuoka 8080135, Japan; [Ibrahim, Zuwairie] Univ Malaysia Pahang, Fac Elect & Elect Engn, Pahang 26600, Malaysia; [Khalid, Marzuki] Univ Teknol Malaysia Int Campus, Ctr Artificial Intelligence & Robot, Kuala Lumpur 54100, Malaysia	Tan, SC (reprint author), Multimedia Univ, Fac Informat Sci & Technol, Bukit Beruang 75450, Malaysia.	sctan@mmu.edu.my; watada@waseda.jp; zuwairie@ump.edu.my; marzuki@utm.my					Alejo R, 2013, PATTERN RECOGN LETT, V34, P380, DOI 10.1016/j.patrec.2012.09.003; EFRON B, 1979, ANN STAT, V7, P1, DOI 10.1214/aos/1176344552; Hong X, 2007, IEEE T NEURAL NETWOR, V18, P28, DOI 10.1109/TNN.2006.882812; Wang S, 2013, IEEE T KNOWL DATA EN, V25, P206, DOI 10.1109/TKDE.2011.207; CARPENTER GA, 1992, IEEE T NEURAL NETWOR, V3, P698, DOI 10.1109/72.159059; Khoshgoftaar TM, 2011, IEEE T SYST MAN CY A, V41, P552, DOI 10.1109/TSMCA.2010.2084081; Chawla NV, 2002, J ARTIF INTELL RES, V16, P321; Pulkkinen P, 2008, ENG APPL ARTIF INTEL, V21, P1330, DOI 10.1016/j.engappai.2008.01.006; Kubat M, 1998, MACH LEARN, V30, P195, DOI 10.1023/A:1007452223027; Khoshgoftaar TM, 2010, IEEE T NEURAL NETWOR, V21, P813, DOI 10.1109/TNN.2010.2042730; Valdez F, 2011, APPL SOFT COMPUT, V11, P2625, DOI 10.1016/j.asoc.2010.10.010; Jiang LX, 2009, IEEE T KNOWL DATA EN, V21, P1361, DOI 10.1109/TKDE.2008.234; Chen S, 2010, IEEE T NEURAL NETWOR, V21, P1624, DOI 10.1109/TNN.2010.2066988; Drown DJ, 2009, IEEE T SYST MAN CY A, V39, P1097, DOI 10.1109/TSMCA.2009.2020804; Igel C, 2003, NEUROCOMPUTING, V50, P105, DOI 10.1016/S0925-2312(01)00700-7; Yao X, 1997, IEEE T NEURAL NETWOR, V8, P694, DOI 10.1109/72.572107; Pulido M, 2011, 2011 INTERNATIONAL JOINT CONFERENCE ON NEURAL NETWORKS (IJCNN), P202, DOI 10.1109/IJCNN.2011.6033222; Perez-Godoy MD, 2010, PATTERN RECOGN LETT, V31, P2375, DOI 10.1016/j.patrec.2010.07.010; Hu QH, 2012, IEEE T KNOWL DATA EN, V24, P2052, DOI 10.1109/TKDE.2011.149; Herrera F, 2003, INT J INTELL SYST, V18, P309, DOI 10.1002/int.10091; Liu XY, 2009, IEEE T SYST MAN CY B, V39, P539, DOI 10.1109/TSMCB.2008.2007853; Soda P, 2011, PATTERN RECOGN, V44, P1801, DOI 10.1016/j.patcog.2011.01.015; Liu YH, 2007, IEEE T NEURAL NETWOR, V18, P178, DOI 10.1109/TNN.2006.883013; Galar M, 2012, IEEE T SYST MAN CY C, V42, P463, DOI 10.1109/TSMCC.2011.2161285; HOLM S, 1979, SCAND J STAT, V6, P65; Bhowan U, 2013, IEEE T EVOLUT COMPUT, V17, P368, DOI 10.1109/TEVC.2012.2199119; Fernandez A, 2010, IEEE T EVOLUT COMPUT, V14, P913, DOI 10.1109/TEVC.2009.2039140; Lin ML, 2013, IEEE T NEUR NET LEAR, V24, P647, DOI 10.1109/TNNLS.2012.2228231; Yen SJ, 2009, EXPERT SYST APPL, V36, P5718, DOI 10.1016/j.eswa.2008.06.108; Kang P, 2012, EXPERT SYST APPL, V39, P6738, DOI 10.1016/j.eswa.2011.12.028; Su CT, 2007, IEEE T KNOWL DATA EN, V19, P1321, DOI 10.1109/TKDE.2007.190623; Chawla NV, 2003, LECT NOTES ARTIF INT, V2838, P107; Seiffert C, 2010, IEEE T SYST MAN CY A, V40, P185, DOI 10.1109/TSMCA.2009.2029559; Li TS, 2009, EXPERT SYST APPL, V36, P374, DOI 10.1016/j.eswa.2007.09.023; He HB, 2009, IEEE T KNOWL DATA EN, V21, P1263, DOI 10.1109/TKDE.2008.239; Wang S, 2012, IEEE T SYST MAN CY B, V42, P1119, DOI 10.1109/TSMCB.2012.2187280; TOMEK I, 1976, IEEE T SYST MAN CYB, V6, P769; Zhou ZH, 2006, IEEE T KNOWL DATA EN, V18, P63; Garcia S, 2009, APPL SOFT COMPUT, V9, P1304, DOI 10.1016/j.asoc.2009.04.004; Oong TH, 2011, IEEE T NEURAL NETWOR, V22, P1823, DOI 10.1109/TNN.2011.2169426; Bache K., 2013, UCI MACHINE LEARNING; Baskar S., 2001, International Journal of Computational Engineering Science, V2, DOI 10.1142/S1465876301000465; Batista G.E.A.P.A., 2004, ACM SIGKDD EXPLORATI, V6, P20, DOI DOI 10.1145/1007730.1007735; Batista GEAPA, 2000, LECT NOTES ARTIF INT, V1793, P315; Carpenter G. A., 1987, COMPUTER VISION GRAP, V13, P37, DOI DOI 10.1016/S0734-189X(87)80014-2; Carpenter GA, 1988, IEEE COMPUT, V21, P77; Castillo O, 2012, EXPERT SYST APPL, V39, P2947, DOI 10.1016/j.eswa.2011.08.156; Chao LC, 2009, EXPERT SYST APPL, V36, P10158, DOI 10.1016/j.eswa.2009.01.003; CHATURVEDI AR, 1993, EXPERT SYST APPL, V6, P23, DOI 10.1016/0957-4174(93)90016-Y; Chawla NV, 2007, LECT NOTES COMPUT SC, V4472, P397; Chou PH, 2010, EXPERT SYST APPL, V37, P4413, DOI 10.1016/j.eswa.2009.11.087; Ding L., 2010, ICIC EL, V4, P2419; Fernandez-Navarro F, 2010, INT J FOOD MICROBIOL, V141, P203, DOI 10.1016/j.ijfoodmicro.2010.05.013; Fernandez-Navarro F, 2011, APPL SOFT COMPUT, V11, P3012, DOI 10.1016/j.asoc.2010.11.027; Fernandez-Navarro F, 2011, PATTERN RECOGN, V44, P1821, DOI 10.1016/j.patcog.2011.02.019; Fernandez-Navarro F, 2011, EXPERT SYST APPL, V38, P12483, DOI 10.1016/j.eswa.2011.04.031; Georgoulas G, 2007, BIOMED SIGNAL PROCES, V2, P69, DOI 10.1016/j.bspc.2007.05.003; Guo H., 2004, SIGKDD EXPLORATIONS, V6, P30; Huang CJ, 2009, APPL SOFT COMPUT, V9, P824, DOI 10.1016/j.asoc.2008.10.002; Huber KP, 1995, 1995 IEEE INTERNATIONAL CONFERENCE ON NEURAL NETWORKS PROCEEDINGS, VOLS 1-6, P1263, DOI 10.1109/ICNN.1995.487337; Japkowicz N., 2002, Intelligent Data Analysis, V6; Jo T., 2004, ACM SIGKDD EXPLORATI, V6, P40, DOI 10.1145/1007730.1007737; Kim KJ, 2008, IEEE T EVOLUT COMPUT, V12, P377, DOI 10.1109/TEVC.2007.906660; Kumar N, 2006, INT J PROD RES, V44, P5019, DOI 10.1080/00207540600596874; Lee D, 2007, IEEE T NEURAL NETWOR, V18, P578, DOI 10.1109/TNN.2006.889495; Lim CP, 1997, NEURAL NETWORKS, V10, P925, DOI 10.1016/S0893-6080(96)00123-2; Man ZH, 2012, IEEE T NEUR NET LEAR, V23, P1974, DOI 10.1109/TNNLS.2012.2218616; Negnevitsky M., 2005, ARTIFICIAL INTELLIGE; Nguwi YY, 2010, EXPERT SYST APPL, V37, P8303, DOI 10.1016/j.eswa.2010.05.054; Sanchez D, 2011, LECT NOTES ARTIF INT, V7095, P331, DOI 10.1007/978-3-642-25330-0_29; Sheskin D.J., 2006, HDB PARAMETRIC NONPA; Tan SC, 2008, APPL SOFT COMPUT, V8, P543, DOI 10.1016/j.asoc.2007.03.006; Tang YC, 2009, IEEE T SYST MAN CY B, V39, P281, DOI 10.1109/TSMCB.2008.2002909; Vapnik V. N., 1995, NATURE STAT LEARNING; Wang CH, 2009, EXPERT SYST APPL, V36, P2554, DOI 10.1016/j.eswa.2008.01.057; Weiss G. M., 2004, ACM SIGKDD EXPLORATI, V6, P7, DOI DOI 10.1145/1007730.1007734; Wu G, 2005, IEEE T KNOWL DATA EN, V17, P786, DOI 10.1109/TKDE.2005.95; Wu ZM, 2005, ADV COMPUT MATH, V23, P1, DOI 10.1007/s10444-004-2232-7; Yip W. K., 2008, P 4 IEEE C AUT SCI E, P236; ZADEH LA, 1965, INFORM CONTROL, V8, P338, DOI 10.1016/S0019-9958(65)90241-X	80	1	1	IEEE-INST ELECTRICAL ELECTRONICS ENGINEERS INC	PISCATAWAY	445 HOES LANE, PISCATAWAY, NJ 08855-4141 USA	2162-237X	2162-2388		IEEE T NEUR NET LEAR	IEEE Trans. Neural Netw. Learn. Syst.	MAY	2015	26	5					933	950		10.1109/TNNLS.2014.2329097		18	Computer Science, Artificial Intelligence; Computer Science, Hardware & Architecture; Computer Science, Theory & Methods; Engineering, Electrical & Electronic	Computer Science; Engineering	CG2RM	WOS:000353122400004		
J	Shimizu, T; Saegusa, R; Ikemoto, S; Ishiguro, H; Metta, G				Shimizu, Toshihiko; Saegusa, Ryo; Ikemoto, Shuhei; Ishiguro, Hiroshi; Metta, Giorgio			Robust Sensorimotor Representation to Physical Interaction Changes in Humanoid Motion Learning	IEEE TRANSACTIONS ON NEURAL NETWORKS AND LEARNING SYSTEMS			English	Article						Change detection; dimensionality reduction; learning from demonstration (LfD); physical human-robot interaction	ROBOT; ADAPTATION; WALKING	This paper proposes a learning from demonstration system based on a motion feature, called phase transfer sequence. The system aims to synthesize the knowledge on humanoid whole body motions learned during teacher-supported interactions, and apply this knowledge during different physical interactions between a robot and its surroundings. The phase transfer sequence represents the temporal order of the changing points in multiple time sequences. It encodes the dynamical aspects of the sequences so as to absorb the gaps in timing and amplitude derived from interaction changes. The phase transfer sequence was evaluated in reinforcement learning of sitting-up and walking motions conducted by a real humanoid robot and compatible simulator. In both tasks, the robotic motions were less dependent on physical interactions when learned by the proposed feature than by conventional similarity measurements. Phase transfer sequence also enhanced the convergence speed of motion learning. Our proposed feature is original primarily because it absorbs the gaps caused by changes of the originally acquired physical interactions, thereby enhancing the learning speed in subsequent interactions.	[Shimizu, Toshihiko] Kobe City Coll Technol, Dept Mech Engn, Kobe, Hyogo 6512194, Japan; [Saegusa, Ryo] Toyohashi Univ Technol, Ctr Human Robot Symbiosis Res, Toyohashi, Aichi 4418580, Japan; [Ikemoto, Shuhei] Osaka Univ, Inst Acad Initiat, Toyonaka, Osaka 5608531, Japan; [Ishiguro, Hiroshi] Osaka Univ, Grad Sch Engn Sci, Dept Syst Innovat, Toyonaka, Osaka 5608531, Japan; [Metta, Giorgio] Ist Italiano Tecnol, Dept Robot Brain & Cognit Sci, I-16163 Genoa, Italy	Shimizu, T (reprint author), Kobe City Coll Technol, Dept Mech Engn, Kobe, Hyogo 6512194, Japan.	ts8@kobe-kosen.ac.jp; ryos@ieee.org; ikemoto@arl.sys.es.osaka-u.ac.jp; ishiguro@sys.es.osaka-u.ac.jp; giorgio.metta@iit.it			Department of Robotics, Brain and Cognitive Sciences, Istituto Italiano di Tecnologia, Genoa, Italy; Japan Society for the Promotion of Science (JSPS) [2457062]; JSPS; Advanced Research Network; European Union (EU); Cooperative Human Robot Interaction Systems [FP7 215805]; EU [FP7 97459]	Manuscript received May 14, 2012; revised June 26, 2013 and December 7, 2013; accepted June 23, 2014. Date of publication July 10, 2014; date of current version April 15, 2015. This work was supported in part by the Department of Robotics, Brain and Cognitive Sciences, Istituto Italiano di Tecnologia, Genoa, Italy, in part by the Grants-in-Aid for Scientific Research, Japan Society for the Promotion of Science (JSPS), under Grant 2457062, in part by the JSPS Core-to-Core Program A, in part by the Advanced Research Network, in part by the European Union (EU) FP7 Project, in part by the Cooperative Human Robot Interaction Systems under Grant FP7 215805, and in part by the EU FP7 Project Xperience entitled the Robots Bootstrapped through Learning and Experience under Grant FP7 97459.	Buchli J, 2011, INT J ROBOT RES, V30, P820, DOI 10.1177/0278364911402527; Kruger V, 2010, IEEE ROBOT AUTOM MAG, V17, P30, DOI 10.1109/MRA.2010.936961; WATKINS CJCH, 1992, MACH LEARN, V8, P279, DOI 10.1007/BF00992698; Ulrich DA, 2001, PEDIATRICS, V108, part. no., DOI 10.1542/peds.108.5.e84; Calinon S, 2007, IEEE T SYST MAN CY B, V37, P286, DOI 10.1109/TSMCB.2006.886952; Huang Q, 2005, IEEE T ROBOT, V21, P977, DOI 10.1109/TRO.2005.851381; Vukobratovic M, 2006, INT J HUM ROBOT, V3, P153, DOI 10.1142/S0219843606000710; Ikemoto S, 2012, IEEE ROBOT AUTOM MAG, V19, P24, DOI 10.1109/MRA.2011.2181676; Nakanishi J, 2004, ROBOT AUTON SYST, V47, P79, DOI 10.1016/j.robot.2004.03.003; Morimoto J, 2001, ROBOT AUTON SYST, V36, P37, DOI 10.1016/S0921-8890(01)00113-0; Bergroth L., 2000, Proceedings Seventh International Symposium on String Processing and Information Retrieval. SPIRE 2000, DOI 10.1109/SPIRE.2000.878178; Hosoda K., 2010, P IEEE 9 INT C DEV L, P317; Ide T, 2005, SIAM PROC S, P571; Ijspeert AJ, 2002, ADV NEURAL INFORM PR, V15, P1523; Kuniyoshi Y, 2004, ROBOT AUTON SYST, V48, P189, DOI 10.1016/j.robot.2004.07.004; Kuwayama K, 2004, PROCEEDINGS OF THE 2004 INTERNATIONAL SYMPOSIUM ON MICRO-NANOMECHATRONICS AND HUMAN SCIENCE, P157; Metta G., 2006, International Journal of Advanced Robotic Systems, V3; Metta G., 2008, P 8 WORKSH PERF METR, P50, DOI 10.1145/1774674.1774683; Mohammad Y, 2009, LECT NOTES ARTIF INT, V5579, P123, DOI 10.1007/978-3-642-02568-6_13; Nakaoka S, 2003, IEEE INT CONF ROBOT, P3905; Nicolescu M. N., 2003, P 2 INT JOINT C AUT, P241; Park CH, 2010, IEEE INT CONF ROBOT, P229; Wang QG, 2011, IEEE T KNOWL DATA EN, V23, P321, DOI 10.1109/TKDE.2010.123; ZELAZO PR, 1972, SCIENCE, V176, P314, DOI 10.1126/science.176.4032.314	24	1	1	IEEE-INST ELECTRICAL ELECTRONICS ENGINEERS INC	PISCATAWAY	445 HOES LANE, PISCATAWAY, NJ 08855-4141 USA	2162-237X	2162-2388		IEEE T NEUR NET LEAR	IEEE Trans. Neural Netw. Learn. Syst.	MAY	2015	26	5					1035	1047		10.1109/TNNLS.2014.2333092		13	Computer Science, Artificial Intelligence; Computer Science, Hardware & Architecture; Computer Science, Theory & Methods; Engineering, Electrical & Electronic	Computer Science; Engineering	CG2RM	WOS:000353122400011		
J	Miyamoto, A; Watanabe, K; Ikeda, K; Sato, MA				Miyamoto, Atsushi; Watanabe, Kazuho; Ikeda, Kazushi; Sato, Masa-Aki			Variational Inference With ARD Prior for NIRS Diffuse Optical Tomography	IEEE TRANSACTIONS ON NEURAL NETWORKS AND LEARNING SYSTEMS			English	Article						Automatic relevance determination (ARD) prior; diffuse optical tomography (DOT); near-infrared spectroscopy (NIRS); phase diagram; variational Bayes (VB) method	AUTOMATIC RELEVANCE DETERMINATION; NEAR-INFRARED SPECTROSCOPY; INVERSE; BAYES; MODEL	Diffuse optical tomography (DOT) reconstructs 3-D tomographic images of brain activities from observations by near-infrared spectroscopy (NIRS) that is formulated as an ill-posed inverse problem. This brief presents a method for NIRS DOT based on a hierarchical Bayesian approach introducing the automatic relevance determination prior and the variational Bayes technique. Although the sparseness of the estimation strongly depends on the hyperparameters, in general, our method has less dependency on the hyperparameters. We confirm through numerical experiments that a schematic phase diagram of sparseness with respect to the hyperparameters has two regions: in one region hyperparameters give sparse solutions and in the other they give dense ones. The experimental results are supported by our theoretical analyses in simple cases.	[Miyamoto, Atsushi] Nikon Inc, Yokohama, Kanagawa 2448533, Japan; [Watanabe, Kazuho] Toyohashi Univ Technol, Dept Comp Sci & Engn, Toyohashi, Aichi 4418580, Japan; [Ikeda, Kazushi] Nara Inst Sci & Technol, Grad Sch Informat Sci, Ikoma 6300192, Japan; [Ikeda, Kazushi; Sato, Masa-Aki] ATR Neural Informat Anal Labs, Kyoto 6310804, Japan	Miyamoto, A (reprint author), Nikon Inc, Yokohama, Kanagawa 2448533, Japan.	Atsushi.Miyamoto@nikon.com; wkazuho@cs.tut.ac.jp; kazushi@is.naist.jp; masa-aki@atr.jp			National Institute of Information and Communications Technology; Japan Society for the Promotion of Science [23700175, 25120014]	Manuscript received June 6, 2013; revised February 4, 2014 and May 22, 2014; accepted May 23, 2014. Date of publication June 18, 2014; date of current version April 15, 2015. This work was supported in part by the National Institute of Information and Communications Technology and in part by the Japan Society for the Promotion of Science under Grant 23700175 and Grant 25120014.	Boas DA, 2005, APPL OPTICS, V44, P1957, DOI 10.1364/AO.44.001957; Zeff BW, 2007, P NATL ACAD SCI USA, V104, P12169, DOI 10.1073/pnas.0611266104; Sitaram R, 2007, NEUROIMAGE, V34, P1416, DOI 10.1016/j.neuroimage.2006.11.005; Li A, 2004, OPT LETT, V29, P256, DOI 10.1364/OL.29.000256; Boas DA, 2001, OPT EXPRESS, V8, P263; Culver JP, 2003, OPT LETT, V28, P2061, DOI 10.1364/OL.28.002061; Sato M, 2001, NEURAL COMPUT, V13, P1649, DOI 10.1162/089976601750265045; Strangman G, 2002, BIOL PSYCHIAT, V52, P679, DOI 10.1016/S0006-3223(02)01550-0; Nummenmaa A, 2007, NEUROIMAGE, V37, P876, DOI 10.1016/j.neuroimage.2007.04.021; Culver JP, 2003, J CEREBR BLOOD F MET, V23, P911, DOI 10.1097/01.WCB.0000076703.71231.BB; Attias H, 1999, UNCERTAINTY IN ARTIFICIAL INTELLIGENCE, PROCEEDINGS, P21; Chappell MA, 2009, IEEE T SIGNAL PROCES, V57, P223, DOI 10.1109/TSP.2008.2005752; Hoyer PO, 2004, J MACH LEARN RES, V5, P1457; Boas D A, 2004, NEUROIMAGE, V23, P275, DOI DOI 10.1016/J.NEUROIMAGE.2004.07.011; Browne A, 2008, IEEE T NEURAL NETWOR, V19, P1101, DOI 10.1109/TNN.2008.2000203; Guven M., 2005, P 34 APPL IM PATT RE, P140; Hillman E., 2002, THESIS U COLL LONDON; Kaji D, 2011, NEUROCOMPUTING, V74, P2002, DOI 10.1016/j.neucom.2010.06.027; Li A, 2005, APPL OPTICS, V44, P1948, DOI 10.1364/AO.44.001948; Lisboa PJG, 2009, IEEE T NEURAL NETWOR, V20, P1403, DOI 10.1109/TNN.2009.2023654; Mackay D., 2003, INFORM THEORY INFERE; Miyamoto A, 2011, 2011 INTERNATIONAL JOINT CONFERENCE ON NEURAL NETWORKS (IJCNN), P1230, DOI 10.1109/IJCNN.2011.6033364; Nakajima S, 2006, LECT NOTES COMPUT SC, V4132, P240; Nakajima S., 2010, P 27 INT C MACH LEAR; Nakajima S, 2007, LECT NOTES COMPUT SC, V4668, P1; Nummemnaa A, 2007, NEUROIMAGE, V35, P669, DOI 10.1016/j.neuroimage.2006.05.001; O'LEARY M. A., 1996, THESIS U PENNSYLVANI; Sato M, 2004, NEUROIMAGE, V23, P806, DOI 10.1016/j.neuroimage.2004.06.037; Thodberg HH, 1996, IEEE T NEURAL NETWOR, V7, P56, DOI 10.1109/72.478392; West M., 1987, BIOMETRIKA, V74, P446; Wipf D. P., 2008, ADV NEURAL INFORM PR, V20	31	0	0	IEEE-INST ELECTRICAL ELECTRONICS ENGINEERS INC	PISCATAWAY	445 HOES LANE, PISCATAWAY, NJ 08855-4141 USA	2162-237X	2162-2388		IEEE T NEUR NET LEAR	IEEE Trans. Neural Netw. Learn. Syst.	MAY	2015	26	5					1109	1114		10.1109/TNNLS.2014.2328576		6	Computer Science, Artificial Intelligence; Computer Science, Hardware & Architecture; Computer Science, Theory & Methods; Engineering, Electrical & Electronic	Computer Science; Engineering	CG2RM	WOS:000353122400017		
J	Samejima, M; Sasaki, R				Samejima, Masaki; Sasaki, Ryoichi			Chance-Constrained Programming Method of IT Risk Countermeasures for Social Consensus Making	IEEE TRANSACTIONS ON SYSTEMS MAN CYBERNETICS-SYSTEMS			English	Article						Chance-constrained programming; constraint aggregation; information technology risk (IT risk); sample average approximation method; social consensus making	APPROXIMATION METHOD; SECURITY	The authors address a social consensus making support in discussing countermeasures for information technology risks (IT risks). For supporting stakeholders' discussion on which IT risk countermeasures the stakeholders should implement, experts of the risk management estimate parameter values of the countermeasure, define a goal and constraints, and formulate the decision problem of the countermeasures to be implemented as one of 0-1 integer programming problems. Because parameter values and constraint values are uncertain, the decision problem is reformulated as a chance-constrained programming problem. The sample average approximation method is a well-known method for solving the chance-constrained programming problem. However, the computational time is still so long that the opinion leaders cannot use a solution of the chance-constrained programming problem in their discussion. The authors propose a high-speed chance-constrained programming method by aggregating the constraints that are generated by approximation of the problem in the sample average method. By applying the proposed method to real decision problems, the authors confirmed that computational time is decreased to 1 min while obtaining the same error rate and the same rate of the feasible solutions as a conventional method.	[Samejima, Masaki] Osaka Univ, Grad Sch Informat Sci & Technol, Dept Multimedia Engn, Suita, Osaka 5650871, Japan; [Sasaki, Ryoichi] Tokyo Denki Univ, Sch Sci & Technol Future Life, Tokyo 1208551, Japan	Samejima, M (reprint author), Osaka Univ, Grad Sch Informat Sci & Technol, Dept Multimedia Engn, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.	samejima@ist.osaka-u.ac.jp			Japanese Society for the Promotion of Science KAKENHI [23300030]	This work was supported in part by the Japanese Society for the Promotion of Science KAKENHI Grant 23300030. This paper was recommended by Associate Editor F.-Y. Wang.	Amer M, 2013, FUTURES, V46, P23, DOI 10.1016/j.futures.2012.10.003; [Anonymous], 2014, MATHEMATICA; [Anonymous], 2014, WEKA; Pagnoncelli BK, 2009, J OPTIMIZ THEORY APP, V142, P399, DOI 10.1007/s10957-009-9523-6; Nemirovski A, 2006, SIAM J OPTIMIZ, V17, P969, DOI 10.1137/050622328; CHARNES A, 1959, MANAGE SCI, V6, P73, DOI 10.1287/mnsc.6.1.73; Baker WH, 2007, IEEE SECUR PRIV, V5, P36, DOI 10.1109/MSP.2007.11; OLSON DL, 1987, J OPER RES SOC, V38, P261; Belsley D. A., 2009, HDB COMPUTATIONAL EC; Birge JR, 2011, SPRINGER SER OPER RE, P3, DOI 10.1007/978-1-4614-0237-4; Brooke PJ, 2003, COMPUT SECUR, V22, P256, DOI 10.1016/S0167-4048(03)00313-4; Cardinal J, 2012, THEOR COMPUT SYST, V51, P4, DOI 10.1007/s00224-011-9371-2; ISACA, 2009, RISK IT; Li X., 2013, CREDIBILISTIC PROGRA; Mun J., 2010, MODELING RISK APPL M; Ohkawara M., 2012, P 3 INT C E ED E BUS, P158; Oldewurtel F, 2008, IEEE DECIS CONTR P, P4731; Pelleg D., 2000, P 17 INT C MACH LEAR, P727; Peltier T. R., 2011, INFORM SECURITY RISK; Samejima M, 2012, IEEE SYS MAN CYBERN, P2751; Sasaki R., 2011, INT J INF PROCESS MA, V2, P2562; Sato K, 2013, IEEE SYS MAN CYBERN, P4789, DOI 10.1109/SMC.2013.815; Stamp M., 2005, INFORM SECURITY PRIN; Sugar CA, 2003, J AM STAT ASSOC, V98, P750, DOI 10.1198/016214503000000666; Taniyama M., 2006, P WORLD ACAD SCI ENG, V45, P284; Vose D, 2000, RISK ANAL QUANTITATI; Witten IH, 2005, DATA MINING PRACTICA; Wolsey L. A., 1998, INTEGER PROGRAMMING	28	0	0	IEEE-INST ELECTRICAL ELECTRONICS ENGINEERS INC	PISCATAWAY	445 HOES LANE, PISCATAWAY, NJ 08855-4141 USA	2168-2216			IEEE T SYST MAN CY-S	IEEE Trans. Syst. Man Cybern. -Syst.	MAY	2015	45	5					725	733		10.1109/TSMC.2014.2376491		9	Automation & Control Systems; Computer Science, Cybernetics	Automation & Control Systems; Computer Science	CG3BO	WOS:000353151800001		
J	Nakayama, Y				Nakayama, Yu			Dynamic Access Network Reorganization for the Depopulation Age	IEEE TRANSACTIONS ON SYSTEMS MAN CYBERNETICS-SYSTEMS			English	Article						Central office; communication systems; geographic information systems (GIS); optimization; telecommunication network	FACILITY LOCATION; POPULATION; ALGORITHM	The populations of industrialized countries will decline over the coming decades. To ensure that we have efficient access networks in the coming age of depopulation, it is important to consider the reorganization of central offices over time. The cost for operating and maintaining central offices can be reduced by efficiently closing central offices. However, dynamic facility location models that have been developed largely focused on the problem of optimally expanding a network over time to meet increasing demand. The practical relevance of the dynamic models is limited because the complexity and the required amount of data are much greater than with static models. This paper proposes a dynamic access network reorganization model for the depopulation age. Although the proposed model is a dynamic model, it is simple because it assumes that the only option will be to close central offices. The model first searches for a set of optimal solutions for each planning period as a capacitated facility location problem. Then, it selects the optimal combination of optimal solutions that can minimize the total number of open offices with the limitation of network reorganization. The validity of the proposed model was evaluated with computer simulations. It was confirmed that although the proposed model is a dynamic model it is simple and practical.	NTT Corp, NTT Access Network Serv Syst Labs, Yokosuka, Kanagawa 2390847, Japan	Nakayama, Y (reprint author), NTT Corp, NTT Access Network Serv Syst Labs, Yokosuka, Kanagawa 2390847, Japan.	naka80yu@gmail.com					[Anonymous], 2012, QUANTUM GIS; An FT, 2004, J LIGHTWAVE TECHNOL, V22, P2557, DOI 10.1109/JLT.2004.836768; Klose A, 2005, EUR J OPER RES, V162, P4, DOI 10.1016/j.ejor.2003.10.031; Chardaire P, 1996, NETWORKS, V28, P117, DOI 10.1002/(SICI)1097-0037(199609)28:2<117::AID-NET5>3.0.CO;2-H; Lutz W, 2001, NATURE, V412, P543, DOI 10.1038/35087589; HAKIMI SL, 1964, OPER RES, V12, P450, DOI 10.1287/opre.12.3.450; BALAKRISHNAN A, 1995, OPER RES, V43, P58, DOI 10.1287/opre.43.1.58; ERLENKOTTER D, 1981, EUR J OPER RES, V6, P133, DOI 10.1016/0377-2217(81)90199-5; Frantzeskakis M., 1989, ANN OPER RES, V18, P187, DOI 10.1007/BF02097803; Gourdin E, 2002, FACILITY LOCATION APPLICATIONS AND THEORY, P275; Harik G. R., 1995, P 6 INT C GEN ALG, P24; Jornsten K., 1994, STUDIES REGIONAL URB, V3, P163; Kaneko R, 2008, JAPANESE J POPULATIO, V6, P76; Lutz W, 2003, SCIENCE, V299, P1991, DOI 10.1126/science.1080316; Nakayama Y., 2011, P FAST TOK JAP, P1; Nakayama Y, 2012, IEEE SYS MAN CYBERN, P941; NTT EAST, 2012, INF STAT WEB; Prat J., 2009, P 11 INT C TRANSP OP, P1; Romauch M, 2005, LECT NOTES COMPUT SC, V3777, P180; Sadahiro Y., 2010, PLANNING ADMINISTRAT, V33, P75; Schilling D. A., 1980, Decision Sciences, V11, DOI 10.1111/j.1540-5915.1980.tb01172.x; SHULMAN A, 1991, OPER RES, V39, P423, DOI 10.1287/opre.39.3.423; Snyder L.V., 2006, IIE T, V38, P547, DOI DOI 10.1061/(ASCE)0733-9488(2007)133:1(51); VANROY TJ, 1982, MANAGE SCI, V28, P1091, DOI 10.1287/mnsc.28.10.1091	24	0	0	IEEE-INST ELECTRICAL ELECTRONICS ENGINEERS INC	PISCATAWAY	445 HOES LANE, PISCATAWAY, NJ 08855-4141 USA	2168-2216			IEEE T SYST MAN CY-S	IEEE Trans. Syst. Man Cybern. -Syst.	MAY	2015	45	5					743	750		10.1109/TSMC.2014.2375156		8	Automation & Control Systems; Computer Science, Cybernetics	Automation & Control Systems; Computer Science	CG3BO	WOS:000353151800003		
J	Tomite, N; Arai, Y; Ohki, Y; Hinata, T; Washio, M				Tomite, Naoto; Arai, Yukitaka; Ohki, Yoshimichi; Hinata, Toru; Washio, Masakazu			Space Charges Remaining in Polymers after Electron Beam Irradiation and the Role of Conductivity in Their Decay Profiles	IEEJ TRANSACTIONS ON ELECTRICAL AND ELECTRONIC ENGINEERING			English	Article						insulating polymer; electron beam; space charge; conductivity	POLYETHYLENE-TEREPHTHALATE; TEFLON; TSC; TEMPERATURE	Five typical insulating polymers and a carbon-loaded polyethylene were irradiated with 200-keV electrons, and the space charge distributions remaining in the polymers were measured. When the polymer film is short-circuited after irradiation, the amount of space charge gradually decreases monotonically. By analyzing such decay profiles, it becomes clear that the decay of the charges remaining after the irradiation is governed by the conductivity of the polymer. (c) 2015 Institute of Electrical Engineers of Japan. Published by John Wiley & Sons, Inc.	[Tomite, Naoto; Arai, Yukitaka; Ohki, Yoshimichi] Waseda Univ, Dept Elect Engn & Biosci, Shinjuku Ku, Tokyo 1698555, Japan; [Ohki, Yoshimichi] Waseda Univ, Res Inst Mat Sci & Technol, Shinjuku Ku, Tokyo 1698555, Japan; [Hinata, Toru; Washio, Masakazu] Waseda Univ, Dept Pure & Appl Phys, Shinjuku Ku, Tokyo 1698555, Japan	Ohki, Y (reprint author), Waseda Univ, Dept Elect Engn & Biosci, Shinjuku Ku, Tokyo 1698555, Japan.	yohki@waseda.jp			Japan Society for the Promotion of Science [24656218, 23360142]	The authors would like to express their thanks to H. Nakamura for his help in the experiments. This work was partly supported by Grants-in-Aid from Japan Society for the Promotion of Science for Challenging Exploratory Research (24656218) and for Scientific Research (B) (23360142).	TAYLOR DM, 1976, J PHYS D APPL PHYS, V9, P2269, DOI 10.1088/0022-3727/9/15/018; Fujii H, 2012, C ELECT INSUL DIEL P, P624, DOI 10.1109/CEIDP.2012.6378858; GROSS B, 1976, J APPL PHYS, V47, P968, DOI 10.1063/1.322688; Hikosaka S, 2011, IEEJ T ELECTR ELECTR, V6, P299, DOI 10.1002/tee.20660; LAPKE G, 1982, J APPL PHYS, V53, P5763, DOI 10.1063/1.331411; MAEDA H, 1979, J APPL PHYS, V50, P758, DOI 10.1063/1.326041; MAYBURG S, 1952, J APPL PHYS, V23, P1006, DOI 10.1063/1.1702336; MEYER RA, 1956, J APPL PHYS, V27, P1012, DOI 10.1063/1.1722531; Nagasawa K, 2010, IEEJ T FUNDAMENTALS, V130, P1105, DOI 10.1541/ieejfms.130.1105; Ohki Y, 2010, IEEE C EL INS DIEL P, P660; PERLMAN MM, 1972, J PHYS D APPL PHYS, V5, P2115, DOI 10.1088/0022-3727/5/11/319; Perrin C, 2008, J PHYS D APPL PHYS, V41, DOI 10.1088/0022-3727/41/20/205417; RIES HR, 1989, J PHYS CHEM SOLIDS, V50, P735, DOI 10.1016/0022-3697(89)90013-9; SESSLER GM, 1979, J APPL PHYS, V50, P3328, DOI 10.1063/1.326374; Yamaguchi A, 2001, IEEE C EL INS DIEL P, P216; YOSHINO K, 1978, J APPL PHYS, V49, P4849, DOI 10.1063/1.325516	16	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1931-4973	1931-4981		IEEJ T ELECTR ELECTR	IEEJ Trans. Electr. Electron. Eng.	MAY	2015	10	3					237	241		10.1002/tee.22077		5	Engineering, Electrical & Electronic	Engineering	CG1KT	WOS:000353032200001		
J	Hu, LC; Kobayashi, H; Okuno, Y				Hu, Liancheng; Kobayashi, Hiromichi; Okuno, Yoshihiro			Analyses on Response of a Liquid Metal MHD Power Generation System to Various External Inputs	IEEJ TRANSACTIONS ON ELECTRICAL AND ELECTRONIC ENGINEERING			English	Article						magnetohydrodynamic generator; liquid metal; electrical efficiency; shape loss		We numerically analyze the response of a liquid metal MHD power generation system to various external inputs of piston force (regular: constant (step), square, sinusoidal; irregular: Piersion-Moskowitz (P-M)) with three different working fluids (NaK78, U-alloy47, and mercury), where the electrical efficiency is mainly examined in the presence of the shape loss due to different cross-sectional areas between the MHD generator and piston driver parts. Although the electrical efficiency is reduced owing to the shape loss, the deterioration can be mitigated by using NaK78 with low density and high electrical conductivity and compensated by the increase in the applied magnetic flux density. For the period shorter than 1 s, the output power markedly decreases, although the electrical efficiency seems to recover toward the ideal value. The irregular force input based on the P-M wave gives no big difference compared to the regular forces when the effective value of the input is the same, which can provide the prospect of utilizing a real ocean wave. (c) 2015 Institute of Electrical Engineers of Japan. Published by John Wiley & Sons, Inc.	[Hu, Liancheng; Okuno, Yoshihiro] Tokyo Inst Technol, Dept Energy Sci, Midori Ku, Yokohama, Kanagawa 2268502, Japan; [Kobayashi, Hiromichi] Keio Univ, Dept Phys, Kohoku Ku, Yokohama, Kanagawa 2238521, Japan	Okuno, Y (reprint author), Tokyo Inst Technol, Dept Energy Sci, Midori Ku, 4259 Nagatsuta Cho, Yokohama, Kanagawa 2268502, Japan.	yokuno@es.titech.ac.jp					PIERSON WJ, 1964, J GEOPHYS RES, V69, P5181, DOI 10.1029/JZ069i024p05181; Branover H, 1986, P 9 INT C MAGN POW G, V5, P1735; Goda Y., 2010, RANDOM SEAS DESIGN M; Japan Society of Civil Engineers, 2000, HYDR FORM COLL; Liu B, 2011, P 21 INT OFFSH POL E, V1, P695; Longuet-Higgins M, 1957, PHILOS T R SOC LON A, V966, P321; Maeda T, 2003, J JPN SOC APPL ELECT, V11, P249; Peng Y, 2008, INT OFFSHORE POLAR E, P388; Rosa RJ, 1968, MAGNETOHYDRODYNAMIC; Sutton G.W., 1962, Transactions of the American Institute of Electrical Engineers, Part I (Communications and Electronics), V80; Zhao L, 2009, P 19 INT OFFSH POL E, V1, P308; Zhao L, 2009, SUSTAINABLE POWER GE	12	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1931-4973	1931-4981		IEEJ T ELECTR ELECTR	IEEJ Trans. Electr. Electron. Eng.	MAY	2015	10	3					268	273		10.1002/tee.22083		6	Engineering, Electrical & Electronic	Engineering	CG1KT	WOS:000353032200006		
J	Hemtiwakorn, K; Mahasitthiwat, V; Tungjitkusolmun, S; Hamamoto, K; Pintavirooj, C				Hemtiwakorn, Khaisang; Mahasitthiwat, Visan; Tungjitkusolmun, Supan; Hamamoto, Kazuhiko; Pintavirooj, Chuchart			Patient-Specific Aided Surgery Approach of Deviated Nasal Septum Using Computational Fluid Dynamics	IEEJ TRANSACTIONS ON ELECTRICAL AND ELECTRONIC ENGINEERING			English	Article						nasal septum deviation; nasal airway obstruction; septoplasty; turbinate hypertrophy reduction; virtual surgery; presurgical planning	AIR-FLOW CHARACTERISTICS; HUMAN NOSE; NUMERICAL SIMULATIONS; INFERIOR TURBINATE; OBSTRUCTION; CAVITY; MODEL; SEPTOPLASTY; RESISTANCE; DISEASE	In treating a patient with deviated nasal septum (DNS), a surgeon draws up a surgical plan based on the patient's rhinomanometry outcomes and self-assessment of nose conditions, e.g. the nasal obstruction septoplasty effectiveness (NOSE) score. However, the procedure fails to localize the DNS and determine the nose's aerodynamic effects. This paper proposes a DNS-aided surgery approach using computational fluid dynamics (CFD) and computed tomography (CT) techniques consisting of three main processes: preoperative, presurgical planning, and postoperative processes. The healthy baseline refers to a benchmark consisting of five subjects without DNS and nasal airway obstructions. To assess the possibility of using the CFD-CT-aided surgery approach as a presurgical planning tool in the DNS operation, comparative tests were carried out with DNS patient #1, who received a conventional nasal surgery without the proposed presurgical planning. Although DNS patient #1's surgical outcome was relatively satisfying to the patient, evaluating from the reduction of the NOSE score the conventional surgical method could induce an excessive excision of nasal airway, resulting in water loss in the nasal mucosa and a large reduction in airflow velocity. In addition, the postoperative nasal resistance measured by a rhinomanometer was not acceptable to the surgeon. Virtual surgery using the CFD-CT approach performed after surgery could suggest suitable patient-specific components of nasal operation with predictable results. Subsequently, implementation of the proposed CFD-CT approach in aid of DNS surgery was performed in DNS patient #2. The benefits of the CFD-CT-aided surgery approach were determined based on the pre- and postoperative outcomes (i.e. nasal geometric data and nasal airflow patterns), NOSE scores, and rhinomanometric data of DNS patient #2, which were compared against those of the healthy baseline benchmark. The CFD-CT approach could assist the surgeon to localize the DNS and determine the defective nasal tissues to be removed. The actual postoperative outcomes were clinically acceptable to the surgeon and DNS patient #2. It is evident that the CFD-CT-aided surgery approach is suitable for and applicable to surgery of DNS patients with small variability from the presurgical planning stage. (c) 2015 Institute of Electrical Engineers of Japan. Published by John Wiley & Sons, Inc.	[Hemtiwakorn, Khaisang; Tungjitkusolmun, Supan; Pintavirooj, Chuchart] KMITL, Fac Engn, Dept Elect Engn, Bangkok, Thailand; [Hemtiwakorn, Khaisang] Mahidol Univ, Fac Med Technol, Dept Radiol Technol, Bangkok 10700, Thailand; [Mahasitthiwat, Visan] Srinakharinwirot Univ, Fac Med, Dept Otolaryngol, Nakornnayok, Thailand; [Hamamoto, Kazuhiko] Tokai Univ, Sch Informat & Telecommun Engn, Dept Informat Media Technol, Tokyo 151, Japan	Pintavirooj, C (reprint author), KMITL, Fac Engn, Dept Elect Engn, Bangkok, Thailand.	kpchucha@kmitl.ac.th			KMITL (KMITL Research Fund); Faculty of Medicine, Srinakarinwirot University, Thailand	The authors wish to thank Prof. Emad S. Ebbini, Department of Electrical and Computer Engineering, University of Minnesota, MN, USA, for the Mimic software program and the Computer Service Center, King Mongkut's Institute of Technology Ladkrabang (KMITL), Thailand, for the STAR-CD software program. This research was a joint project supported by KMITL (KMITL Research Fund to S. Tungjitkusolmun) and the Faculty of Medicine, Srinakarinwirot University, Thailand.	Jeong SJ, 2007, MED ENG PHYS, V29, P637, DOI 10.1016/j.medengphy.2006.08.017; Wen J, 2008, RESP PHYSIOL NEUROBI, V161, P125, DOI 10.1016/j.resp.2008.01.012; Lee JH, 2010, RESP PHYSIOL NEUROBI, V172, P136, DOI 10.1016/j.resp.2010.05.010; Elahi MM, 1997, J OTOLARYNGOL, V26, P236; Stewart MG, 2004, OTOLARYNG HEAD NECK, V130, P157, DOI 10.1016/j.otohns.2003.09.016; HAHN I, 1993, J APPL PHYSIOL, V75, P2273; Keyhani K, 1995, J BIOMECH ENG-T ASME, V117, P429, DOI 10.1115/1.2794204; Ishikawa S, 2006, ARCH OTOLARYNGOL, V132, P1203, DOI 10.1001/archotol.132.11.1203; [Anonymous], 2004, STAR CD 3 22 US GUID; ELAD D, 1993, MED BIOL ENG COMPUT, V31, P585, DOI 10.1007/BF02441806; Stewart MG, 2004, OTOLARYNG HEAD NECK, V130, P283, DOI 10.1016/j.otohns.2003.12.004; [Anonymous], 1994, ICRP PUBL, V24; Rhee JS, 2005, LARYNGOSCOPE, V115, P437, DOI 10.1097/01.mlg.0000157831.46250; Wexler D, 2005, ARCH OTOLARYNGOL, V131, P1102, DOI 10.1001/archotol.131.12.1102; Chen XB, 2009, LARYNGOSCOPE, V119, P1730, DOI 10.1002/lary.20585; Wolfensberger M, 2002, CHEM SENSES, V27, P617, DOI 10.1093/chemse/27.7.617; SCHRECK S, 1993, J APPL PHYSIOL, V75, P1767; Chandra RK, 2009, OTOLARYNG CLIN N AM, V42, P207, DOI 10.1016/j.otc.2009.01.004; Egeli E, 2004, LARYNGOSCOPE, V114, P113, DOI 10.1097/00005537-200401000-00020; Rhee JS, 2011, ARCH FACIAL PLAST S, V13, P305, DOI 10.1001/archfacial.2011.18; Garcia GJM, 2007, J APPL PHYSIOL, V103, P1082, DOI 10.1152/japplphysiol.01118.2006; Rhee JS, 2012, ARCH FACIAL PLAST S, V14, P354, DOI 10.1001/archfacial.2012.182; Kimbell JS, 2013, J BIOMECH, V46, P2634, DOI 10.1016/j.jbiomech.2013.08.007; Segal RA, 2008, ANN BIOMED ENG, V36, P1870, DOI 10.1007/s10439-008-9556-2; Kim SK, 2014, RESP PHYSIOL NEUROBI, V192, P95, DOI 10.1016/j.resp.2013.12.010; Croce C, 2006, ANN BIOMED ENG, V34, P997, DOI 10.1007/s10439-006-9094-8; Ertap A, 2007, OTOLARYNGOLOGY HEAD, V136, P380; Garcia GJM, 2010, AM J RHINOLOGY ALLER, V24, P46; Gulati SP, 2008, INDIAN J OTOLARYNGOL, V60, P133, DOI 10.1007/s12070-007-0119-x; KORANTZIS A, 1992, EUR J OBSTET GYN R B, V44, P41, DOI 10.1016/0028-2243(92)90311-L; Lui T, 2012, ACTA OTO-LARYNGOL, V132, P290; Moghadas H, 2011, RESP PHYSIOL NEUROBI, V177, P9, DOI 10.1016/j.resp.2011.02.011; Na Y, 2012, RESP PHYSIOL NEUROBI, V180, P289, DOI 10.1016/j.resp.2011.12.005; Naftali S, 1998, ANN BIOMED ENG, V26, P831, DOI 10.1114/1.108; Naftali S, 2005, ANN BIOMED ENG, V33, P545, DOI 10.1007/s10439-005-2513-4; Ozlugedik S, 2008, LARYNGOSCOPE, V118, P330, DOI 10.1097/MLG.0b013e318159aa26; Patankar SV, 1972, INT J HEAT MASS TRAN, V15, P1778; Proctor DF, 1982, NOSE UPPER AIRWAY PH, P23; Subramaniam RP, 1998, INHAL TOXICOL, V10, P91; Suzina AH, 2003, J LARYNGOL OTOL, V117, P605; Theissing J, 2011, ENT HEAD NECK SURG E; Valencia MP, 2008, RADIOGRAPHICS, V28, P205, DOI 10.1148/rg.281075049; WARSI ZUA, 1981, AIAA J, V19, P240, DOI 10.2514/3.7763; Yildirim I, 2003, INT J PEDIATR OTORHI, V67, P1203, DOI 10.1016/j.ijporl.2003.07.005	44	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1931-4973	1931-4981		IEEJ T ELECTR ELECTR	IEEJ Trans. Electr. Electron. Eng.	MAY	2015	10	3					274	286		10.1002/tee.22084		13	Engineering, Electrical & Electronic	Engineering	CG1KT	WOS:000353032200007		
J	Xiao, HT; Lou, S; Ogai, H				Xiao, Haitao; Lou, Sheng; Ogai, Harutoshi			A Novel Bridge Structure Damage Diagnosis Algorithm Based on Post-Nonlinear ICA and Statistical Pattern Recognition	IEEJ TRANSACTIONS ON ELECTRICAL AND ELECTRONIC ENGINEERING			English	Article						wireless sensor networks; geometric linearization; independent component analysis; statistical pattern recognition; bridge diagnosis; system design	INDEPENDENT COMPONENT ANALYSIS	Monitoring the health of bridges and diagnosing the damage is vital for government and related institutions in Japan because of frequent earthquakes and the oceanic climate. This paper develops a bridge structure health monitoring system (BSHM), which includes data acquisition and analysis. A two-stage structure damage detection algorithm based on post-nonlinear independent component analysis (ICA) and statistical pattern recognition is proposed to analyze the acquired data and evaluate the health of bridges. First, an improved post-nonlinear ICA algorithm is proposed for denoising, and a data-sample matching based data normalization scheme to reduce the effect of varying environmental and operational condition. Thereafter, fast Fourier transform (FFT) is used to detect the damage. Based on the first stage, a statistical pattern recognition damage detection algorithm, including a new damage sensitive index D-SPR, is proposed to determine the severity and location(s) of damage. In addition to the algorithm, this paper presents several simulations and experiments, including a detection experiment that applies artificial damage to a real bridge to show that our design choices are indeed effective. (c) 2015 Institute of Electrical Engineers of Japan. Published by John Wiley & Sons, Inc.	[Xiao, Haitao; Lou, Sheng; Ogai, Harutoshi] Waseda Univ, Grad Sch Informat Prod & Syst, Wakamatsu Ku, Kitakyushu, Fukuoka 8080135, Japan	Xiao, HT (reprint author), Waseda Univ, Grad Sch Informat Prod & Syst, Wakamatsu Ku, 2-7 Hibikino, Kitakyushu, Fukuoka 8080135, Japan.	sd8015949@hotmail.com			Japan Regional Innovation Strategy Program; Health Monitoring Business Limited Liability Partnership	This study was supported by the Japan Regional Innovation Strategy Program and received financial support from the Health Monitoring Business Limited Liability Partnership.	Andersen EY, 1994, STRAIT CROSSINGS 94, V94, P189; Fritzen CP, 1998, MECH SYST SIGNAL PR, V12, P163, DOI 10.1006/mssp.1997.0139; Zang C, 2004, STRUCT HEALTH MONIT, V3, P69, DOI 10.1177/14759217041876; Gentile A, 2003, INT J SOLIDS STRUCT, V40, P295, DOI 10.1016/S0020-7683(02)00548-6; Farrar CR, 1998, SMART MATER STRUCT, V7, P720, DOI 10.1088/0964-1726/7/5/014; PANDEY AK, 1991, J SOUND VIB, V145, P321, DOI 10.1016/0022-460X(91)90595-B; PANDEY AK, 1994, J SOUND VIB, V169, P3, DOI 10.1006/jsvi.1994.1002; Farrar CR, 1998, SMART MATER STRUCT, V7, P704, DOI 10.1088/0964-1726/7/5/013; [Anonymous], 2005, HIGHW STAT ANN REP; Brownjohn JMW, 2005, STRUCT CONTROL HLTH, V12, P227, DOI 10.1002/stc.67; Brockweii PJC, 1991, LIME SERIES THEORY M, V2nd; Brockwell PJ, 2002, INTRO TIME SERIES FO; Cheng J, 2005, THESIS WASEDA U; Cheon J-I, 2006, SUCE ICASE 2006 INT, P4692; Farrar CR, 1999, 2 INT WORKSH STRUCT; Fujino Y, 2004, 2 EUR WORKSH STRUCT, P3; Li CS, 1996, 12 INT C DAT ENG, P546; Myrvoll F, 2000, P SOC PHOTO-OPT INS, V4062, P827; Nguyen TV, 2005, INT JOINT C NEUR NET, V1, P244; Ou J, 2004, STRUCT ENG MECH, P599; Peter Carden E, 2007, MECH SYSTEMS SIGNAL, V22, P295; Pines D, 2002, STRUCTURAL ENG MAT, V4, P372; Sohn H., 2001, SMART MATER STRUCT, V10, P1; Song HZ, 2005, LECT NOTES ARTIF INT, V3584, P670; Wang ML, 2004, WORKSH BAS STRUCT HL, P113; Wong K-Y, 2004, STRUCT CONTROL HLTH, V11, P91, DOI DOI 10.1002/STC.33; Wu ZS, 2003, STRUCTURAL HEALTH MONITORING AND INTELLIGENT INFRASTRUCTURE, VOLS 1 AND 2, P153; Xiang HF, 2002, WORKSH RES MON LONG, P24; Zang C, 2002, 3 INT C ID ENG SYST, P434; Zhong L, 2006, LECT NOTES CONTR INF, V345, P840; ZIMMERMAN DC, 1992, AIAA J, V30, P1848, DOI 10.2514/3.11146	31	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1931-4973	1931-4981		IEEJ T ELECTR ELECTR	IEEJ Trans. Electr. Electron. Eng.	MAY	2015	10	3					287	300		10.1002/tee.22085		14	Engineering, Electrical & Electronic	Engineering	CG1KT	WOS:000353032200008		
J	Wang, L; Murayama, H				Wang, Lan; Murayama, Hiroshi			A Multi-version CIM-Based Database Platform for Smart Grid	IEEJ TRANSACTIONS ON ELECTRICAL AND ELECTRONIC ENGINEERING			English	Article						smart grid; common information model; UML; IEC 62656; database platform; compatibility		In the smart grid area, the Common Information Model (CIM) for energy management systems is widely used. CIM is developed in a Unified Modeling Language (UML) and its entire content is maintained with one version by the IEC TC57 committee. There are officially four versions of CIM so far. For each CIM entity modeled in UML, such as a class or an attribute, there is no version information by default. This makes it extremely difficult to precisely identify a CIM entity in an application. Consequently, any application utilizing CIM faces an obstacle in maintenance and in exchange of data with other parties that may be utilizing different versions of CIM. Furthermore, CIM in UML format is unsuitable for managing a large number of instances. In order to improve the above-mentioned compatibility and usability problem of CIM, in this paper we introduce a new International Standard, IEC 62656-3. Through this standard, CIM can be decomposed into a set of tabular data each of which has an explicit version and can be described with a spreadsheet. This format is called Parcellized-CIM. Based on Parcellized-CIM, a commercial database platform, Parcimoser, is developed and applied in the engineering of smart grids. (c) 2015 Institute of Electrical Engineers of Japan. Published by John Wiley & Sons, Inc.	[Wang, Lan] TOSHIBA, Corp Res & Dev Ctr, Saiwai Ku, Kawasaki, Kanagawa 2128582, Japan; [Murayama, Hiroshi] TOSHIBA, Toshiba Res Consulting Corp, Saiwai Ku, Kawasaki, Kanagawa 2128582, Japan	Wang, L (reprint author), TOSHIBA, Corp Res & Dev Ctr, Saiwai Ku, 1 Komukai Toshiba Cho, Kawasaki, Kanagawa 2128582, Japan.	lan.wang@toshiba.co.jp					[Anonymous], 2014, 1950522012 ISOIEC; [Anonymous], 2013, 62325301 IEC; [Anonymous], 2010, 6196811 IEC; [Anonymous], 2013, 626561 EC; [Anonymous], 2013, 626563 IEC; [Anonymous], 2014, 1950512012 ISOIEC; [Anonymous], 2013, Patent No. [P2013-107262, 2013107262]; [Anonymous], 2014, 195022005 ISOIEC; [Anonymous], 2013, 619703012013 IEC; Aumueller D., 2005, P 2005 ACM SIGMOD IN, P906, DOI 10.1145/1066157.1066283; Do H.-H., 2002, P 28 INT C VER LARG, P610; Gregor E, 2005, P 20 IEEE ACM INT C, P124; Hiroshi Murayama, 2010, GRID INTEROP FOR; Rahm E, 2004, SIGMOD RECORD, V33, P26; Wang L, 2011, ENRGY PROCED, V12, DOI 10.1016/j.egypro.2011.10.005; Wang S, 2006, P 39 HAW INT C SYST, P1; Yasuyuki Tada, 2012, IEEJ T POWER ENERGY, V132, P829	17	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1931-4973	1931-4981		IEEJ T ELECTR ELECTR	IEEJ Trans. Electr. Electron. Eng.	MAY	2015	10	3					330	339		10.1002/tee.22089		10	Engineering, Electrical & Electronic	Engineering	CG1KT	WOS:000353032200012		
J	Kimura, T; Uno, K; Masuzawa, T				Kimura, Takayuki; Uno, Kazuya; Masuzawa, Toru			Size-Reduced Two-Dimensional Integrated Magnetic Sensor Fabricated in 0.18-mu m CMOS Process	IEEJ TRANSACTIONS ON ELECTRICAL AND ELECTRONIC ENGINEERING			English	Article						Hall sensor; two-dimensional magnetic sensor; CMOS; motor control	OXIDE	Two-dimensional integrated magnetic sensors have been investigated in order to reduce their size for use in a magnetic self-levitation motor. The two-dimensional integrated magnetic sensor investigated in this paper is composed of a 16 x 16 array of Hall sensors and fabricated by a 0.18-m complementary metal-oxide-semiconductor (CMOS) standard process. The sizes of the Hall elements are 1 x 1, 2 x 2, 3 x 3, and 6 x 6 m(2). Hall element of dimension 1 x 1 m(2)was the minimum size in the fabrication process rule. The dimension of one pixel in which the Hall element was embedded was 20 x 20 m(2). The average sensitivity of the arrayed Hall sensors at four sizes was about 0.140 mV/mT with a DC magnetic field. The product sensitivity at four sizes of Hall sensors was about 0.089 mV/(mAmT), which is better than that of our previous work. Degradation of the product sensitivity was not seen in reduced-size Hall elements. These results reveal that a Hall element of size 1 x 1 m(2) has enough sensitivity for sensing the impeller position of a magnetically suspended motor. (c) 2015 Institute of Electrical Engineers of Japan. Published by John Wiley & Sons, Inc.	[Kimura, Takayuki; Uno, Kazuya] Ibaraki Univ, Coll Engn, Dept Elect & Elect Engn, Hitachi, Ibaraki 3168511, Japan; [Masuzawa, Toru] Ibaraki Univ, Coll Engn, Dept Mech Engn, Hitachi, Ibaraki 3168511, Japan	Kimura, T (reprint author), Ibaraki Univ, Coll Engn, Dept Elect & Elect Engn, 4-12-1 Nakanarusawa, Hitachi, Ibaraki 3168511, Japan.	tkimura@mx.ibaraki.ac.jp			JSPS KAKENHI [25420317]; program for Revitalization Promotion, JST; VLSI Design and Education Center (VDEC) of the University of Tokyo; Synopsys, Inc.; Mentor Graphics, Inc.; Cadence Design Systems, Inc.	This study was supported by JSPS KAKENHI Grant Number 25420317, program for Revitalization Promotion, JST, and the VLSI Design and Education Center (VDEC) of the University of Tokyo in collaboration with Synopsys, Inc., Mentor Graphics, Inc., and Cadence Design Systems, Inc. The VLSI chip used in the present study was fabricated as part of the chip fabrication program of the VDEC of the University of Tokyo in collaboration with Rohm Corporation and Toppan Printing Corporation.	GALLAGHE.RC, 1966, SOLID STATE ELECTRON, V9, P571, DOI 10.1016/0038-1101(66)90172-9; Kimura T, 2011, ITE J, V65, P364; Kimura T, 2012, INT C EL ENG 2012; Kimura T, 2010, ITE J, V64, P416; Kimura T, 2006, IEEJ T ELECTR ELECTR, V1, P188, DOI 10.1002/tee.20037; MATHIEU N, 1992, SENSOR ACTUAT A-PHYS, V32, P656, DOI 10.1016/0924-4247(92)80059-C; Sze SM, 1981, PHYS SEMICONDUCTOR D, V2nd, P449; Yang HM, 1996, SENSOR ACTUAT A-PHYS, V57, P9	8	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1931-4973	1931-4981		IEEJ T ELECTR ELECTR	IEEJ Trans. Electr. Electron. Eng.	MAY	2015	10	3					345	349		10.1002/tee.22091		5	Engineering, Electrical & Electronic	Engineering	CG1KT	WOS:000353032200014		
J	Kim, TH; Lee, SW; Gyawali, G; Jo, YH; Sekino, T				Kim, Tae-Ho; Lee, Soo-Wohn; Gyawali, Gobinda; Jo, Yong-Hyun; Sekino, Tohru			Synthesis of TiO2-xNy/Ag-PbMoO4 Composite and Their Photocatalytic Activity Under Simulated Solar Light Irradiation	International Journal of Applied Ceramic Technology			English	Article							ANATASE TIO2 PARTICLES; VISIBLE-LIGHT; TITANIUM-DIOXIDE; THIN-FILMS; PHOTOPHYSICAL PROPERTIES; OPTICAL-PROPERTIES; THIOGLYCOLIC ACID; OXIDE CATALYSTS; CHARGE-TRANSFER; SEMICONDUCTOR	TiO2-xNy/Ag-PbMoO4 composite were synthesized by sonochemical method. The results revealed that the band-gap energy absorption edge of TiO2-xNy/Ag-PbMoO4 composite was shifted to a longer wavelength as compared to TiO2, TiO2-xNy, PbMoO4, and Ag-PbMoO4. The TiO2-xNy/Ag-PbMoO4 composite showed the enhanced photocatalytic activity for degradation of indigo carmine dye (ICD) under simulated solar light irradiation. The TiO2-xNy/Ag-PbMoO4 composite exhibited the highest percentage (95.4%) of degradation of ICD and the highest reaction rate constant (0.0244min(-1)) in 2h. The results suggested that a good combination of Ag and TiO2-xNy nanoparticles has great influence on the photocatalytic behavior of PbMoO4.	[Kim, Tae-Ho; Lee, Soo-Wohn; Gyawali, Gobinda; Jo, Yong-Hyun] Sun Moon Univ, Res Ctr Eco Multifunct Nano Mat, Tangjung Myon 336708, Asan Chungnam, South Korea; [Sekino, Tohru] Tohoku Univ, Inst Multidisciplinary Res Adv Mat IMRAM, Aoba Ku, Sendai, Miyagi 9808577, Japan	Kim, TH (reprint author), Sun Moon Univ, Res Ctr Eco Multifunct Nano Mat, Tangjung Myon 336708, Asan Chungnam, South Korea.	snowman@sunmoon.ac.kr			Global Research Laboratory Program of the National Research Foundation of Korea (NRF) - Ministry of Education, Science and Technology (MEST) of Korea [2010-00339]; National Research Foundation of Korea (NRF) - Ministry of Education, Science and Technology [2012R1A1A4A01011107]	This research was supported by Global Research Laboratory Program of the National Research Foundation of Korea (NRF) funded by the Ministry of Education, Science and Technology (MEST) of Korea (Grant No.: 2010-00339) and also supported by Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education, Science and Technology (2012R1A1A4A01011107).	Li XK, 2008, ADV MATER, V20, P3816, DOI 10.1002/adma.200702975; Sopyan I, 1996, J PHOTOCH PHOTOBIO A, V98, P79, DOI 10.1016/1010-6030(96)04328-6; Marci G, 2001, J PHYS CHEM B, V105, P1033, DOI 10.1021/jp003173j; Wang P, 2008, ANGEW CHEM INT EDIT, V47, P7931, DOI 10.1002/anie.200802483; ANPO M, 1987, REV CHEM INTERMED, V8, P105; Loghman-Estarki MR, 2012, CURR NANOSCI, V8, P767; FUJISHIMA A, 1972, NATURE, V238, P37, DOI 10.1038/238037a0; Mohammadikish M, 2013, CERAM INT, V39, P3173, DOI 10.1016/j.ceramint.2012.10.001; Liu S, 2006, J PHOTOCH PHOTOBIO A, V179, P75, DOI 10.1016/j.jphotochem.2005.07.016; Rosa ILV, 2008, J FLUORESC, V18, P239, DOI 10.1007/s10895-007-0195-z; Li HX, 2006, J PHYS CHEM B, V110, P1559, DOI 10.1021/jp055830j; PASKI EF, 1988, ANAL CHEM, V60, P1224, DOI 10.1021/ac00162a025; HOFFMANN MR, 1995, CHEM REV, V95, P69, DOI 10.1021/cr00033a004; Salavati-Niasari M, 2010, J ALLOY COMPD, V494, P199, DOI 10.1016/j.jallcom.2009.10.265; Davar F, 2012, CRYSTENGCOMM, V14, P7338, DOI 10.1039/c2ce25831e; Yin S, 2005, J MATER CHEM, V15, P674, DOI 10.1039/b413377c; Loghman-Estarki MR, 2013, CRYSTENGCOMM, V15, P5898, DOI 10.1039/c3ce40288f; Li HH, 2012, J CATAL, V286, P273, DOI 10.1016/j.jcat.2011.11.013; ANPO M, 1992, J MOL CATAL, V74, P207, DOI 10.1016/0304-5102(92)80238-C; Yin S, 2003, J MATER CHEM, V13, P2996, DOI 10.1039/b309217h; KAWAI T, 1979, NATURE, V282, P283, DOI 10.1038/282283a0; Ye FX, 2002, SURF COAT TECH, V160, P62, DOI 10.1016/S0257-8972(02)00377-8; He JJ, 1997, J PHYS CHEM B, V101, P9027, DOI 10.1021/jp971550v; Zhang SS, 2011, CATAL COMMUN, V12, P689, DOI 10.1016/j.catcom.2011.01.001; Kim TH, 2013, CATAL TODAY, V212, P75, DOI 10.1016/j.cattod.2012.09.014; Erdem B, 2001, LANGMUIR, V17, P2664, DOI 10.1021/la0015213; SERPONE N, 1995, J PHYS CHEM-US, V99, P16646, DOI 10.1021/j100045a026; Umebayashi T, 2002, APPL PHYS LETT, V81, P454, DOI 10.1063/1.1493647; CHOI WY, 1994, J PHYS CHEM-US, V98, P13669, DOI 10.1021/j100102a038; Wang C, 2002, APPL CATAL B-ENVIRON, V39, P269; Adhikari R, 2013, MATER LETT, V91, P294, DOI 10.1016/j.matlet.2012.10.004; PATTERSON EM, 1977, APPL OPTICS, V16, P729, DOI 10.1364/AO.16.000729; Holland BT, 1999, CHEM MATER, V11, P795, DOI 10.1021/cm980666g; Yu JG, 2008, ENVIRON SCI TECHNOL, V42, P4902, DOI 10.1021/es800036n; Liu G, 2010, J MATER CHEM, V20, P831, DOI 10.1039/B909930A; Ohno T, 2004, CATAL LETT, V98, P255, DOI 10.1007/s10562-004-8689-7; Faure N, 1996, APPL PHYS B-LASERS O, V63, P593; Gyawali G, 2013, J HAZARD MATER, V263, P45, DOI 10.1016/j.jhazmat.2013.03.065; Yu JG, 2005, APPL CATAL B-ENVIRON, V60, P211, DOI 10.1016/j.apcatb.2005.03.009; Ohno T, 2003, APPL CATAL A-GEN, V244, P383, DOI 10.1016/S0926-860X(02)00610-5; Irie H, 2003, CHEM LETT, V32, P772, DOI 10.1246/cl.2003.772; BORGARELLO E, 1982, J AM CHEM SOC, V104, P2996, DOI 10.1021/ja00375a010; Dimitrijevic NM, 2005, J AM CHEM SOC, V127, P1344, DOI 10.1021/ja0458118; Mohammadikish M, 2013, J CLUST SCI, V24, P217, DOI 10.1007/s10876-012-0538-z; Pontes FM, 2003, J EUR CERAM SOC, V23, P3001, DOI 10.1016/S0955-2219(03)00099-2; Yang YL, 2010, J ALLOY COMPD, V505, P239, DOI 10.1016/j.jallcom.2010.06.037; Asahi R, 2001, SCIENCE, V293, P269, DOI 10.1126/science.1061051; Hernandez-Uresti DB, 2012, RES CHEM INTERMEDIAT, V38, P817, DOI 10.1007/s11164-011-0420-x; Wu SY, 2004, J ALLOY COMPD, V375, P39, DOI 10.1016/j.jallcom.2003.11.137; DiPaola A, 1997, J PHYS CHEM B, V101, P876, DOI 10.1021/jp9623599; Anpo M, 2004, B CHEM SOC JPN, V77, P1427, DOI 10.1246/bcsj.77.1427; Chen QC, 2012, CATAL COMMUN, V24, P85, DOI 10.1016/j.catcom.2012.03.033; Fujishima A, 1969, KOGYO KAGAKU ZASSHI, V72, P108; Fujishima A., 2000, J PHOTOCH PHOTOBIO C, V1, P1, DOI DOI 10.1016/S1389-5567(00)00002-2; GOPIDAS KR, 1990, J PHYS CHEM-US, V94, P6435, DOI 10.1021/j100379a051; IBANEZ JG, 1991, J CHEM EDUC, V68, P872; Li X., 2011, J NANOMATER, V1, P1, DOI DOI 10.1155/2011/270974; Loghman-Estarki MR, 2014, CERAM INT, V40, P1405, DOI 10.1016/j.ceramint.2013.07.023; Loghman-Estarki MR, 2013, CERAM INT, V39, P7817, DOI 10.1016/j.ceramint.2013.03.042; Lv KL, 2010, APPL CATAL B-ENVIRON, V95, P383, DOI 10.1016/j.apcatb.2010.01.017; Milanova M, 2009, J NON-CRYST SOLIDS, V355, P379, DOI 10.1016/j.jnoncrysol.2008.12.004; KAMAT PV, 1992, J PHYS CHEM-US, V96, P6829, DOI 10.1021/j100195a055; Rabatic BM, 2006, ADV MATER, V18, P1033, DOI 10.1002/adma.200500988; Salavati-Niasari M., 2009, J ALLOY COMPD, V494, P776; SCHRAUZER GN, 1977, J AM CHEM SOC, V99, P7189, DOI 10.1021/ja00464a015; Shanmugasundaram S., 2004, J PHYS CHEM B, V108, P19384	66	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1546-542X	1744-7402		INT J APPL CERAM TEC	Int. J. Appl. Ceram. Technol.	MAY-JUN	2015	12	3					577	584		10.1111/ijac.12245		8	Materials Science, Ceramics	Materials Science	CG6CG	WOS:000353382500012		
J	Fujiya, K; Chong, JM; Ando, M; Akita, H; Fukuda, A; Nagahama, T; Arai, K				Fujiya, Keiichi; Chong, Ja-Mun; Ando, Masayuki; Akita, Hidetaka; Fukuda, Akira; Nagahama, Takeshi; Arai, Kuniyoshi			Sigmoid volvulus is associated with a decrease in enteric plexuses and ganglion cells: a case-control study	INTERNATIONAL JOURNAL OF COLORECTAL DISEASE			English	Article						CD117; Myopathy; Neuropathy; NSE	GASTROINTESTINAL NEUROMUSCULAR PATHOLOGY; INTERNATIONAL WORKING GROUP; FAMILIAL VISCERAL MYOPATHY; SLOW-TRANSIT CONSTIPATION; INTERSTITIAL-CELLS; NERVOUS-SYSTEM; INTESTINAL PSEUDOOBSTRUCTION; SMOOTH-MUSCLE; DISEASE; COLON	Although sigmoid volvulus (SV) causes acute obstruction, its pathogenesis and mechanism of torsion are unknown, and few reports have described its pathological findings. Here, we evaluated the clinicopathological characteristics of volvulus and factors contributing to volvulus of the sigmoid colon. We compared 14 patients with SV (10 men and 4 women; median age, 78.5 years) with 14 age- and sex-matched control patients for differences in clinical characteristics, focusing on dysmotility (enteric visceral myopathy, neuropathy, and mesenchymopathy). Of the 14 SV patients, 7 had recurrent volvulus, 11 had an associated condition, and 5 required emergency surgery. Atrophy and fibrosis of the inner muscle were more prevalent in the SV than control patients (p = 0.041). Median extent (per centimeter of muscularis propria) of the myenteric plexus (12.5 versus 17.5, p < 0.001) and submucous plexus (15.0 versus 25.5, p < 0.001) was lower in the SV patients, as were the median numbers of myenteric (9.7 versus 30.4, p < 0.001) and submucous ganglion cells (10.0 versus 23.2, p < 0.001). Inflammatory neuropathy was more prevalent in the SV than control patients (p = 0.046); whereas, the prevalence of mesenchymopathy did not differ (p = 0.481). A decrease in the extent of enteric plexus and ganglion cells precedes the clinical manifestation of SV. Although further elucidation is needed, this decrease may play an important role in the diagnosis of SV and in identifying the mechanism leading to torsion in SV.	[Fujiya, Keiichi; Ando, Masayuki; Fukuda, Akira; Nagahama, Takeshi; Arai, Kuniyoshi] Tokyo Metropolitan Hlth & Med Corp Toshima Hosp, Dept Surg, Tokyo, Japan; [Chong, Ja-Mun; Akita, Hidetaka] Tokyo Metropolitan Hlth & Med Corp Toshima Hosp, Dept Pathol, Itabashi Ku, Tokyo 1730015, Japan	Chong, JM (reprint author), Tokyo Metropolitan Hlth & Med Corp Toshima Hosp, Dept Pathol, Itabashi Ku, 33-1 Sakaecho, Tokyo 1730015, Japan.	shikofumi_tei@tokyo-hmt.jp			Tokyo Metropolitan Health and Medical Corporation Toshima Hospital	We thank Yoko Shibasaki, Yuriko Kunimoto, Emi Takahashi, and Kumiko Sudo, who are clinical technologists, for preparing the pathological specimens. This study was supported by a grant from Tokyo Metropolitan Health and Medical Corporation Toshima Hospital.	Lee JI, 2005, J GASTROEN HEPATOL, V20, P1292, DOI 10.1111/j.1400-1746.2005.03809.x; Bernard CE, 2009, NEUROGASTROENT MOTIL, V21, P746, DOI 10.1111/j.1365-2982.2008.01245.x; Knowles CH, 2011, BEST PRACT RES CL GA, V25, P43, DOI 10.1016/j.bpg.2010.12.001; Knowles CH, 2009, ACTA NEUROPATHOL, V118, P271, DOI 10.1007/s00401-009-0527-y; BALLANTYNE GH, 1985, ANN SURG, V202, P83, DOI 10.1097/00000658-198507000-00014; TEGEGNE A, 1995, TROP GEOGR MED, V47, P212; Bassotti G, 2006, GUT, V55, P41, DOI 10.1136/gut.2005.073197; Knowles CH, 2011, NEUROGASTROENT MOTIL, V23, P115, DOI 10.1111/j.1365-2982.2010.01657.x; Amiot A, 2009, AM J SURG PATHOL, V33, P749, DOI 10.1097/PAS.0b013e31819b381a; Gamba E, 2004, J CLIN PATHOL, V57, P1168, DOI 10.1136/jcp.2003.015297; De Giorgio R, 2004, NEUROGASTROENT MOTIL, V16, P143, DOI 10.1111/j.1743-3150.2004.00491.x; Knowles CH, 2010, GUT, V59, P882, DOI 10.1136/gut.2009.200444; BALLANTYNE GH, 1981, DIS COLON RECTUM, V24, P515, DOI 10.1007/BF02604311; Faussone-Pellegrini MS, 1999, GUT, V45, P775; FITZGIBBONS PL, 1987, AM J SURG PATHOL, V11, P846, DOI 10.1097/00000478-198711000-00003; Furuya Y, 2005, WORLD J SURG, V29, P88, DOI 10.1007/s00268-004-7462-9; Goyal RK, 1996, NEW ENGL J MED, V334, P1106; Kapur RP, 2006, AM J CLIN PATHOL, V126, P9, DOI 10.1309/T7REY1N43FML7AA8; Martin JE, 2009, GUT, V58, P1703, DOI 10.1136/gut.2009.184572; MITROS FA, 1982, HUM PATHOL, V13, P825, DOI 10.1016/S0046-8177(82)80079-8; Mostafa RM, 2010, WORLD J GASTROENTERO, V16, P3239, DOI 10.3748/wjg.v16.i26.3239; Ohkubo H, 2014, NEUROGASTROENT MOTIL, V26, P571, DOI 10.1111/nmo.12303; Osiro SB, 2012, AM SURGEON, V78, P271; Raveenthiran V, 2003, INT J COLORECTAL DIS, V18, P177, DOI 10.1007/s00384-002-0456-x; SMITH VV, 1993, PEDIATR PATHOL, V13, P225; SONNENBERG A, 1994, AM J GASTROENTEROL, V89, P62; Tan P, 1999, SEMIN COLON RECTAL S, V10, P122; Yu CS, 2002, INT J COLORECTAL DIS, V17, P253, DOI 10.1007/s00384-001-0380-5	28	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0179-1958	1432-1262		INT J COLORECTAL DIS	Int. J. Colorectal Dis.	MAY	2015	30	5					673	678		10.1007/s00384-015-2159-0		6	Gastroenterology & Hepatology; Surgery	Gastroenterology & Hepatology; Surgery	CG5QQ	WOS:000353348800012		
J	Tsukune, M; Kobayashi, Y; Miyashita, T; Fujie, GM				Tsukune, Mariko; Kobayashi, Yo; Miyashita, Tomoyuki; Fujie, G. Masakatsu			Automated palpation for breast tissue discrimination based on viscoelastic biomechanical properties	International Journal of Computer Assisted Radiology and Surgery			English	Article						Breast tumor diagnosis; Palpation; Nonlinear viscoelastic parameter; Dynamic viscoelastic test; Creep test	IN-VIVO; MR ELASTOGRAPHY; ELASTICITY; ULTRASOUND; PROSTATE; MUSCLE	Accurate, noninvasive methods are sought for breast tumor detection and diagnosis. In particular, a need for noninvasive techniques that measure both the nonlinear elastic and viscoelastic properties of breast tissue has been identified. For diagnostic purposes, it is important to select a nonlinear viscoelastic model with a small number of parameters that highly correlate with histological structure. However, the combination of conventional viscoelastic models with nonlinear elastic models requires a large number of parameters. A nonlinear viscoelastic model of breast tissue based on a simple equation with few parameters was developed and tested. The nonlinear viscoelastic properties of soft tissues in porcine breast were measured experimentally using fresh ex vivo samples. Robotic palpation was used for measurements employed in a finite element model. These measurements were used to calculate nonlinear viscoelastic parameters for fat, fibroglandular breast parenchyma and muscle. The ability of these parameters to distinguish the tissue types was evaluated in a two-step statistical analysis that included Holm's pairwise test. The discrimination error rate of a set of parameters was evaluated by the Mahalanobis distance. Ex vivo testing in porcine breast revealed significant differences in the nonlinear viscoelastic parameters among combinations of three tissue types. The discrimination error rate was low among all tested combinations of three tissue types. Although tissue discrimination was not achieved using only a single nonlinear viscoelastic parameter, a set of four nonlinear viscoelastic parameters were able to reliably and accurately discriminate fat, breast fibroglandular tissue and muscle.	[Tsukune, Mariko] Waseda Univ, Inst Adv Act Aging Res, Grad Sch Creat Sci, Tokyo, Japan; [Kobayashi, Yo] Waseda Univ, Fac Sci & Engn, Res Inst Sci & Engn, Tokyo, Japan; [Miyashita, Tomoyuki; Fujie, G. Masakatsu] Waseda Univ, Fac Sci & Engn, Tokyo, Japan	Tsukune, M (reprint author), Waseda Univ, Inst Adv Act Aging Res, Grad Sch Creat Sci, Tokyo, Japan.	mtsukune@moegi.waseda.jp		Kobayashi, Yo/0000-0003-4358-6294	Grants for Excellent Graduate Schools, Ministry of Education, Culture, Sports, Science and Technology of Japan (MEXT); MEXT [26750171]; Institute of Advanced Active Aging Research in Waseda University, Japan; Cooperative Research Project of the Institute of Development, Aging and Cancer, Tohoku University, Japan	This work was supported in part by Grants for Excellent Graduate Schools, Ministry of Education, Culture, Sports, Science and Technology of Japan (MEXT), a Grant-in-Aid of Scientific Research from MEXT (No. 26750171), Institute of Advanced Active Aging Research in Waseda University, Japan, and the Cooperative Research Project of the Institute of Development, Aging and Cancer, Tohoku University, Japan. This work received guidance from T. Hoshi (Waseda Univ., Japan), Y. Shiraishi (Tohoku Univ., Japan), T. Yambe (Tohoku Univ., Japan) and M. Hashizume (Kyushu Univ., Japan).	CESPEDES I, 1993, ULTRASONIC IMAGING, V15, P73, DOI 10.1006/uimg.1993.1007; Klatt D, 2010, PHYS MED BIOL, V55, P6445, DOI 10.1088/0031-9155/55/21/007; OPHIR J, 1991, ULTRASONIC IMAGING, V13, P111, DOI 10.1016/0161-7346(91)90079-W; Garra BS, 1997, RADIOLOGY, V202, P79; Sack I, 2009, NEUROIMAGE, V46, P652, DOI 10.1016/j.neuroimage.2009.02.040; Kelly JF, 2009, J ACOUST SOC AM, V126, P2072, DOI 10.1121/1.3204304; Porter PL, 2009, SALUD PUBLICA MEXICO, V51, pS141, DOI 10.1590/s0036-36342009000800003; Oberai AA, 2009, PHYS MED BIOL, V54, P1191, DOI 10.1088/0031-9155/54/5/006; Krouskop TA, 1998, ULTRASONIC IMAGING, V20, P260; Lorenz A, 2000, ULTRASCHALL MED, V21, P8; Sack I, 2013, SOFT MATTER, V9, P5672, DOI 10.1039/c3sm50552a; Hall TJ, 2009, IEEE ENG MED BIO, P1967, DOI 10.1109/IEMBS.2009.5333442; KENSINGER RS, 1986, J ANAT, V145, P49; Asbach P, 2008, MAGN RESON MED, V60, P373, DOI 10.1002/mrm.21636; Fung Y.C., 1993, BIOMECHANICS MECH PR, V12; Kobayashi Yo, 2012, Journal of Biomechanical Science and Engineering, V7, DOI 10.1299/jbse.7.177; Marchesseau S, 2010, PROG BIOPHYS MOL BIO, V103, P185, DOI 10.1016/j.pbiomolbio.2010.09.005; Matsumura T, 2009, P IEEE INT ULTR S, P1451; Mehrabian H, 2010, PHYS MED BIOL, V55, P7489, DOI 10.1088/0031-9155/55/24/007; Nitta N, 2002, JPN J APPL PHYS 1, V41, P3572, DOI 10.1143/JJAP.41.3572; Robert B, 2006, P IEEE ULTR S VANC B, P1033; Samani A, 2009, I PHYS ENG MED, V54, P2557; Tsukune M, 2013, P 35 ANN INT C IEEE, P4863; Tsukune M, 2011, IEEE ENG MED BIO, P7405, DOI 10.1109/IEMBS.2011.6091724; Tsukune M, 2012, PROC INFO COMMUN, V3, P125; Wellman PS, 1999, THESIS HARVARD U US	26	0	0	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	1861-6410	1861-6429		INT J COMPUT ASS RAD	Int. J. Comput. Assist. Radiol. Surg.	MAY	2015	10	5					593	601		10.1007/s11548-014-1100-2		9	Engineering, Biomedical; Radiology, Nuclear Medicine & Medical Imaging; Surgery	Engineering; Radiology, Nuclear Medicine & Medical Imaging; Surgery	CG8MD	WOS:000353561200009		
J	Koreeda, Y; Obata, S; Nishio, Y; Miura, S; Kobayashi, Y; Kawamura, K; Souzaki, R; Ieiri, S; Hashizume, M; Fujie, MG				Koreeda, Y.; Obata, S.; Nishio, Y.; Miura, S.; Kobayashi, Y.; Kawamura, K.; Souzaki, R.; Ieiri, S.; Hashizume, M.; Fujie, M. G.			Development and testing of an endoscopic pseudo-viewpoint alternating system	International Journal of Computer Assisted Radiology and Surgery			English	Article						Minimally invasive surgery; Image processing; Endoscope; Depth perception; Virtual reality	MINIMALLY-INVASIVE SURGERY; LAPAROSCOPIC SURGERY; CONCEPTUAL SOLUTION; RECONSTRUCTION; COORDINATION	An endoscopic system is needed that presents informative images irrespective of the surgical situation and the number of degrees of freedom in endoscopic manipulation. This goal may be achieved with a virtual reality view for a region of interest from an arbitrary viewpoint. An endoscopic pseudo-viewpoint alternation system for this purpose was developed and tested. Surgical experts and trainees from an endoscopic surgery training course at the minimally invasive surgery training center of Kyushu University were enrolled in a trial of a virtual reality system. The initial viewpoint was positioned to approximate the horizontal view often seen in laparoscopic surgery, with between the optical axis of the endoscope and the task surface. A right-to-left suturing task with right hand, based on a task from the endoscopic surgery training course, was selected for testing. We compared task outcomes with and without use of a new virtual reality-viewing system. There was a 0.37 mm reduction in total error () with use of the proposed system. Error reduction was composed of 0.1 mm reduction on the y-axis and 0.27 mm reduction on the x-axis. Experts benefited more than novices from use of the proposed system. Most subjects worked at a pseudo-viewpoint of around 34. Suturing performance improved with the new virtual reality endoscopic display system. Viewpoint alternation resulted in an overview that improved depth perception and allowed subjects to better aim the marker. This suggests the proposed method offers users better visualization and control in endoscopic surgery.	[Koreeda, Y.; Nishio, Y.; Miura, S.; Kobayashi, Y.; Fujie, M. G.] Waseda Univ, Grad Sch Sci & Engn, Shinjuku Ward, Tokyo 59309, Japan; [Obata, S.; Souzaki, R.; Ieiri, S.; Hashizume, M.] Kyushu Univ, Ctr Integrat Adv Med & Innovat Technol, Fukuoka 812, Japan; [Kawamura, K.] Chiba Univ, Fac Engn, Chiba 260, Japan; [Kobayashi, Y.; Fujie, M. G.] Waseda Univ, Fac Sci & Engn, Tokyo 59309, Japan	Koreeda, Y (reprint author), Waseda Univ, Grad Sch Sci & Engn, Shinjuku Ward, 3-4-1 Okubo, Tokyo 59309, Japan.	yuta-is-here@ruri.waseda.jp		Kobayashi, Yo/0000-0003-4358-6294	Global Centers of Excellence (COE) Program "Global Robot Academia" from the Ministry of Education, Culture, Sports, Science and Technology of Japan; Ministry of Education, Culture, Sports, Science and Technology of Japan [21700513, 23240088, 25220005, 25560243, 26242061]; Grants for Excellent Graduate Schools from the Ministry of Education, Culture, Sports, Science and Technology of Japan	This work was supported in part by Global Centers of Excellence (COE) Program "Global Robot Academia," in part by Grants for Excellent Graduate Schools, and in part by Grant Scientific Research (21700513), (23240088), (25220005), (25560243), (26242061) from the Ministry of Education, Culture, Sports, Science and Technology of Japan.	Casals A, 1996, IEEE INT CONF ROBOT, P895; Clancy NT, 2011, BIOMED OPT EXPRESS, V2, P3119, DOI 10.1364/BOE.2.003119; Ladicky L, 2012, INT J COMPUT VISION, V100, P122, DOI 10.1007/s11263-011-0489-0; Shang J, 2011, IEEE INT CONF ROBOT, P1147, DOI 10.1109/ICRA.2011.5980261; Korndorffer JR, 2005, J AM COLL SURGEONS, V201, P23, DOI 10.1016/j.jamcollsurg.2005.02.021; Maier-Hein L, 2013, MED IMAGE ANAL, V17, P974, DOI 10.1016/j.media.2013.04.003; Zhang ZY, 2000, IEEE T PATTERN ANAL, V22, P1330, DOI 10.1109/34.888718; Fuchs KH, 2002, ENDOSCOPY, V34, P154, DOI 10.1055/s-2002-19857; Breedveld P, 1999, MINIM INVASIV THER, V8, P227, DOI 10.3109/13645709909153166; Bernhardt S, 2013, LNCS, V7766, P254; Bouguet J.Y., 2013, CAMERA CALIBRATION T; Chew LP, 1989, COMPUTER SCI TECHNIC; Ieiri S, 2010, PEDIATR SURG INT, V26, P947, DOI 10.1007/s00383-010-2665-7; Koppel D, 2004, 2004 2ND IEEE INTERNATIONAL SYMPOSIUM ON BIOMEDICAL IMAGING: MACRO TO NANO, VOLS 1 AND 2, P269; Koreeda Y, 2013, J JSCAS, V15, P126; Rassweiler J, 2011, ROBOTICS IN GENITOURINARY SURGERY, P63, DOI 10.1007/978-1-84882-114-9_5; Wentink M, 2000, MINIM INVASIV THER, V9, P125	17	1	1	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	1861-6410	1861-6429		INT J COMPUT ASS RAD	Int. J. Comput. Assist. Radiol. Surg.	MAY	2015	10	5					619	628		10.1007/s11548-014-1083-z		10	Engineering, Biomedical; Radiology, Nuclear Medicine & Medical Imaging; Surgery	Engineering; Radiology, Nuclear Medicine & Medical Imaging; Surgery	CG8MD	WOS:000353561200011		
J	Wilkmann, C; Ito, N; Penzkofer, T; Isfort, P; Na, HS; Hennes, M; Disselhorst-Klug, C; Mahnken, AH; Kuhl, CK; Bruners, P				Wilkmann, Christoph; Ito, Nobutake; Penzkofer, Tobias; Isfort, Peter; Na, Hong-Sik; Hennes, Michael; Disselhorst-Klug, Catherine; Mahnken, Andreas H.; Kuhl, Christiane K.; Bruners, Philipp			A miniature accelerometer-based guidance device for percutaneous computed tomography-guided punctures	International Journal of Computer Assisted Radiology and Surgery			English	Article						Accelerometers; Assistive devices; Computed tomography; CT-guided intervention; Real-time systems	ORIENTATION TRACKING; ANGLE MEASUREMENT; KALMAN FILTER; INTERVENTIONS; ACCURACY; SYSTEM; TRIAL; TILT	Percutaneous punctures are often performed under computed tomography (CT) guidance using a freehand method. Especially in challenging cases, initial accuracy of the needle placement is highly dependent on the radiologist's experience. Thus, a miniature lightweight guidance device was developed which is capable of assisting a radiologist during the needle placement process. The device utilizes an accelerometer to measure the needle's tilt by calculating a set of orientation angles. This set can be matched with the coordinate system of the CT imaging software during a simple alignment process. After that, the needle's orientation can be expressed in terms of projected angles in the axial and sagittal planes. The accuracy of the device was evaluated in a phantom study, and initial clinical trials were carried out performing facet joint punctures in a swine cadaver. The sensor was embedded in a cube with dimensions of and a total weight of about 11 g which can be attached to the puncture needle at its rear end or handgrip. A graphical user interface (GUAOE) has been created offering visual real-time orientation guidance. Results of the phantom experiments showed differences between planned target and performed puncture angles of for in-plane and for out-of-plane punctures. The results of the phantom and ex vivo study suggest that the device is useful to assist a radiologist in CT-guided percutaneous punctures and helps navigating the needle with high precision.	[Wilkmann, Christoph; Ito, Nobutake; Penzkofer, Tobias; Isfort, Peter; Na, Hong-Sik; Mahnken, Andreas H.; Kuhl, Christiane K.; Bruners, Philipp] RWTH Aachen Univ Hosp, Dept Diagnost & Intervent Radiol, D-52074 Aachen, Germany; [Ito, Nobutake] Keio Univ, Sch Med, Dept Diagnost Radiol, Tokyo 1608582, Japan; [Penzkofer, Tobias] Harvard Univ, Brigham & Womens Hosp, Sch Med, Surg Planning Lab, Boston, MA 02115 USA; [Hennes, Michael; Disselhorst-Klug, Catherine] Rhein Westfal TH Aachen, Inst Appl Med Engn, D-52074 Aachen, Germany; [Mahnken, Andreas H.] Univ Marburg, Univ Hosp Marburg, Dept Diagnost & Intervent Radiol, D-35043 Marburg, Germany	Wilkmann, C (reprint author), RWTH Aachen Univ Hosp, Dept Diagnost & Intervent Radiol, Pauwelsstr 30, D-52074 Aachen, Germany.	Christoph.Wilkmann@rwth-aachen.de					Schubert T, 2013, CARDIOVASC INTER RAD, V36, P1055, DOI 10.1007/s00270-012-0527-5; Cleary K, 2010, ANNU REV BIOMED ENG, V12, P119, DOI 10.1146/annurev-bioeng-070909-105249; Favre J, 2006, ELECTRON LETT, V42, P612, DOI 10.1049/el:20060124; Sabatini AM, 2006, IEEE T BIO-MED ENG, V53, P1346, DOI [10.1109/TBME.2006.875664, 10.1109/TMBE.2006.875664]; Penzkofer T, 2011, MINIM INVASIV THER, V20, P226, DOI 10.3109/13645706.2011.553256; Moser C, 2013, EUR J RADIOL, V82, P627, DOI 10.1016/j.ejrad.2012.10.028; Roetenberg D, 2007, IEEE T BIO-MED ENG, V54, P883, DOI 10.1109/TBME.2006.889184; Hong CW, 2013, CLIN IMAG, V37, P1135, DOI 10.1016/j.clinimag.2013.08.006; Yaniv Z, 2009, MED PHYS, V36, P876, DOI 10.1118/1.3075829; Grzeda V, 2010, LECT NOTES COMPUT SC, V6363, P424; Haid M, 2004, APPL MATH COMPUT, V153, P567, DOI 10.1016/S0096-3003(03)00656-8; Jacobi V, 1999, EUR RADIOL, V9, P137, DOI 10.1007/s003300050644; Joint Committee for Guides in Metrology-Working Group 1, 2008, DET COMB STAND UNC E; Kirchner J, 2002, CLIN RADIOL, V57, P188, DOI 10.1053/crad.2001.0716; Krombach GA, 2000, ROFO-FORTSCHR RONTG, V172, P557, DOI 10.1055/s-2000-3748; Luczak S, 2006, IEEE SENS J, V6, P1669, DOI 10.1109/JSEN.2006.881433; Pereles FS, 1998, ACAD RADIOL, V5, P766, DOI 10.1016/S1076-6332(98)80260-2; Suh YS, 2012, IEEE T INSTRUM MEAS, V61, P1786, DOI 10.1109/TIM.2011.2181910; WELCH PD, 1967, IEEE T ACOUST SPEECH, VAU15, P70, DOI 10.1109/TAU.1967.1161901; Wolff T, 2014, INT J COMPUT ASS RAD, V9, P137, DOI 10.1007/s11548-013-0918-3	20	0	0	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	1861-6410	1861-6429		INT J COMPUT ASS RAD	Int. J. Comput. Assist. Radiol. Surg.	MAY	2015	10	5					629	636		10.1007/s11548-014-1096-7		8	Engineering, Biomedical; Radiology, Nuclear Medicine & Medical Imaging; Surgery	Engineering; Radiology, Nuclear Medicine & Medical Imaging; Surgery	CG8MD	WOS:000353561200012		
J	Tabata, N				Tabata, Nobuko			A simple management of curved nail deformity by using a shape memory alloy device: report of four treated cases	INTERNATIONAL JOURNAL OF DERMATOLOGY			English	Article							TOENAILS		Japanese Red Cross Sendai Hosp, Div Dermatol, Taihaku Ku, Sendai, Miyagi 9828501, Japan	Tabata, N (reprint author), Japanese Red Cross Sendai Hosp, Div Dermatol, Taihaku Ku, 2-43-3 Yagiyamahon Cho, Sendai, Miyagi 9828501, Japan.	noburcs@sendai.jrc.or.jp					Sutou Y, 2004, MAT SCI ENG A-STRUCT, V378, P278, DOI 10.1016/j.msea.2003.12.048; Moriue T, 2008, DERMATOL SURG, V34, P1729, DOI 10.1111/j.1524-4725.2008.34360.x; Ishibashi M, 2008, J DERMATOL TREAT, V19, P291, DOI 10.1080/09546630701759595; Kim JY, 2009, FOOT ANKLE INT, V30, P1083, DOI 10.3113/FAI.2009.1083; Kosaka M, 2010, DERMATOL SURG, V36, P506, DOI 10.1111/j.1524-4725.2010.01478.x	5	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0011-9059	1365-4632		INT J DERMATOL	Int. J. Dermatol.	MAY	2015	54	5					573	575		10.1111/ijd.12054		3	Dermatology	Dermatology	CG6LH	WOS:000353411800040		
J	Kanwar, AJ; Vinay, K; Varma, S; Koga, H; Ishii, N; Hashimoto, T				Kanwar, Amrinder J.; Vinay, Keshavamurthy; Varma, Subhash; Koga, Hiroshi; Ishii, Norito; Hashimoto, Takashi			Anti-desmoglein antibody-negative paraneoplastic pemphigus successfully treated with rituximab	INTERNATIONAL JOURNAL OF DERMATOLOGY			English	Article							AUTOANTIBODIES		[Kanwar, Amrinder J.; Vinay, Keshavamurthy] Postgrad Inst Med Educ & Res, Dept Dermatol Venereol & Leprol, Chandigarh 160012, India; [Varma, Subhash] Postgrad Inst Med Educ & Res, Dept Internal Med, Chandigarh 160012, India; [Koga, Hiroshi; Ishii, Norito; Hashimoto, Takashi] Kurume Univ, Sch Med, Dept Dermatol, Kurume, Fukuoka 830, Japan; [Koga, Hiroshi; Ishii, Norito; Hashimoto, Takashi] Kurume Univ, Inst Cutaneous Cell Biol, Kurume, Fukuoka 830, Japan	Kanwar, AJ (reprint author), Postgrad Inst Med Educ & Res, Dept Dermatol Venereol & Leprol, Sect 12, Chandigarh 160012, India.	ajkanwar1948@gmail.com			Ministry of Education, Culture, Sports, Science and Technology of Japan; Ministry of Health, Labour and Welfare of Japan; Uehara Memorial Foundation; Nakatomi Foundation; Kaibara Morikazu Medical Science Promotion Foundation; Japan Lydia O'Leary Memorial Foundation; Cosmetology Research Foundation; Japanese Dermatological Association; Fukuoka Foundation for Sound Health; Galderma K.K.	This study was supported by Grantsn-id for Scientific Research and Strategic Research Basis Formation Supporting Project from the Ministry of Education, Culture, Sports, Science and Technology of Japan, and by Health and Labour Sciences Research Grants and grants for Research on Measures for Intractable Diseases from the Ministry of Health, Labour and Welfare of Japan. The study was also supported by grants from the Uehara Memorial Foundation, Nakatomi Foundation, Kaibara Morikazu Medical Science Promotion Foundation, Japan Lydia O'Leary Memorial Foundation, Cosmetology Research Foundation, Japanese Dermatological Association (Shiseido Award), Fukuoka Foundation for Sound Health, and Galderma K.K. (Galderma Award).	AMAGAI M, 1995, J INVEST DERMATOL, V104, P895, DOI 10.1111/1523-1747.ep12606168; Amagai M, 1998, J CLIN INVEST, V102, P775, DOI 10.1172/JCI3647; Heizmann M, 2001, AM J HEMATOL, V66, P142, DOI 10.1002/1096-8652(200102)66:2<142::AID-AJH1032>3.0.CO;2-0; Cummins DL, 2007, J AM ACAD DERMATOL, V56, P153, DOI 10.1016/j.jaad.2006.06.007; CAMISA C, 1993, ARCH DERMATOL, V129, P883, DOI 10.1001/archderm.129.7.883; Kaplan I, 2004, ORAL ONCOL, V40, P553, DOI 10.1016/j.oraloncology.2003.09.020; Borradori L, 2001, ARCH DERMATOL, V137, P269; HELOU J, 1995, J AM ACAD DERMATOL, V32, P441, DOI 10.1016/0190-9622(95)90066-7; Inaoki M, 2001, BRIT J DERMATOL, V144, P610, DOI 10.1046/j.1365-2133.2001.04095.x; Kakurai M, 2009, J EUR ACAD DERMATOL, V23, P962, DOI 10.1111/j.1468-3083.2008.03071.x; Ohyama M, 2001, J AM ACAD DERMATOL, V44, P593, DOI 10.1067/mjd.2001.112222	11	1	1	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0011-9059	1365-4632		INT J DERMATOL	Int. J. Dermatol.	MAY	2015	54	5					576	579		10.1111/ijd.12053		4	Dermatology	Dermatology	CG6LH	WOS:000353411800041		
J	Hamada, T; Tada, K; Aoyama, Y; Iwatsuki, K				Hamada, Toshihisa; Tada, Kotaro; Aoyama, Yumi; Iwatsuki, Keiji			Necrobiotic features in both cutaneous and lymph node lesions in a patient with interstitial mycosis fungoides	INTERNATIONAL JOURNAL OF DERMATOLOGY			English	Article							GRANULOMA-ANNULARE; SEZARY-SYNDROME		[Hamada, Toshihisa; Tada, Kotaro; Aoyama, Yumi; Iwatsuki, Keiji] Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Dermatol, Okayama 7008558, Japan; [Tada, Kotaro] Okayama Citizens Hosp, Dept Dermatol, Okayama, Japan	Hamada, T (reprint author), Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Dermatol, 2-5-1 Shikata Cho, Okayama 7008558, Japan.	t-hamada@cc.okayama-u.ac.jp					Nashan D, 2007, BRIT J DERMATOL, V156, P1, DOI 10.1111/j.1365.2133.2006.07526.x; Prince HM, 2009, BLOOD, V114, P4337, DOI 10.1182/blood-2009-07-202895; Hwang ST, 2008, LANCET, V371, P945, DOI 10.1016/S0140-6736(08)60420-1; Kim EJ, 2005, J CLIN INVEST, V115, P798, DOI 10.1172/JCI200524826; Olsen E, 2007, BLOOD, V110, P1713, DOI 10.1182/blood-2007-03-055749; Jouary T, 2002, BRIT J DERMATOL, V146, P1102, DOI 10.1046/j.1365-2133.2002.47321.x; Morizane S, 2009, BRIT J DERMATOL, V161, P115, DOI 10.1111/j.1365-2133.2009.09109.x; Spicknall KE, 2009, INT J DERMATOL, V48, P1, DOI 10.1111/j.1365-4632.2009.03912.x; Su LD, 2002, J CUTAN PATHOL, V29, P135, DOI 10.1034/j.1600-0560.2002.290302.x; Wilcox Ryan A, 2011, Am J Hematol, V86, P928, DOI 10.1002/ajh.22139	10	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0011-9059	1365-4632		INT J DERMATOL	Int. J. Dermatol.	MAY	2015	54	5					E122	E125		10.1111/ijd.12078		4	Dermatology	Dermatology	CG6LH	WOS:000353411800005		
J	Harada, K; Yamaguchi, M; Matsuzawa, M; Shimada, S				Harada, Kazutoshi; Yamaguchi, Miyuki; Matsuzawa, Miyuki; Shimada, Shinji			Ingrown nail with a giant granulation tissue successfully treated with the gutter method	INTERNATIONAL JOURNAL OF DERMATOLOGY			English	Letter							MANAGEMENT; TOENAILS		[Harada, Kazutoshi; Yamaguchi, Miyuki; Matsuzawa, Miyuki; Shimada, Shinji] Univ Yamanashi, Dept Dermatol, Fac Med, Kofu, Yamanashi, Japan	Harada, K (reprint author), Univ Yamanashi, Dept Dermatol, Fac Med, Kofu, Yamanashi, Japan.	kharada@tokyo-med.ac.jp					WALLACE WA, 1979, BRIT MED J, V2, P168; Heidelbaugh JJ, 2009, AM FAM PHYSICIAN, V79, P303; Arai H, 2004, INT J DERMATOL, V43, P759, DOI 10.1111/j.1365-4632.2004.02342.x; Eekhof JA, 2012, COCHRANE DB SYST REV, V4; Gerritsma-Bleeker CLE, 2002, ARCH SURG-CHICAGO, V137, P320, DOI 10.1001/archsurg.137.3.320; Harada K, 2012, CLIN EXP DERMATOL, V37, P703, DOI 10.1111/j.1365-2230.2012.04358.x; Park DH, 2012, BRIT MED J, V344, DOI 10.1136/bmj.e2089	7	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0011-9059	1365-4632		INT J DERMATOL	Int. J. Dermatol.	MAY	2015	54	5					E191	E192		10.1111/ijd.12760		2	Dermatology	Dermatology	CG6LH	WOS:000353411800024		
J	Harada, K; Yamaguchi, M; Kawamura, T; Shibagaki, N; Shimada, S				Harada, Kazutoshi; Yamaguchi, Miyuki; Kawamura, Tatsuyoshi; Shibagaki, Naotaka; Shimada, Shinji			A case of IgG4-related syndrome presenting with a fibroma molle-like nodule	INTERNATIONAL JOURNAL OF DERMATOLOGY			English	Article							SCLEROSING DISEASE		[Harada, Kazutoshi; Yamaguchi, Miyuki; Kawamura, Tatsuyoshi; Shibagaki, Naotaka; Shimada, Shinji] Univ Yamanashi, Fac Med, Dept Dermatol, Kofu, Yamanashi, Japan	Harada, K (reprint author), 1110 Shimogato, Chuo, Yamanashi 4093898, Japan.	kharada@yamanashi.ac.jp					Hamaguchi Y, 2011, DERMATOLOGY, V223, P301, DOI 10.1159/000335372; Hattori T, 2012, J CLIN PATHOL, V65, P815, DOI 10.1136/jclinpath-2012-200749; Cheuk W, 2009, AM J SURG PATHOL, V33, P1713, DOI 10.1097/PAS.0b013e3181b201de; Zen Y, 2010, AM J SURG PATHOL, V34, P1812, DOI 10.1097/PAS.0b013e3181f7266b; Kazakov DV, 2002, J CUTAN PATHOL, V29, P244, DOI 10.1034/j.1600-0560.2002.290408.x; Sato Y, 2010, PATHOL INT, V60, P247, DOI 10.1111/j.1440-1827.2010.02524.x; Shiomi T, 2009, PATHOL INT, V59, P326, DOI 10.1111/j.1440-1827.2009.02374.x	7	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0011-9059	1365-4632		INT J DERMATOL	Int. J. Dermatol.	MAY	2015	54	5					E163	E165		10.1111/ijd.12461		3	Dermatology	Dermatology	CG6LH	WOS:000353411800014		
J	Sumikawa, Y; Kato, J; Kan, Y; Sato, S; Yamashita, T				Sumikawa, Yasuyuki; Kato, Junji; Kan, Yuji; Sato, Sayuri; Yamashita, Toshiharu			Severe atopic dermatitis associated with transient hypogammaglobulinemia of infancy	INTERNATIONAL JOURNAL OF DERMATOLOGY			English	Letter							INTRAVENOUS IMMUNOGLOBULIN; CHILDREN		[Sumikawa, Yasuyuki; Kato, Junji; Kan, Yuji; Sato, Sayuri; Yamashita, Toshiharu] Sapporo Med Univ, Sch Med, Dept Dermatol, Sapporo, Hokkaido, Japan	Sumikawa, Y (reprint author), Sapporo Med Univ, Sch Med, Dept Dermatol, Sapporo, Hokkaido, Japan.	y.sumikawa@sapmed.ac.jp					Artac H, 2013, CLIN EXP MED, V13, P257, DOI 10.1007/s10238-012-0200-y; Moschese V, 2008, INT J IMMUNOPATH PH, V21, P343; Turner PJ, 2012, PEDIATR DERMATOL, V29, P177, DOI 10.1111/j.1525-1470.2011.01654.x; Duse M, 2010, INT J IMMUNOPATH PH, V23, P349; Rutkowska M, 2011, CLIN IMMUNOL, V140, P307, DOI 10.1016/j.clim.2011.04.003; Memmedova Lale, 2013, Pediatr Rep, V5, pe14, DOI 10.4081/pr.2013.e14; ROSEN FS, 1984, NEW ENGL J MED, V311, P300, DOI 10.1056/NEJM198408023110506; Saeki H, 2009, J DERMATOL, V36, P563, DOI 10.1111/j.1346-8138.2009.00706.x; SAURAT JH, 1985, ACTA DERM-VENEREOL, P125; Yasuno T, 2007, PEDIATR INT, V49, P406, DOI 10.1111/j.1442-200X.2007.02360.x	10	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0011-9059	1365-4632		INT J DERMATOL	Int. J. Dermatol.	MAY	2015	54	5					E185	E187		10.1111/ijd.12717		3	Dermatology	Dermatology	CG6LH	WOS:000353411800021		
J	Nishi, E; Tashiro, Y; Sakai, K				Nishi, Eiji; Tashiro, Yukihiro; Sakai, Kenji			Discrimination among individuals using terminal restriction fragment length polymorphism profiling of bacteria derived from forensic evidence	INTERNATIONAL JOURNAL OF LEGAL MEDICINE			English	Article						Forensic science; Bacterial flora; 16S rRNA gene; Terminal restriction fragment length polymorphism; Principal component analysis	RIBOSOMAL-RNA GENES; T-RFLP ANALYSIS; WEB-BASED TOOL; MICROBIAL COMMUNITIES; DIVERSITY; SOIL; PCR; DNA; IDENTIFICATION; 16S	DNA typing from forensic evidence is commonly used to identify individuals. However, when the quantity of the forensic evidence is insufficient, successful identification using DNA typing is impossible. Such evidence may also contain DNA from bacteria that occur naturally on the skin. In this study, we aimed to establish a profiling method using terminal restriction fragment length polymorphisms (T-RFLPs) of the amplified bacterial 16S ribosomal RNA (rRNA) gene. First, the extraction and digestion processes were investigated, and the T-RFLP profiling method using the 16S rRNA gene amplicon was optimized. We then used this method to compare the profiles of bacterial flora from the hands of 12 different individuals. We found that the T-RFLP profiles from one person on different days displayed higher similarity than those between individuals. In a principal component analysis (PCA), T-RFLPs from each individual were closely clustered in 11 out of 12 cases. The clusters could be distinguished from each other, even when the samples were collected from different conditions. No major change of the profile was observed after six months except in two cases. When handprints on glass plates were compared, 11 of 12 individuals were assigned to a few clusters including the cluster corresponding to the correct individual. In conclusion, a method for reproducible T-RFLP profiling of bacteria from trace amounts of handprints was established. The profiles were obtained for particular individuals clustered in PCA and were experimentally separable from other individuals in most cases. This technique could provide useful information for narrowing down a suspect in a criminal investigation.	[Nishi, Eiji; Tashiro, Yukihiro; Sakai, Kenji] Kyushu Univ, Soil Microbiol Lab, Div Appl Mol Microbiol & Biomass Chem, Dept Biosci & Biotechnol,Fac Agr,Grad Sch,Higashi, Fukuoka 8128581, Japan; [Nishi, Eiji] Oita Prefectural Police HQ, Forens Sci Div, Dept Criminal Invest, Oita 8708502, Japan	Sakai, K (reprint author), Kyushu Univ, Soil Microbiol Lab, Div Appl Mol Microbiol & Biomass Chem, Dept Biosci & Biotechnol,Fac Agr,Grad Sch,Higashi, 6-10-1 Hakozaki, Fukuoka 8128581, Japan.	kensak@agr.kyushu-u.ac.jp					Costello EK, 2009, SCIENCE, V326, P1694, DOI 10.1126/science.1177486; Nocker A, 2007, MICROB ECOL, V54, P276, DOI 10.1007/s00248-006-9199-5; Engebretson JJ, 2003, APPL ENVIRON MICROB, V69, P4823, DOI 10.1128/AEM.69.8.4823-4829.2003; Grice EA, 2008, GENOME RES, V18, P1043, DOI 10.1101/gr.075549.107; Macdonald LM, 2008, J APPL MICROBIOL, V105, P813, DOI 10.1111/j.1365-2672.2008.03819.x; Grice EA, 2009, SCIENCE, V324, P1190, DOI 10.1126/science.1171700; Fierer N, 2005, APPL ENVIRON MICROB, V71, P4117, DOI 10.1128/AEM.71.7.4117-4120.2005; Horz HP, 2000, J MICROBIOL METH, V39, P197, DOI 10.1016/S0167-7012(99)00119-0; Benschop CCG, 2012, INT J LEGAL MED, V126, P303, DOI 10.1007/s00414-011-0660-8; Rosch C, 2005, APPL ENVIRON MICROB, V71, P2026, DOI 10.1128/AEM.71.4.2026-2035.2005; Shyu C, 2007, MICROB ECOL, V53, P562, DOI 10.1007/s00248-006-9106-0; Perez-Jimenez JR, 2005, APPL ENVIRON MICROB, V71, P1004, DOI 10.1128/AEM.71.2.1004-1011.2005; Lukow T, 2000, FEMS MICROBIOL ECOL, V32, P241, DOI 10.1016/S0168-6496(00)00033-7; Fierer N, 2008, P NATL ACAD SCI USA, V105, P17994, DOI 10.1073/pnas.0807920105; Talan DA, 1999, NEW ENGL J MED, V340, P85, DOI 10.1056/NEJM199901143400202; Marsh TL, 2000, APPL ENVIRON MICROB, V66, P3616, DOI 10.1128/AEM.66.8.3616-3620.2000; Daly DJ, 2012, FORENSIC SCI INT-GEN, V6, P41, DOI 10.1016/j.fsigen.2010.12.016; Raymond JJ, 2009, FORENSIC SCI INT-GEN, V4, P26, DOI 10.1016/j.fsigen.2009.04.002; Fierer N, 2010, P NATL ACAD SCI USA, V107, P6477, DOI 10.1073/pnas.1000162107; Lueders T, 2003, APPL ENVIRON MICROB, V69, P320, DOI 10.1128/AEM.69.1.320-326.2003; Benschop CCG, 2011, FORENSIC SCI INT-GEN, V5, P316, DOI 10.1016/j.fsigen.2010.06.006; Head IM, 1998, MICROB ECOL, V35, P1, DOI 10.1007/s002489900056; Smith CJ, 2005, FEMS MICROBIOL ECOL, V54, P375, DOI 10.1016/j.femsec.2005.05.002; Rees GN, 2004, ANTON LEEUW INT J G, V86, P339, DOI 10.1007/s10482-004-0498-x; Nakanishi H, 2009, FORENSIC SCI INT, V183, P20, DOI 10.1016/j.forsciint.2008.10.003; Gao Z, 2007, P NATL ACAD SCI USA, V104, P2927, DOI 10.1073/pnas.0607077104; Liu WT, 1997, APPL ENVIRON MICROB, V63, P4516; vanOorschot RAH, 1997, NATURE, V387, P767, DOI 10.1038/42838; Clement BG, 1998, J MICROBIOL METH, V31, P135, DOI 10.1016/S0167-7012(97)00105-X; Dass SC, 2013, INT STAT REV, V81, P175, DOI 10.1111/insr.12017; Flores GE, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028132; Goga H, 2012, INT J LEGAL MED, V126, P815, DOI 10.1007/s00414-012-0733-3; Horswell J, 2002, J FORENSIC SCI, V47, P350; Lenz EJ, 2010, J FORENSIC SCI, V55, P1437, DOI 10.1111/j.1556-4029.2010.01464.x; Macdonald CA, 2011, J FORENSIC SCI, V56, P61, DOI 10.1111/j.1556-4029.2010.01542.x; Maiuta ND, 2011, INT J COSMETIC SCI, V33, P426; Meyers MS, 2008, J FORENSIC SCI, V53, P652, DOI 10.1111/j.1556-4029.2008.00728.x; Nakahara H, 2007, JPN J FORENSIC SCI T, V12, P13, DOI 10.3408/jafst.12.13; R Development Core Team, R LANG ENV STAT COMP; Schutte UME, 2008, APPL MICROBIOL BIOT, V80, P365, DOI 10.1007/s00253-008-1565-4; Thalib L, 1999, ENVIRONMETRICS, V10, P565, DOI 10.1002/(SICI)1099-095X(199909/10)10:5<565::AID-ENV360>3.3.CO;2-I	41	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0937-9827	1437-1596		INT J LEGAL MED	Int. J. Legal Med.	MAY	2015	129	3					425	433		10.1007/s00414-014-1092-z		9	Medicine, Legal	Legal Medicine	CG4DO	WOS:000353233200002		
J	Kimura, A; Ishida, Y; Nosaka, M; Shiraki, M; Hama, M; Kawaguchi, T; Kuninaka, Y; Shimada, E; Yamamoto, H; Takayasu, T; Kondo, T				Kimura, Akihiko; Ishida, Yuko; Nosaka, Mizuho; Shiraki, Maiko; Hama, Mizuki; Kawaguchi, Takashi; Kuninaka, Yumi; Shimada, Emi; Yamamoto, Hiroki; Takayasu, Tatsunori; Kondo, Toshikazu			Autophagy in skin wounds: a novel marker for vital reactions	INTERNATIONAL JOURNAL OF LEGAL MEDICINE			English	Article						Autophagy; Forensic medicine; Mechanical wounds; Vital reactions	AGE-DETERMINATION; EXPRESSION; CELLS; INFLAMMATION; PATHOLOGY; INJURY; FLUX	Detection of vitality of mechanical wounds in human cadavers is one of the important issues in forensic medicine. In order to explore novel markers for vitality of acute mechanical wounds, we investigated autophagy in mouse and human skin wounds. Western blotting analysis of mouse skin wounds showed marked reduction of LC3-II and reciprocal increase of p62 in wound samples with the postinfliction intervals of a parts per thousand yen0.5 h, compared with the uninjured skin tissues. These observations indicated that autophagy level was reduced in the wound sites. In postmortem wound samples, there were no remarkable changes in LC3-II and p62 levels. Furthermore, the postmortem intervals of 1-4 days have no significant effects on the changes of LC3-II and p62 in the antemortem skin wounds. Like murine wound samples, these alterations of LC3-II and p62 could be detected in human skin wound samples. Collectively, our study using animal and human samples implied that the detection of autophagy-related molecules such as LC3-II and p62 might be useful for forensic practice as markers of wound vitality.	[Kimura, Akihiko; Ishida, Yuko; Nosaka, Mizuho; Shiraki, Maiko; Hama, Mizuki; Kawaguchi, Takashi; Kuninaka, Yumi; Shimada, Emi; Yamamoto, Hiroki; Kondo, Toshikazu] Wakayama Med Univ, Dept Forens Med, Wakayama 6418509, Japan; [Takayasu, Tatsunori] Kanazawa Univ, Grad Sch Med Sci, Div Environm Sci, Dept Forens & Social Environm Med, Kanazawa, Ishikawa 9208640, Japan	Kondo, T (reprint author), Wakayama Med Univ, Dept Forens Med, 811-1 Kimiidera, Wakayama 6418509, Japan.	kondot@wakayama-med.ac.jp			Ministry of Education, Science, Sports and Culture of Japan	This study was financially supported by Grants in-Aid for Scientific Research (A) and (B), and Exploratory Research from the Ministry of Education, Science, Sports and Culture of Japan. We sincerely thank Ms. Mariko Kawaguchi for her excellent assistance in preparing this manuscript.	Wada Y, 2014, CURR OPIN GENET DEV, V27, P60, DOI 10.1016/j.gde.2014.03.010; Ishida Y, 2012, J CLIN INVEST, V122, P711, DOI 10.1172/JCI43027; Chang CP, 2013, AUTOPHAGY, V9, P619, DOI 10.4161/auto.23546; Grellner W, 2007, FORENSIC SCI INT, V165, P150, DOI 10.1016/j.forsciint.2006.05.029; Okamoto K, 2014, J CELL BIOL, V205, P435, DOI 10.1083/jcb.201402054; Singer AJ, 1999, NEW ENGL J MED, V341, P738; Takahashi A, 2012, AM J PATHOL, V180, P517, DOI 10.1016/j.ajpath.2011.11.001; Kuma A, 2004, NATURE, V432, P1032, DOI 10.1038/nature03029; Joosten LAB, 2013, SEMIN IMMUNOL, V25, P416, DOI 10.1016/j.smim.2013.10.018; Nakai A, 2007, NAT MED, V13, P619, DOI 10.1038/nm1574; Kimura A, 2010, AM J PATHOL, V176, P40, DOI 10.2353/ajpath.2010.090146; Mizushima Noboru, 2007, Autophagy, V3, P542; Mizushima N, 2011, CELL, V147, P728, DOI 10.1016/j.cell.2011.10.026; Ohshima T, 1998, INT J LEGAL MED, V111, P251, DOI 10.1007/s004140050163; Kondo T, 2010, FORENSIC SCI INT, V203, P93, DOI 10.1016/j.forsciint.2010.07.004; Ishida Y, 2009, INT J LEGAL MED, V123, P299, DOI 10.1007/s00414-009-0320-4; Tuloup-Minguez V, 2013, CELL CYCLE, V12, P3317, DOI 10.4161/cc.26298; Arroyo DS, 2014, INT IMMUNOPHARMACOL, V18, P55, DOI 10.1016/j.intimp.2013.11.001; Avalos Y., 2014, BIOMED RES INT, V2014; BETZ P, 1994, INT J LEGAL MED, V107, P60, DOI 10.1007/BF01225491; Bonelli A, 2003, INT J LEGAL MED, V117, P14, DOI 10.1007/s00414-002-0304-0; Gauchotte G, 2013, INT J LEGAL MED, V127, P957, DOI 10.1007/s00414-013-0880-1; Hayashi T, 2004, INT J LEGAL MED, V118, P320, DOI 10.1007/s00414-004-0468-x; HERNANDEZCUETO C, 1993, INT J LEGAL MED, V106, P145, DOI 10.1007/BF01225236; HERNANDEZCUETO C, 1994, INT J LEGAL MED, V106, P312, DOI 10.1007/BF01224777; Ishida Y, 2008, INT J LEGAL MED, V122, P409, DOI 10.1007/s00414-008-0255-1; Kimura A, 2012, KIDNEY INT, V82, P1093, DOI 10.1038/ki.2012.240; Yang M, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-43; Oehmichen M, 2004, FORENSIC SCI INT, V144, P221, DOI 10.1016/j.forsciint.2004.04.057; Oehmichen M, 2009, FORENSIC SCI INT, V191, P1, DOI 10.1016/j.forsciint.2009.05.020; Zhang XL, 2015, J INVEST DERMATOL, V135, P1016, DOI 10.1038/jid.2014.519	31	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0937-9827	1437-1596		INT J LEGAL MED	Int. J. Legal Med.	MAY	2015	129	3					537	541		10.1007/s00414-015-1168-4		5	Medicine, Legal	Legal Medicine	CG4DO	WOS:000353233200020		
J	Sogawa, N; Michiue, T; Ishikawa, T; Inamori-Kawamoto, O; Oritani, S; Maeda, H				Sogawa, Nozomi; Michiue, Tomomi; Ishikawa, Takaki; Inamori-Kawamoto, Osamu; Oritani, Shigeki; Maeda, Hitoshi			Postmortem CT morphometry of great vessels with regard to the cause of death for investigating terminal circulatory status in forensic autopsy	INTERNATIONAL JOURNAL OF LEGAL MEDICINE			English	Article						Forensic radiology; Postmortem CT; Morphometry; Aorta; Vena cava; Circulatory function	COMPUTED-TOMOGRAPHY; AORTA; DIAMETERS; HEART; PATHOPHYSIOLOGY; RADIOLOGY; AREAS; LUNG; MRI	Postmortem CT (PM-CT) is useful to investigate the viscera in situ before opening the body cavities at autopsy. The present study involved a virtual morphometric analysis of thoracic and abdominal great vessels with regard to the cause of death as a possible index of terminal circulatory status in forensic autopsy cases, using PM-CT data of forensic autopsy cases within 3 days postmortem (n = 93). Perimeters and cross-sectional areas of the aorta and vena cava depended on the age and/or gender of subjects; however, when the vessel flattening index (vFI) was calculated as the ratio of the cross-sectional area (a) to the estimated circle area having the same perimeter (l), using the formula vFI = 4 pi a/l(2), the vFI showed distinct differences among the causes of death without significant postmortem time dependence. The index was low for each vessel in fatal bleeding, while the vFI of the abdominal aorta and inferior vena cava was low in hyperthermia (heatstroke), but higher in drowning, hypothermia (cold exposure) and sudden cardiac death. These CT findings provide quantitative data as supplementary indicators to reinforce autopsy findings for interpreting terminal circulatory status.	[Sogawa, Nozomi; Michiue, Tomomi; Ishikawa, Takaki; Inamori-Kawamoto, Osamu; Oritani, Shigeki; Maeda, Hitoshi] Osaka City Univ, Sch Med, Dept Legal Med, Abeno Ku, Osaka 5458585, Japan; [Sogawa, Nozomi; Michiue, Tomomi; Ishikawa, Takaki; Inamori-Kawamoto, Osamu; Maeda, Hitoshi] Osaka City Univ, Sch Med, Forens Autopsy Sect, MLCPI SC,Abeno Ku, Osaka 5458585, Japan; [Ishikawa, Takaki] Tottori Univ, Fac Med, Div Legal Med, Yonago, Tottori 6838503, Japan	Michiue, T (reprint author), Osaka City Univ, Sch Med, Dept Legal Med, Abeno Ku, Asahi Machi 1-4-3, Osaka 5458585, Japan.	michi.leg@med.osaka-cu.ac.jp					Aghayev E, 2006, AM J ROENTGENOL, V187, P209, DOI 10.2214/AJR.05.0222; Ishikawa N, 2013, J FORENSIC LEG MED, V20, P1075, DOI 10.1016/j.jflm.2013.09.026; Hager A, 2002, J THORAC CARDIOV SUR, V123, P1060, DOI 10.1067/mtc.2002.12231; Rogers IS, 2013, AM J CARDIOL, V111, P1510, DOI 10.1016/j.amjcard.2013.01.306; Martin C, 2013, ANN BIOMED ENG, V41, P2565, DOI 10.1007/s10439-013-0856-9; Akobeng AK, 2007, ACTA PAEDIATR, V96, P644, DOI 10.1111/j.1651-2227.2006.00178.x; Bolliger SA, 2008, EUR RADIOL, V18, P273, DOI 10.1007/s00330-007-0737-4; Leth PM, 2009, AM J FOREN MED PATH, V30, P219, DOI 10.1097/PAF.0b013e318187e0af; Christe A, 2010, LEGAL MED, V12, P215, DOI 10.1016/j.legalmed.2010.05.005; Michiue T, 2013, FORENSIC SCI INT, V232, P199, DOI 10.1016/j.forsciint.2013.07.025; Michiue T, 2012, FORENSIC SCI INT, V220, P232, DOI 10.1016/j.forsciint.2012.03.007; Sakurai T, 2012, FORENSIC SCI MED PAT, V8, P351, DOI 10.1007/s12024-012-9327-0; Shiotani S, 2004, FORENSIC SCI INT, V139, P39, DOI 10.1016/j.forsciint.2003.09.016; Sogawa N, 2014, FORENSIC SCI INT, V241, P112, DOI 10.1016/j.forsciint.2014.05.012; Sogawa N, 2014, LEGAL MED-TOKYO, V16, P187, DOI 10.1016/j.legalmed.2014.03.002; Takahashi N, 2013, FORENSIC SCI INT, V225, P27, DOI 10.1016/j.forsciint.2012.04.037; Thali MJ, 2003, FORENSIC SCI INT, V138, P8, DOI 10.1016/S0379-0738(03)00225-1	17	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0937-9827	1437-1596		INT J LEGAL MED	Int. J. Legal Med.	MAY	2015	129	3					551	558		10.1007/s00414-014-1075-0		8	Medicine, Legal	Legal Medicine	CG4DO	WOS:000353233200022		
J	Torimitsu, S; Makino, Y; Saitoh, H; Sakuma, A; Ishii, N; Hayakawa, M; Yajima, D; Inokuchi, G; Motomura, A; Chiba, F; Iwase, H				Torimitsu, Suguru; Makino, Yohsuke; Saitoh, Hisako; Sakuma, Ayaka; Ishii, Namiko; Hayakawa, Mutsumi; Yajima, Daisuke; Inokuchi, Go; Motomura, Ayumi; Chiba, Fumiko; Iwase, Hirotaro			Stature estimation in Japanese cadavers based on pelvic measurements in three-dimensional multidetector computed tomographic images	INTERNATIONAL JOURNAL OF LEGAL MEDICINE			English	Article						Forensic anthropology; Anthropometry; Multidetector computed tomography; Pelvic bones; Regression analysis; Stature estimation	FORENSIC AGE DIAGNOSTICS; ILIAC CREST; APOPHYSEAL OSSIFICATION; PUBIC BONE; LENGTH; POPULATION; DIMENSIONS; HEIGHT; CT; RECONSTRUCTION	The aim of this study was to examine the feasibility of stature estimation by measuring the pelvic bones of Japanese cadavers using three-dimensional (3D) computed tomography (CT). We assessed 3D reconstructed images of 210 Japanese subjects (108 males, 102 females) who had undergone postmortem CT between May 2011 and November 2013. We defined the linear distance from the anterosuperior margin of the left and right anterior superior iliac spines (ASIS) to the posterior margin of the left and right ischial spines as the LSS and RSS, respectively. We also defined the linear distance from the anterosuperior margin of the left and right ASIS to the anteroinferior margin of the left and right ischial tuberosities as the LST and RST, respectively. The correlation between the cadaver stature (CS) and each parameter (LSS, LST, RSS, and RST) was evaluated using Pearson product-moment correlation coefficients and regression analysis was performed for stature estimation. All four parameters correlated significantly with stature independent of sex, suggesting that they can be used as a tool for stature estimation. The LST had the closest correlation with stature in both sexes.	[Torimitsu, Suguru; Makino, Yohsuke; Saitoh, Hisako; Sakuma, Ayaka; Ishii, Namiko; Hayakawa, Mutsumi; Yajima, Daisuke; Inokuchi, Go; Motomura, Ayumi; Chiba, Fumiko; Iwase, Hirotaro] Chiba Univ, Dept Legal Med, Grad Sch Med, Chuo Ku, Chiba 2608670, Japan	Torimitsu, S (reprint author), Chiba Univ, Dept Legal Med, Grad Sch Med, Chuo Ku, 1-8-1 Inohana, Chiba 2608670, Japan.	number60188@chiba-u.jp; ymakino-tky@umin.ac.jp; hms1466@faculty.chiba-u.jp; a.sakuma@chiba-u.jp; acua2807@chiba-u.jp; moo600@faculty.chiba-u.jp; yajima.d@faculty.chiba-u.jp; goinokuchi@chiba-u.jp; tsunetoa@graduate.chiba-u.jp; chibafumico@chiba-u.jp; iwase@faculty.chiba-u.jp					Ahmed AA, 2013, FORENSIC SCI INT, V228, p[178, e1]; JASON DR, 1995, J FORENSIC SCI, V40, P59; Krishan Kewal, 2007, Legal Medicine, V9, P128, DOI 10.1016/j.legalmed.2006.12.001; Buckberry JL, 2002, AM J PHYS ANTHROPOL, V119, P231, DOI 10.1002/ajpa.10130; TIBBETTS GL, 1981, J FORENSIC SCI, V26, P715; Raxter MH, 2006, AM J PHYS ANTHROPOL, V130, P374, DOI 10.1002/ajpa.20361; Menezes RG, 2011, J FORENSIC LEG MED, V18, P242, DOI 10.1016/j.jflm.2011.04.004; TERAZAWA K, 1990, MED SCI LAW, V30, P354; Lopez-Alcaraz M, 2013, INT J LEGAL MED, V127, P1145, DOI 10.1007/s00414-013-0900-1; Scheuer L, 2002, CLIN ANAT, V15, P297, DOI 10.1002/ca.10028; Karakas HM, 2011, SKELETAL RADIOL, V40, P623, DOI 10.1007/s00256-010-0937-x; Giroux CL, 2008, J FORENSIC SCI, V53, P65, DOI 10.1111/j.1556-4029.2007.00598.x; Pelin C, 2005, J FORENSIC SCI, V50, P294; Arroyo M, 2010, NUTR HOSP, V25, P1053, DOI 10.3305/nh.2010.25.6.4854; Bidmos MA, 2008, J FORENSIC SCI, V53, P1044, DOI 10.1111/j.1556-4029.2008.00808.x; Brooks S, 1990, J HUM EVOL, V1990; Burke RM, 2005, THESIS U IDAHO; Chiba F, 2013, INT J LEGAL MED, V127, P1005, DOI 10.1007/s00414-013-0883-y; Cordeiro C, 2009, FORENSIC SCI INT, V193, p[131, e1]; Cunha E, 2006, FORENSIC ANTHROPOLOGY AND MEDICINE: COMPLEMENTARY SCIENCES FROM RECOVERY TO CAUSE OF DEATH, P39, DOI 10.1007/978-1-59745-099-7_3; Giurazza F, 2013, LEGAL MED-TOKYO, V15, P202, DOI 10.1016/j.legalmed.2013.01.002; Giurazza F, 2012, FORENSIC SCI INT, V222, p[398, e1]; Hasegawa Iwao, 2009, Legal Medicine, V11, P260, DOI 10.1016/j.legalmed.2009.07.004; Hauser R, 2005, FORENSIC SCI INT, V147, P185, DOI 10.1016/j.forsciint.2004.09.070; Jamaiyah H, 2010, Med J Malaysia, V65 Suppl A, P131; Krishan K, 2012, J FORENSIC LEG MED, V19, P285, DOI 10.1016/j.jflm.2011.12.036; Krishan Kewal, 2007, J Forensic Leg Med, V14, P327, DOI 10.1016/j.jcfm.2006.10.008; Marinho L, 2012, FORENSIC SCI INT, V220, p[292, e1]; Moore-Jansen PM, 1994, DATA COLLECTION PROC; OUSLEY S, 1995, J FORENSIC SCI, V40, P768; Pininski M, 2014, FORENSIC SCI INT, V234, p[182, e1]; Sakuma A, 2010, J FORENSIC SCI, V55, P1624, DOI 10.1111/j.1556-4029.2010.01526.x; Schmidt S, 2011, INT J LEGAL MED, V125, P271, DOI 10.1007/s00414-011-0554-9; Singh J, 2011, FORENSIC SCI INT, V206, p[211, e1]; Steyn M, 2008, FORENSIC SCI INT, V179, p[86, e1]; Terazawa K, 1985, NIHON HOIGAKU ZASSHI, V30, P35; Todd TW, 1930, AM J PHYS ANTHROPOL, V14, P255, DOI 10.1002/ajpa.1330140205; Torimitsu S, 2014, LEGAL MED-TOKYO, V16, P14, DOI 10.1016/j.legalmed.2013.10.003; Villa C, 2013, FORENSIC SCI INT, V233, P393, DOI 10.1016/j.forsciint.2013.10.020; WILLEY P, 1991, J FORENSIC SCI, V36, P813; Wittschieber D, 2013, INT J LEGAL MED, V127, P825, DOI 10.1007/s00414-013-0832-9; Wittschieber D, 2013, INT J LEGAL MED, V127, P473, DOI 10.1007/s00414-012-0763-x	42	1	1	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0937-9827	1437-1596		INT J LEGAL MED	Int. J. Legal Med.	MAY	2015	129	3					633	639		10.1007/s00414-014-1000-6		7	Medicine, Legal	Legal Medicine	CG4DO	WOS:000353233200032		
J	Iuchi, T; Dai, M; Sanada, H; Okuwa, M; Nakatani, T; Sugama, J				Iuchi, Terumi; Dai, Misako; Sanada, Hiromi; Okuwa, Mayumi; Nakatani, Toshio; Sugama, Junko			Associations between the treatments and outcomes of patients with upper and lower lymphoedema in Japan: A cross-sectional observational study	INTERNATIONAL JOURNAL OF NURSING STUDIES			English	Article						Cross-sectional studies; Lymphoedema; Outcome assessment; Therapy	LIMB	BACKGROUND: Lymphoedema is not currently curable, and it is important that symptoms are alleviated by appropriate treatment. Treatments aim to delay the progression of swelling and to improve patients' quality of life (QOL). There are many objective and subjective outcomes of lymphoedema, but it is unclear which outcomes should be used to evaluate lymphoedema treatments. OBJECTIVE: This study aimed to examine the associations between lymphoedema treatments and outcomes. DESIGN: A cross-sectional observational study. SETTING: Lymphoedema outpatient clinics in Japan. PARTICIPANTS: A total of 170 patients with lymphoedema were recruited from four outpatient clinics. METHODS: The data were collected from medical records, physical assessments, and interviews. The following objective outcomes were evaluated: circumference measurements, Stemmer sign, cellulitis, and skin hardness. The following subjective outcomes were evaluated: satisfaction with treatment, subjective symptoms, EuroQol-5 dimensions, and a quality of life measure for limb lymphoedema (LYMQOL). Multiple regression analysis was performed to examine the associations between lymphoedema treatments and their outcomes. RESULTS: Secondary lymphoedema was present in 158 patients (92.9%), and 91 patients (53.5%) had lower lymphoedema. The patients using compression garments were 2.63 times more likely to have a positive Stemmer sign and 2.85 times more likely to be satisfied with their treatment than those who were not using compression garments (p = 0.02 for Stemmer sign, p < 0.01 for satisfaction). The patients treated with simple lymphatic drainage (SLD) exhibited a 2.26-fold greater level of satisfaction with treatment than those not receiving this treatment (p < 0.01). The patients treated with complete decongestive therapy (CDT) had higher QOL than did those not receiving this therapy (beta = -0.19, p = 0.04). CONCLUSIONS: The progression of swelling can be evaluated using the Stemmer sign with regard to compression therapy. The degree of satisfaction can be evaluated as the patient's satisfaction with their lymphoedema regarding compression garments and SLD, and improvements in QOL can be evaluated using the LYMQOL with regard to CDT. The subjective outcomes were not associated with every lymphoedema treatment in this study, and the effectiveness of lymphoedema treatment can be evaluated using several different outcomes. (C) 2015 Elsevier Ltd. All rights reserved.	[Iuchi, Terumi] Kanazawa Univ, Grad Course Nursing Sci, Div Hlth Sci, Grad Sch Med Sci, Kanazawa, Ishikawa, Japan; [Dai, Misako; Okuwa, Mayumi; Nakatani, Toshio; Sugama, Junko] Kanazawa Univ, Inst Med Pharmaceut & Hlth Sci, Dept Clin Nursing, Kanazawa, Ishikawa, Japan; [Sanada, Hiromi] Univ Tokyo, Grad Sch Med, Div Hlth Sci & Nursing, Dept Gerontol Nursing Wound Care Management, Tokyo, Japan	Sugama, J (reprint author), 5-11-80 Kodatsuno, Kanazawa, Ishikawa 9200942, Japan.	junkosgm@mhs.mp.kanazawa-u.ac.jp	OKUWA, Mayumi/L-3687-2015; 中谷, 壽男/C-3220-2015	中谷, 壽男/0000-0003-4949-5123	Yasuda Medical Foundation	Terumi Iuchi was funded by a grant from The Yasuda Medical Foundation. The funding sources had no role in the study design, the collection, analysis, or interpretation of the data, the writing of the report, or the decision to submit this study for publication.	Franks PJ, 2006, WOUND REPAIR REGEN, V14, P110, DOI 10.1111/j.1743-6109.2006.00099.x; Faul F, 2007, BEHAV RES METHODS, V39, P175, DOI 10.3758/BRM.41.4.1149; Petrek JA, 1998, CANCER, V83, P2776, DOI 10.1002/(SICI)1097-0142(19981215)83:12B+<2776::AID-CNCR25>3.0.CO;2-V; BERTELLI G, 1991, ANN ONCOL, V2, P575; Herberger K, 2013, DERMATOLOGY, V226, P238, DOI 10.1159/000349988; Japanese EuroQol Translation Team, 1998, IRYO TO SHAKAI, V8, P109; Keeley Vaughan, 2008, Br J Community Nurs, V13, pS22; Keeley V, 2010, J LYMPHOEDEMA, V5, P26; LOHR KN, 1988, INQUIRY-J HEALTH CAR, V25, P37; luchi T., 2014, LYMPHOEDEMA RES PRAC, V2, P1; Lymphoedema Framework, 2006, LIB RESC JUSTC SYST, P1; Oremus M, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-6; Sitzia J, 1998, Eur J Cancer Care (Engl), V7, P255; Sitzia J, 1997, CLIN REHABIL, V11, P181, DOI 10.1177/026921559701100301; Toda H., 2009, BMC CANC, V9	15	0	0	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0020-7489	1873-491X		INT J NURS STUD	Int. J. Nurs. Stud.	MAY	2015	52	5					913	919		10.1016/j.ijnurstu.2015.01.011		7	Nursing	Nursing	CG2DZ	WOS:000353086400003		
J	Memtily, N; Okada, T; Ebihara, T; Sato, M; Kurabayashi, A; Furihata, M; Suga, M; Nishiyama, H; Mio, K; Sato, C				Memtily, Nassirhadjy; Okada, Tomoko; Ebihara, Tatsuhiko; Sato, Mari; Kurabayashi, Atsushi; Furihata, Mutsuo; Suga, Mitsuo; Nishiyama, Hidetoshi; Mio, Kazuhiro; Sato, Chikara			Observation of tissues in open aqueous solution by atmospheric scanning electron microscopy: Applicability to intraoperative cancer diagnosis	INTERNATIONAL JOURNAL OF ONCOLOGY			English	Article						ASEM; tissue; heavy metal staining; scanning electron microscope; ClairScope; kidney; metastatic murine breast cancer	PRIMARY-CELL CULTURES; WET SEM; ASEM; PATHOLOGY; LIQUID	In the atmospheric scanning electron microscope (ASEM), a 2- to 3-mu m layer of the sample resting on a silicon nitride-film window in the base of an open sample dish is imaged, in liquid, at atmospheric pressure, from below by an inverted SEM. Thus, the time-consuming pretreatments generally required for biological samples to withstand the vacuum of a standard electron microscope are avoided. In the present study, various mouse tissues (brain, spinal cord, muscle, heart, lung, liver, kidney, spleen and stomach) were fixed, stained with heavy metals, and visualized in radical scavenger D-glucose solution using the ASEM. While some stains made the nuclei of cells very prominent (platinum-blue, phosphotungstic acid), others also emphasized cell organelles and membranous structures (uranium acetate or the NCMIR method). Notably, symbiotic bacteria were sometimes observed on stomach mucosa. Furthermore, kidney tissue could be stained and successfully imaged in <30 min. Lung and spinal cord tissue from normal mice and mice metastasized with breast cancer cells was also examined. Cancer cells present in lung alveoli and in parts of the spine tissue clearly had larger nuclei than normal cells. The results indicate that the ASEM has the potential to accelerate intraoperative cancer diagnosis, the diagnosis of kidney diseases and pathogen detection. Importantly, in the course of the present study it was possible to increase the observable tissue area by using a new multi-windowed ASEM sample dish and sliding the tissue across its eight windows.	[Memtily, Nassirhadjy; Mio, Kazuhiro; Sato, Chikara] Univ Tsukuba, Grad Sch Comprehens Human Sci, Tsukuba, Ibaraki 3050006, Japan; [Memtily, Nassirhadjy; Okada, Tomoko; Ebihara, Tatsuhiko; Sato, Mari; Mio, Kazuhiro; Sato, Chikara] Natl Inst Adv Ind Sci & Technol, Biomed Res Inst, Tsukuba, Ibaraki 3058568, Japan; [Memtily, Nassirhadjy] Xinjiang Med Univ, Tradit Uyghur Med Inst, Urumqi 830011, Xinjiang Uyghur, Peoples R China; [Suga, Mitsuo; Nishiyama, Hidetoshi] JEOL Ltd, Adv Technol Div, Akishima, Tokyo 1968558, Japan; [Kurabayashi, Atsushi; Furihata, Mutsuo] Kochi Univ, Kochi Med Sch, Dept Pathol, Nankoku, Kochi 7838505, Japan	Sato, C (reprint author), Natl Inst Adv Ind Sci & Technol, Biomed Res Inst, Cent 6,Higashi 1-1-1, Tsukuba, Ibaraki 3058568, Japan.	ti-sato@aist.go.jp			CREST; Ministry of Education, Culture, Sports, Science, and Technology (MEXT); Kambayashi Zaydan-in-Aid for Scientific Research; AIST	We thank Dr Toshihiko Ogura at the National Institute of Advanced Industrial Science and Technology (AIST) for valuable discussions concerning the development of the ClairScope, and also Dr Tatsuo Ushiki (Niigata University) for critical reading of the manuscript, Dr Hirofumi Matsui (Tsukuba University), Dr Shinya Sugimoto and Dr Ken-ichi Okuda (The Jikei University School of Medicine), Dr Tom Kouki (Jichi Medical University), Dr Yuusuke Maruyama and Dr Toshio Moriya (AIST) for discussions during the course of the research. The present study was supported by Grant-in-Aid for Scientific Research on Innovative Areas, Structural Cell Biology (to C.S), by CREST (to C.S), by grants from the Ministry of Education, Culture, Sports, Science, and Technology (MEXT) (to C.S), by grants from the Kambayashi Zaydan-in-Aid for Scientific Research and by AIST. This manuscript was prepared with the assistance of a scientific editing service.	Amann K, 2006, NEPHROL DIAL TRANSPL, V21, P1157, DOI 10.1093/ndt/gfk037; Nishiyama H, 2010, J STRUCT BIOL, V172, P191, DOI 10.1016/j.jsb.2010.08.006; Barshack I, 2004, ULTRASTRUCT PATHOL, V28, P29, DOI 10.1080/01913120490275222; Takahashi M, 2009, CLIN EXP METASTAS, V26, P817, DOI 10.1007/s10585-009-9281-8; Hell SW, 2007, SCIENCE, V316, P1153, DOI 10.1126/science.1137395; Sakai H, 2012, CLIN EXP METASTAS, V29, P327, DOI 10.1007/s10585-012-9453-9; Takahashi M, 2008, CLIN EXP METASTAS, V25, P517, DOI 10.1007/s10585-008-9163-5; Thiberge S, 2004, P NATL ACAD SCI USA, V101, P3346, DOI 10.1073/pnas.0400088101; Akita M, 2013, MICROSC RES TECHNIQ, V76, P844, DOI 10.1002/jemt.22237; Murai T, 2011, J BIOL CHEM, V286, P1999, DOI 10.1074/jbc.M110.184010; Nishiyama H, 2014, ULTRAMICROSCOPY, V147, P86, DOI 10.1016/j.ultramic.2014.06.001; Barshack I, 2004, ULTRASTRUCT PATHOL, V28, P255, DOI 10.1080/01913120490515603; Behar V, 2005, MICROSC MICROANAL, V19, P21; Deerinck T. J., 2010, MICROSCOPY, P6; FERREIRO JA, 1995, MAYO CLIN PROC, V70, P1137; Gage G.J., 2012, JOVE-J VIS EXP, V65, P3564, DOI DOI 10.3791/3564; GAHWILER BH, 1981, J NEUROSCI METH, V4, P329, DOI 10.1016/0165-0270(81)90003-0; Gahwiler BH, 1997, TRENDS NEUROSCI, V20, P471; Golgi C, 1898, B SOC MED CHIR PA, V13, P1; Hirano K, 2014, ULTRAMICROSCOPY, V143, P52, DOI [10.1016/j.ultramic.2013.10.010, 10.1016/J.ultramic.2013.10.010]; Kinoshita T, 2014, MICROSC MICROANAL, V20, P470, DOI 10.1017/S1431927614000178; Kristt D, 2007, J TOXICOL PATHOL, V20, P1, DOI 10.1293/tox.20.1; Maruyama Y, 2012, INT J MOL SCI, V13, P10553, DOI 10.3390/ijms130810553; Maruyama Y, 2012, J STRUCT BIOL, V180, P259, DOI 10.1016/j.jsb.2012.08.006; Mochizuki S, 2001, CLIN EXP NEPHROL, V5, P240, DOI 10.1007/s10157-001-8020-5; Nyska A, 2004, TOXICOL PATHOL, V32, P357, DOI 10.1080/01926230490431772; Sato C, 2012, BIOCHEM BIOPH RES CO, V417, P1213, DOI 10.1016/j.bbrc.2011.12.111; Sato C, 2011, JEOLNEWS, V46, P17; Suga M, 2009, MICROSC MICROANAL, V15, P924, DOI 10.1017/S1431927609095774; Suga M, 2011, ULTRAMICROSCOPY, V111, P1650, DOI 10.1016/j.ultramic.2011.08.001; Wilson LB, 1905, JAMA-J AM MED ASSOC, V45, P1737	31	0	0	SPANDIDOS PUBL LTD	ATHENS	POB 18179, ATHENS, 116 10, GREECE	1019-6439	1791-2423		INT J ONCOL	Int. J. Oncol.	MAY	2015	46	5					1872	1882		10.3892/ijo.2015.2905		11	Oncology	Oncology	CG3LD	WOS:000353180800002		
J	Ito, Y; Kawano, H; Kanai, F; Nakamura, E; Tada, N; Takai, S; Horie, S; Arai, H; Kobayashi, T; Hino, O				Ito, Yoshitaka; Kawano, Haruna; Kanai, Fumio; Nakamura, Eri; Tada, Norihiro; Takai, Setsuo; Horie, Shigeo; Arai, Hajime; Kobayashi, Toshiyuki; Hino, Okio			Establishment of Tsc2-deficient rat embryonic stem cells	INTERNATIONAL JOURNAL OF ONCOLOGY			English	Article						Tsc2; tuberous sclerosis; Eker rat; embryonic stem cell; mTORC1; differentiation	TUBEROUS SCLEROSIS COMPLEX; EKER RAT; MAMMALIAN TARGET; CEREBRAL-LESIONS; TSC2 MUTATION; MOUSE EMBRYOS; GENE; MODEL; PATHOGENESIS; TUMOR	Tuberous sclerosis complex (TSC) is an autosomal dominant disorder caused by TSC1 or TSC2 mutations. TSC causes the development of tumors in various organs such as the brain, skin, kidney, lung, and heart. The protein complex TSC1/2 has been reported to have an inhibitory function on mammalian target of rapamycin complex 1 (mTORC1). Treatment with mammalian target of rapamycin (mTOR) inhibitors has demonstrated tumor-reducing effects in patients with TSC but is also associated with various adverse effects. In recent years, experiments involving in vivo differentiation of pluripotent stem cells have been reported as useful in elucidating mechanisms of pathogenesis and discovering new therapeutic targets for several diseases. To reveal the molecular basis of the pathogenesis caused by the Tsc2 mutation, we derived embryonic stem cells (ESCs) from Eker rats, which have the Tsc2 mutation and develop brain lesions and renal tumors. Although several studies have reported the necessity of Tsc1 and Tsc2 regulation to maintain ESCs and hematopoietic stem cells, we successfully established not only Tsc2(+/+) and Tsc2(+/-) ESCs but also Tsc2 ESCs. We confirmed that these cells express pluripotency markers and retain the ability to differentiate into all three germ layers. Comprehensive gene expression analysis of Tsc2(+/+) and Tsc2(+/-) ESCs revealed similar profiles, whereas the profile of Tsc2(-/-) ESCs was distinct from these two. In vitro differentiation experiments using these ESCs combined with in vivo experiments may reveal the mechanism of the tissue-specific pathogenesis caused by the Tsc2 mutation and identify specific new therapeutic targets.	[Ito, Yoshitaka; Arai, Hajime] Juntendo Univ, Grad Sch Med, Dept Neurosurg, Res Inst Dis Old Age, Tokyo 1138421, Japan; [Ito, Yoshitaka; Kawano, Haruna; Kobayashi, Toshiyuki; Hino, Okio] Juntendo Univ, Grad Sch Med, Dept Mol Pathogenesis, Res Inst Dis Old Age, Tokyo 1138421, Japan; [Kawano, Haruna; Horie, Shigeo] Juntendo Univ, Grad Sch Med, Dept Urol, Res Inst Dis Old Age, Tokyo 1138421, Japan; [Kanai, Fumio; Nakamura, Eri; Tada, Norihiro] Juntendo Univ, Grad Sch Med, Lab Genome Res, Res Inst Dis Old Age, Tokyo 1138421, Japan; [Takai, Setsuo] Hiroshima Int Univ, Fac Hlth Sci, Dept Clin Radiol, Hiroshima, Japan	Hino, O (reprint author), Juntendo Univ, Grad Sch Med, Dept Mol Pathogenesis, Bunkyo Ku, 2-1-1 Hongo, Tokyo 1138421, Japan.	koba396@juntendo.ac.jp; ohino@juntendo.ac.jp			Ministry of Education, Culture, Sports, Science and Technology (MEXT) (Japan); MEXT; Japan Society for the Promotion of Science (Japan); Ministry of Health, Labour and Welfare (Japan); Research Institute for Diseases of Old Age, Juntendo University Graduate School of Medicine	We thank Takako Ikegami, and Tomomi Ikeda, Laboratory of Molecular and Biochemical Research, Research Support Center, Juntendo University Graduate School of Medicine (Tokyo, Japan) for technical assistance. The authors would like to thank Enago (www.enago.jp) for the English language review. This study was supported in part by the following grants: Grants-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology (MEXT) (Japan); MEXT-Supported Program for the Strategic Research Foundation at Private Universities; Grants-in-Aid for Scientific Research from the Japan Society for the Promotion of Science (Japan); and Grants-in-Aid for Scientific Research from the Ministry of Health, Labour and Welfare (Japan). This study was also supported by the Research Institute for Diseases of Old Age, Juntendo University Graduate School of Medicine.	Goorden SMI, 2007, ANN NEUROL, V62, P648, DOI 10.1002/ana.21317; Laplante M, 2012, CELL, V149, P274, DOI 10.1016/j.cell.2012.03.017; Easley CA, 2010, CELL REPROGRAM, V12, P263, DOI 10.1089/cell.2010.0011; Ehninger D, 2008, NAT MED, V14, P843, DOI 10.1038/nm1788; Buehr M, 2008, CELL, V135, P1287, DOI 10.1016/j.cell.2008.12.007; McCormack FX, 2011, NEW ENGL J MED, V364, P1595, DOI 10.1056/NEJMoa1100391; MARTIN GR, 1981, P NATL ACAD SCI-BIOL, V78, P7634, DOI 10.1073/pnas.78.12.7634; Bissler JJ, 2013, LANCET, V381, P817, DOI 10.1016/S0140-6736(12)61767-X; EVANS MJ, 1981, NATURE, V292, P154, DOI 10.1038/292154a0; Betschinger J, 2013, CELL, V153, P335, DOI 10.1016/j.cell.2013.03.012; KOBAYASHI T, 1995, NAT GENET, V9, P70, DOI 10.1038/ng0195-70; Li P, 2008, CELL, V135, P1299, DOI 10.1016/j.cell.2008.12.006; Franz DN, 2013, LANCET, V381, P125, DOI 10.1016/S0140-6736(12)61134-9; Kenerson HL, 2002, CANCER RES, V62, P5645; Rennebeck G, 1998, P NATL ACAD SCI USA, V95, P15629, DOI 10.1073/pnas.95.26.15629; WILLIAMS BO, 1994, EMBO J, V13, P4251; Ebert AD, 2009, NATURE, V457, P277, DOI 10.1038/nature07677; Kielman MF, 2002, NAT GENET, V32, P594, DOI 10.1038/ng1045; Kobayashi T, 1999, CANCER RES, V59, P1206; Onda H, 1999, J CLIN INVEST, V104, P687, DOI 10.1172/JCI7319; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; Meikle L, 2008, J NEUROSCI, V28, P5422, DOI 10.1523/JNEUROSCI.0955-08.2008; Kobayashi T, 2001, P NATL ACAD SCI USA, V98, P8762, DOI 10.1073/pnas.151033798; Thomson JA, 1998, SCIENCE, V282, P1145, DOI 10.1126/science.282.5391.1145; Lee G, 2009, NATURE, V461, P402, DOI 10.1038/nature08320; vanSlegtenhorst M, 1997, SCIENCE, V277, P805; Curatolo P, 2008, LANCET, V372, P657, DOI 10.1016/S0140-6736(08)61279-9; Au KS, 1999, AM J HUM GENET, V65, P1790, DOI 10.1086/302648; Benvenuto G, 2000, ONCOGENE, V19, P6306, DOI 10.1038/sj.onc.1204009; Chan JA, 2004, J NEUROPATH EXP NEUR, V63, P1236; EKER R, 1961, NATURE, V189, P858, DOI 10.1038/189858b0; NELLIST M, 1993, CELL, V75, P1305; Gan B, 2008, P NATL ACAD SCI USA, V105, P19384, DOI 10.1073/pnas.0810584105; He J, 2012, STEM CELLS DEV, V21, P2630, DOI 10.1089/scd.2012.0015; Henske EP, 1996, AM J HUM GENET, V59, P400; HINO O, 1993, CANCER RES, V53, P5856; Kawamata M, 2012, SCI REP-UK, V2, DOI 10.1038/srep00945; Kobayashi T, 2003, P JPN ACAD B-PHYS, V79, P22, DOI 10.2183/pjab.79B.22; Kwiatkowski DJ, 2010, TUBEROUS SCLEROSIS C; Lee L, 2005, GENE CHROMOSOME CANC, V42, P213, DOI 10.1002/gcc.20118; Li SW, 2011, NAT COMMUN, V2, DOI 10.1038/ncomms1236; Mizuguchi Masashi, 2007, Congenital Anomalies, V47, P2, DOI 10.1111/j.1741-4520.2006.00134.x; Mizuguchi M, 2000, J NEUROPATH EXP NEUR, V59, P188; Niida Y, 2001, AM J HUM GENET, V69, P493, DOI 10.1086/321972; Prabhakar S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064224; Shiono M, 2008, ONCOGENE, V27, P6690, DOI 10.1038/onc.2008.283; Takahashi DK, 2004, EPILEPSIA, V45, P1525, DOI 10.1111/j.0013-9580.2004.23004.x; Tucker T, 2002, CLIN GENET, V62, P345, DOI 10.1034/j.1399-0004.2002.620501.x; Yang YM, 2013, CELL STEM CELL, V12, P713, DOI 10.1016/j.stem.2013.04.003; Yeung RS, 1997, AM J PATHOL, V151, P1477	50	1	1	SPANDIDOS PUBL LTD	ATHENS	POB 18179, ATHENS, 116 10, GREECE	1019-6439	1791-2423		INT J ONCOL	Int. J. Oncol.	MAY	2015	46	5					1944	1952		10.3892/ijo.2015.2913		9	Oncology	Oncology	CG3LD	WOS:000353180800009		
J	Takano, N; Hishida, M; Inokawa, Y; Hayashi, M; Kanda, M; Nishikawa, Y; Iwata, N; Kobayashi, D; Tanaka, C; Yamada, S; Nakayama, G; Fujii, T; Sugimoto, H; Koike, M; Fujiwara, M; Kodera, Y; Nomoto, S				Takano, Nao; Hishida, Mitsuhiro; Inokawa, Yoshikuni; Hayashi, Masamichi; Kanda, Mitsuro; Nishikawa, Yoko; Iwata, Naoki; Kobayashi, Daisuke; Tanaka, Chie; Yamada, Suguru; Nakayama, Goro; Fujii, Tsutomu; Sugimoto, Hiroyuki; Koike, Masahiko; Fujiwara, Michitaka; Kodera, Yasuhiro; Nomoto, Shuji			CCNJ detected by triple combination array analysis as a tumor-related gene of hepatocellular carcinoma	INTERNATIONAL JOURNAL OF ONCOLOGY			English	Article						cyclin J; hepatocellular carcinoma; methylation; triple combination array; cancer-related gene	SUPPRESSOR GENE; IDENTIFICATION; EXPRESSION; DNA; CANCER; RISK; G1	Hepatocellular carcinoma (HCC) has a high likelihood of recurrence and a poor prognosis. To detect cancer-related genes of HCC, we developed a new technique: triple combination array analysis, consisting of a methylation array, a gene expression array and a single nucleotide polymorphism array. A surgical specimen obtained from a 68-year-old female HCC patient was analyzed using triple combination array, which identified cyclin J (CCNJ) as a candidate cancer-related gene of HCC. Subsequently, samples from 85 HCC patients were evaluated for CCNJ promoter hypermethylation and expression status using methylation-specific PCR (MSP) and quantitative reverse transcriptase RT-PCR, respectively. CCNJ was found to be hypermethylated (methylation value, 0.906; range, 0-1.0) in cancer tissue, compared with adjacent non-cancerous tissue (0.112) using a methylation array. MSP revealed that CCAU. was hypermethylated in 67 (78.8%) of the tumor samples. CCNJ expression was significantly decreased in cases with hypermethylation (P<0.0001). Furthermore, cases with both promoter hypermethylation and decreased expression of CCNJ in the tumor tissue had a worse overall survival than the other cases (P=0.0383). In conclusion, our results indicated that CCNJ could be a novel prognostic marker of HCC, and this study indicated that triple combination array analysis was effective in detecting new tumor-related genes and their mechanisms.	[Takano, Nao; Hishida, Mitsuhiro; Inokawa, Yoshikuni; Hayashi, Masamichi; Kanda, Mitsuro; Nishikawa, Yoko; Iwata, Naoki; Kobayashi, Daisuke; Tanaka, Chie; Yamada, Suguru; Nakayama, Goro; Fujii, Tsutomu; Sugimoto, Hiroyuki; Koike, Masahiko; Fujiwara, Michitaka; Kodera, Yasuhiro; Nomoto, Shuji] Nagoya Univ, Gastroenterol Surg, Grad Sch Med, Showa Ku, Nagoya, Aichi 4668550, Japan; [Nomoto, Shuji] Aichi Gakuin Univ, Dept Surg, Sch Dent, Chikusa Ku, Nagoya, Aichi 4648651, Japan	Nomoto, S (reprint author), Aichi Gakuin Univ, Dept Surg, Sch Dent, Chikusa Ku, 2-11 Suemori Dori, Nagoya, Aichi 4648651, Japan.	snomoto@dpc.agu.ac.jp	Hayashi, Masamichi/P-9743-2015	Hayashi, Masamichi/0000-0001-6875-2303	Japan Society for the Promotion of Science (JSPS) KAKENHI [22591427]	This work was supported by Japan Society for the Promotion of Science (JSPS) KAKENHI Grant-in-Aid for Scientific Research (C) number 22591427.	Kanda M, 2011, MOL CARCINOGEN, V50, P571, DOI 10.1002/mc.20735; Bennin DA, 2002, J BIOL CHEM, V277, P27449, DOI 10.1074/jbc.M111693200; Okamura Y, 2010, CANCER LETT, V289, P170, DOI 10.1016/j.canlet.2009.08.013; Nannya Y, 2005, CANCER RES, V65, P6071, DOI 10.1158/0008-5472.CAN-05-0465; Ferlay J, 2010, INT J CANCER, V127, P2893, DOI 10.1002/ijc.25516; Kanda M, 2009, INT J ONCOL, V35, P477, DOI 10.3892/ijo_00000359; Nomoto S, 2010, ANN SURG ONCOL, V17, P923, DOI 10.1245/s10434-009-0790-0; Bates S, 1996, ONCOGENE, V13, P1103; Llovet JM, 2008, NEW ENGL J MED, V359, P378, DOI 10.1056/NEJMoa0708857; Sun GG, 2014, TUMOR BIOL, V35, P2631, DOI 10.1007/s13277-013-1346-2; Yu MC, 2004, GASTROENTEROLOGY, V127, pS72, DOI 10.1016/j.gastro.2004.09.018; Kim Y, 2004, CANCER RES, V64, P8980, DOI 10.1158/0008-5472.CAN-04-1926; Kennedy GC, 2003, NAT BIOTECHNOL, V21, P1233, DOI 10.1038/nbt869; Finley RL, 1996, P NATL ACAD SCI USA, V93, P3011, DOI 10.1073/pnas.93.7.3011; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; El-Serag HB, 2007, GASTROENTEROLOGY, V132, P2557, DOI 10.1053/j.gastro.2007.04.061; Harvey RC, 2010, BLOOD, V116, P4874, DOI 10.1182/blood-2009-08-239681; NISHIDA N, 1994, CANCER RES, V54, P3107; Takayasu K, 2006, GASTROENTEROLOGY, V131, P461, DOI 10.1053/j.gastro.2006.05.021; Fornari F, 2009, CANCER RES, V69, P5761, DOI 10.1158/0008-5472.CAN-08-4797; Sun GG, 2014, TUMOR BIOL, V35, P3339, DOI 10.1007/s13277-013-1440-5; Forner A, 2012, LANCET, V379, P1245, DOI 10.1016/S0140-6736(11)61347-0; Livraghi T, 1999, RADIOLOGY, V210, P655; Kolonin MG, 2000, DEV BIOL, V227, P661, DOI 10.1006/dbio.2000.9916; Gramantieri L, 2007, CANCER RES, V67, P6092, DOI 10.1158/0008-5472.CAN-06-4607; Satyanarayana A, 2009, ONCOGENE, V28, P2925, DOI 10.1038/onc.2009.170; Cusnir M, 2004, CANCER J, V10, P97, DOI 10.1097/00130404-200403000-00005; Feliciano A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076247; Hayashi M, 2012, J SURG ONCOL, V105, P381, DOI 10.1002/jso.22135; Hishida M, 2013, INT J ONCOL, V43, P88, DOI 10.3892/ijo.2013.1951; Inokawa Y, 2013, ONCOTARGETS THER, V6, P1417, DOI 10.2147/OTT.S51913; Morgan DO, 1997, ANNU REV CELL DEV BI, V13, P261, DOI 10.1146/annurev.cellbio.13.1.261; Okamura Y, 2011, CANCER LETT, V312, P150, DOI 10.1016/j.canlet.2011.07.028; Okamura Y, 2011, ANN SURG ONCOL, V18, P572, DOI 10.1245/s10434-010-1273-z; Shan G, 2009, CHIN J HISTOCHEM CYT, V18, P267; [石伟 Shi Wei], 2011, [中国细胞生物学学报, Chinese Journal of Cell Biology], V33, P994; Stangegaard Michael, 2009, V529, P133, DOI 10.1007/978-1-59745-538-1_9; Takai Daiya, 2003, In Silico Biology, V3, P235	38	0	0	SPANDIDOS PUBL LTD	ATHENS	POB 18179, ATHENS, 116 10, GREECE	1019-6439	1791-2423		INT J ONCOL	Int. J. Oncol.	MAY	2015	46	5					1963	1970		10.3892/ijo.2015.2892		8	Oncology	Oncology	CG3LD	WOS:000353180800011		
J	Iwamoto, K; Nakashiro, KI; Tanaka, H; Tokuzen, N; Hamakawa, H				Iwamoto, Kazuki; Nakashiro, Koh-Ichi; Tanaka, Hiroshi; Tokuzen, Norihiko; Hamakawa, Hiroyuki			Ribonucleotide reductase M2 is a promising molecular target for the treatment of oral squamous cell carcinoma	INTERNATIONAL JOURNAL OF ONCOLOGY			English	Article						oral squamous cell carcinoma; ribonucleotide reductase M2; gemcitabine; collagen gel droplet embedded culture drug sensitivity test; chemotherapy	MESSENGER-RNA EXPRESSION; DROPLET EMBEDDED CULTURE; PHASE-II TRIAL; IN-VITRO; NECK-CANCER; SUBUNIT M2; HUMAN HEAD; GEMCITABINE; RECURRENT; SURVIVAL	In our previous study, ribonucleotide reductase M2 (RRM2) was identified as a cancer-related gene commonly overexpressed in human oral squamous cell carcinoma (OSCC) cell lines. Herein, we attempted to determine whether targeting RRM2 may be a plausible therapeutic approach for the treatment of patients with OSCC. First, we examined the expression levels of RRM2 in human OSCC cell lines and tissues. Overexpression of RRM2 in OSCC was confirmed by western blot analysis. Subsequently, we investigated the effects of a synthetic small interfering RNA specific for RRM2 and gemcitabine (GEM), an inhibitor of RRM2 enzymatic activity, on the growth of human OSCC cell lines and primary cultured cells. Targeting RRM2 by RNA interference almost completely suppressed the expression of RRM2 and markedly suppressed the growth of both types of cells by >54.8%. GEM also reduced the growth rate of these cells by >83.0%. Finally, we evaluated the antitumor effects of GEM, cisplatin (CDDP), 5-fluorouracil (5-FU), and docetaxel (DOC) against OSCC cells using the collagen gel droplet embedded culture drug sensitivity test. OSCC cells were more sensitive to GEM and DOC than to CDDP and 5-FU, regardless of the expression level of RRM2 mRNA. These results suggested that RRM2 supported the growth of human OSCC cells and that targeting of RRM2, e.g., via GEM treatment, may be a promising therapeutic strategy for OSCC.	[Iwamoto, Kazuki; Nakashiro, Koh-Ichi; Tanaka, Hiroshi; Tokuzen, Norihiko; Hamakawa, Hiroyuki] Ehime Univ, Dept Oral & Maxillofacial Surg, Grad Sch Med, Toon, Ehime 7910295, Japan	Nakashiro, KI (reprint author), Ehime Univ, Dept Oral & Maxillofacial Surg, Grad Sch Med, 454 Shitsukawa, Toon, Ehime 7910295, Japan.	nakako@m.ehime-u.ac.jp			JSPS KAKENHI [17689057]	This work was supported, in part, by JSPS KAKENHI (grant no. 17689057).	Aguilar-Ponce JL, 2004, ANN ONCOL, V15, P301, DOI 10.1093/annonc/mdh071; Senkal CE, 2006, J PHARMACOL EXP THER, V317, P1188, DOI 10.1124/jpet.106.101949; Itoi T, 2007, J GASTROENTEROL, V42, P389, DOI 10.1007/s00535-007-2017-0; Weinstein IB, 2002, SCIENCE, V297, P63, DOI 10.1126/science.1073096; Furuta E, 2010, BBA-REV CANCER, V1805, P141, DOI 10.1016/j.bbcan.2010.01.005; Gupta S, 2009, INT J CANCER, V125, P2159, DOI 10.1002/ijc.24533; BRAAKHUIS BJM, 1991, CANCER RES, V51, P211; Desai AA, 2005, ANN ONCOL, V16, P958, DOI 10.1093/annonc/mdi178; Duxbury MS, 2004, ONCOGENE, V23, P1539, DOI 10.1038/sj.onc.1207272; Grandis JR, 1998, J NATL CANCER I, V90, P824, DOI 10.1093/jnci/90.11.824; Rahman MA, 2013, CLIN CANCER RES, V19, P3416, DOI 10.1158/1078-0432.CCR-13-0073; Shintani S, 2002, ORAL ONCOL, V38, P664, DOI 10.1016/S1368-8375(01)00131-2; Saddoughi SA, 2011, CLIN CANCER RES, V17, P6097, DOI 10.1158/1078-0432.CCR-11-0930; Ang KK, 2002, CANCER RES, V62, P7350; Rahman MA, 2012, J CONTROL RELEASE, V159, P384, DOI 10.1016/j.jconrel.2012.01.045; van Herpen CML, 2008, EUR J CANCER, V44, P2542, DOI 10.1016/j.ejca.2008.08.014; Yabushita H, 2004, ONCOL REP, V12, P307; Shintani S, 2010, INT J ORAL MAX SURG, V39, P1115, DOI 10.1016/j.ijom.2010.02.027; Bonner IA, 2006, NEW ENGL J MED, V354, P567; ERIKSSON S, 1981, J BIOL CHEM, V256, P9436; Fan HZ, 1996, P NATL ACAD SCI USA, V93, P14036, DOI 10.1073/pnas.93.24.14036; Ferlay I, 2010, INT J CANCER, V127, P2893; Fury MG, 2011, CANCER-AM CANCER SOC, V117, P795, DOI 10.1002/cncr.25464; Higashiyama M, 2010, LUNG CANCER, V68, P472, DOI 10.1016/j.lungcan.2009.07.005; Kobayashi H, 2001, JPN J CANCER RES, V92, P203; Mekata E, 2013, MOL CLIN ONCOLOGY, V1, P763; Mori S, 2003, SURG TODAY, V33, P577, DOI 10.1007/s00595-003-2569-4; Morikawa T, 2010, HISTOPATHOLOGY, V57, P885, DOI 10.1111/j.1365-2559.2010.03725.x; PLUNKETT W, 1995, SEMIN ONCOL, V22, P3; Shao J, 2006, CURR CANCER DRUG TAR, V6, P409, DOI 10.2174/156800906777723949; Souglakos J, 2008, BRIT J CANCER, V98, P1710, DOI 10.1038/sj.bjc.6604344; Tanaka H, 2013, ORAL ONCOL, V49, P551, DOI 10.1016/j.oraloncology.2013.02.002; THELANDER M, 1985, J BIOL CHEM, V260, P2737; Vermorken JB, 2008, NEW ENGL J MED, V359, P1116, DOI 10.1056/NEJMoa0802656; Wadler S, 2004, J CLIN ONCOL, V22, P1553, DOI 10.1200/JCO.2004.07.158; Zhang Zu-Ping, 2009, Ai Zheng, V28, P100	36	1	1	SPANDIDOS PUBL LTD	ATHENS	POB 18179, ATHENS, 116 10, GREECE	1019-6439	1791-2423		INT J ONCOL	Int. J. Oncol.	MAY	2015	46	5					1971	1977		10.3892/ijo.2015.2912		7	Oncology	Oncology	CG3LD	WOS:000353180800012		
J	Shiiba, M; Saito, K; Yamagami, H; Nakashima, D; Higo, M; Kasamatsu, A; Sakamoto, Y; Ogawara, K; Uzawa, K; Takiguchi, Y; Tanzawa, H				Shiiba, Masashi; Saito, Kengo; Yamagami, Hitomi; Nakashima, Dai; Higo, Morihiro; Kasamatsu, Atsushi; Sakamoto, Yosuke; Ogawara, Katsunori; Uzawa, Katsuhiro; Takiguchi, Yuichi; Tanzawa, Hideki			Interleukin-1 receptor antagonist (IL1RN) is associated with suppression of early carcinogenic events in human oral malignancies	INTERNATIONAL JOURNAL OF ONCOLOGY			English	Article						interleukin-1 receptor antagonist; oral squamous cell carcinoma; oral premalignant lesion	SQUAMOUS-CELL CARCINOMA; CANCER CELLS; ENHANCES ANGIOGENESIS; EXPRESSION; GROWTH; PROGRESSION; METASTASIS; IL-1-ALPHA; MARKERS; IL-1RA	Inflammatory abnormalities have been implicated in the pathogenesis of various human diseases, including cancer. Interleukin-1 receptor antagonist (IL1RN) is a potent anti-inflammatory molecule that modulates the biological activity of the proinflammatory cytokine, interleukin-1. The aim of this study was to examine the expression of IL1RN in oral squamous cell carcinomas (OSCCs), and to determine its clinical significance. Expression levels of IL1RN in matched normal and tumor specimens from 39 OSCCs were evaluated using real-time quantitative polymerase chain reaction methods, and immunohistochemical analysis. Protein expression of IL1RN was also examined in 18 oral premalignant lesions (OPLs). Expression of IL1RN mRNA was significantly downregulated in OSCCs compared with normal tissues. Decreased expression of IL1RN protein was also observed in OPLs and OSCCs. The IL1RN expression level was lower in the OPL cases with severe dysplasia compared to those with mild/moderate dysplasia. Significantly downregulated IL1RN expression was observed in all OSCC lesion sites examined when compared with the matched normal tissues. However, the decreased level of IL1RN expression did not correspond with tumor progression. Noteworthy, IL1RN expression was higher in the advanced OSCC cases (T3/T4) compared to early cases (T1/T2). Among OSCC samples, relatively higher IL1RN expression was associated with active tumor development in the OSCCs occurring in the buccal mucosa, oral floor, fauces and gingiva, but not the tongue. These data suggest that IL1RN may exhibit opposing characteristics in oral malignancies depending on the stage of cancer development, suppressing early carcinogenic events, yet promoting tumor development in some lesion sites. Thus, IL1RN could represent a reliable biomarker for the early diagnosis of OSCCs. Furthermore, IL1RN may possess unknown and complex functions in the developed OSCC.	[Shiiba, Masashi; Saito, Kengo; Yamagami, Hitomi; Nakashima, Dai; Higo, Morihiro; Kasamatsu, Atsushi; Sakamoto, Yosuke; Ogawara, Katsunori; Uzawa, Katsuhiro; Tanzawa, Hideki] Chiba Univ, Grad Sch Med, Dept Oral Sci, Chuo Ku, Chiba 2608670, Japan; [Shiiba, Masashi; Takiguchi, Yuichi] Chiba Univ, Grad Sch Med, Dept Med Oncol, Chuo Ku, Chiba 2608670, Japan; [Saito, Kengo] Chiba Univ, Grad Sch Med, Dept Mol Virol, Chuo Ku, Chiba 2608670, Japan	Shiiba, M (reprint author), Chiba Univ, Grad Sch Med, Dept Oral Sci, Chuo Ku, 1-8-1 Inohana, Chiba 2608670, Japan.	m.shiiba@faculty.chiba-u.jp					Al-Dakkak Imad, 2010, Evid Based Dent, V11, P91, DOI 10.1038/sj.ebd.6400745; Amagasa T, 2006, ORAL SCI INT, V3, P45; Aggarwal BB, 2009, CURR OPIN PHARMACOL, V9, P351, DOI 10.1016/j.coph.2009.06.020; Matsuo Y, 2009, J SURG RES, V153, P274, DOI 10.1016/j.jss.2008.04.040; Arend WR, 2002, CYTOKINE GROWTH F R, V13, P323, DOI 10.1016/S1359-6101(02)00020-5; Lindahl G, 2011, CANCER RES, V71, P51, DOI 10.1158/0008-5472.CAN-10-2289; Liu W, 2011, HISTOPATHOLOGY, V59, P733, DOI 10.1111/j.1365-2559.2011.03938.x; DINARELLO CA, 1989, ADV IMMUNOL, V44, P153; Znaor A, 2003, INT J CANCER, V105, P681, DOI 10.1002/ijc.11114; Elaraj DM, 2006, CLIN CANCER RES, V12, P1088, DOI 10.1158/1078-0432.CCR-05-1603; La EH, 2001, MOL CARCINOGEN, V30, P218, DOI 10.1002/mc.1031; Dewberry R, 2000, ARTERIOSCL THROM VAS, V20, P2394; Sethi G, 2012, BIOSCIENCE REP, V32, P1, DOI 10.1042/BSR20100136; Ma J, 2008, J SURG RES, V148, P197, DOI 10.1016/j.jss.2007.08.014; Yamamoto N, 2003, ORAL ONCOL, V39, P796, DOI 10.1016/S1368-8375(03)00079-4; Oelmann E, 1997, INT J CANCER, V71, P1066, DOI 10.1002/(SICI)1097-0215(19970611)71:6<1066::AID-IJC25>3.0.CO;2-A; MCCARTY KS, 1986, CANCER RES, V46, P4244; Rafiq S, 2007, GENES IMMUN, V8, P344, DOI 10.1038/sj.gene.6364393; Matsuo Y, 2009, J SURG ONCOL, V99, P361, DOI 10.1002/jso.21245; AREND WP, 1991, J CLIN INVEST, V88, P1445, DOI 10.1172/JCI115453; Bilalovic N, 2004, MODERN PATHOL, V17, P1251, DOI 10.1038/modpathol.3800174; Dinarello C A, 1998, Int Rev Immunol, V16, P457, DOI 10.3109/08830189809043005; Dvorkin T, 2006, J LEUKOCYTE BIOL, V80, P96, DOI 10.1189/jlb.0905509; Fujiwaki R, 2003, GYNECOL ONCOL, V89, P77, DOI 10.1016/S0090-8258(02)00154-3; Gherardi RK, 1996, BLOOD, V87, P1458; HSIEH TC, 1995, CANCER LETT, V95, P119, DOI 10.1016/0304-3835(95)03876-X; Iizuka N, 1999, CANCER LETT, V142, P179, DOI 10.1016/S0304-3835(99)00162-7; Iwagaki H, 1997, SCAND J GASTROENTERO, V32, P577, DOI 10.3109/00365529709025103; Koike H, 2005, INT J ONCOL, V27, P59; Kurzrock R, 2001, BIOMED PHARMACOTHER, V55, P543, DOI 10.1016/S0753-3322(01)00140-8; Lallemant B, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-370; La Vecchia C, 2004, ORAL ONCOL, V40, P433, DOI 10.1016/j.oraloncology.2003.09.013; Parekh DJ, 2007, CANCER EPIDEM BIOMAR, V16, P1966, DOI 10.1158/1055-9965.EPI-07-0302; Patel Mandakini Mansukh, 2004, Indian J Pathol Microbiol, V47, P195; Voronov E, 1999, CANCER RES, V59, P1029; Yamada Y, 1999, LAB INVEST, V79, P1059	36	0	0	SPANDIDOS PUBL LTD	ATHENS	POB 18179, ATHENS, 116 10, GREECE	1019-6439	1791-2423		INT J ONCOL	Int. J. Oncol.	MAY	2015	46	5					1978	1984		10.3892/ijo.2015.2917		7	Oncology	Oncology	CG3LD	WOS:000353180800013		
J	Yamanegi, K; Kawabe, M; Futani, H; Nishiura, H; Yamada, N; Kato-Kogoe, N; Kishimoto, H; Yoshiya, S; Nakasho, K				Yamanegi, Koji; Kawabe, Mutsuki; Futani, Hiroyuki; Nishiura, Hiroshi; Yamada, Naoko; Kato-Kogoe, Nahoko; Kishimoto, Hiromitsu; Yoshiya, Shinichi; Nakasho, Keiji			Sodium valproate, a histone deacetylase inhibitor, modulates the vascular endothelial growth inhibitor-mediated cell death in human osteosarcoma and vascular endothelial cells	INTERNATIONAL JOURNAL OF ONCOLOGY			English	Article						valproic acid; HDAC inhibitor; osteosarcoma; vascular endothelial growth inhibitor	TNF-LIKE LIGAND; DECOY RECEPTOR-3; IN-VITRO; CANCER; EXPRESSION; TL1A; VEGI; OVEREXPRESSION; ANGIOGENESIS; SUPERFAMILY	The level of vascular endothelial growth inhibitor (VEGI) has been reported to be negatively associated with neovascularization in malignant tumors. The soluble form of VEGI is a potent anti-angiogenic factor due to its effects in inhibiting endothelial cell proliferation. This inhibition is mediated by death receptor 3 (DR3), which contains a death domain in its cytoplasmic tail capable of inducing apoptosis that can be subsequently blocked by decoy receptor 3 (DcR3). We investigated the effects of sodium valproate (VPA) and trichostatin A (TSA), histone deacetylase inhibitors, on the expression of VEGI and its related receptors in human osteosarcoma (OS) cell lines and human microvascular endothelial (HMVE) cells. Consequently, treatment with VPA and TSA increased the VEGI and DR3 expression levels without inducing DcR3 production in the OS cell lines. In contrast, the effect on the HMVE cells was limited, with no evidence of growth inhibition or an increase in the DR3 and DcR3 expression. However, VPA-induced soluble VEGI in the OS cell culture medium markedly inhibited the vascular tube formation of HMVE cells, while VEGI overexpression resulted in enhanced OS cell death. Taken together, the HDAC inhibitor has anti-angiogenesis and antitumor activities that mediate soluble VEGI/DR-3-induced apoptosis via both autocrine and paracrine pathways. This study indicates that the HDAC inhibitor may be exploited as a "therapeutic strategy modulating the soluble VEGI/DR3 pathway in osteosarcoma patients.	[Yamanegi, Koji; Kawabe, Mutsuki; Nishiura, Hiroshi; Yamada, Naoko; Kato-Kogoe, Nahoko; Nakasho, Keiji] Hyogo Coll Med, Dept Pathol, Nishinomiya, Hyogo 6638501, Japan; [Kawabe, Mutsuki; Kishimoto, Hiromitsu] Hyogo Coll Med, Dept Oral & Maxillofacial Surg, Nishinomiya, Hyogo 6638501, Japan; [Futani, Hiroyuki; Yoshiya, Shinichi] Hyogo Coll Med, Dept Orthoped Surg, Nishinomiya, Hyogo 6638501, Japan	Yamanegi, K (reprint author), Hyogo Coll Med, Dept Pathol, 1-1 Mukogawa Cho, Nishinomiya, Hyogo 6638501, Japan.	yamanegi@hyo-med.ac.jp			Ministry of Education, Culture, Sports, Science, and Technology of Japan [23792159, 26462279]; Hyogo College of Medicine	This study was supported in part by a Grant-in-Aid for Young Scientists (B) (23792159) and Grant-in-Aid for Scientific Research (C) (26462279) from the Ministry of Education, Culture, Sports, Science, and Technology of Japan, Grant-in-Aid for Researchers, Hyogo College of Medicine, 2012.	Hou W, 2005, CLIN CANCER RES, V11, P5595, DOI 10.1158/1078-0432.CCR-05-0384; Tan KB, 1997, GENE, V204, P35, DOI 10.1016/S0378-1119(97)00509-X; Zhai YF, 1999, FASEB J, V13, P181; Chew LJ, 2002, FASEB J, V16, P742, DOI 10.1096/fj.01-0757fje; Rogawski MA, 2004, NAT REV NEUROSCI, V5, P553, DOI 10.1038/nrn1430; Dickinson M, 2010, INVEST NEW DRUG, V28, pS3, DOI 10.1007/s10637-010-9596-y; Shen H, 2013, CELL, V153, P38, DOI 10.1016/j.cell.2013.03.008; Zhao YX, 2014, INT J ONCOL, V44, P451, DOI 10.3892/ijo.2013.2193; Marks PA, 2009, J CELL BIOCHEM, V107, P600, DOI 10.1002/jcb.22185; Chinnaiyan AM, 1996, SCIENCE, V274, P990, DOI 10.1126/science.274.5289.990; Migone TS, 2002, IMMUNITY, V16, P479, DOI 10.1016/S1074-7613(02)00283-2; Messerschmitt PJ, 2009, J AM ACAD ORTHOP SUR, V17, P515; Kong XG, 2006, MOL CELL BIOL, V26, P2019, DOI 10.1128/MCB.26.6.2019-2028.2006; Bai C, 2000, P NATL ACAD SCI USA, V97, P1230, DOI 10.1073/pnas.97.3.1230; Kristensen LS, 2009, EUR J PHARMACOL, V625, P131, DOI 10.1016/j.ejphar.2009.10.011; Grimaldo S, 2009, APOPTOSIS, V14, P788, DOI 10.1007/s10495-009-0351-9; Ferguson LR, 2011, CURR CANCER DRUG TAR, V11, P199; Yang CR, 2004, CANCER RES, V64, P1122, DOI 10.1158/0008-5472.CAN-03-0609; Qian DZ, 2006, CANCER RES, V66, P8814, DOI 10.1158/0008-5472.CAN-005-4598; Bialer M, 2012, EPILIPSIA, V53, pS26; Ge Zhicheng, 2011, J Exp Ther Oncol, V9, P109; Ge ZC, 2011, EXP THER MED, V2, P167, DOI 10.3892/etm.2011.206; Kang FW, 2012, ONCOL REP, V28, P193, DOI 10.3892/or.2012.1784; Liang PH, 2011, ANGIOGENESIS, V14, P61, DOI 10.1007/s10456-010-9195-8; Muck C, 2010, J GERONTOL A-BIOL, V65, P1165, DOI 10.1093/gerona/glq129; Parr Christian, 2006, Angiogenesis, V9, P73, DOI 10.1007/s10456-006-9033-1; Takahama Yasushi, 2002, Gastric Cancer, V5, P61, DOI 10.1007/s101200200011; Xiao QL, 2005, BIOCHEM J, V388, P913, DOI 10.1042/BJ20041739; Xiao T, 2010, CELL RES, V20, P367, DOI 10.1038/cr.2009.126; Yamanegi K, 2012, ONCOL REP, V28, P1585, DOI 10.3892/or.2012.1981; Zhang Zhisong, 2012, Cancer Microenviron, V5, P237, DOI 10.1007/s12307-012-0117-8; Zong L, 2014, WORLD J GASTROENTERO, V20, P4440, DOI 10.3748/wjg.v20.i15.4440	32	0	0	SPANDIDOS PUBL LTD	ATHENS	POB 18179, ATHENS, 116 10, GREECE	1019-6439	1791-2423		INT J ONCOL	Int. J. Oncol.	MAY	2015	46	5					1994	2002		10.3892/ijo.2015.2924		9	Oncology	Oncology	CG3LD	WOS:000353180800015		
J	Sueta, A; Yamamoto, Y; Yamamoto-Ibusuki, M; Hayashi, M; Takeshita, T; Yamamoto, S; Omoto, Y; Iwase, H				Sueta, Aiko; Yamamoto, Yutaka; Yamamoto-Ibusuki, Mutsuko; Hayashi, Mitsuhiro; Takeshita, Takashi; Yamamoto, Satoko; Omoto, Yoko; Iwase, Hirotaka			Differential role of MACC1 expression and its regulation of the HGF/c-Met pathway between breast and colorectal cancer	INTERNATIONAL JOURNAL OF ONCOLOGY			English	Article						MACC1; breast cancer; prognosis; c-Met signaling; biomarker	HEPATOCYTE GROWTH-FACTOR; C-MET; INVASIVE GROWTH; FACTOR RECEPTOR; GASTRIC-CANCER; FACTOR-I; OVEREXPRESSION; METASTASIS; CARCINOMA; CELLS	The newly identified gene, metastasis-associated in colon cancer 1 (MACC1), is suggested to be a transcriptional regulator of c-Met, leading to cancer progression in colorectal cancer. To date however, little is known of the role of MACC1 in breast cancer. In a series of 300 breast cancer patients, we analyzed the association of MACC1 mRNA and protein expression with breast cancer survival using Cox proportional hazard models. In an in vitro study, we evaluated activities of c-Met protein after transfection with a MACC1-harboring plasmid as well as the binding ability of MACC1 to the c-Met promoter using a chromatin immunoprecipitation (ChIP) assay. In survival analyses, reduced MACC1 expression was associated with patient mortality. MACC1 expression was an independent prognostic factor in multivariate analysis. In the cell lines tested, MACC1 expression was much higher in colorectal than in breast cancer cells. After cells were transfected with MACC1, c-Met expression was not induced in MCF7 cells, whereas corresponding c-Met expression was upregulated in SW480 cells. Further, SW480 cells transfected with MACC1 showed enhanced migratory ability, whereas in MDA-MB-231 cells, transfection of MACC1 had no impact on this ability. In ChIP assay, the binding of MACC1 to the c-Met promoter was suggested in SW480 cells, but not in MCF7 cells. In conclusion, our findings provide some novel insights into the role of MACC1 in breast cancer, indicating that it plays different roles in breast and several other cancers. There is a possibility that MACC1 does not modulate the transcriptional role of c-Met signaling in breast cancer.	[Sueta, Aiko; Yamamoto, Yutaka; Yamamoto-Ibusuki, Mutsuko; Hayashi, Mitsuhiro; Takeshita, Takashi; Yamamoto, Satoko; Omoto, Yoko; Iwase, Hirotaka] Kumamoto Univ, Grad Sch Med Sci, Dept Breast & Endocrine Surg, Kumamoto 8608556, Japan; [Sueta, Aiko; Yamamoto, Yutaka] Kumamoto Univ Hosp, Dept Mol Targeting Therapy Breast Canc, Kumamoto 8608556, Japan	Yamamoto, Y (reprint author), Kumamoto Univ Hosp, Dept Mol Targeting Therapy Breast Canc, Chuo Ku, 1-1-1 Honjo, Kumamoto 8608556, Japan.	ys-yama@triton.ocn.ne.jp			Ministry of Education, Culture, Sports, Science and Technology of Japan [24591909]	The authors are grateful to Y. Azakami for excellent technical support, to A. Okabe for clinical data management, to Dr M. Nakano (Department of Molecular Genetics, Kumamoto University) for providing breast cancer cell lines and technical support, and to Dr K. Kuwahara (Department of Immunology, Kumamoto University) for providing the SW480 cell line. This study was supported by a Grant in Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology of Japan (Y. Yamamoto, Grant no. 24591909).	Lengyel E, 2005, INT J CANCER, V113, P678, DOI 10.1002/ijc.20598; KADONAGA JT, 1986, TRENDS BIOCHEM SCI, V11, P20, DOI 10.1016/0968-0004(86)90226-4; Jiang WG, 2005, CRIT REV ONCOL HEMAT, V53, P35, DOI 10.1016/j.critrevonc.2004.09.004; PAPA V, 1993, CANCER RES, V53, P3736; Turner N, 2010, ONCOGENE, V29, P2013, DOI 10.1038/onc.2009.489; Arlt F, 2009, INT J BIOCHEM CELL B, V41, P2356, DOI 10.1016/j.biocel.2009.08.001; Maulik G, 2002, CYTOKINE GROWTH F R, V13, P41, DOI 10.1016/S1359-6101(01)00029-6; Amemiya H, 2002, ONCOLOGY-BASEL, V63, P286, DOI 10.1159/000065477; Ipsaro JJ, 2009, BLOOD, V113, P5385, DOI 10.1182/blood-2008-10-184358; Parker JS, 2009, J CLIN ONCOL, V27, P1160, DOI 10.1200/JCO.2008.18.1370; Shattuck DL, 2008, CANCER RES, V68, P1471, DOI 10.1158/0008-5472.CAN-07-5962; Kang JY, 2003, CANCER RES, V63, P1101; Law JH, 2008, CANCER RES, V68, P10238, DOI 10.1158/0008-5472.CAN-08-2755; Stein U, 2009, NAT MED, V15, P59, DOI 10.1038/nm.1889; Matsuda T, 2011, JPN J CLIN ONCOL, V41, P139, DOI 10.1093/jjco/hyq169; Goldhirsch A, 2011, ANN ONCOL, V22, P1736, DOI 10.1093/annonc/mdr304; Stein U, 2010, J MOL MED-JMM, V88, P11, DOI 10.1007/s00109-009-0537-1; Pennacchietti S, 2003, CANCER CELL, V3, P347, DOI 10.1016/S1535-6108(03)00085-0; Peschard P, 2007, ONCOGENE, V26, P1276, DOI 10.1038/sj.onc.1210201; Jin L, 1997, CANCER, V79, P749, DOI 10.1002/(SICI)1097-0142(19970215)79:4<749::AID-CNCR12>3.0.CO;2-#; Dowsett M, 2011, J NATL CANCER I, V103, P1656, DOI 10.1093/jnci/djr393; Wang L, 2013, INT J CANCER, V133, P1419, DOI 10.1002/ijc.28140; Trusolino L, 2010, NAT REV MOL CELL BIO, V11, P834, DOI 10.1038/nrm3012; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; DIRENZO MF, 1995, CLIN CANCER RES, V1, P147; Ghoussoub RAD, 1998, CANCER, V82, P1513, DOI 10.1002/(SICI)1097-0142(19980415)82:8<1513::AID-CNCR13>3.0.CO;2-7; Boccaccio C, 2006, NAT REV CANCER, V6, P637, DOI 10.1038/nrc1912; Yamamoto S, 2013, BREAST CANCER-TOKYO, V20, P262, DOI 10.1007/s12282-012-0332-7; HUMPHREY PA, 1995, AM J PATHOL, V147, P386; Camp RL, 1999, CANCER, V86, P2259, DOI 10.1002/(SICI)1097-0142(19991201)86:11<2259::AID-CNCR13>3.0.CO;2-2; Turner N, 2004, NAT REV CANCER, V4, P814, DOI 10.1038/nrc1452; Minuti G, 2012, BRIT J CANCER, V107, P793, DOI 10.1038/bjc.2012.335; Cronin M, 2007, CLIN CHEM, V53, P1084, DOI 10.1373/clinchem.2006.076497; Boardman LA, 2009, GENOME MED, V1, DOI 10.1186/gm36; Hartzell DD, 2009, BMC GENOMICS, V10, DOI 10.1186/1471-2164-10-497; Hiscox S, 2006, ENDOCR-RELAT CANCER, V13, P1085, DOI 10.1677/erc.1.01270; Huang YB, 2013, CELL BIOSCI, V3, DOI 10.1186/2045-3701-3-16; Maemura M, 1998, CANCER LETT, V126, P215, DOI 10.1016/S0304-3835(98)00014-7; Qiu JL, 2011, J TRANSL MED, V9, DOI 10.1186/1479-5876-9-166; RAILO MJ, 1994, EUR J CANCER, V30A, P307, DOI 10.1016/0959-8049(94)90247-X; Shin AS, 2007, BREAST CANCER RES TR, V105, P55, DOI 10.1007/s10549-006-9427-1; Sierra J Rafael, 2011, Ther Adv Med Oncol, V3, pS21, DOI 10.1177/1758834011422557; Stein U, 2009, CELL CYCLE, V8, P2467, DOI 10.4161/cc.8.15.9018; Van't V., 2002, NATURE, V415, P530, DOI [DOI 10.1038/415530A, 10.1038/415530a]; Zhang RT, 2011, J EXP CLIN CANC RES, V30, DOI 10.1186/1756-9966-30-83	45	0	0	SPANDIDOS PUBL LTD	ATHENS	POB 18179, ATHENS, 116 10, GREECE	1019-6439	1791-2423		INT J ONCOL	Int. J. Oncol.	MAY	2015	46	5					2143	2153		10.3892/ijo.2015.2907		11	Oncology	Oncology	CG3LD	WOS:000353180800031		
J	Fujihara, S; Kato, K; Morishita, A; Iwama, H; Nishioka, T; Chiyo, T; Nishiyama, N; Miyoshi, H; Kobayashi, M; Kobara, H; Mori, H; Okano, K; Suzuki, Y; Masaki, T				Fujihara, Shintaro; Kato, Kiyohito; Morishita, Asahiro; Iwama, Hisakazu; Nishioka, Tomoko; Chiyo, Taiga; Nishiyama, Noriko; Miyoshi, Hisaaki; Kobayashi, Mitsuyoshi; Kobara, Hideki; Mori, Hirohito; Okano, Keiichi; Suzuki, Yasuyuki; Masaki, Tsutomu			Antidiabetic drug metformin inhibits esophageal adenocarcinoma cell proliferation in vitro and in vivo	INTERNATIONAL JOURNAL OF ONCOLOGY			English	Article						esophageal adenocarcinoma; metformin; cell cycle; microRNAs; cyclin D1; epidermal growth factor receptor; angiogenesis	HEPATOCELLULAR-CARCINOMA; GASTRIC-CANCER; BARRETTS-ESOPHAGUS; TISSUE INHIBITOR; GROWTH; EXPRESSION; PROTEINS; METALLOPROTEINASE-1; COMBINATION; BIOMARKER	Esophageal carcinoma is the eighth most common cancer worldwide and the sixth leading cause of cancer-related deaths, with one of the worst prognoses of any form of cancer. Treatment with the anti-diabetic drug metformin has been associated with reduced cancer incidence in patients with type 2 diabetes. This study therefore evaluated the effects of metformin on the proliferation, in vitro and in vivo, of human esophageal adenocarcinoma cells, as well as the microRNAs associated with the antitumor effects of metformin. Metformin inhibited the proliferation of the esophageal adenocarcinoma cell lines OE19, OE33, SK-GT4 and OACM 5.1C, blocking the GO to G1 transition in the cell cycle. This was accompanied by strong reductions in G1 cyclins, especially cyclin D1, cyclin-dependent kinase (Cdk)4, and Cdk6, and decreases in retinoblastoma protein phosphorylation. In addition, metformin reduced the phosphorylation of epidermal growth factor receptor and insulin-like growth factor and insulin-like growth factor-1 receptor, as well as angiogenesis-related proteins, such as vascular endothelial growth factor, tissue inhibitor of metalloproteinases (TIMP)-1, and TIMP-2. Metformin also markedly altered microRNA expression. Treatment with metformin of athymic nude mice bearing xenograft tumors reduced tumor proliferation. These findings suggest that metformin may have clinical use in the treatment of esophageal adenocarcinoma.	[Fujihara, Shintaro; Kato, Kiyohito; Morishita, Asahiro; Nishioka, Tomoko; Chiyo, Taiga; Nishiyama, Noriko; Miyoshi, Hisaaki; Kobayashi, Mitsuyoshi; Kobara, Hideki; Mori, Hirohito; Masaki, Tsutomu] Kagawa Univ, Dept Gastroenterol & Neurol, Fac Med, Miki, Kagawa 7610793, Japan; [Iwama, Hisakazu] Kagawa Univ, Life Sci Resarch Ctr, Fac Med, Miki, Kagawa 7610793, Japan; [Okano, Keiichi; Suzuki, Yasuyuki] Kagawa Univ, Gastroenterol Surg, Fac Med, Miki, Kagawa 7610793, Japan	Masaki, T (reprint author), Kagawa Univ, Dept Gastroenterol & Neurol, Fac Med, Grad Sch Med, 1750-1 Ikenobe, Miki, Kagawa 7610793, Japan.	tmasaki@med.kagawa-u.ac.jp					Masaki T, 2003, HEPATOLOGY, V37, P534, DOI 10.1053/jhep.2003.50112; Landman GWD, 2010, DIABETES CARE, V33, P322, DOI 10.2337/dc09-1380; Liu BL, 2009, CELL CYCLE, V8, P2031, DOI 10.4161/cc.8.13.8814; Kato K, 2012, MOL CANCER THER, V11, P549, DOI 10.1158/1535-7163.MCT-11-0594; Libby G, 2009, DIABETES CARE, V32, P1620, DOI 10.2337/dc08-2175; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Carmeliet P, 2005, ONCOLOGY-BASEL, V69, P4, DOI 10.1159/000088478; Ferlay J, 2010, INT J CANCER, V127, P2893, DOI 10.1002/ijc.25516; Vazquez-Martin A, 2009, CELL CYCLE, V8, P88, DOI 10.4161/cc.8.1.7499; Pennathur A, 2009, ANN THORAC SURG, V87, P1048, DOI 10.1016/j.athoracsur.2008.12.060; Pollak M, 2008, NAT REV CANCER, V8, P915, DOI 10.1038/nrc2536; Han S, 1999, J SURG ONCOL, V71, P147, DOI 10.1002/(SICI)1096-9098(199907)71:3<147::AID-JSO3>3.0.CO;2-5; Pennathur A, 2013, LANCET, V381, P400, DOI 10.1016/S0140-6736(12)60643-6; Chen ML, 2012, CANCER EPIDEM BIOMAR, V21, P1126, DOI 10.1158/1055-9965.EPI-12-0020; Mori M, 2000, INT J CANCER, V88, P575, DOI 10.1002/1097-0215(20001115)88:4<575::AID-IJC9>3.0.CO;2-C; Wang LW, 2008, WORLD J GASTROENTERO, V14, P7192, DOI 10.3748/wjg.14.7192; D'Incalci M, 2003, EUR J CANCER, V39, P1920, DOI 10.1016/S0959-8049(03)00490-8; Liu HS, 2012, CANCER LETT, V316, P196, DOI 10.1016/j.canlet.2011.10.034; Vazquez-Martin A, 2011, CELL CYCLE, V10, P1499, DOI 10.4161/cc.10.9.15423; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Edgren G, 2013, GUT, V62, P1406, DOI 10.1136/gutjnl-2012-302412; Enzinger PC, 2003, NEW ENGL J MED, V349, P2241, DOI 10.1056/NEJMra035010; Vazquez-Martin A, 2009, CLIN TRANSL ONCOL, V11, P455, DOI 10.1007/s12094-009-0384-0; Alimova IN, 2009, CELL CYCLE, V8, P909, DOI 10.4161/cc.8.6.7933; Kourelis TV, 2012, MED ONCOL, V29, P1314, DOI 10.1007/s12032-011-9846-7; Miyoshi H, 2014, INT J ONCOL, V45, P322, DOI 10.3892/ijo.2014.2419; Ben Sahra I, 2008, ONCOGENE, V27, P3576, DOI 10.1038/sj.onc.1211024; Anisimov VN, 2010, CELL CYCLE, V9, P188, DOI 10.4161/cc.9.1.10407; Takeshita N, 2013, BRIT J CANCER, V108, P644, DOI 10.1038/bjc.2013.8; Bird-Lieberman EL, 2009, BRIT J CANCER, V101, P1, DOI 10.1038/sj.bjc.6605126; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1006/abio.1976.9999; Kobayashi M, 2013, INT J ONCOL, V42, P517, DOI 10.3892/ijo.2012.1722; Masaki T, 2005, INT J ONCOL, V26, P661; Aoyagi Keishiro, 2000, Kurume Medical Journal, V47, P199; Falk GW, 2002, GASTROENTEROLOGY, V122, P1569, DOI 10.1053/gast.2002.33427; Franciosi M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071583; Fujihara S, 2012, GASTROENT RES PRACT, DOI 10.1155/2012/483623; Ren M, 2009, ACTA PHARMACOL SIN, V30, P113, DOI 10.1038/aps.2008.8; Solaymani-Dodaran M, 2004, GUT, V53, P1070, DOI 10.1136/gut.2003.028076; Tanaka M, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005532; Zeng ZS, 1995, CLIN CANCER RES, V1, P899; Zhang Y, 2011, EMBO REP, V12, P811, DOI 10.1038/embor.2011.98; Zhou XZ, 1942, NAN FANG YI KE DA XU, V30, P1935	43	3	3	SPANDIDOS PUBL LTD	ATHENS	POB 18179, ATHENS, 116 10, GREECE	1019-6439	1791-2423		INT J ONCOL	Int. J. Oncol.	MAY	2015	46	5					2172	2180		10.3892/ijo.2015.2903		9	Oncology	Oncology	CG3LD	WOS:000353180800034		
J	Kawaguchi, T; Hayakawa, M; Koga, H; Torimura, T				Kawaguchi, Takumi; Hayakawa, Masako; Koga, Hironori; Torimura, Takuji			Effects of fucoidan on proliferation, AMP-activated protein kinase, and downstream metabolism- and cell cycle-associated molecules in poorly differentiated human hepatoma HLF cells	INTERNATIONAL JOURNAL OF ONCOLOGY			English	Article						fucoidan; hepatocellular carcinoma; AMP-activated protein kinase; cyclin D1; acetyl-CoA carboxylase	PROSTATE-CANCER CELLS; HEPATOCELLULAR-CARCINOMA; HEPG2 CELLS; IN-VITRO; APOPTOSIS; METFORMIN; INHIBITION; PATHWAY; GROWTH; TRANSLATION	Survival rates are low in patients with poorly differentiated hepatocellular carcinoma (HCC). Fucoidan, a sulfated polysaccharide derived from brown seaweed, has anticancer activity; however, the effects of fucoidan on poorly differentiated HCC remain unclear. In this study, we investigated the effects of fucoidan on AMP-activated protein kinase (AMPK), a proliferation regulator, and its downstream metabolismand cell cycle-related molecules in a poorly differentiated human hepatoma HLF cell line. HLF cells were treated with fucoidan (10, 50, or 100 mu g/ml; n=4) or phosphate buffered saline (control; n=4) for 96 h. Proliferation was evaluated by counting cells every 24 hrAMPK, TSC2, mTOR, GSK3P, acetyl-CoA carboxylase (ACC), ATP-citrate lyase, p53, cyclin D1, cyclin-dependent kinase (CDK) 4, and CDK6 expression and/or phosphorylation were examined by immunoblotting 24 h after treatment with 100 mu g/ml fucoidan. Cell cycle progression was analyzed by fluorescence-activated cell sorter 48 h after treatment. Treatment with 50 or 100 mu g/ml fucoidan significantly and dose- and time-dependently suppressed HLF cell proliferation (P<0.0001). Fucoidan induced AMPK phosphorylation on 5er172 24 h after treatment. Although no differences were seen in expression and phosphorylation levels of TSC2, mTOR, GSK3 beta, ATP-citrate lyase, and p53 between the control and fucoidan-treated HLF cells, fucoidan induced ACC phosphorylation on Ser79. Moreover, fucoidan decreased cyclin D1, CDK4 and CDK6 expression 24 h after treatment. Furthermore, HLF cells were arrested in the Gl/S phase 48 h after fucoidan treatment. We demonstrated that fucoidan suppressed HLF cell proliferation with AMPK phosphorylation. We showed that fucoidan phosphorylated ACC and downregulated cyclin D1, CDK4 and CDK6 expression. Our findings suggest that fucoidan inhibits proliferation through AMPK-associated suppression of fatty acid synthesis and Gl/S transition in HLF cells.	[Kawaguchi, Takumi; Koga, Hironori; Torimura, Takuji] Kurume Univ, Sch Med, Dept Med, Div Gastroenterol, Kurume, Fukuoka 8300011, Japan; [Kawaguchi, Takumi; Hayakawa, Masako; Koga, Hironori; Torimura, Takuji] Kurume Univ, Liver Canc Div, Res Ctr Innovat Canc Therapy, Kurume, Fukuoka 8300011, Japan	Kawaguchi, T (reprint author), Kurume Univ, Sch Med, Dept Med, Div Gastroenterol, 67 Asahi Machi, Kurume, Fukuoka 8300011, Japan.	takumi@med.kurume-u.ac.jp			Health and Labour Sciences Research Grants for Research on Hepatitis from the Ministry of Health, Labour and Welfare of Japan	This study was supported, in part, by Health and Labour Sciences Research Grants for Research on Hepatitis from the Ministry of Health, Labour and Welfare of Japan.	Fukahori S, 2008, MOL MED REP, V1, P537; Rattan R, 2011, J CELL MOL MED, V15, P166, DOI 10.1111/j.1582-4934.2009.00954.x; Hadad SM, 2014, CLIN TRANSL ONCOL, V16, P746, DOI 10.1007/s12094-013-1144-8; Migita T, 2013, AM J PATHOL, V182, P1800, DOI 10.1016/j.ajpath.2013.01.048; Zhu C, 2013, EVID-BASED COMPL ALT, DOI 10.1155/2013/692549; Chang NW, 2013, J NUTR BIOCHEM, V24, P274, DOI 10.1016/j.jnutbio.2012.06.005; Boo HJ, 2013, MAR DRUGS, V11, P2982, DOI 10.3390/md11082982; Kawaguchi T, 2004, AM J PATHOL, V165, P1499, DOI 10.1016/S0002-9440(10)63408-6; Lacher MD, 2010, ONCOGENE, V29, P6543, DOI 10.1038/onc.2010.393; Hardie DG, 2014, CELL METAB, V20, P939, DOI 10.1016/j.cmet.2014.09.013; Nagamine T, 2009, NUTR CANCER, V61, P340, DOI 10.1080/01635580802567133; Min EY, 2014, INT J ONCOL, V45, P47, DOI 10.3892/ijo.2014.2426; Sikka A, 2012, CELL CYCLE, V11, P1374, DOI [10.4161/cc.19798, 10.4161/cc.11.7.19798]; Park HY, 2014, MOLECULES, V19, P5981, DOI 10.3390/molecules19055981; Matsumoto A, 1997, INT J CANCER, V74, P482, DOI 10.1002/(SICI)1097-0215(19971021)74:5<482::AID-IJC2>3.0.CO;2-#; Selvendiran K, 2006, CANCER RES, V66, P4826, DOI 10.1158/0008-5472.CAN-05-4062; Fitton JH, 2011, MAR DRUGS, V9, P1731, DOI 10.3390/md9101731; Leprivier G, 2013, CELL, V153, P1064, DOI 10.1016/j.cell.2013.04.055; Burroughs A, 2004, LANCET ONCOL, V5, P409, DOI 10.1016/S1470-2045(04)01508-6; Motoshima H, 2006, J PHYSIOL-LONDON, V574, P63, DOI 10.1113/jphysiol.2006.108324; Lin VCH, 2012, J AGR FOOD CHEM, V60, P6399, DOI 10.1021/jf301499e; Yuan HD, 2011, BIOSCI BIOTECH BIOCH, V75, P1079, DOI 10.1271/bbb.100881; Banafa AM, 2013, J HUAZHONG U SCI-MED, V33, P717, DOI 10.1007/s11596-013-1186-8; Cui WT, 2014, LAB INVEST, V94, P382, DOI 10.1038/labinvest.2014.12; Hashimoto O, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-292; Hopkins TA, 2003, BIOCHEM SOC T, V31, P207; Kawaguchi T, 2000, HEPATOLOGY, V31, P1285, DOI 10.1053/jhep.2000.7435; Kim EJ, 2010, BMC GASTROENTEROL, V10, DOI 10.1186/1471-230X-10-96; Kluger MD, 2014, J HEPATOL; Lee H, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050624; Roshan S, 2014, J HUAZHONG U SCI-MED, V34, P330, DOI 10.1007/s11596-014-1278-0; Santra MK, 2009, NATURE, V459, P722, DOI 10.1038/nature08011; Scaglia N, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006812; TANAKA K, 1970, FEBS LETT, V9, P45, DOI 10.1016/0014-5793(70)80307-6; Xue ML, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043483; Yamamoto T, 2004, CLIN CANCER RES, V10, P7884, DOI 10.1158/1078-0432.CCR-04-0794; Zi FM, 2015, CANCER LETT, V356, P443, DOI 10.1016/j.canlet.2014.09.050	37	1	1	SPANDIDOS PUBL LTD	ATHENS	POB 18179, ATHENS, 116 10, GREECE	1019-6439	1791-2423		INT J ONCOL	Int. J. Oncol.	MAY	2015	46	5					2216	2222		10.3892/ijo.2015.2928		7	Oncology	Oncology	CG3LD	WOS:000353180800038		
J	Asakura, T; Yamaguchi, N; Ohkawa, K; Yoshida, K				Asakura, Tadashi; Yamaguchi, Noriko; Ohkawa, Kiyoshi; Yoshida, Kiyotsugu			Proteasome inhibitor-resistant cells cause EMT-induction via suppression of E-cadherin by miR-200 and ZEB1	INTERNATIONAL JOURNAL OF ONCOLOGY			English	Article						proteasome inhibitor; drug resistance; epithelial-mesenchymal transition; E-cadherin; ZEB1; miR-200	EPITHELIAL-MESENCHYMAL TRANSITION; TRANSCRIPTION FACTOR SNAIL; UBIQUITIN SYSTEM; TUMOR INVASION; BREAST-CANCER; 26S PROTEASOME; FEEDBACK LOOP; IN-VIVO; METASTASIS; MICRORNAS	Downregulation of E-cadherin (gene: CDH1) plays an important role in epithelial-mesenchymal transition (EMT), which is critical for normal development and disease states. As a result of long-term treatment of endometrial carcinoma Ishikawa cells with epoxomicin (EXM), the cells exhibited the phenotype for EXM-resistance (Ish/EXM cells). Moreover, CDH1 mRNA and its protein were suppressed and EMT was induced in Ish/EXM cells. Ish/EXM cells exhibited drug-resistance to other proteasome inhibitors, MG-132, PSI and PS-341 (Bortezomib). The proteasome inhibitor-resistant cells acquired invasiveness as a result of the chemotherapy. In Ish/EXM cells, E-cadherin was suppressed by upregulation of its transcriptional repressor ZEB1. Furthermore, expression of the miR-200 family (miR-200a, miR-200b, miR-200c and miR-141) found in Ishikawa cells was suppressed in Ish/EXM cells. Overexpression of the miR-200 family in Ish/EXM cells caused by transfection with the pre-miR-200 family induced downregulation of ZEB1 and enhanced expression of E-cadherin. Conversely, suppression of miR-200 expression in the Ishikawa cells by transfection with anti-miR-200 elevated the expression of ZEB1 and suppressed the expression of E-cadherin. These results suggest that acquirement of EXM-resistance in Ish/EXM cells induces up regulation of ZEB1 via suppression of the miR-200 family following suppression of E-cadherin. Since suppression of ZEB1 in Ish/EXM cells by treatment with its siRNA did not restore the miR-200 family expression, miR-200 family was placed upstream of ZEB1 to regulate the expression.	[Asakura, Tadashi; Yamaguchi, Noriko; Ohkawa, Kiyoshi; Yoshida, Kiyotsugu] Jikei Univ, Sch Med, Dept Biochem, Tokyo 1058461, Japan	Asakura, T (reprint author), Jikei Univ, Sch Med, Dept Biochem, Minato Ku, 3-25-8 Nishishinbashi, Tokyo 1058461, Japan.	tad_asakura@jikei.ac.jp			Jikei University	This study was partly supported by The Jikei University Research Fund.	Adams J, 2002, CURR OPIN ONCOL, V14, P628; Adams J, 2002, CURR OPIN CHEM BIOL, V6, P493, DOI 10.1016/S1367-5931(02)00343-5; Bolos V, 2003, J CELL SCI, V116, P499, DOI 10.1242/jcs.00224; Ma L, 2007, NATURE, V449, P682, DOI 10.1038/nature06174; Wienholds E, 2005, SCIENCE, V309, P310, DOI 10.1126/science.1114519; Zhu SM, 2008, CELL RES, V18, P350, DOI 10.1038/cr.2008.24; Huang QH, 2008, NAT CELL BIOL, V10, P202, DOI 10.1038/ncb1681; Duband JL, 1995, ACTA ANAT, V154, P63; Almond JB, 2002, LEUKEMIA, V16, P433, DOI 10.1038/sj/leu/2402417; Yi R, 2003, GENE DEV, V17, P3011, DOI 10.1101/gad.1158803; Hutvagner G, 2001, SCIENCE, V293, P834, DOI 10.1126/science.1062961; Hideshima T, 2001, CANCER RES, V61, P3071; Meng LH, 1999, P NATL ACAD SCI USA, V96, P10403, DOI 10.1073/pnas.96.18.10403; Gregory PA, 2008, NAT CELL BIOL, V10, P593, DOI 10.1038/ncb1722; Ling YH, 2002, MOL CANCER THER, V1, P841; Johnson SM, 2005, CELL, V120, P635, DOI 10.1016/j.cell.2005.01.014; Ciechanover A, 1998, EMBO J, V17, P7151, DOI 10.1093/emboj/17.24.7151; Akao Y, 2006, BIOL PHARM BULL, V29, P903, DOI 10.1248/bpb.29.903; Korpal M, 2008, J BIOL CHEM, V283, P14910, DOI 10.1074/jbc.C800074200; Asangani IA, 2008, ONCOGENE, V27, P2128, DOI 10.1038/sj.onc.1210856; Burk U, 2008, EMBO REP, V9, P582, DOI 10.1038/embor.2008.74; Takamizawa J, 2004, CANCER RES, V64, P3753, DOI 10.1158/0008-5472.CAN-04-0637; Gregory PA, 2008, CELL CYCLE, V7, P3112, DOI 10.4161/cc.7.20.6851; Christofori G, 1999, TRENDS BIOCHEM SCI, V24, P73, DOI 10.1016/S0968-0004(98)01343-7; Hill L, 2013, INT J CANCER, V132, P745, DOI 10.1002/ijc.27708; Bracken CP, 2008, CANCER RES, V68, P7846, DOI 10.1158/0008-5472.CAN-08-1942; Takeichi M, 1993, CURR OPIN CELL BIOL, V5, P806, DOI 10.1016/0955-0674(93)90029-P; Voorhoeve PM, 2006, CELL, V124, P1169, DOI 10.1016/j.cell.2006.02.037; Peter ME, 2009, CELL CYCLE, V8, P843, DOI 10.4161/cc.8.6.7907; Batlle E, 2000, NAT CELL BIOL, V2, P84, DOI 10.1038/35000034; LeBlanc R, 2002, CANCER RES, V62, P4996; Berx G, 1995, EMBO J, V14, P6107; Naujokat C, 2002, LAB INVEST, V82, P965, DOI 10.1097/01.LAB.0000022226.23741.37; Yang J, 2004, CELL, V117, P927, DOI 10.1016/j.cell.2004.06.006; He L, 2005, NATURE, V435, P828, DOI 10.1038/nature03552; Brabletz S, 2010, EMBO REP, V11, P670, DOI 10.1038/embor.2010.117; Orlowski RZ, 2002, J CLIN ONCOL, V20, P4420, DOI 10.1200/JCO.2002.01.133; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Varshavsky A, 1997, TRENDS BIOCHEM SCI, V22, P383, DOI 10.1016/S0968-0004(97)01122-5; Yanaihara N, 2006, CANCER CELL, V9, P189, DOI 10.1016/j.ccr.2006.01.025; Johnson CD, 2007, CANCER RES, V67, P7713, DOI 10.1158/0008-5472.CAN-07-1083; Voges D, 1999, ANNU REV BIOCHEM, V68, P1015, DOI 10.1146/annurev.biochem.68.1.1015; Smith DM, 2002, MOL MED, V8, P382; Tavazoie SF, 2008, NATURE, V451, P147, DOI 10.1038/nature06487; Korpal M, 2008, RNA BIOL, V5, P115; Berx G, 2007, CLIN EXP METASTAS, V24, P587, DOI 10.1007/s10585-007-9114-6; Cano A, 2008, TRENDS CELL BIOL, V18, P357, DOI 10.1016/j.tcb.2008.05.005; Yi R, 2006, NAT GENET, V38, P356, DOI 10.1038/ng1744; Esquela-Kerscher A, 2006, NAT REV CANCER, V6, P259, DOI 10.1038/nrc1840; Hershko A, 2000, NAT MED, V6, P1073, DOI 10.1038/80384; Perez-Moreno MA, 2001, J BIOL CHEM, V276, P27424, DOI 10.1074/jbc.M100827200; Adams J, 1999, CANCER RES, V59, P2615; Brabletz T, 2001, P NATL ACAD SCI USA, V98, P10356, DOI 10.1073/pnas.171610498; Lee Y, 2003, NATURE, V425, P415, DOI 10.1038/nature01957; Sakamoto KM, 2002, MOL GENET METAB, V77, P44, DOI 10.1016/S1096-7192(02)00146-4; Lee DH, 1998, TRENDS CELL BIOL, V8, P397, DOI 10.1016/S0962-8924(98)01346-4; Cano A, 2000, NAT CELL BIOL, V2, P76, DOI 10.1038/35000025; Savagner P, 2001, BIOESSAYS, V23, P912, DOI 10.1002/bies.1132; Birchmeier W, 1994, BIOCHIM BIOPHYS ACTA, V1198, P11; BUSSEMAKERS MJG, 1994, BIOCHEM BIOPH RES CO, V203, P1291, DOI 10.1006/bbrc.1994.2322; Calin GA, 2002, P NATL ACAD SCI USA, V99, P15524, DOI 10.1073/pnas.242606799; Ciechanover A, 2002, HEPATOLOGY, V35, P3, DOI 10.1053/jhep.2002.30316; Comijn J, 2001, MOL CELL, V7, P1267, DOI 10.1016/S1097-2765(01)00260-X; DVORAK HF, 1986, NEW ENGL J MED, V315, P1650; Fuchs IB, 2002, ANTICANCER RES, V22, P3415; Garber K, 2002, J NATL CANCER I, V94, P550; Hernandez AA, 2002, CURR OPIN CHEM BIOL, V6, P459, DOI 10.1016/S1367-5931(02)00345-9; Huang HN, 2014, STEM CELL RES, V12, P338, DOI 10.1016/j.scr.2013.11.009; Moes M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035440; Ohkawa K, 2004, INT J ONCOL, V24, P425; Park SM, GENES DEV; Shah SA, 2002, SURGERY, V131, P595, DOI 10.1067/msy.2002.121890; Spaderna S, 2007, Verh Dtsch Ges Pathol, V91, P21; Spaderna Simone, 2009, Gastroenterology, V136, P1835, DOI 10.1053/j.gastro.2009.03.009; Viebahn C, 1995, ACTA ANAT, V154, P79; Yu R, 2002, J ENDOCRINOL, V174, P379, DOI 10.1677/joe.0.1740379	76	0	0	SPANDIDOS PUBL LTD	ATHENS	POB 18179, ATHENS, 116 10, GREECE	1019-6439	1791-2423		INT J ONCOL	Int. J. Oncol.	MAY	2015	46	5					2251	2260		10.3892/ijo.2015.2916		10	Oncology	Oncology	CG3LD	WOS:000353180800042		
J	Furushima, R; Katou, K; Shimojima, K; Hosokawa, H; Matsumoto, A				Furushima, R.; Katou, K.; Shimojima, K.; Hosokawa, H.; Matsumoto, A.			Control of WC grain sizes and mechanical properties in WC-FeAl composite fabricated from vacuum sintering technique	INTERNATIONAL JOURNAL OF REFRACTORY METALS & HARD MATERIALS			English	Article						Tungsten carbide; Iron aluminide; Grain growth; Vacuum sintering; Carbide material; Oxygen content	FRACTURE-TOUGHNESS; CO HARDMETALS; TUNGSTEN CARBIDE; CEMENTED CARBIDES; GROWTH INHIBITORS; MICROSTRUCTURE; HARDNESS; CERMETS; ALLOYS; VC	This work addressed on size control of WC grains in WC-FeAl composite fabricated from vacuum sintering techniques. Carbide additives and oxygen were candidates for the size controller of WC grains. The carbide additives such as VC and Cr3C2 suppressed the WC grain growth, which was similar to WC-Co system. As a result, they improved Vickers hardness, but degraded transverse rupture strength. On the other hand, some amount of oxygen included in the composite also suppressed the WC grain growth but improved both the hardness and the strength. It is concluded that oxygen is one of the most effective size controller of WC grains in the WC-FeAl system. (C) 2014 Elsevier Ltd. All rights reserved.	[Furushima, R.; Katou, K.; Shimojima, K.; Hosokawa, H.; Matsumoto, A.] Natl Inst Adv Ind Sci & Technol, Mat Res Inst Sustainable Dev, Moriyama Ku, Nagoya, Aichi 4638560, Japan	Furushima, R (reprint author), Natl Inst Adv Ind Sci & Technol, Mat Res Inst Sustainable Dev, Moriyama Ku, 2266-98 Anagahora, Nagoya, Aichi 4638560, Japan.	ryoichi-furushima@aist.go.jp					Kim BK, 1997, J MATER PROCESS TECH, V63, P317, DOI 10.1016/S0924-0136(96)02748-3; Fang ZZ, 2005, INT J REFRACT MET H, V23, P119, DOI 10.1016/j.ijrmhm.2004.11.005; Sivaprahasam D, 2007, INT J REFRACT MET H, V25, P144, DOI 10.1016/j.ijrmhm.2006.03.008; Jia K, 1998, NANOSTRUCT MATER, V10, P875, DOI 10.1016/S0965-9773(98)00123-8; Huang SG, 2008, MAT SCI ENG A-STRUCT, V475, P87, DOI 10.1016/j.msea.2006.12.145; Fang ZZ, 2009, INT J REFRACT MET H, V27, P288, DOI 10.1016/j.ijrmhm.2008.07.011; Mahmoodan M, 2011, T NONFERR METAL SOC, V21, P1080, DOI 10.1016/S1003-6326(11)60825-X; Huang SG, 2008, INT J REFRACT MET H, V26, P389, DOI 10.1016/j.ijrmhm.2007.09.003; Schubert WD, 1998, INT J REFRACT MET H, V16, P133, DOI 10.1016/S0263-4368(98)00028-6; OQuigley DGF, 1996, MAT SCI ENG A-STRUCT, V209, P228, DOI 10.1016/0921-5093(95)10112-8; Konyashin I, 2009, INT J REFRACT MET H, V27, P234, DOI 10.1016/j.ijrmhm.2008.09.001; PETCH NJ, 1953, J IRON STEEL I, V174, P25; Cardinal S, 2009, INT J REFRACT MET H, V27, P521, DOI 10.1016/j.ijrmhm.2008.10.006; Morton CW, 2005, INT J REFRACT MET H, V23, P287, DOI 10.1016/j.ijrmhm.2005.05.011; Soleimanpour AM, 2012, INT J REFRACT MET H, V31, P141, DOI 10.1016/j.ijrmhm.2011.10.004; IMASATO S, 1995, INT J REFRACT MET H, V13, P305, DOI 10.1016/0263-4368(95)92676-B; SHETTY DK, 1985, J MATER SCI, V20, P1873, DOI 10.1007/BF00555296; Kim HC, 2004, INT J REFRACT MET H, V22, P197, DOI 10.1016/j.ijrmhm.2004.06.006; BHAUMIK SK, 1992, CERAM INT, V18, P327, DOI 10.1016/0272-8842(92)90082-O; Demoly A, 2011, INT J REFRACT MET H, V29, P716, DOI 10.1016/j.ijrmhm.2011.05.007; du Randt D, 2000, INT J MATER PROD TEC, V15, P270; ElEskandarany MS, 1996, METALL MATER TRANS A, V27, P4210; Furushima R, 2014, INT J REFRACT MET H, V42, P42, DOI 10.1016/j.ijrmhm.2013.10.008; Furushima R., 2014, MAT T, V55; GURLAND J, 1955, T AM I MIN MET ENG, V203, P311; Hall H. O., 1951, P PHYS SOC B, V64, P747; Huang SG, 2007, MATER LETT, V61, P574, DOI 10.1016/j.matlet.2006.05.011; Kim BK, 1997, NANOSTRUCT MATER, V9, P233, DOI 10.1016/S0965-9773(97)00061-5; LAUGIER MT, 1989, CERAM INT, V15, P121, DOI 10.1016/0272-8842(89)90024-2; Li N, 2007, RARE METAL MAT ENG, V36, P1763; Lin N, 2012, SCRIPTA MATER, V67, P826, DOI 10.1016/j.scriptamat.2012.07.043; Matsumoto A., 2005, 16 INT PLANS SEM, V2, P287; PICKENS JR, 1978, MATER SCI ENG, V33, P135, DOI 10.1016/0025-5416(78)90164-7; Roebuck B., 1992, International Journal of Refractory & Hard Metals, V11, DOI 10.1016/0263-4368(92)90055-7; Tabor D., 1951, HARDNESS METALS; Underwood E., 1970, QUANTITATIVE STEREOL; Zhang G, 2007, T NONFERR METAL SOC, V17, P1063, DOI 10.1016/S1003-6326(07)60226-X	37	3	3	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0263-4368			INT J REFRACT MET H	Int. J. Refract. Met. Hard Mat.	MAY	2015	50						16	22		10.1016/j.ijrmhm.2014.11.007		7	Materials Science, Multidisciplinary; Metallurgy & Metallurgical Engineering	Materials Science; Metallurgy & Metallurgical Engineering	CF6QI	WOS:000352680800003		
J	Eko, A; Fukunaga, O; Ohtake, N				Eko, Akhmadi; Fukunaga, Osamu; Ohtake, Naoto			High pressure sintering of cubic boron nitride using Co-V-Al alloy as bonding media	INTERNATIONAL JOURNAL OF REFRACTORY METALS & HARD MATERIALS			English	Article						cBN; Polycrystalline cBN; High pressure sintering; Metallic alloy binder		Fine-grained polycrystalline cubic boron nitride compacts were prepared using the mixture of cubic BN and Co-V-Al powders at 5.6 GPa and 1700 degrees C for 0.5 h. The weight percent of Co, V and Al to cubic BN powder was 10 wt.% or 20 wt.%. Results of electron dispersive spectrum were suggested that binder composition was changed from metallic binder of Co and V was dominant to VN and AIN mixture was dominant with increase of atomic percent of Al to BN in the sample. Microstructures of the sintered samples were observed by scanning electron microscope and back scattered electron image. The region of atomic weight ratio of Al to V that was about 1-5 showed homogeneously sintered microstructure of less than 3 pm of cubic BN grain size. The Vickers hardness trend that showed higher values in the region of atomic weight ratio of Al to V was about 1-5. The highest Vickers hardness resulted in the present study was about 40.7 GPa for the 20 wt.% metallic binder that contained a 1.39 atomic weight ratio of Al to V and 0.5-2 pm size of starting cubic BN powder was used. (C) 2015 Elsevier Ltd. All rights reserved.	[Eko, Akhmadi] Mitsubishi Mat Corp, Cent Res Inst, Thin Film Coating Dept, Naka, Ibaraki 3110182, Japan; [Eko, Akhmadi; Ohtake, Naoto] Tokyo Inst Technol, Dept Mech Eng & Sci, Meguro Ku, Tokyo 1528550, Japan; [Fukunaga, Osamu] Tokyo Inst Technol, Chiba 2720142, Japan	Eko, A (reprint author), Mitsubishi Mat Corp, Cent Res Inst, Thin Film Coating Dept, 1002-14 Mukohyama, Naka, Ibaraki 3110182, Japan.	eko@mmc.co.jp					Anker A, 2003, IND DIAMOND REV, P34; Fukunaga O, 1999, DIAM RELAT MATER, V8, P2036, DOI 10.1016/S0925-9635(99)00171-5; Angseryd J, 2009, INT J REFRACT MET H, V27, P249, DOI 10.1016/j.ijrmhm.2008.09.008; Rong XZ, 2002, DIAM RELAT MATER, V11, P280, DOI 10.1016/S0925-9635(01)00692-6; Eko A, 2013, DIAM RELAT MATER, V40, P1, DOI 10.1016/j.diamond.2013.09.002; Eko A, 2013, INT J REFRACT MET H, V41, P73, DOI 10.1016/j.ijrmhm.2013.02.005; Li YJ, 2008, J MATER RES, V23, P2366, DOI 10.1557/JMR.2008.0316; Lv R, 2008, DIAM RELAT MATER, V17, P2062, DOI 10.1016/j.diamond.2008.07.002; McKie A, 2011, CERAM INT, V37, P1, DOI 10.1016/j.ceramint.2010.07.034; Pretorius N, 2006, IND DIAMOND REV, P33; RONG XZ, 1994, ADV MAT 93, V14, P1455; SCHUSTER JC, 1985, J MATER SCI, V20, P2787, DOI 10.1007/BF00553040; Wentorf Jr R. H., 1973, US patent, Patent No. 3743489	13	0	0	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0263-4368			INT J REFRACT MET H	Int. J. Refract. Met. Hard Mat.	MAY	2015	50						178	183		10.1016/j.ijrmhm.2015.01.007		6	Materials Science, Multidisciplinary; Metallurgy & Metallurgical Engineering	Materials Science; Metallurgy & Metallurgical Engineering	CF6QI	WOS:000352680800026		
J	Furushima, R; Katou, K; Shimojima, K; Hosokawa, H; Mikami, M; Matsumoto, A				Furushima, Ryoichi; Katou, Kiyotaka; Shimojima, Koji; Hosokawa, Hiroyuki; Mikami, Masashi; Matsumoto, Akihiro			Changes in constituents and FeAl composition with oxygen content in WC-FeAl composites	INTERNATIONAL JOURNAL OF REFRACTORY METALS & HARD MATERIALS			English	Article						Hard material; Tungsten carbide; Iron aluminide; Oxygen content; Grain growth	CURRENT SINTERING TECHNIQUE; CO HARDMETALS; GRAIN-GROWTH; ALLOYS; MICROSTRUCTURE; INHIBITOR	This paper addressed on the changes in constituents and FeAl compositions by oxidation in WC-FeAl composite one of the alternative materials of WC-Co hard material. Two kinds of WC-FeAl samples having different oxygen contents were obtained by controlling the powder preparation processes. Fe3W3C and various oxides including alpha-Al2O3 were present as semi-products in the sample of higher oxygen content whereas AlFe3C0.5 and slight amount of alpha-Al2O3 were present in the sample of lower oxygen content. The composition of FeAl phases depended on the oxygen content; the ratio of Fe in the FeAl phases was larger in the composite of higher oxygen content. It was found that the oxygen content strongly influenced the constituents and FeAl composition, which linked with WC grain growth in WC-FeAl composites. (C) 2015 Elsevier Ltd. All rights reserved.	[Furushima, Ryoichi; Katou, Kiyotaka; Shimojima, Koji; Hosokawa, Hiroyuki; Mikami, Masashi; Matsumoto, Akihiro] Natl Inst Adv Ind Sci & Technol, Mat Res Inst Sustainable Dev, Moriyama Ku, Nagoya, Aichi 4638560, Japan	Furushima, R (reprint author), Natl Inst Adv Ind Sci & Technol, Mat Res Inst Sustainable Dev, Moriyama Ku, 2266-98 Anagahora, Nagoya, Aichi 4638560, Japan.	ryoichi-furushima@aist.go.jp			Development of Environment-Friendly Nano/Micro-Processing Technology of "Knowledge Hub Aichi" Priority Research Project	This research was partially supported by grant in Development of Environment-Friendly Nano/Micro-Processing Technology of "Knowledge Hub Aichi" Priority Research Project.	Kim BK, 1997, J MATER PROCESS TECH, V63, P317, DOI 10.1016/S0924-0136(96)02748-3; Furushima R, 2015, INT J REFRACT MET H, V50, P16, DOI 10.1016/j.ijrmhm.2014.11.007; Reddy BV, 2000, INTERMETALLICS, V8, P1369, DOI 10.1016/S0966-9795(00)00084-4; Huang SG, 2008, MAT SCI ENG A-STRUCT, V475, P87, DOI 10.1016/j.msea.2006.12.145; Huang SG, 2008, INT J REFRACT MET H, V26, P389, DOI 10.1016/j.ijrmhm.2007.09.003; Huang SG, 2009, INT J REFRACT MET H, V27, P1019, DOI 10.1016/j.ijrmhm.2009.07.019; Konyashin I, 2009, INT J REFRACT MET H, V27, P234, DOI 10.1016/j.ijrmhm.2008.09.001; Morton CW, 2005, INT J REFRACT MET H, V23, P287, DOI 10.1016/j.ijrmhm.2005.05.011; du Randt D, 2000, INT J MATER PROD TEC, V15, P270; Fang Z.Z., 2008, INT J REFRACT MET H, V26, P288; Furushima Ryoichi, 2015, Advanced Materials Research, V1088, DOI 10.4028/www.scientific.net/AMR.1088.115; Furushima R, 2014, MATER TRANS, V55, P1792, DOI 10.2320/matertrans.Y-M2014836; Furushima R, 2014, INT J REFRACT MET H, V42, P42, DOI 10.1016/j.ijrmhm.2013.10.008; GURLAND J, 1955, T AM I MIN MET ENG, V203, P311; Kattner U.R., 1990, BINARY ALLOY PHASE D, P147; Ko SH, 1999, INTERMETALLICS, V7, P947, DOI 10.1016/S0966-9795(99)00002-3; Li N, 2007, RARE METAL MAT ENG, V36, P1763; Matsumoto A, 2013, J PHYS CONF SER, V417, DOI [10.1088/1742-6596/417/1/012067, 10.1088/1742-6596/417/012067]; Matsumoto A., 2010, J JPN SOC POWDER POW, V57, P764, DOI 10.2497/jjspm.57.764; OKI K, 1973, JPN J APPL PHYS, V12, P1522, DOI 10.1143/JJAP.12.1522	20	1	1	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0263-4368			INT J REFRACT MET H	Int. J. Refract. Met. Hard Mat.	MAY	2015	50						298	303		10.1016/j.ijrmhm.2015.02.006		6	Materials Science, Multidisciplinary; Metallurgy & Metallurgical Engineering	Materials Science; Metallurgy & Metallurgical Engineering	CF6QI	WOS:000352680800043		
J	Morimoto, H; Shimada, H				Morimoto, Hiroshi; Shimada, Hironori			The Relationship Between Psychological Distress and Coping Strategies: Their Perceived Acceptability Within a Socio-Cultural Context of Employment, and the Motivation Behind Their Choices	INTERNATIONAL JOURNAL OF STRESS MANAGEMENT			English	Article						coping; motivation for employing coping strategy; organizational culture; psychological distress; sociocultural context	STRESS; CULTURE; SELF; INTENSITY; INVENTORY; BELIEFS; LOSSES; GAINS	The purpose of this study was to examine whether the relationship between psychological distress and coping strategies that consider sociocultural beliefs about coping differs depending on the types of coping strategies and the motivation behind their choice. We considered the sociocultural beliefs about coping to be equivalent to the individual's appraisal of the group's acceptance of their coping strategy (i.e., appraisal of coping acceptability). Japanese employees (n = 737; 536 male and 201 female individuals; mean age 38.8 years, SD = 11.0) of an information technology company participated in the study. The results showed that, regardless of the type of coping strategy (i.e., problem-focused, emotion-focused, or avoidant coping), greater use of coping strategies presumed to be in line with sociocultural beliefs was related to lower psychological distress for task stressors, whereas greater use of problem-focused coping presumed to be in line with sociocultural beliefs was related to lower psychological distress for interpersonal stressors. The motivation for employing the chosen coping strategy was significantly related to psychological distress for task stressors, but not for interpersonal stressors. Although there were some significant interactions between the use of coping strategies, presumed being in line with sociocultural beliefs, and the motivation behind that choice, the interaction effect was small. These results suggest that the motivation for using a chosen coping strategy can affect the effectiveness of coping strategies, independent from the selective use of coping strategies made in consideration of sociocultural beliefs.	[Morimoto, Hiroshi] Hiroshima Int Univ, Fac Psychol Sci, Hiroshima 7392695, Japan; [Shimada, Hironori] Waseda Univ, Fac Human Sci, Tokyo, Japan	Morimoto, H (reprint author), Hiroshima Int Univ, Fac Psychol Sci, 555-36 Kurose Gakuendai, Hiroshima 7392695, Japan.	morimoto@he.hirokoku-u.ac.jp					Aiken L. S., 1991, MULTIPLE REGRESSION; Aldwin C M, 1994, STRESS COPING DEV IN; MARKUS HR, 1991, PSYCHOL REV, V98, P224, DOI 10.1037/0033-295X.98.2.224; [Anonymous], 1997, PL S STRESS; HOFSTEDE G, 1990, ADMIN SCI QUART, V35, P286, DOI 10.2307/2393392; SLAVIN LA, 1991, J COUNS DEV, V70, P156; Morimoto H, 2013, INT J STRESS MANAGE, V20, P1, DOI 10.1037/a0031432; Higgins ET, 1997, AM PSYCHOL, V52, P1280, DOI 10.1037/0003-066X.52.12.1280; Cheng C, 2001, J PERS SOC PSYCHOL, V80, P814, DOI 10.1037//3415.80.5.814; HWANG KK, 1979, ACTA PSYCHOL TAIWAN, V21, P117; AJZEN I, 1991, ORGAN BEHAV HUM DEC, V50, P179, DOI 10.1016/0749-5978(91)90020-T; Idson LC, 2000, J EXP SOC PSYCHOL, V36, P252, DOI 10.1006/jesp.1999.1402; SCHEIN EH, 1990, AM PSYCHOL, V45, P109, DOI 10.1037//0003-066X.45.2.109; Chan D, 1998, J APPL PSYCHOL, V83, P234, DOI 10.1037/0021-9010.83.2.234; STONE AA, 1991, J PERS SOC PSYCHOL, V61, P648, DOI 10.1037//0022-3514.61.4.648; Cavanaugh MA, 2000, J APPL PSYCHOL, V85, P65, DOI 10.1037/0021-9010.85.1.65; Morimoto H, 2014, INT J BEHAV MED, V21, P447, DOI 10.1007/s12529-013-9320-3; VITALIANO PP, 1987, J BEHAV MED, V10, P1, DOI 10.1007/BF00845124; Skinner EA, 2003, PSYCHOL BULL, V129, P216, DOI 10.1037/0033-2909.129.2.216; Zou X, 2009, J PERS SOC PSYCHOL, V97, P579, DOI 10.1037/a0016399; TOBIN DL, 1989, COGNITIVE THER RES, V13, P343, DOI 10.1007/BF01173478; JAMES LR, 1984, J APPL PSYCHOL, V69, P85, DOI 10.1037/0021-9010.69.1.85; Bond F. W., 2009, PRELIMINARY PS UNPUB; CARVER CS, 1989, J PERS SOC PSYCHOL, V56, P267, DOI 10.1037//0022-3514.56.2.267; Cohen J., 1988, STAT POWER ANAL BEHA; Coyne JC, 1994, J FAMILY PSYCHOL, V8, P43, DOI DOI 10.1037/0893-3200.8.1.43; Edwards R. D., 2014, INT J STRESS MANAGE, V21, P162; Folkman S., 1984, STRESS APPRAISAL COP; GLICK WH, 1985, ACAD MANAGE REV, V10, P601, DOI 10.2307/258140; Hashimoto H., 2011, JAPANESE J EXPT SOCI, V50, P182, DOI DOI 10.2130/JJESP.50.182; Hayes S. C., 2004, MINDFULNESS ACCEPTAN; Hofstede G. H., 1980, CULTURES CONSEQUENCE; Kamimura E, 1995, B COUNSELING SCH PSY, V33, P41; Kato T, 2000, JPN J EDUC PSYCHOL, V48, P225; Kato T., 2002, JAPANESE J EXPT SOCI, V41, P147; Kishita N., 2008, P ANN M JAP ASS HLTH, V21, P46; Liberman N, 2005, J EXP SOC PSYCHOL, V41, P527, DOI 10.1016/j.jesp.2004.06.007; Ministry of Health Labour and Welfare, 2008, SURV STAT EMPL HLTH; Billings A G, 1981, J Behav Med, V4, P139, DOI 10.1007/BF00844267; Morimoto H., 2011, STRESS SCI RES, V26, P33; Morimoto H., 2010, JOB STRESS RES, V17, P119; Morimoto H., 2012, JAPANESE J BEHAV MED, V18, P3; Obrist P, 1981, CARDIOVASCULAR PSYCH; Rousseau D., 1990, ORG CLIMATE CULTURE, P153; Sakata K., 2006, JAPANESE ASS IND ORG, V19, P13; Shimazu A, 2007, J BEHAV MED, V30, P423, DOI 10.1007/s10865-007-9109-4; Shimomitsu T., 1998, REPORT RES GRANT PRE, P107; Shoji K, 2010, PERS INDIV DIFFER, V48, P270, DOI 10.1016/j.paid.2009.10.009; Suzuki S., 2004, JAPANESE J PSYCHOL, V74, P504; Suzuki S., 1998, JAPANESE J HLTH PSYC, V11, P15; Suzuki S., 2006, JAPANESE J PSYCHOL, V76, P527	51	1	1	AMER PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA	1072-5245	1573-3424		INT J STRESS MANAGE	Int. J. Stress Manage.	MAY	2015	22	2					159	182		10.1037/a0038484		24	Psychology, Applied	Psychology	CG3EW	WOS:000353161900003		
J	Andersson, F; Morimoto, Y; Wittsten, J				Andersson, Fredrik; Morimoto, Yoshinori; Wittsten, Jens			A variational formulation for interpolation of seismic traces with derivative information	INVERSE PROBLEMS			English	Article						interpolation; seismology; anisotropic diffusion	DATA RECONSTRUCTION; EDGE-DETECTION; DIFFUSION; REGULARIZATION; FRAMEWORK; PDES	We construct a variational formulation for the problem of interpolating seismic data in the case of missing traces. We assume that we have derivative information available at the traces. The variational problem is essentially the minimization of the integral over the smallest eigenvalue of the structure tensor associated with the interpolated data. This has the physical meaning of penalizing the local presence of more than one direction in the interpolation. The variational problem is used to justify the solutions of a non-standard anisotropic diffusion problem as reasonable interpolated images. We show existence and uniqueness for this type of anisotropic diffusion. In particular, the uniqueness property is important as it guarantees that the solution can be obtained by the numerical schemes we propose.	[Andersson, Fredrik] Lund Univ, Ctr Math Sci, SE-22100 Lund, Sweden; [Morimoto, Yoshinori; Wittsten, Jens] Kyoto Univ, Grad Sch Human & Environm Studies, Kyoto 6068501, Japan	Andersson, F (reprint author), Lund Univ, Ctr Math Sci, POB 118, SE-22100 Lund, Sweden.	fa@maths.lth.se; morimoto@math.h.kyoto-u.ac.jp; jensw@maths.lth.se			Swedish Research Council [2011-5589]; JSPS Kakenhi Grant, Japan Society for the Promotion of Science [24-02782]	The research of Fredrik Andersson was supported in part by the Swedish Research Council, Grant No. 2011-5589. The research of Yoshinori Morimoto and Jens Wittsten was supported in part by JSPS Kakenhi Grant No. 24-02782, Japan Society for the Promotion of Science. The authors thank Erik Wahlen and Glen Wheeler for helpful discussions and suggestions.	Abma R, 2006, GEOPHYSICS, V71, P91; Adams R.A., 2003, SOBOLEV SPACES PURE, V140; AMUNDSEN L, 1993, GEOPHYSICS, V58, P1335, DOI 10.1190/1.1443516; Weickert J, 1999, INT J COMPUT VISION, V31, P111, DOI 10.1023/A:1008009714131; Tschumperle D, 2005, IEEE T PATTERN ANAL, V27, P506, DOI 10.1109/TPAMI.2005.87; Parker GJM, 2000, J MAGN RESON IMAGING, V11, P702, DOI 10.1002/1522-2586(200006)11:6<702::AID-JMRI18>3.0.CO;2-A; Ruzhansky M, 2010, J FOURIER ANAL APPL, V16, P943, DOI 10.1007/s00041-009-9117-6; Liu B, 2004, GEOPHYSICS, V69, P1560, DOI 10.1190/1.1836829; Sacchi MD, 2005, GEOPHYS PROSPECT, V53, P787, DOI 10.1111/j.1365-2478.2005.00503.x; Andersson F, 2012, J FOURIER ANAL APPL, V18, P146, DOI 10.1007/s00041-011-9192-3; Weickert J, 2001, INT J COMPUT VISION, V45, P245, DOI 10.1023/A:1013614317973; PERONA P, 1990, IEEE T PATTERN ANAL, V12, P629, DOI 10.1109/34.56205; Lewis AS, 1996, MATH OPER RES, V21, P576, DOI 10.1287/moor.21.3.576; KASS M, 1987, COMPUT VISION GRAPH, V37, P362, DOI 10.1016/0734-189X(87)90043-0; Fomel S, 2003, GEOPHYSICS, V68, P733, DOI 10.1190/1.1567243; Brox T, 2006, IMAGE VISION COMPUT, V24, P41, DOI 10.1016/j.imavis.2005.09.010; Amundsen L, 2001, GEOPHYSICS, V66, P327, DOI 10.1190/1.2245468; Morimoto Y, 2009, DISCRETE CONT DYN S, V24, P187, DOI 10.3934/dcds.2009.24.187; CATTE F, 1992, SIAM J NUMER ANAL, V29, P182; Kreimer N, 2013, GEOPHYSICS, V78, pV273, DOI 10.1190/GEO2013-0022.1; SPITZ S, 1991, GEOPHYSICS, V56, P785, DOI 10.1190/1.1443096; Aravkin A, 2014, SIAM J SCI COMPUT, V36, P237; BIGUN J, 1991, IEEE T PATTERN ANAL, V13, P775, DOI 10.1109/34.85668; Bigun J., 1987, Proceedings of the First International Conference on Computer Vision (Cat. No.87CH2465-3); Brezis H., 1983, ANAL FONCTIONELLE; Bunting T, 2013, 13 INT C BRAZ GEOPH, P1177; Carlson D, 2008, 70 EAGE C EXH; Chiu S K, 2014, GEOPHYSICS, V79, P191; Forstner W., 1986, INT ARCH PHOTOGRAMME, V26, P150; Friedman A., 1964, PARTIAL DIFFERENTIAL; Gao J, 2013, GEOPHYSICS, V78, P21; Gao JJ, 2010, APPL GEOPHYS, V7, P229, DOI 10.1007/s11770-010-0246-5; GERIG G, 1992, IEEE T MED IMAGING, V11, P221, DOI 10.1109/42.141646; Hahn J, 2009, J MATH IMAGING VIS, V34, P137, DOI 10.1007/s10851-009-0138-1; Hormander L, 1985, PSEUDODIFFERENTIAL O; KOTHE U, 2003, PATTERN RECOGN, V2781, P25, DOI 10.1007/978-3-540-45243-0_4; Kreimer N, 2012, GEOPHYSICS, V77, P113; Lions J.-L., 1968, PROBLEMES LIMITES NO, V1; Ozbek A, 2010, GEOPHYSICS, V75; Ramirez A C, 2009, GEOPHYSICS, V74, P35; Rao A. R., 1990, COMPUTING ORIENTED T; Ruzhansky M., 2010, THEORY APPL, V2; Stanton A, 2013, GEOPHYSICS, V78, P131; Stanton A, 2011, POCS 2011 SEG ANN M; Stanton A, 2012, TECHNICAL PROGRAM EX; Struwe M., 2000, VARIATIONAL METHODS; Tenghamn R, 2008, 70 EAGE C EXH; Tschumperle D, 2002, INT J COMPUT VISION, V50, P237, DOI 10.1023/A:1020870207168; van den Berg E, 2007, TR200720 U BRIT COL; Vassallo M, 2010, CROSSLINE WAVEFIELD; Vassallo M, 2011, 73 EAGE C EXH; Weickert J., 1998, ANISOTROPIC DIFFUSIO; Weickert J, 2002, CONT MATH, V313, P251; Weickert J, 2006, Visualization and Processing of Tensor Fields, P315, DOI 10.1007/3-540-31272-2_19	54	0	0	IOP PUBLISHING LTD	BRISTOL	TEMPLE CIRCUS, TEMPLE WAY, BRISTOL BS1 6BE, ENGLAND	0266-5611	1361-6420		INVERSE PROBL	Inverse Probl.	MAY	2015	31	5							055002	10.1088/0266-5611/31/5/055002		32	Mathematics, Applied; Physics, Mathematical	Mathematics; Physics	CG8HM	WOS:000353548000002		
J	Kojima, H; Ogura, Y; Yamamoto, N; Togashi, T; Mori, H; Watanabe, T; Nemoto, F; Kurokawa, K; Hayashi, T; Fukui, M				Kojima, Hisaya; Ogura, Yoshitoshi; Yamamoto, Nozomi; Togashi, Tomoaki; Mori, Hiroshi; Watanabe, Tomohiro; Nemoto, Fumiko; Kurokawa, Ken; Hayashi, Tetsuya; Fukui, Manabu			Ecophysiology of Thioploca ingrica as revealed by the complete genome sequence supplemented with proteomic evidence	ISME Journal			English	Article							BACTERIUM ALLOCHROMATIUM-VINOSUM; SULFUR-OXIDIZING BACTERIA; FRESH-WATER BEGGIATOA; DRAFT GENOME; MAXIMUM-LIKELIHOOD; MARINE BEGGIATOA; LAKE BIWA; RNA GENES; OXIDATION; SEDIMENTS	Large sulfur-oxidizing bacteria, which accumulate a high concentration of nitrate, are important constituents of aquatic sediment ecosystems. No representative of this group has been isolated in pure culture, and only fragmented draft genome sequences are available for these microorganisms. In this study, we successfully reconstituted the genome of Thioploca ingrica from metagenomic sequences, thereby generating the first complete genome sequence from this group. The Thioploca samples for the metagenomic analysis were obtained from a freshwater lake in Japan. A PCR-free paired-end library was constructed from the DNA extracted from the samples and was sequenced on the Illumina MiSeq platform. By closing gaps within and between the scaffolds, we obtained a circular chromosome and a plasmid-like element. The reconstituted chromosome was 4.8Mbp in length with a 41.2% GC content. A sulfur oxidation pathway identical to that suggested for the closest relatives of Thioploca was deduced from the reconstituted genome. A full set of genes required for respiratory nitrate reduction to dinitrogen gas was also identified. We further performed a proteomic analysis of the Thioploca sample and detected many enzymes/proteins involved in sulfur oxidation, nitrate respiration and inorganic carbon fixation as major components of the protein extracts from the sample, suggesting that these metabolic activities are strongly associated with the physiology of Thioploca ingrica in lake sediment.	[Kojima, Hisaya; Watanabe, Tomohiro; Nemoto, Fumiko; Fukui, Manabu] Hokkaido Univ, Inst Low Temp Sci, Sapporo, Hokkaido 0600819, Japan; [Ogura, Yoshitoshi; Hayashi, Tetsuya] Miyazaki Univ, Frontier Sci Res Ctr, Dept Genom & Bioenvironm Sci, Div Microbial Genom, Miyazaki, Japan; [Ogura, Yoshitoshi; Hayashi, Tetsuya] Miyazaki Univ, Fac Med, Dept Infect Dis, Div Microbiol, Miyazaki, Japan; [Yamamoto, Nozomi; Kurokawa, Ken] Tokyo Inst Technol, Earth Life Sci Inst, Tokyo 152, Japan; [Togashi, Tomoaki; Mori, Hiroshi; Kurokawa, Ken] Tokyo Inst Technol, Grad Sch Biosci & Biotechnol, Dept Biol Informat, Tokyo 152, Japan	Kojima, H (reprint author), Hokkaido Univ, Inst Low Temp Sci, Kita Ku, Kita 19,Nishi 8, Sapporo, Hokkaido 0600819, Japan.	kojimah@pop.lowtem.hokudai.ac.jp; my-fukui@pop.lowtem.hokudai.ac.jp			KAKENHI for Innovative Areas 'Genome Science' from Ministry of Education, Culture, Sports, Science and Technology (MEXT) of Japan [221S0002]; JSPS KAKENHI Grant [22370005]	This work was supported by a KAKENHI for Innovative Areas 'Genome Science' (No. 221S0002) from the Ministry of Education, Culture, Sports, Science and Technology (MEXT) of Japan. This study was also supported by JSPS KAKENHI Grant Number 22370005.	Jewell T, 2008, APPL ENVIRON MICROB, V74, P5575, DOI 10.1128/AEM.00379-08; Dahl C, 2013, MICROBIOL-SGM, V159, P2626, DOI 10.1099/mic.0.071019-0; Schulz HN, 2005, SCIENCE, V307, P416, DOI 10.1126/science.1103096; Brock J, 2012, ANTON LEEUW INT J G, V101, P347, DOI 10.1007/s10482-011-9640-8; Li H, 2009, BIOINFORMATICS, V25, P1754, DOI 10.1093/bioinformatics/btp324; Ishihama Y, 2005, MOL CELL PROTEOMICS, V4, P1265, DOI 10.1074/mcp.M500061-MCP200; Salman V, 2013, ANTON LEEUW INT J G, V104, P169, DOI 10.1007/s10482-013-9952-y; Hogslund S, 2010, FEMS MICROBIOL ECOL, V73, P110, DOI 10.1111/j.1574-6941.2010.00878.x; Kappler U, 2013, CELL MOL LIFE SCI, V70, P977, DOI 10.1007/s00018-012-1098-y; Kanehisa M, 2014, NUCLEIC ACIDS RES, V42, pD199, DOI 10.1093/nar/gkt1076; Whelan S, 2001, MOL BIOL EVOL, V18, P691; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Lagesen K, 2007, NUCLEIC ACIDS RES, V35, P3100, DOI 10.1093/nar/gkm160; Brock J, 2011, ISME J, V5, P497, DOI 10.1038/ismej.2010.135; Kajitani R, 2014, GENOME RES, V24, P1384, DOI 10.1101/gr.170720.113; Friedrich CG, 2001, APPL ENVIRON MICROB, V67, P2873, DOI 10.1128/AEM.67.7.2873-2882.2001; Kappler U, 2000, J BIOL CHEM, V275, P13202, DOI 10.1074/jbc.275.18.13202; Lowe TM, 1997, NUCLEIC ACIDS RES, V25, P955, DOI 10.1093/nar/25.5.955; McKay LJ, 2012, DEEP-SEA RES PT I, V67, P21, DOI 10.1016/j.dsr.2012.04.011; Noguchi H, 2008, DNA RES, V15, P387, DOI 10.1093/dnares/dsn027; Pott AS, 1998, MICROBIOL-SGM, V144, P1881; Prokopenko MG, 2013, NATURE, V500, P194, DOI 10.1038/nature12365; McHatton SC, 1996, APPL ENVIRON MICROB, V62, P954; Hensen D, 2006, MOL MICROBIOL, V62, P794, DOI 10.1111/j.1365-2958.2006.05408.x; Salman V, 2011, SYST APPL MICROBIOL, V34, P243, DOI 10.1016/j.syapm.2011.02.001; Raes J, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-1-r10; MacGregor BJ, 2013, APPL ENVIRON MICROB, V79, P3974, DOI 10.1128/AEM.03821-12; Katoh K, 2013, MOL BIOL EVOL, V30, P772, DOI 10.1093/molbev/mst010; Kappler U, 2005, J BIOL CHEM, V280, P24999, DOI 10.1074/jbc.M503237200; Li L, 2003, GENOME RES, V13, P2178, DOI 10.1101/gr.1224503; MacGregor BJ, 2013, MAR GENOM, V11, P53, DOI [10.1016/j.margen.2013.08.001, 10.1016/j.margen2013.08.001]; Tamura K, 2011, MOL BIOL EVOL, V28, P2731, DOI 10.1093/molbev/msr121; Beutler M, 2012, ENVIRON MICROBIOL, V14, P2911, DOI 10.1111/j.1462-2920.2012.02851.x; Dermott R, 2002, J GREAT LAKES RES, V28, P688; Kojima H, 2006, MICROB ECOL, V52, P765, DOI 10.1007/s00248-006-9127-8; Kojima H, 2003, APPL ENVIRON MICROB, V69, P390, DOI 10.1128/AEM.69.1.390-398.2003; Kojima H, 2007, FEMS MICROBIOL ECOL, V59, P23, DOI 10.1111/j.1574-6941.2006.00201.x; Lauterborn R., 1907, BER DEUT BOT GES, V25, P238; Lenk S, 2012, ISME J, V6, P2178, DOI 10.1038/ismej.2012.66; LUCHT JM, 1994, FEMS MICROBIOL REV, V14, P3, DOI 10.1016/0168-6445(94)90008-6; MAIER S, 1965, CAN J MICROBIOL, V11, P645; MAIER S, 1984, INT J SYST BACTERIOL, V34, P344; Mumann M., 2007, PLOS BIOL, V5, P1923, DOI DOI 10.1371/J0URNAL.PBI0.0050230; NELSON DC, 1982, ARCH MICROBIOL, V133, P172, DOI 10.1007/BF00414997; Nemoto F, 2012, AQUAT MICROB ECOL, V66, P295, DOI 10.3354/ame01578; Nemoto F, 2011, MICROB ECOL, V62, P753, DOI 10.1007/s00248-011-9916-6; Nishino M, 1998, WATER RES, V32, P953, DOI 10.1016/S0043-1354(97)00227-3; Sleator R. D., 2001, FEMS MICROBIOL REV, V1, P49; Watanabe T, 2012, APPL ENVIRON MICROB, V78, P6545, DOI 10.1128/AEM.01349-12; Winkel M, 2013, ENVIRON MICROBIOL, V16, P1612; Wislouch SM., 1912, BER DEUT BOT GES, V30, P470; Zemskaya TI, 2009, MICROBIOLOGY+, V78, P117, DOI 10.1134/S0026261709010159; Zemskaya TI, 2001, MICROBIOLOGY+, V70, P335, DOI 10.1023/A:1010463613498; Zopfi J, 2001, APPL ENVIRON MICROB, V67, P5530, DOI 10.1128/AEM.67.12.5530-5537.2001	54	1	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1751-7362	1751-7370		ISME J	ISME J.	MAY	2015	9	5					1166	1176		10.1038/ismej.2014.209		11	Ecology; Microbiology	Environmental Sciences & Ecology; Microbiology	CG5SH	WOS:000353354100010		
J	Schmeller, DS; Julliard, R; Bellingham, PJ; Bohm, M; Brummitt, N; Chiarucci, A; Couvet, D; Elmendorf, S; Forsyth, DM; Moreno, JG; Gregory, RD; Magnusson, WE; Martin, LJ; McGeoch, MA; Mihoub, JB; Pereira, HM; Proenca, V; van Swaay, CAM; Yahara, T; Belnap, J				Schmeller, Dirk S.; Julliard, Romain; Bellingham, Peter J.; Boehm, Monika; Brummitt, Neil; Chiarucci, Alessandro; Couvet, Denis; Elmendorf, Sarah; Forsyth, David M.; Moreno, Jaime Garcia; Gregory, Richard D.; Magnusson, William E.; Martin, Laura J.; McGeoch, Melodie A.; Mihoub, Jean-Baptiste; Pereira, Henrique M.; Proenca, Vania; van Swaay, Chris A. M.; Yahara, Tetsukazu; Belnap, Jayne			Towards a global terrestrial species monitoring program	JOURNAL FOR NATURE CONSERVATION			English	Review						Convention on Biological Diversity; Essential Biodiversity Variable; Group of Earth Observation Biodiversity; Observation Network; GEO System of Systems	MULTIPLE POLITICAL JURISDICTIONS; L-BAND SAR; CONSERVATION PRIORITIES; BIODIVERSITY RESEARCH; POPULATION TRENDS; AERIAL VEHICLES; CLIMATE-CHANGE; CAMERA TRAPS; RANGE SHIFTS; LARGE-SCALE	The Convention on Biological Diversity's strategic plan lays out five goals: "(A) address the underlying causes of biodiversity loss by mainstreaming biodiversity across government and society; (B) reduce the direct pressures on biodiversity and promote sustainable use; (C) improve the status of biodiversity by safeguarding ecosystems, species and genetic diversity; (D) enhance the benefits to all from biodiversity and ecosystem services; (E) enhance implementation through participatory planning, knowledge management and capacity building." To meet and inform on the progress towards these goals, a globally coordinated approach is needed for biodiversity monitoring that is linked to environmental data and covers all biogeographic regions. During a series of workshops and expert discussions, we identified nine requirements that we believe are necessary for developing and implementing such a global terrestrial species monitoring program. The program needs to design and implement an integrated information chain from monitoring to policy reporting, to create and implement minimal data standards and common monitoring protocols to be able to inform Essential Biodiversity Variables (EBVs), and to develop and optimize semantics and ontologies for data interoperability and modelling. In order to achieve this, the program needs to coordinate diverse but complementary local nodes and partnerships. In addition, capacities need to be built for technical tasks, and new monitoring technologies need to be integrated. Finally, a global monitoring program needs to facilitate and secure funding for the collection of long-term data and to detect and fill gaps in under-observed regions and taxa. The accomplishment of these nine requirements is essential in order to ensure data is comprehensive, to develop robust models, and to monitor biodiversity trends over large scales. A global terrestrial species monitoring program will enable researchers and policymakers to better understand the status and trends of biodiversity. (C) 2015 Elsevier GmbH. All rights reserved.	[Schmeller, Dirk S.; Mihoub, Jean-Baptiste] UFZ Helmholtz Ctr Environm Res, Dept Conservat Biol, D-04318 Leipzig, Germany; [Schmeller, Dirk S.] Univ Toulouse, UPS, INPT, EcoLab,Lab Ecol Fonct & Environn, F-31062 Toulouse, France; [Schmeller, Dirk S.] CNRS, EcoLab, F-31062 Toulouse, France; [Julliard, Romain; Couvet, Denis] Univ Paris 06, CNRS, Museum Natl Hist Nat, CESCO, F-75005 Paris, France; [Bellingham, Peter J.] Landcare Res, Lincoln 7640, New Zealand; [Boehm, Monika] Zool Soc London, Inst Zool, London NW1 4RY, England; [Brummitt, Neil] Nat Hist Museum, Dept Life Sci, London SW7 5BD, England; [Chiarucci, Alessandro] Alma Mater Studiorum Univ Bologna, Dept Biol Geol & Environm Sci, I-40126 Bologna, Italy; [Elmendorf, Sarah] Natl Ecol Observ Network, Boulder, CO 80301 USA; [Forsyth, David M.] Arthur Rylah Inst Environm Res, Dept Environm & Primary Ind, Heidelberg, Vic 2084, Australia; [Forsyth, David M.] Univ Melbourne, Dept Zool, Melbourne, Vic 3000, Australia; [Gregory, Richard D.] Royal Soc Protect Birds, Ctr Conservat Sci, Sandy SG19 2DL, Beds, England; [Magnusson, William E.] Inst Nacl de Pesquisas da Amazonia, BR-69080971 Manaus, AM, Brazil; [Martin, Laura J.] Cornell Univ, Dept Nat Resources, Ithaca, NY 14853 USA; [McGeoch, Melodie A.] Monash Univ, Sch Biol Sci, Clayton, Vic 3800, Australia; [Pereira, Henrique M.] German Ctr Integrat Biodivers Res iDiv, D-04103 Leipzig, Germany; [Pereira, Henrique M.] Univ Halle Wittenberg, Inst Biol, D-06108 Halle, Germany; [Proenca, Vania] Univ Lisbon, Ctr Innovat Technol & Policy Res, ACAE DEM, Inst Super Tecn,IN, P-1049001 Lisbon, Portugal; [van Swaay, Chris A. M.] Dutch Butterfly Conservat, NL-6700 AM Wageningen, Netherlands; [van Swaay, Chris A. M.] Butterfly Conservat Europe, NL-6700 AM Wageningen, Netherlands; [Yahara, Tetsukazu] Kyushu Univ, Dept Biol, Fukuoka 8128581, Japan; [Belnap, Jayne] US Geol Survey, Southwest Biol Sci Ctr, Moab, UT 84532 USA	Schmeller, DS (reprint author), UFZ Helmholtz Ctr Environm Res, Dept Conservat Biol, Permoserstr 15, D-04318 Leipzig, Germany.	ds@die-schmellers.de	Proenca, Vania/H-9372-2013; Schmeller, Dirk/F-4324-2010; Pereira, Henrique/B-3975-2009; Chiarucci, Alessandro/D-2622-2009; McGeoch, Melodie/F-8353-2011	Proenca, Vania/0000-0001-8245-357X; Schmeller, Dirk/0000-0002-3860-9933; Pereira, Henrique/0000-0003-1043-1675; Chiarucci, Alessandro/0000-0003-1160-235X; McGeoch, Melodie/0000-0003-3388-2241			Aizpurua O., 2015, ECOGRAPHY; Allen RB, 2003, NEW ZEAL J ECOL, V27, P207; Lucas RM, 2007, AQUAT CONSERV, V17, P245, DOI 10.1002/aqc.833; Anderson K, 2013, FRONT ECOL ENVIRON, V11, P138, DOI 10.1890/120150; Pereira HM, 2010, SCIENCE, V330, P1496, DOI 10.1126/science.1196624; Chen IC, 2011, SCIENCE, V333, P1024, DOI 10.1126/science.1206432; Lindenmayer DB, 1996, CONSERV BIOL, V10, P235, DOI 10.1046/j.1523-1739.1996.10010235.x; Butchart SHM, 2010, SCIENCE, V328, P1164, DOI 10.1126/science.1187512; Gilman SE, 2010, TRENDS ECOL EVOL, V25, P325, DOI 10.1016/j.tree.2010.03.002; Koh LP, 2012, TROP CONSERV SCI, V5, P121; Schmeller DS, 2012, NAT CONSERV-BULGARIA, P41, DOI 10.3897/natureconservation.2.3644; Wilson KA, 2006, NATURE, V440, P337, DOI 10.1038/nature04366; Schmeller DS, 2014, J NAT CONSERV, V22, P349, DOI 10.1016/j.jnc.2014.03.002; Christian E, 2005, SPACE POLICY, V21, P105, DOI 10.1016/j.spacepol.2005.03.002; Collen B, 2011, PHILOS T R SOC B, V366, P2577, DOI 10.1098/rstb.2011.0015; COLWELL RK, 1994, PHILOS T ROY SOC B, V345, P101, DOI 10.1098/rstb.1994.0091; MacKenzie DI, 2002, ECOLOGY, V83, P2248, DOI 10.2307/3072056; Hampton SE, 2013, FRONT ECOL ENVIRON, V11, P156, DOI 10.1890/120103; Targetti S, 2014, ECOL INDIC, V45, P434, DOI 10.1016/j.ecolind.2014.04.050; Sutherland WJ, 2006, J APPL ECOL, V43, P599, DOI 10.1111/j.1365-2664.2006.01182.x; Jurgens N, 2012, ENVIRON MONIT ASSESS, V184, P655, DOI 10.1007/s10661-011-1993-y; Julliard R, 2006, ECOL LETT, V9, P1237, DOI 10.1111/j.1461-0248.2006.00977.x; Gregory RD, 2010, ORNITHOL SCI, V9, P3, DOI 10.2326/osj.9.3; van Strien AJ, 2013, J APPL ECOL, V50, P1450, DOI 10.1111/1365-2664.12158; Lenoir J, 2010, ECOGRAPHY, V33, P295, DOI 10.1111/j.1600-0587.2010.06279.x; Balmford A, 2005, PHILOS T ROY SOC B, V360, P221, DOI 10.1098/rstb.2004.1599; Bird TJ, 2014, BIOL CONSERV, V173, P144, DOI 10.1016/j.biocon.2013.07.037; Collen B, 2008, TROP CONSERV SCI, V1, P75; Schmeller DS, 2009, CONSERV BIOL, V23, P307, DOI 10.1111/j.1523-1739.2008.01125.x; Devictor V, 2012, NAT CLIM CHANGE, V2, P121, DOI 10.1038/NCLIMATE1347; Pereira HM, 2012, ANNU REV ENV RESOUR, V37, P25, DOI 10.1146/annurev-environ-042911-093511; Thomas JA, 2004, SCIENCE, V303, P1879, DOI 10.1126/science.1095046; Rowcliffe JM, 2008, J APPL ECOL, V45, P1228, DOI 10.1111/j.1365-2664.2008.01473.x; McGeoch MA, 2010, DIVERS DISTRIB, V16, P95, DOI 10.1111/j.1472-4642.2009.00633.x; Lindenmayer DB, 2012, AUSTRAL ECOL, V37, P285, DOI 10.1111/j.1442-9993.2011.02314.x; van Swaay CAM, 2008, BIODIVERS CONSERV, V17, P3455, DOI 10.1007/s10531-008-9491-4; Marsh DM, 2008, CONSERV BIOL, V22, P647, DOI 10.1111/j.1523-1739.2008.00927.x; Nagendra H, 2013, ECOL INDIC, V33, P45, DOI 10.1016/j.ecolind.2012.09.014; ARNQVIST G, 1995, TRENDS ECOL EVOL, V10, P236, DOI 10.1016/S0169-5347(00)89073-4; Yoccoz NG, 2001, TRENDS ECOL EVOL, V16, P446, DOI 10.1016/S0169-5347(01)02205-4; Pereira HM, 2006, TRENDS ECOL EVOL, V21, P123, DOI 10.1016/j.tree.2005.10.015; Schmeller D, 2008, BIODIVERS CONSERV, V17, P3623, DOI 10.1007/s10531-008-9446-9; Polasky S, 2011, TRENDS ECOL EVOL, V26, P398, DOI 10.1016/j.tree.2011.04.007; Gillson L, 2013, TRENDS ECOL EVOL, V28, P135, DOI 10.1016/j.tree.2012.10.008; Metzger MJ, 2013, GLOBAL ECOL BIOGEOGR, V22, P630, DOI 10.1111/geb.12022; Martin LJ, 2012, FRONT ECOL ENVIRON, V10, P195, DOI 10.1890/110154; Amano T, 2013, P ROY SOC B-BIOL SCI, V280, DOI 10.1098/rspb.2012.2649; Evans MR, 2012, PHILOS T R SOC B, V367, P181, DOI 10.1098/rstb.2011.0172; Scholes RJ, 2012, CURR OPIN ENV SUST, V4, P139, DOI 10.1016/j.cosust.2011.12.005; Pereira HM, 2013, SCIENCE, V339, P277, DOI 10.1126/science.1229931; Gregory RD, 2004, TECH ECOL CONSERVAT, P17; Gaston KJ, 2011, BIOSCIENCE, V61, P354, DOI 10.1525/bio.2011.61.5.4; BUCKLAND S. T., 2010, BIOL DIVERSITY FRONT, P25; Bunce RGH, 2013, ECOL INDIC, V33, P19, DOI 10.1016/j.ecolind.2012.07.014; Caro T., 2010, CONSERVATION PROXY I; Chiarucci A, 2011, PHILOS T R SOC B, V366, P2426, DOI 10.1098/rstb.2011.0065; Costa FRC, 2010, NAT CONSERVACAO, V8, P3, DOI 10.4322/natcon.00801001; Donnelly A., 2013, INT J BIOMETEOROL, P1; Evans MR, 2013, P ROY SOC B-BIOL SCI, V280, DOI 10.1098/rspb.2013.1452; Gitzen R.A., 2012, DESIGN ANAL LONG TER; Harfoot MBJ, 2014, PLOS BIOL, V12, DOI 10.1371/journal.pbio.1001841; Henle K., 2014, SCALING ECOLOGY BIOD; Henle K., 2010, GAIA, V19, P186; Henle K, 2013, ECOL INDIC, V33, P5, DOI 10.1016/j.ecolind.2013.03.028; Henry PY, 2008, BIODIVERS CONSERV, V17, P3357, DOI 10.1007/s10531-008-9417-1; Karl JW, 2013, BIOSCIENCE, V63, P674, DOI 10.1525/bio.2013.63.8.10; Lacher TE, 2012, CONSERV LETT, V5, P327, DOI 10.1111/j.1755-263X.2012.00249.x; Lengyel S, 2008, BIODIVERS CONSERV, V17, P3341, DOI 10.1007/s10531-008-9359-7; Lin YP, 2015, BIOL CONSERV, V181, P102, DOI 10.1016/j.biocon.2014.11.012; Lucas R, 2014, MAR FRESHWATER RES, V65, P589, DOI 10.1071/MF13177; Magnusson W. E., 2013, BIODIVERSITY INTEGRA; Metzger MJ, 2010, J ENVIRON MANAGE, V91, P1357, DOI 10.1016/j.jenvman.2010.02.017; Ortega M, 2013, ECOL INDIC, V33, P36, DOI 10.1016/j.ecolind.2012.12.004; Pagel J, 2014, METHODS ECOL EVOL, V5, P751, DOI 10.1111/2041-210X.12221; Pereira HM, 2010, FRONT ECOL ENVIRON, V8, P458, DOI 10.1890/10.WB.23; Pijanowski BC, 2011, LANDSCAPE ECOL, V26, P1209, DOI 10.1007/s10980-011-9655-6; Rowcliffe JM, 2011, METHODS ECOL EVOL, V2, P464, DOI 10.1111/j.2041-210X.2011.00094.x; Schmeller D, 2008, BIODIVERS CONSERV, V17, P3607, DOI 10.1007/s10531-008-9439-8; Schmeller D. S., 2012, NAT CONSERV, V3, P21, DOI DOI 10.3897/NATUREC0NSERVATI0N.3.3710; Schmeller D. S., 2008, BIODIVERS CONSERV, V17, P3321; Solymos P, 2013, METHODS ECOL EVOL, V4, P1047, DOI 10.1111/2041-210X.12106; Syfert MM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055158; Tittensor D. P., 2014, SCIENCE, V14, P241; Tylianakis J. M., 2011, ECOL LETT, V11, P1351; Walls RL, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089606	85	1	3	ELSEVIER GMBH, URBAN & FISCHER VERLAG	JENA	OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY	1617-1381	1618-1093		J NAT CONSERV	J. Nat. Conserv.	MAY	2015	25						51	57		10.1016/j.jnc.2015.03.003		7	Biodiversity Conservation; Ecology	Biodiversity & Conservation; Environmental Sciences & Ecology	CG5NV	WOS:000353339700007		
J	Khai, HV; Yabe, M				Huynh Viet Khai; Yabe, Mitsuyasu			Consumer preferences for agricultural products considering the value of biodiversity conservation in the Mekong Delta, Vietnam	JOURNAL FOR NATURE CONSERVATION			English	Article						Biodiversity conservation; Choice modeling; Eco-label; Environmentally friendly farming; Mekong Delta	CHOICE EXPERIMENT; ATTRIBUTES; WETLAND; MODEL; RAIN	Because biodiversity conservation is a crucial aspect of multifunctionality in agriculture, consumers may be willing to pay a higher premium for products with environmentally friendly farming techniques to preserve biodiversity. To analyze the effects of biodiversity on the market price of agricultural products, this study applied the choice experiment method to assess consumers' preferences for environmentally certified rice (termed "crane-friendly farming") proposed for growth in Tram Chim National Park, one of Vietnam's eight important bird areas. Our results indicate that the majority of Vietnamese Mekong Delta consumers agreed to buy the proposed environmentally certified rice. They were willing to pay a premium of VND 11 for one kilogram of environmentally certified rice to increase crane numbers and VND 1500 for a 100% increase in the biodiversity level. In addition, their implicit price for rice cultivation without chemical pesticides (organic rice) was VND 6200, a 62% premium over the price of normal rice. (C) 2015 Elsevier GmbH. All rights reserved.	[Huynh Viet Khai] Can Tho Univ, Sch Econ & Business Adm, Dept Agr Resource & Environm Econ, Can Tho City, Vietnam; [Huynh Viet Khai; Yabe, Mitsuyasu] Kyushu Univ, Fac Agr, Dept Agr & Resource Econ, Lab Environm Econ,Higashi Ku, Fukuoka 8128581, Japan	Yabe, M (reprint author), Kyushu Univ, Fac Agr, Dept Agr & Resource Econ, Lab Environm Econ,Higashi Ku, Hakozaki 6-10-1, Fukuoka 8128581, Japan.	hvkhai@ctu.edu.vn; yabe@agr.kyushu-u.ac.jp			Japan Society for the Promotion of Science (JSPS) under the JSPS Postdoc Fellowship project [P12407]	The study is sponsored by the Japan Society for the Promotion of Science (JSPS) under the JSPS Postdoc Fellowship project (No. P12407). Our warmest thanks go to the staff in the department of Agricultural Economics and Resource-Environmental Economics, SEBA, Can Tho University for assisting in data collection.	Loureiro ML, 2007, FOOD POLICY, V32, P496, DOI 10.1016/j.foodpol.2006.11.006; KRINSKY I, 1986, REV ECON STAT, V68, P715, DOI 10.2307/1924536; Do TN, 2009, ENVIRON DEV ECON, V14, P163, DOI 10.1017/S1355770X08004841; Blend JR, 1999, AM J AGR ECON, V81, P1072, DOI 10.2307/1244086; Loureiro ML, 2002, J CONSUM AFF, V36, P203; ARCURY TA, 1987, SEX ROLES, V16, P463, DOI 10.1007/BF00292481; [Anonymous], 2008, 4 COUNTR REP VIETN I; Christie M, 2006, ECOL ECON, V58, P304, DOI 10.1016/j.ecolecon.2005.07.034; Birol E, 2006, ECOL ECON, V60, P145, DOI 10.1016/j.ecolecon.2006.06.002; Rolfe J, 2000, ECOL ECON, V35, P289, DOI 10.1016/S0921-8009(00)00201-9; Moon W, 2002, LAND ECON, V78, P88, DOI 10.2307/3146925; Wessells CR, 1999, AM J AGR ECON, V81, P1084, DOI 10.2307/1244088; Boxall PC, 2002, ENVIRON RESOUR ECON, V23, P421, DOI 10.1023/A:1021351721619; HAUSMAN J, 1984, ECONOMETRICA, V52, P1219, DOI 10.2307/1910997; Adamowicz W, 1998, AM J AGR ECON, V80, P64, DOI 10.2307/3180269; Fischer J, 2008, FRONT ECOL ENVIRON, V6, P382, DOI 10.1890/070019; Baltzer MC, 2001, VISION BIODIVERSITY; Binh N. T., 2011, 2011 INT C HUM SOC C; Brecard D, 2009, ECOL ECON, V69, P115, DOI 10.1016/j.ecolecon.2009.07.017; Buckton S. T., 1999, CONSERVATION KEY WET; Carson R.T., 1995, BIBLIOGRAPHY CONTING; Garschagen M, 2012, ENVIRON SCI ENG, P83, DOI 10.1007/978-94-007-3962-8_4; Greene W. H., 2001, ECONOMETRIC ANAL; GSO, 2010, RES VIET NAM HOUS LI; Hammitt J. K., 1986, R3447EPA; Hensher D. A., 1981, APPL DISCRETE CHOICE; Hill C. T., 1979, PSYCHOL Q, V42, P5; Khai H. V., 2014, INT J ENERGY ENV ENG, V5, P1; Lancaster K. J., 1966, J POLITICAL EC, V71, P25; Louviere J, 2000, STATED CHOICE METHOD; Louviere J. J., 1982, TRANSPORT RES REC, V890, P7; LUCE RD, 1959, J PHILOS, V56, P173, DOI 10.2307/2022058; McFadden D., 1974, FRONTIERS ECONOMETRI; Morrison M. D., 1996, 1 U COLL U NEW S WAL; Pillarisetti J. R., 2013, MULTIFUNCTIONAL AGR; Thuy D. T., 2007, EC ENV PROGRAM SE AS; Tordoff A. W., 2002, DIRECTORY IMPORTANT; Wong J., 2002, THESIS U GEORGIA	38	0	0	ELSEVIER GMBH, URBAN & FISCHER VERLAG	JENA	OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY	1617-1381	1618-1093		J NAT CONSERV	J. Nat. Conserv.	MAY	2015	25						62	71		10.1016/j.jnc.2015.02.004		10	Biodiversity Conservation; Ecology	Biodiversity & Conservation; Environmental Sciences & Ecology	CG5NV	WOS:000353339700009		
J	Murakami, H; Amano, Y; Asahi, R				Murakami, Hideki; Amano, Yoshihisa; Asahi, Ryota			Dynamic effect of inter-firm rivalry on airfares: Case of Japan's full-service and new air carriers	JOURNAL OF AIR TRANSPORT MANAGEMENT			English	Article						Japanese airlines; Entry; Dynamic competition; Consumers' surplus	LOW-COST CARRIERS; AIRLINE INDUSTRY; EMPIRICAL-ANALYSIS; PRICE REACTIONS; MARKET POWER; COMPETITION; CONDUCT; ENTRY; BEHAVIOR	This paper analyzes the dynamic changes in carriers' airfares and outputs and computes the change in the consumers' surplus year by year after new Japanese carriers entered thriving routes and started to compete with Japanese full-service airlines. Using unbalanced panel data from 222 routes and carrier specific sample observations, it finds that new carriers discounted airfares significantly as soon as they entered new markets, but two early carriers, Skymark Airlines and AIRDO, which had entered with very low airfares, raised their prices year by year. On the other hand, both All Nippon Airways and Japan Airlines responded to the new entrants and lowered their airfares to a much lesser extent than the new entrants did, and their airfare levels remained almost unchanged for at least four years after the first entry. The consumers' surplus increased significantly in the first year of each new entry but gradually decreased as the new entrants raised their airfares. (C) 2015 Elsevier Ltd. All rights reserved.	[Murakami, Hideki; Amano, Yoshihisa] Kobe Univ, Grad Sch Business, Nada Ku, Kobe, Hyogo 6578501, Japan; [Asahi, Ryota] Fukuyama Heisei Univ, Fac Business Adm, Fukuyama, Hiroshima 7200001, Japan	Murakami, H (reprint author), Kobe Univ, Grad Sch Business, Nada Ku, 2-1 Rokkodai, Kobe, Hyogo 6578501, Japan.	hidekim@panda.kobe-u.ac.jp; nimes2030@yahoo.co.jp; asahi@heisei-u.ac.jp					Alderighi M., 2004, DISCUSSION PAPER TI; Morrison SA, 2001, J TRANSP ECON POLICY, V35, P239; Slade ME, 2004, J IND ECON, V52, P133, DOI 10.1111/j.0022-1821.2004.00219.x; BERRY S, 1995, ECONOMETRICA, V63, P841, DOI 10.2307/2171802; Zhang Q, 2014, TRANSPORT RES A-POL, V64, P1, DOI 10.1016/j.tra.2014.03.003; Pinkse J, 2004, EUR ECON REV, V48, P617, DOI 10.1016/S0014-2921(02)00328-8; CAVES DW, 1984, RAND J ECON, V15, P471, DOI 10.2307/2555519; Dresner M, 1996, J TRANSP ECON POLICY, V30, P309; BRANDER JA, 1993, INT J IND ORGAN, V11, P407, DOI 10.1016/0167-7187(93)90017-7; BRANDER JA, 1990, RAND J ECON, V21, P567, DOI 10.2307/2555469; Brueckner J., 2013, EC TRANSPORTATIONS, V2, P1; Corts KS, 1999, J ECONOMETRICS, V88, P227, DOI 10.1016/S0304-4076(98)00028-1; Fischer T, 2003, J TRANSP ECON POLICY, V37, P227; Fu XW, 2011, TRANSPORT RES E-LOG, V47, P297, DOI 10.1016/j.tre.2010.11.002; Goolsbee A, 2008, Q J ECON, V123, P1611, DOI 10.1162/qjec.2008.123.4.1611; Huse C, 2012, J TRANSP ECON POLICY, V46, P189; Morrison S. A., 1996, EVOLUTION OF AIRLINE; Murakami H, 2011, PAC ECON REV, V16, P103, DOI 10.1111/j.1468-0106.2010.00537.x; Murakami H, 2011, SINGAP ECON REV, V56, P593, DOI 10.1142/S0217590811004444; Murakami H, 2011, TRANSPORT RES E-LOG, V47, P306, DOI 10.1016/j.tre.2010.11.003; Oliveira AVM, 2009, TRANSPORT RES E-LOG, V45, P307, DOI 10.1016/j.tre.2008.09.003; OUM TH, 1993, J TRANSP ECON POLICY, V27, P171; Pinkse J., 2002, ECONOMETRICA, V70, P1111, DOI 10.1111/1468-0262.00320; Pitfield DE, 2008, J AIR TRANSP MANAG, V14, P113, DOI 10.1016/j.jairtraman.2008.02.006; Pitfield DE, 2005, J TRANSP ECON POLICY, V39, P379; Puller SL, 2009, APPL ECON LETT, V16, P1497, DOI 10.1080/13504850701578900; Vowles T. W., 2000, J TRANSP GEOGR, V8, P121, DOI 10.1016/S0966-6923(99)00033-2	27	0	0	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0969-6997	1873-2089		J AIR TRANSP MANAG	J. Air Transp. Manag.	MAY-JUN	2015	44-45						25	33		10.1016/j.jairtraman.2015.02.002		9	Transportation	Transportation	CG2DD	WOS:000353084200004		
J	Nakamura, I; Goto, Y; Sato, K				Nakamura, Itsumi; Goto, Yusuke; Sato, Katsufumi			Ocean sunfish rewarm at the surface after deep excursions to forage for siphonophores	JOURNAL OF ANIMAL ECOLOGY			English	Article						animal-borne camera; body temperature; foraging; ocean sunfish; siphonophore; thermoregulation	MOLA-MOLA; BODY-TEMPERATURE; DIVING BEHAVIOR; BLUEFIN TUNA; SEA-TURTLES; THERMOREGULATION; MOVEMENTS; PATTERNS; TRACKING; PREDATOR	Ocean sunfish (Mola mola) were believed to be inactive jellyfish feeders because they are often observed lying motionless at the sea surface. Recent tracking studies revealed that they are actually deep divers, but there has been no evidence of foraging in deep water. Furthermore, the surfacing behaviour of ocean sunfish was thought to be related to behavioural thermoregulation, but there was no record of sunfish body temperature. Evidence of ocean sunfish feeding in deep water was obtained using a combination of an animal-borne accelerometer and camera with a light source. Siphonophores were the most abundant prey items captured by ocean sunfish and were typically located at a depth of 50-200m where the water temperature was <12 degrees C. Ocean sunfish were diurnally active, made frequently deep excursions and foraged mainly at 100-200m depths during the day. Ocean sunfish body temperatures were measured under natural conditions. The body temperatures decreased during deep excursions and recovered during subsequent surfacing periods. Heat-budget models indicated that the whole-body heat-transfer coefficient between sunfish and the surrounding water during warming was 3-7 times greater than that during cooling. These results suggest that the main function of surfacing is the recovery of body temperature, and the fish might be able to increase heat gain from the warm surface water by physiological regulation. The thermal environment of ocean sunfish foraging depths was lower than their thermal preference (c.16-17 degrees C). The behavioural and physiological thermoregulation enables the fish to increase foraging time in deep, cold water. Feeding rate during deep excursions was not related to duration or depth of the deep excursions. Cycles of deep foraging and surface warming were explained by a foraging strategy, to maximize foraging time with maintaining body temperature by vertical temperature environment.	[Nakamura, Itsumi; Goto, Yusuke; Sato, Katsufumi] Univ Tokyo, Atmosphere & Ocean Res Inst, Kashiwa, Chiba 2778564, Japan	Nakamura, I (reprint author), Univ Tokyo, Atmosphere & Ocean Res Inst, 5-1-5 Kashiwanoha, Kashiwa, Chiba 2778564, Japan.	itsumi@aori.u-tokyo.ac.jp			Bio-Logging Science at the University of Tokyo (UTBLS); Japan Society of the Promotion of Science [12J07184, 25660152, 24241001]; Canon Foundation; Project Grand Maillet; Cooperative Program of Atmosphere and Ocean Research Institute at the University of Tokyo	This study was supported by Bio-Logging Science at the University of Tokyo (UTBLS), the Grants-in-Aid for Scientific Research from the Japan Society of the Promotion of Science (12J07184, 25660152, 24241001), the Canon Foundation, Project Grand Maillet and the Cooperative Program of Atmosphere and Ocean Research Institute at the University of Tokyo. We thank Dr. Dhugal J. Lindsey for the identification of jellyfish species. We thank Dr. Thomas Doyle for his valuable suggestions to improve the quality of the paper. We deeply thank chief Hideo Sasaki and the fishermen of the Funakoshi Bay Fisheries Cooperative, and captain Hiroshi Shozushima and the crew of the 'Koyo-maru' boat.	Angel M. V., 1982, BIOL OCEANOGRAPHY, V2, P37; Doyle TK, 2007, J EXP MAR BIOL ECOL, V343, P239, DOI 10.1016/j.jembe.2006.12.010; Abe T, 2012, MAR BIOL, V159, P1173, DOI 10.1007/s00227-011-1873-6; CAREY FG, 1990, MAR BIOL, V106, P329, DOI 10.1007/BF01344309; Brunnschweiler JM, 2009, J FISH BIOL, V74, P706, DOI 10.1111/j.1095-8649.2008.02155.x; Kitagawa T, 2001, MAR ECOL PROG SER, V220, P253, DOI 10.3354/meps220253; CAREY FG, 1981, FISH B-NOAA, V79, P277; Hays GC, 2009, J EXP MAR BIOL ECOL, V370, P134, DOI 10.1016/j.jembe.2008.12.009; Pope EC, 2010, REV FISH BIOL FISHER, V20, P471, DOI 10.1007/s11160-009-9155-9; Nakamura I, 2014, MAR BIOL, V161, P1263, DOI 10.1007/s00227-014-2416-8; Cartamil DP, 2004, MAR ECOL PROG SER, V266, P245, DOI 10.3354/meps266245; HOLLAND KN, 1994, ENVIRON BIOL FISH, V40, P319, DOI 10.1007/BF00002520; Haddock SHD, 1999, MAR BIOL, V133, P571, DOI 10.1007/s002270050497; Casey JP, 2014, J EXP BIOL, V217, P2331, DOI 10.1242/jeb.100347; Kino M, 2009, ENVIRON BIOL FISH, V85, P33, DOI 10.1007/s10641-009-9453-z; Sims DW, 2009, J EXP MAR BIOL ECOL, V370, P127, DOI 10.1016/j.jembe.2008.12.011; Naito Y, 2013, FUNCT ECOL, V27, P710, DOI 10.1111/1365-2435.12083; Haddock SHD, 2005, SCIENCE, V309, P263, DOI 10.1126/science.1110441; Potter IF, 2011, J EXP MAR BIOL ECOL, V396, P138, DOI 10.1016/j.jembe.2010.10.014; Dewar H, 2010, J EXP MAR BIOL ECOL, V393, P32, DOI 10.1016/j.jembe.2010.06.023; PYKE GH, 1984, ANNU REV ECOL SYST, V15, P523, DOI 10.1146/annurev.es.15.110184.002515; Aoki K, 2012, MAR ECOL PROG SER, V444, P289, DOI 10.3354/meps09371; CAREY FG, 1969, COMP BIOCHEM PHYSIOL, V28, P199, DOI 10.1016/0010-406X(69)91335-8; CAREY FG, 1969, COMP BIOCHEM PHYSIOL, V28, P205, DOI 10.1016/0010-406X(69)91336-X; Compana S. E., 2011, PLOS ONE, V6; GRAY IE, 1954, BIOL BULL, V107, P219, DOI 10.2307/1538608; Hochscheid S, 2002, PHYSIOL BIOCHEM ZOOL, V75, P66, DOI 10.1086/339050; Houghton JDR, 2009, REV-METHODS TECHNOL, V9, P229, DOI 10.1007/978-1-4020-9640-2_14; Mitsui T., 1999, NUMERICAL SOLUTION S; Nakamura I., 2015, DRYAD DIGITAL REPOSI; Narazaki T, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066043; Potter IF, 2011, MAR BIOL, V158, P531, DOI 10.1007/s00227-010-1578-2; Queiroz N, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032374; R Core Team, 2013, R LANG ENV STAT COMP; Sato K, 2014, J EXP BIOL, V217, P3607, DOI 10.1242/jeb.109470; Shiomi K., 2010, AQUAT BIOL, V8, P289; Silguero JMB, 2000, J PLANKTON RES, V22, P1139, DOI 10.1093/plankt/22.6.1139; Sims DW, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007351; Thorrold SR, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5274; Thums M, 2013, J R SOC INTERFACE, V10, DOI 10.1098/rsif.2012.0477; Watanabe Y, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003446	41	4	4	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0021-8790	1365-2656		J ANIM ECOL	J. Anim. Ecol.	MAY	2015	84	3					590	603		10.1111/1365-2656.12346		14	Ecology; Zoology	Environmental Sciences & Ecology; Zoology	CG6JD	WOS:000353405300002		
J	Yoshimura, S; Sato, W; Uono, S; Toichi, M				Yoshimura, Sayaka; Sato, Wataru; Uono, Shota; Toichi, Motomi			Impaired Overt Facial Mimicry in Response to Dynamic Facial Expressions in High-Functioning Autism Spectrum Disorders	JOURNAL OF AUTISM AND DEVELOPMENTAL DISORDERS			English	Article						Autism spectrum disorders (ASD); Dynamic facial expression; Facial mimicry; Reciprocal social interaction	RATING-SCALE; TOKYO VERSION; PERCEPTION; CHILDREN; RECOGNITION; IMITATION; VOLUNTARY; IDENTITY; EMOTION; SYSTEM	Previous electromyographic studies have reported that individuals with autism spectrum disorders (ASD) exhibited atypical patterns of facial muscle activity in response to facial expression stimuli. However, whether such activity is expressed in visible facial mimicry remains unknown. To investigate this issue, we videotaped facial responses in high-functioning individuals with ASD and controls to dynamic and static facial expressions of anger and happiness. Visual coding of facial muscle activity and the subjective impression ratings showed reduced congruent responses to dynamic expressions in the ASD group. Additionally, this decline was related to social dysfunction. These results suggest that impairment in overt facial mimicry in response to others' dynamic facial expressions may underlie difficulties in reciprocal social interaction among individuals with ASD.	[Yoshimura, Sayaka; Sato, Wataru; Uono, Shota] Kyoto Univ, Grad Sch Med, Dept Neurodev Psychiat Habilitat & Rehabil, Sakyo Ku, Kyoto 6068507, Japan; [Uono, Shota; Toichi, Motomi] Org Promoting Dev Disorder Res, Sakyo Ku, Kyoto 6068392, Japan; [Toichi, Motomi] Kyoto Univ, Grad Sch Med, Fac Human Hlth Sci, Sakyo Ku, Kyoto 6068507, Japan	Yoshimura, S (reprint author), Kyoto Univ, Grad Sch Med, Dept Neurodev Psychiat Habilitat & Rehabil, Sakyo Ku, 54 Shogoin Kawaharacho, Kyoto 6068507, Japan.	yoshimurasayaka@gmail.com			JSPS	The authors thank all participants for their participation in the experiment and Ms. Minemoto and Ms. Yokoyama for their technical assistance. This study was supported by funds from the JSPS Funding Program for Next Generation World-Leading Researchers and the Organization for Promoting Developmental Disorder Research.	American Psychiatric Association, 2000, DIAGN STAT MAN MENT; Dimberg U, 2011, J NONVERBAL BEHAV, V35, P17, DOI 10.1007/s10919-010-0098-6; Koyama T, 2007, PSYCHIAT CLIN NEUROS, V61, P99, DOI 10.1111/j.1440-1819.2007.01617.x; McIntosh DN, 2006, DEVELOPMENTAL SCI, V9, P295, DOI 10.1111/j.1467-7687.2006.00492.x; Kilts CD, 2003, NEUROIMAGE, V18, P156, DOI 10.1006/nimg.2002.1323; Kring AM, 2007, PSYCHOL ASSESSMENT, V19, P210, DOI 10.1037/1040-3590.19.2.210; Nakano T, 2009, P R SOC B, V276, P3635, DOI 10.1098/rspb.2009.0828; Hess U, 2001, INT J PSYCHOPHYSIOL, V40, P129, DOI 10.1016/S0167-8760(00)00161-6; KURITA H, 1989, J AUTISM DEV DISORD, V19, P389, DOI 10.1007/BF02212937; OLDFIELD RC, 1971, NEUROPSYCHOLOGIA, V9, P97, DOI 10.1016/0028-3932(71)90067-4; Beall PM, 2008, J EXP CHILD PSYCHOL, V101, P206, DOI 10.1016/j.jecp.2008.04.004; Sato W, 2004, COGNITIVE BRAIN RES, V20, P81, DOI 10.1016/j.cogbrainres.2004.01.008; Weyers P, 2006, PSYCHOPHYSIOLOGY, V43, P450, DOI 10.1111/j.1469-8986.2006.00451.x; FIELD TM, 1982, SCIENCE, V218, P179, DOI 10.1126/science.7123230; Sato W, 2008, INT J PSYCHOPHYSIOL, V70, P70, DOI 10.1016/j.ijpsycho.2008.06.001; Blairy S, 1999, J NONVERBAL BEHAV, V23, P5, DOI 10.1023/A:1021370825283; LaBar KS, 2003, CEREB CORTEX, V13, P1023, DOI 10.1093/cercor/13.10.1023; Stel M, 2008, J AUTISM DEV DISORD, V38, P1250, DOI 10.1007/s10803-007-0505-y; Pelphrey KA, 2007, SOC COGN AFFECT NEUR, V2, P140, DOI 10.1093/scan/nsm010; CACIOPPO JT, 1986, J PERS SOC PSYCHOL, V50, P260, DOI 10.1037//0022-3514.50.2.260; CACIOPPO JT, 1992, PERS SOC PSYCHOL B, V18, P515, DOI 10.1177/0146167292185001; Tachimori H, 2003, PSYCHIAT CLIN NEUROS, V57, P113, DOI 10.1046/j.1440-1819.2003.01087.x; Tardif C, 2007, J AUTISM DEV DISORD, V37, P1469, DOI 10.1007/s10803-006-0223-x; Cappella J. N., 1993, J LANG SOC PSYCHOL, V12, P13, DOI 10.1177/0261927X93121002; De Seta E, 2010, OTOL NEUROTOL, V31, P1498, DOI 10.1097/MAO.0b013e3181f20822; Ekman P., 1978, FACIAL ACTION CODING; Ekman P., 1998, FACIAL ACTION CODING; Filipo R, 2002, OTOL NEUROTOL, V23, P594, DOI 10.1097/00129492-200207000-00032; Goodwin C., 2002, CURR ANTHROPOL, V43, P19; Hess U., 1999, SOCIAL CONTEXT NONVE, P213; Kessels RPC, 2010, TRANSL NEUROSCI, V1, P228, DOI 10.2478/v10134-010-0033-8; Kirk R.E., 1995, EXPT DESIGN PROCEDUR; Kunecke J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0084053; Magyar CI, 2007, J AUTISM DEV DISORD, V37, P1787, DOI 10.1007/s10803-006-0313-9; MAURER RE, 1983, J COUNS PSYCHOL, V30, P158, DOI 10.1037/0022-0167.30.2.158; Oberman LM, 2009, DEVELOPMENTAL SCI, V12, P510, DOI 10.1111/j.1467-7687.2008.00796.x; Likowski KU, 2012, FRONT HUM NEUROSCI, V6, DOI 10.3389/fnhum.2012.00214; Sato W, 2007, COGNITION, V104, P1, DOI 10.1016/j.cognition.2006.05.001; Sato W, 2012, BMC NEUROSCI, V13, DOI 10.1186/1471-2202-13-99; Sato W, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057889; Schopler E, 1986, CHILDHOOD AUTISM RAT; Tabachnick B. G., 2001, COMPUTER ASSISTED RE; Uono S, 2009, BRAIN COGNITION, V71, P229, DOI 10.1016/j.bandc.2009.08.015; Uono S, 2011, SOC NEUROSCI-UK, V6, P452, DOI 10.1080/17470919.2011.605593; YIRMIYA N, 1989, J CHILD PSYCHOL PSYC, V30, P725, DOI 10.1111/j.1469-7610.1989.tb00785.x	45	1	1	SPRINGER/PLENUM PUBLISHERS	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0162-3257	1573-3432		J AUTISM DEV DISORD	J. Autism Dev. Disord.	MAY	2015	45	5					1318	1328		10.1007/s10803-014-2291-7		11	Psychology, Developmental	Psychology	CG6JS	WOS:000353407200017		
J	Nayar, AS; Dougherty, TJ; Ferguson, KE; Granger, BA; McWilliams, L; Stacey, C; Leach, LJ; Narita, SI; Tokuda, H; Miller, AA; Brown, DG; McLeod, SM				Nayar, Asha S.; Dougherty, Thomas J.; Ferguson, Keith E.; Granger, Brett A.; McWilliams, Lisa; Stacey, Clare; Leach, Lindsey J.; Narita, Shin-ichiro; Tokuda, Hajime; Miller, Alita A.; Brown, Dean G.; McLeod, Sarah M.			Novel Antibacterial Targets and Compounds Revealed by a High-Throughput Cell Wall Reporter Assay	JOURNAL OF BACTERIOLOGY			English	Article							PENICILLIN-BINDING PROTEINS; OUTER-MEMBRANE LIPOPROTEIN; ESCHERICHIA-COLI; PSEUDOMONAS-AERUGINOSA; INHIBITORS; GENE; DISCOVERY; INFECTIONS; RESISTANCE; GLOBOMYCIN	A high-throughput phenotypic screen based on a Citrobacter freundii AmpC reporter expressed in Escherichia coli was executed to discover novel inhibitors of bacterial cell wall synthesis, an attractive, well-validated target for antibiotic intervention. Here we describe the discovery and characterization of sulfonyl piperazine and pyrazole compounds, each with novel mechanisms of action. E. coli mutants resistant to these compounds display no cross-resistance to antibiotics of other classes. Resistance to the sulfonyl piperazine maps to LpxH, which catalyzes the fourth step in the synthesis of lipid A, the outer membrane anchor of lipopolysaccharide (LPS). To our knowledge, this compound is the first reported inhibitor of LpxH. Resistance to the pyrazole compound mapped to mutations in either LolC or LolE, components of the essential LolCDE transporter complex, which is required for trafficking of lipoproteins to the outer membrane. Biochemical experiments with E. coli spheroplasts showed that the pyrazole compound is capable of inhibiting the release of lipoproteins from the inner membrane. Both of these compounds have significant promise as chemical probes to further interrogate the potential of these novel cell wall components for antimicrobial therapy. IMPORTANCE The prevalence of antibacterial resistance, particularly among Gram-negative organisms, signals a need for novel antibacterial agents. A phenotypic screen using AmpC as a sensor for compounds that inhibit processes involved in Gram-negative envelope biogenesis led to the identification of two novel inhibitors with unique mechanisms of action targeting Escherichia coli outer membrane biogenesis. One compound inhibits the transport system for lipoprotein transport to the outer membrane, while the other compound inhibits synthesis of lipopolysaccharide. These results indicate that it is still possible to uncover new compounds with intrinsic antibacterial activity that inhibit novel targets related to the cell envelope, suggesting that the Gram-negative cell envelope still has untapped potential for therapeutic intervention.	[Nayar, Asha S.; Dougherty, Thomas J.; Ferguson, Keith E.; Miller, Alita A.; McLeod, Sarah M.] AstraZeneca R&D Boston, Dept Biosci, Waltham, MA 02451 USA; [Granger, Brett A.; Brown, Dean G.] AstraZeneca R&D Boston, Dept Chem, Infect Innovat Med Unit, Waltham, MA USA; [McWilliams, Lisa; Stacey, Clare; Leach, Lindsey J.] AstraZeneca, Mereside, Discovery Sci, Macclesfield, Cheshire, England; [Narita, Shin-ichiro; Tokuda, Hajime] Univ Morioka, Fac Nutr Sci, Takizawa, Iwate, Japan	McLeod, SM (reprint author), AstraZeneca R&D Boston, Dept Biosci, Waltham, MA 02451 USA.	sarahmmcleod@gmail.com					Rietsch A, 2005, P NATL ACAD SCI USA, V102, P8006, DOI 10.1073/pnas.0503005102; MATSUYAMA S, 1995, EMBO J, V14, P3365; Silver LL, 2011, CLIN MICROBIOL REV, V24, P71, DOI 10.1128/CMR.00030-10; Babinski KJ, 2002, J BIOL CHEM, V277, P25947, DOI 10.1074/jbc.M204068200; Spellberg B, 2008, CLIN INFECT DIS, V46, P155, DOI 10.1086/524891; Bugg TDH, 2011, TRENDS BIOTECHNOL, V29, P167, DOI 10.1016/j.tibtech.2010.12.006; Silver LL, 2007, NAT REV DRUG DISCOV, V6, P41, DOI 10.1038/nrd2202; McClerren AL, 2005, BIOCHEMISTRY-US, V44, P16574, DOI 10.1021/bi0518186; Rice LB, 2008, J INFECT DIS, V197, P1079, DOI 10.1086/533452; Rattan A, 1998, EMERG INFECT DIS, V4, P195; Babinski KJ, 2002, J BIOL CHEM, V277, P25937, DOI 10.1074/jbc.M204067200; Zhang JH, 1999, J BIOMOL SCREEN, V4, P67, DOI 10.1177/108705719900400206; INOUYE M, 1972, J BIOL CHEM, V247, P8154; WANG RF, 1991, GENE, V100, P195, DOI 10.1016/0378-1119(91)90366-J; Zervosen A, 2012, MOLECULES, V17, P12478, DOI 10.3390/molecules171112478; Gwynn MN, 2010, ANN NY ACAD SCI, V1213, P5, DOI 10.1111/j.1749-6632.2010.05828.x; Rex JH, 2013, LANCET INFECT DIS, V13, P269, DOI 10.1016/S1473-3099(12)70293-1; Montgomery JI, 2012, J MED CHEM, V55, P1662, DOI 10.1021/jm2014875; Johnson JW, 2013, ANN NY ACAD SCI, V1277, P54, DOI 10.1111/j.1749-6632.2012.06813.x; Yakushi T, 2000, NAT CELL BIOL, V2, P212; O'Shea R, 2008, J MED CHEM, V51, P2871, DOI 10.1021/jm700967e; Nonejuie P, 2013, P NATL ACAD SCI USA, V110, P16169, DOI 10.1073/pnas.1311066110; Payne DJ, 2007, NAT REV DRUG DISCOV, V6, P29, DOI 10.1038/nrd2201; Okuda S, 2011, ANNU REV MICROBIOL, V65, P239, DOI 10.1146/annurev-micro-090110-102859; Lupoli TJ, 2014, J AM CHEM SOC, V136, P52, DOI 10.1021/ja410813j; Wang XY, 2010, PROG LIPID RES, V49, P97, DOI 10.1016/j.plipres.2009.06.002; Xiao Y, 2012, ANTIMICROB AGENTS CH, V56, P2014, DOI 10.1128/AAC.06148-11; Datsenko KA, 2000, P NATL ACAD SCI USA, V97, P6640, DOI 10.1073/pnas.120163297; CHOI DS, 1986, J BIOL CHEM, V261, P8953; Clinical and Laboratory Standards Institute, 2009, MRWTH DIL ANT SUSC T, V29; de Jonge BLM, 2013, ANTIMICROB AGENTS CH, V57, P6005, DOI 10.1128/AAC.01661-13; Fan J, 2014, ANTIMICROB AGENTS CH, V58, P7264, DOI 10.1128/AAC.03475-14; Hale MR, 2013, BIOORG MED CHEM LETT, V23, P2362, DOI 10.1016/j.bmcl.2013.02.055; Hameed PS, 2014, ACS CHEM BIOL, V9, P2274, DOI 10.1021/cb500360c; HONORE N, 1986, EMBO J, V5, P3709; INUKAI M, 1978, J ANTIBIOT, V31, P1203; INUKAI M, 1979, J BACTERIOL, V140, P1098; Keating TA, 2012, ACS CHEM BIOL, V7, P1866, DOI 10.1021/cb300316n; Lister PD, 2007, EXPERT REV ANTI-INFE, V5, P793, DOI 10.1586/14787210.5.5.793; McLeod SM, 2015, J BACTERIOL, V197, P1075, DOI 10.1128/JB.02352-14; Nikaido H, 1998, CLIN INFECT DIS, V27, pS32; O'Dwyer K, 2015, ANTIMICROB AGENTS CH, V59, P289, DOI 10.1128/AAC.03774-14; Shapiro AB, 2009, J BIOMOL SCREEN, V14, P1008, DOI 10.1177/1087057109341768; Sun DY, 2002, J ANTIBIOT, V55, P279; Thomason LC, 2007, CURR PROTOC MOL BIOL, DOI [10.1002/0471142727.mb0116s78, DOI 10.1002/0471142727.MB0117S79]; Yakushi T, 1997, J BACTERIOL, V179, P2857; Yasuda M, 2009, BIOSCI BIOTECH BIOCH, V73, P2310, DOI 10.1271/bbb.90451; Zeng XM, 2013, FRONT MICROBIOL, V4, DOI 10.3389/fmicb.2013.00128; ZWIEBEL LJ, 1981, J BACTERIOL, V145, P654	49	2	2	AMER SOC MICROBIOLOGY	WASHINGTON	1752 N ST NW, WASHINGTON, DC 20036-2904 USA	0021-9193	1098-5530		J BACTERIOL	J. Bacteriol.	MAY	2015	197	10					1726	1734		10.1128/JB.02552-14		9	Microbiology	Microbiology	CG3EM	WOS:000353160900004		
J	Ishijima, M; Hirota, M; Park, W; Honda, MJ; Tsukimura, N; Isokawa, K; Ishigami, T; Ogawa, T				Ishijima, Manabu; Hirota, Makoto; Park, Wonhee; Honda, Masaki J.; Tsukimura, Naoki; Isokawa, Keitaro; Ishigami, Tomohiko; Ogawa, Takahiro			Osteogenic cell sheets reinforced with photofunctionalized micro-thin titanium	JOURNAL OF BIOMATERIALS APPLICATIONS			English	Article						Ultraviolet light; titanium mesh; periosteum; hydrophilicity; hydrocarbon; bone engineering	MESENCHYMAL STEM-CELLS; IMPLANT SURFACE; UV-PHOTOFUNCTIONALIZATION; REGENERATIVE MEDICINE; PROTEIN ADSORPTION; DENTAL IMPLANTS; BONE; OSSEOINTEGRATION; ADHESION; CHALLENGES	Cell sheet technology has been used to deliver cells in single-sheet form with an intact extracellular matrix for soft tissue repair and regeneration. Here, we hypothesized that titanium-reinforced cell sheets could be constructed for bone tissue engineering and regeneration. Fifty-mu m-thick titanium plates containing apertures were prepared and roughened by acid etching, some of which were photofunctionalized with 12min of UV light treatment. Cell sheets were prepared by culturing rat calvarial periosteum-derived cells on temperature-responsive culture dishes and attached to titanium plates. Titanium-reinforced osteogenic cell sheet construction was conditional on various technical and material factors: cell sheets needed to be double-sided and sandwich the titanium plate, and the titanium plates needed to be micro thin and contain apertures to allow close apposition of the two cell sheets. Critically, titanium plates needed to be UV-photofunctionalized to ensure adherence and retention of cell sheets. Single-sided cell sheets or double-sided cell sheets on as-made titanium contracted and deformed within 4 days of incubation. Titanium-reinforced cell sheets on photofunctionalized titanium were structurally stable at least up to 14 days, developed the expected osteogenic phenotypes (ALP production and mineralization), and maintained structural integrity without functional degradation. Successful construction of titanium-reinforced osteogenic cell sheets was associated with increased cell attachment, retention, and expression of vinculin, an adhesion protein by photofunctionalization. This study identified the technical and material requirements for constructing titanium-reinforced osteogenic cell sheets. Future invivo studies are warranted to test these titanium-reinforced cell sheets as stably transplantable, mechanically durable, and shape controllable osteogenic devices.	[Ishijima, Manabu; Hirota, Makoto; Park, Wonhee; Tsukimura, Naoki; Ogawa, Takahiro] Univ Calif Los Angeles, Sch Dent, Div Adv Prosthodont Biomat & Hosp Dent, LBIS,Weintraub Ctr Reconstruct Biotechnol, Los Angeles, CA 90095 USA; [Ishijima, Manabu; Tsukimura, Naoki; Ishigami, Tomohiko] Nihon Univ, Sch Dent, Dept Partial Denture Prosthodont, Tokyo 101, Japan; [Honda, Masaki J.; Isokawa, Keitaro] Nihon Univ, Sch Dent, Dept Anat, Tokyo 101, Japan	Ogawa, T (reprint author), Univ Calif Los Angeles, Sch Dent, Div Adv Prosthodont Biomat & Hosp Dent, LBIS,Weintraub Ctr Reconstruct Biotechnol, 10833 Le Conte Ave B3-081 CHS,Box 951668, Los Angeles, CA 90095 USA.	togawa@dentistry.ucla.edu					Bose S, 2012, TRENDS BIOTECHNOL, V30, P546, DOI 10.1016/j.tibtech.2012.07.005; Aita H, 2009, ACTA BIOMATER, V5, P3247, DOI 10.1016/j.actbio.2009.04.022; Mendonca G, 2008, BIOMATERIALS, V29, P3822, DOI 10.1016/j.biomaterials.2008.05.012; Yamada M, 2010, ACTA BIOMATER, V6, P4578, DOI 10.1016/j.actbio.2010.07.010; Gongadze E, 2011, INT J NANOMED, V6, P1801, DOI 10.2147/IJN.S21755; Kubo K, 2009, BIOMATERIALS, V30, P5319, DOI 10.1016/j.biomaterials.2009.06.021; Funato A, 2013, INT J ORAL MAX IMPL, V28, P1589, DOI 10.11607/jomi.3232; Amini Ami R., 2012, Critical Reviews in Biomedical Engineering, V40, P363; Klein MO, 2013, CLIN IMPLANT DENT R, V15, P166, DOI 10.1111/j.1708-8208.2011.00339.x; van den Bergh JP, 2012, NAT REV RHEUMATOL, V8, P163, DOI 10.1038/nrrheum.2011.217; Lu HH, 2009, COMB CHEM HIGH T SCR, V12, P589; Haidar ZS, 2009, BIOTECHNOL LETT, V31, P1817, DOI 10.1007/s10529-009-0099-x; Wu KH, 2008, MED HYPOTHESES, V71, P700, DOI 10.1016/j.mehy.2008.04.029; Hutmacher DW, 2005, GENE, V347, P1, DOI 10.1016/j.gene.2004.12.040; Yang J, 2007, BIOMATERIALS, V28, P5033, DOI 10.1016/j.biomaterials.2007.07.052; Cooper LF, 2000, J PROSTHET DENT, V84, P522, DOI 10.1067/mpr.2000.111966; Att W, 2009, BIOMATERIALS, V30, P4268, DOI 10.1016/j.biomaterials.2009.04.048; Ueno T, 2010, BIOMATERIALS, V31, P1546, DOI 10.1016/j.biomaterials.2009.11.018; Miyauchi T, 2010, BIOMATERIALS, V31, P3827, DOI 10.1016/j.biomaterials.2010.01.133; Hori N, 2010, ACTA BIOMATER, V6, P4175, DOI 10.1016/j.actbio.2010.05.006; Aita H, 2009, BIOMATERIALS, V30, P1015, DOI 10.1016/j.biomaterials.2008.11.004; O'Keefe RJ, 2011, TISSUE ENG PART B-RE, V17, P389, DOI [10.1089/ten.TEB.2011.0475, 10.1089/ten.teb.2011.0475]; Elloumi-Hannachi I, 2010, J INTERN MED, V267, P54, DOI 10.1111/j.1365-2796.2009.02185.x; Iwasa F, 2010, BIOMATERIALS, V31, P2717, DOI 10.1016/j.biomaterials.2009.12.024; Sreejit P, 2013, STEM CELL REV REP, V9, P158, DOI 10.1007/s12015-013-9427-6; Patel NG, 2013, ORGANOGENESIS, V9, P93, DOI 10.4161/org.25149; Harvey AG, 2013, EXPERT REV MED DEVIC, V10, P257, DOI [10.1586/erd.12.82, 10.1586/ERD.12.82]; Matsuura K, 2014, J CONTROL RELEASE, V190, P228, DOI 10.1016/j.jconrel.2014.05.024; Suzuki T, 2009, TISSUE ENG PT A, V15, P3679, DOI 10.1089/ten.TEA.2008.0568; Owaki T, 2014, BIOTECHNOL J, V9, P904, DOI 10.1002/biot.201300432; Nagase K, 2009, J R SOC INTERFACE, V6, pS293, DOI 10.1098/rsif.2008.0499.focus; Shalabi MM, 2006, J DENT RES, V85, P496; Suzuki S, 2013, IMPLANT DENT, V22, P481, DOI 10.1097/ID.0b013e31829deb62; Nakamura A, 2010, BONE, V46, P418, DOI 10.1016/j.bone.2009.08.048; Schroeder JE, 2011, INJURY, V42, P609, DOI 10.1016/j.injury.2011.03.029; Att W, 2012, INT J ORAL MAX IMPL, V27, P753; Att Wael, 2009, Biomaterials, V30, P5352, DOI 10.1016/j.biomaterials.2009.06.040; Cerqueira MT, 2014, ACTA BIOMATER, V10, P3145, DOI 10.1016/j.actbio.2014.03.006; Frost SA, 2011, BONE, V49, P553, DOI 10.1016/j.bone.2011.06.002; Funato A, 2013, INT J ORAL MAX IMPL, V28, P1261, DOI 10.11607/jomi.3263; Goriainov V, 2014, ACTA BIOMATER, V10, P4043, DOI 10.1016/j.actbio.2014.06.004; Hitani K, 2008, MOL VIS, V14, P1; Hori N, 2009, J DENT RES, V88, P663, DOI 10.1177/0022034509339567; Kubo K, 2008, J BIOMED MATER RES A, V87A, P380, DOI 10.1002/jbm.a.31791; Kumashiro Y, 2014, J BIOMED MATER RES A, V102, P2849, DOI 10.1002/jbm.a.34959; Lewandowska-Szumiel M, 2011, CURR PHARM BIOTECHNO, V12, P1850; Matsuura K, 2014, ANAT REC, V297, P65, DOI 10.1002/ar.22834; Ogawa T, 2012, ORAL CRANIOFAC TISSU, V2, P151; Razzouk S, 2012, J PERIODONTOL, V83, P547, DOI 10.1902/jop.2011.110384; Stadlinger B, 2012, J CLIN PERIODONTOL, V39, P28, DOI 10.1111/j.1600-051X.2011.01835.x; Takaoka S, 2013, J BONE MINER METAB, V31, P102, DOI 10.1007/s00774-012-0389-6; Tani G, 2010, PEDIATR SURG INT, V26, P179, DOI 10.1007/s00383-009-2543-3	52	0	0	SAGE PUBLICATIONS LTD	LONDON	1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND	0885-3282	1530-8022		J BIOMATER APPL	J. Biomater. Appl.	MAY	2015	29	10					1372	1384		10.1177/0885328214567693		13	Engineering, Biomedical; Materials Science, Biomaterials	Engineering; Materials Science	CG3DB	WOS:000353156600005		
J	Yomoda, M; Sobajima, S; Kasuya, A; Neo, M				Yomoda, Mitsuhiro; Sobajima, Satoshi; Kasuya, Akihiro; Neo, Masashi			Calcium phosphate cement - gelatin powder composite testing in canine models: Clinical implications for treatment of bone defects	JOURNAL OF BIOMATERIALS APPLICATIONS			English	Article						Calcium phosphate cement; gelatin powder; interconnected macroporosity; bone replacement; bone substitute	MESENCHYMAL STEM-CELLS; GROWTH-FACTOR RELEASE; IN-VIVO; TRICALCIUM PHOSPHATE; DRUG-DELIVERY; MICROPARTICLES; MACROPOROSITY; MICROSPHERES; SCAFFOLDS; CERAMICS	Previous studies have reported the excellent biocompatibility of calcium phosphate cement. However, calcium phosphate cement needs further improvement in order for it to promote bone replacement and eventual bone substitution, as it exhibits slow biodegradability and thus remains in the body over an extended period of time. In this study, we mixed calcium phosphate cement with gelatin powder in order to create a composite containing macropores with interconnectivity, and we then implanted it into canine femurs from the diaphysis to the distal metaphysis. Eight dogs were divided into the sham group, the control (C0) group with 100 wt% calcium phosphate cement, the C10 group with 90 wt% calcium phosphate cement and 10 wt% gelatin powder, and the C15 group with 85 wt% calcium phosphate cement and 15 wt% gelatin powder. Bone replaceability in C10 and C15 at 3 and 6 months was evaluated by radiography, micro-CT, histomorphometry, and mineral apposition rate. New bone formation was seen in C10 and C15 although that was not seen in C0 at six months. The mineral apposition rate was significantly higher in C15 than in C10 in both the diaphysis and metaphysis, and the composite was found to have excellent biodegradability and bone replaceability in canine subjects. As the composite is easily and rapidly prepared, it is likely to become a new bone substitute for use in clinical settings.	[Yomoda, Mitsuhiro; Kasuya, Akihiro; Neo, Masashi] Osaka Med Coll, Dept Orthoped Surg, Osaka, Japan; [Sobajima, Satoshi] SOBAJIMA Clin, Higashiosaka, Osaka 5770011, Japan	Sobajima, S (reprint author), SOBAJIMA Clin, 2-2-6 Aramotokita, Higashiosaka, Osaka 5770011, Japan.	orthohealing@soba-cli.com		Neo, Masashi/0000-0001-9208-6419	Japan Science and Technology Agency (Adaptable and Seamless Technology Transfer Program through Target-driven RD AS) [2111230F]	This work was supported in part by a Grant from the Japan Science and Technology Agency (Adaptable and Seamless Technology Transfer Program through Target-driven R&D AS 2111230F).	Geuze RE, 2012, TISSUE ENG PT A, V18, P2052, DOI [10.1089/ten.TEA.2011.0560, 10.1089/ten.tea.2011.0560]; Liao HB, 2011, ACTA BIOMATER, V7, P1752, DOI 10.1016/j.actbio.2010.12.020; Takahashi Y, 2005, BIOMATERIALS, V26, P3587, DOI 10.1016/j.biomaterials.2004.09.046; Ooms EM, 2003, BIOMATERIALS, V24, P989, DOI 10.1016/S0142-9612(02)00438-6; Habraken WJEM, 2007, ADV DRUG DELIVER REV, V59, P234, DOI 10.1016/j.addr.2007.03.011; Lee GS, 2011, ACTA BIOMATER, V7, P3178, DOI 10.1016/j.actbio.2011.04.008; Gauthier O, 2003, J BIOMED MATER RES A, V66A, P47, DOI 10.1002/jbm.a.10506; van der Pol U, 2010, ACTA BIOMATER, V6, P3755, DOI 10.1016/j.actbio.2010.03.028; Weir MD, 2010, J BIOMED MATER RES A, V94A, P223, DOI 10.1002/jbm.a.32665; TABATA Y, 1994, J CONTROL RELEASE, V31, P189, DOI 10.1016/0168-3659(94)00035-2; Gauthier O, 1998, BIOMATERIALS, V19, P133, DOI 10.1016/S0142-9612(97)00180-4; Lu JX, 1998, J BIOMED MATER RES, V42, P357, DOI 10.1002/(SICI)1097-4636(19981205)42:3<357::AID-JBM3>3.0.CO;2-I; Carey LE, 2005, BIOMATERIALS, V26, P5002, DOI 10.1016/j.biomaterials.2005.01.015; Damien E, 2003, J BIOMED MATER RES A, V66A, P241, DOI 10.1002/jbm.a.10564; Habraken WJEM, 2009, J BIOMED MATER RES A, V91A, P614, DOI 10.1002/jbm.a.32263; Peng JA, 2011, J BIOMED MATER RES B, V96B, P316, DOI 10.1002/jbm.b.31770; Link DP, 2009, J BIOMED MATER RES A, V90A, P372, DOI 10.1002/jbm.a.32091; Kasuya A, 2012, J ORTHOP RES, V30, P1103, DOI 10.1002/jor.22044; Kuijpers AJ, 1999, MACROMOLECULES, V32, P3325, DOI 10.1021/ma981929v; Link DP, 2008, BIOMATERIALS, V29, P675, DOI 10.1016/j.biomaterials.2007.10.029; Bigi A, 2004, INT J ARTIF ORGANS, V27, P664; Bigi A, 2006, J BIOMED MATER RES A, V78A, P739, DOI 10.1002/jbm.a.30765; Driskell TD, 1975, US patent, Patent No. 3913229; Foley CH, 2010, INT J ORAL MAX IMPL, V25, P278; Li M, 2010, CLIN ORTHOP RELAT R, V468, P1978, DOI 10.1007/s11999-010-1321-9; Matsumoto G, 2014, J BIOMATER APPL, V28, P1316, DOI 10.1177/0885328213507299; NARAYANI R, 1994, J MICROENCAPSUL, V11, P69, DOI 10.3109/02652049409040439; Oh SA, 2010, J MATER SCI-MATER M, V21, P3019, DOI 10.1007/s10856-010-4152-z; Pan ZH, 2008, J TISSUE ENG REGEN M, V2, P347, DOI 10.1002/term.103; Rose P. I., 1987, ENCY POLYM SCI ENG, V7, P488; ZEKORN D, 1969, BIBL HAEMATOL, P131	31	0	0	SAGE PUBLICATIONS LTD	LONDON	1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND	0885-3282	1530-8022		J BIOMATER APPL	J. Biomater. Appl.	MAY	2015	29	10					1385	1393		10.1177/0885328214565935		9	Engineering, Biomedical; Materials Science, Biomaterials	Engineering; Materials Science	CG3DB	WOS:000353156600006		
J	Oda, S; Otsuki, S; Kurokawa, Y; Hoshiyama, Y; Nakajima, M; Neo, M				Oda, Shuhei; Otsuki, Shuhei; Kurokawa, Yoshitaka; Hoshiyama, Yoshiaki; Nakajima, Mikio; Neo, Masashi			A new method for meniscus repair using type I collagen scaffold and infrapatellar fat pad	JOURNAL OF BIOMATERIALS APPLICATIONS			English	Article						Meniscus; meniscus repair; collagen scaffold; infrapatellar fat pad; mesenchymal stem cell	MESENCHYMAL STEM-CELLS; ACTIN EXPRESSION; ARTIFICIAL SKIN; AVASCULAR ZONE; KNEE; RABBIT; OSTEOARTHRITIS; REGENERATION; MENISCECTOMY; AUTOGRAFT	Aim The aim of this study was to investigate a new method for meniscal repair by combinative transplantation with type I collagen scaffold and infrapatellar fat pad. Methods Two-mm cylindrical defects at the anterior part of bilateral medial menisci were prepared in nine Japanese white rabbits. The 18 knees were equally divided into three groups: I, no treatment; II, collagen scaffold transplantation; and III, collagen scaffold and infrapatellar fat pad transplantation. Another three rabbits (six knees) underwent sham surgery and served as controls. Rabbits were sacrificed at eight weeks after transplantation. Surface area of the medial meniscus was evaluated using macrophotographs. Ishida score for meniscal regeneration was used for assessment. To evaluate the composition of regenerated tissue, immunohistochemistry was analyzed with anti-type I and anti-type II collagen antibodies, and anti-Ki67 antibody. To investigate the effects of collagen scaffold on human meniscus, cells were isolated from human meniscus and infrapatellar fat pad, and cultured with collagen scaffold for three weeks. After that, gene expression was evaluated by using quantitative real-time polymerase chain reaction. Results In group I, the meniscus shrank anterior to posterior, and the surface area was significantly less than that of normal meniscus. However, the surface area was maintained in group III. Ishida score and Ki67-positive cell ratio in group III were significantly higher than that in any other group, and staining with type I and type II collagen was similar to that of the control. Expression of matrix metalloproteinase was significantly lower in cocultures of collagen scaffold, meniscus cell, and infrapatellar fat pad cell than in monocultured meniscus cell, and expression of interleukin-1 was not increased. Conclusion: This new method for meniscal repair by combinative transplantation with type I collagen scaffold and infrapatellar fat pad showed meniscal regeneration and potential for suppressing inflammation.	[Oda, Shuhei; Otsuki, Shuhei; Kurokawa, Yoshitaka; Hoshiyama, Yoshiaki; Nakajima, Mikio; Neo, Masashi] Osaka Med Coll, Dept Orthoped Surg, Takatsuki, Osaka 5698686, Japan	Otsuki, S (reprint author), Osaka Med Coll, Dept Orthoped Surg, 2-7 Daigakumachi, Takatsuki, Osaka 5698686, Japan.	ort182@poh.osaka-med.ac.jp		Neo, Masashi/0000-0001-9208-6419	Uehara Foundation [204]	This work was funded by the Uehara Foundation (No. 204).	Ishida K, 2007, TISSUE ENG, V13, P1103, DOI 10.1089/ten.2006.0193; Kawai K, 2001, J BIOMED MATER RES, V57, P346, DOI 10.1002/1097-4636(20011205)57:3<346::AID-JBM1177>3.0.CO;2-8; Kambic HE, 2000, WOUND REPAIR REGEN, V8, P554, DOI 10.1046/j.1524-475x.2000.00554.x; MARKOLF KL, 1976, J BONE JOINT SURG AM, V58, P583; Verdonk R, 2011, AM J SPORT MED, V39, P774, DOI 10.1177/0363546511398040; Brophy RH, 2012, J BONE JOINT SURG AM, V94A, P385, DOI 10.2106/JBJS.K.00919; VOLOSHIN AS, 1983, J BIOMED ENG, V5, P157, DOI 10.1016/0141-5425(83)90036-5; Harston A, 2012, KNEE SURG SPORT TR A, V20, P135, DOI 10.1007/s00167-011-1579-9; Sakaguchi Y, 2005, ARTHRITIS RHEUM, V52, P2521, DOI 10.1002/art.21212; Makris EA, 2011, BIOMATERIALS, V32, P7411, DOI 10.1016/j.biomaterials.2011.06.037; ARNOCZKY SP, 1982, AM J SPORT MED, V10, P90, DOI 10.1177/036354658201000205; ARNOCZKY SP, 1988, J BONE JOINT SURG AM, V70A, P1209; Rongen JJ, 2014, BIOMATERIALS, V35, P3527, DOI 10.1016/j.biomaterials.2014.01.017; Rodkey WG, 2008, J BONE JOINT SURG AM, V90A, P1413, DOI 10.2106/JBJS.G.00656; YANNAS IV, 1980, J BIOMED MATER RES, V14, P65, DOI 10.1002/jbm.820140108; Toghraie FS, 2011, KNEE, V18, P71, DOI 10.1016/j.knee.2010.03.001; YANNAS IV, 1980, J BIOMED MATER RES, V14, P107, DOI 10.1002/jbm.820140203; Nepple JJ, 2012, J BONE JOINT SURG AM, V94A, P2222, DOI 10.2106/JBJS.K.01584; Driscoll MD, 2013, ARTHROSCOPY, V29, P113, DOI 10.1016/j.arthro.2012.06.023; Furumatsu T, 2012, J ORTHOP RES, V30, P1738, DOI 10.1002/jor.22142; Hatsushika D, 2013, J ORTHOP RES, V31, P1354, DOI 10.1002/jor.22370; Hirschman A, 1996, HISTOCHEMISTRY, V10, P369; JITSUIKI J, 1994, ARTHROSCOPY, V10, P659, DOI 10.1016/S0749-8063(05)80065-9; Kohn D, 1997, INT ORTHOP, V21, P232, DOI 10.1007/s002640050157; KUROSAWA H, 1980, CLIN ORTHOP RELAT R, P283; Lin BY, 2002, WOUND REPAIR REGEN, V10, P259, DOI 10.1046/j.1524-475X.2002.10410.x; Liu CX, 2013, ARCH ORTHOP TRAUM SU, V133, P95, DOI 10.1007/s00402-012-1624-2; MACCONAILL MA, 1950, J BONE JOINT SURG BR, V32, P244; Milachowski K A, 1990, Unfallchirurgie, V16, P190, DOI 10.1007/BF02588774; Mochizuki T, 2006, ARTHRITIS RHEUM, V54, P843, DOI 10.1002/art.21651; Papalia R, 2011, BRIT MED BULL, V99, P89, DOI 10.1093/bmb/ldq043; Petersen W, 2007, ARCH ORTHOP TRAUM SU, V127, P235, DOI 10.1007/s00402-005-0024-2; Ruiz-Iban MA, 2011, ARTHROSCOPY, V27, P1688, DOI 10.1016/j.arthro.2011.06.041; Saliken DJJ, 2012, ARTHRITIS RES THER, V14, DOI 10.1186/ar3889; Zellner J, 2013, J BIOMED MATER RES B, V101, P1133, DOI 10.1002/jbm.b.32922; Zimmy ML, 1988, ACTA ANAT, V133, P35	36	0	0	SAGE PUBLICATIONS LTD	LONDON	1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND	0885-3282	1530-8022		J BIOMATER APPL	J. Biomater. Appl.	MAY	2015	29	10					1439	1448		10.1177/0885328215568984		10	Engineering, Biomedical; Materials Science, Biomaterials	Engineering; Materials Science	CG3DB	WOS:000353156600011		
J	Tanimoto, Y; Inami, T; Yamaguchi, M; Nishiyama, N; Kasai, K				Tanimoto, Yasuhiro; Inami, Toshihiro; Yamaguchi, Masaru; Nishiyama, Norihiro; Kasai, Kazutaka			Preparation, mechanical, and in vitro properties of glass fiber-reinforced polycarbonate composites for orthodontic application	JOURNAL OF BIOMEDICAL MATERIALS RESEARCH PART B-APPLIED BIOMATERIALS			English	Article						mechanical properties; in vitro; biomechanics; fiber-reinforced composite; orthodontic	BRACKETS; BIOCOMPATIBILITY; PULTRUSION; DIAMETER; ARCHWIRE; FAILURE; MATRIX; FPDS	Generally, orthodontic treatment uses metallic wires made from stainless steel, cobalt-chromium-nickel alloy, -titanium alloy, and nickel-titanium (Ni-Ti) alloy. However, these wires are not esthetically pleasing and may induce allergic or toxic reactions. To correct these issues, in the present study we developed glass-fiber-reinforced plastic (GFRP) orthodontic wires made from polycarbonate and E-glass fiber by using pultrusion. After fabricating these GFRP round wires with a diameter of 0.45 mm (0.018 inch), we examined their mechanical and in vitro properties. To investigate how the glass-fiber diameter affected their physical properties, we prepared GFRP wires of varying diameters (7 and 13 mu m). Both the GFRP with 13-mu m fibers (GFRP-13) and GFRP with 7 mu m fibers (GFRP-7) were more transparent than the metallic orthodontic wires. Flexural strengths of GFRP-13 and GFRP-7 were 690.3 +/- 99.2 and 938.1 +/- 95.0 MPa, respectively; flexural moduli of GFRP-13 and GFRP-7 were 25.4 +/- 4.9 and 34.7 +/- 7.7 GPa, respectively. These flexural properties of the GFRP wires were nearly equivalent to those of available Ni-Ti wires. GFRP-7 had better flexural properties than GFRP-13, indicating that the flexural properties of GFRP increase with decreasing fiber diameter. Using thermocycling, we found no significant change in the flexural properties of the GFRPs after 600 or 1,200 cycles. Using a cytotoxicity detection kit, we found that the glass fiber and polycarbonate components comprising the GFRP were not cytotoxic within the limitations of this study. We expect this metal-free GFRP wire composed of polycarbonate and glass fiber to be useful as an esthetically pleasing alternative to current metallic orthodontic wire. (c) 2014 Wiley Periodicals, Inc. J Biomed Mater Res Part B: Appl Biomater, 103B: 743-750, 2015.	[Tanimoto, Yasuhiro; Nishiyama, Norihiro] Nihon Univ, Sch Dent Matsudo, Dept Dent Biomat, Matsudo, Chiba 2718587, Japan; [Inami, Toshihiro; Yamaguchi, Masaru; Kasai, Kazutaka] Nihon Univ, Sch Dent Matsudo, Dept Orthodont, Matsudo, Chiba 2718587, Japan	Tanimoto, Y (reprint author), Nihon Univ, Sch Dent Matsudo, Dept Dent Biomat, 2-870-1 Sakaecho Nishi, Matsudo, Chiba 2718587, Japan.	tanimoto.yasuhiro@nihon-u.ac.jp			Japan Society for the Promotion of Science [24792155]; Nihon University Multidisciplinary Research Grant [11-026]	Contract grant sponsor: Japan Society for the Promotion of Science (Grant-in-Aid for Young Scientists (B)); contract grant number: 24792155; Contract grant sponsor: Nihon University Multidisciplinary Research Grant; contract grant number: 11-026	Thomason JL, 2008, COMPOS PART A-APPL S, V39, P1618, DOI 10.1016/j.compositesa.2008.07.002; Eliades T, 2007, AM J ORTHOD DENTOFAC, V131, P253, DOI 10.1016/j.ajodo.2005.12.029; Lee YK, 2008, EUR J ORTHODONT, V30, P205, DOI 10.1093/ejo/cjm122; Van de Velde K, 2001, COMPOS STRUCT, V54, P355, DOI 10.1016/S0263-8223(01)00110-6; Elayyan F, 2008, EUR J ORTHODONT, V30, P661, DOI 10.1093/ejo/cjn057; Gadam SUK, 2000, COMPOS SCI TECHNOL, V60, P945, DOI 10.1016/S0266-3538(99)00181-5; Monaco C, 2003, INT J PROSTHODONT, V16, P319; Eliades T, 2002, ANGLE ORTHOD, V72, P222; Behr M, 2003, INT J PROSTHODONT, V16, P239; Bandeira AMB, 2011, ANGLE ORTHOD, V81, P484, DOI 10.2319/042810-232.1; BRUNETTE DM, 1983, J DENT RES, V62, P1045, DOI 10.1177/00220345830620100701; Catalbas B, 2010, DENT MATER J, V29, P41; Eliades T., 2012, ORTHODONTICS CURRENT, P1023; Faltermeier A, 2007, EUR J ORTHODONT, V29, P304, DOI 10.1093/ejo/cjm025; Fujihara K, 2004, COMPOS SCI TECHNOL, V64, P775, DOI 10.1016/j.compscitech.2003.09.012; Hensten-Pettersen A, 2003, DENT MAT VIVO AGING, P132; Huang ZM, 2003, BIOMATERIALS, V24, P2941, DOI 10.1016/S0142-9612(03)00093-0; Imai T, 1998, BIOMATERIALS, V19, P2195, DOI 10.1016/S0142-9612(98)00127-6; Kloukos D, 2013, DENT MATER, V29, P35; Kloukos D, 2013, AM J ORTHOD DENTOFAC, V143, P104; Li VC, 1996, COMPOS PART B-ENG, V27, P275, DOI 10.1016/1359-8368(95)00031-3; O'Brien WJ, 2008, DENT MAT THEIR SELEC, V4th, P276; Ohtonen J, 2013, EUR J ORTHODONT, V35, P110, DOI 10.1093/ejo/cjr128; Suwa N, 2003, J BIOMED MATER RES B, V67B, P765, DOI 10.1002/jbm.b.10032; Tanimoto Y, 2004, J BIOMED MATER RES A, V68A, P107, DOI 10.1002/jbm.a.20062; vansRijswijk K, 2007, COMPOS PART A-APPL S, V38, P666; Yu Bin, 2011, J Orthod, V38, P167, DOI 10.1179/14653121141434	27	1	1	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1552-4973	1552-4981		J BIOMED MATER RES B	J. Biomed. Mater. Res. Part B	MAY	2015	103	4					743	750		10.1002/jbm.b.33245		8	Engineering, Biomedical; Materials Science, Biomaterials	Engineering; Materials Science	CG5MU	WOS:000353336800003		
J	Kawase, T; Kamiya, M; Kobayashi, M; Tanaka, T; Okuda, K; Wolff, LF; Yoshie, H				Kawase, Tomoyuki; Kamiya, Mana; Kobayashi, Mito; Tanaka, Takaaki; Okuda, Kazuhiro; Wolff, Larry F.; Yoshie, Hiromasa			The heat-compression technique for the conversion of platelet-rich fibrin preparation to a barrier membrane with a reduced rate of biodegradation	JOURNAL OF BIOMEDICAL MATERIALS RESEARCH PART B-APPLIED BIOMATERIALS			English	Article						platelet-rich fibrin; biodegradability; plasmin; barrier membrane; guided tissue regeneration	REGENERATIVE THERAPY; PLASMA; HYDROXYAPATITE; DEFECTS; PRF	Platelet-rich fibrin (PRF) was developed as an advanced form of platelet-rich plasma to eliminate xenofactors, such as bovine thrombin, and it is mainly used as a source of growth factor for tissue regeneration. Furthermore, although a minor application, PRF in a compressed membrane-like form has also been used as a substitute for commercially available barrier membranes in guided-tissue regeneration (GTR) treatment. However, the PRF membrane is resorbed within 2 weeks or less at implantation sites; therefore, it can barely maintain sufficient space for bone regeneration. In this study, we developed and optimized a heat-compression technique and tested the feasibility of the resulting PRF membrane. Freshly prepared human PRF was first compressed with dry gauze and subsequently with a hot iron. Biodegradability was microscopically examined in vitro by treatment with plasmin at 37 degrees C or in vivo by subcutaneous implantation in nude mice. Compared with the control gauze-compressed PRF, the heat-compressed PRF appeared plasmin-resistant and remained stable for longer than 10 days in vitro. Additionally, in animal implantation studies, the heat-compressed PRF was observed at least for 3 weeks postimplantation in vivo whereas the control PRF was completely resorbed within 2 weeks. Therefore, these findings suggest that the heat-compression technique reduces the rate of biodegradation of the PRF membrane without sacrificing its biocompatibility and that the heat-compressed PRF membrane easily could be prepared at chair-side and applied as a barrier membrane in the GTR treatment. (c) 2014 Wiley Periodicals, Inc. J Biomed Mater Res Part B: Appl Biomater, 103B: 825-831, 2015.	[Kawase, Tomoyuki; Kamiya, Mana; Kobayashi, Mito] Niigata Univ, Div Oral Bioengn, Inst Med & Dent, Niigata 9518514, Japan; [Kamiya, Mana; Kobayashi, Mito; Okuda, Kazuhiro; Yoshie, Hiromasa] Niigata Univ, Inst Med & Dent, Div Periodontol, Niigata 9518514, Japan; [Tanaka, Takaaki] Niigata Univ, Dept Mat Sci & Technol, Niigata 9502181, Japan; [Wolff, Larry F.] Univ Minnesota, Div Periodontol, Dept Dev & Surg Sci, Sch Dent, Minneapolis, MN 55455 USA	Kawase, T (reprint author), Niigata Univ, Div Oral Bioengn, Inst Med & Dent, Niigata 9518514, Japan.	kawase@dent.niigata-u.ac.jp			JSPS KAKENHI [24390443, 24390465, 24659872]	Contract grant sponsor: JSPS KAKENHI; contract grant numbers: 24390443, 24390465, and 24659872	Gassling V, 2013, J CRANIO MAXILL SURG, V41, P76, DOI 10.1016/j.jcms.2012.10.015; Kobayashi M, 2012, BIOLOGICALS, V40, P323, DOI 10.1016/j.biologicals.2012.07.004; Simonpieri A, 2012, CURR PHARM BIOTECHNO, V13, P1231; Kawase T, 2010, J PERIODONTOL, V81, P420, DOI 10.1902/jop.2009.090523; Marx RE, 1998, ORAL SURG ORAL MED O, V85, P638, DOI 10.1016/S1079-2104(98)90029-4; Bottino MC, 2012, DENT MATER, V28, P703, DOI 10.1016/j.dental.2012.04.022; Aurer A, 2005, ACTA STOMA T CROAT, V39, P107; BLUMENTHAL NM, 1988, J PERIODONTOL, V59, P830; DelsCorso M, 2012, CURR PHARM BIOTECHNO, V13, P1207; Dohan David M, 2006, Oral Surg Oral Med Oral Pathol Oral Radiol Endod, V101, pe37, DOI 10.1016/j.tripleo.2005.07.008; Horimizu M, 2013, CRYOBIOLOGY, V66, P223, DOI 10.1016/j.cryobiol.2013.01.006; Kawase T, 2011, J BIOMED MATER RES A, V98A, P100, DOI 10.1002/jbm.a.33074; Nakajima Y, 2012, PLATELETS, V23, P594, DOI 10.3109/09537104.2011.645923; Okuda K, 2013, INT J PERIODONT REST, V33, P281, DOI 10.11607/prd.1545; Pelleitier M, 1975, Methods Achiev Exp Pathol, V7, P149; Shivashankar Vasundara Yayathi, 2013, J Conserv Dent, V16, P261, DOI 10.4103/0972-0707.111329; WALKER KA, 1994, POLYMER, V35, P5012, DOI 10.1016/0032-3861(94)90657-2; Yamamiya K, 2008, J PERIODONTOL, V79, P811, DOI 10.1902/jop.2008.070518 	18	4	4	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1552-4973	1552-4981		J BIOMED MATER RES B	J. Biomed. Mater. Res. Part B	MAY	2015	103	4					825	831		10.1002/jbm.b.33262		7	Engineering, Biomedical; Materials Science, Biomaterials	Engineering; Materials Science	CG5MU	WOS:000353336800012		
J	Rashid, AN; Tsuru, K; Ishikawa, K				Rashid, Ahmed Nafis; Tsuru, Kanji; Ishikawa, Kunio			Effect of calcium-ozone treatment on chemical and biological properties of polyethylene terephthalate	JOURNAL OF BIOMEDICAL MATERIALS RESEARCH PART B-APPLIED BIOMATERIALS			English	Article						poly(ethylene terephthalate); ozone treatment; calcium modification; biocompatibility	SELF-ASSEMBLED MONOLAYERS; SURFACE MODIFICATION; CELL-ADHESION; POLYMER SURFACES; CACL2 SOLUTION; IN-VITRO; PLASMA; DECOMPOSITION; TITANIUM; FILM	Ozone (O-3) treatment of polyethylene terephthalate (PET) in distilled water was performed in the presence and absence of calcium (Ca2+). PET was oxidized and thus carboxylic and hydroxyl functional groups were introduced on its surface after O-3 treatment, regardless of the presence or absence of Ca2+. In the case of O-3 treatment with Ca2+, PET surface was modified with Ca2+. Ca2+ immobilization was confirmed by X-ray photoelectron spectrometric analysis. Hydrophilicity was investigated by measuring contact angles (CA). CA of PET decreased significantly after ozonation. Surface topography of PET before and after ozone treatment was observed by scanning electron microscopy, and showed no morphological changes. In vitro studies showed enhanced rat bone marrow cell responses on the O-3-treated PET surface. Ca2+-O-3 oxidation at 37 degrees C for 6 h is expected to be an effective method to fabricate PET with good biocompatibility. (c) 2014 Wiley Periodicals, Inc. J Biomed Mater Res Part B: Appl Biomater, 103B: 853-860, 2015.	[Rashid, Ahmed Nafis; Tsuru, Kanji; Ishikawa, Kunio] Kyushu Univ, Dept Biomat, Fac Dent Sci, Higashi Ku, Fukuoka 8128582, Japan	Rashid, AN (reprint author), Kyushu Univ, Dept Biomat, Fac Dent Sci, Higashi Ku, 3-1-1 Maidashi, Fukuoka 8128582, Japan.	dr_ahmednafis@hotmail.com			Japan Society for the Promotion of Science and Research [072473]	Contract grant sponsor: Grant-in-Aid for Scientific Research from the Japan Society for the Promotion of Science and Research; contract grant number: 072473	Abdrashitov EF, 2003, HIGH ENERG CHEM+, V37, P279, DOI 10.1023/A:1025760027534; Adamson A. W., 1997, PHYS CHEM SURFACES; Amor SB, 2009, APPL SURF SCI, V255, P5052; Ramires PA, 2000, J BIOMED MATER RES, V51, P535, DOI 10.1002/1097-4636(20000905)51:3<535::AID-JBM31>3.0.CO;2-P; Shenton MJ, 2001, J PHYS D APPL PHYS, V34, P2761, DOI 10.1088/0022-3727/34/18/308; Lim HN, 2002, WATER RES, V36, P219, DOI 10.1016/S0043-1354(01)00239-1; Faucheux N, 2004, BIOMATERIALS, V25, P2721, DOI 10.1016/j.biomaterials.2003.09.069; Pavon-Djavid G, 2007, BIOMACROMOLECULES, V8, P3317, DOI 10.1021/bm070344i; Moroni L, 2006, BIOMATERIALS, V27, P4911, DOI 10.1016/j.biomaterials.2006.05.027; Arima Y, 2007, BIOMATERIALS, V28, P3074, DOI 10.1016/j.biomaterials.2007.03.013; Lee JH, 1998, J COLLOID INTERF SCI, V205, P323, DOI 10.1006/jcis.1998.5688; Goddard JM, 2007, PROG POLYM SCI, V32, P698, DOI 10.1016/j.progpolymsci.2007.04.002; Charpentier PA, 2006, APPL SURF SCI, V252, P6360, DOI 10.1016/j.apsusc.2005.09.064; Nayab SN, 2005, BIOMATERIALS, V26, P4717, DOI 10.1016/j.biomaterials.2004.11.044; Zhang L, 2010, J BIOMED MATER RES A, V95A, P33, DOI 10.1002/jbm.a.32763; MANIATOPOULOS C, 1988, CELL TISSUE RES, V254, P317; Park S, 2000, J BIOMED MATER RES, V53, P568, DOI 10.1002/1097-4636(200009)53:5<568::AID-JBM17>3.0.CO;2-8; O'Hare LA, 2002, SURF INTERFACE ANAL, V33, P335, DOI 10.1002/sia.1217; Tharmalingam S, 2011, J BIOL CHEM, V286, P40922, DOI 10.1074/jbc.M111.265454; Efimenko K, 2002, J COLLOID INTERF SCI, V254, P306, DOI 10.1006/jcis.202.8594; Cooper SL, 1982, ADV CHEM SER, V199; Desgranges P, 2001, J BIOMED MATER RES, V58, P1, DOI 10.1002/1097-4636(2001)58:1<1::AID-JBM10>3.0.CO;2-8; Joshua RM, 2005, BIOMATERIALS, V26, P3173; Kumagai H, 2004, J VAC SCI TECHNOL A, V22, P1, DOI 10.1116/1.1624286; Mathieson I, 1996, INT J ADHES ADHES, V16, P29, DOI 10.1016/0143-7496(96)88482-X; Mendoza MP, 1999, CARBON, V37, P1463; Migita S, 1997, JPN J APPL PHYS 1, V36, P94, DOI 10.1143/JJAP.36.94; Mirzadeh H, 2003, RADIAT PHYS CHEM, V67, P381, DOI 10.1016/S0969-806X(03)00071-9; Murakami TN, 2003, COLLOID SURFACE B, V29, P171, DOI 10.1016/S0927-7765(02)00189-3; Nakagawa M, 2005, J MATER SCI-MATER M, V16, P985, DOI 10.1007/s10856-005-4753-0; PEELING J, 1983, J POLYM SCI POL CHEM, V21, P2047, DOI 10.1002/pol.1983.170210715; PEELING J, 1984, J POLYM SCI POL CHEM, V22, P419, DOI 10.1002/pol.1984.170220213; Sakaguchi M, 2009, ARCH BIOCERAM RES, V9, P163; Seidel C, 1999, APPL SURF SCI, V150, P19, DOI 10.1016/S0169-4332(99)00012-4; Tarique AAM, 2010, J CERAM SOC JPN, V118, P512, DOI 10.2109/jcersj2.118.512; Zhou J, 2007, P ANN INT IEEE EMBS, P5115, DOI 10.1109/IEMBS.2007.4353491	36	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1552-4973	1552-4981		J BIOMED MATER RES B	J. Biomed. Mater. Res. Part B	MAY	2015	103	4					853	860		10.1002/jbm.b.33260		8	Engineering, Biomedical; Materials Science, Biomaterials	Engineering; Materials Science	CG5MU	WOS:000353336800015		
J	Chen, ZJ; Yue, SX; Zhou, G; Greenfield, EM; Murakami, S				Chen, Zhijun; Yue, Susan X.; Zhou, Guang; Greenfield, Edward M.; Murakami, Shunichi			ERK1 and ERK2 Regulate Chondrocyte Terminal Differentiation During Endochondral Bone Formation	JOURNAL OF BONE AND MINERAL RESEARCH			English	Article						ERK; HYPERTROPHIC CHONDROCYTES; TERMINAL DIFFERENTIATION; ENDOCHONDRAL OSSIFICATION; METACHONDROMATOSIS	TRANSCRIPTION FACTOR; TRANSGENIC MICE; CELL-LINE; GROWTH; GENE; OSSIFICATION; PATHWAY; OSTEOBLASTS; EXPRESSION; CARTILAGE	Chondrocytes in the epiphyseal cartilage undergo terminal differentiation prior to their removal through apoptosis. To examine the role of ERK1 and ERK2 in chondrocyte terminal differentiation, we generated Osterix (Osx)-Cre; ERK1(-/-); ERK2(flox/flox) mice (conditional knockout Osx [cKO(osx)]), in which ERK1 and ERK2 were deleted in hypertrophic chondrocytes. These cKO(osx) mice were grossly normal in size at birth, but by 3 weeks of age exhibited shorter long bones. Histological analysis in these mice revealed that the zone of hypertrophic chondrocytes in the growth plate was markedly expanded. In situ hybridization and quantitative real-time PCR analyses demonstrated that Matrix metalloproteinase-13 (Mmp13) and Osteopontin expression was significantly decreased, indicating impaired chondrocyte terminal differentiation. Moreover, Egr1 and Egr2, transcription factors whose expression is restricted to the last layers of hypertrophic chondrocytes in wild-type mice, were also strongly downregulated in these cKO(osx) mice. In transient transfection experiments in the RCS rat chondrosarcoma cell line, the expression of Egr1, Egr2, or a constitutively active mutant of MEK1 increased the activity of an Osteopontin promoter, whereas the MEK1-induced activation of the Osteopontin promoter was inhibited by the coexpression of Nab2, an Egr1 and Egr2 co-repressor. These results suggest that MEK1-ERK signaling activates the Osteopontin promoter in part through Egr1 and Egr2. Finally, our histological analysis of cKO(osx) mice demonstrated enchondroma-like lesions in the bone marrow that are reminiscent of human metachondromatosis, a skeletal disorder caused by mutations in PTPN11. Our observations suggest that the development of enchondromas in metachondromatosis may be caused by reduced extracellular signal-regulated kinase/mitogen-activated protein kinase (ERK MAPK) signaling. (c) 2014 American Society for Bone and Mineral Research.	[Chen, Zhijun; Yue, Susan X.; Zhou, Guang; Greenfield, Edward M.; Murakami, Shunichi] Case Western Reserve Univ, Dept Orthopaed, Cleveland, OH 44106 USA; [Zhou, Guang; Murakami, Shunichi] Case Western Reserve Univ, Dept Genet & Genom Sci, Cleveland, OH 44106 USA; [Greenfield, Edward M.; Murakami, Shunichi] Case Western Reserve Univ, Natl Ctr Regenerat Med, Div Gen Med Sci, Cleveland, OH 44106 USA; [Murakami, Shunichi] Murakami Geka Iin, Kawasaki, Kanagawa, Japan	Murakami, S (reprint author), 11100 Euclid Ave,Hanna House 6th Floor, Cleveland, OH 44106 USA.	shun@case.edu			National Institutes of Health [R01AR055556]; Ray A. Kroc and Robert L. Kroc Scholars Award in Arthritis and Connective Tissue Diseases Research	This work was supported by National Institutes of Health grant R01AR055556 (to SM and EMG), and the Ray A. Kroc and Robert L. Kroc Scholars Award in Arthritis and Connective Tissue Diseases Research (to SM). We thank Teresa Pizzuto for expert technical assistance and Valerie Schmedlen for editorial assistance.	Murakami S, 2004, GENE DEV, V18, P290, DOI 10.1101/gad.1179104; Davey RA, 2012, TRANSGENIC RES, V21, P885, DOI 10.1007/s11248-011-9581-z; LeBlanc SE, 2006, J BIOL CHEM, V281, P5453, DOI 10.1074/jbc.M512159200; Senkel S, 2005, BBA-GENE STRUCT EXPR, V1731, P179, DOI 10.1016/j.bbaexp.2005.10.003; Xiong JH, 2011, NAT MED, V17, P1235, DOI 10.1038/nm.2448; Zhang XR, 2011, J BONE MINER RES, V26, P2622, DOI 10.1002/jbmr.502; Rauen KA, 2013, ANNU REV GENOM HUM G, V14, P355, DOI 10.1146/annurev-genom-091212-153523; Jacob AL, 2006, DEV BIOL, V296, P315, DOI 10.1016/j.ydbio.2006.05.031; Usmani SE, 2012, BONE, V51, P131, DOI 10.1016/j.bone.2012.04.012; Grossmann KS, 2010, ADV CANCER RES, V106, P53, DOI 10.1016/S0065-230X(10)06002-1; Rodda SJ, 2006, DEVELOPMENT, V133, P3231, DOI 10.1242/dev.02480; Kim HKW, 2014, J BONE MINER RES, V29, P761, DOI 10.1002/jbmr.2062; Xiao GZ, 2000, J BIOL CHEM, V275, P4453, DOI 10.1074/jbc.275.6.4453; Rankin EB, 2012, CELL, V149, P63, DOI 10.1016/j.cell.2012.01.051; Stickens D, 2004, DEVELOPMENT, V131, P5883, DOI 10.1242/dev.01461; Murakami S, 2000, P NATL ACAD SCI USA, V97, P1113, DOI 10.1073/pnas.97.3.1113; Yoshida CA, 2002, NAT GENET, V32, P633, DOI 10.1038/ng1015; Sato M, 1998, ONCOGENE, V17, P1517, DOI 10.1038/sj.onc.1202064; Yu JX, 2004, MOL CELL, V15, P83, DOI 10.1016/j.molcel.2004.06.030; Levi G, 1996, DEVELOPMENT, V122, P113; McKay MM, 2007, ONCOGENE, V26, P3113, DOI 10.1038/sj.onc.1210394; Fatherazi S, 2009, J DENT RES, V88, P39, DOI 10.1177/0022034508328072; MUKHOPADHYAY K, 1995, J BIOL CHEM, V270, P27711; Yang WT, 2013, NATURE, V499, P491, DOI 10.1038/nature12396; Matsushita T, 2009, MOL CELL BIOL, V29, P5843, DOI 10.1128/MCB.01549-08; Bowen ME, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004364; Bowen ME, PLOS GENET, V7; Chen JQ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0085161; Hess J, 2001, J BIOL CHEM, V276, P20029, DOI 10.1074/jbc.M010601200; Inada M, 2004, P NATL ACAD SCI USA, V101, P17192, DOI 10.1073/pnas.0407788101; Liu QF, 2009, MOL CELL BIOCHEM, V332, P77, DOI 10.1007/s11010-009-0176-4; Long FX, 2013, CSH PERSPECT BIOL, V5, DOI 10.1101/cshperspect.a008334; Matsushita T, 2009, HUM MOL GENET, V18, P227, DOI 10.1093/hmg/ddn339; Nagarajan Le N, 2005, NAT NEUROSCI, V8, P932; Ouyang ZF, 2014, BONE, V58, P136, DOI 10.1016/j.bone.2013.10.016; Saito K, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054853	36	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0884-0431	1523-4681		J BONE MINER RES	J. Bone Miner. Res.	MAY	2015	30	5					765	774		10.1002/jbmr.2409		10	Endocrinology & Metabolism	Endocrinology & Metabolism	CG2JQ	WOS:000353101100003		
J	Abbarin, N; San Miguel, S; Holcroft, J; Iwasaki, K; Ganss, B				Abbarin, Nastaran; San Miguel, Symone; Holcroft, James; Iwasaki, Kengo; Ganss, Bernhard			The Enamel Protein Amelotin Is a Promoter of Hydroxyapatite Mineralization	JOURNAL OF BONE AND MINERAL RESEARCH			English	Article						AMELOTIN; ENAMEL; HYDROXYAPATITE; BIOMINERALIZATION; ELECTRON MICROSCOPY	IN-VITRO; AMELOGENESIS IMPERFECTA; CALCIUM-PHOSPHATE; MATRIX PROTEINS; INCISOR ENAMEL; OSTEOPONTIN; ADSORPTION; BINDING; GROWTH; BIOMINERALIZATION	Amelotin (AMTN) is a recently discovered protein that is specifically expressed during the maturation stage of dental enamel formation. It is localized at the interface between the enamel surface and the apical surface of ameloblasts. AMTN knock-out mice have hypomineralized enamel, whereas transgenic mice overexpressing AMTN have a compact but disorganized enamel hydroxyapatite (HA) microstructure, indicating a possible involvement of AMTN in regulating HA mineralization directly. In this study, we demonstrated that recombinant human (rh) AMTN dissolved in a metastable buffer system, based on light scattering measurements, promotes HA precipitation. The mineral precipitates were characterized by scanning and transmission electron microscopy and electron diffraction. Colloidal gold immunolabeling of AMTN in the mineral deposits showed that protein molecules were associated with HA crystals. The binding affinity of rh-AMTN to HA was found to be comparable to that of amelogenin, the major protein of the forming enamel matrix. Overexpression of AMTN in mouse calvaria cells also increased the formation of calcium deposits in the culture medium. Overexpression of AMTN during the secretory stage of enamel formation in vivo resulted in rapid and uncontrolled enamel mineralization. Site-specific mutagenesis of the potential serine phosphorylation motif SSEEL reduced the in vitro mineral precipitation to less than 25%, revealing that this motif is important for the HA mineralizing function of the protein. A synthetic short peptide containing the SSEEL motif was only able to facilitate mineralization in its phosphorylated form ((SSEEL)-S-P-S-P), indicating that this motif is necessary but not sufficient for the mineralizing properties of AMTN. These findings demonstrate that AMTN has a direct influence on biomineralization by promoting HA mineralization and suggest a critical role for AMTN in the formation of the compact aprismatic enamel surface layer during the maturation stage of amelogenesis. (c) 2015 American Society for Bone and Mineral Research.	[Abbarin, Nastaran; San Miguel, Symone; Holcroft, James; Ganss, Bernhard] Univ Toronto, Fac Dent, Matrix Dynam Grp, Toronto, ON, Canada; [Iwasaki, Kengo] Tokyo Med & Dent Univ, Grad Sch Med & Dent Sci, Dept Nanomed, Tokyo, Japan	Ganss, B (reprint author), Univ Toronto, Fac Dent, Matrix Dynam Grp, 150 Coll St,Room 235, Toronto, ON, Canada.	b.ganss@utoronto.ca			National Sciences and Engineering Research Council of Canada (NSERC) [490975]; Canadian Institutes of Health Research (CIHR) [MOP-492418]	This project was supported by the National Sciences and Engineering Research Council of Canada (NSERC, operating grant #490975) and the Canadian Institutes of Health Research (CIHR, operating grant MOP-492418) to BG. We thank Dr Esben Sorensen (Aarhus University, Denmark) for providing the milk osteopontin protein and Douglas Holmyard (Advanced Bioimaging Centre, Mount Sinai Hospital, Toronto) for his expert assistance with the TEM imaging.	Smith CE, 2011, J BIOL CHEM, V286, P18149, DOI 10.1074/jbc.M110.194258; Gibson CW, 2001, J BIOL CHEM, V276, P31871, DOI 10.1074/jbc.M104624200; George A, 2008, CHEM REV, V108, P4670, DOI 10.1021/cr0782729; Lacruz RS, 2013, J DENT RES, V92, P122, DOI 10.1177/0022034512470954; Moinichen CB, 1996, J ANAT, V189, P325; Sire JY, 2007, CELLS TISSUES ORGANS, V186, P25, DOI 10.1159/000102679; Fang PA, 2011, P NATL ACAD SCI USA, V108, P14097, DOI 10.1073/pnas.1106228108; Beniash E, 2009, J STRUCT BIOL, V166, P133, DOI 10.1016/j.jsb.2009.02.001; Iafisco M, 2008, LANGMUIR, V24, P4924, DOI 10.1021/la703381h; Ruan QC, 2013, ACTA BIOMATER, V9, P7289, DOI 10.1016/j.actbio.2013.04.004; ten Cate JM, 2012, J DENT RES, V91, P813, DOI 10.1177/0022034512455032; Addison WN, 2007, J BIOL CHEM, V282, P15872, DOI 10.1074/jbc.M701116200; Smith CE, 1998, CRIT REV ORAL BIOL M, V9, P128; Helmerhorst EJ, 2010, J PROTEOME RES, V9, P5413, DOI 10.1021/pr100653r; Moffatt P, 2008, J CELL BIOCHEM, V103, P941, DOI 10.1002/jcb.21465; Yang XD, 2010, J PHYS CHEM B, V114, P2293, DOI 10.1021/jp910219s; Selwitz RH, 2007, LANCET, V369, P51, DOI 10.1016/S0140-6736(07)60031-2; Iwasaki K, 2005, J DENT RES, V84, P1127; Nishio C, 2010, EUR CELLS MATER, V20, P393; McDonald EE, 2011, J DENT RES, V90, P268, DOI 10.1177/0022034510388653; Du C, 2005, SCIENCE, V307, P1450, DOI 10.1126/science.1105675; Hoemann CD, 2009, PATHOL BIOL, V57, P318, DOI 10.1016/j.patbio.2008.06.004; Tarasevich BJ, 2007, J CRYST GROWTH, V304, P407, DOI 10.1016/j.jcrysgro.2007.02.035; Moffatt P, 2006, EUR J ORAL SCI, V114, P139, DOI 10.1111/j.1600-0722.2006.00318.x; Hu JCC, 2008, J BIOL CHEM, V283, P10858, DOI 10.1074/jbc.M710565200; Kawasaki K, 2003, P NATL ACAD SCI USA, V100, P4060, DOI 10.1073/pnas.0638023100; Oyane A, 2003, J BIOMED MATER RES A, V65A, P188, DOI 10.1002/jbm.a.10482; Sodek J, 2000, CRIT REV ORAL BIOL M, V11, P279; Margolis HC, 2006, J DENT RES, V85, P775; Gasse B, 2012, J DENT RES, V91, P1085, DOI 10.1177/0022034512460551; Somogyi-Ganss E, 2012, CELLS TISSUES ORGANS, V195, P535, DOI 10.1159/000329255; Fukumoto S, 2004, J CELL BIOL, V167, P973, DOI 10.1083/jcb.200409077; Hu JCC, 2007, CELLS TISSUES ORGANS, V186, P78, DOI 10.1159/000102683; Moradian-Oldak J, 2012, FRONT BIOSCI-LANDMRK, V17, P1996, DOI 10.2741/4034; SORENSEN ES, 1993, J DAIRY RES, V60, P189; Simmer JP, 2010, J DENT RES, V89, P1024, DOI 10.1177/0022034510375829; He G, 2005, J BIOL CHEM, V280, P33109, DOI 10.1074/jbc.M500159200; Brunauer S, 1938, J AM CHEM SOC, V60, P309, DOI 10.1021/ja01269a023; Kwak SY, 2009, J BIOL CHEM, V284, P18972, DOI 10.1074/jbc.M109.020370; Wang LJ, 2008, J PHYS CHEM C, V112, P5892, DOI 10.1021/jp077105+; AOBA T, 1987, CALCIFIED TISSUE INT, V41, P86, DOI 10.1007/BF02555250; BOSKEY AL, 1993, BONE MINER, V22, P147, DOI 10.1016/S0169-6009(08)80225-5; Boskey AL, 2012, BIOCHEM BIOPH RES CO, V419, P333, DOI 10.1016/j.bbrc.2012.02.024; Bouropoulos N, 2003, CALCIFIED TISSUE INT, V72, P599, DOI 10.1007/s00223-002-1099-1; Buerlein E., 2007, HDB BIOMINERALIZATIO; de Bruyn JR, 2013, PLOS ONE, V8; Goldberg HA, 2001, CONNECT TISSUE RES, V42, P25, DOI 10.3109/03008200109014246; He G, 2005, BIOCHEMISTRY-US, V44, P16140, DOI 10.1021/bi051045l; Holcroft J, 2011, EUR J ORAL SCI, V119, P301, DOI 10.1111/j.1600-0722.2011.00870.x; KRESAK M, 1977, J COLLOID INTERF SCI, V59, P283, DOI 10.1016/0021-9797(77)90010-8; Lacruz RS, 2012, PLOS ONE, V7; Iafisco M, 2010, COLLOID SURFACE B, V81, P274, DOI 10.1016/j.colsurfb.2010.07.022; Lyngstadaas SP, 1998, ANAT REC, V250, P268, DOI 10.1002/(SICI)1097-0185(199803)250:3<268::AID-AR2>3.0.CO;2-X; Milan AM, 2006, EUR J ORAL SCI, V114, P223, DOI 10.1111/j.1600-0722.2006.00347.x; Mohan C, 2003, GUIDE PREPARATION US; Nanci A., 2008, 10 CATES ORAL HISTOL; Neves Dos Santos, 2012, HISTOCHEM CELL BIOL, V137, P329; Parry DA, 2012, AM J HUM GENET, V91, P565, DOI 10.1016/j.ajhg.2012.07.020; Simmer JP, 2009, J BIOL CHEM, V284, P19110, DOI 10.1074/jbc.M109.013623; Stolf D. P., 2013, J INTERDISCIPL HISTO, V1, P236, DOI [10.5455/jihp.20130506045106, DOI 10.5455/JIHP.20130506045106]; Sun Z, 2008, J DENT RES, V87, P1133; WARSHAWSKY H, 1981, ANAT REC, V200, P371, DOI 10.1002/ar.1092000402; Wazen RM, 2009, MATRIX BIOL, V28, P292, DOI 10.1016/j.matbio.2009.04.004; Wright JT, 2008, CELLS TISSUES ORGANS, V189, P224	64	3	3	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0884-0431	1523-4681		J BONE MINER RES	J. Bone Miner. Res.	MAY	2015	30	5					775	785		10.1002/jbmr.2411		11	Endocrinology & Metabolism	Endocrinology & Metabolism	CG2JQ	WOS:000353101100004		
J	Omata, Y; Yasui, T; Hirose, J; Izawa, N; Imai, Y; Matsumoto, T; Masuda, H; Tokuyama, N; Nakamura, S; Tsutsumi, S; Yasuda, H; Okamoto, K; Takayanagi, H; Hikita, A; Imamura, T; Matsuo, K; Saito, T; Kadono, Y; Aburatani, H; Tanaka, S				Omata, Yasunori; Yasui, Tetsuro; Hirose, Jun; Izawa, Naohiro; Imai, Yuuki; Matsumoto, Takumi; Masuda, Hironari; Tokuyama, Naoto; Nakamura, Shinya; Tsutsumi, Shuichi; Yasuda, Hisataka; Okamoto, Kazuo; Takayanagi, Hiroshi; Hikita, Atsuhiko; Imamura, Takeshi; Matsuo, Koichi; Saito, Taku; Kadono, Yuho; Aburatani, Hiroyuki; Tanaka, Sakae			Genomewide Comprehensive Analysis Reveals Critical Cooperation Between Smad and c-Fos in RANKL-Induced Osteoclastogenesis	JOURNAL OF BONE AND MINERAL RESEARCH			English	Article						OSTEOCLAST; MOLECULAR PATHWAYS; CYTOKINES; CELL; TISSUE SIGNALING; TRANSCRIPTION FACTORS	BETA-INDUCED TRANSCRIPTION; TGF-BETA; IN-VITRO; DIFFERENTIATION; PROTEINS; ACTIVATION; RECEPTOR; BINDING; NFATC1; TARGET	We have previously reported that transforming growth factor (TGF-) plays an essential role in receptor activator of nuclear factor-B ligand (RANKL)-induced osteoclastogenesis. However, the detailed underlying molecular mechanisms still remain unclear. Formaldehyde-assisted isolation of regulatory elements (FAIRE) and chromatin immunoprecipitation (ChIP) followed by sequencing (FAIRE-seq and ChIP-seq) analyses indicated the cooperation of Smad2/3 with c-Fos during osteoclastogenesis. Biochemical analysis and immunocytochemical analysis revealed that physical interaction between Smad2/3 and c-Fos is required for their nuclear translocation. The gene expression of nuclear factor of activated T-cells, cytoplasmic 1 (Nfatc1), a key regulator of osteoclastogenesis, was regulated by RANKL and TGF-, and c-Fos binding to open chromatin sites was suppressed by inhibition of TGF- signaling by SB431542. Conversely, Smad2/3 binding to Nfatc1 was impaired by c-Fos deficiency. These results suggest that TGF- regulates RANKL-induced osteoclastogenesis through reciprocal cooperation between Smad2/3 and c-Fos. (c) 2014 American Society for Bone and Mineral Research.	[Omata, Yasunori; Yasui, Tetsuro; Hirose, Jun; Izawa, Naohiro; Matsumoto, Takumi; Masuda, Hironari; Tokuyama, Naoto; Nakamura, Shinya; Saito, Taku; Kadono, Yuho; Tanaka, Sakae] Univ Tokyo, Fac Med, Dept Orthopaed Surg, Tokyo 1130033, Japan; [Imai, Yuuki] Ehime Univ, Grad Sch Med, Proteosci Ctr, Div Integrat Pathophysiol, Matsuyama, Ehime 790, Japan; [Tsutsumi, Shuichi; Aburatani, Hiroyuki] Univ Tokyo, RCAST, Genome Sci Div, Tokyo 1130033, Japan; [Yasuda, Hisataka] Oriental Yeast Co Ltd, Bioind Div, Tokyo, Japan; [Okamoto, Kazuo; Takayanagi, Hiroshi] Univ Tokyo, Grad Sch Med, Dept Immunol, Tokyo 1130033, Japan; [Okamoto, Kazuo; Takayanagi, Hiroshi] Univ Tokyo, Fac Med, Tokyo 1130033, Japan; [Okamoto, Kazuo; Takayanagi, Hiroshi] Japan Sci & Technol Agcy JST, Exploratory Res Adv Technol ERATO Program, Takayanagi Osteonetwork Project, Tokyo, Japan; [Hikita, Atsuhiko; Imamura, Takeshi] Ehime Univ, Grad Sch Med, Dept Mol Med Pathogenesis, Matsuyama, Ehime 790, Japan; [Matsuo, Koichi] Keio Univ, Sch Med, Lab Cell & Tissue Biol, Tokyo, Japan	Tanaka, S (reprint author), Univ Tokyo, Fac Med, Dept Orthopaed Surg, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1130033, Japan.	TANAKAS-ORT@h.u-tokyo.ac.jp			Ministry of Education, Culture, Sports, Science and Technology of Japan	This work was supported in part by Grants-in-Aid from the Ministry of Education, Culture, Sports, Science and Technology of Japan. We thank R. Yamaguchi and J. Sugita (Department of Orthopaedic Surgery, The University of Tokyo) for providing expert technical assistance.	WANG ZQ, 1992, NATURE, V360, P741, DOI 10.1038/360741a0; Hanai J, 1999, J BIOL CHEM, V274, P31577, DOI 10.1074/jbc.274.44.31577; Massague Joan, 1994, Trends in Cell Biology, V4, P172, DOI 10.1016/0962-8924(94)90202-X; Sasaki T, 2006, MOL CELL, V24, P63, DOI 10.1016/j.molcel.2006.08.005; Tondravi MM, 1997, NATURE, V386, P81, DOI 10.1038/386081a0; Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092-8674(00)81569-X; Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534-5807(02)00369-6; Tanaka S, 2007, AM J NEPHROL, V27, P466, DOI 10.1159/000106484; Core LJ, 2008, SCIENCE, V319, P1791, DOI 10.1126/science.1150843; Song LY, 2011, GENOME RES, V21, P1757, DOI 10.1101/gr.121541.111; Norwitz ER, 2002, J BIOL CHEM, V277, P37469, DOI 10.1074/jbc.M206571200; JOHNSON RS, 1992, CELL, V71, P577, DOI 10.1016/0092-8674(92)90592-Z; Massague J, 2006, FEBS LETT, V580, P2811, DOI 10.1016/j.febslet.2006.04.033; Giresi PG, 2009, METHODS, V48, P233, DOI 10.1016/j.ymeth.2009.03.003; Jochum W, 2001, ONCOGENE, V20, P2401, DOI 10.1038/sj.onc.1204389; Zhang Y, 1998, NATURE, V394, P909; Matsuo K, 2000, NAT GENET, V24, P184; Baker JC, 1996, GENE DEV, V10, P1880, DOI 10.1101/gad.10.15.1880; Sharma SM, 2007, J BIOL CHEM, V282, P15921, DOI 10.1074/jbc.M609723200; Biddie SC, 2011, MOL CELL, V43, P145, DOI 10.1016/j.molcel.2011.06.016; Ishida N, 2002, J BIOL CHEM, V277, P41147, DOI 10.1074/jbc.M205063200; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; Suda T, 1999, ENDOCR REV, V20, P345, DOI 10.1210/er.20.3.345; Hua XX, 1998, GENE DEV, V12, P3084, DOI 10.1101/gad.12.19.3084; Sundqvist A, 2013, ONCOGENE, V32, P3606, DOI 10.1038/onc.2012.370; Derynck R, 2003, NATURE, V425, P577, DOI 10.1038/nature02006; Yingling JM, 1997, MOL CELL BIOL, V17, P7019; Matsuo K, 2004, J BIOL CHEM, V279, P26475, DOI 10.1074/jbc.M313973200; Li MO, 2008, CELL, V134, P392, DOI 10.1016/j.cell.2008.07.025; Yasui T, 2011, J BONE MINER RES, V26, P2665, DOI 10.1002/jbmr.464; Yasui T, 2011, J BONE MINER RES, V26, P1447, DOI 10.1002/jbmr.357; Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597; Fox SW, 2003, J IMMUNOL, V170, P3679; Graff JM, 1996, CELL, V85, P479, DOI 10.1016/S0092-8674(00)81249-0; Mansky KC, 2002, J LEUKOCYTE BIOL, V71, P295; Sims Robert J. III, 2004, Genes & Development, V18, P2437, DOI 10.1101/gad.1235904; Zhou S, 1998, MOL CELL, V2, P121, DOI 10.1016/S1097-2765(00)80120-3	37	1	1	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0884-0431	1523-4681		J BONE MINER RES	J. Bone Miner. Res.	MAY	2015	30	5					869	877		10.1002/jbmr.2418		9	Endocrinology & Metabolism	Endocrinology & Metabolism	CG2JQ	WOS:000353101100011		
J	Yuan, JH; Emura, K; Farnham, C				Yuan, Jihui; Emura, Kazuo; Farnham, Craig			A method to measure retro-reflectance and durability of retro-reflective materials for building outer walls	JOURNAL OF BUILDING PHYSICS			English	Article						Heat island; building surface; retro-reflective materials; solar reflectance; retro-reflectance; durability	ROOFS	A method of determining the retro-reflectance of retro-reflective materials used for building coatings is proposed in this article. In addition, the durability of retro-reflective materials over long-term outdoor exposure is also estimated. Retro-reflective materials are currently limited to use in specific purposes, such as road traffic signs in Japan. To consider their application as a building coating, it is also necessary to examine the thermal performance and durability of retro-reflective materials. We proposed a method of determining the retro-reflectance of retro-reflective materials (capsule retro-reflective material and prism retro-reflective material were used in this experiment) by experiment. To explore the durability of retro-reflective materials over long-term outdoor exposure, we measured the changes in solar reflectance and retro-reflectance of retro-reflective materials exposed to the outdoors over about 25 months. The solar reflectance of capsule retro-reflective material decreased from 0.69 to 0.51 and that of prism retro-reflective material decreased from 0.83 to 0.81. The retro-reflectance of capsule retro-reflective material decreased from 0.18 to near 0 (0.0072) and that of prism retro-reflective material decreased from 0.44 to 0.42. At the end of the test period, we cleaned the surface of the retro-reflective materials. Both of the retro-reflective materials recovered about 50% of the lost solar reflectance by cleaning. The retro-reflectance of capsule retro-reflective material increased by about 0.08 (46% recovered) by cleaning and that of prism retro-reflective material increased by only 0.01 (with 50% recovered) by cleaning. We concluded that the durability of prism retro-reflective material is better than that of capsule retro-reflective material for use on building coatings.	[Yuan, Jihui; Emura, Kazuo; Farnham, Craig] Osaka City Univ, Grad Sch Human Life Sci, Dept Housing & Environm Design, Osaka 5588585, Japan	Yuan, JH (reprint author), Osaka City Univ, Grad Sch Human Life Sci, Dept Housing & Environm Design, Sumiyoshi Ku, 3-3-138 Sugimoto, Osaka 5588585, Japan.	yuanjihui@hotmail.co.jp			Foundation of Construction Materials Industrial Promotion Tostem Corporation; Architecture Research Foundation of Takenaka Scholarship Foundation of Japan; Keyence Co., Ltd of Japan; Urban Studies of Osaka City University	This research was supported by the Foundation of Construction Materials Industrial Promotion Tostem Corporation, the Architecture Research Foundation of Takenaka Scholarship Foundation of Japan, Keyence Co., Ltd of Japan, and the Urban Studies of Osaka City University (representative researcher: Prof. Kazuo Emura).	PEREZ R, 1990, SOL ENERGY, V44, P271, DOI 10.1016/0038-092X(90)90055-H; [Anonymous], 1992, 984511992 ISO; [Anonymous], C154909 ASTM; Yuan JH, 2013, J BUILD PHYS, V37, P170, DOI 10.1177/1744259112459263; Brunt D, 1932, Q J ROY METEOR SOC, V58, P389; Akbari H, 1999, ENERGY, V24, P391, DOI 10.1016/S0360-5442(98)00105-4; [Anonymous], 2008, K56022008 JIS; Hagishima A, 2004, J JAPAN SOC HYDROLOG, V17, P536, DOI 10.3178/jjshwr.17.536; Ministry of the Environment Government of Japan, 2010, RES SERV REP ENV IMP, P35; Saber HH, 2012, BUILD ENVIRON, V50, P141, DOI 10.1016/j.buildenv.2011.10.022; Sakai H., 2009, P 2 INT C COUNT URB, P1	11	2	2	SAGE PUBLICATIONS LTD	LONDON	1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND	1744-2591	1744-2583		J BUILD PHYS	J. Build Phys.	MAY	2015	38	6					500	516		10.1177/1744259113517208		17	Construction & Building Technology	Construction & Building Technology	CG3YF	WOS:000353215000002		
J	Kawao, N; Kaji, H				Kawao, Naoyuki; Kaji, Hiroshi			Interactions Between Muscle Tissues and Bone Metabolism	JOURNAL OF CELLULAR BIOCHEMISTRY			English	Article						MUSCLE; BONE; SARCOPENIA; OSTEOPOROSIS	OSTEOBLAST DIFFERENTIATION; SIGNALING PATHWAY; BODY-COMPOSITION; EXPRESSION; MYOSTATIN; CELLS; MASS; OSTEOPOROSIS; SARCOPENIA; EXERCISE	Sarcopenia and osteoporosis have recently been noted for their relationship with locomotive syndrome and increased number of older people. Sarcopenia is defined by decreased muscle mass and impaired muscle function, which may be associated with frailty. Several clinical data have indicated that increased muscle mass is related to increased bone mass and reduced fracture risk. Genetic, endocrine and mechanical factors as well as inflammatory and nutritional states concurrently affect muscle tissues and bone metabolism. Several genes, including myostatin and a-actinin 3, have been shown in a genome-wide association study (GWAS) to be associated with both sarcopenia and osteoporosis. Vitamin D, growth hormone and testosterone as well as pathological disorders, such as an excess in glucocorticoid and diabetes, affect both muscle and bone. Basic and clinical research of bone metabolism and muscle biology suggests that bone interacts with skeletal muscle via signaling from local and humoral factors in addition to their musculoskeletal function. However, the physiological and pathological mechanisms related to muscle and bone interactions remain unclear. We found that Tmem119 may play a critical role in the commitment of myoprogenitor cells to the osteoblast lineage. We also reported that osteoglycin and FAM5C might be muscle-derived humoral osteogenic factors. Other factors, including myostatin, osteonectin, insulin-like growth factor I, irisin and osteocalcin, may be associated with the interactions between muscle tissues and bone metabolism. J. Cell. Biochem. 116: 687-695, 2015. (C) 2014 Wiley Periodicals, Inc.	[Kawao, Naoyuki; Kaji, Hiroshi] Kinki Univ, Fac Med, Dept Physiol & Regenerat Med, Osakasayama, Japan	Kaji, H (reprint author), Kinki Univ, Fac Med, Dept Physiol & Regenerat Med, 377-2 Ohnohigashi, Osaka 5898511, Japan.	hkaji@med.kindai.ac.jp					Johnson RW, 2014, BONE, V64, P47, DOI 10.1016/j.bone.2014.03.053; Daly RM, 2014, CURR OSTEOPOROS REP, V12, P219, DOI 10.1007/s11914-014-0207-2; Huang J, 2014, J BONE MINER RES, V29, P1531, DOI 10.1002/jbmr.2200; Garcia LA, 2011, ENDOCRINOLOGY, V152, P2976, DOI 10.1210/en.2011-0159; Kaji H, 2013, CURR OPIN CLIN NUTR, V16, P272, DOI 10.1097/MCO.0b013e32835fe6a5; Hisa I, 2011, J BIOL CHEM, V286, P9787, DOI 10.1074/jbc.M110.179127; An JH, 2010, BONE, V47, P140, DOI 10.1016/j.bone.2010.04.593; Xi G, 2014, J BONE MINER RES, V29, P2427, DOI 10.1002/jbmr.2282; Guo YF, 2013, HUM GENET, V132, P189, DOI 10.1007/s00439-012-1236-5; Bhat M, 2013, ENDOCRINOLOGY, V154, P4018, DOI 10.1210/en.2013-1369; Anastasilakis AD, 2014, OSTEOPOROSIS INT, V25, P1633, DOI 10.1007/s00198-014-2673-x; McPherron AC, 1997, NATURE, V387, P83, DOI 10.1038/387083a0; Finkelstein JS, 2013, NEW ENGL J MED, V369, P1011, DOI 10.1056/NEJMoa1206168; Zimmers TA, 2002, SCIENCE, V296, P1486, DOI 10.1126/science.1069525; Park KH, 2013, J CLIN ENDOCR METAB, V98, P4899, DOI 10.1210/jc.2013-2373; Juffer P, 2012, AM J PHYSIOL-ENDOC M, V302, pE389, DOI 10.1152/ajpendo.00320.2011; Tanaka K, 2012, BONE, V51, P158, DOI 10.1016/j.bone.2012.04.017; Aoi W, 2013, GUT, V62, P882, DOI 10.1136/gutjnl-2011-300776; Cruz-Jentoft AJ, 2010, AGE AGEING, V39, P412, DOI 10.1093/ageing/afq034; Faul C, 2011, J CLIN INVEST, V121, P4393, DOI 10.1172/JCI46122; Handschin C, 2008, NATURE, V454, P463, DOI 10.1038/nature07206; Tanaka K, 2012, J BIOL CHEM, V287, P11616, DOI 10.1074/jbc.M111.292193; Karasik D, 2008, J BONE MINER RES, V23, P788, DOI [10.1359/jbmr.080218, 10.1359/JBMR.080218]; Bostrom P, 2012, NATURE, V481, P463, DOI 10.1038/nature10777; Robling AG, 2008, J BIOL CHEM, V283, P5866, DOI 10.1074/jbc.M705092200; Terracciano C, 2013, OSTEOPOROSIS INT, V24, P1095, DOI 10.1007/s00198-012-1990-1; LeBrasseur NK, 2012, J BONE MINER RES, V27, P2159, DOI 10.1002/jbmr.1666; Argiles JM, 2014, J CACHEXIA SARCOPENI, V5, P279, DOI 10.1007/s13539-014-0154-x; Bogl LH, 2011, J BONE MINER RES, V26, P79, DOI 10.1002/jbmr.192; Bonnet N, 2014, J BONE MINER RES, V29, pS8; Colaianni G, 2014, INT J ENDOCRINOL, V2014, DOI 10.1155/2014/902186; Fei YR, 2011, J BIOL CHEM, V286, P40575, DOI 10.1074/jbc.M111.274910; Jeong Y, 2014, J BONE MINER RES, V29, pS72; Kaji Hiroshi, 2014, J Bone Metab, V21, P29, DOI 10.11005/jbm.2014.21.1.29; Karasik D, 2012, FRONT PHYSIOL, V3, DOI 10.3389/fphys.2012.00303; Kim JS, 2005, AM J PHYSIOL-ENDOC M, V288, pE1110, DOI 10.1152/ajpendo.00464.2004; Krause A, 2014, J BONE MINER RES, V29, pS8; Liu RJ, 2011, BMC MUSCULOSKEL DIS, V12, DOI 10.1186/1471-2474-12-288; Mao L, 2013, ENDOCR J, V60, P1309; Mera P, 2014, J BONE MINER RES, V29, pS50; Nikawa T, 2004, FASEB J, V18, P522, DOI 10.1096/fj.03-0419fje; Ormsbee MJ, 2014, J CACHEXIA SARCOPENI, V5, P183, DOI 10.1007/s13539-014-0146-x; Qiu J, 2013, P NATL ACAD SCI USA, V110, P18162, DOI 10.1073/pnas.1317049110; Shore EM, 2008, BONE, V43, P427, DOI 10.1016/j.bone.2008.05.013; Tanaka K, 2012, BIOCHEM BIOPH RES CO, V418, P134, DOI 10.1016/j.bbrc.2011.12.147; Tanaka K, 2014, BIOCHEM BIOPH RES CO, V450, P482, DOI 10.1016/j.bbrc.2014.05.145; Baldelli S, 2014, J CELL SCI, V127, P4813, DOI 10.1242/jcs.154229; Xiao LP, 2014, ENDOCRINOLOGY, V155, P965, DOI 10.1210/en.2013-1919; Yang N, 2011, BONE, V49, P790, DOI 10.1016/j.bone.2011.07.009; Yano M, 2014, EXP CLIN ENDOCR DIAB, V122, P7, DOI 10.1055/s-0033-1357129; Zhang J, 2013, J BONE MINER RES, V28, pS127	51	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0730-2312	1097-4644		J CELL BIOCHEM	J. Cell. Biochem.	MAY	2015	116	5					687	695		10.1002/jcb.25040		9	Biochemistry & Molecular Biology; Cell Biology	Biochemistry & Molecular Biology; Cell Biology	CF8ND	WOS:000352817300001		
J	Takano, T; Matsui, K				Takano, Tomoyuki; Matsui, Katsuyuki			Increased Expression of GAP43 in Interneurons in a Rat Model of Experimental Polymicrogyria	JOURNAL OF CHILD NEUROLOGY			English	Article						polymicrogyria; GAP43; interneuron; seizure susceptibility	LONG-TERM POTENTIATION; GAP-43 MESSENGER-RNA; CORTICAL DYSPLASIA; FLUORO-JADE; KAINIC ACID; GLUTAMATE NEUROTOXICITY; INHIBITORY INTERNEURONS; NEURONAL DEGENERATION; STATUS EPILEPTICUS; RECEPTOR SUBUNITS	To investigate seizure susceptibility in polymicrogyria, the seizure threshold and growth-associated protein GAP43 expression were analyzed in a rat experimental model of polymicrogyria induced by intracerebral injection of ibotenate. A total of 72 neonates from 9 pregnant rats were used. Intraperitoneal pentylenetetrazole injection did not induce any seizure activity in the control rats, although it elicited seizures of variable severity in the polymicrogyria rats. Fluoro-Jade B-positive degenerating interneurons were found in the polymicrogyria brains; however, no such neurons were detected in the control brains. In the polymicrogyria rats, the GAP43 expression was significantly and widely distributed in the brain, and the percentage of parvalbumin-positive interneurons in the GAP43-positive cells was significantly higher than that observed in the nonphosphorylated neurofilament-positive pyramidal cells. We conclude that the relatively selective vulnerability of inhibitory interneurons constitutes the basis for the decreased seizure threshold observed in this model of polymicrogyria.	[Takano, Tomoyuki; Matsui, Katsuyuki] Shiga Univ Med Sci, Dept Pediat, Otsu, Shiga 5202192, Japan	Takano, T (reprint author), Shiga Univ Med Sci, Dept Pediat, Otsu, Shiga 5202192, Japan.	tmyktkn@belle.shiga-med.ac.jp			Japan Society for the Promotion of Science;  [22591125]	The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by the Japan Society for the Promotion of Science and a Grant-in-Aid for Scientific Research (C) (No. 22591125).	RACINE RJ, 1972, ELECTROEN CLIN NEURO, V32, P281, DOI 10.1016/0013-4694(72)90177-0; Schmued LC, 1997, BRAIN RES, V751, P37, DOI 10.1016/S0006-8993(96)01387-X; Li S, 2001, NEUROSCIENCE, V107, P675, DOI 10.1016/S0306-4522(01)00385-2; RAMANJANEYULU R, 1984, EUR J PHARMACOL, V98, P337, DOI 10.1016/0014-2999(84)90282-6; Morimoto K, 2004, PROG NEUROBIOL, V73, P1, DOI 10.1016/j.pneurobio.2004.03.009; TAUCK DL, 1985, J NEUROSCI, V5, P1016; Neve RL, 1998, J NEUROSCI, V18, P7757; Mattson MP, 2008, ANN NY ACAD SCI, V1144, P97, DOI 10.1196/annals.1418.005; MELLO LEAM, 1993, EPILEPSIA, V34, P985, DOI 10.1111/j.1528-1157.1993.tb02123.x; Lorincz A, 2002, NAT NEUROSCI, V5, P1185, DOI 10.1038/nn962; LIPTON SA, 1989, TRENDS NEUROSCI, V12, P265, DOI 10.1016/0166-2236(89)90026-X; BenAri Y, 1997, TRENDS NEUROSCI, V20, P523, DOI 10.1016/S0166-2236(97)01147-8; Poirier JL, 2000, NEUROSCIENCE, V97, P59, DOI 10.1016/S0306-4522(00)00026-9; Clancy B, 2001, NEUROSCIENCE, V105, P7, DOI 10.1016/S0306-4522(01)00171-3; Benowitz LI, 1997, TRENDS NEUROSCI, V20, P84, DOI 10.1016/S0166-2236(96)10072-2; CHOI DW, 1988, NEURON, V1, P623, DOI 10.1016/0896-6273(88)90162-6; MCGRAIL KM, 1991, J NEUROSCI, V11, P381; BENOWITZ LI, 1989, J NEUROSCI, V9, P990; Luttjohann A, 2009, PHYSIOL BEHAV, V98, P579, DOI 10.1016/j.physbeh.2009.09.005; Gressens P, 1996, NEUROPATH APPL NEURO, V22, P498, DOI 10.1111/j.1365-2990.1996.tb01123.x; Sanchez RM, 2001, EPILEPSIA, V42, P577, DOI 10.1046/j.1528-1157.2001.12000.x; MARRET S, 1995, J NEUROPATH EXP NEUR, V54, P358, DOI 10.1097/00005072-199505000-00009; Vaillend C, 2002, J NEUROPHYSIOL, V88, P2963, DOI 10.1152/jn.00244.2002; LIPTON SA, 1994, NEW ENGL J MED, V330, P613; STALEY KJ, 1995, SCIENCE, V269, P977, DOI 10.1126/science.7638623; Takano T, 2011, EPILEPSY RES, V96, P1, DOI 10.1016/j.eplepsyres.2011.06.010; RAMZAN IM, 1985, J PHARMACOL EXP THER, V234, P624; Schmued LC, 2000, BRAIN RES, V874, P123, DOI 10.1016/S0006-8993(00)02513-0; LAURIE DJ, 1992, J NEUROSCI, V12, P4151; George AL, 2011, BRAIN RES, V1374, P116, DOI 10.1016/j.brainres.2010.12.020; Bendotti C, 1996, NEUROREPORT, V7, P2539, DOI 10.1097/00001756-199611040-00027; Bittigau P, 1997, J CHILD NEUROL, V12, P471; Brill J, 2010, CEREB CORTEX, V20, P2926, DOI 10.1093/cercor/bhq040; Cantallops I, 1996, J COMP NEUROL, V366, P303; Carmichael S T, 2005, EXP NEUROL, V193, P291; Chassoux F, 2008, EPILEPSIA, V49, P51, DOI 10.1111/j.1528-1167.2007.01267.x; CHOI DW, 1985, NEUROSCI LETT, V58, P293, DOI 10.1016/0304-3940(85)90069-2; Chu Y, 2009, NEUROSCIENCE, V162, P339, DOI 10.1016/j.neuroscience.2009.04.003; CHWEH AY, 1983, J NEUROCHEM, V41, P830, DOI 10.1111/j.1471-4159.1983.tb04815.x; Deguchi K, 2012, BRAIN RES, V1436, P168, DOI 10.1016/j.brainres.2011.12.016; DEKKER LV, 1989, J NEUROCHEM, V52, P24, DOI 10.1111/j.1471-4159.1989.tb10893.x; GASIC GP, 1992, ANNU REV PHYSIOL, V54, P507, DOI 10.1146/annurev.physiol.54.1.507; GIANOTTI C, 1992, NEURON, V8, P843, DOI 10.1016/0896-6273(92)90198-M; Gilbert ME, 2006, MODELS OF SEIZURES AND EPILEPSY, P379, DOI 10.1016/B978-012088554-1/50033-5; Guerrini R, 1999, MARIANI F P, V7, P191; HAAS KZ, 1990, DEV BRAIN RES, V56, P275, DOI 10.1016/0165-3806(90)90093-E; Hablitz JJ, 2010, EPILEPSIA, V51, P52, DOI 10.1111/j.1528-1167.2010.02610.x; Hagemann G, 2003, NEUROSCIENCE, V117, P991, DOI 10.1016/S0306-4522(02)00959-4; Hanaya R, 2007, EXP NEUROL, V204, P720, DOI 10.1016/j.expneurol.2007.01.002; Harding BN, 2004, PATHOLOGY GENETICS D, P49; Hopkins KJ, 2000, BRAIN RES, V864, P69, DOI 10.1016/S0006-8993(00)02137-5; Jacobs KM, 1996, CEREB CORTEX, V6, P514, DOI 10.1093/cercor/6.3.514; Jacobs KM, 2005, J NEUROPHYSIOL, V93, P687, DOI 10.1152/jn.00288.2004; Jacobs KM, 1999, J NEUROPHYSIOL, V81, P159; Jacobs KM, 1999, CEREB CORTEX, V9, P733, DOI 10.1093/cercor/9.7.733; KATER SB, 1989, ANN NY ACAD SCI, V568, P252, DOI 10.1111/j.1749-6632.1989.tb12514.x; Kharazia VN, 2003, NEUROSCIENCE, V120, P207, DOI 10.1016/S0306-4522(03)00282-3; King CE, 2001, NEUROPATH APPL NEURO, V27, P115, DOI 10.1046/j.1365-2990.2001.00317.x; Longo Beatriz, 2005, Epilepsia, V46 Suppl 5, P125, DOI 10.1111/j.1528-1167.2005.01019.x; MARRET S, 1995, DEV MED CHILD NEUROL, V37, P473; MASON CR, 1972, EPILEPSIA, V13, P663, DOI 10.1111/j.1528-1157.1972.tb04401.x; McIntyre DC, 2002, EPILEPSY RES, V50, P79, DOI 10.1016/S0920-1211(02)00071-2; Naffah-Mazzacoratti MG, 1999, NEUROSCIENCE, V91, P485, DOI 10.1016/S0306-4522(98)00631-9; NELSON RB, 1989, J NEUROSCI, V9, P381; Oghlakian RO, 2009, EPILEPSIA, V50, P801, DOI 10.1111/j.1528-1167.2008.01815.x; OLNEY JW, 1990, PROG BRAIN RES, V86, P37; Redecker C, 1998, DEV BRAIN RES, V109, P109, DOI 10.1016/S0165-3806(98)00065-0; Redecker C, 2000, J NEUROSCI, V20, P5045; Sawai C, 2009, J CHILD NEUROL, V24, P275, DOI 10.1177/0883073808323028; Schmidt S, 2006, EXP NEUROL, V201, P270, DOI 10.1016//j.expneurol.2006.03.027; Sutula TP, 2006, MODELS SEIZURES EPIL, P379; Swann J W, 1999, Adv Neurol, V79, P203; Takano T, 2012, EPILEPSY RES, V102, P113, DOI 10.1016/j.eplepsyres.2012.05.001; Takano T, 2010, EPILEPSY BEHAV, V18, P505, DOI 10.1016/j.yebeh.2010.05.014; Takano T, 2004, J CHILD NEUROL, V19, P107; Takase K, 2008, EPILEPSIA, V49, P997, DOI 10.1111/j.1528-1167.2008.01558.x; Tolner EA, 2003, EUR J NEUROSCI, V17, P2369, DOI 10.1046/j.1460-9568.2003.02687.x; Ye XM, 2001, BRAIN RES PROTOC, V8, P104, DOI 10.1016/S1385-299X(01)00086-1; Zhou FW, 2011, CEREB CORTEX, V21, P1645, DOI 10.1093/cercor/bhq234	79	0	0	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0883-0738	1708-8283		J CHILD NEUROL	J. Child Neurol.	MAY	2015	30	6					716	728		10.1177/0883073814541476		13	Clinical Neurology; Pediatrics	Neurosciences & Neurology; Pediatrics	CG8SZ	WOS:000353584100006		
J	Ideno, S; Hatori, E; Takeda, J; Morisaki, H				Ideno, Satoshi; Hatori, Eiki; Takeda, Junzo; Morisaki, Hiroshi			Anesthetic management of a patient with Hermansky-Pudlak syndrome undergoing video-assisted bullectomy	JOURNAL OF CLINICAL ANESTHESIA			English	Article						Bleeding diathesis; Bullectomy; General anesthesia; Hermansky-Pudlak syndrome; Pneumothorax; Pulmonary fibrosis	PULMONARY-FIBROSIS	The Hermansky-Pudlak syndrome (HPS) is a rare set of disorders characterized by oculocutaneous albinism, bleeding diathesis, and pulmonary fibrosis, with the latter 2 conditions presenting major challenges in anesthetic management. We report a 53-year-old woman with pulmonary fibrosis secondary to HPS who underwent video-assisted bullectomy to treat recurrent pneumothorax. Preoperative bleeding time and platelet count were within normal limits, but the surgeons had difficulty with continuous oozing from the incision site; the surgical blood loss was 270 mL, which was a relatively large amount for this surgery. Because of her restrictive lung disease, the patient's tidal volume was only 250 mL under pressure-controlled ventilation, with a peak inspiratory pressure of 30 cm H2O and a positive end-expiratory pressure of 5 cm H2O. She also had postoperative respiratory insufficiency, with a partial pressure of arterial CO2 of 112 mm Hg and a pH of 7.08 on arterial blood gas analysis. Then, the patient needed mechanical ventilation for 4 days. In conclusion, patients with BPS require strict respiratory management to support their restrictive pulmonary dysfunction, and, also, we should consider preventive management for hemostasis and adequate analgesia to reduce the patient's work of breathing. (C) 2014 Elsevier Inc. All rights reserved.	[Ideno, Satoshi; Hatori, Eiki] Keio Univ, Sch Med, Dept Anesthesiol, Shinjuku Ku, Tokyo 1608582, Japan; [Takeda, Junzo; Morisaki, Hiroshi] Keio Univ, Sch Med, Dept Anesthesiol, Anesthesiol,Shinjuku Ku, Tokyo 1608582, Japan	Hatori, E (reprint author), Keio Univ, Sch Med, Dept Anesthesiol, Shinjuku Ku, 35 Shinanomachi, Tokyo 1608582, Japan.	stkdf624@yahoo.co.jp					Pierson DM, 2006, RESPIRATION, V73, P382, DOI 10.1159/000091609; HERMANSKY F, 1959, BLOOD, V14, P162; Horlocker TT, 2011, BRIT J ANAESTH, V107, P96, DOI 10.1093/bja/aer381; Kotani N, 2000, ANESTHESIOLOGY, V93, P15, DOI 10.1097/00000542-200007000-00008; Gahl WA, 2002, MOL GENET METAB, V76, P234, DOI 10.1016/S1096-7192(02)00044-6; Di Pietro SM, 2005, TRAFFIC, V6, P525, DOI 10.1111/j.1600-0854.2005.00299.x; Lederer DJ, 2005, J HEART LUNG TRANSPL, V24, P1697, DOI 10.1016/j.healun.2004.11.015; WIJERMANS PW, 1989, AM J HEMATOL, V30, P154, DOI 10.1002/ajh.2830300307	8	1	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0952-8180	1873-4529		J CLIN ANESTH	J. Clin. Anesth.	MAY	2015	27	3					243	246		10.1016/j.jclinane.2014.10.004		4	Anesthesiology	Anesthesiology	CG5XG	WOS:000353368600011		
J	Imashuku, Y; Kojima, A; Takahashi, K; Kitagawa, H				Imashuku, Yasuhiko; Kojima, Akiko; Takahashi, Kan; Kitagawa, Hirotoshi			The importance of usage guidance from anesthesiologists when disseminating video laryngoscopes throughout emIrgency departments and intensive care units	JOURNAL OF CLINICAL ANESTHESIA			English	Letter									[Imashuku, Yasuhiko; Kojima, Akiko; Takahashi, Kan; Kitagawa, Hirotoshi] Shiga Univ Med Sci, Dept Anesthesiol, Shiga 5202192, Japan	Imashuku, Y (reprint author), Shiga Univ Med Sci, Dept Anesthesiol, Shiga 5202192, Japan.	imashuku@belle.shiga-med.ac.jp					Asai T, 2009, ANESTHESIOLOGY, V110, P898, DOI 10.1097/ALN.0b013e31819c45e5; Maruyama K, 2008, BRIT J ANAESTH, V101, P563, DOI 10.1093/bja/aen207	2	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0952-8180	1873-4529		J CLIN ANESTH	J. Clin. Anesth.	MAY	2015	27	3					273	273		10.1016/j.jclinane.2014.12.001		1	Anesthesiology	Anesthesiology	CG5XG	WOS:000353368600016		
J	Ueshima, H; Noumi, T; Komasawa, N; Kitamura, A				Ueshima, Hironobu; Noumi, Takaomi; Komasawa, Nobuyasu; Kitamura, Akira			A nerve-stimulating needle coated with hard microscopic glass beads can enhance the visibility of ultrasonic images	JOURNAL OF CLINICAL ANESTHESIA			English	Letter									[Ueshima, Hironobu] Saitama Med Univ, Int Med Ctr, Dept Anesthesiol, Saitama, Japan; Osaka Med Coll, Dept Anesthesiol, Osaka, Japan	Ueshima, H (reprint author), Saitama Med Univ, Int Med Ctr, Dept Anesthesiol, Saitama, Japan.	ueshimhi@yahoo.co.jp					Stuart RM, 2004, AM J ROENTGENOL, V182, P123; Gray AT, 2006, ANESTHESIOLOGY, V104, P368, DOI 10.1097/00000542-200602000-00024; Ecoffey C, 2014, EUR J ANAESTH, V31, P606, DOI 10.1097/EJA.0000000000000063	3	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0952-8180	1873-4529		J CLIN ANESTH	J. Clin. Anesth.	MAY	2015	27	3					273	274		10.1016/j.jclinane.2014.12.002		2	Anesthesiology	Anesthesiology	CG5XG	WOS:000353368600017		
J	Fujiwara, S; Komasawa, N; Minami, T				Fujiwara, Shunsuke; Komasawa, Nobuyasu; Minami, Toshiaki			Pectral nerve blocks and serratus-intercostal plane block for intractable postthoracotomy syndrome	JOURNAL OF CLINICAL ANESTHESIA			English	Letter									[Fujiwara, Shunsuke; Komasawa, Nobuyasu; Minami, Toshiaki] Osaka Med Coll, Dept Anesthesiol, Takatsuki, Osaka 5698686, Japan	Komasawa, N (reprint author), Osaka Med Coll, Dept Anesthesiol, Daigaku Machi 2-7, Takatsuki, Osaka 5698686, Japan.	ane078@poh.osaka-med.ac.jp					Blanco R, 2013, ANAESTHESIA, V68, P1107, DOI 10.1111/anae.12344; Meierhenrich R, 2011, BRIT J ANAESTH, V106, P580, DOI 10.1093/bja/aeq418; Fujiwara A, 2015, SPRINGERPLUS, V3, DOI 10.1186/2193-1801-3-409; Karmakar Manoj K, 2004, Thorac Surg Clin, V14, P345, DOI 10.1016/S1547-4127(04)00022-2	4	1	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0952-8180	1873-4529		J CLIN ANESTH	J. Clin. Anesth.	MAY	2015	27	3					275	276		10.1016/j.jclinane.2015.01.007		2	Anesthesiology	Anesthesiology	CG5XG	WOS:000353368600019		
J	Kario, K				Kario, Kazuomi			Systemic Hemodynamic Atherothrombotic Syndrome: A Blind Spot in the Current Management of Hypertension	Journal of Clinical Hypertension			English	Editorial Material							BLOOD-PRESSURE; MORNING SURGE; PROGNOSTIC-SIGNIFICANCE; CLINICAL-PRACTICE; GUIDELINES; SOCIETY; STROKE		[Kario, Kazuomi] Jichi Med Univ, Sch Med, Shimotsuke, Tochigi 3290498, Japan	Kario, K (reprint author), Jichi Med Univ, Sch Med, Dept Sleep & Circadian Cardiol, Dept Med,Div Cardiovasc Med, 3311-1 Yakushiji, Shimotsuke, Tochigi 3290498, Japan.	kkario@jichi.ac.jp					Metoki H, 2006, HYPERTENSION, V47, P149, DOI 10.1161/01.HYP.0000198541.12640.0f; Kario K, 2003, CIRCULATION, V107, P1401, DOI 10.1161/01.CIR.0000056521.67546.AA; Kario K, 2013, NAT REV NEPHROL, V9, P726, DOI 10.1038/nrneph.2013.224; Kario K, 2001, HYPERTENSION, V38, P852, DOI 10.1161/hy1001.092640; Kario K, 2013, HYPERTENS RES, V36, P478, DOI 10.1038/hr.2013.19; Weber MA, 2014, J CLIN HYPERTENS, V16, P14, DOI 10.1111/jch.12237; Parati G, 2013, NAT REV CARDIOL, V10, P143, DOI 10.1038/nrcardio.2013.1; Mancia G, 2013, J HYPERTENS, V31, P1281, DOI 10.1097/01.hjh.0000431740.32696.cc; Kario K, 2010, HYPERTENSION, V56, P765, DOI 10.1161/HYPERTENSIONAHA.110.157149; Kario K, 2015, AM J HYPERTENS, V28, P7, DOI 10.1093/ajh/hpu179; Kario K, 2015, J CLIN HYPE IN PRESS; Sheppard JP, 2015, AM J HYPERTENS, V28, P30, DOI 10.1093/ajh/hpu104; Shimamoto Kazuaki, 2014, Hypertens Res, V37, P253, DOI 10.1038/hr.2014.20	13	2	2	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1524-6175	1751-7176		J CLIN HYPERTENS	J. Clin. Hypertens.	MAY	2015	17	5					328	331		10.1111/jch.12505		4	Peripheral Vascular Disease	Cardiovascular System & Cardiology	CG4GB	WOS:000353242300002		
J	Kario, K; Hoshide, S; Haimoto, H; Yamagiwa, K; Uchiba, K; Nagasaka, S; Yano, Y; Eguchi, K; Matsui, Y; Shimizu, M; Ishikawa, J; Ishikawa, S				Kario, Kazuomi; Hoshide, Satoshi; Haimoto, Hajime; Yamagiwa, Kayo; Uchiba, Kiyoshi; Nagasaka, Shoichiro; Yano, Yuichiro; Eguchi, Kazuo; Matsui, Yoshio; Shimizu, Motohiro; Ishikawa, Joji; Ishikawa, Shizukiyo		J-HOP Study Grp	Sleep Blood Pressure Self-Measured at Home as a Novel Determinant of Organ Damage: Japan Morning Surge Home Blood Pressure (J-HOP) Study	Journal of Clinical Hypertension			English	Article							AMERICAN-HEART-ASSOCIATION; PROTECTION J-TOP; ANTIHYPERTENSIVE TREATMENT; HYPERTENSION GUIDELINES; PROGNOSTIC-SIGNIFICANCE; NATRIURETIC PEPTIDE; RISK; SOCIETY; BIOMARKERS; STATEMENT	To study whether sleep blood pressure (BP) self-measured at home is associated with organ damage, the authors analyzed the data of 2562 participants in the J-HOP study who self-measured sleep BP using a home BP monitoring (HBPM) device, three times during sleep (2am, 3am, 4am), as well as the home morning and evening BPs. The mean sleep home systolic BPs (SBPs) were all correlated with urinary albumin/creatinine ratio (UACR), left ventricular mass index (LVMI), brachial-ankle pulse wave velocity (baPWV), maximum carotid intima-media thickness, and plasma N-terminal pro-hormone pro-brain-type natriuretic peptide (NTproBNP) (all P<.001). After controlling for clinic SBP and home morning and evening SBPs, associations of home sleep SBP with UACR, LVMI, and baPWV remained significant (all P<.008). Even in patients with home morning BP <135/85mmHg, 27% exhibited masked nocturnal hypertension with home sleep SBP 120mmHg and had higher UACR and NTproBNP. Masked nocturnal hypertension, which is associated with advanced organ damage, remains unrecognized by conventional HBPM.	[Kario, Kazuomi; Hoshide, Satoshi; Yano, Yuichiro; Eguchi, Kazuo; Ishikawa, Joji] Jichi Med Univ, Sch Med, Dept Med, Div Cardiovasc Med, Shimotsuke, Tochigi 3290498, Japan; [Kario, Kazuomi; Hoshide, Satoshi] Jichi Med Univ, Sch Med, Dept Sleep & Circadian Cardiol, Shimotsuke, Tochigi 3290498, Japan; [Haimoto, Hajime] Haimoto Clin, Aichi, Japan; [Yamagiwa, Kayo] Yamagiwa Clin, Aichi, Japan; [Uchiba, Kiyoshi] Oooka Clin, Nagano, Japan; [Nagasaka, Shoichiro] Jichi Med Univ, Sch Med, Dept Med, Div Endocrinol & Metab, Shimotsuke, Tochigi 3290498, Japan; [Matsui, Yoshio] Ishikai Hosp, Iwakuni City Med Ctr, Yamaguchi, Japan; [Shimizu, Motohiro] Kyusyu Univ Hosp, Dept Gen Internal Med, Fukuoka, Japan; [Ishikawa, Shizukiyo] Jichi Med Univ, Sch Med, Div Community & Family Med, Shimotsuke, Tochigi 3290498, Japan	Kario, K (reprint author), Jichi Med Univ, Sch Med, Dept Sleep & Circadian Cardiol, Dept Med,Div Cardiovasc Med, 3311-1 Yakushiji, Shimotsuke, Tochigi 3290498, Japan.	kkario@jichi.ac.jp			21st Century Center of Excellence Project run by Japan's Ministry of Education, Culture, Sports, Science and Technology; Foundation for Development of the Community (Tochigi); Omron Healthcare Co., Ltd; Ministry of Education, Culture, Sports, Science and Technology (MEXT) of Japan [21390247]; MEXT [S1101022]	This study was financially supported in part by a grant from the 21st Century Center of Excellence Project run by Japan's Ministry of Education, Culture, Sports, Science and Technology; a grant from the Foundation for Development of the Community (Tochigi); a grant from Omron Healthcare Co., Ltd, a Grant-in-Aid for Scientific Research (B) (21390247) from The Ministry of Education, Culture, Sports, Science and Technology (MEXT) of Japan, 2009-2013; and funds from the MEXT-Supported Program for the Strategic Research Foundation at Private Universities, 2011-2015 Cooperative Basic and Clinical Research on Circadian Medicine (S1101022). (to K.K.). The authors have no conflicts of interest to declare.	Ishikawa J, 2012, HYPERTENSION, V60, P921, DOI 10.1161/HYPERTENSIONAHA.112.198101; Pickering TG, 2008, HYPERTENSION, V52, P10, DOI 10.1161/HYPERTENSIONAHA.107.189010; Kario K, 1996, HYPERTENSION, V27, P130; Kario K, 2003, CIRCULATION, V107, P1401, DOI 10.1161/01.CIR.0000056521.67546.AA; Ohkubo T, 2002, J HYPERTENS, V20, P2183, DOI 10.1097/00004872-200211000-00017; Pickering TG, 2005, HYPERTENSION, V45, P142, DOI 10.1161/01.HYP.0000150859.47929.8e; Imai Y, 2012, HYPERTENS RES, V35, P777, DOI 10.1038/hr.2012.56; Kario K, 2001, HYPERTENSION, V38, P852, DOI 10.1161/hy1001.092640; Kario K, 2005, AM J HYPERTENS, V18, P149, DOI 10.1016/j.amjhyper.2004.09.007; Hoshide S, 2003, AM J HYPERTENS, V16, P434, DOI 10.1016/S0895-7061(03)00567-3; Pikula A, 2012, CIRCULATION, V125, P2100, DOI 10.1161/CIRCULATIONAHA.110.989145; Parati G, 2008, J HYPERTENS, V26, P1505, DOI 10.1097/HJH.0b013e328308da66; Kario K, 2009, HYPERTENS RES, V32, P428, DOI 10.1038/hr.2009.56; Kario K, 2013, HYPERTENS RES, V36, P478, DOI 10.1038/hr.2013.19; Boggia J, 2007, LANCET, V370, P1219, DOI 10.1016/S0140-6736(07)61538-4; Wang TJ, 2004, NEW ENGL J MED, V350, P655, DOI 10.1056/NEJMoa031994; Chonan K, 2001, BLOOD PRESS MONIT, V6, P203, DOI 10.1097/00126097-200108000-00008; Sega R, 2005, CIRCULATION, V111, P1777, DOI 10.1161/01.CIR.0000160923.04524.5B; desLemos JA, 2010, JAMA-J AM MED ASSOC, V304, P2503; Kario K, 2010, J HYPERTENS, V28, P1574, DOI 10.1097/HJH.0b013e3283395267; Munakata M, 2012, HYPERTENS RES, V35, P839, DOI 10.1038/hr.2012.53; Den Ruijter HM, 2012, JAMA-J AM MED ASSOC, V308, P796, DOI 10.1001/jama.2012.9630; Shimizu M, 2012, J HYPERTENS, V30, P1015, DOI 10.1097/HJH.0b013e328351f80b; Shirasaki O, 2011, HYPERTENS RES, V34, P922, DOI 10.1038/hr.2011.52; Stergiou GS, 2012, AM J HYPERTENS, V25, P974, DOI 10.1038/ajh.2012.82; Yano Y, 2012, AM J HYPERTENS, V25, P306, DOI 10.1038/ajh.2011.229	26	1	1	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1524-6175	1751-7176		J CLIN HYPERTENS	J. Clin. Hypertens.	MAY	2015	17	5					340	348		10.1111/jch.12500		9	Peripheral Vascular Disease	Cardiovascular System & Cardiology	CG4GB	WOS:000353242300005		
J	Sevinc, F; Cao, S; Xuan, XN; Sevinc, M; Ceylan, O				Sevinc, Ferda; Cao, Shinuo; Xuan, Xuenan; Sevinc, Mutlu; Ceylan, Onur			Identification and Expression of Babesia ovis Secreted Antigen 1 and Evaluation of Its Diagnostic Potential in an Enzyme-Linked Immunosorbent Assay	JOURNAL OF CLINICAL MICROBIOLOGY			English	Article							RHOPTRY-ASSOCIATED PROTEIN-1; INFECTION; SHEEP; CATTLE; IRAN; SEROPREVALENCE; SERODIAGNOSIS; PROVINCE; GIBSONI; TURKEY	In order to identify immunoreactive proteins that are usable for the immunological diagnosis of Babesia ovis infections, a phage lambda cDNA expression library was constructed and screened using parasite-specific immune serum. Immunoscreening resulted in the identification of a full-length cDNA clone encoding a secreted protein designated Babesia ovis secreted antigen 1 (BoSA1). The full-length BoSA1 cDNA contained a 1,137-bp open reading frame that encoded a protein of 378 amino acids, with a signal peptide and 2 internal repeat domains. The theoretical molecular mass of the mature protein was 42.5 kDa. Recombinant BoSA1 (rBoSA1) protein was expressed in Escherichia coli strain DH5 alpha cells as a glutathione S-transferase (GST) fusion protein and was purified by affinity chromatography. Purified rBoSA1 was tested for reactivity with sera from animals experimentally or naturally infected with B. ovis, in an indirect enzyme-linked immunosorbent assay (ELISA). The results showed that specific antibodies against rBoSA1 were detectable on days 7 and 8 of the experimental infection and were maintained during the sampling period. Additionally, 38 field sera taken from sheep naturally infected with B. ovis gave strong positive reactions in the ELISA between day 20 and day 30 of treatment. As a result, the identified recombinant BoSA1 protein seems to be a promising diagnostic antigen that is usable for the development of serological assays for the diagnosis of ovine babesiosis. This is the first report on the molecular cloning, expression, and potential use of a recombinant antigen for the diagnosis of ovine babesiosis.	[Sevinc, Ferda; Sevinc, Mutlu; Ceylan, Onur] Selcuk Univ, Fac Vet Med, Dept Parasitol, Konya, Turkey; [Cao, Shinuo; Xuan, Xuenan] Obihiro Univ Agr & Vet Med, Natl Res Ctr Protozoan Dis, Obihiro, Hokkaido 080, Japan	Sevinc, F (reprint author), Selcuk Univ, Fac Vet Med, Dept Parasitol, Konya, Turkey.	fsevinc@selcuk.edu.tr			Scientific and Technological Research Council in Turkey [113O336]	This work was supported by the Scientific and Technological Research Council in Turkey (grant number 113O336).	Ahmed JS, 2006, ANN NY ACAD SCI, V1081, P498, DOI 10.1196/annals.1373.074; DUZGUN A, 1991, VET PARASITOL, V39, P225, DOI 10.1016/0304-4017(91)90039-X; Bock R, 2004, PARASITOLOGY, V129, pS247, DOI 10.1017/S0031182004005190; Fakhar M, 2012, TROP ANIM HEALTH PRO, V44, P319, DOI 10.1007/s11250-011-0023-y; Cicek H, 2004, TURK J VET ANIM SCI, V28, P683; Sevinc F, 2013, VET PARASITOL, V191, P35, DOI 10.1016/j.vetpar.2012.07.025; Ekici OD, 2012, VET PARASITOL, V188, P372, DOI 10.1016/j.vetpar.2012.04.001; Huang XH, 2003, J CLIN MICROBIOL, V41, P1147, DOI 10.1128/JCM.41.3.1147-1151.2003; Aktas M, 2005, VET PARASITOL, V133, P277, DOI 10.1016/j.vetpar.2005.05.057; Huang XH, 2006, VET PARASITOL, V140, P158, DOI 10.1016/j.vetpar.2006.03.013; BOSE R, 1995, VET PARASITOL, V57, P61, DOI 10.1016/0304-4017(94)03111-9; Yeruham I, 1998, VET PARASITOL, V74, P153, DOI 10.1016/S0304-4017(97)00143-X; Sevinc F, 2014, SMALL RUMINANT RES, V116, P66, DOI 10.1016/j.smallrumres.2013.10.010; Uilenberg G, 2006, VET PARASITOL, V138, P3, DOI 10.1016/j.vetpar.2006.01.035; Georges K, 2001, VET PARASITOL, V99, P273, DOI 10.1016/S0304-4017(01)00488-5; Sevinc F, 2007, VET PARASITOL, V149, P65, DOI 10.1016/j.vetpar.2007.07.014; Bonin-Debs AL, 2004, EXPERT OPIN BIOL TH, V4, P551, DOI 10.1517/eobt.4.4.551.29788; Boonchit S, 2002, J CLIN MICROBIOL, V40, P3771, DOI 10.1128/JCM.40.10.3771-3775.2002; Ranjbar-Bahadori S, 2012, PARASITOL RES, V110, P1531, DOI 10.1007/s00436-011-2658-z; Goo YK, 2008, EXP PARASITOL, V118, P555, DOI 10.1016/j.exppara.2007.11.010; Carson KH, 2006, THESIS TEXAS A M U C; Emre Z, 2001, TURK J VET ANIM SCI, V25, P759; Guan GQ, 2010, PARASITOLOGY, V137, P927, DOI 10.1017/S0031182009991922; Ikadai H, 2000, INT J PARASITOL, V30, P633, DOI 10.1016/S0020-7519(00)00008-4; Kafsack Bjorn F.C., 2010, Communicative & Integrative Biology, V3, P18; Kumar S, 2002, VET PARASITOL, V107, P295, DOI 10.1016/S0304-4017(02)00161-9; Kuttler KL, 1988, ANN NY ACAD SCI, V1081, P498; Ooka H, 2012, J PARASITOL, V98, P1045, DOI 10.1645/GE-2999.1; Ravindran R, 2008, TRAFFIC, V9, P647; Razmi GR, 2003, SMALL RUMINANT RES, V50, P39, DOI 10.1016/S0921-4488(03)00107-X; Terkawi MA, 2007, PARASITOL RES, V102, P35, DOI 10.1007/s00436-007-0718-1; Wright I.G., 1990, Revue Scientifique et Technique Office International des Epizooties, V9, P345; Zhou JL, 2007, VET PARASITOL, V145, P16, DOI 10.1016/j.vetpar.2006.10.022	33	2	2	AMER SOC MICROBIOLOGY	WASHINGTON	1752 N ST NW, WASHINGTON, DC 20036-2904 USA	0095-1137	1098-660X		J CLIN MICROBIOL	J. Clin. Microbiol.	MAY	2015	53	5					1531	1536		10.1128/JCM.03219-14		6	Microbiology	Microbiology	CG1MK	WOS:000353036500011		
J	Hamada, Y; Sutherland, CA; Nicolau, DP				Hamada, Yukihiro; Sutherland, Christina A.; Nicolau, David P.			Impact of Revised Cefepime CLSI Breakpoints on Escherichia coli and Klebsiella pneumoniae Susceptibility and Potential Impact If Applied to Pseudomonas aeruginosa	JOURNAL OF CLINICAL MICROBIOLOGY			English	Article								The CLSI reduced the cefepime Enterobacteriaceae susceptibility breakpoint and introduced the susceptible-dose-dependent (S-DD) category. In this study, MICs were determined for a Gram-negative collection to assess the impact of this change. For Enterobacteriaceae, this resulted in <2% reduction in susceptibility, with 1% being S-DD. If applied to Pseudomonas aeruginosa, the % susceptibility (%S) dropped from 77% to 43%, with 34% being S-DD. The new breakpoints did little to the Enterobacteriaceae %S, but for P. aeruginosa, a profound reduction was seen in %S. The recognition of a S-DD response to cefepime should alert clinicians to the possible need for higher doses.	[Hamada, Yukihiro; Sutherland, Christina A.; Nicolau, David P.] Hartford Hosp, Ctr Antiinfect Res & Dev, Hartford, CT 06115 USA; [Hamada, Yukihiro] Aichi Med Univ Hosp, Sch Med, Nagakute, Aichi, Japan; [Nicolau, David P.] Hartford Hosp, Div Infect Dis, Hartford, CT 06115 USA	Nicolau, DP (reprint author), Hartford Hosp, Ctr Antiinfect Res & Dev, Hartford, CT 06115 USA.	david.nicolau@hhchealth.org			Center for Anti-Infective Research and Development	This analysis was supported by internal funding from the Center for Anti-Infective Research and Development.	Dortet L, 2012, ANTIMICROB AGENTS CH, V56, P6437, DOI 10.1128/AAC.01395-12; Clinical and Laboratory Standards Institute, 2010, M100S20 CLSI; Clinical and Laboratory Standards Institute, 2014, M100S24 CLSI; Crandon JL, 2010, ANTIMICROB AGENTS CH, V54, P1111, DOI 10.1128/AAC.01183-09; Hospira Inc, 2014, MAX CEF HYDR USP INJ; Jones RN, 2008, DIAGN MICR INFEC DIS, V61, P203, DOI 10.1016/j.diagmicrobio.2008.01.017; Sutherland C, 2014, 54 INT C ANT AG CHEM	7	1	1	AMER SOC MICROBIOLOGY	WASHINGTON	1752 N ST NW, WASHINGTON, DC 20036-2904 USA	0095-1137	1098-660X		J CLIN MICROBIOL	J. Clin. Microbiol.	MAY	2015	53	5					1712	1714		10.1128/JCM.03652-14		3	Microbiology	Microbiology	CG1MK	WOS:000353036500035		
J	Hida, AI; Bando, K; Sugita, A; Maeda, T; Ueda, N; Matsukage, S; Nakanishi, M; Kito, K; Miyazaki, T; Ohtsuki, Y; Oshiro, Y; Inoue, H; Kawaguchi, H; Yamashita, N; Aogi, K; Moriya, T				Hida, Akira I.; Bando, Kenji; Sugita, Atsuro; Maeda, Toshiharu; Ueda, Norifumi; Matsukage, Shoichi; Nakanishi, Mamoru; Kito, Katsumi; Miyazaki, Tatsuhiko; Ohtsuki, Yuji; Oshiro, Yumi; Inoue, Hiromichi; Kawaguchi, Hidetoshi; Yamashita, Natsumi; Aogi, Kenjiro; Moriya, Takuya			Visual assessment of Ki67 using a 5-grade scale (Eye-5) is easy and practical to classify breast cancer subtypes with high reproducibility	JOURNAL OF CLINICAL PATHOLOGY			English	Article							INTERNATIONAL EXPERT CONSENSUS; PRIMARY THERAPY; CLINICAL-ONCOLOGY/COLLEGE; AMERICAN-SOCIETY; LABELING INDEX; KI-67; RECOMMENDATIONS; HIGHLIGHTS; TUMORS	Aims Personalised breast cancer therapy requires pathological characterisation of tumours. The proliferative index, based on Ki67, is pivotal, but a standard method has not been established. Here we look for an easy and practical way to evaluate Ki67. Methods Immunohistochemical staining of estrogen receptors, progesterone receptors, HER2 and Ki67 (MIB-1) was performed on resected specimens from 406 primary invasive ductal carcinomas. Ki67 labelling index (LI) from manual counting was compared with visual assessment using a 5-grade scale (Eye-5). Next, 10 pathologists evaluated 100 samples with marked hot spots by using Eye-5. Another 100 samples without marking were also assessed by eight pathologists. One year later, two pathologists reviewed 222 cases with Eye-5. Prognosis was analysed among estrogen receptor-positive cases with postoperative endocrine therapy. Results Eye-5 showed good correlation to LI. All 136 cases of score 4-5 had LI >20% and all 56 cases of score 1 had LI<20%, which means that manual counting was not necessary for about half of the cases. Interobserver and intraobserver variability was low even when a hot spot was not fixed. Eye-5 also correlated with histological grade and lymph node metastasis. Combining Eye-5 and histological grade created a new algorism to predict LI, which allows 80% of all cases (74% of luminal cases) without manual counting. Cases of Eye-5 score 1-2 had significantly better survival than score 3-5. Conclusions Visual assessment of Ki67 by a 5-grade scale (Eye-5) is fast, easy, and reliable with acceptably low interobserver and intraobserver variability. Eye-5 can replace LI in many luminal tumours, and is a strong candidate as a standard method of evaluating Ki67.	[Hida, Akira I.; Oshiro, Yumi] Matsuyama Red Cross Hosp, Dept Pathol, Matsuyama, Ehime 7908524, Japan; [Bando, Kenji] Saiseikai Imabari Hosp, Dept Pathol, Imabari, Ehime, Japan; [Sugita, Atsuro] Ehime Univ Hosp, Div Pathol, Toon, Ehime, Japan; [Maeda, Toshiharu; Kito, Katsumi] Ehime Prefectural Cent Hosp, Dept Pathol, Matsuyama, Ehime, Japan; [Ueda, Norifumi] Saiseikai Saijo Med Ctr, Saijo, Ehime, Japan; [Matsukage, Shoichi; Nakanishi, Mamoru] Uwajima City Hosp, Div Pathol & Lab Med, Uwajima, Ehime, Japan; [Miyazaki, Tatsuhiko] Gifu Univ Hosp, Div Pathol, Gifu, Japan; [Ohtsuki, Yuji] Matsuyama Shimin Hosp, Div Pathol, Matsuyama, Ehime, Japan; [Inoue, Hiromichi; Kawaguchi, Hidetoshi] Matsuyama Red Cross Hosp, Dept Breast Surg, Matsuyama, Ehime, Japan; [Yamashita, Natsumi] Natl Hosp Org Shikoku Canc Ctr, Clin Res Ctr, Div Clin Biostat, Matsuyama, Ehime, Japan; [Aogi, Kenjiro] Natl Hosp Org Shikoku Canc Ctr, Dept Breast Oncol, Matsuyama, Ehime, Japan; [Moriya, Takuya] Kawasaki Med Univ, Dept Pathol 2, Kurashiki, Okayama, Japan	Hida, AI (reprint author), Matsuyama Red Cross Hosp, Dept Pathol, 1 Bunkyo, Matsuyama, Ehime 7908524, Japan.	gbears@matsuyama.jrc.or.jp			Division of Clinical Research Promotion in National Hospital Organization Shikoku Cancer Center	This study was financially supported by the Division of Clinical Research Promotion in National Hospital Organization Shikoku Cancer Center.	Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Goldhirsch A, 2009, ANN ONCOL, V20, P1319, DOI 10.1093/annonc/mdp322; Loehberg CR, 2013, BREAST CANCER RES TR, V138, P899, DOI 10.1007/s10549-013-2460-y; Goldhirsch A, 2013, ANN ONCOL, V24, P2206, DOI 10.1093/annonc/mdt303; Hammond MEH, 2010, J CLIN ONCOL, V28, P2784, DOI 10.1200/JCO.2009.25.6529; Denkert C, 2013, ANN ONCOL, V24, P2786, DOI 10.1093/annonc/mdt350; Viale G, 2008, J NATL CANCER I, V100, P207, DOI 10.1093/jnci/djm289; Yerushalmi R, 2010, LANCET ONCOL, V11, P174, DOI 10.1016/S1470-2045(09)70262-1; Goldhirsch A, 2011, ANN ONCOL, V22, P1736, DOI 10.1093/annonc/mdr304; Inwald EC, 2013, BREAST CANCER RES TR, V139, P539, DOI 10.1007/s10549-013-2560-8; Wolff AC, 2013, J CLIN ONCOL, V31, P3997, DOI 10.1200/JCO.2013.50.9984; Ohno S, 2013, BREAST CANCER RES TR, V142, P69, DOI 10.1007/s10549-013-2691-y; Adsay V, 2012, AM J SURG PATHOL, V36, P1743, DOI 10.1097/PAS.0b013e318272ff77; Dowsett M, 2011, J NATL CANCER I, V103, P1656, DOI 10.1093/jnci/djr393; Wolff AC, 2007, J CLIN ONCOL, V25, P118, DOI 10.1200/JCO.2006.09.2775; Mengel M, 2002, J PATHOL, V198, P292, DOI 10.1002/path.1218; Spyratos F, 2002, CANCER, V94, P2151, DOI 10.1002/cncr.10458; de Azambuja E, 2007, BRIT J CANCER, V96, P1504, DOI 10.1038/sj.bjc.6603756; Criscitiello C, 2014, BREAST, V23, P69, DOI 10.1016/j.breast.2013.11.007; Delpech Y, BREAST CANC RES TREA; Hida AI, 2015, BREAST CANCER-TOKYO, V22, P129, DOI 10.1007/s12282-013-0460-8; Mikami Y, 2013, CANCER SCI, V104, P1539, DOI 10.1111/cas.12245; Niikura N, 2014, CLIN BREAST CANCER, V14, P323, DOI 10.1016/j.clbc.2013.12.013; Pathmanathan N, 2014, J CLIN PATHOL, V67, DOI 10.1136/jclinpath-2013-201793; Polley MYC, 2013, JNCI-J NATL CANCER I, V105, P1897, DOI 10.1093/jnci/djt306; Schouten HJA, 1982, STAT NEERL, V36, P45, DOI 10.1111/j.1467-9574.1982.tb00774.x; Sheri A, 2012, ANN ONCOL, V23, P219, DOI 10.1093/annonc/mds307	27	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0021-9746	1472-4146		J CLIN PATHOL	J. Clin. Pathol.	MAY	2015	68	5					356	361		10.1136/jclinpath-2014-202695		6	Pathology	Pathology	CG6OC	WOS:000353420500007		
J	Schmeling, F; Tegtmeier, J; Kinoshita, M; Homberg, U				Schmeling, Fabian; Tegtmeier, Jennifer; Kinoshita, Michiyo; Homberg, Uwe			Photoreceptor projections and receptive fields in the dorsal rim area and main retina of the locust eye	JOURNAL OF COMPARATIVE PHYSIOLOGY A-NEUROETHOLOGY SENSORY NEURAL AND BEHAVIORAL PHYSIOLOGY			English	Article						Compound eye; Dorsal rim area; Receptive fields; Photoreceptor projections; Desert locust	1ST OPTIC GANGLION; INSECT VISUAL-SYSTEM; COMPOUND EYE; SCHISTOCERCA-GREGARIA; MONARCH BUTTERFLIES; POLARIZATION VISION; DESERT LOCUST; LAMINA GANGLIONARIS; PHYSIOLOGICAL CHARACTERIZATION; DROSOPHILA-MELANOGASTER	In many insect species, photoreceptors of a small dorsal rim area of the eye are specialized for sensitivity to the oscillation plane of polarized skylight and, thus, serve a role in sky compass orientation. To further understand peripheral mechanisms of polarized-light processing in the optic lobe, we have studied the projections of photoreceptors and their receptive fields in the main eye and dorsal rim area of the desert locust, a model system for polarization vision analysis. In both eye regions, one photoreceptor per ommatidium, R7, has a long visual fiber projecting through the lamina to the medulla. Axonal fibers from R7 receptors of the dorsal rim area have short side branches throughout the depth of the dorsal lamina and maintain retinotopic projections to the dorsal medulla following the first optic chiasma. Receptive fields of dorsal rim photoreceptors are considerably larger (average acceptance angle 33A degrees) than those of the main eye (average acceptance angle 2.04A degrees) and, taken together, cover almost the entire sky. The data challenge previous reports of two long visual fibers per ommatidium in the main eye of the locust and provide data for future analysis of peripheral networks underlying polarization opponency in the locust brain.	[Schmeling, Fabian; Tegtmeier, Jennifer; Homberg, Uwe] Univ Marburg, Fac Biol Anim Physiol, D-35032 Marburg, Germany; [Kinoshita, Michiyo] Sokendai Grad Univ Adv Studies, Lab Neuroethol, Hayama, Kanagawa 2400193, Japan	Homberg, U (reprint author), Univ Marburg, Fac Biol Anim Physiol, D-35032 Marburg, Germany.	homberg@biologie.uni-marburg.de		Tegtmeier, Jennifer/0000-0002-6098-3921	Deutsche Forschungsgemeinschaft [HO 950/20-1]; Japan Society for the Promotion of Science [24570084]	We are grateful to Dr. Erich Buchner (University of Wurzburg) for donation of the anti-synapsin antibody. We thank Matthias Schon for technical assistance and Martina Kern, Jerome Beetz, and Johannes Schuh for maintaining the locust cultures. This work was supported by grants from Deutsche Forschungsgemeinschaft (HO 950/20-1) to UH and the Japan Society for the Promotion of Science (#24570084) to MK.	Spaethe J, 2005, J EXP BIOL, V208, P2347, DOI 10.1242/jeb.01634; Takemura SY, 2005, J COMP NEUROL, V483, P341, DOI 10.1002/cne.20446; Klagges BRE, 1996, J NEUROSCI, V16, P3154; Reppert SM, 2004, CURR BIOL, V14, P155, DOI 10.1016/j.cub.2003.12.034; Wakakuwa M, 2005, NATURWISSENSCHAFTEN, V92, P464, DOI 10.1007/s00114-005-0018-5; Buschbeck EK, 2003, J COMP PHYSIOL A, V189, P617, DOI 10.1007/s00359-003-0443-x; VONPHILIPSBORN A, 1990, J COMP PHYSIOL A, V167, P737; Blum M, 2000, J COMP PHYSIOL A, V186, P119, DOI 10.1007/s003590050012; Homberg U, 1997, J COMP NEUROL, V386, P329; Nassel DR, 1999, MICROSC RES TECHNIQ, V44, P121; Simpson SJ, 1999, BIOL REV, V74, P461, DOI 10.1017/S000632319900540X; Schmeling F, 2014, J EXP BIOL, V217, P3557, DOI 10.1242/jeb.108514; Heinze S, 2008, J COMP NEUROL, V511, P454, DOI 10.1002/cne.21842; Weir PT, 2012, CURR BIOL, V22, P21, DOI 10.1016/j.cub.2011.11.026; RIBI WA, 1975, CELL TISSUE RES, V160, P207; Homberg U, 2003, J COMP NEUROL, V462, P415, DOI 10.1002/cne.10771; FISCHBACH KF, 1989, CELL TISSUE RES, V258, P441; Homberg U, 2002, ARTHROPOD STRUCT DEV, V30, P271, DOI 10.1016/S1467-8039(02)00010-5; Greiner B, 2004, CELL TISSUE RES, V318, P429, DOI 10.1007/s00441-004-0945-z; LILLYWHITE PG, 1978, J COMP PHYSIOL, V125, P13; WOLBURGBUCHHOLZ K, 1979, CELL TISSUE RES, V197, P39; el Jundi B, 2010, J INSECT PHYSIOL, V56, P971, DOI 10.1016/j.jinsphys.2010.05.011; BRUNNER D, 1987, PHYSIOL ENTOMOL, V12, P1, DOI 10.1111/j.1365-3032.1987.tb00718.x; Labhart T, 1999, MICROSC RES TECHNIQ, V47, P368, DOI 10.1002/(SICI)1097-0029(19991215)47:6<368::AID-JEMT2>3.0.CO;2-Q; Stalleicken J, 2006, J COMP PHYSIOL A, V192, P321, DOI 10.1007/s00359-005-0073-6; RIBI WA, 1981, CELL TISSUE RES, V221, P17, DOI 10.1007/BF00216567; Takemura SY, 2008, J COMP NEUROL, V509, P493, DOI 10.1002/cne.21757; Mappes M, 2004, J COMP PHYSIOL A, V190, P61, DOI 10.1007/s00359-003-0473-4; SHAW SR, 1967, Z VERGL PHYSIOL, V55, P183, DOI 10.1007/BF00342253; Labhart T, 1999, J EXP BIOL, V202, P757; LABHART T, 1986, J COMP PHYSIOL A, V158, P1, DOI 10.1007/BF00614514; Wehner R, 2006, P NATL ACAD SCI USA, V103, P12575, DOI 10.1073/pnas.0604430103; Kurylas AE, 2008, CELL TISSUE RES, V333, P125, DOI 10.1007/s00441-008-0620-x; el Jundi B, 2012, J NEUROPHYSIOL, V108, P1695, DOI 10.1152/jn.01023.2011; Labhart T, 2002, CURR OPIN NEUROBIOL, V12, P707, DOI 10.1016/S0959-4388(02)00384-7; HARDIE RC, 1989, NATURE, V339, P704, DOI 10.1038/339704a0; Paulk AC, 2009, J COMP NEUROL, V513, P441, DOI 10.1002/cne.21993; Dacke M, 2003, J EXP BIOL, V206, P1535, DOI 10.1242/jeb.00289; Homberg U, 2011, PHILOS T R SOC B, V366, P680, DOI 10.1098/rstb.2010.0199; Wernet MF, 2004, TRENDS CELL BIOL, V14, P576, DOI 10.1016/j.tcb.2004.09.007; LABHART T, 1988, NATURE, V331, P435, DOI 10.1038/331435a0; ZUFALL F, 1989, J COMP PHYSIOL A, V164, P597, DOI 10.1007/BF00614502; Mouritsen H, 2013, P NATL ACAD SCI USA, V110, P7348, DOI 10.1073/pnas.1221701110; Wernet MF, 2012, CURR BIOL, V22, P12, DOI 10.1016/j.cub.2011.11.028; LABHART T, 1984, J COMP PHYSIOL, V155, P289, DOI 10.1007/BF00610582; POLLACK I, 1991, CELL TISSUE RES, V266, P391, DOI 10.1007/BF00318195; ARMETTKIBEL C, 1985, J COMP NEUROL, V242, P459, DOI 10.1002/cne.902420402; Bech M, 2014, CURR BIOL, V24, P2124, DOI 10.1016/j.cub.2014.07.045; Briscoe AD, 2003, J COMP NEUROL, V458, P334, DOI 10.1002/cne.10582; Burkhardt D, 1965, Z VERGL PHYSIOL, V51, P151; el Jundi B, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027855; Gebhardt S, 2004, CELL TISSUE RES, V317, P195, DOI 10.1007/s00441-004-0841-y; Hamanaka Y, 2013, J COMP PHYSIOL A, V199, P341, DOI 10.1007/s00359-013-0798-6; HARDIE RC, 1981, J COMP PHYSIOL, V145, P139; HARDIE RC, 1987, J COMP PHYSIOL A, V161, P201, DOI 10.1007/BF00615241; Homberg U, 2013, NEW VISUAL NEUROSCIE, P1207; HORRIDGE G A, 1970, Zeitschrift fuer Vergleichende Physiologie, V66, P369, DOI 10.1007/BF00299936; Horvath Gabor, 2004, POLARIZED LIGHT ANIM; Labhart Thomas, 1993, P158; LABHART T, 1980, J COMP PHYSIOL, V141, P19; MEYER EP, 1984, J NEUROCYTOL, V13, P825, DOI 10.1007/BF01148496; NOWEL MS, 1981, CELL TISSUE RES, V216, P377; Oberhauser KS, 2013, P NATL ACAD SCI USA, V110, pE3680, DOI 10.1073/pnas.1308369110; RIBI WA, 1975, CELL TISSUE RES, V165, P103; SHAW SR, 1969, VISION RES, V9, P999, DOI 10.1016/0042-6989(69)90044-3; SHIMOHIGASHI M, 1991, CELL TISSUE RES, V263, P49, DOI 10.1007/BF00318399; SPURR AR, 1969, J ULTRA MOL STRUCT R, V26, P31, DOI 10.1016/S0022-5320(69)90033-1; STRAUSFE.NJ, 1971, Z ZELLFORSCH MIK ANA, V121, P377, DOI 10.1007/BF00337640; von Frisch K, 1949, EXPERIENTIA, V5, P142, DOI DOI 10.1007/BF02174424; Wehner R., 1982, NEUJAHRSBL NATURFORS, V184, P1; Wehner R, 2006, INVERTEBRATE VISION, P291; WENDT B, 1992, J COMP NEUROL, V321, P387, DOI 10.1002/cne.903210307; White RH, 2003, J EXP BIOL, V206, P3337, DOI 10.1242/jeb.00571; WILLIAMS DS, 1983, J COMP PHYSIOL, V150, P509; WILSON M, 1978, CELL TISSUE RES, V195, P205; Zufall F, 1984, THESIS FREIE U BERLI	76	3	3	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0340-7594	1432-1351		J COMP PHYSIOL A	J. Comp. Physiol. A -Neuroethol. Sens. Neural Behav. Physiol.	MAY	2015	201	5					427	440		10.1007/s00359-015-0990-y		14	Behavioral Sciences; Neurosciences; Physiology; Zoology	Behavioral Sciences; Neurosciences & Neurology; Physiology; Zoology	CG5SE	WOS:000353353700001		
J	Arao, Y; Fukui, T; Niwa, T; Kawada, H				Arao, Yoshihiko; Fukui, Taro; Niwa, Tomoyuki; Kawada, Hiroyuki			Dimensional stability of epoxy-based and cyanate-based carbon fiber-reinforced plastics	JOURNAL OF COMPOSITE MATERIALS			English	Article						Polymer-matrix composites; laminate mechanics; moisture absorption; stress relaxation	COMPOSITE-MATERIALS; DEFORMATION; BEHAVIOR	In this article, the dimensional stability of epoxy- and cyanate-based laminates is discussed, focusing on the thermal deformation, moisture-induced deformation, and deformation induced by relaxation of thermal residual stress. Each of the deformations was calculated independently based on the laminate theory. The material properties of the unidirectional laminates were obtained by conducting thermal mechanical analysis, moisture absorption tests, and tensile creep tests. These material properties were adopted to the laminate theory to predict the deformation of quasi-isotropic laminate, and it was calculated that each type of deformation induced micron-level dimensional instability. The moisture-induced deformation was an order of magnitude larger than that caused by the other factors. The validity of the calculations was confirmed by comparing the calculated results with the experimental ones. It is important to control moisture absorption even if cyanate resin, which has high moisture resistance, is used.	[Arao, Yoshihiko] Doshisha Univ, Dept Mech & Syst Engn, Kyoto 6100321, Japan; [Fukui, Taro; Niwa, Tomoyuki; Kawada, Hiroyuki] Waseda Univ, Dept Appl Mech & Aerosp Engn, Tokyo, Japan	Arao, Y (reprint author), Doshisha Univ, Dept Mech & Syst Engn, 1-3 Tataramiyakodani, Kyoto 6100321, Japan.	yoshihiko.arao@gmail.com					Abdel-Magid BM, 2003, TP212407 NASA; Choi HS, 2001, COMPOS PART A-APPL S, V32, P709, DOI 10.1016/S1359-835X(00)00145-7; Goertzen WK, 2006, MAT SCI ENG A-STRUCT, V421, P217, DOI 10.1016/j.msea.2006.01.063; SHEN CH, 1976, J COMPOS MATER, V10, P2, DOI 10.1177/002199837601000101; SCHAPERY RA, 1968, J COMPOS MATER, V2, P380, DOI 10.1177/002199836800200308; Arao A, 2011, COMPOS STRUCT, V93, P1225; Arao Y, 2010, MECH ADV MATER STRUC, V17, P328, DOI 10.1080/15376494.2010.488533; Arao Y, 2009, MECH TIME-DEPEND MAT, V13, P183, DOI 10.1007/s11043-009-9081-1; Arao Yoshihiko, 2010, Journal of Solid Mechanics and Materials Engineering, V4, DOI 10.1299/jmmp.4.1595; Arao Y, 2011, T JAPAN SOC MECH ENG, V77, P1238; Arao Y, 2011, T JAPAN SOC MECH ENG, V77, P38; Cowley KD, 1997, COMPOS SCI TECHNOL, V57, P1445, DOI 10.1016/S0266-3538(97)00048-1; Gibson RF, 2012, PRINCIPLES COMPOSITE, V3rd, P683; HINCKLEY CM, 1990, P SOC PHOTO-OPT INS, V1303, P497; Hu HW, 2000, COMPOS SCI TECHNOL, V60, P2693, DOI 10.1016/S0266-3538(00)00127-5; Ishikawa T, 1981, IRON STEEL I JAPAN, V9, P1440; Kim RY, 2000, COMPOS SCI TECHNOL, V60, P2601, DOI 10.1016/S0266-3538(00)00052-X; Miyano Y, 2000, MECH TIME-DEPEND MAT, V4, P9, DOI 10.1023/A:1009812115971; Morgan B, 2009, J COMPOS MATER, V10, P821; Niels CJ, 2008, COMPOS STRUCT, V82, P310; Niwa T, 2013, T JAPAN SOC MECH ENG, V79, P950; Ozaki T, 2004, SPIE P, V5382, P305; Ozaki T, 2001, ACTA ASTRONAUT, V48, P321, DOI 10.1016/S0094-5765(01)00027-3; Romeo RC, 2006, SPIE P OPT TECHN AST, V6273; WANG JZ, 1995, COMPOS SCI TECHNOL, V54, P405, DOI 10.1016/0266-3538(95)00083-6; Wolff EG, 2004, INTRO DIMENSIONAL ST, P419	26	0	0	SAGE PUBLICATIONS LTD	LONDON	1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND	0021-9983	1530-793X		J COMPOS MATER	J. Compos Mater.	MAY	2015	49	12					1483	1492		10.1177/0021998314535455		10	Materials Science, Composites	Materials Science	CG9KH	WOS:000353633400007		
J	Ihara, K; Hirota, M; Akitsu, T; Urakawa, K; Abe, T; Sumi, M; Okawa, T; Fujii, T				Ihara, K.; Hirota, M.; Akitsu, T.; Urakawa, K.; Abe, T.; Sumi, M.; Okawa, T.; Fujii, T.			Effects of emulsifying components in the continuous phase of cream on the stability of fat globules and the physical properties of whipped cream	JOURNAL OF DAIRY SCIENCE			English	Article						cream; emulsification; physicochemical properties; whipping	IN-WATER EMULSIONS; PARTIAL COALESCENCE; MICROSTRUCTURE; INTERFACES; PROTEIN	The emulsifying components in cream are very important in controlling the physical characteristics of whipped cream. The effects of those components on the stability of fat globules and the physical characteristics of whipped cream were investigated. A low-molecular-weight emulsifier, and protein ingredients such as sodium caseinate and a casein partial hydrolysate (casein peptides), were used as emulsifying components in this investigation. The viscosity of deaerated whipped cream (called the serum viscosity) was measured to evaluate the degree of fat-globule aggregation. Furthermore, the shape-retention ability, which is the degree of reduction in the firmness of whipped cream between immediately after whipping and after 1 d of refrigeration, was explored. The addition of the low-molecular-weight emulsifier in the continuous phase of dairy cream, which does not contain added low-molecular-weight emulsifiers, increased the stability of the fat globules and reduced the shape-retention ability of the whipped cream. The addition of protein ingredients (sodium caseinate and casein peptides) to the continuous phase of dairy cream had little effect. However, the addition of casein peptide in the continuous phase of dairy cream together with the low-molecular-weight emulsifier reduced the effect of the low-molecular-weight emulsifier on the stabilization of fat globules and the shape-retention ability of the whipped cream. The addition of casein peptide did not recover the serum viscosity; thus, other mechanisms might underlie this phenomenon.	[Ihara, K.; Hirota, M.; Urakawa, K.; Abe, T.; Okawa, T.] Morinaga Milk Ind Co Ltd, Food Res & Dev Inst, Zama, Kanagawa 2528583, Japan; [Akitsu, T.; Sumi, M.] Morinaga Milk Ind Co Ltd, Prod Evaluat Ctr, Zama, Kanagawa 2528583, Japan; [Fujii, T.] Tohoku Univ, Fac Agr, Grad Sch Agr Sci, Aoba Ku, Sendai, Miyagi 9818555, Japan	Ihara, K (reprint author), Morinaga Milk Ind Co Ltd, Food Res & Dev Inst, 1-83,5 Chome Higashihara, Zama, Kanagawa 2528583, Japan.	k_ihara@morinagamilk.co.jp					Anderson M., 1988, Advances in food emulsions and foams., P221; Cornec M, 1998, J FOOD SCI, V63, P39, DOI 10.1111/j.1365-2621.1998.tb15671.x; Goff HD, 1997, J DAIRY SCI, V80, P2620; Fredrick E, 2013, FOOD RES INT, V51, P936, DOI 10.1016/j.foodres.2013.02.006; Fredrick E, 2010, ADV COLLOID INTERFAC, V153, P30, DOI 10.1016/j.cis.2009.10.003; BRITTEN M, 1991, J DAIRY SCI, V74, P3318; Dickinson E., 1982, COLLOIDS FOOD, P462; Hotrum NE, 2005, COLLOID SURFACE A, V260, P71, DOI 10.1016/j.colsurfa.2005.03.004; Ihara K, 2005, J JPN SOC FOOD SCI, V52, P553; Ihara K, 2010, J DAIRY SCI, V93, P2887, DOI 10.3168/jds.2009-3012; Kannan K., 2012, FOOD PROTEINS PEPTID, P151; Matsumura Y., 2012, FOOD PROTEINS PEPTID, P125; NODA M, 1986, J TEXTURE STUD, V17, P189, DOI 10.1111/j.1745-4603.1986.tb00404.x; Okuyama S, 1995, J JPN SOC FOOD SCI, V42, P969; Panyam D., 2004, J FOOD SCI, V69; van Aken GA, 2001, COLLOID SURFACE A, V190, P333, DOI 10.1016/S0927-7757(01)00709-9; Walstra P., 2006, DAIRY SCI TECHNOL, V2nd, P447; WILDE PJ, 1993, J COLLOID INTERF SCI, V155, P48, DOI 10.1006/jcis.1993.1008; Wilde PJ, 2007, ROY SOC CH, P385, DOI 10.1039/9781847557698-00383; Zhao QZ, 2013, FOOD CHEM, V141, P1834, DOI 10.1016/j.foodchem.2013.04.086	20	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0022-0302	1525-3198		J DAIRY SCI	J. Dairy Sci.	MAY	2015	98	5					2875	2883		10.3168/jds.2014-8870		9	Agriculture, Dairy & Animal Science; Food Science & Technology	Agriculture; Food Science & Technology	CG4PG	WOS:000353267900006		
J	Izumi, H; Tsuda, M; Sato, Y; Kosaka, N; Ochiya, T; Iwamoto, H; Namba, K; Takeda, Y				Izumi, Hirohisa; Tsuda, Muneya; Sato, Yohei; Kosaka, Nobuyoshi; Ochiya, Takahiro; Iwamoto, Hiroshi; Namba, Kazuyoshi; Takeda, Yasuhiro			Bovine milk exosomes contain microRNA and mRNA and are taken up by human macrophages	JOURNAL OF DAIRY SCIENCE			English	Article						microRNA; mRNA; exosome; milk	IMMUNE-RELATED MICRORNAS; CIRCULATING MICRORNAS; CELL-DIFFERENTIATION; GENE-EXPRESSION; LACTATION; PLASMA; COLOSTRUM; ABUNDANT; SALIVA; FLUID	We reported previously that microRNA (miRNA) are present in whey fractions of human breast milk, bovine milk, and rat milk. Moreover, we also confirmed that so many mRNA species are present in rat milk whey. These RNA were resistant to acidic conditions and to RNase, but were degraded by detergent. Thus, these RNA are likely packaged in membrane vesicles such as exosomes. However, functional extracellular circulating RNA in bodily fluids, such as blood miRNA, are present in various forms. In the current study, we used bovine raw milk and total RNA purified from exosomes (prepared by ultracentrifugation) and ultracentrifuged supernatants, and analyzed them using miRNA and mRNA microarrays to clarify which miRNA and mRNA species are present in exosomes, and which species exist in other forms. Microarray analyses revealed that most mRNA in milk whey were present in exosomes, whereas miRNA in milk whey were present in supernatant as well as exosomes. The RNA in exosomes might exert functional effects because of their stability. Therefore, we also investigated whether bovine milk-derived exosomes could affect human cells using THP-1 cells. Flow cytometry and fluorescent microscopy studies revealed that bovine milk exosomes were incorporated into differentiated THP-1 cells. These results suggest that bovine milk exosomes might have effects in human cells by containing RNA.	[Izumi, Hirohisa; Tsuda, Muneya; Sato, Yohei; Iwamoto, Hiroshi; Namba, Kazuyoshi; Takeda, Yasuhiro] Morinaga Milk Ind Co Ltd, Nutr Sci Inst, Zama, Kanagawa 2528583, Japan; [Kosaka, Nobuyoshi; Ochiya, Takahiro] Natl Canc Ctr, Div Mol & Cellular Med, Res Inst, Chuo Ku, Tokyo 1040045, Japan	Izumi, H (reprint author), Morinaga Milk Ind Co Ltd, Nutr Sci Inst, Zama, Kanagawa 2528583, Japan.	h-izumi@morinagamilk.co.jp					Sun Q, 2013, PROTEIN CELL, V4, P197, DOI 10.1007/s13238-013-2119-9; Simpson RJ, 2009, EXPERT REV PROTEOMIC, V6, P267, DOI [10.1586/epr.09.17, 10.1586/EPR.09.17]; Ogawa Y, 2013, BIOL PHARM BULL, V36, P66; Hino K, 2008, RNA, V14, P1433, DOI 10.1261/rna.810208; Zhang YY, 2013, J CLIN IMMUNOL, V33, P630, DOI 10.1007/s10875-012-9840-7; Kosaka N, 2010, CANCER SCI, V101, P2087, DOI 10.1111/j.1349-7006.2010.01650.x; Maningat PD, 2009, PHYSIOL GENOMICS, V37, P12, DOI 10.1152/physiolgenomics.90341.2008; Wang H, 2007, RNA, V13, P151, DOI 10.1261/rna.234507; Baier SR, 2014, J NUTR, V144, P1495, DOI 10.3945/jn.114.196436; Chen X, 2010, CELL RES, V20, P1128, DOI 10.1038/cr.2010.80; Liu XG, 2010, J IMMUNOL, V185, P7244, DOI 10.4049/jimmunol.1001573; Hata T, 2010, BIOCHEM BIOPH RES CO, V396, P528, DOI 10.1016/j.bbrc.2010.04.135; Izumi H, 2012, J DAIRY SCI, V95, P4831, DOI 10.3168/jds.2012-5489; Vickers KC, 2011, NAT CELL BIOL, V13, P423, DOI 10.1038/ncb2210; Ju SW, 2013, MOL THER, V21, P1345, DOI 10.1038/mt.2013.64; Sato Fumiaki, 2011, FEBS J, V278, P1598, DOI 10.1111/j.1742-4658.2011.08089.x; Zhou Q, 2012, INT J BIOL SCI, V8, P118, DOI 10.7150/ijbs.8.118; Zhang L, 2012, CELL RES, V22, P107, DOI 10.1038/cr.2011.158; Dickinson B, 2013, NAT BIOTECHNOL, V31, P965, DOI 10.1038/nbt.2737; Mestdagh P, 2014, NAT METHODS, V11, P809, DOI [10.1038/nmeth.3014, 10.1038/NMETH.3014]; Weber JA, 2010, CLIN CHEM, V56, P1733, DOI 10.1373/clinchem.2010.147405; Snow JW, 2013, RNA BIOL, V10, P1107, DOI 10.4161/rna.24909; Brenaut P, 2012, J DAIRY SCI, V95, P6130, DOI 10.3168/jds.2012-5604; Mitchell PS, 2008, P NATL ACAD SCI USA, V105, P10513, DOI 10.1073/pnas.0804549105; Argyropoulos C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054662; Arroyo JD, 2011, P NATL ACAD SCI USA, V108, P5003, DOI 10.1073/pnas.1019055108; Cross ML, 2000, BRIT J NUTR, V84, pS81; Gu YR, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043691; Haug A, 2007, LIPIDS HEALTH DIS, V6, DOI [10.1186/1476-511X-6-25, 10.1186/1476-511X-6-29]; Izumi H, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088843; Izumi Hirohisa, 2013, Methods Mol Biol, V1024, P191, DOI 10.1007/978-1-62703-453-1_15; Kosaka Nobuyoshi, 2010, Silence, V1, P7, DOI 10.1186/1758-907X-1-7; Lasser C, 2011, J TRANSL MED, V9, DOI 10.1186/1479-5876-9-9; Lemay DG, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067531; Lukasik A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0099963; Marshall Keri, 2004, Altern Med Rev, V9, P136; Munch EM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0050564; Papetti M, 2011, AM J PHYSIOL-GASTR L, V301, pG508, DOI 10.1152/ajpgi.00066.2011; Romao JM, 2014, BMC GENOMICS, V15, DOI 10.1186/1471-2164-15-137; van Hooijdonk ACM, 2000, BRIT J NUTR, V84, pS127; Wickramasinghe S, 2012, BMC GENOMICS, V13, DOI 10.1186/1471-2164-13-45	41	3	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0022-0302	1525-3198		J DAIRY SCI	J. Dairy Sci.	MAY	2015	98	5					2920	2933		10.3168/jds.2014-9076		14	Agriculture, Dairy & Animal Science; Food Science & Technology	Agriculture; Food Science & Technology	CG4PG	WOS:000353267900010		
J	Piechotta, M; Mysegades, W; Ligges, U; Lilienthal, J; Hoeflich, A; Miyamoto, A; Bollwein, H				Piechotta, M.; Mysegades, W.; Ligges, U.; Lilienthal, J.; Hoeflich, A.; Miyamoto, A.; Bollwein, H.			Antepartal insulin-like growth factor 1 and insulin-like growth factor binding protein 2 concentrations are indicative of ketosis in dairy cows	JOURNAL OF DAIRY SCIENCE			English	Article						dairy cow; transition period; insulin-like growth factor 1; insulin-like growth factor binding protein 2; ketosis	NEGATIVE-ENERGY BALANCE; BODY CONDITION SCORE; I IGF-I; MESSENGER-RNA; MATRIX METALLOPROTEINASES; BETA-HYDROXYBUTYRATE; BOVINE SOMATOTROPIN; TRANSITION PERIOD; ENDOCRINE CHANGES; FEED RESTRICTION	A study involving a small number of cows found that the concentrations of insulin-like growth hormone 1 (IGF1) may be a useful predictor of metabolic disease. Further, IGF1 may provide also a pathophysiological link to metabolic diseases such as ketosis. The objective of the current study was to test whether the low antepartal total IGF1 or IGF1 binding protein (IGFBP) concentrations might predict ketosis under field conditions. Clinical examinations and blood sampling were performed antepartum (262-270 d after artificial insemination) on 377 pluriparous pregnant Holstein Friesian cows. The presence of postpartum diseases were recorded (ketosis, fatty liver, displacement of the abomasum, hypocalcemia, mastitis, retention of fetal membranes, and clinical metritis or endometritis), and the concentrations of IGF1, IGFBP2, IGFBP3, and nonesterified fatty acids were measured. Cows with postpartum clinical ketosis had lower IGF1 concentrations antepartum than healthy cows. The sensitivity of antepartal IGF1 as a marker for postpartum ketosis was 0.87, and the specificity was 0.43; a positive predictive value of 0.91 and a negative predictive value of 0.35 were calculated. The cows with ketosis and retained fetal membranes had lower IGFBP2 concentrations compared with the healthy cows. It can be speculated that lower IGF1 production in the liver during late pregnancy may increase growth hormone secretions and lipolysis, thereby increasing the risk of ketosis. Lower IGFBP2 concentrations may reflect the suppression of IGFBP2 levels through higher growth hormone secretion. In conclusion, compared with nonesterified fatty acids as a predictive parameter, IGF1 and IGFBP2 may represent earlier biomarkers of inadequate metabolic adaptation to the high energy demand required postpartum.	[Piechotta, M.; Mysegades, W.] Univ Vet Med, Clin Cattle, D-30173 Hannover, Germany; [Ligges, U.; Lilienthal, J.] TU Dortmund Univ, Dept Stat, D-44221 Dortmund, Germany; [Hoeflich, A.] Leibniz Inst Farm Anim Biol, Mouse Genet, D-18196 Dummerstorf, Germany; [Miyamoto, A.] Obihiro Univ Agr & Vet Med, Obihiro, Hokkaido 0808555, Japan; [Bollwein, H.] Univ Zurich, Vetsuisse Fac, Clin Reprod Med, CH-8057 Zurich, Switzerland	Piechotta, M (reprint author), Univ Vet Med, Clin Cattle, Bischofsholer Damm 15, D-30173 Hannover, Germany.	marion.piechotta@tiho-hannover.de					Wheatcroft SB, 2009, TRENDS ENDOCRIN MET, V20, P153, DOI 10.1016/j.tem.2009.01.002; Ruan WJ, 2010, ACTA DIABETOL, V47, P5, DOI 10.1007/s00592-009-0142-3; Renaville R, 2000, DOMEST ANIM ENDOCRIN, V18, P165, DOI 10.1016/S0739-7240(99)00076-4; Williams EJ, 2013, REPROD DOMEST ANIM, V48, P53, DOI 10.1111/rda.12205; Roche JR, 2013, VET CLIN N AM-FOOD A, V29, P323, DOI 10.1016/j.cvfa.2013.03.003; Kawashima C, 2007, REPRODUCTION, V133, P155, DOI 10.1530/REP-06-0046; Rajaram S, 1997, ENDOCR REV, V18, P801, DOI 10.1210/er.18.6.801; Gross J, 2011, J DAIRY SCI, V94, P3484, DOI 10.3168/jds.2011-4251; Ospina PA, 2010, J DAIRY SCI, V93, P546, DOI 10.3168/jds.2009-2277; Hammon HM, 2009, J DAIRY SCI, V92, P1554, DOI 10.3168/jds.2008-1634; Fenwick MA, 2008, DOMEST ANIM ENDOCRIN, V34, P31, DOI 10.1016/j.domaniend.2006.10.002; Chapinal N, 2011, J DAIRY SCI, V94, P4897, DOI 10.3168/jds.2010-4075; Wathes DC, 2012, REPROD DOMEST ANIM, V47, P304, DOI 10.1111/j.1439-0531.2012.02090.x; Chagas LM, 2007, J DAIRY SCI, V90, P4022, DOI 10.3168/jds.2006-852; Kobayashi Y, 1999, ENDOCRINOLOGY, V140, P3947, DOI 10.1210/en.140.9.3947; Piechotta M, 2013, J DAIRY SCI, V96, P3737, DOI 10.3168/jds.2012-6341; Cummins SB, 2012, J DAIRY SCI, V95, P3711, DOI 10.3168/jds.2011-4977; Sheldon IM, 2008, VET J, V176, P115, DOI [10.1016/j.tvjl.2007.12.031, 10.1016/j.tvj1.2007.12.031]; EDMONSON AJ, 1989, J DAIRY SCI, V72, P68; Metzger F, 2011, J BIOL CHEM, V286, P19501, DOI 10.1074/jbc.M110.172189; Sargeant JM, 2001, J DAIRY SCI, V84, P2018; Koeck A, 2014, J DAIRY SCI, V97, P7286, DOI 10.3168/jds.2014-8405; Laeger T, 2014, J DAIRY SCI, V97, P2876, DOI 10.3168/jds.2013-7671; COHICK WS, 1992, ENDOCRINOLOGY, V130, P1508, DOI 10.1210/en.130.3.1508; FOWLKES JL, 1994, ENDOCRINOLOGY, V135, P2810, DOI 10.1210/en.135.6.2810; HANNON K, 1991, P SOC EXP BIOL MED, V196, P155; Hennies M, 2003, J IMMUNOL METHODS, V281, P9, DOI 10.1016/S0022-1759(03)00195-9; HERDT TH, 1983, AM J VET RES, V44, P293; Hoeflich Andreas, 2014, Front Endocrinol (Lausanne), V5, P43, DOI 10.3389/fendo.2014.00043; Houseknecht KL, 1997, J ENDOCRINOL, V152, P465, DOI 10.1677/joe.0.1520465; Lanna DPD, 1999, J DAIRY SCI, V82, P60; LEAN IJ, 1994, RES VET SCI, V57, P200, DOI 10.1016/0034-5288(94)90058-2; Lean IJ, 2013, VET CLIN N AM-FOOD A, V29, P337, DOI 10.1016/j.cvfa.2013.03.005; Gohary K, 2014, J DAIRY SCI, V97, P6231, DOI 10.3168/jds.2014-8048; Leblanc S, 2010, J REPROD DEVELOP, V56, pS29; LILLIEFO.HW, 1967, J AM STAT ASSOC, V62, P399, DOI 10.2307/2283970; Lucy M. C., 2001, J DAIRY SCI, V84, P113; Nedbal S, 2000, ARCH TIERZUCHT, V43, P223; Piechotta M, 2012, J DAIRY SCI, V95, P1367, DOI 10.3168/jds.2011-4622; Piechotta M, 2014, J VET SCI, V15, P343, DOI 10.4142/jvs.2014.15.3.343; Rose MT, 2009, DOMEST ANIM ENDOCRIN, V36, P24, DOI 10.1016/j.domaniend.2008.09.001; VICINI JL, 1991, J NUTR, V121, P1656; Wang JG, 2012, MOL CELL BIOCHEM, V362, P87, DOI 10.1007/s11010-011-1130-9; Wu HB, 1999, HORM METAB RES, V31, P186, DOI 10.1055/s-2007-978718	44	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0022-0302	1525-3198		J DAIRY SCI	J. Dairy Sci.	MAY	2015	98	5					3100	3109		10.3168/jds.2014-8885		10	Agriculture, Dairy & Animal Science; Food Science & Technology	Agriculture; Food Science & Technology	CG4PG	WOS:000353267900029		
J	Nakayama, Y; Holcroft, J; Ganss, B				Nakayama, Y.; Holcroft, J.; Ganss, B.			Enamel Hypomineralization and Structural Defects in Amelotin-deficient Mice	JOURNAL OF DENTAL RESEARCH			English	Article						enamel biomineralization; gene expression; molecular biology; transgenic mice; matrix proteins; electron microscopy	AMELOGENESIS IMPERFECTA PHENOTYPE; JUNCTIONAL EPITHELIUM; EXPRESSION; AMELOBLASTIN; PROTEIN; MINERALIZATION; MATURATION; DISPLAY; MMP20; KLK4	Amelotin (AMTN) is a relatively recently discovered enamel protein that is predominantly expressed by ameloblasts during the maturation stage of amelogenesis and is present at lower levels in the junctional epithelium of erupted teeth. Previous studies have suggested a function of this protein in enamel mineralization and cell attachment. Genetic mouse models have been instrumental in defining the role of many enamel-related proteins, but a genetic mouse model lacking the Amtn gene has not been reported. Here, we describe the generation of amelotin-deficient mice and the analysis of their enamel phenotype in comparison with that of wild-type animals. Ablation of AMTN expression resulted in mechanically inferior enamel of mandibular incisors that showed chipping and fractures at the incisal edge. Enamel mineralization was delayed, resulting in hypomineralized inner enamel and structural defects in the outer enamel. Erupted enamel close to the gingival margin showed increased surface roughness. The expression levels of the enamel matrix proteins AMEL, AMBN, ENAM, and ODAM and the enamel proteases MMP-20 and KLK-4 were not significantly altered, although the expression of KLK-4 was delayed. The morphology of ameloblasts showing prominent Tomes' processes during the secretory stage was not altered, and there was no indication of disruption of cell structures or activities, but a residual layer, presumably consisting of organic material, remained at the enamel surface close to the gingival margin. The integrity of the dentogingival attachment at the junctional epithelium appeared unaffected by AMTN deficiency. These observations indicate that AMTN plays a subtle yet critical role in enamel biomineralization, particularly during the establishment of the outer and surface enamel layers. This role appears to be largely independent of other enamel proteins.	[Nakayama, Y.] Nihon Univ Sch Dent, Dept Periodontol, Matsudo, Chiba, Japan; [Nakayama, Y.; Holcroft, J.; Ganss, B.] Univ Toronto, Fac Dent, Matrix Dynam Grp, Toronto, ON M5S 3E2, Canada	Ganss, B (reprint author), Univ Toronto, Fac Dent, Matrix Dynam Grp, 235-150 Coll St, Toronto, ON M5S 3E2, Canada.	b.ganss@utoronto.ca			Canadian Institutes of Health Research (CIHR) [MOP-119310]; Natural Sciences and Engineering Research Council (NSERC) of Canada [RGPIN 403292-11]	We thank all colleagues (see "Materials and Methods") who generously provided antibodies for this study, as well as Douglas Holmyard and Marc Grynpas (Advanced Bioimaging Centre, Mount Sinai Hospital, Toronto, ON, Canada) and Elnaz Ajami (Bone Interface Group, Toronto, ON, Canada) for their expert assistance with electronmicroscopy and microCT imaging. The support by an Operating grant (MOP-119310) from the Canadian Institutes of Health Research (CIHR) and a Discovery grant (RGPIN 403292-11) from the Natural Sciences and Engineering Research Council (NSERC) of Canada is gratefully acknowledged. The authors declare no potential conflicts of interest with respect to the authorship and/or publication of this article.	Abbarin N, 2014, J BONE MINER RES, DOI [10.1002/jbmr.2411, DOI 10.1002/JBMR.2411]; Gibson CW, 2001, J BIOL CHEM, V276, P31871, DOI 10.1074/jbc.M104624200; Moinichen CB, 1996, J ANAT, V189, P325; Smith CE, 2009, EUR J ORAL SCI, V117, P485, DOI 10.1111/j.1600-0722.2009.00666.x; Iwasaki K, 2005, J DENT RES, V84, P1127; Nishio C, 2010, EUR CELLS MATER, V20, P393; Doetschman Thomas, 2009, V530, P423, DOI 10.1007/978-1-59745-471-1_23; Lacruz RS, 2012, J CELL PHYSIOL, V227, P1776, DOI 10.1002/jcp.22911; Sawada T, 2014, J MOL HISTOL, V45, P293, DOI 10.1007/s10735-013-9559-7; Hu JCC, 2008, J BIOL CHEM, V283, P10858, DOI 10.1074/jbc.M710565200; Somogyi-Ganss E, 2012, CELLS TISSUES ORGANS, V195, P535, DOI 10.1159/000329255; Fukumoto S, 2004, J CELL BIOL, V167, P973, DOI 10.1083/jcb.200409077; Wright JT, 2009, CELLS TISSUES ORGANS, V189, P224, DOI 10.1159/000151378; Moradian-Oldak J, 2012, FRONT BIOSCI-LANDMRK, V17, P1996, DOI 10.2741/4034; Lyaruu DM, 2014, J DENT RES, V93, P96, DOI 10.1177/0022034513510944; Simmer JP, 2010, J DENT RES, V89, P1024, DOI 10.1177/0022034510375829; Caterina JJ, 2002, J BIOL CHEM, V277, P49598, DOI 10.1074/jbc.M209100200; LEBLOND CP, 1979, J DENT RES, V58, P950, DOI 10.1177/00220345790580024901; Moffatt P, 2006, BIOCHEM J, V399, P37, DOI 10.1042/BJ20060662; Abe T, 2013, J IMMUNOL METHODS, V394, P49, DOI 10.1016/j.jim.2013.05.002; Bartlett JD, 2013, ISRN DENT, V2013, DOI DOI 10.1155/2013/684607; Dos Santos NJ, 2012, HISTOCHEM CELL BIOL, V137, P329, DOI DOI 10.1007/S00418-011-0901-4; Garcia-Godoy F, 2008, J AM DENT ASSOC S, V139, p25S; Hatakeyama J, 2009, J DENT RES, V88, P318, DOI 10.1177/0022034509334749; Holcroft J, 2011, EUR J ORAL SCI, V119, P301, DOI 10.1111/j.1600-0722.2011.00870.x; Lacruz RS, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035200; Ng AHM, 2007, CALCIFIED TISSUE INT, V81, P215, DOI 10.1007/s00223-007-9047-8; Parry DA, 2012, AM J HUM GENET, V91, P565, DOI 10.1016/j.ajhg.2012.07.020; Simmer JP, 2009, J BIOL CHEM, V284, P19110, DOI 10.1074/jbc.M109.013623; Tye CE, 2010, J DENT RES, V89, P1421, DOI 10.1177/0022034510384625; Wazen RM, 2009, MATRIX BIOL, V28, P292, DOI 10.1016/j.matbio.2009.04.004	31	4	4	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0022-0345	1544-0591		J DENT RES	J. Dent. Res.	MAY	2015	94	5					697	705		10.1177/0022034514566214		9	Dentistry, Oral Surgery & Medicine	Dentistry, Oral Surgery & Medicine	CG3VN	WOS:000353207800009		
J	Kondo, Y; Nakamoto, T; Jaramillo, Y; Choi, S; Catalan, MA; Melvin, JE				Kondo, Y.; Nakamoto, T.; Jaramillo, Y.; Choi, S.; Catalan, M. A.; Melvin, J. E.			Functional Differences in the Acinar Cells of the Murine Major Salivary Glands	JOURNAL OF DENTAL RESEARCH			English	Article						epithelia; physiology; salivary physiology; chloride channel; Na-K-Cl transporter; calcium signaling	FLUID SECRETION; CL--HCO3-EXCHANGE; MOUSE; CHANNEL; TMEM16A; COTRANSPORTERS; ELECTROLYTE; EXPRESSION; TRANSPORT; MICE	In humans, approximately 90% of saliva is secreted by the 3 major salivary glands: the parotid (PG), the submandibular (SMG), and the sublingual glands (SLG). Even though it is known that all 3 major salivary glands secrete saliva by a Cl--dependent mechanism, salivary secretion rates differ greatly among these glands. The goal of this study was to gain insight into the properties of the ion-transporting pathways in acinar cells that might account for the differences among the major salivary glands. Pilocarpine-induced saliva was simultaneously collected in vivo from the 3 major salivary glands of mice. When normalized by gland weight, the amount of saliva secreted by the PG was more than 2-fold larger than that obtained from the SMG and SLG. At the cellular level, carbachol induced an increase in the intracellular [Ca2+] that was more than 2-fold larger in PG and SMG than in SLG acinar cells. Carbachol-stimulated Cl- efflux and the protein levels of the Ca2+-activated Cl- channel TMEM16A, the major apical Cl- efflux pathway in salivary acinar cells, were significantly greater in PG compared with SMG and SLG. In addition, we evaluated the transporter activity of the Na+-K+-2Cl(-) cotransporters (NKCC1) and anion exchangers (AE), the 2 primary basolateral Cl- uptake mechanisms in acinar cells. The SMG NKCC1 activity was about twice that of the PG and more than 12-fold greater than that of the SLG. AE activity was similar in PG and SLG, and both PG and SLG AE activity was about 2-fold larger than that of SMG. In summary, the salivation kinetics of the 3 major glands are distinct, and these differences can be explained by the unique functional properties of each gland related to Cl- movement, including the transporter activities of the Cl- uptake and efflux pathways, and intracellular Ca2+ mobilization.	[Kondo, Y.; Jaramillo, Y.; Choi, S.; Catalan, M. A.; Melvin, J. E.] Natl Inst Dent & Craniofacial Res, Secretory Mech & Dysfunct Sect, NIH, Bethesda, MD 20892 USA; [Kondo, Y.; Nakamoto, T.] Kyushu Dent Univ, Dept Oral Reconstruct & Rehabil, Kitakyushu, Fukuoka, Japan	Melvin, JE (reprint author), Natl Inst Dent & Craniofacial Res, Secretory Mech & Dysfunct Sect, NIH, 10 Ctr Dr,Bldg 10,Room 1N117B, Bethesda, MD 20892 USA.	james.melvin@nih.gov			Intramural Research Program of the National Institutes of Health [NIH, National Institute of Dental and Craniofacial Research (NIDCR)]	The Secretory Mechanisms and Dysfunction Section is supported by the Intramural Research Program of the National Institutes of Health [NIH, National Institute of Dental and Craniofacial Research (NIDCR)]. We are thankful to Drs. Z. Borok, E.D. Crandall, and U.P. Flodby for providing the ACID mice and to Dr. Natalie Porat-Shliom for helping with the data analysis using ImageJ software. The authors declare no potential conflicts of interest with respect to the authorship and/or publication of this article.	Ambudkar IS, 2014, CELL CALCIUM, V55, P297, DOI 10.1016/j.ceca.2014.02.009; Flagella M, 1999, J BIOL CHEM, V274, P26946, DOI 10.1074/jbc.274.38.26946; Warner JD, 2008, AM J PHYSIOL-GASTR L, V295, pG629, DOI 10.1152/ajpgi.90217.2008; NOVAK I, 1986, PFLUG ARCH EUR J PHY, V407, P649, DOI 10.1007/BF00582647; Evans RL, 2000, J BIOL CHEM, V275, P26720; Muzumdar MD, 2007, GENESIS, V45, P593, DOI 10.1002/dvg.20335; Romanenko VG, 2010, J BIOL CHEM, V285, P12990, DOI 10.1074/jbc.M109.068544; Proctor GB, 2007, AUTON NEUROSCI-BASIC, V133, P3, DOI 10.1016/j.autneu.2006.10.006; Melvin JE, 2005, ANNU REV PHYSIOL, V67, P445, DOI 10.1146/annurev.physiol.67.041703.084745; Caputo A, 2008, SCIENCE, V322, P590, DOI 10.1126/science.1163518; Schroeder BC, 2008, CELL, V134, P1019, DOI 10.1016/j.cell.2008.09.003; Flodby P, 2010, AM J RESP CELL MOL, V43, P173, DOI 10.1165/rcmb.2009-0226OC; Yang YD, 2008, NATURE, V455, P1210, DOI 10.1038/nature07313; DAWES C, 1973, ARCH ORAL BIOL, V18, P337, DOI 10.1016/0003-9969(73)90156-8; EDGAR WM, 1990, BRIT DENT J, V169, P96; HAAS M, 1994, AM J PHYSIOL-CELL PH, V267, pC869; HAAS M, 1989, ANNU REV PHYSIOL, V51, P443, DOI 10.1146/annurev.physiol.51.1.443; MARTINEZ JR, 1987, J DENT RES, V66, P638; MELVIN JE, 1992, AM J PHYSIOL, V262, pG393; Nakamoto T, 2007, AM J PHYSIOL-REG I, V292, pR2380, DOI 10.1152/ajpregu.00591.2006; Nakamoto T, 2008, AM J PHYSIOL-CELL PH, V294, pC810, DOI 10.1152/ajpcell.00511.2007; NAUNTOFTE B, 1992, AM J PHYSIOL, V263, pG823; Nguyen HV, 2004, AM J PHYSIOL-GASTR L, V286, pG312, DOI 10.1152/ajpgi.00158.2003; PIRANI D, 1987, PFLUG ARCH EUR J PHY, V408, P178, DOI 10.1007/BF00581349; TURNER RJ, 1988, AM J PHYSIOL, V254, pC391	25	0	0	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0022-0345	1544-0591		J DENT RES	J. Dent. Res.	MAY	2015	94	5					715	721		10.1177/0022034515570943		7	Dentistry, Oral Surgery & Medicine	Dentistry, Oral Surgery & Medicine	CG3VN	WOS:000353207800011		
J	Suenaga, H; Chen, J; Yamaguchi, K; Li, W; Sasaki, K; Swain, M; Li, Q				Suenaga, H.; Chen, J.; Yamaguchi, K.; Li, W.; Sasaki, K.; Swain, M.; Li, Q.			Mechanobiological Bone Reaction Quantified by Positron Emission Tomography	JOURNAL OF DENTAL RESEARCH			English	Article						sodium fluoride; finite element analysis; removable partial denture; bone remodeling; mechanobiological phenomena; occlusal force	ELEMENT STRESS-ANALYSIS; FINITE-ELEMENT; IN-VIVO; PERIODONTAL-LIGAMENT; MINERAL DENSITY; TOOTH MOVEMENT; F-18-FLUORIDE; IMPLANT; BEHAVIOR; TIME	While nuclear medicine has been proven clinically effective for examination of the change in bone turnover as a result of stress injury, quantitative correlation between tracer uptake and mechanical stimulation in the human jawbone remains unclear. This study aimed to investigate the relationship between bone metabolism observed by 18F-fluoride positron emission tomography (PET) images and mechanical stimuli obtained by finite element analysis (FEA) in the residual ridge induced by the insertion of a removable partial denture (RPD). An 18F-fluoride PET/CT (computerized tomography) scan was performed to assess the change of bone metabolism in the residual ridge under the denture before and after RPD treatment. Corresponding patient-specific 3D finite element (FE) models were created from CT images. Boundary conditions were prescribed by the modeling of condylar contacts, and muscular forces were derived from the occlusal forces measured in vivo to generate mechanobiological reactions. Different mechanobiological stimuli, e.g., equivalent von Mises stress (VMS), equivalent strain (EQV), and strain energy density (SED), determined from nonlinear FEA, were quantified and compared with the standardized uptake values (SUVs) of PET. Application of increased occlusal force after RPD insertion induced higher mechanical stimuli in the residual bone. Accordingly, SUV increased in the region of residual ridge with higher mechanical stimuli. Thus, with SUV, a clear correlation was observed with VMS and SED in the cancellous bone, especially after RPD insertion (R-2 > 0.8, P < 0.001). This study revealed a good correlation between bone metabolism and mechanical stimuli induced by RPD insertion. From this patient-specific study, it was shown that metabolic change detected by PET in the loaded bone, in a much shorter duration than conventional x-ray assessment, is associated with mechanical stimuli. The nondestructive nature of PET/CT scans and FEA could potentially provide a new method for clinical examination and monitoring of prosthetically driven bone remodeling.	[Suenaga, H.] Tohoku Univ, Grad Sch Dent, Div Prevent Dent, Sendai, Miyagi 980, Japan; [Chen, J.; Li, W.; Li, Q.] Univ Sydney, Sch Aerosp Mech & Mechatron Engn, Sydney, NSW 2006, Australia; [Yamaguchi, K.] Sendai Kousei Hosp, Dept Radiol, Sendai, Miyagi, Japan; [Sasaki, K.] Tohoku Univ, Grad Sch Dent, Div Adv Prosthet Dent, Sendai, Miyagi 980, Japan; [Swain, M.] Univ Sydney, Fac Dent, Sydney, NSW 2006, Australia	Li, Q (reprint author), Univ Sydney, Sydney, NSW 2006, Australia.	qing.li@sydney.edu.au			Australian Research Council (ARC) [DP1095140, FT120100947]; Ministry of Education, Culture, Sports, Science and Technology of Japan [24792057, 26462912]	This work was supported by the Australian Research Council (ARC) through the Discovery and Fellowship schemes (DP1095140 and FT120100947), and by Grants-in-Aid for Young Scientists (B) (24792057) (2012-2013) and for Scientific Research (C) (26462912) (2014-) from the Ministry of Education, Culture, Sports, Science and Technology of Japan. The authors declare no potential conflicts of interest with respect to the authorship and/or publication of this article.	Ambrus C, 2010, INT UROL NEPHROL, V42, P723, DOI 10.1007/s11255-009-9666-2; Marx RE, 2005, J ORAL MAXIL SURG, V63, P1567, DOI 10.1016/j.joms.2005.07.010; Grant FD, 2008, J NUCL MED, V49, P68, DOI 10.2967/jnumed.106.037200; Fischer DR, 2011, EUR SPINE J, V20, P640, DOI 10.1007/s00586-010-1643-z; Wang HY, 2011, J PROSTHET DENT, V105, P338, DOI 10.1016/S0022-3913(11)60066-8; Lu XL, 2009, J DENT RES, V88, P244, DOI 10.1177/0022034508330432; Wei LL, 2010, J ORAL MAXIL SURG, V68, P2478, DOI 10.1016/j.joms.2010.01.018; Hattori Y, 2003, J DENT RES, V82, P532; Sawada A, 2011, J DENT RES, V90, P590, DOI 10.1177/0022034510396881; Ahmad R, 2013, CLIN ORAL IMPLAN RES, V24, P1273, DOI 10.1111/j.1600-0501.2012.02566.x; BRIDGES T, 1988, AM J ORTHOD DENTOFAC, V93, P245, DOI 10.1016/S0889-5406(88)80010-6; Taylor AF, 2007, AM J PHYSIOL-CELL PH, V292, pC545, DOI 10.1152/ajpcell.00611.2005; Kutzner I, 2013, J BIOMECH, V46, P796, DOI 10.1016/j.jbiomech.2012.11.020; Field C, 2010, J BIOMECH, V43, P1771, DOI 10.1016/j.jbiomech.2010.02.016; Mellal A, 2004, CLIN ORAL IMPLAN RES, V15, P239, DOI 10.1111/j.1600-0501.2004.01000.x; Even-Sapir E, 2007, SEMIN NUCL MED, V37, P462, DOI 10.1053/j.semnuclmed.2007.07.002; KORIOTH TWP, 1992, AM J PHYS ANTHROPOL, V88, P69, DOI 10.1002/ajpa.1330880107; Kanbara R, 2012, DENT MATER J, V31, P297, DOI 10.4012/dmj.2011-165; Chen JN, 2014, J BIOMECH, V47, P1689, DOI 10.1016/j.jbiomech.2014.02.030; Lin D, 2009, J MECH BEHAV BIOMED, V2, P410, DOI 10.1016/j.jmbbm.2008.11.007; Frost HM, 2003, ANAT REC PART A, V275A, P1081, DOI 10.1002/ar.a.10119; Beck BR, 2012, RADIOLOGY, V263, P811, DOI 10.1148/radiol.12102426; Prinz JF, 2007, FOOD HYDROCOLLOID, V21, P402, DOI 10.1016/j.foodhyd.2006.05.005; Brkovic-Popovic S, 2008, GERODONTOLOGY, V25, P118, DOI 10.1111/j.1741-2358.2007.00182.x; Carlsson Gunnar E, 2004, Gerodontology, V21, P65, DOI 10.1111/j.1741-2358.2004.00005.x; Chen JN, 2015, J BIOMECH, V48, P512, DOI 10.1016/j.jbiomech.2014.11.043; Cheng HY, 2013, J BIOMED MATER RES A, V101, P1158, DOI 10.1002/jbm.a.34415; Ichim I, 2006, J BIOMECH, V39, P1903, DOI 10.1016/j.jbiomech.2005.05.022; Kishi M, 1972, SHIKWA GAKUHO, V72, P1043; Kreisler M, 2003, INT J PROSTHODONT, V16, P295; Li JL, 2005, BONE, V37, P819, DOI 10.1016/j.bone.2005.06.022; Li W, 2005, J BIOMED MATER RES B, V74B, P520, DOI 10.1002/jbm.b.30233; LURIE AG, 1976, ORAL SURG ORAL MED O, V42, P726, DOI 10.1016/0030-4220(76)90094-3; PICTON DCA, 1978, J PROSTHET DENT, V40, P263, DOI 10.1016/0022-3913(78)90031-8; Sajewicz E, 2009, TRIBOL INT, V42, P327, DOI 10.1016/j.triboint.2008.07.001; Sasaki H, 2008, INT J ORAL MAX IMPL, V23, P827; Silva MJ, 2006, BONE, V39, P229, DOI 10.1016/j.bone.01.149; Slipman C W, 2001, Pain Physician, V4, P336; Suenaga H, 2012, ANN NUCL MED, V26, P817, DOI 10.1007/s12149-012-0648-6; Suenaga Hanako, 2014, Applied Mechanics and Materials, V553, DOI 10.4028/www.scientific.net/AMM.553.322	40	2	2	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0022-0345	1544-0591		J DENT RES	J. Dent. Res.	MAY	2015	94	5					738	744		10.1177/0022034515573271		7	Dentistry, Oral Surgery & Medicine	Dentistry, Oral Surgery & Medicine	CG3VN	WOS:000353207800014		
J	Kojima, I; Nakagawa, Y; Ohtsu, Y; Hamano, K; Medina, J; Nagasawa, M				Kojima, Itaru; Nakagawa, Yuko; Ohtsu, Yoshiaki; Hamano, Kunihisa; Medina, Johan; Nagasawa, Masahiro			Return of the glucoreceptor: Glucose activates the glucose-sensing receptor T1R3 and facilitates metabolism in pancreatic beta-cells	Journal of Diabetes Investigation			English	Review						Glucose; Insulin secretion; Sweet taste receptor	SWEET TASTE RECEPTOR; STIMULATED INSULIN-SECRETION; SIGNALING SYSTEMS; MAMMALIAN SWEET; LINE MIN6; RELEASE; ANOMERS; ACID; GLUCOKINASE; CONTRIBUTE	Subunits of the sweet taste receptor, namely T1R2 and T1R3, are expressed in mouse pancreatic islets. Quantitatively, the expression of messenger ribonucleic acid for T1R2 is much lower than that of T1R3, and immunoreactive T1R2 is in fact undetectable. Presumably, a homodimer of T1R3 could function as a signaling receptor. Activation of this receptor by adding an artificial sweetener, sucralose, leads to an increase in intracellular adenosine triphosphate ([ATP](c)). This increase in [ATP](c) is observed in the absence of ambient glucose. Sucralose also augments elevation of [ATP](c) induced by methylsuccinate, a substrate for mitochondria. Consequently, activation of T1R3 promotes metabolism in mitochondria and increases [ATP](c). 3-O-Methylglucose, a non-metabolizable analog of glucose, also increases [ATP](c). Conversely, knockdown of T1R3 attenuates elevation of [ATP](c) induced by glucose. Hence, glucose promotes its own metabolism by activating T1R3 and augmenting ATP production. Collectively, a homodimer of T1R3 functions as a cell surface glucose-sensing receptor and participates in the action of glucose on insulin secretion. The glucose-sensing receptor T1R3 might be the putative glucoreceptor proposed decades ago by Niki etal. The glucose-sensing receptor is involved in the action of glucose and modulates glucose metabolism in pancreatic -cells.	[Kojima, Itaru; Nakagawa, Yuko; Ohtsu, Yoshiaki; Hamano, Kunihisa; Medina, Johan; Nagasawa, Masahiro] Gunma Univ, Inst Mol & Cellular Regulat, Maebashi, Gumma 371, Japan	Kojima, I (reprint author), Gunma Univ, Inst Mol & Cellular Regulat, Maebashi, Gumma 371, Japan.	ikojima@gunma-u.ac.jp			Ministry of Education, Science, Sports and Culture of Japan	The authors are grateful to Ms Mayumi Odagiri for secretarial assistance. This study was supported by Grants-in-Aid for Scientific Research from the Ministry of Education, Science, Sports and Culture of Japan. The authors declare no conflict of interest.	RASMUSSEN H, 1990, DIABETES CARE, V13, P655, DOI 10.2337/diacare.13.6.655; Oh DY, 2010, CELL, V142, P687, DOI 10.1016/j.cell.2010.07.041; Shapiro H, 2005, BIOCHEM BIOPH RES CO, V335, P97, DOI 10.1016/j.bbrc.2005.07.042; Roper SD, 2013, SEMIN CELL DEV BIOL, V24, P71, DOI 10.1016/j.semcdb.2012.12.002; NIKI A, 1974, SCIENCE, V186, P150, DOI 10.1126/science.186.4159.150; Nakagawa Y, 2014, ENDOCR J, V61, P119; Geraedts MCP, 2012, AM J PHYSIOL-ENDOC M, V303, pE464, DOI 10.1152/ajpendo.00163.2012; Medina A, 2014, ENDOCR J, V61, P797, DOI 10.1507/endocrj.EJ14-0221; Nelson G, 2001, CELL, V106, P381, DOI 10.1016/S0092-8674(01)00451-2; Matschinsky FM, 1996, DIABETES, V45, P223, DOI 10.2337/diabetes.45.2.223; Zhang YF, 2003, CELL, V112, P293, DOI 10.1016/S0092-8674(03)00071-0; Lindemann B, 2001, NATURE, V413, P219, DOI 10.1038/35093032; Oya M, 2011, GENES CELLS, V16, P608, DOI 10.1111/j.1365-2443.2011.01509.x; Kyriazis GA, 2012, P NATL ACAD SCI USA, V109, pE524, DOI 10.1073/pnas.1115183109; Nakagawa Y, 2013, ENDOCR J, V60, P1191, DOI 10.1507/endocrj.EJ13-0282; Zhao GQ, 2003, CELL, V115, P255, DOI 10.1016/S0092-8674(03)00844-4; Brice NL, 2002, DIABETOLOGIA, V45, P242, DOI 10.1007/s00125-001-0750-0; Conigrave AD, 2007, BIOCHEM SOC T, V35, P1195, DOI 10.1042/BST0351195; GONOI T, 1994, J BIOL CHEM, V269, P16989; HEDESKOV CJ, 1980, PHYSIOL REV, V60, P442; Henquin JC, 2012, SCI SIGNAL, V5, P36; Kogure R, 2011, BIOCHEM BIOPH RES CO, V416, P58, DOI 10.1016/j.bbrc.2011.10.141; Kyriazis GA, 2014, ENDOCRINOLOGY, V155, P2112, DOI 10.1210/en.2013-2015; MALAISSE WJ, 1976, FEBS LETT, V65, P131, DOI 10.1016/0014-5793(76)80463-2; Masubuchi Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054500; MATSCHINSKY FM, 1990, DIABETES, V39, P647, DOI 10.2337/diabetes.39.6.647; Nakagawa Y, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005106; NIKI A, 1988, DIABETOLOGIA, V31, P65; Niki A, 1991, LESSONS ANIMAL DIABE, P87; NIKI A, 1989, BIOMED RES-TOKYO, V10, P169; NIKI A, 1993, BIOMED RES-TOKYO, V14, P13; NIKI A, 1979, ENDOCRINOLOGY, V105, P1051; NIKI A, 1980, BIOMED RES-TOKYO, V1, P189; Ohtsu Y, 2014, MOL CELL ENDOCRINOL, V394, P70, DOI 10.1016/j.mce.2014.07.004; PANGBORN RM, 1961, NATURE, V191, P810, DOI 10.1038/191810a0; QUINLAN ME, 1990, J FOOD SCI, V55, P244, DOI 10.1111/j.1365-2621.1990.tb06061.x; Ren Xueying, 2009, Front Integr Neurosci, V3, P12, DOI 10.3389/neuro.07.012.2009; Shigemura N, 2008, BIOCHEM BIOPH RES CO, V367, P356, DOI [10.1016/j.bbrc.2007.12.146, 10.1016/j.bbre.2007.12.146]; Tordoff MG, 2012, SCI REP-UK, V2, DOI 10.1038/srep00496; ZAWALICH W, 1983, BIOCHEM BIOPH RES CO, V117, P448, DOI 10.1016/0006-291X(83)91221-4	40	3	3	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	2040-1116	2040-1124		J DIABETES INVEST	J. Diabetes Investig.	MAY	2015	6	3					256	263		10.1111/jdi.12304		8	Endocrinology & Metabolism	Endocrinology & Metabolism	CG7QI	WOS:000353498800003		
J	Heianza, Y; Arase, Y; Kodama, S; Tsuji, H; Tanaka, S; Saito, K; Hara, S; Sone, H				Heianza, Yoriko; Arase, Yasuji; Kodama, Satoru; Tsuji, Hiroshi; Tanaka, Shiro; Saito, Kazumi; Hara, Shigeko; Sone, Hirohito			Trajectory of body mass index before the development of type 2 diabetes in Japanese men: Toranomon Hospital Health Management Center Study 15	Journal of Diabetes Investigation			English	Article						Body mass index trajectory; Prediction; Type2 diabetes	RISK-FACTORS; WEIGHT CHANGE; INSULIN SENSITIVITY; WHITEHALL II; OBESITY; DURATION; ADULTHOOD; BMI; DIAGNOSIS; HISTORY	Aims/IntroductionWe aimed to investigate the long-term trajectory of general adiposity assessed by the body mass index (BMI) before the onset of type2 diabetes in Japanese individuals. Materials and MethodsWe retrospectively examined data on 1,553 Japanese men without diabetes. Mean BMI and incident cases of diabetes (diabetes indicated by fasting glucose concentrations 7.0mmol/L, a self-reported history of clinician-diagnosed diabetes, or glycated hemoglobin 6.5% (48mmol/mol) were assessed on an annual basis over a 10-year period after the baseline examination. ResultsMean (standard deviation) BMI at the time of diagnosis was 24.4kg/m(2) (3.1kg/m(2)) among cases of diabetes (n=191). An increasingly high BMI was associated with the early stage of the disease development, such as an 8- to 10-year prediagnosis period; individuals who developed diabetes experienced a prolonged and stable elevated BMI of 24.4kg/m(2) over the 8years before the diagnosis of diabetes. The mean BMI among the non-cases of diabetes did not exceed 23.2kg/m(2) throughout the period. ConclusionsThese results suggested that Japanese men who eventually developed diabetes during the 10-year observation period were not characterized as obese, but had stable high-normal BMIs before the onset of diabetes. Previous evidence showed that values for glycemic markers rapidly increased before the development of diabetes; however, the present study showed a slight gain in BMI in the earlier stage of the natural history of diabetes followed by a prolonged period of overweight.	[Heianza, Yoriko; Kodama, Satoru; Saito, Kazumi; Sone, Hirohito] Niigata Univ, Fac Med, Dept Internal Med, Niigata, Japan; [Heianza, Yoriko; Arase, Yasuji; Kodama, Satoru; Tsuji, Hiroshi; Saito, Kazumi; Hara, Shigeko; Sone, Hirohito] Toranomon Gen Hosp, Hlth Management Ctr, Minato Ku, Tokyo, Japan; [Arase, Yasuji; Tsuji, Hiroshi; Hara, Shigeko] Okinaka Mem Inst Med Res, Tokyo, Japan; [Tanaka, Shiro] Kyoto Univ, Grad Sch Med & Publ Hlth, Dept Pharmacoepidemiol, Kyoto, Japan	Sone, H (reprint author), Niigata Univ, Fac Med, Dept Internal Med, Niigata, Japan.	sone@med.niigata-u.ac.jp			Ministry of Health, Labor and Welfare, Japan; Japan Society for the Promotion of Science	This work is financially supported in part by the Ministry of Health, Labor and Welfare, Japan. H Sone and Y Heianza are recipients of a Grant-in-Aid for Scientific Research from the Japan Society for the Promotion of Science. The sponsors had no role in the design and conduct of the study. All authors sincerely thank the late Professor and Director Kinori Kosaka, MD, PhD, the Health Management Center, Toranomon Hospital, who established the foundation and framework of this project, and was always the foremost pillar of spiritual support of the Toranomon Hospital Health Management Center Study project. The authors declare no conflict of interest.	Abdullah A, 2012, AM J EPIDEMIOL, V176, P99, DOI 10.1093/aje/kwr522; American Diabetes Association, 2010, DIABETES CARE S1, V33, pS62, DOI DOI 10.2337/DC10-S062; Wannamethee SG, 1999, DIABETES CARE, V22, P1266, DOI 10.2337/diacare.22.8.1266; Hillier TA, 2001, DIABETES CARE, V24, P1522, DOI 10.2337/diacare.24.9.1522; Kodama S, 2014, OBES REV, V15, P202, DOI 10.1111/obr.12129; Looker HC, 2001, DIABETES CARE, V24, P1917, DOI 10.2337/diacare.24.11.1917; Matsuba I, 2012, DIABETES CARE, V35, P1853, DOI 10.2337/dc12-0156; Feldstein AC, 2008, DIABETES CARE, V31, P1960, DOI 10.2337/dc08-0426; Lloyd-Jones DM, 2007, CIRCULATION, V115, P1004, DOI 10.1161/CIRCULATIONAHA.106.648642; The NS, 2013, DIABETES CARE, V36, P865, DOI 10.2337/dc12-0536; Yoon KH, 2006, LANCET, V368, P1681, DOI 10.1016/S0140-6736(06)69703-1; CHAN JM, 1994, DIABETES CARE, V17, P961, DOI 10.2337/diacare.17.9.961; Faerch K, 2013, LANCET DIABETES ENDO, V1, P43, DOI 10.1016/S2213-8587(13)70008-1; Schienkiewitz A, 2006, AM J CLIN NUTR, V84, P427; Tirosh A, 2011, NEW ENGL J MED, V364, P1315, DOI 10.1056/NEJMoa1006992; Bouchard DR, 2013, J DIABETES COMPLICAT, V27, P214, DOI 10.1016/j.jdiacomp.2012.11.009; Chan JCN, 2009, JAMA-J AM MED ASSOC, V301, P2129, DOI 10.1001/jama.2009.726; Sone H, 2003, LANCET, V361, P85, DOI 10.1016/S0140-6736(03)12151-4; Tabak AG, 2009, LANCET, V373, P2215, DOI 10.1016/S0140-6736(09)60619-X; EVERHART JE, 1992, DIABETES, V41, P235, DOI 10.2337/diabetes.41.2.235; Wander PL, 2013, DIABETES CARE, V36, P289, DOI 10.2337/dc12-0198; Barba C, 2004, LANCET, V363, P157; Olivarius ND, 2008, DIABETIC MED, V25, P933, DOI 10.1111/j.1464-5491.2008.02472.x; Heianza Y, 2012, DIABETES CARE, V35, P1050, DOI 10.2337/dc11-1793; Jacobs-van der Bruggen MAM, 2010, AM J EPIDEMIOL, V172, P263, DOI 10.1093/aje/kwq134; Jeffreys M, 2006, INT J OBESITY, V30, P507, DOI 10.1038/sj.ijo.0803161; Lean M, 2010, OBESITY EPIDEMIOLOGY, V2nd, P43; Liu R, 2012, DIABETES CARE, V35, P1506, DOI 10.2337/dc11-2060; Odegaard AO, 2009, DIABETES CARE, V32, P1104, DOI 10.2337/dc08-1674; Preis SR, 2013, DIABETES CARE, V36, P1590, DOI 10.2337/dc12-1121; Sasai H, 2010, MAYO CLIN PROC, V85, P36, DOI 10.4065/mcp.2009.0230; Sattar N, 2007, DIABETES, V56, P984, DOI 10.2337/db06-1256; Vistisen D, 2014, ACTA DIABETOL, V51, P315, DOI 10.1007/s00592-012-0429-7; Vistisen D, 2014, PLOS MED, V11, DOI 10.1371/journal.pmed.1001602	34	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	2040-1116	2040-1124		J DIABETES INVEST	J. Diabetes Investig.	MAY	2015	6	3					289	294		10.1111/jdi.12308		6	Endocrinology & Metabolism	Endocrinology & Metabolism	CG7QI	WOS:000353498800008		
J	Joo, E; Muraoka, A; Hamasaki, A; Harada, N; Yamane, S; Kondo, Y; Suzuki, K; Nasteska, D; Shibue, K; Harada, T; Iwasaki, K; Tsuji, H; Shide, K; Inagaki, N				Joo, Erina; Muraoka, Atsushi; Hamasaki, Akihiro; Harada, Norio; Yamane, Shunsuke; Kondo, Yaeko; Suzuki, Kazuyo; Nasteska, Daniela; Shibue, Kimitaka; Harada, Takanari; Iwasaki, Kanako; Tsuji, Hidemi; Shide, Kenichiro; Inagaki, Nobuya			Enteral supplementation with glutamine, fiber, and oligosaccharide modulates incretin and glucagon-like peptide-2 secretion	Journal of Diabetes Investigation			English	Article						Glucagon-like peptide-2; Incretin; Oligosaccharide	GASTRIC-INHIBITORY POLYPEPTIDE; HOMEOSTASIS MODEL ASSESSMENT; INTESTINAL BLOOD-FLOW; CHAIN FATTY-ACIDS; INSULIN-RESISTANCE; DIABETES-MELLITUS; GLUCOSE-TOLERANCE; JAPANESE SUBJECTS; HEALTHY-SUBJECTS; BARRIER FUNCTION	Aims/IntroductionA dietary supplementation product enriched with glutamine, dietary fiber and oligosaccharide (GFO) is widely applied for enteral nutrition support in Japan. The aim of the present study was to evaluate the effects of GFO ingestion on secretion of incretins, gastric inhibitory polypeptide (GIP) and glucagon-like peptide-1 (GLP-1), and glucagon-like peptide-2 (GLP-2). Materials and MethodsWe carried out a cross-over study involving 20 healthy Japanese volunteers. The participants received GFO or 17g of glucose, the equivalent carbohydrate in GFO as the control. Plasma glucose, serum insulin, and plasma total GIP, total GLP-1 and total GLP-2 levels during GFO or glucose loading were determined. ResultsGFO loading produced significantly higher plasma GLP-1 levels at 30min and 60min, area under the curve-GLP-1 value, and area under the curve-GLP-2 value after administration compared with those by glucose loading. In contrast, plasma GIP levels at both 30 and 60min, and area under the curve-GIP value after glucose loading were significantly higher than those after GFO loading. ConclusionsThese results show that GFO ingestion stimulates GLP-1 and GLP-2 secretion, and reduces GIP secretion compared with glucose ingestion. Therefore, GFO could have an intestinotrophic effect as well as an ameliorating effect on metabolic disorders through modification of release of gut hormones.	[Joo, Erina; Muraoka, Atsushi; Hamasaki, Akihiro; Harada, Norio; Yamane, Shunsuke; Kondo, Yaeko; Suzuki, Kazuyo; Nasteska, Daniela; Shibue, Kimitaka; Harada, Takanari; Iwasaki, Kanako; Tsuji, Hidemi; Shide, Kenichiro; Inagaki, Nobuya] Kyoto Univ, Grad Sch Med, Dept Diabet Endocrinol & Nutr, Kyoto, Japan	Inagaki, N (reprint author), Kyoto Univ, Grad Sch Med, Dept Diabet Endocrinol & Nutr, Kyoto, Japan.	inagaki@metab.kuhp.kyoto-u.ac.jp			Takeda; Taisho Pharmaceutical; GlaxoSmithKline; Mitsubishi Tanabe Pharma; MSD; Sanofi; Novartis Pharma; Dainippon Sumitomo Pharma; Kyowa Kirin; Eli Lilly Japan; Shiratori Pharmaceutical; Roche Diagnostics; Japan Diabetes Foundation; Japan Tobacco Inc.; Nippon Boehringer Ingelheim; Astellas Pharma; Daiichi-Sankyo	EJ, AM, AH, NH, SY, YK, KS, DN, KS, TH, KI, HT and KS have no conflict of interest to disclose. NI served as a medical advisor for Takeda, Taisho Pharmaceutical, GlaxoSmithKline and Mitsubishi Tanabe Pharma, he lectured for MSD, Sanofi, Novartis Pharma, Dainippon Sumitomo Pharma, Kyowa Kirin and Mitsubishi Tanabe Pharma, and received payment for his services. NI also received a clinical commissioned/joint research grant from MSD, Eli Lilly Japan, Shiratori Pharmaceutical, Roche Diagnostics and the Japan Diabetes Foundation, and also received a scholarship grant from MSD, Japan Tobacco Inc., Nippon Boehringer Ingelheim, Takeda, Dainippon Sumitomo Pharma, Astellas Pharma, Daiichi-Sankyo and Mitsubishi Tanabe Pharma.	Vilsboll T, 2004, DIABETOLOGIA, V47, P357, DOI 10.1007/s00125-004-1342-6; Nilsson M, 2004, AM J CLIN NUTR, V80, P1246; Reimann F, 2004, DIABETOLOGIA, V47, P1592, DOI 10.1007/s00125-004-1498-0; Wang JH, 2011, J PHARMACOL EXP THER, V339, P464, DOI 10.1124/jpet.111.184788; MATTHEWS DR, 1985, DIABETOLOGIA, V28, P412, DOI 10.1007/BF00280883; Miyawaki K, 2002, NAT MED, V8, P738, DOI 10.1038/nm727; Taylor-Edwards CC, 2011, J DAIRY SCI, V94, P888, DOI 10.3168/jds.2010-3540; Nasteska D, 2014, DIABETES, V63, P2332, DOI 10.2337/db13-1563; Kihara M, 2002, COMP BIOCHEM PHYS A, V132, P333, DOI 10.1016/S1095-6433(02)00029-6; Tolhurst G, 2011, ENDOCRINOLOGY, V152, P405, DOI 10.1210/en.2010-0956; Seino Y, 2010, J DIABETES INVEST, V1, P1, DOI 10.1111/j.2040-1124.2010.00005.x; Tolhurst G, 2012, DIABETES, V61, P364, DOI 10.2337/db11-1019; Guan XF, 2003, GASTROENTEROLOGY, V125, P136, DOI 10.1016/S0016-5085(03)00667-X; Moran-Ramos S, 2012, ADV NUTR, V3, P8, DOI 10.3945/an.111.000976; Holst JJ, 2010, RESULTS PROBL CELL D, V50, P121, DOI 10.1007/400_2009_35; Kashiwagi A, 2012, J DIABETES INVEST, V3, P39, DOI 10.1111/j.2040-1124.2012.00207.x; Karhunen LJ, 2008, REGUL PEPTIDES, V149, P70, DOI 10.1016/j.regpep.2007.10.008; Ma J, 2009, AM J PHYSIOL-GASTR L, V296, pG735, DOI 10.1152/ajpgi.90708.2008; Drucker DJ, 1996, P NATL ACAD SCI USA, V93, P7911, DOI 10.1073/pnas.93.15.7911; Samocha-Bonet D, 2011, J NUTR, V141, P1233, DOI 10.3945/jn.111.139824; Wu GY, 1998, J NUTR, V128, P1249; Aroda VR, 2012, CLIN THER, V34, P1247, DOI 10.1016/j.clinthera.2012.04.013; Greenfield JR, 2009, AM J CLIN NUTR, V89, P106, DOI 10.3945/ajcn.2008.26362; Hsieh J, 2009, GASTROENTEROLOGY, V137, P997, DOI 10.1053/j.gastro.2009.05.051; Vollmer K, 2008, DIABETES, V57, P678, DOI 10.2337/db07-1124; Azuma H, 2009, J TRAUMA, V66, P110, DOI 10.1097/TA.0b013e318193109b; Benjamin MA, 2000, GUT, V47, P112, DOI 10.1136/gut.47.1.112; Bremholm L, 2011, REGUL PEPTIDES, V168, P32, DOI 10.1016/j.regpep.2011.03.003; Cheeseman CI, 1997, AM J PHYSIOL-REG I, V273, pR1965; de Hollanda A, 2014, SURG OBES RELAT DIS, V10, P814, DOI 10.1016/j.soard.2014.01.022; ELLIOTT RM, 1993, J ENDOCRINOL, V138, P159, DOI 10.1677/joe.0.1380159; FLATT PR, 1991, J NUTR, V121, P1123; Fukushima M, 1999, DIABETES CARE, V22, P1911, DOI 10.2337/diacare.22.11.1911; Gatenby SJ, 1996, DIABETIC MED, V13, P358, DOI 10.1002/(SICI)1096-9136(199604)13:4<358::AID-DIA24>3.3.CO;2-R; Harada N, 2011, J DIABETES INVEST, V2, P193, DOI 10.1111/j.2040-1124.2010.00078.x; Jie Zhong, 2000, American Journal of Clinical Nutrition, V72, P1503; Joo E, 2013, NUTRITION, V29, P549, DOI 10.1016/j.nut.2012.09.007; Kosaka K, 1996, DIABETIC MED, V13, pS109; Litvak D A, 1998, J Gastrointest Surg, V2, P146, DOI 10.1016/S1091-255X(98)80005-X; MOJSOV S, 1986, J BIOL CHEM, V261, P1880; Reeds PJ, 2001, J NUTR, V131, p2505S; Reeds PJ, 2000, J NUTR, V130, P978; Russo F, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-56; Suzuki K, 2013, J BIOL CHEM, V288, P1929, DOI 10.1074/jbc.M112.423137; Wojdemann M, 1999, J CLIN ENDOCR METAB, V84, P2513, DOI 10.1210/jc.84.7.2513; Yamane S, 2012, J DIABETES INVEST, V3, P80, DOI 10.1111/j.2040-1124.2011.00143.x	46	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	2040-1116	2040-1124		J DIABETES INVEST	J. Diabetes Investig.	MAY	2015	6	3					302	308		10.1111/jdi.12289		7	Endocrinology & Metabolism	Endocrinology & Metabolism	CG7QI	WOS:000353498800010		
J	Nishi, T; Babazono, A; Maeda, T; Imatoh, T; Une, H				Nishi, Takumi; Babazono, Akira; Maeda, Toshiki; Imatoh, Takuya; Une, Hiroshi			Evaluation of the fatty liver index as a predictor for the development of diabetes among insurance beneficiaries with prediabetes	Journal of Diabetes Investigation			English	Article						Diabetes mellitus; Non-alcoholic fatty liver; Prediabetes	IMPAIRED GLUCOSE-TOLERANCE; RANDOMIZED-CONTROLLED-TRIAL; LIFE-STYLE INTERVENTION; FASTING GLUCOSE; NONALCOHOLIC STEATOHEPATITIS; INSULIN-RESISTANCE; HEPATIC STEATOSIS; KOREAN POPULATION; JAPANESE SUBJECTS; RISK-FACTORS	Aims/IntroductionNon-alcoholic fatty liver disease (NAFLD) is the most common liver disease in developed countries, and it was required to monitor patients with prediabetes. However, there have been few reports establishing the risk for diabetes mellitus (DM) among patients with prediabetes. The purpose of the present study was to evaluate the effect of NAFLD on the progression of DM among insurance beneficiaries with prediabetes, using data from specific health check-ups and the fatty liver index (FLI). Materials and MethodsWe used a retrospective cohort study that enrolled 967 insurance beneficiaries with prediabetes who had rarely drunk or could not drink alcohol, or whose alcohol consumption was <19g/day from two health insurance societies. We divided insurance beneficiaries into FLI <30, intermediates FLIs and FLI 60, and compared the incidence rate of DM among the groups after 3years' follow up, using multiple logistic regression models. ResultsDuring 3years' follow up, progression of diabetes was seen in 65 men (11.5%) and 24 women (6.0%). Logistic regression analyses showed that those with NAFLD had significantly higher risks of developing DM; this was the case in both men (odds ratio 2.68, 95% confidential interval 1.29-5.56) and women (odds ratio 10.35, 95% confidential interval 3.22-33.31). ConclusionsAmong insurance beneficiaries with prediabetes, those with NAFLD had a significantly higher risk of DM than those without NAFLD. The FLI might be useful for detecting individuals who have an especially higher risk for DM, and developing more effective guidance for delivering healthcare services in Japan.	[Nishi, Takumi; Babazono, Akira; Maeda, Toshiki] Kyushu Univ, Grad Sch Med Sci, Dept Hlth Care Adm & Management, Fukuoka, Japan; [Imatoh, Takuya] Fukuoka Univ, Sch Med, Dept Hyg & Prevent Med, Fukuoka 81401, Japan; [Une, Hiroshi] Fukuoka Univ, Sch Med, Med Res Ctr, Fukuoka 81401, Japan	Nishi, T (reprint author), Kyushu Univ, Grad Sch Med Sci, Dept Hlth Care Adm & Management, Fukuoka, Japan.	takumi.nishi.19860614@gmail.com			Ministry of Education, Culture, Sports, Science and Technology of Japan [25293160]	This study was supported in part by a Grant-In-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology of Japan (Grant no. 25293160). The authors declare no conflict of interest.	Belfort R, 2006, NEW ENGL J MED, V355, P2297, DOI 10.1056/NEJMoa060326; Gastaldelli A, 2009, HEPATOLOGY, V49, P1537, DOI 10.1002/hep.22845; Schneider ALC, 2013, DIABETIC MED, V30, P926, DOI 10.1111/dme.12187; Kim JH, 2011, LIVER INT, V31, P1600, DOI 10.1111/j.1478-3231.2011.02580.x; Wong VWS, 2013, J HEPATOL, V59, P536, DOI 10.1016/j.jhep.2013.04.013; Seino Y, 2010, J DIABETES INVEST, V1, P212, DOI 10.1111/j.2040-1124.2010.00074.x; Bedogni G, 2005, HEPATOLOGY, V42, P44, DOI 10.1002/hep.20734; Ortiz-Lopez C, 2012, DIABETES CARE, V35, P873, DOI 10.2337/dc11-1849; Bullard KM, 2013, DIABETES CARE, V36, P2286, DOI 10.2337/dc12-2563; Nishioji K, 2015, J GASTROENTEROL, V50, P95, DOI 10.1007/s00535-014-0948-9; Zelber-Sagi S, 2013, WORLD J GASTROENTERO, V19, P57, DOI 10.3748/wjg.v19.i1.57; Shibata M, 2007, DIABETES CARE, V30, P2940, DOI 10.2337/dc07-0792; Promrat K, 2004, HEPATOLOGY, V39, P188, DOI 10.1002/hep.20012; Kunutsor SK, 2013, AM J EPIDEMIOL, V178, P159, DOI 10.1093/aje/kws469; Tuomilehto J, 2001, NEW ENGL J MED, V344, P1343, DOI 10.1056/NEJM200105033441801; Kodama K, 2013, DIABETES CARE, V36, P1789, DOI 10.2337/dc12-1235; Kashiwagi A, 2012, J DIABETES INVEST, V3, P39, DOI 10.1111/j.2040-1124.2012.00207.x; Knowler WC, 2002, NEW ENGL J MED, V346, P393; Yamada T, 2010, J GASTROEN HEPATOL, V25, P352, DOI 10.1111/j.1440-1746.2009.05998.x; Chan JCN, 2009, JAMA-J AM MED ASSOC, V301, P2129, DOI 10.1001/jama.2009.726; Zelber-Sagi S, 2013, LIVER INT, V33, P1406, DOI 10.1111/liv.12200; Saito T, 2011, ARCH INTERN MED, V171, P1352, DOI 10.1001/archinternmed.2011.275; DeFronzo RA, 2011, NEW ENGL J MED, V364, P1104, DOI 10.1056/NEJMoa1010949; Jung CH, 2013, DIABETIC MED, V30, P428, DOI 10.1111/dme.12104; Babazono A, 2011, J EPIDEMIOL, V21, P75, DOI 10.2188/jea.JE20100095; Balkau B, 2010, BMC GASTROENTEROL, V10, DOI 10.1186/1471-230X-10-56; Bedogni G, 2006, BMC GASTROENTEROL, V6, DOI 10.1186/1471-230X-6-33; Bozkurt L, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032710; Lattuada G, 2011, CURR DIABETES REP, V11, P167, DOI 10.1007/s11892-011-0190-2; Ministry of Health Labour and Welfare, 2013, OUTL RES NAT HLTH NU; Gerstein HC, 2006, LANCET, V368, P1096, DOI 10.1016/S0140-6736(06)69420-8; Mukai N, 2014, J DIABETES INVEST, V5, P162, DOI 10.1111/jdi.12136; Ruckert IM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022932; Sakane N, 2011, BMC PUBLIC HEALTH, V11, DOI 10.1186/1471-2458-11-40	34	1	1	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	2040-1116	2040-1124		J DIABETES INVEST	J. Diabetes Investig.	MAY	2015	6	3					309	316		10.1111/jdi.12290		8	Endocrinology & Metabolism	Endocrinology & Metabolism	CG7QI	WOS:000353498800011		
J	Ohbu-Murayama, K; Adachi, H; Hirai, Y; Enomoto, M; Fukami, A; Obuchi, A; Yoshimura, A; Nakamura, S; Nohara, Y; Nakao, E; Umeki, Y; Fukumoto, Y				Ohbu-Murayama, Kyoko; Adachi, Hisashi; Hirai, Yuji; Enomoto, Mika; Fukami, Ako; Obuchi, Aya; Yoshimura, Ayako; Nakamura, Sachiko; Nohara, Yume; Nakao, Erika; Umeki, Yoko; Fukumoto, Yoshihiro			Ezetimibe combined with standard diet and exercise therapy improves insulin resistance and atherosclerotic markers in patients with metabolic syndrome	Journal of Diabetes Investigation			English	Article						Ezetimibe; Insulin resistance; Metabolic syndrome	LIPID-ALTERING EFFICACY; CORONARY-HEART-DISEASE; JAPANESE PATIENTS; CHOLESTEROL ABSORPTION; GLUCOSE-METABOLISM; GENERAL-POPULATION; OXIDATIVE STRESS; HIGH-RISK; HYPERCHOLESTEROLEMIA; EZETIMIBE/SIMVASTATIN	Aims/IntroductionEzetimibe lowers serum lipid levels by inhibiting intestinal absorption of dietary and biliary cholesterol. However, the effect of ezetimibe on insulin resistance remains unclear. The aim of the present study was to examine this issue in patients with metabolic syndrome in local-dwelling Japanese, who were not being treated with lipid-lowering drugs. Materials and MethodsIn 2009, 1,943 participants received a health examination in the Tanushimaru Study, a Japanese cohort of the Seven Countries Study, of whom 490 participants had metabolic syndrome. Among them, 61 participants (41 men and 20 women) were examined in the present study. They were treated with 10mg of ezetimibe once a day for 24weeks, combined with standard diet and exercise therapy. ResultsBodyweight (P<0.001), body mass index (P<0.001), systolic blood pressure (P=0.003), diastolic blood pressure (P<0.001), triglycerides (P=0.002), non-high-density lipoprotein cholesterol (P=0.001), low-density lipoprotein cholesterol (P<0.001) and homeostasis model assessment of insulin resistance (P=0.011) significantly decreased after the observational period. There were no statistically significant differences in the effects of ezetimibe between men and women. Univariate analysis showed that the reduction of homeostasis model assessment of insulin resistance was not associated with the improvement of other metabolic components. ConclusionsEzetimibe combined with standard diet and exercise therapy improves not only bodyweight and atherogenic lipid profiles, but also insulin resistance, blood pressure and anthropometric factors in metabolic syndrome in local-dwelling Japanese. Interestingly, the improvement of insulin resistance had no correlation with other metabolic components.	[Ohbu-Murayama, Kyoko; Hirai, Yuji; Enomoto, Mika; Fukami, Ako; Obuchi, Aya; Yoshimura, Ayako; Nakamura, Sachiko; Nohara, Yume; Nakao, Erika; Umeki, Yoko; Fukumoto, Yoshihiro] Kurume Univ, Sch Med, Dept Internal Med, Div Cardiovasc Med, Kurume, Fukuoka 830, Japan; [Adachi, Hisashi] Kurume Univ, Sch Med, Dept Community Med, Kurume, Fukuoka 830, Japan	Adachi, H (reprint author), Kurume Univ, Sch Med, Dept Community Med, Kurume, Fukuoka 830, Japan.	hadac@med.kurume-u.ac.jp			Kimura Memorial Heart Foundation (Fukuoka, Japan); Bayer Pharmaceutical Co., Ltd.	We are grateful to the members of the Japan Medical Association of Ukiha, the elected officials and residents of Tanushimaru, and the team of cooperating physicians for their help in carrying out the health examinations. This study was supported in part by the Kimura Memorial Heart Foundation (Fukuoka, Japan) and by Bayer Pharmaceutical Co., Ltd. We also certify that there are no financial or other relationships that could lead to a conflict of interest.	Hirai Y, 2011, CIRC J, V75, P1890, DOI 10.1253/circj.CJ-10-0971; Kumagai E, 2011, HYPERTENSION, V58, P1043, DOI 10.1161/HYPERTENSIONAHA.111.180521; MATTHEWS DR, 1985, DIABETOLOGIA, V28, P412, DOI 10.1007/BF00280883; Kurobe H, 2011, J ATHEROSCLER THROMB, V18, P1080; Haring R, 2012, J ANDROL, V33, P944, DOI 10.2164/jandrol.111.015065; Ridker PM, 2012, LANCET, V380, P565, DOI 10.1016/S0140-6736(12)61190-8; Conard S, 2010, DIABETES OBES METAB, V12, P210, DOI 10.1111/j.1463-1326.2009.01152.x; PIGNOLI P, 1986, CIRCULATION, V74, P1399; Tamaki N, 2012, J ATHEROSCLER THROMB, V19, P532; Rosen JB, 2013, DIABETES VASC DIS RE, V10, P277, DOI 10.1177/1479164112465212; Deushi M, 2007, FEBS LETT, V581, P5664, DOI 10.1016/j.febslet.2007.11.023; Zimmet P, 2005, J ATHEROSCLER THROMB, V12, P295; Yamasaki Y, 2000, DIABETES CARE, V23, P1310, DOI 10.2337/diacare.23.9.1310; Matsuzawa Y, 2005, J ATHEROSCLER THROMB, V12, P301; Knopp RH, 2003, INT J CLIN PRACT, V57, P363; Hayek S, 2013, AM J CARDIOL, V111, P532, DOI 10.1016/j.amjcard.2012.11.002; NAKAJIMA K, 1993, CLIN CHIM ACTA, V223, P53, DOI 10.1016/0009-8981(93)90062-9; Averna M, 2011, DIABETES VASC DIS RE, V8, P262, DOI 10.1177/1479164111418136; Bays HE, 2011, METAB SYNDR RELAT D, V9, P135, DOI 10.1089/met.2010.0068; Dagli N, 2007, INFLAMMATION, V30, P230, DOI 10.1007/s10753-007-9041-3; Denke Margo, 2006, Diab Vasc Dis Res, V3, P93, DOI 10.3132/dvdr.2006.020; Goldberg RB, 2010, DIABETES CARE, V33, P1021, DOI 10.2337/dc09-1762; Hajer GR, 2009, ATHEROSCLEROSIS, V202, P216, DOI 10.1016/j.atherosclerosis.2008.04.035; Hino A, 2004, ATHEROSCLEROSIS, V176, P145, DOI 10.1016/j.atherosclerosis.2004.04.020; Hiramitsu S, 2010, J ATHEROSCLER THROMB, V17, P106; Ichimori S, 2012, J DIABETES INVEST, V3, P179, DOI 10.1111/j.2040-1124.2011.00147.x; Kikuchi K, 2012, J ATHEROSCLER THROMB, V19, P1093; Kotani K, 2012, MED PRIN PRACT, V21, P134, DOI 10.1159/000332436; Miller M, 2013, CARDIOLOGY, V125, P74, DOI 10.1159/000347134; Nochioka K, 2012, CIRC J, V76, P2023, DOI 10.1253/circj.CJ-12-0331; Otsuka M, 2012, J EPIDEMIOL, V22, P395, DOI 10.2188/jea.JE20110121; Robinson JG, 2009, AM J CARDIOL, V103, P1694, DOI 10.1016/j.amjcard.2009.05.003; Sato K, 2012, J ATHEROSCLER THROMB, V19, P986; Takase H, 2012, EUR J CLIN INVEST, V42, P1287, DOI 10.1111/eci.12000; Winkler K, 2009, EUR J CLIN INVEST, V39, P463, DOI 10.1111/j.1365-2362.2009.02126.x; Yagi S, 2010, J ATHEROSCLER THROMB, V17, P173; Yokoi K, 2012, CIRC J, V76, P2779, DOI 10.1253/circj.CJ-12-0469	37	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	2040-1116	2040-1124		J DIABETES INVEST	J. Diabetes Investig.	MAY	2015	6	3					325	333		10.1111/jdi.12298		9	Endocrinology & Metabolism	Endocrinology & Metabolism	CG7QI	WOS:000353498800013		
J	Ishibashi, F; Taniguchi, M; Kojima, R; Kawasaki, A; Kosaka, A; Uetake, H				Ishibashi, Fukashi; Taniguchi, Miki; Kojima, Rie; Kawasaki, Asami; Kosaka, Aiko; Uetake, Harumi			Morphological changes of the peripheral nerves evaluated by high-resolution ultrasonography are associated with the severity of diabetic neuropathy, but not corneal nerve fiber pathology in patients with type 2 diabetes	Journal of Diabetes Investigation			English	Article						Corneal C fiber pathology; Peripheral nerve ultrasonography; Type2 diabetes	CARPAL-TUNNEL-SYNDROME; CONFOCAL MICROSCOPY; MEDIAN NERVE; SENSORIMOTOR POLYNEUROPATHY; SONOGRAPHIC EVALUATION; DIAGNOSTIC-CRITERIA; GLYCEMIC CONTROL; ULTRASOUND; CONDUCTION; ECHOTEXTURE	Aims/IntroductionTo evaluate the morphological changes of the median and posterior tibial nerve using high-resolution ultrasonography, and the corneal Cfiber pathology by corneal confocal microscopy in type2 diabetic patients. Materials and MethodsThe cross-sectional area, hypoechoic area and maximum thickness of the nerve fascicle of both nerves were measured by high-resolution ultrasonography in 200 type2 diabetic patients, stratified by the severity of diabetic neuropathy, and in 40 age- and sex-matched controls. These parameters were associated with corneal Cfiber pathology visualized by corneal confocal microscopy, neurophysiological tests and severity of diabetic neuropathy. ResultsThe cross-sectional area, hypoechoic area and maximum thickness of the nerve fascicle of both nerves in patients without diabetic neuropathy were larger than those in control subjects (P<0.05 to P<0.001), and further increased relative to the severity of neuropathy (P<0.0001). All morphological changes of both nerves were negatively associated with motor and sensory nerve conduction velocity (P=0.01 to P<0.0001), and directly associated with 2,000-Hz current perception threshold (P=0.009 to P<0.001). The significant corneal Cfiber pathology occurred before developing the neuropathy, and deteriorated only in patients with the most severe neuropathy. The association between the morphological changes of both nerves and corneal C fiber pathology was poor. ConclusionsThe morphological changes in peripheral nerves of type2 diabetic patients were found before the onset of neuropathy, and were closely correlated with the severity of diabetic neuropathy, but not with corneal Cfiber pathology.	[Ishibashi, Fukashi; Taniguchi, Miki; Kojima, Rie; Kawasaki, Asami; Kosaka, Aiko; Uetake, Harumi] Ishibashi Clin, Hiroshima, Japan	Ishibashi, F (reprint author), Ishibashi Clin, Hiroshima, Japan.	ishiclic@urban.ne.jp					England JD, 2005, NEUROLOGY, V64, P199; Tesfaye S, 2012, DIABETES-METAB RES, V28, P8, DOI 10.1002/dmrr.2239; Pham M, 2014, CURR OPIN NEUROL, V27, P370, DOI 10.1097/WCO.0000000000000111; Yasuda H, 2007, DIABETES RES CLIN PR, V77, pS178, DOI 10.1016/j.diabres.2007.01.053; Watanabe T, 2010, J ULTRAS MED, V29, P697; Perkins BA, 2002, DIABETES CARE, V25, P565, DOI 10.2337/diacare.25.3.565; Malik RA, 2005, DIABETOLOGIA, V48, P578, DOI 10.1007/s00125-004-1663-5; Schreiber S, 2013, MUSCLE NERVE, V47, P385, DOI 10.1002/mus.23681; Ishibashi F, 2013, J DIABETES INVEST, V4, P492, DOI 10.1111/jdi.12083; Dunnigan SK, 2013, DIABETES CARE, V36, P3684, DOI 10.2337/dc13-0746; Pan H, 2014, MUSCLE NERVE, V49, P804, DOI 10.1002/mus.24127; Wiesler ER, 2006, J HAND SURG-AM, V31A, P1088, DOI 10.1016/j.jhsa.2006.06.007; Oliveira-Soto L, 2001, CORNEA, V20, P374, DOI 10.1097/00003226-200105000-00008; Hossain P, 2005, LANCET, V366, P1340, DOI 10.1016/S0140-6736(05)67546-0; Kashiwagi A, 2012, J DIABETES INVEST, V3, P39, DOI 10.1111/j.2040-1124.2012.00207.x; Dyck PJ, 2011, DIABETES-METAB RES, V27, P620, DOI 10.1002/dmrr.1226; Goedee HS, 2013, EUR J NEUROL, V20, P1342, DOI 10.1111/ene.12182; Petropoulos IN, 2014, INVEST OPHTH VIS SCI, V55, P2071, DOI 10.1167/iovs.13-13787; Quattrini C, 2007, DIABETES, V56, P2148, DOI 10.2337/db07-0285; Malik RA, 2011, DIABETES-METAB RES, V27, P678, DOI 10.1002/dmrr.1222; Riazi S, 2012, DIABETES CARE, V35, P2575, DOI 10.2337/dc12-0739; Hobson-Webb LD, 2013, MUSCLE NERVE, V47, P379, DOI 10.1002/mus.23625; Ishibashi F, 2012, J DIABETES INVEST, V3, P191, DOI 10.1111/j.2040-1124.2011.00157.x; Kikkawa Y, 2005, CLIN NEUROPHYSIOL, V116, P270, DOI 10.1016/j.clinph.2004.08.011; Lee SH, 2011, REGION ANESTH PAIN M, V36, P382, DOI 10.1097/AAP.0b013e318217a7a0; Liu F, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032730; Mojaddidi MA, 2014, DIABETOLOGIA, V57, P1711, DOI 10.1007/s00125-014-3271-3; Moon HI, 2014, CLIN NEUROPHYSIOL, V125, P844, DOI 10.1016/j.clinph.2013.10.041; SILVESTRI E, 1995, RADIOLOGY, V197, P291; Watanabe T, 2009, J ULTRAS MED, V28, P727	30	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	2040-1116	2040-1124		J DIABETES INVEST	J. Diabetes Investig.	MAY	2015	6	3					334	342		10.1111/jdi.12299		9	Endocrinology & Metabolism	Endocrinology & Metabolism	CG7QI	WOS:000353498800014		
J	Kamei, S; Kaneto, H; Tanabe, A; Irie, S; Hirata, Y; Shimoda, M; Kohara, K; Mune, T; Kaku, K				Kamei, Shinji; Kaneto, Hideaki; Tanabe, Akihito; Irie, Shintaro; Hirata, Yurie; Shimoda, Masashi; Kohara, Kenji; Mune, Tomoatsu; Kaku, Kohei			Rapid onset of syndrome of inappropriate antidiuretic hormone secretion induced by duloxetine in an elderly type 2 diabetic patient with painful diabetic neuropathy	Journal of Diabetes Investigation			English	Article						Cytochrome P450; Duloxetine; Syndrome of inappropriate antidiuretic hormone secretion	VASOPRESSIN; RELEASE	Diabetic neuropathy is the most common diabetic complication. Duloxetine, a serotonin noradrenaline reuptake inhibitor (SNRI), is widely used for the treatment of diabetic painful neuropathy (DPN) because of the efficacy and safety profile. Syndrome of inappropriate antidiuretic hormone secretion, which is strongly associated duloxetine, is a rare but occasionally life-threatening adverse effect. Here, we report a case of syndrome of inappropriate antidiuretic hormone secretion that rapidly developed after starting duloxetine in an elderly Japanese female type2 diabetes mellitus patient. Furthermore, we discuss the possible relationship between the onset of syndrome of inappropriate antidiuretic hormone secretion and the gene polymorphism of cytochrome P450 isoform 1A2 and 2D6, both of which are responsible for duloxetine metabolism.	[Kamei, Shinji; Kaneto, Hideaki; Tanabe, Akihito; Irie, Shintaro; Hirata, Yurie; Shimoda, Masashi; Kohara, Kenji; Mune, Tomoatsu; Kaku, Kohei] Kawasaki Med Univ, Div Diabet Metab & Endocrinol, Kurashiki, Okayama, Japan	Kamei, S (reprint author), Kawasaki Med Univ, Div Diabet Metab & Endocrinol, Kurashiki, Okayama, Japan.	s.kamei@med.kawasaki-m.ac.jp					ANDERSON IK, 1992, BRIT J PHARMACOL, V107, P1020; Attal N, 2010, EUR J NEUROL, V17, P1113, DOI 10.1111/j.1468-1331.2010.02999.x; Boulton AJM, 2004, DIABETES CARE, V27, P1458, DOI 10.2337/diacare.27.6.1458; Ellison DH, 2007, NEW ENGL J MED, V356, P2064, DOI 10.1056/NEJMcp066837; Lantz RJ, 2003, DRUG METAB DISPOS, V31, P1142, DOI 10.1124/dmd.31.9.1142; Jornil J, 2013, FORENSIC SCI INT, V226, pE26, DOI 10.1016/j.forsciint.2012.12.020; Braam W, 2013, J INTELL DISABIL RES, V57, P993, DOI 10.1111/j.1365-2788.2012.01595.x; Chiba K, 2012, DRUG METAB PHARMACOK, V27, P405, DOI 10.2133/dmpk.DMPK-11-RG-078; LEIBOWITZ SF, 1990, EXP NEUROL, V110, P298, DOI 10.1016/0014-4886(90)90042-Q; Maramattom BV, 2006, NEUROLOGY, V66, P773, DOI 10.1212/01.wnl.0000200993.33730.95; Skinner MH, 2003, CLIN PHARMACOL THER, V73, P170, DOI 10.1067/mcp.2003.28	11	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	2040-1116	2040-1124		J DIABETES INVEST	J. Diabetes Investig.	MAY	2015	6	3					343	345		10.1111/jdi.12301		3	Endocrinology & Metabolism	Endocrinology & Metabolism	CG7QI	WOS:000353498800015		
J	Takazakura, A; Sakurai, M; Bando, Y; Misu, H; Takeshita, Y; Kita, Y; Shimizu, A; Hayakawa, T; Kato, K; Kaneko, S; Takamura, T				Takazakura, Akiko; Sakurai, Masaru; Bando, Yukihiro; Misu, Hirofumi; Takeshita, Yumie; Kita, Yuki; Shimizu, Akiko; Hayakawa, Tetsuo; Kato, Ken-ichiro; Kaneko, Shuichi; Takamura, Toshinari			Renoprotective effects of atorvastatin compared with pravastatin on progression of early diabetic nephropathy	Journal of Diabetes Investigation			English	Article						Early diabetic nephropathy; Renoprotective effects; Statins	CHRONIC KIDNEY-DISEASE; CORONARY-HEART-DISEASE; CONTROLLED-TRIAL; RENAL OUTCOMES; DOUBLE-BLIND; CYSTATIN-C; STATINS; PEOPLE; ROSUVASTATIN; METAANALYSIS	IntroductionSeveral studies have shown that statins suppress the progression of diabetic nephropathy. However, few reports have directly compared the renoprotective effects between potent and conventional statins. Materials and MethodsPatients with diabetic nephropathy, selected as those with a serum creatinine level of 0.9-1.5mg/dL and simultaneously having either microalbuminuria or positive proteinuria, were randomly assigned to one of three groups: a conventional diet therapy group, a group given 10mg of pravastatin and a group given 10mg of atorvastatin. Renal function was evaluated before and after a 12-month period of therapy. ResultsThe atorvastatin group had a significant decrease in low-density lipoprotein cholesterol at 3months and thereafter compared with the other groups. The urinary albumin-to-creatinine ratio significantly decreased in the atorvastatin group; the degree of this decrease was significantly greater than that in the diet therapy group. The kidney function estimated with cystatin C (CysC) and the estimated glomerular filtration rate calculated from CysC were significantly preserved in the atorvastatin group compared with the pravastatin group. In a multivariate regression analysis, the use of atorvastatin was the only explanatory variable for the changes in CysC; this was independent of changes in low-density lipoprotein cholesterol. ConclusionsAtorvastatin is more effective than pravastatin for the prevention of increase in CysC, and this renoprotective effect was considered to a result of the pleiotropic effect of atorvastatin independent of its lipid-lowering effect. This study was registered with UMIN (no. UMIN 000001774).	[Takazakura, Akiko; Misu, Hirofumi; Takeshita, Yumie; Kita, Yuki; Kato, Ken-ichiro; Kaneko, Shuichi; Takamura, Toshinari] Kanazawa Univ, Grad Sch Med Sci, Dept Dis Control & Homeostasis, Kanazawa, Ishikawa, Japan; [Misu, Hirofumi; Takamura, Toshinari] Kanazawa Univ, Grad Sch Med Sci, Dept Comprehens Metabol, Kanazawa, Ishikawa, Japan; [Sakurai, Masaru] Kanazawa Med Univ, Dept Epidemiol & Publ Hlth, Uchinada, Ishikawa 92002, Japan; [Bando, Yukihiro] Fukui Ken Saiseikai Hosp, Dept Internal Med, Fukui, Fukui, Japan; [Shimizu, Akiko; Hayakawa, Tetsuo] Toyama City Hosp, Dept Internal Med, Toyama, Toyama, Japan	Takamura, T (reprint author), Kanazawa Univ, Grad Sch Med Sci, Dept Dis Control & Homeostasis, Kanazawa, Ishikawa, Japan.	ttakamura@m-kanazawa.jp			Daiichi-Sankyo; Pfizer; Astellas	We thank all of the medical and nursing staff at the Kanazawa University Hospital, Toyama City Hospital, and Fukui-ken Saiseikai Hospital for their dedication and commitment to collecting and examining the patients' blood and urine samples. We thank the registered dietitian for developing the diet therapy, based on guidelines. TT is the guarantor of this work and, as such, had full access to all of the data in the study, and takes responsibility for the integrity of the data and the accuracy of the data analysis. SK has received research grants from Daiichi-Sankyo, Pfizer and Astellas. No other potential conflicts of interest relevant to this article are reported.	Abe M, 2011, J ATHEROSCLER THROMB, V18, P1018; Abe M, 2011, ENDOCR J, V58, P663; Adinortey Michael B, 2011, Indian J Clin Biochem, V26, P261, DOI 10.1007/s12291-010-0101-3; Patel A, 2008, NEW ENGL J MED, V358, P2560; Afzali B, 2004, NEPHROL DIAL TRANSPL, V19, P1032, DOI 10.1093/ndt/gfh105; Matsuo S, 2009, AM J KIDNEY DIS, V53, P982, DOI 10.1053/j.ajkd.2008.12.034; Tonelli M, 2005, CIRCULATION, V112, P171, DOI 10.1161/CIRCULATIONAHA.104.517565; Douglas K, 2006, ANN INTERN MED, V145, P117; Tonelli M, 2003, J AM SOC NEPHROL, V14, P1605, DOI 10.1097/01.ASN.0000068461.45784.2F; Horio M, 2013, AM J KIDNEY DIS, V61, P197, DOI 10.1053/j.ajkd.2012.07.007; Mann JFE, 2008, LANCET, V372, P547, DOI 10.1016/S0140-6736(08)61236-2; Colhoun HM, 2009, AM J KIDNEY DIS, V54, P810, DOI 10.1053/j.ajkd.2009.03.022; Vaziri ND, 2010, J RENAL NUTR, V20, pS35, DOI 10.1053/j.jrn.2010.05.010; Fioretto P, 2010, NAT REV ENDOCRINOL, V6, P19, DOI 10.1038/nrendo.2009.213; Habeos IG, 2008, J MOL MED, V86, P1279, DOI 10.1007/s00109-008-0393-4; Keane WF, 2013, J ATHEROSCLER THROMB, V20, P123; Newman DJ, 2002, ANN CLIN BIOCHEM, V39, P89, DOI 10.1258/0004563021901847; Sandhu S, 2006, J AM SOC NEPHROL, V17, P2006, DOI 10.1681/ASN.2006010012; Makabe S, 2010, ATHEROSCLEROSIS, V213, P377, DOI 10.1016/j.atherosclerosis.2010.07.059; Kashiwagi A, 2012, J DIABETES INVEST, V3, P39, DOI 10.1111/j.2040-1124.2012.00207.x; Shepherd J, 2008, J AM COLL CARDIOL, V51, P1448, DOI 10.1016/j.jacc.2007.11.072; Chartoumpekis D, 2010, BIOCHEM BIOPH RES CO, V396, P463, DOI 10.1016/j.bbrc.2010.04.117; Athyros VG, 2004, J CLIN PATHOL, V57, P728, DOI 10.1136/jcp.2003.012989; Pergola PE, 2011, NEW ENGL J MED, V365, P327, DOI 10.1056/NEJMoa1105351; Du YY, 2012, NEUROSCI LETT, V509, P110, DOI 10.1016/j.neulet.2011.12.054; Bianchi S, 2003, AM J KIDNEY DIS, V41, P565, DOI 10.1053/ajkd.2003.50140; desZeeuw D., 2010, RESULTS PLANET TRIAL; Japan Diabetes Society, 2007, TREATM GUID DIAB; Kimura S, 2012, DIABETES OBES METAB, V14, P666, DOI 10.1111/j.1463-1326.2012.01566.x; Ota T, 2003, DIABETOLOGIA, V46, P843, DOI 10.1007/s00125-003-1099-3; Rutter MK, 2011, DIABETIC MED, V28, P100, DOI 10.1111/j.1464-5491.2010.03139.x; Shimizu-Tokiwa A, 2002, NEPHRON, V92, P224, DOI 10.1159/000064453	32	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	2040-1116	2040-1124		J DIABETES INVEST	J. Diabetes Investig.	MAY	2015	6	3					346	353		10.1111/jdi.12296		8	Endocrinology & Metabolism	Endocrinology & Metabolism	CG7QI	WOS:000353498800016		
J	Kamei, S; Kaneto, H; Hashiramoto, M; Hisano, Y; Tanabe, A; Shimoda, M; Tawaramoto, K; Anno, T; Mune, T; Matsuki, M; Kaku, K				Kamei, Shinji; Kaneto, Hideaki; Hashiramoto, Mitsuru; Hisano, Yuki; Tanabe, Akihito; Shimoda, Masashi; Tawaramoto, Kazuhito; Anno, Takatoshi; Mune, Tomoatsu; Matsuki, Michihiro; Kaku, Kohei			Case of newly onset type 1 diabetes after highly active antiretroviral therapy against HIV infection	Journal of Diabetes Investigation			English	Letter									[Kamei, Shinji; Kaneto, Hideaki; Hashiramoto, Mitsuru; Hisano, Yuki; Tanabe, Akihito; Shimoda, Masashi; Tawaramoto, Kazuhito; Anno, Takatoshi; Mune, Tomoatsu; Matsuki, Michihiro; Kaku, Kohei] Kawasaki Med Univ, Div Diabet Metab & Endocrinol, Kurashiki, Okayama, Japan	Kamei, S (reprint author), Kawasaki Med Univ, Div Diabet Metab & Endocrinol, Kurashiki, Okayama, Japan.	s.kamei@med.kawasaki-m.ac.jp					Ikegami Hiroshi, 2008, Rev Diabet Stud, V5, P64, DOI 10.1900/RDS.2008.5.64; Takarabe D, 2010, J CLIN ENDOCR METAB, V95, P4056, DOI 10.1210/jc.2010-0055; Zandman-Goddard Gisele, 2002, Autoimmunity Reviews, V1, P329, DOI 10.1016/S1568-9972(02)00086-1	3	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	2040-1116	2040-1124		J DIABETES INVEST	J. Diabetes Investig.	MAY	2015	6	3					367	368		10.1111/jdi.12286		2	Endocrinology & Metabolism	Endocrinology & Metabolism	CG7QI	WOS:000353498800019		
J	Shinohara, S				Shinohara, Shigeko			Loanword-specific grammar in Japanese adaptations of Korean words and phrases	JOURNAL OF EAST ASIAN LINGUISTICS			English	Article						Korean laryngeal contrast; Loanword phonology; Japanese phonology; L2 perception	ENGLISH; PERCEPTION; PHONOLOGY	This paper documents present-day Japanese loanwords from Korean and contributes to the debate on input structure in loanword phonology. It argues that loanword patterns may be shaped by loanword-specific grammars. Present-day Korean-to-Japanese phrase adaptation of obstruents provides evidence for the existence of a loanword-specific grammar. In adaptations of Korean names and other phrases, an allophonic alternation in Korean, namely the intersonorant voicing of lenis stops, appears at the word boundary. Comparisons with other word sandhi phenomena reveal that voicing of a lenis in this position is not due to faithful rendition of Korean phonetic inputs but rather to a special rule of Japanese loanword phonology. The point is stressed by another analogous fact that the Korean coda behaves differently from codas of western languages in loanword adaptations, also requiring grammatical explanation for Korean word adaptation.	Sophia Univ, Phonet Lab, Chiyoda Ku, Tokyo 102, Japan	Shinohara, S (reprint author), Sophia Univ, Phonet Lab, Chiyoda Ku, 7-1 Kioi Cho, Tokyo 102, Japan.	shinoh-s@sophia.ac.jp			Sophia University Open Research Center from MEXT	This study is supported by the Sophia University Open Research Center from MEXT. I thank anonymous reviewers of an earlier draft as well as the editors of JEAL and Juhee Lee for their helpful comments, and Hyunsoon Kim, Seong-Rim Ji, Seong Hye Hwang, and Mee Sonu for help with Korean pronunciation. A portion of the loanword data was collected and shared with Hyunsoon Kim in 2006. Remaining errors are solely mine.	Dupoux E, 1999, J EXP PSYCHOL HUMAN, V25, P1568; Shinohara S, 2011, LINGUA, V121, P1461, DOI 10.1016/j.lingua.2011.04.001; Peperkamp S, 2008, PHONOLOGY, V25, P129, DOI 10.1017/S0952675708001425; Aoyama K, 2003, SECOND LANG RES, V19, P251, DOI 10.1191/0267658303sr222oa; Paradis C, 1997, J LINGUIST, V33, P379, DOI 10.1017/S0022226797006786; Kenstowicz M, 2006, LINGUA, V116, P921, DOI 10.1016/j.lingua.2005.05.006; Ayako Tsuchida, 1995, WORKING PAPERS CORNE, V10, P145; Davis S, 2006, LINGUA, V116, P1008, DOI 10.1016/j.lingua.2005.06.006; de Jong K, 2012, LANGUAGE, V88, P341; Diamond Big, 2006, CHIKYUU ARUKIKATA KA; Hayes Bruce, 2004, CONSTRAINTS PHONOLOG, P158; Ito Junko, 2004, JAPANESE MORPHOPHONE; Ito Junko, 1994, HDB PHONOLOGICAL THE, P817; Ito Junko, 1995, U MASSACHUSETTS OCCA, P181; Jacobs Haike, 2000, OPTIMALITY THEORY PH, P193; Jun Sun-Ah, 1994, THEORETICAL ISSUES K, P101; Kang Hyunsook, 2003, STUDIES PHONETICS PH, V9, P311; Kang YJ, 2010, PHONOLOGY, V27, P225, DOI 10.1017/S0952675710000114; Kang Yoonjung, 2011, COMPANION PHONOLOGY, P2258; Kim H, 2008, J EAST ASIAN LINGUIS, V17, P331, DOI 10.1007/s10831-008-9034-8; Kim Hyunsoon, 2005, INTERNAL ORG PHONOLO, P287; Kim MR, 2004, J EAST ASIAN LINGUIS, V13, P59, DOI 10.1023/B:JEAL.0000007344.43938.4e; Kubozono H, 2013, J EAST ASIAN LINGUIS, V22, P303, DOI 10.1007/s10831-013-9109-z; Kurida Shigeo, 2006, TRAVEL STORY 6 SEOUL; Maeda Tadahiko, 2005, THESIS OSAKA U FOREI; McCarthy John J., 1995, PAPERS OPTIMALITY TH, V18, P249; Oh M, 2012, J EAST ASIAN LINGUIS, V21, P267, DOI 10.1007/s10831-012-9089-4; Peperkamp S., 2003, P 15 INT C PHON SCI, P367; Polivanov E. I. D., 1931, TRAVAUX CERCLE LINGU, P79; Prince Alan, 1993, RUCCSTR2; Prince Alan, 2004, CONSTRAINTS PHONOLOG, P245; Rose Y, 2006, LINGUA, V116, P1112, DOI 10.1016/j.lingua.2005.06.011; Rosen E, 2003, CAN J LING/REV CAN L, V48, P1, DOI 10.1353/cjl.2004.0010; Sanspo, GEIN; Shinohara Shigeko, 1997, THESIS U SORBONNE NO; Shinohara Shigeko, 2004, CONSTRAINTS PHONOLOG, P292; Shinohara Shigeko, 1996, CHAHIERS LINGUISTIQU, V25, P87, DOI 10.3406/clao.1996.1493; Shinohara Shigeko, 2013, SOPHIA U WORKING PAP, V2013, P29; Silva D. J., 2006, PHONOLOGY, V23, P287, DOI 10.1017/S0952675706000911; Silverman Daniel, 1992, PHONOLOGY, V9, P289, DOI 10.1017/S0952675700001627; Sohn Ho-Min, 1999, KOREAN LANGUAGE; Yip M, 2006, LINGUA, V116, P950, DOI 10.1016/j.lingua.2005.05.007	42	0	0	SPRINGER	DORDRECHT	VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS	0925-8558	1572-8560		J EAST ASIAN LINGUIS	J. East Asian Linguist.	MAY	2015	24	2					149	191		10.1007/s10831-014-9129-3		43	Linguistics; Language & Linguistics	Linguistics	CG1UW	WOS:000353061400002		
J	Tachiki, Y; Makita, A; Suyama, Y; Satake, A				Tachiki, Yuuya; Makita, Akifumi; Suyama, Yoshihisa; Satake, Akiko			A spatially explicit model for flowering time in bamboos: long rhizomes drive the evolution of delayed flowering	JOURNAL OF ECOLOGY			English	Article						clonal monocarpy; evolutionarily stable strategy; geographic cline; kin competition; lattice modelling; mass flowering; reproductive ecology; rhizome system; spatial structure	INBREEDING DEPRESSION; VEGETATIVE PROPAGATION; POPULATION-DYNAMICS; GENETIC LOAD; PLANTS; SIZE; DISPERSAL; DENSITY; STRATEGIES; HABITATS	Clonal plants produce semi-autonomous modules (ramets). The spatial distribution of ramets affects lifetime reproductive success via self-pollination, kin competition and competition among genotypes over space and nutrients. These, in turn, influence the evolution of the timing of flowering in monocarps (flowering is fatal), such as bamboos. The vegetative growth period (flowering interval) in bamboos shows a geographic cline from tropical (short-interval) to temperate (long-interval) regions. However, the mechanisms underlying the emergence of this geographic trend in flowering interval remain elusive. We hypothesized that differences in flowering interval are determined by ecological features that affect the spatial arrangement of ramets and the degree of kin competition. Using a spatially explicit mathematical model, we examined the effects of rhizome elongation, seed and pollen dispersal ranges and inbreeding depression on the evolution of flowering interval. Flowering interval became longer as rhizome length increased but was shorter as seed dispersal range increased. However, flowering interval was less affected when these ranges were extremely large. These results could be caused by intragenet competition due to the spatial structure of genets. If the rhizome is short, each genet forms a clumping structure by vegetative growth and is subject to high intragenet competition. Early flowering may reduce this competition. When seed dispersal range is shorter, kin competition among seeds becomes greater and delayed flowering is a better strategy. When these parameters are extremely large, the effects of this type of competition are reduced, and flowering interval does not change. The effect of inbreeding depression depends on the spatial distribution of ramets formed by vegetative growth. Inbreeding depression reduces reproductive success, and hence, delayed flowering is selected for when both rhizome length and pollen dispersal range are short, and inbreeding with neighbouring siblings is unavoidable.Synthesis. The evolutionary consequences of flowering interval in clonal plants are affected by the spatial distribution of genets. Geographic patterns in flowering interval of bamboos can be explained by differences in rhizome length. Interspecific comparisons among species with different rhizome lengths should be examined by collecting long-term demographic data on the spatial arrangement of ramets.	[Tachiki, Yuuya; Satake, Akiko] Hokkaido Univ, Grad Sch Earth & Environm Sci, Sapporo, Hokkaido 0600810, Japan; [Makita, Akifumi] Akita Prefectural Univ, Fac Bioresource Sci, Akita 0100195, Japan; [Suyama, Yoshihisa] Tohoku Univ, Grad Sch Agr Sci, Field Sci Ctr, Osaki 98906711, Japan	Tachiki, Y (reprint author), Hokkaido Univ, Grad Sch Earth & Environm Sci, Sapporo, Hokkaido 0600810, Japan.	tachiki@ees.hokudai.ac.jp			JSPS KAKENHI [20380088]; Ministry of Education, Culture, Sports, Science and Technology, Japan [22119009]	This study was performed with support from a Grant-in-Aid for JSPS Fellows to Y.T, JSPS KAKENHI [20380088] to A.M. and Grants-in-Aid from the Ministry of Education, Culture, Sports, Science and Technology, Japan [22119009] to A.S. We thank the following people for their very helpful comments: Kiwako Araki, Ryosuke Iritani, Yoh Iwasa, Ayumi Matsuo, Yuko Miyazaki, Aya Nishiwaki, Hiroshi Tomimatsu, Tomoyuki Saito, Gen Sakurai and Jun-Ichirou Suzuki. We also appreciate for the comments by Editors and Referees.	LANDE R, 1985, EVOLUTION, V39, P24, DOI 10.2307/2408514; Nathan R, 2006, SCIENCE, V313, P786, DOI 10.1126/science.1124975; Vallejo-Marin M, 2010, ANNU REV ECOL EVOL S, V41, P193, DOI 10.1146/annurev.ecolsys.110308.120258; Ellner SP, 2006, AM NAT, V167, P410, DOI 10.1086/499438; Heinz SK, 2009, EVOL ECOL, V23, P53, DOI 10.1007/s10682-008-9251-7; Liao WJ, 2009, ANN BOT-LONDON, V104, P1405, DOI 10.1093/aob/mcp237; Byers DL, 1999, ANNU REV ECOL SYST, V30, P479, DOI 10.1146/annurev.ecolsys.30.1.479; Keeley JE, 1999, AM NAT, V154, P383, DOI 10.1086/303243; Rees M, 2006, AM NAT, V168, pE53, DOI 10.1086/505762; FAHRIG L, 1994, EVOL ECOL, V8, P172, DOI 10.1007/BF01238248; Childs DZ, 2003, P ROY SOC B-BIOL SCI, V270, P1829, DOI 10.1098/rspb.2003.2399; Isagi Y, 2004, MOL ECOL, V13, P2017, DOI 10.1111/j.1365-294X.2004.02197.x; Takada T, 1996, J THEOR BIOL, V182, P179, DOI 10.1006/jtbi.1996.0153; Oborny B, 2012, ECOL MODEL, V234, P20, DOI 10.1016/j.ecolmodel.2011.12.017; JANZEN DH, 1976, ANNU REV ECOL SYST, V7, P347, DOI 10.1146/annurev.es.07.110176.002023; GADGIL M, 1984, BIOTROPICA, V16, P161, DOI 10.2307/2388050; HARADA Y, 1994, RES POPUL ECOL, V36, P237, DOI 10.1007/BF02514940; Bolker BM, 1999, AM NAT, V153, P575, DOI 10.1086/303199; CHARLESWORTH D, 1990, EVOLUTION, V44, P1469, DOI 10.2307/2409330; Ikegami M, 2012, ECOL MODEL, V234, P51, DOI 10.1016/j.ecolmodel.2012.03.026; Levin SA, 2003, ANNU REV ECOL EVOL S, V34, P575, DOI 10.1146/annurev.ecolsys.34.011802.132428; Hisamoto Y, 2013, PLANT SPEC BIOL, V28, P109, DOI 10.1111/j.1442-1984.2012.00369.x; Wesselingh RA, 1997, ECOLOGY, V78, P2118, DOI 10.1890/0012-9658(1997)078[2118:TSFFID]2.0.CO;2; Metcalf CJE, 2008, P NATL ACAD SCI USA, V105, P10466, DOI 10.1073/pnas.0800777105; BELL G, 1980, AM NAT, V116, P45, DOI 10.1086/283611; Campbell JJ, 1985, J AM BAMBOO SOC, V6, P17; Hesse E, 2008, AM NAT, V172, pE196, DOI 10.1086/591683; Klimes L, 1997, ECOLOGY AND EVOLUTION OF CLONAL PLANTS, P1; Lion S, 2010, J EVOLUTION BIOL, V23, P866, DOI 10.1111/j.1420-9101.2010.01952.x; Makita Akifumi, 1998, Plant Species Biology, V13, P85, DOI 10.1111/j.1442-1984.1998.tb00251.x; Matsuo A., 2014, ANN BOT, V114, P1; McClure F. A., 1966, BAMBOOS FRESH PERSPE, P347; Metcalf JC, 2003, TRENDS ECOL EVOL, V18, P471, DOI 10.1016/S0169-5347(03)00162-9; NADGAUDA RS, 1993, TREE PHYSIOL, V13, P401; Nishitani S, 1999, PLANT ECOL, V141, P179, DOI 10.1023/A:1009896111536; Oborny B, 2012, ECOL MODEL, V234, P3, DOI 10.1016/j.ecolmodel.2012.03.010; Pitelka L. F., 1985, POPULATION BIOL EVOL, P399; Porcher E, 2005, EVOLUTION, V59, P46; Tarasjev A, 2005, ACTA OECOL, V27, P93, DOI 10.1016/j.actao.2004.09.007; VENKATESH CS, 1984, BIOTROPICA, V16, P309, DOI 10.2307/2387940; Zobel M, 2010, OIKOS, V119, P802, DOI 10.1111/j.1600-0706.2010.18296.x; Zukewich J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054639	42	2	2	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0022-0477	1365-2745		J ECOL	J. Ecol.	MAY	2015	103	3					585	593		10.1111/1365-2745.12390		9	Plant Sciences; Ecology	Plant Sciences; Environmental Sciences & Ecology	CG9MS	WOS:000353640500006		
J	Kitayama, K; Tsujii, Y; Aoyagi, R; Aiba, S				Kitayama, Kanehiro; Tsujii, Yuki; Aoyagi, Ryota; Aiba, Shin-ichiro			Long-term C, N and P allocation to reproduction in Bornean tropical rain forests	JOURNAL OF ECOLOGY			English	Article						litterfall; long-term monitoring; masting; Mount Kinabalu; P investment; plant-soil interactions; P-use efficiency; reproductive organs; soil nutrients	SOIL-PHOSPHORUS FRACTIONATION; MOUNT-KINABALU; ALTITUDINAL GRADIENTS; MALAY PENINSULA; TREE; PRODUCTIVITY; PHENOLOGY; NITROGEN; CLIMATE; DIPTEROCARPACEAE	Tropical rain forests in SE Asia are well known for the occurrence of supra-annual synchronous reproductive events, masting. Answering the question how trees allocate carbon (C), nitrogen (N) and phosphorus (P) to such irregular but gregarious reproduction requires a long-term observation. We conducted a 10-year continuous monitoring of litterfall in eight tropical rain forests, which differ significantly in P (and N) availability on Mount Kinabalu, Borneo. Mean P concentration in reproductive organ litter decreased significantly with increasing P-use efficiency of net primary production (PUE), an index of P deficiency. Therefore, P in reproductive organ litter became diluted as the magnitude of P deficiency increased. Mean annual litterfall (kgha(-1)yr(-1)) of reproductive organs over the 10years ranged from 128.5 to 730.9 across the eight forests. Long-term C allocation ratio to reproductive organs (i.e. C in reproductive organs per C in total litterfall) varied from 2.0% to 7.8% across the eight forests and did not relate with PUE, indicating that long-term C allocation ratio to reproduction was not controlled by the availability of the most critical soil nutrient. Long-term N allocation ratio to reproduction varied from 2.7% to 9.9% and significantly positively related with C allocation ratio. The quotient of N allocation ratio to C allocation ratio ranged from 1.1 to 1.4. Long-term P allocation ratio to reproduction varied from 9.8% to 16.4%. The quotient of P allocation ratio to C allocation ratio ranged from 1.6 to 5.0. Therefore, tropical trees allocated much greater proportion of P to reproduction than C and N over the 10years. Moreover, trees disproportionately increased P allocation to reproduction with decreasing C allocation to reproduction. Trees adjusted P allocation relative to C allocation and maintained a narrow range of P allocation ratio to reproduction in the long run in each site.Synthesis. Reproduction in Bornean tropical rain forests costs more P than C and N. Our results suggest that reproductive events in these forests are regulated by P at the level of overall long-term mean. Understanding patterns and processes of reproductive events requires a long-term monitoring of nutrient dynamics.	[Kitayama, Kanehiro; Tsujii, Yuki; Aoyagi, Ryota] Kyoto Univ, Grad Sch Agr, Sakyo Ku, Kyoto 6068502, Japan; [Aiba, Shin-ichiro] Kagoshima Univ, Grad Sch Sci & Engn, Kagoshima 8900065, Japan	Kitayama, K (reprint author), Kyoto Univ, Grad Sch Agr, Sakyo Ku, Kitashirakawa Oiwake Cho, Kyoto 6068502, Japan.	kanehiro@kais.kyoto-u.ac.jp	Aiba, Shin-ichiro/A-3011-2010	Aiba, Shin-ichiro/0000-0001-9852-7748	Japanese MESSC [18255003, 22255002]	This long-term monitoring was supported by the Sabah Parks. We are grateful to the staff members of the Sabah Parks and all local field workers. Y. Ichitsuka and S. Nishio assisted in chemical analyses. This study was supported by grants-in-aid from the Japanese MESSC (18255003 and 22255002) to K.K.	Elser JJ, 2007, ECOL LETT, V10, P1135, DOI 10.1111/j.1461-0248.2007.01113.x; White Philip J., 2008, V7, P51; Vitousek PM, 2010, ECOL APPL, V20, P5, DOI 10.1890/08-0127.1; Sakai S, 2006, AM J BOT, V93, P1134, DOI 10.3732/ajb.93.8.1134; Aiba S, 1999, PLANT ECOL, V140, P139, DOI 10.1023/A:1009710618040; Piovesan G, 2001, CAN J BOT, V79, P1039, DOI 10.1139/cjb-79-9-1039; Williamson GB, 2002, OIKOS, V97, P459, DOI 10.1034/j.1600-0706.2002.970317.x; Kudo G, 2004, J TROP ECOL, V20, P563, DOI 10.1017/S0266467404001841; Warton DI, 2012, METHODS ECOL EVOL, V3, P257, DOI 10.1111/j.2041-210X.2011.00153.x; Isagi Y, 1997, J THEOR BIOL, V187, P231, DOI 10.1006/jtbi.1997.0442; VANSCHAIK CP, 1993, ANNU REV ECOL SYST, V24, P353, DOI 10.1146/annurev.es.24.110193.002033; ASHTON PS, 1988, AM NAT, V132, P44, DOI 10.1086/284837; Ichie T, 2013, ECOL RES, V28, P151, DOI 10.1007/s11284-011-0836-1; Cannon CH, 2007, ECOL LETT, V10, P956, DOI 10.1111/j.1461-0248.2007.01089.x; Tully KL, 2013, ECOLOGY, V94, P930, DOI 10.1890/12-0781.1; Kitayama K, 2002, J ECOL, V90, P37, DOI 10.1046/j.0022-0477.2001.00634.x; Sakai S, 1999, AM J BOT, V86, P1414, DOI 10.2307/2656924; Curran LM, 1999, SCIENCE, V286, P2184, DOI 10.1126/science.286.5447.2184; Hidaka A, 2011, J ECOL, V99, P849, DOI 10.1111/j.1365-2745.2011.01805.x; Ichie T, 2005, J TROP ECOL, V21, P237, DOI 10.1017/S0266467404002214; Ichie T, 2005, TREES-STRUCT FUNCT, V19, P703, DOI 10.1007/s00468-005-0434-3; JANZEN D H, 1974, Biotropica, V6, P69, DOI 10.2307/2989823; Kitayama Kanehiro, 2005, Science, V308, P633; Kitayama K, 2014, ARCT ANTARCT ALP RES, V46, P745, DOI 10.1657/1938-4246-46.4.745; Kitayama K, 2004, ECOSYSTEMS, V7, P259, DOI 10.1007/s10021-003-0229-6; Kitayama K, 1998, ECOL RES, V13, P301, DOI 10.1046/j.1440-1703.1998.00264.x; Kitayama K, 2000, OECOLOGIA, V123, P342, DOI 10.1007/s004420051020; Newbery DM, 2005, NEW PHYTOL, V167, P324, DOI 10.1111/j.1469-8137.2005.01468.x; Numata S, 2003, AM J BOT, V90, P1025, DOI 10.3732/ajb.90.7.1025; Paoli GD, 2005, ECOLOGY, V86, P1548, DOI 10.1890/04-1126; R Core Team, 2013, R LANG ENV STAT COMP; Sakai S, 2002, BIOL J LINN SOC, V75, P233, DOI 10.1046/j.1095-8312.2002.00016.x; Wagai R, 2008, GEODERMA, V147, P23, DOI 10.1016/j.geoderma.2008.07.010; Yasuda M, 1999, J TROP ECOL, V15, P437, DOI 10.1017/S0266467499000930	34	0	1	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0022-0477	1365-2745		J ECOL	J. Ecol.	MAY	2015	103	3					606	615		10.1111/1365-2745.12379		10	Plant Sciences; Ecology	Plant Sciences; Environmental Sciences & Ecology	CG9MS	WOS:000353640500008		
J	Kishi, K				Kishi, Keiichi			Dynamic analysis of wage inequality and creative destruction	Journal of Economics			English	Article						Endogenous growth; Innovation; Creative destruction; Wage inequality; Factor-biased technological change; General purpose technologies	GENERAL-PURPOSE TECHNOLOGIES; DIRECTED TECHNICAL CHANGE; RESEARCH-AND-DEVELOPMENT; ECONOMIC-GROWTH; ENDOGENOUS GROWTH; SKILL PREMIUM; INNOVATION; APPROPRIABILITY; MODEL	This paper investigates the transitional dynamics of a basic Schumpeterian growth model under constant relative risk aversion. In this model, there are three patterns governing the evolution of wage inequality, but only if the intertemporal elasticity of substitution in consumption is sufficiently low: (a) skill-biased technological change, i.e., technological progress leads to a widening of wage inequality; (b) unskill-biased technological change, i.e., technological progress leads to a contraction of wage inequality; and (c) unbiased technological change, i.e., technological progress is independent of wage inequality. By conducting comparative dynamics of an unexpected permanent increase in research productivity in any sector, which we interpret as the arrival of new general purpose technologies, we show that the property of technological change shifts entirely from unskill-biased to skill-biased. The evolution of wage inequality in the model is then consistent with the shift in the trend in wage inequality beginning in the 1970s in the US economy.	Osaka Univ, Grad Sch Econ, Toyonaka, Osaka 5600043, Japan	Kishi, K (reprint author), Osaka Univ, Grad Sch Econ, 1-7 Machikaneyama, Toyonaka, Osaka 5600043, Japan.	ba000069@gmail.com			Japanese Ministry of Education, Culture, Sports, Science, and Technology (MEXT)	I am grateful to two anonymous referees for their constructive comments and suggestions on an earlier version of this paper and the encouragement of the editor-in-chief (Giacomo Corneo) in submitting a revision. I especially thank Tatsuro Iwaisako and Yoichi Gokan for their useful comments and encouragement. This research was partly supported by a Grant for Excellent Graduate Schools, from the Japanese Ministry of Education, Culture, Sports, Science, and Technology (MEXT). Of course, all remaining errors are mine.	Acemoglu D, 1998, Q J ECON, V113, P1055, DOI 10.1162/003355398555838; Aghion P., 1998, ENDOGENOUS GROWTH TH; Aghion P, 2002, ECONOMETRICA, V70, P855, DOI 10.1111/1468-0262.00312; Aghion P, 2009, THE ECONOMICS OF GRO; Acemoglu D, 2006, J EUR ECON ASSOC, V4, P37, DOI 10.1162/154247606776014677; NELSON RR, 1966, AM ECON REV, V56, P69; Guvenen F, 2006, J MONETARY ECON, V53, P1451, DOI 10.1016/j.jmoneco.2005.06.001; Autor DH, 2008, REV ECON STAT, V90, P300, DOI 10.1162/rest.90.2.300; Acemoglu D, 2002, REV ECON STUD, V69, P781, DOI 10.1111/1467-937X.00226; Boucekkine R, 2003, J ECON DYN CONTROL, V27, P2007, DOI 10.1016/S0165-1889(02)00114-8; Howitt P, 2000, AM ECON REV, V90, P829, DOI 10.1257/aer.90.4.829; Aghion P, 2002, J ECON GROWTH, V7, P315, DOI 10.1023/A:1020875717066; Segerstrom PS, 2000, J ECON GROWTH, V5, P277, DOI 10.1023/A:1009881717993; BRESNAHAN TF, 1995, J ECONOMETRICS, V65, P83, DOI 10.1016/0304-4076(94)01598-T; Minniti A, 2010, ECON MODEL, V27, P417, DOI 10.1016/j.econmod.2009.10.008; Fang CR, 2008, ECON MODEL, V25, P137, DOI 10.1016/j.econmod.2007.05.002; AGHION P, 1992, ECONOMETRICA, V60, P323, DOI 10.2307/2951599; Arrow KJ, 1962, THE RATE AND DIRECTI, P609; BENHABIB J, 1994, J MONETARY ECON, V34, P143, DOI 10.1016/0304-3932(94)90047-7; Caballero RJ, 1993, NBER MACROECON ANN, P15; Chen BL, 2010, J ECON, V100, P247, DOI 10.1007/s00712-010-0132-5; Cozzi G, 2006, MACROECON DYN, V10, P39, DOI 10.1017/S136510050505011X; Cozzi G, 2005, EUR ECON REV, V49, P627, DOI 10.1016/j.euroecorev.2003.08.003; Galor O, 2000, Q J ECON, V115, P469, DOI 10.1162/003355300554827; GROSSMAN GM, 1991, REV ECON STUD, V58, P43, DOI 10.2307/2298044; Helpman E, 1998, GENERAL PURPOSE TECHNOLOGIES AND ECONOMIC GROWTH, P55; Howitt P, 2005, J MONEY CREDIT BANK, V37, P147, DOI 10.1353/mcb.2005.0006; Howitt P, 1998, J ECON GROWTH, V3, P111, DOI 10.1023/A:1009769717601; Howitt P, 1999, J POLIT ECON, V107, P715, DOI 10.1086/250076; Howitt P, 1998, GENERAL PURPOSE TECHNOLOGIES AND ECONOMIC GROWTH, P219; Jacobs B, 2002, ECON LETT, V74, P243, DOI 10.1016/S0165-1765(01)00551-1; JONES CI, 1995, J POLIT ECON, V103, P759, DOI 10.1086/262002; Jovanovic Boyan, 2005, HANDB ECON, V1B, P1181, DOI DOI 10.1016/S1574-0684(05)01018-X; Machin S, 1998, Q J ECON, V113, P1215, DOI 10.1162/003355398555883; Mattalia C, 2013, J MACROECON, V37, P249, DOI 10.1016/j.jmacro.2013.02.003; Nahuis R, 2004, J ECON, V83, P151, DOI 10.1007/s00712-004-0078-6; Nahuis R, 2002, J ECON GROWTH, V7, P137, DOI 10.1023/A:1015624129031; Vandenbussche J, 2006, J ECON GROWTH, V11, P92; Van Reenen J, 2011, LABOUR ECON, V18, P730, DOI 10.1016/j.labeco.2011.05.006; Walde K, 1999, ECON J, V109, P156, DOI 10.1111/1468-0297.00423; Zeng JL, 2003, J MACROECON, V25, P541, DOI 10.1016/j.jmacro.2002.06.001; Zeng JL, 2002, ECON LETT, V75, P391, DOI 10.1016/S0165-1765(02)00006-X	42	0	0	SPRINGER WIEN	WIEN	SACHSENPLATZ 4-6, PO BOX 89, A-1201 WIEN, AUSTRIA	0931-8658	1617-7134		J ECON	J. Econ.	MAY	2015	115	1					1	23		10.1007/s00712-014-0403-7		23	Economics	Business & Economics	CG4YH	WOS:000353295000001		
J	Suzuki, K				Suzuki, Keishun			Economic growth under two forms of intellectual property rights protection: patents and trade secrets	Journal of Economics			English	Article						Innovation; Patent; Trade secret; Dynamic general equilibrium	INNOVATION; FIRMS	This paper analyzes the effects on growth of strengthened patent protections, where trade secrets are introduced as an additional protection method. Strengthening patent protection decreases the amount of common knowledge, which has two asymmetric effects on incentives to innovate. First, as competitors cannot freely use technological information, it helps successful innovators earn higher profits. Second, less disclosure of information reduces R&D productivity. The model shows that the relative importance of patents versus trade secrets determines whether the former positive effect dominates the latter negative effect. As a result, strengthened patent protection can increase economic growth when the risk of leakage of trade secrets is high. Conversely, when the risk is low, stronger patent protection hinders growth. Similar opposing results are also found in welfare analysis.	[Suzuki, Keishun] Tohoku Univ, Grad Sch Econ & Management, Aoba Ku, Sendai, Miyagi 980, Japan; [Suzuki, Keishun] Japan Soc Promot Sci, Tokyo, Japan	Suzuki, K (reprint author), Tohoku Univ, Grad Sch Econ & Management, Aoba Ku, 27-1 Kawauchi, Sendai, Miyagi 980, Japan.	keishun.suzuki@gmail.com			Japan Society for the Promotion of Science (JSPS) [25-10619]	I would like to thank Ryo Horii, Akiomi Kitagawa, Koki Oikawa, Yunfang Hu, numerous people who commented on earlier versions of the paper in the 2012 Japan Economic Association Spring Meeting at Hokkaido University, attendees at the 2013 Asian Meeting of Econometric Society in Singapore, and three anonymous referees for their helpful comments and suggestions on the manuscripts. This study was financially supported by Grant-in-Aid for Japan Society for the Promotion of Science (JSPS) Fellows (No. 25-10619). Of course, all remaining errors are my own.	Arundel A, 2001, RES POLICY, V30, P611, DOI 10.1016/S0048-7333(00)00100-1; Allred BB, 2007, J INT MANAG, V13, P91, DOI 10.1016/j.intman.2007.02.001; Horii R, 2007, J ECON, V90, P45, DOI 10.1007/s00712-006-0222-6; Arundel A, 1998, RES POLICY, V27, P127, DOI 10.1016/S0048-7333(98)00033-X; Ottoz E, 2008, AM LAW ECON REV, V10, P142, DOI 10.1093/aler/ahn007; Falvey R, 2006, REV DEV ECON, V10, P700, DOI 10.1111/j.1467-9361.2006.00343.x; Allred BB, 2007, J INT BUS STUD, V38, P878, DOI 10.1057/palgrave.jibs.8400306; Horowitz AW, 1996, INT ECON REV, V37, P785, DOI 10.2307/2527311; Park WG, 2008, RES POLICY, V37, P761, DOI 10.1016/j.respol.2008.01.006; Anton JJ, 2004, RAND J ECON, V35, P1, DOI 10.2307/1593727; Cohen WM, 2002, RES POLICY, V31, P1349, DOI 10.1016/S0048-7333(02)00068-9; Thoma J, 2013, RES POLICY, V42, P35, DOI 10.1016/j.respol.2012.04.019; Cohen WM, 2000, 7552 NBER; Futagami K, 2007, J ECON THEORY, V132, P306, DOI 10.1016/j.jet.2005.07.009; GROSSMAN GM, 1991, REV ECON STUD, V58, P43, DOI 10.2307/2298044; MANSFIELD E, 1986, MANAGE SCI, V32, P173, DOI 10.1287/mnsc.32.2.173; Naghavi A, 2014, CANAD J EC IN PRESS; Png I, 2012, WORKING PAPER; Sener F, 2006, WORKING PAPER; Takalo T, 1998, J ECON, V67, P229, DOI 10.1007/BF01234644	20	0	0	SPRINGER WIEN	WIEN	SACHSENPLATZ 4-6, PO BOX 89, A-1201 WIEN, AUSTRIA	0931-8658	1617-7134		J ECON	J. Econ.	MAY	2015	115	1					49	71		10.1007/s00712-014-0410-8		23	Economics	Business & Economics	CG4YH	WOS:000353295000003		
J	Oshita, K; Aoki, H; Fukutani, S; Shiota, K; Fujimori, T; Takaoka, M				Oshita, Kazuyuki; Aoki, Hiroshi; Fukutani, Satoshi; Shiota, Kenji; Fujimori, Takashi; Takaoka, Masaki			Behavior of cesium in municipal solid waste incineration	JOURNAL OF ENVIRONMENTAL RADIOACTIVITY			English	Article						Cesium; Incineration; Municipal solid waste; Equivalence ratio; Radioactive nuclides	ALKALI; CHLORINE; PHASES	As a result of the Fukushima Daiichi Nuclear Power Plant accident on March 11, 2011 in Japan radioactive nuclides, primarily Cs-134 and Cs-137 were released, contaminating municipal solid waste and sewage sludge in the area. Although stabilizing the waste and reducing its volume is an important issue differing from Chernobyl nuclear power plant accident, secondary emission of radioactive nuclides as a result of any intermediate remediation process is of concern. Unfortunately, there is little research on the behavior of radioactive nuclides during waste treatment. This study focuses on waste incineration in an effort to clarify the behavior of radioactive nuclides, specifically, refuse-derived fuel (RDF) with added Cs-133 (stable nuclide) or Cs-134 (radioactive nuclide) was incinerated in laboratory- and pilot-scale experiments. Next, thermogravimetric (TG) and differential thermal analysis (DTA) of stable Cs compounds, as well as an X-ray absorption fine structure (XAFS) analysis of Cs concentrated in the ashes were performed to validate the behavior and chemical forms of Cs during the combustion. Our results showed that at higher temperatures and at larger equivalence ratios,Cs-133 was distributed to the bottom ash at lower concentration, and the influence of the equivalence ratio was more significant at lower temperatures. Cs-134 behaved in a similar fashion as Cs-133. We found through TG DTA and XAFS analysis that a portion of Cs in RDF vaporizes and is transferred to fly ash where it exists as CsCl in the MSW incinerator. We conclude that Cs-contaminated municipal solid wastes could be incinerated at high temperatures resulting in a small amount of fly ash with a high concentration of radioactive Cs, and a bottom ash with low concentrations. (C) 2015 Elsevier Ltd. All rights reserved.	[Oshita, Kazuyuki; Fujimori, Takashi; Takaoka, Masaki] Kyoto Univ, Grad Sch Global Environm Studies, Cluster C, Nishikyo Ku, Kyoto 6158540, Japan; [Oshita, Kazuyuki; Aoki, Hiroshi; Shiota, Kenji; Fujimori, Takashi; Takaoka, Masaki] Kyoto Univ, Grad Sch Engn, Dept Environm Engn, Cluster C,Nishikyo Ku, Kyoto 6158540, Japan; [Oshita, Kazuyuki] Katholieke Univ Leuven, Dept Chem Engn, B-2860 St Katelijne Waver, Belgium; [Fukutani, Satoshi] Kyoto Univ, Inst Res Reactor, Kumatori, Osaka 5900494, Japan	Oshita, K (reprint author), Cluster C, Nishikyo Ku, Kyoto 6158540, Japan.	oshita@epsehost.env.kyoto-u.ac.jp		Shiota, Kenji/0000-0002-2056-3746	Ministry of Environment of Japan [3K122106, 3K143009]	This research was supported financially by the Environment Research and Technology Development Fund, grants no. 3K122106 and 3K143009, from the Ministry of Environment of Japan. The authors were supported in the pilot-scale experiment by Mr. Katsutoshi Torita, Mr. Masanori Kanda, and the members of the Industrial processes Division, NGK Insulators, Ltd. The XAFS spectrums of Cs were measured at BL01B1 in SPring-8 with approval of the Japan Synchrotron Radiation Research Institute (JASRI) (Proposal No. 2012A1081 and 2012131359) supported by Dr. Kiyofumi Nitta of JASRI.	Andres JM, 2011, FUEL PROCESSING TECH, V92, P433; Piao G, 2000, WASTE MANAGE, V20, P443, DOI 10.1016/S0956-053X(00)00009-X; Saffarzadeh A, 2014, J ENVIRON RADIOACTIV, V136, P76, DOI 10.1016/j.jenvrad.2014.05.009; Hess NJ, 2000, J NUCL MATER, V281, P22, DOI 10.1016/S0022-3115(00)00191-4; Amiro BD, 1996, SCI TOTAL ENVIRON, V187, P93, DOI 10.1016/0048-9697(96)05125-X; Wei XL, 2005, FUEL, V84, P841, DOI 10.1016/j.fuel.2004.11.022; Hammond C. R., 2005, CRC HDB CHEM PHYS, P4; HUANG JM, 1987, THERMOCHIM ACTA, V115, P57, DOI 10.1016/0040-6031(87)88351-X; IAEA, 2012, FUK DAIICH STAT REP; IAEA, 2006, 1527 IAEA TECDOC, P20; Kawano T., 2013, TAKUMA TECH REP, V21; Kobayashi N., 2005, POWER TECHNOL, V151, P87; Li Q, 2013, J HAZARD MATER, V262, P325, DOI 10.1016/j.jhazmat.2013.08.049; Mineralogical Society of America, 2001, HDB MIN; Ministry of Education Culture Sports Science & Technology Japan (MEXT), 1992, RAD MEAS METH SER, V7; Ministry of Environment Government of Japan, 2014, AM SPEC WAST; Ministry of the Environment Government of Japan, 2014, PROGR TREATM DEBR GR; Nakayama K., 2006, J JPN SOC WASTE MANA, V17, P428; National Institute for Environmental Studies (NIES) Center for Material Cycles and Waste Management Research (CMW), 2012, PROP TREATM WAST CON, V5; Poole D, 2008, FUEL, V87, P1318, DOI 10.1016/j.fuel.2007.07.017; Takeda S., 2012, JPN J HLTH PHYS, V47, P247; Yang H.C., 2002, J KOREAN NUCL SOC, V34, P80	22	2	2	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0265-931X	1879-1700		J ENVIRON RADIOACTIV	J. Environ. Radioact.	MAY	2015	143						1	6		10.1016/j.jenvrad.2015.01.019		6	Environmental Sciences	Environmental Sciences & Ecology	CG2HX	WOS:000353096600001		
J	Fuma, S; Ihara, S; Kawaguchi, I; Ishikawa, T; Watanabe, Y; Kubota, Y; Sato, Y; Takahashi, H; Aono, T; Ishii, N; Soeda, H; Matsui, K; Une, Y; Minamiya, Y; Yoshida, S				Fuma, Shoichi; Ihara, Sadao; Kawaguchi, Isao; Ishikawa, Takahiro; Watanabe, Yoshito; Kubota, Yoshihisa; Sato, Youji; Takahashi, Hiroyuki; Aono, Tatsuo; Ishii, Nobuyoshi; Soeda, Haruhi; Matsui, Kumi; Une, Yumi; Minamiya, Yukio; Yoshida, Satoshi			Dose rate estimation of the Tohoku hynobiid salamander, Hynobius lichenatus, in Fukushima	JOURNAL OF ENVIRONMENTAL RADIOACTIVITY			English	Article						Amphibian; Radiation; Risk; Radiocesium; ERICA; In situ measurement	POWER-PLANT ACCIDENT; NUCLEAR ACCIDENT; MARINE BIOTA; ERICA TOOL; RADIATION; CHERNOBYL; EXPOSURE; JAPAN; AREA; POPULATION	The radiological risks to the Tohoku hynobiid salamanders (class Amphibia), Hynobius lichenatus due to the Fukushima Dai-ichi Nuclear Power Plant accident were assessed in Fukushima Prefecture, including evacuation areas. Aquatic egg clutches (n = 1 for each sampling date and site; n = 4 in total), over-wintering larvae (n = 1-5 for each sampling date and site; n = 17 in total), and terrestrial juveniles or adults (n = 1 or 3 for each sampling date and site; n = 12 in total) of H. lichenatus were collected from the end of April 2011 to April 2013. Environmental media such as litter (n = 1-5 for each sampling date and site; n = 30 in total), soil (n = 1-8 for each sampling date and site; n = 31 in total), water (n = 1 for each sampling date and site; n = 17 in total), and sediment (n = 1 for each sampling date and site; n = 17 in total) were also collected. Activity concentrations of Cs-134 + Cs-137 were 1.9-2800, 0.13-320, and 0.51-220 kBq (dry kg)(-1) in the litter, soil, and sediment samples, respectively, and were 0.31-220 and <0.29-40 kBq (wet kg)(-1) in the adult and larval salamanders, respectively. External and internal absorbed dose rates to H. lichenatus were calculated from these activity concentration data, using the ERICA Assessment Tool methodology. External dose rates were also measured in situ with glass dosimeters. There was agreement within a factor of 2 between the calculated and measured external dose rates. In the most severely contaminated habitat of this salamander, a northern part of Abukuma Mountains, the highest total dose rates were estimated to be 50 and 15 mu Gy h(-1) for the adults and overwintering larvae, respectively. Growth and survival of H. lichenatus was not affected at a dose rate of up to 490 mu Gy h(-1) in the previous laboratory chronic gamma-irradiation experiment, and thus growth and survival of this salamander would not be affected, even in the most severely contaminated habitat in Fukushima Prefecture. However, further studies of the adult salamanders may be required in order to examine whether the most severe radioactive contamination has any effects on sensitive endpoints, since the estimated highest dose rate to the adults exceeded some of the guidance dose rates proposed by various organisations and programmes for the protection of amphibians, which range from 4 to 400 mu Gy h(-1). Conversely, at one site in Nakadori, a moderately contaminated region in Fukushima Prefecture, the dose rate to the adult salamanders in spring of 2012 was estimated to be 0.2 mu Gy h(-1). Estimated dose rates to the overwintering larvae in spring of 2012 were 1 and 0.2 mu Gy h(-1) at one site in Nakadori, and in Aizu, a less contaminated region in Fukushima Prefecture, respectively. These results suggest that there is a low risk that H. lichenatus will be affected by radioactive contamination in these districts, though further studies on dose rate estimation are required for definitive risk characterisation. (C) 2015 Elsevier Ltd. All rights reserved.	[Fuma, Shoichi; Kawaguchi, Isao; Watanabe, Yoshito; Kubota, Yoshihisa; Aono, Tatsuo; Soeda, Haruhi; Yoshida, Satoshi] Natl Inst Radiol Sci, Fukushima Project Headquarters, Project Environm Dynam & Radiat Effects, Inage Ku, Chiba 2638555, Japan; [Ihara, Sadao] Hokkaido Univ, Kushiro, Hokkaido 0858580, Japan; [Ishikawa, Takahiro] Natl Inst Radiol Sci, Res Dev & Support Ctr, Dept Tech Support & Dev, Inage Ku, Chiba 2638555, Japan; [Sato, Youji] Fukushima Wildlife Workshop, Tokyo, Japan; [Takahashi, Hiroyuki] Tokyo Nucl Serv Co Ltd, Taito Ku, Tokyo 1100016, Japan; [Ishii, Nobuyoshi] Natl Inst Radiol Sci, Res Ctr Radiat Protect, Off Biospher Assessment Waste Disposal, Inage Ku, Chiba 2638555, Japan; [Matsui, Kumi] Azabu Univ, Sch Vet Med, Lab Vet Physiol 1, Chuo Ku, Sagamihara, Kanagawa 2525201, Japan; [Une, Yumi] Azabu Univ, Sch Vet Med, Lab Vet Pathol, Chuo Ku, Sagamihara, Kanagawa 2525201, Japan; [Minamiya, Yukio] Yokohama Natl Univ, Grad Sch Environm & Informat Sci, Yokohama, Kanagawa 2408501, Japan	Fuma, S (reprint author), Natl Inst Radiol Sci, Fukushima Project Headquarters, Project Environm Dynam & Radiat Effects, Inage Ku, 4-9-1 Anagawa, Chiba 2638555, Japan.	fuma@nirs.go.jp		Une, Yumi/0000-0002-2112-1894	Mitsubishi Foundation, Japan [25143]	The authors are indebted to Dr. Taizo Nakamori, at the Graduate School of Environment and Information Sciences, Yokohama National University, Japan, and Prof. Gennichi Kuriki, at the Department of Oral Function and Molecular Biology, Ohu University, Japan, for kindly providing some litter, soil, and soil invertebrate samples. This work was partially supported by the Mitsubishi Foundation, Japan (ID: 25143).	Ann ICRP, 2008, ANN ICRP, V38, P1, DOI DOI 10.1016/J.ICRP.2008.08.003; Moller AP, 2012, ENVIRON POLLUT, V164, P36, DOI 10.1016/j.envpol.2012.01.008; Beresford NA, 2008, J ENVIRON RADIOACTIV, V99, P1496, DOI 10.1016/j.jenvrad.2008.03.002; Yamashiro H, 2013, SCI REP-UK, V3, DOI 10.1038/srep02850; Kryshev II, 2012, J ENVIRON RADIOACTIV, V114, P157, DOI 10.1016/j.jenvrad.2012.04.015; Fisher NS, 2013, P NATL ACAD SCI USA, V110, P10670, DOI 10.1073/pnas.1221834110; Garnier-Laplace J, 2010, J RADIOL PROT, V30, P215, DOI 10.1088/0952-4746/30/2/S02; Yamamoto Tomonori, 2011, Current Herpetology, V30, P7; Brown JE, 2008, J ENVIRON RADIOACTIV, V99, P1371, DOI 10.1016/j.jenvrad.2008.01.008; Hiyama A, 2012, SCI REP-UK, V2, DOI 10.1038/srep00570; Evangeliou N, 2013, ENVIRON SCI TECHNOL, V47, P5803, DOI 10.1021/es400372u; Steinhauser G, 2014, SCI TOTAL ENVIRON, V470, P800, DOI 10.1016/j.scitotenv.2013.10.029; Moller AP, 2013, ECOL INDIC, V24, P75, DOI 10.1016/j.ecolind.2012.06.001; Akimoto S, 2014, ECOL EVOL, V4, P355, DOI 10.1002/ece3.949; Batlle JVI, 2011, RADIAT ENVIRON BIOPH, V50, P231, DOI 10.1007/s00411-010-0346-5; Callaway E, 2013, NATURE, V499, P265, DOI 10.1038/499265a; Environment Agency, 2003, P3101SP1A R D EA; Environment Canada, 1997, 2CC3E EPS ENV CAN CH; Fukushima Prefectural Government, 2013, RES MON IRR PONDS NO; Fuma S, 2014, J ENVIRON RADIOACTIV, V135, P84, DOI 10.1016/j.jenvrad.2014.04.001; Fuma S, 2012, J ENVIRON RADIOACTIV, V103, P15, DOI 10.1016/j.jenvrad.2011.09.004; Gamier-Laplace J., 2011, ENVIRON SCI TECHNOL, V45, P5077; Garnier-Laplace J., 2008, J RADIOL PROTECT, V99, P1474; Garnier-Laplace J., 2006, DERIVATION PREDICTED; IAEA, 1992, IAEATECDOC332, P74; Ihara Sadao, 2013, Current Herpetology, V32, P77, DOI 10.5358/hsj.32.77; Johansen M.P., 2014, ENVIRON SCI TECHNOL, V49, P1277; Johansen MP, 2012, SCI TOTAL ENVIRON, V427, P238, DOI 10.1016/j.scitotenv.2012.04.031; Kubota Y, 2015, J ENVIRON RADIOACTIV, V142, P124, DOI 10.1016/j.jenvrad.2015.01.014; MAFF (Ministry of Agriculture Forestry and Fisheries), 2013, RES SURV RAD FOR; METI (Ministry of Economy Trade and Industry), 2011, RESTR AR DEL EV AR R; MEXT (Ministry of Education Culture Sports Science and Technology), 2011, RES AIRB MON SURV ME; MEXT (Ministry of Education Culture Sports Science and Technology), 1982, DET RAD SER, V13, P20; Ministry of Economy Trade and Industry (METI) Government of Japan, 2013, AR WHICH EV ORD HAV; MOE (Ministry of the Environment), 2013, FY2012 RAD MAT MON S; PANTER HC, 1986, J EXP ZOOL, V238, P193, DOI 10.1002/jez.1402380209; Schiermeier Q., 2011, NAT NEWS; Schiermeier Q, 2011, NATURE, V472, P145, DOI 10.1038/472145a; Beaugelin-Seiller K, 2014, J ENVIRON RADIOACTIV, V138, P60, DOI 10.1016/j.jenvrad.2014.07.027; Strand P, 2014, ENVIRON SCI TECH LET, V1, P198, DOI 10.1021/ez500019j; Takahashi J, 2015, J ENVIRON RADIOACTIV, V139, P351, DOI 10.1016/j.jenvrad.2014.07.004; Taranenko V, 2004, J RADIOL PROT, V24, pA35, DOI 10.1088/0952-4746/24/4A/003; UNSCEAR, 1996, REP GEN ASS SCI ANN, P86; US DOE, 2002, DOESTD11532002; Wood MD, 2009, J ENVIRON RADIOACTIV, V100, P1034, DOI 10.1016/j.jenvrad.2009.04.010; Woodhead D., 2003, RAD EFFECTS PLANTS A	46	0	0	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0265-931X	1879-1700		J ENVIRON RADIOACTIV	J. Environ. Radioact.	MAY	2015	143						123	134		10.1016/j.jenvrad.2015.02.020		12	Environmental Sciences	Environmental Sciences & Ecology	CG2HX	WOS:000353096600017		
J	Asakura, K; Haga, M; Sasaki, S				Asakura, Keiko; Haga, Megumi; Sasaki, Satoshi			Relative Validity and Reproducibility of a Brief-Type Self-Administered Diet History Questionnaire for Japanese Children Aged 3-6 Years: Application of a Questionnaire Established for Adults in Preschool Children	JOURNAL OF EPIDEMIOLOGY			English	Article						validity; reproducibility; diet history questionnaire; Japanese; preschool children	FOOD FREQUENCY QUESTIONNAIRE; LABELED WATER METHOD; ENERGY-INTAKE; CARDIOVASCULAR-DISEASE; VALIDATION; ADOLESCENTS; NUTRIENTS; ACCURACY; PATTERNS; RECALLS	Background: Dietary intake assessment and subsequent dietary education or intervention in young children is important in decreasing prevalence of various noncontagious diseases in adulthood. Validation of diet assessment questionnaires for preschool children has just started in Japan. In this study, we rearranged the brief-type self-administered diet history questionnaire (BDHQ), a convenient diet assessment questionnaire that is widely used in a range of situations for adults, for use in children aged 3-6 years (BDHQ3y) and then validated the BDHQ3y in Japanese children. Methods: The guardians of 61 children aged 3-4 years completed the BDHQ3y twice at an interval of 1 month, along with a 3-nonconsecutive-day diet record (DR) between the two administrations of the BDHQ3y. Dietary intakes for energy and 42 selected nutrients were estimated using both the DR and the BDHQ3y. Mean intakes estimated by the two methods were compared, and correlation coefficients were calculated. Reproducibility of the BDHQ3y estimates was investigated using intra-class correlation coefficients (ICCs). Results: No significant differences in mean intakes estimated by the DR and the BDHQ3y were observed for one- to two-thirds of energy and examined nutrients. The median of Pearson correlation coefficients between intakes energy-adjusted by the residual method was 0.31 (interquartile range, 0.24 to 0.38). The median ICC was 0.72 (interquartile range, 0.63 to 0.76) for the crude nutrient intakes. Conclusions: Although the BDHQ3y might be a good candidate for dietary intake assessment in Japanese preschool children, its validity is currently moderate to low. Shortcomings should be overcome by obtaining and utilizing more information about children's dietary habits.	[Asakura, Keiko] Univ Tokyo, Interfac Initiat Informat Studies, Tokyo 1130033, Japan; [Asakura, Keiko; Sasaki, Satoshi] Univ Tokyo, Dept Social & Prevent Epidemiol, Sch Publ Hlth, Tokyo 1130033, Japan; [Haga, Megumi] Ishinomaki Senshu Univ, Res Ctr Creat Partnerships, Ishinomaki, Miyagi, Japan	Sasaki, S (reprint author), Univ Tokyo, Dept Social & Prevent Epidemiol, Sch Publ Hlth, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1130033, Japan.	stssasak@m.u-tokyo.ac.jp			JSPS [19650212]	The authors would like to thank the children and their guardians who kindly agreed to participate in this study. We also appreciate the dietitians of Tome City Government and three dietetic students of Shokei Gakuin University-Makiko Kudo, Tomoyo Sasaki, and Aya Kanno-for their support. This study was financially supported by JSPS KAKENHI (Grants-in-Aid for Scientific Research) Grant Number 19650212.	SHROUT PE, 1979, PSYCHOL BULL, V86, P420, DOI 10.1037//0033-2909.86.2.420; Yoshino K, 2005, J EPIDEMIOL, V15, P29, DOI 10.2188/jea.15.29; Dutman AE, 2011, PUBLIC HEALTH NUTR, V14, P410, DOI 10.1017/S1368980010002119; Baxter SD, 1999, NUTRITION, V15, P848, DOI 10.1016/S0899-9007(99)00179-3; Kobayashi S, 2011, PUBLIC HEALTH NUTR, V14, P1200, DOI 10.1017/S1368980011000504; Fumagalli F, 2008, NUTRITION, V24, P427, DOI 10.1016/j.nut.2008.01.008; LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310; BARANOWSKI T, 1991, J AM DIET ASSOC, V91, P669; Sasaki S, 2000, J NUTR SCI VITAMINOL, V46, P285; Murakami K, 2012, NUTRITION, V28, P532, DOI 10.1016/j.nut.2011.08.011; Livingstone MBE, 2004, BRIT J NUTR, V92, pS213, DOI 10.1079/BJN20041169; Sasaki S, 1998, JPN CIRC J, V62, P431, DOI 10.1253/jcj.62.431; Kobayashi S, 2012, J EPIDEMIOL, V22, P151, DOI [10.2188/jeaJE20110075, 10.2188/jea.JE20110075]; Parrish LA, 2003, EPIDEMIOLOGY, V14, P213, DOI 10.1097/00001648-200303000-00016; Wilson AMR, 2004, J AM DIET ASSOC, V104, P373, DOI 10.1016/j.jada.2003.12.021; Asakura K, J NUTR SCI IN PRESS; Blum R E, 1999, Matern Child Health J, V3, P167, DOI 10.1023/A:1022350023163; Chambers E, 2000, J AM DIET ASSOC, V100, P891, DOI 10.1016/S0002-8223(00)00259-5; Council for Science and Technology, 2010, STAND TABL FOOD COMP; Engelfriet P, 2010, EUR J CARDIOV PREV R, V17, P50, DOI 10.1097/HJR.0b013e32832f3a76; Fukumoto A, 2013, J EPIDEMIOL, V23, P178, DOI 10.2188/jea.JE20120106; Kelly CNM, 2003, P NUTR SOC, V62, P583, DOI 10.1079/PNS2003272; Kimura N, 2003, J NUTR SCI VITAMINOL, V49, P149; Kobayashi T, 2011, NUTR J, V10, DOI 10.1186/1475-2891-10-27; Mikkila V, 2005, BRIT J NUTR, V93, P923, DOI 10.1079/BJN20051418; Ministry of Education Culture Sports Science and Technology [homepage on the Internet], GAKK HOK TOUK CHOUS; Ministry of Health Labour and Welfare, 2009, DIRT REF INT JAP 201; Ministry of Health Labour and Welfare [homepage on the Internet], NYUUYOUJI SHINTAI HA; Okubo H, 2008, EUR J CLIN NUTR, V62, P1343, DOI 10.1038/sj.ejcn.1602858; Okubo H, 2012, BRIT J NUTR, V107, P1526, DOI 10.1017/S0007114511004636; Orton HD, 2008, EUR J CLIN NUTR, V62, P733, DOI 10.1038/sj.ejcn.1602763; Sahashi Y, 2011, J NUTR SCI VITAMINOL, V57, P372, DOI 10.3177/jnsv.57.372; Sasaki S, 1998, J Epidemiol, V8, P203; Shatenstein B, 2010, J PEDIATR GASTR NUTR, V51, P645, DOI 10.1097/MPG.0b013e3181eb6881; STEIN AD, 1992, AM J EPIDEMIOL, V135, P667; Suga H, 2014, NUTR J, V13, DOI 10.1186/1475-2891-13-51; Watkins MP, 1993, FDN CLIN RES APPL PR; Willett W, 2013, NUTR EPIDEMIOLOGY; Willett WC, 1997, AM J CLIN NUTR S, V65, p9S; Willett WC, 1997, AM J CLIN NUTR, V65, P1220	40	0	0	JAPAN EPIDEMIOLOGICAL ASSOC	TOKYO	C/O UNIBO PRESS, HONGO MT BLDG 4F, 7-2-2 HONGO, BUNKYO-KU, TOKYO, 113-0033, JAPAN	0917-5040	1349-9092		J EPIDEMIOL	J. Epidemiol.	MAY	2015	25	5					341	350		10.2188/jea.JE20140174		10	Public, Environmental & Occupational Health	Public, Environmental & Occupational Health	CG8VB	WOS:000353591700001		
J	Uemura, M; Yatsuya, H; Hilawe, EH; Li, YY; Wang, CC; Chiang, C; Otsuka, R; Toyoshima, H; Tamakoshi, K; Aoyama, A				Uemura, Mayu; Yatsuya, Hiroshi; Hilawe, Esayas Haregot; Li, Yuanying; Wang, Chaochen; Chiang, Chifa; Otsuka, Rei; Toyoshima, Hideaki; Tamakoshi, Koji; Aoyama, Atsuko			Breakfast Skipping is Positively Associated With Incidence of Type 2 Diabetes Mellitus: Evidence From the Aichi Workers' Cohort Study	JOURNAL OF EPIDEMIOLOGY			English	Article						breakfast; diabetes mellitus; cohort study; Japan	DIET HISTORY QUESTIONNAIRES; EATING FREQUENCY; JAPANESE ADULTS; HEALTH; RISK; PREVALENCE; VALIDITY; PATTERNS; WOMEN	Background: Skipping breakfast has been suspected as a risk factor for type 2 diabetes (T2DM), but the associations are not entirely consistent across ethnicities or sexes, and the issue has not been adequately addressed in the Japanese population. Methods: We followed 4631 participants (3600 men and 1031 women) in a work-site cohort of participants aged 35-66 years in 2002 through 2011 for T2DM development. Frequency of eating breakfast was self-reported and was subsequently dichotomized to breakfast skippers, who eat breakfast 3-5 times/week or less, and to eaters. Cox proportional hazards models were used to adjust for potential confounding factors, including dietary factors, smoking and other lifestyles, body mass index (BMI), and fasting blood glucose (FBG) at baseline. Results: During 8.9 years of follow-up, 285 T2DM cases (231 men and 54 women) developed. Compared to participants who reported eating breakfast every day, maximally-adjusted hazard ratios and 95% confidence intervals (CI) of those with the frequency of almost every day and 3-5, 1-2, and 0 days/week were: 1.06 (95% CI, 0.73-1.53), 2.07 (95% CI, 1.20-3.56), 1.37 (95% CI, 0.82-2.29), and 2.12 (95% CI, 1.19-3.76), respectively. In a dichotomized analysis, breakfast skipping was positively associated with T2DM incidence (maximally-adjusted hazard ratio 1.73; 95% CI, 1.24-2.42). The positive associations were found in both men and women, current and non-current smokers, normal weight and overweight (BMI = 25 kg/m(2)), and normal glycemic status and impaired fasting glycemic status (FBG 110 to < 126 mg/dL) individuals at baseline (Ps for interaction all > 0.05). Conclusions: The present study in middle-aged Japanese men and women suggests that skipping breakfast may increase the risk of T2DM independent of lifestyles and baseline levels of BMI and FBG.	[Uemura, Mayu; Yatsuya, Hiroshi; Hilawe, Esayas Haregot; Wang, Chaochen; Chiang, Chifa; Aoyama, Atsuko] Nagoya Univ, Grad Sch Med, Dept Publ Hlth & Hlth Syst, Nagoya, Aichi 4648601, Japan; [Yatsuya, Hiroshi; Li, Yuanying] Fujita Hlth Univ, Sch Med, Dept Publ Hlth, Toyoake, Aichi 4701192, Japan; [Otsuka, Rei] Natl Ctr Geriatr & Gerontol, Natl Inst Longev Sci NILS LSA, Sect Longitudinal Study Aging, Obu, Aichi, Japan; [Toyoshima, Hideaki] Anjo Kosei Hosp, Anjo, Aichi, Japan; [Tamakoshi, Koji] Nagoya Univ, Grad Sch Med, Dept Nursing, Nagoya, Aichi 4648601, Japan	Yatsuya, H (reprint author), Fujita Hlth Univ, Sch Med, Toyoake, Aichi 4701192, Japan.	yatsuya@gmail.com			JSPS [13470087, 17390185, 17790384, 22390133, 23659346, 26293153, 16590499, 18590594, 20590641, 30262900]; Ministry of Health, Labor and Welfare, Health and Labor Sciences research grants, Japan [H26-Junkankitou[Seisaku]-Ippan-001]; Japan Atherosclerosis Prevention Fund; Uehara Memorial Foundation; Meiji Yasuda Life Foundation of Health and Welfare; Aichi Health Promotion Foundation	The authors wish to express their sincere appreciation to the participants as well as to the healthcare personnel of the local government office. This work was supported by JSPS KAKENHI Grant Numbers 13470087 and 17390185 (Hideaki Toyoshima), 17790384, 22390133, 23659346 and 26293153 (Hiroshi Yatsuya) and 16590499, 18590594, 20590641 and 30262900 (Koji Tamakoshi), a grant-in-aid from the Ministry of Health, Labor and Welfare, Health and Labor Sciences research grants, Japan (Comprehensive Research on Cardiovascular and Life-Style Related Diseases: H26-Junkankitou[Seisaku]-Ippan-001), and funds from the Japan Atherosclerosis Prevention Fund, the Uehara Memorial Foundation, Meiji Yasuda Life Foundation of Health and Welfare, and Aichi Health Promotion Foundation.	Esquirol Y, 2009, CHRONOBIOL INT, V26, P544, DOI 10.1080/07420520902821176; Odegaard AO, 2013, DIABETES CARE, V36, P3100, DOI 10.2337/dc13-0316; Sugimori H, 1998, J Med Syst, V22, P27, DOI 10.1023/A:1022650305109; Mekary RA, 2012, AM J CLIN NUTR, V95, P1182, DOI 10.3945/ajcn.111.028209; Cahill LE, 2013, CIRCULATION, V128, P337, DOI 10.1161/CIRCULATIONAHA.113.001474; Keski-Rahkonen A, 2003, EUR J CLIN NUTR, V57, P842, DOI 10.1038/sj.ejcn.1601618; Timlin MT, 2007, NUTR REV, V65, P268, DOI 10.1301/nr.2007.jun.268-281; Wild S, 2004, DIABETES CARE, V27, P1047, DOI 10.2337/diacare.27.5.1047; Kobayashi S, 2011, PUBLIC HEALTH NUTR, V14, P1200, DOI 10.1017/S1368980011000504; Farshchi HR, 2005, AM J CLIN NUTR, V81, P388; Mekary RA, 2013, AM J CLIN NUTR, V98, P436, DOI 10.3945/ajcn.112.057521; Wada K, 2009, J CLIN EPIDEMIOL, V62, P306, DOI 10.1016/j.jclinepi.2008.04.006; Nakamura Y, 2008, DIABETES, V57, P2661, DOI 10.2337/db07-1103; Kochar J, 2007, OBESITY, V15, P3039, DOI 10.1038/oby.2007.362; Danaei G, 2011, LANCET, V378, P31, DOI 10.1016/S0140-6736(11)60679-X; Kobayashi S, 2012, J EPIDEMIOL, V22, P151, DOI [10.2188/jeaJE20110075, 10.2188/jea.JE20110075]; Goto A, 2013, J EPIDEMIOL, V23, P295, DOI 10.2188/jea.JE20120221; Institute for Health Metrics and Evaluation UoW, 2013, GBD COUNTR PROF JAP; Ministry of Health Labour and Welfare, 2011, NAT HLTH NUTR SURV J; Selvin E, 2014, CLIN CHEM, V60, P1409, DOI 10.1373/clinchem.2014.229427; Uehara A, 2014, DIABETES RES CLIN PR, V106, P118, DOI 10.1016/j.diabres.2014.07.013; Yatsuya H, 2003, J EPIDEMIOL, V13, P235; Yoshizaki T., 2010, Journal of Japanese Society of Nutrition and Food Science, V63, P161	23	0	0	JAPAN EPIDEMIOLOGICAL ASSOC	TOKYO	C/O UNIBO PRESS, HONGO MT BLDG 4F, 7-2-2 HONGO, BUNKYO-KU, TOKYO, 113-0033, JAPAN	0917-5040	1349-9092		J EPIDEMIOL	J. Epidemiol.	MAY	2015	25	5					351	358		10.2188/jea.JE20140109		8	Public, Environmental & Occupational Health	Public, Environmental & Occupational Health	CG8VB	WOS:000353591700002		
J	Sakai, R; Fink, G; Wang, W; Kawachi, I				Sakai, Rie; Fink, Guenther; Wang, Wei; Kawachi, Ichiro			Correlation Between Pediatrician Supply and Public Health in Japan as Evidenced by Vaccination Coverage in 2010: Secondary Data Analysis	JOURNAL OF EPIDEMIOLOGY			English	Article						human resources; physician supply; vaccination coverage; healthcare utilization; Japan	GEOGRAPHIC-DISTRIBUTION; IMMUNIZATION COVERAGE; CHILDHOOD VACCINATION; SPATIAL-DISTRIBUTION; DEVELOPING-COUNTRIES; INFANT-MORTALITY; PRIMARY-CARE; PHYSICIANS; DETERMINANTS; CHILDREN	Background: In industrialized countries, assessment of the causal effect of physician supply on population health has yielded mixed results. Since the scope of child vaccination is an indicator of preventive health service utilization, this study investigates the correlation between vaccination coverage and pediatrician supply as a reflection of overall pediatric health during a time of increasing pediatrician numbers in Japan. Methods: Cross-sectional data were collected from publicly available sources for 2010. Dependent variables were vaccination coverage for measles and diphtheria, pertussis, and tetanus (DPT) by region. The primary predictor of interest was number of pediatricians per 10 000-child population (pediatrician density) at the municipality level. Multivariate logistic regression models were used to estimate associations of interest, conditional on a large range of demographic and infrastructure-related factors as covariates, including non-pediatric physician density, total population, per capita income, occupation, unemployment rate, prevalence of single motherhood, number of hospital beds per capita, length of roads, crime rate, accident rate, and metropolitan area code as urban/rural status. The percentage of the population who completed college-level education or higher in 2010 was included in the model as a proxy for education level. Results: Pediatrician density was positively and significantly associated with vaccination coverage for both vaccine series. On average, each unit of pediatrician density increased odds by 1.012 for measles (95% confidence interval, 1.010-1.015) and 1.019 for DPT (95% confidence interval, 1.016-1.022). Conclusions: Policies increasing pediatrician supply contribute to improved preventive healthcare services utilization, such as immunizations, and presumably improved child health status in Japan.	[Sakai, Rie; Kawachi, Ichiro] Harvard Univ, Sch Publ Hlth, Dept Social & Behav Sci, Boston, MA 02115 USA; [Sakai, Rie] Juntendo Univ, Sch Med, Dept Med Educ, Tokyo 113, Japan; [Sakai, Rie] Juntendo Univ, Sch Med, Dept Pediat & Adolescent Med, Tokyo 113, Japan; [Fink, Guenther] Harvard Univ, Sch Publ Hlth, Dept Global Hlth & Populat, Boston, MA 02115 USA; [Wang, Wei] Brigham & Womens Hosp, Dept Sleep Med, Boston, MA 02115 USA	Sakai, R (reprint author), Harvard Univ, Sch Publ Hlth, Dept Social & Behav Sci, 665 Huntington Ave, Boston, MA 02115 USA.	ris245@mail.harvard.edu			Harvard Catalyst; Takemi Program in International Health at the Department of Global Health and Population, Harvard School of Public Health; Japan Society for the Promotion of Science; Ministry of Education, Culture, Sports, Science and Technology [26460843]; Social Science Research Council	This study was conducted with the support of Harvard Catalyst and the Takemi Program in International Health at the Department of Global Health and Population, Harvard School of Public Health. We would like to express our sincere appreciation to Usheer Kanjee, PhD at the Department of Immunology and Infectious Diseases, Harvard School of Public Health, for his very helpful comments. This study is supported by the Japan Society for the Promotion of Science, Grant-in-Aid for Scientific Research (C) from the Ministry of Education, Culture, Sports, Science and Technology (No. 26460843). Rie Sakai gratefully acknowledges support from the Social Science Research Council through the Abe Fellowship Program for her academic endeavors at Harvard University.	Alexander C, 1998, Aust J Rural Health, V6, P136, DOI 10.1111/j.1440-1584.1998.tb00299.x; Wright JA, 2006, EUR J PUBLIC HEALTH, V16, P137, DOI 10.1093/eurpub/cki194; Gidengil C, 2012, VACCINE, V30, P3445, DOI 10.1016/j.vaccine.2012.03.022; von Dadelszen P, 2011, LANCET, V377, P219, DOI 10.1016/S0140-6736(10)61351-7; Rosenthal MB, 2005, HEALTH SERV RES, V40, P1931, DOI 10.1111/j.1475-6773.2005.00440.x; SCHWARTZ WB, 1980, NEW ENGL J MED, V303, P1032, DOI 10.1056/NEJM198010303031803; Or Z, 2005, J HEALTH ECON, V24, P531, DOI 10.1016/j.jhealeco.2004.09.00; Pickering LK, 2009, CLIN INFECT DIS, V49, P817, DOI 10.1086/605430; Hann M, 2004, BRIT J GEN PRACT, V54, P894; Goodman DC, 2002, NEW ENGL J MED, V346, P1538, DOI 10.1056/NEJMoa011921; Matsumoto M, 2010, HEALTH POLICY, V96, P255, DOI 10.1016/j.healthpol.2010.02.012; Anand S, 2007, LANCET, V369, P1277, DOI 10.1016/S0140-6736(07)60599-6; KOBAYASHI Y, 1992, LANCET, V340, P1391, DOI 10.1016/0140-6736(92)92569-2; Bates AS, 1998, PEDIATRICS, V101, P591, DOI 10.1542/peds.101.4.591; Mendoza JA, 2011, PEDIATRICS, V128, pE537, DOI 10.1542/peds.2010-3486; Maciosek MV, 2006, AM J PREV MED, V31, P52, DOI 10.1016/j.amepre.2006.03.012; Bondy JN, 2009, VACCINE, V27, P169, DOI 10.1016/j.vaccine.2008.08.042; Australian Medical Workforce Advisory Committee (AMWAC), 2000, AUST HEALTH REV, V23, P8; Bureau of Statistics Ministry of Internal Affairs and Communications, NAM MUN MAJ METR AR; Bureau of the Census, STAT PREF MUN; Centers for Disease Control and Prevention, LEAD CAUS DEATH PREL; Cochrane AL, 1997, J EPIDEMIOL COMMUN H, V51, P344, DOI 10.1136/jech.51.4.344; Danis K, 2010, VACCINE, V28, P1861, DOI 10.1016/j.vaccine.2009.11.078; DERKSEN S, 1992, BRIT J MATH STAT PSY, V45, P265; Doshi P, 2010, CAMB Q HEALTHC ETHIC, V19, P283, DOI 10.1017/S0963180110000058; Eckhert NL, 2002, MED EDUC, V36, P606, DOI 10.1046/j.1365-2923.2002.01257.x; Fernandez RC, 2011, RURAL REMOTE HEALTH, V11; Goetz S. J., 1996, Review of Agricultural Economics, V18, P547, DOI 10.2307/1349589; Gorman D, 2007, INTERN MED J, V37, P669, DOI 10.1111/j.1445-5994.2007.01461.x; Gravelle H, 2001, J Health Serv Res Policy, V6, P6, DOI 10.1258/1355819011927143; GROSSMAN M, 1981, DEMOGRAPHY, V18, P695, DOI 10.2307/2060956; Infectious Diseases Surveillance Center, NUMB REP INF DIS YEA; Infectious Diseases Surveillance Center, 2010, IMM SCHED JAP 2010; KIM KK, 1992, SOC SCI MED, V34, P837, DOI 10.1016/0277-9536(92)90253-M; KRISHNAN V, 1992, SOCIO ECON PLAN SCI, V26, P111, DOI 10.1016/0038-0121(92)90018-Z; Kruk ME, 2009, HUM RESOUR HEALTH, V7, DOI 10.1186/1478-4491-7-27; Kubo K, 2012, JAPANESE SOC CHILD H, V71, P393; LANGWELL KM, 1987, PUBLIC HEALTH REP, V102, P317; LeBaron CW, 2001, PEDIATRICS, V107, DOI 10.1542/peds.107.3.e31; Matsumoto M, 2010, HEALTH PLACE, V16, P164, DOI 10.1016/j.healthplace.2009.07.005; McEldowney R P, 1995, J Manag Med, V9, P68, DOI 10.1108/02689239510096839; Meek R, 2009, EMERG MED AUSTRALAS, V21, P323, DOI 10.1111/j.1742-6723.2009.01204.x; MILLER MK, 1978, J HEALTH SOC BEHAV, V19, P263, DOI 10.2307/2136559; Ministry of Health Labor and Welfare, 2009, ARCH STAT TABL UNPUB; Ministry of Health Labor and Welfare, SURV IMPL STAT 1 2 3; Ministry of Health Labor and Welfare, PREV GUID MEASL; Ministry of Health Labor and Welfare, 2002, ARCH STAT TABL UNPUB; Ministry of Health Labor and Welfare, NUMB CHILDR WHO REC; Ministry of Health Labor and Welfare, 2003, ARCH STAT TABL UNPUB; Ministry of Health Labor and Welfare, 2010, ARCH STAT TABL UNPUB; Ministry of Health Labor and Welfare, 2007, ARCH STAT TABL UNPUB; Ministry of Health Labor and Welfare, 2005, ARCH STAT TABL UNPUB; Ministry of Health Labor and Welfare, 2001, ARCH STAT TABL UNPUB; Ministry of Health Labor and Welfare, 2004, ARCH STAT TABL UNPUB; Ministry of Health Labor and Welfare, 2008, ARCH STAT TABL UNPUB; Ministry of Health Labor and Welfare, 2006, ARCH STAT TABL UNPUB; Ministry of Health Labour and Welfare, SURV PHYS DENT PHARM; Ministry of Health Labour and Welfare, REP REG PUBL HLTH SE; Ministry of Health Labour and Welfare, SURV SUMM; Ministry of Internal Affairs and Communications, BAS RES REG; Ministry of Internal Affairs and Communications in Japan, ANN REP SOC WELF IND; Mitchell AD, 2008, HUM RESOUR HEALTH, V6, DOI 10.1186/1478-4491-6-29; Mutua MK, 2011, BMC PUBLIC HEALTH, V11, DOI 10.1186/1471-2458-11-6; National Institute of Infectious Diseases, INF AG SURV REP TOP, V35; Niel X, 2001, Cah Sociol Demogr Med, V41, P141; Odusanya OO, 2008, BMC PUBLIC HEALTH, V8, DOI 10.1186/1471-2458-8-381; Ohga A, 2005, JPN J MATERN HLTH, V45, P423; Okabe Nobuhiko, 2007, Uirusu, V57, P171, DOI 10.2222/jsv.57.171; Otaki J, 1998, ACAD MED, V73, P662, DOI 10.1097/00001888-199806000-00013; PAMPEL FC, 1986, DEMOGRAPHY, V23, P525, DOI 10.2307/2061349; Rammohan A, 2012, BMC PUBLIC HEALTH, V12, DOI 10.1186/1471-2458-12-336; Sakai R, 2014, J EPIDEMIOL, V24, P239, DOI 10.2188/jea.JE20130117; Sanou A, 2009, BMC INT HEALTH HUM R, V9, DOI 10.1186/1472-698X-9-S1-S10; Shimada Naoki, 2004, Nihon Koshu Eisei Zasshi, V51, P117; Speybroeck N, 2006, BACKGROUND PAPER PRE; Stordeur S, 2010, HUM RESOUR HEALTH, V8, DOI 10.1186/1478-4491-8-28; Takahashi K, 2011, BMC HEALTH SERV RES, V11, DOI 10.1186/1472-6963-11-254; Toyabe S, 2009, INT J EQUITY HEALTH, V8, DOI 10.1186/1475-9276-8-5; Vanasse Alain, 2007, Rural Remote Health, V7, P812; Vogel RL, 1998, INT J HEALTH SERV, V28, P183, DOI 10.2190/3B1X-EE5T-T7GR-KGUD; Waldhoer T, 1997, EUR J EPIDEMIOL, V13, P145, DOI 10.1023/A:1007359632218; World Health Organization (WHO), MEASL; Yang B M, 1989, Asia Pac J Public Health, V3, P68; Yang BM, 1989, ASIA-PAC J PUBLIC HE, V3, P85	84	0	0	JAPAN EPIDEMIOLOGICAL ASSOC	TOKYO	C/O UNIBO PRESS, HONGO MT BLDG 4F, 7-2-2 HONGO, BUNKYO-KU, TOKYO, 113-0033, JAPAN	0917-5040	1349-9092		J EPIDEMIOL	J. Epidemiol.	MAY	2015	25	5					359	369		10.2188/jea.JE20140121		11	Public, Environmental & Occupational Health	Public, Environmental & Occupational Health	CG8VB	WOS:000353591700003		
J	Nanri, H; Hara, M; Nishida, Y; Shimanoe, C; Nakamura, K; Higaki, Y; Imaizumi, T; Taguchi, N; Sakamoto, T; Horita, M; Shinchi, K; Kokaze, A; Tanaka, K				Nanri, Hinako; Hara, Megumi; Nishida, Yuichiro; Shimanoe, Chisato; Nakamura, Kazuyo; Higaki, Yasuki; Imaizumi, Takeshi; Taguchi, Naoto; Sakamoto, Tatsuhiko; Horita, Mikako; Shinchi, Koichi; Kokaze, Akatsuki; Tanaka, Keitaro			Dietary Patterns and Serum Gamma-Glutamyl Transferase in Japanese Men and Women	JOURNAL OF EPIDEMIOLOGY			English	Article						dietary pattern; gamma-glutamyl transferase; factor analysis	FOOD FREQUENCY QUESTIONNAIRE; YOUNG-ADULTS CARDIA; OXIDATIVE STRESS; ALANINE AMINOTRANSFERASE; METABOLIC SYNDROME; COFFEE CONSUMPTION; RISK DEVELOPMENT; LIVER-DISEASE; ASSOCIATION; POPULATION	Background: Although specific foods and nutrients have been examined as potential determinants of serum gamma-glutamyl transferase (GGT) concentrations, the relationship between dietary patterns and GGT remains unknown. The present cross-sectional study aimed to determine relationships between dietary patterns and GGT concentrations, and the effects of lifestyle factors on GGT. Methods: Relationships between dietary patterns and GGT were analyzed in 9803 Japanese individuals (3723 men and 6080 women age 40-69 years) without a history of liver diseases or elevated serum aminotransferase. We examined major dietary patterns by factor analysis of 46 items determined from a validated, short food frequency questionnaire. Results: We defined dietary patterns as healthy, Western, seafood, bread, and dessert. The healthy pattern was inversely related to GGT in men (odds ratio [OR] for highest vs lowest quartile, 0.72; 95% confidence interval [CI], 0.57-0.92; P < 0.01 for trend) and women (OR 0.82; 95% CI, 0.66-1.0; P = 0.05 for trend), whereas the seafood pattern was positively related to GGT in men (OR 1.27; 95% CI, 1.01-1.61; P = 0.03 for trend) and women (OR 1.21; 95% CI, 0.98-1.49; P = 0.05 for trend). Male-specific inverse associations with GGT were found for bread and dessert patterns (OR 0.63; 95% CI, 0.50-0.80 and OR 0.53; 95% CI, 0.41-0.68, respectively; P < 0.01 for both trends). Seafood or bread patterns and alcohol consumption significantly interacted with GGT in men (P = 0.03 and < 0.01 for interaction, respectively) and between the dessert pattern and body mass index or smoking habit in women (P = 0.03 and < 0.01, respectively, for interaction). Conclusions: Dietary patterns may be important determinants of GGT, and their possible clinical implications warrant further investigation.	[Nanri, Hinako; Kokaze, Akatsuki] Showa Univ, Sch Med, Dept Publ Hlth, Tokyo 1428555, Japan; [Hara, Megumi; Nishida, Yuichiro; Shimanoe, Chisato; Imaizumi, Takeshi; Taguchi, Naoto; Horita, Mikako; Tanaka, Keitaro] Saga Univ, Fac Med, Dept Prevent Med, Saga 840, Japan; [Nakamura, Kazuyo] St Marys Coll, Fac Nursing, Kurume, Fukuoka, Japan; [Higaki, Yasuki] Fukuoka Univ, Fac Sports & Hlth Sci, Lab Exercise Physiol, Fukuoka 81401, Japan; [Sakamoto, Tatsuhiko] Fukuoka Prefectural Govt, Chikushi Off Hlth Human Serv & Environm Issues, Fukuoka, Japan; [Shinchi, Koichi] Saga Univ, Fac Med, Div Int Hlth & Nursing, Saga 840, Japan	Nanri, H (reprint author), Showa Univ, Sch Med, Dept Publ Hlth, Shinagawa Ku, 1-5-8 Hatanodai, Tokyo 1428555, Japan.	nanrih@med.showa-u.ac.jp			Ministry of Education, Culture, Sports, Science and Technology, Japan [17015018, 221S0001, 20249038, 19200049, 20689014, 18790380, 25870517]	This study was supported in part by Grants-in-Aid for Scientific Research on Special Priority Areas of Cancer (No. 17015018) and Innovative Areas (No. 221S0001), Scientific Research (A) (No. 20249038), Strategic Research Infrastructure (No. 19200049), and Young Scientists (A) (No. 20689014), (B) (No. 18790380), (B) (No. 25870517) from the Ministry of Education, Culture, Sports, Science and Technology, Japan. We are grateful to Shinkan Tokudome at the National Institute of Health and Nutrition (formerly Nagoya City University), Chiho Goto at Nagoya Bunri University, Nahomi Imaeda at Nagoya Women's University, Yuko Tokudome at Nagoya University of Arts and Sciences, Masato Ikeda at the University of Occupational and Environmental Health, and Shinzo Maki at the Aichi Prefectural Dietetic Association for granting us permission to use the FFQ and for providing the SAS program for estimating nutrient intake. The contributions of authors were as follows: H.N. contributed to data collection, data analysis, and manuscript preparation; Y.N., C.S., K.N., T.I., N.T., T.S., M. Horita, K.S., and A.K. contributed to data collection; M. Hara and Y.H. contributed to study design, data collection, and data management; and K.T. contributed to study design, data collection, statistical programming support, and manuscript preparation.	Akter S, 2013, NUTR METAB, V10, DOI 10.1186/1743-7075-10-30; Hara M, 2010, J EPIDEMIOL, V20, P40, DOI 10.2188/jea.JE20090062; Lee DH, 2004, CLIN CHEM, V50, P582, DOI 10.1373/clinchem.2003.028852; Lee DH, 2005, ATHEROSCLEROSIS, V178, P327, DOI 10.1016/j.atherosclerosis.2004.08.027; Tokudome Y, 2005, J EPIDEMIOL, V15, P135, DOI 10.2188/jea.15.135; Mente A, 2009, ARCH INTERN MED, V169, P659, DOI 10.1001/archinternmed.2009.38; Lee S, 2007, HEPATOLOGY, V45, P841, DOI 10.1002/hep.21645; Lee DH, 2004, AM J CLIN NUTR, V79, P600; Ruhl CE, 2009, GASTROENTEROLOGY, V136, P477, DOI 10.1053/j.gastro.2008.10.052; Lee DH, 2004, FREE RADICAL RES, V38, P535, DOI 10.1080/10715760410001694026; Valtuena S, 2008, AM J CLIN NUTR, V87, P1290; Karp DR, 2001, J BIOL CHEM, V276, P3798, DOI 10.1074/jbc.M008484200; Ruttmann E, 2005, CIRCULATION, V112, P2130, DOI 10.1161/CIRCULATIONAHA.105.552547; Ottestad I, 2012, BRIT J NUTR, V108, P315, DOI 10.1017/S0007114511005484; Yamada J, 2006, ATHEROSCLEROSIS, V189, P198, DOI 10.1016/j.atherosclerosis.2005.11.036; Hamajima N, 2007, ASIAN PAC J CANCER P, V8, P317; Imaeda N, 2007, J EPIDEMIOL, V17, P100, DOI 10.2188/jea.17.100; Breitling LP, 2010, PLOS ONE, V5; El-Badry AM, 2007, J HEPATOL, V47, P718, DOI 10.1016/j.jhep.2007.08.005; Fujimoto S, 1968, Nihon Eiseigaku Zasshi, V23, P443; Goto C., 2006, Scandinavian Journal of Food & Nutrition, V50, P77, DOI 10.1080/11026480600568720; Gunter EW, 1996, LAB PROCEDURES USED; Health Promortion and Nutrition Division Health Service Bureau Ministry of Health and Welfare of Japan, 1994, 5 REV REC DIET ALL J; Japan Science and Technology Agency, 2000, STAND TABL FOOD COMP; Lawlor DA, 2005, AM J EPIDEMIOL, V161, P1081, DOI 10.1093/aje/kwi125; NAKAJIMA T, 1994, AM J CLIN NUTR, V60, P87; Nanri A, 2008, DIABETES CARE, V31, P1568, DOI 10.2337/dc08-0297; Nanri H, 2011, J EPIDEMIOL, V21, P122, DOI 10.2188/jea.JE20100110; Park EY, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063439; Patere SN, 2011, INDIAN J PHARM SCI, V73, P152, DOI 10.4103/0250-474X.91578; RYBACK RS, 1982, JAMA-J AM MED ASSOC, V248, P2261, DOI 10.1001/jama.248.18.2261; Simopoulos A. P., 1999, AM J CLIN NUTR, V70, P560; Tanaka K, 1998, INT J EPIDEMIOL, V27, P438, DOI 10.1093/ije/27.3.438; Tokudome Shinkan, 2004, Asian Pac J Cancer Prev, V5, P40; Tzima N, 2009, NUTR METAB, V6, DOI 10.1186/1743-7075-6-30; Wang ZJ, 2012, BMC ENDOCR DISORD, V12, DOI 10.1186/1472-6823-12-24	36	0	0	JAPAN EPIDEMIOLOGICAL ASSOC	TOKYO	C/O UNIBO PRESS, HONGO MT BLDG 4F, 7-2-2 HONGO, BUNKYO-KU, TOKYO, 113-0033, JAPAN	0917-5040	1349-9092		J EPIDEMIOL	J. Epidemiol.	MAY	2015	25	5					378	386		10.2188/jea.JE20140158		9	Public, Environmental & Occupational Health	Public, Environmental & Occupational Health	CG8VB	WOS:000353591700005		
J	Chiang, CF; Singeo, ST; Yatsuya, H; Honjo, K; Mita, T; Ikerdeu, E; Cui, RZ; Li, YY; Watson, BM; Ngirmang, G; Iso, H; Aoyama, A				Chiang, Chifa; Singeo, Singeru Travis, Jr.; Yatsuya, Hiroshi; Honjo, Kaori; Mita, Takashi; Ikerdeu, Edolem; Cui, Renzhe; Li, Yuanying; Watson, Berry Moon; Ngirmang, Gregorio; Iso, Hiroyasu; Aoyama, Atsuko			Profile of Non-communicable Disease Risk Factors Among Young People in Palau	JOURNAL OF EPIDEMIOLOGY			English	Article						non-communicable disease; WHO STEPS; obesity; tobacco use; Pacific islanders		Background: Although non-communicable diseases (NCDs) have become the predominant health problems of Palauan society, there have been no comprehensive data on NCD risk factors available to develop effective control strategies. Therefore, the first Palauan national STEPwise approach to risk factor Surveillance (STEPS) was completed in mid-2013 to provide information on its adult population aged 25 to 64 years. This study aims to obtain corresponding data from the younger adults aged 18 to 24 years, who remained to be surveyed. Methods: We conducted an epidemiological study, targeting the 18- to 24-year-old age group. A survey station and a mobile team were established to recruit voluntary participants dwelling in Koror. A slightly modified WHO STEPS instrument was used, including a structured questionnaire for behavioral risk factors, physical measurements, and blood tests. Results: A total of 356 young people were recruited during the survey. In both sexes, nearly half of the participants were overweight/obese. The prevalence of hypertension was higher in men than in women (17.6% vs 1.7%). Raised blood glucose and impaired fasting glucose were observed in 3.5% and 5.2% of the total participants, respectively. About 36% of the subjects were observed to have raised levels of total cholesterol. More than 70% of the young people were current tobacco users, in terms of all kinds of tobacco products. Conclusions: The current survey, for the first time, revealed a high prevalence of NCD risk factors, especially overweight/obesity and tobacco use, among young people in Palau. This indicates that swift measures against NCDs are required even in this young age group.	[Chiang, Chifa; Yatsuya, Hiroshi; Aoyama, Atsuko] Nagoya Univ, Sch Med, Dept Publ Hlth & Hlth Syst, Nagoya, Aichi 4668550, Japan; [Singeo, Singeru Travis, Jr.; Ikerdeu, Edolem; Watson, Berry Moon; Ngirmang, Gregorio] Minist Hlth, Koror, Palau; [Yatsuya, Hiroshi; Li, Yuanying] Fujita Hlth Univ, Sch Med, Dept Publ Hlth, Toyoake, Aichi 47011, Japan; [Honjo, Kaori; Mita, Takashi] Osaka Univ, Global Collaborat Ctr, Suita, Osaka, Japan; [Mita, Takashi] Osaka Univ, Inst Acad Initiat, Suita, Osaka, Japan; [Cui, Renzhe; Iso, Hiroyasu] Osaka Univ, Publ Hlth Grad Sch Med, Suita, Osaka, Japan	Chiang, C (reprint author), Nagoya Univ, Sch Med, Dept Publ Hlth & Hlth Syst, Showa Ku, 65 Tsurumai Cho, Nagoya, Aichi 4668550, Japan.	keihatsu@med.nagoya-u.ac.jp		Iso, Hiroyasu/0000-0002-9241-7289	Ministry of Health, Labour and Welfare, Government of Japan [H24-chikyukibo-ippan-004]	The authors wish to thank staff members of the Health Policy, Research, and Development (HPRD) office and the NCD Unit, Ministry of Health, Palau, for assistance in data collection and for providing valuable advice during the survey process. Appreciation is also given to the President, the Dean, and other members of Palau Community College for their great help in preparation of the venue and promotion for the survey. This study was supported by the Health and Labour Sciences Research Grants for Research on Global Health Issues (H24-chikyukibo-ippan-004) to A.A. from the Ministry of Health, Labour and Welfare, Government of Japan.	Chobanian AV, 2003, JAMA-J AM MED ASSOC, V289, P2560, DOI 10.1001/jama.289.19.2560; Armstrong Timothy, 2003, Ethn Dis, V13, pS13; Cash H, 2012, PALAU EPIDEMIOLOGICA; HANKIN J, 1970, AM J CLIN NUTR, V23, P346; HANKIN JH, 1972, AM J CLIN NUTR, V25, P348; Health United States, 2014, HLTH US 2013 SPEC FE; LABARTHE D, 1973, AM J EPIDEMIOL, V98, P161; Ministry of Health Labour and Welfare, 2013, NAT HLTH NUTR SURV J; Ministry of Health Republic of the Marshall Islands, 2007, REP MARSH ISL NCD RI; National Cholesterol Education Program (NCEP); Expert Panel on Detection Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III), 2002, CIRCULATION, V106, P3143, DOI DOI 10.1001/ARCHINTE.1991.00400060019005; World Health Organization, 2006, DEF DIAGN DIAB MELL	11	1	1	JAPAN EPIDEMIOLOGICAL ASSOC	TOKYO	C/O UNIBO PRESS, HONGO MT BLDG 4F, 7-2-2 HONGO, BUNKYO-KU, TOKYO, 113-0033, JAPAN	0917-5040	1349-9092		J EPIDEMIOL	J. Epidemiol.	MAY	2015	25	5					392	397		10.2188/jea.JE20140156		6	Public, Environmental & Occupational Health	Public, Environmental & Occupational Health	CG8VB	WOS:000353591700007		
J	Islam, TM; Tareque, MI; Sugawa, M; Kawahara, K				Islam, Towfiqua Mahfuza; Tareque, Md. Ismail; Sugawa, Makiko; Kawahara, Kazuo			Correlates of Intimate Partner Violence Against Women in Bangladesh	JOURNAL OF FAMILY VIOLENCE			English	Article						Intimate partner violence; Parental ipv; Justified wife beating; Women; Bangladesh	RURAL BANGLADESH; PHYSICAL VIOLENCE; DOMESTIC VIOLENCE; SPOUSAL VIOLENCE; PREVALENCE; EXPERIENCES; COMMUNITY; HUSBANDS; MARRIAGE; RISK	This study uses the Bangladesh Demographic and Health Survey-2007 to identify factors associated with Intimate Partner Violence (IPV) for currently married Bangladeshi women. Twenty five percent of women reported experiencing at least one form of IPV. The most prevalent form of IPV is slapping; and, according to respondents, the main reason given for IPV is without any reason. However, results show that women who think their husbands are justified in beating them, and who witnessed their fathers hit or beat their mothers, are more likely to experience IPV. Results revealed that such women are, respectively, 1.21 and 2.37 times more likely to experience violence than their counterparts. Therefore, these two important factors need urgent attention to reduce IPV against women in Bangladesh.	[Islam, Towfiqua Mahfuza; Sugawa, Makiko; Kawahara, Kazuo] Tokyo Med & Dent Univ, Grad Sch Med & Dent Sci, Dept Hlth Care Management & Planning, Bunkyo Ku, Tokyo 1138519, Japan; [Tareque, Md. Ismail] Rajshahi Univ, Dept Populat Sci & Human Resource Dev, Rajshahi 6205, Bangladesh	Islam, TM (reprint author), Tokyo Med & Dent Univ, Grad Sch Med & Dent Sci, Dept Hlth Care Management & Planning, Bunkyo Ku, 1-5-45 Yushima, Tokyo 1138519, Japan.	tmisathee@yahoo.com					Ahmed K., 2004, SOC SCI MED, V59, P311, DOI DOI 10.1016/J.S0CSCIMED.2004.01.020; STRAUS MA, 1979, J MARRIAGE FAM, V41, P75, DOI 10.2307/351733; Schuler SR, 1996, SOC SCI MED, V43, P1729, DOI 10.1016/S0277-9536(96)00068-8; Johnson KB, 2009, J INTERPERS VIOLENCE, V24, P977, DOI 10.1177/0886260508319368; Sabarwal S, 2012, J BIOSOC SCI, V44, P43, DOI 10.1017/S002193201100037X; Dalal K, 2009, J BIOSOC SCI, V41, P561, DOI 10.1017/S0021932009990046; Johnston HB, 2008, J HEALTH POPUL NUTR, V26, P366; Rahman M, 2011, J FAM VIOLENCE, V26, P411, DOI 10.1007/s10896-011-9375-3; Naved RT, 2005, STUD FAMILY PLANN, V36, P289, DOI 10.1111/j.1728-4465.2005.00071.x; Schuler SR, 2008, STUD FAMILY PLANN, V39, P49, DOI 10.1111/j.1728-4465.2008.00150.x; Ahmed SM, 2005, J HEALTH POPUL NUTR, V23, P95; Koenig MA, 2003, DEMOGRAPHY, V40, P269, DOI 10.2307/3180801; Kaur R, 2010, ASIA-PAC J PUBLIC HE, V22, P242, DOI 10.1177/1010539509343949; Devries KM, 2010, REPROD HEALTH MATTER, V18, P158, DOI 10.1016/S0968-8080(10)36533-5; Naved RT, 2010, J FAM ISSUES, V31, P830, DOI 10.1177/0192513X09357554; Okenwa LE, 2009, J FAM VIOLENCE, V24, P517, DOI 10.1007/s10896-009-9250-7; Naved RT, 2006, SOC SCI MED, V62, P2917, DOI 10.1016/j.soescimed.2005.12.001; Black M. C., 2011, THE NATIONAL INTIMAT; Egeland B., 1993, CURRENT CONTROVERSIE, P197; Ellsberg M, 2000, SOC SCI MED, V51, P1595, DOI 10.1016/S0277-9536(00)00056-3; Field E, 2008, J POLIT ECON, V116, P881, DOI 10.1086/593333; Garcia Moreno C., 2005, WHO MULTICOUNTRY STU; Hadi S. T., 2009, Bangladesh e-Journal of Sociology, V6, P4; Heise L., 1999, POPULATION REPORTS S, V11; International Center for Research on Women [ICRW], 2009, INTIMATE PARTNER VIO; Jensen R, 2003, GENDER DEV, V11, P9, DOI DOI 10.1080/741954311; Johnson K., 2004, PROFILIN DOMESTIC VI; Kish L., 1965, SURVEY SAMPLING; NIPORT Mitra and Associates & Macro International, 2009, BANGLADESH DEMOGRAPH; NIPORT Mitra and Associates & ORC Macro, 2005, BANGLADESH DEMOGRAPH; Rahman M, 2012, BMC PUBLIC HEALTH, V12, DOI 10.1186/1471-2458-12-913; Straus M. A., 1990, PHYSICCAL VIOLENCE I; United Nations Development Programme, 2006, HUMAN DEVELOPMENT RE; Uthman OA, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027738; World Health Organization, 2002, WORLD REPORT ON VIOL; World Health Organization, 2012, PLAN OF ACTION FOR T; Yuksel-Kaptanoglu I, 2012, J INTERPERS VIOLENCE, V27, P2743, DOI 10.1177/0886260512438283; Zaman H, 1999, WOMEN STUD INT FORUM, V22, P37, DOI 10.1016/S0277-5395(98)00093-4	38	0	0	SPRINGER/PLENUM PUBLISHERS	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0885-7482	1573-2851		J FAM VIOLENCE	J. Fam. Violence	MAY	2015	30	4					433	444		10.1007/s10896-015-9683-0		12	Psychology, Clinical; Family Studies	Psychology; Family Studies	CG7TG	WOS:000353507400003		
J	Umeda, M; Kawakami, N; Kessler, RC; Miller, E				Umeda, Maki; Kawakami, Norito; Kessler, Ronald C.; Miller, Elizabeth		World Mental Hlth Japan Survey Grp	Childhood Adversities and Adult Use of Potentially Injurious Physical Discipline in Japan	JOURNAL OF FAMILY VIOLENCE			English	Article						Intergenerational transmission; Child physical abuse; Childhood adversity; Japan; Physical discipline; World Mental Health Survey	LONG-TERM CONSEQUENCES; MENTAL-HEALTH SURVEYS; INTERGENERATIONAL TRANSMISSION; CORPORAL PUNISHMENT; RISK-FACTORS; DOMESTIC VIOLENCE; INTERPARENTAL VIOLENCE; ABUSE; MALTREATMENT; CHILDREN	This study examined the intergenerational continuity of potentially injurious physical discipline of children in a community sample from Japan and the confounding effects of childhood adversities on the continuity. Using the data from the World Mental Health Japan Survey (n = 1186), we found that experience of physical discipline as children was significantly associated with the use of physical discipline as parents independent of other childhood adversities. This association was also independent of the respondents' mental disorders and household income. No significant gender differences were found in the associations between childhood physical discipline and adult perpetration. The current study on Japan provided empirical support consistent with results found in other countries regarding the intergenerational transmission of child physical abuse.	[Umeda, Maki; Kawakami, Norito] Univ Tokyo, Grad Sch Med, Dept Mental Hlth, Bunkyo Ku, Tokyo, Japan; [Kessler, Ronald C.] Harvard Univ, Sch Med, Dept Hlth Care Policy, Boston, MA 02115 USA; [Miller, Elizabeth] Univ Pittsburgh, Childrens Hosp Pittsburgh, Sch Med, Div Adolescent & Young Adult Med, Pittsburgh, PA 15213 USA	Umeda, M (reprint author), Univ Tokyo, Grad Sch Med, Dept Mental Hlth, Bunkyo Ku, 7-3-1 Hongo, Tokyo, Japan.	makiumeda-tky@umin.ac.jp			Grant for Research on Psychiatric and Neurological Diseases and Mental Health from the Japan Ministry of Health, Labour, and Welfare [H13-SHOGAI-023, H14-TOKUBETSU-026, H16-KOKORO-013, H19-KOKORO-IPPAN-011]; US National Institute of Mental Health [R01MH070884]; John D. and Catherine T. MacArthur Foundation; Pfizer Foundation; US Public Health Service [R13-MH066849, R01-MH069864, R01 DA016558]; Fogarty International Center [FIRCA R01-TW006481]; Pan American Health Organization; Eli Lilly and Company; Ortho-McNeil Pharmaceutical, Inc.; GlaxoSmithKline; Bristol-Myers Squibb	The study was supported by the Grant for Research on Psychiatric and Neurological Diseases and Mental Health from the Japan Ministry of Health, Labour, and Welfare (H13-SHOGAI-023, H14-TOKUBETSU-026, H16-KOKORO-013, H19-KOKORO-IPPAN-011). We would like to thank staff members, filed coordinators, and interviewers of the WMH Japan 2002-2006 Survey. The WMH Japan 2002-2006 Survey was carried out in conjunction with the World Health Organization World Mental Health (WMH) Survey Initiative. We also thank the WMH staff for assistance with instrumentation, fieldwork, and data analysis. These activities were supported by the US National Institute of Mental Health (R01MH070884), the John D. and Catherine T. MacArthur Foundation, the Pfizer Foundation, the US Public Health Service (R13-MH066849, R01-MH069864, and R01 DA016558), the Fogarty International Center (FIRCA R01-TW006481), the Pan American Health Organization, Eli Lilly and Company, Ortho-McNeil Pharmaceutical, Inc., GlaxoSmithKline, and Bristol-Myers Squibb. A complete list of WMH publications can be found at http://www.hcp.med.harvard.edu/wmh/publications.php.	Black DA, 2001, AGGRESS VIOLENT BEH, V6, P121, DOI 10.1016/S1359-1789(00)00021-5; STRAUS MA, 1979, J MARRIAGE FAM, V41, P75, DOI 10.2307/351733; Jouriles EN, 2008, VIOLENCE VICTIMS, V23, P221, DOI 10.1891/0886-6708.23.2.221; Turner HA, 2006, SOC SCI MED, V62, P13, DOI 10.1016/j.socscimed.2005.05.030; Merikangas KR, 2007, ARCH GEN PSYCHIAT, V64, P1180, DOI 10.1001/archpsyc.64.10.1180; Wong WCW, 2009, SOC SCI MED, V68, P1819, DOI 10.1016/j.socscimed.2009.03.001; Coulton CJ, 2007, CHILD ABUSE NEGLECT, V31, P1117, DOI 10.1016/j.chiabu.2007.03.023; Lee BJ, 1999, CHILD YOUTH SERV REV, V21, P755, DOI 10.1016/S0190-7409(99)00053-5; Gage AJ, 2010, CHILD ABUSE NEGLECT, V34, P523, DOI 10.1016/j.chiabu.2009.12.004; Currie J, 2010, CHILD MALTREATMENT, V15, P111, DOI 10.1177/1077559509355316; ANDREASEN NC, 1977, ARCH GEN PSYCHIAT, V34, P1229; Durrant JE, 2008, J DEV BEHAV PEDIATR, V29, P55, DOI 10.1097/DBP.0b013e318135448a; Dixon L, 2005, J CHILD PSYCHOL PSYC, V46, P47, DOI 10.1111/j.1469-7610.2004.00339.x; Scott KM, 2008, PSYCHOSOM MED, V70, P1035, DOI 10.1097/PSY.0b013e318187a2fb; Cicchetti D, 2005, ANNU REV CLIN PSYCHO, V1, P409, DOI 10.1146/annurev.clinpsy.1.102803.144029; Herrenkohl TI, 2008, TRAUMA VIOLENCE ABUS, V9, P84, DOI 10.1177/1524838008314797; Haro JM, 2006, INT J METH PSYCH RES, V15, P167, DOI 10.1002/mpr.196; Yamamura E, 2011, ECON EDUC REV, V30, P380, DOI 10.1016/j.econedurev.2010.11.006; Miller E, 2011, J EPIDEMIOL COMMUN H, V65, P1006, DOI 10.1136/jech.2009.105429; Dong MX, 2004, CHILD ABUSE NEGLECT, V28, P771, DOI 10.1016/j.chiabu.2004.01.008; Dube SR, 2003, PREV MED, V37, P268, DOI 10.1016/S0091-7435(03)00123-3; Gershoff ET, 2002, PSYCHOL BULL, V128, P539, DOI 10.1037//0033-2909.128.4.539; Roustit C, 2009, J EPIDEMIOL COMMUN H, V63, P563, DOI 10.1136/jech.2008.077750; Renner LM, 2006, CHILD ABUSE NEGLECT, V30, P599, DOI 10.1016/j.chiabu.2005.12.005; Widom CS, 1996, PSYCHOL ASSESSMENT, V8, P412, DOI 10.1037//1040-3590.8.4.412; KAUFMAN J, 1987, AM J ORTHOPSYCHIAT, V57, P186; Shaffer A, 2008, CHILD ABUSE NEGLECT, V32, P682, DOI 10.1016/j.chiabu.2007.09.010; Milner JS, 2010, CHILD ABUSE NEGLECT, V34, P332, DOI 10.1016/j.chiabu.2009.09.017; Gracia E, 2008, CHILD ABUSE NEGLECT, V32, P1058, DOI 10.1016/j.chiabu.2008.05.004; Plant DT, 2013, PSYCHOL MED, V43, P519, DOI 10.1017/S0033291712001298; Cullerton-Sen C, 2008, CHILD DEV, V79, P1736, DOI 10.1111/j.1467-8624.2008.01222.x; Heyman RE, 2002, J MARRIAGE FAM, V64, P864, DOI 10.1111/j.1741-3737.2002.00864.x; Sidebotham P, 2006, CHILD ABUSE NEGLECT, V30, P497, DOI 10.1016/j.chiabu.2005.11.005; DODGE KA, 1995, J ABNORM PSYCHOL, V104, P632, DOI 10.1037//0021-843X.104.4.632; Kessler RC, 1997, PSYCHOL MED, V27, P1101, DOI 10.1017/S0033291797005588; Akmatov MK, 2011, INT J EPIDEMIOL, V40, P219, DOI 10.1093/ije/dyq168; Courtney ME, 2001, CHILD WELFARE, V80, P685; Kawakami N, 2005, PSYCHIAT CLIN NEUROS, V59, P441, DOI 10.1111/j.1440-1819.2005.01397.x; Kessler RC, 2004, INT J METH PSYCH RES, V13, P93, DOI 10.1002/mpr.168; Ertem IO, 2000, LANCET, V356, P814, DOI 10.1016/S0140-6736(00)02656-8; Gilbert R, 2009, LANCET, V373, P68, DOI 10.1016/S0140-6736(08)61706-7; Lee V, 2007, CHILD MALTREATMENT, V12, P281, DOI 10.1177/1077559507303778; Zielinski DS, 2009, CHILD ABUSE NEGLECT, V33, P666, DOI 10.1016/j.chiabu.2009.09.001; Kessler RC, 2010, BRIT J PSYCHIAT, V197, P378, DOI 10.1192/bjp.bp.110.080499; Pears KC, 2001, CHILD ABUSE NEGLECT, V25, P1439, DOI 10.1016/S0145-2134(01)00286-1; Berlin LJ, 2011, CHILD DEV, V82, P162, DOI 10.1111/j.1467-8624.2010.01547.x; Beller E, 2006, FUTURE CHILD, V16, P19, DOI 10.1353/foc.2006.0012; Benjet C, 2010, J PSYCHIATR RES, V44, P732, DOI 10.1016/j.jpsychires.2010.01.004; Fujiwara T, 2011, J PSYCHIATR RES, V45, P481, DOI 10.1016/j.jpsychires.2010.08.002; Banyard Victoria L, 2003, Child Maltreat, V8, P334, DOI 10.1177/1077559503257106; BAUMRIND D, 1994, FAM RELAT, V43, P360, DOI 10.2307/585365; BELSKY J, 1993, PSYCHOL BULL, V114, P413, DOI 10.1037//0033-2909.114.3.413; Cappell C., 1990, J FAMILY VIOLENCE, V5, P135, DOI 10.1007/BF00978516; Chiba H., 2006, SYUKUTOKU SHINRI KEN, V3, P19; Coohey C, 1997, CHILD ABUSE NEGLECT, V21, P1081, DOI 10.1016/S0145-2134(97)00067-7; Dearter-Deckard K., 2003, J FAMILY PSYCHOL, V17, P351, DOI [10.1037/0893-3200.17.3.351, DOI 10.1037/0893-3200.17.3.351]; DOUMAS D, 1994, J FAM VIOLENCE, V9, P157, DOI 10.1007/BF01531961; Dussich JPJ, 2001, INT J OFFENDER THER, V45, P278, DOI 10.1177/0306624X01453002; Ferrari AM, 2002, CHILD ABUSE NEGLECT, V26, P793, DOI 10.1016/S0145-2134(02)00345-9; Fisher HL, 2011, CHILD ABUSE NEGLECT, V35, P117, DOI 10.1016/j.chiabu.2010.10.003; Fujiwara T, 2010, PSYCHOLOGIA, V53, P211; Gustafson P, 2005, STAT MED, V24, P2089, DOI 10.1002/sim.2093; Haapasalo J., 1999, CHILD ABUSE REV, V8, P231, DOI DOI 10.1002/(SICI)1099-0852(199907/08)8:4\LT231::AID-CAR547\GT3.0.CO;2-C; Iwai H., 2010, JGSS RES SERIES, V10, P49; Jakupcevic KK, 2011, CROAT MED J, V52, P25, DOI 10.3325/cmj.2011.52.25; Kessler RC, 2008, WHO WORLD MENTAL HLT; Kim J, 2009, CHILD YOUTH SERV REV, V31, P761, DOI 10.1016/j.childyouth.2009.02.002; Lee S. J., 2010, J INTERPERS VIOLENCE, V26, P71; Ma YT, 2011, CHILD ABUSE NEGLECT, V35, P592, DOI 10.1016/j.chiabu.2011.04.006; MALINOSKYRUMMELL R, 1993, PSYCHOL BULL, V114, P68, DOI 10.1037//0033-2909.114.1.68; Medley A, 2009, J AFFECT DISORDERS, V113, P244, DOI 10.1016/j.jad.2008.05.020; Milner J. S., 1990, J FAMILY VIOLENCE, V5, P15, DOI 10.1007/BF00979136; Ministry of Health Labor and Welfare Japan, 2011, INV MURD CAS CHILD M; Ministry of Health Labor andWelfare Japan, 2013, SOC CAR SERV CHILDR; Montes MP, 2001, CHILD ABUSE NEGLECT, V25, P1015; Muller RT, 1996, J FAM PSYCHOL, V10, P474, DOI 10.1037/0893-3200.10.4.474; MULLER RT, 1995, CHILD ABUSE NEGLECT, V19, P1323, DOI 10.1016/0145-2134(95)00103-F; Newcomb MD, 2001, CHILD ABUSE NEGLECT, V25, P1219, DOI 10.1016/S0145-2134(01)00267-8; Saimura J., 2011, JUDICIAL SCRIVENER, V467, P10; Slep AMS, 2007, J CONSULT CLIN PSYCH, V75, P739, DOI 10.1037/0022-006X.75.5.739; Straus MA, 2000, CHILD ABUSE NEGLECT, V24, P1109, DOI 10.1016/S0145-2134(00)00180-0; Straus MA, 1990, PHYS VIOLENCE AM FAM	82	0	0	SPRINGER/PLENUM PUBLISHERS	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0885-7482	1573-2851		J FAM VIOLENCE	J. Fam. Violence	MAY	2015	30	4					515	527		10.1007/s10896-015-9692-z		13	Psychology, Clinical; Family Studies	Psychology; Family Studies	CG7TG	WOS:000353507400011		
J	Ikeda, N; Konno, T				Ikeda, Natsumi; Konno, Tsutomu			Highly regio- and stereoselective hydrosilylation of beta-fluoroalkylated alpha,beta-unsaturated ketones	JOURNAL OF FLUORINE CHEMISTRY			English	Article						Hydrosilylation; beta-Fluoroalkylated alpha,beta-unsaturated ketones; Dicobalt octacarbonyl; Regioselective; Stereoselective; Aldol reaction	SILYL ENOL ETHERS; MUKAIYAMA ALDOL REACTION; INTERNAL ACETYLENE DERIVATIVES; QUATERNARY CARBON CENTERS; TRIFLUOROMETHYL KETONES; CASCADE REACTION; MICHAEL REACTION; COMPLEXES; CONSTRUCTION; 1,4-HYDROSILYLATION	Treatment of beta-fluoroalkylated alpha,beta-unsaturated ketones with 10.2 equiv of triethylsilane in the presence of 3 mol% of Co-2(CO)(8) in dichloroethane at the reflux temperature for 4 h gave 1,4-hydrosilylated adducts in a highly regio- and stereoselective manner. Thus-obtained silyl enol ethers underwent a smooth Mukaiyama aldol reaction with benzaldehyde in the presence of 1.2 equiv of TiCl4 in CH2Cl2 at -78 degrees C for 1 h, affording the corresponding alpha-(2,2,2-trifluoroethyl)-beta-hydroxy ketones with high syn stereoselectivity in good yields. (C) 2015 Elsevier B.V. All rights reserved.	[Ikeda, Natsumi; Konno, Tsutomu] Kyoto Inst Technol, Dept Chem & Mat Technol, Sakyo Ku, Kyoto 6068585, Japan	Konno, T (reprint author), Kyoto Inst Technol, Dept Chem & Mat Technol, Sakyo Ku, Kyoto 6068585, Japan.	konno@kit.ac.jp					Anada M, 2006, CHEM PHARM BULL, V54, P1622, DOI 10.1248/cpb.54.1622; YAMAZAKI T, 1995, J ORG CHEM, V60, P6046, DOI 10.1021/jo00124a013; Konno T, 2014, TETRAHEDRON, V70, P2455, DOI 10.1016/j.tet.2014.02.015; Livieri A, 2012, CHEM-EUR J, V18, P11662, DOI 10.1002/chem.201201214; Nihei T, 2014, ORG LETT, V16, P4170, DOI 10.1021/ol5018596; Konno T, 2003, TETRAHEDRON, V59, P7571, DOI 10.1016/S0040-4020(03)01199-2; Pham PV, 2011, ANGEW CHEM INT EDIT, V50, P6119, DOI 10.1002/anie.201101861; Lyons TW, 2013, CHEM-EUR J, V19, P10124, DOI 10.1002/chem.201301502; Shibatomi K, 2008, ANGEW CHEM INT EDIT, V47, P5796, DOI 10.1002/anie.200801682; Liu Y, 2008, ORG LETT, V10, P1605, DOI 10.1021/ol800298n; Konno T, 2006, J FLUORINE CHEM, V127, P36, DOI 10.1016/j.jfluchem.2005.09.015; Heng R, 2011, CHEM COMMUN, V47, P3296, DOI 10.1039/c0cc04725b; Inamoto Y, 2012, ORG LETT, V14, P1168, DOI 10.1021/ol3001443; Okamoto K, 2007, ORG LETT, V9, P5067, DOI 10.1021/ol702357n; Chen Q, 2014, CHEM COMMUN, V50, P3344, DOI 10.1039/c3cc49524h; Chae JH, 2003, J FLUORINE CHEM, V120, P185, DOI 10.1016/S0022-1139(02)00328-7; Li L, 2014, J ORG CHEM, V79, P5145, DOI 10.1021/jo500713f; Schnermann MJ, 2012, ANGEW CHEM INT EDIT, V51, P9581, DOI 10.1002/anie.201205001; Sedrani R, 2003, J AM CHEM SOC, V125, P3849, DOI 10.1021/ja021327y; Mei YJ, 2010, J AM CHEM SOC, V132, P12871, DOI 10.1021/ja107197p; Gupta V, 2012, ANGEW CHEM INT EDIT, V51, P12609, DOI 10.1002/anie.201207058; Kimura M, 2004, ORG LETT, V6, P4651, DOI 10.1021/ol0481941; Anada M, 2007, ORG LETT, V9, P4559, DOI 10.1021/o1702019b; Vita MV, 2013, ORG LETT, V15, P3246, DOI 10.1021/ol401229v; Dunsford JJ, 2011, J ORGANOMET CHEM, V696, P188, DOI 10.1016/j.jorganchem.2010.08.045; Arai T, 2008, CHEM-EUR J, V14, P882, DOI 10.1002/chem.200701371; Huckaba AJ, 2013, ORGANOMETALLICS, V32, P6248, DOI 10.1021/om400452q; Jung ME, 2012, ORG LETT, V14, P4898, DOI 10.1021/ol302234a; Jankowska J, 2007, J ORG CHEM, V72, P2228, DOI 10.1021/jo0621470; Zhu LZ, 2013, J ORG CHEM, V78, P7912, DOI 10.1021/jo401105q; Boxer MB, 2006, J AM CHEM SOC, V128, P48, DOI 10.1021/ja054725k; Benohoud M, 2011, CHEM-EUR J, V17, P8404, DOI 10.1002/chem.201100655; Konno T, 2009, ORG BIOMOL CHEM, V7, P1167, DOI 10.1039/b819476a; Basu S, 2014, ORG LETT, V16, P274, DOI 10.1021/ol403275k; BURK MJ, 1991, J AM CHEM SOC, V113, P2209, DOI 10.1021/ja00006a045; CHAN TH, 1979, TETRAHEDRON LETT, P4029; Duan XH, 2010, ORG LETT, V12, P2238, DOI 10.1021/ol100592j; Funabiki K, 2003, J ORG CHEM, V68, P2853, DOI 10.1021/jo026697j; Hajra S, 2007, J ORG CHEM, V72, P4872, DOI 10.1021/jo070614n; Hamada T, 2003, J AM CHEM SOC, V125, P2989, DOI 10.1021/ja028698z; Konkol LC, 2009, ORG LETT, V11, P5550, DOI 10.1021/ol902400q; Konno T, 2012, BEILSTEIN J ORG CHEM, V8, P2207, DOI 10.3762/bjoc.8.249; Konno T., 2014, SYNLETT, P1350; Konno T, 2004, CHEM COMMUN, P690, DOI 10.1039/b316065c; Konno T, 2008, SYNTHESIS-STUTTGART, P564, DOI 10.1055/s-2008-1032143; Lee D., 2005, TETRAHEDRON LETT, V46, P2036; Lipshutz BH, 2000, TETRAHEDRON, V56, P2779, DOI 10.1016/S0040-4020(00)00132-0; Matsumoto T, 2014, ORGANOMETALLICS, V33, P1341, DOI 10.1021/om500065n; Matsuo J, 2013, ANGEW CHEM INT EDIT, V52, P9109, DOI 10.1002/anie.201303192; Mei YJ, 2012, J ORG CHEM, V77, P5624, DOI 10.1021/jo300800b; MUKAIYAM.T, 1974, J AM CHEM SOC, V96, P7503, DOI 10.1021/ja00831a019; Mukaiyama T, 2004, ANGEW CHEM INT EDIT, V43, P5590, DOI 10.1002/anie.200300641; Ollevier T, 2012, CHEM COMMUN, V48, P2289, DOI 10.1039/c1cc16409k; Onodera G, 2014, TETRAHEDRON LETT, V55, P310, DOI 10.1016/j.tetlet.2013.10.085; Ping X., 2012, SYNLETT, P2269; Plancq B., 2013, EUR J ORG CHEM, P6525; Rubio M., 2011, ORG LETT, V13, P5236; Russo V, 2009, CHEM COMMUN, P595, DOI 10.1039/b818399f; Sasamori T, 2010, POLYHEDRON, V29, P425, DOI 10.1016/j.poly.2009.06.043; Sato Y, 2005, CHEM LETT, V34, P588, DOI 10.1246/cl.2005.588; Shimada T, 2006, ORG LETT, V8, P1129, DOI 10.1021/ol0531435; Sumida Y, 2009, J ORG CHEM, V74, P7986, DOI 10.1021/jo901513v; Tamagaki H, 2010, CHEM COMMUN, V46, P5930, DOI 10.1039/c0cc01110j; Turks M, 2005, CHEM-EUR J, V11, P465, DOI 10.1002/chem.200400825; Wang W, 2005, ORG LETT, V7, P1637, DOI 10.1021/ol0503337; Wang WG, 2011, SYNLETT, P2705, DOI 10.1055/s-0031-1289535; Watanabe T, 2007, J AM CHEM SOC, V129, P11338, DOI 10.1021/ja074629e; Yanai H, 2010, J ORG CHEM, V75, P5375, DOI 10.1021/jo100915e	68	0	0	ELSEVIER SCIENCE SA	LAUSANNE	PO BOX 564, 1001 LAUSANNE, SWITZERLAND	0022-1139	1873-3328		J FLUORINE CHEM	J. Fluor. Chem.	MAY	2015	173						69	76		10.1016/j.jfluchem.2015.02.010		8	Chemistry, Inorganic & Nuclear; Chemistry, Organic	Chemistry	CG2EF	WOS:000353087000011		
J	Miwa, H; Haruma, K; Sakamoto, S; Sanada, K; Hiroi, S; Kinoshita, Y				Miwa, Hiroto; Haruma, Ken; Sakamoto, Shigeru; Sanada, Katsuyuki; Hiroi, Shinzo; Kinoshita, Yoshikazu			Demography and treatment response in patients with predominant non-erosive reflux disease or functional dyspepsia	JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY			English	Article						dyspepsia; gastroesophageal reflux disease; lansoprazole	HEALTHY JAPANESE SUBJECTS; CAPSAICIN RECEPTOR TRPV1; IRRITABLE-BOWEL-SYNDROME; ROME III CRITERIA; CLINICAL CHARACTERISTICS; DUODENAL ACIDIFICATION; SENSORIMOTOR FUNCTION; ACID REFLUX; SYMPTOMS; CLASSIFICATION	Background and AimNon-erosive reflux disease (NERD) and functional dyspepsia (FD) share some common features, and the appropriateness of managing these diseases independently has been questioned. A post-hoc subgroup analysis of the LEGEND study was performed to compare demographics and treatment response between patients with NERD and patients with FD. MethodsPatients with reflux and dyspepsia symptoms who had no endoscopic evidence of mucosal breaks and/or erosions were included and divided into groups with predominant NERD (n=1546) or FD (n=614). Patients received lansoprazole for 4 weeks, and their symptoms were evaluated using questionnaires. ResultsFD patients were significantly younger than NERD patients (54 vs 60 years), more likely to have a body mass index <25kg/m(2) (72.4% vs 67.1%), less likely to have a hiatal hernia (24.0% vs 31.2%), and more likely to feel continuous stress (54.7% vs 48.0%). After 4 weeks of treatment, >60% of both patients reported an improvement in reflux symptoms and in most dyspepsia symptoms. The improvement rate for reflux symptoms was lower in FD patients than in NERD patients (P<0.05), whereas the improvement rate for dyspepsia symptoms did not differ between patient groups. ConclusionAlthough no clinically significant differences in pathophysiology exist between NERD and FD, there are some between-group differences in demographic characteristics and improvement rates for reflux symptoms after treatment with lansoprazole. It remains to be discussed whether it is necessary to make a strict differential diagnosis between these two conditions.	[Miwa, Hiroto] Hyogo Coll Med, Dept Internal Med, Div Gastroenterol, Nishinomiya, Hyogo 6638501, Japan; [Haruma, Ken] Kawasaki Med Univ, Div Gastroenterol, Dept Internal Med, Kurashiki, Okayama, Japan; [Sakamoto, Shigeru; Sanada, Katsuyuki; Hiroi, Shinzo] Takeda Pharmaceut Co Ltd, Dept Pharmacovigilance, Osaka, Osaka, Japan; [Kinoshita, Yoshikazu] Shimane Univ, Sch Med, Dept Gastroenterol & Hepatol, Izumo, Shimane, Japan	Miwa, H (reprint author), Hyogo Coll Med, Dept Internal Med, Div Gastroenterol, 1-1 Mukogawa Cho, Nishinomiya, Hyogo 6638501, Japan.	miwahgi@hyo-med.ac.jp			Takeda Pharmaceutical Company Limited; Takeda	This post-marketing surveillance study of lansoprazole was supported by Takeda Pharmaceutical Company Limited. The authors would like to thank all the investigators and participants at the 1611 clinics and hospitals in Japan who were members of the LEGEND study group. Editorial assistance was provided by Content Ed Net, with financial support from Takeda.	Adachi K, 2012, DIGEST DIS SCI, V57, P1609, DOI 10.1007/s10620-012-2087-6; Hongo M, 2006, J GASTROENTEROL, V41, P95, DOI 10.1007/s00535-006-1775-4; Ren TH, 2007, AM J PHYSIOL-GASTR L, V292, pG849, DOI 10.1152/ajpgi.00400.2006; Lundell LR, 1999, GUT, V45, P172; Vakil N, 2006, AM J GASTROENTEROL, V101, P1900, DOI 10.1111/j.1572-0241.2006.00630.x; Talley NJ, 2006, ALIMENT PHARM THERAP, V23, P923, DOI 10.1111/j.1365-2036.2006.02845.x; Dunphy RC, 2003, PAIN, V102, P79, DOI 10.1016/S0304-3959(02)00342-1; Yamasaki T, 2013, J GASTROENTEROL, V48, P360, DOI 10.1007/s00535-012-0665-1; Tack J, 2005, GUT, V54, P1370, DOI 10.1136/gut.2004.053355; Matthews PJ, 2004, EUR J GASTROEN HEPAT, V16, P897, DOI 10.1097/00042737-200409000-00014; Savarino E, 2009, GUT, V58, P1185, DOI 10.1136/gut.2008.175810; Miller V, 2009, INT J CLIN EXP HYP, V57, P279, DOI 10.1080/00207140902881098; Geeraerts B, 2009, NEUROGASTROENT MOTIL, V21, P33, DOI 10.1111/j.1365-2982.2008.01178.x; Henningsen P, 2003, PSYCHOSOM MED, V65, P528, DOI 10.1097/01.PSY.0000075977.90337.E7; Tack J, 2006, GASTROENTEROLOGY, V130, P1466, DOI 10.1053/j.gastro.2005.11.059; Barreau F, 2007, PEDIATR RES, V62, P240, DOI 10.1203/PDR.0b013e3180db2949; Aro P, 2009, GASTROENTEROLOGY, V137, P94, DOI 10.1053/j.gastro.2009.03.039; SHI G, 1995, GUT, V37, P457, DOI 10.1136/gut.37.4.457; Miwa H, 2007, ALIMENT PHARM THERAP, V26, P257, DOI 10.1111/j.1365-2036.2007.03367.x; Bhat YM, 2006, EUR J GASTROEN HEPAT, V18, P263, DOI 10.1097/00042737-200603000-00006; Cicala M, 2003, ALIMENT PHARM THERAP, V18, P605, DOI 10.1046/j.1365-2036.2003.01702.x; Fass R, 2002, GUT, V51, P885, DOI 10.1136/gut.51.6.885; Ishii M, 2008, J GASTROENTEROL, V43, P935, DOI 10.1007/s00535-008-2303-5; KANEKO H, 1993, J GASTROEN HEPATOL, V8, P322, DOI 10.1111/j.1440-1746.1993.tb01521.x; Keohane J, 2006, Minerva Gastroenterol Dietol, V52, P261; Kinoshita Y, 2011, INTERNAL MED, V50, P2269, DOI 10.2169/internalmedicine.50.5678; Kinoshita Y, 2014, J GASTROENTEROL, V49, P628, DOI 10.1007/s00535-013-0812-3; Lasch H, 1997, AM J PHYSIOL-GASTR L, V272, pG1; Lee KJ, 2004, AM J PHYSIOL-GASTR L, V286, pG278, DOI 10.1152/ajpgi.00086.2003; Manabe N, 2010, SCAND J GASTROENTERO, V45, P567, DOI 10.3109/00365521003592663; Miwa H, 2004, ALIMENT PHARM THERAP, V20, P112, DOI 10.1111/j.1365-2036.2004.01990.x; Orlando RC, 1997, AM J GASTROENTEROL, V92, pS3; Orlando RC, 1997, AM J GASTROENTEROL, V92, pS5; Oshima T, 2012, ALIMENT PHARM THER, V35, P175, DOI 10.1111/j.1365-2036.2011.04918.x; Peura DA, 2004, AM J MED, V116, P740, DOI 10.1016/j.amjmed.2004.01.008; Quigley EMM, 2004, BEST PRACT RES CL GA, V18, P695, DOI 10.1016/j.bpg.2004.04.004	36	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0815-9319	1440-1746		J GASTROEN HEPATOL	J. Gastroenterol. Hepatol.	MAY	2015	30	5					834	841		10.1111/jgh.12877		8	Gastroenterology & Hepatology	Gastroenterology & Hepatology	CF8JF	WOS:000352803400009		
J	Kanno, T; Iijima, K; Abe, Y; Yagi, M; Asonuma, S; Ohyauchi, M; Ito, H; Koike, T; Shimosegawa, T				Kanno, Takeshi; Iijima, Katsunori; Abe, Yasuhiko; Yagi, Makoto; Asonuma, Sho; Ohyauchi, Motoki; Ito, Hirotaka; Koike, Tomoyuki; Shimosegawa, Tooru			A multicenter prospective study on the prevalence of Helicobacter pylori-negative and nonsteroidal anti-inflammatory drugs-negative idiopathic peptic ulcers in Japan	JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY			English	Article						Helicobacter pylori; idiopathic peptic ulcers; nonsteroidal anti-inflammatory drug; risk factors	DUODENAL-ULCER; BLEEDING ULCERS; GENERAL-POPULATION; INFECTION; DISEASE; RISK; EPIDEMIOLOGY; MANAGEMENT; GASTRITIS; THERAPY	Background and AimThe prevalence of Helicobacter pylori-negative and nonsteroidal anti-inflammatory drug-negative peptic ulcers, commonly known as idiopathic peptic ulcers (IPUs), has been reported to be very low (0.9-2.6%) in Japan based on data from the 1990s. However, recent trends have yet to be been reported. Herein, we present a multicenter prospective analysis between 2012 and 2013 investigating current trends in the prevalence and characteristics of IPUs in Japan. MethodsClinical data of all peptic ulcer subjects detected via endoscopy at four participating hospitals were prospectively collected between April 2012 and March 2013. Enrolled subjects were classified according to H.pylori infection status and intake of nonsteroidal anti-inflammatory drugs. Multiple logistic regression analyses were used to determine the risk factors for IPUs. ResultsOf 382 enrolled patients with peptic ulcers, 46 (12%) were judged to have IPUs. Compared with those with simple H.pylori-positive ulcers, patients with IPUs were significantly older (P<0.02) and more often had underlying comorbidities such as hypertension (P<0.02) and hyperlipidemia (P<0.05). Multivariate regression analysis indicated that the presence of multiple underlying diseases was the only significant risk factor for IPUs, with an odds ratio of 3.8 (95% confidence interval, 1.3-11.1). ConclusionsThis study revealed that the prevalence of IPUs in patients with peptic ulcers in Japan is 12%, much higher than previously reported. Presence of multiple underlying comorbid diseases, rather than aging itself, is an important risk factor for IPUs.	[Kanno, Takeshi; Iijima, Katsunori; Koike, Tomoyuki; Shimosegawa, Tooru] Tohoku Univ, Grad Sch Med, Div Gastroenterol, Sendai, Miyagi 9808574, Japan; [Abe, Yasuhiko; Yagi, Makoto] Yamagata Univ, Fac Med, Dept Gastroenterol, Yamagata 990, Japan; [Asonuma, Sho] South Miyagi Med Ctr, Dept Gastroenterol, Ogawara, Japan; [Ohyauchi, Motoki; Ito, Hirotaka] Osaki Citizen Hosp, Dept Gastroenterol, Osaki, Japan	Iijima, K (reprint author), Tohoku Univ, Grad Sch Med, Div Gastroenterol, Aoba Ku, 1-1 Seiryo Machi, Sendai, Miyagi 9808574, Japan.	kiijima@med.tohoku.ac.jp					Kanno T, 2013, J GASTROENTEROL, V48, P483, DOI 10.1007/s00535-012-0681-1; TAYLOR DN, 1991, EPIDEMIOL REV, V13, P42; Malfertheiner P, 2009, LANCET, V374, P1449, DOI 10.1016/S0140-6736(09)60938-7; Laine L, 2008, GASTROENTEROLOGY, V135, P41, DOI 10.1053/j.gastro.2008.05.030; Nishikawa K, 2000, EUR J GASTROEN HEPAT, V12, P635, DOI 10.1097/00042737-200012060-00010; Kang JM, 2012, SCAND J GASTROENTERO, V47, P36, DOI 10.3109/00365521.2011.639083; Bytzer P, 2001, AM J GASTROENTEROL, V96, P1409; Xia HHX, 2001, ALIMENT PHARM THERAP, V15, P1875, DOI 10.1046/j.1365-2036.2001.01115.x; Wong GLH, 2012, CLIN GASTROENTEROL H, V10, P1124, DOI 10.1016/j.cgh.2012.06.012; Charpignon C, 2013, ALIMENT PHARM THER, V38, P946, DOI 10.1111/apt.12465; Ekstrom AM, 2001, GASTROENTEROLOGY, V121, P784, DOI 10.1053/gast.2001.27999; Kamada T, 2003, DIGEST DIS SCI, V48, P644, DOI 10.1023/A:1022808003014; Ciociola AA, 1999, AM J GASTROENTEROL, V94, P1834, DOI 10.1111/j.1572-0241.1999.01214.x; Quan C, 2002, AM J GASTROENTEROL, V97, P2950; Ootani H, 2006, J GASTROENTEROL, V41, P41, DOI 10.1007/s00535-005-1720-y; Wong GLH, 2009, GASTROENTEROLOGY, V137, P525, DOI 10.1053/j.gastro.2009.05.006; Kokkola A, 2003, APMIS, V111, P619, DOI 10.1034/j.1600-0463.2003.1110604.x; Goh KL, 2011, HELICOBACTER, V16, P1, DOI 10.1111/j.1523-5378.2011.00874.x; Tsuji H, 1999, J GASTROENTEROL, V34, P455, DOI 10.1007/s005350050296; Fujisawa T, 1999, AM J GASTROENTEROL, V94, P2094; Ong TZ, 2006, J CLIN GASTROENTEROL, V40, P795, DOI 10.1097/01.mcg.0000225610.41105.7f; Chan HLY, 2001, GASTROINTEST ENDOSC, V53, P438, DOI 10.1067/mge.2001.112840; Hung LCT, 2005, GASTROENTEROLOGY, V128, P1845, DOI 10.1053/j.gastro.2005.03.026; Gisbert JP, 2009, ALIMENT PHARM THER, V30, P791, DOI 10.1111/j.1365-2036.2009.04105.x; Jyotheeswaran S, 1998, AM J GASTROENTEROL, V93, P574; Meucci G, 2000, J CLIN GASTROENTEROL, V31, P42, DOI 10.1097/00004836-200007000-00010; Higuchi K, 1999, AM J GASTROENTEROL, V94, P3083, DOI 10.1111/j.1572-0241.1999.03083.x; Sugiyama T, 2001, DIGEST DIS SCI, V46, P307, DOI 10.1023/A:1005600831851; Aoyama Nobuo, 2000, Journal of Gastroenterology, V35, P33; Iijima K, 2014, WORLD J GASTROENTERO, V20, P706, DOI 10.3748/wjg.v20.i3.706; ISENBERG JI, 1973, GASTROENTEROLOGY, V65, P140; Jang HJ, 2008, DIGEST DIS SCI, V53, P1527, DOI 10.1007/s10620-007-0028-6; Kawaguchi H, 1996, AM J GASTROENTEROL, V91, P959; Kemppainen H, 1997, GERONTOLOGY, V43, P283; Kimura K, 1969, ENDOSCOPY, V3, P87, DOI DOI 10.1055/S-0028-1098086; Konturek SJ, 2003, SCAND J GASTROENTERO, V38, P923, DOI 10.1080/00365520310004696; Luthra GK, 1998, AM J GASTROENTEROL, V93, P1291; McJunkin B, 2011, AM J MED, V124, P260, DOI 10.1016/j.amjmed.2010.11.013; Nakajima S, 2010, J GASTROEN HEPATOL, V25, pS99, DOI 10.1111/j.1440-1746.2009.06214.x; Shiota S, 2013, EXPERT REV GASTROENT, V7, P35, DOI [10.1586/egh.12.67, 10.1586/EGH.12.67]; Sugano K, 2014, DIGEST DIS, V32, P281, DOI 10.1159/000357859	41	2	2	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0815-9319	1440-1746		J GASTROEN HEPATOL	J. Gastroenterol. Hepatol.	MAY	2015	30	5					842	848		10.1111/jgh.12876		7	Gastroenterology & Hepatology	Gastroenterology & Hepatology	CF8JF	WOS:000352803400010		
